##SAMPLE=<ID=GS140127_01,Status=affected>
##SAMPLE=<ID=GS140549_01,Status=control>
##SAMPLE=<ID=GS140550_01,Status=control>
##DESCRIPTION=GS140127_01=GS140127_01 genotype (affected)
##DESCRIPTION=GS140549_01=GS140549_01 genotype (control)
##DESCRIPTION=GS140550_01=GS140550_01 genotype (control)
##DESCRIPTION=filter=Annotations for filtering and ranking variants.
##DESCRIPTION=quality=Quality parameters - SNP quality (QUAL), depth (DP), allele frequency (AF), mean mapping quality of alternate allele (MQM), genotype, depth and allele frequency for child, mother and father (TRIO).
##DESCRIPTION=gene=Affected gene list (comma-separated).
##DESCRIPTION=variant_type=Variant type.
##DESCRIPTION=coding_and_splicing=Coding and splicing details (Gene, NM number, type, impact, exon number, HGVS.c, HGVS.p).
##DESCRIPTION=RepeatMasker=RepeatMasker annotation.
##DESCRIPTION=dbSNP=Identifier in dbSNP database.
##DESCRIPTION=1000g=Allele frequency in all populations of 1000g project.
##DESCRIPTION=ExAC=Allele frequency in all populations of ExAC project.
##DESCRIPTION=ExAC_hom=Homoyzgous counts for populations ALL, NFE and AFR of ExAC project.
##DESCRIPTION=Kaviar=Allele frequency in Kaviar database.
##DESCRIPTION=phyloP=phyloP (100way vertebrate) annotation. Deleterious threshold > 1.6.
##DESCRIPTION=Sift=Sift effect prediction: D=damaging, T=tolerated.
##DESCRIPTION=MetaLR=MetaLR effect prediction: D=damaging, T=tolerated.
##DESCRIPTION=PolyPhen2=PolyPhen2 (HVAR) effect prediction: D=probably damaging, P=possibly damaging, B=benign.
##DESCRIPTION=FATHMM=FATHMM effect prediction: D=damaging, T=tolerated.
##DESCRIPTION=CADD=CADD pathogenicity prediction scores (scaled phred-like). Deleterious threshold > 15-20.
##DESCRIPTION=OMIM=OMIM database annotation.
##DESCRIPTION=ClinVar=ClinVar database annotation.
##DESCRIPTION=HGMD=HGMD database annotation.
##DESCRIPTION=COSMIC=COSMIC somatic variant database anntotation.
##DESCRIPTION=ihdb_allsys_hom=Homozygous variant counts in NGSD independent of the processing system.
##DESCRIPTION=ihdb_allsys_het=Heterozygous variant counts in NGSD independent of the processing system.
##DESCRIPTION=classification=Classification from the NGSD.
##DESCRIPTION=classification_comment=Classification comment from the NGSD.
##DESCRIPTION=validated=Validation information from the NGSD. Validation results of other samples are listed in brackets!
##DESCRIPTION=comment=Comments from the NGSD. Comments of other samples are listed in brackets!
##DESCRIPTION=gene_info=Gene information from NGSD (inheritance mode, ExAC pLI score).
##FILTER=anno_high_impact=Variant annotated to have high impact by SnpEff.
##FILTER=anno_pathogenic_clinvar=Variant annotated to be pathogenic by ClinVar.
##FILTER=anno_pathogenic_hgmd=Variant annotated to be pathogenic by HGMD.
##FILTER=gene_blacklist=The gene(s) are contained on the blacklist of unreliable genes.
##FILTER=low_DP=Depth less than 20.
##FILTER=low_MQM=Mean mapping quality of alternate allele less than Q50.
##FILTER=low_QUAL=Variant quality less than Q30.
##FILTER=pred_pathogenic=Variant predicted to be pathogenic by one or more tools (conservation or effect prediction).
#chr	start	end	ref	obs	GS140127_01	GS140549_01	GS140550_01	filter	quality	gene	variant_type	coding_and_splicing	RepeatMasker	dbSNP	1000g	ExAC	ExAC_hom	Kaviar	phyloP	Sift	MetaLR	PolyPhen2	FATHMM	CADD	OMIM	ClinVar	HGMD	COSMIC	ihdb_allsys_hom	ihdb_allsys_het	classification	classification_comment	validated	comment	gene_info
chr1	977330	977330	T	C	hom	hom	hom	low_DP	QUAL=1743;DP=13,20,26;MQM=60	AGRN	splice_region&intron	AGRN:NM_001305275.1:splice_region&intron:LOW:exon6/37:c.1178-6T>C:,AGRN:NM_198576.3:splice_region&intron:LOW:exon6/35:c.1178-6T>C:		rs2799066	0.8852	0.9166	49652/26935/2511	0.8736							103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];	RCV000116254.2 [benign]; 			1295	238					AGRN (inh=AR pLI=0.17)
chr1	981931	981931	A	G	hom	hom	hom		QUAL=6340;DP=55,73,96;MQM=59	AGRN	synonymous	AGRN:NM_001305275.1:synonymous:LOW:exon18/38:c.3066A>G:p.Ser1022Ser,AGRN:NM_198576.3:synonymous:LOW:exon18/36:c.3066A>G:p.Ser1022Ser		rs2465128	0.7977	0.8767	45286/25865/1210	0.8293							103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];	RCV000116259.2 [benign]; 		COSM1126908	1224	302				n/a (storniert, da VUS4 in SYNGAP1 SBW 2.03.2016)	AGRN (inh=AR pLI=0.17)
chr1	982994	982994	T	C	hom	hom	hom		QUAL=15575;DP=143,143,208;MQM=59	AGRN	synonymous	AGRN:NM_001305275.1:synonymous:LOW:exon21/38:c.3558T>C:p.Phe1186Phe,AGRN:NM_198576.3:synonymous:LOW:exon21/36:c.3558T>C:p.Phe1186Phe		rs10267	0.8359	0.8989	49550/27787/1439	0.8697							103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];	RCV000116264.2 [benign]; 		COSM4144271	1280	252					AGRN (inh=AR pLI=0.17)
chr1	984302	984302	T	C	het	wt	hom	low_DP	QUAL=572;DP=10,17,19;MQM=60	AGRN	synonymous	AGRN:NM_001305275.1:synonymous:LOW:exon24/38:c.4161T>C:p.Thr1387Thr,AGRN:NM_198576.3:synonymous:LOW:exon24/36:c.4161T>C:p.Thr1387Thr		rs9442391	0.5457	0.6295	6170/2886/108	0.4528							103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];	RCV000116269.2 [benign]; 			474	735					AGRN (inh=AR pLI=0.17)
chr1	987200	987200	C	T	hom	hom	hom		QUAL=11199;DP=65,144,160;MQM=60	AGRN	splice_region&intron,sequence_feature	AGRN:NM_001305275.1:splice_region&intron:LOW:exon33/37:c.5660+5C>T:,AGRN:NM_198576.3:splice_region&intron:LOW:exon33/35:c.5651+5C>T:,AGRN:NM_198576.3:sequence_feature:LOW::c.5651+5C>T:		rs9803031	0.7887	0.8757	47145/27015/1042	0.8466							103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];	RCV000116279.2 [benign]; 			1237	293					AGRN (inh=AR pLI=0.17)
chr1	990280	990280	C	T	wt	het	het		QUAL=4769;DP=106,174,207;MQM=60	AGRN	synonymous	AGRN:NM_001305275.1:synonymous:LOW:exon38/38:c.6123C>T:p.Asp2041Asp,AGRN:NM_198576.3:synonymous:LOW:exon36/36:c.6057C>T:p.Asp2019Asp		rs4275402	0.5853	0.6376	4436/2169/120	0.4702							103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];	RCV000116281.2 [benign]; 			719	679					AGRN (inh=AR pLI=0.17)
chr1	990380	990380	C	T	hom	het	het		QUAL=12528;DP=170,332,435;MQM=60	AGRN	3'UTR	AGRN:NM_001305275.1:3'UTR:MODIFIER:exon38/38:c.*19C>T:,AGRN:NM_198576.3:3'UTR:MODIFIER:exon36/36:c.*19C>T:		rs3121561	0.3435	0.3334	938/271/224	0.1369							103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];	RCV000252490.1 [benign]; 			84	387					AGRN (inh=AR pLI=0.17)
chr1	990417	990417	T	C	hom	het	het		QUAL=16882;DP=198,389,507;MQM=59	AGRN	3'UTR	AGRN:NM_001305275.1:3'UTR:MODIFIER:exon38/38:c.*56T>C:,AGRN:NM_198576.3:3'UTR:MODIFIER:exon36/36:c.*56T>C:		rs2465136	0.3840	0.0000	0/0/0	0.0612							103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];				86	388					AGRN (inh=AR pLI=0.17)
chr1	990517	990517	C	T	hom	het	hom		QUAL=18598;DP=126,285,376;MQM=59	AGRN	3'UTR	AGRN:NM_001305275.1:3'UTR:MODIFIER:exon38/38:c.*156C>T:,AGRN:NM_198576.3:3'UTR:MODIFIER:exon36/36:c.*156C>T:		rs2710872	0.9179	0.0000	0/0/0	0.1403							103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];				177	50					AGRN (inh=AR pLI=0.17)
chr1	990773	990773	C	T	hom	het	hom		QUAL=22636;DP=190,297,405;MQM=60	AGRN	3'UTR	AGRN:NM_001305275.1:3'UTR:MODIFIER:exon38/38:c.*412C>T:,AGRN:NM_198576.3:3'UTR:MODIFIER:exon36/36:c.*412C>T:		rs2799072	0.8460	0.0000	0/0/0	0.1377							103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];				171	51					AGRN (inh=AR pLI=0.17)
chr1	990806	990806	G	A	hom	het	hom		QUAL=24719;DP=227,312,451;MQM=59	AGRN	3'UTR	AGRN:NM_001305275.1:3'UTR:MODIFIER:exon38/38:c.*445G>A:,AGRN:NM_198576.3:3'UTR:MODIFIER:exon36/36:c.*445G>A:		rs2799073	0.8462	0.0000	0/0/0	0.7988							103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];				171	51					AGRN (inh=AR pLI=0.17)
chr1	990984	990984	G	A	hom	het	hom		QUAL=16025;DP=154,190,273;MQM=59	AGRN	3'UTR	AGRN:NM_001305275.1:3'UTR:MODIFIER:exon38/38:c.*623G>A:,AGRN:NM_198576.3:3'UTR:MODIFIER:exon36/36:c.*623G>A:		rs8014	0.9223	0.0000	0/0/0	0.8263							103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];				175	49					AGRN (inh=AR pLI=0.17)
chr1	1957037	1957037	T	C	het	wt	het		QUAL=6920;DP=173,342,399;MQM=59	GABRD	synonymous	GABRD:NM_000815.4:synonymous:LOW:exon4/9:c.330T>C:p.Gly110Gly		rs2229110	0.5613	0.5934	22096/14241/2764	0.5736							137163 [GABRD (confirmed) Epilepsy,generalized,with febrile seizures plus,type 5,susceptibility to,613060|Epilepsy,idiopathic generalized,10,613060|Epilepsy,juvenile myoclonic,susceptibility to,613060];	RCV000254456.1 [benign]; 		COSM424897	686	656					GABRD (inh=n/a pLI=0.92)
chr1	1960674	1960674	C	T	het	het	wt		QUAL=4915;DP=126,266,386;MQM=59	GABRD	synonymous	GABRD:NM_000815.4:synonymous:LOW:exon7/9:c.816C>T:p.Ser272Ser		rs28408173	0.1983	0.2873	1279/346/4	0.1500							137163 [GABRD (confirmed) Epilepsy,generalized,with febrile seizures plus,type 5,susceptibility to,613060|Epilepsy,idiopathic generalized,10,613060|Epilepsy,juvenile myoclonic,susceptibility to,613060];	RCV000248963.1 [benign]; 			45	317					GABRD (inh=n/a pLI=0.92)
chr1	2337277	2337277	C	T	het	wt	wt	low_DP	QUAL=119;DP=22,1,1;MQM=60	PEX10	splice_region&intron	PEX10:NM_153818.1:splice_region&intron:LOW:exon5/5:c.973-4G>A:,PEX10:NM_002617.3:splice_region&intron:LOW:exon5/5:c.913-4G>A:		rs11586985	0.0809	0.1530	377/256/3	0.0874							602859 [PEX10 (confirmed) Peroxisome biogenesis disorder 6A (Zellweger),614870|Peroxisome biogenesis disorder 6B,614871];	RCV000251204.1 [benign]; RCV000341363.1 [likely benign]; 			57	607					PEX10 (inh=AR pLI=0.01)
chr1	2340200	2340200	T	C	wt	het	het		QUAL=985;DP=48,39,48;MQM=60	PEX10	synonymous	PEX10:NM_153818.1:synonymous:LOW:exon3/6:c.291A>G:p.Thr97Thr,PEX10:NM_002617.3:synonymous:LOW:exon3/6:c.291A>G:p.Thr97Thr		rs2494598	0.6989	0.7714	36152/21821/1868	0.7640							602859 [PEX10 (confirmed) Peroxisome biogenesis disorder 6A (Zellweger),614870|Peroxisome biogenesis disorder 6B,614871];	RCV000117902.3 [other]; RCV000326499.1 [benign]; 			1686	862	1	[1] Peter Bauer 11.12.2014			PEX10 (inh=AR pLI=0.01)
chr1	5926507	5926507	T	C	het	wt	hom		QUAL=8816;DP=279,156,182;MQM=59	NPHP4	synonymous,non_coding_transcript_exon	NPHP4:NM_015102.4:synonymous:LOW:exon26/30:c.3570A>G:p.Glu1190Glu,NPHP4:NM_001291593.1:synonymous:LOW:exon23/27:c.2031A>G:p.Glu677Glu,NPHP4:NM_001291594.1:synonymous:LOW:exon22/26:c.2034A>G:p.Glu678Glu,NPHP4:NR_111987.1:non_coding_transcript_exon:MODIFIER:exon29/33:n.4385A>G:		rs555164	0.3197	0.4604	7291/4640/147	0.3694							607215 [NPHP4 (provisional) Nephronophthisis 4,606966|Senior-Loken syndrome 4,606996];	RCV000081716.5 [benign]; RCV000266333.1 [benign]; RCV000324301.1 [benign]; 		COSM1126976	260	743					NPHP4 (inh=AR pLI=0.00)
chr1	5927943	5927943	G	A	wt	wt	het	anno_pathogenic_hgmd	QUAL=3599;DP=135,269,360;MQM=60	NPHP4	missense,non_coding_transcript_exon	NPHP4:NM_015102.4:missense:MODERATE:exon24/30:c.3329C>T:p.Ala1110Val,NPHP4:NM_001291593.1:missense:MODERATE:exon21/27:c.1790C>T:p.Ala597Val,NPHP4:NM_001291594.1:missense:MODERATE:exon20/26:c.1793C>T:p.Ala598Val,NPHP4:NR_111987.1:non_coding_transcript_exon:MODIFIER:exon27/33:n.4144C>T:		rs139767853	0.0014	0.0036	0/0/0	0.0034	0.0280	T	T	B,B	T	6.77	607215 [NPHP4 (provisional) Nephronophthisis 4,606966|Senior-Loken syndrome 4,606996];	RCV000081715.5 [uncertain significance]; RCV000292444.1 [uncertain significance]; RCV000331197.1 [uncertain significance]; 	CM125782 [CLASS=DM MUT=ALT PHEN="Cardiovascular malformations" GENE=NPHP4]; 		0	11					NPHP4 (inh=AR pLI=0.00)
chr1	5935162	5935162	A	T	het	hom	het	anno_high_impact	QUAL=4972;DP=90,87,128;MQM=60	NPHP4	splice_acceptor	NPHP4:NM_015102.4:splice_acceptor:HIGH:exon20/29:c.2818-2T>A:,NPHP4:NM_001291593.1:splice_acceptor:HIGH:exon17/26:c.1279-2T>A:,NPHP4:NM_001291594.1:splice_acceptor:HIGH:exon16/25:c.1282-2T>A:,NPHP4:NR_111987.1:splice_acceptor:HIGH:exon23/32:n.3633-2T>A:		rs1287637	0.8433	0.8362	35542/19394/3252	0.8135	0.4520					18.68	607215 [NPHP4 (provisional) Nephronophthisis 4,606966|Senior-Loken syndrome 4,606996];	RCV000153587.2 [benign]; 		COSM3751327	1002	486	1	[1] auto-classification 16.06.2016  [2] Ute Grasshoff 24.11.2015			NPHP4 (inh=AR pLI=0.00)
chr1	5965381	5965381	C	T	wt	wt	het		QUAL=2689;DP=211,206,263;MQM=60	NPHP4	synonymous,non_coding_transcript_exon	NPHP4:NM_015102.4:synonymous:LOW:exon15/30:c.1926G>A:p.Glu642Glu,NPHP4:NM_001291593.1:synonymous:LOW:exon12/27:c.387G>A:p.Glu129Glu,NPHP4:NM_001291594.1:synonymous:LOW:exon11/26:c.390G>A:p.Glu130Glu,NPHP4:NR_111987.1:non_coding_transcript_exon:MODIFIER:exon15/33:n.2191G>A:		rs12120967	0.0841	0.1327	1256/1005/8	0.1276							607215 [NPHP4 (provisional) Nephronophthisis 4,606966|Senior-Loken syndrome 4,606996];	RCV000081706.5 [benign]; RCV000348170.1 [likely benign]; RCV000392232.1 [likely benign]; 			24	390					NPHP4 (inh=AR pLI=0.00)
chr1	6526183	6526183	G	A	het	wt	het	low_DP	QUAL=378;DP=16,5,20;MQM=59	TNFRSF25,PLEKHG5	5'UTR,3'UTR	TNFRSF25:NM_148965.1:5'UTR:MODIFIER:exon1/10:c.-16C>T:,TNFRSF25:NM_003790.2:5'UTR:MODIFIER:exon1/10:c.-16C>T:,TNFRSF25:NM_148966.1:5'UTR:MODIFIER:exon1/9:c.-16C>T:,TNFRSF25:NM_148967.1:5'UTR:MODIFIER:exon1/9:c.-16C>T:,TNFRSF25:NM_148970.1:5'UTR:MODIFIER:exon1/5:c.-16C>T:,TNFRSF25:NM_001039664.1:5'UTR:MODIFIER:exon1/5:c.-16C>T:,PLEKHG5:NM_001265592.1:3'UTR:MODIFIER:exon22/22:c.*1440C>T:,PLEKHG5:NM_001265593.1:3'UTR:MODIFIER:exon21/21:c.*1440C>T:,PLEKHG5:NM_001042665.1:3'UTR:MODIFIER:exon21/21:c.*1440C>T:,PLEKHG5:NM_001042664.1:3'UTR:MODIFIER:exon21/21:c.*1440C>T:,PLEKHG5:NM_001265594.1:3'UTR:MODIFIER:exon22/22:c.*1468C>T:,PLEKHG5:NM_020631.4:3'UTR:MODIFIER:exon21/21:c.*1440C>T:,PLEKHG5:NM_001042663.1:3'UTR:MODIFIER:exon22/22:c.*1440C>T:,PLEKHG5:NM_198681.3:3'UTR:MODIFIER:exon22/22:c.*1440C>T:		rs3007417	0.2023	0.1694	440/67/329	0.0754							611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067|Charcot-Marie-Tooth disease,recessive intermediate C,615376];	RCV000399468.1 [benign]; 			13	155					TNFRSF25 (inh=n/a pLI=0.45), PLEKHG5 (inh=AR pLI=0.00)
chr1	6526203	6526210	CGTGCTCT	-	het	wt	het	low_DP	QUAL=389;DP=17,6,21;MQM=59	TNFRSF25,PLEKHG5	5'UTR,3'UTR	TNFRSF25:NM_148965.1:5'UTR:MODIFIER:exon1/10:c.-43_-36delAGAGCACG:,TNFRSF25:NM_003790.2:5'UTR:MODIFIER:exon1/10:c.-43_-36delAGAGCACG:,TNFRSF25:NM_148966.1:5'UTR:MODIFIER:exon1/9:c.-43_-36delAGAGCACG:,TNFRSF25:NM_148967.1:5'UTR:MODIFIER:exon1/9:c.-43_-36delAGAGCACG:,TNFRSF25:NM_148970.1:5'UTR:MODIFIER:exon1/5:c.-43_-36delAGAGCACG:,TNFRSF25:NM_001039664.1:5'UTR:MODIFIER:exon1/5:c.-43_-36delAGAGCACG:,PLEKHG5:NM_001265592.1:3'UTR:MODIFIER:exon22/22:c.*1413_*1420delAGAGCACG:,PLEKHG5:NM_001265593.1:3'UTR:MODIFIER:exon21/21:c.*1413_*1420delAGAGCACG:,PLEKHG5:NM_001042665.1:3'UTR:MODIFIER:exon21/21:c.*1413_*1420delAGAGCACG:,PLEKHG5:NM_001042664.1:3'UTR:MODIFIER:exon21/21:c.*1413_*1420delAGAGCACG:,PLEKHG5:NM_001265594.1:3'UTR:MODIFIER:exon22/22:c.*1441_*1448delAGAGCACG:,PLEKHG5:NM_020631.4:3'UTR:MODIFIER:exon21/21:c.*1413_*1420delAGAGCACG:,PLEKHG5:NM_001042663.1:3'UTR:MODIFIER:exon22/22:c.*1413_*1420delAGAGCACG:,PLEKHG5:NM_198681.3:3'UTR:MODIFIER:exon22/22:c.*1413_*1420delAGAGCACG:		rs45616733	0.2027	0.0954	62/10/43	0.0586							611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067|Charcot-Marie-Tooth disease,recessive intermediate C,615376];	RCV000302421.1 [benign]; 			4	112					TNFRSF25 (inh=n/a pLI=0.45), PLEKHG5 (inh=AR pLI=0.00)
chr1	6526241	6526244	CGCC	-	het	wt	het	low_DP	QUAL=326;DP=11,3,15;MQM=59	TNFRSF25,PLEKHG5	5'UTR,3'UTR	TNFRSF25:NM_148965.1:5'UTR:MODIFIER:exon1/10:c.-77_-74delGGCG:,TNFRSF25:NM_003790.2:5'UTR:MODIFIER:exon1/10:c.-77_-74delGGCG:,TNFRSF25:NM_148966.1:5'UTR:MODIFIER:exon1/9:c.-77_-74delGGCG:,TNFRSF25:NM_148967.1:5'UTR:MODIFIER:exon1/9:c.-77_-74delGGCG:,TNFRSF25:NM_148970.1:5'UTR:MODIFIER:exon1/5:c.-77_-74delGGCG:,TNFRSF25:NM_001039664.1:5'UTR:MODIFIER:exon1/5:c.-77_-74delGGCG:,PLEKHG5:NM_001265592.1:3'UTR:MODIFIER:exon22/22:c.*1379_*1382delGGCG:,PLEKHG5:NM_001265593.1:3'UTR:MODIFIER:exon21/21:c.*1379_*1382delGGCG:,PLEKHG5:NM_001042665.1:3'UTR:MODIFIER:exon21/21:c.*1379_*1382delGGCG:,PLEKHG5:NM_001042664.1:3'UTR:MODIFIER:exon21/21:c.*1379_*1382delGGCG:,PLEKHG5:NM_001265594.1:3'UTR:MODIFIER:exon22/22:c.*1407_*1410delGGCG:,PLEKHG5:NM_020631.4:3'UTR:MODIFIER:exon21/21:c.*1379_*1382delGGCG:,PLEKHG5:NM_001042663.1:3'UTR:MODIFIER:exon22/22:c.*1379_*1382delGGCG:,PLEKHG5:NM_198681.3:3'UTR:MODIFIER:exon22/22:c.*1379_*1382delGGCG:		rs45542640	0.2025	0.0000	0/0/0	0.0856							611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067|Charcot-Marie-Tooth disease,recessive intermediate C,615376];	RCV000361894.1 [benign]; 			0	20					TNFRSF25 (inh=n/a pLI=0.45), PLEKHG5 (inh=AR pLI=0.00)
chr1	6526319	6526319	C	T	het	wt	het		QUAL=293;DP=31,30,33;MQM=60	PLEKHG5	3'UTR	PLEKHG5:NM_001265592.1:3'UTR:MODIFIER:exon22/22:c.*1304G>A:,PLEKHG5:NM_001265593.1:3'UTR:MODIFIER:exon21/21:c.*1304G>A:,PLEKHG5:NM_001042665.1:3'UTR:MODIFIER:exon21/21:c.*1304G>A:,PLEKHG5:NM_001042664.1:3'UTR:MODIFIER:exon21/21:c.*1304G>A:,PLEKHG5:NM_001265594.1:3'UTR:MODIFIER:exon22/22:c.*1332G>A:,PLEKHG5:NM_020631.4:3'UTR:MODIFIER:exon21/21:c.*1304G>A:,PLEKHG5:NM_001042663.1:3'UTR:MODIFIER:exon22/22:c.*1304G>A:,PLEKHG5:NM_198681.3:3'UTR:MODIFIER:exon22/22:c.*1304G>A:		rs45604837	0.0863	0.0000	0/0/0	0.0598							611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067|Charcot-Marie-Tooth disease,recessive intermediate C,615376];	RCV000263899.1 [likely benign]; 			1	27					PLEKHG5 (inh=AR pLI=0.00)
chr1	6526465	6526465	C	G	het	wt	het		QUAL=3463;DP=85,150,199;MQM=60	PLEKHG5	3'UTR	PLEKHG5:NM_001265592.1:3'UTR:MODIFIER:exon22/22:c.*1158G>C:,PLEKHG5:NM_001265593.1:3'UTR:MODIFIER:exon21/21:c.*1158G>C:,PLEKHG5:NM_001042665.1:3'UTR:MODIFIER:exon21/21:c.*1158G>C:,PLEKHG5:NM_001042664.1:3'UTR:MODIFIER:exon21/21:c.*1158G>C:,PLEKHG5:NM_001265594.1:3'UTR:MODIFIER:exon22/22:c.*1186G>C:,PLEKHG5:NM_020631.4:3'UTR:MODIFIER:exon21/21:c.*1158G>C:,PLEKHG5:NM_001042663.1:3'UTR:MODIFIER:exon22/22:c.*1158G>C:,PLEKHG5:NM_198681.3:3'UTR:MODIFIER:exon22/22:c.*1158G>C:	MIR3	rs2986754	0.2043	0.0000	0/0/0	0.0168							611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067|Charcot-Marie-Tooth disease,recessive intermediate C,615376];	RCV000387093.1 [benign]; 			1	38					PLEKHG5 (inh=AR pLI=0.00)
chr1	6527333	6527333	A	G	het	wt	het		QUAL=1629;DP=78,53,59;MQM=59	PLEKHG5	3'UTR	PLEKHG5:NM_001265592.1:3'UTR:MODIFIER:exon22/22:c.*290T>C:,PLEKHG5:NM_001265593.1:3'UTR:MODIFIER:exon21/21:c.*290T>C:,PLEKHG5:NM_001042665.1:3'UTR:MODIFIER:exon21/21:c.*290T>C:,PLEKHG5:NM_001042664.1:3'UTR:MODIFIER:exon21/21:c.*290T>C:,PLEKHG5:NM_001265594.1:3'UTR:MODIFIER:exon22/22:c.*318T>C:,PLEKHG5:NM_020631.4:3'UTR:MODIFIER:exon21/21:c.*290T>C:,PLEKHG5:NM_001042663.1:3'UTR:MODIFIER:exon22/22:c.*290T>C:,PLEKHG5:NM_198681.3:3'UTR:MODIFIER:exon22/22:c.*290T>C:		rs14708	0.2670	0.0000	0/0/0	0.0273							611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067|Charcot-Marie-Tooth disease,recessive intermediate C,615376];	RCV000311319.1 [benign]; 			7	66					PLEKHG5 (inh=AR pLI=0.00)
chr1	6529183	6529185	TCC	-	wt	wt	het		QUAL=668;DP=56,66,109;MQM=59	PLEKHG5	disruptive_inframe_deletion	PLEKHG5:NM_001265592.1:disruptive_inframe_deletion:MODERATE:exon20/22:c.2403_2405delGGA:p.Glu802del,PLEKHG5:NM_001265593.1:disruptive_inframe_deletion:MODERATE:exon19/21:c.2373_2375delGGA:p.Glu792del,PLEKHG5:NM_001042665.1:disruptive_inframe_deletion:MODERATE:exon19/21:c.2166_2168delGGA:p.Glu723del,PLEKHG5:NM_001042664.1:disruptive_inframe_deletion:MODERATE:exon19/21:c.2166_2168delGGA:p.Glu723del,PLEKHG5:NM_001265594.1:disruptive_inframe_deletion:MODERATE:exon19/22:c.2166_2168delGGA:p.Glu723del,PLEKHG5:NM_020631.4:disruptive_inframe_deletion:MODERATE:exon19/21:c.2166_2168delGGA:p.Glu723del,PLEKHG5:NM_001042663.1:disruptive_inframe_deletion:MODERATE:exon20/22:c.2334_2336delGGA:p.Glu779del,PLEKHG5:NM_198681.3:disruptive_inframe_deletion:MODERATE:exon20/22:c.2397_2399delGGA:p.Glu800del	(TCC)n	rs113541584;rs766801954	0.0972	0.1130	262/98/114	0.0898							611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067|Charcot-Marie-Tooth disease,recessive intermediate C,615376];	RCV000175472.2 [benign]; RCV000320159.1 [likely benign]; 		COSM911543	10	186					PLEKHG5 (inh=AR pLI=0.00)
chr1	6529443	6529443	A	G	het	wt	het		QUAL=9849;DP=342,392,488;MQM=59	PLEKHG5	synonymous	PLEKHG5:NM_001265592.1:synonymous:LOW:exon19/22:c.2238T>C:p.Ser746Ser,PLEKHG5:NM_001265593.1:synonymous:LOW:exon18/21:c.2208T>C:p.Ser736Ser,PLEKHG5:NM_001042665.1:synonymous:LOW:exon18/21:c.2001T>C:p.Ser667Ser,PLEKHG5:NM_001042664.1:synonymous:LOW:exon18/21:c.2001T>C:p.Ser667Ser,PLEKHG5:NM_001265594.1:synonymous:LOW:exon18/22:c.2001T>C:p.Ser667Ser,PLEKHG5:NM_020631.4:synonymous:LOW:exon18/21:c.2001T>C:p.Ser667Ser,PLEKHG5:NM_001042663.1:synonymous:LOW:exon19/22:c.2169T>C:p.Ser723Ser,PLEKHG5:NM_198681.3:synonymous:LOW:exon19/22:c.2232T>C:p.Ser744Ser		rs730600	0.2696	0.1723	2980/684/1843	0.1670							611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067|Charcot-Marie-Tooth disease,recessive intermediate C,615376];	RCV000175354.2 [benign]; RCV000288519.1 [benign]; 			55	446					PLEKHG5 (inh=AR pLI=0.00)
chr1	6531589	6531589	C	T	het	wt	het		QUAL=1721;DP=39,115,115;MQM=59	PLEKHG5	missense	PLEKHG5:NM_001265592.1:missense:MODERATE:exon13/22:c.1477G>A:p.Ala493Thr,PLEKHG5:NM_001265593.1:missense:MODERATE:exon12/21:c.1447G>A:p.Ala483Thr,PLEKHG5:NM_001042665.1:missense:MODERATE:exon12/21:c.1240G>A:p.Ala414Thr,PLEKHG5:NM_001042664.1:missense:MODERATE:exon12/21:c.1240G>A:p.Ala414Thr,PLEKHG5:NM_001265594.1:missense:MODERATE:exon12/22:c.1240G>A:p.Ala414Thr,PLEKHG5:NM_020631.4:missense:MODERATE:exon12/21:c.1240G>A:p.Ala414Thr,PLEKHG5:NM_001042663.1:missense:MODERATE:exon13/22:c.1408G>A:p.Ala470Thr,PLEKHG5:NM_198681.3:missense:MODERATE:exon13/22:c.1471G>A:p.Ala491Thr		rs74809741	0.0553	0.0629	169/106/28	0.0493	0.6410	T,T,T,T,T,T,T,T,T,T,T,T,T	T	B,B,B,B,B	T,T,T,T,T,T,T,T,T,T,T,T	12.65	611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067|Charcot-Marie-Tooth disease,recessive intermediate C,615376];	RCV000317056.1 [likely benign]; 		COSM4144152, COSM4144153	10	192					PLEKHG5 (inh=AR pLI=0.00)
chr1	6533393	6533393	G	C	het	wt	het	low_DP	QUAL=407;DP=23,19,25;MQM=60	PLEKHG5	missense	PLEKHG5:NM_001265592.1:missense:MODERATE:exon9/22:c.950C>G:p.Thr317Ser,PLEKHG5:NM_001265593.1:missense:MODERATE:exon8/21:c.920C>G:p.Thr307Ser,PLEKHG5:NM_001042665.1:missense:MODERATE:exon8/21:c.713C>G:p.Thr238Ser,PLEKHG5:NM_001042664.1:missense:MODERATE:exon8/21:c.713C>G:p.Thr238Ser,PLEKHG5:NM_001265594.1:missense:MODERATE:exon8/22:c.713C>G:p.Thr238Ser,PLEKHG5:NM_020631.4:missense:MODERATE:exon8/21:c.713C>G:p.Thr238Ser,PLEKHG5:NM_001042663.1:missense:MODERATE:exon9/22:c.881C>G:p.Thr294Ser,PLEKHG5:NM_198681.3:missense:MODERATE:exon9/22:c.944C>G:p.Thr315Ser		rs61741379	0.2857	0.2212	796/120/537	0.1178	0.8480	T,T,T,T,T,T,T,T,T,T,T,T,T	T	B,B,B,B,B	T,T,T,T,T,T,T,T,T,T,T,T	0.01	611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067|Charcot-Marie-Tooth disease,recessive intermediate C,615376];	RCV000180356.2 [benign]; RCV000346358.1 [benign]; 		COSM3751353, COSM3751354	49	446					PLEKHG5 (inh=AR pLI=0.00)
chr1	6579521	6579521	G	C	het	het	het		QUAL=3471;DP=124,78,91;MQM=59	PLEKHG5	missense	PLEKHG5:NM_198681.3:missense:MODERATE:exon1/22:c.51C>G:p.Ser17Arg		rs17438786	0.0136	0.0252	51/36/0	0.0243	0.0870	T,T	T	B,B	T,T	5.81	611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067|Charcot-Marie-Tooth disease,recessive intermediate C,615376];				0	86					PLEKHG5 (inh=AR pLI=0.00)
chr1	6579607	6579607	C	T	hom	hom	hom		QUAL=20275;DP=186,206,271;MQM=59	PLEKHG5	5'UTR	PLEKHG5:NM_198681.3:5'UTR:MODIFIER:exon1/22:c.-36G>A:		rs1556035	0.7460	0.8523	44471/25994/1339	0.8284							611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067|Charcot-Marie-Tooth disease,recessive intermediate C,615376];				568	180					PLEKHG5 (inh=AR pLI=0.00)
chr1	6579843	6579843	C	T	hom	hom	hom		QUAL=41968;DP=296,454,585;MQM=59	PLEKHG5	5'UTR	PLEKHG5:NM_198681.3:5'UTR:MODIFIER:exon1/22:c.-272G>A:		rs1010584	0.7354	0.0000	0/0/0	0.1412							611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067|Charcot-Marie-Tooth disease,recessive intermediate C,615376];				159	68					PLEKHG5 (inh=AR pLI=0.00)
chr1	10318652	10318652	C	G	wt	het	wt		QUAL=2875;DP=314,229,250;MQM=60	KIF1B	synonymous	KIF1B:NM_015074.3:synonymous:LOW:exon4/47:c.285C>G:p.Ala95Ala,KIF1B:NM_183416.3:synonymous:LOW:exon4/21:c.285C>G:p.Ala95Ala		rs12402052	0.2300	0.2689	4681/2785/49	0.2676							605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210|Pheochromocytoma,171300|Neuroblastoma,susceptibility to,1,256700];	RCV000117406.5 [other]; RCV000275235.1 [benign]; RCV000311574.1 [benign]; RCV000355892.1 [benign]; 		COSM146390, COSM146389	120	562					KIF1B (inh=AD pLI=1.00)
chr1	10355834	10355834	C	T	wt	het	wt		QUAL=1539;DP=134,128,158;MQM=60	KIF1B	splice_region&intron,sequence_feature	KIF1B:NM_015074.3:splice_region&intron:LOW:exon17/46:c.1639+10C>T:,KIF1B:NM_183416.3:splice_region&intron:LOW:exon17/20:c.1639+10C>T:,KIF1B:NM_015074.3:sequence_feature:LOW::c.1639+10C>T:,KIF1B:NM_183416.3:sequence_feature:LOW::c.1639+10C>T:		rs3753037	0.2640	0.2787	4812/2788/179	0.2732							605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210|Pheochromocytoma,171300|Neuroblastoma,susceptibility to,1,256700];	RCV000154624.2 [benign]; RCV000305524.1 [benign]; RCV000341720.1 [benign]; RCV000402526.1 [benign]; 		COSM146392, COSM146391	120	567					KIF1B (inh=AD pLI=1.00)
chr1	10366487	10366487	T	G	wt	het	wt		QUAL=2585;DP=250,230,227;MQM=60	KIF1B	3'UTR,intron	KIF1B:NM_183416.3:3'UTR:MODIFIER:exon21/21:c.*1782T>G:,KIF1B:NM_015074.3:intron:MODIFIER:exon20/46:c.1977+9183T>G:		rs8019	0.3838	0.0000	0/0/0	0.0618							605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210|Pheochromocytoma,171300|Neuroblastoma,susceptibility to,1,256700];				27	96					KIF1B (inh=AD pLI=1.00)
chr1	10366692	10366692	C	G	wt	het	wt		QUAL=2910;DP=293,253,287;MQM=59	KIF1B	3'UTR,intron	KIF1B:NM_183416.3:3'UTR:MODIFIER:exon21/21:c.*1987C>G:,KIF1B:NM_015074.3:intron:MODIFIER:exon20/46:c.1977+9388C>G:	7SLRNA	rs4623	0.3343	0.0000	0/0/0	0.0534							605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210|Pheochromocytoma,171300|Neuroblastoma,susceptibility to,1,256700];				19	66					KIF1B (inh=AD pLI=1.00)
chr1	10367424	10367424	G	A	wt	het	wt		QUAL=343;DP=113,43,46;MQM=60	KIF1B	3'UTR,intron	KIF1B:NM_183416.3:3'UTR:MODIFIER:exon21/21:c.*2719G>A:,KIF1B:NM_015074.3:intron:MODIFIER:exon20/46:c.1977+10120G>A:	AluSx	rs2004034	0.2316	0.0000	0/0/0	0.2540							605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210|Pheochromocytoma,171300|Neuroblastoma,susceptibility to,1,256700];				17	88					KIF1B (inh=AD pLI=1.00)
chr1	10367591	10367591	T	C	wt	het	wt		QUAL=1134;DP=189,87,99;MQM=60	KIF1B	3'UTR,intron	KIF1B:NM_183416.3:3'UTR:MODIFIER:exon21/21:c.*2886T>C:,KIF1B:NM_015074.3:intron:MODIFIER:exon20/46:c.1977+10287T>C:	AluSx	rs1065828	0.3341	0.0000	0/0/0	0.3148							605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210|Pheochromocytoma,171300|Neuroblastoma,susceptibility to,1,256700];				25	86					KIF1B (inh=AD pLI=1.00)
chr1	10435324	10435324	C	A	het	het	het		QUAL=7247;DP=299,116,147;MQM=60	KIF1B	synonymous	KIF1B:NM_015074.3:synonymous:LOW:exon46/47:c.5163C>A:p.Thr1721Thr		rs11121552	0.2316	0.2717	4770/2846/50	0.2705							605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210|Pheochromocytoma,171300|Neuroblastoma,susceptibility to,1,256700];	RCV000117408.5 [other]; RCV000262668.1 [benign]; RCV000317736.1 [benign]; RCV000353894.1 [benign]; 		COSM146393	121	565					KIF1B (inh=AD pLI=1.00)
chr1	10436892	10436892	-	AC	het	het	wt		QUAL=4808;DP=130,110,126;MQM=59	KIF1B	3'UTR	KIF1B:NM_015074.3:3'UTR:MODIFIER:exon47/47:c.*279_*280dupCA:		rs146112447;rs769994641	0.0000	0.0000	0/0/0	0.0182							605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210|Pheochromocytoma,171300|Neuroblastoma,susceptibility to,1,256700];	RCV000300776.1 [uncertain significance]; RCV000336997.1 [uncertain significance]; RCV000406423.1 [uncertain significance]; RCV000285279.1 [uncertain significance]; RCV000340430.1 [uncertain significance]; RCV000407758.1 [uncertain significance]; RCV000288857.1 [uncertain significance]; RCV000343808.1 [uncertain significance]; RCV000379702.1 [uncertain significance]; 			0	15					KIF1B (inh=AD pLI=1.00)
chr1	10436924	10436924	C	T	het	wt	het		QUAL=4808;DP=130,110,126;MQM=59	KIF1B	3'UTR	KIF1B:NM_015074.3:3'UTR:MODIFIER:exon47/47:c.*279C>T:	(AC)n	rs78490707	0.0403	0.0000	0/0/0	0.0118							605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210|Pheochromocytoma,171300|Neuroblastoma,susceptibility to,1,256700];	RCV000313395.1 [likely benign]; RCV000334533.1 [likely benign]; RCV000391449.1 [likely benign]; 			0	6					KIF1B (inh=AD pLI=1.00)
chr1	10438006	10438006	A	T	het	het	wt		QUAL=1434;DP=82,59,73;MQM=59	KIF1B	3'UTR	KIF1B:NM_015074.3:3'UTR:MODIFIER:exon47/47:c.*1361A>T:	AluSg	rs2847347	0.0182	0.0000	0/0/0	0.0388							605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210|Pheochromocytoma,171300|Neuroblastoma,susceptibility to,1,256700];	RCV000273631.1 [likely benign]; RCV000313452.1 [likely benign]; RCV000370496.1 [likely benign]; 			1	27					KIF1B (inh=AD pLI=1.00)
chr1	10438687	10438687	C	T	het	het	het		QUAL=12161;DP=255,281,354;MQM=59	KIF1B	3'UTR	KIF1B:NM_015074.3:3'UTR:MODIFIER:exon47/47:c.*2042C>T:		rs1536262	0.5465	0.0000	0/0/0	0.0817							605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210|Pheochromocytoma,171300|Neuroblastoma,susceptibility to,1,256700];	RCV000264101.1 [benign]; RCV000321672.1 [benign]; RCV000361157.1 [benign]; 			75	163					KIF1B (inh=AD pLI=1.00)
chr1	10438892	10438892	G	A	het	het	het		QUAL=8905;DP=286,160,193;MQM=59	KIF1B	3'UTR	KIF1B:NM_015074.3:3'UTR:MODIFIER:exon47/47:c.*2247G>A:		rs1002076	0.3337	0.0000	0/0/0	0.0557							605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210|Pheochromocytoma,171300|Neuroblastoma,susceptibility to,1,256700];	RCV000263064.1 [benign]; RCV000315959.1 [benign]; RCV000373975.1 [benign]; 			26	104					KIF1B (inh=AD pLI=1.00)
chr1	10440556	10440556	A	G	het	het	het		QUAL=8674;DP=321,181,226;MQM=51	KIF1B	3'UTR	KIF1B:NM_015074.3:3'UTR:MODIFIER:exon47/47:c.*3911A>G:	AluSx	rs1138791	0.3488	0.0000	0/0/0	0.2200							605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210|Pheochromocytoma,171300|Neuroblastoma,susceptibility to,1,256700];	RCV000270484.1 [benign]; RCV000315156.1 [benign]; RCV000369878.1 [benign]; 			29	81					KIF1B (inh=AD pLI=1.00)
chr1	10441664	10441664	T	C	het	het	het		QUAL=13528;DP=457,272,349;MQM=60	KIF1B-PGD	intergenic_region	KIF1B-PGD:KIF1B-PGD:intergenic_region:MODIFIER::n.10441664T>C:		rs3748581	0.5270	0.0000	0/0/0	0.4740							605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210|Pheochromocytoma,171300|Neuroblastoma,susceptibility to,1,256700];	RCV000289173.1 [benign]; RCV000343588.1 [benign]; RCV000394684.1 [benign]; 			48	94					KIF1B-PGD (inh=n/a pLI=n/a)
chr1	11085004	11085004	-	TGTTT	het	het	hom		QUAL=16980;DP=384,258,272;MQM=59	TARDBP	3'UTR	TARDBP:NM_007375.3:3'UTR:MODIFIER:exon6/6:c.*2294_*2295insGTTTT:		rs3059695;rs5772439	0.9151	0.0000	0/0/0	0.7595							605078 [TARDBP (confirmed) Amyotrophic lateral sclerosis 10,with or without FTD,612069|Frontotemporal lobar degeneration,TARDBP-related,612069];	RCV000267829.1 [benign]; RCV000353235.1 [benign]; RCV000394679.1 [benign]; 			159	89					TARDBP (inh=AD pLI=0.98)
chr1	11846092	11846092	-	T	hom	hom	hom		QUAL=4482;DP=109,37,51;MQM=59	MTHFR,C1orf167	3'UTR,intron	MTHFR:NM_005957.4:3'UTR:MODIFIER:exon12/12:c.*4644dupA:,C1orf167:NM_001010881.1:intron:MODIFIER:exon16/20:c.3567+757dupT:		rs397709443	0.9513	0.0000	0/0/0	0.6457							607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250|Schizophrenia,susceptibility to,181500|Vascular disease,susceptibility to|Neural tube defects,susceptibility to,601634|Thromboembolism,susceptibility to,188050];	RCV000339671.1 [benign]; 			109	120					MTHFR (inh=AR pLI=0.00), C1orf167 (inh=n/a pLI=0.16)
chr1	11846252	11846252	G	A	hom	het	het		QUAL=14879;DP=330,159,182;MQM=59	MTHFR,C1orf167	3'UTR,intron	MTHFR:NM_005957.4:3'UTR:MODIFIER:exon12/12:c.*4485C>T:,C1orf167:NM_001010881.1:intron:MODIFIER:exon16/20:c.3567+906G>A:	Tigger15a	rs4846048	0.7065	0.0000	0/0/0	0.1252							607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250|Schizophrenia,susceptibility to,181500|Vascular disease,susceptibility to|Neural tube defects,susceptibility to,601634|Thromboembolism,susceptibility to,188050];	RCV000301152.1 [likely benign]; 			117	111					MTHFR (inh=AR pLI=0.00), C1orf167 (inh=n/a pLI=0.16)
chr1	11846447	11846447	G	A	hom	hom	hom		QUAL=25316;DP=383,182,216;MQM=60	MTHFR,C1orf167	3'UTR,intron	MTHFR:NM_005957.4:3'UTR:MODIFIER:exon12/12:c.*4290C>T:,C1orf167:NM_001010881.1:intron:MODIFIER:exon16/20:c.3568-998G>A:		rs4845884	0.9333	0.0000	0/0/0	0.1465							607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250|Schizophrenia,susceptibility to,181500|Vascular disease,susceptibility to|Neural tube defects,susceptibility to,601634|Thromboembolism,susceptibility to,188050];	RCV000405207.1 [benign]; 			261	0					MTHFR (inh=AR pLI=0.00), C1orf167 (inh=n/a pLI=0.16)
chr1	11846660	11846663	TTTT	-	hom	hom	hom		QUAL=1919;DP=83,30,38;MQM=57	MTHFR,C1orf167	3'UTR,intron	MTHFR:NM_005957.4:3'UTR:MODIFIER:exon12/12:c.*4074_*4077delAAAA:,C1orf167:NM_001010881.1:intron:MODIFIER:exon16/20:c.3568-770_3568-767delTTTT:	AluJr	rs55780505;rs796422158	0.7772	0.0000	0/0/0	0.4441							607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250|Schizophrenia,susceptibility to,181500|Vascular disease,susceptibility to|Neural tube defects,susceptibility to,601634|Thromboembolism,susceptibility to,188050];	RCV000308474.1 [likely benign]; 			43	79					MTHFR (inh=AR pLI=0.00), C1orf167 (inh=n/a pLI=0.16)
chr1	11847334	11847334	-	GAA	hom	het	het		QUAL=9728;DP=231,133,222;MQM=59	MTHFR,C1orf167	3'UTR,intron	MTHFR:NM_005957.4:3'UTR:MODIFIER:exon12/12:c.*3400_*3402dupTTC:,C1orf167:NM_001010881.1:intron:MODIFIER:exon16/20:c.3568-108_3568-106dupAGA:		rs113394969;rs70983598	0.5701	0.0000	0/0/0	0.5640							607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250|Schizophrenia,susceptibility to,181500|Vascular disease,susceptibility to|Neural tube defects,susceptibility to,601634|Thromboembolism,susceptibility to,188050];				116	156					MTHFR (inh=AR pLI=0.00), C1orf167 (inh=n/a pLI=0.16)
chr1	11847759	11847759	C	T	hom	het	het		QUAL=12117;DP=201,245,294;MQM=59	MTHFR,C1orf167	3'UTR,intron	MTHFR:NM_005957.4:3'UTR:MODIFIER:exon12/12:c.*2978G>A:,C1orf167:NM_001010881.1:intron:MODIFIER:exon17/20:c.3674-171C>T:		rs3737966	0.5585	0.0000	0/0/0	0.6176							607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250|Schizophrenia,susceptibility to,181500|Vascular disease,susceptibility to|Neural tube defects,susceptibility to,601634|Thromboembolism,susceptibility to,188050];	RCV000309373.1 [likely benign]; 			115	164					MTHFR (inh=AR pLI=0.00), C1orf167 (inh=n/a pLI=0.16)
chr1	11848139	11848139	G	A	wt	het	het		QUAL=2672;DP=125,85,122;MQM=60	MTHFR,C1orf167	3'UTR,intron	MTHFR:NM_005957.4:3'UTR:MODIFIER:exon12/12:c.*2598C>T:,C1orf167:NM_001010881.1:intron:MODIFIER:exon18/20:c.3848+35G>A:		rs11559040	0.1268	0.2368	372/105/1	0.0511							607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250|Schizophrenia,susceptibility to,181500|Vascular disease,susceptibility to|Neural tube defects,susceptibility to,601634|Thromboembolism,susceptibility to,188050];	RCV000385841.1 [likely benign]; 			66	366					MTHFR (inh=AR pLI=0.00), C1orf167 (inh=n/a pLI=0.16)
chr1	11848879	11848879	A	G	hom	hom	hom		QUAL=19089;DP=250,151,217;MQM=59	MTHFR,C1orf167	3'UTR,intron	MTHFR:NM_005957.4:3'UTR:MODIFIER:exon12/12:c.*1858T>C:,C1orf167:NM_001010881.1:intron:MODIFIER:exon20/20:c.4173+76A>G:		rs2077360	0.9305	0.0000	0/0/0	0.1471							607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250|Schizophrenia,susceptibility to,181500|Vascular disease,susceptibility to|Neural tube defects,susceptibility to,601634|Thromboembolism,susceptibility to,188050];	RCV000404791.1 [benign]; 			391	2					MTHFR (inh=AR pLI=0.00), C1orf167 (inh=n/a pLI=0.16)
chr1	11849447	11849447	A	G	hom	hom	hom		QUAL=17848;DP=153,188,227;MQM=59	C1orf167,MTHFR	missense,3'UTR	C1orf167:NM_001010881.1:missense:MODERATE:exon21/21:c.4294A>G:p.Arg1432Gly,MTHFR:NM_005957.4:3'UTR:MODIFIER:exon12/12:c.*1290T>C:		rs868014	0.9329	0.9871	7319/2565/292	0.2955	-4.9500	.,.,.,T	T,T	.,B	.,T	1.61	607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250|Schizophrenia,susceptibility to,181500|Vascular disease,susceptibility to|Neural tube defects,susceptibility to,601634|Thromboembolism,susceptibility to,188050];	RCV000277799.1 [benign]; 		COSM4142235, COSM4142236	1089	8					C1orf167 (inh=n/a pLI=0.16), MTHFR (inh=AR pLI=0.00)
chr1	11850365	11850365	T	G	hom	het	het		QUAL=18960;DP=314,351,383;MQM=59	MTHFR	3'UTR	MTHFR:NM_005957.4:3'UTR:MODIFIER:exon12/12:c.*372A>C:		rs4846049	0.6284	0.0000	0/0/0	0.1056							607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250|Schizophrenia,susceptibility to,181500|Vascular disease,susceptibility to|Neural tube defects,susceptibility to,601634|Thromboembolism,susceptibility to,188050];	RCV000405126.1 [likely benign]; 	CR125703 [CLASS=DFP MUT=REF PHEN="Coronary heart disease increased risk association with" GENE=MTHFR]; 		109	118					MTHFR (inh=AR pLI=0.00)
chr1	11854457	11854457	G	A	hom	hom	hom		QUAL=18571;DP=121,205,264;MQM=60	MTHFR	synonymous	MTHFR:NM_005957.4:synonymous:LOW:exon8/12:c.1305C>T:p.Phe435Phe		rs4846051	0.9030	0.9697	57567/33195/2451	0.9399							607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250|Schizophrenia,susceptibility to,181500|Vascular disease,susceptibility to|Neural tube defects,susceptibility to,601634|Thromboembolism,susceptibility to,188050];	RCV000153514.3 [benign]; RCV000293357.1 [benign]; 	CM044675 [CLASS=DP MUT=REF PHEN="Preeclampsia association with" GENE=MTHFR]; 		1665	19					MTHFR (inh=AR pLI=0.00)
chr1	11854476	11854476	T	G	wt	het	het	pred_pathogenic	QUAL=7158;DP=169,228,287;MQM=60	MTHFR	missense	MTHFR:NM_005957.4:missense:MODERATE:exon8/12:c.1286A>C:p.Glu429Ala		rs1801131	0.2494	0.2950	5872/3485/147	0.2898	3.7920	T,T,T,T	T	B,B	T,T,T,T	19.89	607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250|Schizophrenia,susceptibility to,181500|Vascular disease,susceptibility to|Neural tube defects,susceptibility to,601634|Thromboembolism,susceptibility to,188050];	RCV000003698.3 [benign]; RCV000003699.3 [other]; RCV000144922.1 [uncertain significance]; RCV000153515.4 [other]; RCV000211350.1 [drug response]; RCV000350590.1 [likely benign]; 	CM981315 [CLASS=DFP MUT=ALT PHEN="Neural tube defect increased risk association with" GENE=MTHFR]; 	COSM3735923, COSM3735924	214	739					MTHFR (inh=AR pLI=0.00)
chr1	12009955	12009955	C	T	het	het	het		QUAL=6861;DP=124,190,248;MQM=59	PLOD1	synonymous	PLOD1:NM_001316320.1:synonymous:LOW:exon4/20:c.435C>T:p.Phe145Phe,PLOD1:NM_000302.3:synonymous:LOW:exon3/19:c.294C>T:p.Phe98Phe		rs7529452	0.2678	0.3281	7178/3488/33	0.3168							153454 [PLOD1 (provisional) Ehlers-Danlos syndrome,type VI,225400];	RCV000243254.1 [benign]; RCV000370739.1 [benign]; 		COSM3996779, COSM3996782, COSM3996781, COSM3996780	173	661					PLOD1 (inh=AR pLI=0.00)
chr1	12009956	12009956	G	A	wt	het	wt		QUAL=2008;DP=148,188,243;MQM=60	PLOD1	missense	PLOD1:NM_001316320.1:missense:MODERATE:exon4/20:c.436G>A:p.Ala146Thr,PLOD1:NM_000302.3:missense:MODERATE:exon3/19:c.295G>A:p.Ala99Thr		rs7551175	0.2995	0.1934	3109/830/1533	0.1891	1.4470	T,T,T,T,T,T	T	B,B	T,T,T,T	12.95	153454 [PLOD1 (provisional) Ehlers-Danlos syndrome,type VI,225400];	RCV000177032.2 [benign]; RCV000276149.1 [benign]; 	CM068658 [CLASS=DP MUT=ALT PHEN="Bone mineral density association with" GENE=PLOD1]; 	COSM3750286, COSM3750287, COSM3750288, COSM3750285	41	413					PLOD1 (inh=AR pLI=0.00)
chr1	12024235	12024235	C	T	het	het	het	low_DP	QUAL=1188;DP=19,36,54;MQM=59	PLOD1	synonymous	PLOD1:NM_001316320.1:synonymous:LOW:exon13/20:c.1347C>T:p.Asn449Asn,PLOD1:NM_000302.3:synonymous:LOW:exon12/19:c.1206C>T:p.Asn402Asn		rs1130529	0.3484	0.3631	8340/3773/429	0.3478							153454 [PLOD1 (provisional) Ehlers-Danlos syndrome,type VI,225400];	RCV000252620.2 [benign]; RCV000350343.1 [benign]; 		COSM3996784, COSM3996785	177	678					PLOD1 (inh=AR pLI=0.00)
chr1	12040324	12040324	A	G	het	hom	het		QUAL=4167;DP=34,101,123;MQM=60	MFN2	5'UTR	MFN2:NM_001127660.1:5'UTR:MODIFIER:exon1/18:c.-222A>G:,MFN2:NM_014874.3:5'UTR:MODIFIER:exon1/19:c.-367A>G:		rs2236054	0.5729	0.0000	0/0/0	0.4549							608507 [MFN2 (confirmed) Charcot-Marie-Tooth disease,axonal,type 2A2A,609260|Hereditary motor and sensory neuropathy VIA,601152|Charcot-Marie-Tooth disease,axonal,type 2A2B,617087];	RCV000293763.1 [benign]; RCV000331244.1 [benign]; RCV000337093.1 [benign]; 			44	121					MFN2 (inh=AR+AD pLI=1.00)
chr1	12040479	12040479	T	C	het	hom	het		QUAL=5233;DP=57,112,130;MQM=60	MFN2	5'UTR	MFN2:NM_001127660.1:5'UTR:MODIFIER:exon1/18:c.-67T>C:,MFN2:NM_014874.3:5'UTR:MODIFIER:exon1/19:c.-212T>C:		rs2180183	0.6100	0.0000	0/0/0	0.4980							608507 [MFN2 (confirmed) Charcot-Marie-Tooth disease,axonal,type 2A2A,609260|Hereditary motor and sensory neuropathy VIA,601152|Charcot-Marie-Tooth disease,axonal,type 2A2B,617087];	RCV000332649.1 [benign]; RCV000370987.1 [benign]; RCV000387990.1 [benign]; 			46	120					MFN2 (inh=AR+AD pLI=1.00)
chr1	12071680	12071680	A	G	hom	hom	hom		QUAL=29308;DP=257,322,418;MQM=59	MFN2	3'UTR	MFN2:NM_001127660.1:3'UTR:MODIFIER:exon18/18:c.*58A>G:,MFN2:NM_014874.3:3'UTR:MODIFIER:exon19/19:c.*58A>G:		rs1042842	0.7324	0.0000	0/0/0	0.1320							608507 [MFN2 (confirmed) Charcot-Marie-Tooth disease,axonal,type 2A2A,609260|Hereditary motor and sensory neuropathy VIA,601152|Charcot-Marie-Tooth disease,axonal,type 2A2B,617087];	RCV000275398.1 [benign]; RCV000330515.1 [benign]; 			405	443					MFN2 (inh=AR+AD pLI=1.00)
chr1	12072518	12072518	G	C	hom	hom	hom		QUAL=12885;DP=112,143,173;MQM=59	MFN2	3'UTR	MFN2:NM_001127660.1:3'UTR:MODIFIER:exon18/18:c.*896G>C:,MFN2:NM_014874.3:3'UTR:MODIFIER:exon19/19:c.*896G>C:		rs3088064	0.5441	0.0000	0/0/0	0.0960							608507 [MFN2 (confirmed) Charcot-Marie-Tooth disease,axonal,type 2A2A,609260|Hereditary motor and sensory neuropathy VIA,601152|Charcot-Marie-Tooth disease,axonal,type 2A2B,617087];	RCV000321687.1 [benign]; RCV000376417.1 [benign]; 			97	127					MFN2 (inh=AR+AD pLI=1.00)
chr1	12072534	12072534	C	T	wt	het	wt		QUAL=1666;DP=107,145,190;MQM=60	MFN2	3'UTR	MFN2:NM_001127660.1:3'UTR:MODIFIER:exon18/18:c.*912C>T:,MFN2:NM_014874.3:3'UTR:MODIFIER:exon19/19:c.*912C>T:		rs14305	0.0843	0.0000	0/0/0	0.0131							608507 [MFN2 (confirmed) Charcot-Marie-Tooth disease,axonal,type 2A2A,609260|Hereditary motor and sensory neuropathy VIA,601152|Charcot-Marie-Tooth disease,axonal,type 2A2B,617087];	RCV000286750.1 [likely benign]; RCV000323029.1 [likely benign]; 			2	36					MFN2 (inh=AR+AD pLI=1.00)
chr1	16371067	16371067	G	T	het	hom	hom	low_DP;pred_pathogenic	QUAL=234;DP=4,1,5;MQM=60	CLCNKB	missense	CLCNKB:NM_000085.4:missense:MODERATE:exon2/20:c.80G>T:p.Arg27Leu		rs2015352	0.5555	0.6413	18450/10701/377	0.5711	-0.4670	D,D	T	B	D	24.00	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364|Bartter syndrome,type 4b,digenic,613090];			COSM3750546	645	656					CLCNKB (inh=AR pLI=0.00)
chr1	16373124	16373124	A	G	hom	hom	hom		QUAL=23237;DP=186,249,312;MQM=59	CLCNKB	synonymous	CLCNKB:NM_000085.4:synonymous:LOW:exon4/20:c.324A>G:p.Ser108Ser		rs5257	0.7404	0.8022	40313/21921/836	0.7831							602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364|Bartter syndrome,type 4b,digenic,613090];				1059	448					CLCNKB (inh=AR pLI=0.00)
chr1	16374533	16374533	G	C	hom	hom	hom	low_DP	QUAL=383;DP=5,5,3;MQM=60	CLCNKB	synonymous	CLCNKB:NM_000085.4:synonymous:LOW:exon5/20:c.492G>C:p.Gly164Gly		rs2014562	0.8940	0.9298	52555/29576/3019	0.9087							602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364|Bartter syndrome,type 4b,digenic,613090];				1347	177					CLCNKB (inh=AR pLI=0.00)
chr1	16374994	16374994	C	T	hom	hom	hom	low_MQM	QUAL=18061;DP=162,204,246;MQM=46	CLCNKB	splice_region&intron	CLCNKB:NM_000085.4:splice_region&intron:LOW:exon6/19:c.577-5C>T:		rs34666902	0.7386	0.8008	40086/21748/810	0.7275							602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364|Bartter syndrome,type 4b,digenic,613090];				1051	451					CLCNKB (inh=AR pLI=0.00)
chr1	16375063	16375063	C	G	hom	hom	hom	pred_pathogenic	QUAL=17380;DP=195,174,218;MQM=52	CLCNKB	missense	CLCNKB:NM_000085.4:missense:MODERATE:exon7/20:c.641C>G:p.Ala214Gly		rs45612832	0.8273	0.9006	49725/28393/1668	0.7830	-0.0370	T	T	B	D	0.36	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364|Bartter syndrome,type 4b,digenic,613090];				1329	216					CLCNKB (inh=AR pLI=0.00)
chr1	16375064	16375064	A	C	hom	hom	hom		QUAL=17380;DP=195,174,218;MQM=52	CLCNKB	synonymous	CLCNKB:NM_000085.4:synonymous:LOW:exon7/20:c.642A>C:p.Ala214Ala		rs1889790;rs45575235	0.8273	0.9006	49718/28392/1667	0.7821							602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364|Bartter syndrome,type 4b,digenic,613090];				1329	216					CLCNKB (inh=AR pLI=0.00)
chr1	16375354	16375354	C	T	hom	hom	hom		QUAL=19099;DP=180,203,238;MQM=59	CLCNKB	5'UTR,intron	CLCNKB:NM_001165945.2:5'UTR:MODIFIER:exon1/13:c.-113C>T:,CLCNKB:NM_000085.4:intron:MODIFIER:exon7/19:c.656-261C>T:	MIR	rs9442227	0.7274	0.0000	0/0/0	0.1226							602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364|Bartter syndrome,type 4b,digenic,613090];				147	69					CLCNKB (inh=AR pLI=0.00)
chr1	16376191	16376191	C	T	hom	hom	hom	low_MQM;pred_pathogenic	QUAL=25793;DP=188,314,406;MQM=46	CLCNKB	missense	CLCNKB:NM_000085.4:missense:MODERATE:exon9/20:c.860C>T:p.Ala287Val,CLCNKB:NM_001165945.2:missense:MODERATE:exon2/13:c.353C>T:p.Ala118Val		rs34188929	0.8299	0.9096	49342/28428/1594	0.7882	-0.3350	T,T	T	B,B	D,D	0.01	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364|Bartter syndrome,type 4b,digenic,613090];			COSM4142953, COSM4142952	1354	187					CLCNKB (inh=AR pLI=0.00)
chr1	16376319	16376319	T	C	hom	hom	hom		QUAL=33079;DP=194,362,486;MQM=59	CLCNKB	synonymous	CLCNKB:NM_000085.4:synonymous:LOW:exon10/20:c.876T>C:p.Cys292Cys,CLCNKB:NM_001165945.2:synonymous:LOW:exon3/13:c.369T>C:p.Cys123Cys		rs7368151	0.8301	0.9114	51203/29597/1694	0.8821							602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364|Bartter syndrome,type 4b,digenic,613090];			COSM4142955, COSM4142954	1359	189					CLCNKB (inh=AR pLI=0.00)
chr1	16378739	16378739	G	A	wt	het	wt	low_DP	QUAL=107;DP=27,22,16;MQM=60	CLCNKB	synonymous	CLCNKB:NM_000085.4:synonymous:LOW:exon15/20:c.1455G>A:p.Ala485Ala,CLCNKB:NM_001165945.2:synonymous:LOW:exon8/13:c.948G>A:p.Ala316Ala		rs34652156	0.0302	0.0270	77/38/18	0.0257							602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364|Bartter syndrome,type 4b,digenic,613090];				3	74					CLCNKB (inh=AR pLI=0.00)
chr1	16380196	16380196	T	C	hom	hom	hom	pred_pathogenic	QUAL=28369;DP=304,253,369;MQM=51	CLCNKB	missense	CLCNKB:NM_000085.4:missense:MODERATE:exon16/20:c.1685T>C:p.Met562Thr,CLCNKB:NM_001165945.2:missense:MODERATE:exon9/13:c.1178T>C:p.Met393Thr		rs5253	0.8383	0.9310	52942/31936/2492	0.9081	-0.9230	T,T,T,T	T	B,B	D,D,D	0.01	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364|Bartter syndrome,type 4b,digenic,613090];				1477	86					CLCNKB (inh=AR pLI=0.00)
chr1	16380243	16380243	A	G	hom	het	hom	low_MQM;pred_pathogenic;anno_pathogenic_hgmd	QUAL=15409;DP=132,233,311;MQM=48	CLCNKB	missense	CLCNKB:NM_000085.4:missense:MODERATE:exon16/20:c.1732A>G:p.Lys578Glu,CLCNKB:NM_001165945.2:missense:MODERATE:exon9/13:c.1225A>G:p.Lys409Glu		rs2275166	0.7017	0.6586	26455/14211/3279	0.6456	0.8530	T,T,T,T	T	B,B	D,D,D	4.33	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364|Bartter syndrome,type 4b,digenic,613090];		CM1514575 [CLASS=DM? MUT=ALT PHEN="Migraine without aura" GENE=CLCNKB]; 		665	684	1	[1] swoedl 28.06.2016			CLCNKB (inh=AR pLI=0.00)
chr1	16380252	16380252	C	T	hom	het	hom	low_MQM	QUAL=14431;DP=124,219,302;MQM=48	CLCNKB	synonymous	CLCNKB:NM_000085.4:synonymous:LOW:exon16/20:c.1741C>T:p.Leu581Leu,CLCNKB:NM_001165945.2:synonymous:LOW:exon9/13:c.1234C>T:p.Leu412Leu		rs2275167	0.6136	0.6210	23581/13624/1758	0.6095							602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364|Bartter syndrome,type 4b,digenic,613090];				622	700					CLCNKB (inh=AR pLI=0.00)
chr1	16383402	16383402	C	T	het	wt	wt	low_MQM	QUAL=650;DP=261,140,143;MQM=34	CLCNKB	synonymous	CLCNKB:NM_000085.4:synonymous:LOW:exon20/20:c.2055C>T:p.Ala685Ala,CLCNKB:NM_001165945.2:synonymous:LOW:exon13/13:c.1545C>T:p.Ala515Ala		rs6698427	0.0000	0.0010	1/0/1	0.0003							602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364|Bartter syndrome,type 4b,digenic,613090];				0	17					CLCNKB (inh=AR pLI=0.00)
chr1	16383448	16383448	A	C	het	hom	hom	low_MQM	QUAL=15861;DP=219,241,290;MQM=40	CLCNKB	3'UTR	CLCNKB:NM_000085.4:3'UTR:MODIFIER:exon20/20:c.*37A>C:,CLCNKB:NM_001165945.2:3'UTR:MODIFIER:exon13/13:c.*37A>C:		rs10803415	0.9010	0.9401	50420/29364/4051	0.8222							602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364|Bartter syndrome,type 4b,digenic,613090];				712	195					CLCNKB (inh=AR pLI=0.00)
chr1	16383547	16383547	T	C	wt	wt	het	low_MQM	QUAL=529;DP=238,399,597;MQM=31	CLCNKB	3'UTR	CLCNKB:NM_000085.4:3'UTR:MODIFIER:exon20/20:c.*136T>C:,CLCNKB:NM_001165945.2:3'UTR:MODIFIER:exon13/13:c.*136T>C:		rs1057839	0.0000	0.0000	0/0/0	0.0013							602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364|Bartter syndrome,type 4b,digenic,613090];				0	51					CLCNKB (inh=AR pLI=0.00)
chr1	16383574	16383574	A	T	het	wt	het	low_MQM	QUAL=889;DP=247,381,616;MQM=32	CLCNKB	3'UTR	CLCNKB:NM_000085.4:3'UTR:MODIFIER:exon20/20:c.*163A>T:,CLCNKB:NM_001165945.2:3'UTR:MODIFIER:exon13/13:c.*163A>T:		rs1057841	0.0000	0.0000	0/0/0	0.0071							602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364|Bartter syndrome,type 4b,digenic,613090];				0	85					CLCNKB (inh=AR pLI=0.00)
chr1	16383581	16383581	G	T	het	het	het	low_MQM	QUAL=19835;DP=250,383,618;MQM=37	CLCNKB	3'UTR	CLCNKB:NM_000085.4:3'UTR:MODIFIER:exon20/20:c.*170G>T:,CLCNKB:NM_001165945.2:3'UTR:MODIFIER:exon13/13:c.*170G>T:		rs1057844	0.0000	0.0000	0/0/0	0.1624							602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364|Bartter syndrome,type 4b,digenic,613090];				70	291					CLCNKB (inh=AR pLI=0.00)
chr1	16383605	16383605	A	G	het	het	het	low_MQM	QUAL=19776;DP=200,403,647;MQM=37	CLCNKB	3'UTR	CLCNKB:NM_000085.4:3'UTR:MODIFIER:exon20/20:c.*194A>G:,CLCNKB:NM_001165945.2:3'UTR:MODIFIER:exon13/13:c.*194A>G:		rs1057845	0.0000	0.0000	0/0/0	0.1193							602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364|Bartter syndrome,type 4b,digenic,613090];				56	320					CLCNKB (inh=AR pLI=0.00)
chr1	16383668	16383668	T	G	hom	hom	hom	low_MQM	QUAL=32767;DP=174,360,661;MQM=41	CLCNKB	3'UTR	CLCNKB:NM_000085.4:3'UTR:MODIFIER:exon20/20:c.*257T>G:,CLCNKB:NM_001165945.2:3'UTR:MODIFIER:exon13/13:c.*257T>G:		rs6660218	1.0000	0.9999	7654/2609/519	0.2301							602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364|Bartter syndrome,type 4b,digenic,613090];				1097	0					CLCNKB (inh=AR pLI=0.00)
chr1	16383682	16383682	G	C	het	wt	het	low_MQM;pred_pathogenic;anno_pathogenic_hgmd	QUAL=4435;DP=223,322,651;MQM=41	CLCNKB	3'UTR	CLCNKB:NM_000085.4:3'UTR:MODIFIER:exon20/20:c.*271G>C:,CLCNKB:NM_001165945.2:3'UTR:MODIFIER:exon13/13:c.*271G>C:		rs1057854	0.0000	0.3197	10/0/8	0.0088	-3.2740	D	T			0.06	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364|Bartter syndrome,type 4b,digenic,613090];		CR133355 [CLASS=DM? MUT=REF PHEN="Bartter syndrome 3" GENE=CLCNKB]; 		0	658	1	[1] Ute Grasshoff 13.08.2014			CLCNKB (inh=AR pLI=0.00)
chr1	16383742	16383742	C	G	het	hom	het		QUAL=18366;DP=357,224,519;MQM=57	CLCNKB	3'UTR	CLCNKB:NM_000085.4:3'UTR:MODIFIER:exon20/20:c.*331C>G:,CLCNKB:NM_001165945.2:3'UTR:MODIFIER:exon13/13:c.*331C>G:		rs1057857	0.0000	0.6207	2104/825/99	0.0503	-0.3020	T,T,T	T		T	4.97	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364|Bartter syndrome,type 4b,digenic,613090];			COSM4142956	308	785					CLCNKB (inh=AR pLI=0.00)
chr1	17312743	17312743	C	T	het	hom	het	low_DP;pred_pathogenic	QUAL=772;DP=23,19,25;MQM=59	ATP13A2	missense,synonymous	ATP13A2:NM_001141974.2:missense:MODERATE:exon27/27:c.3214G>A:p.Ala1072Thr,ATP13A2:NM_022089.3:synonymous:LOW:exon29/29:c.3516G>A:p.Pro1172Pro,ATP13A2:NM_001141973.2:synonymous:LOW:exon29/29:c.3501G>A:p.Pro1167Pro		rs3170740	0.3313	0.5065	12467/8266/189	0.4263	-2.5480	T,T	T	B	D,D	10.40	610513 [ATP13A2 (confirmed) Kufor-Rakeb syndrome,606693|Spastic paraplegia 78,autosomal recessive,617225];	RCV000116444.3 [benign]; RCV000336632.1 [benign]; 		COSM3750607, COSM3750606	589	1086					ATP13A2 (inh=AR pLI=0.00)
chr1	17313343	17313343	G	A	het	hom	het		QUAL=10735;DP=99,200,283;MQM=59	ATP13A2	synonymous	ATP13A2:NM_022089.3:synonymous:LOW:exon27/29:c.3192C>T:p.Ala1064Ala,ATP13A2:NM_001141973.2:synonymous:LOW:exon27/29:c.3177C>T:p.Ala1059Ala,ATP13A2:NM_001141974.2:synonymous:LOW:exon26/27:c.3060C>T:p.Ala1020Ala		rs9435659	0.3385	0.4648	13360/8833/197	0.4508							610513 [ATP13A2 (confirmed) Kufor-Rakeb syndrome,606693|Spastic paraplegia 78,autosomal recessive,617225];	RCV000116442.2 [benign]; RCV000309613.1 [benign]; 		COSM3747591, COSM3747592	596	1086					ATP13A2 (inh=AR pLI=0.00)
chr1	17313454	17313454	G	A	het	wt	het		QUAL=2372;DP=64,138,177;MQM=59	ATP13A2	splice_region&intron	ATP13A2:NM_022089.3:splice_region&intron:LOW:exon26/28:c.3084-3C>T:,ATP13A2:NM_001141973.2:splice_region&intron:LOW:exon26/28:c.3069-3C>T:,ATP13A2:NM_001141974.2:splice_region&intron:LOW:exon25/26:c.2952-3C>T:		rs7531163	0.3065	0.2739	5114/1978/157	0.2721							610513 [ATP13A2 (confirmed) Kufor-Rakeb syndrome,606693|Spastic paraplegia 78,autosomal recessive,617225];	RCV000116440.2 [benign]; RCV000324328.1 [benign]; 			122	827					ATP13A2 (inh=AR pLI=0.00)
chr1	17313654	17313654	C	T	het	hom	het		QUAL=10630;DP=71,245,280;MQM=60	ATP13A2	synonymous	ATP13A2:NM_022089.3:synonymous:LOW:exon26/29:c.2970G>A:p.Val990Val,ATP13A2:NM_001141973.2:synonymous:LOW:exon26/29:c.2955G>A:p.Val985Val,ATP13A2:NM_001141974.2:synonymous:LOW:exon25/27:c.2838G>A:p.Val946Val		rs761421	0.3462	0.4639	13375/8738/258	0.4399							610513 [ATP13A2 (confirmed) Kufor-Rakeb syndrome,606693|Spastic paraplegia 78,autosomal recessive,617225];	RCV000116439.2 [benign]; RCV000360410.1 [benign]; 		COSM3750609, COSM3750608	592	1090					ATP13A2 (inh=AR pLI=0.00)
chr1	17314702	17314702	C	T	het	wt	het		QUAL=11025;DP=286,497,583;MQM=60	ATP13A2	synonymous	ATP13A2:NM_022089.3:synonymous:LOW:exon25/29:c.2790G>A:p.Ser930Ser,ATP13A2:NM_001141973.2:synonymous:LOW:exon25/29:c.2775G>A:p.Ser925Ser,ATP13A2:NM_001141974.2:synonymous:LOW:exon24/27:c.2658G>A:p.Ser886Ser		rs3738815	0.2909	0.2414	4267/1325/125	0.2410							610513 [ATP13A2 (confirmed) Kufor-Rakeb syndrome,606693|Spastic paraplegia 78,autosomal recessive,617225];	RCV000116437.2 [benign]; RCV000281364.1 [benign]; 		COSM3750611, COSM3750610	96	702					ATP13A2 (inh=AR pLI=0.00)
chr1	17314942	17314942	G	A	het	hom	het		QUAL=14158;DP=313,263,322;MQM=59	ATP13A2	synonymous	ATP13A2:NM_022089.3:synonymous:LOW:exon24/29:c.2637C>T:p.Gly879Gly,ATP13A2:NM_001141973.2:synonymous:LOW:exon24/29:c.2622C>T:p.Gly874Gly,ATP13A2:NM_001141974.2:synonymous:LOW:exon23/27:c.2505C>T:p.Gly835Gly		rs9435662	0.3387	0.4590	13485/8859/203	0.4503							610513 [ATP13A2 (confirmed) Kufor-Rakeb syndrome,606693|Spastic paraplegia 78,autosomal recessive,617225];	RCV000116435.2 [benign]; RCV000331660.1 [benign]; 		COSM3750613, COSM3750612	593	1089					ATP13A2 (inh=AR pLI=0.00)
chr1	17319011	17319011	G	A	het	hom	het		QUAL=6564;DP=83,126,152;MQM=60	ATP13A2	synonymous	ATP13A2:NM_022089.3:synonymous:LOW:exon17/29:c.1815C>T:p.Pro605Pro,ATP13A2:NM_001141973.2:synonymous:LOW:exon17/29:c.1800C>T:p.Pro600Pro,ATP13A2:NM_001141974.2:synonymous:LOW:exon17/27:c.1800C>T:p.Pro600Pro		rs2076603	0.4485	0.5540	19279/12838/984	0.5496							610513 [ATP13A2 (confirmed) Kufor-Rakeb syndrome,606693|Spastic paraplegia 78,autosomal recessive,617225];	RCV000116434.2 [benign]; RCV000299686.1 [benign]; 		COSM3997076, COSM3997075	821	1017					ATP13A2 (inh=AR pLI=0.00)
chr1	17331268	17331268	C	T	wt	het	wt		QUAL=639;DP=141,74,122;MQM=60	ATP13A2	synonymous	ATP13A2:NM_022089.3:synonymous:LOW:exon5/29:c.396G>A:p.Ala132Ala,ATP13A2:NM_001141973.2:synonymous:LOW:exon5/29:c.396G>A:p.Ala132Ala,ATP13A2:NM_001141974.2:synonymous:LOW:exon5/27:c.396G>A:p.Ala132Ala		rs140631323	0.0000	0.0001	0/0/0	0.0001	-4.6690		T			15.96	610513 [ATP13A2 (confirmed) Kufor-Rakeb syndrome,606693|Spastic paraplegia 78,autosomal recessive,617225];	RCV000275889.1 [uncertain significance]; 			0	5					ATP13A2 (inh=AR pLI=0.00)
chr1	19198064	19198064	T	G	het	wt	het		QUAL=3432;DP=98,149,185;MQM=59	ALDH4A1	3'UTR	ALDH4A1:NM_003748.3:3'UTR:MODIFIER:exon15/15:c.*1275A>C:,ALDH4A1:NM_001161504.1:3'UTR:MODIFIER:exon15/15:c.*1275A>C:,ALDH4A1:NM_001319218.1:3'UTR:MODIFIER:exon14/14:c.*1275A>C:,ALDH4A1:NM_170726.2:3'UTR:MODIFIER:exon16/16:c.*262A>C:		rs1138333	0.1793	0.0000	0/0/0	0.0378							606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	RCV000395442.1 [likely benign]; 			18	96					ALDH4A1 (inh=AR pLI=0.00)
chr1	19198100	19198100	C	G	het	wt	het		QUAL=3434;DP=99,144,166;MQM=59	ALDH4A1	3'UTR	ALDH4A1:NM_003748.3:3'UTR:MODIFIER:exon15/15:c.*1239G>C:,ALDH4A1:NM_001161504.1:3'UTR:MODIFIER:exon15/15:c.*1239G>C:,ALDH4A1:NM_001319218.1:3'UTR:MODIFIER:exon14/14:c.*1239G>C:,ALDH4A1:NM_170726.2:3'UTR:MODIFIER:exon16/16:c.*226G>C:		rs1138328	0.1651	0.0000	0/0/0	0.0366							606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	RCV000305397.1 [likely benign]; 			18	94					ALDH4A1 (inh=AR pLI=0.00)
chr1	19198141	19198141	T	C	het	wt	het		QUAL=3367;DP=121,139,146;MQM=60	ALDH4A1	3'UTR	ALDH4A1:NM_003748.3:3'UTR:MODIFIER:exon15/15:c.*1198A>G:,ALDH4A1:NM_001161504.1:3'UTR:MODIFIER:exon15/15:c.*1198A>G:,ALDH4A1:NM_001319218.1:3'UTR:MODIFIER:exon14/14:c.*1198A>G:,ALDH4A1:NM_170726.2:3'UTR:MODIFIER:exon16/16:c.*185A>G:		rs7366541	0.1799	0.0000	0/0/0	0.0379							606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	RCV000390012.1 [likely benign]; 			18	91					ALDH4A1 (inh=AR pLI=0.00)
chr1	19198414	19198414	G	A	het	wt	het		QUAL=4601;DP=171,168,195;MQM=59	ALDH4A1	3'UTR,intron	ALDH4A1:NM_003748.3:3'UTR:MODIFIER:exon15/15:c.*925C>T:,ALDH4A1:NM_001161504.1:3'UTR:MODIFIER:exon15/15:c.*925C>T:,ALDH4A1:NM_001319218.1:3'UTR:MODIFIER:exon14/14:c.*925C>T:,ALDH4A1:NM_170726.2:intron:MODIFIER:exon15/15:c.*42-130C>T:		rs1140477	0.1935	0.0000	0/0/0	0.0384							606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	RCV000369725.1 [likely benign]; 			13	63					ALDH4A1 (inh=AR pLI=0.00)
chr1	19198418	19198418	C	T	het	wt	het		QUAL=4601;DP=171,168,195;MQM=59	ALDH4A1	3'UTR,intron	ALDH4A1:NM_003748.3:3'UTR:MODIFIER:exon15/15:c.*921G>A:,ALDH4A1:NM_001161504.1:3'UTR:MODIFIER:exon15/15:c.*921G>A:,ALDH4A1:NM_001319218.1:3'UTR:MODIFIER:exon14/14:c.*921G>A:,ALDH4A1:NM_170726.2:intron:MODIFIER:exon15/15:c.*42-134G>A:		rs1138269	0.1933	0.0000	0/0/0	0.0383							606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	RCV000273844.1 [likely benign]; 			13	63					ALDH4A1 (inh=AR pLI=0.00)
chr1	19198576	19198576	A	G	hom	hom	hom		QUAL=29983;DP=378,239,313;MQM=59	ALDH4A1	3'UTR,intron	ALDH4A1:NM_003748.3:3'UTR:MODIFIER:exon15/15:c.*763T>C:,ALDH4A1:NM_001161504.1:3'UTR:MODIFIER:exon15/15:c.*763T>C:,ALDH4A1:NM_001319218.1:3'UTR:MODIFIER:exon14/14:c.*763T>C:,ALDH4A1:NM_170726.2:intron:MODIFIER:exon15/15:c.*42-292T>C:		rs1138267	0.6751	0.0000	0/0/0	0.7021							606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	RCV000369525.1 [likely benign]; 			81	55					ALDH4A1 (inh=AR pLI=0.00)
chr1	19198627	19198627	G	A	het	wt	het		QUAL=6409;DP=296,204,264;MQM=60	ALDH4A1	3'UTR,intron	ALDH4A1:NM_003748.3:3'UTR:MODIFIER:exon15/15:c.*712C>T:,ALDH4A1:NM_001161504.1:3'UTR:MODIFIER:exon15/15:c.*712C>T:,ALDH4A1:NM_001319218.1:3'UTR:MODIFIER:exon14/14:c.*712C>T:,ALDH4A1:NM_170726.2:intron:MODIFIER:exon15/15:c.*42-343C>T:		rs14311	0.1935	0.0000	0/0/0	0.2258							606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	RCV000325202.1 [likely benign]; 			13	63					ALDH4A1 (inh=AR pLI=0.00)
chr1	19198637	19198637	G	A	het	hom	het		QUAL=12517;DP=243,206,259;MQM=59	ALDH4A1	3'UTR,intron	ALDH4A1:NM_003748.3:3'UTR:MODIFIER:exon15/15:c.*702C>T:,ALDH4A1:NM_001161504.1:3'UTR:MODIFIER:exon15/15:c.*702C>T:,ALDH4A1:NM_001319218.1:3'UTR:MODIFIER:exon14/14:c.*702C>T:,ALDH4A1:NM_170726.2:intron:MODIFIER:exon15/15:c.*42-353C>T:		rs3202002	0.4744	0.0000	0/0/0	0.4715							606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	RCV000384464.1 [likely benign]; 			29	70					ALDH4A1 (inh=AR pLI=0.00)
chr1	19198682	19198682	C	-	het	hom	het		QUAL=7969;DP=114,176,196;MQM=59	ALDH4A1	3'UTR,intron	ALDH4A1:NM_003748.3:3'UTR:MODIFIER:exon15/15:c.*657delG:,ALDH4A1:NM_001161504.1:3'UTR:MODIFIER:exon15/15:c.*657delG:,ALDH4A1:NM_001319218.1:3'UTR:MODIFIER:exon14/14:c.*657delG:,ALDH4A1:NM_170726.2:intron:MODIFIER:exon15/15:c.*42-398delG:		rs11311839	0.4677	0.0000	0/0/0	0.4034							606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	RCV000321565.1 [likely benign]; 			29	71					ALDH4A1 (inh=AR pLI=0.00)
chr1	19198895	19198895	A	G	het	wt	het		QUAL=5086;DP=202,194,246;MQM=59	ALDH4A1	3'UTR,intron	ALDH4A1:NM_003748.3:3'UTR:MODIFIER:exon15/15:c.*444T>C:,ALDH4A1:NM_001161504.1:3'UTR:MODIFIER:exon15/15:c.*444T>C:,ALDH4A1:NM_001319218.1:3'UTR:MODIFIER:exon14/14:c.*444T>C:,ALDH4A1:NM_170726.2:intron:MODIFIER:exon15/15:c.*41+403T>C:		rs9117	0.1102	0.0000	0/0/0	0.0315							606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	RCV000394585.1 [likely benign]; 			12	56					ALDH4A1 (inh=AR pLI=0.00)
chr1	19199221	19199221	C	T	het	hom	het		QUAL=20955;DP=220,404,488;MQM=60	ALDH4A1	3'UTR,intron	ALDH4A1:NM_003748.3:3'UTR:MODIFIER:exon15/15:c.*118G>A:,ALDH4A1:NM_001161504.1:3'UTR:MODIFIER:exon15/15:c.*118G>A:,ALDH4A1:NM_001319218.1:3'UTR:MODIFIER:exon14/14:c.*118G>A:,ALDH4A1:NM_170726.2:intron:MODIFIER:exon15/15:c.*41+77G>A:		rs11740	0.4714	0.0000	0/0/0	0.0911							606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	RCV000402241.1 [likely benign]; 			30	70					ALDH4A1 (inh=AR pLI=0.00)
chr1	19201956	19201956	A	G	hom	hom	hom		QUAL=18486;DP=322,132,139;MQM=59	ALDH4A1	synonymous,sequence_feature	ALDH4A1:NM_003748.3:synonymous:LOW:exon13/15:c.1380T>C:p.Asp460Asp,ALDH4A1:NM_001161504.1:synonymous:LOW:exon13/15:c.1200T>C:p.Asp400Asp,ALDH4A1:NM_001319218.1:synonymous:LOW:exon12/14:c.1227T>C:p.Asp409Asp,ALDH4A1:NM_170726.2:synonymous:LOW:exon13/16:c.1380T>C:p.Asp460Asp,ALDH4A1:NM_003748.3:sequence_feature:LOW:exon13/15:c.1380T>C:,ALDH4A1:NM_001319218.1:sequence_feature:LOW:exon12/14:c.1227T>C:		rs2230708	0.7372	0.7298	32562/17258/2502	0.7237							606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	RCV000316598.1 [benign]; 			849	620					ALDH4A1 (inh=AR pLI=0.00)
chr1	19202896	19202896	G	A	hom	het	hom		QUAL=7483;DP=139,72,97;MQM=59	ALDH4A1	synonymous,intron	ALDH4A1:NM_003748.3:synonymous:LOW:exon12/15:c.1251C>T:p.Ala417Ala,ALDH4A1:NM_001161504.1:synonymous:LOW:exon12/15:c.1071C>T:p.Ala357Ala,ALDH4A1:NM_170726.2:synonymous:LOW:exon12/16:c.1251C>T:p.Ala417Ala,ALDH4A1:NM_001319218.1:intron:MODIFIER:exon11/13:c.1185+806C>T:		rs2230707	0.5160	0.5069	15519/7243/1007	0.4927							606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	RCV000295896.1 [likely benign]; 		COSM4143135, COSM4143136	371	786					ALDH4A1 (inh=AR pLI=0.00)
chr1	19202917	19202917	T	C	hom	hom	hom		QUAL=7752;DP=108,73,87;MQM=59	ALDH4A1	synonymous,intron	ALDH4A1:NM_003748.3:synonymous:LOW:exon12/15:c.1230A>G:p.Ser410Ser,ALDH4A1:NM_001161504.1:synonymous:LOW:exon12/15:c.1050A>G:p.Ser350Ser,ALDH4A1:NM_170726.2:synonymous:LOW:exon12/16:c.1230A>G:p.Ser410Ser,ALDH4A1:NM_001319218.1:intron:MODIFIER:exon11/13:c.1185+785A>G:		rs7550938	0.6609	0.7024	27774/14964/1171	0.6671							606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	RCV000350845.1 [benign]; 		COSM1337325, COSM1337326	788	642					ALDH4A1 (inh=AR pLI=0.00)
chr1	19202926	19202926	T	C	hom	hom	hom		QUAL=6368;DP=70,73,87;MQM=59	ALDH4A1	synonymous,intron	ALDH4A1:NM_003748.3:synonymous:LOW:exon12/15:c.1221A>G:p.Ala407Ala,ALDH4A1:NM_001161504.1:synonymous:LOW:exon12/15:c.1041A>G:p.Ala347Ala,ALDH4A1:NM_170726.2:synonymous:LOW:exon12/16:c.1221A>G:p.Ala407Ala,ALDH4A1:NM_001319218.1:intron:MODIFIER:exon11/13:c.1185+776A>G:		rs2230706	0.6601	0.7061	26738/14365/1117	0.6465							606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	RCV000397654.1 [benign]; 		COSM1337327, COSM1337328	787	641					ALDH4A1 (inh=AR pLI=0.00)
chr1	19203997	19203997	C	G	hom	hom	hom		QUAL=7639;DP=87,56,107;MQM=59	ALDH4A1	synonymous	ALDH4A1:NM_003748.3:synonymous:LOW:exon10/15:c.1050G>C:p.Ala350Ala,ALDH4A1:NM_001161504.1:synonymous:LOW:exon10/15:c.870G>C:p.Ala290Ala,ALDH4A1:NM_001319218.1:synonymous:LOW:exon10/14:c.1050G>C:p.Ala350Ala,ALDH4A1:NM_170726.2:synonymous:LOW:exon10/16:c.1050G>C:p.Ala350Ala		rs2230705	0.6416	0.7072	26078/15560/2381	0.6561							606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	RCV000267887.1 [benign]; 		COSM1473186, COSM424869	718	683					ALDH4A1 (inh=AR pLI=0.00)
chr1	21889635	21889635	T	C	hom	hom	het		QUAL=4846;DP=33,90,125;MQM=59	ALPL	sequence_feature,synonymous	ALPL:NM_000478.5:sequence_feature:MODERATE:exon5/12:c.330T>C:,ALPL:NM_001127501.3:sequence_feature:MODERATE:exon4/11:c.165T>C:,ALPL:NM_001177520.2:sequence_feature:MODERATE:exon3/10:c.99T>C:,ALPL:NM_000478.5:synonymous:LOW:exon5/12:c.330T>C:p.Ser110Ser,ALPL:NM_001127501.3:synonymous:LOW:exon4/11:c.165T>C:p.Ser55Ser,ALPL:NM_001177520.2:synonymous:LOW:exon3/10:c.99T>C:p.Ser33Ser,ALPL:NM_000478.5:sequence_feature:LOW:exon5/12:c.330T>C:,ALPL:NM_000478.5:sequence_feature:LOW:exon5/12:c.330T>C:,ALPL:NM_001127501.3:sequence_feature:LOW:exon4/11:c.165T>C:,ALPL:NM_001127501.3:sequence_feature:LOW:exon4/11:c.165T>C:,ALPL:NM_001177520.2:sequence_feature:LOW:exon3/10:c.99T>C:,ALPL:NM_001177520.2:sequence_feature:LOW:exon3/10:c.99T>C:		rs1780316	0.9295	0.9450	54032/29655/3879	0.9141							171760 [ALPL (confirmed) Hypophosphatasia,infantile,241500|Hypophosphatasia,childhood,241510|Odontohypophosphatasia,146300|Hypophosphatasia,adult,146300];	RCV000178778.1 [benign]; 		COSM3746801	1415	146					ALPL (inh=AR+AD pLI=0.00)
chr1	21904206	21904206	C	T	wt	het	wt		QUAL=1738;DP=68,173,236;MQM=60	ALPL	3'UTR	ALPL:NM_000478.5:3'UTR:MODIFIER:exon12/12:c.*65C>T:,ALPL:NM_001127501.3:3'UTR:MODIFIER:exon11/11:c.*65C>T:,ALPL:NM_001177520.2:3'UTR:MODIFIER:exon10/10:c.*65C>T:		rs1697405	0.3367	0.0000	0/0/0	0.3474							171760 [ALPL (confirmed) Hypophosphatasia,infantile,241500|Hypophosphatasia,childhood,241510|Odontohypophosphatasia,146300|Hypophosphatasia,adult,146300];	RCV000310997.1 [likely benign]; RCV000370356.1 [benign]; 			146	342					ALPL (inh=AR+AD pLI=0.00)
chr1	21904263	21904263	C	-	het	het	wt		QUAL=5373;DP=210,243,288;MQM=59	ALPL	3'UTR	ALPL:NM_000478.5:3'UTR:MODIFIER:exon12/12:c.*124delC:,ALPL:NM_001127501.3:3'UTR:MODIFIER:exon11/11:c.*124delC:,ALPL:NM_001177520.2:3'UTR:MODIFIER:exon10/10:c.*124delC:		rs140511985	0.0228	0.0000	0/0/0	0.0368							171760 [ALPL (confirmed) Hypophosphatasia,infantile,241500|Hypophosphatasia,childhood,241510|Odontohypophosphatasia,146300|Hypophosphatasia,adult,146300];	RCV000325855.1 [likely benign]; 			1	30					ALPL (inh=AR+AD pLI=0.00)
chr1	21904267	21904267	A	G	hom	hom	hom		QUAL=23868;DP=221,245,296;MQM=59	ALPL	3'UTR	ALPL:NM_000478.5:3'UTR:MODIFIER:exon12/12:c.*126A>G:,ALPL:NM_001127501.3:3'UTR:MODIFIER:exon11/11:c.*126A>G:,ALPL:NM_001177520.2:3'UTR:MODIFIER:exon10/10:c.*126A>G:		rs1697406	0.8682	0.0000	0/0/0	0.1755							171760 [ALPL (confirmed) Hypophosphatasia,infantile,241500|Hypophosphatasia,childhood,241510|Odontohypophosphatasia,146300|Hypophosphatasia,adult,146300];	RCV000382769.1 [benign]; 			176	48					ALPL (inh=AR+AD pLI=0.00)
chr1	21904374	21904374	A	C	wt	wt	het		QUAL=2236;DP=131,190,197;MQM=60	ALPL	3'UTR	ALPL:NM_000478.5:3'UTR:MODIFIER:exon12/12:c.*233A>C:,ALPL:NM_001127501.3:3'UTR:MODIFIER:exon11/11:c.*233A>C:,ALPL:NM_001177520.2:3'UTR:MODIFIER:exon10/10:c.*233A>C:		rs1772719	0.1645	0.0000	0/0/0	0.0291							171760 [ALPL (confirmed) Hypophosphatasia,infantile,241500|Hypophosphatasia,childhood,241510|Odontohypophosphatasia,146300|Hypophosphatasia,adult,146300];	RCV000329197.1 [benign]; 			7	74					ALPL (inh=AR+AD pLI=0.00)
chr1	22149183	22149183	G	C	het	wt	hom		QUAL=1423;DP=27,28,42;MQM=60	LDLRAD2,HSPG2	3'UTR	LDLRAD2:NM_001013693.2:3'UTR:MODIFIER:exon5/5:c.*475G>C:,HSPG2:NM_001291860.1:3'UTR:MODIFIER:exon97/97:c.*626C>G:,HSPG2:NM_005529.6:3'UTR:MODIFIER:exon97/97:c.*626C>G:		rs1049644	0.3199	0.0000	0/0/0	0.0441							142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800|Dyssegmental dysplasia,Silverman-Handmaker type,224410];	RCV000297630.1 [benign]; RCV000354787.1 [benign]; 			14	60					LDLRAD2 (inh=n/a pLI=0.00), HSPG2 (inh=AR pLI=0.00)
chr1	22149935	22149935	T	C	hom	hom	hom		QUAL=15305;DP=116,144,233;MQM=59	HSPG2,LDLRAD2	synonymous,3'UTR	HSPG2:NM_001291860.1:synonymous:LOW:exon97/97:c.13053A>G:p.Ser4351Ser,HSPG2:NM_005529.6:synonymous:LOW:exon97/97:c.13050A>G:p.Ser4350Ser,LDLRAD2:NM_001013693.2:3'UTR:MODIFIER:exon5/5:c.*1227T>C:		rs897467	0.7804	0.8204	29345/16802/1769	0.7612							142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800|Dyssegmental dysplasia,Silverman-Handmaker type,224410];	RCV000302221.1 [benign]; RCV000359351.1 [benign]; 		COSM3750884	1071	395					HSPG2 (inh=AR pLI=0.00), LDLRAD2 (inh=n/a pLI=0.00)
chr1	22150118	22150118	C	T	wt	wt	het		QUAL=3338;DP=149,207,315;MQM=60	HSPG2,LDLRAD2	missense,sequence_feature,3'UTR	HSPG2:NM_001291860.1:missense:MODERATE:exon96/97:c.12997G>A:p.Val4333Ile,HSPG2:NM_005529.6:missense:MODERATE:exon96/97:c.12994G>A:p.Val4332Ile,HSPG2:NM_005529.6:sequence_feature:LOW:exon96/97:c.12994G>A:,LDLRAD2:NM_001013693.2:3'UTR:MODIFIER:exon5/5:c.*1410C>T:		rs1138469	0.0453	0.0585	260/137/5	0.0559	-1.4120	T	T	B,B	T	0.55	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800|Dyssegmental dysplasia,Silverman-Handmaker type,224410];	RCV000274764.1 [likely benign]; RCV000318163.1 [likely benign]; 		COSM3750885	14	193					HSPG2 (inh=AR pLI=0.00), LDLRAD2 (inh=n/a pLI=0.00)
chr1	22150120	22150120	C	T	het	wt	het		QUAL=5840;DP=155,209,317;MQM=59	HSPG2,LDLRAD2	missense,3'UTR	HSPG2:NM_001291860.1:missense:MODERATE:exon96/97:c.12995G>A:p.Ser4332Asn,HSPG2:NM_005529.6:missense:MODERATE:exon96/97:c.12992G>A:p.Ser4331Asn,LDLRAD2:NM_001013693.2:3'UTR:MODIFIER:exon5/5:c.*1412C>T:		rs3736360	0.1761	0.1849	2248/1110/30	0.1787	0.0960	T	T	B	T	13.76	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800|Dyssegmental dysplasia,Silverman-Handmaker type,224410];	RCV000278239.1 [benign]; RCV000375072.1 [benign]; 		COSM3750886	42	418					HSPG2 (inh=AR pLI=0.00), LDLRAD2 (inh=n/a pLI=0.00)
chr1	22150160	22150160	G	T	het	wt	het		QUAL=8183;DP=304,206,324;MQM=59	HSPG2,LDLRAD2	synonymous,3'UTR	HSPG2:NM_001291860.1:synonymous:LOW:exon96/97:c.12955C>A:p.Arg4319Arg,HSPG2:NM_005529.6:synonymous:LOW:exon96/97:c.12952C>A:p.Arg4318Arg,LDLRAD2:NM_001013693.2:3'UTR:MODIFIER:exon5/5:c.*1452G>T:		rs3736358	0.0000	0.1808	2228/1111/9	0.1696							142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800|Dyssegmental dysplasia,Silverman-Handmaker type,224410];	RCV000286377.1 [benign]; RCV000339035.1 [benign]; 		COSM3750887	42	416					HSPG2 (inh=AR pLI=0.00), LDLRAD2 (inh=n/a pLI=0.00)
chr1	22154845	22154845	A	G	het	wt	hom		QUAL=1286;DP=45,38,32;MQM=60	HSPG2	synonymous,sequence_feature	HSPG2:NM_001291860.1:synonymous:LOW:exon89/97:c.12315T>C:p.Asp4105Asp,HSPG2:NM_005529.6:synonymous:LOW:exon89/97:c.12312T>C:p.Asp4104Asp,HSPG2:NM_005529.6:sequence_feature:LOW:exon89/97:c.12312T>C:		rs2228347	0.2572	0.2982	5929/3255/98	0.2914							142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800|Dyssegmental dysplasia,Silverman-Handmaker type,224410];	RCV000319755.1 [benign]; RCV000353544.1 [benign]; 		COSM3746805	164	642					HSPG2 (inh=AR pLI=0.00)
chr1	22159774	22159774	G	A	het	wt	het		QUAL=4229;DP=147,207,238;MQM=59	HSPG2	synonymous	HSPG2:NM_001291860.1:synonymous:LOW:exon80/97:c.11085C>T:p.Pro3695Pro,HSPG2:NM_005529.6:synonymous:LOW:exon80/97:c.11082C>T:p.Pro3694Pro		rs2229486	0.0859	0.0792	484/201/147	0.0785							142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800|Dyssegmental dysplasia,Silverman-Handmaker type,224410];	RCV000304022.1 [likely benign]; RCV000393030.1 [likely benign]; 			16	251					HSPG2 (inh=AR pLI=0.00)
chr1	22160043	22160043	C	T	het	wt	het		QUAL=5275;DP=190,225,287;MQM=60	HSPG2	missense	HSPG2:NM_001291860.1:missense:MODERATE:exon79/97:c.10898G>A:p.Arg3633Gln,HSPG2:NM_005529.6:missense:MODERATE:exon79/97:c.10895G>A:p.Arg3632Gln		rs2229493	0.0859	0.0795	487/202/148	0.0786	-0.0650	T,T	T	B,B	T,T	4.68	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800|Dyssegmental dysplasia,Silverman-Handmaker type,224410];	RCV000276227.1 [likely benign]; RCV000389238.1 [likely benign]; 			16	252					HSPG2 (inh=AR pLI=0.00)
chr1	22163390	22163390	G	A	het	wt	het		QUAL=5476;DP=182,227,353;MQM=60	HSPG2	synonymous	HSPG2:NM_001291860.1:synonymous:LOW:exon75/97:c.10263C>T:p.His3421His,HSPG2:NM_005529.6:synonymous:LOW:exon75/97:c.10260C>T:p.His3420His		rs35444472	0.0861	0.1274	211/66/72	0.0598							142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800|Dyssegmental dysplasia,Silverman-Handmaker type,224410];	RCV000293149.1 [likely benign]; RCV000352651.1 [likely benign]; 		COSM3750889	15	247					HSPG2 (inh=AR pLI=0.00)
chr1	22163402	22163402	G	A	wt	wt	het	anno_pathogenic_hgmd	QUAL=5292;DP=180,223,348;MQM=60	HSPG2	synonymous	HSPG2:NM_001291860.1:synonymous:LOW:exon75/97:c.10251C>T:p.Ser3417Ser,HSPG2:NM_005529.6:synonymous:LOW:exon75/97:c.10248C>T:p.Ser3416Ser		rs41310390	0.0437	0.0976	94/46/4	0.0426							142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800|Dyssegmental dysplasia,Silverman-Handmaker type,224410];	RCV000356605.1 [likely benign]; RCV000391634.1 [likely benign]; 	CS011537 [CLASS=DM? MUT=ALT PHEN="Dyssegmental dysplasia Silverman-Handmaker type" GENE=HSPG2]; 	COSM3750890	14	194	2	[2] old entry - no details available			HSPG2 (inh=AR pLI=0.00)
chr1	22165901	22165901	A	G	het	wt	het		QUAL=2711;DP=85,39,88;MQM=59	HSPG2	synonymous	HSPG2:NM_001291860.1:synonymous:LOW:exon73/97:c.9855T>C:p.Ala3285Ala,HSPG2:NM_005529.6:synonymous:LOW:exon73/97:c.9852T>C:p.Ala3284Ala		rs2291826	0.3460	0.2876	5587/2297/1470	0.2821							142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800|Dyssegmental dysplasia,Silverman-Handmaker type,224410];	RCV000336014.1 [benign]; RCV000399444.1 [benign]; 			115	586					HSPG2 (inh=AR pLI=0.00)
chr1	22167605	22167605	C	T	het	wt	het		QUAL=2093;DP=53,164,183;MQM=59	HSPG2	missense	HSPG2:NM_001291860.1:missense:MODERATE:exon71/97:c.9505G>A:p.Ala3169Thr,HSPG2:NM_005529.6:missense:MODERATE:exon71/97:c.9502G>A:p.Ala3168Thr		rs2228349	0.0837	0.1176	377/153/103	0.0719	0.9110	T	T	B,B	T	13.43	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800|Dyssegmental dysplasia,Silverman-Handmaker type,224410];	RCV000259415.1 [likely benign]; RCV000316947.1 [likely benign]; 			16	249					HSPG2 (inh=AR pLI=0.00)
chr1	22168801	22168801	T	C	het	wt	het		QUAL=1512;DP=69,76,87;MQM=59	HSPG2	missense,sequence_feature	HSPG2:NM_001291860.1:missense:MODERATE:exon68/97:c.8986A>G:p.Ser2996Gly,HSPG2:NM_005529.6:missense:MODERATE:exon68/97:c.8983A>G:p.Ser2995Gly,HSPG2:NM_005529.6:sequence_feature:LOW:exon68/97:c.8983A>G:		rs2229491	0.0887	0.0812	498/194/166	0.0791	-0.0660	T	T	B,B	T	0.01	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800|Dyssegmental dysplasia,Silverman-Handmaker type,224410];	RCV000313160.1 [likely benign]; RCV000370135.1 [likely benign]; 			16	255					HSPG2 (inh=AR pLI=0.00)
chr1	22168845	22168845	A	T	het	wt	het	pred_pathogenic	QUAL=1052;DP=50,44,57;MQM=59	HSPG2	missense	HSPG2:NM_001291860.1:missense:MODERATE:exon68/97:c.8942T>A:p.Leu2981His,HSPG2:NM_005529.6:missense:MODERATE:exon68/97:c.8939T>A:p.Leu2980His		rs2229489	0.0343	0.0560	210/96/0	0.0487	1.8860	T	T	B,B	T	7.97	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800|Dyssegmental dysplasia,Silverman-Handmaker type,224410];	RCV000262561.1 [likely benign]; RCV000354940.1 [likely benign]; 		COSM425370	6	204					HSPG2 (inh=AR pLI=0.00)
chr1	22173990	22173990	A	G	het	wt	het		QUAL=7236;DP=164,327,426;MQM=59	HSPG2	splice_region&intron	HSPG2:NM_001291860.1:splice_region&intron:LOW:exon61/96:c.8029-5T>C:,HSPG2:NM_005529.6:splice_region&intron:LOW:exon61/96:c.8026-5T>C:		rs35917892	0.0347	0.0505	223/104/0	0.0489							142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800|Dyssegmental dysplasia,Silverman-Handmaker type,224410];	RCV000308491.1 [likely benign]; RCV000407500.1 [likely benign]; 			6	202					HSPG2 (inh=AR pLI=0.00)
chr1	22174518	22174518	G	T	het	wt	het		QUAL=7681;DP=288,359,362;MQM=59	HSPG2	synonymous	HSPG2:NM_001291860.1:synonymous:LOW:exon60/97:c.7809C>A:p.Val2603Val,HSPG2:NM_005529.6:synonymous:LOW:exon60/97:c.7806C>A:p.Val2602Val		rs12737091	0.0347	0.0511	220/102/0	0.0498							142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800|Dyssegmental dysplasia,Silverman-Handmaker type,224410];	RCV000318918.1 [likely benign]; RCV000375837.1 [likely benign]; 			6	202					HSPG2 (inh=AR pLI=0.00)
chr1	22179244	22179244	C	T	het	wt	het		QUAL=3591;DP=92,152,204;MQM=59	HSPG2	missense	HSPG2:NM_001291860.1:missense:MODERATE:exon52/97:c.6676G>A:p.Gly2226Ser,HSPG2:NM_005529.6:missense:MODERATE:exon52/97:c.6673G>A:p.Gly2225Ser		rs35669711	0.0347	0.0509	222/103/0	0.0493	-0.1820	T	T	B,B	T	12.31	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800|Dyssegmental dysplasia,Silverman-Handmaker type,224410];	RCV000306325.1 [likely benign]; RCV000398821.1 [likely benign]; 			6	201					HSPG2 (inh=AR pLI=0.00)
chr1	22179451	22179451	C	T	het	wt	het		QUAL=5828;DP=86,272,434;MQM=59	HSPG2	synonymous	HSPG2:NM_001291860.1:synonymous:LOW:exon51/97:c.6555G>A:p.Thr2185Thr,HSPG2:NM_005529.6:synonymous:LOW:exon51/97:c.6552G>A:p.Thr2184Thr		rs34443576	0.0345	0.0512	219/102/0	0.0488							142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800|Dyssegmental dysplasia,Silverman-Handmaker type,224410];	RCV000263025.1 [likely benign]; RCV000318160.1 [likely benign]; 			6	201					HSPG2 (inh=AR pLI=0.00)
chr1	22180723	22180723	C	T	het	wt	het		QUAL=3074;DP=84,144,197;MQM=60	HSPG2	synonymous	HSPG2:NM_001291860.1:synonymous:LOW:exon50/97:c.6405G>A:p.Val2135Val,HSPG2:NM_005529.6:synonymous:LOW:exon50/97:c.6402G>A:p.Val2134Val		rs12742444	0.0345	0.0895	149/60/0	0.0422							142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800|Dyssegmental dysplasia,Silverman-Handmaker type,224410];	RCV000289771.1 [benign]; RCV000294008.1 [likely benign]; RCV000330249.1 [likely benign]; 			4	199					HSPG2 (inh=AR pLI=0.00)
chr1	22181895	22181895	C	T	het	wt	het	pred_pathogenic	QUAL=5770;DP=168,261,311;MQM=59	HSPG2	missense	HSPG2:NM_001291860.1:missense:MODERATE:exon47/97:c.5902G>A:p.Val1968Ile,HSPG2:NM_005529.6:missense:MODERATE:exon47/97:c.5899G>A:p.Val1967Ile		rs2229475	0.0347	0.0536	207/95/0	0.0490	1.8290	T	T	D	T	24.30	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800|Dyssegmental dysplasia,Silverman-Handmaker type,224410];	RCV000339647.1 [likely benign]; RCV000375538.1 [likely benign]; 			5	202					HSPG2 (inh=AR pLI=0.00)
chr1	22191454	22191454	G	A	het	hom	wt	pred_pathogenic	QUAL=7192;DP=128,210,349;MQM=59	HSPG2	missense	HSPG2:NM_001291860.1:missense:MODERATE:exon36/97:c.4511C>T:p.Ala1504Val,HSPG2:NM_005529.6:missense:MODERATE:exon36/97:c.4508C>T:p.Ala1503Val		rs897471	0.6915	0.7463	25154/14147/1363	0.6776	2.2600	T	T	D	T	23.30	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800|Dyssegmental dysplasia,Silverman-Handmaker type,224410];	RCV000274418.1 [benign]; RCV000299057.1 [benign]; RCV000371265.1 [benign]; 		COSM3750893	847	592					HSPG2 (inh=AR pLI=0.00)
chr1	22199245	22199245	C	T	het	hom	wt		QUAL=3097;DP=48,81,76;MQM=60	HSPG2	synonymous	HSPG2:NM_001291860.1:synonymous:LOW:exon32/97:c.3900G>A:p.Val1300Val,HSPG2:NM_005529.6:synonymous:LOW:exon32/97:c.3897G>A:p.Val1299Val		rs2229482	0.4249	0.6066	17522/12414/386	0.5224							142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800|Dyssegmental dysplasia,Silverman-Handmaker type,224410];	RCV000269271.1 [benign]; RCV000346655.1 [benign]; RCV000366230.1 [benign]; 		COSM425375	585	727					HSPG2 (inh=AR pLI=0.00)
chr1	22206649	22206649	T	C	hom	hom	hom		QUAL=22322;DP=206,239,255;MQM=60	HSPG2	missense	HSPG2:NM_001291860.1:missense:MODERATE:exon17/97:c.2297A>G:p.Asn766Ser,HSPG2:NM_005529.6:missense:MODERATE:exon17/97:c.2294A>G:p.Asn765Ser		rs989994	0.9299	0.9811	58602/33315/3265	0.9180	0.8030	T	T	B	T	16.97	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800|Dyssegmental dysplasia,Silverman-Handmaker type,224410];	RCV000317586.1 [benign]; RCV000372262.1 [benign]; 			1574	7					HSPG2 (inh=AR pLI=0.00)
chr1	22206942	22206942	G	A	hom	hom	hom		QUAL=8248;DP=135,61,74;MQM=59	HSPG2	synonymous	HSPG2:NM_001291860.1:synonymous:LOW:exon16/97:c.2112C>T:p.Ala704Ala,HSPG2:NM_005529.6:synonymous:LOW:exon16/97:c.2109C>T:p.Ala703Ala		rs1874793	0.9299	0.9812	58461/33240/3259	0.9258							142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800|Dyssegmental dysplasia,Silverman-Handmaker type,224410];	RCV000282418.1 [benign]; RCV000318734.1 [benign]; 		COSM4143367	1574	7					HSPG2 (inh=AR pLI=0.00)
chr1	22207235	22207235	T	C	hom	hom	hom		QUAL=11349;DP=170,74,132;MQM=59	HSPG2	missense	HSPG2:NM_001291860.1:missense:MODERATE:exon15/97:c.1915A>G:p.Met639Val,HSPG2:NM_005529.6:missense:MODERATE:exon15/97:c.1912A>G:p.Met638Val		rs1874792	0.9736	0.9931	47715/27169/3347	0.9216	1.5550	T	T	B	T	0.01	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800|Dyssegmental dysplasia,Silverman-Handmaker type,224410];	RCV000260399.1 [benign]; RCV000296869.1 [benign]; 			1579	1					HSPG2 (inh=AR pLI=0.00)
chr1	22214127	22214127	A	G	hom	het	hom	pred_pathogenic	QUAL=12838;DP=125,183,214;MQM=59	HSPG2	synonymous	HSPG2:NM_001291860.1:synonymous:LOW:exon8/97:c.744T>C:p.Leu248Leu,HSPG2:NM_005529.6:synonymous:LOW:exon8/97:c.744T>C:p.Leu248Leu		rs2229478	0.5363	0.4175	11513/3745/2116	0.4036	-0.2600	D,T	T	B	T,D	0.03	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800|Dyssegmental dysplasia,Silverman-Handmaker type,224410];	RCV000267416.1 [benign]; RCV000317902.1 [benign]; 		COSM3750895, COSM3750894	206	702					HSPG2 (inh=AR pLI=0.00)
chr1	22217108	22217108	G	A	hom	hom	hom		QUAL=25902;DP=224,277,332;MQM=59	HSPG2	synonymous	HSPG2:NM_001291860.1:synonymous:LOW:exon4/97:c.324C>T:p.Phe108Phe,HSPG2:NM_005529.6:synonymous:LOW:exon4/97:c.324C>T:p.Phe108Phe		rs2501260	0.9481	0.9861	59156/33346/3754	0.9229							142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800|Dyssegmental dysplasia,Silverman-Handmaker type,224410];	RCV000289547.1 [benign]; RCV000406389.1 [benign]; 			1576	5					HSPG2 (inh=AR pLI=0.00)
chr1	22779159	22779159	T	C	hom	hom	hom		QUAL=28748;DP=268,255,394;MQM=60	ZBTB40	5'UTR,intron	ZBTB40:NM_001083621.1:5'UTR:MODIFIER:exon2/19:c.-350T>C:,ZBTB40:NM_014870.3:intron:MODIFIER:exon1/17:c.-70+662T>C:	MER58B	rs10737466	0.9698	0.0000	0/0/0	0.8720											227	0					ZBTB40 (inh=n/a pLI=0.00)
chr1	22832743	22832743	A	T	hom	het	hom		QUAL=15555;DP=213,168,209;MQM=60	ZBTB40	splice_region&intron	ZBTB40:NM_001083621.1:splice_region&intron:LOW:exon7/18:c.1360+9A>T:,ZBTB40:NM_014870.3:splice_region&intron:LOW:exon6/17:c.1360+9A>T:		rs209732	0.7991	0.6929	29845/12471/4048	0.6696										COSM3746831	688	629					ZBTB40 (inh=n/a pLI=0.00)
chr1	22835677	22835677	A	G	hom	het	hom		QUAL=24886;DP=342,273,306;MQM=59	ZBTB40	missense	ZBTB40:NM_001083621.1:missense:MODERATE:exon10/19:c.1784A>G:p.Tyr595Cys,ZBTB40:NM_014870.3:missense:MODERATE:exon9/18:c.1784A>G:p.Tyr595Cys		rs209729	0.8225	0.7648	35937/17374/4314	0.7455	0.2230	T,T,T	T	B,B	T,T,T	4.98				COSM3746832	863	571					ZBTB40 (inh=n/a pLI=0.00)
chr1	22846709	22846709	G	A	hom	hom	hom	pred_pathogenic	QUAL=12120;DP=169,93,135;MQM=59	ZBTB40	missense	ZBTB40:NM_001083621.1:missense:MODERATE:exon15/19:c.2989G>A:p.Val997Met,ZBTB40:NM_014870.3:missense:MODERATE:exon14/18:c.2989G>A:p.Val997Met		rs209720	0.9984	0.9970	60319/33052/5194	0.9674	2.3000	T,T,T	T	B,B	T,T,T	14.26					1558	8					ZBTB40 (inh=n/a pLI=0.00)
chr1	22852715	22852715	G	C	hom	het	hom		QUAL=10923;DP=174,108,140;MQM=60	ZBTB40	synonymous	ZBTB40:NM_001083621.1:synonymous:LOW:exon19/19:c.3546G>C:p.Pro1182Pro,ZBTB40:NM_014870.3:synonymous:LOW:exon18/18:c.3546G>C:p.Pro1182Pro		rs881646	0.3181	0.3422	7646/4486/132	0.3386										COSM3746849	225	687					ZBTB40 (inh=n/a pLI=0.00)
chr1	22853141	22853141	G	A	hom	het	hom		QUAL=17671;DP=157,234,316;MQM=59	ZBTB40	3'UTR	ZBTB40:NM_001083621.1:3'UTR:MODIFIER:exon19/19:c.*252G>A:,ZBTB40:NM_014870.3:3'UTR:MODIFIER:exon18/18:c.*252G>A:		rs2281354	0.2378	0.0000	0/0/0	0.2992											19	105					ZBTB40 (inh=n/a pLI=0.00)
chr1	22855194	22855194	-	T	hom	wt	hom		QUAL=627;DP=49,39,48;MQM=59	ZBTB40	3'UTR	ZBTB40:NM_001083621.1:3'UTR:MODIFIER:exon19/19:c.*2320dupT:,ZBTB40:NM_014870.3:3'UTR:MODIFIER:exon18/18:c.*2320dupT:	AluJo	rs35637563;rs778707681	0.0000	0.0000	0/0/0	0.1538											0	41					ZBTB40 (inh=n/a pLI=0.00)
chr1	22856601	22856601	T	C	hom	het	hom		QUAL=19089;DP=229,218,284;MQM=59	ZBTB40	3'UTR	ZBTB40:NM_001083621.1:3'UTR:MODIFIER:exon19/19:c.*3712T>C:,ZBTB40:NM_014870.3:3'UTR:MODIFIER:exon18/18:c.*3712T>C:		rs1062663	0.3295	0.0000	0/0/0	0.0605											28	106					ZBTB40 (inh=n/a pLI=0.00)
chr1	22965438	22965438	A	G	het	hom	het	low_DP	QUAL=330;DP=14,2,5;MQM=60	C1QA	synonymous	C1QA:NM_015991.2:synonymous:LOW:exon3/3:c.276A>G:p.Gly92Gly		rs172378	0.6164	0.5387	11213/3757/1982	0.4598	-0.2960	T	T			0.30	120550 [C1QA (confirmed) C1q deficiency,613652];		CM035950 [CLASS=DP MUT=REF PHEN="Subacute cutaneous lupus erythematosus association with" GENE=C1QA]; 	COSM3721050	268	702					C1QA (inh=AR pLI=0.05)
chr1	22974297	22974297	C	A	wt	het	wt		QUAL=577;DP=126,66,94;MQM=59	C1QC	3'UTR	C1QC:NM_001114101.1:3'UTR:MODIFIER:exon3/3:c.*21C>A:,C1QC:NM_172369.3:3'UTR:MODIFIER:exon3/3:c.*21C>A:		rs9434	0.5877	0.4438	12702/4506/3268	0.4315							120575 [C1QC (provisional) C1q deficiency,613652];				103	347					C1QC (inh=AR pLI=0.02)
chr1	22974380	22974396	CCACCAGATGGACTTCT	-	wt	het	wt	low_DP	QUAL=52;DP=27,18,16;MQM=59	C1QC	3'UTR	C1QC:NM_001114101.1:3'UTR:MODIFIER:exon3/3:c.*106_*122delACCAGATGGACTTCTCC:,C1QC:NM_172369.3:3'UTR:MODIFIER:exon3/3:c.*106_*122delACCAGATGGACTTCTCC:	L2d2	rs142916975	0.3764	0.0000	0/0/0	0.2551							120575 [C1QC (provisional) C1q deficiency,613652];				26	73					C1QC (inh=AR pLI=0.02)
chr1	22974534	22974534	T	-	het	wt	het		QUAL=525;DP=54,39,67;MQM=59	C1QC	3'UTR	C1QC:NM_001114101.1:3'UTR:MODIFIER:exon3/3:c.*273delT:,C1QC:NM_172369.3:3'UTR:MODIFIER:exon3/3:c.*273delT:	L2d2	rs71020441	0.0000	0.0000	0/0/0	0.0096							120575 [C1QC (provisional) C1q deficiency,613652];				1	54					C1QC (inh=AR pLI=0.02)
chr1	22974566	22974566	T	G	het	wt	wt		QUAL=76;DP=53,51,65;MQM=57	C1QC	3'UTR	C1QC:NM_001114101.1:3'UTR:MODIFIER:exon3/3:c.*290T>G:,C1QC:NM_172369.3:3'UTR:MODIFIER:exon3/3:c.*290T>G:			0.0000	0.0000	0/0/0	0.0001							120575 [C1QC (provisional) C1q deficiency,613652];				0	10					C1QC (inh=AR pLI=0.02)
chr1	22987958	22987958	A	G	hom	hom	hom		QUAL=38139;DP=417,349,455;MQM=59	C1QB	3'UTR	C1QB:NM_000491.3:3'UTR:MODIFIER:exon3/3:c.*79A>G:		rs10580	0.9914	0.0000	0/0/0	0.1772							120570 [C1QB (confirmed) C1q deficiency,613652];				217	15					C1QB (inh=AR pLI=0.09)
chr1	24128467	24128467	C	T	hom	het	hom		QUAL=30088;DP=380,345,430;MQM=59	HMGCL	3'UTR	HMGCL:NM_000191.2:3'UTR:MODIFIER:exon9/9:c.*486G>A:,HMGCL:NM_001166059.1:3'UTR:MODIFIER:exon7/7:c.*486G>A:		rs11714	0.8834	0.0000	0/0/0	0.1532							613898 [HMGCL (provisional) HMG-CoA lyase deficiency,246450];	RCV000343484.1 [benign]; RCV000345640.1 [benign]; 			193	35					HMGCL (inh=AR pLI=0.00)
chr1	24134721	24134721	T	C	hom	het	hom		QUAL=21813;DP=293,226,287;MQM=59	HMGCL	synonymous	HMGCL:NM_000191.2:synonymous:LOW:exon7/9:c.654A>G:p.Leu218Leu,HMGCL:NM_001166059.1:synonymous:LOW:exon5/7:c.441A>G:p.Leu147Leu		rs719400	0.8874	0.9042	49752/27714/4863	0.8959	0.8730		T			7.75	613898 [HMGCL (provisional) HMG-CoA lyase deficiency,246450];	RCV000078343.6 [benign]; RCV000268428.1 [benign]; 			1292	252					HMGCL (inh=AR pLI=0.00)
chr1	24180962	24180962	T	C	het	wt	hom	pred_pathogenic	QUAL=9699;DP=254,210,202;MQM=60	FUCA1	missense	FUCA1:NM_000147.4:missense:MODERATE:exon5/8:c.857A>G:p.Gln286Arg		rs13551	0.2113	0.2791	5299/3906/125	0.2771	0.6520	D,D	T	B	T	12.55	612280 [FUCA1 (confirmed) Fucosidosis,230000];	RCV000000726.2 [benign]; RCV000382814.1 [benign]; 		COSM3746875	118	619					FUCA1 (inh=AR pLI=0.00)
chr1	24194748	24194748	G	C	wt	het	wt		QUAL=1444;DP=174,116,133;MQM=60	FUCA1	missense	FUCA1:NM_000147.4:missense:MODERATE:exon1/8:c.29C>G:p.Pro10Arg		rs2070956	0.1430	0.1465	138/38/6	0.0590	-0.0120	T	T	B	T	14.62	612280 [FUCA1 (confirmed) Fucosidosis,230000];	RCV000173072.1 [benign]; RCV000306112.1 [benign]; 			25	266					FUCA1 (inh=AR pLI=0.00)
chr1	24194770	24194770	C	G	het	het	wt		QUAL=2651;DP=160,107,114;MQM=59	FUCA1	missense	FUCA1:NM_000147.4:missense:MODERATE:exon1/8:c.7G>C:p.Ala3Pro		rs61996282	0.0134	0.0161	4/0/0	0.0067	-2.4990	T	T	B	T	17.53	612280 [FUCA1 (confirmed) Fucosidosis,230000];	RCV000358584.1 [likely benign]; 			0	24					FUCA1 (inh=AR pLI=0.00)
chr1	24194773	24194773	G	A	wt	het	wt	pred_pathogenic	QUAL=1215;DP=137,104,114;MQM=60	FUCA1	missense	FUCA1:NM_000147.4:missense:MODERATE:exon1/8:c.4C>T:p.Arg2Trp		rs2070955	0.1430	0.1420	118/26/5	0.0618	-1.0170	D	T	B	T	25.70	612280 [FUCA1 (confirmed) Fucosidosis,230000];	RCV000173071.1 [benign]; RCV000266098.1 [benign]; RCV000328139.1 [uncertain significance]; 			24	262					FUCA1 (inh=AR pLI=0.00)
chr1	24194788	24194788	A	G	wt	het	wt		QUAL=1137;DP=90,96,100;MQM=60	FUCA1	5'UTR	FUCA1:NM_000147.4:5'UTR:MODIFIER:exon1/8:c.-12T>C:		rs2070954	0.1428	0.1357	101/23/5	0.0572							612280 [FUCA1 (confirmed) Fucosidosis,230000];	RCV000173070.1 [benign]; RCV000385101.1 [likely benign]; 			14	167					FUCA1 (inh=AR pLI=0.00)
chr1	24194862	24194862	A	C	wt	het	wt		QUAL=417;DP=32,49,33;MQM=59	FUCA1-CNR2	intergenic_region	FUCA1-CNR2:FUCA1-CNR2:intergenic_region:MODIFIER::n.24194862A>C:		rs2070953	0.1428	0.0000	0/0/0	0.1152							612280 [FUCA1 (confirmed) Fucosidosis,230000];	RCV000303631.1 [likely benign]; 			3	27					FUCA1-CNR2 (inh=n/a pLI=n/a)
chr1	26131654	26131654	G	A	hom	hom	het		QUAL=15817;DP=161,221,333;MQM=59	SEPN1	missense	SEPN1:NM_020451.2:missense:MODERATE:exon4/13:c.425G>A:p.Cys142Tyr,SEPN1:NM_206926.1:missense:MODERATE:exon3/12:c.323G>A:p.Cys108Tyr		rs7349185	0.8419	0.8144	40353/20231/2986	0.7933	0.9620	T,T,T	T	B,B	T,T,T	0.02	606210 [SEPN1 (confirmed) Muscular dystrophy,rigid spine,1,602771|Myopathy,congenital,with fiber-type disproportion,255310];	RCV000082016.8 [benign]; RCV000371932.1 [benign]; 			1056	505					SELENON (inh=AR+AD pLI=0.00)
chr1	26138262	26138262	T	C	hom	hom	het		QUAL=25217;DP=235,352,489;MQM=59	SEPN1	synonymous	SEPN1:NM_020451.2:synonymous:LOW:exon9/13:c.1173T>C:p.Pro391Pro,SEPN1:NM_206926.1:synonymous:LOW:exon8/12:c.1071T>C:p.Pro357Pro		rs760597	0.7919	0.8132	26670/14099/1304	0.7410							606210 [SEPN1 (confirmed) Muscular dystrophy,rigid spine,1,602771|Myopathy,congenital,with fiber-type disproportion,255310];	RCV000082009.7 [benign]; RCV000358370.1 [benign]; 		COSM1127046	1051	505					SELENON (inh=AR+AD pLI=0.00)
chr1	26140573	26140573	C	A	hom	hom	het	pred_pathogenic	QUAL=22048;DP=218,326,440;MQM=59	SEPN1	missense	SEPN1:NM_020451.2:missense:MODERATE:exon12/13:c.1506C>A:p.Asn502Lys,SEPN1:NM_206926.1:missense:MODERATE:exon11/12:c.1404C>A:p.Asn468Lys		rs2294228	0.6975	0.7747	37783/20184/467	0.7542	0.1580	T,T,D	T	B,B	D,D,D	22.10	606210 [SEPN1 (confirmed) Muscular dystrophy,rigid spine,1,602771|Myopathy,congenital,with fiber-type disproportion,255310];	RCV000082012.7 [benign]; RCV000299948.1 [benign]; 		COSM4143697	1032	522					SELENON (inh=AR+AD pLI=0.00)
chr1	26143704	26143704	-	TTTTG	hom	hom	het		QUAL=13450;DP=154,192,230;MQM=58	SEPN1	3'UTR	SEPN1:NM_020451.2:3'UTR:MODIFIER:exon13/13:c.*1511_*1515dupTTTTG:,SEPN1:NM_206926.1:3'UTR:MODIFIER:exon12/12:c.*1511_*1515dupTTTTG:		rs397712756	0.0000	0.0000	0/0/0	0.5204							606210 [SEPN1 (confirmed) Muscular dystrophy,rigid spine,1,602771|Myopathy,congenital,with fiber-type disproportion,255310];				153	69					SELENON (inh=AR+AD pLI=0.00)
chr1	26143821	26143821	T	C	hom	hom	het		QUAL=16548;DP=249,180,268;MQM=54	SEPN1	3'UTR	SEPN1:NM_020451.2:3'UTR:MODIFIER:exon13/13:c.*1612T>C:,SEPN1:NM_206926.1:3'UTR:MODIFIER:exon12/12:c.*1612T>C:	AluSx	rs3203750	0.7630	0.0000	0/0/0	0.7252							606210 [SEPN1 (confirmed) Muscular dystrophy,rigid spine,1,602771|Myopathy,congenital,with fiber-type disproportion,255310];	RCV000365105.1 [benign]; 			150	67					SELENON (inh=AR+AD pLI=0.00)
chr1	26143931	26143931	T	C	hom	hom	het		QUAL=22045;DP=340,231,349;MQM=53	SEPN1	3'UTR	SEPN1:NM_020451.2:3'UTR:MODIFIER:exon13/13:c.*1722T>C:,SEPN1:NM_206926.1:3'UTR:MODIFIER:exon12/12:c.*1722T>C:	AluSx	rs4659383	0.8622	0.0000	0/0/0	0.7578							606210 [SEPN1 (confirmed) Muscular dystrophy,rigid spine,1,602771|Myopathy,congenital,with fiber-type disproportion,255310];	RCV000378653.1 [benign]; 			137	58					SELENON (inh=AR+AD pLI=0.00)
chr1	26144438	26144438	C	-	hom	hom	het		QUAL=4305;DP=74,80,108;MQM=59	SEPN1	3'UTR	SEPN1:NM_020451.2:3'UTR:MODIFIER:exon13/13:c.*2236delC:,SEPN1:NM_206926.1:3'UTR:MODIFIER:exon12/12:c.*2236delC:		rs397752421;rs558875165	0.7666	0.0000	0/0/0	0.7264							606210 [SEPN1 (confirmed) Muscular dystrophy,rigid spine,1,602771|Myopathy,congenital,with fiber-type disproportion,255310];	RCV000351112.1 [uncertain significance]; 			154	68					SELENON (inh=AR+AD pLI=0.00)
chr1	27106975	27106975	C	T	wt	wt	het		QUAL=3131;DP=162,190,237;MQM=60	ARID1A	synonymous	ARID1A:NM_006015.4:synonymous:LOW:exon20/20:c.6586C>T:p.Leu2196Leu,ARID1A:NM_139135.2:synonymous:LOW:exon20/20:c.5935C>T:p.Leu1979Leu		rs149633292	0.0016	0.0051	5/1/0	0.0045	0.8780		T			8.94	603024 [ARID1A (provisional) Coffin-Siris syndrome 2,614607];	RCV000193475.1 [uncertain significance]; 		COSM3724478	0	18	2	Prima Vista kein Anhalt f?r Splice-Defekt; 160727 [2] ahwalds1 28.07.2016			ARID1A (inh=AD pLI=1.00)
chr1	33245802	33245802	C	G	het	het	het		QUAL=9423;DP=261,187,252;MQM=60	YARS	synonymous	YARS:NM_003680.3:synonymous:LOW:exon11/13:c.1218G>C:p.Leu406Leu		rs699005	0.0875	0.0982	815/337/52	0.0950							603623 [YARS (confirmed) Charcot-Marie-Tooth disease,dominant intermediate C,608323];	RCV000355335.1 [benign]; 			16	248					YARS (inh=AD pLI=0.00)
chr1	33283528	33283528	G	A	het	wt	wt	low_DP	QUAL=44;DP=9,187,1;MQM=60	YARS,S100PBP	5'UTR,intron	YARS:NM_003680.3:5'UTR:MODIFIER:exon1/13:c.-683C>T:,S100PBP:NM_001256121.1:intron:MODIFIER:exon1/6:c.-120+328G>A:,S100PBP:NM_022753.3:intron:MODIFIER:exon1/6:c.-120+238G>A:		rs72654022	0.0603	0.0000	0/0/0	0.0139							603623 [YARS (confirmed) Charcot-Marie-Tooth disease,dominant intermediate C,608323];	RCV000377277.1 [benign]; 			4	13					YARS (inh=AD pLI=0.00), S100PBP (inh=n/a pLI=0.95)
chr1	33475639	33475639	G	A	het	het	het	low_MQM	QUAL=1234;DP=716,553,541;MQM=33	AK2	3'UTR,non_coding_transcript_exon	AK2:NM_001199199.1:3'UTR:MODIFIER:exon7/7:c.*791C>T:,AK2:NM_001319139.1:3'UTR:MODIFIER:exon8/8:c.*791C>T:,AK2:NM_001319141.1:3'UTR:MODIFIER:exon8/8:c.*840C>T:,AK2:NM_001319142.1:3'UTR:MODIFIER:exon6/6:c.*791C>T:,AK2:NM_013411.4:3'UTR:MODIFIER:exon7/7:c.*791C>T:,AK2:NR_134976.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.1478C>T:		rs138902451	0.0000	0.1262	0/0/0	0.0021							103020 [AK2 (confirmed) Reticular dysgenesis,267500];				0	143					AK2 (inh=AR pLI=0.01)
chr1	33475650	33475650	T	C	het	het	het	low_MQM	QUAL=1340;DP=668,550,557;MQM=33	AK2	3'UTR,non_coding_transcript_exon	AK2:NM_001199199.1:3'UTR:MODIFIER:exon7/7:c.*780A>G:,AK2:NM_001319139.1:3'UTR:MODIFIER:exon8/8:c.*780A>G:,AK2:NM_001319141.1:3'UTR:MODIFIER:exon8/8:c.*829A>G:,AK2:NM_001319142.1:3'UTR:MODIFIER:exon6/6:c.*780A>G:,AK2:NM_013411.4:3'UTR:MODIFIER:exon7/7:c.*780A>G:,AK2:NR_134976.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.1467A>G:		rs141799861	0.0000	0.1567	0/0/0	0.0020							103020 [AK2 (confirmed) Reticular dysgenesis,267500];				0	138					AK2 (inh=AR pLI=0.01)
chr1	33475687	33475687	C	G	het	het	het	low_MQM	QUAL=2564;DP=384,606,581;MQM=33	AK2	3'UTR,non_coding_transcript_exon	AK2:NM_001199199.1:3'UTR:MODIFIER:exon7/7:c.*743G>C:,AK2:NM_001319139.1:3'UTR:MODIFIER:exon8/8:c.*743G>C:,AK2:NM_001319141.1:3'UTR:MODIFIER:exon8/8:c.*792G>C:,AK2:NM_001319142.1:3'UTR:MODIFIER:exon6/6:c.*743G>C:,AK2:NM_013411.4:3'UTR:MODIFIER:exon7/7:c.*743G>C:,AK2:NR_134976.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.1430G>C:		rs201444233	0.0000	0.1149	0/0/0	0.0009							103020 [AK2 (confirmed) Reticular dysgenesis,267500];				0	99					AK2 (inh=AR pLI=0.01)
chr1	33475721	33475721	G	C	het	het	het	low_MQM	QUAL=4116;DP=336,608,552;MQM=34	AK2	3'UTR,non_coding_transcript_exon	AK2:NM_001199199.1:3'UTR:MODIFIER:exon7/7:c.*709C>G:,AK2:NM_001319139.1:3'UTR:MODIFIER:exon8/8:c.*709C>G:,AK2:NM_001319141.1:3'UTR:MODIFIER:exon8/8:c.*758C>G:,AK2:NM_001319142.1:3'UTR:MODIFIER:exon6/6:c.*709C>G:,AK2:NM_013411.4:3'UTR:MODIFIER:exon7/7:c.*709C>G:,AK2:NR_134976.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.1396C>G:		rs139591926	0.0000	0.2199	0/0/0	0.0031							103020 [AK2 (confirmed) Reticular dysgenesis,267500];				0	131					AK2 (inh=AR pLI=0.01)
chr1	33475750	33475750	A	G	het	het	het	low_MQM	QUAL=4731;DP=438,577,530;MQM=39	AK2	3'UTR,non_coding_transcript_exon	AK2:NM_001199199.1:3'UTR:MODIFIER:exon7/7:c.*680T>C:,AK2:NM_001319139.1:3'UTR:MODIFIER:exon8/8:c.*680T>C:,AK2:NM_001319141.1:3'UTR:MODIFIER:exon8/8:c.*729T>C:,AK2:NM_001319142.1:3'UTR:MODIFIER:exon6/6:c.*680T>C:,AK2:NM_013411.4:3'UTR:MODIFIER:exon7/7:c.*680T>C:,AK2:NR_134976.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.1367T>C:		rs142975905	0.0000	0.4931	0/0/0	0.0034							103020 [AK2 (confirmed) Reticular dysgenesis,267500];				0	212					AK2 (inh=AR pLI=0.01)
chr1	33475767	33475767	G	A	het	het	het	low_MQM	QUAL=4608;DP=520,548,514;MQM=41	AK2	3'UTR,non_coding_transcript_exon	AK2:NM_001199199.1:3'UTR:MODIFIER:exon7/7:c.*663C>T:,AK2:NM_001319139.1:3'UTR:MODIFIER:exon8/8:c.*663C>T:,AK2:NM_001319141.1:3'UTR:MODIFIER:exon8/8:c.*712C>T:,AK2:NM_001319142.1:3'UTR:MODIFIER:exon6/6:c.*663C>T:,AK2:NM_013411.4:3'UTR:MODIFIER:exon7/7:c.*663C>T:,AK2:NR_134976.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.1350C>T:		rs74066436	0.0000	0.4981	0/0/0	0.0035							103020 [AK2 (confirmed) Reticular dysgenesis,267500];				0	215					AK2 (inh=AR pLI=0.01)
chr1	33475791	33475791	A	G	het	het	het	low_MQM	QUAL=7358;DP=535,613,526;MQM=42	AK2	3'UTR,non_coding_transcript_exon	AK2:NM_001199199.1:3'UTR:MODIFIER:exon7/7:c.*639T>C:,AK2:NM_001319139.1:3'UTR:MODIFIER:exon8/8:c.*639T>C:,AK2:NM_001319141.1:3'UTR:MODIFIER:exon8/8:c.*688T>C:,AK2:NM_001319142.1:3'UTR:MODIFIER:exon6/6:c.*639T>C:,AK2:NM_013411.4:3'UTR:MODIFIER:exon7/7:c.*639T>C:,AK2:NR_134976.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.1326T>C:		rs6884	0.0000	0.5495	554/81/22	0.0243							103020 [AK2 (confirmed) Reticular dysgenesis,267500];				25	204					AK2 (inh=AR pLI=0.01)
chr1	33475879	33475879	C	T	het	het	het		QUAL=9315;DP=581,398,348;MQM=54	AK2	3'UTR,non_coding_transcript_exon	AK2:NM_001199199.1:3'UTR:MODIFIER:exon7/7:c.*551G>A:,AK2:NM_001319139.1:3'UTR:MODIFIER:exon8/8:c.*551G>A:,AK2:NM_001319141.1:3'UTR:MODIFIER:exon8/8:c.*600G>A:,AK2:NM_001319142.1:3'UTR:MODIFIER:exon6/6:c.*551G>A:,AK2:NM_013411.4:3'UTR:MODIFIER:exon7/7:c.*551G>A:,AK2:NR_134976.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.1238G>A:		rs61800917	0.0000	0.5000	0/0/0	0.0299							103020 [AK2 (confirmed) Reticular dysgenesis,267500];				0	230					AK2 (inh=AR pLI=0.01)
chr1	33475967	33475967	G	A	het	het	het	low_MQM	QUAL=2822;DP=417,173,193;MQM=47	AK2	3'UTR,non_coding_transcript_exon	AK2:NM_001199199.1:3'UTR:MODIFIER:exon7/7:c.*463C>T:,AK2:NM_001319139.1:3'UTR:MODIFIER:exon8/8:c.*463C>T:,AK2:NM_001319141.1:3'UTR:MODIFIER:exon8/8:c.*512C>T:,AK2:NM_001319142.1:3'UTR:MODIFIER:exon6/6:c.*463C>T:,AK2:NM_013411.4:3'UTR:MODIFIER:exon7/7:c.*463C>T:,AK2:NR_134976.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.1150C>T:		rs74066437	0.0000	0.4888	0/0/0	0.0036							103020 [AK2 (confirmed) Reticular dysgenesis,267500];				0	208					AK2 (inh=AR pLI=0.01)
chr1	33475977	33475977	G	A	het	het	het	low_MQM	QUAL=692;DP=328,148,158;MQM=40	AK2	3'UTR,non_coding_transcript_exon	AK2:NM_001199199.1:3'UTR:MODIFIER:exon7/7:c.*453C>T:,AK2:NM_001319139.1:3'UTR:MODIFIER:exon8/8:c.*453C>T:,AK2:NM_001319141.1:3'UTR:MODIFIER:exon8/8:c.*502C>T:,AK2:NM_001319142.1:3'UTR:MODIFIER:exon6/6:c.*453C>T:,AK2:NM_013411.4:3'UTR:MODIFIER:exon7/7:c.*453C>T:,AK2:NR_134976.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.1140C>T:		rs115408325	0.0000	0.4714	0/0/0	0.0001							103020 [AK2 (confirmed) Reticular dysgenesis,267500];				0	94					AK2 (inh=AR pLI=0.01)
chr1	33475979	33475979	A	G	het	het	het	low_MQM	QUAL=692;DP=328,148,158;MQM=40	AK2	3'UTR,non_coding_transcript_exon	AK2:NM_001199199.1:3'UTR:MODIFIER:exon7/7:c.*451T>C:,AK2:NM_001319139.1:3'UTR:MODIFIER:exon8/8:c.*451T>C:,AK2:NM_001319141.1:3'UTR:MODIFIER:exon8/8:c.*500T>C:,AK2:NM_001319142.1:3'UTR:MODIFIER:exon6/6:c.*451T>C:,AK2:NM_013411.4:3'UTR:MODIFIER:exon7/7:c.*451T>C:,AK2:NR_134976.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.1138T>C:		rs4045165	0.0000	0.4669	0/0/0	0.0001							103020 [AK2 (confirmed) Reticular dysgenesis,267500];				0	66					AK2 (inh=AR pLI=0.01)
chr1	33475982	33475982	C	A	het	het	het	low_MQM	QUAL=692;DP=328,148,158;MQM=40	AK2	3'UTR,non_coding_transcript_exon	AK2:NM_001199199.1:3'UTR:MODIFIER:exon7/7:c.*448G>T:,AK2:NM_001319139.1:3'UTR:MODIFIER:exon8/8:c.*448G>T:,AK2:NM_001319141.1:3'UTR:MODIFIER:exon8/8:c.*497G>T:,AK2:NM_001319142.1:3'UTR:MODIFIER:exon6/6:c.*448G>T:,AK2:NM_013411.4:3'UTR:MODIFIER:exon7/7:c.*448G>T:,AK2:NR_134976.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.1135G>T:		rs114902220	0.0000	0.4632	0/0/0	0.0003							103020 [AK2 (confirmed) Reticular dysgenesis,267500];				0	66					AK2 (inh=AR pLI=0.01)
chr1	33475993	33475993	-	C	wt	het	het	low_MQM	QUAL=430;DP=293,149,159;MQM=39	AK2	3'UTR,non_coding_transcript_exon	AK2:NM_001199199.1:3'UTR:MODIFIER:exon7/7:c.*436dupG:,AK2:NM_001319139.1:3'UTR:MODIFIER:exon8/8:c.*436dupG:,AK2:NM_001319141.1:3'UTR:MODIFIER:exon8/8:c.*485dupG:,AK2:NM_001319142.1:3'UTR:MODIFIER:exon6/6:c.*436dupG:,AK2:NM_013411.4:3'UTR:MODIFIER:exon7/7:c.*436dupG:,AK2:NR_134976.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.1123dupG:		rs67040956;rs753076639	0.0000	0.0773	0/0/0	0.0017							103020 [AK2 (confirmed) Reticular dysgenesis,267500];				0	11					AK2 (inh=AR pLI=0.01)
chr1	33476032	33476032	T	C	het	het	het	low_MQM	QUAL=247;DP=231,129,155;MQM=35	AK2	3'UTR,non_coding_transcript_exon	AK2:NM_001199199.1:3'UTR:MODIFIER:exon7/7:c.*398A>G:,AK2:NM_001319139.1:3'UTR:MODIFIER:exon8/8:c.*398A>G:,AK2:NM_001319141.1:3'UTR:MODIFIER:exon8/8:c.*447A>G:,AK2:NM_001319142.1:3'UTR:MODIFIER:exon6/6:c.*398A>G:,AK2:NM_013411.4:3'UTR:MODIFIER:exon7/7:c.*398A>G:,AK2:NR_134976.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.1085A>G:		rs77170021	0.0000	0.1585	0/0/0	0.0169							103020 [AK2 (confirmed) Reticular dysgenesis,267500];				0	129					AK2 (inh=AR pLI=0.01)
chr1	33476065	33476065	G	A	het	het	het	low_MQM	QUAL=1053;DP=324,114,150;MQM=34	AK2	3'UTR,non_coding_transcript_exon	AK2:NM_001199199.1:3'UTR:MODIFIER:exon7/7:c.*365C>T:,AK2:NM_001319139.1:3'UTR:MODIFIER:exon8/8:c.*365C>T:,AK2:NM_001319141.1:3'UTR:MODIFIER:exon8/8:c.*414C>T:,AK2:NM_001319142.1:3'UTR:MODIFIER:exon6/6:c.*365C>T:,AK2:NM_013411.4:3'UTR:MODIFIER:exon7/7:c.*365C>T:,AK2:NR_134976.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.1052C>T:		rs143947377	0.0000	0.4761	0/0/0	0.0088							103020 [AK2 (confirmed) Reticular dysgenesis,267500];				0	159					AK2 (inh=AR pLI=0.01)
chr1	33476074	33476074	A	T	het	het	wt	low_MQM	QUAL=1142;DP=344,119,156;MQM=34	AK2	3'UTR,non_coding_transcript_exon	AK2:NM_001199199.1:3'UTR:MODIFIER:exon7/7:c.*356T>A:,AK2:NM_001319139.1:3'UTR:MODIFIER:exon8/8:c.*356T>A:,AK2:NM_001319141.1:3'UTR:MODIFIER:exon8/8:c.*405T>A:,AK2:NM_001319142.1:3'UTR:MODIFIER:exon6/6:c.*356T>A:,AK2:NM_013411.4:3'UTR:MODIFIER:exon7/7:c.*356T>A:,AK2:NR_134976.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.1043T>A:		rs199780633	0.0000	0.4727	0/0/0	0.0002							103020 [AK2 (confirmed) Reticular dysgenesis,267500];				0	168					AK2 (inh=AR pLI=0.01)
chr1	33476090	33476090	T	C	het	het	het	low_MQM	QUAL=1466;DP=395,119,154;MQM=34	AK2	3'UTR,non_coding_transcript_exon	AK2:NM_001199199.1:3'UTR:MODIFIER:exon7/7:c.*340A>G:,AK2:NM_001319139.1:3'UTR:MODIFIER:exon8/8:c.*340A>G:,AK2:NM_001319141.1:3'UTR:MODIFIER:exon8/8:c.*389A>G:,AK2:NM_001319142.1:3'UTR:MODIFIER:exon6/6:c.*340A>G:,AK2:NM_013411.4:3'UTR:MODIFIER:exon7/7:c.*340A>G:,AK2:NR_134976.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.1027A>G:		rs140167370	0.0000	0.4540	0/0/0	0.0100							103020 [AK2 (confirmed) Reticular dysgenesis,267500];				0	164					AK2 (inh=AR pLI=0.01)
chr1	33476143	33476143	G	A	het	het	het	low_MQM	QUAL=136;DP=259,86,111;MQM=36	AK2	3'UTR,non_coding_transcript_exon	AK2:NM_001199199.1:3'UTR:MODIFIER:exon7/7:c.*287C>T:,AK2:NM_001319139.1:3'UTR:MODIFIER:exon8/8:c.*287C>T:,AK2:NM_001319141.1:3'UTR:MODIFIER:exon8/8:c.*336C>T:,AK2:NM_001319142.1:3'UTR:MODIFIER:exon6/6:c.*287C>T:,AK2:NM_013411.4:3'UTR:MODIFIER:exon7/7:c.*287C>T:,AK2:NR_134976.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.974C>T:		rs201412582	0.0000	0.0365	0/0/0	0.0049							103020 [AK2 (confirmed) Reticular dysgenesis,267500];				0	154					AK2 (inh=AR pLI=0.01)
chr1	33476224	33476225	AC	-	het	het	het	low_MQM	QUAL=1538;DP=219,71,74;MQM=46	AK2	3'UTR,non_coding_transcript_exon	AK2:NM_001199199.1:3'UTR:MODIFIER:exon7/7:c.*205_*206delGT:,AK2:NM_001319139.1:3'UTR:MODIFIER:exon8/8:c.*205_*206delGT:,AK2:NM_001319141.1:3'UTR:MODIFIER:exon8/8:c.*254_*255delGT:,AK2:NM_001319142.1:3'UTR:MODIFIER:exon6/6:c.*205_*206delGT:,AK2:NM_013411.4:3'UTR:MODIFIER:exon7/7:c.*205_*206delGT:,AK2:NR_134976.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.892_893delGT:		rs67829320	0.4665	0.4937	0/0/0	0.0352							103020 [AK2 (confirmed) Reticular dysgenesis,267500];				0	184					AK2 (inh=AR pLI=0.01)
chr1	33476239	33476239	T	C	het	het	het	low_MQM	QUAL=2629;DP=269,72,81;MQM=48	AK2	3'UTR,non_coding_transcript_exon	AK2:NM_001199199.1:3'UTR:MODIFIER:exon7/7:c.*191A>G:,AK2:NM_001319139.1:3'UTR:MODIFIER:exon8/8:c.*191A>G:,AK2:NM_001319141.1:3'UTR:MODIFIER:exon8/8:c.*240A>G:,AK2:NM_001319142.1:3'UTR:MODIFIER:exon6/6:c.*191A>G:,AK2:NM_013411.4:3'UTR:MODIFIER:exon7/7:c.*191A>G:,AK2:NR_134976.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.878A>G:		rs74066438	0.0000	0.4945	0/0/0	0.0136							103020 [AK2 (confirmed) Reticular dysgenesis,267500];				0	193					AK2 (inh=AR pLI=0.01)
chr1	33476292	33476292	A	G	het	het	het		QUAL=4626;DP=270,136,119;MQM=50	AK2	3'UTR,non_coding_transcript_exon	AK2:NM_001199199.1:3'UTR:MODIFIER:exon7/7:c.*138T>C:,AK2:NM_001319139.1:3'UTR:MODIFIER:exon8/8:c.*138T>C:,AK2:NM_001319141.1:3'UTR:MODIFIER:exon8/8:c.*187T>C:,AK2:NM_001319142.1:3'UTR:MODIFIER:exon6/6:c.*138T>C:,AK2:NM_013411.4:3'UTR:MODIFIER:exon7/7:c.*138T>C:,AK2:NR_134976.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.825T>C:		rs74066439	0.0000	0.4912	1/1/0	0.0128							103020 [AK2 (confirmed) Reticular dysgenesis,267500];			COSN163035	1	201					AK2 (inh=AR pLI=0.01)
chr1	33476353	33476353	C	T	het	het	het	low_MQM	QUAL=2535;DP=235,155,144;MQM=47	AK2	3'UTR,non_coding_transcript_exon	AK2:NM_001199199.1:3'UTR:MODIFIER:exon7/7:c.*77G>A:,AK2:NM_001319139.1:3'UTR:MODIFIER:exon8/8:c.*77G>A:,AK2:NM_001319141.1:3'UTR:MODIFIER:exon8/8:c.*126G>A:,AK2:NM_001319142.1:3'UTR:MODIFIER:exon6/6:c.*77G>A:,AK2:NM_013411.4:3'UTR:MODIFIER:exon7/7:c.*77G>A:,AK2:NR_134976.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.764G>A:		rs66599471	0.0000	0.3611	0/0/0	0.0023							103020 [AK2 (confirmed) Reticular dysgenesis,267500];				7	223					AK2 (inh=AR pLI=0.01)
chr1	33476385	33476385	C	G	het	het	het	low_MQM	QUAL=1365;DP=228,137,136;MQM=47	AK2	3'UTR,non_coding_transcript_exon	AK2:NM_001199199.1:3'UTR:MODIFIER:exon7/7:c.*45G>C:,AK2:NM_001319139.1:3'UTR:MODIFIER:exon8/8:c.*45G>C:,AK2:NM_001319141.1:3'UTR:MODIFIER:exon8/8:c.*94G>C:,AK2:NM_001319142.1:3'UTR:MODIFIER:exon6/6:c.*45G>C:,AK2:NM_013411.4:3'UTR:MODIFIER:exon7/7:c.*45G>C:,AK2:NR_134976.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.732G>C:		rs76881767	0.0000	0.2172	0/0/0	0.0001							103020 [AK2 (confirmed) Reticular dysgenesis,267500];				8	243					AK2 (inh=AR pLI=0.01)
chr1	33476387	33476387	C	T	het	het	het	low_MQM	QUAL=1365;DP=228,137,136;MQM=47	AK2	3'UTR,non_coding_transcript_exon	AK2:NM_001199199.1:3'UTR:MODIFIER:exon7/7:c.*43G>A:,AK2:NM_001319139.1:3'UTR:MODIFIER:exon8/8:c.*43G>A:,AK2:NM_001319141.1:3'UTR:MODIFIER:exon8/8:c.*92G>A:,AK2:NM_001319142.1:3'UTR:MODIFIER:exon6/6:c.*43G>A:,AK2:NM_013411.4:3'UTR:MODIFIER:exon7/7:c.*43G>A:,AK2:NR_134976.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.730G>A:		rs201842558	0.0000	0.2102	0/0/0	0.0001							103020 [AK2 (confirmed) Reticular dysgenesis,267500];				8	241					AK2 (inh=AR pLI=0.01)
chr1	33476396	33476396	G	A	het	het	het	low_MQM	QUAL=1717;DP=234,132,137;MQM=47	AK2	3'UTR,non_coding_transcript_exon	AK2:NM_001199199.1:3'UTR:MODIFIER:exon7/7:c.*34C>T:,AK2:NM_001319139.1:3'UTR:MODIFIER:exon8/8:c.*34C>T:,AK2:NM_001319141.1:3'UTR:MODIFIER:exon8/8:c.*83C>T:,AK2:NM_001319142.1:3'UTR:MODIFIER:exon6/6:c.*34C>T:,AK2:NM_013411.4:3'UTR:MODIFIER:exon7/7:c.*34C>T:,AK2:NR_134976.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.721C>T:		rs79824855	0.0000	0.1762	0/0/0	0.0005							103020 [AK2 (confirmed) Reticular dysgenesis,267500];				7	270					AK2 (inh=AR pLI=0.01)
chr1	33476404	33476404	T	G	het	het	het	low_MQM	QUAL=1360;DP=221,127,132;MQM=47	AK2	3'UTR,non_coding_transcript_exon	AK2:NM_001199199.1:3'UTR:MODIFIER:exon7/7:c.*26A>C:,AK2:NM_001319139.1:3'UTR:MODIFIER:exon8/8:c.*26A>C:,AK2:NM_001319141.1:3'UTR:MODIFIER:exon8/8:c.*75A>C:,AK2:NM_001319142.1:3'UTR:MODIFIER:exon6/6:c.*26A>C:,AK2:NM_013411.4:3'UTR:MODIFIER:exon7/7:c.*26A>C:,AK2:NR_134976.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.713A>C:		rs76230073	0.0000	0.1717	0/0/0	0.0004							103020 [AK2 (confirmed) Reticular dysgenesis,267500];				7	246					AK2 (inh=AR pLI=0.01)
chr1	33478931	33478931	G	C	het	wt	wt	low_MQM;pred_pathogenic	QUAL=1074;DP=678,477,594;MQM=37	AK2	missense,3'UTR,non_coding_transcript_exon	AK2:NM_001625.3:missense:MODERATE:exon6/6:c.571C>G:p.His191Asp,AK2:NM_001199199.1:missense:MODERATE:exon6/7:c.547C>G:p.His183Asp,AK2:NM_001319139.1:missense:MODERATE:exon7/8:c.427C>G:p.His143Asp,AK2:NM_001319141.1:missense:MODERATE:exon6/8:c.571C>G:p.His191Asp,AK2:NM_001319142.1:missense:MODERATE:exon5/6:c.445C>G:p.His149Asp,AK2:NM_013411.4:missense:MODERATE:exon6/7:c.571C>G:p.His191Asp,AK2:NM_001319140.1:missense:MODERATE:exon7/7:c.427C>G:p.His143Asp,AK2:NM_001319143.1:3'UTR:MODIFIER:exon5/5:c.*74C>G:,AK2:NR_134976.1:non_coding_transcript_exon:MODIFIER:exon5/6:n.559C>G:		rs80324279	0.0000	0.3397	0/0/0	0.0002	9.8270	D,D,D,D	T	B,P,P,B	T,T,T,T	26.40	103020 [AK2 (confirmed) Reticular dysgenesis,267500];			COSM4143820, COSM4143819	1	403					AK2 (inh=AR pLI=0.01)
chr1	33478959	33478959	C	G	het	wt	wt	low_MQM;pred_pathogenic	QUAL=1182;DP=650,425,556;MQM=38	AK2	missense,sequence_feature,3'UTR,non_coding_transcript_exon	AK2:NM_001625.3:missense:MODERATE:exon6/6:c.543G>C:p.Lys181Asn,AK2:NM_001199199.1:missense:MODERATE:exon6/7:c.519G>C:p.Lys173Asn,AK2:NM_001319139.1:missense:MODERATE:exon7/8:c.399G>C:p.Lys133Asn,AK2:NM_001319141.1:missense:MODERATE:exon6/8:c.543G>C:p.Lys181Asn,AK2:NM_001319142.1:missense:MODERATE:exon5/6:c.417G>C:p.Lys139Asn,AK2:NM_013411.4:missense:MODERATE:exon6/7:c.543G>C:p.Lys181Asn,AK2:NM_001319140.1:missense:MODERATE:exon7/7:c.399G>C:p.Lys133Asn,AK2:NM_001625.3:sequence_feature:MODERATE:exon6/6:c.543G>C:,AK2:NM_001319143.1:3'UTR:MODIFIER:exon5/5:c.*46G>C:,AK2:NR_134976.1:non_coding_transcript_exon:MODIFIER:exon5/6:n.531G>C:		rs72884305	0.0000	0.4088	0/0/0	0.0001	-0.4040	D,D,D,D	T	B,B,B,B	T,T,T,T	23.60	103020 [AK2 (confirmed) Reticular dysgenesis,267500];			COSM4143821, COSM4143822	0	390					AK2 (inh=AR pLI=0.01)
chr1	35246848	35246848	-	C	wt	wt	het	low_DP	QUAL=136;DP=15,10,14;MQM=60	GJB3	5'UTR	GJB3:NM_024009.2:5'UTR:MODIFIER:exon1/2:c.-551dupC:		rs869222397	0.0000	0.0000	0/0/0	0.1424							603324 [GJB3 (confirmed) Erythrokeratodermia variabilis et progressiva,133200|Deafness,autosomal dominant 2B,612644|Deafness,autosomal recessive|Deafness,autosomal dominant,with peripheral neuropathy|Deafness,digenic,GJB2/GJB3,220290];				7	46					GJB3 (inh=n/a pLI=0.00)
chr1	35251229	35251229	G	A	wt	het	het		QUAL=9691;DP=272,358,378;MQM=59	GJB3	3'UTR	GJB3:NM_001005752.1:3'UTR:MODIFIER:exon2/2:c.*53G>A:,GJB3:NM_024009.2:3'UTR:MODIFIER:exon2/2:c.*53G>A:		rs476220	0.4040	0.0000	0/0/0	0.0782							603324 [GJB3 (confirmed) Erythrokeratodermia variabilis et progressiva,133200|Deafness,autosomal dominant 2B,612644|Deafness,autosomal recessive|Deafness,autosomal dominant,with peripheral neuropathy|Deafness,digenic,GJB2/GJB3,220290];	RCV000322370.1 [benign]; RCV000379270.1 [benign]; 			150	354					GJB3 (inh=n/a pLI=0.00)
chr1	39492080	39492080	G	T	het	hom	het		QUAL=4687;DP=95,91,115;MQM=60	NDUFS5	splice_region&intron	NDUFS5:NM_001184979.1:splice_region&intron:LOW:exon1/2:c.-3+10G>T:,NDUFS5:NM_004552.2:splice_region&intron:LOW:exon1/2:c.-3+6G>T:		rs1122472	0.5377	0.0000	0/0/0	0.6956											132	81					NDUFS5 (inh=n/a pLI=0.10)
chr1	40539076	40539076	C	T	hom	het	het		QUAL=18386;DP=388,208,252;MQM=59	PPT1	3'UTR	PPT1:NM_000310.3:3'UTR:MODIFIER:exon9/9:c.*657G>A:,PPT1:NM_001142604.1:3'UTR:MODIFIER:exon6/6:c.*657G>A:		rs1126973	0.6673	0.0000	0/0/0	0.7027							600722 [PPT1 (confirmed) Ceroid lipofuscinosis,neuronal,1,256730];	RCV000407971.1 [benign]; 			121	89					PPT1 (inh=AR pLI=0.00)
chr1	40539203	40539203	-	TGAT	hom	het	het		QUAL=21578;DP=351,365,460;MQM=59	PPT1	3'UTR	PPT1:NM_000310.3:3'UTR:MODIFIER:exon9/9:c.*526_*529dupATCA:,PPT1:NM_001142604.1:3'UTR:MODIFIER:exon6/6:c.*526_*529dupATCA:		rs3841663;rs397730033	0.6140	0.0000	0/0/0	0.6307							600722 [PPT1 (confirmed) Ceroid lipofuscinosis,neuronal,1,256730];	RCV000404464.1 [benign]; 			119	91					PPT1 (inh=AR pLI=0.00)
chr1	40539228	40539228	G	C	hom	het	het		QUAL=29600;DP=535,425,539;MQM=59	PPT1	3'UTR	PPT1:NM_000310.3:3'UTR:MODIFIER:exon9/9:c.*505C>G:,PPT1:NM_001142604.1:3'UTR:MODIFIER:exon6/6:c.*505C>G:		rs1126972	0.6607	0.0000	0/0/0	0.1107							600722 [PPT1 (confirmed) Ceroid lipofuscinosis,neuronal,1,256730];	RCV000308813.1 [benign]; 			121	89					PPT1 (inh=AR pLI=0.00)
chr1	40539448	40539448	A	C	hom	het	het		QUAL=39256;DP=867,416,464;MQM=59	PPT1	3'UTR	PPT1:NM_000310.3:3'UTR:MODIFIER:exon9/9:c.*285T>G:,PPT1:NM_001142604.1:3'UTR:MODIFIER:exon6/6:c.*285T>G:		rs1126970	0.6611	0.0000	0/0/0	0.7010							600722 [PPT1 (confirmed) Ceroid lipofuscinosis,neuronal,1,256730];	RCV000330027.1 [benign]; 			121	89					PPT1 (inh=AR pLI=0.00)
chr1	40539572	40539572	A	G	het	wt	het		QUAL=7546;DP=344,237,267;MQM=60	PPT1	3'UTR	PPT1:NM_000310.3:3'UTR:MODIFIER:exon9/9:c.*161T>C:,PPT1:NM_001142604.1:3'UTR:MODIFIER:exon6/6:c.*161T>C:		rs11552578	0.1514	0.0000	0/0/0	0.0189							600722 [PPT1 (confirmed) Ceroid lipofuscinosis,neuronal,1,256730];	RCV000261946.1 [likely benign]; 			2	43					PPT1 (inh=AR pLI=0.00)
chr1	40557033	40557033	A	G	het	wt	het	pred_pathogenic	QUAL=9320;DP=434,345,350;MQM=59	PPT1	missense,intron	PPT1:NM_000310.3:missense:MODERATE:exon4/9:c.401T>C:p.Ile134Thr,PPT1:NM_001142604.1:intron:MODIFIER:exon1/5:c.125-1849T>C:		rs1800205	0.0739	0.0667	410/111/0	0.0631	0.5740	T,T,T,T	T	B,B	D,D,D,D	15.55	600722 [PPT1 (confirmed) Ceroid lipofuscinosis,neuronal,1,256730];	RCV000118047.4 [other]; RCV000306615.1 [likely benign]; 		COSM3751190	6	169					PPT1 (inh=AR pLI=0.00)
chr1	40562993	40562993	T	C	hom	hom	hom		QUAL=5986;DP=36,62,101;MQM=59	PPT1	5'UTR	PPT1:NM_000310.3:5'UTR:MODIFIER:exon1/9:c.-83A>G:,PPT1:NM_001142604.1:5'UTR:MODIFIER:exon1/6:c.-83A>G:		rs6600313	0.8327	0.0000	0/0/0	0.1595							600722 [PPT1 (confirmed) Ceroid lipofuscinosis,neuronal,1,256730];	RCV000354321.1 [benign]; 			174	46					PPT1 (inh=AR pLI=0.00)
chr1	40563019	40563019	G	T	het	wt	het		QUAL=1556;DP=32,53,87;MQM=60	PPT1	5'UTR	PPT1:NM_000310.3:5'UTR:MODIFIER:exon1/9:c.-109C>A:,PPT1:NM_001142604.1:5'UTR:MODIFIER:exon1/6:c.-109C>A:		rs41301070	0.1138	0.0000	0/0/0	0.0524							600722 [PPT1 (confirmed) Ceroid lipofuscinosis,neuronal,1,256730];	RCV000259483.1 [likely benign]; 			2	20					PPT1 (inh=AR pLI=0.00)
chr1	43199024	43199024	C	T	het	wt	het		QUAL=6613;DP=220,253,338;MQM=59	CLDN19	3'UTR	CLDN19:NM_148960.2:3'UTR:MODIFIER:exon5/5:c.*1733G>A:,CLDN19:NM_001123395.1:3'UTR:MODIFIER:exon4/4:c.*2515G>A:,CLDN19:NM_001185117.1:3'UTR:MODIFIER:exon3/3:c.*2409G>A:	AluSx1	rs112310775	0.1254	0.0000	0/0/0	0.1126							610036 [CLDN19 (confirmed) Hypomagnesemia 5,renal,with ocular involvement,248190];	RCV000380298.1 [likely benign]; 			5	45					CLDN19 (inh=AR pLI=0.18)
chr1	43199115	43199115	A	G	het	wt	het		QUAL=10924;DP=412,354,441;MQM=60	CLDN19	3'UTR	CLDN19:NM_148960.2:3'UTR:MODIFIER:exon5/5:c.*1642T>C:,CLDN19:NM_001123395.1:3'UTR:MODIFIER:exon4/4:c.*2424T>C:,CLDN19:NM_001185117.1:3'UTR:MODIFIER:exon3/3:c.*2318T>C:		rs56345167	0.1907	0.0000	0/0/0	0.0288							610036 [CLDN19 (confirmed) Hypomagnesemia 5,renal,with ocular involvement,248190];	RCV000345414.1 [benign]; 			8	59					CLDN19 (inh=AR pLI=0.18)
chr1	43200526	43200526	T	C	het	het	het		QUAL=5078;DP=139,127,142;MQM=59	CLDN19	3'UTR	CLDN19:NM_148960.2:3'UTR:MODIFIER:exon5/5:c.*231A>G:,CLDN19:NM_001123395.1:3'UTR:MODIFIER:exon4/4:c.*1013A>G:,CLDN19:NM_001185117.1:3'UTR:MODIFIER:exon3/3:c.*907A>G:		rs912075	0.6068	0.0000	0/0/0	0.1020							610036 [CLDN19 (confirmed) Hypomagnesemia 5,renal,with ocular involvement,248190];	RCV000328599.1 [benign]; 			80	112					CLDN19 (inh=AR pLI=0.18)
chr1	43200855	43200855	G	A	het	het	het		QUAL=7353;DP=130,212,254;MQM=59	CLDN19	3'UTR,intron	CLDN19:NM_001123395.1:3'UTR:MODIFIER:exon4/4:c.*684C>T:,CLDN19:NM_001185117.1:3'UTR:MODIFIER:exon3/3:c.*578C>T:,CLDN19:NM_148960.2:intron:MODIFIER:exon4/4:c.627-50C>T:		rs74885359	0.0387	0.0995	677/577/2	0.0929							610036 [CLDN19 (confirmed) Hypomagnesemia 5,renal,with ocular involvement,248190];				7	147					CLDN19 (inh=AR pLI=0.18)
chr1	43201216	43201216	A	C	het	het	het		QUAL=10576;DP=197,286,353;MQM=59	CLDN19	3'UTR,intron	CLDN19:NM_001123395.1:3'UTR:MODIFIER:exon4/4:c.*323T>G:,CLDN19:NM_001185117.1:3'UTR:MODIFIER:exon3/3:c.*217T>G:,CLDN19:NM_148960.2:intron:MODIFIER:exon4/4:c.626+333T>G:	L2b	rs12141833	0.5569	0.0000	0/0/0	0.0994							610036 [CLDN19 (confirmed) Hypomagnesemia 5,renal,with ocular involvement,248190];				49	74					CLDN19 (inh=AR pLI=0.18)
chr1	43201534	43201534	G	A	het	wt	het	pred_pathogenic	QUAL=4072;DP=92,175,243;MQM=59	CLDN19	missense,splice_region&intron,3'UTR	CLDN19:NM_001185117.1:missense:MODERATE:exon3/3:c.556C>T:p.Arg186Cys,CLDN19:NM_148960.2:splice_region&intron:LOW:exon4/4:c.626+15C>T:,CLDN19:NM_001123395.1:3'UTR:MODIFIER:exon4/4:c.*5C>T:		rs4660658	0.1905	0.2648	749/338/145	0.1378	-1.1650	D	T	B	D	4.82	610036 [CLDN19 (confirmed) Hypomagnesemia 5,renal,with ocular involvement,248190];	RCV000401216.1 [benign]; 		COSM3746967	47	388					CLDN19 (inh=AR pLI=0.18)
chr1	43212111	43212111	C	T	het	het	het		QUAL=9137;DP=306,181,206;MQM=59	P3H1	3'UTR	P3H1:NM_001243246.1:3'UTR:MODIFIER:exon14/14:c.*472G>A:,P3H1:NM_001146289.1:3'UTR:MODIFIER:exon15/15:c.*393G>A:,P3H1:NM_022356.3:3'UTR:MODIFIER:exon15/15:c.*257G>A:		rs6882	0.6625	0.0000	0/0/0	0.1144							610339 [LEPRE1 (confirmed) Osteogenesis imperfecta,type VIII,610915];				99	106					P3H1 (inh=AR pLI=0.00)
chr1	43212431	43212431	A	G	hom	hom	hom		QUAL=23826;DP=237,214,347;MQM=59	P3H1	synonymous,3'UTR	P3H1:NM_022356.3:synonymous:LOW:exon15/15:c.2148T>C:p.Gly716Gly,P3H1:NM_001243246.1:3'UTR:MODIFIER:exon14/14:c.*152T>C:,P3H1:NM_001146289.1:3'UTR:MODIFIER:exon15/15:c.*73T>C:		rs4660662	1.0000	1.0000	14842/7042/1411	0.8090							610339 [LEPRE1 (confirmed) Osteogenesis imperfecta,type VIII,610915];	RCV000174947.1 [likely benign]; 			1564	0					P3H1 (inh=AR pLI=0.00)
chr1	43212869	43212869	A	T	het	wt	het	pred_pathogenic	QUAL=2982;DP=114,74,126;MQM=60	P3H1	missense,intron	P3H1:NM_001243246.1:missense:MODERATE:exon14/14:c.2129T>A:p.Phe710Tyr,P3H1:NM_001146289.1:intron:MODIFIER:exon14/14:c.2074+55T>A:,P3H1:NM_022356.3:intron:MODIFIER:exon14/14:c.2055+74T>A:		rs3738496	0.1210	0.1234	1074/441/34	0.1224	-0.0100	D	T	B	T	9.96	610339 [LEPRE1 (confirmed) Osteogenesis imperfecta,type VIII,610915];				25	290					P3H1 (inh=AR pLI=0.00)
chr1	43392250	43392250	C	G	wt	het	wt		QUAL=2136;DP=301,226,267;MQM=60	SLC2A1	3'UTR	SLC2A1:NM_006516.2:3'UTR:MODIFIER:exon10/10:c.*462G>C:		rs4658	0.3834	0.0000	0/0/0	0.0535							138140 [SLC2A1 (confirmed) GLUT1 deficiency syndrome 1,infantile onset,severe,606777|GLUT1 deficiency syndrome 2,childhood onset,612126|Epilepsy,idiopathic generalized,susceptibility to,12,614847|Dystonia 9,601042|Stomatin-deficient cryohydrocytosis with neurologic defects,608885];	RCV000329519.1 [benign]; RCV000386431.1 [benign]; 			52	230					SLC2A1 (inh=AR+AD pLI=0.94)
chr1	43395635	43395635	C	T	wt	het	wt		QUAL=1581;DP=120,164,236;MQM=60	SLC2A1	synonymous	SLC2A1:NM_006516.2:synonymous:LOW:exon5/10:c.588G>A:p.Pro196Pro		rs2229682	0.1196	0.1823	2251/1501/16	0.1797							138140 [SLC2A1 (confirmed) GLUT1 deficiency syndrome 1,infantile onset,severe,606777|GLUT1 deficiency syndrome 2,childhood onset,612126|Epilepsy,idiopathic generalized,susceptibility to,12,614847|Dystonia 9,601042|Stomatin-deficient cryohydrocytosis with neurologic defects,608885];	RCV000081436.7 [benign]; RCV000263600.1 [benign]; RCV000374556.1 [benign]; 			120	923					SLC2A1 (inh=AR+AD pLI=0.94)
chr1	43396414	43396414	G	A	wt	het	wt		QUAL=2465;DP=256,155,166;MQM=59	SLC2A1	synonymous	SLC2A1:NM_006516.2:synonymous:LOW:exon4/10:c.399C>T:p.Cys133Cys		rs11537641	0.1414	0.1902	2278/1459/44	0.1851							138140 [SLC2A1 (confirmed) GLUT1 deficiency syndrome 1,infantile onset,severe,606777|GLUT1 deficiency syndrome 2,childhood onset,612126|Epilepsy,idiopathic generalized,susceptibility to,12,614847|Dystonia 9,601042|Stomatin-deficient cryohydrocytosis with neurologic defects,608885];	RCV000081433.8 [benign]; RCV000289611.1 [benign]; RCV000381688.1 [benign]; 		COSM3751205, COSM3751206, COSM3751204	124	913					SLC2A1 (inh=AR+AD pLI=0.94)
chr1	43408966	43408966	G	A	het	het	wt		QUAL=7602;DP=303,350,490;MQM=60	SLC2A1	synonymous	SLC2A1:NM_006516.2:synonymous:LOW:exon2/10:c.45C>T:p.Ala15Ala		rs1385129	0.2404	0.2446	3400/1609/153	0.2354							138140 [SLC2A1 (confirmed) GLUT1 deficiency syndrome 1,infantile onset,severe,606777|GLUT1 deficiency syndrome 2,childhood onset,612126|Epilepsy,idiopathic generalized,susceptibility to,12,614847|Dystonia 9,601042|Stomatin-deficient cryohydrocytosis with neurologic defects,608885];	RCV000081435.7 [benign]; RCV000311968.1 [benign]; RCV000366638.1 [benign]; 		COSM3751209, COSM3751207, COSM3751208	157	992					SLC2A1 (inh=AR+AD pLI=0.94)
chr1	44290530	44290530	A	G	het	het	hom		QUAL=7859;DP=266,116,112;MQM=60	ST3GAL3	missense,intron	ST3GAL3:NM_174963.3:missense:MODERATE:exon5/13:c.382A>G:p.Thr128Ala,ST3GAL3:NM_174968.3:missense:MODERATE:exon5/13:c.337A>G:p.Thr113Ala,ST3GAL3:NM_174971.3:missense:MODERATE:exon4/12:c.289A>G:p.Thr97Ala,ST3GAL3:NM_001270459.1:intron:MODIFIER:exon4/11:c.209+9925A>G:,ST3GAL3:NM_001270460.1:intron:MODIFIER:exon4/10:c.209+9925A>G:,ST3GAL3:NM_001270461.1:intron:MODIFIER:exon3/8:c.161+9925A>G:,ST3GAL3:NM_001270462.1:intron:MODIFIER:exon3/7:c.161+9925A>G:,ST3GAL3:NM_001270463.1:intron:MODIFIER:exon3/7:c.206+9925A>G:,ST3GAL3:NM_001270464.1:intron:MODIFIER:exon3/7:c.161+9925A>G:,ST3GAL3:NM_001270465.1:intron:MODIFIER:exon3/7:c.206+9925A>G:,ST3GAL3:NM_001270466.1:intron:MODIFIER:exon3/4:c.161+9925A>G:,ST3GAL3:NM_006279.3:intron:MODIFIER:exon4/11:c.209+9925A>G:,ST3GAL3:NM_174964.2:intron:MODIFIER:exon4/11:c.254+9925A>G:,ST3GAL3:NM_174965.2:intron:MODIFIER:exon4/6:c.254+9925A>G:,ST3GAL3:NM_174966.2:intron:MODIFIER:exon4/9:c.209+9925A>G:,ST3GAL3:NM_174967.2:intron:MODIFIER:exon4/6:c.209+9925A>G:,ST3GAL3:NM_174969.2:intron:MODIFIER:exon3/10:c.161+9925A>G:,ST3GAL3:NM_174970.2:intron:MODIFIER:exon3/5:c.161+9925A>G:,ST3GAL3:NR_073016.1:intron:MODIFIER:exon4/11:n.400+9925A>G:,ST3GAL3:NR_073017.1:intron:MODIFIER:exon2/9:n.310-13361A>G:,ST3GAL3:NR_073018.1:intron:MODIFIER:exon4/10:n.400+9925A>G:,ST3GAL3:NR_073019.1:intron:MODIFIER:exon2/8:n.310-69525A>G:,ST3GAL3:NR_073020.1:intron:MODIFIER:exon3/9:n.352+9925A>G:,ST3GAL3:NR_073021.1:intron:MODIFIER:exon4/9:n.400+9925A>G:,ST3GAL3:NR_073023.1:intron:MODIFIER:exon4/8:n.400+9925A>G:	MER5B	rs37458	0.2364	0.3476	3717/2596/394	0.2577	-0.1510	T,T,T,T,T,T	T	B,B,B	T,T,T,T,T,T	0.01	606494 [ST3GAL3 (provisional) Mental retardation,autosomal recessive 12,611090|Epileptic encephalopathy,early infantile,15,615006];	RCV000118418.3 [other]; 		COSM3751230	162	692					ST3GAL3 (inh=AR pLI=0.57)
chr1	44396196	44396196	A	G	het	wt	het		QUAL=3247;DP=160,78,120;MQM=59	ST3GAL3	3'UTR,non_coding_transcript_exon	ST3GAL3:NM_174963.3:3'UTR:MODIFIER:exon13/13:c.*303A>G:,ST3GAL3:NM_001270459.1:3'UTR:MODIFIER:exon12/12:c.*303A>G:,ST3GAL3:NM_001270460.1:3'UTR:MODIFIER:exon11/11:c.*303A>G:,ST3GAL3:NM_001270461.1:3'UTR:MODIFIER:exon9/9:c.*303A>G:,ST3GAL3:NM_001270462.1:3'UTR:MODIFIER:exon8/8:c.*303A>G:,ST3GAL3:NM_001270463.1:3'UTR:MODIFIER:exon8/8:c.*341A>G:,ST3GAL3:NM_001270464.1:3'UTR:MODIFIER:exon8/8:c.*341A>G:,ST3GAL3:NM_001270465.1:3'UTR:MODIFIER:exon8/8:c.*415A>G:,ST3GAL3:NM_001270466.1:3'UTR:MODIFIER:exon5/5:c.*341A>G:,ST3GAL3:NM_006279.3:3'UTR:MODIFIER:exon12/12:c.*303A>G:,ST3GAL3:NM_174964.2:3'UTR:MODIFIER:exon12/12:c.*303A>G:,ST3GAL3:NM_174965.2:3'UTR:MODIFIER:exon7/7:c.*322A>G:,ST3GAL3:NM_174966.2:3'UTR:MODIFIER:exon10/10:c.*303A>G:,ST3GAL3:NM_174967.2:3'UTR:MODIFIER:exon7/7:c.*322A>G:,ST3GAL3:NM_174968.3:3'UTR:MODIFIER:exon13/13:c.*303A>G:,ST3GAL3:NM_174969.2:3'UTR:MODIFIER:exon11/11:c.*303A>G:,ST3GAL3:NM_174970.2:3'UTR:MODIFIER:exon6/6:c.*322A>G:,ST3GAL3:NM_174971.3:3'UTR:MODIFIER:exon12/12:c.*303A>G:,ST3GAL3:NR_073016.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.1654A>G:,ST3GAL3:NR_073017.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1531A>G:,ST3GAL3:NR_073018.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.1501A>G:,ST3GAL3:NR_073019.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.1470A>G:,ST3GAL3:NR_073020.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1387A>G:,ST3GAL3:NR_073021.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1315A>G:,ST3GAL3:NR_073023.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.1275A>G:		rs12561948	0.0507	0.0000	0/0/0	0.0090							606494 [ST3GAL3 (provisional) Mental retardation,autosomal recessive 12,611090|Epileptic encephalopathy,early infantile,15,615006];				0	22					ST3GAL3 (inh=AR pLI=0.57)
chr1	44396646	44396646	C	G	het	hom	het		QUAL=13577;DP=234,222,264;MQM=59	ST3GAL3	3'UTR,non_coding_transcript_exon	ST3GAL3:NM_174963.3:3'UTR:MODIFIER:exon13/13:c.*753C>G:,ST3GAL3:NM_001270459.1:3'UTR:MODIFIER:exon12/12:c.*753C>G:,ST3GAL3:NM_001270460.1:3'UTR:MODIFIER:exon11/11:c.*753C>G:,ST3GAL3:NM_001270461.1:3'UTR:MODIFIER:exon9/9:c.*753C>G:,ST3GAL3:NM_001270462.1:3'UTR:MODIFIER:exon8/8:c.*753C>G:,ST3GAL3:NM_001270463.1:3'UTR:MODIFIER:exon8/8:c.*791C>G:,ST3GAL3:NM_001270464.1:3'UTR:MODIFIER:exon8/8:c.*791C>G:,ST3GAL3:NM_001270465.1:3'UTR:MODIFIER:exon8/8:c.*865C>G:,ST3GAL3:NM_001270466.1:3'UTR:MODIFIER:exon5/5:c.*791C>G:,ST3GAL3:NM_006279.3:3'UTR:MODIFIER:exon12/12:c.*753C>G:,ST3GAL3:NM_174964.2:3'UTR:MODIFIER:exon12/12:c.*753C>G:,ST3GAL3:NM_174965.2:3'UTR:MODIFIER:exon7/7:c.*772C>G:,ST3GAL3:NM_174966.2:3'UTR:MODIFIER:exon10/10:c.*753C>G:,ST3GAL3:NM_174967.2:3'UTR:MODIFIER:exon7/7:c.*772C>G:,ST3GAL3:NM_174968.3:3'UTR:MODIFIER:exon13/13:c.*753C>G:,ST3GAL3:NM_174969.2:3'UTR:MODIFIER:exon11/11:c.*753C>G:,ST3GAL3:NM_174970.2:3'UTR:MODIFIER:exon6/6:c.*772C>G:,ST3GAL3:NM_174971.3:3'UTR:MODIFIER:exon12/12:c.*753C>G:,ST3GAL3:NR_073016.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.2104C>G:,ST3GAL3:NR_073017.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1981C>G:,ST3GAL3:NR_073018.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.1951C>G:,ST3GAL3:NR_073019.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.1920C>G:,ST3GAL3:NR_073020.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1837C>G:,ST3GAL3:NR_073021.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1765C>G:,ST3GAL3:NR_073023.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.1725C>G:		rs6801	0.5188	0.0000	0/0/0	0.1143							606494 [ST3GAL3 (provisional) Mental retardation,autosomal recessive 12,611090|Epileptic encephalopathy,early infantile,15,615006];				124	96					ST3GAL3 (inh=AR pLI=0.57)
chr1	45285534	45285534	A	C	wt	het	wt		QUAL=164;DP=127,26,28;MQM=60	PTCH2	3'UTR	PTCH2:NM_001166292.1:3'UTR:MODIFIER:exon23/23:c.*827T>G:		rs181782534	0.0104	0.0000	0/0/0	0.0017							603673 [PTCH2 (provisional) Medulloblastoma,somatic,155255|Basal cell carcinoma,somatic,605462|Basal cell nevus syndrome,109400];				0	6					PTCH2 (inh=AD pLI=0.00)
chr1	45285648	45285648	C	T	hom	het	het		QUAL=20148;DP=522,168,178;MQM=59	PTCH2	3'UTR	PTCH2:NM_001166292.1:3'UTR:MODIFIER:exon23/23:c.*713G>A:	U5	rs41269085	0.2290	0.0000	0/0/0	0.0328							603673 [PTCH2 (provisional) Medulloblastoma,somatic,155255|Basal cell carcinoma,somatic,605462|Basal cell nevus syndrome,109400];				9	40					PTCH2 (inh=AD pLI=0.00)
chr1	45292866	45292866	G	A	hom	het	het		QUAL=9055;DP=168,149,208;MQM=59	PTCH2	synonymous	PTCH2:NM_003738.4:synonymous:LOW:exon16/22:c.2487C>T:p.Asp829Asp,PTCH2:NM_001166292.1:synonymous:LOW:exon16/23:c.2487C>T:p.Asp829Asp		rs2295996	0.1478	0.1608	1683/926/42	0.1606							603673 [PTCH2 (provisional) Medulloblastoma,somatic,155255|Basal cell carcinoma,somatic,605462|Basal cell nevus syndrome,109400];			COSM3751243	48	458					PTCH2 (inh=AD pLI=0.00)
chr1	45293518	45293518	A	G	hom	het	het		QUAL=13200;DP=202,269,323;MQM=59	PTCH2	synonymous	PTCH2:NM_003738.4:synonymous:LOW:exon14/22:c.2055T>C:p.Ala685Ala,PTCH2:NM_001166292.1:synonymous:LOW:exon14/23:c.2055T>C:p.Ala685Ala		rs7525308	0.4455	0.3846	9301/4018/1766	0.3798							603673 [PTCH2 (provisional) Medulloblastoma,somatic,155255|Basal cell carcinoma,somatic,605462|Basal cell nevus syndrome,109400];			COSM3751244	198	763					PTCH2 (inh=AD pLI=0.00)
chr1	45340282	45340282	C	T	hom	het	het		QUAL=20673;DP=403,252,315;MQM=60	EIF2B3	3'UTR,intron	EIF2B3:NM_001166588.2:3'UTR:MODIFIER:exon10/10:c.*31G>A:,EIF2B3:NM_020365.4:intron:MODIFIER:exon10/11:c.1202+68G>A:,EIF2B3:NM_001261418.1:intron:MODIFIER:exon10/10:c.1202+68G>A:	HAL1	rs9988451	0.4517	0.4112	9682/4009/1747	0.3862							606273 [EIF2B3 (provisional) Leukoencephalopathy with vanishing white matter,603896];				109	344					EIF2B3 (inh=AR pLI=0.39)
chr1	45452227	45452227	G	C	hom	het	het		QUAL=6946;DP=130,108,187;MQM=59	EIF2B3	5'UTR	EIF2B3:NM_020365.4:5'UTR:MODIFIER:exon1/12:c.-72C>G:,EIF2B3:NM_001261418.1:5'UTR:MODIFIER:exon1/11:c.-72C>G:,EIF2B3:NM_001166588.2:5'UTR:MODIFIER:exon1/10:c.-72C>G:		rs489676	0.4806	0.0000	0/0/0	0.4437							606273 [EIF2B3 (provisional) Leukoencephalopathy with vanishing white matter,603896];	RCV000343867.1 [benign]; 			49	89					EIF2B3 (inh=AR pLI=0.39)
chr1	45975166	45975166	A	G	wt	wt	het		QUAL=1052;DP=209,130,149;MQM=59	MMACHC	3'UTR	MMACHC:NM_015506.2:3'UTR:MODIFIER:exon4/4:c.*279A>G:	AluSg7	rs9729395	0.2634	0.0000	0/0/0	0.2228							609831 [MMACHC (confirmed) Methylmalonic aciduria and homocystinuria,cblC type,277400];	RCV000387796.1 [benign]; 			13	78					MMACHC (inh=AR pLI=0.00)
chr1	45975300	45975300	G	A	wt	het	wt		QUAL=2063;DP=199,139,195;MQM=59	MMACHC	3'UTR	MMACHC:NM_015506.2:3'UTR:MODIFIER:exon4/4:c.*413G>A:	AluSg7	rs12021717	0.1184	0.0000	0/0/0	0.1696							609831 [MMACHC (confirmed) Methylmalonic aciduria and homocystinuria,cblC type,277400];	RCV000384248.1 [likely benign]; 			5	52					MMACHC (inh=AR pLI=0.00)
chr1	45975740	45975741	CT	-	wt	wt	het		QUAL=1678;DP=245,180,191;MQM=58	MMACHC	3'UTR	MMACHC:NM_015506.2:3'UTR:MODIFIER:exon4/4:c.*855_*856delCT:	AluSx4	rs398052965	0.7438	0.0000	0/0/0	0.5546							609831 [MMACHC (confirmed) Methylmalonic aciduria and homocystinuria,cblC type,277400];	RCV000297985.1 [benign]; 			78	61					MMACHC (inh=AR pLI=0.00)
chr1	45976147	45976147	G	A	wt	wt	het		QUAL=4630;DP=346,282,403;MQM=59	MMACHC	3'UTR	MMACHC:NM_015506.2:3'UTR:MODIFIER:exon4/4:c.*1260G>A:	AluJr	rs882803	0.7438	0.0000	0/0/0	0.1089							609831 [MMACHC (confirmed) Methylmalonic aciduria and homocystinuria,cblC type,277400];	RCV000365287.1 [benign]; 			118	77					MMACHC (inh=AR pLI=0.00)
chr1	45976263	45976263	-	T	wt	wt	het		QUAL=3869;DP=321,263,316;MQM=60	MMACHC	3'UTR	MMACHC:NM_015506.2:3'UTR:MODIFIER:exon4/4:c.*1376_*1377insT:		rs5773883	0.7438	0.0000	0/0/0	0.6396							609831 [MMACHC (confirmed) Methylmalonic aciduria and homocystinuria,cblC type,277400];	RCV000378508.1 [benign]; 			122	87					MMACHC (inh=AR pLI=0.00)
chr1	45976587	45976587	A	G	wt	wt	het		QUAL=2431;DP=270,153,171;MQM=60	MMACHC	3'UTR	MMACHC:NM_015506.2:3'UTR:MODIFIER:exon4/4:c.*1700A>G:		rs1044717	0.8255	0.0000	0/0/0	0.1135							609831 [MMACHC (confirmed) Methylmalonic aciduria and homocystinuria,cblC type,277400];	RCV000280469.1 [benign]; 			124	86					MMACHC (inh=AR pLI=0.00)
chr1	46164846	46164846	A	T	hom	het	hom		QUAL=21027;DP=306,179,299;MQM=60	IPP	3'UTR,intron	IPP:NM_005897.2:3'UTR:MODIFIER:exon9/9:c.*792T>A:,IPP:NM_001145349.1:intron:MODIFIER:exon9/9:c.1651+896T>A:		rs10749856	0.3249	0.0000	0/0/0	0.0537											26	101					IPP (inh=n/a pLI=0.00)
chr1	46195375	46195375	T	C	hom	het	hom	pred_pathogenic	QUAL=10538;DP=231,60,65;MQM=60	IPP	missense	IPP:NM_005897.2:missense:MODERATE:exon4/9:c.791A>G:p.Lys264Arg,IPP:NM_001145349.1:missense:MODERATE:exon4/10:c.791A>G:p.Lys264Arg		rs28375469	0.3149	0.3040	5748/2867/309	0.3012	7.6230	T,T	T	B,B	T,T	16.17				COSM146501, COSM3751253	132	456					IPP (inh=n/a pLI=0.00)
chr1	46655158	46655158	T	C	hom	hom	hom	pred_pathogenic	QUAL=12742;DP=142,142,128;MQM=59	POMGNT1	missense&splice_region,missense	POMGNT1:NM_001243766.1:missense&splice_region:MODERATE:exon21/23:c.1867A>G:p.Met623Val,POMGNT1:NM_001290129.1:missense:MODERATE:exon20/22:c.1801A>G:p.Met601Val,POMGNT1:NM_001290130.1:missense:MODERATE:exon20/22:c.1438A>G:p.Met480Val,POMGNT1:NM_017739.3:missense:MODERATE:exon21/22:c.1867A>G:p.Met623Val		rs6659553	0.9425	0.9838	58446/33140/3478	0.9299	5.7560	T,T,T,T	T	B,B,B	D,D,D,D	5.36	606822 [POMGNT1 (confirmed) Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,3,253280|Muscular dystrophy-dystroglycanopathy (congenital with mental retardation),type B,3,613151|Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,3,613157|Retinitis pigmentosa 76,617123];	RCV000153758.3 [benign]; 			1563	1					POMGNT1 (inh=AR pLI=0.00)
chr1	46660295	46660295	T	C	hom	hom	het	pred_pathogenic	QUAL=17633;DP=264,199,302;MQM=59	POMGNT1	synonymous	POMGNT1:NM_001243766.1:synonymous:LOW:exon8/23:c.681A>G:p.Lys227Lys,POMGNT1:NM_001290129.1:synonymous:LOW:exon7/22:c.615A>G:p.Lys205Lys,POMGNT1:NM_001290130.1:synonymous:LOW:exon7/22:c.252A>G:p.Lys84Lys,POMGNT1:NM_017739.3:synonymous:LOW:exon8/22:c.681A>G:p.Lys227Lys		rs2292487	0.3335	0.3549	8093/4203/641	0.3477	0.5750	D	T			6.38	606822 [POMGNT1 (confirmed) Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,3,253280|Muscular dystrophy-dystroglycanopathy (congenital with mental retardation),type B,3,613151|Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,3,613157|Retinitis pigmentosa 76,617123];	RCV000081805.9 [other]; RCV000304915.1 [likely benign]; RCV000343385.1 [likely benign]; 		COSM3751255, COSM3751254	205	691					POMGNT1 (inh=AR pLI=0.00)
chr1	47716041	47716042	AA	-	het	het	wt		QUAL=5398;DP=257,175,176;MQM=56	STIL	3'UTR	STIL:NM_001048166.1:3'UTR:MODIFIER:exon17/17:c.*766_*767delTT:,STIL:NM_001282936.1:3'UTR:MODIFIER:exon18/18:c.*766_*767delTT:,STIL:NM_001282937.1:3'UTR:MODIFIER:exon18/18:c.*766_*767delTT:,STIL:NM_001282938.1:3'UTR:MODIFIER:exon19/19:c.*766_*767delTT:,STIL:NM_001282939.1:3'UTR:MODIFIER:exon19/19:c.*766_*767delTT:,STIL:NM_003035.2:3'UTR:MODIFIER:exon17/17:c.*766_*767delTT:		rs398089260	0.3926	0.0000	0/0/0	0.4191							181590 [STIL (confirmed) Microcephaly 7,primary,autosomal recessive,612703];	RCV000312243.1 [benign]; 			72	117					STIL (inh=AR pLI=0.20)
chr1	47717189	47717189	A	G	het	het	wt		QUAL=8355;DP=443,230,306;MQM=59	STIL	synonymous	STIL:NM_001048166.1:synonymous:LOW:exon17/17:c.3486T>C:p.Pro1162Pro,STIL:NM_001282936.1:synonymous:LOW:exon18/18:c.3483T>C:p.Pro1161Pro,STIL:NM_001282937.1:synonymous:LOW:exon18/18:c.3432T>C:p.Pro1144Pro,STIL:NM_001282938.1:synonymous:LOW:exon19/19:c.3345T>C:p.Pro1115Pro,STIL:NM_001282939.1:synonymous:LOW:exon19/19:c.3291T>C:p.Pro1097Pro,STIL:NM_003035.2:synonymous:LOW:exon17/17:c.3483T>C:p.Pro1161Pro		rs2758735	0.3934	0.4979	15897/9723/152	0.4882							181590 [STIL (confirmed) Microcephaly 7,primary,autosomal recessive,612703];	RCV000147697.1 [benign]; RCV000080044.7 [benign]; RCV000265706.1 [benign]; 			440	794					STIL (inh=AR pLI=0.20)
chr1	47726087	47726087	T	C	het	het	het		QUAL=6435;DP=210,117,176;MQM=60	STIL	missense	STIL:NM_001048166.1:missense:MODERATE:exon16/17:c.2954A>G:p.His985Arg,STIL:NM_001282936.1:missense:MODERATE:exon17/18:c.2951A>G:p.His984Arg,STIL:NM_001282937.1:missense:MODERATE:exon17/18:c.2900A>G:p.His967Arg,STIL:NM_001282938.1:missense:MODERATE:exon18/19:c.2813A>G:p.His938Arg,STIL:NM_001282939.1:missense:MODERATE:exon18/19:c.2759A>G:p.His920Arg,STIL:NM_003035.2:missense:MODERATE:exon16/17:c.2951A>G:p.His984Arg		rs13376679	0.1783	0.2421	4067/3002/232	0.2413	0.0410	T,T,T,T,T	T	B,B,B	T,T,T,T,T	0.01	181590 [STIL (confirmed) Microcephaly 7,primary,autosomal recessive,612703];	RCV000080043.6 [benign]; RCV000279688.1 [likely benign]; 		COSM4144058	129	613					STIL (inh=AR pLI=0.20)
chr1	47767914	47767914	G	A	het	het	hom	pred_pathogenic	QUAL=13793;DP=245,186,259;MQM=60	STIL	missense	STIL:NM_001048166.1:missense:MODERATE:exon4/17:c.257C>T:p.Ala86Val,STIL:NM_001282936.1:missense:MODERATE:exon5/18:c.257C>T:p.Ala86Val,STIL:NM_001282937.1:missense:MODERATE:exon5/18:c.257C>T:p.Ala86Val,STIL:NM_001282938.1:missense:MODERATE:exon5/19:c.257C>T:p.Ala86Val,STIL:NM_001282939.1:missense:MODERATE:exon5/19:c.257C>T:p.Ala86Val,STIL:NM_003035.2:missense:MODERATE:exon4/17:c.257C>T:p.Ala86Val		rs3125630	0.6064	0.5034	16139/7072/3680	0.5027	5.1820	T,T,T,T,T,T,T	T	B,B,B,B	T,T,T,T,T,T,T	9.33	181590 [STIL (confirmed) Microcephaly 7,primary,autosomal recessive,612703];	RCV000020526.1 [benign]; RCV000147687.2 [other]; RCV000262563.1 [benign]; 			333	788					STIL (inh=AR pLI=0.20)
chr1	51066088	51066088	T	C	het	het	wt		QUAL=3510;DP=166,136,172;MQM=60	FAF1	intron	FAF1:NM_007051.2:intron:MODIFIER:exon8/18:c.745-4200A>G:	Charlie1a	rs6679854	0.1695	0.0000	0/0/0	0.2165											12	64					FAF1 (inh=n/a pLI=1.00)
chr1	53676448	53676448	G	A	het	wt	hom	pred_pathogenic	QUAL=11045;DP=289,215,229;MQM=59	CPT2	missense	CPT2:NM_000098.2:missense:MODERATE:exon4/5:c.1102G>A:p.Val368Ile		rs1799821	0.4131	0.4841	15346/9849/451	0.4864	-0.0540	T	T	B	D	0.01	600650 [CPT2 (confirmed) CPT II deficiency,myopathic,stress-induced,255110|CPT II deficiency,infantile,600649|CPT II deficiency,lethal neonatal,608836|Encephalopathy,acute,infection-induced,4,susceptibility to,614212];	RCV000023026.3 [other]; RCV000078116.6 [benign]; RCV000202483.2 [benign]; 	CM139511 [CLASS=DP MUT=ALT PHEN="Infuenza infection-associated encephalopathy" GENE=CPT2]; 	COSM3751293	394	717	2	[2] old entry - no details available			CPT2 (inh=AR pLI=0.00)
chr1	53679229	53679229	A	G	het	wt	het	pred_pathogenic	QUAL=6097;DP=270,179,238;MQM=60	CPT2	missense	CPT2:NM_000098.2:missense:MODERATE:exon5/5:c.1939A>G:p.Met647Val		rs1799822	0.1004	0.1620	1862/1554/9	0.1630	7.4450	D	T	B	D	23.00	600650 [CPT2 (confirmed) CPT II deficiency,myopathic,stress-induced,255110|CPT II deficiency,infantile,600649|CPT II deficiency,lethal neonatal,608836|Encephalopathy,acute,infection-induced,4,susceptibility to,614212];	RCV000078120.6 [benign]; RCV000202533.2 [other]; 		COSM3751294	62	465					CPT2 (inh=AR pLI=0.00)
chr1	53679878	53679878	T	C	wt	wt	het		QUAL=693;DP=107,48,47;MQM=60	C1orf123	3'UTR	C1orf123:NM_017887.2:3'UTR:MODIFIER:exon8/8:c.*453A>G:,C1orf123:NM_001304759.1:3'UTR:MODIFIER:exon7/7:c.*453A>G:,C1orf123:NM_001304760.1:3'UTR:MODIFIER:exon6/6:c.*453A>G:		rs1056438	0.2282	0.0000	0/0/0	0.0516							600650 [CPT2 (confirmed) CPT II deficiency,myopathic,stress-induced,255110|CPT II deficiency,infantile,600649|CPT II deficiency,lethal neonatal,608836|Encephalopathy,acute,infection-induced,4,susceptibility to,614212];	RCV000354722.1 [benign]; 			26	88					C1orf123 (inh=n/a pLI=0.00)
chr1	55315351	55315351	T	C	hom	hom	hom		QUAL=17342;DP=256,129,158;MQM=59	DHCR24	3'UTR	DHCR24:NM_014762.3:3'UTR:MODIFIER:exon9/9:c.*2555A>G:		rs657688	0.9998	0.0000	0/0/0	0.1799							606418 [DHCR24 (confirmed) Desmosterolosis,602398];	RCV000322714.1 [benign]; 			230	0					DHCR24 (inh=AR pLI=0.97)
chr1	55315941	55315941	G	T	het	wt	het		QUAL=10507;DP=447,318,386;MQM=60	DHCR24	3'UTR	DHCR24:NM_014762.3:3'UTR:MODIFIER:exon9/9:c.*1965C>A:		rs11555500	0.0102	0.0000	0/0/0	0.0046							606418 [DHCR24 (confirmed) Desmosterolosis,602398];	RCV000349713.1 [likely benign]; 			0	12					DHCR24 (inh=AR pLI=0.97)
chr1	55316082	55316082	A	C	hom	hom	hom		QUAL=25133;DP=320,190,258;MQM=59	DHCR24	3'UTR	DHCR24:NM_014762.3:3'UTR:MODIFIER:exon9/9:c.*1824T>G:		rs654561	0.9832	0.0000	0/0/0	0.1488							606418 [DHCR24 (confirmed) Desmosterolosis,602398];	RCV000281973.1 [benign]; 			230	1					DHCR24 (inh=AR pLI=0.97)
chr1	55319902	55319902	A	G	hom	hom	hom	low_DP	QUAL=600;DP=7,3,9;MQM=60	DHCR24	synonymous	DHCR24:NM_014762.3:synonymous:LOW:exon7/9:c.1026T>C:p.Ile342Ile		rs718265	0.6276	0.6651	27364/15776/1954	0.6551							606418 [DHCR24 (confirmed) Desmosterolosis,602398];	RCV000263910.1 [benign]; 		COSM4144102	691	682					DHCR24 (inh=AR pLI=0.97)
chr1	55464743	55464743	T	C	hom	hom	het		QUAL=35603;DP=348,531,648;MQM=59	BSND	5'UTR	BSND:NM_057176.2:5'UTR:MODIFIER:exon1/4:c.-117T>C:		rs2500340	0.5941	0.0000	0/0/0	0.1345							606412 [BSND (provisional) Bartter syndrome,type 4a,602522|Sensorineural deafness with mild renal dysfunction,602522];	RCV000268082.1 [benign]; 			132	81					BSND (inh=AR pLI=0.00)
chr1	55464790	55464790	C	G	hom	hom	het		QUAL=37360;DP=331,567,758;MQM=60	BSND	5'UTR_premature_start_codon_gain,5'UTR	BSND:NM_057176.2:5'UTR_premature_start_codon_gain:LOW:exon1/4:c.-70C>G:,BSND:NM_057176.2:5'UTR:MODIFIER:exon1/4:c.-70C>G:		rs2500341	0.5950	0.0000	0/0/0	0.1350							606412 [BSND (provisional) Bartter syndrome,type 4a,602522|Sensorineural deafness with mild renal dysfunction,602522];	RCV000320898.1 [benign]; 			430	266					BSND (inh=AR pLI=0.00)
chr1	55474325	55474325	A	C	het	wt	hom		QUAL=18420;DP=304,322,452;MQM=59	BSND	3'UTR	BSND:NM_057176.2:3'UTR:MODIFIER:exon4/4:c.*24A>C:		rs6682884	0.3624	0.3755	9028/5896/1215	0.3730							606412 [BSND (provisional) Bartter syndrome,type 4a,602522|Sensorineural deafness with mild renal dysfunction,602522];	RCV000304051.1 [benign]; 			157	388					BSND (inh=AR pLI=0.00)
chr1	57340727	57340727	C	A	het	hom	wt		QUAL=5784;DP=135,141,210;MQM=60	C8A	missense	C8A:NM_000562.2:missense:MODERATE:exon3/11:c.277C>A:p.Gln93Lys		rs652785	0.3437	0.3684	8692/4750/225	0.3641	0.1090	T	T	B	T	0.10	120950 [C8A (confirmed) C8 deficiency,type I,613790];	RCV000018567.2 [benign]; 			291	756					C8A (inh=AR pLI=0.00)
chr1	57383358	57383358	C	T	wt	wt	het		QUAL=6227;DP=369,378,467;MQM=60	C8A	missense	C8A:NM_000562.2:missense:MODERATE:exon11/11:c.1724C>T:p.Pro575Leu		rs17300936	0.0613	0.0963	674/535/5	0.0965	0.7220	T	T	B	T	0.18	120950 [C8A (confirmed) C8 deficiency,type I,613790];			COSM3751318	15	290					C8A (inh=AR pLI=0.00)
chr1	57395020	57395020	A	G	het	het	wt		QUAL=14134;DP=543,531,781;MQM=60	C8B	3'UTR	C8B:NM_000066.3:3'UTR:MODIFIER:exon12/12:c.*57T>C:,C8B:NM_001278543.1:3'UTR:MODIFIER:exon13/13:c.*57T>C:,C8B:NM_001278544.1:3'UTR:MODIFIER:exon13/13:c.*57T>C:		rs2795	0.3672	0.0000	0/0/0	0.0691							120960 [C8B (confirmed) C8 deficiency,type II,613789];				119	194					C8B (inh=AR pLI=0.00)
chr1	57422484	57422484	C	T	hom	hom	hom		QUAL=26325;DP=298,249,266;MQM=60	C8B	missense	C8B:NM_000066.3:missense:MODERATE:exon3/12:c.349G>A:p.Gly117Arg,C8B:NM_001278543.1:missense:MODERATE:exon4/13:c.193G>A:p.Gly65Arg,C8B:NM_001278544.1:missense:MODERATE:exon4/13:c.163G>A:p.Gly55Arg		rs1013579	0.9864	0.9773	58006/31300/5137	0.9214	0.5350	T,T,T	T	B,B	T,T,T	14.76	120960 [C8B (confirmed) C8 deficiency,type II,613789];				1467	92					C8B (inh=AR pLI=0.00)
chr1	63881552	63881552	C	T	het	het	hom	pred_pathogenic	QUAL=7428;DP=250,64,87;MQM=60	ALG6	missense	ALG6:NM_013339.3:missense:MODERATE:exon11/15:c.911C>T:p.Ser304Phe		rs4630153	0.8305	0.7514	34408/15616/3808	0.7375	0.9670	T,T	T	B	D,D	14.01	604566 [ALG6 (provisional) Congenital disorder of glycosylation,type Ic,603147];	RCV000081560.8 [other]; RCV000323730.1 [benign]; 	CM001812 [CLASS=DFP MUT=REF PHEN="Congenital disorder of glycosylation 1c mild" GENE=ALG6]; 		1466	1014	2	[2] Peter Bauer 25.08.2014			ALG6 (inh=AR pLI=0.06)
chr1	63903452	63903452	T	C	het	het	hom	low_DP	QUAL=2117;DP=96,14,21;MQM=60	ALG6	3'UTR	ALG6:NM_013339.3:3'UTR:MODIFIER:exon15/15:c.*761T>C:		rs3009572	0.6847	0.0000	0/0/0	0.0965							604566 [ALG6 (provisional) Congenital disorder of glycosylation,type Ic,603147];	RCV000401182.1 [benign]; 			68	108					ALG6 (inh=AR pLI=0.06)
chr1	67465969	67465969	C	T	wt	hom	hom	low_QUAL;low_DP	QUAL=13;DP=35,6,9;MQM=59	SLC35D1	3'UTR	SLC35D1:NM_015139.2:3'UTR:MODIFIER:exon12/12:c.*4054G>A:	AluJr		0.0000	0.0000	0/0/0	0.0001							610804 [SLC35D1 (confirmed) Schneckenbecken dysplasia,269250];				0	37					SLC35D1 (inh=AR pLI=0.00)
chr1	67465988	67465988	A	T	wt	hom	hom	low_QUAL;low_DP	QUAL=13;DP=35,6,9;MQM=59	SLC35D1	3'UTR	SLC35D1:NM_015139.2:3'UTR:MODIFIER:exon12/12:c.*4035T>A:		rs7540819	0.0000	0.0000	0/0/0	0.0386							610804 [SLC35D1 (confirmed) Schneckenbecken dysplasia,269250];				14	137					SLC35D1 (inh=AR pLI=0.00)
chr1	67520060	67520061	CA	-	het	het	hom	low_DP	QUAL=458;DP=26,8,12;MQM=59	SLC35D1	5'UTR	SLC35D1:NM_015139.2:5'UTR:MODIFIER:exon1/12:c.-365_-364delTG:		rs397707349;rs760658879	0.6562	0.0000	0/0/0	0.5830							610804 [SLC35D1 (confirmed) Schneckenbecken dysplasia,269250];				85	88					SLC35D1 (inh=AR pLI=0.00)
chr1	67520083	67520083	C	T	het	het	wt	low_DP	QUAL=238;DP=17,6,7;MQM=59	SLC35D1-C1orf141	intergenic_region	SLC35D1-C1orf141:SLC35D1-C1orf141:intergenic_region:MODIFIER::n.67520083C>T:		rs3806321	0.1567	0.0000	0/0/0	0.1649							610804 [SLC35D1 (confirmed) Schneckenbecken dysplasia,269250];				10	40					SLC35D1-C1orf141 (inh=n/a pLI=n/a)
chr1	76190216	76190216	G	A	hom	het	het	low_DP	QUAL=2288;DP=17,77,108;MQM=59	ACADM	5'UTR	ACADM:NM_001286043.1:5'UTR:MODIFIER:exon1/13:c.-257G>A:,ACADM:NM_000016.5:5'UTR:MODIFIER:exon1/12:c.-257G>A:,ACADM:NM_001127328.2:5'UTR:MODIFIER:exon1/12:c.-257G>A:,ACADM:NM_001286042.1:5'UTR:MODIFIER:exon1/11:c.-277G>A:,ACADM:NM_001286044.1:5'UTR:MODIFIER:exon1/9:c.-554G>A:		rs17848068	0.2043	0.0000	0/0/0	0.0461							607008 [ACADM (provisional) Acyl-CoA dehydrogenase,medium chain,deficiency of,201450];	RCV000322244.1 [likely benign]; 			23	95					ACADM (inh=AR pLI=0.00)
chr1	76229326	76229326	T	C	wt	het	het	low_DP	QUAL=125;DP=31,6,10;MQM=60	ACADM	3'UTR	ACADM:NM_001286043.1:3'UTR:MODIFIER:exon13/13:c.*878T>C:,ACADM:NM_000016.5:3'UTR:MODIFIER:exon12/12:c.*878T>C:,ACADM:NM_001127328.2:3'UTR:MODIFIER:exon12/12:c.*878T>C:,ACADM:NM_001286042.1:3'UTR:MODIFIER:exon11/11:c.*878T>C:,ACADM:NM_001286044.1:3'UTR:MODIFIER:exon9/9:c.*878T>C:		rs1146587	0.6917	0.0000	0/0/0	0.1104							607008 [ACADM (provisional) Acyl-CoA dehydrogenase,medium chain,deficiency of,201450];	RCV000405507.1 [benign]; 			81	100					ACADM (inh=AR pLI=0.00)
chr1	92940411	92940411	C	T	het	wt	het		QUAL=6192;DP=282,119,164;MQM=60	GFI1	3'UTR	GFI1:NM_001127215.1:3'UTR:MODIFIER:exon7/7:c.*1175G>A:,GFI1:NM_001127216.1:3'UTR:MODIFIER:exon7/7:c.*1175G>A:,GFI1:NM_005263.3:3'UTR:MODIFIER:exon7/7:c.*1175G>A:		rs41313373	0.0673	0.0000	0/0/0	0.0173							600871 [GFI1 (confirmed) Neutropenia,severe congenital 2,autosomal dominant,613107|Neutropenia,nonimmune chronic idiopathic,of adults,607847];	RCV000343388.1 [benign]; 			0	61					GFI1 (inh=AD pLI=0.03)
chr1	92941357	92941357	A	G	wt	het	wt		QUAL=3066;DP=456,230,280;MQM=60	GFI1	3'UTR	GFI1:NM_001127215.1:3'UTR:MODIFIER:exon7/7:c.*229T>C:,GFI1:NM_001127216.1:3'UTR:MODIFIER:exon7/7:c.*229T>C:,GFI1:NM_005263.3:3'UTR:MODIFIER:exon7/7:c.*229T>C:		rs4970714	0.8083	0.0000	0/0/0	0.1102							600871 [GFI1 (confirmed) Neutropenia,severe congenital 2,autosomal dominant,613107|Neutropenia,nonimmune chronic idiopathic,of adults,607847];	RCV000344425.1 [benign]; 			102	98					GFI1 (inh=AD pLI=0.03)
chr1	92944315	92944320	AGAGAG	-	hom	hom	hom		QUAL=4081;DP=59,98,149;MQM=59	GFI1	splice_region&intron	GFI1:NM_001127215.1:splice_region&intron:LOW:exon5/6:c.925-10_925-5delCTCTCT:,GFI1:NM_001127216.1:splice_region&intron:LOW:exon5/6:c.925-10_925-5delCTCTCT:,GFI1:NM_005263.3:splice_region&intron:LOW:exon5/6:c.925-10_925-5delCTCTCT:	(AG)n	rs200902533	0.0000	0.1647	369/265/7	0.0872							600871 [GFI1 (confirmed) Neutropenia,severe congenital 2,autosomal dominant,613107|Neutropenia,nonimmune chronic idiopathic,of adults,607847];	RCV000376604.1 [benign]; 			97	60					GFI1 (inh=AD pLI=0.03)
chr1	92948938	92948938	C	T	het	het	wt	pred_pathogenic	QUAL=3369;DP=105,267,325;MQM=60	GFI1	missense	GFI1:NM_001127215.1:missense:MODERATE:exon2/7:c.107G>A:p.Ser36Asn,GFI1:NM_001127216.1:missense:MODERATE:exon2/7:c.107G>A:p.Ser36Asn,GFI1:NM_005263.3:missense:MODERATE:exon2/7:c.107G>A:p.Ser36Asn		rs34631763	0.0194	0.0445	118/99/1	0.0380	4.3840	T,T,T	T	B	T,T,T	20.70	600871 [GFI1 (confirmed) Neutropenia,severe congenital 2,autosomal dominant,613107|Neutropenia,nonimmune chronic idiopathic,of adults,607847];	RCV000245181.1 [benign]; RCV000334859.1 [benign]; 		COSM3747114	4	121					GFI1 (inh=AD pLI=0.03)
chr1	97543752	97543752	G	A	het	het	het		QUAL=15965;DP=471,323,438;MQM=60	DPYD	3'UTR	DPYD:NM_000110.3:3'UTR:MODIFIER:exon23/23:c.*780C>T:		rs291593	0.3850	0.0000	0/0/0	0.0568							612779 [DPYD (confirmed) Dihydropyrimidine dehydrogenase deficiency,274270|5-fluorouracil toxicity,274270];	RCV000086445.1 [not provided]; RCV000320911.1 [likely benign]; 			15	89					DPYD (inh=AR pLI=0.00)
chr1	97543764	97543764	C	T	het	het	het		QUAL=15424;DP=403,340,463;MQM=60	DPYD	3'UTR	DPYD:NM_000110.3:3'UTR:MODIFIER:exon23/23:c.*768G>A:		rs291592	0.5775	0.0000	0/0/0	0.0816							612779 [DPYD (confirmed) Dihydropyrimidine dehydrogenase deficiency,274270|5-fluorouracil toxicity,274270];	RCV000086446.1 [not provided]; RCV000384818.1 [benign]; 			40	110					DPYD (inh=AR pLI=0.00)
chr1	97543959	97543959	C	T	het	het	wt		QUAL=7018;DP=325,214,287;MQM=60	DPYD	3'UTR	DPYD:NM_000110.3:3'UTR:MODIFIER:exon23/23:c.*573G>A:		rs1042482	0.0895	0.0000	0/0/0	0.0145							612779 [DPYD (confirmed) Dihydropyrimidine dehydrogenase deficiency,274270|5-fluorouracil toxicity,274270];	RCV000086448.1 [not provided]; RCV000381756.1 [likely benign]; 			2	24					DPYD (inh=AR pLI=0.00)
chr1	97915624	97915624	A	G	het	wt	het		QUAL=4765;DP=205,150,187;MQM=60	DPYD	synonymous	DPYD:NM_000110.3:synonymous:LOW:exon14/23:c.1896T>C:p.Phe632Phe		rs17376848	0.0521	0.0468	204/58/2	0.0484							612779 [DPYD (confirmed) Dihydropyrimidine dehydrogenase deficiency,274270|5-fluorouracil toxicity,274270];	RCV000086470.1 [not provided]; RCV000244711.1 [benign]; RCV000270743.1 [likely benign]; 			3	122					DPYD (inh=AR pLI=0.00)
chr1	98144726	98144726	T	C	wt	wt	het	pred_pathogenic;anno_pathogenic_hgmd	QUAL=585;DP=168,36,55;MQM=60	DPYD	missense	DPYD:NM_000110.3:missense:MODERATE:exon8/23:c.775A>G:p.Lys259Glu		rs45589337	0.0044	0.0102	3/2/0	0.0060	4.4930	D	D	B	D	23.40	612779 [DPYD (confirmed) Dihydropyrimidine dehydrogenase deficiency,274270|5-fluorouracil toxicity,274270];	RCV000224513.1 [likely benign]; RCV000249889.1 [benign]; 	CM033369 [CLASS=DM MUT=ALT PHEN="Dihydropyrimidine dehydrogenase deficiency" GENE=DPYD]; 		0	35	1	[3] Stephan Waldm?ller 18.11.2015 [n/a] comment imported from detected variant: HGMD: DM f?r Dihydropyrimidine dehydrogenase deficiency, Literatur nicht ?berzeugend, VUS3, swal 151118 [1] ahbuchr1 26.09.2016 MAF>1%, homozygote in ExAC			DPYD (inh=AR pLI=0.00)
chr1	98185527	98185527	A	G	hom	hom	hom		QUAL=15775;DP=206,123,150;MQM=60	DPYD	3'UTR,intron	DPYD:NM_001160301.1:3'UTR:MODIFIER:exon6/6:c.*917T>C:,DPYD:NM_000110.3:intron:MODIFIER:exon5/22:c.483+1539T>C:		rs2151562	0.9978	0.0000	0/0/0	0.1495							612779 [DPYD (confirmed) Dihydropyrimidine dehydrogenase deficiency,274270|5-fluorouracil toxicity,274270];				230	0					DPYD (inh=AR pLI=0.00)
chr1	98186077	98186077	T	C	hom	hom	hom		QUAL=20084;DP=282,138,192;MQM=60	DPYD	3'UTR,intron	DPYD:NM_001160301.1:3'UTR:MODIFIER:exon6/6:c.*367A>G:,DPYD:NM_000110.3:intron:MODIFIER:exon5/22:c.483+989A>G:		rs1333718	0.9978	0.0000	0/0/0	0.1495							612779 [DPYD (confirmed) Dihydropyrimidine dehydrogenase deficiency,274270|5-fluorouracil toxicity,274270];				230	0					DPYD (inh=AR pLI=0.00)
chr1	98348885	98348885	G	A	hom	hom	het	pred_pathogenic;anno_pathogenic_clinvar;anno_pathogenic_hgmd	QUAL=15099;DP=217,163,217;MQM=60	DPYD	missense	DPYD:NM_000110.3:missense:MODERATE:exon2/23:c.85C>T:p.Arg29Cys,DPYD:NM_001160301.1:missense:MODERATE:exon2/6:c.85C>T:p.Arg29Cys		rs1801265	0.7398	0.7652	35865/20266/1770	0.7480	2.2350	T,T	T	P	D,D	23.70	612779 [DPYD (confirmed) Dihydropyrimidine dehydrogenase deficiency,274270|5-fluorouracil toxicity,274270];	RCV000000464.2 [pathogenic]; RCV000086506.1 [not provided]; 	CM970421 [CLASS=DM? MUT=REF PHEN="Dihydropyrimidine dehydrogenase deficiency" GENE=DPYD]; 	COSM3735988, COSM3735989	927	589	2	[2] old entry - no details available			DPYD (inh=AR pLI=0.00)
chr1	98454469	98454469	G	T	wt	wt	het		QUAL=705;DP=248,71,74;MQM=60	MIR137HG	non_coding_transcript_exon	MIR137HG:NR_046105.1:non_coding_transcript_exon:MODIFIER:exon5/5:n.1556C>A:		rs41285694	0.0962	0.0000	0/0/0	0.1168											2	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98455957	98455957	G	A	wt	wt	het		QUAL=1440;DP=175,115,145;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon4/4:n.900-832C>T:	L1PA13	rs61785886	0.0966	0.0000	0/0/0	0.1169											2	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98456643	98456643	G	A	wt	wt	het		QUAL=655;DP=144,45,77;MQM=58	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon4/4:n.900-1518C>T:	AluY	rs61785887	0.0737	0.0000	0/0/0	0.0521											0	30					MIR137HG (inh=n/a pLI=n/a)
chr1	98456731	98456731	C	T	wt	wt	het		QUAL=964;DP=217,57,114;MQM=59	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon4/4:n.900-1606G>A:	AluY	rs61785888	0.0964	0.0000	0/0/0	0.1173											2	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98456907	98456907	C	A	wt	wt	het		QUAL=1313;DP=193,87,96;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon4/4:n.900-1782G>T:		rs4573558	0.1060	0.0000	0/0/0	0.1203											2	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98457303	98457303	C	G	wt	wt	het		QUAL=2096;DP=279,106,175;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon4/4:n.900-2178G>C:		rs2893376	0.1492	0.0000	0/0/0	0.1333											2	43					MIR137HG (inh=n/a pLI=n/a)
chr1	98457523	98457523	A	T	wt	wt	het		QUAL=1559;DP=205,63,126;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon4/4:n.900-2398T>A:		rs2391873	0.1378	0.0000	0/0/0	0.1294											2	43					MIR137HG (inh=n/a pLI=n/a)
chr1	98460060	98460060	A	C	het	wt	het		QUAL=2938;DP=159,63,88;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon4/4:n.899+412T>G:	AluSx		0.0000	0.0000	0/0/0	0.0000											0	2					MIR137HG (inh=n/a pLI=n/a)
chr1	98460106	98460106	G	A	hom	hom	het		QUAL=9176;DP=171,87,125;MQM=59	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon4/4:n.899+366C>T:	AluSx	rs9440288	0.8552	0.0000	0/0/0	0.7862											105	43					MIR137HG (inh=n/a pLI=n/a)
chr1	98461132	98461132	G	C	hom	hom	het		QUAL=22273;DP=266,282,368;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-576C>G:	L2a	rs9324380	0.9267	0.0000	0/0/0	0.8295											120	30					MIR137HG (inh=n/a pLI=n/a)
chr1	98461257	98461257	-	TTGT	hom	hom	het		QUAL=16857;DP=239,212,275;MQM=59	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-702_815-701insACAA:		rs10655213	0.8936	0.0000	0/0/0	0.7612											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98461443	98461443	C	T	het	het	het		QUAL=4939;DP=163,96,103;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-887G>A:		rs9662365	0.4657	0.0000	0/0/0	0.4819											32	85					MIR137HG (inh=n/a pLI=n/a)
chr1	98461954	98461954	T	C	hom	hom	het		QUAL=5952;DP=151,26,33;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-1398A>G:		rs1938570	0.8936	0.0000	0/0/0	0.7934											103	44					MIR137HG (inh=n/a pLI=n/a)
chr1	98462921	98462921	C	A	het	wt	het		QUAL=5239;DP=253,157,184;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-2365G>T:		rs146033831	0.0176	0.0000	0/0/0	0.0090											0	3					MIR137HG (inh=n/a pLI=n/a)
chr1	98465528	98465528	G	A	hom	hom	het		QUAL=22761;DP=310,253,336;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-4972C>T:		rs2154403	0.9034	0.0000	0/0/0	0.8005											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98465840	98465840	G	A	het	het	wt		QUAL=5673;DP=284,226,308;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-5284C>T:	L2a	rs116319667	0.0046	0.0000	0/0/0	0.0104											0	7					MIR137HG (inh=n/a pLI=n/a)
chr1	98466786	98466786	T	C	wt	het	wt		QUAL=1948;DP=338,144,175;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-6230A>G:		rs12138817	0.1697	0.0000	0/0/0	0.2578											10	71					MIR137HG (inh=n/a pLI=n/a)
chr1	98468539	98468540	TA	-	hom	hom	het		QUAL=16913;DP=330,145,207;MQM=59	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-7984_815-7983delTA:		rs775004417	0.8920	0.0000	0/0/0	0.7663											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98469687	98469687	A	-	het	wt	het		QUAL=6817;DP=227,251,318;MQM=59	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-9131delT:		rs564190891	0.0036	0.0000	0/0/0	0.0035											0	2					MIR137HG (inh=n/a pLI=n/a)
chr1	98470051	98470051	-	AT	hom	hom	het		QUAL=23926;DP=520,129,233;MQM=59	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-9496_815-9495insAT:		rs10655252;rs141251091	0.8636	0.0000	0/0/0	0.7729											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98470605	98470605	A	G	hom	hom	het		QUAL=6798;DP=179,20,25;MQM=59	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-10049T>C:		rs10747495	0.9022	0.0000	0/0/0	0.7966											106	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98471787	98471787	C	A	wt	het	wt		QUAL=230;DP=278,55,89;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-11231G>T:	L1ME4a	rs55635742	0.0106	0.0000	0/0/0	0.0202											0	8					MIR137HG (inh=n/a pLI=n/a)
chr1	98472208	98472208	A	G	het	wt	het		QUAL=2956;DP=167,75,97;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-11652T>C:	(ATTAC)n	rs78878051	0.0633	0.0000	0/0/0	0.0389											0	3					MIR137HG (inh=n/a pLI=n/a)
chr1	98472879	98472879	C	T	hom	hom	het		QUAL=20970;DP=327,193,254;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-12323G>A:		rs1938564	0.8137	0.0000	0/0/0	0.7712											105	43					MIR137HG (inh=n/a pLI=n/a)
chr1	98472958	98472958	T	A	hom	hom	het		QUAL=15823;DP=223,170,183;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-12402A>T:		rs1938563	0.9014	0.0000	0/0/0	0.7957											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98473716	98473716	T	A	hom	hom	het		QUAL=18931;DP=397,117,129;MQM=59	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-13160A>T:		rs1938562	0.9014	0.0000	0/0/0	0.7962											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98474767	98474767	C	T	hom	hom	het		QUAL=15240;DP=288,116,162;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-14211G>A:		rs2391902	0.8247	0.0000	0/0/0	0.7712											105	43					MIR137HG (inh=n/a pLI=n/a)
chr1	98475522	98475522	T	C	hom	hom	het		QUAL=16468;DP=309,118,172;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-14966A>G:		rs2154402	0.9255	0.0000	0/0/0	0.8296											120	30					MIR137HG (inh=n/a pLI=n/a)
chr1	98475913	98475913	G	A	hom	hom	het		QUAL=14309;DP=297,88,127;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-15357C>T:		rs9324381	0.8606	0.0000	0/0/0	0.7821											105	43					MIR137HG (inh=n/a pLI=n/a)
chr1	98476718	98476718	G	A	hom	hom	het		QUAL=26022;DP=420,219,280;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-16162C>T:		rs1938561	0.9022	0.0000	0/0/0	0.7998											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98476950	98476950	T	C	hom	hom	het		QUAL=25133;DP=337,268,329;MQM=59	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-16394A>G:	L2c	rs9440293	0.9024	0.0000	0/0/0	0.6403											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98476958	98476958	C	T	hom	hom	het		QUAL=25465;DP=344,269,338;MQM=59	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-16402G>A:	L2c	rs9727941	0.8614	0.0000	0/0/0	0.6352											105	43					MIR137HG (inh=n/a pLI=n/a)
chr1	98476966	98476966	G	C	hom	hom	het		QUAL=25209;DP=343,265,342;MQM=59	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-16410C>G:	L2c	rs9724773	0.8614	0.0000	0/0/0	0.6354											105	43					MIR137HG (inh=n/a pLI=n/a)
chr1	98478159	98478159	-	AC	hom	hom	het		QUAL=10804;DP=248,119,167;MQM=59	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-17605_815-17604dupGT:	MIRb	rs112555829;rs397754812;rs58879433	0.7742	0.0000	0/0/0	0.4118											8	140					MIR137HG (inh=n/a pLI=n/a)
chr1	98478544	98478544	A	T	hom	hom	het		QUAL=29696;DP=410,333,453;MQM=59	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-17988T>A:	L2c	rs1938565	0.9024	0.0000	0/0/0	0.7993											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98478981	98478981	C	T	hom	hom	het		QUAL=5344;DP=128,22,28;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-18425G>A:		rs1938566	0.8247	0.0000	0/0/0	0.7323											105	43					MIR137HG (inh=n/a pLI=n/a)
chr1	98480128	98480128	T	C	hom	hom	het		QUAL=22156;DP=410,195,222;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-19572A>G:	MER102b	rs1938567	0.8772	0.0000	0/0/0	0.7932											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98480212	98480212	C	T	het	het	wt		QUAL=7964;DP=430,148,203;MQM=59	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-19656G>A:	MER102b	rs11165944	0.3331	0.0000	0/0/0	0.3586											16	72					MIR137HG (inh=n/a pLI=n/a)
chr1	98480332	98480332	G	A	hom	hom	hom		QUAL=190;DP=171,48,72;MQM=52	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-19776C>T:	A-rich		0.0000	0.0000	0/0/0	0.0002											0	25					MIR137HG (inh=n/a pLI=n/a)
chr1	98480337	98480337	C	A	het	wt	wt		QUAL=423;DP=214,72,113;MQM=52	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-19781G>T:	A-rich		0.0000	0.0000	0/0/0	0.0002											0	22					MIR137HG (inh=n/a pLI=n/a)
chr1	98481750	98481750	C	T	het	het	wt		QUAL=6511;DP=333,216,299;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-21194G>A:		rs6683447	0.3187	0.0000	0/0/0	0.3452											15	63					MIR137HG (inh=n/a pLI=n/a)
chr1	98482580	98482580	G	A	hom	hom	het		QUAL=14223;DP=269,105,171;MQM=59	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-22024C>T:	L1MB1	rs2391903	0.9259	0.0000	0/0/0	0.8199											120	30					MIR137HG (inh=n/a pLI=n/a)
chr1	98482693	98482693	A	G	hom	hom	het		QUAL=16846;DP=242,159,246;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-22137T>C:	L1MB1	rs1892549	0.8710	0.0000	0/0/0	0.7905											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98482828	98482828	A	G	hom	hom	het		QUAL=15807;DP=302,122,139;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-22272T>C:	L1MB1	rs1892550	0.8710	0.0000	0/0/0	0.7905											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98482961	98482961	C	T	hom	hom	het		QUAL=14130;DP=281,97,134;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-22405G>A:	L1MB1	rs1892551	0.8710	0.0000	0/0/0	0.7844											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98483035	98483035	G	A	hom	hom	het		QUAL=9774;DP=215,54,75;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-22479C>T:		rs1892552	0.8710	0.0000	0/0/0	0.7821											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98483150	98483150	A	G	hom	hom	het	low_DP	QUAL=6153;DP=147,19,34;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-22594T>C:		rs2391904	0.8710	0.0000	0/0/0	0.7714											107	40					MIR137HG (inh=n/a pLI=n/a)
chr1	98483230	98483230	T	A	wt	het	wt		QUAL=146;DP=227,29,54;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-22674A>T:		rs116414424	0.0152	0.0000	0/0/0	0.0285											1	11					MIR137HG (inh=n/a pLI=n/a)
chr1	98483322	98483322	T	C	hom	hom	het		QUAL=6597;DP=154,33,49;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-22766A>G:		rs9324382	0.8692	0.0000	0/0/0	0.7729											104	44					MIR137HG (inh=n/a pLI=n/a)
chr1	98484152	98484152	T	C	hom	hom	het		QUAL=7933;DP=167,53,91;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-23596A>G:		rs1938571	0.8157	0.0000	0/0/0	0.7732											105	43					MIR137HG (inh=n/a pLI=n/a)
chr1	98484291	98484291	G	A	hom	hom	het		QUAL=11171;DP=210,97,108;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-23735C>T:		rs4447033	0.8710	0.0000	0/0/0	0.7890											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98484474	98484474	T	C	hom	hom	het		QUAL=3412;DP=60,40,39;MQM=57	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-23918A>G:	AluSx1	rs1938572	0.8710	0.0000	0/0/0	0.7868											106	42					MIR137HG (inh=n/a pLI=n/a)
chr1	98484617	98484617	C	T	hom	hom	het	low_DP	QUAL=3227;DP=80,12,27;MQM=59	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-24061G>A:	AluSx1	rs1938573	0.8706	0.0000	0/0/0	0.7658											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98484954	98484954	G	T	hom	hom	het		QUAL=19123;DP=335,157,223;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-24398C>A:		rs1938558	0.8708	0.0000	0/0/0	0.7888											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98485102	98485102	G	A	hom	hom	het		QUAL=13942;DP=249,128,154;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-24546C>T:	MIR	rs1938559	0.8710	0.0000	0/0/0	0.7887											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98485192	98485192	C	T	hom	hom	het		QUAL=22238;DP=509,106,138;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-24636G>A:	MIR	rs1938560	0.8710	0.0000	0/0/0	0.7891											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98485573	98485573	C	T	hom	hom	het		QUAL=8871;DP=148,88,74;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-25017G>A:		rs9324383	0.8710	0.0000	0/0/0	0.7911											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98485698	98485698	-	TTT	hom	hom	wt	low_DP	QUAL=470;DP=25,1,2;MQM=58	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-25145_815-25143dupAAA:		rs10637296;rs10695922;rs34150565	0.8578	0.0000	0/0/0	0.4872											26	27					MIR137HG (inh=n/a pLI=n/a)
chr1	98485927	98485927	T	C	hom	hom	het		QUAL=7083;DP=107,83,108;MQM=57	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-25371A>G:	AluSx1	rs9725319	0.8710	0.0000	0/0/0	0.7903											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98485991	98485991	C	T	het	wt	het		QUAL=2548;DP=111,137,160;MQM=59	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.815-25435G>A:	AluSx1	rs74829086	0.0527	0.0000	0/0/0	0.0194											0	3					MIR137HG (inh=n/a pLI=n/a)
chr1	98486162	98486162	T	C	hom	hom	het		QUAL=7636;DP=152,66,73;MQM=59	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+25402A>G:		rs4477335	0.8710	0.0000	0/0/0	0.7882											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98486242	98486242	-	A	hom	hom	het	low_DP	QUAL=4611;DP=129,19,23;MQM=59	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+25321dupT:		rs397709296	0.8678	0.0000	0/0/0	0.7504											106	42					MIR137HG (inh=n/a pLI=n/a)
chr1	98486370	98486370	G	A	hom	hom	het		QUAL=4995;DP=101,32,42;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+25194C>T:		rs4480407	0.8928	0.0000	0/0/0	0.7799											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98486694	98486694	A	C	wt	het	wt		QUAL=1888;DP=497,160,184;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+24870T>G:		rs79792869	0.0152	0.0000	0/0/0	0.0291											1	12					MIR137HG (inh=n/a pLI=n/a)
chr1	98487080	98487080	A	G	wt	het	wt		QUAL=3003;DP=492,177,218;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+24484T>C:		rs77482155	0.0222	0.0000	0/0/0	0.0357											1	17					MIR137HG (inh=n/a pLI=n/a)
chr1	98487333	98487333	A	G	hom	hom	het		QUAL=20750;DP=273,220,282;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+24231T>C:		rs9659624	0.8710	0.0000	0/0/0	0.7909											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98487510	98487510	C	A	hom	hom	het		QUAL=20809;DP=390,163,204;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+24054G>T:		rs5005705	0.8690	0.0000	0/0/0	0.7895											105	43					MIR137HG (inh=n/a pLI=n/a)
chr1	98487566	98487566	C	T	hom	hom	het		QUAL=13847;DP=235,130,144;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+23998G>A:		rs9324384	0.8710	0.0000	0/0/0	0.7897											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98487763	98487763	G	A	hom	hom	het		QUAL=18171;DP=309,165,182;MQM=59	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+23801C>T:		rs4634961	0.8710	0.0000	0/0/0	0.7913											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98487899	98487899	C	A	hom	hom	het		QUAL=19922;DP=274,232,262;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+23665G>T:		rs9324385	0.8710	0.0000	0/0/0	0.7913											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98487959	98487959	G	A	hom	hom	het		QUAL=26008;DP=377,265,326;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+23605C>T:		rs9324386	0.8710	0.0000	0/0/0	0.7911											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98488030	98488030	G	A	hom	hom	het		QUAL=22558;DP=331,214,332;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+23534C>T:		rs9324387	0.8712	0.0000	0/0/0	0.7899											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98488155	98488155	G	A	hom	hom	het		QUAL=17795;DP=284,169,197;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+23409C>T:		rs9324388	0.8710	0.0000	0/0/0	0.7905											106	42					MIR137HG (inh=n/a pLI=n/a)
chr1	98488863	98488863	A	G	hom	hom	het		QUAL=16835;DP=323,126,131;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+22701T>C:		rs9659996	0.8710	0.0000	0/0/0	0.7595											106	42					MIR137HG (inh=n/a pLI=n/a)
chr1	98488895	98488895	C	T	hom	hom	het		QUAL=10423;DP=172,101,92;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+22669G>A:		rs9658841	0.8710	0.0000	0/0/0	0.7566											106	42					MIR137HG (inh=n/a pLI=n/a)
chr1	98489080	98489080	G	A	hom	hom	het		QUAL=7306;DP=173,26,38;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+22484C>T:		rs9661157	0.8710	0.0000	0/0/0	0.7711											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98489277	98489277	-	TACTT	het	hom	het		QUAL=6221;DP=138,56,88;MQM=59	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+22286_814+22287insAAGTA:		rs142603792;rs71071680	0.8708	0.0000	0/0/0	0.7380											89	59					MIR137HG (inh=n/a pLI=n/a)
chr1	98489330	98489330	C	T	hom	hom	het		QUAL=9465;DP=220,52,81;MQM=59	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+22234G>A:		rs10747496	0.8710	0.0000	0/0/0	0.7704											106	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98489478	98489478	A	G	hom	hom	het		QUAL=19540;DP=402,125,163;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+22086T>C:		rs4584446	0.8710	0.0000	0/0/0	0.7895											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98489735	98489735	T	C	hom	hom	het		QUAL=14574;DP=328,57,130;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+21829A>G:		rs2391905	0.8710	0.0000	0/0/0	0.7857											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98490012	98490013	TT	-	hom	hom	het		QUAL=10563;DP=299,78,95;MQM=59	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+21551_814+21552delAA:	L2a	rs55633609;rs58960152	0.8706	0.0000	0/0/0	0.5632											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98490165	98490165	C	T	hom	hom	het		QUAL=8589;DP=179,46,73;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+21399G>A:		rs4950117	0.8940	0.0000	0/0/0	0.7923											106	42					MIR137HG (inh=n/a pLI=n/a)
chr1	98490358	98490358	G	T	hom	hom	het		QUAL=16004;DP=258,155,168;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+21206C>A:		rs4950118	0.8710	0.0000	0/0/0	0.7832											106	42					MIR137HG (inh=n/a pLI=n/a)
chr1	98490636	98490636	T	C	hom	hom	het		QUAL=18224;DP=371,121,172;MQM=59	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+20928A>G:		rs10783082	0.8710	0.0000	0/0/0	0.7864											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98490770	98490770	-	TTAAGTAT	hom	hom	het		QUAL=16756;DP=229,155,151;MQM=59	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+20786_814+20793dupATACTTAA:		rs397733292	0.8710	0.0000	0/0/0	0.6869											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98491248	98491248	A	C	hom	hom	het		QUAL=18353;DP=339,140,192;MQM=59	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+20316T>G:	MIR3	rs4950119	0.8682	0.0000	0/0/0	0.7714											97	50					MIR137HG (inh=n/a pLI=n/a)
chr1	98491382	98491382	G	A	hom	hom	het		QUAL=14533;DP=270,105,175;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+20182C>T:	MIRb	rs4950120	0.8710	0.0000	0/0/0	0.7898											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98491473	98491473	A	C	hom	hom	het		QUAL=17739;DP=353,116,173;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+20091T>G:	MIRb	rs4245673	0.8710	0.0000	0/0/0	0.7880											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98491732	98491732	T	C	hom	hom	het		QUAL=18299;DP=251,193,287;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+19832A>G:		rs1938568	0.8710	0.0000	0/0/0	0.7908											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98492462	98492462	C	T	hom	hom	het		QUAL=22574;DP=421,185,198;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+19102G>A:		rs9440393	0.8710	0.0000	0/0/0	0.7908											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98492580	98492580	A	G	het	het	het		QUAL=13352;DP=471,263,285;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+18984T>C:		rs9440302	0.4575	0.0000	0/0/0	0.4788											32	85					MIR137HG (inh=n/a pLI=n/a)
chr1	98492854	98492854	T	C	hom	hom	het		QUAL=16862;DP=356,95,113;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+18710A>G:		rs9324389	0.8710	0.0000	0/0/0	0.7912											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98492901	98492901	G	A	wt	het	wt		QUAL=1380;DP=324,92,90;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+18663C>T:		rs74700717	0.0106	0.0000	0/0/0	0.0213											0	8					MIR137HG (inh=n/a pLI=n/a)
chr1	98493263	98493263	A	G	hom	hom	het		QUAL=13426;DP=217,124,187;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+18301T>C:		rs1938569	0.8706	0.0000	0/0/0	0.7844											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98493785	98493785	G	A	hom	hom	het	low_DP	QUAL=3173;DP=63,11,14;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+17779C>T:		rs2022864	0.8712	0.0000	0/0/0	0.6366											106	37					MIR137HG (inh=n/a pLI=n/a)
chr1	98493789	98493789	A	G	hom	hom	het	low_DP	QUAL=3173;DP=63,11,14;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+17775T>C:		rs2022865	0.8712	0.0000	0/0/0	0.6393											106	38					MIR137HG (inh=n/a pLI=n/a)
chr1	98494185	98494185	G	A	hom	hom	het		QUAL=12898;DP=217,104,153;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+17379C>T:		rs10875124	0.8710	0.0000	0/0/0	0.7126											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98494200	98494200	A	C	hom	hom	het		QUAL=12349;DP=218,97,140;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+17364T>G:		rs10875125	0.8710	0.0000	0/0/0	0.7278											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98494388	98494388	-	A	hom	hom	het		QUAL=7544;DP=186,48,83;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+17175dupT:		rs869272703	0.8700	0.0000	0/0/0	0.7178											78	70					MIR137HG (inh=n/a pLI=n/a)
chr1	98494606	98494606	A	G	hom	hom	het		QUAL=14526;DP=242,132,151;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+16958T>C:		rs1198574	0.8712	0.0000	0/0/0	0.7876											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98495513	98495513	T	C	hom	hom	het		QUAL=10041;DP=153,95,129;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+16051A>G:		rs1198573	0.8708	0.0000	0/0/0	0.7762											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98496512	98496512	T	-	het	het	wt		QUAL=3674;DP=218,105,145;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+15052delA:		rs377025796	0.0000	0.0000	0/0/0	0.0028											0	6					MIR137HG (inh=n/a pLI=n/a)
chr1	98497176	98497176	A	C	hom	hom	het	low_DP	QUAL=6040;DP=157,16,15;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+14388T>G:		rs1198572	0.8441	0.0000	0/0/0	0.7421											94	52					MIR137HG (inh=n/a pLI=n/a)
chr1	98497355	98497355	A	G	het	het	wt	low_DP	QUAL=773;DP=54,14,10;MQM=58	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+14209T>C:		rs188465986	0.0022	0.0000	0/0/0	0.0034											0	5					MIR137HG (inh=n/a pLI=n/a)
chr1	98497672	98497672	A	G	hom	hom	het		QUAL=4984;DP=120,21,35;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+13892T>C:		rs1198571	0.8706	0.0000	0/0/0	0.7711											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98498339	98498339	C	T	wt	het	wt		QUAL=2121;DP=595,197,248;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+13225G>A:		rs17371457	0.1374	0.0000	0/0/0	0.2131											5	63					MIR137HG (inh=n/a pLI=n/a)
chr1	98498898	98498898	C	A	hom	hom	het		QUAL=24030;DP=426,190,268;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+12666G>T:		rs1782815	0.8686	0.0000	0/0/0	0.7872											105	43					MIR137HG (inh=n/a pLI=n/a)
chr1	98499590	98499590	A	-	het	wt	het		QUAL=1528;DP=84,30,34;MQM=58	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+11974delT:	(AGAA)n	rs143336786	0.0000	0.0000	0/0/0	0.0058											0	8					MIR137HG (inh=n/a pLI=n/a)
chr1	98499647	98499647	G	A	het	het	het	low_DP	QUAL=359;DP=69,17,14;MQM=53	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+11917C>T:	(AGAA)n	rs12405733	0.0000	0.0000	0/0/0	0.0157											0	93					MIR137HG (inh=n/a pLI=n/a)
chr1	98499651	98499651	G	A	het	het	het	low_DP	QUAL=495;DP=80,18,14;MQM=52	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+11913C>T:	(AGAA)n	rs1782814	0.0000	0.0000	0/0/0	0.0060											0	27					MIR137HG (inh=n/a pLI=n/a)
chr1	98499659	98499659	G	A	het	het	het	low_DP	QUAL=1926;DP=64,16,13;MQM=55	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+11905C>T:	(AGAA)n	rs58126792	0.0000	0.0000	0/0/0	0.0409											0	140					MIR137HG (inh=n/a pLI=n/a)
chr1	98499663	98499663	A	G	het	het	het	low_DP	QUAL=1926;DP=64,16,13;MQM=55	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+11901T>C:	(AGAA)n	rs60475427	0.0000	0.0000	0/0/0	0.0699											1	141					MIR137HG (inh=n/a pLI=n/a)
chr1	98499843	98499843	T	C	hom	hom	het		QUAL=10102;DP=168,95,159;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+11721A>G:		rs1782813	0.8890	0.0000	0/0/0	0.7944											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98500045	98500045	G	C	het	het	wt		QUAL=6848;DP=389,133,168;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+11519C>G:	UCON1	rs7554283	0.3195	0.0000	0/0/0	0.3462											15	63					MIR137HG (inh=n/a pLI=n/a)
chr1	98501011	98501011	T	C	het	het	wt		QUAL=7047;DP=317,201,249;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+10553A>G:		rs4950101	0.2772	0.0000	0/0/0	0.3019											13	60					MIR137HG (inh=n/a pLI=n/a)
chr1	98501984	98501984	T	C	hom	hom	het		QUAL=13773;DP=276,84,106;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+9580A>G:		rs1702294	0.8401	0.0000	0/0/0	0.7529											95	52					MIR137HG (inh=n/a pLI=n/a)
chr1	98502159	98502159	G	C	hom	hom	het		QUAL=29026;DP=321,361,439;MQM=59	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+9405C>G:	Tigger3a	rs1702293	0.9257	0.0000	0/0/0	0.8287											120	30					MIR137HG (inh=n/a pLI=n/a)
chr1	98502340	98502340	G	A	hom	hom	het		QUAL=18817;DP=241,231,244;MQM=59	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+9224C>T:	Tigger3a	rs1782810	0.7967	0.0000	0/0/0	0.7526											93	54					MIR137HG (inh=n/a pLI=n/a)
chr1	98502410	98502410	A	C	hom	hom	het		QUAL=21509;DP=277,249,297;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+9154T>G:	Tigger3a	rs1782811	0.9026	0.0000	0/0/0	0.7998											107	41					MIR137HG (inh=n/a pLI=n/a)
chr1	98502594	98502594	A	C	hom	hom	het		QUAL=17993;DP=242,208,271;MQM=59	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+8970T>G:		rs1628294	0.9257	0.0000	0/0/0	0.8274											120	30					MIR137HG (inh=n/a pLI=n/a)
chr1	98502934	98502934	G	T	hom	hom	het		QUAL=10727;DP=213,73,107;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+8630C>A:		rs1625579	0.7969	0.0000	0/0/0	0.7290											95	52					MIR137HG (inh=n/a pLI=n/a)
chr1	98506616	98506616	-	TTCATTCATTCATTCA	wt	hom	wt		QUAL=1348;DP=80,20,37;MQM=59	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+4932_814+4947dupTGAATGAATGAATGAA:		rs71988022	0.1258	0.0000	0/0/0	0.0497											0	34					MIR137HG (inh=n/a pLI=n/a)
chr1	98506616	98506616	-	TTCATTCA	hom	wt	het		QUAL=1348;DP=80,20,37;MQM=59	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+4940_814+4947dupTGAATGAA:		rs35835879	0.0000	0.0000	0/0/0	0.0212											2	29					MIR137HG (inh=n/a pLI=n/a)
chr1	98507696	98507696	A	G	hom	hom	het	low_DP	QUAL=6043;DP=154,15,35;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+3868T>C:		rs4292998	0.8129	0.0000	0/0/0	0.7547											95	51					MIR137HG (inh=n/a pLI=n/a)
chr1	98507718	98507718	C	A	hom	hom	het	low_DP	QUAL=7191;DP=184,18,38;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+3846G>T:		rs4411173	0.8896	0.0000	0/0/0	0.7927											107	40					MIR137HG (inh=n/a pLI=n/a)
chr1	98508258	98508258	C	T	hom	hom	het		QUAL=39483;DP=578,412,500;MQM=59	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+3306G>A:		rs2802535	0.8097	0.0000	0/0/0	0.7556											95	52					MIR137HG (inh=n/a pLI=n/a)
chr1	98508488	98508488	G	A	het	wt	het		QUAL=8642;DP=419,173,196;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon3/4:n.814+3076C>T:		rs78924727	0.0527	0.0000	0/0/0	0.0321											0	3					MIR137HG (inh=n/a pLI=n/a)
chr1	98512127	98512127	G	T	hom	hom	het		QUAL=32994;DP=411,412,497;MQM=59	MIR137HG	non_coding_transcript_exon	MIR137HG:NR_046105.1:non_coding_transcript_exon:MODIFIER:exon2/5:n.373C>A:		rs2660304	0.8468	0.0000	0/0/0	0.7675											96	51					MIR137HG (inh=n/a pLI=n/a)
chr1	98513144	98513144	T	A	hom	hom	het		QUAL=13152;DP=231,116,133;MQM=60	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon1/4:n.317-961A>T:		rs2660303	0.9259	0.0000	0/0/0	0.7861											120	30					MIR137HG (inh=n/a pLI=n/a)
chr1	98513676	98513676	-	CGCA	hom	hom	hom	low_DP	QUAL=3176;DP=48,15,84;MQM=57	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon1/4:n.316+1257_316+1258insTGCG:		rs150117500	0.0000	0.0000	0/0/0	0.2080											0	1					MIR137HG (inh=n/a pLI=n/a)
chr1	98513712	98513712	-	CACACACC	hom	hom	hom	low_DP	QUAL=3176;DP=48,15,84;MQM=57	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon1/4:n.316+1221_316+1222insGGTGTGTG:	(CA)n		0.0000	0.0000	0/0/0	0.0007											0	0					MIR137HG (inh=n/a pLI=n/a)
chr1	98513845	98513845	G	A	hom	hom	het		QUAL=13347;DP=150,186,260;MQM=59	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon1/4:n.316+1089C>T:		rs61786696	0.9263	0.0000	0/0/0	0.8281											120	30					MIR137HG (inh=n/a pLI=n/a)
chr1	98513959	98513959	A	G	hom	hom	het		QUAL=18117;DP=248,210,277;MQM=59	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon1/4:n.316+975T>C:		rs61786697	0.9261	0.0000	0/0/0	0.8280											120	30					MIR137HG (inh=n/a pLI=n/a)
chr1	98514590	98514590	-	CT	wt	wt	het		QUAL=150;DP=255,123,140;MQM=59	MIR137HG	intron	MIR137HG:NR_046105.1:intron:MODIFIER:exon1/4:n.316+342_316+343dupAG:		rs573652638	0.0068	0.0000	0/0/0	0.0022											0	5					MIR137HG (inh=n/a pLI=n/a)
chr1	100316589	100316589	A	G	wt	het	wt	anno_high_impact	QUAL=1880;DP=311,107,144;MQM=60	AGL	splice_acceptor,5'UTR_premature_start_codon_gain,5'UTR	AGL:NM_000644.2:splice_acceptor:HIGH:exon1/33:c.-8-2A>G:,AGL:NM_000028.2:5'UTR_premature_start_codon_gain:LOW:exon2/34:c.-10A>G:,AGL:NM_000642.2:5'UTR_premature_start_codon_gain:LOW:exon2/34:c.-10A>G:,AGL:NM_000643.2:5'UTR_premature_start_codon_gain:LOW:exon2/34:c.-10A>G:,AGL:NM_000646.2:5'UTR_premature_start_codon_gain:LOW:exon1/34:c.-201A>G:,AGL:NM_000028.2:5'UTR:MODIFIER:exon2/34:c.-10A>G:,AGL:NM_000642.2:5'UTR:MODIFIER:exon2/34:c.-10A>G:,AGL:NM_000643.2:5'UTR:MODIFIER:exon2/34:c.-10A>G:,AGL:NM_000646.2:5'UTR:MODIFIER:exon1/34:c.-201A>G:		rs2307130	0.4271	0.4687	13772/7855/351	0.4536							610860 [AGL (confirmed) Glycogen storage disease IIIa,232400|Glycogen storage disease IIIb,232400];	RCV000175636.2 [benign]; RCV000287312.1 [benign]; 			364	750	1	[1] auto-classification 16.06.2016  [2] Ute Grasshoff 24.11.2015			AGL (inh=AR pLI=0.00)
chr1	100327026	100327026	C	T	het	het	het		QUAL=12699;DP=436,201,300;MQM=60	AGL	5'UTR_premature_start_codon_gain,5'UTR,intron	AGL:NM_000645.2:5'UTR_premature_start_codon_gain:LOW:exon1/32:c.-2C>T:,AGL:NM_000645.2:5'UTR:MODIFIER:exon1/32:c.-2C>T:,AGL:NM_000028.2:intron:MODIFIER:exon2/33:c.83-33C>T:,AGL:NM_000642.2:intron:MODIFIER:exon2/33:c.83-33C>T:,AGL:NM_000643.2:intron:MODIFIER:exon2/33:c.83-33C>T:,AGL:NM_000644.2:intron:MODIFIER:exon2/33:c.83-33C>T:,AGL:NM_000646.2:intron:MODIFIER:exon2/33:c.35-33C>T:		rs2307129	0.2272	0.1962	2368/1011/766	0.1846							610860 [AGL (confirmed) Glycogen storage disease IIIa,232400|Glycogen storage disease IIIb,232400];	RCV000248220.1 [benign]; 			74	499					AGL (inh=AR pLI=0.00)
chr1	100336361	100336361	C	T	het	hom	het		QUAL=8597;DP=341,98,117;MQM=60	AGL	synonymous	AGL:NM_000028.2:synonymous:LOW:exon7/34:c.894C>T:p.Leu298Leu,AGL:NM_000642.2:synonymous:LOW:exon7/34:c.894C>T:p.Leu298Leu,AGL:NM_000643.2:synonymous:LOW:exon7/34:c.894C>T:p.Leu298Leu,AGL:NM_000644.2:synonymous:LOW:exon7/34:c.894C>T:p.Leu298Leu,AGL:NM_000646.2:synonymous:LOW:exon7/34:c.846C>T:p.Leu282Leu,AGL:NM_000645.2:synonymous:LOW:exon5/32:c.843C>T:p.Leu281Leu		rs2230306	0.7626	0.7214	31587/16316/4105	0.7110							610860 [AGL (confirmed) Glycogen storage disease IIIa,232400|Glycogen storage disease IIIb,232400];	RCV000179774.2 [benign]; RCV000327447.1 [benign]; 			817	638					AGL (inh=AR pLI=0.00)
chr1	100346741	100346741	T	C	wt	het	wt		QUAL=2696;DP=288,209,285;MQM=60	AGL	splice_region&intron	AGL:NM_000028.2:splice_region&intron:LOW:exon15/33:c.2001+8T>C:,AGL:NM_000642.2:splice_region&intron:LOW:exon15/33:c.2001+8T>C:,AGL:NM_000643.2:splice_region&intron:LOW:exon15/33:c.2001+8T>C:,AGL:NM_000644.2:splice_region&intron:LOW:exon15/33:c.2001+8T>C:,AGL:NM_000646.2:splice_region&intron:LOW:exon15/33:c.1953+8T>C:,AGL:NM_000645.2:splice_region&intron:LOW:exon13/31:c.1950+8T>C:		rs3736296	0.5585	0.5517	18801/9660/1002	0.5490							610860 [AGL (confirmed) Glycogen storage disease IIIa,232400|Glycogen storage disease IIIb,232400];	RCV000254071.1 [benign]; RCV000351044.1 [benign]; 		COSM3747457	428	781					AGL (inh=AR pLI=0.00)
chr1	100358103	100358103	C	T	het	het	het	pred_pathogenic	QUAL=8351;DP=249,182,223;MQM=60	AGL	missense	AGL:NM_000028.2:missense:MODERATE:exon24/34:c.3199C>T:p.Pro1067Ser,AGL:NM_000642.2:missense:MODERATE:exon24/34:c.3199C>T:p.Pro1067Ser,AGL:NM_000643.2:missense:MODERATE:exon24/34:c.3199C>T:p.Pro1067Ser,AGL:NM_000644.2:missense:MODERATE:exon24/34:c.3199C>T:p.Pro1067Ser,AGL:NM_000646.2:missense:MODERATE:exon24/34:c.3151C>T:p.Pro1051Ser,AGL:NM_000645.2:missense:MODERATE:exon22/32:c.3148C>T:p.Pro1050Ser		rs3753494	0.1106	0.1361	1249/817/71	0.1324	7.2300	D,D,D,D,D,D,D	T	B,B,B	T,T,T,T,T,T,T	18.13	610860 [AGL (confirmed) Glycogen storage disease IIIa,232400|Glycogen storage disease IIIb,232400];	RCV000241565.1 [benign]; RCV000363737.1 [likely benign]; 			48	421					AGL (inh=AR pLI=0.00)
chr1	100387479	100387479	G	T	wt	het	wt		QUAL=1096;DP=306,85,96;MQM=60	AGL	3'UTR	AGL:NM_000028.2:3'UTR:MODIFIER:exon34/34:c.*272G>T:,AGL:NM_000642.2:3'UTR:MODIFIER:exon34/34:c.*272G>T:,AGL:NM_000643.2:3'UTR:MODIFIER:exon34/34:c.*272G>T:,AGL:NM_000644.2:3'UTR:MODIFIER:exon34/34:c.*272G>T:,AGL:NM_000646.2:3'UTR:MODIFIER:exon34/34:c.*272G>T:,AGL:NM_000645.2:3'UTR:MODIFIER:exon32/32:c.*272G>T:		rs1804808	0.3321	0.0000	0/0/0	0.0690							610860 [AGL (confirmed) Glycogen storage disease IIIa,232400|Glycogen storage disease IIIb,232400];	RCV000407316.1 [benign]; 			36	92					AGL (inh=AR pLI=0.00)
chr1	100387939	100387939	C	T	het	hom	het		QUAL=4269;DP=172,41,53;MQM=59	AGL	3'UTR	AGL:NM_000028.2:3'UTR:MODIFIER:exon34/34:c.*732C>T:,AGL:NM_000642.2:3'UTR:MODIFIER:exon34/34:c.*732C>T:,AGL:NM_000643.2:3'UTR:MODIFIER:exon34/34:c.*732C>T:,AGL:NM_000644.2:3'UTR:MODIFIER:exon34/34:c.*732C>T:,AGL:NM_000646.2:3'UTR:MODIFIER:exon34/34:c.*732C>T:,AGL:NM_000645.2:3'UTR:MODIFIER:exon32/32:c.*732C>T:		rs3766600	0.5905	0.0000	0/0/0	0.1231							610860 [AGL (confirmed) Glycogen storage disease IIIa,232400|Glycogen storage disease IIIb,232400];	RCV000355131.1 [benign]; 			88	110					AGL (inh=AR pLI=0.00)
chr1	100388235	100388235	C	T	wt	het	wt		QUAL=258;DP=191,42,62;MQM=60	AGL	3'UTR	AGL:NM_000028.2:3'UTR:MODIFIER:exon34/34:c.*1028C>T:,AGL:NM_000642.2:3'UTR:MODIFIER:exon34/34:c.*1028C>T:,AGL:NM_000643.2:3'UTR:MODIFIER:exon34/34:c.*1028C>T:,AGL:NM_000644.2:3'UTR:MODIFIER:exon34/34:c.*1028C>T:,AGL:NM_000646.2:3'UTR:MODIFIER:exon34/34:c.*1028C>T:,AGL:NM_000645.2:3'UTR:MODIFIER:exon32/32:c.*1028C>T:		rs3766601	0.4683	0.0000	0/0/0	0.0999							610860 [AGL (confirmed) Glycogen storage disease IIIa,232400|Glycogen storage disease IIIb,232400];	RCV000294197.1 [benign]; 			51	109					AGL (inh=AR pLI=0.00)
chr1	100388503	100388503	A	C	wt	het	wt		QUAL=894;DP=222,61,69;MQM=60	AGL	3'UTR	AGL:NM_000028.2:3'UTR:MODIFIER:exon34/34:c.*1296A>C:,AGL:NM_000642.2:3'UTR:MODIFIER:exon34/34:c.*1296A>C:,AGL:NM_000643.2:3'UTR:MODIFIER:exon34/34:c.*1296A>C:,AGL:NM_000644.2:3'UTR:MODIFIER:exon34/34:c.*1296A>C:,AGL:NM_000646.2:3'UTR:MODIFIER:exon34/34:c.*1296A>C:,AGL:NM_000645.2:3'UTR:MODIFIER:exon32/32:c.*1296A>C:		rs1804809	0.3758	0.0000	0/0/0	0.4535							610860 [AGL (confirmed) Glycogen storage disease IIIa,232400|Glycogen storage disease IIIb,232400];	RCV000398834.1 [benign]; 			42	100					AGL (inh=AR pLI=0.00)
chr1	100388748	100388748	T	C	wt	het	wt		QUAL=1706;DP=267,123,168;MQM=60	AGL	3'UTR	AGL:NM_000028.2:3'UTR:MODIFIER:exon34/34:c.*1541T>C:,AGL:NM_000642.2:3'UTR:MODIFIER:exon34/34:c.*1541T>C:,AGL:NM_000643.2:3'UTR:MODIFIER:exon34/34:c.*1541T>C:,AGL:NM_000644.2:3'UTR:MODIFIER:exon34/34:c.*1541T>C:,AGL:NM_000646.2:3'UTR:MODIFIER:exon34/34:c.*1541T>C:,AGL:NM_000645.2:3'UTR:MODIFIER:exon32/32:c.*1541T>C:		rs3766603	0.4018	0.0000	0/0/0	0.4611							610860 [AGL (confirmed) Glycogen storage disease IIIa,232400|Glycogen storage disease IIIb,232400];	RCV000286279.1 [benign]; 			43	100					AGL (inh=AR pLI=0.00)
chr1	100652729	100652729	G	A	wt	het	wt		QUAL=321;DP=111,38,41;MQM=60	DBT	3'UTR	DBT:NM_001918.3:3'UTR:MODIFIER:exon11/11:c.*9082C>T:		rs72728160	0.0577	0.0000	0/0/0	0.1232							248610 [DBT (confirmed) Maple syrup urine disease,type II,248600];	RCV000298307.1 [likely benign]; 			5	53					DBT (inh=AR pLI=0.00)
chr1	100654908	100654908	A	-	het	wt	hom	low_DP	QUAL=1042;DP=44,7,1;MQM=56	DBT	3'UTR	DBT:NM_001918.3:3'UTR:MODIFIER:exon11/11:c.*6903delT:	AluSz	rs774983659	0.0000	0.0000	0/0/0	0.2479							248610 [DBT (confirmed) Maple syrup urine disease,type II,248600];	RCV000399929.1 [uncertain significance]; 			9	95					DBT (inh=AR pLI=0.00)
chr1	100654908	100654908	A	T	het	hom	wt	low_DP	QUAL=1042;DP=44,7,1;MQM=59	DBT	3'UTR	DBT:NM_001918.3:3'UTR:MODIFIER:exon11/11:c.*6903T>A:	AluSz	rs10783125	0.9339	0.0000	0/0/0	0.1954							248610 [DBT (confirmed) Maple syrup urine disease,type II,248600];	RCV000314460.1 [benign]; 			53	125					DBT (inh=AR pLI=0.00)
chr1	100654909	100654909	A	T	het	wt	hom	low_DP	QUAL=1042;DP=44,7,1;MQM=56	DBT	3'UTR	DBT:NM_001918.3:3'UTR:MODIFIER:exon11/11:c.*6902T>A:	AluSz	rs200943386	0.0000	0.0000	0/0/0	0.0172							248610 [DBT (confirmed) Maple syrup urine disease,type II,248600];				9	95					DBT (inh=AR pLI=0.00)
chr1	100655583	100655583	T	A	hom	hom	hom	low_DP	QUAL=4243;DP=101,15,13;MQM=59	DBT	3'UTR	DBT:NM_001918.3:3'UTR:MODIFIER:exon11/11:c.*6228A>T:	MER3	rs4281338	0.7668	0.0000	0/0/0	0.7349							248610 [DBT (confirmed) Maple syrup urine disease,type II,248600];	RCV000308827.1 [benign]; 			155	50					DBT (inh=AR pLI=0.00)
chr1	100655696	100655697	AA	-	het	wt	het		QUAL=3391;DP=182,57,89;MQM=59	DBT	3'UTR	DBT:NM_001918.3:3'UTR:MODIFIER:exon11/11:c.*6114_*6115delTT:	MLT1J2	rs3081711	0.0000	0.0000	0/0/0	0.1587							248610 [DBT (confirmed) Maple syrup urine disease,type II,248600];	RCV000365742.1 [uncertain significance]; 			12	71					DBT (inh=AR pLI=0.00)
chr1	100656265	100656265	C	T	hom	hom	hom		QUAL=13997;DP=174,106,140;MQM=60	DBT	3'UTR	DBT:NM_001918.3:3'UTR:MODIFIER:exon11/11:c.*5546G>A:		rs11166412	0.8007	0.0000	0/0/0	0.8565							248610 [DBT (confirmed) Maple syrup urine disease,type II,248600];	RCV000319712.1 [benign]; 			174	52					DBT (inh=AR pLI=0.00)
chr1	100656494	100656494	A	G	wt	het	wt		QUAL=1899;DP=403,187,261;MQM=60	DBT	3'UTR	DBT:NM_001918.3:3'UTR:MODIFIER:exon11/11:c.*5317T>C:		rs11166413	0.2638	0.0000	0/0/0	0.3572							248610 [DBT (confirmed) Maple syrup urine disease,type II,248600];	RCV000280316.1 [benign]; 			33	96					DBT (inh=AR pLI=0.00)
chr1	100656661	100656661	T	C	hom	hom	hom		QUAL=24018;DP=361,156,208;MQM=60	DBT	3'UTR	DBT:NM_001918.3:3'UTR:MODIFIER:exon11/11:c.*5150A>G:		rs6701655	0.7696	0.0000	0/0/0	0.8410							248610 [DBT (confirmed) Maple syrup urine disease,type II,248600];	RCV000351715.1 [benign]; 			166	59					DBT (inh=AR pLI=0.00)
chr1	100657304	100657331	ATACACACACACACACACACACACACAC	-	wt	hom	het	low_DP	QUAL=2968;DP=17,39,54;MQM=59	DBT	3'UTR	DBT:NM_001918.3:3'UTR:MODIFIER:exon11/11:c.*4480_*4507delGTGTGTGTGTGTGTGTGTGTGTGTGTAT:	(AC)n	rs140341302;rs762705983	0.0000	0.0000	0/0/0	0.2233							248610 [DBT (confirmed) Maple syrup urine disease,type II,248600];				19	11					DBT (inh=AR pLI=0.00)
chr1	100657304	100657329	ATACACACACACACACACACACACAC	-	wt	wt	het	low_DP	QUAL=2968;DP=17,39,54;MQM=60	DBT	3'UTR	DBT:NM_001918.3:3'UTR:MODIFIER:exon11/11:c.*4482_*4507delGTGTGTGTGTGTGTGTGTGTGTGTAT:	(AC)n		0.0000	0.0000	0/0/0	0.0059							248610 [DBT (confirmed) Maple syrup urine disease,type II,248600];				0	3					DBT (inh=AR pLI=0.00)
chr1	100657305	100657305	T	C	hom	wt	wt	low_DP	QUAL=2968;DP=17,39,54;MQM=51	DBT	3'UTR	DBT:NM_001918.3:3'UTR:MODIFIER:exon11/11:c.*4506A>G:		rs112901689	0.7816	0.0000	0/0/0	0.1982							248610 [DBT (confirmed) Maple syrup urine disease,type II,248600];	RCV000350352.1 [benign]; 			122	44					DBT (inh=AR pLI=0.00)
chr1	100658578	100658578	G	A	hom	hom	hom		QUAL=34963;DP=348,323,478;MQM=59	DBT	3'UTR	DBT:NM_001918.3:3'UTR:MODIFIER:exon11/11:c.*3233C>T:		rs2784174	0.7696	0.0000	0/0/0	0.8374							248610 [DBT (confirmed) Maple syrup urine disease,type II,248600];	RCV000329977.1 [benign]; 			165	60					DBT (inh=AR pLI=0.00)
chr1	100671866	100671866	T	A	wt	het	wt		QUAL=887;DP=287,80,113;MQM=59	DBT	splice_region&intron	DBT:NM_001918.3:splice_region&intron:LOW:exon9/10:c.1210-9A>T:		rs34229137	0.2684	0.3586	3284/2079/33	0.2762							248610 [DBT (confirmed) Maple syrup urine disease,type II,248600];	RCV000079929.6 [benign]; RCV000370215.1 [benign]; 			85	755					DBT (inh=AR pLI=0.00)
chr1	100672060	100672060	T	C	hom	hom	hom	pred_pathogenic;anno_pathogenic_clinvar;anno_pathogenic_hgmd	QUAL=28958;DP=345,246,301;MQM=60	DBT	missense	DBT:NM_001918.3:missense:MODERATE:exon9/11:c.1150A>G:p.Ser384Gly		rs12021720	0.8918	0.9138	50877/27619/3051	0.8594	1.9050	T,T	T	B	T	1.11	248610 [DBT (confirmed) Maple syrup urine disease,type II,248600];	RCV000012727.23 [pathogenic]; RCV000116865.5 [other]; 	CM983430 [CLASS=DM? MUT=REF PHEN="Maple syrup urine disease" GENE=DBT]; 		1275	263	2	[2] old entry - no details available			DBT (inh=AR pLI=0.00)
chr1	109771063	109771063	T	C	hom	hom	hom		QUAL=21662;DP=237,203,230;MQM=60	SARS	splice_region&intron	SARS:NM_006513.3:splice_region&intron:LOW:exon3/10:c.288+9T>C:		rs683182	0.6799	0.7571	35558/21327/1142	0.7545										COSM3747470, COSM3747471	689	390					SARS (inh=n/a pLI=1.00)
chr1	110709719	110709719	T	C	het	het	hom		QUAL=18596;DP=267,333,387;MQM=59	SLC6A17	synonymous	SLC6A17:NM_001010898.2:synonymous:LOW:exon2/12:c.168T>C:p.Asp56Asp		rs7527375	0.3930	0.4656	12998/8876/1288	0.4280							610299 [SLC6A17 (provisional) Mental retardation,autosomal recessive 48,616269];				322	551					SLC6A17 (inh=AR pLI=0.96)
chr1	110709720	110709720	G	A	het	wt	hom		QUAL=18596;DP=267,333,387;MQM=59	SLC6A17	missense	SLC6A17:NM_001010898.2:missense:MODERATE:exon2/12:c.169G>A:p.Ala57Thr		rs12737742	0.2502	0.3771	8912/6485/50	0.3483	0.5380	T,T	T	B	T	13.72	610299 [SLC6A17 (provisional) Mental retardation,autosomal recessive 48,616269];				241	554					SLC6A17 (inh=AR pLI=0.96)
chr1	110709734	110709734	G	A	wt	het	wt		QUAL=4221;DP=260,314,375;MQM=59	SLC6A17	synonymous	SLC6A17:NM_001010898.2:synonymous:LOW:exon2/12:c.183G>A:p.Pro61Pro		rs41281364	0.0389	0.0536	227/182/17	0.0520							610299 [SLC6A17 (provisional) Mental retardation,autosomal recessive 48,616269];				2	129					SLC6A17 (inh=AR pLI=0.96)
chr1	110738296	110738296	G	A	het	het	het		QUAL=16245;DP=299,383,544;MQM=59	SLC6A17	synonymous	SLC6A17:NM_001010898.2:synonymous:LOW:exon10/12:c.1581G>A:p.Ser527Ser		rs2784140	0.2897	0.4141	11537/8339/52	0.4097							610299 [SLC6A17 (provisional) Mental retardation,autosomal recessive 48,616269];			COSM146574	214	547					SLC6A17 (inh=AR pLI=0.96)
chr1	110741081	110741081	C	G	het	het	wt		QUAL=2579;DP=145,120,160;MQM=59	SLC6A17	3'UTR	SLC6A17:NM_001010898.2:3'UTR:MODIFIER:exon12/12:c.*15C>G:		rs2761446	0.0170	0.0390	108/93/0	0.0354							610299 [SLC6A17 (provisional) Mental retardation,autosomal recessive 48,616269];				5	82					SLC6A17 (inh=AR pLI=0.96)
chr1	110741086	110741086	C	T	wt	het	wt		QUAL=1776;DP=145,143,211;MQM=60	SLC6A17	3'UTR	SLC6A17:NM_001010898.2:3'UTR:MODIFIER:exon12/12:c.*20C>T:		rs41306175	0.0497	0.0776	427/354/31	0.0716							610299 [SLC6A17 (provisional) Mental retardation,autosomal recessive 48,616269];				6	150					SLC6A17 (inh=AR pLI=0.96)
chr1	110741349	110741349	G	T	het	hom	het		QUAL=17284;DP=384,273,332;MQM=59	SLC6A17	3'UTR	SLC6A17:NM_001010898.2:3'UTR:MODIFIER:exon12/12:c.*283G>T:		rs2603580	0.5425	0.0000	0/0/0	0.0967							610299 [SLC6A17 (provisional) Mental retardation,autosomal recessive 48,616269];				72	111					SLC6A17 (inh=AR pLI=0.96)
chr1	110741583	110741583	C	G	het	hom	het		QUAL=10073;DP=175,177,214;MQM=59	SLC6A17	3'UTR	SLC6A17:NM_001010898.2:3'UTR:MODIFIER:exon12/12:c.*517C>G:		rs2784141	0.5447	0.0000	0/0/0	0.0967							610299 [SLC6A17 (provisional) Mental retardation,autosomal recessive 48,616269];				72	111					SLC6A17 (inh=AR pLI=0.96)
chr1	110742085	110742085	T	C	het	hom	het		QUAL=27307;DP=287,500,681;MQM=59	SLC6A17	3'UTR	SLC6A17:NM_001010898.2:3'UTR:MODIFIER:exon12/12:c.*1019T>C:		rs2603579	0.5449	0.0000	0/0/0	0.5684							610299 [SLC6A17 (provisional) Mental retardation,autosomal recessive 48,616269];				72	110					SLC6A17 (inh=AR pLI=0.96)
chr1	110742502	110742502	A	G	het	het	het		QUAL=1540;DP=177,83,104;MQM=58	SLC6A17	3'UTR	SLC6A17:NM_001010898.2:3'UTR:MODIFIER:exon12/12:c.*1436A>G:	(GATG)n	rs2361044	0.2883	0.0000	0/0/0	0.2934							610299 [SLC6A17 (provisional) Mental retardation,autosomal recessive 48,616269];				42	87					SLC6A17 (inh=AR pLI=0.96)
chr1	110742615	110742615	A	G	het	het	het		QUAL=2501;DP=127,70,105;MQM=60	SLC6A17	3'UTR	SLC6A17:NM_001010898.2:3'UTR:MODIFIER:exon12/12:c.*1549A>G:	GA-rich	rs12133992	0.2867	0.0000	0/0/0	0.3792							610299 [SLC6A17 (provisional) Mental retardation,autosomal recessive 48,616269];				37	92					SLC6A17 (inh=AR pLI=0.96)
chr1	110742992	110742992	T	G	het	het	het		QUAL=7256;DP=180,182,269;MQM=59	SLC6A17	3'UTR	SLC6A17:NM_001010898.2:3'UTR:MODIFIER:exon12/12:c.*1926T>G:		rs2784142	0.3079	0.0000	0/0/0	0.4179							610299 [SLC6A17 (provisional) Mental retardation,autosomal recessive 48,616269];				43	108					SLC6A17 (inh=AR pLI=0.96)
chr1	110743588	110743588	G	C	het	wt	het		QUAL=8345;DP=167,389,473;MQM=60	SLC6A17	3'UTR	SLC6A17:NM_001010898.2:3'UTR:MODIFIER:exon12/12:c.*2522G>C:		rs151008748	0.0132	0.0000	0/0/0	0.0028							610299 [SLC6A17 (provisional) Mental retardation,autosomal recessive 48,616269];				1	10					SLC6A17 (inh=AR pLI=0.96)
chr1	110743835	110743835	G	A	wt	het	wt		QUAL=2273;DP=226,164,185;MQM=60	SLC6A17	3'UTR	SLC6A17:NM_001010898.2:3'UTR:MODIFIER:exon12/12:c.*2769G>A:		rs12138403	0.0491	0.0000	0/0/0	0.0126							610299 [SLC6A17 (provisional) Mental retardation,autosomal recessive 48,616269];				1	41					SLC6A17 (inh=AR pLI=0.96)
chr1	110744181	110744181	C	T	wt	het	wt		QUAL=1081;DP=101,96,124;MQM=60	SLC6A17	3'UTR	SLC6A17:NM_001010898.2:3'UTR:MODIFIER:exon12/12:c.*3115C>T:		rs62621393	0.0491	0.0000	0/0/0	0.0739							610299 [SLC6A17 (provisional) Mental retardation,autosomal recessive 48,616269];				1	42					SLC6A17 (inh=AR pLI=0.96)
chr1	115247750	115247750	A	-	wt	het	wt		QUAL=974;DP=229,81,124;MQM=59	NRAS	3'UTR	NRAS:NM_002524.4:3'UTR:MODIFIER:exon7/7:c.*2965delT:		rs61652108;rs796171414	0.1516	0.0000	0/0/0	0.1790							164790 [NRAS (confirmed) RAS-associated autoimmune lymphoproliferative syndrome type IV,somatic,614470|Noonan syndrome 6,613224|Epidermal nevus,somatic,162900|Thyroid carcinoma,follicular,somatic,188470|Colorectal cancer,somatic,114500|Melanocytic nevus syndrome,congenital,somatic,137550|Neurocutaneous melanosis,somatic,249400|Schimmelpenning-Feuerstein-Mims syndrome,somatic mosaic,163200];	RCV000300681.1 [likely benign]; 			19	83					NRAS (inh=AD pLI=0.91)
chr1	115249843	115249843	G	A	wt	het	wt		QUAL=1560;DP=407,125,196;MQM=60	NRAS	3'UTR	NRAS:NM_002524.4:3'UTR:MODIFIER:exon7/7:c.*872C>T:		rs14804	0.1510	0.0000	0/0/0	0.1920							164790 [NRAS (confirmed) RAS-associated autoimmune lymphoproliferative syndrome type IV,somatic,614470|Noonan syndrome 6,613224|Epidermal nevus,somatic,162900|Thyroid carcinoma,follicular,somatic,188470|Colorectal cancer,somatic,114500|Melanocytic nevus syndrome,congenital,somatic,137550|Neurocutaneous melanosis,somatic,249400|Schimmelpenning-Feuerstein-Mims syndrome,somatic mosaic,163200];	RCV000345781.1 [likely benign]; 			20	82					NRAS (inh=AD pLI=0.91)
chr1	115259401	115259401	C	T	het	wt	het		QUAL=3853;DP=190,118,138;MQM=59	NRAS	5'UTR	NRAS:NM_002524.4:5'UTR:MODIFIER:exon1/7:c.-140G>A:			0.0000	0.0000	0/0/0	0.0000							164790 [NRAS (confirmed) RAS-associated autoimmune lymphoproliferative syndrome type IV,somatic,614470|Noonan syndrome 6,613224|Epidermal nevus,somatic,162900|Thyroid carcinoma,follicular,somatic,188470|Colorectal cancer,somatic,114500|Melanocytic nevus syndrome,congenital,somatic,137550|Neurocutaneous melanosis,somatic,249400|Schimmelpenning-Feuerstein-Mims syndrome,somatic mosaic,163200];				0	2					NRAS (inh=AD pLI=0.91)
chr1	115576023	115576023	A	G	hom	hom	hom	anno_pathogenic_hgmd	QUAL=17910;DP=260,135,149;MQM=59	TSHB	missense	TSHB:NM_000549.4:missense:MODERATE:exon2/3:c.40A>G:p.Thr14Ala		rs10776792	0.9836	0.9707	57192/31035/5156	0.9401	0.2240	T,T	T	B	T,T	0.01	188540 [TSHB (confirmed) Hypothryoidism,congenital,nongoitrous 4,275100];	RCV000242832.1 [benign]; RCV000396537.1 [benign]; 	CM991218 [CLASS=DM? MUT=REF PHEN="Hypothyroidism" GENE=TSHB]; 		1461	101	2	[2] Peter Bauer 25.08.2014			TSHB (inh=AR pLI=0.01)
chr1	115829313	115829313	G	A	hom	het	hom	pred_pathogenic	QUAL=20368;DP=190,277,390;MQM=60	NGF	missense	NGF:NM_002506.2:missense:MODERATE:exon3/3:c.104C>T:p.Ala35Val		rs6330	0.2474	0.3656	8859/6583/196	0.3653	2.2980	D	T	B	T	19.04	162030 [NGF (confirmed) Neuropathy,hereditary sensory and autonomic,type V,608654];	RCV000268865.1 [benign]; 	CM086294 [CLASS=DFP MUT=REF PHEN="Anxiety-related traits gender-dependent association with" GENE=NGF]; 	COSM3735921	236	734					NGF (inh=AR pLI=0.70)
chr1	119965519	119965519	C	T	het	wt	het		QUAL=10741;DP=468,297,354;MQM=59	HSD3B2	3'UTR	HSD3B2:NM_000198.3:3'UTR:MODIFIER:exon4/4:c.*276C>T:,HSD3B2:NM_001166120.1:3'UTR:MODIFIER:exon4/4:c.*276C>T:		rs1819698	0.3101	0.0000	0/0/0	0.0342							613890 [HSD3B2 (confirmed) Adrenal hyperplasia,congenital,due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency,201810];	RCV000335090.1 [benign]; 			6	53					HSD3B2 (inh=n/a pLI=0.00)
chr1	119965564	119965564	C	G	het	wt	het		QUAL=10623;DP=436,291,356;MQM=60	HSD3B2	3'UTR	HSD3B2:NM_000198.3:3'UTR:MODIFIER:exon4/4:c.*321C>G:,HSD3B2:NM_001166120.1:3'UTR:MODIFIER:exon4/4:c.*321C>G:		rs1361530	0.2560	0.0000	0/0/0	0.0311							613890 [HSD3B2 (confirmed) Adrenal hyperplasia,congenital,due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency,201810];	RCV000379840.1 [likely benign]; 			5	51					HSD3B2 (inh=n/a pLI=0.00)
chr1	147228529	147228529	G	A	wt	het	wt		QUAL=1680;DP=351,146,217;MQM=60	GJA5	3'UTR	GJA5:NM_005266.6:3'UTR:MODIFIER:exon2/2:c.*1741C>T:,GJA5:NM_181703.3:3'UTR:MODIFIER:exon2/2:c.*1741C>T:			0.0000	0.0000	0/0/0	0.0000							121013 [GJA5 (confirmed) Atrial fibrillation,familial,11,614049|Atrial standstill,digenic (GJA5/SCN5A),108770];				0	2					GJA5 (inh=AD pLI=0.10)
chr1	147228874	147228874	C	T	het	het	wt		QUAL=6217;DP=268,193,301;MQM=60	GJA5	3'UTR	GJA5:NM_005266.6:3'UTR:MODIFIER:exon2/2:c.*1396G>A:,GJA5:NM_181703.3:3'UTR:MODIFIER:exon2/2:c.*1396G>A:		rs11240121	0.4073	0.0000	0/0/0	0.0510							121013 [GJA5 (confirmed) Atrial fibrillation,familial,11,614049|Atrial standstill,digenic (GJA5/SCN5A),108770];				19	89					GJA5 (inh=AD pLI=0.10)
chr1	147229299	147229299	G	A	hom	hom	het		QUAL=12825;DP=219,133,162;MQM=59	GJA5	3'UTR	GJA5:NM_005266.6:3'UTR:MODIFIER:exon2/2:c.*971C>T:,GJA5:NM_181703.3:3'UTR:MODIFIER:exon2/2:c.*971C>T:		rs1043806	0.8662	0.0000	0/0/0	0.1397							121013 [GJA5 (confirmed) Atrial fibrillation,familial,11,614049|Atrial standstill,digenic (GJA5/SCN5A),108770];				152	68					GJA5 (inh=AD pLI=0.10)
chr1	147229382	147229382	G	A	hom	hom	hom		QUAL=22626;DP=255,196,277;MQM=60	GJA5	3'UTR	GJA5:NM_005266.6:3'UTR:MODIFIER:exon2/2:c.*888C>T:,GJA5:NM_181703.3:3'UTR:MODIFIER:exon2/2:c.*888C>T:		rs10900395	0.9886	0.0000	0/0/0	0.1492							121013 [GJA5 (confirmed) Atrial fibrillation,familial,11,614049|Atrial standstill,digenic (GJA5/SCN5A),108770];				230	0					GJA5 (inh=AD pLI=0.10)
chr1	147229563	147229563	G	A	het	het	wt		QUAL=7586;DP=356,317,383;MQM=60	GJA5	3'UTR	GJA5:NM_005266.6:3'UTR:MODIFIER:exon2/2:c.*707C>T:,GJA5:NM_181703.3:3'UTR:MODIFIER:exon2/2:c.*707C>T:		rs1043802	0.3191	0.0000	0/0/0	0.0410							121013 [GJA5 (confirmed) Atrial fibrillation,familial,11,614049|Atrial standstill,digenic (GJA5/SCN5A),108770];				16	86					GJA5 (inh=AD pLI=0.10)
chr1	147229628	147229628	-	GGGCATTTGCCAGAGGTACATACCA	het	het	het		QUAL=11474;DP=217,287,373;MQM=59	GJA5	3'UTR	GJA5:NM_005266.6:3'UTR:MODIFIER:exon2/2:c.*617_*641dupTGGTATGTACCTCTGGCAAATGCCC:,GJA5:NM_181703.3:3'UTR:MODIFIER:exon2/2:c.*617_*641dupTGGTATGTACCTCTGGCAAATGCCC:		rs371724095	0.4667	0.0000	0/0/0	0.2850							121013 [GJA5 (confirmed) Atrial fibrillation,familial,11,614049|Atrial standstill,digenic (GJA5/SCN5A),108770];				72	95					GJA5 (inh=AD pLI=0.10)
chr1	147229662	147229662	G	A	wt	wt	het		QUAL=5577;DP=438,380,482;MQM=60	GJA5	3'UTR	GJA5:NM_005266.6:3'UTR:MODIFIER:exon2/2:c.*608C>T:,GJA5:NM_181703.3:3'UTR:MODIFIER:exon2/2:c.*608C>T:		rs36005900	0.0675	0.0000	0/0/0	0.1478							121013 [GJA5 (confirmed) Atrial fibrillation,familial,11,614049|Atrial standstill,digenic (GJA5/SCN5A),108770];	RCV000295375.1 [likely benign]; 			9	63					GJA5 (inh=AD pLI=0.10)
chr1	147230217	147230217	T	C	hom	hom	het		QUAL=19860;DP=325,192,233;MQM=59	GJA5	3'UTR	GJA5:NM_005266.6:3'UTR:MODIFIER:exon2/2:c.*53A>G:,GJA5:NM_181703.3:3'UTR:MODIFIER:exon2/2:c.*53A>G:		rs1692141	0.8804	0.0000	0/0/0	0.1667							121013 [GJA5 (confirmed) Atrial fibrillation,familial,11,614049|Atrial standstill,digenic (GJA5/SCN5A),108770];				524	205					GJA5 (inh=AD pLI=0.10)
chr1	147232646	147232646	G	A	wt	het	wt		QUAL=3094;DP=307,251,364;MQM=60	GJA5	5'UTR,intron	GJA5:NM_181703.3:5'UTR:MODIFIER:exon1/2:c.-73C>T:,GJA5:NM_005266.6:intron:MODIFIER:exon1/1:c.-33-1267C>T:	L2c	rs191717313	0.0004	0.0000	0/0/0	0.0030							121013 [GJA5 (confirmed) Atrial fibrillation,familial,11,614049|Atrial standstill,digenic (GJA5/SCN5A),108770];				0	5					GJA5 (inh=AD pLI=0.10)
chr1	147245474	147245474	G	C	hom	hom	hom		QUAL=20888;DP=217,184,278;MQM=60	GJA5-GJA8	intergenic_region	GJA5-GJA8:GJA5-GJA8:intergenic_region:MODIFIER::n.147245474G>C:		rs791286	0.9748	0.0000	0/0/0	0.8714							121013 [GJA5 (confirmed) Atrial fibrillation,familial,11,614049|Atrial standstill,digenic (GJA5/SCN5A),108770];	RCV000277169.1 [likely benign]; 			229	1					GJA5-GJA8 (inh=n/a pLI=n/a)
chr1	150771703	150771703	T	C	hom	hom	hom		QUAL=35017;DP=355,341,363;MQM=60	CTSK	synonymous	CTSK:NM_000396.3:synonymous:LOW:exon7/8:c.831A>G:p.Ala277Ala		rs10788796	0.9633	0.9887	59361/33273/4455	0.9513							601105 [CTSK (provisional) Pycnodysostosis,265800];				1555	10					CTSK (inh=AR pLI=0.00)
chr1	151313774	151313774	A	G	het	hom	wt		QUAL=6544;DP=286,90,137;MQM=59	RFX5	3'UTR	RFX5:NM_000449.3:3'UTR:MODIFIER:exon11/11:c.*888T>C:,RFX5:NM_001025603.1:3'UTR:MODIFIER:exon11/11:c.*888T>C:		rs7552906	0.6280	0.0000	0/0/0	0.1066							601863 [RFX5 (confirmed) Bare lymphocyte syndrome,type II,complementation group C,209920|Bare lymphocyte syndrome,type II,complementation group E,209920];	RCV000373841.1 [benign]; 			96	114					RFX5 (inh=AR+AD pLI=0.00)
chr1	151314379	151314379	T	C	het	hom	het		QUAL=8286;DP=200,113,157;MQM=60	RFX5	3'UTR	RFX5:NM_000449.3:3'UTR:MODIFIER:exon11/11:c.*283A>G:,RFX5:NM_001025603.1:3'UTR:MODIFIER:exon11/11:c.*283A>G:	MLT1K	rs1752387	0.7644	0.0000	0/0/0	0.0919							601863 [RFX5 (confirmed) Bare lymphocyte syndrome,type II,complementation group C,209920|Bare lymphocyte syndrome,type II,complementation group E,209920];	RCV000352021.1 [benign]; 			132	66					RFX5 (inh=AR+AD pLI=0.00)
chr1	151315287	151315287	G	C	het	het	wt	pred_pathogenic	QUAL=3266;DP=123,139,187;MQM=59	RFX5	missense	RFX5:NM_000449.3:missense:MODERATE:exon11/11:c.1226C>G:p.Pro409Arg,RFX5:NM_001025603.1:missense:MODERATE:exon11/11:c.1226C>G:p.Pro409Arg		rs2233854	0.0635	0.1188	1090/898/5	0.1190	1.7460	D,D,D,D,D	T	B,B	T,T,T,T,T	15.46	601863 [RFX5 (confirmed) Bare lymphocyte syndrome,type II,complementation group C,209920|Bare lymphocyte syndrome,type II,complementation group E,209920];	RCV000268166.1 [likely benign]; 		COSM3750354	39	374					RFX5 (inh=AR+AD pLI=0.00)
chr1	151316161	151316161	G	A	hom	hom	hom		QUAL=13269;DP=190,93,132;MQM=59	RFX5	synonymous	RFX5:NM_000449.3:synonymous:LOW:exon9/11:c.753C>T:p.Leu251Leu,RFX5:NM_001025603.1:synonymous:LOW:exon9/11:c.753C>T:p.Leu251Leu		rs1752386	0.9780	0.9934	59713/33243/4434	0.9320							601863 [RFX5 (confirmed) Bare lymphocyte syndrome,type II,complementation group C,209920|Bare lymphocyte syndrome,type II,complementation group E,209920];				1563	1					RFX5 (inh=AR+AD pLI=0.00)
chr1	152274685	152274685	T	A	hom	hom	hom	gene_blacklist	QUAL=8578;DP=95,63,107;MQM=60	FLG	3'UTR	FLG:NM_002016.1:3'UTR:MODIFIER:exon3/3:c.*491A>T:		rs1933061	0.9994	0.0000	0/0/0	0.1761							135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				227	2					FLG (inh=AD pLI=n/a)
chr1	152276149	152276149	C	T	het	het	het	gene_blacklist	QUAL=45774;DP=518,1333,1859;MQM=58	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.11213G>A:p.Arg3738His		rs77422831	0.2869	0.2288	4735/817/4	0.2111	-2.2530	T	T	B	T	10.76	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM3996928	66	382					FLG (inh=AD pLI=n/a)
chr1	152276377	152276377	C	G	wt	het	het	low_MQM;gene_blacklist;pred_pathogenic	QUAL=10006;DP=496,1479,2046;MQM=28	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.10985G>C:p.Ser3662Thr		rs75235053	0.0000	0.0383	0/0/0	0.0001	-0.7420	D	T	P	T	11.21	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM226460	0	289					FLG (inh=AD pLI=n/a)
chr1	152276459	152276459	C	T	wt	het	het	low_MQM;gene_blacklist;pred_pathogenic	QUAL=17124;DP=416,1546,2207;MQM=30	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.10903G>A:p.Asp3635Asn		rs75448155	0.0000	0.1948	2/0/0	0.0035	1.6290	D	T	D	T	22.60	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM4142668	0	359					FLG (inh=AD pLI=n/a)
chr1	152276583	152276583	C	G	wt	het	het	low_MQM;gene_blacklist	QUAL=12658;DP=332,923,649;MQM=34	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.10779G>C:p.Glu3593Asp		rs12083389	0.3614	0.0877	1923/178/1006	0.0930	0.3080	T	T	B	T	0.15	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM3734007	14	202					FLG (inh=AD pLI=n/a)
chr1	152276598	152276598	G	A	wt	het	hom	low_MQM;gene_blacklist	QUAL=13279;DP=369,839,444;MQM=33	FLG	synonymous	FLG:NM_002016.1:synonymous:LOW:exon3/3:c.10764C>T:p.His3588His		rs12742178	0.0887	0.0334	444/65/12	0.0039							135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM4142669	67	95					FLG (inh=AD pLI=n/a)
chr1	152276626	152276626	G	C	het	het	hom	low_MQM;gene_blacklist	QUAL=9260;DP=471,823,338;MQM=36	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.10736C>G:p.Thr3579Arg		rs3126075	0.4778	0.0523	1683/83/1243	0.0751	-5.4480	T	T	B	T	0.16	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM4142671	84	166					FLG (inh=AD pLI=n/a)
chr1	152276671	152276671	C	T	wt	het	het	low_MQM;gene_blacklist	QUAL=1440;DP=658,962,553;MQM=44	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.10691G>A:p.Arg3564His		rs7518080	0.2564	0.1950	0/0/0	0.0087	-1.3060	T	T	B	T	0.01	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM4142673	0	159					FLG (inh=AD pLI=n/a)
chr1	152276699	152276699	A	G	het	het	het	low_MQM;gene_blacklist	QUAL=13578;DP=561,979,623;MQM=38	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.10663T>C:p.Trp3555Arg		rs12728605	0.0000	0.1928	11/3/0	0.0065	-1.1810	T	T	B	T	0.01	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM4142674	2	259					FLG (inh=AD pLI=n/a)
chr1	152276772	152276772	C	A	het	het	het	gene_blacklist;pred_pathogenic	QUAL=31885;DP=429,1167,725;MQM=56	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.10590G>T:p.Arg3530Ser		rs72697000	0.2905	0.2343	5402/1033/6	0.2047	-5.0060	T	T	D	T	1.14	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM3996929	64	387					FLG (inh=AD pLI=n/a)
chr1	152276871	152276871	A	G	het	het	hom	gene_blacklist	QUAL=38354;DP=539,1133,643;MQM=58	FLG	synonymous,sequence_feature	FLG:NM_002016.1:synonymous:LOW:exon3/3:c.10491T>C:p.Asp3497Asp,FLG:NM_002016.1:sequence_feature:LOW:exon3/3:c.10491T>C:		rs3126066	0.4471	0.2779	6890/1057/1209	0.2535							135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM3996930	83	383					FLG (inh=AD pLI=n/a)
chr1	152276889	152276889	A	G	het	het	hom	gene_blacklist	QUAL=37876;DP=537,1146,633;MQM=58	FLG	synonymous	FLG:NM_002016.1:synonymous:LOW:exon3/3:c.10473T>C:p.Asn3491Asn		rs3126067	0.5226	0.3007	8467/1093/2670	0.2726							135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM3996931	91	386					FLG (inh=AD pLI=n/a)
chr1	152277055	152277055	C	G	het	het	het	gene_blacklist	QUAL=26512;DP=469,892,613;MQM=53	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.10307G>C:p.Gly3436Ala		rs2065955	0.5142	0.2987	8272/1051/2636	0.2665	-0.5970	T	T	P	T	8.40	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM4142675	68	409					FLG (inh=AD pLI=n/a)
chr1	152277168	152277168	A	G	het	het	hom	gene_blacklist	QUAL=46973;DP=514,1099,959;MQM=51	FLG	synonymous	FLG:NM_002016.1:synonymous:LOW:exon3/3:c.10194T>C:p.Ser3398Ser		rs3091276	0.4736	0.2896	7123/1067/1406	0.2597							135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM3996932	83	408					FLG (inh=AD pLI=n/a)
chr1	152277309	152277309	G	A	wt	wt	het	gene_blacklist	QUAL=25934;DP=621,1368,2030;MQM=53	FLG	synonymous	FLG:NM_002016.1:synonymous:LOW:exon3/3:c.10053C>T:p.Asp3351Asp		rs34687484	0.0028	0.0039	6/3/0	0.0036							135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				0	13					FLG (inh=AD pLI=n/a)
chr1	152277345	152277345	C	T	het	het	het	gene_blacklist	QUAL=47107;DP=556,1341,1992;MQM=58	FLG	synonymous	FLG:NM_002016.1:synonymous:LOW:exon3/3:c.10017G>A:p.Gln3339Gln		rs2065956	0.2875	0.2293	4811/838/4	0.2121							135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM3996933	68	379					FLG (inh=AD pLI=n/a)
chr1	152277396	152277396	T	C	het	het	hom	gene_blacklist	QUAL=80878;DP=522,1289,1872;MQM=58	FLG	synonymous	FLG:NM_002016.1:synonymous:LOW:exon3/3:c.9966A>G:p.Gln3322Gln		rs6681433	0.3411	0.2611	5728/1092/77	0.2421							135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				79	404					FLG (inh=AD pLI=n/a)
chr1	152277554	152277554	G	A	wt	wt	het	gene_blacklist;pred_pathogenic	QUAL=19291;DP=499,1198,1547;MQM=59	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.9808C>T:p.Arg3270Cys		rs35621145	0.0250	0.0233	74/19/0	0.0214	-0.5000	D,D	T	P	T	17.89	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				0	44					FLG (inh=AD pLI=n/a)
chr1	152277717	152277717	C	A	het	het	hom	low_MQM;gene_blacklist	QUAL=42828;DP=273,975,1117;MQM=48	FLG	synonymous	FLG:NM_002016.1:synonymous:LOW:exon3/3:c.9645G>T:p.Val3215Val		rs9436066	0.4696	0.2992	7303/1113/1196	0.0247							135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				86	383					FLG (inh=AD pLI=n/a)
chr1	152277822	152277822	T	C	het	het	hom	low_MQM;gene_blacklist	QUAL=11953;DP=325,814,400;MQM=38	FLG	synonymous	FLG:NM_002016.1:synonymous:LOW:exon3/3:c.9540A>G:p.Ser3180Ser		rs3126069	0.2238	0.0917	2823/434/32	0.0902							135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				72	105					FLG (inh=AD pLI=n/a)
chr1	152277826	152277826	A	C	het	het	hom	low_MQM;gene_blacklist	QUAL=11953;DP=325,814,400;MQM=38	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.9536T>G:p.Val3179Gly		rs2065957	0.3936	0.1330	4141/444/1188	0.1313	-0.6040	T	T	B	T	0.01	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				80	114					FLG (inh=AD pLI=n/a)
chr1	152278434	152278434	T	G	het	het	wt	low_MQM;gene_blacklist	QUAL=2785;DP=449,492,552;MQM=39	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.8928A>C:p.Glu2976Asp		rs61816760	0.2873	0.4220	129/24/98	0.0132	-1.3040	T	T	B	T	0.01	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM3801882	16	600					FLG (inh=AD pLI=n/a)
chr1	152278484	152278484	C	T	wt	wt	het	low_MQM;gene_blacklist	QUAL=3317;DP=441,709,879;MQM=39	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.8878G>A:p.Gly2960Ser		rs61690342	0.0000	0.0321	1/0/1	0.0005	-1.1870	T	T	B	T	0.01	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				0	44					FLG (inh=AD pLI=n/a)
chr1	152278555	152278555	T	C	het	het	het	low_MQM;gene_blacklist	QUAL=26984;DP=450,1314,1616;MQM=45	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.8807A>G:p.Asp2936Gly		rs80221306	0.0000	0.2147	4/0/3	0.0073	-0.3860	T	T	B	T	0.38	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM1317676	0	452					FLG (inh=AD pLI=n/a)
chr1	152278689	152278689	C	A	het	het	hom	gene_blacklist	QUAL=144558;DP=681,2485,3301;MQM=50	FLG	synonymous	FLG:NM_002016.1:synonymous:LOW:exon3/3:c.8673G>T:p.Val2891Val		rs57672167	0.3964	0.2692	6196/1077/556	0.2319							135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				86	406					FLG (inh=AD pLI=n/a)
chr1	152278814	152278814	C	T	wt	het	het	low_MQM;gene_blacklist	QUAL=15987;DP=1101,2872,4094;MQM=37	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.8548G>A:p.Gly2850Ser		rs2184952	0.0000	0.1115	0/0/0	0.0023	-2.5340	T,T	T	B	T	10.22	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM4142676	0	220					FLG (inh=AD pLI=n/a)
chr1	152278856	152278856	T	G	het	het	het	gene_blacklist	QUAL=16438;DP=845,2636,3913;MQM=50	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.8506A>C:p.Ser2836Arg		rs11582087	0.0000	0.1893	0/0/0	0.0053		T,T	T	B	T	13.01	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				0	403					FLG (inh=AD pLI=n/a)
chr1	152279019	152279019	G	A	het	het	het	low_MQM;gene_blacklist	QUAL=8430;DP=994,2438,4119;MQM=35	FLG	synonymous	FLG:NM_002016.1:synonymous:LOW:exon3/3:c.8343C>T:p.Asp2781Asp		rs57670307	0.0000	0.1823	0/0/0	0.0037							135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM1319976	0	335					FLG (inh=AD pLI=n/a)
chr1	152279729	152279729	C	T	het	het	hom	gene_blacklist	QUAL=70999;DP=577,1198,1550;MQM=58	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.7633G>A:p.Gly2545Arg		rs3126072	0.4748	0.2974	7255/1075/1480	0.2769	-0.2430	T	T	B	T	1.03	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM3996934	85	421					FLG (inh=AD pLI=n/a)
chr1	152279841	152279841	G	C	het	het	hom	gene_blacklist	QUAL=72444;DP=483,1197,1580;MQM=58	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.7521C>G:p.His2507Gln		rs3126074	0.4623	0.2943	6970/1076/1209	0.2657	-7.9550	T	T	B	T	0.01	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				83	418					FLG (inh=AD pLI=n/a)
chr1	152279920	152279920	A	G	het	het	hom	gene_blacklist	QUAL=75412;DP=461,1216,1664;MQM=59	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.7442T>C:p.Leu2481Ser		rs55650366	0.3425	0.2608	5666/1064/88	0.2342	-1.3450	T	T	B	T	0.01	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM3996935	79	408					FLG (inh=AD pLI=n/a)
chr1	152279964	152279964	C	T	wt	wt	het	gene_blacklist	QUAL=22688;DP=628,1229,1671;MQM=59	FLG	synonymous	FLG:NM_002016.1:synonymous:LOW:exon3/3:c.7398G>A:p.Pro2466Pro		rs71625199	0.0248	0.0231	59/14/0	0.0215							135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM1157872	0	42					FLG (inh=AD pLI=n/a)
chr1	152280032	152280032	T	C	het	het	hom	gene_blacklist	QUAL=82464;DP=556,1332,1836;MQM=58	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.7330A>G:p.Lys2444Glu		rs71625200	0.3431	0.2608	5660/1063/88	0.2414	-0.8890	T	T	B	T	0.01	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM3996936	80	407					FLG (inh=AD pLI=n/a)
chr1	152280170	152280170	C	G	het	het	hom	low_MQM;gene_blacklist	QUAL=56531;DP=457,1167,1442;MQM=47	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.7192G>C:p.Glu2398Gln		rs71625201	0.3305	0.2585	5456/1036/72	0.2275	-1.3100	T,T	T	B	T	0.02	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM3996937	64	416					FLG (inh=AD pLI=n/a)
chr1	152280265	152280265	C	G	het	het	het	low_MQM;gene_blacklist;pred_pathogenic	QUAL=35095;DP=506,1102,1088;MQM=38	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.7097G>C:p.Ser2366Thr		rs71625202	0.0000	0.2062	197/29/0	0.0158	0.0300	D,D	T	D	T	14.66	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM3747555	7	416					FLG (inh=AD pLI=n/a)
chr1	152280347	152280347	C	T	het	het	het	low_MQM;gene_blacklist;pred_pathogenic	QUAL=30219;DP=475,1162,1021;MQM=37	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.7015G>A:p.Asp2339Asn		rs139476473	0.0000	0.1512	30/15/0	0.0083	1.6910	D,T	T	D	T	24.30	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM146618	2	243					FLG (inh=AD pLI=n/a)
chr1	152280372	152280372	G	A	het	het	hom	low_MQM;gene_blacklist	QUAL=41242;DP=518,1128,1040;MQM=36	FLG	synonymous	FLG:NM_002016.1:synonymous:LOW:exon3/3:c.6990C>T:p.His2330His		rs6664985	0.4535	0.2788	6451/965/1061	0.0258							135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM3996938	80	337					FLG (inh=AD pLI=n/a)
chr1	152280471	152280471	C	G	het	het	het	low_MQM;gene_blacklist	QUAL=10449;DP=683,1352,1878;MQM=37	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.6891G>C:p.Glu2297Asp		rs78179835	0.0000	0.2086	23/0/23	0.0064	-0.9250	T,T	T	B	T	0.01	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM4142679	1	447					FLG (inh=AD pLI=n/a)
chr1	152280736	152280736	T	C	het	het	het	gene_blacklist	QUAL=22837;DP=802,1509,2389;MQM=53	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.6626A>G:p.His2209Arg		rs66977240	0.0000	0.2357	1/0/1	0.0039	-5.2630	T	T	B	T	0.09	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM4142690	0	461					FLG (inh=AD pLI=n/a)
chr1	152280759	152280759	A	G	het	het	het	gene_blacklist	QUAL=35982;DP=882,1570,2678;MQM=53	FLG	synonymous,sequence_feature	FLG:NM_002016.1:synonymous:LOW:exon3/3:c.6603T>C:p.Asp2201Asp,FLG:NM_002016.1:sequence_feature:LOW:exon3/3:c.6603T>C:		rs2338554	0.3672	0.2416	650/0/643	0.0189							135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM4142691	1	488					FLG (inh=AD pLI=n/a)
chr1	152280782	152280782	A	G	het	het	hom	gene_blacklist	QUAL=131894;DP=889,1662,2800;MQM=56	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.6580T>C:p.Tyr2194His		rs2184953	0.5397	0.3176	8529/1108/2650	0.3030	-2.7490	T	T	B	T	0.01	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM3927615	92	421					FLG (inh=AD pLI=n/a)
chr1	152280788	152280788	T	G	het	het	het	gene_blacklist	QUAL=71910;DP=898,1669,2840;MQM=54	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.6574A>C:p.Lys2192Gln		rs66954353	0.0000	0.2371	61/14/1	0.0070	0.2450	T	T	B	T	0.03	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				0	493					FLG (inh=AD pLI=n/a)
chr1	152280864	152280864	A	G	het	het	hom	gene_blacklist	QUAL=112174;DP=520,1525,2569;MQM=54	FLG	synonymous	FLG:NM_002016.1:synonymous:LOW:exon3/3:c.6498T>C:p.Ser2166Ser		rs2184954	0.4637	0.2946	6956/1068/1210	0.2781							135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				84	416					FLG (inh=AD pLI=n/a)
chr1	152280900	152280900	T	G	het	het	het	gene_blacklist	QUAL=31668;DP=707,1482,2359;MQM=51	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.6462A>C:p.Gln2154His		rs74129452	0.3439	0.2366	0/0/0	0.0172	-3.3340	T	T	B	T	0.01	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				0	488					FLG (inh=AD pLI=n/a)
chr1	152281007	152281007	A	G	het	het	het	gene_blacklist	QUAL=28960;DP=826,1589,2308;MQM=59	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.6355T>C:p.Tyr2119His		rs7512553	0.3277	0.2207	0/0/0	0.0157	0.1210	T	T	B	T	0.01	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				0	462					FLG (inh=AD pLI=n/a)
chr1	152281008	152281008	A	G	het	het	het	gene_blacklist	QUAL=28960;DP=826,1589,2308;MQM=59	FLG	synonymous	FLG:NM_002016.1:synonymous:LOW:exon3/3:c.6354T>C:p.His2118His		rs7512554	0.3277	0.2207	0/0/0	0.0158							135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				0	461					FLG (inh=AD pLI=n/a)
chr1	152281039	152281039	G	A	het	het	het	gene_blacklist	QUAL=33474;DP=956,1656,2398;MQM=59	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.6323C>T:p.Ala2108Val		rs7522925	0.0000	0.2208	0/0/0	0.0093	-3.7960	T	T	B	T	10.05	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM4142692	0	465					FLG (inh=AD pLI=n/a)
chr1	152281228	152281228	C	G	het	het	het	gene_blacklist	QUAL=38205;DP=742,1969,2615;MQM=53	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.6134G>C:p.Ser2045Thr		rs7546186	0.0000	0.2189	1/1/0	0.0067	1.5140	T	T	P	T	4.80	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				0	449					FLG (inh=AD pLI=n/a)
chr1	152281290	152281290	A	G	het	het	het	gene_blacklist	QUAL=35643;DP=692,1998,2597;MQM=50	FLG	synonymous	FLG:NM_002016.1:synonymous:LOW:exon3/3:c.6072T>C:p.His2024His		rs80353812	0.3281	0.2205	0/0/0	0.0142							135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM4142693	0	446					FLG (inh=AD pLI=n/a)
chr1	152281304	152281304	A	C	het	het	het	gene_blacklist;pred_pathogenic	QUAL=37065;DP=691,1972,2612;MQM=51	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.6058T>G:p.Ser2020Ala		rs7512857	0.0000	0.2186	0/0/0	0.0040	0.3910	T	T	D	T	0.82	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM4142694	0	457					FLG (inh=AD pLI=n/a)
chr1	152281317	152281317	G	T	wt	wt	het	gene_blacklist	QUAL=21085;DP=812,2036,2650;MQM=59	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.6045C>A:p.Asp2015Glu		rs71626704	0.0248	0.0231	59/14/0	0.0222	0.0390	T	T	B	T	12.11	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				0	42					FLG (inh=AD pLI=n/a)
chr1	152281479	152281479	G	T	het	het	hom	gene_blacklist	QUAL=106048;DP=894,1623,2002;MQM=56	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.5883C>A:p.His1961Gln		rs3126079	0.5381	0.3173	8527/1116/2651	0.3045	-4.7080	T	T	B	T	0.01	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM4142695	93	423					FLG (inh=AD pLI=n/a)
chr1	152281523	152281523	A	C	het	het	het	low_MQM;gene_blacklist	QUAL=20209;DP=835,1559,1842;MQM=48	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.5839T>G:p.Trp1947Gly		rs80059102	0.0000	0.2197	0/0/0	0.0022	-0.5530	T	T	B	T	0.45	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				0	440					FLG (inh=AD pLI=n/a)
chr1	152281534	152281534	A	T	het	het	het	low_MQM;gene_blacklist	QUAL=17162;DP=765,1518,1786;MQM=48	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.5828T>A:p.Leu1943His		rs113544881	0.3135	0.2157	1/0/0	0.0117	-2.7300	T	T	B	T	1.98	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				0	409					FLG (inh=AD pLI=n/a)
chr1	152281690	152281690	C	T	het	het	het	gene_blacklist	QUAL=41373;DP=548,1176,1373;MQM=59	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.5672G>A:p.Arg1891Gln		rs12407748	0.2875	0.2286	4730/821/4	0.2177	-4.0060	T,T	T	B	T	11.35	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM3996939	62	389					FLG (inh=AD pLI=n/a)
chr1	152281691	152281691	G	A	wt	wt	het	gene_blacklist;pred_pathogenic	QUAL=16088;DP=560,1179,1377;MQM=59	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.5671C>T:p.Arg1891Trp		rs36006086	0.0250	0.0232	62/17/0	0.0225	-2.2050	D,T	T	D	T	24.20	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				0	43					FLG (inh=AD pLI=n/a)
chr1	152281745	152281745	G	T	wt	wt	het	gene_blacklist;pred_pathogenic	QUAL=16150;DP=635,1195,1421;MQM=59	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.5617C>A:p.Gln1873Lys		rs62623409	0.0250	0.0232	63/17/0	0.0226	-0.9500	D,D	T	B	T	1.68	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				0	42					FLG (inh=AD pLI=n/a)
chr1	152281907	152281907	A	G	wt	wt	het	low_MQM;gene_blacklist;pred_pathogenic	QUAL=1096;DP=462,1049,1642;MQM=47	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.5455T>C:p.Ser1819Pro		rs754699295	0.0000	0.0001	0/0/0	0.0001	0.7120	D,T	T	P	T	10.50	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				0	8					FLG (inh=AD pLI=n/a)
chr1	152281911	152281911	T	C	wt	wt	het	low_MQM;gene_blacklist	QUAL=1096;DP=462,1049,1642;MQM=47	FLG	synonymous	FLG:NM_002016.1:synonymous:LOW:exon3/3:c.5451A>G:p.Pro1817Pro		rs546421577	0.0020	0.0005	0/0/0	0.0001							135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				0	8					FLG (inh=AD pLI=n/a)
chr1	152281948	152281948	G	A	het	het	het	gene_blacklist;pred_pathogenic	QUAL=37411;DP=471,1123,1995;MQM=58	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.5414C>T:p.Ala1805Val		rs12405241	0.2875	0.2288	4747/824/4	0.2118	-5.6230	T,T	T	D	T	10.19	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM3996940	67	381					FLG (inh=AD pLI=n/a)
chr1	152282092	152282092	T	C	wt	wt	het	gene_blacklist	QUAL=2855;DP=548,1254,2009;MQM=51	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.5270A>G:p.Glu1757Gly		rs778942937	0.0000	0.0001	0/0/0	0.0001	1.2300	T	T	B	T	9.33	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				0	6					FLG (inh=AD pLI=n/a)
chr1	152282267	152282267	G	A	het	het	het	gene_blacklist;pred_pathogenic	QUAL=36513;DP=436,1239,1533;MQM=59	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.5095C>T:p.Arg1699Cys		rs12405278	0.2877	0.2288	4748/823/4	0.2209	0.1370	D	T	D	T	23.80	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM3996941	67	380					FLG (inh=AD pLI=n/a)
chr1	152282311	152282311	C	T	het	het	het	gene_blacklist;pred_pathogenic	QUAL=39336;DP=526,1241,1517;MQM=59	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.5051G>A:p.Arg1684His		rs12407807	0.2967	0.2320	4772/823/25	0.2241	-2.4830	T	T	D	T	17.66	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				67	384					FLG (inh=AD pLI=n/a)
chr1	152282522	152282522	C	T	wt	het	wt	gene_blacklist	QUAL=11014;DP=560,1014,1248;MQM=60	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.4840G>A:p.Ala1614Thr			0.0000	0.0000	0/0/0	0.0000	-1.2150	T	T	B	T	12.03	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM244545	0	1					FLG (inh=AD pLI=n/a)
chr1	152282794	152282794	G	A	wt	wt	het	gene_blacklist;pred_pathogenic	QUAL=16901;DP=450,1156,1467;MQM=59	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.4568C>T:p.Thr1523Ile		rs12750081	0.0250	0.0232	62/17/0	0.0225	-0.3320	D	T	B	T	12.76	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				0	42					FLG (inh=AD pLI=n/a)
chr1	152282910	152282910	G	C	wt	wt	het	gene_blacklist	QUAL=18566;DP=496,1081,1494;MQM=59	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.4452C>G:p.Asp1484Glu		rs71626706	0.0248	0.0231	62/17/0	0.0225	-4.8400	T	T	B	T	0.35	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				0	42					FLG (inh=AD pLI=n/a)
chr1	152282917	152282917	G	T	het	het	het	gene_blacklist;pred_pathogenic	QUAL=38140;DP=490,1078,1524;MQM=59	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.4445C>A:p.Ser1482Tyr		rs11204978	0.2871	0.2287	4739/822/4	0.2208	0.2470	D	T	B	T	20.70	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM3996942	66	381					FLG (inh=AD pLI=n/a)
chr1	152282952	152282952	A	G	wt	wt	het	gene_blacklist	QUAL=19667;DP=556,1148,1575;MQM=59	FLG	synonymous	FLG:NM_002016.1:synonymous:LOW:exon3/3:c.4410T>C:p.His1470His		rs12732920	0.0250	0.0232	63/17/0	0.0226							135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				0	42					FLG (inh=AD pLI=n/a)
chr1	152283053	152283053	G	A	wt	wt	het	gene_blacklist;pred_pathogenic	QUAL=20733;DP=586,1205,1694;MQM=59	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.4309C>T:p.Arg1437Cys		rs12750571	0.0048	0.0050	7/4/0	0.0048	-0.2720	D	T	P	T	22.30	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				0	18					FLG (inh=AD pLI=n/a)
chr1	152283236	152283236	T	C	het	het	hom	gene_blacklist	QUAL=75862;DP=528,1310,1682;MQM=55	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.4126A>G:p.Arg1376Gly		rs11581433	0.3431	0.2614	5670/1074/84	0.0395	-2.3740	T	T	B	T	0.01	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				79	411					FLG (inh=AD pLI=n/a)
chr1	152283283	152283283	C	T	het	het	het	gene_blacklist	QUAL=39991;DP=525,1249,1663;MQM=53	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.4079G>A:p.Arg1360His		rs11586631	0.2877	0.2289	4733/821/5	0.2194	-6.3060	T	T	B	T	15.37	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM4142696	66	386					FLG (inh=AD pLI=n/a)
chr1	152283862	152283862	G	C	het	het	hom	gene_blacklist	QUAL=61859;DP=539,1071,1395;MQM=54	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.3500C>G:p.Ala1167Gly		rs58001094	0.5341	0.3040	7080/917/2165	0.2837		T	T	B	T	0.01	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM1600315	74	437					FLG (inh=AD pLI=n/a)
chr1	152283975	152283975	A	G	het	het	hom	gene_blacklist	QUAL=72530;DP=573,1176,1637;MQM=52	FLG	synonymous	FLG:NM_002016.1:synonymous:LOW:exon3/3:c.3387T>C:p.Ser1129Ser		rs66831674	0.4631	0.2943	6959/1082/1208	0.2818							135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM3996943	83	417					FLG (inh=AD pLI=n/a)
chr1	152284377	152284377	G	A	het	wt	het	gene_blacklist	QUAL=30395;DP=584,1297,1614;MQM=55	FLG	synonymous	FLG:NM_002016.1:synonymous:LOW:exon3/3:c.2985C>T:p.His995His		rs373872833	0.0000	0.0001	0/0/0	0.0001							135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				0	6					FLG (inh=AD pLI=n/a)
chr1	152284424	152284424	G	C	wt	wt	het	gene_blacklist	QUAL=22445;DP=720,1279,1687;MQM=55	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.2938C>G:p.His980Asp		rs12756586	0.0339	0.0254	63/17/1	0.0043	-1.1170	T,T	T	B	T	0.01	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				0	62					FLG (inh=AD pLI=n/a)
chr1	152284478	152284478	A	G	wt	wt	het	low_MQM;gene_blacklist	QUAL=1327;DP=541,1274,1857;MQM=36	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.2884T>C:p.Trp962Arg		rs199888588	0.0000	0.0147	0/0/0	0.0001	-0.8200	T,T	T	B	T	0.01	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				0	57					FLG (inh=AD pLI=n/a)
chr1	152284497	152284497	A	G	wt	wt	het	low_MQM;gene_blacklist	QUAL=3480;DP=515,1311,2016;MQM=36	FLG	synonymous	FLG:NM_002016.1:synonymous:LOW:exon3/3:c.2865T>C:p.His955His		rs144437056	0.0513	0.0204	0/0/0	0.0017							135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				0	51					FLG (inh=AD pLI=n/a)
chr1	152284505	152284505	C	G	wt	wt	het	low_MQM;gene_blacklist	QUAL=3863;DP=543,1347,2075;MQM=37	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.2857G>C:p.Glu953Gln		rs201137357	0.1368	0.0242	4/0/4	0.0046	-0.3120	T,T	T	P	T	13.65	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM403232	0	53					FLG (inh=AD pLI=n/a)
chr1	152284576	152284576	C	A	wt	wt	het	low_MQM;gene_blacklist	QUAL=4776;DP=596,1434,2233;MQM=38	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.2786G>T:p.Gly929Val		rs143382793	0.0000	0.0029	0/0/0	0.0001	-0.1670	T,T	T	P	T	16.63	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				0	52					FLG (inh=AD pLI=n/a)
chr1	152284597	152284597	A	C	wt	wt	het	low_MQM;gene_blacklist	QUAL=3090;DP=531,1426,2231;MQM=38	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.2765T>G:p.Ile922Ser		rs201928359	0.0000	0.0011	1/0/0	0.0001	-2.7080	T	T	B	T	0.01	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				0	26					FLG (inh=AD pLI=n/a)
chr1	152284605	152284605	A	C	wt	wt	het	low_MQM;gene_blacklist	QUAL=1710;DP=521,1395,2145;MQM=38	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.2757T>G:p.His919Gln		rs773570353	0.0000	0.0001	0/0/0	0.0001	-3.3070	T	T	B	T	0.01	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				0	8					FLG (inh=AD pLI=n/a)
chr1	152284606	152284606	T	C	wt	wt	het	low_MQM;gene_blacklist	QUAL=1710;DP=521,1395,2145;MQM=38	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.2756A>G:p.His919Arg			0.0000	0.0000	0/0/0	0.0000	-2.7280	T	T	B	T	0.01	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				0	8					FLG (inh=AD pLI=n/a)
chr1	152284607	152284607	G	A	wt	wt	het	low_MQM;gene_blacklist	QUAL=1710;DP=521,1395,2145;MQM=38	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.2755C>T:p.His919Tyr		rs749754687	0.0000	0.0001	0/0/0	0.0001	-0.2850	T	T	B	T	0.40	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				0	8					FLG (inh=AD pLI=n/a)
chr1	152284623	152284623	G	A	wt	wt	het	low_MQM;gene_blacklist	QUAL=1027;DP=556,1427,2121;MQM=38	FLG	synonymous	FLG:NM_002016.1:synonymous:LOW:exon3/3:c.2739C>T:p.His913His		rs199849330	0.0000	0.0002	0/0/0	0.0001							135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				0	3					FLG (inh=AD pLI=n/a)
chr1	152284629	152284629	T	C	wt	wt	het	low_MQM;gene_blacklist	QUAL=202;DP=556,1422,2044;MQM=39	FLG	synonymous	FLG:NM_002016.1:synonymous:LOW:exon3/3:c.2733A>G:p.Ser911Ser		rs540595062	0.0000	0.0005	0/0/0	0.0001							135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				0	4					FLG (inh=AD pLI=n/a)
chr1	152284854	152284854	A	G	het	het	hom	gene_blacklist	QUAL=57077;DP=488,879,1248;MQM=58	FLG	synonymous	FLG:NM_002016.1:synonymous:LOW:exon3/3:c.2508T>C:p.Asp836Asp		rs3120653	0.4732	0.2978	7162/1091/1406	0.2741							135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				83	420					FLG (inh=AD pLI=n/a)
chr1	152285099	152285099	C	T	het	het	hom	gene_blacklist;pred_pathogenic	QUAL=86468;DP=493,1423,1887;MQM=59	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.2263G>A:p.Glu755Lys		rs74129461	0.3277	0.2559	5584/1073/29	0.2420	-0.3080	T	T	B	T	22.60	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM3996944	76	408					FLG (inh=AD pLI=n/a)
chr1	152285181	152285181	G	T	wt	wt	het	gene_blacklist	QUAL=22878;DP=469,1381,1842;MQM=59	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.2181C>A:p.His727Gln		rs7512779	0.0250	0.0232	62/17/0	0.0225	-2.7380	T	T	B	T	0.01	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				0	42					FLG (inh=AD pLI=n/a)
chr1	152285930	152285930	G	A	het	het	hom	gene_blacklist	QUAL=70377;DP=522,1181,1576;MQM=59	FLG	missense	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.1432C>T:p.Pro478Ser		rs11584340	0.3446	0.2613	5646/1060/89	0.2526	-1.8930	T,T	T	B	T	0.01	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];		CM084968 [CLASS=DP MUT=ALT PHEN="Psoriasis increased risk association with" GENE=FLG]; 		79	408					FLG (inh=AD pLI=n/a)
chr1	152286002	152286002	T	C	het	het	hom	anno_pathogenic_hgmd	QUAL=68436;DP=457,1157,1577;MQM=59	FLG,FLG-AS1	missense,non_coding_transcript_exon	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.1360A>G:p.Thr454Ala,FLG-AS1:NR_103778.1:non_coding_transcript_exon:MODIFIER:exon1/7:n.68T>C:		rs2011331	0.4641	0.2949	6975/1079/1214	0.2817	-2.8550	T	T	B	T	1.41	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];		CM1611993 [CLASS=DM? MUT=ALT PHEN="Ichthyosis vulgaris" GENE=FLG]; 	COSM4142699	83	417					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152286032	152286032	C	T	het	het	het		QUAL=40732;DP=577,1214,1566;MQM=59	FLG,FLG-AS1	missense,non_coding_transcript_exon	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.1330G>A:p.Gly444Arg,FLG-AS1:NR_103778.1:non_coding_transcript_exon:MODIFIER:exon1/7:n.98C>T:		rs11588170	0.2871	0.2287	4727/813/4	0.2210	-0.6390	T	T	P	T	6.88	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM3996946	66	382					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152286126	152286126	A	G	het	het	wt		QUAL=20453;DP=473,1206,1528;MQM=59	FLG,FLG-AS1	synonymous,non_coding_transcript_exon	FLG:NM_002016.1:synonymous:LOW:exon3/3:c.1236T>C:p.Arg412Arg,FLG-AS1:NR_103778.1:non_coding_transcript_exon:MODIFIER:exon1/7:n.192A>G:		rs11582620	0.0861	0.1176	1007/442/1	0.1100							135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			COSM146620	21	230					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	152286367	152286367	C	A	het	het	hom	pred_pathogenic	QUAL=59549;DP=570,915,1284;MQM=59	FLG,FLG-AS1	missense,non_coding_transcript_exon	FLG:NM_002016.1:missense:MODERATE:exon3/3:c.995G>T:p.Gly332Val,FLG-AS1:NR_103778.1:non_coding_transcript_exon:MODIFIER:exon1/7:n.433C>A:		rs41267154	0.3407	0.2603	5628/1059/75	0.2508	-1.0200	T	T	D	T	15.37	135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];				77	406					FLG (inh=AD pLI=n/a), FLG-AS1 (inh=n/a pLI=n/a)
chr1	154128672	154128672	G	A	wt	het	wt		QUAL=802;DP=184,87,125;MQM=60	TPM3	3'UTR,non_coding_transcript_exon	TPM3:NM_001278191.1:3'UTR:MODIFIER:exon8/8:c.*1443C>T:,TPM3:NM_001043351.1:3'UTR:MODIFIER:exon8/8:c.*1443C>T:,TPM3:NM_001043352.1:3'UTR:MODIFIER:exon8/8:c.*2773C>T:,TPM3:NM_001043353.1:3'UTR:MODIFIER:exon8/8:c.*2773C>T:,TPM3:NM_001278188.1:3'UTR:MODIFIER:exon7/7:c.*1443C>T:,TPM3:NM_001278189.1:3'UTR:MODIFIER:exon9/9:c.*1522C>T:,TPM3:NM_001278190.1:3'UTR:MODIFIER:exon7/7:c.*1443C>T:,TPM3:NM_153649.3:3'UTR:MODIFIER:exon8/8:c.*1443C>T:,TPM3:NR_103461.1:non_coding_transcript_exon:MODIFIER:exon8/8:n.2316C>T:	AluSq2	rs4540651	0.7151	0.0000	0/0/0	0.5416							191030 [TPM3 (confirmed) Nemaline myopathy 1,autosomal dominant or recessive,609284|CAP myopathy 1,609284|Myopathy,congenital,with fiber-type disproportion,255310];				78	91					TPM3 (inh=AR+AD pLI=0.19)
chr1	154129265	154129265	A	G	wt	het	wt	low_DP	QUAL=131;DP=106,11,19;MQM=59	TPM3	3'UTR,non_coding_transcript_exon	TPM3:NM_001278191.1:3'UTR:MODIFIER:exon8/8:c.*850T>C:,TPM3:NM_001043351.1:3'UTR:MODIFIER:exon8/8:c.*850T>C:,TPM3:NM_001043352.1:3'UTR:MODIFIER:exon8/8:c.*2180T>C:,TPM3:NM_001043353.1:3'UTR:MODIFIER:exon8/8:c.*2180T>C:,TPM3:NM_001278188.1:3'UTR:MODIFIER:exon7/7:c.*850T>C:,TPM3:NM_001278189.1:3'UTR:MODIFIER:exon9/9:c.*929T>C:,TPM3:NM_001278190.1:3'UTR:MODIFIER:exon7/7:c.*850T>C:,TPM3:NM_153649.3:3'UTR:MODIFIER:exon8/8:c.*850T>C:,TPM3:NR_103461.1:non_coding_transcript_exon:MODIFIER:exon8/8:n.1723T>C:		rs1051370	0.3229	0.0000	0/0/0	0.2955							191030 [TPM3 (confirmed) Nemaline myopathy 1,autosomal dominant or recessive,609284|CAP myopathy 1,609284|Myopathy,congenital,with fiber-type disproportion,255310];				38	97					TPM3 (inh=AR+AD pLI=0.19)
chr1	154134557	154134557	A	C	wt	het	wt		QUAL=1969;DP=473,219,366;MQM=60	TPM3	3'UTR,intron	TPM3:NM_152263.3:3'UTR:MODIFIER:exon10/10:c.*5856T>G:,TPM3:NM_001278191.1:intron:MODIFIER:exon7/7:c.395-4360T>G:,TPM3:NM_001043351.1:intron:MODIFIER:exon7/7:c.665-4360T>G:,TPM3:NM_001043352.1:intron:MODIFIER:exon7/7:c.665-3033T>G:,TPM3:NM_001043353.1:intron:MODIFIER:exon7/7:c.665-3033T>G:,TPM3:NM_001278188.1:intron:MODIFIER:exon6/6:c.467-4360T>G:,TPM3:NM_001278189.1:intron:MODIFIER:exon8/8:c.744-4360T>G:,TPM3:NM_001278190.1:intron:MODIFIER:exon6/6:c.602-4360T>G:,TPM3:NM_153649.3:intron:MODIFIER:exon7/7:c.665-4360T>G:,TPM3:NR_103461.1:intron:MODIFIER:exon7/7:n.791-4360T>G:		rs3196889	0.3215	0.0000	0/0/0	0.3619							191030 [TPM3 (confirmed) Nemaline myopathy 1,autosomal dominant or recessive,609284|CAP myopathy 1,609284|Myopathy,congenital,with fiber-type disproportion,255310];	RCV000304879.1 [benign]; RCV000395347.1 [benign]; 			39	95					TPM3 (inh=AR+AD pLI=0.19)
chr1	154138228	154138228	G	A	wt	het	wt		QUAL=639;DP=198,37,58;MQM=59	TPM3	3'UTR,intron	TPM3:NM_152263.3:3'UTR:MODIFIER:exon10/10:c.*2185C>T:,TPM3:NM_001278191.1:intron:MODIFIER:exon7/7:c.394+4648C>T:,TPM3:NM_001043351.1:intron:MODIFIER:exon7/7:c.664+4648C>T:,TPM3:NM_001043352.1:intron:MODIFIER:exon7/7:c.664+4648C>T:,TPM3:NM_001043353.1:intron:MODIFIER:exon7/7:c.664+4648C>T:,TPM3:NM_001278188.1:intron:MODIFIER:exon6/6:c.466+4648C>T:,TPM3:NM_001278189.1:intron:MODIFIER:exon8/8:c.743+3553C>T:,TPM3:NM_001278190.1:intron:MODIFIER:exon6/6:c.601+4648C>T:,TPM3:NM_153649.3:intron:MODIFIER:exon7/7:c.664+4648C>T:,TPM3:NR_103461.1:intron:MODIFIER:exon7/7:n.790+4648C>T:	AluSq2	rs10908723	0.3201	0.0000	0/0/0	0.3208							191030 [TPM3 (confirmed) Nemaline myopathy 1,autosomal dominant or recessive,609284|CAP myopathy 1,609284|Myopathy,congenital,with fiber-type disproportion,255310];	RCV000336225.1 [benign]; RCV000394567.1 [benign]; 			34	64					TPM3 (inh=AR+AD pLI=0.19)
chr1	154138283	154138283	G	A	hom	hom	hom		QUAL=446;DP=153,30,46;MQM=53	TPM3	3'UTR,intron	TPM3:NM_152263.3:3'UTR:MODIFIER:exon10/10:c.*2130C>T:,TPM3:NM_001278191.1:intron:MODIFIER:exon7/7:c.394+4593C>T:,TPM3:NM_001043351.1:intron:MODIFIER:exon7/7:c.664+4593C>T:,TPM3:NM_001043352.1:intron:MODIFIER:exon7/7:c.664+4593C>T:,TPM3:NM_001043353.1:intron:MODIFIER:exon7/7:c.664+4593C>T:,TPM3:NM_001278188.1:intron:MODIFIER:exon6/6:c.466+4593C>T:,TPM3:NM_001278189.1:intron:MODIFIER:exon8/8:c.743+3498C>T:,TPM3:NM_001278190.1:intron:MODIFIER:exon6/6:c.601+4593C>T:,TPM3:NM_153649.3:intron:MODIFIER:exon7/7:c.664+4593C>T:,TPM3:NR_103461.1:intron:MODIFIER:exon7/7:n.790+4593C>T:	AluSq2	rs200411262	0.0000	0.0000	0/0/0	0.0002							191030 [TPM3 (confirmed) Nemaline myopathy 1,autosomal dominant or recessive,609284|CAP myopathy 1,609284|Myopathy,congenital,with fiber-type disproportion,255310];				0	60					TPM3 (inh=AR+AD pLI=0.19)
chr1	154139165	154139165	-	T	wt	het	wt		QUAL=150;DP=177,37,38;MQM=59	TPM3	3'UTR,intron	TPM3:NM_152263.3:3'UTR:MODIFIER:exon10/10:c.*1247dupA:,TPM3:NM_001278191.1:intron:MODIFIER:exon7/7:c.394+3710dupA:,TPM3:NM_001043351.1:intron:MODIFIER:exon7/7:c.664+3710dupA:,TPM3:NM_001043352.1:intron:MODIFIER:exon7/7:c.664+3710dupA:,TPM3:NM_001043353.1:intron:MODIFIER:exon7/7:c.664+3710dupA:,TPM3:NM_001278188.1:intron:MODIFIER:exon6/6:c.466+3710dupA:,TPM3:NM_001278189.1:intron:MODIFIER:exon8/8:c.743+2615dupA:,TPM3:NM_001278190.1:intron:MODIFIER:exon6/6:c.601+3710dupA:,TPM3:NM_153649.3:intron:MODIFIER:exon7/7:c.664+3710dupA:,TPM3:NR_103461.1:intron:MODIFIER:exon7/7:n.790+3710dupA:		rs34361401;rs373439338	0.3409	0.0000	0/0/0	0.2501							191030 [TPM3 (confirmed) Nemaline myopathy 1,autosomal dominant or recessive,609284|CAP myopathy 1,609284|Myopathy,congenital,with fiber-type disproportion,255310];	RCV000307028.1 [likely benign]; RCV000398242.1 [likely benign]; RCV000315274.1 [benign]; RCV000369925.1 [benign]; 			6	92					TPM3 (inh=AR+AD pLI=0.19)
chr1	154139381	154139381	A	C	wt	het	wt		QUAL=547;DP=149,62,71;MQM=60	TPM3	3'UTR,intron	TPM3:NM_152263.3:3'UTR:MODIFIER:exon10/10:c.*1032T>G:,TPM3:NM_001278191.1:intron:MODIFIER:exon7/7:c.394+3495T>G:,TPM3:NM_001043351.1:intron:MODIFIER:exon7/7:c.664+3495T>G:,TPM3:NM_001043352.1:intron:MODIFIER:exon7/7:c.664+3495T>G:,TPM3:NM_001043353.1:intron:MODIFIER:exon7/7:c.664+3495T>G:,TPM3:NM_001278188.1:intron:MODIFIER:exon6/6:c.466+3495T>G:,TPM3:NM_001278189.1:intron:MODIFIER:exon8/8:c.743+2400T>G:,TPM3:NM_001278190.1:intron:MODIFIER:exon6/6:c.601+3495T>G:,TPM3:NM_153649.3:intron:MODIFIER:exon7/7:c.664+3495T>G:,TPM3:NR_103461.1:intron:MODIFIER:exon7/7:n.790+3495T>G:	AluSx1	rs6673171	0.3229	0.0000	0/0/0	0.3214							191030 [TPM3 (confirmed) Nemaline myopathy 1,autosomal dominant or recessive,609284|CAP myopathy 1,609284|Myopathy,congenital,with fiber-type disproportion,255310];	RCV000281571.1 [benign]; RCV000371927.1 [benign]; 			27	63					TPM3 (inh=AR+AD pLI=0.19)
chr1	154245142	154245142	T	G	wt	wt	het		QUAL=2991;DP=391,171,247;MQM=60	HAX1	5'UTR_premature_start_codon_gain,5'UTR	HAX1:NM_006118.3:5'UTR_premature_start_codon_gain:LOW:exon1/7:c.-58T>G:,HAX1:NM_001018837.1:5'UTR_premature_start_codon_gain:LOW:exon1/7:c.-58T>G:,HAX1:NM_006118.3:5'UTR:MODIFIER:exon1/7:c.-58T>G:,HAX1:NM_001018837.1:5'UTR:MODIFIER:exon1/7:c.-58T>G:		rs11265425	0.2077	0.0000	0/0/0	0.0849							605998 [HAX1 (confirmed) Neutropenia,severe congenital 3,autosomal recessive,610738];	RCV000370824.1 [benign]; 			40	253					HAX1 (inh=AR pLI=0.00)
chr1	154548721	154548721	T	C	hom	hom	het		QUAL=8969;DP=115,126,110;MQM=59	CHRNB2	3'UTR	CHRNB2:NM_000748.2:3'UTR:MODIFIER:exon6/6:c.*313T>C:		rs2072660	0.6927	0.0000	0/0/0	0.7343							118507 [CHRNB2 (confirmed) Epilepsy,nocturnal frontal lobe,3,605375];				141	77					CHRNB2 (inh=AD pLI=0.72)
chr1	154548880	154548880	G	A	wt	wt	het		QUAL=1185;DP=82,62,106;MQM=60	CHRNB2	3'UTR	CHRNB2:NM_000748.2:3'UTR:MODIFIER:exon6/6:c.*472G>A:		rs2072661	0.2646	0.0000	0/0/0	0.0422							118507 [CHRNB2 (confirmed) Epilepsy,nocturnal frontal lobe,3,605375];				8	81					CHRNB2 (inh=AD pLI=0.72)
chr1	154549470	154549470	T	C	wt	wt	het		QUAL=3416;DP=317,241,300;MQM=60	CHRNB2	3'UTR	CHRNB2:NM_000748.2:3'UTR:MODIFIER:exon6/6:c.*1062T>C:		rs12130403	0.2859	0.0000	0/0/0	0.2937							118507 [CHRNB2 (confirmed) Epilepsy,nocturnal frontal lobe,3,605375];				21	102					CHRNB2 (inh=AD pLI=0.72)
chr1	154550944	154550945	AG	-	wt	wt	het		QUAL=3272;DP=275,214,268;MQM=60	CHRNB2	3'UTR	CHRNB2:NM_000748.2:3'UTR:MODIFIER:exon6/6:c.*2538_*2539delAG:		rs397726663	0.2668	0.0000	0/0/0	0.2419							118507 [CHRNB2 (confirmed) Epilepsy,nocturnal frontal lobe,3,605375];				12	86					CHRNB2 (inh=AD pLI=0.72)
chr1	154552010	154552010	C	G	het	het	wt		QUAL=8476;DP=299,337,413;MQM=59	CHRNB2	3'UTR	CHRNB2:NM_000748.2:3'UTR:MODIFIER:exon6/6:c.*3602C>G:			0.0000	0.0000	0/0/0	0.0000							118507 [CHRNB2 (confirmed) Epilepsy,nocturnal frontal lobe,3,605375];				0	2					CHRNB2 (inh=AD pLI=0.72)
chr1	156025096	156025096	C	T	wt	het	wt		QUAL=1258;DP=86,108,167;MQM=60	LAMTOR2	synonymous	LAMTOR2:NM_014017.3:synonymous:LOW:exon2/4:c.111C>T:p.Tyr37Tyr,LAMTOR2:NM_001145264.1:synonymous:LOW:exon2/3:c.111C>T:p.Tyr37Tyr		rs7541	0.0717	0.1203	1085/886/9	0.1200							610389 [LAMTOR2 (provisional) Immunodeficiency due to defect in MAPBP-interacting protein,610798];				52	361					LAMTOR2 (inh=AR pLI=0.48)
chr1	156105028	156105028	T	C	wt	het	wt		QUAL=338;DP=99,36,54;MQM=60	LMNA	synonymous	LMNA:NM_170707.3:synonymous:LOW:exon5/12:c.861T>C:p.Ala287Ala,LMNA:NM_001282625.1:synonymous:LOW:exon8/13:c.861T>C:p.Ala287Ala,LMNA:NM_005572.3:synonymous:LOW:exon5/10:c.861T>C:p.Ala287Ala,LMNA:NM_001282626.1:synonymous:LOW:exon5/12:c.861T>C:p.Ala287Ala,LMNA:NM_170708.3:synonymous:LOW:exon5/11:c.861T>C:p.Ala287Ala,LMNA:NM_001282624.1:synonymous:LOW:exon6/11:c.618T>C:p.Ala206Ala,LMNA:NM_001257374.2:synonymous:LOW:exon5/13:c.525T>C:p.Ala175Ala		rs538089	0.1931	0.1094	1433/201/1046	0.1054							150330 [LMNA (confirmed) Emery-Dreifuss muscular dystrophy 2,AD,181350|Cardiomyopathy,dilated,1A,115200|Lipodystrophy,familial partial,type 2,151660|Emery-Dreifuss muscular dystrophy 3,AR,616516|Charcot-Marie-Tooth disease,type 2B1,605588|Muscular dystrophy,congenital,613205|Muscular dystrophy,limb-girdle,type 1B,159001|Mandibuloacral dysplasia,248370|Hutchinson-Gilford progeria,176670|Restrictive dermopathy,lethal,275210|Heart-hand syndrome,Slovenian type,610140|Malouf syndrome,212112];	RCV000041374.11 [other]; RCV000057475.3 [not provided]; RCV000249986.1 [benign]; RCV000278366.1 [benign]; RCV000281700.1 [benign]; RCV000303946.1 [benign]; RCV000332471.1 [benign]; RCV000335802.1 [benign]; RCV000339029.1 [benign]; RCV000374142.1 [benign]; RCV000385848.1 [benign]; RCV000389150.1 [benign]; RCV000408212.1 [benign]; 			38	283					LMNA (inh=AR+AD pLI=0.99)
chr1	156106185	156106185	T	C	wt	het	wt		QUAL=1107;DP=48,108,140;MQM=60	LMNA	synonymous	LMNA:NM_170707.3:synonymous:LOW:exon7/12:c.1338T>C:p.Asp446Asp,LMNA:NM_001282625.1:synonymous:LOW:exon10/13:c.1338T>C:p.Asp446Asp,LMNA:NM_005572.3:synonymous:LOW:exon7/10:c.1338T>C:p.Asp446Asp,LMNA:NM_001282626.1:synonymous:LOW:exon7/12:c.1338T>C:p.Asp446Asp,LMNA:NM_170708.3:synonymous:LOW:exon7/11:c.1338T>C:p.Asp446Asp,LMNA:NM_001282624.1:synonymous:LOW:exon8/11:c.1095T>C:p.Asp365Asp,LMNA:NM_001257374.2:synonymous:LOW:exon7/13:c.1002T>C:p.Asp334Asp		rs505058	0.2492	0.1611	2238/182/1875	0.1198	-0.3620					5.31	150330 [LMNA (confirmed) Emery-Dreifuss muscular dystrophy 2,AD,181350|Cardiomyopathy,dilated,1A,115200|Lipodystrophy,familial partial,type 2,151660|Emery-Dreifuss muscular dystrophy 3,AR,616516|Charcot-Marie-Tooth disease,type 2B1,605588|Muscular dystrophy,congenital,613205|Muscular dystrophy,limb-girdle,type 1B,159001|Mandibuloacral dysplasia,248370|Hutchinson-Gilford progeria,176670|Restrictive dermopathy,lethal,275210|Heart-hand syndrome,Slovenian type,610140|Malouf syndrome,212112];	RCV000041315.11 [other]; RCV000057270.3 [not provided]; RCV000252403.1 [benign]; RCV000268754.1 [benign]; RCV000278595.1 [benign]; RCV000300868.1 [benign]; RCV000304015.1 [benign]; RCV000326241.1 [benign]; RCV000351015.1 [benign]; RCV000357954.1 [benign]; RCV000360967.1 [benign]; RCV000392971.1 [benign]; RCV000402362.1 [benign]; 			41	253					LMNA (inh=AR+AD pLI=0.99)
chr1	156107534	156107534	C	T	het	wt	het		QUAL=6821;DP=153,263,353;MQM=59	LMNA	splice_region&synonymous,synonymous,intron	LMNA:NM_170707.3:splice_region&synonymous:LOW:exon10/12:c.1698C>T:p.His566His,LMNA:NM_001282626.1:splice_region&synonymous:LOW:exon10/12:c.1698C>T:p.His566His,LMNA:NM_001257374.2:splice_region&synonymous:LOW:exon10/13:c.1362C>T:p.His454His,LMNA:NM_001282625.1:synonymous:LOW:exon13/13:c.1698C>T:p.His566His,LMNA:NM_005572.3:synonymous:LOW:exon10/10:c.1698C>T:p.His566His,LMNA:NM_001282624.1:synonymous:LOW:exon11/11:c.1455C>T:p.His485His,LMNA:NM_170708.3:intron:MODIFIER:exon9/10:c.1608+511C>T:		rs4641	0.2202	0.2655	756/324/16	0.1137							150330 [LMNA (confirmed) Emery-Dreifuss muscular dystrophy 2,AD,181350|Cardiomyopathy,dilated,1A,115200|Lipodystrophy,familial partial,type 2,151660|Emery-Dreifuss muscular dystrophy 3,AR,616516|Charcot-Marie-Tooth disease,type 2B1,605588|Muscular dystrophy,congenital,613205|Muscular dystrophy,limb-girdle,type 1B,159001|Mandibuloacral dysplasia,248370|Hutchinson-Gilford progeria,176670|Restrictive dermopathy,lethal,275210|Heart-hand syndrome,Slovenian type,610140|Malouf syndrome,212112];	RCV000041327.8 [other]; RCV000057348.2 [not provided]; RCV000225004.1 [benign]; RCV000252567.1 [benign]; RCV000280696.1 [benign]; RCV000307278.1 [benign]; RCV000310337.1 [benign]; RCV000313972.1 [benign]; RCV000335127.1 [benign]; RCV000339153.1 [benign]; RCV000350197.1 [benign]; RCV000375103.1 [benign]; RCV000393593.1 [benign]; RCV000398387.1 [benign]; 	CM003892 [CLASS=DP MUT=ALT PHEN="Metabolic syndrome association with" GENE=LMNA]; 	COSM3750412, COSM3750413	125	594					LMNA (inh=AR+AD pLI=0.99)
chr1	156108976	156108976	G	C	wt	het	wt	low_DP	QUAL=34;DP=71,7,15;MQM=60	LMNA	3'UTR,intron	LMNA:NM_170707.3:3'UTR:MODIFIER:exon12/12:c.*79G>C:,LMNA:NM_001282626.1:3'UTR:MODIFIER:exon12/12:c.*79G>C:,LMNA:NM_170708.3:3'UTR:MODIFIER:exon11/11:c.*79G>C:,LMNA:NM_001257374.2:intron:MODIFIER:exon12/12:c.1655+83G>C:		rs7339	0.1853	0.0000	0/0/0	0.0183							150330 [LMNA (confirmed) Emery-Dreifuss muscular dystrophy 2,AD,181350|Cardiomyopathy,dilated,1A,115200|Lipodystrophy,familial partial,type 2,151660|Emery-Dreifuss muscular dystrophy 3,AR,616516|Charcot-Marie-Tooth disease,type 2B1,605588|Muscular dystrophy,congenital,613205|Muscular dystrophy,limb-girdle,type 1B,159001|Mandibuloacral dysplasia,248370|Hutchinson-Gilford progeria,176670|Restrictive dermopathy,lethal,275210|Heart-hand syndrome,Slovenian type,610140|Malouf syndrome,212112];	RCV000057212.1 [not provided]; 			11	78					LMNA (inh=AR+AD pLI=0.99)
chr1	156785617	156785617	G	A	hom	hom	hom		QUAL=22498;DP=200,211,301;MQM=59	NTRK1,SH2D2A	5'UTR,intron	NTRK1:NM_001007792.1:5'UTR:MODIFIER:exon1/17:c.-5G>A:,SH2D2A:NM_001161441.1:intron:MODIFIER:exon2/8:c.123+181C>T:,SH2D2A:NM_001161443.1:intron:MODIFIER:exon1/7:c.39+181C>T:,SH2D2A:NM_001161442.1:intron:MODIFIER:exon2/8:c.69+181C>T:,SH2D2A:NM_003975.3:intron:MODIFIER:exon2/8:c.123+181C>T:,SH2D2A:NM_001161444.1:intron:MODIFIER:exon2/7:c.123+181C>T:		rs1800601	0.6370	0.6674	27406/15332/1316	0.6650							191315 [NTRK1 (confirmed) Insensitivity to pain,congenital,with anhidrosis,256800|Medullary thyroid carcinoma,familial,155240];				719	703					NTRK1 (inh=AR+AD pLI=0.00), SH2D2A (inh=n/a pLI=0.00)
chr1	156846233	156846233	G	A	het	hom	wt		QUAL=6482;DP=156,150,147;MQM=60	NTRK1	synonymous	NTRK1:NM_002529.3:synonymous:LOW:exon14/17:c.1674G>A:p.Gln558Gln,NTRK1:NM_001007792.1:synonymous:LOW:exon14/17:c.1566G>A:p.Gln522Gln,NTRK1:NM_001012331.1:synonymous:LOW:exon13/16:c.1656G>A:p.Gln552Gln		rs6334	0.2129	0.2203	3033/1498/102	0.2177							191315 [NTRK1 (confirmed) Insensitivity to pain,congenital,with anhidrosis,256800|Medullary thyroid carcinoma,familial,155240];	RCV000366755.1 [benign]; 		COSM3750439, COSM3750440	85	519					NTRK1 (inh=AR+AD pLI=0.00)
chr1	156848995	156848995	C	T	het	wt	hom		QUAL=3913;DP=53,104,128;MQM=59	NTRK1	synonymous	NTRK1:NM_002529.3:synonymous:LOW:exon15/17:c.1887C>T:p.Ala629Ala,NTRK1:NM_001007792.1:synonymous:LOW:exon15/17:c.1779C>T:p.Ala593Ala,NTRK1:NM_001012331.1:synonymous:LOW:exon14/16:c.1869C>T:p.Ala623Ala		rs6337	0.3341	0.5724	22665/17445/216	0.5593							191315 [NTRK1 (confirmed) Insensitivity to pain,congenital,with anhidrosis,256800|Medullary thyroid carcinoma,familial,155240];	RCV000127264.1 [benign]; RCV000287221.1 [benign]; 		COSM4142850, COSM4142851	721	691					NTRK1 (inh=AR+AD pLI=0.00)
chr1	160009121	160009121	A	C	het	het	wt		QUAL=3032;DP=174,68,81;MQM=59	KCNJ10	3'UTR	KCNJ10:NM_002241.4:3'UTR:MODIFIER:exon2/2:c.*2062T>G:		rs1053074	0.4810	0.0000	0/0/0	0.0662							602208 [KCNJ10 (confirmed) SESAME syndrome,612780|Enlarged vestibular aqueduct,digenic,600791];	RCV000275599.1 [likely benign]; RCV000328225.1 [likely benign]; RCV000367826.1 [likely benign]; 			37	107					KCNJ10 (inh=AR pLI=0.60)
chr1	160009143	160009143	G	C	hom	hom	hom		QUAL=8499;DP=145,59,69;MQM=59	KCNJ10	3'UTR	KCNJ10:NM_002241.4:3'UTR:MODIFIER:exon2/2:c.*2040C>G:		rs2486254	0.9982	0.0000	0/0/0	0.8711							602208 [KCNJ10 (confirmed) SESAME syndrome,612780|Enlarged vestibular aqueduct,digenic,600791];	RCV000288441.1 [benign]; RCV000326994.1 [benign]; RCV000385122.1 [benign]; 			221	0					KCNJ10 (inh=AR pLI=0.60)
chr1	160009164	160009171	ACACACAC	-	hom	wt	wt	low_DP	QUAL=463;DP=9,34,42;MQM=60	KCNJ10	3'UTR	KCNJ10:NM_002241.4:3'UTR:MODIFIER:exon2/2:c.*2012_*2019delGTGTGTGT:	(AC)n	rs68110005;rs777546653	0.0000	0.0000	0/0/0	0.0684							602208 [KCNJ10 (confirmed) SESAME syndrome,612780|Enlarged vestibular aqueduct,digenic,600791];	RCV000271458.1 [uncertain significance]; RCV000310224.1 [uncertain significance]; RCV000362624.1 [uncertain significance]; 			2	6					KCNJ10 (inh=AR pLI=0.60)
chr1	160009164	160009169	ACACAC	-	wt	hom	wt	low_DP	QUAL=463;DP=9,34,42;MQM=60	KCNJ10	3'UTR	KCNJ10:NM_002241.4:3'UTR:MODIFIER:exon2/2:c.*2014_*2019delGTGTGT:	(AC)n		0.0000	0.0000	0/0/0	0.0000							602208 [KCNJ10 (confirmed) SESAME syndrome,612780|Enlarged vestibular aqueduct,digenic,600791];	RCV000269859.1 [uncertain significance]; RCV000323131.1 [uncertain significance]; RCV000380060.1 [uncertain significance]; 			0	4					KCNJ10 (inh=AR pLI=0.60)
chr1	160009419	160009419	A	C	hom	hom	hom		QUAL=31957;DP=369,263,346;MQM=59	KCNJ10	3'UTR	KCNJ10:NM_002241.4:3'UTR:MODIFIER:exon2/2:c.*1764T>G:		rs2486253	0.8628	0.0000	0/0/0	0.1419							602208 [KCNJ10 (confirmed) SESAME syndrome,612780|Enlarged vestibular aqueduct,digenic,600791];	RCV000262610.1 [benign]; RCV000302435.1 [benign]; RCV000359621.1 [benign]; 			157	66					KCNJ10 (inh=AR pLI=0.60)
chr1	160010151	160010151	C	T	wt	het	wt		QUAL=2264;DP=336,197,283;MQM=60	KCNJ10	3'UTR	KCNJ10:NM_002241.4:3'UTR:MODIFIER:exon2/2:c.*1032G>A:		rs17375748	0.0244	0.0000	0/0/0	0.0080							602208 [KCNJ10 (confirmed) SESAME syndrome,612780|Enlarged vestibular aqueduct,digenic,600791];				1	29					KCNJ10 (inh=AR pLI=0.60)
chr1	160246990	160246990	T	-	het	het	wt		QUAL=216;DP=292,137,191;MQM=59	PEX19	3'UTR,non_coding_transcript_exon	PEX19:NM_002857.3:3'UTR:MODIFIER:exon8/8:c.*2351delA:,PEX19:NM_001193644.1:3'UTR:MODIFIER:exon8/8:c.*2359delA:,PEX19:NR_036492.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.3168delA:,PEX19:NR_036493.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.3192delA:	Charlie10	rs751979135	0.0000	0.2690	0/0/0	0.0189							615820 [DCAF8 (provisional) Giant axonal neuropathy 2,autosomal dominant,610100]:600279 [PEX19 (confirmed) Peroxisome biogenesis disorder 12A (Zellweger),614886];				0	13					PEX19 (inh=AR pLI=0.04)
chr1	160247185	160247185	G	C	het	wt	hom		QUAL=10232;DP=284,167,217;MQM=60	PEX19	3'UTR,non_coding_transcript_exon	PEX19:NM_002857.3:3'UTR:MODIFIER:exon8/8:c.*2156C>G:,PEX19:NM_001193644.1:3'UTR:MODIFIER:exon8/8:c.*2164C>G:,PEX19:NR_036492.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.2973C>G:,PEX19:NR_036493.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.2997C>G:	Charlie10	rs10594	0.4523	0.5641	1766/279/19	0.1258							615820 [DCAF8 (provisional) Giant axonal neuropathy 2,autosomal dominant,610100]:600279 [PEX19 (confirmed) Peroxisome biogenesis disorder 12A (Zellweger),614886];	RCV000334144.1 [benign]; 			436	688					PEX19 (inh=AR pLI=0.04)
chr1	161140278	161140278	A	-	het	wt	het	anno_high_impact	QUAL=6153;DP=232,330,376;MQM=59	PPOX	frameshift	PPOX:NM_000309.3:frameshift:HIGH:exon10/13:c.1067delA:p.Gln356fs,PPOX:NM_001122764.1:frameshift:HIGH:exon10/13:c.1067delA:p.Gln356fs			0.0000	0.0000	0/0/0	0.0000							600923 [PPOX (provisional) Porphyria variegata,176200];				0	2					PPOX (inh=AR+AD pLI=0.33)
chr1	161184097	161184097	A	G	wt	wt	het		QUAL=2157;DP=364,186,252;MQM=59	NDUFS2	3'UTR	NDUFS2:NM_004550.4:3'UTR:MODIFIER:exon15/15:c.*114A>G:,NDUFS2:NM_001166159.1:3'UTR:MODIFIER:exon13/13:c.*366A>G:		rs1136224	0.1821	0.0000	0/0/0	0.0297							602985 [NDUFS2 (provisional) Mitochondrial complex I deficiency,252010];	RCV000377195.1 [likely benign]; 			4	33					NDUFS2 (inh=AR pLI=1.00)
chr1	161274648	161274648	G	C	wt	het	het		QUAL=66;DP=36,28,34;MQM=60	MPZ	3'UTR	MPZ:NM_001315491.1:3'UTR:MODIFIER:exon6/6:c.*826C>G:,MPZ:NM_000530.7:3'UTR:MODIFIER:exon6/6:c.*1018C>G:		rs185093979	0.0000	0.0000	0/0/0	0.0008							159440 [MPZ (confirmed) Charcot-Marie-Tooth disease,type 1B,118200|Dejerine-Sottas disease,145900|Neuropathy,congenital hypomyelinating,605253|Charcot-Marie-Tooth disease,type 2J,607736|Roussy-Levy syndrome,180800|Charcot-Marie-Tooth disease,type 2I,607677|Charcot-Marie-Tooth disease,dominant intermediate D,607791];				0	18					MPZ (inh=AR+AD pLI=0.69)
chr1	161274905	161274905	T	C	wt	het	wt	low_DP	QUAL=171;DP=69,29,18;MQM=60	MPZ	3'UTR	MPZ:NM_001315491.1:3'UTR:MODIFIER:exon6/6:c.*569A>G:,MPZ:NM_000530.7:3'UTR:MODIFIER:exon6/6:c.*761A>G:		rs16832786	0.1364	0.0000	0/0/0	0.0179							159440 [MPZ (confirmed) Charcot-Marie-Tooth disease,type 1B,118200|Dejerine-Sottas disease,145900|Neuropathy,congenital hypomyelinating,605253|Charcot-Marie-Tooth disease,type 2J,607736|Roussy-Levy syndrome,180800|Charcot-Marie-Tooth disease,type 2I,607677|Charcot-Marie-Tooth disease,dominant intermediate D,607791];	RCV000282450.1 [benign]; RCV000316529.1 [benign]; RCV000331888.1 [benign]; RCV000373521.1 [benign]; 			1	40					MPZ (inh=AR+AD pLI=0.69)
chr1	167399868	167399868	-	AG	hom	hom	hom		QUAL=15645;DP=191,147,177;MQM=59	POU2F1-CD247	intergenic_region	POU2F1-CD247:POU2F1-CD247:intergenic_region:MODIFIER::n.167399868_167399869insAG:		rs397750029	0.9870	0.0000	0/0/0	0.8746							186780 [CD247 (confirmed) Immunodeficiency 25,610163];				228	1					POU2F1-CD247 (inh=n/a pLI=n/a)
chr1	167399962	167399962	T	C	hom	hom	hom		QUAL=39723;DP=389,381,464;MQM=59	CD247	3'UTR	CD247:NM_198053.2:3'UTR:MODIFIER:exon8/8:c.*956A>G:,CD247:NM_000734.3:3'UTR:MODIFIER:exon8/8:c.*956A>G:		rs947480	0.9874	0.0000	0/0/0	0.1492							186780 [CD247 (confirmed) Immunodeficiency 25,610163];				229	1					CD247 (inh=AR pLI=0.66)
chr1	167400074	167400074	T	A	hom	hom	hom		QUAL=45607;DP=406,433,593;MQM=59	CD247	3'UTR	CD247:NM_198053.2:3'UTR:MODIFIER:exon8/8:c.*844A>T:,CD247:NM_000734.3:3'UTR:MODIFIER:exon8/8:c.*844A>T:		rs1052231	0.8111	0.0000	0/0/0	0.1405							186780 [CD247 (confirmed) Immunodeficiency 25,610163];				171	51					CD247 (inh=AR pLI=0.66)
chr1	179519880	179519880	T	C	hom	hom	hom		QUAL=27918;DP=268,272,330;MQM=60	NPHS2,AXDND1	3'UTR,intron	NPHS2:NM_014625.3:3'UTR:MODIFIER:exon8/8:c.*428A>G:,NPHS2:NM_001297575.1:3'UTR:MODIFIER:exon7/7:c.*428A>G:,AXDND1:NM_144696.5:intron:MODIFIER:exon25/25:c.3032-3767T>C:,AXDND1:NR_073544.1:intron:MODIFIER:exon25/25:n.3152-3767T>C:		rs1060775	0.9018	0.0000	0/0/0	0.1442							604766 [NPHS2 (confirmed) Nephrotic syndrome,type 2,600995];	RCV000210058.1 [benign]; RCV000263320.1 [benign]; 			191	38					NPHS2 (inh=AR pLI=0.01), AXDND1 (inh=n/a pLI=0.00)
chr1	179520050	179520050	T	C	het	hom	wt		QUAL=7951;DP=330,121,177;MQM=60	NPHS2,AXDND1	3'UTR,intron	NPHS2:NM_014625.3:3'UTR:MODIFIER:exon8/8:c.*258A>G:,NPHS2:NM_001297575.1:3'UTR:MODIFIER:exon7/7:c.*258A>G:,AXDND1:NM_144696.5:intron:MODIFIER:exon25/25:c.3032-3597T>C:,AXDND1:NR_073544.1:intron:MODIFIER:exon25/25:n.3152-3597T>C:		rs2274622	0.2831	0.0000	0/0/0	0.0495							604766 [NPHS2 (confirmed) Nephrotic syndrome,type 2,600995];	RCV000210053.1 [benign]; RCV000354410.1 [likely benign]; 			23	81					NPHS2 (inh=AR pLI=0.01), AXDND1 (inh=n/a pLI=0.00)
chr1	179520151	179520151	C	T	hom	hom	hom		QUAL=24234;DP=290,194,263;MQM=59	NPHS2,AXDND1	3'UTR,intron	NPHS2:NM_014625.3:3'UTR:MODIFIER:exon8/8:c.*157G>A:,NPHS2:NM_001297575.1:3'UTR:MODIFIER:exon7/7:c.*157G>A:,AXDND1:NM_144696.5:intron:MODIFIER:exon25/25:c.3032-3496C>T:,AXDND1:NR_073544.1:intron:MODIFIER:exon25/25:n.3152-3496C>T:		rs1410590	0.9052	0.0000	0/0/0	0.1444							604766 [NPHS2 (confirmed) Nephrotic syndrome,type 2,600995];	RCV000210055.1 [benign]; RCV000265258.1 [benign]; 			192	38					NPHS2 (inh=AR pLI=0.01), AXDND1 (inh=n/a pLI=0.00)
chr1	179520254	179520254	C	G	hom	hom	hom		QUAL=22119;DP=393,131,174;MQM=59	NPHS2,AXDND1	3'UTR,intron	NPHS2:NM_014625.3:3'UTR:MODIFIER:exon8/8:c.*54G>C:,NPHS2:NM_001297575.1:3'UTR:MODIFIER:exon7/7:c.*54G>C:,AXDND1:NM_144696.5:intron:MODIFIER:exon25/25:c.3032-3393C>G:,AXDND1:NR_073544.1:intron:MODIFIER:exon25/25:n.3152-3393C>G:		rs1410591	0.5879	0.0000	0/0/0	0.1217							604766 [NPHS2 (confirmed) Nephrotic syndrome,type 2,600995];	RCV000320321.1 [likely benign]; 			349	432					NPHS2 (inh=AR pLI=0.01), AXDND1 (inh=n/a pLI=0.00)
chr1	179520506	179520506	G	A	hom	hom	hom		QUAL=20741;DP=346,128,184;MQM=60	NPHS2,AXDND1	synonymous,intron	NPHS2:NM_014625.3:synonymous:LOW:exon8/8:c.954C>T:p.Ala318Ala,NPHS2:NM_001297575.1:synonymous:LOW:exon7/7:c.750C>T:p.Ala250Ala,AXDND1:NM_144696.5:intron:MODIFIER:exon25/25:c.3032-3141G>A:,AXDND1:NR_073544.1:intron:MODIFIER:exon25/25:n.3152-3141G>A:		rs1410592	0.5877	0.6192	23360/13445/1870	0.6111							604766 [NPHS2 (confirmed) Nephrotic syndrome,type 2,600995];	RCV000243457.1 [benign]; RCV000289839.1 [likely benign]; 		COSM146700	587	750					NPHS2 (inh=AR pLI=0.01), AXDND1 (inh=n/a pLI=0.00)
chr1	179521731	179521731	T	C	wt	het	wt		QUAL=1107;DP=138,114,198;MQM=60	NPHS2,AXDND1	splice_region&intron,intron	NPHS2:NM_014625.3:splice_region&intron:LOW:exon7/7:c.873+7A>G:,NPHS2:NM_001297575.1:splice_region&intron:LOW:exon6/6:c.669+7A>G:,AXDND1:NM_144696.5:intron:MODIFIER:exon25/25:c.3032-1916T>C:,AXDND1:NR_073544.1:intron:MODIFIER:exon25/25:n.3152-1916T>C:		rs115778946	0.0160	0.0341	94/86/0	0.0312							604766 [NPHS2 (confirmed) Nephrotic syndrome,type 2,600995];	RCV000248095.1 [benign]; 			5	159					NPHS2 (inh=AR pLI=0.01), AXDND1 (inh=n/a pLI=0.00)
chr1	179544898	179544898	T	C	hom	hom	hom	low_DP	QUAL=441;DP=1,3,13;MQM=60	NPHS2	synonymous	NPHS2:NM_014625.3:synonymous:LOW:exon1/8:c.102A>G:p.Gly34Gly,NPHS2:NM_001297575.1:synonymous:LOW:exon1/7:c.102A>G:p.Gly34Gly		rs1079292	0.9309	0.9616	4890/1600/105	0.5163							604766 [NPHS2 (confirmed) Nephrotic syndrome,type 2,600995];	RCV000247522.1 [benign]; RCV000361602.1 [benign]; 		COSM3749013	1388	57					NPHS2 (inh=AR pLI=0.01)
chr1	179545050	179545050	C	A	wt	wt	het	low_DP;anno_pathogenic_clinvar	QUAL=195;DP=1,9,18;MQM=60	NPHS2	5'UTR_premature_start_codon_gain,5'UTR	NPHS2:NM_014625.3:5'UTR_premature_start_codon_gain:LOW:exon1/8:c.-51G>T:,NPHS2:NM_001297575.1:5'UTR_premature_start_codon_gain:LOW:exon1/7:c.-51G>T:,NPHS2:NM_014625.3:5'UTR:MODIFIER:exon1/8:c.-51G>T:,NPHS2:NM_001297575.1:5'UTR:MODIFIER:exon1/7:c.-51G>T:		rs12406197	0.1833	0.3654	507/322/14	0.1514							604766 [NPHS2 (confirmed) Nephrotic syndrome,type 2,600995];	RCV000210779.1 [pathogenic]; RCV000210804.1 [likely pathogenic]; RCV000358624.1 [likely benign]; 	CR068160 [CLASS=FP MUT=ALT PHEN="Reduced expression" GENE=NPHS2]; 		37	226					NPHS2 (inh=AR pLI=0.01)
chr1	180235728	180235728	C	T	het	wt	het		QUAL=1870;DP=76,91,108;MQM=59	LHX4	splice_region&synonymous	LHX4:NM_033343.3:splice_region&synonymous:LOW:exon3/6:c.450C>T:p.Asn150Asn		rs16855642	0.0427	0.0218	65/3/50	0.0194							602146 [LHX4 (confirmed) Pituitary hormone deficiency,combined,4,262700];	RCV000246585.1 [benign]; RCV000341510.1 [likely benign]; 			0	39					LHX4 (inh=AR+AD pLI=0.40)
chr1	180240510	180240510	T	C	het	het	wt		QUAL=1640;DP=69,77,115;MQM=60	LHX4,LHX4-AS1	splice_region&intron,non_coding_transcript_exon	LHX4:NM_033343.3:splice_region&intron:LOW:exon3/5:c.452-5T>C:,LHX4-AS1:NR_037642.1:non_coding_transcript_exon:MODIFIER:exon5/5:n.945A>G:		rs2764449	0.0413	0.0665	352/213/2	0.0644							602146 [LHX4 (confirmed) Pituitary hormone deficiency,combined,4,262700];	RCV000301831.1 [likely benign]; 		COSM3997105	12	234					LHX4 (inh=AR+AD pLI=0.40), LHX4-AS1 (inh=n/a pLI=n/a)
chr1	180243524	180243524	A	G	het	het	het	pred_pathogenic	QUAL=7708;DP=211,155,204;MQM=60	LHX4,LHX4-AS1	missense,intron	LHX4:NM_033343.3:missense:MODERATE:exon6/6:c.983A>G:p.Asn328Ser,LHX4-AS1:NR_037642.1:intron:MODIFIER:exon1/4:n.31+262T>C:		rs7536561	0.4263	0.4850	15435/9207/216	0.4810	2.5290	T	T	B	D	0.46	602146 [LHX4 (confirmed) Pituitary hormone deficiency,combined,4,262700];	RCV000242291.1 [benign]; RCV000313852.1 [benign]; 		COSM3746684	460	709					LHX4 (inh=AR+AD pLI=0.40), LHX4-AS1 (inh=n/a pLI=n/a)
chr1	183155228	183155228	C	A	wt	het	wt		QUAL=2678;DP=186,258,322;MQM=60	LAMC2	5'UTR	LAMC2:NM_005562.2:5'UTR:MODIFIER:exon1/23:c.-260C>A:,LAMC2:NM_018891.2:5'UTR:MODIFIER:exon1/22:c.-260C>A:		rs2276544	0.1603	0.0000	0/0/0	0.1980							150292 [LAMC2 (confirmed) Epidermolysis bullosa,junctional,Herlitz type,226700|Epidermolysis bullosa,junctional,non-Herlitz type,226650];	RCV000269193.1 [benign]; 			9	63					LAMC2 (inh=AR pLI=0.00)
chr1	183155305	183155305	G	A	het	wt	hom		QUAL=20062;DP=281,367,522;MQM=60	LAMC2	5'UTR	LAMC2:NM_005562.2:5'UTR:MODIFIER:exon1/23:c.-183G>A:,LAMC2:NM_018891.2:5'UTR:MODIFIER:exon1/22:c.-183G>A:		rs2276543	0.2989	0.0000	0/0/0	0.0498							150292 [LAMC2 (confirmed) Epidermolysis bullosa,junctional,Herlitz type,226700|Epidermolysis bullosa,junctional,non-Herlitz type,226650];	RCV000387645.1 [benign]; 			13	90					LAMC2 (inh=AR pLI=0.00)
chr1	183155399	183155399	A	G	wt	het	wt		QUAL=3374;DP=378,287,409;MQM=60	LAMC2	5'UTR	LAMC2:NM_005562.2:5'UTR:MODIFIER:exon1/23:c.-89A>G:,LAMC2:NM_018891.2:5'UTR:MODIFIER:exon1/22:c.-89A>G:		rs2276542	0.2091	0.0000	0/0/0	0.0363							150292 [LAMC2 (confirmed) Epidermolysis bullosa,junctional,Herlitz type,226700|Epidermolysis bullosa,junctional,non-Herlitz type,226650];	RCV000329719.1 [benign]; 			9	64					LAMC2 (inh=AR pLI=0.00)
chr1	183155482	183155482	C	A	wt	wt	het		QUAL=884;DP=32,69,97;MQM=60	LAMC2	5'UTR	LAMC2:NM_005562.2:5'UTR:MODIFIER:exon1/23:c.-6C>A:,LAMC2:NM_018891.2:5'UTR:MODIFIER:exon1/22:c.-6C>A:		rs684527	0.2748	0.3799	4579/2122/38	0.2721							150292 [LAMC2 (confirmed) Epidermolysis bullosa,junctional,Herlitz type,226700|Epidermolysis bullosa,junctional,non-Herlitz type,226650];	RCV000371725.1 [benign]; 			148	647					LAMC2 (inh=AR pLI=0.00)
chr1	183184616	183184616	C	T	wt	het	wt		QUAL=2920;DP=272,244,345;MQM=60	LAMC2	synonymous	LAMC2:NM_005562.2:synonymous:LOW:exon3/23:c.297C>T:p.Ser99Ser,LAMC2:NM_018891.2:synonymous:LOW:exon3/22:c.297C>T:p.Ser99Ser		rs2274980	0.3137	0.2460	4348/1059/789	0.2429							150292 [LAMC2 (confirmed) Epidermolysis bullosa,junctional,Herlitz type,226700|Epidermolysis bullosa,junctional,non-Herlitz type,226650];	RCV000253816.1 [benign]; RCV000310410.1 [benign]; 		COSM3750687	79	446					LAMC2 (inh=AR pLI=0.00)
chr1	183187603	183187603	C	T	wt	het	wt		QUAL=3062;DP=199,251,324;MQM=60	LAMC2	synonymous	LAMC2:NM_005562.2:synonymous:LOW:exon4/23:c.483C>T:p.Val161Val,LAMC2:NM_018891.2:synonymous:LOW:exon4/22:c.483C>T:p.Val161Val		rs1129723	0.3139	0.2566	4180/1009/764	0.2421							150292 [LAMC2 (confirmed) Epidermolysis bullosa,junctional,Herlitz type,226700|Epidermolysis bullosa,junctional,non-Herlitz type,226650];	RCV000250771.1 [benign]; RCV000274277.1 [benign]; 			79	445					LAMC2 (inh=AR pLI=0.00)
chr1	183192304	183192304	T	G	wt	het	wt		QUAL=2753;DP=230,207,281;MQM=60	LAMC2	synonymous	LAMC2:NM_005562.2:synonymous:LOW:exon7/23:c.798T>G:p.Gly266Gly,LAMC2:NM_018891.2:synonymous:LOW:exon7/22:c.798T>G:p.Gly266Gly		rs1047980	0.3550	0.2589	4960/1071/1350	0.2547							150292 [LAMC2 (confirmed) Epidermolysis bullosa,junctional,Herlitz type,226700|Epidermolysis bullosa,junctional,non-Herlitz type,226650];	RCV000242761.1 [benign]; RCV000320325.1 [benign]; 		COSM146708	87	455					LAMC2 (inh=AR pLI=0.00)
chr1	183201970	183201970	G	C	wt	het	wt	pred_pathogenic	QUAL=907;DP=128,109,163;MQM=60	LAMC2	missense	LAMC2:NM_005562.2:missense:MODERATE:exon14/23:c.2198G>C:p.Ser733Thr,LAMC2:NM_018891.2:missense:MODERATE:exon14/22:c.2198G>C:p.Ser733Thr		rs2296303	0.1450	0.1384	1320/552/267	0.1392	1.2070	T,D,D	T	B,B,B	T,T	11.25	150292 [LAMC2 (confirmed) Epidermolysis bullosa,junctional,Herlitz type,226700|Epidermolysis bullosa,junctional,non-Herlitz type,226650];	RCV000253521.1 [benign]; RCV000357861.1 [likely benign]; 			35	296					LAMC2 (inh=AR pLI=0.00)
chr1	183206573	183206573	G	A	wt	het	wt		QUAL=3682;DP=364,276,405;MQM=60	LAMC2	synonymous	LAMC2:NM_005562.2:synonymous:LOW:exon18/23:c.2688G>A:p.Gln896Gln,LAMC2:NM_018891.2:synonymous:LOW:exon18/22:c.2688G>A:p.Gln896Gln		rs1047981	0.3524	0.2579	4926/1066/1338	0.2542							150292 [LAMC2 (confirmed) Epidermolysis bullosa,junctional,Herlitz type,226700|Epidermolysis bullosa,junctional,non-Herlitz type,226650];	RCV000248863.1 [benign]; RCV000328991.1 [benign]; 			86	450					LAMC2 (inh=AR pLI=0.00)
chr1	183210381	183210381	A	-	wt	het	wt	low_DP	QUAL=81;DP=20,11,4;MQM=60	LAMC2	3'UTR,intron	LAMC2:NM_018891.2:3'UTR:MODIFIER:exon22/22:c.*862delA:,LAMC2:NM_005562.2:intron:MODIFIER:exon22/22:c.3328+870delA:	AluSx1	rs397861678	0.0000	0.0000	0/0/0	0.0172							150292 [LAMC2 (confirmed) Epidermolysis bullosa,junctional,Herlitz type,226700|Epidermolysis bullosa,junctional,non-Herlitz type,226650];				3	22					LAMC2 (inh=AR pLI=0.00)
chr1	183212548	183212548	T	G	wt	het	wt		QUAL=2477;DP=216,175,248;MQM=60	LAMC2	3'UTR	LAMC2:NM_005562.2:3'UTR:MODIFIER:exon23/23:c.*13T>G:		rs3768593	0.3109	0.2372	4189/907/719	0.2347							150292 [LAMC2 (confirmed) Epidermolysis bullosa,junctional,Herlitz type,226700|Epidermolysis bullosa,junctional,non-Herlitz type,226650];	RCV000331497.1 [benign]; 			53	270					LAMC2 (inh=AR pLI=0.00)
chr1	183213410	183213410	G	T	wt	het	wt		QUAL=2293;DP=277,178,200;MQM=60	LAMC2	3'UTR	LAMC2:NM_005562.2:3'UTR:MODIFIER:exon23/23:c.*875G>T:		rs10797863	0.0913	0.0000	0/0/0	0.0222							150292 [LAMC2 (confirmed) Epidermolysis bullosa,junctional,Herlitz type,226700|Epidermolysis bullosa,junctional,non-Herlitz type,226650];	RCV000304990.1 [likely benign]; 			6	52					LAMC2 (inh=AR pLI=0.00)
chr1	183213933	183213933	C	T	wt	wt	het		QUAL=4915;DP=469,284,396;MQM=60	LAMC2	3'UTR	LAMC2:NM_005562.2:3'UTR:MODIFIER:exon23/23:c.*1398C>T:		rs564740740	0.0012	0.0000	0/0/0	0.0029							150292 [LAMC2 (confirmed) Epidermolysis bullosa,junctional,Herlitz type,226700|Epidermolysis bullosa,junctional,non-Herlitz type,226650];	RCV000287816.1 [uncertain significance]; 			0	3					LAMC2 (inh=AR pLI=0.00)
chr1	183524855	183524855	C	A	hom	hom	hom		QUAL=44594;DP=476,391,547;MQM=59	NCF2	3'UTR	NCF2:NM_000433.3:3'UTR:MODIFIER:exon15/15:c.*398G>T:,NCF2:NM_001190789.1:3'UTR:MODIFIER:exon13/13:c.*398G>T:,NCF2:NM_001190794.1:3'UTR:MODIFIER:exon14/14:c.*398G>T:,NCF2:NM_001127651.2:3'UTR:MODIFIER:exon16/16:c.*398G>T:		rs796860	0.9393	0.0000	0/0/0	0.5022							608515 [NCF2 (confirmed) Chronic granulomatous disease due to deficiency of NCF-2,233710];	RCV000361687.1 [benign]; 			184	42					NCF2 (inh=AR pLI=0.00)
chr1	183542387	183542387	T	C	hom	hom	het		QUAL=18383;DP=259,191,267;MQM=59	NCF2	missense,intron	NCF2:NM_000433.3:missense:MODERATE:exon5/15:c.542A>G:p.Lys181Arg,NCF2:NM_001190794.1:missense:MODERATE:exon4/14:c.407A>G:p.Lys136Arg,NCF2:NM_001127651.2:missense:MODERATE:exon6/16:c.542A>G:p.Lys181Arg,NCF2:NM_001190789.1:intron:MODIFIER:exon3/12:c.367-2413A>G:		rs2274064	0.4916	0.4895	15075/7092/687	0.4881	0.5830	T,T,T,T	T	B,B	T,T,T	7.83	608515 [NCF2 (confirmed) Chronic granulomatous disease due to deficiency of NCF-2,233710];	RCV000243467.1 [benign]; RCV000388595.1 [benign]; 		COSM3750690	360	904					NCF2 (inh=AR pLI=0.00)
chr1	196642233	196642233	G	A	wt	het	wt	pred_pathogenic	QUAL=910;DP=232,82,139;MQM=60	CFH	missense	CFH:NM_000186.3:missense:MODERATE:exon2/22:c.184G>A:p.Val62Ile,CFH:NM_001014975.2:missense:MODERATE:exon2/10:c.184G>A:p.Val62Ile		rs800292	0.4681	0.3210	7386/1884/2670	0.3154	1.7340	T,T,T,T	T	B,B,B,B	T,T,T	0.04	134370 [CFH (confirmed) Hemolytic uremic syndrome,atypical,susceptibility to,1,235400|Complement factor H deficiency,609814|Macular degeneration,age-related,4,610698|Basal laminar drusen,126700];	RCV000018017.4 [other]; RCV000190297.1 [not provided]; RCV000274380.1 [benign]; RCV000281564.1 [benign]; RCV000331871.1 [benign]; RCV000374816.1 [benign]; 	CM062505 [CLASS=DFP MUT=REF PHEN="Membranoproliferative glomerulonephritis association" GENE=CFH]; 	COSM146716	105	567					CFH (inh=AR+AD pLI=1.00)
chr1	196654324	196654324	A	C	het	het	het		QUAL=9439;DP=287,209,266;MQM=60	CFH	synonymous	CFH:NM_000186.3:synonymous:LOW:exon7/22:c.921A>C:p.Ala307Ala,CFH:NM_001014975.2:synonymous:LOW:exon7/10:c.921A>C:p.Ala307Ala		rs1061147	0.7131	0.6666	27692/12666/1709	0.6631							134370 [CFH (confirmed) Hemolytic uremic syndrome,atypical,susceptibility to,1,235400|Complement factor H deficiency,609814|Macular degeneration,age-related,4,610698|Basal laminar drusen,126700];	RCV000267123.1 [benign]; RCV000305955.1 [benign]; RCV000354801.1 [benign]; RCV000358116.1 [benign]; 	CM057396 [CLASS=DP MUT=REF PHEN="Macular degeneration age-related association with" GENE=CFH]; 	COSM3750723	639	722					CFH (inh=AR+AD pLI=1.00)
chr1	196659237	196659237	C	T	het	het	het	anno_pathogenic_clinvar	QUAL=5463;DP=191,104,108;MQM=56	CFH	missense	CFH:NM_000186.3:missense:MODERATE:exon9/22:c.1204C>T:p.His402Tyr,CFH:NM_001014975.2:missense:MODERATE:exon9/10:c.1204C>T:p.His402Tyr		rs1061170	0.7334	0.6721	27768/12485/2037	0.6661	-6.7150	T,T,T,T	T	B,B	T,T,T	0.01	134370 [CFH (confirmed) Hemolytic uremic syndrome,atypical,susceptibility to,1,235400|Complement factor H deficiency,609814|Macular degeneration,age-related,4,610698|Basal laminar drusen,126700];	RCV000018015.5 [other]; RCV000018016.31 [pathogenic]; RCV000296616.1 [benign]; RCV000327040.1 [benign]; RCV000349294.1 [benign]; RCV000388493.1 [benign]; 	CM051020 [CLASS=DFP MUT=REF PHEN="Macular degeneration age-related association with" GENE=CFH]; 	COSM424915	642	718	2	[2] old entry - no details available			CFH (inh=AR+AD pLI=1.00)
chr1	196682947	196682947	G	A	het	het	het		QUAL=8619;DP=262,192,257;MQM=60	CFH	synonymous	CFH:NM_000186.3:synonymous:LOW:exon10/22:c.1419G>A:p.Ala473Ala		rs2274700	0.4790	0.4431	12010/5836/1095	0.4374							134370 [CFH (confirmed) Hemolytic uremic syndrome,atypical,susceptibility to,1,235400|Complement factor H deficiency,609814|Macular degeneration,age-related,4,610698|Basal laminar drusen,126700];	RCV000281469.1 [benign]; RCV000338900.1 [benign]; RCV000387444.1 [benign]; RCV000404891.1 [benign]; RCV000018023.3 [other]; 	CM062504 [CLASS=DP MUT=ALT PHEN="Membranoproliferative glomerulonephritis association" GENE=CFH]; 	COSM3750724	338	746					CFH (inh=AR+AD pLI=1.00)
chr1	196709816	196709816	G	T	het	wt	het	pred_pathogenic;anno_pathogenic_hgmd	QUAL=6969;DP=285,187,216;MQM=59	CFH	missense	CFH:NM_000186.3:missense:MODERATE:exon18/22:c.2850G>T:p.Gln950His		rs149474608	0.0016	0.0036	5/5/0	0.0038	-0.2730	D	T	B	T	21.40	134370 [CFH (confirmed) Hemolytic uremic syndrome,atypical,susceptibility to,1,235400|Complement factor H deficiency,609814|Macular degeneration,age-related,4,610698|Basal laminar drusen,126700];	RCV000273876.1 [likely benign]; RCV000308622.1 [likely benign]; RCV000333684.1 [likely benign]; RCV000367943.1 [likely benign]; 	CM034428 [CLASS=DM MUT=ALT PHEN="Haemolytic uraemic syndrome" GENE=CFH]; 		0	21	2	[2] Ute Grasshoff 30.01.2015 [n/a] comment imported from detected variant: conflicting evidence			CFH (inh=AR+AD pLI=1.00)
chr1	196712577	196712577	T	C	wt	het	wt	low_MQM	QUAL=304;DP=180,132,120;MQM=45	CFH	splice_region&intron	CFH:NM_000186.3:splice_region&intron:LOW:exon19/21:c.3134-5T>C:		rs513699	0.0000	0.2585	0/0/0	0.0001							134370 [CFH (confirmed) Hemolytic uremic syndrome,atypical,susceptibility to,1,235400|Complement factor H deficiency,609814|Macular degeneration,age-related,4,610698|Basal laminar drusen,126700];			COSM3997120	0	361					CFH (inh=AR+AD pLI=1.00)
chr1	196712586	196712586	C	T	wt	het	wt	low_MQM	QUAL=512;DP=192,149,135;MQM=46	CFH	synonymous	CFH:NM_000186.3:synonymous:LOW:exon20/22:c.3138C>T:p.Thr1046Thr		rs61822181	0.0000	0.2657	0/0/0	0.0010							134370 [CFH (confirmed) Hemolytic uremic syndrome,atypical,susceptibility to,1,235400|Complement factor H deficiency,609814|Macular degeneration,age-related,4,610698|Basal laminar drusen,126700];	RCV000295182.1 [benign]; RCV000352377.1 [benign]; RCV000391333.1 [benign]; RCV000404495.1 [benign]; 		COSM4143141	0	531					CFH (inh=AR+AD pLI=1.00)
chr1	197053373	197053373	G	A	hom	hom	hom		QUAL=19127;DP=241,138,201;MQM=59	ASPM	3'UTR	ASPM:NM_018136.4:3'UTR:MODIFIER:exon28/28:c.*81C>T:,ASPM:NM_001206846.1:3'UTR:MODIFIER:exon27/27:c.*81C>T:		rs12677	0.7823	0.0000	0/0/0	0.1862							605481 [ASPM (confirmed) Microcephaly 5,primary,autosomal recessive,608716];	RCV000353007.1 [benign]; 			211	29					ASPM (inh=AR pLI=0.00)
chr1	197055925	197055925	T	C	hom	hom	hom		QUAL=13664;DP=170,108,137;MQM=60	ASPM	splice_region&intron	ASPM:NM_018136.4:splice_region&intron:LOW:exon27/27:c.10331+8A>G:,ASPM:NM_001206846.1:splice_region&intron:LOW:exon26/26:c.5576+8A>G:		rs10754213	0.7827	0.8786	47902/27379/1065	0.8565							605481 [ASPM (confirmed) Microcephaly 5,primary,autosomal recessive,608716];	RCV000145076.3 [other]; RCV000368400.1 [benign]; 			1256	277					ASPM (inh=AR pLI=0.00)
chr1	197070521	197070521	C	G	wt	het	wt		QUAL=1187;DP=302,97,129;MQM=60	ASPM	missense,intron	ASPM:NM_018136.4:missense:MODERATE:exon18/28:c.7860G>C:p.Gln2620His,ASPM:NM_001206846.1:intron:MODIFIER:exon17/26:c.4066-5227G>C:		rs12138336	0.0288	0.0511	193/162/2	0.0508	-1.0940	T,T	T	B,B	T	0.10	605481 [ASPM (confirmed) Microcephaly 5,primary,autosomal recessive,608716];	RCV000020799.1 [benign]; RCV000145202.3 [benign]; RCV000291643.1 [likely benign]; 			5	142					ASPM (inh=AR pLI=0.00)
chr1	197070776	197070776	C	T	het	het	het		QUAL=8716;DP=228,190,246;MQM=59	ASPM	synonymous,intron	ASPM:NM_018136.4:synonymous:LOW:exon18/28:c.7605G>A:p.Val2535Val,ASPM:NM_001206846.1:intron:MODIFIER:exon17/26:c.4066-5482G>A:		rs10922162	0.2949	0.2396	5351/822/16	0.2387							605481 [ASPM (confirmed) Microcephaly 5,primary,autosomal recessive,608716];	RCV000020793.1 [benign]; RCV000145189.3 [benign]; RCV000261841.1 [benign]; 			61	410					ASPM (inh=AR pLI=0.00)
chr1	197070815	197070815	T	C	hom	hom	hom		QUAL=19710;DP=238,155,198;MQM=59	ASPM	synonymous,intron	ASPM:NM_018136.4:synonymous:LOW:exon18/28:c.7566A>G:p.Leu2522Leu,ASPM:NM_001206846.1:intron:MODIFIER:exon17/26:c.4066-5521A>G:		rs1412640	0.8159	0.8876	48397/27386/1582	0.8660							605481 [ASPM (confirmed) Microcephaly 5,primary,autosomal recessive,608716];	RCV000020792.1 [benign]; RCV000145187.6 [other]; RCV000317009.1 [benign]; 			1258	279					ASPM (inh=AR pLI=0.00)
chr1	197070901	197070901	A	G	hom	hom	hom	pred_pathogenic	QUAL=23221;DP=320,168,206;MQM=60	ASPM	missense,intron	ASPM:NM_018136.4:missense:MODERATE:exon18/28:c.7480T>C:p.Tyr2494His,ASPM:NM_001206846.1:intron:MODIFIER:exon17/26:c.4066-5607T>C:		rs964201	0.9974	0.9956	60051/32876/5182	0.9733	2.9990	T,T	T	B,B	T	8.34	605481 [ASPM (confirmed) Microcephaly 5,primary,autosomal recessive,608716];	RCV000020789.1 [benign]; RCV000145183.6 [benign]; RCV000332016.1 [benign]; 			1558	6					ASPM (inh=AR pLI=0.00)
chr1	197091537	197091537	A	T	hom	hom	hom		QUAL=24417;DP=311,203,251;MQM=59	ASPM	synonymous	ASPM:NM_018136.4:synonymous:LOW:exon14/28:c.3579T>A:p.Ser1193Ser,ASPM:NM_001206846.1:synonymous:LOW:exon14/27:c.3579T>A:p.Ser1193Ser		rs4915337	0.7825	0.8779	47849/27354/1075	0.8135							605481 [ASPM (confirmed) Microcephaly 5,primary,autosomal recessive,608716];	RCV000020768.1 [benign]; RCV000145113.2 [other]; RCV000304377.1 [benign]; 			1255	279					ASPM (inh=AR pLI=0.00)
chr1	197094030	197094030	C	T	het	het	het		QUAL=9400;DP=394,152,185;MQM=59	ASPM	synonymous	ASPM:NM_018136.4:synonymous:LOW:exon12/28:c.3138G>A:p.Arg1046Arg,ASPM:NM_001206846.1:synonymous:LOW:exon12/27:c.3138G>A:p.Arg1046Arg		rs6676084	0.2167	0.2801	5028/3284/147	0.2687							605481 [ASPM (confirmed) Microcephaly 5,primary,autosomal recessive,608716];	RCV000020763.1 [benign]; RCV000145109.2 [benign]; RCV000259745.1 [likely benign]; 		COSM3750735	161	642					ASPM (inh=AR pLI=0.00)
chr1	197108946	197108946	A	G	het	het	wt		QUAL=4087;DP=256,109,143;MQM=60	ASPM	synonymous	ASPM:NM_018136.4:synonymous:LOW:exon4/28:c.1977T>C:p.Ile659Ile,ASPM:NM_001206846.1:synonymous:LOW:exon4/27:c.1977T>C:p.Ile659Ile		rs17550662	0.0192	0.0454	165/144/0	0.0431							605481 [ASPM (confirmed) Microcephaly 5,primary,autosomal recessive,608716];	RCV000020751.1 [benign]; RCV000145092.1 [benign]; RCV000353888.1 [likely benign]; 			6	150					ASPM (inh=AR pLI=0.00)
chr1	197112533	197112533	G	A	hom	hom	hom		QUAL=7448;DP=113,61,52;MQM=60	ASPM	sequence_feature,synonymous	ASPM:NM_018136.4:sequence_feature:MODERATE:exon3/28:c.849C>T:,ASPM:NM_001206846.1:sequence_feature:MODERATE:exon3/27:c.849C>T:,ASPM:NM_018136.4:synonymous:LOW:exon3/28:c.849C>T:p.Ser283Ser,ASPM:NM_001206846.1:synonymous:LOW:exon3/27:c.849C>T:p.Ser283Ser		rs6677082	0.7556	0.8698	47376/27349/752	0.8055							605481 [ASPM (confirmed) Microcephaly 5,primary,autosomal recessive,608716];	RCV000081938.7 [other]; RCV000284938.1 [benign]; 			1246	288					ASPM (inh=AR pLI=0.00)
chr1	198661668	198661668	G	A	het	het	wt	low_DP	QUAL=807;DP=56,7,5;MQM=60	PTPRC	intron,non_coding_transcript_exon	PTPRC:NM_002838.4:intron:MODIFIER:exon3/32:c.100+166G>A:,PTPRC:NM_001267798.1:intron:MODIFIER:exon3/3:c.100+166G>A:,PTPRC:NM_080921.3:intron:MODIFIER:exon3/29:c.100+166G>A:,PTPRC:NR_052021.1:non_coding_transcript_exon:MODIFIER:exon3/3:n.479G>A:		rs115067628	0.0040	0.0000	0/0/0	0.0015							151460 [PTPRC (confirmed) Hepatitic C virus,susceptibility to,609532|Severe combined immunodeficiency,T cell-negative,B-cell/natural killer-cell positive,608971];				0	7					PTPRC (inh=AR pLI=1.00)
chr1	198665917	198665917	C	G	wt	het	wt		QUAL=3196;DP=452,207,293;MQM=60	PTPRC	synonymous,intron	PTPRC:NM_002838.4:synonymous:LOW:exon4/33:c.177C>G:p.Pro59Pro,PTPRC:NM_080921.3:intron:MODIFIER:exon3/29:c.100+4415C>G:		rs17612648	0.0044	0.0091	13/9/0	0.0092							151460 [PTPRC (confirmed) Hepatitic C virus,susceptibility to,609532|Severe combined immunodeficiency,T cell-negative,B-cell/natural killer-cell positive,608971];		CS952043 [CLASS=DFP MUT=ALT PHEN="Defective splicing" GENE=PTPRC]; 		1	38					PTPRC (inh=AR pLI=1.00)
chr1	201012597	201012597	G	A	hom	wt	hom	low_DP	QUAL=366;DP=10,3,4;MQM=60	CACNA1S	synonymous	CACNA1S:NM_000069.2:synonymous:LOW:exon40/44:c.4860C>T:p.Pro1620Pro		rs41267497	0.0461	0.1065	954/852/5	0.1072							114208 [CACNA1S (confirmed) Hypokalemic periodic paralysis,type 1,170400|Malignant hyperthermia susceptibility 5,601887|Thyrotoxic periodic paralysis,susceptibility to,1,188580];	RCV000254312.1 [benign]; RCV000335360.1 [benign]; RCV000373693.1 [benign]; 			33	291					CACNA1S (inh=AD pLI=0.00)
chr1	201016296	201016296	G	A	wt	wt	het	pred_pathogenic	QUAL=3274;DP=350,183,245;MQM=60	CACNA1S	missense	CACNA1S:NM_000069.2:missense:MODERATE:exon38/44:c.4615C>T:p.Arg1539Cys		rs3850625	0.0841	0.1172	1039/474/4	0.1130	6.1940	D,D	T	B	T,T	34.00	114208 [CACNA1S (confirmed) Hypokalemic periodic paralysis,type 1,170400|Malignant hyperthermia susceptibility 5,601887|Thyrotoxic periodic paralysis,susceptibility to,1,188580];	RCV000177926.2 [benign]; RCV000261312.1 [benign]; RCV000358880.1 [benign]; 		COSM3750744	43	319					CACNA1S (inh=AD pLI=0.00)
chr1	201020105	201020105	A	G	wt	het	het		QUAL=6144;DP=136,212,276;MQM=60	CACNA1S	splice_region&intron	CACNA1S:NM_000069.2:splice_region&intron:LOW:exon33/43:c.4113+7T>C:		rs6702590	0.8804	0.7705	36993/15192/4539	0.7404							114208 [CACNA1S (confirmed) Hypokalemic periodic paralysis,type 1,170400|Malignant hyperthermia susceptibility 5,601887|Thyrotoxic periodic paralysis,susceptibility to,1,188580];	RCV000181033.2 [benign]; RCV000305099.1 [benign]; RCV000390372.1 [benign]; 			837	597					CACNA1S (inh=AD pLI=0.00)
chr1	201038687	201038687	A	G	het	wt	het		QUAL=8183;DP=223,344,428;MQM=60	CACNA1S	synonymous	CACNA1S:NM_000069.2:synonymous:LOW:exon18/44:c.2403T>C:p.Phe801Phe		rs7415038	0.2941	0.4034	3683/2641/749	0.2790							114208 [CACNA1S (confirmed) Hypokalemic periodic paralysis,type 1,170400|Malignant hyperthermia susceptibility 5,601887|Thyrotoxic periodic paralysis,susceptibility to,1,188580];	RCV000252908.1 [benign]; RCV000276522.1 [benign]; RCV000333904.1 [benign]; 			208	637					CACNA1S (inh=AD pLI=0.00)
chr1	201044748	201044748	A	G	het	wt	hom		QUAL=10600;DP=155,261,280;MQM=59	CACNA1S	splice_region&intron	CACNA1S:NM_000069.2:splice_region&intron:LOW:exon12/43:c.1828-5T>C:		rs1998721	0.7596	0.7814	37595/20198/1541	0.7622							114208 [CACNA1S (confirmed) Hypokalemic periodic paralysis,type 1,170400|Malignant hyperthermia susceptibility 5,601887|Thyrotoxic periodic paralysis,susceptibility to,1,188580];	RCV000254042.1 [benign]; RCV000345729.1 [benign]; RCV000388676.1 [benign]; 			947	526					CACNA1S (inh=AD pLI=0.00)
chr1	201047062	201047062	G	A	hom	hom	het		QUAL=14951;DP=142,261,263;MQM=59	CACNA1S	synonymous	CACNA1S:NM_000069.2:synonymous:LOW:exon11/44:c.1564C>T:p.Leu522Leu		rs4915476	0.1909	0.2072	2934/1790/385	0.2032							114208 [CACNA1S (confirmed) Hypokalemic periodic paralysis,type 1,170400|Malignant hyperthermia susceptibility 5,601887|Thyrotoxic periodic paralysis,susceptibility to,1,188580];	RCV000254329.1 [benign]; RCV000278332.1 [benign]; RCV000335825.1 [benign]; 	CM023570 [CLASS=DP MUT=ALT PHEN="Hypokalaemic periodic paralysis association with" GENE=CACNA1S]; 	COSM3750745	97	541					CACNA1S (inh=AD pLI=0.00)
chr1	201047075	201047075	A	G	hom	hom	het		QUAL=17599;DP=190,270,286;MQM=59	CACNA1S	synonymous	CACNA1S:NM_000069.2:synonymous:LOW:exon11/44:c.1551T>C:p.Gly517Gly		rs4915477	0.5711	0.5839	22620/14306/4198	0.5821							114208 [CACNA1S (confirmed) Hypokalemic periodic paralysis,type 1,170400|Malignant hyperthermia susceptibility 5,601887|Thyrotoxic periodic paralysis,susceptibility to,1,188580];	RCV000249332.1 [benign]; RCV000305536.1 [benign]; RCV000397592.1 [benign]; 	CM023569 [CLASS=DP MUT=REF PHEN="Hypokalaemic periodic paralysis association with" GENE=CACNA1S]; 	COSM4143154	602	682					CACNA1S (inh=AD pLI=0.00)
chr1	201060865	201060865	G	A	wt	wt	het		QUAL=2468;DP=169,158,185;MQM=60	CACNA1S	synonymous,sequence_feature	CACNA1S:NM_000069.2:synonymous:LOW:exon5/44:c.597C>T:p.Ile199Ile,CACNA1S:NM_000069.2:sequence_feature:LOW:exon5/44:c.597C>T:		rs2296383	0.3051	0.3887	9733/6190/64	0.3860							114208 [CACNA1S (confirmed) Hypokalemic periodic paralysis,type 1,170400|Malignant hyperthermia susceptibility 5,601887|Thyrotoxic periodic paralysis,susceptibility to,1,188580];	RCV000251904.1 [benign]; RCV000330113.1 [benign]; RCV000389135.1 [benign]; 		COSM4143157	245	760					CACNA1S (inh=AD pLI=0.00)
chr1	209788213	209788213	T	C	hom	het	het		QUAL=5589;DP=150,41,72;MQM=60	CAMK1G-LAMB3	intergenic_region	CAMK1G-LAMB3:CAMK1G-LAMB3:intergenic_region:MODIFIER::n.209788213T>C:		rs926387	0.7748	0.0000	0/0/0	0.1206							150310 [LAMB3 (provisional) Epidermolysis bullosa,junctional,Herlitz type,226700|Epidermolysis bullosa,junctional,non-Herlitz type,226650|Amelogenesis imperfecta,type IA,104530];	RCV000307061.1 [benign]; 			97	103					CAMK1G-LAMB3 (inh=n/a pLI=n/a)
chr1	209788514	209788514	G	A	het	wt	het		QUAL=5399;DP=185,241,263;MQM=60	LAMB3	3'UTR	LAMB3:NM_000228.2:3'UTR:MODIFIER:exon23/23:c.*102C>T:,LAMB3:NM_001017402.1:3'UTR:MODIFIER:exon22/22:c.*102C>T:,LAMB3:NM_001127641.1:3'UTR:MODIFIER:exon23/23:c.*102C>T:		rs2566	0.2951	0.0000	0/0/0	0.0576							150310 [LAMB3 (provisional) Epidermolysis bullosa,junctional,Herlitz type,226700|Epidermolysis bullosa,junctional,non-Herlitz type,226650|Amelogenesis imperfecta,type IA,104530];	RCV000266238.1 [benign]; 	CR1010233 [CLASS=DP MUT=ALT PHEN="Cervical cancer increased risk association with" GENE=LAMB3]; 		20	81					LAMB3 (inh=AR+AD pLI=0.00)
chr1	209799253	209799253	A	G	het	hom	het		QUAL=21322;DP=304,383,547;MQM=59	LAMB3	synonymous	LAMB3:NM_000228.2:synonymous:LOW:exon14/23:c.1716T>C:p.Cys572Cys,LAMB3:NM_001017402.1:synonymous:LOW:exon13/22:c.1716T>C:p.Cys572Cys,LAMB3:NM_001127641.1:synonymous:LOW:exon14/23:c.1716T>C:p.Cys572Cys		rs2179402	0.7650	0.7565	34184/18267/3036	0.7444							150310 [LAMB3 (provisional) Epidermolysis bullosa,junctional,Herlitz type,226700|Epidermolysis bullosa,junctional,non-Herlitz type,226650|Amelogenesis imperfecta,type IA,104530];	RCV000253193.1 [benign]; RCV000341091.1 [benign]; 		COSM3746765	934	521					LAMB3 (inh=AR+AD pLI=0.00)
chr1	209807972	209807972	G	A	hom	hom	hom		QUAL=5431;DP=37,58,91;MQM=60	LAMB3	synonymous	LAMB3:NM_000228.2:synonymous:LOW:exon6/23:c.384C>T:p.Pro128Pro,LAMB3:NM_001017402.1:synonymous:LOW:exon5/22:c.384C>T:p.Pro128Pro,LAMB3:NM_001127641.1:synonymous:LOW:exon6/23:c.384C>T:p.Pro128Pro		rs1130667	0.2454	0.3625	7446/5200/99	0.3375							150310 [LAMB3 (provisional) Epidermolysis bullosa,junctional,Herlitz type,226700|Epidermolysis bullosa,junctional,non-Herlitz type,226650|Amelogenesis imperfecta,type IA,104530];	RCV000242747.1 [benign]; RCV000339606.1 [benign]; 		COSM3746766	225	740					LAMB3 (inh=AR+AD pLI=0.00)
chr1	209811886	209811886	T	G	hom	hom	hom		QUAL=18952;DP=256,137,211;MQM=59	LAMB3	synonymous	LAMB3:NM_000228.2:synonymous:LOW:exon4/23:c.291A>C:p.Ser97Ser,LAMB3:NM_001017402.1:synonymous:LOW:exon3/22:c.291A>C:p.Ser97Ser,LAMB3:NM_001127641.1:synonymous:LOW:exon4/23:c.291A>C:p.Ser97Ser		rs2076356	0.4325	0.5709	20809/14492/881	0.5628							150310 [LAMB3 (provisional) Epidermolysis bullosa,junctional,Herlitz type,226700|Epidermolysis bullosa,junctional,non-Herlitz type,226650|Amelogenesis imperfecta,type IA,104530];	RCV000250461.1 [benign]; RCV000361905.1 [benign]; 		COSM146753	639	708					LAMB3 (inh=AR+AD pLI=0.00)
chr1	209959614	209959614	G	T	het	wt	het		QUAL=6941;DP=339,126,185;MQM=57	IRF6	3'UTR	IRF6:NM_006147.3:3'UTR:MODIFIER:exon9/9:c.*2151C>A:,IRF6:NM_001206696.1:3'UTR:MODIFIER:exon7/7:c.*2151C>A:		rs1044516	0.3099	0.0000	0/0/0	0.0443							607199 [IRF6 (confirmed) van der Woude syndrome,119300|Popliteal pterygium syndrome 1,119500|Orofacial cleft 6,608864];	RCV000264919.1 [benign]; RCV000323553.1 [benign]; RCV000378096.1 [benign]; 			7	36					IRF6 (inh=n/a pLI=0.98)
chr1	209959872	209959872	G	A	hom	hom	hom		QUAL=18993;DP=311,124,150;MQM=56	IRF6	3'UTR	IRF6:NM_006147.3:3'UTR:MODIFIER:exon9/9:c.*1893C>T:,IRF6:NM_001206696.1:3'UTR:MODIFIER:exon7/7:c.*1893C>T:		rs680331	0.8081	0.0000	0/0/0	0.7942							607199 [IRF6 (confirmed) van der Woude syndrome,119300|Popliteal pterygium syndrome 1,119500|Orofacial cleft 6,608864];	RCV000282539.1 [benign]; RCV000350498.1 [benign]; RCV000401160.1 [benign]; 			100	41					IRF6 (inh=n/a pLI=0.98)
chr1	209960087	209960087	A	-	wt	wt	het		QUAL=1632;DP=267,131,119;MQM=59	IRF6	3'UTR	IRF6:NM_006147.3:3'UTR:MODIFIER:exon9/9:c.*1678delT:,IRF6:NM_001206696.1:3'UTR:MODIFIER:exon7/7:c.*1678delT:		rs141112353	0.1673	0.0000	0/0/0	0.1637							607199 [IRF6 (confirmed) van der Woude syndrome,119300|Popliteal pterygium syndrome 1,119500|Orofacial cleft 6,608864];	RCV000273049.1 [benign]; RCV000328070.1 [benign]; RCV000358357.1 [benign]; 			2	34					IRF6 (inh=n/a pLI=0.98)
chr1	209960152	209960152	T	A	wt	wt	het		QUAL=1216;DP=265,102,104;MQM=59	IRF6	3'UTR	IRF6:NM_006147.3:3'UTR:MODIFIER:exon9/9:c.*1613A>T:,IRF6:NM_001206696.1:3'UTR:MODIFIER:exon7/7:c.*1613A>T:			0.0000	0.0000	0/0/0	0.0000							607199 [IRF6 (confirmed) van der Woude syndrome,119300|Popliteal pterygium syndrome 1,119500|Orofacial cleft 6,608864];				0	1					IRF6 (inh=n/a pLI=0.98)
chr1	209960436	209960436	G	A	het	wt	het		QUAL=6339;DP=256,202,248;MQM=59	IRF6	3'UTR	IRF6:NM_006147.3:3'UTR:MODIFIER:exon9/9:c.*1329C>T:,IRF6:NM_001206696.1:3'UTR:MODIFIER:exon7/7:c.*1329C>T:	AluJo	rs2235372	0.2991	0.0000	0/0/0	0.2137							607199 [IRF6 (confirmed) van der Woude syndrome,119300|Popliteal pterygium syndrome 1,119500|Orofacial cleft 6,608864];	RCV000279720.1 [benign]; RCV000334805.1 [benign]; RCV000374211.1 [benign]; 			7	36					IRF6 (inh=n/a pLI=0.98)
chr1	209960922	209960922	A	C	het	hom	wt		QUAL=2823;DP=125,44,126;MQM=60	IRF6	3'UTR	IRF6:NM_006147.3:3'UTR:MODIFIER:exon9/9:c.*843T>G:,IRF6:NM_001206696.1:3'UTR:MODIFIER:exon7/7:c.*843T>G:		rs599021	0.3043	0.0000	0/0/0	0.3674							607199 [IRF6 (confirmed) van der Woude syndrome,119300|Popliteal pterygium syndrome 1,119500|Orofacial cleft 6,608864];	RCV000263360.1 [benign]; RCV000318759.1 [benign]; RCV000373362.1 [benign]; 			36	82					IRF6 (inh=n/a pLI=0.98)
chr1	209960925	209960925	T	C	het	wt	het		QUAL=3095;DP=128,43,125;MQM=59	IRF6	3'UTR	IRF6:NM_006147.3:3'UTR:MODIFIER:exon9/9:c.*840A>G:,IRF6:NM_001206696.1:3'UTR:MODIFIER:exon7/7:c.*840A>G:		rs742214	0.2971	0.0000	0/0/0	0.2500							607199 [IRF6 (confirmed) van der Woude syndrome,119300|Popliteal pterygium syndrome 1,119500|Orofacial cleft 6,608864];	RCV000259961.1 [benign]; RCV000324588.1 [benign]; RCV000379305.1 [benign]; 			7	36					IRF6 (inh=n/a pLI=0.98)
chr1	209961023	209961023	T	A	het	wt	het		QUAL=2200;DP=98,51,82;MQM=60	IRF6	3'UTR	IRF6:NM_006147.3:3'UTR:MODIFIER:exon9/9:c.*742A>T:,IRF6:NM_001206696.1:3'UTR:MODIFIER:exon7/7:c.*742A>T:		rs742215	0.3037	0.0000	0/0/0	0.0429							607199 [IRF6 (confirmed) van der Woude syndrome,119300|Popliteal pterygium syndrome 1,119500|Orofacial cleft 6,608864];	RCV000313232.1 [benign]; RCV000349382.1 [benign]; RCV000406738.1 [benign]; 			7	36					IRF6 (inh=n/a pLI=0.98)
chr1	209961314	209961314	T	C	het	wt	het		QUAL=6575;DP=269,189,241;MQM=60	IRF6	3'UTR	IRF6:NM_006147.3:3'UTR:MODIFIER:exon9/9:c.*451A>G:,IRF6:NM_001206696.1:3'UTR:MODIFIER:exon7/7:c.*451A>G:		rs17317411	0.0875	0.0000	0/0/0	0.0199							607199 [IRF6 (confirmed) van der Woude syndrome,119300|Popliteal pterygium syndrome 1,119500|Orofacial cleft 6,608864];	RCV000300766.1 [benign]; RCV000349717.1 [benign]; RCV000400523.1 [benign]; 			6	34					IRF6 (inh=n/a pLI=0.98)
chr1	209961354	209961354	G	A	wt	wt	het		QUAL=2591;DP=332,163,209;MQM=60	IRF6	3'UTR	IRF6:NM_006147.3:3'UTR:MODIFIER:exon9/9:c.*411C>T:,IRF6:NM_001206696.1:3'UTR:MODIFIER:exon7/7:c.*411C>T:	MIR3	rs187379424	0.0008	0.0000	0/0/0	0.0032							607199 [IRF6 (confirmed) van der Woude syndrome,119300|Popliteal pterygium syndrome 1,119500|Orofacial cleft 6,608864];	RCV000303929.1 [likely benign]; RCV000334718.1 [likely benign]; RCV000401416.1 [likely benign]; 			0	1					IRF6 (inh=n/a pLI=0.98)
chr1	209968684	209968684	C	A	het	wt	hom		QUAL=18456;DP=339,326,458;MQM=60	IRF6	synonymous	IRF6:NM_006147.3:synonymous:LOW:exon5/9:c.459G>T:p.Ser153Ser,IRF6:NM_001206696.1:synonymous:LOW:exon3/7:c.174G>T:p.Ser58Ser		rs2013162	0.4038	0.4020	10291/4614/392	0.3976							607199 [IRF6 (confirmed) van der Woude syndrome,119300|Popliteal pterygium syndrome 1,119500|Orofacial cleft 6,608864];	RCV000251393.1 [benign]; RCV000288076.1 [benign]; RCV000345570.1 [benign]; RCV000402163.1 [benign]; 		COSM3746770	183	694					IRF6 (inh=n/a pLI=0.98)
chr1	209969902	209969902	G	C	het	wt	hom		QUAL=4762;DP=210,51,86;MQM=60	IRF6	splice_region&intron	IRF6:NM_006147.3:splice_region&intron:LOW:exon3/8:c.175-5C>G:,IRF6:NM_001206696.1:splice_region&intron:LOW:exon1/6:c.-111-5C>G:		rs7552506	0.2710	0.3260	6527/4149/370	0.3161							607199 [IRF6 (confirmed) van der Woude syndrome,119300|Popliteal pterygium syndrome 1,119500|Orofacial cleft 6,608864];	RCV000243913.1 [benign]; RCV000300705.1 [benign]; 			163	644					IRF6 (inh=n/a pLI=0.98)
chr1	209975386	209975386	A	G	het	hom	wt		QUAL=11915;DP=286,263,353;MQM=60	IRF6	splice_region,5'UTR,intron	IRF6:NM_006147.3:splice_region:LOW:exon2/9:c.-73T>C:,IRF6:NM_006147.3:5'UTR:MODIFIER:exon2/9:c.-73T>C:,IRF6:NM_001206696.1:intron:MODIFIER:exon1/6:c.-112+3906T>C:		rs861019	0.3864	0.0000	0/0/0	0.3907							607199 [IRF6 (confirmed) van der Woude syndrome,119300|Popliteal pterygium syndrome 1,119500|Orofacial cleft 6,608864];	RCV000294795.1 [benign]; RCV000352053.1 [benign]; RCV000382341.1 [benign]; 			49	120					IRF6 (inh=n/a pLI=0.98)
chr1	209979518	209979518	T	A	wt	wt	het		QUAL=1269;DP=35,94,128;MQM=60	IRF6	5'UTR_premature_start_codon_gain,5'UTR	IRF6:NM_006147.3:5'UTR_premature_start_codon_gain:LOW:exon1/9:c.-302A>T:,IRF6:NM_001206696.1:5'UTR_premature_start_codon_gain:LOW:exon1/7:c.-338A>T:,IRF6:NM_006147.3:5'UTR:MODIFIER:exon1/9:c.-302A>T:,IRF6:NM_001206696.1:5'UTR:MODIFIER:exon1/7:c.-338A>T:		rs12403006	0.1180	0.0000	0/0/0	0.1604							607199 [IRF6 (confirmed) van der Woude syndrome,119300|Popliteal pterygium syndrome 1,119500|Orofacial cleft 6,608864];	RCV000272391.1 [benign]; RCV000327413.1 [benign]; RCV000386552.1 [benign]; 			5	39					IRF6 (inh=n/a pLI=0.98)
chr1	209979529	209979529	A	T	wt	wt	het		QUAL=1221;DP=28,82,120;MQM=60	IRF6-DIEXF	intergenic_region	IRF6-DIEXF:IRF6-DIEXF:intergenic_region:MODIFIER::n.209979529A>T:		rs34743335	0.1182	0.0000	0/0/0	0.1604							607199 [IRF6 (confirmed) van der Woude syndrome,119300|Popliteal pterygium syndrome 1,119500|Orofacial cleft 6,608864];	RCV000275407.1 [benign]; RCV000332869.1 [benign]; RCV000389793.1 [benign]; 			5	39					IRF6-DIEXF (inh=n/a pLI=n/a)
chr1	215796350	215796350	T	G	het	wt	hom	gene_blacklist	QUAL=13518;DP=354,178,266;MQM=60	USH2A	3'UTR	USH2A:NM_206933.2:3'UTR:MODIFIER:exon72/72:c.*2773A>C:		rs6667509	0.1030	0.0000	0/0/0	0.0167							608400 [USH2A (confirmed) Usher syndrome,type 2A,276901|Retinitis pigmentosa 39,613809];				5	40					USH2A (inh=AR pLI=0.00)
chr1	215798014	215798014	G	A	hom	hom	hom	gene_blacklist	QUAL=33490;DP=447,227,326;MQM=60	USH2A	3'UTR	USH2A:NM_206933.2:3'UTR:MODIFIER:exon72/72:c.*1109C>T:		rs2797255	0.9912	0.0000	0/0/0	0.1493							608400 [USH2A (confirmed) Usher syndrome,type 2A,276901|Retinitis pigmentosa 39,613809];				229	0					USH2A (inh=AR pLI=0.00)
chr1	215808007	215808007	G	A	het	het	wt	gene_blacklist;pred_pathogenic;anno_pathogenic_hgmd	QUAL=3650;DP=177,136,196;MQM=60	USH2A	missense	USH2A:NM_206933.2:missense:MODERATE:exon70/72:c.15091C>T:p.Arg5031Trp		rs56038610	0.0060	0.0157	24/14/1	0.0153	3.0690	T,T	T	B	T,T	23.00	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901|Retinitis pigmentosa 39,613809];	RCV000041778.2 [benign]; RCV000087008.3 [not provided]; 	CM165975 [CLASS=DM? MUT=ALT PHEN="Retinitis pigmentosa" GENE=USH2A]; 		0	36					USH2A (inh=AR pLI=0.00)
chr1	215848062	215848062	C	T	het	het	wt	gene_blacklist	QUAL=8136;DP=379,246,314;MQM=60	USH2A	synonymous	USH2A:NM_206933.2:synonymous:LOW:exon63/72:c.13191G>A:p.Glu4397Glu		rs2009923	0.2035	0.1993	2705/1107/12	0.1983							608400 [USH2A (confirmed) Usher syndrome,type 2A,276901|Retinitis pigmentosa 39,613809];	RCV000041736.5 [benign]; 		COSM3746785, COSM3746784	59	480					USH2A (inh=AR pLI=0.00)
chr1	215848587	215848587	T	C	wt	het	wt	gene_blacklist	QUAL=3262;DP=277,246,319;MQM=60	USH2A	synonymous	USH2A:NM_206933.2:synonymous:LOW:exon63/72:c.12666A>G:p.Thr4222Thr		rs2797234	0.3031	0.3651	8435/4994/270	0.3588							608400 [USH2A (confirmed) Usher syndrome,type 2A,276901|Retinitis pigmentosa 39,613809];	RCV000041726.5 [benign]; 		COSM146764	199	705					USH2A (inh=AR pLI=0.00)
chr1	215848641	215848641	T	C	het	het	hom	gene_blacklist	QUAL=20824;DP=390,281,377;MQM=60	USH2A	synonymous	USH2A:NM_206933.2:synonymous:LOW:exon63/72:c.12612A>G:p.Thr4204Thr		rs2797235	0.6897	0.7662	35716/21979/2019	0.7585							608400 [USH2A (confirmed) Usher syndrome,type 2A,276901|Retinitis pigmentosa 39,613809];	RCV000152568.2 [benign]; RCV000154669.2 [benign]; 		COSM146765	1006	495					USH2A (inh=AR pLI=0.00)
chr1	215901492	215901492	C	T	hom	het	hom	gene_blacklist	QUAL=39520;DP=412,545,642;MQM=59	USH2A	synonymous	USH2A:NM_206933.2:synonymous:LOW:exon61/72:c.11946G>A:p.Leu3982Leu		rs2820718	0.1188	0.1560	1676/1148/143	0.1530							608400 [USH2A (confirmed) Usher syndrome,type 2A,276901|Retinitis pigmentosa 39,613809];	RCV000041709.5 [benign]; 			45	450					USH2A (inh=AR pLI=0.00)
chr1	215914751	215914751	G	T	het	het	wt	gene_blacklist;pred_pathogenic;anno_pathogenic_hgmd	QUAL=5400;DP=209,194,254;MQM=60	USH2A	missense	USH2A:NM_206933.2:missense:MODERATE:exon60/72:c.11677C>A:p.Pro3893Thr		rs41303285	0.0062	0.0173	29/22/0	0.0168	5.6550	T,T	T	D	T,T	27.70	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901|Retinitis pigmentosa 39,613809];	RCV000041701.3 [benign]; 	CM165987 [CLASS=DM? MUT=ALT PHEN="Usher syndrome 2" GENE=USH2A]; 		0	40					USH2A (inh=AR pLI=0.00)
chr1	215931928	215931928	T	A	wt	wt	het	gene_blacklist	QUAL=2189;DP=224,178,197;MQM=60	USH2A	splice_region&intron	USH2A:NM_206933.2:splice_region&intron:LOW:exon58/71:c.11389+9A>T:		rs12095085	0.0749	0.1034	824/584/90	0.0974							608400 [USH2A (confirmed) Usher syndrome,type 2A,276901|Retinitis pigmentosa 39,613809];	RCV000041693.3 [benign]; 			28	287					USH2A (inh=AR pLI=0.00)
chr1	215960153	215960153	A	C	het	wt	wt	gene_blacklist;pred_pathogenic;anno_pathogenic_hgmd	QUAL=76;DP=237,232,279;MQM=59	USH2A	missense	USH2A:NM_206933.2:missense:MODERATE:exon52/72:c.10246T>G:p.Cys3416Gly		rs527236140	0.0000	0.3805	0/0/0	0.0006	5.2280	D,D	T	D	T,T	25.20	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901|Retinitis pigmentosa 39,613809];	RCV000132699.1 [likely benign]; 	CM135012 [CLASS=DM MUT=ALT PHEN="Usher syndrome" GENE=USH2A]; 	COSM130095, COSM4143327	0	59	2	[2] old entry - no details available			USH2A (inh=AR pLI=0.00)
chr1	215960167	215960167	T	G	hom	hom	hom	gene_blacklist;pred_pathogenic	QUAL=27367;DP=235,288,369;MQM=59	USH2A	missense	USH2A:NM_206933.2:missense:MODERATE:exon52/72:c.10232A>C:p.Glu3411Ala		rs10864198	0.5887	0.5469	18352/9040/2437	0.5381	2.5980	T,T	T	B	T,T	2.89	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901|Retinitis pigmentosa 39,613809];	RCV000154357.1 [benign]; RCV000041665.8 [benign]; 		COSM3750864, COSM3750863	470	760					USH2A (inh=AR pLI=0.00)
chr1	215987222	215987222	T	C	wt	wt	het	gene_blacklist	QUAL=3233;DP=271,169,280;MQM=60	USH2A	missense	USH2A:NM_206933.2:missense:MODERATE:exon49/72:c.9595A>G:p.Asn3199Asp		rs4129843	0.0871	0.0553	311/48/37	0.0557	0.1850	T,T	T	B	T,T	0.01	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901|Retinitis pigmentosa 39,613809];	RCV000041957.4 [benign]; 			7	127					USH2A (inh=AR pLI=0.00)
chr1	216011361	216011361	T	C	wt	wt	het	gene_blacklist	QUAL=3249;DP=342,239,263;MQM=60	USH2A	missense	USH2A:NM_206933.2:missense:MODERATE:exon47/72:c.9343A>G:p.Thr3115Ala		rs56032526	0.0647	0.0487	275/48/0	0.0498	0.1260	T,T	T	B	T,T	0.01	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901|Retinitis pigmentosa 39,613809];	RCV000041949.3 [benign]; RCV000087015.3 [not provided]; 			5	123					USH2A (inh=AR pLI=0.00)
chr1	216051125	216051125	G	A	wt	wt	het	gene_blacklist;pred_pathogenic	QUAL=2911;DP=195,198,216;MQM=60	USH2A	missense	USH2A:NM_206933.2:missense:MODERATE:exon43/72:c.8656C>T:p.Leu2886Phe		rs41277200	0.0777	0.0520	278/46/19	0.0515	6.9260	T,T	T	B	T,T	13.20	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901|Retinitis pigmentosa 39,613809];	RCV000041933.4 [benign]; 	CM1413302 [CLASS=R MUT=ALT PHEN="Hearing loss" GENE=USH2A]; 		5	118					USH2A (inh=AR pLI=0.00)
chr1	216166454	216166454	T	G	het	het	wt	gene_blacklist;pred_pathogenic;anno_pathogenic_hgmd	QUAL=2793;DP=128,94,98;MQM=60	USH2A	missense	USH2A:NM_206933.2:missense:MODERATE:exon35/72:c.6713A>C:p.Glu2238Ala		rs41277212	0.0076	0.0220	42/29/0	0.0217	4.8840	D,D	T	P	T,T	27.10	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901|Retinitis pigmentosa 39,613809];	RCV000041894.3 [benign]; RCV000087012.3 [not provided]; 	CM140482 [CLASS=DM? MUT=ALT PHEN="Retinitis pigmentosa autosomal recessive" GENE=USH2A]; 	COSM3750866, COSM3750865	1	65					USH2A (inh=AR pLI=0.00)
chr1	216172380	216172380	A	G	hom	hom	hom	gene_blacklist;pred_pathogenic	QUAL=19062;DP=181,189,229;MQM=60	USH2A	missense	USH2A:NM_206933.2:missense:MODERATE:exon34/72:c.6506T>C:p.Ile2169Thr		rs10864219	0.5935	0.5567	19463/8401/992	0.5355	2.3950	T,T	T	B	T,T	16.28	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901|Retinitis pigmentosa 39,613809];	RCV000041888.5 [benign]; 		COSM3750868, COSM3750867	469	694					USH2A (inh=AR pLI=0.00)
chr1	216219781	216219781	A	G	het	het	hom	gene_blacklist	QUAL=8795;DP=201,125,146;MQM=60	USH2A	missense	USH2A:NM_206933.2:missense:MODERATE:exon32/72:c.6317T>C:p.Ile2106Thr		rs6657250	0.5956	0.6069	23304/15047/3022	0.6040	0.9880	T,T	T	B	T,T	6.63	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901|Retinitis pigmentosa 39,613809];	RCV000154356.2 [benign]; RCV000154111.3 [benign]; 		COSM146769	666	680					USH2A (inh=AR pLI=0.00)
chr1	216258194	216258194	G	T	het	het	het		QUAL=5971;DP=156,133,177;MQM=60	USH2A,LOC102723833	synonymous,intron	USH2A:NM_206933.2:synonymous:LOW:exon25/72:c.5013C>A:p.Gly1671Gly,LOC102723833:NR_125992.1:intron:MODIFIER:exon2/2:n.266-1870G>T:,LOC102723833:NR_125993.1:intron:MODIFIER:exon1/1:n.137-1870G>T:		rs56110889	0.1058	0.1353	1316/977/195	0.1345							608400 [USH2A (confirmed) Usher syndrome,type 2A,276901|Retinitis pigmentosa 39,613809];	RCV000041853.8 [benign]; 		COSM3746786, COSM3746787	35	385					USH2A (inh=AR pLI=0.00), LOC102723833 (inh=n/a pLI=n/a)
chr1	216347452	216347452	C	A	het	het	wt	gene_blacklist	QUAL=3567;DP=218,108,121;MQM=60	USH2A	3'UTR,intron	USH2A:NM_007123.5:3'UTR:MODIFIER:exon21/21:c.*1128G>T:,USH2A:NM_206933.2:intron:MODIFIER:exon21/71:c.4627+1142G>T:		rs401269	0.1945	0.0000	0/0/0	0.0355							608400 [USH2A (confirmed) Usher syndrome,type 2A,276901|Retinitis pigmentosa 39,613809];	RCV000292348.1 [likely benign]; RCV000347288.1 [likely benign]; 			9	81					USH2A (inh=AR pLI=0.00)
chr1	216347556	216347556	A	G	het	het	wt	gene_blacklist	QUAL=3710;DP=224,56,55;MQM=60	USH2A	3'UTR,intron	USH2A:NM_007123.5:3'UTR:MODIFIER:exon21/21:c.*1024T>C:,USH2A:NM_206933.2:intron:MODIFIER:exon21/71:c.4627+1038T>C:		rs439940	0.1953	0.0000	0/0/0	0.0423							608400 [USH2A (confirmed) Usher syndrome,type 2A,276901|Retinitis pigmentosa 39,613809];	RCV000343421.1 [likely benign]; RCV000394423.1 [likely benign]; 			9	80					USH2A (inh=AR pLI=0.00)
chr1	216348764	216348764	C	T	het	het	hom	gene_blacklist	QUAL=29533;DP=481,456,507;MQM=60	USH2A	missense	USH2A:NM_206933.2:missense:MODERATE:exon21/72:c.4457G>A:p.Arg1486Lys,USH2A:NM_007123.5:missense:MODERATE:exon21/21:c.4457G>A:p.Arg1486Lys		rs1805049	0.6623	0.6580	26453/12968/1738	0.6501	-1.6250	T,T,T	T	B,B	T,T,T	6.14	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901|Retinitis pigmentosa 39,613809];	RCV000154339.2 [benign]; RCV000154668.1 [benign]; 		COSM3746790, COSM3746789, COSM3746788	647	697					USH2A (inh=AR pLI=0.00)
chr1	216371934	216371934	A	C	het	het	wt	gene_blacklist	QUAL=4085;DP=223,82,90;MQM=59	USH2A	splice_region&intron	USH2A:NM_206933.2:splice_region&intron:LOW:exon17/71:c.3812-8T>G:,USH2A:NM_007123.5:splice_region&intron:LOW:exon17/20:c.3812-8T>G:		rs646094	0.1977	0.2217	2706/1683/130	0.2097							608400 [USH2A (confirmed) Usher syndrome,type 2A,276901|Retinitis pigmentosa 39,613809];	RCV000041834.4 [benign]; RCV000261033.1 [likely benign]; RCV000316207.1 [likely benign]; 			87	512					USH2A (inh=AR pLI=0.00)
chr1	216592003	216592003	T	C	hom	hom	hom	gene_blacklist	QUAL=18945;DP=160,190,254;MQM=60	USH2A	synonymous	USH2A:NM_206933.2:synonymous:LOW:exon3/72:c.504A>G:p.Thr168Thr,USH2A:NM_007123.5:synonymous:LOW:exon3/21:c.504A>G:p.Thr168Thr		rs4253963	0.6328	0.6485	25942/13990/1291	0.6464							608400 [USH2A (confirmed) Usher syndrome,type 2A,276901|Retinitis pigmentosa 39,613809];	RCV000041854.4 [benign]; RCV000260536.1 [benign]; RCV000332187.1 [benign]; 			602	711					USH2A (inh=AR pLI=0.00)
chr1	216595306	216595306	C	T	hom	hom	hom	gene_blacklist	QUAL=32981;DP=294,279,445;MQM=60	USH2A	missense	USH2A:NM_206933.2:missense:MODERATE:exon2/72:c.373G>A:p.Ala125Thr,USH2A:NM_007123.5:missense:MODERATE:exon2/21:c.373G>A:p.Ala125Thr		rs10779261	0.7612	0.7293	32387/16635/2945	0.7235	0.3550	T,T,T	T	B,B	T,T,T	2.86	608400 [USH2A (confirmed) Usher syndrome,type 2A,276901|Retinitis pigmentosa 39,613809];	RCV000041833.5 [benign]; RCV000291734.1 [benign]; RCV000344307.1 [benign]; 			747	637					USH2A (inh=AR pLI=0.00)
chr1	220323449	220323449	T	-	het	wt	wt		QUAL=51;DP=149,44,53;MQM=59	RAB3GAP2	3'UTR	RAB3GAP2:NM_012414.3:3'UTR:MODIFIER:exon35/35:c.*1144delA:	FLAM_C	rs11316594;rs778873874	0.0000	0.0000	0/0/0	0.1353							609275 [RAB3GAP2 (provisional) Martsolf syndrome,212720|Warburg micro syndrome 2,614225];	RCV000295570.1 [uncertain significance]; RCV000407502.1 [uncertain significance]; 			10	64					RAB3GAP2 (inh=AR pLI=1.00)
chr1	220324189	220324189	A	G	het	wt	het		QUAL=9776;DP=417,218,266;MQM=60	RAB3GAP2	3'UTR	RAB3GAP2:NM_012414.3:3'UTR:MODIFIER:exon35/35:c.*404T>C:		rs1059140	0.0627	0.0000	0/0/0	0.0139							609275 [RAB3GAP2 (provisional) Martsolf syndrome,212720|Warburg micro syndrome 2,614225];	RCV000333488.1 [likely benign]; RCV000387992.1 [likely benign]; 			4	41					RAB3GAP2 (inh=AR pLI=1.00)
chr1	220330672	220330672	C	T	het	wt	het		QUAL=9349;DP=417,211,288;MQM=60	RAB3GAP2	synonymous	RAB3GAP2:NM_012414.3:synonymous:LOW:exon31/35:c.3495G>A:p.Leu1165Leu		rs11547779	0.0605	0.0876	537/319/0	0.0856							609275 [RAB3GAP2 (provisional) Martsolf syndrome,212720|Warburg micro syndrome 2,614225];	RCV000118107.3 [other]; RCV000276331.1 [likely benign]; RCV000331360.1 [likely benign]; 		COSM3750881	22	331					RAB3GAP2 (inh=AR pLI=1.00)
chr1	220331205	220331205	C	G	het	wt	het	pred_pathogenic	QUAL=6485;DP=291,182,248;MQM=60	RAB3GAP2	missense	RAB3GAP2:NM_012414.3:missense:MODERATE:exon30/35:c.3275G>C:p.Ser1092Thr		rs2289189	0.0603	0.0895	513/299/0	0.0852	7.4300	T	T	P,P	T	26.80	609275 [RAB3GAP2 (provisional) Martsolf syndrome,212720|Warburg micro syndrome 2,614225];	RCV000118106.3 [other]; RCV000318653.1 [likely benign]; RCV000373355.1 [likely benign]; 		COSM3750882	22	331					RAB3GAP2 (inh=AR pLI=1.00)
chr1	220369746	220369746	A	-	wt	het	wt		QUAL=751;DP=162,92,96;MQM=60	RAB3GAP2	splice_region&intron	RAB3GAP2:NM_012414.3:splice_region&intron:LOW:exon9/34:c.812-6delT:		rs35396665;rs397861265	0.3041	0.3371	3614/1451/256	0.2658							609275 [RAB3GAP2 (provisional) Martsolf syndrome,212720|Warburg micro syndrome 2,614225];	RCV000308689.1 [benign]; RCV000365648.1 [benign]; 			65	654					RAB3GAP2 (inh=AR pLI=1.00)
chr1	223177574	223177574	A	G	wt	wt	het		QUAL=5285;DP=509,263,406;MQM=60	DISP1	synonymous	DISP1:NM_032890.3:synonymous:LOW:exon10/10:c.2835A>G:p.Lys945Lys		rs2609355	0.2414	0.2884	5093/3013/176	0.2834								RCV000246791.1 [benign]; 			111	655					DISP1 (inh=n/a pLI=0.00)
chr1	223178561	223178561	A	C	hom	hom	het		QUAL=20411;DP=190,287,374;MQM=60	DISP1	synonymous	DISP1:NM_032890.3:synonymous:LOW:exon10/10:c.3822A>C:p.Pro1274Pro		rs9441941	0.4980	0.5453	18095/11104/998	0.5367								RCV000249331.1 [benign]; 		COSM146786	537	754					DISP1 (inh=n/a pLI=0.00)
chr1	225589473	225589473	C	T	het	wt	het		QUAL=8375;DP=323,267,352;MQM=59	LBR	3'UTR	LBR:NM_002296.3:3'UTR:MODIFIER:exon14/14:c.*1532G>A:,LBR:NM_194442.2:3'UTR:MODIFIER:exon14/14:c.*1532G>A:		rs7406	0.2726	0.0000	0/0/0	0.0295							600024 [LBR (confirmed) Pelger-Huet anomaly,169400|Greenberg skeletal dysplasia,215140|Reynolds syndrome,613471];	RCV000353652.1 [benign]; 			3	58					LBR (inh=AR+AD pLI=1.00)
chr1	225590750	225590750	G	C	het	wt	het		QUAL=4466;DP=313,47,56;MQM=60	LBR	3'UTR	LBR:NM_002296.3:3'UTR:MODIFIER:exon14/14:c.*255C>G:,LBR:NM_194442.2:3'UTR:MODIFIER:exon14/14:c.*255C>G:		rs11551874	0.1020	0.0000	0/0/0	0.0174							600024 [LBR (confirmed) Pelger-Huet anomaly,169400|Greenberg skeletal dysplasia,215140|Reynolds syndrome,613471];	RCV000347591.1 [benign]; 			3	44					LBR (inh=AR+AD pLI=1.00)
chr1	225607144	225607144	C	T	het	hom	het	pred_pathogenic	QUAL=1826;DP=75,20,47;MQM=60	LBR	missense	LBR:NM_002296.3:missense:MODERATE:exon5/14:c.461G>A:p.Ser154Asn,LBR:NM_194442.2:missense:MODERATE:exon5/14:c.461G>A:p.Ser154Asn		rs2230419	0.7123	0.8009	39850/23754/916	0.7769	-0.1880	T,T,T	T	B,B	D,D,T	0.01	600024 [LBR (confirmed) Pelger-Huet anomaly,169400|Greenberg skeletal dysplasia,215140|Reynolds syndrome,613471];	RCV000245894.1 [benign]; RCV000287243.1 [benign]; 			1078	427					LBR (inh=AR+AD pLI=1.00)
chr1	225609884	225609884	A	G	het	hom	het	low_DP	QUAL=2398;DP=127,16,18;MQM=59	LBR	synonymous	LBR:NM_002296.3:synonymous:LOW:exon3/14:c.261T>C:p.Pro87Pro,LBR:NM_194442.2:synonymous:LOW:exon3/14:c.261T>C:p.Pro87Pro		rs1056608	0.6709	0.7502	35255/20940/767	0.7317							600024 [LBR (confirmed) Pelger-Huet anomaly,169400|Greenberg skeletal dysplasia,215140|Reynolds syndrome,613471];	RCV000250536.1 [benign]; RCV000373671.1 [benign]; 			953	536					LBR (inh=AR+AD pLI=1.00)
chr1	225611661	225611661	C	T	het	het	hom		QUAL=17114;DP=367,210,283;MQM=60	LBR	synonymous	LBR:NM_002296.3:synonymous:LOW:exon2/14:c.117G>A:p.Val39Val,LBR:NM_194442.2:synonymous:LOW:exon2/14:c.117G>A:p.Val39Val		rs1056607	0.6571	0.7112	31217/18389/2091	0.6882							600024 [LBR (confirmed) Pelger-Huet anomaly,169400|Greenberg skeletal dysplasia,215140|Reynolds syndrome,613471];	RCV000245794.1 [benign]; RCV000338935.1 [benign]; 			823	613					LBR (inh=AR+AD pLI=1.00)
chr1	226548554	226548554	A	G	wt	het	wt		QUAL=848;DP=169,77,97;MQM=60	PARP1	3'UTR	PARP1:NM_001618.3:3'UTR:MODIFIER:exon23/23:c.*607T>C:		rs8679	0.1428	0.0000	0/0/0	0.0323									CR122378 [CLASS=DP MUT=ALT PHEN="Bladder cancer increased risk association with" GENE=PARP1]; 		15	79					PARP1 (inh=n/a pLI=0.01)
chr1	226555302	226555302	A	G	het	wt	het	pred_pathogenic	QUAL=5831;DP=200,220,303;MQM=59	PARP1	missense	PARP1:NM_001618.3:missense:MODERATE:exon17/23:c.2285T>C:p.Val762Ala		rs1136410	0.1969	0.2018	3399/997/11	0.1990	8.9570	T	T	P	T	32.00			CM042761 [CLASS=DFP MUT=ALT PHEN="Prostate cancer susceptibility association with" GENE=PARP1]; 	COSM3997295	47	513					PARP1 (inh=n/a pLI=0.01)
chr1	226570840	226570840	T	C	het	hom	het		QUAL=4927;DP=95,73,92;MQM=59	PARP1	synonymous	PARP1:NM_001618.3:synonymous:LOW:exon8/23:c.1056A>G:p.Lys352Lys		rs1805415	0.7893	0.7939	39108/22757/4192	0.7879										COSM3746819	1197	507					PARP1 (inh=n/a pLI=0.01)
chr1	226573364	226573364	A	G	het	wt	het		QUAL=4659;DP=152,208,248;MQM=60	PARP1	synonymous	PARP1:NM_001618.3:synonymous:LOW:exon7/23:c.852T>C:p.Ala284Ala		rs1805414	0.5166	0.4228	12034/4017/1535	0.4146									CM071915 [CLASS=DP MUT=ALT PHEN="Colorectal adenoma association with" GENE=PARP1]; 	COSM4143411	226	792					PARP1 (inh=n/a pLI=0.01)
chr1	226589958	226589958	G	A	het	wt	het		QUAL=9300;DP=303,299,470;MQM=59	PARP1	synonymous	PARP1:NM_001618.3:synonymous:LOW:exon2/23:c.243C>T:p.Asp81Asp		rs1805404	0.2183	0.2085	3496/997/92	0.2046										COSM3997297, COSM3997296	48	516					PARP1 (inh=n/a pLI=0.01)
chr1	226595647	226595647	C	G	het	wt	het		QUAL=2447;DP=43,147,161;MQM=59	PARP1	5'UTR	PARP1:NM_001618.3:5'UTR:MODIFIER:exon1/23:c.-17G>C:		rs907187	0.1991	0.2035	3026/886/10	0.1974										COSN392383	34	320					PARP1 (inh=n/a pLI=0.01)
chr1	227149203	227149203	G	A	wt	het	wt		QUAL=292;DP=75,31,36;MQM=60	COQ8A	synonymous	COQ8A:NM_020247.4:synonymous:LOW:exon2/15:c.117G>A:p.Ala39Ala		rs11549708	0.0807	0.1643	2142/1839/12	0.1645							606980 [ADCK3 (confirmed) Coenzyme Q10 deficiency,primary,4,612016];	RCV000116234.3 [other]; RCV000316094.1 [benign]; RCV000379956.1 [benign]; 		COSM3750928	141	882					COQ8A (inh=AR pLI=0.00)
chr1	227172290	227172290	C	T	het	hom	wt		QUAL=15897;DP=342,382,506;MQM=60	COQ8A	synonymous	COQ8A:NM_020247.4:synonymous:LOW:exon12/15:c.1440C>T:p.Phe480Phe		rs12593	0.2386	0.3525	8437/6747/207	0.3538							606980 [ADCK3 (confirmed) Coenzyme Q10 deficiency,primary,4,612016];	RCV000116235.2 [likely benign]; RCV000330955.1 [benign]; RCV000373810.1 [benign]; 		COSM146801, COSM146800	506	1233					COQ8A (inh=AR pLI=0.00)
chr1	227174145	227174145	T	C	het	hom	wt		QUAL=4263;DP=115,88,169;MQM=59	COQ8A	splice_region&intron	COQ8A:NM_020247.4:splice_region&intron:LOW:exon14/14:c.1660-9T>C:		rs7552783	0.3516	0.4155	11096/8198/896	0.4116							606980 [ADCK3 (confirmed) Coenzyme Q10 deficiency,primary,4,612016];	RCV000285548.1 [benign]; RCV000406694.1 [benign]; 			647	1296					COQ8A (inh=AR pLI=0.00)
chr1	227174210	227174210	T	C	het	hom	wt		QUAL=5280;DP=160,119,185;MQM=59	COQ8A	synonymous	COQ8A:NM_020247.4:synonymous:LOW:exon15/15:c.1716T>C:p.Ser572Ser		rs3738725	0.3139	0.4054	10713/8223/489	0.4055							606980 [ADCK3 (confirmed) Coenzyme Q10 deficiency,primary,4,612016];	RCV000116236.2 [likely benign]; RCV000277497.1 [benign]; RCV000363761.1 [benign]; 		COSM3997300, COSM3997301	636	1299					COQ8A (inh=AR pLI=0.00)
chr1	227174823	227174823	-	T	het	hom	wt		QUAL=13660;DP=258,381,484;MQM=59	COQ8A	3'UTR	COQ8A:NM_020247.4:3'UTR:MODIFIER:exon15/15:c.*389dupT:		rs11420839	0.2927	0.0000	0/0/0	0.3878							606980 [ADCK3 (confirmed) Coenzyme Q10 deficiency,primary,4,612016];	RCV000267417.1 [benign]; RCV000324404.1 [benign]; 			43	122					COQ8A (inh=AR pLI=0.00)
chr1	227175245	227175245	-	T	het	hom	wt		QUAL=8168;DP=167,222,333;MQM=59	COQ8A	3'UTR	COQ8A:NM_020247.4:3'UTR:MODIFIER:exon15/15:c.*797_*798insT:		rs397803535	0.2548	0.0000	0/0/0	0.3782							606980 [ADCK3 (confirmed) Coenzyme Q10 deficiency,primary,4,612016];	RCV000333606.1 [benign]; RCV000385912.1 [benign]; 			36	108					COQ8A (inh=AR pLI=0.00)
chr1	227175253	227175253	C	T	het	hom	wt		QUAL=8741;DP=167,218,326;MQM=59	COQ8A-CDC42BPA	intergenic_region	COQ8A-CDC42BPA:COQ8A-CDC42BPA:intergenic_region:MODIFIER::n.227175253C>T:		rs10495274	0.4191	0.0000	0/0/0	0.3433							606980 [ADCK3 (confirmed) Coenzyme Q10 deficiency,primary,4,612016];	RCV000292165.1 [benign]; RCV000346994.1 [benign]; 			70	102					COQ8A-CDC42BPA (inh=n/a pLI=n/a)
chr1	228346936	228346936	G	A	het	wt	het		QUAL=2306;DP=45,92,131;MQM=59	GJC2	3'UTR	GJC2:NM_020435.3:3'UTR:MODIFIER:exon2/2:c.*157G>A:		rs45491398	0.0234	0.0000	0/0/0	0.0105							608803 [GJC2 (confirmed) Leukodystrophy,hypomyelinating,2,608804|Spastic paraplegia 44,autosomal recessive,613206|Lymphedema,hereditary,IC,613480];				2	28					GJC2 (inh=AR+AD pLI=0.48)
chr1	228347352	228347352	A	G	hom	hom	hom	low_DP	QUAL=1580;DP=33,8,13;MQM=59	GJC2	3'UTR	GJC2:NM_020435.3:3'UTR:MODIFIER:exon2/2:c.*573A>G:		rs6668719	0.8043	0.0000	0/0/0	0.1524							608803 [GJC2 (confirmed) Leukodystrophy,hypomyelinating,2,608804|Spastic paraplegia 44,autosomal recessive,613206|Lymphedema,hereditary,IC,613480];				196	28					GJC2 (inh=AR+AD pLI=0.48)
chr1	228612838	228612838	G	T	het	het	hom		QUAL=18647;DP=289,287,387;MQM=60	HIST3H3	synonymous	HIST3H3:NM_003493.2:synonymous:LOW:exon1/1:c.189C>A:p.Ile63Ile		rs2230656	0.6903	0.8208	42225/25958/845	0.8103										COSM4143485	1166	351					HIST3H3 (inh=n/a pLI=0.00)
chr1	228612892	228612892	G	A	wt	wt	het		QUAL=2231;DP=182,213,261;MQM=60	HIST3H3	synonymous	HIST3H3:NM_003493.2:synonymous:LOW:exon1/1:c.135C>T:p.Gly45Gly		rs56336130	0.0433	0.0706	381/270/0	0.0680										COSM3722048	13	219					HIST3H3 (inh=n/a pLI=0.00)
chr1	229569803	229569803	A	G	het	het	het		QUAL=3138;DP=68,74,109;MQM=59	ACTA1	5'UTR	ACTA1:NM_001100.3:5'UTR:MODIFIER:exon1/7:c.-65T>C:		rs605430	0.6302	0.0000	0/0/0	0.3849							102610 [ACTA1 (confirmed) Nemaline myopathy 3,autosomal dominant or recessive,161800|Myopathy,actin,congenital,with excess of thin myofilaments,161800|Myopathy,actin,congenital,with cores,161800|Myopathy,congenital,with fiber-type disproportion 1,255310|Myopathy,scapulohumeroperoneal,616852];	RCV000290269.1 [likely benign]; RCV000349853.1 [likely benign]; RCV000384487.1 [likely benign]; 			79	114					ACTA1 (inh=AD pLI=0.01)
chr1	229569804	229569804	G	A	het	het	het		QUAL=3138;DP=68,74,109;MQM=59	ACTA1	5'UTR	ACTA1:NM_001100.3:5'UTR:MODIFIER:exon1/7:c.-66C>T:		rs605428	0.6436	0.0000	0/0/0	0.3659							102610 [ACTA1 (confirmed) Nemaline myopathy 3,autosomal dominant or recessive,161800|Myopathy,actin,congenital,with excess of thin myofilaments,161800|Myopathy,actin,congenital,with cores,161800|Myopathy,congenital,with fiber-type disproportion 1,255310|Myopathy,scapulohumeroperoneal,616852];	RCV000300855.1 [likely benign]; RCV000355646.1 [likely benign]; RCV000393746.1 [likely benign]; 			79	114					ACTA1 (inh=AD pLI=0.01)
chr1	231377081	231377081	C	T	hom	hom	het		QUAL=19215;DP=318,253,318;MQM=59	GNPAT	5'UTR	GNPAT:NM_014236.3:5'UTR:MODIFIER:exon1/16:c.-44C>T:,GNPAT:NM_001316350.1:5'UTR:MODIFIER:exon1/15:c.-44C>T:		rs518686	0.5819	0.5490	18565/9146/1688	0.5463							602744 [GNPAT (provisional) Rhizomelic chondrodysplasia punctata,type 2,222765];	RCV000320754.1 [benign]; 			270	443					GNPAT (inh=AR pLI=0.29)
chr1	231401902	231401902	G	A	hom	het	het		QUAL=17575;DP=348,202,258;MQM=60	GNPAT	synonymous	GNPAT:NM_014236.3:synonymous:LOW:exon7/16:c.915G>A:p.Glu305Glu,GNPAT:NM_001316350.1:synonymous:LOW:exon6/15:c.732G>A:p.Glu244Glu		rs574553	0.6286	0.5676	19885/9534/2503	0.5651							602744 [GNPAT (provisional) Rhizomelic chondrodysplasia punctata,type 2,222765];	RCV000245766.1 [benign]; RCV000334462.1 [benign]; 		COSM3750988	483	752					GNPAT (inh=AR pLI=0.29)
chr1	231500353	231500353	-	T	hom	het	hom		QUAL=17746;DP=351,164,185;MQM=59	EGLN1	3'UTR	EGLN1:NM_022051.2:3'UTR:MODIFIER:exon5/5:c.*1803dupA:		rs3215625;rs541569859	0.0000	0.0000	0/0/0	0.4445							606425 [EGLN1 (confirmed) Erythrocytosis,familial,3,609820|Hemoglobin,high altitude adaptation,609070];	RCV000346291.1 [uncertain significance]; 			101	99					EGLN1 (inh=AD pLI=0.93)
chr1	231557255	231557255	C	G	het	hom	wt	low_DP;pred_pathogenic	QUAL=206;DP=3,9,3;MQM=60	EGLN1	missense	EGLN1:NM_022051.2:missense:MODERATE:exon1/5:c.380G>C:p.Cys127Ser	(GCC)n	rs12097901	0.2604	0.0000	11/3/4	0.0290	-0.0310	T	T	B	D	0.05	606425 [EGLN1 (confirmed) Erythrocytosis,familial,3,609820|Hemoglobin,high altitude adaptation,609070];	RCV000144173.3 [other]; RCV000348869.1 [benign]; 	CM140742 [CLASS=DFP MUT=ALT PHEN="Reduced haemoglobin levels" GENE=EGLN1]; 	COSM4143508	31	216					EGLN1 (inh=AD pLI=0.93)
chr1	231559226	231559226	A	G	het	hom	wt		QUAL=5115;DP=198,70,82;MQM=60	EGLN1	5'UTR	EGLN1:NM_022051.2:5'UTR:MODIFIER:exon1/5:c.-1592T>C:		rs12406290	0.2915	0.0000	0/0/0	0.0388							606425 [EGLN1 (confirmed) Erythrocytosis,familial,3,609820|Hemoglobin,high altitude adaptation,609070];	RCV000366629.1 [benign]; 			13	64					EGLN1 (inh=AD pLI=0.93)
chr1	231560220	231560220	A	G	het	hom	wt		QUAL=15577;DP=596,212,206;MQM=60	EGLN1	5'UTR	EGLN1:NM_022051.2:5'UTR:MODIFIER:exon1/5:c.-2586T>C:		rs2153364	0.2939	0.0000	0/0/0	0.2292							606425 [EGLN1 (confirmed) Erythrocytosis,familial,3,609820|Hemoglobin,high altitude adaptation,609070];	RCV000363746.1 [benign]; 			13	63					EGLN1 (inh=AD pLI=0.93)
chr1	235825643	235825643	G	A	het	het	wt		QUAL=2726;DP=207,30,66;MQM=60	LYST,MIR5096	3'UTR,intron	LYST:NM_000081.3:3'UTR:MODIFIER:exon53/53:c.*597C>T:,LYST:NM_001301365.1:3'UTR:MODIFIER:exon53/53:c.*597C>T:,MIR5096:NR_039973.1.2:intron:MODIFIER:exon1/1:n.52-55752G>A:			0.0000	0.0000	0/0/0	0.0000							606897 [LYST (confirmed) Chediak-Higashi syndrome,214500];				0	2					LYST (inh=AR pLI=1.00), MIR5096 (inh=n/a pLI=n/a)
chr1	235826383	235826383	A	-	hom	het	hom		QUAL=14828;DP=234,194,276;MQM=59	LYST,MIR5096	splice_region&intron,intron	LYST:NM_000081.3:splice_region&intron:LOW:exon52/52:c.11268-5delT:,LYST:NM_001301365.1:splice_region&intron:LOW:exon52/52:c.11268-5delT:,MIR5096:NR_039973.1.2:intron:MODIFIER:exon1/1:n.52-55000delA:		rs36014994;rs556428133;rs796277765	0.4227	0.5064	8946/5649/2095	0.4303							606897 [LYST (confirmed) Chediak-Higashi syndrome,214500];				310	838	1	[1] old entry - no details available			LYST (inh=AR pLI=1.00), MIR5096 (inh=n/a pLI=n/a)
chr1	235940450	235940450	C	T	hom	het	hom		QUAL=17710;DP=241,202,237;MQM=60	LYST	synonymous	LYST:NM_000081.3:synonymous:LOW:exon17/53:c.5373G>A:p.Lys1791Lys,LYST:NM_001301365.1:synonymous:LOW:exon17/53:c.5373G>A:p.Lys1791Lys		rs2273584	0.3009	0.3483	8275/5496/1288	0.3457							606897 [LYST (confirmed) Chediak-Higashi syndrome,214500];	RCV000246380.1 [benign]; RCV000308180.1 [benign]; 		COSM3746866	256	731					LYST (inh=AR pLI=1.00)
chr1	235945294	235945294	T	C	hom	het	hom		QUAL=15537;DP=184,151,234;MQM=60	LYST	synonymous	LYST:NM_000081.3:synonymous:LOW:exon15/53:c.4956A>G:p.Leu1652Leu,LYST:NM_001301365.1:synonymous:LOW:exon15/53:c.4956A>G:p.Leu1652Leu		rs6696123	0.3035	0.3501	8327/5510/1294	0.3472							606897 [LYST (confirmed) Chediak-Higashi syndrome,214500];	RCV000253208.1 [benign]; RCV000398616.1 [benign]; 		COSM3746867	258	731					LYST (inh=AR pLI=1.00)
chr1	235955150	235955150	G	A	wt	wt	het		QUAL=6495;DP=581,415,522;MQM=60	LYST	synonymous	LYST:NM_000081.3:synonymous:LOW:exon12/53:c.4392C>T:p.Asn1464Asn,LYST:NM_001301365.1:synonymous:LOW:exon12/53:c.4392C>T:p.Asn1464Asn		rs11583387	0.0643	0.0859	502/391/22	0.0871							606897 [LYST (confirmed) Chediak-Higashi syndrome,214500];	RCV000243266.1 [benign]; RCV000264697.1 [likely benign]; 			28	325					LYST (inh=AR pLI=1.00)
chr1	235971763	235971763	A	G	het	het	het		QUAL=8439;DP=203,197,267;MQM=60	LYST	synonymous	LYST:NM_000081.3:synonymous:LOW:exon5/53:c.2355T>C:p.Leu785Leu,LYST:NM_001301365.1:synonymous:LOW:exon5/53:c.2355T>C:p.Leu785Leu		rs3768066	0.0707	0.1035	758/615/24	0.1031							606897 [LYST (confirmed) Chediak-Higashi syndrome,214500];	RCV000242666.1 [benign]; RCV000377101.1 [likely benign]; 			41	382					LYST (inh=AR pLI=1.00)
chr1	235972435	235972435	T	C	hom	het	hom		QUAL=27834;DP=484,197,286;MQM=60	LYST	synonymous	LYST:NM_000081.3:synonymous:LOW:exon5/53:c.1683A>G:p.Leu561Leu,LYST:NM_001301365.1:synonymous:LOW:exon5/53:c.1683A>G:p.Leu561Leu		rs3820553	0.3027	0.3499	8325/5507/1300	0.3466							606897 [LYST (confirmed) Chediak-Higashi syndrome,214500];	RCV000243167.1 [benign]; RCV000369958.1 [benign]; 		COSM3746868	260	730					LYST (inh=AR pLI=1.00)
chr1	235972867	235972867	T	C	hom	het	hom		QUAL=27810;DP=456,191,305;MQM=59	LYST	synonymous	LYST:NM_000081.3:synonymous:LOW:exon5/53:c.1251A>G:p.Gln417Gln,LYST:NM_001301365.1:synonymous:LOW:exon5/53:c.1251A>G:p.Gln417Gln		rs1063128	0.3033	0.3500	8312/5503/1292	0.3467							606897 [LYST (confirmed) Chediak-Higashi syndrome,214500];	RCV000246231.1 [benign]; RCV000271690.1 [benign]; 		COSM3746869	259	731					LYST (inh=AR pLI=1.00)
chr1	236557771	236557771	G	A	hom	hom	hom	pred_pathogenic	QUAL=24473;DP=251,225,289;MQM=60	EDARADD	missense	EDARADD:NM_145861.2:missense:MODERATE:exon1/6:c.27G>A:p.Met9Ile		rs966365	0.7768	0.8308	42529/23173/1467	0.8123	-0.0830	D	T	B	T	3.35	606603 [EDARADD (confirmed) Ectodermal dysplasia 11B,hypohidrotic/hair/tooth type,autosomal recessive,614941|Ectodermal dysplasia 11A,hypohidrotic/hair/tooth type,autosomal dominant,614940];	RCV000249322.1 [benign]; RCV000262285.1 [benign]; 		COSM3746871	1103	419					EDARADD (inh=AD pLI=0.10)
chr1	236645670	236645670	C	T	wt	wt	het		QUAL=5248;DP=211,359,483;MQM=60	EDARADD	synonymous,sequence_feature	EDARADD:NM_145861.2:synonymous:LOW:exon6/6:c.369C>T:p.Asp123Asp,EDARADD:NM_080738.3:synonymous:LOW:exon6/6:c.339C>T:p.Asp113Asp,EDARADD:NM_145861.2:sequence_feature:LOW:exon6/6:c.369C>T:,EDARADD:NM_080738.3:sequence_feature:LOW:exon6/6:c.339C>T:		rs604070	0.1332	0.2024	2910/2272/16	0.2010							606603 [EDARADD (confirmed) Ectodermal dysplasia 11B,hypohidrotic/hair/tooth type,autosomal recessive,614941|Ectodermal dysplasia 11A,hypohidrotic/hair/tooth type,autosomal dominant,614940];	RCV000244680.1 [benign]; RCV000288299.1 [likely benign]; 		COSM3751016	89	563					EDARADD (inh=AD pLI=0.10)
chr1	236647511	236647511	T	C	het	het	hom		QUAL=13119;DP=280,142,225;MQM=59	EDARADD	3'UTR	EDARADD:NM_145861.2:3'UTR:MODIFIER:exon6/6:c.*1562T>C:,EDARADD:NM_080738.3:3'UTR:MODIFIER:exon6/6:c.*1562T>C:		rs7513402	0.2540	0.0000	0/0/0	0.0566							606603 [EDARADD (confirmed) Ectodermal dysplasia 11B,hypohidrotic/hair/tooth type,autosomal recessive,614941|Ectodermal dysplasia 11A,hypohidrotic/hair/tooth type,autosomal dominant,614940];	RCV000300675.1 [likely benign]; 			34	101					EDARADD (inh=AD pLI=0.10)
chr1	236647550	236647550	C	G	het	het	hom		QUAL=13992;DP=335,127,224;MQM=59	EDARADD	3'UTR	EDARADD:NM_145861.2:3'UTR:MODIFIER:exon6/6:c.*1601C>G:,EDARADD:NM_080738.3:3'UTR:MODIFIER:exon6/6:c.*1601C>G:		rs3916983	0.2033	0.0000	0/0/0	0.0388							606603 [EDARADD (confirmed) Ectodermal dysplasia 11B,hypohidrotic/hair/tooth type,autosomal recessive,614941|Ectodermal dysplasia 11A,hypohidrotic/hair/tooth type,autosomal dominant,614940];	RCV000389958.1 [likely benign]; RCV000313375.1 [likely benign]; 			20	91					EDARADD (inh=AD pLI=0.10)
chr1	236647736	236647736	C	T	het	het	hom		QUAL=7352;DP=163,74,131;MQM=59	EDARADD	3'UTR	EDARADD:NM_145861.2:3'UTR:MODIFIER:exon6/6:c.*1787C>T:,EDARADD:NM_080738.3:3'UTR:MODIFIER:exon6/6:c.*1787C>T:		rs6428955	0.1378	0.0000	0/0/0	0.0328							606603 [EDARADD (confirmed) Ectodermal dysplasia 11B,hypohidrotic/hair/tooth type,autosomal recessive,614941|Ectodermal dysplasia 11A,hypohidrotic/hair/tooth type,autosomal dominant,614940];	RCV000268785.1 [likely benign]; 			14	83					EDARADD (inh=AD pLI=0.10)
chr1	236648008	236648008	G	A	hom	hom	hom	low_DP	QUAL=869;DP=10,15,27;MQM=57	EDARADD	splice_region,3'UTR	EDARADD:NM_145861.2:splice_region:LOW:exon6/6:c.*2059G>A:,EDARADD:NM_080738.3:splice_region:LOW:exon6/6:c.*2059G>A:,EDARADD:NM_145861.2:3'UTR:MODIFIER:exon6/6:c.*2059G>A:,EDARADD:NM_080738.3:3'UTR:MODIFIER:exon6/6:c.*2059G>A:	AluSc	rs200288312	0.0000	0.0000	0/0/0	0.0002							606603 [EDARADD (confirmed) Ectodermal dysplasia 11B,hypohidrotic/hair/tooth type,autosomal recessive,614941|Ectodermal dysplasia 11A,hypohidrotic/hair/tooth type,autosomal dominant,614940];				1	26					EDARADD (inh=AD pLI=0.10)
chr1	236990141	236990141	G	A	wt	het	wt	pred_pathogenic	QUAL=1803;DP=295,153,221;MQM=60	MTR	missense,5'UTR	MTR:NM_000254.2:missense:MODERATE:exon11/33:c.940G>A:p.Asp314Asn,MTR:NM_001291939.1:missense:MODERATE:exon11/32:c.940G>A:p.Asp314Asn,MTR:NM_001291940.1:5'UTR:MODIFIER:exon11/32:c.-169G>A:		rs2229274	0.0084	0.0191	39/35/0	0.0191	4.0160	T,T,T	T	B,B,B	T,T	22.60	156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940|Neural tube defects,folate-sensitive,susceptibility to,601634];	RCV000357779.1 [likely benign]; 			2	68					MTR (inh=AR pLI=0.00)
chr1	237054569	237054569	A	G	het	het	hom		QUAL=7272;DP=103,101,145;MQM=59	MTR	synonymous	MTR:NM_000254.2:synonymous:LOW:exon29/33:c.3144A>G:p.Ala1048Ala,MTR:NM_001291939.1:synonymous:LOW:exon28/32:c.2991A>G:p.Ala997Ala,MTR:NM_001291940.1:synonymous:LOW:exon28/32:c.1923A>G:p.Ala641Ala		rs2229276	0.3233	0.3833	9367/5488/217	0.3826							156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940|Neural tube defects,folate-sensitive,susceptibility to,601634];	RCV000126869.2 [benign]; RCV000366897.1 [benign]; 		COSM3751028	230	741					MTR (inh=AR pLI=0.00)
chr1	237058744	237058744	C	A	het	het	hom		QUAL=14706;DP=218,223,310;MQM=60	MTR	synonymous	MTR:NM_000254.2:synonymous:LOW:exon31/33:c.3492C>A:p.Arg1164Arg,MTR:NM_001291939.1:synonymous:LOW:exon30/32:c.3339C>A:p.Arg1113Arg,MTR:NM_001291940.1:synonymous:LOW:exon30/32:c.2271C>A:p.Arg757Arg		rs12070777	0.3215	0.4330	6783/3972/162	0.3545							156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940|Neural tube defects,folate-sensitive,susceptibility to,601634];	RCV000126862.2 [benign]; RCV000316970.1 [benign]; 		COSM3751029	228	735					MTR (inh=AR pLI=0.00)
chr1	237058828	237058828	C	T	wt	het	het		QUAL=4192;DP=136,168,182;MQM=60	MTR	synonymous	MTR:NM_000254.2:synonymous:LOW:exon31/33:c.3576C>T:p.Leu1192Leu,MTR:NM_001291939.1:synonymous:LOW:exon30/32:c.3423C>T:p.Leu1141Leu,MTR:NM_001291940.1:synonymous:LOW:exon30/32:c.2355C>T:p.Leu785Leu		rs1131449	0.5292	0.6193	10790/5490/613	0.5126							156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940|Neural tube defects,folate-sensitive,susceptibility to,601634];	RCV000126863.2 [benign]; RCV000320660.1 [benign]; 		COSM425684	469	766					MTR (inh=AR pLI=0.00)
chr1	237061056	237061056	A	C	het	het	hom		QUAL=10754;DP=311,80,153;MQM=59	MTR	3'UTR	MTR:NM_000254.2:3'UTR:MODIFIER:exon33/33:c.*112A>C:,MTR:NM_001291939.1:3'UTR:MODIFIER:exon32/32:c.*112A>C:,MTR:NM_001291940.1:3'UTR:MODIFIER:exon32/32:c.*112A>C:		rs2853522	0.5401	0.0000	0/0/0	0.1182							156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940|Neural tube defects,folate-sensitive,susceptibility to,601634];	RCV000369614.1 [benign]; 			143	174					MTR (inh=AR pLI=0.00)
chr1	237061705	237061705	T	-	het	het	hom		QUAL=1748;DP=108,32,42;MQM=57	MTR	3'UTR	MTR:NM_000254.2:3'UTR:MODIFIER:exon33/33:c.*773delT:,MTR:NM_001291939.1:3'UTR:MODIFIER:exon32/32:c.*773delT:,MTR:NM_001291940.1:3'UTR:MODIFIER:exon32/32:c.*773delT:	AluY	rs796166778	0.4605	0.0000	0/0/0	0.1949							156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940|Neural tube defects,folate-sensitive,susceptibility to,601634];	RCV000322819.1 [benign]; 			41	156					MTR (inh=AR pLI=0.00)
chr1	237061849	237061849	G	A	het	het	wt		QUAL=1239;DP=81,34,66;MQM=51	MTR	3'UTR	MTR:NM_000254.2:3'UTR:MODIFIER:exon33/33:c.*905G>A:,MTR:NM_001291939.1:3'UTR:MODIFIER:exon32/32:c.*905G>A:,MTR:NM_001291940.1:3'UTR:MODIFIER:exon32/32:c.*905G>A:	AluY	rs1131450	0.2460	0.0000	0/0/0	0.2902							156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940|Neural tube defects,folate-sensitive,susceptibility to,601634];	RCV000328630.1 [benign]; 			24	81					MTR (inh=AR pLI=0.00)
chr1	237062198	237062198	A	C	het	het	hom		QUAL=16868;DP=267,245,296;MQM=60	MTR	3'UTR	MTR:NM_000254.2:3'UTR:MODIFIER:exon33/33:c.*1254A>C:,MTR:NM_001291939.1:3'UTR:MODIFIER:exon32/32:c.*1254A>C:,MTR:NM_001291940.1:3'UTR:MODIFIER:exon32/32:c.*1254A>C:		rs2853523	0.7646	0.0000	0/0/0	0.1176							156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940|Neural tube defects,folate-sensitive,susceptibility to,601634];	RCV000360926.1 [benign]; 			124	105					MTR (inh=AR pLI=0.00)
chr1	237062305	237062305	A	G	het	het	hom		QUAL=21941;DP=415,296,370;MQM=60	MTR	3'UTR	MTR:NM_000254.2:3'UTR:MODIFIER:exon33/33:c.*1361A>G:,MTR:NM_001291939.1:3'UTR:MODIFIER:exon32/32:c.*1361A>G:,MTR:NM_001291940.1:3'UTR:MODIFIER:exon32/32:c.*1361A>G:		rs1050993	0.7644	0.0000	0/0/0	0.1177							156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940|Neural tube defects,folate-sensitive,susceptibility to,601634];	RCV000270883.1 [benign]; 			123	105					MTR (inh=AR pLI=0.00)
chr1	237063335	237063335	G	C	het	het	hom		QUAL=12927;DP=228,207,222;MQM=60	MTR	3'UTR	MTR:NM_000254.2:3'UTR:MODIFIER:exon33/33:c.*2391G>C:,MTR:NM_001291939.1:3'UTR:MODIFIER:exon32/32:c.*2391G>C:,MTR:NM_001291940.1:3'UTR:MODIFIER:exon32/32:c.*2391G>C:	L1ME3F	rs1050996	0.7328	0.0000	0/0/0	0.1060							156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940|Neural tube defects,folate-sensitive,susceptibility to,601634];	RCV000275160.1 [benign]; 			193	218					MTR (inh=AR pLI=0.00)
chr1	237063504	237063504	A	G	het	het	hom		QUAL=11930;DP=380,106,148;MQM=60	MTR	3'UTR	MTR:NM_000254.2:3'UTR:MODIFIER:exon33/33:c.*2560A>G:,MTR:NM_001291939.1:3'UTR:MODIFIER:exon32/32:c.*2560A>G:,MTR:NM_001291940.1:3'UTR:MODIFIER:exon32/32:c.*2560A>G:	L1ME3F	rs9779	0.3219	0.3793	440/132/8	0.0915							156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940|Neural tube defects,folate-sensitive,susceptibility to,601634];	RCV000369642.1 [benign]; 			156	459					MTR (inh=AR pLI=0.00)
chr1	237063709	237063709	-	A	hom	hom	hom		QUAL=9455;DP=88,62,184;MQM=59	MTR	3'UTR	MTR:NM_000254.2:3'UTR:MODIFIER:exon33/33:c.*2774dupA:,MTR:NM_001291939.1:3'UTR:MODIFIER:exon32/32:c.*2774dupA:,MTR:NM_001291940.1:3'UTR:MODIFIER:exon32/32:c.*2774dupA:	L1ME3F	rs537046483;rs757040639;rs796715143	0.6516	0.0000	0/0/0	0.4014							156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940|Neural tube defects,folate-sensitive,susceptibility to,601634];	RCV000356838.1 [uncertain significance]; RCV000316041.1 [benign]; 			182	34					MTR (inh=AR pLI=0.00)
chr1	237064626	237064626	T	G	het	het	hom		QUAL=33769;DP=424,514,672;MQM=60	MTR	3'UTR	MTR:NM_000254.2:3'UTR:MODIFIER:exon33/33:c.*3682T>G:,MTR:NM_001291939.1:3'UTR:MODIFIER:exon32/32:c.*3682T>G:,MTR:NM_001291940.1:3'UTR:MODIFIER:exon32/32:c.*3682T>G:		rs6676866	0.5397	0.0000	0/0/0	0.1004							156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940|Neural tube defects,folate-sensitive,susceptibility to,601634];	RCV000320905.1 [benign]; 			106	115					MTR (inh=AR pLI=0.00)
chr1	237065326	237065326	C	T	het	het	hom		QUAL=8093;DP=170,114,157;MQM=60	MTR	3'UTR	MTR:NM_000254.2:3'UTR:MODIFIER:exon33/33:c.*4382C>T:,MTR:NM_001291939.1:3'UTR:MODIFIER:exon32/32:c.*4382C>T:,MTR:NM_001291940.1:3'UTR:MODIFIER:exon32/32:c.*4382C>T:		rs4659746	0.5447	0.0000	0/0/0	0.1009							156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940|Neural tube defects,folate-sensitive,susceptibility to,601634];	RCV000405275.1 [benign]; 			109	112					MTR (inh=AR pLI=0.00)
chr1	237065583	237065583	G	T	het	het	hom		QUAL=13268;DP=220,176,257;MQM=59	MTR	3'UTR	MTR:NM_000254.2:3'UTR:MODIFIER:exon33/33:c.*4639G>T:,MTR:NM_001291939.1:3'UTR:MODIFIER:exon32/32:c.*4639G>T:,MTR:NM_001291940.1:3'UTR:MODIFIER:exon32/32:c.*4639G>T:		rs10925264	0.7646	0.0000	0/0/0	0.1174							156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940|Neural tube defects,folate-sensitive,susceptibility to,601634];	RCV000363593.1 [benign]; 			124	105					MTR (inh=AR pLI=0.00)
chr1	237065810	237065810	T	G	het	wt	het		QUAL=4783;DP=177,180,171;MQM=60	MTR	3'UTR	MTR:NM_000254.2:3'UTR:MODIFIER:exon33/33:c.*4866T>G:,MTR:NM_001291939.1:3'UTR:MODIFIER:exon32/32:c.*4866T>G:,MTR:NM_001291940.1:3'UTR:MODIFIER:exon32/32:c.*4866T>G:	L2c	rs45563435	0.0076	0.0000	0/0/0	0.0027							156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940|Neural tube defects,folate-sensitive,susceptibility to,601634];	RCV000274054.1 [uncertain significance]; 			0	20					MTR (inh=AR pLI=0.00)
chr1	237066114	237066114	A	G	het	het	wt		QUAL=3157;DP=158,86,114;MQM=59	MTR	3'UTR	MTR:NM_000254.2:3'UTR:MODIFIER:exon33/33:c.*5170A>G:,MTR:NM_001291939.1:3'UTR:MODIFIER:exon32/32:c.*5170A>G:,MTR:NM_001291940.1:3'UTR:MODIFIER:exon32/32:c.*5170A>G:		rs6680753	0.0104	0.0000	0/0/0	0.0033							156570 [MTR (confirmed) Homocystinuria-megaloblastic anemia,cblG complementation type,250940|Neural tube defects,folate-sensitive,susceptibility to,601634];	RCV000388244.1 [likely benign]; 			0	11					MTR (inh=AR pLI=0.00)
chr1	240939104	240939104	G	A	het	hom	wt		QUAL=9081;DP=345,146,165;MQM=60	RGS7	3'UTR	RGS7:NM_002924.5:3'UTR:MODIFIER:exon18/18:c.*359C>T:,RGS7:NM_001282773.1:3'UTR:MODIFIER:exon16/16:c.*416C>T:,RGS7:NM_001282775.1:3'UTR:MODIFIER:exon18/18:c.*416C>T:,RGS7:NM_001282778.1:3'UTR:MODIFIER:exon17/17:c.*359C>T:		rs35557904	0.1727	0.0000	0/0/0	0.0229											2	43					RGS7 (inh=n/a pLI=0.78)
chr1	240939152	240939152	A	G	het	hom	wt		QUAL=9436;DP=319,181,209;MQM=59	RGS7	3'UTR	RGS7:NM_002924.5:3'UTR:MODIFIER:exon18/18:c.*311T>C:,RGS7:NM_001282773.1:3'UTR:MODIFIER:exon16/16:c.*368T>C:,RGS7:NM_001282775.1:3'UTR:MODIFIER:exon18/18:c.*368T>C:,RGS7:NM_001282778.1:3'UTR:MODIFIER:exon17/17:c.*311T>C:		rs16840577	0.1727	0.0000	0/0/0	0.0229											2	42					RGS7 (inh=n/a pLI=0.78)
chr1	240939391	240939391	C	T	het	het	wt		QUAL=12776;DP=503,553,688;MQM=60	RGS7	3'UTR	RGS7:NM_002924.5:3'UTR:MODIFIER:exon18/18:c.*72G>A:,RGS7:NM_001282773.1:3'UTR:MODIFIER:exon16/16:c.*129G>A:,RGS7:NM_001282775.1:3'UTR:MODIFIER:exon18/18:c.*129G>A:,RGS7:NM_001282778.1:3'UTR:MODIFIER:exon17/17:c.*72G>A:		rs12757054	0.0497	0.0000	0/0/0	0.0139											2	58					RGS7 (inh=n/a pLI=0.78)
chr1	240975213	240975213	T	C	het	wt	hom		QUAL=11065;DP=255,201,237;MQM=60	RGS7	splice_region&intron	RGS7:NM_002924.5:splice_region&intron:LOW:exon14/17:c.1082+5A>G:,RGS7:NM_001282773.1:splice_region&intron:LOW:exon12/15:c.923+5A>G:,RGS7:NM_001282775.1:splice_region&intron:LOW:exon14/17:c.1082+5A>G:,RGS7:NM_001282778.1:splice_region&intron:LOW:exon14/16:c.1082+5A>G:		rs2275742	0.4046	0.5060	16301/10968/360	0.5040										COSM146839	498	704					RGS7 (inh=n/a pLI=0.78)
chr1	241519098	241519098	T	A	hom	hom	hom		QUAL=35182;DP=434,287,423;MQM=60	RGS7	5'UTR	RGS7:NM_002924.5:5'UTR:MODIFIER:exon2/18:c.-22A>T:,RGS7:NM_001282773.1:5'UTR:MODIFIER:exon2/16:c.-22A>T:,RGS7:NM_001282775.1:5'UTR:MODIFIER:exon2/18:c.-22A>T:,RGS7:NM_001282778.1:5'UTR:MODIFIER:exon2/17:c.-22A>T:		rs4659599	0.9483	0.9778	57908/32328/3876	0.9442											885	26					RGS7 (inh=n/a pLI=0.78)
chr1	247581560	247581560	A	T	het	wt	het		QUAL=12620;DP=502,357,471;MQM=59	NLRP3	5'UTR	NLRP3:NM_001079821.2:5'UTR:MODIFIER:exon2/11:c.-71A>T:,NLRP3:NM_001127461.2:5'UTR:MODIFIER:exon2/9:c.-537A>T:,NLRP3:NM_001127462.2:5'UTR:MODIFIER:exon1/8:c.-537A>T:,NLRP3:NM_001243133.1:5'UTR:MODIFIER:exon1/9:c.-543A>T:,NLRP3:NM_004895.4:5'UTR:MODIFIER:exon1/9:c.-537A>T:,NLRP3:NM_183395.2:5'UTR:MODIFIER:exon1/7:c.-537A>T:		rs116502550	0.0030	0.0000	0/0/0	0.0032							606416 [NLRP3 (confirmed) Familial cold-induced inflammatory syndrome 1,120100|Muckle-Wells syndrome,191900|CINCA syndrome,607115];	RCV000272392.1 [likely benign]; RCV000307404.1 [likely benign]; RCV000362149.1 [likely benign]; 			0	13					NLRP3 (inh=AD pLI=0.45)
chr1	247581692	247581692	T	C	hom	hom	hom		QUAL=17568;DP=264,161,169;MQM=58	NLRP3	5'UTR,intron	NLRP3:NM_001127461.2:5'UTR:MODIFIER:exon2/9:c.-405T>C:,NLRP3:NM_001127462.2:5'UTR:MODIFIER:exon1/8:c.-405T>C:,NLRP3:NM_001243133.1:5'UTR:MODIFIER:exon1/9:c.-411T>C:,NLRP3:NM_004895.4:5'UTR:MODIFIER:exon1/9:c.-405T>C:,NLRP3:NM_183395.2:5'UTR:MODIFIER:exon1/7:c.-405T>C:,NLRP3:NM_001079821.2:intron:MODIFIER:exon2/10:c.-39+100T>C:	AluSx1	rs7523422	0.9978	0.0000	0/0/0	0.8774							606416 [NLRP3 (confirmed) Familial cold-induced inflammatory syndrome 1,120100|Muckle-Wells syndrome,191900|CINCA syndrome,607115];	RCV000307398.1 [benign]; RCV000342282.1 [benign]; RCV000396602.1 [benign]; 			217	1					NLRP3 (inh=AD pLI=0.45)
chr1	247581872	247581872	G	A	het	het	het		QUAL=5043;DP=217,67,85;MQM=58	NLRP3	5'UTR,intron	NLRP3:NM_001127461.2:5'UTR:MODIFIER:exon2/9:c.-225G>A:,NLRP3:NM_001127462.2:5'UTR:MODIFIER:exon1/8:c.-225G>A:,NLRP3:NM_001243133.1:5'UTR:MODIFIER:exon1/9:c.-231G>A:,NLRP3:NM_004895.4:5'UTR:MODIFIER:exon1/9:c.-225G>A:,NLRP3:NM_183395.2:5'UTR:MODIFIER:exon1/7:c.-225G>A:,NLRP3:NM_001079821.2:intron:MODIFIER:exon2/10:c.-38-187G>A:	AluSx1	rs138900557	0.0158	0.0000	0/0/0	0.0301							606416 [NLRP3 (confirmed) Familial cold-induced inflammatory syndrome 1,120100|Muckle-Wells syndrome,191900|CINCA syndrome,607115];	RCV000313147.1 [likely benign]; RCV000347982.1 [likely benign]; RCV000396614.1 [likely benign]; 			1	28					NLRP3 (inh=AD pLI=0.45)
chr1	247582063	247582063	G	T	het	het	het		QUAL=9894;DP=333,232,287;MQM=60	NLRP3	5'UTR	NLRP3:NM_001079821.2:5'UTR:MODIFIER:exon3/11:c.-34G>T:,NLRP3:NM_001127461.2:5'UTR:MODIFIER:exon2/9:c.-34G>T:,NLRP3:NM_001127462.2:5'UTR:MODIFIER:exon1/8:c.-34G>T:,NLRP3:NM_001243133.1:5'UTR:MODIFIER:exon1/9:c.-40G>T:,NLRP3:NM_004895.4:5'UTR:MODIFIER:exon1/9:c.-34G>T:,NLRP3:NM_183395.2:5'UTR:MODIFIER:exon1/7:c.-34G>T:		rs73136263	0.0270	0.0367	112/64/9	0.0357							606416 [NLRP3 (confirmed) Familial cold-induced inflammatory syndrome 1,120100|Muckle-Wells syndrome,191900|CINCA syndrome,607115];	RCV000291636.1 [benign]; RCV000348931.1 [benign]; RCV000383741.1 [benign]; 			2	73					NLRP3 (inh=AD pLI=0.45)
chr1	247587477	247587477	G	A	het	het	het		QUAL=6296;DP=167,155,192;MQM=60	NLRP3	synonymous	NLRP3:NM_001079821.2:synonymous:LOW:exon5/11:c.732G>A:p.Ala244Ala,NLRP3:NM_001127461.2:synonymous:LOW:exon4/9:c.732G>A:p.Ala244Ala,NLRP3:NM_001127462.2:synonymous:LOW:exon3/8:c.732G>A:p.Ala244Ala,NLRP3:NM_001243133.1:synonymous:LOW:exon3/9:c.726G>A:p.Ala242Ala,NLRP3:NM_004895.4:synonymous:LOW:exon3/9:c.732G>A:p.Ala244Ala,NLRP3:NM_183395.2:synonymous:LOW:exon3/7:c.732G>A:p.Ala244Ala		rs3806268	0.3874	0.4996	16070/10284/74	0.4990							606416 [NLRP3 (confirmed) Familial cold-induced inflammatory syndrome 1,120100|Muckle-Wells syndrome,191900|CINCA syndrome,607115];	RCV000245535.1 [benign]; RCV000260400.1 [benign]; RCV000318048.1 [benign]; RCV000371499.1 [benign]; 		COSM146848	508	747					NLRP3 (inh=AD pLI=0.45)
chr1	247587531	247587531	A	G	hom	hom	hom		QUAL=14196;DP=158,120,162;MQM=60	NLRP3	synonymous	NLRP3:NM_001079821.2:synonymous:LOW:exon5/11:c.786A>G:p.Arg262Arg,NLRP3:NM_001127461.2:synonymous:LOW:exon4/9:c.786A>G:p.Arg262Arg,NLRP3:NM_001127462.2:synonymous:LOW:exon3/8:c.786A>G:p.Arg262Arg,NLRP3:NM_001243133.1:synonymous:LOW:exon3/9:c.780A>G:p.Arg260Arg,NLRP3:NM_004895.4:synonymous:LOW:exon3/9:c.786A>G:p.Arg262Arg,NLRP3:NM_183395.2:synonymous:LOW:exon3/7:c.786A>G:p.Arg262Arg		rs4925543	0.9199	0.9426	54053/30707/3740	0.9142							606416 [NLRP3 (confirmed) Familial cold-induced inflammatory syndrome 1,120100|Muckle-Wells syndrome,191900|CINCA syndrome,607115];	RCV000127219.1 [benign]; 			1424	134					NLRP3 (inh=AD pLI=0.45)
chr1	247612036	247612036	G	C	hom	hom	hom		QUAL=50300;DP=706,384,505;MQM=59	NLRP3	3'UTR	NLRP3:NM_001079821.2:3'UTR:MODIFIER:exon11/11:c.*230G>C:,NLRP3:NM_001127461.2:3'UTR:MODIFIER:exon9/9:c.*230G>C:,NLRP3:NM_001127462.2:3'UTR:MODIFIER:exon8/8:c.*230G>C:,NLRP3:NM_001243133.1:3'UTR:MODIFIER:exon9/9:c.*230G>C:,NLRP3:NM_004895.4:3'UTR:MODIFIER:exon9/9:c.*230G>C:,NLRP3:NM_183395.2:3'UTR:MODIFIER:exon7/7:c.*230G>C:		rs10754558	0.6536	0.0000	0/0/0	0.1047							606416 [NLRP3 (confirmed) Familial cold-induced inflammatory syndrome 1,120100|Muckle-Wells syndrome,191900|CINCA syndrome,607115];	RCV000284662.1 [benign]; RCV000339908.1 [benign]; RCV000379007.1 [benign]; 	CR098789 [CLASS=DFP MUT=REF PHEN="Anaphylaxis food-induced association with" GENE=NLRP3]; 		67	102					NLRP3 (inh=AD pLI=0.45)
chr2	1417244	1417244	A	G	het	wt	het		QUAL=8243;DP=243,223,355;MQM=60	TPO	5'UTR_premature_start_codon_gain,5'UTR	TPO:NM_000547.5:5'UTR_premature_start_codon_gain:LOW:exon1/17:c.-80A>G:,TPO:NM_001206744.1:5'UTR_premature_start_codon_gain:LOW:exon1/17:c.-75A>G:,TPO:NM_001206745.1:5'UTR_premature_start_codon_gain:LOW:exon1/16:c.-75A>G:,TPO:NM_175719.3:5'UTR_premature_start_codon_gain:LOW:exon1/16:c.-80A>G:,TPO:NM_000547.5:5'UTR:MODIFIER:exon1/17:c.-80A>G:,TPO:NM_001206744.1:5'UTR:MODIFIER:exon1/17:c.-75A>G:,TPO:NM_001206745.1:5'UTR:MODIFIER:exon1/16:c.-75A>G:,TPO:NM_175719.3:5'UTR:MODIFIER:exon1/16:c.-80A>G:		rs2071403	0.6324	0.0000	0/0/0	0.5693							606765 [TPO (confirmed) Thyroid dyshormonogenesis 2A,274500];	RCV000326086.1 [likely benign]; 	CR146967 [CLASS=FP MUT=ALT PHEN="Decreased thyroid mRNA expression association with" GENE=TPO]; 		53	121					TPO (inh=AR pLI=0.00)
chr2	1460004	1460004	G	T	wt	wt	het	pred_pathogenic	QUAL=6081;DP=269,371,559;MQM=60	TPO	missense	TPO:NM_000547.5:missense:MODERATE:exon7/17:c.769G>T:p.Ala257Ser,TPO:NM_001206744.1:missense:MODERATE:exon7/17:c.769G>T:p.Ala257Ser,TPO:NM_001206745.1:missense:MODERATE:exon7/16:c.769G>T:p.Ala257Ser,TPO:NM_175719.3:missense:MODERATE:exon7/16:c.769G>T:p.Ala257Ser,TPO:NM_175721.3:missense:MODERATE:exon6/15:c.769G>T:p.Ala257Ser,TPO:NM_175722.3:missense:MODERATE:exon6/15:c.769G>T:p.Ala257Ser		rs4927611	0.3654	0.3791	8919/4546/703	0.3723	1.0550	D,T,D,T,T,T,T,T	T	B,B,B,B	T,T,T,T,T,T,T,T	6.63	606765 [TPO (confirmed) Thyroid dyshormonogenesis 2A,274500];	RCV000248792.1 [benign]; RCV000285484.1 [likely benign]; 			235	729					TPO (inh=AR pLI=0.00)
chr2	1481155	1481155	G	T	het	hom	wt	low_DP	QUAL=693;DP=10,22,21;MQM=60	TPO	missense,intron	TPO:NM_000547.5:missense:MODERATE:exon8/17:c.1117G>T:p.Ala373Ser,TPO:NM_001206744.1:missense:MODERATE:exon8/17:c.1117G>T:p.Ala373Ser,TPO:NM_001206745.1:missense:MODERATE:exon8/16:c.1117G>T:p.Ala373Ser,TPO:NM_175719.3:missense:MODERATE:exon8/16:c.1117G>T:p.Ala373Ser,TPO:NM_175721.3:missense:MODERATE:exon7/15:c.1117G>T:p.Ala373Ser,TPO:NM_175722.3:intron:MODIFIER:exon6/14:c.820-7213G>T:		rs2280132	0.4081	0.4578	1258/473/48	0.2461	0.1730	T,T,T,T,T,T,T	T	B,B,B	T,T,T,T,T,T	0.01	606765 [TPO (confirmed) Thyroid dyshormonogenesis 2A,274500];	RCV000250722.1 [benign]; RCV000407447.1 [likely benign]; 	CM146545 [CLASS=DFP MUT=ALT PHEN="Thyroid dyshormonogenesis" GENE=TPO]; 	COSM3749597, COSM3749598	325	749					TPO (inh=AR pLI=0.00)
chr2	1481231	1481231	G	C	hom	hom	wt	low_DP;pred_pathogenic	QUAL=287;DP=4,8,12;MQM=60	TPO	missense,intron	TPO:NM_000547.5:missense:MODERATE:exon8/17:c.1193G>C:p.Ser398Thr,TPO:NM_001206744.1:missense:MODERATE:exon8/17:c.1193G>C:p.Ser398Thr,TPO:NM_001206745.1:missense:MODERATE:exon8/16:c.1193G>C:p.Ser398Thr,TPO:NM_175719.3:missense:MODERATE:exon8/16:c.1193G>C:p.Ser398Thr,TPO:NM_175721.3:missense:MODERATE:exon7/15:c.1193G>C:p.Ser398Thr,TPO:NM_175722.3:intron:MODIFIER:exon6/14:c.820-7137G>C:		rs2175977	0.7103	0.6400	2234/500/70	0.2582	1.2970	T,T,T,T,T,T,T	T,T	.,D,D,D	.,T,T,T,T,T,T	23.50	606765 [TPO (confirmed) Thyroid dyshormonogenesis 2A,274500];	RCV000242879.1 [benign]; RCV000311144.1 [benign]; 		COSM1579950, COSM3749599	595	680					TPO (inh=AR pLI=0.00)
chr2	1497803	1497803	C	T	wt	wt	het		QUAL=1886;DP=125,166,216;MQM=60	TPO	synonymous	TPO:NM_000547.5:synonymous:LOW:exon11/17:c.1998C>T:p.Asp666Asp,TPO:NM_001206744.1:synonymous:LOW:exon11/17:c.1998C>T:p.Asp666Asp,TPO:NM_001206745.1:synonymous:LOW:exon10/16:c.1827C>T:p.Asp609Asp,TPO:NM_175719.3:synonymous:LOW:exon10/16:c.1827C>T:p.Asp609Asp,TPO:NM_175721.3:synonymous:LOW:exon10/15:c.1998C>T:p.Asp666Asp,TPO:NM_175722.3:synonymous:LOW:exon9/15:c.1479C>T:p.Asp493Asp		rs1126797	0.3590	0.3630	8017/4231/519	0.3584	-4.0380		T			10.64	606765 [TPO (confirmed) Thyroid dyshormonogenesis 2A,274500];	RCV000252817.1 [benign]; RCV000358553.1 [likely benign]; 		COSM3757660, COSM3757661	214	734					TPO (inh=AR pLI=0.00)
chr2	1499899	1499899	C	T	wt	wt	het	pred_pathogenic	QUAL=440;DP=111,115,113;MQM=60	TPO	synonymous	TPO:NM_000547.5:synonymous:LOW:exon12/17:c.2145C>T:p.Pro715Pro,TPO:NM_001206744.1:synonymous:LOW:exon12/17:c.2145C>T:p.Pro715Pro,TPO:NM_001206745.1:synonymous:LOW:exon11/16:c.1974C>T:p.Pro658Pro,TPO:NM_175719.3:synonymous:LOW:exon11/16:c.1974C>T:p.Pro658Pro,TPO:NM_175721.3:synonymous:LOW:exon11/15:c.2145C>T:p.Pro715Pro,TPO:NM_175722.3:synonymous:LOW:exon10/15:c.1626C>T:p.Pro542Pro		rs732608	0.4389	0.4109	10125/4744/946	0.4089	-1.5590	D	T		T	11.43	606765 [TPO (confirmed) Thyroid dyshormonogenesis 2A,274500];	RCV000246542.1 [benign]; RCV000269620.1 [likely benign]; 		COSM3757666, COSM1685440	255	756					TPO (inh=AR pLI=0.00)
chr2	1499927	1499927	A	C	wt	wt	het	pred_pathogenic	QUAL=259;DP=108,112,101;MQM=60	TPO	missense	TPO:NM_000547.5:missense:MODERATE:exon12/17:c.2173A>C:p.Thr725Pro,TPO:NM_001206744.1:missense:MODERATE:exon12/17:c.2173A>C:p.Thr725Pro,TPO:NM_001206745.1:missense:MODERATE:exon11/16:c.2002A>C:p.Thr668Pro,TPO:NM_175719.3:missense:MODERATE:exon11/16:c.2002A>C:p.Thr668Pro,TPO:NM_175721.3:missense:MODERATE:exon11/15:c.2173A>C:p.Thr725Pro,TPO:NM_175722.3:missense:MODERATE:exon10/15:c.1654A>C:p.Thr552Pro		rs732609	0.4984	0.4280	11232/4790/1896	0.4250	3.4710	T,T,T,T,T,T,T,T,T	T	B,B,B,B	T,T,T,T,T,T,T,T,T	0.09	606765 [TPO (confirmed) Thyroid dyshormonogenesis 2A,274500];	RCV000251285.1 [benign]; RCV000334090.1 [likely benign]; 	CM141568 [CLASS=DFP MUT=ALT PHEN="Hypothyroidism association with" GENE=TPO]; 	COSM3812428, COSM3812429	259	758					TPO (inh=AR pLI=0.00)
chr2	1520676	1520676	T	C	het	wt	hom		QUAL=10050;DP=244,219,228;MQM=59	TPO	missense	TPO:NM_000547.5:missense:MODERATE:exon15/17:c.2540T>C:p.Val847Ala,TPO:NM_001206744.1:missense:MODERATE:exon15/17:c.2540T>C:p.Val847Ala,TPO:NM_001206745.1:missense:MODERATE:exon14/16:c.2369T>C:p.Val790Ala,TPO:NM_175719.3:missense:MODERATE:exon14/16:c.2369T>C:p.Val790Ala,TPO:NM_175721.3:missense:MODERATE:exon13/15:c.2408T>C:p.Val803Ala,TPO:NM_175722.3:missense:MODERATE:exon13/15:c.2021T>C:p.Val674Ala		rs1126799	0.6639	0.5898	21459/9540/3194	0.5800	0.6090	T,T,T,T,T,T,T,T,T,T,.	T,.	B,B,B,B,.	T,T,T,T,T,T,T,T,T,T,.	0.02	606765 [TPO (confirmed) Thyroid dyshormonogenesis 2A,274500];	RCV000253477.1 [benign]; RCV000333699.1 [benign]; 		COSM3927753, COSM148793	447	766					TPO (inh=AR pLI=0.00)
chr2	1546327	1546327	C	G	het	hom	wt		QUAL=21208;DP=482,501,714;MQM=60	TPO	3'UTR	TPO:NM_000547.5:3'UTR:MODIFIER:exon17/17:c.*81C>G:,TPO:NM_001206744.1:3'UTR:MODIFIER:exon17/17:c.*81C>G:,TPO:NM_001206745.1:3'UTR:MODIFIER:exon16/16:c.*81C>G:,TPO:NM_175719.3:3'UTR:MODIFIER:exon16/16:c.*81C>G:,TPO:NM_175721.3:3'UTR:MODIFIER:exon15/15:c.*81C>G:,TPO:NM_175722.3:3'UTR:MODIFIER:exon15/15:c.*81C>G:		rs1042589	0.3526	0.4594	7417/4802/237	0.3892	-1.1970	T,.	T,T		T,.	0.57	606765 [TPO (confirmed) Thyroid dyshormonogenesis 2A,274500];	RCV000309201.1 [likely benign]; 		COSM4001255	224	506					TPO (inh=AR pLI=0.00)
chr2	11911761	11911761	C	T	het	hom	wt		QUAL=18152;DP=262,445,575;MQM=59	LPIN1	synonymous	LPIN1:NM_001261428.1:synonymous:LOW:exon5/22:c.699C>T:p.Ile233Ile,LPIN1:NM_001261429.1:synonymous:LOW:exon5/10:c.570C>T:p.Ile190Ile,LPIN1:NM_001261427.1:synonymous:LOW:exon5/21:c.570C>T:p.Ile190Ile,LPIN1:NM_145693.2:synonymous:LOW:exon4/20:c.552C>T:p.Ile184Ile		rs11538448	0.0507	0.1329	610/525/3	0.0957							605518 [LPIN1 (provisional) Myoglobinuria,acute recurrent,autosomal recessive,268200];	RCV000082649.5 [benign]; RCV000260825.1 [likely benign]; 			41	349					LPIN1 (inh=AR pLI=0.00)
chr2	11943082	11943082	C	T	wt	het	wt	pred_pathogenic	QUAL=6230;DP=343,427,468;MQM=60	LPIN1	missense	LPIN1:NM_001261428.1:missense:MODERATE:exon16/22:c.2083C>T:p.Pro695Ser,LPIN1:NM_001261427.1:missense:MODERATE:exon15/21:c.1846C>T:p.Pro616Ser,LPIN1:NM_145693.2:missense:MODERATE:exon14/20:c.1828C>T:p.Pro610Ser		rs4669781	0.0280	0.0455	155/91/0	0.0442	2.1550	T,T,T,T,T,T,T	T	B,B,B	T,T,T,T,T,T,T	13.27	605518 [LPIN1 (provisional) Myoglobinuria,acute recurrent,autosomal recessive,268200];	RCV000246076.1 [benign]; RCV000267070.1 [likely benign]; 		COSM1179789	2	151					LPIN1 (inh=AR pLI=0.00)
chr2	11965229	11965229	C	T	wt	wt	het		QUAL=2607;DP=164,175,229;MQM=60	LPIN1	3'UTR	LPIN1:NM_001261428.1:3'UTR:MODIFIER:exon22/22:c.*312C>T:,LPIN1:NM_001261427.1:3'UTR:MODIFIER:exon21/21:c.*312C>T:,LPIN1:NM_145693.2:3'UTR:MODIFIER:exon20/20:c.*312C>T:		rs555851933	0.0002	0.0000	0/0/0	0.0001							605518 [LPIN1 (provisional) Myoglobinuria,acute recurrent,autosomal recessive,268200];				0	1					LPIN1 (inh=AR pLI=0.00)
chr2	11965541	11965541	A	G	wt	het	het		QUAL=2865;DP=158,88,113;MQM=60	LPIN1	3'UTR	LPIN1:NM_001261428.1:3'UTR:MODIFIER:exon22/22:c.*624A>G:,LPIN1:NM_001261427.1:3'UTR:MODIFIER:exon21/21:c.*624A>G:,LPIN1:NM_145693.2:3'UTR:MODIFIER:exon20/20:c.*624A>G:		rs2716639	0.6949	0.0000	0/0/0	0.1235							605518 [LPIN1 (provisional) Myoglobinuria,acute recurrent,autosomal recessive,268200];	RCV000405105.1 [benign]; 			150	70					LPIN1 (inh=AR pLI=0.00)
chr2	11965814	11965814	C	T	wt	het	het		QUAL=4363;DP=307,149,177;MQM=60	LPIN1	3'UTR	LPIN1:NM_001261428.1:3'UTR:MODIFIER:exon22/22:c.*897C>T:,LPIN1:NM_001261427.1:3'UTR:MODIFIER:exon21/21:c.*897C>T:,LPIN1:NM_145693.2:3'UTR:MODIFIER:exon20/20:c.*897C>T:		rs1050800	0.1164	0.0000	0/0/0	0.0262							605518 [LPIN1 (provisional) Myoglobinuria,acute recurrent,autosomal recessive,268200];	RCV000396979.1 [likely benign]; 			6	74					LPIN1 (inh=AR pLI=0.00)
chr2	25383887	25383887	G	A	wt	het	wt		QUAL=1098;DP=113,94,134;MQM=60	POMC	3'UTR	POMC:NM_000939.3:3'UTR:MODIFIER:exon3/3:c.*63C>T:,POMC:NM_001035256.2:3'UTR:MODIFIER:exon4/4:c.*63C>T:,POMC:NM_001319204.1:3'UTR:MODIFIER:exon4/4:c.*63C>T:,POMC:NM_001319205.1:3'UTR:MODIFIER:exon3/3:c.*63C>T:		rs1042571	0.1156	0.0000	0/0/0	0.0297							176830 [POMC (confirmed) Obesity,adrenal insufficiency,and red hair due to POMC deficiency,609734|Obesity,early-onset,susceptibility to,601665];	RCV000272308.1 [likely benign]; RCV000329597.1 [likely benign]; 	CR035490 [CLASS=FP MUT=ALT PHEN="Decreased serum leptin levels in lean individuals" GENE=POMC]; 		35	188					POMC (inh=AR pLI=0.00)
chr2	26413917	26413917	C	T	hom	hom	hom		QUAL=37578;DP=558,258,360;MQM=59	HADHA	3'UTR	HADHA:NM_000182.4:3'UTR:MODIFIER:exon20/20:c.*202G>A:		rs7260	0.7875	0.0000	0/0/0	0.1366							600890 [HADHA (confirmed) LCHAD deficiency,609016|Trifunctional protein deficiency,609015|HELLP syndrome,maternal,of pregnancy,609016|Fatty liver,acute,of pregnancy,609016];	RCV000269209.1 [benign]; RCV000361491.1 [benign]; 			151	71					HADHA (inh=AR pLI=0.02)
chr2	26467666	26467666	G	A	hom	hom	hom		QUAL=5581;DP=44,61,98;MQM=60	HADHB	5'UTR	HADHB:NM_000183.2:5'UTR:MODIFIER:exon1/16:c.-201G>A:,HADHB:NM_001281512.1:5'UTR:MODIFIER:exon1/15:c.-201G>A:,HADHB:NM_001281513.1:5'UTR:MODIFIER:exon1/17:c.-350G>A:		rs3806516	0.4573	0.0000	0/0/0	0.5540							143450 [HADHB (confirmed) Trifunctional protein deficiency,609015];	RCV000336882.1 [benign]; RCV000395927.1 [benign]; 			112	95					HADHB (inh=AR pLI=0.00)
chr2	26477125	26477125	-	ACT	hom	hom	hom		QUAL=18752;DP=277,115,181;MQM=59	HADHB	disruptive_inframe_insertion,5'UTR	HADHB:NM_000183.2:disruptive_inframe_insertion:MODERATE:exon2/16:c.5_7dupCTA:p.Thr2dup,HADHB:NM_001281512.1:disruptive_inframe_insertion:MODERATE:exon2/15:c.5_7dupCTA:p.Thr2dup,HADHB:NM_001281513.1:5'UTR:MODIFIER:exon2/17:c.-145_-143dupCTA:		rs147970487	0.7095	0.8315	44610/29087/3978	0.7772							143450 [HADHB (confirmed) Trifunctional protein deficiency,609015];	RCV000078340.5 [benign]; RCV000144492.1 [not provided]; RCV000270663.1 [benign]; 			1291	229					HADHB (inh=AR pLI=0.00)
chr2	26512957	26512957	G	C	hom	hom	hom		QUAL=38065;DP=470,300,367;MQM=59	HADHB	3'UTR	HADHB:NM_000183.2:3'UTR:MODIFIER:exon16/16:c.*136G>C:,HADHB:NM_001281512.1:3'UTR:MODIFIER:exon15/15:c.*136G>C:,HADHB:NM_001281513.1:3'UTR:MODIFIER:exon17/17:c.*136G>C:		rs1056471	0.7111	0.0000	0/0/0	0.1581							143450 [HADHB (confirmed) Trifunctional protein deficiency,609015];	RCV000395328.1 [benign]; 			182	45					HADHB (inh=AR pLI=0.00)
chr2	27589810	27589810	T	C	het	wt	hom		QUAL=18564;DP=333,300,416;MQM=60	EIF2B4	splice_region&intron	EIF2B4:NM_001318965.1:splice_region&intron:LOW:exon9/11:c.1077-7A>G:,EIF2B4:NM_001318968.1:splice_region&intron:LOW:exon9/11:c.429-7A>G:,EIF2B4:NM_172195.3:splice_region&intron:LOW:exon9/11:c.1074-7A>G:,EIF2B4:NM_001318966.1:splice_region&intron:LOW:exon10/12:c.969-7A>G:,EIF2B4:NM_001034116.1:splice_region&intron:LOW:exon10/12:c.1014-7A>G:,EIF2B4:NM_001318967.1:splice_region&intron:LOW:exon10/12:c.921-7A>G:,EIF2B4:NM_001318969.1:splice_region&intron:LOW:exon10/12:c.396-7A>G:,EIF2B4:NM_015636.3:splice_region&intron:LOW:exon10/12:c.1011-7A>G:		rs2280737	0.3834	0.3986	10318/4965/1266	0.3789							606687 [EIF2B4 (provisional) Leukoencephaly with vanishing white matter,603896|Ovarioleukodystrophy,603896];	RCV000081778.5 [benign]; RCV000296534.1 [benign]; 			335	1228					EIF2B4 (inh=AR pLI=0.83)
chr2	27590666	27590666	C	T	wt	het	wt		QUAL=2523;DP=649,267,347;MQM=60	EIF2B4	synonymous	EIF2B4:NM_001318965.1:synonymous:LOW:exon7/12:c.792G>A:p.Pro264Pro,EIF2B4:NM_001318968.1:synonymous:LOW:exon7/12:c.144G>A:p.Pro48Pro,EIF2B4:NM_172195.3:synonymous:LOW:exon7/12:c.789G>A:p.Pro263Pro,EIF2B4:NM_001318966.1:synonymous:LOW:exon8/13:c.684G>A:p.Pro228Pro,EIF2B4:NM_001034116.1:synonymous:LOW:exon8/13:c.729G>A:p.Pro243Pro,EIF2B4:NM_001318967.1:synonymous:LOW:exon8/13:c.636G>A:p.Pro212Pro,EIF2B4:NM_001318969.1:synonymous:LOW:exon8/13:c.111G>A:p.Pro37Pro,EIF2B4:NM_015636.3:synonymous:LOW:exon8/13:c.726G>A:p.Pro242Pro		rs41288829	0.0100	0.0169	24/21/0	0.0171							606687 [EIF2B4 (provisional) Leukoencephaly with vanishing white matter,603896|Ovarioleukodystrophy,603896];	RCV000116971.3 [other]; 			3	136					EIF2B4 (inh=AR pLI=0.83)
chr2	31749714	31749714	C	T	het	wt	het		QUAL=7042;DP=266,228,259;MQM=60	SRD5A2	3'UTR	SRD5A2:NM_000348.3:3'UTR:MODIFIER:exon5/5:c.*1552G>A:	UCON44	rs1042578	0.1669	0.0000	0/0/0	0.1314							607306 [SRD5A2 (confirmed) Pseudovaginal perineoscrotal hypospadias,264600];	RCV000083670.1 [not provided]; RCV000392570.1 [benign]; 			8	64					SRD5A2 (inh=AR pLI=n/a)
chr2	31749910	31749910	T	G	het	wt	het		QUAL=11043;DP=521,217,275;MQM=59	SRD5A2	3'UTR	SRD5A2:NM_000348.3:3'UTR:MODIFIER:exon5/5:c.*1356A>C:	UCON44	rs28383087	0.0046	0.0000	0/0/0	0.0074							607306 [SRD5A2 (confirmed) Pseudovaginal perineoscrotal hypospadias,264600];	RCV000083669.1 [not provided]; RCV000297080.1 [uncertain significance]; 			0	5					SRD5A2 (inh=AR pLI=n/a)
chr2	31751223	31751223	C	T	het	wt	het		QUAL=5049;DP=262,95,113;MQM=60	SRD5A2	3'UTR	SRD5A2:NM_000348.3:3'UTR:MODIFIER:exon5/5:c.*43G>A:		rs28383082	0.0034	0.0073	1/1/0	0.0047							607306 [SRD5A2 (confirmed) Pseudovaginal perineoscrotal hypospadias,264600];				0	18					SRD5A2 (inh=AR pLI=n/a)
chr2	31805706	31805706	G	C	het	het	het		QUAL=10914;DP=124,309,411;MQM=59	SRD5A2	synonymous	SRD5A2:NM_000348.3:synonymous:LOW:exon1/5:c.264C>G:p.Ala88Ala		rs523349	0.6522	0.6999	17653/10654/1699	0.6070							607306 [SRD5A2 (confirmed) Pseudovaginal perineoscrotal hypospadias,264600];	RCV000083650.1 [not provided]; RCV000250955.1 [benign]; 			752	681					SRD5A2 (inh=AR pLI=n/a)
chr2	31805880	31805880	-	G	het	hom	hom	anno_high_impact	QUAL=13380;DP=60,179,254;MQM=59	SRD5A2	frameshift	SRD5A2:NM_000348.3:frameshift:HIGH:exon1/5:c.89dupC:p.Pro31fs		rs142200057	1.0000	1.0000	58283/31916/4520	0.9316							607306 [SRD5A2 (confirmed) Pseudovaginal perineoscrotal hypospadias,264600];				1582	32	1	[1] auto-classification 16.06.2016  21.04.2016 ahdoeha1: Artefakt ssHC			SRD5A2 (inh=AR pLI=n/a)
chr2	31806031	31806031	C	G	het	het	het		QUAL=1678;DP=33,45,51;MQM=59	SRD5A2	5'UTR	SRD5A2:NM_000348.3:5'UTR:MODIFIER:exon1/5:c.-62G>C:		rs632148	0.6404	0.0000	0/0/0	0.1124							607306 [SRD5A2 (confirmed) Pseudovaginal perineoscrotal hypospadias,264600];	RCV000083635.1 [not provided]; RCV000359892.1 [benign]; 			394	357					SRD5A2 (inh=AR pLI=n/a)
chr2	32381110	32381110	T	G	het	hom	het	low_DP	QUAL=375;DP=37,2,9;MQM=57	SPAST	3'UTR	SPAST:NM_014946.3:3'UTR:MODIFIER:exon17/17:c.*1545T>G:,SPAST:NM_199436.1:3'UTR:MODIFIER:exon16/16:c.*1545T>G:	AluSp	rs9789593	0.3379	0.0000	0/0/0	0.1642							604277 [SPAST (confirmed) Spastic paraplegia 4,autosomal dominant,182601];	RCV000365577.1 [benign]; 			11	110					SPAST (inh=AD pLI=1.00)
chr2	32381727	32381727	-	AGG	het	hom	het		QUAL=9988;DP=320,118,144;MQM=60	SPAST	3'UTR	SPAST:NM_014946.3:3'UTR:MODIFIER:exon17/17:c.*2164_*2165insGAG:,SPAST:NM_199436.1:3'UTR:MODIFIER:exon16/16:c.*2164_*2165insGAG:		rs141200833;rs3040810	0.9820	0.0000	0/0/0	0.9019							604277 [SPAST (confirmed) Spastic paraplegia 4,autosomal dominant,182601];	RCV000339636.1 [benign]; 			223	6					SPAST (inh=AD pLI=1.00)
chr2	32381829	32381829	G	A	het	het	het		QUAL=6327;DP=233,112,128;MQM=60	SPAST	3'UTR	SPAST:NM_014946.3:3'UTR:MODIFIER:exon17/17:c.*2264G>A:,SPAST:NM_199436.1:3'UTR:MODIFIER:exon16/16:c.*2264G>A:		rs3769602	0.4800	0.0000	0/0/0	0.0687							604277 [SPAST (confirmed) Spastic paraplegia 4,autosomal dominant,182601];	RCV000304584.1 [benign]; 			50	116					SPAST (inh=AD pLI=1.00)
chr2	39209047	39209047	A	G	hom	hom	hom		QUAL=20388;DP=282,143,191;MQM=59	SOS1	3'UTR	SOS1:NM_005633.3:3'UTR:MODIFIER:exon23/23:c.*3918T>C:		rs1043793	0.7476	0.0000	0/0/0	0.1466							182530 [SOS1 (confirmed) Fibromatosis,gingival,1,135300|Noonan syndrome 4,610733];	RCV000278864.1 [likely benign]; RCV000397761.1 [likely benign]; 			187	41					SOS1 (inh=AD pLI=1.00)
chr2	39209426	39209426	A	G	hom	hom	hom		QUAL=29135;DP=462,181,229;MQM=60	SOS1	3'UTR	SOS1:NM_005633.3:3'UTR:MODIFIER:exon23/23:c.*3539T>C:		rs1037495	0.7466	0.0000	0/0/0	0.1467							182530 [SOS1 (confirmed) Fibromatosis,gingival,1,135300|Noonan syndrome 4,610733];	RCV000264420.1 [likely benign]; RCV000319593.1 [likely benign]; 			187	40					SOS1 (inh=AD pLI=1.00)
chr2	39210398	39210398	A	T	hom	hom	hom		QUAL=30095;DP=336,255,321;MQM=60	SOS1	3'UTR	SOS1:NM_005633.3:3'UTR:MODIFIER:exon23/23:c.*2567T>A:		rs6704656	0.8996	0.0000	0/0/0	0.1557							182530 [SOS1 (confirmed) Fibromatosis,gingival,1,135300|Noonan syndrome 4,610733];	RCV000307023.1 [likely benign]; RCV000343245.1 [likely benign]; 			196	33					SOS1 (inh=AD pLI=1.00)
chr2	39210719	39210719	-	TA	hom	hom	hom		QUAL=21435;DP=344,139,176;MQM=59	SOS1	3'UTR	SOS1:NM_005633.3:3'UTR:MODIFIER:exon23/23:c.*2244_*2245dupTA:		rs35129186;rs397813136;rs55672510	0.7476	0.0000	0/0/0	0.7968							182530 [SOS1 (confirmed) Fibromatosis,gingival,1,135300|Noonan syndrome 4,610733];	RCV000193464.1 [likely benign]; RCV000260090.1 [likely benign]; RCV000334114.1 [likely benign]; 			185	43					SOS1 (inh=AD pLI=1.00)
chr2	39211121	39211121	T	C	hom	hom	hom		QUAL=32493;DP=443,238,290;MQM=59	SOS1	3'UTR	SOS1:NM_005633.3:3'UTR:MODIFIER:exon23/23:c.*1844A>G:		rs10166395	0.7622	0.0000	0/0/0	0.1476							182530 [SOS1 (confirmed) Fibromatosis,gingival,1,135300|Noonan syndrome 4,610733];	RCV000340008.1 [likely benign]; RCV000395187.1 [likely benign]; 			186	42					SOS1 (inh=AD pLI=1.00)
chr2	39211359	39211359	A	-	hom	hom	hom		QUAL=33377;DP=425,295,325;MQM=59	SOS1	3'UTR	SOS1:NM_005633.3:3'UTR:MODIFIER:exon23/23:c.*1606delT:		rs398080194	0.8976	0.0000	0/0/0	0.8462							182530 [SOS1 (confirmed) Fibromatosis,gingival,1,135300|Noonan syndrome 4,610733];	RCV000192447.1 [likely benign]; RCV000271859.1 [likely benign]; RCV000329110.1 [likely benign]; 			195	34					SOS1 (inh=AD pLI=1.00)
chr2	39212565	39212565	-	TG	hom	hom	hom		QUAL=11581;DP=155,99,126;MQM=59	SOS1	3'UTR	SOS1:NM_005633.3:3'UTR:MODIFIER:exon23/23:c.*399_*400insCA:		rs144104838;rs58580760	0.9026	0.0000	0/0/0	0.8140							182530 [SOS1 (confirmed) Fibromatosis,gingival,1,135300|Noonan syndrome 4,610733];	RCV000303815.1 [likely benign]; RCV000356097.1 [likely benign]; 			179	48					SOS1 (inh=AD pLI=1.00)
chr2	39212637	39212637	T	C	het	hom	wt		QUAL=11530;DP=498,145,178;MQM=59	SOS1	3'UTR	SOS1:NM_005633.3:3'UTR:MODIFIER:exon23/23:c.*328A>G:		rs1059310	0.5234	0.0000	0/0/0	0.1047							182530 [SOS1 (confirmed) Fibromatosis,gingival,1,135300|Noonan syndrome 4,610733];	RCV000263668.1 [likely benign]; RCV000297792.1 [likely benign]; 			88	118					SOS1 (inh=AD pLI=1.00)
chr2	39262348	39262348	C	G	het	wt	het		QUAL=3186;DP=161,93,109;MQM=60	SOS1	splice_region&intron	SOS1:NM_005633.3:splice_region&intron:LOW:exon8/22:c.1074+5G>C:		rs145155424	0.0028	0.0098	4/3/0	0.0075							182530 [SOS1 (confirmed) Fibromatosis,gingival,1,135300|Noonan syndrome 4,610733];	RCV000038508.8 [benign]; RCV000128195.4 [benign]; RCV000157008.2 [other]; RCV000224268.1 [likely benign]; RCV000296571.1 [likely benign]; 			0	23	2	[2] Stefanie Beck-Woedl 04.03.2015			SOS1 (inh=AD pLI=1.00)
chr2	44114074	44114074	G	A	hom	hom	hom		QUAL=16666;DP=212,131,188;MQM=59	LRPPRC	3'UTR	LRPPRC:NM_133259.3:3'UTR:MODIFIER:exon38/38:c.*1665C>T:	AluSz6	rs1139250	0.6006	0.0000	0/0/0	0.5634							607544 [LRPPRC (confirmed) Leigh syndrome,French-Canadian type,220111];	RCV000375009.1 [benign]; RCV000292352.1 [uncertain significance]; 			87	103					LRPPRC (inh=AR pLI=0.00)
chr2	44115183	44115183	T	A	het	wt	het		QUAL=2242;DP=116,40,56;MQM=60	LRPPRC	3'UTR	LRPPRC:NM_133259.3:3'UTR:MODIFIER:exon38/38:c.*556A>T:		rs1136998	0.0603	0.0000	0/0/0	0.0132							607544 [LRPPRC (confirmed) Leigh syndrome,French-Canadian type,220111];	RCV000301796.1 [likely benign]; 			2	45					LRPPRC (inh=AR pLI=0.00)
chr2	44209477	44209477	C	T	hom	het	hom		QUAL=8924;DP=167,60,82;MQM=60	LRPPRC	synonymous	LRPPRC:NM_133259.3:synonymous:LOW:exon2/38:c.246G>A:p.Gln82Gln		rs6741066	0.5040	0.6240	25833/17604/2539	0.6155							607544 [LRPPRC (confirmed) Leigh syndrome,French-Canadian type,220111];	RCV000117556.2 [likely benign]; RCV000311110.1 [benign]; 		COSM1408165	712	660					LRPPRC (inh=AR pLI=0.00)
chr2	44223131	44223131	C	T	wt	het	het	low_DP	QUAL=66;DP=167,7,7;MQM=60	LRPPRC	5'UTR	LRPPRC:NM_133259.3:5'UTR:MODIFIER:exon1/38:c.-45G>A:		rs11124961	0.0393	0.0930	52/15/0	0.0227							607544 [LRPPRC (confirmed) Leigh syndrome,French-Canadian type,220111];	RCV000349366.1 [benign]; 			7	148					LRPPRC (inh=AR pLI=0.00)
chr2	45171842	45171842	A	G	hom	hom	hom		QUAL=10931;DP=44,130,185;MQM=59	SIX3	synonymous	SIX3:NM_005413.3:synonymous:LOW:exon2/2:c.942A>G:p.Ala314Ala		rs338074	0.9375	0.9215	39340/21492/3257	0.8440							603714 [SIX3 (confirmed) Holoprosencephaly 2,157170|Schizencephaly,269160];	RCV000153953.5 [benign]; 			1313	234					SIX3 (inh=AD pLI=0.35)
chr2	45172447	45172447	G	T	het	wt	wt	low_MQM	QUAL=32;DP=71,22,36;MQM=48	SIX3	3'UTR	SIX3:NM_005413.3:3'UTR:MODIFIER:exon2/2:c.*548G>T:			0.0000	0.0000	0/0/0	0.0002							603714 [SIX3 (confirmed) Holoprosencephaly 2,157170|Schizencephaly,269160];				0	5					SIX3 (inh=AD pLI=0.35)
chr2	45172485	45172485	G	A	het	het	het	low_DP	QUAL=595;DP=56,4,9;MQM=53	SIX3	3'UTR	SIX3:NM_005413.3:3'UTR:MODIFIER:exon2/2:c.*586G>A:	A-rich	rs60528008	0.0000	0.0000	0/0/0	0.0209							603714 [SIX3 (confirmed) Holoprosencephaly 2,157170|Schizencephaly,269160];				5	97					SIX3 (inh=AD pLI=0.35)
chr2	45172557	45172557	T	-	het	het	het	low_DP	QUAL=2095;DP=123,18,26;MQM=59	SIX3	3'UTR	SIX3:NM_005413.3:3'UTR:MODIFIER:exon2/2:c.*666delT:	(CT)n	rs61475963;rs796089108	0.4643	0.0000	0/0/0	0.2521							603714 [SIX3 (confirmed) Holoprosencephaly 2,157170|Schizencephaly,269160];				17	88					SIX3 (inh=AD pLI=0.35)
chr2	45172925	45172925	G	A	het	het	het		QUAL=8928;DP=294,172,246;MQM=60	SIX3	3'UTR	SIX3:NM_005413.3:3'UTR:MODIFIER:exon2/2:c.*1026G>A:	(TC)n	rs13022334	0.2384	0.0000	0/0/0	0.0394							603714 [SIX3 (confirmed) Holoprosencephaly 2,157170|Schizencephaly,269160];				11	82					SIX3 (inh=AD pLI=0.35)
chr2	46583281	46583281	C	T	het	hom	wt		QUAL=9404;DP=191,246,201;MQM=59	EPAS1	splice_region&intron	EPAS1:NM_001430.4:splice_region&intron:LOW:exon2/15:c.218-9C>T:		rs75984373	0.0663	0.4037	9868/3862/1591	0.3073							603349 [EPAS1 (confirmed) Erythrocytosis,familial,4,611783];	RCV000298342.1 [benign]; 			288	429					EPAS1 (inh=AD pLI=1.00)
chr2	46603671	46603671	C	G	het	wt	hom	low_DP	QUAL=1014;DP=23,15,26;MQM=60	EPAS1	splice_region&intron	EPAS1:NM_001430.4:splice_region&intron:LOW:exon8/15:c.1035-7C>G:		rs7557402	0.3125	0.4104	11112/8162/371	0.3905							603349 [EPAS1 (confirmed) Erythrocytosis,familial,4,611783];	RCV000329925.1 [benign]; 		COSM4001689	372	773					EPAS1 (inh=AD pLI=1.00)
chr2	46612327	46612328	TT	-	het	wt	hom		QUAL=2523;DP=137,42,53;MQM=59	EPAS1	3'UTR	EPAS1:NM_001430.4:3'UTR:MODIFIER:exon16/16:c.*539_*540delTT:		rs397984477;rs759043045	0.8858	0.0000	0/0/0	0.5399							603349 [EPAS1 (confirmed) Erythrocytosis,familial,4,611783];	RCV000353138.1 [benign]; 			140	81					EPAS1 (inh=AD pLI=1.00)
chr2	46613038	46613038	A	G	het	wt	het		QUAL=10385;DP=337,345,476;MQM=60	EPAS1	3'UTR	EPAS1:NM_001430.4:3'UTR:MODIFIER:exon16/16:c.*1239A>G:		rs11539645	0.0172	0.0000	0/0/0	0.0077							603349 [EPAS1 (confirmed) Erythrocytosis,familial,4,611783];	RCV000298454.1 [likely benign]; 			3	26					EPAS1 (inh=AD pLI=1.00)
chr2	48914615	48914615	C	G	het	het	wt		QUAL=3431;DP=214,50,85;MQM=60	LHCGR,STON1-GTF2A1L	3'UTR,intron	LHCGR:NM_000233.3:3'UTR:MODIFIER:exon11/11:c.*221G>C:,STON1-GTF2A1L:NM_001198593.1:intron:MODIFIER:exon10/10:c.3441+15796C>G:	MER5C	rs62137532	0.1627	0.0000	0/0/0	0.1851							152790 [LHCGR (provisional) Precocious puberty,male,176410|Leydig cell hypoplasia with pseudohermaphroditism,238320|Leydig cell hypoplasia with hypergonadotropic hypogonadism,238320|Luteinizing hormone resistance,female,238320|Leydig cell adenoma,somatic,with precocious puberty,176410];	RCV000269092.1 [benign]; RCV000324261.1 [benign]; RCV000363622.1 [benign]; 			8	56					LHCGR (inh=AR pLI=0.00), STON1-GTF2A1L (inh=n/a pLI=0.00)
chr2	48915871	48915871	A	G	wt	wt	het		QUAL=5676;DP=355,294,440;MQM=60	LHCGR,STON1-GTF2A1L	synonymous,intron	LHCGR:NM_000233.3:synonymous:LOW:exon11/11:c.1065T>C:p.Asp355Asp,STON1-GTF2A1L:NM_001198593.1:intron:MODIFIER:exon10/10:c.3441+17052A>G:		rs11125179	0.5923	0.6026	23150/11598/489	0.6009							152790 [LHCGR (provisional) Precocious puberty,male,176410|Leydig cell hypoplasia with pseudohermaphroditism,238320|Leydig cell hypoplasia with hypergonadotropic hypogonadism,238320|Luteinizing hormone resistance,female,238320|Leydig cell adenoma,somatic,with precocious puberty,176410];	RCV000249750.1 [benign]; RCV000260201.1 [benign]; RCV000334166.1 [benign]; RCV000388700.1 [benign]; 			590	728					LHCGR (inh=AR pLI=0.00), STON1-GTF2A1L (inh=n/a pLI=0.00)
chr2	48921375	48921375	T	C	wt	wt	het		QUAL=1342;DP=238,109,127;MQM=60	LHCGR,STON1-GTF2A1L	missense,intron	LHCGR:NM_000233.3:missense:MODERATE:exon10/11:c.935A>G:p.Asn312Ser,STON1-GTF2A1L:NM_001198593.1:intron:MODIFIER:exon10/10:c.3441+22556T>C:		rs2293275	0.5911	0.6376	19594/9485/409	0.5912	1.1850	T,T,T,T	T	B	T,T,T,T	0.01	152790 [LHCGR (provisional) Precocious puberty,male,176410|Leydig cell hypoplasia with pseudohermaphroditism,238320|Leydig cell hypoplasia with hypergonadotropic hypogonadism,238320|Luteinizing hormone resistance,female,238320|Leydig cell adenoma,somatic,with precocious puberty,176410];	RCV000247916.1 [benign]; RCV000290924.1 [benign]; RCV000345770.1 [benign]; RCV000399694.1 [benign]; 	CM125685 [CLASS=DP MUT=REF PHEN="Polycystic ovary syndrome increased risk" GENE=LHCGR]; 	COSM3766585	592	729					LHCGR (inh=AR pLI=0.00), STON1-GTF2A1L (inh=n/a pLI=0.00)
chr2	48925746	48925746	C	T	het	hom	het		QUAL=8067;DP=103,121,218;MQM=60	LHCGR,STON1-GTF2A1L	splice_region&intron,intron	LHCGR:NM_000233.3:splice_region&intron:LOW:exon9/10:c.866+8G>A:,STON1-GTF2A1L:NM_001198593.1:intron:MODIFIER:exon10/10:c.3441+26927C>T:		rs6755901	0.7374	0.7657	36619/22916/3879	0.7622							152790 [LHCGR (provisional) Precocious puberty,male,176410|Leydig cell hypoplasia with pseudohermaphroditism,238320|Leydig cell hypoplasia with hypergonadotropic hypogonadism,238320|Luteinizing hormone resistance,female,238320|Leydig cell adenoma,somatic,with precocious puberty,176410];	RCV000243145.1 [benign]; RCV000262221.1 [benign]; RCV000302553.1 [benign]; RCV000357135.1 [benign]; 		COSM4001691	1079	452					LHCGR (inh=AR pLI=0.00), STON1-GTF2A1L (inh=n/a pLI=0.00)
chr2	58388696	58388696	A	G	het	het	het		QUAL=10427;DP=317,198,260;MQM=60	FANCL	synonymous,sequence_feature	FANCL:NM_001114636.1:synonymous:LOW:exon12/14:c.996T>C:p.Ser332Ser,FANCL:NM_018062.3:synonymous:LOW:exon12/14:c.981T>C:p.Ser327Ser,FANCL:NM_001114636.1:sequence_feature:LOW:exon12/14:c.996T>C:,FANCL:NM_018062.3:sequence_feature:LOW:exon12/14:c.981T>C:		rs848291	0.7065	0.6487	25916/12325/4274	0.6371							608111 [FANCL (provisional) Fanconi anemia,complementation group L,614083];	RCV000253562.1 [benign]; RCV000282580.1 [benign]; 		COSM4001713	747	1047					FANCL (inh=AR pLI=0.00)
chr2	61276263	61276263	G	A	hom	hom	hom		QUAL=13372;DP=233,72,106;MQM=60	PEX13	3'UTR	PEX13:NM_002618.3:3'UTR:MODIFIER:exon4/4:c.*358G>A:		rs1177230	0.9952	0.0000	0/0/0	0.9019							601789 [PEX13 (provisional) Peroxisome biogenesis disorder 11A (Zellweger),614883|Peroxisome biogenesis disorder 11B,614885];	RCV000399354.1 [benign]; 			225	5					PEX13 (inh=AR pLI=0.02)
chr2	61276857	61276857	C	T	het	het	wt		QUAL=1394;DP=58,62,51;MQM=59	PEX13	3'UTR	PEX13:NM_002618.3:3'UTR:MODIFIER:exon4/4:c.*952C>T:	AluSp	rs56739127	0.3039	0.0000	0/0/0	0.2822							601789 [PEX13 (provisional) Peroxisome biogenesis disorder 11A (Zellweger),614883|Peroxisome biogenesis disorder 11B,614885];	RCV000385469.1 [benign]; 			24	103					PEX13 (inh=AR pLI=0.02)
chr2	61277099	61277099	G	A	het	het	wt		QUAL=1907;DP=121,46,81;MQM=59	PEX13	3'UTR	PEX13:NM_002618.3:3'UTR:MODIFIER:exon4/4:c.*1194G>A:		rs75205376	0.0763	0.0000	0/0/0	0.1399							601789 [PEX13 (provisional) Peroxisome biogenesis disorder 11A (Zellweger),614883|Peroxisome biogenesis disorder 11B,614885];	RCV000317941.1 [likely benign]; 			8	82					PEX13 (inh=AR pLI=0.02)
chr2	61278052	61278052	A	G	hom	het	hom		QUAL=5954;DP=98,71,63;MQM=59	PEX13	3'UTR	PEX13:NM_002618.3:3'UTR:MODIFIER:exon4/4:c.*2147A>G:	AluY	rs2564097	0.6160	0.0000	0/0/0	0.5281							601789 [PEX13 (provisional) Peroxisome biogenesis disorder 11A (Zellweger),614883|Peroxisome biogenesis disorder 11B,614885];	RCV000368512.1 [benign]; 			90	109					PEX13 (inh=AR pLI=0.02)
chr2	69547236	69547236	G	C	het	wt	het		QUAL=7606;DP=235,226,325;MQM=55	GFPT1	3'UTR	GFPT1:NM_001244710.1:3'UTR:MODIFIER:exon20/20:c.*6085C>G:,GFPT1:NM_002056.3:3'UTR:MODIFIER:exon19/19:c.*6085C>G:		rs7642	0.6554	0.0000	0/0/0	0.5861							138292 [GFPT1 (confirmed) Myasthenia,congenital,12,with tubular aggregates,610542];	RCV000403310.1 [benign]; 			81	101					GFPT1 (inh=AR pLI=0.97)
chr2	69548320	69548320	C	T	het	wt	het		QUAL=7096;DP=374,111,152;MQM=59	GFPT1	3'UTR	GFPT1:NM_001244710.1:3'UTR:MODIFIER:exon20/20:c.*5001G>A:,GFPT1:NM_002056.3:3'UTR:MODIFIER:exon19/19:c.*5001G>A:		rs13396883	0.6587	0.0000	0/0/0	0.5884							138292 [GFPT1 (confirmed) Myasthenia,congenital,12,with tubular aggregates,610542];	RCV000318156.1 [benign]; 			82	100					GFPT1 (inh=AR pLI=0.97)
chr2	69548591	69548591	C	T	het	wt	het		QUAL=6701;DP=313,112,132;MQM=60	GFPT1	3'UTR	GFPT1:NM_001244710.1:3'UTR:MODIFIER:exon20/20:c.*4730G>A:,GFPT1:NM_002056.3:3'UTR:MODIFIER:exon19/19:c.*4730G>A:		rs28694003	0.6386	0.0000	0/0/0	0.5815							138292 [GFPT1 (confirmed) Myasthenia,congenital,12,with tubular aggregates,610542];	RCV000379130.1 [benign]; 			81	101					GFPT1 (inh=AR pLI=0.97)
chr2	69549262	69549262	T	C	het	wt	het		QUAL=5380;DP=252,107,144;MQM=60	GFPT1	3'UTR	GFPT1:NM_001244710.1:3'UTR:MODIFIER:exon20/20:c.*4059A>G:,GFPT1:NM_002056.3:3'UTR:MODIFIER:exon19/19:c.*4059A>G:		rs13751	0.6476	0.0000	0/0/0	0.5836							138292 [GFPT1 (confirmed) Myasthenia,congenital,12,with tubular aggregates,610542];	RCV000396983.1 [benign]; 			80	102					GFPT1 (inh=AR pLI=0.97)
chr2	69550036	69550036	T	C	het	wt	het		QUAL=15066;DP=572,409,530;MQM=59	GFPT1	3'UTR	GFPT1:NM_001244710.1:3'UTR:MODIFIER:exon20/20:c.*3285A>G:,GFPT1:NM_002056.3:3'UTR:MODIFIER:exon19/19:c.*3285A>G:		rs7579532	0.6587	0.0000	0/0/0	0.5878							138292 [GFPT1 (confirmed) Myasthenia,congenital,12,with tubular aggregates,610542];	RCV000376118.1 [benign]; 			83	99					GFPT1 (inh=AR pLI=0.97)
chr2	69550230	69550230	T	G	het	wt	het		QUAL=7740;DP=293,141,209;MQM=59	GFPT1	3'UTR	GFPT1:NM_001244710.1:3'UTR:MODIFIER:exon20/20:c.*3091A>C:,GFPT1:NM_002056.3:3'UTR:MODIFIER:exon19/19:c.*3091A>C:		rs7582334	0.6476	0.0000	0/0/0	0.5834							138292 [GFPT1 (confirmed) Myasthenia,congenital,12,with tubular aggregates,610542];	RCV000327454.1 [uncertain significance]; RCV000384360.1 [benign]; 			81	101					GFPT1 (inh=AR pLI=0.97)
chr2	69550256	69550256	C	T	het	wt	het		QUAL=8184;DP=302,121,201;MQM=60	GFPT1	3'UTR	GFPT1:NM_001244710.1:3'UTR:MODIFIER:exon20/20:c.*3065G>A:,GFPT1:NM_002056.3:3'UTR:MODIFIER:exon19/19:c.*3065G>A:		rs7568296	0.6635	0.0000	0/0/0	0.5869							138292 [GFPT1 (confirmed) Myasthenia,congenital,12,with tubular aggregates,610542];	RCV000345588.1 [benign]; 			82	100					GFPT1 (inh=AR pLI=0.97)
chr2	69550652	69550652	G	A	het	wt	het		QUAL=7252;DP=313,173,263;MQM=59	GFPT1	3'UTR	GFPT1:NM_001244710.1:3'UTR:MODIFIER:exon20/20:c.*2669C>T:,GFPT1:NM_002056.3:3'UTR:MODIFIER:exon19/19:c.*2669C>T:	AluJb	rs10185336	0.6384	0.0000	0/0/0	0.5447							138292 [GFPT1 (confirmed) Myasthenia,congenital,12,with tubular aggregates,610542];	RCV000357113.1 [benign]; 			81	101					GFPT1 (inh=AR pLI=0.97)
chr2	69550811	69550811	T	-	het	wt	wt	low_DP	QUAL=141;DP=110,15,17;MQM=58	GFPT1	3'UTR	GFPT1:NM_001244710.1:3'UTR:MODIFIER:exon20/20:c.*2510delA:,GFPT1:NM_002056.3:3'UTR:MODIFIER:exon19/19:c.*2510delA:	AluJb:AluSc	rs370178312	0.0000	0.0000	0/0/0	0.0070							138292 [GFPT1 (confirmed) Myasthenia,congenital,12,with tubular aggregates,610542];	RCV000395185.1 [uncertain significance]; 			6	64					GFPT1 (inh=AR pLI=0.97)
chr2	69551011	69551011	T	C	het	wt	het	low_DP;low_MQM	QUAL=396;DP=36,3,5;MQM=45	GFPT1	3'UTR	GFPT1:NM_001244710.1:3'UTR:MODIFIER:exon20/20:c.*2310A>G:,GFPT1:NM_002056.3:3'UTR:MODIFIER:exon19/19:c.*2310A>G:	AluSc	rs10198150	0.6384	0.0000	0/0/0	0.5451							138292 [GFPT1 (confirmed) Myasthenia,congenital,12,with tubular aggregates,610542];	RCV000294511.1 [benign]; 			74	62					GFPT1 (inh=AR pLI=0.97)
chr2	69551052	69551052	T	C	het	wt	het	low_DP	QUAL=717;DP=55,2,8;MQM=50	GFPT1	3'UTR	GFPT1:NM_001244710.1:3'UTR:MODIFIER:exon20/20:c.*2269A>G:,GFPT1:NM_002056.3:3'UTR:MODIFIER:exon19/19:c.*2269A>G:	AluSc	rs10198171	0.6494	0.0000	0/0/0	0.5567							138292 [GFPT1 (confirmed) Myasthenia,congenital,12,with tubular aggregates,610542];	RCV000333128.1 [benign]; 			77	74					GFPT1 (inh=AR pLI=0.97)
chr2	69552521	69552521	C	A	het	wt	het		QUAL=9111;DP=470,183,292;MQM=60	GFPT1	3'UTR	GFPT1:NM_001244710.1:3'UTR:MODIFIER:exon20/20:c.*800G>T:,GFPT1:NM_002056.3:3'UTR:MODIFIER:exon19/19:c.*800G>T:		rs2667	0.6382	0.0000	0/0/0	0.1131							138292 [GFPT1 (confirmed) Myasthenia,congenital,12,with tubular aggregates,610542];	RCV000260888.1 [benign]; 			81	101					GFPT1 (inh=AR pLI=0.97)
chr2	69553376	69553376	A	-	het	wt	het		QUAL=860;DP=93,58,83;MQM=59	GFPT1	splice_region&intron	GFPT1:NM_001244710.1:splice_region&intron:LOW:exon19/19:c.2056-11delT:,GFPT1:NM_002056.3:splice_region&intron:LOW:exon18/18:c.2002-11delT:	(A)n	rs201330278;rs879120371	0.0000	0.5003	4291/2540/705	0.0447							138292 [GFPT1 (confirmed) Myasthenia,congenital,12,with tubular aggregates,610542];	RCV000276530.1 [uncertain significance]; 			333	735					GFPT1 (inh=AR pLI=0.97)
chr2	69573029	69573029	T	C	het	wt	het		QUAL=4686;DP=184,129,178;MQM=60	GFPT1	splice_region&intron	GFPT1:NM_001244710.1:splice_region&intron:LOW:exon12/19:c.1105+7A>G:,GFPT1:NM_002056.3:splice_region&intron:LOW:exon11/18:c.1051+7A>G:		rs6722492	0.6472	0.5961	22189/11621/3832	0.5887							138292 [GFPT1 (confirmed) Myasthenia,congenital,12,with tubular aggregates,610542];	RCV000117140.3 [benign]; RCV000324739.1 [benign]; 			582	721					GFPT1 (inh=AR pLI=0.97)
chr2	71680950	71680950	C	A	het	het	wt		QUAL=2042;DP=79,107,127;MQM=59	DYSF	5'UTR	DYSF:NM_001130976.1:5'UTR:MODIFIER:exon1/54:c.-179C>A:,DYSF:NM_001130977.1:5'UTR:MODIFIER:exon1/55:c.-179C>A:,DYSF:NM_001130978.1:5'UTR:MODIFIER:exon1/56:c.-179C>A:,DYSF:NM_001130979.1:5'UTR:MODIFIER:exon1/56:c.-179C>A:,DYSF:NM_001130980.1:5'UTR:MODIFIER:exon1/55:c.-179C>A:,DYSF:NM_001130981.1:5'UTR:MODIFIER:exon1/56:c.-179C>A:,DYSF:NM_003494.3:5'UTR:MODIFIER:exon1/55:c.-179C>A:		rs6741336	0.2049	0.0000	0/0/0	0.0251							603009 [DYSF (confirmed) Muscular dystrophy,limb-girdle,type 2B,253601|Myopathy,distal,with anterior tibial onset,606768|Miyoshi muscular dystrophy 1,254130];				2	41					DYSF (inh=AR pLI=0.00)
chr2	71738987	71738987	C	T	wt	wt	het		QUAL=1612;DP=68,64,109;MQM=60	DYSF	synonymous	DYSF:NM_001130987.1:synonymous:LOW:exon5/56:c.396C>T:p.Pro132Pro,DYSF:NM_001130976.1:synonymous:LOW:exon5/54:c.393C>T:p.Pro131Pro,DYSF:NM_001130977.1:synonymous:LOW:exon5/55:c.393C>T:p.Pro131Pro,DYSF:NM_001130978.1:synonymous:LOW:exon5/56:c.393C>T:p.Pro131Pro,DYSF:NM_001130979.1:synonymous:LOW:exon5/56:c.393C>T:p.Pro131Pro,DYSF:NM_001130980.1:synonymous:LOW:exon5/55:c.393C>T:p.Pro131Pro,DYSF:NM_001130981.1:synonymous:LOW:exon5/56:c.393C>T:p.Pro131Pro,DYSF:NM_003494.3:synonymous:LOW:exon5/55:c.393C>T:p.Pro131Pro,DYSF:NM_001130455.1:synonymous:LOW:exon5/55:c.396C>T:p.Pro132Pro,DYSF:NM_001130982.1:synonymous:LOW:exon5/56:c.396C>T:p.Pro132Pro,DYSF:NM_001130983.1:synonymous:LOW:exon5/56:c.396C>T:p.Pro132Pro,DYSF:NM_001130984.1:synonymous:LOW:exon5/55:c.396C>T:p.Pro132Pro,DYSF:NM_001130985.1:synonymous:LOW:exon5/55:c.396C>T:p.Pro132Pro,DYSF:NM_001130986.1:synonymous:LOW:exon5/54:c.396C>T:p.Pro132Pro		rs34603128	0.1122	0.1015	149/62/63	0.0415							603009 [DYSF (confirmed) Muscular dystrophy,limb-girdle,type 2B,253601|Myopathy,distal,with anterior tibial onset,606768|Miyoshi muscular dystrophy 1,254130];	RCV000080278.9 [other]; RCV000309578.1 [likely benign]; RCV000366553.1 [likely benign]; 			13	357					DYSF (inh=AR pLI=0.00)
chr2	71740958	71740958	T	C	wt	wt	het		QUAL=3128;DP=188,223,313;MQM=60	DYSF	synonymous	DYSF:NM_001130987.1:synonymous:LOW:exon7/56:c.666T>C:p.Pro222Pro,DYSF:NM_001130976.1:synonymous:LOW:exon6/54:c.570T>C:p.Pro190Pro,DYSF:NM_001130977.1:synonymous:LOW:exon6/55:c.570T>C:p.Pro190Pro,DYSF:NM_001130978.1:synonymous:LOW:exon6/56:c.570T>C:p.Pro190Pro,DYSF:NM_001130979.1:synonymous:LOW:exon7/56:c.663T>C:p.Pro221Pro,DYSF:NM_001130980.1:synonymous:LOW:exon7/55:c.663T>C:p.Pro221Pro,DYSF:NM_001130981.1:synonymous:LOW:exon7/56:c.663T>C:p.Pro221Pro,DYSF:NM_003494.3:synonymous:LOW:exon6/55:c.570T>C:p.Pro190Pro,DYSF:NM_001130455.1:synonymous:LOW:exon6/55:c.573T>C:p.Pro191Pro,DYSF:NM_001130982.1:synonymous:LOW:exon7/56:c.666T>C:p.Pro222Pro,DYSF:NM_001130983.1:synonymous:LOW:exon6/56:c.573T>C:p.Pro191Pro,DYSF:NM_001130984.1:synonymous:LOW:exon6/55:c.573T>C:p.Pro191Pro,DYSF:NM_001130985.1:synonymous:LOW:exon7/55:c.666T>C:p.Pro222Pro,DYSF:NM_001130986.1:synonymous:LOW:exon6/54:c.573T>C:p.Pro191Pro		rs35392229	0.0178	0.0322	91/62/0	0.0315							603009 [DYSF (confirmed) Muscular dystrophy,limb-girdle,type 2B,253601|Myopathy,distal,with anterior tibial onset,606768|Miyoshi muscular dystrophy 1,254130];	RCV000080311.8 [other]; RCV000281402.1 [likely benign]; RCV000320140.1 [likely benign]; 			3	109					DYSF (inh=AR pLI=0.00)
chr2	71743376	71743376	T	C	wt	wt	het	anno_pathogenic_hgmd	QUAL=4287;DP=272,260,305;MQM=60	DYSF	splice_region&intron	DYSF:NM_001130987.1:splice_region&intron:LOW:exon9/55:c.951+4T>C:,DYSF:NM_001130976.1:splice_region&intron:LOW:exon8/53:c.855+4T>C:,DYSF:NM_001130977.1:splice_region&intron:LOW:exon8/54:c.855+4T>C:,DYSF:NM_001130978.1:splice_region&intron:LOW:exon8/55:c.855+4T>C:,DYSF:NM_001130979.1:splice_region&intron:LOW:exon9/55:c.948+4T>C:,DYSF:NM_001130980.1:splice_region&intron:LOW:exon9/54:c.948+4T>C:,DYSF:NM_001130981.1:splice_region&intron:LOW:exon9/55:c.948+4T>C:,DYSF:NM_003494.3:splice_region&intron:LOW:exon8/54:c.855+4T>C:,DYSF:NM_001130455.1:splice_region&intron:LOW:exon8/54:c.858+4T>C:,DYSF:NM_001130982.1:splice_region&intron:LOW:exon9/55:c.951+4T>C:,DYSF:NM_001130983.1:splice_region&intron:LOW:exon8/55:c.858+4T>C:,DYSF:NM_001130984.1:splice_region&intron:LOW:exon8/54:c.858+4T>C:,DYSF:NM_001130985.1:splice_region&intron:LOW:exon9/54:c.951+4T>C:,DYSF:NM_001130986.1:splice_region&intron:LOW:exon8/53:c.858+4T>C:		rs11903960	0.0775	0.0788	434/267/78	0.0783							603009 [DYSF (confirmed) Muscular dystrophy,limb-girdle,type 2B,253601|Myopathy,distal,with anterior tibial onset,606768|Miyoshi muscular dystrophy 1,254130];	RCV000080332.9 [other]; RCV000367595.1 [likely benign]; RCV000405200.1 [likely benign]; 	CS161458 [CLASS=DM MUT=ALT PHEN="Dysferlinopathy" GENE=DYSF]; 		8	203					DYSF (inh=AR pLI=0.00)
chr2	71780215	71780215	T	C	het	hom	het		QUAL=21671;DP=298,372,545;MQM=60	DYSF	synonymous	DYSF:NM_001130987.1:synonymous:LOW:exon20/56:c.1881T>C:p.Asp627Asp,DYSF:NM_001130976.1:synonymous:LOW:exon19/54:c.1785T>C:p.Asp595Asp,DYSF:NM_001130977.1:synonymous:LOW:exon19/55:c.1785T>C:p.Asp595Asp,DYSF:NM_001130978.1:synonymous:LOW:exon20/56:c.1827T>C:p.Asp609Asp,DYSF:NM_001130979.1:synonymous:LOW:exon21/56:c.1920T>C:p.Asp640Asp,DYSF:NM_001130980.1:synonymous:LOW:exon20/55:c.1878T>C:p.Asp626Asp,DYSF:NM_001130981.1:synonymous:LOW:exon20/56:c.1878T>C:p.Asp626Asp,DYSF:NM_003494.3:synonymous:LOW:exon20/55:c.1827T>C:p.Asp609Asp,DYSF:NM_001130455.1:synonymous:LOW:exon20/55:c.1830T>C:p.Asp610Asp,DYSF:NM_001130982.1:synonymous:LOW:exon21/56:c.1923T>C:p.Asp641Asp,DYSF:NM_001130983.1:synonymous:LOW:exon20/56:c.1830T>C:p.Asp610Asp,DYSF:NM_001130984.1:synonymous:LOW:exon19/55:c.1788T>C:p.Asp596Asp,DYSF:NM_001130985.1:synonymous:LOW:exon20/55:c.1881T>C:p.Asp627Asp,DYSF:NM_001130986.1:synonymous:LOW:exon19/54:c.1788T>C:p.Asp596Asp		rs2303596	0.5755	0.6430	26416/16845/3200	0.6379							603009 [DYSF (confirmed) Muscular dystrophy,limb-girdle,type 2B,253601|Myopathy,distal,with anterior tibial onset,606768|Miyoshi muscular dystrophy 1,254130];	RCV000080244.9 [other]; RCV000302229.1 [benign]; RCV000357010.1 [benign]; 		COSM4001738, COSM4001739	735	676					DYSF (inh=AR pLI=0.00)
chr2	71795152	71795152	A	T	het	hom	het		QUAL=1121;DP=34,21,33;MQM=60	DYSF	synonymous	DYSF:NM_001130987.1:synonymous:LOW:exon25/56:c.2637A>T:p.Ser879Ser,DYSF:NM_001130976.1:synonymous:LOW:exon24/54:c.2541A>T:p.Ser847Ser,DYSF:NM_001130977.1:synonymous:LOW:exon24/55:c.2541A>T:p.Ser847Ser,DYSF:NM_001130978.1:synonymous:LOW:exon25/56:c.2583A>T:p.Ser861Ser,DYSF:NM_001130979.1:synonymous:LOW:exon26/56:c.2676A>T:p.Ser892Ser,DYSF:NM_001130980.1:synonymous:LOW:exon25/55:c.2634A>T:p.Ser878Ser,DYSF:NM_001130981.1:synonymous:LOW:exon25/56:c.2634A>T:p.Ser878Ser,DYSF:NM_003494.3:synonymous:LOW:exon25/55:c.2583A>T:p.Ser861Ser,DYSF:NM_001130455.1:synonymous:LOW:exon25/55:c.2586A>T:p.Ser862Ser,DYSF:NM_001130982.1:synonymous:LOW:exon26/56:c.2679A>T:p.Ser893Ser,DYSF:NM_001130983.1:synonymous:LOW:exon25/56:c.2586A>T:p.Ser862Ser,DYSF:NM_001130984.1:synonymous:LOW:exon24/55:c.2544A>T:p.Ser848Ser,DYSF:NM_001130985.1:synonymous:LOW:exon25/55:c.2637A>T:p.Ser879Ser,DYSF:NM_001130986.1:synonymous:LOW:exon24/54:c.2544A>T:p.Ser848Ser		rs2288355	0.5505	0.6042	23766/15206/3432	0.5991							603009 [DYSF (confirmed) Muscular dystrophy,limb-girdle,type 2B,253601|Myopathy,distal,with anterior tibial onset,606768|Miyoshi muscular dystrophy 1,254130];	RCV000080254.9 [other]; RCV000283608.1 [benign]; RCV000378035.1 [benign]; 		COSM3766590, COSM3766591	628	727					DYSF (inh=AR pLI=0.00)
chr2	71838597	71838597	C	A	het	het	het		QUAL=5805;DP=101,163,271;MQM=60	DYSF	splice_region&synonymous,sequence_feature	DYSF:NM_001130987.1:splice_region&synonymous:LOW:exon38/56:c.4062C>A:p.Ile1354Ile,DYSF:NM_001130976.1:splice_region&synonymous:LOW:exon37/54:c.3966C>A:p.Ile1322Ile,DYSF:NM_001130977.1:splice_region&synonymous:LOW:exon37/55:c.3966C>A:p.Ile1322Ile,DYSF:NM_001130978.1:splice_region&synonymous:LOW:exon38/56:c.4008C>A:p.Ile1336Ile,DYSF:NM_001130979.1:splice_region&synonymous:LOW:exon39/56:c.4101C>A:p.Ile1367Ile,DYSF:NM_001130980.1:splice_region&synonymous:LOW:exon38/55:c.4059C>A:p.Ile1353Ile,DYSF:NM_001130981.1:splice_region&synonymous:LOW:exon38/56:c.4059C>A:p.Ile1353Ile,DYSF:NM_003494.3:splice_region&synonymous:LOW:exon38/55:c.4008C>A:p.Ile1336Ile,DYSF:NM_001130455.1:splice_region&synonymous:LOW:exon38/55:c.4011C>A:p.Ile1337Ile,DYSF:NM_001130982.1:splice_region&synonymous:LOW:exon39/56:c.4104C>A:p.Ile1368Ile,DYSF:NM_001130983.1:splice_region&synonymous:LOW:exon38/56:c.4011C>A:p.Ile1337Ile,DYSF:NM_001130984.1:splice_region&synonymous:LOW:exon37/55:c.3969C>A:p.Ile1323Ile,DYSF:NM_001130985.1:splice_region&synonymous:LOW:exon38/55:c.4062C>A:p.Ile1354Ile,DYSF:NM_001130986.1:splice_region&synonymous:LOW:exon37/54:c.3969C>A:p.Ile1323Ile,DYSF:NM_001130987.1:sequence_feature:LOW:exon38/56:c.4062C>A:,DYSF:NM_001130978.1:sequence_feature:LOW:exon38/56:c.4008C>A:,DYSF:NM_001130979.1:sequence_feature:LOW:exon39/56:c.4101C>A:,DYSF:NM_001130980.1:sequence_feature:LOW:exon38/55:c.4059C>A:,DYSF:NM_001130981.1:sequence_feature:LOW:exon38/56:c.4059C>A:,DYSF:NM_001130455.1:sequence_feature:LOW:exon38/55:c.4011C>A:,DYSF:NM_001130982.1:sequence_feature:LOW:exon39/56:c.4104C>A:,DYSF:NM_001130983.1:sequence_feature:LOW:exon38/56:c.4011C>A:,DYSF:NM_001130984.1:sequence_feature:LOW:exon37/55:c.3969C>A:,DYSF:NM_001130985.1:sequence_feature:LOW:exon38/55:c.4062C>A:		rs2303606	0.4495	0.5015	15435/9359/839	0.4964							603009 [DYSF (confirmed) Muscular dystrophy,limb-girdle,type 2B,253601|Myopathy,distal,with anterior tibial onset,606768|Miyoshi muscular dystrophy 1,254130];	RCV000080282.9 [other]; RCV000288114.1 [benign]; RCV000382443.1 [benign]; 			440	733					DYSF (inh=AR pLI=0.00)
chr2	71906278	71906278	A	C	wt	het	wt		QUAL=3339;DP=265,286,326;MQM=60	DYSF	synonymous	DYSF:NM_001130987.1:synonymous:LOW:exon53/56:c.5976A>C:p.Pro1992Pro,DYSF:NM_001130976.1:synonymous:LOW:exon51/54:c.5817A>C:p.Pro1939Pro,DYSF:NM_001130977.1:synonymous:LOW:exon52/55:c.5880A>C:p.Pro1960Pro,DYSF:NM_001130978.1:synonymous:LOW:exon53/56:c.5922A>C:p.Pro1974Pro,DYSF:NM_001130979.1:synonymous:LOW:exon53/56:c.5952A>C:p.Pro1984Pro,DYSF:NM_001130980.1:synonymous:LOW:exon52/55:c.5910A>C:p.Pro1970Pro,DYSF:NM_001130981.1:synonymous:LOW:exon53/56:c.5973A>C:p.Pro1991Pro,DYSF:NM_003494.3:synonymous:LOW:exon52/55:c.5859A>C:p.Pro1953Pro,DYSF:NM_001130455.1:synonymous:LOW:exon52/55:c.5862A>C:p.Pro1954Pro,DYSF:NM_001130982.1:synonymous:LOW:exon53/56:c.5955A>C:p.Pro1985Pro,DYSF:NM_001130983.1:synonymous:LOW:exon53/56:c.5925A>C:p.Pro1975Pro,DYSF:NM_001130984.1:synonymous:LOW:exon52/55:c.5883A>C:p.Pro1961Pro,DYSF:NM_001130985.1:synonymous:LOW:exon52/55:c.5913A>C:p.Pro1971Pro,DYSF:NM_001130986.1:synonymous:LOW:exon51/54:c.5820A>C:p.Pro1940Pro		rs17718530	0.1689	0.2178	3253/2252/145	0.2145							603009 [DYSF (confirmed) Muscular dystrophy,limb-girdle,type 2B,253601|Myopathy,distal,with anterior tibial onset,606768|Miyoshi muscular dystrophy 1,254130];	RCV000080315.9 [other]; RCV000282030.1 [likely benign]; RCV000316074.1 [likely benign]; 			91	543					DYSF (inh=AR pLI=0.00)
chr2	73613031	73613031	-	GGA	hom	hom	hom	low_DP	QUAL=352;DP=1,6,14;MQM=59	ALMS1	disruptive_inframe_insertion	ALMS1:NM_015120.4:disruptive_inframe_insertion:MODERATE:exon1/23:c.72_74dupGGA:p.Glu25dup		rs193922695;rs55889738;rs764804760;rs772724963;rs778948871	0.0000	0.0370	3/2/0	0.0383							606844 [ALMS1 (confirmed) Alstrom syndrome,203800];	RCV000250027.1 [likely benign]; RCV000400085.1 [uncertain significance]; RCV000334392.1 [uncertain significance]; RCV000286389.1 [likely benign]; RCV000029331.1 [uncertain significance]; RCV000202933.4 [other]; RCV000206303.2 [other]; 			369	220	1	[1] old entry - no details available			ALMS1 (inh=AR pLI=0.00)
chr2	73651967	73651967	C	T	het	wt	het		QUAL=7802;DP=310,272,312;MQM=60	ALMS1	missense	ALMS1:NM_015120.4:missense:MODERATE:exon5/23:c.1174C>T:p.Arg392Cys		rs3813227	0.3636	0.2712	6226/1811/2992	0.2608	0.2600	T,T,T	T	B,B	T,T,T	0.09	606844 [ALMS1 (confirmed) Alstrom syndrome,203800];				88	523					ALMS1 (inh=AR pLI=0.00)
chr2	73675227	73675227	-	CTC	het	hom	het		QUAL=15046;DP=161,299,323;MQM=59	ALMS1	disruptive_inframe_insertion	ALMS1:NM_015120.4:disruptive_inframe_insertion:MODERATE:exon8/23:c.1571_1573dupCTC:p.Ser524_Leu525insPro		rs34628045;rs587621330	0.6004	0.6384	25241/13578/636	0.5967							606844 [ALMS1 (confirmed) Alstrom syndrome,203800];	RCV000205185.1 [benign]; 			686	721	1	[1] old entry - no details available			ALMS1 (inh=AR pLI=0.00)
chr2	73675669	73675669	T	G	hom	hom	hom		QUAL=29406;DP=300,287,325;MQM=59	ALMS1	missense	ALMS1:NM_015120.4:missense:MODERATE:exon8/23:c.2012T>G:p.Val671Gly		rs2037814	0.8722	0.8627	45056/24926/3971	0.8512	-0.5500	T,T,T	T	B,B,B	T,T,T	0.66	606844 [ALMS1 (confirmed) Alstrom syndrome,203800];				1171	407					ALMS1 (inh=AR pLI=0.00)
chr2	73675844	73675844	C	T	het	hom	het		QUAL=14783;DP=254,230,325;MQM=60	ALMS1	synonymous	ALMS1:NM_015120.4:synonymous:LOW:exon8/23:c.2187C>T:p.Phe729Phe		rs7598901	0.5264	0.5991	22804/13264/187	0.5778							606844 [ALMS1 (confirmed) Alstrom syndrome,203800];				662	725					ALMS1 (inh=AR pLI=0.00)
chr2	73677833	73677833	A	G	het	wt	het		QUAL=8805;DP=175,359,465;MQM=59	ALMS1	synonymous,sequence_feature	ALMS1:NM_015120.4:synonymous:LOW:exon8/23:c.4176A>G:p.Gln1392Gln,ALMS1:NM_015120.4:sequence_feature:LOW:exon8/23:c.4176A>G:		rs6546836	0.3383	0.2609	5695/1808/2469	0.2542							606844 [ALMS1 (confirmed) Alstrom syndrome,203800];			COSM1409404	84	530					ALMS1 (inh=AR pLI=0.00)
chr2	73677898	73677898	G	C	het	wt	het		QUAL=9043;DP=215,337,451;MQM=59	ALMS1	missense	ALMS1:NM_015120.4:missense:MODERATE:exon8/23:c.4241G>C:p.Gly1414Ala		rs6546837	0.3636	0.2681	6259/1823/2999	0.2540	-2.3660	T,T,T	T	B,B,B	T,T,T	0.01	606844 [ALMS1 (confirmed) Alstrom syndrome,203800];				89	527					ALMS1 (inh=AR pLI=0.00)
chr2	73679280	73679280	A	G	het	wt	het		QUAL=9602;DP=298,291,380;MQM=60	ALMS1	missense	ALMS1:NM_015120.4:missense:MODERATE:exon8/23:c.5623A>G:p.Ile1875Val		rs6546838	0.3588	0.2676	6146/1827/2890	0.2604	-0.1850	T,T,T	T	B,B,B	T,T,T	0.01	606844 [ALMS1 (confirmed) Alstrom syndrome,203800];				89	528					ALMS1 (inh=AR pLI=0.00)
chr2	73679866	73679866	T	C	het	wt	het		QUAL=6784;DP=277,198,237;MQM=60	ALMS1	missense	ALMS1:NM_015120.4:missense:MODERATE:exon8/23:c.6209T>C:p.Ile2070Thr		rs10496192	0.1036	0.1432	1355/899/31	0.1393	-0.1900	T,T,T	T	B,B,B	T,T,T	0.01	606844 [ALMS1 (confirmed) Alstrom syndrome,203800];				44	415					ALMS1 (inh=AR pLI=0.00)
chr2	73679990	73679990	T	A	het	wt	het		QUAL=5300;DP=198,186,220;MQM=60	ALMS1	missense	ALMS1:NM_015120.4:missense:MODERATE:exon8/23:c.6333T>A:p.Ser2111Arg		rs6724782	0.3638	0.2699	6205/1830/2944	0.2619	-0.2040	T,T,T	T	B,B,B	T,T,T	0.01	606844 [ALMS1 (confirmed) Alstrom syndrome,203800];			COSM4133927	88	528					ALMS1 (inh=AR pLI=0.00)
chr2	73680059	73680059	A	G	wt	het	wt		QUAL=3114;DP=416,240,326;MQM=60	ALMS1	synonymous	ALMS1:NM_015120.4:synonymous:LOW:exon8/23:c.6402A>G:p.Pro2134Pro			0.0000	0.0000	0/0/0	0.0000							606844 [ALMS1 (confirmed) Alstrom syndrome,203800];				0	1					ALMS1 (inh=AR pLI=0.00)
chr2	73680508	73680508	G	C	het	wt	het	pred_pathogenic	QUAL=9776;DP=418,286,271;MQM=60	ALMS1	missense	ALMS1:NM_015120.4:missense:MODERATE:exon8/23:c.6851G>C:p.Arg2284Pro		rs6546839	0.3644	0.2696	6267/1836/2991	0.2619	2.6600	T,T,T	T	B,B,B	T,T,T	17.18	606844 [ALMS1 (confirmed) Alstrom syndrome,203800];				89	529					ALMS1 (inh=AR pLI=0.00)
chr2	73717567	73717567	G	T	het	wt	het		QUAL=5821;DP=240,135,221;MQM=60	ALMS1	missense	ALMS1:NM_015120.4:missense:MODERATE:exon10/23:c.8478G>T:p.Arg2826Ser		rs2056486	0.3582	0.2663	6089/1794/2866	0.2590	-0.0370	T,T	T	B,B,B	T,T	0.29	606844 [ALMS1 (confirmed) Alstrom syndrome,203800];			COSM4133929	89	524					ALMS1 (inh=AR pLI=0.00)
chr2	73717656	73717656	A	G	het	wt	het		QUAL=8615;DP=321,235,314;MQM=60	ALMS1	missense	ALMS1:NM_015120.4:missense:MODERATE:exon10/23:c.8567A>G:p.Asn2856Ser		rs10193972	0.3582	0.2661	6099/1798/2869	0.2592	-0.6910	T,T	T	B,B,B	T,T	0.01	606844 [ALMS1 (confirmed) Alstrom syndrome,203800];				89	526					ALMS1 (inh=AR pLI=0.00)
chr2	73746923	73746923	C	T	het	wt	het		QUAL=3520;DP=154,67,101;MQM=60	ALMS1	synonymous	ALMS1:NM_015120.4:synonymous:LOW:exon11/23:c.9558C>T:p.Thr3186Thr		rs11884776	0.2568	0.2169	3536/1663/1229	0.2130							606844 [ALMS1 (confirmed) Alstrom syndrome,203800];				76	513					ALMS1 (inh=AR pLI=0.00)
chr2	73828538	73828538	G	A	het	hom	het		QUAL=12355;DP=204,197,279;MQM=60	ALMS1	missense	ALMS1:NM_015120.4:missense:MODERATE:exon19/23:c.12086G>A:p.Arg4029Lys		rs1052161	0.5823	0.6334	24870/13499/538	0.6260	-1.7990	T,T	T	B,B	T,T	0.01	606844 [ALMS1 (confirmed) Alstrom syndrome,203800];			COSM4133930	662	722					ALMS1 (inh=AR pLI=0.00)
chr2	73829372	73829372	C	T	het	wt	het		QUAL=8135;DP=395,213,274;MQM=59	ALMS1	synonymous	ALMS1:NM_015120.4:synonymous:LOW:exon20/23:c.12172C>T:p.Leu4058Leu		rs1052162	0.3417	0.2636	5895/1786/2706	0.2579							606844 [ALMS1 (confirmed) Alstrom syndrome,203800];				88	522					ALMS1 (inh=AR pLI=0.00)
chr2	73836844	73836844	A	G	wt	het	wt		QUAL=3557;DP=360,328,434;MQM=60	ALMS1	3'UTR	ALMS1:NM_015120.4:3'UTR:MODIFIER:exon23/23:c.*105A>G:		rs553541249	0.0000	0.0000	0/0/0	0.0004							606844 [ALMS1 (confirmed) Alstrom syndrome,203800];	RCV000342678.1 [uncertain significance]; 			0	3					ALMS1 (inh=AR pLI=0.00)
chr2	73837006	73837006	T	A	het	wt	hom		QUAL=9755;DP=211,177,229;MQM=60	ALMS1	3'UTR	ALMS1:NM_015120.4:3'UTR:MODIFIER:exon23/23:c.*267T>A:		rs62149804	0.1052	0.0000	0/0/0	0.0237							606844 [ALMS1 (confirmed) Alstrom syndrome,203800];	RCV000334312.1 [likely benign]; 			9	59					ALMS1 (inh=AR pLI=0.00)
chr2	74185876	74185876	A	T	hom	het	hom		QUAL=10459;DP=108,130,165;MQM=60	DGUOK,DGUOK-AS1	3'UTR,intron,non_coding_transcript_exon	DGUOK:NM_080916.2:3'UTR:MODIFIER:exon7/7:c.*13A>T:,DGUOK:NM_001318859.1:3'UTR:MODIFIER:exon5/5:c.*13A>T:,DGUOK:NM_001318860.1:3'UTR:MODIFIER:exon6/6:c.*13A>T:,DGUOK:NM_001318861.1:3'UTR:MODIFIER:exon7/7:c.*13A>T:,DGUOK:NM_001318862.1:3'UTR:MODIFIER:exon7/7:c.*13A>T:,DGUOK:NM_001318863.1:3'UTR:MODIFIER:exon6/6:c.*13A>T:,DGUOK:NM_080918.2:3'UTR:MODIFIER:exon5/5:c.*13A>T:,DGUOK-AS1:NR_104029.1:intron:MODIFIER:exon1/1:n.332-542T>A:,DGUOK-AS1:NR_104030.1:intron:MODIFIER:exon1/1:n.306-542T>A:,DGUOK:NR_134893.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.555A>T:,DGUOK:NR_134894.1:non_coding_transcript_exon:MODIFIER:exon5/5:n.703A>T:,DGUOK:NR_134895.1:non_coding_transcript_exon:MODIFIER:exon3/3:n.367A>T:,DGUOK:NR_134896.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.537A>T:,DGUOK:NR_134897.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.747A>T:,DGUOK:NR_134898.1:non_coding_transcript_exon:MODIFIER:exon5/5:n.671A>T:		rs4777	0.5308	0.5858	21034/12311/1303	0.5778							601465 [DGUOK (provisional) Mitochondrial DNA depletion syndrome 3 (hepatocerebral type),251880|Progressive external ophthalmoplegia with mitochondrial DNA deletions,autosomal recessive 4,617070|Portal hypertension,noncirrhotic,617068];	RCV000124678.3 [benign]; RCV000351874.1 [benign]; 			324	492					DGUOK (inh=AR pLI=0.37), DGUOK-AS1 (inh=n/a pLI=n/a)
chr2	84650707	84650707	A	G	hom	hom	hom		QUAL=17133;DP=230,160,148;MQM=60	SUCLG1	3'UTR	SUCLG1:NM_003849.3:3'UTR:MODIFIER:exon9/9:c.*163T>C:		rs2832	0.8021	0.0000	0/0/0	0.1401							611224 [SUCLG1 (provisional) Mitochondrial DNA depletion syndrome 9 (encephalomyopathic type with methylmalonic aciduria),245400];	RCV000301645.1 [benign]; RCV000399966.1 [benign]; 			198	28					SUCLG1 (inh=AR pLI=0.06)
chr2	85894308	85894308	G	T	het	wt	hom		QUAL=4203;DP=168,115,87;MQM=60	SFTPB	splice_region&intron	SFTPB:NM_000542.3:splice_region&intron:LOW:exon3/11:c.232-8C>A:,SFTPB:NM_198843.2:splice_region&intron:LOW:exon3/11:c.232-8C>A:		rs3024798	0.2969	0.3553	7917/4570/53	0.3505							178640 [SFTPB (confirmed) Surfactant metabolism dysfunction,pulmonary,1,265120];	RCV000151852.2 [benign]; RCV000318879.1 [benign]; 			254	753					SFTPB (inh=AR pLI=0.04)
chr2	85895338	85895338	T	G	het	wt	hom		QUAL=5197;DP=123,105,120;MQM=59	SFTPB	missense	SFTPB:NM_000542.3:missense:MODERATE:exon2/12:c.5A>C:p.His2Pro,SFTPB:NM_198843.2:missense:MODERATE:exon2/12:c.5A>C:p.His2Pro		rs2077079	0.4185	0.4254	1818/709/187	0.1472	0.8210	T,T	T	B	T,T	0.01	178640 [SFTPB (confirmed) Surfactant metabolism dysfunction,pulmonary,1,265120];	RCV000151854.2 [benign]; RCV000344398.1 [benign]; 	CR077669 [CLASS=FP MUT=ALT PHEN="Increased promoter activity" GENE=SFTPB]; 	COSM3766592	255	710					SFTPB (inh=AR pLI=0.04)
chr2	86088311	86088311	T	C	wt	het	wt		QUAL=3276;DP=220,241,238;MQM=60	ST3GAL5	missense	ST3GAL5:NM_003896.3:missense:MODERATE:exon3/7:c.311A>G:p.His104Arg,ST3GAL5:NM_001042437.1:missense:MODERATE:exon3/7:c.242A>G:p.His81Arg		rs1138484	0.2091	0.2225	3375/1591/35	0.2178	0.8450	T,T,T,T,T	T	B,B,B	T,T,T,T,T	0.32	604402 [ST3GAL5 (confirmed) Salt and pepper developmental regression syndrome,609056];	RCV000118422.2 [benign]; RCV000305958.1 [benign]; 			81	507					ST3GAL5 (inh=AR pLI=0.03)
chr2	86441303	86441303	A	C	hom	het	het		QUAL=24190;DP=399,367,500;MQM=59	REEP1	3'UTR	REEP1:NM_001164730.1:3'UTR:MODIFIER:exon7/7:c.*2920T>G:,REEP1:NM_001164731.1:3'UTR:MODIFIER:exon6/6:c.*2920T>G:,REEP1:NM_001164732.1:3'UTR:MODIFIER:exon5/5:c.*2859T>G:,REEP1:NM_022912.2:3'UTR:MODIFIER:exon7/7:c.*2920T>G:		rs708600	0.3736	0.0000	0/0/0	0.0686							609139 [REEP1 (provisional) Spastic paraplegia 31,autosomal dominant,610250|Neuronopathy,distal hereditary motor,type VB,614751];	RCV000388753.1 [benign]; 			37	97					REEP1 (inh=AD pLI=0.94)
chr2	86441334	86441334	-	TGTT	hom	het	het		QUAL=20520;DP=287,352,498;MQM=59	REEP1	3'UTR	REEP1:NM_001164730.1:3'UTR:MODIFIER:exon7/7:c.*2885_*2888dupAACA:,REEP1:NM_001164731.1:3'UTR:MODIFIER:exon6/6:c.*2885_*2888dupAACA:,REEP1:NM_001164732.1:3'UTR:MODIFIER:exon5/5:c.*2824_*2827dupAACA:,REEP1:NM_022912.2:3'UTR:MODIFIER:exon7/7:c.*2885_*2888dupAACA:		rs397794472	0.3730	0.0000	0/0/0	0.3587							609139 [REEP1 (provisional) Spastic paraplegia 31,autosomal dominant,610250|Neuronopathy,distal hereditary motor,type VB,614751];	RCV000296783.1 [benign]; 			36	99					REEP1 (inh=AD pLI=0.94)
chr2	86442112	86442112	-	A	het	het	het		QUAL=1569;DP=129,32,69;MQM=59	REEP1	3'UTR	REEP1:NM_001164730.1:3'UTR:MODIFIER:exon7/7:c.*2110dupT:,REEP1:NM_001164731.1:3'UTR:MODIFIER:exon6/6:c.*2110dupT:,REEP1:NM_001164732.1:3'UTR:MODIFIER:exon5/5:c.*2049dupT:,REEP1:NM_022912.2:3'UTR:MODIFIER:exon7/7:c.*2110dupT:		rs200132323	0.4267	0.0000	0/0/0	0.2568							609139 [REEP1 (provisional) Spastic paraplegia 31,autosomal dominant,610250|Neuronopathy,distal hereditary motor,type VB,614751];	RCV000332274.1 [benign]; 			3	110					REEP1 (inh=AD pLI=0.94)
chr2	86481835	86481835	C	T	hom	het	het		QUAL=11637;DP=221,159,205;MQM=60	REEP1	synonymous,intron	REEP1:NM_001164730.1:synonymous:LOW:exon4/7:c.306G>A:p.Thr102Thr,REEP1:NM_001164731.1:synonymous:LOW:exon3/6:c.204G>A:p.Thr68Thr,REEP1:NM_022912.2:synonymous:LOW:exon4/7:c.285G>A:p.Thr95Thr,REEP1:NM_001164732.1:intron:MODIFIER:exon3/4:c.182+9253G>A:		rs2276625	0.4287	0.4673	13960/6927/274	0.4615							609139 [REEP1 (provisional) Spastic paraplegia 31,autosomal dominant,610250|Neuronopathy,distal hereditary motor,type VB,614751];	RCV000118136.4 [other]; RCV000386509.1 [benign]; 		COSM3758400	466	1002					REEP1 (inh=AD pLI=0.94)
chr2	87012073	87012073	A	G	het	het	het		QUAL=9929;DP=306,155,231;MQM=59	CD8A	3'UTR,non_coding_transcript_exon	CD8A:NM_001145873.1:3'UTR:MODIFIER:exon9/9:c.*970T>C:,CD8A:NM_001768.6:3'UTR:MODIFIER:exon6/6:c.*970T>C:,CD8A:NM_171827.3:3'UTR:MODIFIER:exon5/5:c.*970T>C:,CD8A:NR_027353.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.2153T>C:		rs1051386	0.1861	0.1368	115/24/5	0.0419							186910 [CD8A (confirmed) CD8 deficiency,familial,608957];				16	183					CD8A (inh=AR pLI=0.02)
chr2	87012293	87012293	A	G	het	het	het		QUAL=3964;DP=217,31,41;MQM=59	CD8A	3'UTR,non_coding_transcript_exon	CD8A:NM_001145873.1:3'UTR:MODIFIER:exon9/9:c.*750T>C:,CD8A:NM_001768.6:3'UTR:MODIFIER:exon6/6:c.*750T>C:,CD8A:NM_171827.3:3'UTR:MODIFIER:exon5/5:c.*750T>C:,CD8A:NR_027353.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.1933T>C:		rs3020729	0.1861	0.1368	115/24/5	0.0412							186910 [CD8A (confirmed) CD8 deficiency,familial,608957];				15	184					CD8A (inh=AR pLI=0.02)
chr2	87012399	87012399	-	AA	het	het	het		QUAL=579;DP=98,27,21;MQM=59	CD8A	3'UTR,non_coding_transcript_exon	CD8A:NM_001145873.1:3'UTR:MODIFIER:exon9/9:c.*642_*643dupTT:,CD8A:NM_001768.6:3'UTR:MODIFIER:exon6/6:c.*642_*643dupTT:,CD8A:NM_171827.3:3'UTR:MODIFIER:exon5/5:c.*642_*643dupTT:,CD8A:NR_027353.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.1825_1826dupTT:		rs10628397;rs538181811	0.1723	0.1533	1/1/0	0.0284							186910 [CD8A (confirmed) CD8 deficiency,familial,608957];				7	140					CD8A (inh=AR pLI=0.02)
chr2	87012706	87012706	C	T	wt	het	wt		QUAL=1499;DP=179,135,190;MQM=60	CD8A	3'UTR,non_coding_transcript_exon	CD8A:NM_001145873.1:3'UTR:MODIFIER:exon9/9:c.*337G>A:,CD8A:NM_001768.6:3'UTR:MODIFIER:exon6/6:c.*337G>A:,CD8A:NM_171827.3:3'UTR:MODIFIER:exon5/5:c.*337G>A:,CD8A:NR_027353.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.1520G>A:	MIRc	rs7563485	0.0479	0.0462	15/8/3	0.0164							186910 [CD8A (confirmed) CD8 deficiency,familial,608957];				4	80					CD8A (inh=AR pLI=0.02)
chr2	87016506	87016506	A	G	het	het	het		QUAL=7343;DP=125,212,303;MQM=59	CD8A	synonymous,intron,non_coding_transcript_exon	CD8A:NM_001145873.1:synonymous:LOW:exon7/9:c.565T>C:p.Leu189Leu,CD8A:NM_001768.6:synonymous:LOW:exon4/6:c.565T>C:p.Leu189Leu,CD8A:NM_171827.3:intron:MODIFIER:exon3/4:c.514+257T>C:,CD8A:NR_027353.1:non_coding_transcript_exon:MODIFIER:exon5/7:n.1040T>C:		rs3020726	0.0821	0.1177	997/852/34	0.1199							186910 [CD8A (confirmed) CD8 deficiency,familial,608957];			COSM4001774	37	411					CD8A (inh=AR pLI=0.02)
chr2	87017575	87017575	C	T	wt	het	wt		QUAL=5184;DP=174,462,612;MQM=60	CD8A	synonymous,non_coding_transcript_exon	CD8A:NM_001145873.1:synonymous:LOW:exon5/9:c.279G>A:p.Arg93Arg,CD8A:NM_001768.6:synonymous:LOW:exon2/6:c.279G>A:p.Arg93Arg,CD8A:NM_171827.3:synonymous:LOW:exon2/5:c.279G>A:p.Arg93Arg,CD8A:NR_027353.1:non_coding_transcript_exon:MODIFIER:exon3/7:n.754G>A:		rs2229240	0.0365	0.0597	278/219/36	0.0596							186910 [CD8A (confirmed) CD8 deficiency,familial,608957];			COSM4133968	7	190					CD8A (inh=AR pLI=0.02)
chr2	87017662	87017662	G	T	wt	het	wt		QUAL=4026;DP=198,388,502;MQM=60	CD8A	synonymous,sequence_feature,non_coding_transcript_exon	CD8A:NM_001145873.1:synonymous:LOW:exon5/9:c.192C>A:p.Ala64Ala,CD8A:NM_001768.6:synonymous:LOW:exon2/6:c.192C>A:p.Ala64Ala,CD8A:NM_171827.3:synonymous:LOW:exon2/5:c.192C>A:p.Ala64Ala,CD8A:NM_001768.6:sequence_feature:LOW:exon2/6:c.192C>A:,CD8A:NM_171827.3:sequence_feature:LOW:exon2/5:c.192C>A:,CD8A:NR_027353.1:non_coding_transcript_exon:MODIFIER:exon3/7:n.667C>A:		rs2229239	0.0365	0.0603	271/214/34	0.0586							186910 [CD8A (confirmed) CD8 deficiency,familial,608957];			COSM4133969	7	183					CD8A (inh=AR pLI=0.02)
chr2	87017989	87017989	G	T	wt	het	wt		QUAL=689;DP=75,72,77;MQM=60	CD8A	5'UTR,non_coding_transcript_exon	CD8A:NM_001145873.1:5'UTR:MODIFIER:exon4/9:c.-41C>A:,CD8A:NM_001768.6:5'UTR:MODIFIER:exon1/6:c.-41C>A:,CD8A:NM_171827.3:5'UTR:MODIFIER:exon1/5:c.-41C>A:,CD8A:NR_027353.1:non_coding_transcript_exon:MODIFIER:exon2/7:n.435C>A:		rs36227194	0.0365	0.0419	11/6/1	0.0230	-0.4010	T	T	B	T	9.56	186910 [CD8A (confirmed) CD8 deficiency,familial,608957];			COSM4133970	6	158					CD8A (inh=AR pLI=0.02)
chr2	87018452	87018452	A	G	hom	hom	hom		QUAL=39501;DP=524,316,405;MQM=59	CD8A	5'UTR,intron	CD8A:NM_001768.6:5'UTR:MODIFIER:exon1/6:c.-504T>C:,CD8A:NM_171827.3:5'UTR:MODIFIER:exon1/5:c.-504T>C:,CD8A:NM_001145873.1:intron:MODIFIER:exon3/8:c.-270-234T>C:,CD8A:NR_027353.1:intron:MODIFIER:exon1/6:n.205+181T>C:		rs6743139	0.6581	0.0000	0/0/0	0.1266							186910 [CD8A (confirmed) CD8 deficiency,familial,608957];				124	88					CD8A (inh=AR pLI=0.02)
chr2	87018547	87018547	A	G	het	hom	het		QUAL=16953;DP=322,283,327;MQM=59	CD8A	5'UTR,intron	CD8A:NM_001768.6:5'UTR:MODIFIER:exon1/6:c.-599T>C:,CD8A:NM_171827.3:5'UTR:MODIFIER:exon1/5:c.-599T>C:,CD8A:NM_001145873.1:intron:MODIFIER:exon3/8:c.-270-329T>C:,CD8A:NR_027353.1:intron:MODIFIER:exon1/6:n.205+86T>C:		rs3810831	0.1312	0.0000	0/0/0	0.1847							186910 [CD8A (confirmed) CD8 deficiency,familial,608957];				6	73					CD8A (inh=AR pLI=0.02)
chr2	88874891	88874891	C	A	hom	hom	hom	pred_pathogenic	QUAL=37058;DP=394,327,410;MQM=60	EIF2AK3,LOC101928371	missense,non_coding_transcript_exon	EIF2AK3:NM_004836.6:missense:MODERATE:exon13/17:c.2110G>T:p.Ala704Ser,EIF2AK3:NM_001313915.1:missense:MODERATE:exon13/17:c.1657G>T:p.Ala553Ser,LOC101928371:NR_110236.1:non_coding_transcript_exon:MODIFIER:exon3/3:n.1510C>A:		rs1805165	0.7206	0.7021	30514/17236/4704	0.6894	2.4940	T,T,T,T	T	B	T,T,T	15.98	604032 [EIF2AK3 (confirmed) Wolcott-Rallison syndrome,226980];	RCV000116968.2 [likely benign]; RCV000374096.1 [benign]; 			814	614					EIF2AK3 (inh=AR pLI=0.01), LOC101928371 (inh=n/a pLI=n/a)
chr2	88879131	88879131	T	C	het	wt	het		QUAL=5031;DP=276,127,115;MQM=60	EIF2AK3	synonymous	EIF2AK3:NM_004836.6:synonymous:LOW:exon11/17:c.1791A>G:p.Gln597Gln,EIF2AK3:NM_001313915.1:synonymous:LOW:exon11/17:c.1338A>G:p.Gln446Gln		rs1805164	0.2582	0.2854	5151/3017/242	0.2830							604032 [EIF2AK3 (confirmed) Wolcott-Rallison syndrome,226980];	RCV000116967.2 [likely benign]; RCV000396340.1 [benign]; 		COSM3746552, COSM3746551	128	583					EIF2AK3 (inh=AR pLI=0.01)
chr2	88882942	88882942	T	A	wt	het	wt		QUAL=284;DP=122,34,47;MQM=60	EIF2AK3	splice_region&intron,sequence_feature	EIF2AK3:NM_004836.6:splice_region&intron:LOW:exon10/16:c.1763+6A>T:,EIF2AK3:NM_001313915.1:splice_region&intron:LOW:exon10/16:c.1310+6A>T:,EIF2AK3:NM_004836.6:sequence_feature:LOW::c.1763+6A>T:		rs6750998	0.2043	0.2542	4404/2908/61	0.2475							604032 [EIF2AK3 (confirmed) Wolcott-Rallison syndrome,226980];	RCV000116966.2 [likely benign]; RCV000307874.1 [benign]; 		COSM148896	174	642					EIF2AK3 (inh=AR pLI=0.01)
chr2	88895123	88895123	T	C	hom	hom	hom	pred_pathogenic	QUAL=24629;DP=365,171,211;MQM=60	EIF2AK3	missense,sequence_feature	EIF2AK3:NM_004836.6:missense:MODERATE:exon3/17:c.497A>G:p.Gln166Arg,EIF2AK3:NM_001313915.1:missense:MODERATE:exon3/17:c.44A>G:p.Gln15Arg,EIF2AK3:NM_004836.6:sequence_feature:LOW:exon3/17:c.497A>G:		rs13045	0.6490	0.6379	25325/14844/3911	0.6323	5.4970	T,T,T,T	T	B	T,T,T	11.15	604032 [EIF2AK3 (confirmed) Wolcott-Rallison syndrome,226980];	RCV000116970.3 [other]; RCV000283479.1 [benign]; 	CM138802 [CLASS=R MUT=ALT PHEN="Wolcott-Rallison syndrome" GENE=EIF2AK3]; 	COSM4001780, COSM4001781	704	677	2	[2] Peter Bauer 25.08.2014			EIF2AK3 (inh=AR pLI=0.01)
chr2	88926730	88926732	CAG	-	hom	het	hom	low_DP	QUAL=550;DP=11,14,15;MQM=59	EIF2AK3	conservative_inframe_deletion	EIF2AK3:NM_004836.6:conservative_inframe_deletion:MODERATE:exon1/17:c.61_63delCTG:p.Leu21del	(CAG)n	rs144052332;rs72416210	0.7965	0.6612	1883/442/59	0.1367							604032 [EIF2AK3 (confirmed) Wolcott-Rallison syndrome,226980];	RCV000173359.3 [benign]; RCV000344451.1 [benign]; 			695	512					EIF2AK3 (inh=AR pLI=0.01)
chr2	96778665	96778665	-	A	het	hom	wt		QUAL=1456;DP=130,95,115;MQM=59	ADRA2B	3'UTR	ADRA2B:NM_000682.6:3'UTR:MODIFIER:exon1/1:c.*1879dupT:		rs11464083;rs34790807	0.6280	0.0000	0/0/0	0.3956							104260 [ADRA2B (confirmed) Epilepsy,myoclonic,familial adult,2,607876];				1	198					ADRA2B (inh=AD pLI=0.00)
chr2	96780122	96780122	G	T	het	wt	hom		QUAL=6477;DP=112,142,164;MQM=59	ADRA2B	3'UTR	ADRA2B:NM_000682.6:3'UTR:MODIFIER:exon1/1:c.*423C>A:		rs4907299	0.3335	0.0000	0/0/0	0.0683							104260 [ADRA2B (confirmed) Epilepsy,myoclonic,familial adult,2,607876];				19	101					ADRA2B (inh=AD pLI=0.00)
chr2	96780185	96780185	G	T	het	het	wt		QUAL=3806;DP=188,132,147;MQM=59	ADRA2B	3'UTR	ADRA2B:NM_000682.6:3'UTR:MODIFIER:exon1/1:c.*360C>A:			0.0000	0.0000	0/0/0	0.0000							104260 [ADRA2B (confirmed) Epilepsy,myoclonic,familial adult,2,607876];				0	2					ADRA2B (inh=AD pLI=0.00)
chr2	96780716	96780716	T	G	het	hom	wt		QUAL=14002;DP=369,305,452;MQM=59	ADRA2B	synonymous	ADRA2B:NM_000682.6:synonymous:LOW:exon1/1:c.1173A>C:p.Gly391Gly		rs2229169	0.7053	0.6785	26959/14687/2620	0.6634							104260 [ADRA2B (confirmed) Epilepsy,myoclonic,familial adult,2,607876];				859	599					ADRA2B (inh=AD pLI=0.00)
chr2	96780986	96780986	-	TCCTCCTCT	het	hom	het		QUAL=7743;DP=173,152,234;MQM=59	ADRA2B	disruptive_inframe_insertion	ADRA2B:NM_000682.6:disruptive_inframe_insertion:MODERATE:exon1/1:c.894_902dupAGAGGAGGA:p.Glu299_Glu301dup	(CTC)n	rs28365031;rs29000568;rs34667759;rs4066772	0.4706	0.6982	7673/3576/1062	0.5353							104260 [ADRA2B (confirmed) Epilepsy,myoclonic,familial adult,2,607876];			COSM1023814, COSM1023812	779	594					ADRA2B (inh=AD pLI=0.00)
chr2	98330052	98330052	C	A	het	het	het		QUAL=3455;DP=158,58,82;MQM=60	ZAP70	5'UTR	ZAP70:NM_001079.3:5'UTR:MODIFIER:exon1/14:c.-186C>A:		rs2276645	0.1935	0.0000	0/0/0	0.3252							176947 [ZAP70 (confirmed) Autoimmune disease,multisystem,infantile-onset,2,617006|Immunodeficiency 48,269840];	RCV000357744.1 [benign]; 			41	101					ZAP70 (inh=AR pLI=0.27)
chr2	98354511	98354511	G	A	het	het	het		QUAL=13319;DP=289,295,381;MQM=59	ZAP70	synonymous	ZAP70:NM_001079.3:synonymous:LOW:exon13/14:c.1677G>A:p.Glu559Glu,ZAP70:NM_207519.1:synonymous:LOW:exon5/6:c.756G>A:p.Glu252Glu		rs3192177	0.1484	0.3012	5449/4154/79	0.2677							176947 [ZAP70 (confirmed) Autoimmune disease,multisystem,infantile-onset,2,617006|Immunodeficiency 48,269840];	RCV000126355.2 [benign]; RCV000356778.1 [benign]; 		COSM4134221	152	624					ZAP70 (inh=AR pLI=0.27)
chr2	98355990	98355990	G	A	het	het	het		QUAL=2107;DP=37,47,70;MQM=59	ZAP70	3'UTR	ZAP70:NM_001079.3:3'UTR:MODIFIER:exon14/14:c.*29G>A:,ZAP70:NM_207519.1:3'UTR:MODIFIER:exon6/6:c.*29G>A:		rs11678558	0.1486	0.2916	4892/3746/63	0.2482							176947 [ZAP70 (confirmed) Autoimmune disease,multisystem,infantile-onset,2,617006|Immunodeficiency 48,269840];	RCV000366961.1 [benign]; 			73	308					ZAP70 (inh=AR pLI=0.27)
chr2	98356250	98356250	G	C	het	het	wt	low_DP	QUAL=245;DP=21,17,21;MQM=59	ZAP70	3'UTR	ZAP70:NM_001079.3:3'UTR:MODIFIER:exon14/14:c.*289G>C:,ZAP70:NM_207519.1:3'UTR:MODIFIER:exon6/6:c.*289G>C:		rs2278699	0.1488	0.0000	0/0/0	0.1265							176947 [ZAP70 (confirmed) Autoimmune disease,multisystem,infantile-onset,2,617006|Immunodeficiency 48,269840];	RCV000331946.1 [benign]; 			4	60					ZAP70 (inh=AR pLI=0.27)
chr2	99172243	99172243	C	T	het	wt	het		QUAL=2986;DP=137,130,173;MQM=60	INPP4A	synonymous,intron	INPP4A:NM_001134224.1:synonymous:LOW:exon17/26:c.1809C>T:p.Ser603Ser,INPP4A:NM_001134225.1:synonymous:LOW:exon16/25:c.1794C>T:p.Ser598Ser,INPP4A:NM_001566.2:intron:MODIFIER:exon17/25:c.1720+89C>T:,INPP4A:NM_004027.2:intron:MODIFIER:exon17/25:c.1720+89C>T:		rs41486345	0.0254	0.0803	202/133/0	0.0533											9	202					INPP4A (inh=n/a pLI=0.99)
chr2	105977776	105977776	G	A	het	het	wt		QUAL=10160;DP=571,215,339;MQM=60	FHL2	synonymous	FHL2:NM_001039492.2:synonymous:LOW:exon7/7:c.804C>T:p.Asp268Asp,FHL2:NM_001318896.1:synonymous:LOW:exon6/6:c.804C>T:p.Asp268Asp,FHL2:NM_001318899.1:synonymous:LOW:exon8/8:c.480C>T:p.Asp160Asp,FHL2:NM_001318895.1:synonymous:LOW:exon7/7:c.804C>T:p.Asp268Asp,FHL2:NM_001318898.1:synonymous:LOW:exon6/6:c.462C>T:p.Asp154Asp,FHL2:NM_001450.3:synonymous:LOW:exon6/6:c.804C>T:p.Asp268Asp,FHL2:NM_201555.1:synonymous:LOW:exon8/8:c.804C>T:p.Asp268Asp,FHL2:NM_001318894.1:synonymous:LOW:exon6/6:c.804C>T:p.Asp268Asp,FHL2:NM_001318897.1:synonymous:LOW:exon5/5:c.462C>T:p.Asp154Asp,FHL2:NM_201557.3:synonymous:LOW:exon6/6:c.804C>T:p.Asp268Asp		rs3087523	0.0517	0.0913	588/461/3	0.0907								RCV000041652.3 [benign]; 		COSM1398595	16	322					FHL2 (inh=n/a pLI=0.00)
chr2	106015412	106015412	G	C	wt	het	het	low_DP	QUAL=199;DP=1,11,8;MQM=60	FHL2	splice_region&intron,5'UTR,intron	FHL2:NM_001039492.2:splice_region&intron:LOW:exon1/6:c.-76+15C>G:,FHL2:NM_001318896.1:splice_region&intron:LOW:exon1/5:c.-25+15C>G:,FHL2:NM_001318899.1:splice_region&intron:LOW:exon1/7:c.-522+15C>G:,FHL2:NM_001318895.1:5'UTR:MODIFIER:exon1/7:c.-189C>G:,FHL2:NM_001318898.1:5'UTR:MODIFIER:exon1/6:c.-356C>G:,FHL2:NM_001450.3:5'UTR:MODIFIER:exon1/6:c.-138C>G:,FHL2:NM_201555.1:5'UTR:MODIFIER:exon1/8:c.-310C>G:,FHL2:NM_001318894.1:intron:MODIFIER:exon1/5:c.-25+267C>G:,FHL2:NM_001318897.1:intron:MODIFIER:exon1/4:c.-191-12415C>G:,FHL2:NM_201557.3:intron:MODIFIER:exon1/5:c.-24-12415C>G:		rs76810592	0.0671	0.0953	136/74/10	0.0533	-1.1610	T	T	B	T	7.33					3	132					FHL2 (inh=n/a pLI=0.00)
chr2	106509907	106509907	C	T	wt	het	het		QUAL=4022;DP=191,143,189;MQM=60	NCK2	3'UTR	NCK2:NM_001004720.2:3'UTR:MODIFIER:exon4/4:c.*275C>T:,NCK2:NM_001004722.3:3'UTR:MODIFIER:exon4/4:c.*444C>T:,NCK2:NM_003581.4:3'UTR:MODIFIER:exon5/5:c.*275C>T:		rs10469862	0.3061	0.0000	0/0/0	0.0544											22	95					NCK2 (inh=n/a pLI=0.70)
chr2	106510191	106510191	-	AAAG	hom	hom	hom		QUAL=17434;DP=175,169,208;MQM=59	NCK2	3'UTR	NCK2:NM_001004720.2:3'UTR:MODIFIER:exon4/4:c.*562_*565dupAGAA:,NCK2:NM_001004722.3:3'UTR:MODIFIER:exon4/4:c.*731_*734dupAGAA:,NCK2:NM_003581.4:3'UTR:MODIFIER:exon5/5:c.*562_*565dupAGAA:		rs10645562	0.9591	0.0000	0/0/0	0.8405											199	30					NCK2 (inh=n/a pLI=0.70)
chr2	106510455	106510455	-	CACA	wt	wt	het	low_DP	QUAL=1407;DP=68,3,72;MQM=59	NCK2	3'UTR	NCK2:NM_001004720.2:3'UTR:MODIFIER:exon4/4:c.*841_*844dupACAC:,NCK2:NM_001004722.3:3'UTR:MODIFIER:exon4/4:c.*1010_*1013dupACAC:,NCK2:NM_003581.4:3'UTR:MODIFIER:exon5/5:c.*841_*844dupACAC:	PRIMA4-int	rs140853322;rs4012805;rs70953541	0.0000	0.0000	0/0/0	0.1416											14	55					NCK2 (inh=n/a pLI=0.70)
chr2	106510455	106510455	-	CA	wt	wt	het	low_DP	QUAL=1407;DP=68,3,72;MQM=59	NCK2	3'UTR	NCK2:NM_001004720.2:3'UTR:MODIFIER:exon4/4:c.*843_*844dupAC:,NCK2:NM_001004722.3:3'UTR:MODIFIER:exon4/4:c.*1012_*1013dupAC:,NCK2:NM_003581.4:3'UTR:MODIFIER:exon5/5:c.*843_*844dupAC:	PRIMA4-int	rs140853322;rs4012805;rs763666468	0.0000	0.0000	0/0/0	0.1074											5	50					NCK2 (inh=n/a pLI=0.70)
chr2	106510477	106510477	T	A	het	het	wt	low_DP	QUAL=142;DP=84,6,74;MQM=56	NCK2	3'UTR	NCK2:NM_001004720.2:3'UTR:MODIFIER:exon4/4:c.*845T>A:,NCK2:NM_001004722.3:3'UTR:MODIFIER:exon4/4:c.*1014T>A:,NCK2:NM_003581.4:3'UTR:MODIFIER:exon5/5:c.*845T>A:	PRIMA4-int	rs73946608	0.0000	0.0000	0/0/0	0.0027											0	6					NCK2 (inh=n/a pLI=0.70)
chr2	106510478	106510478	A	C	het	het	wt	low_DP	QUAL=142;DP=84,6,74;MQM=56	NCK2	3'UTR	NCK2:NM_001004720.2:3'UTR:MODIFIER:exon4/4:c.*846A>C:,NCK2:NM_001004722.3:3'UTR:MODIFIER:exon4/4:c.*1015A>C:,NCK2:NM_003581.4:3'UTR:MODIFIER:exon5/5:c.*846A>C:	PRIMA4-int	rs73946609	0.0000	0.0000	0/0/0	0.0027											0	6					NCK2 (inh=n/a pLI=0.70)
chr2	109389463	109389463	G	A	hom	hom	hom		QUAL=16314;DP=168,173,167;MQM=60	RANBP2	synonymous	RANBP2:NM_006267.4:synonymous:LOW:exon23/29:c.8253G>A:p.Glu2751Glu		rs826580	0.9872	0.9959	59941/33182/4734	0.9418							601181 [RANBP2 (provisional) Encephalopathy,acute,infection-induced,3,susceptibility to,608033];				1564	2					RANBP2 (inh=AD pLI=1.00)
chr2	109510933	109510937	TAATG	-	het	wt	het	low_DP	QUAL=2911;DP=80,11,17;MQM=59	EDAR	3'UTR	EDAR:NM_022336.3:3'UTR:MODIFIER:exon12/12:c.*2426_*2430delCATTA:		rs555061424	0.0026	0.0000	0/0/0	0.0044							604095 [EDAR (confirmed) Ectodermal dysplasia 10A,hypohidrotic/hair/nail type,autosomal dominant,129490|Ectodermal dysplasia 10B,hypohidrotic/hair/tooth type,autosomal recessive,224900|Hair morphology 1,hair thickness,612630];	RCV000357958.1 [uncertain significance]; 			0	4					EDAR (inh=AR+AD pLI=0.00)
chr2	109510937	109510937	G	A	het	hom	het	low_DP	QUAL=2911;DP=80,11,17;MQM=60	EDAR	3'UTR	EDAR:NM_022336.3:3'UTR:MODIFIER:exon12/12:c.*2426C>T:		rs1478517	0.5317	0.0000	0/0/0	0.1220							604095 [EDAR (confirmed) Ectodermal dysplasia 10A,hypohidrotic/hair/nail type,autosomal dominant,129490|Ectodermal dysplasia 10B,hypohidrotic/hair/tooth type,autosomal recessive,224900|Hair morphology 1,hair thickness,612630];	RCV000268013.1 [benign]; 			114	80					EDAR (inh=AR+AD pLI=0.00)
chr2	109511765	109511765	A	G	hom	hom	hom		QUAL=23775;DP=409,131,187;MQM=60	EDAR	3'UTR	EDAR:NM_022336.3:3'UTR:MODIFIER:exon12/12:c.*1598T>C:		rs10865025	0.6699	0.0000	0/0/0	0.1344							604095 [EDAR (confirmed) Ectodermal dysplasia 10A,hypohidrotic/hair/nail type,autosomal dominant,129490|Ectodermal dysplasia 10B,hypohidrotic/hair/tooth type,autosomal recessive,224900|Hair morphology 1,hair thickness,612630];	RCV000374162.1 [benign]; 			167	54					EDAR (inh=AR+AD pLI=0.00)
chr2	109512234	109512234	T	C	hom	hom	hom		QUAL=41846;DP=417,372,504;MQM=59	EDAR	3'UTR	EDAR:NM_022336.3:3'UTR:MODIFIER:exon12/12:c.*1129A>G:	MIR3	rs13001699	0.7208	0.0000	0/0/0	0.1380							604095 [EDAR (confirmed) Ectodermal dysplasia 10A,hypohidrotic/hair/nail type,autosomal dominant,129490|Ectodermal dysplasia 10B,hypohidrotic/hair/tooth type,autosomal recessive,224900|Hair morphology 1,hair thickness,612630];	RCV000400545.1 [benign]; 			173	48					EDAR (inh=AR+AD pLI=0.00)
chr2	109513321	109513321	C	A	hom	hom	hom		QUAL=20607;DP=250,163,240;MQM=59	EDAR	3'UTR	EDAR:NM_022336.3:3'UTR:MODIFIER:exon12/12:c.*42G>T:		rs7607563	0.8830	0.9066	34504/18960/2193	0.8647							604095 [EDAR (confirmed) Ectodermal dysplasia 10A,hypohidrotic/hair/nail type,autosomal dominant,129490|Ectodermal dysplasia 10B,hypohidrotic/hair/tooth type,autosomal recessive,224900|Hair morphology 1,hair thickness,612630];	RCV000143979.1 [not provided]; RCV000367811.1 [benign]; 			617	134					EDAR (inh=AR+AD pLI=0.00)
chr2	109513654	109513654	G	A	hom	hom	hom		QUAL=23709;DP=250,211,313;MQM=59	EDAR	synonymous	EDAR:NM_022336.3:synonymous:LOW:exon12/12:c.1056C>T:p.Cys352Cys		rs12623957	0.7119	0.8103	40324/23145/924	0.7975							604095 [EDAR (confirmed) Ectodermal dysplasia 10A,hypohidrotic/hair/nail type,autosomal dominant,129490|Ectodermal dysplasia 10B,hypohidrotic/hair/tooth type,autosomal recessive,224900|Hair morphology 1,hair thickness,612630];	RCV000143982.1 [uncertain significance]; RCV000150610.3 [benign]; RCV000269800.1 [benign]; 			1067	435					EDAR (inh=AR+AD pLI=0.00)
chr2	109526969	109526969	G	A	hom	hom	hom		QUAL=24329;DP=247,196,307;MQM=59	EDAR	synonymous	EDAR:NM_022336.3:synonymous:LOW:exon9/12:c.750C>T:p.Ser250Ser		rs260632	0.9213	0.9170	50929/27250/4027	0.8948							604095 [EDAR (confirmed) Ectodermal dysplasia 10A,hypohidrotic/hair/nail type,autosomal dominant,129490|Ectodermal dysplasia 10B,hypohidrotic/hair/tooth type,autosomal recessive,224900|Hair morphology 1,hair thickness,612630];	RCV000143987.1 [uncertain significance]; RCV000150611.2 [benign]; RCV000285005.1 [benign]; 		COSM3766486, COSM3766485	1309	241					EDAR (inh=AR+AD pLI=0.00)
chr2	110922703	110922703	C	T	hom	het	het		QUAL=11612;DP=217,145,191;MQM=60	NPHP1	synonymous	NPHP1:NM_000272.3:synonymous:LOW:exon7/20:c.654G>A:p.Glu218Glu,NPHP1:NM_001128178.1:synonymous:LOW:exon7/20:c.654G>A:p.Glu218Glu,NPHP1:NM_001128179.1:synonymous:LOW:exon5/18:c.468G>A:p.Glu156Glu,NPHP1:NM_207181.2:synonymous:LOW:exon7/20:c.654G>A:p.Glu218Glu		rs11675767	0.4744	0.3793	9426/3514/1250	0.3768							607100 [NPHP1 (confirmed) Nephronophthisis 1,juvenile,256100|Senior-Loken syndrome-1,266900|Joubert syndrome 4,609583];	RCV000078490.9 [other]; RCV000313743.1 [benign]; RCV000367290.1 [benign]; RCV000400518.1 [benign]; 			356	1182					NPHP1 (inh=AR pLI=0.00)
chr2	113820476	113820476	T	C	het	het	het		QUAL=4008;DP=169,78,120;MQM=60	IL36RN	3'UTR	IL36RN:NM_012275.2:3'UTR:MODIFIER:exon5/5:c.*222T>C:,IL36RN:NM_173170.1:3'UTR:MODIFIER:exon5/5:c.*222T>C:		rs2515401	0.7153	0.0000	0/0/0	0.1115							605507 [IL36RN (confirmed) Psoriasis 14,pustular,614204];	RCV000262540.1 [benign]; 			91	108					IL36RN (inh=AR pLI=0.00)
chr2	113820530	113820530	A	G	het	het	het		QUAL=4095;DP=174,85,114;MQM=59	IL36RN	3'UTR	IL36RN:NM_012275.2:3'UTR:MODIFIER:exon5/5:c.*276A>G:,IL36RN:NM_173170.1:3'UTR:MODIFIER:exon5/5:c.*276A>G:		rs1800930	0.7155	0.0000	0/0/0	0.6546							605507 [IL36RN (confirmed) Psoriasis 14,pustular,614204];	RCV000317835.1 [benign]; 			90	109					IL36RN (inh=AR pLI=0.00)
chr2	113820580	113820580	C	A	het	het	het		QUAL=4316;DP=183,97,152;MQM=60	IL36RN	3'UTR	IL36RN:NM_012275.2:3'UTR:MODIFIER:exon5/5:c.*326C>A:,IL36RN:NM_173170.1:3'UTR:MODIFIER:exon5/5:c.*326C>A:		rs2515402	0.7155	0.0000	0/0/0	0.6544							605507 [IL36RN (confirmed) Psoriasis 14,pustular,614204];	RCV000323693.1 [benign]; 			92	105					IL36RN (inh=AR pLI=0.00)
chr2	113820655	113820655	A	T	het	het	het		QUAL=7343;DP=189,163,249;MQM=60	IL36RN	3'UTR	IL36RN:NM_012275.2:3'UTR:MODIFIER:exon5/5:c.*401A>T:,IL36RN:NM_173170.1:3'UTR:MODIFIER:exon5/5:c.*401A>T:		rs3180234	0.7151	0.0000	0/0/0	0.1110							605507 [IL36RN (confirmed) Psoriasis 14,pustular,614204];	RCV000377776.1 [uncertain significance]; RCV000283822.1 [benign]; 			91	108					IL36RN (inh=AR pLI=0.00)
chr2	113820672	113820672	A	G	het	het	het		QUAL=8420;DP=218,176,265;MQM=60	IL36RN	3'UTR	IL36RN:NM_012275.2:3'UTR:MODIFIER:exon5/5:c.*418A>G:,IL36RN:NM_173170.1:3'UTR:MODIFIER:exon5/5:c.*418A>G:		rs3180235	0.7151	0.0000	0/0/0	0.1112							605507 [IL36RN (confirmed) Psoriasis 14,pustular,614204];	RCV000348147.1 [benign]; 			91	107					IL36RN (inh=AR pLI=0.00)
chr2	113820732	113820732	T	C	het	het	het		QUAL=9904;DP=278,246,311;MQM=59	IL36RN	3'UTR	IL36RN:NM_012275.2:3'UTR:MODIFIER:exon5/5:c.*478T>C:,IL36RN:NM_173170.1:3'UTR:MODIFIER:exon5/5:c.*478T>C:		rs2515403	0.7153	0.0000	0/0/0	0.6537							605507 [IL36RN (confirmed) Psoriasis 14,pustular,614204];	RCV000384030.1 [benign]; 			91	107					IL36RN (inh=AR pLI=0.00)
chr2	113820814	113820814	C	G	het	het	het		QUAL=7791;DP=224,203,232;MQM=60	IL36RN	3'UTR	IL36RN:NM_012275.2:3'UTR:MODIFIER:exon5/5:c.*560C>G:,IL36RN:NM_173170.1:3'UTR:MODIFIER:exon5/5:c.*560C>G:		rs2472188	0.7153	0.0000	0/0/0	0.1113							605507 [IL36RN (confirmed) Psoriasis 14,pustular,614204];	RCV000289570.1 [benign]; 			91	108					IL36RN (inh=AR pLI=0.00)
chr2	113821117	113821117	C	T	het	het	het		QUAL=6757;DP=330,108,140;MQM=60	IL36RN	3'UTR	IL36RN:NM_012275.2:3'UTR:MODIFIER:exon5/5:c.*863C>T:,IL36RN:NM_173170.1:3'UTR:MODIFIER:exon5/5:c.*863C>T:	L1ME4a	rs2515404	0.8698	0.0000	0/0/0	0.1293							605507 [IL36RN (confirmed) Psoriasis 14,pustular,614204];	RCV000349605.1 [benign]; 			109	85					IL36RN (inh=AR pLI=0.00)
chr2	113821200	113821200	T	C	het	het	het		QUAL=5044;DP=163,107,131;MQM=60	IL36RN	3'UTR	IL36RN:NM_012275.2:3'UTR:MODIFIER:exon5/5:c.*946T>C:,IL36RN:NM_173170.1:3'UTR:MODIFIER:exon5/5:c.*946T>C:		rs957201	0.7153	0.0000	0/0/0	0.1115							605507 [IL36RN (confirmed) Psoriasis 14,pustular,614204];	RCV000300576.1 [benign]; 			88	102					IL36RN (inh=AR pLI=0.00)
chr2	113821653	113821653	T	C	het	het	het		QUAL=12895;DP=370,276,408;MQM=59	IL36RN	3'UTR	IL36RN:NM_012275.2:3'UTR:MODIFIER:exon5/5:c.*1399T>C:,IL36RN:NM_173170.1:3'UTR:MODIFIER:exon5/5:c.*1399T>C:	MLT1C2	rs768627	0.7153	0.0000	0/0/0	0.1116							605507 [IL36RN (confirmed) Psoriasis 14,pustular,614204];	RCV000361128.1 [benign]; 			84	90					IL36RN (inh=AR pLI=0.00)
chr2	113875509	113875509	G	A	wt	het	wt		QUAL=1894;DP=221,155,162;MQM=60	IL1RN	5'UTR	IL1RN:NM_173841.2:5'UTR:MODIFIER:exon1/6:c.-87G>A:,IL1RN:NM_000577.4:5'UTR:MODIFIER:exon1/5:c.-87G>A:,IL1RN:NM_001318914.1:5'UTR:MODIFIER:exon1/7:c.-369G>A:,IL1RN:NM_173843.2:5'UTR:MODIFIER:exon1/6:c.-306G>A:		rs2234677	0.1865	0.0000	0/0/0	0.0465							147679 [IL1RN (confirmed) Gastric cancer risk after H. pylori infection,137215|Microvascular complications of diabetes 4,612628|Interleukin 1 receptor antagonist deficiency,612852];	RCV000402395.1 [benign]; 			24	95					IL1RN (inh=AR pLI=0.34)
chr2	113875565	113875565	A	G	wt	het	wt		QUAL=2339;DP=288,169,201;MQM=60	IL1RN	5'UTR	IL1RN:NM_173841.2:5'UTR:MODIFIER:exon1/6:c.-31A>G:,IL1RN:NM_000577.4:5'UTR:MODIFIER:exon1/5:c.-31A>G:,IL1RN:NM_001318914.1:5'UTR:MODIFIER:exon1/7:c.-313A>G:,IL1RN:NM_173843.2:5'UTR:MODIFIER:exon1/6:c.-250A>G:	L3b	rs2234678	0.1859	0.2448	4175/2484/18	0.2411							147679 [IL1RN (confirmed) Gastric cancer risk after H. pylori infection,137215|Microvascular complications of diabetes 4,612628|Interleukin 1 receptor antagonist deficiency,612852];	RCV000264084.1 [benign]; 			75	352					IL1RN (inh=AR pLI=0.34)
chr2	113875584	113875584	G	C	wt	het	wt		QUAL=2316;DP=237,164,177;MQM=59	IL1RN	5'UTR	IL1RN:NM_173841.2:5'UTR:MODIFIER:exon1/6:c.-12G>C:,IL1RN:NM_000577.4:5'UTR:MODIFIER:exon1/5:c.-12G>C:,IL1RN:NM_001318914.1:5'UTR:MODIFIER:exon1/7:c.-294G>C:,IL1RN:NM_173843.2:5'UTR:MODIFIER:exon1/6:c.-231G>C:	L3b	rs2234679	0.1859	0.2448	4174/2483/18	0.2417							147679 [IL1RN (confirmed) Gastric cancer risk after H. pylori infection,137215|Microvascular complications of diabetes 4,612628|Interleukin 1 receptor antagonist deficiency,612852];	RCV000309920.1 [benign]; 			80	370					IL1RN (inh=AR pLI=0.34)
chr2	113877713	113877713	A	C	wt	het	het		QUAL=6211;DP=173,216,284;MQM=60	IL1RN	splice_region&intron,intron	IL1RN:NM_173841.2:splice_region&intron:LOW:exon2/5:c.73+8A>C:,IL1RN:NM_001318914.1:splice_region&intron:LOW:exon2/6:c.-210+8A>C:,IL1RN:NM_000577.4:intron:MODIFIER:exon1/4:c.10+2108A>C:,IL1RN:NM_173843.2:intron:MODIFIER:exon1/5:c.-209-1312A>C:		rs878972	0.1897	0.2457	4164/2463/21	0.2362							147679 [IL1RN (confirmed) Gastric cancer risk after H. pylori infection,137215|Microvascular complications of diabetes 4,612628|Interleukin 1 receptor antagonist deficiency,612852];	RCV000364652.1 [benign]; 			108	574					IL1RN (inh=AR pLI=0.34)
chr2	113887207	113887207	T	C	het	hom	wt		QUAL=2257;DP=110,29,46;MQM=60	IL1RN	synonymous	IL1RN:NM_173841.2:synonymous:LOW:exon4/6:c.180T>C:p.Ala60Ala,IL1RN:NM_000577.4:synonymous:LOW:exon3/5:c.117T>C:p.Ala39Ala,IL1RN:NM_001318914.1:synonymous:LOW:exon5/7:c.69T>C:p.Ala23Ala,IL1RN:NM_173843.2:synonymous:LOW:exon4/6:c.69T>C:p.Ala23Ala,IL1RN:NM_173842.2:synonymous:LOW:exon2/4:c.171T>C:p.Ala57Ala		rs419598	0.1917	0.2491	4299/2596/27	0.2452							147679 [IL1RN (confirmed) Gastric cancer risk after H. pylori infection,137215|Microvascular complications of diabetes 4,612628|Interleukin 1 receptor antagonist deficiency,612852];	RCV000389038.1 [benign]; 	CM025329 [CLASS=DP MUT=ALT PHEN="Alopecia areata association with" GENE=IL1RN]; 	COSM3766494, COSM3766495, COSM3766493	116	579					IL1RN (inh=AR pLI=0.34)
chr2	113890304	113890304	T	C	wt	wt	het		QUAL=1510;DP=198,116,153;MQM=60	IL1RN	synonymous	IL1RN:NM_173841.2:synonymous:LOW:exon6/6:c.399T>C:p.Ser133Ser,IL1RN:NM_000577.4:synonymous:LOW:exon5/5:c.336T>C:p.Ser112Ser,IL1RN:NM_001318914.1:synonymous:LOW:exon7/7:c.288T>C:p.Ser96Ser,IL1RN:NM_173843.2:synonymous:LOW:exon6/6:c.288T>C:p.Ser96Ser,IL1RN:NM_173842.2:synonymous:LOW:exon4/4:c.390T>C:p.Ser130Ser		rs315952	0.3500	0.3082	6588/2918/995	0.3087							147679 [IL1RN (confirmed) Gastric cancer risk after H. pylori infection,137215|Microvascular complications of diabetes 4,612628|Interleukin 1 receptor antagonist deficiency,612852];	RCV000330957.1 [benign]; 			115	590					IL1RN (inh=AR pLI=0.34)
chr2	113890586	113890586	C	G	wt	wt	het		QUAL=4236;DP=189,311,388;MQM=60	IL1RN	3'UTR	IL1RN:NM_173841.2:3'UTR:MODIFIER:exon6/6:c.*138C>G:,IL1RN:NM_000577.4:3'UTR:MODIFIER:exon5/5:c.*138C>G:,IL1RN:NM_001318914.1:3'UTR:MODIFIER:exon7/7:c.*138C>G:,IL1RN:NM_173843.2:3'UTR:MODIFIER:exon6/6:c.*138C>G:,IL1RN:NM_173842.2:3'UTR:MODIFIER:exon4/4:c.*138C>G:		rs315951	0.3550	0.0000	0/0/0	0.0570							147679 [IL1RN (confirmed) Gastric cancer risk after H. pylori infection,137215|Microvascular complications of diabetes 4,612628|Interleukin 1 receptor antagonist deficiency,612852];	RCV000279064.1 [benign]; 			15	101					IL1RN (inh=AR pLI=0.34)
chr2	113891412	113891412	G	A	hom	hom	het		QUAL=12529;DP=148,169,245;MQM=59	IL1RN	3'UTR	IL1RN:NM_173841.2:3'UTR:MODIFIER:exon6/6:c.*964G>A:,IL1RN:NM_000577.4:3'UTR:MODIFIER:exon5/5:c.*964G>A:,IL1RN:NM_001318914.1:3'UTR:MODIFIER:exon7/7:c.*964G>A:,IL1RN:NM_173843.2:3'UTR:MODIFIER:exon6/6:c.*964G>A:,IL1RN:NM_173842.2:3'UTR:MODIFIER:exon4/4:c.*964G>A:	L2b	rs9005	0.3199	0.0000	0/0/0	0.0539							147679 [IL1RN (confirmed) Gastric cancer risk after H. pylori infection,137215|Microvascular complications of diabetes 4,612628|Interleukin 1 receptor antagonist deficiency,612852];	RCV000355397.1 [benign]; 			30	104					IL1RN (inh=AR pLI=0.34)
chr2	113973632	113973632	G	A	wt	wt	het		QUAL=1965;DP=289,112,151;MQM=60	PAX8	3'UTR	PAX8:NM_003466.3:3'UTR:MODIFIER:exon12/12:c.*2478C>T:,PAX8:NM_013952.3:3'UTR:MODIFIER:exon12/12:c.*2555C>T:,PAX8:NM_013953.3:3'UTR:MODIFIER:exon10/10:c.*2555C>T:,PAX8:NM_013992.3:3'UTR:MODIFIER:exon9/9:c.*2555C>T:		rs2019137	0.4557	0.0000	0/0/0	0.3553							167415 [PAX8 (confirmed) Hypothyroidism,congenital,due to thyroid dysgenesis or hypoplasia,218700];	RCV000346185.1 [likely benign]; 			51	109					PAX8 (inh=n/a pLI=0.90)
chr2	113973801	113973801	T	C	wt	het	het		QUAL=3451;DP=240,109,160;MQM=60	PAX8	3'UTR	PAX8:NM_003466.3:3'UTR:MODIFIER:exon12/12:c.*2309A>G:,PAX8:NM_013952.3:3'UTR:MODIFIER:exon12/12:c.*2386A>G:,PAX8:NM_013953.3:3'UTR:MODIFIER:exon10/10:c.*2386A>G:,PAX8:NM_013992.3:3'UTR:MODIFIER:exon9/9:c.*2386A>G:		rs1077855	0.7943	0.0000	0/0/0	0.0954							167415 [PAX8 (confirmed) Hypothyroidism,congenital,due to thyroid dysgenesis or hypoplasia,218700];	RCV000311544.1 [benign]; 			116	97					PAX8 (inh=n/a pLI=0.90)
chr2	113973964	113973964	T	C	wt	wt	het		QUAL=3386;DP=272,158,246;MQM=60	PAX8	3'UTR	PAX8:NM_003466.3:3'UTR:MODIFIER:exon12/12:c.*2146A>G:,PAX8:NM_013952.3:3'UTR:MODIFIER:exon12/12:c.*2223A>G:,PAX8:NM_013953.3:3'UTR:MODIFIER:exon10/10:c.*2223A>G:,PAX8:NM_013992.3:3'UTR:MODIFIER:exon9/9:c.*2223A>G:		rs895412	0.4543	0.0000	0/0/0	0.3564							167415 [PAX8 (confirmed) Hypothyroidism,congenital,due to thyroid dysgenesis or hypoplasia,218700];	RCV000300927.1 [likely benign]; 			55	113					PAX8 (inh=n/a pLI=0.90)
chr2	113974196	113974196	G	C	wt	het	wt		QUAL=5571;DP=534,452,642;MQM=60	PAX8	3'UTR	PAX8:NM_003466.3:3'UTR:MODIFIER:exon12/12:c.*1914C>G:,PAX8:NM_013952.3:3'UTR:MODIFIER:exon12/12:c.*1991C>G:,PAX8:NM_013953.3:3'UTR:MODIFIER:exon10/10:c.*1991C>G:,PAX8:NM_013992.3:3'UTR:MODIFIER:exon9/9:c.*1991C>G:		rs874898	0.3249	0.0000	0/0/0	0.0457							167415 [PAX8 (confirmed) Hypothyroidism,congenital,due to thyroid dysgenesis or hypoplasia,218700];	RCV000322907.1 [likely benign]; 			15	75					PAX8 (inh=n/a pLI=0.90)
chr2	113975110	113975110	A	G	hom	het	het		QUAL=9499;DP=169,136,184;MQM=60	PAX8	3'UTR	PAX8:NM_003466.3:3'UTR:MODIFIER:exon12/12:c.*1000T>C:,PAX8:NM_013952.3:3'UTR:MODIFIER:exon12/12:c.*1077T>C:,PAX8:NM_013953.3:3'UTR:MODIFIER:exon10/10:c.*1077T>C:,PAX8:NM_013992.3:3'UTR:MODIFIER:exon9/9:c.*1077T>C:		rs1049137	0.1460	0.0000	0/0/0	0.0235							167415 [PAX8 (confirmed) Hypothyroidism,congenital,due to thyroid dysgenesis or hypoplasia,218700];	RCV000381833.1 [likely benign]; 			14	98					PAX8 (inh=n/a pLI=0.90)
chr2	113975820	113975820	C	T	wt	wt	het		QUAL=2017;DP=93,115,169;MQM=60	PAX8	3'UTR	PAX8:NM_003466.3:3'UTR:MODIFIER:exon12/12:c.*290G>A:,PAX8:NM_013952.3:3'UTR:MODIFIER:exon12/12:c.*367G>A:,PAX8:NM_013953.3:3'UTR:MODIFIER:exon10/10:c.*367G>A:,PAX8:NM_013992.3:3'UTR:MODIFIER:exon9/9:c.*367G>A:		rs144113497	0.0040	0.0000	0/0/0	0.0018							167415 [PAX8 (confirmed) Hypothyroidism,congenital,due to thyroid dysgenesis or hypoplasia,218700];				1	14					PAX8 (inh=n/a pLI=0.90)
chr2	114036436	114036436	G	C	hom	hom	hom	anno_pathogenic_hgmd	QUAL=11806;DP=82,137,168;MQM=60	PAX8	5'UTR	PAX8:NM_003466.3:5'UTR:MODIFIER:exon1/12:c.-104C>G:,PAX8:NM_013952.3:5'UTR:MODIFIER:exon1/12:c.-104C>G:,PAX8:NM_013953.3:5'UTR:MODIFIER:exon1/10:c.-104C>G:,PAX8:NM_013992.3:5'UTR:MODIFIER:exon1/9:c.-104C>G:		rs2084163	0.9764	0.0000	0/0/0	0.1495							167415 [PAX8 (confirmed) Hypothyroidism,congenital,due to thyroid dysgenesis or hypoplasia,218700];		CR161107 [CLASS=DM? MUT=REF PHEN="Thyroid dysgenesis" GENE=PAX8]; 		230	0					PAX8 (inh=n/a pLI=0.90)
chr2	121726447	121726447	G	A	hom	hom	hom		QUAL=9532;DP=83,108,148;MQM=60	GLI2	synonymous	GLI2:NM_005270.4:synonymous:LOW:exon5/13:c.801G>A:p.Ser267Ser		rs2592595	0.8273	0.9401	54822/32314/1206	0.9099	-5.5090	T,T	T	B		8.35	165230 [GLI2 (confirmed) Holoprosencephaly 9,610829|Culler-Jones syndrome,615849];	RCV000247010.1 [benign]; RCV000346541.1 [benign]; 			1462	94					GLI2 (inh=AD pLI=1.00)
chr2	121746956	121746956	G	T	hom	hom	hom		QUAL=16964;DP=89,178,296;MQM=59	GLI2	missense	GLI2:NM_005270.4:missense:MODERATE:exon13/13:c.3466G>T:p.Ala1156Ser		rs3738880	0.5090	0.6296	23928/16654/739	0.6228	-0.3680	T,T	T	B,B	T,T	2.06	165230 [GLI2 (confirmed) Holoprosencephaly 9,610829|Culler-Jones syndrome,615849];	RCV000081284.5 [benign]; RCV000273393.1 [benign]; 			710	663					GLI2 (inh=AD pLI=1.00)
chr2	121747406	121747406	G	A	hom	hom	hom	pred_pathogenic	QUAL=21143;DP=189,213,270;MQM=59	GLI2	missense	GLI2:NM_005270.4:missense:MODERATE:exon13/13:c.3916G>A:p.Asp1306Asn		rs12711538	0.5671	0.6464	24934/16738/1632	0.6370	2.1560	T,T	T	B,B	T,T	0.39	165230 [GLI2 (confirmed) Holoprosencephaly 9,610829|Culler-Jones syndrome,615849];	RCV000081285.5 [benign]; RCV000340352.1 [benign]; 		COSM3757603	724	664					GLI2 (inh=AD pLI=1.00)
chr2	121747429	121747429	A	G	hom	hom	hom		QUAL=22752;DP=193,233,307;MQM=59	GLI2	synonymous	GLI2:NM_005270.4:synonymous:LOW:exon13/13:c.3939A>G:p.Pro1313Pro		rs10167980	0.5124	0.6344	24344/16984/768	0.6008							165230 [GLI2 (confirmed) Holoprosencephaly 9,610829|Culler-Jones syndrome,615849];	RCV000081286.5 [benign]; RCV000287111.1 [benign]; 		COSM3721935	721	667					GLI2 (inh=AD pLI=1.00)
chr2	121749067	121749067	G	C	hom	hom	hom		QUAL=20242;DP=247,160,227;MQM=60	GLI2	3'UTR	GLI2:NM_005270.4:3'UTR:MODIFIER:exon13/13:c.*816G>C:		rs2278741	0.5078	0.0000	0/0/0	0.1090							165230 [GLI2 (confirmed) Holoprosencephaly 9,610829|Culler-Jones syndrome,615849];	RCV000314058.1 [benign]; 			115	95					GLI2 (inh=AD pLI=1.00)
chr2	121749584	121749589	ACACAC	-	hom	wt	hom		QUAL=1688;DP=57,28,89;MQM=59	GLI2	3'UTR	GLI2:NM_005270.4:3'UTR:MODIFIER:exon13/13:c.*1371_*1376delACACAC:	(AC)n		0.0000	0.0000	0/0/0	0.0001							165230 [GLI2 (confirmed) Holoprosencephaly 9,610829|Culler-Jones syndrome,615849];	RCV000384685.1 [uncertain significance]; 			0	1					GLI2 (inh=AD pLI=1.00)
chr2	121749583	121749583	-	ACAC	wt	hom	wt		QUAL=1688;DP=57,28,89;MQM=59	GLI2	3'UTR	GLI2:NM_005270.4:3'UTR:MODIFIER:exon13/13:c.*1373_*1376dupACAC:		rs878912620	0.0000	0.0000	0/0/0	0.0002							165230 [GLI2 (confirmed) Holoprosencephaly 9,610829|Culler-Jones syndrome,615849];				5	4					GLI2 (inh=AD pLI=1.00)
chr2	127816632	127816632	G	A	wt	het	wt		QUAL=1158;DP=33,90,118;MQM=60	BIN1	synonymous	BIN1:NM_139343.2:synonymous:LOW:exon11/19:c.957C>T:p.Ala319Ala,BIN1:NM_001320634.1:synonymous:LOW:exon10/13:c.792C>T:p.Ala264Ala,BIN1:NM_001320642.1:synonymous:LOW:exon11/19:c.876C>T:p.Ala292Ala,BIN1:NM_001320632.1:synonymous:LOW:exon11/14:c.909C>T:p.Ala303Ala,BIN1:NM_001320633.1:synonymous:LOW:exon11/15:c.957C>T:p.Ala319Ala,BIN1:NM_001320640.1:synonymous:LOW:exon11/16:c.957C>T:p.Ala319Ala,BIN1:NM_001320641.1:synonymous:LOW:exon10/18:c.864C>T:p.Ala288Ala,BIN1:NM_004305.3:synonymous:LOW:exon11/15:c.909C>T:p.Ala303Ala,BIN1:NM_139344.2:synonymous:LOW:exon11/18:c.957C>T:p.Ala319Ala,BIN1:NM_139345.2:synonymous:LOW:exon11/16:c.957C>T:p.Ala319Ala,BIN1:NM_139346.2:synonymous:LOW:exon11/16:c.909C>T:p.Ala303Ala,BIN1:NM_139347.2:synonymous:LOW:exon10/16:c.864C>T:p.Ala288Ala,BIN1:NM_139348.2:synonymous:LOW:exon10/15:c.864C>T:p.Ala288Ala,BIN1:NM_139349.2:synonymous:LOW:exon10/15:c.864C>T:p.Ala288Ala,BIN1:NM_139350.2:synonymous:LOW:exon10/14:c.864C>T:p.Ala288Ala,BIN1:NM_139351.2:synonymous:LOW:exon10/13:c.864C>T:p.Ala288Ala		rs2276579	0.0946	0.2553	863/681/5	0.1294							601248 [BIN1 (provisional) Myopathy,centronuclear,autosomal recessive,255200];	RCV000145353.4 [other]; RCV000319647.1 [likely benign]; RCV000145352.1 [uncertain significance]; RCV000145351.1 [uncertain significance]; 		COSM3757611, COSM3757610	58	483					BIN1 (inh=AR pLI=0.47)
chr2	127819777	127819777	C	T	het	wt	het		QUAL=5043;DP=161,236,315;MQM=59	BIN1	splice_region&intron	BIN1:NM_139343.2:splice_region&intron:LOW:exon9/18:c.775-4G>A:,BIN1:NM_001320634.1:splice_region&intron:LOW:exon8/12:c.610-4G>A:,BIN1:NM_001320642.1:splice_region&intron:LOW:exon9/18:c.694-4G>A:,BIN1:NM_001320632.1:splice_region&intron:LOW:exon8/13:c.682-4G>A:,BIN1:NM_001320633.1:splice_region&intron:LOW:exon9/14:c.775-4G>A:,BIN1:NM_001320640.1:splice_region&intron:LOW:exon9/15:c.775-4G>A:,BIN1:NM_001320641.1:splice_region&intron:LOW:exon8/17:c.682-4G>A:,BIN1:NM_004305.3:splice_region&intron:LOW:exon8/14:c.682-4G>A:,BIN1:NM_139344.2:splice_region&intron:LOW:exon9/17:c.775-4G>A:,BIN1:NM_139345.2:splice_region&intron:LOW:exon9/15:c.775-4G>A:,BIN1:NM_139346.2:splice_region&intron:LOW:exon8/15:c.682-4G>A:,BIN1:NM_139347.2:splice_region&intron:LOW:exon8/15:c.682-4G>A:,BIN1:NM_139348.2:splice_region&intron:LOW:exon8/14:c.682-4G>A:,BIN1:NM_139349.2:splice_region&intron:LOW:exon8/14:c.682-4G>A:,BIN1:NM_139350.2:splice_region&intron:LOW:exon8/13:c.682-4G>A:,BIN1:NM_139351.2:splice_region&intron:LOW:exon8/12:c.682-4G>A:		rs61748157	0.0972	0.1580	711/375/15	0.1055							601248 [BIN1 (provisional) Myopathy,centronuclear,autosomal recessive,255200];	RCV000145347.3 [benign]; RCV000381094.1 [likely benign]; 			26	374					BIN1 (inh=AR pLI=0.47)
chr2	127826533	127826533	A	G	wt	het	wt		QUAL=2331;DP=193,232,325;MQM=60	BIN1	synonymous	BIN1:NM_139343.2:synonymous:LOW:exon6/19:c.486T>C:p.Thr162Thr,BIN1:NM_001320634.1:synonymous:LOW:exon6/13:c.414T>C:p.Thr138Thr,BIN1:NM_001320642.1:synonymous:LOW:exon6/19:c.405T>C:p.Thr135Thr,BIN1:NM_001320632.1:synonymous:LOW:exon6/14:c.486T>C:p.Thr162Thr,BIN1:NM_001320633.1:synonymous:LOW:exon6/15:c.486T>C:p.Thr162Thr,BIN1:NM_001320640.1:synonymous:LOW:exon6/16:c.486T>C:p.Thr162Thr,BIN1:NM_001320641.1:synonymous:LOW:exon6/18:c.486T>C:p.Thr162Thr,BIN1:NM_004305.3:synonymous:LOW:exon6/15:c.486T>C:p.Thr162Thr,BIN1:NM_139344.2:synonymous:LOW:exon6/18:c.486T>C:p.Thr162Thr,BIN1:NM_139345.2:synonymous:LOW:exon6/16:c.486T>C:p.Thr162Thr,BIN1:NM_139346.2:synonymous:LOW:exon6/16:c.486T>C:p.Thr162Thr,BIN1:NM_139347.2:synonymous:LOW:exon6/16:c.486T>C:p.Thr162Thr,BIN1:NM_139348.2:synonymous:LOW:exon6/15:c.486T>C:p.Thr162Thr,BIN1:NM_139349.2:synonymous:LOW:exon6/15:c.486T>C:p.Thr162Thr,BIN1:NM_139350.2:synonymous:LOW:exon6/14:c.486T>C:p.Thr162Thr,BIN1:NM_139351.2:synonymous:LOW:exon6/13:c.486T>C:p.Thr162Thr		rs1060743	0.3546	0.3344	7107/3039/337	0.3288							601248 [BIN1 (provisional) Myopathy,centronuclear,autosomal recessive,255200];	RCV000145343.3 [other]; RCV000349850.1 [likely benign]; 		COSM3766508, COSM3766507	178	683					BIN1 (inh=AR pLI=0.47)
chr2	135677471	135677471	-	GTTT	het	het	het		QUAL=5897;DP=220,138,206;MQM=59	CCNT2	splice_region&intron	CCNT2:NM_058241.2:splice_region&intron:LOW:exon2/8:c.240+13_240+14insTGTT:,CCNT2:NM_001241.3:splice_region&intron:LOW:exon2/9:c.240+13_240+14insTGTT:,CCNT2:NM_001320748.1:splice_region&intron:LOW:exon2/9:c.-287+13_-287+14insTGTT:,CCNT2:NM_001320749.1:splice_region&intron:LOW:exon2/9:c.-373+13_-373+14insTGTT:,CCNT2:NR_037649.1:splice_region&intron:LOW:exon2/10:n.273+13_273+14insTGTT:,CCNT2:NR_135468.1:splice_region&intron:LOW:exon2/9:n.273+13_273+14insTGTT:		rs3841862;rs45507394	0.4173	0.3331	7509/3221/1074	0.3099											205	534					CCNT2 (inh=n/a pLI=0.50)
chr2	135711516	135711516	C	T	het	het	hom		QUAL=15482;DP=361,190,250;MQM=60	CCNT2	synonymous,non_coding_transcript_exon	CCNT2:NM_058241.2:synonymous:LOW:exon9/9:c.1491C>T:p.Asp497Asp,CCNT2:NM_001241.3:synonymous:LOW:exon9/10:c.1491C>T:p.Asp497Asp,CCNT2:NM_001320748.1:synonymous:LOW:exon10/10:c.1059C>T:p.Asp353Asp,CCNT2:NM_001320749.1:synonymous:LOW:exon10/10:c.966C>T:p.Asp322Asp,CCNT2:NR_037649.1:non_coding_transcript_exon:MODIFIER:exon10/11:n.1611C>T:,CCNT2:NR_135468.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1930C>T:		rs3814355	0.7328	0.5894	23022/9042/2736	0.5780											545	444					CCNT2 (inh=n/a pLI=0.50)
chr2	135711657	135711657	G	A	het	het	hom		QUAL=25388;DP=414,365,469;MQM=59	CCNT2	synonymous,non_coding_transcript_exon	CCNT2:NM_058241.2:synonymous:LOW:exon9/9:c.1632G>A:p.Lys544Lys,CCNT2:NM_001241.3:synonymous:LOW:exon9/10:c.1632G>A:p.Lys544Lys,CCNT2:NM_001320748.1:synonymous:LOW:exon10/10:c.1200G>A:p.Lys400Lys,CCNT2:NM_001320749.1:synonymous:LOW:exon10/10:c.1107G>A:p.Lys369Lys,CCNT2:NR_037649.1:non_coding_transcript_exon:MODIFIER:exon10/11:n.1752G>A:,CCNT2:NR_135468.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.2071G>A:		rs3814354	0.7021	0.5800	22314/8992/2134	0.5691										COSM1399489, COSM1179790	533	451					CCNT2 (inh=n/a pLI=0.50)
chr2	135713386	135713389	AAAA	-	het	het	het		QUAL=7607;DP=263,110,177;MQM=59	CCNT2	3'UTR,non_coding_transcript_exon	CCNT2:NM_058241.2:3'UTR:MODIFIER:exon9/9:c.*1170_*1173delAAAA:,CCNT2:NM_001241.3:3'UTR:MODIFIER:exon10/10:c.*1270_*1273delAAAA:,CCNT2:NM_001320748.1:3'UTR:MODIFIER:exon10/10:c.*1170_*1173delAAAA:,CCNT2:NM_001320749.1:3'UTR:MODIFIER:exon10/10:c.*1170_*1173delAAAA:,CCNT2:NR_037649.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.3382_3385delAAAA:,CCNT2:NR_135468.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.3802_3805delAAAA:		rs397897552	0.0000	0.0000	0/0/0	0.1458											25	101					CCNT2 (inh=n/a pLI=0.50)
chr2	135713703	135713703	G	A	het	het	hom		QUAL=9297;DP=261,70,146;MQM=60	CCNT2	3'UTR,non_coding_transcript_exon	CCNT2:NM_058241.2:3'UTR:MODIFIER:exon9/9:c.*1485G>A:,CCNT2:NM_001241.3:3'UTR:MODIFIER:exon10/10:c.*1585G>A:,CCNT2:NM_001320748.1:3'UTR:MODIFIER:exon10/10:c.*1485G>A:,CCNT2:NM_001320749.1:3'UTR:MODIFIER:exon10/10:c.*1485G>A:,CCNT2:NR_037649.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.3697G>A:,CCNT2:NR_135468.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4117G>A:		rs3769023	0.7059	0.0000	0/0/0	0.0989											93	111					CCNT2 (inh=n/a pLI=0.50)
chr2	135715169	135715169	T	G	wt	wt	het		QUAL=3013;DP=333,177,215;MQM=60	CCNT2	3'UTR,non_coding_transcript_exon	CCNT2:NM_058241.2:3'UTR:MODIFIER:exon9/9:c.*2951T>G:,CCNT2:NM_001241.3:3'UTR:MODIFIER:exon10/10:c.*3051T>G:,CCNT2:NM_001320748.1:3'UTR:MODIFIER:exon10/10:c.*2951T>G:,CCNT2:NM_001320749.1:3'UTR:MODIFIER:exon10/10:c.*2951T>G:,CCNT2:NR_037649.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.5163T>G:,CCNT2:NR_135468.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5583T>G:		rs10167500	0.3435	0.0000	0/0/0	0.2744											16	56					CCNT2 (inh=n/a pLI=0.50)
chr2	135715175	135715175	C	-	het	het	hom		QUAL=13043;DP=325,169,208;MQM=60	CCNT2	3'UTR,non_coding_transcript_exon	CCNT2:NM_058241.2:3'UTR:MODIFIER:exon9/9:c.*2957delC:,CCNT2:NM_001241.3:3'UTR:MODIFIER:exon10/10:c.*3057delC:,CCNT2:NM_001320748.1:3'UTR:MODIFIER:exon10/10:c.*2957delC:,CCNT2:NM_001320749.1:3'UTR:MODIFIER:exon10/10:c.*2957delC:,CCNT2:NR_037649.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.5169delC:,CCNT2:NR_135468.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5589delC:		rs10709967	0.0000	0.0000	0/0/0	0.3683											64	71					CCNT2 (inh=n/a pLI=0.50)
chr2	135715219	135715219	G	A	wt	wt	het		QUAL=2956;DP=308,169,206;MQM=60	CCNT2	3'UTR,non_coding_transcript_exon	CCNT2:NM_058241.2:3'UTR:MODIFIER:exon9/9:c.*3001G>A:,CCNT2:NM_001241.3:3'UTR:MODIFIER:exon10/10:c.*3101G>A:,CCNT2:NM_001320748.1:3'UTR:MODIFIER:exon10/10:c.*3001G>A:,CCNT2:NM_001320749.1:3'UTR:MODIFIER:exon10/10:c.*3001G>A:,CCNT2:NR_037649.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.5213G>A:,CCNT2:NR_135468.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5633G>A:		rs17258232	0.0194	0.0000	0/0/0	0.0387											0	8					CCNT2 (inh=n/a pLI=0.50)
chr2	135715466	135715469	TAAT	-	het	het	hom		QUAL=11143;DP=325,119,175;MQM=59	CCNT2	3'UTR,non_coding_transcript_exon	CCNT2:NM_058241.2:3'UTR:MODIFIER:exon9/9:c.*3252_*3255delTAAT:,CCNT2:NM_001241.3:3'UTR:MODIFIER:exon10/10:c.*3352_*3355delTAAT:,CCNT2:NM_001320748.1:3'UTR:MODIFIER:exon10/10:c.*3252_*3255delTAAT:,CCNT2:NM_001320749.1:3'UTR:MODIFIER:exon10/10:c.*3252_*3255delTAAT:,CCNT2:NR_037649.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.5464_5467delTAAT:,CCNT2:NR_135468.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5884_5887delTAAT:		rs570752784	0.0000	0.0000	0/0/0	0.3652											63	72					CCNT2 (inh=n/a pLI=0.50)
chr2	135715957	135715957	A	G	het	het	hom		QUAL=11406;DP=418,178,146;MQM=59	CCNT2	3'UTR,non_coding_transcript_exon	CCNT2:NM_058241.2:3'UTR:MODIFIER:exon9/9:c.*3739A>G:,CCNT2:NM_001241.3:3'UTR:MODIFIER:exon10/10:c.*3839A>G:,CCNT2:NM_001320748.1:3'UTR:MODIFIER:exon10/10:c.*3739A>G:,CCNT2:NM_001320749.1:3'UTR:MODIFIER:exon10/10:c.*3739A>G:,CCNT2:NR_037649.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.5951A>G:,CCNT2:NR_135468.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.6371A>G:		rs1947112	0.7055	0.0000	0/0/0	0.0980											64	71					CCNT2 (inh=n/a pLI=0.50)
chr2	135716598	135716598	T	C	wt	wt	het		QUAL=2698;DP=416,137,193;MQM=60	CCNT2	3'UTR,non_coding_transcript_exon	CCNT2:NM_058241.2:3'UTR:MODIFIER:exon9/9:c.*4380T>C:,CCNT2:NM_001241.3:3'UTR:MODIFIER:exon10/10:c.*4480T>C:,CCNT2:NM_001320748.1:3'UTR:MODIFIER:exon10/10:c.*4380T>C:,CCNT2:NM_001320749.1:3'UTR:MODIFIER:exon10/10:c.*4380T>C:,CCNT2:NR_037649.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.6592T>C:,CCNT2:NR_135468.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.7012T>C:		rs13389642	0.3435	0.0000	0/0/0	0.0475											16	56					CCNT2 (inh=n/a pLI=0.50)
chr2	135893372	135893372	A	G	wt	het	wt	pred_pathogenic	QUAL=6600;DP=474,510,591;MQM=60	RAB3GAP1	missense	RAB3GAP1:NM_001172435.1:missense:MODERATE:exon17/25:c.1793A>G:p.Asn598Ser,RAB3GAP1:NM_012233.2:missense:MODERATE:exon17/24:c.1793A>G:p.Asn598Ser		rs10445686	0.2145	0.2008	3313/1328/10	0.1943	5.0260	T,T,T	T	B,B	T,T,T	8.67	602536 [RAB3GAP1 (provisional) Warburg micro syndrome 1,600118];	RCV000118091.3 [other]; RCV000307086.1 [benign]; 			138	543					RAB3GAP1 (inh=AR pLI=0.00)
chr2	135911422	135911422	T	C	wt	het	wt		QUAL=3348;DP=163,251,349;MQM=60	RAB3GAP1	synonymous	RAB3GAP1:NM_001172435.1:synonymous:LOW:exon19/25:c.2265T>C:p.Phe755Phe,RAB3GAP1:NM_012233.2:synonymous:LOW:exon19/24:c.2265T>C:p.Phe755Phe		rs17261772	0.7867	0.5174	20988/4925/3972	0.4894							602536 [RAB3GAP1 (provisional) Warburg micro syndrome 1,600118];	RCV000118094.3 [other]; RCV000356679.1 [benign]; 			510	613					RAB3GAP1 (inh=AR pLI=0.00)
chr2	145142173	145142173	T	-	het	wt	het		QUAL=2205;DP=153,34,73;MQM=59	ZEB2	3'UTR	ZEB2:NM_014795.3:3'UTR:MODIFIER:exon10/10:c.*4845delA:,ZEB2:NM_001171653.1:3'UTR:MODIFIER:exon9/9:c.*4845delA:		rs201661554	0.0885	0.0000	0/0/0	0.0230							605802 [ZEB2 (confirmed) Mowat-Wilson syndrome,235730];	RCV000269026.1 [benign]; 			0	14					ZEB2 (inh=AD pLI=1.00)
chr2	145143934	145143934	G	A	het	hom	wt		QUAL=3363;DP=173,36,49;MQM=60	ZEB2	3'UTR	ZEB2:NM_014795.3:3'UTR:MODIFIER:exon10/10:c.*3084C>T:,ZEB2:NM_001171653.1:3'UTR:MODIFIER:exon9/9:c.*3084C>T:		rs62169201	0.0397	0.0000	0/0/0	0.0937							605802 [ZEB2 (confirmed) Mowat-Wilson syndrome,235730];	RCV000289693.1 [benign]; 			4	32					ZEB2 (inh=AD pLI=1.00)
chr2	145144501	145144501	A	C	wt	het	het	low_QUAL;low_DP	QUAL=11;DP=69,17,27;MQM=60	ZEB2	3'UTR	ZEB2:NM_014795.3:3'UTR:MODIFIER:exon10/10:c.*2517T>G:,ZEB2:NM_001171653.1:3'UTR:MODIFIER:exon9/9:c.*2517T>G:			0.0000	0.0000	0/0/0	0.0001							605802 [ZEB2 (confirmed) Mowat-Wilson syndrome,235730];				0	34					ZEB2 (inh=AD pLI=1.00)
chr2	145144612	145144612	-	TA	hom	het	het		QUAL=546;DP=30,28,42;MQM=59	ZEB2	3'UTR	ZEB2:NM_014795.3:3'UTR:MODIFIER:exon10/10:c.*2404_*2405dupTA:,ZEB2:NM_001171653.1:3'UTR:MODIFIER:exon9/9:c.*2404_*2405dupTA:	(TG)n	rs143648355;rs767117745	0.0000	0.0000	0/0/0	0.1746							605802 [ZEB2 (confirmed) Mowat-Wilson syndrome,235730];	RCV000326271.1 [uncertain significance]; RCV000380731.1,RCV000294757.1 [uncertain significance,uncertain significance]; 			6	86					ZEB2 (inh=AD pLI=1.00)
chr2	145145034	145145034	A	G	hom	hom	hom		QUAL=17099;DP=263,113,142;MQM=60	ZEB2	3'UTR	ZEB2:NM_014795.3:3'UTR:MODIFIER:exon10/10:c.*1984T>C:,ZEB2:NM_001171653.1:3'UTR:MODIFIER:exon9/9:c.*1984T>C:		rs10179925	0.9958	0.0000	0/0/0	0.8648							605802 [ZEB2 (confirmed) Mowat-Wilson syndrome,235730];	RCV000368446.1 [benign]; 			180	0					ZEB2 (inh=AD pLI=1.00)
chr2	149270710	149270710	A	G	hom	het	het		QUAL=15036;DP=329,157,167;MQM=60	MBD5	3'UTR	MBD5:NM_018328.4:3'UTR:MODIFIER:exon15/15:c.*200A>G:		rs16828708	0.4491	0.0000	0/0/0	0.0657							611472 [MBD5 (provisional) Mental retardation,autosomal dominant 1,156200];	RCV000380890.1 [likely benign]; 			22	95					MBD5 (inh=AD pLI=1.00)
chr2	149881076	149881076	A	G	hom	hom	hom		QUAL=4686;DP=95,45,84;MQM=55	KIF5C	3'UTR,non_coding_transcript_exon	KIF5C:NM_004522.2:3'UTR:MODIFIER:exon26/26:c.*1492A>G:,KIF5C:NR_111932.1:non_coding_transcript_exon:MODIFIER:exon20/20:n.3990A>G:	(GT)n	rs78917133	0.0000	0.0000	0/0/0	0.0008							604593 [KIF5C (provisional) Cortical dysplasia,complex,with other brain malformations 2,615282];				0	6					KIF5C (inh=AD pLI=1.00)
chr2	152346553	152346553	G	A	het	het	wt	gene_blacklist;anno_high_impact;pred_pathogenic;anno_pathogenic_hgmd	QUAL=4950;DP=279,145,227;MQM=60	NEB	stop_gained	NEB:NM_001271208.1:stop_gained:HIGH:exon182/183:c.25441C>T:p.Arg8481*,NEB:NM_001164507.1:stop_gained:HIGH:exon181/182:c.25336C>T:p.Arg8446*,NEB:NM_001164508.1:stop_gained:HIGH:exon181/182:c.25336C>T:p.Arg8446*,NEB:NM_004543.4:stop_gained:HIGH:exon148/149:c.19732C>T:p.Arg6578*		rs200731870	0.0000	0.0001	0/0/0	0.0001	2.9000					60.00	161650 [NEB (confirmed) Nemaline myopathy 2,autosomal recessive,256030];		CM1413908 [CLASS=DM MUT=ALT PHEN="Nemaline myopathy" GENE=NEB]; 	COSM1590777, COSM1007385, COSM1007383	0	2					NEB (inh=AR pLI=0.00)
chr2	152346979	152346979	T	C	het	het	het	gene_blacklist	QUAL=10901;DP=291,240,301;MQM=60	NEB	missense	NEB:NM_001271208.1:missense:MODERATE:exon181/183:c.25309A>G:p.Ile8437Val,NEB:NM_001164507.1:missense:MODERATE:exon180/182:c.25204A>G:p.Ile8402Val,NEB:NM_001164508.1:missense:MODERATE:exon180/182:c.25204A>G:p.Ile8402Val,NEB:NM_004543.4:missense:MODERATE:exon147/149:c.19600A>G:p.Ile6534Val		rs1061305	0.3343	0.4136	7524/4880/826	0.3635	-0.6960	T,T,T,T,T,T,T,T	T	B,B,B,B	T,T,T,T,T,T,T	12.31	161650 [NEB (confirmed) Nemaline myopathy 2,autosomal recessive,256030];	RCV000081132.9 [other]; RCV000398581.1 [benign]; 			240	690					NEB (inh=AR pLI=0.00)
chr2	152352843	152352843	C	G	hom	hom	hom	gene_blacklist;pred_pathogenic	QUAL=34171;DP=329,321,415;MQM=59	NEB	missense	NEB:NM_001271208.1:missense:MODERATE:exon174/183:c.24538G>C:p.Ala8180Pro,NEB:NM_001164507.1:missense:MODERATE:exon173/182:c.24433G>C:p.Ala8145Pro,NEB:NM_001164508.1:missense:MODERATE:exon173/182:c.24433G>C:p.Ala8145Pro,NEB:NM_004543.4:missense:MODERATE:exon140/149:c.18829G>C:p.Ala6277Pro		rs7575451	0.6278	0.6499	24235/13117/1701	0.6285	3.0990	T,T,T,T,T,T,T,T,.,.	T,T,.	B,B,B,B,.,.	T,T,T,T,T,T,T,T,.,.	23.20	161650 [NEB (confirmed) Nemaline myopathy 2,autosomal recessive,256030];	RCV000081126.9 [other]; RCV000266979.1 [benign]; 		COSM4154530, COSM4154529, COSM4154531	647	700					NEB (inh=AR pLI=0.00)
chr2	152354239	152354239	G	A	het	het	wt	gene_blacklist	QUAL=4768;DP=187,221,314;MQM=58	NEB	splice_region&intron,intron	NEB:NM_001271208.1:splice_region&intron:LOW:exon171/182:c.24313-7C>T:,NEB:NM_001164507.1:splice_region&intron:LOW:exon170/181:c.24208-7C>T:,NEB:NM_001164508.1:splice_region&intron:LOW:exon170/181:c.24208-7C>T:,NEB:NM_004543.4:intron:MODIFIER:exon139/148:c.18790-1357C>T:		rs113048349	0.0050	0.0160	2/1/0	0.0072							161650 [NEB (confirmed) Nemaline myopathy 2,autosomal recessive,256030];	RCV000223141.2 [other]; 			0	33					NEB (inh=AR pLI=0.00)
chr2	152387553	152387553	T	C	hom	hom	hom	gene_blacklist	QUAL=36292;DP=376,311,450;MQM=60	NEB	synonymous	NEB:NM_001271208.1:synonymous:LOW:exon146/183:c.21690A>G:p.Thr7230Thr,NEB:NM_001164507.1:synonymous:LOW:exon145/182:c.21585A>G:p.Thr7195Thr,NEB:NM_001164508.1:synonymous:LOW:exon145/182:c.21585A>G:p.Thr7195Thr,NEB:NM_004543.4:synonymous:LOW:exon117/149:c.16446A>G:p.Thr5482Thr		rs4664475	0.4916	0.5830	20606/12509/761	0.5728							161650 [NEB (confirmed) Nemaline myopathy 2,autosomal recessive,256030];	RCV000081120.9 [other]; RCV000375369.1 [benign]; 			570	731					NEB (inh=AR pLI=0.00)
chr2	152388416	152388416	T	-	hom	hom	hom	gene_blacklist	QUAL=18751;DP=190,153,259;MQM=59	NEB	splice_region&intron	NEB:NM_001271208.1:splice_region&intron:LOW:exon144/182:c.21523-6delA:,NEB:NM_001164507.1:splice_region&intron:LOW:exon143/181:c.21418-6delA:,NEB:NM_001164508.1:splice_region&intron:LOW:exon143/181:c.21418-6delA:,NEB:NM_004543.4:splice_region&intron:LOW:exon115/148:c.16279-6delA:		rs398090759	0.4912	0.6045	14652/8850/622	0.5208							161650 [NEB (confirmed) Nemaline myopathy 2,autosomal recessive,256030];	RCV000081118.5 [benign]; RCV000305612.1 [benign]; 			567	733					NEB (inh=AR pLI=0.00)
chr2	152402516	152402516	A	-	wt	wt	hom	gene_blacklist	QUAL=727;DP=121,70,113;MQM=59	NEB	splice_region&intron	NEB:NM_001271208.1:splice_region&intron:LOW:exon134/182:c.20467-4delT:,NEB:NM_001164507.1:splice_region&intron:LOW:exon134/181:c.20467-4delT:,NEB:NM_001164508.1:splice_region&intron:LOW:exon134/181:c.20467-4delT:,NEB:NM_004543.4:splice_region&intron:LOW:exon106/148:c.15328-4delT:	(A)n	rs779970363	0.0000	0.1554	0/0/0	0.0403							161650 [NEB (confirmed) Nemaline myopathy 2,autosomal recessive,256030];	RCV000173947.1 [other]; 			3	20					NEB (inh=AR pLI=0.00)
chr2	152422076	152422076	C	G	het	het	hom	gene_blacklist;pred_pathogenic	QUAL=20112;DP=415,275,328;MQM=60	NEB	missense	NEB:NM_001271208.1:missense:MODERATE:exon116/183:c.18305G>C:p.Arg6102Thr,NEB:NM_001164507.1:missense:MODERATE:exon116/182:c.18305G>C:p.Arg6102Thr,NEB:NM_001164508.1:missense:MODERATE:exon116/182:c.18305G>C:p.Arg6102Thr,NEB:NM_004543.4:missense:MODERATE:exon88/149:c.13166G>C:p.Arg4389Thr		rs2288210	0.6532	0.6707	24879/13497/1824	0.6517	5.7170	T,T,T,T,T,T	T	B	T,T,T,T,T	15.63	161650 [NEB (confirmed) Nemaline myopathy 2,autosomal recessive,256030];	RCV000081115.9 [other]; RCV000293399.1 [benign]; 		COSM4154536, COSM4154537, COSM4154535	670	699					NEB (inh=AR pLI=0.00)
chr2	152422087	152422087	A	G	wt	wt	het	gene_blacklist	QUAL=3934;DP=396,277,322;MQM=60	NEB	synonymous	NEB:NM_001271208.1:synonymous:LOW:exon116/183:c.18294T>C:p.Tyr6098Tyr,NEB:NM_001164507.1:synonymous:LOW:exon116/182:c.18294T>C:p.Tyr6098Tyr,NEB:NM_001164508.1:synonymous:LOW:exon116/182:c.18294T>C:p.Tyr6098Tyr,NEB:NM_004543.4:synonymous:LOW:exon88/149:c.13155T>C:p.Tyr4385Tyr		rs2288211	0.2238	0.2955	4493/2705/34	0.2739							161650 [NEB (confirmed) Nemaline myopathy 2,autosomal recessive,256030];	RCV000081114.9 [other]; RCV000329702.1 [benign]; 		COSM4001213, COSM148950, COSM4001214	150	605					NEB (inh=AR pLI=0.00)
chr2	152424933	152424933	-	A	het	het	hom	gene_blacklist	QUAL=2695;DP=139,77,84;MQM=59	NEB	splice_region&intron	NEB:NM_001271208.1:splice_region&intron:LOW:exon111/182:c.17635-3dupT:,NEB:NM_001164507.1:splice_region&intron:LOW:exon111/181:c.17635-3dupT:,NEB:NM_001164508.1:splice_region&intron:LOW:exon111/181:c.17635-3dupT:,NEB:NM_004543.4:splice_region&intron:LOW:exon83/148:c.12496-3dupT:		rs3214503;rs397772995;rs539518038	0.5066	0.4669	2228/1284/229	0.0712							161650 [NEB (confirmed) Nemaline myopathy 2,autosomal recessive,256030];	RCV000360408.1,RCV000305873.1 [uncertain significance,benign]; 		COSM1613493, COSM1613494, COSM1613492	285	857					NEB (inh=AR pLI=0.00)
chr2	152432311	152432311	T	C	het	het	wt	gene_blacklist	QUAL=4116;DP=220,117,160;MQM=60	NEB	splice_region&synonymous	NEB:NM_001271208.1:splice_region&synonymous:LOW:exon107/183:c.16911A>G:p.Pro5637Pro,NEB:NM_001164507.1:splice_region&synonymous:LOW:exon107/182:c.16911A>G:p.Pro5637Pro,NEB:NM_001164508.1:splice_region&synonymous:LOW:exon107/182:c.16911A>G:p.Pro5637Pro,NEB:NM_004543.4:splice_region&synonymous:LOW:exon79/149:c.11772A>G:p.Pro3924Pro		rs33988153	0.1102	0.1984	2894/2179/12	0.1876							161650 [NEB (confirmed) Nemaline myopathy 2,autosomal recessive,256030];	RCV000081112.9 [other]; RCV000333036.1 [likely benign]; 		COSM3757669, COSM3757668, COSM3757670	100	575					NEB (inh=AR pLI=0.00)
chr2	152436012	152436012	T	G	wt	wt	het	low_MQM;gene_blacklist;pred_pathogenic	QUAL=3801;DP=139,541,681;MQM=25	NEB	missense,intron	NEB:NM_001271208.1:missense:MODERATE:exon105/183:c.16544A>C:p.Lys5515Thr,NEB:NM_001164507.1:missense:MODERATE:exon105/182:c.16544A>C:p.Lys5515Thr,NEB:NM_001164508.1:missense:MODERATE:exon105/182:c.16544A>C:p.Lys5515Thr,NEB:NM_004543.4:intron:MODIFIER:exon77/148:c.11566-3144A>C:		rs62174690	0.0000	0.3436	182/141/1	0.0094	2.1850	D,D,D	T	B	T,T,T	19.94	161650 [NEB (confirmed) Nemaline myopathy 2,autosomal recessive,256030];	RCV000241589.1 [benign]; 		COSM3766519, COSM3766518	122	379					NEB (inh=AR pLI=0.00)
chr2	152448640	152448640	T	C	wt	het	wt	low_MQM;gene_blacklist	QUAL=1828;DP=275,330,407;MQM=37	NEB	missense,intron	NEB:NM_001271208.1:missense:MODERATE:exon95/183:c.14734A>G:p.Asn4912Asp,NEB:NM_001164507.1:missense:MODERATE:exon95/182:c.14734A>G:p.Asn4912Asp,NEB:NM_001164508.1:missense:MODERATE:exon95/182:c.14734A>G:p.Asn4912Asp,NEB:NM_004543.4:intron:MODIFIER:exon77/148:c.11566-15772A>G:		rs10909569	0.0000	0.1775	5/2/1	0.0001	0.5200	T,T	T		T,T	12.71	161650 [NEB (confirmed) Nemaline myopathy 2,autosomal recessive,256030];	RCV000252862.1 [benign]; 		COSM4001216, COSM4001215	3	239					NEB (inh=AR pLI=0.00)
chr2	152459116	152459116	G	A	wt	hom	wt	low_DP;low_MQM;gene_blacklist	QUAL=50;DP=2,3,407;MQM=30	NEB	synonymous,intron	NEB:NM_001271208.1:synonymous:LOW:exon87/183:c.13353C>T:p.Ala4451Ala,NEB:NM_001164507.1:synonymous:LOW:exon87/182:c.13353C>T:p.Ala4451Ala,NEB:NM_001164508.1:synonymous:LOW:exon87/182:c.13353C>T:p.Ala4451Ala,NEB:NM_004543.4:intron:MODIFIER:exon77/148:c.11565+7207C>T:		rs774726264	0.0000	0.0000	0/0/0	0.0001							161650 [NEB (confirmed) Nemaline myopathy 2,autosomal recessive,256030];	RCV000221608.2 [other]; 			343	16					NEB (inh=AR pLI=0.00)
chr2	152476028	152476028	C	G	wt	het	wt	gene_blacklist;pred_pathogenic	QUAL=7244;DP=464,625,906;MQM=60	NEB	missense	NEB:NM_001271208.1:missense:MODERATE:exon73/183:c.10809G>C:p.Trp3603Cys,NEB:NM_001164507.1:missense:MODERATE:exon73/182:c.10809G>C:p.Trp3603Cys,NEB:NM_001164508.1:missense:MODERATE:exon73/182:c.10809G>C:p.Trp3603Cys,NEB:NM_004543.4:missense:MODERATE:exon69/149:c.10044G>C:p.Trp3348Cys		rs10172023	0.2198	0.2891	5272/3422/93	0.2850	1.4940	D,D,D,D	T	D	T,T,T,T	26.80	161650 [NEB (confirmed) Nemaline myopathy 2,autosomal recessive,256030];	RCV000081108.9 [other]; RCV000276282.1 [benign]; 			157	668					NEB (inh=AR pLI=0.00)
chr2	152476130	152476130	C	T	wt	wt	het	gene_blacklist	QUAL=10308;DP=477,633,853;MQM=60	NEB	synonymous	NEB:NM_001271208.1:synonymous:LOW:exon73/183:c.10707G>A:p.Lys3569Lys,NEB:NM_001164507.1:synonymous:LOW:exon73/182:c.10707G>A:p.Lys3569Lys,NEB:NM_001164508.1:synonymous:LOW:exon73/182:c.10707G>A:p.Lys3569Lys,NEB:NM_004543.4:synonymous:LOW:exon69/149:c.9942G>A:p.Lys3314Lys		rs6717213	0.1406	0.0598	497/11/241	0.0588							161650 [NEB (confirmed) Nemaline myopathy 2,autosomal recessive,256030];	RCV000117777.4 [other]; RCV000353559.1 [likely benign]; 			5	87					NEB (inh=AR pLI=0.00)
chr2	152490219	152490219	A	G	wt	het	het	gene_blacklist	QUAL=18152;DP=459,645,813;MQM=59	NEB	synonymous,intron	NEB:NM_001271208.1:synonymous:LOW:exon65/183:c.9363T>C:p.Pro3121Pro,NEB:NM_001164507.1:synonymous:LOW:exon65/182:c.9363T>C:p.Pro3121Pro,NEB:NM_001164508.1:synonymous:LOW:exon65/182:c.9363T>C:p.Pro3121Pro,NEB:NM_004543.4:intron:MODIFIER:exon62/148:c.8854-2886T>C:		rs6709886	0.6260	0.6362	24834/13232/1379	0.6245							161650 [NEB (confirmed) Nemaline myopathy 2,autosomal recessive,256030];	RCV000220675.2 [benign]; 			607	740					NEB (inh=AR pLI=0.00)
chr2	152490236	152490236	C	T	wt	het	wt	gene_blacklist	QUAL=9345;DP=483,711,894;MQM=59	NEB	missense,intron	NEB:NM_001271208.1:missense:MODERATE:exon65/183:c.9346G>A:p.Glu3116Lys,NEB:NM_001164507.1:missense:MODERATE:exon65/182:c.9346G>A:p.Glu3116Lys,NEB:NM_001164508.1:missense:MODERATE:exon65/182:c.9346G>A:p.Glu3116Lys,NEB:NM_004543.4:intron:MODIFIER:exon62/148:c.8854-2903G>A:		rs193042896	0.0014	0.0022	1/1/0	0.0021	0.2920	T,T	T		T,T	18.10	161650 [NEB (confirmed) Nemaline myopathy 2,autosomal recessive,256030];				0	7					NEB (inh=AR pLI=0.00)
chr2	152490458	152490458	A	G	hom	hom	hom	gene_blacklist;pred_pathogenic	QUAL=45358;DP=402,434,605;MQM=59	NEB	missense,intron	NEB:NM_001271208.1:missense:MODERATE:exon65/183:c.9124T>C:p.Cys3042Arg,NEB:NM_001164507.1:missense:MODERATE:exon65/182:c.9124T>C:p.Cys3042Arg,NEB:NM_001164508.1:missense:MODERATE:exon65/182:c.9124T>C:p.Cys3042Arg,NEB:NM_004543.4:intron:MODIFIER:exon62/148:c.8854-3125T>C:		rs6710212	0.9720	0.9928	59546/33349/4133	0.9227	1.6720	T,T	T		T,T	9.50	161650 [NEB (confirmed) Nemaline myopathy 2,autosomal recessive,256030];	RCV000215771.2 [benign]; 			1559	3					NEB (inh=AR pLI=0.00)
chr2	152496526	152496526	A	G	het	het	het	gene_blacklist;pred_pathogenic	QUAL=7721;DP=181,204,288;MQM=60	NEB	missense	NEB:NM_001271208.1:missense:MODERATE:exon62/183:c.8734T>C:p.Ser2912Pro,NEB:NM_001164507.1:missense:MODERATE:exon62/182:c.8734T>C:p.Ser2912Pro,NEB:NM_001164508.1:missense:MODERATE:exon62/182:c.8734T>C:p.Ser2912Pro,NEB:NM_004543.4:missense:MODERATE:exon62/149:c.8734T>C:p.Ser2912Pro		rs6713162	0.4453	0.2540	5615/909/2004	0.2502	5.5460	T,T,T,T	T	B	T,T,T,T	16.29	161650 [NEB (confirmed) Nemaline myopathy 2,autosomal recessive,256030];	RCV000117776.4 [other]; RCV000383498.1 [benign]; 		COSM148951, COSM3757671, COSM3757672	91	471					NEB (inh=AR pLI=0.00)
chr2	152497088	152497088	G	A	het	het	wt	gene_blacklist	QUAL=13542;DP=439,712,902;MQM=53	NEB	synonymous	NEB:NM_001271208.1:synonymous:LOW:exon61/183:c.8466C>T:p.His2822His,NEB:NM_001164507.1:synonymous:LOW:exon61/182:c.8466C>T:p.His2822His,NEB:NM_001164508.1:synonymous:LOW:exon61/182:c.8466C>T:p.His2822His,NEB:NM_004543.4:synonymous:LOW:exon61/149:c.8466C>T:p.His2822His		rs61730771	0.0323	0.0216	35/6/9	0.0202							161650 [NEB (confirmed) Nemaline myopathy 2,autosomal recessive,256030];	RCV000117774.4 [other]; RCV000313699.1 [likely benign]; 		COSM3694907, COSM3694906, COSM3694905	1	76					NEB (inh=AR pLI=0.00)
chr2	152499143	152499143	C	T	het	het	wt	gene_blacklist;pred_pathogenic	QUAL=7419;DP=245,275,378;MQM=60	NEB	missense	NEB:NM_001271208.1:missense:MODERATE:exon60/183:c.8318G>A:p.Arg2773Gln,NEB:NM_001164507.1:missense:MODERATE:exon60/182:c.8318G>A:p.Arg2773Gln,NEB:NM_001164508.1:missense:MODERATE:exon60/182:c.8318G>A:p.Arg2773Gln,NEB:NM_004543.4:missense:MODERATE:exon60/149:c.8318G>A:p.Arg2773Gln		rs35974308	0.0206	0.0236	37/16/0	0.0229	3.9180	T,D,D,T	T	D	T,T,T,T	26.40	161650 [NEB (confirmed) Nemaline myopathy 2,autosomal recessive,256030];	RCV000117773.4 [other]; RCV000300645.1 [likely benign]; 		COSM3757674, COSM3757673, COSM3757675	3	89					NEB (inh=AR pLI=0.00)
chr2	152511778	152511778	A	C	het	het	het	gene_blacklist	QUAL=4466;DP=124,71,86;MQM=60	NEB	splice_region&intron	NEB:NM_001271208.1:splice_region&intron:LOW:exon51/182:c.6807+6T>G:,NEB:NM_001164507.1:splice_region&intron:LOW:exon51/181:c.6807+6T>G:,NEB:NM_001164508.1:splice_region&intron:LOW:exon51/181:c.6807+6T>G:,NEB:NM_004543.4:splice_region&intron:LOW:exon51/148:c.6807+6T>G:		rs10930723	0.4309	0.3411	5084/857/1656	0.2358							161650 [NEB (confirmed) Nemaline myopathy 2,autosomal recessive,256030];	RCV000117771.8 [other]; RCV000335316.1 [benign]; 			89	471					NEB (inh=AR pLI=0.00)
chr2	152521096	152521096	C	T	het	het	het	gene_blacklist	QUAL=3490;DP=169,62,85;MQM=60	NEB	synonymous	NEB:NM_001271208.1:synonymous:LOW:exon44/183:c.5370G>A:p.Glu1790Glu,NEB:NM_001164507.1:synonymous:LOW:exon44/182:c.5370G>A:p.Glu1790Glu,NEB:NM_001164508.1:synonymous:LOW:exon44/182:c.5370G>A:p.Glu1790Glu,NEB:NM_004543.4:synonymous:LOW:exon44/149:c.5370G>A:p.Glu1790Glu		rs10170273	0.4349	0.3018	4373/710/1512	0.2420							161650 [NEB (confirmed) Nemaline myopathy 2,autosomal recessive,256030];	RCV000117761.4 [other]; RCV000376756.1 [benign]; 		COSM3757676, COSM148953, COSM3757677	90	479					NEB (inh=AR pLI=0.00)
chr2	152527572	152527572	C	T	het	het	het	gene_blacklist;pred_pathogenic	QUAL=14815;DP=303,314,432;MQM=59	NEB	missense	NEB:NM_001271208.1:missense:MODERATE:exon38/183:c.4471G>A:p.Val1491Met,NEB:NM_001164507.1:missense:MODERATE:exon38/182:c.4471G>A:p.Val1491Met,NEB:NM_001164508.1:missense:MODERATE:exon38/182:c.4471G>A:p.Val1491Met,NEB:NM_004543.4:missense:MODERATE:exon38/149:c.4471G>A:p.Val1491Met		rs7426114	0.5331	0.7386	34995/23317/423	0.7197	2.6960	D,T,T,D	T	B	T,T,T,T	25.80	161650 [NEB (confirmed) Nemaline myopathy 2,autosomal recessive,256030];	RCV000081137.9 [other]; RCV000348796.1 [benign]; 	CM1414605 [CLASS=DP MUT=ALT PHEN="Stress fracture association with" GENE=NEB]; 	COSM4001231, COSM4001233, COSM4001232	996	477					NEB (inh=AR pLI=0.00)
chr2	152527608	152527608	C	T	het	het	het	gene_blacklist	QUAL=13856;DP=330,368,515;MQM=60	NEB	missense	NEB:NM_001271208.1:missense:MODERATE:exon38/183:c.4435G>A:p.Val1479Ile,NEB:NM_001164507.1:missense:MODERATE:exon38/182:c.4435G>A:p.Val1479Ile,NEB:NM_001164508.1:missense:MODERATE:exon38/182:c.4435G>A:p.Val1479Ile,NEB:NM_004543.4:missense:MODERATE:exon38/149:c.4435G>A:p.Val1479Ile		rs34577613	0.3353	0.1899	3255/393/738	0.1888	0.0190	T,T,T,T	T	B	T,T,T,T	12.95	161650 [NEB (confirmed) Nemaline myopathy 2,autosomal recessive,256030];	RCV000117759.4 [other]; RCV000402157.1 [benign]; 		COSM3757679, COSM3757678, COSM148955	49	367					NEB (inh=AR pLI=0.00)
chr2	152527636	152527636	C	G	het	het	wt	gene_blacklist;pred_pathogenic	QUAL=10215;DP=424,401,545;MQM=60	NEB	missense	NEB:NM_001271208.1:missense:MODERATE:exon38/183:c.4407G>C:p.Glu1469Asp,NEB:NM_001164507.1:missense:MODERATE:exon38/182:c.4407G>C:p.Glu1469Asp,NEB:NM_001164508.1:missense:MODERATE:exon38/182:c.4407G>C:p.Glu1469Asp,NEB:NM_004543.4:missense:MODERATE:exon38/149:c.4407G>C:p.Glu1469Asp		rs34800215	0.0272	0.0201	37/6/20	0.0195	0.3640	T,T,T,T	T	D	T,T,T,T	23.20	161650 [NEB (confirmed) Nemaline myopathy 2,autosomal recessive,256030];	RCV000117758.4 [other]; RCV000313738.1 [likely benign]; 		COSM3694913, COSM3694911, COSM3694912	0	70					NEB (inh=AR pLI=0.00)
chr2	152531077	152531077	A	G	het	het	het	gene_blacklist	QUAL=6951;DP=256,148,206;MQM=60	NEB	missense	NEB:NM_001271208.1:missense:MODERATE:exon36/183:c.3901T>C:p.Tyr1301His,NEB:NM_001164507.1:missense:MODERATE:exon36/182:c.3901T>C:p.Tyr1301His,NEB:NM_001164508.1:missense:MODERATE:exon36/182:c.3901T>C:p.Tyr1301His,NEB:NM_004543.4:missense:MODERATE:exon36/149:c.3901T>C:p.Tyr1301His		rs6711382	0.7161	0.8265	41970/26480/2028	0.8069	1.3400	T,T,T,T	T	B	T,T,T,T	14.24	161650 [NEB (confirmed) Nemaline myopathy 2,autosomal recessive,256030];	RCV000153548.3 [benign]; 		COSM4001236, COSM4001235, COSM4001234	1165	360					NEB (inh=AR pLI=0.00)
chr2	152536427	152536427	C	T	het	het	wt	gene_blacklist	QUAL=8915;DP=293,398,425;MQM=60	NEB	splice_region&intron	NEB:NM_001271208.1:splice_region&intron:LOW:exon31/182:c.3147+5G>A:,NEB:NM_001164507.1:splice_region&intron:LOW:exon31/181:c.3147+5G>A:,NEB:NM_001164508.1:splice_region&intron:LOW:exon31/181:c.3147+5G>A:,NEB:NM_004543.4:splice_region&intron:LOW:exon31/148:c.3147+5G>A:		rs74859201	0.0114	0.0157	17/6/0	0.0152							161650 [NEB (confirmed) Nemaline myopathy 2,autosomal recessive,256030];	RCV000117754.3 [benign]; 			0	64					NEB (inh=AR pLI=0.00)
chr2	152536498	152536498	T	A	het	het	hom	gene_blacklist;pred_pathogenic	QUAL=23492;DP=396,373,420;MQM=59	NEB	missense	NEB:NM_001271208.1:missense:MODERATE:exon31/183:c.3081A>T:p.Lys1027Asn,NEB:NM_001164507.1:missense:MODERATE:exon31/182:c.3081A>T:p.Lys1027Asn,NEB:NM_001164508.1:missense:MODERATE:exon31/182:c.3081A>T:p.Lys1027Asn,NEB:NM_004543.4:missense:MODERATE:exon31/149:c.3081A>T:p.Lys1027Asn		rs6735208	0.5835	0.7499	35419/23029/770	0.7362	-0.4180	T,T,T,T	T	P	T,T,T,T	23.20	161650 [NEB (confirmed) Nemaline myopathy 2,autosomal recessive,256030];	RCV000081134.9 [other]; RCV000265121.1 [benign]; 			998	467					NEB (inh=AR pLI=0.00)
chr2	152573981	152573981	A	G	het	het	hom	gene_blacklist	QUAL=14852;DP=354,182,252;MQM=59	NEB	synonymous	NEB:NM_001271208.1:synonymous:LOW:exon10/183:c.771T>C:p.Ala257Ala,NEB:NM_001164507.1:synonymous:LOW:exon10/182:c.771T>C:p.Ala257Ala,NEB:NM_001164508.1:synonymous:LOW:exon10/182:c.771T>C:p.Ala257Ala,NEB:NM_004543.4:synonymous:LOW:exon10/149:c.771T>C:p.Ala257Ala		rs4611637	0.5693	0.7438	34969/22935/596	0.7248							161650 [NEB (confirmed) Nemaline myopathy 2,autosomal recessive,256030];	RCV000081142.9 [other]; RCV000374203.1 [benign]; 		COSM4001250, COSM4001251, COSM4001249	995	476					NEB (inh=AR pLI=0.00)
chr2	152580766	152580766	A	G	het	het	wt	gene_blacklist	QUAL=4603;DP=153,245,388;MQM=60	NEB	splice_region&intron	NEB:NM_001271208.1:splice_region&intron:LOW:exon8/182:c.612+8T>C:,NEB:NM_001164507.1:splice_region&intron:LOW:exon8/181:c.612+8T>C:,NEB:NM_001164508.1:splice_region&intron:LOW:exon8/181:c.612+8T>C:,NEB:NM_004543.4:splice_region&intron:LOW:exon8/148:c.612+8T>C:		rs113095802	0.0254	0.0242	26/4/13	0.0184							161650 [NEB (confirmed) Nemaline myopathy 2,autosomal recessive,256030];	RCV000117768.4 [other]; RCV000281896.1 [likely benign]; 			0	71					NEB (inh=AR pLI=0.00)
chr2	152690248	152690248	G	A	hom	hom	hom		QUAL=16516;DP=304,82,111;MQM=60	CACNB4	3'UTR	CACNB4:NM_000726.4:3'UTR:MODIFIER:exon14/14:c.*5385C>T:,CACNB4:NM_001330118.1:3'UTR:MODIFIER:exon14/14:c.*5385C>T:,CACNB4:NM_001005747.3:3'UTR:MODIFIER:exon13/13:c.*5385C>T:,CACNB4:NM_001320722.2:3'UTR:MODIFIER:exon14/14:c.*5385C>T:,CACNB4:NM_001330114.1:3'UTR:MODIFIER:exon13/13:c.*5385C>T:,CACNB4:NM_001330115.1:3'UTR:MODIFIER:exon10/10:c.*5385C>T:,CACNB4:NM_001330116.1:3'UTR:MODIFIER:exon11/11:c.*5385C>T:,CACNB4:NM_001330117.1:3'UTR:MODIFIER:exon15/15:c.*5385C>T:,CACNB4:NM_001005746.3:3'UTR:MODIFIER:exon14/14:c.*5385C>T:,CACNB4:NM_001330113.1:3'UTR:MODIFIER:exon11/11:c.*5385C>T:,CACNB4:NM_001145798.2:3'UTR:MODIFIER:exon13/13:c.*5385C>T:		rs1568673	0.8784	0.0000	0/0/0	0.1566							601949 [CACNB4 (confirmed) Epilepsy,juvenile myoclonic,susceptibility to,6,607682|Epilepsy,idiopathic generalized,susceptibility to,9,607682|Episodic ataxia,type 5,613855];	RCV000270694.1 [benign]; RCV000307038.1 [benign]; 			216	13					CACNB4 (inh=AD pLI=0.01)
chr2	152691829	152691829	C	G	het	het	wt		QUAL=6394;DP=340,123,187;MQM=60	CACNB4	3'UTR	CACNB4:NM_000726.4:3'UTR:MODIFIER:exon14/14:c.*3804G>C:,CACNB4:NM_001330118.1:3'UTR:MODIFIER:exon14/14:c.*3804G>C:,CACNB4:NM_001005747.3:3'UTR:MODIFIER:exon13/13:c.*3804G>C:,CACNB4:NM_001320722.2:3'UTR:MODIFIER:exon14/14:c.*3804G>C:,CACNB4:NM_001330114.1:3'UTR:MODIFIER:exon13/13:c.*3804G>C:,CACNB4:NM_001330115.1:3'UTR:MODIFIER:exon10/10:c.*3804G>C:,CACNB4:NM_001330116.1:3'UTR:MODIFIER:exon11/11:c.*3804G>C:,CACNB4:NM_001330117.1:3'UTR:MODIFIER:exon15/15:c.*3804G>C:,CACNB4:NM_001005746.3:3'UTR:MODIFIER:exon14/14:c.*3804G>C:,CACNB4:NM_001330113.1:3'UTR:MODIFIER:exon11/11:c.*3804G>C:,CACNB4:NM_001145798.2:3'UTR:MODIFIER:exon13/13:c.*3804G>C:		rs2344734	0.4603	0.0000	0/0/0	0.0510							601949 [CACNB4 (confirmed) Epilepsy,juvenile myoclonic,susceptibility to,6,607682|Epilepsy,idiopathic generalized,susceptibility to,9,607682|Episodic ataxia,type 5,613855];	RCV000287445.1 [benign]; RCV000342430.1 [benign]; 			10	75					CACNB4 (inh=AD pLI=0.01)
chr2	152693977	152693977	A	G	het	het	wt		QUAL=5973;DP=311,134,237;MQM=60	CACNB4	3'UTR	CACNB4:NM_000726.4:3'UTR:MODIFIER:exon14/14:c.*1656T>C:,CACNB4:NM_001330118.1:3'UTR:MODIFIER:exon14/14:c.*1656T>C:,CACNB4:NM_001005747.3:3'UTR:MODIFIER:exon13/13:c.*1656T>C:,CACNB4:NM_001320722.2:3'UTR:MODIFIER:exon14/14:c.*1656T>C:,CACNB4:NM_001330114.1:3'UTR:MODIFIER:exon13/13:c.*1656T>C:,CACNB4:NM_001330115.1:3'UTR:MODIFIER:exon10/10:c.*1656T>C:,CACNB4:NM_001330116.1:3'UTR:MODIFIER:exon11/11:c.*1656T>C:,CACNB4:NM_001330117.1:3'UTR:MODIFIER:exon15/15:c.*1656T>C:,CACNB4:NM_001005746.3:3'UTR:MODIFIER:exon14/14:c.*1656T>C:,CACNB4:NM_001330113.1:3'UTR:MODIFIER:exon11/11:c.*1656T>C:,CACNB4:NM_001145798.2:3'UTR:MODIFIER:exon13/13:c.*1656T>C:		rs62174451	0.0236	0.0000	0/0/0	0.0041							601949 [CACNB4 (confirmed) Epilepsy,juvenile myoclonic,susceptibility to,6,607682|Epilepsy,idiopathic generalized,susceptibility to,9,607682|Episodic ataxia,type 5,613855];	RCV000274412.1 [likely benign]; RCV000389857.1 [likely benign]; 			0	12					CACNB4 (inh=AD pLI=0.01)
chr2	152695191	152695191	C	T	het	het	wt		QUAL=2120;DP=135,21,39;MQM=59	CACNB4	3'UTR	CACNB4:NM_000726.4:3'UTR:MODIFIER:exon14/14:c.*442G>A:,CACNB4:NM_001330118.1:3'UTR:MODIFIER:exon14/14:c.*442G>A:,CACNB4:NM_001005747.3:3'UTR:MODIFIER:exon13/13:c.*442G>A:,CACNB4:NM_001320722.2:3'UTR:MODIFIER:exon14/14:c.*442G>A:,CACNB4:NM_001330114.1:3'UTR:MODIFIER:exon13/13:c.*442G>A:,CACNB4:NM_001330115.1:3'UTR:MODIFIER:exon10/10:c.*442G>A:,CACNB4:NM_001330116.1:3'UTR:MODIFIER:exon11/11:c.*442G>A:,CACNB4:NM_001330117.1:3'UTR:MODIFIER:exon15/15:c.*442G>A:,CACNB4:NM_001005746.3:3'UTR:MODIFIER:exon14/14:c.*442G>A:,CACNB4:NM_001330113.1:3'UTR:MODIFIER:exon11/11:c.*442G>A:,CACNB4:NM_001145798.2:3'UTR:MODIFIER:exon13/13:c.*442G>A:		rs7597215	0.4842	0.0000	0/0/0	0.0381							601949 [CACNB4 (confirmed) Epilepsy,juvenile myoclonic,susceptibility to,6,607682|Epilepsy,idiopathic generalized,susceptibility to,9,607682|Episodic ataxia,type 5,613855];	RCV000290411.1 [benign]; RCV000347650.1 [benign]; 			10	76					CACNB4 (inh=AD pLI=0.01)
chr2	152717331	152717331	A	T	het	het	wt		QUAL=4631;DP=227,185,267;MQM=60	CACNB4	synonymous,intron	CACNB4:NM_000726.4:synonymous:LOW:exon10/14:c.762T>A:p.Ile254Ile,CACNB4:NM_001330118.1:synonymous:LOW:exon10/14:c.621T>A:p.Ile207Ile,CACNB4:NM_001005747.3:synonymous:LOW:exon9/13:c.660T>A:p.Ile220Ile,CACNB4:NM_001320722.2:synonymous:LOW:exon10/14:c.621T>A:p.Ile207Ile,CACNB4:NM_001330114.1:synonymous:LOW:exon9/13:c.108T>A:p.Ile36Ile,CACNB4:NM_001330117.1:synonymous:LOW:exon11/15:c.204T>A:p.Ile68Ile,CACNB4:NM_001005746.3:synonymous:LOW:exon10/14:c.708T>A:p.Ile236Ile,CACNB4:NM_001145798.2:synonymous:LOW:exon10/13:c.762T>A:p.Ile254Ile,CACNB4:NM_001330115.1:intron:MODIFIER:exon6/9:c.578-5442T>A:,CACNB4:NM_001330116.1:intron:MODIFIER:exon7/10:c.539-5442T>A:,CACNB4:NM_001330113.1:intron:MODIFIER:exon7/10:c.626-5442T>A:		rs61736804	0.0503	0.0330	111/21/74	0.0317							601949 [CACNB4 (confirmed) Epilepsy,juvenile myoclonic,susceptibility to,6,607682|Epilepsy,idiopathic generalized,susceptibility to,9,607682|Episodic ataxia,type 5,613855];	RCV000116535.2 [likely benign]; RCV000287797.1 [benign]; RCV000384571.1 [benign]; 		COSM3757681, COSM3757680, COSM3757683, COSM3757682	2	137					CACNB4 (inh=AD pLI=0.01)
chr2	166170127	166170127	T	C	hom	hom	hom		QUAL=20756;DP=189,189,270;MQM=60	SCN2A	splice_region&intron	SCN2A:NM_001040142.1:splice_region&intron:LOW:exon8/26:c.1035-3T>C:,SCN2A:NM_021007.2:splice_region&intron:LOW:exon8/26:c.1035-3T>C:,SCN2A:NM_001040143.1:splice_region&intron:LOW:exon7/25:c.1035-3T>C:		rs2121371	0.7724	0.8016	39160/23066/3402	0.7900							182390 [SCN2A (confirmed) Seizures,benign familial infantile,3,607745|Epileptic encephalopathy,early infantile,11,613721];	RCV000118252.2 [benign]; RCV000264306.1 [benign]; RCV000303132.1 [benign]; 			1012	478					SCN2A (inh=AD pLI=1.00)
chr2	166246710	166246710	A	C	het	wt	wt		QUAL=660;DP=352,106,187;MQM=59	SCN2A	3'UTR	SCN2A:NM_001040142.1:3'UTR:MODIFIER:exon27/27:c.*376A>C:,SCN2A:NM_021007.2:3'UTR:MODIFIER:exon27/27:c.*376A>C:,SCN2A:NM_001040143.1:3'UTR:MODIFIER:exon26/26:c.*376A>C:		rs376498111	0.0000	0.0000	0/0/0	0.0007							182390 [SCN2A (confirmed) Seizures,benign familial infantile,3,607745|Epileptic encephalopathy,early infantile,11,613721];				0	26					SCN2A (inh=AD pLI=1.00)
chr2	166248047	166248047	G	A	het	het	het		QUAL=8529;DP=360,122,174;MQM=60	SCN2A	3'UTR	SCN2A:NM_001040142.1:3'UTR:MODIFIER:exon27/27:c.*1713G>A:,SCN2A:NM_021007.2:3'UTR:MODIFIER:exon27/27:c.*1713G>A:,SCN2A:NM_001040143.1:3'UTR:MODIFIER:exon26/26:c.*1713G>A:		rs1007722	0.3834	0.0000	0/0/0	0.0706							182390 [SCN2A (confirmed) Seizures,benign familial infantile,3,607745|Epileptic encephalopathy,early infantile,11,613721];	RCV000306459.1 [benign]; RCV000370498.1 [benign]; 			37	107					SCN2A (inh=AD pLI=1.00)
chr2	166846016	166846016	G	A	wt	het	wt		QUAL=1249;DP=367,101,133;MQM=60	SCN1A,LOC102724058	3'UTR,intron	SCN1A:NM_001165963.1:3'UTR:MODIFIER:exon26/26:c.*1739C>T:,SCN1A:NM_001165964.1:3'UTR:MODIFIER:exon26/26:c.*1739C>T:,SCN1A:NM_006920.4:3'UTR:MODIFIER:exon26/26:c.*1739C>T:,SCN1A:NM_001202435.1:3'UTR:MODIFIER:exon28/28:c.*1739C>T:,LOC102724058:NR_110598.1:intron:MODIFIER:exon1/3:n.176-26107G>A:		rs1813502	0.7588	0.0000	0/0/0	0.1143							182389 [SCN1A (confirmed) Epilepsy,generalized,with febrile seizures plus,type 2,604403|Dravet syndrome,607208|Migraine,familial hemiplegic,3,609634|Febrile seizures,familial,3A,604403];	RCV000298852.1 [benign]; RCV000337344.1 [benign]; 			103	107					SCN1A (inh=AD pLI=1.00), LOC102724058 (inh=n/a pLI=n/a)
chr2	166847034	166847034	T	C	hom	hom	hom		QUAL=15770;DP=286,76,108;MQM=60	SCN1A,LOC102724058	3'UTR,intron	SCN1A:NM_001165963.1:3'UTR:MODIFIER:exon26/26:c.*721A>G:,SCN1A:NM_001165964.1:3'UTR:MODIFIER:exon26/26:c.*721A>G:,SCN1A:NM_006920.4:3'UTR:MODIFIER:exon26/26:c.*721A>G:,SCN1A:NM_001202435.1:3'UTR:MODIFIER:exon28/28:c.*721A>G:,LOC102724058:NR_110598.1:intron:MODIFIER:exon1/3:n.176-25089T>C:		rs4667859	0.9972	0.0000	0/0/0	0.1511							182389 [SCN1A (confirmed) Epilepsy,generalized,with febrile seizures plus,type 2,604403|Dravet syndrome,607208|Migraine,familial hemiplegic,3,609634|Febrile seizures,familial,3A,604403];	RCV000308219.1 [benign]; RCV000398925.1 [benign]; 			230	0					SCN1A (inh=AD pLI=1.00), LOC102724058 (inh=n/a pLI=n/a)
chr2	166848367	166848367	C	T	wt	het	wt		QUAL=4176;DP=489,328,417;MQM=55	SCN1A,LOC102724058	synonymous,intron	SCN1A:NM_001165963.1:synonymous:LOW:exon26/26:c.5418G>A:p.Glu1806Glu,SCN1A:NM_001165964.1:synonymous:LOW:exon26/26:c.5334G>A:p.Glu1778Glu,SCN1A:NM_006920.4:synonymous:LOW:exon26/26:c.5385G>A:p.Glu1795Glu,SCN1A:NM_001202435.1:synonymous:LOW:exon28/28:c.5418G>A:p.Glu1806Glu,LOC102724058:NR_110598.1:intron:MODIFIER:exon1/3:n.176-23756C>T:		rs140237315	0.0094	0.0138	31/9/0	0.0125							182389 [SCN1A (confirmed) Epilepsy,generalized,with febrile seizures plus,type 2,604403|Dravet syndrome,607208|Migraine,familial hemiplegic,3,609634|Febrile seizures,familial,3A,604403];	RCV000079589.10 [benign]; RCV000233940.1 [benign]; RCV000312763.1 [likely benign]; RCV000390483.1 [likely benign]; 		COSM328108	2	81					SCN1A (inh=AD pLI=1.00), LOC102724058 (inh=n/a pLI=n/a)
chr2	166892788	166892788	C	T	hom	het	hom	pred_pathogenic	QUAL=17092;DP=247,188,211;MQM=60	SCN1A,LOC102724058	missense,non_coding_transcript_exon	SCN1A:NM_001165963.1:missense:MODERATE:exon16/26:c.3199G>A:p.Ala1067Thr,SCN1A:NM_001165964.1:missense:MODERATE:exon16/26:c.3115G>A:p.Ala1039Thr,SCN1A:NM_006920.4:missense:MODERATE:exon16/26:c.3166G>A:p.Ala1056Thr,SCN1A:NM_001202435.1:missense:MODERATE:exon18/28:c.3199G>A:p.Ala1067Thr,LOC102724058:NR_110598.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.618C>T:		rs2298771	0.7885	0.7252	32206/15293/3539	0.7198	-0.5650	T,T,T,T	T	B,B,B	D,D,D,D	12.04	182389 [SCN1A (confirmed) Epilepsy,generalized,with febrile seizures plus,type 2,604403|Dravet syndrome,607208|Migraine,familial hemiplegic,3,609634|Febrile seizures,familial,3A,604403];	RCV000030432.1 [benign]; RCV000079572.10 [other]; RCV000338109.1 [benign]; RCV000401331.1 [benign]; 	CM144700 [CLASS=DP MUT=ALT PHEN="Epilepsy symptomatic reduced risk" GENE=SCN1A]; 	COSM3757723, COSM3757724, COSM3757725	674	663					SCN1A (inh=AD pLI=1.00), LOC102724058 (inh=n/a pLI=n/a)
chr2	166897864	166897864	A	G	hom	het	hom		QUAL=10229;DP=157,79,119;MQM=59	SCN1A	synonymous	SCN1A:NM_001165963.1:synonymous:LOW:exon13/26:c.2292T>C:p.Val764Val,SCN1A:NM_001165964.1:synonymous:LOW:exon13/26:c.2208T>C:p.Val736Val,SCN1A:NM_006920.4:synonymous:LOW:exon13/26:c.2259T>C:p.Val753Val,SCN1A:NM_001202435.1:synonymous:LOW:exon15/28:c.2292T>C:p.Val764Val		rs6432860	0.7889	0.7260	32433/15442/3550	0.7205							182389 [SCN1A (confirmed) Epilepsy,generalized,with febrile seizures plus,type 2,604403|Dravet syndrome,607208|Migraine,familial hemiplegic,3,609634|Febrile seizures,familial,3A,604403];	RCV000030431.1 [benign]; RCV000079565.9 [other]; RCV000275349.1 [benign]; RCV000332804.1 [benign]; RCV000127878.2 [benign]; 		COSM3757728, COSM3757726, COSM3757727	672	665					SCN1A (inh=AD pLI=1.00)
chr2	166897989	166897989	-	A	het	het	hom	low_DP	QUAL=543;DP=53,12,29;MQM=60	SCN1A	splice_region&intron	SCN1A:NM_001165963.1:splice_region&intron:LOW:exon12/25:c.2177-11dupT:,SCN1A:NM_001165964.1:splice_region&intron:LOW:exon12/25:c.2093-11dupT:,SCN1A:NM_006920.4:splice_region&intron:LOW:exon12/25:c.2144-11dupT:,SCN1A:NM_001202435.1:splice_region&intron:LOW:exon14/27:c.2177-11dupT:		rs11394960;rs397959165	0.4347	0.4303	1173/588/64	0.3555							182389 [SCN1A (confirmed) Epilepsy,generalized,with febrile seizures plus,type 2,604403|Dravet syndrome,607208|Migraine,familial hemiplegic,3,609634|Febrile seizures,familial,3A,604403];	RCV000350738.1 [benign]; RCV000386585.1 [benign]; 			73	239					SCN1A (inh=AD pLI=1.00)
chr2	166903445	166903445	T	C	hom	het	hom		QUAL=11324;DP=135,144,161;MQM=59	SCN1A	synonymous	SCN1A:NM_001165963.1:synonymous:LOW:exon9/26:c.1212A>G:p.Val404Val,SCN1A:NM_001165964.1:synonymous:LOW:exon9/26:c.1212A>G:p.Val404Val,SCN1A:NM_006920.4:synonymous:LOW:exon9/26:c.1212A>G:p.Val404Val,SCN1A:NM_001202435.1:synonymous:LOW:exon11/28:c.1212A>G:p.Val404Val		rs7580482	0.7093	0.7034	30492/15443/1727	0.6985							182389 [SCN1A (confirmed) Epilepsy,generalized,with febrile seizures plus,type 2,604403|Dravet syndrome,607208|Migraine,familial hemiplegic,3,609634|Febrile seizures,familial,3A,604403];	RCV000030430.1 [benign]; RCV000079554.9 [other]; RCV000290590.1 [benign]; RCV000384881.1 [benign]; 		COSM3757729, COSM3757730, COSM3757731	663	669					SCN1A (inh=AD pLI=1.00)
chr2	166903495	166903496	AA	-	wt	wt	het		QUAL=1233;DP=144,86,120;MQM=60	SCN1A	splice_region&intron	SCN1A:NM_001165963.1:splice_region&intron:LOW:exon8/25:c.1171-10_1171-9delTT:,SCN1A:NM_001165964.1:splice_region&intron:LOW:exon8/25:c.1171-10_1171-9delTT:,SCN1A:NM_006920.4:splice_region&intron:LOW:exon8/25:c.1171-10_1171-9delTT:,SCN1A:NM_001202435.1:splice_region&intron:LOW:exon10/27:c.1171-10_1171-9delTT:		rs796052950	0.0118	0.0268	59/50/1	0.0255							182389 [SCN1A (confirmed) Epilepsy,generalized,with febrile seizures plus,type 2,604403|Dravet syndrome,607208|Migraine,familial hemiplegic,3,609634|Febrile seizures,familial,3A,604403];	RCV000079553.8 [benign]; RCV000195838.3 [benign]; RCV000326892.1 [likely benign]; RCV000380997.1,RCV000079553.8 [likely benign,benign]; RCV000195838.3 [benign]; RCV000326892.1 [likely benign]; RCV000380997.1 [likely benign]; 			0	85					SCN1A (inh=AD pLI=1.00)
chr2	167052328	167052328	A	G	wt	wt	het		QUAL=2474;DP=293,131,198;MQM=60	SCN9A,LOC101929680	3'UTR,intron	SCN9A:NM_002977.3:3'UTR:MODIFIER:exon27/27:c.*2854T>C:,LOC101929680:NR_110260.1:intron:MODIFIER:exon3/11:n.432-3821A>G:	AluJr	rs73017538	0.0885	0.0000	0/0/0	0.0779							603415 [SCN9A (confirmed) Erythermalgia,primary,133020|Paroxysmal extreme pain disorder,167400,|Insensitivity to pain,congenital,243000|Febrile seizures,familial,3B,613863|Epilepsy,generalized,with febrile seizures plus,type 7,613863|Small fiber neuropathy,133020|Dravet syndrome,modifier of,607208|HSAN2D,autosomal recessive,243000];	RCV000282314.1 [benign]; RCV000298332.1 [benign]; RCV000311164.1 [benign]; RCV000337355.1 [benign]; RCV000369388.1 [benign]; RCV000399646.1 [benign]; RCV000401648.1 [benign]; 			0	34					SCN9A (inh=AR+AD pLI=0.00), LOC101929680 (inh=n/a pLI=n/a)
chr2	167052885	167052885	T	A	wt	wt	het		QUAL=279;DP=131,20,32;MQM=60	SCN9A,LOC101929680	3'UTR,intron	SCN9A:NM_002977.3:3'UTR:MODIFIER:exon27/27:c.*2297A>T:,LOC101929680:NR_110260.1:intron:MODIFIER:exon3/11:n.432-3264T>A:		rs75345520	0.0323	0.0000	0/0/0	0.0114							603415 [SCN9A (confirmed) Erythermalgia,primary,133020|Paroxysmal extreme pain disorder,167400,|Insensitivity to pain,congenital,243000|Febrile seizures,familial,3B,613863|Epilepsy,generalized,with febrile seizures plus,type 7,613863|Small fiber neuropathy,133020|Dravet syndrome,modifier of,607208|HSAN2D,autosomal recessive,243000];	RCV000267308.1 [benign]; RCV000273252.1 [benign]; RCV000324675.1 [benign]; RCV000325935.1 [benign]; RCV000364240.1 [benign]; RCV000365029.1 [benign]; RCV000376947.1 [benign]; 			0	30					SCN9A (inh=AR+AD pLI=0.00), LOC101929680 (inh=n/a pLI=n/a)
chr2	167053028	167053028	G	C	wt	het	wt		QUAL=198;DP=158,40,51;MQM=60	SCN9A,LOC101929680	3'UTR,intron	SCN9A:NM_002977.3:3'UTR:MODIFIER:exon27/27:c.*2154C>G:,LOC101929680:NR_110260.1:intron:MODIFIER:exon3/11:n.432-3121G>C:		rs17804037	0.0669	0.0000	0/0/0	0.0139							603415 [SCN9A (confirmed) Erythermalgia,primary,133020|Paroxysmal extreme pain disorder,167400,|Insensitivity to pain,congenital,243000|Febrile seizures,familial,3B,613863|Epilepsy,generalized,with febrile seizures plus,type 7,613863|Small fiber neuropathy,133020|Dravet syndrome,modifier of,607208|HSAN2D,autosomal recessive,243000];	RCV000284995.1 [benign]; RCV000286111.1 [benign]; RCV000336414.1 [benign]; RCV000339869.1 [benign]; RCV000380513.1 [benign]; RCV000384040.1 [benign]; RCV000397783.1 [benign]; 			4	52					SCN9A (inh=AR+AD pLI=0.00), LOC101929680 (inh=n/a pLI=n/a)
chr2	167053036	167053036	C	G	wt	wt	het		QUAL=518;DP=183,45,50;MQM=60	SCN9A,LOC101929680	3'UTR,intron	SCN9A:NM_002977.3:3'UTR:MODIFIER:exon27/27:c.*2146G>C:,LOC101929680:NR_110260.1:intron:MODIFIER:exon3/11:n.432-3113C>G:		rs1062844	0.0467	0.0000	0/0/0	0.0650							603415 [SCN9A (confirmed) Erythermalgia,primary,133020|Paroxysmal extreme pain disorder,167400,|Insensitivity to pain,congenital,243000|Febrile seizures,familial,3B,613863|Epilepsy,generalized,with febrile seizures plus,type 7,613863|Small fiber neuropathy,133020|Dravet syndrome,modifier of,607208|HSAN2D,autosomal recessive,243000];	RCV000275838.1 [benign]; RCV000300570.1 [benign]; RCV000307597.1 [benign]; RCV000311197.1 [benign]; RCV000336844.1 [benign]; RCV000370484.1 [benign]; RCV000397793.1 [benign]; 			0	35					SCN9A (inh=AR+AD pLI=0.00), LOC101929680 (inh=n/a pLI=n/a)
chr2	167053386	167053386	G	A	wt	wt	het		QUAL=1143;DP=272,91,120;MQM=60	SCN9A,LOC101929680	3'UTR,intron	SCN9A:NM_002977.3:3'UTR:MODIFIER:exon27/27:c.*1796C>T:,LOC101929680:NR_110260.1:intron:MODIFIER:exon3/11:n.432-2763G>A:		rs16851751	0.0837	0.0000	0/0/0	0.0135							603415 [SCN9A (confirmed) Erythermalgia,primary,133020|Paroxysmal extreme pain disorder,167400,|Insensitivity to pain,congenital,243000|Febrile seizures,familial,3B,613863|Epilepsy,generalized,with febrile seizures plus,type 7,613863|Small fiber neuropathy,133020|Dravet syndrome,modifier of,607208|HSAN2D,autosomal recessive,243000];	RCV000263670.1 [benign]; RCV000266558.1 [benign]; RCV000293129.1 [benign]; RCV000316954.1 [benign]; RCV000318792.1 [benign]; RCV000353093.1 [benign]; RCV000387408.1 [benign]; 			0	35					SCN9A (inh=AR+AD pLI=0.00), LOC101929680 (inh=n/a pLI=n/a)
chr2	167053408	167053408	C	T	wt	wt	het		QUAL=1088;DP=192,79,113;MQM=60	SCN9A,LOC101929680	3'UTR,intron	SCN9A:NM_002977.3:3'UTR:MODIFIER:exon27/27:c.*1774G>A:,LOC101929680:NR_110260.1:intron:MODIFIER:exon3/11:n.432-2741C>T:		rs114843828	0.0323	0.0000	0/0/0	0.0091							603415 [SCN9A (confirmed) Erythermalgia,primary,133020|Paroxysmal extreme pain disorder,167400,|Insensitivity to pain,congenital,243000|Febrile seizures,familial,3B,613863|Epilepsy,generalized,with febrile seizures plus,type 7,613863|Small fiber neuropathy,133020|Dravet syndrome,modifier of,607208|HSAN2D,autosomal recessive,243000];	RCV000289218.1 [benign]; RCV000290914.1 [benign]; RCV000334156.1 [benign]; RCV000341101.1 [benign]; RCV000344161.1 [benign]; RCV000388679.1 [benign]; RCV000404015.1 [benign]; 			0	30					SCN9A (inh=AR+AD pLI=0.00), LOC101929680 (inh=n/a pLI=n/a)
chr2	167053577	167053577	A	-	wt	wt	het	low_DP	QUAL=289;DP=105,9,26;MQM=59	SCN9A,LOC101929680	3'UTR,intron	SCN9A:NM_002977.3:3'UTR:MODIFIER:exon27/27:c.*1605delT:,LOC101929680:NR_110260.1:intron:MODIFIER:exon3/11:n.432-2572delA:		rs148459420	0.0325	0.0000	0/0/0	0.0470							603415 [SCN9A (confirmed) Erythermalgia,primary,133020|Paroxysmal extreme pain disorder,167400,|Insensitivity to pain,congenital,243000|Febrile seizures,familial,3B,613863|Epilepsy,generalized,with febrile seizures plus,type 7,613863|Small fiber neuropathy,133020|Dravet syndrome,modifier of,607208|HSAN2D,autosomal recessive,243000];	RCV000268985.1 [benign]; RCV000300920.1 [benign]; RCV000307776.1 [benign]; RCV000313771.1 [benign]; RCV000348804.1 [benign]; RCV000370566.1 [benign]; RCV000397647.1 [benign]; 			1	26					SCN9A (inh=AR+AD pLI=0.00), LOC101929680 (inh=n/a pLI=n/a)
chr2	167054063	167054063	-	TG	wt	wt	het		QUAL=3822;DP=279,239,308;MQM=60	SCN9A,LOC101929680	3'UTR,intron	SCN9A:NM_002977.3:3'UTR:MODIFIER:exon27/27:c.*1118_*1119insCA:,LOC101929680:NR_110260.1:intron:MODIFIER:exon3/11:n.432-2086_432-2085insTG:		rs140616949	0.0885	0.0000	0/0/0	0.0779							603415 [SCN9A (confirmed) Erythermalgia,primary,133020|Paroxysmal extreme pain disorder,167400,|Insensitivity to pain,congenital,243000|Febrile seizures,familial,3B,613863|Epilepsy,generalized,with febrile seizures plus,type 7,613863|Small fiber neuropathy,133020|Dravet syndrome,modifier of,607208|HSAN2D,autosomal recessive,243000];	RCV000274983.1 [benign]; RCV000299806.1 [benign]; RCV000305824.1 [benign]; RCV000353605.1 [benign]; RCV000357016.1 [benign]; RCV000395623.1 [benign]; RCV000395645.1 [benign]; 			0	36					SCN9A (inh=AR+AD pLI=0.00), LOC101929680 (inh=n/a pLI=n/a)
chr2	167054169	167054169	G	A	wt	wt	het		QUAL=4919;DP=480,302,397;MQM=60	SCN9A,LOC101929680	3'UTR,intron	SCN9A:NM_002977.3:3'UTR:MODIFIER:exon27/27:c.*1013C>T:,LOC101929680:NR_110260.1:intron:MODIFIER:exon3/11:n.432-1980G>A:		rs16851754	0.0835	0.0000	0/0/0	0.0130							603415 [SCN9A (confirmed) Erythermalgia,primary,133020|Paroxysmal extreme pain disorder,167400,|Insensitivity to pain,congenital,243000|Febrile seizures,familial,3B,613863|Epilepsy,generalized,with febrile seizures plus,type 7,613863|Small fiber neuropathy,133020|Dravet syndrome,modifier of,607208|HSAN2D,autosomal recessive,243000];	RCV000279403.1 [benign]; RCV000285205.1 [benign]; RCV000336748.1 [benign]; RCV000342424.1 [benign]; RCV000377310.1 [benign]; RCV000404321.1 [benign]; RCV000405628.1 [benign]; 			0	35					SCN9A (inh=AR+AD pLI=0.00), LOC101929680 (inh=n/a pLI=n/a)
chr2	167054409	167054409	-	TT	wt	wt	het		QUAL=607;DP=257,80,93;MQM=60	SCN9A,LOC101929680	3'UTR,intron	SCN9A:NM_002977.3:3'UTR:MODIFIER:exon27/27:c.*771_*772dupAA:,LOC101929680:NR_110260.1:intron:MODIFIER:exon3/11:n.432-1739_432-1738dupTT:		rs144515054	0.0467	0.0000	0/0/0	0.0662							603415 [SCN9A (confirmed) Erythermalgia,primary,133020|Paroxysmal extreme pain disorder,167400,|Insensitivity to pain,congenital,243000|Febrile seizures,familial,3B,613863|Epilepsy,generalized,with febrile seizures plus,type 7,613863|Small fiber neuropathy,133020|Dravet syndrome,modifier of,607208|HSAN2D,autosomal recessive,243000];	RCV000293873.1 [benign]; RCV000299664.1 [benign]; RCV000335502.1 [benign]; RCV000348745.1 [benign]; RCV000352233.1 [benign]; RCV000388164.1 [benign]; RCV000403917.1 [benign]; 			0	35					SCN9A (inh=AR+AD pLI=0.00), LOC101929680 (inh=n/a pLI=n/a)
chr2	167054765	167054765	-	A	wt	wt	het		QUAL=1585;DP=372,85,120;MQM=60	SCN9A,LOC101929680	3'UTR,intron	SCN9A:NM_002977.3:3'UTR:MODIFIER:exon27/27:c.*416dupT:,LOC101929680:NR_110260.1:intron:MODIFIER:exon3/11:n.432-1381dupA:		rs397840995	0.0885	0.0000	0/0/0	0.0778							603415 [SCN9A (confirmed) Erythermalgia,primary,133020|Paroxysmal extreme pain disorder,167400,|Insensitivity to pain,congenital,243000|Febrile seizures,familial,3B,613863|Epilepsy,generalized,with febrile seizures plus,type 7,613863|Small fiber neuropathy,133020|Dravet syndrome,modifier of,607208|HSAN2D,autosomal recessive,243000];	RCV000274625.1 [benign]; RCV000309588.1 [benign]; RCV000314449.1 [benign]; RCV000329739.1 [benign]; RCV000364317.1 [benign]; RCV000369228.1 [benign]; RCV000398126.1 [benign]; 			0	36					SCN9A (inh=AR+AD pLI=0.00), LOC101929680 (inh=n/a pLI=n/a)
chr2	167054934	167054934	-	AATC	het	het	het		QUAL=4887;DP=188,79,128;MQM=59	SCN9A,LOC101929680	3'UTR,intron	SCN9A:NM_002977.3:3'UTR:MODIFIER:exon27/27:c.*244_*247dupGATT:,LOC101929680:NR_110260.1:intron:MODIFIER:exon3/11:n.432-1213_432-1210dupATCA:		rs397744175	0.7458	0.0000	0/0/0	0.6779							603415 [SCN9A (confirmed) Erythermalgia,primary,133020|Paroxysmal extreme pain disorder,167400,|Insensitivity to pain,congenital,243000|Febrile seizures,familial,3B,613863|Epilepsy,generalized,with febrile seizures plus,type 7,613863|Small fiber neuropathy,133020|Dravet syndrome,modifier of,607208|HSAN2D,autosomal recessive,243000];	RCV000283356.1 [benign]; RCV000289285.1 [benign]; RCV000312409.1 [benign]; RCV000347662.1 [benign]; RCV000352131.1 [benign]; RCV000402766.1 [benign]; RCV000406754.1 [benign]; 			133	81					SCN9A (inh=AR+AD pLI=0.00), LOC101929680 (inh=n/a pLI=n/a)
chr2	167056337	167056337	C	A	wt	wt	het		QUAL=7079;DP=360,388,482;MQM=59	LOC101929680,SCN9A	splice_region&intron,synonymous	LOC101929680:NR_110260.1:splice_region&intron:LOW:exon4/11:n.611+9C>A:,SCN9A:NM_002977.3:synonymous:LOW:exon27/27:c.4779G>T:p.Val1593Val		rs149207258	0.0319	0.0620	304/249/13	0.0609							603415 [SCN9A (confirmed) Erythermalgia,primary,133020|Paroxysmal extreme pain disorder,167400,|Insensitivity to pain,congenital,243000|Febrile seizures,familial,3B,613863|Epilepsy,generalized,with febrile seizures plus,type 7,613863|Small fiber neuropathy,133020|Dravet syndrome,modifier of,607208|HSAN2D,autosomal recessive,243000];	RCV000118308.3 [other]; RCV000286759.1 [benign]; RCV000309081.1 [benign]; RCV000339487.1 [benign]; RCV000347548.1 [benign]; RCV000378791.1 [benign]; RCV000391322.1 [benign]; RCV000405619.1 [benign]; 			5	178					LOC101929680 (inh=n/a pLI=n/a), SCN9A (inh=AR+AD pLI=0.00)
chr2	167060981	167060984	AAAC	-	het	het	hom		QUAL=4575;DP=81,64,100;MQM=60	SCN9A,LOC101929680	splice_region&intron,intron	SCN9A:NM_002977.3:splice_region&intron:LOW:exon24/26:c.4366-10_4366-7delGTTT:,LOC101929680:NR_110260.1:intron:MODIFIER:exon4/11:n.611+4660_611+4663delCAAA:		rs546230376	0.8988	0.8811	46221/24837/4352	0.8102							603415 [SCN9A (confirmed) Erythermalgia,primary,133020|Paroxysmal extreme pain disorder,167400,|Insensitivity to pain,congenital,243000|Febrile seizures,familial,3B,613863|Epilepsy,generalized,with febrile seizures plus,type 7,613863|Small fiber neuropathy,133020|Dravet syndrome,modifier of,607208|HSAN2D,autosomal recessive,243000];	RCV000153913.4 [benign]; RCV000264835.1 [benign]; RCV000270584.1 [benign]; RCV000300254.1 [benign]; RCV000324833.1 [benign]; RCV000359605.1 [benign]; RCV000360774.1 [benign]; RCV000405665.1 [benign]; 	CD072486 [CLASS=R MUT=ALT PHEN="Congenital indifference to pain" GENE=SCN9A]; 		1000	306	1	[1] old entry - no details available			SCN9A (inh=AR+AD pLI=0.00), LOC101929680 (inh=n/a pLI=n/a)
chr2	167089976	167089976	T	C	wt	wt	het		QUAL=1983;DP=212,117,147;MQM=60	SCN9A,LOC101929680	splice_region&intron,intron	SCN9A:NM_002977.3:splice_region&intron:LOW:exon20/26:c.3769-4A>G:,LOC101929680:NR_110260.1:intron:MODIFIER:exon4/11:n.612-14729T>C:		rs75230218	0.0321	0.0737	295/244/12	0.0617							603415 [SCN9A (confirmed) Erythermalgia,primary,133020|Paroxysmal extreme pain disorder,167400,|Insensitivity to pain,congenital,243000|Febrile seizures,familial,3B,613863|Epilepsy,generalized,with febrile seizures plus,type 7,613863|Small fiber neuropathy,133020|Dravet syndrome,modifier of,607208|HSAN2D,autosomal recessive,243000];	RCV000118304.7 [other]; RCV000266266.1 [benign]; RCV000286080.1 [benign]; RCV000291623.1 [benign]; RCV000321146.1 [benign]; RCV000345747.1 [benign]; RCV000380369.1 [benign]; RCV000381425.1 [benign]; 			9	183					SCN9A (inh=AR+AD pLI=0.00), LOC101929680 (inh=n/a pLI=n/a)
chr2	167099158	167099158	A	G	het	het	hom	pred_pathogenic	QUAL=12011;DP=228,177,201;MQM=60	SCN9A,LOC101929680	missense,intron	SCN9A:NM_002977.3:missense:MODERATE:exon19/27:c.3448T>C:p.Trp1150Arg,LOC101929680:NR_110260.1:intron:MODIFIER:exon4/11:n.612-5547A>G:		rs6746030	0.8872	0.8693	9228/4075/1003	0.5988	0.9510	T,T,T,T	T	B	D,D,D,D	9.09	603415 [SCN9A (confirmed) Erythermalgia,primary,133020|Paroxysmal extreme pain disorder,167400,|Insensitivity to pain,congenital,243000|Febrile seizures,familial,3B,613863|Epilepsy,generalized,with febrile seizures plus,type 7,613863|Small fiber neuropathy,133020|Dravet syndrome,modifier of,607208|HSAN2D,autosomal recessive,243000];	RCV000020514.1 [benign]; RCV000239769.1 [benign]; RCV000239769.1 [benign]; 	CM051623 [CLASS=DFP MUT=REF PHEN="Erythermalgia primary" GENE=SCN9A]; 		1183	352					SCN9A (inh=AR+AD pLI=0.00), LOC101929680 (inh=n/a pLI=n/a)
chr2	167144974	167144974	A	T	het	het	wt		QUAL=1668;DP=106,53,83;MQM=60	SCN9A,LOC101929680	synonymous,intron	SCN9A:NM_002977.3:synonymous:LOW:exon10/27:c.1287T>A:p.Arg429Arg,LOC101929680:NR_110260.1:intron:MODIFIER:exon8/11:n.1030-6101A>T:		rs6747673	0.5467	0.4944	15287/7551/2822	0.4778							603415 [SCN9A (confirmed) Erythermalgia,primary,133020|Paroxysmal extreme pain disorder,167400,|Insensitivity to pain,congenital,243000|Febrile seizures,familial,3B,613863|Epilepsy,generalized,with febrile seizures plus,type 7,613863|Small fiber neuropathy,133020|Dravet syndrome,modifier of,607208|HSAN2D,autosomal recessive,243000];	RCV000118293.4 [other]; RCV000267710.1 [benign]; RCV000282544.1 [benign]; RCV000292831.1 [benign]; RCV000317687.1 [benign]; RCV000318943.1 [benign]; RCV000372285.1 [benign]; RCV000387463.1 [benign]; 		COSM4001294, COSM4001293	361	715					SCN9A (inh=AR+AD pLI=0.00), LOC101929680 (inh=n/a pLI=n/a)
chr2	167144995	167144995	T	C	het	het	wt		QUAL=2355;DP=158,57,96;MQM=60	SCN9A,LOC101929680	synonymous,intron	SCN9A:NM_002977.3:synonymous:LOW:exon10/27:c.1266A>G:p.Glu422Glu,LOC101929680:NR_110260.1:intron:MODIFIER:exon8/11:n.1030-6080T>C:		rs13402180	0.3544	0.3730	8581/5243/710	0.3640							603415 [SCN9A (confirmed) Erythermalgia,primary,133020|Paroxysmal extreme pain disorder,167400,|Insensitivity to pain,congenital,243000|Febrile seizures,familial,3B,613863|Epilepsy,generalized,with febrile seizures plus,type 7,613863|Small fiber neuropathy,133020|Dravet syndrome,modifier of,607208|HSAN2D,autosomal recessive,243000];	RCV000118292.4 [other]; RCV000289711.1 [benign]; RCV000309654.1 [benign]; RCV000344725.1 [benign]; RCV000352364.1 [benign]; RCV000359549.1 [benign]; RCV000397247.1 [benign]; RCV000399562.1 [benign]; 		COSM3757732, COSM3757733	229	698					SCN9A (inh=AR+AD pLI=0.00), LOC101929680 (inh=n/a pLI=n/a)
chr2	167145142	167145142	A	G	het	het	wt		QUAL=1915;DP=116,41,57;MQM=60	SCN9A,LOC101929680	synonymous,intron	SCN9A:NM_002977.3:synonymous:LOW:exon10/27:c.1119T>C:p.Ala373Ala,LOC101929680:NR_110260.1:intron:MODIFIER:exon8/11:n.1030-5933A>G:		rs13414203	0.3544	0.3740	8517/5205/702	0.3633							603415 [SCN9A (confirmed) Erythermalgia,primary,133020|Paroxysmal extreme pain disorder,167400,|Insensitivity to pain,congenital,243000|Febrile seizures,familial,3B,613863|Epilepsy,generalized,with febrile seizures plus,type 7,613863|Small fiber neuropathy,133020|Dravet syndrome,modifier of,607208|HSAN2D,autosomal recessive,243000];	RCV000118290.4 [other]; RCV000271006.1 [benign]; RCV000286417.1 [benign]; RCV000321452.1 [benign]; RCV000341529.1 [benign]; RCV000372805.1 [benign]; RCV000376267.1 [benign]; RCV000384212.1 [benign]; 			228	696					SCN9A (inh=AR+AD pLI=0.00), LOC101929680 (inh=n/a pLI=n/a)
chr2	167163043	167163043	T	C	het	het	het		QUAL=6253;DP=243,137,139;MQM=60	SCN9A	synonymous	SCN9A:NM_002977.3:synonymous:LOW:exon4/27:c.444A>G:p.Pro148Pro		rs9646771	0.6412	0.6841	14286/7626/2360	0.5923							603415 [SCN9A (confirmed) Erythermalgia,primary,133020|Paroxysmal extreme pain disorder,167400,|Insensitivity to pain,congenital,243000|Febrile seizures,familial,3B,613863|Epilepsy,generalized,with febrile seizures plus,type 7,613863|Small fiber neuropathy,133020|Dravet syndrome,modifier of,607208|HSAN2D,autosomal recessive,243000];	RCV000118307.3 [other]; RCV000283990.1 [benign]; RCV000297056.1 [benign]; RCV000341457.1 [benign]; RCV000354313.1 [benign]; RCV000390493.1 [benign]; RCV000396292.1 [benign]; RCV000400502.1 [benign]; 		COSM3933365, COSM3933366	653	700					SCN9A (inh=AR+AD pLI=0.00)
chr2	167168093	167168093	C	T	het	het	het		QUAL=11464;DP=296,256,313;MQM=60	SCN9A	synonymous	SCN9A:NM_002977.3:synonymous:LOW:exon2/27:c.174G>A:p.Gln58Gln		rs6432901	0.5743	0.5874	21462/13126/2784	0.5803							603415 [SCN9A (confirmed) Erythermalgia,primary,133020|Paroxysmal extreme pain disorder,167400,|Insensitivity to pain,congenital,243000|Febrile seizures,familial,3B,613863|Epilepsy,generalized,with febrile seizures plus,type 7,613863|Small fiber neuropathy,133020|Dravet syndrome,modifier of,607208|HSAN2D,autosomal recessive,243000];	RCV000118295.3 [other]; RCV000265880.1 [benign]; RCV000271887.1 [benign]; RCV000310588.1 [benign]; RCV000323339.1 [benign]; RCV000358311.1 [benign]; RCV000363455.1 [benign]; RCV000380181.1 [benign]; 			585	708					SCN9A (inh=AR+AD pLI=0.00)
chr2	169779712	169779712	T	C	wt	het	wt		QUAL=712;DP=283,68,84;MQM=60	ABCB11	3'UTR	ABCB11:NM_003742.2:3'UTR:MODIFIER:exon28/28:c.*420A>G:	L2b	rs496550	0.5072	0.0000	0/0/0	0.0792							603201 [ABCB11 (confirmed) Cholestasis,progressive familial intrahepatic 2,601847|Cholestasis,benign recurrent intrahepatic,2,605479];	RCV000338441.1 [benign]; 			75	104					ABCB11 (inh=AR pLI=0.00)
chr2	169779764	169779764	C	T	wt	het	wt		QUAL=1504;DP=269,124,171;MQM=60	ABCB11	3'UTR	ABCB11:NM_003742.2:3'UTR:MODIFIER:exon28/28:c.*368G>A:	L2b	rs495714	0.5068	0.0000	0/0/0	0.0915							603201 [ABCB11 (confirmed) Cholestasis,progressive familial intrahepatic 2,601847|Cholestasis,benign recurrent intrahepatic,2,605479];	RCV000399919.1 [benign]; 			74	105					ABCB11 (inh=AR pLI=0.00)
chr2	169779896	169779896	T	C	wt	het	wt		QUAL=1633;DP=292,141,172;MQM=60	ABCB11	3'UTR	ABCB11:NM_003742.2:3'UTR:MODIFIER:exon28/28:c.*236A>G:		rs473351	0.7292	0.0000	0/0/0	0.1130							603201 [ABCB11 (confirmed) Cholestasis,progressive familial intrahepatic 2,601847|Cholestasis,benign recurrent intrahepatic,2,605479];	RCV000304818.1 [benign]; 			80	105					ABCB11 (inh=AR pLI=0.00)
chr2	169789016	169789016	T	C	wt	het	wt		QUAL=3224;DP=203,271,383;MQM=60	ABCB11	synonymous	ABCB11:NM_003742.2:synonymous:LOW:exon24/28:c.3084A>G:p.Ala1028Ala		rs497692	0.4968	0.5557	18475/9590/356	0.5319							603201 [ABCB11 (confirmed) Cholestasis,progressive familial intrahepatic 2,601847|Cholestasis,benign recurrent intrahepatic,2,605479];	RCV000246223.2 [benign]; RCV000324953.1 [benign]; 	CM092757 [CLASS=DFP MUT=ALT PHEN="Primary biliary cirrhosis association with" GENE=ABCB11]; 	COSM148984	476	757					ABCB11 (inh=AR pLI=0.00)
chr2	169828367	169828367	T	G	het	wt	wt	pred_pathogenic	QUAL=69;DP=112,155,208;MQM=60	ABCB11	missense	ABCB11:NM_003742.2:missense:MODERATE:exon14/28:c.1628A>C:p.Asp543Ala		rs200687717	0.0000	0.1037	0/0/0	0.0001	1.8360	T	T	B	D	15.29	603201 [ABCB11 (confirmed) Cholestasis,progressive familial intrahepatic 2,601847|Cholestasis,benign recurrent intrahepatic,2,605479];			COSM3736641, COSM3736640	0	30					ABCB11 (inh=AR pLI=0.00)
chr2	169830328	169830328	A	G	het	het	hom	pred_pathogenic	QUAL=19410;DP=454,277,305;MQM=60	ABCB11	missense	ABCB11:NM_003742.2:missense:MODERATE:exon13/28:c.1331T>C:p.Val444Ala		rs2287622	0.5887	0.5794	20582/11827/1670	0.5743	2.0330	T	T	B	D	15.16	603201 [ABCB11 (confirmed) Cholestasis,progressive familial intrahepatic 2,601847|Cholestasis,benign recurrent intrahepatic,2,605479];	RCV000174528.2 [benign]; RCV000273829.1 [benign]; 	CM071525 [CLASS=DFP MUT=ALT PHEN="Cholestasis drug-induced association with" GENE=ABCB11]; 		581	726					ABCB11 (inh=AR pLI=0.00)
chr2	169984043	169984043	T	AA	wt	wt	het	low_DP	QUAL=351;DP=19,10,6;MQM=52	LRP2	3'UTR	LRP2:NM_004525.2:3'UTR:MODIFIER:exon79/79:c.*1130delAinsTT:	FLAM_A		0.0000	0.0000	0/0/0	0.0000							600073 [LRP2 (confirmed) Donnai-Barrow syndrome,222448];				0	0					LRP2 (inh=AR pLI=1.00)
chr2	169984262	169984262	-	TT	wt	wt	het		QUAL=9749;DP=202,120,169;MQM=59	LRP2	3'UTR	LRP2:NM_004525.2:3'UTR:MODIFIER:exon79/79:c.*909_*910dupAA:		rs11411235	0.0000	0.0000	0/0/0	0.0171							600073 [LRP2 (confirmed) Donnai-Barrow syndrome,222448];	RCV000349309.1 [uncertain significance]; RCV000398084.1 [uncertain significance]; RCV000296745.1 [benign]; 			0	10					LRP2 (inh=AR pLI=1.00)
chr2	169984262	169984262	-	T	hom	hom	het		QUAL=9749;DP=202,120,169;MQM=59	LRP2	3'UTR	LRP2:NM_004525.2:3'UTR:MODIFIER:exon79/79:c.*910dupA:		rs11411235;rs397941904	0.6619	0.0000	0/0/0	0.4423							600073 [LRP2 (confirmed) Donnai-Barrow syndrome,222448];	RCV000349309.1 [uncertain significance]; RCV000398084.1 [uncertain significance]; RCV000296745.1 [benign]; 			17	200					LRP2 (inh=AR pLI=1.00)
chr2	170003432	170003432	T	G	hom	hom	hom	pred_pathogenic	QUAL=18211;DP=186,176,210;MQM=60	LRP2	missense	LRP2:NM_004525.2:missense:MODERATE:exon69/79:c.12628A>C:p.Ile4210Leu		rs4667591	0.5559	0.7176	32407/20298/321	0.7053	6.2840	D	T	D	D	31.00	600073 [LRP2 (confirmed) Donnai-Barrow syndrome,222448];	RCV000117509.3 [other]; RCV000372220.1 [benign]; 	CM065295 [CLASS=DP MUT=REF PHEN="Colorectal cancer increased risk association with" GENE=LRP2]; 	COSM1401028	972	521					LRP2 (inh=AR pLI=1.00)
chr2	170010985	170010985	T	C	hom	hom	hom	pred_pathogenic	QUAL=23381;DP=340,153,211;MQM=60	LRP2	missense	LRP2:NM_004525.2:missense:MODERATE:exon66/79:c.12280A>G:p.Lys4094Glu		rs2075252	0.7780	0.7621	35867/18792/4168	0.7517	4.7880	T	T	B	D	16.49	600073 [LRP2 (confirmed) Donnai-Barrow syndrome,222448];	RCV000117508.3 [other]; RCV000310751.1 [benign]; 		COSM4001308	1002	498					LRP2 (inh=AR pLI=1.00)
chr2	170025083	170025083	A	G	het	wt	het	pred_pathogenic	QUAL=10280;DP=426,251,357;MQM=59	LRP2	synonymous	LRP2:NM_004525.2:synonymous:LOW:exon61/79:c.11601T>C:p.Cys3867Cys		rs2229268	0.1907	0.2026	2904/1434/12	0.2005	2.0780	T	T			4.95	600073 [LRP2 (confirmed) Donnai-Barrow syndrome,222448];	RCV000117501.3 [other]; RCV000263671.1 [benign]; 		COSM4133221	61	541					LRP2 (inh=AR pLI=1.00)
chr2	170032989	170032989	C	T	het	hom	het		QUAL=18613;DP=392,300,417;MQM=59	LRP2	synonymous	LRP2:NM_004525.2:synonymous:LOW:exon54/79:c.10503G>A:p.Gln3501Gln		rs2229265	0.3796	0.4725	14603/8567/539	0.4678							600073 [LRP2 (confirmed) Donnai-Barrow syndrome,222448];	RCV000117498.3 [other]; RCV000300800.1 [benign]; 		COSM4133222	446	767					LRP2 (inh=AR pLI=1.00)
chr2	170092395	170092395	A	G	het	wt	het		QUAL=8650;DP=161,313,448;MQM=60	LRP2	synonymous	LRP2:NM_004525.2:synonymous:LOW:exon29/79:c.4875T>C:p.Cys1625Cys		rs2229267	0.4613	0.3337	7934/2189/2243	0.3265							600073 [LRP2 (confirmed) Donnai-Barrow syndrome,222448];	RCV000117534.3 [other]; RCV000335299.1 [benign]; 		COSM4133227	134	636					LRP2 (inh=AR pLI=1.00)
chr2	170099473	170099473	T	C	hom	hom	het		QUAL=19832;DP=248,260,293;MQM=60	LRP2	synonymous	LRP2:NM_004525.2:synonymous:LOW:exon24/79:c.3660A>G:p.Ala1220Ala		rs831042	0.5819	0.5231	17509/6874/1874	0.5123							600073 [LRP2 (confirmed) Donnai-Barrow syndrome,222448];	RCV000117527.3 [other]; RCV000282794.1 [benign]; 			432	770					LRP2 (inh=AR pLI=1.00)
chr2	170103336	170103336	T	C	hom	hom	het		QUAL=31117;DP=420,366,515;MQM=60	LRP2	synonymous	LRP2:NM_004525.2:synonymous:LOW:exon21/79:c.3069A>G:p.Thr1023Thr		rs831043	0.6186	0.5385	18669/7113/2485	0.5267							600073 [LRP2 (confirmed) Donnai-Barrow syndrome,222448];	RCV000117524.3 [other]; RCV000314964.1 [benign]; 			457	766					LRP2 (inh=AR pLI=1.00)
chr2	170103351	170103351	G	T	hom	hom	het		QUAL=29733;DP=366,385,517;MQM=60	LRP2	synonymous	LRP2:NM_004525.2:synonymous:LOW:exon21/79:c.3054C>A:p.Thr1018Thr		rs2075249	0.4565	0.4921	15497/7144/407	0.4819							600073 [LRP2 (confirmed) Donnai-Barrow syndrome,222448];	RCV000117523.3 [other]; RCV000369606.1 [benign]; 			379	752					LRP2 (inh=AR pLI=1.00)
chr2	170115588	170115588	T	C	hom	hom	het		QUAL=16616;DP=236,177,241;MQM=60	LRP2	synonymous	LRP2:NM_004525.2:synonymous:LOW:exon17/79:c.2460A>G:p.Thr820Thr		rs2241190	0.6224	0.5464	19120/7438/2458	0.5350							600073 [LRP2 (confirmed) Donnai-Barrow syndrome,222448];	RCV000117518.3 [other]; RCV000288847.1 [benign]; 			472	767					LRP2 (inh=AR pLI=1.00)
chr2	170129528	170129528	G	A	het	wt	hom		QUAL=16200;DP=312,295,396;MQM=60	LRP2	synonymous	LRP2:NM_004525.2:synonymous:LOW:exon15/79:c.2025C>T:p.Val675Val		rs830994	0.6096	0.6245	24489/14495/1399	0.6243							600073 [LRP2 (confirmed) Donnai-Barrow syndrome,222448];	RCV000117515.3 [other]; RCV000404343.1 [benign]; 			655	688					LRP2 (inh=AR pLI=1.00)
chr2	170150671	170150671	G	A	het	hom	wt		QUAL=11236;DP=267,228,304;MQM=60	LRP2	synonymous	LRP2:NM_004525.2:synonymous:LOW:exon6/79:c.639C>T:p.Asp213Asp		rs2229266	0.3702	0.3204	7064/2430/620	0.3166							600073 [LRP2 (confirmed) Donnai-Barrow syndrome,222448];	RCV000117541.3 [other]; RCV000330283.1 [benign]; 		COSM3757758	143	586					LRP2 (inh=AR pLI=1.00)
chr2	170218847	170218847	C	G	hom	hom	hom		QUAL=6541;DP=55,67,108;MQM=59	LRP2	synonymous	LRP2:NM_004525.2:synonymous:LOW:exon1/79:c.63G>C:p.Ala21Ala		rs1559014	0.9846	0.9971	20105/10407/1277	0.8499							600073 [LRP2 (confirmed) Donnai-Barrow syndrome,222448];	RCV000117542.3 [other]; RCV000366077.1 [benign]; 		COSM3749605	1555	1					LRP2 (inh=AR pLI=1.00)
chr2	172291616	172291616	C	T	het	wt	het		QUAL=8524;DP=295,214,283;MQM=60	DCAF17	synonymous,non_coding_transcript_exon	DCAF17:NM_025000.3:synonymous:LOW:exon2/14:c.150C>T:p.Val50Val,DCAF17:NM_001164821.1:synonymous:LOW:exon2/12:c.150C>T:p.Val50Val,DCAF17:NR_028482.1:non_coding_transcript_exon:MODIFIER:exon2/13:n.477C>T:		rs6751956	0.3067	0.2723	4779/1780/705	0.2668							612515 [DCAF17 (provisional) Woodhouse-Sakati syndrome,241080];	RCV000116869.2 [likely benign]; RCV000280952.1 [benign]; 			83	600					DCAF17 (inh=AR pLI=0.00)
chr2	172330393	172330393	A	G	het	wt	het		QUAL=8211;DP=359,208,310;MQM=60	DCAF17	synonymous,intron,non_coding_transcript_exon	DCAF17:NM_025000.3:synonymous:LOW:exon10/14:c.999A>G:p.Gln333Gln,DCAF17:NM_001164821.1:intron:MODIFIER:exon9/11:c.982-4104A>G:,DCAF17:NR_028482.1:non_coding_transcript_exon:MODIFIER:exon9/13:n.1220A>G:		rs3731983	0.2067	0.2267	3293/1285/171	0.2203	0.4960		T			0.05	612515 [DCAF17 (provisional) Woodhouse-Sakati syndrome,241080];	RCV000116872.2 [likely benign]; RCV000261719.1 [benign]; 		COSM4001323	67	543					DCAF17 (inh=AR pLI=0.00)
chr2	172336541	172336541	C	T	het	wt	het		QUAL=6522;DP=264,151,243;MQM=60	DCAF17	splice_region&intron	DCAF17:NM_025000.3:splice_region&intron:LOW:exon12/13:c.1267-7C>T:,DCAF17:NM_001164821.1:splice_region&intron:LOW:exon10/11:c.1066-7C>T:,DCAF17:NR_028482.1:splice_region&intron:LOW:exon11/12:n.1488-7C>T:		rs3731981	0.2061	0.2243	3337/1318/169	0.2187							612515 [DCAF17 (provisional) Woodhouse-Sakati syndrome,241080];	RCV000116867.2 [likely benign]; RCV000331955.1 [benign]; 		COSM4001324	67	541					DCAF17 (inh=AR pLI=0.00)
chr2	172337812	172337812	T	A	wt	wt	het		QUAL=1507;DP=246,119,145;MQM=60	DCAF17	3'UTR,non_coding_transcript_exon	DCAF17:NM_025000.3:3'UTR:MODIFIER:exon14/14:c.*188T>A:,DCAF17:NM_001164821.1:3'UTR:MODIFIER:exon12/12:c.*188T>A:,DCAF17:NR_028482.1:non_coding_transcript_exon:MODIFIER:exon13/13:n.1972T>A:		rs142315519	0.0098	0.0143	6/3/0	0.0081							612515 [DCAF17 (provisional) Woodhouse-Sakati syndrome,241080];	RCV000408089.1 [uncertain significance]; 			0	36					DCAF17 (inh=AR pLI=0.00)
chr2	172338194	172338194	G	A	het	wt	het		QUAL=7143;DP=344,132,217;MQM=60	DCAF17	3'UTR,non_coding_transcript_exon	DCAF17:NM_025000.3:3'UTR:MODIFIER:exon14/14:c.*570G>A:,DCAF17:NM_001164821.1:3'UTR:MODIFIER:exon12/12:c.*570G>A:,DCAF17:NR_028482.1:non_coding_transcript_exon:MODIFIER:exon13/13:n.2354G>A:		rs3795998	0.2065	0.2633	405/80/1	0.0563							612515 [DCAF17 (provisional) Woodhouse-Sakati syndrome,241080];	RCV000390781.1 [benign]; 			24	227					DCAF17 (inh=AR pLI=0.00)
chr2	172338300	172338300	T	G	het	wt	het		QUAL=7519;DP=294,150,231;MQM=60	DCAF17	3'UTR,non_coding_transcript_exon	DCAF17:NM_025000.3:3'UTR:MODIFIER:exon14/14:c.*676T>G:,DCAF17:NM_001164821.1:3'UTR:MODIFIER:exon12/12:c.*676T>G:,DCAF17:NR_028482.1:non_coding_transcript_exon:MODIFIER:exon13/13:n.2460T>G:		rs3821084	0.2061	0.2631	404/80/1	0.0565							612515 [DCAF17 (provisional) Woodhouse-Sakati syndrome,241080];	RCV000299788.1 [benign]; 			24	226					DCAF17 (inh=AR pLI=0.00)
chr2	172339964	172339964	C	T	hom	hom	hom		QUAL=36717;DP=380,334,410;MQM=59	DCAF17	3'UTR,non_coding_transcript_exon	DCAF17:NM_025000.3:3'UTR:MODIFIER:exon14/14:c.*2340C>T:,DCAF17:NM_001164821.1:3'UTR:MODIFIER:exon12/12:c.*2340C>T:,DCAF17:NR_028482.1:non_coding_transcript_exon:MODIFIER:exon13/13:n.4124C>T:		rs888428	0.9774	0.9986	5382/1369/88	0.2297							612515 [DCAF17 (provisional) Woodhouse-Sakati syndrome,241080];	RCV000391394.1 [benign]; 			651	1					DCAF17 (inh=AR pLI=0.00)
chr2	172340049	172340049	T	A	het	wt	het		QUAL=9869;DP=454,300,352;MQM=60	DCAF17	3'UTR,non_coding_transcript_exon	DCAF17:NM_025000.3:3'UTR:MODIFIER:exon14/14:c.*2425T>A:,DCAF17:NM_001164821.1:3'UTR:MODIFIER:exon12/12:c.*2425T>A:,DCAF17:NR_028482.1:non_coding_transcript_exon:MODIFIER:exon13/13:n.4209T>A:		rs12151641	0.2065	0.2643	408/80/1	0.0563							612515 [DCAF17 (provisional) Woodhouse-Sakati syndrome,241080];	RCV000391085.1 [benign]; 			24	227					DCAF17 (inh=AR pLI=0.00)
chr2	172340419	172340419	T	C	het	wt	het		QUAL=9731;DP=397,238,320;MQM=60	DCAF17	3'UTR,non_coding_transcript_exon	DCAF17:NM_025000.3:3'UTR:MODIFIER:exon14/14:c.*2795T>C:,DCAF17:NM_001164821.1:3'UTR:MODIFIER:exon12/12:c.*2795T>C:,DCAF17:NR_028482.1:non_coding_transcript_exon:MODIFIER:exon13/13:n.4579T>C:		rs17221346	0.2718	0.2825	465/88/3	0.0651							612515 [DCAF17 (provisional) Woodhouse-Sakati syndrome,241080];	RCV000269174.1 [benign]; 			28	247					DCAF17 (inh=AR pLI=0.00)
chr2	172340736	172340736	C	G	het	wt	het		QUAL=5900;DP=242,150,185;MQM=60	DCAF17	3'UTR,non_coding_transcript_exon	DCAF17:NM_025000.3:3'UTR:MODIFIER:exon14/14:c.*3112C>G:,DCAF17:NM_001164821.1:3'UTR:MODIFIER:exon12/12:c.*3112C>G:,DCAF17:NR_028482.1:non_coding_transcript_exon:MODIFIER:exon13/13:n.4896C>G:		rs17221367	0.2065	0.2648	400/80/1	0.0565							612515 [DCAF17 (provisional) Woodhouse-Sakati syndrome,241080];	RCV000375173.1 [benign]; 			24	223					DCAF17 (inh=AR pLI=0.00)
chr2	172341327	172341327	A	G	het	wt	het		QUAL=5046;DP=165,132,196;MQM=60	DCAF17	3'UTR,non_coding_transcript_exon	DCAF17:NM_025000.3:3'UTR:MODIFIER:exon14/14:c.*3703A>G:,DCAF17:NM_001164821.1:3'UTR:MODIFIER:exon12/12:c.*3703A>G:,DCAF17:NR_028482.1:non_coding_transcript_exon:MODIFIER:exon13/13:n.5487A>G:	L1ME2z	rs9789572	0.2065	0.2634	407/80/1	0.0566							612515 [DCAF17 (provisional) Woodhouse-Sakati syndrome,241080];	RCV000316959.1 [benign]; 			22	197					DCAF17 (inh=AR pLI=0.00)
chr2	173339808	173339808	G	A	het	wt	hom	pred_pathogenic	QUAL=13435;DP=230,279,321;MQM=59	ITGA6	missense	ITGA6:NM_001079818.2:missense:MODERATE:exon7/25:c.1138G>A:p.Ala380Thr,ITGA6:NM_001316306.1:missense:MODERATE:exon7/26:c.781G>A:p.Ala261Thr,ITGA6:NM_000210.3:missense:MODERATE:exon7/26:c.1138G>A:p.Ala380Thr		rs11895564	0.2516	0.2810	5014/2867/580	0.2750	3.1200	T,T,T,T,T,T,T,T	T	B,B,P,P	T,T,T,T,T,T,T,T	22.30	147556 [ITGA6 (provisional) Epidermolysis bullosa,junctional,with pyloric stenosis,226730];	RCV000279397.1 [benign]; 		COSM3757774, COSM3757775, COSM3757773	155	681					ITGA6 (inh=AR pLI=0.01)
chr2	173344474	173344474	A	G	het	wt	hom		QUAL=12733;DP=351,219,290;MQM=59	ITGA6	splice_region&intron	ITGA6:NM_001079818.2:splice_region&intron:LOW:exon10/24:c.1487+7A>G:,ITGA6:NM_001316306.1:splice_region&intron:LOW:exon10/25:c.1130+7A>G:,ITGA6:NM_000210.3:splice_region&intron:LOW:exon10/25:c.1487+7A>G:		rs1920979	0.4071	0.3710	8645/3834/1379	0.3634							147556 [ITGA6 (provisional) Epidermolysis bullosa,junctional,with pyloric stenosis,226730];	RCV000406071.1 [benign]; 		COSM4001327, COSM4001326, COSM4001325	213	737					ITGA6 (inh=AR pLI=0.01)
chr2	173352103	173352103	C	T	wt	wt	het		QUAL=6405;DP=679,320,449;MQM=60	ITGA6	synonymous	ITGA6:NM_001079818.2:synonymous:LOW:exon15/25:c.2082C>T:p.Asp694Asp,ITGA6:NM_001316306.1:synonymous:LOW:exon15/26:c.1725C>T:p.Asp575Asp,ITGA6:NM_000210.3:synonymous:LOW:exon15/26:c.2082C>T:p.Asp694Asp		rs2293649	0.3466	0.2974	6274/1604/245	0.2908							147556 [ITGA6 (provisional) Epidermolysis bullosa,junctional,with pyloric stenosis,226730];	RCV000324684.1 [benign]; 		COSM3757778, COSM3757776, COSM3757777	112	581					ITGA6 (inh=AR pLI=0.01)
chr2	173369000	173369000	-	T	wt	wt	het		QUAL=1505;DP=285,60,116;MQM=60	ITGA6	3'UTR	ITGA6:NM_001079818.2:3'UTR:MODIFIER:exon25/25:c.*20_*21insT:,ITGA6:NM_001316306.1:3'UTR:MODIFIER:exon26/26:c.*204_*205insT:,ITGA6:NM_000210.3:3'UTR:MODIFIER:exon26/26:c.*204_*205insT:		rs61499296	0.1058	0.1679	212/136/4	0.0791							147556 [ITGA6 (provisional) Epidermolysis bullosa,junctional,with pyloric stenosis,226730];	RCV000332266.1 [likely benign]; 			19	281					ITGA6 (inh=AR pLI=0.01)
chr2	173369231	173369231	A	G	het	wt	hom		QUAL=10124;DP=271,162,220;MQM=59	ITGA6	3'UTR	ITGA6:NM_001079818.2:3'UTR:MODIFIER:exon25/25:c.*251A>G:,ITGA6:NM_001316306.1:3'UTR:MODIFIER:exon26/26:c.*435A>G:,ITGA6:NM_000210.3:3'UTR:MODIFIER:exon26/26:c.*435A>G:		rs17664	0.6340	0.0000	0/0/0	0.0886							147556 [ITGA6 (provisional) Epidermolysis bullosa,junctional,with pyloric stenosis,226730];	RCV000331172.1 [benign]; 			32	120					ITGA6 (inh=AR pLI=0.01)
chr2	175624108	175624108	A	-	wt	het	wt		QUAL=4161;DP=295,329,360;MQM=60	CHRNA1	splice_region&intron	CHRNA1:NM_001039523.2:splice_region&intron:LOW:exon2/9:c.190-5delT:,CHRNA1:NM_000079.3:splice_region&intron:LOW:exon2/8:c.190-5delT:		rs397986745	0.2754	0.4059	10906/8202/62	0.3667							100690 [CHRNA1 (confirmed) Myasthenic syndrome,congenital,1A,slow-channel,601462|Myasthenic syndrome,congenital,1B,fast-channel,608930|Multiple pterygium syndrome,lethal type,253290];	RCV000253666.1 [benign]; RCV000311146.1 [benign]; RCV000401626.1 [benign]; 			333	731					CHRNA1 (inh=AR+AD pLI=0.00)
chr2	178404735	178404735	-	AAAG	hom	hom	hom	low_DP	QUAL=1725;DP=48,6,9;MQM=59	AGPS	3'UTR	AGPS:NM_003659.3:3'UTR:MODIFIER:exon20/20:c.*1814_*1815insAGAA:		rs139584283	0.8850	0.0000	0/0/0	0.6555							603051 [AGPS (provisional) Rhizomelic chondrodysplasia punctata,type 3,600121];	RCV000300781.1 [benign]; 			158	60					AGPS (inh=AR pLI=1.00)
chr2	178404789	178404789	A	G	hom	hom	hom	low_DP	QUAL=1364;DP=34,3,11;MQM=59	AGPS	3'UTR	AGPS:NM_003659.3:3'UTR:MODIFIER:exon20/20:c.*1866A>G:	(TA)n	rs10930795	0.8944	0.0000	0/0/0	0.3260							603051 [AGPS (provisional) Rhizomelic chondrodysplasia punctata,type 3,600121];	RCV000377269.1 [benign]; 			173	47					AGPS (inh=AR pLI=1.00)
chr2	178404802	178404805	TATA	-	hom	hom	hom	low_DP	QUAL=1076;DP=40,5,14;MQM=59	AGPS	3'UTR	AGPS:NM_003659.3:3'UTR:MODIFIER:exon20/20:c.*1896_*1899delATAT:	(TA)n	rs144293437;rs72185133;rs773223731	0.9101	0.0000	0/0/0	0.3978							603051 [AGPS (provisional) Rhizomelic chondrodysplasia punctata,type 3,600121];	RCV000292898.1 [other]; 			141	53					AGPS (inh=AR pLI=1.00)
chr2	178406481	178406481	C	T	hom	het	hom		QUAL=14530;DP=310,87,102;MQM=60	AGPS	3'UTR	AGPS:NM_003659.3:3'UTR:MODIFIER:exon20/20:c.*3558C>T:		rs8941	0.6967	0.0000	0/0/0	0.1426							603051 [AGPS (provisional) Rhizomelic chondrodysplasia punctata,type 3,600121];	RCV000344624.1 [benign]; 			131	86					AGPS (inh=AR pLI=1.00)
chr2	178406769	178406769	-	T	hom	hom	hom		QUAL=11906;DP=205,73,104;MQM=59	AGPS	3'UTR	AGPS:NM_003659.3:3'UTR:MODIFIER:exon20/20:c.*3854dupT:		rs397783598	0.8902	0.0000	0/0/0	0.7601							603051 [AGPS (provisional) Rhizomelic chondrodysplasia punctata,type 3,600121];	RCV000295522.1 [benign]; 			175	50					AGPS (inh=AR pLI=1.00)
chr2	178407176	178407176	C	A	hom	hom	hom		QUAL=15591;DP=267,87,133;MQM=60	AGPS	3'UTR	AGPS:NM_003659.3:3'UTR:MODIFIER:exon20/20:c.*4253C>A:		rs10803912	0.8770	0.0000	0/0/0	0.1334							603051 [AGPS (provisional) Rhizomelic chondrodysplasia punctata,type 3,600121];	RCV000361548.1 [benign]; 			173	52					AGPS (inh=AR pLI=1.00)
chr2	178407439	178407440	AT	-	wt	het	wt		QUAL=1717;DP=395,187,258;MQM=60	AGPS	3'UTR	AGPS:NM_003659.3:3'UTR:MODIFIER:exon20/20:c.*4516_*4517delAT:		rs3215354	0.1761	0.0000	0/0/0	0.1126							603051 [AGPS (provisional) Rhizomelic chondrodysplasia punctata,type 3,600121];	RCV000267098.1 [benign]; 			3	44					AGPS (inh=AR pLI=1.00)
chr2	178407897	178407897	T	C	hom	hom	hom		QUAL=22405;DP=266,180,279;MQM=59	AGPS	3'UTR	AGPS:NM_003659.3:3'UTR:MODIFIER:exon20/20:c.*4974T>C:		rs2293475	0.8764	0.0000	0/0/0	0.1283							603051 [AGPS (provisional) Rhizomelic chondrodysplasia punctata,type 3,600121];	RCV000269027.1 [benign]; 			173	52					AGPS (inh=AR pLI=1.00)
chr2	179315444	179315444	T	G	het	het	het	low_DP	QUAL=721;DP=42,16,16;MQM=59	PRKRA,MIR548N	sequence_feature,5'UTR,intron	PRKRA:NM_003690.4:sequence_feature:MODERATE::c.65+249A>C:,PRKRA:NM_001139517.1:5'UTR:MODIFIER:exon1/7:c.-274A>C:,MIR548N:NR_031666.1:intron:MODIFIER:exon3/4:n.36+51746T>G:,PRKRA:NM_003690.4:intron:MODIFIER:exon1/7:c.65+249A>C:,PRKRA:NM_001316362.1:intron:MODIFIER:exon1/8:c.-385+249A>C:		rs184658426	0.0088	0.0000	0/0/0	0.0115							603424 [PRKRA (confirmed) Dystonia 16,612067];				1	8					PRKRA (inh=AR pLI=0.15), MIR548N (inh=n/a pLI=n/a)
chr2	179395554	179395554	G	A	het	het	wt	pred_pathogenic	QUAL=4377;DP=312,98,169;MQM=60	TTN,MIR548N,TTN-AS1	missense,intron	TTN:NM_001267550.2:missense:MODERATE:exon358/363:c.105788C>T:p.Ala35263Val,TTN:NM_001256850.1:missense:MODERATE:exon308/313:c.100865C>T:p.Ala33622Val,TTN:NM_133437.4:missense:MODERATE:exon187/192:c.79169C>T:p.Ala26390Val,TTN:NM_003319.4:missense:MODERATE:exon186/191:c.78593C>T:p.Ala26198Val,TTN:NM_133378.4:missense:MODERATE:exon307/312:c.98084C>T:p.Ala32695Val,TTN:NM_133432.3:missense:MODERATE:exon187/192:c.78968C>T:p.Ala26323Val,MIR548N:NR_031666.1:intron:MODIFIER:exon3/4:n.37-97961G>A:,TTN-AS1:NR_038272.1:intron:MODIFIER:exon2/16:n.220-4905G>A:,TTN-AS1:NR_038271.1:intron:MODIFIER:exon1/6:n.446+7191G>A:		rs66961115	0.0052	0.0114	20/18/0	0.0105	2.3280	T,T,T,T,T	T	B,B,B,B	T,T,T,T	20.80	188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000040971.8 [other]; RCV000242301.1 [likely benign]; 			0	43					TTN (inh=AD pLI=0.00), MIR548N (inh=n/a pLI=n/a), TTN-AS1 (inh=n/a pLI=n/a)
chr2	179395555	179395555	C	A	het	het	wt	pred_pathogenic	QUAL=4377;DP=312,98,169;MQM=60	TTN,MIR548N,TTN-AS1	missense,intron	TTN:NM_001267550.2:missense:MODERATE:exon358/363:c.105787G>T:p.Ala35263Ser,TTN:NM_001256850.1:missense:MODERATE:exon308/313:c.100864G>T:p.Ala33622Ser,TTN:NM_133437.4:missense:MODERATE:exon187/192:c.79168G>T:p.Ala26390Ser,TTN:NM_003319.4:missense:MODERATE:exon186/191:c.78592G>T:p.Ala26198Ser,TTN:NM_133378.4:missense:MODERATE:exon307/312:c.98083G>T:p.Ala32695Ser,TTN:NM_133432.3:missense:MODERATE:exon187/192:c.78967G>T:p.Ala26323Ser,MIR548N:NR_031666.1:intron:MODIFIER:exon3/4:n.37-97960C>A:,TTN-AS1:NR_038272.1:intron:MODIFIER:exon2/16:n.220-4904C>A:,TTN-AS1:NR_038271.1:intron:MODIFIER:exon1/6:n.446+7192C>A:		rs67254537	0.0052	0.0113	20/18/0	0.0105	2.6440	T,T,T,T,T	T	B,B,B,B	T,T,T,T	18.00	188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000040970.8 [other]; RCV000247062.1 [likely benign]; 			0	43					TTN (inh=AD pLI=0.00), MIR548N (inh=n/a pLI=n/a), TTN-AS1 (inh=n/a pLI=n/a)
chr2	179395573	179395573	C	T	het	het	wt	pred_pathogenic	QUAL=5161;DP=333,95,174;MQM=60	TTN,MIR548N,TTN-AS1	missense,intron	TTN:NM_001267550.2:missense:MODERATE:exon358/363:c.105769G>A:p.Glu35257Lys,TTN:NM_001256850.1:missense:MODERATE:exon308/313:c.100846G>A:p.Glu33616Lys,TTN:NM_133437.4:missense:MODERATE:exon187/192:c.79150G>A:p.Glu26384Lys,TTN:NM_003319.4:missense:MODERATE:exon186/191:c.78574G>A:p.Glu26192Lys,TTN:NM_133378.4:missense:MODERATE:exon307/312:c.98065G>A:p.Glu32689Lys,TTN:NM_133432.3:missense:MODERATE:exon187/192:c.78949G>A:p.Glu26317Lys,MIR548N:NR_031666.1:intron:MODIFIER:exon3/4:n.37-97942C>T:,TTN-AS1:NR_038272.1:intron:MODIFIER:exon2/16:n.220-4886C>T:,TTN-AS1:NR_038271.1:intron:MODIFIER:exon1/6:n.446+7210C>T:		rs56324595	0.0066	0.0139	27/23/0	0.0135	7.8180	D,D,D,D,D	T	D,D,D,D	T,T,T,T	23.60	188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000040968.8 [other]; RCV000232021.1 [benign]; RCV000232021.1 [benign]; RCV000250202.1 [benign]; 			0	59					TTN (inh=AD pLI=0.00), MIR548N (inh=n/a pLI=n/a), TTN-AS1 (inh=n/a pLI=n/a)
chr2	179404498	179404498	G	C	het	wt	het	pred_pathogenic	QUAL=15914;DP=509,526,648;MQM=60	TTN,MIR548N,TTN-AS1	missense,intron,non_coding_transcript_exon	TTN:NM_001267550.2:missense:MODERATE:exon352/363:c.98294C>G:p.Ala32765Gly,TTN:NM_001256850.1:missense:MODERATE:exon302/313:c.93371C>G:p.Ala31124Gly,TTN:NM_133437.4:missense:MODERATE:exon181/192:c.71675C>G:p.Ala23892Gly,TTN:NM_003319.4:missense:MODERATE:exon180/191:c.71099C>G:p.Ala23700Gly,TTN:NM_133378.4:missense:MODERATE:exon301/312:c.90590C>G:p.Ala30197Gly,TTN:NM_133432.3:missense:MODERATE:exon181/192:c.71474C>G:p.Ala23825Gly,MIR548N:NR_031666.1:intron:MODIFIER:exon3/4:n.37-89017G>C:,TTN-AS1:NR_038271.1:intron:MODIFIER:exon1/6:n.446+16135G>C:,TTN-AS1:NR_038272.1:non_coding_transcript_exon:MODIFIER:exon5/17:n.1721G>C:		rs72648273	0.0010	0.0028	0/0/0	0.0027	9.8690	D,D,D,D,D	D	D,D,D,D	T,T,T,T	21.70	188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000040867.5 [likely benign]; RCV000118794.4 [likely benign]; RCV000248345.1 [likely benign]; RCV000260558.1 [uncertain significance]; RCV000264048.1 [uncertain significance]; RCV000321435.1 [uncertain significance]; RCV000322722.1 [uncertain significance]; RCV000354955.1 [uncertain significance]; RCV000361061.1 [uncertain significance]; 			1	24					TTN (inh=AD pLI=0.00), MIR548N (inh=n/a pLI=n/a), TTN-AS1 (inh=n/a pLI=n/a)
chr2	179424048	179424048	T	C	wt	wt	het		QUAL=2478;DP=383,145,205;MQM=60	TTN,MIR548N,TTN-AS1	synonymous,intron	TTN:NM_001267550.2:synonymous:LOW:exon326/363:c.86811A>G:p.Val28937Val,TTN:NM_001256850.1:synonymous:LOW:exon276/313:c.81888A>G:p.Val27296Val,TTN:NM_133437.4:synonymous:LOW:exon155/192:c.60192A>G:p.Val20064Val,TTN:NM_003319.4:synonymous:LOW:exon154/191:c.59616A>G:p.Val19872Val,TTN:NM_133378.4:synonymous:LOW:exon275/312:c.79107A>G:p.Val26369Val,TTN:NM_133432.3:synonymous:LOW:exon155/192:c.59991A>G:p.Val19997Val,MIR548N:NR_031666.1:intron:MODIFIER:exon3/4:n.37-69467T>C:,TTN-AS1:NR_038272.1:intron:MODIFIER:exon7/16:n.2043+16960T>C:,TTN-AS1:NR_038271.1:intron:MODIFIER:exon1/6:n.447-11979T>C:		rs55972010	0.0162	0.0243	43/34/0	0.0228							188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000040726.8 [other]; RCV000247545.1 [benign]; RCV000280956.1 [likely benign]; RCV000286756.1 [likely benign]; RCV000317088.1 [likely benign]; RCV000330035.1 [likely benign]; RCV000371748.1 [likely benign]; RCV000375435.1 [likely benign]; 			4	106					TTN (inh=AD pLI=0.00), MIR548N (inh=n/a pLI=n/a), TTN-AS1 (inh=n/a pLI=n/a)
chr2	179432185	179432185	A	G	het	hom	wt	pred_pathogenic	QUAL=20892;DP=503,416,543;MQM=60	TTN,MIR548N,TTN-AS1	missense,intron	TTN:NM_001267550.2:missense:MODERATE:exon326/363:c.78674T>C:p.Ile26225Thr,TTN:NM_001256850.1:missense:MODERATE:exon276/313:c.73751T>C:p.Ile24584Thr,TTN:NM_133437.4:missense:MODERATE:exon155/192:c.52055T>C:p.Ile17352Thr,TTN:NM_003319.4:missense:MODERATE:exon154/191:c.51479T>C:p.Ile17160Thr,TTN:NM_133378.4:missense:MODERATE:exon275/312:c.70970T>C:p.Ile23657Thr,TTN:NM_133432.3:missense:MODERATE:exon155/192:c.51854T>C:p.Ile17285Thr,MIR548N:NR_031666.1:intron:MODIFIER:exon3/4:n.37-61330A>G:,TTN-AS1:NR_038272.1:intron:MODIFIER:exon7/16:n.2044-15114A>G:,TTN-AS1:NR_038271.1:intron:MODIFIER:exon1/6:n.447-3842A>G:		rs12463674	0.1300	0.2368	4109/3069/7	0.2337	5.9890	T,D,T,T,D	T	B,B,B,B	T,T,T,T	22.90	188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000040637.11 [benign]; RCV000252077.1 [benign]; RCV000277833.1 [likely benign]; RCV000299007.1 [likely benign]; RCV000311963.1 [likely benign]; RCV000338511.1 [likely benign]; RCV000369992.1 [likely benign]; RCV000399563.1 [likely benign]; 			137	622					TTN (inh=AD pLI=0.00), MIR548N (inh=n/a pLI=n/a), TTN-AS1 (inh=n/a pLI=n/a)
chr2	179440029	179440029	G	A	het	hom	wt		QUAL=13316;DP=381,285,396;MQM=59	TTN,MIR548N,TTN-AS1	synonymous,intron	TTN:NM_001267550.2:synonymous:LOW:exon326/363:c.70830C>T:p.Ser23610Ser,TTN:NM_001256850.1:synonymous:LOW:exon276/313:c.65907C>T:p.Ser21969Ser,TTN:NM_133437.4:synonymous:LOW:exon155/192:c.44211C>T:p.Ser14737Ser,TTN:NM_003319.4:synonymous:LOW:exon154/191:c.43635C>T:p.Ser14545Ser,TTN:NM_133378.4:synonymous:LOW:exon275/312:c.63126C>T:p.Ser21042Ser,TTN:NM_133432.3:synonymous:LOW:exon155/192:c.44010C>T:p.Ser14670Ser,MIR548N:NR_031666.1:intron:MODIFIER:exon3/4:n.37-53486G>A:,TTN-AS1:NR_038272.1:intron:MODIFIER:exon7/16:n.2044-7270G>A:,TTN-AS1:NR_038271.1:intron:MODIFIER:exon2/6:n.596+3853G>A:		rs12464787	0.1466	0.2400	4061/2996/58	0.2345							188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000040563.9 [benign]; RCV000247860.1 [benign]; RCV000266148.1 [likely benign]; RCV000297946.1 [likely benign]; RCV000306054.1 [likely benign]; RCV000355113.1 [likely benign]; RCV000358526.1 [likely benign]; RCV000398179.1 [likely benign]; 		COSM4133286, COSM4133285, COSM4133282, COSM4133284, COSM4133283	137	618					TTN (inh=AD pLI=0.00), MIR548N (inh=n/a pLI=n/a), TTN-AS1 (inh=n/a pLI=n/a)
chr2	179444768	179444768	C	G	hom	hom	hom		QUAL=59878;DP=523,561,773;MQM=60	TTN,MIR548N,TTN-AS1	missense,intron	TTN:NM_001267550.2:missense:MODERATE:exon318/363:c.67246G>C:p.Ala22416Pro,TTN:NM_001256850.1:missense:MODERATE:exon268/313:c.62323G>C:p.Ala20775Pro,TTN:NM_133437.4:missense:MODERATE:exon147/192:c.40627G>C:p.Ala13543Pro,TTN:NM_003319.4:missense:MODERATE:exon146/191:c.40051G>C:p.Ala13351Pro,TTN:NM_133378.4:missense:MODERATE:exon267/312:c.59542G>C:p.Ala19848Pro,TTN:NM_133432.3:missense:MODERATE:exon147/192:c.40426G>C:p.Ala13476Pro,MIR548N:NR_031666.1:intron:MODIFIER:exon3/4:n.37-48747C>G:,TTN-AS1:NR_038272.1:intron:MODIFIER:exon7/16:n.2044-2531C>G:,TTN-AS1:NR_038271.1:intron:MODIFIER:exon2/6:n.596+8592C>G:		rs4145333	0.9946	0.9986	60192/33352/4769	0.9353	0.6560	T,T,T,T,T	T	B,B,B	T,T,T,T	2.49	188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000040520.7 [benign]; RCV000248869.1 [benign]; RCV000282280.1 [likely benign]; RCV000286185.1 [likely benign]; RCV000317492.1 [likely benign]; RCV000339521.1 [likely benign]; RCV000374422.1 [likely benign]; RCV000407028.1 [likely benign]; 			1664	1					TTN (inh=AD pLI=0.00), MIR548N (inh=n/a pLI=n/a), TTN-AS1 (inh=n/a pLI=n/a)
chr2	179453796	179453796	C	T	het	wt	het	pred_pathogenic	QUAL=8369;DP=331,259,298;MQM=59	TTN,MIR548N,TTN-AS1	missense,intron	TTN:NM_001267550.2:missense:MODERATE:exon304/363:c.62656G>A:p.Asp20886Asn,TTN:NM_001256850.1:missense:MODERATE:exon254/313:c.57733G>A:p.Asp19245Asn,TTN:NM_133437.4:missense:MODERATE:exon133/192:c.36037G>A:p.Asp12013Asn,TTN:NM_003319.4:missense:MODERATE:exon132/191:c.35461G>A:p.Asp11821Asn,TTN:NM_133378.4:missense:MODERATE:exon253/312:c.54952G>A:p.Asp18318Asn,TTN:NM_133432.3:missense:MODERATE:exon133/192:c.35836G>A:p.Asp11946Asn,MIR548N:NR_031666.1:intron:MODIFIER:exon3/4:n.37-39719C>T:,TTN-AS1:NR_038272.1:intron:MODIFIER:exon11/16:n.3189-2070C>T:,TTN-AS1:NR_038271.1:intron:MODIFIER:exon2/6:n.597-8527C>T:			0.0000	0.0000	0/0/0	0.0000	7.8180	T,D,D,D,D	T	D,D,D,D	T,T,T,T	22.70	188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];				0	2					TTN (inh=AD pLI=0.00), MIR548N (inh=n/a pLI=n/a), TTN-AS1 (inh=n/a pLI=n/a)
chr2	179462494	179462494	A	G	het	hom	wt		QUAL=22293;DP=578,462,664;MQM=60	TTN,MIR548N,TTN-AS1	synonymous,intron	TTN:NM_001267550.2:synonymous:LOW:exon294/363:c.57315T>C:p.His19105His,TTN:NM_001256850.1:synonymous:LOW:exon244/313:c.52392T>C:p.His17464His,TTN:NM_133437.4:synonymous:LOW:exon123/192:c.30696T>C:p.His10232His,TTN:NM_003319.4:synonymous:LOW:exon122/191:c.30120T>C:p.His10040His,TTN:NM_133378.4:synonymous:LOW:exon243/312:c.49611T>C:p.His16537His,TTN:NM_133432.3:synonymous:LOW:exon123/192:c.30495T>C:p.His10165His,MIR548N:NR_031666.1:intron:MODIFIER:exon3/4:n.37-31021A>G:,TTN-AS1:NR_038272.1:intron:MODIFIER:exon13/16:n.3450+86A>G:,TTN-AS1:NR_038271.1:intron:MODIFIER:exon3/6:n.682+86A>G:		rs35833641	0.1270	0.2349	4069/3055/8	0.2318							188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000040390.5 [benign]; RCV000251182.1 [benign]; RCV000287439.1 [likely benign]; RCV000295798.1 [likely benign]; RCV000326309.1 [likely benign]; RCV000327457.1 [likely benign]; RCV000384352.1 [likely benign]; RCV000387828.1 [likely benign]; 		COSM4001385, COSM4001388, COSM4001386, COSM4001387, COSM4001389	136	619					TTN (inh=AD pLI=0.00), MIR548N (inh=n/a pLI=n/a), TTN-AS1 (inh=n/a pLI=n/a)
chr2	179498042	179498042	T	C	wt	wt	het	pred_pathogenic	QUAL=4097;DP=434,236,308;MQM=60	TTN,MIR548N	missense,intron	TTN:NM_001267550.2:missense:MODERATE:exon233/363:c.42958A>G:p.Lys14320Glu,TTN:NM_001256850.1:missense:MODERATE:exon183/313:c.38035A>G:p.Lys12679Glu,TTN:NM_133437.4:missense:MODERATE:exon62/192:c.16339A>G:p.Lys5447Glu,TTN:NM_003319.4:missense:MODERATE:exon61/191:c.15763A>G:p.Lys5255Glu,TTN:NM_133378.4:missense:MODERATE:exon182/312:c.35254A>G:p.Lys11752Glu,TTN:NM_133432.3:missense:MODERATE:exon62/192:c.16138A>G:p.Lys5380Glu,MIR548N:NR_031666.1:intron:MODIFIER:exon4/4:n.48+4516T>C:		rs6723526	0.0509	0.0830	551/395/2	0.0816	6.2350	T,D,T,T,D	T	D,D,D,D	T,T,T,T	19.24	188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000040233.6 [benign]; RCV000247761.1 [benign]; RCV000271309.1 [likely benign]; RCV000277023.1 [likely benign]; RCV000307821.1 [likely benign]; RCV000332097.1 [likely benign]; RCV000362475.1 [likely benign]; RCV000368148.1 [likely benign]; 		COSM3757801, COSM3757802, COSM3757804, COSM3757803	25	321					TTN (inh=AD pLI=0.00), MIR548N (inh=n/a pLI=n/a)
chr2	179542469	179542489	TTCCTCTTCTTCAGGTAGAAC	-	wt	wt	het		QUAL=5571;DP=183,580,665;MQM=59	TTN	conservative_inframe_deletion,intron	TTN:NM_001267550.2:conservative_inframe_deletion:MODERATE:exon146/363:c.34150_34170delGTTCTACCTGAAGAAGAGGAA:p.Val11384_Glu11390del,TTN:NM_001256850.1:conservative_inframe_deletion:MODERATE:exon144/313:c.33199_33219delGTTCTACCTGAAGAAGAGGAA:p.Val11067_Glu11073del,TTN:NM_133378.4:conservative_inframe_deletion:MODERATE:exon143/312:c.30418_30438delGTTCTACCTGAAGAAGAGGAA:p.Val10140_Glu10146del,TTN:NM_133437.4:intron:MODIFIER:exon47/191:c.13859-35445_13859-35425delGTTCTACCTGAAGAAGAGGAA:,TTN:NM_003319.4:intron:MODIFIER:exon46/190:c.13283-35445_13283-35425delGTTCTACCTGAAGAAGAGGAA:,TTN:NM_133432.3:intron:MODIFIER:exon47/191:c.13658-35445_13658-35425delGTTCTACCTGAAGAAGAGGAA:		rs587780487	0.0000	0.0012	1/0/0	0.0001							188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000118749.1 [uncertain significance]; RCV000228807.1 [benign]; RCV000228807.1 [benign]; 			0	3					TTN (inh=AD pLI=0.00)
chr2	179542499	179542499	T	C	het	wt	wt		QUAL=864;DP=293,658,744;MQM=54	TTN	synonymous,intron	TTN:NM_001267550.2:synonymous:LOW:exon146/363:c.34140A>G:p.Glu11380Glu,TTN:NM_001256850.1:synonymous:LOW:exon144/313:c.33189A>G:p.Glu11063Glu,TTN:NM_133378.4:synonymous:LOW:exon143/312:c.30408A>G:p.Glu10136Glu,TTN:NM_133437.4:intron:MODIFIER:exon47/191:c.13859-35455A>G:,TTN:NM_003319.4:intron:MODIFIER:exon46/190:c.13283-35455A>G:,TTN:NM_133432.3:intron:MODIFIER:exon47/191:c.13658-35455A>G:		rs147418835	0.0030	0.0001	0/0/0	0.0002							188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000259807.1 [uncertain significance]; RCV000275254.1 [uncertain significance]; RCV000317393.1 [uncertain significance]; RCV000332773.1 [uncertain significance]; RCV000371038.1 [uncertain significance]; RCV000374409.1 [uncertain significance]; 			0	3					TTN (inh=AD pLI=0.00)
chr2	179545859	179545859	C	T	het	hom	wt		QUAL=8789;DP=347,131,226;MQM=60	TTN	missense,intron	TTN:NM_001267550.2:missense:MODERATE:exon138/363:c.33287G>A:p.Arg11096His,TTN:NM_001256850.1:missense:MODERATE:exon136/313:c.32336G>A:p.Arg10779His,TTN:NM_133378.4:missense:MODERATE:exon135/312:c.29555G>A:p.Arg9852His,TTN:NM_133437.4:intron:MODIFIER:exon47/191:c.13859-38815G>A:,TTN:NM_003319.4:intron:MODIFIER:exon46/190:c.13283-38815G>A:,TTN:NM_133432.3:intron:MODIFIER:exon47/191:c.13658-38815G>A:		rs36051007	0.1260	0.2347	3963/2974/7	0.2305	-0.5180	T	T	B	T	18.18	188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000040156.7 [benign]; RCV000251495.1 [benign]; RCV000270218.1 [likely benign]; RCV000273725.1 [likely benign]; RCV000327674.1 [likely benign]; RCV000331522.1 [likely benign]; RCV000362564.1 [likely benign]; RCV000384442.1 [likely benign]; 		COSM4001412, COSM4001413	139	606					TTN (inh=AD pLI=0.00)
chr2	179554305	179554305	C	T	het	hom	wt	pred_pathogenic	QUAL=11498;DP=436,199,261;MQM=60	TTN	missense,intron	TTN:NM_001267550.2:missense:MODERATE:exon123/363:c.31864G>A:p.Gly10622Arg,TTN:NM_001256850.1:missense:MODERATE:exon121/313:c.30913G>A:p.Gly10305Arg,TTN:NM_133378.4:missense:MODERATE:exon120/312:c.28132G>A:p.Gly9378Arg,TTN:NM_133437.4:intron:MODIFIER:exon47/191:c.13859-47261G>A:,TTN:NM_003319.4:intron:MODIFIER:exon46/190:c.13283-47261G>A:,TTN:NM_133432.3:intron:MODIFIER:exon47/191:c.13658-47261G>A:		rs2244492	0.4133	0.3995	8028/3459/1608	0.3705	3.2520	T,T	T		T,T	23.70	188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000040129.6 [benign]; RCV000245743.1 [benign]; RCV000266150.1 [likely benign]; RCV000269588.1 [likely benign]; RCV000305987.1 [likely benign]; RCV000321271.1 [likely benign]; RCV000360822.1 [likely benign]; RCV000364010.1 [likely benign]; 			219	744					TTN (inh=AD pLI=0.00)
chr2	179569387	179569387	T	A	het	wt	het	pred_pathogenic	QUAL=7668;DP=324,162,257;MQM=60	TTN	missense,intron	TTN:NM_001267550.2:missense:MODERATE:exon105/363:c.29812A>T:p.Thr9938Ser,TTN:NM_001256850.1:missense:MODERATE:exon103/313:c.28861A>T:p.Thr9621Ser,TTN:NM_133378.4:missense:MODERATE:exon102/312:c.26080A>T:p.Thr8694Ser,TTN:NM_133437.4:intron:MODIFIER:exon47/191:c.13858+33422A>T:,TTN:NM_003319.4:intron:MODIFIER:exon46/190:c.13282+33422A>T:,TTN:NM_133432.3:intron:MODIFIER:exon47/191:c.13657+33422A>T:		rs72650006	0.0106	0.0199	22/18/0	0.0188	6.2960	T	T	B	T	19.00	188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000040096.6 [benign]; RCV000204308.2 [benign]; RCV000204308.2 [benign]; RCV000252332.1 [benign]; RCV000307512.1 [likely benign]; RCV000308804.1 [likely benign]; RCV000359919.1 [likely benign]; RCV000365787.1 [likely benign]; RCV000395851.1 [likely benign]; RCV000395854.1 [likely benign]; 			1	84					TTN (inh=AD pLI=0.00)
chr2	179583317	179583317	G	A	wt	wt	het		QUAL=3401;DP=239,233,307;MQM=60	TTN	synonymous,intron	TTN:NM_001267550.2:synonymous:LOW:exon85/363:c.24516C>T:p.Thr8172Thr,TTN:NM_001256850.1:synonymous:LOW:exon83/313:c.23565C>T:p.Thr7855Thr,TTN:NM_133378.4:synonymous:LOW:exon82/312:c.20784C>T:p.Thr6928Thr,TTN:NM_133437.4:intron:MODIFIER:exon47/191:c.13858+19492C>T:,TTN:NM_003319.4:intron:MODIFIER:exon46/190:c.13282+19492C>T:,TTN:NM_133432.3:intron:MODIFIER:exon47/191:c.13657+19492C>T:		rs72648978	0.0735	0.0897	569/393/30	0.0873							188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000040004.6 [benign]; RCV000241868.1 [benign]; RCV000265243.1 [likely benign]; RCV000268850.1 [likely benign]; RCV000305142.1 [likely benign]; RCV000308650.1 [likely benign]; RCV000357627.1 [likely benign]; RCV000365789.1 [likely benign]; 		COSM3757809, COSM3757810	28	319					TTN (inh=AD pLI=0.00)
chr2	179585266	179585266	C	T	hom	hom	hom		QUAL=14818;DP=260,81,125;MQM=60	TTN	synonymous,intron	TTN:NM_001267550.2:synonymous:LOW:exon80/363:c.23223G>A:p.Gln7741Gln,TTN:NM_001256850.1:synonymous:LOW:exon78/313:c.22272G>A:p.Gln7424Gln,TTN:NM_133378.4:synonymous:LOW:exon77/312:c.19491G>A:p.Gln6497Gln,TTN:NM_133437.4:intron:MODIFIER:exon47/191:c.13858+17543G>A:,TTN:NM_003319.4:intron:MODIFIER:exon46/190:c.13282+17543G>A:,TTN:NM_133432.3:intron:MODIFIER:exon47/191:c.13657+17543G>A:		rs2562831	0.9820	0.9950	59606/33233/4367	0.9314							188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000039984.9 [benign]; RCV000254037.1 [benign]; RCV000271518.1 [likely benign]; RCV000296181.1 [likely benign]; RCV000325238.1 [likely benign]; RCV000331319.1 [likely benign]; RCV000365884.1 [likely benign]; RCV000385735.1 [likely benign]; 			1666	1					TTN (inh=AD pLI=0.00)
chr2	179586604	179586604	C	G	wt	wt	het	pred_pathogenic	QUAL=7578;DP=490,392,579;MQM=60	TTN	missense,intron	TTN:NM_001267550.2:missense:MODERATE:exon78/363:c.22786G>C:p.Asp7596His,TTN:NM_001256850.1:missense:MODERATE:exon76/313:c.21835G>C:p.Asp7279His,TTN:NM_133378.4:missense:MODERATE:exon75/312:c.19054G>C:p.Asp6352His,TTN:NM_133437.4:intron:MODIFIER:exon47/191:c.13858+16205G>C:,TTN:NM_003319.4:intron:MODIFIER:exon46/190:c.13282+16205G>C:,TTN:NM_133432.3:intron:MODIFIER:exon47/191:c.13657+16205G>C:		rs72648970	0.0202	0.0298	71/45/0	0.0275	4.0580	T	T	D	T	19.84	188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000039975.8 [other]; RCV000244106.1 [benign]; RCV000287489.1 [likely benign]; RCV000313086.1 [likely benign]; RCV000347161.1 [likely benign]; RCV000349189.1 [likely benign]; RCV000381895.1 [likely benign]; RCV000393874.1 [likely benign]; 			7	124					TTN (inh=AD pLI=0.00)
chr2	179600563	179600563	G	A	hom	hom	hom		QUAL=21278;DP=287,124,234;MQM=60	TTN	synonymous,intron	TTN:NM_001267550.2:synonymous:LOW:exon50/363:c.14610C>T:p.Ser4870Ser,TTN:NM_001256850.1:synonymous:LOW:exon48/313:c.13659C>T:p.Ser4553Ser,TTN:NM_133378.4:synonymous:LOW:exon47/312:c.10878C>T:p.Ser3626Ser,TTN:NM_133437.4:intron:MODIFIER:exon47/191:c.13858+2246C>T:,TTN:NM_003319.4:intron:MODIFIER:exon46/190:c.13282+2246C>T:,TTN:NM_133432.3:intron:MODIFIER:exon47/191:c.13657+2246C>T:		rs2742348	0.9818	0.9949	59643/33284/4359	0.9314							188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000039860.9 [benign]; RCV000245943.1 [benign]; RCV000266820.1 [likely benign]; RCV000302107.1 [likely benign]; RCV000306880.1 [likely benign]; RCV000345343.1 [likely benign]; RCV000359096.1 [likely benign]; RCV000397599.1 [likely benign]; 			1667	1					TTN (inh=AD pLI=0.00)
chr2	179610967	179610967	C	T	het	wt	het	pred_pathogenic	QUAL=8276;DP=394,172,207;MQM=60	TTN	missense,intron	TTN:NM_133379.4:missense:MODERATE:exon46/46:c.16160G>A:p.Cys5387Tyr,TTN:NM_001267550.2:intron:MODIFIER:exon47/362:c.11312-4319G>A:,TTN:NM_001256850.1:intron:MODIFIER:exon45/312:c.10361-4319G>A:,TTN:NM_133437.4:intron:MODIFIER:exon45/191:c.10799-4319G>A:,TTN:NM_003319.4:intron:MODIFIER:exon44/190:c.10223-4319G>A:,TTN:NM_133378.4:intron:MODIFIER:exon45/311:c.10360+6884G>A:,TTN:NM_133432.3:intron:MODIFIER:exon45/191:c.10598-4319G>A:		rs72648913	0.0012	0.0029	1/1/0	0.0028	1.6850	D,D	T	B	T	14.66	188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000041064.5 [other]; RCV000172706.4 [likely benign]; 			0	21					TTN (inh=AD pLI=0.00)
chr2	179614952	179614952	A	G	hom	hom	hom		QUAL=49250;DP=587,395,510;MQM=60	TTN	synonymous,intron	TTN:NM_133379.4:synonymous:LOW:exon46/46:c.12175T>C:p.Leu4059Leu,TTN:NM_001267550.2:intron:MODIFIER:exon47/362:c.11311+2899T>C:,TTN:NM_001256850.1:intron:MODIFIER:exon45/312:c.10360+2899T>C:,TTN:NM_133437.4:intron:MODIFIER:exon45/191:c.10798+2899T>C:,TTN:NM_003319.4:intron:MODIFIER:exon44/190:c.10222+2899T>C:,TTN:NM_133378.4:intron:MODIFIER:exon45/311:c.10360+2899T>C:,TTN:NM_133432.3:intron:MODIFIER:exon45/191:c.10597+2899T>C:		rs10803917	0.9750	0.9926	59714/33307/4396	0.9670							188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000041012.3 [benign]; 			1657	7					TTN (inh=AD pLI=0.00)
chr2	179615887	179615887	T	C	hom	hom	hom	pred_pathogenic	QUAL=24534;DP=371,159,221;MQM=60	TTN	missense,intron	TTN:NM_133379.4:missense:MODERATE:exon46/46:c.11240A>G:p.Asp3747Gly,TTN:NM_001267550.2:intron:MODIFIER:exon47/362:c.11311+1964A>G:,TTN:NM_001256850.1:intron:MODIFIER:exon45/312:c.10360+1964A>G:,TTN:NM_133437.4:intron:MODIFIER:exon45/191:c.10798+1964A>G:,TTN:NM_003319.4:intron:MODIFIER:exon44/190:c.10222+1964A>G:,TTN:NM_133378.4:intron:MODIFIER:exon45/311:c.10360+1964A>G:,TTN:NM_133432.3:intron:MODIFIER:exon45/191:c.10597+1964A>G:		rs922984	0.7330	0.8271	42438/28413/1803	0.8284	1.9380	T	T	B	T	8.53	188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000041005.4 [benign]; 			1416	241					TTN (inh=AD pLI=0.00)
chr2	179615931	179615931	C	G	hom	hom	hom		QUAL=19566;DP=273,136,182;MQM=60	TTN	missense,intron	TTN:NM_133379.4:missense:MODERATE:exon46/46:c.11196G>C:p.Leu3732Phe,TTN:NM_001267550.2:intron:MODIFIER:exon47/362:c.11311+1920G>C:,TTN:NM_001256850.1:intron:MODIFIER:exon45/312:c.10360+1920G>C:,TTN:NM_133437.4:intron:MODIFIER:exon45/191:c.10798+1920G>C:,TTN:NM_003319.4:intron:MODIFIER:exon44/190:c.10222+1920G>C:,TTN:NM_133378.4:intron:MODIFIER:exon45/311:c.10360+1920G>C:,TTN:NM_133432.3:intron:MODIFIER:exon45/191:c.10597+1920G>C:		rs922985	0.9750	0.9926	59376/33139/4336	0.9586	-0.1470	T	T	B	T	4.29	188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000041004.4 [benign]; 			1656	8					TTN (inh=AD pLI=0.00)
chr2	179615994	179615994	T	C	hom	hom	hom		QUAL=16792;DP=223,119,164;MQM=60	TTN	synonymous,intron	TTN:NM_133379.4:synonymous:LOW:exon46/46:c.11133A>G:p.Thr3711Thr,TTN:NM_001267550.2:intron:MODIFIER:exon47/362:c.11311+1857A>G:,TTN:NM_001256850.1:intron:MODIFIER:exon45/312:c.10360+1857A>G:,TTN:NM_133437.4:intron:MODIFIER:exon45/191:c.10798+1857A>G:,TTN:NM_003319.4:intron:MODIFIER:exon44/190:c.10222+1857A>G:,TTN:NM_133378.4:intron:MODIFIER:exon45/311:c.10360+1857A>G:,TTN:NM_133432.3:intron:MODIFIER:exon45/191:c.10597+1857A>G:		rs922986	0.9750	0.9926	59578/33255/4387	0.9668							188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000041002.3 [benign]; 			1664	7					TTN (inh=AD pLI=0.00)
chr2	179616771	179616771	A	-	hom	hom	hom		QUAL=3062;DP=140,25,44;MQM=59	TTN	splice_region&intron,intron	TTN:NM_133379.4:splice_region&intron:LOW:exon45/45:c.10361-5delT:,TTN:NM_001267550.2:intron:MODIFIER:exon47/362:c.11311+1080delT:,TTN:NM_001256850.1:intron:MODIFIER:exon45/312:c.10360+1080delT:,TTN:NM_133437.4:intron:MODIFIER:exon45/191:c.10798+1080delT:,TTN:NM_003319.4:intron:MODIFIER:exon44/190:c.10222+1080delT:,TTN:NM_133378.4:intron:MODIFIER:exon45/311:c.10360+1080delT:,TTN:NM_133432.3:intron:MODIFIER:exon45/191:c.10597+1080delT:		rs397986815;rs577374633;rs58651353;rs770426988	0.5262	0.4728	1119/496/80	0.4346							188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000040993.2 [likely benign]; RCV000415616.1 [uncertain significance]; RCV000415691.1 [uncertain significance]; 			350	528	1	[1] old entry - no details available			TTN (inh=AD pLI=0.00)
chr2	179620951	179620951	C	T	hom	hom	hom	pred_pathogenic	QUAL=12423;DP=254,67,93;MQM=59	TTN	missense&splice_region,intron	TTN:NM_001267550.2:missense&splice_region:MODERATE:exon46/363:c.11252G>A:p.Gly3751Asp,TTN:NM_133437.4:missense&splice_region:MODERATE:exon44/192:c.10739G>A:p.Gly3580Asp,TTN:NM_001256850.1:intron:MODIFIER:exon44/312:c.10303+2760G>A:,TTN:NM_003319.4:intron:MODIFIER:exon43/190:c.10165+2760G>A:,TTN:NM_133378.4:intron:MODIFIER:exon44/311:c.10303+2760G>A:,TTN:NM_133432.3:intron:MODIFIER:exon44/191:c.10540+1318G>A:,TTN:NM_133379.4:intron:MODIFIER:exon44/45:c.10303+2760G>A:		rs7585334	0.8045	0.8508	44227/28583/3438	0.8449	3.7080	T	T	B	T	22.80	188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000041121.4 [benign]; 			1419	227					TTN (inh=AD pLI=0.00)
chr2	179621184	179621184	G	A	het	het	wt		QUAL=10405;DP=475,355,489;MQM=60	TTN	synonymous,intron	TTN:NM_001267550.2:synonymous:LOW:exon46/363:c.11019C>T:p.Cys3673Cys,TTN:NM_133437.4:synonymous:LOW:exon44/192:c.10506C>T:p.Cys3502Cys,TTN:NM_001256850.1:intron:MODIFIER:exon44/312:c.10303+2527C>T:,TTN:NM_003319.4:intron:MODIFIER:exon43/190:c.10165+2527C>T:,TTN:NM_133378.4:intron:MODIFIER:exon44/311:c.10303+2527C>T:,TTN:NM_133432.3:intron:MODIFIER:exon44/191:c.10540+1085C>T:,TTN:NM_133379.4:intron:MODIFIER:exon44/45:c.10303+2527C>T:		rs72955212	0.0052	0.0114	22/19/0	0.0112							188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000041119.3 [benign]; RCV000226302.1 [benign]; RCV000226302.1 [benign]; 			0	43					TTN (inh=AD pLI=0.00)
chr2	179621477	179621477	C	T	hom	hom	hom	pred_pathogenic	QUAL=13190;DP=238,83,115;MQM=59	TTN	missense,intron	TTN:NM_001267550.2:missense:MODERATE:exon46/363:c.10726G>A:p.Ala3576Thr,TTN:NM_133437.4:missense:MODERATE:exon44/192:c.10213G>A:p.Ala3405Thr,TTN:NM_001256850.1:intron:MODIFIER:exon44/312:c.10303+2234G>A:,TTN:NM_003319.4:intron:MODIFIER:exon43/190:c.10165+2234G>A:,TTN:NM_133378.4:intron:MODIFIER:exon44/311:c.10303+2234G>A:,TTN:NM_133432.3:intron:MODIFIER:exon44/191:c.10540+792G>A:,TTN:NM_133379.4:intron:MODIFIER:exon44/45:c.10303+2234G>A:		rs6433728	0.9990	0.9997	60261/33342/4863	0.9361	0.2260	T	T	B	T	22.80	188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000155422.1 [likely benign]; RCV000152471.4 [other]; 			1672	0					TTN (inh=AD pLI=0.00)
chr2	179621503	179621503	C	T	het	het	wt		QUAL=2979;DP=210,67,102;MQM=60	TTN	missense,intron	TTN:NM_001267550.2:missense:MODERATE:exon46/363:c.10700G>A:p.Ser3567Asn,TTN:NM_133437.4:missense:MODERATE:exon44/192:c.10187G>A:p.Ser3396Asn,TTN:NM_001256850.1:intron:MODIFIER:exon44/312:c.10303+2208G>A:,TTN:NM_003319.4:intron:MODIFIER:exon43/190:c.10165+2208G>A:,TTN:NM_133378.4:intron:MODIFIER:exon44/311:c.10303+2208G>A:,TTN:NM_133432.3:intron:MODIFIER:exon44/191:c.10540+766G>A:,TTN:NM_133379.4:intron:MODIFIER:exon44/45:c.10303+2208G>A:		rs72955213	0.0064	0.0141	24/20/0	0.0138	1.3030	T	T	B	T	18.73	188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000041115.4 [benign]; RCV000227153.1 [benign]; RCV000227153.1 [benign]; 			0	57					TTN (inh=AD pLI=0.00)
chr2	179623758	179623758	C	T	hom	hom	hom		QUAL=16196;DP=239,115,136;MQM=60	TTN	missense	TTN:NM_001267550.2:missense:MODERATE:exon44/363:c.10256G>A:p.Ser3419Asn,TTN:NM_001256850.1:missense:MODERATE:exon44/313:c.10256G>A:p.Ser3419Asn,TTN:NM_133437.4:missense:MODERATE:exon43/192:c.10118G>A:p.Ser3373Asn,TTN:NM_003319.4:missense:MODERATE:exon43/191:c.10118G>A:p.Ser3373Asn,TTN:NM_133378.4:missense:MODERATE:exon44/312:c.10256G>A:p.Ser3419Asn,TTN:NM_133432.3:missense:MODERATE:exon43/192:c.10118G>A:p.Ser3373Asn,TTN:NM_133379.4:missense:MODERATE:exon44/46:c.10256G>A:p.Ser3419Asn		rs2291310	0.8089	0.8512	44905/28700/3721	0.8522	0.3980	T,T,T,T,T,T,T	T	B,B,B,B	T,T,T,T,T	15.07	188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000039852.10 [benign]; RCV000251067.1 [benign]; RCV000275658.1 [likely benign]; RCV000301488.1 [likely benign]; RCV000333056.1 [likely benign]; RCV000354685.1 [likely benign]; RCV000367878.1 [likely benign]; RCV000400937.1 [likely benign]; 			1426	233					TTN (inh=AD pLI=0.00)
chr2	179629363	179629363	T	C	hom	hom	hom		QUAL=44979;DP=501,401,509;MQM=60	TTN	synonymous	TTN:NM_001267550.2:synonymous:LOW:exon42/363:c.9879A>G:p.Glu3293Glu,TTN:NM_001256850.1:synonymous:LOW:exon42/313:c.9879A>G:p.Glu3293Glu,TTN:NM_133437.4:synonymous:LOW:exon41/192:c.9741A>G:p.Glu3247Glu,TTN:NM_003319.4:synonymous:LOW:exon41/191:c.9741A>G:p.Glu3247Glu,TTN:NM_133378.4:synonymous:LOW:exon42/312:c.9879A>G:p.Glu3293Glu,TTN:NM_133432.3:synonymous:LOW:exon41/192:c.9741A>G:p.Glu3247Glu,TTN:NM_133379.4:synonymous:LOW:exon42/46:c.9879A>G:p.Glu3293Glu		rs4894043	0.9736	0.9921	59764/33351/4343	0.9588							188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000040976.9 [benign]; RCV000248023.1 [benign]; RCV000259982.1 [likely benign]; RCV000265831.1 [likely benign]; RCV000300096.1 [likely benign]; RCV000305792.1 [likely benign]; RCV000354969.1 [likely benign]; RCV000360490.1 [likely benign]; 			1666	7					TTN (inh=AD pLI=0.00)
chr2	179629461	179629461	C	T	hom	hom	hom	pred_pathogenic	QUAL=45091;DP=435,430,544;MQM=59	TTN	missense	TTN:NM_001267550.2:missense:MODERATE:exon42/363:c.9781G>A:p.Val3261Met,TTN:NM_001256850.1:missense:MODERATE:exon42/313:c.9781G>A:p.Val3261Met,TTN:NM_133437.4:missense:MODERATE:exon41/192:c.9643G>A:p.Val3215Met,TTN:NM_003319.4:missense:MODERATE:exon41/191:c.9643G>A:p.Val3215Met,TTN:NM_133378.4:missense:MODERATE:exon42/312:c.9781G>A:p.Val3261Met,TTN:NM_133432.3:missense:MODERATE:exon41/192:c.9643G>A:p.Val3215Met,TTN:NM_133379.4:missense:MODERATE:exon42/46:c.9781G>A:p.Val3261Met		rs2291311	0.8049	0.8500	44778/28694/3593	0.8499	1.0930	T,T,T,T,T,T	T	P,P,P,P	T,T,T,T,T	21.60	188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000040961.10 [benign]; RCV000251159.1 [benign]; RCV000272076.1 [likely benign]; RCV000296790.1 [likely benign]; RCV000320840.1 [likely benign]; RCV000327097.1 [likely benign]; RCV000381817.1 [likely benign]; RCV000384754.1 [likely benign]; 			1431	234					TTN (inh=AD pLI=0.00)
chr2	179634421	179634421	T	G	het	wt	wt	pred_pathogenic	QUAL=425;DP=105,104,137;MQM=58	TTN	missense	TTN:NM_001267550.2:missense:MODERATE:exon37/363:c.8887A>C:p.Thr2963Pro,TTN:NM_001256850.1:missense:MODERATE:exon37/313:c.8887A>C:p.Thr2963Pro,TTN:NM_133437.4:missense:MODERATE:exon36/192:c.8749A>C:p.Thr2917Pro,TTN:NM_003319.4:missense:MODERATE:exon36/191:c.8749A>C:p.Thr2917Pro,TTN:NM_133378.4:missense:MODERATE:exon37/312:c.8887A>C:p.Thr2963Pro,TTN:NM_133432.3:missense:MODERATE:exon36/192:c.8749A>C:p.Thr2917Pro,TTN:NM_133379.4:missense:MODERATE:exon37/46:c.8887A>C:p.Thr2963Pro		rs200875815	0.2155	0.3891	5/5/0	0.0071	5.9120	T,T,T,T,T,D	D	D,D,D,D,D	T,T,T,T,T	18.25	188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000172804.2 [benign]; 		COSM146063, COSM146062, COSM146060, COSM146061	0	141					TTN (inh=AD pLI=0.00)
chr2	179638238	179638238	G	A	wt	wt	het		QUAL=3568;DP=387,272,291;MQM=60	TTN	synonymous	TTN:NM_001267550.2:synonymous:LOW:exon32/363:c.7545C>T:p.Tyr2515Tyr,TTN:NM_001256850.1:synonymous:LOW:exon32/313:c.7545C>T:p.Tyr2515Tyr,TTN:NM_133437.4:synonymous:LOW:exon31/192:c.7407C>T:p.Tyr2469Tyr,TTN:NM_003319.4:synonymous:LOW:exon31/191:c.7407C>T:p.Tyr2469Tyr,TTN:NM_133378.4:synonymous:LOW:exon32/312:c.7545C>T:p.Tyr2515Tyr,TTN:NM_133432.3:synonymous:LOW:exon31/192:c.7407C>T:p.Tyr2469Tyr,TTN:NM_133379.4:synonymous:LOW:exon32/46:c.7545C>T:p.Tyr2515Tyr		rs2291306	0.0755	0.0915	594/420/29	0.0911							188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000040690.8 [benign]; RCV000251404.1 [benign]; RCV000277834.1 [likely benign]; RCV000308132.1 [likely benign]; RCV000311833.1 [likely benign]; RCV000368827.1 [likely benign]; RCV000370151.1 [likely benign]; RCV000403538.1 [likely benign]; 		COSM3757815, COSM3757816, COSM3757814, COSM3757817, COSM3757818	29	339					TTN (inh=AD pLI=0.00)
chr2	179642425	179642425	G	A	het	hom	het		QUAL=5128;DP=174,61,65;MQM=60	TTN,LOC101927055	splice_region&intron,non_coding_transcript_exon	TTN:NM_001267550.2:splice_region&intron:LOW:exon25/362:c.4480+6C>T:,TTN:NM_001256850.1:splice_region&intron:LOW:exon25/312:c.4480+6C>T:,TTN:NM_133437.4:splice_region&intron:LOW:exon24/191:c.4342+6C>T:,TTN:NM_003319.4:splice_region&intron:LOW:exon24/190:c.4342+6C>T:,TTN:NM_133378.4:splice_region&intron:LOW:exon25/311:c.4480+6C>T:,TTN:NM_133432.3:splice_region&intron:LOW:exon24/191:c.4342+6C>T:,TTN:NM_133379.4:splice_region&intron:LOW:exon25/45:c.4480+6C>T:,LOC101927055:NR_120594.1:non_coding_transcript_exon:MODIFIER:exon1/2:n.773G>A:		rs719201	0.9115	0.9588	55886/32629/3762	0.9463							188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000040333.9 [benign]; RCV000266351.1 [likely benign]; RCV000272158.1 [likely benign]; RCV000303750.1 [likely benign]; RCV000323768.1 [likely benign]; RCV000358588.1 [likely benign]; RCV000382980.1 [likely benign]; 			1605	67					TTN (inh=AD pLI=0.00), LOC101927055 (inh=n/a pLI=n/a)
chr2	179644035	179644035	G	A	het	hom	het	pred_pathogenic	QUAL=13416;DP=289,183,194;MQM=60	TTN,LOC101927055	missense,intron	TTN:NM_001267550.2:missense:MODERATE:exon23/363:c.3884C>T:p.Ser1295Leu,TTN:NM_001256850.1:missense:MODERATE:exon23/313:c.3884C>T:p.Ser1295Leu,TTN:NM_133437.4:missense:MODERATE:exon22/192:c.3746C>T:p.Ser1249Leu,TTN:NM_003319.4:missense:MODERATE:exon22/191:c.3746C>T:p.Ser1249Leu,TTN:NM_133378.4:missense:MODERATE:exon23/312:c.3884C>T:p.Ser1295Leu,TTN:NM_133432.3:missense:MODERATE:exon22/192:c.3746C>T:p.Ser1249Leu,TTN:NM_133379.4:missense:MODERATE:exon23/46:c.3884C>T:p.Ser1295Leu,LOC101927055:NR_120594.1:intron:MODIFIER:exon1/1:n.1831-530G>A:		rs1552280	0.9201	0.9606	55941/32580/3872	0.9564	6.2480	T,T,T,T,T,T	T	B,B,B,B	T,T,T,T,T	19.99	188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000040271.10 [benign]; RCV000241712.1 [benign]; RCV000264528.1 [likely benign]; RCV000268224.1 [likely benign]; RCV000299899.1 [likely benign]; RCV000303354.1 [likely benign]; RCV000357032.1 [likely benign]; RCV000360628.1 [likely benign]; 			1601	65					TTN (inh=AD pLI=0.00), LOC101927055 (inh=n/a pLI=n/a)
chr2	179644855	179644855	T	C	het	hom	het	pred_pathogenic	QUAL=6197;DP=217,65,98;MQM=60	TTN	missense	TTN:NM_001267550.2:missense:MODERATE:exon22/363:c.3601A>G:p.Lys1201Glu,TTN:NM_001256850.1:missense:MODERATE:exon22/313:c.3601A>G:p.Lys1201Glu,TTN:NM_133437.4:missense:MODERATE:exon21/192:c.3463A>G:p.Lys1155Glu,TTN:NM_003319.4:missense:MODERATE:exon21/191:c.3463A>G:p.Lys1155Glu,TTN:NM_133378.4:missense:MODERATE:exon22/312:c.3601A>G:p.Lys1201Glu,TTN:NM_133432.3:missense:MODERATE:exon21/192:c.3463A>G:p.Lys1155Glu,TTN:NM_133379.4:missense:MODERATE:exon22/46:c.3601A>G:p.Lys1201Glu		rs10497520	0.5002	0.6944	32542/24959/1082	0.6951	4.1160	T,T,T,T,T,T	T	B,B,B,B,P	T,T,T,T,T	19.62	188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000040243.9 [benign]; RCV000246507.1 [benign]; RCV000270311.1 [likely benign]; RCV000305380.1 [likely benign]; RCV000309003.1 [likely benign]; RCV000340634.1 [likely benign]; RCV000362447.1 [likely benign]; RCV000391742.1 [likely benign]; 		COSM4001424, COSM4001425, COSM4001423, COSM4001421, COSM4001422	1171	422					TTN (inh=AD pLI=0.00)
chr2	179650701	179650701	C	T	het	hom	wt		QUAL=22536;DP=623,488,607;MQM=60	TTN	synonymous	TTN:NM_001267550.2:synonymous:LOW:exon14/363:c.2244G>A:p.Glu748Glu,TTN:NM_001256850.1:synonymous:LOW:exon14/313:c.2244G>A:p.Glu748Glu,TTN:NM_133437.4:synonymous:LOW:exon13/192:c.2106G>A:p.Glu702Glu,TTN:NM_003319.4:synonymous:LOW:exon13/191:c.2106G>A:p.Glu702Glu,TTN:NM_133378.4:synonymous:LOW:exon14/312:c.2244G>A:p.Glu748Glu,TTN:NM_133432.3:synonymous:LOW:exon13/192:c.2106G>A:p.Glu702Glu,TTN:NM_133379.4:synonymous:LOW:exon14/46:c.2244G>A:p.Glu748Glu		rs6715406	0.2047	0.3192	7161/5389/191	0.3182							188840 [TTN (confirmed) Cardiomyopathy,familial hypertrophic,9,613765|Cardiomyopathy,dilated,1G,604145|Tibial muscular dystrophy,tardive,600334|Muscular dystrophy,limb-girdle,type 2J,608807|Myopathy,proximal,with early respiratory muscle involvement,603689|Myopathy,early-onset,with fatal cardiomyopathy,611705];	RCV000040044.5 [benign]; RCV000243970.1 [benign]; RCV000283289.1 [likely benign]; RCV000286612.1 [likely benign]; RCV000322867.1 [likely benign]; RCV000338218.1 [likely benign]; RCV000377759.1 [likely benign]; RCV000400193.1 [likely benign]; 		COSM4001429, COSM4001431, COSM4001430, COSM4001426, COSM4001428, COSM4001427	258	733					TTN (inh=AD pLI=0.00)
chr2	190430177	190430177	A	G	hom	hom	hom		QUAL=30890;DP=295,276,397;MQM=59	SLC40A1	synonymous	SLC40A1:NM_014585.5:synonymous:LOW:exon6/8:c.663T>C:p.Val221Val		rs2304704	0.5501	0.6142	24088/13127/244	0.6130							604653 [SLC40A1 (confirmed) Hemochromatosis,type 4,606069];	RCV000247963.1 [benign]; RCV000281104.1 [benign]; 			610	728					SLC40A1 (inh=n/a pLI=0.98)
chr2	190445495	190445495	-	CCG	hom	het	hom	low_DP	QUAL=1535;DP=15,30,40;MQM=60	SLC40A1	5'UTR	SLC40A1:NM_014585.5:5'UTR:MODIFIER:exon1/8:c.-312_-310dupCGG:		rs16836041;rs3833570	0.5335	0.0000	0/0/0	0.3782							604653 [SLC40A1 (confirmed) Hemochromatosis,type 4,606069];	RCV000259537.1 [benign]; RCV000319381.1 [benign]; RCV000374128.1 [uncertain significance]; 			51	60					SLC40A1 (inh=n/a pLI=0.98)
chr2	191069434	191069434	G	A	het	wt	het		QUAL=3249;DP=229,51,69;MQM=60	HIBCH	3'UTR	HIBCH:NM_014362.3:3'UTR:MODIFIER:exon14/14:c.*409C>T:,HIBCH:NM_198047.2:3'UTR:MODIFIER:exon13/13:c.*519C>T:		rs1058230	0.3632	0.0000	0/0/0	0.0515							610690 [HIBCH (provisional) 3-hydroxyisobutryl-CoA hydrolase deficiency,250620];				19	85					HIBCH (inh=AR pLI=0.00)
chr2	191069476	191069476	C	T	het	wt	het		QUAL=5403;DP=328,96,126;MQM=60	HIBCH	3'UTR	HIBCH:NM_014362.3:3'UTR:MODIFIER:exon14/14:c.*367G>A:,HIBCH:NM_198047.2:3'UTR:MODIFIER:exon13/13:c.*477G>A:		rs1058227	0.3636	0.0000	0/0/0	0.0515							610690 [HIBCH (provisional) 3-hydroxyisobutryl-CoA hydrolase deficiency,250620];				19	86					HIBCH (inh=AR pLI=0.00)
chr2	191069689	191069689	T	A	het	wt	het		QUAL=8108;DP=293,221,329;MQM=59	HIBCH	3'UTR	HIBCH:NM_014362.3:3'UTR:MODIFIER:exon14/14:c.*154A>T:,HIBCH:NM_198047.2:3'UTR:MODIFIER:exon13/13:c.*264A>T:	MER58B	rs11542	0.3480	0.0000	0/0/0	0.0508							610690 [HIBCH (provisional) 3-hydroxyisobutryl-CoA hydrolase deficiency,250620];				20	74					HIBCH (inh=AR pLI=0.00)
chr2	191110893	191110893	C	T	het	wt	het	pred_pathogenic	QUAL=3824;DP=217,47,85;MQM=60	HIBCH	missense	HIBCH:NM_014362.3:missense:MODERATE:exon10/14:c.796G>A:p.Asp266Asn,HIBCH:NM_198047.2:missense:MODERATE:exon10/13:c.796G>A:p.Asp266Asn		rs144053672	0.0008	0.0027	1/1/0	0.0027	2.5220	T,T,T,T,T	T	B,B	T,T	23.30	610690 [HIBCH (provisional) 3-hydroxyisobutryl-CoA hydrolase deficiency,250620];	RCV000224515.1 [uncertain significance]; 			0	11					HIBCH (inh=AR pLI=0.00)
chr2	191161622	191161622	T	C	het	hom	het	pred_pathogenic	QUAL=14883;DP=313,229,278;MQM=60	HIBCH	missense,sequence_feature	HIBCH:NM_014362.3:missense:MODERATE:exon3/14:c.136A>G:p.Thr46Ala,HIBCH:NM_198047.2:missense:MODERATE:exon3/13:c.136A>G:p.Thr46Ala,HIBCH:NM_014362.3:sequence_feature:LOW:exon3/14:c.136A>G:,HIBCH:NM_198047.2:sequence_feature:LOW:exon3/13:c.136A>G:		rs1058180	0.6843	0.7393	33450/18999/2177	0.7279	2.9820	T,T,T	T	B,B	T,T,T	9.02	610690 [HIBCH (provisional) 3-hydroxyisobutryl-CoA hydrolase deficiency,250620];				800	633					HIBCH (inh=AR pLI=0.00)
chr2	191184475	191184475	A	G	het	hom	het	anno_high_impact;pred_pathogenic	QUAL=5024;DP=134,86,143;MQM=60	HIBCH	start_lost,sequence_feature	HIBCH:NM_014362.3:start_lost:HIGH:exon1/14:c.2T>C:p.Met1?,HIBCH:NM_198047.2:start_lost:HIGH:exon1/13:c.2T>C:p.Met1?,HIBCH:NM_014362.3:sequence_feature:MODERATE:exon1/14:c.2T>C:,HIBCH:NM_198047.2:sequence_feature:MODERATE:exon1/13:c.2T>C:		rs291466	0.4317	0.5279	16666/11152/971	0.5117	1.2900	D,D	T	B,B	T,T	15.22	610690 [HIBCH (provisional) 3-hydroxyisobutryl-CoA hydrolase deficiency,250620];		CM1311889 [CLASS=FP MUT=ALT PHEN="Increased methylmalonic acid concentrations" GENE=HIBCH]; 		542	759	1	[1] auto-classification 16.06.2016  			HIBCH (inh=AR pLI=0.00)
chr2	191184520	191184520	G	A	wt	het	het		QUAL=15786;DP=250,119,190;MQM=60	HIBCH	5'UTR_premature_start_codon_gain,5'UTR	HIBCH:NM_014362.3:5'UTR_premature_start_codon_gain:LOW:exon1/14:c.-44C>T:,HIBCH:NM_198047.2:5'UTR_premature_start_codon_gain:LOW:exon1/13:c.-44C>T:,HIBCH:NM_014362.3:5'UTR:MODIFIER:exon1/14:c.-44C>T:,HIBCH:NM_198047.2:5'UTR:MODIFIER:exon1/13:c.-44C>T:		rs191031819	0.0004	0.0021	1/1/0	0.0018							610690 [HIBCH (provisional) 3-hydroxyisobutryl-CoA hydrolase deficiency,250620];				0	4					HIBCH (inh=AR pLI=0.00)
chr2	191184524	191184524	C	T	hom	hom	hom		QUAL=15786;DP=250,119,190;MQM=60	HIBCH	5'UTR	HIBCH:NM_014362.3:5'UTR:MODIFIER:exon1/14:c.-48G>A:,HIBCH:NM_198047.2:5'UTR:MODIFIER:exon1/13:c.-48G>A:		rs3749022	0.5487	0.6843	19853/13606/545	0.6317							610690 [HIBCH (provisional) 3-hydroxyisobutryl-CoA hydrolase deficiency,250620];			COSN166358	480	226					HIBCH (inh=AR pLI=0.00)
chr2	191841759	191841759	G	A	het	wt	het		QUAL=4966;DP=231,116,172;MQM=60	STAT1	splice_region&intron	STAT1:NM_007315.3:splice_region&intron:LOW:exon21/24:c.1874-8C>T:,STAT1:NM_139266.2:splice_region&intron:LOW:exon21/22:c.1874-8C>T:		rs2066804	0.2266	0.2260	3440/1838/154	0.2283							600555 [STAT1 (provisional) Immunodeficiency 31A,mycobacteriosis,autosomal dominant,614892|Immunodeficiency 31B,mycobacterial and viral infections,autosomal recessive,613796|Immunodeficiency 31C,autosomal dominant,614162];	RCV000335899.1 [benign]; 			86	622					STAT1 (inh=AR+AD pLI=1.00)
chr2	198362018	198362018	T	C	hom	hom	hom		QUAL=32193;DP=445,241,307;MQM=59	HSPD1	sequence_feature,synonymous	HSPD1:NM_199440.1:sequence_feature:MODERATE:exon3/12:c.273A>G:,HSPD1:NM_002156.4:synonymous:LOW:exon3/12:c.273A>G:p.Lys91Lys,HSPD1:NM_199440.1:synonymous:LOW:exon3/12:c.273A>G:p.Lys91Lys		rs8539	0.6546	0.6490	26123/15686/2679	0.6417							118190 [HSPD1 (confirmed) Spastic paraplegia 13,autosomal dominant,605280|Leukodystrophy,hypomyelinating,4,612233];	RCV000117240.3 [other]; RCV000291547.1 [benign]; 		COSM3757861, COSM3757863, COSM3757862	1063	841					HSPD1 (inh=AR+AD pLI=0.99)
chr2	198363504	198363504	A	G	het	het	wt		QUAL=2917;DP=207,60,86;MQM=56	HSPD1	synonymous	HSPD1:NM_002156.4:synonymous:LOW:exon2/12:c.69T>C:p.Thr23Thr,HSPD1:NM_199440.1:synonymous:LOW:exon2/12:c.69T>C:p.Thr23Thr		rs1050347	0.1581	0.1643	506/311/29	0.1604							118190 [HSPD1 (confirmed) Spastic paraplegia 13,autosomal dominant,605280|Leukodystrophy,hypomyelinating,4,612233];	RCV000117242.3 [other]; RCV000387107.1 [benign]; 			77	593					HSPD1 (inh=AR+AD pLI=0.99)
chr2	198364518	198364518	G	A	het	het	wt		QUAL=1295;DP=23,52,63;MQM=60	HSPD1	5'UTR_premature_start_codon_gain,5'UTR,intron	HSPD1:NM_002156.4:5'UTR_premature_start_codon_gain:LOW:exon1/12:c.-15C>T:,HSPD1:NM_002156.4:5'UTR:MODIFIER:exon1/12:c.-15C>T:,HSPD1:NM_199440.1:intron:MODIFIER:exon1/11:c.-3+366C>T:		rs13165	0.2332	0.0000	0/0/0	0.2059							118190 [HSPD1 (confirmed) Spastic paraplegia 13,autosomal dominant,605280|Leukodystrophy,hypomyelinating,4,612233];	RCV000125394.1 [benign]; RCV000349661.1 [benign]; 			11	64					HSPD1 (inh=AR+AD pLI=0.99)
chr2	200134420	200134420	-	AA	hom	hom	hom	low_DP	QUAL=2079;DP=99,9,6;MQM=58	SATB2	3'UTR	SATB2:NM_001172509.1:3'UTR:MODIFIER:exon11/11:c.*2512_*2513dupTT:,SATB2:NM_001172517.1:3'UTR:MODIFIER:exon12/12:c.*2512_*2513dupTT:,SATB2:NM_015265.3:3'UTR:MODIFIER:exon12/12:c.*2512_*2513dupTT:		rs386392269;rs58333872	0.0000	0.0000	0/0/0	0.3208							608148 [SATB2 (confirmed) Glass syndrome,612313];				85	97					SATB2 (inh=AD pLI=1.00)
chr2	200135233	200135233	-	A	hom	wt	hom		QUAL=1948;DP=314,126,169;MQM=59	SATB2	3'UTR	SATB2:NM_001172509.1:3'UTR:MODIFIER:exon11/11:c.*1700dupT:,SATB2:NM_001172517.1:3'UTR:MODIFIER:exon12/12:c.*1700dupT:,SATB2:NM_015265.3:3'UTR:MODIFIER:exon12/12:c.*1700dupT:		rs397987298;rs67882050	0.5377	0.0000	0/0/0	0.1536							608148 [SATB2 (confirmed) Glass syndrome,612313];				6	157					SATB2 (inh=AD pLI=1.00)
chr2	200136284	200136284	A	-	het	het	wt		QUAL=1798;DP=99,75,66;MQM=59	SATB2	3'UTR	SATB2:NM_001172509.1:3'UTR:MODIFIER:exon11/11:c.*650delT:,SATB2:NM_001172517.1:3'UTR:MODIFIER:exon12/12:c.*650delT:,SATB2:NM_015265.3:3'UTR:MODIFIER:exon12/12:c.*650delT:		rs397987299	0.4403	0.0000	0/0/0	0.3245							608148 [SATB2 (confirmed) Glass syndrome,612313];				53	120					SATB2 (inh=AD pLI=1.00)
chr2	200136583	200136583	T	A	hom	hom	hom		QUAL=16760;DP=204,121,199;MQM=59	SATB2	3'UTR	SATB2:NM_001172509.1:3'UTR:MODIFIER:exon11/11:c.*351A>T:,SATB2:NM_001172517.1:3'UTR:MODIFIER:exon12/12:c.*351A>T:,SATB2:NM_015265.3:3'UTR:MODIFIER:exon12/12:c.*351A>T:		rs6435006	0.9325	0.0000	0/0/0	0.1460							608148 [SATB2 (confirmed) Glass syndrome,612313];				229	1					SATB2 (inh=AD pLI=1.00)
chr2	200173684	200173684	T	G	hom	hom	hom		QUAL=20796;DP=127,238,302;MQM=60	SATB2	splice_region&intron	SATB2:NM_001172509.1:splice_region&intron:LOW:exon9/10:c.1543-4A>C:,SATB2:NM_001172517.1:splice_region&intron:LOW:exon10/11:c.1543-4A>C:,SATB2:NM_015265.3:splice_region&intron:LOW:exon10/11:c.1543-4A>C:		rs10153730	0.9309	0.9820	58446/33219/3290	0.9524							608148 [SATB2 (confirmed) Glass syndrome,612313];				1556	7					SATB2 (inh=AD pLI=1.00)
chr2	202565570	202565570	C	T	het	het	wt		QUAL=4513;DP=243,138,171;MQM=60	ALS2	3'UTR	ALS2:NM_020919.3:3'UTR:MODIFIER:exon34/34:c.*1004G>A:		rs11300	0.1024	0.0000	0/0/0	0.0172							606352 [ALS2 (confirmed) Amyotrophic lateral sclerosis 2,juvenile,205100|Primary lateral sclerosis,juvenile,606353|Spastic paralysis,infantile onset ascending,607225];	RCV000305695.1 [likely benign]; RCV000360466.1 [likely benign]; 			2	40					ALS2 (inh=AR pLI=0.00)
chr2	202565681	202565681	G	A	het	het	wt		QUAL=4559;DP=280,102,169;MQM=60	ALS2	3'UTR	ALS2:NM_020919.3:3'UTR:MODIFIER:exon34/34:c.*893C>T:		rs3219174	0.0897	0.0000	0/0/0	0.0800							606352 [ALS2 (confirmed) Amyotrophic lateral sclerosis 2,juvenile,205100|Primary lateral sclerosis,juvenile,606353|Spastic paralysis,infantile onset ascending,607225];	RCV000326977.1 [likely benign]; RCV000381762.1 [likely benign]; 			1	31					ALS2 (inh=AR pLI=0.00)
chr2	202575821	202575821	G	A	hom	hom	het		QUAL=16533;DP=255,149,194;MQM=60	ALS2	synonymous	ALS2:NM_020919.3:synonymous:LOW:exon26/34:c.4015C>T:p.Leu1339Leu		rs3219168	0.9054	0.9232	51524/28358/3331	0.8971							606352 [ALS2 (confirmed) Amyotrophic lateral sclerosis 2,juvenile,205100|Primary lateral sclerosis,juvenile,606353|Spastic paralysis,infantile onset ascending,607225];	RCV000250217.1 [benign]; RCV000283291.1 [benign]; RCV000347093.1 [benign]; 			1814	281					ALS2 (inh=AR pLI=0.00)
chr2	202593280	202593280	G	A	het	het	wt		QUAL=7402;DP=337,242,313;MQM=60	ALS2	synonymous	ALS2:NM_020919.3:synonymous:LOW:exon15/34:c.2796C>T:p.Ser932Ser		rs3219161	0.1150	0.0978	745/261/26	0.0973							606352 [ALS2 (confirmed) Amyotrophic lateral sclerosis 2,juvenile,205100|Primary lateral sclerosis,juvenile,606353|Spastic paralysis,infantile onset ascending,607225];	RCV000254279.1 [benign]; RCV000267099.1 [likely benign]; RCV000322182.1 [likely benign]; 		COSM3757885	28	347					ALS2 (inh=AR pLI=0.00)
chr2	202598113	202598113	C	T	het	het	het		QUAL=5337;DP=190,90,128;MQM=60	ALS2	synonymous	ALS2:NM_020919.3:synonymous:LOW:exon13/34:c.2466G>A:p.Val822Val		rs2276615	0.3724	0.5272	18156/12226/133	0.5216							606352 [ALS2 (confirmed) Amyotrophic lateral sclerosis 2,juvenile,205100|Primary lateral sclerosis,juvenile,606353|Spastic paralysis,infantile onset ascending,607225];	RCV000249292.1 [benign]; RCV000288406.1 [benign]; RCV000352784.1 [benign]; 		COSM149044	745	974					ALS2 (inh=AR pLI=0.00)
chr2	202625615	202625615	C	T	hom	hom	het		QUAL=24039;DP=492,165,252;MQM=59	ALS2	missense	ALS2:NM_020919.3:missense:MODERATE:exon4/34:c.1102G>A:p.Val368Met,ALS2:NM_001135745.1:missense:MODERATE:exon4/4:c.1102G>A:p.Val368Met		rs3219156	0.8966	0.9106	50185/27117/3007	0.8768	-2.3570	T,T	T	B,B,B,B	T,T	0.03	606352 [ALS2 (confirmed) Amyotrophic lateral sclerosis 2,juvenile,205100|Primary lateral sclerosis,juvenile,606353|Spastic paralysis,infantile onset ascending,607225];	RCV000243956.1 [benign]; RCV000269440.1 [benign]; RCV000326864.1 [benign]; 			1696	390					ALS2 (inh=AR pLI=0.00)
chr2	202633668	202633668	C	T	wt	wt	het		QUAL=1729;DP=221,89,140;MQM=60	ALS2	splice_region,5'UTR	ALS2:NM_020919.3:splice_region:LOW:exon2/34:c.-60G>A:,ALS2:NM_001135745.1:splice_region:LOW:exon2/4:c.-60G>A:,ALS2:NM_020919.3:5'UTR:MODIFIER:exon2/34:c.-60G>A:,ALS2:NM_001135745.1:5'UTR:MODIFIER:exon2/4:c.-60G>A:			0.0000	0.0000	0/0/0	0.0000							606352 [ALS2 (confirmed) Amyotrophic lateral sclerosis 2,juvenile,205100|Primary lateral sclerosis,juvenile,606353|Spastic paralysis,infantile onset ascending,607225];				0	1					ALS2 (inh=AR pLI=0.00)
chr2	204821494	204821494	C	T	wt	het	wt		QUAL=1079;DP=219,93,130;MQM=60	ICOS	splice_region&intron	ICOS:NM_012092.3:splice_region&intron:LOW:exon3/4:c.501+6C>T:		rs4264550	0.1615	0.1550	1595/672/40	0.1512							604558 [ICOS (provisional) Immunodeficiency,common variable,1,607594];	RCV000380844.1 [likely benign]; 			49	464					ICOS (inh=AR pLI=0.05)
chr2	204824324	204824324	A	C	wt	het	wt		QUAL=3115;DP=414,218,300;MQM=60	ICOS	3'UTR	ICOS:NM_012092.3:3'UTR:MODIFIER:exon5/5:c.*2A>C:		rs10183087	0.3077	0.2617	4446/1774/867	0.2584							604558 [ICOS (provisional) Immunodeficiency,common variable,1,607594];	RCV000311000.1 [likely benign]; 			122	630					ICOS (inh=AR pLI=0.05)
chr2	204825286	204825286	T	C	wt	het	wt		QUAL=2256;DP=230,145,207;MQM=60	ICOS	3'UTR	ICOS:NM_012092.3:3'UTR:MODIFIER:exon5/5:c.*964T>C:		rs4404254	0.3089	0.0000	0/0/0	0.0445							604558 [ICOS (provisional) Immunodeficiency,common variable,1,607594];	RCV000264417.1 [likely benign]; 			16	89					ICOS (inh=AR pLI=0.05)
chr2	204825729	204825729	G	A	wt	het	wt		QUAL=1633;DP=249,146,234;MQM=60	ICOS	3'UTR	ICOS:NM_012092.3:3'UTR:MODIFIER:exon5/5:c.*1407G>A:		rs1559931	0.3061	0.0000	0/0/0	0.0444							604558 [ICOS (provisional) Immunodeficiency,common variable,1,607594];	RCV000298214.1 [likely benign]; 			16	89					ICOS (inh=AR pLI=0.05)
chr2	204826095	204826095	G	C	wt	het	wt		QUAL=3479;DP=339,280,339;MQM=60	ICOS	3'UTR	ICOS:NM_012092.3:3'UTR:MODIFIER:exon5/5:c.*1773G>C:		rs4675379	0.1871	0.0000	0/0/0	0.1656							604558 [ICOS (provisional) Immunodeficiency,common variable,1,607594];	RCV000336703.1 [likely benign]; 			8	56					ICOS (inh=AR pLI=0.05)
chr2	206988573	206988573	C	A	wt	het	wt		QUAL=657;DP=252,92,171;MQM=60	NDUFS1	3'UTR	NDUFS1:NM_001199984.1:3'UTR:MODIFIER:exon19/19:c.*336G>T:,NDUFS1:NM_001199981.1:3'UTR:MODIFIER:exon18/18:c.*336G>T:,NDUFS1:NM_001199982.1:3'UTR:MODIFIER:exon16/16:c.*336G>T:,NDUFS1:NM_001199983.1:3'UTR:MODIFIER:exon18/18:c.*336G>T:,NDUFS1:NM_005006.6:3'UTR:MODIFIER:exon19/19:c.*336G>T:		rs1044120	0.4772	0.0000	0/0/0	0.0707							157655 [NDUFS1 (provisional) Mitochondrial complex I deficiency,252010];	RCV000275804.1 [likely benign]; RCV000368047.1 [likely benign]; 			52	94					NDUFS1 (inh=AR pLI=0.00)
chr2	206988751	206988751	A	G	het	het	wt		QUAL=5405;DP=278,98,131;MQM=60	NDUFS1	3'UTR	NDUFS1:NM_001199984.1:3'UTR:MODIFIER:exon19/19:c.*158T>C:,NDUFS1:NM_001199981.1:3'UTR:MODIFIER:exon18/18:c.*158T>C:,NDUFS1:NM_001199982.1:3'UTR:MODIFIER:exon16/16:c.*158T>C:,NDUFS1:NM_001199983.1:3'UTR:MODIFIER:exon18/18:c.*158T>C:,NDUFS1:NM_005006.6:3'UTR:MODIFIER:exon19/19:c.*158T>C:		rs3770989	0.0256	0.0000	0/0/0	0.0046							157655 [NDUFS1 (provisional) Mitochondrial complex I deficiency,252010];	RCV000260695.1 [uncertain significance]; RCV000318219.1 [uncertain significance]; 			0	21					NDUFS1 (inh=AR pLI=0.00)
chr2	206992537	206992537	A	C	het	wt	wt	pred_pathogenic	QUAL=1524;DP=236,132,161;MQM=60	NDUFS1	missense	NDUFS1:NM_001199984.1:missense:MODERATE:exon16/19:c.1910T>G:p.Ile637Arg,NDUFS1:NM_001199981.1:missense:MODERATE:exon15/18:c.1760T>G:p.Ile587Arg,NDUFS1:NM_001199982.1:missense:MODERATE:exon13/16:c.1535T>G:p.Ile512Arg,NDUFS1:NM_001199983.1:missense:MODERATE:exon15/18:c.1697T>G:p.Ile566Arg,NDUFS1:NM_005006.6:missense:MODERATE:exon16/19:c.1868T>G:p.Ile623Arg		rs201634181	0.0000	0.0045	0/0/0	0.0001	9.2840	D,D,D,D,D,D,D	D	D,P,P,P	D,D,D,D,D,D,D	28.90	157655 [NDUFS1 (provisional) Mitochondrial complex I deficiency,252010];	RCV000197616.1 [uncertain significance]; 		COSM215852	0	58					NDUFS1 (inh=AR pLI=0.00)
chr2	207006676	207006676	T	C	wt	het	wt		QUAL=2014;DP=186,163,229;MQM=60	NDUFS1	synonymous	NDUFS1:NM_001199984.1:synonymous:LOW:exon12/19:c.1293A>G:p.Arg431Arg,NDUFS1:NM_001199981.1:synonymous:LOW:exon11/18:c.1143A>G:p.Arg381Arg,NDUFS1:NM_001199982.1:synonymous:LOW:exon9/16:c.918A>G:p.Arg306Arg,NDUFS1:NM_001199983.1:synonymous:LOW:exon11/18:c.1080A>G:p.Arg360Arg,NDUFS1:NM_005006.6:synonymous:LOW:exon12/19:c.1251A>G:p.Arg417Arg		rs1801318	0.3099	0.3105	6032/3411/1036	0.3054							157655 [NDUFS1 (provisional) Mitochondrial complex I deficiency,252010];	RCV000117709.3 [other]; RCV000301574.1 [likely benign]; RCV000358690.1 [likely benign]; 		COSM4001476	170	646					NDUFS1 (inh=AR pLI=0.00)
chr2	207008763	207008763	C	A	wt	het	wt		QUAL=2727;DP=320,206,256;MQM=60	NDUFS1	synonymous	NDUFS1:NM_001199984.1:synonymous:LOW:exon10/19:c.1008G>T:p.Ala336Ala,NDUFS1:NM_001199981.1:synonymous:LOW:exon9/18:c.858G>T:p.Ala286Ala,NDUFS1:NM_001199982.1:synonymous:LOW:exon7/16:c.633G>T:p.Ala211Ala,NDUFS1:NM_001199983.1:synonymous:LOW:exon9/18:c.795G>T:p.Ala265Ala,NDUFS1:NM_005006.6:synonymous:LOW:exon10/19:c.966G>T:p.Ala322Ala		rs1127566	0.4623	0.4537	13031/6988/2153	0.4446							157655 [NDUFS1 (provisional) Mitochondrial complex I deficiency,252010];	RCV000117710.3 [other]; RCV000328157.1 [likely benign]; RCV000385000.1 [likely benign]; 		COSM1129370	328	725					NDUFS1 (inh=AR pLI=0.00)
chr2	207024107	207024107	G	C	wt	het	wt		QUAL=1266;DP=346,91,111;MQM=60	NDUFS1	5'UTR	NDUFS1:NM_001199981.1:5'UTR:MODIFIER:exon1/18:c.-47C>G:,NDUFS1:NM_001199982.1:5'UTR:MODIFIER:exon1/16:c.-103C>G:,NDUFS1:NM_001199983.1:5'UTR:MODIFIER:exon1/18:c.-126C>G:,NDUFS1:NM_005006.6:5'UTR:MODIFIER:exon1/19:c.-47C>G:		rs4147707	0.3802	0.0000	0/0/0	0.3839							157655 [NDUFS1 (provisional) Mitochondrial complex I deficiency,252010];	RCV000333207.1 [likely benign]; RCV000371529.1 [likely benign]; 			49	92					NDUFS1 (inh=AR pLI=0.00)
chr2	207025444	207025444	T	C	wt	het	wt		QUAL=2155;DP=174,163,221;MQM=60	EEF1B2	splice_region&intron	EEF1B2:NM_001037663.1:splice_region&intron:LOW:exon3/6:c.203+10T>C:,EEF1B2:NM_001959.3:splice_region&intron:LOW:exon2/5:c.203+10T>C:,EEF1B2:NM_021121.3:splice_region&intron:LOW:exon3/6:c.203+10T>C:		rs11689362	0.4603	0.4556	13110/7024/2162	0.4461										COSM4001477	329	731					EEF1B2 (inh=n/a pLI=0.33)
chr2	207026131	207026131	G	A	het	het	wt	pred_pathogenic	QUAL=6049;DP=227,294,379;MQM=55	EEF1B2	missense	EEF1B2:NM_001037663.1:missense:MODERATE:exon4/7:c.265G>A:p.Gly89Arg,EEF1B2:NM_001959.3:missense:MODERATE:exon3/6:c.265G>A:p.Gly89Arg,EEF1B2:NM_021121.3:missense:MODERATE:exon4/7:c.265G>A:p.Gly89Arg		rs11546386	0.0178	0.0126	25/3/0	0.0118	5.3110	T,T,T,T	T	B	T,T,T,T	22.00				COSM3695209	3	44					EEF1B2 (inh=n/a pLI=0.33)
chr2	207630471	207630471	A	G	wt	het	wt	anno_pathogenic_hgmd	QUAL=2198;DP=242,151,233;MQM=60	FASTKD2	splice_region,5'UTR,intron	FASTKD2:NM_001136193.1:splice_region:LOW:exon1/12:c.-51A>G:,FASTKD2:NM_001136193.1:5'UTR:MODIFIER:exon1/12:c.-51A>G:,FASTKD2:NM_001136194.1:5'UTR:MODIFIER:exon1/12:c.-66A>G:,FASTKD2:NM_014929.3:intron:MODIFIER:exon1/11:c.-51+93A>G:		rs116297724	0.0024	0.0000	0/0/0	0.0075							612322 [FASTKD2 (provisional) Mitochondrial complex IV deficiency,220110];	RCV000124989.1 [benign]; RCV000224346.1 [likely benign]; 	CS151601 [CLASS=DM? MUT=ALT PHEN="Cerebellar ataxia" GENE=FASTKD2]; 		0	7					FASTKD2 (inh=AR pLI=0.00)
chr2	207656613	207656613	A	G	wt	het	wt		QUAL=2562;DP=330,173,232;MQM=60	FASTKD2	3'UTR	FASTKD2:NM_001136193.1:3'UTR:MODIFIER:exon12/12:c.*87A>G:,FASTKD2:NM_001136194.1:3'UTR:MODIFIER:exon12/12:c.*87A>G:,FASTKD2:NM_014929.3:3'UTR:MODIFIER:exon12/12:c.*87A>G:		rs115098389	0.0136	0.0000	0/0/0	0.0061							612322 [FASTKD2 (provisional) Mitochondrial complex IV deficiency,220110];	RCV000341044.1 [uncertain significance]; 			0	23					FASTKD2 (inh=AR pLI=0.00)
chr2	207657153	207657153	T	C	wt	wt	het		QUAL=651;DP=261,44,56;MQM=60	FASTKD2	3'UTR	FASTKD2:NM_001136193.1:3'UTR:MODIFIER:exon12/12:c.*627T>C:,FASTKD2:NM_001136194.1:3'UTR:MODIFIER:exon12/12:c.*627T>C:,FASTKD2:NM_014929.3:3'UTR:MODIFIER:exon12/12:c.*627T>C:		rs1048783	0.4577	0.0000	0/0/0	0.0659							612322 [FASTKD2 (provisional) Mitochondrial complex IV deficiency,220110];	RCV000397582.1 [likely benign]; 			27	94					FASTKD2 (inh=AR pLI=0.00)
chr2	207657706	207657706	G	C	het	wt	het		QUAL=4824;DP=192,126,177;MQM=59	FASTKD2	3'UTR	FASTKD2:NM_001136193.1:3'UTR:MODIFIER:exon12/12:c.*1180G>C:,FASTKD2:NM_001136194.1:3'UTR:MODIFIER:exon12/12:c.*1180G>C:,FASTKD2:NM_014929.3:3'UTR:MODIFIER:exon12/12:c.*1180G>C:	AluSc	rs114333222	0.0016	0.0000	0/0/0	0.0049							612322 [FASTKD2 (provisional) Mitochondrial complex IV deficiency,220110];	RCV000364221.1 [uncertain significance]; 			0	5					FASTKD2 (inh=AR pLI=0.00)
chr2	207659760	207659760	-	T	wt	wt	het		QUAL=3519;DP=307,230,287;MQM=60	FASTKD2	3'UTR	FASTKD2:NM_001136193.1:3'UTR:MODIFIER:exon12/12:c.*3234_*3235insT:,FASTKD2:NM_001136194.1:3'UTR:MODIFIER:exon12/12:c.*3234_*3235insT:,FASTKD2:NM_014929.3:3'UTR:MODIFIER:exon12/12:c.*3234_*3235insT:	Charlie17b	rs5838044	0.0000	0.0000	0/0/0	0.2529							612322 [FASTKD2 (provisional) Mitochondrial complex IV deficiency,220110];				26	100					FASTKD2 (inh=AR pLI=0.00)
chr2	207659976	207659976	G	C	wt	het	wt		QUAL=2886;DP=285,255,332;MQM=59	FASTKD2	3'UTR	FASTKD2:NM_001136193.1:3'UTR:MODIFIER:exon12/12:c.*3450G>C:,FASTKD2:NM_001136194.1:3'UTR:MODIFIER:exon12/12:c.*3450G>C:,FASTKD2:NM_014929.3:3'UTR:MODIFIER:exon12/12:c.*3450G>C:	AluY	rs141681457	0.0134	0.0000	0/0/0	0.0306							612322 [FASTKD2 (provisional) Mitochondrial complex IV deficiency,220110];				2	19					FASTKD2 (inh=AR pLI=0.00)
chr2	211060050	211060050	T	G	wt	het	wt	pred_pathogenic	QUAL=1714;DP=331,148,206;MQM=60	ACADL	missense	ACADL:NM_001608.3:missense:MODERATE:exon9/11:c.997A>C:p.Lys333Gln		rs2286963	0.2111	0.3011	5851/3972/114	0.2986	6.8420	T	T	P	D	25.60		RCV000115027.2 [uncertain significance]; RCV000328841.1 [benign]; 	CM144346 [CLASS=DP MUT=ALT PHEN="Sudden infant death increased risk" GENE=ACADL]; 	COSM4133423	167	677					ACADL (inh=n/a pLI=0.00)
chr2	211421452	211421452	-	TCT	hom	het	het		QUAL=12769;DP=254,166,195;MQM=59	CPS1	conservative_inframe_insertion,5'UTR	CPS1:NM_001122633.2:conservative_inframe_insertion:MODERATE:exon2/39:c.15_16insTTC:p.Ile5_Lys6insPhe,CPS1:NM_001875.4:5'UTR:MODIFIER:exon1/38:c.-4_-3insTTC:		rs3835047;rs61509952	0.4770	0.4350	11669/5397/1790	0.4083							608307 [CPS1 (confirmed) Carbamoylphosphate synthetase I deficiency,237300|Pulmonary hypertension,neonatal,susceptibility to,615371|Venoocclusive disease after bone marrow transplantation];	RCV000185816.2 [benign]; RCV000377067.1 [benign]; 			330	725	1	[1] old entry - no details available			CPS1 (inh=AR pLI=0.08)
chr2	211456637	211456637	A	G	hom	hom	het	pred_pathogenic	QUAL=15942;DP=210,178,254;MQM=60	CPS1	missense	CPS1:NM_001122633.2:missense:MODERATE:exon11/39:c.1048A>G:p.Thr350Ala,CPS1:NM_001875.4:missense:MODERATE:exon10/38:c.1030A>G:p.Thr344Ala		rs1047883	0.0000	0.5697	19535/10771/1924	0.5152	0.2530	T,T,T,T	T	B	D,D	4.19	608307 [CPS1 (confirmed) Carbamoylphosphate synthetase I deficiency,237300|Pulmonary hypertension,neonatal,susceptibility to,615371|Venoocclusive disease after bone marrow transplantation];	RCV000116829.5 [other]; RCV000364698.1 [benign]; RCV000275942.1 [benign]; RCV000396067.1 [likely benign]; 		COSM4133424, COSM4133425	581	701					CPS1 (inh=AR pLI=0.08)
chr2	211456639	211456639	C	T	hom	hom	het		QUAL=15942;DP=210,178,254;MQM=60	CPS1	synonymous	CPS1:NM_001122633.2:synonymous:LOW:exon11/39:c.1050C>T:p.Thr350Thr,CPS1:NM_001875.4:synonymous:LOW:exon10/38:c.1032C>T:p.Thr344Thr		rs2229589	0.5913	0.5736	19866/10782/2240	0.5436							608307 [CPS1 (confirmed) Carbamoylphosphate synthetase I deficiency,237300|Pulmonary hypertension,neonatal,susceptibility to,615371|Venoocclusive disease after bone marrow transplantation];	RCV000116830.5 [other]; RCV000302372.1 [benign]; 			583	699					CPS1 (inh=AR pLI=0.08)
chr2	211481257	211481257	C	G	hom	hom	het		QUAL=15598;DP=142,254,292;MQM=60	CPS1	synonymous	CPS1:NM_001122633.2:synonymous:LOW:exon22/39:c.2697C>G:p.Gly899Gly,CPS1:NM_001875.4:synonymous:LOW:exon21/38:c.2679C>G:p.Gly893Gly,CPS1:NM_001122634.3:synonymous:LOW:exon11/28:c.1326C>G:p.Gly442Gly		rs2287599	0.6492	0.5861	21467/10811/3868	0.5735							608307 [CPS1 (confirmed) Carbamoylphosphate synthetase I deficiency,237300|Pulmonary hypertension,neonatal,susceptibility to,615371|Venoocclusive disease after bone marrow transplantation];	RCV000116831.4 [other]; RCV000347604.1 [benign]; 			563	718					CPS1 (inh=AR pLI=0.08)
chr2	211540507	211540507	C	A	wt	het	wt	pred_pathogenic	QUAL=2499;DP=334,189,258;MQM=60	CPS1	missense,sequence_feature	CPS1:NM_001122633.2:missense:MODERATE:exon37/39:c.4235C>A:p.Thr1412Asn,CPS1:NM_001875.4:missense:MODERATE:exon36/38:c.4217C>A:p.Thr1406Asn,CPS1:NM_001122634.3:missense:MODERATE:exon26/28:c.2864C>A:p.Thr955Asn,CPS1:NM_001122633.2:sequence_feature:LOW:exon37/39:c.4235C>A:,CPS1:NM_001875.4:sequence_feature:LOW:exon36/38:c.4217C>A:		rs1047891	0.2885	0.3034	5692/3187/724	0.2985	1.7560	T,T,T,T	T	B,B	D,D,D	22.10	608307 [CPS1 (confirmed) Carbamoylphosphate synthetase I deficiency,237300|Pulmonary hypertension,neonatal,susceptibility to,615371|Venoocclusive disease after bone marrow transplantation];	RCV000116832.4 [other]; RCV000274786.1 [benign]; 	CM109955 [CLASS=DFP MUT=ALT PHEN="Hyperammonaemia association with" GENE=CPS1]; 	COSM4001490, COSM4001489	158	662					CPS1 (inh=AR pLI=0.08)
chr2	211543055	211543055	T	C	wt	het	wt		QUAL=656;DP=288,92,109;MQM=60	CPS1	3'UTR	CPS1:NM_001122633.2:3'UTR:MODIFIER:exon39/39:c.*346T>C:,CPS1:NM_001875.4:3'UTR:MODIFIER:exon38/38:c.*346T>C:,CPS1:NM_001122634.3:3'UTR:MODIFIER:exon28/28:c.*346T>C:		rs715	0.2362	0.0000	0/0/0	0.0467							608307 [CPS1 (confirmed) Carbamoylphosphate synthetase I deficiency,237300|Pulmonary hypertension,neonatal,susceptibility to,615371|Venoocclusive disease after bone marrow transplantation];	RCV000343467.1 [benign]; 			25	95					CPS1 (inh=AR pLI=0.08)
chr2	211543147	211543147	T	G	het	het	het		QUAL=7846;DP=273,93,130;MQM=59	CPS1	3'UTR	CPS1:NM_001122633.2:3'UTR:MODIFIER:exon39/39:c.*438T>G:,CPS1:NM_001875.4:3'UTR:MODIFIER:exon38/38:c.*438T>G:,CPS1:NM_001122634.3:3'UTR:MODIFIER:exon28/28:c.*438T>G:		rs7684	0.2690	0.0000	0/0/0	0.0542							608307 [CPS1 (confirmed) Carbamoylphosphate synthetase I deficiency,237300|Pulmonary hypertension,neonatal,susceptibility to,615371|Venoocclusive disease after bone marrow transplantation];	RCV000335404.1 [benign]; 			28	112					CPS1 (inh=AR pLI=0.08)
chr2	211543401	211543401	C	G	wt	wt	het		QUAL=2887;DP=278,172,232;MQM=60	CPS1	3'UTR	CPS1:NM_001122633.2:3'UTR:MODIFIER:exon39/39:c.*692C>G:,CPS1:NM_001875.4:3'UTR:MODIFIER:exon38/38:c.*692C>G:,CPS1:NM_001122634.3:3'UTR:MODIFIER:exon28/28:c.*692C>G:	AluSc	rs12476133	0.2458	0.0000	0/0/0	0.0420							608307 [CPS1 (confirmed) Carbamoylphosphate synthetase I deficiency,237300|Pulmonary hypertension,neonatal,susceptibility to,615371|Venoocclusive disease after bone marrow transplantation];	RCV000405913.1 [benign]; 			18	89					CPS1 (inh=AR pLI=0.08)
chr2	215796302	215796302	-	ACAA	het	hom	wt		QUAL=6985;DP=218,156,282;MQM=59	ABCA12,LOC101928103	3'UTR,intron,non_coding_transcript_exon	ABCA12:NM_173076.2:3'UTR:MODIFIER:exon53/53:c.*1052_*1055dupTTGT:,ABCA12:NM_015657.3:3'UTR:MODIFIER:exon45/45:c.*1052_*1055dupTTGT:,LOC101928103:NR_110292.1:intron:MODIFIER:exon2/3:n.322-16243_322-16240dupAACA:,ABCA12:NR_103740.1:non_coding_transcript_exon:MODIFIER:exon55/55:n.9140_9143dupTTGT:		rs57011945	0.3015	0.0000	0/0/0	0.3540							607800 [ABCA12 (confirmed) Ichthyosis,congenital,autosomal recessive 4A,601277|Ichthyosis,congenital,autosomal recessive 4B (harlequin),242500];	RCV000285776.1 [benign]; 			39	98					ABCA12 (inh=AR pLI=0.00), LOC101928103 (inh=n/a pLI=n/a)
chr2	215796568	215796568	T	C	hom	hom	hom		QUAL=19207;DP=226,159,203;MQM=59	ABCA12,LOC101928103	3'UTR,intron,non_coding_transcript_exon	ABCA12:NM_173076.2:3'UTR:MODIFIER:exon53/53:c.*790A>G:,ABCA12:NM_015657.3:3'UTR:MODIFIER:exon45/45:c.*790A>G:,LOC101928103:NR_110292.1:intron:MODIFIER:exon2/3:n.322-15981T>C:,ABCA12:NR_103740.1:non_coding_transcript_exon:MODIFIER:exon55/55:n.8878A>G:		rs12694349	0.5939	0.0000	0/0/0	0.5229							607800 [ABCA12 (confirmed) Ichthyosis,congenital,autosomal recessive 4A,601277|Ichthyosis,congenital,autosomal recessive 4B (harlequin),242500];	RCV000365901.1 [benign]; 			65	104					ABCA12 (inh=AR pLI=0.00), LOC101928103 (inh=n/a pLI=n/a)
chr2	215797332	215797332	C	T	hom	hom	het		QUAL=15380;DP=321,82,127;MQM=60	ABCA12,LOC101928103	3'UTR,intron,non_coding_transcript_exon	ABCA12:NM_173076.2:3'UTR:MODIFIER:exon53/53:c.*26G>A:,ABCA12:NM_015657.3:3'UTR:MODIFIER:exon45/45:c.*26G>A:,LOC101928103:NR_110292.1:intron:MODIFIER:exon2/3:n.322-15217C>T:,ABCA12:NR_103740.1:non_coding_transcript_exon:MODIFIER:exon55/55:n.8114G>A:		rs17426207	0.3982	0.4314	10530/5449/641	0.4090							607800 [ABCA12 (confirmed) Ichthyosis,congenital,autosomal recessive 4A,601277|Ichthyosis,congenital,autosomal recessive 4B (harlequin),242500];	RCV000267300.1 [benign]; 			166	450					ABCA12 (inh=AR pLI=0.00), LOC101928103 (inh=n/a pLI=n/a)
chr2	215820013	215820013	G	A	het	hom	het		QUAL=13130;DP=328,196,265;MQM=60	ABCA12,LOC101928103	synonymous,intron,non_coding_transcript_exon	ABCA12:NM_173076.2:synonymous:LOW:exon43/53:c.6306C>T:p.Tyr2102Tyr,ABCA12:NM_015657.3:synonymous:LOW:exon35/45:c.5352C>T:p.Tyr1784Tyr,LOC101928103:NR_110292.1:intron:MODIFIER:exon3/3:n.445-6521G>A:,ABCA12:NR_103740.1:non_coding_transcript_exon:MODIFIER:exon45/55:n.6606C>T:		rs10498027	0.3500	0.4051	10283/6091/513	0.3990							607800 [ABCA12 (confirmed) Ichthyosis,congenital,autosomal recessive 4A,601277|Ichthyosis,congenital,autosomal recessive 4B (harlequin),242500];	RCV000254526.1 [benign]; RCV000300175.1 [benign]; RCV000357340.1 [uncertain significance]; 		COSM3757935	273	779					ABCA12 (inh=AR pLI=0.00), LOC101928103 (inh=n/a pLI=n/a)
chr2	215839570	215839570	C	T	het	wt	het		QUAL=8765;DP=334,246,339;MQM=60	ABCA12	synonymous,non_coding_transcript_exon	ABCA12:NM_173076.2:synonymous:LOW:exon35/53:c.5400G>A:p.Thr1800Thr,ABCA12:NM_015657.3:synonymous:LOW:exon27/45:c.4446G>A:p.Thr1482Thr,ABCA12:NR_103740.1:non_coding_transcript_exon:MODIFIER:exon37/55:n.5700G>A:		rs16853022	0.1196	0.0477	495/3/440	0.0467							607800 [ABCA12 (confirmed) Ichthyosis,congenital,autosomal recessive 4A,601277|Ichthyosis,congenital,autosomal recessive 4B (harlequin),242500];	RCV000246212.1 [benign]; RCV000271010.1 [benign]; 			6	122					ABCA12 (inh=AR pLI=0.00)
chr2	215851303	215851303	A	G	hom	het	hom		QUAL=15522;DP=180,163,248;MQM=60	ABCA12	synonymous,non_coding_transcript_exon	ABCA12:NM_173076.2:synonymous:LOW:exon28/53:c.4126T>C:p.Leu1376Leu,ABCA12:NM_015657.3:synonymous:LOW:exon20/45:c.3172T>C:p.Leu1058Leu,ABCA12:NR_103740.1:non_coding_transcript_exon:MODIFIER:exon30/55:n.4426T>C:		rs34351934	0.2071	0.1356	1703/316/769	0.1327							607800 [ABCA12 (confirmed) Ichthyosis,congenital,autosomal recessive 4A,601277|Ichthyosis,congenital,autosomal recessive 4B (harlequin),242500];	RCV000248405.1 [benign]; RCV000305663.1 [benign]; 			32	359					ABCA12 (inh=AR pLI=0.00)
chr2	215854156	215854156	C	T	het	het	het		QUAL=14250;DP=345,348,456;MQM=60	ABCA12	synonymous,non_coding_transcript_exon	ABCA12:NM_173076.2:synonymous:LOW:exon26/53:c.3726G>A:p.Pro1242Pro,ABCA12:NM_015657.3:synonymous:LOW:exon18/45:c.2772G>A:p.Pro924Pro,ABCA12:NR_103740.1:non_coding_transcript_exon:MODIFIER:exon28/55:n.4026G>A:		rs71428357	0.0719	0.0653	427/98/43	0.0645							607800 [ABCA12 (confirmed) Ichthyosis,congenital,autosomal recessive 4A,601277|Ichthyosis,congenital,autosomal recessive 4B (harlequin),242500];	RCV000243239.1 [benign]; RCV000331070.1 [likely benign]; 			9	189					ABCA12 (inh=AR pLI=0.00)
chr2	215876166	215876166	A	T	hom	hom	hom		QUAL=15166;DP=215,127,162;MQM=60	ABCA12	missense,non_coding_transcript_exon	ABCA12:NM_173076.2:missense:MODERATE:exon17/53:c.2329T>A:p.Ser777Thr,ABCA12:NM_015657.3:missense:MODERATE:exon9/45:c.1375T>A:p.Ser459Thr,ABCA12:NR_103740.1:non_coding_transcript_exon:MODIFIER:exon18/55:n.2573T>A:		rs7560008	0.9984	0.9994	60286/33210/5059	0.9375	-1.4110	T,T	T	B,B	T,T	0.08	607800 [ABCA12 (confirmed) Ichthyosis,congenital,autosomal recessive 4A,601277|Ichthyosis,congenital,autosomal recessive 4B (harlequin),242500];	RCV000248760.1 [benign]; RCV000319091.1 [benign]; 			1560	2					ABCA12 (inh=AR pLI=0.00)
chr2	215876371	215876371	T	C	hom	het	het		QUAL=10498;DP=185,135,211;MQM=60	ABCA12	splice_region&synonymous,splice_region&non_coding_transcript_exon	ABCA12:NM_173076.2:splice_region&synonymous:LOW:exon17/53:c.2124A>G:p.Ala708Ala,ABCA12:NM_015657.3:splice_region&synonymous:LOW:exon9/45:c.1170A>G:p.Ala390Ala,ABCA12:NR_103740.1:splice_region&non_coding_transcript_exon:LOW:exon18/55:n.2368A>G:		rs10198064	0.2794	0.1520	2861/266/1963	0.1490							607800 [ABCA12 (confirmed) Ichthyosis,congenital,autosomal recessive 4A,601277|Ichthyosis,congenital,autosomal recessive 4B (harlequin),242500];	RCV000243989.1 [benign]; RCV000288434.1 [benign]; 			35	348					ABCA12 (inh=AR pLI=0.00)
chr2	215901774	215901774	C	T	het	wt	het		QUAL=7551;DP=320,203,236;MQM=60	ABCA12	synonymous,non_coding_transcript_exon	ABCA12:NM_173076.2:synonymous:LOW:exon8/53:c.888G>A:p.Val296Val,ABCA12:NR_103740.1:non_coding_transcript_exon:MODIFIER:exon9/55:n.1132G>A:		rs17501837	0.2234	0.2057	2859/1304/104	0.2082							607800 [ABCA12 (confirmed) Ichthyosis,congenital,autosomal recessive 4A,601277|Ichthyosis,congenital,autosomal recessive 4B (harlequin),242500];	RCV000245963.1 [benign]; RCV000347345.1 [benign]; 		COSM50991	45	436					ABCA12 (inh=AR pLI=0.00)
chr2	216176807	216176807	T	G	het	wt	het		QUAL=2406;DP=41,130,174;MQM=60	ATIC	5'UTR	ATIC:NM_004044.6:5'UTR:MODIFIER:exon1/16:c.-59T>G:		rs4535042	0.2448	0.0000	0/0/0	0.0471							601731 [ATIC (provisional) AICA-ribosiduria due to ATIC deficiency,608688];				109	388					ATIC (inh=AR pLI=0.00)
chr2	216214492	216214492	T	G	het	hom	het		QUAL=10116;DP=210,164,206;MQM=59	ATIC	3'UTR	ATIC:NM_004044.6:3'UTR:MODIFIER:exon16/16:c.*114T>G:		rs10498036	0.5952	0.0000	0/0/0	0.1200							601731 [ATIC (provisional) AICA-ribosiduria due to ATIC deficiency,608688];				54	120					ATIC (inh=AR pLI=0.00)
chr2	217277249	217277249	C	T	het	wt	hom		QUAL=8659;DP=114,173,254;MQM=60	SMARCAL1	5'UTR	SMARCAL1:NM_014140.3:5'UTR:MODIFIER:exon1/18:c.-218C>T:		rs3755141	0.2079	0.0000	0/0/0	0.2680							606622 [SMARCAL1 (provisional) Schimke immunoosseous dysplasia,242900];	RCV000265625.1 [benign]; 			18	85					SMARCAL1 (inh=AR pLI=0.00)
chr2	219646547	219646547	-	C	hom	hom	hom		QUAL=4527;DP=52,56,59;MQM=59	CYP27A1	5'UTR	CYP27A1:NM_000784.3:5'UTR:MODIFIER:exon1/9:c.-357dupC:		rs397795841	0.9998	0.0000	0/0/0	0.9125							606530 [CYP27A1 (provisional) Cerebrotendinous xanthomatosis,213700];	RCV000322434.1 [benign]; 			222	8					CYP27A1 (inh=AR pLI=0.00)
chr2	219755011	219755011	T	A	wt	het	wt	pred_pathogenic;anno_pathogenic_clinvar;anno_pathogenic_hgmd	QUAL=666;DP=79,64,73;MQM=60	WNT10A	missense	WNT10A:NM_025216.2:missense:MODERATE:exon3/4:c.682T>A:p.Phe228Ile		rs121908120	0.0060	0.0127	14/14/0	0.0133	7.7440	D	D	D	D	32.00	606268 [WNT10A (confirmed) Odontoonychodermal dysplasia,257980|Schopf-Schulz-Passarge syndrome,224750|Tooth agenesis,selective,4,150400];	RCV000004717.4 [other]; RCV000023529.3 [pathogenic]; RCV000255788.2 [pathogenic]; RCV000278695.1 [likely benign]; RCV000373155.1 [likely benign]; 	CM094237 [CLASS=DM MUT=ALT PHEN="Ectodermal dysplasia" GENE=WNT10A]; 	COSM1235675	0	46					WNT10A (inh=AR+AD pLI=0.01)
chr2	219940484	219940484	C	T	hom	hom	hom		QUAL=16790;DP=291,114,123;MQM=59	NHEJ1	3'UTR	NHEJ1:NM_024782.2:3'UTR:MODIFIER:exon8/8:c.*619G>A:		rs359960	0.9852	0.0000	0/0/0	0.1537							611290 [NHEJ1 (provisional) Severe combined immunodeficiency with microcephaly,growth retardation,and sensitivity to ionizing radiation,611291];				222	8					NHEJ1 (inh=n/a pLI=0.03)
chr2	219941063	219941063	G	A	hom	het	hom		QUAL=20190;DP=326,199,235;MQM=59	NHEJ1	3'UTR	NHEJ1:NM_024782.2:3'UTR:MODIFIER:exon8/8:c.*40C>T:		rs897477	0.6384	0.7109	31172/19666/2546	0.7014							611290 [NHEJ1 (provisional) Severe combined immunodeficiency with microcephaly,growth retardation,and sensitivity to ionizing radiation,611291];			COSM4001506	612	447					NHEJ1 (inh=n/a pLI=0.03)
chr2	220283259	220283259	A	G	het	hom	hom	low_DP	QUAL=4879;DP=6,63,104;MQM=60	DES	synonymous	DES:NM_001927.3:synonymous:LOW:exon1/9:c.75A>G:p.Pro25Pro		rs1318299	0.8862	0.9652	49754/28119/1579	0.8660							125660 [DES (confirmed) Myopathy,myofibrillar,1,601419|Cardiomyopathy,dilated,1I,604765|Scapuloperoneal syndrome,neurogenic,Kaeser type,181400|Muscular dystrophy,limb-girdle,type 2R,615325];	RCV000154433.1 [benign]; RCV000029660.1 [benign]; RCV000037251.10 [benign]; RCV000250669.1 [benign]; RCV000299687.1 [benign]; RCV000356753.1 [benign]; RCV000395699.1 [benign]; RCV000395883.1 [benign]; 		COSM3757962	1551	49					DES (inh=AR+AD pLI=0.00)
chr2	220283277	220283277	T	C	hom	hom	hom	low_DP	QUAL=5311;DP=7,67,102;MQM=60	DES	sequence_feature,synonymous	DES:NM_001927.3:sequence_feature:MODERATE:exon1/9:c.93T>C:,DES:NM_001927.3:synonymous:LOW:exon1/9:c.93T>C:p.Ser31Ser		rs2017800	0.8660	0.9611	48951/27937/1280	0.8687							125660 [DES (confirmed) Myopathy,myofibrillar,1,601419|Cardiomyopathy,dilated,1I,604765|Scapuloperoneal syndrome,neurogenic,Kaeser type,181400|Muscular dystrophy,limb-girdle,type 2R,615325];	RCV000154434.1 [benign]; RCV000029661.1 [benign]; RCV000037256.10 [benign]; RCV000242424.1 [benign]; RCV000277612.1 [benign]; RCV000312502.1 [benign]; RCV000325693.1 [benign]; RCV000369464.1 [benign]; 		COSM3749630	1565	56					DES (inh=AR+AD pLI=0.00)
chr2	220285309	220285309	C	T	hom	hom	hom		QUAL=37665;DP=393,372,451;MQM=59	DES	synonymous	DES:NM_001927.3:synonymous:LOW:exon4/9:c.828C>T:p.Asp276Asp		rs1058261	0.3375	0.3363	6988/4285/1016	0.3349							125660 [DES (confirmed) Myopathy,myofibrillar,1,601419|Cardiomyopathy,dilated,1I,604765|Scapuloperoneal syndrome,neurogenic,Kaeser type,181400|Muscular dystrophy,limb-girdle,type 2R,615325];	RCV000037254.8 [benign]; RCV000247557.1 [benign]; RCV000311313.1 [benign]; RCV000338231.1 [benign]; RCV000390698.1 [benign]; RCV000397462.1 [benign]; 			238	729					DES (inh=AR+AD pLI=0.00)
chr2	220285666	220285666	G	C	hom	hom	hom		QUAL=35360;DP=179,419,534;MQM=59	DES	synonymous	DES:NM_001927.3:synonymous:LOW:exon5/9:c.1014G>C:p.Leu338Leu		rs12920	0.3377	0.3414	6724/4097/1020	0.3317							125660 [DES (confirmed) Myopathy,myofibrillar,1,601419|Cardiomyopathy,dilated,1I,604765|Scapuloperoneal syndrome,neurogenic,Kaeser type,181400|Muscular dystrophy,limb-girdle,type 2R,615325];	RCV000037222.8 [benign]; RCV000250707.1 [benign]; RCV000270208.1 [benign]; RCV000293964.1 [benign]; RCV000325316.1 [benign]; RCV000388336.1 [benign]; 		COSM4133480	239	728					DES (inh=AR+AD pLI=0.00)
chr2	220286142	220286142	G	A	hom	hom	hom		QUAL=29889;DP=207,317,467;MQM=59	DES	synonymous	DES:NM_001927.3:synonymous:LOW:exon6/9:c.1104G>A:p.Ala368Ala		rs1058284	0.3337	0.3362	7020/4314/1009	0.3356							125660 [DES (confirmed) Myopathy,myofibrillar,1,601419|Cardiomyopathy,dilated,1I,604765|Scapuloperoneal syndrome,neurogenic,Kaeser type,181400|Muscular dystrophy,limb-girdle,type 2R,615325];	RCV000037225.9 [benign]; RCV000242476.1 [benign]; RCV000305879.1 [benign]; RCV000342152.1 [benign]; RCV000403379.1 [benign]; RCV000405738.1 [benign]; 		COSM4001515	238	728					DES (inh=AR+AD pLI=0.00)
chr2	223064768	223064768	G	A	wt	het	het		QUAL=16181;DP=430,556,701;MQM=60	PAX3	3'UTR	PAX3:NM_181459.3:3'UTR:MODIFIER:exon10/10:c.*1125C>T:,PAX3:NM_001127366.2:3'UTR:MODIFIER:exon9/9:c.*1359C>T:,PAX3:NM_181458.3:3'UTR:MODIFIER:exon9/9:c.*1359C>T:,PAX3:NM_181460.3:3'UTR:MODIFIER:exon9/9:c.*1172C>T:,PAX3:NM_181461.3:3'UTR:MODIFIER:exon8/8:c.*1355C>T:		rs12620338	0.1741	0.0000	0/0/0	0.0323							606597 [PAX3 (confirmed) Waardenburg syndrome,type 1,193500|Waardenburg syndrome,type 3,148820|Craniofacial-deafness-hand syndrome,122880|Rhabdomyosarcoma 2,alveolar,268220];				3	83					PAX3 (inh=AR+AD pLI=0.90)
chr2	223065870	223065870	C	G	wt	het	het		QUAL=6673;DP=300,235,331;MQM=60	PAX3	3'UTR	PAX3:NM_181459.3:3'UTR:MODIFIER:exon10/10:c.*23G>C:,PAX3:NM_001127366.2:3'UTR:MODIFIER:exon9/9:c.*257G>C:,PAX3:NM_181458.3:3'UTR:MODIFIER:exon9/9:c.*257G>C:,PAX3:NM_181460.3:3'UTR:MODIFIER:exon9/9:c.*70G>C:,PAX3:NM_181461.3:3'UTR:MODIFIER:exon8/8:c.*253G>C:		rs3731858	0.1733	0.1896	2374/1186/6	0.1830							606597 [PAX3 (confirmed) Waardenburg syndrome,type 1,193500|Waardenburg syndrome,type 3,148820|Craniofacial-deafness-hand syndrome,122880|Rhabdomyosarcoma 2,alveolar,268220];				38	295					PAX3 (inh=AR+AD pLI=0.90)
chr2	223066536	223066536	-	A	wt	het	het		QUAL=326;DP=155,111,155;MQM=60	PAX3	3'UTR,intron	PAX3:NM_181457.3:3'UTR:MODIFIER:exon8/8:c.*106dupT:,PAX3:NM_181459.3:intron:MODIFIER:exon8/9:c.1420+126dupT:,PAX3:NM_001127366.2:intron:MODIFIER:exon8/8:c.1417+126dupT:,PAX3:NM_181458.3:intron:MODIFIER:exon8/8:c.1420+126dupT:,PAX3:NM_181460.3:intron:MODIFIER:exon7/8:c.1174-376dupT:,PAX3:NM_181461.3:intron:MODIFIER:exon7/7:c.1174-376dupT:		rs552778546	0.0000	0.0000	0/0/0	0.0308							606597 [PAX3 (confirmed) Waardenburg syndrome,type 1,193500|Waardenburg syndrome,type 3,148820|Craniofacial-deafness-hand syndrome,122880|Rhabdomyosarcoma 2,alveolar,268220];	RCV000310012.1 [uncertain significance]; RCV000408277.1 [uncertain significance]; 			0	62					PAX3 (inh=AR+AD pLI=0.90)
chr2	223158653	223158653	T	-	hom	hom	hom		QUAL=17030;DP=166,194,235;MQM=59	PAX3	3'UTR,intron	PAX3:NM_000438.5:3'UTR:MODIFIER:exon4/4:c.*171delA:,PAX3:NM_181459.3:intron:MODIFIER:exon4/9:c.586+233delA:,PAX3:NM_001127366.2:intron:MODIFIER:exon4/8:c.583+233delA:,PAX3:NM_181458.3:intron:MODIFIER:exon4/8:c.586+233delA:,PAX3:NM_181460.3:intron:MODIFIER:exon4/8:c.586+233delA:,PAX3:NM_181461.3:intron:MODIFIER:exon4/7:c.586+233delA:,PAX3:NM_181457.3:intron:MODIFIER:exon4/7:c.586+233delA:,PAX3:NM_013942.4:intron:MODIFIER:exon4/4:c.587-177delA:		rs397987956	1.0000	0.0000	0/0/0	0.9164							606597 [PAX3 (confirmed) Waardenburg syndrome,type 1,193500|Waardenburg syndrome,type 3,148820|Craniofacial-deafness-hand syndrome,122880|Rhabdomyosarcoma 2,alveolar,268220];				151	0					PAX3 (inh=AR+AD pLI=0.90)
chr2	223161889	223161889	A	G	hom	hom	hom		QUAL=8521;DP=55,125,131;MQM=59	PAX3	synonymous	PAX3:NM_181459.3:synonymous:LOW:exon2/10:c.129T>C:p.Gly43Gly,PAX3:NM_001127366.2:synonymous:LOW:exon2/9:c.129T>C:p.Gly43Gly,PAX3:NM_181458.3:synonymous:LOW:exon2/9:c.129T>C:p.Gly43Gly,PAX3:NM_181460.3:synonymous:LOW:exon2/9:c.129T>C:p.Gly43Gly,PAX3:NM_181461.3:synonymous:LOW:exon2/8:c.129T>C:p.Gly43Gly,PAX3:NM_181457.3:synonymous:LOW:exon2/8:c.129T>C:p.Gly43Gly,PAX3:NM_000438.5:synonymous:LOW:exon2/4:c.129T>C:p.Gly43Gly,PAX3:NM_013942.4:synonymous:LOW:exon2/5:c.129T>C:p.Gly43Gly		rs12623857	0.9044	0.8872	35371/17979/2524	0.8157							606597 [PAX3 (confirmed) Waardenburg syndrome,type 1,193500|Waardenburg syndrome,type 3,148820|Craniofacial-deafness-hand syndrome,122880|Rhabdomyosarcoma 2,alveolar,268220];	RCV000176002.3 [benign]; RCV000326158.1 [benign]; RCV000362250.1 [benign]; 			1217	323					PAX3 (inh=AR+AD pLI=0.90)
chr2	227867719	227867719	G	A	het	het	wt		QUAL=7022;DP=387,151,199;MQM=59	COL4A4	3'UTR	COL4A4:NM_000092.4:3'UTR:MODIFIER:exon48/48:c.*4322C>T:		rs1054413	0.5399	0.0000	0/0/0	0.0769							120131 [COL4A4 (confirmed) Alport syndrome,autosomal recessive,203780|Hematuria,familial benign];	RCV000346117.1 [benign]; 			34	123					COL4A4 (inh=AR pLI=0.00)
chr2	227868854	227868854	C	T	het	het	wt		QUAL=5734;DP=285,146,173;MQM=59	COL4A4	3'UTR	COL4A4:NM_000092.4:3'UTR:MODIFIER:exon48/48:c.*3187G>A:	L2c	rs56324594	0.4683	0.0000	0/0/0	0.0729							120131 [COL4A4 (confirmed) Alport syndrome,autosomal recessive,203780|Hematuria,familial benign];	RCV000351903.1 [benign]; 			33	111					COL4A4 (inh=AR pLI=0.00)
chr2	227869921	227869921	T	-	het	het	wt		QUAL=4323;DP=316,92,117;MQM=59	COL4A4	3'UTR	COL4A4:NM_000092.4:3'UTR:MODIFIER:exon48/48:c.*2120delA:		rs71821803	0.2871	0.0000	0/0/0	0.2362							120131 [COL4A4 (confirmed) Alport syndrome,autosomal recessive,203780|Hematuria,familial benign];	RCV000267226.1 [benign]; 			27	123					COL4A4 (inh=AR pLI=0.00)
chr2	227871266	227871266	-	T	het	het	wt		QUAL=4233;DP=255,180,234;MQM=59	COL4A4	3'UTR	COL4A4:NM_000092.4:3'UTR:MODIFIER:exon48/48:c.*774dupA:		rs370368184;rs59918285	0.5154	0.0000	0/0/0	0.4069							120131 [COL4A4 (confirmed) Alport syndrome,autosomal recessive,203780|Hematuria,familial benign];	RCV000393839.1 [benign]; 			33	124					COL4A4 (inh=AR pLI=0.00)
chr2	227871475	227871475	T	-	het	het	wt		QUAL=2965;DP=234,91,101;MQM=59	COL4A4	3'UTR	COL4A4:NM_000092.4:3'UTR:MODIFIER:exon48/48:c.*566delA:		rs796331910	0.4806	0.0000	0/0/0	0.2780							120131 [COL4A4 (confirmed) Alport syndrome,autosomal recessive,203780|Hematuria,familial benign];	RCV000311172.1 [benign]; 			31	126					COL4A4 (inh=AR pLI=0.00)
chr2	227872182	227872182	G	A	het	het	wt		QUAL=5371;DP=210,189,200;MQM=60	COL4A4	synonymous	COL4A4:NM_000092.4:synonymous:LOW:exon48/48:c.4932C>T:p.Phe1644Phe		rs2228557	0.5144	0.4657	13498/5686/1763	0.4423							120131 [COL4A4 (confirmed) Alport syndrome,autosomal recessive,203780|Hematuria,familial benign];	RCV000247000.1 [benign]; RCV000291655.1 [benign]; 		COSM3757991	273	784					COL4A4 (inh=AR pLI=0.00)
chr2	227872995	227872995	T	C	het	het	wt		QUAL=4275;DP=110,230,225;MQM=60	COL4A4	synonymous	COL4A4:NM_000092.4:synonymous:LOW:exon47/48:c.4548A>G:p.Val1516Val		rs2228555	0.6406	0.5602	19250/8400/2574	0.5480							120131 [COL4A4 (confirmed) Alport syndrome,autosomal recessive,203780|Hematuria,familial benign];	RCV000250409.1 [benign]; RCV000284418.1 [benign]; 		COSM3757992	412	801					COL4A4 (inh=AR pLI=0.00)
chr2	227873028	227873028	A	G	het	het	wt		QUAL=4395;DP=142,179,176;MQM=59	COL4A4	splice_region&intron	COL4A4:NM_000092.4:splice_region&intron:LOW:exon46/47:c.4523-8T>C:		rs13419076	0.5156	0.4649	13136/5504/1736	0.4514							120131 [COL4A4 (confirmed) Alport syndrome,autosomal recessive,203780|Hematuria,familial benign];	RCV000245457.1 [benign]; RCV000339277.1 [benign]; 			276	781					COL4A4 (inh=AR pLI=0.00)
chr2	227886773	227886773	A	G	het	het	wt	pred_pathogenic	QUAL=4776;DP=233,136,203;MQM=60	COL4A4	missense	COL4A4:NM_000092.4:missense:MODERATE:exon44/48:c.4207T>C:p.Ser1403Pro		rs3752895	0.5262	0.4763	14088/6128/1982	0.4637	3.4190	T,T	T	B	D,D	20.60	120131 [COL4A4 (confirmed) Alport syndrome,autosomal recessive,203780|Hematuria,familial benign];	RCV000249698.1 [benign]; RCV000407614.1 [benign]; 		COSM3757993	296	786					COL4A4 (inh=AR pLI=0.00)
chr2	227892619	227892619	C	T	het	het	wt		QUAL=4996;DP=256,69,82;MQM=60	COL4A4	synonymous	COL4A4:NM_000092.4:synonymous:LOW:exon42/48:c.4080G>A:p.Pro1360Pro		rs2228556	0.4918	0.4700	13568/6287/1395	0.4581							120131 [COL4A4 (confirmed) Alport syndrome,autosomal recessive,203780|Hematuria,familial benign];	RCV000253144.1 [benign]; RCV000329823.1 [benign]; 		COSM1752390	296	788					COL4A4 (inh=AR pLI=0.00)
chr2	227892720	227892720	C	T	het	het	wt	pred_pathogenic;anno_pathogenic_clinvar	QUAL=4077;DP=161,96,91;MQM=60	COL4A4	missense	COL4A4:NM_000092.4:missense:MODERATE:exon42/48:c.3979G>A:p.Val1327Met		rs2229813	0.4930	0.4879	12092/5508/1240	0.4507	-0.1400	T,T	T	B	D,D	14.35	120131 [COL4A4 (confirmed) Alport syndrome,autosomal recessive,203780|Hematuria,familial benign];	RCV000171504.1 [likely pathogenic]; RCV000246048.1 [benign]; RCV000271269.1 [benign]; 		COSM1752392	298	788	1	[1] harmuth 03.04.2017			COL4A4 (inh=AR pLI=0.00)
chr2	227896652	227896652	C	G	het	het	wt		QUAL=6928;DP=322,185,270;MQM=60	COL4A4	splice_region&intron	COL4A4:NM_000092.4:splice_region&intron:LOW:exon40/47:c.3817+9G>C:		rs13423714	0.4960	0.4801	13242/6080/1363	0.4545							120131 [COL4A4 (confirmed) Alport syndrome,autosomal recessive,203780|Hematuria,familial benign];	RCV000249465.1 [benign]; RCV000326292.1 [benign]; 			300	785					COL4A4 (inh=AR pLI=0.00)
chr2	227896886	227896886	C	T	het	het	wt		QUAL=3595;DP=210,97,165;MQM=60	COL4A4	synonymous	COL4A4:NM_000092.4:synonymous:LOW:exon39/48:c.3684G>A:p.Lys1228Lys		rs2229812	0.4956	0.4716	13744/6323/1371	0.4591							120131 [COL4A4 (confirmed) Alport syndrome,autosomal recessive,203780|Hematuria,familial benign];	RCV000244180.1 [benign]; RCV000286046.1 [benign]; 		COSM3757994	299	786					COL4A4 (inh=AR pLI=0.00)
chr2	227896976	227896976	C	T	het	het	wt		QUAL=3707;DP=294,42,72;MQM=59	COL4A4	synonymous	COL4A4:NM_000092.4:synonymous:LOW:exon39/48:c.3594G>A:p.Gly1198Gly		rs10203363	0.4950	0.4746	13401/6131/1351	0.4579							120131 [COL4A4 (confirmed) Alport syndrome,autosomal recessive,203780|Hematuria,familial benign];	RCV000252184.1 [benign]; RCV000322357.1 [benign]; 		COSM3757995	299	787					COL4A4 (inh=AR pLI=0.00)
chr2	227915832	227915832	G	A	het	het	wt	pred_pathogenic	QUAL=8110;DP=316,266,384;MQM=60	COL4A4	missense	COL4A4:NM_000092.4:missense:MODERATE:exon33/48:c.3011C>T:p.Pro1004Leu		rs1800517	0.5473	0.5205	16667/7960/1561	0.5061	4.3580	D,D	T	B	D,D	20.90	120131 [COL4A4 (confirmed) Alport syndrome,autosomal recessive,203780|Hematuria,familial benign];	RCV000251893.1 [benign]; RCV000389933.1 [benign]; 		COSM4001525	398	794					COL4A4 (inh=AR pLI=0.00)
chr2	227954599	227954599	G	A	het	het	wt	pred_pathogenic	QUAL=2729;DP=140,112,152;MQM=60	COL4A4	missense	COL4A4:NM_000092.4:missense:MODERATE:exon21/48:c.1444C>T:p.Pro482Ser		rs2229814	0.5485	0.5344	17676/8236/1270	0.5246	0.6240	T,T	T	B	D,D	1.22	120131 [COL4A4 (confirmed) Alport syndrome,autosomal recessive,203780|Hematuria,familial benign];	RCV000248568.1 [benign]; RCV000299491.1 [benign]; 		COSM3757996	399	797					COL4A4 (inh=AR pLI=0.00)
chr2	228102723	228102723	G	C	wt	wt	het	pred_pathogenic	QUAL=3557;DP=301,218,301;MQM=60	COL4A3,LOC654841	missense,sequence_feature,intron	COL4A3:NM_000091.4:missense:MODERATE:exon2/52:c.127G>C:p.Gly43Arg,COL4A3:NM_000091.4:sequence_feature:LOW:exon2/52:c.127G>C:,LOC654841:NR_102371.1:intron:MODIFIER:exon10/13:n.1681+79C>G:		rs13424243	0.2302	0.2884	5825/4456/489	0.2760	1.2450	D,D,D,D,D	T	D,P,D,D	D	24.50	120070 [COL4A3 (confirmed) Alport syndrome,autosomal recessive,203780|Hematuria,benign familial,141200|Alport syndrome,autosomal dominant,104200];	RCV000253119.1 [benign]; RCV000283989.1 [benign]; 		COSM3757997, COSM3757998	137	660					COL4A3 (inh=AR+AD pLI=0.00), LOC654841 (inh=n/a pLI=n/a)
chr2	228111435	228111435	T	C	het	het	het	pred_pathogenic	QUAL=8339;DP=297,124,180;MQM=60	COL4A3,LOC654841	missense,intron	COL4A3:NM_000091.4:missense:MODERATE:exon7/52:c.422T>C:p.Leu141Pro,LOC654841:NR_102371.1:intron:MODIFIER:exon9/13:n.1593-8545A>G:		rs10178458	0.7967	0.8302	41833/23030/1954	0.8190	0.3960	T,T,T,T,T	T	B,B,B,B	D	0.04	120070 [COL4A3 (confirmed) Alport syndrome,autosomal recessive,203780|Hematuria,benign familial,141200|Alport syndrome,autosomal dominant,104200];	RCV000245465.1 [benign]; RCV000399711.1 [benign]; 			1061	444					COL4A3 (inh=AR+AD pLI=0.00), LOC654841 (inh=n/a pLI=n/a)
chr2	228113175	228113175	A	G	het	het	het	pred_pathogenic	QUAL=8519;DP=342,115,181;MQM=59	COL4A3,LOC654841	missense,intron	COL4A3:NM_000091.4:missense:MODERATE:exon9/52:c.485A>G:p.Glu162Gly,LOC654841:NR_102371.1:intron:MODIFIER:exon9/13:n.1593-10285T>C:		rs6436669	0.7963	0.8304	41904/23062/1956	0.8204	0.2100	T,T,T,T,T	T	B,B,B,B	D	9.66	120070 [COL4A3 (confirmed) Alport syndrome,autosomal recessive,203780|Hematuria,benign familial,141200|Alport syndrome,autosomal dominant,104200];	RCV000242416.1 [benign]; RCV000295878.1 [benign]; 			1062	444					COL4A3 (inh=AR+AD pLI=0.00), LOC654841 (inh=n/a pLI=n/a)
chr2	228128540	228128540	C	T	hom	hom	hom		QUAL=9947;DP=147,70,102;MQM=59	COL4A3,LOC654841	synonymous,intron	COL4A3:NM_000091.4:synonymous:LOW:exon21/52:c.1195C>T:p.Leu399Leu,LOC654841:NR_102371.1:intron:MODIFIER:exon8/13:n.1486+845G>A:		rs10205042	0.7676	0.7667	35528/17828/2160	0.7528							120070 [COL4A3 (confirmed) Alport syndrome,autosomal recessive,203780|Hematuria,benign familial,141200|Alport syndrome,autosomal dominant,104200];	RCV000245175.1 [benign]; RCV000363958.1 [benign]; 			802	603					COL4A3 (inh=AR+AD pLI=0.00), LOC654841 (inh=n/a pLI=n/a)
chr2	228135631	228135631	C	T	hom	hom	het	pred_pathogenic	QUAL=9723;DP=193,76,103;MQM=59	COL4A3,LOC654841	missense,intron	COL4A3:NM_000091.4:missense:MODERATE:exon25/52:c.1721C>T:p.Pro574Leu,LOC654841:NR_102371.1:intron:MODIFIER:exon4/13:n.423-2146G>A:		rs28381984	0.4000	0.4694	13946/7735/189	0.4616	2.1930	D,D,D,D,D	T	D,D,D,D	D	26.10	120070 [COL4A3 (confirmed) Alport syndrome,autosomal recessive,203780|Hematuria,benign familial,141200|Alport syndrome,autosomal dominant,104200];	RCV000247531.1 [benign]; RCV000296144.1 [benign]; 		COSM3758002, COSM3758001	340	735					COL4A3 (inh=AR+AD pLI=0.00), LOC654841 (inh=n/a pLI=n/a)
chr2	228147093	228147093	A	G	het	wt	het	pred_pathogenic	QUAL=3605;DP=245,71,77;MQM=60	COL4A3,LOC654841	missense,intron	COL4A3:NM_000091.4:missense:MODERATE:exon32/52:c.2501A>G:p.Lys834Arg,LOC654841:NR_102371.1:intron:MODIFIER:exon2/13:n.244-588T>C:		rs56226424	0.0056	0.0124	15/13/0	0.0122	-0.2720	T,T,T,T,T	T	B,B,B,B	D	0.14	120070 [COL4A3 (confirmed) Alport syndrome,autosomal recessive,203780|Hematuria,benign familial,141200|Alport syndrome,autosomal dominant,104200];	RCV000244722.1 [benign]; 			1	41					COL4A3 (inh=AR+AD pLI=0.00), LOC654841 (inh=n/a pLI=n/a)
chr2	228176901	228176901	A	C	hom	hom	hom		QUAL=38934;DP=587,241,346;MQM=60	COL4A3,LOC654841	3'UTR,intron	COL4A3:NM_000091.4:3'UTR:MODIFIER:exon52/52:c.*315A>C:,LOC654841:NR_102371.1:intron:MODIFIER:exon1/13:n.48-6530T>G:		rs2070735	0.7290	0.0000	0/0/0	0.1634							120070 [COL4A3 (confirmed) Alport syndrome,autosomal recessive,203780|Hematuria,benign familial,141200|Alport syndrome,autosomal dominant,104200];	RCV000271870.1 [benign]; 			169	54					COL4A3 (inh=AR+AD pLI=0.00), LOC654841 (inh=n/a pLI=n/a)
chr2	228177479	228177479	C	T	hom	hom	hom		QUAL=27975;DP=416,179,254;MQM=60	COL4A3,LOC654841	3'UTR,intron	COL4A3:NM_000091.4:3'UTR:MODIFIER:exon52/52:c.*893C>T:,LOC654841:NR_102371.1:intron:MODIFIER:exon1/13:n.48-7108G>A:		rs7587228	0.8476	0.0000	0/0/0	0.1507							120070 [COL4A3 (confirmed) Alport syndrome,autosomal recessive,203780|Hematuria,benign familial,141200|Alport syndrome,autosomal dominant,104200];	RCV000318374.1 [benign]; 			183	44					COL4A3 (inh=AR+AD pLI=0.00), LOC654841 (inh=n/a pLI=n/a)
chr2	228177567	228177567	C	T	wt	wt	het		QUAL=2773;DP=356,171,223;MQM=60	COL4A3,LOC654841	3'UTR,intron	COL4A3:NM_000091.4:3'UTR:MODIFIER:exon52/52:c.*981C>T:,LOC654841:NR_102371.1:intron:MODIFIER:exon1/13:n.48-7196G>A:		rs1134745	0.1560	0.0000	0/0/0	0.0297							120070 [COL4A3 (confirmed) Alport syndrome,autosomal recessive,203780|Hematuria,benign familial,141200|Alport syndrome,autosomal dominant,104200];	RCV000375376.1 [likely benign]; 			4	69					COL4A3 (inh=AR+AD pLI=0.00), LOC654841 (inh=n/a pLI=n/a)
chr2	228177643	228177643	A	-	wt	het	het		QUAL=1331;DP=172,99,127;MQM=59	COL4A3,LOC654841	3'UTR,intron	COL4A3:NM_000091.4:3'UTR:MODIFIER:exon52/52:c.*1070delA:,LOC654841:NR_102371.1:intron:MODIFIER:exon1/13:n.48-7272delT:		rs11297279	0.0000	0.0000	0/0/0	0.0443							120070 [COL4A3 (confirmed) Alport syndrome,autosomal recessive,203780|Hematuria,benign familial,141200|Alport syndrome,autosomal dominant,104200];	RCV000348686.1 [uncertain significance]; 			24	145					COL4A3 (inh=AR+AD pLI=0.00), LOC654841 (inh=n/a pLI=n/a)
chr2	228177751	228177751	G	A	hom	hom	het		QUAL=24343;DP=462,195,253;MQM=60	COL4A3,LOC654841	3'UTR,intron	COL4A3:NM_000091.4:3'UTR:MODIFIER:exon52/52:c.*1165G>A:,LOC654841:NR_102371.1:intron:MODIFIER:exon1/13:n.48-7380C>T:		rs28554165	0.2690	0.0000	0/0/0	0.0553							120070 [COL4A3 (confirmed) Alport syndrome,autosomal recessive,203780|Hematuria,benign familial,141200|Alport syndrome,autosomal dominant,104200];	RCV000365583.1 [benign]; 			33	100					COL4A3 (inh=AR+AD pLI=0.00), LOC654841 (inh=n/a pLI=n/a)
chr2	228177825	228177825	C	G	hom	hom	hom		QUAL=28548;DP=414,189,253;MQM=60	COL4A3,LOC654841	3'UTR,intron	COL4A3:NM_000091.4:3'UTR:MODIFIER:exon52/52:c.*1239C>G:,LOC654841:NR_102371.1:intron:MODIFIER:exon1/13:n.48-7454G>C:	L2d	rs10188531	0.9161	0.0000	0/0/0	0.1569							120070 [COL4A3 (confirmed) Alport syndrome,autosomal recessive,203780|Hematuria,benign familial,141200|Alport syndrome,autosomal dominant,104200];	RCV000392111.1 [benign]; 			190	34					COL4A3 (inh=AR+AD pLI=0.00), LOC654841 (inh=n/a pLI=n/a)
chr2	228178645	228178645	C	G	hom	hom	hom		QUAL=19235;DP=304,118,166;MQM=59	COL4A3,LOC654841	3'UTR,intron	COL4A3:NM_000091.4:3'UTR:MODIFIER:exon52/52:c.*2059C>G:,LOC654841:NR_102371.1:intron:MODIFIER:exon1/13:n.48-8274G>C:	MER5A	rs4290648	0.9161	0.0000	0/0/0	0.1807							120070 [COL4A3 (confirmed) Alport syndrome,autosomal recessive,203780|Hematuria,benign familial,141200|Alport syndrome,autosomal dominant,104200];	RCV000372136.1 [benign]; 			164	32					COL4A3 (inh=AR+AD pLI=0.00), LOC654841 (inh=n/a pLI=n/a)
chr2	228178780	228178780	A	C	hom	hom	hom		QUAL=18546;DP=321,109,126;MQM=59	COL4A3,LOC654841	3'UTR,intron	COL4A3:NM_000091.4:3'UTR:MODIFIER:exon52/52:c.*2194A>C:,LOC654841:NR_102371.1:intron:MODIFIER:exon1/13:n.48-8409T>G:		rs7567291	1.0000	0.0000	0/0/0	0.1498							120070 [COL4A3 (confirmed) Alport syndrome,autosomal recessive,203780|Hematuria,benign familial,141200|Alport syndrome,autosomal dominant,104200];	RCV000292828.1 [benign]; 			230	0					COL4A3 (inh=AR+AD pLI=0.00), LOC654841 (inh=n/a pLI=n/a)
chr2	228179038	228179038	T	C	wt	wt	het		QUAL=3020;DP=307,172,218;MQM=60	COL4A3,LOC654841	3'UTR,intron	COL4A3:NM_000091.4:3'UTR:MODIFIER:exon52/52:c.*2452T>C:,LOC654841:NR_102371.1:intron:MODIFIER:exon1/13:n.48-8667A>G:		rs4470338	0.1546	0.0000	0/0/0	0.0297							120070 [COL4A3 (confirmed) Alport syndrome,autosomal recessive,203780|Hematuria,benign familial,141200|Alport syndrome,autosomal dominant,104200];	RCV000344501.1 [likely benign]; 			4	69					COL4A3 (inh=AR+AD pLI=0.00), LOC654841 (inh=n/a pLI=n/a)
chr2	231036866	231036866	G	A	wt	wt	het		QUAL=4000;DP=328,248,296;MQM=60	SP110	synonymous	SP110:NM_080424.2:synonymous:LOW:exon16/19:c.1731C>T:p.Cys577Cys,SP110:NM_004509.3:synonymous:LOW:exon16/18:c.1731C>T:p.Cys577Cys		rs13018234	0.0681	0.0970	681/514/46	0.0955							604457 [SP110 (confirmed) Hepatic venoocclusive disease with immunodeficiency,235550|Mycobacterium tuberculosis,susceptibility to,607948];	RCV000311701.1 [likely benign]; 			23	276					SP110 (inh=AR pLI=0.00)
chr2	231042276	231042276	A	G	wt	wt	het		QUAL=2738;DP=252,211,215;MQM=59	SP110	missense	SP110:NM_080424.2:missense:MODERATE:exon14/19:c.1568T>C:p.Met523Thr,SP110:NM_004509.3:missense:MODERATE:exon14/18:c.1568T>C:p.Met523Thr,SP110:NM_004510.3:missense:MODERATE:exon14/15:c.1568T>C:p.Met523Thr,SP110:NM_001185015.1:missense:MODERATE:exon15/16:c.1586T>C:p.Met529Thr		rs1135791	0.3249	0.4256	12009/8955/306	0.4093	-0.5270	T,T,T,T,T,T	T	B,B,B,B,B	T,T,T,T,T,T	0.03	604457 [SP110 (confirmed) Hepatic venoocclusive disease with immunodeficiency,235550|Mycobacterium tuberculosis,susceptibility to,607948];	RCV000362881.1 [benign]; 		COSM3758010, COSM3758011	388	749					SP110 (inh=AR pLI=0.00)
chr2	231050715	231050715	A	G	hom	hom	hom		QUAL=23133;DP=228,206,294;MQM=59	SP110	missense	SP110:NM_080424.2:missense:MODERATE:exon11/19:c.1274T>C:p.Leu425Ser,SP110:NM_004509.3:missense:MODERATE:exon11/18:c.1274T>C:p.Leu425Ser,SP110:NM_004510.3:missense:MODERATE:exon11/15:c.1274T>C:p.Leu425Ser,SP110:NM_001185015.1:missense:MODERATE:exon12/16:c.1292T>C:p.Leu431Ser		rs3948464	0.9040	0.8869	47894/25126/3764	0.8654	-0.3640	T,T,T,T,T,T	T	B,B,B,B,B	T,T,T,T,T,T	0.01	604457 [SP110 (confirmed) Hepatic venoocclusive disease with immunodeficiency,235550|Mycobacterium tuberculosis,susceptibility to,607948];	RCV000005877.5 [uncertain significance]; 	CM066604 [CLASS=DP MUT=REF PHEN="Tuberculosis reduced susceptibility association with" GENE=SP110]; 		1222	312					SP110 (inh=AR pLI=0.00)
chr2	231072709	231072709	C	T	hom	hom	hom		QUAL=20466;DP=315,137,163;MQM=60	SP110	missense	SP110:NM_080424.2:missense:MODERATE:exon8/19:c.895G>A:p.Gly299Arg,SP110:NM_004509.3:missense:MODERATE:exon8/18:c.895G>A:p.Gly299Arg,SP110:NM_004510.3:missense:MODERATE:exon8/15:c.895G>A:p.Gly299Arg,SP110:NM_001185015.1:missense:MODERATE:exon9/16:c.913G>A:p.Gly305Arg		rs1365776	0.8025	0.7087	24440/9224/3778	0.6518	-0.2260	T,T,T,T,T,T	T	B,B,B,B	T,T,T,T,T,T	18.52	604457 [SP110 (confirmed) Hepatic venoocclusive disease with immunodeficiency,235550|Mycobacterium tuberculosis,susceptibility to,607948];	RCV000335389.1 [benign]; 			655	690					SP110 (inh=AR pLI=0.00)
chr2	231077110	231077110	C	T	het	wt	het		QUAL=7696;DP=295,346,398;MQM=60	SP110	missense	SP110:NM_080424.2:missense:MODERATE:exon5/19:c.619G>A:p.Glu207Lys,SP110:NM_004509.3:missense:MODERATE:exon5/18:c.619G>A:p.Glu207Lys,SP110:NM_004510.3:missense:MODERATE:exon5/15:c.619G>A:p.Glu207Lys,SP110:NM_001185015.1:missense:MODERATE:exon6/16:c.637G>A:p.Glu213Lys		rs9061	0.1306	0.1142	1025/327/31	0.1102	-0.4510	T,T,T,T,T,T	T	B,B,B,B	T,T,T,T,T,T	11.56	604457 [SP110 (confirmed) Hepatic venoocclusive disease with immunodeficiency,235550|Mycobacterium tuberculosis,susceptibility to,607948];	RCV000350537.1 [benign]; 	CM131316 [CLASS=DP MUT=ALT PHEN="Pulmonary tuberculosis association with" GENE=SP110]; 	COSM149088, COSM3927760	35	336					SP110 (inh=AR pLI=0.00)
chr2	231077112	231077112	G	A	het	hom	wt	pred_pathogenic	QUAL=14747;DP=288,344,399;MQM=60	SP110	missense	SP110:NM_080424.2:missense:MODERATE:exon5/19:c.617C>T:p.Ala206Val,SP110:NM_004509.3:missense:MODERATE:exon5/18:c.617C>T:p.Ala206Val,SP110:NM_004510.3:missense:MODERATE:exon5/15:c.617C>T:p.Ala206Val,SP110:NM_001185015.1:missense:MODERATE:exon6/16:c.635C>T:p.Ala212Val		rs28930679	0.1591	0.2108	2792/1894/113	0.2071	-0.0850	D,D,T,T,T,D,D	T	B,B,B,B	T,T,T,T,T,T,T	5.33	604457 [SP110 (confirmed) Hepatic venoocclusive disease with immunodeficiency,235550|Mycobacterium tuberculosis,susceptibility to,607948];	RCV000293290.1 [benign]; 			109	579					SP110 (inh=AR pLI=0.00)
chr2	231077154	231077154	G	A	het	hom	wt		QUAL=11549;DP=203,281,335;MQM=60	SP110	splice_region&intron	SP110:NM_080424.2:splice_region&intron:LOW:exon4/18:c.584-9C>T:,SP110:NM_004509.3:splice_region&intron:LOW:exon4/17:c.584-9C>T:,SP110:NM_004510.3:splice_region&intron:LOW:exon4/14:c.584-9C>T:,SP110:NM_001185015.1:splice_region&intron:LOW:exon5/15:c.602-9C>T:		rs41309096	0.2288	0.2379	3534/2034/619	0.2367							604457 [SP110 (confirmed) Hepatic venoocclusive disease with immunodeficiency,235550|Mycobacterium tuberculosis,susceptibility to,607948];	RCV000315466.1 [benign]; 			129	602					SP110 (inh=AR pLI=0.00)
chr2	231077676	231077676	G	A	het	wt	het	pred_pathogenic	QUAL=2165;DP=45,93,125;MQM=60	SP110	missense	SP110:NM_080424.2:missense:MODERATE:exon4/19:c.383C>T:p.Ala128Val,SP110:NM_004509.3:missense:MODERATE:exon4/18:c.383C>T:p.Ala128Val,SP110:NM_004510.3:missense:MODERATE:exon4/15:c.383C>T:p.Ala128Val,SP110:NM_001185015.1:missense:MODERATE:exon5/16:c.401C>T:p.Ala134Val		rs11556887	0.0966	0.1040	924/350/5	0.1003	0.1220	T,T,D,D,D,D,D	T	B,B,P,D	T,T,T,T,T,T,T	15.74	604457 [SP110 (confirmed) Hepatic venoocclusive disease with immunodeficiency,235550|Mycobacterium tuberculosis,susceptibility to,607948];	RCV000264680.1 [benign]; 		COSM149089, COSM3927761	34	329					SP110 (inh=AR pLI=0.00)
chr2	231077725	231077725	A	G	hom	hom	hom		QUAL=7981;DP=116,62,85;MQM=60	SP110	missense	SP110:NM_080424.2:missense:MODERATE:exon4/19:c.334T>C:p.Trp112Arg,SP110:NM_004509.3:missense:MODERATE:exon4/18:c.334T>C:p.Trp112Arg,SP110:NM_004510.3:missense:MODERATE:exon4/15:c.334T>C:p.Trp112Arg,SP110:NM_001185015.1:missense:MODERATE:exon5/16:c.352T>C:p.Trp118Arg		rs1129411	0.9511	0.9091	50293/25799/4991	0.8871	-0.1940	T,T,T,T,T,T,T	T	B,B,B,B	T,T,T,T,T,T,T	0.07	604457 [SP110 (confirmed) Hepatic venoocclusive disease with immunodeficiency,235550|Mycobacterium tuberculosis,susceptibility to,607948];				1277	256					SP110 (inh=AR pLI=0.00)
chr2	233390937	233390937	A	G	hom	het	hom	low_DP	QUAL=473;DP=4,6,11;MQM=60	CHRND	synonymous,5'UTR	CHRND:NM_000751.2:synonymous:LOW:exon1/12:c.12A>G:p.Pro4Pro,CHRND:NM_001256657.1:synonymous:LOW:exon1/11:c.12A>G:p.Pro4Pro,CHRND:NM_001311195.1:5'UTR:MODIFIER:exon1/10:c.-260A>G:,CHRND:NM_001311196.1:5'UTR:MODIFIER:exon1/12:c.-260A>G:		rs2245601	0.4834	0.5010	15364/7802/728	0.4877							100720 [CHRND (confirmed) Myasthenic syndrome,congenital,3A,slow-channel,616321|Myasthenic syndrome,congenital,3B,fast-channel,616322|Myasthenic syndrome,congenital,3C,associated with acetylcholine receptor deficiency,616323|Multiple pterygium syndrome,lethal type,253290];	RCV000116730.3 [benign]; RCV000306623.1 [benign]; RCV000395212.1 [benign]; 		COSM149097	360	753					CHRND (inh=AR pLI=0.00)
chr2	233400074	233400074	A	G	het	het	het		QUAL=6324;DP=166,172,185;MQM=60	CHRND	3'UTR	CHRND:NM_000751.2:3'UTR:MODIFIER:exon12/12:c.*52A>G:,CHRND:NM_001256657.1:3'UTR:MODIFIER:exon11/11:c.*52A>G:,CHRND:NM_001311195.1:3'UTR:MODIFIER:exon10/10:c.*52A>G:,CHRND:NM_001311196.1:3'UTR:MODIFIER:exon12/12:c.*52A>G:		rs2767	0.4159	0.4119	10267/4146/388	0.3937							100720 [CHRND (confirmed) Myasthenic syndrome,congenital,3A,slow-channel,616321|Myasthenic syndrome,congenital,3B,fast-channel,616322|Myasthenic syndrome,congenital,3C,associated with acetylcholine receptor deficiency,616323|Multiple pterygium syndrome,lethal type,253290];	RCV000277975.1 [other]; RCV000319987.1 [benign]; 			203	625					CHRND (inh=AR pLI=0.00)
chr2	233400907	233400907	T	C	het	het	het		QUAL=9011;DP=271,184,238;MQM=59	CHRND	3'UTR	CHRND:NM_000751.2:3'UTR:MODIFIER:exon12/12:c.*885T>C:,CHRND:NM_001256657.1:3'UTR:MODIFIER:exon11/11:c.*885T>C:,CHRND:NM_001311195.1:3'UTR:MODIFIER:exon10/10:c.*885T>C:,CHRND:NM_001311196.1:3'UTR:MODIFIER:exon12/12:c.*885T>C:	MLT1F	rs1004175	0.4159	0.4124	941/173/11	0.1016							100720 [CHRND (confirmed) Myasthenic syndrome,congenital,3A,slow-channel,616321|Myasthenic syndrome,congenital,3B,fast-channel,616322|Myasthenic syndrome,congenital,3C,associated with acetylcholine receptor deficiency,616323|Multiple pterygium syndrome,lethal type,253290];	RCV000261184.1 [benign]; RCV000329395.1 [other]; 			74	273					CHRND (inh=AR pLI=0.00)
chr2	233401047	233401047	A	G	wt	wt	het		QUAL=4519;DP=470,263,345;MQM=60	CHRND	3'UTR	CHRND:NM_000751.2:3'UTR:MODIFIER:exon12/12:c.*1025A>G:,CHRND:NM_001256657.1:3'UTR:MODIFIER:exon11/11:c.*1025A>G:,CHRND:NM_001311195.1:3'UTR:MODIFIER:exon10/10:c.*1025A>G:,CHRND:NM_001311196.1:3'UTR:MODIFIER:exon12/12:c.*1025A>G:	MLT1F	rs115132742	0.0152	0.0244	7/5/0	0.0065							100720 [CHRND (confirmed) Myasthenic syndrome,congenital,3A,slow-channel,616321|Myasthenic syndrome,congenital,3B,fast-channel,616322|Myasthenic syndrome,congenital,3C,associated with acetylcholine receptor deficiency,616323|Multiple pterygium syndrome,lethal type,253290];	RCV000266518.1 [likely benign]; RCV000321601.1 [likely benign]; 			1	48					CHRND (inh=AR pLI=0.00)
chr2	233411039	233411039	A	T	het	wt	wt	low_QUAL	QUAL=7;DP=158,61,93;MQM=58	CHRNG-TIGD1	intergenic_region	CHRNG-TIGD1:CHRNG-TIGD1:intergenic_region:MODIFIER::n.233411039A>T:	(T)n		0.0000	0.0000	0/0/0	0.0021							100730 [CHRNG (confirmed) Escobar syndrome,265000|Multiple pterygium syndrome,lethal type,253290];				0	4					CHRNG-TIGD1 (inh=n/a pLI=n/a)
chr2	238232752	238232752	C	A	het	hom	het		QUAL=2699;DP=98,41,52;MQM=59	COL6A3	3'UTR	COL6A3:NM_004369.3:3'UTR:MODIFIER:exon44/44:c.*665G>T:,COL6A3:NM_057166.4:3'UTR:MODIFIER:exon41/41:c.*665G>T:,COL6A3:NM_057167.3:3'UTR:MODIFIER:exon43/43:c.*665G>T:		rs1050785	0.6879	0.0000	0/0/0	0.5273							120250 [COL6A3 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090|Dystonia 27,616411];	RCV000329533.1 [benign]; 			68	117					COL6A3 (inh=AR+AD pLI=0.00)
chr2	238232811	238232811	T	A	het	het	wt		QUAL=4343;DP=273,92,111;MQM=60	COL6A3	3'UTR	COL6A3:NM_004369.3:3'UTR:MODIFIER:exon44/44:c.*606A>T:,COL6A3:NM_057166.4:3'UTR:MODIFIER:exon41/41:c.*606A>T:,COL6A3:NM_057167.3:3'UTR:MODIFIER:exon43/43:c.*606A>T:		rs7436	0.1556	0.0000	0/0/0	0.0190							120250 [COL6A3 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090|Dystonia 27,616411];	RCV000275535.1 [benign]; 			2	41					COL6A3 (inh=AR+AD pLI=0.00)
chr2	238233410	238233410	C	G	het	het	wt		QUAL=7207;DP=362,264,541;MQM=60	COL6A3	3'UTR	COL6A3:NM_004369.3:3'UTR:MODIFIER:exon44/44:c.*7G>C:,COL6A3:NM_057166.4:3'UTR:MODIFIER:exon41/41:c.*7G>C:,COL6A3:NM_057167.3:3'UTR:MODIFIER:exon43/43:c.*7G>C:		rs4663722	0.2099	0.1415	1487/343/291	0.1389							120250 [COL6A3 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090|Dystonia 27,616411];	RCV000080905.6 [benign]; RCV000372374.1 [benign]; 			30	323					COL6A3 (inh=AR+AD pLI=0.00)
chr2	238234285	238234285	A	G	wt	wt	het		QUAL=4310;DP=340,248,326;MQM=60	COL6A3	sequence_feature,synonymous	COL6A3:NM_004369.3:sequence_feature:MODERATE:exon43/44:c.9411T>C:,COL6A3:NM_057166.4:sequence_feature:MODERATE:exon40/41:c.7590T>C:,COL6A3:NM_004369.3:synonymous:LOW:exon43/44:c.9411T>C:p.Cys3137Cys,COL6A3:NM_057166.4:synonymous:LOW:exon40/41:c.7590T>C:p.Cys2530Cys,COL6A3:NM_057167.3:synonymous:LOW:exon42/43:c.8793T>C:p.Cys2931Cys		rs112290343	0.0104	0.0127	14/11/0	0.0135							120250 [COL6A3 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090|Dystonia 27,616411];	RCV000081026.6 [other]; RCV000404714.1 [likely benign]; 			1	41					COL6A3 (inh=AR+AD pLI=0.00)
chr2	238243285	238243285	G	A	het	het	wt		QUAL=3491;DP=173,106,139;MQM=60	COL6A3	synonymous	COL6A3:NM_004369.3:synonymous:LOW:exon41/44:c.9213C>T:p.His3071His,COL6A3:NM_057166.4:synonymous:LOW:exon38/41:c.7392C>T:p.His2464His,COL6A3:NM_057167.3:synonymous:LOW:exon40/43:c.8595C>T:p.His2865His		rs2270671	0.1004	0.1055	706/372/43	0.1024							120250 [COL6A3 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090|Dystonia 27,616411];	RCV000081024.8 [other]; RCV000306390.1 [benign]; 			25	342					COL6A3 (inh=AR+AD pLI=0.00)
chr2	238243292	238243292	G	A	wt	wt	het		QUAL=1775;DP=157,115,150;MQM=60	COL6A3	missense	COL6A3:NM_004369.3:missense:MODERATE:exon41/44:c.9206C>T:p.Thr3069Ile,COL6A3:NM_057166.4:missense:MODERATE:exon38/41:c.7385C>T:p.Thr2462Ile,COL6A3:NM_057167.3:missense:MODERATE:exon40/43:c.8588C>T:p.Thr2863Ile		rs1131296	0.3462	0.3884	9340/5478/412	0.3811	0.6030	T,T,T,T,T,T	T	B,B,B	T,T,T,T,T,T	15.24	120250 [COL6A3 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090|Dystonia 27,616411];	RCV000081023.6 [benign]; RCV000365788.1 [benign]; 	CM151273 [CLASS=R MUT=ALT PHEN="Neuromuscular disorder" GENE=COL6A3]; 	COSM4001575	244	734					COL6A3 (inh=AR+AD pLI=0.00)
chr2	238243464	238243464	C	G	hom	hom	hom	pred_pathogenic	QUAL=17044;DP=202,167,189;MQM=59	COL6A3	missense	COL6A3:NM_004369.3:missense:MODERATE:exon41/44:c.9034G>C:p.Ala3012Pro,COL6A3:NM_057166.4:missense:MODERATE:exon38/41:c.7213G>C:p.Ala2405Pro,COL6A3:NM_057167.3:missense:MODERATE:exon40/43:c.8416G>C:p.Ala2806Pro		rs2270669	0.7923	0.7729	36619/20313/4735	0.7657	5.5020	T,T,T,T,T,T	T	B,B,B	T,T,T,T,T,T	21.50	120250 [COL6A3 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090|Dystonia 27,616411];	RCV000081019.6 [benign]; RCV000261014.1 [benign]; 	CM151272 [CLASS=R MUT=ALT PHEN="Neuromuscular disorder" GENE=COL6A3]; 		945	554	2	[2] Ute Grasshoff 24.11.2015			COL6A3 (inh=AR+AD pLI=0.00)
chr2	238244963	238244963	A	G	het	het	het	pred_pathogenic	QUAL=7758;DP=200,185,257;MQM=59	COL6A3	missense	COL6A3:NM_004369.3:missense:MODERATE:exon40/44:c.8780T>C:p.Met2927Thr,COL6A3:NM_057166.4:missense:MODERATE:exon37/41:c.6959T>C:p.Met2320Thr,COL6A3:NM_057167.3:missense:MODERATE:exon39/43:c.8162T>C:p.Met2721Thr		rs6728818	0.6366	0.6386	25150/14679/3160	0.6330	1.7470	T,T,T,T,T,T	T	B,B,B	D,D,D,D,D,D	3.84	120250 [COL6A3 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090|Dystonia 27,616411];	RCV000081013.7 [benign]; RCV000382239.1 [benign]; 	CM151271 [CLASS=R MUT=ALT PHEN="Neuromuscular disorder" GENE=COL6A3]; 		678	711	2	[2] Ute Grasshoff 24.11.2015			COL6A3 (inh=AR+AD pLI=0.00)
chr2	238247734	238247734	C	G	het	het	het	pred_pathogenic	QUAL=2127;DP=166,64,84;MQM=60	COL6A3	missense	COL6A3:NM_004369.3:missense:MODERATE:exon39/44:c.8491G>C:p.Asp2831His,COL6A3:NM_057166.4:missense:MODERATE:exon36/41:c.6670G>C:p.Asp2224His,COL6A3:NM_057167.3:missense:MODERATE:exon38/43:c.7873G>C:p.Asp2625His		rs36104025	0.0325	0.0673	354/278/6	0.0616	5.4160	D,D,D,D,D,D	T	D,D,D	D,D,D,D,D,D	22.90	120250 [COL6A3 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090|Dystonia 27,616411];	RCV000081011.6 [benign]; RCV000297122.1 [benign]; 			8	242					COL6A3 (inh=AR+AD pLI=0.00)
chr2	238249630	238249630	C	T	wt	wt	het		QUAL=4572;DP=303,293,351;MQM=60	COL6A3	synonymous	COL6A3:NM_004369.3:synonymous:LOW:exon38/44:c.7929G>A:p.Ala2643Ala,COL6A3:NM_057166.4:synonymous:LOW:exon35/41:c.6108G>A:p.Ala2036Ala,COL6A3:NM_057167.3:synonymous:LOW:exon37/43:c.7311G>A:p.Ala2437Ala		rs4433949	0.3425	0.3987	10026/6131/341	0.3951							120250 [COL6A3 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090|Dystonia 27,616411];	RCV000081003.6 [benign]; RCV000300148.1 [benign]; 		COSM3758061	263	752					COL6A3 (inh=AR+AD pLI=0.00)
chr2	238253065	238253065	C	T	het	het	het		QUAL=12004;DP=263,339,467;MQM=60	COL6A3	synonymous	COL6A3:NM_004369.3:synonymous:LOW:exon36/44:c.7596G>A:p.Lys2532Lys,COL6A3:NM_057166.4:synonymous:LOW:exon33/41:c.5775G>A:p.Lys1925Lys,COL6A3:NM_057167.3:synonymous:LOW:exon35/43:c.6978G>A:p.Lys2326Lys		rs2291795	0.1548	0.1292	1110/416/144	0.1219							120250 [COL6A3 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090|Dystonia 27,616411];	RCV000080995.6 [benign]; RCV000367078.1 [benign]; 		COSM4001576	24	311					COL6A3 (inh=AR+AD pLI=0.00)
chr2	238253149	238253149	G	A	het	het	wt		QUAL=10631;DP=450,478,664;MQM=59	COL6A3	synonymous	COL6A3:NM_004369.3:synonymous:LOW:exon36/44:c.7512C>T:p.Asn2504Asn,COL6A3:NM_057166.4:synonymous:LOW:exon33/41:c.5691C>T:p.Asn1897Asn,COL6A3:NM_057167.3:synonymous:LOW:exon35/43:c.6894C>T:p.Asn2298Asn		rs2646258	0.1084	0.1085	778/369/44	0.1064							120250 [COL6A3 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090|Dystonia 27,616411];	RCV000080994.8 [other]; RCV000274813.1 [benign]; 			23	351					COL6A3 (inh=AR+AD pLI=0.00)
chr2	238253214	238253214	T	C	wt	wt	het	pred_pathogenic;anno_pathogenic_clinvar;anno_pathogenic_hgmd	QUAL=7155;DP=417,447,591;MQM=60	COL6A3	missense	COL6A3:NM_004369.3:missense:MODERATE:exon36/44:c.7447A>G:p.Lys2483Glu,COL6A3:NM_057166.4:missense:MODERATE:exon33/41:c.5626A>G:p.Lys1876Glu,COL6A3:NM_057167.3:missense:MODERATE:exon35/43:c.6829A>G:p.Lys2277Glu		rs139260335	0.0000	0.0006	0/0/0	0.0005	4.9660	D,D,D,D,D,D	D	D,D,D,D	D,D,D,D,D,D	20.50	120250 [COL6A3 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090|Dystonia 27,616411];	RCV000177877.1 [uncertain significance]; RCV000352490.1 [pathogenic]; 	CM1010426 [CLASS=DM MUT=ALT PHEN="Collagen VI myopathy" GENE=COL6A3]; 		0	3					COL6A3 (inh=AR+AD pLI=0.00)
chr2	238257013	238257013	G	A	het	het	wt		QUAL=7206;DP=440,166,201;MQM=60	COL6A3	synonymous	COL6A3:NM_004369.3:synonymous:LOW:exon30/44:c.6945C>T:p.Phe2315Phe,COL6A3:NM_057166.4:synonymous:LOW:exon27/41:c.5124C>T:p.Phe1708Phe,COL6A3:NM_057167.3:synonymous:LOW:exon29/43:c.6327C>T:p.Phe2109Phe		rs2646265	0.1064	0.1100	800/393/37	0.1082							120250 [COL6A3 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090|Dystonia 27,616411];	RCV000080980.8 [other]; RCV000365938.1 [benign]; 			23	364					COL6A3 (inh=AR+AD pLI=0.00)
chr2	238258814	238258814	C	G	het	het	hom		QUAL=11478;DP=222,172,226;MQM=60	COL6A3	synonymous	COL6A3:NM_004369.3:synonymous:LOW:exon28/44:c.6855G>C:p.Gly2285Gly,COL6A3:NM_057166.4:synonymous:LOW:exon25/41:c.5034G>C:p.Gly1678Gly,COL6A3:NM_057167.3:synonymous:LOW:exon27/43:c.6237G>C:p.Gly2079Gly		rs3790993	0.5543	0.5489	18509/10030/1764	0.5441							120250 [COL6A3 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090|Dystonia 27,616411];	RCV000080973.6 [benign]; RCV000276863.1 [benign]; 			442	793					COL6A3 (inh=AR+AD pLI=0.00)
chr2	238267717	238267717	C	T	het	het	wt		QUAL=10617;DP=489,393,540;MQM=59	COL6A3	synonymous	COL6A3:NM_004369.3:synonymous:LOW:exon20/44:c.6369G>A:p.Leu2123Leu,COL6A3:NM_057166.4:synonymous:LOW:exon17/41:c.4548G>A:p.Leu1516Leu,COL6A3:NM_057167.3:synonymous:LOW:exon19/43:c.5751G>A:p.Leu1917Leu		rs2646254	0.3309	0.2129	3532/644/1227	0.2077							120250 [COL6A3 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090|Dystonia 27,616411];	RCV000080967.6 [benign]; RCV000376283.1 [benign]; 			47	444					COL6A3 (inh=AR+AD pLI=0.00)
chr2	238277573	238277573	C	A	het	het	wt		QUAL=2279;DP=183,82,98;MQM=59	COL6A3	synonymous	COL6A3:NM_004369.3:synonymous:LOW:exon10/44:c.4533G>T:p.Gly1511Gly,COL6A3:NM_057166.4:synonymous:LOW:exon7/41:c.2712G>T:p.Gly904Gly,COL6A3:NM_057167.3:synonymous:LOW:exon9/43:c.3915G>T:p.Gly1305Gly		rs2645774	0.2656	0.2355	3441/1524/409	0.2283							120250 [COL6A3 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090|Dystonia 27,616411];	RCV000080941.6 [benign]; RCV000311595.1 [benign]; 		COSM3758064	65	536					COL6A3 (inh=AR+AD pLI=0.00)
chr2	238277795	238277795	A	G	het	hom	wt	low_DP	QUAL=41;DP=12,1,1;MQM=60	COL6A3	synonymous	COL6A3:NM_004369.3:synonymous:LOW:exon10/44:c.4311T>C:p.Ile1437Ile,COL6A3:NM_057166.4:synonymous:LOW:exon7/41:c.2490T>C:p.Ile830Ile,COL6A3:NM_057167.3:synonymous:LOW:exon9/43:c.3693T>C:p.Ile1231Ile		rs2646260	0.3884	0.2889	5612/1830/1780	0.2848							120250 [COL6A3 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090|Dystonia 27,616411];	RCV000149961.1 [uncertain significance]; RCV000080938.6 [benign]; RCV000405778.1 [benign]; 		COSM3749639	87	551					COL6A3 (inh=AR+AD pLI=0.00)
chr2	238283605	238283605	G	A	hom	het	het		QUAL=2378;DP=64,43,44;MQM=59	COL6A3	synonymous	COL6A3:NM_004369.3:synonymous:LOW:exon8/44:c.3129C>T:p.Gly1043Gly,COL6A3:NM_057166.4:synonymous:LOW:exon5/41:c.1308C>T:p.Gly436Gly,COL6A3:NM_057167.3:synonymous:LOW:exon7/43:c.2511C>T:p.Gly837Gly,COL6A3:NM_057164.4:synonymous:LOW:exon6/7:c.1908C>T:p.Gly636Gly,COL6A3:NM_057165.4:synonymous:LOW:exon7/8:c.2511C>T:p.Gly837Gly		rs12622093	0.2159	0.2327	3330/1920/92	0.2305							120250 [COL6A3 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090|Dystonia 27,616411];	RCV000080926.6 [benign]; RCV000289678.1 [benign]; 		COSM1482931, COSM442555	84	567					COL6A3 (inh=AR+AD pLI=0.00)
chr2	238289980	238289980	G	C	het	het	wt	pred_pathogenic	QUAL=8160;DP=270,291,377;MQM=60	COL6A3	missense	COL6A3:NM_004369.3:missense:MODERATE:exon5/44:c.1475C>G:p.Thr492Ser,COL6A3:NM_057166.4:missense:MODERATE:exon3/41:c.254C>G:p.Thr85Ser,COL6A3:NM_057167.3:missense:MODERATE:exon4/43:c.857C>G:p.Thr286Ser,COL6A3:NM_057164.4:missense:MODERATE:exon3/7:c.254C>G:p.Thr85Ser,COL6A3:NM_057165.4:missense:MODERATE:exon4/8:c.857C>G:p.Thr286Ser		rs113897824	0.0036	0.0075	8/3/0	0.0071	0.2260	T,T,T,T,T,T,T,T,T	T	B,B,B,B,B,B	D,D,D,D,D,D,D,D,D	8.32	120250 [COL6A3 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090|Dystonia 27,616411];	RCV000080913.6 [other]; RCV000303469.1 [likely benign]; 			1	32					COL6A3 (inh=AR+AD pLI=0.00)
chr2	238289984	238289984	C	G	het	het	wt	pred_pathogenic	QUAL=8160;DP=270,291,377;MQM=60	COL6A3	missense	COL6A3:NM_004369.3:missense:MODERATE:exon5/44:c.1471G>C:p.Asp491His,COL6A3:NM_057166.4:missense:MODERATE:exon3/41:c.250G>C:p.Asp84His,COL6A3:NM_057167.3:missense:MODERATE:exon4/43:c.853G>C:p.Asp285His,COL6A3:NM_057164.4:missense:MODERATE:exon3/7:c.250G>C:p.Asp84His,COL6A3:NM_057165.4:missense:MODERATE:exon4/8:c.853G>C:p.Asp285His		rs112010940	0.0036	0.0075	8/3/0	0.0071	0.8220	D,D,D,D,D,D,D,D,D	T	B,P,B,B,P,B	D,D,D,D,D,D,D,D,D	22.80	120250 [COL6A3 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090|Dystonia 27,616411];	RCV000080912.6 [other]; RCV000358271.1 [likely benign]; 			1	32					COL6A3 (inh=AR+AD pLI=0.00)
chr2	238322712	238322712	C	T	het	het	wt		QUAL=2579;DP=144,76,92;MQM=60	COL6A3	5'UTR	COL6A3:NM_004369.3:5'UTR:MODIFIER:exon1/44:c.-147G>A:,COL6A3:NM_057166.4:5'UTR:MODIFIER:exon1/41:c.-147G>A:,COL6A3:NM_057167.3:5'UTR:MODIFIER:exon1/43:c.-147G>A:,COL6A3:NM_057164.4:5'UTR:MODIFIER:exon1/7:c.-147G>A:,COL6A3:NM_057165.4:5'UTR:MODIFIER:exon1/8:c.-147G>A:		rs113567254	0.0006	0.0000	0/0/0	0.0013							120250 [COL6A3 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090|Dystonia 27,616411];	RCV000340388.1 [likely benign]; 			0	2					COL6A3 (inh=AR+AD pLI=0.00)
chr2	239969974	239969974	G	C	hom	het	het		QUAL=22615;DP=345,359,469;MQM=59	HDAC4	3'UTR	HDAC4:NM_006037.3:3'UTR:MODIFIER:exon27/27:c.*4819C>G:		rs1055333	0.2346	0.0000	0/0/0	0.0424											13	75					HDAC4 (inh=AD pLI=1.00)
chr2	239970256	239970256	-	ATAGATAGATAGATAG	wt	wt	het		QUAL=8060;DP=111,178,216;MQM=59	HDAC4	3'UTR	HDAC4:NM_006037.3:3'UTR:MODIFIER:exon27/27:c.*4521_*4536dupCTATCTATCTATCTAT:		rs3841081	0.1450	0.0000	0/0/0	0.0551											9	21					HDAC4 (inh=AD pLI=1.00)
chr2	239970256	239970256	-	ATAGATAGATAG	hom	het	wt		QUAL=8060;DP=111,178,216;MQM=59	HDAC4	3'UTR	HDAC4:NM_006037.3:3'UTR:MODIFIER:exon27/27:c.*4525_*4536dupCTATCTATCTAT:		rs3841081	0.0491	0.0000	0/0/0	0.0240											3	19					HDAC4 (inh=AD pLI=1.00)
chr2	239970256	239970256	-	ATAG	wt	het	het		QUAL=8060;DP=111,178,216;MQM=59	HDAC4	3'UTR	HDAC4:NM_006037.3:3'UTR:MODIFIER:exon27/27:c.*4533_*4536dupCTAT:		rs3841081;rs560535182;rs75312371	0.1573	0.0000	0/0/0	0.1590											17	50					HDAC4 (inh=AD pLI=1.00)
chr2	239970360	239970360	A	C	hom	het	het		QUAL=15265;DP=276,207,289;MQM=59	HDAC4	3'UTR	HDAC4:NM_006037.3:3'UTR:MODIFIER:exon27/27:c.*4433T>G:		rs895808	0.3343	0.0000	0/0/0	0.0693											27	100					HDAC4 (inh=AD pLI=1.00)
chr2	239972369	239972369	C	T	wt	het	het		QUAL=9328;DP=262,305,384;MQM=60	HDAC4	3'UTR	HDAC4:NM_006037.3:3'UTR:MODIFIER:exon27/27:c.*2424G>A:		rs10174562	0.1589	0.0000	0/0/0	0.0267											8	59					HDAC4 (inh=AD pLI=1.00)
chr2	239972883	239972883	C	T	het	het	wt		QUAL=2788;DP=147,83,143;MQM=60	HDAC4	3'UTR	HDAC4:NM_006037.3:3'UTR:MODIFIER:exon27/27:c.*1910G>A:		rs4852010	0.3361	0.0000	0/0/0	0.0605											13	107					HDAC4 (inh=AD pLI=1.00)
chr2	239974241	239974241	-	C	het	wt	hom		QUAL=3109;DP=110,88,109;MQM=59	HDAC4	3'UTR	HDAC4:NM_006037.3:3'UTR:MODIFIER:exon27/27:c.*551dupG:		rs397972964	0.0000	0.0000	0/0/0	0.0540											5	51					HDAC4 (inh=AD pLI=1.00)
chr2	240003870	240003870	G	A	hom	hom	hom		QUAL=6183;DP=81,51,73;MQM=60	HDAC4	synonymous	HDAC4:NM_006037.3:synonymous:LOW:exon21/27:c.2565C>T:p.Pro855Pro		rs1063639	0.5952	0.5333	17909/7374/1651	0.5226										COSM4133597	429	746					HDAC4 (inh=AD pLI=1.00)
chr2	240066417	240066417	A	G	hom	hom	hom		QUAL=8190;DP=68,93,103;MQM=60	HDAC4	splice_region&intron	HDAC4:NM_006037.3:splice_region&intron:LOW:exon7/26:c.734-7T>C:		rs2290087	0.8878	0.8616	45478/24708/4858	0.8534											1196	338					HDAC4 (inh=AD pLI=1.00)
chr2	241531479	241531479	A	G	het	wt	het		QUAL=1391;DP=40,27,50;MQM=60	CAPN10	synonymous	CAPN10:NM_023083.3:synonymous:LOW:exon4/12:c.600A>G:p.Pro200Pro,CAPN10:NM_023085.3:synonymous:LOW:exon4/10:c.600A>G:p.Pro200Pro		rs3792269	0.1176	0.1823	1333/816/11	0.1361							605286 [CAPN10 (confirmed) Diabetes mellitus,noninsulin-dependent 1,601283];				45	397					CAPN10 (inh=n/a pLI=0.00)
chr2	241536126	241536126	A	G	het	wt	het	low_DP;pred_pathogenic	QUAL=294;DP=26,6,7;MQM=60	CAPN10	missense,intron	CAPN10:NM_023083.3:missense:MODERATE:exon9/12:c.1510A>G:p.Thr504Ala,CAPN10:NM_023085.3:intron:MODIFIER:exon7/9:c.1279-1179A>G:		rs7607759	0.1168	0.1474	1289/853/10	0.1325	-0.3280	T,T	T	B,B	D,D	0.01	605286 [CAPN10 (confirmed) Diabetes mellitus,noninsulin-dependent 1,601283];		CM043260 [CLASS=DP MUT=ALT PHEN="Diabetes mellitus 2 association with" GENE=CAPN10]; 		46	387					CAPN10 (inh=n/a pLI=0.00)
chr2	241537421	241537421	G	A	het	hom	wt		QUAL=2861;DP=122,50,63;MQM=60	CAPN10	synonymous	CAPN10:NM_023083.3:synonymous:LOW:exon10/12:c.1860G>A:p.Ala620Ala,CAPN10:NM_023085.3:synonymous:LOW:exon8/10:c.1395G>A:p.Ala465Ala		rs3749166	0.5118	0.5811	20691/12428/493	0.5758							605286 [CAPN10 (confirmed) Diabetes mellitus,noninsulin-dependent 1,601283];			COSM4133667, COSM4133668	542	766					CAPN10 (inh=n/a pLI=0.00)
chr2	241538061	241538061	T	C	het	wt	het		QUAL=2067;DP=83,40,65;MQM=60	CAPN10	splice_region&intron	CAPN10:NM_023083.3:splice_region&intron:LOW:exon11/11:c.1990-7T>C:,CAPN10:NM_023085.3:splice_region&intron:LOW:exon9/9:c.1525-7T>C:		rs55878652	0.1204	0.1915	644/369/7	0.1131							605286 [CAPN10 (confirmed) Diabetes mellitus,noninsulin-dependent 1,601283];			COSM3766550, COSM3766549	45	396					CAPN10 (inh=n/a pLI=0.00)
chr2	241538074	241538074	A	G	hom	hom	hom	pred_pathogenic	QUAL=5183;DP=86,34,52;MQM=59	CAPN10	missense	CAPN10:NM_023083.3:missense:MODERATE:exon12/12:c.1996A>G:p.Ile666Val,CAPN10:NM_023085.3:missense:MODERATE:exon10/10:c.1531A>G:p.Ile511Val		rs2975766	0.9898	0.9799	29606/16386/3095	0.8886	-0.9330	T,T,T	T	B,B,B	D,T,D	0.01	605286 [CAPN10 (confirmed) Diabetes mellitus,noninsulin-dependent 1,601283];				1453	108					CAPN10 (inh=n/a pLI=0.00)
chr2	241538229	241538229	A	G	hom	hom	het		QUAL=4391;DP=60,61,82;MQM=60	CAPN10	3'UTR	CAPN10:NM_023083.3:3'UTR:MODIFIER:exon12/12:c.*132A>G:,CAPN10:NM_023085.3:3'UTR:MODIFIER:exon10/10:c.*132A>G:		rs2975767	0.7264	0.0000	0/0/0	0.1583							605286 [CAPN10 (confirmed) Diabetes mellitus,noninsulin-dependent 1,601283];				157	66					CAPN10 (inh=n/a pLI=0.00)
chr2	241538531	241538531	T	C	het	wt	het		QUAL=876;DP=52,41,54;MQM=60	CAPN10-GPR35	intergenic_region	CAPN10-GPR35:CAPN10-GPR35:intergenic_region:MODIFIER::n.241538531T>C:		rs17846983	0.0767	0.0000	0/0/0	0.0154							605286 [CAPN10 (confirmed) Diabetes mellitus,noninsulin-dependent 1,601283];				3	29					CAPN10-GPR35 (inh=n/a pLI=n/a)
chr3	3191388	3191388	T	A	hom	hom	hom		QUAL=35180;DP=465,265,326;MQM=59	CRBN	3'UTR	CRBN:NM_016302.3:3'UTR:MODIFIER:exon11/11:c.*1161A>T:,CRBN:NM_001173482.1:3'UTR:MODIFIER:exon11/11:c.*1161A>T:		rs711628	0.9048	0.0000	0/0/0	0.8880							612907 [TRNT1 (provisional) Sideroblastic anemia with B-cell immunodeficiency,periodic fevers,and developmental delay,616084|Retinitis pigmentosa and erythrocytic microcytosis,616959]:609262 [CRBN (confirmed) Mental retardation,autosomal recessive 2,607417];				149	1					CRBN (inh=AR pLI=0.04)
chr3	3191426	3191426	T	C	het	het	het		QUAL=13420;DP=377,253,325;MQM=60	CRBN	3'UTR	CRBN:NM_016302.3:3'UTR:MODIFIER:exon11/11:c.*1123A>G:,CRBN:NM_001173482.1:3'UTR:MODIFIER:exon11/11:c.*1123A>G:		rs1045433	0.1292	0.0000	0/0/0	0.1406							612907 [TRNT1 (provisional) Sideroblastic anemia with B-cell immunodeficiency,periodic fevers,and developmental delay,616084|Retinitis pigmentosa and erythrocytic microcytosis,616959]:609262 [CRBN (confirmed) Mental retardation,autosomal recessive 2,607417];				4	52					CRBN (inh=AR pLI=0.04)
chr3	3191776	3191776	T	C	hom	hom	hom		QUAL=20079;DP=354,118,132;MQM=60	CRBN	3'UTR	CRBN:NM_016302.3:3'UTR:MODIFIER:exon11/11:c.*773A>G:,CRBN:NM_001173482.1:3'UTR:MODIFIER:exon11/11:c.*773A>G:		rs711627	0.9048	0.0000	0/0/0	0.1514							612907 [TRNT1 (provisional) Sideroblastic anemia with B-cell immunodeficiency,periodic fevers,and developmental delay,616084|Retinitis pigmentosa and erythrocytic microcytosis,616959]:609262 [CRBN (confirmed) Mental retardation,autosomal recessive 2,607417];				227	3					CRBN (inh=AR pLI=0.04)
chr3	3192007	3192007	A	G	wt	het	wt		QUAL=1753;DP=301,131,172;MQM=60	CRBN	3'UTR	CRBN:NM_016302.3:3'UTR:MODIFIER:exon11/11:c.*542T>C:,CRBN:NM_001173482.1:3'UTR:MODIFIER:exon11/11:c.*542T>C:		rs562453087	0.0000	0.0000	0/0/0	0.0011							612907 [TRNT1 (provisional) Sideroblastic anemia with B-cell immunodeficiency,periodic fevers,and developmental delay,616084|Retinitis pigmentosa and erythrocytic microcytosis,616959]:609262 [CRBN (confirmed) Mental retardation,autosomal recessive 2,607417];				0	6					CRBN (inh=AR pLI=0.04)
chr3	3192524	3192524	-	TAAC	het	het	het		QUAL=7124;DP=196,156,203;MQM=59	CRBN	3'UTR	CRBN:NM_016302.3:3'UTR:MODIFIER:exon11/11:c.*21_*24dupGTTA:,CRBN:NM_001173482.1:3'UTR:MODIFIER:exon11/11:c.*21_*24dupGTTA:		rs3830315;rs397828468;rs4183	0.0000	0.5523	16578/12513/512	0.4891							612907 [TRNT1 (provisional) Sideroblastic anemia with B-cell immunodeficiency,periodic fevers,and developmental delay,616084|Retinitis pigmentosa and erythrocytic microcytosis,616959]:609262 [CRBN (confirmed) Mental retardation,autosomal recessive 2,607417];				298	343					CRBN (inh=AR pLI=0.04)
chr3	3215954	3215954	A	G	hom	hom	hom		QUAL=21559;DP=332,130,208;MQM=60	CRBN	splice_region&intron	CRBN:NM_016302.3:splice_region&intron:LOW:exon2/10:c.175-9T>C:,CRBN:NM_001173482.1:splice_region&intron:LOW:exon2/10:c.172-9T>C:		rs1669321	0.8838	0.9673	57252/33213/2185	0.9362							609262 [CRBN (confirmed) Mental retardation,autosomal recessive 2,607417];	RCV000116835.1 [benign]; 			1544	21					CRBN (inh=AR pLI=0.04)
chr3	4403153	4403153	T	G	wt	het	wt		QUAL=4601;DP=416,315,414;MQM=60	SUMF1	3'UTR	SUMF1:NM_182760.3:3'UTR:MODIFIER:exon9/9:c.*675A>C:,SUMF1:NM_001164674.1:3'UTR:MODIFIER:exon8/8:c.*675A>C:,SUMF1:NM_001164675.1:3'UTR:MODIFIER:exon8/8:c.*675A>C:		rs14275	0.4816	0.0000	0/0/0	0.1075							607939 [SUMF1 (provisional) Multiple sulfatase deficiency,272200];	RCV000349876.1 [benign]; 			111	97					SUMF1 (inh=AR pLI=0.04)
chr3	4403357	4403357	A	C	hom	hom	hom		QUAL=16466;DP=254,103,140;MQM=59	SUMF1	3'UTR	SUMF1:NM_182760.3:3'UTR:MODIFIER:exon9/9:c.*471T>G:,SUMF1:NM_001164674.1:3'UTR:MODIFIER:exon8/8:c.*471T>G:,SUMF1:NM_001164675.1:3'UTR:MODIFIER:exon8/8:c.*471T>G:		rs2259818	0.8802	0.0000	0/0/0	0.6096							607939 [SUMF1 (provisional) Multiple sulfatase deficiency,272200];	RCV000303426.1 [benign]; 			217	12					SUMF1 (inh=AR pLI=0.04)
chr3	4403365	4403368	CTCA	-	hom	hom	hom		QUAL=13824;DP=239,90,128;MQM=59	SUMF1	3'UTR	SUMF1:NM_182760.3:3'UTR:MODIFIER:exon9/9:c.*460_*463delTGAG:,SUMF1:NM_001164674.1:3'UTR:MODIFIER:exon8/8:c.*460_*463delTGAG:,SUMF1:NM_001164675.1:3'UTR:MODIFIER:exon8/8:c.*460_*463delTGAG:		rs3835161	0.7047	0.0000	0/0/0	0.5351							607939 [SUMF1 (provisional) Multiple sulfatase deficiency,272200];	RCV000358113.1 [benign]; 			72	114					SUMF1 (inh=AR pLI=0.04)
chr3	4403537	4403537	C	T	hom	hom	hom		QUAL=16273;DP=267,111,161;MQM=59	SUMF1	3'UTR	SUMF1:NM_182760.3:3'UTR:MODIFIER:exon9/9:c.*291G>A:,SUMF1:NM_001164674.1:3'UTR:MODIFIER:exon8/8:c.*291G>A:,SUMF1:NM_001164675.1:3'UTR:MODIFIER:exon8/8:c.*291G>A:	MIR3	rs4685744	0.4281	0.0000	0/0/0	0.0837							607939 [SUMF1 (provisional) Multiple sulfatase deficiency,272200];	RCV000260015.1 [benign]; 			57	112					SUMF1 (inh=AR pLI=0.04)
chr3	4403767	4403767	A	G	hom	hom	hom		QUAL=19853;DP=292,153,172;MQM=59	SUMF1	3'UTR	SUMF1:NM_182760.3:3'UTR:MODIFIER:exon9/9:c.*61T>C:,SUMF1:NM_001164674.1:3'UTR:MODIFIER:exon8/8:c.*61T>C:,SUMF1:NM_001164675.1:3'UTR:MODIFIER:exon8/8:c.*61T>C:		rs2819561	0.7045	0.0000	0/0/0	0.1203							607939 [SUMF1 (provisional) Multiple sulfatase deficiency,272200];	RCV000330948.1 [benign]; 			289	368					SUMF1 (inh=AR pLI=0.04)
chr3	4403817	4403817	T	A	hom	hom	hom		QUAL=18277;DP=185,196,234;MQM=59	SUMF1	3'UTR	SUMF1:NM_182760.3:3'UTR:MODIFIER:exon9/9:c.*11A>T:,SUMF1:NM_001164674.1:3'UTR:MODIFIER:exon8/8:c.*11A>T:,SUMF1:NM_001164675.1:3'UTR:MODIFIER:exon8/8:c.*11A>T:		rs2633851	0.7268	0.6334	24987/10216/3098	0.5679							607939 [SUMF1 (provisional) Multiple sulfatase deficiency,272200];	RCV000082713.5 [benign]; RCV000387786.1 [benign]; 			366	452					SUMF1 (inh=AR pLI=0.04)
chr3	4403818	4403818	T	C	hom	hom	hom		QUAL=18277;DP=185,196,234;MQM=59	SUMF1	3'UTR	SUMF1:NM_182760.3:3'UTR:MODIFIER:exon9/9:c.*10A>G:,SUMF1:NM_001164674.1:3'UTR:MODIFIER:exon8/8:c.*10A>G:,SUMF1:NM_001164675.1:3'UTR:MODIFIER:exon8/8:c.*10A>G:		rs35083095	0.4321	0.4936	15396/8297/295	0.4387							607939 [SUMF1 (provisional) Multiple sulfatase deficiency,272200];	RCV000082712.5 [benign]; RCV000295742.1 [benign]; 			343	496					SUMF1 (inh=AR pLI=0.04)
chr3	4403837	4403837	A	G	hom	hom	hom		QUAL=21313;DP=175,223,269;MQM=60	SUMF1	synonymous	SUMF1:NM_182760.3:synonymous:LOW:exon9/9:c.1116T>C:p.Thr372Thr,SUMF1:NM_001164674.1:synonymous:LOW:exon8/8:c.1041T>C:p.Thr347Thr,SUMF1:NM_001164675.1:synonymous:LOW:exon8/8:c.1056T>C:p.Thr352Thr		rs2633852	0.7604	0.6440	26090/10370/3935	0.6169							607939 [SUMF1 (provisional) Multiple sulfatase deficiency,272200];	RCV000082714.5 [benign]; RCV000325033.1 [benign]; 		COSM3760098	594	725					SUMF1 (inh=AR pLI=0.04)
chr3	4508742	4508742	C	T	het	het	wt	pred_pathogenic	QUAL=834;DP=41,28,27;MQM=60	SUMF1	missense	SUMF1:NM_182760.3:missense:MODERATE:exon1/9:c.188G>A:p.Ser63Asn,SUMF1:NM_001164674.1:missense:MODERATE:exon1/8:c.188G>A:p.Ser63Asn,SUMF1:NM_001164675.1:missense:MODERATE:exon1/8:c.188G>A:p.Ser63Asn		rs2819590	0.1166	0.2851	1161/941/1	0.1665	0.5130	T,T,T,T,D,T	T	P,P,P,B	D,D,D,D,D	21.10	607939 [SUMF1 (provisional) Multiple sulfatase deficiency,272200];	RCV000244602.1 [benign]; RCV000362882.1 [benign]; 		COSM3760113, COSM3760112	105	561					SUMF1 (inh=AR pLI=0.04)
chr3	4712413	4712413	G	A	het	hom	wt		QUAL=6286;DP=122,162,165;MQM=60	ITPR1	splice_region&synonymous	ITPR1:NM_001168272.1:splice_region&synonymous:LOW:exon19/61:c.1962G>A:p.Lys654Lys,ITPR1:NM_001099952.2:splice_region&synonymous:LOW:exon20/59:c.2007G>A:p.Lys669Lys,ITPR1:NM_002222.5:splice_region&synonymous:LOW:exon19/58:c.1962G>A:p.Lys654Lys		rs2306875	0.6140	0.6832	14002/7958/1444	0.6073							147265 [ITPR1 (confirmed) Spinocerebellar ataxia 15,606658|Spinocerebellar ataxia 29,congenital nonprogressive,117360|Gillespie syndrome,206700];	RCV000117299.2 [likely benign]; RCV000369453.1 [benign]; 			1152	1196					ITPR1 (inh=AD pLI=1.00)
chr3	4716811	4716811	A	C	het	het	wt		QUAL=4917;DP=221,172,239;MQM=59	ITPR1	synonymous	ITPR1:NM_001168272.1:synonymous:LOW:exon22/61:c.2613A>C:p.Leu871Leu,ITPR1:NM_001099952.2:synonymous:LOW:exon23/59:c.2658A>C:p.Leu886Leu,ITPR1:NM_002222.5:synonymous:LOW:exon22/58:c.2613A>C:p.Leu871Leu		rs2306877	0.3329	0.2692	4898/1268/611	0.2582							147265 [ITPR1 (confirmed) Spinocerebellar ataxia 15,606658|Spinocerebellar ataxia 29,congenital nonprogressive,117360|Gillespie syndrome,206700];	RCV000117300.2 [likely benign]; RCV000323015.1 [benign]; 			120	858					ITPR1 (inh=AD pLI=1.00)
chr3	4767262	4767262	T	C	hom	hom	hom		QUAL=21988;DP=319,153,264;MQM=59	ITPR1	synonymous,intron	ITPR1:NM_001168272.1:synonymous:LOW:exon40/61:c.5124T>C:p.Thr1708Thr,ITPR1:NM_001099952.2:intron:MODIFIER:exon39/58:c.5077-7510T>C:,ITPR1:NM_002222.5:intron:MODIFIER:exon38/57:c.5032-7510T>C:		rs7613447	0.5122	0.6893	29493/21347/1060	0.6702							147265 [ITPR1 (confirmed) Spinocerebellar ataxia 15,606658|Spinocerebellar ataxia 29,congenital nonprogressive,117360|Gillespie syndrome,206700];				1583	881					ITPR1 (inh=AD pLI=1.00)
chr3	4817057	4817057	T	C	hom	hom	hom		QUAL=19477;DP=259,133,205;MQM=60	ITPR1	synonymous	ITPR1:NM_001168272.1:synonymous:LOW:exon46/61:c.6066T>C:p.Asn2022Asn,ITPR1:NM_001099952.2:synonymous:LOW:exon44/59:c.5967T>C:p.Asn1989Asn,ITPR1:NM_002222.5:synonymous:LOW:exon43/58:c.5922T>C:p.Asn1974Asn		rs6442905	0.9627	0.9701	56862/31392/4478	0.9422							147265 [ITPR1 (confirmed) Spinocerebellar ataxia 15,606658|Spinocerebellar ataxia 29,congenital nonprogressive,117360|Gillespie syndrome,206700];				2510	176					ITPR1 (inh=AD pLI=1.00)
chr3	4829732	4829732	A	G	wt	het	wt		QUAL=3790;DP=327,336,420;MQM=60	ITPR1	synonymous	ITPR1:NM_001168272.1:synonymous:LOW:exon51/61:c.6672A>G:p.Thr2224Thr,ITPR1:NM_001099952.2:synonymous:LOW:exon49/59:c.6573A>G:p.Thr2191Thr,ITPR1:NM_002222.5:synonymous:LOW:exon48/58:c.6528A>G:p.Thr2176Thr		rs13079522	0.2456	0.3294	5613/3401/365	0.2948							147265 [ITPR1 (confirmed) Spinocerebellar ataxia 15,606658|Spinocerebellar ataxia 29,congenital nonprogressive,117360|Gillespie syndrome,206700];	RCV000117302.2 [likely benign]; RCV000404506.1 [benign]; 		COSM3760141, COSM3760142, COSM3760143	299	1106					ITPR1 (inh=AD pLI=1.00)
chr3	4842231	4842231	C	T	het	wt	het		QUAL=6842;DP=304,188,265;MQM=59	ITPR1	synonymous	ITPR1:NM_001168272.1:synonymous:LOW:exon53/61:c.7009C>T:p.Leu2337Leu,ITPR1:NM_001099952.2:synonymous:LOW:exon51/59:c.6910C>T:p.Leu2304Leu,ITPR1:NM_002222.5:synonymous:LOW:exon50/58:c.6865C>T:p.Leu2289Leu		rs2291862	0.2646	0.2868	5218/2657/88	0.2843							147265 [ITPR1 (confirmed) Spinocerebellar ataxia 15,606658|Spinocerebellar ataxia 29,congenital nonprogressive,117360|Gillespie syndrome,206700];	RCV000117303.2 [likely benign]; RCV000404711.1 [benign]; 		COSM3760145, COSM3760144, COSM3760146	224	1107					ITPR1 (inh=AD pLI=1.00)
chr3	4856180	4856180	T	C	hom	hom	hom		QUAL=11754;DP=141,111,121;MQM=59	ITPR1	synonymous	ITPR1:NM_001168272.1:synonymous:LOW:exon57/61:c.7590T>C:p.Thr2530Thr,ITPR1:NM_001099952.2:synonymous:LOW:exon55/59:c.7491T>C:p.Thr2497Thr,ITPR1:NM_002222.5:synonymous:LOW:exon54/58:c.7446T>C:p.Thr2482Thr		rs711631	0.7909	0.8244	41384/23153/2400	0.8122							147265 [ITPR1 (confirmed) Spinocerebellar ataxia 15,606658|Spinocerebellar ataxia 29,congenital nonprogressive,117360|Gillespie syndrome,206700];	RCV000117304.2 [likely benign]; RCV000288234.1 [benign]; 			1795	801					ITPR1 (inh=AD pLI=1.00)
chr3	4856234	4856234	G	A	het	het	hom		QUAL=4181;DP=127,62,71;MQM=60	ITPR1	synonymous	ITPR1:NM_001168272.1:synonymous:LOW:exon57/61:c.7644G>A:p.Lys2548Lys,ITPR1:NM_001099952.2:synonymous:LOW:exon55/59:c.7545G>A:p.Lys2515Lys,ITPR1:NM_002222.5:synonymous:LOW:exon54/58:c.7500G>A:p.Lys2500Lys		rs901854	0.5875	0.6054	22215/12504/1523	0.5815							147265 [ITPR1 (confirmed) Spinocerebellar ataxia 15,606658|Spinocerebellar ataxia 29,congenital nonprogressive,117360|Gillespie syndrome,206700];	RCV000117305.2 [likely benign]; RCV000379072.1 [benign]; 			1076	1200					ITPR1 (inh=AD pLI=1.00)
chr3	4889079	4889079	-	AA	hom	wt	hom	low_DP	QUAL=1232;DP=107,21,19;MQM=59	ITPR1	3'UTR	ITPR1:NM_001168272.1:3'UTR:MODIFIER:exon61/61:c.*1183_*1184dupAA:,ITPR1:NM_001099952.2:3'UTR:MODIFIER:exon59/59:c.*1183_*1184dupAA:,ITPR1:NM_002222.5:3'UTR:MODIFIER:exon58/58:c.*1183_*1184dupAA:		rs3079679;rs36064013;rs71779262	0.0000	0.0000	0/0/0	0.0289							147265 [ITPR1 (confirmed) Spinocerebellar ataxia 15,606658|Spinocerebellar ataxia 29,congenital nonprogressive,117360|Gillespie syndrome,206700];				28	110					ITPR1 (inh=AD pLI=1.00)
chr3	4889079	4889079	-	A	wt	hom	wt	low_DP	QUAL=1232;DP=107,21,19;MQM=60	ITPR1	3'UTR	ITPR1:NM_001168272.1:3'UTR:MODIFIER:exon61/61:c.*1184dupA:,ITPR1:NM_001099952.2:3'UTR:MODIFIER:exon59/59:c.*1184dupA:,ITPR1:NM_002222.5:3'UTR:MODIFIER:exon58/58:c.*1184dupA:			0.0000	0.0000	0/0/0	0.0049							147265 [ITPR1 (confirmed) Spinocerebellar ataxia 15,606658|Spinocerebellar ataxia 29,congenital nonprogressive,117360|Gillespie syndrome,206700];				4	61					ITPR1 (inh=AD pLI=1.00)
chr3	8775589	8775589	C	T	hom	het	het		QUAL=20991;DP=272,405,529;MQM=60	CAV3	synonymous	CAV3:NM_001234.4:synonymous:LOW:exon1/3:c.27C>T:p.Leu9Leu,CAV3:NM_033337.2:synonymous:LOW:exon1/2:c.27C>T:p.Leu9Leu		rs1974763	0.0425	0.0873	639/570/3	0.0876							601253 [CAV3 (confirmed) Muscular dystrophy,limb-girdle,type IC,607801|Rippling muscle disease,606072|Creatine phosphokinase,elevated serum,123320|Myopathy,distal,Tateyama type,614321|Cardiomyopathy,familial hypertrophic,192600|Long QT syndrome 9,611818];	RCV000024400.1 [not provided]; RCV000039803.10 [other]; RCV000241900.1 [benign]; RCV000284784.1 [likely benign]; RCV000324622.1 [likely benign]; RCV000339745.1 [likely benign]; RCV000379199.1 [likely benign]; RCV000397797.1 [likely benign]; 			18	312					CAV3 (inh=AR+AD pLI=0.34)
chr3	8775661	8775661	C	T	wt	wt	het	anno_pathogenic_clinvar	QUAL=5042;DP=127,347,444;MQM=60	CAV3	synonymous	CAV3:NM_001234.4:synonymous:LOW:exon1/3:c.99C>T:p.Asn33Asn,CAV3:NM_033337.2:synonymous:LOW:exon1/2:c.99C>T:p.Asn33Asn		rs1008642	0.3710	0.3010	5873/2334/1581	0.2931							601253 [CAV3 (confirmed) Muscular dystrophy,limb-girdle,type IC,607801|Rippling muscle disease,606072|Creatine phosphokinase,elevated serum,123320|Myopathy,distal,Tateyama type,614321|Cardiomyopathy,familial hypertrophic,192600|Long QT syndrome 9,611818];	RCV000008786.3 [pathogenic]; RCV000024392.3 [not provided]; RCV000039807.11 [other]; RCV000243559.1 [benign]; RCV000280736.1 [likely benign]; RCV000314528.1 [likely benign]; RCV000335806.1 [likely benign]; RCV000369159.1 [likely benign]; RCV000401708.1 [likely benign]; 		COSM3760257	135	660	1	[1] Stephan Waldm?ller 04.08.2014			CAV3 (inh=AR+AD pLI=0.34)
chr3	8787220	8787220	T	C	het	het	wt		QUAL=4850;DP=193,236,308;MQM=59	CAV3	synonymous	CAV3:NM_001234.4:synonymous:LOW:exon2/3:c.123T>C:p.Phe41Phe,CAV3:NM_033337.2:synonymous:LOW:exon2/2:c.123T>C:p.Phe41Phe		rs13087941	0.1530	0.1886	2652/1897/430	0.1860							601253 [CAV3 (confirmed) Muscular dystrophy,limb-girdle,type IC,607801|Rippling muscle disease,606072|Creatine phosphokinase,elevated serum,123320|Myopathy,distal,Tateyama type,614321|Cardiomyopathy,familial hypertrophic,192600|Long QT syndrome 9,611818];	RCV000024401.3 [not provided]; RCV000039797.11 [other]; RCV000246688.1 [benign]; RCV000271441.1 [likely benign]; RCV000310948.1 [likely benign]; RCV000326617.1 [likely benign]; RCV000366101.1 [likely benign]; RCV000393888.1 [likely benign]; 		COSM1131343	61	475					CAV3 (inh=AR+AD pLI=0.34)
chr3	8787330	8787330	C	T	wt	het	wt	pred_pathogenic;anno_pathogenic_clinvar;anno_pathogenic_hgmd	QUAL=3065;DP=148,255,303;MQM=60	CAV3	missense	CAV3:NM_001234.4:missense:MODERATE:exon2/3:c.233C>T:p.Thr78Met,CAV3:NM_033337.2:missense:MODERATE:exon2/2:c.233C>T:p.Thr78Met		rs72546668	0.0020	0.0030	1/1/0	0.0028	3.5800	T,T	D	P	D,D	23.70	601253 [CAV3 (confirmed) Muscular dystrophy,limb-girdle,type IC,607801|Rippling muscle disease,606072|Creatine phosphokinase,elevated serum,123320|Myopathy,distal,Tateyama type,614321|Cardiomyopathy,familial hypertrophic,192600|Long QT syndrome 9,611818];	RCV000119382.1 [not provided]; RCV000008790.2 [pathogenic]; RCV000008791.2 [pathogenic]; RCV000024406.8 [not provided]; RCV000039801.6 [other]; RCV000168328.4 [other]; RCV000242756.1 [likely benign]; 	CM065052 [CLASS=DM MUT=ALT PHEN="Long QT syndrome" GENE=CAV3]; 		0	17	2	[2] old entry - no details available			CAV3 (inh=AR+AD pLI=0.34)
chr3	8788096	8788096	T	C	het	het	wt		QUAL=8265;DP=411,195,268;MQM=60	CAV3	3'UTR	CAV3:NM_001234.4:3'UTR:MODIFIER:exon3/3:c.*447T>C:,CAV3:NM_033337.2:3'UTR:MODIFIER:exon2/2:c.*543T>C:		rs13093809	0.0503	0.0000	0/0/0	0.0176							601253 [CAV3 (confirmed) Muscular dystrophy,limb-girdle,type IC,607801|Rippling muscle disease,606072|Creatine phosphokinase,elevated serum,123320|Myopathy,distal,Tateyama type,614321|Cardiomyopathy,familial hypertrophic,192600|Long QT syndrome 9,611818];	RCV000024402.1 [not provided]; RCV000259430.1 [likely benign]; RCV000301199.1 [likely benign]; RCV000314609.1 [likely benign]; RCV000354374.1 [likely benign]; RCV000369265.1 [likely benign]; 			7	61					CAV3 (inh=AR+AD pLI=0.34)
chr3	8788198	8788198	A	T	het	het	het		QUAL=9928;DP=253,199,268;MQM=60	CAV3	3'UTR	CAV3:NM_001234.4:3'UTR:MODIFIER:exon3/3:c.*549A>T:,CAV3:NM_033337.2:3'UTR:MODIFIER:exon2/2:c.*645A>T:		rs11476	0.3482	0.0000	0/0/0	0.0659							601253 [CAV3 (confirmed) Muscular dystrophy,limb-girdle,type IC,607801|Rippling muscle disease,606072|Creatine phosphokinase,elevated serum,123320|Myopathy,distal,Tateyama type,614321|Cardiomyopathy,familial hypertrophic,192600|Long QT syndrome 9,611818];	RCV000024384.1 [not provided]; RCV000283263.1 [likely benign]; RCV000286772.1 [likely benign]; RCV000323134.1 [likely benign]; RCV000377518.1 [likely benign]; RCV000381151.1 [likely benign]; 			38	123					CAV3 (inh=AR+AD pLI=0.34)
chr3	8788336	8788336	A	G	het	het	het		QUAL=10593;DP=318,238,320;MQM=59	CAV3	3'UTR	CAV3:NM_001234.4:3'UTR:MODIFIER:exon3/3:c.*687A>G:,CAV3:NM_033337.2:3'UTR:MODIFIER:exon2/2:c.*783A>G:		rs7629329	0.2716	0.0000	0/0/0	0.0521							601253 [CAV3 (confirmed) Muscular dystrophy,limb-girdle,type IC,607801|Rippling muscle disease,606072|Creatine phosphokinase,elevated serum,123320|Myopathy,distal,Tateyama type,614321|Cardiomyopathy,familial hypertrophic,192600|Long QT syndrome 9,611818];	RCV000024404.1 [not provided]; RCV000294459.1 [likely benign]; RCV000347017.1 [likely benign]; RCV000352834.1 [likely benign]; RCV000390368.1 [likely benign]; RCV000396877.1 [likely benign]; 			26	124					CAV3 (inh=AR+AD pLI=0.34)
chr3	8788364	8788364	C	-	het	het	wt		QUAL=12072;DP=402,252,313;MQM=59	CAV3	3'UTR	CAV3:NM_001234.4:3'UTR:MODIFIER:exon3/3:c.*717delC:,CAV3:NM_033337.2:3'UTR:MODIFIER:exon2/2:c.*813delC:		rs66667169	0.0467	0.0000	0/0/0	0.0834							601253 [CAV3 (confirmed) Muscular dystrophy,limb-girdle,type IC,607801|Rippling muscle disease,606072|Creatine phosphokinase,elevated serum,123320|Myopathy,distal,Tateyama type,614321|Cardiomyopathy,familial hypertrophic,192600|Long QT syndrome 9,611818];	RCV000277007.1 [likely benign]; RCV000289785.1 [likely benign]; RCV000329785.1 [likely benign]; RCV000386519.1 [likely benign]; RCV000387830.1 [likely benign]; 			5	57					CAV3 (inh=AR+AD pLI=0.34)
chr3	8788364	8788364	C	G	wt	wt	het		QUAL=12072;DP=402,252,313;MQM=59	CAV3	3'UTR	CAV3:NM_001234.4:3'UTR:MODIFIER:exon3/3:c.*715C>G:,CAV3:NM_033337.2:3'UTR:MODIFIER:exon2/2:c.*811C>G:		rs10882	0.3227	0.0000	0/0/0	0.1972							601253 [CAV3 (confirmed) Muscular dystrophy,limb-girdle,type IC,607801|Rippling muscle disease,606072|Creatine phosphokinase,elevated serum,123320|Myopathy,distal,Tateyama type,614321|Cardiomyopathy,familial hypertrophic,192600|Long QT syndrome 9,611818];	RCV000024385.1 [not provided]; RCV000289056.1 [likely benign]; RCV000341746.1 [likely benign]; RCV000347204.1 [likely benign]; RCV000380774.1 [likely benign]; RCV000395641.1 [likely benign]; 			17	97					CAV3 (inh=AR+AD pLI=0.34)
chr3	10085536	10085536	A	G	het	het	het	low_MQM	QUAL=7196;DP=415,375,490;MQM=43	FANCD2	synonymous	FANCD2:NM_033084.4:synonymous:LOW:exon14/43:c.1122A>G:p.Val374Val,FANCD2:NM_001018115.2:synonymous:LOW:exon14/44:c.1122A>G:p.Val374Val,FANCD2:NM_001319984.1:synonymous:LOW:exon14/44:c.1122A>G:p.Val374Val		rs34046352	0.0000	0.1239	37/0/37	0.0074							613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];	RCV000247209.1 [benign]; RCV000377963.1 [benign]; 		COSM3759562, COSM3759563	1	957	1	[1] Ilnaz Sepahi 29-03-2016 batch import			FANCD2 (inh=AR pLI=0.00)
chr3	10088266	10088266	G	T	het	het	het		QUAL=4244;DP=255,202,363;MQM=50	FANCD2	splice_region&synonymous	FANCD2:NM_033084.4:splice_region&synonymous:LOW:exon15/43:c.1137G>T:p.Val379Val,FANCD2:NM_001018115.2:splice_region&synonymous:LOW:exon15/44:c.1137G>T:p.Val379Val,FANCD2:NM_001319984.1:splice_region&synonymous:LOW:exon15/44:c.1137G>T:p.Val379Val		rs72492997	0.0000	0.3745	0/0/0	0.0030							613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];	RCV000347785.1 [benign]; 		COSM4157095, COSM4157094	1	1403					FANCD2 (inh=AR pLI=0.00)
chr3	10088299	10088299	C	T	het	het	het	low_MQM	QUAL=5895;DP=332,244,449;MQM=48	FANCD2	synonymous	FANCD2:NM_033084.4:synonymous:LOW:exon15/43:c.1170C>T:p.Ser390Ser,FANCD2:NM_001018115.2:synonymous:LOW:exon15/44:c.1170C>T:p.Ser390Ser,FANCD2:NM_001319984.1:synonymous:LOW:exon15/44:c.1170C>T:p.Ser390Ser		rs112887807	0.0000	0.4304	0/0/0	0.0032							613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];	RCV000400148.1 [benign]; 			1	1912	1	[1] Ilnaz Sepahi 29-03-2016 batch import			FANCD2 (inh=AR pLI=0.00)
chr3	10088308	10088308	T	C	het	het	het	low_MQM	QUAL=6472;DP=302,249,463;MQM=48	FANCD2	synonymous	FANCD2:NM_033084.4:synonymous:LOW:exon15/43:c.1179T>C:p.Thr393Thr,FANCD2:NM_001018115.2:synonymous:LOW:exon15/44:c.1179T>C:p.Thr393Thr,FANCD2:NM_001319984.1:synonymous:LOW:exon15/44:c.1179T>C:p.Thr393Thr		rs72492998	0.0000	0.4331	0/0/0	0.0035							613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];	RCV000289250.1 [benign]; 		COSM4152592, COSM4152593	0	2026	1	[1] Ilnaz Sepahi 29-03-2016 batch import			FANCD2 (inh=AR pLI=0.00)
chr3	10088343	10088343	A	G	het	het	het	low_MQM	QUAL=6096;DP=425,256,472;MQM=45	FANCD2	missense	FANCD2:NM_033084.4:missense:MODERATE:exon15/43:c.1214A>G:p.Asn405Ser,FANCD2:NM_001018115.2:missense:MODERATE:exon15/44:c.1214A>G:p.Asn405Ser,FANCD2:NM_001319984.1:missense:MODERATE:exon15/44:c.1214A>G:p.Asn405Ser		rs73126218	0.0000	0.4201	0/0/0	0.0069	0.2110	T,T,T,T	T	B,B	T,T,T,T	3.37	613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];	RCV000352188.1 [benign]; 		COSM4152595, COSM4152594	0	2070	1	[1] Ilnaz Sepahi 29-03-2016 batch import			FANCD2 (inh=AR pLI=0.00)
chr3	10088404	10088404	C	T	wt	het	het	low_MQM	QUAL=3573;DP=160,181,313;MQM=42	FANCD2	synonymous	FANCD2:NM_033084.4:synonymous:LOW:exon15/43:c.1275C>T:p.Tyr425Tyr,FANCD2:NM_001018115.2:synonymous:LOW:exon15/44:c.1275C>T:p.Tyr425Tyr,FANCD2:NM_001319984.1:synonymous:LOW:exon15/44:c.1275C>T:p.Tyr425Tyr		rs764447374	0.0000	0.0674	0/0/0	0.0001							613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];			COSM1417229, COSM1417230	0	1704	1	[1] Ilnaz Sepahi 29-03-2016 batch import			FANCD2 (inh=AR pLI=0.00)
chr3	10088408	10088408	G	-	wt	het	het	low_MQM;anno_high_impact	QUAL=3573;DP=160,181,313;MQM=42	FANCD2	splice_donor	FANCD2:NM_033084.4:splice_donor:HIGH:exon15/42:c.1278+1delG:,FANCD2:NM_001018115.2:splice_donor:HIGH:exon15/43:c.1278+1delG:,FANCD2:NM_001319984.1:splice_donor:HIGH:exon15/43:c.1278+1delG:		rs750338758	0.0000	0.0348	0/0/0	0.0001							613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];			COSM1417231, COSM1417232	0	1662	1	[1] Ute Grasshoff 22.04.2015 [n/a] comment imported from detected variant: frameshift Ver?nderung durch 1bp del. 			FANCD2 (inh=AR pLI=0.00)
chr3	10088410	10088412	AAG	-	wt	het	het	low_MQM	QUAL=3573;DP=160,181,313;MQM=42	FANCD2	splice_region&intron	FANCD2:NM_033084.4:splice_region&intron:LOW:exon15/42:c.1278+3_1278+5delAAG:,FANCD2:NM_001018115.2:splice_region&intron:LOW:exon15/43:c.1278+3_1278+5delAAG:,FANCD2:NM_001319984.1:splice_region&intron:LOW:exon15/43:c.1278+3_1278+5delAAG:		rs375350046	0.0000	0.0345	0/0/0	0.0001							613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];				0	1662	1	[1] Ilnaz Sepahi 29-03-2016 batch import			FANCD2 (inh=AR pLI=0.00)
chr3	10089723	10089723	G	A	het	het	het		QUAL=9610;DP=278,255,430;MQM=58	FANCD2	synonymous	FANCD2:NM_033084.4:synonymous:LOW:exon16/43:c.1401G>A:p.Thr467Thr,FANCD2:NM_001018115.2:synonymous:LOW:exon16/44:c.1401G>A:p.Thr467Thr,FANCD2:NM_001319984.1:synonymous:LOW:exon16/44:c.1401G>A:p.Thr467Thr		rs12330369	0.0000	0.4495	0/0/0	0.0059							613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];	RCV000354534.1 [benign]; 		COSM4157098, COSM4157099	0	2523	1	[1] Ilnaz Sepahi 29-03-2016 batch import			FANCD2 (inh=AR pLI=0.00)
chr3	10089738	10089738	A	G	het	het	het		QUAL=8689;DP=247,241,410;MQM=57	FANCD2	splice_region&intron	FANCD2:NM_033084.4:splice_region&intron:LOW:exon16/42:c.1413+3A>G:,FANCD2:NM_001018115.2:splice_region&intron:LOW:exon16/43:c.1413+3A>G:,FANCD2:NM_001319984.1:splice_region&intron:LOW:exon16/43:c.1413+3A>G:		rs62245508	0.0000	0.4417	0/0/0	0.0019							613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];	RCV000259684.1 [benign]; 			0	2516	1	[1] old entry - no details available	n/a (1xTP, 0xFP)		FANCD2 (inh=AR pLI=0.00)
chr3	10091049	10091049	C	T	het	het	wt	low_MQM	QUAL=1065;DP=159,108,151;MQM=38	FANCD2	splice_region&intron	FANCD2:NM_033084.4:splice_region&intron:LOW:exon16/42:c.1414-9C>T:,FANCD2:NM_001018115.2:splice_region&intron:LOW:exon16/43:c.1414-9C>T:,FANCD2:NM_001319984.1:splice_region&intron:LOW:exon16/43:c.1414-9C>T:		rs35557429	0.0000	0.0719	212/81/45	0.0034							613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];	RCV000230800.2 [other]; RCV000249372.1 [benign]; 			10	140	1	[1] Ilnaz Sepahi 29-03-2016 batch import			FANCD2 (inh=AR pLI=0.00)
chr3	10091153	10091153	C	T	het	het	het	low_MQM	QUAL=35;DP=310,185,237;MQM=37	FANCD2	synonymous	FANCD2:NM_033084.4:synonymous:LOW:exon17/43:c.1509C>T:p.Asn503Asn,FANCD2:NM_001018115.2:synonymous:LOW:exon17/44:c.1509C>T:p.Asn503Asn,FANCD2:NM_001319984.1:synonymous:LOW:exon17/44:c.1509C>T:p.Asn503Asn		rs6785756	0.0000	0.0075	97/35/34	0.0158							613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];	RCV000254141.1 [benign]; 			25	425					FANCD2 (inh=AR pLI=0.00)
chr3	10106532	10106532	C	T	het	het	het	low_MQM	QUAL=6345;DP=212,171,240;MQM=43	FANCD2	missense	FANCD2:NM_033084.4:missense:MODERATE:exon23/43:c.2141C>T:p.Pro714Leu,FANCD2:NM_001018115.2:missense:MODERATE:exon23/44:c.2141C>T:p.Pro714Leu,FANCD2:NM_001319984.1:missense:MODERATE:exon23/44:c.2141C>T:p.Pro714Leu		rs3864017	0.0000	0.1545	988/525/211	0.0161	-0.1810	T,T,T,T	T	B,B	T,T,T,T	1.75	613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];	RCV000120989.2 [benign]; RCV000372215.1 [benign]; 			65	882	1	[1] Ilnaz Sepahi 29-03-2016 batch import			FANCD2 (inh=AR pLI=0.00)
chr3	10138069	10138069	T	G	het	het	het		QUAL=5928;DP=281,78,112;MQM=60	FANCD2,FANCD2OS	synonymous,intron	FANCD2:NM_033084.4:synonymous:LOW:exon42/43:c.4098T>G:p.Leu1366Leu,FANCD2:NM_001018115.2:synonymous:LOW:exon42/44:c.4098T>G:p.Leu1366Leu,FANCD2:NM_001319984.1:synonymous:LOW:exon42/44:c.4098T>G:p.Leu1366Leu,FANCD2OS:NM_173472.1:intron:MODIFIER:exon2/2:c.*43+7813A>C:		rs2272125	0.2422	0.1868	2695/850/1177	0.1836							613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];	RCV000252662.1 [benign]; RCV000264931.1 [benign]; 	CM066071 [CLASS=DP MUT=ALT PHEN="Breast cancer increased risk association with" GENE=FANCD2]; 	COSM3759565, COSM3759566	92	894	1	[1] Ilnaz Sepahi 29-03-2016 batch import			FANCD2 (inh=AR pLI=0.00), FANCD2OS (inh=n/a pLI=0.05)
chr3	10140671	10140671	G	A	het	het	het		QUAL=13940;DP=474,311,452;MQM=59	FANCD2,FANCD2OS	3'UTR,intron	FANCD2:NM_033084.4:3'UTR:MODIFIER:exon43/43:c.*37G>A:,FANCD2:NM_001018115.2:intron:MODIFIER:exon43/43:c.4281+172G>A:,FANCD2:NM_001319984.1:intron:MODIFIER:exon43/43:c.4281+172G>A:,FANCD2OS:NM_173472.1:intron:MODIFIER:exon2/2:c.*43+5211C>T:		rs7626117	0.3452	0.2285	4893/1088/2964	0.2213							613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];	RCV000325651.1 [benign]; 			43	348					FANCD2 (inh=AR pLI=0.00), FANCD2OS (inh=n/a pLI=0.05)
chr3	10140696	10140696	A	G	het	het	het		QUAL=14993;DP=517,305,428;MQM=60	FANCD2,FANCD2OS	3'UTR,intron	FANCD2:NM_033084.4:3'UTR:MODIFIER:exon43/43:c.*62A>G:,FANCD2:NM_001018115.2:intron:MODIFIER:exon43/43:c.4281+197A>G:,FANCD2:NM_001319984.1:intron:MODIFIER:exon43/43:c.4281+197A>G:,FANCD2OS:NM_173472.1:intron:MODIFIER:exon2/2:c.*43+5186T>C:		rs7647987	0.2412	0.0000	0/0/0	0.0353							613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];	RCV000290667.1 [benign]; 			32	321					FANCD2 (inh=AR pLI=0.00), FANCD2OS (inh=n/a pLI=0.05)
chr3	10141065	10141065	T	G	het	het	het		QUAL=4667;DP=159,84,67;MQM=60	FANCD2,FANCD2OS	3'UTR,intron	FANCD2:NM_033084.4:3'UTR:MODIFIER:exon43/43:c.*431T>G:,FANCD2:NM_001018115.2:intron:MODIFIER:exon43/43:c.4281+566T>G:,FANCD2:NM_001319984.1:intron:MODIFIER:exon43/43:c.4281+566T>G:,FANCD2OS:NM_173472.1:intron:MODIFIER:exon2/2:c.*43+4817A>C:	FLAM_C	rs3826	0.2420	0.0000	0/0/0	0.0302							613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];	RCV000392441.1 [benign]; 			5	60					FANCD2 (inh=AR pLI=0.00), FANCD2OS (inh=n/a pLI=0.05)
chr3	10141184	10141184	C	T	het	het	het	low_DP	QUAL=738;DP=56,16,14;MQM=58	FANCD2,FANCD2OS	3'UTR,intron	FANCD2:NM_033084.4:3'UTR:MODIFIER:exon43/43:c.*550C>T:,FANCD2:NM_001018115.2:intron:MODIFIER:exon43/43:c.4281+685C>T:,FANCD2:NM_001319984.1:intron:MODIFIER:exon43/43:c.4281+685C>T:,FANCD2OS:NM_173472.1:intron:MODIFIER:exon2/2:c.*43+4698G>A:	AluSg	rs11716842	0.2061	0.0000	0/0/0	0.3041							613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];	RCV000392450.1 [benign]; 			47	97					FANCD2 (inh=AR pLI=0.00), FANCD2OS (inh=n/a pLI=0.05)
chr3	10142949	10142949	C	T	het	het	het		QUAL=6640;DP=168,189,221;MQM=60	FANCD2,FANCD2OS	3'UTR,intron	FANCD2:NM_001018115.2:3'UTR:MODIFIER:exon44/44:c.*3C>T:,FANCD2:NM_001319984.1:3'UTR:MODIFIER:exon44/44:c.*3C>T:,FANCD2OS:NM_173472.1:intron:MODIFIER:exon2/2:c.*43+2933G>A:		rs3172417	0.2147	0.3281	7582/6000/24	0.3246							613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];	RCV000251855.1 [benign]; 		COSN166813	531	1537	1	[1] Ilnaz Sepahi 29-03-2016 batch import			FANCD2 (inh=AR pLI=0.00), FANCD2OS (inh=n/a pLI=0.05)
chr3	10143274	10143274	C	T	het	het	het		QUAL=7537;DP=244,159,216;MQM=59	FANCD2,FANCD2OS	3'UTR,intron	FANCD2:NM_001018115.2:3'UTR:MODIFIER:exon44/44:c.*328C>T:,FANCD2:NM_001319984.1:3'UTR:MODIFIER:exon44/44:c.*328C>T:,FANCD2OS:NM_173472.1:intron:MODIFIER:exon2/2:c.*43+2608G>A:	AluSc8	rs58275763	0.1917	0.0000	0/0/0	0.1602							613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];				4	51					FANCD2 (inh=AR pLI=0.00), FANCD2OS (inh=n/a pLI=0.05)
chr3	10143328	10143328	A	T	het	het	het		QUAL=11469;DP=350,268,314;MQM=58	FANCD2,FANCD2OS	3'UTR,intron	FANCD2:NM_001018115.2:3'UTR:MODIFIER:exon44/44:c.*382A>T:,FANCD2:NM_001319984.1:3'UTR:MODIFIER:exon44/44:c.*382A>T:,FANCD2OS:NM_173472.1:intron:MODIFIER:exon2/2:c.*43+2554T>A:	AluSc8	rs59318799	0.1925	0.0000	0/0/0	0.1603							613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];				3	54					FANCD2 (inh=AR pLI=0.00), FANCD2OS (inh=n/a pLI=0.05)
chr3	12526002	12526002	G	A	wt	het	wt		QUAL=4839;DP=56,190,306;MQM=60	TSEN2	5'UTR_premature_start_codon_gain,5'UTR,non_coding_transcript_exon	TSEN2:NM_001321278.1:5'UTR_premature_start_codon_gain:LOW:exon1/12:c.-32G>A:,TSEN2:NM_001145393.2:5'UTR_premature_start_codon_gain:LOW:exon1/11:c.-32G>A:,TSEN2:NM_001145394.1:5'UTR_premature_start_codon_gain:LOW:exon1/13:c.-32G>A:,TSEN2:NM_001321277.1:5'UTR_premature_start_codon_gain:LOW:exon1/12:c.-32G>A:,TSEN2:NM_001321278.1:5'UTR:MODIFIER:exon1/12:c.-32G>A:,TSEN2:NM_001145393.2:5'UTR:MODIFIER:exon1/11:c.-32G>A:,TSEN2:NM_001145394.1:5'UTR:MODIFIER:exon1/13:c.-32G>A:,TSEN2:NM_001321277.1:5'UTR:MODIFIER:exon1/12:c.-32G>A:,TSEN2:NR_135607.1:non_coding_transcript_exon:MODIFIER:exon1/13:n.72G>A:		rs577952599	0.0008	0.0000	0/0/0	0.0013							608753 [TSEN2 (provisional) Pontocerebellar hypoplasia type 2B,612389];				0	1					TSEN2 (inh=AR pLI=0.00)
chr3	12526006	12526006	G	A	het	hom	wt		QUAL=4839;DP=56,190,306;MQM=60	TSEN2	5'UTR,non_coding_transcript_exon	TSEN2:NM_001321278.1:5'UTR:MODIFIER:exon1/12:c.-28G>A:,TSEN2:NM_001145393.2:5'UTR:MODIFIER:exon1/11:c.-28G>A:,TSEN2:NM_001145394.1:5'UTR:MODIFIER:exon1/13:c.-28G>A:,TSEN2:NM_001321277.1:5'UTR:MODIFIER:exon1/12:c.-28G>A:,TSEN2:NR_135607.1:non_coding_transcript_exon:MODIFIER:exon1/13:n.76G>A:		rs3806662	0.0791	0.0000	0/0/0	0.0571							608753 [TSEN2 (provisional) Pontocerebellar hypoplasia type 2B,612389];	RCV000302493.1 [likely benign]; 			5	23					TSEN2 (inh=AR pLI=0.00)
chr3	12526188	12526188	G	T	het	wt	het		QUAL=7476;DP=215,301,361;MQM=60	TSEN2	5'UTR,intron	TSEN2:NM_025265.3:5'UTR:MODIFIER:exon1/12:c.-209G>T:,TSEN2:NM_001321279.1:5'UTR:MODIFIER:exon1/11:c.-209G>T:,TSEN2:NM_001321278.1:intron:MODIFIER:exon1/11:c.-18+172G>T:,TSEN2:NM_001145393.2:intron:MODIFIER:exon1/10:c.-18+172G>T:,TSEN2:NM_001145394.1:intron:MODIFIER:exon1/12:c.-18+172G>T:,TSEN2:NM_001321277.1:intron:MODIFIER:exon1/11:c.-18+172G>T:,TSEN2:NR_135607.1:intron:MODIFIER:exon1/12:n.86+172G>T:,TSEN2:NM_001145392.1:intron:MODIFIER:exon1/11:c.-18+61G>T:		rs709161	0.4545	0.0000	0/0/0	0.4486							608753 [TSEN2 (provisional) Pontocerebellar hypoplasia type 2B,612389];	RCV000330522.1 [benign]; 			55	106					TSEN2 (inh=AR pLI=0.00)
chr3	12526297	12526299	GCA	-	wt	wt	het		QUAL=2085;DP=87,191,192;MQM=60	TSEN2	5'UTR,intron	TSEN2:NM_025265.3:5'UTR:MODIFIER:exon1/12:c.-98_-96delAGC:,TSEN2:NM_001321279.1:5'UTR:MODIFIER:exon1/11:c.-98_-96delAGC:,TSEN2:NM_001321278.1:intron:MODIFIER:exon1/11:c.-18+283_-18+285delAGC:,TSEN2:NM_001145393.2:intron:MODIFIER:exon1/10:c.-18+283_-18+285delAGC:,TSEN2:NM_001145394.1:intron:MODIFIER:exon1/12:c.-18+283_-18+285delAGC:,TSEN2:NM_001321277.1:intron:MODIFIER:exon1/11:c.-18+283_-18+285delAGC:,TSEN2:NR_135607.1:intron:MODIFIER:exon1/12:n.86+283_86+285delAGC:,TSEN2:NM_001145392.1:intron:MODIFIER:exon1/11:c.-18+172_-18+174delAGC:		rs540848445	0.0022	0.0000	0/0/0	0.0089							608753 [TSEN2 (provisional) Pontocerebellar hypoplasia type 2B,612389];				0	10					TSEN2 (inh=AR pLI=0.00)
chr3	12544829	12544829	G	A	het	hom	wt		QUAL=7396;DP=137,183,243;MQM=60	TSEN2	missense,non_coding_transcript_exon	TSEN2:NM_001321278.1:missense:MODERATE:exon5/12:c.377G>A:p.Arg126His,TSEN2:NM_001145393.2:missense:MODERATE:exon5/11:c.377G>A:p.Arg126His,TSEN2:NM_001145394.1:missense:MODERATE:exon5/13:c.377G>A:p.Arg126His,TSEN2:NM_001321277.1:missense:MODERATE:exon5/12:c.377G>A:p.Arg126His,TSEN2:NM_001145392.1:missense:MODERATE:exon5/12:c.377G>A:p.Arg126His,TSEN2:NM_025265.3:missense:MODERATE:exon5/12:c.377G>A:p.Arg126His,TSEN2:NM_001321279.1:missense:MODERATE:exon5/11:c.377G>A:p.Arg126His,TSEN2:NR_135607.1:non_coding_transcript_exon:MODIFIER:exon5/13:n.480G>A:		rs33955793	0.0587	0.0778	827/113/21	0.0718	-0.3930	T,T,T,T,T,T,T,T,T	T	B,B,B,B	T,T,T,T,T,T,T,T	0.14	608753 [TSEN2 (provisional) Pontocerebellar hypoplasia type 2B,612389];	RCV000082253.7 [benign]; RCV000310262.1 [benign]; 			14	265					TSEN2 (inh=AR pLI=0.00)
chr3	12571421	12571421	T	-	het	wt	het		QUAL=4836;DP=244,156,231;MQM=59	TSEN2	intron	TSEN2:NM_001321278.1:intron:MODIFIER:exon10/11:c.1248+61delT:,TSEN2:NM_001145393.2:intron:MODIFIER:exon9/10:c.1170+61delT:,TSEN2:NM_001145394.1:intron:MODIFIER:exon11/12:c.1071+61delT:,TSEN2:NM_001321277.1:intron:MODIFIER:exon10/11:c.1248+61delT:,TSEN2:NR_135607.1:intron:MODIFIER:exon10/12:n.1351+61delT:,TSEN2:NM_001145392.1:intron:MODIFIER:exon10/11:c.1248+61delT:,TSEN2:NM_025265.3:intron:MODIFIER:exon10/11:c.1248+61delT:,TSEN2:NM_001321279.1:intron:MODIFIER:exon9/10:c.1170+61delT:		rs35445022	0.0000	0.2084	318/249/0	0.1378							608753 [TSEN2 (provisional) Pontocerebellar hypoplasia type 2B,612389];				31	793					TSEN2 (inh=AR pLI=0.00)
chr3	12574512	12574512	G	T	het	wt	het		QUAL=3570;DP=256,38,42;MQM=60	TSEN2	3'UTR,intron	TSEN2:NM_001145393.2:3'UTR:MODIFIER:exon11/11:c.*292G>T:,TSEN2:NM_001145394.1:3'UTR:MODIFIER:exon13/13:c.*292G>T:,TSEN2:NM_001321277.1:3'UTR:MODIFIER:exon12/12:c.*292G>T:,TSEN2:NM_001145392.1:3'UTR:MODIFIER:exon12/12:c.*292G>T:,TSEN2:NM_025265.3:3'UTR:MODIFIER:exon12/12:c.*292G>T:,TSEN2:NM_001321279.1:3'UTR:MODIFIER:exon11/11:c.*292G>T:,TSEN2:NM_001321278.1:intron:MODIFIER:exon11/11:c.1338+1354G>T:,TSEN2:NR_135607.1:intron:MODIFIER:exon12/12:n.1553+240G>T:		rs299643	0.4219	0.0000	0/0/0	0.0708							608753 [TSEN2 (provisional) Pontocerebellar hypoplasia type 2B,612389];	RCV000301498.1 [benign]; 			55	101					TSEN2 (inh=AR pLI=0.00)
chr3	12625747	12625747	G	A	het	hom	wt		QUAL=21864;DP=460,514,701;MQM=59	RAF1	3'UTR	RAF1:NM_002880.3:3'UTR:MODIFIER:exon17/17:c.*266C>T:		rs1051208	0.1739	0.0000	0/0/0	0.0266							164760 [RAF1 (confirmed) Noonan syndrome 5,611553|LEOPARD syndrome 2,611554|Cardiomyopathy,dilated,1NN,615916];	RCV000273821.1 [likely benign]; RCV000368248.1 [likely benign]; 			8	66					RAF1 (inh=AD pLI=1.00)
chr3	14174427	14174427	A	T	wt	wt	het		QUAL=5075;DP=202,291,371;MQM=60	TMEM43	missense	TMEM43:NM_024334.2:missense:MODERATE:exon6/12:c.504A>T:p.Lys168Asn		rs4685076	0.3526	0.3209	6564/2617/452	0.3178	0.9050	T	T	B	T	19.40	612048 [TMEM43 (confirmed) Arrhythmogenic right ventricular dysplasia 5,604400|Emery-Dreifuss muscular dystrophy 7,AD,614302];	RCV000039387.10 [benign]; RCV000242086.1 [benign]; RCV000325369.1 [likely benign]; 		COSM3759801	111	657					TMEM43 (inh=AD pLI=0.00)
chr3	14175262	14175262	T	C	wt	wt	het	pred_pathogenic	QUAL=2994;DP=224,143,216;MQM=60	TMEM43	missense	TMEM43:NM_024334.2:missense:MODERATE:exon7/12:c.536T>C:p.Met179Thr		rs2340917	0.4633	0.3724	9463/2754/940	0.3689	3.0480	T	T	B	T	6.86	612048 [TMEM43 (confirmed) Arrhythmogenic right ventricular dysplasia 5,604400|Emery-Dreifuss muscular dystrophy 7,AD,614302];	RCV000039389.10 [benign]; RCV000244862.1 [benign]; RCV000379959.1 [likely benign]; 		COSM3759802	133	673					TMEM43 (inh=AD pLI=0.00)
chr3	14183410	14183410	T	C	het	hom	het		QUAL=17617;DP=296,336,375;MQM=59	TMEM43	3'UTR	TMEM43:NM_024334.2:3'UTR:MODIFIER:exon12/12:c.*115T>C:		rs1043943	0.6891	0.0000	0/0/0	0.1071							612048 [TMEM43 (confirmed) Arrhythmogenic right ventricular dysplasia 5,604400|Emery-Dreifuss muscular dystrophy 7,AD,614302];	RCV000366934.1 [likely benign]; RCV000374920.1 [benign]; 			80	93					TMEM43 (inh=AD pLI=0.00)
chr3	14183758	14183758	A	G	het	hom	wt		QUAL=12675;DP=370,254,324;MQM=60	TMEM43	3'UTR	TMEM43:NM_024334.2:3'UTR:MODIFIER:exon12/12:c.*463A>G:		rs1043953	0.0927	0.0000	0/0/0	0.0311							612048 [TMEM43 (confirmed) Arrhythmogenic right ventricular dysplasia 5,604400|Emery-Dreifuss muscular dystrophy 7,AD,614302];	RCV000284996.1 [likely benign]; RCV000295901.1 [likely benign]; 			6	72					TMEM43 (inh=AD pLI=0.00)
chr3	14184074	14184074	A	C	het	hom	wt		QUAL=11978;DP=399,204,286;MQM=60	TMEM43	3'UTR	TMEM43:NM_024334.2:3'UTR:MODIFIER:exon12/12:c.*779A>C:		rs13069	0.1300	0.0000	0/0/0	0.0306							612048 [TMEM43 (confirmed) Arrhythmogenic right ventricular dysplasia 5,604400|Emery-Dreifuss muscular dystrophy 7,AD,614302];	RCV000287769.1 [likely benign]; RCV000296687.1 [likely benign]; 			9	83					TMEM43 (inh=AD pLI=0.00)
chr3	14184669	14184669	T	C	het	hom	wt		QUAL=10614;DP=303,207,229;MQM=60	TMEM43	3'UTR	TMEM43:NM_024334.2:3'UTR:MODIFIER:exon12/12:c.*1374T>C:		rs8516	0.1048	0.0000	0/0/0	0.0266							612048 [TMEM43 (confirmed) Arrhythmogenic right ventricular dysplasia 5,604400|Emery-Dreifuss muscular dystrophy 7,AD,614302];	RCV000302250.1 [likely benign]; RCV000318138.1 [likely benign]; 			6	72					TMEM43 (inh=AD pLI=0.00)
chr3	14184719	14184719	T	C	het	hom	wt		QUAL=9704;DP=331,171,205;MQM=60	TMEM43	3'UTR	TMEM43:NM_024334.2:3'UTR:MODIFIER:exon12/12:c.*1424T>C:		rs10468	0.1306	0.0000	0/0/0	0.0302							612048 [TMEM43 (confirmed) Arrhythmogenic right ventricular dysplasia 5,604400|Emery-Dreifuss muscular dystrophy 7,AD,614302];	RCV000340739.1 [likely benign]; RCV000372953.1 [likely benign]; 			9	83					TMEM43 (inh=AD pLI=0.00)
chr3	14186757	14186757	C	G	hom	hom	hom		QUAL=17949;DP=277,130,157;MQM=60	XPC	3'UTR,non_coding_transcript_exon	XPC:NM_004628.4:3'UTR:MODIFIER:exon16/16:c.*684G>C:,XPC:NR_027299.1:non_coding_transcript_exon:MODIFIER:exon15/15:n.3487G>C:		rs1126547	0.9189	0.9177	3487/770/66	0.2094							613208 [XPC (confirmed) Xeroderma pigmentosum,group C,278720];	RCV000355609.1 [benign]; RCV000397507.1 [likely benign]; 			493	145					XPC (inh=AR pLI=0.00)
chr3	14186823	14186823	T	C	het	hom	wt		QUAL=12347;DP=302,245,301;MQM=59	XPC	3'UTR,non_coding_transcript_exon	XPC:NM_004628.4:3'UTR:MODIFIER:exon16/16:c.*618A>G:,XPC:NR_027299.1:non_coding_transcript_exon:MODIFIER:exon15/15:n.3421A>G:		rs2470458	0.1078	0.1288	122/56/2	0.0251							613208 [XPC (confirmed) Xeroderma pigmentosum,group C,278720];	RCV000263158.1 [likely benign]; RCV000305702.1 [likely benign]; 			29	205					XPC (inh=AR pLI=0.00)
chr3	14186830	14186830	A	T	het	hom	wt		QUAL=12742;DP=313,251,312;MQM=59	XPC	3'UTR,non_coding_transcript_exon	XPC:NM_004628.4:3'UTR:MODIFIER:exon16/16:c.*611T>A:,XPC:NR_027299.1:non_coding_transcript_exon:MODIFIER:exon15/15:n.3414T>A:		rs2470352	0.1082	0.1282	121/55/2	0.0354							613208 [XPC (confirmed) Xeroderma pigmentosum,group C,278720];	RCV000296984.1 [likely benign]; RCV000353421.1 [likely benign]; 			29	206					XPC (inh=AR pLI=0.00)
chr3	14187345	14187345	G	C	het	hom	wt		QUAL=6477;DP=216,137,223;MQM=59	XPC	3'UTR,non_coding_transcript_exon	XPC:NM_004628.4:3'UTR:MODIFIER:exon16/16:c.*96C>G:,XPC:NR_027299.1:non_coding_transcript_exon:MODIFIER:exon15/15:n.2899C>G:		rs2229090	0.2550	0.3533	2507/1406/39	0.2237							613208 [XPC (confirmed) Xeroderma pigmentosum,group C,278720];	RCV000273637.1 [likely benign]; RCV000289517.1 [benign]; 			47	229					XPC (inh=AR pLI=0.00)
chr3	14187449	14187449	G	T	het	hom	het	pred_pathogenic	QUAL=13423;DP=305,198,331;MQM=59	XPC	missense,non_coding_transcript_exon	XPC:NM_004628.4:missense:MODERATE:exon16/16:c.2815C>A:p.Gln939Lys,XPC:NR_027299.1:non_coding_transcript_exon:MODIFIER:exon15/15:n.2795C>A:		rs2228001	0.6847	0.6325	24273/11654/2594	0.6119	2.9050	T,T	T	B,B	T,T	12.01	613208 [XPC (confirmed) Xeroderma pigmentosum,group C,278720];	RCV000170436.2 [benign]; RCV000211268.1 [drug response]; RCV000331098.1 [likely benign]; RCV000380504.1 [benign]; 	CM070359 [CLASS=DFP MUT=REF PHEN="DNA repair rate association with" GENE=XPC]; 	COSM4002478	977	1372					XPC (inh=AR pLI=0.00)
chr3	14190237	14190237	T	G	het	hom	het		QUAL=15305;DP=202,266,363;MQM=59	XPC	splice_region&intron	XPC:NM_004628.4:splice_region&intron:LOW:exon12/15:c.2251-6A>C:,XPC:NR_027299.1:splice_region&intron:LOW:exon11/14:n.2231-6A>C:		rs2279017	0.6797	0.6302	24122/11660/2445	0.6138							613208 [XPC (confirmed) Xeroderma pigmentosum,group C,278720];	RCV000170435.2 [benign]; RCV000301008.1 [benign]; 			980	1375					XPC (inh=AR pLI=0.00)
chr3	14193889	14193889	C	T	wt	wt	het	pred_pathogenic	QUAL=5380;DP=396,314,423;MQM=60	XPC	synonymous,non_coding_transcript_exon	XPC:NM_004628.4:synonymous:LOW:exon11/16:c.2061G>A:p.Arg687Arg,XPC:NR_027299.1:non_coding_transcript_exon:MODIFIER:exon10/15:n.2041G>A:		rs2227998	0.2354	0.2734	3890/2045/448	0.2477	2.3260	T	T			15.05	613208 [XPC (confirmed) Xeroderma pigmentosum,group C,278720];	RCV000122327.2 [benign]; RCV000314393.1 [benign]; 		COSM3759803	193	1038					XPC (inh=AR pLI=0.00)
chr3	14197987	14197987	A	T	hom	hom	hom		QUAL=26408;DP=155,290,394;MQM=60	XPC	synonymous,non_coding_transcript_exon	XPC:NM_004628.4:synonymous:LOW:exon10/16:c.1881T>A:p.Ala627Ala,XPC:NR_027299.1:non_coding_transcript_exon:MODIFIER:exon9/15:n.1861T>A:		rs2958057	1.0000	1.0000	60391/33370/4907	0.9326							613208 [XPC (confirmed) Xeroderma pigmentosum,group C,278720];	RCV000170433.1 [benign]; 			2931	0					XPC (inh=AR pLI=0.00)
chr3	14199887	14199887	G	A	het	hom	wt		QUAL=14092;DP=425,303,390;MQM=60	XPC	missense,non_coding_transcript_exon	XPC:NM_004628.4:missense:MODERATE:exon9/16:c.1496C>T:p.Ala499Val,XPC:NR_027299.1:non_coding_transcript_exon:MODIFIER:exon8/15:n.1476C>T:		rs2228000	0.2330	0.2378	3688/2040/44	0.2362		T,T	T	B,B	T,T	3.20	613208 [XPC (confirmed) Xeroderma pigmentosum,group C,278720];	RCV000122343.2 [benign]; RCV000325908.1 [benign]; 	CM057944 [CLASS=DP MUT=ALT PHEN="Lung cancer association with" GENE=XPC]; 		182	987					XPC (inh=AR pLI=0.00)
chr3	14220095	14220095	C	G	het	hom	het		QUAL=9826;DP=110,195,212;MQM=60	XPC	5'UTR,non_coding_transcript_exon	XPC:NM_004628.4:5'UTR:MODIFIER:exon1/16:c.-27G>C:,XPC:NR_027299.1:non_coding_transcript_exon:MODIFIER:exon1/15:n.78G>C:		rs2607775	0.3279	0.4211	11016/7269/639	0.4063							613208 [XPC (confirmed) Xeroderma pigmentosum,group C,278720];	RCV000247851.1 [benign]; RCV000346126.1 [benign]; 			329	747					XPC (inh=AR pLI=0.00)
chr3	15563250	15563253	GTGC	-	wt	het	wt		QUAL=78;DP=117,93,146;MQM=60	COLQ	5'UTR	COLQ:NM_005677.3:5'UTR:MODIFIER:exon1/17:c.-121_-118delGCAC:,COLQ:NM_080539.3:5'UTR:MODIFIER:exon1/16:c.-121_-118delGCAC:	(GT)n		0.0000	0.0000	0/0/0	0.0027							603033 [COLQ (confirmed) Myasthenic syndrome,congenital,5,603034];	RCV000277951.1 [uncertain significance]; 			0	6					COLQ (inh=AR pLI=0.00)
chr3	15563259	15563259	T	C	wt	het	wt		QUAL=109;DP=124,96,142;MQM=60	COLQ-HACL1	intergenic_region	COLQ-HACL1:COLQ-HACL1:intergenic_region:MODIFIER::n.15563259T>C:	(GT)n		0.0000	0.0000	0/0/0	0.0000							603033 [COLQ (confirmed) Myasthenic syndrome,congenital,5,603034];				0	11					COLQ-HACL1 (inh=n/a pLI=n/a)
chr3	15563268	15563268	C	G	wt	het	wt		QUAL=584;DP=119,77,125;MQM=59	COLQ-HACL1	intergenic_region	COLQ-HACL1:COLQ-HACL1:intergenic_region:MODIFIER::n.15563268C>G:	(GT)n	rs9836565	0.4201	0.0000	0/0/0	0.1437							603033 [COLQ (confirmed) Myasthenic syndrome,congenital,5,603034];	RCV000403115.1 [benign]; 			31	89					COLQ-HACL1 (inh=n/a pLI=n/a)
chr3	15677019	15677019	G	A	het	wt	het	pred_pathogenic;anno_pathogenic_clinvar;anno_pathogenic_hgmd	QUAL=8630;DP=263,309,394;MQM=59	BTD	missense	BTD:NM_001281723.2:missense:MODERATE:exon2/4:c.139G>A:p.Gly47Arg,BTD:NM_001281726.1:missense:MODERATE:exon2/3:c.133G>A:p.Gly45Arg,BTD:NM_000060.4:missense:MODERATE:exon2/4:c.133G>A:p.Gly45Arg,BTD:NM_001281724.2:missense:MODERATE:exon4/6:c.139G>A:p.Gly47Arg,BTD:NM_001323582.1:missense:MODERATE:exon3/5:c.73G>A:p.Gly25Arg,BTD:NM_001281725.2:missense:MODERATE:exon2/4:c.73G>A:p.Gly25Arg		rs34885143	0.0038	0.0099	11/9/0	0.0099	-0.0370	T,T,T,T,T,T	T	B,B,B	D,D,D,D,D,D	3.52	609019 [BTD (provisional) Biotinidase deficiency,253260];	RCV000021888.2 [pathogenic]; RCV000021889.1 [pathogenic]; RCV000021890.1 [pathogenic]; RCV000185799.2 [other]; 	CM993540 [CLASS=DM? MUT=ALT PHEN="Biotinidase deficiency" GENE=BTD]; 		1	62	2	[2] old entry - no details available			BTD (inh=AR pLI=0.00)
chr3	24159008	24159008	G	A	het	wt	het		QUAL=9716;DP=343,278,425;MQM=60	THRB	3'UTR	THRB:NM_000461.4:3'UTR:MODIFIER:exon10/10:c.*5367C>T:,THRB:NM_001128176.2:3'UTR:MODIFIER:exon11/11:c.*5367C>T:,THRB:NM_001128177.1:3'UTR:MODIFIER:exon11/11:c.*5367C>T:,THRB:NM_001252634.1:3'UTR:MODIFIER:exon12/12:c.*5367C>T:	MLT1K	rs2167116	0.2145	0.0000	0/0/0	0.1131							190160 [THRB (confirmed) Thyroid hormone resistance,188570|Thyroid hormone resistance,autosomal recessive,274300|Thyroid hormone resistance,selective pituitary,145650];	RCV000260123.1 [benign]; 			0	33					THRB (inh=AR+AD pLI=0.99)
chr3	24159023	24159023	G	A	het	wt	het		QUAL=9377;DP=340,257,384;MQM=60	THRB	3'UTR	THRB:NM_000461.4:3'UTR:MODIFIER:exon10/10:c.*5352C>T:,THRB:NM_001128176.2:3'UTR:MODIFIER:exon11/11:c.*5352C>T:,THRB:NM_001128177.1:3'UTR:MODIFIER:exon11/11:c.*5352C>T:,THRB:NM_001252634.1:3'UTR:MODIFIER:exon12/12:c.*5352C>T:	MLT1K	rs56204436	0.1160	0.0000	0/0/0	0.0776							190160 [THRB (confirmed) Thyroid hormone resistance,188570|Thyroid hormone resistance,autosomal recessive,274300|Thyroid hormone resistance,selective pituitary,145650];	RCV000317658.1 [benign]; 			1	26					THRB (inh=AR+AD pLI=0.99)
chr3	24159387	24159387	A	G	het	hom	het		QUAL=17336;DP=236,270,355;MQM=60	THRB	3'UTR	THRB:NM_000461.4:3'UTR:MODIFIER:exon10/10:c.*4988T>C:,THRB:NM_001128176.2:3'UTR:MODIFIER:exon11/11:c.*4988T>C:,THRB:NM_001128177.1:3'UTR:MODIFIER:exon11/11:c.*4988T>C:,THRB:NM_001252634.1:3'UTR:MODIFIER:exon12/12:c.*4988T>C:		rs1349265	0.4802	0.0000	0/0/0	0.6206							190160 [THRB (confirmed) Thyroid hormone resistance,188570|Thyroid hormone resistance,autosomal recessive,274300|Thyroid hormone resistance,selective pituitary,145650];	RCV000399046.1 [benign]; 			102	100					THRB (inh=AR+AD pLI=0.99)
chr3	24163021	24163021	T	C	wt	wt	het		QUAL=4257;DP=542,272,347;MQM=60	THRB	3'UTR	THRB:NM_000461.4:3'UTR:MODIFIER:exon10/10:c.*1354A>G:,THRB:NM_001128176.2:3'UTR:MODIFIER:exon11/11:c.*1354A>G:,THRB:NM_001128177.1:3'UTR:MODIFIER:exon11/11:c.*1354A>G:,THRB:NM_001252634.1:3'UTR:MODIFIER:exon12/12:c.*1354A>G:		rs844107	0.5054	0.0000	0/0/0	0.0761							190160 [THRB (confirmed) Thyroid hormone resistance,188570|Thyroid hormone resistance,autosomal recessive,274300|Thyroid hormone resistance,selective pituitary,145650];	RCV000315009.1 [benign]; 			48	106					THRB (inh=AR+AD pLI=0.99)
chr3	24163645	24163645	C	G	wt	wt	het		QUAL=4467;DP=285,274,341;MQM=60	THRB	3'UTR	THRB:NM_000461.4:3'UTR:MODIFIER:exon10/10:c.*730G>C:,THRB:NM_001128176.2:3'UTR:MODIFIER:exon11/11:c.*730G>C:,THRB:NM_001128177.1:3'UTR:MODIFIER:exon11/11:c.*730G>C:,THRB:NM_001252634.1:3'UTR:MODIFIER:exon12/12:c.*730G>C:		rs826371	0.2508	0.0000	0/0/0	0.2658							190160 [THRB (confirmed) Thyroid hormone resistance,188570|Thyroid hormone resistance,autosomal recessive,274300|Thyroid hormone resistance,selective pituitary,145650];	RCV000376155.1 [benign]; 			20	82					THRB (inh=AR+AD pLI=0.99)
chr3	24163705	24163705	T	C	wt	wt	het		QUAL=4008;DP=298,251,322;MQM=59	THRB	3'UTR	THRB:NM_000461.4:3'UTR:MODIFIER:exon10/10:c.*670A>G:,THRB:NM_001128176.2:3'UTR:MODIFIER:exon11/11:c.*670A>G:,THRB:NM_001128177.1:3'UTR:MODIFIER:exon11/11:c.*670A>G:,THRB:NM_001252634.1:3'UTR:MODIFIER:exon12/12:c.*670A>G:		rs826372	0.2528	0.0000	0/0/0	0.0458							190160 [THRB (confirmed) Thyroid hormone resistance,188570|Thyroid hormone resistance,autosomal recessive,274300|Thyroid hormone resistance,selective pituitary,145650];	RCV000281693.1 [benign]; 			20	82					THRB (inh=AR+AD pLI=0.99)
chr3	24163773	24163773	C	G	wt	wt	het		QUAL=5774;DP=313,328,418;MQM=60	THRB	3'UTR	THRB:NM_000461.4:3'UTR:MODIFIER:exon10/10:c.*602G>C:,THRB:NM_001128176.2:3'UTR:MODIFIER:exon11/11:c.*602G>C:,THRB:NM_001128177.1:3'UTR:MODIFIER:exon11/11:c.*602G>C:,THRB:NM_001252634.1:3'UTR:MODIFIER:exon12/12:c.*602G>C:		rs826373	0.2790	0.0000	0/0/0	0.2725							190160 [THRB (confirmed) Thyroid hormone resistance,188570|Thyroid hormone resistance,autosomal recessive,274300|Thyroid hormone resistance,selective pituitary,145650];	RCV000336600.1 [benign]; RCV000395611.1 [uncertain significance]; 			20	83					THRB (inh=AR+AD pLI=0.99)
chr3	24163921	24163921	A	C	wt	wt	het		QUAL=7565;DP=321,356,520;MQM=60	THRB	3'UTR	THRB:NM_000461.4:3'UTR:MODIFIER:exon10/10:c.*454T>G:,THRB:NM_001128176.2:3'UTR:MODIFIER:exon11/11:c.*454T>G:,THRB:NM_001128177.1:3'UTR:MODIFIER:exon11/11:c.*454T>G:,THRB:NM_001252634.1:3'UTR:MODIFIER:exon12/12:c.*454T>G:		rs826374	0.2512	0.0000	0/0/0	0.0453							190160 [THRB (confirmed) Thyroid hormone resistance,188570|Thyroid hormone resistance,autosomal recessive,274300|Thyroid hormone resistance,selective pituitary,145650];	RCV000395616.1 [benign]; 			20	82					THRB (inh=AR+AD pLI=0.99)
chr3	24163964	24163964	T	C	wt	wt	het		QUAL=7234;DP=397,333,468;MQM=60	THRB	3'UTR	THRB:NM_000461.4:3'UTR:MODIFIER:exon10/10:c.*411A>G:,THRB:NM_001128176.2:3'UTR:MODIFIER:exon11/11:c.*411A>G:,THRB:NM_001128177.1:3'UTR:MODIFIER:exon11/11:c.*411A>G:,THRB:NM_001252634.1:3'UTR:MODIFIER:exon12/12:c.*411A>G:		rs826375	0.2750	0.0000	0/0/0	0.0471							190160 [THRB (confirmed) Thyroid hormone resistance,188570|Thyroid hormone resistance,autosomal recessive,274300|Thyroid hormone resistance,selective pituitary,145650];	RCV000312360.1 [benign]; 			21	82					THRB (inh=AR+AD pLI=0.99)
chr3	24168981	24168981	C	T	het	het	wt		QUAL=336;DP=23,27,57;MQM=60	THRB	splice_region&intron	THRB:NM_000461.4:splice_region&intron:LOW:exon9/9:c.1144+9G>A:,THRB:NM_001128176.2:splice_region&intron:LOW:exon10/10:c.1144+9G>A:,THRB:NM_001128177.1:splice_region&intron:LOW:exon10/10:c.1144+9G>A:,THRB:NM_001252634.1:splice_region&intron:LOW:exon11/11:c.1144+9G>A:		rs13063628	0.0629	0.1103	912/696/17	0.1049							190160 [THRB (confirmed) Thyroid hormone resistance,188570|Thyroid hormone resistance,autosomal recessive,274300|Thyroid hormone resistance,selective pituitary,145650];	RCV000248310.1 [benign]; RCV000360381.1 [benign]; 			36	313					THRB (inh=AR+AD pLI=0.99)
chr3	24270500	24270500	-	A	hom	het	het		QUAL=6532;DP=138,95,107;MQM=59	THRB	splice_region&intron	THRB:NM_000461.4:splice_region&intron:LOW:exon2/9:c.-42-9dupT:,THRB:NM_001128176.2:splice_region&intron:LOW:exon3/10:c.-42-9dupT:,THRB:NM_001128177.1:splice_region&intron:LOW:exon3/10:c.-42-9dupT:,THRB:NM_001252634.1:splice_region&intron:LOW:exon4/11:c.-42-9dupT:		rs397841135	0.0000	0.3224	7102/2298/1738	0.2855							190160 [THRB (confirmed) Thyroid hormone resistance,188570|Thyroid hormone resistance,autosomal recessive,274300|Thyroid hormone resistance,selective pituitary,145650];	RCV000372287.1 [benign]; 			74	313					THRB (inh=AR+AD pLI=0.99)
chr3	30733402	30733403	TA	-	hom	hom	wt	low_DP	QUAL=84;DP=7,2,107;MQM=60	TGFBR2	3'UTR	TGFBR2:NM_001024847.2:3'UTR:MODIFIER:exon8/8:c.*328_*329delAT:,TGFBR2:NM_003242.5:3'UTR:MODIFIER:exon7/7:c.*328_*329delAT:	(TA)n	rs750106981	0.0000	0.0000	0/0/0	0.1168							190182 [TGFBR2 (confirmed) Colorectal cancer,hereditary nonpolyposis,type 6,614331|Esophageal cancer,somatic,133239|Loeys-Dietz syndrome 2,610168];				29	60					TGFBR2 (inh=AD pLI=0.04)
chr3	30735156	30735156	C	T	het	wt	het		QUAL=9002;DP=397,223,265;MQM=60	TGFBR2	3'UTR	TGFBR2:NM_001024847.2:3'UTR:MODIFIER:exon8/8:c.*2065C>T:,TGFBR2:NM_003242.5:3'UTR:MODIFIER:exon7/7:c.*2065C>T:		rs11466536	0.0232	0.0000	0/0/0	0.0080							190182 [TGFBR2 (confirmed) Colorectal cancer,hereditary nonpolyposis,type 6,614331|Esophageal cancer,somatic,133239|Loeys-Dietz syndrome 2,610168];	RCV000288089.1 [benign]; RCV000345353.1 [benign]; RCV000389525.1 [benign]; 			1	20					TGFBR2 (inh=AD pLI=0.04)
chr3	30735330	30735330	-	T	het	wt	het		QUAL=2196;DP=229,159,206;MQM=59	TGFBR2	3'UTR	TGFBR2:NM_001024847.2:3'UTR:MODIFIER:exon8/8:c.*2248dupT:,TGFBR2:NM_003242.5:3'UTR:MODIFIER:exon7/7:c.*2248dupT:		rs542768261	0.2065	0.0000	0/0/0	0.1859							190182 [TGFBR2 (confirmed) Colorectal cancer,hereditary nonpolyposis,type 6,614331|Esophageal cancer,somatic,133239|Loeys-Dietz syndrome 2,610168];	RCV000260690.1 [benign]; RCV000299574.1 [benign]; RCV000356795.1 [benign]; 			15	73					TGFBR2 (inh=AD pLI=0.04)
chr3	33055721	33055721	A	G	hom	hom	hom	pred_pathogenic;anno_pathogenic_hgmd	QUAL=20080;DP=125,195,332;MQM=59	GLB1	missense	GLB1:NM_001317040.1:missense:MODERATE:exon16/17:c.1705T>C:p.Cys569Arg,GLB1:NM_001079811.2:missense:MODERATE:exon15/16:c.1471T>C:p.Cys491Arg,GLB1:NM_000404.3:missense:MODERATE:exon15/16:c.1561T>C:p.Cys521Arg,GLB1:NM_001135602.2:missense:MODERATE:exon12/13:c.1168T>C:p.Cys390Arg		rs4302331	0.9271	0.9800	58208/33273/2982	0.9289	0.3470	T,T,T,T	T	B	D,D,D,D	6.85	611458 [GLB1 (confirmed) GM1-gangliosidosis,type I,230500|GM1-gangliosidosis,type II,230600|GM1-gangliosidosis,type III,230650|Mucopolysaccharidosis type IVB (Morquio),253010];	RCV000252845.1 [benign]; RCV000153326.2 [benign]; 	CM051080 [CLASS=DM? MUT=REF PHEN="Gangliosidosis GM1" GENE=GLB1]; 		3209	29	2	[2] Peter Bauer 25.08.2014			GLB1 (inh=AR pLI=0.00)
chr3	33063050	33063050	A	G	wt	het	het		QUAL=4731;DP=212,149,225;MQM=60	GLB1	splice_region&intron	GLB1:NM_001317040.1:splice_region&intron:LOW:exon13/16:c.1377+8T>C:,GLB1:NM_001079811.2:splice_region&intron:LOW:exon12/15:c.1143+8T>C:,GLB1:NM_000404.3:splice_region&intron:LOW:exon12/15:c.1233+8T>C:,GLB1:NM_001135602.2:splice_region&intron:LOW:exon9/12:c.840+8T>C:		rs13093698	0.1635	0.2084	2292/1507/203	0.1902							611458 [GLB1 (confirmed) GM1-gangliosidosis,type I,230500|GM1-gangliosidosis,type II,230600|GM1-gangliosidosis,type III,230650|Mucopolysaccharidosis type IVB (Morquio),253010];	RCV000078700.6 [benign]; RCV000300510.1 [likely benign]; RCV000353081.1 [likely benign]; 			138	989					GLB1 (inh=AR pLI=0.00)
chr3	33138544	33138544	A	G	het	hom	wt	low_DP	QUAL=3476;DP=17,115,204;MQM=60	GLB1	synonymous	GLB1:NM_001317040.1:synonymous:LOW:exon1/17:c.34T>C:p.Leu12Leu,GLB1:NM_000404.3:synonymous:LOW:exon1/16:c.34T>C:p.Leu12Leu,GLB1:NM_001135602.2:synonymous:LOW:exon1/13:c.34T>C:p.Leu12Leu		rs7614776	0.9277	0.9052	48924/25458/3600	0.8611							611458 [GLB1 (confirmed) GM1-gangliosidosis,type I,230500|GM1-gangliosidosis,type II,230600|GM1-gangliosidosis,type III,230650|Mucopolysaccharidosis type IVB (Morquio),253010];	RCV000078712.9 [other]; RCV000302471.1 [benign]; RCV000392270.1 [benign]; 		COSM4157974, COSM4157973	2579	534					GLB1 (inh=AR pLI=0.00)
chr3	33138549	33138549	G	A	het	hom	wt	low_DP;pred_pathogenic	QUAL=3131;DP=17,114,201;MQM=60	GLB1	missense	GLB1:NM_001317040.1:missense:MODERATE:exon1/17:c.29C>T:p.Pro10Leu,GLB1:NM_000404.3:missense:MODERATE:exon1/16:c.29C>T:p.Pro10Leu,GLB1:NM_001135602.2:missense:MODERATE:exon1/13:c.29C>T:p.Pro10Leu		rs7637099	0.4319	0.5625	19740/12821/102	0.5334	0.1970	T,T,T,D,T	T	B,B	D,D,D,D,D	12.82	611458 [GLB1 (confirmed) GM1-gangliosidosis,type I,230500|GM1-gangliosidosis,type II,230600|GM1-gangliosidosis,type III,230650|Mucopolysaccharidosis type IVB (Morquio),253010];	RCV000078711.9 [other]; RCV000340960.1 [benign]; RCV000402607.1 [benign]; 	CM055955 [CLASS=R MUT=ALT PHEN="Gangliosidosis GM1" GENE=GLB1]; 	COSM4157976, COSM4157975	1282	1363					GLB1 (inh=AR pLI=0.00)
chr3	33174156	33174156	T	G	het	hom	wt		QUAL=10182;DP=208,256,339;MQM=60	CRTAP	synonymous	CRTAP:NM_006371.4:synonymous:LOW:exon5/7:c.1032T>G:p.Thr344Thr		rs1135127	0.2935	0.3752	9267/6573/378	0.3704							605497 [CRTAP (confirmed) Osteogenesis imperfecta,type VII,610682];	RCV000246595.1 [benign]; RCV000263971.1 [benign]; 		COSM149349	318	726					CRTAP (inh=AR pLI=0.00)
chr3	33174168	33174168	G	A	het	hom	wt		QUAL=9298;DP=174,243,322;MQM=60	CRTAP	synonymous	CRTAP:NM_006371.4:synonymous:LOW:exon5/7:c.1044G>A:p.Ser348Ser		rs1135128	0.2935	0.3751	9265/6572/378	0.3677							605497 [CRTAP (confirmed) Osteogenesis imperfecta,type VII,610682];	RCV000251530.1 [benign]; RCV000321518.1 [benign]; 			317	726					CRTAP (inh=AR pLI=0.00)
chr3	33184209	33184209	C	T	wt	wt	het		QUAL=4649;DP=230,306,403;MQM=59	CRTAP	3'UTR	CRTAP:NM_006371.4:3'UTR:MODIFIER:exon7/7:c.*269C>T:	AluSx	rs143237314	0.0106	0.0000	0/0/0	0.0315							605497 [CRTAP (confirmed) Osteogenesis imperfecta,type VII,610682];	RCV000295408.1 [uncertain significance]; 			0	16					CRTAP (inh=AR pLI=0.00)
chr3	33185027	33185027	-	GAACTA	het	hom	wt		QUAL=7427;DP=306,125,159;MQM=59	CRTAP	3'UTR	CRTAP:NM_006371.4:3'UTR:MODIFIER:exon7/7:c.*1090_*1095dupACTAGA:	L2a	rs5847775	0.3387	0.0000	0/0/0	0.4286							605497 [CRTAP (confirmed) Osteogenesis imperfecta,type VII,610682];	RCV000362361.1 [benign]; 			62	72					CRTAP (inh=AR pLI=0.00)
chr3	33185407	33185407	G	A	het	wt	het		QUAL=8951;DP=350,329,426;MQM=59	CRTAP	3'UTR	CRTAP:NM_006371.4:3'UTR:MODIFIER:exon7/7:c.*1467G>A:	L2a	rs4678475	0.3019	0.0000	0/0/0	0.2617							605497 [CRTAP (confirmed) Osteogenesis imperfecta,type VII,610682];	RCV000281743.1 [benign]; 			16	52					CRTAP (inh=AR pLI=0.00)
chr3	33185522	33185522	C	A	wt	wt	het		QUAL=3120;DP=336,175,245;MQM=59	CRTAP	3'UTR	CRTAP:NM_006371.4:3'UTR:MODIFIER:exon7/7:c.*1582C>A:	L2a	rs1137463	0.1534	0.0000	0/0/0	0.1580							605497 [CRTAP (confirmed) Osteogenesis imperfecta,type VII,610682];	RCV000391367.1 [likely benign]; 			3	40					CRTAP (inh=AR pLI=0.00)
chr3	33185798	33185798	T	A	hom	hom	hom		QUAL=19458;DP=256,159,180;MQM=59	CRTAP	3'UTR	CRTAP:NM_006371.4:3'UTR:MODIFIER:exon7/7:c.*1858T>A:	L2a	rs4678476	0.8960	0.0000	0/0/0	0.9465							605497 [CRTAP (confirmed) Osteogenesis imperfecta,type VII,610682];	RCV000391352.1 [benign]; 			173	2					CRTAP (inh=AR pLI=0.00)
chr3	33186087	33186087	A	G	wt	wt	het		QUAL=1488;DP=135,115,112;MQM=60	CRTAP	3'UTR	CRTAP:NM_006371.4:3'UTR:MODIFIER:exon7/7:c.*2147A>G:	LTR16A1	rs4355234	0.1841	0.0000	0/0/0	0.1782							605497 [CRTAP (confirmed) Osteogenesis imperfecta,type VII,610682];	RCV000306824.1 [likely benign]; 			3	51					CRTAP (inh=AR pLI=0.00)
chr3	33186356	33186356	T	C	het	wt	het		QUAL=5877;DP=216,141,236;MQM=60	CRTAP	3'UTR	CRTAP:NM_006371.4:3'UTR:MODIFIER:exon7/7:c.*2416T>C:	L2a	rs1127898	0.3610	0.0000	0/0/0	0.3161							605497 [CRTAP (confirmed) Osteogenesis imperfecta,type VII,610682];	RCV000370650.1 [benign]; 			15	83					CRTAP (inh=AR pLI=0.00)
chr3	33187082	33187082	G	A	wt	wt	het		QUAL=3717;DP=258,136,235;MQM=60	CRTAP	3'UTR	CRTAP:NM_006371.4:3'UTR:MODIFIER:exon7/7:c.*3142G>A:		rs12635415	0.1623	0.0000	0/0/0	0.1723							605497 [CRTAP (confirmed) Osteogenesis imperfecta,type VII,610682];	RCV000393472.1 [likely benign]; 			5	57					CRTAP (inh=AR pLI=0.00)
chr3	33187425	33187425	G	A	het	hom	wt		QUAL=15652;DP=523,283,350;MQM=60	CRTAP	3'UTR	CRTAP:NM_006371.4:3'UTR:MODIFIER:exon7/7:c.*3485G>A:		rs1132392	0.3199	0.0000	0/0/0	0.4533							605497 [CRTAP (confirmed) Osteogenesis imperfecta,type VII,610682];	RCV000260313.1 [benign]; 			81	109					CRTAP (inh=AR pLI=0.00)
chr3	33187831	33187831	C	T	het	wt	het		QUAL=8142;DP=181,357,461;MQM=60	CRTAP	3'UTR	CRTAP:NM_006371.4:3'UTR:MODIFIER:exon7/7:c.*3891C>T:		rs4678478	0.3037	0.0000	0/0/0	0.2979							605497 [CRTAP (confirmed) Osteogenesis imperfecta,type VII,610682];	RCV000267264.1 [benign]; 			15	83					CRTAP (inh=AR pLI=0.00)
chr3	33189163	33189163	T	A	het	het	wt		QUAL=3055;DP=175,71,100;MQM=60	CRTAP	3'UTR	CRTAP:NM_006371.4:3'UTR:MODIFIER:exon7/7:c.*5223T>A:		rs192685869	0.0008	0.0000	0/0/0	0.0011							605497 [CRTAP (confirmed) Osteogenesis imperfecta,type VII,610682];				0	6					CRTAP (inh=AR pLI=0.00)
chr3	38184370	38184370	A	G	wt	wt	het		QUAL=1835;DP=248,103,149;MQM=60	MYD88	3'UTR	MYD88:NM_001172567.1:3'UTR:MODIFIER:exon5/5:c.*1593A>G:,MYD88:NM_001172566.1:3'UTR:MODIFIER:exon3/3:c.*1727A>G:,MYD88:NM_001172568.1:3'UTR:MODIFIER:exon4/4:c.*1593A>G:,MYD88:NM_001172569.1:3'UTR:MODIFIER:exon4/4:c.*1727A>G:,MYD88:NM_002468.4:3'UTR:MODIFIER:exon5/5:c.*1593A>G:		rs6853	0.1332	0.0000	0/0/0	0.0191							602170 [MYD88 (provisional) Pyogenic bacterial infections,recurrent,due to MYD88 deficiency,612260|Macroglobulinemia,Waldenstrom,somatic,153600];				4	45					MYD88 (inh=AD pLI=0.71)
chr3	41241154	41241154	C	G	het	het	wt		QUAL=1790;DP=90,98,107;MQM=59	CTNNB1	5'UTR_premature_start_codon_gain,5'UTR	CTNNB1:NM_001098209.1:5'UTR_premature_start_codon_gain:LOW:exon1/16:c.-56C>G:,CTNNB1:NM_001098210.1:5'UTR_premature_start_codon_gain:LOW:exon1/16:c.-56C>G:,CTNNB1:NM_001904.3:5'UTR_premature_start_codon_gain:LOW:exon1/15:c.-56C>G:,CTNNB1:NM_001098209.1:5'UTR:MODIFIER:exon1/16:c.-56C>G:,CTNNB1:NM_001098210.1:5'UTR:MODIFIER:exon1/16:c.-56C>G:,CTNNB1:NM_001904.3:5'UTR:MODIFIER:exon1/15:c.-56C>G:		rs11564435	0.0032	0.0000	0/0/0	0.0078							116806 [CTNNB1 (confirmed) Mental retardation,autosomal dominant 19,615075|Colorectal cancer,somatic,114500|Pilomatricoma,somatic,132600|Ovarian cancer,somatic,167000|Hepatocellular carcinoma,somatic,114550|Medulloblastoma,somatic,155255];				0	8					CTNNB1 (inh=AD pLI=1.00)
chr3	41281388	41281388	T	G	het	het	het		QUAL=2042;DP=76,46,60;MQM=59	CTNNB1	3'UTR	CTNNB1:NM_001098209.1:3'UTR:MODIFIER:exon16/16:c.*250T>G:,CTNNB1:NM_001098210.1:3'UTR:MODIFIER:exon16/16:c.*91T>G:,CTNNB1:NM_001904.3:3'UTR:MODIFIER:exon15/15:c.*555T>G:		rs2953	0.3652	0.0000	0/0/0	0.0697							116806 [CTNNB1 (confirmed) Mental retardation,autosomal dominant 19,615075|Colorectal cancer,somatic,114500|Pilomatricoma,somatic,132600|Ovarian cancer,somatic,167000|Hepatocellular carcinoma,somatic,114550|Medulloblastoma,somatic,155255];				48	111					CTNNB1 (inh=AD pLI=1.00)
chr3	41281413	41281413	T	A	het	hom	het	low_DP	QUAL=931;DP=87,17,14;MQM=60	CTNNB1	3'UTR	CTNNB1:NM_001098209.1:3'UTR:MODIFIER:exon16/16:c.*275T>A:,CTNNB1:NM_001098210.1:3'UTR:MODIFIER:exon16/16:c.*116T>A:,CTNNB1:NM_001904.3:3'UTR:MODIFIER:exon15/15:c.*580T>A:	(T)n	rs4135387	0.2700	0.0000	0/0/0	0.2217							116806 [CTNNB1 (confirmed) Mental retardation,autosomal dominant 19,615075|Colorectal cancer,somatic,114500|Pilomatricoma,somatic,132600|Ovarian cancer,somatic,167000|Hepatocellular carcinoma,somatic,114550|Medulloblastoma,somatic,155255];				5	136					CTNNB1 (inh=AD pLI=1.00)
chr3	41281600	41281600	-	TAAT	het	het	het	low_DP	QUAL=1812;DP=122,15,14;MQM=60	CTNNB1	3'UTR	CTNNB1:NM_001098209.1:3'UTR:MODIFIER:exon16/16:c.*464_*467dupAATT:,CTNNB1:NM_001098210.1:3'UTR:MODIFIER:exon16/16:c.*305_*308dupAATT:,CTNNB1:NM_001904.3:3'UTR:MODIFIER:exon15/15:c.*769_*772dupAATT:		rs3834205;rs71623294	0.3580	0.0000	0/0/0	0.3884							116806 [CTNNB1 (confirmed) Mental retardation,autosomal dominant 19,615075|Colorectal cancer,somatic,114500|Pilomatricoma,somatic,132600|Ovarian cancer,somatic,167000|Hepatocellular carcinoma,somatic,114550|Medulloblastoma,somatic,155255];				42	116					CTNNB1 (inh=AD pLI=1.00)
chr3	43760062	43760062	T	G	wt	het	wt		QUAL=7476;DP=444,559,649;MQM=60	ABHD5	3'UTR	ABHD5:NM_016006.4:3'UTR:MODIFIER:exon7/7:c.*38T>G:		rs887472	0.1034	0.0564	344/24/89	0.0544							604780 [ABHD5 (confirmed) Chanarin-Dorfman syndrome,275630];	RCV000380356.1 [likely benign]; 			6	66					ABHD5 (inh=AR pLI=0.00)
chr3	43760305	43760305	C	A	wt	het	wt		QUAL=1049;DP=244,72,106;MQM=60	ABHD5	3'UTR	ABHD5:NM_016006.4:3'UTR:MODIFIER:exon7/7:c.*281C>A:		rs34226283	0.0897	0.0000	0/0/0	0.0092							604780 [ABHD5 (confirmed) Chanarin-Dorfman syndrome,275630];	RCV000317774.1 [likely benign]; 			0	12					ABHD5 (inh=AR pLI=0.00)
chr3	43761134	43761134	G	C	wt	het	wt		QUAL=1048;DP=364,100,142;MQM=60	ABHD5	3'UTR	ABHD5:NM_016006.4:3'UTR:MODIFIER:exon7/7:c.*1110G>C:		rs2191361	0.1396	0.0000	0/0/0	0.0888							604780 [ABHD5 (confirmed) Chanarin-Dorfman syndrome,275630];	RCV000352551.1 [likely benign]; 			1	32					ABHD5 (inh=AR pLI=0.00)
chr3	43761441	43761441	A	G	hom	het	hom		QUAL=24205;DP=383,221,263;MQM=60	ABHD5	3'UTR	ABHD5:NM_016006.4:3'UTR:MODIFIER:exon7/7:c.*1417A>G:		rs3733156	0.5487	0.0000	0/0/0	0.6881							604780 [ABHD5 (confirmed) Chanarin-Dorfman syndrome,275630];	RCV000308938.1 [benign]; 			109	102					ABHD5 (inh=AR pLI=0.00)
chr3	43761637	43761637	T	C	wt	het	wt		QUAL=3583;DP=636,290,394;MQM=60	ABHD5	3'UTR	ABHD5:NM_016006.4:3'UTR:MODIFIER:exon7/7:c.*1613T>C:		rs12491747	0.1404	0.0000	0/0/0	0.0891							604780 [ABHD5 (confirmed) Chanarin-Dorfman syndrome,275630];	RCV000359846.1 [likely benign]; 			1	32					ABHD5 (inh=AR pLI=0.00)
chr3	43761780	43761780	G	T	wt	het	wt		QUAL=1177;DP=297,164,253;MQM=60	ABHD5	3'UTR	ABHD5:NM_016006.4:3'UTR:MODIFIER:exon7/7:c.*1756G>T:		rs34048061	0.0897	0.0000	0/0/0	0.0531							604780 [ABHD5 (confirmed) Chanarin-Dorfman syndrome,275630];	RCV000356909.1 [likely benign]; 			0	12					ABHD5 (inh=AR pLI=0.00)
chr3	43761782	43761782	-	G	wt	het	wt		QUAL=1177;DP=297,164,253;MQM=60	ABHD5	3'UTR	ABHD5:NM_016006.4:3'UTR:MODIFIER:exon7/7:c.*1758_*1759insG:		rs34011416	0.0895	0.0000	0/0/0	0.0419							604780 [ABHD5 (confirmed) Chanarin-Dorfman syndrome,275630];	RCV000331278.1 [likely benign]; 			0	12					ABHD5 (inh=AR pLI=0.00)
chr3	43761858	43761858	C	G	wt	het	wt		QUAL=1254;DP=339,168,288;MQM=60	ABHD5	3'UTR	ABHD5:NM_016006.4:3'UTR:MODIFIER:exon7/7:c.*1834C>G:		rs12488350	0.1404	0.0000	0/0/0	0.0890							604780 [ABHD5 (confirmed) Chanarin-Dorfman syndrome,275630];	RCV000385622.1 [likely benign]; 			1	32					ABHD5 (inh=AR pLI=0.00)
chr3	43761887	43761887	G	A	wt	het	wt		QUAL=1352;DP=469,181,297;MQM=60	ABHD5	3'UTR	ABHD5:NM_016006.4:3'UTR:MODIFIER:exon7/7:c.*1863G>A:		rs12488392	0.1404	0.0000	0/0/0	0.0889							604780 [ABHD5 (confirmed) Chanarin-Dorfman syndrome,275630];	RCV000332306.1 [likely benign]; 			1	32					ABHD5 (inh=AR pLI=0.00)
chr3	43762348	43762348	G	T	wt	het	wt		QUAL=1130;DP=176,116,161;MQM=60	ABHD5	3'UTR	ABHD5:NM_016006.4:3'UTR:MODIFIER:exon7/7:c.*2324G>T:		rs17075919	0.1404	0.0000	0/0/0	0.0890							604780 [ABHD5 (confirmed) Chanarin-Dorfman syndrome,275630];	RCV000298873.1 [likely benign]; 			1	32					ABHD5 (inh=AR pLI=0.00)
chr3	43762959	43762959	C	A	wt	het	wt		QUAL=656;DP=145,39,47;MQM=60	ABHD5	3'UTR	ABHD5:NM_016006.4:3'UTR:MODIFIER:exon7/7:c.*2935C>A:	AluJr	rs10433606	0.0897	0.0000	0/0/0	0.0429							604780 [ABHD5 (confirmed) Chanarin-Dorfman syndrome,275630];	RCV000324938.1 [likely benign]; 			0	12					ABHD5 (inh=AR pLI=0.00)
chr3	43763277	43763277	A	T	wt	het	wt		QUAL=1353;DP=199,100,157;MQM=60	ABHD5	3'UTR	ABHD5:NM_016006.4:3'UTR:MODIFIER:exon7/7:c.*3253A>T:	L1MC5a:L1MC5a	rs10433548	0.1404	0.0000	0/0/0	0.0891							604780 [ABHD5 (confirmed) Chanarin-Dorfman syndrome,275630];	RCV000377144.1 [likely benign]; 			1	22					ABHD5 (inh=AR pLI=0.00)
chr3	43763976	43763976	T	C	wt	het	wt		QUAL=1282;DP=328,114,128;MQM=60	ABHD5	3'UTR	ABHD5:NM_016006.4:3'UTR:MODIFIER:exon7/7:c.*3952T>C:	L1MC5a	rs758729	0.0897	0.0000	0/0/0	0.0542							604780 [ABHD5 (confirmed) Chanarin-Dorfman syndrome,275630];	RCV000313988.1 [likely benign]; 			0	8					ABHD5 (inh=AR pLI=0.00)
chr3	43764171	43764171	G	T	wt	het	wt		QUAL=1324;DP=260,134,170;MQM=60	ABHD5	3'UTR	ABHD5:NM_016006.4:3'UTR:MODIFIER:exon7/7:c.*4147G>T:	L1MC5a	rs758728	0.1026	0.0000	0/0/0	0.0581							604780 [ABHD5 (confirmed) Chanarin-Dorfman syndrome,275630];	RCV000364090.1 [likely benign]; 			0	8					ABHD5 (inh=AR pLI=0.00)
chr3	46944274	46944274	T	C	het	hom	het		QUAL=22780;DP=363,372,473;MQM=59	PTH1R	synonymous	PTH1R:NM_000316.2:synonymous:LOW:exon15/16:c.1389T>C:p.Asn463Asn,PTH1R:NM_001184744.1:synonymous:LOW:exon14/15:c.1389T>C:p.Asn463Asn		rs1138518	0.6434	0.6141	22990/12787/3275	0.6084							168468 [PTH1R (confirmed) Metaphyseal chondrodysplasia,Murk Jansen type,156400|Chondrodysplasia,Blomstrand type,215045|Eiken syndrome,600002|Failure of tooth eruption,primary,125350];	RCV000288818.1 [benign]; RCV000404246.1 [benign]; 		COSM149372	615	687					PTH1R (inh=AR+AD pLI=0.74)
chr3	46945000	46945000	G	A	het	wt	het	pred_pathogenic	QUAL=3447;DP=148,106,126;MQM=59	PTH1R	missense	PTH1R:NM_000316.2:missense:MODERATE:exon16/16:c.1636G>A:p.Glu546Lys,PTH1R:NM_001184744.1:missense:MODERATE:exon15/15:c.1636G>A:p.Glu546Lys		rs77048718	0.0086	0.0166	27/25/0	0.0171	1.8400	T,T,T,T,.,T	T	B	T,T,T,T,T	17.14	168468 [PTH1R (confirmed) Metaphyseal chondrodysplasia,Murk Jansen type,156400|Chondrodysplasia,Blomstrand type,215045|Eiken syndrome,600002|Failure of tooth eruption,primary,125350];	RCV000261080.1 [likely benign]; RCV000369795.1 [likely benign]; 			0	54					PTH1R (inh=AR+AD pLI=0.74)
chr3	46945263	46945263	-	A	het	hom	wt		QUAL=947;DP=81,33,56;MQM=59	PTH1R	3'UTR	PTH1R:NM_000316.2:3'UTR:MODIFIER:exon16/16:c.*127dupA:,PTH1R:NM_001184744.1:3'UTR:MODIFIER:exon15/15:c.*127dupA:	A-rich	rs552713678	0.1532	0.0000	0/0/0	0.1530							168468 [PTH1R (confirmed) Metaphyseal chondrodysplasia,Murk Jansen type,156400|Chondrodysplasia,Blomstrand type,215045|Eiken syndrome,600002|Failure of tooth eruption,primary,125350];	RCV000268644.1 [benign]; RCV000377157.1 [benign]; 			8	87					PTH1R (inh=AR+AD pLI=0.74)
chr3	48508585	48508585	C	T	het	wt	het		QUAL=6156;DP=287,188,246;MQM=59	TREX1	synonymous	TREX1:NM_016381.5:synonymous:LOW:exon1/1:c.696C>T:p.Tyr232Tyr,TREX1:NM_007248.3:synonymous:LOW:exon2/2:c.501C>T:p.Tyr167Tyr,TREX1:NM_033629.4:synonymous:LOW:exon2/2:c.531C>T:p.Tyr177Tyr		rs11797	0.3133	0.3706	8747/6279/391	0.3719							606609 [TREX1 (confirmed) Aicardi-Goutieres syndrome 1,dominant and recessive,225750|Chilblain lupus,610448|Vasculopathy,retinal,with cerebral leukodystrophy,192315|Systemic lupus erythematosus,susceptibility to,152700];	RCV000082324.6 [benign]; RCV000341237.1 [benign]; RCV000405847.1 [benign]; 		COSM4002723	323	796					TREX1 (inh=AR+AD pLI=0.09)
chr3	48605076	48605076	A	-	het	het	wt		QUAL=2480;DP=64,199,270;MQM=59	COL7A1	splice_region&intron	COL7A1:NM_000094.3:splice_region&intron:LOW:exon107/117:c.7984-7delT:		rs397989501	0.0697	0.0421	169/43/37	0.0397							120120 [COL7A1 (confirmed) Epidermolysis bullosa dystrophica,AD,131750|Epidermolysis bullosa dystrophica,AR,226600|Epidermolysis bullosa,pretibial,131850|EBD,Bart type,132000|EBD,localisata variant|Transient bullous of the newborn,131705|Epidermolysis bullosa pruriginosa,604129|Toenail dystrophy,isolated,607523|EBD inversa,226600];	RCV000380496.1 [likely benign]; 			3	123					COL7A1 (inh=AR+AD pLI=0.00)
chr3	48625266	48625266	T	C	hom	het	het		QUAL=11578;DP=251,136,161;MQM=59	COL7A1	synonymous	COL7A1:NM_000094.3:synonymous:LOW:exon21/118:c.2817A>G:p.Pro939Pro		rs1264194	0.6811	0.6799	28442/16228/4229	0.6683							120120 [COL7A1 (confirmed) Epidermolysis bullosa dystrophica,AD,131750|Epidermolysis bullosa dystrophica,AR,226600|Epidermolysis bullosa,pretibial,131850|EBD,Bart type,132000|EBD,localisata variant|Transient bullous of the newborn,131705|Epidermolysis bullosa pruriginosa,604129|Toenail dystrophy,isolated,607523|EBD inversa,226600];	RCV000243500.1 [benign]; RCV000408231.1 [benign]; 		COSM446657	732	635					COL7A1 (inh=AR+AD pLI=0.00)
chr3	49162040	49162040	T	G	het	het	wt	pred_pathogenic	QUAL=2496;DP=108,82,102;MQM=60	LAMB2	missense	LAMB2:NM_002292.3:missense:MODERATE:exon22/32:c.3115A>C:p.Thr1039Pro		rs747604203	0.0000	0.0001	0/0/0	0.0001	1.8160	D,D	T	B	T,T	22.80	150325 [LAMB2 (confirmed) Nephrotic syndrome,type 5,with or without ocular abnormalities,614199|Pierson syndrome,609049];	RCV000333358.1 [uncertain significance]; RCV000387637.1 [uncertain significance]; 			0	2					LAMB2 (inh=AR pLI=0.00)
chr3	49506273	49506273	-	T	het	hom	hom	low_DP	QUAL=1277;DP=46,14,9;MQM=58	DAG1	5'UTR	DAG1:NM_001177643.2:5'UTR:MODIFIER:exon1/3:c.-320dupT:	AluJb	rs71080520	0.6699	0.0000	0/0/0	0.4375							128239 [DAG1 (provisional) Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,9,613818|Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,9,616538];				11	105					DAG1 (inh=AR pLI=0.94)
chr3	49506299	49506299	C	T	hom	hom	hom	low_DP	QUAL=1799;DP=40,15,14;MQM=59	DAG1	5'UTR	DAG1:NM_001177643.2:5'UTR:MODIFIER:exon1/3:c.-306C>T:	AluJb	rs6797164	0.9659	0.0000	0/0/0	0.7671							128239 [DAG1 (provisional) Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,9,613818|Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,9,616538];				147	0					DAG1 (inh=AR pLI=0.94)
chr3	49507847	49507847	G	A	hom	het	het	low_DP	QUAL=184;DP=4,6,5;MQM=60	DAG1	5'UTR,intron	DAG1:NM_001165928.3:5'UTR:MODIFIER:exon1/6:c.-497G>A:,DAG1:NM_001177634.2:5'UTR:MODIFIER:exon1/6:c.-440G>A:,DAG1:NM_001177636.2:5'UTR:MODIFIER:exon1/5:c.-418G>A:,DAG1:NM_001177637.2:5'UTR:MODIFIER:exon1/4:c.-256G>A:,DAG1:NM_001177638.2:5'UTR:MODIFIER:exon1/4:c.-287G>A:,DAG1:NM_001177640.2:5'UTR:MODIFIER:exon1/4:c.-193G>A:,DAG1:NM_001177641.2:5'UTR:MODIFIER:exon1/4:c.-283G>A:,DAG1:NM_001177642.2:5'UTR:MODIFIER:exon1/4:c.-188G>A:,DAG1:NM_001177644.2:5'UTR:MODIFIER:exon1/3:c.-276G>A:,DAG1:NM_004393.5:5'UTR:MODIFIER:exon1/3:c.-136G>A:,DAG1:NM_001177643.2:intron:MODIFIER:exon1/2:c.-117+1359G>A:,DAG1:NM_001177635.2:intron:MODIFIER:exon1/3:c.-169+140G>A:,DAG1:NM_001177639.2:intron:MODIFIER:exon1/2:c.-117+140G>A:		rs4855839	0.5829	0.0000	0/0/0	0.4355							128239 [DAG1 (provisional) Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,9,613818|Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,9,616538];				30	74					DAG1 (inh=AR pLI=0.94)
chr3	49524778	49524778	G	C	wt	het	het		QUAL=10327;DP=360,339,407;MQM=60	DAG1	5'UTR,intron	DAG1:NM_001165928.3:5'UTR:MODIFIER:exon2/6:c.-386G>C:,DAG1:NM_001177634.2:5'UTR:MODIFIER:exon4/6:c.-187G>C:,DAG1:NM_001177636.2:5'UTR:MODIFIER:exon2/5:c.-307G>C:,DAG1:NM_001177643.2:intron:MODIFIER:exon1/2:c.-117+18290G>C:,DAG1:NM_001177635.2:intron:MODIFIER:exon2/3:c.-117+10445G>C:,DAG1:NM_001177637.2:intron:MODIFIER:exon1/3:c.-236-1281G>C:,DAG1:NM_001177638.2:intron:MODIFIER:exon1/3:c.-267-5478G>C:,DAG1:NM_001177639.2:intron:MODIFIER:exon1/2:c.-117+17071G>C:,DAG1:NM_001177640.2:intron:MODIFIER:exon2/3:c.-117+10440G>C:,DAG1:NM_001177641.2:intron:MODIFIER:exon1/3:c.-263-5482G>C:,DAG1:NM_001177642.2:intron:MODIFIER:exon2/3:c.-117+10445G>C:,DAG1:NM_001177644.2:intron:MODIFIER:exon1/2:c.-117+16772G>C:,DAG1:NM_004393.5:intron:MODIFIER:exon1/2:c.-117+16912G>C:		rs6783003	0.1110	0.0000	0/0/0	0.1822							128239 [DAG1 (provisional) Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,9,613818|Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,9,616538];				19	80					DAG1 (inh=AR pLI=0.94)
chr3	49548008	49548008	C	G	hom	hom	hom	pred_pathogenic	QUAL=35044;DP=312,341,448;MQM=60	DAG1	missense	DAG1:NM_001165928.3:missense:MODERATE:exon5/6:c.41C>G:p.Ser14Trp,DAG1:NM_001177643.2:missense:MODERATE:exon2/3:c.41C>G:p.Ser14Trp,DAG1:NM_001177634.2:missense:MODERATE:exon5/6:c.41C>G:p.Ser14Trp,DAG1:NM_001177635.2:missense:MODERATE:exon3/4:c.41C>G:p.Ser14Trp,DAG1:NM_001177636.2:missense:MODERATE:exon4/5:c.41C>G:p.Ser14Trp,DAG1:NM_001177637.2:missense:MODERATE:exon3/4:c.41C>G:p.Ser14Trp,DAG1:NM_001177638.2:missense:MODERATE:exon3/4:c.41C>G:p.Ser14Trp,DAG1:NM_001177639.2:missense:MODERATE:exon2/3:c.41C>G:p.Ser14Trp,DAG1:NM_001177640.2:missense:MODERATE:exon3/4:c.41C>G:p.Ser14Trp,DAG1:NM_001177641.2:missense:MODERATE:exon3/4:c.41C>G:p.Ser14Trp,DAG1:NM_001177642.2:missense:MODERATE:exon3/4:c.41C>G:p.Ser14Trp,DAG1:NM_001177644.2:missense:MODERATE:exon2/3:c.41C>G:p.Ser14Trp,DAG1:NM_004393.5:missense:MODERATE:exon2/3:c.41C>G:p.Ser14Trp		rs2131107	0.9659	0.9923	59800/33354/4367	0.9479	2.0690	T,T,T,T,T,T,T,T,T,T,T,T,T,.	T	B	T,T,T,T,T,T,T,T,T,T,T,T,T	14.90	128239 [DAG1 (provisional) Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,9,613818|Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,9,616538];	RCV000024443.1 [not provided]; RCV000214409.1 [benign]; 			1564	3					DAG1 (inh=AR pLI=0.94)
chr3	49570882	49570882	T	C	hom	het	het		QUAL=6774;DP=174,50,61;MQM=59	DAG1	3'UTR	DAG1:NM_001165928.3:3'UTR:MODIFIER:exon6/6:c.*250T>C:,DAG1:NM_001177643.2:3'UTR:MODIFIER:exon3/3:c.*250T>C:,DAG1:NM_001177634.2:3'UTR:MODIFIER:exon6/6:c.*250T>C:,DAG1:NM_001177635.2:3'UTR:MODIFIER:exon4/4:c.*250T>C:,DAG1:NM_001177636.2:3'UTR:MODIFIER:exon5/5:c.*250T>C:,DAG1:NM_001177637.2:3'UTR:MODIFIER:exon4/4:c.*250T>C:,DAG1:NM_001177638.2:3'UTR:MODIFIER:exon4/4:c.*250T>C:,DAG1:NM_001177639.2:3'UTR:MODIFIER:exon3/3:c.*250T>C:,DAG1:NM_001177640.2:3'UTR:MODIFIER:exon4/4:c.*250T>C:,DAG1:NM_001177641.2:3'UTR:MODIFIER:exon4/4:c.*250T>C:,DAG1:NM_001177642.2:3'UTR:MODIFIER:exon4/4:c.*250T>C:,DAG1:NM_001177644.2:3'UTR:MODIFIER:exon3/3:c.*250T>C:,DAG1:NM_004393.5:3'UTR:MODIFIER:exon3/3:c.*250T>C:		rs1050088	0.5541	0.5639	2135/268/24	0.1458							128239 [DAG1 (provisional) Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,9,613818|Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,9,616538];	RCV000024448.1 [not provided]; 			232	487					DAG1 (inh=AR pLI=0.94)
chr3	49571462	49571462	G	T	wt	het	het		QUAL=905;DP=121,34,48;MQM=60	DAG1	3'UTR	DAG1:NM_001165928.3:3'UTR:MODIFIER:exon6/6:c.*830G>T:,DAG1:NM_001177643.2:3'UTR:MODIFIER:exon3/3:c.*830G>T:,DAG1:NM_001177634.2:3'UTR:MODIFIER:exon6/6:c.*830G>T:,DAG1:NM_001177635.2:3'UTR:MODIFIER:exon4/4:c.*830G>T:,DAG1:NM_001177636.2:3'UTR:MODIFIER:exon5/5:c.*830G>T:,DAG1:NM_001177637.2:3'UTR:MODIFIER:exon4/4:c.*830G>T:,DAG1:NM_001177638.2:3'UTR:MODIFIER:exon4/4:c.*830G>T:,DAG1:NM_001177639.2:3'UTR:MODIFIER:exon3/3:c.*830G>T:,DAG1:NM_001177640.2:3'UTR:MODIFIER:exon4/4:c.*830G>T:,DAG1:NM_001177641.2:3'UTR:MODIFIER:exon4/4:c.*830G>T:,DAG1:NM_001177642.2:3'UTR:MODIFIER:exon4/4:c.*830G>T:,DAG1:NM_001177644.2:3'UTR:MODIFIER:exon3/3:c.*830G>T:,DAG1:NM_004393.5:3'UTR:MODIFIER:exon3/3:c.*830G>T:		rs12583	0.1625	0.0000	0/0/0	0.1956							128239 [DAG1 (provisional) Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,9,613818|Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,9,616538];	RCV000024449.1 [not provided]; 			19	86					DAG1 (inh=AR pLI=0.94)
chr3	49572894	49572894	T	C	hom	hom	hom		QUAL=13192;DP=163,120,141;MQM=59	DAG1	3'UTR	DAG1:NM_001165928.3:3'UTR:MODIFIER:exon6/6:c.*2262T>C:,DAG1:NM_001177643.2:3'UTR:MODIFIER:exon3/3:c.*2262T>C:,DAG1:NM_001177634.2:3'UTR:MODIFIER:exon6/6:c.*2262T>C:,DAG1:NM_001177635.2:3'UTR:MODIFIER:exon4/4:c.*2262T>C:,DAG1:NM_001177636.2:3'UTR:MODIFIER:exon5/5:c.*2262T>C:,DAG1:NM_001177637.2:3'UTR:MODIFIER:exon4/4:c.*2262T>C:,DAG1:NM_001177638.2:3'UTR:MODIFIER:exon4/4:c.*2262T>C:,DAG1:NM_001177639.2:3'UTR:MODIFIER:exon3/3:c.*2262T>C:,DAG1:NM_001177640.2:3'UTR:MODIFIER:exon4/4:c.*2262T>C:,DAG1:NM_001177641.2:3'UTR:MODIFIER:exon4/4:c.*2262T>C:,DAG1:NM_001177642.2:3'UTR:MODIFIER:exon4/4:c.*2262T>C:,DAG1:NM_001177644.2:3'UTR:MODIFIER:exon3/3:c.*2262T>C:,DAG1:NM_004393.5:3'UTR:MODIFIER:exon3/3:c.*2262T>C:		rs6446283	0.9758	0.0000	0/0/0	0.1502							128239 [DAG1 (provisional) Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,9,613818|Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,9,616538];	RCV000024451.1 [not provided]; 			269	0					DAG1 (inh=AR pLI=0.94)
chr3	52017423	52017423	G	C	het	het	wt	low_DP	QUAL=264;DP=10,18,36;MQM=60	ACY1,ABHD14A-ACY1	5'UTR,intron	ACY1:NM_000666.2:5'UTR:MODIFIER:exon1/15:c.-201G>C:,ACY1:NM_001198895.1:5'UTR:MODIFIER:exon1/15:c.-196G>C:,ACY1:NM_001198896.1:5'UTR:MODIFIER:exon1/13:c.-201G>C:,ACY1:NM_001198897.1:5'UTR:MODIFIER:exon1/13:c.-201G>C:,ACY1:NM_001198898.1:5'UTR:MODIFIER:exon1/14:c.-201G>C:,ABHD14A-ACY1:NM_001316331.1:intron:MODIFIER:exon3/16:c.253-640G>C:		rs554462231	0.0018	0.0000	0/0/0	0.0015							104620 [ACY1 (confirmed) Aminoacylase 1 deficiency,609924];				0	3					ACY1 (inh=AR pLI=0.00), ABHD14A-ACY1 (inh=n/a pLI=0.00)
chr3	53122969	53122969	G	A	het	het	wt	low_DP;low_MQM	QUAL=972;DP=78,19,24;MQM=45	RFT1	3'UTR	RFT1:NM_052859.3:3'UTR:MODIFIER:exon13/13:c.*2950C>T:	AluSx4	rs2082093	0.4904	0.0000	0/0/0	0.4983							611908 [RFT1 (confirmed) Congenital disorder of glycosylation,type In,612015];	RCV000265760.1 [benign]; 			43	78					RFT1 (inh=AR pLI=0.00)
chr3	53123032	53123032	C	T	hom	het	het	low_MQM	QUAL=3186;DP=95,37,34;MQM=47	RFT1	3'UTR	RFT1:NM_052859.3:3'UTR:MODIFIER:exon13/13:c.*2887G>A:	AluSx4	rs2099162	0.7185	0.0000	0/0/0	0.6347							611908 [RFT1 (confirmed) Congenital disorder of glycosylation,type In,612015];	RCV000320857.1 [benign]; 			82	66					RFT1 (inh=AR pLI=0.00)
chr3	53123079	53123079	A	T	het	wt	het		QUAL=2056;DP=126,57,65;MQM=57	RFT1	3'UTR	RFT1:NM_052859.3:3'UTR:MODIFIER:exon13/13:c.*2840T>A:	AluSx4	rs9875573	0.1699	0.0000	0/0/0	0.1083							611908 [RFT1 (confirmed) Congenital disorder of glycosylation,type In,612015];	RCV000380214.1 [likely benign]; 			0	44					RFT1 (inh=AR pLI=0.00)
chr3	53123273	53123273	A	G	het	het	wt		QUAL=6809;DP=283,219,315;MQM=59	RFT1	3'UTR	RFT1:NM_052859.3:3'UTR:MODIFIER:exon13/13:c.*2646T>C:		rs891368	0.4904	0.0000	0/0/0	0.0967							611908 [RFT1 (confirmed) Congenital disorder of glycosylation,type In,612015];	RCV000385844.1 [benign]; 			67	111					RFT1 (inh=AR pLI=0.00)
chr3	53123486	53123486	G	A	het	het	wt		QUAL=6342;DP=271,234,328;MQM=59	RFT1	3'UTR	RFT1:NM_052859.3:3'UTR:MODIFIER:exon13/13:c.*2433C>T:		rs1078968	0.4904	0.0000	0/0/0	0.0969							611908 [RFT1 (confirmed) Congenital disorder of glycosylation,type In,612015];	RCV000351024.1 [benign]; 			67	112					RFT1 (inh=AR pLI=0.00)
chr3	53125297	53125297	G	C	het	wt	het		QUAL=5271;DP=292,124,138;MQM=60	RFT1	3'UTR	RFT1:NM_052859.3:3'UTR:MODIFIER:exon13/13:c.*622C>G:	L2a	rs7645611	0.1669	0.0000	0/0/0	0.0194							611908 [RFT1 (confirmed) Congenital disorder of glycosylation,type In,612015];	RCV000397822.1 [likely benign]; 			2	56					RFT1 (inh=AR pLI=0.00)
chr3	53125429	53125429	A	T	wt	wt	het		QUAL=3251;DP=330,217,249;MQM=60	RFT1	3'UTR	RFT1:NM_052859.3:3'UTR:MODIFIER:exon13/13:c.*490T>A:		rs62255926	0.1480	0.0000	0/0/0	0.0380							611908 [RFT1 (confirmed) Congenital disorder of glycosylation,type In,612015];	RCV000343545.1 [likely benign]; 			23	89					RFT1 (inh=AR pLI=0.00)
chr3	53125469	53125469	G	A	hom	het	het		QUAL=15301;DP=311,199,234;MQM=60	RFT1	3'UTR	RFT1:NM_052859.3:3'UTR:MODIFIER:exon13/13:c.*450C>T:		rs2564922	0.6508	0.0000	0/0/0	0.6820							611908 [RFT1 (confirmed) Congenital disorder of glycosylation,type In,612015];	RCV000400025.1 [benign]; 			104	97					RFT1 (inh=AR pLI=0.00)
chr3	53125585	53125585	T	C	het	het	wt		QUAL=5035;DP=302,104,137;MQM=60	RFT1	3'UTR	RFT1:NM_052859.3:3'UTR:MODIFIER:exon13/13:c.*334A>G:		rs2564921	0.4904	0.0000	0/0/0	0.0971							611908 [RFT1 (confirmed) Congenital disorder of glycosylation,type In,612015];	RCV000365605.1 [benign]; 			67	112					RFT1 (inh=AR pLI=0.00)
chr3	53125922	53125922	T	C	het	het	wt		QUAL=6838;DP=304,234,261;MQM=59	RFT1	synonymous	RFT1:NM_052859.3:synonymous:LOW:exon13/13:c.1623A>G:p.Thr541Thr		rs11242	0.4904	0.5510	19154/10709/334	0.5492							611908 [RFT1 (confirmed) Congenital disorder of glycosylation,type In,612015];	RCV000082329.4 [benign]; RCV000353816.1 [benign]; 			471	757					RFT1 (inh=AR pLI=0.00)
chr3	55499781	55499781	T	C	hom	het	het		QUAL=7361;DP=119,116,131;MQM=60	WNT5A	3'UTR	WNT5A:NM_003392.4:3'UTR:MODIFIER:exon5/5:c.*4339A>G:,WNT5A:NM_001256105.1:3'UTR:MODIFIER:exon5/5:c.*4339A>G:		rs1047898	0.4840	0.0000	0/0/0	0.0846							164975 [WNT5A (provisional) Robinow syndrome,autosomal dominant 1,180700];	RCV000326383.1 [benign]; 			44	115					WNT5A (inh=AD pLI=0.97)
chr3	55500408	55500408	T	A	hom	het	het		QUAL=8051;DP=151,101,143;MQM=60	WNT5A	3'UTR	WNT5A:NM_003392.4:3'UTR:MODIFIER:exon5/5:c.*3712A>T:,WNT5A:NM_001256105.1:3'UTR:MODIFIER:exon5/5:c.*3712A>T:		rs10865994	0.4595	0.0000	0/0/0	0.0829							164975 [WNT5A (provisional) Robinow syndrome,autosomal dominant 1,180700];	RCV000338759.1 [benign]; 			43	115					WNT5A (inh=AD pLI=0.97)
chr3	55501002	55501002	G	C	hom	het	hom		QUAL=16748;DP=263,132,177;MQM=60	WNT5A	3'UTR	WNT5A:NM_003392.4:3'UTR:MODIFIER:exon5/5:c.*3118C>G:,WNT5A:NM_001256105.1:3'UTR:MODIFIER:exon5/5:c.*3118C>G:		rs669889	0.8095	0.0000	0/0/0	0.1314							164975 [WNT5A (provisional) Robinow syndrome,autosomal dominant 1,180700];	RCV000385334.1 [benign]; 			125	89					WNT5A (inh=AD pLI=0.97)
chr3	55501175	55501175	T	C	hom	het	het		QUAL=13138;DP=252,166,201;MQM=60	WNT5A	3'UTR	WNT5A:NM_003392.4:3'UTR:MODIFIER:exon5/5:c.*2945A>G:,WNT5A:NM_001256105.1:3'UTR:MODIFIER:exon5/5:c.*2945A>G:		rs1829556	0.4655	0.0000	0/0/0	0.0842							164975 [WNT5A (provisional) Robinow syndrome,autosomal dominant 1,180700];	RCV000275582.1 [benign]; 			43	115					WNT5A (inh=AD pLI=0.97)
chr3	55501393	55501393	T	-	hom	het	wt		QUAL=1574;DP=114,51,56;MQM=59	WNT5A	3'UTR	WNT5A:NM_003392.4:3'UTR:MODIFIER:exon5/5:c.*2727delA:,WNT5A:NM_001256105.1:3'UTR:MODIFIER:exon5/5:c.*2727delA:	(T)n	rs34280613;rs397873965	0.0000	0.0000	0/0/0	0.1971							164975 [WNT5A (provisional) Robinow syndrome,autosomal dominant 1,180700];				2	76					WNT5A (inh=AD pLI=0.97)
chr3	55502167	55502168	AA	-	hom	hom	hom	low_DP	QUAL=635;DP=44,19,23;MQM=59	WNT5A	3'UTR	WNT5A:NM_003392.4:3'UTR:MODIFIER:exon5/5:c.*1952_*1953delTT:,WNT5A:NM_001256105.1:3'UTR:MODIFIER:exon5/5:c.*1952_*1953delTT:	(A)n	rs796958500	0.0000	0.0000	0/0/0	0.0365							164975 [WNT5A (provisional) Robinow syndrome,autosomal dominant 1,180700];	RCV000277253.1 [uncertain significance]; 			3	23					WNT5A (inh=AD pLI=0.97)
chr3	55503522	55503522	T	A	wt	wt	het		QUAL=1939;DP=260,120,164;MQM=60	WNT5A	3'UTR	WNT5A:NM_003392.4:3'UTR:MODIFIER:exon5/5:c.*598A>T:,WNT5A:NM_001256105.1:3'UTR:MODIFIER:exon5/5:c.*598A>T:		rs3773606	0.1358	0.0000	0/0/0	0.0173							164975 [WNT5A (provisional) Robinow syndrome,autosomal dominant 1,180700];	RCV000321198.1 [benign]; 			3	45					WNT5A (inh=AD pLI=0.97)
chr3	58080583	58080583	A	G	het	het	wt	pred_pathogenic	QUAL=5362;DP=250,219,291;MQM=60	FLNB	missense	FLNB:NM_001164317.1:missense:MODERATE:exon5/47:c.808A>G:p.Met270Val,FLNB:NM_001164318.1:missense:MODERATE:exon5/46:c.808A>G:p.Met270Val,FLNB:NM_001164319.1:missense:MODERATE:exon5/45:c.808A>G:p.Met270Val,FLNB:NM_001457.3:missense:MODERATE:exon5/46:c.808A>G:p.Met270Val		rs145036794	0.0002	0.0006	0/0/0	0.0006	2.5940	T,T,T,T,T,T,T,T	T	B,B,B,B,B,B	D,D,D,D,D,D,D,D	11.37	603381 [FLNB (confirmed) Spondylocarpotarsal synostosis syndrome,272460|Larsen syndrome,150250|Atelosteogenesis,type I,108720|Atelosteogenesis,type III,108721|Boomerang dysplasia,112310];	RCV000238833.2 [uncertain significance]; 		COSM1485422, COSM1485423	0	5	3	[3] Stephan Waldm?ller 12.08.2014			FLNB (inh=AR+AD pLI=0.00)
chr3	58081888	58081888	T	C	het	wt	het		QUAL=8922;DP=298,353,453;MQM=59	FLNB	synonymous	FLNB:NM_001164317.1:synonymous:LOW:exon6/47:c.927T>C:p.Ser309Ser,FLNB:NM_001164318.1:synonymous:LOW:exon6/46:c.927T>C:p.Ser309Ser,FLNB:NM_001164319.1:synonymous:LOW:exon6/45:c.927T>C:p.Ser309Ser,FLNB:NM_001457.3:synonymous:LOW:exon6/46:c.927T>C:p.Ser309Ser		rs1522384	0.6420	0.4647	15585/3520/1517	0.4466							603381 [FLNB (confirmed) Spondylocarpotarsal synostosis syndrome,272460|Larsen syndrome,150250|Atelosteogenesis,type I,108720|Atelosteogenesis,type III,108721|Boomerang dysplasia,112310];	RCV000248165.1 [benign]; RCV000367630.1 [likely benign]; 			215	708					FLNB (inh=AR+AD pLI=0.00)
chr3	58109162	58109162	G	A	het	wt	het	pred_pathogenic	QUAL=6801;DP=178,253,363;MQM=60	FLNB	missense	FLNB:NM_001164317.1:missense:MODERATE:exon21/47:c.3469G>A:p.Asp1157Asn,FLNB:NM_001164318.1:missense:MODERATE:exon21/46:c.3469G>A:p.Asp1157Asn,FLNB:NM_001164319.1:missense:MODERATE:exon21/45:c.3469G>A:p.Asp1157Asn,FLNB:NM_001457.3:missense:MODERATE:exon21/46:c.3469G>A:p.Asp1157Asn		rs1131356	0.5461	0.3732	10732/2038/923	0.3699	9.8690	T,T,T,T,T,T,T,T	T	D,D,D,P,D,D	D,D,D,D,D,D,D,D	26.30	603381 [FLNB (confirmed) Spondylocarpotarsal synostosis syndrome,272460|Larsen syndrome,150250|Atelosteogenesis,type I,108720|Atelosteogenesis,type III,108721|Boomerang dysplasia,112310];	RCV000250004.2 [benign]; RCV000333788.1 [likely benign]; 		COSM4158258, COSM4158257, COSM4158256	138	593					FLNB (inh=AR+AD pLI=0.00)
chr3	58112440	58112440	A	G	het	het	hom		QUAL=12449;DP=251,171,227;MQM=60	FLNB	synonymous	FLNB:NM_001164317.1:synonymous:LOW:exon24/47:c.4173A>G:p.Ala1391Ala,FLNB:NM_001164318.1:synonymous:LOW:exon24/46:c.4173A>G:p.Ala1391Ala,FLNB:NM_001164319.1:synonymous:LOW:exon24/45:c.4173A>G:p.Ala1391Ala,FLNB:NM_001457.3:synonymous:LOW:exon24/46:c.4173A>G:p.Ala1391Ala		rs2362903	0.8333	0.7079	31452/13071/4263	0.6893							603381 [FLNB (confirmed) Spondylocarpotarsal synostosis syndrome,272460|Larsen syndrome,150250|Atelosteogenesis,type I,108720|Atelosteogenesis,type III,108721|Boomerang dysplasia,112310];	RCV000242336.1 [benign]; RCV000296871.1 [likely benign]; 		COSM4158260, COSM4158259, COSM4158261	704	693					FLNB (inh=AR+AD pLI=0.00)
chr3	58112488	58112488	C	T	het	wt	het		QUAL=4167;DP=168,123,167;MQM=59	FLNB	splice_region&synonymous	FLNB:NM_001164317.1:splice_region&synonymous:LOW:exon24/47:c.4221C>T:p.Pro1407Pro,FLNB:NM_001164318.1:splice_region&synonymous:LOW:exon24/46:c.4221C>T:p.Pro1407Pro,FLNB:NM_001164319.1:splice_region&synonymous:LOW:exon24/45:c.4221C>T:p.Pro1407Pro,FLNB:NM_001457.3:splice_region&synonymous:LOW:exon24/46:c.4221C>T:p.Pro1407Pro		rs2362904	0.6486	0.4091	13314/2047/2719	0.3910							603381 [FLNB (confirmed) Spondylocarpotarsal synostosis syndrome,272460|Larsen syndrome,150250|Atelosteogenesis,type I,108720|Atelosteogenesis,type III,108721|Boomerang dysplasia,112310];	RCV000247133.1 [benign]; RCV000277932.1 [likely benign]; 		COSM4158262, COSM4158264, COSM4158263	160	596					FLNB (inh=AR+AD pLI=0.00)
chr3	58118555	58118555	G	A	het	wt	het	pred_pathogenic	QUAL=9295;DP=268,343,484;MQM=60	FLNB	missense	FLNB:NM_001164317.1:missense:MODERATE:exon27/47:c.4504G>A:p.Val1502Met,FLNB:NM_001164318.1:missense:MODERATE:exon26/46:c.4411G>A:p.Val1471Met,FLNB:NM_001164319.1:missense:MODERATE:exon26/45:c.4411G>A:p.Val1471Met,FLNB:NM_001457.3:missense:MODERATE:exon26/46:c.4411G>A:p.Val1471Met		rs12632456	0.6082	0.3952	12348/2052/1840	0.3793	2.9510	T,T,T,T,T,T,T,T	T	B,B,B,B,B,B	D,D,D,D,D,D,D,D	26.60	603381 [FLNB (confirmed) Spondylocarpotarsal synostosis syndrome,272460|Larsen syndrome,150250|Atelosteogenesis,type I,108720|Atelosteogenesis,type III,108721|Boomerang dysplasia,112310];	RCV000247641.1 [benign]; RCV000271883.1 [likely benign]; 		COSM4158266, COSM4158267, COSM4158265	153	601					FLNB (inh=AR+AD pLI=0.00)
chr3	58145363	58145363	A	C	het	wt	wt	pred_pathogenic	QUAL=56;DP=154,162,190;MQM=59	FLNB	missense	FLNB:NM_001164317.1:missense:MODERATE:exon43/47:c.7064A>C:p.His2355Pro,FLNB:NM_001164318.1:missense:MODERATE:exon42/46:c.6938A>C:p.His2313Pro,FLNB:NM_001164319.1:missense:MODERATE:exon41/45:c.6899A>C:p.His2300Pro,FLNB:NM_001457.3:missense:MODERATE:exon42/46:c.6971A>C:p.His2324Pro		rs202222289	0.0000	0.0031	0/0/0	0.0001	9.3390	T,T,T,T,T,T,T	D	B,B,B,B,B,B	D,D,D,D,D,D,D	20.10	603381 [FLNB (confirmed) Spondylocarpotarsal synostosis syndrome,272460|Larsen syndrome,150250|Atelosteogenesis,type I,108720|Atelosteogenesis,type III,108721|Boomerang dysplasia,112310];			COSM304726	0	49					FLNB (inh=AR+AD pLI=0.00)
chr3	58154327	58154327	C	T	het	wt	het		QUAL=7770;DP=297,296,377;MQM=59	FLNB,LOC105377105	synonymous,intron	FLNB:NM_001164317.1:synonymous:LOW:exon45/47:c.7452C>T:p.Ser2484Ser,FLNB:NM_001164318.1:synonymous:LOW:exon44/46:c.7326C>T:p.Ser2442Ser,FLNB:NM_001164319.1:synonymous:LOW:exon43/45:c.7287C>T:p.Ser2429Ser,FLNB:NM_001457.3:synonymous:LOW:exon44/46:c.7359C>T:p.Ser2453Ser,LOC105377105:NR_135534.1:intron:MODIFIER:exon1/1:n.139+1897G>A:		rs8640	0.5713	0.3852	11362/2159/1400	0.3837							603381 [FLNB (confirmed) Spondylocarpotarsal synostosis syndrome,272460|Larsen syndrome,150250|Atelosteogenesis,type I,108720|Atelosteogenesis,type III,108721|Boomerang dysplasia,112310];	RCV000243570.1 [benign]; RCV000395617.1 [likely benign]; 			156	604					FLNB (inh=AR+AD pLI=0.00), LOC105377105 (inh=n/a pLI=n/a)
chr3	58157519	58157519	G	C	het	het	hom		QUAL=20302;DP=379,288,369;MQM=60	FLNB	3'UTR	FLNB:NM_001164317.1:3'UTR:MODIFIER:exon47/47:c.*1030G>C:,FLNB:NM_001164318.1:3'UTR:MODIFIER:exon46/46:c.*1030G>C:,FLNB:NM_001164319.1:3'UTR:MODIFIER:exon45/45:c.*1030G>C:,FLNB:NM_001457.3:3'UTR:MODIFIER:exon46/46:c.*1030G>C:		rs1131264	0.6931	0.0000	0/0/0	0.0855							603381 [FLNB (confirmed) Spondylocarpotarsal synostosis syndrome,272460|Larsen syndrome,150250|Atelosteogenesis,type I,108720|Atelosteogenesis,type III,108721|Boomerang dysplasia,112310];	RCV000405717.1 [likely benign]; 			47	111					FLNB (inh=AR+AD pLI=0.00)
chr3	58157799	58157799	T	G	het	wt	wt		QUAL=46;DP=193,188,196;MQM=58	FLNB	3'UTR	FLNB:NM_001164317.1:3'UTR:MODIFIER:exon47/47:c.*1310T>G:,FLNB:NM_001164318.1:3'UTR:MODIFIER:exon46/46:c.*1310T>G:,FLNB:NM_001164319.1:3'UTR:MODIFIER:exon45/45:c.*1310T>G:,FLNB:NM_001457.3:3'UTR:MODIFIER:exon46/46:c.*1310T>G:		rs761905985	0.0000	0.0000	0/0/0	0.0008							603381 [FLNB (confirmed) Spondylocarpotarsal synostosis syndrome,272460|Larsen syndrome,150250|Atelosteogenesis,type I,108720|Atelosteogenesis,type III,108721|Boomerang dysplasia,112310];				0	37					FLNB (inh=AR+AD pLI=0.00)
chr3	58413405	58413405	T	C	het	wt	het		QUAL=2000;DP=132,58,75;MQM=60	PDHB	3'UTR,non_coding_transcript_exon	PDHB:NM_000925.3:3'UTR:MODIFIER:exon10/10:c.*356A>G:,PDHB:NM_001173468.1:3'UTR:MODIFIER:exon11/11:c.*356A>G:,PDHB:NM_001315536.1:3'UTR:MODIFIER:exon9/9:c.*356A>G:,PDHB:NR_033384.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.1549A>G:		rs1126737	0.3674	0.4889	418/38/0	0.0791							179060 [PDHB (provisional) Pyruvate dehydrogenase E1-beta deficiency,614111];	RCV000272368.1 [benign]; 			55	250					PDHB (inh=AR pLI=0.36)
chr3	58413408	58413408	A	G	het	hom	wt		QUAL=3603;DP=137,61,77;MQM=59	PDHB	3'UTR,non_coding_transcript_exon	PDHB:NM_000925.3:3'UTR:MODIFIER:exon10/10:c.*353T>C:,PDHB:NM_001173468.1:3'UTR:MODIFIER:exon11/11:c.*353T>C:,PDHB:NM_001315536.1:3'UTR:MODIFIER:exon9/9:c.*353T>C:,PDHB:NR_033384.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.1546T>C:		rs1126735	0.1847	0.3209	332/185/0	0.0676							179060 [PDHB (provisional) Pyruvate dehydrogenase E1-beta deficiency,614111];	RCV000324992.1 [benign]; 			65	308					PDHB (inh=AR pLI=0.36)
chr3	58413465	58413465	G	C	hom	hom	het		QUAL=16218;DP=258,160,192;MQM=59	PDHB	3'UTR,non_coding_transcript_exon	PDHB:NM_000925.3:3'UTR:MODIFIER:exon10/10:c.*296C>G:,PDHB:NM_001173468.1:3'UTR:MODIFIER:exon11/11:c.*296C>G:,PDHB:NM_001315536.1:3'UTR:MODIFIER:exon9/9:c.*296C>G:,PDHB:NR_033384.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.1489C>G:		rs7231	0.7418	0.7950	3406/888/41	0.2006							179060 [PDHB (provisional) Pyruvate dehydrogenase E1-beta deficiency,614111];	RCV000381952.1 [benign]; 			413	211					PDHB (inh=AR pLI=0.36)
chr3	58413518	58413518	T	G	het	hom	wt		QUAL=10454;DP=207,231,277;MQM=60	PDHB	3'UTR,non_coding_transcript_exon	PDHB:NM_000925.3:3'UTR:MODIFIER:exon10/10:c.*243A>C:,PDHB:NM_001173468.1:3'UTR:MODIFIER:exon11/11:c.*243A>C:,PDHB:NM_001315536.1:3'UTR:MODIFIER:exon9/9:c.*243A>C:,PDHB:NR_033384.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.1436A>C:		rs1126722	0.2005	0.2944	544/289/8	0.0765							179060 [PDHB (provisional) Pyruvate dehydrogenase E1-beta deficiency,614111];	RCV000285224.1 [benign]; 			68	306					PDHB (inh=AR pLI=0.36)
chr3	58413662	58413662	G	A	het	wt	het		QUAL=8186;DP=248,288,378;MQM=60	PDHB	3'UTR,non_coding_transcript_exon	PDHB:NM_000925.3:3'UTR:MODIFIER:exon10/10:c.*99C>T:,PDHB:NM_001173468.1:3'UTR:MODIFIER:exon11/11:c.*99C>T:,PDHB:NM_001315536.1:3'UTR:MODIFIER:exon9/9:c.*99C>T:,PDHB:NR_033384.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.1292C>T:		rs7230	0.3672	0.4084	2235/587/10	0.2594							179060 [PDHB (provisional) Pyruvate dehydrogenase E1-beta deficiency,614111];	RCV000376551.1 [benign]; 			55	256					PDHB (inh=AR pLI=0.36)
chr3	58413669	58413669	G	T	het	hom	wt		QUAL=13150;DP=274,276,375;MQM=60	PDHB	3'UTR,non_coding_transcript_exon	PDHB:NM_000925.3:3'UTR:MODIFIER:exon10/10:c.*92C>A:,PDHB:NM_001173468.1:3'UTR:MODIFIER:exon11/11:c.*92C>A:,PDHB:NM_001315536.1:3'UTR:MODIFIER:exon9/9:c.*92C>A:,PDHB:NR_033384.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.1285C>A:		rs4228	0.2047	0.3390	2180/1608/100	0.2387							179060 [PDHB (provisional) Pyruvate dehydrogenase E1-beta deficiency,614111];	RCV000284383.1 [benign]; 			68	306					PDHB (inh=AR pLI=0.36)
chr3	58416535	58416535	C	T	het	hom	wt		QUAL=30480;DP=283,311,410;MQM=60	PDHB	splice_region&intron,synonymous,non_coding_transcript_exon	PDHB:NM_001173468.1:splice_region&intron:LOW:exon6/10:c.404-20G>A:,PDHB:NM_000925.3:synonymous:LOW:exon6/10:c.438G>A:p.Gly146Gly,PDHB:NM_001315536.1:synonymous:LOW:exon5/9:c.384G>A:p.Gly128Gly,PDHB:NR_033384.1:non_coding_transcript_exon:MODIFIER:exon5/9:n.551G>A:		rs1126551	0.2047	0.2832	5680/4480/230	0.2755							179060 [PDHB (provisional) Pyruvate dehydrogenase E1-beta deficiency,614111];	RCV000117898.2 [likely benign]; RCV000367428.1 [benign]; 		COSM3760211	193	711					PDHB (inh=AR pLI=0.36)
chr3	58416538	58416538	T	C	hom	hom	hom		QUAL=30480;DP=283,311,410;MQM=60	PDHB	synonymous,intron,non_coding_transcript_exon	PDHB:NM_000925.3:synonymous:LOW:exon6/10:c.435A>G:p.Arg145Arg,PDHB:NM_001315536.1:synonymous:LOW:exon5/9:c.381A>G:p.Arg127Arg,PDHB:NM_001173468.1:intron:MODIFIER:exon6/10:c.404-23A>G:,PDHB:NR_033384.1:non_coding_transcript_exon:MODIFIER:exon5/9:n.548A>G:		rs4264746	0.9848	0.9948	60093/33348/4655	0.9540							179060 [PDHB (provisional) Pyruvate dehydrogenase E1-beta deficiency,614111];	RCV000127406.1 [benign]; 			1562	4					PDHB (inh=AR pLI=0.36)
chr3	58417610	58417610	T	C	wt	het	wt		QUAL=5568;DP=527,423,646;MQM=60	PDHB	synonymous,non_coding_transcript_exon	PDHB:NM_000925.3:synonymous:LOW:exon3/10:c.198A>G:p.Ala66Ala,PDHB:NM_001173468.1:synonymous:LOW:exon3/11:c.198A>G:p.Ala66Ala,PDHB:NM_001315536.1:synonymous:LOW:exon2/9:c.144A>G:p.Ala48Ala,PDHB:NR_033384.1:non_coding_transcript_exon:MODIFIER:exon2/9:n.311A>G:		rs138621975	0.0002	0.0016	0/0/0	0.0018							179060 [PDHB (provisional) Pyruvate dehydrogenase E1-beta deficiency,614111];	RCV000127403.1 [benign]; 			0	6					PDHB (inh=AR pLI=0.36)
chr3	63850298	63850298	T	G	het	het	hom		QUAL=12280;DP=300,167,251;MQM=59	ATXN7	5'UTR	ATXN7:NM_000333.3:5'UTR:MODIFIER:exon1/13:c.-488T>G:		rs6779372	0.7492	0.0000	0/0/0	0.5121							607640 [ATXN7 (confirmed) Spinocerebellar ataxia 7,164500];				133	86					ATXN7 (inh=AD pLI=0.93)
chr3	63850299	63850299	G	C	het	het	hom		QUAL=12280;DP=300,167,251;MQM=59	ATXN7	5'UTR	ATXN7:NM_000333.3:5'UTR:MODIFIER:exon1/13:c.-487G>C:		rs3733120	0.7490	0.0000	0/0/0	0.5005							607640 [ATXN7 (confirmed) Spinocerebellar ataxia 7,164500];				133	86					ATXN7 (inh=AD pLI=0.93)
chr3	63850660	63850660	C	G	het	wt	het		QUAL=6045;DP=266,173,225;MQM=59	ATXN7	5'UTR	ATXN7:NM_000333.3:5'UTR:MODIFIER:exon1/13:c.-126C>G:		rs3733121	0.1088	0.0000	0/0/0	0.1239							607640 [ATXN7 (confirmed) Spinocerebellar ataxia 7,164500];				4	60					ATXN7 (inh=AD pLI=0.93)
chr3	63967900	63967900	A	G	het	wt	het	pred_pathogenic	QUAL=4861;DP=176,140,202;MQM=60	ATXN7	missense	ATXN7:NM_001177387.1:missense:MODERATE:exon6/13:c.791A>G:p.Lys264Arg,ATXN7:NM_000333.3:missense:MODERATE:exon7/13:c.791A>G:p.Lys264Arg,ATXN7:NM_001128149.2:missense:MODERATE:exon3/9:c.356A>G:p.Lys119Arg		rs1053338	0.1146	0.1344	1256/660/9	0.1321	4.0620	T,T,T,T,T	T	D,B,B	T,T,T,T,T	13.92	607640 [ATXN7 (confirmed) Spinocerebellar ataxia 7,164500];	RCV000116489.2 [likely benign]; 	CM1413188 [CLASS=DP MUT=ALT PHEN="Breast cancer susceptibility to" GENE=ATXN7]; 		37	368					ATXN7 (inh=AD pLI=0.93)
chr3	63981635	63981635	C	T	het	het	wt		QUAL=7048;DP=278,260,327;MQM=59	ATXN7	synonymous	ATXN7:NM_001177387.1:synonymous:LOW:exon11/13:c.2137C>T:p.Leu713Leu,ATXN7:NM_000333.3:synonymous:LOW:exon12/13:c.2137C>T:p.Leu713Leu,ATXN7:NM_001128149.2:synonymous:LOW:exon8/9:c.1702C>T:p.Leu568Leu		rs3733125	0.0905	0.0968	739/381/2	0.0980							607640 [ATXN7 (confirmed) Spinocerebellar ataxia 7,164500];	RCV000116486.2 [likely benign]; 		COSM149408	20	277					ATXN7 (inh=AD pLI=0.93)
chr3	63982082	63982082	G	A	hom	het	hom		QUAL=21351;DP=255,209,316;MQM=60	ATXN7	missense	ATXN7:NM_001177387.1:missense:MODERATE:exon11/13:c.2584G>A:p.Val862Met,ATXN7:NM_000333.3:missense:MODERATE:exon12/13:c.2584G>A:p.Val862Met,ATXN7:NM_001128149.2:missense:MODERATE:exon8/9:c.2149G>A:p.Val717Met		rs3774729	0.4377	0.3477	7726/3392/1615	0.3443	-0.2650	T,T,T,T,T,T	T	B,B,B	T,T,T,T,T,T	7.16	607640 [ATXN7 (confirmed) Spinocerebellar ataxia 7,164500];	RCV000116488.2 [likely benign]; 		COSM1567155, COSM1567156	188	664					ATXN7 (inh=AD pLI=0.93)
chr3	63986047	63986047	T	-	het	wt	hom		QUAL=5586;DP=199,66,113;MQM=59	ATXN7	3'UTR	ATXN7:NM_001177387.1:3'UTR:MODIFIER:exon13/13:c.*815delT:,ATXN7:NM_000333.3:3'UTR:MODIFIER:exon13/13:c.*907delT:,ATXN7:NM_001128149.2:3'UTR:MODIFIER:exon9/9:c.*907delT:		rs397841163	0.1999	0.0000	0/0/0	0.1606							607640 [ATXN7 (confirmed) Spinocerebellar ataxia 7,164500];				4	73					ATXN7 (inh=AD pLI=0.93)
chr3	63986170	63986170	A	G	hom	het	hom		QUAL=23462;DP=394,208,256;MQM=59	ATXN7	3'UTR	ATXN7:NM_001177387.1:3'UTR:MODIFIER:exon13/13:c.*935A>G:,ATXN7:NM_000333.3:3'UTR:MODIFIER:exon13/13:c.*1027A>G:,ATXN7:NM_001128149.2:3'UTR:MODIFIER:exon9/9:c.*1027A>G:		rs13272	0.5104	0.0000	0/0/0	0.0669							607640 [ATXN7 (confirmed) Spinocerebellar ataxia 7,164500];				27	114					ATXN7 (inh=AD pLI=0.93)
chr3	63988171	63988171	C	T	het	wt	hom		QUAL=11836;DP=355,171,245;MQM=59	ATXN7	3'UTR	ATXN7:NM_001177387.1:3'UTR:MODIFIER:exon13/13:c.*2936C>T:,ATXN7:NM_000333.3:3'UTR:MODIFIER:exon13/13:c.*3028C>T:,ATXN7:NM_001128149.2:3'UTR:MODIFIER:exon9/9:c.*3028C>T:	(TG)n	rs3733126	0.1861	0.0000	0/0/0	0.1565							607640 [ATXN7 (confirmed) Spinocerebellar ataxia 7,164500];				4	74					ATXN7 (inh=AD pLI=0.93)
chr3	63988174	63988174	C	T	het	het	wt		QUAL=6462;DP=354,164,240;MQM=59	ATXN7	3'UTR	ATXN7:NM_001177387.1:3'UTR:MODIFIER:exon13/13:c.*2939C>T:,ATXN7:NM_000333.3:3'UTR:MODIFIER:exon13/13:c.*3031C>T:,ATXN7:NM_001128149.2:3'UTR:MODIFIER:exon9/9:c.*3031C>T:	(TG)n	rs3733127	0.2634	0.0000	0/0/0	0.1641							607640 [ATXN7 (confirmed) Spinocerebellar ataxia 7,164500];				4	66					ATXN7 (inh=AD pLI=0.93)
chr3	63988193	63988194	GT	-	wt	wt	het		QUAL=2530;DP=435,158,221;MQM=60	ATXN7	3'UTR	ATXN7:NM_001177387.1:3'UTR:MODIFIER:exon13/13:c.*2966_*2967delGT:,ATXN7:NM_000333.3:3'UTR:MODIFIER:exon13/13:c.*3058_*3059delGT:,ATXN7:NM_001128149.2:3'UTR:MODIFIER:exon9/9:c.*3058_*3059delGT:	(TG)n	rs796227729	0.0571	0.0000	0/0/0	0.0342							607640 [ATXN7 (confirmed) Spinocerebellar ataxia 7,164500];				0	11					ATXN7 (inh=AD pLI=0.93)
chr3	81539382	81539382	C	T	wt	het	het		QUAL=2600;DP=215,85,111;MQM=60	GBE1	3'UTR	GBE1:NM_000158.3:3'UTR:MODIFIER:exon16/16:c.*176G>A:		rs846	0.3091	0.0000	0/0/0	0.0652							607839 [GBE1 (provisional) Glycogen storage disease IV,232500|Polyglucosan body disease,adult form,263570];	RCV000315195.1 [benign]; RCV000400849.1 [benign]; 			37	116					GBE1 (inh=AR pLI=0.00)
chr3	81643167	81643167	T	C	hom	hom	hom	pred_pathogenic	QUAL=27307;DP=330,223,281;MQM=60	GBE1	missense	GBE1:NM_000158.3:missense:MODERATE:exon8/16:c.1000A>G:p.Ile334Val		rs2172397	0.9836	0.9728	26318/13594/2692	0.9120	5.5970	T,T,T,T	T	B,B	T,T	7.74	607839 [GBE1 (provisional) Glycogen storage disease IV,232500|Polyglucosan body disease,adult form,263570];				2510	175					GBE1 (inh=AR pLI=0.00)
chr3	81698130	81698130	T	C	het	wt	het	pred_pathogenic	QUAL=4841;DP=211,103,156;MQM=60	GBE1	missense	GBE1:NM_000158.3:missense:MODERATE:exon5/16:c.568A>G:p.Arg190Gly		rs2229519	0.3215	0.3746	5135/2559/322	0.3028	3.4770	D,D,D	T	B,B	D,D	23.10	607839 [GBE1 (provisional) Glycogen storage disease IV,232500|Polyglucosan body disease,adult form,263570];	RCV000178721.2 [benign]; RCV000318439.1 [benign]; RCV000375379.1 [benign]; 			224	1058	1	[1] auto-classification 16.06.2016  [2] harmuth 13.04.2016; in-house frequency: 156x hom/ 700x het and is also too frequent in open databases			GBE1 (inh=AR pLI=0.00)
chr3	81810702	81810702	-	G	hom	hom	hom	low_DP	QUAL=1354;DP=24,14,14;MQM=59	GBE1	5'UTR	GBE1:NM_000158.3:5'UTR:MODIFIER:exon1/16:c.-35dupC:		rs11391701	0.9968	0.9998	38368/21124/2671	0.9100							607839 [GBE1 (provisional) Glycogen storage disease IV,232500|Polyglucosan body disease,adult form,263570];				1789	48					GBE1 (inh=AR pLI=0.00)
chr3	81810725	81810725	C	T	het	wt	het	low_DP	QUAL=161;DP=14,10,11;MQM=58	GBE1	5'UTR	GBE1:NM_000158.3:5'UTR:MODIFIER:exon1/16:c.-57G>A:		rs2290081	0.4209	0.4536	2523/1143/280	0.2923							607839 [GBE1 (provisional) Glycogen storage disease IV,232500|Polyglucosan body disease,adult form,263570];				203	803					GBE1 (inh=AR pLI=0.00)
chr3	87308831	87308831	C	T	hom	hom	hom	low_DP	QUAL=2157;DP=46,9,16;MQM=60	POU1F1	3'UTR	POU1F1:NM_001122757.2:3'UTR:MODIFIER:exon6/6:c.*213G>A:,POU1F1:NM_000306.3:3'UTR:MODIFIER:exon6/6:c.*213G>A:		rs6792500	1.0000	0.0000	0/0/0	0.1492							173110 [POU1F1 (confirmed) Pituitary hormone deficiency,combined,1,613038];	RCV000280492.1 [benign]; RCV000407251.1 [benign]; 			230	0					POU1F1 (inh=AR+AD pLI=0.62)
chr3	87308904	87308904	T	A	het	hom	wt		QUAL=3569;DP=151,43,62;MQM=60	POU1F1	3'UTR	POU1F1:NM_001122757.2:3'UTR:MODIFIER:exon6/6:c.*140A>T:,POU1F1:NM_000306.3:3'UTR:MODIFIER:exon6/6:c.*140A>T:		rs33936108	0.2508	0.0000	0/0/0	0.2863							173110 [POU1F1 (confirmed) Pituitary hormone deficiency,combined,1,613038];	RCV000308985.1 [likely benign]; RCV000337782.1 [benign]; 			42	113					POU1F1 (inh=AR+AD pLI=0.62)
chr3	101370530	101370531	AA	-	hom	wt	hom		QUAL=429;DP=88,38,64;MQM=59	ZBTB11	splice_region&intron	ZBTB11:NM_014415.3:splice_region&intron:LOW:exon10/10:c.2645-4_2645-3delTT:	(A)n	rs796206524	0.0000	0.2316	9/1/8	0.1188											6	14					ZBTB11 (inh=n/a pLI=0.27)
chr3	101383562	101383562	G	A	het	wt	het		QUAL=5784;DP=267,163,203;MQM=60	ZBTB11	splice_region&intron	ZBTB11:NM_014415.3:splice_region&intron:LOW:exon4/10:c.1624-4C>T:		rs11712748	0.3307	0.3273	6673/4027/969	0.3235										COSM4002354	104	452					ZBTB11 (inh=n/a pLI=0.27)
chr3	121488995	121488995	C	G	hom	het	hom		QUAL=16903;DP=307,124,166;MQM=59	IQCB1	3'UTR,non_coding_transcript_exon	IQCB1:NM_001023570.3:3'UTR:MODIFIER:exon15/15:c.*197G>C:,IQCB1:NM_001023571.3:3'UTR:MODIFIER:exon12/12:c.*197G>C:,IQCB1:NM_001319107.1:3'UTR:MODIFIER:exon15/15:c.*197G>C:,IQCB1:NR_134968.1:non_coding_transcript_exon:MODIFIER:exon14/14:n.2098G>C:		rs1135750	0.6212	0.0000	0/0/0	0.0988							609237 [IQCB1 (provisional) Senior-Loken syndrome 5,609254];	RCV000394184.1 [benign]; 			80	106					IQCB1 (inh=AR pLI=0.00)
chr3	121500699	121500699	C	T	het	wt	het	pred_pathogenic	QUAL=3175;DP=194,57,76;MQM=60	IQCB1	missense,non_coding_transcript_exon	IQCB1:NM_001023570.3:missense:MODERATE:exon13/15:c.1301G>A:p.Cys434Tyr,IQCB1:NM_001023571.3:missense:MODERATE:exon10/12:c.902G>A:p.Cys301Tyr,IQCB1:NM_001319107.1:missense:MODERATE:exon13/15:c.1301G>A:p.Cys434Tyr,IQCB1:NR_134968.1:non_coding_transcript_exon:MODIFIER:exon12/14:n.1405G>A:		rs17849995	0.3027	0.2889	6050/1960/301	0.2815	2.8010	T,T	T	B,P	T,T	22.00	609237 [IQCB1 (provisional) Senior-Loken syndrome 5,609254];	RCV000245543.1 [benign]; RCV000369501.1 [benign]; 			121	598					IQCB1 (inh=AR pLI=0.00)
chr3	121526204	121526204	G	A	hom	het	hom		QUAL=17764;DP=308,119,187;MQM=59	IQCB1	synonymous,non_coding_transcript_exon	IQCB1:NM_001023570.3:synonymous:LOW:exon7/15:c.574C>T:p.Leu192Leu,IQCB1:NM_001023571.3:synonymous:LOW:exon7/12:c.574C>T:p.Leu192Leu,IQCB1:NM_001319107.1:synonymous:LOW:exon7/15:c.574C>T:p.Leu192Leu,IQCB1:NR_134968.1:non_coding_transcript_exon:MODIFIER:exon7/14:n.788C>T:		rs4543051	0.6200	0.6275	24452/12877/2663	0.6162							609237 [IQCB1 (provisional) Senior-Loken syndrome 5,609254];	RCV000179799.2 [benign]; RCV000372741.1 [benign]; 			593	678					IQCB1 (inh=AR pLI=0.00)
chr3	121553853	121553858	CTCCCA	-	hom	het	hom		QUAL=9992;DP=199,140,153;MQM=59	IQCB1	5'UTR,non_coding_transcript_exon	IQCB1:NM_001023570.3:5'UTR:MODIFIER:exon1/15:c.-147_-142delTGGGAG:,IQCB1:NM_001023571.3:5'UTR:MODIFIER:exon1/12:c.-147_-142delTGGGAG:,IQCB1:NM_001319107.1:5'UTR:MODIFIER:exon1/15:c.-146_-141delTGGGAG:,IQCB1:NR_134968.1:non_coding_transcript_exon:MODIFIER:exon1/14:n.69_74delTGGGAG:		rs72421117	0.6218	0.0000	0/0/0	0.5761							609237 [IQCB1 (provisional) Senior-Loken syndrome 5,609254];	RCV000313102.1 [benign]; 			81	107					IQCB1 (inh=AR pLI=0.00)
chr3	121903266	121903266	G	A	hom	het	hom	low_DP	QUAL=3024;DP=12,44,76;MQM=60	CASR	5'UTR,intron	CASR:NM_001178065.1:5'UTR:MODIFIER:exon1/7:c.-353G>A:,CASR:NM_000388.3:intron:MODIFIER:exon1/6:c.-243+607G>A:		rs9883981	0.2179	0.0000	0/0/0	0.2521							601199 [CASR (confirmed) Hypocalciuric hypercalcemia,type I,145980|Hyperparathyroidism,neonatal,239200|Hypocalcemia,autosomal dominant,601198|Hypocalcemia,autosomal dominant,with Bartter syndrome,601198|Epilepsy idiopathic generalized,susceptibility to,8,612899|Hypercalciuric hypercalcemia|Calcium,serum level of];				10	52					CASR (inh=AD pLI=0.37)
chr3	122003045	122003045	G	C	hom	hom	hom		QUAL=35494;DP=330,362,413;MQM=59	CASR	synonymous	CASR:NM_001178065.1:synonymous:LOW:exon7/7:c.2274G>C:p.Pro758Pro,CASR:NM_000388.3:synonymous:LOW:exon7/7:c.2244G>C:p.Pro748Pro		rs2036400	0.9728	0.9916	59427/33130/4241	0.9374							601199 [CASR (confirmed) Hypocalciuric hypercalcemia,type I,145980|Hyperparathyroidism,neonatal,239200|Hypocalcemia,autosomal dominant,601198|Hypocalcemia,autosomal dominant,with Bartter syndrome,601198|Epilepsy idiopathic generalized,susceptibility to,8,612899|Hypercalciuric hypercalcemia|Calcium,serum level of];	RCV000234246.1 [benign]; RCV000234246.1 [benign]; RCV000152932.2 [benign]; 			1559	4					CASR (inh=AD pLI=0.37)
chr3	122003832	122003832	G	C	het	het	hom	pred_pathogenic	QUAL=20480;DP=276,309,391;MQM=59	CASR	missense	CASR:NM_001178065.1:missense:MODERATE:exon7/7:c.3061G>C:p.Glu1021Gln,CASR:NM_000388.3:missense:MODERATE:exon7/7:c.3031G>C:p.Glu1011Gln		rs1801726	0.9241	0.9446	54228/30247/3532	0.9161	1.1740	T,T,T	T	B	D,D,D	0.11	601199 [CASR (confirmed) Hypocalciuric hypercalcemia,type I,145980|Hyperparathyroidism,neonatal,239200|Hypocalcemia,autosomal dominant,601198|Hypocalcemia,autosomal dominant,with Bartter syndrome,601198|Epilepsy idiopathic generalized,susceptibility to,8,612899|Hypercalciuric hypercalcemia|Calcium,serum level of];	RCV000229426.1 [benign]; RCV000229426.1 [benign]; RCV000152934.3 [benign]; 	CM045983 [CLASS=FP MUT=REF PHEN="Increased blood ionised calcium level" GENE=CASR]; 		1433	131					CASR (inh=AD pLI=0.37)
chr3	122004098	122004098	A	T	het	het	hom		QUAL=16926;DP=339,221,325;MQM=60	CASR	3'UTR	CASR:NM_001178065.1:3'UTR:MODIFIER:exon7/7:c.*60A>T:,CASR:NM_000388.3:3'UTR:MODIFIER:exon7/7:c.*60A>T:		rs4677948	0.9201	0.0000	0/0/0	0.1737							601199 [CASR (confirmed) Hypocalciuric hypercalcemia,type I,145980|Hyperparathyroidism,neonatal,239200|Hypocalcemia,autosomal dominant,601198|Hypocalcemia,autosomal dominant,with Bartter syndrome,601198|Epilepsy idiopathic generalized,susceptibility to,8,612899|Hypercalciuric hypercalcemia|Calcium,serum level of];	RCV000283415.1 [benign]; RCV000287022.1 [benign]; RCV000341909.1 [benign]; RCV000403732.1 [benign]; 			686	71					CASR (inh=AD pLI=0.37)
chr3	122004612	122004612	C	G	hom	hom	hom		QUAL=40168;DP=445,358,425;MQM=59	CASR	3'UTR	CASR:NM_001178065.1:3'UTR:MODIFIER:exon7/7:c.*574C>G:,CASR:NM_000388.3:3'UTR:MODIFIER:exon7/7:c.*574C>G:		rs6438718	0.9687	0.0000	0/0/0	0.1498							601199 [CASR (confirmed) Hypocalciuric hypercalcemia,type I,145980|Hyperparathyroidism,neonatal,239200|Hypocalcemia,autosomal dominant,601198|Hypocalcemia,autosomal dominant,with Bartter syndrome,601198|Epilepsy idiopathic generalized,susceptibility to,8,612899|Hypercalciuric hypercalcemia|Calcium,serum level of];	RCV000285264.1 [benign]; RCV000321599.1 [benign]; RCV000376273.1 [benign]; RCV000379619.1 [benign]; 			229	1					CASR (inh=AD pLI=0.37)
chr3	122005053	122005053	A	G	het	wt	het		QUAL=6478;DP=231,219,270;MQM=60	CASR	3'UTR	CASR:NM_001178065.1:3'UTR:MODIFIER:exon7/7:c.*1015A>G:,CASR:NM_000388.3:3'UTR:MODIFIER:exon7/7:c.*1015A>G:		rs9740	0.1815	0.0000	0/0/0	0.0437							601199 [CASR (confirmed) Hypocalciuric hypercalcemia,type I,145980|Hyperparathyroidism,neonatal,239200|Hypocalcemia,autosomal dominant,601198|Hypocalcemia,autosomal dominant,with Bartter syndrome,601198|Epilepsy idiopathic generalized,susceptibility to,8,612899|Hypercalciuric hypercalcemia|Calcium,serum level of];	RCV000269865.1 [benign]; RCV000324896.1 [benign]; RCV000384053.1 [benign]; RCV000388912.1 [benign]; 			22	95					CASR (inh=AD pLI=0.37)
chr3	122005236	122005236	T	C	het	wt	het		QUAL=6045;DP=321,106,151;MQM=59	CASR	3'UTR	CASR:NM_001178065.1:3'UTR:MODIFIER:exon7/7:c.*1198T>C:,CASR:NM_000388.3:3'UTR:MODIFIER:exon7/7:c.*1198T>C:	MIRb	rs10190	0.5331	0.0000	0/0/0	0.1053							601199 [CASR (confirmed) Hypocalciuric hypercalcemia,type I,145980|Hyperparathyroidism,neonatal,239200|Hypocalcemia,autosomal dominant,601198|Hypocalcemia,autosomal dominant,with Bartter syndrome,601198|Epilepsy idiopathic generalized,susceptibility to,8,612899|Hypercalciuric hypercalcemia|Calcium,serum level of];	RCV000273862.1 [benign]; RCV000319605.1 [benign]; RCV000374172.1 [benign]; RCV000386740.1 [benign]; 			97	72					CASR (inh=AD pLI=0.37)
chr3	122005273	122005273	A	G	wt	het	wt		QUAL=1147;DP=300,101,139;MQM=60	CASR	3'UTR	CASR:NM_001178065.1:3'UTR:MODIFIER:exon7/7:c.*1235A>G:,CASR:NM_000388.3:3'UTR:MODIFIER:exon7/7:c.*1235A>G:	MIRb	rs34042920	0.0308	0.0000	0/0/0	0.0114							601199 [CASR (confirmed) Hypocalciuric hypercalcemia,type I,145980|Hyperparathyroidism,neonatal,239200|Hypocalcemia,autosomal dominant,601198|Hypocalcemia,autosomal dominant,with Bartter syndrome,601198|Epilepsy idiopathic generalized,susceptibility to,8,612899|Hypercalciuric hypercalcemia|Calcium,serum level of];	RCV000291326.1 [benign]; RCV000340206.1 [benign]; RCV000346217.1 [benign]; RCV000402843.1 [benign]; 			1	30					CASR (inh=AD pLI=0.37)
chr3	128598470	128598471	GT	-	wt	wt	het		QUAL=1909;DP=125,155,189;MQM=59	ACAD9	5'UTR,non_coding_transcript_exon	ACAD9:NM_014049.4:5'UTR:MODIFIER:exon1/18:c.-57_-56delGT:,ACAD9:NR_033426.1:non_coding_transcript_exon:MODIFIER:exon1/18:n.146_147delGT:		rs397874507	0.4523	0.3372	7486/2761/1841	0.2998							611103 [ACAD9 (confirmed) Mitochondrial complex I deficiency due to ACAD9 deficiency,611126];	RCV000359314.1 [benign]; 			102	425					ACAD9 (inh=AR pLI=0.00)
chr3	128614185	128614185	A	C	wt	wt	het		QUAL=5823;DP=235,371,470;MQM=60	ACAD9	synonymous,non_coding_transcript_exon	ACAD9:NM_014049.4:synonymous:LOW:exon4/18:c.379A>C:p.Arg127Arg,ACAD9:NR_033426.1:non_coding_transcript_exon:MODIFIER:exon4/18:n.757A>C:		rs1680778	0.5433	0.4018	9963/2887/2813	0.3832							611103 [ACAD9 (confirmed) Mitochondrial complex I deficiency due to ACAD9 deficiency,611126];	RCV000152729.3 [benign]; RCV000293617.1 [benign]; 		COSM3759716	160	660					ACAD9 (inh=AR pLI=0.00)
chr3	128622922	128622922	G	A	het	wt	het	pred_pathogenic;anno_pathogenic_clinvar	QUAL=11119;DP=423,363,526;MQM=60	ACAD9	missense,non_coding_transcript_exon	ACAD9:NM_014049.4:missense:MODERATE:exon10/18:c.976G>A:p.Ala326Thr,ACAD9:NR_033426.1:non_coding_transcript_exon:MODIFIER:exon10/18:n.1354G>A:		rs115532916	0.0078	0.0182	35/29/0	0.0171	6.9770	D,D	D	D,D	D	34.00	611103 [ACAD9 (confirmed) Mitochondrial complex I deficiency due to ACAD9 deficiency,611126];	RCV000123467.1 [benign]; RCV000201693.1 [pathogenic]; RCV000395019.1 [likely benign]; RCV000023868.3 [pathogenic]; RCV000198883.2 [pathogenic]; 			1	94	2	[2] Peter Bauer 28.01.2015			ACAD9 (inh=AR pLI=0.00)
chr3	128627021	128627021	A	G	wt	wt	het		QUAL=5192;DP=165,331,447;MQM=60	ACAD9	splice_region&intron	ACAD9:NM_014049.4:splice_region&intron:LOW:exon12/17:c.1279-7A>G:,ACAD9:NR_033426.1:splice_region&intron:LOW:exon12/17:n.1657-7A>G:		rs1683787	0.5182	0.3752	9762/3142/2633	0.3717							611103 [ACAD9 (confirmed) Mitochondrial complex I deficiency due to ACAD9 deficiency,611126];	RCV000152730.3 [benign]; RCV000361183.1 [benign]; 			157	663					ACAD9 (inh=AR pLI=0.00)
chr3	128627933	128627933	C	T	wt	wt	het		QUAL=451;DP=89,48,42;MQM=60	ACAD9	synonymous,non_coding_transcript_exon	ACAD9:NM_014049.4:synonymous:LOW:exon14/18:c.1476C>T:p.Pro492Pro,ACAD9:NR_033426.1:non_coding_transcript_exon:MODIFIER:exon14/18:n.1854C>T:		rs876755	0.3103	0.2533	4366/1531/391	0.2520							611103 [ACAD9 (confirmed) Mitochondrial complex I deficiency due to ACAD9 deficiency,611126];	RCV000368633.1 [benign]; 		COSM3759717	77	523					ACAD9 (inh=AR pLI=0.00)
chr3	128887147	128887147	C	T	hom	hom	hom		QUAL=28052;DP=310,232,315;MQM=59	CNBP	3'UTR	CNBP:NM_001127192.1:3'UTR:MODIFIER:exon5/5:c.*2149G>A:,CNBP:NM_001127193.1:3'UTR:MODIFIER:exon5/5:c.*2149G>A:,CNBP:NM_001127194.1:3'UTR:MODIFIER:exon5/5:c.*2149G>A:,CNBP:NM_001127195.1:3'UTR:MODIFIER:exon5/5:c.*2149G>A:,CNBP:NM_001127196.1:3'UTR:MODIFIER:exon5/5:c.*2149G>A:,CNBP:NM_003418.4:3'UTR:MODIFIER:exon5/5:c.*2149G>A:		rs9880375	0.9780	0.0000	0/0/0	0.8918							116955 [CNBP (confirmed) Myotonic dystrophy 2,602668];				216	11					CNBP (inh=AD pLI=0.92)
chr3	128887527	128887527	A	G	hom	hom	hom		QUAL=7096;DP=139,44,37;MQM=60	CNBP	3'UTR	CNBP:NM_001127192.1:3'UTR:MODIFIER:exon5/5:c.*1769T>C:,CNBP:NM_001127193.1:3'UTR:MODIFIER:exon5/5:c.*1769T>C:,CNBP:NM_001127194.1:3'UTR:MODIFIER:exon5/5:c.*1769T>C:,CNBP:NM_001127195.1:3'UTR:MODIFIER:exon5/5:c.*1769T>C:,CNBP:NM_001127196.1:3'UTR:MODIFIER:exon5/5:c.*1769T>C:,CNBP:NM_003418.4:3'UTR:MODIFIER:exon5/5:c.*1769T>C:	AluSq2	rs12633752	0.8764	0.0000	0/0/0	0.8507							116955 [CNBP (confirmed) Myotonic dystrophy 2,602668];				157	11					CNBP (inh=AD pLI=0.92)
chr3	128887783	128887783	-	A	het	wt	het	low_DP	QUAL=140;DP=9,1,5;MQM=54	CNBP	3'UTR	CNBP:NM_001127192.1:3'UTR:MODIFIER:exon5/5:c.*1512dupT:,CNBP:NM_001127193.1:3'UTR:MODIFIER:exon5/5:c.*1512dupT:,CNBP:NM_001127194.1:3'UTR:MODIFIER:exon5/5:c.*1512dupT:,CNBP:NM_001127195.1:3'UTR:MODIFIER:exon5/5:c.*1512dupT:,CNBP:NM_001127196.1:3'UTR:MODIFIER:exon5/5:c.*1512dupT:,CNBP:NM_003418.4:3'UTR:MODIFIER:exon5/5:c.*1512dupT:	AluY	rs11401192	0.8157	0.0000	0/0/0	0.5365							116955 [CNBP (confirmed) Myotonic dystrophy 2,602668];				39	36					CNBP (inh=AD pLI=0.92)
chr3	128887862	128887862	A	G	hom	wt	wt	low_DP;low_MQM	QUAL=323;DP=11,1,5;MQM=43	CNBP	3'UTR	CNBP:NM_001127192.1:3'UTR:MODIFIER:exon5/5:c.*1434T>C:,CNBP:NM_001127193.1:3'UTR:MODIFIER:exon5/5:c.*1434T>C:,CNBP:NM_001127194.1:3'UTR:MODIFIER:exon5/5:c.*1434T>C:,CNBP:NM_001127195.1:3'UTR:MODIFIER:exon5/5:c.*1434T>C:,CNBP:NM_001127196.1:3'UTR:MODIFIER:exon5/5:c.*1434T>C:,CNBP:NM_003418.4:3'UTR:MODIFIER:exon5/5:c.*1434T>C:	AluY	rs6792159	0.9687	0.0000	0/0/0	0.7929							116955 [CNBP (confirmed) Myotonic dystrophy 2,602668];				89	8					CNBP (inh=AD pLI=0.92)
chr3	128890350	128890350	G	A	hom	hom	hom		QUAL=37084;DP=385,338,409;MQM=59	CNBP	synonymous,sequence_feature	CNBP:NM_001127192.1:synonymous:LOW:exon3/5:c.156C>T:p.Asp52Asp,CNBP:NM_001127193.1:synonymous:LOW:exon3/5:c.156C>T:p.Asp52Asp,CNBP:NM_001127194.1:synonymous:LOW:exon3/5:c.135C>T:p.Asp45Asp,CNBP:NM_001127195.1:synonymous:LOW:exon3/5:c.135C>T:p.Asp45Asp,CNBP:NM_001127196.1:synonymous:LOW:exon3/5:c.135C>T:p.Asp45Asp,CNBP:NM_003418.4:synonymous:LOW:exon3/5:c.156C>T:p.Asp52Asp,CNBP:NM_001127192.1:sequence_feature:LOW:exon3/5:c.156C>T:,CNBP:NM_001127193.1:sequence_feature:LOW:exon3/5:c.156C>T:,CNBP:NM_001127194.1:sequence_feature:LOW:exon3/5:c.135C>T:,CNBP:NM_001127196.1:sequence_feature:LOW:exon3/5:c.135C>T:,CNBP:NM_003418.4:sequence_feature:LOW:exon3/5:c.156C>T:		rs4303883	0.7572	0.8900	49449/31266/983	0.8873							116955 [CNBP (confirmed) Myotonic dystrophy 2,602668];				1363	183					CNBP (inh=AD pLI=0.92)
chr3	142168331	142168331	C	T	het	het	hom		QUAL=23422;DP=520,318,404;MQM=60	ATR	synonymous	ATR:NM_001184.3:synonymous:LOW:exon47/47:c.7875G>A:p.Gln2625Gln		rs1802904	0.9163	0.8646	45665/23944/4913	0.8579							601215 [ATR (confirmed) Seckel syndrome 1,210600|Cutaneous telangiectasia and cancer syndrome,familial,614564];	RCV000079601.6 [other]; RCV000366216.1 [benign]; 			2376	746	1	[1] Ilnaz Sepahi 29-03-2016 batch import			ATR (inh=AR pLI=0.70)
chr3	142178144	142178144	C	T	het	het	het		QUAL=10045;DP=396,178,272;MQM=60	ATR	missense	ATR:NM_001184.3:missense:MODERATE:exon43/47:c.7274G>A:p.Arg2425Gln		rs2229032	0.1022	0.1328	1212/874/28	0.1324	0.0440	T,T	T	B	T,T	11.30	601215 [ATR (confirmed) Seckel syndrome 1,210600|Cutaneous telangiectasia and cancer syndrome,familial,614564];	RCV000145330.2 [benign]; RCV000321936.1 [likely benign]; 		COSM149485	76	774	1	[1] Ilnaz Sepahi 29-03-2016 batch import			ATR (inh=AR pLI=0.70)
chr3	142217537	142217537	A	G	wt	wt	het		QUAL=994;DP=221,83,101;MQM=60	ATR	synonymous	ATR:NM_001184.3:synonymous:LOW:exon32/47:c.5460T>C:p.Tyr1820Tyr		rs2227932	0.0669	0.0942	705/391/2	0.0915							601215 [ATR (confirmed) Seckel syndrome 1,210600|Cutaneous telangiectasia and cancer syndrome,familial,614564];	RCV000145320.2 [other]; RCV000330742.1 [likely benign]; 			38	531	1	[1] Ilnaz Sepahi 29-03-2016 batch import			ATR (inh=AR pLI=0.70)
chr3	142277575	142277575	A	T	het	het	het		QUAL=7934;DP=161,172,220;MQM=60	ATR	synonymous	ATR:NM_001184.3:synonymous:LOW:exon8/47:c.1776T>A:p.Gly592Gly		rs2227930	0.5980	0.5529	19239/11031/3356	0.5329							601215 [ATR (confirmed) Seckel syndrome 1,210600|Cutaneous telangiectasia and cancer syndrome,familial,614564];	RCV000145291.5 [other]; RCV000306424.1 [benign]; 		COSM149486	1079	1518	1	[1] Ilnaz Sepahi 29-03-2016 batch import			ATR (inh=AR pLI=0.70)
chr3	142281612	142281612	A	G	het	het	het		QUAL=8138;DP=255,163,202;MQM=60	ATR	missense	ATR:NM_001184.3:missense:MODERATE:exon4/47:c.632T>C:p.Met211Thr		rs2227928	0.5974	0.5540	19098/10972/3300	0.5505	1.2730	T,T	T	B	T,T	1.62	601215 [ATR (confirmed) Seckel syndrome 1,210600|Cutaneous telangiectasia and cancer syndrome,familial,614564];	RCV000079600.6 [other]; RCV000267092.1 [benign]; 		COSM149487	1077	1517	1	[1] Ilnaz Sepahi 29-03-2016 batch import			ATR (inh=AR pLI=0.70)
chr3	150644247	150644247	C	T	het	hom	wt		QUAL=8586;DP=297,154,161;MQM=59	CLRN1	3'UTR	CLRN1:NM_052995.2:3'UTR:MODIFIER:exon4/4:c.*392G>A:		rs3796239	0.6408	0.0000	0/0/0	0.1015							606397 [CLRN1 (confirmed) Usher syndrome,type 3A,276902|Retinitis pigmentosa 61,614180];				93	104					CLRN1 (inh=AR pLI=0.00)
chr3	150645351	150645351	G	A	het	hom	wt		QUAL=5156;DP=252,71,148;MQM=60	CLRN1	3'UTR,intron,non_coding_transcript_exon	CLRN1:NM_001195794.1:3'UTR:MODIFIER:exon4/4:c.*372C>T:,CLRN1:NM_001256819.1:3'UTR:MODIFIER:exon4/4:c.*685C>T:,CLRN1:NM_174878.2:3'UTR:MODIFIER:exon3/3:c.*372C>T:,CLRN1:NM_052995.2:intron:MODIFIER:exon3/3:c.342+501C>T:,CLRN1:NR_046380.2:non_coding_transcript_exon:MODIFIER:exon5/5:n.1552C>T:		rs4680058	0.7778	0.6037	2011/520/79	0.1625							606397 [CLRN1 (confirmed) Usher syndrome,type 3A,276902|Retinitis pigmentosa 61,614180];	RCV000313684.1 [benign]; RCV000368414.1 [benign]; 			335	253					CLRN1 (inh=AR pLI=0.00)
chr3	150645408	150645408	G	A	het	hom	wt		QUAL=5632;DP=241,77,125;MQM=59	CLRN1	3'UTR,intron,non_coding_transcript_exon	CLRN1:NM_001195794.1:3'UTR:MODIFIER:exon4/4:c.*315C>T:,CLRN1:NM_001256819.1:3'UTR:MODIFIER:exon4/4:c.*628C>T:,CLRN1:NM_174878.2:3'UTR:MODIFIER:exon3/3:c.*315C>T:,CLRN1:NM_052995.2:intron:MODIFIER:exon3/3:c.342+444C>T:,CLRN1:NR_046380.2:non_coding_transcript_exon:MODIFIER:exon5/5:n.1495C>T:		rs1456138	0.7768	0.6293	2081/568/90	0.1723							606397 [CLRN1 (confirmed) Usher syndrome,type 3A,276902|Retinitis pigmentosa 61,614180];	RCV000273387.1 [benign]; RCV000319087.1 [benign]; 			336	252					CLRN1 (inh=AR pLI=0.00)
chr3	150645419	150645420	AC	-	het	hom	wt		QUAL=3375;DP=208,62,97;MQM=59	CLRN1	3'UTR,intron,non_coding_transcript_exon	CLRN1:NM_001195794.1:3'UTR:MODIFIER:exon4/4:c.*303_*304delGT:,CLRN1:NM_001256819.1:3'UTR:MODIFIER:exon4/4:c.*616_*617delGT:,CLRN1:NM_174878.2:3'UTR:MODIFIER:exon3/3:c.*303_*304delGT:,CLRN1:NM_052995.2:intron:MODIFIER:exon3/3:c.342+432_342+433delGT:,CLRN1:NR_046380.2:non_coding_transcript_exon:MODIFIER:exon5/5:n.1483_1484delGT:	(AC)n	rs34027634;rs397897647	0.6300	0.4455	299/94/6	0.0854							606397 [CLRN1 (confirmed) Usher syndrome,type 3A,276902|Retinitis pigmentosa 61,614180];	RCV000291402.1 [benign]; RCV000376478.1 [benign]; 			96	145					CLRN1 (inh=AR pLI=0.00)
chr3	150661842	150661842	T	G	het	wt	het		QUAL=9913;DP=419,338,439;MQM=59	CLRN1	5'UTR,intron	CLRN1:NM_052995.2:5'UTR:MODIFIER:exon1/4:c.-211A>C:,CLRN1:NM_001195794.1:intron:MODIFIER:exon1/3:c.254-2294A>C:,CLRN1:NM_001256819.1:intron:MODIFIER:exon1/3:c.254-64A>C:,CLRN1:NM_174878.2:intron:MODIFIER:exon1/2:c.254-2294A>C:,CLRN1:NR_046380.2:intron:MODIFIER:exon2/4:n.695+1474A>C:	L2a	rs11914988	0.2720	0.0000	0/0/0	0.0455							606397 [CLRN1 (confirmed) Usher syndrome,type 3A,276902|Retinitis pigmentosa 61,614180];				49	235					CLRN1 (inh=AR pLI=0.00)
chr3	150690566	150690566	T	C	het	hom	het		QUAL=28019;DP=422,471,601;MQM=59	CLRN1,CLRN1-AS1	5'UTR,non_coding_transcript_exon	CLRN1:NM_001195794.1:5'UTR:MODIFIER:exon1/4:c.-71A>G:,CLRN1:NM_001256819.1:5'UTR:MODIFIER:exon1/4:c.-71A>G:,CLRN1:NM_174878.2:5'UTR:MODIFIER:exon1/3:c.-71A>G:,CLRN1-AS1:NR_024066.1:non_coding_transcript_exon:MODIFIER:exon1/6:n.102T>C:,CLRN1:NR_046380.2:non_coding_transcript_exon:MODIFIER:exon1/5:n.221A>G:		rs3796240	0.4692	0.5500	15307/9075/649	0.4760							606397 [CLRN1 (confirmed) Usher syndrome,type 3A,276902|Retinitis pigmentosa 61,614180];	RCV000298678.1 [likely benign]; RCV000401177.1 [likely benign]; 			185	271					CLRN1 (inh=AR pLI=0.00), CLRN1-AS1 (inh=n/a pLI=n/a)
chr3	155572067	155572067	G	A	het	het	wt		QUAL=2580;DP=61,136,175;MQM=60	SLC33A1	5'UTR	SLC33A1:NM_001190992.1:5'UTR:MODIFIER:exon1/7:c.-281C>T:,SLC33A1:NM_004733.3:5'UTR:MODIFIER:exon1/6:c.-281C>T:		rs560777515	0.0000	0.0000	0/0/0	0.0020							603690 [SLC33A1 (confirmed) Spastic paraplegia 42,autosomal dominant,612539|Congenital cataracts,hearing loss,and neurodegeneration,614482];	RCV000342609.1 [uncertain significance]; 			0	4					SLC33A1 (inh=AR+AD pLI=0.10)
chr3	155572129	155572129	C	T	wt	wt	het		QUAL=2263;DP=221,152,201;MQM=60	SLC33A1	5'UTR	SLC33A1:NM_001190992.1:5'UTR:MODIFIER:exon1/7:c.-343G>A:,SLC33A1:NM_004733.3:5'UTR:MODIFIER:exon1/6:c.-343G>A:		rs1131925	0.4894	0.0000	0/0/0	0.5679							603690 [SLC33A1 (confirmed) Spastic paraplegia 42,autosomal dominant,612539|Congenital cataracts,hearing loss,and neurodegeneration,614482];	RCV000395890.1 [benign]; 			83	113					SLC33A1 (inh=AR+AD pLI=0.10)
chr3	158362391	158362391	C	T	hom	hom	het		QUAL=10101;DP=156,127,213;MQM=59	GFM1	5'UTR	GFM1:NM_001308164.1:5'UTR:MODIFIER:exon1/19:c.-33C>T:,GFM1:NM_001308166.1:5'UTR:MODIFIER:exon1/14:c.-33C>T:,GFM1:NM_024996.5:5'UTR:MODIFIER:exon1/18:c.-33C>T:		rs28372852	0.1474	0.2044	379/223/14	0.1041							606639 [GFM1 (confirmed) Combined oxidative phosphorylation deficiency 1,609060];	RCV000295077.1 [likely benign]; 			33	256					GFM1 (inh=AR pLI=0.00)
chr3	158362441	158362441	T	C	hom	hom	het		QUAL=11953;DP=230,116,220;MQM=59	GFM1	synonymous	GFM1:NM_001308164.1:synonymous:LOW:exon1/19:c.18T>C:p.Ala6Ala,GFM1:NM_001308166.1:synonymous:LOW:exon1/14:c.18T>C:p.Ala6Ala,GFM1:NM_024996.5:synonymous:LOW:exon1/18:c.18T>C:p.Ala6Ala		rs1864507	0.5831	0.6302	7683/3873/1112	0.4546							606639 [GFM1 (confirmed) Combined oxidative phosphorylation deficiency 1,609060];	RCV000282348.1 [benign]; 		COSM3721924	529	726					GFM1 (inh=AR pLI=0.00)
chr3	158363463	158363463	A	G	wt	wt	het	pred_pathogenic	QUAL=2875;DP=266,194,216;MQM=60	GFM1	missense	GFM1:NM_001308164.1:missense:MODERATE:exon2/19:c.127A>G:p.Asn43Asp,GFM1:NM_001308166.1:missense:MODERATE:exon2/14:c.127A>G:p.Asn43Asp,GFM1:NM_024996.5:missense:MODERATE:exon2/18:c.127A>G:p.Asn43Asp		rs35942089	0.0050	0.0098	11/8/0	0.0098	8.6290	T,T,T	T	B,B	T,T,T	16.79	606639 [GFM1 (confirmed) Combined oxidative phosphorylation deficiency 1,609060];	RCV000125223.1 [benign]; RCV000361226.1 [uncertain significance]; 			0	39					GFM1 (inh=AR pLI=0.00)
chr3	158366900	158366900	G	A	hom	hom	het	pred_pathogenic	QUAL=12890;DP=239,115,140;MQM=60	GFM1	missense	GFM1:NM_001308164.1:missense:MODERATE:exon5/19:c.643G>A:p.Val215Ile,GFM1:NM_001308166.1:missense:MODERATE:exon5/14:c.643G>A:p.Val215Ile,GFM1:NM_024996.5:missense:MODERATE:exon5/18:c.643G>A:p.Val215Ile		rs2303909	0.5833	0.5467	18614/9501/2707	0.5396	3.3150	T,T,T	T	B,B,B	T,T,T	13.77	606639 [GFM1 (confirmed) Combined oxidative phosphorylation deficiency 1,609060];	RCV000334159.1 [benign]; 		COSM4002505	529	728					GFM1 (inh=AR pLI=0.00)
chr3	158409262	158409262	C	T	hom	hom	het		QUAL=17169;DP=298,142,236;MQM=60	GFM1	3'UTR	GFM1:NM_001308164.1:3'UTR:MODIFIER:exon19/19:c.*6C>T:,GFM1:NM_024996.5:3'UTR:MODIFIER:exon18/18:c.*6C>T:		rs1047355	0.4091	0.3657	8751/4710/1822	0.3599							606639 [GFM1 (confirmed) Combined oxidative phosphorylation deficiency 1,609060];	RCV000317038.1 [benign]; 			264	739					GFM1 (inh=AR pLI=0.00)
chr3	158409482	158409482	C	T	hom	hom	het	low_DP	QUAL=3311;DP=89,7,6;MQM=60	GFM1	3'UTR	GFM1:NM_001308164.1:3'UTR:MODIFIER:exon19/19:c.*226C>T:,GFM1:NM_024996.5:3'UTR:MODIFIER:exon18/18:c.*226C>T:		rs1047366	0.5833	0.0000	0/0/0	0.0903							606639 [GFM1 (confirmed) Combined oxidative phosphorylation deficiency 1,609060];	RCV000262965.1 [benign]; 			75	113					GFM1 (inh=AR pLI=0.00)
chr3	158409708	158409710	TTG	-	hom	hom	het		QUAL=8403;DP=164,78,90;MQM=59	GFM1	3'UTR	GFM1:NM_001308164.1:3'UTR:MODIFIER:exon19/19:c.*454_*456delGTT:,GFM1:NM_024996.5:3'UTR:MODIFIER:exon18/18:c.*454_*456delGTT:		rs367730845	0.1472	0.0000	0/0/0	0.1726							606639 [GFM1 (confirmed) Combined oxidative phosphorylation deficiency 1,609060];	RCV000377206.1 [likely benign]; 			10	77					GFM1 (inh=AR pLI=0.00)
chr3	158409947	158409947	T	A	hom	hom	het		QUAL=9752;DP=152,96,134;MQM=60	GFM1	3'UTR	GFM1:NM_001308164.1:3'UTR:MODIFIER:exon19/19:c.*691T>A:,GFM1:NM_024996.5:3'UTR:MODIFIER:exon18/18:c.*691T>A:		rs8650	0.4091	0.0000	0/0/0	0.0614							606639 [GFM1 (confirmed) Combined oxidative phosphorylation deficiency 1,609060];	RCV000288969.1 [benign]; 			37	106					GFM1 (inh=AR pLI=0.00)
chr3	159976432	159976432	-	A	wt	het	het		QUAL=3851;DP=173,193,223;MQM=59	IFT80	splice_region&intron	IFT80:NM_020800.2:splice_region&intron:LOW:exon19/19:c.2224-10dupT:,IFT80:NM_001190242.1:splice_region&intron:LOW:exon18/18:c.1813-10dupT:,IFT80:NM_001190241.1:splice_region&intron:LOW:exon20/20:c.1813-10dupT:		rs397969922;rs58665245;rs780048487	0.2444	0.2984	2269/1374/248	0.2414							611177 [IFT80 (confirmed) Short-rib thoracic dysplasia 2 with or without polydactyly,611263];	RCV000196193.4 [other]; 			91	582					IFT80 (inh=AR pLI=0.00)
chr3	159997061	159997061	T	A	wt	het	het	pred_pathogenic	QUAL=1432;DP=218,65,54;MQM=60	IFT80	missense	IFT80:NM_020800.2:missense:MODERATE:exon16/20:c.1756A>T:p.Thr586Ser,IFT80:NM_001190242.1:missense:MODERATE:exon15/19:c.1345A>T:p.Thr449Ser,IFT80:NM_001190241.1:missense:MODERATE:exon17/21:c.1345A>T:p.Thr449Ser		rs6778728	0.2614	0.2311	3945/2125/1260	0.2297	2.6440	T,T,T	T	B	T,T,T	7.44	611177 [IFT80 (confirmed) Short-rib thoracic dysplasia 2 with or without polydactyly,611263];	RCV000279039.1 [benign]; 		COSM3759849	97	557					IFT80 (inh=AR pLI=0.00)
chr3	182755209	182755209	T	G	hom	het	het		QUAL=11069;DP=188,202,245;MQM=60	MCCC1	missense,intron,non_coding_transcript_exon	MCCC1:NM_020166.4:missense:MODERATE:exon13/19:c.1391A>C:p.His464Pro,MCCC1:NM_001293273.1:missense:MODERATE:exon11/17:c.1040A>C:p.His347Pro,MCCC1:NR_120640.1:intron:MODIFIER:exon12/18:n.2044+1605A>C:,MCCC1:NR_120639.1:non_coding_transcript_exon:MODIFIER:exon11/16:n.1305A>C:		rs2270968	0.4649	0.6248	25068/17346/404	0.6185	1.1180	T,T,T,T,T,T	T	B,B,B	T,T,T,T	17.25	609010 [MCCC1 (confirmed) 3-Methylcrotonyl-CoA carboxylase 1 deficiency,210200];	RCV000081992.4 [benign]; RCV000262405.1 [benign]; 	CM162758 [CLASS=R MUT=ALT PHEN="3-methylcrotonyl-CoA carboxylase deficiency" GENE=MCCC1]; 	COSM4002526	861	753					MCCC1 (inh=AR pLI=0.00)
chr3	182790249	182790249	G	A	hom	hom	hom		QUAL=16280;DP=188,116,201;MQM=60	MCCC1	synonymous,intron,non_coding_transcript_exon	MCCC1:NM_020166.4:synonymous:LOW:exon5/19:c.396C>T:p.Leu132Leu,MCCC1:NM_001293273.1:intron:MODIFIER:exon3/16:c.141-1104C>T:,MCCC1:NR_120640.1:non_coding_transcript_exon:MODIFIER:exon5/19:n.1063C>T:,MCCC1:NR_120639.1:non_coding_transcript_exon:MODIFIER:exon3/16:n.310C>T:		rs7622479	0.9155	0.9297	52539/28967/3232	0.9073							609010 [MCCC1 (confirmed) 3-Methylcrotonyl-CoA carboxylase 1 deficiency,210200];	RCV000081994.5 [benign]; RCV000291937.1 [benign]; 			1540	260					MCCC1 (inh=AR pLI=0.00)
chr3	182817328	182817328	C	G	hom	hom	hom		QUAL=16483;DP=74,207,268;MQM=59	MCCC1	5'UTR,non_coding_transcript_exon	MCCC1:NM_020166.4:5'UTR:MODIFIER:exon1/19:c.-100G>C:,MCCC1:NM_001293273.1:5'UTR:MODIFIER:exon1/17:c.-192G>C:,MCCC1:NR_120639.1:non_coding_transcript_exon:MODIFIER:exon1/16:n.48G>C:		rs937652	0.5449	0.0000	0/0/0	0.1172							609010 [MCCC1 (confirmed) 3-Methylcrotonyl-CoA carboxylase 1 deficiency,210200];	RCV000392572.1 [benign]; 			132	90					MCCC1 (inh=AR pLI=0.00)
chr3	183863085	183863086	AG	-	wt	het	het		QUAL=1192;DP=168,57,60;MQM=60	EIF2B5	3'UTR	EIF2B5:NM_003907.2:3'UTR:MODIFIER:exon16/16:c.*360_*361delAG:		rs398063089	0.4886	0.0000	0/0/0	0.4539							603945 [EIF2B5 (confirmed) Leukoencephalopathy with vanishing white matter,603896|Ovarioleukodystrophy,603896];	RCV000320739.1 [benign]; 			49	116					EIF2B5 (inh=AR pLI=1.00)
chr3	183960252	183960252	A	C	wt	het	het		QUAL=10901;DP=287,452,607;MQM=59	ALG3	3'UTR,non_coding_transcript_exon	ALG3:NM_005787.5:3'UTR:MODIFIER:exon9/9:c.*50T>G:,ALG3:NM_001006941.2:3'UTR:MODIFIER:exon9/9:c.*50T>G:,ALG3:NR_024533.1:non_coding_transcript_exon:MODIFIER:exon8/8:n.1298T>G:,ALG3:NR_024534.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.1361T>G:		rs706584	0.2490	0.3160	1879/1026/281	0.1910							608750 [ALG3 (provisional) Congenital disorder of glycosylation,type Id,601110];	RCV000246992.1 [benign]; RCV000324207.1 [likely benign]; 			51	393					ALG3 (inh=AR pLI=0.00)
chr3	184071063	184071063	G	C	wt	het	het	pred_pathogenic	QUAL=4473;DP=218,159,193;MQM=60	CLCN2	missense	CLCN2:NM_004366.5:missense:MODERATE:exon17/24:c.2003C>G:p.Thr668Ser,CLCN2:NM_001171087.2:missense:MODERATE:exon17/24:c.1952C>G:p.Thr651Ser,CLCN2:NM_001171088.2:missense:MODERATE:exon16/23:c.1871C>G:p.Thr624Ser,CLCN2:NM_001171089.2:missense:MODERATE:exon17/23:c.2003C>G:p.Thr668Ser		rs9820367	0.4613	0.4896	15744/10042/2418	0.4825	0.7900	T,T,T,T	T	B,B,B,B	D,D,D,D	8.55	600570 [CLCN2 (confirmed) Epilepsy,juvenile myoclonic,susceptibility to,8,607628|Epilepsy,juvenile absence,susceptibility to,2,607628|Epilepsy,idiopathic generalized,susceptibility to,11,607628|Leukoencephalopathy with ataxia,615651];	RCV000201825.1 [uncertain significance]; 		COSM149533	473	779					CLCN2 (inh=AR pLI=0.00)
chr3	190023552	190023552	T	C	hom	hom	het		QUAL=12141;DP=226,87,140;MQM=59	CLDN1	3'UTR	CLDN1:NM_021101.4:3'UTR:MODIFIER:exon4/4:c.*2514A>G:		rs8298	0.7212	0.0000	0/0/0	0.1279							603718 [CLDN1 (confirmed) Ichthyosis,leukocyte vacuoles,alopecia,and sclerosing cholangitis,607626];				84	99					CLDN1 (inh=AR pLI=0.06)
chr3	190023837	190023837	A	G	hom	hom	het		QUAL=21492;DP=390,177,249;MQM=60	CLDN1	3'UTR	CLDN1:NM_021101.4:3'UTR:MODIFIER:exon4/4:c.*2229T>C:		rs8798	0.7143	0.0000	0/0/0	0.1108							603718 [CLDN1 (confirmed) Ichthyosis,leukocyte vacuoles,alopecia,and sclerosing cholangitis,607626];				87	99					CLDN1 (inh=AR pLI=0.06)
chr3	190024057	190024057	C	T	hom	hom	het		QUAL=34483;DP=644,263,333;MQM=60	CLDN1	3'UTR	CLDN1:NM_021101.4:3'UTR:MODIFIER:exon4/4:c.*2009G>A:		rs1364722	0.7005	0.0000	0/0/0	0.1101							603718 [CLDN1 (confirmed) Ichthyosis,leukocyte vacuoles,alopecia,and sclerosing cholangitis,607626];				87	100					CLDN1 (inh=AR pLI=0.06)
chr3	190024103	190024103	T	C	hom	hom	het		QUAL=30764;DP=551,249,296;MQM=59	CLDN1	3'UTR	CLDN1:NM_021101.4:3'UTR:MODIFIER:exon4/4:c.*1963A>G:		rs1895708	0.7021	0.0000	0/0/0	0.1101							603718 [CLDN1 (confirmed) Ichthyosis,leukocyte vacuoles,alopecia,and sclerosing cholangitis,607626];				87	100					CLDN1 (inh=AR pLI=0.06)
chr3	190024188	190024188	G	A	hom	hom	het		QUAL=25001;DP=476,192,243;MQM=60	CLDN1	3'UTR	CLDN1:NM_021101.4:3'UTR:MODIFIER:exon4/4:c.*1878C>T:		rs2204226	0.6969	0.0000	0/0/0	0.1256							603718 [CLDN1 (confirmed) Ichthyosis,leukocyte vacuoles,alopecia,and sclerosing cholangitis,607626];				87	100					CLDN1 (inh=AR pLI=0.06)
chr3	190024457	190024457	A	G	hom	hom	het		QUAL=37159;DP=555,400,538;MQM=60	CLDN1	3'UTR	CLDN1:NM_021101.4:3'UTR:MODIFIER:exon4/4:c.*1609T>C:	MIRc	rs9290928	0.7011	0.0000	0/0/0	0.1107							603718 [CLDN1 (confirmed) Ichthyosis,leukocyte vacuoles,alopecia,and sclerosing cholangitis,607626];				86	100					CLDN1 (inh=AR pLI=0.06)
chr3	190024643	190024643	G	T	hom	hom	het		QUAL=55820;DP=714,727,1010;MQM=59	CLDN1	3'UTR	CLDN1:NM_021101.4:3'UTR:MODIFIER:exon4/4:c.*1423C>A:		rs1060680	0.1166	0.0000	0/0/0	0.1515							603718 [CLDN1 (confirmed) Ichthyosis,leukocyte vacuoles,alopecia,and sclerosing cholangitis,607626];				9	72					CLDN1 (inh=AR pLI=0.06)
chr3	190025617	190025617	T	A	hom	hom	het		QUAL=15939;DP=236,163,199;MQM=60	CLDN1	3'UTR	CLDN1:NM_021101.4:3'UTR:MODIFIER:exon4/4:c.*449A>T:		rs9825098	0.6975	0.0000	0/0/0	0.0705							603718 [CLDN1 (confirmed) Ichthyosis,leukocyte vacuoles,alopecia,and sclerosing cholangitis,607626];				86	101					CLDN1 (inh=AR pLI=0.06)
chr3	190025618	190025618	A	G	hom	hom	het		QUAL=15939;DP=236,163,199;MQM=60	CLDN1	3'UTR	CLDN1:NM_021101.4:3'UTR:MODIFIER:exon4/4:c.*448T>C:		rs9842576	0.6969	0.0000	0/0/0	0.0705							603718 [CLDN1 (confirmed) Ichthyosis,leukocyte vacuoles,alopecia,and sclerosing cholangitis,607626];				86	101					CLDN1 (inh=AR pLI=0.06)
chr3	190025805	190025805	G	T	hom	hom	het		QUAL=9946;DP=213,59,83;MQM=60	CLDN1	3'UTR	CLDN1:NM_021101.4:3'UTR:MODIFIER:exon4/4:c.*261C>A:		rs1043747	0.7007	0.0000	0/0/0	0.1088							603718 [CLDN1 (confirmed) Ichthyosis,leukocyte vacuoles,alopecia,and sclerosing cholangitis,607626];				87	100					CLDN1 (inh=AR pLI=0.06)
chr3	190025964	190025964	C	T	wt	het	wt		QUAL=1749;DP=226,111,125;MQM=60	CLDN1	3'UTR	CLDN1:NM_021101.4:3'UTR:MODIFIER:exon4/4:c.*102G>A:		rs3172404	0.1126	0.0000	0/0/0	0.0347							603718 [CLDN1 (confirmed) Ichthyosis,leukocyte vacuoles,alopecia,and sclerosing cholangitis,607626];				7	69					CLDN1 (inh=AR pLI=0.06)
chr3	190030680	190030680	A	G	hom	hom	hom		QUAL=16519;DP=131,173,236;MQM=60	CLDN1	synonymous	CLDN1:NM_021101.4:synonymous:LOW:exon2/4:c.369T>C:p.Gly123Gly		rs9869263	0.8111	0.8334	42235/24128/3079	0.8177							603718 [CLDN1 (confirmed) Ichthyosis,leukocyte vacuoles,alopecia,and sclerosing cholangitis,607626];	RCV000175932.2 [benign]; 			1136	390					CLDN1 (inh=AR pLI=0.06)
chr3	190040008	190040008	C	G	het	het	wt		QUAL=4694;DP=196,222,290;MQM=59	CLDN1	5'UTR	CLDN1:NM_021101.4:5'UTR:MODIFIER:exon1/4:c.-13G>C:		rs17429833	0.0509	0.0682	311/223/7	0.0644							603718 [CLDN1 (confirmed) Ichthyosis,leukocyte vacuoles,alopecia,and sclerosing cholangitis,607626];	RCV000251825.2 [benign]; 			5	137					CLDN1 (inh=AR pLI=0.06)
chr3	190040207	190040207	C	A	het	hom	het		QUAL=5053;DP=283,38,61;MQM=60	CLDN1	5'UTR	CLDN1:NM_021101.4:5'UTR:MODIFIER:exon1/4:c.-212G>T:		rs12696600	0.6625	0.0000	0/0/0	0.0900							603718 [CLDN1 (confirmed) Ichthyosis,leukocyte vacuoles,alopecia,and sclerosing cholangitis,607626];				48	114					CLDN1 (inh=AR pLI=0.06)
chr3	193334991	193334991	G	A	wt	wt	het	pred_pathogenic	QUAL=1671;DP=234,90,135;MQM=60	OPA1	missense,intron	OPA1:NM_130837.2:missense:MODERATE:exon4/31:c.473G>A:p.Ser158Asn,OPA1:NM_015560.2:missense:MODERATE:exon4/29:c.473G>A:p.Ser158Asn,OPA1:NM_130834.2:missense:MODERATE:exon4/30:c.473G>A:p.Ser158Asn,OPA1:NM_130836.2:missense:MODERATE:exon4/30:c.473G>A:p.Ser158Asn,OPA1:NM_130831.2:intron:MODIFIER:exon3/27:c.448+1432G>A:,OPA1:NM_130832.2:intron:MODIFIER:exon3/28:c.449-582G>A:,OPA1:NM_130833.2:intron:MODIFIER:exon3/28:c.448+1432G>A:,OPA1:NM_130835.2:intron:MODIFIER:exon3/29:c.449-582G>A:		rs7624750	0.4681	0.4683	13568/7452/1691	0.4610	3.4350	T,T,T,T,T,T,.	T,T	B,B,B,B,.	D,D,D,D,T,T,.	17.44	605290 [OPA1 (confirmed) Optic atrophy 1,165500|Glaucoma,normal tension,susceptibility to,606657|Optic atrophy plus syndrome,125250|Behr syndrome,210000|Mitochondrial DNA depletion syndrome 14 (encephalocardiomyopathic type),616896];	RCV000081768.7 [benign]; RCV000339112.1 [benign]; 		COSM446194	668	1603					OPA1 (inh=AR+AD pLI=0.99)
chr3	193355074	193355074	T	C	hom	het	hom		QUAL=10928;DP=158,105,149;MQM=60	OPA1	splice_region&intron	OPA1:NM_130837.2:splice_region&intron:LOW:exon10/30:c.1035+4T>C:,OPA1:NM_015560.2:splice_region&intron:LOW:exon8/28:c.870+4T>C:,OPA1:NM_130831.2:splice_region&intron:LOW:exon7/27:c.762+4T>C:,OPA1:NM_130832.2:splice_region&intron:LOW:exon8/28:c.816+4T>C:,OPA1:NM_130833.2:splice_region&intron:LOW:exon8/28:c.873+4T>C:,OPA1:NM_130834.2:splice_region&intron:LOW:exon9/29:c.924+4T>C:,OPA1:NM_130835.2:splice_region&intron:LOW:exon9/29:c.927+4T>C:,OPA1:NM_130836.2:splice_region&intron:LOW:exon9/29:c.981+4T>C:		rs166850	0.9229	0.8718	46256/23201/4866	0.8351							605290 [OPA1 (confirmed) Optic atrophy 1,165500|Glaucoma,normal tension,susceptibility to,606657|Optic atrophy plus syndrome,125250|Behr syndrome,210000|Mitochondrial DNA depletion syndrome 14 (encephalocardiomyopathic type),616896];	RCV000081773.7 [benign]; RCV000275012.1 [benign]; 			2302	849					OPA1 (inh=AR+AD pLI=0.99)
chr3	193374964	193374964	T	C	wt	wt	het		QUAL=2357;DP=273,147,186;MQM=60	OPA1	synonymous	OPA1:NM_130837.2:synonymous:LOW:exon23/31:c.2274T>C:p.Ala758Ala,OPA1:NM_015560.2:synonymous:LOW:exon21/29:c.2109T>C:p.Ala703Ala,OPA1:NM_130831.2:synonymous:LOW:exon20/28:c.2001T>C:p.Ala667Ala,OPA1:NM_130832.2:synonymous:LOW:exon21/29:c.2055T>C:p.Ala685Ala,OPA1:NM_130833.2:synonymous:LOW:exon21/29:c.2112T>C:p.Ala704Ala,OPA1:NM_130834.2:synonymous:LOW:exon22/30:c.2163T>C:p.Ala721Ala,OPA1:NM_130835.2:synonymous:LOW:exon22/30:c.2166T>C:p.Ala722Ala,OPA1:NM_130836.2:synonymous:LOW:exon22/30:c.2220T>C:p.Ala740Ala		rs9851685	0.4665	0.4668	13535/7463/1701	0.4595							605290 [OPA1 (confirmed) Optic atrophy 1,165500|Glaucoma,normal tension,susceptibility to,606657|Optic atrophy plus syndrome,125250|Behr syndrome,210000|Mitochondrial DNA depletion syndrome 14 (encephalocardiomyopathic type),616896];	RCV000081757.7 [benign]; RCV000284298.1 [benign]; 			670	1598					OPA1 (inh=AR+AD pLI=0.99)
chr3	193412672	193412672	A	G	het	wt	hom		QUAL=12970;DP=327,233,252;MQM=60	OPA1	3'UTR	OPA1:NM_130837.2:3'UTR:MODIFIER:exon31/31:c.*283A>G:,OPA1:NM_015560.2:3'UTR:MODIFIER:exon29/29:c.*283A>G:,OPA1:NM_130831.2:3'UTR:MODIFIER:exon28/28:c.*283A>G:,OPA1:NM_130832.2:3'UTR:MODIFIER:exon29/29:c.*283A>G:,OPA1:NM_130833.2:3'UTR:MODIFIER:exon29/29:c.*283A>G:,OPA1:NM_130834.2:3'UTR:MODIFIER:exon30/30:c.*283A>G:,OPA1:NM_130835.2:3'UTR:MODIFIER:exon30/30:c.*283A>G:,OPA1:NM_130836.2:3'UTR:MODIFIER:exon30/30:c.*283A>G:		rs1061648	0.6412	0.0000	0/0/0	0.6289							605290 [OPA1 (confirmed) Optic atrophy 1,165500|Glaucoma,normal tension,susceptibility to,606657|Optic atrophy plus syndrome,125250|Behr syndrome,210000|Mitochondrial DNA depletion syndrome 14 (encephalocardiomyopathic type),616896];	RCV000261365.1 [benign]; 			96	100					OPA1 (inh=AR+AD pLI=0.99)
chr3	193412949	193412949	T	C	hom	het	hom		QUAL=20036;DP=335,187,192;MQM=60	OPA1	3'UTR	OPA1:NM_130837.2:3'UTR:MODIFIER:exon31/31:c.*560T>C:,OPA1:NM_015560.2:3'UTR:MODIFIER:exon29/29:c.*560T>C:,OPA1:NM_130831.2:3'UTR:MODIFIER:exon28/28:c.*560T>C:,OPA1:NM_130832.2:3'UTR:MODIFIER:exon29/29:c.*560T>C:,OPA1:NM_130833.2:3'UTR:MODIFIER:exon29/29:c.*560T>C:,OPA1:NM_130834.2:3'UTR:MODIFIER:exon30/30:c.*560T>C:,OPA1:NM_130835.2:3'UTR:MODIFIER:exon30/30:c.*560T>C:,OPA1:NM_130836.2:3'UTR:MODIFIER:exon30/30:c.*560T>C:		rs7643844	0.9137	0.0000	0/0/0	0.8036							605290 [OPA1 (confirmed) Optic atrophy 1,165500|Glaucoma,normal tension,susceptibility to,606657|Optic atrophy plus syndrome,125250|Behr syndrome,210000|Mitochondrial DNA depletion syndrome 14 (encephalocardiomyopathic type),616896];	RCV000265010.1 [benign]; 			166	58					OPA1 (inh=AR+AD pLI=0.99)
chr3	193413502	193413502	C	T	het	wt	hom		QUAL=8562;DP=277,127,135;MQM=60	OPA1	3'UTR	OPA1:NM_130837.2:3'UTR:MODIFIER:exon31/31:c.*1113C>T:,OPA1:NM_015560.2:3'UTR:MODIFIER:exon29/29:c.*1113C>T:,OPA1:NM_130831.2:3'UTR:MODIFIER:exon28/28:c.*1113C>T:,OPA1:NM_130832.2:3'UTR:MODIFIER:exon29/29:c.*1113C>T:,OPA1:NM_130833.2:3'UTR:MODIFIER:exon29/29:c.*1113C>T:,OPA1:NM_130834.2:3'UTR:MODIFIER:exon30/30:c.*1113C>T:,OPA1:NM_130835.2:3'UTR:MODIFIER:exon30/30:c.*1113C>T:,OPA1:NM_130836.2:3'UTR:MODIFIER:exon30/30:c.*1113C>T:		rs12630	0.5958	0.0000	0/0/0	0.5632							605290 [OPA1 (confirmed) Optic atrophy 1,165500|Glaucoma,normal tension,susceptibility to,606657|Optic atrophy plus syndrome,125250|Behr syndrome,210000|Mitochondrial DNA depletion syndrome 14 (encephalocardiomyopathic type),616896];	RCV000290844.1 [benign]; 			70	100					OPA1 (inh=AR+AD pLI=0.99)
chr3	193413732	193413732	A	G	het	wt	hom		QUAL=13276;DP=339,215,263;MQM=60	OPA1	3'UTR	OPA1:NM_130837.2:3'UTR:MODIFIER:exon31/31:c.*1343A>G:,OPA1:NM_015560.2:3'UTR:MODIFIER:exon29/29:c.*1343A>G:,OPA1:NM_130831.2:3'UTR:MODIFIER:exon28/28:c.*1343A>G:,OPA1:NM_130832.2:3'UTR:MODIFIER:exon29/29:c.*1343A>G:,OPA1:NM_130833.2:3'UTR:MODIFIER:exon29/29:c.*1343A>G:,OPA1:NM_130834.2:3'UTR:MODIFIER:exon30/30:c.*1343A>G:,OPA1:NM_130835.2:3'UTR:MODIFIER:exon30/30:c.*1343A>G:,OPA1:NM_130836.2:3'UTR:MODIFIER:exon30/30:c.*1343A>G:		rs1056366	0.6963	0.0000	0/0/0	0.6478							605290 [OPA1 (confirmed) Optic atrophy 1,165500|Glaucoma,normal tension,susceptibility to,606657|Optic atrophy plus syndrome,125250|Behr syndrome,210000|Mitochondrial DNA depletion syndrome 14 (encephalocardiomyopathic type),616896];	RCV000348053.1 [benign]; 			96	100					OPA1 (inh=AR+AD pLI=0.99)
chr3	193414481	193414481	C	T	wt	wt	het		QUAL=2279;DP=261,141,187;MQM=60	OPA1	3'UTR	OPA1:NM_130837.2:3'UTR:MODIFIER:exon31/31:c.*2092C>T:,OPA1:NM_015560.2:3'UTR:MODIFIER:exon29/29:c.*2092C>T:,OPA1:NM_130831.2:3'UTR:MODIFIER:exon28/28:c.*2092C>T:,OPA1:NM_130832.2:3'UTR:MODIFIER:exon29/29:c.*2092C>T:,OPA1:NM_130833.2:3'UTR:MODIFIER:exon29/29:c.*2092C>T:,OPA1:NM_130834.2:3'UTR:MODIFIER:exon30/30:c.*2092C>T:,OPA1:NM_130835.2:3'UTR:MODIFIER:exon30/30:c.*2092C>T:,OPA1:NM_130836.2:3'UTR:MODIFIER:exon30/30:c.*2092C>T:		rs1056390	0.4389	0.0000	0/0/0	0.4175							605290 [OPA1 (confirmed) Optic atrophy 1,165500|Glaucoma,normal tension,susceptibility to,606657|Optic atrophy plus syndrome,125250|Behr syndrome,210000|Mitochondrial DNA depletion syndrome 14 (encephalocardiomyopathic type),616896];	RCV000297019.1 [benign]; 			38	120					OPA1 (inh=AR+AD pLI=0.99)
chr3	193414733	193414733	A	G	wt	wt	het		QUAL=1590;DP=209,129,148;MQM=60	OPA1	3'UTR	OPA1:NM_130837.2:3'UTR:MODIFIER:exon31/31:c.*2344A>G:,OPA1:NM_015560.2:3'UTR:MODIFIER:exon29/29:c.*2344A>G:,OPA1:NM_130831.2:3'UTR:MODIFIER:exon28/28:c.*2344A>G:,OPA1:NM_130832.2:3'UTR:MODIFIER:exon29/29:c.*2344A>G:,OPA1:NM_130833.2:3'UTR:MODIFIER:exon29/29:c.*2344A>G:,OPA1:NM_130834.2:3'UTR:MODIFIER:exon30/30:c.*2344A>G:,OPA1:NM_130835.2:3'UTR:MODIFIER:exon30/30:c.*2344A>G:,OPA1:NM_130836.2:3'UTR:MODIFIER:exon30/30:c.*2344A>G:		rs1056392	0.3379	0.0000	0/0/0	0.3356							605290 [OPA1 (confirmed) Optic atrophy 1,165500|Glaucoma,normal tension,susceptibility to,606657|Optic atrophy plus syndrome,125250|Behr syndrome,210000|Mitochondrial DNA depletion syndrome 14 (encephalocardiomyopathic type),616896];	RCV000304099.1 [benign]; 			20	104					OPA1 (inh=AR+AD pLI=0.99)
chr3	193414780	193414780	T	C	wt	wt	het		QUAL=1471;DP=266,113,151;MQM=60	OPA1	3'UTR	OPA1:NM_130837.2:3'UTR:MODIFIER:exon31/31:c.*2391T>C:,OPA1:NM_015560.2:3'UTR:MODIFIER:exon29/29:c.*2391T>C:,OPA1:NM_130831.2:3'UTR:MODIFIER:exon28/28:c.*2391T>C:,OPA1:NM_130832.2:3'UTR:MODIFIER:exon29/29:c.*2391T>C:,OPA1:NM_130833.2:3'UTR:MODIFIER:exon29/29:c.*2391T>C:,OPA1:NM_130834.2:3'UTR:MODIFIER:exon30/30:c.*2391T>C:,OPA1:NM_130835.2:3'UTR:MODIFIER:exon30/30:c.*2391T>C:,OPA1:NM_130836.2:3'UTR:MODIFIER:exon30/30:c.*2391T>C:		rs11719309	0.4383	0.0000	0/0/0	0.4180							605290 [OPA1 (confirmed) Optic atrophy 1,165500|Glaucoma,normal tension,susceptibility to,606657|Optic atrophy plus syndrome,125250|Behr syndrome,210000|Mitochondrial DNA depletion syndrome 14 (encephalocardiomyopathic type),616896];	RCV000361318.1 [benign]; 			38	120					OPA1 (inh=AR+AD pLI=0.99)
chr3	196769762	196769762	-	T	hom	hom	hom		QUAL=13796;DP=207,116,100;MQM=59	DLG1	3'UTR	DLG1:NM_004087.2:3'UTR:MODIFIER:exon26/26:c.*1731dupA:,DLG1:NM_001204387.1:3'UTR:MODIFIER:exon22/22:c.*1731dupA:,DLG1:NM_001204388.1:3'UTR:MODIFIER:exon21/21:c.*1731dupA:,DLG1:NM_001098424.1:3'UTR:MODIFIER:exon26/26:c.*1731dupA:,DLG1:NM_001204386.1:3'UTR:MODIFIER:exon25/25:c.*1731dupA:,DLG1:NM_001290983.1:3'UTR:MODIFIER:exon26/26:c.*1731dupA:		rs386399009	0.0000	0.0000	0/0/0	0.5299											126	93					DLG1 (inh=n/a pLI=1.00)
chr3	196769797	196769797	A	G	hom	hom	hom		QUAL=15370;DP=247,103,103;MQM=59	DLG1	3'UTR	DLG1:NM_004087.2:3'UTR:MODIFIER:exon26/26:c.*1697T>C:,DLG1:NM_001204387.1:3'UTR:MODIFIER:exon22/22:c.*1697T>C:,DLG1:NM_001204388.1:3'UTR:MODIFIER:exon21/21:c.*1697T>C:,DLG1:NM_001098424.1:3'UTR:MODIFIER:exon26/26:c.*1697T>C:,DLG1:NM_001204386.1:3'UTR:MODIFIER:exon25/25:c.*1697T>C:,DLG1:NM_001290983.1:3'UTR:MODIFIER:exon26/26:c.*1697T>C:		rs7753	0.6174	0.0000	0/0/0	0.1279											90	107					DLG1 (inh=n/a pLI=1.00)
chr3	196769982	196769982	C	G	het	hom	het		QUAL=11418;DP=366,131,178;MQM=60	DLG1	3'UTR	DLG1:NM_004087.2:3'UTR:MODIFIER:exon26/26:c.*1512G>C:,DLG1:NM_001204387.1:3'UTR:MODIFIER:exon22/22:c.*1512G>C:,DLG1:NM_001204388.1:3'UTR:MODIFIER:exon21/21:c.*1512G>C:,DLG1:NM_001098424.1:3'UTR:MODIFIER:exon26/26:c.*1512G>C:,DLG1:NM_001204386.1:3'UTR:MODIFIER:exon25/25:c.*1512G>C:,DLG1:NM_001290983.1:3'UTR:MODIFIER:exon26/26:c.*1512G>C:		rs7641	0.3636	0.0000	0/0/0	0.0708											37	109					DLG1 (inh=n/a pLI=1.00)
chr3	196770356	196770359	AAGG	-	hom	hom	hom		QUAL=9507;DP=165,69,103;MQM=59	DLG1	3'UTR	DLG1:NM_004087.2:3'UTR:MODIFIER:exon26/26:c.*1135_*1138delCCTT:,DLG1:NM_001204387.1:3'UTR:MODIFIER:exon22/22:c.*1135_*1138delCCTT:,DLG1:NM_001204388.1:3'UTR:MODIFIER:exon21/21:c.*1135_*1138delCCTT:,DLG1:NM_001098424.1:3'UTR:MODIFIER:exon26/26:c.*1135_*1138delCCTT:,DLG1:NM_001204386.1:3'UTR:MODIFIER:exon25/25:c.*1135_*1138delCCTT:,DLG1:NM_001290983.1:3'UTR:MODIFIER:exon26/26:c.*1135_*1138delCCTT:		rs569151903	0.7562	0.0000	0/0/0	0.6613											117	97					DLG1 (inh=n/a pLI=1.00)
chr3	196771245	196771245	G	A	hom	hom	hom		QUAL=34015;DP=501,257,280;MQM=59	DLG1	3'UTR	DLG1:NM_004087.2:3'UTR:MODIFIER:exon26/26:c.*249C>T:,DLG1:NM_001204387.1:3'UTR:MODIFIER:exon22/22:c.*249C>T:,DLG1:NM_001204388.1:3'UTR:MODIFIER:exon21/21:c.*249C>T:,DLG1:NM_001098424.1:3'UTR:MODIFIER:exon26/26:c.*249C>T:,DLG1:NM_001204386.1:3'UTR:MODIFIER:exon25/25:c.*249C>T:,DLG1:NM_001290983.1:3'UTR:MODIFIER:exon26/26:c.*249C>T:		rs4916600	0.7478	0.0000	0/0/0	0.1279											125	93					DLG1 (inh=n/a pLI=1.00)
chr3	196865242	196865242	C	T	het	wt	het	pred_pathogenic;anno_pathogenic_hgmd	QUAL=2528;DP=146,55,72;MQM=60	DLG1	missense	DLG1:NM_004087.2:missense:MODERATE:exon10/26:c.833G>A:p.Arg278Gln,DLG1:NM_001204387.1:missense:MODERATE:exon5/22:c.485G>A:p.Arg162Gln,DLG1:NM_001204388.1:missense:MODERATE:exon5/21:c.485G>A:p.Arg162Gln,DLG1:NM_001098424.1:missense:MODERATE:exon10/26:c.833G>A:p.Arg278Gln,DLG1:NM_001204386.1:missense:MODERATE:exon9/25:c.734G>A:p.Arg245Gln,DLG1:NM_001290983.1:missense:MODERATE:exon10/26:c.833G>A:p.Arg278Gln		rs1134986	0.1280	0.1550	1948/737/4	0.1493	7.4450	T,T,T,T,T,T,T,T,T,T,T,T,T	T	B,B,D,D,D,P,D	T,T,T,T,T,T,T,T,T,T,T	24.20			CM146495 [CLASS=DM? MUT=ALT PHEN="Crohn's disease susceptibility to" GENE=DLG1]; 		58	325					DLG1 (inh=n/a pLI=1.00)
chr3	197409392	197409392	T	A	wt	het	wt	pred_pathogenic	QUAL=1598;DP=122,130,181;MQM=60	RUBCN	missense	RUBCN:NM_014687.2:missense:MODERATE:exon14/20:c.2075A>T:p.Glu692Val,RUBCN:NM_001145642.3:missense:MODERATE:exon15/21:c.1940A>T:p.Glu647Val		rs201343662	0.0002	0.0007	0/0/0	0.0006	8.0400	D,D,D,.	T,T	D,D,D,.		34.00	613516 [KIAA0226 (provisional) Spinocerebellar ataxia,autosomal recessive 15,615705];				0	2					RUBCN (inh=AR pLI=0.00)
chr4	1807894	1807894	G	A	hom	hom	hom		QUAL=33835;DP=132,410,568;MQM=59	FGFR3	synonymous	FGFR3:NM_001163213.1:synonymous:LOW:exon14/18:c.1959G>A:p.Thr653Thr,FGFR3:NM_000142.4:synonymous:LOW:exon14/18:c.1953G>A:p.Thr651Thr,FGFR3:NM_022965.3:synonymous:LOW:exon12/16:c.1617G>A:p.Thr539Thr		rs7688609	0.9561	0.9873	58288/32669/3762	0.9484							134934 [FGFR3 (confirmed) Achondroplasia,100800|Hypochondroplasia,146000|Thanatophoric dysplasia,type I,187600|Crouzon syndrome with acanthosis nigricans,612247|Muenke syndrome,602849|Bladder cancer,somatic,109800|Colorectal cancer,somatic,114500|Cervical cancer,somatic,603956|LADD syndrome,149730|CATSHL syndrome,610474|Nevus,epidermal,somatic,162900|Thanatophoric dysplasia,type II,187601|Spermatocytic seminoma,somatic,273300|SADDAN,616482];				1636	8					FGFR3 (inh=AR+AD pLI=0.00)
chr4	1809128	1809129	GT	-	hom	hom	hom		QUAL=6769;DP=61,87,108;MQM=59	FGFR3	3'UTR	FGFR3:NM_001163213.1:3'UTR:MODIFIER:exon18/18:c.*156_*157delTG:,FGFR3:NM_000142.4:3'UTR:MODIFIER:exon18/18:c.*156_*157delTG:,FGFR3:NM_022965.3:3'UTR:MODIFIER:exon16/16:c.*156_*157delTG:	(TG)n	rs34562534;rs796200908	0.0000	0.6816	1890/694/149	0.2460							134934 [FGFR3 (confirmed) Achondroplasia,100800|Hypochondroplasia,146000|Thanatophoric dysplasia,type I,187600|Crouzon syndrome with acanthosis nigricans,612247|Muenke syndrome,602849|Bladder cancer,somatic,109800|Colorectal cancer,somatic,114500|Cervical cancer,somatic,603956|LADD syndrome,149730|CATSHL syndrome,610474|Nevus,epidermal,somatic,162900|Thanatophoric dysplasia,type II,187601|Spermatocytic seminoma,somatic,273300|SADDAN,616482];			COSN504966, COSN504965	963	29					FGFR3 (inh=AR+AD pLI=0.00)
chr4	1809787	1809787	C	T	hom	hom	hom		QUAL=9298;DP=166,70,85;MQM=59	FGFR3	3'UTR	FGFR3:NM_001163213.1:3'UTR:MODIFIER:exon18/18:c.*798C>T:,FGFR3:NM_000142.4:3'UTR:MODIFIER:exon18/18:c.*798C>T:,FGFR3:NM_022965.3:3'UTR:MODIFIER:exon16/16:c.*798C>T:		rs3135904	0.8982	0.0000	0/0/0	0.1480							134934 [FGFR3 (confirmed) Achondroplasia,100800|Hypochondroplasia,146000|Thanatophoric dysplasia,type I,187600|Crouzon syndrome with acanthosis nigricans,612247|Muenke syndrome,602849|Bladder cancer,somatic,109800|Colorectal cancer,somatic,114500|Cervical cancer,somatic,603956|LADD syndrome,149730|CATSHL syndrome,610474|Nevus,epidermal,somatic,162900|Thanatophoric dysplasia,type II,187601|Spermatocytic seminoma,somatic,273300|SADDAN,616482];				292	5					FGFR3 (inh=AR+AD pLI=0.00)
chr4	1981229	1981229	G	T	het	het	wt		QUAL=6389;DP=262,237,288;MQM=59	WHSC1	3'UTR	WHSC1:NM_001042424.2:3'UTR:MODIFIER:exon22/22:c.*593G>T:,WHSC1:NM_133330.2:3'UTR:MODIFIER:exon24/24:c.*593G>T:,WHSC1:NM_133331.2:3'UTR:MODIFIER:exon23/23:c.*593G>T:,WHSC1:NM_133335.3:3'UTR:MODIFIER:exon22/22:c.*593G>T:		rs73202837	0.0443	0.0000	0/0/0	0.0088								RCV000268221.1 [likely benign]; 			0	22					NSD2 (inh=n/a pLI=1.00)
chr4	1984514	1984514	-	CTGT	wt	het	het		QUAL=5038;DP=225,159,222;MQM=59	NELFA	3'UTR	NELFA:NM_005663.4:3'UTR:MODIFIER:exon11/11:c.*528_*531dupACAG:		rs71167764	0.0669	0.0000	0/0/0	0.1115											3	60					NELFA (inh=n/a pLI=0.17)
chr4	1984732	1984732	-	AACA	wt	het	het		QUAL=844;DP=87,36,43;MQM=60	NELFA	3'UTR	NELFA:NM_005663.4:3'UTR:MODIFIER:exon11/11:c.*310_*313dupTGTT:		rs16342	0.2634	0.0000	0/0/0	0.3056											27	112					NELFA (inh=n/a pLI=0.17)
chr4	3475252	3475252	T	C	hom	hom	hom		QUAL=7670;DP=62,60,134;MQM=60	DOK7	synonymous	DOK7:NM_001301071.1:synonymous:LOW:exon3/10:c.220T>C:p.Leu74Leu,DOK7:NM_001164673.1:synonymous:LOW:exon3/7:c.220T>C:p.Leu74Leu,DOK7:NM_173660.4:synonymous:LOW:exon3/7:c.220T>C:p.Leu74Leu		rs4325970	1.0000	1.0000	59627/32806/4807	0.9315							610285 [DOK7 (confirmed) Myasthenic syndrome,congenital,10,254300|Fetal akinesia deformation sequence,208150];	RCV000177424.1 [benign]; 			1567	0					DOK7 (inh=AR pLI=0.00)
chr4	3486511	3486511	C	T	wt	wt	het		QUAL=3145;DP=124,195,244;MQM=60	DOK7	5'UTR_premature_start_codon_gain,5'UTR,intron	DOK7:NM_001256896.1:5'UTR_premature_start_codon_gain:LOW:exon1/4:c.-458C>T:,DOK7:NM_001256896.1:5'UTR:MODIFIER:exon1/4:c.-458C>T:,DOK7:NM_001301071.1:intron:MODIFIER:exon4/9:c.533-755C>T:,DOK7:NM_001164673.1:intron:MODIFIER:exon4/6:c.522-755C>T:,DOK7:NM_173660.4:intron:MODIFIER:exon4/6:c.533-755C>T:		rs3827767	0.1701	0.0000	0/0/0	0.1814							610285 [DOK7 (confirmed) Myasthenic syndrome,congenital,10,254300|Fetal akinesia deformation sequence,208150];				4	44					DOK7 (inh=AR pLI=0.00)
chr4	3494600	3494600	A	G	hom	het	het	pred_pathogenic	QUAL=6715;DP=89,157,206;MQM=60	DOK7	missense,5'UTR,3'UTR	DOK7:NM_001301071.1:missense:MODERATE:exon7/10:c.887A>G:p.Gln296Arg,DOK7:NM_173660.4:missense:MODERATE:exon7/7:c.887A>G:p.Gln296Arg,DOK7:NM_001256896.1:5'UTR:MODIFIER:exon4/4:c.-44A>G:,DOK7:NM_001164673.1:3'UTR:MODIFIER:exon7/7:c.*108A>G:		rs6811423	0.2181	0.2685	2920/1258/10	0.2118	1.6510	T,T	T	B,B	T,T	0.04	610285 [DOK7 (confirmed) Myasthenic syndrome,congenital,10,254300|Fetal akinesia deformation sequence,208150];	RCV000116896.3 [benign]; 		COSM4159034, COSM447809	76	479					DOK7 (inh=AR pLI=0.00)
chr4	3494826	3494826	A	C	hom	het	het		QUAL=1332;DP=23,35,41;MQM=59	DOK7	synonymous,3'UTR	DOK7:NM_001301071.1:synonymous:LOW:exon7/10:c.1113A>C:p.Ser371Ser,DOK7:NM_173660.4:synonymous:LOW:exon7/7:c.1113A>C:p.Ser371Ser,DOK7:NM_001256896.1:synonymous:LOW:exon4/4:c.183A>C:p.Ser61Ser,DOK7:NM_001164673.1:3'UTR:MODIFIER:exon7/7:c.*334A>C:		rs6811856	0.2169	0.3001	1576/709/9	0.1929							610285 [DOK7 (confirmed) Myasthenic syndrome,congenital,10,254300|Fetal akinesia deformation sequence,208150];	RCV000116884.3 [benign]; 		COSM3760590, COSM3760589	75	468					DOK7 (inh=AR pLI=0.00)
chr4	3494847	3494847	G	A	hom	het	het		QUAL=1186;DP=28,28,36;MQM=59	DOK7	synonymous,3'UTR	DOK7:NM_001301071.1:synonymous:LOW:exon7/10:c.1134G>A:p.Ala378Ala,DOK7:NM_173660.4:synonymous:LOW:exon7/7:c.1134G>A:p.Ala378Ala,DOK7:NM_001256896.1:synonymous:LOW:exon4/4:c.204G>A:p.Ala68Ala,DOK7:NM_001164673.1:3'UTR:MODIFIER:exon7/7:c.*355G>A:		rs6831659	0.2149	0.2981	1923/822/10	0.1844							610285 [DOK7 (confirmed) Myasthenic syndrome,congenital,10,254300|Fetal akinesia deformation sequence,208150];	RCV000116885.3 [benign]; 		COSM3749873, COSM3749874	71	454					DOK7 (inh=AR pLI=0.00)
chr4	3494898	3494898	C	T	hom	het	het		QUAL=2130;DP=53,25,36;MQM=59	DOK7	synonymous,3'UTR	DOK7:NM_001301071.1:synonymous:LOW:exon7/10:c.1185C>T:p.Tyr395Tyr,DOK7:NM_173660.4:synonymous:LOW:exon7/7:c.1185C>T:p.Tyr395Tyr,DOK7:NM_001256896.1:synonymous:LOW:exon4/4:c.255C>T:p.Tyr85Tyr,DOK7:NM_001164673.1:3'UTR:MODIFIER:exon7/7:c.*406C>T:		rs6850908	0.2196	0.2722	2979/1280/14	0.2119							610285 [DOK7 (confirmed) Myasthenic syndrome,congenital,10,254300|Fetal akinesia deformation sequence,208150];	RCV000116887.3 [benign]; 		COSM3760591, COSM447810	72	473					DOK7 (inh=AR pLI=0.00)
chr4	3495095	3495095	G	A	wt	wt	het	pred_pathogenic	QUAL=1606;DP=47,121,146;MQM=60	DOK7	missense,3'UTR	DOK7:NM_001301071.1:missense:MODERATE:exon7/10:c.1382G>A:p.Gly461Asp,DOK7:NM_173660.4:missense:MODERATE:exon7/7:c.1382G>A:p.Gly461Asp,DOK7:NM_001256896.1:missense:MODERATE:exon4/4:c.452G>A:p.Gly151Asp,DOK7:NM_001164673.1:3'UTR:MODIFIER:exon7/7:c.*603G>A:		rs9684786	0.1955	0.2520	1971/878/57	0.1761	2.7420	D,D	T	B,P,B	T,T	12.18	610285 [DOK7 (confirmed) Myasthenic syndrome,congenital,10,254300|Fetal akinesia deformation sequence,208150];	RCV000116891.3 [benign]; 		COSM3760593, COSM3760592	73	493					DOK7 (inh=AR pLI=0.00)
chr4	3495283	3495283	C	G	wt	het	het		QUAL=4571;DP=91,148,215;MQM=60	DOK7	3'UTR,intron	DOK7:NM_001164673.1:3'UTR:MODIFIER:exon7/7:c.*791C>G:,DOK7:NM_173660.4:3'UTR:MODIFIER:exon7/7:c.*55C>G:,DOK7:NM_001256896.1:3'UTR:MODIFIER:exon4/4:c.*55C>G:,DOK7:NM_001301071.1:intron:MODIFIER:exon7/9:c.1497+73C>G:		rs11733064	0.3542	0.0000	0/0/0	0.0690							610285 [DOK7 (confirmed) Myasthenic syndrome,congenital,10,254300|Fetal akinesia deformation sequence,208150];				127	446					DOK7 (inh=AR pLI=0.00)
chr4	3495446	3495446	C	T	hom	het	hom		QUAL=10481;DP=114,153,186;MQM=59	DOK7	3'UTR,intron	DOK7:NM_001164673.1:3'UTR:MODIFIER:exon7/7:c.*954C>T:,DOK7:NM_173660.4:3'UTR:MODIFIER:exon7/7:c.*218C>T:,DOK7:NM_001256896.1:3'UTR:MODIFIER:exon4/4:c.*218C>T:,DOK7:NM_001301071.1:intron:MODIFIER:exon7/9:c.1497+236C>T:		rs10022432	0.6342	0.0000	0/0/0	0.1053							610285 [DOK7 (confirmed) Myasthenic syndrome,congenital,10,254300|Fetal akinesia deformation sequence,208150];				86	107					DOK7 (inh=AR pLI=0.00)
chr4	3495477	3495477	T	C	hom	hom	hom		QUAL=16894;DP=139,178,228;MQM=59	DOK7	3'UTR,intron	DOK7:NM_001164673.1:3'UTR:MODIFIER:exon7/7:c.*985T>C:,DOK7:NM_173660.4:3'UTR:MODIFIER:exon7/7:c.*249T>C:,DOK7:NM_001256896.1:3'UTR:MODIFIER:exon4/4:c.*249T>C:,DOK7:NM_001301071.1:intron:MODIFIER:exon7/9:c.1497+267T>C:		rs2858030	0.7406	0.0000	0/0/0	0.1244							610285 [DOK7 (confirmed) Myasthenic syndrome,congenital,10,254300|Fetal akinesia deformation sequence,208150];				126	88					DOK7 (inh=AR pLI=0.00)
chr4	3495493	3495493	G	A	wt	het	wt		QUAL=2697;DP=186,195,246;MQM=60	DOK7	3'UTR,intron	DOK7:NM_001164673.1:3'UTR:MODIFIER:exon7/7:c.*1001G>A:,DOK7:NM_173660.4:3'UTR:MODIFIER:exon7/7:c.*265G>A:,DOK7:NM_001256896.1:3'UTR:MODIFIER:exon4/4:c.*265G>A:,DOK7:NM_001301071.1:intron:MODIFIER:exon7/9:c.1497+283G>A:		rs35748957	0.1050	0.0000	0/0/0	0.0189							610285 [DOK7 (confirmed) Myasthenic syndrome,congenital,10,254300|Fetal akinesia deformation sequence,208150];				0	61					DOK7 (inh=AR pLI=0.00)
chr4	3495726	3495726	T	-	wt	wt	het		QUAL=1307;DP=79,58,110;MQM=60	DOK7	3'UTR,intron	DOK7:NM_001164673.1:3'UTR:MODIFIER:exon7/7:c.*1234delT:,DOK7:NM_173660.4:3'UTR:MODIFIER:exon7/7:c.*498delT:,DOK7:NM_001256896.1:3'UTR:MODIFIER:exon4/4:c.*498delT:,DOK7:NM_001301071.1:intron:MODIFIER:exon7/9:c.1497+516delT:		rs34564851	0.4227	0.0000	0/0/0	0.3551							610285 [DOK7 (confirmed) Myasthenic syndrome,congenital,10,254300|Fetal akinesia deformation sequence,208150];				33	102					DOK7 (inh=AR pLI=0.00)
chr4	3495941	3495941	T	C	hom	het	het		QUAL=5213;DP=91,93,116;MQM=59	DOK7	3'UTR,intron	DOK7:NM_001164673.1:3'UTR:MODIFIER:exon7/7:c.*1449T>C:,DOK7:NM_173660.4:3'UTR:MODIFIER:exon7/7:c.*713T>C:,DOK7:NM_001256896.1:3'UTR:MODIFIER:exon4/4:c.*713T>C:,DOK7:NM_001301071.1:intron:MODIFIER:exon7/9:c.1497+731T>C:		rs1054661	0.4367	0.0000	0/0/0	0.0737							610285 [DOK7 (confirmed) Myasthenic syndrome,congenital,10,254300|Fetal akinesia deformation sequence,208150];				43	104					DOK7 (inh=AR pLI=0.00)
chr4	3496110	3496110	C	T	wt	wt	het		QUAL=3667;DP=156,255,338;MQM=60	DOK7	3'UTR,intron	DOK7:NM_001164673.1:3'UTR:MODIFIER:exon7/7:c.*1618C>T:,DOK7:NM_173660.4:3'UTR:MODIFIER:exon7/7:c.*882C>T:,DOK7:NM_001256896.1:3'UTR:MODIFIER:exon4/4:c.*882C>T:,DOK7:NM_001301071.1:intron:MODIFIER:exon7/9:c.1497+900C>T:		rs10937930	0.2472	0.0000	0/0/0	0.0391							610285 [DOK7 (confirmed) Myasthenic syndrome,congenital,10,254300|Fetal akinesia deformation sequence,208150];				15	84					DOK7 (inh=AR pLI=0.00)
chr4	3496150	3496150	A	G	hom	het	hom		QUAL=23183;DP=236,291,378;MQM=59	DOK7	3'UTR,intron	DOK7:NM_001164673.1:3'UTR:MODIFIER:exon7/7:c.*1658A>G:,DOK7:NM_173660.4:3'UTR:MODIFIER:exon7/7:c.*922A>G:,DOK7:NM_001256896.1:3'UTR:MODIFIER:exon4/4:c.*922A>G:,DOK7:NM_001301071.1:intron:MODIFIER:exon7/9:c.1497+940A>G:		rs1054662	0.6554	0.0000	0/0/0	0.1072							610285 [DOK7 (confirmed) Myasthenic syndrome,congenital,10,254300|Fetal akinesia deformation sequence,208150];				86	107					DOK7 (inh=AR pLI=0.00)
chr4	3496205	3496205	C	T	hom	hom	hom		QUAL=23217;DP=160,263,329;MQM=60	DOK7	3'UTR,intron	DOK7:NM_001164673.1:3'UTR:MODIFIER:exon7/7:c.*1713C>T:,DOK7:NM_173660.4:3'UTR:MODIFIER:exon7/7:c.*977C>T:,DOK7:NM_001256896.1:3'UTR:MODIFIER:exon4/4:c.*977C>T:,DOK7:NM_001301071.1:intron:MODIFIER:exon7/9:c.1497+995C>T:		rs2105849	0.7390	0.0000	0/0/0	0.1248							610285 [DOK7 (confirmed) Myasthenic syndrome,congenital,10,254300|Fetal akinesia deformation sequence,208150];				125	88					DOK7 (inh=AR pLI=0.00)
chr4	5564191	5564191	A	T	hom	hom	hom		QUAL=15522;DP=268,105,126;MQM=60	EVC2	3'UTR	EVC2:NM_147127.4:3'UTR:MODIFIER:exon22/22:c.*384T>A:,EVC2:NM_001166136.1:3'UTR:MODIFIER:exon22/22:c.*384T>A:		rs2287576	0.5409	0.0000	0/0/0	0.1243							607261 [EVC2 (confirmed) Ellis-van Creveld syndrome,225500|Weyers acrofacial dysostosis,193530];	RCV000354242.1 [benign]; 			119	76					EVC2 (inh=AR+AD pLI=0.00)
chr4	5570221	5570221	G	A	het	het	hom		QUAL=4952;DP=86,62,106;MQM=60	EVC2	synonymous	EVC2:NM_147127.4:synonymous:LOW:exon20/22:c.3507C>T:p.His1169His,EVC2:NM_001166136.1:synonymous:LOW:exon20/22:c.3267C>T:p.His1089His		rs12511039	0.4409	0.4847	7484/2238/122	0.3517							607261 [EVC2 (confirmed) Ellis-van Creveld syndrome,225500|Weyers acrofacial dysostosis,193530];	RCV000176126.2 [benign]; RCV000328377.1 [benign]; 		COSM3760662, COSM330193	221	670					EVC2 (inh=AR+AD pLI=0.00)
chr4	5624670	5624670	T	C	wt	wt	het		QUAL=4088;DP=155,219,334;MQM=60	EVC2	missense	EVC2:NM_147127.4:missense:MODERATE:exon14/22:c.2095A>G:p.Thr699Ala,EVC2:NM_001166136.1:missense:MODERATE:exon14/22:c.1855A>G:p.Thr619Ala		rs730469	0.5176	0.3706	9780/2656/3246	0.3622	1.4800	T,T,T	T	B	T,T,T	0.01	607261 [EVC2 (confirmed) Ellis-van Creveld syndrome,225500|Weyers acrofacial dysostosis,193530];	RCV000250571.1 [benign]; RCV000349643.1 [benign]; 		COSM3721683, COSM3721684	158	615					EVC2 (inh=AR+AD pLI=0.00)
chr4	5624704	5624704	A	G	wt	het	wt		QUAL=1476;DP=127,148,216;MQM=60	EVC2	synonymous	EVC2:NM_147127.4:synonymous:LOW:exon14/22:c.2061T>C:p.Arg687Arg,EVC2:NM_001166136.1:synonymous:LOW:exon14/22:c.1821T>C:p.Arg607Arg		rs73198153	0.1180	0.0746	578/95/319	0.0710							607261 [EVC2 (confirmed) Ellis-van Creveld syndrome,225500|Weyers acrofacial dysostosis,193530];	RCV000245836.1 [benign]; RCV000385540.1 [benign]; 			10	216					EVC2 (inh=AR+AD pLI=0.00)
chr4	5630471	5630471	A	-	wt	wt	het		QUAL=1044;DP=117,76,93;MQM=60	EVC2	splice_region&intron	EVC2:NM_147127.4:splice_region&intron:LOW:exon11/21:c.1711-10delT:,EVC2:NM_001166136.1:splice_region&intron:LOW:exon11/21:c.1471-10delT:		rs35103377;rs547083740	0.4133	0.3813	6490/2038/945	0.3089							607261 [EVC2 (confirmed) Ellis-van Creveld syndrome,225500|Weyers acrofacial dysostosis,193530];				125	540	2	[2] Ute Grasshoff 09.04.2015			EVC2 (inh=AR+AD pLI=0.00)
chr4	5710647	5710647	A	G	het	wt	het		QUAL=4383;DP=113,193,244;MQM=60	EVC2	5'UTR	EVC2:NM_001166136.1:5'UTR:MODIFIER:exon1/22:c.-104T>C:		rs2013183	0.3800	0.0000	0/0/0	0.4226							607261 [EVC2 (confirmed) Ellis-van Creveld syndrome,225500|Weyers acrofacial dysostosis,193530];				50	107					EVC2 (inh=AR+AD pLI=0.00)
chr4	5710856	5710856	G	A	het	het	wt	low_DP	QUAL=740;DP=52,17,40;MQM=60	EVC2	5'UTR	EVC2:NM_001166136.1:5'UTR:MODIFIER:exon1/22:c.-313C>T:		rs3755842	0.2133	0.0000	0/0/0	0.2197							607261 [EVC2 (confirmed) Ellis-van Creveld syndrome,225500|Weyers acrofacial dysostosis,193530];				17	82					EVC2 (inh=AR+AD pLI=0.00)
chr4	5710988	5710990	AGG	-	het	het	wt		QUAL=562;DP=70,21,31;MQM=59	EVC2	5'UTR	EVC2:NM_001166136.1:5'UTR:MODIFIER:exon1/22:c.-447_-445delCCT:	(AGG)n	rs67550450;rs772310935	0.2274	0.0000	0/0/0	0.2273							607261 [EVC2 (confirmed) Ellis-van Creveld syndrome,225500|Weyers acrofacial dysostosis,193530];				19	84					EVC2 (inh=AR+AD pLI=0.00)
chr4	5711095	5711095	G	A	het	het	het		QUAL=3299;DP=109,97,107;MQM=59	EVC2	5'UTR	EVC2:NM_001166136.1:5'UTR:MODIFIER:exon1/22:c.-552C>T:		rs10000314	0.4625	0.0000	0/0/0	0.4627							607261 [EVC2 (confirmed) Ellis-van Creveld syndrome,225500|Weyers acrofacial dysostosis,193530];				58	94					EVC2 (inh=AR+AD pLI=0.00)
chr4	5721049	5721049	A	G	het	wt	het		QUAL=9743;DP=307,404,469;MQM=60	EVC	synonymous	EVC:NM_153717.2:synonymous:LOW:exon2/21:c.249A>G:p.Ser83Ser,EVC:NM_001306092.1:synonymous:LOW:exon2/12:c.249A>G:p.Ser83Ser,EVC:NM_001306090.1:synonymous:LOW:exon2/21:c.249A>G:p.Ser83Ser		rs35870680	0.0695	0.1153	1009/753/5	0.1136							604831 [EVC (provisional) Ellis-van Creveld syndrome,225500|Weyers acrodental dysostosis,193530];	RCV000242088.1 [benign]; RCV000300455.1 [benign]; RCV000355391.1 [benign]; 		COSM3760673	39	407					EVC (inh=AR+AD pLI=0.00)
chr4	5743509	5743509	C	T	hom	hom	hom		QUAL=14833;DP=275,83,130;MQM=60	EVC	synonymous	EVC:NM_153717.2:synonymous:LOW:exon6/21:c.769C>T:p.Leu257Leu,EVC:NM_001306092.1:synonymous:LOW:exon6/12:c.769C>T:p.Leu257Leu,EVC:NM_001306090.1:synonymous:LOW:exon6/21:c.769C>T:p.Leu257Leu		rs6446393	0.9667	0.9456	54081/29003/5020	0.9106							604831 [EVC (provisional) Ellis-van Creveld syndrome,225500|Weyers acrodental dysostosis,193530];	RCV000179557.2 [benign]; RCV000284741.1 [benign]; RCV000337462.1 [benign]; 			1349	208					EVC (inh=AR+AD pLI=0.00)
chr4	5743512	5743512	T	C	hom	het	het	pred_pathogenic	QUAL=14833;DP=275,83,130;MQM=60	EVC	missense	EVC:NM_153717.2:missense:MODERATE:exon6/21:c.772T>C:p.Tyr258His,EVC:NM_001306092.1:missense:MODERATE:exon6/12:c.772T>C:p.Tyr258His,EVC:NM_001306090.1:missense:MODERATE:exon6/21:c.772T>C:p.Tyr258His		rs6414624	0.7448	0.7951	38535/21387/1423	0.7752	1.9260	T,T,T	T	B	T,T,T	8.78	604831 [EVC (provisional) Ellis-van Creveld syndrome,225500|Weyers acrodental dysostosis,193530];	RCV000179558.2 [benign]; RCV000297646.1 [benign]; RCV000400923.1 [benign]; 			950	527					EVC (inh=AR+AD pLI=0.00)
chr4	5747072	5747072	C	T	het	hom	het		QUAL=1445;DP=35,24,32;MQM=60	EVC	splice_region&intron	EVC:NM_153717.2:splice_region&intron:LOW:exon7/20:c.939+4C>T:,EVC:NM_001306092.1:splice_region&intron:LOW:exon7/11:c.939+4C>T:,EVC:NM_001306090.1:splice_region&intron:LOW:exon7/20:c.939+4C>T:		rs2286343	0.4093	0.3729	9048/3301/402	0.3654							604831 [EVC (provisional) Ellis-van Creveld syndrome,225500|Weyers acrodental dysostosis,193530];	RCV000248656.1 [benign]; RCV000268637.1 [benign]; RCV000321339.1 [benign]; 			217	687					EVC (inh=AR+AD pLI=0.00)
chr4	5747078	5747078	A	G	het	wt	het		QUAL=755;DP=33,22,30;MQM=60	EVC	splice_region&intron	EVC:NM_153717.2:splice_region&intron:LOW:exon7/20:c.939+10A>G:,EVC:NM_001306092.1:splice_region&intron:LOW:exon7/11:c.939+10A>G:,EVC:NM_001306090.1:splice_region&intron:LOW:exon7/20:c.939+10A>G:		rs2286342	0.5931	0.6295	24638/15565/2662	0.6164							604831 [EVC (provisional) Ellis-van Creveld syndrome,225500|Weyers acrodental dysostosis,193530];	RCV000244100.1 [benign]; RCV000281637.1 [benign]; RCV000373771.1 [benign]; 			665	688					EVC (inh=AR+AD pLI=0.00)
chr4	5749904	5749904	T	C	wt	het	het		QUAL=5128;DP=223,203,261;MQM=60	EVC	synonymous	EVC:NM_153717.2:synonymous:LOW:exon8/21:c.969T>C:p.Asn323Asn,EVC:NM_001306092.1:synonymous:LOW:exon8/12:c.969T>C:p.Asn323Asn,EVC:NM_001306090.1:synonymous:LOW:exon8/21:c.969T>C:p.Asn323Asn		rs4688963	0.4714	0.4177	10996/4446/1168	0.4129							604831 [EVC (provisional) Ellis-van Creveld syndrome,225500|Weyers acrodental dysostosis,193530];	RCV000253613.1 [benign]; RCV000294312.1 [benign]; RCV000349207.1 [benign]; 			228	733					EVC (inh=AR+AD pLI=0.00)
chr4	5749961	5749961	G	C	wt	het	het		QUAL=5691;DP=391,217,284;MQM=60	EVC	synonymous	EVC:NM_153717.2:synonymous:LOW:exon8/21:c.1026G>C:p.Leu342Leu,EVC:NM_001306092.1:synonymous:LOW:exon8/12:c.1026G>C:p.Leu342Leu,EVC:NM_001306090.1:synonymous:LOW:exon8/21:c.1026G>C:p.Leu342Leu		rs4688962	0.5829	0.4920	15251/6260/2784	0.4859							604831 [EVC (provisional) Ellis-van Creveld syndrome,225500|Weyers acrodental dysostosis,193530];	RCV000247308.1 [benign]; RCV000345568.1 [benign]; RCV000400026.1 [benign]; 			313	763					EVC (inh=AR+AD pLI=0.00)
chr4	5750003	5750003	A	G	het	wt	het		QUAL=6951;DP=251,175,217;MQM=60	EVC	synonymous	EVC:NM_153717.2:synonymous:LOW:exon8/21:c.1068A>G:p.Leu356Leu,EVC:NM_001306092.1:synonymous:LOW:exon8/12:c.1068A>G:p.Leu356Leu,EVC:NM_001306090.1:synonymous:LOW:exon8/21:c.1068A>G:p.Leu356Leu		rs33929747	0.2175	0.2925	5696/4231/69	0.2904							604831 [EVC (provisional) Ellis-van Creveld syndrome,225500|Weyers acrodental dysostosis,193530];	RCV000252072.1 [benign]; RCV000310572.1 [benign]; RCV000365218.1 [benign]; 			183	662					EVC (inh=AR+AD pLI=0.00)
chr4	5755542	5755542	C	A	het	het	hom		QUAL=18364;DP=164,287,383;MQM=60	EVC	missense	EVC:NM_153717.2:missense:MODERATE:exon10/21:c.1346C>A:p.Thr449Lys,EVC:NM_001306092.1:missense:MODERATE:exon10/12:c.1346C>A:p.Thr449Lys,EVC:NM_001306090.1:missense:MODERATE:exon10/21:c.1346C>A:p.Thr449Lys		rs2302075	0.8446	0.7965	38777/20992/4783	0.7919	0.3130	T,T,T	T	B	T,T,T	5.81	604831 [EVC (provisional) Ellis-van Creveld syndrome,225500|Weyers acrodental dysostosis,193530];	RCV000153204.4 [benign]; RCV000360127.1 [benign]; RCV000390155.1 [benign]; 			931	546					EVC (inh=AR+AD pLI=0.00)
chr4	5785442	5785442	G	A	hom	het	het	pred_pathogenic	QUAL=9497;DP=140,198,226;MQM=60	EVC	missense	EVC:NM_153717.2:missense:MODERATE:exon12/21:c.1727G>A:p.Arg576Gln,EVC:NM_001306090.1:missense:MODERATE:exon12/21:c.1727G>A:p.Arg576Gln		rs1383180	0.3015	0.3472	7250/4461/210	0.3393	4.5440	T,T	T	D	T,T	24.90	604831 [EVC (provisional) Ellis-van Creveld syndrome,225500|Weyers acrodental dysostosis,193530];	RCV000254232.1 [benign]; RCV000315414.1 [benign]; RCV000369969.1 [benign]; 		COSM3760684	204	715					EVC (inh=AR+AD pLI=0.00)
chr4	5795412	5795412	C	T	wt	het	het		QUAL=5481;DP=137,202,250;MQM=60	EVC	synonymous	EVC:NM_153717.2:synonymous:LOW:exon13/21:c.1854C>T:p.Gly618Gly,EVC:NM_001306090.1:synonymous:LOW:exon13/21:c.1854C>T:p.Gly618Gly		rs11737221	0.3339	0.3857	1755/472/20	0.1675							604831 [EVC (provisional) Ellis-van Creveld syndrome,225500|Weyers acrodental dysostosis,193530];	RCV000244611.1 [benign]; RCV000337032.1 [benign]; RCV000386726.1 [benign]; 		COSM1430367	215	689					EVC (inh=AR+AD pLI=0.00)
chr4	5803669	5803669	T	C	het	hom	het		QUAL=2986;DP=84,45,53;MQM=60	EVC	splice_region&intron	EVC:NM_153717.2:splice_region&intron:LOW:exon15/20:c.2305-8T>C:,EVC:NM_001306090.1:splice_region&intron:LOW:exon15/20:c.2305-8T>C:		rs1031919	0.6905	0.7270	31597/17587/2630	0.7074							604831 [EVC (provisional) Ellis-van Creveld syndrome,225500|Weyers acrodental dysostosis,193530];	RCV000245625.1 [benign]; RCV000288198.1 [benign]; RCV000348046.1 [benign]; 			840	601					EVC (inh=AR+AD pLI=0.00)
chr4	5803830	5803830	C	-	wt	het	het		QUAL=1375;DP=60,68,75;MQM=60	EVC	splice_region&intron	EVC:NM_153717.2:splice_region&intron:LOW:exon16/20:c.2449+15delC:,EVC:NM_001306090.1:splice_region&intron:LOW:exon16/20:c.2449+15delC:		rs398092136	0.3586	0.3620	8598/3628/143	0.3343							604831 [EVC (provisional) Ellis-van Creveld syndrome,225500|Weyers acrodental dysostosis,193530];	RCV000250153.1 [likely benign]; RCV000321022.1 [benign]; RCV000378021.1 [benign]; 			221	702					EVC (inh=AR+AD pLI=0.00)
chr4	5812778	5812778	G	A	het	hom	het		QUAL=15841;DP=250,275,341;MQM=60	EVC	3'UTR	EVC:NM_153717.2:3'UTR:MODIFIER:exon21/21:c.*14G>A:,EVC:NM_001306090.1:3'UTR:MODIFIER:exon21/21:c.*14G>A:		rs2291151	0.5337	0.6099	18375/10766/1831	0.5634							604831 [EVC (provisional) Ellis-van Creveld syndrome,225500|Weyers acrodental dysostosis,193530];	RCV000250767.1 [benign]; RCV000352324.1 [benign]; RCV000393278.1 [benign]; 		COSN167150	347	493					EVC (inh=AR+AD pLI=0.00)
chr4	5812974	5812974	C	A	het	het	wt		QUAL=6853;DP=374,204,339;MQM=60	EVC	3'UTR	EVC:NM_153717.2:3'UTR:MODIFIER:exon21/21:c.*210C>A:,EVC:NM_001306090.1:3'UTR:MODIFIER:exon21/21:c.*210C>A:		rs16837692	0.0885	0.0000	0/0/0	0.0187							604831 [EVC (provisional) Ellis-van Creveld syndrome,225500|Weyers acrodental dysostosis,193530];	RCV000306076.1 [benign]; RCV000353920.1 [benign]; 			2	48					EVC (inh=AR+AD pLI=0.00)
chr4	5813695	5813695	T	C	het	hom	het		QUAL=36965;DP=492,672,792;MQM=59	EVC	3'UTR	EVC:NM_153717.2:3'UTR:MODIFIER:exon21/21:c.*931T>C:,EVC:NM_001306090.1:3'UTR:MODIFIER:exon21/21:c.*931T>C:		rs6840435	0.4369	0.0000	0/0/0	0.4527							604831 [EVC (provisional) Ellis-van Creveld syndrome,225500|Weyers acrodental dysostosis,193530];	RCV000280739.1 [benign]; RCV000338164.1 [benign]; 			52	122					EVC (inh=AR+AD pLI=0.00)
chr4	5813824	5813824	A	C	het	het	wt		QUAL=6300;DP=385,656,1032;MQM=53	EVC	3'UTR	EVC:NM_153717.2:3'UTR:MODIFIER:exon21/21:c.*1060A>C:,EVC:NM_001306090.1:3'UTR:MODIFIER:exon21/21:c.*1060A>C:		rs71599848	0.1168	0.0000	0/0/0	0.0786							604831 [EVC (provisional) Ellis-van Creveld syndrome,225500|Weyers acrodental dysostosis,193530];	RCV000312762.1 [benign]; RCV000397345.1 [benign]; 			1	54					EVC (inh=AR+AD pLI=0.00)
chr4	5813847	5813847	T	G	wt	het	wt		QUAL=5955;DP=246,622,943;MQM=53	EVC	3'UTR	EVC:NM_153717.2:3'UTR:MODIFIER:exon21/21:c.*1083T>G:,EVC:NM_001306090.1:3'UTR:MODIFIER:exon21/21:c.*1083T>G:		rs71599850	0.0966	0.0000	0/0/0	0.0228							604831 [EVC (provisional) Ellis-van Creveld syndrome,225500|Weyers acrodental dysostosis,193530];	RCV000306850.1 [benign]; RCV000364046.1 [benign]; 			1	34					EVC (inh=AR+AD pLI=0.00)
chr4	5813876	5813876	T	C	het	het	wt		QUAL=5959;DP=330,515,741;MQM=53	EVC	3'UTR	EVC:NM_153717.2:3'UTR:MODIFIER:exon21/21:c.*1112T>C:,EVC:NM_001306090.1:3'UTR:MODIFIER:exon21/21:c.*1112T>C:		rs28460555	0.0000	0.0000	0/0/0	0.0320							604831 [EVC (provisional) Ellis-van Creveld syndrome,225500|Weyers acrodental dysostosis,193530];				4	79					EVC (inh=AR+AD pLI=0.00)
chr4	5813887	5813887	A	G	het	het	wt		QUAL=7656;DP=424,575,814;MQM=53	EVC	3'UTR	EVC:NM_153717.2:3'UTR:MODIFIER:exon21/21:c.*1123A>G:,EVC:NM_001306090.1:3'UTR:MODIFIER:exon21/21:c.*1123A>G:		rs112378896	0.0000	0.0000	0/0/0	0.0178							604831 [EVC (provisional) Ellis-van Creveld syndrome,225500|Weyers acrodental dysostosis,193530];				1	54					EVC (inh=AR+AD pLI=0.00)
chr4	5813982	5813982	C	T	wt	het	het		QUAL=15279;DP=751,701,906;MQM=58	EVC	3'UTR	EVC:NM_153717.2:3'UTR:MODIFIER:exon21/21:c.*1218C>T:,EVC:NM_001306090.1:3'UTR:MODIFIER:exon21/21:c.*1218C>T:		rs12501119	0.1941	0.0000	0/0/0	0.1486							604831 [EVC (provisional) Ellis-van Creveld syndrome,225500|Weyers acrodental dysostosis,193530];	RCV000323510.1 [benign]; RCV000380445.1 [benign]; 			6	81					EVC (inh=AR+AD pLI=0.00)
chr4	5814608	5814608	T	-	het	hom	het		QUAL=20065;DP=401,344,462;MQM=59	EVC	3'UTR	EVC:NM_153717.2:3'UTR:MODIFIER:exon21/21:c.*1845delT:,EVC:NM_001306090.1:3'UTR:MODIFIER:exon21/21:c.*1845delT:		rs397690241	0.3748	0.0000	0/0/0	0.3828							604831 [EVC (provisional) Ellis-van Creveld syndrome,225500|Weyers acrodental dysostosis,193530];	RCV000334732.1 [benign]; RCV000396615.1 [benign]; 			35	118					EVC (inh=AR+AD pLI=0.00)
chr4	5815032	5815032	G	A	wt	het	het		QUAL=3517;DP=219,89,134;MQM=59	EVC	3'UTR	EVC:NM_153717.2:3'UTR:MODIFIER:exon21/21:c.*2268G>A:,EVC:NM_001306090.1:3'UTR:MODIFIER:exon21/21:c.*2268G>A:	AluSx3	rs4261923	0.2702	0.0000	0/0/0	0.2614							604831 [EVC (provisional) Ellis-van Creveld syndrome,225500|Weyers acrodental dysostosis,193530];	RCV000286485.1 [benign]; RCV000341423.1 [benign]; 			18	86					EVC (inh=AR+AD pLI=0.00)
chr4	5815181	5815181	T	C	het	hom	het		QUAL=4595;DP=213,42,59;MQM=59	EVC	3'UTR	EVC:NM_153717.2:3'UTR:MODIFIER:exon21/21:c.*2417T>C:,EVC:NM_001306090.1:3'UTR:MODIFIER:exon21/21:c.*2417T>C:	AluSx3	rs6848370	0.7230	0.0000	0/0/0	0.6730							604831 [EVC (provisional) Ellis-van Creveld syndrome,225500|Weyers acrodental dysostosis,193530];	RCV000320168.1 [benign]; RCV000356240.1 [benign]; 			110	106					EVC (inh=AR+AD pLI=0.00)
chr4	5815381	5815381	G	A	het	hom	het		QUAL=9630;DP=213,147,239;MQM=60	EVC	3'UTR	EVC:NM_153717.2:3'UTR:MODIFIER:exon21/21:c.*2617G>A:,EVC:NM_001306090.1:3'UTR:MODIFIER:exon21/21:c.*2617G>A:	L3	rs3733186	0.3876	0.0000	0/0/0	0.0698							604831 [EVC (provisional) Ellis-van Creveld syndrome,225500|Weyers acrodental dysostosis,193530];	RCV000291760.1 [benign]; RCV000346690.1 [benign]; 			35	122					EVC (inh=AR+AD pLI=0.00)
chr4	5815444	5815444	G	A	het	het	wt		QUAL=2988;DP=191,118,200;MQM=59	EVC	3'UTR	EVC:NM_153717.2:3'UTR:MODIFIER:exon21/21:c.*2680G>A:,EVC:NM_001306090.1:3'UTR:MODIFIER:exon21/21:c.*2680G>A:		rs3733187	0.0745	0.0000	0/0/0	0.1104							604831 [EVC (provisional) Ellis-van Creveld syndrome,225500|Weyers acrodental dysostosis,193530];	RCV000295943.1 [benign]; RCV000402734.1 [benign]; 			2	53					EVC (inh=AR+AD pLI=0.00)
chr4	5815477	5815477	C	T	het	hom	het		QUAL=9549;DP=200,136,193;MQM=59	EVC	3'UTR	EVC:NM_153717.2:3'UTR:MODIFIER:exon21/21:c.*2713C>T:,EVC:NM_001306090.1:3'UTR:MODIFIER:exon21/21:c.*2713C>T:		rs3733188	0.3852	0.0000	0/0/0	0.4090							604831 [EVC (provisional) Ellis-van Creveld syndrome,225500|Weyers acrodental dysostosis,193530];	RCV000298149.1 [benign]; RCV000401280.1 [benign]; 			35	121					EVC (inh=AR+AD pLI=0.00)
chr4	5815635	5815635	C	T	het	het	wt		QUAL=6422;DP=282,289,321;MQM=59	EVC	3'UTR	EVC:NM_153717.2:3'UTR:MODIFIER:exon21/21:c.*2871C>T:,EVC:NM_001306090.1:3'UTR:MODIFIER:exon21/21:c.*2871C>T:		rs3733189	0.0731	0.0000	0/0/0	0.0189							604831 [EVC (provisional) Ellis-van Creveld syndrome,225500|Weyers acrodental dysostosis,193530];	RCV000267907.1 [benign]; RCV000352963.1 [benign]; 			2	53					EVC (inh=AR+AD pLI=0.00)
chr4	5815929	5815929	T	C	het	het	wt		QUAL=7936;DP=250,401,495;MQM=60	EVC	3'UTR	EVC:NM_153717.2:3'UTR:MODIFIER:exon21/21:c.*3165T>C:,EVC:NM_001306090.1:3'UTR:MODIFIER:exon21/21:c.*3165T>C:	LTR89	rs3755847	0.0815	0.0000	0/0/0	0.0194							604831 [EVC (provisional) Ellis-van Creveld syndrome,225500|Weyers acrodental dysostosis,193530];	RCV000289033.1 [benign]; RCV000383501.1 [benign]; 			2	53					EVC (inh=AR+AD pLI=0.00)
chr4	6292915	6292915	A	G	het	het	wt		QUAL=3047;DP=68,204,246;MQM=59	WFS1	splice_region&intron	WFS1:NM_001145853.1:splice_region&intron:LOW:exon4/7:c.461-9A>G:,WFS1:NM_006005.3:splice_region&intron:LOW:exon4/7:c.461-9A>G:		rs10010131	0.7288	0.6555	26281/11622/2223	0.6374							606201 [WFS1 (confirmed) Wolfram syndrome,222300|Deafness,autosomal dominant 6/14/38,600965|Wolfram-like syndrome,autosomal dominant,614296|Diabetes mellitus,noninsulin-dependent,association with,125853|Cataract 41,116400];	RCV000004785.4 [other]; RCV000038664.7 [other]; RCV000273205.1 [benign]; RCV000325882.1 [benign]; 			1093	1326					WFS1 (inh=AR+AD pLI=n/a)
chr4	6293696	6293696	C	G	het	hom	wt		QUAL=2363;DP=58,52,67;MQM=59	WFS1	synonymous	WFS1:NM_001145853.1:synonymous:LOW:exon6/8:c.684C>G:p.Arg228Arg,WFS1:NM_006005.3:synonymous:LOW:exon6/8:c.684C>G:p.Arg228Arg		rs1801213	0.7564	0.7212	28093/13548/2082	0.6613	-0.0970		T			12.77	606201 [WFS1 (confirmed) Wolfram syndrome,222300|Deafness,autosomal dominant 6/14/38,600965|Wolfram-like syndrome,autosomal dominant,614296|Diabetes mellitus,noninsulin-dependent,association with,125853|Cataract 41,116400];	RCV000038665.7 [other]; RCV000261705.1 [benign]; RCV000319343.1 [benign]; 		COSM448012	1372	1196					WFS1 (inh=AR+AD pLI=n/a)
chr4	6302519	6302519	G	A	het	hom	wt	pred_pathogenic	QUAL=21813;DP=394,524,661;MQM=60	WFS1	missense	WFS1:NM_001145853.1:missense:MODERATE:exon8/8:c.997G>A:p.Val333Ile,WFS1:NM_006005.3:missense:MODERATE:exon8/8:c.997G>A:p.Val333Ile		rs1801212	0.8844	0.7818	37650/17117/4752	0.7624	3.7380	T,T	T	B	D,D	5.06	606201 [WFS1 (confirmed) Wolfram syndrome,222300|Deafness,autosomal dominant 6/14/38,600965|Wolfram-like syndrome,autosomal dominant,614296|Diabetes mellitus,noninsulin-dependent,association with,125853|Cataract 41,116400];	RCV000038668.8 [benign]; RCV000259675.1 [benign]; RCV000155337.1 [benign]; 	CM115388 [CLASS=DFP MUT=ALT PHEN="Wolframin variant" GENE=WFS1]; 		1608	1056					WFS1 (inh=AR+AD pLI=n/a)
chr4	6302545	6302545	C	T	wt	het	wt		QUAL=6917;DP=411,529,683;MQM=60	WFS1	synonymous	WFS1:NM_001145853.1:synonymous:LOW:exon8/8:c.1023C>T:p.Phe341Phe,WFS1:NM_006005.3:synonymous:LOW:exon8/8:c.1023C>T:p.Phe341Phe		rs56072215	0.0268	0.0547	237/194/0	0.0552	-0.5070		T			11.97	606201 [WFS1 (confirmed) Wolfram syndrome,222300|Deafness,autosomal dominant 6/14/38,600965|Wolfram-like syndrome,autosomal dominant,614296|Diabetes mellitus,noninsulin-dependent,association with,125853|Cataract 41,116400];	RCV000038632.9 [benign]; RCV000319531.1 [likely benign]; RCV000374136.1 [likely benign]; 			20	412					WFS1 (inh=AR+AD pLI=n/a)
chr4	6302707	6302707	C	T	het	het	wt		QUAL=9445;DP=280,442,561;MQM=60	WFS1	synonymous	WFS1:NM_001145853.1:synonymous:LOW:exon8/8:c.1185C>T:p.Val395Val,WFS1:NM_006005.3:synonymous:LOW:exon8/8:c.1185C>T:p.Val395Val		rs1801206	0.6416	0.6245	24439/11648/1139	0.6086							606201 [WFS1 (confirmed) Wolfram syndrome,222300|Deafness,autosomal dominant 6/14/38,600965|Wolfram-like syndrome,autosomal dominant,614296|Diabetes mellitus,noninsulin-dependent,association with,125853|Cataract 41,116400];	RCV000038635.10 [other]; RCV000344908.1 [benign]; RCV000380942.1 [benign]; 	CM021362 [CLASS=DP MUT=REF PHEN="Diabetes type 1 association with" GENE=WFS1]; 		1031	1343					WFS1 (inh=AR+AD pLI=n/a)
chr4	6303022	6303022	C	T	het	het	wt		QUAL=7238;DP=225,321,344;MQM=60	WFS1	synonymous	WFS1:NM_001145853.1:synonymous:LOW:exon8/8:c.1500C>T:p.Asn500Asn,WFS1:NM_006005.3:synonymous:LOW:exon8/8:c.1500C>T:p.Asn500Asn		rs1801214	0.7294	0.6595	26970/12016/2381	0.6406							606201 [WFS1 (confirmed) Wolfram syndrome,222300|Deafness,autosomal dominant 6/14/38,600965|Wolfram-like syndrome,autosomal dominant,614296|Diabetes mellitus,noninsulin-dependent,association with,125853|Cataract 41,116400];	RCV000038641.10 [other]; RCV000294241.1 [benign]; RCV000330600.1 [benign]; 			1082	1341					WFS1 (inh=AR+AD pLI=n/a)
chr4	6303247	6303247	C	T	wt	het	wt		QUAL=2223;DP=199,163,183;MQM=60	WFS1	synonymous	WFS1:NM_001145853.1:synonymous:LOW:exon8/8:c.1725C>T:p.Ala575Ala,WFS1:NM_006005.3:synonymous:LOW:exon8/8:c.1725C>T:p.Ala575Ala		rs2230719	0.0445	0.0588	252/181/32	0.0590							606201 [WFS1 (confirmed) Wolfram syndrome,222300|Deafness,autosomal dominant 6/14/38,600965|Wolfram-like syndrome,autosomal dominant,614296|Diabetes mellitus,noninsulin-dependent,association with,125853|Cataract 41,116400];	RCV000038642.11 [other]; RCV000361141.1 [likely benign]; RCV000396690.1 [likely benign]; 		COSM4159132	17	407					WFS1 (inh=AR+AD pLI=n/a)
chr4	6303354	6303354	G	A	het	het	wt	pred_pathogenic	QUAL=4679;DP=265,143,201;MQM=60	WFS1	missense	WFS1:NM_001145853.1:missense:MODERATE:exon8/8:c.1832G>A:p.Arg611His,WFS1:NM_006005.3:missense:MODERATE:exon8/8:c.1832G>A:p.Arg611His		rs734312	0.4692	0.5367	18996/9719/74	0.5341	4.7040	T,T	T	B	D,D	11.69	606201 [WFS1 (confirmed) Wolfram syndrome,222300|Deafness,autosomal dominant 6/14/38,600965|Wolfram-like syndrome,autosomal dominant,614296|Diabetes mellitus,noninsulin-dependent,association with,125853|Cataract 41,116400];	RCV000038646.10 [other]; RCV000339307.1 [benign]; RCV000404430.1 [benign]; 	CM000447 [CLASS=DP MUT=REF PHEN="Diabetes type 1 association with" GENE=WFS1]; 	COSM149634	817	1389					WFS1 (inh=AR+AD pLI=n/a)
chr4	6303844	6303844	G	A	wt	het	wt		QUAL=5513;DP=320,403,606;MQM=60	WFS1	synonymous	WFS1:NM_001145853.1:synonymous:LOW:exon8/8:c.2322G>A:p.Lys774Lys,WFS1:NM_006005.3:synonymous:LOW:exon8/8:c.2322G>A:p.Lys774Lys		rs2230721	0.0579	0.0667	329/177/34	0.0646							606201 [WFS1 (confirmed) Wolfram syndrome,222300|Deafness,autosomal dominant 6/14/38,600965|Wolfram-like syndrome,autosomal dominant,614296|Diabetes mellitus,noninsulin-dependent,association with,125853|Cataract 41,116400];	RCV000038656.11 [other]; RCV000315287.1 [likely benign]; RCV000404074.1 [likely benign]; 			20	418					WFS1 (inh=AR+AD pLI=n/a)
chr4	6303955	6303955	G	A	het	het	wt		QUAL=5440;DP=196,251,319;MQM=59	WFS1	synonymous	WFS1:NM_001145853.1:synonymous:LOW:exon8/8:c.2433G>A:p.Lys811Lys,WFS1:NM_006005.3:synonymous:LOW:exon8/8:c.2433G>A:p.Lys811Lys		rs1046314	0.6532	0.6294	24206/11393/1309	0.6091							606201 [WFS1 (confirmed) Wolfram syndrome,222300|Deafness,autosomal dominant 6/14/38,600965|Wolfram-like syndrome,autosomal dominant,614296|Diabetes mellitus,noninsulin-dependent,association with,125853|Cataract 41,116400];	RCV000038659.10 [other]; RCV000292566.1 [benign]; RCV000352148.1 [benign]; 	CM021365 [CLASS=DP MUT=REF PHEN="Diabetes type 1 association with" GENE=WFS1]; 	COSM3760688	1026	1359					WFS1 (inh=AR+AD pLI=n/a)
chr4	6304087	6304087	A	G	het	hom	wt		QUAL=9970;DP=210,247,292;MQM=60	WFS1	synonymous	WFS1:NM_001145853.1:synonymous:LOW:exon8/8:c.2565A>G:p.Ser855Ser,WFS1:NM_006005.3:synonymous:LOW:exon8/8:c.2565A>G:p.Ser855Ser		rs1046316	0.7800	0.7228	31745/15023/2981	0.6852							606201 [WFS1 (confirmed) Wolfram syndrome,222300|Deafness,autosomal dominant 6/14/38,600965|Wolfram-like syndrome,autosomal dominant,614296|Diabetes mellitus,noninsulin-dependent,association with,125853|Cataract 41,116400];	RCV000038660.10 [other]; RCV000272258.1 [benign]; RCV000329623.1 [benign]; 	CM021366 [CLASS=DP MUT=REF PHEN="Diabetes type 1 association with" GENE=WFS1]; 	COSM448013	1395	1194					WFS1 (inh=AR+AD pLI=n/a)
chr4	6304242	6304242	T	C	het	hom	wt		QUAL=13842;DP=179,359,477;MQM=59	WFS1	3'UTR	WFS1:NM_001145853.1:3'UTR:MODIFIER:exon8/8:c.*47T>C:,WFS1:NM_006005.3:3'UTR:MODIFIER:exon8/8:c.*47T>C:		rs1046317	0.7837	0.7247	30808/14412/2933	0.6888							606201 [WFS1 (confirmed) Wolfram syndrome,222300|Deafness,autosomal dominant 6/14/38,600965|Wolfram-like syndrome,autosomal dominant,614296|Diabetes mellitus,noninsulin-dependent,association with,125853|Cataract 41,116400];	RCV000288103.1 [benign]; RCV000393152.1 [benign]; 	CR1510534 [CLASS=DP MUT=REF PHEN="Diabetes type 2 association with" GENE=WFS1]; 		370	354					WFS1 (inh=AR+AD pLI=n/a)
chr4	6304285	6304285	G	A	wt	het	wt		QUAL=13815;DP=224,388,525;MQM=60	WFS1	3'UTR	WFS1:NM_001145853.1:3'UTR:MODIFIER:exon8/8:c.*90G>A:,WFS1:NM_006005.3:3'UTR:MODIFIER:exon8/8:c.*90G>A:		rs1802453	0.0789	0.0000	0/0/0	0.0132							606201 [WFS1 (confirmed) Wolfram syndrome,222300|Deafness,autosomal dominant 6/14/38,600965|Wolfram-like syndrome,autosomal dominant,614296|Diabetes mellitus,noninsulin-dependent,association with,125853|Cataract 41,116400];	RCV000310820.1 [likely benign]; RCV000367887.1 [likely benign]; 			3	44					WFS1 (inh=AR+AD pLI=n/a)
chr4	6304286	6304286	C	T	het	hom	wt		QUAL=13815;DP=224,388,525;MQM=60	WFS1	3'UTR	WFS1:NM_001145853.1:3'UTR:MODIFIER:exon8/8:c.*91C>T:,WFS1:NM_006005.3:3'UTR:MODIFIER:exon8/8:c.*91C>T:		rs1046319	0.8480	0.0000	0/0/0	0.1621							606201 [WFS1 (confirmed) Wolfram syndrome,222300|Deafness,autosomal dominant 6/14/38,600965|Wolfram-like syndrome,autosomal dominant,614296|Diabetes mellitus,noninsulin-dependent,association with,125853|Cataract 41,116400];	RCV000314379.1 [benign]; RCV000397008.1 [benign]; 			118	82					WFS1 (inh=AR+AD pLI=n/a)
chr4	6304344	6304344	G	A	het	het	wt		QUAL=10458;DP=251,521,678;MQM=60	WFS1	3'UTR	WFS1:NM_001145853.1:3'UTR:MODIFIER:exon8/8:c.*149G>A:,WFS1:NM_006005.3:3'UTR:MODIFIER:exon8/8:c.*149G>A:		rs1046320	0.6066	0.0000	0/0/0	0.5593							606201 [WFS1 (confirmed) Wolfram syndrome,222300|Deafness,autosomal dominant 6/14/38,600965|Wolfram-like syndrome,autosomal dominant,614296|Diabetes mellitus,noninsulin-dependent,association with,125853|Cataract 41,116400];	RCV000317741.1 [benign]; RCV000356153.1 [benign]; 			75	98					WFS1 (inh=AR+AD pLI=n/a)
chr4	6304448	6304448	G	A	wt	het	wt		QUAL=7325;DP=497,598,774;MQM=60	WFS1	3'UTR	WFS1:NM_001145853.1:3'UTR:MODIFIER:exon8/8:c.*253G>A:,WFS1:NM_006005.3:3'UTR:MODIFIER:exon8/8:c.*253G>A:		rs1046322	0.0819	0.0000	0/0/0	0.0175							606201 [WFS1 (confirmed) Wolfram syndrome,222300|Deafness,autosomal dominant 6/14/38,600965|Wolfram-like syndrome,autosomal dominant,614296|Diabetes mellitus,noninsulin-dependent,association with,125853|Cataract 41,116400];	RCV000323988.1 [likely benign]; RCV000380949.1 [likely benign]; 	CR137743 [CLASS=DFP MUT=ALT PHEN="Higher aggression association with" GENE=WFS1]; 		4	48					WFS1 (inh=AR+AD pLI=n/a)
chr4	6304762	6304762	C	G	het	wt	het		QUAL=4725;DP=191,141,159;MQM=60	WFS1	3'UTR	WFS1:NM_001145853.1:3'UTR:MODIFIER:exon8/8:c.*567C>G:,WFS1:NM_006005.3:3'UTR:MODIFIER:exon8/8:c.*567C>G:		rs12508118	0.0114	0.0000	0/0/0	0.0257							606201 [WFS1 (confirmed) Wolfram syndrome,222300|Deafness,autosomal dominant 6/14/38,600965|Wolfram-like syndrome,autosomal dominant,614296|Diabetes mellitus,noninsulin-dependent,association with,125853|Cataract 41,116400];	RCV000336866.1 [likely benign]; RCV000403353.1 [likely benign]; 			2	17					WFS1 (inh=AR+AD pLI=n/a)
chr4	6304799	6304799	G	C	het	het	wt		QUAL=4113;DP=192,126,148;MQM=59	WFS1	3'UTR	WFS1:NM_001145853.1:3'UTR:MODIFIER:exon8/8:c.*604G>C:,WFS1:NM_006005.3:3'UTR:MODIFIER:exon8/8:c.*604G>C:		rs9457	0.6262	0.0000	0/0/0	0.5428							606201 [WFS1 (confirmed) Wolfram syndrome,222300|Deafness,autosomal dominant 6/14/38,600965|Wolfram-like syndrome,autosomal dominant,614296|Diabetes mellitus,noninsulin-dependent,association with,125853|Cataract 41,116400];	RCV000302430.1 [benign]; RCV000341007.1 [benign]; 			77	94					WFS1 (inh=AR+AD pLI=n/a)
chr4	6304878	6304878	C	T	het	het	wt		QUAL=3660;DP=187,134,179;MQM=60	WFS1	3'UTR	WFS1:NM_001145853.1:3'UTR:MODIFIER:exon8/8:c.*683C>T:,WFS1:NM_006005.3:3'UTR:MODIFIER:exon8/8:c.*683C>T:		rs3200	0.6476	0.0000	0/0/0	0.5333							606201 [WFS1 (confirmed) Wolfram syndrome,222300|Deafness,autosomal dominant 6/14/38,600965|Wolfram-like syndrome,autosomal dominant,614296|Diabetes mellitus,noninsulin-dependent,association with,125853|Cataract 41,116400];	RCV000278025.1 [benign]; RCV000388760.1 [benign]; 			78	96					WFS1 (inh=AR+AD pLI=n/a)
chr4	15483288	15483288	T	C	wt	wt	het		QUAL=441;DP=127,53,50;MQM=60	CC2D2A	3'UTR,intron	CC2D2A:NM_001164720.1:3'UTR:MODIFIER:exon5/5:c.*379T>C:,CC2D2A:NM_020785.2:3'UTR:MODIFIER:exon7/7:c.*452T>C:,CC2D2A:NM_001080522.2:intron:MODIFIER:exon5/37:c.247+837T>C:	MSTB	rs3087622	0.2033	0.0000	0/0/0	0.0515							612013 [CC2D2A (confirmed) Joubert syndrome 9,612285|Meckel syndrome 6,612284|COACH syndrome,216360];				32	112					CC2D2A (inh=AR pLI=0.00)
chr4	15568992	15568992	T	C	hom	hom	het		QUAL=19703;DP=236,232,327;MQM=59	CC2D2A	splice_region&intron	CC2D2A:NM_001080522.2:splice_region&intron:LOW:exon25/37:c.3183-8T>C:		rs13121363	0.6625	0.7122	30227/17461/1967	0.6940							612013 [CC2D2A (confirmed) Joubert syndrome 9,612285|Meckel syndrome 6,612284|COACH syndrome,216360];	RCV000114172.3 [other]; RCV000277403.1 [benign]; RCV000367210.1 [benign]; 			1400	1038					CC2D2A (inh=AR pLI=0.00)
chr4	15569018	15569018	G	A	wt	wt	het		QUAL=4565;DP=301,285,389;MQM=60	CC2D2A	synonymous	CC2D2A:NM_001080522.2:synonymous:LOW:exon26/38:c.3201G>A:p.Ser1067Ser		rs73125627	0.1518	0.2120	2924/1973/85	0.2073							612013 [CC2D2A (confirmed) Joubert syndrome 9,612285|Meckel syndrome 6,612284|COACH syndrome,216360];	RCV000114173.3 [other]; RCV000328791.1 [likely benign]; RCV000383144.1 [likely benign]; 		COSM1131209, COSM3760450	159	933					CC2D2A (inh=AR pLI=0.00)
chr4	15603069	15603069	G	C	hom	hom	het		QUAL=21251;DP=298,229,296;MQM=60	CC2D2A	3'UTR	CC2D2A:NM_001080522.2:3'UTR:MODIFIER:exon38/38:c.*21G>C:		rs1134634	0.5669	0.6053	7077/4110/793	0.4890							612013 [CC2D2A (confirmed) Joubert syndrome 9,612285|Meckel syndrome 6,612284|COACH syndrome,216360];	RCV000243242.1 [benign]; RCV000291712.1 [likely benign]; RCV000381390.1 [likely benign]; 			683	820					CC2D2A (inh=AR pLI=0.00)
chr4	17488064	17488064	T	C	hom	hom	hom		QUAL=31275;DP=285,305,362;MQM=60	QDPR	3'UTR	QDPR:NM_000320.2:3'UTR:MODIFIER:exon7/7:c.*690A>G:,QDPR:NM_001306140.1:3'UTR:MODIFIER:exon6/6:c.*690A>G:		rs1031326	0.6260	0.0000	0/0/0	0.6319							612676 [QDPR (confirmed) Hyperphenylalaninemia,BH4-deficient,C,261630];	RCV000396492.1 [benign]; 			90	98					QDPR (inh=AR pLI=0.07)
chr4	17488072	17488072	T	C	hom	hom	hom		QUAL=33779;DP=341,313,374;MQM=59	QDPR	3'UTR	QDPR:NM_000320.2:3'UTR:MODIFIER:exon7/7:c.*682A>G:,QDPR:NM_001306140.1:3'UTR:MODIFIER:exon6/6:c.*682A>G:		rs699459	0.6595	0.0000	0/0/0	0.6743							612676 [QDPR (confirmed) Hyperphenylalaninemia,BH4-deficient,C,261630];	RCV000306402.1 [benign]; 			105	91					QDPR (inh=AR pLI=0.07)
chr4	17488132	17488132	A	G	hom	het	het		QUAL=19115;DP=355,272,355;MQM=60	QDPR	3'UTR	QDPR:NM_000320.2:3'UTR:MODIFIER:exon7/7:c.*622T>C:,QDPR:NM_001306140.1:3'UTR:MODIFIER:exon6/6:c.*622T>C:		rs10604	0.2324	0.0000	0/0/0	0.0550							612676 [QDPR (confirmed) Hyperphenylalaninemia,BH4-deficient,C,261630];	RCV000360834.1 [benign]; 			31	93					QDPR (inh=AR pLI=0.07)
chr4	17488244	17488244	G	A	hom	hom	hom		QUAL=20107;DP=300,147,174;MQM=60	QDPR	3'UTR	QDPR:NM_000320.2:3'UTR:MODIFIER:exon7/7:c.*510C>T:,QDPR:NM_001306140.1:3'UTR:MODIFIER:exon6/6:c.*510C>T:		rs1031327	0.6585	0.0000	0/0/0	0.1147							612676 [QDPR (confirmed) Hyperphenylalaninemia,BH4-deficient,C,261630];	RCV000302420.1 [benign]; 			105	92					QDPR (inh=AR pLI=0.07)
chr4	17488286	17488286	T	G	hom	hom	hom		QUAL=17438;DP=242,135,154;MQM=60	QDPR	3'UTR	QDPR:NM_000320.2:3'UTR:MODIFIER:exon7/7:c.*468A>C:,QDPR:NM_001306140.1:3'UTR:MODIFIER:exon6/6:c.*468A>C:		rs699460	0.6591	0.0000	0/0/0	0.1148							612676 [QDPR (confirmed) Hyperphenylalaninemia,BH4-deficient,C,261630];	RCV000357320.1 [benign]; 			105	92					QDPR (inh=AR pLI=0.07)
chr4	17488508	17488508	C	-	hom	het	het		QUAL=23517;DP=455,356,461;MQM=59	QDPR	3'UTR	QDPR:NM_000320.2:3'UTR:MODIFIER:exon7/7:c.*246delG:,QDPR:NM_001306140.1:3'UTR:MODIFIER:exon6/6:c.*246delG:		rs71810044	0.1877	0.0000	0/0/0	0.2355							612676 [QDPR (confirmed) Hyperphenylalaninemia,BH4-deficient,C,261630];	RCV000387060.1 [benign]; 			24	91					QDPR (inh=AR pLI=0.07)
chr4	17488533	17488533	C	T	hom	hom	hom		QUAL=38687;DP=436,328,428;MQM=59	QDPR	3'UTR	QDPR:NM_000320.2:3'UTR:MODIFIER:exon7/7:c.*221G>A:,QDPR:NM_001306140.1:3'UTR:MODIFIER:exon6/6:c.*221G>A:		rs1049582	0.6589	0.0000	0/0/0	0.5265							612676 [QDPR (confirmed) Hyperphenylalaninemia,BH4-deficient,C,261630];	RCV000293200.1 [benign]; 			105	92					QDPR (inh=AR pLI=0.07)
chr4	17488534	17488534	A	G	hom	hom	hom		QUAL=38687;DP=436,328,428;MQM=59	QDPR	3'UTR	QDPR:NM_000320.2:3'UTR:MODIFIER:exon7/7:c.*220T>C:,QDPR:NM_001306140.1:3'UTR:MODIFIER:exon6/6:c.*220T>C:		rs1049581	0.6593	0.0000	0/0/0	0.0896							612676 [QDPR (confirmed) Hyperphenylalaninemia,BH4-deficient,C,261630];	RCV000383998.1 [benign]; 			105	92					QDPR (inh=AR pLI=0.07)
chr4	17503382	17503382	C	T	hom	het	het		QUAL=13171;DP=317,117,201;MQM=60	QDPR	synonymous	QDPR:NM_000320.2:synonymous:LOW:exon4/7:c.396G>A:p.Leu132Leu,QDPR:NM_001306140.1:synonymous:LOW:exon3/6:c.303G>A:p.Leu101Leu		rs2597775	0.2324	0.2879	5710/3657/299	0.2835							612676 [QDPR (confirmed) Hyperphenylalaninemia,BH4-deficient,C,261630];	RCV000241633.1 [benign]; RCV000397696.1 [benign]; 			199	690					QDPR (inh=AR pLI=0.07)
chr4	17513724	17513724	G	C	wt	het	het	low_DP	QUAL=100;DP=317,6,10;MQM=60	QDPR	5'UTR	QDPR:NM_000320.2:5'UTR:MODIFIER:exon1/7:c.-47C>G:,QDPR:NM_001306140.1:5'UTR:MODIFIER:exon1/6:c.-47C>G:		rs2244788	0.3756	0.5057	1017/306/134	0.1622							612676 [QDPR (confirmed) Hyperphenylalaninemia,BH4-deficient,C,261630];	RCV000331176.1 [benign]; 			78	292					QDPR (inh=AR pLI=0.07)
chr4	52888026	52888026	A	C	hom	hom	hom		QUAL=10103;DP=172,61,87;MQM=60	SGCB	3'UTR	SGCB:NM_000232.4:3'UTR:MODIFIER:exon6/6:c.*2097T>G:		rs170424	0.4786	0.0000	0/0/0	0.1032							600900 [SGCB (confirmed) Muscular dystrophy,limb-girdle,type 2E,604286];	RCV000277701.1 [benign]; RCV000369836.1 [benign]; 			128	87					SGCB (inh=AR pLI=0.00)
chr4	52888499	52888499	G	A	wt	het	het		QUAL=3377;DP=298,124,157;MQM=60	SGCB	3'UTR	SGCB:NM_000232.4:3'UTR:MODIFIER:exon6/6:c.*1624C>T:		rs225163	0.3550	0.0000	0/0/0	0.0827							600900 [SGCB (confirmed) Muscular dystrophy,limb-girdle,type 2E,604286];	RCV000342259.1 [benign]; RCV000403281.1 [benign]; 			80	108					SGCB (inh=AR pLI=0.00)
chr4	52888557	52888557	A	G	wt	het	het		QUAL=3454;DP=310,122,154;MQM=60	SGCB	3'UTR	SGCB:NM_000232.4:3'UTR:MODIFIER:exon6/6:c.*1566T>C:		rs13989	0.3552	0.0000	0/0/0	0.0825							600900 [SGCB (confirmed) Muscular dystrophy,limb-girdle,type 2E,604286];	RCV000278995.1 [benign]; RCV000336538.1 [benign]; 			80	108					SGCB (inh=AR pLI=0.00)
chr4	52889602	52889602	T	A	wt	het	het		QUAL=5261;DP=366,186,195;MQM=60	SGCB	3'UTR	SGCB:NM_000232.4:3'UTR:MODIFIER:exon6/6:c.*521A>T:		rs225165	0.3490	0.0000	0/0/0	0.0988							600900 [SGCB (confirmed) Muscular dystrophy,limb-girdle,type 2E,604286];	RCV000363640.1 [benign]; RCV000394612.1 [benign]; 			80	108					SGCB (inh=AR pLI=0.00)
chr4	56236328	56236328	C	T	het	het	wt		QUAL=8042;DP=406,268,326;MQM=59	SRD5A3,SRD5A3-AS1	3'UTR,intron	SRD5A3:NM_024592.4:3'UTR:MODIFIER:exon5/5:c.*70C>T:,SRD5A3-AS1:NR_037969.1:intron:MODIFIER:exon3/3:n.364-2998G>A:		rs2538	0.2676	0.0000	0/0/0	0.0528							611715 [SRD5A3 (confirmed) Congenital disorder of glycosylation,type Iq,612379|Kahrizi syndrome,612713];	RCV000308866.1 [likely benign]; 			74	167					SRD5A3 (inh=AR pLI=0.04), SRD5A3-AS1 (inh=n/a pLI=n/a)
chr4	56236568	56236575	AACCGAAA	-	het	het	wt		QUAL=7858;DP=219,88,82;MQM=59	SRD5A3,SRD5A3-AS1	3'UTR,intron	SRD5A3:NM_024592.4:3'UTR:MODIFIER:exon5/5:c.*319_*326delACCGAAAA:,SRD5A3-AS1:NR_037969.1:intron:MODIFIER:exon3/3:n.364-3245_364-3238delTTTCGGTT:		rs767292453	0.2678	0.0000	0/0/0	0.2092							611715 [SRD5A3 (confirmed) Congenital disorder of glycosylation,type Iq,612379|Kahrizi syndrome,612713];	RCV000369292.1 [likely benign]; 			26	82					SRD5A3 (inh=AR pLI=0.04), SRD5A3-AS1 (inh=n/a pLI=n/a)
chr4	56236579	56236579	C	T	het	wt	het		QUAL=7858;DP=219,88,82;MQM=59	SRD5A3,SRD5A3-AS1	3'UTR,intron	SRD5A3:NM_024592.4:3'UTR:MODIFIER:exon5/5:c.*321C>T:,SRD5A3-AS1:NR_037969.1:intron:MODIFIER:exon3/3:n.364-3249G>A:		rs13149568	0.3592	0.0000	0/0/0	0.1999							611715 [SRD5A3 (confirmed) Congenital disorder of glycosylation,type Iq,612379|Kahrizi syndrome,612713];	RCV000276891.1 [benign]; 			20	101					SRD5A3 (inh=AR pLI=0.04), SRD5A3-AS1 (inh=n/a pLI=n/a)
chr4	56236599	56236610	CACACACACACA	-	hom	hom	wt		QUAL=3519;DP=105,67,72;MQM=59	SRD5A3,SRD5A3-AS1	3'UTR,intron	SRD5A3:NM_024592.4:3'UTR:MODIFIER:exon5/5:c.*371_*382delCACACACACACA:,SRD5A3-AS1:NR_037969.1:intron:MODIFIER:exon3/3:n.364-3280_364-3269delTGTGTGTGTGTG:	(CA)n	rs148010163;rs57961190	0.0000	0.0000	0/0/0	0.0818							611715 [SRD5A3 (confirmed) Congenital disorder of glycosylation,type Iq,612379|Kahrizi syndrome,612713];				29	29					SRD5A3 (inh=AR pLI=0.04), SRD5A3-AS1 (inh=n/a pLI=n/a)
chr4	56236599	56236600	CA	-	wt	wt	hom		QUAL=3519;DP=105,67,72;MQM=59	SRD5A3,SRD5A3-AS1	3'UTR,intron	SRD5A3:NM_024592.4:3'UTR:MODIFIER:exon5/5:c.*381_*382delCA:,SRD5A3-AS1:NR_037969.1:intron:MODIFIER:exon3/3:n.364-3270_364-3269delTG:	(CA)n	rs768037796;rs869160722	0.5535	0.0000	0/0/0	0.2442							611715 [SRD5A3 (confirmed) Congenital disorder of glycosylation,type Iq,612379|Kahrizi syndrome,612713];	RCV000261815.1 [benign]; 			5	29					SRD5A3 (inh=AR pLI=0.04), SRD5A3-AS1 (inh=n/a pLI=n/a)
chr4	56236804	56236804	G	A	het	het	wt		QUAL=3488;DP=173,93,111;MQM=59	SRD5A3,SRD5A3-AS1	3'UTR,intron	SRD5A3:NM_024592.4:3'UTR:MODIFIER:exon5/5:c.*546G>A:,SRD5A3-AS1:NR_037969.1:intron:MODIFIER:exon3/3:n.364-3474C>T:	AluJb	rs573960	0.2676	0.0000	0/0/0	0.0430							611715 [SRD5A3 (confirmed) Congenital disorder of glycosylation,type Iq,612379|Kahrizi syndrome,612713];	RCV000376255.1 [likely benign]; 			23	57					SRD5A3 (inh=AR pLI=0.04), SRD5A3-AS1 (inh=n/a pLI=n/a)
chr4	56237137	56237137	C	T	het	het	wt		QUAL=2071;DP=122,23,29;MQM=59	SRD5A3,SRD5A3-AS1	3'UTR,intron	SRD5A3:NM_024592.4:3'UTR:MODIFIER:exon5/5:c.*879C>T:,SRD5A3-AS1:NR_037969.1:intron:MODIFIER:exon3/3:n.364-3807G>A:		rs576732	0.2674	0.0000	0/0/0	0.0454							611715 [SRD5A3 (confirmed) Congenital disorder of glycosylation,type Iq,612379|Kahrizi syndrome,612713];	RCV000380494.1 [likely benign]; 			26	85					SRD5A3 (inh=AR pLI=0.04), SRD5A3-AS1 (inh=n/a pLI=n/a)
chr4	56237327	56237327	G	A	hom	het	het		QUAL=10324;DP=236,78,128;MQM=59	SRD5A3,SRD5A3-AS1	3'UTR,intron	SRD5A3:NM_024592.4:3'UTR:MODIFIER:exon5/5:c.*1069G>A:,SRD5A3-AS1:NR_037969.1:intron:MODIFIER:exon3/3:n.363+3711C>T:		rs501679	0.6887	0.0000	0/0/0	0.1137							611715 [SRD5A3 (confirmed) Congenital disorder of glycosylation,type Iq,612379|Kahrizi syndrome,612713];	RCV000345775.1 [benign]; 			84	112					SRD5A3 (inh=AR pLI=0.04), SRD5A3-AS1 (inh=n/a pLI=n/a)
chr4	56238263	56238263	T	C	het	het	wt		QUAL=4155;DP=210,102,148;MQM=60	SRD5A3,SRD5A3-AS1	3'UTR,intron	SRD5A3:NM_024592.4:3'UTR:MODIFIER:exon5/5:c.*2005T>C:,SRD5A3-AS1:NR_037969.1:intron:MODIFIER:exon3/3:n.363+2775A>G:		rs819269	0.2692	0.0000	0/0/0	0.0459							611715 [SRD5A3 (confirmed) Congenital disorder of glycosylation,type Iq,612379|Kahrizi syndrome,612713];	RCV000356067.1 [likely benign]; 			14	52					SRD5A3 (inh=AR pLI=0.04), SRD5A3-AS1 (inh=n/a pLI=n/a)
chr4	56238321	56238321	G	A	het	het	wt		QUAL=5156;DP=315,97,149;MQM=60	SRD5A3,SRD5A3-AS1	3'UTR,intron	SRD5A3:NM_024592.4:3'UTR:MODIFIER:exon5/5:c.*2063G>A:,SRD5A3-AS1:NR_037969.1:intron:MODIFIER:exon3/3:n.363+2717C>T:		rs73236134	0.0162	0.0000	0/0/0	0.0052							611715 [SRD5A3 (confirmed) Congenital disorder of glycosylation,type Iq,612379|Kahrizi syndrome,612713];	RCV000263698.1 [likely benign]; 			0	21					SRD5A3 (inh=AR pLI=0.04), SRD5A3-AS1 (inh=n/a pLI=n/a)
chr4	56238626	56238626	G	A	het	het	wt		QUAL=10173;DP=465,318,467;MQM=60	SRD5A3,SRD5A3-AS1	3'UTR,intron	SRD5A3:NM_024592.4:3'UTR:MODIFIER:exon5/5:c.*2368G>A:,SRD5A3-AS1:NR_037969.1:intron:MODIFIER:exon3/3:n.363+2412C>T:		rs819270	0.2676	0.0000	0/0/0	0.0455							611715 [SRD5A3 (confirmed) Congenital disorder of glycosylation,type Iq,612379|Kahrizi syndrome,612713];	RCV000293555.1 [likely benign]; 			14	52					SRD5A3 (inh=AR pLI=0.04), SRD5A3-AS1 (inh=n/a pLI=n/a)
chr4	56238847	56238847	G	A	hom	het	het		QUAL=16006;DP=337,174,242;MQM=60	SRD5A3,SRD5A3-AS1	3'UTR,intron	SRD5A3:NM_024592.4:3'UTR:MODIFIER:exon5/5:c.*2589G>A:,SRD5A3-AS1:NR_037969.1:intron:MODIFIER:exon3/3:n.363+2191C>T:		rs819271	0.7500	0.0000	0/0/0	0.1170							611715 [SRD5A3 (confirmed) Congenital disorder of glycosylation,type Iq,612379|Kahrizi syndrome,612713];	RCV000335842.1 [benign]; 			51	73					SRD5A3 (inh=AR pLI=0.04), SRD5A3-AS1 (inh=n/a pLI=n/a)
chr4	56239103	56239103	A	-	hom	het	het		QUAL=1680;DP=97,25,27;MQM=59	SRD5A3,SRD5A3-AS1	3'UTR,intron	SRD5A3:NM_024592.4:3'UTR:MODIFIER:exon5/5:c.*2858delA:,SRD5A3-AS1:NR_037969.1:intron:MODIFIER:exon3/3:n.363+1935delT:		rs750107327	0.0000	0.0000	0/0/0	0.2567							611715 [SRD5A3 (confirmed) Congenital disorder of glycosylation,type Iq,612379|Kahrizi syndrome,612713];	RCV000307927.1 [uncertain significance]; 			5	115					SRD5A3 (inh=AR pLI=0.04), SRD5A3-AS1 (inh=n/a pLI=n/a)
chr4	68603535	68603535	C	A	het	het	het		QUAL=6105;DP=244,84,134;MQM=60	GNRHR	3'UTR	GNRHR:NM_000406.2:3'UTR:MODIFIER:exon3/3:c.*2663G>T:,GNRHR:NM_001012763.1:3'UTR:MODIFIER:exon3/3:c.*2772G>T:		rs1038426	0.3452	0.0000	0/0/0	0.3623							138850 [GNRHR (confirmed) Hypogonadotropic hypogonadism 7 without anosmia,146110];	RCV000386570.1 [likely benign]; 	CR113071 [CLASS=DFP MUT=ALT PHEN="Polycystic ovary syndrome association with" GENE=GNRHR]; 		49	111					GNRHR (inh=AD pLI=0.01)
chr4	68603702	68603702	C	T	het	het	het		QUAL=2107;DP=134,32,32;MQM=59	GNRHR	3'UTR	GNRHR:NM_000406.2:3'UTR:MODIFIER:exon3/3:c.*2496G>A:,GNRHR:NM_001012763.1:3'UTR:MODIFIER:exon3/3:c.*2605G>A:		rs1038427	0.3452	0.0000	0/0/0	0.3261							138850 [GNRHR (confirmed) Hypogonadotropic hypogonadism 7 without anosmia,146110];	RCV000290190.1 [likely benign]; 			47	101					GNRHR (inh=AD pLI=0.01)
chr4	68603757	68603757	A	G	het	wt	het		QUAL=2454;DP=112,23,46;MQM=60	GNRHR	3'UTR	GNRHR:NM_000406.2:3'UTR:MODIFIER:exon3/3:c.*2441T>C:,GNRHR:NM_001012763.1:3'UTR:MODIFIER:exon3/3:c.*2550T>C:	(AATTAT)n	rs2319657	0.0421	0.0000	0/0/0	0.0376							138850 [GNRHR (confirmed) Hypogonadotropic hypogonadism 7 without anosmia,146110];				3	23					GNRHR (inh=AD pLI=0.01)
chr4	68604032	68604032	C	T	het	het	het		QUAL=2272;DP=158,20,37;MQM=60	GNRHR	3'UTR	GNRHR:NM_000406.2:3'UTR:MODIFIER:exon3/3:c.*2166G>A:,GNRHR:NM_001012763.1:3'UTR:MODIFIER:exon3/3:c.*2275G>A:	Charlie4a	rs7666201	0.3492	0.0000	0/0/0	0.3493							138850 [GNRHR (confirmed) Hypogonadotropic hypogonadism 7 without anosmia,146110];	RCV000381028.1 [likely benign]; 			49	109					GNRHR (inh=AD pLI=0.01)
chr4	68604143	68604143	C	T	het	het	het		QUAL=4228;DP=180,78,101;MQM=60	GNRHR	3'UTR	GNRHR:NM_000406.2:3'UTR:MODIFIER:exon3/3:c.*2055G>A:,GNRHR:NM_001012763.1:3'UTR:MODIFIER:exon3/3:c.*2164G>A:		rs17635749	0.1773	0.0000	0/0/0	0.2249							138850 [GNRHR (confirmed) Hypogonadotropic hypogonadism 7 without anosmia,146110];	RCV000343215.1 [likely benign]; 			20	91					GNRHR (inh=AD pLI=0.01)
chr4	68604307	68604307	A	C	het	het	het		QUAL=6432;DP=233,106,137;MQM=60	GNRHR	3'UTR	GNRHR:NM_000406.2:3'UTR:MODIFIER:exon3/3:c.*1891T>G:,GNRHR:NM_001012763.1:3'UTR:MODIFIER:exon3/3:c.*2000T>G:		rs12508464	0.1855	0.0000	0/0/0	0.2280							138850 [GNRHR (confirmed) Hypogonadotropic hypogonadism 7 without anosmia,146110];	RCV000354694.1 [likely benign]; 			20	93					GNRHR (inh=AD pLI=0.01)
chr4	68604938	68604938	C	A	het	het	het		QUAL=10082;DP=284,199,252;MQM=60	GNRHR	3'UTR	GNRHR:NM_000406.2:3'UTR:MODIFIER:exon3/3:c.*1260G>T:,GNRHR:NM_001012763.1:3'UTR:MODIFIER:exon3/3:c.*1369G>T:		rs13150734	0.1855	0.0000	0/0/0	0.2284							138850 [GNRHR (confirmed) Hypogonadotropic hypogonadism 7 without anosmia,146110];	RCV000328188.1 [likely benign]; 			20	93					GNRHR (inh=AD pLI=0.01)
chr4	68605369	68605369	A	G	het	het	het		QUAL=7668;DP=365,94,128;MQM=60	GNRHR	3'UTR	GNRHR:NM_000406.2:3'UTR:MODIFIER:exon3/3:c.*829T>C:,GNRHR:NM_001012763.1:3'UTR:MODIFIER:exon3/3:c.*938T>C:		rs17635850	0.3492	0.0000	0/0/0	0.0642							138850 [GNRHR (confirmed) Hypogonadotropic hypogonadism 7 without anosmia,146110];	RCV000338992.1 [likely benign]; 			49	112					GNRHR (inh=AD pLI=0.01)
chr4	68605389	68605389	G	A	het	het	het		QUAL=7201;DP=331,100,123;MQM=60	GNRHR	3'UTR	GNRHR:NM_000406.2:3'UTR:MODIFIER:exon3/3:c.*809C>T:,GNRHR:NM_001012763.1:3'UTR:MODIFIER:exon3/3:c.*918C>T:		rs35683646	0.1859	0.0000	0/0/0	0.0309							138850 [GNRHR (confirmed) Hypogonadotropic hypogonadism 7 without anosmia,146110];	RCV000281409.1 [likely benign]; 			20	93					GNRHR (inh=AD pLI=0.01)
chr4	68605396	68605396	C	G	het	het	het		QUAL=7398;DP=334,109,124;MQM=60	GNRHR	3'UTR	GNRHR:NM_000406.2:3'UTR:MODIFIER:exon3/3:c.*802G>C:,GNRHR:NM_001012763.1:3'UTR:MODIFIER:exon3/3:c.*911G>C:		rs35610027	0.1859	0.0000	0/0/0	0.2187							138850 [GNRHR (confirmed) Hypogonadotropic hypogonadism 7 without anosmia,146110];	RCV000393012.1 [likely benign]; 			20	93					GNRHR (inh=AD pLI=0.01)
chr4	68605615	68605615	T	C	het	het	het		QUAL=7429;DP=277,156,187;MQM=59	GNRHR	3'UTR	GNRHR:NM_000406.2:3'UTR:MODIFIER:exon3/3:c.*583A>G:,GNRHR:NM_001012763.1:3'UTR:MODIFIER:exon3/3:c.*692A>G:		rs35845954	0.1855	0.0000	0/0/0	0.2279							138850 [GNRHR (confirmed) Hypogonadotropic hypogonadism 7 without anosmia,146110];	RCV000351476.1 [likely benign]; 			20	93					GNRHR (inh=AD pLI=0.01)
chr4	68606400	68606400	C	T	wt	wt	het	pred_pathogenic;anno_pathogenic_clinvar;anno_pathogenic_hgmd	QUAL=2243;DP=279,167,196;MQM=60	GNRHR	missense,synonymous	GNRHR:NM_000406.2:missense:MODERATE:exon3/3:c.785G>A:p.Arg262Gln,GNRHR:NM_001012763.1:synonymous:LOW:exon3/3:c.657G>A:p.Thr219Thr		rs104893837	0.0006	0.0020	1/1/0	0.0018	7.3910	D	D	D	T	35.00	138850 [GNRHR (confirmed) Hypogonadotropic hypogonadism 7 without anosmia,146110];	RCV000030908.25 [pathogenic]; 	CM970687 [CLASS=DM MUT=ALT PHEN="Hypogonadotropic hypogonadism" GENE=GNRHR]; 		0	8					GNRHR (inh=AD pLI=0.01)
chr4	68620277	68620277	T	C	hom	hom	hom		QUAL=15725;DP=278,84,114;MQM=60	GNRHR	5'UTR	GNRHR:NM_000406.2:5'UTR:MODIFIER:exon1/3:c.-224A>G:,GNRHR:NM_001012763.1:5'UTR:MODIFIER:exon1/3:c.-224A>G:		rs2627260	0.9810	0.0000	0/0/0	0.9113							138850 [GNRHR (confirmed) Hypogonadotropic hypogonadism 7 without anosmia,146110];	RCV000317207.1 [benign]; 			227	3					GNRHR (inh=AD pLI=0.01)
chr4	68620957	68620957	T	C	het	wt	het		QUAL=5435;DP=198,87,137;MQM=59	GNRHR	5'UTR	GNRHR:NM_000406.2:5'UTR:MODIFIER:exon1/3:c.-904A>G:,GNRHR:NM_001012763.1:5'UTR:MODIFIER:exon1/3:c.-904A>G:		rs6552113	0.4663	0.0000	0/0/0	0.4882							138850 [GNRHR (confirmed) Hypogonadotropic hypogonadism 7 without anosmia,146110];	RCV000307832.1 [likely benign]; 			64	112					GNRHR (inh=AD pLI=0.01)
chr4	68621197	68621197	A	G	het	wt	het		QUAL=4216;DP=162,49,76;MQM=60	GNRHR	5'UTR	GNRHR:NM_000406.2:5'UTR:MODIFIER:exon1/3:c.-1144T>C:,GNRHR:NM_001012763.1:5'UTR:MODIFIER:exon1/3:c.-1144T>C:	L2a	rs2062303	0.4417	0.0000	0/0/0	0.4272							138850 [GNRHR (confirmed) Hypogonadotropic hypogonadism 7 without anosmia,146110];	RCV000353486.1 [likely benign]; 			64	110					GNRHR (inh=AD pLI=0.01)
chr4	68621308	68621308	A	G	het	wt	het		QUAL=4739;DP=202,123,150;MQM=60	GNRHR	5'UTR	GNRHR:NM_000406.2:5'UTR:MODIFIER:exon1/3:c.-1255T>C:,GNRHR:NM_001012763.1:5'UTR:MODIFIER:exon1/3:c.-1255T>C:		rs2062302	0.4669	0.0000	0/0/0	0.4747							138850 [GNRHR (confirmed) Hypogonadotropic hypogonadism 7 without anosmia,146110];	RCV000332699.1 [likely benign]; 			64	110					GNRHR (inh=AD pLI=0.01)
chr4	68621332	68621332	C	T	het	wt	het		QUAL=6840;DP=249,149,194;MQM=60	GNRHR	5'UTR	GNRHR:NM_000406.2:5'UTR:MODIFIER:exon1/3:c.-1279G>A:,GNRHR:NM_001012763.1:5'UTR:MODIFIER:exon1/3:c.-1279G>A:	LTR16D	rs2062301	0.4659	0.0000	0/0/0	0.4748							138850 [GNRHR (confirmed) Hypogonadotropic hypogonadism 7 without anosmia,146110];	RCV000389546.1 [likely benign]; 			64	110					GNRHR (inh=AD pLI=0.01)
chr4	68621550	68621550	G	A	het	wt	het		QUAL=4756;DP=229,56,92;MQM=60	GNRHR	5'UTR_premature_start_codon_gain,5'UTR	GNRHR:NM_000406.2:5'UTR_premature_start_codon_gain:LOW:exon1/3:c.-1497C>T:,GNRHR:NM_001012763.1:5'UTR_premature_start_codon_gain:LOW:exon1/3:c.-1497C>T:,GNRHR:NM_000406.2:5'UTR:MODIFIER:exon1/3:c.-1497C>T:,GNRHR:NM_001012763.1:5'UTR:MODIFIER:exon1/3:c.-1497C>T:		rs13138607	0.4661	0.0000	0/0/0	0.5008							138850 [GNRHR (confirmed) Hypogonadotropic hypogonadism 7 without anosmia,146110];	RCV000291948.1 [likely benign]; 			65	111					GNRHR (inh=AD pLI=0.01)
chr4	68621586	68621586	A	-	het	wt	het		QUAL=4478;DP=245,49,84;MQM=60	GNRHR	5'UTR	GNRHR:NM_000406.2:5'UTR:MODIFIER:exon1/3:c.-1533delT:,GNRHR:NM_001012763.1:5'UTR:MODIFIER:exon1/3:c.-1533delT:		rs34993359	0.4675	0.0000	0/0/0	0.3285							138850 [GNRHR (confirmed) Hypogonadotropic hypogonadism 7 without anosmia,146110];	RCV000344654.1 [likely benign]; 			65	109					GNRHR (inh=AD pLI=0.01)
chr4	72425863	72425863	C	T	hom	hom	hom		QUAL=27049;DP=237,256,333;MQM=60	SLC4A4	synonymous	SLC4A4:NM_001134742.1:synonymous:LOW:exon23/25:c.2991C>T:p.His997His,SLC4A4:NM_001098484.2:synonymous:LOW:exon23/26:c.2991C>T:p.His997His,SLC4A4:NM_003759.3:synonymous:LOW:exon20/23:c.2859C>T:p.His953His		rs1453458	0.7823	0.8891	48487/30393/2232	0.8830							603345 [SLC4A4 (provisional) Renal tubular acidosis,proximal,with ocular abnormalities,604278];				1295	250					SLC4A4 (inh=AR pLI=1.00)
chr4	72433759	72433759	C	T	hom	hom	hom		QUAL=21945;DP=299,148,217;MQM=60	SLC4A4	3'UTR	SLC4A4:NM_001134742.1:3'UTR:MODIFIER:exon25/25:c.*149C>T:,SLC4A4:NM_001098484.2:3'UTR:MODIFIER:exon26/26:c.*291C>T:,SLC4A4:NM_003759.3:3'UTR:MODIFIER:exon23/23:c.*291C>T:		rs1453453	0.9115	0.0000	0/0/0	0.1524							603345 [SLC4A4 (provisional) Renal tubular acidosis,proximal,with ocular abnormalities,604278];				222	8					SLC4A4 (inh=AR pLI=1.00)
chr4	72433879	72433879	G	C	hom	hom	hom		QUAL=35339;DP=501,250,313;MQM=59	SLC4A4	3'UTR	SLC4A4:NM_001134742.1:3'UTR:MODIFIER:exon25/25:c.*269G>C:,SLC4A4:NM_001098484.2:3'UTR:MODIFIER:exon26/26:c.*411G>C:,SLC4A4:NM_003759.3:3'UTR:MODIFIER:exon23/23:c.*411G>C:		rs1453452	0.8882	0.0000	0/0/0	0.8822							603345 [SLC4A4 (provisional) Renal tubular acidosis,proximal,with ocular abnormalities,604278];	RCV000372159.1 [benign]; 			222	8					SLC4A4 (inh=AR pLI=1.00)
chr4	72434457	72434457	T	A	het	wt	het		QUAL=6533;DP=258,182,245;MQM=60	SLC4A4	3'UTR	SLC4A4:NM_001134742.1:3'UTR:MODIFIER:exon25/25:c.*847T>A:,SLC4A4:NM_001098484.2:3'UTR:MODIFIER:exon26/26:c.*989T>A:,SLC4A4:NM_003759.3:3'UTR:MODIFIER:exon23/23:c.*989T>A:		rs34921070	0.0286	0.0000	0/0/0	0.0105							603345 [SLC4A4 (provisional) Renal tubular acidosis,proximal,with ocular abnormalities,604278];	RCV000308244.1 [likely benign]; 			3	27					SLC4A4 (inh=AR pLI=1.00)
chr4	72435944	72435973	TAACTCATCATTTCAGCCTCTGAGTAGAGG	-	hom	hom	hom		QUAL=15889;DP=263,145,198;MQM=59	SLC4A4	3'UTR	SLC4A4:NM_001134742.1:3'UTR:MODIFIER:exon25/25:c.*2337_*2366delCTCATCATTTCAGCCTCTGAGTAGAGGTAA:,SLC4A4:NM_001098484.2:3'UTR:MODIFIER:exon26/26:c.*2479_*2508delCTCATCATTTCAGCCTCTGAGTAGAGGTAA:,SLC4A4:NM_003759.3:3'UTR:MODIFIER:exon23/23:c.*2479_*2508delCTCATCATTTCAGCCTCTGAGTAGAGGTAA:		rs71822971	0.3185	0.0000	0/0/0	0.3697							603345 [SLC4A4 (provisional) Renal tubular acidosis,proximal,with ocular abnormalities,604278];				50	105					SLC4A4 (inh=AR pLI=1.00)
chr4	72436235	72436235	A	G	hom	hom	hom		QUAL=31106;DP=427,216,289;MQM=60	SLC4A4	3'UTR	SLC4A4:NM_001134742.1:3'UTR:MODIFIER:exon25/25:c.*2625A>G:,SLC4A4:NM_001098484.2:3'UTR:MODIFIER:exon26/26:c.*2767A>G:,SLC4A4:NM_003759.3:3'UTR:MODIFIER:exon23/23:c.*2767A>G:		rs1043218	0.6206	0.0000	0/0/0	0.1202							603345 [SLC4A4 (provisional) Renal tubular acidosis,proximal,with ocular abnormalities,604278];	RCV000319414.1 [benign]; 			125	84					SLC4A4 (inh=AR pLI=1.00)
chr4	72436498	72436498	G	A	hom	hom	hom		QUAL=29711;DP=322,252,338;MQM=60	SLC4A4	3'UTR	SLC4A4:NM_001134742.1:3'UTR:MODIFIER:exon25/25:c.*2888G>A:,SLC4A4:NM_001098484.2:3'UTR:MODIFIER:exon26/26:c.*3030G>A:,SLC4A4:NM_003759.3:3'UTR:MODIFIER:exon23/23:c.*3030G>A:		rs9997127	0.9191	0.0000	0/0/0	0.8887							603345 [SLC4A4 (provisional) Renal tubular acidosis,proximal,with ocular abnormalities,604278];				222	8					SLC4A4 (inh=AR pLI=1.00)
chr4	72436804	72436804	G	A	hom	hom	hom		QUAL=27566;DP=426,168,231;MQM=60	SLC4A4	3'UTR	SLC4A4:NM_001134742.1:3'UTR:MODIFIER:exon25/25:c.*3194G>A:,SLC4A4:NM_001098484.2:3'UTR:MODIFIER:exon26/26:c.*3336G>A:,SLC4A4:NM_003759.3:3'UTR:MODIFIER:exon23/23:c.*3336G>A:		rs9997398	0.9191	0.0000	0/0/0	0.1526							603345 [SLC4A4 (provisional) Renal tubular acidosis,proximal,with ocular abnormalities,604278];				222	8					SLC4A4 (inh=AR pLI=1.00)
chr4	79186171	79186171	G	A	hom	hom	hom		QUAL=26911;DP=357,209,278;MQM=60	FRAS1	splice_region&intron	FRAS1:NM_025074.6:splice_region&intron:LOW:exon6/73:c.604-8G>A:,FRAS1:NM_001166133.1:splice_region&intron:LOW:exon6/41:c.604-8G>A:		rs2867014	0.9221	0.9741	56632/32848/3056	0.9399							607830 [FRAS1 (provisional) Fraser syndrome,219000];	RCV000252006.1 [benign]; RCV000381460.1 [benign]; 		COSM4003160, COSM4003159, COSM4003158, COSM4003161	1540	25					FRAS1 (inh=AR pLI=0.00)
chr4	79188595	79188595	C	T	het	wt	het		QUAL=6576;DP=176,319,411;MQM=59	FRAS1	splice_region&intron	FRAS1:NM_025074.6:splice_region&intron:LOW:exon9/73:c.981+9C>T:,FRAS1:NM_001166133.1:splice_region&intron:LOW:exon9/41:c.981+9C>T:		rs112081709	0.0092	0.0222	27/23/0	0.0190							607830 [FRAS1 (provisional) Fraser syndrome,219000];	RCV000308483.1 [likely benign]; 			1	60					FRAS1 (inh=AR pLI=0.00)
chr4	79205699	79205699	T	A	het	het	het	pred_pathogenic	QUAL=10843;DP=209,292,410;MQM=60	FRAS1	missense	FRAS1:NM_025074.6:missense:MODERATE:exon13/74:c.1396T>A:p.Leu466Ile,FRAS1:NM_001166133.1:missense:MODERATE:exon13/42:c.1396T>A:p.Leu466Ile		rs12504081	0.3211	0.3508	7558/4179/160	0.3430	0.9550	.,T,T,T,T	T,T	.,P,P,D,D	.,T,T,T	21.10	607830 [FRAS1 (provisional) Fraser syndrome,219000];	RCV000243148.1 [benign]; RCV000333069.1 [benign]; 		COSM4003163, COSM4003162, COSM4003164, COSM4003165	188	724					FRAS1 (inh=AR pLI=0.00)
chr4	79238649	79238649	T	C	het	het	hom		QUAL=9255;DP=192,147,194;MQM=60	FRAS1	synonymous,sequence_feature	FRAS1:NM_025074.6:synonymous:LOW:exon17/74:c.1947T>C:p.His649His,FRAS1:NM_001166133.1:synonymous:LOW:exon17/42:c.1947T>C:p.His649His,FRAS1:NM_025074.6:sequence_feature:LOW:exon17/74:c.1947T>C:,FRAS1:NM_001166133.1:sequence_feature:LOW:exon17/42:c.1947T>C:		rs345514	0.0000	0.7442	33581/19735/3516	0.7103	-2.4890		T,T			0.03	607830 [FRAS1 (provisional) Fraser syndrome,219000];	RCV000175235.2 [benign]; RCV000407507.1 [benign]; 		COSM4159211, COSM4159212, COSM4159210, COSM4159209	786	641					FRAS1 (inh=AR pLI=0.00)
chr4	79240063	79240063	A	G	het	het	het		QUAL=8809;DP=263,175,216;MQM=59	FRAS1	missense	FRAS1:NM_025074.6:missense:MODERATE:exon18/74:c.2060A>G:p.Asp687Gly,FRAS1:NM_001166133.1:missense:MODERATE:exon18/42:c.2060A>G:p.Asp687Gly		rs345513	0.4343	0.4101	10166/5124/1170	0.3998	0.4320	T,T,T,.,.	T,T,.	B,B,B,.,.	T,T,T,.,.	0.01	607830 [FRAS1 (provisional) Fraser syndrome,219000];	RCV000252679.1 [benign]; RCV000312084.1 [benign]; 		COSM4003168, COSM4003166, COSM4003167, COSM4003169	258	739					FRAS1 (inh=AR pLI=0.00)
chr4	79284694	79284694	C	T	wt	wt	het		QUAL=2246;DP=137,113,178;MQM=60	FRAS1	missense	FRAS1:NM_025074.6:missense:MODERATE:exon21/74:c.2450C>T:p.Ala817Val,FRAS1:NM_001166133.1:missense:MODERATE:exon21/42:c.2450C>T:p.Ala817Val		rs6835769	0.3355	0.4870	14898/10398/159	0.4667	-0.0880	T,T	T	B,B	T,T	2.18	607830 [FRAS1 (provisional) Fraser syndrome,219000];	RCV000242783.1 [benign]; RCV000378902.1 [benign]; 		COSM3760768, COSM3760766, COSM3760767	387	752					FRAS1 (inh=AR pLI=0.00)
chr4	79300993	79300993	G	A	wt	het	wt	pred_pathogenic	QUAL=824;DP=254,78,128;MQM=60	FRAS1	missense	FRAS1:NM_025074.6:missense:MODERATE:exon27/74:c.3406G>A:p.Glu1136Lys,FRAS1:NM_001166133.1:missense:MODERATE:exon27/42:c.3406G>A:p.Glu1136Lys		rs12512164	0.2133	0.2644	4482/2680/111	0.2579	3.8820	T,D	T	B,B	T,T	11.41	607830 [FRAS1 (provisional) Fraser syndrome,219000];	RCV000176766.2 [benign]; RCV000266510.1 [benign]; 		COSM1131044, COSM1131043, COSM1131042	121	599					FRAS1 (inh=AR pLI=0.00)
chr4	79343111	79343111	G	A	wt	wt	het		QUAL=3312;DP=220,213,293;MQM=60	FRAS1	synonymous	FRAS1:NM_025074.6:synonymous:LOW:exon34/74:c.4635G>A:p.Pro1545Pro,FRAS1:NM_001166133.1:synonymous:LOW:exon34/42:c.4635G>A:p.Pro1545Pro		rs78575519	0.0990	0.1786	2361/1920/42	0.1751							607830 [FRAS1 (provisional) Fraser syndrome,219000];	RCV000243307.1 [benign]; RCV000349386.1 [likely benign]; 			55	450					FRAS1 (inh=AR pLI=0.00)
chr4	79371474	79371474	C	T	wt	wt	het		QUAL=2506;DP=133,97,182;MQM=60	FRAS1	synonymous	FRAS1:NM_025074.6:synonymous:LOW:exon45/74:c.6444C>T:p.Thr2148Thr		rs17003235	0.1496	0.1686	2140/1557/371	0.1666	-0.5850		T			12.11	607830 [FRAS1 (provisional) Fraser syndrome,219000];	RCV000243803.1 [benign]; RCV000396201.1 [benign]; 			52	415					FRAS1 (inh=AR pLI=0.00)
chr4	79372930	79372930	C	T	hom	hom	hom		QUAL=18800;DP=171,171,241;MQM=60	FRAS1	synonymous	FRAS1:NM_025074.6:synonymous:LOW:exon46/74:c.6468C>T:p.His2156His		rs753752	0.5795	0.6829	27638/18398/1428	0.6645	-2.3510		T			7.84	607830 [FRAS1 (provisional) Fraser syndrome,219000];	RCV000178609.3 [benign]; RCV000309112.1 [benign]; 		COSM1131036, COSM1131035	731	637					FRAS1 (inh=AR pLI=0.00)
chr4	79385632	79385632	C	T	het	wt	het	pred_pathogenic	QUAL=10054;DP=353,254,344;MQM=60	FRAS1	synonymous	FRAS1:NM_025074.6:synonymous:LOW:exon49/74:c.6924C>T:p.Val2308Val		rs13123710	0.0244	0.0583	286/239/1	0.0576	2.6800					13.93	607830 [FRAS1 (provisional) Fraser syndrome,219000];	RCV000253422.1 [benign]; RCV000354292.1 [likely benign]; 			9	176					FRAS1 (inh=AR pLI=0.00)
chr4	79385719	79385719	G	A	het	het	het		QUAL=11143;DP=284,232,323;MQM=60	FRAS1	synonymous	FRAS1:NM_025074.6:synonymous:LOW:exon49/74:c.7011G>A:p.Ala2337Ala		rs6851427	0.2975	0.3658	8459/5063/140	0.3563	-2.2490		T			9.91	607830 [FRAS1 (provisional) Fraser syndrome,219000];	RCV000246034.1 [benign]; RCV000376269.1 [benign]; 		COSM3760769, COSM3760770	205	707					FRAS1 (inh=AR pLI=0.00)
chr4	79387442	79387442	C	T	het	het	het		QUAL=13885;DP=359,351,538;MQM=59	FRAS1	synonymous	FRAS1:NM_025074.6:synonymous:LOW:exon50/74:c.7110C>T:p.His2370His		rs7660664	0.3221	0.3169	6533/4256/1175	0.3142	-0.0540		T			12.91	607830 [FRAS1 (provisional) Fraser syndrome,219000];	RCV000249146.1 [benign]; RCV000351573.1 [benign]; 		COSM1131033, COSM1131032	154	681					FRAS1 (inh=AR pLI=0.00)
chr4	79387464	79387464	A	G	hom	hom	hom	pred_pathogenic	QUAL=42740;DP=437,353,540;MQM=60	FRAS1	missense	FRAS1:NM_025074.6:missense:MODERATE:exon50/74:c.7132A>G:p.Lys2378Glu		rs7684722	0.9677	0.9901	59254/33229/4018	0.9567	7.6740	.,T	T,T	.,B	.,T	17.36	607830 [FRAS1 (provisional) Fraser syndrome,219000];	RCV000253922.1 [benign]; RCV000395153.1 [benign]; 			1555	9					FRAS1 (inh=AR pLI=0.00)
chr4	79400868	79400868	C	T	het	het	het		QUAL=7615;DP=308,171,221;MQM=59	FRAS1	synonymous	FRAS1:NM_025074.6:synonymous:LOW:exon56/74:c.8439C>T:p.Asp2813Asp		rs11098194	0.2913	0.3904	7770/4810/133	0.3499	1.3810		T			6.49	607830 [FRAS1 (provisional) Fraser syndrome,219000];	RCV000251274.1 [benign]; RCV000385525.1 [benign]; 		COSM3760774, COSM3760773	204	663					FRAS1 (inh=AR pLI=0.00)
chr4	79403682	79403682	C	T	wt	wt	het		QUAL=2273;DP=169,139,181;MQM=60	FRAS1	synonymous	FRAS1:NM_025074.6:synonymous:LOW:exon58/74:c.8745C>T:p.Phe2915Phe		rs41327848	0.1609	0.1689	2236/1511/530	0.1677	1.1990		T			15.21	607830 [FRAS1 (provisional) Fraser syndrome,219000];	RCV000243075.1 [benign]; RCV000307968.1 [benign]; 			48	397					FRAS1 (inh=AR pLI=0.00)
chr4	79420869	79420869	C	T	het	het	wt		QUAL=2918;DP=169,95,144;MQM=60	FRAS1	splice_region&intron	FRAS1:NM_025074.6:splice_region&intron:LOW:exon60/73:c.9116-6C>T:		rs76630865	0.1725	0.1790	2016/1223/146	0.1581							607830 [FRAS1 (provisional) Fraser syndrome,219000];	RCV000241899.1 [benign]; 			64	448					FRAS1 (inh=AR pLI=0.00)
chr4	79420870	79420870	C	G	het	het	wt		QUAL=2918;DP=169,95,144;MQM=60	FRAS1	splice_region&intron	FRAS1:NM_025074.6:splice_region&intron:LOW:exon60/73:c.9116-5C>G:		rs7695038	0.5917	0.5076	16318/6527/2057	0.4655							607830 [FRAS1 (provisional) Fraser syndrome,219000];	RCV000250938.1 [benign]; RCV000263121.1 [benign]; 			436	718					FRAS1 (inh=AR pLI=0.00)
chr4	79421011	79421011	G	T	wt	wt	het		QUAL=2747;DP=291,179,255;MQM=60	FRAS1	synonymous	FRAS1:NM_025074.6:synonymous:LOW:exon61/74:c.9252G>T:p.Arg3084Arg		rs11933630	0.0807	0.1428	1616/1423/32	0.1441	-0.1890					8.66	607830 [FRAS1 (provisional) Fraser syndrome,219000];	RCV000246697.1 [benign]; RCV000342606.1 [likely benign]; 			42	374					FRAS1 (inh=AR pLI=0.00)
chr4	79434685	79434685	T	G	wt	wt	het	pred_pathogenic	QUAL=4513;DP=289,281,355;MQM=60	FRAS1	missense	FRAS1:NM_025074.6:missense:MODERATE:exon65/74:c.10153T>G:p.Tyr3385Asp		rs35933858	0.0797	0.1383	1522/1332/30	0.1380	1.7680	.,T	T,T	.,B	.,T	12.08	607830 [FRAS1 (provisional) Fraser syndrome,219000];	RCV000253044.1 [benign]; RCV000317853.1 [likely benign]; 			40	363					FRAS1 (inh=AR pLI=0.00)
chr4	79437155	79437155	C	T	het	het	wt		QUAL=4201;DP=204,222,306;MQM=60	FRAS1	synonymous	FRAS1:NM_025074.6:synonymous:LOW:exon66/74:c.10377C>T:p.Thr3459Thr		rs3749487	0.1765	0.1910	2009/1201/163	0.1775	-1.6450		T			12.18	607830 [FRAS1 (provisional) Fraser syndrome,219000];	RCV000244857.1 [benign]; RCV000378270.1 [benign]; 		COSM1131030, COSM1131029	63	460					FRAS1 (inh=AR pLI=0.00)
chr4	79447763	79447763	T	C	het	het	wt		QUAL=7261;DP=397,170,240;MQM=60	FRAS1	missense	FRAS1:NM_025074.6:missense:MODERATE:exon70/74:c.10877T>C:p.Val3626Ala		rs34670941	0.1454	0.1762	773/305/110	0.1151	0.3720	T	T	B	T	0.32	607830 [FRAS1 (provisional) Fraser syndrome,219000];	RCV000250854.1 [benign]; RCV000388114.1 [benign]; 			18	280					FRAS1 (inh=AR pLI=0.00)
chr4	79455714	79455714	C	G	het	het	wt		QUAL=8830;DP=468,269,366;MQM=60	FRAS1	synonymous	FRAS1:NM_025074.6:synonymous:LOW:exon71/74:c.11037C>G:p.Pro3679Pro		rs4975070	0.5150	0.4884	15351/6473/591	0.4768	0.4930		T			10.72	607830 [FRAS1 (provisional) Fraser syndrome,219000];	RCV000245809.1 [benign]; RCV000292730.1 [benign]; 		COSM4005806, COSM4005805	405	730					FRAS1 (inh=AR pLI=0.00)
chr4	79455733	79455733	C	T	het	het	wt		QUAL=7620;DP=412,250,337;MQM=60	FRAS1	synonymous	FRAS1:NM_025074.6:synonymous:LOW:exon71/74:c.11056C>T:p.Leu3686Leu		rs4975139	0.5150	0.4884	15331/6469/590	0.4767	1.1260		T			12.50	607830 [FRAS1 (provisional) Fraser syndrome,219000];	RCV000250559.1 [benign]; RCV000333665.1 [benign]; 		COSM4005807, COSM4005808	405	729					FRAS1 (inh=AR pLI=0.00)
chr4	79462311	79462311	T	A	het	het	het		QUAL=5826;DP=261,95,143;MQM=60	FRAS1	3'UTR	FRAS1:NM_025074.6:3'UTR:MODIFIER:exon74/74:c.*33T>A:		rs72659058	0.1056	0.2467	1095/948/27	0.1488							607830 [FRAS1 (provisional) Fraser syndrome,219000];	RCV000372407.1 [benign]; 			32	199					FRAS1 (inh=AR pLI=0.00)
chr4	79462560	79462560	A	T	het	het	het		QUAL=14676;DP=479,263,346;MQM=60	FRAS1	3'UTR	FRAS1:NM_025074.6:3'UTR:MODIFIER:exon74/74:c.*282A>T:		rs3749485	0.2023	0.0000	0/0/0	0.0451							607830 [FRAS1 (provisional) Fraser syndrome,219000];	RCV000342970.1 [benign]; 			20	101					FRAS1 (inh=AR pLI=0.00)
chr4	79462808	79462808	G	A	wt	het	wt		QUAL=1806;DP=408,139,208;MQM=60	FRAS1	3'UTR	FRAS1:NM_025074.6:3'UTR:MODIFIER:exon74/74:c.*530G>A:		rs544866402	0.0006	0.0000	0/0/0	0.0009							607830 [FRAS1 (provisional) Fraser syndrome,219000];	RCV000350325.1 [uncertain significance]; 			0	3					FRAS1 (inh=AR pLI=0.00)
chr4	79464432	79464432	C	T	het	het	het		QUAL=15437;DP=372,353,449;MQM=60	FRAS1	3'UTR	FRAS1:NM_025074.6:3'UTR:MODIFIER:exon74/74:c.*2154C>T:		rs3811747	0.6617	0.0000	0/0/0	0.1144							607830 [FRAS1 (provisional) Fraser syndrome,219000];	RCV000395453.1 [benign]; 			105	96					FRAS1 (inh=AR pLI=0.00)
chr4	79464767	79464767	T	C	het	het	het		QUAL=18066;DP=420,390,413;MQM=60	FRAS1	3'UTR	FRAS1:NM_025074.6:3'UTR:MODIFIER:exon74/74:c.*2489T>C:		rs11098227	0.6617	0.0000	0/0/0	0.1340							607830 [FRAS1 (provisional) Fraser syndrome,219000];	RCV000360200.1 [benign]; 			106	97					FRAS1 (inh=AR pLI=0.00)
chr4	79464978	79464978	G	A	het	het	het		QUAL=10586;DP=314,211,267;MQM=59	FRAS1	3'UTR	FRAS1:NM_025074.6:3'UTR:MODIFIER:exon74/74:c.*2700G>A:		rs11098228	0.6404	0.0000	0/0/0	0.6461							607830 [FRAS1 (provisional) Fraser syndrome,219000];	RCV000365626.1 [benign]; 			92	103					FRAS1 (inh=AR pLI=0.00)
chr4	79465100	79465100	-	TTTT	het	het	het		QUAL=12525;DP=454,231,336;MQM=59	FRAS1	3'UTR	FRAS1:NM_025074.6:3'UTR:MODIFIER:exon74/74:c.*2824_*2825insTTTT:		rs397724155	0.6406	0.0000	0/0/0	0.5787							607830 [FRAS1 (provisional) Fraser syndrome,219000];	RCV000331007.1 [benign]; 			92	103					FRAS1 (inh=AR pLI=0.00)
chr4	80823880	80823880	-	T	hom	het	hom		QUAL=4998;DP=185,69,83;MQM=59	ANTXR2	3'UTR	ANTXR2:NM_001286781.1:3'UTR:MODIFIER:exon17/17:c.*4702dupA:,ANTXR2:NM_058172.5:3'UTR:MODIFIER:exon17/17:c.*4702dupA:,ANTXR2:NM_001286780.1:3'UTR:MODIFIER:exon17/17:c.*4702dupA:		rs34821632;rs397702828	0.5996	0.0000	0/0/0	0.4044							608041 [ANTXR2 (provisional) Hyaline fibromatosis syndrome,228600];				5	209					ANTXR2 (inh=AR pLI=0.41)
chr4	80824302	80824302	-	A	het	wt	het		QUAL=9376;DP=165,112,165;MQM=58	ANTXR2	3'UTR	ANTXR2:NM_001286781.1:3'UTR:MODIFIER:exon17/17:c.*4280dupT:,ANTXR2:NM_058172.5:3'UTR:MODIFIER:exon17/17:c.*4280dupT:,ANTXR2:NM_001286780.1:3'UTR:MODIFIER:exon17/17:c.*4280dupT:	AluSz6	rs373264816	0.0000	0.0000	0/0/0	0.1016							608041 [ANTXR2 (provisional) Hyaline fibromatosis syndrome,228600];				0	38					ANTXR2 (inh=AR pLI=0.41)
chr4	80824311	80824311	G	A	hom	hom	hom		QUAL=9376;DP=165,112,165;MQM=58	ANTXR2	3'UTR	ANTXR2:NM_001286781.1:3'UTR:MODIFIER:exon17/17:c.*4272C>T:,ANTXR2:NM_058172.5:3'UTR:MODIFIER:exon17/17:c.*4272C>T:,ANTXR2:NM_001286780.1:3'UTR:MODIFIER:exon17/17:c.*4272C>T:	AluSz6	rs56708107	0.4858	0.0000	0/0/0	0.1701							608041 [ANTXR2 (provisional) Hyaline fibromatosis syndrome,228600];				68	116					ANTXR2 (inh=AR pLI=0.41)
chr4	80824527	80824527	A	T	hom	het	hom		QUAL=14991;DP=312,137,188;MQM=59	ANTXR2	3'UTR	ANTXR2:NM_001286781.1:3'UTR:MODIFIER:exon17/17:c.*4056T>A:,ANTXR2:NM_058172.5:3'UTR:MODIFIER:exon17/17:c.*4056T>A:,ANTXR2:NM_001286780.1:3'UTR:MODIFIER:exon17/17:c.*4056T>A:		rs11946205	0.2516	0.0000	0/0/0	0.2827							608041 [ANTXR2 (provisional) Hyaline fibromatosis syndrome,228600];				7	141					ANTXR2 (inh=AR pLI=0.41)
chr4	80824888	80824888	A	G	hom	hom	hom		QUAL=19263;DP=310,125,162;MQM=60	ANTXR2	3'UTR	ANTXR2:NM_001286781.1:3'UTR:MODIFIER:exon17/17:c.*3695T>C:,ANTXR2:NM_058172.5:3'UTR:MODIFIER:exon17/17:c.*3695T>C:,ANTXR2:NM_001286780.1:3'UTR:MODIFIER:exon17/17:c.*3695T>C:		rs4611863	0.9798	0.0000	0/0/0	0.8733							608041 [ANTXR2 (provisional) Hyaline fibromatosis syndrome,228600];				230	0					ANTXR2 (inh=AR pLI=0.41)
chr4	80825271	80825271	A	-	hom	hom	hom		QUAL=9431;DP=197,41,53;MQM=60	ANTXR2	3'UTR	ANTXR2:NM_001286781.1:3'UTR:MODIFIER:exon17/17:c.*3312delT:,ANTXR2:NM_058172.5:3'UTR:MODIFIER:exon17/17:c.*3312delT:,ANTXR2:NM_001286780.1:3'UTR:MODIFIER:exon17/17:c.*3312delT:		rs796643476	0.4858	0.0000	0/0/0	0.5031							608041 [ANTXR2 (provisional) Hyaline fibromatosis syndrome,228600];				75	110					ANTXR2 (inh=AR pLI=0.41)
chr4	80826920	80826920	C	T	het	het	wt		QUAL=5010;DP=325,117,147;MQM=60	ANTXR2	3'UTR	ANTXR2:NM_001286781.1:3'UTR:MODIFIER:exon17/17:c.*1663G>A:,ANTXR2:NM_058172.5:3'UTR:MODIFIER:exon17/17:c.*1663G>A:,ANTXR2:NM_001286780.1:3'UTR:MODIFIER:exon17/17:c.*1663G>A:		rs113322831	0.0200	0.0000	0/0/0	0.0339							608041 [ANTXR2 (provisional) Hyaline fibromatosis syndrome,228600];				1	27					ANTXR2 (inh=AR pLI=0.41)
chr4	80827062	80827062	T	C	hom	hom	hom		QUAL=23516;DP=251,194,281;MQM=60	ANTXR2	3'UTR	ANTXR2:NM_001286781.1:3'UTR:MODIFIER:exon17/17:c.*1521A>G:,ANTXR2:NM_058172.5:3'UTR:MODIFIER:exon17/17:c.*1521A>G:,ANTXR2:NM_001286780.1:3'UTR:MODIFIER:exon17/17:c.*1521A>G:		rs7747	0.8516	0.0000	0/0/0	0.1310							608041 [ANTXR2 (provisional) Hyaline fibromatosis syndrome,228600];				149	71					ANTXR2 (inh=AR pLI=0.41)
chr4	80827798	80827798	A	G	hom	hom	hom		QUAL=34009;DP=456,251,328;MQM=60	ANTXR2	3'UTR	ANTXR2:NM_001286781.1:3'UTR:MODIFIER:exon17/17:c.*785T>C:,ANTXR2:NM_058172.5:3'UTR:MODIFIER:exon17/17:c.*785T>C:,ANTXR2:NM_001286780.1:3'UTR:MODIFIER:exon17/17:c.*785T>C:		rs63539261	0.8492	0.0000	0/0/0	0.0977							608041 [ANTXR2 (provisional) Hyaline fibromatosis syndrome,228600];				149	71					ANTXR2 (inh=AR pLI=0.41)
chr4	80827799	80827799	A	C	hom	hom	hom		QUAL=34009;DP=456,251,328;MQM=60	ANTXR2	3'UTR	ANTXR2:NM_001286781.1:3'UTR:MODIFIER:exon17/17:c.*784T>G:,ANTXR2:NM_058172.5:3'UTR:MODIFIER:exon17/17:c.*784T>G:,ANTXR2:NM_001286780.1:3'UTR:MODIFIER:exon17/17:c.*784T>G:		rs1139638	0.8494	0.0000	0/0/0	0.0975							608041 [ANTXR2 (provisional) Hyaline fibromatosis syndrome,228600];				149	71					ANTXR2 (inh=AR pLI=0.41)
chr4	80828555	80828555	G	A	wt	het	wt		QUAL=5476;DP=544,406,492;MQM=60	ANTXR2	3'UTR	ANTXR2:NM_001286781.1:3'UTR:MODIFIER:exon17/17:c.*28C>T:,ANTXR2:NM_058172.5:3'UTR:MODIFIER:exon17/17:c.*28C>T:,ANTXR2:NM_001286780.1:3'UTR:MODIFIER:exon17/17:c.*28C>T:		rs61048419	0.1434	0.0870	810/177/539	0.0845							608041 [ANTXR2 (provisional) Hyaline fibromatosis syndrome,228600];				8	125					ANTXR2 (inh=AR pLI=0.41)
chr4	80905990	80905990	C	G	hom	het	hom	pred_pathogenic	QUAL=4954;DP=87,52,49;MQM=60	ANTXR2	missense	ANTXR2:NM_001145794.1:missense:MODERATE:exon13/16:c.1069G>C:p.Ala357Pro,ANTXR2:NM_001286781.1:missense:MODERATE:exon13/17:c.838G>C:p.Ala280Pro,ANTXR2:NM_058172.5:missense:MODERATE:exon13/17:c.1069G>C:p.Ala357Pro,ANTXR2:NM_001286780.1:missense:MODERATE:exon13/17:c.838G>C:p.Ala280Pro		rs12647691	0.8027	0.7699	32664/15944/2320	0.7124	2.2410	T,T,T,T	T	B,B,B	T,T,T,T	1.67	608041 [ANTXR2 (provisional) Hyaline fibromatosis syndrome,228600];	RCV000284632.1 [benign]; 	CM121492 [CLASS=DFP MUT=ALT PHEN="Anthrax toxin sensitivity association with" GENE=ANTXR2]; 	COSM3760783, COSM3760782	882	575					ANTXR2 (inh=AR pLI=0.41)
chr4	80977078	80977078	T	G	hom	het	hom		QUAL=9673;DP=182,80,84;MQM=60	ANTXR2	splice_region&intron	ANTXR2:NM_001145794.1:splice_region&intron:LOW:exon4/15:c.378+8A>C:,ANTXR2:NM_001286781.1:splice_region&intron:LOW:exon4/16:c.147+8A>C:,ANTXR2:NM_058172.5:splice_region&intron:LOW:exon4/16:c.378+8A>C:,ANTXR2:NM_001286780.1:splice_region&intron:LOW:exon4/16:c.147+8A>C:		rs4594664	0.6973	0.7023	9612/3853/571	0.5720							608041 [ANTXR2 (provisional) Hyaline fibromatosis syndrome,228600];	RCV000275377.1 [benign]; 			609	700					ANTXR2 (inh=AR pLI=0.41)
chr4	80993796	80993796	G	T	wt	het	wt		QUAL=387;DP=72,45,69;MQM=60	ANTXR2	5'UTR,intron	ANTXR2:NM_001145794.1:5'UTR:MODIFIER:exon1/16:c.-82C>A:,ANTXR2:NM_058172.5:5'UTR:MODIFIER:exon1/17:c.-82C>A:,ANTXR2:NM_001286781.1:intron:MODIFIER:exon1/16:c.-80+67C>A:,ANTXR2:NM_001286780.1:intron:MODIFIER:exon1/16:c.-80+753C>A:		rs13140055	0.3772	0.0000	0/0/0	0.0599							608041 [ANTXR2 (provisional) Hyaline fibromatosis syndrome,228600];	RCV000376264.1 [benign]; 			33	104					ANTXR2 (inh=AR pLI=0.41)
chr4	80994124	80994124	C	T	wt	het	wt		QUAL=37;DP=27,21,21;MQM=60	ANTXR2	5'UTR,intron	ANTXR2:NM_001145794.1:5'UTR:MODIFIER:exon1/16:c.-410G>A:,ANTXR2:NM_001286781.1:5'UTR:MODIFIER:exon1/17:c.-341G>A:,ANTXR2:NM_058172.5:5'UTR:MODIFIER:exon1/17:c.-410G>A:,ANTXR2:NM_001286780.1:intron:MODIFIER:exon1/16:c.-80+425G>A:		rs72869605	0.1426	0.0000	0/0/0	0.0297							608041 [ANTXR2 (provisional) Hyaline fibromatosis syndrome,228600];	RCV000311655.1 [likely benign]; 			12	72					ANTXR2 (inh=AR pLI=0.41)
chr4	84188850	84188850	G	A	het	wt	het		QUAL=2678;DP=143,116,111;MQM=59	COQ2	synonymous	COQ2:NM_015697.7:synonymous:LOW:exon6/7:c.990C>T:p.Ser330Ser		rs1129617	0.2103	0.2788	1012/529/24	0.1615							609825 [COQ2 (provisional) Coenzyme Q10 deficiency,primary,1,607426|Multiple system atrophy,susceptibility to,146500];	RCV000116809.4 [other]; RCV000385321.1 [likely benign]; 			177	986					COQ2 (inh=AR pLI=0.00)
chr4	84191031	84191031	A	G	het	hom	het		QUAL=10873;DP=217,174,208;MQM=60	COQ2	synonymous	COQ2:NM_015697.7:synonymous:LOW:exon5/7:c.894T>C:p.Asp298Asp		rs6535454	0.7782	0.7380	32565/16698/3262	0.7229							609825 [COQ2 (provisional) Coenzyme Q10 deficiency,primary,1,607426|Multiple system atrophy,susceptibility to,146500];	RCV000116808.4 [other]; RCV000350741.1 [benign]; 			1188	1017					COQ2 (inh=AR pLI=0.00)
chr4	84205872	84205872	C	A	hom	hom	hom	low_DP	QUAL=682;DP=5,10,9;MQM=60	COQ2	missense	COQ2:NM_015697.7:missense:MODERATE:exon1/7:c.196G>T:p.Val66Leu		rs6818847	0.6498	0.7249	3350/959/47	0.4124	-1.9210	T,T,T	T	B	T,T,T	5.04	609825 [COQ2 (provisional) Coenzyme Q10 deficiency,primary,1,607426|Multiple system atrophy,susceptibility to,146500];	RCV000116807.5 [other]; RCV000297119.1 [benign]; 			1068	861					COQ2 (inh=AR pLI=0.00)
chr4	87515790	87515790	A	C	wt	wt	het		QUAL=796;DP=72,49,64;MQM=60	PTPN13	5'UTR	PTPN13:NM_080685.2:5'UTR:MODIFIER:exon1/48:c.-158A>C:,PTPN13:NM_006264.2:5'UTR:MODIFIER:exon1/47:c.-158A>C:,PTPN13:NM_080683.2:5'UTR:MODIFIER:exon1/48:c.-158A>C:,PTPN13:NM_080684.2:5'UTR:MODIFIER:exon1/45:c.-158A>C:		rs56178389	0.2624	0.0000	0/0/0	0.3248											19	98					PTPN13 (inh=n/a pLI=0.00)
chr4	87515832	87515832	T	A	wt	wt	het		QUAL=547;DP=85,34,46;MQM=60	PTPN13	5'UTR	PTPN13:NM_080685.2:5'UTR:MODIFIER:exon1/48:c.-116T>A:,PTPN13:NM_006264.2:5'UTR:MODIFIER:exon1/47:c.-116T>A:,PTPN13:NM_080683.2:5'UTR:MODIFIER:exon1/48:c.-116T>A:,PTPN13:NM_080684.2:5'UTR:MODIFIER:exon1/45:c.-116T>A:		rs7694723	0.3319	0.0000	0/0/0	0.3407											25	92					PTPN13 (inh=n/a pLI=0.00)
chr4	87684031	87684031	A	G	het	hom	wt		QUAL=11295;DP=340,245,388;MQM=60	PTPN13	synonymous	PTPN13:NM_080685.2:synonymous:LOW:exon24/48:c.3705A>G:p.Pro1235Pro,PTPN13:NM_006264.2:synonymous:LOW:exon23/47:c.3648A>G:p.Pro1216Pro,PTPN13:NM_080683.2:synonymous:LOW:exon24/48:c.3705A>G:p.Pro1235Pro,PTPN13:NM_080684.2:synonymous:LOW:exon21/45:c.3132A>G:p.Pro1044Pro		rs710832	0.7109	0.7113	30965/18126/3402	0.7044											762	661					PTPN13 (inh=n/a pLI=0.00)
chr4	87685796	87685796	T	G	het	het	wt	pred_pathogenic	QUAL=6322;DP=262,178,196;MQM=60	PTPN13	missense	PTPN13:NM_080685.2:missense:MODERATE:exon25/48:c.4068T>G:p.Phe1356Leu,PTPN13:NM_006264.2:missense:MODERATE:exon24/47:c.4011T>G:p.Phe1337Leu,PTPN13:NM_080683.2:missense:MODERATE:exon25/48:c.4068T>G:p.Phe1356Leu,PTPN13:NM_080684.2:missense:MODERATE:exon22/45:c.3495T>G:p.Phe1165Leu		rs10033029	0.0521	0.1503	379/323/12	0.0767	2.6660	T,T,T,T,T,T	T	B,B,B,B	T,T,T,T,T	10.67					11	270					PTPN13 (inh=n/a pLI=0.00)
chr4	87692393	87692393	G	A	het	het	wt	pred_pathogenic	QUAL=9875;DP=478,312,413;MQM=60	PTPN13	missense	PTPN13:NM_080685.2:missense:MODERATE:exon31/48:c.4888G>A:p.Glu1630Lys,PTPN13:NM_006264.2:missense:MODERATE:exon30/47:c.4816G>A:p.Glu1606Lys,PTPN13:NM_080683.2:missense:MODERATE:exon31/48:c.4873G>A:p.Glu1625Lys,PTPN13:NM_080684.2:missense:MODERATE:exon28/45:c.4300G>A:p.Glu1434Lys		rs12500797	0.0443	0.0993	441/376/4	0.0782	5.2760	T,T,T,T,T,T	T	B,B,B,B	T,T,T,T,T	20.10			CM067710 [CLASS=DP MUT=ALT PHEN="Lung cancer susceptibility to association with" GENE=PTPN13]; 		10	277					PTPN13 (inh=n/a pLI=0.00)
chr4	87696470	87696470	A	G	het	het	wt		QUAL=4625;DP=269,82,114;MQM=60	PTPN13	synonymous	PTPN13:NM_080685.2:synonymous:LOW:exon34/48:c.5670A>G:p.Thr1890Thr,PTPN13:NM_006264.2:synonymous:LOW:exon33/47:c.5598A>G:p.Thr1866Thr,PTPN13:NM_080683.2:synonymous:LOW:exon34/48:c.5655A>G:p.Thr1885Thr,PTPN13:NM_080684.2:synonymous:LOW:exon31/45:c.5082A>G:p.Thr1694Thr		rs12507034	0.0705	0.0855	519/404/51	0.0850											12	281					PTPN13 (inh=n/a pLI=0.00)
chr4	87696476	87696476	G	A	het	het	wt		QUAL=4425;DP=260,84,116;MQM=60	PTPN13	synonymous	PTPN13:NM_080685.2:synonymous:LOW:exon34/48:c.5676G>A:p.Thr1892Thr,PTPN13:NM_006264.2:synonymous:LOW:exon33/47:c.5604G>A:p.Thr1868Thr,PTPN13:NM_080683.2:synonymous:LOW:exon34/48:c.5661G>A:p.Thr1887Thr,PTPN13:NM_080684.2:synonymous:LOW:exon31/45:c.5088G>A:p.Thr1696Thr		rs12499471	0.0705	0.0857	520/404/52	0.0852											12	283					PTPN13 (inh=n/a pLI=0.00)
chr4	87736307	87736307	A	C	het	het	wt		QUAL=4562;DP=249,147,178;MQM=60	PTPN13	3'UTR	PTPN13:NM_080685.2:3'UTR:MODIFIER:exon48/48:c.*603A>C:,PTPN13:NM_006264.2:3'UTR:MODIFIER:exon47/47:c.*603A>C:,PTPN13:NM_080683.2:3'UTR:MODIFIER:exon48/48:c.*603A>C:,PTPN13:NM_080684.2:3'UTR:MODIFIER:exon45/45:c.*603A>C:		rs17750575	0.0657	0.0000	0/0/0	0.0147											0	38					PTPN13 (inh=n/a pLI=0.00)
chr4	88584148	88584148	C	T	het	wt	het		QUAL=7638;DP=277,301,382;MQM=60	DMP1	synonymous	DMP1:NM_004407.3:synonymous:LOW:exon6/6:c.1218C>T:p.Ser406Ser,DMP1:NM_001079911.2:synonymous:LOW:exon5/5:c.1170C>T:p.Ser390Ser		rs2615498	0.1757	0.1915	2452/1239/25	0.1900							600980 [DMP1 (confirmed) Hypophosphatemic rickets,AR,241520];	RCV000266071.1 [benign]; 		COSM3760817	86	500					DMP1 (inh=AR pLI=0.00)
chr4	88584160	88584160	G	A	het	wt	het		QUAL=8226;DP=285,281,369;MQM=60	DMP1	synonymous	DMP1:NM_004407.3:synonymous:LOW:exon6/6:c.1230G>A:p.Glu410Glu,DMP1:NM_001079911.2:synonymous:LOW:exon5/5:c.1182G>A:p.Glu394Glu		rs2615497	0.3213	0.2594	4358/1760/849	0.2545							600980 [DMP1 (confirmed) Hypophosphatemic rickets,AR,241520];	RCV000321108.1 [benign]; 		COSM3760818	140	582					DMP1 (inh=AR pLI=0.00)
chr4	88584507	88584507	G	A	het	wt	het		QUAL=8482;DP=304,263,321;MQM=60	DMP1	3'UTR	DMP1:NM_004407.3:3'UTR:MODIFIER:exon6/6:c.*35G>A:,DMP1:NM_001079911.2:3'UTR:MODIFIER:exon5/5:c.*35G>A:		rs2627724	0.3213	0.2596	4346/1761/832	0.2529							600980 [DMP1 (confirmed) Hypophosphatemic rickets,AR,241520];	RCV000351172.1 [benign]; 			71	279					DMP1 (inh=AR pLI=0.00)
chr4	88585079	88585079	A	G	het	wt	het		QUAL=8169;DP=438,123,138;MQM=60	DMP1	3'UTR	DMP1:NM_004407.3:3'UTR:MODIFIER:exon6/6:c.*607A>G:,DMP1:NM_001079911.2:3'UTR:MODIFIER:exon5/5:c.*607A>G:	L2c	rs2627725	0.6661	0.0000	0/0/0	0.1023							600980 [DMP1 (confirmed) Hypophosphatemic rickets,AR,241520];	RCV000359119.1 [benign]; 			61	113					DMP1 (inh=AR pLI=0.00)
chr4	88585218	88585219	TT	-	het	het	het		QUAL=11094;DP=222,151,174;MQM=59	DMP1	3'UTR	DMP1:NM_004407.3:3'UTR:MODIFIER:exon6/6:c.*757_*758delTT:,DMP1:NM_001079911.2:3'UTR:MODIFIER:exon5/5:c.*757_*758delTT:		rs35239689;rs60181711	0.3486	0.0000	0/0/0	0.1939							600980 [DMP1 (confirmed) Hypophosphatemic rickets,AR,241520];	RCV000300425.1 [benign]; 			22	97					DMP1 (inh=AR pLI=0.00)
chr4	88585218	88585218	T	-	het	het	het		QUAL=11094;DP=222,151,174;MQM=59	DMP1	3'UTR	DMP1:NM_004407.3:3'UTR:MODIFIER:exon6/6:c.*758delT:,DMP1:NM_001079911.2:3'UTR:MODIFIER:exon5/5:c.*758delT:		rs34488194;rs35239689;rs398083277;rs545768168	0.4824	0.0000	0/0/0	0.2974							600980 [DMP1 (confirmed) Hypophosphatemic rickets,AR,241520];				26	126					DMP1 (inh=AR pLI=0.00)
chr4	88997102	88997102	C	T	wt	het	wt		QUAL=635;DP=298,60,93;MQM=60	PKD2	3'UTR	PKD2:NM_000297.3:3'UTR:MODIFIER:exon15/15:c.*256C>T:		rs2728121	0.1931	0.0000	0/0/0	0.0296							173910 [PKD2 (confirmed) Polycystic kidney disease 2,613095];	RCV000359175.1 [likely benign]; 			3	39					PKD2 (inh=AD pLI=1.00)
chr4	88997876	88997876	G	A	wt	het	wt		QUAL=263;DP=136,24,30;MQM=60	PKD2	3'UTR	PKD2:NM_000297.3:3'UTR:MODIFIER:exon15/15:c.*1030G>A:	AluJb	rs2725202	0.0986	0.0000	0/0/0	0.0991							173910 [PKD2 (confirmed) Polycystic kidney disease 2,613095];	RCV000349819.1 [likely benign]; 			1	34					PKD2 (inh=AD pLI=1.00)
chr4	103552709	103552709	C	T	wt	het	het		QUAL=3930;DP=239,133,178;MQM=60	MANBA	3'UTR	MANBA:NM_005908.3:3'UTR:MODIFIER:exon17/17:c.*505G>A:		rs1054037	0.5503	0.0000	0/0/0	0.5396							609489 [MANBA (confirmed) Mannosidosis,beta,248510];	RCV000282019.1 [benign]; 			82	95					MANBA (inh=AR pLI=0.00)
chr4	103552813	103552813	C	T	wt	het	het		QUAL=4143;DP=214,187,227;MQM=60	MANBA	3'UTR	MANBA:NM_005908.3:3'UTR:MODIFIER:exon17/17:c.*401G>A:		rs4013	0.5503	0.0000	0/0/0	0.5406							609489 [MANBA (confirmed) Mannosidosis,beta,248510];	RCV000406421.1 [benign]; 			82	100					MANBA (inh=AR pLI=0.00)
chr4	103552830	103552830	G	A	wt	het	het		QUAL=3927;DP=235,186,213;MQM=60	MANBA	3'UTR	MANBA:NM_005908.3:3'UTR:MODIFIER:exon17/17:c.*384C>T:		rs4019	0.5503	0.0000	0/0/0	0.5405							609489 [MANBA (confirmed) Mannosidosis,beta,248510];	RCV000297145.1 [benign]; 			82	99					MANBA (inh=AR pLI=0.00)
chr4	103553053	103553053	G	A	wt	het	het		QUAL=5827;DP=263,193,282;MQM=60	MANBA	3'UTR	MANBA:NM_005908.3:3'UTR:MODIFIER:exon17/17:c.*161C>T:		rs1054029	0.5503	0.0000	0/0/0	0.5403							609489 [MANBA (confirmed) Mannosidosis,beta,248510];	RCV000308561.1 [benign]; 			83	101					MANBA (inh=AR pLI=0.00)
chr4	103553090	103553090	A	G	wt	het	het		QUAL=7189;DP=336,238,350;MQM=60	MANBA	3'UTR	MANBA:NM_005908.3:3'UTR:MODIFIER:exon17/17:c.*124T>C:		rs3194585	0.5503	0.0000	0/0/0	0.1044							609489 [MANBA (confirmed) Mannosidosis,beta,248510];	RCV000363290.1 [benign]; 			82	102					MANBA (inh=AR pLI=0.00)
chr4	103553448	103553448	A	-	wt	het	het		QUAL=4504;DP=219,142,246;MQM=60	MANBA	splice_region&intron	MANBA:NM_005908.3:splice_region&intron:LOW:exon16/16:c.2416-10delT:		rs5860729;rs796862916	0.5539	0.5997	14960/7196/1698	0.4923							609489 [MANBA (confirmed) Mannosidosis,beta,248510];				384	751					MANBA (inh=AR pLI=0.00)
chr4	103555992	103555992	A	G	wt	het	het		QUAL=5574;DP=196,193,262;MQM=60	MANBA	synonymous	MANBA:NM_005908.3:synonymous:LOW:exon16/17:c.2368T>C:p.Leu790Leu		rs2272697	0.5497	0.5330	17832/8612/2065	0.5276							609489 [MANBA (confirmed) Mannosidosis,beta,248510];	RCV000081337.4 [benign]; RCV000374634.1 [benign]; 		COSM1131313	427	749					MANBA (inh=AR pLI=0.00)
chr4	103557077	103557077	G	A	wt	het	het	pred_pathogenic	QUAL=8957;DP=443,329,350;MQM=60	MANBA	missense	MANBA:NM_005908.3:missense:MODERATE:exon15/17:c.2102C>T:p.Thr701Met		rs2866413	0.5491	0.5327	17813/8596/2066	0.5280	1.8020	T,T	T	B,B	T,T	6.51	609489 [MANBA (confirmed) Mannosidosis,beta,248510];	RCV000081336.4 [benign]; RCV000403534.1 [benign]; 		COSM1179818	427	749					MANBA (inh=AR pLI=0.00)
chr4	103611845	103611845	C	T	hom	het	het		QUAL=8499;DP=148,135,164;MQM=60	MANBA	missense	MANBA:NM_005908.3:missense:MODERATE:exon6/17:c.757G>A:p.Val253Ile		rs227368	0.3766	0.4427	12586/7817/184	0.4206	-0.2430	T,T	T	B,B	T,T	6.84	609489 [MANBA (confirmed) Mannosidosis,beta,248510];	RCV000354084.1 [benign]; 		COSM4155100	400	715					MANBA (inh=AR pLI=0.00)
chr4	107236941	107236941	G	A	wt	het	wt		QUAL=3418;DP=557,321,375;MQM=60	AIMP1,TBCK	5'UTR,intron	AIMP1:NM_004757.3:5'UTR:MODIFIER:exon1/7:c.-586G>A:,TBCK:NM_001163435.2:intron:MODIFIER:exon1/25:c.-30+147C>T:,TBCK:NM_001163437.2:intron:MODIFIER:exon1/25:c.-30+147C>T:,TBCK:NM_001290768.1:intron:MODIFIER:exon1/26:c.-647+147C>T:,TBCK:NM_033115.4:intron:MODIFIER:exon1/23:c.-30+147C>T:,TBCK:NM_001163436.2:intron:MODIFIER:exon1/25:c.-30+764C>T:,AIMP1:NM_001142415.1:intron:MODIFIER:exon1/6:c.-26+148G>A:		rs72660532	0.0605	0.0000	0/0/0	0.0598							616899 [TBCK (provisional) Hypotonia,infantile,with psychomotor retardation and characteristic facies 3,616900]:603605 [AIMP1 (provisional) Leukodystrophy,hypomyelinating,3,260600];				0	35					AIMP1 (inh=AR pLI=0.00), TBCK (inh=n/a pLI=0.00)
chr4	107270027	107270027	G	A	het	wt	het		QUAL=8735;DP=363,228,263;MQM=60	AIMP1	3'UTR	AIMP1:NM_001142416.1:3'UTR:MODIFIER:exon7/7:c.*1178G>A:,AIMP1:NM_001142415.1:3'UTR:MODIFIER:exon7/7:c.*1178G>A:,AIMP1:NM_004757.3:3'UTR:MODIFIER:exon7/7:c.*1178G>A:		rs13534	0.1785	0.0000	0/0/0	0.0376							603605 [AIMP1 (provisional) Leukodystrophy,hypomyelinating,3,260600];				15	85					AIMP1 (inh=AR pLI=0.00)
chr4	108931039	108931039	T	C	hom	hom	hom	pred_pathogenic	QUAL=21968;DP=353,151,187;MQM=60	HADH	missense,sequence_feature	HADH:NM_001184705.2:missense:MODERATE:exon2/9:c.257T>C:p.Leu86Pro,HADH:NM_005327.4:missense:MODERATE:exon2/8:c.257T>C:p.Leu86Pro,HADH:NM_005327.4:sequence_feature:LOW:exon2/8:c.257T>C:		rs4956145	0.8690	0.9150	51193/28932/2554	0.8942	4.8010	T,T,T,T	T	B,B,B	T,T,T	10.80	601609 [HADH (confirmed) 3-hydroxyacyl-CoA dehydrogenase deficiency,231530|Hyperinsulinemic hypoglycemia,familial,4,609975];	RCV000153344.2 [benign]; 			1313	236					HADH (inh=AR pLI=0.00)
chr4	108955622	108955622	T	A	wt	het	wt		QUAL=2190;DP=406,190,276;MQM=60	HADH	3'UTR	HADH:NM_001184705.2:3'UTR:MODIFIER:exon9/9:c.*109T>A:,HADH:NM_005327.4:3'UTR:MODIFIER:exon8/8:c.*109T>A:		rs221347	0.0697	0.0000	0/0/0	0.0180							601609 [HADH (confirmed) 3-hydroxyacyl-CoA dehydrogenase deficiency,231530|Hyperinsulinemic hypoglycemia,familial,4,609975];	RCV000263458.1 [likely benign]; RCV000355889.1 [likely benign]; 			3	36					HADH (inh=AR pLI=0.00)
chr4	110661937	110661937	G	A	hom	hom	hom		QUAL=13180;DP=253,75,86;MQM=60	CFI	3'UTR	CFI:NM_001318057.1:3'UTR:MODIFIER:exon14/14:c.*112C>T:,CFI:NM_000204.4:3'UTR:MODIFIER:exon13/13:c.*112C>T:		rs551	0.9537	0.9882	27997/14744/1528	0.8710							217030 [CFI (confirmed) Complement factor I deficiency,610984|Hemolytic uremic syndrome,atypical,susceptibility to,3,612923|Macular degeneration,age-related,13,susceptibility to,615439];	RCV000344762.1 [benign]; 			942	8					CFI (inh=AR pLI=0.00)
chr4	110678925	110678925	T	C	hom	hom	hom	pred_pathogenic	QUAL=8991;DP=168,44,61;MQM=59	CFI	missense	CFI:NM_001318057.1:missense:MODERATE:exon8/14:c.922A>G:p.Thr308Ala,CFI:NM_000204.4:missense:MODERATE:exon7/13:c.898A>G:p.Thr300Ala		rs11098044	0.9669	0.9906	54184/29997/3457	0.9263	-0.2530	T,T,T	T	B,B	D,D	0.01	217030 [CFI (confirmed) Complement factor I deficiency,610984|Hemolytic uremic syndrome,atypical,susceptibility to,3,612923|Macular degeneration,age-related,13,susceptibility to,615439];				1550	10					CFI (inh=AR pLI=0.00)
chr4	113558359	113558359	C	A	wt	wt	het		QUAL=740;DP=47,33,67;MQM=60	LARP7	5'UTR,non_coding_transcript_exon	LARP7:NM_001267039.1:5'UTR:MODIFIER:exon1/15:c.-226C>A:,LARP7:NM_016648.3:5'UTR:MODIFIER:exon1/13:c.-39C>A:,LARP7:NR_049768.1:non_coding_transcript_exon:MODIFIER:exon1/13:n.240C>A:		rs28364857	0.0373	0.0000	0/0/0	0.0630							612026 [LARP7 (provisional) Alazami syndrome,615071];				2	31					LARP7 (inh=AR pLI=0.02)
chr4	113558640	113558640	C	A	wt	wt	het		QUAL=5328;DP=232,257,334;MQM=60	LARP7	5'UTR,intron	LARP7:NM_015454.2:5'UTR:MODIFIER:exon1/13:c.-122C>A:,LARP7:NM_001267039.1:intron:MODIFIER:exon1/14:c.-189-160C>A:,LARP7:NM_016648.3:intron:MODIFIER:exon1/12:c.-3+245C>A:,LARP7:NR_049768.1:intron:MODIFIER:exon1/12:n.276+245C>A:		rs78940827	0.0375	0.0000	0/0/0	0.0631							612026 [LARP7 (provisional) Alazami syndrome,615071];				2	32					LARP7 (inh=AR pLI=0.02)
chr4	113565887	113565889	AAG	-	het	het	wt		QUAL=2516;DP=107,102,121;MQM=59	LARP7	disruptive_inframe_deletion,non_coding_transcript_exon	LARP7:NM_001267039.1:disruptive_inframe_deletion:MODERATE:exon4/15:c.86_88delAAG:p.Glu29del,LARP7:NM_016648.3:disruptive_inframe_deletion:MODERATE:exon2/13:c.65_67delAAG:p.Glu22del,LARP7:NM_015454.2:disruptive_inframe_deletion:MODERATE:exon2/13:c.65_67delAAG:p.Glu22del,LARP7:NR_049768.1:non_coding_transcript_exon:MODIFIER:exon2/13:n.343_345delAAG:		rs570445594	0.0012	0.0027	1/0/0	0.0024							612026 [LARP7 (provisional) Alazami syndrome,615071];				0	10					LARP7 (inh=AR pLI=0.02)
chr4	113568359	113568359	G	C	wt	het	wt		QUAL=2418;DP=330,182,219;MQM=60	LARP7	missense,non_coding_transcript_exon	LARP7:NM_001267039.1:missense:MODERATE:exon9/15:c.672G>C:p.Glu224Asp,LARP7:NM_016648.3:missense:MODERATE:exon7/13:c.651G>C:p.Glu217Asp,LARP7:NM_015454.2:missense:MODERATE:exon7/13:c.651G>C:p.Glu217Asp,LARP7:NR_049768.1:non_coding_transcript_exon:MODIFIER:exon7/13:n.826G>C:	GA-rich	rs141178932	0.0056	0.0097	6/4/0	0.0093	0.1380	T,T,T,T	T	B,B	T,T,T,T	13.63	612026 [LARP7 (provisional) Alazami syndrome,615071];	RCV000117486.2 [likely benign]; 			0	23					LARP7 (inh=AR pLI=0.02)
chr4	119201532	119201533	TT	-	het	hom	wt		QUAL=7817;DP=307,128,161;MQM=59	PRSS12	3'UTR	PRSS12:NM_003619.3:3'UTR:MODIFIER:exon13/13:c.*1558_*1559delAA:		rs397839202	0.2312	0.0000	0/0/0	0.3204							606709 [PRSS12 (provisional) Mental retardation,autosomal recessive 1,249500];	RCV000355255.1 [benign]; 			15	59					PRSS12 (inh=AR pLI=0.00)
chr4	119201587	119201587	C	T	het	wt	het		QUAL=7535;DP=364,183,238;MQM=60	PRSS12	3'UTR	PRSS12:NM_003619.3:3'UTR:MODIFIER:exon13/13:c.*1504G>A:		rs1045817	0.0958	0.0000	0/0/0	0.0217							606709 [PRSS12 (provisional) Mental retardation,autosomal recessive 1,249500];	RCV000262931.1 [likely benign]; 			9	46					PRSS12 (inh=AR pLI=0.00)
chr4	119203221	119203221	C	T	wt	wt	het	pred_pathogenic	QUAL=6344;DP=444,376,534;MQM=60	PRSS12	missense	PRSS12:NM_003619.3:missense:MODERATE:exon13/13:c.2498G>A:p.Arg833Gln		rs17594503	0.0256	0.0440	203/180/3	0.0446	4.6440	T	T	D	D	32.00	606709 [PRSS12 (provisional) Mental retardation,autosomal recessive 1,249500];	RCV000118074.2 [likely benign]; RCV000313428.1 [likely benign]; 			4	148					PRSS12 (inh=AR pLI=0.00)
chr4	119219909	119219909	C	A	het	wt	het	pred_pathogenic	QUAL=8295;DP=248,269,362;MQM=60	PRSS12	missense	PRSS12:NM_003619.3:missense:MODERATE:exon9/13:c.1816G>T:p.Ala606Ser		rs28661939	0.1246	0.1479	1534/739/83	0.1441	0.8120	T	T	B	D	15.33	606709 [PRSS12 (provisional) Mental retardation,autosomal recessive 1,249500];	RCV000118070.2 [likely benign]; RCV000272402.1 [likely benign]; 			48	407					PRSS12 (inh=AR pLI=0.00)
chr4	119237348	119237348	T	C	het	wt	hom		QUAL=10549;DP=223,170,232;MQM=60	PRSS12	synonymous	PRSS12:NM_003619.3:synonymous:LOW:exon6/13:c.1281A>G:p.Gln427Gln		rs2292597	0.5453	0.5547	18794/9996/1198	0.5486							606709 [PRSS12 (provisional) Mental retardation,autosomal recessive 1,249500];	RCV000118068.2 [likely benign]; RCV000376373.1 [benign]; 		COSM149728	513	733					PRSS12 (inh=AR pLI=0.00)
chr4	122742217	122742217	T	C	hom	hom	hom		QUAL=18127;DP=245,103,199;MQM=60	CCNA2	missense	CCNA2:NM_001237.3:missense:MODERATE:exon3/8:c.487A>G:p.Ile163Val		rs769242	0.9687	0.9629	56293/30604/5095	0.9415	1.1430	T	T	B	T	8.60					1479	83					CCNA2 (inh=n/a pLI=0.99)
chr4	122744942	122744942	G	A	hom	hom	het		QUAL=10408;DP=61,186,214;MQM=60	CCNA2	5'UTR_premature_start_codon_gain,5'UTR	CCNA2:NM_001237.3:5'UTR_premature_start_codon_gain:LOW:exon1/8:c.-159C>T:,CCNA2:NM_001237.3:5'UTR:MODIFIER:exon1/8:c.-159C>T:	(CAGCC)n	rs769238	0.2494	0.0000	0/0/0	0.0475											32	95					CCNA2 (inh=n/a pLI=0.99)
chr4	122744979	122744979	G	A	het	het	wt		QUAL=2234;DP=52,141,191;MQM=60	CCNA2	5'UTR_premature_start_codon_gain,5'UTR	CCNA2:NM_001237.3:5'UTR_premature_start_codon_gain:LOW:exon1/8:c.-196C>T:,CCNA2:NM_001237.3:5'UTR:MODIFIER:exon1/8:c.-196C>T:		rs769237	0.0208	0.0000	0/0/0	0.0029											0	17					CCNA2 (inh=n/a pLI=0.99)
chr4	122745729	122745729	C	T	hom	hom	het		QUAL=11636;DP=199,114,137;MQM=60	BBS7	3'UTR	BBS7:NM_176824.2:3'UTR:MODIFIER:exon19/19:c.*1286G>A:		rs1507996	0.1723	0.0000	0/0/0	0.0338							607590 [BBS7 (confirmed) Bardet-Biedl syndrome 7,615984];	RCV000260314.1 [likely benign]; 			26	76					BBS7 (inh=AR pLI=0.00)
chr4	122746325	122746325	A	G	hom	hom	het		QUAL=22203;DP=411,160,217;MQM=60	BBS7	3'UTR	BBS7:NM_176824.2:3'UTR:MODIFIER:exon19/19:c.*690T>C:	MamSINE1	rs3217753	0.2494	0.0000	0/0/0	0.0477							607590 [BBS7 (confirmed) Bardet-Biedl syndrome 7,615984];	RCV000401212.1 [benign]; 			32	96					BBS7 (inh=AR pLI=0.00)
chr4	145701128	145701128	T	G	hom	hom	hom		QUAL=25863;DP=364,174,240;MQM=60	HHIP-ANAPC10	intergenic_region	HHIP-ANAPC10:HHIP-ANAPC10:intergenic_region:MODIFIER::n.145701128T>G:		rs4835188	0.9589	0.0000	0/0/0	0.8686											150	0					HHIP-ANAPC10 (inh=n/a pLI=n/a)
chr4	146572227	146572227	G	A	wt	het	wt		QUAL=3373;DP=347,305,412;MQM=60	MMAA	synonymous	MMAA:NM_172250.2:synonymous:LOW:exon5/7:c.747G>A:p.Ser249Ser		rs11721553	0.0491	0.0726	410/342/21	0.0728							607481 [MMAA (provisional) Methylmalonic aciduria,vitamin B12-responsive,251100];	RCV000126788.3 [benign]; RCV000261924.1 [likely benign]; 		COSM3760417	19	235					MMAA (inh=AR pLI=0.00)
chr4	146579194	146579194	T	C	het	het	het		QUAL=5920;DP=286,77,132;MQM=60	MMAA	3'UTR	MMAA:NM_172250.2:3'UTR:MODIFIER:exon7/7:c.*2608T>C:	MSTB	rs7699187	0.5657	0.0000	0/0/0	0.0819							607481 [MMAA (provisional) Methylmalonic aciduria,vitamin B12-responsive,251100];	RCV000338170.1 [benign]; 			33	76					MMAA (inh=AR pLI=0.00)
chr4	146579205	146579208	CTCA	-	wt	het	wt		QUAL=697;DP=259,77,133;MQM=60	MMAA	3'UTR	MMAA:NM_172250.2:3'UTR:MODIFIER:exon7/7:c.*2622_*2625delACTC:	MSTB	rs111858031	0.1354	0.0000	0/0/0	0.1191							607481 [MMAA (provisional) Methylmalonic aciduria,vitamin B12-responsive,251100];	RCV000279524.1 [likely benign]; 			2	40					MMAA (inh=AR pLI=0.00)
chr4	146579354	146579354	A	T	het	het	het		QUAL=4150;DP=147,86,127;MQM=60	MMAA	3'UTR	MMAA:NM_172250.2:3'UTR:MODIFIER:exon7/7:c.*2768A>T:	MSTB	rs7699166	0.5657	0.0000	0/0/0	0.0825							607481 [MMAA (provisional) Methylmalonic aciduria,vitamin B12-responsive,251100];	RCV000302001.1 [benign]; 			41	88					MMAA (inh=AR pLI=0.00)
chr4	146579452	146579452	A	G	het	wt	het		QUAL=7531;DP=422,103,180;MQM=60	MMAA	3'UTR	MMAA:NM_172250.2:3'UTR:MODIFIER:exon7/7:c.*2866A>G:	MIR:MIR	rs17020500	0.2742	0.0000	0/0/0	0.0473							607481 [MMAA (provisional) Methylmalonic aciduria,vitamin B12-responsive,251100];	RCV000309727.1 [benign]; 			12	85					MMAA (inh=AR pLI=0.00)
chr4	146579844	146579844	A	-	het	wt	wt		QUAL=253;DP=266,81,99;MQM=59	MMAA	3'UTR	MMAA:NM_172250.2:3'UTR:MODIFIER:exon7/7:c.*3274delA:	(A)n	rs33978754	0.2766	0.0000	0/0/0	0.0653							607481 [MMAA (provisional) Methylmalonic aciduria,vitamin B12-responsive,251100];	RCV000374061.1 [likely benign]; 			1	114					MMAA (inh=AR pLI=0.00)
chr4	148560210	148560210	G	A	wt	wt	het		QUAL=3419;DP=349,185,235;MQM=60	PRMT9	synonymous	PRMT9:NM_138364.3:synonymous:LOW:exon11/12:c.2223C>T:p.Asp741Asp,PRMT9:NM_001304458.1:synonymous:LOW:exon10/11:c.1884C>T:p.Asp628Asp		rs34852471	0.0130	0.0285	93/72/1	0.0284											2	80					PRMT9 (inh=n/a pLI=0.00)
chr4	149000024	149000024	C	T	hom	hom	hom		QUAL=21264;DP=399,115,161;MQM=60	NR3C2	3'UTR	NR3C2:NM_000901.4:3'UTR:MODIFIER:exon9/9:c.*2471G>A:,NR3C2:NM_001166104.1:3'UTR:MODIFIER:exon8/8:c.*2471G>A:		rs2871	0.7163	0.0000	0/0/0	0.1228							600983 [NR3C2 (confirmed) Pseudohypoaldosteronism type I,autosomal dominant,177735|Hypertension,early-onset,autosomal dominant,with exacerbation in pregnancy,605115];	RCV000351462.1 [benign]; 			118	110					NR3C2 (inh=AD pLI=0.93)
chr4	149001085	149001085	T	C	hom	hom	het		QUAL=19988;DP=332,172,259;MQM=60	NR3C2	3'UTR	NR3C2:NM_000901.4:3'UTR:MODIFIER:exon9/9:c.*1410A>G:,NR3C2:NM_001166104.1:3'UTR:MODIFIER:exon8/8:c.*1410A>G:		rs5534	0.5535	0.0000	0/0/0	0.1027							600983 [NR3C2 (confirmed) Pseudohypoaldosteronism type I,autosomal dominant,177735|Hypertension,early-onset,autosomal dominant,with exacerbation in pregnancy,605115];	RCV000298395.1 [benign]; 	CR1111313 [CLASS=DFP MUT=REF PHEN="Myocardial infarction increased risk association with" GENE=NR3C2]; 		85	120					NR3C2 (inh=AD pLI=0.93)
chr4	149001463	149001463	C	T	wt	wt	het		QUAL=3169;DP=197,181,249;MQM=60	NR3C2	3'UTR	NR3C2:NM_000901.4:3'UTR:MODIFIER:exon9/9:c.*1032G>A:,NR3C2:NM_001166104.1:3'UTR:MODIFIER:exon8/8:c.*1032G>A:		rs61763141	0.0615	0.0000	0/0/0	0.0151							600983 [NR3C2 (confirmed) Pseudohypoaldosteronism type I,autosomal dominant,177735|Hypertension,early-onset,autosomal dominant,with exacerbation in pregnancy,605115];	RCV000332461.1 [uncertain significance]; RCV000389272.1 [benign]; 			6	50					NR3C2 (inh=AD pLI=0.93)
chr4	149002017	149002017	T	-	hom	hom	hom		QUAL=5959;DP=121,31,37;MQM=59	NR3C2	3'UTR	NR3C2:NM_000901.4:3'UTR:MODIFIER:exon9/9:c.*478delA:,NR3C2:NM_001166104.1:3'UTR:MODIFIER:exon8/8:c.*478delA:	(T)n	rs397779293;rs63748994	0.0000	0.7082	2874/771/34	0.1391							600983 [NR3C2 (confirmed) Pseudohypoaldosteronism type I,autosomal dominant,177735|Hypertension,early-onset,autosomal dominant,with exacerbation in pregnancy,605115];				475	464					NR3C2 (inh=AD pLI=0.93)
chr4	149075970	149075970	T	G	wt	het	het	low_QUAL	QUAL=12;DP=23,25,36;MQM=58	NR3C2	synonymous,intron	NR3C2:NM_000901.4:synonymous:LOW:exon5/9:c.2097A>C:p.Pro699Pro,NR3C2:NM_001166104.1:intron:MODIFIER:exon4/7:c.2015-2206A>C:		rs780645360	0.0000	0.0003	0/0/0	0.0001							600983 [NR3C2 (confirmed) Pseudohypoaldosteronism type I,autosomal dominant,177735|Hypertension,early-onset,autosomal dominant,with exacerbation in pregnancy,605115];				1	335					NR3C2 (inh=AD pLI=0.93)
chr4	149075976	149075976	T	G	wt	het	het	low_DP	QUAL=66;DP=17,15,22;MQM=59	NR3C2	synonymous,intron	NR3C2:NM_000901.4:synonymous:LOW:exon5/9:c.2091A>C:p.Pro697Pro,NR3C2:NM_001166104.1:intron:MODIFIER:exon4/7:c.2015-2212A>C:		rs748615309	0.0000	0.0006	0/0/0	0.0001							600983 [NR3C2 (confirmed) Pseudohypoaldosteronism type I,autosomal dominant,177735|Hypertension,early-onset,autosomal dominant,with exacerbation in pregnancy,605115];			COSM1721301	3	247					NR3C2 (inh=AD pLI=0.93)
chr4	149356516	149356516	A	G	hom	hom	hom		QUAL=33543;DP=397,265,371;MQM=59	NR3C2	synonymous	NR3C2:NM_000901.4:synonymous:LOW:exon2/9:c.1497T>C:p.Asp499Asp,NR3C2:NM_001166104.1:synonymous:LOW:exon2/8:c.1497T>C:p.Asp499Asp		rs5525	0.8920	0.8819	47268/26588/4307	0.8722							600983 [NR3C2 (confirmed) Pseudohypoaldosteronism type I,autosomal dominant,177735|Hypertension,early-onset,autosomal dominant,with exacerbation in pregnancy,605115];	RCV000253646.1 [benign]; RCV000348059.1 [benign]; 			1310	242					NR3C2 (inh=AD pLI=0.93)
chr4	149357475	149357475	C	T	hom	hom	hom	pred_pathogenic	QUAL=27706;DP=370,236,247;MQM=60	NR3C2	missense	NR3C2:NM_000901.4:missense:MODERATE:exon2/9:c.538G>A:p.Val180Ile,NR3C2:NM_001166104.1:missense:MODERATE:exon2/8:c.538G>A:p.Val180Ile		rs5522	0.8920	0.8812	47201/26545/4300	0.8729	-0.3800	T,T,T,T,T,T,T	T	B,B	D,D,D,D,D,D	0.01	600983 [NR3C2 (confirmed) Pseudohypoaldosteronism type I,autosomal dominant,177735|Hypertension,early-onset,autosomal dominant,with exacerbation in pregnancy,605115];	RCV000245161.1 [benign]; RCV000313848.1 [benign]; 	CM030066 [CLASS=DFP MUT=REF PHEN="Reduced expression" GENE=NR3C2]; 		1306	244					NR3C2 (inh=AD pLI=0.93)
chr4	149358014	149358014	G	C	hom	het	het		QUAL=17721;DP=310,251,318;MQM=60	NR3C2	splice_region,5'UTR	NR3C2:NM_000901.4:splice_region:LOW:exon2/9:c.-2C>G:,NR3C2:NM_001166104.1:splice_region:LOW:exon2/8:c.-2C>G:,NR3C2:NM_000901.4:5'UTR:MODIFIER:exon2/9:c.-2C>G:,NR3C2:NM_001166104.1:5'UTR:MODIFIER:exon2/8:c.-2C>G:		rs2070951	0.5008	0.5510	16376/7303/255	0.5127							600983 [NR3C2 (confirmed) Pseudohypoaldosteronism type I,autosomal dominant,177735|Hypertension,early-onset,autosomal dominant,with exacerbation in pregnancy,605115];	RCV000248688.1 [benign]; RCV000355928.1 [benign]; 	CR030126 [CLASS=DFP MUT=REF PHEN="Increased blood pressure association with" GENE=NR3C2]; 		379	715					NR3C2 (inh=AD pLI=0.93)
chr4	159601676	159601676	C	T	hom	hom	hom	pred_pathogenic	QUAL=25364;DP=259,228,272;MQM=60	ETFDH	missense,intron	ETFDH:NM_004453.3:missense:MODERATE:exon2/13:c.92C>T:p.Thr31Ile,ETFDH:NM_001281737.1:intron:MODIFIER:exon1/11:c.35-1671C>T:		rs11559290	0.6727	0.8119	42011/25002/287	0.8056	1.1210	T	T	B	D	16.37	231675 [ETFDH (confirmed) Glutaric acidemia IIC,231680];	RCV000081080.4 [benign]; RCV000355141.1 [benign]; 		COSM4158888	1490	438					ETFDH (inh=AR pLI=0.00)
chr4	178352679	178352679	T	G	hom	hom	hom		QUAL=11591;DP=228,45,77;MQM=60	AGA	3'UTR,non_coding_transcript_exon	AGA:NM_000027.3:3'UTR:MODIFIER:exon9/9:c.*183A>C:,AGA:NM_001171988.1:3'UTR:MODIFIER:exon9/9:c.*183A>C:,AGA:NR_033655.1:non_coding_transcript_exon:MODIFIER:exon8/8:n.1276A>C:		rs1061814	0.4569	0.6106	2634/1161/36	0.1840							613228 [AGA (confirmed) Aspartylglucosaminuria,208400];	RCV000389140.1 [benign]; 			262	303					AGA (inh=AR pLI=0.00)
chr4	178359960	178359960	G	C	hom	hom	hom	pred_pathogenic	QUAL=19377;DP=243,154,203;MQM=60	AGA	missense,sequence_feature,non_coding_transcript_exon	AGA:NM_000027.3:missense:MODERATE:exon4/9:c.446C>G:p.Thr149Ser,AGA:NM_001171988.1:missense:MODERATE:exon4/9:c.446C>G:p.Thr149Ser,AGA:NM_000027.3:sequence_feature:LOW:exon4/9:c.446C>G:,AGA:NR_033655.1:non_coding_transcript_exon:MODIFIER:exon4/8:n.574C>G:		rs2228119	0.9209	0.9782	58324/33314/3038	0.9310	-0.1550	.,T,T	T,T	.,B	.,D,D	0.01	613228 [AGA (confirmed) Aspartylglucosaminuria,208400];	RCV000077944.5 [benign]; RCV000394488.1 [benign]; 			1549	13					AGA (inh=AR pLI=0.00)
chr4	184367559	184367561	CTG	-	wt	wt	het		QUAL=2779;DP=295,190,234;MQM=60	CDKN2AIP	disruptive_inframe_deletion,sequence_feature,3'UTR	CDKN2AIP:NM_017632.3:disruptive_inframe_deletion:MODERATE:exon3/3:c.723_725delTGC:p.Ala242del,CDKN2AIP:NM_017632.3:sequence_feature:MODERATE:exon3/3:c.722_724delCTG:,CDKN2AIP:NM_001317343.1:3'UTR:MODIFIER:exon3/3:c.*311_*313delTGC:		rs147291711	0.3630	0.5767	22817/18090/218	0.5451											527	454					CDKN2AIP (inh=n/a pLI=0.99)
chr4	184369040	184369040	G	A	hom	het	het		QUAL=12196;DP=289,99,141;MQM=60	CDKN2AIP	3'UTR	CDKN2AIP:NM_017632.3:3'UTR:MODIFIER:exon3/3:c.*460G>A:,CDKN2AIP:NM_001317343.1:3'UTR:MODIFIER:exon3/3:c.*1791G>A:		rs3187025	0.0719	0.0000	0/0/0	0.0136											7	39					CDKN2AIP (inh=n/a pLI=0.99)
chr4	186064424	186064424	C	T	wt	het	wt	low_DP	QUAL=587;DP=12,61,64;MQM=60	SLC25A4	5'UTR	SLC25A4:NM_001151.3:5'UTR:MODIFIER:exon1/4:c.-103C>T:		rs190592847	0.0006	0.0000	0/0/0	0.0006							103220 [SLC25A4 (confirmed) Progressive external ophthalmoplegia with mitochondrial DNA deletions,autosomal dominant 2,609283|Mitochondrial DNA depletion syndrome 12A (cardiomyopathic type) AD,617184|Mitochondrial DNA depletion syndrome 12B (cardiomyopathic type) AR,615418];	RCV000269684.1 [likely benign]; 			0	1					SLC25A4 (inh=AR+AD pLI=0.48)
chr4	186068637	186068637	A	G	hom	hom	hom		QUAL=14520;DP=213,123,119;MQM=60	SLC25A4	3'UTR	SLC25A4:NM_001151.3:3'UTR:MODIFIER:exon4/4:c.*512A>G:		rs7660552	0.9365	0.0000	0/0/0	0.9016							103220 [SLC25A4 (confirmed) Progressive external ophthalmoplegia with mitochondrial DNA deletions,autosomal dominant 2,609283|Mitochondrial DNA depletion syndrome 12A (cardiomyopathic type) AD,617184|Mitochondrial DNA depletion syndrome 12B (cardiomyopathic type) AR,615418];	RCV000265917.1 [benign]; 			187	37					SLC25A4 (inh=AR+AD pLI=0.48)
chr4	186069178	186069178	T	C	hom	het	hom		QUAL=10524;DP=154,101,139;MQM=59	SLC25A4	3'UTR	SLC25A4:NM_001151.3:3'UTR:MODIFIER:exon4/4:c.*1053T>C:	MLT1A0	rs55905558	0.4399	0.0000	0/0/0	0.5046							103220 [SLC25A4 (confirmed) Progressive external ophthalmoplegia with mitochondrial DNA deletions,autosomal dominant 2,609283|Mitochondrial DNA depletion syndrome 12A (cardiomyopathic type) AD,617184|Mitochondrial DNA depletion syndrome 12B (cardiomyopathic type) AR,615418];	RCV000282068.1 [benign]; 			51	62					SLC25A4 (inh=AR+AD pLI=0.48)
chr4	186070432	186070432	T	C	hom	het	hom		QUAL=38759;DP=462,450,565;MQM=59	SLC25A4	3'UTR	SLC25A4:NM_001151.3:3'UTR:MODIFIER:exon4/4:c.*2307T>C:		rs2046535	0.4687	0.0000	0/0/0	0.5228							103220 [SLC25A4 (confirmed) Progressive external ophthalmoplegia with mitochondrial DNA deletions,autosomal dominant 2,609283|Mitochondrial DNA depletion syndrome 12A (cardiomyopathic type) AD,617184|Mitochondrial DNA depletion syndrome 12B (cardiomyopathic type) AR,615418];	RCV000308687.1 [benign]; 			61	96					SLC25A4 (inh=AR+AD pLI=0.48)
chr4	186071068	186071068	G	A	hom	het	hom		QUAL=22208;DP=337,195,260;MQM=59	SLC25A4	3'UTR	SLC25A4:NM_001151.3:3'UTR:MODIFIER:exon4/4:c.*2943G>A:		rs7675110	0.4305	0.0000	0/0/0	0.5058							103220 [SLC25A4 (confirmed) Progressive external ophthalmoplegia with mitochondrial DNA deletions,autosomal dominant 2,609283|Mitochondrial DNA depletion syndrome 12A (cardiomyopathic type) AD,617184|Mitochondrial DNA depletion syndrome 12B (cardiomyopathic type) AR,615418];	RCV000295164.1 [benign]; 			58	97					SLC25A4 (inh=AR+AD pLI=0.48)
chr4	186997767	186997767	C	A	het	het	hom		QUAL=9373;DP=259,139,161;MQM=60	TLR3	splice_region,5'UTR	TLR3:NM_003265.2:splice_region:LOW:exon2/5:c.-7C>A:,TLR3:NM_003265.2:5'UTR:MODIFIER:exon2/5:c.-7C>A:		rs3775296	0.1817	0.1824	2017/1125/125	0.1819							603029 [TLR3 (provisional) Herpes simplex encephalitis,susceptibility to,2 613002|HIV1 infection,resistance to,609423];		CR1314907 [CLASS=DFP MUT=REF PHEN="Osteoarthritis knee association with" GENE=TLR3]; 		57	471					TLR3 (inh=n/a pLI=0.00)
chr4	187004074	187004074	C	T	het	het	wt	pred_pathogenic	QUAL=7682;DP=360,232,299;MQM=59	TLR3	missense	TLR3:NM_003265.2:missense:MODERATE:exon4/5:c.1234C>T:p.Leu412Phe		rs3775291	0.2318	0.2712	4813/2945/20	0.2704	4.0310	D,D,D,D	T	D	T,T,T	23.80	603029 [TLR3 (provisional) Herpes simplex encephalitis,susceptibility to,2 613002|HIV1 infection,resistance to,609423];	RCV000034357.3 [other]; 	CM073380 [CLASS=DFP MUT=ALT PHEN="Altered activity association with" GENE=TLR3]; 	COSM149771	118	648	1	[1] Ute Grasshoff 13.08.2014			TLR3 (inh=n/a pLI=0.00)
chr4	187004217	187004217	C	T	het	het	hom		QUAL=18798;DP=458,239,290;MQM=60	TLR3	synonymous	TLR3:NM_003265.2:synonymous:LOW:exon4/5:c.1377C>T:p.Phe459Phe		rs3775290	0.2722	0.3007	5608/3033/193	0.2988							603029 [TLR3 (provisional) Herpes simplex encephalitis,susceptibility to,2 613002|HIV1 infection,resistance to,609423];			COSM1428947	144	618					TLR3 (inh=n/a pLI=0.00)
chr4	187158034	187158034	G	A	het	hom	het	pred_pathogenic;anno_pathogenic_clinvar	QUAL=18120;DP=372,280,382;MQM=59	KLKB1	missense,5'UTR	KLKB1:NM_000892.4:missense:MODERATE:exon5/15:c.428G>A:p.Ser143Asn,KLKB1:NM_001318394.1:missense:MODERATE:exon6/15:c.314G>A:p.Ser105Asn,KLKB1:NM_001318396.1:5'UTR:MODIFIER:exon5/15:c.-210G>A:		rs3733402	0.6046	0.5365	18108/8547/2824	0.5331	3.7480	T,T,T,T,T,T,.	T,T	B,.	D,D,D,D,D,.	0.07	229000 [KLKB1 (provisional) Fletcher factor (prekallikrein) deficiency,612423];	RCV000012817.25 [pathogenic]; 	CM073166 [CLASS=DFP MUT=REF PHEN="Prekallikrein deficiency" GENE=KLKB1]; 	COSM3760537, COSM149774	378	774	2	[2] old entry - no details available			KLKB1 (inh=AR pLI=0.00)
chr4	187172665	187172665	C	T	wt	wt	het	pred_pathogenic	QUAL=5220;DP=354,277,362;MQM=60	KLKB1	missense	KLKB1:NM_000892.4:missense:MODERATE:exon9/15:c.893C>T:p.Pro298Leu,KLKB1:NM_001318394.1:missense:MODERATE:exon10/15:c.779C>T:p.Pro260Leu,KLKB1:NM_001318396.1:missense:MODERATE:exon9/15:c.287C>T:p.Pro96Leu		rs200398188	0.0002	0.0003	0/0/0	0.0003	0.1850	T,T,T,.	T,T	B,B,B,.	D,D,.	18.91	229000 [KLKB1 (provisional) Fletcher factor (prekallikrein) deficiency,612423];				0	1					KLKB1 (inh=AR pLI=0.00)
chr4	187178473	187178473	G	A	wt	wt	het	pred_pathogenic	QUAL=548;DP=93,25,66;MQM=60	KLKB1	missense,intron	KLKB1:NM_000892.4:missense:MODERATE:exon14/15:c.1679G>A:p.Arg560Gln,KLKB1:NM_001318396.1:missense:MODERATE:exon14/15:c.1073G>A:p.Arg358Gln,KLKB1:NM_001318394.1:intron:MODIFIER:exon14/14:c.1472-702G>A:		rs4253325	0.2282	0.1631	2012/377/279	0.1535	2.3240	.,T	T,T	.,B,B	.,D	16.50	229000 [KLKB1 (provisional) Fletcher factor (prekallikrein) deficiency,612423];		CM071826 [CLASS=DP MUT=ALT PHEN="Hypertension association with" GENE=KLKB1]; 	COSM3760538, COSM3760539	26	352					KLKB1 (inh=AR pLI=0.00)
chr4	187179210	187179210	T	C	het	hom	het	pred_pathogenic	QUAL=13107;DP=184,238,295;MQM=60	KLKB1	missense,synonymous	KLKB1:NM_001318394.1:missense:MODERATE:exon15/15:c.1507T>C:p.Trp503Arg,KLKB1:NM_000892.4:synonymous:LOW:exon15/15:c.1761T>C:p.Asn587Asn,KLKB1:NM_001318396.1:synonymous:LOW:exon15/15:c.1155T>C:p.Asn385Asn		rs925453	0.6581	0.6682	27709/15526/2259	0.6668	-3.8940	.,T,T	T,T	.,B	.,D	0.11	229000 [KLKB1 (provisional) Fletcher factor (prekallikrein) deficiency,612423];				667	671					KLKB1 (inh=AR pLI=0.00)
chr4	187179486	187179486	A	G	het	hom	het		QUAL=14781;DP=313,228,293;MQM=60	KLKB1	3'UTR	KLKB1:NM_000892.4:3'UTR:MODIFIER:exon15/15:c.*120A>G:,KLKB1:NM_001318394.1:3'UTR:MODIFIER:exon15/15:c.*238A>G:,KLKB1:NM_001318396.1:3'UTR:MODIFIER:exon15/15:c.*120A>G:	MIRb	rs3087505	0.9185	0.0000	0/0/0	0.1633							229000 [KLKB1 (provisional) Fletcher factor (prekallikrein) deficiency,612423];				180	48					KLKB1 (inh=AR pLI=0.00)
chr4	190862083	190862083	T	C	wt	het	het	gene_blacklist	QUAL=3219;DP=200,122,158;MQM=60	FRG1	5'UTR	FRG1:NM_004477.2:5'UTR:MODIFIER:exon1/9:c.-82T>C:		rs1138726	0.4649	0.0000	0/0/0	0.0668											29	109					FRG1 (inh=n/a pLI=0.00)
chr4	190862155	190862155	T	G	wt	het	het	gene_blacklist	QUAL=2552;DP=98,106,135;MQM=60	FRG1	5'UTR_premature_start_codon_gain,5'UTR	FRG1:NM_004477.2:5'UTR_premature_start_codon_gain:LOW:exon1/9:c.-10T>G:,FRG1:NM_004477.2:5'UTR:MODIFIER:exon1/9:c.-10T>G:		rs4145515	0.2688	0.2798	4822/3112/307	0.2650											185	699					FRG1 (inh=n/a pLI=0.00)
chr4	190862182	190862182	C	T	wt	het	het	gene_blacklist	QUAL=2393;DP=116,95,115;MQM=60	FRG1	synonymous	FRG1:NM_004477.2:synonymous:LOW:exon1/9:c.18C>T:p.Tyr6Tyr		rs2411530	0.4643	0.3495	8377/3266/2797	0.3310										COSM3760550	202	714					FRG1 (inh=n/a pLI=0.00)
chr4	190874234	190874234	C	T	het	het	het	low_MQM;gene_blacklist;pred_pathogenic	QUAL=2910;DP=199,169,239;MQM=41	FRG1	missense	FRG1:NM_004477.2:missense:MODERATE:exon4/9:c.271C>T:p.Pro91Ser		rs200620299	0.0000	0.4387	0/0/0	0.0001	7.0600	D,D	D	D	T,T	29.80					0	1101					FRG1 (inh=n/a pLI=0.00)
chr4	190874256	190874256	C	T	wt	het	het	low_MQM;gene_blacklist;pred_pathogenic	QUAL=2742;DP=179,166,244;MQM=34	FRG1	missense	FRG1:NM_004477.2:missense:MODERATE:exon4/9:c.293C>T:p.Thr98Met		rs201275486	0.0000	0.4080	0/0/0	0.0004	4.3140	D,T	T	B	T,T	32.00				COSM4158959	0	1033					FRG1 (inh=n/a pLI=0.00)
chr4	190874290	190874290	T	A	wt	het	het	low_MQM;gene_blacklist	QUAL=86;DP=244,161,238;MQM=33	FRG1	splice_region&intron	FRG1:NM_004477.2:splice_region&intron:LOW:exon4/8:c.317+10T>A:		rs111797658	0.0000	0.0050	0/0/0	0.0001											0	68	2	[2] old entry - no details available			FRG1 (inh=n/a pLI=0.00)
chr4	190876195	190876195	C	T	wt	het	het	low_MQM;gene_blacklist	QUAL=6035;DP=171,190,301;MQM=49	FRG1	synonymous	FRG1:NM_004477.2:synonymous:LOW:exon5/9:c.321C>T:p.Ile107Ile		rs7684300	0.2907	0.5007	3353/2201/287	0.0386											99	1110					FRG1 (inh=n/a pLI=0.00)
chr4	190876204	190876204	G	A	wt	het	het	low_MQM;gene_blacklist	QUAL=4743;DP=215,211,350;MQM=38	FRG1	synonymous	FRG1:NM_004477.2:synonymous:LOW:exon5/9:c.330G>A:p.Lys110Lys		rs3207892	0.0000	0.4521	0/0/0	0.0001										COSM4158960	0	1103					FRG1 (inh=n/a pLI=0.00)
chr4	190876242	190876242	G	A	wt	het	het	low_MQM;gene_blacklist;pred_pathogenic	QUAL=11742;DP=275,309,513;MQM=40	FRG1	missense	FRG1:NM_004477.2:missense:MODERATE:exon5/9:c.368G>A:p.Gly123Glu		rs1061653	0.0000	0.4897	0/0/0	0.0017	7.4130	T,T	T	B	T,T	25.20					2	1463					FRG1 (inh=n/a pLI=0.00)
chr4	190876256	190876256	C	T	wt	het	het	low_MQM;gene_blacklist;pred_pathogenic	QUAL=58;DP=255,319,524;MQM=42	FRG1	missense	FRG1:NM_004477.2:missense:MODERATE:exon5/9:c.382C>T:p.Arg128Cys		rs140599307	0.0000	0.0984	0/0/0	0.0787	7.2920	D,D	T	B	T,T	28.60					0	145					FRG1 (inh=n/a pLI=0.00)
chr4	190878563	190878563	C	A	wt	het	het	low_MQM;gene_blacklist;pred_pathogenic	QUAL=468;DP=480,456,561;MQM=32	FRG1	missense	FRG1:NM_004477.2:missense:MODERATE:exon6/9:c.443C>A:p.Ala148Asp		rs137858630	0.0000	0.0761	0/0/0	0.0010	7.5720	D,D,D	T	D	T,T	27.20					0	601					FRG1 (inh=n/a pLI=0.00)
chr4	190878597	190878597	C	T	het	het	het	low_MQM;gene_blacklist	QUAL=13138;DP=536,473,637;MQM=34	FRG1	synonymous	FRG1:NM_004477.2:synonymous:LOW:exon6/9:c.477C>T:p.Cys159Cys		rs62345290	0.0000	0.4977	0/0/0	0.0107										COSM4158962	0	1536					FRG1 (inh=n/a pLI=0.00)
chr4	190878654	190878654	C	G	het	het	het	low_MQM;gene_blacklist;pred_pathogenic	QUAL=3798;DP=485,475,637;MQM=33	FRG1	missense	FRG1:NM_004477.2:missense:MODERATE:exon6/9:c.534C>G:p.Ile178Met		rs78653319	0.0000	0.4769	1/0/0	0.0024	0.0290	D,D,D	T	P	T,T	23.20				COSM4158963	0	1223					FRG1 (inh=n/a pLI=0.00)
chr4	190878661	190878661	A	T	het	het	het	low_MQM;gene_blacklist	QUAL=11975;DP=473,478,633;MQM=34	FRG1	splice_region&intron	FRG1:NM_004477.2:splice_region&intron:LOW:exon6/8:c.537+4A>T:		rs62345291	0.0000	0.4992	2/1/1	0.0026											0	1503					FRG1 (inh=n/a pLI=0.00)
chr5	224633	224633	A	G	wt	het	wt		QUAL=1252;DP=200,139,156;MQM=58	SDHA	synonymous	SDHA:NM_004168.3:synonymous:LOW:exon3/15:c.309A>G:p.Ala103Ala,SDHA:NM_001294332.1:synonymous:LOW:exon3/14:c.309A>G:p.Ala103Ala		rs1139424	0.2400	0.1529	2023/429/1370	0.1467							600857 [SDHA (confirmed) Leigh syndrome,256000|Mitochondrial respiratory chain complex II deficiency,252011|Cardiomyopathy,dilated,1GG,613642|Paragangliomas 5,614165];	RCV000118318.3 [other]; RCV000162942.1 [benign]; RCV000261547.1 [likely benign]; RCV000319629.1 [likely benign]; RCV000385778.1 [likely benign]; 		COSM3761191	26	336					SDHA (inh=AR+AD pLI=0.00)
chr5	226160	226160	A	C	wt	het	wt		QUAL=1502;DP=92,145,152;MQM=59	SDHA	splice_region&synonymous	SDHA:NM_004168.3:splice_region&synonymous:LOW:exon5/15:c.619A>C:p.Arg207Arg,SDHA:NM_001294332.1:splice_region&synonymous:LOW:exon4/14:c.475A>C:p.Arg159Arg		rs6555055	0.2474	0.1568	2372/545/1494	0.1526							600857 [SDHA (confirmed) Leigh syndrome,256000|Mitochondrial respiratory chain complex II deficiency,252011|Cardiomyopathy,dilated,1GG,613642|Paragangliomas 5,614165];	RCV000118319.3 [other]; RCV000162480.1 [benign]; RCV000263653.1 [likely benign]; RCV000298743.1 [likely benign]; RCV000355926.1 [likely benign]; 			26	340					SDHA (inh=AR+AD pLI=0.00)
chr5	228362	228362	T	C	wt	het	wt		QUAL=2861;DP=223,217,270;MQM=59	SDHA	synonymous	SDHA:NM_004168.3:synonymous:LOW:exon6/15:c.684T>C:p.Asn228Asn,SDHA:NM_001294332.1:synonymous:LOW:exon5/14:c.540T>C:p.Asn180Asn		rs2115272	0.2474	0.1565	2368/547/1485	0.1499							600857 [SDHA (confirmed) Leigh syndrome,256000|Mitochondrial respiratory chain complex II deficiency,252011|Cardiomyopathy,dilated,1GG,613642|Paragangliomas 5,614165];	RCV000118320.3 [other]; RCV000162481.1 [benign]; RCV000276689.1 [likely benign]; RCV000311792.1 [likely benign]; RCV000368927.1 [likely benign]; 		COSM3761192	26	345					SDHA (inh=AR+AD pLI=0.00)
chr5	231111	231111	T	C	hom	hom	hom		QUAL=11160;DP=109,118,144;MQM=56	SDHA	synonymous	SDHA:NM_004168.3:synonymous:LOW:exon7/15:c.891T>C:p.Pro297Pro,SDHA:NM_001294332.1:synonymous:LOW:exon6/14:c.747T>C:p.Pro249Pro		rs1126417	0.6534	0.7078	31200/19114/3161	0.6868							600857 [SDHA (confirmed) Leigh syndrome,256000|Mitochondrial respiratory chain complex II deficiency,252011|Cardiomyopathy,dilated,1GG,613642|Paragangliomas 5,614165];	RCV000118321.3 [other]; RCV000162482.1 [benign]; RCV000308030.1 [likely benign]; RCV000347829.1 [likely benign]; RCV000400279.1 [likely benign]; 		COSM4159838	818	708					SDHA (inh=AR+AD pLI=0.00)
chr5	233734	233734	C	G	wt	het	wt		QUAL=4148;DP=252,328,484;MQM=59	SDHA	synonymous	SDHA:NM_004168.3:synonymous:LOW:exon8/15:c.1038C>G:p.Ser346Ser,SDHA:NM_001294332.1:synonymous:LOW:exon7/14:c.894C>G:p.Ser298Ser		rs1041949	0.2578	0.1597	2574/563/1665	0.1554							600857 [SDHA (confirmed) Leigh syndrome,256000|Mitochondrial respiratory chain complex II deficiency,252011|Cardiomyopathy,dilated,1GG,613642|Paragangliomas 5,614165];	RCV000118311.3 [other]; RCV000162943.1 [benign]; RCV000274141.1 [likely benign]; RCV000319420.1 [likely benign]; RCV000368680.1 [likely benign]; 		COSM3761193	26	343					SDHA (inh=AR+AD pLI=0.00)
chr5	251469	251469	G	A	wt	het	wt	low_MQM	QUAL=3442;DP=232,340,524;MQM=45	SDHA	synonymous	SDHA:NM_004168.3:synonymous:LOW:exon13/15:c.1680G>A:p.Thr560Thr,SDHA:NM_001294332.1:synonymous:LOW:exon12/14:c.1536G>A:p.Thr512Thr		rs10039029	0.2484	0.1527	1873/443/1185	0.1343							600857 [SDHA (confirmed) Leigh syndrome,256000|Mitochondrial respiratory chain complex II deficiency,252011|Cardiomyopathy,dilated,1GG,613642|Paragangliomas 5,614165];	RCV000118314.3 [other]; RCV000162436.1 [benign]; RCV000298674.1 [likely benign]; RCV000353507.1 [likely benign]; RCV000398522.1,RCV000118314.3 [likely benign,other]; RCV000162436.1 [benign]; RCV000298674.1 [likely benign]; RCV000353507.1 [likely benign]; RCV000398522.1 [likely benign]; 			26	335					SDHA (inh=AR+AD pLI=0.00)
chr5	251541	251541	A	G	wt	het	wt		QUAL=4946;DP=308,443,616;MQM=55	SDHA	synonymous	SDHA:NM_004168.3:synonymous:LOW:exon13/15:c.1752A>G:p.Ala584Ala,SDHA:NM_001294332.1:synonymous:LOW:exon12/14:c.1608A>G:p.Ala536Ala		rs13070	0.2484	0.1559	2311/529/1473	0.1501							600857 [SDHA (confirmed) Leigh syndrome,256000|Mitochondrial respiratory chain complex II deficiency,252011|Cardiomyopathy,dilated,1GG,613642|Paragangliomas 5,614165];	RCV000118315.3 [other]; RCV000162485.1 [benign]; RCV000268103.1 [likely benign]; RCV000323384.1 [likely benign]; RCV000359489.1 [likely benign]; 			26	342					SDHA (inh=AR+AD pLI=0.00)
chr5	254599	254599	A	T	wt	het	wt	low_MQM;pred_pathogenic	QUAL=1142;DP=35,149,230;MQM=34	SDHA	missense	SDHA:NM_004168.3:missense:MODERATE:exon14/15:c.1886A>T:p.Tyr629Phe,SDHA:NM_001294332.1:missense:MODERATE:exon13/14:c.1742A>T:p.Tyr581Phe		rs6960	0.0000	0.1515	500/91/340	0.0732	4.0020	D,T,T,T,T	T,T	.,B,B,B,B	D,T,T,T	7.45	600857 [SDHA (confirmed) Leigh syndrome,256000|Mitochondrial respiratory chain complex II deficiency,252011|Cardiomyopathy,dilated,1GG,613642|Paragangliomas 5,614165];	RCV000210491.1 [benign]; RCV000210491.1 [benign]; RCV000243534.1 [benign]; RCV000270762.1 [likely benign]; RCV000325852.1 [likely benign]; RCV000389777.1 [likely benign]; 		COSM1666612	17	272					SDHA (inh=AR+AD pLI=0.00)
chr5	256472	256472	G	A	wt	het	wt		QUAL=2912;DP=398,245,276;MQM=51	SDHA	synonymous	SDHA:NM_004168.3:synonymous:LOW:exon15/15:c.1932G>A:p.Val644Val,SDHA:NM_001294332.1:synonymous:LOW:exon14/14:c.1788G>A:p.Val596Val		rs6961	0.3353	0.1716	2406/550/1520	0.1649							600857 [SDHA (confirmed) Leigh syndrome,256000|Mitochondrial respiratory chain complex II deficiency,252011|Cardiomyopathy,dilated,1GG,613642|Paragangliomas 5,614165];	RCV000118316.3 [other]; RCV000162483.1 [benign]; RCV000273207.1 [likely benign]; RCV000303618.1 [likely benign]; RCV000358445.1 [likely benign]; 			26	693					SDHA (inh=AR+AD pLI=0.00)
chr5	256509	256509	G	A	wt	het	wt	pred_pathogenic	QUAL=3272;DP=421,301,364;MQM=58	SDHA	missense	SDHA:NM_004168.3:missense:MODERATE:exon15/15:c.1969G>A:p.Val657Ile,SDHA:NM_001294332.1:missense:MODERATE:exon14/14:c.1825G>A:p.Val609Ile		rs6962	0.1753	0.1298	796/295/357	0.1240	4.2330	T,T,T,T	T	B,B,B,B	T,T,T	10.15	600857 [SDHA (confirmed) Leigh syndrome,256000|Mitochondrial respiratory chain complex II deficiency,252011|Cardiomyopathy,dilated,1GG,613642|Paragangliomas 5,614165];	RCV000118317.3 [other]; RCV000162484.1 [benign]; RCV000269248.1 [likely benign]; RCV000309260.1 [likely benign]; RCV000363917.1 [likely benign]; 		COSM1666598	7	334					SDHA (inh=AR+AD pLI=0.00)
chr5	1393063	1393063	A	G	wt	wt	het		QUAL=2618;DP=129,173,234;MQM=60	SLC6A3	3'UTR	SLC6A3:NM_001044.4:3'UTR:MODIFIER:exon15/15:c.*1787T>C:		rs1809939	0.1701	0.0000	0/0/0	0.0341							126455 [SLC6A3 (confirmed) Nicotine dependence,protection against,188890|Parkinsonism-dystonia,infantile,613135];				51	162					SLC6A3 (inh=AR pLI=1.00)
chr5	1393344	1393344	C	T	wt	wt	het		QUAL=1932;DP=178,122,141;MQM=60	SLC6A3	3'UTR	SLC6A3:NM_001044.4:3'UTR:MODIFIER:exon15/15:c.*1506G>A:		rs3797200	0.1773	0.0000	0/0/0	0.0353							126455 [SLC6A3 (confirmed) Nicotine dependence,protection against,188890|Parkinsonism-dystonia,infantile,613135];				50	163					SLC6A3 (inh=AR pLI=1.00)
chr5	1393588	1393590	TGT	-	het	het	wt		QUAL=6481;DP=331,265,350;MQM=59	SLC6A3	3'UTR	SLC6A3:NM_001044.4:3'UTR:MODIFIER:exon15/15:c.*1260_*1262delACA:			0.0000	0.0000	0/0/0	0.0003							126455 [SLC6A3 (confirmed) Nicotine dependence,protection against,188890|Parkinsonism-dystonia,infantile,613135];				0	3					SLC6A3 (inh=AR pLI=1.00)
chr5	1393753	1393753	A	G	wt	wt	het		QUAL=951;DP=130,130,121;MQM=59	SLC6A3	3'UTR	SLC6A3:NM_001044.4:3'UTR:MODIFIER:exon15/15:c.*1097T>C:		rs11564775	0.1895	0.0000	0/0/0	0.1448							126455 [SLC6A3 (confirmed) Nicotine dependence,protection against,188890|Parkinsonism-dystonia,infantile,613135];				39	331					SLC6A3 (inh=AR pLI=1.00)
chr5	1393878	1393878	G	A	wt	wt	het		QUAL=402;DP=54,22,33;MQM=58	SLC6A3	3'UTR	SLC6A3:NM_001044.4:3'UTR:MODIFIER:exon15/15:c.*972C>T:		rs6876890	0.2242	0.0000	0/0/0	0.1663							126455 [SLC6A3 (confirmed) Nicotine dependence,protection against,188890|Parkinsonism-dystonia,infantile,613135];				64	335					SLC6A3 (inh=AR pLI=1.00)
chr5	1394815	1394815	A	G	wt	wt	het		QUAL=8272;DP=353,516,591;MQM=60	SLC6A3	3'UTR	SLC6A3:NM_001044.4:3'UTR:MODIFIER:exon15/15:c.*35T>C:		rs1042098	0.2951	0.2545	4525/2663/1049	0.2516							126455 [SLC6A3 (confirmed) Nicotine dependence,protection against,188890|Parkinsonism-dystonia,infantile,613135];				129	536					SLC6A3 (inh=AR pLI=1.00)
chr5	6599493	6599493	G	-	het	het	het		QUAL=3527;DP=127,51,114;MQM=58	NSUN2	3'UTR,non_coding_transcript_exon	NSUN2:NM_017755.5:3'UTR:MODIFIER:exon19/19:c.*546delC:,NSUN2:NM_001193455.1:3'UTR:MODIFIER:exon18/18:c.*546delC:,NSUN2:NR_037947.1:non_coding_transcript_exon:MODIFIER:exon18/18:n.3146delC:		rs200230801	0.0248	0.0000	0/0/0	0.0409							610916 [NSUN2 (provisional) Mental retardation,autosomal recessive 5,611091];	RCV000385790.1 [likely benign]; 			0	31					NSUN2 (inh=AR pLI=0.96)
chr5	6599940	6599940	C	T	het	het	wt		QUAL=8656;DP=361,299,470;MQM=59	NSUN2	3'UTR,non_coding_transcript_exon	NSUN2:NM_017755.5:3'UTR:MODIFIER:exon19/19:c.*99G>A:,NSUN2:NM_001193455.1:3'UTR:MODIFIER:exon18/18:c.*99G>A:,NSUN2:NR_037947.1:non_coding_transcript_exon:MODIFIER:exon18/18:n.2699G>A:		rs3776448	0.1462	0.0000	0/0/0	0.0276							610916 [NSUN2 (provisional) Mental retardation,autosomal recessive 5,611091];	RCV000389172.1 [likely benign]; 			3	50					NSUN2 (inh=AR pLI=0.96)
chr5	6600064	6600064	G	T	het	het	het		QUAL=16863;DP=407,371,574;MQM=59	NSUN2	missense,non_coding_transcript_exon	NSUN2:NM_017755.5:missense:MODERATE:exon19/19:c.2279C>A:p.Pro760Gln,NSUN2:NM_001193455.1:missense:MODERATE:exon18/18:c.2174C>A:p.Pro725Gln,NSUN2:NR_037947.1:non_coding_transcript_exon:MODIFIER:exon18/18:n.2575C>A:		rs61744358	0.0551	0.0588	230/152/17	0.0578	0.6020	T,T,T	T	B,B,B	T,T,T	7.56	610916 [NSUN2 (provisional) Mental retardation,autosomal recessive 5,611091];	RCV000117858.2 [likely benign]; RCV000396216.1 [likely benign]; 			23	244					NSUN2 (inh=AR pLI=0.96)
chr5	6600150	6600150	G	A	het	het	wt		QUAL=12581;DP=444,600,851;MQM=59	NSUN2	synonymous,non_coding_transcript_exon	NSUN2:NM_017755.5:synonymous:LOW:exon19/19:c.2193C>T:p.Asp731Asp,NSUN2:NM_001193455.1:synonymous:LOW:exon18/18:c.2088C>T:p.Asp696Asp,NSUN2:NR_037947.1:non_coding_transcript_exon:MODIFIER:exon18/18:n.2489C>T:		rs3822434	0.1735	0.1743	2085/729/46	0.1703							610916 [NSUN2 (provisional) Mental retardation,autosomal recessive 5,611091];	RCV000117856.2 [likely benign]; RCV000342691.1 [benign]; 		COSM1438254	41	384					NSUN2 (inh=AR pLI=0.96)
chr5	6622122	6622122	T	A	het	het	het		QUAL=9717;DP=252,246,300;MQM=60	NSUN2	splice_region&intron,intron	NSUN2:NM_017755.5:splice_region&intron:LOW:exon6/18:c.622+7A>T:,NSUN2:NM_001193455.1:splice_region&intron:LOW:exon5/17:c.517+7A>T:,NSUN2:NR_037947.1:intron:MODIFIER:exon5/17:n.918+1205A>T:		rs16877704	0.0160	0.0384	130/109/1	0.0397							610916 [NSUN2 (provisional) Mental retardation,autosomal recessive 5,611091];	RCV000117861.2 [likely benign]; RCV000322271.1 [likely benign]; 			8	145					NSUN2 (inh=AR pLI=0.96)
chr5	7869235	7869235	T	C	het	het	het		QUAL=4611;DP=51,132,228;MQM=60	MTRR	5'UTR,non_coding_transcript_exon	MTRR:NM_024010.2:5'UTR:MODIFIER:exon1/15:c.-12T>C:,MTRR:NM_002454.2:5'UTR:MODIFIER:exon1/15:c.-119T>C:,MTRR:NR_134480.1:non_coding_transcript_exon:MODIFIER:exon1/15:n.19T>C:,MTRR:NR_134481.1:non_coding_transcript_exon:MODIFIER:exon1/14:n.19T>C:,MTRR:NR_134482.1:non_coding_transcript_exon:MODIFIER:exon1/14:n.19T>C:		rs72716536	0.2290	0.1586	2132/387/521	0.1553							602568 [MTRR (provisional) Homocystinuria-megaloblastic anemia,cbl E type,236270|Neural tube defects,folate-sensitive,susceptibility to,601634];	RCV000126883.2 [benign]; RCV000362823.1 [benign]; 			25	256					MTRR (inh=AR pLI=0.00)
chr5	7870973	7870973	A	G	wt	het	wt	pred_pathogenic	QUAL=4198;DP=526,310,430;MQM=60	MTRR	missense,non_coding_transcript_exon	MTRR:NM_024010.2:missense:MODERATE:exon2/15:c.147A>G:p.Ile49Met,MTRR:NM_002454.2:missense:MODERATE:exon2/15:c.66A>G:p.Ile22Met,MTRR:NR_134480.1:non_coding_transcript_exon:MODIFIER:exon2/15:n.203A>G:,MTRR:NR_134481.1:non_coding_transcript_exon:MODIFIER:exon2/14:n.203A>G:,MTRR:NR_134482.1:non_coding_transcript_exon:MODIFIER:exon2/14:n.203A>G:		rs1801394	0.3642	0.4730	14901/10275/399	0.4692	0.1770	D,D,D,D,T,D	T	D	T,T,T,T,T,T	23.30	602568 [MTRR (provisional) Homocystinuria-megaloblastic anemia,cbl E type,236270|Neural tube defects,folate-sensitive,susceptibility to,601634];	RCV000007444.2 [other]; RCV000007445.2 [other]; RCV000126873.4 [benign]; RCV000144926.1 [uncertain significance]; RCV000211244.1 [drug response]; RCV000264714.1 [benign]; 	CM004563 [CLASS=DFP MUT=REF PHEN="Coronary artery disease association with" GENE=MTRR]; 		527	881					MTRR (inh=AR pLI=0.00)
chr5	7878179	7878179	C	T	wt	wt	het		QUAL=7319;DP=526,403,581;MQM=60	MTRR	missense,non_coding_transcript_exon	MTRR:NM_024010.2:missense:MODERATE:exon5/15:c.605C>T:p.Ser202Leu,MTRR:NM_002454.2:missense:MODERATE:exon5/15:c.524C>T:p.Ser175Leu,MTRR:NR_134480.1:non_coding_transcript_exon:MODIFIER:exon5/15:n.647C>T:,MTRR:NR_134481.1:non_coding_transcript_exon:MODIFIER:exon5/14:n.661C>T:,MTRR:NR_134482.1:non_coding_transcript_exon:MODIFIER:exon4/14:n.507C>T:		rs1532268	0.2700	0.3155	6442/4315/366	0.3133	-1.5900	T,T	T	B	T,T	0.05	602568 [MTRR (provisional) Homocystinuria-megaloblastic anemia,cbl E type,236270|Neural tube defects,folate-sensitive,susceptibility to,601634];	RCV000126884.3 [benign]; RCV000144927.1 [uncertain significance]; RCV000405120.1 [benign]; 	CM025887 [CLASS=FP MUT=REF PHEN="Altered activity" GENE=MTRR]; 	COSM4003607	269	813					MTRR (inh=AR pLI=0.00)
chr5	7878192	7878192	T	C	het	het	wt		QUAL=12145;DP=510,427,614;MQM=59	MTRR	synonymous,non_coding_transcript_exon	MTRR:NM_024010.2:synonymous:LOW:exon5/15:c.618T>C:p.Leu206Leu,MTRR:NM_002454.2:synonymous:LOW:exon5/15:c.537T>C:p.Leu179Leu,MTRR:NR_134480.1:non_coding_transcript_exon:MODIFIER:exon5/15:n.660T>C:,MTRR:NR_134481.1:non_coding_transcript_exon:MODIFIER:exon5/14:n.674T>C:,MTRR:NR_134482.1:non_coding_transcript_exon:MODIFIER:exon4/14:n.520T>C:		rs161870	0.2530	0.1711	2515/475/787	0.1677	-3.7990		T			0.02	602568 [MTRR (provisional) Homocystinuria-megaloblastic anemia,cbl E type,236270|Neural tube defects,folate-sensitive,susceptibility to,601634];	RCV000126885.2 [benign]; RCV000307309.1 [benign]; 			46	404					MTRR (inh=AR pLI=0.00)
chr5	7885959	7885959	A	G	het	het	wt		QUAL=4987;DP=139,239,344;MQM=60	MTRR	missense,non_coding_transcript_exon	MTRR:NM_024010.2:missense:MODERATE:exon7/15:c.1130A>G:p.Lys377Arg,MTRR:NM_002454.2:missense:MODERATE:exon7/15:c.1049A>G:p.Lys350Arg,MTRR:NR_134480.1:non_coding_transcript_exon:MODIFIER:exon7/15:n.1172A>G:,MTRR:NR_134481.1:non_coding_transcript_exon:MODIFIER:exon7/14:n.1186A>G:,MTRR:NR_134482.1:non_coding_transcript_exon:MODIFIER:exon6/14:n.1032A>G:		rs162036	0.2532	0.1711	2514/474/785	0.1677	1.2300	T,T	T	B	T,T	8.29	602568 [MTRR (provisional) Homocystinuria-megaloblastic anemia,cbl E type,236270|Neural tube defects,folate-sensitive,susceptibility to,601634];	RCV000126870.2 [benign]; RCV000144925.1 [uncertain significance]; RCV000317483.1 [benign]; 			46	403					MTRR (inh=AR pLI=0.00)
chr5	7897191	7897191	C	T	het	het	wt	pred_pathogenic	QUAL=6665;DP=260,223,255;MQM=59	MTRR	missense,non_coding_transcript_exon	MTRR:NM_024010.2:missense:MODERATE:exon14/15:c.1864C>T:p.His622Tyr,MTRR:NM_002454.2:missense:MODERATE:exon14/15:c.1783C>T:p.His595Tyr,MTRR:NR_134480.1:non_coding_transcript_exon:MODIFIER:exon14/15:n.1906C>T:,MTRR:NR_134481.1:non_coding_transcript_exon:MODIFIER:exon13/14:n.1831C>T:,MTRR:NR_134482.1:non_coding_transcript_exon:MODIFIER:exon13/14:n.1766C>T:		rs10380	0.2194	0.1509	2003/337/542	0.1475	0.5320	T,T	T	B	D,D	5.61	602568 [MTRR (provisional) Homocystinuria-megaloblastic anemia,cbl E type,236270|Neural tube defects,folate-sensitive,susceptibility to,601634];	RCV000126880.2 [benign]; RCV000144924.1 [uncertain significance]; RCV000302798.1 [benign]; 	CM083724 [CLASS=DFP MUT=ALT PHEN="Pancreatic cancer increased risk association with" GENE=MTRR]; 		32	359	1	[1] auto-classification 16.06.2016  [2] harmuth 06.04.2016; ih-frequency homo: 21, het: 177			MTRR (inh=AR pLI=0.00)
chr5	7897283	7897283	G	A	het	het	wt		QUAL=8325;DP=366,298,325;MQM=60	MTRR	synonymous,sequence_feature,non_coding_transcript_exon	MTRR:NM_024010.2:synonymous:LOW:exon14/15:c.1956G>A:p.Val652Val,MTRR:NM_002454.2:synonymous:LOW:exon14/15:c.1875G>A:p.Val625Val,MTRR:NM_024010.2:sequence_feature:LOW:exon14/15:c.1956G>A:,MTRR:NR_134480.1:non_coding_transcript_exon:MODIFIER:exon14/15:n.1998G>A:,MTRR:NR_134481.1:non_coding_transcript_exon:MODIFIER:exon13/14:n.1923G>A:,MTRR:NR_134482.1:non_coding_transcript_exon:MODIFIER:exon13/14:n.1858G>A:		rs12347	0.2438	0.1678	2431/470/756	0.1643							602568 [MTRR (provisional) Homocystinuria-megaloblastic anemia,cbl E type,236270|Neural tube defects,folate-sensitive,susceptibility to,601634];	RCV000126881.2 [benign]; RCV000341345.1 [benign]; 			46	398					MTRR (inh=AR pLI=0.00)
chr5	7897319	7897319	G	A	wt	wt	het		QUAL=3762;DP=218,260,286;MQM=60	MTRR	synonymous,non_coding_transcript_exon	MTRR:NM_024010.2:synonymous:LOW:exon14/15:c.1992G>A:p.Ala664Ala,MTRR:NM_002454.2:synonymous:LOW:exon14/15:c.1911G>A:p.Ala637Ala,MTRR:NR_134480.1:non_coding_transcript_exon:MODIFIER:exon14/15:n.2034G>A:,MTRR:NR_134481.1:non_coding_transcript_exon:MODIFIER:exon13/14:n.1959G>A:,MTRR:NR_134482.1:non_coding_transcript_exon:MODIFIER:exon13/14:n.1894G>A:		rs1802059	0.2664	0.3142	6414/4311/334	0.3094							602568 [MTRR (provisional) Homocystinuria-megaloblastic anemia,cbl E type,236270|Neural tube defects,folate-sensitive,susceptibility to,601634];	RCV000126882.3 [benign]; RCV000390684.1 [benign]; 		COSM4003608	268	819					MTRR (inh=AR pLI=0.00)
chr5	7900712	7900712	G	A	het	het	wt		QUAL=2506;DP=214,27,35;MQM=60	MTRR	3'UTR,non_coding_transcript_exon	MTRR:NM_024010.2:3'UTR:MODIFIER:exon15/15:c.*541G>A:,MTRR:NM_002454.2:3'UTR:MODIFIER:exon15/15:c.*541G>A:,MTRR:NR_134480.1:non_coding_transcript_exon:MODIFIER:exon15/15:n.2761G>A:,MTRR:NR_134481.1:non_coding_transcript_exon:MODIFIER:exon14/14:n.2686G>A:,MTRR:NR_134482.1:non_coding_transcript_exon:MODIFIER:exon14/14:n.2621G>A:		rs9332	0.2472	0.0000	0/0/0	0.0282							602568 [MTRR (provisional) Homocystinuria-megaloblastic anemia,cbl E type,236270|Neural tube defects,folate-sensitive,susceptibility to,601634];	RCV000389294.1 [benign]; 			7	43					MTRR (inh=AR pLI=0.00)
chr5	7900833	7900833	T	A	wt	het	het		QUAL=1670;DP=199,67,71;MQM=60	MTRR	3'UTR,non_coding_transcript_exon	MTRR:NM_024010.2:3'UTR:MODIFIER:exon15/15:c.*662T>A:,MTRR:NM_002454.2:3'UTR:MODIFIER:exon15/15:c.*662T>A:,MTRR:NR_134480.1:non_coding_transcript_exon:MODIFIER:exon15/15:n.2882T>A:,MTRR:NR_134481.1:non_coding_transcript_exon:MODIFIER:exon14/14:n.2807T>A:,MTRR:NR_134482.1:non_coding_transcript_exon:MODIFIER:exon14/14:n.2742T>A:		rs8659	0.4856	0.0000	0/0/0	0.0541							602568 [MTRR (provisional) Homocystinuria-megaloblastic anemia,cbl E type,236270|Neural tube defects,folate-sensitive,susceptibility to,601634];	RCV000383687.1 [benign]; 			84	100					MTRR (inh=AR pLI=0.00)
chr5	7900997	7900997	C	-	wt	het	het		QUAL=5982;DP=306,196,228;MQM=60	MTRR	3'UTR,non_coding_transcript_exon	MTRR:NM_024010.2:3'UTR:MODIFIER:exon15/15:c.*826delC:,MTRR:NM_002454.2:3'UTR:MODIFIER:exon15/15:c.*826delC:,MTRR:NR_134480.1:non_coding_transcript_exon:MODIFIER:exon15/15:n.3046delC:,MTRR:NR_134481.1:non_coding_transcript_exon:MODIFIER:exon14/14:n.2971delC:,MTRR:NR_134482.1:non_coding_transcript_exon:MODIFIER:exon14/14:n.2906delC:		rs36045697	0.4862	0.0000	0/0/0	0.5215							602568 [MTRR (provisional) Homocystinuria-megaloblastic anemia,cbl E type,236270|Neural tube defects,folate-sensitive,susceptibility to,601634];	RCV000377992.1 [benign]; 			84	101					MTRR (inh=AR pLI=0.00)
chr5	7901230	7901230	T	C	wt	het	wt		QUAL=373;DP=169,33,36;MQM=60	MTRR	3'UTR,non_coding_transcript_exon	MTRR:NM_024010.2:3'UTR:MODIFIER:exon15/15:c.*1059T>C:,MTRR:NM_002454.2:3'UTR:MODIFIER:exon15/15:c.*1059T>C:,MTRR:NR_134480.1:non_coding_transcript_exon:MODIFIER:exon15/15:n.3279T>C:,MTRR:NR_134481.1:non_coding_transcript_exon:MODIFIER:exon14/14:n.3204T>C:,MTRR:NR_134482.1:non_coding_transcript_exon:MODIFIER:exon14/14:n.3139T>C:		rs10520873	0.1783	0.0000	0/0/0	0.2268							602568 [MTRR (provisional) Homocystinuria-megaloblastic anemia,cbl E type,236270|Neural tube defects,folate-sensitive,susceptibility to,601634];	RCV000340298.1 [benign]; 			10	88					MTRR (inh=AR pLI=0.00)
chr5	10250430	10250430	G	A	hom	hom	hom		QUAL=4950;DP=51,51,68;MQM=60	CCT5	5'UTR,intron	CCT5:NM_012073.4:5'UTR:MODIFIER:exon1/11:c.-23G>A:,CCT5:NM_001306154.1:5'UTR:MODIFIER:exon1/10:c.-23G>A:,CCT5:NM_001306153.1:intron:MODIFIER:exon1/10:c.42+273G>A:		rs2548546	0.6853	0.7889	38433/24216/1013	0.7843							610150 [CCT5 (provisional) Neuropathy,hereditary sensory,with spastic paraplegia,256840];	RCV000279502.1 [benign]; 			993	434					CCT5 (inh=AR pLI=1.00)
chr5	10250443	10250443	T	C	hom	hom	hom		QUAL=4797;DP=44,51,64;MQM=60	CCT5	5'UTR_premature_start_codon_gain,5'UTR,intron	CCT5:NM_012073.4:5'UTR_premature_start_codon_gain:LOW:exon1/11:c.-10T>C:,CCT5:NM_001306154.1:5'UTR_premature_start_codon_gain:LOW:exon1/10:c.-10T>C:,CCT5:NM_012073.4:5'UTR:MODIFIER:exon1/11:c.-10T>C:,CCT5:NM_001306154.1:5'UTR:MODIFIER:exon1/10:c.-10T>C:,CCT5:NM_001306153.1:intron:MODIFIER:exon1/10:c.42+286T>C:		rs2578618	0.6853	0.7892	38594/24311/1021	0.7858							610150 [CCT5 (provisional) Neuropathy,hereditary sensory,with spastic paraplegia,256840];	RCV000336837.1 [benign]; 			1415	599					CCT5 (inh=AR pLI=1.00)
chr5	10254817	10254817	A	G	hom	hom	hom		QUAL=16305;DP=156,165,194;MQM=59	CCT5	synonymous,intron	CCT5:NM_012073.4:synonymous:LOW:exon3/11:c.198A>G:p.Gly66Gly,CCT5:NM_001306153.1:synonymous:LOW:exon3/11:c.135A>G:p.Gly45Gly,CCT5:NM_001306156.1:synonymous:LOW:exon3/11:c.84A>G:p.Gly28Gly,CCT5:NM_001306154.1:intron:MODIFIER:exon2/9:c.166+500A>G:,CCT5:NM_001306155.1:intron:MODIFIER:exon2/9:c.52+500A>G:		rs2578617	0.6859	0.7895	38838/24492/1032	0.7875							610150 [CCT5 (provisional) Neuropathy,hereditary sensory,with spastic paraplegia,256840];	RCV000292326.1 [benign]; 			1415	601					CCT5 (inh=AR pLI=1.00)
chr5	10256161	10256161	T	C	hom	hom	hom		QUAL=16114;DP=276,105,123;MQM=60	CCT5	synonymous	CCT5:NM_012073.4:synonymous:LOW:exon4/11:c.426T>C:p.Arg142Arg,CCT5:NM_001306153.1:synonymous:LOW:exon4/11:c.363T>C:p.Arg121Arg,CCT5:NM_001306154.1:synonymous:LOW:exon3/10:c.261T>C:p.Arg87Arg,CCT5:NM_001306155.1:synonymous:LOW:exon3/10:c.147T>C:p.Arg49Arg,CCT5:NM_001306156.1:synonymous:LOW:exon4/11:c.312T>C:p.Arg104Arg		rs1042392	0.6925	0.7948	39246/24749/1097	0.7936							610150 [CCT5 (provisional) Neuropathy,hereditary sensory,with spastic paraplegia,256840];	RCV000349478.1 [benign]; 			1435	586					CCT5 (inh=AR pLI=1.00)
chr5	10258512	10258512	G	A	wt	het	wt		QUAL=4494;DP=326,340,450;MQM=60	CCT5	synonymous	CCT5:NM_012073.4:synonymous:LOW:exon6/11:c.738G>A:p.Ala246Ala,CCT5:NM_001306153.1:synonymous:LOW:exon6/11:c.675G>A:p.Ala225Ala,CCT5:NM_001306154.1:synonymous:LOW:exon5/10:c.573G>A:p.Ala191Ala,CCT5:NM_001306155.1:synonymous:LOW:exon5/10:c.459G>A:p.Ala153Ala,CCT5:NM_001306156.1:synonymous:LOW:exon6/11:c.624G>A:p.Ala208Ala		rs11557649	0.0100	0.0266	66/53/0	0.0260							610150 [CCT5 (provisional) Neuropathy,hereditary sensory,with spastic paraplegia,256840];	RCV000229368.1 [benign]; RCV000309049.1 [likely benign]; 			1	129					CCT5 (inh=AR pLI=1.00)
chr5	10262740	10262740	C	A	hom	hom	hom		QUAL=11823;DP=85,114,188;MQM=60	CCT5	splice_region&intron	CCT5:NM_012073.4:splice_region&intron:LOW:exon9/10:c.1317+10C>A:,CCT5:NM_001306153.1:splice_region&intron:LOW:exon9/10:c.1254+10C>A:,CCT5:NM_001306154.1:splice_region&intron:LOW:exon8/9:c.1152+10C>A:,CCT5:NM_001306155.1:splice_region&intron:LOW:exon8/9:c.1038+10C>A:,CCT5:NM_001306156.1:splice_region&intron:LOW:exon9/10:c.1203+10C>A:		rs2578642	0.6859	0.7894	38834/24488/1033	0.7885							610150 [CCT5 (provisional) Neuropathy,hereditary sensory,with spastic paraplegia,256840];	RCV000316106.1 [benign]; 			1412	601					CCT5 (inh=AR pLI=1.00)
chr5	10264962	10264962	A	G	hom	hom	hom		QUAL=18719;DP=259,134,176;MQM=59	CCT5	3'UTR	CCT5:NM_012073.4:3'UTR:MODIFIER:exon11/11:c.*67A>G:,CCT5:NM_001306153.1:3'UTR:MODIFIER:exon11/11:c.*67A>G:,CCT5:NM_001306154.1:3'UTR:MODIFIER:exon10/10:c.*67A>G:,CCT5:NM_001306155.1:3'UTR:MODIFIER:exon10/10:c.*67A>G:,CCT5:NM_001306156.1:3'UTR:MODIFIER:exon11/11:c.*67A>G:		rs544	0.6857	0.0000	0/0/0	0.1614							610150 [CCT5 (provisional) Neuropathy,hereditary sensory,with spastic paraplegia,256840];	RCV000295243.1 [benign]; 			516	239					CCT5 (inh=AR pLI=1.00)
chr5	10265076	10265076	C	T	hom	hom	hom		QUAL=13475;DP=220,83,110;MQM=59	CCT5	3'UTR	CCT5:NM_012073.4:3'UTR:MODIFIER:exon11/11:c.*181C>T:,CCT5:NM_001306153.1:3'UTR:MODIFIER:exon11/11:c.*181C>T:,CCT5:NM_001306154.1:3'UTR:MODIFIER:exon10/10:c.*181C>T:,CCT5:NM_001306155.1:3'UTR:MODIFIER:exon10/10:c.*181C>T:,CCT5:NM_001306156.1:3'UTR:MODIFIER:exon11/11:c.*181C>T:		rs699113	0.6859	0.0000	0/0/0	0.1373							610150 [CCT5 (provisional) Neuropathy,hereditary sensory,with spastic paraplegia,256840];	RCV000381495.1 [benign]; 			151	70					CCT5 (inh=AR pLI=1.00)
chr5	10265278	10265278	A	G	hom	hom	hom		QUAL=21680;DP=375,143,167;MQM=60	CCT5	3'UTR	CCT5:NM_012073.4:3'UTR:MODIFIER:exon11/11:c.*383A>G:,CCT5:NM_001306153.1:3'UTR:MODIFIER:exon11/11:c.*383A>G:,CCT5:NM_001306154.1:3'UTR:MODIFIER:exon10/10:c.*383A>G:,CCT5:NM_001306155.1:3'UTR:MODIFIER:exon10/10:c.*383A>G:,CCT5:NM_001306156.1:3'UTR:MODIFIER:exon11/11:c.*383A>G:		rs2662533	0.6859	0.0000	0/0/0	0.1505							610150 [CCT5 (provisional) Neuropathy,hereditary sensory,with spastic paraplegia,256840];	RCV000305058.1 [benign]; 			152	69					CCT5 (inh=AR pLI=1.00)
chr5	10265462	10265462	G	A	hom	hom	hom		QUAL=24262;DP=225,245,312;MQM=59	CCT5	3'UTR	CCT5:NM_012073.4:3'UTR:MODIFIER:exon11/11:c.*567G>A:,CCT5:NM_001306153.1:3'UTR:MODIFIER:exon11/11:c.*567G>A:,CCT5:NM_001306154.1:3'UTR:MODIFIER:exon10/10:c.*567G>A:,CCT5:NM_001306155.1:3'UTR:MODIFIER:exon10/10:c.*567G>A:,CCT5:NM_001306156.1:3'UTR:MODIFIER:exon11/11:c.*567G>A:		rs2607286	0.0000	0.0000	0/0/0	0.1150							610150 [CCT5 (provisional) Neuropathy,hereditary sensory,with spastic paraplegia,256840];				151	69					CCT5 (inh=AR pLI=1.00)
chr5	10265488	10265488	A	G	hom	hom	hom		QUAL=22612;DP=228,219,268;MQM=59	CCT5	3'UTR	CCT5:NM_012073.4:3'UTR:MODIFIER:exon11/11:c.*593A>G:,CCT5:NM_001306153.1:3'UTR:MODIFIER:exon11/11:c.*593A>G:,CCT5:NM_001306154.1:3'UTR:MODIFIER:exon10/10:c.*593A>G:,CCT5:NM_001306155.1:3'UTR:MODIFIER:exon10/10:c.*593A>G:,CCT5:NM_001306156.1:3'UTR:MODIFIER:exon11/11:c.*593A>G:		rs2578640	0.6861	0.0000	0/0/0	0.8063							610150 [CCT5 (provisional) Neuropathy,hereditary sensory,with spastic paraplegia,256840];	RCV000274243.1 [benign]; 			151	69					CCT5 (inh=AR pLI=1.00)
chr5	10265719	10265719	C	G	hom	hom	hom		QUAL=31559;DP=547,200,229;MQM=59	CCT5	3'UTR	CCT5:NM_012073.4:3'UTR:MODIFIER:exon11/11:c.*824C>G:,CCT5:NM_001306153.1:3'UTR:MODIFIER:exon11/11:c.*824C>G:,CCT5:NM_001306154.1:3'UTR:MODIFIER:exon10/10:c.*824C>G:,CCT5:NM_001306155.1:3'UTR:MODIFIER:exon10/10:c.*824C>G:,CCT5:NM_001306156.1:3'UTR:MODIFIER:exon11/11:c.*824C>G:		rs2578639	0.6631	0.0000	0/0/0	0.1362							610150 [CCT5 (provisional) Neuropathy,hereditary sensory,with spastic paraplegia,256840];	RCV000388774.1 [benign]; 			152	69					CCT5 (inh=AR pLI=1.00)
chr5	10265886	10265886	-	TCTAT	hom	hom	hom		QUAL=16103;DP=251,134,144;MQM=59	CCT5	3'UTR	CCT5:NM_012073.4:3'UTR:MODIFIER:exon11/11:c.*994_*995insATTCT:,CCT5:NM_001306153.1:3'UTR:MODIFIER:exon11/11:c.*994_*995insATTCT:,CCT5:NM_001306154.1:3'UTR:MODIFIER:exon10/10:c.*994_*995insATTCT:,CCT5:NM_001306155.1:3'UTR:MODIFIER:exon10/10:c.*994_*995insATTCT:,CCT5:NM_001306156.1:3'UTR:MODIFIER:exon11/11:c.*994_*995insATTCT:	MIR	rs112586209;rs70943997	0.6809	0.0000	0/0/0	0.6957							610150 [CCT5 (provisional) Neuropathy,hereditary sensory,with spastic paraplegia,256840];				148	67					CCT5 (inh=AR pLI=1.00)
chr5	10266067	10266067	G	T	hom	hom	hom		QUAL=36470;DP=437,296,378;MQM=60	CCT5	3'UTR	CCT5:NM_012073.4:3'UTR:MODIFIER:exon11/11:c.*1172G>T:,CCT5:NM_001306153.1:3'UTR:MODIFIER:exon11/11:c.*1172G>T:,CCT5:NM_001306154.1:3'UTR:MODIFIER:exon10/10:c.*1172G>T:,CCT5:NM_001306155.1:3'UTR:MODIFIER:exon10/10:c.*1172G>T:,CCT5:NM_001306156.1:3'UTR:MODIFIER:exon11/11:c.*1172G>T:		rs2578638	0.8880	0.0000	0/0/0	0.8985							610150 [CCT5 (provisional) Neuropathy,hereditary sensory,with spastic paraplegia,256840];	RCV000278944.1 [benign]; 			183	42					CCT5 (inh=AR pLI=1.00)
chr5	10972889	10972889	T	-	wt	het	wt		QUAL=388;DP=197,103,128;MQM=59	CTNND2	3'UTR,non_coding_transcript_exon	CTNND2:NM_001332.3:3'UTR:MODIFIER:exon22/22:c.*676delA:,CTNND2:NM_001288715.1:3'UTR:MODIFIER:exon21/21:c.*676delA:,CTNND2:NM_001288716.1:3'UTR:MODIFIER:exon19/19:c.*676delA:,CTNND2:NM_001288717.1:3'UTR:MODIFIER:exon21/21:c.*676delA:,CTNND2:NR_109988.1:non_coding_transcript_exon:MODIFIER:exon22/22:n.3985delA:		rs70947237	0.0000	0.0000	0/0/0	0.0040											0	26					CTNND2 (inh=n/a pLI=1.00)
chr5	11117583	11117583	C	T	het	wt	het		QUAL=9316;DP=395,207,342;MQM=60	CTNND2	synonymous,non_coding_transcript_exon	CTNND2:NM_001332.3:synonymous:LOW:exon13/22:c.2256G>A:p.Gly752Gly,CTNND2:NM_001288715.1:synonymous:LOW:exon12/21:c.1983G>A:p.Gly661Gly,CTNND2:NM_001288716.1:synonymous:LOW:exon10/19:c.1245G>A:p.Gly415Gly,CTNND2:NM_001288717.1:synonymous:LOW:exon12/21:c.957G>A:p.Gly319Gly,CTNND2:NR_109988.1:non_coding_transcript_exon:MODIFIER:exon11/22:n.1708G>A:		rs2285975	0.2236	0.1184	1649/108/182	0.1177										COSM4003253	15	159					CTNND2 (inh=n/a pLI=1.00)
chr5	16474795	16474795	C	T	hom	hom	wt		QUAL=333;DP=159,36,41;MQM=57	FAM134B	3'UTR	FAM134B:NM_001034850.2:3'UTR:MODIFIER:exon9/9:c.*55G>A:,FAM134B:NM_019000.4:3'UTR:MODIFIER:exon7/7:c.*55G>A:	(TTTTTC)n	rs879020809	0.0000	0.0000	0/0/0	0.0002							613114 [FAM134B (provisional) Neuropathy,hereditary sensory and autonomic,type IIB,613115];				1	43					FAM134B (inh=AR pLI=0.01)
chr5	16478200	16478200	G	A	hom	hom	hom		QUAL=12416;DP=202,74,103;MQM=60	FAM134B	synonymous	FAM134B:NM_001034850.2:synonymous:LOW:exon7/9:c.816C>T:p.Asp272Asp,FAM134B:NM_019000.4:synonymous:LOW:exon5/7:c.393C>T:p.Asp131Asp		rs162848	0.6775	0.6661	25890/15604/3106	0.6521							613114 [FAM134B (provisional) Neuropathy,hereditary sensory and autonomic,type IIB,613115];	RCV000360491.1 [benign]; 			845	720					FAM134B (inh=AR pLI=0.01)
chr5	16508898	16508898	T	C	het	het	wt		QUAL=5947;DP=257,226,307;MQM=60	FAM134B	5'UTR,intron	FAM134B:NM_019000.4:5'UTR:MODIFIER:exon1/7:c.-177A>G:,FAM134B:NM_001034850.2:intron:MODIFIER:exon3/8:c.459-25317A>G:		rs33684	0.5431	0.0000	0/0/0	0.6291							613114 [FAM134B (provisional) Neuropathy,hereditary sensory and autonomic,type IIB,613115];				107	101					FAM134B (inh=AR pLI=0.01)
chr5	33988054	33988054	T	C	wt	wt	het		QUAL=2115;DP=255,84,164;MQM=60	AMACR,C1QTNF3-AMACR	3'UTR,non_coding_transcript_exon	AMACR:NM_001167595.1:3'UTR:MODIFIER:exon6/6:c.*359A>G:,AMACR:NM_014324.5:3'UTR:MODIFIER:exon5/5:c.*1144A>G:,AMACR:NM_203382.2:3'UTR:MODIFIER:exon4/4:c.*1535A>G:,C1QTNF3-AMACR:NR_037951.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.2649A>G:	MER119	rs840380	0.0731	0.0000	0/0/0	0.0557							604489 [AMACR (provisional) Alpha-methylacyl-CoA racemase deficiency,614307|Bile acid synthesis defect,congenital,4,214950];	RCV000283159.1 [likely benign]; RCV000359526.1 [likely benign]; 			1	5					AMACR (inh=AR pLI=0.13), C1QTNF3-AMACR (inh=n/a pLI=n/a)
chr5	33988535	33988535	C	T	wt	het	wt		QUAL=3622;DP=290,248,313;MQM=60	AMACR,C1QTNF3-AMACR	3'UTR,intron,non_coding_transcript_exon	AMACR:NM_014324.5:3'UTR:MODIFIER:exon5/5:c.*663G>A:,AMACR:NM_203382.2:3'UTR:MODIFIER:exon4/4:c.*1054G>A:,AMACR:NM_001167595.1:intron:MODIFIER:exon5/5:c.1132-69G>A:,C1QTNF3-AMACR:NR_037951.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.2168G>A:		rs15612	0.1937	0.0000	0/0/0	0.0408							604489 [AMACR (provisional) Alpha-methylacyl-CoA racemase deficiency,614307|Bile acid synthesis defect,congenital,4,214950];	RCV000292807.1 [benign]; RCV000344126.1 [likely benign]; 			77	261					AMACR (inh=AR pLI=0.13), C1QTNF3-AMACR (inh=n/a pLI=n/a)
chr5	33988581	33988581	C	A	het	wt	het		QUAL=7274;DP=321,223,247;MQM=60	AMACR,C1QTNF3-AMACR	3'UTR,intron,non_coding_transcript_exon	AMACR:NM_014324.5:3'UTR:MODIFIER:exon5/5:c.*617G>T:,AMACR:NM_203382.2:3'UTR:MODIFIER:exon4/4:c.*1008G>T:,AMACR:NM_001167595.1:intron:MODIFIER:exon5/5:c.1132-115G>T:,C1QTNF3-AMACR:NR_037951.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.2122G>T:		rs12659370	0.0749	0.0000	0/0/0	0.0108							604489 [AMACR (provisional) Alpha-methylacyl-CoA racemase deficiency,614307|Bile acid synthesis defect,congenital,4,214950];	RCV000350176.1 [likely benign]; RCV000403059.1 [likely benign]; 			2	25					AMACR (inh=AR pLI=0.13), C1QTNF3-AMACR (inh=n/a pLI=n/a)
chr5	33989518	33989518	C	T	hom	het	hom	pred_pathogenic	QUAL=26504;DP=333,255,384;MQM=60	AMACR,C1QTNF3-AMACR	missense,3'UTR,non_coding_transcript_exon	AMACR:NM_001167595.1:missense:MODERATE:exon5/6:c.829G>A:p.Glu277Lys,AMACR:NM_014324.5:missense:MODERATE:exon5/5:c.829G>A:p.Glu277Lys,AMACR:NM_203382.2:3'UTR:MODIFIER:exon4/4:c.*71G>A:,C1QTNF3-AMACR:NR_037951.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.1185G>A:		rs2278008	0.6961	0.7016	30827/18374/3205	0.7023	2.0460	T,T,T	T	B,B,B	T,T,T	19.02	604489 [AMACR (provisional) Alpha-methylacyl-CoA racemase deficiency,614307|Bile acid synthesis defect,congenital,4,214950];	RCV000116324.2 [likely benign]; RCV000302812.1 [benign]; RCV000368392.1 [benign]; 	CM078460 [CLASS=DP MUT=REF PHEN="Advanced distal colorectal adenoma increased risk association" GENE=AMACR]; 	COSM3761202	1343	1074					AMACR (inh=AR pLI=0.13), C1QTNF3-AMACR (inh=n/a pLI=n/a)
chr5	33998768	33998768	C	A	het	het	het	pred_pathogenic	QUAL=6587;DP=204,138,167;MQM=60	AMACR,C1QTNF3-AMACR	missense,non_coding_transcript_exon	AMACR:NM_001167595.1:missense:MODERATE:exon4/6:c.717G>T:p.Gln239His,AMACR:NM_014324.5:missense:MODERATE:exon4/5:c.717G>T:p.Gln239His,AMACR:NM_203382.2:missense:MODERATE:exon3/4:c.556G>T:p.Val186Phe,C1QTNF3-AMACR:NR_037951.1:non_coding_transcript_exon:MODIFIER:exon8/9:n.1073G>T:		rs34677	0.1144	0.1268	1051/604/17	0.1246	1.8670	D,D,D,T,T	T,T	B,B,B,B,D,P	T,T,T,T,T	23.30	604489 [AMACR (provisional) Alpha-methylacyl-CoA racemase deficiency,614307|Bile acid synthesis defect,congenital,4,214950];	RCV000116323.2 [likely benign]; RCV000306332.1 [likely benign]; 		COSM149809	37	624					AMACR (inh=AR pLI=0.13), C1QTNF3-AMACR (inh=n/a pLI=n/a)
chr5	33998883	33998883	A	G	hom	het	hom		QUAL=15948;DP=239,151,177;MQM=60	AMACR,C1QTNF3-AMACR	missense,synonymous,non_coding_transcript_exon	AMACR:NM_001167595.1:missense:MODERATE:exon4/6:c.602T>C:p.Leu201Ser,AMACR:NM_014324.5:missense:MODERATE:exon4/5:c.602T>C:p.Leu201Ser,AMACR:NM_203382.2:synonymous:LOW:exon3/4:c.441T>C:p.Ile147Ile,C1QTNF3-AMACR:NR_037951.1:non_coding_transcript_exon:MODIFIER:exon8/9:n.958T>C:		rs2287939	0.7149	0.6994	30273/16686/3479	0.6984	-0.7150	T,T,T	T	B,B,B	T,T,T	0.09	604489 [AMACR (provisional) Alpha-methylacyl-CoA racemase deficiency,614307|Bile acid synthesis defect,congenital,4,214950];	RCV000116322.2 [likely benign]; RCV000276161.1 [benign]; 	CM078459 [CLASS=DP MUT=REF PHEN="Advanced distal colorectal adenoma increased risk association" GENE=AMACR]; 		1249	1153					AMACR (inh=AR pLI=0.13), C1QTNF3-AMACR (inh=n/a pLI=n/a)
chr5	35861068	35861068	T	C	wt	het	het	anno_pathogenic_clinvar	QUAL=7614;DP=362,234,325;MQM=60	IL7R	missense,non_coding_transcript_exon	IL7R:NM_002185.3:missense:MODERATE:exon2/8:c.197T>C:p.Ile66Thr,IL7R:NR_120485.1:non_coding_transcript_exon:MODIFIER:exon2/6:n.300T>C:		rs1494558	0.5998	0.6279	24636/15204/2960	0.6226	0.3370	T,T,T,T	T	B	T,T,T,T	0.02	146661 [IL7R (confirmed) Severe combined immunodeficiency,T-cell negative,B-cell/natural killer cell-positive type,608971];	RCV000015964.25 [pathogenic]; RCV000121212.2 [benign]; RCV000340761.1 [benign]; 	CM1111762 [CLASS=DP MUT=REF PHEN="Acute graft versus host disease association with" GENE=IL7R]; 	COSM149813	691	709	2	[2] old entry - no details available			IL7R (inh=AR pLI=0.00)
chr5	35871190	35871190	G	A	wt	het	het	anno_pathogenic_clinvar	QUAL=5299;DP=182,165,224;MQM=60	IL7R	missense,non_coding_transcript_exon	IL7R:NM_002185.3:missense:MODERATE:exon4/8:c.412G>A:p.Val138Ile,IL7R:NR_120485.1:non_coding_transcript_exon:MODIFIER:exon4/6:n.515G>A:		rs1494555	0.6669	0.6519	26551/15442/4006	0.6459	-0.0310	T,T,T	T	B	T,T,T	0.11	146661 [IL7R (confirmed) Severe combined immunodeficiency,T-cell negative,B-cell/natural killer cell-positive type,608971];	RCV000015965.26 [pathogenic]; RCV000121214.2 [benign]; RCV000397982.1 [benign]; 	CM088536 [CLASS=DP MUT=REF PHEN="Gastric cancer increased risk association with" GENE=IL7R]; 	COSM149814	717	698	2	[2] old entry - no details available			IL7R (inh=AR pLI=0.00)
chr5	35876274	35876274	A	G	wt	het	het		QUAL=7807;DP=431,266,349;MQM=60	IL7R	missense,non_coding_transcript_exon	IL7R:NM_002185.3:missense:MODERATE:exon8/8:c.1066A>G:p.Ile356Val,IL7R:NR_120485.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.906A>G:		rs3194051	0.2208	0.2445	3982/2508/650	0.2396	0.5760	T,T	T	B	T,T	0.01	146661 [IL7R (confirmed) Severe combined immunodeficiency,T-cell negative,B-cell/natural killer cell-positive type,608971];	RCV000121222.1 [not provided]; RCV000284806.1 [benign]; 	CM058270 [CLASS=DFP MUT=ALT PHEN="Multiple sclerosis association with" GENE=IL7R]; 		157	657					IL7R (inh=AR pLI=0.00)
chr5	38475507	38475507	G	A	het	het	het		QUAL=4792;DP=119,93,130;MQM=60	LIFR	3'UTR	LIFR:NM_001127671.1:3'UTR:MODIFIER:exon20/20:c.*6190C>T:,LIFR:NM_002310.5:3'UTR:MODIFIER:exon20/20:c.*6190C>T:		rs1046224	0.3728	0.0000	0/0/0	0.0658							151443 [LIFR (confirmed) Stuve-Wiedemann syndrome/Schwartz-Jampel type 2 syndrome,601559];	RCV000317607.1 [benign]; 			27	101					LIFR (inh=AR pLI=0.00)
chr5	38476027	38476027	T	C	het	het	het		QUAL=9811;DP=309,145,228;MQM=59	LIFR	3'UTR	LIFR:NM_001127671.1:3'UTR:MODIFIER:exon20/20:c.*5670A>G:,LIFR:NM_002310.5:3'UTR:MODIFIER:exon20/20:c.*5670A>G:		rs3822425	0.3255	0.0000	0/0/0	0.0598							151443 [LIFR (confirmed) Stuve-Wiedemann syndrome/Schwartz-Jampel type 2 syndrome,601559];	RCV000308441.1 [benign]; 			29	100					LIFR (inh=AR pLI=0.00)
chr5	38476624	38476624	-	T	het	het	het		QUAL=3600;DP=279,96,136;MQM=59	LIFR	3'UTR	LIFR:NM_001127671.1:3'UTR:MODIFIER:exon20/20:c.*5072dupA:,LIFR:NM_002310.5:3'UTR:MODIFIER:exon20/20:c.*5072dupA:		rs397997444	0.3107	0.0000	0/0/0	0.2070							151443 [LIFR (confirmed) Stuve-Wiedemann syndrome/Schwartz-Jampel type 2 syndrome,601559];	RCV000331944.1 [benign]; 			4	123					LIFR (inh=AR pLI=0.00)
chr5	38477863	38477863	G	C	het	het	het		QUAL=8891;DP=294,162,196;MQM=60	LIFR	3'UTR	LIFR:NM_001127671.1:3'UTR:MODIFIER:exon20/20:c.*3834C>G:,LIFR:NM_002310.5:3'UTR:MODIFIER:exon20/20:c.*3834C>G:		rs34130318	0.3223	0.0000	0/0/0	0.3506							151443 [LIFR (confirmed) Stuve-Wiedemann syndrome/Schwartz-Jampel type 2 syndrome,601559];	RCV000271506.1 [benign]; 			27	99					LIFR (inh=AR pLI=0.00)
chr5	38480227	38480227	A	C	het	het	het		QUAL=6130;DP=259,66,111;MQM=60	LIFR	3'UTR	LIFR:NM_001127671.1:3'UTR:MODIFIER:exon20/20:c.*1470T>G:,LIFR:NM_002310.5:3'UTR:MODIFIER:exon20/20:c.*1470T>G:	(AACA)n	rs13156520	0.3181	0.0000	0/0/0	0.3458							151443 [LIFR (confirmed) Stuve-Wiedemann syndrome/Schwartz-Jampel type 2 syndrome,601559];	RCV000376016.1 [benign]; 			27	101					LIFR (inh=AR pLI=0.00)
chr5	38481271	38481271	C	T	het	het	wt		QUAL=7323;DP=429,200,247;MQM=60	LIFR	3'UTR	LIFR:NM_001127671.1:3'UTR:MODIFIER:exon20/20:c.*426G>A:,LIFR:NM_002310.5:3'UTR:MODIFIER:exon20/20:c.*426G>A:		rs116625329	0.0048	0.0000	0/0/0	0.0024							151443 [LIFR (confirmed) Stuve-Wiedemann syndrome/Schwartz-Jampel type 2 syndrome,601559];				0	11					LIFR (inh=AR pLI=0.00)
chr5	38481335	38481335	C	T	het	het	het		QUAL=13609;DP=469,261,323;MQM=60	LIFR	3'UTR	LIFR:NM_001127671.1:3'UTR:MODIFIER:exon20/20:c.*362G>A:,LIFR:NM_002310.5:3'UTR:MODIFIER:exon20/20:c.*362G>A:		rs1005017	0.7290	0.0000	0/0/0	0.1141							151443 [LIFR (confirmed) Stuve-Wiedemann syndrome/Schwartz-Jampel type 2 syndrome,601559];	RCV000275248.1 [benign]; 			102	100					LIFR (inh=AR pLI=0.00)
chr5	38482731	38482731	T	C	het	het	wt	low_DP;pred_pathogenic	QUAL=1475;DP=95,13,16;MQM=60	LIFR	missense	LIFR:NM_001127671.1:missense:MODERATE:exon19/20:c.2630A>G:p.Glu877Gly,LIFR:NM_002310.5:missense:MODERATE:exon19/20:c.2630A>G:p.Glu877Gly			0.0000	0.0000	0/0/0	0.0000	3.9330	T,T	T	D	T,T	25.70	151443 [LIFR (confirmed) Stuve-Wiedemann syndrome/Schwartz-Jampel type 2 syndrome,601559];				0	2					LIFR (inh=AR pLI=0.00)
chr5	38528952	38528955	ACAC	-	wt	het	het		QUAL=2915;DP=21,54,77;MQM=60	LIFR	splice_region&intron	LIFR:NM_001127671.1:splice_region&intron:LOW:exon2/19:c.143-13_143-10delGTGT:,LIFR:NM_002310.5:splice_region&intron:LOW:exon2/19:c.143-13_143-10delGTGT:	(AC)n	rs762238623	0.0000	0.0911	0/0/0	0.0208							151443 [LIFR (confirmed) Stuve-Wiedemann syndrome/Schwartz-Jampel type 2 syndrome,601559];	RCV000363123.1 [uncertain significance]; 			13	69					LIFR (inh=AR pLI=0.00)
chr5	38528952	38528953	AC	-	hom	het	het		QUAL=2915;DP=21,54,77;MQM=59	LIFR	splice_region&intron	LIFR:NM_001127671.1:splice_region&intron:LOW:exon2/19:c.143-11_143-10delGT:,LIFR:NM_002310.5:splice_region&intron:LOW:exon2/19:c.143-11_143-10delGT:	(AC)n	rs34759137;rs760641742	0.0000	0.3454	80/56/1	0.1152							151443 [LIFR (confirmed) Stuve-Wiedemann syndrome/Schwartz-Jampel type 2 syndrome,601559];	RCV000308475.1 [uncertain significance]; 			416	244					LIFR (inh=AR pLI=0.00)
chr5	38919158	38919158	G	A	het	wt	het	pred_pathogenic	QUAL=4304;DP=153,150,176;MQM=60	OSMR	missense	OSMR:NM_001323506.1:missense:MODERATE:exon11/18:c.1582G>A:p.Glu528Lys,OSMR:NM_001323507.1:missense:MODERATE:exon11/12:c.1579G>A:p.Glu527Lys,OSMR:NM_001323505.1:missense:MODERATE:exon11/18:c.1579G>A:p.Glu527Lys,OSMR:NM_003999.2:missense:MODERATE:exon11/18:c.1579G>A:p.Glu527Lys		rs10941412	0.1464	0.1558	1607/957/306	0.1518	2.3480	T,T	T	P	T,T	22.00	601743 [OSMR (confirmed) Amyloidosis,primary localized cutaneous,1,105250];				31	395					OSMR (inh=AD pLI=0.00)
chr5	38933645	38933645	G	A	wt	het	wt		QUAL=4800;DP=406,380,409;MQM=60	OSMR	3'UTR	OSMR:NM_001323506.1:3'UTR:MODIFIER:exon18/18:c.*99G>A:,OSMR:NM_001323505.1:3'UTR:MODIFIER:exon18/18:c.*99G>A:,OSMR:NM_003999.2:3'UTR:MODIFIER:exon18/18:c.*99G>A:		rs1051977	0.0304	0.0000	0/0/0	0.0119							601743 [OSMR (confirmed) Amyloidosis,primary localized cutaneous,1,105250];				0	51					OSMR (inh=AD pLI=0.00)
chr5	38933749	38933749	C	T	hom	het	het		QUAL=17042;DP=300,313,306;MQM=60	OSMR	3'UTR	OSMR:NM_001323506.1:3'UTR:MODIFIER:exon18/18:c.*203C>T:,OSMR:NM_001323505.1:3'UTR:MODIFIER:exon18/18:c.*203C>T:,OSMR:NM_003999.2:3'UTR:MODIFIER:exon18/18:c.*203C>T:		rs1239344	0.4491	0.0000	0/0/0	0.0771							601743 [OSMR (confirmed) Amyloidosis,primary localized cutaneous,1,105250];				35	117					OSMR (inh=AD pLI=0.00)
chr5	38935101	38935101	G	C	hom	het	het		QUAL=10822;DP=178,187,229;MQM=54	OSMR	3'UTR	OSMR:NM_001323506.1:3'UTR:MODIFIER:exon18/18:c.*1555G>C:,OSMR:NM_001323505.1:3'UTR:MODIFIER:exon18/18:c.*1555G>C:,OSMR:NM_003999.2:3'UTR:MODIFIER:exon18/18:c.*1555G>C:	AluSp	rs357252	0.6404	0.0000	0/0/0	0.5581							601743 [OSMR (confirmed) Amyloidosis,primary localized cutaneous,1,105250];				55	70					OSMR (inh=AD pLI=0.00)
chr5	38935412	38935414	CAA	-	hom	het	het		QUAL=23560;DP=367,491,624;MQM=59	OSMR	3'UTR	OSMR:NM_001323506.1:3'UTR:MODIFIER:exon18/18:c.*1870_*1872delAAC:,OSMR:NM_001323505.1:3'UTR:MODIFIER:exon18/18:c.*1870_*1872delAAC:,OSMR:NM_003999.2:3'UTR:MODIFIER:exon18/18:c.*1870_*1872delAAC:		rs16351	0.6432	0.0000	0/0/0	0.5550							601743 [OSMR (confirmed) Amyloidosis,primary localized cutaneous,1,105250];				55	70					OSMR (inh=AD pLI=0.00)
chr5	38935682	38935682	C	T	hom	het	het		QUAL=6228;DP=170,27,51;MQM=60	OSMR	3'UTR	OSMR:NM_001323506.1:3'UTR:MODIFIER:exon18/18:c.*2136C>T:,OSMR:NM_001323505.1:3'UTR:MODIFIER:exon18/18:c.*2136C>T:,OSMR:NM_003999.2:3'UTR:MODIFIER:exon18/18:c.*2136C>T:		rs7318	0.3620	0.0000	0/0/0	0.0682							601743 [OSMR (confirmed) Amyloidosis,primary localized cutaneous,1,105250];				21	76					OSMR (inh=AD pLI=0.00)
chr5	39284415	39284415	T	A	wt	wt	het		QUAL=1809;DP=268,98,106;MQM=60	C9	3'UTR	C9:NM_001737.4:3'UTR:MODIFIER:exon11/11:c.*886A>T:	ORSL-2b	rs79311110	0.0659	0.0000	0/0/0	0.0139							120940 [C9 (confirmed) C9 deficiency,613825|Macular degeneration,age-related,15,susceptibility to,615591];				3	41					C9 (inh=n/a pLI=0.00)
chr5	39285139	39285139	T	A	hom	hom	hom		QUAL=24140;DP=391,154,205;MQM=59	C9	3'UTR	C9:NM_001737.4:3'UTR:MODIFIER:exon11/11:c.*162A>T:		rs261738	0.8067	0.0000	0/0/0	0.1363							120940 [C9 (confirmed) C9 deficiency,613825|Macular degeneration,age-related,15,susceptibility to,615591];				185	44					C9 (inh=n/a pLI=0.00)
chr5	39342308	39342308	C	T	het	hom	wt		QUAL=8217;DP=269,150,200;MQM=60	C9	splice_region&intron	C9:NM_001737.4:splice_region&intron:LOW:exon1/10:c.78-10G>A:		rs476569	0.6278	0.5364	18011/8200/3495	0.5255							120940 [C9 (confirmed) C9 deficiency,613825|Macular degeneration,age-related,15,susceptibility to,615591];				477	736					C9 (inh=n/a pLI=0.00)
chr5	39364554	39364554	G	A	wt	het	het		QUAL=8416;DP=461,264,366;MQM=60	C9	missense	C9:NM_001737.4:missense:MODERATE:exon1/11:c.13C>T:p.Arg5Trp		rs700233	0.2861	0.3643	8427/5713/348	0.3547	-2.5510	T	T	B	T	6.62	120940 [C9 (confirmed) C9 deficiency,613825|Macular degeneration,age-related,15,susceptibility to,615591];				280	731					C9 (inh=n/a pLI=0.00)
chr5	40949997	40949997	C	T	hom	hom	hom		QUAL=17688;DP=147,191,213;MQM=60	C7	splice_region&intron	C7:NM_000587.2:splice_region&intron:LOW:exon8/17:c.983-9C>T:		rs1450656	0.6585	0.6909	12563/6452/1565	0.5809							217070 [C7 (confirmed) C7 deficiency,610102];				675	682					C7 (inh=AR pLI=0.00)
chr5	40955561	40955561	G	C	hom	hom	hom	pred_pathogenic	QUAL=32233;DP=360,280,359;MQM=60	C7	missense	C7:NM_000587.2:missense:MODERATE:exon10/18:c.1166G>C:p.Ser389Thr		rs1063499	0.4812	0.5700	20093/12300/512	0.5549	1.3790	T,T	T	P	T	23.40	217070 [C7 (confirmed) C7 deficiency,610102];			COSM3761227	570	742					C7 (inh=AR pLI=0.00)
chr5	40964852	40964852	A	C	wt	het	wt		QUAL=3383;DP=216,258,343;MQM=60	C7	missense	C7:NM_000587.2:missense:MODERATE:exon14/18:c.1759A>C:p.Thr587Pro		rs13157656	0.1927	0.2391	3806/1920/20	0.2307	-1.4420	T,T	T	B	T	2.80	217070 [C7 (confirmed) C7 deficiency,610102];		CM1111531 [CLASS=DP MUT=ALT PHEN="Haemolytic uraemic syndrome reduced susceptibility" GENE=C7]; 	COSM3761228	104	572					C7 (inh=AR pLI=0.00)
chr5	40964885	40964885	A	T	wt	wt	het		QUAL=4812;DP=374,298,396;MQM=60	C7	missense	C7:NM_000587.2:missense:MODERATE:exon14/18:c.1792A>T:p.Thr598Ser		rs60714178	0.0661	0.1171	1038/844/11	0.1164	0.7560	T,T	T	B	T	1.47	217070 [C7 (confirmed) C7 deficiency,610102];			COSM3761229	23	379					C7 (inh=AR pLI=0.00)
chr5	40981689	40981689	C	A	wt	het	het		QUAL=11861;DP=227,410,527;MQM=59	C7	3'UTR	C7:NM_000587.2:3'UTR:MODIFIER:exon18/18:c.*14C>A:		rs1061429	0.3878	0.4385	9864/5544/734	0.4034							217070 [C7 (confirmed) C7 deficiency,610102];				180	438					C7 (inh=AR pLI=0.00)
chr5	40981769	40981771	CTT	-	het	het	wt		QUAL=8742;DP=364,438,545;MQM=59	C7	3'UTR	C7:NM_000587.2:3'UTR:MODIFIER:exon18/18:c.*99_*101delTCT:		rs35249475	0.3009	0.0000	0/0/0	0.2178							217070 [C7 (confirmed) C7 deficiency,610102];				12	89					C7 (inh=AR pLI=0.00)
chr5	40982031	40982031	T	C	wt	wt	het		QUAL=4450;DP=295,236,323;MQM=60	C7	3'UTR	C7:NM_000587.2:3'UTR:MODIFIER:exon18/18:c.*356T>C:		rs10473230	0.1595	0.0000	0/0/0	0.0262							217070 [C7 (confirmed) C7 deficiency,610102];				3	55					C7 (inh=AR pLI=0.00)
chr5	40982175	40982175	T	C	het	het	wt		QUAL=5668;DP=243,190,243;MQM=60	C7	3'UTR	C7:NM_000587.2:3'UTR:MODIFIER:exon18/18:c.*500T>C:		rs16870568	0.3015	0.0000	0/0/0	0.0404							217070 [C7 (confirmed) C7 deficiency,610102];				11	77					C7 (inh=AR pLI=0.00)
chr5	40982456	40982456	C	T	wt	het	wt	low_DP	QUAL=58;DP=90,10,15;MQM=60	C7	3'UTR	C7:NM_000587.2:3'UTR:MODIFIER:exon18/18:c.*781C>T:	AluSx1	rs1138523	0.2003	0.0000	0/0/0	0.2123							217070 [C7 (confirmed) C7 deficiency,610102];				20	85					C7 (inh=AR pLI=0.00)
chr5	40982460	40982460	C	T	het	het	wt	low_DP	QUAL=1102;DP=93,11,15;MQM=54	C7	3'UTR	C7:NM_000587.2:3'UTR:MODIFIER:exon18/18:c.*785C>T:	AluSx1	rs12153342	0.2240	0.0000	0/0/0	0.1947							217070 [C7 (confirmed) C7 deficiency,610102];				13	84					C7 (inh=AR pLI=0.00)
chr5	40982490	40982490	C	T	wt	het	wt	low_DP	QUAL=90;DP=84,12,27;MQM=60	C7	3'UTR	C7:NM_000587.2:3'UTR:MODIFIER:exon18/18:c.*815C>T:	AluSx1	rs1138524	0.2017	0.0000	0/0/0	0.2117							217070 [C7 (confirmed) C7 deficiency,610102];				20	86					C7 (inh=AR pLI=0.00)
chr5	40982620	40982620	G	T	het	het	wt		QUAL=2194;DP=151,61,88;MQM=60	C7	3'UTR	C7:NM_000587.2:3'UTR:MODIFIER:exon18/18:c.*945G>T:		rs1061442	0.2238	0.0000	0/0/0	0.0279							217070 [C7 (confirmed) C7 deficiency,610102];				12	88					C7 (inh=AR pLI=0.00)
chr5	40982622	40982622	G	T	het	het	wt		QUAL=2194;DP=151,61,88;MQM=60	C7	3'UTR	C7:NM_000587.2:3'UTR:MODIFIER:exon18/18:c.*947G>T:		rs1061443	0.2113	0.0000	0/0/0	0.0276							217070 [C7 (confirmed) C7 deficiency,610102];				12	88					C7 (inh=AR pLI=0.00)
chr5	40982780	40982780	A	G	wt	wt	het		QUAL=569;DP=198,78,79;MQM=60	C7	3'UTR	C7:NM_000587.2:3'UTR:MODIFIER:exon18/18:c.*1105A>G:		rs8264	0.1599	0.0000	0/0/0	0.0262							217070 [C7 (confirmed) C7 deficiency,610102];				3	56					C7 (inh=AR pLI=0.00)
chr5	40982977	40982977	A	G	het	het	wt		QUAL=1829;DP=162,26,23;MQM=60	C7	3'UTR	C7:NM_000587.2:3'UTR:MODIFIER:exon18/18:c.*1302A>G:		rs14190	0.2115	0.0000	0/0/0	0.2113							217070 [C7 (confirmed) C7 deficiency,610102];				12	85					C7 (inh=AR pLI=0.00)
chr5	41142573	41142573	G	T	het	het	wt		QUAL=4933;DP=300,112,150;MQM=60	C6	3'UTR	C6:NM_000065.3:3'UTR:MODIFIER:exon18/18:c.*354C>A:,C6:NM_001115131.2:3'UTR:MODIFIER:exon18/18:c.*354C>A:		rs10067242	0.0172	0.0000	0/0/0	0.0033							217050 [C6 (confirmed) C6 deficiency,612446|Combined C6/C7 deficiency];				0	22					C6 (inh=AR pLI=0.00)
chr5	41142606	41142606	C	T	het	het	wt		QUAL=6067;DP=377,134,201;MQM=60	C6	3'UTR	C6:NM_000065.3:3'UTR:MODIFIER:exon18/18:c.*321G>A:,C6:NM_001115131.2:3'UTR:MODIFIER:exon18/18:c.*321G>A:		rs9200	0.6707	0.0000	0/0/0	0.0978							217050 [C6 (confirmed) C6 deficiency,612446|Combined C6/C7 deficiency];				68	111					C6 (inh=AR pLI=0.00)
chr5	41158863	41158863	G	A	hom	hom	hom		QUAL=25822;DP=242,248,297;MQM=60	C6	synonymous	C6:NM_000065.3:synonymous:LOW:exon13/18:c.1881C>T:p.Asp627Asp,C6:NM_001115131.2:synonymous:LOW:exon13/18:c.1881C>T:p.Asp627Asp		rs6866352	0.9982	0.9996	60472/33296/5202	0.9448							217050 [C6 (confirmed) C6 deficiency,612446|Combined C6/C7 deficiency];				1581	0					C6 (inh=AR pLI=0.00)
chr5	41199959	41199959	G	T	het	het	het	pred_pathogenic	QUAL=10556;DP=252,261,314;MQM=60	C6	missense	C6:NM_000065.3:missense:MODERATE:exon4/18:c.356C>A:p.Ala119Glu,C6:NM_001115131.2:missense:MODERATE:exon4/18:c.356C>A:p.Ala119Glu		rs1801033	0.5539	0.5936	21755/13246/1588	0.5828	2.5510	T,T,T	T	B	T,T,T	10.34	217050 [C6 (confirmed) C6 deficiency,612446|Combined C6/C7 deficiency];			COSM4159876	632	731					C6 (inh=AR pLI=0.00)
chr5	52394019	52394019	C	-	het	het	het		QUAL=1192;DP=70,21,24;MQM=60	MOCS2	3'UTR	MOCS2:NM_004531.4:3'UTR:MODIFIER:exon7/7:c.*413delG:,MOCS2:NM_176806.3:3'UTR:MODIFIER:exon7/7:c.*900delG:		rs3839261	0.1520	0.0000	0/0/0	0.1247							603708 [MOCS2 (provisional) Molybdenum cofactor deficiency B,252160];	RCV000267699.1 [likely benign]; RCV000388960.1 [benign]; 			3	58					MOCS2 (inh=AR pLI=0.04)
chr5	52397311	52397311	T	C	het	het	wt		QUAL=3770;DP=187,83,114;MQM=60	MOCS2	synonymous,3'UTR	MOCS2:NM_004531.4:synonymous:LOW:exon5/7:c.255A>G:p.Lys85Lys,MOCS2:NM_176806.3:3'UTR:MODIFIER:exon5/7:c.*175A>G:		rs2233216	0.0363	0.0381	120/49/3	0.0376							603708 [MOCS2 (provisional) Molybdenum cofactor deficiency B,252160];	RCV000292675.1 [likely benign]; 			4	117					MOCS2 (inh=AR pLI=0.04)
chr5	52398005	52398005	T	C	het	het	wt	pred_pathogenic	QUAL=6455;DP=306,178,276;MQM=60	MOCS2	missense,3'UTR	MOCS2:NM_004531.4:missense:MODERATE:exon4/7:c.148A>G:p.Thr50Ala,MOCS2:NM_176806.3:3'UTR:MODIFIER:exon4/7:c.*68A>G:		rs2233213	0.0363	0.0392	116/47/3	0.0385	4.5420	T,D	T	B	T	12.85	603708 [MOCS2 (provisional) Molybdenum cofactor deficiency B,252160];	RCV000349961.1 [likely benign]; 			4	121	1	[1] ahbuchr1 18.04.2016 MAF>5%			MOCS2 (inh=AR pLI=0.04)
chr5	52405174	52405174	C	A	het	het	het		QUAL=6401;DP=121,119,204;MQM=60	MOCS2	5'UTR_premature_start_codon_gain,5'UTR,intron	MOCS2:NM_004531.4:5'UTR_premature_start_codon_gain:LOW:exon1/7:c.-263G>T:,MOCS2:NM_004531.4:5'UTR:MODIFIER:exon1/7:c.-263G>T:,MOCS2:NM_176806.3:intron:MODIFIER:exon1/6:c.18+368G>T:		rs77585010	0.0000	0.0000	0/0/0	0.1085							603708 [MOCS2 (provisional) Molybdenum cofactor deficiency B,252160];				3	58					MOCS2 (inh=AR pLI=0.04)
chr5	52942083	52942083	A	C	hom	hom	hom		QUAL=17221;DP=218,126,209;MQM=60	NDUFS4	synonymous,non_coding_transcript_exon	NDUFS4:NM_002495.3:synonymous:LOW:exon3/5:c.198A>C:p.Gly66Gly,NDUFS4:NM_001318051.1:synonymous:LOW:exon3/4:c.198A>C:p.Gly66Gly,NDUFS4:NR_134473.1:non_coding_transcript_exon:MODIFIER:exon4/6:n.400A>C:,NDUFS4:NR_134474.1:non_coding_transcript_exon:MODIFIER:exon4/6:n.317A>C:,NDUFS4:NR_134475.1:non_coding_transcript_exon:MODIFIER:exon4/6:n.352A>C:		rs31304	0.9435	0.9553	54795/30657/4900	0.9383							602694 [NDUFS4 (provisional) Leigh syndrome,256000|Mitochondrial complex I deficiency,252010];	RCV000117714.2 [likely benign]; RCV000280222.1 [benign]; RCV000342200.1 [benign]; 			1440	121					NDUFS4 (inh=AR pLI=0.00)
chr5	52942197	52942197	A	G	het	het	wt		QUAL=7848;DP=400,189,294;MQM=60	NDUFS4	synonymous,non_coding_transcript_exon	NDUFS4:NM_002495.3:synonymous:LOW:exon3/5:c.312A>G:p.Arg104Arg,NDUFS4:NM_001318051.1:synonymous:LOW:exon3/4:c.312A>G:p.Arg104Arg,NDUFS4:NR_134473.1:non_coding_transcript_exon:MODIFIER:exon4/6:n.514A>G:,NDUFS4:NR_134474.1:non_coding_transcript_exon:MODIFIER:exon4/6:n.431A>G:,NDUFS4:NR_134475.1:non_coding_transcript_exon:MODIFIER:exon4/6:n.466A>G:		rs31303	0.8001	0.7734	36419/19269/3799	0.7649							602694 [NDUFS4 (provisional) Leigh syndrome,256000|Mitochondrial complex I deficiency,252010];	RCV000117715.2 [likely benign]; RCV000302455.1 [benign]; RCV000398452.1 [benign]; 		COSM4159887	862	590					NDUFS4 (inh=AR pLI=0.00)
chr5	52979097	52979097	G	A	het	het	wt		QUAL=5923;DP=294,138,175;MQM=60	NDUFS4	3'UTR,non_coding_transcript_exon	NDUFS4:NM_002495.3:3'UTR:MODIFIER:exon5/5:c.*46G>A:,NDUFS4:NM_001318051.1:3'UTR:MODIFIER:exon4/4:c.*137G>A:,NDUFS4:NR_134473.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.776G>A:,NDUFS4:NR_134474.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.693G>A:,NDUFS4:NR_134475.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.728G>A:		rs567	0.3786	0.4485	12338/7266/394	0.4356							602694 [NDUFS4 (provisional) Leigh syndrome,256000|Mitochondrial complex I deficiency,252010];	RCV000270413.1 [likely benign]; RCV000313869.1 [likely benign]; 			167	372					NDUFS4 (inh=AR pLI=0.00)
chr5	53751901	53751901	G	A	wt	het	wt		QUAL=2893;DP=299,197,217;MQM=60	HSPB3	synonymous	HSPB3:NM_006308.2:synonymous:LOW:exon1/1:c.282G>A:p.Leu94Leu		rs7699	0.4826	0.5543	19217/12387/1047	0.5460							604624 [HSPB3 (provisional) Neuronopathy,distal hereditary motor,type IIC,613376];	RCV000286420.1 [benign]; 			591	741					HSPB3 (inh=AD pLI=0.00)
chr5	53751988	53751988	T	C	wt	het	wt		QUAL=1696;DP=227,127,159;MQM=60	HSPB3	synonymous	HSPB3:NM_006308.2:synonymous:LOW:exon1/1:c.369T>C:p.Gly123Gly		rs7823	0.5779	0.5918	21947/12988/2846	0.5839							604624 [HSPB3 (provisional) Neuronopathy,distal hereditary motor,type IIC,613376];	RCV000347126.1 [benign]; 		COSM1132147	632	723					HSPB3 (inh=AD pLI=0.00)
chr5	55660603	55660603	T	G	het	het	het		QUAL=8189;DP=292,155,210;MQM=60	ANKRD55-LOC102467147	intergenic_region	ANKRD55-LOC102467147:ANKRD55-LOC102467147:intergenic_region:MODIFIER::n.55660603T>G:	L2c	rs1900155	0.3728	0.0000	0/0/0	0.3621											24	80					ANKRD55-LOC102467147 (inh=n/a pLI=n/a)
chr5	60170337	60170337	A	G	het	hom	het		QUAL=5724;DP=204,52,79;MQM=60	ERCC8	3'UTR	ERCC8:NM_000082.3:3'UTR:MODIFIER:exon12/12:c.*105T>C:,ERCC8:NM_001007233.2:3'UTR:MODIFIER:exon13/13:c.*105T>C:,ERCC8:NM_001290285.1:3'UTR:MODIFIER:exon11/11:c.*105T>C:		rs3117	0.3067	0.0000	0/0/0	0.0640							609412 [ERCC8 (confirmed) Cockayne syndrome,type A,216400|UV-sensitive syndrome 2,614621];	RCV000363687.1 [benign]; 			36	114					ERCC8 (inh=AR pLI=0.00)
chr5	60240986	60240986	A	G	het	wt	het		QUAL=7404;DP=282,273,372;MQM=59	NDUFAF2	5'UTR	NDUFAF2:NM_174889.4:5'UTR:MODIFIER:exon1/4:c.-97A>G:		rs158922	0.7242	0.0000	0/0/0	0.6317							609653 [NDUFAF2 (provisional) Mitochondrial complex I deficiency,252010|Leigh syndrome,256000];	RCV000297972.1 [benign]; RCV000337453.1 [benign]; RCV000401969.1 [benign]; 			97	109					NDUFAF2 (inh=n/a pLI=0.00)
chr5	60241142	60241142	G	A	het	wt	het		QUAL=7788;DP=238,334,414;MQM=54	NDUFAF2	synonymous	NDUFAF2:NM_174889.4:synonymous:LOW:exon1/4:c.60G>A:p.Lys20Lys		rs158921	0.6929	0.6387	23562/10617/1815	0.6318							609653 [NDUFAF2 (provisional) Mitochondrial complex I deficiency,252010|Leigh syndrome,256000];	RCV000117705.2 [likely benign]; RCV000278856.1 [benign]; RCV000290995.1 [benign]; RCV000348449.1 [benign]; 		COSM3761271	514	844					NDUFAF2 (inh=n/a pLI=0.00)
chr5	68788261	68788261	G	A	hom	hom	hom		QUAL=10225;DP=51,130,162;MQM=59	OCLN	5'UTR	OCLN:NM_002538.3:5'UTR:MODIFIER:exon1/9:c.-294G>A:		rs3733742	0.8516	0.0000	0/0/0	0.8277							602876 [OCLN (confirmed) Band-like calcification with simplified gyration and polymicrogyria,251290];				172	54					OCLN (inh=AR pLI=0.49)
chr5	68850922	68850922	G	C	het	hom	wt	low_DP;low_MQM	QUAL=215;DP=45,6,11;MQM=28	OCLN	3'UTR	OCLN:NM_001205254.1:3'UTR:MODIFIER:exon9/9:c.*1424G>C:,OCLN:NM_002538.3:3'UTR:MODIFIER:exon9/9:c.*1424G>C:,OCLN:NM_001205255.1:3'UTR:MODIFIER:exon7/7:c.*1424G>C:	AluSx4	rs76123058	0.5627	0.0000	0/0/0	0.1248							602876 [OCLN (confirmed) Band-like calcification with simplified gyration and polymicrogyria,251290];				72	46					OCLN (inh=AR pLI=0.49)
chr5	68853877	68853877	C	T	het	wt	het	low_MQM	QUAL=6382;DP=341,198,385;MQM=28	OCLN	3'UTR	OCLN:NM_001205254.1:3'UTR:MODIFIER:exon9/9:c.*4379C>T:,OCLN:NM_002538.3:3'UTR:MODIFIER:exon9/9:c.*4379C>T:,OCLN:NM_001205255.1:3'UTR:MODIFIER:exon7/7:c.*4379C>T:		rs200773462	0.0000	0.0000	0/0/0	0.0264							602876 [OCLN (confirmed) Band-like calcification with simplified gyration and polymicrogyria,251290];				2	42					OCLN (inh=AR pLI=0.49)
chr5	70883136	70883136	A	G	het	hom	het	low_DP	QUAL=1130;DP=6,28,34;MQM=59	MCCC2	5'UTR	MCCC2:NM_022132.4:5'UTR:MODIFIER:exon1/17:c.-117A>G:		rs11746722	0.0000	0.0000	0/0/0	0.1160							609014 [MCCC2 (confirmed) 3-Methylcrotonyl-CoA carboxylase 2 deficiency,210210];				152	58					MCCC2 (inh=AR pLI=0.00)
chr5	70945075	70945075	A	G	hom	hom	hom		QUAL=24705;DP=223,252,305;MQM=59	MCCC2	synonymous	MCCC2:NM_022132.4:synonymous:LOW:exon14/17:c.1368A>G:p.Ala456Ala		rs10064079	0.8514	0.8781	47117/25267/2558	0.8559							609014 [MCCC2 (confirmed) 3-Methylcrotonyl-CoA carboxylase 2 deficiency,210210];	RCV000082093.5 [benign]; RCV000333305.1 [benign]; 			1224	310					MCCC2 (inh=AR pLI=0.00)
chr5	70952934	70952934	C	T	hom	hom	hom		QUAL=21922;DP=377,124,150;MQM=59	MCCC2	3'UTR	MCCC2:NM_022132.4:3'UTR:MODIFIER:exon17/17:c.*247C>T:	MIR	rs1135667	0.8111	0.0000	0/0/0	0.1339							609014 [MCCC2 (confirmed) 3-Methylcrotonyl-CoA carboxylase 2 deficiency,210210];	RCV000384930.1 [benign]; 			163	44					MCCC2 (inh=AR pLI=0.00)
chr5	70953239	70953239	C	T	wt	wt	het		QUAL=4114;DP=315,171,304;MQM=60	MCCC2	3'UTR	MCCC2:NM_022132.4:3'UTR:MODIFIER:exon17/17:c.*552C>T:	L1MB3	rs544574975	0.0020	0.0000	0/0/0	0.0014							609014 [MCCC2 (confirmed) 3-Methylcrotonyl-CoA carboxylase 2 deficiency,210210];				0	2					MCCC2 (inh=AR pLI=0.00)
chr5	70953280	70953280	G	T	het	wt	het		QUAL=4434;DP=200,138,245;MQM=59	MCCC2	3'UTR	MCCC2:NM_022132.4:3'UTR:MODIFIER:exon17/17:c.*593G>T:	AluSz	rs60069076	0.1154	0.0000	0/0/0	0.0836							609014 [MCCC2 (confirmed) 3-Methylcrotonyl-CoA carboxylase 2 deficiency,210210];	RCV000404190.1 [likely benign]; 			1	27					MCCC2 (inh=AR pLI=0.00)
chr5	70953885	70953885	C	T	wt	wt	het		QUAL=7078;DP=652,316,487;MQM=60	MCCC2	3'UTR	MCCC2:NM_022132.4:3'UTR:MODIFIER:exon17/17:c.*1198C>T:	L2c	rs277975	0.3207	0.0000	0/0/0	0.0609							609014 [MCCC2 (confirmed) 3-Methylcrotonyl-CoA carboxylase 2 deficiency,210210];	RCV000268763.1 [benign]; 			17	69					MCCC2 (inh=AR pLI=0.00)
chr5	70953930	70953930	G	C	hom	hom	hom		QUAL=38850;DP=419,292,482;MQM=59	MCCC2	3'UTR	MCCC2:NM_022132.4:3'UTR:MODIFIER:exon17/17:c.*1243G>C:	L2c	rs7731970	0.0000	0.0000	0/0/0	0.1078							609014 [MCCC2 (confirmed) 3-Methylcrotonyl-CoA carboxylase 2 deficiency,210210];				127	35					MCCC2 (inh=AR pLI=0.00)
chr5	73980960	73980960	C	T	wt	hom	wt	low_DP	QUAL=98;DP=419,8,4;MQM=60	HEXB	intron	HEXB:NM_001292004.1:intron:MODIFIER:exon1/13:c.-376-4193C>T:	G-rich	rs71627068	0.5104	0.0000	0/0/0	0.4280							606873 [HEXB (confirmed) Sandhoff disease,infantile,juvenile,and adult forms,268800];	RCV000343015.1 [benign]; 			55	55					HEXB (inh=AR pLI=0.00)
chr5	73980964	73980964	C	-	wt	hom	wt	low_DP	QUAL=98;DP=419,8,4;MQM=60	HEXB	intron	HEXB:NM_001292004.1:intron:MODIFIER:exon1/13:c.-376-4189delC:	G-rich	rs70976124	0.5104	0.0000	0/0/0	0.4631							606873 [HEXB (confirmed) Sandhoff disease,infantile,juvenile,and adult forms,268800];	RCV000406221.1 [benign]; 			54	56					HEXB (inh=AR pLI=0.00)
chr5	73981270	73981270	T	C	hom	hom	het	low_DP;anno_pathogenic_clinvar;anno_pathogenic_hgmd	QUAL=4412;DP=17,86,144;MQM=59	HEXB	missense,intron	HEXB:NM_000521.3:missense:MODERATE:exon1/14:c.185T>C:p.Leu62Ser,HEXB:NM_001292004.1:intron:MODIFIER:exon1/13:c.-376-3883T>C:		rs820878	0.9814	0.9708	53506/28644/4303	0.9328	0.9630	T	T		T	0.10	606873 [HEXB (confirmed) Sandhoff disease,infantile,juvenile,and adult forms,268800];	RCV000004086.3 [pathogenic]; RCV000153357.2 [benign]; 	CM952225 [CLASS=DM? MUT=REF PHEN="Sandhoff disease" GENE=HEXB]; 	COSM450042	2522	170	2	[2] old entry - no details available [import GPD] Julia Bickmann 2014-04-01 14:28:01 -type: mutation details L62S wurde bisher nur einmal im Zusammenhang mit einer infantilen Sandhoff-Erkrankung beschrieben (Zhang et al., 1995); das Kind trug eine 50kb-Deletion auf dem anderen HEXB-Allel; die Hexosaminidase-Aktivit?t war nicht bestimmt worden. In Abh?ngigkeit von der Restaktivit?t der HEX kann bei HEXB-Mutationen ein breites Symptomenspektrum bis hin zur Symptomfreiheit bestehen.  Die HEX-Akt. Bestimmung ist daher obligat.			HEXB (inh=AR pLI=0.00)
chr5	73985215	73985215	A	G	het	wt	het	pred_pathogenic	QUAL=9391;DP=365,301,344;MQM=60	HEXB	missense,5'UTR	HEXB:NM_000521.3:missense:MODERATE:exon2/14:c.362A>G:p.Lys121Arg,HEXB:NM_001292004.1:5'UTR:MODIFIER:exon2/14:c.-314A>G:		rs11556045	0.2226	0.1988	2615/1053/383	0.1948	-0.9130	T	T	B	D	0.01	606873 [HEXB (confirmed) Sandhoff disease,infantile,juvenile,and adult forms,268800];	RCV000004078.2 [benign]; RCV000079063.5 [benign]; RCV000336190.1 [likely benign]; 		COSM149850	115	778					HEXB (inh=AR pLI=0.00)
chr5	74009327	74009327	A	G	het	het	wt		QUAL=5289;DP=173,203,248;MQM=60	HEXB	splice_region&intron	HEXB:NM_000521.3:splice_region&intron:LOW:exon6/13:c.772-4A>G:,HEXB:NM_001292004.1:splice_region&intron:LOW:exon6/13:c.97-4A>G:		rs17561000	0.0395	0.0729	502/386/2	0.0719							606873 [HEXB (confirmed) Sandhoff disease,infantile,juvenile,and adult forms,268800];	RCV000079066.5 [benign]; RCV000351167.1 [likely benign]; 			20	400					HEXB (inh=AR pLI=0.00)
chr5	76506728	76506728	G	T	wt	wt	het	low_DP	QUAL=81;DP=173,2,12;MQM=60	PDE8B	5'UTR	PDE8B:NM_003719.3:5'UTR:MODIFIER:exon1/22:c.-23G>T:,PDE8B:NM_001029851.2:5'UTR:MODIFIER:exon1/19:c.-23G>T:,PDE8B:NM_001029852.2:5'UTR:MODIFIER:exon1/21:c.-23G>T:,PDE8B:NM_001029853.2:5'UTR:MODIFIER:exon1/21:c.-23G>T:,PDE8B:NM_001029854.2:5'UTR:MODIFIER:exon1/21:c.-23G>T:		rs574193520	0.0016	0.0038	0/0/0	0.0004							603390 [PDE8B (confirmed) Pigmented nodular adrenocortical disease,primary,3,614190|Striatal degeneration,autosomal dominant,609161];	RCV000387760.1 [likely benign]; 			0	1					PDE8B (inh=AD pLI=0.99)
chr5	76704849	76704849	T	C	hom	hom	hom		QUAL=23492;DP=244,211,284;MQM=59	PDE8B	synonymous,intron	PDE8B:NM_003719.3:synonymous:LOW:exon14/22:c.1497T>C:p.Pro499Pro,PDE8B:NM_001029851.2:synonymous:LOW:exon11/19:c.1206T>C:p.Pro402Pro,PDE8B:NM_001029853.2:synonymous:LOW:exon13/21:c.1437T>C:p.Pro479Pro,PDE8B:NM_001029854.2:synonymous:LOW:exon13/21:c.1356T>C:p.Pro452Pro,PDE8B:NM_001029852.2:intron:MODIFIER:exon13/20:c.1365+1567T>C:		rs186753	0.0000	1.0000	60699/33367/5201	0.9123							603390 [PDE8B (confirmed) Pigmented nodular adrenocortical disease,primary,3,614190|Striatal degeneration,autosomal dominant,609161];				1565	0					PDE8B (inh=AD pLI=0.99)
chr5	76722442	76722442	C	T	het	het	wt		QUAL=7617;DP=347,150,179;MQM=60	PDE8B	3'UTR	PDE8B:NM_003719.3:3'UTR:MODIFIER:exon22/22:c.*63C>T:,PDE8B:NM_001029851.2:3'UTR:MODIFIER:exon19/19:c.*63C>T:,PDE8B:NM_001029852.2:3'UTR:MODIFIER:exon21/21:c.*63C>T:,PDE8B:NM_001029853.2:3'UTR:MODIFIER:exon21/21:c.*63C>T:,PDE8B:NM_001029854.2:3'UTR:MODIFIER:exon21/21:c.*63C>T:		rs62362531	0.1098	0.0000	0/0/0	0.0281							603390 [PDE8B (confirmed) Pigmented nodular adrenocortical disease,primary,3,614190|Striatal degeneration,autosomal dominant,609161];	RCV000272908.1 [benign]; 			21	170					PDE8B (inh=AD pLI=0.99)
chr5	76722443	76722443	G	A	het	het	hom		QUAL=11334;DP=346,150,177;MQM=59	PDE8B	3'UTR	PDE8B:NM_003719.3:3'UTR:MODIFIER:exon22/22:c.*64G>A:,PDE8B:NM_001029851.2:3'UTR:MODIFIER:exon19/19:c.*64G>A:,PDE8B:NM_001029852.2:3'UTR:MODIFIER:exon21/21:c.*64G>A:,PDE8B:NM_001029853.2:3'UTR:MODIFIER:exon21/21:c.*64G>A:,PDE8B:NM_001029854.2:3'UTR:MODIFIER:exon21/21:c.*64G>A:		rs40594	0.6611	0.0000	0/0/0	0.1113							603390 [PDE8B (confirmed) Pigmented nodular adrenocortical disease,primary,3,614190|Striatal degeneration,autosomal dominant,609161];	RCV000267169.1 [benign]; 			231	360					PDE8B (inh=AD pLI=0.99)
chr5	76722877	76722877	C	-	het	wt	het		QUAL=7042;DP=294,93,126;MQM=59	PDE8B	3'UTR	PDE8B:NM_003719.3:3'UTR:MODIFIER:exon22/22:c.*498delC:,PDE8B:NM_001029851.2:3'UTR:MODIFIER:exon19/19:c.*498delC:,PDE8B:NM_001029852.2:3'UTR:MODIFIER:exon21/21:c.*498delC:,PDE8B:NM_001029853.2:3'UTR:MODIFIER:exon21/21:c.*498delC:,PDE8B:NM_001029854.2:3'UTR:MODIFIER:exon21/21:c.*498delC:		rs567378113	0.0000	0.0000	0/0/0	0.0422							603390 [PDE8B (confirmed) Pigmented nodular adrenocortical disease,primary,3,614190|Striatal degeneration,autosomal dominant,609161];				1	11					PDE8B (inh=AD pLI=0.99)
chr5	76722877	76722877	C	A	wt	het	het		QUAL=7042;DP=294,93,126;MQM=59	PDE8B	3'UTR	PDE8B:NM_003719.3:3'UTR:MODIFIER:exon22/22:c.*498C>A:,PDE8B:NM_001029851.2:3'UTR:MODIFIER:exon19/19:c.*498C>A:,PDE8B:NM_001029852.2:3'UTR:MODIFIER:exon21/21:c.*498C>A:,PDE8B:NM_001029853.2:3'UTR:MODIFIER:exon21/21:c.*498C>A:,PDE8B:NM_001029854.2:3'UTR:MODIFIER:exon21/21:c.*498C>A:		rs1061405	0.0000	0.0000	0/0/0	0.1776							603390 [PDE8B (confirmed) Pigmented nodular adrenocortical disease,primary,3,614190|Striatal degeneration,autosomal dominant,609161];				16	101					PDE8B (inh=AD pLI=0.99)
chr5	76722891	76722891	T	C	het	het	hom		QUAL=9578;DP=304,96,143;MQM=59	PDE8B	3'UTR	PDE8B:NM_003719.3:3'UTR:MODIFIER:exon22/22:c.*512T>C:,PDE8B:NM_001029851.2:3'UTR:MODIFIER:exon19/19:c.*512T>C:,PDE8B:NM_001029852.2:3'UTR:MODIFIER:exon21/21:c.*512T>C:,PDE8B:NM_001029853.2:3'UTR:MODIFIER:exon21/21:c.*512T>C:,PDE8B:NM_001029854.2:3'UTR:MODIFIER:exon21/21:c.*512T>C:		rs460267	0.4455	0.0000	0/0/0	0.4044							603390 [PDE8B (confirmed) Pigmented nodular adrenocortical disease,primary,3,614190|Striatal degeneration,autosomal dominant,609161];	RCV000366496.1 [benign]; 			48	116					PDE8B (inh=AD pLI=0.99)
chr5	76723227	76723228	AA	-	hom	hom	hom	low_DP	QUAL=1218;DP=35,3,17;MQM=59	PDE8B	3'UTR	PDE8B:NM_003719.3:3'UTR:MODIFIER:exon22/22:c.*863_*864delAA:,PDE8B:NM_001029851.2:3'UTR:MODIFIER:exon19/19:c.*863_*864delAA:,PDE8B:NM_001029852.2:3'UTR:MODIFIER:exon21/21:c.*863_*864delAA:,PDE8B:NM_001029853.2:3'UTR:MODIFIER:exon21/21:c.*863_*864delAA:,PDE8B:NM_001029854.2:3'UTR:MODIFIER:exon21/21:c.*863_*864delAA:	(A)n	rs771815865	0.6236	0.0000	0/0/0	0.2811							603390 [PDE8B (confirmed) Pigmented nodular adrenocortical disease,primary,3,614190|Striatal degeneration,autosomal dominant,609161];	RCV000262351.1 [benign]; 			36	92					PDE8B (inh=AD pLI=0.99)
chr5	77298619	77298619	A	T	wt	het	wt		QUAL=1951;DP=274,161,200;MQM=60	AP3B1	3'UTR	AP3B1:NM_003664.4:3'UTR:MODIFIER:exon27/27:c.*107T>A:,AP3B1:NM_001271769.1:3'UTR:MODIFIER:exon27/27:c.*107T>A:		rs11552314	0.3123	0.0000	0/0/0	0.0601							603401 [AP3B1 (provisional) Hermansky-Pudlak syndrome 2,608233];	RCV000317532.1 [benign]; 			20	75					AP3B1 (inh=AR pLI=1.00)
chr5	77412011	77412011	A	G	wt	het	wt		QUAL=927;DP=291,89,100;MQM=60	AP3B1	synonymous	AP3B1:NM_003664.4:synonymous:LOW:exon18/27:c.2016T>C:p.Ala672Ala,AP3B1:NM_001271769.1:synonymous:LOW:exon18/27:c.1869T>C:p.Ala623Ala		rs42360	0.1889	0.2071	2892/1673/355	0.2059							603401 [AP3B1 (provisional) Hermansky-Pudlak syndrome 2,608233];	RCV000150162.2 [benign]; RCV000363077.1 [benign]; 		COSM450073	68	493					AP3B1 (inh=AR pLI=1.00)
chr5	77425028	77425028	A	T	hom	hom	het	pred_pathogenic	QUAL=12409;DP=224,97,158;MQM=60	AP3B1	missense	AP3B1:NM_003664.4:missense:MODERATE:exon16/27:c.1754T>A:p.Val585Glu,AP3B1:NM_001271769.1:missense:MODERATE:exon16/27:c.1607T>A:p.Val536Glu		rs6453373	0.0000	0.8628	46196/28358/4696	0.8285	6.3070	T,T,T,T	T	B	T,T	10.84	603401 [AP3B1 (provisional) Hermansky-Pudlak syndrome 2,608233];	RCV000150163.2 [benign]; RCV000324616.1 [benign]; 			1282	254					AP3B1 (inh=AR pLI=1.00)
chr5	77473165	77473165	A	G	wt	het	wt		QUAL=1273;DP=171,109,140;MQM=60	AP3B1	splice_region&synonymous	AP3B1:NM_003664.4:splice_region&synonymous:LOW:exon9/27:c.1038T>C:p.Asn346Asn,AP3B1:NM_001271769.1:splice_region&synonymous:LOW:exon9/27:c.891T>C:p.Asn297Asn		rs4532349	0.1428	0.1866	2392/1520/69	0.1865							603401 [AP3B1 (provisional) Hermansky-Pudlak syndrome 2,608233];	RCV000155462.2 [benign]; RCV000306736.1 [benign]; 		COSM1438698	57	457					AP3B1 (inh=AR pLI=1.00)
chr5	78073245	78073245	C	A	hom	hom	hom		QUAL=8578;DP=105,70,87;MQM=60	ARSB	3'UTR	ARSB:NM_000046.3:3'UTR:MODIFIER:exon8/8:c.*2975G>T:	L1MB5	rs3088247	0.7374	0.0000	0/0/0	0.1248							611542 [ARSB (confirmed) Mucopolysaccharidosis type VI (Maroteaux-Lamy),253200];	RCV000360826.1 [benign]; 			100	55					ARSB (inh=AR pLI=0.00)
chr5	78074198	78074198	A	C	het	wt	hom		QUAL=18779;DP=419,300,407;MQM=60	ARSB	3'UTR	ARSB:NM_000046.3:3'UTR:MODIFIER:exon8/8:c.*2022T>G:		rs7704939	0.4467	0.0000	0/0/0	0.0705							611542 [ARSB (confirmed) Mucopolysaccharidosis type VI (Maroteaux-Lamy),253200];	RCV000383970.1 [benign]; 			45	106					ARSB (inh=AR pLI=0.00)
chr5	78074751	78074751	G	A	het	wt	het		QUAL=2370;DP=166,24,26;MQM=59	ARSB	3'UTR	ARSB:NM_000046.3:3'UTR:MODIFIER:exon8/8:c.*1469C>T:	AluJr	rs55710452	0.0427	0.0000	0/0/0	0.0635							611542 [ARSB (confirmed) Mucopolysaccharidosis type VI (Maroteaux-Lamy),253200];	RCV000404729.1 [likely benign]; 			4	37					ARSB (inh=AR pLI=0.00)
chr5	78074918	78074918	C	A	het	het	hom		QUAL=4624;DP=148,48,62;MQM=60	ARSB	3'UTR	ARSB:NM_000046.3:3'UTR:MODIFIER:exon8/8:c.*1302G>T:		rs754566	0.5026	0.0000	0/0/0	0.0872							611542 [ARSB (confirmed) Mucopolysaccharidosis type VI (Maroteaux-Lamy),253200];	RCV000306657.1 [benign]; 			73	107					ARSB (inh=AR pLI=0.00)
chr5	78074963	78074963	T	G	wt	het	wt		QUAL=1236;DP=169,84,94;MQM=60	ARSB	3'UTR	ARSB:NM_000046.3:3'UTR:MODIFIER:exon8/8:c.*1257A>C:		rs754567	0.1713	0.0000	0/0/0	0.0436							611542 [ARSB (confirmed) Mucopolysaccharidosis type VI (Maroteaux-Lamy),253200];	RCV000321479.1 [likely benign]; 			21	108					ARSB (inh=AR pLI=0.00)
chr5	78135201	78135201	C	T	het	het	wt		QUAL=2336;DP=158,70,123;MQM=60	ARSB	synonymous	ARSB:NM_000046.3:synonymous:LOW:exon6/8:c.1191G>A:p.Pro397Pro,ARSB:NM_198709.2:synonymous:LOW:exon7/8:c.1191G>A:p.Pro397Pro		rs25413	0.2592	0.2007	3295/1263/1388	0.1971							611542 [ARSB (confirmed) Mucopolysaccharidosis type VI (Maroteaux-Lamy),253200];	RCV000078001.5 [benign]; RCV000372416.1 [benign]; 		COSM3761329, COSM3761330	105	546					ARSB (inh=AR pLI=0.00)
chr5	78181477	78181477	C	T	het	het	het	pred_pathogenic	QUAL=10429;DP=288,211,300;MQM=59	ARSB	missense	ARSB:NM_000046.3:missense:MODERATE:exon5/8:c.1072G>A:p.Val358Met,ARSB:NM_198709.2:missense:MODERATE:exon6/8:c.1072G>A:p.Val358Met		rs1065757	0.2855	0.3907	10273/6619/62	0.3851	3.9850	T,T	T	D,D	D,D	26.70	611542 [ARSB (confirmed) Mucopolysaccharidosis type VI (Maroteaux-Lamy),253200];	RCV000077997.5 [benign]; RCV000352809.1 [benign]; 	CM088428 [CLASS=FP MUT=ALT PHEN="Reduced activity" GENE=ARSB]; 		222	728					ARSB (inh=AR pLI=0.00)
chr5	78181577	78181577	T	C	het	wt	het		QUAL=4922;DP=160,192,253;MQM=60	ARSB	synonymous	ARSB:NM_000046.3:synonymous:LOW:exon5/8:c.972A>G:p.Gly324Gly,ARSB:NM_198709.2:synonymous:LOW:exon6/8:c.972A>G:p.Gly324Gly		rs72762973	0.0266	0.0527	221/173/3	0.0521							611542 [ARSB (confirmed) Mucopolysaccharidosis type VI (Maroteaux-Lamy),253200];	RCV000078006.5 [benign]; RCV000381815.1 [likely benign]; 			5	130					ARSB (inh=AR pLI=0.00)
chr5	78281373	78281373	T	C	hom	hom	hom		QUAL=13240;DP=248,79,96;MQM=60	ARSB	5'UTR	ARSB:NM_000046.3:5'UTR:MODIFIER:exon1/8:c.-302A>G:,ARSB:NM_198709.2:5'UTR:MODIFIER:exon2/8:c.-302A>G:		rs163127	0.9052	0.0000	0/0/0	0.9516							611542 [ARSB (confirmed) Mucopolysaccharidosis type VI (Maroteaux-Lamy),253200];	RCV000369905.1 [benign]; 			226	4					ARSB (inh=AR pLI=0.00)
chr5	78281383	78281383	-	A	wt	wt	het		QUAL=981;DP=197,80,94;MQM=60	ARSB	splice_region&intron,5'UTR	ARSB:NM_198709.2:splice_region&intron:LOW:exon1/7:c.-310-3dupT:,ARSB:NM_000046.3:5'UTR:MODIFIER:exon1/8:c.-313dupT:		rs566085793	0.2121	0.0000	0/0/0	0.0826							611542 [ARSB (confirmed) Mucopolysaccharidosis type VI (Maroteaux-Lamy),253200];	RCV000277172.1 [likely benign]; 			1	47					ARSB (inh=AR pLI=0.00)
chr5	78281635	78281635	T	C	het	het	wt		QUAL=7383;DP=363,230,258;MQM=60	ARSB	5'UTR,intron	ARSB:NM_000046.3:5'UTR:MODIFIER:exon1/8:c.-564A>G:,ARSB:NM_198709.2:intron:MODIFIER:exon1/7:c.-311+87A>G:		rs59558132	0.1719	0.0000	0/0/0	0.1694							611542 [ARSB (confirmed) Mucopolysaccharidosis type VI (Maroteaux-Lamy),253200];	RCV000328506.1 [likely benign]; 			14	68					ARSB (inh=AR pLI=0.00)
chr5	78281909	78281909	-	TG	hom	hom	hom		QUAL=30786;DP=312,266,375;MQM=59	ARSB	5'UTR	ARSB:NM_000046.3:5'UTR:MODIFIER:exon1/8:c.-840_-839dupCA:		rs397805372	0.9519	0.0000	0/0/0	0.8971							611542 [ARSB (confirmed) Mucopolysaccharidosis type VI (Maroteaux-Lamy),253200];	RCV000341282.1 [benign]; 			225	4					ARSB (inh=AR pLI=0.00)
chr5	78281977	78281977	G	C	het	het	wt		QUAL=11600;DP=530,307,402;MQM=59	ARSB	5'UTR_premature_start_codon_gain,5'UTR	ARSB:NM_000046.3:5'UTR_premature_start_codon_gain:LOW:exon1/8:c.-906C>G:,ARSB:NM_000046.3:5'UTR:MODIFIER:exon1/8:c.-906C>G:		rs62377914	0.1456	0.0000	0/0/0	0.1627							611542 [ARSB (confirmed) Mucopolysaccharidosis type VI (Maroteaux-Lamy),253200];	RCV000335980.1 [likely benign]; 			13	65					ARSB (inh=AR pLI=0.00)
chr5	78282029	78282029	T	C	het	het	wt		QUAL=10920;DP=554,260,362;MQM=59	ARSB	5'UTR	ARSB:NM_000046.3:5'UTR:MODIFIER:exon1/8:c.-958A>G:		rs57586329	0.1629	0.0000	0/0/0	0.1676							611542 [ARSB (confirmed) Mucopolysaccharidosis type VI (Maroteaux-Lamy),253200];	RCV000403354.1 [likely benign]; 			12	59					ARSB (inh=AR pLI=0.00)
chr5	78282249	78282249	T	C	het	het	hom		QUAL=11762;DP=291,130,171;MQM=60	ARSB	5'UTR_premature_start_codon_gain,5'UTR	ARSB:NM_000046.3:5'UTR_premature_start_codon_gain:LOW:exon1/8:c.-1178A>G:,ARSB:NM_000046.3:5'UTR:MODIFIER:exon1/8:c.-1178A>G:	LTR37A	rs163126	0.8163	0.0000	0/0/0	0.8080							611542 [ARSB (confirmed) Mucopolysaccharidosis type VI (Maroteaux-Lamy),253200];	RCV000403805.1 [benign]; 			108	49					ARSB (inh=AR pLI=0.00)
chr5	88015544	88015544	-	C	wt	het	wt		QUAL=15078;DP=317,98,115;MQM=60	MEF2C	3'UTR	MEF2C:NM_001193347.1:3'UTR:MODIFIER:exon12/12:c.*2876_*2877insG:,MEF2C:NM_001193348.1:3'UTR:MODIFIER:exon8/8:c.*2876_*2877insG:,MEF2C:NM_001193349.1:3'UTR:MODIFIER:exon9/9:c.*2876_*2877insG:,MEF2C:NM_001308002.1:3'UTR:MODIFIER:exon9/9:c.*2876_*2877insG:,MEF2C:NM_001193350.1:3'UTR:MODIFIER:exon11/11:c.*2876_*2877insG:,MEF2C:NM_002397.4:3'UTR:MODIFIER:exon11/11:c.*2876_*2877insG:,MEF2C:NM_001131005.2:3'UTR:MODIFIER:exon11/11:c.*2876_*2877insG:		rs747960685	0.0000	0.0000	0/0/0	0.0003							600662 [MEF2C (confirmed) Mental retardation,stereotypic movements,epilepsy,and/or cerebral malformations,613443|Chromosome 5q14.3 deletion syndrome,613443];				0	4					MEF2C (inh=n/a pLI=0.00)
chr5	88015545	88015545	A	C	hom	het	het		QUAL=15078;DP=317,98,115;MQM=60	MEF2C	3'UTR	MEF2C:NM_001193347.1:3'UTR:MODIFIER:exon12/12:c.*2876T>G:,MEF2C:NM_001193348.1:3'UTR:MODIFIER:exon8/8:c.*2876T>G:,MEF2C:NM_001193349.1:3'UTR:MODIFIER:exon9/9:c.*2876T>G:,MEF2C:NM_001308002.1:3'UTR:MODIFIER:exon9/9:c.*2876T>G:,MEF2C:NM_001193350.1:3'UTR:MODIFIER:exon11/11:c.*2876T>G:,MEF2C:NM_002397.4:3'UTR:MODIFIER:exon11/11:c.*2876T>G:,MEF2C:NM_001131005.2:3'UTR:MODIFIER:exon11/11:c.*2876T>G:		rs34316	0.4824	0.0000	0/0/0	0.0907							600662 [MEF2C (confirmed) Mental retardation,stereotypic movements,epilepsy,and/or cerebral malformations,613443|Chromosome 5q14.3 deletion syndrome,613443];	RCV000380721.1 [benign]; 			62	122					MEF2C (inh=n/a pLI=0.00)
chr5	88015545	88015545	-	C	wt	het	wt		QUAL=15078;DP=317,98,115;MQM=60	MEF2C	3'UTR	MEF2C:NM_001193347.1:3'UTR:MODIFIER:exon12/12:c.*2875_*2876insG:,MEF2C:NM_001193348.1:3'UTR:MODIFIER:exon8/8:c.*2875_*2876insG:,MEF2C:NM_001193349.1:3'UTR:MODIFIER:exon9/9:c.*2875_*2876insG:,MEF2C:NM_001308002.1:3'UTR:MODIFIER:exon9/9:c.*2875_*2876insG:,MEF2C:NM_001193350.1:3'UTR:MODIFIER:exon11/11:c.*2875_*2876insG:,MEF2C:NM_002397.4:3'UTR:MODIFIER:exon11/11:c.*2875_*2876insG:,MEF2C:NM_001131005.2:3'UTR:MODIFIER:exon11/11:c.*2875_*2876insG:			0.0000	0.0000	0/0/0	0.0000							600662 [MEF2C (confirmed) Mental retardation,stereotypic movements,epilepsy,and/or cerebral malformations,613443|Chromosome 5q14.3 deletion syndrome,613443];				0	4					MEF2C (inh=n/a pLI=0.00)
chr5	88016008	88016008	A	G	hom	hom	het		QUAL=30854;DP=452,311,454;MQM=59	MEF2C	3'UTR	MEF2C:NM_001193347.1:3'UTR:MODIFIER:exon12/12:c.*2413T>C:,MEF2C:NM_001193348.1:3'UTR:MODIFIER:exon8/8:c.*2413T>C:,MEF2C:NM_001193349.1:3'UTR:MODIFIER:exon9/9:c.*2413T>C:,MEF2C:NM_001308002.1:3'UTR:MODIFIER:exon9/9:c.*2413T>C:,MEF2C:NM_001193350.1:3'UTR:MODIFIER:exon11/11:c.*2413T>C:,MEF2C:NM_002397.4:3'UTR:MODIFIER:exon11/11:c.*2413T>C:,MEF2C:NM_001131005.2:3'UTR:MODIFIER:exon11/11:c.*2413T>C:		rs34317	0.7013	0.0000	0/0/0	0.1247							600662 [MEF2C (confirmed) Mental retardation,stereotypic movements,epilepsy,and/or cerebral malformations,613443|Chromosome 5q14.3 deletion syndrome,613443];	RCV000279558.1 [benign]; 			114	98					MEF2C (inh=n/a pLI=0.00)
chr5	88016153	88016153	-	T	hom	hom	het		QUAL=6856;DP=213,57,89;MQM=59	MEF2C	3'UTR	MEF2C:NM_001193347.1:3'UTR:MODIFIER:exon12/12:c.*2267dupA:,MEF2C:NM_001193348.1:3'UTR:MODIFIER:exon8/8:c.*2267dupA:,MEF2C:NM_001193349.1:3'UTR:MODIFIER:exon9/9:c.*2267dupA:,MEF2C:NM_001308002.1:3'UTR:MODIFIER:exon9/9:c.*2267dupA:,MEF2C:NM_001193350.1:3'UTR:MODIFIER:exon11/11:c.*2267dupA:,MEF2C:NM_002397.4:3'UTR:MODIFIER:exon11/11:c.*2267dupA:,MEF2C:NM_001131005.2:3'UTR:MODIFIER:exon11/11:c.*2267dupA:		rs398109145	0.6384	0.0000	0/0/0	0.3821							600662 [MEF2C (confirmed) Mental retardation,stereotypic movements,epilepsy,and/or cerebral malformations,613443|Chromosome 5q14.3 deletion syndrome,613443];	RCV000397122.1 [uncertain significance]; RCV000348923.1 [benign]; 			15	155					MEF2C (inh=n/a pLI=0.00)
chr5	88016605	88016605	T	-	hom	hom	het		QUAL=9887;DP=286,29,35;MQM=60	MEF2C	3'UTR	MEF2C:NM_001193347.1:3'UTR:MODIFIER:exon12/12:c.*1816delA:,MEF2C:NM_001193348.1:3'UTR:MODIFIER:exon8/8:c.*1816delA:,MEF2C:NM_001193349.1:3'UTR:MODIFIER:exon9/9:c.*1816delA:,MEF2C:NM_001308002.1:3'UTR:MODIFIER:exon9/9:c.*1816delA:,MEF2C:NM_001193350.1:3'UTR:MODIFIER:exon11/11:c.*1816delA:,MEF2C:NM_002397.4:3'UTR:MODIFIER:exon11/11:c.*1816delA:,MEF2C:NM_001131005.2:3'UTR:MODIFIER:exon11/11:c.*1816delA:		rs397780880	0.4828	0.0000	0/0/0	0.4628							600662 [MEF2C (confirmed) Mental retardation,stereotypic movements,epilepsy,and/or cerebral malformations,613443|Chromosome 5q14.3 deletion syndrome,613443];	RCV000269394.1 [benign]; 			67	117					MEF2C (inh=n/a pLI=0.00)
chr5	88018389	88018389	A	-	wt	wt	het		QUAL=1203;DP=269,108,181;MQM=59	MEF2C	3'UTR	MEF2C:NM_001193347.1:3'UTR:MODIFIER:exon12/12:c.*32delT:,MEF2C:NM_001193348.1:3'UTR:MODIFIER:exon8/8:c.*32delT:,MEF2C:NM_001193349.1:3'UTR:MODIFIER:exon9/9:c.*32delT:,MEF2C:NM_001308002.1:3'UTR:MODIFIER:exon9/9:c.*32delT:,MEF2C:NM_001193350.1:3'UTR:MODIFIER:exon11/11:c.*32delT:,MEF2C:NM_002397.4:3'UTR:MODIFIER:exon11/11:c.*32delT:,MEF2C:NM_001131005.2:3'UTR:MODIFIER:exon11/11:c.*32delT:		rs373455781;rs56660854	0.0000	0.3667	218/51/130	0.0034							600662 [MEF2C (confirmed) Mental retardation,stereotypic movements,epilepsy,and/or cerebral malformations,613443|Chromosome 5q14.3 deletion syndrome,613443];				3	132					MEF2C (inh=n/a pLI=0.00)
chr5	88179070	88179070	A	G	het	wt	het	low_DP	QUAL=111;DP=7,17,16;MQM=60	MEF2C	5'UTR,intron	MEF2C:NM_001193350.1:5'UTR:MODIFIER:exon1/11:c.-438T>C:,MEF2C:NM_002397.4:5'UTR:MODIFIER:exon1/11:c.-441T>C:,MEF2C:NM_001193347.1:intron:MODIFIER:exon2/11:c.-143+4249T>C:,MEF2C:NM_001131005.2:intron:MODIFIER:exon2/10:c.-143+4249T>C:	(GC)n		0.0000	0.0000	0/0/0	0.0003							600662 [MEF2C (confirmed) Mental retardation,stereotypic movements,epilepsy,and/or cerebral malformations,613443|Chromosome 5q14.3 deletion syndrome,613443];				2	27					MEF2C (inh=n/a pLI=0.00)
chr5	89938587	89938587	C	T	wt	het	het	gene_blacklist	QUAL=1394;DP=180,61,73;MQM=60	ADGRV1	splice_region&intron	ADGRV1:NM_032119.3:splice_region&intron:LOW:exon12/89:c.2367+8C>T:,ADGRV1:NR_003149.1:splice_region&intron:LOW:exon12/89:n.2463+8C>T:		rs2366773	0.8213	0.7322	32668/15093/4195	0.7187							602851 [GPR98 (confirmed) Febrile seizures,familial,4,604352|Usher syndrome,type 2C,605472|Usher syndrome,type 2C,GPR98/PDZD7 digenic,605472];	RCV000150756.1 [benign]; RCV000039561.9 [other]; 			702	673					ADGRV1 (inh=AR+AD pLI=0.00)
chr5	89943571	89943571	G	T	wt	het	het	gene_blacklist	QUAL=4235;DP=182,139,209;MQM=60	ADGRV1	missense,non_coding_transcript_exon	ADGRV1:NM_032119.3:missense:MODERATE:exon17/90:c.3279G>T:p.Leu1093Phe,ADGRV1:NR_003149.1:non_coding_transcript_exon:MODIFIER:exon17/90:n.3375G>T:		rs2366777	0.8103	0.7096	30747/13819/4106	0.6927	0.2040	.,T,T,T	.,T	.,B	.,T	8.20	602851 [GPR98 (confirmed) Febrile seizures,familial,4,604352|Usher syndrome,type 2C,605472|Usher syndrome,type 2C,GPR98/PDZD7 digenic,605472];	RCV000154363.1 [benign]; RCV000039569.6 [other]; 			668	698					ADGRV1 (inh=AR+AD pLI=0.00)
chr5	89971253	89971253	G	A	wt	wt	het	gene_blacklist	QUAL=3578;DP=184,277,315;MQM=60	ADGRV1	synonymous,non_coding_transcript_exon	ADGRV1:NM_032119.3:synonymous:LOW:exon24/90:c.5304G>A:p.Glu1768Glu,ADGRV1:NR_003149.1:non_coding_transcript_exon:MODIFIER:exon24/90:n.5400G>A:		rs41303346	0.0060	0.0144	13/11/0	0.0126							602851 [GPR98 (confirmed) Febrile seizures,familial,4,604352|Usher syndrome,type 2C,605472|Usher syndrome,type 2C,GPR98/PDZD7 digenic,605472];	RCV000039590.5 [other]; 			0	36					ADGRV1 (inh=AR+AD pLI=0.00)
chr5	89979589	89979589	G	A	wt	het	het	gene_blacklist	QUAL=9121;DP=406,296,445;MQM=60	ADGRV1	missense,non_coding_transcript_exon	ADGRV1:NM_032119.3:missense:MODERATE:exon28/90:c.5851G>A:p.Val1951Ile,ADGRV1:NR_003149.1:non_coding_transcript_exon:MODIFIER:exon28/90:n.5947G>A:		rs4916684	0.8037	0.7078	30515/13712/3998	0.6960	0.5690	T,T,T	T	B	T	0.01	602851 [GPR98 (confirmed) Febrile seizures,familial,4,604352|Usher syndrome,type 2C,605472|Usher syndrome,type 2C,GPR98/PDZD7 digenic,605472];	RCV000039599.8 [other]; 		COSM3736391	665	697					ADGRV1 (inh=AR+AD pLI=0.00)
chr5	89979698	89979698	C	T	wt	het	het	gene_blacklist;pred_pathogenic	QUAL=8662;DP=321,302,386;MQM=60	ADGRV1	missense,non_coding_transcript_exon	ADGRV1:NM_032119.3:missense:MODERATE:exon28/90:c.5960C>T:p.Pro1987Leu,ADGRV1:NR_003149.1:non_coding_transcript_exon:MODIFIER:exon28/90:n.6056C>T:		rs4916685	0.3373	0.3542	7836/3511/315	0.3463	3.8030	T,T,T	T	D	T	23.60	602851 [GPR98 (confirmed) Febrile seizures,familial,4,604352|Usher syndrome,type 2C,605472|Usher syndrome,type 2C,GPR98/PDZD7 digenic,605472];	RCV000039601.6 [other]; 		COSM149880	129	650					ADGRV1 (inh=AR+AD pLI=0.00)
chr5	89985882	89985882	A	G	wt	het	het	gene_blacklist;pred_pathogenic	QUAL=3938;DP=170,151,143;MQM=60	ADGRV1	missense,non_coding_transcript_exon	ADGRV1:NM_032119.3:missense:MODERATE:exon30/90:c.6695A>G:p.Tyr2232Cys,ADGRV1:NR_003149.1:non_coding_transcript_exon:MODIFIER:exon30/90:n.6791A>G:		rs10037067	0.3498	0.3874	2922/1365/216	0.3053	2.1720	D,D,D	T	P	T	26.90	602851 [GPR98 (confirmed) Febrile seizures,familial,4,604352|Usher syndrome,type 2C,605472|Usher syndrome,type 2C,GPR98/PDZD7 digenic,605472];	RCV000039612.5 [other]; 		COSM3761369	132	654					ADGRV1 (inh=AR+AD pLI=0.00)
chr5	89988504	89988504	A	G	wt	het	het	gene_blacklist;pred_pathogenic	QUAL=6154;DP=351,238,267;MQM=60	ADGRV1	missense,non_coding_transcript_exon	ADGRV1:NM_032119.3:missense:MODERATE:exon32/90:c.7034A>G:p.Asn2345Ser,ADGRV1:NR_003149.1:non_coding_transcript_exon:MODIFIER:exon32/90:n.7047A>G:		rs2366926	0.3223	0.3729	7229/3265/200	0.3425	9.0740	T,T	T	D	T	24.60	602851 [GPR98 (confirmed) Febrile seizures,familial,4,604352|Usher syndrome,type 2C,605472|Usher syndrome,type 2C,GPR98/PDZD7 digenic,605472];	RCV000039616.5 [other]; 		COSM149882	129	649					ADGRV1 (inh=AR+AD pLI=0.00)
chr5	89989779	89989779	G	A	wt	het	het	gene_blacklist	QUAL=4763;DP=290,177,244;MQM=60	ADGRV1	synonymous,non_coding_transcript_exon	ADGRV1:NM_032119.3:synonymous:LOW:exon33/90:c.7206G>A:p.Glu2402Glu,ADGRV1:NR_003149.1:non_coding_transcript_exon:MODIFIER:exon33/90:n.7219G>A:		rs16876822	0.3221	0.3574	7623/3472/208	0.3421							602851 [GPR98 (confirmed) Febrile seizures,familial,4,604352|Usher syndrome,type 2C,605472|Usher syndrome,type 2C,GPR98/PDZD7 digenic,605472];	RCV000039621.5 [other]; 		COSM3761370	130	648					ADGRV1 (inh=AR+AD pLI=0.00)
chr5	89990324	89990324	A	G	wt	het	het	gene_blacklist;pred_pathogenic	QUAL=5914;DP=373,200,273;MQM=60	ADGRV1	missense,sequence_feature,non_coding_transcript_exon	ADGRV1:NM_032119.3:missense:MODERATE:exon33/90:c.7751A>G:p.Asn2584Ser,ADGRV1:NM_032119.3:sequence_feature:LOW:exon33/90:c.7751A>G:,ADGRV1:NR_003149.1:non_coding_transcript_exon:MODIFIER:exon33/90:n.7764A>G:		rs1878878	0.8085	0.7090	30779/13775/4133	0.6816	6.5320	.,T,T	T,T	.,B,B	.,T	8.32	602851 [GPR98 (confirmed) Febrile seizures,familial,4,604352|Usher syndrome,type 2C,605472|Usher syndrome,type 2C,GPR98/PDZD7 digenic,605472];	RCV000039635.5 [other]; 		COSM3736393	669	695					ADGRV1 (inh=AR+AD pLI=0.00)
chr5	90001237	90001237	G	A	wt	wt	het	gene_blacklist;pred_pathogenic	QUAL=2752;DP=238,184,249;MQM=60	ADGRV1	missense,non_coding_transcript_exon	ADGRV1:NM_032119.3:missense:MODERATE:exon37/90:c.8407G>A:p.Ala2803Thr,ADGRV1:NR_003149.1:non_coding_transcript_exon:MODIFIER:exon37/90:n.8420G>A:		rs111033530	0.0048	0.0104	11/9/0	0.0106	9.0430	D,D	T	D,D	T	33.00	602851 [GPR98 (confirmed) Febrile seizures,familial,4,604352|Usher syndrome,type 2C,605472|Usher syndrome,type 2C,GPR98/PDZD7 digenic,605472];	RCV000039645.5 [other]; 			0	32					ADGRV1 (inh=AR+AD pLI=0.00)
chr5	90002220	90002220	-	T	wt	het	het	gene_blacklist	QUAL=1174;DP=111,94,103;MQM=60	ADGRV1	intron	ADGRV1:NM_032119.3:intron:MODIFIER:exon38/89:c.8730+21dupT:,ADGRV1:NR_003149.1:intron:MODIFIER:exon38/89:n.8743+21dupT:		rs397817530;rs60522638	0.0000	0.4806	1439/716/259	0.3531							602851 [GPR98 (confirmed) Febrile seizures,familial,4,604352|Usher syndrome,type 2C,605472|Usher syndrome,type 2C,GPR98/PDZD7 digenic,605472];	RCV000177957.1 [likely benign]; 			282	785					ADGRV1 (inh=AR+AD pLI=0.00)
chr5	90020923	90020923	T	G	wt	het	het	gene_blacklist	QUAL=1097;DP=192,44,80;MQM=60	ADGRV1	synonymous,non_coding_transcript_exon	ADGRV1:NM_032119.3:synonymous:LOW:exon47/90:c.9927T>G:p.Pro3309Pro,ADGRV1:NR_003149.1:non_coding_transcript_exon:MODIFIER:exon47/90:n.9940T>G:		rs16869042	0.0000	0.3525	7412/3333/207	0.3327	0.0110		T			10.49	602851 [GPR98 (confirmed) Febrile seizures,familial,4,604352|Usher syndrome,type 2C,605472|Usher syndrome,type 2C,GPR98/PDZD7 digenic,605472];	RCV000039665.7 [other]; 		COSM149884	129	641					ADGRV1 (inh=AR+AD pLI=0.00)
chr5	90024735	90024735	G	A	wt	het	het	gene_blacklist;pred_pathogenic	QUAL=4164;DP=274,132,181;MQM=60	ADGRV1	missense,non_coding_transcript_exon	ADGRV1:NM_032119.3:missense:MODERATE:exon49/90:c.10411G>A:p.Glu3471Lys,ADGRV1:NR_003149.1:non_coding_transcript_exon:MODIFIER:exon49/90:n.10424G>A:		rs2366928	0.8291	0.7484	33863/15424/4062	0.7293	4.3840	T,T	T	B,B	T	16.35	602851 [GPR98 (confirmed) Febrile seizures,familial,4,604352|Usher syndrome,type 2C,605472|Usher syndrome,type 2C,GPR98/PDZD7 digenic,605472];	RCV000039504.6 [other]; 			769	645					ADGRV1 (inh=AR+AD pLI=0.00)
chr5	90052263	90052263	-	C	wt	het	het	gene_blacklist;anno_high_impact	QUAL=2008;DP=150,105,125;MQM=60	ADGRV1	splice_acceptor	ADGRV1:NM_032119.3:splice_acceptor:HIGH:exon55/89:c.11581-3dupC:,ADGRV1:NR_003149.1:splice_acceptor:HIGH:exon55/89:n.11594-3dupC:		rs34894132	0.3852	0.4303	11585/6020/206	0.3990							602851 [GPR98 (confirmed) Febrile seizures,familial,4,604352|Usher syndrome,type 2C,605472|Usher syndrome,type 2C,GPR98/PDZD7 digenic,605472];	RCV000039512.4 [benign]; 			226	692	1	[1] auto-classification 16.06.2016  			ADGRV1 (inh=AR+AD pLI=0.00)
chr5	90052289	90052289	G	A	wt	het	het	gene_blacklist;pred_pathogenic	QUAL=3097;DP=208,130,155;MQM=60	ADGRV1	missense,non_coding_transcript_exon	ADGRV1:NM_032119.3:missense:MODERATE:exon56/90:c.11599G>A:p.Glu3867Lys,ADGRV1:NR_003149.1:non_coding_transcript_exon:MODIFIER:exon56/90:n.11612G>A:		rs10062026	0.2961	0.3465	8245/3779/35	0.3435	3.0710	T,T,.	T,.	B,B,.	T,.	16.64	602851 [GPR98 (confirmed) Febrile seizures,familial,4,604352|Usher syndrome,type 2C,605472|Usher syndrome,type 2C,GPR98/PDZD7 digenic,605472];	RCV000039513.6 [other]; 		COSM3761373	132	630					ADGRV1 (inh=AR+AD pLI=0.00)
chr5	90052372	90052372	C	T	wt	het	het	gene_blacklist	QUAL=4918;DP=232,159,208;MQM=60	ADGRV1	synonymous,non_coding_transcript_exon	ADGRV1:NM_032119.3:synonymous:LOW:exon56/90:c.11682C>T:p.Pro3894Pro,ADGRV1:NR_003149.1:non_coding_transcript_exon:MODIFIER:exon56/90:n.11695C>T:		rs2438349	0.5393	0.4830	14795/6547/2256	0.4771	0.6200	T	T		T	13.06	602851 [GPR98 (confirmed) Febrile seizures,familial,4,604352|Usher syndrome,type 2C,605472|Usher syndrome,type 2C,GPR98/PDZD7 digenic,605472];	RCV000039514.6 [other]; 		COSM3761374	269	772					ADGRV1 (inh=AR+AD pLI=0.00)
chr5	90079820	90079820	A	G	wt	het	wt	gene_blacklist	QUAL=1348;DP=91,118,209;MQM=60	ADGRV1	synonymous,non_coding_transcript_exon	ADGRV1:NM_032119.3:synonymous:LOW:exon67/90:c.13599A>G:p.Thr4533Thr,ADGRV1:NR_003149.1:non_coding_transcript_exon:MODIFIER:exon67/90:n.13612A>G:		rs17554631	0.0923	0.1724	1999/1597/9	0.1610							602851 [GPR98 (confirmed) Febrile seizures,familial,4,604352|Usher syndrome,type 2C,605472|Usher syndrome,type 2C,GPR98/PDZD7 digenic,605472];	RCV000039524.5 [other]; 			77	461					ADGRV1 (inh=AR+AD pLI=0.00)
chr5	90107108	90107108	A	G	hom	hom	hom	gene_blacklist	QUAL=14045;DP=173,101,153;MQM=60	ADGRV1	missense,non_coding_transcript_exon	ADGRV1:NM_032119.3:missense:MODERATE:exon74/90:c.16031A>G:p.Glu5344Gly,ADGRV1:NR_003149.1:non_coding_transcript_exon:MODIFIER:exon74/90:n.16044A>G:		rs2438374	0.9461	0.9686	56122/31251/3507	0.9401	1.3490	T,T,T	T	B,B,B	T,T	11.33	602851 [GPR98 (confirmed) Febrile seizures,familial,4,604352|Usher syndrome,type 2C,605472|Usher syndrome,type 2C,GPR98/PDZD7 digenic,605472];	RCV000039538.9 [other]; 			1469	90					ADGRV1 (inh=AR+AD pLI=0.00)
chr5	90119324	90119324	G	A	hom	hom	hom	gene_blacklist	QUAL=34744;DP=393,298,380;MQM=60	ADGRV1	missense,non_coding_transcript_exon	ADGRV1:NM_032119.3:missense:MODERATE:exon76/90:c.16279G>A:p.Val5427Met,ADGRV1:NR_003149.1:non_coding_transcript_exon:MODIFIER:exon76/90:n.16292G>A:		rs2438378	0.9722	0.9920	59457/33328/4077	0.9247	-0.0070	T,T,T	T	B,B,B	T,T	0.01	602851 [GPR98 (confirmed) Febrile seizures,familial,4,604352|Usher syndrome,type 2C,605472|Usher syndrome,type 2C,GPR98/PDZD7 digenic,605472];	RCV000039541.6 [other]; 			1560	8					ADGRV1 (inh=AR+AD pLI=0.00)
chr5	90151589	90151589	G	A	het	hom	wt	gene_blacklist;pred_pathogenic	QUAL=6450;DP=244,121,156;MQM=60	ADGRV1	missense,non_coding_transcript_exon	ADGRV1:NM_032119.3:missense:MODERATE:exon82/90:c.17626G>A:p.Val5876Ile,ADGRV1:NR_003149.1:non_coding_transcript_exon:MODIFIER:exon82/90:n.17639G>A:		rs2247870	0.4591	0.5393	18353/9977/172	0.5294	2.8990	T,T,T	T	B,B,B	T,T	20.50	602851 [GPR98 (confirmed) Febrile seizures,familial,4,604352|Usher syndrome,type 2C,605472|Usher syndrome,type 2C,GPR98/PDZD7 digenic,605472];	RCV000039547.5 [other]; 		COSM149886	454	749					ADGRV1 (inh=AR+AD pLI=0.00)
chr5	90449031	90449031	T	C	hom	hom	hom	gene_blacklist	QUAL=14009;DP=179,115,151;MQM=60	ADGRV1	splice_region&intron	ADGRV1:NM_032119.3:splice_region&intron:LOW:exon88/89:c.18625-7T>C:,ADGRV1:NR_003149.1:splice_region&intron:LOW:exon88/89:n.18638-7T>C:		rs7726023	0.8984	0.9264	41170/23329/2844	0.9024							602851 [GPR98 (confirmed) Febrile seizures,familial,4,604352|Usher syndrome,type 2C,605472|Usher syndrome,type 2C,GPR98/PDZD7 digenic,605472];	RCV000154372.1 [benign]; RCV000039555.5 [other]; 			1369	179					ADGRV1 (inh=AR+AD pLI=0.00)
chr5	90449154	90449154	G	A	wt	het	wt	gene_blacklist	QUAL=1575;DP=247,144,252;MQM=60	ADGRV1	synonymous,non_coding_transcript_exon	ADGRV1:NM_032119.3:synonymous:LOW:exon89/90:c.18741G>A:p.Gly6247Gly,ADGRV1:NR_003149.1:non_coding_transcript_exon:MODIFIER:exon89/90:n.18754G>A:		rs13158963	0.1382	0.1275	878/381/75	0.1178							602851 [GPR98 (confirmed) Febrile seizures,familial,4,604352|Usher syndrome,type 2C,605472|Usher syndrome,type 2C,GPR98/PDZD7 digenic,605472];	RCV000039556.6 [other]; 		COSM3761375	31	347					ADGRV1 (inh=AR+AD pLI=0.00)
chr5	118788196	118788196	C	G	het	wt	hom		QUAL=9595;DP=183,164,243;MQM=59	HSD17B4	5'UTR	HSD17B4:NM_001199291.2:5'UTR:MODIFIER:exon1/25:c.-253C>G:,HSD17B4:NM_000414.3:5'UTR:MODIFIER:exon1/24:c.-75C>G:,HSD17B4:NM_001199292.1:5'UTR:MODIFIER:exon1/23:c.-75C>G:,HSD17B4:NM_001292027.1:5'UTR:MODIFIER:exon1/25:c.-212C>G:,HSD17B4:NM_001292028.1:5'UTR:MODIFIER:exon1/24:c.-674C>G:		rs26180	0.4064	0.0000	0/0/0	0.0852							601860 [HSD17B4 (provisional) D-bifunctional protein deficiency,261515|Perrault syndrome 1,233400];	RCV000294626.1 [benign]; RCV000316794.1 [benign]; 			81	131					HSD17B4 (inh=AR pLI=0.00)
chr5	118811533	118811533	G	A	het	wt	hom	pred_pathogenic;anno_pathogenic_clinvar	QUAL=11627;DP=385,139,191;MQM=59	HSD17B4	missense,5'UTR	HSD17B4:NM_001199291.2:missense:MODERATE:exon7/25:c.392G>A:p.Arg131His,HSD17B4:NM_000414.3:missense:MODERATE:exon6/24:c.317G>A:p.Arg106His,HSD17B4:NM_001199292.1:missense:MODERATE:exon5/23:c.263G>A:p.Arg88His,HSD17B4:NM_001292027.1:missense:MODERATE:exon7/25:c.245G>A:p.Arg82His,HSD17B4:NM_001292028.1:5'UTR:MODIFIER:exon6/24:c.-95G>A:		rs25640	0.3626	0.4400	12496/7227/164	0.4357	7.6330	D,D,D,D	T	P,B,P,B	D,D,D,D	34.00	601860 [HSD17B4 (provisional) D-bifunctional protein deficiency,261515|Perrault syndrome 1,233400];	RCV000179310.3 [benign]; RCV000362861.1 [benign]; RCV000391832.1 [benign]; RCV000008096.2 [pathogenic]; 		COSM1432658	473	985	2	[2] Ute Grasshoff 08.07.2014			HSD17B4 (inh=AR pLI=0.00)
chr5	118861713	118861713	A	G	het	wt	hom	pred_pathogenic	QUAL=12673;DP=284,229,283;MQM=60	HSD17B4	missense	HSD17B4:NM_001199291.2:missense:MODERATE:exon20/25:c.1750A>G:p.Ile584Val,HSD17B4:NM_000414.3:missense:MODERATE:exon19/24:c.1675A>G:p.Ile559Val,HSD17B4:NM_001199292.1:missense:MODERATE:exon18/23:c.1621A>G:p.Ile541Val,HSD17B4:NM_001292027.1:missense:MODERATE:exon20/25:c.1603A>G:p.Ile535Val,HSD17B4:NM_001292028.1:missense:MODERATE:exon19/24:c.1255A>G:p.Ile419Val		rs11205	0.4002	0.4110	10654/5794/812	0.4033	3.8360	T,T,T,T,T,T,T	T	B,B,B,B,B	T,T,T,T,T,T,T	21.10	601860 [HSD17B4 (provisional) D-bifunctional protein deficiency,261515|Perrault syndrome 1,233400];	RCV000221678.2 [benign]; RCV000290935.1 [benign]; RCV000385277.1 [benign]; 		COSM1130959	445	1114					HSD17B4 (inh=AR pLI=0.00)
chr5	118877933	118877933	-	A	het	wt	hom		QUAL=5117;DP=270,76,88;MQM=59	HSD17B4	3'UTR	HSD17B4:NM_001199291.2:3'UTR:MODIFIER:exon25/25:c.*250dupA:,HSD17B4:NM_000414.3:3'UTR:MODIFIER:exon24/24:c.*250dupA:,HSD17B4:NM_001199292.1:3'UTR:MODIFIER:exon23/23:c.*250dupA:,HSD17B4:NM_001292027.1:3'UTR:MODIFIER:exon25/25:c.*250dupA:,HSD17B4:NM_001292028.1:3'UTR:MODIFIER:exon24/24:c.*250dupA:		rs149778406;rs34381335	0.5639	0.0000	0/0/0	0.4964							601860 [HSD17B4 (provisional) D-bifunctional protein deficiency,261515|Perrault syndrome 1,233400];				84	104					HSD17B4 (inh=AR pLI=0.00)
chr5	125877635	125877635	A	G	hom	het	hom		QUAL=3793;DP=76,32,30;MQM=59	ALDH7A1	3'UTR	ALDH7A1:NM_001182.4:3'UTR:MODIFIER:exon18/18:c.*3022T>C:,ALDH7A1:NM_001201377.1:3'UTR:MODIFIER:exon18/18:c.*3022T>C:,ALDH7A1:NM_001202404.1:3'UTR:MODIFIER:exon16/16:c.*3022T>C:		rs2035471	0.4718	0.0000	0/0/0	0.0867							107323 [ALDH7A1 (confirmed) Epilepsy,pyridoxine-dependent,266100];	RCV000262757.1 [benign]; 			44	69					ALDH7A1 (inh=AR pLI=0.00)
chr5	125877659	125877659	-	A	hom	hom	hom		QUAL=2938;DP=48,26,31;MQM=60	ALDH7A1	3'UTR	ALDH7A1:NM_001182.4:3'UTR:MODIFIER:exon18/18:c.*2997dupT:,ALDH7A1:NM_001201377.1:3'UTR:MODIFIER:exon18/18:c.*2997dupT:,ALDH7A1:NM_001202404.1:3'UTR:MODIFIER:exon16/16:c.*2997dupT:		rs397760043	0.9625	0.0000	0/0/0	0.3297							107323 [ALDH7A1 (confirmed) Epilepsy,pyridoxine-dependent,266100];	RCV000377264.1 [uncertain significance]; RCV000320284.1 [benign]; 			46	104					ALDH7A1 (inh=AR pLI=0.00)
chr5	125877838	125877838	G	A	hom	hom	hom	low_DP	QUAL=1231;DP=47,12,19;MQM=57	ALDH7A1	3'UTR	ALDH7A1:NM_001182.4:3'UTR:MODIFIER:exon18/18:c.*2819C>T:,ALDH7A1:NM_001201377.1:3'UTR:MODIFIER:exon18/18:c.*2819C>T:,ALDH7A1:NM_001202404.1:3'UTR:MODIFIER:exon16/16:c.*2819C>T:			0.0000	0.0000	0/0/0	0.0005							107323 [ALDH7A1 (confirmed) Epilepsy,pyridoxine-dependent,266100];				0	11					ALDH7A1 (inh=AR pLI=0.00)
chr5	125878158	125878158	C	T	hom	het	hom		QUAL=18498;DP=282,176,230;MQM=59	ALDH7A1	3'UTR	ALDH7A1:NM_001182.4:3'UTR:MODIFIER:exon18/18:c.*2499G>A:,ALDH7A1:NM_001201377.1:3'UTR:MODIFIER:exon18/18:c.*2499G>A:,ALDH7A1:NM_001202404.1:3'UTR:MODIFIER:exon16/16:c.*2499G>A:	AluJr	rs7715516	0.4856	0.0000	0/0/0	0.0849							107323 [ALDH7A1 (confirmed) Epilepsy,pyridoxine-dependent,266100];	RCV000402037.1 [benign]; 			44	70					ALDH7A1 (inh=AR pLI=0.00)
chr5	125878908	125878908	C	A	hom	het	het		QUAL=19970;DP=390,226,328;MQM=59	ALDH7A1	3'UTR	ALDH7A1:NM_001182.4:3'UTR:MODIFIER:exon18/18:c.*1749G>T:,ALDH7A1:NM_001201377.1:3'UTR:MODIFIER:exon18/18:c.*1749G>T:,ALDH7A1:NM_001202404.1:3'UTR:MODIFIER:exon16/16:c.*1749G>T:		rs744722	0.3732	0.0000	0/0/0	0.2795							107323 [ALDH7A1 (confirmed) Epilepsy,pyridoxine-dependent,266100];	RCV000320250.1 [benign]; 			34	107					ALDH7A1 (inh=AR pLI=0.00)
chr5	125878909	125878909	A	T	hom	het	het		QUAL=19970;DP=390,226,328;MQM=59	ALDH7A1	3'UTR	ALDH7A1:NM_001182.4:3'UTR:MODIFIER:exon18/18:c.*1748T>A:,ALDH7A1:NM_001201377.1:3'UTR:MODIFIER:exon18/18:c.*1748T>A:,ALDH7A1:NM_001202404.1:3'UTR:MODIFIER:exon16/16:c.*1748T>A:		rs744721	0.3732	0.0000	0/0/0	0.2767							107323 [ALDH7A1 (confirmed) Epilepsy,pyridoxine-dependent,266100];	RCV000280862.1 [benign]; 			34	107					ALDH7A1 (inh=AR pLI=0.00)
chr5	125878955	125878955	A	-	hom	het	hom		QUAL=22583;DP=397,153,232;MQM=59	ALDH7A1	3'UTR	ALDH7A1:NM_001182.4:3'UTR:MODIFIER:exon18/18:c.*1702delT:,ALDH7A1:NM_001201377.1:3'UTR:MODIFIER:exon18/18:c.*1702delT:,ALDH7A1:NM_001202404.1:3'UTR:MODIFIER:exon16/16:c.*1702delT:		rs796838466	0.5705	0.0000	0/0/0	0.5105							107323 [ALDH7A1 (confirmed) Epilepsy,pyridoxine-dependent,266100];	RCV000296078.1 [benign]; 			66	107					ALDH7A1 (inh=AR pLI=0.00)
chr5	125879549	125879549	C	T	hom	het	hom		QUAL=12141;DP=250,94,103;MQM=60	ALDH7A1	3'UTR	ALDH7A1:NM_001182.4:3'UTR:MODIFIER:exon18/18:c.*1108G>A:,ALDH7A1:NM_001201377.1:3'UTR:MODIFIER:exon18/18:c.*1108G>A:,ALDH7A1:NM_001202404.1:3'UTR:MODIFIER:exon16/16:c.*1108G>A:		rs1483780	0.4916	0.0000	0/0/0	0.0900							107323 [ALDH7A1 (confirmed) Epilepsy,pyridoxine-dependent,266100];	RCV000263699.1 [benign]; 			65	111					ALDH7A1 (inh=AR pLI=0.00)
chr5	125879677	125879677	G	T	het	het	het		QUAL=71;DP=136,41,58;MQM=60	ALDH7A1	3'UTR	ALDH7A1:NM_001182.4:3'UTR:MODIFIER:exon18/18:c.*980C>A:,ALDH7A1:NM_001201377.1:3'UTR:MODIFIER:exon18/18:c.*980C>A:,ALDH7A1:NM_001202404.1:3'UTR:MODIFIER:exon16/16:c.*980C>A:	AluSx1	rs74892068	0.0000	0.0000	0/0/0	0.0003							107323 [ALDH7A1 (confirmed) Epilepsy,pyridoxine-dependent,266100];				0	17					ALDH7A1 (inh=AR pLI=0.00)
chr5	125879839	125879839	C	T	wt	het	wt	low_QUAL;low_DP	QUAL=26;DP=65,5,7;MQM=60	ALDH7A1	3'UTR	ALDH7A1:NM_001182.4:3'UTR:MODIFIER:exon18/18:c.*818G>A:,ALDH7A1:NM_001201377.1:3'UTR:MODIFIER:exon18/18:c.*818G>A:,ALDH7A1:NM_001202404.1:3'UTR:MODIFIER:exon16/16:c.*818G>A:	AluSx1	rs1138005	0.4010	0.0000	0/0/0	0.3950							107323 [ALDH7A1 (confirmed) Epilepsy,pyridoxine-dependent,266100];	RCV000345823.1 [benign]; 			53	87					ALDH7A1 (inh=AR pLI=0.00)
chr5	125879850	125879850	G	C	hom	het	hom	low_DP	QUAL=2106;DP=69,3,6;MQM=59	ALDH7A1	3'UTR	ALDH7A1:NM_001182.4:3'UTR:MODIFIER:exon18/18:c.*807C>G:,ALDH7A1:NM_001201377.1:3'UTR:MODIFIER:exon18/18:c.*807C>G:,ALDH7A1:NM_001202404.1:3'UTR:MODIFIER:exon16/16:c.*807C>G:	AluSx1	rs1807	0.5759	0.0000	0/0/0	0.5148							107323 [ALDH7A1 (confirmed) Epilepsy,pyridoxine-dependent,266100];	RCV000395618.1 [benign]; 			63	84					ALDH7A1 (inh=AR pLI=0.00)
chr5	125879931	125879931	G	A	wt	het	wt	low_DP	QUAL=140;DP=125,13,16;MQM=58	ALDH7A1	3'UTR	ALDH7A1:NM_001182.4:3'UTR:MODIFIER:exon18/18:c.*726C>T:,ALDH7A1:NM_001201377.1:3'UTR:MODIFIER:exon18/18:c.*726C>T:,ALDH7A1:NM_001202404.1:3'UTR:MODIFIER:exon16/16:c.*726C>T:	AluSx1	rs1060857	0.4008	0.0000	0/0/0	0.0673							107323 [ALDH7A1 (confirmed) Epilepsy,pyridoxine-dependent,266100];	RCV000306046.1 [benign]; 			50	110					ALDH7A1 (inh=AR pLI=0.00)
chr5	125879981	125879981	G	A	hom	hom	hom		QUAL=4828;DP=85,32,35;MQM=59	ALDH7A1	3'UTR	ALDH7A1:NM_001182.4:3'UTR:MODIFIER:exon18/18:c.*676C>T:,ALDH7A1:NM_001201377.1:3'UTR:MODIFIER:exon18/18:c.*676C>T:,ALDH7A1:NM_001202404.1:3'UTR:MODIFIER:exon16/16:c.*676C>T:		rs7447380	0.9974	0.0000	0/0/0	0.1496							107323 [ALDH7A1 (confirmed) Epilepsy,pyridoxine-dependent,266100];				230	0					ALDH7A1 (inh=AR pLI=0.00)
chr5	125880109	125880109	G	A	wt	het	wt		QUAL=1460;DP=161,137,138;MQM=60	ALDH7A1	3'UTR	ALDH7A1:NM_001182.4:3'UTR:MODIFIER:exon18/18:c.*548C>T:,ALDH7A1:NM_001201377.1:3'UTR:MODIFIER:exon18/18:c.*548C>T:,ALDH7A1:NM_001202404.1:3'UTR:MODIFIER:exon16/16:c.*548C>T:		rs1060856	0.0976	0.0000	0/0/0	0.0211							107323 [ALDH7A1 (confirmed) Epilepsy,pyridoxine-dependent,266100];	RCV000357159.1 [likely benign]; 			11	52					ALDH7A1 (inh=AR pLI=0.00)
chr5	125880589	125880589	T	C	hom	het	het		QUAL=10830;DP=209,128,161;MQM=58	ALDH7A1	3'UTR	ALDH7A1:NM_001182.4:3'UTR:MODIFIER:exon18/18:c.*68A>G:,ALDH7A1:NM_001201377.1:3'UTR:MODIFIER:exon18/18:c.*68A>G:,ALDH7A1:NM_001202404.1:3'UTR:MODIFIER:exon16/16:c.*68A>G:		rs2775	0.3606	0.0000	0/0/0	0.0868							107323 [ALDH7A1 (confirmed) Epilepsy,pyridoxine-dependent,266100];	RCV000277754.1 [benign]; 			151	315					ALDH7A1 (inh=AR pLI=0.00)
chr5	125931022	125931022	T	G	hom	het	het		QUAL=1293;DP=24,30,33;MQM=59	ALDH7A1	5'UTR	ALDH7A1:NM_001182.4:5'UTR:MODIFIER:exon1/18:c.-132A>C:,ALDH7A1:NM_001201377.1:5'UTR:MODIFIER:exon1/18:c.-216A>C:,ALDH7A1:NM_001202404.1:5'UTR:MODIFIER:exon1/16:c.-132A>C:		rs900641	0.2464	0.0000	0/0/0	0.0210							107323 [ALDH7A1 (confirmed) Epilepsy,pyridoxine-dependent,266100];	RCV000326835.1 [benign]; 			9	166					ALDH7A1 (inh=AR pLI=0.00)
chr5	126112580	126112580	T	C	het	het	wt		QUAL=462;DP=35,33,43;MQM=60	LMNB1	5'UTR,non_coding_transcript_exon	LMNB1:NM_005573.3:5'UTR:MODIFIER:exon1/11:c.-621T>C:,LMNB1:NR_134488.1:non_coding_transcript_exon:MODIFIER:exon1/12:n.266T>C:		rs35091677	0.2324	0.0000	0/0/0	0.2185							150340 [LMNB1 (confirmed) Leukodystrophy,adult-onset,autosomal dominant,169500];	RCV000397765.1 [benign]; 			7	48					LMNB1 (inh=AD pLI=0.95)
chr5	126171999	126171999	T	C	hom	hom	hom		QUAL=17467;DP=215,116,198;MQM=60	LMNB1	3'UTR,non_coding_transcript_exon	LMNB1:NM_005573.3:3'UTR:MODIFIER:exon11/11:c.*43T>C:,LMNB1:NM_001198557.1:3'UTR:MODIFIER:exon11/11:c.*43T>C:,LMNB1:NR_134488.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.2768T>C:		rs1051643	0.6727	0.6751	27655/14739/2303	0.6616							150340 [LMNB1 (confirmed) Leukodystrophy,adult-onset,autosomal dominant,169500];	RCV000369546.1 [benign]; 			408	383					LMNB1 (inh=AD pLI=0.95)
chr5	126172195	126172195	C	T	het	hom	het		QUAL=3724;DP=125,45,54;MQM=60	LMNB1	3'UTR,non_coding_transcript_exon	LMNB1:NM_005573.3:3'UTR:MODIFIER:exon11/11:c.*239C>T:,LMNB1:NM_001198557.1:3'UTR:MODIFIER:exon11/11:c.*239C>T:,LMNB1:NR_134488.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.2964C>T:		rs1051644	0.4479	0.0000	0/0/0	0.0793							150340 [LMNB1 (confirmed) Leukodystrophy,adult-onset,autosomal dominant,169500];	RCV000277393.1 [benign]; 			50	114					LMNB1 (inh=AD pLI=0.95)
chr5	127593732	127593732	C	T	wt	wt	het		QUAL=966;DP=185,115,143;MQM=60	FBN2	3'UTR	FBN2:NM_001999.3:3'UTR:MODIFIER:exon65/65:c.*1415G>A:		rs1050687	0.2446	0.0000	0/0/0	0.1284							612570 [FBN2 (provisional) Contractural arachnodactyly,congenital,121050|Macular degeneration,early-onset,616118];	RCV000404131.1 [benign]; 			0	44					FBN2 (inh=AD pLI=1.00)
chr5	127593870	127593870	C	T	wt	wt	het		QUAL=5491;DP=634,370,552;MQM=60	FBN2	3'UTR	FBN2:NM_001999.3:3'UTR:MODIFIER:exon65/65:c.*1277G>A:		rs7288	0.1142	0.0000	0/0/0	0.0175							612570 [FBN2 (provisional) Contractural arachnodactyly,congenital,121050|Macular degeneration,early-onset,616118];	RCV000348358.1 [benign]; 			0	45					FBN2 (inh=AD pLI=1.00)
chr5	127594414	127594414	A	T	wt	wt	het		QUAL=3033;DP=383,173,219;MQM=60	FBN2	3'UTR	FBN2:NM_001999.3:3'UTR:MODIFIER:exon65/65:c.*733T>A:		rs13305	0.2622	0.0000	0/0/0	0.0254							612570 [FBN2 (provisional) Contractural arachnodactyly,congenital,121050|Macular degeneration,early-onset,616118];	RCV000266922.1 [benign]; 			1	44					FBN2 (inh=AD pLI=1.00)
chr5	127594512	127594512	T	C	hom	hom	hom		QUAL=18597;DP=247,135,185;MQM=60	FBN2	3'UTR	FBN2:NM_001999.3:3'UTR:MODIFIER:exon65/65:c.*635A>G:		rs27858	0.9856	0.0000	0/0/0	0.1519							612570 [FBN2 (provisional) Contractural arachnodactyly,congenital,121050|Macular degeneration,early-onset,616118];	RCV000372113.1 [benign]; 			214	15					FBN2 (inh=AD pLI=1.00)
chr5	127597518	127597518	G	A	wt	wt	het		QUAL=2850;DP=264,175,208;MQM=60	FBN2	synonymous	FBN2:NM_001999.3:synonymous:LOW:exon64/65:c.8274C>T:p.Ser2758Ser		rs10070365	0.1128	0.1043	778/459/151	0.1037							612570 [FBN2 (provisional) Contractural arachnodactyly,congenital,121050|Macular degeneration,early-onset,616118];	RCV000117034.4 [benign]; RCV000243294.1 [benign]; RCV000403969.1 [benign]; 			17	312					FBN2 (inh=AD pLI=1.00)
chr5	127614472	127614472	A	G	wt	wt	het		QUAL=2780;DP=265,263,301;MQM=60	FBN2	synonymous	FBN2:NM_001999.3:synonymous:LOW:exon57/65:c.7200T>C:p.Ser2400Ser		rs190450	0.7266	0.7281	32454/17179/2016	0.7156							612570 [FBN2 (provisional) Contractural arachnodactyly,congenital,121050|Macular degeneration,early-onset,616118];	RCV000117030.4 [benign]; RCV000254449.1 [benign]; RCV000269057.1 [benign]; 			855	611					FBN2 (inh=AD pLI=1.00)
chr5	127638759	127638759	A	G	het	het	wt		QUAL=3966;DP=268,68,128;MQM=60	FBN2	synonymous	FBN2:NM_001999.3:synonymous:LOW:exon46/65:c.5823T>C:p.His1941His		rs11955288	0.0929	0.0949	584/328/52	0.0937							612570 [FBN2 (provisional) Contractural arachnodactyly,congenital,121050|Macular degeneration,early-onset,616118];	RCV000117025.4 [benign]; RCV000245587.1 [benign]; RCV000278198.1 [likely benign]; 		COSM4159390, COSM4159389	31	260					FBN2 (inh=AD pLI=1.00)
chr5	127640783	127640783	G	A	het	het	het		QUAL=7403;DP=180,147,246;MQM=60	FBN2	splice_region&intron	FBN2:NM_001999.3:splice_region&intron:LOW:exon44/64:c.5675-9C>T:		rs27713	0.7344	0.7258	26406/14136/1341	0.6731							612570 [FBN2 (provisional) Contractural arachnodactyly,congenital,121050|Macular degeneration,early-onset,616118];	RCV000117024.5 [other]; RCV000374659.1 [benign]; 			846	619					FBN2 (inh=AD pLI=1.00)
chr5	127685135	127685135	C	T	hom	het	het	pred_pathogenic	QUAL=15309;DP=302,206,275;MQM=60	FBN2	missense	FBN2:NM_001999.3:missense:MODERATE:exon23/65:c.2893G>A:p.Val965Ile		rs154001	0.7310	0.7234	32094/15903/1986	0.7148	3.8840	T,T,T	T	B,B	D,D,D	22.30	612570 [FBN2 (provisional) Contractural arachnodactyly,congenital,121050|Macular degeneration,early-onset,616118];	RCV000117020.4 [benign]; RCV000244792.1 [benign]; RCV000342582.1 [benign]; 	CM1413000 [CLASS=DP MUT=REF PHEN="Macular degeneration age related association with" GENE=FBN2]; 		803	622					FBN2 (inh=AD pLI=1.00)
chr5	127873094	127873094	G	A	het	het	wt	pred_pathogenic	QUAL=2017;DP=53,134,192;MQM=59	FBN2	missense	FBN2:NM_001999.3:missense:MODERATE:exon1/65:c.203C>T:p.Ala68Val		rs62390671	0.0148	0.0331	68/61/0	0.0292	1.9370	T,T,T,T	T	B,B,B,B	D,D,D,T	15.39	612570 [FBN2 (provisional) Contractural arachnodactyly,congenital,121050|Macular degeneration,early-onset,616118];	RCV000079963.10 [other]; RCV000247352.1 [benign]; RCV000383512.1 [likely benign]; 			1	106					FBN2 (inh=AD pLI=1.00)
chr5	127873114	127873114	G	C	wt	wt	het		QUAL=2947;DP=61,161,223;MQM=60	FBN2	synonymous	FBN2:NM_001999.3:synonymous:LOW:exon1/65:c.183C>G:p.Pro61Pro		rs73348287	0.0994	0.0920	465/212/141	0.0762							612570 [FBN2 (provisional) Contractural arachnodactyly,congenital,121050|Macular degeneration,early-onset,616118];	RCV000117017.5 [other]; RCV000248936.1 [benign]; RCV000270275.1 [benign]; 			15	247					FBN2 (inh=AD pLI=1.00)
chr5	127873186	127873186	C	T	wt	wt	het		QUAL=2034;DP=79,186,230;MQM=60	FBN2	synonymous	FBN2:NM_001999.3:synonymous:LOW:exon1/65:c.111G>A:p.Pro37Pro	G-rich	rs55715053	0.1378	0.1174	430/120/224	0.0742							612570 [FBN2 (provisional) Contractural arachnodactyly,congenital,121050|Macular degeneration,early-onset,616118];	RCV000117015.4 [other]; RCV000243412.1 [benign]; RCV000325371.1 [benign]; 		COSM3749898, COSM3749897	16	249					FBN2 (inh=AD pLI=1.00)
chr5	127873605	127873605	T	C	het	het	het		QUAL=2624;DP=76,59,69;MQM=59	FBN2	5'UTR	FBN2:NM_001999.3:5'UTR:MODIFIER:exon1/65:c.-309A>G:		rs7732639	0.4375	0.0000	0/0/0	0.0554							612570 [FBN2 (provisional) Contractural arachnodactyly,congenital,121050|Macular degeneration,early-onset,616118];	RCV000406164.1 [benign]; 			16	86					FBN2 (inh=AD pLI=1.00)
chr5	131705458	131705458	C	G	het	wt	het	low_DP	QUAL=134;DP=6,4,8;MQM=60	SLC22A5,LOC553103	5'UTR,intron	SLC22A5:NM_001308122.1:5'UTR:MODIFIER:exon1/11:c.-207C>G:,SLC22A5:NM_003060.3:5'UTR:MODIFIER:exon1/10:c.-207C>G:,LOC553103:NR_110997.1:intron:MODIFIER:exon1/7:n.73+78G>C:		rs2631367	0.7330	0.0000	0/0/0	0.0936							603377 [SLC22A5 (confirmed) Carnitine deficiency,systemic primary,212140];	RCV000022284.2 [not provided]; RCV000265402.1 [benign]; 	CR041140 [CLASS=DFP MUT=REF PHEN="Crohn's disease susceptibility association with" GENE=SLC22A5]; 		56	96					SLC22A5 (inh=AR pLI=0.00), LOC553103 (inh=n/a pLI=n/a)
chr5	131705949	131705949	T	C	het	wt	het		QUAL=3123;DP=39,217,311;MQM=57	SLC22A5	synonymous	SLC22A5:NM_001308122.1:synonymous:LOW:exon1/11:c.285T>C:p.Leu95Leu,SLC22A5:NM_003060.3:synonymous:LOW:exon1/10:c.285T>C:p.Leu95Leu	(GGAGCT)n	rs2631365	0.4862	0.4968	6001/2365/201	0.3654							603377 [SLC22A5 (confirmed) Carnitine deficiency,systemic primary,212140];	RCV000022310.2 [not provided]; RCV000080053.5 [benign]; RCV000406963.1 [benign]; 		COSM4005841, COSM4005840	320	716					SLC22A5 (inh=AR pLI=0.00)
chr5	131706028	131706028	G	T	het	wt	het	pred_pathogenic;anno_pathogenic_clinvar;anno_pathogenic_hgmd	QUAL=7123;DP=178,355,467;MQM=59	SLC22A5	missense	SLC22A5:NM_001308122.1:missense:MODERATE:exon1/11:c.364G>T:p.Asp122Tyr,SLC22A5:NM_003060.3:missense:MODERATE:exon1/10:c.364G>T:p.Asp122Tyr		rs201082652	0.0000	0.0004	0/0/0	0.0004	6.0270	D,D,D	D	D,D	D,T,T	26.30	603377 [SLC22A5 (confirmed) Carnitine deficiency,systemic primary,212140];	RCV000022318.3 [pathogenic]; RCV000186160.3 [pathogenic]; 	CM104584 [CLASS=DM MUT=ALT PHEN="Carnitine deficiency systemic primary" GENE=SLC22A5]; 		0	5					SLC22A5 (inh=AR pLI=0.00)
chr5	131719999	131719999	A	G	hom	hom	hom		QUAL=28847;DP=218,290,408;MQM=60	SLC22A5	splice_region&intron,sequence_feature	SLC22A5:NM_001308122.1:splice_region&intron:LOW:exon4/10:c.724+6A>G:,SLC22A5:NM_003060.3:splice_region&intron:LOW:exon3/9:c.652+6A>G:,SLC22A5:NM_001308122.1:sequence_feature:LOW::c.724+6A>G:,SLC22A5:NM_003060.3:sequence_feature:LOW::c.652+6A>G:		rs4551059	1.0000	1.0000	60705/33370/5203	0.9363							603377 [SLC22A5 (confirmed) Carnitine deficiency,systemic primary,212140];	RCV000022335.3 [benign]; RCV000080057.6 [benign]; 			1566	0					SLC22A5 (inh=AR pLI=0.00)
chr5	131721174	131721174	A	G	het	wt	het		QUAL=9108;DP=430,239,315;MQM=60	SLC22A5	synonymous	SLC22A5:NM_001308122.1:synonymous:LOW:exon5/11:c.879A>G:p.Leu293Leu,SLC22A5:NM_003060.3:synonymous:LOW:exon4/10:c.807A>G:p.Leu269Leu		rs274558	0.4862	0.4393	12476/5231/669	0.4317							603377 [SLC22A5 (confirmed) Carnitine deficiency,systemic primary,212140];	RCV000022346.2 [not provided]; RCV000080060.5 [benign]; RCV000402674.1 [benign]; 		COSM3760912, COSM3760913	320	733					SLC22A5 (inh=AR pLI=0.00)
chr5	131730011	131730011	C	T	het	wt	het		QUAL=11989;DP=478,329,441;MQM=59	SLC22A5	3'UTR	SLC22A5:NM_001308122.1:3'UTR:MODIFIER:exon11/11:c.*47C>T:,SLC22A5:NM_003060.3:3'UTR:MODIFIER:exon10/10:c.*47C>T:		rs1045020	0.0517	0.1033	909/622/3	0.1000							603377 [SLC22A5 (confirmed) Carnitine deficiency,systemic primary,212140];	RCV000022391.3 [likely benign]; 			9	170					SLC22A5 (inh=AR pLI=0.00)
chr5	131730053	131730053	A	-	hom	hom	hom		QUAL=30418;DP=319,294,391;MQM=59	SLC22A5	3'UTR	SLC22A5:NM_001308122.1:3'UTR:MODIFIER:exon11/11:c.*92delA:,SLC22A5:NM_003060.3:3'UTR:MODIFIER:exon10/10:c.*92delA:		rs397999277	0.7552	0.0000	0/0/0	0.1669							603377 [SLC22A5 (confirmed) Carnitine deficiency,systemic primary,212140];	RCV000278333.1 [benign]; 			254	126					SLC22A5 (inh=AR pLI=0.00)
chr5	131730807	131730807	T	C	hom	hom	hom		QUAL=20582;DP=404,100,116;MQM=59	SLC22A5	3'UTR	SLC22A5:NM_001308122.1:3'UTR:MODIFIER:exon11/11:c.*843T>C:,SLC22A5:NM_003060.3:3'UTR:MODIFIER:exon10/10:c.*843T>C:	(TTTG)n	rs274548	0.7442	0.0000	0/0/0	0.1265							603377 [SLC22A5 (confirmed) Carnitine deficiency,systemic primary,212140];	RCV000347688.1 [benign]; 			157	65					SLC22A5 (inh=AR pLI=0.00)
chr5	131730920	131730920	T	A	het	het	het		QUAL=2071;DP=88,31,40;MQM=59	SLC22A5	3'UTR	SLC22A5:NM_001308122.1:3'UTR:MODIFIER:exon11/11:c.*956T>A:,SLC22A5:NM_003060.3:3'UTR:MODIFIER:exon10/10:c.*956T>A:	(T)n	rs72795171	0.0000	0.0000	0/0/0	0.0025							603377 [SLC22A5 (confirmed) Carnitine deficiency,systemic primary,212140];				8	42					SLC22A5 (inh=AR pLI=0.00)
chr5	131730923	131730923	A	C	het	het	het		QUAL=2071;DP=88,31,40;MQM=59	SLC22A5	3'UTR	SLC22A5:NM_001308122.1:3'UTR:MODIFIER:exon11/11:c.*959A>C:,SLC22A5:NM_003060.3:3'UTR:MODIFIER:exon10/10:c.*959A>C:		rs14701	0.0000	0.0000	0/0/0	0.0055							603377 [SLC22A5 (confirmed) Carnitine deficiency,systemic primary,212140];				8	126					SLC22A5 (inh=AR pLI=0.00)
chr5	131731304	131731304	A	T	hom	hom	hom		QUAL=10677;DP=230,41,66;MQM=60	SLC22A5	splice_region,3'UTR	SLC22A5:NM_001308122.1:splice_region:LOW:exon11/11:c.*1340A>T:,SLC22A5:NM_003060.3:splice_region:LOW:exon10/10:c.*1340A>T:,SLC22A5:NM_001308122.1:3'UTR:MODIFIER:exon11/11:c.*1340A>T:,SLC22A5:NM_003060.3:3'UTR:MODIFIER:exon10/10:c.*1340A>T:		rs274547	0.7442	0.0000	0/0/0	0.7418							603377 [SLC22A5 (confirmed) Carnitine deficiency,systemic primary,212140];				157	63					SLC22A5 (inh=AR pLI=0.00)
chr5	131892979	131892979	G	A	hom	hom	hom		QUAL=13652;DP=182,103,159;MQM=60	RAD50	5'UTR	RAD50:NM_005732.3:5'UTR:MODIFIER:exon1/25:c.-38G>A:		rs4526098	0.9249	0.9752	57988/33161/2994	0.9411							604040 [RAD50 (provisional) Nijmegen breakage syndrome-like disorder,613078];	RCV000160912.1 [benign]; 			1137	15					RAD50 (inh=AR pLI=0.00)
chr5	132203997	132203997	A	G	het	wt	hom		QUAL=19542;DP=406,326,435;MQM=59	UQCRQ	3'UTR	UQCRQ:NM_014402.4:3'UTR:MODIFIER:exon3/3:c.*723A>G:	MIR	rs17166297	0.1707	0.0000	0/0/0	0.1820							612080 [UQCRQ (provisional) Mitochondrial complex III deficiency,nuclear type 4,615159];	RCV000360846.1 [likely benign]; 			10	49					UQCRQ (inh=AR pLI=0.09)
chr5	132204031	132204031	G	A	het	wt	hom		QUAL=16599;DP=377,301,368;MQM=59	UQCRQ	3'UTR	UQCRQ:NM_014402.4:3'UTR:MODIFIER:exon3/3:c.*757G>A:	MIR	rs17624157	0.0479	0.0000	0/0/0	0.1134							612080 [UQCRQ (provisional) Mitochondrial complex III deficiency,nuclear type 4,615159];	RCV000321398.1 [likely benign]; 			9	43					UQCRQ (inh=AR pLI=0.09)
chr5	132204448	132204448	G	-	het	hom	wt		QUAL=13741;DP=412,293,363;MQM=59	UQCRQ	3'UTR	UQCRQ:NM_014402.4:3'UTR:MODIFIER:exon3/3:c.*1175delG:		rs67367845	0.4253	0.0000	0/0/0	0.4455							612080 [UQCRQ (provisional) Mitochondrial complex III deficiency,nuclear type 4,615159];	RCV000293411.1 [likely benign]; 			38	78					UQCRQ (inh=AR pLI=0.09)
chr5	132204467	132204467	A	G	het	hom	wt		QUAL=15584;DP=491,294,368;MQM=59	UQCRQ	3'UTR	UQCRQ:NM_014402.4:3'UTR:MODIFIER:exon3/3:c.*1193A>G:		rs254284	0.0000	0.0000	0/0/0	0.3917							612080 [UQCRQ (provisional) Mitochondrial complex III deficiency,nuclear type 4,615159];				39	79					UQCRQ (inh=AR pLI=0.09)
chr5	133956668	133956668	G	A	wt	het	wt		QUAL=3562;DP=361,302,398;MQM=60	SAR1B	synonymous	SAR1B:NM_001033503.2:synonymous:LOW:exon4/8:c.133C>T:p.Leu45Leu,SAR1B:NM_016103.3:synonymous:LOW:exon3/7:c.133C>T:p.Leu45Leu		rs11558540	0.1679	0.1458	2025/423/12	0.1435							607690 [SAR1B (provisional) Chylomicron retention disease,246700];			COSM4003284	24	345					SAR1B (inh=AR pLI=0.01)
chr5	137206560	137206560	A	C	hom	hom	hom	pred_pathogenic;anno_pathogenic_hgmd	QUAL=21668;DP=180,242,261;MQM=59	MYOT	missense,splice_region&intron,intron	MYOT:NM_006790.2:missense:MODERATE:exon2/10:c.220A>C:p.Lys74Gln,MYOT:NM_001300911.1:splice_region&intron:LOW:exon2/10:c.-120-6A>C:,MYOT:NM_001135940.1:intron:MODIFIER:exon2/9:c.-197+346A>C:		rs6890689	0.0000	0.9959	60215/33356/4749	0.8996	2.8090	T	T	B	T	0.66	604103 [MYOT (confirmed) Muscular dystrophy,limb-girdle,type 1A,159000|Myopathy,myofibrillar,3,609200|Myopathy,spheroid body,182920];	RCV000153527.3 [benign]; 	CM056011 [CLASS=DM MUT=REF PHEN="Myotilinopathy" GENE=MYOT]; 		1482	3	2	[2] old entry - no details available			MYOT (inh=AD pLI=0.00)
chr5	138456815	138456815	T	C	het	wt	hom		QUAL=16336;DP=246,298,406;MQM=59	SIL1	synonymous	SIL1:NM_001037633.1:synonymous:LOW:exon4/11:c.153A>G:p.Thr51Thr,SIL1:NM_022464.4:synonymous:LOW:exon3/10:c.153A>G:p.Thr51Thr		rs3088052	0.4269	0.4354	12233/6708/2342	0.4277							608005 [SIL1 (confirmed) Marinesco-Sjogren syndrome,248800];	RCV000082151.8 [other]; RCV000270107.1 [benign]; 			659	1577	1	[1] Florian Harmuth 23.11.2015 [n/a] comment imported from detected variant: frequency is almost 50% in different databases			SIL1 (inh=AR pLI=0.00)
chr5	138609609	138609609	C	G	het	wt	het		QUAL=5213;DP=232,195,245;MQM=60	MATR3,SNHG4	5'UTR,non_coding_transcript_exon	MATR3:NM_001194954.1:5'UTR:MODIFIER:exon1/17:c.-528C>G:,MATR3:NM_001282278.1:5'UTR:MODIFIER:exon1/17:c.-535C>G:,MATR3:NM_199189.2:5'UTR:MODIFIER:exon1/18:c.-610C>G:,SNHG4:NR_003141.3:non_coding_transcript_exon:MODIFIER:exon1/4:n.169C>G:,SNHG4:NR_036536.1:non_coding_transcript_exon:MODIFIER:exon1/5:n.169C>G:		rs11242456	0.4203	0.6325	2230/568/10	0.1454							164015 [MATR3 (provisional) Amyotrophic lateral sclerosis 21,606070];	RCV000312604.1 [benign]; 			242	261					MATR3 (inh=AD pLI=1.00), SNHG4 (inh=n/a pLI=n/a)
chr5	138614072	138614072	T	G	het	wt	wt		QUAL=363;DP=266,166,203;MQM=60	MATR3,SNHG4	5'UTR,intron,non_coding_transcript_exon	MATR3:NM_001282278.1:5'UTR:MODIFIER:exon3/17:c.-207T>G:,MATR3:NM_199189.2:5'UTR:MODIFIER:exon3/18:c.-282T>G:,MATR3:NM_001194954.1:intron:MODIFIER:exon2/16:c.-256-668T>G:,SNHG4:NR_003141.3:non_coding_transcript_exon:MODIFIER:exon3/4:n.497T>G:,SNHG4:NR_036536.1:non_coding_transcript_exon:MODIFIER:exon3/5:n.497T>G:		rs776067427	0.0000	0.0001	0/0/0	0.0001							164015 [MATR3 (provisional) Amyotrophic lateral sclerosis 21,606070];				0	8					MATR3 (inh=AD pLI=1.00), SNHG4 (inh=n/a pLI=n/a)
chr5	138642997	138642997	-	T	het	wt	hom		QUAL=6447;DP=239,72,117;MQM=59	MATR3	5'UTR,intron	MATR3:NM_001194954.1:5'UTR:MODIFIER:exon4/17:c.-103dupT:,MATR3:NM_199189.2:5'UTR:MODIFIER:exon5/18:c.-103dupT:,MATR3:NM_018834.5:5'UTR:MODIFIER:exon2/15:c.-103dupT:,MATR3:NM_001194955.1:5'UTR:MODIFIER:exon2/15:c.-103dupT:,MATR3:NM_001282278.1:intron:MODIFIER:exon4/16:c.-102-7362dupT:,MATR3:NM_001194956.1:intron:MODIFIER:exon1/13:c.49-7362dupT:		rs112107315;rs59150359	0.4317	0.0000	0/0/0	0.5447							164015 [MATR3 (provisional) Amyotrophic lateral sclerosis 21,606070];				79	84					MATR3 (inh=AD pLI=1.00)
chr5	138643062	138643062	T	A	het	wt	hom		QUAL=6225;DP=182,85,120;MQM=59	MATR3	5'UTR,intron	MATR3:NM_001194954.1:5'UTR:MODIFIER:exon4/17:c.-43T>A:,MATR3:NM_199189.2:5'UTR:MODIFIER:exon5/18:c.-43T>A:,MATR3:NM_018834.5:5'UTR:MODIFIER:exon2/15:c.-43T>A:,MATR3:NM_001194955.1:5'UTR:MODIFIER:exon2/15:c.-43T>A:,MATR3:NM_001282278.1:intron:MODIFIER:exon4/16:c.-102-7302T>A:,MATR3:NM_001194956.1:intron:MODIFIER:exon1/13:c.49-7302T>A:		rs12153162	0.4465	0.6510	19481/12762/240	0.5511							164015 [MATR3 (provisional) Amyotrophic lateral sclerosis 21,606070];	RCV000253508.1 [benign]; RCV000265860.1 [benign]; 			334	296					MATR3 (inh=AD pLI=1.00)
chr5	138665756	138665756	G	A	het	wt	hom		QUAL=7146;DP=293,71,95;MQM=59	MATR3	3'UTR	MATR3:NM_001194954.1:3'UTR:MODIFIER:exon17/17:c.*672G>A:,MATR3:NM_001282278.1:3'UTR:MODIFIER:exon17/17:c.*672G>A:,MATR3:NM_199189.2:3'UTR:MODIFIER:exon18/18:c.*672G>A:,MATR3:NM_018834.5:3'UTR:MODIFIER:exon15/15:c.*672G>A:,MATR3:NM_001194955.1:3'UTR:MODIFIER:exon15/15:c.*672G>A:,MATR3:NM_001194956.1:3'UTR:MODIFIER:exon14/14:c.*672G>A:		rs7305	0.0000	0.6235	2459/799/9	0.1367							164015 [MATR3 (provisional) Amyotrophic lateral sclerosis 21,606070];	RCV000285762.1 [benign]; 			281	300					MATR3 (inh=AD pLI=1.00)
chr5	138665792	138665792	T	C	wt	het	wt		QUAL=1420;DP=299,93,123;MQM=60	MATR3	3'UTR	MATR3:NM_001194954.1:3'UTR:MODIFIER:exon17/17:c.*708T>C:,MATR3:NM_001282278.1:3'UTR:MODIFIER:exon17/17:c.*708T>C:,MATR3:NM_199189.2:3'UTR:MODIFIER:exon18/18:c.*708T>C:,MATR3:NM_018834.5:3'UTR:MODIFIER:exon15/15:c.*708T>C:,MATR3:NM_001194955.1:3'UTR:MODIFIER:exon15/15:c.*708T>C:,MATR3:NM_001194956.1:3'UTR:MODIFIER:exon14/14:c.*708T>C:		rs14109	0.0184	0.0166	10/5/0	0.0076							164015 [MATR3 (provisional) Amyotrophic lateral sclerosis 21,606070];	RCV000336157.1 [likely benign]; 			1	69					MATR3 (inh=AD pLI=1.00)
chr5	138665906	138665906	A	G	wt	wt	het		QUAL=2262;DP=398,145,197;MQM=60	MATR3	3'UTR	MATR3:NM_001194954.1:3'UTR:MODIFIER:exon17/17:c.*822A>G:,MATR3:NM_001282278.1:3'UTR:MODIFIER:exon17/17:c.*822A>G:,MATR3:NM_199189.2:3'UTR:MODIFIER:exon18/18:c.*822A>G:,MATR3:NM_018834.5:3'UTR:MODIFIER:exon15/15:c.*822A>G:,MATR3:NM_001194955.1:3'UTR:MODIFIER:exon15/15:c.*822A>G:,MATR3:NM_001194956.1:3'UTR:MODIFIER:exon14/14:c.*822A>G:			0.0000	0.0000	0/0/0	0.0000							164015 [MATR3 (provisional) Amyotrophic lateral sclerosis 21,606070];				0	1					MATR3 (inh=AD pLI=1.00)
chr5	138666372	138666372	T	G	het	wt	hom		QUAL=5329;DP=257,42,73;MQM=60	MATR3	3'UTR	MATR3:NM_001194954.1:3'UTR:MODIFIER:exon17/17:c.*1288T>G:,MATR3:NM_001282278.1:3'UTR:MODIFIER:exon17/17:c.*1288T>G:,MATR3:NM_199189.2:3'UTR:MODIFIER:exon18/18:c.*1288T>G:,MATR3:NM_018834.5:3'UTR:MODIFIER:exon15/15:c.*1288T>G:,MATR3:NM_001194955.1:3'UTR:MODIFIER:exon15/15:c.*1288T>G:,MATR3:NM_001194956.1:3'UTR:MODIFIER:exon14/14:c.*1288T>G:		rs10515507	0.4000	0.6574	2424/680/5	0.1469							164015 [MATR3 (provisional) Amyotrophic lateral sclerosis 21,606070];	RCV000308658.1 [benign]; 			257	256					MATR3 (inh=AD pLI=1.00)
chr5	140027216	140027216	T	C	het	wt	het		QUAL=4824;DP=169,241,259;MQM=60	NDUFA2	5'UTR,non_coding_transcript_exon	NDUFA2:NM_002488.4:5'UTR:MODIFIER:exon1/3:c.-48A>G:,NDUFA2:NM_001185012.1:5'UTR:MODIFIER:exon1/3:c.-48A>G:,NDUFA2:NR_033697.1:non_coding_transcript_exon:MODIFIER:exon1/2:n.155A>G:		rs778593	0.3778	0.4773	7804/4470/296	0.3896							602137 [NDUFA2 (confirmed) Leigh syndrome due to mitochondrial complex I deficiency,256000];	RCV000355665.1 [likely benign]; 			204	557					NDUFA2 (inh=AR pLI=0.34)
chr5	140027304	140027304	T	C	het	wt	het		QUAL=3283;DP=189,134,152;MQM=60	NDUFA2	5'UTR_premature_start_codon_gain,5'UTR,non_coding_transcript_exon	NDUFA2:NM_002488.4:5'UTR_premature_start_codon_gain:LOW:exon1/3:c.-136A>G:,NDUFA2:NM_001185012.1:5'UTR_premature_start_codon_gain:LOW:exon1/3:c.-136A>G:,NDUFA2:NM_002488.4:5'UTR:MODIFIER:exon1/3:c.-136A>G:,NDUFA2:NM_001185012.1:5'UTR:MODIFIER:exon1/3:c.-136A>G:,NDUFA2:NR_033697.1:non_coding_transcript_exon:MODIFIER:exon1/2:n.67A>G:		rs778594	0.3776	0.4899	4137/2347/159	0.3324							602137 [NDUFA2 (confirmed) Leigh syndrome due to mitochondrial complex I deficiency,256000];	RCV000333463.1 [likely benign]; 			94	276					NDUFA2 (inh=AR pLI=0.34)
chr5	146258290	146258290	-	GCTGCTGCTGCTGCT	wt	wt	het	low_DP	QUAL=182;DP=3,32,58;MQM=59	PPP2R2B	conservative_inframe_insertion,5'UTR,intron,non_coding_transcript_exon	PPP2R2B:NM_181675.3:conservative_inframe_insertion:MODERATE:exon1/10:c.43_57dupAGCAGCAGCAGCAGC:p.Ser15_Ser19dup,PPP2R2B:NM_001271948.1:5'UTR:MODIFIER:exon1/10:c.-789_-775dupAGCAGCAGCAGCAGC:,PPP2R2B:NM_001271899.1:intron:MODIFIER:exon2/9:c.89-177600_89-177586dupAGCAGCAGCAGCAGC:,PPP2R2B:NM_001271900.1:intron:MODIFIER:exon2/10:c.51-547_51-533dupAGCAGCAGCAGCAGC:,PPP2R2B:NM_181674.2:intron:MODIFIER:exon1/9:c.75-547_75-533dupAGCAGCAGCAGCAGC:,PPP2R2B:NM_181676.2:intron:MODIFIER:exon1/8:c.79+176923_79+176937dupAGCAGCAGCAGCAGC:,PPP2R2B:NM_181677.2:intron:MODIFIER:exon3/10:c.10+156427_10+156441dupAGCAGCAGCAGCAGC:,PPP2R2B:NM_181678.2:intron:MODIFIER:exon2/10:c.-48-22159_-48-22145dupAGCAGCAGCAGCAGC:,PPP2R2B:NR_073526.1:non_coding_transcript_exon:MODIFIER:exon1/9:n.44_58dupAGCAGCAGCAGCAGC:,PPP2R2B:NR_073527.1:non_coding_transcript_exon:MODIFIER:exon1/10:n.186_200dupAGCAGCAGCAGCAGC:			0.0000	0.0000	0/0/0	0.0119							604325 [PPP2R2B (provisional) Spinocerebellar ataxia 12,604326];				40	127	1	[1] bauer 22.12.2015			PPP2R2B (inh=AD pLI=0.90)
chr5	146258290	146258290	-	GCTGCTGCT	wt	het	wt	low_DP	QUAL=182;DP=3,32,58;MQM=59	PPP2R2B	conservative_inframe_insertion,5'UTR,intron,non_coding_transcript_exon	PPP2R2B:NM_181675.3:conservative_inframe_insertion:MODERATE:exon1/10:c.49_57dupAGCAGCAGC:p.Ser17_Ser19dup,PPP2R2B:NM_001271948.1:5'UTR:MODIFIER:exon1/10:c.-783_-775dupAGCAGCAGC:,PPP2R2B:NM_001271899.1:intron:MODIFIER:exon2/9:c.89-177594_89-177586dupAGCAGCAGC:,PPP2R2B:NM_001271900.1:intron:MODIFIER:exon2/10:c.51-541_51-533dupAGCAGCAGC:,PPP2R2B:NM_181674.2:intron:MODIFIER:exon1/9:c.75-541_75-533dupAGCAGCAGC:,PPP2R2B:NM_181676.2:intron:MODIFIER:exon1/8:c.79+176929_79+176937dupAGCAGCAGC:,PPP2R2B:NM_181677.2:intron:MODIFIER:exon3/10:c.10+156433_10+156441dupAGCAGCAGC:,PPP2R2B:NM_181678.2:intron:MODIFIER:exon2/10:c.-48-22153_-48-22145dupAGCAGCAGC:,PPP2R2B:NR_073526.1:non_coding_transcript_exon:MODIFIER:exon1/9:n.50_58dupAGCAGCAGC:,PPP2R2B:NR_073527.1:non_coding_transcript_exon:MODIFIER:exon1/10:n.192_200dupAGCAGCAGC:			0.2440	0.0000	0/0/0	0.1024							604325 [PPP2R2B (provisional) Spinocerebellar ataxia 12,604326];				50	146					PPP2R2B (inh=AD pLI=0.90)
chr5	146435580	146435580	A	G	het	het	hom		QUAL=10513;DP=286,156,187;MQM=60	PPP2R2B	5'UTR,intron	PPP2R2B:NM_181674.2:5'UTR:MODIFIER:exon1/10:c.-279T>C:,PPP2R2B:NM_181676.2:5'UTR:MODIFIER:exon1/9:c.-274T>C:,PPP2R2B:NM_001271899.1:intron:MODIFIER:exon2/9:c.88+25042T>C:,PPP2R2B:NM_001271900.1:intron:MODIFIER:exon2/10:c.50+25042T>C:,PPP2R2B:NM_181677.2:intron:MODIFIER:exon2/10:c.-62-20777T>C:,PPP2R2B:NM_181678.2:intron:MODIFIER:exon2/10:c.-49+25042T>C:		rs1480153	0.6585	0.0000	0/0/0	0.1125							604325 [PPP2R2B (provisional) Spinocerebellar ataxia 12,604326];				99	118					PPP2R2B (inh=AD pLI=0.90)
chr5	146460691	146460691	T	A	wt	wt	het		QUAL=4173;DP=397,255,319;MQM=60	PPP2R2B	missense,5'UTR	PPP2R2B:NM_001271899.1:missense:MODERATE:exon2/10:c.19A>T:p.Thr7Ser,PPP2R2B:NM_001271900.1:5'UTR:MODIFIER:exon2/11:c.-20A>T:,PPP2R2B:NM_181677.2:5'UTR:MODIFIER:exon2/11:c.-132A>T:,PPP2R2B:NM_181678.2:5'UTR:MODIFIER:exon2/11:c.-118A>T:		rs17524553	0.0609	0.0434	18/17/0	0.0188	0.3120	T	T	B	T	0.01	604325 [PPP2R2B (provisional) Spinocerebellar ataxia 12,604326];				24	325					PPP2R2B (inh=AD pLI=0.90)
chr5	147450016	147450016	G	A	wt	wt	het		QUAL=2277;DP=263,149,168;MQM=60	SPINK5	splice_region&intron	SPINK5:NM_001127698.1:splice_region&intron:LOW:exon3/33:c.209+3G>A:,SPINK5:NM_001127699.1:splice_region&intron:LOW:exon3/27:c.209+3G>A:,SPINK5:NM_006846.3:splice_region&intron:LOW:exon3/32:c.209+3G>A:		rs750310449	0.0000	0.0001	0/0/0	0.0001							605010 [SPINK5 (provisional) Netherton syndrome,256500|Atopy,147050];				0	1					SPINK5 (inh=AR+AD pLI=0.00)
chr5	147466001	147466001	G	A	wt	wt	het		QUAL=4366;DP=272,250,353;MQM=60	SPINK5	missense	SPINK5:NM_001127698.1:missense:MODERATE:exon5/34:c.316G>A:p.Asp106Asn,SPINK5:NM_001127699.1:missense:MODERATE:exon5/28:c.316G>A:p.Asp106Asn,SPINK5:NM_006846.3:missense:MODERATE:exon5/33:c.316G>A:p.Asp106Asn		rs17860502	0.0523	0.0442	192/49/0	0.0447	0.1680	T,T,T,T	T	B,B,B,B	T,T,T,T	7.06	605010 [SPINK5 (provisional) Netherton syndrome,256500|Atopy,147050];	RCV000128215.1 [benign]; RCV000375382.1 [likely benign]; 	CM127007 [CLASS=R MUT=ALT PHEN="Netherton syndrome" GENE=SPINK5]; 		2	92	2	[2] Ute Grasshoff 25.06.2014			SPINK5 (inh=AR+AD pLI=0.00)
chr5	147469113	147469113	G	A	het	het	wt		QUAL=10471;DP=388,487,635;MQM=60	SPINK5	synonymous	SPINK5:NM_001127698.1:synonymous:LOW:exon7/34:c.531G>A:p.Arg177Arg,SPINK5:NM_001127699.1:synonymous:LOW:exon7/28:c.531G>A:p.Arg177Arg,SPINK5:NM_006846.3:synonymous:LOW:exon7/33:c.531G>A:p.Arg177Arg		rs35121983	0.0469	0.0337	107/14/12	0.0312							605010 [SPINK5 (provisional) Netherton syndrome,256500|Atopy,147050];	RCV000128216.2 [benign]; RCV000261854.1 [likely benign]; 		COSM149969	1	84					SPINK5 (inh=AR+AD pLI=0.00)
chr5	147475386	147475386	A	G	het	het	het		QUAL=7594;DP=246,139,207;MQM=60	SPINK5	missense	SPINK5:NM_001127698.1:missense:MODERATE:exon10/34:c.800A>G:p.Gln267Arg,SPINK5:NM_001127699.1:missense:MODERATE:exon10/28:c.800A>G:p.Gln267Arg,SPINK5:NM_006846.3:missense:MODERATE:exon10/33:c.800A>G:p.Gln267Arg		rs6892205	0.5090	0.5213	16635/8528/1026	0.5139	-4.0170	T,T,T,T	T	B,B,B	T,T,T,T	0.01	605010 [SPINK5 (provisional) Netherton syndrome,256500|Atopy,147050];	RCV000128217.1 [benign]; RCV000253065.1 [benign]; RCV000350117.1 [benign]; 		COSM4003377, COSM4003378	435	743					SPINK5 (inh=AR+AD pLI=0.00)
chr5	147477551	147477551	C	T	het	het	het	pred_pathogenic	QUAL=7329;DP=198,172,202;MQM=60	SPINK5	missense	SPINK5:NM_001127698.1:missense:MODERATE:exon11/34:c.1004C>T:p.Ala335Val,SPINK5:NM_001127699.1:missense:MODERATE:exon11/28:c.1004C>T:p.Ala335Val,SPINK5:NM_006846.3:missense:MODERATE:exon11/33:c.1004C>T:p.Ala335Val		rs34482796	0.4465	0.5070	15959/8512/445	0.4999	0.0650	T,T,T,T	T	B,B,B	T,T,T,T	23.10	605010 [SPINK5 (provisional) Netherton syndrome,256500|Atopy,147050];	RCV000128218.1 [benign]; RCV000247440.1 [benign]; RCV000346513.1 [benign]; 			424	746					SPINK5 (inh=AR+AD pLI=0.00)
chr5	147480027	147480027	G	A	het	het	het		QUAL=12361;DP=199,265,377;MQM=59	SPINK5	missense	SPINK5:NM_001127698.1:missense:MODERATE:exon13/34:c.1103G>A:p.Ser368Asn,SPINK5:NM_001127699.1:missense:MODERATE:exon13/28:c.1103G>A:p.Ser368Asn,SPINK5:NM_006846.3:missense:MODERATE:exon13/33:c.1103G>A:p.Ser368Asn		rs2303063	0.4315	0.5057	16068/8742/304	0.4944	0.0360	T,T,T,T	T	B,B,B	T,T,T,T	7.21	605010 [SPINK5 (provisional) Netherton syndrome,256500|Atopy,147050];	RCV000249359.1 [benign]; RCV000343258.1 [benign]; 	CM013814 [CLASS=DP MUT=ALT PHEN="Atopy maternally inherited association with" GENE=SPINK5]; 	COSM4003379, COSM4003380	431	737					SPINK5 (inh=AR+AD pLI=0.00)
chr5	147480080	147480080	G	A	het	het	het	pred_pathogenic	QUAL=12983;DP=389,313,430;MQM=60	SPINK5	missense	SPINK5:NM_001127698.1:missense:MODERATE:exon13/34:c.1156G>A:p.Asp386Asn,SPINK5:NM_001127699.1:missense:MODERATE:exon13/28:c.1156G>A:p.Asp386Asn,SPINK5:NM_006846.3:missense:MODERATE:exon13/33:c.1156G>A:p.Asp386Asn		rs2303064	0.3482	0.2119	3871/550/1206	0.2058	1.8960	T,T,T,T	T	B,B,B,B	T,T,T,T	23.50	605010 [SPINK5 (provisional) Netherton syndrome,256500|Atopy,147050];	RCV000128219.2 [benign]; RCV000303587.1 [benign]; 			62	400					SPINK5 (inh=AR+AD pLI=0.00)
chr5	147480112	147480112	T	C	het	het	het		QUAL=14746;DP=297,307,400;MQM=60	SPINK5	synonymous	SPINK5:NM_001127698.1:synonymous:LOW:exon13/34:c.1188T>C:p.His396His,SPINK5:NM_001127699.1:synonymous:LOW:exon13/28:c.1188T>C:p.His396His,SPINK5:NM_006846.3:synonymous:LOW:exon13/33:c.1188T>C:p.His396His		rs2303065	0.4329	0.5072	16217/8832/309	0.4926							605010 [SPINK5 (provisional) Netherton syndrome,256500|Atopy,147050];	RCV000128220.1 [benign]; RCV000243483.1 [benign]; RCV000358416.1 [benign]; 		COSM149970, COSM4003381	429	740					SPINK5 (inh=AR+AD pLI=0.00)
chr5	147480955	147480955	A	G	het	het	het		QUAL=9090;DP=207,240,291;MQM=60	SPINK5	missense	SPINK5:NM_001127698.1:missense:MODERATE:exon14/34:c.1258A>G:p.Lys420Glu,SPINK5:NM_001127699.1:missense:MODERATE:exon14/28:c.1258A>G:p.Lys420Glu,SPINK5:NM_006846.3:missense:MODERATE:exon14/33:c.1258A>G:p.Lys420Glu		rs2303067	0.4331	0.5079	16138/8797/306	0.5007	0.1530	T,T,T,T	T	B,B,B	T,T,T,T	7.83	605010 [SPINK5 (provisional) Netherton syndrome,256500|Atopy,147050];	RCV000005585.2 [other]; RCV000005586.2 [other]; RCV000005587.2 [other]; RCV000248431.2 [benign]; RCV000299337.1 [benign]; 	CM013815 [CLASS=DFP MUT=REF PHEN="Atopy maternally inherited association with" GENE=SPINK5]; 	COSM4003382, COSM4003383	430	737					SPINK5 (inh=AR+AD pLI=0.00)
chr5	147481430	147481430	A	G	het	het	het		QUAL=12030;DP=315,287,337;MQM=59	SPINK5	synonymous	SPINK5:NM_001127698.1:synonymous:LOW:exon15/34:c.1389A>G:p.Gly463Gly,SPINK5:NM_001127699.1:synonymous:LOW:exon15/28:c.1389A>G:p.Gly463Gly,SPINK5:NM_006846.3:synonymous:LOW:exon15/33:c.1389A>G:p.Gly463Gly		rs6896303	0.4329	0.5076	16230/8836/309	0.5003							605010 [SPINK5 (provisional) Netherton syndrome,256500|Atopy,147050];	RCV000250366.1 [benign]; RCV000259308.1 [benign]; 		COSM4003384, COSM149971	431	736					SPINK5 (inh=AR+AD pLI=0.00)
chr5	147486677	147486677	C	A	het	het	het		QUAL=14922;DP=334,348,511;MQM=59	SPINK5	synonymous	SPINK5:NM_001127698.1:synonymous:LOW:exon17/34:c.1557C>A:p.Gly519Gly,SPINK5:NM_001127699.1:synonymous:LOW:exon17/28:c.1557C>A:p.Gly519Gly,SPINK5:NM_006846.3:synonymous:LOW:exon17/33:c.1557C>A:p.Gly519Gly		rs880687	0.4293	0.5061	16185/8818/288	0.4996							605010 [SPINK5 (provisional) Netherton syndrome,256500|Atopy,147050];	RCV000253690.1 [benign]; RCV000275565.1 [benign]; 		COSM4003385, COSM149972	428	742					SPINK5 (inh=AR+AD pLI=0.00)
chr5	147488367	147488367	C	T	het	het	het		QUAL=8238;DP=291,202,235;MQM=60	SPINK5	synonymous	SPINK5:NM_001127698.1:synonymous:LOW:exon18/34:c.1659C>T:p.Val553Val,SPINK5:NM_001127699.1:synonymous:LOW:exon18/28:c.1659C>T:p.Val553Val,SPINK5:NM_006846.3:synonymous:LOW:exon18/33:c.1659C>T:p.Val553Val	GA-rich	rs2303071	0.6020	0.5527	18995/8871/2833	0.5372							605010 [SPINK5 (provisional) Netherton syndrome,256500|Atopy,147050];	RCV000175321.2 [benign]; RCV000345642.1 [benign]; 		COSM149973, COSM449063	422	712					SPINK5 (inh=AR+AD pLI=0.00)
chr5	147492461	147492461	T	C	wt	wt	het		QUAL=2770;DP=269,226,267;MQM=60	SPINK5	synonymous	SPINK5:NM_001127698.1:synonymous:LOW:exon20/34:c.1851T>C:p.Ala617Ala,SPINK5:NM_001127699.1:synonymous:LOW:exon20/28:c.1851T>C:p.Ala617Ala,SPINK5:NM_006846.3:synonymous:LOW:exon20/33:c.1851T>C:p.Ala617Ala	A-rich	rs17718737	0.0539	0.0448	179/44/1	0.0448							605010 [SPINK5 (provisional) Netherton syndrome,256500|Atopy,147050];	RCV000128222.2 [benign]; RCV000342268.1 [likely benign]; 			2	97					SPINK5 (inh=AR+AD pLI=0.00)
chr5	147498019	147498019	G	A	het	het	het	pred_pathogenic	QUAL=11689;DP=291,236,392;MQM=60	SPINK5	missense	SPINK5:NM_001127698.1:missense:MODERATE:exon23/34:c.2132G>A:p.Arg711Gln,SPINK5:NM_001127699.1:missense:MODERATE:exon23/28:c.2132G>A:p.Arg711Gln,SPINK5:NM_006846.3:missense:MODERATE:exon23/33:c.2132G>A:p.Arg711Gln		rs3777134	0.4884	0.5830	21117/12616/603	0.5758	0.4400	T,T,T,T	T	B,B,B	T,T,T,T	22.70	605010 [SPINK5 (provisional) Netherton syndrome,256500|Atopy,147050];	RCV000247596.1 [benign]; RCV000338362.1 [benign]; 		COSM4003386, COSM149974	578	719					SPINK5 (inh=AR+AD pLI=0.00)
chr5	147499616	147499616	C	T	het	het	het		QUAL=11668;DP=348,226,313;MQM=60	SPINK5	synonymous	SPINK5:NM_001127698.1:synonymous:LOW:exon25/34:c.2358C>T:p.Leu786Leu,SPINK5:NM_001127699.1:synonymous:LOW:exon25/28:c.2358C>T:p.Leu786Leu,SPINK5:NM_006846.3:synonymous:LOW:exon25/33:c.2358C>T:p.Leu786Leu		rs17704908	0.4874	0.5829	20947/12512/601	0.5753							605010 [SPINK5 (provisional) Netherton syndrome,256500|Atopy,147050];	RCV000250545.1 [benign]; RCV000402422.1 [benign]; 		COSM4003388, COSM4003387	578	718					SPINK5 (inh=AR+AD pLI=0.00)
chr5	147499670	147499670	C	T	het	het	het		QUAL=11194;DP=354,247,340;MQM=60	SPINK5	synonymous	SPINK5:NM_001127698.1:synonymous:LOW:exon25/34:c.2412C>T:p.Gly804Gly,SPINK5:NM_001127699.1:synonymous:LOW:exon25/28:c.2412C>T:p.Gly804Gly,SPINK5:NM_006846.3:synonymous:LOW:exon25/33:c.2412C>T:p.Gly804Gly		rs33920397	0.4884	0.5825	21043/12566/601	0.5756							605010 [SPINK5 (provisional) Netherton syndrome,256500|Atopy,147050];	RCV000242523.1 [benign]; RCV000367051.1 [benign]; 		COSM4003389, COSM149975	578	718					SPINK5 (inh=AR+AD pLI=0.00)
chr5	147499891	147499891	G	T	het	het	wt		QUAL=8411;DP=326,358,418;MQM=60	SPINK5	missense	SPINK5:NM_001127698.1:missense:MODERATE:exon26/34:c.2475G>T:p.Glu825Asp,SPINK5:NM_001127699.1:missense:MODERATE:exon26/28:c.2475G>T:p.Glu825Asp,SPINK5:NM_006846.3:missense:MODERATE:exon26/33:c.2475G>T:p.Glu825Asp		rs2303070	0.1745	0.1563	1229/249/42	0.1238	-0.6140	T,T,T,T	T	B,B,B,B	T,T,T,T	11.84	605010 [SPINK5 (provisional) Netherton syndrome,256500|Atopy,147050];	RCV000128223.2 [benign]; RCV000272403.1 [benign]; 			38	318					SPINK5 (inh=AR+AD pLI=0.00)
chr5	147505116	147505116	G	A	het	het	het		QUAL=16075;DP=471,325,459;MQM=59	SPINK5	synonymous,intron	SPINK5:NM_001127698.1:synonymous:LOW:exon29/34:c.2769G>A:p.Ala923Ala,SPINK5:NM_006846.3:intron:MODIFIER:exon28/32:c.2740-170G>A:		rs3764930	0.4533	0.5748	20523/12421/306	0.5601							605010 [SPINK5 (provisional) Netherton syndrome,256500|Atopy,147050];			COSM4003390	572	722					SPINK5 (inh=AR+AD pLI=0.00)
chr5	147506593	147506593	A	G	wt	wt	het		QUAL=906;DP=259,96,121;MQM=60	SPINK5	missense	SPINK5:NM_001127698.1:missense:MODERATE:exon31/34:c.3005A>G:p.His1002Arg,SPINK5:NM_006846.3:missense:MODERATE:exon30/33:c.2915A>G:p.His972Arg		rs17705005	0.0102	0.0247	58/44/0	0.0236	1.2690	T,T	T	B,B	T,T	12.37	605010 [SPINK5 (provisional) Netherton syndrome,256500|Atopy,147050];	RCV000408157.1 [likely benign]; 			1	68					SPINK5 (inh=AR+AD pLI=0.00)
chr5	147510866	147510866	T	C	het	het	het		QUAL=9858;DP=266,237,290;MQM=60	SPINK5	synonymous	SPINK5:NM_001127698.1:synonymous:LOW:exon32/34:c.3099T>C:p.Gly1033Gly,SPINK5:NM_006846.3:synonymous:LOW:exon31/33:c.3009T>C:p.Gly1003Gly		rs2400478	0.5092	0.5888	21404/12623/854	0.5597							605010 [SPINK5 (provisional) Netherton syndrome,256500|Atopy,147050];	RCV000243537.1 [benign]; RCV000351049.1 [benign]; 		COSM149978, COSM149977	581	716					SPINK5 (inh=AR+AD pLI=0.00)
chr5	147516598	147516598	T	C	het	het	het		QUAL=8313;DP=212,160,227;MQM=60	SPINK5	3'UTR	SPINK5:NM_001127698.1:3'UTR:MODIFIER:exon34/34:c.*44T>C:,SPINK5:NM_006846.3:3'UTR:MODIFIER:exon33/33:c.*44T>C:		rs4349706	0.4910	0.4117	10657/4872/1635	0.4059							605010 [SPINK5 (provisional) Netherton syndrome,256500|Atopy,147050];	RCV000323363.1 [benign]; 			163	441					SPINK5 (inh=AR+AD pLI=0.00)
chr5	147516762	147516762	C	G	het	het	het		QUAL=16228;DP=543,295,422;MQM=59	SPINK5	3'UTR	SPINK5:NM_001127698.1:3'UTR:MODIFIER:exon34/34:c.*208C>G:,SPINK5:NM_006846.3:3'UTR:MODIFIER:exon33/33:c.*208C>G:		rs3088193	0.4910	0.0000	0/0/0	0.4163							605010 [SPINK5 (provisional) Netherton syndrome,256500|Atopy,147050];	RCV000318164.1 [benign]; 			37	102					SPINK5 (inh=AR+AD pLI=0.00)
chr5	147516884	147516884	T	C	het	het	wt		QUAL=5063;DP=251,165,202;MQM=59	SPINK5	3'UTR	SPINK5:NM_001127698.1:3'UTR:MODIFIER:exon34/34:c.*330T>C:,SPINK5:NM_006846.3:3'UTR:MODIFIER:exon33/33:c.*330T>C:		rs72660265	0.1743	0.0000	0/0/0	0.0210							605010 [SPINK5 (provisional) Netherton syndrome,256500|Atopy,147050];	RCV000278242.1 [benign]; 			6	42					SPINK5 (inh=AR+AD pLI=0.00)
chr5	147516914	147516914	-	CTC	het	het	het		QUAL=4328;DP=189,89,136;MQM=59	SPINK5	3'UTR	SPINK5:NM_001127698.1:3'UTR:MODIFIER:exon34/34:c.*361_*363dupCTC:,SPINK5:NM_006846.3:3'UTR:MODIFIER:exon33/33:c.*361_*363dupCTC:		rs35952402;rs397704765	0.4910	0.0000	0/0/0	0.3680							605010 [SPINK5 (provisional) Netherton syndrome,256500|Atopy,147050];	RCV000387737.1 [benign]; 			36	101					SPINK5 (inh=AR+AD pLI=0.00)
chr5	148361720	148361720	-	T	hom	hom	hom		QUAL=8848;DP=108,94,137;MQM=59	SH3TC2	3'UTR	SH3TC2:NM_024577.3:3'UTR:MODIFIER:exon17/17:c.*22553dupA:		rs397725504	0.4810	0.0000	0/0/0	0.3594							608206 [SH3TC2 (provisional) Charcot-Marie-Tooth disease,type 4C,601596|Mononeuropathy of the median nerve,mild,613353];	RCV000287595.1 [uncertain significance]; RCV000344961.1 [uncertain significance]; RCV000327529.1 [likely benign]; RCV000384368.1 [likely benign]; 			47	101					SH3TC2 (inh=AR+AD pLI=0.00)
chr5	148364355	148364355	A	G	hom	hom	hom		QUAL=34928;DP=459,265,332;MQM=59	SH3TC2	3'UTR	SH3TC2:NM_024577.3:3'UTR:MODIFIER:exon17/17:c.*19919T>C:		rs2217638	0.8023	0.0000	0/0/0	0.8132							608206 [SH3TC2 (provisional) Charcot-Marie-Tooth disease,type 4C,601596|Mononeuropathy of the median nerve,mild,613353];	RCV000290364.1 [benign]; RCV000328936.1 [benign]; 			169	72					SH3TC2 (inh=AR+AD pLI=0.00)
chr5	148364701	148364701	C	T	hom	hom	hom		QUAL=14297;DP=233,105,148;MQM=59	SH3TC2	3'UTR	SH3TC2:NM_024577.3:3'UTR:MODIFIER:exon17/17:c.*19573G>A:		rs4560536	0.4716	0.0000	0/0/0	0.5094							608206 [SH3TC2 (provisional) Charcot-Marie-Tooth disease,type 4C,601596|Mononeuropathy of the median nerve,mild,613353];	RCV000289231.1 [likely benign]; RCV000381325.1 [likely benign]; 			96	102					SH3TC2 (inh=AR+AD pLI=0.00)
chr5	148364709	148364709	-	A	het	hom	hom		QUAL=7135;DP=219,76,98;MQM=59	SH3TC2	3'UTR	SH3TC2:NM_024577.3:3'UTR:MODIFIER:exon17/17:c.*19564dupT:		rs398109536	0.6817	0.0000	0/0/0	0.4156							608206 [SH3TC2 (provisional) Charcot-Marie-Tooth disease,type 4C,601596|Mononeuropathy of the median nerve,mild,613353];	RCV000286675.1 [uncertain significance]; RCV000341638.1 [uncertain significance]; RCV000341925.1 [benign]; RCV000380226.1 [benign]; 			30	191					SH3TC2 (inh=AR+AD pLI=0.00)
chr5	148365234	148365234	T	C	hom	hom	hom		QUAL=27137;DP=444,176,200;MQM=60	SH3TC2	3'UTR	SH3TC2:NM_024577.3:3'UTR:MODIFIER:exon17/17:c.*19040A>G:	L1ME1	rs930205	0.5092	0.0000	0/0/0	0.5525							608206 [SH3TC2 (provisional) Charcot-Marie-Tooth disease,type 4C,601596|Mononeuropathy of the median nerve,mild,613353];	RCV000335430.1 [likely benign]; RCV000375959.1 [likely benign]; 			88	87					SH3TC2 (inh=AR+AD pLI=0.00)
chr5	148365720	148365720	C	A	hom	hom	hom		QUAL=30772;DP=377,234,315;MQM=60	SH3TC2	3'UTR	SH3TC2:NM_024577.3:3'UTR:MODIFIER:exon17/17:c.*18554G>T:	MIR	rs10040598	0.7973	0.0000	0/0/0	0.8113							608206 [SH3TC2 (provisional) Charcot-Marie-Tooth disease,type 4C,601596|Mononeuropathy of the median nerve,mild,613353];	RCV000307128.1 [benign]; RCV000366485.1 [benign]; 			166	71					SH3TC2 (inh=AR+AD pLI=0.00)
chr5	148366571	148366571	T	C	hom	hom	hom		QUAL=19443;DP=374,93,131;MQM=60	SH3TC2	3'UTR	SH3TC2:NM_024577.3:3'UTR:MODIFIER:exon17/17:c.*17703A>G:		rs4235739	0.6234	0.0000	0/0/0	0.6211							608206 [SH3TC2 (provisional) Charcot-Marie-Tooth disease,type 4C,601596|Mononeuropathy of the median nerve,mild,613353];	RCV000294977.1 [benign]; RCV000345191.1 [benign]; 			105	108					SH3TC2 (inh=AR+AD pLI=0.00)
chr5	148367324	148367324	A	G	hom	hom	hom		QUAL=22978;DP=418,98,188;MQM=59	SH3TC2	3'UTR	SH3TC2:NM_024577.3:3'UTR:MODIFIER:exon17/17:c.*16950T>C:		rs10040798	0.7881	0.0000	0/0/0	0.1383							608206 [SH3TC2 (provisional) Charcot-Marie-Tooth disease,type 4C,601596|Mononeuropathy of the median nerve,mild,613353];	RCV000330950.1 [benign]; RCV000366902.1 [benign]; 			166	73					SH3TC2 (inh=AR+AD pLI=0.00)
chr5	148367373	148367376	TGTG	-	hom	hom	hom		QUAL=1515;DP=49,45,62;MQM=59	SH3TC2	3'UTR	SH3TC2:NM_024577.3:3'UTR:MODIFIER:exon17/17:c.*16898_*16901delCACA:	(TG)n	rs878950160	0.0000	0.0000	0/0/0	0.0003							608206 [SH3TC2 (provisional) Charcot-Marie-Tooth disease,type 4C,601596|Mononeuropathy of the median nerve,mild,613353];	RCV000312003.1 [uncertain significance]; RCV000392874.1 [uncertain significance]; 			2	11					SH3TC2 (inh=AR+AD pLI=0.00)
chr5	148367643	148367643	C	T	hom	hom	het		QUAL=19934;DP=333,183,257;MQM=59	SH3TC2	3'UTR	SH3TC2:NM_024577.3:3'UTR:MODIFIER:exon17/17:c.*16631G>A:		rs4705303	0.4613	0.0000	0/0/0	0.5174							608206 [SH3TC2 (provisional) Charcot-Marie-Tooth disease,type 4C,601596|Mononeuropathy of the median nerve,mild,613353];	RCV000278313.1 [likely benign]; RCV000338018.1 [likely benign]; 			90	110					SH3TC2 (inh=AR+AD pLI=0.00)
chr5	148368254	148368254	T	G	hom	hom	hom		QUAL=19402;DP=268,148,211;MQM=60	SH3TC2	3'UTR	SH3TC2:NM_024577.3:3'UTR:MODIFIER:exon17/17:c.*16020A>C:	MLT1F	rs4543254	0.6180	0.0000	0/0/0	0.6203							608206 [SH3TC2 (provisional) Charcot-Marie-Tooth disease,type 4C,601596|Mononeuropathy of the median nerve,mild,613353];	RCV000319489.1 [benign]; RCV000385662.1 [benign]; 			96	83					SH3TC2 (inh=AR+AD pLI=0.00)
chr5	148368451	148368451	A	G	hom	hom	hom		QUAL=26442;DP=492,141,183;MQM=60	SH3TC2	3'UTR	SH3TC2:NM_024577.3:3'UTR:MODIFIER:exon17/17:c.*15823T>C:		rs4562031	0.7981	0.0000	0/0/0	0.8114							608206 [SH3TC2 (provisional) Charcot-Marie-Tooth disease,type 4C,601596|Mononeuropathy of the median nerve,mild,613353];	RCV000287464.1 [benign]; RCV000389063.1 [benign]; RCV000345018.1 [uncertain significance]; RCV000399580.1 [uncertain significance]; 			165	69					SH3TC2 (inh=AR+AD pLI=0.00)
chr5	148372163	148372163	G	TT	hom	hom	hom	low_DP	QUAL=4406;DP=40,8,28;MQM=53	SH3TC2	3'UTR	SH3TC2:NM_024577.3:3'UTR:MODIFIER:exon17/17:c.*12111delCinsAA:			0.0000	0.0000	0/0/0	0.0000							608206 [SH3TC2 (provisional) Charcot-Marie-Tooth disease,type 4C,601596|Mononeuropathy of the median nerve,mild,613353];				0	0					SH3TC2 (inh=AR+AD pLI=0.00)
chr5	148373306	148373306	C	T	het	hom	wt		QUAL=6556;DP=201,117,148;MQM=60	SH3TC2	3'UTR	SH3TC2:NM_024577.3:3'UTR:MODIFIER:exon17/17:c.*10968G>A:		rs13166730	0.0723	0.0000	0/0/0	0.1210							608206 [SH3TC2 (provisional) Charcot-Marie-Tooth disease,type 4C,601596|Mononeuropathy of the median nerve,mild,613353];	RCV000266379.1 [likely benign]; RCV000321531.1 [likely benign]; 			5	71					SH3TC2 (inh=AR+AD pLI=0.00)
chr5	148374164	148374167	TGGT	-	hom	hom	het		QUAL=4373;DP=37,126,163;MQM=59	SH3TC2	3'UTR	SH3TC2:NM_024577.3:3'UTR:MODIFIER:exon17/17:c.*10107_*10110delACCA:	(TGGT)n	rs72253703	0.0000	0.0000	0/0/0	0.0041							608206 [SH3TC2 (provisional) Charcot-Marie-Tooth disease,type 4C,601596|Mononeuropathy of the median nerve,mild,613353];	RCV000309325.1 [uncertain significance]; RCV000342655.1 [uncertain significance]; 			39	11					SH3TC2 (inh=AR+AD pLI=0.00)
chr5	148381138	148381138	C	T	hom	hom	het		QUAL=24849;DP=509,183,192;MQM=60	SH3TC2	3'UTR	SH3TC2:NM_024577.3:3'UTR:MODIFIER:exon17/17:c.*3136G>A:		rs1019927	0.9904	0.0000	0/0/0	0.8948							608206 [SH3TC2 (provisional) Charcot-Marie-Tooth disease,type 4C,601596|Mononeuropathy of the median nerve,mild,613353];	RCV000312130.1 [benign]; RCV000394389.1 [benign]; 			243	14					SH3TC2 (inh=AR+AD pLI=0.00)
chr5	148383412	148383412	C	A	hom	hom	hom	low_DP	QUAL=207;DP=19,10,10;MQM=60	SH3TC2	3'UTR	SH3TC2:NM_024577.3:3'UTR:MODIFIER:exon17/17:c.*862G>T:	FRAM		0.0000	0.0000	0/0/0	0.0001							608206 [SH3TC2 (provisional) Charcot-Marie-Tooth disease,type 4C,601596|Mononeuropathy of the median nerve,mild,613353];				0	1					SH3TC2 (inh=AR+AD pLI=0.00)
chr5	148407708	148407708	A	C	hom	hom	het		QUAL=19009;DP=215,277,364;MQM=59	SH3TC2	synonymous	SH3TC2:NM_024577.3:synonymous:LOW:exon11/17:c.1587T>G:p.Arg529Arg		rs1432794	0.9906	0.9785	58110/31287/5147	0.9472							608206 [SH3TC2 (provisional) Charcot-Marie-Tooth disease,type 4C,601596|Mononeuropathy of the median nerve,mild,613353];	RCV000118336.4 [other]; RCV000362334.1 [benign]; RCV000405810.1 [benign]; 			1490	74					SH3TC2 (inh=AR+AD pLI=0.00)
chr5	149360877	149360877	T	C	hom	hom	hom	pred_pathogenic;anno_pathogenic_hgmd	QUAL=31042;DP=373,257,324;MQM=59	SLC26A2	missense	SLC26A2:NM_000112.3:missense:MODERATE:exon3/3:c.1721T>C:p.Ile574Thr		rs30832	0.0000	0.9928	59817/32644/5173	0.9291	1.6390	T	T	B	D	0.01	606718 [SLC26A2 (confirmed) Diastrophic dysplasia,222600|Atelosteogenesis II,256050|Achondrogenesis Ib,600972|Epiphyseal dysplasia,multiple,4,226900|Diastrophic dysplasia,broad bone-platyspondylic variant,222600|De la Chapelle dysplasia,256050];	RCV000176982.2 [benign]; RCV000265444.1 [benign]; RCV000271433.1 [benign]; RCV000320835.1 [benign]; RCV000360315.1 [benign]; RCV000384666.1 [benign]; 	CM016008 [CLASS=DM? MUT=REF PHEN="Diastrophic dysplasia" GENE=SLC26A2]; 		1545	20	2	[2] old entry - no details available			SLC26A2 (inh=AR pLI=0.00)
chr5	149362400	149362400	T	G	het	wt	hom		QUAL=13143;DP=395,198,243;MQM=59	SLC26A2	3'UTR	SLC26A2:NM_000112.3:3'UTR:MODIFIER:exon3/3:c.*1024T>G:		rs8073	0.2740	0.0000	0/0/0	0.0411							606718 [SLC26A2 (confirmed) Diastrophic dysplasia,222600|Atelosteogenesis II,256050|Achondrogenesis Ib,600972|Epiphyseal dysplasia,multiple,4,226900|Diastrophic dysplasia,broad bone-platyspondylic variant,222600|De la Chapelle dysplasia,256050];	RCV000260778.1 [benign]; RCV000319505.1 [benign]; RCV000322895.1 [benign]; RCV000371846.1 [benign]; RCV000379855.1 [benign]; 			13	89					SLC26A2 (inh=AR pLI=0.00)
chr5	149364780	149364780	C	T	hom	het	hom		QUAL=34230;DP=509,300,435;MQM=59	SLC26A2	3'UTR	SLC26A2:NM_000112.3:3'UTR:MODIFIER:exon3/3:c.*3404C>T:		rs30833	0.9920	0.0000	0/0/0	0.1543							606718 [SLC26A2 (confirmed) Diastrophic dysplasia,222600|Atelosteogenesis II,256050|Achondrogenesis Ib,600972|Epiphyseal dysplasia,multiple,4,226900|Diastrophic dysplasia,broad bone-platyspondylic variant,222600|De la Chapelle dysplasia,256050];	RCV000266589.1 [benign]; RCV000272616.1 [benign]; RCV000326393.1 [benign]; RCV000327968.1 [benign]; RCV000381077.1 [benign]; 			223	7					SLC26A2 (inh=AR pLI=0.00)
chr5	149365837	149365837	T	-	het	wt	hom		QUAL=1791;DP=97,21,24;MQM=60	SLC26A2	3'UTR	SLC26A2:NM_000112.3:3'UTR:MODIFIER:exon3/3:c.*4469delT:		rs397883627	0.4681	0.0000	0/0/0	0.1719							606718 [SLC26A2 (confirmed) Diastrophic dysplasia,222600|Atelosteogenesis II,256050|Achondrogenesis Ib,600972|Epiphyseal dysplasia,multiple,4,226900|Diastrophic dysplasia,broad bone-platyspondylic variant,222600|De la Chapelle dysplasia,256050];	RCV000272293.1 [benign]; RCV000295584.1 [benign]; RCV000329667.1 [benign]; RCV000383113.1 [benign]; RCV000387479.1 [benign]; 			33	109					SLC26A2 (inh=AR pLI=0.00)
chr5	149907533	149907533	T	G	hom	het	het		QUAL=28917;DP=417,558,769;MQM=59	NDST1	synonymous	NDST1:NM_001543.4:synonymous:LOW:exon3/15:c.681T>G:p.Val227Val,NDST1:NM_001301063.1:synonymous:LOW:exon3/14:c.681T>G:p.Val227Val		rs2273235	0.3658	0.4512	12745/7315/426	0.4422							600853 [NDST1 (confirmed) Mental retardation,autosomal recessive 46,616116];			COSM4159647	282	762					NDST1 (inh=AR pLI=1.00)
chr5	149907602	149907602	A	G	hom	het	het		QUAL=23691;DP=290,553,724;MQM=59	NDST1	synonymous	NDST1:NM_001543.4:synonymous:LOW:exon3/15:c.750A>G:p.Pro250Pro,NDST1:NM_001301063.1:synonymous:LOW:exon3/14:c.750A>G:p.Pro250Pro		rs2273234	0.2995	0.4206	11292/6936/139	0.4099							600853 [NDST1 (confirmed) Mental retardation,autosomal recessive 46,616116];				271	763					NDST1 (inh=AR pLI=1.00)
chr5	149919739	149919739	G	C	hom	het	hom		QUAL=19358;DP=287,205,249;MQM=59	NDST1	synonymous	NDST1:NM_001543.4:synonymous:LOW:exon8/15:c.1662G>C:p.Thr554Thr,NDST1:NM_001301063.1:synonymous:LOW:exon8/14:c.1662G>C:p.Thr554Thr		rs1290147	0.8069	0.7156	31517/14234/4433	0.7075							600853 [NDST1 (confirmed) Mental retardation,autosomal recessive 46,616116];				663	704					NDST1 (inh=AR pLI=1.00)
chr5	149933899	149933899	A	T	het	het	wt	low_DP	QUAL=148;DP=18,6,6;MQM=60	NDST1	3'UTR	NDST1:NM_001543.4:3'UTR:MODIFIER:exon15/15:c.*1005A>T:,NDST1:NM_001301063.1:3'UTR:MODIFIER:exon14/14:c.*1005A>T:	(TA)n		0.0000	0.0000	0/0/0	0.0000							600853 [NDST1 (confirmed) Mental retardation,autosomal recessive 46,616116];				0	2					NDST1 (inh=AR pLI=1.00)
chr5	149935171	149935171	T	C	hom	hom	het		QUAL=26579;DP=253,378,498;MQM=59	NDST1	3'UTR	NDST1:NM_001543.4:3'UTR:MODIFIER:exon15/15:c.*2277T>C:,NDST1:NM_001301063.1:3'UTR:MODIFIER:exon14/14:c.*2277T>C:		rs13181064	0.5735	0.0000	0/0/0	0.6789							600853 [NDST1 (confirmed) Mental retardation,autosomal recessive 46,616116];				140	79					NDST1 (inh=AR pLI=1.00)
chr5	149935680	149935680	A	G	hom	het	het		QUAL=23359;DP=447,282,414;MQM=59	NDST1	3'UTR	NDST1:NM_001543.4:3'UTR:MODIFIER:exon15/15:c.*2786A>G:,NDST1:NM_001301063.1:3'UTR:MODIFIER:exon14/14:c.*2786A>G:	MamRep137	rs11542921	0.2430	0.0000	0/0/0	0.0563							600853 [NDST1 (confirmed) Mental retardation,autosomal recessive 46,616116];				28	120					NDST1 (inh=AR pLI=1.00)
chr5	149935893	149935893	T	C	wt	het	wt		QUAL=1262;DP=321,134,199;MQM=60	NDST1	3'UTR	NDST1:NM_001543.4:3'UTR:MODIFIER:exon15/15:c.*2999T>C:,NDST1:NM_001301063.1:3'UTR:MODIFIER:exon14/14:c.*2999T>C:	MamRep137	rs35953241	0.0162	0.0000	0/0/0	0.0054							600853 [NDST1 (confirmed) Mental retardation,autosomal recessive 46,616116];				1	17					NDST1 (inh=AR pLI=1.00)
chr5	149937496	149937496	A	-	hom	het	het		QUAL=11897;DP=224,195,300;MQM=59	NDST1	3'UTR	NDST1:NM_001543.4:3'UTR:MODIFIER:exon15/15:c.*4602delA:,NDST1:NM_001301063.1:3'UTR:MODIFIER:exon14/14:c.*4602delA:		rs36071594	0.2426	0.0000	0/0/0	0.3185							600853 [NDST1 (confirmed) Mental retardation,autosomal recessive 46,616116];				27	120					NDST1 (inh=AR pLI=1.00)
chr5	149937739	149937739	G	A	hom	het	het		QUAL=12713;DP=227,214,256;MQM=60	NDST1	3'UTR	NDST1:NM_001543.4:3'UTR:MODIFIER:exon15/15:c.*4845G>A:,NDST1:NM_001301063.1:3'UTR:MODIFIER:exon14/14:c.*4845G>A:		rs11994	0.3131	0.0000	0/0/0	0.0757							600853 [NDST1 (confirmed) Mental retardation,autosomal recessive 46,616116];				29	120					NDST1 (inh=AR pLI=1.00)
chr5	155754192	155754192	C	G	het	hom	het		QUAL=13161;DP=214,233,286;MQM=60	SGCD	5'UTR	SGCD:NM_000337.5:5'UTR:MODIFIER:exon1/9:c.-94C>G:,SGCD:NM_172244.2:5'UTR:MODIFIER:exon1/8:c.-94C>G:,SGCD:NM_001128209.1:5'UTR:MODIFIER:exon1/8:c.-51C>G:		rs13170573	0.4605	0.0000	0/0/0	0.4694							601411 [SGCD (confirmed) Muscular dystrophy,limb-girdle,type 2F,601287|Cardiomyopathy,dilated,1L,606685];	RCV000041400.2 [benign]; RCV000262050.1 [benign]; RCV000297384.1 [benign]; RCV000354555.1 [benign]; 			64	134					SGCD (inh=AR+AD pLI=0.00)
chr5	155771579	155771579	T	C	het	hom	het		QUAL=7855;DP=194,105,139;MQM=59	SGCD	synonymous	SGCD:NM_000337.5:synonymous:LOW:exon3/9:c.84T>C:p.Tyr28Tyr,SGCD:NM_172244.2:synonymous:LOW:exon3/8:c.84T>C:p.Tyr28Tyr,SGCD:NM_001128209.1:synonymous:LOW:exon2/8:c.81T>C:p.Tyr27Tyr		rs1801193	0.4854	0.4660	13829/6317/346	0.4589							601411 [SGCD (confirmed) Muscular dystrophy,limb-girdle,type 2F,601287|Cardiomyopathy,dilated,1L,606685];	RCV000041413.9 [benign]; RCV000283555.1 [benign]; RCV000326284.1 [benign]; RCV000383249.1 [benign]; 		COSM4159670, COSM4159671	388	800					SGCD (inh=AR+AD pLI=0.00)
chr5	156187928	156187928	C	T	het	het	het		QUAL=13867;DP=516,253,322;MQM=60	SGCD	3'UTR	SGCD:NM_000337.5:3'UTR:MODIFIER:exon9/9:c.*1527C>T:,SGCD:NM_001128209.1:3'UTR:MODIFIER:exon8/8:c.*1527C>T:		rs284445	0.2073	0.0000	0/0/0	0.0511							601411 [SGCD (confirmed) Muscular dystrophy,limb-girdle,type 2F,601287|Cardiomyopathy,dilated,1L,606685];	RCV000279631.1 [benign]; RCV000315995.1 [benign]; RCV000374429.1 [benign]; 			30	80					SGCD (inh=AR+AD pLI=0.00)
chr5	156193118	156193118	G	A	hom	hom	hom		QUAL=22806;DP=369,124,195;MQM=59	SGCD	3'UTR	SGCD:NM_000337.5:3'UTR:MODIFIER:exon9/9:c.*6717G>A:,SGCD:NM_001128209.1:3'UTR:MODIFIER:exon8/8:c.*6717G>A:		rs1827368	0.9271	0.0000	0/0/0	0.1496							601411 [SGCD (confirmed) Muscular dystrophy,limb-girdle,type 2F,601287|Cardiomyopathy,dilated,1L,606685];	RCV000278707.1 [benign]; RCV000333002.1 [benign]; RCV000373610.1 [benign]; 			182	43					SGCD (inh=AR+AD pLI=0.00)
chr5	156680685	156680685	A	G	hom	hom	hom		QUAL=29098;DP=353,230,324;MQM=59	ITK	3'UTR	ITK:NM_005546.3:3'UTR:MODIFIER:exon17/17:c.*997A>G:		rs27988	0.8335	0.0000	0/0/0	0.1441							186973 [ITK (confirmed) Lymphoproliferative syndrome 1,613011];	RCV000295939.1 [benign]; 			180	46					ITK (inh=AR pLI=0.00)
chr5	156681547	156681547	C	T	wt	wt	het		QUAL=2496;DP=371,113,160;MQM=60	ITK	3'UTR	ITK:NM_005546.3:3'UTR:MODIFIER:exon17/17:c.*1859C>T:		rs780591680	0.0000	0.0000	0/0/0	0.0002							186973 [ITK (confirmed) Lymphoproliferative syndrome 1,613011];				0	1					ITK (inh=AR pLI=0.00)
chr5	158742014	158742014	G	T	hom	hom	hom		QUAL=24041;DP=168,275,343;MQM=59	IL12B	3'UTR	IL12B:NM_002187.2:3'UTR:MODIFIER:exon8/8:c.*1095C>A:		rs1368439	0.9203	0.0000	0/0/0	0.7603							161561 [IL12B (confirmed) Immunodeficiency 29,mycobacteriosis,614890];	RCV000267660.1 [benign]; 			164	59					IL12B (inh=n/a pLI=0.00)
chr5	161275302	161275302	A	G	wt	wt	het		QUAL=4443;DP=214,300,403;MQM=60	GABRA1	5'UTR	GABRA1:NM_000806.5:5'UTR:MODIFIER:exon2/11:c.-142A>G:,GABRA1:NM_001127643.1:5'UTR:MODIFIER:exon2/11:c.-142A>G:,GABRA1:NM_001127644.1:5'UTR:MODIFIER:exon1/10:c.-142A>G:		rs12658835	0.1795	0.0000	0/0/0	0.2105							137160 [GABRA1 (confirmed) Epilepsy,juvenile myoclonic,susceptibility to,5,611136|Epilepsy,childhood absence,susceptibility to,4,611136|Epileptic encephalopathy,early infantile,19,615744];	RCV000298600.1 [likely benign]; 			17	81					GABRA1 (inh=n/a pLI=0.96)
chr5	161275540	161275541	GA	-	wt	wt	het	low_DP	QUAL=47;DP=5,17,31;MQM=60	GABRA1	5'UTR,intron	GABRA1:NM_001127645.1:5'UTR:MODIFIER:exon1/10:c.-78_-77delGA:,GABRA1:NM_000806.5:intron:MODIFIER:exon2/10:c.-16+128_-16+129delGA:,GABRA1:NM_001127643.1:intron:MODIFIER:exon2/10:c.-16+128_-16+129delGA:,GABRA1:NM_001127644.1:intron:MODIFIER:exon1/9:c.-16+128_-16+129delGA:	G-rich:GA-rich	rs763900656	0.0000	0.0000	0/0/0	0.1886							137160 [GABRA1 (confirmed) Epilepsy,juvenile myoclonic,susceptibility to,5,611136|Epilepsy,childhood absence,susceptibility to,4,611136|Epileptic encephalopathy,early infantile,19,615744];				34	70					GABRA1 (inh=n/a pLI=0.96)
chr5	161281245	161281245	T	C	wt	wt	het		QUAL=2668;DP=245,187,217;MQM=60	GABRA1	synonymous	GABRA1:NM_000806.5:synonymous:LOW:exon4/11:c.156T>C:p.Gly52Gly,GABRA1:NM_001127643.1:synonymous:LOW:exon4/11:c.156T>C:p.Gly52Gly,GABRA1:NM_001127644.1:synonymous:LOW:exon3/10:c.156T>C:p.Gly52Gly,GABRA1:NM_001127645.1:synonymous:LOW:exon3/10:c.156T>C:p.Gly52Gly,GABRA1:NM_001127648.1:synonymous:LOW:exon2/9:c.156T>C:p.Gly52Gly		rs1129647	0.2288	0.2591	4227/2493/83	0.2566							137160 [GABRA1 (confirmed) Epilepsy,juvenile myoclonic,susceptibility to,5,611136|Epilepsy,childhood absence,susceptibility to,4,611136|Epileptic encephalopathy,early infantile,19,615744];	RCV000117109.2 [benign]; RCV000328710.1 [likely benign]; 		COSM4003435	150	605					GABRA1 (inh=n/a pLI=0.96)
chr5	161324898	161324898	A	G	hom	hom	het		QUAL=9342;DP=199,52,70;MQM=59	GABRA1	3'UTR	GABRA1:NM_000806.5:3'UTR:MODIFIER:exon11/11:c.*470A>G:,GABRA1:NM_001127643.1:3'UTR:MODIFIER:exon11/11:c.*470A>G:,GABRA1:NM_001127644.1:3'UTR:MODIFIER:exon10/10:c.*470A>G:,GABRA1:NM_001127645.1:3'UTR:MODIFIER:exon10/10:c.*470A>G:,GABRA1:NM_001127648.1:3'UTR:MODIFIER:exon9/9:c.*470A>G:		rs2290732	0.5811	0.0000	0/0/0	0.1040							137160 [GABRA1 (confirmed) Epilepsy,juvenile myoclonic,susceptibility to,5,611136|Epilepsy,childhood absence,susceptibility to,4,611136|Epileptic encephalopathy,early infantile,19,615744];	RCV000308049.1 [likely benign]; 			79	116					GABRA1 (inh=n/a pLI=0.96)
chr5	161325934	161325934	A	C	hom	hom	het		QUAL=16323;DP=289,102,168;MQM=60	GABRA1	3'UTR	GABRA1:NM_000806.5:3'UTR:MODIFIER:exon11/11:c.*1506A>C:,GABRA1:NM_001127643.1:3'UTR:MODIFIER:exon11/11:c.*1506A>C:,GABRA1:NM_001127644.1:3'UTR:MODIFIER:exon10/10:c.*1506A>C:,GABRA1:NM_001127645.1:3'UTR:MODIFIER:exon10/10:c.*1506A>C:,GABRA1:NM_001127648.1:3'UTR:MODIFIER:exon9/9:c.*1506A>C:		rs998754	0.5805	0.0000	0/0/0	0.1044							137160 [GABRA1 (confirmed) Epilepsy,juvenile myoclonic,susceptibility to,5,611136|Epilepsy,childhood absence,susceptibility to,4,611136|Epileptic encephalopathy,early infantile,19,615744];	RCV000319995.1 [likely benign]; 			80	116					GABRA1 (inh=n/a pLI=0.96)
chr5	161494852	161494852	C	T	het	wt	het		QUAL=7294;DP=256,278,381;MQM=60	GABRG2	5'UTR	GABRG2:NM_198903.2:5'UTR:MODIFIER:exon1/11:c.-154C>T:,GABRG2:NM_000816.3:5'UTR:MODIFIER:exon1/9:c.-154C>T:,GABRG2:NM_198904.2:5'UTR:MODIFIER:exon1/10:c.-154C>T:		rs3219203	0.0361	0.0000	0/0/0	0.0088							137164 [GABRG2 (confirmed) Epilepsy,generalized,with febrile seizures plus,type 3,611277|Epilepsy,childhood absence,susceptibility to,2,607681|Febrile seizures,familial,8,611277];	RCV000288933.1 [likely benign]; RCV000341647.1 [likely benign]; 			0	34					GABRG2 (inh=AD pLI=0.96)
chr5	161529571	161529571	A	G	hom	hom	hom		QUAL=2378;DP=31,20,26;MQM=60	GABRG2	missense,intron	GABRG2:NM_198903.2:missense:MODERATE:exon6/11:c.643A>G:p.Ile215Val,GABRG2:NM_000816.3:intron:MODIFIER:exon5/8:c.631+1248A>G:,GABRG2:NM_198904.2:intron:MODIFIER:exon5/9:c.631+1248A>G:	AluJb	rs211035	0.8213	0.8206	3639/835/70	0.1967		T	T	B	T	0.35	137164 [GABRG2 (confirmed) Epilepsy,generalized,with febrile seizures plus,type 3,611277|Epilepsy,childhood absence,susceptibility to,2,607681|Febrile seizures,familial,8,611277];				883	393					GABRG2 (inh=AD pLI=0.96)
chr5	161580983	161580983	C	T	wt	wt	het		QUAL=3548;DP=345,186,255;MQM=60	GABRG2	3'UTR	GABRG2:NM_198903.2:3'UTR:MODIFIER:exon11/11:c.*609C>T:,GABRG2:NM_000816.3:3'UTR:MODIFIER:exon9/9:c.*609C>T:,GABRG2:NM_198904.2:3'UTR:MODIFIER:exon10/10:c.*609C>T:		rs418210	0.3794	0.0000	0/0/0	0.0517							137164 [GABRG2 (confirmed) Epilepsy,generalized,with febrile seizures plus,type 3,611277|Epilepsy,childhood absence,susceptibility to,2,607681|Febrile seizures,familial,8,611277];	RCV000288247.1 [benign]; RCV000329146.1 [benign]; 			9	78					GABRG2 (inh=AD pLI=0.96)
chr5	161581035	161581035	T	A	wt	wt	het		QUAL=4320;DP=391,219,310;MQM=60	GABRG2	3'UTR	GABRG2:NM_198903.2:3'UTR:MODIFIER:exon11/11:c.*661T>A:,GABRG2:NM_000816.3:3'UTR:MODIFIER:exon9/9:c.*661T>A:,GABRG2:NM_198904.2:3'UTR:MODIFIER:exon10/10:c.*661T>A:		rs424740	0.5146	0.0000	0/0/0	0.0768							137164 [GABRG2 (confirmed) Epilepsy,generalized,with febrile seizures plus,type 3,611277|Epilepsy,childhood absence,susceptibility to,2,607681|Febrile seizures,familial,8,611277];	RCV000284562.1 [benign]; RCV000383744.1 [benign]; 			28	107					GABRG2 (inh=AD pLI=0.96)
chr5	161582494	161582495	AT	-	wt	wt	het		QUAL=1916;DP=274,127,161;MQM=60	GABRG2	3'UTR	GABRG2:NM_198903.2:3'UTR:MODIFIER:exon11/11:c.*2120_*2121delAT:,GABRG2:NM_000816.3:3'UTR:MODIFIER:exon9/9:c.*2120_*2121delAT:,GABRG2:NM_198904.2:3'UTR:MODIFIER:exon10/10:c.*2120_*2121delAT:		rs34705786	0.3023	0.0000	0/0/0	0.2346							137164 [GABRG2 (confirmed) Epilepsy,generalized,with febrile seizures plus,type 3,611277|Epilepsy,childhood absence,susceptibility to,2,607681|Febrile seizures,familial,8,611277];	RCV000310208.1 [benign]; RCV000364948.1 [benign]; 			8	77					GABRG2 (inh=AD pLI=0.96)
chr5	172659511	172659511	C	A	hom	hom	het		QUAL=5397;DP=37,113,96;MQM=60	NKX2-5	3'UTR	NKX2-5:NM_004387.3:3'UTR:MODIFIER:exon2/2:c.*61G>T:,NKX2-5:NM_001166175.1:3'UTR:MODIFIER:exon2/2:c.*989G>T:,NKX2-5:NM_001166176.1:3'UTR:MODIFIER:exon2/2:c.*835G>T:		rs703752	0.2556	0.0000	0/0/0	0.0606							600584 [NKX2-5 (confirmed) Atrial septal defect 7,with or without AV conduction defects,108900|Tetralogy of Fallot,187500|Hypothyroidism,congenital nongoitrous,5,225250|Ventricular septal defect 3,614432|Hypoplastic left heart syndrome 2,614435|Conotruncal heart malformations,variable,217095];	RCV000192692.1 [benign]; 			100	322					NKX2-5 (inh=AR+AD pLI=0.86)
chr5	172662024	172662024	T	C	wt	wt	het		QUAL=3390;DP=59,278,299;MQM=60	NKX2-5	synonymous	NKX2-5:NM_004387.3:synonymous:LOW:exon1/2:c.63A>G:p.Glu21Glu,NKX2-5:NM_001166175.1:synonymous:LOW:exon1/2:c.63A>G:p.Glu21Glu,NKX2-5:NM_001166176.1:synonymous:LOW:exon1/2:c.63A>G:p.Glu21Glu		rs2277923	0.5357	0.4052	10547/2879/2046	0.3810							600584 [NKX2-5 (confirmed) Atrial septal defect 7,with or without AV conduction defects,108900|Tetralogy of Fallot,187500|Hypothyroidism,congenital nongoitrous,5,225250|Ventricular septal defect 3,614432|Hypoplastic left heart syndrome 2,614435|Conotruncal heart malformations,variable,217095];	RCV000037967.10 [benign]; 	CM1312416 [CLASS=DFP MUT=ALT PHEN="Cardiac disease modifier of" GENE=NKX2-5]; 	COSM3761113	212	664					NKX2-5 (inh=AR+AD pLI=0.86)
chr5	176636882	176636882	C	T	het	hom	wt		QUAL=6352;DP=214,108,119;MQM=60	NSD1	synonymous	NSD1:NM_022455.4:synonymous:LOW:exon5/23:c.1482C>T:p.Cys494Cys,NSD1:NM_172349.2:synonymous:LOW:exon6/24:c.675C>T:p.Cys225Cys		rs1363405	0.4681	0.2999	6927/1374/2480	0.2926							606681 [NSD1 (confirmed) Sotos syndrome 1,117550|Leukemia,acute myeloid,601626|Beckwith-Wiedemann syndrome,130650];	RCV000082100.6 [benign]; RCV000319604.1 [benign]; RCV000371717.1 [benign]; 			101	601					NSD1 (inh=AD pLI=1.00)
chr5	176637149	176637149	G	A	het	hom	wt		QUAL=8454;DP=304,165,235;MQM=60	NSD1	synonymous	NSD1:NM_022455.4:synonymous:LOW:exon5/23:c.1749G>A:p.Glu583Glu,NSD1:NM_172349.2:synonymous:LOW:exon6/24:c.942G>A:p.Glu314Glu		rs3733874	0.0000	0.1765	2686/572/21	0.1645							606681 [NSD1 (confirmed) Sotos syndrome 1,117550|Leukemia,acute myeloid,601626|Beckwith-Wiedemann syndrome,130650];	RCV000082103.6 [benign]; RCV000283379.1 [benign]; RCV000379961.1 [benign]; 			37	372					NSD1 (inh=AD pLI=1.00)
chr5	176637240	176637240	G	T	het	hom	wt	pred_pathogenic	QUAL=12381;DP=517,205,306;MQM=59	NSD1	missense	NSD1:NM_022455.4:missense:MODERATE:exon5/23:c.1840G>T:p.Val614Leu,NSD1:NM_172349.2:missense:MODERATE:exon6/24:c.1033G>T:p.Val345Leu		rs3733875	0.2286	0.1762	2633/566/20	0.1710	-0.3010	T,T,T,T,T	T	B,B,B	D,D,D,D	0.01	606681 [NSD1 (confirmed) Sotos syndrome 1,117550|Leukemia,acute myeloid,601626|Beckwith-Wiedemann syndrome,130650];	RCV000082107.6 [benign]; RCV000291627.1 [benign]; RCV000344352.1 [benign]; 			37	371					NSD1 (inh=AD pLI=1.00)
chr5	176637576	176637576	T	C	het	hom	wt	pred_pathogenic	QUAL=12405;DP=605,151,268;MQM=60	NSD1	missense	NSD1:NM_022455.4:missense:MODERATE:exon5/23:c.2176T>C:p.Ser726Pro,NSD1:NM_172349.2:missense:MODERATE:exon6/24:c.1369T>C:p.Ser457Pro		rs28932178	0.2496	0.1987	3137/808/47	0.1949	0.3970	D,D,D,D,D	T	D,P,P	D,D,D,D	0.01	606681 [NSD1 (confirmed) Sotos syndrome 1,117550|Leukemia,acute myeloid,601626|Beckwith-Wiedemann syndrome,130650];	RCV000082108.6 [benign]; RCV000313455.1 [benign]; RCV000354270.1 [benign]; 			49	457					NSD1 (inh=AD pLI=1.00)
chr5	176721198	176721198	T	C	het	wt	hom		QUAL=11521;DP=380,150,213;MQM=59	NSD1	synonymous	NSD1:NM_022455.4:synonymous:LOW:exon23/23:c.6829T>C:p.Leu2277Leu,NSD1:NM_172349.2:synonymous:LOW:exon24/24:c.6022T>C:p.Leu2008Leu		rs28580074	0.7714	0.8242	42011/25695/4422	0.8081							606681 [NSD1 (confirmed) Sotos syndrome 1,117550|Leukemia,acute myeloid,601626|Beckwith-Wiedemann syndrome,130650];	RCV000082138.7 [other]; RCV000127260.1 [benign]; RCV000268880.1 [benign]; RCV000379229.1 [benign]; 		COSM4003461, COSM150019	1260	374					NSD1 (inh=AD pLI=1.00)
chr5	176721272	176721272	G	C	wt	wt	het		QUAL=2033;DP=259,108,179;MQM=60	NSD1	synonymous	NSD1:NM_022455.4:synonymous:LOW:exon23/23:c.6903G>C:p.Gly2301Gly,NSD1:NM_172349.2:synonymous:LOW:exon24/24:c.6096G>C:p.Gly2032Gly		rs11740250	0.1080	0.1915	2765/2036/16	0.1842							606681 [NSD1 (confirmed) Sotos syndrome 1,117550|Leukemia,acute myeloid,601626|Beckwith-Wiedemann syndrome,130650];	RCV000082139.6 [benign]; RCV000328643.1 [benign]; RCV000383147.1 [benign]; 		COSM4159761, COSM4159760	100	548					NSD1 (inh=AD pLI=1.00)
chr5	176726002	176726002	T	C	het	wt	hom		QUAL=13743;DP=458,254,250;MQM=60	NSD1	3'UTR	NSD1:NM_022455.4:3'UTR:MODIFIER:exon23/23:c.*3542T>C:,NSD1:NM_172349.2:3'UTR:MODIFIER:exon24/24:c.*3542T>C:		rs4976682	0.7640	0.0000	0/0/0	0.1364							606681 [NSD1 (confirmed) Sotos syndrome 1,117550|Leukemia,acute myeloid,601626|Beckwith-Wiedemann syndrome,130650];	RCV000273146.1 [benign]; RCV000364585.1 [benign]; 			184	42					NSD1 (inh=AD pLI=1.00)
chr5	176727058	176727058	G	C	hom	hom	hom	low_DP	QUAL=1467;DP=28,9,33;MQM=54	NSD1	3'UTR	NSD1:NM_022455.4:3'UTR:MODIFIER:exon23/23:c.*4598G>C:,NSD1:NM_172349.2:3'UTR:MODIFIER:exon24/24:c.*4598G>C:			0.0000	0.0000	0/0/0	0.0000							606681 [NSD1 (confirmed) Sotos syndrome 1,117550|Leukemia,acute myeloid,601626|Beckwith-Wiedemann syndrome,130650];				0	9					NSD1 (inh=AD pLI=1.00)
chr5	176727072	176727072	G	C	hom	hom	hom	low_DP	QUAL=1467;DP=28,9,33;MQM=54	NSD1	3'UTR	NSD1:NM_022455.4:3'UTR:MODIFIER:exon23/23:c.*4612G>C:,NSD1:NM_172349.2:3'UTR:MODIFIER:exon24/24:c.*4612G>C:	(C)n	rs867075292	0.0000	0.0000	0/0/0	0.0015							606681 [NSD1 (confirmed) Sotos syndrome 1,117550|Leukemia,acute myeloid,601626|Beckwith-Wiedemann syndrome,130650];				0	61					NSD1 (inh=AD pLI=1.00)
chr5	177031348	177031348	T	C	het	hom	het		QUAL=4589;DP=50,115,113;MQM=59	B4GALT7	synonymous	B4GALT7:NM_007255.2:synonymous:LOW:exon2/6:c.219T>C:p.Arg73Arg		rs11537644	0.6613	0.6608	23835/12353/1963	0.6396							604327 [B4GALT7 (confirmed) Ehlers-Danlos syndrome with short stature and limb anomalies,130070];			COSM3761139	629	724					B4GALT7 (inh=AR pLI=0.00)
chr5	177035964	177035964	T	C	het	hom	het		QUAL=12525;DP=191,214,263;MQM=59	B4GALT7	synonymous	B4GALT7:NM_007255.2:synonymous:LOW:exon5/6:c.777T>C:p.His259His		rs729459	0.6050	0.5903	21537/10771/1974	0.5831							604327 [B4GALT7 (confirmed) Ehlers-Danlos syndrome with short stature and limb anomalies,130070];			COSM3761140	480	785					B4GALT7 (inh=AR pLI=0.00)
chr5	177419658	177419658	C	T	wt	het	wt		QUAL=2595;DP=289,210,238;MQM=60	PROP1	3'UTR	PROP1:NM_006261.4:3'UTR:MODIFIER:exon3/3:c.*52G>A:		rs2233787	0.0058	0.0000	0/0/0	0.0018							601538 [PROP1 (provisional) Pituitary hormone deficiency,combined,2,262600];	RCV000356628.1 [uncertain significance]; 			0	26					PROP1 (inh=AR pLI=0.30)
chr5	177419761	177419761	T	G	wt	het	het	low_QUAL	QUAL=8;DP=52,54,65;MQM=58	PROP1	synonymous	PROP1:NM_006261.4:synonymous:LOW:exon3/3:c.630A>C:p.Pro210Pro		rs535993919	0.0158	0.0007	0/0/0	0.0005							601538 [PROP1 (provisional) Pituitary hormone deficiency,combined,2,262600];	RCV000288943.1 [likely benign]; 		COSM1543130	0	338					PROP1 (inh=AR pLI=0.30)
chr5	177419967	177419967	C	T	wt	het	wt	pred_pathogenic	QUAL=3131;DP=181,289,344;MQM=60	PROP1	missense	PROP1:NM_006261.4:missense:MODERATE:exon3/3:c.424G>A:p.Ala142Thr		rs1800197	0.2047	0.2450	3723/2420/91	0.2430	-0.8140	T	T	B	D	0.01	601538 [PROP1 (provisional) Pituitary hormone deficiency,combined,2,262600];	RCV000177255.2 [benign]; RCV000331489.1 [likely benign]; 		COSM150022	103	578					PROP1 (inh=AR pLI=0.30)
chr5	177422823	177422823	C	T	wt	het	wt		QUAL=1402;DP=253,102,142;MQM=60	PROP1	splice_region&intron	PROP1:NM_006261.4:splice_region&intron:LOW:exon1/2:c.109+3G>A:		rs4072924	0.5066	0.5113	16166/10044/1720	0.5061							601538 [PROP1 (provisional) Pituitary hormone deficiency,combined,2,262600];	RCV000343439.1 [benign]; 			402	756					PROP1 (inh=AR pLI=0.30)
chr5	177422876	177422876	T	C	hom	hom	hom	pred_pathogenic	QUAL=17249;DP=172,177,249;MQM=59	PROP1	missense	PROP1:NM_006261.4:missense:MODERATE:exon1/3:c.59A>G:p.Asn20Ser		rs7445271	0.9994	0.9999	60692/33365/5194	0.9333	-0.4890	T	T	B	D	0.01	601538 [PROP1 (provisional) Pituitary hormone deficiency,combined,2,262600];				1565	0					PROP1 (inh=AR pLI=0.30)
chr5	177422908	177422908	A	G	hom	het	hom		QUAL=15860;DP=149,232,304;MQM=60	PROP1	synonymous	PROP1:NM_006261.4:synonymous:LOW:exon1/3:c.27T>C:p.Ala9Ala		rs1135320	0.4477	0.4758	14261/6913/404	0.4643							601538 [PROP1 (provisional) Pituitary hormone deficiency,combined,2,262600];	RCV000377173.1 [benign]; 		COSM4159781	402	755					PROP1 (inh=AR pLI=0.30)
chr5	177423144	177423144	T	G	hom	het	hom		QUAL=32074;DP=354,408,531;MQM=59	PROP1	5'UTR	PROP1:NM_006261.4:5'UTR:MODIFIER:exon1/3:c.-210A>C:		rs13187293	0.3303	0.0000	0/0/0	0.0580							601538 [PROP1 (provisional) Pituitary hormone deficiency,combined,2,262600];	RCV000337498.1 [likely benign]; 			40	101					PROP1 (inh=AR pLI=0.30)
chr6	3224825	3224825	A	-	hom	hom	hom		QUAL=42698;DP=395,422,551;MQM=59	TUBB2B	3'UTR	TUBB2B:NM_178012.4:3'UTR:MODIFIER:exon4/4:c.*160delT:		rs398000197	0.0000	0.0000	0/0/0	0.5135							615101 [TUBB2A (provisional) Cortical dysplasia,complex,with other brain malformations 5,615763]:612850 [TUBB2B (provisional) Polymicrogyria,symmetric or asymmetric,610031];				195	33					TUBB2B (inh=AD pLI=n/a)
chr6	7542148	7542148	-	A	het	het	wt	anno_high_impact	QUAL=1795;DP=60,115,121;MQM=59	DSP	frameshift&start_lost,sequence_feature	DSP:NM_004415.3:frameshift&start_lost:HIGH:exon1/24:c.1dupA:p.Met1fs,DSP:NM_001008844.2:frameshift&start_lost:HIGH:exon1/24:c.1dupA:p.Met1fs,DSP:NM_001319034.1:frameshift&start_lost:HIGH:exon1/24:c.1dupA:p.Met1fs,DSP:NM_004415.3:sequence_feature:LOW:exon1/24:c.-1_1insA:,DSP:NM_004415.3:sequence_feature:LOW:exon1/24:c.-1_1insA:,DSP:NM_001008844.2:sequence_feature:LOW:exon1/24:c.-1_1insA:,DSP:NM_001008844.2:sequence_feature:LOW:exon1/24:c.-1_1insA:		rs606231377	0.1997	0.1994	1480/549/173	0.1474							125647 [DSP (confirmed) Keratosis palmoplantaris striata II,612908|Cardiomyopathy,dilated,with woolly hair and keratoderma,605676|Arrhythmogenic right ventricular dysplasia 8,607450|Skin fragility-woolly hair syndrome,607655|Epidermolysis bullosa,lethal acantholytic,609638|Dilated cardiomyopathy with woolly hair,keratoderma,and tooth agenesis,615821];	RCV000029674.1 [uncertain significance]; RCV000037982.7 [other]; RCV000292424.1 [benign]; RCV000332106.1 [benign]; RCV000346732.1 [benign]; RCV000389020.1,RCV000029674.1 [benign,uncertain significance]; RCV000037982.7 [other]; RCV000292424.1 [benign]; RCV000332106.1 [benign]; RCV000346732.1 [benign]; RCV000389020.1 [benign]; 			38	361	1	[1] auto-classification 16.06.2016  [2] old entry - no details available			DSP (inh=AR+AD pLI=1.00)
chr6	7542253	7542253	G	A	wt	wt	het		QUAL=571;DP=41,73,83;MQM=60	DSP	synonymous	DSP:NM_004415.3:synonymous:LOW:exon1/24:c.105G>A:p.Gly35Gly,DSP:NM_001008844.2:synonymous:LOW:exon1/24:c.105G>A:p.Gly35Gly,DSP:NM_001319034.1:synonymous:LOW:exon1/24:c.105G>A:p.Gly35Gly		rs77445784	0.0034	0.0094	1/1/0	0.0049							125647 [DSP (confirmed) Keratosis palmoplantaris striata II,612908|Cardiomyopathy,dilated,with woolly hair and keratoderma,605676|Arrhythmogenic right ventricular dysplasia 8,607450|Skin fragility-woolly hair syndrome,607655|Epidermolysis bullosa,lethal acantholytic,609638|Dilated cardiomyopathy with woolly hair,keratoderma,and tooth agenesis,615821];	RCV000029675.1 [benign]; RCV000037983.7 [other]; RCV000227163.1 [benign]; RCV000227163.1 [benign]; RCV000271030.1 [likely benign]; RCV000328428.1 [likely benign]; RCV000330639.1 [likely benign]; RCV000387490.1 [likely benign]; 			0	19	2	[2] old entry - no details available			DSP (inh=AR+AD pLI=1.00)
chr6	7542274	7542274	T	C	het	wt	het		QUAL=1094;DP=20,63,71;MQM=60	DSP	synonymous	DSP:NM_004415.3:synonymous:LOW:exon1/24:c.126T>C:p.Tyr42Tyr,DSP:NM_001008844.2:synonymous:LOW:exon1/24:c.126T>C:p.Tyr42Tyr,DSP:NM_001319034.1:synonymous:LOW:exon1/24:c.126T>C:p.Tyr42Tyr		rs36087964	0.0609	0.0980	95/49/18	0.0417							125647 [DSP (confirmed) Keratosis palmoplantaris striata II,612908|Cardiomyopathy,dilated,with woolly hair and keratoderma,605676|Arrhythmogenic right ventricular dysplasia 8,607450|Skin fragility-woolly hair syndrome,607655|Epidermolysis bullosa,lethal acantholytic,609638|Dilated cardiomyopathy with woolly hair,keratoderma,and tooth agenesis,615821];	RCV000037988.3 [benign]; RCV000288715.1 [benign]; RCV000341384.1 [benign]; RCV000379727.1 [benign]; RCV000380793.1 [benign]; 		COSM451787	8	168					DSP (inh=AR+AD pLI=1.00)
chr6	7556063	7556063	C	T	wt	wt	het		QUAL=2732;DP=124,210,273;MQM=60	DSP	splice_region&intron	DSP:NM_004415.3:splice_region&intron:LOW:exon2/23:c.273+10C>T:,DSP:NM_001008844.2:splice_region&intron:LOW:exon2/23:c.273+10C>T:,DSP:NM_001319034.1:splice_region&intron:LOW:exon2/23:c.273+10C>T:		rs56148603	0.0126	0.0251	48/44/0	0.0232							125647 [DSP (confirmed) Keratosis palmoplantaris striata II,612908|Cardiomyopathy,dilated,with woolly hair and keratoderma,605676|Arrhythmogenic right ventricular dysplasia 8,607450|Skin fragility-woolly hair syndrome,607655|Epidermolysis bullosa,lethal acantholytic,609638|Dilated cardiomyopathy with woolly hair,keratoderma,and tooth agenesis,615821];	RCV000038013.3 [benign]; RCV000269015.1 [likely benign]; RCV000274004.1 [likely benign]; RCV000312765.1 [likely benign]; RCV000366031.1 [likely benign]; 			1	85	2	[2] old entry - no details available			DSP (inh=AR+AD pLI=1.00)
chr6	7563983	7563983	T	G	hom	hom	hom		QUAL=32492;DP=451,231,314;MQM=59	DSP	synonymous	DSP:NM_004415.3:synonymous:LOW:exon6/24:c.741T>G:p.Ala247Ala,DSP:NM_001008844.2:synonymous:LOW:exon6/24:c.741T>G:p.Ala247Ala,DSP:NM_001319034.1:synonymous:LOW:exon6/24:c.741T>G:p.Ala247Ala		rs2806234	1.0000	0.9991	60601/33273/5200	0.9624							125647 [DSP (confirmed) Keratosis palmoplantaris striata II,612908|Cardiomyopathy,dilated,with woolly hair and keratoderma,605676|Arrhythmogenic right ventricular dysplasia 8,607450|Skin fragility-woolly hair syndrome,607655|Epidermolysis bullosa,lethal acantholytic,609638|Dilated cardiomyopathy with woolly hair,keratoderma,and tooth agenesis,615821];	RCV000154388.1 [likely benign]; RCV000038087.3 [other]; RCV000038088.2 [likely benign]; 			1676	3					DSP (inh=AR+AD pLI=1.00)
chr6	7565727	7565727	A	T	het	wt	het	pred_pathogenic	QUAL=7274;DP=228,281,404;MQM=60	DSP	missense	DSP:NM_004415.3:missense:MODERATE:exon7/24:c.913A>T:p.Ile305Phe,DSP:NM_001008844.2:missense:MODERATE:exon7/24:c.913A>T:p.Ile305Phe,DSP:NM_001319034.1:missense:MODERATE:exon7/24:c.913A>T:p.Ile305Phe		rs17604693	0.0184	0.0299	85/59/0	0.0300	9.2100	D,D,D	D	P,P	D,D	27.80	125647 [DSP (confirmed) Keratosis palmoplantaris striata II,612908|Cardiomyopathy,dilated,with woolly hair and keratoderma,605676|Arrhythmogenic right ventricular dysplasia 8,607450|Skin fragility-woolly hair syndrome,607655|Epidermolysis bullosa,lethal acantholytic,609638|Dilated cardiomyopathy with woolly hair,keratoderma,and tooth agenesis,615821];	RCV000279302.1 [uncertain significance]; RCV000311275.1 [uncertain significance]; RCV000350684.1 [uncertain significance]; RCV000403981.1 [uncertain significance]; RCV000029686.1 [benign]; RCV000038119.5 [other]; RCV000143884.1 [uncertain significance]; RCV000202852.1 [benign]; RCV000249794.1 [benign]; RCV000310554.1 [likely benign]; RCV000349765.1 [likely benign]; RCV000362961.1 [likely benign]; RCV000395135.1 [likely benign]; 	CM150219 [CLASS=R MUT=ALT PHEN="Arrhythmogenic right ventricular cardiomyopathy" GENE=DSP]; 	COSM1685467	4	143	3	[3] Stephan Waldm?ller 09.11.2015 [n/a] comment imported from detected variant: HGMD: DM? f?r ARVC, VUS3, swal 151109			DSP (inh=AR+AD pLI=1.00)
chr6	7565730	7565730	G	A	wt	het	wt	pred_pathogenic;anno_pathogenic_hgmd	QUAL=3340;DP=215,270,398;MQM=60	DSP	missense	DSP:NM_004415.3:missense:MODERATE:exon7/24:c.916G>A:p.Ala306Thr,DSP:NM_001008844.2:missense:MODERATE:exon7/24:c.916G>A:p.Ala306Thr,DSP:NM_001319034.1:missense:MODERATE:exon7/24:c.916G>A:p.Ala306Thr		rs368193211	0.0000	0.0001	0/0/0	0.0001	2.6700	T,T,T	T	B,B	D,D	21.90	125647 [DSP (confirmed) Keratosis palmoplantaris striata II,612908|Cardiomyopathy,dilated,with woolly hair and keratoderma,605676|Arrhythmogenic right ventricular dysplasia 8,607450|Skin fragility-woolly hair syndrome,607655|Epidermolysis bullosa,lethal acantholytic,609638|Dilated cardiomyopathy with woolly hair,keratoderma,and tooth agenesis,615821];	RCV000038120.3 [uncertain significance]; 	CM1413441 [CLASS=DM? MUT=ALT PHEN="Sudden cardiac death" GENE=DSP]; 		0	1					DSP (inh=AR+AD pLI=1.00)
chr6	7572262	7572262	A	G	hom	hom	hom		QUAL=14095;DP=198,98,146;MQM=60	DSP	synonymous	DSP:NM_004415.3:synonymous:LOW:exon15/24:c.2091A>G:p.Gly697Gly,DSP:NM_001008844.2:synonymous:LOW:exon15/24:c.2091A>G:p.Gly697Gly,DSP:NM_001319034.1:synonymous:LOW:exon15/24:c.2091A>G:p.Gly697Gly		rs2076304	0.7744	0.7614	35334/19903/3342	0.7531							125647 [DSP (confirmed) Keratosis palmoplantaris striata II,612908|Cardiomyopathy,dilated,with woolly hair and keratoderma,605676|Arrhythmogenic right ventricular dysplasia 8,607450|Skin fragility-woolly hair syndrome,607655|Epidermolysis bullosa,lethal acantholytic,609638|Dilated cardiomyopathy with woolly hair,keratoderma,and tooth agenesis,615821];	RCV000154389.1 [benign]; RCV000206052.1 [benign]; RCV000206052.1 [benign]; RCV000038004.2 [benign]; 			995	598					DSP (inh=AR+AD pLI=1.00)
chr6	7576527	7576527	G	A	hom	hom	hom		QUAL=10117;DP=178,56,89;MQM=60	DSP	splice_region&synonymous	DSP:NM_004415.3:splice_region&synonymous:LOW:exon19/24:c.2631G>A:p.Arg877Arg,DSP:NM_001008844.2:splice_region&synonymous:LOW:exon19/24:c.2631G>A:p.Arg877Arg,DSP:NM_001319034.1:splice_region&synonymous:LOW:exon19/24:c.2631G>A:p.Arg877Arg		rs1016835	0.7354	0.7718	36242/21321/2142	0.7704							125647 [DSP (confirmed) Keratosis palmoplantaris striata II,612908|Cardiomyopathy,dilated,with woolly hair and keratoderma,605676|Arrhythmogenic right ventricular dysplasia 8,607450|Skin fragility-woolly hair syndrome,607655|Epidermolysis bullosa,lethal acantholytic,609638|Dilated cardiomyopathy with woolly hair,keratoderma,and tooth agenesis,615821];	RCV000154390.1 [benign]; RCV000038011.3 [benign]; RCV000250214.1 [benign]; RCV000289404.1 [benign]; RCV000292946.1 [benign]; RCV000352543.1 [benign]; RCV000388191.1 [benign]; 			1030	566					DSP (inh=AR+AD pLI=1.00)
chr6	7577260	7577260	C	T	wt	het	wt		QUAL=1079;DP=210,107,145;MQM=60	DSP	synonymous	DSP:NM_004415.3:synonymous:LOW:exon20/24:c.2862C>T:p.Cys954Cys,DSP:NM_001008844.2:synonymous:LOW:exon20/24:c.2862C>T:p.Cys954Cys,DSP:NM_001319034.1:synonymous:LOW:exon20/24:c.2862C>T:p.Cys954Cys		rs2064217	0.2752	0.2438	3585/1539/708	0.2378							125647 [DSP (confirmed) Keratosis palmoplantaris striata II,612908|Cardiomyopathy,dilated,with woolly hair and keratoderma,605676|Arrhythmogenic right ventricular dysplasia 8,607450|Skin fragility-woolly hair syndrome,607655|Epidermolysis bullosa,lethal acantholytic,609638|Dilated cardiomyopathy with woolly hair,keratoderma,and tooth agenesis,615821];	RCV000038021.3 [benign]; RCV000299963.1 [benign]; RCV000368899.1 [benign]; RCV000397417.1 [benign]; RCV000402854.1 [benign]; 		COSM150041	126	597					DSP (inh=AR+AD pLI=1.00)
chr6	7584617	7584617	C	T	hom	het	hom		QUAL=23047;DP=442,161,222;MQM=59	DSP	synonymous	DSP:NM_004415.3:synonymous:LOW:exon24/24:c.7122C>T:p.Thr2374Thr,DSP:NM_001008844.2:synonymous:LOW:exon24/24:c.5325C>T:p.Thr1775Thr,DSP:NM_001319034.1:synonymous:LOW:exon24/24:c.5793C>T:p.Thr1931Thr		rs2076300	0.2117	0.2881	5622/4248/152	0.2873							125647 [DSP (confirmed) Keratosis palmoplantaris striata II,612908|Cardiomyopathy,dilated,with woolly hair and keratoderma,605676|Arrhythmogenic right ventricular dysplasia 8,607450|Skin fragility-woolly hair syndrome,607655|Epidermolysis bullosa,lethal acantholytic,609638|Dilated cardiomyopathy with woolly hair,keratoderma,and tooth agenesis,615821];	RCV000038083.3 [benign]; RCV000280755.1 [benign]; RCV000295739.1 [benign]; RCV000348344.1 [benign]; RCV000391444.1 [benign]; 		COSM150043	219	744					DSP (inh=AR+AD pLI=1.00)
chr6	7585967	7585967	G	C	hom	het	hom		QUAL=18002;DP=258,178,260;MQM=59	DSP	synonymous,sequence_feature	DSP:NM_004415.3:synonymous:LOW:exon24/24:c.8472G>C:p.Gly2824Gly,DSP:NM_001008844.2:synonymous:LOW:exon24/24:c.6675G>C:p.Gly2225Gly,DSP:NM_001319034.1:synonymous:LOW:exon24/24:c.7143G>C:p.Gly2381Gly,DSP:NM_004415.3:sequence_feature:LOW:exon24/24:c.8472G>C:,DSP:NM_001008844.2:sequence_feature:LOW:exon24/24:c.6675G>C:		rs2744380	0.7095	0.7117	30649/16753/2060	0.6999							125647 [DSP (confirmed) Keratosis palmoplantaris striata II,612908|Cardiomyopathy,dilated,with woolly hair and keratoderma,605676|Arrhythmogenic right ventricular dysplasia 8,607450|Skin fragility-woolly hair syndrome,607655|Epidermolysis bullosa,lethal acantholytic,609638|Dilated cardiomyopathy with woolly hair,keratoderma,and tooth agenesis,615821];	RCV000154391.1 [benign]; RCV000038104.4 [benign]; RCV000241982.1 [benign]; RCV000273141.1 [benign]; RCV000304085.1 [benign]; RCV000328251.1 [benign]; RCV000363396.1 [benign]; 			834	672					DSP (inh=AR+AD pLI=1.00)
chr6	7586308	7586308	C	T	wt	het	wt		QUAL=2164;DP=423,193,278;MQM=60	DSP	3'UTR	DSP:NM_004415.3:3'UTR:MODIFIER:exon24/24:c.*197C>T:,DSP:NM_001008844.2:3'UTR:MODIFIER:exon24/24:c.*197C>T:,DSP:NM_001319034.1:3'UTR:MODIFIER:exon24/24:c.*197C>T:		rs12250	0.2736	0.0000	0/0/0	0.0397							125647 [DSP (confirmed) Keratosis palmoplantaris striata II,612908|Cardiomyopathy,dilated,with woolly hair and keratoderma,605676|Arrhythmogenic right ventricular dysplasia 8,607450|Skin fragility-woolly hair syndrome,607655|Epidermolysis bullosa,lethal acantholytic,609638|Dilated cardiomyopathy with woolly hair,keratoderma,and tooth agenesis,615821];	RCV000261707.1 [benign]; RCV000297258.1 [benign]; RCV000302899.1 [benign]; RCV000356719.1 [benign]; 			21	64					DSP (inh=AR+AD pLI=1.00)
chr6	16300824	16300824	A	C	wt	het	wt		QUAL=296;DP=172,40,39;MQM=60	ATXN1	3'UTR	ATXN1:NM_000332.3:3'UTR:MODIFIER:exon9/9:c.*5736T>G:,ATXN1:NM_001128164.1:3'UTR:MODIFIER:exon8/8:c.*5736T>G:	(ATAAA)n	rs16877817	0.2027	0.0000	0/0/0	0.0282							601556 [ATXN1 (confirmed) Spinocerebellar ataxia 1,164400];				12	72					ATXN1 (inh=AD pLI=0.40)
chr6	16301316	16301316	-	TTT	wt	het	wt		QUAL=295;DP=195,48,68;MQM=58	ATXN1	3'UTR	ATXN1:NM_000332.3:3'UTR:MODIFIER:exon9/9:c.*5241_*5243dupAAA:,ATXN1:NM_001128164.1:3'UTR:MODIFIER:exon8/8:c.*5241_*5243dupAAA:		rs60830508;rs66843340	0.3263	0.0000	0/0/0	0.1444							601556 [ATXN1 (confirmed) Spinocerebellar ataxia 1,164400];				6	45					ATXN1 (inh=AD pLI=0.40)
chr6	16305506	16305506	A	-	het	het	wt		QUAL=69;DP=146,76,98;MQM=59	ATXN1	3'UTR	ATXN1:NM_000332.3:3'UTR:MODIFIER:exon9/9:c.*1054delT:,ATXN1:NM_001128164.1:3'UTR:MODIFIER:exon8/8:c.*1054delT:		rs878992657	0.0000	0.0000	0/0/0	0.0014							601556 [ATXN1 (confirmed) Spinocerebellar ataxia 1,164400];				0	18					ATXN1 (inh=AD pLI=0.40)
chr6	16306202	16306202	A	G	wt	het	wt		QUAL=2028;DP=223,157,186;MQM=60	ATXN1	3'UTR	ATXN1:NM_000332.3:3'UTR:MODIFIER:exon9/9:c.*358T>C:,ATXN1:NM_001128164.1:3'UTR:MODIFIER:exon8/8:c.*358T>C:		rs180017	0.3514	0.0000	0/0/0	0.0637							601556 [ATXN1 (confirmed) Spinocerebellar ataxia 1,164400];				34	119					ATXN1 (inh=AD pLI=0.40)
chr6	16327330	16327330	T	C	wt	het	wt		QUAL=4178;DP=148,313,438;MQM=60	ATXN1	synonymous	ATXN1:NM_000332.3:synonymous:LOW:exon8/9:c.1212A>G:p.Glu404Glu,ATXN1:NM_001128164.1:synonymous:LOW:exon7/8:c.1212A>G:p.Glu404Glu		rs2075974	0.3692	0.2710	5186/1398/1016	0.2684							601556 [ATXN1 (confirmed) Spinocerebellar ataxia 1,164400];	RCV000116468.2 [likely benign]; 			114	534					ATXN1 (inh=AD pLI=0.40)
chr6	16327615	16327615	A	G	het	het	het		QUAL=4440;DP=107,146,186;MQM=59	ATXN1	synonymous	ATXN1:NM_000332.3:synonymous:LOW:exon8/9:c.927T>C:p.Ala309Ala,ATXN1:NM_001128164.1:synonymous:LOW:exon7/8:c.927T>C:p.Ala309Ala		rs179990	0.7802	0.7320	32824/15394/3257	0.7221							601556 [ATXN1 (confirmed) Spinocerebellar ataxia 1,164400];	RCV000116476.2 [likely benign]; RCV000116475.2 [likely benign]; 		COSM3761638	737	659					ATXN1 (inh=AD pLI=0.40)
chr6	16327864	16327864	-	TGC	wt	het	het	low_DP	QUAL=1038;DP=2,71,97;MQM=59	ATXN1	disruptive_inframe_insertion	ATXN1:NM_000332.3:disruptive_inframe_insertion:MODERATE:exon8/9:c.675_677dupGCA:p.Gln225dup,ATXN1:NM_001128164.1:disruptive_inframe_insertion:MODERATE:exon7/8:c.675_677dupGCA:p.Gln225dup		rs765686161;rs769091061	0.0000	0.0594	74/57/6	0.0846							601556 [ATXN1 (confirmed) Spinocerebellar ataxia 1,164400];				156	626					ATXN1 (inh=AD pLI=0.40)
chr6	16327915	16327915	-	TGC	wt	het	wt	low_DP	QUAL=412;DP=1,61,79;MQM=59	ATXN1	disruptive_inframe_insertion	ATXN1:NM_000332.3:disruptive_inframe_insertion:MODERATE:exon8/9:c.624_626dupGCA:p.Gln208dup,ATXN1:NM_001128164.1:disruptive_inframe_insertion:MODERATE:exon7/8:c.624_626dupGCA:p.Gln208dup	(TGC)n	rs864309555	0.0000	0.0000	0/0/0	0.0001							601556 [ATXN1 (confirmed) Spinocerebellar ataxia 1,164400];	RCV000202699.1 [likely benign]; 		COSM3718779	47	339	2	[2] Julia Bickmann 23.09.2014			ATXN1 (inh=AD pLI=0.40)
chr6	18122506	18122506	G	A	het	wt	het	pred_pathogenic;anno_pathogenic_hgmd	QUAL=2093;DP=56,90,108;MQM=59	NHLRC1	missense	NHLRC1:NM_198586.2:missense:MODERATE:exon1/1:c.332C>T:p.Pro111Leu		rs10949483	0.3429	0.4211	8525/4596/226	0.3755	1.4920	D	D	B	D	18.92	608072 [NHLRC1 (confirmed) Epilepsy,progressive myoclonic 2B (Lafora),254780];	RCV000117782.7 [benign]; RCV000280891.1 [benign]; 	CM065338 [CLASS=DM? MUT=ALT PHEN="Myoclonic epilepsy of Lafora" GENE=NHLRC1]; 	COSM3749962	387	1312	2	[2] old entry - no details available [n/a] comment imported from detected variant: GS140155; too often in 1000g and esp6500 and in house; 18.06.2014; FH 			NHLRC1 (inh=AR pLI=0.04)
chr6	18122526	18122526	A	G	wt	wt	het		QUAL=645;DP=77,75,93;MQM=60	NHLRC1	synonymous	NHLRC1:NM_198586.2:synonymous:LOW:exon1/1:c.312T>C:p.His104His		rs115931931	0.1158	0.1047	420/184/125	0.0781							608072 [NHLRC1 (confirmed) Epilepsy,progressive myoclonic 2B (Lafora),254780];	RCV000117781.8 [other]; RCV000338229.1 [likely benign]; 		COSM1329196	26	397					NHLRC1 (inh=AR pLI=0.04)
chr6	24503590	24503590	C	T	wt	wt	het		QUAL=1151;DP=184,81,105;MQM=60	ALDH5A1	missense	ALDH5A1:NM_170740.1:missense:MODERATE:exon3/11:c.538C>T:p.His180Tyr,ALDH5A1:NM_001080.3:missense:MODERATE:exon3/10:c.538C>T:p.His180Tyr		rs2760118	0.3147	0.3195	6544/3798/1065	0.3153	0.8120	T,T,T,T	T	B,B	T,T,T,T	7.49	610045 [ALDH5A1 (confirmed) Succinic semialdehyde dehydrogenase deficiency,271980];	RCV000116307.3 [other]; RCV000375656.1 [benign]; 	CM083577 [CLASS=DFP MUT=ALT PHEN="Impaired cognitive function association with" GENE=ALDH5A1]; 	COSM4003827	129	680					ALDH5A1 (inh=AR pLI=0.00)
chr6	24505221	24505221	G	A	wt	wt	het		QUAL=213;DP=36,26,34;MQM=60	ALDH5A1	splice_region&intron	ALDH5A1:NM_170740.1:splice_region&intron:LOW:exon4/10:c.726+8G>A:,ALDH5A1:NM_001080.3:splice_region&intron:LOW:exon4/9:c.726+8G>A:		rs2817220	0.1927	0.2241	3332/2273/390	0.2219							610045 [ALDH5A1 (confirmed) Succinic semialdehyde dehydrogenase deficiency,271980];	RCV000394327.1 [benign]; 			75	511					ALDH5A1 (inh=AR pLI=0.00)
chr6	24532392	24532392	T	C	het	het	wt		QUAL=5964;DP=268,198,304;MQM=60	ALDH5A1	synonymous	ALDH5A1:NM_170740.1:synonymous:LOW:exon10/11:c.1428T>C:p.Asp476Asp,ALDH5A1:NM_001080.3:synonymous:LOW:exon9/10:c.1389T>C:p.Asp463Asp		rs58747567	0.0026	0.0062	7/7/0	0.0066							610045 [ALDH5A1 (confirmed) Succinic semialdehyde dehydrogenase deficiency,271980];	RCV000367251.1 [benign]; 			0	21	2	[2] swoedl 19.10.2016			ALDH5A1 (inh=AR pLI=0.00)
chr6	24532412	24532412	G	A	het	het	wt		QUAL=4652;DP=203,192,289;MQM=60	ALDH5A1	splice_region&intron	ALDH5A1:NM_170740.1:splice_region&intron:LOW:exon10/10:c.1441+7G>A:,ALDH5A1:NM_001080.3:splice_region&intron:LOW:exon9/9:c.1402+7G>A:		rs12211574	0.0507	0.0808	506/363/2	0.0803							610045 [ALDH5A1 (confirmed) Succinic semialdehyde dehydrogenase deficiency,271980];	RCV000265081.1 [likely benign]; 			13	202					ALDH5A1 (inh=AR pLI=0.00)
chr6	24534193	24534193	C	A	wt	wt	het		QUAL=2684;DP=231,172,259;MQM=60	ALDH5A1	3'UTR	ALDH5A1:NM_170740.1:3'UTR:MODIFIER:exon11/11:c.*253C>A:,ALDH5A1:NM_001080.3:3'UTR:MODIFIER:exon10/10:c.*253C>A:		rs1054899	0.3806	0.0000	0/0/0	0.0554							610045 [ALDH5A1 (confirmed) Succinic semialdehyde dehydrogenase deficiency,271980];	RCV000261010.1 [benign]; 			35	95					ALDH5A1 (inh=AR pLI=0.00)
chr6	24535179	24535179	T	G	het	het	wt		QUAL=8505;DP=392,235,272;MQM=60	ALDH5A1	3'UTR	ALDH5A1:NM_170740.1:3'UTR:MODIFIER:exon11/11:c.*1239T>G:,ALDH5A1:NM_001080.3:3'UTR:MODIFIER:exon10/10:c.*1239T>G:		rs191960134	0.0026	0.0000	0/0/0	0.0012							610045 [ALDH5A1 (confirmed) Succinic semialdehyde dehydrogenase deficiency,271980];	RCV000277246.1 [uncertain significance]; 			0	4					ALDH5A1 (inh=AR pLI=0.00)
chr6	24535780	24535780	G	A	wt	wt	het		QUAL=1698;DP=247,143,158;MQM=60	ALDH5A1	3'UTR	ALDH5A1:NM_170740.1:3'UTR:MODIFIER:exon11/11:c.*1840G>A:,ALDH5A1:NM_001080.3:3'UTR:MODIFIER:exon10/10:c.*1840G>A:	AluY	rs2744602	0.2680	0.0000	0/0/0	0.2471							610045 [ALDH5A1 (confirmed) Succinic semialdehyde dehydrogenase deficiency,271980];	RCV000338129.1 [benign]; 			29	75					ALDH5A1 (inh=AR pLI=0.00)
chr6	24535817	24535817	A	G	het	het	wt		QUAL=3074;DP=216,117,140;MQM=56	ALDH5A1	3'UTR	ALDH5A1:NM_170740.1:3'UTR:MODIFIER:exon11/11:c.*1877A>G:,ALDH5A1:NM_001080.3:3'UTR:MODIFIER:exon10/10:c.*1877A>G:	AluY	rs41271787	0.0026	0.0000	0/0/0	0.0072							610045 [ALDH5A1 (confirmed) Succinic semialdehyde dehydrogenase deficiency,271980];				0	3					ALDH5A1 (inh=AR pLI=0.00)
chr6	26027135	26027135	G	A	het	het	wt		QUAL=3021;DP=148,125,168;MQM=60	HIST1H4B	3'UTR	HIST1H4B:NM_003544.2:3'UTR:MODIFIER:exon1/1:c.*34C>T:		rs3752420	0.3918	0.4103	9809/4918/151	0.3922											145	389					HIST1H4B (inh=n/a pLI=0.01)
chr6	26027433	26027433	G	A	het	het	wt		QUAL=3851;DP=174,194,233;MQM=60	HIST1H4B	synonymous	HIST1H4B:NM_003544.2:synonymous:LOW:exon1/1:c.48C>T:p.Ala16Ala		rs3752419	0.3944	0.4047	10715/5188/165	0.4046										COSM4160437	176	495					HIST1H4B (inh=n/a pLI=0.01)
chr6	31829172	31829172	C	T	wt	het	wt		QUAL=1042;DP=166,87,97;MQM=60	NEU1	synonymous	NEU1:NM_000434.3.3:synonymous:LOW:exon3/6:c.408G>A:p.Gly136Gly		rs41267074	0.0006	0.0011	0/0/0	0.0011							608272 [NEU1 (confirmed) Sialidosis,type I,256550|Sialidosis,type II,256550];				0	11					NEU1 (inh=AR pLI=0.00)
chr6	31830593	31830593	A	C	het	het	wt		QUAL=8056;DP=413,298,453;MQM=59	NEU1	5'UTR	NEU1:NM_000434.3.3:5'UTR:MODIFIER:exon1/6:c.-40T>G:		rs41267082	0.0511	0.0455	197/63/2	0.0415							608272 [NEU1 (confirmed) Sialidosis,type I,256550|Sialidosis,type II,256550];	RCV000320437.1 [likely benign]; 			1	63					NEU1 (inh=AR pLI=0.00)
chr6	31964621	31964621	-	CT	het	het	wt	low_DP;low_MQM;anno_high_impact;anno_pathogenic_hgmd	QUAL=163;DP=21,14,2;MQM=36	C4A,C4B,C4B_2	frameshift	C4A:NM_007293.2.5:frameshift:HIGH:exon29/41:c.3694_3695dupTC:p.Val1233fs,C4B:NM_001002029.3:frameshift:HIGH:exon29/41:c.3694_3695dupTC:p.Val1233fs,C4B_2:NM_001242823.2:frameshift:HIGH:exon29/41:c.3694_3695dupTC:p.Val1233fs,C4A:NM_001252204.1.3:frameshift:HIGH:exon29/40:c.3694_3695dupTC:p.Val1233fs		rs760602547	0.0000	0.0047	0/0/0	0.0002							120810 [C4A (confirmed) C4a deficiency,614380|Blood group,Rodgers,614374];		CI931069 [CLASS=DM MUT=ALT PHEN="Complement C4a deficiency" GENE=C4A]; 		1	17					C4A (inh=AR pLI=n/a), C4B (inh=n/a pLI=n/a), C4B_2 (inh=n/a pLI=n/a)
chr6	31973863	31973863	C	T	het	wt	hom	low_MQM	QUAL=7831;DP=151,213,222;MQM=48	CYP21A2,CYP21A1P	splice_region&intron,intron,non_coding_transcript_exon	CYP21A2:NM_000500.7:splice_region&intron:LOW:exon2/11:c.292+9C>T:,CYP21A2:NM_001128590.3:intron:MODIFIER:exon1/10:c.202+196C>T:,CYP21A1P:NR_040090.1:non_coding_transcript_exon:MODIFIER:exon1/8:n.451C>T:		rs28361033	0.4123	0.5372	12668/7204/514	0.3890							120810 [C4A (confirmed) C4a deficiency,614380|Blood group,Rodgers,614374]:613815 [CYP21A2 (confirmed) Adrenal hyperplasia,congenital,due to 21-hydroxylase deficiency,201910|Hyperandrogenism,nonclassic type,due to 21-hydroxylase deficiency,201910];			COSN167727	480	561					CYP21A2 (inh=AR pLI=0.67), CYP21A1P (inh=n/a pLI=n/a)
chr6	31975463	31975463	T	C	het	wt	hom	low_MQM;anno_high_impact	QUAL=703;DP=78,236,35;MQM=37	CYP21A2,CYP21A1P	stop_lost,non_coding_transcript_exon	CYP21A2:NM_000500.7:stop_lost:HIGH:exon10/12:c.943T>C:p.Ter315Glnext*?,CYP21A2:NM_001128590.3:stop_lost:HIGH:exon9/11:c.853T>C:p.Ter285Glnext*?,CYP21A1P:NR_040090.1:non_coding_transcript_exon:MODIFIER:exon6/8:n.1386T>C:		rs370433041	0.0541	0.0023	19/1/3	0.0055							120810 [C4A (confirmed) C4a deficiency,614380|Blood group,Rodgers,614374]:613815 [CYP21A2 (confirmed) Adrenal hyperplasia,congenital,due to 21-hydroxylase deficiency,201910|Hyperandrogenism,nonclassic type,due to 21-hydroxylase deficiency,201910];				24	24	2	[2] Ute Grasshoff 24.11.2015			CYP21A2 (inh=AR pLI=0.67), CYP21A1P (inh=n/a pLI=n/a)
chr6	31975577	31975577	T	C	hom	wt	hom	low_DP;low_MQM	QUAL=359;DP=20,248,5;MQM=34	CYP21A2,CYP21A1P	missense,non_coding_transcript_exon	CYP21A2:NM_000500.7:missense:MODERATE:exon10/12:c.1057T>C:p.Trp353Arg,CYP21A2:NM_001128590.3:missense:MODERATE:exon9/11:c.967T>C:p.Trp323Arg,CYP21A1P:NR_040090.1:non_coding_transcript_exon:MODIFIER:exon6/8:n.1500T>C:		rs147390813	0.2943	0.0006	6/3/0	0.0274							120810 [C4A (confirmed) C4a deficiency,614380|Blood group,Rodgers,614374]:613815 [CYP21A2 (confirmed) Adrenal hyperplasia,congenital,due to 21-hydroxylase deficiency,201910|Hyperandrogenism,nonclassic type,due to 21-hydroxylase deficiency,201910];				326	57					CYP21A2 (inh=AR pLI=0.67), CYP21A1P (inh=n/a pLI=n/a)
chr6	31976228	31976228	C	T	hom	het	wt	low_MQM	QUAL=6263;DP=114,370,258;MQM=44	CYP21A2,TNXB,CYP21A1P,TNXA	3'UTR,non_coding_transcript_exon	CYP21A2:NM_000500.7:3'UTR:MODIFIER:exon12/12:c.*52C>T:,TNXB:NM_032470.3:3'UTR:MODIFIER:exon13/13:c.*163G>A:,CYP21A2:NM_001128590.3:3'UTR:MODIFIER:exon11/11:c.*52C>T:,CYP21A1P:NR_040090.1:non_coding_transcript_exon:MODIFIER:exon8/8:n.1971C>T:,TNXA:NR_001284.2:non_coding_transcript_exon:MODIFIER:exon13/13:n.2752G>A:		rs182239097	0.2656	0.0000	0/0/0	0.1020							120810 [C4A (confirmed) C4a deficiency,614380|Blood group,Rodgers,614374]:613815 [CYP21A2 (confirmed) Adrenal hyperplasia,congenital,due to 21-hydroxylase deficiency,201910|Hyperandrogenism,nonclassic type,due to 21-hydroxylase deficiency,201910]:600985 [TNXB (provisional) Ehlers-Danlos syndrome due to tenascin X deficiency,606408|Vesicoureteral reflux 8,615963];				30	127					CYP21A2 (inh=AR pLI=0.67), TNXB (inh=AR pLI=0.77), CYP21A1P (inh=n/a pLI=n/a), TNXA (inh=n/a pLI=n/a)
chr6	31994782	31994782	C	T	het	hom	het	low_DP;low_MQM	QUAL=2728;DP=5,77,141;MQM=29	C4B,C4B_2	synonymous	C4B:NM_001002029.3.2:synonymous:LOW:exon20/41:c.2475C>T:p.Val825Val,C4B_2:NM_001242823.2.2:synonymous:LOW:exon20/41:c.2475C>T:p.Val825Val		rs451637	0.1028	0.1844	2087/1733/15	0.1363							613815 [CYP21A2 (confirmed) Adrenal hyperplasia,congenital,due to 21-hydroxylase deficiency,201910|Hyperandrogenism,nonclassic type,due to 21-hydroxylase deficiency,201910]:600985 [TNXB (provisional) Ehlers-Danlos syndrome due to tenascin X deficiency,606408|Vesicoureteral reflux 8,615963];			COSM4160886, COSM4160885	129	273					C4B (inh=n/a pLI=n/a), C4B_2 (inh=n/a pLI=n/a)
chr6	31997401	31997401	G	A	het	wt	het	low_MQM	QUAL=455;DP=39,63,67;MQM=31	C4B,C4B_2	synonymous	C4B:NM_001002029.3.2:synonymous:LOW:exon29/41:c.3735G>A:p.Pro1245Pro,C4B_2:NM_001242823.2.2:synonymous:LOW:exon29/41:c.3735G>A:p.Pro1245Pro		rs12526327	0.0000	0.2397	11/3/0	0.0030							613815 [CYP21A2 (confirmed) Adrenal hyperplasia,congenital,due to 21-hydroxylase deficiency,201910|Hyperandrogenism,nonclassic type,due to 21-hydroxylase deficiency,201910]:600985 [TNXB (provisional) Ehlers-Danlos syndrome due to tenascin X deficiency,606408|Vesicoureteral reflux 8,615963];				2	529					C4B (inh=n/a pLI=n/a), C4B_2 (inh=n/a pLI=n/a)
chr6	32006119	32006119	A	C	het	het	wt		QUAL=3871;DP=159,165,225;MQM=52	CYP21A2	5'UTR	CYP21A2:NM_000500.7.2:5'UTR:MODIFIER:exon1/10:c.-81A>C:,CYP21A2:NM_001128590.3.2:5'UTR:MODIFIER:exon1/9:c.-81A>C:		rs554941446	0.0026	0.0000	0/0/0	0.0044							613815 [CYP21A2 (confirmed) Adrenal hyperplasia,congenital,due to 21-hydroxylase deficiency,201910|Hyperandrogenism,nonclassic type,due to 21-hydroxylase deficiency,201910]:600985 [TNXB (provisional) Ehlers-Danlos syndrome due to tenascin X deficiency,606408|Vesicoureteral reflux 8,615963];				0	6					CYP21A2 (inh=AR pLI=0.67)
chr6	32006215	32006217	CTG	-	het	wt	het	low_MQM	QUAL=2805;DP=138,241,335;MQM=45	CYP21A2	disruptive_inframe_deletion	CYP21A2:NM_000500.7.2:disruptive_inframe_deletion:MODERATE:exon1/10:c.29_31delTGC:p.Leu10del,CYP21A2:NM_001128590.3.2:disruptive_inframe_deletion:MODERATE:exon1/9:c.29_31delTGC:p.Leu10del	(TGC)n	rs754295868	0.2169	0.2924	787/441/4	0.1466							613815 [CYP21A2 (confirmed) Adrenal hyperplasia,congenital,due to 21-hydroxylase deficiency,201910|Hyperandrogenism,nonclassic type,due to 21-hydroxylase deficiency,201910]:600985 [TNXB (provisional) Ehlers-Danlos syndrome due to tenascin X deficiency,606408|Vesicoureteral reflux 8,615963];	RCV000079017.5 [benign]; 		COSM1077762	183	574					CYP21A2 (inh=AR pLI=0.67)
chr6	32006317	32006317	C	T	hom	het	hom	low_MQM	QUAL=20502;DP=205,292,419;MQM=40	CYP21A2	synonymous	CYP21A2:NM_000500.7.2:synonymous:LOW:exon1/10:c.118C>T:p.Leu40Leu,CYP21A2:NM_001128590.3.2:synonymous:LOW:exon1/9:c.118C>T:p.Leu40Leu		rs6468	0.0000	0.7891	29981/15454/3159	0.0998							613815 [CYP21A2 (confirmed) Adrenal hyperplasia,congenital,due to 21-hydroxylase deficiency,201910|Hyperandrogenism,nonclassic type,due to 21-hydroxylase deficiency,201910]:600985 [TNXB (provisional) Ehlers-Danlos syndrome due to tenascin X deficiency,606408|Vesicoureteral reflux 8,615963];	RCV000244556.1 [benign]; 		COSM4160891	857	550					CYP21A2 (inh=AR pLI=0.67)
chr6	32006337	32006337	C	A	hom	het	hom	low_MQM	QUAL=18897;DP=187,272,389;MQM=37	CYP21A2	synonymous	CYP21A2:NM_000500.7.2:synonymous:LOW:exon1/10:c.138C>A:p.Pro46Pro,CYP21A2:NM_001128590.3.2:synonymous:LOW:exon1/9:c.138C>A:p.Pro46Pro		rs6464	0.0000	0.6636	15896/8501/1149	0.0448							613815 [CYP21A2 (confirmed) Adrenal hyperplasia,congenital,due to 21-hydroxylase deficiency,201910|Hyperandrogenism,nonclassic type,due to 21-hydroxylase deficiency,201910]:600985 [TNXB (provisional) Ehlers-Danlos syndrome due to tenascin X deficiency,606408|Vesicoureteral reflux 8,615963];	RCV000247881.1 [benign]; 		COSM4160892	660	654					CYP21A2 (inh=AR pLI=0.67)
chr6	32006597	32006597	C	T	het	wt	hom	low_MQM	QUAL=9594;DP=93,172,289;MQM=49	CYP21A2	splice_region&intron,intron	CYP21A2:NM_000500.7.2:splice_region&intron:LOW:exon2/9:c.292+9C>T:,CYP21A2:NM_001128590.3.2:intron:MODIFIER:exon1/8:c.202+196C>T:		rs6462	0.7115	0.7421	21254/11276/1484	0.6273							613815 [CYP21A2 (confirmed) Adrenal hyperplasia,congenital,due to 21-hydroxylase deficiency,201910|Hyperandrogenism,nonclassic type,due to 21-hydroxylase deficiency,201910]:600985 [TNXB (provisional) Ehlers-Danlos syndrome due to tenascin X deficiency,606408|Vesicoureteral reflux 8,615963];	RCV000251542.1 [benign]; 			771	681					CYP21A2 (inh=AR pLI=0.67)
chr6	32006886	32006886	G	A	het	wt	het		QUAL=2289;DP=78,210,146;MQM=59	CYP21A2	missense	CYP21A2:NM_000500.7.2:missense:MODERATE:exon3/10:c.308G>A:p.Arg103Lys,CYP21A2:NM_001128590.3.2:missense:MODERATE:exon2/9:c.218G>A:p.Arg73Lys		rs6474	0.2149	0.3341	5625/3562/20	0.2871	-1.0340	T,T,T,T	T	B,B	T,T,T,T	0.01	613815 [CYP21A2 (confirmed) Adrenal hyperplasia,congenital,due to 21-hydroxylase deficiency,201910|Hyperandrogenism,nonclassic type,due to 21-hydroxylase deficiency,201910]:600985 [TNXB (provisional) Ehlers-Danlos syndrome due to tenascin X deficiency,606408|Vesicoureteral reflux 8,615963];	RCV000055817.1 [benign]; RCV000245772.1 [benign]; 		COSM1319109	214	643					CYP21A2 (inh=AR pLI=0.67)
chr6	32008963	32008963	C	T	het	het	hom	low_MQM	QUAL=15751;DP=113,288,416;MQM=48	CYP21A2,TNXB	3'UTR	CYP21A2:NM_000500.7.2:3'UTR:MODIFIER:exon10/10:c.*52C>T:,TNXB:NM_019105.6:3'UTR:MODIFIER:exon44/44:c.*163G>A:,CYP21A2:NM_001128590.3.2:3'UTR:MODIFIER:exon9/9:c.*52C>T:,TNXB:NM_032470.3.2:3'UTR:MODIFIER:exon13/13:c.*163G>A:		rs1058152	0.4996	0.5638	12122/6662/301	0.4481							613815 [CYP21A2 (confirmed) Adrenal hyperplasia,congenital,due to 21-hydroxylase deficiency,201910|Hyperandrogenism,nonclassic type,due to 21-hydroxylase deficiency,201910]:600985 [TNXB (provisional) Ehlers-Danlos syndrome due to tenascin X deficiency,606408|Vesicoureteral reflux 8,615963];				103	320					CYP21A2 (inh=AR pLI=0.67), TNXB (inh=AR pLI=0.77)
chr6	32009456	32009456	A	G	het	wt	het	low_MQM;gene_blacklist	QUAL=4803;DP=169,342,434;MQM=46	TNXB	intron	TNXB:NM_019105.6:intron:MODIFIER:exon43/43:c.12627+92T>C:,TNXB:NM_032470.3.2:intron:MODIFIER:exon12/12:c.1920+92T>C:		rs3128757	0.0000	0.0000	0/0/0	0.0601							613815 [CYP21A2 (confirmed) Adrenal hyperplasia,congenital,due to 21-hydroxylase deficiency,201910|Hyperandrogenism,nonclassic type,due to 21-hydroxylase deficiency,201910]:600985 [TNXB (provisional) Ehlers-Danlos syndrome due to tenascin X deficiency,606408|Vesicoureteral reflux 8,615963];				14	52					TNXB (inh=AR pLI=0.77)
chr6	32793523	32793523	G	A	wt	het	wt		QUAL=1059;DP=249,84,136;MQM=60	TAP2	3'UTR,intron	TAP2:NM_000544.3:3'UTR:MODIFIER:exon12/12:c.*3109C>T:,TAP2:NM_001290043.1:3'UTR:MODIFIER:exon12/12:c.*3160C>T:,TAP2:NM_018833.2:intron:MODIFIER:exon11/11:c.1933-3428C>T:	L2	rs13501	0.4010	0.0000	0/0/0	0.0594							170261 [TAP2 (confirmed) Bare lymphocyte syndrome,type I,due to TAP2 deficiency,604571|Wegener-like granulomatosis];				36	101					TAP2 (inh=AR pLI=0.00)
chr6	32793981	32793981	A	C	het	het	hom		QUAL=11037;DP=308,118,162;MQM=59	TAP2	3'UTR,intron	TAP2:NM_000544.3:3'UTR:MODIFIER:exon12/12:c.*2651T>G:,TAP2:NM_001290043.1:3'UTR:MODIFIER:exon12/12:c.*2702T>G:,TAP2:NM_018833.2:intron:MODIFIER:exon11/11:c.1932+3196T>G:		rs1044043	0.8211	0.0000	0/0/0	0.1342							170261 [TAP2 (confirmed) Bare lymphocyte syndrome,type I,due to TAP2 deficiency,604571|Wegener-like granulomatosis];				157	85					TAP2 (inh=AR pLI=0.00)
chr6	32794676	32794676	T	C	wt	het	wt		QUAL=2176;DP=298,162,220;MQM=60	TAP2	3'UTR,intron	TAP2:NM_000544.3:3'UTR:MODIFIER:exon12/12:c.*1956A>G:,TAP2:NM_001290043.1:3'UTR:MODIFIER:exon12/12:c.*2007A>G:,TAP2:NM_018833.2:intron:MODIFIER:exon11/11:c.1932+2501A>G:		rs2857101	0.2869	0.0000	0/0/0	0.0468							170261 [TAP2 (confirmed) Bare lymphocyte syndrome,type I,due to TAP2 deficiency,604571|Wegener-like granulomatosis];				23	105					TAP2 (inh=AR pLI=0.00)
chr6	32795032	32795032	G	A	het	wt	het		QUAL=7880;DP=363,209,280;MQM=60	TAP2	3'UTR,intron	TAP2:NM_000544.3:3'UTR:MODIFIER:exon12/12:c.*1600C>T:,TAP2:NM_001290043.1:3'UTR:MODIFIER:exon12/12:c.*1651C>T:,TAP2:NM_018833.2:intron:MODIFIER:exon11/11:c.1932+2145C>T:		rs10484565	0.0511	0.0000	0/0/0	0.0123							170261 [TAP2 (confirmed) Bare lymphocyte syndrome,type I,due to TAP2 deficiency,604571|Wegener-like granulomatosis];				1	34					TAP2 (inh=AR pLI=0.00)
chr6	32795504	32795680	GGAACAGTGTGTGCTCTGAAAAGGATCTCTGCAGCAGGGCTTGAGAGCACCTGAAGGAATTTCCAGAAATGCCATCATCGTATGTGACACAGAATTTAGAAAAATGACTTTGTGAAGAATGGCCGGAAGAGGGAAGCTAATGGTAGAGAAACCTCTCTGGTGATGGGATCATCTTAA	-	wt	het	wt		QUAL=1325;DP=363,145,280;MQM=59	TAP2	3'UTR,intron	TAP2:NM_000544.3:3'UTR:MODIFIER:exon12/12:c.*952_*1128del:,TAP2:NM_001290043.1:3'UTR:MODIFIER:exon12/12:c.*1003_*1179del:,TAP2:NM_018833.2:intron:MODIFIER:exon11/11:c.1932+1497_1932+1673del:	L2c	rs67511410	0.0000	0.0000	0/0/0	0.0175							170261 [TAP2 (confirmed) Bare lymphocyte syndrome,type I,due to TAP2 deficiency,604571|Wegener-like granulomatosis];				95	12					TAP2 (inh=AR pLI=0.00)
chr6	32795965	32795965	G	A	wt	het	wt		QUAL=3821;DP=546,323,404;MQM=60	TAP2	3'UTR,intron	TAP2:NM_000544.3:3'UTR:MODIFIER:exon12/12:c.*667C>T:,TAP2:NM_001290043.1:3'UTR:MODIFIER:exon12/12:c.*718C>T:,TAP2:NM_018833.2:intron:MODIFIER:exon11/11:c.1932+1212C>T:	MIRb	rs241456	0.3005	0.0000	0/0/0	0.0477							170261 [TAP2 (confirmed) Bare lymphocyte syndrome,type I,due to TAP2 deficiency,604571|Wegener-like granulomatosis];				26	104					TAP2 (inh=AR pLI=0.00)
chr6	32796019	32796019	C	A	wt	het	wt		QUAL=2891;DP=399,262,343;MQM=60	TAP2	3'UTR,intron	TAP2:NM_000544.3:3'UTR:MODIFIER:exon12/12:c.*613G>T:,TAP2:NM_001290043.1:3'UTR:MODIFIER:exon12/12:c.*664G>T:,TAP2:NM_018833.2:intron:MODIFIER:exon11/11:c.1932+1158G>T:	MIRb	rs241455	0.3005	0.0000	0/0/0	0.0477							170261 [TAP2 (confirmed) Bare lymphocyte syndrome,type I,due to TAP2 deficiency,604571|Wegener-like granulomatosis];				28	104					TAP2 (inh=AR pLI=0.00)
chr6	32796057	32796057	G	A	wt	het	wt		QUAL=3177;DP=347,270,337;MQM=60	TAP2	3'UTR,intron	TAP2:NM_000544.3:3'UTR:MODIFIER:exon12/12:c.*575C>T:,TAP2:NM_001290043.1:3'UTR:MODIFIER:exon12/12:c.*626C>T:,TAP2:NM_018833.2:intron:MODIFIER:exon11/11:c.1932+1120C>T:		rs2071546	0.2959	0.0000	0/0/0	0.0308							170261 [TAP2 (confirmed) Bare lymphocyte syndrome,type I,due to TAP2 deficiency,604571|Wegener-like granulomatosis];				27	104					TAP2 (inh=AR pLI=0.00)
chr6	32796058	32796058	C	T	wt	het	wt		QUAL=3177;DP=347,270,337;MQM=60	TAP2	3'UTR,intron	TAP2:NM_000544.3:3'UTR:MODIFIER:exon12/12:c.*574G>A:,TAP2:NM_001290043.1:3'UTR:MODIFIER:exon12/12:c.*625G>A:,TAP2:NM_018833.2:intron:MODIFIER:exon11/11:c.1932+1119G>A:		rs2071545	0.3003	0.0000	0/0/0	0.0314							170261 [TAP2 (confirmed) Bare lymphocyte syndrome,type I,due to TAP2 deficiency,604571|Wegener-like granulomatosis];				27	104					TAP2 (inh=AR pLI=0.00)
chr6	32796144	32796144	A	G	wt	het	wt		QUAL=2919;DP=347,248,344;MQM=60	TAP2	3'UTR,intron	TAP2:NM_000544.3:3'UTR:MODIFIER:exon12/12:c.*488T>C:,TAP2:NM_001290043.1:3'UTR:MODIFIER:exon12/12:c.*539T>C:,TAP2:NM_018833.2:intron:MODIFIER:exon11/11:c.1932+1033T>C:		rs241454	0.3011	0.0000	0/0/0	0.0475							170261 [TAP2 (confirmed) Bare lymphocyte syndrome,type I,due to TAP2 deficiency,604571|Wegener-like granulomatosis];				28	104					TAP2 (inh=AR pLI=0.00)
chr6	32796226	32796226	G	A	wt	het	wt		QUAL=1608;DP=250,155,238;MQM=60	TAP2	3'UTR,intron	TAP2:NM_000544.3:3'UTR:MODIFIER:exon12/12:c.*406C>T:,TAP2:NM_001290043.1:3'UTR:MODIFIER:exon12/12:c.*457C>T:,TAP2:NM_018833.2:intron:MODIFIER:exon11/11:c.1932+951C>T:	L1ME4a	rs241453	0.2869	0.0000	0/0/0	0.0470							170261 [TAP2 (confirmed) Bare lymphocyte syndrome,type I,due to TAP2 deficiency,604571|Wegener-like granulomatosis];				24	104					TAP2 (inh=AR pLI=0.00)
chr6	32796346	32796346	T	C	wt	het	wt		QUAL=667;DP=171,49,89;MQM=60	TAP2	3'UTR,intron	TAP2:NM_000544.3:3'UTR:MODIFIER:exon12/12:c.*286A>G:,TAP2:NM_001290043.1:3'UTR:MODIFIER:exon12/12:c.*337A>G:,TAP2:NM_018833.2:intron:MODIFIER:exon11/11:c.1932+831A>G:		rs241452	0.3015	0.0000	0/0/0	0.0531							170261 [TAP2 (confirmed) Bare lymphocyte syndrome,type I,due to TAP2 deficiency,604571|Wegener-like granulomatosis];				21	99					TAP2 (inh=AR pLI=0.00)
chr6	32796451	32796451	A	C	het	wt	het		QUAL=1644;DP=102,45,79;MQM=59	TAP2	3'UTR,intron	TAP2:NM_000544.3:3'UTR:MODIFIER:exon12/12:c.*181T>G:,TAP2:NM_001290043.1:3'UTR:MODIFIER:exon12/12:c.*232T>G:,TAP2:NM_018833.2:intron:MODIFIER:exon11/11:c.1932+726T>G:		rs141809764	0.0038	0.0000	0/0/0	0.0028							170261 [TAP2 (confirmed) Bare lymphocyte syndrome,type I,due to TAP2 deficiency,604571|Wegener-like granulomatosis];				0	5					TAP2 (inh=AR pLI=0.00)
chr6	32796455	32796455	C	T	wt	het	wt		QUAL=151;DP=85,44,73;MQM=60	TAP2	3'UTR,intron	TAP2:NM_000544.3:3'UTR:MODIFIER:exon12/12:c.*177G>A:,TAP2:NM_001290043.1:3'UTR:MODIFIER:exon12/12:c.*228G>A:,TAP2:NM_018833.2:intron:MODIFIER:exon11/11:c.1932+722G>A:	(CCCCA)n	rs2621318	0.2853	0.0000	0/0/0	0.0612							170261 [TAP2 (confirmed) Bare lymphocyte syndrome,type I,due to TAP2 deficiency,604571|Wegener-like granulomatosis];				3	56					TAP2 (inh=AR pLI=0.00)
chr6	32796480	32796480	T	C	wt	het	wt		QUAL=153;DP=50,20,44;MQM=57	TAP2	3'UTR,intron	TAP2:NM_000544.3:3'UTR:MODIFIER:exon12/12:c.*152A>G:,TAP2:NM_001290043.1:3'UTR:MODIFIER:exon12/12:c.*203A>G:,TAP2:NM_018833.2:intron:MODIFIER:exon11/11:c.1932+697A>G:	(CCCCA)n	rs241451	0.3592	0.0000	0/0/0	0.0306							170261 [TAP2 (confirmed) Bare lymphocyte syndrome,type I,due to TAP2 deficiency,604571|Wegener-like granulomatosis];				36	101					TAP2 (inh=AR pLI=0.00)
chr6	32796521	32796521	C	T	wt	het	wt		QUAL=406;DP=96,41,75;MQM=60	TAP2	3'UTR,intron	TAP2:NM_000544.3:3'UTR:MODIFIER:exon12/12:c.*111G>A:,TAP2:NM_001290043.1:3'UTR:MODIFIER:exon12/12:c.*162G>A:,TAP2:NM_018833.2:intron:MODIFIER:exon11/11:c.1932+656G>A:		rs17034	0.2977	0.0000	0/0/0	0.0425							170261 [TAP2 (confirmed) Bare lymphocyte syndrome,type I,due to TAP2 deficiency,604571|Wegener-like granulomatosis];				28	110					TAP2 (inh=AR pLI=0.00)
chr6	32796653	32796653	C	A	wt	het	wt		QUAL=1840;DP=98,124,185;MQM=60	TAP2	synonymous,3'UTR,intron	TAP2:NM_000544.3:synonymous:LOW:exon12/12:c.2091G>T:p.Val697Val,TAP2:NM_001290043.1:3'UTR:MODIFIER:exon12/12:c.*30G>T:,TAP2:NM_018833.2:intron:MODIFIER:exon11/11:c.1932+524G>T:		rs241449	0.3005	0.3489	959/269/18	0.1066							170261 [TAP2 (confirmed) Bare lymphocyte syndrome,type I,due to TAP2 deficiency,604571|Wegener-like granulomatosis];				153	615					TAP2 (inh=AR pLI=0.00)
chr6	32796685	32796685	A	G	wt	het	wt	anno_high_impact	QUAL=1784;DP=120,135,206;MQM=60	TAP2	stop_lost,intron	TAP2:NM_000544.3:stop_lost:HIGH:exon12/12:c.2059T>C:p.Ter687Glnext*?,TAP2:NM_001290043.1:stop_lost:HIGH:exon12/12:c.2059T>C:p.Ter687Glnext*?,TAP2:NM_018833.2:intron:MODIFIER:exon11/11:c.1932+492T>C:		rs241448	0.3111	0.3494	988/282/26	0.1218	-0.9900					3.50	170261 [TAP2 (confirmed) Bare lymphocyte syndrome,type I,due to TAP2 deficiency,604571|Wegener-like granulomatosis];	RCV000014729.2 [benign]; 	CM920660 [CLASS=DP MUT=REF PHEN="Diabetes type 1 association with" GENE=TAP2]; 		154	612	1	[1] auto-classification 16.06.2016  [2] Ute Grasshoff 24.11.2015			TAP2 (inh=AR pLI=0.00)
chr6	32796751	32796751	T	C	wt	het	wt	pred_pathogenic	QUAL=2181;DP=197,174,271;MQM=60	TAP2	missense,intron	TAP2:NM_000544.3:missense:MODERATE:exon12/12:c.1993A>G:p.Thr665Ala,TAP2:NM_001290043.1:missense:MODERATE:exon12/12:c.1993A>G:p.Thr665Ala,TAP2:NM_018833.2:intron:MODIFIER:exon11/11:c.1932+426A>G:		rs241447	0.3017	0.3633	1132/364/24	0.1610	4.3710	D	T	B	D	7.17	170261 [TAP2 (confirmed) Bare lymphocyte syndrome,type I,due to TAP2 deficiency,604571|Wegener-like granulomatosis];	RCV000014728.2 [benign]; 	CM920659 [CLASS=DP MUT=REF PHEN="Diabetes type 1 association with" GENE=TAP2]; 		150	601					TAP2 (inh=AR pLI=0.00)
chr6	32796793	32796793	G	A	het	het	wt	pred_pathogenic	QUAL=4028;DP=187,168,252;MQM=59	TAP2	missense,intron	TAP2:NM_000544.3:missense:MODERATE:exon12/12:c.1951C>T:p.Arg651Cys,TAP2:NM_001290043.1:missense:MODERATE:exon12/12:c.1951C>T:p.Arg651Cys,TAP2:NM_018833.2:intron:MODIFIER:exon11/11:c.1932+384C>T:		rs4148876	0.0585	0.0763	66/42/0	0.0354	0.0370	T	T	P,P	D	5.98	170261 [TAP2 (confirmed) Bare lymphocyte syndrome,type I,due to TAP2 deficiency,604571|Wegener-like granulomatosis];		CM077979 [CLASS=DP MUT=ALT PHEN="Diabetes type 1 association with" GENE=TAP2]; 		6	183					TAP2 (inh=AR pLI=0.00)
chr6	32797168	32797168	G	A	wt	het	wt		QUAL=459;DP=76,66,149;MQM=60	TAP2	splice_region&intron	TAP2:NM_000544.3:splice_region&intron:LOW:exon11/11:c.1932+9C>T:,TAP2:NM_018833.2:splice_region&intron:LOW:exon11/11:c.1932+9C>T:,TAP2:NM_001290043.1:splice_region&intron:LOW:exon11/11:c.1932+9C>T:		rs241442	0.2915	0.3377	2829/1206/93	0.2516							170261 [TAP2 (confirmed) Bare lymphocyte syndrome,type I,due to TAP2 deficiency,604571|Wegener-like granulomatosis];				155	631					TAP2 (inh=AR pLI=0.00)
chr6	32797297	32797297	T	C	wt	het	wt		QUAL=963;DP=142,99,156;MQM=60	TAP2	synonymous	TAP2:NM_000544.3:synonymous:LOW:exon11/12:c.1812A>G:p.Gly604Gly,TAP2:NM_018833.2:synonymous:LOW:exon11/12:c.1812A>G:p.Gly604Gly,TAP2:NM_001290043.1:synonymous:LOW:exon11/12:c.1812A>G:p.Gly604Gly		rs241441	0.2991	0.2978	5600/2346/170	0.2865							170261 [TAP2 (confirmed) Bare lymphocyte syndrome,type I,due to TAP2 deficiency,604571|Wegener-like granulomatosis];			COSM3723789, COSM3723790	156	639					TAP2 (inh=AR pLI=0.00)
chr6	32797876	32797876	A	G	wt	het	het		QUAL=4575;DP=243,156,240;MQM=60	TAP2	splice_region&intron	TAP2:NM_000544.3:splice_region&intron:LOW:exon9/11:c.1636-10T>C:,TAP2:NM_018833.2:splice_region&intron:LOW:exon9/11:c.1636-10T>C:,TAP2:NM_001290043.1:splice_region&intron:LOW:exon9/11:c.1636-10T>C:		rs241436	0.4343	0.4812	13866/7269/327	0.4558							170261 [TAP2 (confirmed) Bare lymphocyte syndrome,type I,due to TAP2 deficiency,604571|Wegener-like granulomatosis];			COSM4004016, COSM4004017	401	771					TAP2 (inh=AR pLI=0.00)
chr6	32798548	32798548	G	A	wt	het	wt		QUAL=1833;DP=172,137,183;MQM=60	TAP2	synonymous	TAP2:NM_000544.3:synonymous:LOW:exon8/12:c.1308C>T:p.Asn436Asn,TAP2:NM_018833.2:synonymous:LOW:exon8/12:c.1308C>T:p.Asn436Asn,TAP2:NM_001290043.1:synonymous:LOW:exon8/12:c.1308C>T:p.Asn436Asn		rs1042116	0.0427	0.0873	508/341/4	0.0755							170261 [TAP2 (confirmed) Bare lymphocyte syndrome,type I,due to TAP2 deficiency,604571|Wegener-like granulomatosis];			COSM3761959, COSM3761960	11	259					TAP2 (inh=AR pLI=0.00)
chr6	32800224	32800224	C	A	het	het	wt		QUAL=2818;DP=165,81,99;MQM=60	TAP2	synonymous	TAP2:NM_000544.3:synonymous:LOW:exon7/12:c.1158G>T:p.Gly386Gly,TAP2:NM_018833.2:synonymous:LOW:exon7/12:c.1158G>T:p.Gly386Gly,TAP2:NM_001290043.1:synonymous:LOW:exon7/12:c.1158G>T:p.Gly386Gly		rs2228397	0.2442	0.2546	3643/1674/239	0.2435							170261 [TAP2 (confirmed) Bare lymphocyte syndrome,type I,due to TAP2 deficiency,604571|Wegener-like granulomatosis];				127	590					TAP2 (inh=AR pLI=0.00)
chr6	32805307	32805307	C	T	wt	wt	het		QUAL=1435;DP=124,106,113;MQM=60	TAP2	splice_region&intron	TAP2:NM_000544.3:splice_region&intron:LOW:exon3/11:c.608+7G>A:,TAP2:NM_018833.2:splice_region&intron:LOW:exon3/11:c.608+7G>A:,TAP2:NM_001290043.1:splice_region&intron:LOW:exon3/11:c.608+7G>A:		rs2071466	0.2484	0.2844	4491/2800/289	0.2642							170261 [TAP2 (confirmed) Bare lymphocyte syndrome,type I,due to TAP2 deficiency,604571|Wegener-like granulomatosis];			COSM4004018, COSM4004019	153	640					TAP2 (inh=AR pLI=0.00)
chr6	32806461	32806461	A	G	wt	wt	het		QUAL=1031;DP=55,44,86;MQM=60	TAP2	5'UTR	TAP2:NM_000544.3:5'UTR:MODIFIER:exon1/12:c.-36T>C:,TAP2:NM_018833.2:5'UTR:MODIFIER:exon1/12:c.-36T>C:,TAP2:NM_001290043.1:5'UTR:MODIFIER:exon1/12:c.-36T>C:		rs2071552	0.4696	0.0000	0/0/0	0.4269							170261 [TAP2 (confirmed) Bare lymphocyte syndrome,type I,due to TAP2 deficiency,604571|Wegener-like granulomatosis];				53	107					TAP2 (inh=AR pLI=0.00)
chr6	32806530	32806530	C	G	het	wt	het		QUAL=2080;DP=66,47,85;MQM=60	TAP2	5'UTR	TAP2:NM_000544.3:5'UTR:MODIFIER:exon1/12:c.-105G>C:,TAP2:NM_018833.2:5'UTR:MODIFIER:exon1/12:c.-105G>C:,TAP2:NM_001290043.1:5'UTR:MODIFIER:exon1/12:c.-105G>C:		rs146973617	0.0032	0.0000	0/0/0	0.0058							170261 [TAP2 (confirmed) Bare lymphocyte syndrome,type I,due to TAP2 deficiency,604571|Wegener-like granulomatosis];				0	7					TAP2 (inh=AR pLI=0.00)
chr6	32813279	32813279	C	A	hom	het	het		QUAL=26004;DP=438,412,605;MQM=59	TAP1,PSMB8-AS1	3'UTR,non_coding_transcript_exon	TAP1:NM_000593.5:3'UTR:MODIFIER:exon11/11:c.*77G>T:,TAP1:NM_001292022.1:3'UTR:MODIFIER:exon11/11:c.*77G>T:,PSMB8-AS1:NR_037173.1:non_coding_transcript_exon:MODIFIER:exon3/3:n.500C>A:,PSMB8-AS1:NR_037174.1:non_coding_transcript_exon:MODIFIER:exon2/2:n.362C>A:,PSMB8-AS1:NR_037175.1:non_coding_transcript_exon:MODIFIER:exon3/3:n.335C>A:,PSMB8-AS1:NR_037176.1:non_coding_transcript_exon:MODIFIER:exon2/2:n.274C>A:		rs1057373	0.0909	0.0000	0/0/0	0.0191							170260 [TAP1 (confirmed) Bare lymphocyte syndrome,type I,604571];				5	54					TAP1 (inh=AR pLI=0.29), PSMB8-AS1 (inh=n/a pLI=n/a)
chr6	32814909	32814909	C	T	het	wt	het	pred_pathogenic;anno_pathogenic_clinvar;anno_pathogenic_hgmd	QUAL=4880;DP=272,172,189;MQM=60	TAP1	missense	TAP1:NM_000593.5:missense:MODERATE:exon10/11:c.2156G>A:p.Arg719Gln,TAP1:NM_001292022.1:missense:MODERATE:exon10/11:c.1373G>A:p.Arg458Gln		rs121917702	0.0008	0.0016	1/1/0	0.0015	3.0610	D,D	D	P	D,D	34.00	170260 [TAP1 (confirmed) Bare lymphocyte syndrome,type I,604571];	RCV000014734.4 [pathogenic]; 	CM963078 [CLASS=DM MUT=ALT PHEN="HLA class I deficiency" GENE=TAP1]; 		0	7					TAP1 (inh=AR pLI=0.29)
chr6	32814975	32814975	T	C	hom	het	het	pred_pathogenic	QUAL=9508;DP=207,141,161;MQM=59	TAP1	missense	TAP1:NM_000593.5:missense:MODERATE:exon10/11:c.2090A>G:p.Asp697Gly,TAP1:NM_001292022.1:missense:MODERATE:exon10/11:c.1307A>G:p.Asp436Gly		rs1135216	0.1915	0.1739	1823/753/239	0.1629	4.9980	T,T	T	B	D,D	11.88	170260 [TAP1 (confirmed) Bare lymphocyte syndrome,type I,604571];	RCV000014733.2 [benign]; 	CM920657 [CLASS=DP MUT=ALT PHEN="Nasopharyngeal carcinoma reduced risk association with" GENE=TAP1]; 	COSM4161045	36	414					TAP1 (inh=AR pLI=0.29)
chr6	32818774	32818774	T	C	hom	het	het	pred_pathogenic	QUAL=15037;DP=231,263,332;MQM=59	TAP1	missense	TAP1:NM_000593.5:missense:MODERATE:exon4/11:c.1177A>G:p.Ile393Val,TAP1:NM_001292022.1:missense:MODERATE:exon4/11:c.394A>G:p.Ile132Val		rs1057141	0.2282	0.2047	2584/1032/318	0.1917	-0.5640	T,T	T	B	D,D	0.06	170260 [TAP1 (confirmed) Bare lymphocyte syndrome,type I,604571];	RCV000014732.2 [benign]; 	CM920656 [CLASS=DP MUT=ALT PHEN="Nasopharyngeal carcinoma reduced risk association with" GENE=TAP1]; 		51	451					TAP1 (inh=AR pLI=0.29)
chr6	33267672	33267672	A	G	hom	hom	het		QUAL=35312;DP=496,471,565;MQM=59	TAPBP	3'UTR	TAPBP:NM_003190.4:3'UTR:MODIFIER:exon8/8:c.*1865T>C:,TAPBP:NM_172209.2.5:3'UTR:MODIFIER:exon7/7:c.*1865T>C:	L2b	rs1059288	0.5905	0.0000	0/0/0	0.1041							601962 [TAPBP (provisional) Bare lymphocyte syndrome,type I,604571];				81	102					TAPBP (inh=AR pLI=0.00)
chr6	33267908	33267908	G	A	het	wt	het		QUAL=9073;DP=363,332,414;MQM=59	TAPBP	3'UTR	TAPBP:NM_003190.4:3'UTR:MODIFIER:exon8/8:c.*1629C>T:,TAPBP:NM_172209.2.5:3'UTR:MODIFIER:exon7/7:c.*1629C>T:		rs147996331	0.0020	0.0000	0/0/0	0.0081							601962 [TAPBP (provisional) Bare lymphocyte syndrome,type I,604571];				1	7					TAPBP (inh=AR pLI=0.00)
chr6	33268437	33268437	-	AGAAAAAA	hom	hom	het	low_DP	QUAL=2536;DP=80,15,18;MQM=53	TAPBP	3'UTR	TAPBP:NM_003190.4:3'UTR:MODIFIER:exon8/8:c.*1092_*1099dupTTTTTTCT:,TAPBP:NM_172209.2.5:3'UTR:MODIFIER:exon7/7:c.*1092_*1099dupTTTTTTCT:	AluY	rs71536179	0.0000	0.0000	0/0/0	0.1252							601962 [TAPBP (provisional) Bare lymphocyte syndrome,type I,604571];				48	65					TAPBP (inh=AR pLI=0.00)
chr6	33268737	33268737	C	A	het	wt	het	low_DP;low_MQM	QUAL=704;DP=69,2,2;MQM=45	TAPBP	3'UTR	TAPBP:NM_003190.4:3'UTR:MODIFIER:exon8/8:c.*800G>T:,TAPBP:NM_172209.2.5:3'UTR:MODIFIER:exon7/7:c.*800G>T:	AluY	rs3130259	0.2210	0.0000	0/0/0	0.1386							601962 [TAPBP (provisional) Bare lymphocyte syndrome,type I,604571];				24	28					TAPBP (inh=AR pLI=0.00)
chr6	33268743	33268743	A	-	wt	wt	hom	low_QUAL;low_DP	QUAL=10;DP=45,1,2;MQM=53	TAPBP	3'UTR	TAPBP:NM_003190.4:3'UTR:MODIFIER:exon8/8:c.*794delT:,TAPBP:NM_172209.2.5:3'UTR:MODIFIER:exon7/7:c.*794delT:	AluY	rs9280395	0.3359	0.0000	0/0/0	0.0767							601962 [TAPBP (provisional) Bare lymphocyte syndrome,type I,604571];				3	50					TAPBP (inh=AR pLI=0.00)
chr6	33269351	33269351	A	-	wt	het	wt	low_DP	QUAL=30;DP=55,16,14;MQM=57	TAPBP	3'UTR	TAPBP:NM_003190.4:3'UTR:MODIFIER:exon8/8:c.*186delT:,TAPBP:NM_172209.2.5:3'UTR:MODIFIER:exon7/7:c.*186delT:	AluSx	rs11350807	0.0000	0.0000	0/0/0	0.0193							601962 [TAPBP (provisional) Bare lymphocyte syndrome,type I,604571];				2	50					TAPBP (inh=AR pLI=0.00)
chr6	33272813	33272813	T	G	het	wt	wt	low_QUAL;pred_pathogenic	QUAL=17;DP=134,238,315;MQM=59	TAPBP	missense	TAPBP:NM_172208.2.4:missense:MODERATE:exon4/7:c.821A>C:p.His274Pro,TAPBP:NM_003190.4:missense:MODERATE:exon4/8:c.821A>C:p.His274Pro,TAPBP:NM_172209.2.5:missense:MODERATE:exon3/7:c.560A>C:p.His187Pro		rs201276892	0.0000	0.0223	0/0/0	0.0001	2.2540	D,D,T,D,D,.,.	T	D,D,D,D,D,D	T,T,T,T,T	25.50	601962 [TAPBP (provisional) Bare lymphocyte syndrome,type I,604571];				0	25					TAPBP (inh=AR pLI=0.00)
chr6	33272855	33272855	G	C	hom	hom	het		QUAL=24421;DP=265,339,462;MQM=59	TAPBP	missense	TAPBP:NM_172208.2.4:missense:MODERATE:exon4/7:c.779C>G:p.Thr260Arg,TAPBP:NM_003190.4:missense:MODERATE:exon4/8:c.779C>G:p.Thr260Arg,TAPBP:NM_172209.2.5:missense:MODERATE:exon3/7:c.518C>G:p.Thr173Arg		rs2071888	0.5913	0.5682	20032/10182/2907	0.5494	0.9400	T,T,T,T,T,.,.	T	B,B,B,B	T,T,T,T,T	2.41	601962 [TAPBP (provisional) Bare lymphocyte syndrome,type I,604571];		CM056992 [CLASS=DP MUT=ALT PHEN="Rheumatoid arthritis juvenile association with" GENE=TAPBP]; 	COSM1180607, COSM1180608	503	759					TAPBP (inh=AR pLI=0.00)
chr6	33281842	33281842	G	T	het	het	het		QUAL=7103;DP=126,206,280;MQM=59	TAPBP	5'UTR	TAPBP:NM_172208.2.4:5'UTR:MODIFIER:exon1/7:c.-24C>A:,TAPBP:NM_003190.4:5'UTR:MODIFIER:exon1/8:c.-24C>A:,TAPBP:NM_172209.2.5:5'UTR:MODIFIER:exon1/7:c.-24C>A:		rs2239841	0.2206	0.2965	5751/3310/15	0.2723							601962 [TAPBP (provisional) Bare lymphocyte syndrome,type I,604571];				93	348					TAPBP (inh=AR pLI=0.00)
chr6	33281843	33281843	A	T	het	het	het		QUAL=7103;DP=126,206,280;MQM=59	TAPBP	5'UTR	TAPBP:NM_172208.2.4:5'UTR:MODIFIER:exon1/7:c.-25T>A:,TAPBP:NM_003190.4:5'UTR:MODIFIER:exon1/8:c.-25T>A:,TAPBP:NM_172209.2.5:5'UTR:MODIFIER:exon1/7:c.-25T>A:		rs2239840	0.2206	0.2962	5749/3309/15	0.2723							601962 [TAPBP (provisional) Bare lymphocyte syndrome,type I,604571];				93	348					TAPBP (inh=AR pLI=0.00)
chr6	33282002	33282002	C	T	hom	hom	het		QUAL=8695;DP=100,152,196;MQM=60	TAPBP	5'UTR	TAPBP:NM_172208.2.4:5'UTR:MODIFIER:exon1/7:c.-184G>A:,TAPBP:NM_003190.4:5'UTR:MODIFIER:exon1/8:c.-184G>A:,TAPBP:NM_172209.2.5:5'UTR:MODIFIER:exon1/7:c.-184G>A:		rs3106189	0.5186	0.0000	0/0/0	0.0760							601962 [TAPBP (provisional) Bare lymphocyte syndrome,type I,604571];				49	68					TAPBP (inh=AR pLI=0.00)
chr6	33408542	33408542	G	A	het	het	het		QUAL=2341;DP=66,72,59;MQM=59	SYNGAP1	synonymous	SYNGAP1:NM_006772.2:synonymous:LOW:exon11/19:c.1713G>A:p.Ser571Ser		rs411136	0.4377	0.4861	8796/4235/338	0.3767							603384 [SYNGAP1 (confirmed) Mental retardation,autosomal dominant 5,612621];	RCV000118564.2 [likely benign]; 		COSM150074, COSM150073	259	752					SYNGAP1 (inh=AD pLI=1.00)
chr6	35423662	35423662	A	C	het	het	het		QUAL=2462;DP=63,72,70;MQM=60	FANCE	synonymous	FANCE:NM_021922.2:synonymous:LOW:exon2/10:c.387A>C:p.Pro129Pro		rs4713867	0.7780	0.7211	31791/15371/3918	0.7107							613976 [FANCE (provisional) Fanconi anemia,complementation group E,600901];	RCV000246343.1 [benign]; RCV000357472.1 [benign]; 			1466	1389	1	[1] Ilnaz Sepahi 29-03-2016 batch import			FANCE (inh=AR pLI=0.00)
chr6	35423886	35423886	C	T	wt	wt	het	pred_pathogenic	QUAL=4216;DP=194,214,290;MQM=60	FANCE	missense	FANCE:NM_021922.2:missense:MODERATE:exon2/10:c.611C>T:p.Ser204Leu		rs7761870	0.0353	0.0177	59/12/46	0.0175	1.7210	T	T	B	T	11.01	613976 [FANCE (provisional) Fanconi anemia,complementation group E,600901];	RCV000121007.2 [benign]; RCV000370225.1 [likely benign]; 			1	70	1	[1] Ilnaz Sepahi 29-03-2016 batch import			FANCE (inh=AR pLI=0.00)
chr6	35430686	35430686	G	A	wt	wt	het		QUAL=1869;DP=157,99,155;MQM=60	FANCE	missense	FANCE:NM_021922.2:missense:MODERATE:exon9/10:c.1504G>A:p.Ala502Thr		rs9462088	0.1895	0.0979	1131/116/695	0.0944	0.9210	T	T	B	T	13.77	613976 [FANCE (provisional) Fanconi anemia,complementation group E,600901];	RCV000121019.2 [benign]; RCV000336618.1 [benign]; 			10	346	1	[1] Ilnaz Sepahi 29-03-2016 batch import			FANCE (inh=AR pLI=0.00)
chr6	35434273	35434273	A	G	wt	wt	het		QUAL=4624;DP=152,288,350;MQM=60	FANCE	3'UTR	FANCE:NM_021922.2:3'UTR:MODIFIER:exon10/10:c.*151A>G:		rs16876572	0.0463	0.0000	0/0/0	0.0059							613976 [FANCE (provisional) Fanconi anemia,complementation group E,600901];	RCV000390487.1 [likely benign]; 			0	9					FANCE (inh=AR pLI=0.00)
chr6	42931628	42931631	TTTA	-	het	wt	hom	low_DP	QUAL=525;DP=7,16,19;MQM=58	PEX6	3'UTR,non_coding_transcript_exon	PEX6:NM_000287.3:3'UTR:MODIFIER:exon17/17:c.*442_*445delTAAA:,PEX6:NM_001316313.1:3'UTR:MODIFIER:exon17/17:c.*442_*445delTAAA:,PEX6:NR_133009.1:non_coding_transcript_exon:MODIFIER:exon15/15:n.3231_3234delTAAA:		rs144286892	0.6474	0.0000	0/0/0	0.5488							606628 [GNMT (provisional) Glycine N-methyltransferase deficiency,606664]:601498 [PEX6 (confirmed) Peroxisome biogenesis disorder 4A (Zellweger),614862|Peroxisome biogenesis disorder 4B,614863|Heimler syndrome 2,616617];	RCV000360304.1 [benign]; 			80	66					PEX6 (inh=AR pLI=0.00)
chr6	42931666	42931666	A	C	wt	het	het	low_DP	QUAL=39;DP=10,18,11;MQM=58	PEX6	3'UTR,non_coding_transcript_exon	PEX6:NM_000287.3:3'UTR:MODIFIER:exon17/17:c.*407T>G:,PEX6:NM_001316313.1:3'UTR:MODIFIER:exon17/17:c.*407T>G:,PEX6:NR_133009.1:non_coding_transcript_exon:MODIFIER:exon15/15:n.3196T>G:			0.0000	0.0000	0/0/0	0.0000							601498 [PEX6 (confirmed) Peroxisome biogenesis disorder 4A (Zellweger),614862|Peroxisome biogenesis disorder 4B,614863|Heimler syndrome 2,616617];	RCV000267803.1 [uncertain significance]; 			0	4					PEX6 (inh=AR pLI=0.00)
chr6	42931674	42931674	A	C	wt	het	het	low_DP	QUAL=147;DP=18,26,24;MQM=58	PEX6	3'UTR,non_coding_transcript_exon	PEX6:NM_000287.3:3'UTR:MODIFIER:exon17/17:c.*399T>G:,PEX6:NM_001316313.1:3'UTR:MODIFIER:exon17/17:c.*399T>G:,PEX6:NR_133009.1:non_coding_transcript_exon:MODIFIER:exon15/15:n.3188T>G:			0.0000	0.0000	0/0/0	0.0000							601498 [PEX6 (confirmed) Peroxisome biogenesis disorder 4A (Zellweger),614862|Peroxisome biogenesis disorder 4B,614863|Heimler syndrome 2,616617];				0	4					PEX6 (inh=AR pLI=0.00)
chr6	42932200	42932200	G	T	het	wt	het	pred_pathogenic	QUAL=2505;DP=99,69,71;MQM=60	PEX6	missense,non_coding_transcript_exon	PEX6:NM_000287.3:missense:MODERATE:exon17/17:c.2816C>A:p.Pro939Gln,PEX6:NM_001316313.1:missense:MODERATE:exon17/17:c.2552C>A:p.Pro851Gln,PEX6:NR_133009.1:non_coding_transcript_exon:MODIFIER:exon15/15:n.2662C>A:		rs1129187	0.3315	0.3911	9823/6476/723	0.3714	0.2320	T	T	B	D	14.40	601498 [PEX6 (confirmed) Peroxisome biogenesis disorder 4A (Zellweger),614862|Peroxisome biogenesis disorder 4B,614863|Heimler syndrome 2,616617];	RCV000078574.6 [benign]; RCV000407233.1 [benign]; 		COSM1444600	313	754					PEX6 (inh=AR pLI=0.00)
chr6	42932202	42932202	C	T	het	wt	hom		QUAL=2505;DP=99,69,71;MQM=60	PEX6	synonymous,non_coding_transcript_exon	PEX6:NM_000287.3:synonymous:LOW:exon17/17:c.2814G>A:p.Glu938Glu,PEX6:NM_001316313.1:synonymous:LOW:exon17/17:c.2550G>A:p.Glu850Glu,PEX6:NR_133009.1:non_coding_transcript_exon:MODIFIER:exon15/15:n.2660G>A:		rs1129186	0.4936	0.4911	15519/8954/2749	0.4659							601498 [PEX6 (confirmed) Peroxisome biogenesis disorder 4A (Zellweger),614862|Peroxisome biogenesis disorder 4B,614863|Heimler syndrome 2,616617];	RCV000078573.6 [benign]; RCV000292393.1 [benign]; 		COSM1444601	448	727					PEX6 (inh=AR pLI=0.00)
chr6	42933464	42933464	G	A	wt	wt	het	pred_pathogenic;anno_pathogenic_hgmd	QUAL=2488;DP=170,156,178;MQM=60	PEX6	missense,non_coding_transcript_exon	PEX6:NM_000287.3:missense:MODERATE:exon13/17:c.2426C>T:p.Ala809Val,PEX6:NM_001316313.1:missense:MODERATE:exon13/17:c.2162C>T:p.Ala721Val,PEX6:NR_133009.1:non_coding_transcript_exon:MODIFIER:exon11/15:n.2272C>T:		rs35830695	0.0751	0.0582	268/99/86	0.0559	9.8420	D,D	D,D	D,.	D,D	34.00	601498 [PEX6 (confirmed) Peroxisome biogenesis disorder 4A (Zellweger),614862|Peroxisome biogenesis disorder 4B,614863|Heimler syndrome 2,616617];	RCV000153690.3 [benign]; RCV000307162.1 [likely benign]; 	CM092994 [CLASS=DM? MUT=ALT PHEN="Zellweger syndrome" GENE=PEX6]; 		5	146	2	[2] Ute Grasshoff 13.08.2014			PEX6 (inh=AR pLI=0.00)
chr6	42942779	42942779	A	G	het	wt	het		QUAL=7160;DP=188,242,339;MQM=60	PEX6	splice_region&intron	PEX6:NM_000287.3:splice_region&intron:LOW:exon1/16:c.883-3T>C:,PEX6:NM_001316313.1:splice_region&intron:LOW:exon1/16:c.619-3T>C:,PEX6:NR_133009.1:splice_region&intron:LOW:exon1/14:n.976-3T>C:		rs9986447	0.2897	0.3776	9493/6582/266	0.3720							601498 [PEX6 (confirmed) Peroxisome biogenesis disorder 4A (Zellweger),614862|Peroxisome biogenesis disorder 4B,614863|Heimler syndrome 2,616617];	RCV000078578.5 [benign]; RCV000296765.1 [benign]; 			316	756					PEX6 (inh=AR pLI=0.00)
chr6	42946490	42946490	C	A	het	wt	het		QUAL=1692;DP=75,68,88;MQM=59	PEX6	synonymous,non_coding_transcript_exon	PEX6:NM_000287.3:synonymous:LOW:exon1/17:c.399G>T:p.Val133Val,PEX6:NM_001316313.1:synonymous:LOW:exon1/17:c.399G>T:p.Val133Val,PEX6:NR_133009.1:non_coding_transcript_exon:MODIFIER:exon1/15:n.492G>T:		rs9462858	0.3319	0.4494	1242/436/36	0.2284							601498 [PEX6 (confirmed) Peroxisome biogenesis disorder 4A (Zellweger),614862|Peroxisome biogenesis disorder 4B,614863|Heimler syndrome 2,616617];	RCV000078576.6 [benign]; RCV000288691.1 [benign]; 		COSM3749975	321	737					PEX6 (inh=AR pLI=0.00)
chr6	42946943	42946943	G	A	het	wt	het		QUAL=5954;DP=212,225,348;MQM=60	PEX6	5'UTR,non_coding_transcript_exon	PEX6:NM_000287.3:5'UTR:MODIFIER:exon1/17:c.-55C>T:,PEX6:NM_001316313.1:5'UTR:MODIFIER:exon1/17:c.-55C>T:,PEX6:NR_133009.1:non_coding_transcript_exon:MODIFIER:exon1/15:n.39C>T:		rs9462859	0.3339	0.0000	0/0/0	0.3783							601498 [PEX6 (confirmed) Peroxisome biogenesis disorder 4A (Zellweger),614862|Peroxisome biogenesis disorder 4B,614863|Heimler syndrome 2,616617];	RCV000408150.1 [benign]; 			138	362					PEX6 (inh=AR pLI=0.00)
chr6	43584323	43584323	-	A	het	wt	hom		QUAL=2288;DP=187,108,138;MQM=59	POLH	3'UTR	POLH:NM_006502.2:3'UTR:MODIFIER:exon11/11:c.*2043dupA:,POLH:NM_001291969.1:3'UTR:MODIFIER:exon9/9:c.*2043dupA:,POLH:NM_001291970.1:3'UTR:MODIFIER:exon11/11:c.*2869dupA:	AluSg4	rs368089629	0.1971	0.0000	0/0/0	0.0574							603968 [POLH (confirmed) Xeroderma pigmentosum,variant type,278750];	RCV000297657.1 [uncertain significance]; RCV000266624.1 [benign]; 			2	63					POLH (inh=AR pLI=0.00)
chr6	49398115	49398115	C	T	wt	wt	het		QUAL=3512;DP=493,225,277;MQM=60	MUT	3'UTR	MUT:NM_000255.3:3'UTR:MODIFIER:exon13/13:c.*1326G>A:		rs9381784	0.3293	0.0000	0/0/0	0.0661							609058 [MUT (confirmed) Methylmalonic aciduria,mut(0) type,251000];	RCV000293438.1 [benign]; 			13	62					MUT (inh=AR pLI=0.00)
chr6	49398861	49398861	T	C	hom	hom	het		QUAL=15901;DP=227,174,192;MQM=60	MUT	3'UTR	MUT:NM_000255.3:3'UTR:MODIFIER:exon13/13:c.*580A>G:		rs11757098	0.1136	0.0000	0/0/0	0.0216							609058 [MUT (confirmed) Methylmalonic aciduria,mut(0) type,251000];	RCV000356186.1 [likely benign]; 			7	50					MUT (inh=AR pLI=0.00)
chr6	49399315	49399315	T	C	het	het	wt		QUAL=3475;DP=214,87,104;MQM=60	MUT	3'UTR	MUT:NM_000255.3:3'UTR:MODIFIER:exon13/13:c.*126A>G:		rs192605776	0.0014	0.0000	0/0/0	0.0006							609058 [MUT (confirmed) Methylmalonic aciduria,mut(0) type,251000];	RCV000328175.1 [uncertain significance]; 			0	4					MUT (inh=AR pLI=0.00)
chr6	49403282	49403282	T	C	hom	hom	het	pred_pathogenic	QUAL=18083;DP=308,173,233;MQM=60	MUT	missense	MUT:NM_000255.3:missense:MODERATE:exon12/13:c.2011A>G:p.Ile671Val		rs8589	0.5495	0.5768	20583/12465/1819	0.5664	3.8290	T,T	T	B	D	3.02	609058 [MUT (confirmed) Methylmalonic aciduria,mut(0) type,251000];	RCV000203350.1 [benign]; RCV000078444.5 [benign]; RCV000372712.1 [benign]; 	CM0911477 [CLASS=R MUT=ALT PHEN="Methylmalonic aciduria" GENE=MUT]; 	COSM4004063	576	736	2	[2] Ute Grasshoff 28.10.2015			MUT (inh=AR pLI=0.00)
chr6	49425521	49425521	C	T	hom	hom	het		QUAL=28703;DP=570,235,323;MQM=60	MUT	sequence_feature,synonymous	MUT:NM_000255.3:sequence_feature:MODERATE:exon3/13:c.636G>A:,MUT:NM_000255.3:synonymous:LOW:exon3/13:c.636G>A:p.Lys212Lys		rs2229384	0.5515	0.5736	20580/12475/1731	0.5691							609058 [MUT (confirmed) Methylmalonic aciduria,mut(0) type,251000];	RCV000203353.1 [benign]; RCV000078447.6 [benign]; RCV000276310.1 [benign]; 			658	840					MUT (inh=AR pLI=0.00)
chr6	51480486	51480486	G	T	hom	het	hom		QUAL=15885;DP=205,172,213;MQM=60	PKHD1	3'UTR	PKHD1:NM_138694.3:3'UTR:MODIFIER:exon67/67:c.*3393C>A:		rs2784198	0.6867	0.0000	0/0/0	0.6489							606702 [PKHD1 (confirmed) Polycystic kidney and hepatic disease,263200];	RCV000266442.1 [benign]; 			82	108					PKHD1 (inh=AR pLI=0.00)
chr6	51480853	51480853	T	C	hom	het	hom		QUAL=10185;DP=210,56,91;MQM=59	PKHD1	3'UTR	PKHD1:NM_138694.3:3'UTR:MODIFIER:exon67/67:c.*3026A>G:		rs2784199	0.7548	0.0000	0/0/0	0.1317							606702 [PKHD1 (confirmed) Polycystic kidney and hepatic disease,263200];	RCV000318185.1 [benign]; 			98	99					PKHD1 (inh=AR pLI=0.00)
chr6	51481315	51481315	T	C	hom	het	hom		QUAL=15904;DP=299,127,156;MQM=59	PKHD1	3'UTR	PKHD1:NM_138694.3:3'UTR:MODIFIER:exon67/67:c.*2564A>G:		rs1414504	0.8834	0.0000	0/0/0	0.8505							606702 [PKHD1 (confirmed) Polycystic kidney and hepatic disease,263200];	RCV000348066.1 [benign]; 			170	51					PKHD1 (inh=AR pLI=0.00)
chr6	51481325	51481325	-	T	wt	wt	het		QUAL=249;DP=161,104,115;MQM=59	PKHD1	3'UTR	PKHD1:NM_138694.3:3'UTR:MODIFIER:exon67/67:c.*2553dupA:		rs113144792	0.0000	0.0000	0/0/0	0.0089							606702 [PKHD1 (confirmed) Polycystic kidney and hepatic disease,263200];	RCV000308434.1 [uncertain significance]; RCV000390683.1 [uncertain significance]; 			0	23					PKHD1 (inh=AR pLI=0.00)
chr6	51481671	51481671	T	C	het	wt	het		QUAL=6272;DP=349,106,151;MQM=60	PKHD1	3'UTR	PKHD1:NM_138694.3:3'UTR:MODIFIER:exon67/67:c.*2208A>G:	L2	rs2784200	0.1316	0.0000	0/0/0	0.0201							606702 [PKHD1 (confirmed) Polycystic kidney and hepatic disease,263200];	RCV000304505.1 [likely benign]; 			5	39					PKHD1 (inh=AR pLI=0.00)
chr6	51483505	51483505	A	G	hom	hom	hom		QUAL=63772;DP=859,469,585;MQM=60	PKHD1	3'UTR	PKHD1:NM_138694.3:3'UTR:MODIFIER:exon67/67:c.*374T>C:		rs2784201	0.9968	0.0000	0/0/0	0.9115							606702 [PKHD1 (confirmed) Polycystic kidney and hepatic disease,263200];	RCV000273846.1 [benign]; 			229	1					PKHD1 (inh=AR pLI=0.00)
chr6	51483961	51483961	T	C	het	het	het	pred_pathogenic	QUAL=11232;DP=436,169,237;MQM=59	PKHD1	missense	PKHD1:NM_138694.3:missense:MODERATE:exon67/67:c.12143A>G:p.Gln4048Arg		rs9381994	0.5657	0.5630	19326/9873/1178	0.5570	0.4300	T	T	B	D	21.60	606702 [PKHD1 (confirmed) Polycystic kidney and hepatic disease,263200];	RCV000082526.6 [benign]; RCV000325223.1 [benign]; 	CM1513513 [CLASS=R MUT=ALT PHEN="Polycystic kidney disease" GENE=PKHD1]; 	COSM1445058	481	814					PKHD1 (inh=AR pLI=0.00)
chr6	51491884	51491884	T	C	het	het	het	pred_pathogenic	QUAL=7382;DP=219,171,214;MQM=60	PKHD1	missense	PKHD1:NM_138694.3:missense:MODERATE:exon66/67:c.11696A>G:p.Gln3899Arg		rs4715227	0.5533	0.5550	18800/9647/1205	0.5493	1.9650	D	T	B	D	19.85	606702 [PKHD1 (confirmed) Polycystic kidney and hepatic disease,263200];	RCV000082522.6 [benign]; RCV000376208.1 [benign]; 		COSM4004068	456	822					PKHD1 (inh=AR pLI=0.00)
chr6	51586771	51586771	G	A	hom	het	het		QUAL=15803;DP=307,218,297;MQM=60	PKHD1	3'UTR,intron	PKHD1:NM_170724.2:3'UTR:MODIFIER:exon61/61:c.*13C>T:,PKHD1:NM_138694.3:intron:MODIFIER:exon60/66:c.10156+22412C>T:		rs9349593	0.7660	0.6506	26722/9600/3178	0.6145							606702 [PKHD1 (confirmed) Polycystic kidney and hepatic disease,263200];				363	466					PKHD1 (inh=AR pLI=0.00)
chr6	51586772	51586772	C	T	het	het	wt		QUAL=15803;DP=307,218,297;MQM=59	PKHD1	3'UTR,intron	PKHD1:NM_170724.2:3'UTR:MODIFIER:exon61/61:c.*12G>A:,PKHD1:NM_138694.3:intron:MODIFIER:exon60/66:c.10156+22411G>A:		rs45451196	0.2194	0.1691	1988/724/757	0.1559							606702 [PKHD1 (confirmed) Polycystic kidney and hepatic disease,263200];			COSN167788	23	276					PKHD1 (inh=AR pLI=0.00)
chr6	51613177	51613177	C	T	het	wt	het		QUAL=7691;DP=222,264,330;MQM=59	PKHD1	synonymous	PKHD1:NM_138694.3:synonymous:LOW:exon58/67:c.9237G>A:p.Ala3079Ala,PKHD1:NM_170724.2:synonymous:LOW:exon58/61:c.9237G>A:p.Ala3079Ala		rs765525	0.3860	0.4041	11292/4413/49	0.3992							606702 [PKHD1 (confirmed) Polycystic kidney and hepatic disease,263200];	RCV000082591.6 [benign]; RCV000351510.1 [benign]; 			221	719					PKHD1 (inh=AR pLI=0.00)
chr6	51732807	51732807	C	T	hom	hom	hom		QUAL=21165;DP=269,158,228;MQM=60	PKHD1	synonymous	PKHD1:NM_138694.3:synonymous:LOW:exon48/67:c.7587G>A:p.Gly2529Gly,PKHD1:NM_170724.2:synonymous:LOW:exon48/61:c.7587G>A:p.Gly2529Gly		rs12210295	0.3676	0.5067	17299/13446/613	0.5039							606702 [PKHD1 (confirmed) Polycystic kidney and hepatic disease,263200];	RCV000082571.6 [benign]; RCV000273935.1 [benign]; 		COSM1179828, COSM1179827	629	760					PKHD1 (inh=AR pLI=0.00)
chr6	51875250	51875250	A	C	hom	hom	hom	pred_pathogenic	QUAL=24114;DP=193,232,334;MQM=60	PKHD1	missense	PKHD1:NM_138694.3:missense:MODERATE:exon35/67:c.5608T>G:p.Leu1870Val,PKHD1:NM_170724.2:missense:MODERATE:exon35/61:c.5608T>G:p.Leu1870Val		rs2435322	0.9559	0.9872	59245/33342/3858	0.9240	5.0500	T,T,T	T	B,B	D,D	3.30	606702 [PKHD1 (confirmed) Polycystic kidney and hepatic disease,263200];	RCV000082560.6 [benign]; RCV000329286.1 [benign]; 	CM1513512 [CLASS=R MUT=ALT PHEN="Polycystic kidney disease" GENE=PKHD1]; 		1616	9					PKHD1 (inh=AR pLI=0.00)
chr6	51890823	51890823	G	A	hom	het	hom	pred_pathogenic	QUAL=16326;DP=248,159,229;MQM=59	PKHD1	missense	PKHD1:NM_138694.3:missense:MODERATE:exon32/67:c.3785C>T:p.Ala1262Val,PKHD1:NM_170724.2:missense:MODERATE:exon32/61:c.3785C>T:p.Ala1262Val		rs9296669	0.3546	0.4698	14368/9136/109	0.4652	0.2650	T,T,T	T	B,B	D,D	0.16	606702 [PKHD1 (confirmed) Polycystic kidney and hepatic disease,263200];	RCV000082549.6 [benign]; RCV000282648.1 [benign]; 		COSM4004073, COSM4004072	418	758					PKHD1 (inh=AR pLI=0.00)
chr6	51890852	51890852	C	G	het	wt	het		QUAL=6389;DP=213,174,288;MQM=59	PKHD1	synonymous	PKHD1:NM_138694.3:synonymous:LOW:exon32/67:c.3756G>C:p.Leu1252Leu,PKHD1:NM_170724.2:synonymous:LOW:exon32/61:c.3756G>C:p.Leu1252Leu		rs9689306	0.0186	0.0379	144/123/0	0.0388							606702 [PKHD1 (confirmed) Polycystic kidney and hepatic disease,263200];	RCV000153717.4 [benign]; RCV000314391.1 [likely benign]; 		COSM3762128, COSM3762127	2	117					PKHD1 (inh=AR pLI=0.00)
chr6	51893107	51893107	T	C	het	het	wt	pred_pathogenic;anno_pathogenic_hgmd	QUAL=5549;DP=290,154,188;MQM=60	PKHD1	missense	PKHD1:NM_138694.3:missense:MODERATE:exon30/67:c.3407A>G:p.Tyr1136Cys,PKHD1:NM_170724.2:missense:MODERATE:exon30/61:c.3407A>G:p.Tyr1136Cys		rs41273726	0.0026	0.0079	14/12/0	0.0076	-0.0620	T,T,T	T	P,P	D,D	0.07	606702 [PKHD1 (confirmed) Polycystic kidney and hepatic disease,263200];	RCV000153718.4 [other]; RCV000168029.3 [other]; RCV000224414.1 [likely benign]; 	CM051142 [CLASS=DM? MUT=ALT PHEN="Polycystic kidney disease" GENE=PKHD1]; 		1	51					PKHD1 (inh=AR pLI=0.00)
chr6	51914956	51914956	G	A	hom	het	hom	pred_pathogenic	QUAL=5159;DP=96,51,59;MQM=60	PKHD1	missense&splice_region	PKHD1:NM_138694.3:missense&splice_region:MODERATE:exon22/67:c.2278C>T:p.Arg760Cys,PKHD1:NM_170724.2:missense&splice_region:MODERATE:exon22/61:c.2278C>T:p.Arg760Cys		rs9370096	0.3558	0.4652	14183/8985/110	0.4591	-0.4870	T,T,T	T	B,B	D,D	18.79	606702 [PKHD1 (confirmed) Polycystic kidney and hepatic disease,263200];	RCV000082536.6 [benign]; RCV000278857.1 [benign]; 			414	757					PKHD1 (inh=AR pLI=0.00)
chr6	51917968	51917968	T	G	wt	het	wt		QUAL=2057;DP=286,211,307;MQM=60	PKHD1	synonymous	PKHD1:NM_138694.3:synonymous:LOW:exon21/67:c.2046A>C:p.Pro682Pro,PKHD1:NM_170724.2:synonymous:LOW:exon21/61:c.2046A>C:p.Pro682Pro		rs4715271	0.0587	0.0862	546/417/3	0.0856							606702 [PKHD1 (confirmed) Polycystic kidney and hepatic disease,263200];	RCV000082534.6 [benign]; RCV000296328.1 [likely benign]; 			25	315					PKHD1 (inh=AR pLI=0.00)
chr6	51923409	51923409	A	T	wt	het	wt		QUAL=1746;DP=179,155,189;MQM=60	PKHD1	splice_region&intron	PKHD1:NM_138694.3:splice_region&intron:LOW:exon15/66:c.1234-10T>A:,PKHD1:NM_170724.2:splice_region&intron:LOW:exon15/60:c.1234-10T>A:		rs4715272	0.1166	0.1506	1511/992/36	0.1486							606702 [PKHD1 (confirmed) Polycystic kidney and hepatic disease,263200];	RCV000082527.6 [benign]; RCV000263218.1 [likely benign]; 			67	473					PKHD1 (inh=AR pLI=0.00)
chr6	51924774	51924774	A	G	hom	hom	hom		QUAL=25599;DP=327,188,270;MQM=60	PKHD1	synonymous	PKHD1:NM_138694.3:synonymous:LOW:exon15/67:c.1185T>C:p.Asp395Asp,PKHD1:NM_170724.2:synonymous:LOW:exon15/61:c.1185T>C:p.Asp395Asp		rs1896976	0.9583	0.9883	59343/33329/3980	0.9250							606702 [PKHD1 (confirmed) Polycystic kidney and hepatic disease,263200];	RCV000082524.6 [benign]; RCV000169626.2 [benign]; 			1615	10					PKHD1 (inh=AR pLI=0.00)
chr6	51947257	51947257	G	A	wt	het	wt		QUAL=3992;DP=366,316,454;MQM=60	PKHD1	synonymous	PKHD1:NM_138694.3:synonymous:LOW:exon4/67:c.214C>T:p.Leu72Leu,PKHD1:NM_170724.2:synonymous:LOW:exon4/61:c.214C>T:p.Leu72Leu		rs6901799	0.0705	0.0931	620/456/32	0.0922							606702 [PKHD1 (confirmed) Polycystic kidney and hepatic disease,263200];	RCV000082535.6 [benign]; RCV000287004.1 [likely benign]; 			29	333					PKHD1 (inh=AR pLI=0.00)
chr6	52303399	52303399	A	G	wt	wt	het		QUAL=3044;DP=174,163,252;MQM=60	EFHC1	splice_region&intron	EFHC1:NM_018100.3:splice_region&intron:LOW:exon3/10:c.573+10A>G:,EFHC1:NR_033327.1:splice_region&intron:LOW:exon3/9:n.788+10A>G:,EFHC1:NM_001172420.1:splice_region&intron:LOW:exon4/11:c.516+10A>G:		rs9349626	0.2029	0.2286	3846/1298/91	0.2211							608815 [EFHC1 (confirmed) Myoclonic epilepsy,juvenile,susceptibility to,1,254770|Epilepsy,juvenile absence,susceptibility to,1,607631];	RCV000116951.3 [other]; RCV000359153.1 [likely benign]; 			60	478					EFHC1 (inh=n/a pLI=0.00)
chr6	52357260	52357260	C	A	hom	hom	hom		QUAL=14733;DP=202,128,139;MQM=60	EFHC1	3'UTR,non_coding_transcript_exon	EFHC1:NM_018100.3:3'UTR:MODIFIER:exon11/11:c.*121C>A:,EFHC1:NM_001172420.1:3'UTR:MODIFIER:exon12/12:c.*121C>A:,EFHC1:NR_033327.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.3516C>A:		rs7757370	0.9000	0.8947	11217/4932/959	0.6960							608815 [EFHC1 (confirmed) Myoclonic epilepsy,juvenile,susceptibility to,1,254770|Epilepsy,juvenile absence,susceptibility to,1,607631];	RCV000353494.1 [benign]; 			494	141					EFHC1 (inh=n/a pLI=0.00)
chr6	52358010	52358010	C	G	het	hom	wt		QUAL=5830;DP=142,137,169;MQM=59	EFHC1	3'UTR,non_coding_transcript_exon	EFHC1:NM_018100.3:3'UTR:MODIFIER:exon11/11:c.*871C>G:,EFHC1:NM_001172420.1:3'UTR:MODIFIER:exon12/12:c.*871C>G:,EFHC1:NR_033327.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4266C>G:	MLT2B4	rs78956562	0.1721	0.1754	180/30/0	0.0382							608815 [EFHC1 (confirmed) Myoclonic epilepsy,juvenile,susceptibility to,1,254770|Epilepsy,juvenile absence,susceptibility to,1,607631];	RCV000326025.1 [likely benign]; 			13	123					EFHC1 (inh=n/a pLI=0.00)
chr6	52358020	52358020	A	T	hom	hom	hom		QUAL=13286;DP=134,137,159;MQM=59	EFHC1	3'UTR,non_coding_transcript_exon	EFHC1:NM_018100.3:3'UTR:MODIFIER:exon11/11:c.*881A>T:,EFHC1:NM_001172420.1:3'UTR:MODIFIER:exon12/12:c.*881A>T:,EFHC1:NR_033327.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4276A>T:	MLT2B4	rs6926242	0.9331	0.9019	4405/1019/76	0.2220							608815 [EFHC1 (confirmed) Myoclonic epilepsy,juvenile,susceptibility to,1,254770|Epilepsy,juvenile absence,susceptibility to,1,607631];	RCV000385142.1 [likely benign]; 			447	124					EFHC1 (inh=n/a pLI=0.00)
chr6	52358319	52358319	G	A	hom	hom	hom		QUAL=5762;DP=103,46,50;MQM=59	EFHC1	3'UTR,non_coding_transcript_exon	EFHC1:NM_018100.3:3'UTR:MODIFIER:exon11/11:c.*1180G>A:,EFHC1:NM_001172420.1:3'UTR:MODIFIER:exon12/12:c.*1180G>A:,EFHC1:NR_033327.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4575G>A:	AluSx	rs4455668	0.9000	0.8945	3309/807/57	0.2036							608815 [EFHC1 (confirmed) Myoclonic epilepsy,juvenile,susceptibility to,1,254770|Epilepsy,juvenile absence,susceptibility to,1,607631];	RCV000329068.1 [benign]; 			457	130					EFHC1 (inh=n/a pLI=0.00)
chr6	52358453	52358453	-	A	het	hom	wt		QUAL=4445;DP=213,116,170;MQM=59	EFHC1	3'UTR,non_coding_transcript_exon	EFHC1:NM_018100.3:3'UTR:MODIFIER:exon11/11:c.*1325dupA:,EFHC1:NM_001172420.1:3'UTR:MODIFIER:exon12/12:c.*1325dupA:,EFHC1:NR_033327.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4720dupA:	AluSx	rs35994917;rs539728759	0.2278	0.3281	4/0/0	0.0328							608815 [EFHC1 (confirmed) Myoclonic epilepsy,juvenile,susceptibility to,1,254770|Epilepsy,juvenile absence,susceptibility to,1,607631];	RCV000383689.1 [likely benign]; 			1	163					EFHC1 (inh=n/a pLI=0.00)
chr6	52358629	52358629	C	A	wt	wt	het		QUAL=3559;DP=287,203,283;MQM=60	EFHC1	3'UTR,non_coding_transcript_exon	EFHC1:NM_018100.3:3'UTR:MODIFIER:exon11/11:c.*1490C>A:,EFHC1:NM_001172420.1:3'UTR:MODIFIER:exon12/12:c.*1490C>A:,EFHC1:NR_033327.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4885C>A:		rs2397092	0.1999	0.2394	349/58/2	0.0545							608815 [EFHC1 (confirmed) Myoclonic epilepsy,juvenile,susceptibility to,1,254770|Epilepsy,juvenile absence,susceptibility to,1,607631];	RCV000324166.1 [likely benign]; 			23	206					EFHC1 (inh=n/a pLI=0.00)
chr6	52358887	52358887	-	CA	hom	hom	hom		QUAL=18566;DP=269,156,206;MQM=59	EFHC1	3'UTR,non_coding_transcript_exon	EFHC1:NM_018100.3:3'UTR:MODIFIER:exon11/11:c.*1749_*1750insAC:,EFHC1:NM_001172420.1:3'UTR:MODIFIER:exon12/12:c.*1749_*1750insAC:,EFHC1:NR_033327.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5144_5145insAC:		rs58779695;rs77236493	0.8996	0.8983	4372/1014/65	0.2083							608815 [EFHC1 (confirmed) Myoclonic epilepsy,juvenile,susceptibility to,1,254770|Epilepsy,juvenile absence,susceptibility to,1,607631];				459	170					EFHC1 (inh=n/a pLI=0.00)
chr6	52360111	52360111	C	G	wt	wt	het		QUAL=2358;DP=292,135,177;MQM=60	EFHC1	3'UTR,non_coding_transcript_exon	EFHC1:NM_018100.3:3'UTR:MODIFIER:exon11/11:c.*2972C>G:,EFHC1:NM_001172420.1:3'UTR:MODIFIER:exon12/12:c.*2972C>G:,EFHC1:NR_033327.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.6367C>G:	LTR78	rs9367485	0.2031	0.2450	365/60/2	0.0560							608815 [EFHC1 (confirmed) Myoclonic epilepsy,juvenile,susceptibility to,1,254770|Epilepsy,juvenile absence,susceptibility to,1,607631];	RCV000306638.1 [likely benign]; 			25	205					EFHC1 (inh=n/a pLI=0.00)
chr6	52360283	52360283	T	A	hom	hom	het		QUAL=20852;DP=322,214,287;MQM=60	EFHC1	3'UTR,non_coding_transcript_exon	EFHC1:NM_018100.3:3'UTR:MODIFIER:exon11/11:c.*3144T>A:,EFHC1:NM_001172420.1:3'UTR:MODIFIER:exon12/12:c.*3144T>A:,EFHC1:NR_033327.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.6539T>A:	LTR78	rs3789772	0.6991	0.6546	2355/587/46	0.1662							608815 [EFHC1 (confirmed) Myoclonic epilepsy,juvenile,susceptibility to,1,254770|Epilepsy,juvenile absence,susceptibility to,1,607631];	RCV000365942.1 [likely benign]; 			282	248					EFHC1 (inh=n/a pLI=0.00)
chr6	52360545	52360545	T	C	het	wt	het		QUAL=10124;DP=439,263,366;MQM=59	EFHC1	3'UTR,non_coding_transcript_exon	EFHC1:NM_018100.3:3'UTR:MODIFIER:exon11/11:c.*3406T>C:,EFHC1:NM_001172420.1:3'UTR:MODIFIER:exon12/12:c.*3406T>C:,EFHC1:NR_033327.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.6801T>C:		rs6919266	0.2794	0.4492	16/7/1	0.0779							608815 [EFHC1 (confirmed) Myoclonic epilepsy,juvenile,susceptibility to,1,254770|Epilepsy,juvenile absence,susceptibility to,1,607631];	RCV000303058.1 [likely benign]; 			109	266					EFHC1 (inh=n/a pLI=0.00)
chr6	52878637	52878637	T	C	wt	het	wt		QUAL=4740;DP=261,421,567;MQM=60	ICK	synonymous	ICK:NM_014920.3:synonymous:LOW:exon9/14:c.975A>G:p.Pro325Pro,ICK:NM_016513.4:synonymous:LOW:exon10/15:c.975A>G:p.Pro325Pro		rs2297211	0.2482	0.2471	4115/2454/933	0.2401							612325 [ICK (provisional) Endocrine-cerebroosteodysplasia,612651];			COSM150107	125	586					ICK (inh=AR pLI=0.11)
chr6	57055354	57055354	C	T	wt	wt	het	pred_pathogenic	QUAL=4391;DP=499,333,383;MQM=60	RAB23	missense,non_coding_transcript_exon	RAB23:NM_001278666.1:missense:MODERATE:exon7/7:c.619G>A:p.Gly207Ser,RAB23:NM_001278668.1:missense:MODERATE:exon7/7:c.619G>A:p.Gly207Ser,RAB23:NM_183227.2:missense:MODERATE:exon7/7:c.619G>A:p.Gly207Ser,RAB23:NM_001278667.1:missense:MODERATE:exon7/7:c.619G>A:p.Gly207Ser,RAB23:NM_016277.4:missense:MODERATE:exon7/7:c.619G>A:p.Gly207Ser,RAB23:NR_103822.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.478G>A:		rs1040461	0.1154	0.0979	682/245/164	0.0943	4.0150	T,T	T	B	T,T	17.61	606144 [RAB23 (confirmed) Carpenter syndrome,201000];	RCV000279277.1 [likely benign]; 			5	196					RAB23 (inh=AR pLI=0.04)
chr6	81053642	81053642	G	A	hom	hom	het		QUAL=28010;DP=455,279,342;MQM=60	BCKDHB	3'UTR,intron,non_coding_transcript_exon	BCKDHB:NM_001318975.1:3'UTR:MODIFIER:exon10/10:c.*121G>A:,BCKDHB:NM_183050.3:3'UTR:MODIFIER:exon10/10:c.*121G>A:,BCKDHB:NM_000056.4:intron:MODIFIER:exon10/10:c.*8+113G>A:,BCKDHB:NR_134945.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.1478G>A:		rs926733	0.7151	0.0000	0/0/0	0.1780							248611 [BCKDHB (confirmed) Maple syrup urine disease,type Ib,248600];	RCV000338517.1 [benign]; 			150	55					BCKDHB (inh=AR pLI=0.00)
chr6	81053717	81053719	TTG	-	hom	hom	het		QUAL=8662;DP=210,78,93;MQM=59	BCKDHB	3'UTR,intron,non_coding_transcript_exon	BCKDHB:NM_001318975.1:3'UTR:MODIFIER:exon10/10:c.*210_*212delGTT:,BCKDHB:NM_183050.3:3'UTR:MODIFIER:exon10/10:c.*210_*212delGTT:,BCKDHB:NM_000056.4:intron:MODIFIER:exon10/10:c.*8+202_*8+204delGTT:,BCKDHB:NR_134945.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.1567_1569delGTT:	AluSx1	rs869224641	0.0000	0.0000	0/0/0	0.5775							248611 [BCKDHB (confirmed) Maple syrup urine disease,type Ib,248600];				152	51					BCKDHB (inh=AR pLI=0.00)
chr6	81053814	81053814	T	C	hom	hom	het		QUAL=4791;DP=92,52,56;MQM=56	BCKDHB	3'UTR,intron,non_coding_transcript_exon	BCKDHB:NM_001318975.1:3'UTR:MODIFIER:exon10/10:c.*293T>C:,BCKDHB:NM_183050.3:3'UTR:MODIFIER:exon10/10:c.*293T>C:,BCKDHB:NM_000056.4:intron:MODIFIER:exon10/10:c.*8+285T>C:,BCKDHB:NR_134945.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.1650T>C:	AluSx1	rs926732	0.7155	0.0000	0/0/0	0.6874							248611 [BCKDHB (confirmed) Maple syrup urine disease,type Ib,248600];	RCV000312717.1 [benign]; 			130	37					BCKDHB (inh=AR pLI=0.00)
chr6	81053825	81053825	G	A	hom	hom	het		QUAL=4332;DP=77,50,50;MQM=54	BCKDHB	3'UTR,intron,non_coding_transcript_exon	BCKDHB:NM_001318975.1:3'UTR:MODIFIER:exon10/10:c.*304G>A:,BCKDHB:NM_183050.3:3'UTR:MODIFIER:exon10/10:c.*304G>A:,BCKDHB:NM_000056.4:intron:MODIFIER:exon10/10:c.*8+296G>A:,BCKDHB:NR_134945.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.1661G>A:	AluSx1	rs926731	0.7159	0.0000	0/0/0	0.6928							248611 [BCKDHB (confirmed) Maple syrup urine disease,type Ib,248600];	RCV000348834.1 [benign]; 			130	38					BCKDHB (inh=AR pLI=0.00)
chr6	81053866	81053866	C	T	hom	hom	het		QUAL=5283;DP=139,34,29;MQM=55	BCKDHB	3'UTR,intron,non_coding_transcript_exon	BCKDHB:NM_001318975.1:3'UTR:MODIFIER:exon10/10:c.*345C>T:,BCKDHB:NM_183050.3:3'UTR:MODIFIER:exon10/10:c.*345C>T:,BCKDHB:NM_000056.4:intron:MODIFIER:exon10/10:c.*8+337C>T:,BCKDHB:NR_134945.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.1702C>T:	AluSx1	rs1811844	0.5899	0.0000	0/0/0	0.6874							248611 [BCKDHB (confirmed) Maple syrup urine disease,type Ib,248600];	RCV000389995.1 [benign]; 			128	43					BCKDHB (inh=AR pLI=0.00)
chr6	81053916	81053916	G	T	hom	hom	het	low_DP	QUAL=4782;DP=148,12,15;MQM=59	BCKDHB	3'UTR,intron,non_coding_transcript_exon	BCKDHB:NM_001318975.1:3'UTR:MODIFIER:exon10/10:c.*395G>T:,BCKDHB:NM_183050.3:3'UTR:MODIFIER:exon10/10:c.*395G>T:,BCKDHB:NM_000056.4:intron:MODIFIER:exon10/10:c.*8+387G>T:,BCKDHB:NR_134945.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.1752G>T:	AluSx1	rs4706116	0.9585	0.0000	0/0/0	0.8727							248611 [BCKDHB (confirmed) Maple syrup urine disease,type Ib,248600];	RCV000314077.1 [benign]; 			163	17					BCKDHB (inh=AR pLI=0.00)
chr6	81054066	81054067	TT	-	hom	wt	het	low_DP	QUAL=139;DP=12,12,2;MQM=58	BCKDHB	3'UTR,intron,non_coding_transcript_exon	BCKDHB:NM_001318975.1:3'UTR:MODIFIER:exon10/10:c.*559_*560delTT:,BCKDHB:NM_183050.3:3'UTR:MODIFIER:exon10/10:c.*559_*560delTT:,BCKDHB:NM_000056.4:intron:MODIFIER:exon10/10:c.*8+551_*8+552delTT:,BCKDHB:NR_134945.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.1916_1917delTT:	AluSc	rs869223033	0.8930	0.0000	0/0/0	0.5400							248611 [BCKDHB (confirmed) Maple syrup urine disease,type Ib,248600];	RCV000264302.1 [benign]; 			65	26					BCKDHB (inh=AR pLI=0.00)
chr6	81054148	81054148	T	C	hom	hom	het	low_DP	QUAL=2388;DP=71,5,19;MQM=57	BCKDHB	3'UTR,intron,non_coding_transcript_exon	BCKDHB:NM_001318975.1:3'UTR:MODIFIER:exon10/10:c.*627T>C:,BCKDHB:NM_183050.3:3'UTR:MODIFIER:exon10/10:c.*627T>C:,BCKDHB:NM_000056.4:intron:MODIFIER:exon10/10:c.*8+619T>C:,BCKDHB:NR_134945.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.1984T>C:	AluSc	rs4706838	0.7153	0.0000	0/0/0	0.7183							248611 [BCKDHB (confirmed) Maple syrup urine disease,type Ib,248600];	RCV000324200.1 [benign]; 			131	38					BCKDHB (inh=AR pLI=0.00)
chr6	81054252	81054252	C	T	hom	hom	het		QUAL=4916;DP=92,58,66;MQM=51	BCKDHB	3'UTR,intron,non_coding_transcript_exon	BCKDHB:NM_001318975.1:3'UTR:MODIFIER:exon10/10:c.*731C>T:,BCKDHB:NM_183050.3:3'UTR:MODIFIER:exon10/10:c.*731C>T:,BCKDHB:NM_000056.4:intron:MODIFIER:exon10/10:c.*8+723C>T:,BCKDHB:NR_134945.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.2088C>T:	AluSc	rs4706117	0.3998	0.0000	0/0/0	0.4442							248611 [BCKDHB (confirmed) Maple syrup urine disease,type Ib,248600];	RCV000315644.1 [benign]; 			53	85					BCKDHB (inh=AR pLI=0.00)
chr6	81054310	81054310	C	T	hom	hom	het		QUAL=7972;DP=125,98,138;MQM=56	BCKDHB	3'UTR,intron,non_coding_transcript_exon	BCKDHB:NM_001318975.1:3'UTR:MODIFIER:exon10/10:c.*789C>T:,BCKDHB:NM_183050.3:3'UTR:MODIFIER:exon10/10:c.*789C>T:,BCKDHB:NM_000056.4:intron:MODIFIER:exon10/10:c.*8+781C>T:,BCKDHB:NR_134945.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.2146C>T:	AluSc	rs4706118	0.7155	0.0000	0/0/0	0.6925							248611 [BCKDHB (confirmed) Maple syrup urine disease,type Ib,248600];	RCV000280897.1 [benign]; 			153	52					BCKDHB (inh=AR pLI=0.00)
chr6	81054326	81054326	T	C	hom	hom	het		QUAL=8497;DP=114,113,158;MQM=59	BCKDHB	3'UTR,intron,non_coding_transcript_exon	BCKDHB:NM_001318975.1:3'UTR:MODIFIER:exon10/10:c.*805T>C:,BCKDHB:NM_183050.3:3'UTR:MODIFIER:exon10/10:c.*805T>C:,BCKDHB:NM_000056.4:intron:MODIFIER:exon10/10:c.*8+797T>C:,BCKDHB:NR_134945.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.2162T>C:	AluSc	rs4706839	0.7155	0.0000	0/0/0	0.6922							248611 [BCKDHB (confirmed) Maple syrup urine disease,type Ib,248600];	RCV000349945.1 [benign]; 			157	51					BCKDHB (inh=AR pLI=0.00)
chr6	81054515	81054515	G	A	hom	hom	het		QUAL=19876;DP=335,170,255;MQM=60	BCKDHB	3'UTR,intron,non_coding_transcript_exon	BCKDHB:NM_001318975.1:3'UTR:MODIFIER:exon10/10:c.*994G>A:,BCKDHB:NM_183050.3:3'UTR:MODIFIER:exon10/10:c.*994G>A:,BCKDHB:NM_000056.4:intron:MODIFIER:exon10/10:c.*8+986G>A:,BCKDHB:NR_134945.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.2351G>A:		rs4502885	0.7153	0.0000	0/0/0	0.1334							248611 [BCKDHB (confirmed) Maple syrup urine disease,type Ib,248600];	RCV000306621.1 [benign]; 			158	60					BCKDHB (inh=AR pLI=0.00)
chr6	81054663	81054663	C	G	hom	hom	het		QUAL=14710;DP=224,138,178;MQM=60	BCKDHB	3'UTR,intron,non_coding_transcript_exon	BCKDHB:NM_001318975.1:3'UTR:MODIFIER:exon10/10:c.*1142C>G:,BCKDHB:NM_183050.3:3'UTR:MODIFIER:exon10/10:c.*1142C>G:,BCKDHB:NM_000056.4:intron:MODIFIER:exon10/10:c.*9-1029C>G:,BCKDHB:NR_134945.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.2499C>G:		rs1042367	0.6887	0.0000	0/0/0	0.1323							248611 [BCKDHB (confirmed) Maple syrup urine disease,type Ib,248600];	RCV000397289.1 [benign]; 			158	59					BCKDHB (inh=AR pLI=0.00)
chr6	81054762	81054762	A	G	hom	hom	het		QUAL=15976;DP=267,134,187;MQM=60	BCKDHB	3'UTR,intron,non_coding_transcript_exon	BCKDHB:NM_001318975.1:3'UTR:MODIFIER:exon10/10:c.*1241A>G:,BCKDHB:NM_183050.3:3'UTR:MODIFIER:exon10/10:c.*1241A>G:,BCKDHB:NM_000056.4:intron:MODIFIER:exon10/10:c.*9-930A>G:,BCKDHB:NR_134945.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.2598A>G:		rs1042368	0.7153	0.0000	0/0/0	0.1555							248611 [BCKDHB (confirmed) Maple syrup urine disease,type Ib,248600];	RCV000304701.1 [benign]; 			158	60					BCKDHB (inh=AR pLI=0.00)
chr6	81054965	81054965	T	C	hom	hom	het		QUAL=12762;DP=306,43,79;MQM=60	BCKDHB	3'UTR,intron,non_coding_transcript_exon	BCKDHB:NM_001318975.1:3'UTR:MODIFIER:exon10/10:c.*1444T>C:,BCKDHB:NM_183050.3:3'UTR:MODIFIER:exon10/10:c.*1444T>C:,BCKDHB:NM_000056.4:intron:MODIFIER:exon10/10:c.*9-727T>C:,BCKDHB:NR_134945.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.2801T>C:		rs3805848	0.7153	0.0000	0/0/0	0.1337							248611 [BCKDHB (confirmed) Maple syrup urine disease,type Ib,248600];	RCV000260047.1 [benign]; 			157	61					BCKDHB (inh=AR pLI=0.00)
chr6	81055299	81055299	A	G	hom	hom	het		QUAL=22313;DP=317,234,309;MQM=59	BCKDHB	3'UTR,intron,non_coding_transcript_exon	BCKDHB:NM_001318975.1:3'UTR:MODIFIER:exon10/10:c.*1778A>G:,BCKDHB:NM_183050.3:3'UTR:MODIFIER:exon10/10:c.*1778A>G:,BCKDHB:NM_000056.4:intron:MODIFIER:exon10/10:c.*9-393A>G:,BCKDHB:NR_134945.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.3135A>G:		rs7758761	0.7149	0.0000	0/0/0	0.1568							248611 [BCKDHB (confirmed) Maple syrup urine disease,type Ib,248600];	RCV000374633.1 [benign]; 			157	61					BCKDHB (inh=AR pLI=0.00)
chr6	81055331	81055331	T	C	hom	hom	het		QUAL=23186;DP=352,230,322;MQM=60	BCKDHB	3'UTR,intron,non_coding_transcript_exon	BCKDHB:NM_001318975.1:3'UTR:MODIFIER:exon10/10:c.*1810T>C:,BCKDHB:NM_183050.3:3'UTR:MODIFIER:exon10/10:c.*1810T>C:,BCKDHB:NM_000056.4:intron:MODIFIER:exon10/10:c.*9-361T>C:,BCKDHB:NR_134945.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.3167T>C:		rs7740932	0.7153	0.0000	0/0/0	0.1339							248611 [BCKDHB (confirmed) Maple syrup urine disease,type Ib,248600];	RCV000330559.1 [benign]; 			156	62					BCKDHB (inh=AR pLI=0.00)
chr6	81055396	81055396	G	A	hom	hom	het		QUAL=25947;DP=387,275,409;MQM=59	BCKDHB	3'UTR,intron,non_coding_transcript_exon	BCKDHB:NM_001318975.1:3'UTR:MODIFIER:exon10/10:c.*1875G>A:,BCKDHB:NM_183050.3:3'UTR:MODIFIER:exon10/10:c.*1875G>A:,BCKDHB:NM_000056.4:intron:MODIFIER:exon10/10:c.*9-296G>A:,BCKDHB:NR_134945.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.3232G>A:		rs7759304	0.7153	0.0000	0/0/0	0.1338							248611 [BCKDHB (confirmed) Maple syrup urine disease,type Ib,248600];	RCV000389776.1 [benign]; 			158	60					BCKDHB (inh=AR pLI=0.00)
chr6	81055413	81055413	T	C	hom	hom	het		QUAL=27888;DP=420,286,416;MQM=59	BCKDHB	3'UTR,intron,non_coding_transcript_exon	BCKDHB:NM_001318975.1:3'UTR:MODIFIER:exon10/10:c.*1892T>C:,BCKDHB:NM_183050.3:3'UTR:MODIFIER:exon10/10:c.*1892T>C:,BCKDHB:NM_000056.4:intron:MODIFIER:exon10/10:c.*9-279T>C:,BCKDHB:NR_134945.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.3249T>C:		rs7740958	0.7153	0.0000	0/0/0	0.1332							248611 [BCKDHB (confirmed) Maple syrup urine disease,type Ib,248600];	RCV000295762.1 [benign]; 			158	60					BCKDHB (inh=AR pLI=0.00)
chr6	81055792	81055792	G	A	hom	hom	het		QUAL=8195;DP=181,46,50;MQM=60	BCKDHB	3'UTR,non_coding_transcript_exon	BCKDHB:NM_000056.4:3'UTR:MODIFIER:exon11/11:c.*109G>A:,BCKDHB:NM_001318975.1:3'UTR:MODIFIER:exon10/10:c.*2271G>A:,BCKDHB:NM_183050.3:3'UTR:MODIFIER:exon10/10:c.*2271G>A:,BCKDHB:NR_134945.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.3628G>A:		rs15062	0.7159	0.0000	0/0/0	0.1287							248611 [BCKDHB (confirmed) Maple syrup urine disease,type Ib,248600];	RCV000381873.1 [benign]; 			158	60					BCKDHB (inh=AR pLI=0.00)
chr6	81055803	81055803	C	T	hom	hom	het		QUAL=8089;DP=175,51,49;MQM=60	BCKDHB	3'UTR,non_coding_transcript_exon	BCKDHB:NM_000056.4:3'UTR:MODIFIER:exon11/11:c.*120C>T:,BCKDHB:NM_001318975.1:3'UTR:MODIFIER:exon10/10:c.*2282C>T:,BCKDHB:NM_183050.3:3'UTR:MODIFIER:exon10/10:c.*2282C>T:,BCKDHB:NR_134945.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.3639C>T:		rs10864	0.7157	0.0000	0/0/0	0.1288							248611 [BCKDHB (confirmed) Maple syrup urine disease,type Ib,248600];	RCV000289821.1 [benign]; 			158	60					BCKDHB (inh=AR pLI=0.00)
chr6	88221391	88221391	C	T	het	het	wt		QUAL=11721;DP=536,354,459;MQM=60	SLC35A1	3'UTR	SLC35A1:NM_006416.4:3'UTR:MODIFIER:exon8/8:c.*147C>T:,SLC35A1:NM_001168398.1:3'UTR:MODIFIER:exon7/7:c.*147C>T:		rs55960393	0.0230	0.0000	0/0/0	0.0073							605634 [SLC35A1 (confirmed) Congenital disorder of glycosylation,type IIf,603585];	RCV000391275.1 [likely benign]; 			0	12					SLC35A1 (inh=AR pLI=0.21)
chr6	88221546	88221546	A	G	hom	het	het		QUAL=21539;DP=470,174,244;MQM=59	SLC35A1	3'UTR	SLC35A1:NM_006416.4:3'UTR:MODIFIER:exon8/8:c.*302A>G:,SLC35A1:NM_001168398.1:3'UTR:MODIFIER:exon7/7:c.*302A>G:		rs1051131	0.6392	0.0000	0/0/0	0.0992							605634 [SLC35A1 (confirmed) Congenital disorder of glycosylation,type IIf,603585];	RCV000368571.1 [benign]; RCV000402620.1 [benign]; 			59	107					SLC35A1 (inh=AR pLI=0.21)
chr6	88221763	88221763	-	TGAA	hom	het	het		QUAL=15837;DP=328,185,317;MQM=59	SLC35A1	3'UTR	SLC35A1:NM_006416.4:3'UTR:MODIFIER:exon8/8:c.*521_*522insAATG:,SLC35A1:NM_001168398.1:3'UTR:MODIFIER:exon7/7:c.*521_*522insAATG:		rs10681831	0.6556	0.0000	0/0/0	0.4164							605634 [SLC35A1 (confirmed) Congenital disorder of glycosylation,type IIf,603585];	RCV000270571.1 [benign]; RCV000303190.1 [benign]; 			59	105					SLC35A1 (inh=AR pLI=0.21)
chr6	88221767	88221767	-	TAAC	het	wt	het		QUAL=8042;DP=304,179,305;MQM=59	SLC35A1	3'UTR	SLC35A1:NM_006416.4:3'UTR:MODIFIER:exon8/8:c.*525_*528dupAACT:,SLC35A1:NM_001168398.1:3'UTR:MODIFIER:exon7/7:c.*525_*528dupAACT:			0.0000	0.0000	0/0/0	0.0197							605634 [SLC35A1 (confirmed) Congenital disorder of glycosylation,type IIf,603585];	RCV000283029.1 [uncertain significance]; 			16	79					SLC35A1 (inh=AR pLI=0.21)
chr6	88221892	88221892	T	G	hom	het	het		QUAL=12811;DP=306,83,109;MQM=59	SLC35A1	3'UTR	SLC35A1:NM_006416.4:3'UTR:MODIFIER:exon8/8:c.*648T>G:,SLC35A1:NM_001168398.1:3'UTR:MODIFIER:exon7/7:c.*648T>G:		rs1051148	0.6386	0.0000	0/0/0	0.0991							605634 [SLC35A1 (confirmed) Congenital disorder of glycosylation,type IIf,603585];	RCV000321728.1 [benign]; RCV000364789.1 [benign]; 			59	106					SLC35A1 (inh=AR pLI=0.21)
chr6	88240570	88240570	C	T	het	wt	het		QUAL=7833;DP=336,199,271;MQM=59	RARS2	missense,non_coding_transcript_exon	RARS2:NM_020320.4:missense:MODERATE:exon9/20:c.703G>A:p.Val235Met,RARS2:NM_001318785.1:missense:MODERATE:exon8/19:c.178G>A:p.Val60Met,RARS2:NR_134857.1:non_coding_transcript_exon:MODIFIER:exon9/20:n.778G>A:		rs35862137	0.0206	0.0321	89/52/1	0.0322	-1.0730	T	T	B	T	0.55	611524 [RARS2 (confirmed) Pontocerebellar hypoplasia,type 6,611523];	RCV000118126.2 [benign]; RCV000279986.1 [likely benign]; 			4	153					RARS2 (inh=AR pLI=0.00)
chr6	89883013	89883013	A	T	het	het	hom		QUAL=9035;DP=161,91,178;MQM=60	PM20D2-GABRR1	intergenic_region	PM20D2-GABRR1:PM20D2-GABRR1:intergenic_region:MODIFIER::n.89883013A>T:		rs9353650	0.1625	0.0000	0/0/0	0.1823											10	55					PM20D2-GABRR1 (inh=n/a pLI=n/a)
chr6	97337537	97337537	C	T	hom	het	het		QUAL=24361;DP=446,322,432;MQM=59	NDUFAF4	3'UTR	NDUFAF4:NM_014165.3:3'UTR:MODIFIER:exon3/3:c.*1443G>A:		rs7758762	0.2748	0.0000	0/0/0	0.2540							611776 [NDUFAF4 (confirmed) Mitochondrial complex I deficiency,252010];	RCV000262685.1 [likely benign]; 			22	79					NDUFAF4 (inh=n/a pLI=0.38)
chr6	97338598	97338598	A	T	hom	hom	hom		QUAL=38394;DP=460,308,426;MQM=59	NDUFAF4	3'UTR	NDUFAF4:NM_014165.3:3'UTR:MODIFIER:exon3/3:c.*382T>A:		rs1971475	0.9341	0.0000	0/0/0	0.8211							611776 [NDUFAF4 (confirmed) Mitochondrial complex I deficiency,252010];	RCV000299285.1 [benign]; 			177	51					NDUFAF4 (inh=n/a pLI=0.38)
chr6	97338648	97338648	T	A	wt	het	wt		QUAL=2848;DP=304,239,342;MQM=60	NDUFAF4	3'UTR	NDUFAF4:NM_014165.3:3'UTR:MODIFIER:exon3/3:c.*332A>T:		rs10499008	0.2913	0.0000	0/0/0	0.2883							611776 [NDUFAF4 (confirmed) Mitochondrial complex I deficiency,252010];	RCV000273464.1 [likely benign]; 			21	92					NDUFAF4 (inh=n/a pLI=0.38)
chr6	97338679	97338679	A	T	hom	het	het		QUAL=17675;DP=330,198,281;MQM=60	NDUFAF4	3'UTR	NDUFAF4:NM_014165.3:3'UTR:MODIFIER:exon3/3:c.*301T>A:		rs1854268	0.2750	0.0000	0/0/0	0.0429							611776 [NDUFAF4 (confirmed) Mitochondrial complex I deficiency,252010];	RCV000369579.1 [likely benign]; 			22	79					NDUFAF4 (inh=n/a pLI=0.38)
chr6	97339078	97339078	A	G	hom	het	hom		QUAL=13233;DP=244,99,109;MQM=60	NDUFAF4	synonymous	NDUFAF4:NM_014165.3:synonymous:LOW:exon3/3:c.430T>C:p.Leu144Leu		rs6684	0.5150	0.5178	16639/8429/792	0.5066							611776 [NDUFAF4 (confirmed) Mitochondrial complex I deficiency,252010];	RCV000117707.2 [likely benign]; RCV000271558.1 [likely benign]; 		COSM3762230	403	784					NDUFAF4 (inh=n/a pLI=0.38)
chr6	97339088	97339088	C	T	hom	hom	hom		QUAL=15509;DP=248,101,114;MQM=60	NDUFAF4	synonymous	NDUFAF4:NM_014165.3:synonymous:LOW:exon3/3:c.420G>A:p.Gln140Gln		rs11402	0.9339	0.8944	48572/24796/4675	0.8621							611776 [NDUFAF4 (confirmed) Mitochondrial complex I deficiency,252010];	RCV000117706.2 [likely benign]; RCV000328919.1 [benign]; 			1184	358					NDUFAF4 (inh=n/a pLI=0.38)
chr6	97339275	97339275	-	A	hom	hom	hom		QUAL=4493;DP=119,52,52;MQM=59	NDUFAF4	splice_region&intron	NDUFAF4:NM_014165.3:splice_region&intron:LOW:exon2/2:c.241-9dupT:		rs34213186;rs397799265	0.6701	0.6070	10741/5817/962	0.0946							611776 [NDUFAF4 (confirmed) Mitochondrial complex I deficiency,252010];	RCV000376533.1 [likely benign]; 			629	849					NDUFAF4 (inh=n/a pLI=0.38)
chr6	100837889	100837889	T	A	het	het	het		QUAL=14543;DP=413,267,352;MQM=60	SIM1	3'UTR	SIM1:NM_005068.2:3'UTR:MODIFIER:exon11/11:c.*348A>T:		rs1395119	0.3988	0.0000	0/0/0	0.0683							603128 [SIM1 (confirmed) Obesity,severe,601665];	RCV000265406.1 [benign]; 			37	111					SIM1 (inh=n/a pLI=1.00)
chr6	100838124	100838124	T	A	wt	wt	het		QUAL=1808;DP=315,133,144;MQM=60	SIM1	3'UTR	SIM1:NM_005068.2:3'UTR:MODIFIER:exon11/11:c.*113A>T:		rs41318039	0.0122	0.0000	0/0/0	0.0063							603128 [SIM1 (confirmed) Obesity,severe,601665];	RCV000384192.1 [likely benign]; 			0	24					SIM1 (inh=n/a pLI=1.00)
chr6	100964147	100964147	G	C	wt	het	wt	pred_pathogenic	QUAL=2019;DP=383,166,210;MQM=60	ASCC3	missense	ASCC3:NM_006828.3:missense:MODERATE:exon39/42:c.5984C>G:p.Ser1995Cys		rs240780	0.7678	0.6592	27090/11759/4148	0.6485	3.0290	T	T	B	T	19.95			CM064987 [CLASS=DP MUT=REF PHEN="Colorectal cancer increased risk association with" GENE=ASCC3]; 	COSM1132075	630	710					ASCC3 (inh=n/a pLI=0.00)
chr6	100988267	100988267	A	-	het	wt	wt	low_QUAL	QUAL=9;DP=188,67,105;MQM=59	ASCC3	splice_region&intron	ASCC3:NM_006828.3:splice_region&intron:LOW:exon36/41:c.5551-4delT:		rs760353390	0.0000	0.4182	13/1/12	0.0028										COSM1620704	1	70					ASCC3 (inh=n/a pLI=0.00)
chr6	101094554	101094554	A	G	hom	het	hom		QUAL=19828;DP=309,209,210;MQM=60	ASCC3	synonymous	ASCC3:NM_006828.3:synonymous:LOW:exon22/42:c.3570T>C:p.Pro1190Pro		rs239239	0.5713	0.5419	18410/9136/1860	0.5409										COSM3761400	451	752					ASCC3 (inh=n/a pLI=0.00)
chr6	101166095	101166095	G	A	wt	het	wt		QUAL=2518;DP=305,178,269;MQM=60	ASCC3	synonymous	ASCC3:NM_006828.3:synonymous:LOW:exon12/42:c.1935C>T:p.Leu645Leu,ASCC3:NM_001284271.1:synonymous:LOW:exon12/13:c.1935C>T:p.Leu645Leu		rs41288423	0.4587	0.4817	14677/8426/1096	0.4731										COSM150147	451	870					ASCC3 (inh=n/a pLI=0.00)
chr6	101215224	101215224	A	-	hom	hom	hom		QUAL=12587;DP=196,117,131;MQM=59	ASCC3	splice_region&intron	ASCC3:NM_006828.3:splice_region&intron:LOW:exon8/41:c.1396-3delT:,ASCC3:NM_001284271.1:splice_region&intron:LOW:exon8/12:c.1396-3delT:		rs397888735	0.9696	0.9895	58759/32771/4206	0.8873											1550	24					ASCC3 (inh=n/a pLI=0.00)
chr6	101248173	101248173	T	C	wt	wt	het		QUAL=1051;DP=78,70,74;MQM=60	ASCC3	splice_region&intron	ASCC3:NM_006828.3:splice_region&intron:LOW:exon6/41:c.1127+3A>G:,ASCC3:NM_001284271.1:splice_region&intron:LOW:exon6/12:c.1127+3A>G:		rs41288435	0.0423	0.0937	779/727/2	0.0953											17	307					ASCC3 (inh=n/a pLI=0.00)
chr6	101296389	101296389	G	A	het	wt	hom	pred_pathogenic	QUAL=12038;DP=424,170,188;MQM=60	ASCC3	missense	ASCC3:NM_006828.3:missense:MODERATE:exon4/42:c.436C>T:p.Leu146Phe,ASCC3:NM_001284271.1:missense:MODERATE:exon4/13:c.436C>T:p.Leu146Phe		rs9390698	0.2454	0.3651	8953/6620/77	0.3678	2.5230	T,T,T	T	B,B,B	T,T,T	13.00				COSM150148	267	737					ASCC3 (inh=n/a pLI=0.00)
chr6	101304332	101304332	T	C	het	wt	het		QUAL=6830;DP=286,120,201;MQM=60	ASCC3	3'UTR,intron	ASCC3:NM_022091.4:3'UTR:MODIFIER:exon4/4:c.*2652A>G:,ASCC3:NM_006828.3:intron:MODIFIER:exon3/41:c.241+7608A>G:,ASCC3:NM_001284271.1:intron:MODIFIER:exon3/12:c.241+7608A>G:		rs78942177	0.0395	0.0000	0/0/0	0.0096											0	27					ASCC3 (inh=n/a pLI=0.00)
chr6	101304411	101304411	A	C	wt	wt	het		QUAL=1844;DP=317,115,140;MQM=60	ASCC3	3'UTR,intron	ASCC3:NM_022091.4:3'UTR:MODIFIER:exon4/4:c.*2573T>G:,ASCC3:NM_006828.3:intron:MODIFIER:exon3/41:c.241+7529T>G:,ASCC3:NM_001284271.1:intron:MODIFIER:exon3/12:c.241+7529T>G:	L1ME3	rs9386259	0.2642	0.0000	0/0/0	0.0434											15	69					ASCC3 (inh=n/a pLI=0.00)
chr6	101304644	101304644	C	T	het	wt	het		QUAL=7234;DP=336,173,205;MQM=60	ASCC3	3'UTR,intron	ASCC3:NM_022091.4:3'UTR:MODIFIER:exon4/4:c.*2340G>A:,ASCC3:NM_006828.3:intron:MODIFIER:exon3/41:c.241+7296G>A:,ASCC3:NM_001284271.1:intron:MODIFIER:exon3/12:c.241+7296G>A:	L1ME3	rs80004866	0.0058	0.0000	0/0/0	0.0019											0	3					ASCC3 (inh=n/a pLI=0.00)
chr6	101304829	101304829	C	T	het	wt	hom		QUAL=9062;DP=319,146,171;MQM=60	ASCC3	3'UTR,intron	ASCC3:NM_022091.4:3'UTR:MODIFIER:exon4/4:c.*2155G>A:,ASCC3:NM_006828.3:intron:MODIFIER:exon3/41:c.241+7111G>A:,ASCC3:NM_001284271.1:intron:MODIFIER:exon3/12:c.241+7111G>A:	L1ME3	rs705599	0.6667	0.0000	0/0/0	0.1198											82	62					ASCC3 (inh=n/a pLI=0.00)
chr6	101304889	101304889	G	C	wt	wt	het		QUAL=3294;DP=360,201,235;MQM=60	ASCC3	3'UTR,intron	ASCC3:NM_022091.4:3'UTR:MODIFIER:exon4/4:c.*2095C>G:,ASCC3:NM_006828.3:intron:MODIFIER:exon3/41:c.241+7051C>G:,ASCC3:NM_001284271.1:intron:MODIFIER:exon3/12:c.241+7051C>G:	L1ME3	rs9377237	0.3019	0.0000	0/0/0	0.0471											11	55					ASCC3 (inh=n/a pLI=0.00)
chr6	101305757	101305757	-	AC	wt	wt	hom		QUAL=2647;DP=199,123,158;MQM=59	ASCC3	3'UTR,intron	ASCC3:NM_022091.4:3'UTR:MODIFIER:exon4/4:c.*1225_*1226dupGT:,ASCC3:NM_006828.3:intron:MODIFIER:exon3/41:c.241+6181_241+6182dupGT:,ASCC3:NM_001284271.1:intron:MODIFIER:exon3/12:c.241+6181_241+6182dupGT:	(CA)n	rs34597123;rs398110480	0.0000	0.0000	0/0/0	0.1431											2	93					ASCC3 (inh=n/a pLI=0.00)
chr6	101305983	101305983	A	T	hom	hom	hom	low_DP	QUAL=5702;DP=141,8,18;MQM=60	ASCC3	3'UTR,intron	ASCC3:NM_022091.4:3'UTR:MODIFIER:exon4/4:c.*1001T>A:,ASCC3:NM_006828.3:intron:MODIFIER:exon3/41:c.241+5957T>A:,ASCC3:NM_001284271.1:intron:MODIFIER:exon3/12:c.241+5957T>A:	L1ME3	rs846793	0.9471	0.0000	0/0/0	0.1461											140	20					ASCC3 (inh=n/a pLI=0.00)
chr6	101306006	101306010	TAAAT	-	het	wt	het	low_DP	QUAL=1568;DP=124,8,17;MQM=60	ASCC3	3'UTR,intron	ASCC3:NM_022091.4:3'UTR:MODIFIER:exon4/4:c.*974_*978delATTTA:,ASCC3:NM_006828.3:intron:MODIFIER:exon3/41:c.241+5930_241+5934delATTTA:,ASCC3:NM_001284271.1:intron:MODIFIER:exon3/12:c.241+5930_241+5934delATTTA:	L1ME3	rs67936868	0.1601	0.0000	0/0/0	0.2060											10	64					ASCC3 (inh=n/a pLI=0.00)
chr6	101312097	101312097	C	T	hom	hom	hom		QUAL=12444;DP=164,82,136;MQM=60	ASCC3	splice_region&intron	ASCC3:NM_006828.3:splice_region&intron:LOW:exon2/41:c.91-7G>A:,ASCC3:NM_001284271.1:splice_region&intron:LOW:exon2/12:c.91-7G>A:,ASCC3:NM_022091.4:splice_region&intron:LOW:exon2/3:c.91-7G>A:		rs846791	0.9800	0.9605	55882/30230/5020	0.9015											1427	132					ASCC3 (inh=n/a pLI=0.00)
chr6	101329173	101329173	A	C	het	wt	hom		QUAL=22120;DP=184,502,659;MQM=59	ASCC3	5'UTR_premature_start_codon_gain,5'UTR	ASCC3:NM_006828.3:5'UTR_premature_start_codon_gain:LOW:exon1/42:c.-278T>G:,ASCC3:NM_001284271.1:5'UTR_premature_start_codon_gain:LOW:exon1/13:c.-278T>G:,ASCC3:NM_022091.4:5'UTR_premature_start_codon_gain:LOW:exon1/4:c.-278T>G:,ASCC3:NM_006828.3:5'UTR:MODIFIER:exon1/42:c.-278T>G:,ASCC3:NM_001284271.1:5'UTR:MODIFIER:exon1/13:c.-278T>G:,ASCC3:NM_022091.4:5'UTR:MODIFIER:exon1/4:c.-278T>G:	(CAGA)n	rs12530388	0.5194	0.0000	0/0/0	0.4806											63	110					ASCC3 (inh=n/a pLI=0.00)
chr6	102247673	102247673	T	C	wt	het	wt		QUAL=1985;DP=147,161,205;MQM=60	GRIK2	splice_region&intron	GRIK2:NM_021956.4:splice_region&intron:LOW:exon7/15:c.1095+7T>C:,GRIK2:NM_001166247.1:splice_region&intron:LOW:exon7/16:c.1095+7T>C:,GRIK2:NM_175768.3:splice_region&intron:LOW:exon7/16:c.1095+7T>C:		rs6922753	0.4151	0.2537	5449/710/998	0.2490							138244 [GRIK2 (confirmed) Mental retardation,autosomal recessive,6,611092];	RCV000117158.2 [likely benign]; 			59	419					GRIK2 (inh=AR pLI=0.99)
chr6	102376517	102376517	G	A	het	wt	het		QUAL=5101;DP=196,172,193;MQM=60	GRIK2	splice_region&intron	GRIK2:NM_021956.4:splice_region&intron:LOW:exon13/15:c.2085+10G>A:,GRIK2:NM_001166247.1:splice_region&intron:LOW:exon13/16:c.2085+10G>A:,GRIK2:NM_175768.3:splice_region&intron:LOW:exon13/16:c.2085+10G>A:		rs2243355	0.1705	0.2764	5091/3711/20	0.2652							138244 [GRIK2 (confirmed) Mental retardation,autosomal recessive,6,611092];	RCV000117160.2 [likely benign]; 			169	682					GRIK2 (inh=AR pLI=0.99)
chr6	102503196	102503196	C	T	wt	het	het	low_DP	QUAL=115;DP=39,5,13;MQM=60	GRIK2	splice_region&intron	GRIK2:NM_021956.4:splice_region&intron:LOW:exon14/15:c.2312-9C>T:,GRIK2:NM_001166247.1:splice_region&intron:LOW:exon14/16:c.2312-9C>T:,GRIK2:NM_175768.3:splice_region&intron:LOW:exon14/16:c.2312-9C>T:		rs2227281	0.2738	0.3058	5788/3519/295	0.3048							138244 [GRIK2 (confirmed) Mental retardation,autosomal recessive,6,611092];	RCV000117163.2 [likely benign]; 			146	653					GRIK2 (inh=AR pLI=0.99)
chr6	102503317	102503317	G	A	het	hom	het	low_DP	QUAL=1679;DP=53,17,34;MQM=60	GRIK2	synonymous	GRIK2:NM_021956.4:synonymous:LOW:exon15/16:c.2424G>A:p.Glu808Glu,GRIK2:NM_001166247.1:synonymous:LOW:exon15/17:c.2424G>A:p.Glu808Glu,GRIK2:NM_175768.3:synonymous:LOW:exon15/17:c.2424G>A:p.Glu808Glu		rs2227283	0.3275	0.3913	9631/6345/417	0.3868							138244 [GRIK2 (confirmed) Mental retardation,autosomal recessive,6,611092];	RCV000117164.2 [likely benign]; 		COSM3761402, COSM3761401, COSM3761403	257	779					GRIK2 (inh=AR pLI=0.99)
chr6	107475278	107475278	-	A	het	het	wt		QUAL=2037;DP=204,97,132;MQM=59	PDSS2	3'UTR	PDSS2:NM_020381.3:3'UTR:MODIFIER:exon8/8:c.*544dupT:	AluSq2	rs35619837;rs397807908	0.1815	0.0000	0/0/0	0.1710							610564 [PDSS2 (confirmed) Coenzyme Q10 deficiency,primary,3,614652];	RCV000286678.1 [likely benign]; 			6	101					PDSS2 (inh=AR pLI=0.00)
chr6	107475512	107475512	C	T	het	wt	het		QUAL=6426;DP=220,204,269;MQM=60	PDSS2	3'UTR	PDSS2:NM_020381.3:3'UTR:MODIFIER:exon8/8:c.*311G>A:		rs41292442	0.0333	0.0000	0/0/0	0.0095							610564 [PDSS2 (confirmed) Coenzyme Q10 deficiency,primary,3,614652];	RCV000390812.1 [uncertain significance]; 			0	34					PDSS2 (inh=AR pLI=0.00)
chr6	108363645	108363645	G	C	het	wt	het		QUAL=1821;DP=83,30,39;MQM=58	OSTM1	3'UTR	OSTM1:NM_014028.3:3'UTR:MODIFIER:exon6/6:c.*2344C>G:	AluJb	rs113263335	0.1392	0.0000	0/0/0	0.0569							607649 [OSTM1 (provisional) Osteopetrosis,autosomal recessive 5,259720];	RCV000316918.1 [benign]; 			1	15					OSTM1 (inh=AR pLI=0.06)
chr6	108363660	108363660	C	A	het	wt	het		QUAL=1748;DP=79,37,52;MQM=59	OSTM1	3'UTR	OSTM1:NM_014028.3:3'UTR:MODIFIER:exon6/6:c.*2329G>T:	AluJb	rs112792700	0.1392	0.0000	0/0/0	0.0671							607649 [OSTM1 (provisional) Osteopetrosis,autosomal recessive 5,259720];	RCV000355405.1 [benign]; 			0	15					OSTM1 (inh=AR pLI=0.06)
chr6	108363688	108363688	T	C	het	wt	het		QUAL=2544;DP=117,47,63;MQM=59	OSTM1	3'UTR	OSTM1:NM_014028.3:3'UTR:MODIFIER:exon6/6:c.*2301A>G:	AluJb	rs9386700	0.3441	0.0000	0/0/0	0.2720							607649 [OSTM1 (provisional) Osteopetrosis,autosomal recessive 5,259720];	RCV000320564.1 [benign]; 			13	72					OSTM1 (inh=AR pLI=0.06)
chr6	108363706	108363706	A	G	het	wt	het		QUAL=2907;DP=142,53,66;MQM=59	OSTM1	3'UTR	OSTM1:NM_014028.3:3'UTR:MODIFIER:exon6/6:c.*2283T>C:	AluJb	rs112283202	0.1392	0.0000	0/0/0	0.0654							607649 [OSTM1 (provisional) Osteopetrosis,autosomal recessive 5,259720];	RCV000379201.1 [benign]; 			1	16					OSTM1 (inh=AR pLI=0.06)
chr6	108363936	108363936	G	A	het	wt	het		QUAL=10544;DP=459,232,280;MQM=60	OSTM1	3'UTR	OSTM1:NM_014028.3:3'UTR:MODIFIER:exon6/6:c.*2053C>T:		rs17069215	0.0757	0.0000	0/0/0	0.0106							607649 [OSTM1 (provisional) Osteopetrosis,autosomal recessive 5,259720];	RCV000290425.1 [likely benign]; 			0	26					OSTM1 (inh=AR pLI=0.06)
chr6	108364106	108364106	A	G	het	wt	het		QUAL=8915;DP=432,127,168;MQM=60	OSTM1	3'UTR	OSTM1:NM_014028.3:3'UTR:MODIFIER:exon6/6:c.*1883T>C:		rs7662	0.3441	0.0000	0/0/0	0.0525							607649 [OSTM1 (provisional) Osteopetrosis,autosomal recessive 5,259720];	RCV000294002.1 [benign]; 			16	99					OSTM1 (inh=AR pLI=0.06)
chr6	108364548	108364548	T	-	het	wt	het		QUAL=7042;DP=313,184,286;MQM=59	OSTM1	3'UTR	OSTM1:NM_014028.3:3'UTR:MODIFIER:exon6/6:c.*1441delA:		rs140320992	0.1256	0.0000	0/0/0	0.0709							607649 [OSTM1 (provisional) Osteopetrosis,autosomal recessive 5,259720];	RCV000402959.1 [benign]; 			0	27					OSTM1 (inh=AR pLI=0.06)
chr6	108364637	108364637	T	C	het	wt	het		QUAL=6267;DP=318,79,125;MQM=60	OSTM1	3'UTR	OSTM1:NM_014028.3:3'UTR:MODIFIER:exon6/6:c.*1352A>G:		rs9372179	0.0757	0.0000	0/0/0	0.0106							607649 [OSTM1 (provisional) Osteopetrosis,autosomal recessive 5,259720];	RCV000360961.1 [likely benign]; 			0	26					OSTM1 (inh=AR pLI=0.06)
chr6	108364655	108364655	A	G	het	wt	het		QUAL=5211;DP=251,59,108;MQM=60	OSTM1	3'UTR	OSTM1:NM_014028.3:3'UTR:MODIFIER:exon6/6:c.*1334T>C:		rs9374008	0.0757	0.0000	0/0/0	0.0106							607649 [OSTM1 (provisional) Osteopetrosis,autosomal recessive 5,259720];	RCV000268721.1 [likely benign]; 			0	26					OSTM1 (inh=AR pLI=0.06)
chr6	108365658	108365658	T	C	het	wt	het		QUAL=2929;DP=144,50,55;MQM=60	OSTM1	3'UTR	OSTM1:NM_014028.3:3'UTR:MODIFIER:exon6/6:c.*331A>G:		rs9320250	0.4764	0.0000	0/0/0	0.0649							607649 [OSTM1 (provisional) Osteopetrosis,autosomal recessive 5,259720];	RCV000391311.1 [benign]; 			21	102					OSTM1 (inh=AR pLI=0.06)
chr6	110106234	110106234	A	G	hom	hom	hom		QUAL=21830;DP=318,133,230;MQM=60	FIG4	splice_region&intron	FIG4:NM_014845.5:splice_region&intron:LOW:exon17/22:c.1948+3A>G:		rs10499054	0.3588	0.5265	18582/14556/244	0.5282							609390 [FIG4 (provisional) Charcot-Marie-Tooth disease,type 4J,611228|Amyotrophic lateral sclerosis 11,612577|Yunis-Varon syndrome,216340|Polymicrogyria,bilateral temporooccipital,612691];	RCV000244780.2 [benign]; RCV000287031.1 [benign]; RCV000321790.1 [benign]; 			833	969					FIG4 (inh=AR+AD pLI=0.00)
chr6	110146303	110146303	G	A	hom	hom	het		QUAL=20286;DP=276,226,332;MQM=60	FIG4	synonymous	FIG4:NM_014845.5:synonymous:LOW:exon23/23:c.2559G>A:p.Ser853Ser		rs1127771	0.3958	0.4289	11975/5732/114	0.4259							609390 [FIG4 (provisional) Charcot-Marie-Tooth disease,type 4J,611228|Amyotrophic lateral sclerosis 11,612577|Yunis-Varon syndrome,216340|Polymicrogyria,bilateral temporooccipital,612691];	RCV000245906.1 [benign]; RCV000321034.1 [benign]; RCV000375677.1 [benign]; 			438	1037					FIG4 (inh=AR+AD pLI=0.00)
chr6	110146588	110146588	C	T	hom	hom	het		QUAL=22876;DP=275,297,385;MQM=59	FIG4	3'UTR	FIG4:NM_014845.5:3'UTR:MODIFIER:exon23/23:c.*120C>T:		rs1127775	0.4483	0.0000	0/0/0	0.0898							609390 [FIG4 (provisional) Charcot-Marie-Tooth disease,type 4J,611228|Amyotrophic lateral sclerosis 11,612577|Yunis-Varon syndrome,216340|Polymicrogyria,bilateral temporooccipital,612691];	RCV000308451.1 [benign]; RCV000400280.1 [benign]; 			49	114					FIG4 (inh=AR+AD pLI=0.00)
chr6	110931764	110931764	G	A	wt	het	wt		QUAL=683;DP=303,56,81;MQM=60	CDK19	3'UTR	CDK19:NM_015076.4:3'UTR:MODIFIER:exon13/13:c.*3974C>T:,CDK19:NM_001300960.1:3'UTR:MODIFIER:exon12/12:c.*3974C>T:,CDK19:NM_001300963.1:3'UTR:MODIFIER:exon14/14:c.*3974C>T:,CDK19:NM_001300964.1:3'UTR:MODIFIER:exon13/13:c.*3974C>T:		rs13220055	0.0881	0.0000	0/0/0	0.0187											8	48					CDK19 (inh=n/a pLI=1.00)
chr6	110932032	110932032	T	C	wt	het	wt		QUAL=3146;DP=455,255,389;MQM=60	CDK19	3'UTR	CDK19:NM_015076.4:3'UTR:MODIFIER:exon13/13:c.*3706A>G:,CDK19:NM_001300960.1:3'UTR:MODIFIER:exon12/12:c.*3706A>G:,CDK19:NM_001300963.1:3'UTR:MODIFIER:exon14/14:c.*3706A>G:,CDK19:NM_001300964.1:3'UTR:MODIFIER:exon13/13:c.*3706A>G:		rs1543991	0.3225	0.0000	0/0/0	0.0483											17	83					CDK19 (inh=n/a pLI=1.00)
chr6	110932865	110932865	C	T	wt	het	het		QUAL=4948;DP=254,157,221;MQM=59	CDK19	3'UTR	CDK19:NM_015076.4:3'UTR:MODIFIER:exon13/13:c.*2873G>A:,CDK19:NM_001300960.1:3'UTR:MODIFIER:exon12/12:c.*2873G>A:,CDK19:NM_001300963.1:3'UTR:MODIFIER:exon14/14:c.*2873G>A:,CDK19:NM_001300964.1:3'UTR:MODIFIER:exon13/13:c.*2873G>A:	AluSx	rs2817802	0.5703	0.0000	0/0/0	0.4406											43	108					CDK19 (inh=n/a pLI=1.00)
chr6	110933257	110933257	G	A	wt	het	wt		QUAL=3484;DP=600,330,431;MQM=60	CDK19	3'UTR	CDK19:NM_015076.4:3'UTR:MODIFIER:exon13/13:c.*2481C>T:,CDK19:NM_001300960.1:3'UTR:MODIFIER:exon12/12:c.*2481C>T:,CDK19:NM_001300963.1:3'UTR:MODIFIER:exon14/14:c.*2481C>T:,CDK19:NM_001300964.1:3'UTR:MODIFIER:exon13/13:c.*2481C>T:			0.0000	0.0000	0/0/0	0.0000											0	1					CDK19 (inh=n/a pLI=1.00)
chr6	110933901	110933901	C	T	wt	het	wt		QUAL=1436;DP=388,157,204;MQM=60	CDK19	3'UTR	CDK19:NM_015076.4:3'UTR:MODIFIER:exon13/13:c.*1837G>A:,CDK19:NM_001300960.1:3'UTR:MODIFIER:exon12/12:c.*1837G>A:,CDK19:NM_001300963.1:3'UTR:MODIFIER:exon14/14:c.*1837G>A:,CDK19:NM_001300964.1:3'UTR:MODIFIER:exon13/13:c.*1837G>A:		rs2691197	0.3071	0.0000	0/0/0	0.0476											17	82					CDK19 (inh=n/a pLI=1.00)
chr6	110934428	110934429	TT	-	wt	het	wt		QUAL=182;DP=174,43,58;MQM=60	CDK19	3'UTR	CDK19:NM_015076.4:3'UTR:MODIFIER:exon13/13:c.*1309_*1310delAA:,CDK19:NM_001300960.1:3'UTR:MODIFIER:exon12/12:c.*1309_*1310delAA:,CDK19:NM_001300963.1:3'UTR:MODIFIER:exon14/14:c.*1309_*1310delAA:,CDK19:NM_001300964.1:3'UTR:MODIFIER:exon13/13:c.*1309_*1310delAA:		rs5879077	0.0000	0.0000	0/0/0	0.1917											17	82					CDK19 (inh=n/a pLI=1.00)
chr6	116597644	116597644	G	C	wt	wt	het		QUAL=2476;DP=509,174,156;MQM=60	TSPYL1,DSE	3'UTR,intron	TSPYL1:NM_003309.3:3'UTR:MODIFIER:exon1/1:c.*2036C>G:,DSE:NM_001322937.1:intron:MODIFIER:exon2/6:c.-54+17514G>C:,DSE:NM_001322938.1:intron:MODIFIER:exon2/6:c.-54+17514G>C:,DSE:NM_001322940.1:intron:MODIFIER:exon2/6:c.-611+17514G>C:		rs183668323	0.0016	0.0000	0/0/0	0.0015							605942 [DSE (provisional) Ehlers-Danlos syndrome,musculocontractural type 2,615539]:604714 [TSPYL1 (confirmed) Sudden infant death with dysgenesis of the testes syndrome,608800];				0	2					TSPYL1 (inh=AR pLI=0.01), DSE (inh=AR pLI=0.39)
chr6	116597724	116597724	C	G	wt	het	wt		QUAL=1640;DP=351,134,113;MQM=60	TSPYL1,DSE	3'UTR,intron	TSPYL1:NM_003309.3:3'UTR:MODIFIER:exon1/1:c.*1956G>C:,DSE:NM_001322937.1:intron:MODIFIER:exon2/6:c.-54+17594C>G:,DSE:NM_001322938.1:intron:MODIFIER:exon2/6:c.-54+17594C>G:,DSE:NM_001322940.1:intron:MODIFIER:exon2/6:c.-611+17594C>G:		rs10484838	0.7019	0.0000	0/0/0	0.5317							605942 [DSE (provisional) Ehlers-Danlos syndrome,musculocontractural type 2,615539]:604714 [TSPYL1 (confirmed) Sudden infant death with dysgenesis of the testes syndrome,608800];				38	84					TSPYL1 (inh=AR pLI=0.01), DSE (inh=AR pLI=0.39)
chr6	116598853	116598853	A	G	wt	het	wt		QUAL=1958;DP=257,156,225;MQM=59	TSPYL1,DSE	3'UTR,intron	TSPYL1:NM_003309.3:3'UTR:MODIFIER:exon1/1:c.*827T>C:,DSE:NM_001322937.1:intron:MODIFIER:exon2/6:c.-54+18723A>G:,DSE:NM_001322938.1:intron:MODIFIER:exon2/6:c.-54+18723A>G:,DSE:NM_001322940.1:intron:MODIFIER:exon2/6:c.-611+18723A>G:	AluSg	rs1128261	0.7428	0.0000	0/0/0	0.0925							605942 [DSE (provisional) Ehlers-Danlos syndrome,musculocontractural type 2,615539]:604714 [TSPYL1 (confirmed) Sudden infant death with dysgenesis of the testes syndrome,608800];				55	116					TSPYL1 (inh=AR pLI=0.01), DSE (inh=AR pLI=0.39)
chr6	116600465	116600465	-	CAC	wt	het	wt		QUAL=2583;DP=288,268,382;MQM=59	TSPYL1,DSE	conservative_inframe_insertion,intron	TSPYL1:NM_003309.3:conservative_inframe_insertion:MODERATE:exon1/1:c.526_528dupGTG:p.Val176dup,DSE:NM_001322937.1:intron:MODIFIER:exon2/6:c.-54+20340_-54+20342dupACC:,DSE:NM_001322938.1:intron:MODIFIER:exon2/6:c.-54+20340_-54+20342dupACC:,DSE:NM_001322940.1:intron:MODIFIER:exon2/6:c.-611+20340_-611+20342dupACC:		rs397735194;rs56100880	0.8722	0.7628	36430/14430/4407	0.7106							605942 [DSE (provisional) Ehlers-Danlos syndrome,musculocontractural type 2,615539]:604714 [TSPYL1 (confirmed) Sudden infant death with dysgenesis of the testes syndrome,608800];			COSM112143	763	677					TSPYL1 (inh=AR pLI=0.01), DSE (inh=AR pLI=0.39)
chr6	129371106	129371106	C	T	wt	het	wt		QUAL=3306;DP=189,263,322;MQM=60	LAMA2	synonymous	LAMA2:NM_000426.3:synonymous:LOW:exon2/65:c.156C>T:p.Ile52Ile,LAMA2:NM_001079823.1:synonymous:LOW:exon2/64:c.156C>T:p.Ile52Ile		rs1140366	0.0707	0.0996	706/510/2	0.0999							156225 [LAMA2 (confirmed) Muscular dystrophy,congenital merosin-deficient,607855|Muscular dystrophy,congenital,due to partial LAMA2 deficiency,607855];	RCV000078746.6 [benign]; RCV000332492.1 [likely benign]; 			25	321					LAMA2 (inh=AR pLI=0.00)
chr6	129381026	129381026	C	A	hom	hom	hom		QUAL=20222;DP=223,194,219;MQM=60	LAMA2	synonymous	LAMA2:NM_000426.3:synonymous:LOW:exon3/65:c.381C>A:p.Thr127Thr,LAMA2:NM_001079823.1:synonymous:LOW:exon3/64:c.381C>A:p.Thr127Thr		rs4404787	0.9367	0.9578	55756/31416/4252	0.9363							156225 [LAMA2 (confirmed) Muscular dystrophy,congenital merosin-deficient,607855|Muscular dystrophy,congenital,due to partial LAMA2 deficiency,607855];	RCV000078766.6 [benign]; RCV000374091.1 [benign]; 			1528	96					LAMA2 (inh=AR pLI=0.00)
chr6	129571330	129571330	G	A	het	wt	het		QUAL=8124;DP=348,248,330;MQM=60	LAMA2	missense	LAMA2:NM_000426.3:missense:MODERATE:exon13/65:c.1856G>A:p.Arg619His,LAMA2:NM_001079823.1:missense:MODERATE:exon13/64:c.1856G>A:p.Arg619His		rs3816665	0.2710	0.1828	2946/585/1562	0.1772	-1.5750	T,T,T	T	B,B	T	0.77	156225 [LAMA2 (confirmed) Muscular dystrophy,congenital merosin-deficient,607855|Muscular dystrophy,congenital,due to partial LAMA2 deficiency,607855];	RCV000078752.7 [benign]; RCV000285061.1 [benign]; 			41	464					LAMA2 (inh=AR pLI=0.00)
chr6	129612808	129612808	A	G	het	wt	het		QUAL=7216;DP=285,131,199;MQM=60	LAMA2	synonymous	LAMA2:NM_000426.3:synonymous:LOW:exon20/65:c.2799A>G:p.Gln933Gln,LAMA2:NM_001079823.1:synonymous:LOW:exon20/64:c.2799A>G:p.Gln933Gln		rs1027199	0.3139	0.2683	4524/1657/543	0.2647							156225 [LAMA2 (confirmed) Muscular dystrophy,congenital merosin-deficient,607855|Muscular dystrophy,congenital,due to partial LAMA2 deficiency,607855];	RCV000078759.6 [benign]; RCV000315857.1 [benign]; 		COSM3761478	110	593					LAMA2 (inh=AR pLI=0.00)
chr6	129691132	129691132	C	G	hom	het	het		QUAL=14999;DP=303,189,258;MQM=60	LAMA2	synonymous	LAMA2:NM_000426.3:synonymous:LOW:exon34/65:c.4956C>G:p.Thr1652Thr,LAMA2:NM_001079823.1:synonymous:LOW:exon34/64:c.4956C>G:p.Thr1652Thr		rs17057184	0.0966	0.0857	614/154/69	0.0816							156225 [LAMA2 (confirmed) Muscular dystrophy,congenital merosin-deficient,607855|Muscular dystrophy,congenital,due to partial LAMA2 deficiency,607855];	RCV000078774.6 [benign]; RCV000264034.1 [likely benign]; 			21	241					LAMA2 (inh=AR pLI=0.00)
chr6	129722389	129722389	A	G	het	hom	wt		QUAL=14678;DP=322,328,431;MQM=59	LAMA2	synonymous	LAMA2:NM_000426.3:synonymous:LOW:exon38/65:c.5466A>G:p.Glu1822Glu,LAMA2:NM_001079823.1:synonymous:LOW:exon38/64:c.5466A>G:p.Glu1822Glu		rs3749877	0.5445	0.4978	15361/7378/2018	0.4910							156225 [LAMA2 (confirmed) Muscular dystrophy,congenital merosin-deficient,607855|Muscular dystrophy,congenital,due to partial LAMA2 deficiency,607855];	RCV000078777.6 [benign]; RCV000387332.1 [benign]; 			384	789					LAMA2 (inh=AR pLI=0.00)
chr6	129722425	129722425	G	A	het	hom	wt		QUAL=18733;DP=531,375,484;MQM=59	LAMA2	synonymous	LAMA2:NM_000426.3:synonymous:LOW:exon38/65:c.5502G>A:p.Glu1834Glu,LAMA2:NM_001079823.1:synonymous:LOW:exon38/64:c.5502G>A:p.Glu1834Glu		rs3749878	0.5433	0.4963	15250/7305/2017	0.4884							156225 [LAMA2 (confirmed) Muscular dystrophy,congenital merosin-deficient,607855|Muscular dystrophy,congenital,due to partial LAMA2 deficiency,607855];	RCV000078778.6 [benign]; RCV000338699.1 [benign]; 		COSM4160174	384	788					LAMA2 (inh=AR pLI=0.00)
chr6	129762112	129762112	G	A	het	wt	het		QUAL=7817;DP=289,284,321;MQM=59	LAMA2	synonymous	LAMA2:NM_000426.3:synonymous:LOW:exon43/65:c.6237G>A:p.Thr2079Thr,LAMA2:NM_001079823.1:synonymous:LOW:exon43/64:c.6237G>A:p.Thr2079Thr		rs2297738	0.1825	0.1683	1867/800/105	0.1662							156225 [LAMA2 (confirmed) Muscular dystrophy,congenital merosin-deficient,607855|Muscular dystrophy,congenital,due to partial LAMA2 deficiency,607855];	RCV000078786.7 [benign]; RCV000314145.1 [likely benign]; 		COSM3761479	50	438					LAMA2 (inh=AR pLI=0.00)
chr6	129807629	129807629	C	T	het	het	wt	pred_pathogenic	QUAL=3996;DP=202,143,199;MQM=60	LAMA2	missense	LAMA2:NM_000426.3:missense:MODERATE:exon56/65:c.7760C>T:p.Ala2587Val,LAMA2:NM_001079823.1:missense:MODERATE:exon55/64:c.7748C>T:p.Ala2583Val		rs2229848	0.5839	0.6678	27343/16984/1093	0.6645	4.4990	T,T,T,T	D	D,D	T	34.00	156225 [LAMA2 (confirmed) Muscular dystrophy,congenital merosin-deficient,607855|Muscular dystrophy,congenital,due to partial LAMA2 deficiency,607855];	RCV000153440.2 [benign]; 	CM023406 [CLASS=DP MUT=REF PHEN="Tuberculoid leprosy association with" GENE=LAMA2]; 	COSM1440401	795	667					LAMA2 (inh=AR pLI=0.00)
chr6	129807699	129807699	G	C	het	het	wt		QUAL=6298;DP=340,181,249;MQM=60	LAMA2	synonymous	LAMA2:NM_000426.3:synonymous:LOW:exon56/65:c.7830G>C:p.Val2610Val,LAMA2:NM_001079823.1:synonymous:LOW:exon55/64:c.7818G>C:p.Val2606Val		rs2229849	0.5843	0.6682	27409/17019/1102	0.6656							156225 [LAMA2 (confirmed) Muscular dystrophy,congenital merosin-deficient,607855|Muscular dystrophy,congenital,due to partial LAMA2 deficiency,607855];	RCV000078800.7 [benign]; RCV000262042.1 [benign]; 			795	669					LAMA2 (inh=AR pLI=0.00)
chr6	129807714	129807714	G	A	het	het	hom		QUAL=15812;DP=332,181,249;MQM=60	LAMA2	synonymous	LAMA2:NM_000426.3:synonymous:LOW:exon56/65:c.7845G>A:p.Pro2615Pro,LAMA2:NM_001079823.1:synonymous:LOW:exon55/64:c.7833G>A:p.Pro2611Pro		rs2229850	0.4038	0.3080	6146/2190/1514	0.3031							156225 [LAMA2 (confirmed) Muscular dystrophy,congenital merosin-deficient,607855|Muscular dystrophy,congenital,due to partial LAMA2 deficiency,607855];	RCV000078801.7 [benign]; RCV000300807.1 [benign]; 			135	630					LAMA2 (inh=AR pLI=0.00)
chr6	129813053	129813053	A	G	wt	wt	het	pred_pathogenic	QUAL=540;DP=83,47,49;MQM=60	LAMA2	missense	LAMA2:NM_000426.3:missense:MODERATE:exon57/65:c.7906A>G:p.Thr2636Ala,LAMA2:NM_001079823.1:missense:MODERATE:exon56/64:c.7894A>G:p.Thr2632Ala		rs2244008	0.1116	0.0925	544/184/63	0.0857	4.0110	D,D,D,T	T	B,B	T	17.27	156225 [LAMA2 (confirmed) Muscular dystrophy,congenital merosin-deficient,607855|Muscular dystrophy,congenital,due to partial LAMA2 deficiency,607855];	RCV000078802.7 [benign]; RCV000353465.1 [likely benign]; 		COSM150181	13	215					LAMA2 (inh=AR pLI=0.00)
chr6	129837681	129837683	AAT	-	hom	het	hom		QUAL=9285;DP=243,36,55;MQM=59	LAMA2	3'UTR	LAMA2:NM_000426.3:3'UTR:MODIFIER:exon65/65:c.*193_*195delATA:,LAMA2:NM_001079823.1:3'UTR:MODIFIER:exon64/64:c.*193_*195delATA:		rs371188338	0.7051	0.0000	0/0/0	0.7281							156225 [LAMA2 (confirmed) Muscular dystrophy,congenital merosin-deficient,607855|Muscular dystrophy,congenital,due to partial LAMA2 deficiency,607855];	RCV000358086.1 [benign]; 			147	76					LAMA2 (inh=AR pLI=0.00)
chr6	132212694	132212694	A	G	wt	wt	het		QUAL=3664;DP=345,267,315;MQM=60	ENPP1	3'UTR	ENPP1:NM_006208.2:3'UTR:MODIFIER:exon25/25:c.*1043A>G:		rs7754561	0.5547	0.0000	0/0/0	0.0657							173335 [ENPP1 (confirmed) Diabetes mellitus,non-insulin-dependent,susceptibility to,125853|Obesity,susceptibility to,601665|Arterial calcification,generalized,of infancy,1,208000|Hypophosphatemic rickets,autosomal recessive,2,613312|Cole disease,615522];	RCV000022719.3 [other]; RCV000280683.1 [benign]; RCV000372927.1 [benign]; 	CR052970 [CLASS=DP MUT=ALT PHEN="Obesity association with" GENE=ENPP1]; 		31	101					ENPP1 (inh=AR+AD pLI=0.00)
chr6	132212742	132212742	A	C	wt	wt	het		QUAL=2969;DP=340,239,281;MQM=60	ENPP1	3'UTR	ENPP1:NM_006208.2:3'UTR:MODIFIER:exon25/25:c.*1091A>C:		rs7754586	0.4127	0.0000	0/0/0	0.3140							173335 [ENPP1 (confirmed) Diabetes mellitus,non-insulin-dependent,susceptibility to,125853|Obesity,susceptibility to,601665|Arterial calcification,generalized,of infancy,1,208000|Hypophosphatemic rickets,autosomal recessive,2,613312|Cole disease,615522];	RCV000338108.1 [benign]; RCV000405247.1 [benign]; 			23	88					ENPP1 (inh=AR+AD pLI=0.00)
chr6	132212808	132212808	C	T	wt	wt	het		QUAL=1434;DP=256,119,150;MQM=60	ENPP1	3'UTR	ENPP1:NM_006208.2:3'UTR:MODIFIER:exon25/25:c.*1157C>T:		rs7754859	0.5537	0.0000	0/0/0	0.0653							173335 [ENPP1 (confirmed) Diabetes mellitus,non-insulin-dependent,susceptibility to,125853|Obesity,susceptibility to,601665|Arterial calcification,generalized,of infancy,1,208000|Hypophosphatemic rickets,autosomal recessive,2,613312|Cole disease,615522];	RCV000311650.1 [benign]; RCV000368934.1 [benign]; 			31	101					ENPP1 (inh=AR+AD pLI=0.00)
chr6	132212889	132212890	TT	-	hom	wt	wt	low_DP	QUAL=166;DP=42,12,17;MQM=60	ENPP1	3'UTR	ENPP1:NM_006208.2:3'UTR:MODIFIER:exon25/25:c.*1255_*1256delTT:		rs769107294	0.0000	0.0000	0/0/0	0.0368							173335 [ENPP1 (confirmed) Diabetes mellitus,non-insulin-dependent,susceptibility to,125853|Obesity,susceptibility to,601665|Arterial calcification,generalized,of infancy,1,208000|Hypophosphatemic rickets,autosomal recessive,2,613312|Cole disease,615522];				0	0					ENPP1 (inh=AR+AD pLI=0.00)
chr6	132213623	132213623	G	C	wt	wt	het		QUAL=4502;DP=365,286,381;MQM=60	ENPP1	3'UTR	ENPP1:NM_006208.2:3'UTR:MODIFIER:exon25/25:c.*1972G>C:	L1MDa	rs1931006	0.6476	0.0000	0/0/0	0.0845							173335 [ENPP1 (confirmed) Diabetes mellitus,non-insulin-dependent,susceptibility to,125853|Obesity,susceptibility to,601665|Arterial calcification,generalized,of infancy,1,208000|Hypophosphatemic rickets,autosomal recessive,2,613312|Cole disease,615522];	RCV000296172.1 [benign]; RCV000334744.1 [benign]; 			58	87					ENPP1 (inh=AR+AD pLI=0.00)
chr6	132215375	132215375	C	T	wt	wt	het		QUAL=2266;DP=177,82,169;MQM=60	ENPP1	3'UTR	ENPP1:NM_006208.2:3'UTR:MODIFIER:exon25/25:c.*3724C>T:	AluYm1	rs2327154	0.5675	0.0000	0/0/0	0.2649							173335 [ENPP1 (confirmed) Diabetes mellitus,non-insulin-dependent,susceptibility to,125853|Obesity,susceptibility to,601665|Arterial calcification,generalized,of infancy,1,208000|Hypophosphatemic rickets,autosomal recessive,2,613312|Cole disease,615522];	RCV000328720.1 [benign]; RCV000364825.1 [benign]; 			27	77					ENPP1 (inh=AR+AD pLI=0.00)
chr6	135715915	135715915	G	A	het	wt	wt	low_DP	QUAL=261;DP=23,2,12;MQM=60	AHI1	splice_region&synonymous	AHI1:NM_001134830.1:splice_region&synonymous:LOW:exon21/27:c.3108C>T:p.Thr1036Thr,AHI1:NM_001134831.1:splice_region&synonymous:LOW:exon23/29:c.3108C>T:p.Thr1036Thr,AHI1:NM_017651.4:splice_region&synonymous:LOW:exon22/28:c.3108C>T:p.Thr1036Thr,AHI1:NM_001134832.1:splice_region&synonymous:LOW:exon22/23:c.3108C>T:p.Thr1036Thr		rs761976492	0.0000	0.0001	0/0/0	0.0001	-3.5700		T			6.43	608894 [AHI1 (confirmed) Joubert syndrome-3,608629];				0	1					AHI1 (inh=AR pLI=0.00)
chr6	135818897	135818897	C	A	het	hom	het	low_DP	QUAL=4655;DP=10,113,163;MQM=59	AHI1	5'UTR	AHI1:NM_001134830.1:5'UTR:MODIFIER:exon1/27:c.-231G>T:,AHI1:NM_001134831.1:5'UTR:MODIFIER:exon1/29:c.-378G>T:,AHI1:NM_017651.4:5'UTR:MODIFIER:exon1/28:c.-293G>T:,AHI1:NM_001134832.1:5'UTR:MODIFIER:exon1/23:c.-293G>T:		rs13197384	0.3011	0.0000	5/2/0	0.0611							608894 [AHI1 (confirmed) Joubert syndrome-3,608629];	RCV000383693.1 [benign]; 			86	296					AHI1 (inh=AR pLI=0.00)
chr6	137166790	137166790	A	C	het	wt	het	pred_pathogenic	QUAL=8128;DP=364,203,268;MQM=60	PEX7	missense	PEX7:NM_000288.3:missense:MODERATE:exon4/10:c.377A>C:p.Gln126Pro		rs113268723	0.0014	0.0038	0/0/0	0.0036	5.5310	T,T	T	P	D,D	23.60	601757 [PEX7 (provisional) Rhizomelic chondrodysplasia punctata,type 1,215100|Peroxisome biogenesis disorder 9B,614879];	RCV000245920.2 [benign]; 			0	14	1	[1] ahdeinn1 10.03.2017 VUS1, NDE, 10.03.2017, da ExAc > 1% [3] Julia Bickmann 19.11.2014 			PEX7 (inh=AR pLI=0.00)
chr6	137234919	137234919	-	GTA	het	hom	wt		QUAL=6226;DP=277,93,110;MQM=59	PEX7	3'UTR	PEX7:NM_000288.3:3'UTR:MODIFIER:exon10/10:c.*257_*258insAGT:		rs141139220	0.5230	0.0000	0/0/0	0.4473							601757 [PEX7 (provisional) Rhizomelic chondrodysplasia punctata,type 1,215100|Peroxisome biogenesis disorder 9B,614879];	RCV000306073.1 [benign]; RCV000360761.1 [benign]; 			60	120					PEX7 (inh=AR pLI=0.00)
chr6	137234970	137234970	T	G	het	hom	wt		QUAL=3823;DP=186,56,61;MQM=60	PEX7	3'UTR	PEX7:NM_000288.3:3'UTR:MODIFIER:exon10/10:c.*306T>G:		rs1050803	0.5206	0.0000	0/0/0	0.0854							601757 [PEX7 (provisional) Rhizomelic chondrodysplasia punctata,type 1,215100|Peroxisome biogenesis disorder 9B,614879];	RCV000291136.1 [benign]; RCV000380781.1 [benign]; 			61	117					PEX7 (inh=AR pLI=0.00)
chr6	137540520	137540520	A	G	wt	het	wt		QUAL=742;DP=64,76,114;MQM=60	IFNGR1	5'UTR	IFNGR1:NM_000416.2:5'UTR:MODIFIER:exon1/7:c.-56T>C:		rs2234711	0.5024	0.0000	0/0/0	0.0749							107470 [IFNGR1 (confirmed) Immunodeficiency 27A,mycobacteriosis,AR,209950|H. pylori infection,susceptibility to,600263|Tuberculosis,susceptibility to,607948|Immunodeficiency 27B,mycobacteriosis,AD,615978|Tuberculosis infection,protection against,607948|Hepatitis B virus infection,susceptibility to,610424];	RCV000336756.1 [benign]; 	CR025333 [CLASS=DFP MUT=ALT PHEN="Malaria susceptibility association with" GENE=IFNGR1]; 		193	431					IFNGR1 (inh=AR+AD pLI=0.33)
chr6	143810682	143810682	A	T	het	hom	wt	low_DP	QUAL=129;DP=12,2,3;MQM=60	PEX3	3'UTR	PEX3:NM_003630.2:3'UTR:MODIFIER:exon12/12:c.*319A>T:	(AT)n	rs223234	0.7927	0.0000	0/0/0	0.1002							603164 [PEX3 (confirmed) Peroxisome biogenesis disorder 10A (Zellweger),614882];	RCV000380691.1 [benign]; 			102	49					PEX3 (inh=AR pLI=0.00)
chr6	143810909	143810909	A	G	het	het	wt	low_DP	QUAL=982;DP=62,15,18;MQM=59	PEX3	3'UTR	PEX3:NM_003630.2:3'UTR:MODIFIER:exon12/12:c.*546A>G:		rs10809	0.1290	0.0000	0/0/0	0.0295							603164 [PEX3 (confirmed) Peroxisome biogenesis disorder 10A (Zellweger),614882];	RCV000399211.1 [likely benign]; 			8	91					PEX3 (inh=AR pLI=0.00)
chr6	144509845	144509845	-	A	hom	hom	het	low_DP	QUAL=894;DP=36,12,22;MQM=59	STX11	3'UTR	STX11:NM_003764.3:3'UTR:MODIFIER:exon2/2:c.*1221dupA:		rs397725572	0.5583	0.0000	0/0/0	0.3712							605014 [STX11 (confirmed) Hemophagocytic lymphohistiocytosis,familial,4,603552];	RCV000287281.1 [other]; 			8	116					STX11 (inh=AR pLI=0.02)
chr6	144509855	144509855	C	T	het	wt	wt	low_DP;low_MQM	QUAL=36;DP=52,9,14;MQM=48	STX11	3'UTR	STX11:NM_003764.3:3'UTR:MODIFIER:exon2/2:c.*1227C>T:	AluSc8	rs148087652	0.0000	0.0000	0/0/0	0.0005							605014 [STX11 (confirmed) Hemophagocytic lymphohistiocytosis,familial,4,603552];				4	76					STX11 (inh=AR pLI=0.02)
chr6	144510421	144510421	A	C	het	het	het		QUAL=5810;DP=178,100,146;MQM=59	STX11	3'UTR	STX11:NM_003764.3:3'UTR:MODIFIER:exon2/2:c.*1793A>C:	AluJo	rs4896705	0.2730	0.0000	0/0/0	0.2854							605014 [STX11 (confirmed) Hemophagocytic lymphohistiocytosis,familial,4,603552];	RCV000266623.1 [benign]; 			26	91					STX11 (inh=AR pLI=0.02)
chr6	144510926	144510926	C	T	het	het	het		QUAL=8979;DP=352,179,189;MQM=60	STX11	3'UTR	STX11:NM_003764.3:3'UTR:MODIFIER:exon2/2:c.*2298C>T:		rs3734227	0.2670	0.0000	0/0/0	0.0524							605014 [STX11 (confirmed) Hemophagocytic lymphohistiocytosis,familial,4,603552];	RCV000375338.1 [likely benign]; 			23	107					STX11 (inh=AR pLI=0.02)
chr6	144512671	144512671	-	A	hom	hom	hom		QUAL=10671;DP=259,66,65;MQM=59	STX11	3'UTR	STX11:NM_003764.3:3'UTR:MODIFIER:exon2/2:c.*4054dupA:		rs11397393;rs397795966	0.9277	0.0000	0/0/0	0.6539							605014 [STX11 (confirmed) Hemophagocytic lymphohistiocytosis,familial,4,603552];	RCV000337242.1 [uncertain significance]; RCV000282258.1 [benign]; 			89	141					STX11 (inh=AR pLI=0.02)
chr6	145947080	145947080	C	T	hom	hom	hom		QUAL=29676;DP=388,205,308;MQM=60	EPM2A	3'UTR,intron	EPM2A:NM_005670.3:3'UTR:MODIFIER:exon4/4:c.*1472G>A:,EPM2A:NM_001018041.1:intron:MODIFIER:exon4/4:c.925-220G>A:	MIRb	rs1045820	0.4471	0.0000	0/0/0	0.4167							607566 [EPM2A (confirmed) Epilepsy,progressive myoclonic 2A (Lafora),254780]:608072 [EPM2A (confirmed) Epilepsy,progressive myoclonic 2B (Lafora),254780];				84	161					EPM2A (inh=AR pLI=0.00)
chr6	146056848	146056848	T	C	het	wt	hom	low_DP	QUAL=90;DP=5,205,2;MQM=60	EPM2A,LOC100507557	5'UTR_premature_start_codon_gain,5'UTR,intron	EPM2A:NM_005670.3:5'UTR_premature_start_codon_gain:LOW:exon1/4:c.-214A>G:,EPM2A:NM_001018041.1:5'UTR_premature_start_codon_gain:LOW:exon1/5:c.-214A>G:,EPM2A:NM_005670.3:5'UTR:MODIFIER:exon1/4:c.-214A>G:,EPM2A:NM_001018041.1:5'UTR:MODIFIER:exon1/5:c.-214A>G:,LOC100507557:NR_038246.1:intron:MODIFIER:exon1/2:n.52+792T>C:		rs2235481	0.7352	0.0000	0/0/0	0.1182							607566 [EPM2A (confirmed) Epilepsy,progressive myoclonic 2A (Lafora),254780]:608072 [EPM2A (confirmed) Epilepsy,progressive myoclonic 2B (Lafora),254780];				51	33					EPM2A (inh=AR pLI=0.00), LOC100507557 (inh=n/a pLI=n/a)
chr6	152442904	152442905	TT	-	wt	het	wt	low_QUAL;low_DP	QUAL=18;DP=43,5,5;MQM=60	SYNE1,ESR1	3'UTR,intron	SYNE1:NM_182961.3:3'UTR:MODIFIER:exon146/146:c.*666_*667delAA:,SYNE1:NM_033071.3:3'UTR:MODIFIER:exon146/146:c.*666_*667delAA:,ESR1:NM_001328100.1:intron:MODIFIER:exon6/6:c.851-3488_851-3487delTT:		rs71660056;rs869310488	0.1627	0.0000	0/0/0	0.0901							608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000311216.1 [benign]; RCV000368782.1 [benign]; 			7	38					SYNE1 (inh=AR+AD pLI=0.00), ESR1 (inh=AR pLI=0.99)
chr6	152443389	152443389	C	T	wt	wt	het		QUAL=5898;DP=305,308,467;MQM=60	SYNE1,ESR1	3'UTR,intron	SYNE1:NM_182961.3:3'UTR:MODIFIER:exon146/146:c.*182G>A:,SYNE1:NM_033071.3:3'UTR:MODIFIER:exon146/146:c.*182G>A:,ESR1:NM_001328100.1:intron:MODIFIER:exon6/6:c.851-3012C>T:		rs12681	0.1959	0.0000	0/0/0	0.0341							608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000299236.1 [benign]; RCV000400141.1 [benign]; 			14	71					SYNE1 (inh=AR+AD pLI=0.00), ESR1 (inh=AR pLI=0.99)
chr6	152443468	152443468	G	T	het	het	wt		QUAL=13547;DP=539,484,732;MQM=59	SYNE1,ESR1	3'UTR,intron	SYNE1:NM_182961.3:3'UTR:MODIFIER:exon146/146:c.*103C>A:,SYNE1:NM_033071.3:3'UTR:MODIFIER:exon146/146:c.*103C>A:,ESR1:NM_001328100.1:intron:MODIFIER:exon6/6:c.851-2933G>T:		rs2250122	0.2452	0.0000	0/0/0	0.0486							608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000259269.1 [benign]; RCV000356387.1 [benign]; 			13	86					SYNE1 (inh=AR+AD pLI=0.00), ESR1 (inh=AR pLI=0.99)
chr6	152453291	152453291	G	A	wt	wt	het	pred_pathogenic	QUAL=4002;DP=295,283,359;MQM=60	SYNE1	missense	SYNE1:NM_182961.3:missense:MODERATE:exon144/146:c.26060C>T:p.Thr8687Ile,SYNE1:NM_033071.3:missense:MODERATE:exon144/146:c.25916C>T:p.Thr8639Ile		rs35591210	0.0258	0.0513	203/176/2	0.0526	2.7960	T,D,T,D,T,T,T,T,.,D,D,D	T	B,B,B,B,B	T,T,T,T,T,T,T,T,T,T	14.97	608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000118473.3 [other]; RCV000278421.1 [benign]; RCV000338123.1 [benign]; 			13	393					SYNE1 (inh=AR+AD pLI=0.00)
chr6	152464839	152464839	A	G	het	hom	wt		QUAL=15246;DP=432,292,387;MQM=60	SYNE1	synonymous	SYNE1:NM_182961.3:synonymous:LOW:exon138/146:c.25038T>C:p.Arg8346Arg,SYNE1:NM_033071.3:synonymous:LOW:exon138/146:c.24894T>C:p.Arg8298Arg		rs2256135	0.6897	0.6109	23222/10072/3002	0.6054							608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000118470.3 [other]; RCV000313035.1 [benign]; RCV000367836.1 [benign]; 			941	1426					SYNE1 (inh=AR+AD pLI=0.00)
chr6	152466674	152466674	T	C	het	het	wt		QUAL=7249;DP=316,245,295;MQM=60	SYNE1	synonymous,intron	SYNE1:NM_033071.3:synonymous:LOW:exon137/146:c.24780A>G:p.Glu8260Glu,SYNE1:NM_182961.3:intron:MODIFIER:exon137/145:c.24977-1774A>G:		rs2747662	0.3662	0.3452	7689/3414/609	0.3417							608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000118469.2 [benign]; RCV000277927.1 [benign]; RCV000333086.1 [benign]; 		COSM3761563, COSM3761562	344	1328					SYNE1 (inh=AR+AD pLI=0.00)
chr6	152469188	152469188	C	G	het	het	wt	pred_pathogenic	QUAL=3713;DP=171,135,209;MQM=60	SYNE1	missense	SYNE1:NM_182961.3:missense:MODERATE:exon137/146:c.24968G>C:p.Gly8323Ala,SYNE1:NM_033071.3:missense:MODERATE:exon136/146:c.24755G>C:p.Gly8252Ala		rs2252755	0.3994	0.3592	8245/3497/1029	0.3546	2.6650	T,T,T,T,T,T,T,T,.,T,T,T	T	B,B,B,B,B	T,T,T,T,T,T,T,T,T,T	9.18	608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000118468.3 [other]; RCV000259202.1 [benign]; RCV000355142.1 [benign]; 			362	1338					SYNE1 (inh=AR+AD pLI=0.00)
chr6	152469204	152469204	G	A	het	het	wt	pred_pathogenic	QUAL=3829;DP=183,157,230;MQM=60	SYNE1	missense	SYNE1:NM_182961.3:missense:MODERATE:exon137/146:c.24952C>T:p.Leu8318Phe,SYNE1:NM_033071.3:missense:MODERATE:exon136/146:c.24739C>T:p.Leu8247Phe		rs141716975	0.0022	0.0053	2/2/0	0.0050	6.9680	D,D,D,T,D,T,D,D,.,T,T,T	T	B,B,P,B,B	T,T,T,T,T,T,T,T,T,T	22.00	608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000174640.2 [other]; RCV000266178.1 [likely benign]; RCV000321230.1 [likely benign]; 			1	40	2	VUS2, MR, 14.07.2016, ExAC >0,5% [3] Julia Bickmann 29.01.2015 [2] ahrautm1 14.07.2016			SYNE1 (inh=AR+AD pLI=0.00)
chr6	152469331	152469331	C	T	het	het	wt		QUAL=5708;DP=231,259,375;MQM=60	SYNE1	synonymous	SYNE1:NM_182961.3:synonymous:LOW:exon137/146:c.24825G>A:p.Pro8275Pro,SYNE1:NM_033071.3:synonymous:LOW:exon136/146:c.24612G>A:p.Pro8204Pro		rs2252748	0.3395	0.3130	6398/2580/499	0.3098							608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000118467.3 [other]; RCV000345658.1 [benign]; RCV000381473.1 [benign]; 		COSM3761568, COSM3761564, COSM3761567, COSM3761566, COSM3761565	277	1253	1	[1] old entry - no details available			SYNE1 (inh=AR+AD pLI=0.00)
chr6	152532702	152532702	T	C	het	wt	het	pred_pathogenic	QUAL=7134;DP=340,146,235;MQM=60	SYNE1,MIR3163	missense,intron	SYNE1:NM_182961.3:missense:MODERATE:exon124/146:c.22516A>G:p.Ser7506Gly,SYNE1:NM_033071.3:missense:MODERATE:exon123/146:c.22303A>G:p.Ser7435Gly,MIR3163:NR_036121.1.2:intron:MODIFIER:exon5/5:n.53-13545T>C:		rs35763277	0.0046	0.0137	24/22/0	0.0133	7.9410	T,T,T,T,T,T,T,T	T	D,D,D,D	T,T,T,T,T,T,T,T	27.90	608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000118462.2 [likely benign]; RCV000348766.1 [likely benign]; RCV000394571.1 [likely benign]; 			0	101					SYNE1 (inh=AR+AD pLI=0.00), MIR3163 (inh=n/a pLI=n/a)
chr6	152534768	152534768	C	T	het	wt	het		QUAL=7394;DP=293,213,275;MQM=60	SYNE1,MIR3163	synonymous,intron	SYNE1:NM_182961.3:synonymous:LOW:exon123/146:c.22473G>A:p.Leu7491Leu,SYNE1:NM_033071.3:synonymous:LOW:exon122/146:c.22260G>A:p.Leu7420Leu,MIR3163:NR_036121.1.2:intron:MODIFIER:exon5/5:n.53-11479C>T:		rs34891041	0.0206	0.0261	60/47/7	0.0246							608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000118461.3 [other]; RCV000298409.1 [likely benign]; RCV000394551.1 [likely benign]; 			4	162					SYNE1 (inh=AR+AD pLI=0.00), MIR3163 (inh=n/a pLI=n/a)
chr6	152540278	152540278	A	C	hom	hom	hom		QUAL=26106;DP=310,215,278;MQM=59	SYNE1,MIR3163	missense,intron	SYNE1:NM_182961.3:missense:MODERATE:exon120/146:c.21904T>G:p.Phe7302Val,SYNE1:NM_033071.3:missense:MODERATE:exon119/146:c.21691T>G:p.Phe7231Val,MIR3163:NR_036121.1.2:intron:MODIFIER:exon5/5:n.53-5969A>C:		rs2147377	0.9956	0.9923	59771/32617/5183	0.9696	1.3490	T,T,T,T,T,T,T	T	B,B,B,B	T,T,T,T,T,T,T	0.98	608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000118459.4 [other]; RCV000269574.1 [benign]; RCV000361971.1 [benign]; 			2918	50	1	[1] old entry - no details available	n/a (11xTP, 0xFP)		SYNE1 (inh=AR+AD pLI=0.00), MIR3163 (inh=n/a pLI=n/a)
chr6	152615200	152615200	G	A	hom	het	het		QUAL=18883;DP=366,245,296;MQM=60	SYNE1	synonymous	SYNE1:NM_182961.3:synonymous:LOW:exon94/146:c.17745C>T:p.His5915His,SYNE1:NM_033071.3:synonymous:LOW:exon93/146:c.17532C>T:p.His5844His		rs12664753	0.1478	0.1875	2359/1241/12	0.1843							608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000118454.3 [other]; RCV000330934.1 [benign]; RCV000385411.1 [benign]; 			136	893	1	[1] Julia Bickmann 18.09.2014	n/a (2xTP, 0xFP)		SYNE1 (inh=AR+AD pLI=0.00)
chr6	152629617	152629617	C	T	wt	het	wt		QUAL=2025;DP=196,166,190;MQM=60	SYNE1	splice_region&intron	SYNE1:NM_182961.3:splice_region&intron:LOW:exon91/145:c.17346+7G>A:,SYNE1:NM_033071.3:splice_region&intron:LOW:exon90/145:c.17133+7G>A:		rs9383985	0.3043	0.3236	6952/3486/29	0.3152							608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000118452.3 [other]; RCV000336490.1 [benign]; RCV000394440.1 [benign]; 			359	1329	1	[1] Julia Bickmann 18.09.2014	n/a (6xTP, 0xFP)		SYNE1 (inh=AR+AD pLI=0.00)
chr6	152629773	152629773	A	-	het	het	wt		QUAL=484;DP=155,70,86;MQM=59	SYNE1	splice_region&intron	SYNE1:NM_182961.3:splice_region&intron:LOW:exon90/145:c.17203-6delT:,SYNE1:NM_033071.3:splice_region&intron:LOW:exon89/145:c.16994-10delT:		rs535229755;rs55633181;rs796838050	0.4265	0.4174	1972/899/64	0.0455							608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000203031.1 [benign]; 			197	1428					SYNE1 (inh=AR+AD pLI=0.00)
chr6	152647681	152647681	A	T	het	het	het	pred_pathogenic	QUAL=16374;DP=488,323,425;MQM=60	SYNE1	missense	SYNE1:NM_182961.3:missense:MODERATE:exon79/146:c.15043T>A:p.Leu5015Met,SYNE1:NM_033071.3:missense:MODERATE:exon78/146:c.14830T>A:p.Leu4944Met		rs2306916	0.8147	0.7797	37372/19174/4518	0.7737	2.9340	T,T,T,T,T	T	B,B,B,B	T,T,T,T,T	16.07	608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000118448.3 [other]; RCV000296846.1 [benign]; RCV000335569.1 [benign]; 			1586	1155					SYNE1 (inh=AR+AD pLI=0.00)
chr6	152652034	152652034	A	T	het	het	het		QUAL=9480;DP=189,189,257;MQM=60	SYNE1	missense	SYNE1:NM_182961.3:missense:MODERATE:exon78/146:c.13786T>A:p.Ser4596Thr,SYNE1:NM_033071.3:missense:MODERATE:exon77/146:c.13573T>A:p.Ser4525Thr		rs6911096	0.8033	0.7760	36980/19174/4081	0.7705	-2.5130	T,T,T,T,T	T	B,B,B,B	T,T,T,T,T	0.01	608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000118444.3 [other]; RCV000290438.1 [benign]; RCV000387036.1 [benign]; 		COSM450728, COSM450729, COSM1487365	1584	1160					SYNE1 (inh=AR+AD pLI=0.00)
chr6	152658062	152658062	C	G	het	wt	het	pred_pathogenic	QUAL=7816;DP=318,173,310;MQM=60	SYNE1	missense	SYNE1:NM_182961.3:missense:MODERATE:exon76/146:c.12442G>C:p.Asp4148His,SYNE1:NM_033071.3:missense:MODERATE:exon75/146:c.12229G>C:p.Asp4077His		rs117501809	0.0124	0.0272	70/46/0	0.0262	7.8150	D,D,D,D,D	T	D,D,D,D	T,T,T,T,T	32.00	608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000118441.2 [likely benign]; RCV000270994.1 [likely benign]; RCV000365811.1 [likely benign]; 			9	200					SYNE1 (inh=AR+AD pLI=0.00)
chr6	152658142	152658142	T	C	het	het	het		QUAL=7102;DP=155,133,247;MQM=60	SYNE1	missense	SYNE1:NM_182961.3:missense:MODERATE:exon76/146:c.12362A>G:p.Lys4121Arg,SYNE1:NM_033071.3:missense:MODERATE:exon75/146:c.12149A>G:p.Lys4050Arg		rs9479297	0.7931	0.7547	34481/18325/4464	0.7260	1.4310	T,T,T,T,T	T	B,B,B,B	T,T,T,T,T	6.36	608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000118439.4 [other]; RCV000267635.1 [benign]; RCV000317782.1 [benign]; 			1542	1171					SYNE1 (inh=AR+AD pLI=0.00)
chr6	152660451	152660451	G	A	wt	wt	het		QUAL=4540;DP=464,300,364;MQM=60	SYNE1	synonymous	SYNE1:NM_182961.3:synonymous:LOW:exon75/146:c.12276C>T:p.Leu4092Leu,SYNE1:NM_033071.3:synonymous:LOW:exon74/146:c.12063C>T:p.Leu4021Leu		rs71575926	0.0733	0.1142	1021/689/40	0.1117							608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000118438.3 [likely benign]; RCV000337521.1 [benign]; RCV000387540.1 [benign]; 			33	548					SYNE1 (inh=AR+AD pLI=0.00)
chr6	152665261	152665261	C	A	wt	het	het	pred_pathogenic	QUAL=6401;DP=361,232,319;MQM=60	SYNE1	missense	SYNE1:NM_182961.3:missense:MODERATE:exon74/146:c.12180G>T:p.Glu4060Asp,SYNE1:NM_033071.3:missense:MODERATE:exon73/146:c.11967G>T:p.Glu3989Asp		rs4645434	0.5455	0.5761	20413/12184/1044	0.5766	0.4260	T,T,T,T,D	T	B,B,B,B	T,T,T,T,T	5.05	608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000118437.3 [other]; RCV000307999.1 [benign]; RCV000393801.1 [benign]; 		COSM1441465, COSM3748319, COSM42924, COSM136573, COSM3748318	1096	1354					SYNE1 (inh=AR+AD pLI=0.00)
chr6	152671475	152671475	A	C	wt	het	het		QUAL=2163;DP=184,83,120;MQM=60	SYNE1	splice_region&intron,intron	SYNE1:NM_182961.3:splice_region&intron:LOW:exon71/145:c.11734-5T>G:,SYNE1:NM_033071.3:intron:MODIFIER:exon71/145:c.11688+278T>G:		rs9478320	0.5875	0.5846	20873/12070/1657	0.5799							608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000243119.1 [benign]; 			1083	1372	1	[1] Julia Bickmann 18.09.2014	n/a (10xTP, 0xFP)		SYNE1 (inh=AR+AD pLI=0.00)
chr6	152675854	152675854	A	G	wt	het	het		QUAL=13211;DP=534,474,579;MQM=60	SYNE1	splice_region&intron,synonymous	SYNE1:NM_033071.3:splice_region&intron:LOW:exon67/145:c.10881+6T>C:,SYNE1:NM_182961.3:synonymous:LOW:exon67/146:c.10866T>C:p.Ser3622Ser		rs9397102	0.5683	0.5799	20587/12085/1356	0.5808							608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000118433.3 [other]; RCV000269796.1 [benign]; RCV000364406.1 [benign]; 			1085	1368					SYNE1 (inh=AR+AD pLI=0.00)
chr6	152683413	152683413	G	T	wt	het	het		QUAL=3671;DP=331,153,161;MQM=60	SYNE1	synonymous	SYNE1:NM_182961.3:synonymous:LOW:exon64/146:c.10191C>A:p.Gly3397Gly,SYNE1:NM_033071.3:synonymous:LOW:exon64/146:c.10212C>A:p.Gly3404Gly		rs4407724	0.6591	0.6541	26136/14783/1715	0.6560							608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000118428.3 [other]; RCV000273784.1 [benign]; RCV000375408.1 [benign]; 			1331	1279	1	[1] old entry - no details available			SYNE1 (inh=AR+AD pLI=0.00)
chr6	152688435	152688435	G	A	wt	het	wt	pred_pathogenic	QUAL=2782;DP=336,220,346;MQM=60	SYNE1	missense	SYNE1:NM_182961.3:missense:MODERATE:exon62/146:c.9890C>T:p.Thr3297Met,SYNE1:NM_033071.3:missense:MODERATE:exon62/146:c.9911C>T:p.Thr3304Met		rs150912982	0.0052	0.0017	2/0/2	0.0016	4.6140	.,T,T,T,T,T	T,T	.,B,B,B,B,B	.,T,T,T,T,T	23.50	608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000118494.1 [uncertain significance]; RCV000327827.1 [likely benign]; RCV000385261.1 [likely benign]; 			0	3	1	VUS1, MR, 08.06.2016 [1] ahrautm1 08.06.2016			SYNE1 (inh=AR+AD pLI=0.00)
chr6	152694184	152694184	T	C	wt	wt	het		QUAL=924;DP=136,45,78;MQM=60	SYNE1	synonymous	SYNE1:NM_182961.3:synonymous:LOW:exon59/146:c.9495A>G:p.Glu3165Glu,SYNE1:NM_033071.3:synonymous:LOW:exon59/146:c.9516A>G:p.Glu3172Glu		rs6913579	0.4683	0.4993	15391/9570/1201	0.4813	0.8250		T,T			2.26	608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000118493.4 [other]; RCV000271232.1 [benign]; RCV000328747.1 [benign]; 			823	1413					SYNE1 (inh=AR+AD pLI=0.00)
chr6	152697675	152697675	G	T	het	het	wt		QUAL=4423;DP=228,133,220;MQM=60	SYNE1	synonymous	SYNE1:NM_182961.3:synonymous:LOW:exon58/146:c.9165C>A:p.Ser3055Ser,SYNE1:NM_033071.3:synonymous:LOW:exon58/146:c.9186C>A:p.Ser3062Ser		rs117020413	0.0068	0.0135	23/10/0	0.0125	1.2490		T			6.88	608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000249270.1 [likely benign]; RCV000292676.1 [likely benign]; RCV000374319.1 [likely benign]; 			0	90					SYNE1 (inh=AR+AD pLI=0.00)
chr6	152772264	152772264	A	G	hom	het	het	pred_pathogenic	QUAL=18097;DP=347,199,278;MQM=59	SYNE1	missense	SYNE1:NM_182961.3:missense:MODERATE:exon26/146:c.3104T>C:p.Val1035Ala,SYNE1:NM_033071.3:missense:MODERATE:exon26/146:c.3125T>C:p.Val1042Ala		rs214976	0.6072	0.4811	15138/6165/2930	0.4769	8.6440	D,D,D,D,D,D,D,D	D	B,B,B,B,B,B	T,T,T,T,T,D,D,D	23.40	608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000118478.3 [other]; RCV000283687.1 [benign]; RCV000340993.1 [benign]; 			623	1417	1	[1] old entry - no details available			SYNE1 (inh=AR+AD pLI=0.00)
chr6	152774753	152774753	C	T	het	het	wt	pred_pathogenic	QUAL=4906;DP=244,123,142;MQM=59	SYNE1	missense	SYNE1:NM_182961.3:missense:MODERATE:exon25/146:c.2995G>A:p.Glu999Lys,SYNE1:NM_033071.3:missense:MODERATE:exon25/146:c.3016G>A:p.Glu1006Lys		rs148346599	0.0020	0.0034	2/0/0	0.0029	7.3880	D,D,D,D,D,D,T,D,T	T	P,P,P,D,D,P,D	T,T,T,T,T,T,T,T,T	27.30	608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000310826.1 [likely benign]; RCV000314697.1 [benign]; RCV000400469.1 [likely benign]; 		COSM231095, COSM231094	0	12					SYNE1 (inh=AR+AD pLI=0.00)
chr6	152809527	152809527	A	T	hom	het	het		QUAL=8860;DP=181,88,136;MQM=59	SYNE1	splice_region&intron	SYNE1:NM_182961.3:splice_region&intron:LOW:exon12/145:c.1047+4T>A:,SYNE1:NM_033071.3:splice_region&intron:LOW:exon12/145:c.1068+4T>A:		rs9397106	0.5893	0.4810	14464/6127/2331	0.4715							608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000118432.4 [other]; RCV000320090.1 [benign]; RCV000374713.1 [benign]; 			631	1394	1	[1] Julia Bickmann 18.09.2014	n/a (4xTP, 0xFP)		SYNE1 (inh=AR+AD pLI=0.00)
chr6	152958461	152958461	G	A	het	wt	het		QUAL=1282;DP=52,86,104;MQM=60	SYNE1	5'UTR	SYNE1:NM_182961.3:5'UTR:MODIFIER:exon1/146:c.-529C>T:		rs9478345	0.3301	0.0000	0/0/0	0.4113							608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];				21	112					SYNE1 (inh=AR+AD pLI=0.00)
chr6	157522360	157522360	G	A	het	het	wt		QUAL=6665;DP=203,311,419;MQM=59	ARID1B	synonymous	ARID1B:NM_020732.3:synonymous:LOW:exon18/20:c.4632G>A:p.Pro1544Pro,ARID1B:NM_017519.2:synonymous:LOW:exon17/19:c.4593G>A:p.Pro1531Pro		rs61738955	0.0184	0.0269	52/40/0	0.0270							614556 [ARID1B (confirmed) Coffin-Siris syndrome 1,135900];	RCV000114277.1 [benign]; 			5	90					ARID1B (inh=AD pLI=1.00)
chr6	157529844	157529844	C	T	het	wt	het		QUAL=393;DP=105,37,39;MQM=55	ARID1B	3'UTR	ARID1B:NM_020732.3:3'UTR:MODIFIER:exon20/20:c.*819C>T:,ARID1B:NM_017519.2:3'UTR:MODIFIER:exon19/19:c.*819C>T:	(T)n	rs879242544	0.0000	0.0000	0/0/0	0.0007							614556 [ARID1B (confirmed) Coffin-Siris syndrome 1,135900];				1	91					ARID1B (inh=AD pLI=1.00)
chr6	157529849	157529849	C	T	hom	hom	hom	low_DP	QUAL=878;DP=73,6,9;MQM=54	ARID1B	3'UTR	ARID1B:NM_020732.3:3'UTR:MODIFIER:exon20/20:c.*824C>T:,ARID1B:NM_017519.2:3'UTR:MODIFIER:exon19/19:c.*824C>T:	(T)n	rs139366986	0.0000	0.0000	0/0/0	0.0014							614556 [ARID1B (confirmed) Coffin-Siris syndrome 1,135900];				5	130					ARID1B (inh=AD pLI=1.00)
chr6	158613375	158613375	A	-	het	het	wt		QUAL=1051;DP=224,68,87;MQM=59	GTF2H5	3'UTR	GTF2H5:NM_207118.2:3'UTR:MODIFIER:exon3/3:c.*198delA:		rs3841147	0.3193	0.0000	0/0/0	0.1269							608780 [GTF2H5 (confirmed) Trichothiodystrophy 3,photosensitive,616395];				7	83					GTF2H5 (inh=AR pLI=0.05)
chr6	158613603	158613603	A	C	het	het	het		QUAL=12177;DP=328,273,316;MQM=60	GTF2H5	3'UTR	GTF2H5:NM_207118.2:3'UTR:MODIFIER:exon3/3:c.*414A>C:		rs4425618	0.4239	0.0000	0/0/0	0.0606							608780 [GTF2H5 (confirmed) Trichothiodystrophy 3,photosensitive,616395];				24	102					GTF2H5 (inh=AR pLI=0.05)
chr6	158613910	158613910	G	A	het	het	het		QUAL=3157;DP=132,47,59;MQM=60	GTF2H5	3'UTR	GTF2H5:NM_207118.2:3'UTR:MODIFIER:exon3/3:c.*721G>A:	FRAM	rs9457163	0.4239	0.0000	0/0/0	0.0610							608780 [GTF2H5 (confirmed) Trichothiodystrophy 3,photosensitive,616395];				22	80					GTF2H5 (inh=AR pLI=0.05)
chr6	158614236	158614236	-	AGGAGGATGGCTTAAGCCC	het	het	het		QUAL=5018;DP=125,121,161;MQM=59	GTF2H5	3'UTR	GTF2H5:NM_207118.2:3'UTR:MODIFIER:exon3/3:c.*1053_*1054insATGGCTTAAGCCCAGGAGG:	AluJo	rs6149883	0.3786	0.0000	0/0/0	0.2559							608780 [GTF2H5 (confirmed) Trichothiodystrophy 3,photosensitive,616395];				16	85					GTF2H5 (inh=AR pLI=0.05)
chr6	158614528	158614528	G	A	het	wt	het		QUAL=7503;DP=338,181,239;MQM=59	GTF2H5	3'UTR	GTF2H5:NM_207118.2:3'UTR:MODIFIER:exon3/3:c.*1339G>A:		rs35508045	0.0935	0.0000	0/0/0	0.0180							608780 [GTF2H5 (confirmed) Trichothiodystrophy 3,photosensitive,616395];				7	63					GTF2H5 (inh=AR pLI=0.05)
chr6	158615926	158615926	A	T	het	het	het		QUAL=11204;DP=389,202,249;MQM=60	GTF2H5	3'UTR	GTF2H5:NM_207118.2:3'UTR:MODIFIER:exon3/3:c.*2737A>T:		rs1019682	0.7798	0.0000	0/0/0	0.6672							608780 [GTF2H5 (confirmed) Trichothiodystrophy 3,photosensitive,616395];				117	96					GTF2H5 (inh=AR pLI=0.05)
chr6	158616335	158616335	A	C	het	het	het		QUAL=4427;DP=204,35,50;MQM=60	GTF2H5	3'UTR	GTF2H5:NM_207118.2:3'UTR:MODIFIER:exon3/3:c.*3146A>C:		rs10946159	0.3722	0.0000	0/0/0	0.3409							608780 [GTF2H5 (confirmed) Trichothiodystrophy 3,photosensitive,616395];				22	104					GTF2H5 (inh=AR pLI=0.05)
chr6	158616727	158616727	C	T	het	het	het		QUAL=11223;DP=443,152,232;MQM=58	GTF2H5	3'UTR	GTF2H5:NM_207118.2:3'UTR:MODIFIER:exon3/3:c.*3538C>T:		rs1047876	0.4233	0.0000	0/0/0	0.3550							608780 [GTF2H5 (confirmed) Trichothiodystrophy 3,photosensitive,616395];				25	101					GTF2H5 (inh=AR pLI=0.05)
chr6	158616876	158616876	A	C	het	wt	het		QUAL=7032;DP=312,133,221;MQM=55	GTF2H5	3'UTR	GTF2H5:NM_207118.2:3'UTR:MODIFIER:exon3/3:c.*3687A>C:		rs4354181	0.0986	0.0000	0/0/0	0.1076							608780 [GTF2H5 (confirmed) Trichothiodystrophy 3,photosensitive,616395];				7	65					GTF2H5 (inh=AR pLI=0.05)
chr6	158617572	158617572	G	A	wt	wt	het		QUAL=1349;DP=253,51,88;MQM=60	GTF2H5	3'UTR	GTF2H5:NM_207118.2:3'UTR:MODIFIER:exon3/3:c.*4383G>A:	HSMAR2	rs628039	0.3978	0.0000	0/0/0	0.3798							608780 [GTF2H5 (confirmed) Trichothiodystrophy 3,photosensitive,616395];				36	72					GTF2H5 (inh=AR pLI=0.05)
chr6	158617694	158617694	A	T	het	wt	het		QUAL=5262;DP=300,103,136;MQM=60	GTF2H5	3'UTR	GTF2H5:NM_207118.2:3'UTR:MODIFIER:exon3/3:c.*4505A>T:	HSMAR2	rs144679213	0.0126	0.0000	0/0/0	0.0257							608780 [GTF2H5 (confirmed) Trichothiodystrophy 3,photosensitive,616395];				1	14					GTF2H5 (inh=AR pLI=0.05)
chr6	158619039	158619039	A	C	wt	het	wt		QUAL=852;DP=169,56,60;MQM=60	GTF2H5	3'UTR	GTF2H5:NM_207118.2:3'UTR:MODIFIER:exon3/3:c.*5850A>C:	HSMAR2	rs1570219	0.2123	0.0000	0/0/0	0.1775							608780 [GTF2H5 (confirmed) Trichothiodystrophy 3,photosensitive,616395];				9	51					GTF2H5 (inh=AR pLI=0.05)
chr6	158619409	158619409	G	A	hom	hom	hom		QUAL=32038;DP=470,214,285;MQM=59	GTF2H5	3'UTR	GTF2H5:NM_207118.2:3'UTR:MODIFIER:exon3/3:c.*6220G>A:		rs599345	0.8912	0.0000	0/0/0	0.7328							608780 [GTF2H5 (confirmed) Trichothiodystrophy 3,photosensitive,616395];				128	86					GTF2H5 (inh=AR pLI=0.05)
chr6	158619713	158619713	C	G	hom	hom	het		QUAL=13106;DP=269,100,149;MQM=59	GTF2H5	3'UTR	GTF2H5:NM_207118.2:3'UTR:MODIFIER:exon3/3:c.*6524C>G:	AluSz	rs615107	0.5677	0.0000	0/0/0	0.5252							608780 [GTF2H5 (confirmed) Trichothiodystrophy 3,photosensitive,616395];				84	104					GTF2H5 (inh=AR pLI=0.05)
chr6	158619948	158619948	G	C	het	wt	het		QUAL=4640;DP=301,91,96;MQM=60	GTF2H5	3'UTR	GTF2H5:NM_207118.2:3'UTR:MODIFIER:exon3/3:c.*6759G>C:		rs71563797	0.1032	0.0000	0/0/0	0.1082							608780 [GTF2H5 (confirmed) Trichothiodystrophy 3,photosensitive,616395];				7	62					GTF2H5 (inh=AR pLI=0.05)
chr6	158620285	158620285	A	G	wt	het	wt		QUAL=2225;DP=312,172,200;MQM=60	GTF2H5	3'UTR	GTF2H5:NM_207118.2:3'UTR:MODIFIER:exon3/3:c.*7096A>G:	L1PA17	rs1128568	0.2177	0.0000	0/0/0	0.2223							608780 [GTF2H5 (confirmed) Trichothiodystrophy 3,photosensitive,616395];				10	53					GTF2H5 (inh=AR pLI=0.05)
chr6	161132146	161132146	C	T	het	het	wt		QUAL=6046;DP=229,310,369;MQM=55	PLG	synonymous	PLG:NM_000301.3:synonymous:LOW:exon4/19:c.330C>T:p.Asn110Asn,PLG:NM_001168338.1:synonymous:LOW:exon4/4:c.330C>T:p.Asn110Asn		rs4757	0.2494	0.2627	5054/3267/1239	0.2487							173350 [PLG (confirmed) Dysplasminogenemia,217090|Plasminogen deficiency,type I,217090];				187	664					PLG (inh=AR pLI=0.00)
chr6	161132417	161132417	T	G	het	het	wt	low_MQM	QUAL=6350;DP=322,209,281;MQM=48	PLG	sequence_feature,3'UTR,intron	PLG:NM_000301.3:sequence_feature:LOW::c.407+194T>G:,PLG:NM_000301.3:sequence_feature:LOW::c.407+194T>G:,PLG:NM_001168338.1:3'UTR:MODIFIER:exon4/4:c.*190T>G:,PLG:NM_000301.3:intron:MODIFIER:exon4/18:c.407+194T>G:	MER2	rs4252082	0.2486	0.0000	0/0/0	0.1593							173350 [PLG (confirmed) Dysplasminogenemia,217090|Plasminogen deficiency,type I,217090];				17	73					PLG (inh=AR pLI=0.00)
chr6	161132725	161132725	T	C	het	het	wt		QUAL=6300;DP=257,162,198;MQM=57	PLG	sequence_feature,3'UTR,intron	PLG:NM_000301.3:sequence_feature:LOW::c.407+502T>C:,PLG:NM_000301.3:sequence_feature:LOW::c.407+502T>C:,PLG:NM_001168338.1:3'UTR:MODIFIER:exon4/4:c.*498T>C:,PLG:NM_000301.3:intron:MODIFIER:exon4/18:c.407+502T>C:		rs4252086	0.2486	0.0000	0/0/0	0.2239							173350 [PLG (confirmed) Dysplasminogenemia,217090|Plasminogen deficiency,type I,217090];				17	73					PLG (inh=AR pLI=0.00)
chr6	161132804	161132804	T	C	het	het	wt		QUAL=7321;DP=284,213,317;MQM=56	PLG	sequence_feature,3'UTR,intron	PLG:NM_000301.3:sequence_feature:LOW::c.407+581T>C:,PLG:NM_000301.3:sequence_feature:LOW::c.407+581T>C:,PLG:NM_001168338.1:3'UTR:MODIFIER:exon4/4:c.*577T>C:,PLG:NM_000301.3:intron:MODIFIER:exon4/18:c.407+581T>C:		rs1853018	0.2486	0.0000	0/0/0	0.1989							173350 [PLG (confirmed) Dysplasminogenemia,217090|Plasminogen deficiency,type I,217090];				17	72					PLG (inh=AR pLI=0.00)
chr6	161132830	161132830	G	A	hom	hom	hom		QUAL=30607;DP=347,243,332;MQM=58	PLG	sequence_feature,3'UTR,intron	PLG:NM_000301.3:sequence_feature:LOW::c.407+607G>A:,PLG:NM_000301.3:sequence_feature:LOW::c.407+607G>A:,PLG:NM_001168338.1:3'UTR:MODIFIER:exon4/4:c.*603G>A:,PLG:NM_000301.3:intron:MODIFIER:exon4/18:c.407+607G>A:		rs1830519	0.6066	0.0000	0/0/0	0.5591							173350 [PLG (confirmed) Dysplasminogenemia,217090|Plasminogen deficiency,type I,217090];				90	53					PLG (inh=AR pLI=0.00)
chr6	161137779	161137779	T	C	het	het	hom		QUAL=5663;DP=133,55,97;MQM=60	PLG	synonymous	PLG:NM_000301.3:synonymous:LOW:exon7/19:c.771T>C:p.Cys257Cys		rs14224	0.4499	0.4217	10982/5880/1443	0.4175							173350 [PLG (confirmed) Dysplasminogenemia,217090|Plasminogen deficiency,type I,217090];				317	788					PLG (inh=AR pLI=0.00)
chr6	161137790	161137790	G	A	het	het	wt	pred_pathogenic	QUAL=1394;DP=112,51,84;MQM=60	PLG	missense	PLG:NM_000301.3:missense:MODERATE:exon7/19:c.782G>A:p.Arg261His		rs4252187	0.0008	0.0031	1/1/0	0.0031	4.4140	D	T	P	T	25.10	173350 [PLG (confirmed) Dysplasminogenemia,217090|Plasminogen deficiency,type I,217090];				0	11					PLG (inh=AR pLI=0.00)
chr6	161139480	161139480	C	T	het	het	hom		QUAL=11006;DP=325,114,185;MQM=60	PLG	synonymous	PLG:NM_000301.3:synonymous:LOW:exon8/19:c.942C>T:p.Phe314Phe		rs1130656	0.3498	0.3785	8956/5424/342	0.3757							173350 [PLG (confirmed) Dysplasminogenemia,217090|Plasminogen deficiency,type I,217090];			COSM1131985	250	714					PLG (inh=AR pLI=0.00)
chr6	161139857	161139857	A	G	het	het	wt		QUAL=5035;DP=219,186,260;MQM=59	PLG	synonymous	PLG:NM_000301.3:synonymous:LOW:exon9/19:c.1083A>G:p.Gln361Gln		rs13231	0.1364	0.2155	3405/2875/155	0.2157							173350 [PLG (confirmed) Dysplasminogenemia,217090|Plasminogen deficiency,type I,217090];				111	615					PLG (inh=AR pLI=0.00)
chr6	161143608	161143608	T	C	het	het	wt		QUAL=3780;DP=192,153,189;MQM=60	PLG	splice_region&intron	PLG:NM_000301.3:splice_region&intron:LOW:exon10/18:c.1256+9T>C:		rs4252120	0.1400	0.2171	3457/2904/170	0.2057							173350 [PLG (confirmed) Dysplasminogenemia,217090|Plasminogen deficiency,type I,217090];				112	616					PLG (inh=AR pLI=0.00)
chr6	161152240	161152240	G	A	het	het	wt		QUAL=4322;DP=217,153,199;MQM=60	PLG	missense	PLG:NM_000301.3:missense:MODERATE:exon11/19:c.1414G>A:p.Asp472Asn		rs4252125	0.1398	0.2171	3455/2903/170	0.2179	0.0580	T	T	B	T	0.10	173350 [PLG (confirmed) Dysplasminogenemia,217090|Plasminogen deficiency,type I,217090];		CM043559 [CLASS=DFP MUT=ALT PHEN="Invasive aspergillosis susceptibility" GENE=PLG]; 		111	618					PLG (inh=AR pLI=0.00)
chr6	161173946	161173946	T	G	wt	het	het		QUAL=1529;DP=117,66,97;MQM=58	PLG	synonymous	PLG:NM_000301.3:synonymous:LOW:exon19/19:c.2286T>G:p.Gly762Gly		rs11060	0.6811	0.6119	23832/9553/1440	0.5875							173350 [PLG (confirmed) Dysplasminogenemia,217090|Plasminogen deficiency,type I,217090];			COSM3829605	468	760					PLG (inh=AR pLI=0.00)
chr6	161174138	161174138	A	G	wt	het	het	low_MQM	QUAL=3471;DP=316,110,168;MQM=36	PLG	3'UTR	PLG:NM_000301.3:3'UTR:MODIFIER:exon19/19:c.*45A>G:		rs6690	0.6755	0.5449	5311/1955/356	0.4083							173350 [PLG (confirmed) Dysplasminogenemia,217090|Plasminogen deficiency,type I,217090];				200	375					PLG (inh=AR pLI=0.00)
chr6	161174378	161174378	T	-	wt	het	het		QUAL=4785;DP=250,176,197;MQM=59	PLG	3'UTR	PLG:NM_000301.3:3'UTR:MODIFIER:exon19/19:c.*289delT:		rs796846604	0.6773	0.0000	0/0/0	0.5402							173350 [PLG (confirmed) Dysplasminogenemia,217090|Plasminogen deficiency,type I,217090];				38	79					PLG (inh=AR pLI=0.00)
chr6	161174579	161174579	T	C	wt	het	het		QUAL=6724;DP=246,250,282;MQM=56	PLG	3'UTR	PLG:NM_000301.3:3'UTR:MODIFIER:exon19/19:c.*486T>C:		rs783169	0.6524	0.0000	0/0/0	0.4618							173350 [PLG (confirmed) Dysplasminogenemia,217090|Plasminogen deficiency,type I,217090];				35	76					PLG (inh=AR pLI=0.00)
chr6	161174594	161174594	A	G	wt	het	het		QUAL=6230;DP=202,225,278;MQM=55	PLG	3'UTR	PLG:NM_000301.3:3'UTR:MODIFIER:exon19/19:c.*501A>G:		rs783168	0.6773	0.0000	0/0/0	0.3070							173350 [PLG (confirmed) Dysplasminogenemia,217090|Plasminogen deficiency,type I,217090];				35	76					PLG (inh=AR pLI=0.00)
chr6	161174658	161174658	G	A	het	hom	het	low_MQM	QUAL=11403;DP=243,180,198;MQM=46	PLG	3'UTR	PLG:NM_000301.3:3'UTR:MODIFIER:exon19/19:c.*565G>A:		rs783167	0.8738	0.0000	0/0/0	0.5201							173350 [PLG (confirmed) Dysplasminogenemia,217090|Plasminogen deficiency,type I,217090];				101	47					PLG (inh=AR pLI=0.00)
chr6	161174871	161174871	C	G	wt	het	het		QUAL=14120;DP=557,481,586;MQM=59	PLG	3'UTR	PLG:NM_000301.3:3'UTR:MODIFIER:exon19/19:c.*778C>G:		rs11902	0.6552	0.0000	0/0/0	0.5397							173350 [PLG (confirmed) Dysplasminogenemia,217090|Plasminogen deficiency,type I,217090];				36	75					PLG (inh=AR pLI=0.00)
chr6	161174933	161174933	C	T	het	wt	het		QUAL=14184;DP=456,539,656;MQM=60	PLG	3'UTR	PLG:NM_000301.3:3'UTR:MODIFIER:exon19/19:c.*840C>T:		rs4252199	0.0110	0.0000	0/0/0	0.0156							173350 [PLG (confirmed) Dysplasminogenemia,217090|Plasminogen deficiency,type I,217090];				1	8					PLG (inh=AR pLI=0.00)
chr6	161175004	161175004	C	T	het	het	wt		QUAL=13966;DP=537,541,653;MQM=55	PLG	3'UTR	PLG:NM_000301.3:3'UTR:MODIFIER:exon19/19:c.*911C>T:		rs4252181	0.1126	0.0000	0/0/0	0.1956							173350 [PLG (confirmed) Dysplasminogenemia,217090|Plasminogen deficiency,type I,217090];				11	68					PLG (inh=AR pLI=0.00)
chr6	161768651	161768651	G	T	het	wt	hom	low_DP	QUAL=238;DP=37,541,2;MQM=54	PARK2	3'UTR	PARK2:NM_004562.2:3'UTR:MODIFIER:exon12/12:c.*2480C>A:,PARK2:NM_013987.2:3'UTR:MODIFIER:exon11/11:c.*2480C>A:,PARK2:NM_013988.2:3'UTR:MODIFIER:exon9/9:c.*2480C>A:	AluSg4	rs68121389	0.4990	0.0000	0/0/0	0.1519							602544 [PARK2 (confirmed) Parkinson disease,juvenile,type 2,600116|Adenocarcinoma of lung,somatic,211980|Adenocarcinoma,ovarian,somatic,167000|Leprosy,susceptibility to,607572];	RCV000377590.1 [benign]; 			22	58					PARK2 (inh=AR pLI=0.02)
chr6	161769835	161769835	T	C	het	wt	het		QUAL=11219;DP=420,359,444;MQM=59	PARK2	3'UTR	PARK2:NM_004562.2:3'UTR:MODIFIER:exon12/12:c.*1296A>G:,PARK2:NM_013987.2:3'UTR:MODIFIER:exon11/11:c.*1296A>G:,PARK2:NM_013988.2:3'UTR:MODIFIER:exon9/9:c.*1296A>G:		rs3734464	0.0577	0.0000	0/0/0	0.0132							602544 [PARK2 (confirmed) Parkinson disease,juvenile,type 2,600116|Adenocarcinoma of lung,somatic,211980|Adenocarcinoma,ovarian,somatic,167000|Leprosy,susceptibility to,607572];	RCV000376877.1 [likely benign]; 			2	47					PARK2 (inh=AR pLI=0.02)
chr6	167344583	167344583	A	G	wt	wt	het		QUAL=5014;DP=419,320,402;MQM=60	RNASET2	synonymous	RNASET2:NM_003730.4:synonymous:LOW:exon8/9:c.516T>C:p.Leu172Leu		rs13213697	0.1845	0.1731	2190/1175/626	0.1703							612944 [RNASET2 (provisional) Leukoencephalopathy,cystic,without megalencephaly,612951];	RCV000273891.1 [benign]; 		COSM3761656	81	656					RNASET2 (inh=AR pLI=0.01)
chr6	167369897	167369897	C	A	het	wt	het	low_DP	QUAL=1197;DP=18,60,86;MQM=59	RNASET2	5'UTR	RNASET2:NM_003730.4:5'UTR:MODIFIER:exon1/9:c.-227G>T:		rs1044059	0.6737	0.0000	0/0/0	0.5184							612944 [RNASET2 (provisional) Leukoencephalopathy,cystic,without megalencephaly,612951];	RCV000402342.1 [benign]; 			65	101					RNASET2 (inh=AR pLI=0.01)
chr6	167369992	167369992	A	G	het	wt	het	low_DP	QUAL=598;DP=11,26,38;MQM=60	RNASET2	5'UTR	RNASET2:NM_003730.4:5'UTR:MODIFIER:exon1/9:c.-322T>C:		rs2247325	0.6396	0.0000	0/0/0	0.0817							612944 [RNASET2 (provisional) Leukoencephalopathy,cystic,without megalencephaly,612951];	RCV000260374.1 [benign]; 			35	88					RNASET2 (inh=AR pLI=0.01)
chr6	170871013	170871013	-	CAG	wt	het	het	low_DP	QUAL=6133;DP=18,373,320;MQM=59	TBP	disruptive_inframe_insertion	TBP:NM_003194.4:disruptive_inframe_insertion:MODERATE:exon3/8:c.213_215dupGCA:p.Gln72dup,TBP:NM_001172085.1:disruptive_inframe_insertion:MODERATE:exon2/7:c.153_155dupGCA:p.Gln52dup	(GCA)n	rs201732168;rs71010672;rs748407795	0.0000	0.0000	0/0/0	0.0433							600075 [TBP (confirmed) Spinocerebellar ataxia 17,607136|Parkinson disease,susceptibility to,168600];			COSM247745	369	371	1	[1] old entry - no details available			TBP (inh=AD pLI=0.49)
chr6	170871040	170871040	A	G	het	wt	het	low_DP	QUAL=7055;DP=16,449,379;MQM=59	TBP	synonymous	TBP:NM_003194.4:synonymous:LOW:exon3/8:c.216A>G:p.Gln72Gln,TBP:NM_001172085.1:synonymous:LOW:exon2/7:c.156A>G:p.Gln52Gln	(GCA)n	rs55736770	0.0000	0.0082	3/2/0	0.0024							600075 [TBP (confirmed) Spinocerebellar ataxia 17,607136|Parkinson disease,susceptibility to,168600];	RCV000118598.2 [likely benign]; 		COSM3723811	106	792					TBP (inh=AD pLI=0.49)
chr6	170871043	170871043	G	A	het	wt	het	low_DP	QUAL=7055;DP=16,449,379;MQM=59	TBP	synonymous	TBP:NM_003194.4:synonymous:LOW:exon3/8:c.219G>A:p.Gln73Gln,TBP:NM_001172085.1:synonymous:LOW:exon2/7:c.159G>A:p.Gln53Gln	(GCA)n	rs764035011	0.0000	0.0001	0/0/0	0.0007							600075 [TBP (confirmed) Spinocerebellar ataxia 17,607136|Parkinson disease,susceptibility to,168600];			COSM1076231	70	516	1	[1] Tanja Benkert 20.04.2015 [n/a] comment imported from detected variant: 20.04.2015, TCB: Poly-Q, auch in Kontrolle (SCA-V4)			TBP (inh=AD pLI=0.49)
chr6	170871046	170871046	A	G	het	wt	het	low_DP	QUAL=7055;DP=16,449,379;MQM=59	TBP	synonymous	TBP:NM_003194.4:synonymous:LOW:exon3/8:c.222A>G:p.Gln74Gln,TBP:NM_001172085.1:synonymous:LOW:exon2/7:c.162A>G:p.Gln54Gln	(GCA)n	rs62430309	0.0000	0.0029	4/3/0	0.0003							600075 [TBP (confirmed) Spinocerebellar ataxia 17,607136|Parkinson disease,susceptibility to,168600];			COSM2156799	134	703					TBP (inh=AD pLI=0.49)
chr6	170871046	170871046	-	CAG	wt	het	wt	low_DP	QUAL=7055;DP=16,449,379;MQM=59	TBP	disruptive_inframe_insertion	TBP:NM_003194.4:disruptive_inframe_insertion:MODERATE:exon3/8:c.279_281dupGCA:p.Gln94dup,TBP:NM_001172085.1:disruptive_inframe_insertion:MODERATE:exon2/7:c.219_221dupGCA:p.Gln74dup	(GCA)n	rs775224229	0.0000	0.0033	2/1/0	0.0001							600075 [TBP (confirmed) Spinocerebellar ataxia 17,607136|Parkinson disease,susceptibility to,168600];				13	49					TBP (inh=AD pLI=0.49)
chr6	170871049	170871049	G	A	het	wt	het	low_DP	QUAL=7055;DP=16,449,379;MQM=59	TBP	synonymous	TBP:NM_003194.4:synonymous:LOW:exon3/8:c.225G>A:p.Gln75Gln,TBP:NM_001172085.1:synonymous:LOW:exon2/7:c.165G>A:p.Gln55Gln	(GCA)n	rs56241301	0.0000	0.0066	3/2/0	0.0002							600075 [TBP (confirmed) Spinocerebellar ataxia 17,607136|Parkinson disease,susceptibility to,168600];			COSM595316	120	654	1	[1] Tanja Benkert 20.04.2015 [n/a] comment imported from detected variant: 20.04.2015, TCB: Poly-Q, auch in Kontrolle (SCA-V4)			TBP (inh=AD pLI=0.49)
chr6	170871055	170871055	G	A	wt	wt	het		QUAL=3801;DP=20,508,630;MQM=59	TBP	synonymous	TBP:NM_003194.4:synonymous:LOW:exon3/8:c.231G>A:p.Gln77Gln,TBP:NM_001172085.1:synonymous:LOW:exon2/7:c.171G>A:p.Gln57Gln	(GCA)n	rs112928724	0.0000	0.0043	3/2/0	0.0001							600075 [TBP (confirmed) Spinocerebellar ataxia 17,607136|Parkinson disease,susceptibility to,168600];			COSM1442362	20	439					TBP (inh=AD pLI=0.49)
chr6	170878793	170878793	T	C	hom	het	het		QUAL=17626;DP=309,250,338;MQM=59	TBP	synonymous	TBP:NM_003194.4:synonymous:LOW:exon6/8:c.771T>C:p.Asn257Asn,TBP:NM_001172085.1:synonymous:LOW:exon5/7:c.711T>C:p.Asn237Asn		rs1042327	0.6146	0.5319	17709/8802/2320	0.5301	0.3870		T			7.96	600075 [TBP (confirmed) Spinocerebellar ataxia 17,607136|Parkinson disease,susceptibility to,168600];	RCV000118601.2 [likely benign]; 			429	825					TBP (inh=AD pLI=0.49)
chr7	193091	193091	C	T	wt	het	wt	low_DP	QUAL=62;DP=309,8,6;MQM=60	FAM20C	5'UTR_premature_start_codon_gain,5'UTR	FAM20C:NM_020223.3:5'UTR_premature_start_codon_gain:LOW:exon1/10:c.-109C>T:,FAM20C:NM_020223.3:5'UTR:MODIFIER:exon1/10:c.-109C>T:		rs116903250	0.0290	0.0000	0/0/0	0.0069							611061 [FAM20C (confirmed) Raine syndrome,259775];				2	17					FAM20C (inh=AR pLI=0.59)
chr7	286402	286402	A	G	het	hom	wt		QUAL=5419;DP=165,147,325;MQM=59	FAM20C	synonymous	FAM20C:NM_020223.3:synonymous:LOW:exon4/10:c.885A>G:p.Thr295Thr		rs141256626	0.2883	0.2681	691/195/228	0.0719							611061 [FAM20C (confirmed) Raine syndrome,259775];	RCV000303341.1 [benign]; 		COSM4162129	80	517					FAM20C (inh=AR pLI=0.59)
chr7	286468	286468	-	GACAGGTGAGCCCTTCCTTCCTCCCTCCATCCGC	wt	wt	het		QUAL=1591;DP=41,63,151;MQM=59	FAM20C	intron	FAM20C:NM_020223.3:intron:MODIFIER:exon4/9:c.953_956+30dupACAGGTGAGCCCTTCCTTCCTCCCTCCATCCGCG:		rs774848096	0.0000	0.2443	294/183/48	0.0145							611061 [FAM20C (confirmed) Raine syndrome,259775];				121	282	2	[2] old entry - no details available			FAM20C (inh=AR pLI=0.59)
chr7	286502	286502	-	GACAGGTGAGCCCTTCCTTCCTCCCTCCATCCGT	wt	hom	wt		QUAL=1591;DP=41,63,151;MQM=60	FAM20C	intron	FAM20C:NM_020223.3:intron:MODIFIER:exon4/9:c.956+30_956+31insACAGGTGAGCCCTTCCTTCCTCCCTCCATCCGTG:		rs761327749	0.0000	0.1733	279/95/139	0.0055							611061 [FAM20C (confirmed) Raine syndrome,259775];				27	125					FAM20C (inh=AR pLI=0.59)
chr7	296739	296739	G	A	wt	wt	het		QUAL=2858;DP=149,200,238;MQM=60	FAM20C	splice_region&intron	FAM20C:NM_020223.3:splice_region&intron:LOW:exon7/9:c.1363+10G>A:		rs36156504	0.2522	0.3214	886/438/35	0.0936							611061 [FAM20C (confirmed) Raine syndrome,259775];				207	698					FAM20C (inh=AR pLI=0.59)
chr7	299843	299843	G	A	wt	het	wt	pred_pathogenic	QUAL=1217;DP=78,108,145;MQM=60	FAM20C	missense	FAM20C:NM_020223.3:missense:MODERATE:exon10/10:c.1652G>A:p.Arg551His		rs150231592	0.0078	0.0204	8/6/0	0.0063	6.8210	T	T	B	T	19.74	611061 [FAM20C (confirmed) Raine syndrome,259775];	RCV000353679.1 [benign]; 			1	65					FAM20C (inh=AR pLI=0.59)
chr7	299850	299850	G	T	wt	wt	het		QUAL=1658;DP=83,113,137;MQM=60	FAM20C	synonymous	FAM20C:NM_020223.3:synonymous:LOW:exon10/10:c.1659G>T:p.Val553Val		rs36170987	0.5312	0.4735	1855/650/380	0.1330							611061 [FAM20C (confirmed) Raine syndrome,259775];	RCV000173884.1 [benign]; 			362	753					FAM20C (inh=AR pLI=0.59)
chr7	299881	299881	A	G	wt	wt	het	pred_pathogenic	QUAL=1555;DP=135,102,116;MQM=60	FAM20C	missense	FAM20C:NM_020223.3:missense:MODERATE:exon10/10:c.1690A>G:p.Asn564Asp		rs36139924	0.5254	0.4725	1843/650/376	0.1347	3.8720	T	T	B	T	5.06	611061 [FAM20C (confirmed) Raine syndrome,259775];	RCV000173885.1 [benign]; 			358	761					FAM20C (inh=AR pLI=0.59)
chr7	299940	299940	G	A	wt	het	wt		QUAL=1168;DP=119,104,102;MQM=60	FAM20C	synonymous	FAM20C:NM_020223.3:synonymous:LOW:exon10/10:c.1749G>A:p.Ala583Ala		rs143027699	0.0371	0.0639	28/12/1	0.0165							611061 [FAM20C (confirmed) Raine syndrome,259775];				8	172					FAM20C (inh=AR pLI=0.59)
chr7	299976	299976	G	A	wt	wt	het		QUAL=1385;DP=78,111,109;MQM=60	FAM20C	3'UTR	FAM20C:NM_020223.3:3'UTR:MODIFIER:exon10/10:c.*30G>A:		rs36173075	0.2206	0.2711	237/133/3	0.0726							611061 [FAM20C (confirmed) Raine syndrome,259775];				81	316					FAM20C (inh=AR pLI=0.59)
chr7	299987	299987	C	G	wt	het	het		QUAL=2638;DP=76,110,113;MQM=60	FAM20C	3'UTR	FAM20C:NM_020223.3:3'UTR:MODIFIER:exon10/10:c.*41C>G:		rs36138803	0.5941	0.5701	881/362/224	0.1516							611061 [FAM20C (confirmed) Raine syndrome,259775];				273	358					FAM20C (inh=AR pLI=0.59)
chr7	300181	300181	G	A	wt	het	wt		QUAL=2001;DP=145,151,233;MQM=60	FAM20C	3'UTR	FAM20C:NM_020223.3:3'UTR:MODIFIER:exon10/10:c.*235G>A:		rs11546481	0.0282	0.0000	0/0/0	0.0102							611061 [FAM20C (confirmed) Raine syndrome,259775];				1	29					FAM20C (inh=AR pLI=0.59)
chr7	300513	300513	T	C	wt	het	het		QUAL=5638;DP=142,202,293;MQM=60	FAM20C	3'UTR	FAM20C:NM_020223.3:3'UTR:MODIFIER:exon10/10:c.*567T>C:		rs1134015	0.3760	0.0000	0/0/0	0.0791							611061 [FAM20C (confirmed) Raine syndrome,259775];				45	101					FAM20C (inh=AR pLI=0.59)
chr7	4831675	4831675	G	A	het	het	wt		QUAL=1962;DP=63,116,150;MQM=60	AP5Z1	3'UTR	AP5Z1:NM_014855.2:3'UTR:MODIFIER:exon17/17:c.*659G>A:		rs140612456	0.0136	0.0000	0/0/0	0.0348							613653 [AP5Z1 (confirmed) Spastic paraplegia 48,autosomal recessive,613647];				0	20					AP5Z1 (inh=AR pLI=n/a)
chr7	6013049	6013049	C	G	wt	wt	het	low_MQM;pred_pathogenic	QUAL=1464;DP=82,45,124;MQM=39	PMS2	missense,non_coding_transcript_exon	PMS2:NM_001322014.1:missense:MODERATE:exon15/15:c.2603G>C:p.Gly868Ala,PMS2:NM_001322005.1:missense:MODERATE:exon15/15:c.2165G>C:p.Gly722Ala,PMS2:NM_001322009.1:missense:MODERATE:exon15/15:c.2198G>C:p.Gly733Ala,PMS2:NM_000535.6:missense:MODERATE:exon15/15:c.2570G>C:p.Gly857Ala,PMS2:NM_001322003.1:missense:MODERATE:exon15/15:c.2165G>C:p.Gly722Ala,PMS2:NM_001322004.1:missense:MODERATE:exon14/14:c.2165G>C:p.Gly722Ala,PMS2:NM_001322006.1:missense:MODERATE:exon14/14:c.2414G>C:p.Gly805Ala,PMS2:NM_001322007.1:missense:MODERATE:exon14/14:c.2252G>C:p.Gly751Ala,PMS2:NM_001322008.1:missense:MODERATE:exon13/13:c.2252G>C:p.Gly751Ala,PMS2:NM_001322010.1:missense:MODERATE:exon13/13:c.2009G>C:p.Gly670Ala,PMS2:NM_001322011.1:missense:MODERATE:exon15/15:c.1637G>C:p.Gly546Ala,PMS2:NM_001322012.1:missense:MODERATE:exon15/15:c.1637G>C:p.Gly546Ala,PMS2:NM_001322013.1:missense:MODERATE:exon14/14:c.1997G>C:p.Gly666Ala,PMS2:NM_001322015.1:missense:MODERATE:exon15/15:c.2261G>C:p.Gly754Ala,PMS2:NR_136154.1:non_coding_transcript_exon:MODIFIER:exon15/15:n.2614G>C:		rs1802683	0.0000	0.3702	2453/1125/339	0.2026	5.1600	T,T,T,T	T	B,B,B	D,D,T	9.77	600259 [PMS2 (confirmed) Mismatch repair cancer syndrome,276300|Colorectal cancer,hereditary nonpolyposis,type 4,614337];	RCV000030370.5 [benign]; RCV000034628.1 [benign]; RCV000079109.6 [benign]; RCV000130363.2 [benign]; RCV000144646.1 [benign]; 		COSM3833052	153	684					PMS2 (inh=AR+AD pLI=0.00)
chr7	6026775	6026775	T	C	hom	hom	hom	pred_pathogenic	QUAL=31806;DP=190,324,487;MQM=56	PMS2	missense,non_coding_transcript_exon	PMS2:NM_001322014.1:missense:MODERATE:exon11/15:c.1621A>G:p.Lys541Glu,PMS2:NM_001322005.1:missense:MODERATE:exon11/15:c.1216A>G:p.Lys406Glu,PMS2:NM_001322009.1:missense:MODERATE:exon11/15:c.1216A>G:p.Lys406Glu,PMS2:NM_000535.6:missense:MODERATE:exon11/15:c.1621A>G:p.Lys541Glu,PMS2:NM_001322003.1:missense:MODERATE:exon11/15:c.1216A>G:p.Lys406Glu,PMS2:NM_001322004.1:missense:MODERATE:exon10/14:c.1216A>G:p.Lys406Glu,PMS2:NM_001322006.1:missense:MODERATE:exon10/14:c.1465A>G:p.Lys489Glu,PMS2:NM_001322007.1:missense:MODERATE:exon10/14:c.1303A>G:p.Lys435Glu,PMS2:NM_001322008.1:missense:MODERATE:exon9/13:c.1303A>G:p.Lys435Glu,PMS2:NM_001322010.1:missense:MODERATE:exon9/13:c.1060A>G:p.Lys354Glu,PMS2:NM_001322011.1:missense:MODERATE:exon11/15:c.688A>G:p.Lys230Glu,PMS2:NM_001322012.1:missense:MODERATE:exon11/15:c.688A>G:p.Lys230Glu,PMS2:NM_001322013.1:missense:MODERATE:exon10/14:c.1048A>G:p.Lys350Glu,PMS2:NM_001322015.1:missense:MODERATE:exon11/15:c.1312A>G:p.Lys438Glu,PMS2:NR_136154.1:non_coding_transcript_exon:MODIFIER:exon11/15:n.1708A>G:		rs2228006	0.8832	0.8514	44055/24216/4305	0.8176	1.4430	T,T,T,T	T	B,B,B	T,T,D	0.14	600259 [PMS2 (confirmed) Mismatch repair cancer syndrome,276300|Colorectal cancer,hereditary nonpolyposis,type 4,614337];	RCV000030365.3 [benign]; RCV000034619.3 [benign]; RCV000212862.1 [benign]; RCV000121840.3 [benign]; 	BM1497492 [CLASS=R MUT=REF PHEN="Colorectal cancer non-polyposis" GENE=PMS2]; 	COSM4162329	2561	837	1	[1] Tanja Benkert 16.04.2015			PMS2 (inh=AR+AD pLI=0.00)
chr7	6026959	6026959	G	C	het	wt	het	low_MQM;pred_pathogenic;anno_pathogenic_hgmd	QUAL=3707;DP=175,120,198;MQM=47	PMS2	missense,non_coding_transcript_exon	PMS2:NM_001322014.1:missense:MODERATE:exon11/15:c.1437C>G:p.His479Gln,PMS2:NM_001322005.1:missense:MODERATE:exon11/15:c.1032C>G:p.His344Gln,PMS2:NM_001322009.1:missense:MODERATE:exon11/15:c.1032C>G:p.His344Gln,PMS2:NM_000535.6:missense:MODERATE:exon11/15:c.1437C>G:p.His479Gln,PMS2:NM_001322003.1:missense:MODERATE:exon11/15:c.1032C>G:p.His344Gln,PMS2:NM_001322004.1:missense:MODERATE:exon10/14:c.1032C>G:p.His344Gln,PMS2:NM_001322006.1:missense:MODERATE:exon10/14:c.1281C>G:p.His427Gln,PMS2:NM_001322007.1:missense:MODERATE:exon10/14:c.1119C>G:p.His373Gln,PMS2:NM_001322008.1:missense:MODERATE:exon9/13:c.1119C>G:p.His373Gln,PMS2:NM_001322010.1:missense:MODERATE:exon9/13:c.876C>G:p.His292Gln,PMS2:NM_001322011.1:missense:MODERATE:exon11/15:c.504C>G:p.His168Gln,PMS2:NM_001322012.1:missense:MODERATE:exon11/15:c.504C>G:p.His168Gln,PMS2:NM_001322013.1:missense:MODERATE:exon10/14:c.864C>G:p.His288Gln,PMS2:NM_001322015.1:missense:MODERATE:exon11/15:c.1128C>G:p.His376Gln,PMS2:NR_136154.1:non_coding_transcript_exon:MODIFIER:exon11/15:n.1524C>G:		rs63750685	0.0028	0.0045	3/2/0	0.0005	0.1820	T,T,T,T	T	B,B,B	T,T,D	0.65	600259 [PMS2 (confirmed) Mismatch repair cancer syndrome,276300|Colorectal cancer,hereditary nonpolyposis,type 4,614337];	RCV000166894.1 [likely benign]; RCV000034615.3 [benign]; RCV000076809.5 [uncertain significance]; RCV000121844.2 [benign]; RCV000162366.1 [benign]; 	CM1612932 [CLASS=DM? MUT=ALT PHEN="Breast and/or ovarian cancer" GENE=PMS2]; 		0	26	3	[3] Ilnaz Sepahi 29-03-2016 batch import			PMS2 (inh=AR+AD pLI=0.00)
chr7	6026988	6026988	G	A	hom	het	het	pred_pathogenic	QUAL=9619;DP=217,102,165;MQM=52	PMS2	missense,non_coding_transcript_exon	PMS2:NM_001322014.1:missense:MODERATE:exon11/15:c.1408C>T:p.Pro470Ser,PMS2:NM_001322005.1:missense:MODERATE:exon11/15:c.1003C>T:p.Pro335Ser,PMS2:NM_001322009.1:missense:MODERATE:exon11/15:c.1003C>T:p.Pro335Ser,PMS2:NM_000535.6:missense:MODERATE:exon11/15:c.1408C>T:p.Pro470Ser,PMS2:NM_001322003.1:missense:MODERATE:exon11/15:c.1003C>T:p.Pro335Ser,PMS2:NM_001322004.1:missense:MODERATE:exon10/14:c.1003C>T:p.Pro335Ser,PMS2:NM_001322006.1:missense:MODERATE:exon10/14:c.1252C>T:p.Pro418Ser,PMS2:NM_001322007.1:missense:MODERATE:exon10/14:c.1090C>T:p.Pro364Ser,PMS2:NM_001322008.1:missense:MODERATE:exon9/13:c.1090C>T:p.Pro364Ser,PMS2:NM_001322010.1:missense:MODERATE:exon9/13:c.847C>T:p.Pro283Ser,PMS2:NM_001322011.1:missense:MODERATE:exon11/15:c.475C>T:p.Pro159Ser,PMS2:NM_001322012.1:missense:MODERATE:exon11/15:c.475C>T:p.Pro159Ser,PMS2:NM_001322013.1:missense:MODERATE:exon10/14:c.835C>T:p.Pro279Ser,PMS2:NM_001322015.1:missense:MODERATE:exon11/15:c.1099C>T:p.Pro367Ser,PMS2:NR_136154.1:non_coding_transcript_exon:MODIFIER:exon11/15:n.1495C>T:		rs1805321	0.3582	0.3854	9186/5718/417	0.3781	0.2650	T,T,T,T	T	B,B,B	T,T,D	0.09	600259 [PMS2 (confirmed) Mismatch repair cancer syndrome,276300|Colorectal cancer,hereditary nonpolyposis,type 4,614337];	RCV000030364.4 [benign]; RCV000034614.1 [benign]; RCV000079103.7 [benign]; RCV000130721.2 [benign]; RCV000144645.1 [benign]; 		COSM3736445	624	1654	1	[1] old entry - no details available			PMS2 (inh=AR+AD pLI=0.00)
chr7	6036980	6036980	G	C	hom	hom	hom		QUAL=7014;DP=124,47,40;MQM=60	PMS2	synonymous,5'UTR,non_coding_transcript_exon	PMS2:NM_001322014.1:synonymous:LOW:exon7/15:c.780C>G:p.Ser260Ser,PMS2:NM_001322005.1:synonymous:LOW:exon7/15:c.375C>G:p.Ser125Ser,PMS2:NM_001322009.1:synonymous:LOW:exon7/15:c.375C>G:p.Ser125Ser,PMS2:NM_000535.6:synonymous:LOW:exon7/15:c.780C>G:p.Ser260Ser,PMS2:NM_001322003.1:synonymous:LOW:exon7/15:c.375C>G:p.Ser125Ser,PMS2:NM_001322004.1:synonymous:LOW:exon6/14:c.375C>G:p.Ser125Ser,PMS2:NM_001322006.1:synonymous:LOW:exon7/14:c.780C>G:p.Ser260Ser,PMS2:NM_001322007.1:synonymous:LOW:exon6/14:c.462C>G:p.Ser154Ser,PMS2:NM_001322008.1:synonymous:LOW:exon5/13:c.462C>G:p.Ser154Ser,PMS2:NM_001322010.1:synonymous:LOW:exon6/13:c.375C>G:p.Ser125Ser,PMS2:NM_001322013.1:synonymous:LOW:exon6/14:c.207C>G:p.Ser69Ser,PMS2:NM_001322015.1:synonymous:LOW:exon7/15:c.471C>G:p.Ser157Ser,PMS2:NM_001322011.1:5'UTR:MODIFIER:exon7/15:c.-154C>G:,PMS2:NM_001322012.1:5'UTR:MODIFIER:exon7/15:c.-154C>G:,PMS2:NR_136154.1:non_coding_transcript_exon:MODIFIER:exon7/15:n.867C>G:		rs1805319	0.8313	0.8109	39906/22309/3695	0.7970							600259 [PMS2 (confirmed) Mismatch repair cancer syndrome,276300|Colorectal cancer,hereditary nonpolyposis,type 4,614337];	RCV000162392.1 [benign]; RCV000030372.4 [benign]; RCV000079112.6 [benign]; RCV000131484.2 [benign]; RCV000229294.1 [likely benign]; 		COSM4162330	2340	1011	1	[1] Ilnaz Sepahi 29-03-2016 batch import			PMS2 (inh=AR+AD pLI=0.00)
chr7	6037058	6037058	A	-	hom	het	het	low_DP	QUAL=344;DP=17,32,29;MQM=59	PMS2	splice_region&intron	PMS2:NM_001322014.1:splice_region&intron:LOW:exon6/14:c.706-4delT:,PMS2:NM_001322005.1:splice_region&intron:LOW:exon6/14:c.301-4delT:,PMS2:NM_001322009.1:splice_region&intron:LOW:exon6/14:c.301-4delT:,PMS2:NM_000535.6:splice_region&intron:LOW:exon6/14:c.706-4delT:,PMS2:NM_001322003.1:splice_region&intron:LOW:exon6/14:c.301-4delT:,PMS2:NM_001322004.1:splice_region&intron:LOW:exon5/13:c.301-4delT:,PMS2:NM_001322006.1:splice_region&intron:LOW:exon6/13:c.706-4delT:,PMS2:NM_001322007.1:splice_region&intron:LOW:exon5/13:c.388-4delT:,PMS2:NM_001322008.1:splice_region&intron:LOW:exon4/12:c.388-4delT:,PMS2:NM_001322010.1:splice_region&intron:LOW:exon5/12:c.301-4delT:,PMS2:NM_001322011.1:splice_region&intron:LOW:exon6/14:c.-228-4delT:,PMS2:NM_001322012.1:splice_region&intron:LOW:exon6/14:c.-228-4delT:,PMS2:NM_001322013.1:splice_region&intron:LOW:exon5/13:c.133-4delT:,PMS2:NM_001322015.1:splice_region&intron:LOW:exon6/14:c.397-4delT:,PMS2:NR_136154.1:splice_region&intron:LOW:exon6/14:n.793-4delT:	(A)n	rs549498051;rs549793612;rs60794673;rs796382014	0.4531	0.4422	321/196/10	0.3329							600259 [PMS2 (confirmed) Mismatch repair cancer syndrome,276300|Colorectal cancer,hereditary nonpolyposis,type 4,614337];	RCV000203188.1 [benign]; RCV000415703.1,RCV000203188.1 [uncertain significance,benign]; RCV000415703.1 [uncertain significance]; 			338	1987					PMS2 (inh=AR+AD pLI=0.00)
chr7	6045627	6045627	C	T	wt	het	wt	pred_pathogenic;anno_pathogenic_hgmd	QUAL=1843;DP=291,188,205;MQM=60	PMS2	missense,5'UTR,intron,non_coding_transcript_exon	PMS2:NM_001322014.1:missense:MODERATE:exon2/15:c.59G>A:p.Arg20Gln,PMS2:NM_000535.6:missense:MODERATE:exon2/15:c.59G>A:p.Arg20Gln,PMS2:NM_001322006.1:missense:MODERATE:exon2/14:c.59G>A:p.Arg20Gln,PMS2:NM_001322005.1:5'UTR:MODIFIER:exon2/15:c.-347G>A:,PMS2:NM_001322009.1:5'UTR:MODIFIER:exon2/15:c.-347G>A:,PMS2:NM_001322003.1:5'UTR:MODIFIER:exon2/15:c.-347G>A:,PMS2:NM_001322007.1:5'UTR:MODIFIER:exon2/14:c.-157G>A:,PMS2:NM_001322011.1:5'UTR:MODIFIER:exon2/15:c.-826G>A:,PMS2:NM_001322012.1:5'UTR:MODIFIER:exon2/15:c.-826G>A:,PMS2:NM_001322013.1:5'UTR:MODIFIER:exon2/14:c.-347G>A:,PMS2:NM_001322015.1:5'UTR:MODIFIER:exon2/15:c.-426G>A:,PMS2:NM_001322004.1:intron:MODIFIER:exon1/13:c.-242-1938G>A:,PMS2:NM_001322008.1:intron:MODIFIER:exon1/12:c.-52-1938G>A:,PMS2:NM_001322010.1:intron:MODIFIER:exon1/12:c.-242-1938G>A:,PMS2:NR_136154.1:non_coding_transcript_exon:MODIFIER:exon2/15:n.146G>A:		rs10254120	0.0757	0.0782	410/247/37	0.0684	0.1130	T,T,T	T	B,B,B	D,D,D	21.70	600259 [PMS2 (confirmed) Mismatch repair cancer syndrome,276300|Colorectal cancer,hereditary nonpolyposis,type 4,614337];	RCV000219300.1 [uncertain significance]; RCV000034632.1 [benign]; RCV000076879.3 [benign]; RCV000121854.3 [benign]; RCV000130423.2 [benign]; RCV000144652.1 [benign]; 	CM941176 [CLASS=DM? MUT=ALT PHEN="Colorectal cancer non-polyposis" GENE=PMS2]; 		18	380	1	[1] old entry - no details available			PMS2 (inh=AR+AD pLI=0.00)
chr7	22980929	22980929	-	AC	het	wt	hom		QUAL=4808;DP=127,66,100;MQM=59	FAM126A	3'UTR	FAM126A:NM_032581.3:3'UTR:MODIFIER:exon11/11:c.*4278_*4279insGT:		rs35708583;rs55691833	0.4275	0.0000	0/0/0	0.3715							610531 [FAM126A (provisional) Leukodystrophy,hypomyelinating,5,610532];	RCV000330372.1 [benign]; 			34	106					FAM126A (inh=AR pLI=0.80)
chr7	22981404	22981404	T	G	het	hom	wt		QUAL=4841;DP=150,102,128;MQM=59	FAM126A	3'UTR	FAM126A:NM_032581.3:3'UTR:MODIFIER:exon11/11:c.*3804A>C:		rs34683819	0.2250	0.0000	0/0/0	0.2726							610531 [FAM126A (provisional) Leukodystrophy,hypomyelinating,5,610532];	RCV000319011.1 [benign]; 			32	88					FAM126A (inh=AR pLI=0.80)
chr7	22981528	22981528	T	C	het	wt	hom		QUAL=8018;DP=203,86,167;MQM=59	FAM126A	3'UTR	FAM126A:NM_032581.3:3'UTR:MODIFIER:exon11/11:c.*3680A>G:		rs3815348	0.4275	0.0000	0/0/0	0.0703							610531 [FAM126A (provisional) Leukodystrophy,hypomyelinating,5,610532];	RCV000283853.1 [benign]; 			34	105					FAM126A (inh=AR pLI=0.80)
chr7	22981942	22981942	G	A	wt	het	wt		QUAL=1421;DP=270,100,124;MQM=60	FAM126A	3'UTR	FAM126A:NM_032581.3:3'UTR:MODIFIER:exon11/11:c.*3266C>T:		rs75393023	0.0302	0.0000	0/0/0	0.0629							610531 [FAM126A (provisional) Leukodystrophy,hypomyelinating,5,610532];	RCV000289717.1 [likely benign]; 			1	40					FAM126A (inh=AR pLI=0.80)
chr7	22982207	22982207	T	C	het	wt	hom		QUAL=8371;DP=261,94,139;MQM=60	FAM126A	3'UTR	FAM126A:NM_032581.3:3'UTR:MODIFIER:exon11/11:c.*3001A>G:		rs2286495	0.4277	0.0000	0/0/0	0.0708							610531 [FAM126A (provisional) Leukodystrophy,hypomyelinating,5,610532];	RCV000346964.1 [benign]; 			34	107					FAM126A (inh=AR pLI=0.80)
chr7	22982547	22982547	G	A	het	hom	wt		QUAL=5820;DP=276,80,152;MQM=60	FAM126A	3'UTR	FAM126A:NM_032581.3:3'UTR:MODIFIER:exon11/11:c.*2661C>T:		rs13222017	0.2206	0.0000	0/0/0	0.0455							610531 [FAM126A (provisional) Leukodystrophy,hypomyelinating,5,610532];	RCV000315359.1 [benign]; 			30	89					FAM126A (inh=AR pLI=0.80)
chr7	22982826	22982827	AT	-	het	wt	hom		QUAL=7427;DP=298,99,114;MQM=59	FAM126A	3'UTR	FAM126A:NM_032581.3:3'UTR:MODIFIER:exon11/11:c.*2381_*2382delAT:		rs143367578	0.1086	0.0000	0/0/0	0.1113							610531 [FAM126A (provisional) Leukodystrophy,hypomyelinating,5,610532];	RCV000261140.1 [likely benign]; 			5	65					FAM126A (inh=AR pLI=0.80)
chr7	22983600	22983600	T	C	het	hom	wt		QUAL=10760;DP=428,158,215;MQM=60	FAM126A	3'UTR	FAM126A:NM_032581.3:3'UTR:MODIFIER:exon11/11:c.*1608A>G:		rs10488277	0.2250	0.0000	0/0/0	0.0468							610531 [FAM126A (provisional) Leukodystrophy,hypomyelinating,5,610532];	RCV000385752.1 [benign]; 			30	91					FAM126A (inh=AR pLI=0.80)
chr7	22983702	22983702	A	T	hom	hom	hom		QUAL=32399;DP=490,239,308;MQM=59	FAM126A	3'UTR	FAM126A:NM_032581.3:3'UTR:MODIFIER:exon11/11:c.*1506T>A:		rs4607514	0.6671	0.0000	0/0/0	0.1183							610531 [FAM126A (provisional) Leukodystrophy,hypomyelinating,5,610532];	RCV000351086.1 [benign]; 			144	120					FAM126A (inh=AR pLI=0.80)
chr7	22983890	22983890	T	C	hom	hom	hom		QUAL=30281;DP=340,226,350;MQM=60	FAM126A	3'UTR	FAM126A:NM_032581.3:3'UTR:MODIFIER:exon11/11:c.*1318A>G:		rs1583511	0.6721	0.0000	0/0/0	0.1193							610531 [FAM126A (provisional) Leukodystrophy,hypomyelinating,5,610532];	RCV000406825.1 [benign]; 			118	91					FAM126A (inh=AR pLI=0.80)
chr7	22984772	22984772	A	C	het	wt	hom		QUAL=17653;DP=505,265,347;MQM=59	FAM126A	3'UTR	FAM126A:NM_032581.3:3'UTR:MODIFIER:exon11/11:c.*436T>G:		rs10085448	0.4301	0.0000	0/0/0	0.0461							610531 [FAM126A (provisional) Leukodystrophy,hypomyelinating,5,610532];	RCV000384924.1 [benign]; 			34	106					FAM126A (inh=AR pLI=0.80)
chr7	22984773	22984773	G	A	het	wt	hom		QUAL=17653;DP=505,265,347;MQM=59	FAM126A	3'UTR	FAM126A:NM_032581.3:3'UTR:MODIFIER:exon11/11:c.*435C>T:		rs10085739	0.4273	0.0000	0/0/0	0.0454							610531 [FAM126A (provisional) Leukodystrophy,hypomyelinating,5,610532];	RCV000331632.1 [benign]; 			34	106					FAM126A (inh=AR pLI=0.80)
chr7	22984824	22984824	T	C	hom	hom	hom		QUAL=37253;DP=592,246,303;MQM=60	FAM126A	3'UTR	FAM126A:NM_032581.3:3'UTR:MODIFIER:exon11/11:c.*384A>G:		rs2286494	0.6530	0.0000	0/0/0	0.1175							610531 [FAM126A (provisional) Leukodystrophy,hypomyelinating,5,610532];	RCV000388447.1 [benign]; 			116	92					FAM126A (inh=AR pLI=0.80)
chr7	22984967	22984967	A	G	het	hom	wt		QUAL=7369;DP=286,116,156;MQM=60	FAM126A	3'UTR	FAM126A:NM_032581.3:3'UTR:MODIFIER:exon11/11:c.*241T>C:		rs2286493	0.2025	0.0000	0/0/0	0.0457							610531 [FAM126A (provisional) Leukodystrophy,hypomyelinating,5,610532];	RCV000335061.1 [benign]; 			29	90					FAM126A (inh=AR pLI=0.80)
chr7	22985010	22985010	A	C	wt	het	wt		QUAL=1500;DP=348,119,164;MQM=60	FAM126A	3'UTR	FAM126A:NM_032581.3:3'UTR:MODIFIER:exon11/11:c.*198T>G:		rs2286492	0.0697	0.0000	0/0/0	0.0151							610531 [FAM126A (provisional) Leukodystrophy,hypomyelinating,5,610532];	RCV000281285.1 [likely benign]; 			2	43					FAM126A (inh=AR pLI=0.80)
chr7	23015831	23015831	T	C	het	wt	hom	pred_pathogenic	QUAL=11183;DP=269,203,225;MQM=60	FAM126A	splice_region&synonymous	FAM126A:NM_032581.3:splice_region&synonymous:LOW:exon7/11:c.624A>G:p.Ser208Ser		rs3735231	0.3748	0.3738	8519/4256/634	0.3676	1.6430		T			11.59	610531 [FAM126A (provisional) Leukodystrophy,hypomyelinating,5,610532];	RCV000020929.3 [benign]; RCV000244607.1 [benign]; 			233	932	1	[1] old entry - no details available			FAM126A (inh=AR pLI=0.80)
chr7	30634313	30634313	G	A	wt	wt	het		QUAL=3193;DP=175,177,265;MQM=60	LOC401320-GARS	intergenic_region	LOC401320-GARS:LOC401320-GARS:intergenic_region:MODIFIER::n.30634313G>A:		rs148593022	0.0038	0.0000	0/0/0	0.0069							600287 [GARS (confirmed) Charcot-Marie-Tooth disease,type 2D,601472|Neuropathy,distal hereditary motor,type VA,600794];	RCV000276196.1 [likely benign]; RCV000326537.1 [likely benign]; RCV000362552.1 [likely benign]; 			0	5					LOC401320-GARS (inh=n/a pLI=n/a)
chr7	30634661	30634661	C	G	hom	hom	hom	low_DP	QUAL=3762;DP=19,44,71;MQM=59	GARS	missense,5'UTR	GARS:NM_002047.3:missense:MODERATE:exon1/17:c.124C>G:p.Pro42Ala,GARS:NM_001316772.1:5'UTR:MODIFIER:exon1/17:c.-39C>G:		rs1049402	0.6494	0.7030	10805/6788/464	0.6091	-0.6710	T	T	B	T	0.01	600287 [GARS (confirmed) Charcot-Marie-Tooth disease,type 2D,601472|Neuropathy,distal hereditary motor,type VA,600794];	RCV000249303.1 [benign]; RCV000305283.1 [benign]; RCV000340289.1 [benign]; RCV000396526.1 [benign]; 		COSM3762627	1192	731					GARS (inh=AD pLI=0.79)
chr7	30673345	30673345	C	T	hom	hom	hom		QUAL=20047;DP=205,185,241;MQM=60	GARS	splice_region&intron	GARS:NM_002047.3:splice_region&intron:LOW:exon16/16:c.2095-6C>T:,GARS:NM_001316772.1:splice_region&intron:LOW:exon16/16:c.1933-6C>T:		rs2240401	0.4042	0.5525	19754/13801/124	0.5485							600287 [GARS (confirmed) Charcot-Marie-Tooth disease,type 2D,601472|Neuropathy,distal hereditary motor,type VA,600794];	RCV000241978.1 [benign]; RCV000301521.1 [benign]; RCV000367864.1 [benign]; RCV000393359.1 [benign]; 		COSM4004448	773	954					GARS (inh=AD pLI=0.79)
chr7	30673513	30673513	A	-	hom	hom	hom		QUAL=9245;DP=277,189,238;MQM=59	GARS	3'UTR	GARS:NM_002047.3:3'UTR:MODIFIER:exon17/17:c.*51delA:,GARS:NM_001316772.1:3'UTR:MODIFIER:exon17/17:c.*51delA:		rs70983380;rs755441530	0.0000	0.4340	1411/1015/47	0.3560							600287 [GARS (confirmed) Charcot-Marie-Tooth disease,type 2D,601472|Neuropathy,distal hereditary motor,type VA,600794];	RCV000280689.1 [uncertain significance]; RCV000338090.1 [uncertain significance]; RCV000406647.1 [uncertain significance]; 			195	357					GARS (inh=AD pLI=0.79)
chr7	42000924	42000924	C	T	wt	wt	het		QUAL=5091;DP=361,319,407;MQM=60	GLI3	3'UTR	GLI3:NM_000168.5:3'UTR:MODIFIER:exon15/15:c.*3004G>A:		rs3735361	0.3113	0.0000	0/0/0	0.0603							165240 [GLI3 (confirmed) Greig cephalopolysyndactyly syndrome,175700|Pallister-Hall syndrome,146510|Polydactyly,preaxial,type IV,174700|Polydactyly,postaxial,types A1 and B,174200|Hypothalamic hamartomas,somatic,241800];	RCV000287285.1 [benign]; RCV000342275.1 [benign]; RCV000379575.1 [benign]; 			26	102					GLI3 (inh=AD pLI=1.00)
chr7	42001171	42001171	G	A	wt	wt	het		QUAL=5362;DP=378,308,441;MQM=60	GLI3	3'UTR	GLI3:NM_000168.5:3'UTR:MODIFIER:exon15/15:c.*2757C>T:		rs3823720	0.2662	0.0000	0/0/0	0.0528							165240 [GLI3 (confirmed) Greig cephalopolysyndactyly syndrome,175700|Pallister-Hall syndrome,146510|Polydactyly,preaxial,type IV,174700|Polydactyly,postaxial,types A1 and B,174200|Hypothalamic hamartomas,somatic,241800];	RCV000288412.1 [benign]; RCV000347961.1 [benign]; RCV000382828.1 [benign]; 			18	101					GLI3 (inh=AD pLI=1.00)
chr7	42001570	42001570	A	-	wt	wt	het		QUAL=1680;DP=167,103,147;MQM=59	GLI3	3'UTR	GLI3:NM_000168.5:3'UTR:MODIFIER:exon15/15:c.*2358delT:	A-rich	rs144064690	0.0000	0.0000	0/0/0	0.0068							165240 [GLI3 (confirmed) Greig cephalopolysyndactyly syndrome,175700|Pallister-Hall syndrome,146510|Polydactyly,preaxial,type IV,174700|Polydactyly,postaxial,types A1 and B,174200|Hypothalamic hamartomas,somatic,241800];	RCV000298377.1 [uncertain significance]; RCV000334670.1 [uncertain significance]; RCV000404956.1 [uncertain significance]; 			0	14					GLI3 (inh=AD pLI=1.00)
chr7	42003500	42003500	G	A	wt	wt	het		QUAL=650;DP=175,38,64;MQM=60	GLI3	3'UTR	GLI3:NM_000168.5:3'UTR:MODIFIER:exon15/15:c.*428C>T:		rs2051935	0.4517	0.0000	0/0/0	0.0757							165240 [GLI3 (confirmed) Greig cephalopolysyndactyly syndrome,175700|Pallister-Hall syndrome,146510|Polydactyly,preaxial,type IV,174700|Polydactyly,postaxial,types A1 and B,174200|Hypothalamic hamartomas,somatic,241800];	RCV000289654.1 [benign]; RCV000328387.1 [benign]; RCV000385228.1 [benign]; 			31	114					GLI3 (inh=AD pLI=1.00)
chr7	42003662	42003662	-	T	wt	wt	hom	low_DP	QUAL=212;DP=83,3,12;MQM=59	GLI3	3'UTR	GLI3:NM_000168.5:3'UTR:MODIFIER:exon15/15:c.*265dupA:			0.3918	0.0000	0/0/0	0.0895							165240 [GLI3 (confirmed) Greig cephalopolysyndactyly syndrome,175700|Pallister-Hall syndrome,146510|Polydactyly,preaxial,type IV,174700|Polydactyly,postaxial,types A1 and B,174200|Hypothalamic hamartomas,somatic,241800];	RCV000296647.1 [benign]; RCV000334979.1 [benign]; RCV000392620.1 [benign]; 			4	41					GLI3 (inh=AD pLI=1.00)
chr7	42005678	42005678	G	A	wt	wt	het	pred_pathogenic	QUAL=589;DP=37,33,49;MQM=60	GLI3	missense	GLI3:NM_000168.5:missense:MODERATE:exon15/15:c.2993C>T:p.Pro998Leu		rs929387	0.4215	0.4558	5815/1796/79	0.3344	4.7580	T	T	B	T	8.30	165240 [GLI3 (confirmed) Greig cephalopolysyndactyly syndrome,175700|Pallister-Hall syndrome,146510|Polydactyly,preaxial,type IV,174700|Polydactyly,postaxial,types A1 and B,174200|Hypothalamic hamartomas,somatic,241800];	RCV000245039.2 [benign]; RCV000274578.1 [benign]; RCV000311017.1 [benign]; RCV000366034.1 [benign]; 	CM068412 [CLASS=DFP MUT=REF PHEN="Talipes equinovarus congential idiopathic association with" GENE=GLI3]; 	COSM3750024	186	664					GLI3 (inh=AD pLI=1.00)
chr7	44183976	44183976	G	-	wt	het	wt		QUAL=242;DP=73,37,45;MQM=60	GCK	3'UTR	GCK:NM_033507.1:3'UTR:MODIFIER:exon10/10:c.*759delC:,GCK:NM_033508.1:3'UTR:MODIFIER:exon11/11:c.*759delC:,GCK:NM_000162.3:3'UTR:MODIFIER:exon10/10:c.*759delC:		rs55714218	0.4111	0.0000	0/0/0	0.2316							138079 [GCK (confirmed) MODY,type II,125851|Diabetes mellitus,noninsulin-dependent,late onset,125853|Hyperinsulinemic hypoglycemia,familial,3,602485|Diabetes mellitus,permanent neonatal,606176];	RCV000300132.1 [benign]; RCV000335205.1 [benign]; RCV000368903.1 [benign]; RCV000402400.1 [benign]; 			8	68					GCK (inh=AD pLI=0.20)
chr7	44184403	44184403	C	T	het	het	wt		QUAL=2265;DP=118,79,119;MQM=59	GCK	3'UTR	GCK:NM_033507.1:3'UTR:MODIFIER:exon10/10:c.*332G>A:,GCK:NM_033508.1:3'UTR:MODIFIER:exon11/11:c.*332G>A:,GCK:NM_000162.3:3'UTR:MODIFIER:exon10/10:c.*332G>A:		rs13306388	0.1520	0.0000	0/0/0	0.0376							138079 [GCK (confirmed) MODY,type II,125851|Diabetes mellitus,noninsulin-dependent,late onset,125853|Hyperinsulinemic hypoglycemia,familial,3,602485|Diabetes mellitus,permanent neonatal,606176];	RCV000290517.1 [benign]; RCV000296546.1 [benign]; RCV000344515.1 [benign]; RCV000382811.1 [benign]; 			14	88					GCK (inh=AD pLI=0.20)
chr7	44185088	44185088	G	A	wt	het	wt	low_DP	QUAL=109;DP=76,14,25;MQM=60	GCK	splice_region&intron	GCK:NM_033507.1:splice_region&intron:LOW:exon9/9:c.1256+8C>T:,GCK:NM_033508.1:splice_region&intron:LOW:exon10/10:c.1250+8C>T:,GCK:NM_000162.3:splice_region&intron:LOW:exon9/9:c.1253+8C>T:		rs2908274	0.4131	0.3681	4576/872/1823	0.2485							138079 [GCK (confirmed) MODY,type II,125851|Diabetes mellitus,noninsulin-dependent,late onset,125853|Hyperinsulinemic hypoglycemia,familial,3,602485|Diabetes mellitus,permanent neonatal,606176];	RCV000117136.3 [other]; RCV000285372.1 [benign]; RCV000291162.1 [benign]; RCV000320390.1 [benign]; RCV000377488.1 [benign]; 			70	507					GCK (inh=AD pLI=0.20)
chr7	47865325	47865325	C	A	hom	hom	hom	gene_blacklist	QUAL=19261;DP=316,142,150;MQM=60	PKD1L1	intron	PKD1L1:NM_138295.3:intron:MODIFIER:exon45/56:c.6854+1623G>T:		rs4720618	0.9802	0.0000	0/0/0	0.8727							609721 [PKD1L1 (provisional) Heterotaxy,visceral,8,autosomal,617205];				150	0					PKD1L1 (inh=n/a pLI=0.00)
chr7	50560382	50560382	A	T	het	hom	wt		QUAL=7046;DP=287,140,227;MQM=59	DDC	3'UTR,intron	DDC:NM_001242890.1:3'UTR:MODIFIER:exon10/10:c.*249T>A:,DDC:NM_000790.3:intron:MODIFIER:exon9/14:c.944+2666T>A:,DDC:NM_001242886.1:intron:MODIFIER:exon8/13:c.830+2666T>A:,DDC:NM_001242887.1:intron:MODIFIER:exon8/13:c.800+2666T>A:,DDC:NM_001242888.1:intron:MODIFIER:exon7/12:c.710+2666T>A:,DDC:NM_001242889.1:intron:MODIFIER:exon7/12:c.665+2666T>A:,DDC:NM_001082971.1:intron:MODIFIER:exon9/14:c.944+2666T>A:		rs866666526	0.0000	0.0000	0/0/0	0.0011							107930 [DDC (confirmed) Aromatic L-amino acid decarboxylase deficiency,608643];				61	78					DDC (inh=AR pLI=0.00)
chr7	50560384	50560388	TTTCC	-	het	hom	wt		QUAL=7046;DP=287,140,227;MQM=59	DDC	3'UTR,intron	DDC:NM_001242890.1:3'UTR:MODIFIER:exon10/10:c.*243_*247delGGAAA:,DDC:NM_000790.3:intron:MODIFIER:exon9/14:c.944+2660_944+2664delGGAAA:,DDC:NM_001242886.1:intron:MODIFIER:exon8/13:c.830+2660_830+2664delGGAAA:,DDC:NM_001242887.1:intron:MODIFIER:exon8/13:c.800+2660_800+2664delGGAAA:,DDC:NM_001242888.1:intron:MODIFIER:exon7/12:c.710+2660_710+2664delGGAAA:,DDC:NM_001242889.1:intron:MODIFIER:exon7/12:c.665+2660_665+2664delGGAAA:,DDC:NM_001082971.1:intron:MODIFIER:exon9/14:c.944+2660_944+2664delGGAAA:			0.0000	0.0000	0/0/0	0.0000							107930 [DDC (confirmed) Aromatic L-amino acid decarboxylase deficiency,608643];				61	78					DDC (inh=AR pLI=0.00)
chr7	50560391	50560391	-	CTC	het	hom	wt		QUAL=8282;DP=301,156,246;MQM=59	DDC	3'UTR,intron	DDC:NM_001242890.1:3'UTR:MODIFIER:exon10/10:c.*239_*240insGAG:,DDC:NM_000790.3:intron:MODIFIER:exon9/14:c.944+2656_944+2657insGAG:,DDC:NM_001242886.1:intron:MODIFIER:exon8/13:c.830+2656_830+2657insGAG:,DDC:NM_001242887.1:intron:MODIFIER:exon8/13:c.800+2656_800+2657insGAG:,DDC:NM_001242888.1:intron:MODIFIER:exon7/12:c.710+2656_710+2657insGAG:,DDC:NM_001242889.1:intron:MODIFIER:exon7/12:c.665+2656_665+2657insGAG:,DDC:NM_001082971.1:intron:MODIFIER:exon9/14:c.944+2656_944+2657insGAG:		rs774393354	0.0000	0.0000	0/0/0	0.0001							107930 [DDC (confirmed) Aromatic L-amino acid decarboxylase deficiency,608643];				61	78					DDC (inh=AR pLI=0.00)
chr7	50560394	50560394	G	TCCTCTCTC	het	hom	wt		QUAL=8376;DP=287,159,243;MQM=59	DDC	3'UTR,intron	DDC:NM_001242890.1:3'UTR:MODIFIER:exon10/10:c.*237delCinsGAGAGAGGA:,DDC:NM_000790.3:intron:MODIFIER:exon9/14:c.944+2654delCinsGAGAGAGGA:,DDC:NM_001242886.1:intron:MODIFIER:exon8/13:c.830+2654delCinsGAGAGAGGA:,DDC:NM_001242887.1:intron:MODIFIER:exon8/13:c.800+2654delCinsGAGAGAGGA:,DDC:NM_001242888.1:intron:MODIFIER:exon7/12:c.710+2654delCinsGAGAGAGGA:,DDC:NM_001242889.1:intron:MODIFIER:exon7/12:c.665+2654delCinsGAGAGAGGA:,DDC:NM_001082971.1:intron:MODIFIER:exon9/14:c.944+2654delCinsGAGAGAGGA:			0.0000	0.0000	0/0/0	0.0000							107930 [DDC (confirmed) Aromatic L-amino acid decarboxylase deficiency,608643];				60	77					DDC (inh=AR pLI=0.00)
chr7	50611735	50611735	T	C	hom	hom	hom		QUAL=33279;DP=235,343,466;MQM=59	DDC	missense	DDC:NM_000790.3:missense:MODERATE:exon2/15:c.49A>G:p.Met17Val,DDC:NM_001242886.1:missense:MODERATE:exon2/14:c.49A>G:p.Met17Val,DDC:NM_001242887.1:missense:MODERATE:exon2/14:c.49A>G:p.Met17Val,DDC:NM_001242888.1:missense:MODERATE:exon2/13:c.49A>G:p.Met17Val,DDC:NM_001242889.1:missense:MODERATE:exon2/13:c.49A>G:p.Met17Val,DDC:NM_001082971.1:missense:MODERATE:exon2/15:c.49A>G:p.Met17Val,DDC:NM_001242890.1:missense:MODERATE:exon2/10:c.49A>G:p.Met17Val		rs6264	0.9932	0.9982	60489/33368/5000	0.9346	-0.6030	T,T,T,T,T,T	T	B	T,T,T,T,T,T	0.36	107930 [DDC (confirmed) Aromatic L-amino acid decarboxylase deficiency,608643];				1760	1					DDC (inh=AR pLI=0.00)
chr7	50628740	50628743	CTCT	-	het	wt	hom		QUAL=7905;DP=256,218,185;MQM=59	DDC	5'UTR,intron	DDC:NM_000790.3:5'UTR:MODIFIER:exon1/15:c.-61_-58delAGAG:,DDC:NM_001242886.1:5'UTR:MODIFIER:exon1/14:c.-61_-58delAGAG:,DDC:NM_001242887.1:5'UTR:MODIFIER:exon1/14:c.-61_-58delAGAG:,DDC:NM_001242888.1:5'UTR:MODIFIER:exon1/13:c.-61_-58delAGAG:,DDC:NM_001242889.1:5'UTR:MODIFIER:exon1/13:c.-61_-58delAGAG:,DDC:NM_001242890.1:5'UTR:MODIFIER:exon1/10:c.-61_-58delAGAG:,DDC:NM_001082971.1:intron:MODIFIER:exon1/14:c.-29+4239_-29+4242delAGAG:	(CT)n	rs10600316;rs3837091	0.2929	0.0000	0/0/0	0.2399							107930 [DDC (confirmed) Aromatic L-amino acid decarboxylase deficiency,608643];	RCV000369935.1 [benign]; 			30	149					DDC (inh=AR pLI=0.00)
chr7	65425894	65425894	A	G	hom	het	het	pred_pathogenic	QUAL=31959;DP=465,593,757;MQM=59	GUSB	missense,non_coding_transcript_exon	GUSB:NM_000181.3:missense:MODERATE:exon12/12:c.1946T>C:p.Leu649Pro,GUSB:NM_001284290.1:missense:MODERATE:exon10/10:c.1508T>C:p.Leu503Pro,GUSB:NM_001293104.1:missense:MODERATE:exon11/11:c.1376T>C:p.Leu459Pro,GUSB:NM_001293105.1:missense:MODERATE:exon10/10:c.1289T>C:p.Leu430Pro,GUSB:NR_120531.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.1992T>C:		rs9530	0.5807	0.5796	21049/10611/711	0.5757	-0.0470	T,T,T	T	B,B	D,D,D	0.37	611499 [GUSB (confirmed) Mucopolysaccharidosis VII,253220];	RCV000078327.5 [benign]; RCV000394365.1 [benign]; 			527	741					GUSB (inh=AR pLI=0.00)
chr7	65447242	65447242	C	A	het	het	wt	low_DP	QUAL=439;DP=24,15,22;MQM=59	GUSB	5'UTR,non_coding_transcript_exon	GUSB:NM_000181.3:5'UTR:MODIFIER:exon1/12:c.-72G>T:,GUSB:NM_001284290.1:5'UTR:MODIFIER:exon1/10:c.-72G>T:,GUSB:NM_001293104.1:5'UTR:MODIFIER:exon1/11:c.-457G>T:,GUSB:NM_001293105.1:5'UTR:MODIFIER:exon1/10:c.-401G>T:,GUSB:NR_120531.1:non_coding_transcript_exon:MODIFIER:exon1/11:n.60G>T:		rs2279904	0.0377	0.0000	0/0/0	0.0523							611499 [GUSB (confirmed) Mucopolysaccharidosis VII,253220];	RCV000390830.1 [likely benign]; 			0	20					GUSB (inh=AR pLI=0.00)
chr7	66094008	66094008	C	T	wt	het	het	low_DP	QUAL=257;DP=6,25,15;MQM=60	KCTD7	5'UTR	KCTD7:NM_153033.4:5'UTR:MODIFIER:exon1/4:c.-44C>T:,KCTD7:NM_001167961.2:5'UTR:MODIFIER:exon1/5:c.-44C>T:		rs35526611	0.4573	0.4235	1301/432/264	0.2236							611725 [KCTD7 (provisional) Epilepsy,progressive myoclonic 3,with or without intracellular inclusions,611726];	RCV000370915.1 [benign]; 			148	359					KCTD7 (inh=AR pLI=0.50)
chr7	66104909	66104909	G	C	het	het	wt		QUAL=5392;DP=248,185,218;MQM=59	KCTD7	3'UTR,intron	KCTD7:NM_153033.4:3'UTR:MODIFIER:exon4/4:c.*690G>C:,KCTD7:NM_001167961.2:intron:MODIFIER:exon4/4:c.867-472G>C:		rs4718382	0.0407	0.0000	0/0/0	0.0092							611725 [KCTD7 (provisional) Epilepsy,progressive myoclonic 3,with or without intracellular inclusions,611726];	RCV000297291.1 [likely benign]; 			0	26					KCTD7 (inh=AR pLI=0.50)
chr7	66105163	66105163	C	G	het	hom	het		QUAL=18258;DP=344,273,335;MQM=59	KCTD7	3'UTR,intron	KCTD7:NM_153033.4:3'UTR:MODIFIER:exon4/4:c.*944C>G:,KCTD7:NM_001167961.2:intron:MODIFIER:exon4/4:c.867-218C>G:		rs9791712	0.6238	0.0000	0/0/0	0.6275							611725 [KCTD7 (provisional) Epilepsy,progressive myoclonic 3,with or without intracellular inclusions,611726];	RCV000323024.1 [benign]; 			77	125					KCTD7 (inh=AR pLI=0.50)
chr7	66105198	66105198	C	A	het	hom	het		QUAL=14975;DP=247,238,292;MQM=60	KCTD7	3'UTR,intron	KCTD7:NM_153033.4:3'UTR:MODIFIER:exon4/4:c.*979C>A:,KCTD7:NM_001167961.2:intron:MODIFIER:exon4/4:c.867-183C>A:		rs9791713	0.6236	0.0000	0/0/0	0.1070							611725 [KCTD7 (provisional) Epilepsy,progressive myoclonic 3,with or without intracellular inclusions,611726];	RCV000361429.1 [benign]; 			77	125					KCTD7 (inh=AR pLI=0.50)
chr7	66105946	66105946	G	C	het	het	wt		QUAL=6332;DP=306,250,318;MQM=60	KCTD7	3'UTR	KCTD7:NM_153033.4:3'UTR:MODIFIER:exon4/4:c.*1727G>C:,KCTD7:NM_001167961.2:3'UTR:MODIFIER:exon5/5:c.*565G>C:		rs17229513	0.0371	0.0000	0/0/0	0.0090							611725 [KCTD7 (provisional) Epilepsy,progressive myoclonic 3,with or without intracellular inclusions,611726];	RCV000279549.1 [likely benign]; 			0	26					KCTD7 (inh=AR pLI=0.50)
chr7	66106875	66106875	A	G	het	hom	het		QUAL=21078;DP=379,334,352;MQM=60	KCTD7	3'UTR	KCTD7:NM_153033.4:3'UTR:MODIFIER:exon4/4:c.*2656A>G:,KCTD7:NM_001167961.2:3'UTR:MODIFIER:exon5/5:c.*1494A>G:		rs1860469	0.6234	0.0000	0/0/0	0.1067							611725 [KCTD7 (provisional) Epilepsy,progressive myoclonic 3,with or without intracellular inclusions,611726];	RCV000266102.1 [benign]; 			77	125					KCTD7 (inh=AR pLI=0.50)
chr7	66107252	66107252	T	C	wt	het	het		QUAL=6210;DP=331,215,255;MQM=60	KCTD7	3'UTR	KCTD7:NM_153033.4:3'UTR:MODIFIER:exon4/4:c.*3033T>C:,KCTD7:NM_001167961.2:3'UTR:MODIFIER:exon5/5:c.*1871T>C:		rs1860468	0.4539	0.0000	0/0/0	0.0748							611725 [KCTD7 (provisional) Epilepsy,progressive myoclonic 3,with or without intracellular inclusions,611726];	RCV000277983.1 [benign]; 			36	127					KCTD7 (inh=AR pLI=0.50)
chr7	66108153	66108155	ACA	-	wt	het	het		QUAL=4103;DP=313,166,208;MQM=59	KCTD7	3'UTR	KCTD7:NM_153033.4:3'UTR:MODIFIER:exon4/4:c.*3938_*3940delCAA:,KCTD7:NM_001167961.2:3'UTR:MODIFIER:exon5/5:c.*2776_*2778delCAA:		rs10601698	0.4579	0.0000	0/0/0	0.4280							611725 [KCTD7 (provisional) Epilepsy,progressive myoclonic 3,with or without intracellular inclusions,611726];	RCV000383716.1 [benign]; 			15	81					KCTD7 (inh=AR pLI=0.50)
chr7	73442480	73442480	C	T	het	wt	het	low_DP	QUAL=129;DP=5,8,11;MQM=60	ELN	5'UTR_premature_start_codon_gain,5'UTR	ELN:NM_001278939.1:5'UTR_premature_start_codon_gain:LOW:exon1/34:c.-38C>T:,ELN:NM_000501.3:5'UTR_premature_start_codon_gain:LOW:exon1/33:c.-38C>T:,ELN:NM_001081752.2:5'UTR_premature_start_codon_gain:LOW:exon1/30:c.-38C>T:,ELN:NM_001081753.2:5'UTR_premature_start_codon_gain:LOW:exon1/31:c.-38C>T:,ELN:NM_001081754.2:5'UTR_premature_start_codon_gain:LOW:exon1/32:c.-38C>T:,ELN:NM_001081755.2:5'UTR_premature_start_codon_gain:LOW:exon1/32:c.-38C>T:,ELN:NM_001278912.1:5'UTR_premature_start_codon_gain:LOW:exon1/32:c.-38C>T:,ELN:NM_001278913.1:5'UTR_premature_start_codon_gain:LOW:exon1/29:c.-38C>T:,ELN:NM_001278914.1:5'UTR_premature_start_codon_gain:LOW:exon1/31:c.-38C>T:,ELN:NM_001278915.1:5'UTR_premature_start_codon_gain:LOW:exon1/33:c.-38C>T:,ELN:NM_001278916.1:5'UTR_premature_start_codon_gain:LOW:exon1/29:c.-38C>T:,ELN:NM_001278917.1:5'UTR_premature_start_codon_gain:LOW:exon1/32:c.-38C>T:,ELN:NM_001278918.1:5'UTR_premature_start_codon_gain:LOW:exon1/28:c.-38C>T:,ELN:NM_001278939.1:5'UTR:MODIFIER:exon1/34:c.-38C>T:,ELN:NM_000501.3:5'UTR:MODIFIER:exon1/33:c.-38C>T:,ELN:NM_001081752.2:5'UTR:MODIFIER:exon1/30:c.-38C>T:,ELN:NM_001081753.2:5'UTR:MODIFIER:exon1/31:c.-38C>T:,ELN:NM_001081754.2:5'UTR:MODIFIER:exon1/32:c.-38C>T:,ELN:NM_001081755.2:5'UTR:MODIFIER:exon1/32:c.-38C>T:,ELN:NM_001278912.1:5'UTR:MODIFIER:exon1/32:c.-38C>T:,ELN:NM_001278913.1:5'UTR:MODIFIER:exon1/29:c.-38C>T:,ELN:NM_001278914.1:5'UTR:MODIFIER:exon1/31:c.-38C>T:,ELN:NM_001278915.1:5'UTR:MODIFIER:exon1/33:c.-38C>T:,ELN:NM_001278916.1:5'UTR:MODIFIER:exon1/29:c.-38C>T:,ELN:NM_001278917.1:5'UTR:MODIFIER:exon1/32:c.-38C>T:,ELN:NM_001278918.1:5'UTR:MODIFIER:exon1/28:c.-38C>T:		rs41410045	0.0260	0.0211	54/3/0	0.0168							608512 [NCF1 (provisional) Chronic granulomatous disease due to deficiency of NCF-1,233700]:130160 [ELN (confirmed) Supravalvar aortic stenosis,185500|Cutis laxa,AD,123700];	RCV000195554.1 [benign]; RCV000300581.1 [benign]; RCV000406190.1 [benign]; 			2	48					ELN (inh=AD pLI=0.00)
chr7	73483531	73483531	-	A	het	wt	het		QUAL=4590;DP=145,181,246;MQM=59	ELN	3'UTR	ELN:NM_001278939.1:3'UTR:MODIFIER:exon34/34:c.*501_*502insA:,ELN:NM_000501.3:3'UTR:MODIFIER:exon33/33:c.*501_*502insA:,ELN:NM_001081752.2:3'UTR:MODIFIER:exon30/30:c.*501_*502insA:,ELN:NM_001081753.2:3'UTR:MODIFIER:exon31/31:c.*501_*502insA:,ELN:NM_001081754.2:3'UTR:MODIFIER:exon32/32:c.*501_*502insA:,ELN:NM_001081755.2:3'UTR:MODIFIER:exon32/32:c.*501_*502insA:,ELN:NM_001278912.1:3'UTR:MODIFIER:exon32/32:c.*501_*502insA:,ELN:NM_001278913.1:3'UTR:MODIFIER:exon29/29:c.*501_*502insA:,ELN:NM_001278914.1:3'UTR:MODIFIER:exon31/31:c.*501_*502insA:,ELN:NM_001278915.1:3'UTR:MODIFIER:exon33/33:c.*501_*502insA:,ELN:NM_001278916.1:3'UTR:MODIFIER:exon29/29:c.*501_*502insA:,ELN:NM_001278917.1:3'UTR:MODIFIER:exon32/32:c.*501_*502insA:,ELN:NM_001278918.1:3'UTR:MODIFIER:exon28/28:c.*501_*502insA:		rs34208922	0.2901	0.0000	0/0/0	0.2328							608512 [NCF1 (provisional) Chronic granulomatous disease due to deficiency of NCF-1,233700]:130160 [ELN (confirmed) Supravalvar aortic stenosis,185500|Cutis laxa,AD,123700];	RCV000265718.1 [benign]; RCV000358024.1 [benign]; 			8	98					ELN (inh=AD pLI=0.00)
chr7	74167490	74167490	C	T	wt	het	wt	low_MQM	QUAL=366;DP=77,77,87;MQM=33	GTF2I	synonymous	GTF2I:NM_032999.3:synonymous:LOW:exon29/35:c.2622C>T:p.Asp874Asp,GTF2I:NM_001163636.2:synonymous:LOW:exon28/34:c.2556C>T:p.Asp852Asp,GTF2I:NM_001518.4:synonymous:LOW:exon27/33:c.2499C>T:p.Asp833Asp,GTF2I:NM_033000.3:synonymous:LOW:exon28/34:c.2562C>T:p.Asp854Asp,GTF2I:NM_033001.3:synonymous:LOW:exon28/34:c.2559C>T:p.Asp853Asp		rs373607978	0.0000	0.2941	0/0/0	0.0025							608512 [NCF1 (provisional) Chronic granulomatous disease due to deficiency of NCF-1,233700];				1	480					GTF2I (inh=n/a pLI=1.00)
chr7	74193668	74193668	G	A	het	het	het	low_DP;low_MQM	QUAL=11518;DP=14,275,542;MQM=36	NCF1	missense	NCF1:NM_000265.5:missense:MODERATE:exon4/11:c.295G>A:p.Gly99Ser		rs10614	0.6312	0.4984	7339/4021/264	0.0573	0.5180	T,T,T,.	T	B,B	T,T,T	0.03	608512 [NCF1 (provisional) Chronic granulomatous disease due to deficiency of NCF-1,233700];			COSM4162428	679	822					NCF1 (inh=AR pLI=0.92)
chr7	75163169	75163169	A	G	hom	hom	hom		QUAL=28291;DP=241,282,348;MQM=59	HIP1	3'UTR	HIP1:NM_005338.6:3'UTR:MODIFIER:exon31/31:c.*4324T>C:,HIP1:NM_001243198.2:3'UTR:MODIFIER:exon29/29:c.*4324T>C:		rs1167827	0.5280	0.0000	0/0/0	0.4847							601767 [HIP1 (confirmed) Prostate cancer,progression of,176807];				49	78					HIP1 (inh=n/a pLI=1.00)
chr7	75163397	75163397	A	G	wt	het	wt		QUAL=2856;DP=318,214,312;MQM=60	HIP1	3'UTR	HIP1:NM_005338.6:3'UTR:MODIFIER:exon31/31:c.*4096T>C:,HIP1:NM_001243198.2:3'UTR:MODIFIER:exon29/29:c.*4096T>C:		rs1167828	0.1042	0.0000	0/0/0	0.0273							601767 [HIP1 (confirmed) Prostate cancer,progression of,176807];				11	57					HIP1 (inh=n/a pLI=1.00)
chr7	75163761	75163761	T	-	wt	wt	het	low_QUAL;low_DP	QUAL=7;DP=53,5,10;MQM=60	HIP1	3'UTR	HIP1:NM_005338.6:3'UTR:MODIFIER:exon31/31:c.*3732delA:,HIP1:NM_001243198.2:3'UTR:MODIFIER:exon29/29:c.*3732delA:	AluSx1		0.0000	0.0000	0/0/0	0.0001							601767 [HIP1 (confirmed) Prostate cancer,progression of,176807];				0	3					HIP1 (inh=n/a pLI=1.00)
chr7	75165018	75165018	G	A	wt	het	wt		QUAL=1783;DP=301,163,254;MQM=60	HIP1	3'UTR	HIP1:NM_005338.6:3'UTR:MODIFIER:exon31/31:c.*2475C>T:,HIP1:NM_001243198.2:3'UTR:MODIFIER:exon29/29:c.*2475C>T:		rs1167829	0.1030	0.0000	0/0/0	0.0268							601767 [HIP1 (confirmed) Prostate cancer,progression of,176807];				11	58					HIP1 (inh=n/a pLI=1.00)
chr7	75166401	75166401	C	T	hom	hom	hom		QUAL=31149;DP=310,317,382;MQM=59	HIP1	3'UTR	HIP1:NM_005338.6:3'UTR:MODIFIER:exon31/31:c.*1092G>A:,HIP1:NM_001243198.2:3'UTR:MODIFIER:exon29/29:c.*1092G>A:		rs1167830	0.3758	0.0000	0/0/0	0.3046							601767 [HIP1 (confirmed) Prostate cancer,progression of,176807];				37	97					HIP1 (inh=n/a pLI=1.00)
chr7	75166426	75166426	C	T	hom	het	hom		QUAL=21458;DP=220,284,347;MQM=59	HIP1	3'UTR	HIP1:NM_005338.6:3'UTR:MODIFIER:exon31/31:c.*1067G>A:,HIP1:NM_001243198.2:3'UTR:MODIFIER:exon29/29:c.*1067G>A:		rs55859405	0.0940	0.0000	0/0/0	0.0079							601767 [HIP1 (confirmed) Prostate cancer,progression of,176807];				3	22					HIP1 (inh=n/a pLI=1.00)
chr7	75172270	75172270	G	A	wt	het	wt		QUAL=1746;DP=175,114,190;MQM=60	HIP1	synonymous	HIP1:NM_005338.6:synonymous:LOW:exon28/31:c.2790C>T:p.Pro930Pro,HIP1:NM_001243198.2:synonymous:LOW:exon26/29:c.2637C>T:p.Pro879Pro		rs1167794	0.0691	0.1357	1424/1119/21	0.1325							601767 [HIP1 (confirmed) Prostate cancer,progression of,176807];			COSM3762831	39	372					HIP1 (inh=n/a pLI=1.00)
chr7	75176300	75176300	T	C	wt	het	wt		QUAL=4619;DP=347,318,438;MQM=60	HIP1	synonymous,intron	HIP1:NM_005338.6:synonymous:LOW:exon25/31:c.2496A>G:p.Gln832Gln,HIP1:NM_001243198.2:intron:MODIFIER:exon23/28:c.2407-1814A>G:		rs1167801	0.0695	0.2170	796/645/8	0.1180							601767 [HIP1 (confirmed) Prostate cancer,progression of,176807];			COSM3762832	40	375					HIP1 (inh=n/a pLI=1.00)
chr7	75183403	75183403	A	G	hom	hom	hom		QUAL=14789;DP=174,131,178;MQM=59	HIP1	splice_region&intron	HIP1:NM_005338.6:splice_region&intron:LOW:exon21/30:c.2158+9T>C:,HIP1:NM_001243198.2:splice_region&intron:LOW:exon21/28:c.2158+9T>C:		rs1167807	0.6759	0.6247	22903/10533/3491	0.5960							601767 [HIP1 (confirmed) Prostate cancer,progression of,176807];			COSM3950799	515	746					HIP1 (inh=n/a pLI=1.00)
chr7	75513062	75513062	A	G	hom	hom	hom		QUAL=26003;DP=234,262,332;MQM=59	RHBDD2	synonymous	RHBDD2:NM_001040456.1:synonymous:LOW:exon3/4:c.633A>G:p.Ala211Ala,RHBDD2:NM_001040457.1:synonymous:LOW:exon4/5:c.210A>G:p.Ala70Ala		rs42183	0.9866	0.9677	56605/30549/4852	0.9432	-2.5140	T	T			0.22					1100	55					RHBDD2 (inh=n/a pLI=0.65)
chr7	75544455	75544455	A	C	hom	het	het	low_DP	QUAL=354;DP=4,26,31;MQM=60	POR	5'UTR	POR:NM_000941.2:5'UTR:MODIFIER:exon1/16:c.-47A>C:		rs3823884	0.4836	0.0000	0/0/0	0.0580							124015 [POR (confirmed) Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis,201750|Disordered steroidogenesis due to cytochrome P450 oxidoreductase,613571];	RCV000379412.1 [benign]; 			84	381					POR (inh=AR pLI=0.00)
chr7	75583325	75583325	A	G	het	het	wt		QUAL=4004;DP=122,248,323;MQM=60	POR	synonymous	POR:NM_000941.2:synonymous:LOW:exon2/16:c.15A>G:p.Gly5Gly		rs10262966	0.1046	0.0745	315/2/265	0.0326							124015 [POR (confirmed) Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis,201750|Disordered steroidogenesis due to cytochrome P450 oxidoreductase,613571];	RCV000018413.29 [other]; 			3	52					POR (inh=AR pLI=0.00)
chr7	75609677	75609677	A	G	het	het	het		QUAL=8006;DP=136,207,295;MQM=59	POR	synonymous	POR:NM_000941.2:synonymous:LOW:exon5/16:c.387A>G:p.Pro129Pro		rs1135612	0.2494	0.2659	4863/2221/20	0.2624	-5.4830		T			0.11	124015 [POR (confirmed) Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis,201750|Disordered steroidogenesis due to cytochrome P450 oxidoreductase,613571];	RCV000248116.1 [benign]; RCV000363541.1 [likely benign]; 		COSM453393	110	595					POR (inh=AR pLI=0.00)
chr7	75614953	75614953	T	C	hom	hom	hom		QUAL=5471;DP=65,63,58;MQM=59	POR	synonymous	POR:NM_000941.2:synonymous:LOW:exon13/16:c.1455T>C:p.Ala485Ala		rs2228104	0.8353	0.9226	39379/24462/1441	0.8517	-6.5840		T			0.41	124015 [POR (confirmed) Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis,201750|Disordered steroidogenesis due to cytochrome P450 oxidoreductase,613571];	RCV000127583.3 [benign]; RCV000308656.1 [benign]; 		COSM4162446, COSM4162445	1447	122					POR (inh=AR pLI=0.00)
chr7	75615006	75615006	C	T	wt	wt	het	pred_pathogenic	QUAL=824;DP=66,87,97;MQM=60	POR	missense	POR:NM_000941.2:missense:MODERATE:exon13/16:c.1508C>T:p.Ala503Val		rs1057868	0.2861	0.3639	3475/1728/101	0.2615	0.9070	T,T,T,T,T,T	T	B,B,B,B	D,D,D,D,D,D	8.85	124015 [POR (confirmed) Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis,201750|Disordered steroidogenesis due to cytochrome P450 oxidoreductase,613571];	RCV000251974.1 [benign]; RCV000405449.1 [likely benign]; 	CM057356 [CLASS=DFP MUT=ALT PHEN="Altered enzyme activity" GENE=POR]; 	COSM3762833, COSM3762834	131	638					POR (inh=AR pLI=0.00)
chr7	75615287	75615287	G	A	het	het	wt		QUAL=6043;DP=200,285,385;MQM=59	POR	synonymous	POR:NM_000941.2:synonymous:LOW:exon14/16:c.1716G>A:p.Ser572Ser		rs1057870	0.1953	0.3811	2930/2239/46	0.2344	-2.3900		T			8.21	124015 [POR (confirmed) Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis,201750|Disordered steroidogenesis due to cytochrome P450 oxidoreductase,613571];	RCV000243975.1 [benign]; RCV000356109.1 [likely benign]; 		COSM3762835, COSM3762836	188	680					POR (inh=AR pLI=0.00)
chr7	75615875	75615875	G	A	het	het	wt		QUAL=3664;DP=153,127,143;MQM=60	POR	3'UTR	POR:NM_000941.2:3'UTR:MODIFIER:exon16/16:c.*76G>A:		rs55909219	0.0000	0.0000	0/0/0	0.0005							124015 [POR (confirmed) Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis,201750|Disordered steroidogenesis due to cytochrome P450 oxidoreductase,613571];	RCV000283879.1 [uncertain significance]; 			1	6					POR (inh=AR pLI=0.00)
chr7	75616105	75616105	G	A	wt	wt	het		QUAL=954;DP=83,59,70;MQM=60	POR	3'UTR	POR:NM_000941.2:3'UTR:MODIFIER:exon16/16:c.*306G>A:		rs17685	0.2688	0.0000	0/0/0	0.0473							124015 [POR (confirmed) Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis,201750|Disordered steroidogenesis due to cytochrome P450 oxidoreductase,613571];	RCV000299302.1 [likely benign]; 			30	110					POR (inh=AR pLI=0.00)
chr7	82993252	82993252	G	A	het	wt	hom	low_DP;low_MQM	QUAL=379;DP=20,10,9;MQM=40	SEMA3E	3'UTR	SEMA3E:NM_012431.2:3'UTR:MODIFIER:exon17/17:c.*3650C>T:,SEMA3E:NM_001178129.1:3'UTR:MODIFIER:exon17/17:c.*3650C>T:	AluYb8	rs111864994	0.0747	0.0000	0/0/0	0.0590							608166 [SEMA3E (provisional) CHARGE syndrome,214800];				2	27					SEMA3E (inh=AD pLI=0.03)
chr7	82993432	82993432	G	A	het	wt	het	low_MQM	QUAL=3568;DP=185,107,151;MQM=43	SEMA3E	3'UTR	SEMA3E:NM_012431.2:3'UTR:MODIFIER:exon17/17:c.*3470C>T:,SEMA3E:NM_001178129.1:3'UTR:MODIFIER:exon17/17:c.*3470C>T:	AluYb8	rs181922588	0.0096	0.0000	0/0/0	0.0123							608166 [SEMA3E (provisional) CHARGE syndrome,214800];				0	20					SEMA3E (inh=AD pLI=0.03)
chr7	82993568	82993568	T	C	het	wt	hom		QUAL=13643;DP=383,245,266;MQM=59	SEMA3E	3'UTR	SEMA3E:NM_012431.2:3'UTR:MODIFIER:exon17/17:c.*3334A>G:,SEMA3E:NM_001178129.1:3'UTR:MODIFIER:exon17/17:c.*3334A>G:		rs112935076	0.1008	0.0000	0/0/0	0.0189							608166 [SEMA3E (provisional) CHARGE syndrome,214800];				4	49					SEMA3E (inh=AD pLI=0.03)
chr7	82994067	82994067	C	G	het	wt	hom		QUAL=12135;DP=344,205,242;MQM=59	SEMA3E	3'UTR	SEMA3E:NM_012431.2:3'UTR:MODIFIER:exon17/17:c.*2835G>C:,SEMA3E:NM_001178129.1:3'UTR:MODIFIER:exon17/17:c.*2835G>C:		rs73709849	0.1008	0.0000	0/0/0	0.0189							608166 [SEMA3E (provisional) CHARGE syndrome,214800];				4	49					SEMA3E (inh=AD pLI=0.03)
chr7	82995006	82995006	T	A	het	hom	wt		QUAL=5405;DP=152,100,141;MQM=60	SEMA3E	3'UTR	SEMA3E:NM_012431.2:3'UTR:MODIFIER:exon17/17:c.*1896A>T:,SEMA3E:NM_001178129.1:3'UTR:MODIFIER:exon17/17:c.*1896A>T:		rs2723017	0.6384	0.0000	0/0/0	0.1401							608166 [SEMA3E (provisional) CHARGE syndrome,214800];				121	96					SEMA3E (inh=AD pLI=0.03)
chr7	82995443	82995443	A	G	het	het	wt		QUAL=2714;DP=170,51,65;MQM=60	SEMA3E	3'UTR	SEMA3E:NM_012431.2:3'UTR:MODIFIER:exon17/17:c.*1459T>C:,SEMA3E:NM_001178129.1:3'UTR:MODIFIER:exon17/17:c.*1459T>C:		rs571661220	0.0000	0.0000	0/0/0	0.0023							608166 [SEMA3E (provisional) CHARGE syndrome,214800];				0	7					SEMA3E (inh=AD pLI=0.03)
chr7	82995774	82995774	A	-	het	wt	hom		QUAL=4635;DP=196,48,60;MQM=60	SEMA3E	3'UTR	SEMA3E:NM_012431.2:3'UTR:MODIFIER:exon17/17:c.*1128delT:,SEMA3E:NM_001178129.1:3'UTR:MODIFIER:exon17/17:c.*1128delT:		rs146062755	0.1010	0.0000	0/0/0	0.0925							608166 [SEMA3E (provisional) CHARGE syndrome,214800];				3	48					SEMA3E (inh=AD pLI=0.03)
chr7	82996706	82996706	A	T	het	wt	hom		QUAL=7934;DP=361,69,80;MQM=60	SEMA3E	3'UTR	SEMA3E:NM_012431.2:3'UTR:MODIFIER:exon17/17:c.*196T>A:,SEMA3E:NM_001178129.1:3'UTR:MODIFIER:exon17/17:c.*196T>A:		rs3801661	0.0907	0.0000	0/0/0	0.0148							608166 [SEMA3E (provisional) CHARGE syndrome,214800];				4	49					SEMA3E (inh=AD pLI=0.03)
chr7	82996831	82996831	A	T	het	het	wt		QUAL=2850;DP=201,38,38;MQM=59	SEMA3E	3'UTR	SEMA3E:NM_012431.2:3'UTR:MODIFIER:exon17/17:c.*71T>A:,SEMA3E:NM_001178129.1:3'UTR:MODIFIER:exon17/17:c.*71T>A:		rs75164403	0.1046	0.0000	0/0/0	0.0210							608166 [SEMA3E (provisional) CHARGE syndrome,214800];				3	69					SEMA3E (inh=AD pLI=0.03)
chr7	83029438	83029438	C	T	het	hom	wt		QUAL=9443;DP=236,187,284;MQM=60	SEMA3E	synonymous	SEMA3E:NM_012431.2:synonymous:LOW:exon11/17:c.1272G>A:p.Leu424Leu,SEMA3E:NM_001178129.1:synonymous:LOW:exon11/17:c.1092G>A:p.Leu364Leu		rs2722974	0.3395	0.4223	11543/6819/84	0.4181							608166 [SEMA3E (provisional) CHARGE syndrome,214800];	RCV000241775.1 [benign]; 			299	748					SEMA3E (inh=AD pLI=0.03)
chr7	83037731	83037731	C	G	het	wt	hom	pred_pathogenic	QUAL=8461;DP=230,127,181;MQM=60	SEMA3E	missense	SEMA3E:NM_012431.2:missense:MODERATE:exon6/17:c.623G>C:p.Arg208Pro,SEMA3E:NM_001178129.1:missense:MODERATE:exon6/17:c.443G>C:p.Arg148Pro		rs61729612	0.0976	0.1132	885/621/34	0.1138	1.1470	T,T,T,T	T	B	T,T,T	23.20	608166 [SEMA3E (provisional) CHARGE syndrome,214800];	RCV000251301.1 [benign]; 		COSM4162479	20	318					SEMA3E (inh=AD pLI=0.03)
chr7	83037751	83037751	C	A	het	hom	wt		QUAL=7069;DP=201,139,191;MQM=60	SEMA3E	synonymous	SEMA3E:NM_012431.2:synonymous:LOW:exon6/17:c.603G>T:p.Ala201Ala,SEMA3E:NM_001178129.1:synonymous:LOW:exon6/17:c.423G>T:p.Ala141Ala		rs2722985	0.5563	0.6078	23793/11809/245	0.6004							608166 [SEMA3E (provisional) CHARGE syndrome,214800];	RCV000246563.1 [benign]; 		COSM3762861	536	753					SEMA3E (inh=AD pLI=0.03)
chr7	83278198	83278198	G	A	hom	wt	wt		QUAL=84;DP=107,30,111;MQM=59	SEMA3E	5'UTR_premature_start_codon_gain,5'UTR	SEMA3E:NM_012431.2:5'UTR_premature_start_codon_gain:LOW:exon1/17:c.-340C>T:,SEMA3E:NM_012431.2:5'UTR:MODIFIER:exon1/17:c.-340C>T:		rs200070960	0.0000	0.0000	0/0/0	0.0001							608166 [SEMA3E (provisional) CHARGE syndrome,214800];				0	15					SEMA3E (inh=AD pLI=0.03)
chr7	83278227	83278227	C	A	het	hom	wt		QUAL=3505;DP=238,52,158;MQM=58	SEMA3E	5'UTR	SEMA3E:NM_012431.2:5'UTR:MODIFIER:exon1/17:c.-369G>T:	(A)n	rs302114	0.7534	0.0000	0/0/0	0.2857							608166 [SEMA3E (provisional) CHARGE syndrome,214800];				111	98					SEMA3E (inh=AD pLI=0.03)
chr7	87079406	87079406	T	A	het	wt	het		QUAL=5897;DP=254,189,212;MQM=60	ABCB4	splice_region&synonymous	ABCB4:NM_018849.2:splice_region&synonymous:LOW:exon8/28:c.711A>T:p.Ile237Ile,ABCB4:NM_000443.3:splice_region&synonymous:LOW:exon8/28:c.711A>T:p.Ile237Ile,ABCB4:NM_018850.2:splice_region&synonymous:LOW:exon8/27:c.711A>T:p.Ile237Ile		rs2109505	0.2614	0.2101	2748/1022/514	0.2062							171060 [ABCB4 (confirmed) Cholestasis,progressive familial intrahepatic 3,602347|Cholestasis,intrahepatic,of pregnancy,3,614972|Gallbladder disease 1,600803];	RCV000247989.2 [benign]; RCV000275204.1 [likely benign]; RCV000385962.1 [likely benign]; 	CM031116 [CLASS=DP MUT=ALT PHEN="Intrahepatic cholestasis of pregnancy association" GENE=ABCB4]; 	COSM3982275	61	476					ABCB4 (inh=AR+AD pLI=0.00)
chr7	87082292	87082292	G	A	wt	het	wt		QUAL=1418;DP=264,97,164;MQM=60	ABCB4	synonymous	ABCB4:NM_018849.2:synonymous:LOW:exon6/28:c.504C>T:p.Asn168Asn,ABCB4:NM_000443.3:synonymous:LOW:exon6/28:c.504C>T:p.Asn168Asn,ABCB4:NM_018850.2:synonymous:LOW:exon6/27:c.504C>T:p.Asn168Asn		rs1202283	0.3478	0.4765	15059/10290/66	0.4763							171060 [ABCB4 (confirmed) Cholestasis,progressive familial intrahepatic 3,602347|Cholestasis,intrahepatic,of pregnancy,3,614972|Gallbladder disease 1,600803];	RCV000179313.2 [benign]; RCV000288953.1 [benign]; RCV000346207.1 [benign]; 	CM096001 [CLASS=DP MUT=ALT PHEN="Intrahepatic cholestasis of pregnancy association" GENE=ABCB4]; 	COSM3762867	418	752					ABCB4 (inh=AR+AD pLI=0.00)
chr7	87092185	87092185	G	A	het	wt	het		QUAL=1542;DP=87,38,48;MQM=60	ABCB4	synonymous	ABCB4:NM_018849.2:synonymous:LOW:exon4/28:c.175C>T:p.Leu59Leu,ABCB4:NM_000443.3:synonymous:LOW:exon4/28:c.175C>T:p.Leu59Leu,ABCB4:NM_018850.2:synonymous:LOW:exon4/27:c.175C>T:p.Leu59Leu		rs2302387	0.2524	0.1752	2299/650/1032	0.1728							171060 [ABCB4 (confirmed) Cholestasis,progressive familial intrahepatic 3,602347|Cholestasis,intrahepatic,of pregnancy,3,614972|Gallbladder disease 1,600803];	RCV000245179.1 [benign]; RCV000340525.1 [benign]; RCV000400898.1 [benign]; 			44	392					ABCB4 (inh=AR+AD pLI=0.00)
chr7	92129162	92129162	A	-	hom	hom	hom		QUAL=10069;DP=167,115,158;MQM=60	PEX1	splice_region&intron	PEX1:NM_000466.2:splice_region&intron:LOW:exon15/23:c.2584-10delT:,PEX1:NM_001282677.1:splice_region&intron:LOW:exon14/22:c.2413-10delT:,PEX1:NM_001282678.1:splice_region&intron:LOW:exon15/23:c.1960-10delT:		rs5885806;rs878955850	0.0000	0.6319	14857/9143/874	0.5697							602136 [PEX1 (confirmed) Peroxisome biogenesis disorder 1A (Zellweger),214100|Peroxisome biogenesis disorder 1B (NALD/IRD),601539|Heimler syndrome 1,234580];	RCV000353186.1 [uncertain significance]; 			799	551	2	[2] Ute Grasshoff 09.04.2015			PEX1 (inh=AR pLI=0.00)
chr7	92131289	92131289	G	T	hom	hom	hom		QUAL=23261;DP=421,113,201;MQM=60	PEX1	synonymous	PEX1:NM_000466.2:synonymous:LOW:exon14/24:c.2331C>A:p.Gly777Gly,PEX1:NM_001282677.1:synonymous:LOW:exon13/23:c.2160C>A:p.Gly720Gly,PEX1:NM_001282678.1:synonymous:LOW:exon14/24:c.1707C>A:p.Gly569Gly		rs10278857	0.9499	0.9218	51668/27598/4958	0.8698							602136 [PEX1 (confirmed) Peroxisome biogenesis disorder 1A (Zellweger),214100|Peroxisome biogenesis disorder 1B (NALD/IRD),601539|Heimler syndrome 1,234580];	RCV000078920.8 [other]; RCV000380113.1 [benign]; 			1344	209					PEX1 (inh=AR pLI=0.00)
chr7	94024057	94024057	C	T	wt	het	wt		QUAL=735;DP=164,83,111;MQM=60	COL1A2	5'UTR	COL1A2:NM_000089.3:5'UTR:MODIFIER:exon1/52:c.-287C>T:		rs190926256	0.0054	0.0000	0/0/0	0.0015							120160 [COL1A2 (confirmed) Ehlers-Danlos syndrome,type VIIB,130060|Osteogenesis imperfecta,type IV,166220|Osteogenesis imperfecta,type III,259420|Osteogenesis imperfecta,type II,166210|Osteoporosis,postmenopausal,166710|Ehlers-Danlos syndrome,cardiac valvular form,225320];	RCV000281371.1 [likely benign]; RCV000373257.1 [likely benign]; 			0	6					COL1A2 (inh=AR+AD pLI=1.00)
chr7	94030899	94030899	T	C	wt	het	wt		QUAL=393;DP=97,32,68;MQM=60	COL1A2	synonymous	COL1A2:NM_000089.3:synonymous:LOW:exon6/52:c.246T>C:p.Asp82Asp		rs1800222	0.3043	0.1744	2941/562/1436	0.1743							120160 [COL1A2 (confirmed) Ehlers-Danlos syndrome,type VIIB,130060|Osteogenesis imperfecta,type IV,166220|Osteogenesis imperfecta,type III,259420|Osteogenesis imperfecta,type II,166210|Osteoporosis,postmenopausal,166710|Ehlers-Danlos syndrome,cardiac valvular form,225320];	RCV000251681.2 [benign]; RCV000318261.1 [benign]; RCV000375392.1 [benign]; 		COSM3762899	42	369					COL1A2 (inh=AR+AD pLI=1.00)
chr7	94039032	94039032	C	T	het	het	het		QUAL=13081;DP=336,299,351;MQM=60	COL1A2	splice_region&intron	COL1A2:NM_000089.3:splice_region&intron:LOW:exon18/51:c.937-3C>T:		rs42519	0.8243	0.7742	36721/19160/4223	0.7588							120160 [COL1A2 (confirmed) Ehlers-Danlos syndrome,type VIIB,130060|Osteogenesis imperfecta,type IV,166220|Osteogenesis imperfecta,type III,259420|Osteogenesis imperfecta,type II,166210|Osteoporosis,postmenopausal,166710|Ehlers-Danlos syndrome,cardiac valvular form,225320];	RCV000253006.2 [benign]; RCV000274743.1 [benign]; RCV000329587.1 [benign]; 	CS151749 [CLASS=R MUT=ALT PHEN="Osteogenesis imperfecta" GENE=COL1A2]; 		834	591	2	[2] Ute Grasshoff 24.11.2015			COL1A2 (inh=AR+AD pLI=1.00)
chr7	94041937	94041937	A	C	het	het	het		QUAL=8906;DP=239,183,234;MQM=59	COL1A2	synonymous	COL1A2:NM_000089.3:synonymous:LOW:exon25/52:c.1446A>C:p.Pro482Pro		rs412777	0.3273	0.3459	7333/4586/646	0.3424							120160 [COL1A2 (confirmed) Ehlers-Danlos syndrome,type VIIB,130060|Osteogenesis imperfecta,type IV,166220|Osteogenesis imperfecta,type III,259420|Osteogenesis imperfecta,type II,166210|Osteoporosis,postmenopausal,166710|Ehlers-Danlos syndrome,cardiac valvular form,225320];	RCV000252784.1 [benign]; RCV000367790.1 [benign]; RCV000395576.1 [benign]; 		COSM1452968	206	694					COL1A2 (inh=AR+AD pLI=1.00)
chr7	94043239	94043239	C	G	het	het	het	pred_pathogenic	QUAL=19066;DP=626,394,499;MQM=60	COL1A2	missense	COL1A2:NM_000089.3:missense:MODERATE:exon28/52:c.1645C>G:p.Pro549Ala		rs42524	0.8217	0.7693	36256/18737/4121	0.7519	1.2480	T,T	T	B	D	11.45	120160 [COL1A2 (confirmed) Ehlers-Danlos syndrome,type VIIB,130060|Osteogenesis imperfecta,type IV,166220|Osteogenesis imperfecta,type III,259420|Osteogenesis imperfecta,type II,166210|Osteoporosis,postmenopausal,166710|Ehlers-Danlos syndrome,cardiac valvular form,225320];	RCV000244604.1 [benign]; RCV000269609.1 [benign]; RCV000323983.1 [benign]; 	CM040403 [CLASS=DP MUT=REF PHEN="Intracranial aneurysm susceptibility association with" GENE=COL1A2]; 	COSM3762900	821	598					COL1A2 (inh=AR+AD pLI=1.00)
chr7	94059899	94059899	C	T	wt	wt	het		QUAL=3092;DP=301,170,221;MQM=60	COL1A2	3'UTR	COL1A2:NM_000089.3:3'UTR:MODIFIER:exon52/52:c.*194C>T:		rs1060399	0.2214	0.0000	0/0/0	0.0443							120160 [COL1A2 (confirmed) Ehlers-Danlos syndrome,type VIIB,130060|Osteogenesis imperfecta,type IV,166220|Osteogenesis imperfecta,type III,259420|Osteogenesis imperfecta,type II,166210|Osteoporosis,postmenopausal,166710|Ehlers-Danlos syndrome,cardiac valvular form,225320];	RCV000320444.1 [benign]; RCV000375087.1 [benign]; 			20	85					COL1A2 (inh=AR+AD pLI=1.00)
chr7	94060359	94060359	-	GTTGTCC	wt	het	het		QUAL=3320;DP=147,116,146;MQM=60	COL1A2	3'UTR	COL1A2:NM_000089.3:3'UTR:MODIFIER:exon52/52:c.*654_*655insGTTGTCC:		rs3917	0.7879	0.0000	0/0/0	0.5809							120160 [COL1A2 (confirmed) Ehlers-Danlos syndrome,type VIIB,130060|Osteogenesis imperfecta,type IV,166220|Osteogenesis imperfecta,type III,259420|Osteogenesis imperfecta,type II,166210|Osteoporosis,postmenopausal,166710|Ehlers-Danlos syndrome,cardiac valvular form,225320];	RCV000324325.1 [benign]; RCV000358049.1 [benign]; 			78	115					COL1A2 (inh=AR+AD pLI=1.00)
chr7	94060509	94060509	G	T	wt	het	wt		QUAL=1678;DP=171,151,239;MQM=60	COL1A2	3'UTR	COL1A2:NM_000089.3:3'UTR:MODIFIER:exon52/52:c.*804G>T:		rs1062394	0.0723	0.0000	0/0/0	0.0143							120160 [COL1A2 (confirmed) Ehlers-Danlos syndrome,type VIIB,130060|Osteogenesis imperfecta,type IV,166220|Osteogenesis imperfecta,type III,259420|Osteogenesis imperfecta,type II,166210|Osteoporosis,postmenopausal,166710|Ehlers-Danlos syndrome,cardiac valvular form,225320];	RCV000265671.1 [likely benign]; RCV000318349.1 [likely benign]; 			3	42					COL1A2 (inh=AR+AD pLI=1.00)
chr7	99699169	99699169	A	T	het	wt	het		QUAL=438;DP=20,26,30;MQM=60	MCM7,AP4M1	5'UTR	MCM7:NM_005916.4:5'UTR:MODIFIER:exon1/15:c.-252T>A:,AP4M1:NM_004722.3:5'UTR:MODIFIER:exon1/15:c.-169A>T:,MCM7:NM_001278595.1:5'UTR:MODIFIER:exon1/14:c.-855T>A:		rs1534310	0.2772	0.0000	0/0/0	0.0453							602296 [AP4M1 (confirmed) Spastic paraplegia 50,autosomal recessive,612936];				10	56					MCM7 (inh=n/a pLI=0.00), AP4M1 (inh=AR pLI=0.00)
chr7	99704796	99704796	A	T	hom	hom	hom		QUAL=6416;DP=128,48,54;MQM=59	AP4M1,TAF6	3'UTR,non_coding_transcript_exon	AP4M1:NM_004722.3:3'UTR:MODIFIER:exon15/15:c.*291A>T:,TAF6:NM_001190415.1:3'UTR:MODIFIER:exon15/15:c.*73T>A:,TAF6:NM_005641.3:3'UTR:MODIFIER:exon15/15:c.*73T>A:,TAF6:NM_139315.2:3'UTR:MODIFIER:exon15/15:c.*73T>A:,TAF6:NR_033792.1:non_coding_transcript_exon:MODIFIER:exon15/15:n.2210T>A:		rs13309	0.6352	0.0000	0/0/0	0.1226							602296 [AP4M1 (confirmed) Spastic paraplegia 50,autosomal recessive,612936]:602955 [TAF6 (provisional) Alazami-Yuan syndrome,617126];				71	126					AP4M1 (inh=AR pLI=0.00), TAF6 (inh=n/a pLI=0.00)
chr7	103112862	103112862	C	T	hom	hom	hom		QUAL=19845;DP=379,87,118;MQM=60	RELN,LOC101927870	3'UTR,intron	RELN:NM_005045.3:3'UTR:MODIFIER:exon65/65:c.*397G>A:,RELN:NM_173054.2:3'UTR:MODIFIER:exon64/64:c.*397G>A:,LOC101927870:NR_110141.1:intron:MODIFIER:exon2/3:n.1365+25747C>T:		rs7811262	0.9984	0.0000	0/0/0	0.1566							600514 [RELN (confirmed) Lissencephaly 2 (Norman-Roberts type),257320|Epilepsy,familial temporal lobe,7,616436];	RCV000292267.1 [benign]; 			230	0					RELN (inh=AR+AD pLI=1.00), LOC101927870 (inh=n/a pLI=n/a)
chr7	103138517	103138517	C	G	hom	hom	hom		QUAL=23510;DP=207,217,300;MQM=59	RELN,LOC101927870	splice_region&intron,intron	RELN:NM_005045.3:splice_region&intron:LOW:exon54/64:c.8843+7G>C:,RELN:NM_173054.2:splice_region&intron:LOW:exon54/63:c.8843+7G>C:,LOC101927870:NR_110141.1:intron:MODIFIER:exon2/3:n.1366-6334C>G:		rs2711885	0.9956	0.9870	59119/32274/5179	0.9650							600514 [RELN (confirmed) Lissencephaly 2 (Norman-Roberts type),257320|Epilepsy,familial temporal lobe,7,616436];	RCV000081246.8 [other]; RCV000320073.1 [benign]; 			2627	79					RELN (inh=AR+AD pLI=1.00), LOC101927870 (inh=n/a pLI=n/a)
chr7	103155705	103155705	A	G	het	hom	wt		QUAL=3825;DP=132,78,64;MQM=59	RELN	synonymous	RELN:NM_005045.3:synonymous:LOW:exon50/65:c.8046T>C:p.His2682His,RELN:NM_173054.2:synonymous:LOW:exon50/64:c.8046T>C:p.His2682His		rs2229864	0.6484	0.4722	15217/4311/3118	0.4642							600514 [RELN (confirmed) Lissencephaly 2 (Norman-Roberts type),257320|Epilepsy,familial temporal lobe,7,616436];	RCV000081242.8 [other]; RCV000404542.1 [benign]; 			492	1275					RELN (inh=AR+AD pLI=1.00)
chr7	103155864	103155864	A	G	het	hom	wt		QUAL=1904;DP=78,50,42;MQM=59	RELN	synonymous	RELN:NM_005045.3:synonymous:LOW:exon50/65:c.7887T>C:p.Pro2629Pro,RELN:NM_173054.2:synonymous:LOW:exon50/64:c.7887T>C:p.Pro2629Pro		rs56345626	0.1749	0.1816	2079/1124/72	0.1797							600514 [RELN (confirmed) Lissencephaly 2 (Norman-Roberts type),257320|Epilepsy,familial temporal lobe,7,616436];	RCV000118171.3 [other]; RCV000393435.1 [benign]; 		COSM3762300	111	833					RELN (inh=AR+AD pLI=1.00)
chr7	103191675	103191675	G	A	wt	het	wt		QUAL=61;DP=61,25,31;MQM=60	RELN	synonymous	RELN:NM_005045.3:synonymous:LOW:exon41/65:c.6141C>T:p.Phe2047Phe,RELN:NM_173054.2:synonymous:LOW:exon41/64:c.6141C>T:p.Phe2047Phe		rs79161241	0.0006	0.0007	0/0/0	0.0008							600514 [RELN (confirmed) Lissencephaly 2 (Norman-Roberts type),257320|Epilepsy,familial temporal lobe,7,616436];	RCV000178467.1 [uncertain significance]; 		COSM1446974	0	2					RELN (inh=AR+AD pLI=1.00)
chr7	103202406	103202406	C	A	hom	hom	hom		QUAL=3463;DP=90,24,28;MQM=57	RELN	splice_region&intron	RELN:NM_005045.3:splice_region&intron:LOW:exon34/64:c.5211-6G>T:,RELN:NM_173054.2:splice_region&intron:LOW:exon34/63:c.5211-6G>T:			0.0000	0.0000	0/0/0	0.0001							600514 [RELN (confirmed) Lissencephaly 2 (Norman-Roberts type),257320|Epilepsy,familial temporal lobe,7,616436];			COSM1622159	3	36					RELN (inh=AR+AD pLI=1.00)
chr7	103206001	103206001	-	A	het	het	het		QUAL=4072;DP=147,123,148;MQM=59	RELN	splice_region&intron	RELN:NM_005045.3:splice_region&intron:LOW:exon33/64:c.4937-4dupT:,RELN:NM_173054.2:splice_region&intron:LOW:exon33/63:c.4937-4dupT:		rs35268159;rs397763920	0.2508	0.3149	367/232/42	0.2239							600514 [RELN (confirmed) Lissencephaly 2 (Norman-Roberts type),257320|Epilepsy,familial temporal lobe,7,616436];	RCV000177788.1 [benign]; RCV000224572.1 [benign]; RCV000273179.1 [benign]; 			67	1142					RELN (inh=AR+AD pLI=1.00)
chr7	103292224	103292224	T	C	wt	het	wt		QUAL=1670;DP=125,132,173;MQM=60	RELN	synonymous,sequence_feature	RELN:NM_005045.3:synonymous:LOW:exon15/65:c.1776A>G:p.Glu592Glu,RELN:NM_173054.2:synonymous:LOW:exon15/64:c.1776A>G:p.Glu592Glu,RELN:NM_005045.3:sequence_feature:LOW:exon15/65:c.1776A>G:,RELN:NM_173054.2:sequence_feature:LOW:exon15/64:c.1776A>G:		rs2072403	0.1204	0.0765	507/82/190	0.0731							600514 [RELN (confirmed) Lissencephaly 2 (Norman-Roberts type),257320|Epilepsy,familial temporal lobe,7,616436];	RCV000118143.2 [likely benign]; RCV000285541.1 [likely benign]; 			6	246					RELN (inh=AR+AD pLI=1.00)
chr7	103389954	103389954	A	G	het	wt	het		QUAL=8034;DP=288,215,288;MQM=60	RELN	splice_region&intron	RELN:NM_005045.3:splice_region&intron:LOW:exon5/64:c.578-3T>C:,RELN:NM_173054.2:splice_region&intron:LOW:exon5/63:c.578-3T>C:		rs607755	0.4655	0.4960	15270/9719/1029	0.4925							600514 [RELN (confirmed) Lissencephaly 2 (Norman-Roberts type),257320|Epilepsy,familial temporal lobe,7,616436];	RCV000081236.8 [other]; RCV000402466.1 [benign]; 			765	1326					RELN (inh=AR+AD pLI=1.00)
chr7	107356759	107356759	G	A	wt	wt	het		QUAL=1196;DP=265,102,90;MQM=60	SLC26A4	3'UTR	SLC26A4:NM_000441.1:3'UTR:MODIFIER:exon21/21:c.*868G>A:		rs2712218	0.2414	0.0000	0/0/0	0.0405							605646 [SLC26A4 (confirmed) Pendred syndrome,274600|Deafness,autosomal recessive 4,with enlarged vestibular aqueduct,600791];	RCV000355703.1 [likely benign]; RCV000403414.1 [likely benign]; 			18	72					SLC26A4 (inh=AR pLI=0.00)
chr7	107545799	107545799	T	C	het	het	hom		QUAL=10834;DP=245,118,178;MQM=60	DLD	splice_region&intron,intron	DLD:NM_000108.4:splice_region&intron:LOW:exon6/13:c.439-7T>C:,DLD:NM_001289750.1:splice_region&intron:LOW:exon4/11:c.142-7T>C:,DLD:NM_001289751.1:splice_region&intron:LOW:exon5/12:c.370-7T>C:,DLD:NM_001289752.1:intron:MODIFIER:exon6/12:c.438+296T>C:		rs10263341	0.7161	0.6182	23373/11110/3206	0.6106							238331 [DLD (confirmed) Dihydrolipoamide dehydrogenase deficiency,246900];	RCV000179713.3 [other]; RCV000264516.1 [benign]; RCV000301000.1 [benign]; RCV000355848.1 [benign]; 			621	672					DLD (inh=AR pLI=0.37)
chr7	107559502	107559502	A	C	het	wt	het		QUAL=8505;DP=361,202,292;MQM=59	DLD	synonymous	DLD:NM_000108.4:synonymous:LOW:exon13/14:c.1422A>C:p.Gly474Gly,DLD:NM_001289750.1:synonymous:LOW:exon11/12:c.1125A>C:p.Gly375Gly,DLD:NM_001289751.1:synonymous:LOW:exon12/13:c.1353A>C:p.Gly451Gly,DLD:NM_001289752.1:synonymous:LOW:exon12/13:c.1278A>C:p.Gly426Gly		rs34453495	0.0048	0.0088	7/4/0	0.0087							238331 [DLD (confirmed) Dihydrolipoamide dehydrogenase deficiency,246900];	RCV000124696.2 [benign]; 			0	27					DLD (inh=AR pLI=0.37)
chr7	107559722	107559722	A	T	het	het	het	low_DP	QUAL=3693;DP=197,15,46;MQM=60	DLD	3'UTR	DLD:NM_000108.4:3'UTR:MODIFIER:exon14/14:c.*18A>T:,DLD:NM_001289750.1:3'UTR:MODIFIER:exon12/12:c.*18A>T:,DLD:NM_001289751.1:3'UTR:MODIFIER:exon13/13:c.*18A>T:,DLD:NM_001289752.1:3'UTR:MODIFIER:exon13/13:c.*18A>T:		rs8721	0.2758	0.3602	7987/5250/71	0.3353							238331 [DLD (confirmed) Dihydrolipoamide dehydrogenase deficiency,246900];	RCV000124697.3 [benign]; RCV000279168.1 [benign]; RCV000350587.1 [benign]; RCV000400340.1 [benign]; 			156	430					DLD (inh=AR pLI=0.37)
chr7	107559911	107559911	G	A	het	het	hom		QUAL=7556;DP=267,55,94;MQM=60	DLD	3'UTR	DLD:NM_000108.4:3'UTR:MODIFIER:exon14/14:c.*207G>A:,DLD:NM_001289750.1:3'UTR:MODIFIER:exon12/12:c.*207G>A:,DLD:NM_001289751.1:3'UTR:MODIFIER:exon13/13:c.*207G>A:,DLD:NM_001289752.1:3'UTR:MODIFIER:exon13/13:c.*207G>A:		rs4564	0.7107	0.0000	0/0/0	0.1101							238331 [DLD (confirmed) Dihydrolipoamide dehydrogenase deficiency,246900];	RCV000267242.1 [benign]; RCV000324559.1 [benign]; RCV000358247.1 [benign]; 			102	95					DLD (inh=AR pLI=0.37)
chr7	107560191	107560191	C	T	het	het	hom		QUAL=12956;DP=255,159,223;MQM=60	DLD	3'UTR	DLD:NM_000108.4:3'UTR:MODIFIER:exon14/14:c.*487C>T:,DLD:NM_001289750.1:3'UTR:MODIFIER:exon12/12:c.*487C>T:,DLD:NM_001289751.1:3'UTR:MODIFIER:exon13/13:c.*487C>T:,DLD:NM_001289752.1:3'UTR:MODIFIER:exon13/13:c.*487C>T:		rs4518	0.7145	0.0000	0/0/0	0.1116							238331 [DLD (confirmed) Dihydrolipoamide dehydrogenase deficiency,246900];	RCV000290158.1 [benign]; RCV000347564.1 [benign]; RCV000393003.1 [benign]; 			104	96					DLD (inh=AR pLI=0.37)
chr7	107560651	107560651	G	T	het	het	het		QUAL=10513;DP=345,219,306;MQM=60	DLD	3'UTR	DLD:NM_000108.4:3'UTR:MODIFIER:exon14/14:c.*947G>T:,DLD:NM_001289750.1:3'UTR:MODIFIER:exon12/12:c.*947G>T:,DLD:NM_001289751.1:3'UTR:MODIFIER:exon13/13:c.*947G>T:,DLD:NM_001289752.1:3'UTR:MODIFIER:exon13/13:c.*947G>T:		rs7777259	0.2724	0.0000	0/0/0	0.3618							238331 [DLD (confirmed) Dihydrolipoamide dehydrogenase deficiency,246900];	RCV000275277.1 [likely benign]; RCV000332301.1 [likely benign]; RCV000386065.1 [likely benign]; 			49	108					DLD (inh=AR pLI=0.37)
chr7	107560682	107560682	T	C	het	het	hom		QUAL=19296;DP=478,263,325;MQM=59	DLD	3'UTR	DLD:NM_000108.4:3'UTR:MODIFIER:exon14/14:c.*978T>C:,DLD:NM_001289750.1:3'UTR:MODIFIER:exon12/12:c.*978T>C:,DLD:NM_001289751.1:3'UTR:MODIFIER:exon13/13:c.*978T>C:,DLD:NM_001289752.1:3'UTR:MODIFIER:exon13/13:c.*978T>C:		rs2158835	0.7147	0.0000	0/0/0	0.6488							238331 [DLD (confirmed) Dihydrolipoamide dehydrogenase deficiency,246900];	RCV000288290.1 [benign]; RCV000328083.1 [benign]; RCV000384986.1 [benign]; 			103	94					DLD (inh=AR pLI=0.37)
chr7	107561155	107561155	T	C	het	het	hom		QUAL=13231;DP=364,140,201;MQM=60	DLD	3'UTR	DLD:NM_000108.4:3'UTR:MODIFIER:exon14/14:c.*1451T>C:,DLD:NM_001289750.1:3'UTR:MODIFIER:exon12/12:c.*1451T>C:,DLD:NM_001289751.1:3'UTR:MODIFIER:exon13/13:c.*1451T>C:,DLD:NM_001289752.1:3'UTR:MODIFIER:exon13/13:c.*1451T>C:	L1MEb	rs2108223	0.7153	0.0000	0/0/0	0.6519							238331 [DLD (confirmed) Dihydrolipoamide dehydrogenase deficiency,246900];	RCV000276849.1 [benign]; RCV000312034.1 [benign]; RCV000370203.1 [benign]; 			101	72					DLD (inh=AR pLI=0.37)
chr7	107561392	107561392	G	A	het	het	het		QUAL=12412;DP=443,169,269;MQM=60	DLD	3'UTR	DLD:NM_000108.4:3'UTR:MODIFIER:exon14/14:c.*1688G>A:,DLD:NM_001289750.1:3'UTR:MODIFIER:exon12/12:c.*1688G>A:,DLD:NM_001289751.1:3'UTR:MODIFIER:exon13/13:c.*1688G>A:,DLD:NM_001289752.1:3'UTR:MODIFIER:exon13/13:c.*1688G>A:	L1MEb	rs8440	0.2722	0.0000	0/0/0	0.3616							238331 [DLD (confirmed) Dihydrolipoamide dehydrogenase deficiency,246900];	RCV000272023.1 [likely benign]; RCV000329448.1 [likely benign]; RCV000369006.1 [likely benign]; 			49	107					DLD (inh=AR pLI=0.37)
chr7	112092211	112092211	T	-	hom	het	hom		QUAL=15061;DP=306,225,307;MQM=59	IFRD1	5'UTR,intron	IFRD1:NM_001197079.1:5'UTR:MODIFIER:exon1/12:c.-400delT:,IFRD1:NM_001007245.2:intron:MODIFIER:exon2/12:c.94+1386delT:,IFRD1:NM_001197080.1:intron:MODIFIER:exon1/11:c.-56-3595delT:,IFRD1:NM_001550.3:intron:MODIFIER:exon1/11:c.94+1386delT:,IFRD1:NR_120333.1:intron:MODIFIER:exon1/11:n.275+1386delT:	AluJr	rs796411555	0.8345	0.0000	0/0/0	0.5266											14	126					IFRD1 (inh=n/a pLI=0.11)
chr7	112092254	112092254	G	A	wt	wt	het		QUAL=3625;DP=325,254,324;MQM=59	IFRD1	5'UTR,intron	IFRD1:NM_001197079.1:5'UTR:MODIFIER:exon1/12:c.-369G>A:,IFRD1:NM_001007245.2:intron:MODIFIER:exon2/12:c.94+1417G>A:,IFRD1:NM_001197080.1:intron:MODIFIER:exon1/11:c.-56-3564G>A:,IFRD1:NM_001550.3:intron:MODIFIER:exon1/11:c.94+1417G>A:,IFRD1:NR_120333.1:intron:MODIFIER:exon1/11:n.275+1417G>A:	AluJr	rs12705819	0.2965	0.0000	0/0/0	0.2070											7	52					IFRD1 (inh=n/a pLI=0.11)
chr7	112092347	112092347	C	T	het	wt	het		QUAL=6059;DP=249,199,231;MQM=60	IFRD1	5'UTR,intron	IFRD1:NM_001197079.1:5'UTR:MODIFIER:exon1/12:c.-276C>T:,IFRD1:NM_001007245.2:intron:MODIFIER:exon2/12:c.94+1510C>T:,IFRD1:NM_001197080.1:intron:MODIFIER:exon1/11:c.-56-3471C>T:,IFRD1:NM_001550.3:intron:MODIFIER:exon1/11:c.94+1510C>T:,IFRD1:NR_120333.1:intron:MODIFIER:exon1/11:n.275+1510C>T:	AluJr	rs4727771	0.2087	0.0000	0/0/0	0.1507											4	28					IFRD1 (inh=n/a pLI=0.11)
chr7	112102355	112102355	T	G	wt	het	wt		QUAL=4763;DP=552,324,428;MQM=60	IFRD1	synonymous,non_coding_transcript_exon	IFRD1:NM_001007245.2:synonymous:LOW:exon9/13:c.828T>G:p.Ser276Ser,IFRD1:NM_001197080.1:synonymous:LOW:exon8/12:c.678T>G:p.Ser226Ser,IFRD1:NM_001550.3:synonymous:LOW:exon8/12:c.828T>G:p.Ser276Ser,IFRD1:NM_001197079.1:synonymous:LOW:exon8/12:c.678T>G:p.Ser226Ser,IFRD1:NR_120333.1:non_coding_transcript_exon:MODIFIER:exon7/12:n.851T>G:		rs2253962	0.2368	0.2378	3539/1988/540	0.2335											117	569					IFRD1 (inh=n/a pLI=0.11)
chr7	112112279	112112279	G	A	wt	het	wt		QUAL=2999;DP=237,248,334;MQM=60	IFRD1	synonymous,non_coding_transcript_exon	IFRD1:NM_001007245.2:synonymous:LOW:exon11/13:c.1047G>A:p.Arg349Arg,IFRD1:NM_001197080.1:synonymous:LOW:exon10/12:c.897G>A:p.Arg299Arg,IFRD1:NM_001550.3:synonymous:LOW:exon10/12:c.1047G>A:p.Arg349Arg,IFRD1:NM_001197079.1:synonymous:LOW:exon10/12:c.897G>A:p.Arg299Arg,IFRD1:NR_120333.1:non_coding_transcript_exon:MODIFIER:exon9/12:n.1070G>A:		rs2074796	0.2462	0.2398	3644/1998/635	0.2358											117	568					IFRD1 (inh=n/a pLI=0.11)
chr7	112112892	112112892	G	A	het	het	wt		QUAL=6121;DP=253,225,306;MQM=60	IFRD1	synonymous,non_coding_transcript_exon	IFRD1:NM_001007245.2:synonymous:LOW:exon12/13:c.1242G>A:p.Thr414Thr,IFRD1:NM_001197080.1:synonymous:LOW:exon11/12:c.1092G>A:p.Thr364Thr,IFRD1:NM_001550.3:synonymous:LOW:exon11/12:c.1242G>A:p.Thr414Thr,IFRD1:NM_001197079.1:synonymous:LOW:exon11/12:c.1092G>A:p.Thr364Thr,IFRD1:NR_120333.1:non_coding_transcript_exon:MODIFIER:exon10/12:n.1265G>A:		rs11542468	0.0453	0.0655	345/210/9	0.0647										COSM3762331	6	246					IFRD1 (inh=n/a pLI=0.11)
chr7	112115658	112115658	C	T	het	wt	het		QUAL=3823;DP=236,69,65;MQM=60	IFRD1	3'UTR,non_coding_transcript_exon	IFRD1:NM_001007245.2:3'UTR:MODIFIER:exon13/13:c.*84C>T:,IFRD1:NM_001197080.1:3'UTR:MODIFIER:exon12/12:c.*84C>T:,IFRD1:NM_001550.3:3'UTR:MODIFIER:exon12/12:c.*84C>T:,IFRD1:NM_001197079.1:3'UTR:MODIFIER:exon12/12:c.*84C>T:,IFRD1:NR_120333.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.1557C>T:		rs7817	0.3930	0.0000	0/0/0	0.0867									CR092300 [CLASS=DFP MUT=ALT PHEN="Severity in cystic fibrosis association with" GENE=IFRD1]; 		52	127					IFRD1 (inh=n/a pLI=0.11)
chr7	112116198	112116198	G	A	het	hom	wt		QUAL=16936;DP=410,311,435;MQM=60	IFRD1	3'UTR,non_coding_transcript_exon	IFRD1:NM_001007245.2:3'UTR:MODIFIER:exon13/13:c.*624G>A:,IFRD1:NM_001197080.1:3'UTR:MODIFIER:exon12/12:c.*624G>A:,IFRD1:NM_001550.3:3'UTR:MODIFIER:exon12/12:c.*624G>A:,IFRD1:NM_001197079.1:3'UTR:MODIFIER:exon12/12:c.*624G>A:,IFRD1:NR_120333.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.2097G>A:		rs7467	0.2851	0.0000	0/0/0	0.0569											21	98					IFRD1 (inh=n/a pLI=0.11)
chr7	112116241	112116241	A	G	wt	het	wt		QUAL=4257;DP=445,342,471;MQM=60	IFRD1	3'UTR,non_coding_transcript_exon	IFRD1:NM_001007245.2:3'UTR:MODIFIER:exon13/13:c.*667A>G:,IFRD1:NM_001197080.1:3'UTR:MODIFIER:exon12/12:c.*667A>G:,IFRD1:NM_001550.3:3'UTR:MODIFIER:exon12/12:c.*667A>G:,IFRD1:NM_001197079.1:3'UTR:MODIFIER:exon12/12:c.*667A>G:,IFRD1:NR_120333.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.2140A>G:		rs3183621	0.1965	0.0000	0/0/0	0.0367											13	78					IFRD1 (inh=n/a pLI=0.11)
chr7	112116537	112116537	A	C	het	wt	het		QUAL=7686;DP=318,307,413;MQM=59	IFRD1	3'UTR,non_coding_transcript_exon	IFRD1:NM_001007245.2:3'UTR:MODIFIER:exon13/13:c.*963A>C:,IFRD1:NM_001197080.1:3'UTR:MODIFIER:exon12/12:c.*963A>C:,IFRD1:NM_001550.3:3'UTR:MODIFIER:exon12/12:c.*963A>C:,IFRD1:NM_001197079.1:3'UTR:MODIFIER:exon12/12:c.*963A>C:,IFRD1:NR_120333.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.2436A>C:	AluJo	rs2190587	0.3990	0.0000	0/0/0	0.4249											31	75					IFRD1 (inh=n/a pLI=0.11)
chr7	112116659	112116659	T	C	hom	hom	het		QUAL=25247;DP=369,263,429;MQM=59	IFRD1	3'UTR,non_coding_transcript_exon	IFRD1:NM_001007245.2:3'UTR:MODIFIER:exon13/13:c.*1085T>C:,IFRD1:NM_001197080.1:3'UTR:MODIFIER:exon12/12:c.*1085T>C:,IFRD1:NM_001550.3:3'UTR:MODIFIER:exon12/12:c.*1085T>C:,IFRD1:NM_001197079.1:3'UTR:MODIFIER:exon12/12:c.*1085T>C:,IFRD1:NR_120333.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.2558T>C:	AluJo	rs2190588	0.7049	0.0000	0/0/0	0.7068											89	54					IFRD1 (inh=n/a pLI=0.11)
chr7	112116685	112116685	C	T	het	wt	het		QUAL=8613;DP=360,239,382;MQM=59	IFRD1	3'UTR,non_coding_transcript_exon	IFRD1:NM_001007245.2:3'UTR:MODIFIER:exon13/13:c.*1111C>T:,IFRD1:NM_001197080.1:3'UTR:MODIFIER:exon12/12:c.*1111C>T:,IFRD1:NM_001550.3:3'UTR:MODIFIER:exon12/12:c.*1111C>T:,IFRD1:NM_001197079.1:3'UTR:MODIFIER:exon12/12:c.*1111C>T:,IFRD1:NR_120333.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.2584C>T:	AluJo	rs12532656	0.1034	0.0000	0/0/0	0.0755											1	19					IFRD1 (inh=n/a pLI=0.11)
chr7	112116980	112116980	C	T	het	wt	het		QUAL=6888;DP=305,175,248;MQM=60	IFRD1	3'UTR,non_coding_transcript_exon	IFRD1:NM_001007245.2:3'UTR:MODIFIER:exon13/13:c.*1406C>T:,IFRD1:NM_001197080.1:3'UTR:MODIFIER:exon12/12:c.*1406C>T:,IFRD1:NM_001550.3:3'UTR:MODIFIER:exon12/12:c.*1406C>T:,IFRD1:NM_001197079.1:3'UTR:MODIFIER:exon12/12:c.*1406C>T:,IFRD1:NR_120333.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.2879C>T:		rs1054043	0.3994	0.0000	0/0/0	0.4321											31	75					IFRD1 (inh=n/a pLI=0.11)
chr7	114330185	114330186	TT	-	hom	hom	hom	low_DP	QUAL=326;DP=67,16,23;MQM=59	FOXP2	3'UTR,non_coding_transcript_exon	FOXP2:NM_148898.3:3'UTR:MODIFIER:exon18/18:c.*219_*220delTT:,FOXP2:NM_001172766.2:3'UTR:MODIFIER:exon17/17:c.*219_*220delTT:,FOXP2:NM_014491.3:3'UTR:MODIFIER:exon17/17:c.*219_*220delTT:,FOXP2:NM_148900.3:3'UTR:MODIFIER:exon18/18:c.*219_*220delTT:,FOXP2:NR_033766.1:non_coding_transcript_exon:MODIFIER:exon20/20:n.2752_2753delTT:,FOXP2:NR_033767.1:non_coding_transcript_exon:MODIFIER:exon18/18:n.2799_2800delTT:	(T)n	rs58777789;rs796306184	0.0000	0.2943	27/18/0	0.0508							605317 [FOXP2 (confirmed) Speech-language disorder-1,602081];	RCV000290888.1 [uncertain significance]; 			74	176					FOXP2 (inh=AD pLI=1.00)
chr7	114331999	114331999	A	-	het	het	het		QUAL=1920;DP=253,68,121;MQM=58	FOXP2	3'UTR,non_coding_transcript_exon	FOXP2:NM_148898.3:3'UTR:MODIFIER:exon18/18:c.*2030delA:,FOXP2:NM_001172766.2:3'UTR:MODIFIER:exon17/17:c.*2030delA:,FOXP2:NM_014491.3:3'UTR:MODIFIER:exon17/17:c.*2030delA:,FOXP2:NM_148900.3:3'UTR:MODIFIER:exon18/18:c.*2030delA:,FOXP2:NR_033766.1:non_coding_transcript_exon:MODIFIER:exon20/20:n.4563delA:,FOXP2:NR_033767.1:non_coding_transcript_exon:MODIFIER:exon18/18:n.4610delA:	(A)n	rs58804519;rs796214969	0.2430	0.4199	90/62/2	0.0149							605317 [FOXP2 (confirmed) Speech-language disorder-1,602081];	RCV000303357.1 [benign]; 			0	177					FOXP2 (inh=AD pLI=1.00)
chr7	114332246	114332246	G	T	het	het	het		QUAL=11061;DP=435,189,194;MQM=60	FOXP2	3'UTR,non_coding_transcript_exon	FOXP2:NM_148898.3:3'UTR:MODIFIER:exon18/18:c.*2265G>T:,FOXP2:NM_001172766.2:3'UTR:MODIFIER:exon17/17:c.*2265G>T:,FOXP2:NM_014491.3:3'UTR:MODIFIER:exon17/17:c.*2265G>T:,FOXP2:NM_148900.3:3'UTR:MODIFIER:exon18/18:c.*2265G>T:,FOXP2:NR_033766.1:non_coding_transcript_exon:MODIFIER:exon20/20:n.4798G>T:,FOXP2:NR_033767.1:non_coding_transcript_exon:MODIFIER:exon18/18:n.4845G>T:		rs12705977	0.2230	0.3262	589/160/3	0.0847							605317 [FOXP2 (confirmed) Speech-language disorder-1,602081];	RCV000320009.1 [benign]; 			85	269					FOXP2 (inh=AD pLI=1.00)
chr7	114333664	114333664	C	T	wt	het	wt		QUAL=1215;DP=253,117,170;MQM=60	FOXP2	3'UTR,non_coding_transcript_exon	FOXP2:NM_148898.3:3'UTR:MODIFIER:exon18/18:c.*3683C>T:,FOXP2:NM_001172766.2:3'UTR:MODIFIER:exon17/17:c.*3683C>T:,FOXP2:NM_014491.3:3'UTR:MODIFIER:exon17/17:c.*3683C>T:,FOXP2:NM_148900.3:3'UTR:MODIFIER:exon18/18:c.*3683C>T:,FOXP2:NR_033766.1:non_coding_transcript_exon:MODIFIER:exon20/20:n.6216C>T:,FOXP2:NR_033767.1:non_coding_transcript_exon:MODIFIER:exon18/18:n.6263C>T:		rs1058335	0.2127	0.2149	219/59/0	0.0523							605317 [FOXP2 (confirmed) Speech-language disorder-1,602081];	RCV000274097.1 [benign]; 			20	201					FOXP2 (inh=AD pLI=1.00)
chr7	117120141	117120141	G	C	wt	wt	het	anno_pathogenic_hgmd	QUAL=2932;DP=51,167,230;MQM=60	CFTR	5'UTR	CFTR:NM_000492.3:5'UTR:MODIFIER:exon1/27:c.-8G>C:		rs1800501	0.0274	0.0455	175/114/1	0.0445							602421 [CFTR (confirmed) Cystic fibrosis,219700|Congenital bilateral absence of vas deferens,277180|Sweat chloride elevation without CF|Pancreatitis,idiopathic,167800|Hypertrypsinemia,neonatal|Bronchiectasis with or without elevated sweat chloride 1,modifier of,211400];	RCV000078974.5 [benign]; RCV000280367.1 [likely benign]; 	CR162721 [CLASS=DM? MUT=ALT PHEN="Cystic fibrosis" GENE=CFTR]; 		4	146					CFTR (inh=AR pLI=0.00)
chr7	117188736	117188736	C	A	het	het	wt	low_MQM;pred_pathogenic	QUAL=818;DP=176,95,146;MQM=32	CFTR	missense	CFTR:NM_000492.3:missense:MODERATE:exon10/27:c.1251C>A:p.Asn417Lys	(AAAAC)n	rs4727853	0.0000	0.0189	0/0/0	0.0023	-0.0310	T,T	T	B	D,D	0.20	602421 [CFTR (confirmed) Cystic fibrosis,219700|Congenital bilateral absence of vas deferens,277180|Sweat chloride elevation without CF|Pancreatitis,idiopathic,167800|Hypertrypsinemia,neonatal|Bronchiectasis with or without elevated sweat chloride 1,modifier of,211400];	RCV000173697.1 [benign]; RCV000224343.1 [benign]; RCV000366455.1 [likely benign]; 		COSM4161731	0	855					CFTR (inh=AR pLI=0.00)
chr7	117188750	117188750	C	T	het	wt	wt	low_MQM;pred_pathogenic	QUAL=255;DP=192,113,154;MQM=33	CFTR	missense	CFTR:NM_000492.3:missense:MODERATE:exon10/27:c.1265C>T:p.Ser422Phe		rs201880593	0.0000	0.0025	0/0/0	0.0001	3.1910	T,T	D	B	D,D	13.07	602421 [CFTR (confirmed) Cystic fibrosis,219700|Congenital bilateral absence of vas deferens,277180|Sweat chloride elevation without CF|Pancreatitis,idiopathic,167800|Hypertrypsinemia,neonatal|Bronchiectasis with or without elevated sweat chloride 1,modifier of,211400];			COSM1284105	0	206					CFTR (inh=AR pLI=0.00)
chr7	117188797	117188797	A	G	het	wt	wt	low_MQM;pred_pathogenic	QUAL=516;DP=260,138,187;MQM=34	CFTR	missense	CFTR:NM_000492.3:missense:MODERATE:exon10/27:c.1312A>G:p.Thr438Ala		rs201434579	0.0000	0.0023	0/0/0	0.0002	0.1610	T,T	T	B	D,D	6.33	602421 [CFTR (confirmed) Cystic fibrosis,219700|Congenital bilateral absence of vas deferens,277180|Sweat chloride elevation without CF|Pancreatitis,idiopathic,167800|Hypertrypsinemia,neonatal|Bronchiectasis with or without elevated sweat chloride 1,modifier of,211400];	RCV000173699.1 [uncertain significance]; RCV000265349.1 [uncertain significance]; 		COSM3734028	0	180					CFTR (inh=AR pLI=0.00)
chr7	117188850	117188850	G	T	het	wt	wt	low_MQM	QUAL=580;DP=391,159,203;MQM=34	CFTR	synonymous	CFTR:NM_000492.3:synonymous:LOW:exon10/27:c.1365G>T:p.Ala455Ala		rs79074685	0.0000	0.0007	0/0/0	0.0019							602421 [CFTR (confirmed) Cystic fibrosis,219700|Congenital bilateral absence of vas deferens,277180|Sweat chloride elevation without CF|Pancreatitis,idiopathic,167800|Hypertrypsinemia,neonatal|Bronchiectasis with or without elevated sweat chloride 1,modifier of,211400];			COSM3774275	0	197					CFTR (inh=AR pLI=0.00)
chr7	117199533	117199533	G	A	het	hom	het	pred_pathogenic	QUAL=8169;DP=227,105,157;MQM=60	CFTR	missense	CFTR:NM_000492.3:missense:MODERATE:exon11/27:c.1408G>A:p.Val470Met		rs213950	0.5821	0.4829	15242/5854/3908	0.4711	2.6080	T,T,T	T	B	D,D,D	13.09	602421 [CFTR (confirmed) Cystic fibrosis,219700|Congenital bilateral absence of vas deferens,277180|Sweat chloride elevation without CF|Pancreatitis,idiopathic,167800|Hypertrypsinemia,neonatal|Bronchiectasis with or without elevated sweat chloride 1,modifier of,211400];	RCV000119035.2 [benign]; RCV000152994.2 [benign]; RCV000007550.3 [other]; RCV000036517.10 [other]; 	CM034388 [CLASS=DFP MUT=REF PHEN="Respiratory/pancreatic disease association with" GENE=CFTR]; 	COSM3762337	238	772					CFTR (inh=AR pLI=0.00)
chr7	117235055	117235055	T	G	wt	het	het		QUAL=5285;DP=290,196,254;MQM=60	CFTR	synonymous	CFTR:NM_000492.3:synonymous:LOW:exon15/27:c.2562T>G:p.Thr854Thr		rs1042077	0.4792	0.3889	9874/3525/2173	0.3714							602421 [CFTR (confirmed) Cystic fibrosis,219700|Congenital bilateral absence of vas deferens,277180|Sweat chloride elevation without CF|Pancreatitis,idiopathic,167800|Hypertrypsinemia,neonatal|Bronchiectasis with or without elevated sweat chloride 1,modifier of,211400];	RCV000036519.10 [other]; RCV000329705.1 [likely benign]; 	CS042144 [CLASS=FP MUT=ALT PHEN="Altered splicing" GENE=CFTR]; 	COSM4161733	151	660					CFTR (inh=AR pLI=0.00)
chr7	117307108	117307108	G	A	wt	het	wt		QUAL=1774;DP=308,131,226;MQM=60	CFTR	synonymous	CFTR:NM_000492.3:synonymous:LOW:exon27/27:c.4389G>A:p.Gln1463Gln		rs1800136	0.1861	0.2253	3569/2048/313	0.2174							602421 [CFTR (confirmed) Cystic fibrosis,219700|Congenital bilateral absence of vas deferens,277180|Sweat chloride elevation without CF|Pancreatitis,idiopathic,167800|Hypertrypsinemia,neonatal|Bronchiectasis with or without elevated sweat chloride 1,modifier of,211400];	RCV000079007.9 [other]; RCV000353586.1 [likely benign]; 	CS042143 [CLASS=DFP MUT=ALT PHEN="Altered splicing" GENE=CFTR]; 	COSM3762339	78	512					CFTR (inh=AR pLI=0.00)
chr7	117307287	117307287	T	-	wt	het	het		QUAL=4859;DP=235,202,245;MQM=59	CFTR	3'UTR	CFTR:NM_000492.3:3'UTR:MODIFIER:exon27/27:c.*133delT:		rs372350028	0.4980	0.0000	0/0/0	0.2746							602421 [CFTR (confirmed) Cystic fibrosis,219700|Congenital bilateral absence of vas deferens,277180|Sweat chloride elevation without CF|Pancreatitis,idiopathic,167800|Hypertrypsinemia,neonatal|Bronchiectasis with or without elevated sweat chloride 1,modifier of,211400];	RCV000303090.1 [likely benign]; 			25	97					CFTR (inh=AR pLI=0.00)
chr7	117308413	117308413	C	T	wt	het	wt	low_DP	QUAL=63;DP=83,7,8;MQM=60	CFTR	3'UTR	CFTR:NM_000492.3:3'UTR:MODIFIER:exon27/27:c.*1251C>T:		rs1042180	0.1873	0.0000	0/0/0	0.0318							602421 [CFTR (confirmed) Cystic fibrosis,219700|Congenital bilateral absence of vas deferens,277180|Sweat chloride elevation without CF|Pancreatitis,idiopathic,167800|Hypertrypsinemia,neonatal|Bronchiectasis with or without elevated sweat chloride 1,modifier of,211400];	RCV000335249.1 [likely benign]; 			12	71					CFTR (inh=AR pLI=0.00)
chr7	121714653	121714653	C	T	het	wt	hom		QUAL=5006;DP=159,88,85;MQM=60	AASS	3'UTR	AASS:NM_005763.3:3'UTR:MODIFIER:exon24/24:c.*1890G>A:	L1MB8	rs12217	0.6697	0.0000	0/0/0	0.5708							605113 [AASS (provisional) Hyperlysinemia,238700|Saccharopinuria,268700];				58	66					AASS (inh=AR pLI=0.00)
chr7	121715965	121715965	C	T	het	wt	hom		QUAL=4067;DP=148,46,65;MQM=60	AASS	3'UTR	AASS:NM_005763.3:3'UTR:MODIFIER:exon24/24:c.*578G>A:		rs1206380	0.6673	0.0000	0/0/0	0.5626							605113 [AASS (provisional) Hyperlysinemia,238700|Saccharopinuria,268700];				75	100					AASS (inh=AR pLI=0.00)
chr7	121738926	121738926	T	A	hom	wt	hom	low_DP;low_MQM	QUAL=45;DP=18,4,3;MQM=48	AASS	splice_region&intron	AASS:NM_005763.3:splice_region&intron:LOW:exon13/23:c.1407-6A>T:			0.0000	0.0000	0/0/0	0.0001							605113 [AASS (provisional) Hyperlysinemia,238700|Saccharopinuria,268700];				0	8	2	[2] Stefanie Beck-Woedl 07.10.2015		n/a (in GS150233_01 vermutl. Artefakt, swal 150921)	AASS (inh=AR pLI=0.00)
chr7	127950724	127950724	C	T	het	wt	het		QUAL=9569;DP=364,330,443;MQM=59	RBM28	3'UTR	RBM28:NM_018077.2:3'UTR:MODIFIER:exon19/19:c.*126G>A:,RBM28:NM_001166135.1:3'UTR:MODIFIER:exon15/15:c.*126G>A:		rs141043380	0.0126	0.0000	0/0/0	0.0072							612074 [RBM28 (confirmed) Alopecia,neurologic defects,and endocrinopathy syndrome,612079];				1	23					RBM28 (inh=AR pLI=0.00)
chr7	127950725	127950725	G	A	het	hom	het		QUAL=21590;DP=364,330,447;MQM=60	RBM28	3'UTR	RBM28:NM_018077.2:3'UTR:MODIFIER:exon19/19:c.*125C>T:,RBM28:NM_001166135.1:3'UTR:MODIFIER:exon15/15:c.*125C>T:		rs12850	0.3399	0.0000	0/0/0	0.0839							612074 [RBM28 (confirmed) Alopecia,neurologic defects,and endocrinopathy syndrome,612079];				33	104					RBM28 (inh=AR pLI=0.00)
chr7	128470482	128470482	G	A	hom	hom	hom	low_DP	QUAL=1058;DP=2,18,26;MQM=59	CCDC136-FLNC	intergenic_region	CCDC136-FLNC:CCDC136-FLNC:intergenic_region:MODIFIER::n.128470482G>A:	(CCCGG)n	rs2639138	1.0000	0.0000	0/0/0	0.7584							102565 [FLNC (confirmed) Myopathy,myofibrillar,5,609524|Myopathy,distal,4,614065|Cardiomyopathy,familial hypertrophic,26|Cardiomyopathy,familial restrictive 5,617047];				197	1					CCDC136-FLNC (inh=n/a pLI=n/a)
chr7	128485240	128485240	C	T	wt	het	wt	pred_pathogenic;anno_pathogenic_hgmd	QUAL=1276;DP=152,127,184;MQM=60	FLNC	missense	FLNC:NM_001458.4:missense:MODERATE:exon21/48:c.3721C>T:p.Arg1241Cys,FLNC:NM_001127487.1:missense:MODERATE:exon21/47:c.3721C>T:p.Arg1241Cys		rs146953558	0.0020	0.0063	4/3/0	0.0063	1.0680	D,D	D	P,B	D,D	27.00	102565 [FLNC (confirmed) Myopathy,myofibrillar,5,609524|Myopathy,distal,4,614065|Cardiomyopathy,familial hypertrophic,26|Cardiomyopathy,familial restrictive 5,617047];	RCV000243106.2 [benign]; 	CM152311 [CLASS=DM? MUT=ALT PHEN="Myopathy myofibrillar" GENE=FLNC]; 	COSM3762367	0	17					FLNC (inh=AD pLI=1.00)
chr7	128487866	128487866	T	C	hom	hom	hom		QUAL=6140;DP=49,69,81;MQM=60	FLNC	synonymous	FLNC:NM_001458.4:synonymous:LOW:exon25/48:c.4404T>C:p.Asp1468Asp,FLNC:NM_001127487.1:synonymous:LOW:exon25/47:c.4404T>C:p.Asp1468Asp		rs2249128	0.9906	0.9973	59996/33309/4599	0.9298							102565 [FLNC (confirmed) Myopathy,myofibrillar,5,609524|Myopathy,distal,4,614065|Cardiomyopathy,familial hypertrophic,26|Cardiomyopathy,familial restrictive 5,617047];	RCV000221141.2 [benign]; 			1565	0					FLNC (inh=AD pLI=1.00)
chr7	128489228	128489228	T	C	het	wt	het		QUAL=3312;DP=165,92,138;MQM=59	FLNC	splice_region&intron	FLNC:NM_001458.4:splice_region&intron:LOW:exon28/47:c.4928-7T>C:,FLNC:NM_001127487.1:splice_region&intron:LOW:exon28/46:c.4928-7T>C:		rs201957008	0.0040	0.0047	3/2/0	0.0044							102565 [FLNC (confirmed) Myopathy,myofibrillar,5,609524|Myopathy,distal,4,614065|Cardiomyopathy,familial hypertrophic,26|Cardiomyopathy,familial restrictive 5,617047];	RCV000176925.2 [benign]; 			0	18					FLNC (inh=AD pLI=1.00)
chr7	139784641	139784641	A	G	hom	hom	hom	low_DP	QUAL=1483;DP=38,5,7;MQM=60	KDM7A	3'UTR	KDM7A:NM_030647.1:3'UTR:MODIFIER:exon20/20:c.*6253T>C:		rs12703525	0.9960	0.0000	0/0/0	0.1804											225	3					KDM7A (inh=n/a pLI=1.00)
chr7	139785024	139785024	C	A	het	het	het		QUAL=8610;DP=313,180,246;MQM=60	KDM7A	3'UTR	KDM7A:NM_030647.1:3'UTR:MODIFIER:exon20/20:c.*5870G>T:		rs10984	0.3596	0.0000	0/0/0	0.2366											56	96					KDM7A (inh=n/a pLI=1.00)
chr7	139785028	139785030	AAG	-	het	wt	het		QUAL=8610;DP=313,180,246;MQM=59	KDM7A	3'UTR	KDM7A:NM_030647.1:3'UTR:MODIFIER:exon20/20:c.*5864_*5866delCTT:		rs371560827	0.1991	0.0000	0/0/0	0.1692											16	65					KDM7A (inh=n/a pLI=1.00)
chr7	139785651	139785651	A	G	wt	het	wt		QUAL=2178;DP=356,156,179;MQM=60	KDM7A	3'UTR	KDM7A:NM_030647.1:3'UTR:MODIFIER:exon20/20:c.*5243T>C:		rs62491373	0.0268	0.0000	0/0/0	0.0103											1	30					KDM7A (inh=n/a pLI=1.00)
chr7	139786186	139786186	G	A	het	het	het		QUAL=3119;DP=166,26,53;MQM=60	KDM7A	3'UTR	KDM7A:NM_030647.1:3'UTR:MODIFIER:exon20/20:c.*4708C>T:		rs11972958	0.3712	0.0000	0/0/0	0.0650											56	96					KDM7A (inh=n/a pLI=1.00)
chr7	139787189	139787189	G	A	het	wt	het		QUAL=9686;DP=529,191,225;MQM=60	KDM7A	3'UTR	KDM7A:NM_030647.1:3'UTR:MODIFIER:exon20/20:c.*3705C>T:		rs1476619	0.1687	0.0000	0/0/0	0.0390											31	82					KDM7A (inh=n/a pLI=1.00)
chr7	139787853	139787853	A	-	het	het	het		QUAL=8099;DP=260,163,178;MQM=59	KDM7A	3'UTR	KDM7A:NM_030647.1:3'UTR:MODIFIER:exon20/20:c.*3041delT:		rs398006590	0.3598	0.0000	0/0/0	0.3615											57	94					KDM7A (inh=n/a pLI=1.00)
chr7	139788306	139788306	C	T	wt	het	wt		QUAL=3345;DP=635,281,379;MQM=60	KDM7A	3'UTR	KDM7A:NM_030647.1:3'UTR:MODIFIER:exon20/20:c.*2588G>A:		rs78491696	0.0292	0.0000	0/0/0	0.0105											1	30					KDM7A (inh=n/a pLI=1.00)
chr7	139797431	139797431	G	T	het	wt	het	pred_pathogenic	QUAL=5884;DP=294,172,192;MQM=60	KDM7A	missense	KDM7A:NM_030647.1:missense:MODERATE:exon15/20:c.1930C>A:p.Arg644Ser		rs6950119	0.3275	0.3218	6322/3998/730	0.3114	2.4720	T,T	T	B	T,T	18.85				COSM321080	172	503					KDM7A (inh=n/a pLI=1.00)
chr7	139801777	139801777	T	G	het	wt	het		QUAL=6373;DP=194,222,299;MQM=60	KDM7A	synonymous	KDM7A:NM_030647.1:synonymous:LOW:exon12/20:c.1612A>C:p.Arg538Arg		rs1062277	0.3335	0.3223	6492/4085/766	0.3184										COSM3762429	172	502					KDM7A (inh=n/a pLI=1.00)
chr7	143016928	143016928	C	T	het	het	wt		QUAL=6089;DP=242,247,324;MQM=60	CLCN1	synonymous,non_coding_transcript_exon	CLCN1:NM_000083.2:synonymous:LOW:exon2/23:c.261C>T:p.Thr87Thr,CLCN1:NR_046453.1:non_coding_transcript_exon:MODIFIER:exon2/22:n.348C>T:		rs6962852	0.3229	0.2966	6310/3421/1707	0.2929							118425 [CLCN1 (provisional) Myotonia congenita,recessive,255700|Myotonia congenita,dominant,160800|Myotonia levior,recessive];	RCV000353487.1 [benign]; 		COSM3762451	221	698					CLCN1 (inh=AR+AD pLI=0.00)
chr7	143017807	143017807	G	T	hom	hom	hom	pred_pathogenic;anno_pathogenic_hgmd	QUAL=23061;DP=237,180,307;MQM=59	CLCN1	missense,non_coding_transcript_exon	CLCN1:NM_000083.2:missense:MODERATE:exon3/23:c.352G>T:p.Gly118Trp,CLCN1:NR_046453.1:non_coding_transcript_exon:MODIFIER:exon3/22:n.439G>T:		rs10282312	0.9936	0.9861	59039/31948/5160	0.9617	5.9710	T	T	B	D	18.83	118425 [CLCN1 (provisional) Myotonia congenita,recessive,255700|Myotonia congenita,dominant,160800|Myotonia levior,recessive];		CM127929 [CLASS=DM? MUT=REF PHEN="Myotonia" GENE=CLCN1]; 		1524	39	2	[2] old entry - no details available			CLCN1 (inh=AR+AD pLI=0.00)
chr7	143036337	143036337	C	T	het	het	het		QUAL=7301;DP=328,130,195;MQM=60	CLCN1	splice_region&intron	CLCN1:NM_000083.2:splice_region&intron:LOW:exon12/22:c.1402-9C>T:,CLCN1:NR_046453.1:splice_region&intron:LOW:exon11/21:n.1342-9C>T:		rs2272252	0.4143	0.4108	10743/6061/1715	0.3951							118425 [CLCN1 (provisional) Myotonia congenita,recessive,255700|Myotonia congenita,dominant,160800|Myotonia levior,recessive];	RCV000367247.1 [benign]; 		COSM4004350	309	741					CLCN1 (inh=AR+AD pLI=0.00)
chr7	143043240	143043240	C	T	het	het	het	pred_pathogenic	QUAL=9069;DP=121,271,367;MQM=60	CLCN1	missense,non_coding_transcript_exon	CLCN1:NM_000083.2:missense:MODERATE:exon18/23:c.2180C>T:p.Pro727Leu,CLCN1:NR_046453.1:non_coding_transcript_exon:MODIFIER:exon17/22:n.2120C>T:		rs13438232	0.3694	0.3974	9877/6021/928	0.3881	0.8500	T	T	B	D	15.32	118425 [CLCN1 (provisional) Myotonia congenita,recessive,255700|Myotonia congenita,dominant,160800|Myotonia levior,recessive];	RCV000343234.1 [benign]; 		COSM3737851	306	744					CLCN1 (inh=AR+AD pLI=0.00)
chr7	145813854	145813854	G	A	hom	het	het	low_DP	QUAL=1103;DP=25,16,24;MQM=60	CNTNAP2	5'UTR	CNTNAP2:NM_014141.5:5'UTR:MODIFIER:exon1/24:c.-115G>A:		rs2462603	0.5120	0.0000	0/0/0	0.5126							604569 [CNTNAP2 (confirmed) Cortical dysplasia-focal epilepsy syndrome,610042|Autism susceptibility 15,612100|Pitt-Hopkins like syndrome 1,610042];	RCV000368639.1 [benign]; RCV000403598.1 [benign]; 			74	107					CNTNAP2 (inh=AR pLI=0.00)
chr7	145814006	145814006	T	A	het	wt	wt	low_QUAL;low_DP;pred_pathogenic	QUAL=21;DP=7,2,1;MQM=50	CNTNAP2	missense	CNTNAP2:NM_014141.5:missense:MODERATE:exon1/24:c.38T>A:p.Leu13His			0.0000	0.0000	0/0/0	0.0000	4.1240	D	T	B	D	22.80	604569 [CNTNAP2 (confirmed) Cortical dysplasia-focal epilepsy syndrome,610042|Autism susceptibility 15,612100|Pitt-Hopkins like syndrome 1,610042];				0	1					CNTNAP2 (inh=AR pLI=0.00)
chr7	145814017	145814017	A	C	het	wt	wt	low_QUAL;low_DP;pred_pathogenic	QUAL=21;DP=8,2,1;MQM=50	CNTNAP2	missense	CNTNAP2:NM_014141.5:missense:MODERATE:exon1/24:c.49A>C:p.Ile17Leu			0.0000	0.0000	0/0/0	0.0000	0.7260	T	T	B	D	0.07	604569 [CNTNAP2 (confirmed) Cortical dysplasia-focal epilepsy syndrome,610042|Autism susceptibility 15,612100|Pitt-Hopkins like syndrome 1,610042];				0	1					CNTNAP2 (inh=AR pLI=0.00)
chr7	147092861	147092861	G	A	het	het	wt		QUAL=5843;DP=188,253,311;MQM=59	CNTNAP2	synonymous	CNTNAP2:NM_014141.5:synonymous:LOW:exon10/24:c.1659G>A:p.Ala553Ala		rs34592169	0.0937	0.1875	2610/1938/14	0.1845							604569 [CNTNAP2 (confirmed) Cortical dysplasia-focal epilepsy syndrome,610042|Autism susceptibility 15,612100|Pitt-Hopkins like syndrome 1,610042];	RCV000081587.8 [other]; RCV000332935.1 [benign]; RCV000389811.1 [benign]; 		COSM3762462	52	485					CNTNAP2 (inh=AR pLI=0.00)
chr7	147183143	147183143	A	G	wt	het	wt		QUAL=3190;DP=183,247,318;MQM=60	CNTNAP2	splice_region&intron	CNTNAP2:NM_014141.5:splice_region&intron:LOW:exon11/23:c.1777+10A>G:		rs2286127	0.2746	0.2255	3511/900/294	0.2190							604569 [CNTNAP2 (confirmed) Cortical dysplasia-focal epilepsy syndrome,610042|Autism susceptibility 15,612100|Pitt-Hopkins like syndrome 1,610042];	RCV000081590.8 [other]; RCV000286532.1 [benign]; RCV000334280.1 [benign]; 		COSM150413	56	477					CNTNAP2 (inh=AR pLI=0.00)
chr7	148106477	148106477	C	G	het	hom	het		QUAL=12290;DP=248,192,239;MQM=59	CNTNAP2	splice_region&intron	CNTNAP2:NM_014141.5:splice_region&intron:LOW:exon22/23:c.3716-6C>G:		rs77025884	0.0000	0.0046	10/7/0	0.0163							604569 [CNTNAP2 (confirmed) Cortical dysplasia-focal epilepsy syndrome,610042|Autism susceptibility 15,612100|Pitt-Hopkins like syndrome 1,610042];	RCV000081603.8 [benign]; 		COSM3785030	497	723					CNTNAP2 (inh=AR pLI=0.00)
chr7	148106490	148106490	G	A	het	hom	het		QUAL=13121;DP=267,211,267;MQM=59	CNTNAP2	synonymous	CNTNAP2:NM_014141.5:synonymous:LOW:exon23/24:c.3723G>A:p.Ala1241Ala		rs9648691	0.5491	0.5407	18239/10331/2268	0.5019							604569 [CNTNAP2 (confirmed) Cortical dysplasia-focal epilepsy syndrome,610042|Autism susceptibility 15,612100|Pitt-Hopkins like syndrome 1,610042];	RCV000081604.8 [other]; RCV000264064.1 [benign]; RCV000358915.1 [benign]; 		COSM3762466	498	724					CNTNAP2 (inh=AR pLI=0.00)
chr7	148112872	148112872	-	A	hom	het	hom		QUAL=3834;DP=154,42,56;MQM=59	CNTNAP2	3'UTR	CNTNAP2:NM_014141.5:3'UTR:MODIFIER:exon24/24:c.*175dupA:		rs397763623	0.5226	0.0000	0/0/0	0.3827							604569 [CNTNAP2 (confirmed) Cortical dysplasia-focal epilepsy syndrome,610042|Autism susceptibility 15,612100|Pitt-Hopkins like syndrome 1,610042];	RCV000286714.1 [uncertain significance]; RCV000371939.1 [uncertain significance]; RCV000282167.1 [benign]; RCV000336012.1 [benign]; 			15	170					CNTNAP2 (inh=AR pLI=0.00)
chr7	148112987	148112987	C	A	het	het	het		QUAL=5955;DP=232,86,128;MQM=60	CNTNAP2	3'UTR	CNTNAP2:NM_014141.5:3'UTR:MODIFIER:exon24/24:c.*279C>A:		rs987456	0.6607	0.0000	0/0/0	0.1308							604569 [CNTNAP2 (confirmed) Cortical dysplasia-focal epilepsy syndrome,610042|Autism susceptibility 15,612100|Pitt-Hopkins like syndrome 1,610042];	RCV000301852.1 [benign]; RCV000347489.1 [benign]; 			150	73					CNTNAP2 (inh=AR pLI=0.00)
chr7	148113520	148113520	-	T	wt	wt	het		QUAL=1996;DP=306,147,176;MQM=60	CNTNAP2	3'UTR	CNTNAP2:NM_014141.5:3'UTR:MODIFIER:exon24/24:c.*818dupT:		rs145690138	0.0158	0.0000	0/0/0	0.0324							604569 [CNTNAP2 (confirmed) Cortical dysplasia-focal epilepsy syndrome,610042|Autism susceptibility 15,612100|Pitt-Hopkins like syndrome 1,610042];	RCV000273601.1 [likely benign]; RCV000319214.1 [likely benign]; 			0	20					CNTNAP2 (inh=AR pLI=0.00)
chr7	148113624	148113628	TAGTT	-	hom	hom	hom		QUAL=20916;DP=344,156,172;MQM=59	CNTNAP2	3'UTR	CNTNAP2:NM_014141.5:3'UTR:MODIFIER:exon24/24:c.*921_*925delTAGTT:		rs569195865	0.9844	0.0000	0/0/0	0.8975							604569 [CNTNAP2 (confirmed) Cortical dysplasia-focal epilepsy syndrome,610042|Autism susceptibility 15,612100|Pitt-Hopkins like syndrome 1,610042];	RCV000316499.1 [benign]; RCV000380508.1 [benign]; 			230	0					CNTNAP2 (inh=AR pLI=0.00)
chr7	148113895	148113895	G	A	het	wt	het		QUAL=9303;DP=356,264,339;MQM=60	CNTNAP2	3'UTR	CNTNAP2:NM_014141.5:3'UTR:MODIFIER:exon24/24:c.*1187G>A:		rs2530312	0.3746	0.0000	0/0/0	0.0752							604569 [CNTNAP2 (confirmed) Cortical dysplasia-focal epilepsy syndrome,610042|Autism susceptibility 15,612100|Pitt-Hopkins like syndrome 1,610042];	RCV000300173.1 [benign]; RCV000353051.1 [benign]; 			47	103					CNTNAP2 (inh=AR pLI=0.00)
chr7	148114265	148114265	A	C	het	wt	het		QUAL=8183;DP=335,188,300;MQM=60	CNTNAP2	3'UTR	CNTNAP2:NM_014141.5:3'UTR:MODIFIER:exon24/24:c.*1557A>C:		rs3194	0.3944	0.0000	0/0/0	0.0801							604569 [CNTNAP2 (confirmed) Cortical dysplasia-focal epilepsy syndrome,610042|Autism susceptibility 15,612100|Pitt-Hopkins like syndrome 1,610042];	RCV000281058.1 [benign]; RCV000338399.1 [benign]; 			52	102					CNTNAP2 (inh=AR pLI=0.00)
chr7	148114865	148114865	A	G	het	wt	het		QUAL=6559;DP=368,113,156;MQM=60	CNTNAP2	3'UTR	CNTNAP2:NM_014141.5:3'UTR:MODIFIER:exon24/24:c.*2157A>G:		rs1062072	0.5371	0.0000	0/0/0	0.0884							604569 [CNTNAP2 (confirmed) Cortical dysplasia-focal epilepsy syndrome,610042|Autism susceptibility 15,612100|Pitt-Hopkins like syndrome 1,610042];	RCV000334512.1 [benign]; RCV000379277.1 [benign]; 			59	100					CNTNAP2 (inh=AR pLI=0.00)
chr7	148115639	148115640	AA	-	het	het	het		QUAL=10090;DP=291,231,263;MQM=59	CNTNAP2	3'UTR	CNTNAP2:NM_014141.5:3'UTR:MODIFIER:exon24/24:c.*2935_*2936delAA:		rs869179688	0.7817	0.0000	0/0/0	0.7450							604569 [CNTNAP2 (confirmed) Cortical dysplasia-focal epilepsy syndrome,610042|Autism susceptibility 15,612100|Pitt-Hopkins like syndrome 1,610042];	RCV000340157.1 [benign]; RCV000383226.1 [benign]; 			155	67					CNTNAP2 (inh=AR pLI=0.00)
chr7	148116450	148116450	A	G	het	wt	het		QUAL=8144;DP=313,190,245;MQM=60	CNTNAP2	3'UTR	CNTNAP2:NM_014141.5:3'UTR:MODIFIER:exon24/24:c.*3742A>G:		rs2530311	0.5210	0.0000	0/0/0	0.0871							604569 [CNTNAP2 (confirmed) Cortical dysplasia-focal epilepsy syndrome,610042|Autism susceptibility 15,612100|Pitt-Hopkins like syndrome 1,610042];	RCV000281772.1 [benign]; RCV000394541.1 [benign]; 			55	103					CNTNAP2 (inh=AR pLI=0.00)
chr7	148116692	148116692	-	T	wt	het	het		QUAL=293;DP=65,72,80;MQM=57	CNTNAP2	3'UTR	CNTNAP2:NM_014141.5:3'UTR:MODIFIER:exon24/24:c.*3999dupT:	AluSx1	rs35835723;rs397890079	0.5571	0.0000	0/0/0	0.4029							604569 [CNTNAP2 (confirmed) Cortical dysplasia-focal epilepsy syndrome,610042|Autism susceptibility 15,612100|Pitt-Hopkins like syndrome 1,610042];	RCV000319050.1 [benign]; RCV000375765.1 [benign]; 			9	124					CNTNAP2 (inh=AR pLI=0.00)
chr7	148117505	148117505	G	C	het	het	het		QUAL=12304;DP=349,258,346;MQM=60	CNTNAP2	3'UTR	CNTNAP2:NM_014141.5:3'UTR:MODIFIER:exon24/24:c.*4797G>C:		rs2717829	0.7935	0.0000	0/0/0	0.1383							604569 [CNTNAP2 (confirmed) Cortical dysplasia-focal epilepsy syndrome,610042|Autism susceptibility 15,612100|Pitt-Hopkins like syndrome 1,610042];	RCV000320910.1 [benign]; RCV000379990.1 [benign]; 			156	66					CNTNAP2 (inh=AR pLI=0.00)
chr7	148117642	148117642	C	T	het	wt	het		QUAL=6567;DP=297,158,230;MQM=60	CNTNAP2	3'UTR	CNTNAP2:NM_014141.5:3'UTR:MODIFIER:exon24/24:c.*4934C>T:		rs2530310	0.3860	0.0000	0/0/0	0.0669							604569 [CNTNAP2 (confirmed) Cortical dysplasia-focal epilepsy syndrome,610042|Autism susceptibility 15,612100|Pitt-Hopkins like syndrome 1,610042];	RCV000291529.1 [benign]; RCV000381253.1 [benign]; 			46	107					CNTNAP2 (inh=AR pLI=0.00)
chr7	155604941	155604941	C	T	wt	het	wt	anno_pathogenic_hgmd	QUAL=2742;DP=145,232,300;MQM=60	SHH	5'UTR	SHH:NM_000193.3:5'UTR:MODIFIER:exon1/3:c.-125G>A:	(CTCT)n	rs9333594	0.0681	0.0000	0/0/0	0.0108							600725 [SHH (confirmed) Holoprosencephaly 3,142945|Single median maxillary central incisor,147250|Microphthalmia with coloboma 5,611638|Schizencephaly,269160];		CR080773 [CLASS=DM? MUT=ALT PHEN="Poly / syndactyly" GENE=SHH]; 		2	26					SHH (inh=AD pLI=0.91)
chr8	1729217	1729217	C	T	hom	hom	hom		QUAL=20979;DP=268,168,238;MQM=59	CLN8	3'UTR	CLN8:NM_018941.3:3'UTR:MODIFIER:exon3/3:c.*484C>T:		rs11778824	0.8097	0.0000	0/0/0	0.1362							607837 [CLN8 (provisional) Ceroid lipofuscinosis,neuronal,8,600143|Ceroid lipofuscinosis,neuronal,8,Northern epilepsy variant,610003];				170	47					CLN8 (inh=AR pLI=0.00)
chr8	1729514	1729514	A	G	hom	hom	hom		QUAL=8939;DP=116,71,105;MQM=56	CLN8	3'UTR	CLN8:NM_018941.3:3'UTR:MODIFIER:exon3/3:c.*781A>G:	AluSz	rs1137514	0.6220	0.0000	0/0/0	0.5738							607837 [CLN8 (provisional) Ceroid lipofuscinosis,neuronal,8,600143|Ceroid lipofuscinosis,neuronal,8,Northern epilepsy variant,610003];				89	77					CLN8 (inh=AR pLI=0.00)
chr8	1729582	1729582	-	TGG	hom	hom	hom		QUAL=12720;DP=155,105,169;MQM=59	CLN8	3'UTR	CLN8:NM_018941.3:3'UTR:MODIFIER:exon3/3:c.*853_*855dupTGG:		rs397698661	0.6190	0.0000	0/0/0	0.3769							607837 [CLN8 (provisional) Ceroid lipofuscinosis,neuronal,8,600143|Ceroid lipofuscinosis,neuronal,8,Northern epilepsy variant,610003];				99	92					CLN8 (inh=AR pLI=0.00)
chr8	1730119	1730119	-	TG	hom	hom	hom		QUAL=9835;DP=112,112,188;MQM=59	CLN8	3'UTR	CLN8:NM_018941.3:3'UTR:MODIFIER:exon3/3:c.*1413_*1414dupTG:		rs878945350	0.5948	0.0000	0/0/0	0.3357							607837 [CLN8 (provisional) Ceroid lipofuscinosis,neuronal,8,600143|Ceroid lipofuscinosis,neuronal,8,Northern epilepsy variant,610003];				7	124					CLN8 (inh=AR pLI=0.00)
chr8	1731855	1731855	C	T	wt	wt	het		QUAL=8619;DP=418,439,655;MQM=60	CLN8	3'UTR	CLN8:NM_018941.3:3'UTR:MODIFIER:exon3/3:c.*3122C>T:		rs10089616	0.1338	0.0000	0/0/0	0.0357							607837 [CLN8 (provisional) Ceroid lipofuscinosis,neuronal,8,600143|Ceroid lipofuscinosis,neuronal,8,Northern epilepsy variant,610003];				24	100					CLN8 (inh=AR pLI=0.00)
chr8	1732224	1732224	G	C	hom	hom	hom		QUAL=17435;DP=229,165,172;MQM=55	CLN8	3'UTR	CLN8:NM_018941.3:3'UTR:MODIFIER:exon3/3:c.*3491G>C:	AluSz	rs10089222	0.7123	0.0000	0/0/0	0.6544							607837 [CLN8 (provisional) Ceroid lipofuscinosis,neuronal,8,600143|Ceroid lipofuscinosis,neuronal,8,Northern epilepsy variant,610003];				102	60					CLN8 (inh=AR pLI=0.00)
chr8	1732580	1732580	C	G	hom	hom	hom		QUAL=29394;DP=318,283,317;MQM=59	CLN8	3'UTR	CLN8:NM_018941.3:3'UTR:MODIFIER:exon3/3:c.*3847C>G:	MLT1A1	rs7827009	0.8079	0.0000	0/0/0	0.1359							607837 [CLN8 (provisional) Ceroid lipofuscinosis,neuronal,8,600143|Ceroid lipofuscinosis,neuronal,8,Northern epilepsy variant,610003];				144	38					CLN8 (inh=AR pLI=0.00)
chr8	1732756	1732756	C	A	hom	hom	hom		QUAL=32013;DP=288,287,432;MQM=59	CLN8	3'UTR	CLN8:NM_018941.3:3'UTR:MODIFIER:exon3/3:c.*4023C>A:		rs7827285	0.8057	0.0000	0/0/0	0.1356							607837 [CLN8 (provisional) Ceroid lipofuscinosis,neuronal,8,600143|Ceroid lipofuscinosis,neuronal,8,Northern epilepsy variant,610003];				159	44					CLN8 (inh=AR pLI=0.00)
chr8	1734452	1734452	C	G	hom	hom	hom		QUAL=6686;DP=131,32,53;MQM=60	CLN8	3'UTR	CLN8:NM_018941.3:3'UTR:MODIFIER:exon3/3:c.*5719C>G:		rs3812477	0.6983	0.0000	0/0/0	0.1212							607837 [CLN8 (provisional) Ceroid lipofuscinosis,neuronal,8,600143|Ceroid lipofuscinosis,neuronal,8,Northern epilepsy variant,610003];				132	88					CLN8 (inh=AR pLI=0.00)
chr8	1806229	1806229	A	C	wt	het	wt		QUAL=1053;DP=119,101,126;MQM=60	ARHGEF10	synonymous	ARHGEF10:NM_001308153.1:synonymous:LOW:exon4/30:c.213A>C:p.Pro71Pro,ARHGEF10:NM_001308152.1:synonymous:LOW:exon3/28:c.141A>C:p.Pro47Pro,ARHGEF10:NM_014629.3:synonymous:LOW:exon3/29:c.141A>C:p.Pro47Pro		rs4875950	0.3057	0.3039	5763/2716/533	0.2979							608136 [ARHGEF10 (confirmed) Slowed nerve conduction velocity,AD,608236];				161	647					ARHGEF10 (inh=AD pLI=0.00)
chr8	1857548	1857548	T	C	het	het	het		QUAL=4354;DP=179,51,123;MQM=59	ARHGEF10	synonymous	ARHGEF10:NM_001308153.1:synonymous:LOW:exon19/30:c.2127T>C:p.Tyr709Tyr,ARHGEF10:NM_001308152.1:synonymous:LOW:exon17/28:c.1941T>C:p.Tyr647Tyr,ARHGEF10:NM_014629.3:synonymous:LOW:exon18/29:c.2055T>C:p.Tyr685Tyr		rs2294038	0.1569	0.1527	1464/753/76	0.1520							608136 [ARHGEF10 (confirmed) Slowed nerve conduction velocity,AD,608236];			COSM3982453, COSM3982452	38	373					ARHGEF10 (inh=AD pLI=0.00)
chr8	1876631	1876631	C	T	het	het	wt		QUAL=3055;DP=147,107,162;MQM=60	ARHGEF10	synonymous	ARHGEF10:NM_001308153.1:synonymous:LOW:exon25/30:c.2808C>T:p.Ile936Ile,ARHGEF10:NM_001308152.1:synonymous:LOW:exon23/28:c.2622C>T:p.Ile874Ile,ARHGEF10:NM_014629.3:synonymous:LOW:exon24/29:c.2736C>T:p.Ile912Ile		rs2272611	0.1444	0.1564	1592/690/85	0.1536							608136 [ARHGEF10 (confirmed) Slowed nerve conduction velocity,AD,608236];			COSM1455922, COSM1455921	42	394					ARHGEF10 (inh=AD pLI=0.00)
chr8	1877480	1877480	T	G	wt	wt	het	pred_pathogenic	QUAL=2647;DP=169,153,192;MQM=60	ARHGEF10	missense	ARHGEF10:NM_001308153.1:missense:MODERATE:exon26/30:c.3022T>G:p.Ser1008Ala,ARHGEF10:NM_001308152.1:missense:MODERATE:exon24/28:c.2836T>G:p.Ser946Ala,ARHGEF10:NM_014629.3:missense:MODERATE:exon25/29:c.2950T>G:p.Ser984Ala		rs17683288	0.0306	0.0546	231/178/3	0.0541	3.4970	T,T,T,T,T,T	T	B,B	T,T,T,T,T,T	11.79	608136 [ARHGEF10 (confirmed) Slowed nerve conduction velocity,AD,608236];				15	204					ARHGEF10 (inh=AD pLI=0.00)
chr8	1900911	1900911	C	T	het	het	wt		QUAL=3105;DP=137,123,150;MQM=59	ARHGEF10	synonymous	ARHGEF10:NM_001308153.1:synonymous:LOW:exon29/30:c.3510C>T:p.His1170His,ARHGEF10:NM_001308152.1:synonymous:LOW:exon27/28:c.3324C>T:p.His1108His,ARHGEF10:NM_014629.3:synonymous:LOW:exon28/29:c.3438C>T:p.His1146His		rs2272608	0.2151	0.1619	1853/514/530	0.1583							608136 [ARHGEF10 (confirmed) Slowed nerve conduction velocity,AD,608236];			COSM3982456, COSM3982455	38	353					ARHGEF10 (inh=AD pLI=0.00)
chr8	1905615	1905615	G	A	het	wt	het		QUAL=8863;DP=350,284,357;MQM=60	ARHGEF10	3'UTR	ARHGEF10:NM_001308153.1:3'UTR:MODIFIER:exon30/30:c.*186G>A:,ARHGEF10:NM_001308152.1:3'UTR:MODIFIER:exon28/28:c.*186G>A:,ARHGEF10:NM_014629.3:3'UTR:MODIFIER:exon29/29:c.*186G>A:			0.0000	0.0000	0/0/0	0.0000							608136 [ARHGEF10 (confirmed) Slowed nerve conduction velocity,AD,608236];				0	2					ARHGEF10 (inh=AD pLI=0.00)
chr8	1905728	1905728	G	A	hom	hom	hom		QUAL=16176;DP=192,148,158;MQM=59	ARHGEF10	3'UTR	ARHGEF10:NM_001308153.1:3'UTR:MODIFIER:exon30/30:c.*299G>A:,ARHGEF10:NM_001308152.1:3'UTR:MODIFIER:exon28/28:c.*299G>A:,ARHGEF10:NM_014629.3:3'UTR:MODIFIER:exon29/29:c.*299G>A:		rs6558566	0.9453	0.0000	0/0/0	0.1457							608136 [ARHGEF10 (confirmed) Slowed nerve conduction velocity,AD,608236];				211	19					ARHGEF10 (inh=AD pLI=0.00)
chr8	1905823	1905823	A	G	het	het	wt		QUAL=2822;DP=164,54,53;MQM=60	ARHGEF10	3'UTR	ARHGEF10:NM_001308153.1:3'UTR:MODIFIER:exon30/30:c.*394A>G:,ARHGEF10:NM_001308152.1:3'UTR:MODIFIER:exon28/28:c.*394A>G:,ARHGEF10:NM_014629.3:3'UTR:MODIFIER:exon29/29:c.*394A>G:		rs6991392	0.3970	0.0000	0/0/0	0.0672							608136 [ARHGEF10 (confirmed) Slowed nerve conduction velocity,AD,608236];				41	114					ARHGEF10 (inh=AD pLI=0.00)
chr8	1906630	1906630	G	T	hom	hom	hom		QUAL=52487;DP=415,559,667;MQM=59	ARHGEF10	3'UTR	ARHGEF10:NM_001308153.1:3'UTR:MODIFIER:exon30/30:c.*1201G>T:,ARHGEF10:NM_001308152.1:3'UTR:MODIFIER:exon28/28:c.*1201G>T:,ARHGEF10:NM_014629.3:3'UTR:MODIFIER:exon29/29:c.*1201G>T:		rs14375	0.9519	0.0000	0/0/0	0.1470							608136 [ARHGEF10 (confirmed) Slowed nerve conduction velocity,AD,608236];				211	19					ARHGEF10 (inh=AD pLI=0.00)
chr8	6264130	6264130	G	C	het	hom	het	low_DP	QUAL=2173;DP=11,48,54;MQM=60	MCPH1	5'UTR,non_coding_transcript_exon	MCPH1:NM_001322042.1:5'UTR:MODIFIER:exon1/15:c.-59G>C:,MCPH1:NM_001172574.1:5'UTR:MODIFIER:exon1/8:c.-59G>C:,MCPH1:NM_001172575.1:5'UTR:MODIFIER:exon1/7:c.-59G>C:,MCPH1:NM_001322043.1:5'UTR:MODIFIER:exon1/8:c.-59G>C:,MCPH1:NM_024596.4:5'UTR:MODIFIER:exon1/14:c.-59G>C:,MCPH1:NR_136159.1:non_coding_transcript_exon:MODIFIER:exon1/7:n.18G>C:		rs2305023	0.5387	0.0000	0/0/0	0.1118							607117 [MCPH1 (confirmed) Microcephaly 1,primary,autosomal recessive,251200];	RCV000365880.1 [benign]; 			404	286					MCPH1 (inh=AR pLI=0.00)
chr8	6272399	6272399	G	T	het	hom	het		QUAL=5864;DP=204,70,81;MQM=60	MCPH1	synonymous,non_coding_transcript_exon	MCPH1:NM_001322042.1:synonymous:LOW:exon3/15:c.228G>T:p.Val76Val,MCPH1:NM_001172574.1:synonymous:LOW:exon3/8:c.228G>T:p.Val76Val,MCPH1:NM_001172575.1:synonymous:LOW:exon3/7:c.228G>T:p.Val76Val,MCPH1:NM_001322043.1:synonymous:LOW:exon3/8:c.222G>T:p.Val74Val,MCPH1:NM_024596.4:synonymous:LOW:exon3/14:c.228G>T:p.Val76Val,MCPH1:NM_001322045.1:synonymous:LOW:exon3/8:c.126G>T:p.Val42Val,MCPH1:NR_136159.1:non_coding_transcript_exon:MODIFIER:exon3/7:n.304G>T:		rs2305022	0.6781	0.7719	36743/21237/956	0.7606							607117 [MCPH1 (confirmed) Microcephaly 1,primary,autosomal recessive,251200];	RCV000146307.2 [other]; RCV000373167.1 [benign]; 			916	569					MCPH1 (inh=AR pLI=0.00)
chr8	6296550	6296550	G	T	hom	hom	hom		QUAL=24334;DP=277,200,269;MQM=60	MCPH1	missense,intron,non_coding_transcript_exon	MCPH1:NM_001322042.1:missense:MODERATE:exon6/15:c.513G>T:p.Arg171Ser,MCPH1:NM_001172574.1:missense:MODERATE:exon6/8:c.513G>T:p.Arg171Ser,MCPH1:NM_001322043.1:missense:MODERATE:exon6/8:c.507G>T:p.Arg169Ser,MCPH1:NM_024596.4:missense:MODERATE:exon6/14:c.513G>T:p.Arg171Ser,MCPH1:NM_001322045.1:missense:MODERATE:exon6/8:c.411G>T:p.Arg137Ser,MCPH1:NM_001172575.1:intron:MODIFIER:exon5/6:c.436+2867G>T:,MCPH1:NR_136159.1:non_coding_transcript_exon:MODIFIER:exon5/7:n.474G>T:		rs2442513	0.9169	0.9662	56549/32517/2976	0.9410	-0.2920	T,T	T	B,B	T,T	0.01	607117 [MCPH1 (confirmed) Microcephaly 1,primary,autosomal recessive,251200];	RCV000194980.2 [benign]; 			1502	63					MCPH1 (inh=AR pLI=0.00)
chr8	6302106	6302106	C	A	het	wt	het	pred_pathogenic	QUAL=10134;DP=369,230,351;MQM=60	MCPH1	missense,non_coding_transcript_exon	MCPH1:NM_001322042.1:missense:MODERATE:exon8/15:c.863C>A:p.Pro288His,MCPH1:NM_001172574.1:missense:MODERATE:exon8/8:c.863C>A:p.Pro288His,MCPH1:NM_001172575.1:missense:MODERATE:exon7/7:c.719C>A:p.Pro240His,MCPH1:NM_001322043.1:missense:MODERATE:exon8/8:c.857C>A:p.Pro286His,MCPH1:NM_024596.4:missense:MODERATE:exon8/14:c.863C>A:p.Pro288His,MCPH1:NM_001322045.1:missense:MODERATE:exon8/8:c.761C>A:p.Pro254His,MCPH1:NR_136159.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.824C>A:		rs35590577	0.0693	0.0289	215/6/199	0.0273	2.1950	D,D,D	T	D,D,D	T,T,T	25.10	607117 [MCPH1 (confirmed) Microcephaly 1,primary,autosomal recessive,251200];	RCV000146333.2 [benign]; RCV000356618.1 [likely benign]; 			2	70					MCPH1 (inh=AR pLI=0.00)
chr8	6302183	6302183	G	C	het	hom	het	pred_pathogenic	QUAL=20871;DP=440,289,394;MQM=60	MCPH1	missense,non_coding_transcript_exon	MCPH1:NM_001322042.1:missense:MODERATE:exon8/15:c.940G>C:p.Asp314His,MCPH1:NM_001172574.1:missense:MODERATE:exon8/8:c.940G>C:p.Asp314His,MCPH1:NM_001172575.1:missense:MODERATE:exon7/7:c.796G>C:p.Asp266His,MCPH1:NM_001322043.1:missense:MODERATE:exon8/8:c.934G>C:p.Asp312His,MCPH1:NM_024596.4:missense:MODERATE:exon8/14:c.940G>C:p.Asp314His,MCPH1:NM_001322045.1:missense:MODERATE:exon8/8:c.838G>C:p.Asp280His,MCPH1:NR_136159.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.901G>C:		rs930557	0.6448	0.7714	36968/21790/538	0.7592	0.3110	T,D,D	T	D,D,D	T,T,T	23.50	607117 [MCPH1 (confirmed) Microcephaly 1,primary,autosomal recessive,251200];	RCV000020903.1 [benign]; RCV000146337.2 [other]; RCV000353105.1 [benign]; 			961	519					MCPH1 (inh=AR pLI=0.00)
chr8	6302418	6302418	A	G	hom	hom	hom		QUAL=29954;DP=275,310,358;MQM=59	MCPH1	missense,non_coding_transcript_exon	MCPH1:NM_001322042.1:missense:MODERATE:exon8/15:c.1175A>G:p.Asp392Gly,MCPH1:NM_001172574.1:missense:MODERATE:exon8/8:c.1175A>G:p.Asp392Gly,MCPH1:NM_001172575.1:missense:MODERATE:exon7/7:c.1031A>G:p.Asp344Gly,MCPH1:NM_001322043.1:missense:MODERATE:exon8/8:c.1169A>G:p.Asp390Gly,MCPH1:NM_024596.4:missense:MODERATE:exon8/14:c.1175A>G:p.Asp392Gly,MCPH1:NM_001322045.1:missense:MODERATE:exon8/8:c.1073A>G:p.Asp358Gly,MCPH1:NR_136159.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.1136A>G:		rs2515569	0.9944	0.9980	60074/33307/4660	0.9307	-3.5300	T,T,T	T	B,B,B	T,T,T	0.01	607117 [MCPH1 (confirmed) Microcephaly 1,primary,autosomal recessive,251200];	RCV000082198.7 [other]; RCV000267656.1 [benign]; 			1563	2					MCPH1 (inh=AR pLI=0.00)
chr8	6302671	6302671	C	T	het	wt	het		QUAL=8317;DP=282,211,279;MQM=60	MCPH1	synonymous,non_coding_transcript_exon	MCPH1:NM_001322042.1:synonymous:LOW:exon8/15:c.1428C>T:p.Phe476Phe,MCPH1:NM_001172574.1:synonymous:LOW:exon8/8:c.1428C>T:p.Phe476Phe,MCPH1:NM_001172575.1:synonymous:LOW:exon7/7:c.1284C>T:p.Phe428Phe,MCPH1:NM_001322043.1:synonymous:LOW:exon8/8:c.1422C>T:p.Phe474Phe,MCPH1:NM_024596.4:synonymous:LOW:exon8/14:c.1428C>T:p.Phe476Phe,MCPH1:NM_001322045.1:synonymous:LOW:exon8/8:c.1326C>T:p.Phe442Phe,MCPH1:NR_136159.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.1389C>T:		rs2920676	0.2081	0.0852	1241/14/880	0.0823							607117 [MCPH1 (confirmed) Microcephaly 1,primary,autosomal recessive,251200];	RCV000082200.6 [benign]; RCV000382916.1 [benign]; 			6	138					MCPH1 (inh=AR pLI=0.00)
chr8	6303025	6303025	G	A	het	hom	het		QUAL=20055;DP=466,297,318;MQM=59	MCPH1	synonymous,non_coding_transcript_exon	MCPH1:NM_001322042.1:synonymous:LOW:exon8/15:c.1782G>A:p.Thr594Thr,MCPH1:NM_001172574.1:synonymous:LOW:exon8/8:c.1782G>A:p.Thr594Thr,MCPH1:NM_001172575.1:synonymous:LOW:exon7/7:c.1638G>A:p.Thr546Thr,MCPH1:NM_001322043.1:synonymous:LOW:exon8/8:c.1776G>A:p.Thr592Thr,MCPH1:NM_024596.4:synonymous:LOW:exon8/14:c.1782G>A:p.Thr594Thr,MCPH1:NM_001322045.1:synonymous:LOW:exon8/8:c.1680G>A:p.Thr560Thr,MCPH1:NR_136159.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.1743G>A:		rs2584	0.1322	0.2616	4880/3762/25	0.2548							607117 [MCPH1 (confirmed) Microcephaly 1,primary,autosomal recessive,251200];	RCV000146282.2 [benign]; RCV000336395.1 [likely benign]; 			138	585					MCPH1 (inh=AR pLI=0.00)
chr8	6303409	6303409	T	G	het	wt	het		QUAL=6240;DP=336,169,211;MQM=60	MCPH1	3'UTR,intron,non_coding_transcript_exon	MCPH1:NM_001172574.1:3'UTR:MODIFIER:exon8/8:c.*333T>G:,MCPH1:NM_001172575.1:3'UTR:MODIFIER:exon7/7:c.*333T>G:,MCPH1:NM_001322043.1:3'UTR:MODIFIER:exon8/8:c.*333T>G:,MCPH1:NM_001322045.1:3'UTR:MODIFIER:exon8/8:c.*333T>G:,MCPH1:NM_001322042.1:intron:MODIFIER:exon8/14:c.1825+341T>G:,MCPH1:NM_024596.4:intron:MODIFIER:exon8/13:c.1825+341T>G:,MCPH1:NR_136159.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.2127T>G:		rs2916750	0.2935	0.0000	0/0/0	0.0359							607117 [MCPH1 (confirmed) Microcephaly 1,primary,autosomal recessive,251200];				5	52					MCPH1 (inh=AR pLI=0.00)
chr8	6303434	6303434	T	A	het	hom	het		QUAL=10273;DP=234,143,168;MQM=60	MCPH1	3'UTR,intron,non_coding_transcript_exon	MCPH1:NM_001172574.1:3'UTR:MODIFIER:exon8/8:c.*358T>A:,MCPH1:NM_001172575.1:3'UTR:MODIFIER:exon7/7:c.*358T>A:,MCPH1:NM_001322043.1:3'UTR:MODIFIER:exon8/8:c.*358T>A:,MCPH1:NM_001322045.1:3'UTR:MODIFIER:exon8/8:c.*358T>A:,MCPH1:NM_001322042.1:intron:MODIFIER:exon8/14:c.1825+366T>A:,MCPH1:NM_024596.4:intron:MODIFIER:exon8/13:c.1825+366T>A:,MCPH1:NR_136159.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.2152T>A:		rs2515570	0.6536	0.0000	0/0/0	0.1296							607117 [MCPH1 (confirmed) Microcephaly 1,primary,autosomal recessive,251200];				93	51					MCPH1 (inh=AR pLI=0.00)
chr8	6303511	6303511	T	A	het	hom	het		QUAL=6086;DP=187,67,77;MQM=60	MCPH1	3'UTR,intron,non_coding_transcript_exon	MCPH1:NM_001172574.1:3'UTR:MODIFIER:exon8/8:c.*435T>A:,MCPH1:NM_001172575.1:3'UTR:MODIFIER:exon7/7:c.*435T>A:,MCPH1:NM_001322043.1:3'UTR:MODIFIER:exon8/8:c.*435T>A:,MCPH1:NM_001322045.1:3'UTR:MODIFIER:exon8/8:c.*435T>A:,MCPH1:NM_001322042.1:intron:MODIFIER:exon8/14:c.1825+443T>A:,MCPH1:NM_024596.4:intron:MODIFIER:exon8/13:c.1825+443T>A:,MCPH1:NR_136159.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.2229T>A:		rs1054073	0.6691	0.0000	0/0/0	0.1304							607117 [MCPH1 (confirmed) Microcephaly 1,primary,autosomal recessive,251200];				93	51					MCPH1 (inh=AR pLI=0.00)
chr8	6303614	6303614	A	C	het	hom	het		QUAL=3503;DP=150,20,44;MQM=59	MCPH1	3'UTR,intron,non_coding_transcript_exon	MCPH1:NM_001172574.1:3'UTR:MODIFIER:exon8/8:c.*538A>C:,MCPH1:NM_001172575.1:3'UTR:MODIFIER:exon7/7:c.*538A>C:,MCPH1:NM_001322043.1:3'UTR:MODIFIER:exon8/8:c.*538A>C:,MCPH1:NM_001322045.1:3'UTR:MODIFIER:exon8/8:c.*538A>C:,MCPH1:NM_001322042.1:intron:MODIFIER:exon8/14:c.1825+546A>C:,MCPH1:NM_024596.4:intron:MODIFIER:exon8/13:c.1825+546A>C:,MCPH1:NR_136159.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.2332A>C:		rs1054074	0.6609	0.0000	0/0/0	0.1538							607117 [MCPH1 (confirmed) Microcephaly 1,primary,autosomal recessive,251200];				92	52					MCPH1 (inh=AR pLI=0.00)
chr8	6303846	6303846	A	G	het	wt	het		QUAL=4298;DP=132,125,206;MQM=60	MCPH1	3'UTR,intron,non_coding_transcript_exon	MCPH1:NM_001172574.1:3'UTR:MODIFIER:exon8/8:c.*770A>G:,MCPH1:NM_001172575.1:3'UTR:MODIFIER:exon7/7:c.*770A>G:,MCPH1:NM_001322043.1:3'UTR:MODIFIER:exon8/8:c.*770A>G:,MCPH1:NM_001322045.1:3'UTR:MODIFIER:exon8/8:c.*770A>G:,MCPH1:NM_001322042.1:intron:MODIFIER:exon8/14:c.1825+778A>G:,MCPH1:NM_024596.4:intron:MODIFIER:exon8/13:c.1825+778A>G:,MCPH1:NR_136159.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.2564A>G:		rs79010412	0.0705	0.0000	0/0/0	0.0046							607117 [MCPH1 (confirmed) Microcephaly 1,primary,autosomal recessive,251200];				0	5					MCPH1 (inh=AR pLI=0.00)
chr8	6303859	6303859	C	T	het	hom	het		QUAL=9093;DP=121,135,237;MQM=60	MCPH1	3'UTR,intron,non_coding_transcript_exon	MCPH1:NM_001172574.1:3'UTR:MODIFIER:exon8/8:c.*783C>T:,MCPH1:NM_001172575.1:3'UTR:MODIFIER:exon7/7:c.*783C>T:,MCPH1:NM_001322043.1:3'UTR:MODIFIER:exon8/8:c.*783C>T:,MCPH1:NM_001322045.1:3'UTR:MODIFIER:exon8/8:c.*783C>T:,MCPH1:NM_001322042.1:intron:MODIFIER:exon8/14:c.1825+791C>T:,MCPH1:NM_024596.4:intron:MODIFIER:exon8/13:c.1825+791C>T:,MCPH1:NR_136159.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.2577C>T:		rs2440415	0.6442	0.0000	0/0/0	0.1288							607117 [MCPH1 (confirmed) Microcephaly 1,primary,autosomal recessive,251200];				93	51					MCPH1 (inh=AR pLI=0.00)
chr8	6304259	6304259	G	A	het	hom	het		QUAL=5365;DP=154,79,89;MQM=60	MCPH1	3'UTR,intron,non_coding_transcript_exon	MCPH1:NM_001172574.1:3'UTR:MODIFIER:exon8/8:c.*1183G>A:,MCPH1:NM_001172575.1:3'UTR:MODIFIER:exon7/7:c.*1183G>A:,MCPH1:NM_001322043.1:3'UTR:MODIFIER:exon8/8:c.*1183G>A:,MCPH1:NM_001322045.1:3'UTR:MODIFIER:exon8/8:c.*1183G>A:,MCPH1:NM_001322042.1:intron:MODIFIER:exon8/14:c.1825+1191G>A:,MCPH1:NM_024596.4:intron:MODIFIER:exon8/13:c.1825+1191G>A:,MCPH1:NR_136159.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.2977G>A:		rs2515571	0.6534	0.0000	0/0/0	0.7595							607117 [MCPH1 (confirmed) Microcephaly 1,primary,autosomal recessive,251200];				93	51					MCPH1 (inh=AR pLI=0.00)
chr8	6304348	6304348	C	T	het	hom	het		QUAL=7549;DP=186,110,139;MQM=60	MCPH1	3'UTR,intron,non_coding_transcript_exon	MCPH1:NM_001172574.1:3'UTR:MODIFIER:exon8/8:c.*1272C>T:,MCPH1:NM_001172575.1:3'UTR:MODIFIER:exon7/7:c.*1272C>T:,MCPH1:NM_001322043.1:3'UTR:MODIFIER:exon8/8:c.*1272C>T:,MCPH1:NM_001322045.1:3'UTR:MODIFIER:exon8/8:c.*1272C>T:,MCPH1:NM_001322042.1:intron:MODIFIER:exon8/14:c.1825+1280C>T:,MCPH1:NM_024596.4:intron:MODIFIER:exon8/13:c.1825+1280C>T:,MCPH1:NR_136159.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.3066C>T:		rs2166006	0.6725	0.0000	0/0/0	0.7773							607117 [MCPH1 (confirmed) Microcephaly 1,primary,autosomal recessive,251200];				93	52					MCPH1 (inh=AR pLI=0.00)
chr8	6304522	6304535	CAGGCAGGGGTGTC	-	het	hom	het		QUAL=8119;DP=212,149,245;MQM=59	MCPH1	3'UTR,intron,non_coding_transcript_exon	MCPH1:NM_001172574.1:3'UTR:MODIFIER:exon8/8:c.*1455_*1468delGTGTCCAGGCAGGG:,MCPH1:NM_001172575.1:3'UTR:MODIFIER:exon7/7:c.*1455_*1468delGTGTCCAGGCAGGG:,MCPH1:NM_001322043.1:3'UTR:MODIFIER:exon8/8:c.*1455_*1468delGTGTCCAGGCAGGG:,MCPH1:NM_001322045.1:3'UTR:MODIFIER:exon8/8:c.*1455_*1468delGTGTCCAGGCAGGG:,MCPH1:NM_001322042.1:intron:MODIFIER:exon8/14:c.1825+1463_1825+1476delGTGTCCAGGCAGGG:,MCPH1:NM_024596.4:intron:MODIFIER:exon8/13:c.1825+1463_1825+1476delGTGTCCAGGCAGGG:,MCPH1:NR_136159.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.3249_3262delGTGTCCAGGCAGGG:		rs370636933	0.6482	0.0000	0/0/0	0.6422							607117 [MCPH1 (confirmed) Microcephaly 1,primary,autosomal recessive,251200];				92	53					MCPH1 (inh=AR pLI=0.00)
chr8	6304694	6304694	A	G	het	hom	het		QUAL=13738;DP=249,204,282;MQM=60	MCPH1	3'UTR,intron,non_coding_transcript_exon	MCPH1:NM_001172574.1:3'UTR:MODIFIER:exon8/8:c.*1618A>G:,MCPH1:NM_001172575.1:3'UTR:MODIFIER:exon7/7:c.*1618A>G:,MCPH1:NM_001322043.1:3'UTR:MODIFIER:exon8/8:c.*1618A>G:,MCPH1:NM_001322045.1:3'UTR:MODIFIER:exon8/8:c.*1618A>G:,MCPH1:NM_001322042.1:intron:MODIFIER:exon8/14:c.1825+1626A>G:,MCPH1:NM_024596.4:intron:MODIFIER:exon8/13:c.1825+1626A>G:,MCPH1:NR_136159.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.3412A>G:		rs1129703	0.6573	0.0000	0/0/0	0.7732							607117 [MCPH1 (confirmed) Microcephaly 1,primary,autosomal recessive,251200];				93	52					MCPH1 (inh=AR pLI=0.00)
chr8	6304730	6304730	A	C	het	hom	het		QUAL=12580;DP=278,172,252;MQM=60	MCPH1	3'UTR,intron,non_coding_transcript_exon	MCPH1:NM_001172574.1:3'UTR:MODIFIER:exon8/8:c.*1654A>C:,MCPH1:NM_001172575.1:3'UTR:MODIFIER:exon7/7:c.*1654A>C:,MCPH1:NM_001322043.1:3'UTR:MODIFIER:exon8/8:c.*1654A>C:,MCPH1:NM_001322045.1:3'UTR:MODIFIER:exon8/8:c.*1654A>C:,MCPH1:NM_001322042.1:intron:MODIFIER:exon8/14:c.1825+1662A>C:,MCPH1:NM_024596.4:intron:MODIFIER:exon8/13:c.1825+1662A>C:,MCPH1:NR_136159.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.3448A>C:		rs1129704	0.6492	0.0000	0/0/0	0.7712							607117 [MCPH1 (confirmed) Microcephaly 1,primary,autosomal recessive,251200];				93	52					MCPH1 (inh=AR pLI=0.00)
chr8	6304814	6304814	A	G	het	hom	het		QUAL=14667;DP=247,227,289;MQM=60	MCPH1	3'UTR,intron,non_coding_transcript_exon	MCPH1:NM_001172574.1:3'UTR:MODIFIER:exon8/8:c.*1738A>G:,MCPH1:NM_001172575.1:3'UTR:MODIFIER:exon7/7:c.*1738A>G:,MCPH1:NM_001322043.1:3'UTR:MODIFIER:exon8/8:c.*1738A>G:,MCPH1:NM_001322045.1:3'UTR:MODIFIER:exon8/8:c.*1738A>G:,MCPH1:NM_001322042.1:intron:MODIFIER:exon8/14:c.1825+1746A>G:,MCPH1:NM_024596.4:intron:MODIFIER:exon8/13:c.1825+1746A>G:,MCPH1:NR_136159.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.3532A>G:		rs1129706	0.6573	0.0000	0/0/0	0.7726							607117 [MCPH1 (confirmed) Microcephaly 1,primary,autosomal recessive,251200];				93	52					MCPH1 (inh=AR pLI=0.00)
chr8	8559832	8559832	G	A	het	hom	wt		QUAL=1679;DP=39,47,79;MQM=59	CLDN23	5'UTR	CLDN23:NM_194284.2:5'UTR:MODIFIER:exon1/1:c.-77G>A:		rs9644774	0.2163	0.0000	0/0/0	0.0504											27	106					CLDN23 (inh=n/a pLI=0.00)
chr8	10581882	10581882	A	C	hom	hom	hom		QUAL=21014;DP=321,159,207;MQM=60	SOX7	3'UTR	SOX7:NM_031439.3:3'UTR:MODIFIER:exon2/2:c.*1366T>G:		rs11250064	0.6781	0.0000	0/0/0	0.1109											104	98					SOX7 (inh=n/a pLI=0.13)
chr8	10581910	10581910	C	G	wt	het	wt		QUAL=2729;DP=277,204,257;MQM=60	SOX7	3'UTR	SOX7:NM_031439.3:3'UTR:MODIFIER:exon2/2:c.*1338G>C:		rs58772184	0.1813	0.0000	0/0/0	0.0211											1	41					SOX7 (inh=n/a pLI=0.13)
chr8	10582097	10582097	C	G	wt	het	wt		QUAL=5112;DP=533,442,605;MQM=60	SOX7	3'UTR	SOX7:NM_031439.3:3'UTR:MODIFIER:exon2/2:c.*1151G>C:		rs1139843	0.1552	0.0000	0/0/0	0.0197											1	40					SOX7 (inh=n/a pLI=0.13)
chr8	10582266	10582266	C	T	wt	het	wt		QUAL=2105;DP=244,215,238;MQM=59	SOX7	3'UTR	SOX7:NM_031439.3:3'UTR:MODIFIER:exon2/2:c.*982G>A:	AluSq2	rs1139066	0.2035	0.0000	0/0/0	0.1202											1	40					SOX7 (inh=n/a pLI=0.13)
chr8	10582523	10582523	T	G	het	wt	het	low_DP	QUAL=1023;DP=77,11,15;MQM=58	SOX7	3'UTR	SOX7:NM_031439.3:3'UTR:MODIFIER:exon2/2:c.*725A>C:	AluSq2	rs145522498	0.0296	0.0000	0/0/0	0.0094											1	24					SOX7 (inh=n/a pLI=0.13)
chr8	10583203	10583203	A	G	hom	hom	hom		QUAL=26903;DP=215,295,341;MQM=59	SOX7	3'UTR	SOX7:NM_031439.3:3'UTR:MODIFIER:exon2/2:c.*45T>C:		rs10110624	0.6500	0.6501	24815/14571/3315	0.6158											349	323					SOX7 (inh=n/a pLI=0.13)
chr8	10583506	10583506	A	G	het	hom	wt		QUAL=2777;DP=74,64,73;MQM=59	SOX7	synonymous	SOX7:NM_031439.3:synonymous:LOW:exon2/2:c.909T>C:p.Leu303Leu		rs4841432	0.4327	0.3709	8812/4334/2921	0.3602											140	540					SOX7 (inh=n/a pLI=0.13)
chr8	15622454	15622454	C	T	wt	het	het		QUAL=7901;DP=261,242,333;MQM=60	TUSC3	3'UTR	TUSC3:NM_006765.3:3'UTR:MODIFIER:exon11/11:c.*789C>T:,TUSC3:NM_178234.2:3'UTR:MODIFIER:exon10/10:c.*727C>T:		rs352809	0.7442	0.0000	0/0/0	0.1259							601385 [TUSC3 (confirmed) Mental retardation,autosomal recessive 7,611093];	RCV000375052.1 [benign]; 			79	65					TUSC3 (inh=AR pLI=0.00)
chr8	15622519	15622519	T	C	wt	het	het		QUAL=6140;DP=275,167,252;MQM=60	TUSC3	3'UTR	TUSC3:NM_006765.3:3'UTR:MODIFIER:exon11/11:c.*854T>C:,TUSC3:NM_178234.2:3'UTR:MODIFIER:exon10/10:c.*792T>C:		rs352810	0.7546	0.0000	0/0/0	0.1281							601385 [TUSC3 (confirmed) Mental retardation,autosomal recessive 7,611093];	RCV000280435.1 [benign]; 			83	62					TUSC3 (inh=AR pLI=0.00)
chr8	15622953	15622953	G	A	wt	wt	het		QUAL=2786;DP=427,141,205;MQM=60	TUSC3	3'UTR	TUSC3:NM_006765.3:3'UTR:MODIFIER:exon11/11:c.*1288G>A:,TUSC3:NM_178234.2:3'UTR:MODIFIER:exon10/10:c.*1226G>A:		rs79587346	0.0469	0.0000	0/0/0	0.0133							601385 [TUSC3 (confirmed) Mental retardation,autosomal recessive 7,611093];	RCV000367189.1 [likely benign]; 			1	31					TUSC3 (inh=AR pLI=0.00)
chr8	15623608	15623608	-	TT	wt	het	het		QUAL=2226;DP=351,109,152;MQM=60	TUSC3	3'UTR	TUSC3:NM_006765.3:3'UTR:MODIFIER:exon11/11:c.*1943_*1944insTT:,TUSC3:NM_178234.2:3'UTR:MODIFIER:exon10/10:c.*1881_*1882insTT:		rs55894244	0.1148	0.0000	0/0/0	0.1467							601385 [TUSC3 (confirmed) Mental retardation,autosomal recessive 7,611093];	RCV000356832.1 [likely benign]; 			9	69					TUSC3 (inh=AR pLI=0.00)
chr8	15623609	15623609	C	T	wt	het	het		QUAL=2226;DP=351,109,152;MQM=60	TUSC3	3'UTR	TUSC3:NM_006765.3:3'UTR:MODIFIER:exon11/11:c.*1944C>T:,TUSC3:NM_178234.2:3'UTR:MODIFIER:exon10/10:c.*1882C>T:		rs34145513	0.1152	0.0000	0/0/0	0.0583							601385 [TUSC3 (confirmed) Mental retardation,autosomal recessive 7,611093];	RCV000264450.1 [likely benign]; 			9	69					TUSC3 (inh=AR pLI=0.00)
chr8	15624028	15624028	-	A	wt	het	het		QUAL=4057;DP=286,136,185;MQM=59	TUSC3	3'UTR	TUSC3:NM_006765.3:3'UTR:MODIFIER:exon11/11:c.*2368dupA:,TUSC3:NM_178234.2:3'UTR:MODIFIER:exon10/10:c.*2306dupA:		rs549656634	0.1414	0.0000	0/0/0	0.1300							601385 [TUSC3 (confirmed) Mental retardation,autosomal recessive 7,611093];	RCV000293536.1 [likely benign]; 			9	69					TUSC3 (inh=AR pLI=0.00)
chr8	15624121	15624121	C	A	wt	het	wt		QUAL=2539;DP=499,218,281;MQM=60	TUSC3	3'UTR	TUSC3:NM_006765.3:3'UTR:MODIFIER:exon11/11:c.*2456C>A:,TUSC3:NM_178234.2:3'UTR:MODIFIER:exon10/10:c.*2394C>A:		rs13267717	0.1146	0.0000	0/0/0	0.0359							601385 [TUSC3 (confirmed) Mental retardation,autosomal recessive 7,611093];	RCV000406451.1 [likely benign]; 			9	66					TUSC3 (inh=AR pLI=0.00)
chr8	22021037	22021037	C	A	wt	het	het	pred_pathogenic	QUAL=1461;DP=161,84,74;MQM=60	SFTPC	missense	SFTPC:NM_001172410.1:missense:MODERATE:exon4/6:c.413C>A:p.Thr138Asn,SFTPC:NM_001172357.1:missense:MODERATE:exon4/5:c.413C>A:p.Thr138Asn,SFTPC:NM_001317778.1:missense:MODERATE:exon4/6:c.413C>A:p.Thr138Asn,SFTPC:NM_001317779.1:missense:MODERATE:exon3/5:c.254C>A:p.Thr85Asn,SFTPC:NM_001317780.1:missense:MODERATE:exon4/6:c.413C>A:p.Thr138Asn,SFTPC:NM_003018.3:missense:MODERATE:exon4/6:c.413C>A:p.Thr138Asn		rs4715	0.1975	0.2523	3915/2457/20	0.2465	0.9200	T,D,D,D,D,T,T	T	P,B,P	T,T,T,T,T,T,T	23.40	178620 [SFTPC (confirmed) Surfactant metabolism dysfunction,pulmonary,2,610913];	RCV000151856.1 [benign]; RCV000289134.1 [benign]; RCV000311252.1 [likely benign]; RCV000387624.1 [benign]; 	CM040798 [CLASS=DP MUT=REF PHEN="Perinatal respiratory disease association with" GENE=SFTPC]; 	COSM3763249	128	596					SFTPC (inh=AD pLI=0.07)
chr8	22021517	22021517	G	A	wt	het	het		QUAL=3365;DP=143,130,160;MQM=60	SFTPC	missense	SFTPC:NM_001172410.1:missense:MODERATE:exon5/6:c.557G>A:p.Ser186Asn,SFTPC:NM_001172357.1:missense:MODERATE:exon5/5:c.539G>A:p.Ser180Asn,SFTPC:NM_001317778.1:missense:MODERATE:exon5/6:c.539G>A:p.Ser180Asn,SFTPC:NM_001317779.1:missense:MODERATE:exon4/5:c.398G>A:p.Ser133Asn,SFTPC:NM_001317780.1:missense:MODERATE:exon5/6:c.539G>A:p.Ser180Asn,SFTPC:NM_003018.3:missense:MODERATE:exon5/6:c.557G>A:p.Ser186Asn		rs1124	0.2360	0.3001	5638/3709/63	0.2934	0.6100	T,T,T	T	B	T,T,T	11.66	178620 [SFTPC (confirmed) Surfactant metabolism dysfunction,pulmonary,2,610913];	RCV000151858.1 [benign]; RCV000277733.1 [benign]; RCV000367594.1 [benign]; RCV000401939.1 [benign]; 	CM040800 [CLASS=DP MUT=REF PHEN="Perinatal respiratory disease association with" GENE=SFTPC]; 	COSM3763250	171	639					SFTPC (inh=AD pLI=0.07)
chr8	22021739	22021739	-	A	wt	het	het		QUAL=5844;DP=192,231,277;MQM=59	SFTPC	3'UTR,intron	SFTPC:NM_001172357.1:3'UTR:MODIFIER:exon5/5:c.*186dupA:,SFTPC:NM_001172410.1:intron:MODIFIER:exon5/5:c.*11-39dupA:,SFTPC:NM_001317778.1:intron:MODIFIER:exon5/5:c.*19-39dupA:,SFTPC:NM_001317779.1:intron:MODIFIER:exon4/4:c.*19-39dupA:,SFTPC:NM_001317780.1:intron:MODIFIER:exon5/5:c.*11-39dupA:,SFTPC:NM_003018.3:intron:MODIFIER:exon5/5:c.*19-39dupA:		rs397797745	0.3345	0.3028	600/216/57	0.1068							178620 [SFTPC (confirmed) Surfactant metabolism dysfunction,pulmonary,2,610913];				117	403					SFTPC (inh=AD pLI=0.07)
chr8	22021883	22021883	G	A	wt	het	het		QUAL=1493;DP=107,98,108;MQM=59	SFTPC	3'UTR	SFTPC:NM_001172410.1:3'UTR:MODIFIER:exon6/6:c.*115G>A:,SFTPC:NM_001172357.1:3'UTR:MODIFIER:exon5/5:c.*329G>A:,SFTPC:NM_001317778.1:3'UTR:MODIFIER:exon6/6:c.*123G>A:,SFTPC:NM_001317779.1:3'UTR:MODIFIER:exon5/5:c.*123G>A:,SFTPC:NM_001317780.1:3'UTR:MODIFIER:exon6/6:c.*115G>A:,SFTPC:NM_003018.3:3'UTR:MODIFIER:exon6/6:c.*123G>A:		rs7592	0.3343	0.3116	571/196/57	0.0848							178620 [SFTPC (confirmed) Surfactant metabolism dysfunction,pulmonary,2,610913];	RCV000301511.1 [benign]; RCV000353332.1 [benign]; RCV000398642.1 [benign]; 			132	453					SFTPC (inh=AD pLI=0.07)
chr8	22021933	22021933	C	T	het	wt	het	pred_pathogenic	QUAL=2513;DP=172,66,66;MQM=59	SFTPC	3'UTR	SFTPC:NM_001172410.1:3'UTR:MODIFIER:exon6/6:c.*165C>T:,SFTPC:NM_001172357.1:3'UTR:MODIFIER:exon5/5:c.*379C>T:,SFTPC:NM_001317778.1:3'UTR:MODIFIER:exon6/6:c.*173C>T:,SFTPC:NM_001317779.1:3'UTR:MODIFIER:exon5/5:c.*173C>T:,SFTPC:NM_001317780.1:3'UTR:MODIFIER:exon6/6:c.*165C>T:,SFTPC:NM_003018.3:3'UTR:MODIFIER:exon6/6:c.*173C>T:		rs1126931	0.1044	0.2060	175/41/1	0.0373	-1.7130	D	T		T	8.09	178620 [SFTPC (confirmed) Surfactant metabolism dysfunction,pulmonary,2,610913];	RCV000262820.1 [likely benign]; RCV000269681.1 [benign]; RCV000326755.1 [benign]; 			31	300					SFTPC (inh=AD pLI=0.07)
chr8	22021934	22021934	G	A	wt	het	het		QUAL=476;DP=171,57,67;MQM=60	SFTPC	3'UTR	SFTPC:NM_001172410.1:3'UTR:MODIFIER:exon6/6:c.*166G>A:,SFTPC:NM_001172357.1:3'UTR:MODIFIER:exon5/5:c.*380G>A:,SFTPC:NM_001317778.1:3'UTR:MODIFIER:exon6/6:c.*174G>A:,SFTPC:NM_001317779.1:3'UTR:MODIFIER:exon5/5:c.*174G>A:,SFTPC:NM_001317780.1:3'UTR:MODIFIER:exon6/6:c.*166G>A:,SFTPC:NM_003018.3:3'UTR:MODIFIER:exon6/6:c.*174G>A:		rs1139547	0.2410	0.3132	295/116/6	0.0631							178620 [SFTPC (confirmed) Surfactant metabolism dysfunction,pulmonary,2,610913];	RCV000264445.1 [benign]; RCV000272766.1 [benign]; RCV000314169.1 [benign]; 			117	423					SFTPC (inh=AD pLI=0.07)
chr8	24809067	24809067	C	T	hom	hom	hom		QUAL=29216;DP=397,215,283;MQM=60	NEFL	3'UTR	NEFL:NM_006158.4:3'UTR:MODIFIER:exon5/5:c.*1256G>A:		rs2979704	0.7196	0.0000	0/0/0	0.8063							162280 [NEFL (confirmed) Charcot-Marie-Tooth disease,type 2E,607684|Charcot-Marie-Tooth disease,type 1F,607734];	RCV000311138.1 [benign]; 			172	77					NEFL (inh=AR+AD pLI=n/a)
chr8	24809168	24809168	A	C	wt	wt	het		QUAL=2314;DP=293,135,153;MQM=60	NEFL	3'UTR	NEFL:NM_006158.4:3'UTR:MODIFIER:exon5/5:c.*1155T>G:		rs116881703	0.0058	0.0000	0/0/0	0.0093							162280 [NEFL (confirmed) Charcot-Marie-Tooth disease,type 2E,607684|Charcot-Marie-Tooth disease,type 1F,607734];	RCV000392666.1 [likely benign]; 			0	11					NEFL (inh=AR+AD pLI=n/a)
chr8	24809636	24809636	C	G	hom	hom	hom		QUAL=19101;DP=242,147,201;MQM=60	NEFL	3'UTR	NEFL:NM_006158.4:3'UTR:MODIFIER:exon5/5:c.*687G>C:		rs2976439	0.5427	0.0000	0/0/0	0.6238							162280 [NEFL (confirmed) Charcot-Marie-Tooth disease,type 2E,607684|Charcot-Marie-Tooth disease,type 1F,607734];	RCV000264408.1 [benign]; 			90	122					NEFL (inh=AR+AD pLI=n/a)
chr8	24810088	24810088	T	A	hom	hom	hom		QUAL=33012;DP=382,299,344;MQM=59	NEFL	3'UTR	NEFL:NM_006158.4:3'UTR:MODIFIER:exon5/5:c.*235A>T:		rs1059111	0.7208	0.0000	0/0/0	0.8084							162280 [NEFL (confirmed) Charcot-Marie-Tooth disease,type 2E,607684|Charcot-Marie-Tooth disease,type 1F,607734];	RCV000294023.1 [benign]; 			214	82					NEFL (inh=AR+AD pLI=n/a)
chr8	24811065	24811065	G	-	hom	hom	hom	anno_high_impact	QUAL=33485;DP=197,377,558;MQM=59	NEFL	splice_acceptor&splice_donor	NEFL:NM_006158.4:splice_acceptor&splice_donor:HIGH:exon3/4:c.1413+1delC:		rs397788090	1.0000	1.0000	59987/33132/4877	0.9316							162280 [NEFL (confirmed) Charcot-Marie-Tooth disease,type 2E,607684|Charcot-Marie-Tooth disease,type 1F,607734];				1563	0	1	[1] auto-classification 16.06.2016  [2] Ute Grasshoff 24.11.2015			NEFL (inh=AR+AD pLI=n/a)
chr8	27317337	27317337	A	G	hom	hom	hom		QUAL=41620;DP=281,416,600;MQM=59	CHRNA2	3'UTR	CHRNA2:NM_000742.3:3'UTR:MODIFIER:exon7/7:c.*1809T>C:,CHRNA2:NM_001282455.1:3'UTR:MODIFIER:exon7/7:c.*1809T>C:		rs2280375	0.8057	0.0000	0/0/0	0.8149							118502 [CHRNA2 (confirmed) Epilepsy,nocturnal frontal lobe,type 4,610353];	RCV000302439.1 [benign]; 			171	53					CHRNA2 (inh=AD pLI=0.00)
chr8	27317445	27317445	G	T	het	hom	het		QUAL=20525;DP=187,374,582;MQM=60	CHRNA2	3'UTR	CHRNA2:NM_000742.3:3'UTR:MODIFIER:exon7/7:c.*1701C>A:,CHRNA2:NM_001282455.1:3'UTR:MODIFIER:exon7/7:c.*1701C>A:		rs1057137	0.4052	0.0000	0/0/0	0.3634							118502 [CHRNA2 (confirmed) Epilepsy,nocturnal frontal lobe,type 4,610353];	RCV000365839.1 [benign]; 			30	116					CHRNA2 (inh=AD pLI=0.00)
chr8	27317762	27317762	G	A	het	wt	het		QUAL=4911;DP=185,166,234;MQM=59	CHRNA2	3'UTR	CHRNA2:NM_000742.3:3'UTR:MODIFIER:exon7/7:c.*1384C>T:,CHRNA2:NM_001282455.1:3'UTR:MODIFIER:exon7/7:c.*1384C>T:		rs2280376	0.2218	0.0000	0/0/0	0.2632							118502 [CHRNA2 (confirmed) Epilepsy,nocturnal frontal lobe,type 4,610353];	RCV000386550.1 [benign]; 			18	95					CHRNA2 (inh=AD pLI=0.00)
chr8	27317987	27317987	A	G	het	wt	het		QUAL=7647;DP=289,280,387;MQM=59	CHRNA2	3'UTR	CHRNA2:NM_000742.3:3'UTR:MODIFIER:exon7/7:c.*1159T>C:,CHRNA2:NM_001282455.1:3'UTR:MODIFIER:exon7/7:c.*1159T>C:		rs1560344	0.3654	0.0000	0/0/0	0.4341							118502 [CHRNA2 (confirmed) Epilepsy,nocturnal frontal lobe,type 4,610353];	RCV000338226.1 [benign]; 			48	123					CHRNA2 (inh=AD pLI=0.00)
chr8	27318391	27318391	C	T	het	wt	het		QUAL=6893;DP=277,221,303;MQM=59	CHRNA2	3'UTR	CHRNA2:NM_000742.3:3'UTR:MODIFIER:exon7/7:c.*755G>A:,CHRNA2:NM_001282455.1:3'UTR:MODIFIER:exon7/7:c.*755G>A:		rs2292974	0.3614	0.0000	0/0/0	0.4282							118502 [CHRNA2 (confirmed) Epilepsy,nocturnal frontal lobe,type 4,610353];	RCV000363849.1 [benign]; 			47	122					CHRNA2 (inh=AD pLI=0.00)
chr8	27318425	27318425	C	A	het	wt	het		QUAL=7218;DP=289,206,265;MQM=59	CHRNA2	3'UTR	CHRNA2:NM_000742.3:3'UTR:MODIFIER:exon7/7:c.*721G>T:,CHRNA2:NM_001282455.1:3'UTR:MODIFIER:exon7/7:c.*721G>T:		rs2292975	0.3590	0.0000	0/0/0	0.4263							118502 [CHRNA2 (confirmed) Epilepsy,nocturnal frontal lobe,type 4,610353];	RCV000269317.1 [benign]; 			47	122					CHRNA2 (inh=AD pLI=0.00)
chr8	27318544	27318544	A	G	hom	hom	hom		QUAL=26622;DP=238,275,332;MQM=59	CHRNA2	3'UTR	CHRNA2:NM_000742.3:3'UTR:MODIFIER:exon7/7:c.*602T>C:,CHRNA2:NM_001282455.1:3'UTR:MODIFIER:exon7/7:c.*602T>C:		rs2292976	0.7867	0.0000	0/0/0	0.8046							118502 [CHRNA2 (confirmed) Epilepsy,nocturnal frontal lobe,type 4,610353];	RCV000369848.1 [benign]; 			171	53					CHRNA2 (inh=AD pLI=0.00)
chr8	27318635	27318635	C	G	hom	hom	hom		QUAL=27758;DP=296,264,330;MQM=59	CHRNA2	3'UTR	CHRNA2:NM_000742.3:3'UTR:MODIFIER:exon7/7:c.*511G>C:,CHRNA2:NM_001282455.1:3'UTR:MODIFIER:exon7/7:c.*511G>C:		rs2292977	0.7819	0.0000	0/0/0	0.7954							118502 [CHRNA2 (confirmed) Epilepsy,nocturnal frontal lobe,type 4,610353];	RCV000274845.1 [benign]; 			163	61					CHRNA2 (inh=AD pLI=0.00)
chr8	27324822	27324822	T	C	hom	het	het		QUAL=14302;DP=222,236,317;MQM=60	CHRNA2	missense	CHRNA2:NM_000742.3:missense:MODERATE:exon5/7:c.373A>G:p.Thr125Ala,CHRNA2:NM_001282455.1:missense:MODERATE:exon5/7:c.328A>G:p.Thr110Ala		rs891398	0.6102	0.5311	17658/8288/3096	0.5286	0.6030	T,T,T	T	B	T,T,T	0.01	118502 [CHRNA2 (confirmed) Epilepsy,nocturnal frontal lobe,type 4,610353];	RCV000116712.4 [other]; RCV000355819.1 [benign]; 	CM144682 [CLASS=DP MUT=ALT PHEN="Nicotine dependence association with" GENE=CHRNA2]; 		400	764					CHRNA2 (inh=AD pLI=0.00)
chr8	27336446	27336446	T	G	het	wt	wt		QUAL=207;DP=117,121,187;MQM=58	CHRNA2	5'UTR	CHRNA2:NM_000742.3:5'UTR:MODIFIER:exon1/7:c.-242A>C:,CHRNA2:NM_001282455.1:5'UTR:MODIFIER:exon1/7:c.-242A>C:		rs368160505	0.0000	0.0000	0/0/0	0.0005							118502 [CHRNA2 (confirmed) Epilepsy,nocturnal frontal lobe,type 4,610353];				0	68					CHRNA2 (inh=AD pLI=0.00)
chr8	27661066	27661066	-	ACAC	het	het	wt		QUAL=9079;DP=220,79,128;MQM=57	ESCO2	3'UTR	ESCO2:NM_001017420.2:3'UTR:MODIFIER:exon11/11:c.*126_*129dupACAC:	(AC)n	rs144484866	0.0000	0.0000	0/0/0	0.1015							609353 [ESCO2 (confirmed) Roberts syndrome,268300|SC phocomelia syndrome,269000];	RCV000296185.1 [uncertain significance]; RCV000280785.1 [uncertain significance]; RCV000325452.1 [uncertain significance]; RCV000291483.1 [uncertain significance]; 			20	77					ESCO2 (inh=AR pLI=0.18)
chr8	27661066	27661066	-	AC	het	het	hom		QUAL=9079;DP=220,79,128;MQM=59	ESCO2	3'UTR	ESCO2:NM_001017420.2:3'UTR:MODIFIER:exon11/11:c.*128_*129dupAC:	(AC)n	rs144484866;rs56062620	0.0000	0.0000	0/0/0	0.1961							609353 [ESCO2 (confirmed) Roberts syndrome,268300|SC phocomelia syndrome,269000];	RCV000296185.1 [uncertain significance]; RCV000280785.1 [uncertain significance]; RCV000325452.1 [uncertain significance]; RCV000291483.1 [uncertain significance]; 			19	116					ESCO2 (inh=AR pLI=0.18)
chr8	27661085	27661085	G	A	het	het	wt		QUAL=9079;DP=220,79,128;MQM=57	ESCO2	3'UTR	ESCO2:NM_001017420.2:3'UTR:MODIFIER:exon11/11:c.*130G>A:	(AC)n	rs62498042	0.4970	0.0000	0/0/0	0.1875							609353 [ESCO2 (confirmed) Roberts syndrome,268300|SC phocomelia syndrome,269000];	RCV000400982.1 [benign]; 			48	103					ESCO2 (inh=AR pLI=0.18)
chr8	33356562	33356562	G	-	het	hom	het		QUAL=12249;DP=331,177,221;MQM=60	MAK16,TTI2	3'UTR	MAK16:NM_032509.3:3'UTR:MODIFIER:exon10/10:c.*416delG:,TTI2:NM_001102401.2:3'UTR:MODIFIER:exon8/8:c.*129delC:,TTI2:NM_001265581.1:3'UTR:MODIFIER:exon8/8:c.*129delC:,TTI2:NM_025115.3:3'UTR:MODIFIER:exon7/7:c.*129delC:		rs397698667	0.5815	0.0000	0/0/0	0.5547							614426 [TTI2 (provisional) Mental retardation,autosomal recessive 39,615541];				61	71					MAK16 (inh=n/a pLI=0.99), TTI2 (inh=AR pLI=0.00)
chr8	33369944	33369944	T	C	het	hom	het	pred_pathogenic	QUAL=13859;DP=288,188,304;MQM=59	TTI2	missense	TTI2:NM_001102401.2:missense:MODERATE:exon2/8:c.188A>G:p.Glu63Gly,TTI2:NM_001265581.1:missense:MODERATE:exon2/8:c.188A>G:p.Glu63Gly,TTI2:NM_025115.3:missense:MODERATE:exon1/7:c.188A>G:p.Glu63Gly		rs2304748	0.5068	0.5614	19675/12776/1112	0.5583	0.7680	D,D,D,D,T,T	T	B,B,B	T,T,T,T	15.23	614426 [TTI2 (provisional) Mental retardation,autosomal recessive 39,615541];				511	769					TTI2 (inh=AR pLI=0.00)
chr8	33369994	33369994	A	G	het	hom	het		QUAL=15371;DP=416,190,321;MQM=59	TTI2	synonymous	TTI2:NM_001102401.2:synonymous:LOW:exon2/8:c.138T>C:p.Asn46Asn,TTI2:NM_001265581.1:synonymous:LOW:exon2/8:c.138T>C:p.Asn46Asn,TTI2:NM_025115.3:synonymous:LOW:exon1/7:c.138T>C:p.Asn46Asn		rs3098657	0.5789	0.6016	22504/14012/2332	0.5966							614426 [TTI2 (provisional) Mental retardation,autosomal recessive 39,615541];				562	765					TTI2 (inh=AR pLI=0.00)
chr8	33370261	33370261	G	A	het	hom	het	low_DP	QUAL=1767;DP=113,15,31;MQM=60	TTI2	5'UTR,intron	TTI2:NM_025115.3:5'UTR:MODIFIER:exon1/7:c.-130C>T:,TTI2:NM_001102401.2:intron:MODIFIER:exon1/7:c.-99-31C>T:,TTI2:NM_001265581.1:intron:MODIFIER:exon1/7:c.-99-31C>T:		rs34226219	0.2206	0.0000	0/0/0	0.0685							614426 [TTI2 (provisional) Mental retardation,autosomal recessive 39,615541];				33	123					TTI2 (inh=AR pLI=0.00)
chr8	37603856	37603856	A	G	wt	wt	het		QUAL=2673;DP=256,139,198;MQM=60	ERLIN2	3'UTR,intron	ERLIN2:NM_001003791.2:3'UTR:MODIFIER:exon7/7:c.*735A>G:,ERLIN2:NM_001003790.3:3'UTR:MODIFIER:exon7/7:c.*735A>G:,ERLIN2:NM_007175.6:intron:MODIFIER:exon6/11:c.424+1642A>G:		rs147997467	0.0056	0.0000	0/0/0	0.0012							611605 [ERLIN2 (provisional) Spastic paraplegia 18,autosomal recessive,611225];				0	12					ERLIN2 (inh=AR pLI=0.11)
chr8	38000267	38000267	T	C	hom	hom	hom		QUAL=27669;DP=285,255,344;MQM=59	STAR	3'UTR	STAR:NM_000349.2:3'UTR:MODIFIER:exon7/7:c.*1524A>G:	AluSx	rs3990403	0.5505	0.0000	0/0/0	0.6766							600617 [STAR (provisional) Lipoid adrenal hyperplasia,201710];	RCV000406235.1 [benign]; 			165	61					STAR (inh=AR pLI=0.00)
chr8	38000824	38000827	TTTT	-	hom	wt	wt		QUAL=1482;DP=64,27,58;MQM=60	STAR	3'UTR	STAR:NM_000349.2:3'UTR:MODIFIER:exon7/7:c.*964_*967delAAAA:	AluSc8		0.0000	0.0000	0/0/0	0.0000							600617 [STAR (provisional) Lipoid adrenal hyperplasia,201710];				0	0					STAR (inh=AR pLI=0.00)
chr8	38000824	38000824	T	-	wt	hom	hom		QUAL=1482;DP=64,27,58;MQM=59	STAR	3'UTR	STAR:NM_000349.2:3'UTR:MODIFIER:exon7/7:c.*967delA:	AluSc8	rs747926723	0.7867	0.0000	0/0/0	0.3713							600617 [STAR (provisional) Lipoid adrenal hyperplasia,201710];	RCV000396156.1 [benign]; 			5	56					STAR (inh=AR pLI=0.00)
chr8	38005835	38005835	T	C	hom	hom	hom		QUAL=13399;DP=136,138,156;MQM=59	STAR	synonymous	STAR:NM_000349.2:synonymous:LOW:exon3/7:c.189A>G:p.Leu63Leu		rs2229620	0.9954	0.9986	60504/33353/5041	0.9349						8.02	600617 [STAR (provisional) Lipoid adrenal hyperplasia,201710];			COSM4162974	1564	1					STAR (inh=AR pLI=0.00)
chr8	38269514	38269514	T	C	wt	wt	het		QUAL=1921;DP=213,158,201;MQM=60	FGFR1	3'UTR	FGFR1:NM_001174067.1:3'UTR:MODIFIER:exon19/19:c.*1632A>G:,FGFR1:NM_001174065.1:3'UTR:MODIFIER:exon18/18:c.*1632A>G:,FGFR1:NM_001174066.1:3'UTR:MODIFIER:exon17/17:c.*1632A>G:,FGFR1:NM_001174063.1:3'UTR:MODIFIER:exon18/18:c.*1632A>G:,FGFR1:NM_001174064.1:3'UTR:MODIFIER:exon19/19:c.*1632A>G:,FGFR1:NM_015850.3:3'UTR:MODIFIER:exon18/18:c.*1632A>G:,FGFR1:NM_023105.2:3'UTR:MODIFIER:exon17/17:c.*1632A>G:,FGFR1:NM_023106.2:3'UTR:MODIFIER:exon17/17:c.*1632A>G:,FGFR1:NM_023110.2:3'UTR:MODIFIER:exon18/18:c.*1632A>G:		rs13317	0.2250	0.0000	0/0/0	0.0420							136350 [FGFR1 (confirmed) Pfeiffer syndrome,101600|Jackson-Weiss syndrome,123150|Hypogonadotropic hypogonadism 2 with or without anosmia,147950|Osteoglophonic dysplasia,166250|Trigonocephaly 1,190440|Hartsfield syndrome,615465|Encephalocraniocutaneous lipomatosis,613001];	RCV000289421.1 [benign]; RCV000292916.1 [benign]; RCV000328076.1 [benign]; RCV000350094.1 [benign]; RCV000384896.1 [benign]; 			19	82					FGFR1 (inh=AD pLI=0.99)
chr8	38326046	38326046	G	A	het	het	hom	low_DP	QUAL=653;DP=7,11,21;MQM=60	FGFR1	5'UTR_premature_start_codon_gain,5'UTR	FGFR1:NM_001174063.1:5'UTR_premature_start_codon_gain:LOW:exon1/18:c.-636C>T:,FGFR1:NM_001174064.1:5'UTR_premature_start_codon_gain:LOW:exon1/19:c.-728C>T:,FGFR1:NM_015850.3:5'UTR_premature_start_codon_gain:LOW:exon1/18:c.-636C>T:,FGFR1:NM_023105.2:5'UTR_premature_start_codon_gain:LOW:exon1/17:c.-636C>T:,FGFR1:NM_023106.2:5'UTR_premature_start_codon_gain:LOW:exon1/17:c.-636C>T:,FGFR1:NM_023110.2:5'UTR_premature_start_codon_gain:LOW:exon1/18:c.-636C>T:,FGFR1:NM_001174063.1:5'UTR:MODIFIER:exon1/18:c.-636C>T:,FGFR1:NM_001174064.1:5'UTR:MODIFIER:exon1/19:c.-728C>T:,FGFR1:NM_015850.3:5'UTR:MODIFIER:exon1/18:c.-636C>T:,FGFR1:NM_023105.2:5'UTR:MODIFIER:exon1/17:c.-636C>T:,FGFR1:NM_023106.2:5'UTR:MODIFIER:exon1/17:c.-636C>T:,FGFR1:NM_023110.2:5'UTR:MODIFIER:exon1/18:c.-636C>T:	(GCCGCCC)n	rs3213849	0.3407	0.0000	0/0/0	0.3611							136350 [FGFR1 (confirmed) Pfeiffer syndrome,101600|Jackson-Weiss syndrome,123150|Hypogonadotropic hypogonadism 2 with or without anosmia,147950|Osteoglophonic dysplasia,166250|Trigonocephaly 1,190440|Hartsfield syndrome,615465|Encephalocraniocutaneous lipomatosis,613001];	RCV000275562.1 [benign]; RCV000276380.1 [benign]; RCV000326643.1 [benign]; RCV000330645.1 [benign]; RCV000370929.1 [benign]; 			32	79					FGFR1 (inh=AD pLI=0.99)
chr8	38326161	38326161	G	A	hom	hom	hom		QUAL=2238;DP=49,23,25;MQM=60	FGFR1	5'UTR	FGFR1:NM_001174063.1:5'UTR:MODIFIER:exon1/18:c.-751C>T:,FGFR1:NM_001174064.1:5'UTR:MODIFIER:exon1/19:c.-843C>T:,FGFR1:NM_015850.3:5'UTR:MODIFIER:exon1/18:c.-751C>T:,FGFR1:NM_023105.2:5'UTR:MODIFIER:exon1/17:c.-751C>T:,FGFR1:NM_023106.2:5'UTR:MODIFIER:exon1/17:c.-751C>T:,FGFR1:NM_023110.2:5'UTR:MODIFIER:exon1/18:c.-751C>T:		rs2445003	0.9569	0.0000	0/0/0	0.8478							136350 [FGFR1 (confirmed) Pfeiffer syndrome,101600|Jackson-Weiss syndrome,123150|Hypogonadotropic hypogonadism 2 with or without anosmia,147950|Osteoglophonic dysplasia,166250|Trigonocephaly 1,190440|Hartsfield syndrome,615465|Encephalocraniocutaneous lipomatosis,613001];	RCV000278211.1 [benign]; RCV000337915.1 [benign]; RCV000341549.1 [benign]; RCV000391766.1 [benign]; RCV000392555.1 [benign]; 			209	0					FGFR1 (inh=AD pLI=0.99)
chr8	43054553	43054553	T	C	hom	hom	hom		QUAL=30540;DP=411,231,302;MQM=60	HGSNAT	synonymous	HGSNAT:NM_152419.2:synonymous:LOW:exon18/18:c.1749T>C:p.Tyr583Tyr		rs1126058	0.9916	0.9974	52329/29275/4110	0.9369							610453 [HGSNAT (confirmed) Mucopolysaccharidosis type IIIC (Sanfilippo C),252930|Retinitis pigmentosa 73,616544];	RCV000082655.5 [benign]; RCV000407246.1 [benign]; 			1558	6					HGSNAT (inh=AR pLI=0.00)
chr8	43056513	43056513	T	C	hom	hom	hom		QUAL=33068;DP=217,428,438;MQM=59	HGSNAT	3'UTR	HGSNAT:NM_152419.2:3'UTR:MODIFIER:exon18/18:c.*1801T>C:	L2d2	rs3739431	0.8219	0.0000	0/0/0	0.8981							610453 [HGSNAT (confirmed) Mucopolysaccharidosis type IIIC (Sanfilippo C),252930|Retinitis pigmentosa 73,616544];	RCV000391978.1 [benign]; 			210	19					HGSNAT (inh=AR pLI=0.00)
chr8	48691068	48691068	G	A	wt	wt	het		QUAL=4466;DP=245,276,398;MQM=60	PRKDC	synonymous	PRKDC:NM_006904.6:synonymous:LOW:exon83/86:c.11802C>T:p.Gly3934Gly,PRKDC:NM_001081640.1:synonymous:LOW:exon82/85:c.11709C>T:p.Gly3903Gly		rs8178249	0.0018	0.0055	5/3/0	0.0048	-3.9230		T			9.11	600899 [PRKDC (confirmed) Immunodeficiency 26,with or without neurologic abnormalities,615966];				0	32					PRKDC (inh=AR pLI=1.00)
chr8	48739305	48739305	G	A	wt	wt	het	pred_pathogenic	QUAL=1233;DP=113,82,110;MQM=60	PRKDC	missense	PRKDC:NM_006904.6:missense:MODERATE:exon63/86:c.8692C>T:p.Arg2898Cys,PRKDC:NM_001081640.1:missense:MODERATE:exon63/85:c.8692C>T:p.Arg2898Cys		rs4278157	0.0160	0.0431	135/116/0	0.0379	4.1250	D,D	T	B,B	T,T	23.30	600899 [PRKDC (confirmed) Immunodeficiency 26,with or without neurologic abnormalities,615966];				5	171					PRKDC (inh=AR pLI=1.00)
chr8	48805816	48805816	-	G	hom	hom	hom	anno_high_impact	QUAL=16843;DP=177,176,212;MQM=59	PRKDC	frameshift	PRKDC:NM_006904.6:frameshift:HIGH:exon31/86:c.3729dupC:p.Phe1244fs,PRKDC:NM_001081640.1:frameshift:HIGH:exon31/85:c.3729dupC:p.Phe1244fs		rs397814002	1.0000	1.0000	58497/32352/4644	0.9346							600899 [PRKDC (confirmed) Immunodeficiency 26,with or without neurologic abnormalities,615966];				1839	0	1	[1] old entry - no details available			PRKDC (inh=AR pLI=1.00)
chr8	48846519	48846519	T	C	hom	hom	het		QUAL=17742;DP=262,191,242;MQM=60	PRKDC	splice_region&intron	PRKDC:NM_006904.6:splice_region&intron:LOW:exon15/85:c.1623+6A>G:,PRKDC:NM_001081640.1:splice_region&intron:LOW:exon15/84:c.1623+6A>G:		rs1231202	0.9836	0.9598	55684/29495/4825	0.9316							600899 [PRKDC (confirmed) Immunodeficiency 26,with or without neurologic abnormalities,615966];				1651	172					PRKDC (inh=AR pLI=1.00)
chr8	61102553	61102553	A	-	wt	wt	het		QUAL=177;DP=96,76,96;MQM=59	CA8	splice_region&intron	CA8:NM_001321839.1:splice_region&intron:LOW:exon7/7:c.*36-9delT:,CA8:NM_004056.5:splice_region&intron:LOW:exon8/8:c.*36-9delT:,CA8:NR_135821.1:splice_region&intron:LOW:exon9/9:n.1235-9delT:		rs57677078	0.0000	0.0000	0/0/0	0.0058							114815 [CA8 (provisional) Cerebellar ataxia and mental retardation with or without quadrupedal locomotion 3,613227];				0	34					CA8 (inh=AR pLI=0.78)
chr8	61178574	61178574	T	C	hom	hom	het		QUAL=18635;DP=280,189,233;MQM=59	CA8	synonymous,non_coding_transcript_exon	CA8:NM_001321837.1:synonymous:LOW:exon3/8:c.327A>G:p.Glu109Glu,CA8:NM_001321839.1:synonymous:LOW:exon3/8:c.327A>G:p.Glu109Glu,CA8:NM_004056.5:synonymous:LOW:exon3/9:c.327A>G:p.Glu109Glu,CA8:NM_001321838.1:synonymous:LOW:exon3/9:c.327A>G:p.Glu109Glu,CA8:NR_135821.1:non_coding_transcript_exon:MODIFIER:exon3/10:n.603A>G:		rs7464181	0.5010	0.4279	11930/5706/3069	0.4206							114815 [CA8 (provisional) Cerebellar ataxia and mental retardation with or without quadrupedal locomotion 3,613227];	RCV000116510.2 [likely benign]; 		COSM3763364	464	1322					CA8 (inh=AR pLI=0.78)
chr8	61193760	61193760	T	G	hom	hom	het		QUAL=12585;DP=51,267,400;MQM=59	CA8	5'UTR,non_coding_transcript_exon	CA8:NM_001321837.1:5'UTR:MODIFIER:exon1/8:c.-54A>C:,CA8:NM_001321839.1:5'UTR:MODIFIER:exon1/8:c.-54A>C:,CA8:NM_004056.5:5'UTR:MODIFIER:exon1/9:c.-54A>C:,CA8:NM_001321838.1:5'UTR:MODIFIER:exon1/9:c.-54A>C:,CA8:NR_135821.1:non_coding_transcript_exon:MODIFIER:exon1/10:n.223A>C:		rs10101374	0.6266	0.0000	0/0/0	0.4764							114815 [CA8 (provisional) Cerebellar ataxia and mental retardation with or without quadrupedal locomotion 3,613227];				262	374					CA8 (inh=AR pLI=0.78)
chr8	61193809	61193809	A	G	hom	hom	het		QUAL=14485;DP=90,282,412;MQM=59	CA8	5'UTR,non_coding_transcript_exon	CA8:NM_001321837.1:5'UTR:MODIFIER:exon1/8:c.-103T>C:,CA8:NM_001321839.1:5'UTR:MODIFIER:exon1/8:c.-103T>C:,CA8:NM_004056.5:5'UTR:MODIFIER:exon1/9:c.-103T>C:,CA8:NM_001321838.1:5'UTR:MODIFIER:exon1/9:c.-103T>C:,CA8:NR_135821.1:non_coding_transcript_exon:MODIFIER:exon1/10:n.174T>C:		rs10086341	0.6258	0.0000	0/0/0	0.0868							114815 [CA8 (provisional) Cerebellar ataxia and mental retardation with or without quadrupedal locomotion 3,613227];				78	94					CA8 (inh=AR pLI=0.78)
chr8	61193828	61193828	A	G	hom	hom	het		QUAL=14962;DP=95,293,425;MQM=59	CA8	5'UTR,non_coding_transcript_exon	CA8:NM_001321837.1:5'UTR:MODIFIER:exon1/8:c.-122T>C:,CA8:NM_001321839.1:5'UTR:MODIFIER:exon1/8:c.-122T>C:,CA8:NM_004056.5:5'UTR:MODIFIER:exon1/9:c.-122T>C:,CA8:NM_001321838.1:5'UTR:MODIFIER:exon1/9:c.-122T>C:,CA8:NR_135821.1:non_coding_transcript_exon:MODIFIER:exon1/10:n.155T>C:		rs10086352	0.4329	0.0000	0/0/0	0.0517							114815 [CA8 (provisional) Cerebellar ataxia and mental retardation with or without quadrupedal locomotion 3,613227];				44	87					CA8 (inh=AR pLI=0.78)
chr8	61193843	61193843	C	G	hom	hom	het		QUAL=15298;DP=91,286,425;MQM=59	CA8	5'UTR,non_coding_transcript_exon	CA8:NM_001321837.1:5'UTR:MODIFIER:exon1/8:c.-137G>C:,CA8:NM_001321839.1:5'UTR:MODIFIER:exon1/8:c.-137G>C:,CA8:NM_004056.5:5'UTR:MODIFIER:exon1/9:c.-137G>C:,CA8:NM_001321838.1:5'UTR:MODIFIER:exon1/9:c.-137G>C:,CA8:NR_135821.1:non_coding_transcript_exon:MODIFIER:exon1/10:n.140G>C:		rs10086449	0.4329	0.0000	0/0/0	0.0605							114815 [CA8 (provisional) Cerebellar ataxia and mental retardation with or without quadrupedal locomotion 3,613227];				40	86					CA8 (inh=AR pLI=0.78)
chr8	61591436	61591436	C	T	wt	het	wt		QUAL=587;DP=70,51,79;MQM=60	CHD7	5'UTR_premature_start_codon_gain,5'UTR	CHD7:NM_017780.3:5'UTR_premature_start_codon_gain:LOW:exon1/38:c.-380C>T:,CHD7:NM_017780.3:5'UTR:MODIFIER:exon1/38:c.-380C>T:		rs113958504	0.1334	0.0000	0/0/0	0.1324							608892 [CHD7 (confirmed) CHARGE syndrome,214800|Hypogonadotropic hypogonadism 5 with or without anosmia,612370];	RCV000308088.1 [likely benign]; RCV000397066.1 [likely benign]; 			7	57					CHD7 (inh=AD pLI=1.00)
chr8	61779681	61779681	A	C	het	hom	het		QUAL=15277;DP=505,164,224;MQM=60	CHD7	3'UTR	CHD7:NM_017780.3:3'UTR:MODIFIER:exon38/38:c.*1189A>C:,CHD7:NM_001316690.1:3'UTR:MODIFIER:exon5/5:c.*1189A>C:		rs4738834	0.5004	0.0000	0/0/0	0.5740							608892 [CHD7 (confirmed) CHARGE syndrome,214800|Hypogonadotropic hypogonadism 5 with or without anosmia,612370];	RCV000305229.1 [benign]; RCV000406415.1 [benign]; 			56	63					CHD7 (inh=AD pLI=1.00)
chr8	61779936	61779936	T	G	het	hom	het		QUAL=15991;DP=539,188,291;MQM=60	CHD7	3'UTR	CHD7:NM_017780.3:3'UTR:MODIFIER:exon38/38:c.*1444T>G:,CHD7:NM_001316690.1:3'UTR:MODIFIER:exon5/5:c.*1444T>G:		rs4237040	0.4958	0.0000	0/0/0	0.5710							608892 [CHD7 (confirmed) CHARGE syndrome,214800|Hypogonadotropic hypogonadism 5 with or without anosmia,612370];	RCV000335254.1 [benign]; RCV000404449.1 [benign]; 			56	62					CHD7 (inh=AD pLI=1.00)
chr8	61780220	61780220	T	C	het	hom	het		QUAL=13092;DP=419,141,233;MQM=60	CHD7	3'UTR	CHD7:NM_017780.3:3'UTR:MODIFIER:exon38/38:c.*1728T>C:,CHD7:NM_001316690.1:3'UTR:MODIFIER:exon5/5:c.*1728T>C:		rs2280917	0.7376	0.0000	0/0/0	0.6715							608892 [CHD7 (confirmed) CHARGE syndrome,214800|Hypogonadotropic hypogonadism 5 with or without anosmia,612370];	RCV000292386.1 [benign]; RCV000392132.1 [benign]; 			72	56					CHD7 (inh=AD pLI=1.00)
chr8	61780289	61780289	C	T	het	hom	het		QUAL=12048;DP=361,155,219;MQM=60	CHD7	3'UTR	CHD7:NM_017780.3:3'UTR:MODIFIER:exon38/38:c.*1797C>T:,CHD7:NM_001316690.1:3'UTR:MODIFIER:exon5/5:c.*1797C>T:		rs6985168	0.4962	0.0000	0/0/0	0.5729							608892 [CHD7 (confirmed) CHARGE syndrome,214800|Hypogonadotropic hypogonadism 5 with or without anosmia,612370];	RCV000314602.1 [benign]; RCV000362265.1 [benign]; 			57	62					CHD7 (inh=AD pLI=1.00)
chr8	62562872	62562872	C	T	het	het	hom		QUAL=22750;DP=431,304,384;MQM=60	ASPH	intron	ASPH:NM_004318.3:intron:MODIFIER:exon5/24:c.490+737G>A:,ASPH:NM_001164750.1:intron:MODIFIER:exon5/24:c.403+737G>A:,ASPH:NM_001164751.1:intron:MODIFIER:exon6/14:c.448+737G>A:,ASPH:NM_001164752.1:intron:MODIFIER:exon6/13:c.448+737G>A:,ASPH:NM_001164753.1:intron:MODIFIER:exon6/13:c.448+737G>A:,ASPH:NM_032468.4:intron:MODIFIER:exon6/14:c.448+737G>A:,ASPH:NM_001164754.1:intron:MODIFIER:exon5/12:c.490+737G>A:,ASPH:NM_001164755.1:intron:MODIFIER:exon5/12:c.490+737G>A:,ASPH:NM_032466.3:intron:MODIFIER:exon5/13:c.490+737G>A:		rs2350590	0.8045	0.0000	0/0/0	0.8198							600582 [ASPH (confirmed) Traboulsi syndrome,601552];				104	41					ASPH (inh=AR pLI=0.00)
chr8	62563718	62563718	G	T	wt	het	wt		QUAL=2540;DP=301,205,262;MQM=60	ASPH	intron	ASPH:NM_004318.3:intron:MODIFIER:exon4/24:c.416-35C>A:,ASPH:NM_001164750.1:intron:MODIFIER:exon4/24:c.329-35C>A:,ASPH:NM_001164751.1:intron:MODIFIER:exon5/14:c.374-35C>A:,ASPH:NM_001164752.1:intron:MODIFIER:exon5/13:c.374-35C>A:,ASPH:NM_001164753.1:intron:MODIFIER:exon5/13:c.374-35C>A:,ASPH:NM_032468.4:intron:MODIFIER:exon5/14:c.374-35C>A:,ASPH:NM_001164754.1:intron:MODIFIER:exon4/12:c.416-35C>A:,ASPH:NM_001164755.1:intron:MODIFIER:exon4/12:c.416-35C>A:,ASPH:NM_032466.3:intron:MODIFIER:exon4/13:c.416-35C>A:		rs7016408	0.2218	0.2099	2936/1143/146	0.2017							600582 [ASPH (confirmed) Traboulsi syndrome,601552];				34	237					ASPH (inh=AR pLI=0.00)
chr8	62563764	62563764	A	G	het	het	hom		QUAL=12109;DP=262,154,205;MQM=60	ASPH	intron	ASPH:NM_004318.3:intron:MODIFIER:exon4/24:c.416-81T>C:,ASPH:NM_001164750.1:intron:MODIFIER:exon4/24:c.329-81T>C:,ASPH:NM_001164751.1:intron:MODIFIER:exon5/14:c.374-81T>C:,ASPH:NM_001164752.1:intron:MODIFIER:exon5/13:c.374-81T>C:,ASPH:NM_001164753.1:intron:MODIFIER:exon5/13:c.374-81T>C:,ASPH:NM_032468.4:intron:MODIFIER:exon5/14:c.374-81T>C:,ASPH:NM_001164754.1:intron:MODIFIER:exon4/12:c.416-81T>C:,ASPH:NM_001164755.1:intron:MODIFIER:exon4/12:c.416-81T>C:,ASPH:NM_032466.3:intron:MODIFIER:exon4/13:c.416-81T>C:		rs7016141	0.8051	0.0000	0/0/0	0.1837							600582 [ASPH (confirmed) Traboulsi syndrome,601552];				113	45					ASPH (inh=AR pLI=0.00)
chr8	62565088	62565088	A	-	wt	het	wt		QUAL=1253;DP=172,101,116;MQM=60	ASPH	intron	ASPH:NM_004318.3:intron:MODIFIER:exon4/24:c.415+1039delT:,ASPH:NM_001164750.1:intron:MODIFIER:exon4/24:c.328+1039delT:,ASPH:NM_001164751.1:intron:MODIFIER:exon5/14:c.373+1039delT:,ASPH:NM_001164752.1:intron:MODIFIER:exon5/13:c.373+1039delT:,ASPH:NM_001164753.1:intron:MODIFIER:exon5/13:c.373+1039delT:,ASPH:NM_032468.4:intron:MODIFIER:exon5/14:c.373+1039delT:,ASPH:NM_001164754.1:intron:MODIFIER:exon4/12:c.415+1039delT:,ASPH:NM_001164755.1:intron:MODIFIER:exon4/12:c.415+1039delT:,ASPH:NM_032466.3:intron:MODIFIER:exon4/13:c.415+1039delT:		rs34800191	0.0839	0.0000	0/0/0	0.0863							600582 [ASPH (confirmed) Traboulsi syndrome,601552];				2	33					ASPH (inh=AR pLI=0.00)
chr8	62565897	62565897	G	A	het	wt	hom		QUAL=19385;DP=585,244,360;MQM=60	ASPH	intron	ASPH:NM_004318.3:intron:MODIFIER:exon4/24:c.415+230C>T:,ASPH:NM_001164750.1:intron:MODIFIER:exon4/24:c.328+230C>T:,ASPH:NM_001164751.1:intron:MODIFIER:exon5/14:c.373+230C>T:,ASPH:NM_001164752.1:intron:MODIFIER:exon5/13:c.373+230C>T:,ASPH:NM_001164753.1:intron:MODIFIER:exon5/13:c.373+230C>T:,ASPH:NM_032468.4:intron:MODIFIER:exon5/14:c.373+230C>T:,ASPH:NM_001164754.1:intron:MODIFIER:exon4/12:c.415+230C>T:,ASPH:NM_001164755.1:intron:MODIFIER:exon4/12:c.415+230C>T:,ASPH:NM_032466.3:intron:MODIFIER:exon4/13:c.415+230C>T:	MIRc	rs949761	0.1034	0.0000	0/0/0	0.1171							600582 [ASPH (confirmed) Traboulsi syndrome,601552];				2	34					ASPH (inh=AR pLI=0.00)
chr8	62566832	62566832	G	T	wt	het	wt		QUAL=1718;DP=362,146,197;MQM=60	ASPH	intron	ASPH:NM_004318.3:intron:MODIFIER:exon3/24:c.323-613C>A:,ASPH:NM_001164750.1:intron:MODIFIER:exon3/24:c.236-613C>A:,ASPH:NM_001164751.1:intron:MODIFIER:exon4/14:c.281-613C>A:,ASPH:NM_001164752.1:intron:MODIFIER:exon4/13:c.281-613C>A:,ASPH:NM_001164753.1:intron:MODIFIER:exon4/13:c.281-613C>A:,ASPH:NM_032468.4:intron:MODIFIER:exon4/14:c.281-613C>A:,ASPH:NM_001164754.1:intron:MODIFIER:exon3/12:c.323-613C>A:,ASPH:NM_001164755.1:intron:MODIFIER:exon3/12:c.323-613C>A:,ASPH:NM_032466.3:intron:MODIFIER:exon3/13:c.323-613C>A:		rs6471969	0.2226	0.0000	0/0/0	0.1949							600582 [ASPH (confirmed) Traboulsi syndrome,601552];				5	42					ASPH (inh=AR pLI=0.00)
chr8	62567097	62567097	C	T	het	wt	hom		QUAL=19342;DP=678,243,344;MQM=60	ASPH	intron	ASPH:NM_004318.3:intron:MODIFIER:exon3/24:c.323-878G>A:,ASPH:NM_001164750.1:intron:MODIFIER:exon3/24:c.236-878G>A:,ASPH:NM_001164751.1:intron:MODIFIER:exon4/14:c.281-878G>A:,ASPH:NM_001164752.1:intron:MODIFIER:exon4/13:c.281-878G>A:,ASPH:NM_001164753.1:intron:MODIFIER:exon4/13:c.281-878G>A:,ASPH:NM_032468.4:intron:MODIFIER:exon4/14:c.281-878G>A:,ASPH:NM_001164754.1:intron:MODIFIER:exon3/12:c.323-878G>A:,ASPH:NM_001164755.1:intron:MODIFIER:exon3/12:c.323-878G>A:,ASPH:NM_032466.3:intron:MODIFIER:exon3/13:c.323-878G>A:		rs10504331	0.1034	0.0000	0/0/0	0.1171							600582 [ASPH (confirmed) Traboulsi syndrome,601552];				2	34					ASPH (inh=AR pLI=0.00)
chr8	62567214	62567214	G	C	het	het	hom		QUAL=19950;DP=387,252,349;MQM=60	ASPH	intron	ASPH:NM_004318.3:intron:MODIFIER:exon3/24:c.323-995C>G:,ASPH:NM_001164750.1:intron:MODIFIER:exon3/24:c.236-995C>G:,ASPH:NM_001164751.1:intron:MODIFIER:exon4/14:c.281-995C>G:,ASPH:NM_001164752.1:intron:MODIFIER:exon4/13:c.281-995C>G:,ASPH:NM_001164753.1:intron:MODIFIER:exon4/13:c.281-995C>G:,ASPH:NM_032468.4:intron:MODIFIER:exon4/14:c.281-995C>G:,ASPH:NM_001164754.1:intron:MODIFIER:exon3/12:c.323-995C>G:,ASPH:NM_001164755.1:intron:MODIFIER:exon3/12:c.323-995C>G:,ASPH:NM_032466.3:intron:MODIFIER:exon3/13:c.323-995C>G:		rs9283975	0.7829	0.0000	0/0/0	0.8070							600582 [ASPH (confirmed) Traboulsi syndrome,601552];				103	42					ASPH (inh=AR pLI=0.00)
chr8	63972324	63972324	C	T	het	het	hom	low_DP	QUAL=304;DP=20,4,2;MQM=60	TTPA	3'UTR	TTPA:NM_000370.3:3'UTR:MODIFIER:exon5/5:c.*1487G>A:		rs6472068	0.5284	0.0000	0/0/0	0.3766							600415 [TTPA (confirmed) Ataxia with isolated vitamin E deficiency,277460];	RCV000362358.1 [benign]; 			35	46					TTPA (inh=AR pLI=0.01)
chr8	63972718	63972718	C	T	het	hom	het		QUAL=14550;DP=364,184,303;MQM=60	TTPA	3'UTR	TTPA:NM_000370.3:3'UTR:MODIFIER:exon5/5:c.*1093G>A:		rs4587328	0.6755	0.0000	0/0/0	0.0935							600415 [TTPA (confirmed) Ataxia with isolated vitamin E deficiency,277460];	RCV000285681.1 [benign]; 			43	66					TTPA (inh=AR pLI=0.01)
chr8	63973233	63973235	AAA	-	het	hom	het		QUAL=3355;DP=146,81,70;MQM=59	TTPA	3'UTR	TTPA:NM_000370.3:3'UTR:MODIFIER:exon5/5:c.*576_*578delTTT:	AluSz6	rs35504965;rs759014557	0.6747	0.0000	0/0/0	0.3481							600415 [TTPA (confirmed) Ataxia with isolated vitamin E deficiency,277460];	RCV000314689.1 [benign]; 			41	68					TTPA (inh=AR pLI=0.01)
chr8	63978659	63978659	A	-	hom	hom	hom		QUAL=14908;DP=190,123,171;MQM=59	TTPA	splice_region&intron	TTPA:NM_000370.3:splice_region&intron:LOW:exon2/4:c.359-3delT:		rs398008072	1.0000	1.0000	59537/32668/5107	0.9379							600415 [TTPA (confirmed) Ataxia with isolated vitamin E deficiency,277460];	RCV000078673.4 [benign]; RCV000383973.1 [benign]; 			2690	0					TTPA (inh=AR pLI=0.01)
chr8	75262798	75262798	G	C	hom	hom	hom		QUAL=36496;DP=272,361,501;MQM=59	GDAP1	synonymous,intron,non_coding_transcript_exon	GDAP1:NM_018972.2:synonymous:LOW:exon1/6:c.102G>C:p.Ser34Ser,GDAP1:NM_001040875.2:intron:MODIFIER:exon1/5:c.-64+91G>C:,GDAP1:NR_046346.1:non_coding_transcript_exon:MODIFIER:exon1/6:n.181G>C:		rs7828201	0.9956	0.9973	60381/33363/5201	0.9339							606598 [GDAP1 (confirmed) Charcot-Marie-Tooth disease,type 4A,214400|Charcot-Marie-Tooth disease,axonal,with vocal cord paresis,607706|Charcot-Marie-Tooth disease,axonal,type 2K,607831|Charcot-Marie-Tooth disease,recessive intermediate,A,608340];			COSM4163063	1564	1					GDAP1 (inh=AR+AD pLI=0.00)
chr8	75274141	75274141	T	G	het	wt	hom		QUAL=13573;DP=293,249,318;MQM=59	GDAP1	synonymous,non_coding_transcript_exon	GDAP1:NM_018972.2:synonymous:LOW:exon4/6:c.507T>G:p.Ser169Ser,GDAP1:NM_001040875.2:synonymous:LOW:exon4/6:c.303T>G:p.Ser101Ser,GDAP1:NR_046346.1:non_coding_transcript_exon:MODIFIER:exon4/6:n.441T>G:		rs11554166	0.2192	0.2774	5106/3653/70	0.2780							606598 [GDAP1 (confirmed) Charcot-Marie-Tooth disease,type 4A,214400|Charcot-Marie-Tooth disease,axonal,with vocal cord paresis,607706|Charcot-Marie-Tooth disease,axonal,type 2K,607831|Charcot-Marie-Tooth disease,recessive intermediate,A,608340];	RCV000251902.1 [benign]; RCV000325881.1 [benign]; RCV000380453.1 [benign]; 		COSM3763403	172	625					GDAP1 (inh=AR+AD pLI=0.00)
chr8	75276959	75276959	A	G	wt	het	wt		QUAL=3533;DP=280,256,337;MQM=60	GDAP1	3'UTR,non_coding_transcript_exon	GDAP1:NM_018972.2:3'UTR:MODIFIER:exon6/6:c.*357A>G:,GDAP1:NM_001040875.2:3'UTR:MODIFIER:exon6/6:c.*357A>G:,GDAP1:NR_046346.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.1368A>G:		rs1135715	0.2334	0.2334	319/51/6	0.0553							606598 [GDAP1 (confirmed) Charcot-Marie-Tooth disease,type 4A,214400|Charcot-Marie-Tooth disease,axonal,with vocal cord paresis,607706|Charcot-Marie-Tooth disease,axonal,type 2K,607831|Charcot-Marie-Tooth disease,recessive intermediate,A,608340];	RCV000285881.1 [benign]; RCV000322193.1 [benign]; 			23	213					GDAP1 (inh=AR+AD pLI=0.00)
chr8	75277399	75277399	A	G	hom	hom	hom		QUAL=20051;DP=268,155,190;MQM=60	GDAP1	3'UTR,non_coding_transcript_exon	GDAP1:NM_018972.2:3'UTR:MODIFIER:exon6/6:c.*797A>G:,GDAP1:NM_001040875.2:3'UTR:MODIFIER:exon6/6:c.*797A>G:,GDAP1:NR_046346.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.1808A>G:		rs7007283	0.9898	0.9876	5259/1363/93	0.2308							606598 [GDAP1 (confirmed) Charcot-Marie-Tooth disease,type 4A,214400|Charcot-Marie-Tooth disease,axonal,with vocal cord paresis,607706|Charcot-Marie-Tooth disease,axonal,type 2K,607831|Charcot-Marie-Tooth disease,recessive intermediate,A,608340];	RCV000309016.1 [benign]; RCV000363745.1 [benign]; 			651	2					GDAP1 (inh=AR+AD pLI=0.00)
chr8	75277432	75277432	C	G	wt	het	wt		QUAL=1995;DP=204,143,169;MQM=60	GDAP1	3'UTR,non_coding_transcript_exon	GDAP1:NM_018972.2:3'UTR:MODIFIER:exon6/6:c.*830C>G:,GDAP1:NM_001040875.2:3'UTR:MODIFIER:exon6/6:c.*830C>G:,GDAP1:NR_046346.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.1841C>G:		rs4737414	0.2334	0.2334	319/51/6	0.0547							606598 [GDAP1 (confirmed) Charcot-Marie-Tooth disease,type 4A,214400|Charcot-Marie-Tooth disease,axonal,with vocal cord paresis,607706|Charcot-Marie-Tooth disease,axonal,type 2K,607831|Charcot-Marie-Tooth disease,recessive intermediate,A,608340];	RCV000268688.1 [benign]; RCV000323750.1 [benign]; 			23	213					GDAP1 (inh=AR+AD pLI=0.00)
chr8	75278457	75278457	A	G	het	wt	hom		QUAL=18609;DP=768,161,235;MQM=60	GDAP1	3'UTR,non_coding_transcript_exon	GDAP1:NM_018972.2:3'UTR:MODIFIER:exon6/6:c.*1855A>G:,GDAP1:NM_001040875.2:3'UTR:MODIFIER:exon6/6:c.*1855A>G:,GDAP1:NR_046346.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.2866A>G:		rs6472842	0.2668	0.2413	414/180/17	0.0719							606598 [GDAP1 (confirmed) Charcot-Marie-Tooth disease,type 4A,214400|Charcot-Marie-Tooth disease,axonal,with vocal cord paresis,607706|Charcot-Marie-Tooth disease,axonal,type 2K,607831|Charcot-Marie-Tooth disease,recessive intermediate,A,608340];	RCV000283960.1 [benign]; RCV000378391.1 [benign]; 			75	267					GDAP1 (inh=AR+AD pLI=0.00)
chr8	75278480	75278480	G	T	wt	het	wt		QUAL=2013;DP=599,160,224;MQM=60	GDAP1	3'UTR,non_coding_transcript_exon	GDAP1:NM_018972.2:3'UTR:MODIFIER:exon6/6:c.*1878G>T:,GDAP1:NM_001040875.2:3'UTR:MODIFIER:exon6/6:c.*1878G>T:,GDAP1:NR_046346.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.2889G>T:		rs16938896	0.2336	0.2275	344/62/11	0.0567							606598 [GDAP1 (confirmed) Charcot-Marie-Tooth disease,type 4A,214400|Charcot-Marie-Tooth disease,axonal,with vocal cord paresis,607706|Charcot-Marie-Tooth disease,axonal,type 2K,607831|Charcot-Marie-Tooth disease,recessive intermediate,A,608340];	RCV000320798.1 [benign]; RCV000375447.1 [benign]; 			23	212					GDAP1 (inh=AR+AD pLI=0.00)
chr8	75278816	75278816	A	G	het	wt	hom		QUAL=12804;DP=404,139,214;MQM=60	GDAP1	3'UTR,non_coding_transcript_exon	GDAP1:NM_018972.2:3'UTR:MODIFIER:exon6/6:c.*2214A>G:,GDAP1:NM_001040875.2:3'UTR:MODIFIER:exon6/6:c.*2214A>G:,GDAP1:NR_046346.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.3225A>G:		rs10504580	0.2294	0.2329	343/132/2	0.0672							606598 [GDAP1 (confirmed) Charcot-Marie-Tooth disease,type 4A,214400|Charcot-Marie-Tooth disease,axonal,with vocal cord paresis,607706|Charcot-Marie-Tooth disease,axonal,type 2K,607831|Charcot-Marie-Tooth disease,recessive intermediate,A,608340];	RCV000308042.1 [benign]; RCV000391330.1 [benign]; 			75	266					GDAP1 (inh=AR+AD pLI=0.00)
chr8	75279333	75279333	C	AAA	hom	hom	hom		QUAL=1637;DP=71,85,99;MQM=54	GDAP1	splice_region,splice_region&non_coding_transcript_exon,3'UTR	GDAP1:NM_018972.2:splice_region:LOW:exon6/6:c.*2731delCinsAAA:,GDAP1:NM_001040875.2:splice_region:LOW:exon6/6:c.*2731delCinsAAA:,GDAP1:NR_046346.1:splice_region&non_coding_transcript_exon:LOW:exon6/6:n.3742delCinsAAA:,GDAP1:NM_018972.2:3'UTR:MODIFIER:exon6/6:c.*2731delCinsAAA:,GDAP1:NM_001040875.2:3'UTR:MODIFIER:exon6/6:c.*2731delCinsAAA:			0.0000	0.0000	0/0/0	0.0000							606598 [GDAP1 (confirmed) Charcot-Marie-Tooth disease,type 4A,214400|Charcot-Marie-Tooth disease,axonal,with vocal cord paresis,607706|Charcot-Marie-Tooth disease,axonal,type 2K,607831|Charcot-Marie-Tooth disease,recessive intermediate,A,608340];				0	0					GDAP1 (inh=AR+AD pLI=0.00)
chr8	77892834	77892834	A	T	het	het	het		QUAL=8995;DP=238,190,252;MQM=60	PEX2	3'UTR	PEX2:NM_000318.2:3'UTR:MODIFIER:exon4/4:c.*2663T>A:,PEX2:NM_001079867.1:3'UTR:MODIFIER:exon3/3:c.*2663T>A:,PEX2:NM_001172086.1:3'UTR:MODIFIER:exon5/5:c.*2663T>A:,PEX2:NM_001172087.1:3'UTR:MODIFIER:exon3/3:c.*2663T>A:	MLT1K	rs28435921	0.5180	0.0000	0/0/0	0.5682							170993 [PEX2 (confirmed) Peroxisome biogenesis disorder 5A (Zellweger),614866|Peroxisome biogenesis disorder 5B,614867];	RCV000316203.1 [benign]; 			76	83					PEX2 (inh=AR pLI=0.06)
chr8	77893120	77893120	T	C	hom	hom	hom		QUAL=29461;DP=430,211,238;MQM=60	PEX2	3'UTR	PEX2:NM_000318.2:3'UTR:MODIFIER:exon4/4:c.*2377A>G:,PEX2:NM_001079867.1:3'UTR:MODIFIER:exon3/3:c.*2377A>G:,PEX2:NM_001172086.1:3'UTR:MODIFIER:exon5/5:c.*2377A>G:,PEX2:NM_001172087.1:3'UTR:MODIFIER:exon3/3:c.*2377A>G:		rs4388434	0.9543	0.0000	0/0/0	0.1520							170993 [PEX2 (confirmed) Peroxisome biogenesis disorder 5A (Zellweger),614866|Peroxisome biogenesis disorder 5B,614867];	RCV000275336.1 [benign]; 			220	10					PEX2 (inh=AR pLI=0.06)
chr8	77894303	77894303	T	C	hom	hom	hom		QUAL=15691;DP=245,112,113;MQM=60	PEX2	3'UTR	PEX2:NM_000318.2:3'UTR:MODIFIER:exon4/4:c.*1194A>G:,PEX2:NM_001079867.1:3'UTR:MODIFIER:exon3/3:c.*1194A>G:,PEX2:NM_001172086.1:3'UTR:MODIFIER:exon5/5:c.*1194A>G:,PEX2:NM_001172087.1:3'UTR:MODIFIER:exon3/3:c.*1194A>G:		rs4311633	0.9858	0.0000	0/0/0	0.1529							170993 [PEX2 (confirmed) Peroxisome biogenesis disorder 5A (Zellweger),614866|Peroxisome biogenesis disorder 5B,614867];	RCV000324558.1 [benign]; 			220	10					PEX2 (inh=AR pLI=0.06)
chr8	77894770	77894770	A	G	hom	hom	hom		QUAL=19738;DP=336,110,172;MQM=59	PEX2	3'UTR	PEX2:NM_000318.2:3'UTR:MODIFIER:exon4/4:c.*727T>C:,PEX2:NM_001079867.1:3'UTR:MODIFIER:exon3/3:c.*727T>C:,PEX2:NM_001172086.1:3'UTR:MODIFIER:exon5/5:c.*727T>C:,PEX2:NM_001172087.1:3'UTR:MODIFIER:exon3/3:c.*727T>C:	AluSc8	rs4610720	0.9543	0.0000	0/0/0	0.1520							170993 [PEX2 (confirmed) Peroxisome biogenesis disorder 5A (Zellweger),614866|Peroxisome biogenesis disorder 5B,614867];	RCV000335628.1 [benign]; 			219	9					PEX2 (inh=AR pLI=0.06)
chr8	77895865	77895865	A	G	hom	hom	hom	pred_pathogenic	QUAL=21972;DP=274,159,216;MQM=60	PEX2	missense	PEX2:NM_000318.2:missense:MODERATE:exon4/4:c.550T>C:p.Cys184Arg,PEX2:NM_001079867.1:missense:MODERATE:exon3/3:c.550T>C:p.Cys184Arg,PEX2:NM_001172086.1:missense:MODERATE:exon5/5:c.550T>C:p.Cys184Arg,PEX2:NM_001172087.1:missense:MODERATE:exon3/3:c.550T>C:p.Cys184Arg		rs10087163	0.9962	0.9878	59201/32347/5149	0.9661	6.1730	T,T,T,T	T	B	T,T,T,T	2.37	170993 [PEX2 (confirmed) Peroxisome biogenesis disorder 5A (Zellweger),614866|Peroxisome biogenesis disorder 5B,614867];	RCV000153682.2 [benign]; 			2618	71					PEX2 (inh=AR pLI=0.06)
chr8	77912230	77912230	G	T	het	wt	het		QUAL=4444;DP=147,155,203;MQM=60	PEX2	5'UTR	PEX2:NM_000318.2:5'UTR:MODIFIER:exon1/4:c.-164C>A:,PEX2:NM_001079867.1:5'UTR:MODIFIER:exon1/3:c.-132C>A:,PEX2:NM_001172086.1:5'UTR:MODIFIER:exon2/5:c.-164C>A:,PEX2:NM_001172087.1:5'UTR:MODIFIER:exon2/3:c.-22C>A:		rs12718	0.2778	0.2518	428/84/24	0.0645							170993 [PEX2 (confirmed) Peroxisome biogenesis disorder 5A (Zellweger),614866|Peroxisome biogenesis disorder 5B,614867];	RCV000292942.1 [benign]; 			52	337					PEX2 (inh=AR pLI=0.06)
chr8	77912424	77912424	T	G	hom	hom	hom		QUAL=35393;DP=432,296,390;MQM=59	PEX2	5'UTR,intron	PEX2:NM_000318.2:5'UTR:MODIFIER:exon1/4:c.-358A>C:,PEX2:NM_001079867.1:5'UTR:MODIFIER:exon1/3:c.-326A>C:,PEX2:NM_001172086.1:intron:MODIFIER:exon1/4:c.-302-56A>C:,PEX2:NM_001172087.1:intron:MODIFIER:exon1/2:c.-160-56A>C:		rs10081480	0.9655	0.0000	0/0/0	0.8956							170993 [PEX2 (confirmed) Peroxisome biogenesis disorder 5A (Zellweger),614866|Peroxisome biogenesis disorder 5B,614867];				284	11					PEX2 (inh=AR pLI=0.06)
chr8	86376130	86376130	A	T	hom	hom	hom	low_DP	QUAL=1235;DP=15,17,15;MQM=59	CA3-AS1	intron	CA3-AS1:NR_121630.1:intron:MODIFIER:exon1/2:n.334+681T>A:,CA3-AS1:NR_121631.1:intron:MODIFIER:exon1/2:n.106+327T>A:		rs11261477	0.9988	0.0000	0/0/0	0.0882							611492 [CA2 (confirmed) Osteopetrosis,autosomal recessive 3,with renal tubular acidosis,259730];	RCV000363093.1 [benign]; 			208	5					CA3-AS1 (inh=n/a pLI=n/a)
chr8	86389403	86389403	T	C	hom	hom	hom		QUAL=36634;DP=405,329,402;MQM=60	CA2	synonymous	CA2:NM_000067.2:synonymous:LOW:exon6/7:c.562T>C:p.Leu188Leu,CA2:NM_001293675.1:synonymous:LOW:exon5/6:c.259T>C:p.Leu87Leu		rs703	0.5777	0.5893	21573/12965/2655	0.5664							611492 [CA2 (confirmed) Osteopetrosis,autosomal recessive 3,with renal tubular acidosis,259730];	RCV000242714.1 [benign]; RCV000386953.1 [benign]; 		COSM3982612	624	696	1	Prima vista kein Anhalt f?r Splice Defekt, swal, 160405 [1] ahwalds1 05.04.2016			CA2 (inh=AR pLI=0.10)
chr8	90946056	90946056	A	G	het	wt	hom		QUAL=5398;DP=212,48,71;MQM=60	NBN	3'UTR	NBN:NM_002485.4:3'UTR:MODIFIER:exon16/16:c.*1754T>C:,NBN:NM_001024688.2:3'UTR:MODIFIER:exon17/17:c.*1754T>C:	L1MEf	rs9995	0.3355	0.0000	0/0/0	0.0572							602667 [NBN (confirmed) Nijmegen breakage syndrome,251260|Aplastic anemia,609135|Leukemia,acute lymphoblastic,613065];	RCV000397319.1 [benign]; 			17	63					NBN (inh=AR pLI=0.00)
chr8	90946601	90946601	T	G	het	wt	hom		QUAL=20538;DP=534,328,406;MQM=60	NBN	3'UTR	NBN:NM_002485.4:3'UTR:MODIFIER:exon16/16:c.*1209A>C:,NBN:NM_001024688.2:3'UTR:MODIFIER:exon17/17:c.*1209A>C:	LTR67B	rs1063054	0.3353	0.0000	0/0/0	0.0572							602667 [NBN (confirmed) Nijmegen breakage syndrome,251260|Aplastic anemia,609135|Leukemia,acute lymphoblastic,613065];	RCV000366927.1 [benign]; 			18	93					NBN (inh=AR pLI=0.00)
chr8	90947269	90947269	C	G	het	wt	hom		QUAL=6151;DP=224,68,99;MQM=60	NBN	3'UTR	NBN:NM_002485.4:3'UTR:MODIFIER:exon16/16:c.*541G>C:,NBN:NM_001024688.2:3'UTR:MODIFIER:exon17/17:c.*541G>C:		rs2735383	0.3303	0.0000	0/0/0	0.0570							602667 [NBN (confirmed) Nijmegen breakage syndrome,251260|Aplastic anemia,609135|Leukemia,acute lymphoblastic,613065];	RCV000272651.1 [benign]; 	CR121123 [CLASS=DFP MUT=ALT PHEN="Lung cancer increased risk association with" GENE=NBN]; 		18	93					NBN (inh=AR pLI=0.00)
chr8	90947409	90947409	G	C	het	het	wt		QUAL=3852;DP=199,60,90;MQM=60	NBN	3'UTR	NBN:NM_002485.4:3'UTR:MODIFIER:exon16/16:c.*401C>G:,NBN:NM_001024688.2:3'UTR:MODIFIER:exon17/17:c.*401C>G:	L1ME4b	rs104895030	0.0012	0.0000	0/0/0	0.0042							602667 [NBN (confirmed) Nijmegen breakage syndrome,251260|Aplastic anemia,609135|Leukemia,acute lymphoblastic,613065];	RCV000114873.1 [not provided]; RCV000316124.1 [uncertain significance]; 			0	4					NBN (inh=AR pLI=0.00)
chr8	90947537	90947537	C	T	het	wt	hom		QUAL=6771;DP=200,105,130;MQM=60	NBN	3'UTR	NBN:NM_002485.4:3'UTR:MODIFIER:exon16/16:c.*273G>A:,NBN:NM_001024688.2:3'UTR:MODIFIER:exon17/17:c.*273G>A:	L1ME4b	rs1063053	0.3219	0.0000	0/0/0	0.0559							602667 [NBN (confirmed) Nijmegen breakage syndrome,251260|Aplastic anemia,609135|Leukemia,acute lymphoblastic,613065];	RCV000373039.1 [benign]; 			18	92					NBN (inh=AR pLI=0.00)
chr8	90958422	90958422	T	C	het	wt	hom		QUAL=8837;DP=281,96,163;MQM=60	NBN	synonymous	NBN:NM_002485.4:synonymous:LOW:exon13/16:c.2016A>G:p.Pro672Pro,NBN:NM_001024688.2:synonymous:LOW:exon14/17:c.1770A>G:p.Pro590Pro		rs1061302	0.3528	0.3451	7411/3552/277	0.3422							602667 [NBN (confirmed) Nijmegen breakage syndrome,251260|Aplastic anemia,609135|Leukemia,acute lymphoblastic,613065];	RCV000162357.1 [benign]; RCV000243757.1 [benign]; RCV000393183.1 [benign]; 		COSM3763441	385	1550	1	[1] Alexandra Doehring 27.08.2015			NBN (inh=AR pLI=0.00)
chr8	90958530	90958530	T	C	het	wt	hom		QUAL=8109;DP=286,104,137;MQM=60	NBN	splice_region&intron	NBN:NM_002485.4:splice_region&intron:LOW:exon12/15:c.1915-7A>G:,NBN:NM_001024688.2:splice_region&intron:LOW:exon13/16:c.1669-7A>G:		rs2308962	0.3790	0.3529	7684/3567/522	0.3497							602667 [NBN (confirmed) Nijmegen breakage syndrome,251260|Aplastic anemia,609135|Leukemia,acute lymphoblastic,613065];	RCV000251758.1 [benign]; RCV000363485.1 [benign]; 			386	1560	1	[1] Alexandra Doehring 27.08.2015			NBN (inh=AR pLI=0.00)
chr8	90967711	90967711	A	G	het	wt	hom		QUAL=5887;DP=177,100,116;MQM=60	NBN	synonymous	NBN:NM_002485.4:synonymous:LOW:exon10/16:c.1197T>C:p.Asp399Asp,NBN:NM_001024688.2:synonymous:LOW:exon11/17:c.951T>C:p.Asp317Asp		rs709816	0.6086	0.4676	14308/4457/3067	0.4608							602667 [NBN (confirmed) Nijmegen breakage syndrome,251260|Aplastic anemia,609135|Leukemia,acute lymphoblastic,613065];	RCV000162376.1 [benign]; RCV000173761.2 [benign]; RCV000322749.1 [benign]; 		COSM3763442	493	1629	1	[1] Alexandra Doehring 27.08.2015			NBN (inh=AR pLI=0.00)
chr8	90990479	90990479	C	G	het	wt	hom	pred_pathogenic	QUAL=10500;DP=286,138,217;MQM=60	NBN	missense	NBN:NM_002485.4:missense:MODERATE:exon5/16:c.553G>C:p.Glu185Gln,NBN:NM_001024688.2:missense:MODERATE:exon6/17:c.307G>C:p.Glu103Gln		rs1805794	0.3570	0.3453	7417/3546/292	0.3425	2.1330	T,T,T,T	T	B	T,T,T	6.33	602667 [NBN (confirmed) Nijmegen breakage syndrome,251260|Aplastic anemia,609135|Leukemia,acute lymphoblastic,613065];	RCV000121620.3 [benign]; RCV000162358.2 [benign]; RCV000374656.1 [benign]; 	CM034886 [CLASS=DP MUT=ALT PHEN="Lung cancer association with" GENE=NBN]; 	COSM3763443	381	1558	1	[1] Christopher Schroeder 27.04.2015			NBN (inh=AR pLI=0.00)
chr8	90995019	90995019	C	T	het	wt	hom		QUAL=13525;DP=408,210,269;MQM=60	NBN	synonymous,5'UTR	NBN:NM_002485.4:synonymous:LOW:exon2/16:c.102G>A:p.Leu34Leu,NBN:NM_001024688.2:5'UTR:MODIFIER:exon2/17:c.-195G>A:		rs1063045	0.3792	0.3527	7704/3573/531	0.3497							602667 [NBN (confirmed) Nijmegen breakage syndrome,251260|Aplastic anemia,609135|Leukemia,acute lymphoblastic,613065];	RCV000162359.1 [benign]; RCV000242759.1 [benign]; RCV000387572.1 [benign]; 		COSM3763444	388	1538	1	[1] Alexandra Doehring 27.08.2015			NBN (inh=AR pLI=0.00)
chr8	94794620	94794620	C	T	het	hom	wt		QUAL=5438;DP=134,116,142;MQM=60	TMEM67	splice_region&intron	TMEM67:NM_153704.5:splice_region&intron:LOW:exon10/27:c.1066-3C>T:,TMEM67:NM_001142301.1:splice_region&intron:LOW:exon11/28:c.823-3C>T:,TMEM67:NR_024522.1:splice_region&intron:LOW:exon10/28:n.1137-3C>T:		rs3097427	0.7151	0.6341	24646/11127/3055	0.6253							609884 [TMEM67 (confirmed) Meckel syndrome 3,607361|Joubert syndrome 6,610688|Bardet-Biedl syndrome 14,modifier of,615991|COACH syndrome,216360|Nephronophthisis 11,613550];	RCV000082681.9 [other]; RCV000310098.1 [benign]; RCV000364741.1 [benign]; RCV000397297.1 [benign]; 			904	1147					TMEM67 (inh=AR pLI=0.00)
chr8	94808165	94808165	A	G	het	hom	wt	pred_pathogenic	QUAL=4452;DP=220,58,93;MQM=60	TMEM67	missense,non_coding_transcript_exon	TMEM67:NM_153704.5:missense:MODERATE:exon18/28:c.1810A>G:p.Ile604Val,TMEM67:NM_001142301.1:missense:MODERATE:exon19/29:c.1567A>G:p.Ile523Val,TMEM67:NR_024522.1:non_coding_transcript_exon:MODIFIER:exon18/29:n.1881A>G:		rs3134031	0.6929	0.6369	25016/12052/2777	0.6307	0.3570	T,T	T	B,B	D,D	1.81	609884 [TMEM67 (confirmed) Meckel syndrome 3,607361|Joubert syndrome 6,610688|Bardet-Biedl syndrome 14,modifier of,615991|COACH syndrome,216360|Nephronophthisis 11,613550];	RCV000114244.3 [other]; RCV000278248.1 [benign]; RCV000323495.1 [benign]; RCV000378100.1 [benign]; 		COSM3763454, COSM3763455, COSM3763456	974	1285					TMEM67 (inh=AR pLI=0.00)
chr8	94929079	94929079	T	A	hom	hom	het	low_DP	QUAL=364;DP=3,7,11;MQM=60	MIR378D2-PDP1	intergenic_region	MIR378D2-PDP1:MIR378D2-PDP1:intergenic_region:MODIFIER::n.94929079T>A:		rs4469422	0.4966	0.0000	0/0/0	0.3476							605993 [PDP1 (provisional) Pyruvate dehydrogenase phosphatase deficiency,608782];	RCV000367981.1 [benign]; 			61	96					MIR378D2-PDP1 (inh=n/a pLI=n/a)
chr8	94935937	94935937	T	C	het	hom	het		QUAL=16765;DP=558,203,280;MQM=60	PDP1	3'UTR	PDP1:NM_001161779.1:3'UTR:MODIFIER:exon3/3:c.*36T>C:,PDP1:NM_018444.3:3'UTR:MODIFIER:exon2/2:c.*36T>C:,PDP1:NM_001161780.1:3'UTR:MODIFIER:exon3/3:c.*36T>C:,PDP1:NM_001161781.1:3'UTR:MODIFIER:exon2/2:c.*36T>C:		rs4735258	0.4952	0.4676	13945/5556/805	0.4548							605993 [PDP1 (provisional) Pyruvate dehydrogenase phosphatase deficiency,608782];	RCV000291077.1 [benign]; 			140	341					PDP1 (inh=AR pLI=0.34)
chr8	94936532	94936532	G	C	het	hom	het		QUAL=10112;DP=301,110,167;MQM=60	PDP1	3'UTR	PDP1:NM_001161779.1:3'UTR:MODIFIER:exon3/3:c.*631G>C:,PDP1:NM_018444.3:3'UTR:MODIFIER:exon2/2:c.*631G>C:,PDP1:NM_001161780.1:3'UTR:MODIFIER:exon3/3:c.*631G>C:,PDP1:NM_001161781.1:3'UTR:MODIFIER:exon2/2:c.*631G>C:		rs911	0.5939	0.0000	0/0/0	0.0871							605993 [PDP1 (provisional) Pyruvate dehydrogenase phosphatase deficiency,608782];	RCV000367070.1 [benign]; 			40	110					PDP1 (inh=AR pLI=0.34)
chr8	94936567	94936567	G	-	wt	wt	het		QUAL=1274;DP=216,72,111;MQM=60	PDP1	3'UTR	PDP1:NM_001161779.1:3'UTR:MODIFIER:exon3/3:c.*668delG:,PDP1:NM_018444.3:3'UTR:MODIFIER:exon2/2:c.*668delG:,PDP1:NM_001161780.1:3'UTR:MODIFIER:exon3/3:c.*668delG:,PDP1:NM_001161781.1:3'UTR:MODIFIER:exon2/2:c.*668delG:		rs139623857	0.0052	0.0000	0/0/0	0.0212							605993 [PDP1 (provisional) Pyruvate dehydrogenase phosphatase deficiency,608782];				0	7					PDP1 (inh=AR pLI=0.34)
chr8	94937549	94937549	-	T	wt	het	wt	low_QUAL	QUAL=26;DP=163,21,31;MQM=60	PDP1	3'UTR	PDP1:NM_001161779.1:3'UTR:MODIFIER:exon3/3:c.*1661dupT:,PDP1:NM_018444.3:3'UTR:MODIFIER:exon2/2:c.*1661dupT:,PDP1:NM_001161780.1:3'UTR:MODIFIER:exon3/3:c.*1661dupT:,PDP1:NM_001161781.1:3'UTR:MODIFIER:exon2/2:c.*1661dupT:	(TT)n	rs778564057	0.0000	0.0000	0/0/0	0.0158							605993 [PDP1 (provisional) Pyruvate dehydrogenase phosphatase deficiency,608782];				0	53					PDP1 (inh=AR pLI=0.34)
chr8	96047806	96047806	-	A	hom	het	hom	anno_pathogenic_clinvar	QUAL=2743;DP=91,36,34;MQM=59	NDUFAF6	splice_region&intron	NDUFAF6:NM_152416.3:splice_region&intron:LOW:exon3/8:c.420+15dupA:		rs34960210;rs397749867	0.6376	0.5179	1933/1128/159	0.0898							612392 [NDUFAF6 (provisional) Leigh syndrome due to mitochondrial complex I deficiency,256000];	RCV000198813.1 [pathogenic]; 			573	886	1	[1] old entry - no details available			NDUFAF6 (inh=AR pLI=0.00)
chr8	96070181	96070181	T	C	hom	hom	hom		QUAL=8781;DP=96,83,95;MQM=60	NDUFAF6	3'UTR	NDUFAF6:NM_152416.3:3'UTR:MODIFIER:exon9/9:c.*16T>C:		rs2678832	0.9265	0.9433	49924/26745/3260	0.9138							612392 [NDUFAF6 (provisional) Leigh syndrome due to mitochondrial complex I deficiency,256000];				864	89					NDUFAF6 (inh=AR pLI=0.00)
chr8	97239126	97239126	T	C	hom	hom	het		QUAL=10876;DP=237,61,82;MQM=60	UQCRB	3'UTR,non_coding_transcript_exon	UQCRB:NM_001254752.1:3'UTR:MODIFIER:exon5/5:c.*4207A>G:,UQCRB:NM_001199975.2:3'UTR:MODIFIER:exon5/5:c.*4157A>G:,UQCRB:NM_006294.4:3'UTR:MODIFIER:exon4/4:c.*4157A>G:,UQCRB:NR_045639.1:non_coding_transcript_exon:MODIFIER:exon5/5:n.4887A>G:		rs7827095	0.5100	0.4778	1259/303/51	0.1150							191330 [UQCRB (provisional) Mitochondrial complex III deficiency,nuclear type 3,615158];				154	266					UQCRB (inh=AR pLI=0.21)
chr8	97239613	97239613	A	C	hom	hom	het		QUAL=16670;DP=181,232,283;MQM=57	UQCRB	3'UTR,non_coding_transcript_exon	UQCRB:NM_001254752.1:3'UTR:MODIFIER:exon5/5:c.*3720T>G:,UQCRB:NM_001199975.2:3'UTR:MODIFIER:exon5/5:c.*3670T>G:,UQCRB:NM_006294.4:3'UTR:MODIFIER:exon4/4:c.*3670T>G:,UQCRB:NR_045639.1:non_coding_transcript_exon:MODIFIER:exon5/5:n.4400T>G:		rs2292836	0.3664	0.4170	981/298/21	0.1029							191330 [UQCRB (provisional) Mitochondrial complex III deficiency,nuclear type 3,615158];				161	308					UQCRB (inh=AR pLI=0.21)
chr8	97240129	97240129	C	T	hom	hom	het		QUAL=14559;DP=312,88,124;MQM=51	UQCRB	3'UTR,non_coding_transcript_exon	UQCRB:NM_001254752.1:3'UTR:MODIFIER:exon5/5:c.*3204G>A:,UQCRB:NM_001199975.2:3'UTR:MODIFIER:exon5/5:c.*3154G>A:,UQCRB:NM_006294.4:3'UTR:MODIFIER:exon4/4:c.*3154G>A:,UQCRB:NR_045639.1:non_coding_transcript_exon:MODIFIER:exon5/5:n.3884G>A:		rs10504961	0.3664	0.4169	981/299/20	0.1013							191330 [UQCRB (provisional) Mitochondrial complex III deficiency,nuclear type 3,615158];				162	310					UQCRB (inh=AR pLI=0.21)
chr8	97240847	97240847	A	G	hom	hom	het		QUAL=27248;DP=346,303,409;MQM=59	UQCRB	3'UTR,non_coding_transcript_exon	UQCRB:NM_001254752.1:3'UTR:MODIFIER:exon5/5:c.*2486T>C:,UQCRB:NM_001199975.2:3'UTR:MODIFIER:exon5/5:c.*2436T>C:,UQCRB:NM_006294.4:3'UTR:MODIFIER:exon4/4:c.*2436T>C:,UQCRB:NR_045639.1:non_coding_transcript_exon:MODIFIER:exon5/5:n.3166T>C:	MIR	rs13253635	0.3666	0.4174	982/299/21	0.1038							191330 [UQCRB (provisional) Mitochondrial complex III deficiency,nuclear type 3,615158];				162	303					UQCRB (inh=AR pLI=0.21)
chr8	97242124	97242124	G	A	hom	hom	het		QUAL=19159;DP=309,186,229;MQM=59	UQCRB	3'UTR,non_coding_transcript_exon	UQCRB:NM_001254752.1:3'UTR:MODIFIER:exon5/5:c.*1209C>T:,UQCRB:NM_001199975.2:3'UTR:MODIFIER:exon5/5:c.*1159C>T:,UQCRB:NM_006294.4:3'UTR:MODIFIER:exon4/4:c.*1159C>T:,UQCRB:NR_045639.1:non_coding_transcript_exon:MODIFIER:exon5/5:n.1889C>T:		rs7002575	0.3658	0.4166	978/296/20	0.1014							191330 [UQCRB (provisional) Mitochondrial complex III deficiency,nuclear type 3,615158];				162	308					UQCRB (inh=AR pLI=0.21)
chr8	97242134	97242135	CT	-	hom	hom	het		QUAL=18731;DP=316,200,247;MQM=59	UQCRB	3'UTR,non_coding_transcript_exon	UQCRB:NM_001254752.1:3'UTR:MODIFIER:exon5/5:c.*1198_*1199delAG:,UQCRB:NM_001199975.2:3'UTR:MODIFIER:exon5/5:c.*1148_*1149delAG:,UQCRB:NM_006294.4:3'UTR:MODIFIER:exon4/4:c.*1148_*1149delAG:,UQCRB:NR_045639.1:non_coding_transcript_exon:MODIFIER:exon5/5:n.1878_1879delAG:		rs35954659	0.2330	0.3377	659/174/4	0.0772							191330 [UQCRB (provisional) Mitochondrial complex III deficiency,nuclear type 3,615158];				107	298					UQCRB (inh=AR pLI=0.21)
chr8	97242849	97242849	C	T	hom	hom	het		QUAL=13068;DP=245,88,141;MQM=59	UQCRB	3'UTR,non_coding_transcript_exon	UQCRB:NM_001254752.1:3'UTR:MODIFIER:exon5/5:c.*484G>A:,UQCRB:NM_001199975.2:3'UTR:MODIFIER:exon5/5:c.*434G>A:,UQCRB:NM_006294.4:3'UTR:MODIFIER:exon4/4:c.*434G>A:,UQCRB:NR_045639.1:non_coding_transcript_exon:MODIFIER:exon5/5:n.1164G>A:		rs7836698	0.2336	0.3382	660/175/4	0.0800							191330 [UQCRB (provisional) Mitochondrial complex III deficiency,nuclear type 3,615158];				107	299					UQCRB (inh=AR pLI=0.21)
chr8	97243720	97243720	G	A	hom	hom	het		QUAL=18858;DP=284,175,281;MQM=60	UQCRB	synonymous,intron,non_coding_transcript_exon	UQCRB:NM_001254752.1:synonymous:LOW:exon4/5:c.282C>T:p.His94His,UQCRB:NM_001199975.2:intron:MODIFIER:exon4/4:c.162+282C>T:,UQCRB:NM_006294.4:intron:MODIFIER:exon3/3:c.258+282C>T:,UQCRB:NR_045639.1:non_coding_transcript_exon:MODIFIER:exon4/5:n.386C>T:	MIR3	rs2292835	0.2334	0.3419	724/233/5	0.0946							191330 [UQCRB (provisional) Mitochondrial complex III deficiency,nuclear type 3,615158];				227	675					UQCRB (inh=AR pLI=0.21)
chr8	100133706	100133706	T	G	het	hom	het	anno_high_impact	QUAL=19339;DP=360,282,369;MQM=60	VPS13B	stop_gained,intron,non_coding_transcript_exon	VPS13B:NM_181661.2:stop_gained:HIGH:exon8/8:c.1239T>G:p.Tyr413*,VPS13B:NM_017890.4:intron:MODIFIER:exon8/61:c.1206+33T>G:,VPS13B:NM_015243.2:intron:MODIFIER:exon8/17:c.1206+33T>G:,VPS13B:NM_152564.4:intron:MODIFIER:exon8/61:c.1206+33T>G:,VPS13B:NR_047582.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.1465T>G:		rs7460625	0.7051	0.7503	34863/21188/2427	0.7356	0.0410					3.40	607817 [VPS13B (confirmed) Cohen syndrome,216550];	RCV000245799.1 [benign]; 			1045	447	1	[1] auto-classification 16.06.2016  [2] old entry - no details available			VPS13B (inh=AR pLI=0.00)
chr8	100493820	100493820	C	T	wt	wt	het		QUAL=2090;DP=181,139,175;MQM=60	VPS13B	splice_region&intron	VPS13B:NM_017890.4:splice_region&intron:LOW:exon24/61:c.3667-7C>T:,VPS13B:NM_152564.4:splice_region&intron:LOW:exon24/61:c.3667-7C>T:		rs35543295	0.0204	0.0374	125/112/0	0.0356							607817 [VPS13B (confirmed) Cohen syndrome,216550];	RCV000081895.8 [other]; RCV000302317.1 [likely benign]; 			9	160					VPS13B (inh=AR pLI=0.00)
chr8	100844595	100844595	A	T	het	wt	het	anno_high_impact;pred_pathogenic	QUAL=81;DP=103,85,99;MQM=54	VPS13B	splice_acceptor	VPS13B:NM_017890.4:splice_acceptor:HIGH:exon51/61:c.9406-2A>T:,VPS13B:NM_152564.4:splice_acceptor:HIGH:exon51/61:c.9331-2A>T:		rs74485751	0.3738	0.0828	0/0/0	0.0121	6.2810					23.60	607817 [VPS13B (confirmed) Cohen syndrome,216550];				0	21	2	[2] kehrer 22.04.2016 H?ufigkeit			VPS13B (inh=AR pLI=0.00)
chr8	100844758	100844758	T	C	het	wt	het		QUAL=9409;DP=344,287,385;MQM=60	VPS13B	synonymous	VPS13B:NM_017890.4:synonymous:LOW:exon52/62:c.9567T>C:p.Ser3189Ser,VPS13B:NM_152564.4:synonymous:LOW:exon52/62:c.9492T>C:p.Ser3164Ser		rs36074608	0.1971	0.1926	2869/959/32	0.1914							607817 [VPS13B (confirmed) Cohen syndrome,216550];	RCV000081923.9 [other]; RCV000366445.1 [benign]; 		COSM3982312, COSM3982313	47	412					VPS13B (inh=AR pLI=0.00)
chr8	100888323	100888325	TAT	-	hom	het	het		QUAL=10226;DP=213,135,142;MQM=59	VPS13B	3'UTR	VPS13B:NM_017890.4:3'UTR:MODIFIER:exon62/62:c.*434_*436delTTA:,VPS13B:NM_152564.4:3'UTR:MODIFIER:exon62/62:c.*434_*436delTTA:		rs10542428	0.5519	0.0000	0/0/0	0.4135							607817 [VPS13B (confirmed) Cohen syndrome,216550];	RCV000301501.1 [benign]; 			39	122					VPS13B (inh=AR pLI=0.00)
chr8	103218466	103218466	-	A	het	wt	het		QUAL=2979;DP=165,83,124;MQM=59	RRM2B	3'UTR	RRM2B:NM_001172477.1:3'UTR:MODIFIER:exon9/9:c.*1894dupT:,RRM2B:NM_001172478.1:3'UTR:MODIFIER:exon8/8:c.*1894dupT:,RRM2B:NM_015713.4:3'UTR:MODIFIER:exon9/9:c.*1894dupT:		rs150629554	0.0853	0.0000	0/0/0	0.0742							604712 [RRM2B (provisional) Mitochondrial DNA depletion syndrome 8A (encephalomyopathic type with renal tubulopathy),612075|Progressive external ophthalmoplegia with mitochondrial DNA deletions,autosomal dominant 5,613077|Mitochondrial DNA depletion syndrome 8B (MNGIE type),612075];	RCV000339322.1 [benign]; RCV000407292.1 [benign]; 			2	42					RRM2B (inh=AR+AD pLI=0.16)
chr8	103218873	103218873	C	G	het	wt	het		QUAL=5313;DP=292,127,139;MQM=60	RRM2B	3'UTR	RRM2B:NM_001172477.1:3'UTR:MODIFIER:exon9/9:c.*1488G>C:,RRM2B:NM_001172478.1:3'UTR:MODIFIER:exon8/8:c.*1488G>C:,RRM2B:NM_015713.4:3'UTR:MODIFIER:exon9/9:c.*1488G>C:		rs1265116	0.0777	0.0000	0/0/0	0.0136							604712 [RRM2B (provisional) Mitochondrial DNA depletion syndrome 8A (encephalomyopathic type with renal tubulopathy),612075|Progressive external ophthalmoplegia with mitochondrial DNA deletions,autosomal dominant 5,613077|Mitochondrial DNA depletion syndrome 8B (MNGIE type),612075];	RCV000261106.1 [benign]; RCV000316397.1 [benign]; 			3	31					RRM2B (inh=AR+AD pLI=0.16)
chr8	103220351	103220351	A	G	hom	hom	hom		QUAL=18458;DP=305,108,149;MQM=60	RRM2B	3'UTR	RRM2B:NM_001172477.1:3'UTR:MODIFIER:exon9/9:c.*10T>C:,RRM2B:NM_001172478.1:3'UTR:MODIFIER:exon8/8:c.*10T>C:,RRM2B:NM_015713.4:3'UTR:MODIFIER:exon9/9:c.*10T>C:		rs1265117	1.0000	0.9999	60515/33321/5108	0.9353							604712 [RRM2B (provisional) Mitochondrial DNA depletion syndrome 8A (encephalomyopathic type with renal tubulopathy),612075|Progressive external ophthalmoplegia with mitochondrial DNA deletions,autosomal dominant 5,613077|Mitochondrial DNA depletion syndrome 8B (MNGIE type),612075];				2795	1					RRM2B (inh=AR+AD pLI=0.16)
chr8	103250991	103250991	C	T	wt	wt	het		QUAL=4971;DP=224,301,418;MQM=60	RRM2B	synonymous,intron	RRM2B:NM_001172477.1:synonymous:LOW:exon1/9:c.60G>A:p.Leu20Leu,RRM2B:NM_001172478.1:intron:MODIFIER:exon1/7:c.48+64G>A:,RRM2B:NM_015713.4:intron:MODIFIER:exon1/8:c.48+64G>A:		rs28999669	0.0507	0.1081	758/668/7	0.0975	0.6430		T			8.35	604712 [RRM2B (provisional) Mitochondrial DNA depletion syndrome 8A (encephalomyopathic type with renal tubulopathy),612075|Progressive external ophthalmoplegia with mitochondrial DNA deletions,autosomal dominant 5,613077|Mitochondrial DNA depletion syndrome 8B (MNGIE type),612075];	RCV000127810.1 [benign]; 			50	536					RRM2B (inh=AR+AD pLI=0.16)
chr8	103251190	103251190	G	T	wt	het	wt		QUAL=1261;DP=91,112,189;MQM=60	RRM2B	5'UTR	RRM2B:NM_001172478.1:5'UTR:MODIFIER:exon1/8:c.-88C>A:,RRM2B:NM_015713.4:5'UTR:MODIFIER:exon1/9:c.-88C>A:		rs72554091	0.0457	0.0000	0/0/0	0.0124							604712 [RRM2B (provisional) Mitochondrial DNA depletion syndrome 8A (encephalomyopathic type with renal tubulopathy),612075|Progressive external ophthalmoplegia with mitochondrial DNA deletions,autosomal dominant 5,613077|Mitochondrial DNA depletion syndrome 8B (MNGIE type),612075];	RCV000287075.1 [likely benign]; RCV000372168.1 [likely benign]; 			3	34					RRM2B (inh=AR+AD pLI=0.16)
chr8	103251259	103251259	C	T	wt	wt	het		QUAL=865;DP=150,76,94;MQM=59	RRM2B	5'UTR	RRM2B:NM_001172478.1:5'UTR:MODIFIER:exon1/8:c.-157G>A:,RRM2B:NM_015713.4:5'UTR:MODIFIER:exon1/9:c.-157G>A:		rs28927991	0.0459	0.0000	0/0/0	0.0159							604712 [RRM2B (provisional) Mitochondrial DNA depletion syndrome 8A (encephalomyopathic type with renal tubulopathy),612075|Progressive external ophthalmoplegia with mitochondrial DNA deletions,autosomal dominant 5,613077|Mitochondrial DNA depletion syndrome 8B (MNGIE type),612075];	RCV000306315.1 [benign]; RCV000393138.1 [benign]; 			6	53					RRM2B (inh=AR+AD pLI=0.16)
chr8	105440271	105440271	G	C	het	het	wt		QUAL=4536;DP=230,68,87;MQM=60	DPYS	synonymous	DPYS:NM_001385.2:synonymous:LOW:exon6/10:c.1029C>G:p.Thr343Thr		rs117104587	0.0046	0.0105	6/4/0	0.0102							613326 [DPYS (provisional) Dihydropyrimidinuria,222748];	RCV000086522.1 [not provided]; RCV000400960.1 [uncertain significance]; 			0	27					DPYS (inh=AR pLI=0.00)
chr8	105479149	105479149	A	G	het	wt	hom	low_DP	QUAL=941;DP=6,37,35;MQM=60	DPYS	5'UTR	DPYS:NM_001385.2:5'UTR:MODIFIER:exon1/10:c.-1T>C:		rs2959023	0.6362	0.6383	1301/322/107	0.2415							613326 [DPYS (provisional) Dihydropyrimidinuria,222748];	RCV000086534.1 [not provided]; RCV000260513.1 [benign]; 			562	688					DPYS (inh=AR pLI=0.00)
chr8	119936246	119936246	C	T	het	wt	het		QUAL=4759;DP=300,55,63;MQM=59	TNFRSF11B	3'UTR	TNFRSF11B:NM_002546.3:3'UTR:MODIFIER:exon5/5:c.*367G>A:		rs7815884	0.0887	0.0000	0/0/0	0.0256							602643 [TNFRSF11B (confirmed) Paget disease of bone 5,juvenile-onset,239000];	RCV000382499.1 [benign]; 			0	4					TNFRSF11B (inh=AR pLI=0.27)
chr8	119936330	119936330	-	T	het	wt	het		QUAL=2112;DP=194,86,111;MQM=59	TNFRSF11B	3'UTR	TNFRSF11B:NM_002546.3:3'UTR:MODIFIER:exon5/5:c.*282dupA:		rs112977670	0.0000	0.0000	0/0/0	0.0022							602643 [TNFRSF11B (confirmed) Paget disease of bone 5,juvenile-onset,239000];				0	6					TNFRSF11B (inh=AR pLI=0.27)
chr8	119936669	119936669	A	G	het	wt	het		QUAL=9350;DP=362,268,380;MQM=59	TNFRSF11B	synonymous	TNFRSF11B:NM_002546.3:synonymous:LOW:exon5/5:c.1150T>C:p.Leu384Leu		rs1804854	0.0881	0.0261	451/0/450	0.0248							602643 [TNFRSF11B (confirmed) Paget disease of bone 5,juvenile-onset,239000];	RCV000402907.1 [benign]; 			2	13					TNFRSF11B (inh=AR pLI=0.27)
chr8	119941173	119941173	A	G	hom	het	hom		QUAL=16709;DP=244,182,222;MQM=60	TNFRSF11B	splice_region&intron	TNFRSF11B:NM_002546.3:splice_region&intron:LOW:exon2/4:c.401-5T>C:		rs3134046	0.9237	0.9339	52979/29951/4361	0.9167							602643 [TNFRSF11B (confirmed) Paget disease of bone 5,juvenile-onset,239000];	RCV000177160.3 [benign]; RCV000299224.1 [benign]; 			1383	172					TNFRSF11B (inh=AR pLI=0.27)
chr8	119964052	119964052	G	C	hom	hom	het		QUAL=2850;DP=30,47,79;MQM=60	TNFRSF11B	missense	TNFRSF11B:NM_002546.3:missense:MODERATE:exon1/5:c.9C>G:p.Asn3Lys		rs2073618	0.6667	0.6024	11044/4287/2280	0.4782	0.6450	T	T	B	T	15.99	602643 [TNFRSF11B (confirmed) Paget disease of bone 5,juvenile-onset,239000];	RCV000250490.1 [benign]; RCV000291754.1 [benign]; 	CM045665 [CLASS=DP MUT=ALT PHEN="Osteoporotic fractures association with" GENE=TNFRSF11B]; 	COSM453917, COSM1488949	439	768					TNFRSF11B (inh=AR pLI=0.27)
chr8	119964283	119964283	G	A	hom	het	het		QUAL=2636;DP=56,51,68;MQM=60	TNFRSF11B	5'UTR	TNFRSF11B:NM_002546.3:5'UTR:MODIFIER:exon1/5:c.-223C>T:		rs2073617	0.6216	0.0000	0/0/0	0.0904							602643 [TNFRSF11B (confirmed) Paget disease of bone 5,juvenile-onset,239000];	RCV000404609.1 [benign]; 	CR021403 [CLASS=DFP MUT=REF PHEN="Increased intima-media thickness association" GENE=TNFRSF11B]; 		61	115					TNFRSF11B (inh=AR pLI=0.27)
chr8	120790304	120790304	T	C	wt	het	wt		QUAL=374;DP=190,32,57;MQM=60	TAF2	synonymous	TAF2:NM_003184.3:synonymous:LOW:exon18/26:c.2319A>G:p.Thr773Thr		rs1509348	0.5459	0.5695	19236/11098/2294	0.5543							604912 [TAF2 (provisional) Mental retardation,autosomal recessive 40,615599];				539	715					TAF2 (inh=AR pLI=0.57)
chr8	120790378	120790378	-	A	wt	het	wt		QUAL=288;DP=94,22,39;MQM=60	TAF2	splice_region&intron	TAF2:NM_003184.3:splice_region&intron:LOW:exon17/25:c.2254-10dupT:		rs397699035	0.2630	0.2691	3619/1538/1015	0.2255							604912 [TAF2 (provisional) Mental retardation,autosomal recessive 40,615599];				110	565					TAF2 (inh=AR pLI=0.57)
chr8	120793296	120793296	C	T	wt	het	wt		QUAL=776;DP=176,65,115;MQM=60	TAF2	synonymous	TAF2:NM_003184.3:synonymous:LOW:exon17/26:c.2250G>A:p.Gln750Gln		rs7002501	0.2632	0.2532	4450/2008/1218	0.2404							604912 [TAF2 (provisional) Mental retardation,autosomal recessive 40,615599];				117	567					TAF2 (inh=AR pLI=0.57)
chr8	120803637	120803637	C	G	het	het	het	pred_pathogenic	QUAL=11597;DP=341,239,294;MQM=60	TAF2	missense	TAF2:NM_003184.3:missense:MODERATE:exon11/26:c.1340G>C:p.Ser447Thr		rs9297605	0.6583	0.6851	28820/16734/3013	0.6757	4.7700	T,.	T,T	B,.	T,.	13.85	604912 [TAF2 (provisional) Mental retardation,autosomal recessive 40,615599];			COSM3982377, COSM150523	819	604					TAF2 (inh=AR pLI=0.57)
chr8	120803654	120803654	C	T	wt	het	wt		QUAL=2812;DP=340,221,288;MQM=60	TAF2	synonymous	TAF2:NM_003184.3:synonymous:LOW:exon11/26:c.1323G>A:p.Leu441Leu		rs11996390	0.1755	0.2113	3089/1837/512	0.2047	-1.6030		T			13.34	604912 [TAF2 (provisional) Mental retardation,autosomal recessive 40,615599];			COSM3763025, COSM3763026	97	564					TAF2 (inh=AR pLI=0.57)
chr8	120844782	120844782	G	A	wt	het	wt	pred_pathogenic	QUAL=1486;DP=204,110,169;MQM=60	TAF2	missense	TAF2:NM_003184.3:missense:MODERATE:exon1/26:c.23C>T:p.Pro8Leu		rs17818842	0.0893	0.1448	1458/982/42	0.1397	2.3550	D	T	B	T	23.00	604912 [TAF2 (provisional) Mental retardation,autosomal recessive 40,615599];				60	459					TAF2 (inh=AR pLI=0.57)
chr8	120845035	120845035	G	A	wt	het	wt		QUAL=2108;DP=376,166,234;MQM=60	TAF2	5'UTR	TAF2:NM_003184.3:5'UTR:MODIFIER:exon1/26:c.-231C>T:		rs16893214	0.2077	0.0000	0/0/0	0.1913							604912 [TAF2 (provisional) Mental retardation,autosomal recessive 40,615599];				11	74					TAF2 (inh=AR pLI=0.57)
chr8	126044527	126044527	C	T	wt	het	wt		QUAL=1957;DP=396,190,222;MQM=60	KIAA0196	synonymous	KIAA0196:NM_014846.3:synonymous:LOW:exon27/29:c.3291G>A:p.Ala1097Ala		rs11542889	0.1368	0.0664	884/52/794	0.0643							610657 [KIAA0196 (confirmed) Spastic paraplegia 8,autosomal dominant,603563|Ritscher-Schinzel syndrome 1,220210];	RCV000117383.2 [likely benign]; RCV000365603.1 [benign]; 			10	177					WASHC5 (inh=AR+AD pLI=0.00)
chr8	133133361	133133361	C	T	het	hom	het		QUAL=11887;DP=360,146,219;MQM=60	KCNQ3	3'UTR	KCNQ3:NM_004519.3:3'UTR:MODIFIER:exon15/15:c.*8148G>A:,KCNQ3:NM_001204824.1:3'UTR:MODIFIER:exon15/15:c.*8148G>A:		rs1437822	0.1352	0.0000	0/0/0	0.1985							602232 [KCNQ3 (confirmed) Seizures,benign neonatal,type 2,121201];	RCV000262306.1 [benign]; RCV000301153.1 [benign]; 			11	73					KCNQ3 (inh=AD pLI=0.99)
chr8	133134003	133134003	G	A	het	wt	het		QUAL=2036;DP=77,48,66;MQM=60	KCNQ3	3'UTR	KCNQ3:NM_004519.3:3'UTR:MODIFIER:exon15/15:c.*7506C>T:,KCNQ3:NM_001204824.1:3'UTR:MODIFIER:exon15/15:c.*7506C>T:		rs11785257	0.1222	0.0000	0/0/0	0.1429							602232 [KCNQ3 (confirmed) Seizures,benign neonatal,type 2,121201];	RCV000340625.1 [benign]; RCV000378860.1 [benign]; 			2	55					KCNQ3 (inh=AD pLI=0.99)
chr8	133134045	133134045	G	T	wt	het	wt		QUAL=924;DP=102,82,106;MQM=60	KCNQ3	3'UTR	KCNQ3:NM_004519.3:3'UTR:MODIFIER:exon15/15:c.*7464C>A:,KCNQ3:NM_001204824.1:3'UTR:MODIFIER:exon15/15:c.*7464C>A:		rs35604597	0.0172	0.0000	0/0/0	0.0248							602232 [KCNQ3 (confirmed) Seizures,benign neonatal,type 2,121201];	RCV000280690.1 [likely benign]; RCV000405900.1 [likely benign]; 			0	9					KCNQ3 (inh=AD pLI=0.99)
chr8	133134288	133134288	G	A	het	hom	het		QUAL=15554;DP=285,266,343;MQM=60	KCNQ3	3'UTR	KCNQ3:NM_004519.3:3'UTR:MODIFIER:exon15/15:c.*7221C>T:,KCNQ3:NM_001204824.1:3'UTR:MODIFIER:exon15/15:c.*7221C>T:		rs2436124	0.1352	0.0000	0/0/0	0.1986							602232 [KCNQ3 (confirmed) Seizures,benign neonatal,type 2,121201];	RCV000329099.1 [benign]; RCV000358302.1 [benign]; 			11	73					KCNQ3 (inh=AD pLI=0.99)
chr8	133134366	133134366	T	C	het	hom	het		QUAL=13891;DP=397,192,266;MQM=60	KCNQ3	3'UTR	KCNQ3:NM_004519.3:3'UTR:MODIFIER:exon15/15:c.*7143A>G:,KCNQ3:NM_001204824.1:3'UTR:MODIFIER:exon15/15:c.*7143A>G:	MIRb	rs2436125	0.1352	0.0000	0/0/0	0.1982							602232 [KCNQ3 (confirmed) Seizures,benign neonatal,type 2,121201];	RCV000279047.1 [benign]; RCV000380491.1 [benign]; 			11	73					KCNQ3 (inh=AD pLI=0.99)
chr8	133134390	133134390	G	A	het	hom	het		QUAL=14876;DP=386,209,301;MQM=60	KCNQ3	3'UTR	KCNQ3:NM_004519.3:3'UTR:MODIFIER:exon15/15:c.*7119C>T:,KCNQ3:NM_001204824.1:3'UTR:MODIFIER:exon15/15:c.*7119C>T:	MIRb	rs2436126	0.1352	0.0000	0/0/0	0.1982							602232 [KCNQ3 (confirmed) Seizures,benign neonatal,type 2,121201];	RCV000282775.1 [benign]; RCV000347079.1 [benign]; 			11	73					KCNQ3 (inh=AD pLI=0.99)
chr8	133134434	133134434	T	C	het	hom	het		QUAL=15946;DP=423,226,323;MQM=60	KCNQ3	3'UTR	KCNQ3:NM_004519.3:3'UTR:MODIFIER:exon15/15:c.*7075A>G:,KCNQ3:NM_001204824.1:3'UTR:MODIFIER:exon15/15:c.*7075A>G:	MIRb	rs2436127	0.1348	0.0000	0/0/0	0.1969							602232 [KCNQ3 (confirmed) Seizures,benign neonatal,type 2,121201];	RCV000352720.1 [benign]; RCV000405641.1 [benign]; 			11	72					KCNQ3 (inh=AD pLI=0.99)
chr8	133134476	133134476	A	G	het	hom	het		QUAL=18323;DP=520,239,365;MQM=60	KCNQ3	3'UTR	KCNQ3:NM_004519.3:3'UTR:MODIFIER:exon15/15:c.*7033T>C:,KCNQ3:NM_001204824.1:3'UTR:MODIFIER:exon15/15:c.*7033T>C:	MIRb	rs2436128	0.1348	0.0000	0/0/0	0.1971							602232 [KCNQ3 (confirmed) Seizures,benign neonatal,type 2,121201];	RCV000313012.1 [benign]; RCV000367650.1 [benign]; 			11	73					KCNQ3 (inh=AD pLI=0.99)
chr8	133134553	133134553	T	C	het	hom	het		QUAL=14369;DP=373,202,319;MQM=60	KCNQ3	3'UTR	KCNQ3:NM_004519.3:3'UTR:MODIFIER:exon15/15:c.*6956A>G:,KCNQ3:NM_001204824.1:3'UTR:MODIFIER:exon15/15:c.*6956A>G:		rs2469630	0.1360	0.0000	0/0/0	0.1978							602232 [KCNQ3 (confirmed) Seizures,benign neonatal,type 2,121201];	RCV000259863.1 [benign]; RCV000354805.1 [benign]; 			11	73					KCNQ3 (inh=AD pLI=0.99)
chr8	133134635	133134635	G	C	het	hom	het		QUAL=12070;DP=378,157,217;MQM=60	KCNQ3	3'UTR	KCNQ3:NM_004519.3:3'UTR:MODIFIER:exon15/15:c.*6874C>G:,KCNQ3:NM_001204824.1:3'UTR:MODIFIER:exon15/15:c.*6874C>G:	L4_C_Mam	rs2436129	0.1348	0.0000	0/0/0	0.1975							602232 [KCNQ3 (confirmed) Seizures,benign neonatal,type 2,121201];	RCV000324405.1 [benign]; RCV000360374.1 [benign]; 			11	73					KCNQ3 (inh=AD pLI=0.99)
chr8	133135063	133135063	T	-	wt	het	wt		QUAL=2379;DP=507,201,290;MQM=60	KCNQ3	3'UTR	KCNQ3:NM_004519.3:3'UTR:MODIFIER:exon15/15:c.*6446delA:,KCNQ3:NM_001204824.1:3'UTR:MODIFIER:exon15/15:c.*6446delA:		rs35153843	0.0176	0.0000	0/0/0	0.0248							602232 [KCNQ3 (confirmed) Seizures,benign neonatal,type 2,121201];	RCV000298526.1 [likely benign]; RCV000334819.1 [likely benign]; 			0	9					KCNQ3 (inh=AD pLI=0.99)
chr8	133135169	133135169	C	T	het	hom	het		QUAL=10936;DP=308,128,185;MQM=60	KCNQ3	3'UTR	KCNQ3:NM_004519.3:3'UTR:MODIFIER:exon15/15:c.*6340G>A:,KCNQ3:NM_001204824.1:3'UTR:MODIFIER:exon15/15:c.*6340G>A:		rs2469629	0.1392	0.0000	0/0/0	0.1986							602232 [KCNQ3 (confirmed) Seizures,benign neonatal,type 2,121201];	RCV000264257.1 [benign]; RCV000359034.1 [benign]; 			11	73					KCNQ3 (inh=AD pLI=0.99)
chr8	133135577	133135577	T	G	het	hom	het		QUAL=15381;DP=321,245,290;MQM=59	KCNQ3	3'UTR	KCNQ3:NM_004519.3:3'UTR:MODIFIER:exon15/15:c.*5932A>C:,KCNQ3:NM_001204824.1:3'UTR:MODIFIER:exon15/15:c.*5932A>C:		rs2436130	0.1352	0.0000	0/0/0	0.1984							602232 [KCNQ3 (confirmed) Seizures,benign neonatal,type 2,121201];	RCV000301653.1 [benign]; RCV000347178.1 [benign]; 			11	73					KCNQ3 (inh=AD pLI=0.99)
chr8	133135790	133135790	G	A	het	wt	het		QUAL=7835;DP=314,207,299;MQM=60	KCNQ3	3'UTR	KCNQ3:NM_004519.3:3'UTR:MODIFIER:exon15/15:c.*5719C>T:,KCNQ3:NM_001204824.1:3'UTR:MODIFIER:exon15/15:c.*5719C>T:		rs11786417	0.1222	0.0000	0/0/0	0.1433							602232 [KCNQ3 (confirmed) Seizures,benign neonatal,type 2,121201];	RCV000314411.1 [benign]; RCV000369033.1 [benign]; 			2	55					KCNQ3 (inh=AD pLI=0.99)
chr8	133136551	133136551	T	C	hom	hom	hom		QUAL=20848;DP=262,146,223;MQM=59	KCNQ3	3'UTR	KCNQ3:NM_004519.3:3'UTR:MODIFIER:exon15/15:c.*4958A>G:,KCNQ3:NM_001204824.1:3'UTR:MODIFIER:exon15/15:c.*4958A>G:		rs1437824	0.7228	0.0000	0/0/0	0.7947							602232 [KCNQ3 (confirmed) Seizures,benign neonatal,type 2,121201];	RCV000264487.1 [benign]; RCV000359207.1 [benign]; 			105	44					KCNQ3 (inh=AD pLI=0.99)
chr8	133136762	133136762	-	CTGT	hom	hom	hom		QUAL=22274;DP=190,218,303;MQM=59	KCNQ3	3'UTR	KCNQ3:NM_004519.3:3'UTR:MODIFIER:exon15/15:c.*4746_*4747insACAG:,KCNQ3:NM_001204824.1:3'UTR:MODIFIER:exon15/15:c.*4746_*4747insACAG:		rs112550767	0.2863	0.0000	0/0/0	0.3801							602232 [KCNQ3 (confirmed) Seizures,benign neonatal,type 2,121201];	RCV000295226.1 [benign]; RCV000389474.1 [benign]; 			44	74					KCNQ3 (inh=AD pLI=0.99)
chr8	133137266	133137266	T	A	hom	hom	hom		QUAL=26613;DP=381,205,221;MQM=60	KCNQ3	3'UTR	KCNQ3:NM_004519.3:3'UTR:MODIFIER:exon15/15:c.*4243A>T:,KCNQ3:NM_001204824.1:3'UTR:MODIFIER:exon15/15:c.*4243A>T:		rs2436131	0.2863	0.0000	0/0/0	0.3957							602232 [KCNQ3 (confirmed) Seizures,benign neonatal,type 2,121201];	RCV000269907.1 [benign]; RCV000362145.1 [benign]; 			44	74					KCNQ3 (inh=AD pLI=0.99)
chr8	133137532	133137532	C	T	hom	hom	hom		QUAL=16213;DP=288,92,119;MQM=59	KCNQ3	3'UTR	KCNQ3:NM_004519.3:3'UTR:MODIFIER:exon15/15:c.*3977G>A:,KCNQ3:NM_001204824.1:3'UTR:MODIFIER:exon15/15:c.*3977G>A:		rs2469628	0.3109	0.0000	0/0/0	0.4023							602232 [KCNQ3 (confirmed) Seizures,benign neonatal,type 2,121201];	RCV000286936.1 [benign]; RCV000339629.1 [benign]; 			44	74					KCNQ3 (inh=AD pLI=0.99)
chr8	133137912	133137912	C	T	hom	hom	hom		QUAL=15931;DP=303,77,87;MQM=60	KCNQ3	3'UTR	KCNQ3:NM_004519.3:3'UTR:MODIFIER:exon15/15:c.*3597G>A:,KCNQ3:NM_001204824.1:3'UTR:MODIFIER:exon15/15:c.*3597G>A:		rs1025436	0.7208	0.0000	0/0/0	0.7924							602232 [KCNQ3 (confirmed) Seizures,benign neonatal,type 2,121201];	RCV000340577.1 [benign]; RCV000383538.1 [benign]; 			103	46					KCNQ3 (inh=AD pLI=0.99)
chr8	133138474	133138474	T	C	het	hom	het		QUAL=16747;DP=243,136,179;MQM=60	KCNQ3	3'UTR	KCNQ3:NM_004519.3:3'UTR:MODIFIER:exon15/15:c.*3035A>G:,KCNQ3:NM_001204824.1:3'UTR:MODIFIER:exon15/15:c.*3035A>G:		rs2469627	0.1432	0.0000	0/0/0	0.2117							602232 [KCNQ3 (confirmed) Seizures,benign neonatal,type 2,121201];	RCV000332027.1 [benign]; RCV000388882.1 [benign]; 			14	73					KCNQ3 (inh=AD pLI=0.99)
chr8	133138477	133138477	T	C	hom	hom	hom		QUAL=16747;DP=243,136,179;MQM=60	KCNQ3	3'UTR	KCNQ3:NM_004519.3:3'UTR:MODIFIER:exon15/15:c.*3032A>G:,KCNQ3:NM_001204824.1:3'UTR:MODIFIER:exon15/15:c.*3032A>G:		rs2469626	0.2931	0.0000	0/0/0	0.4086							602232 [KCNQ3 (confirmed) Seizures,benign neonatal,type 2,121201];	RCV000293171.1 [benign]; RCV000350482.1 [benign]; 			48	72					KCNQ3 (inh=AD pLI=0.99)
chr8	133139343	133139343	T	C	wt	het	wt		QUAL=1665;DP=334,119,180;MQM=60	KCNQ3	3'UTR	KCNQ3:NM_004519.3:3'UTR:MODIFIER:exon15/15:c.*2166A>G:,KCNQ3:NM_001204824.1:3'UTR:MODIFIER:exon15/15:c.*2166A>G:		rs35279095	0.0180	0.0000	0/0/0	0.0043							602232 [KCNQ3 (confirmed) Seizures,benign neonatal,type 2,121201];	RCV000280663.1 [likely benign]; RCV000386708.1 [likely benign]; 			0	9					KCNQ3 (inh=AD pLI=0.99)
chr8	133139755	133139755	G	A	hom	hom	hom		QUAL=43706;DP=579,344,419;MQM=60	KCNQ3	3'UTR	KCNQ3:NM_004519.3:3'UTR:MODIFIER:exon15/15:c.*1754C>T:,KCNQ3:NM_001204824.1:3'UTR:MODIFIER:exon15/15:c.*1754C>T:		rs977939	0.2686	0.0000	0/0/0	0.0605							602232 [KCNQ3 (confirmed) Seizures,benign neonatal,type 2,121201];	RCV000340516.1 [benign]; RCV000391929.1 [benign]; 			41	78					KCNQ3 (inh=AD pLI=0.99)
chr8	133139812	133139812	G	C	wt	het	wt		QUAL=5072;DP=604,371,461;MQM=60	KCNQ3	3'UTR	KCNQ3:NM_004519.3:3'UTR:MODIFIER:exon15/15:c.*1697C>G:,KCNQ3:NM_001204824.1:3'UTR:MODIFIER:exon15/15:c.*1697C>G:		rs71526238	0.0176	0.0000	0/0/0	0.0042							602232 [KCNQ3 (confirmed) Seizures,benign neonatal,type 2,121201];	RCV000310079.1 [likely benign]; RCV000343865.1 [likely benign]; 			0	9					KCNQ3 (inh=AD pLI=0.99)
chr8	133140755	133140760	TGTGTG	-	hom	wt	hom		QUAL=3782;DP=104,58,115;MQM=59	KCNQ3	3'UTR	KCNQ3:NM_004519.3:3'UTR:MODIFIER:exon15/15:c.*749_*754delCACACA:,KCNQ3:NM_001204824.1:3'UTR:MODIFIER:exon15/15:c.*749_*754delCACACA:	(TG)n	rs201964249	0.0000	0.0000	0/0/0	0.0507							602232 [KCNQ3 (confirmed) Seizures,benign neonatal,type 2,121201];				7	37					KCNQ3 (inh=AD pLI=0.99)
chr8	133140755	133140756	TG	-	wt	hom	wt		QUAL=3782;DP=104,58,115;MQM=60	KCNQ3	3'UTR	KCNQ3:NM_004519.3:3'UTR:MODIFIER:exon15/15:c.*753_*754delCA:,KCNQ3:NM_001204824.1:3'UTR:MODIFIER:exon15/15:c.*753_*754delCA:	(TG)n	rs35230760;rs752316312	0.1486	0.0000	0/0/0	0.1138							602232 [KCNQ3 (confirmed) Seizures,benign neonatal,type 2,121201];	RCV000329060.1 [benign]; 			6	38					KCNQ3 (inh=AD pLI=0.99)
chr8	133883671	133883671	C	T	het	wt	het	gene_blacklist;pred_pathogenic	QUAL=10247;DP=332,320,514;MQM=59	TG	missense	TG:NM_003235.4:missense:MODERATE:exon4/48:c.353C>T:p.Pro118Leu		rs114322847	0.0058	0.0147	19/15/0	0.0151	5.2540	T,T,.	D	D	D,D	24.50	188450 [TG (confirmed) Thyroid dyshormonogenesis 3,274700|Autoimmune thyroid disease,susceptibility to,3,608175];				1	56					TG (inh=AR pLI=0.00)
chr8	133900252	133900252	T	G	het	het	wt	gene_blacklist;pred_pathogenic	QUAL=1826;DP=103,71,70;MQM=59	TG	missense	TG:NM_003235.4:missense:MODERATE:exon10/48:c.2200T>G:p.Ser734Ala		rs180223	0.6763	0.5870	20870/9287/2702	0.5724	6.0760	T,T,.	T	B	T,T	6.49	188450 [TG (confirmed) Thyroid dyshormonogenesis 3,274700|Autoimmune thyroid disease,susceptibility to,3,608175];	RCV000013534.3 [other]; RCV000253912.1 [benign]; RCV000309189.1 [likely benign]; 		COSM4162675	515	750					TG (inh=AR pLI=0.00)
chr8	133900386	133900386	T	C	het	het	wt	gene_blacklist	QUAL=6312;DP=283,209,285;MQM=59	TG	synonymous	TG:NM_003235.4:synonymous:LOW:exon10/48:c.2334T>C:p.Pro778Pro		rs2069550	0.6727	0.5829	20815/9308/2601	0.5768							188450 [TG (confirmed) Thyroid dyshormonogenesis 3,274700|Autoimmune thyroid disease,susceptibility to,3,608175];	RCV000246346.1 [benign]; RCV000331886.1 [likely benign]; 			517	751					TG (inh=AR pLI=0.00)
chr8	133909974	133909974	A	G	het	het	wt	gene_blacklist	QUAL=8746;DP=436,247,343;MQM=59	TG	missense	TG:NM_003235.4:missense:MODERATE:exon12/48:c.3082A>G:p.Met1028Val		rs853326	0.6749	0.5842	21191/9469/2712	0.5782	-0.4530	T,T	T	B	T,T	0.01	188450 [TG (confirmed) Thyroid dyshormonogenesis 3,274700|Autoimmune thyroid disease,susceptibility to,3,608175];	RCV000013535.3 [other]; RCV000254213.1 [benign]; RCV000368266.1 [likely benign]; 		COSM4162676	519	752					TG (inh=AR pLI=0.00)
chr8	133920518	133920518	A	G	hom	hom	het	gene_blacklist;pred_pathogenic	QUAL=15198;DP=232,161,199;MQM=59	TG	missense	TG:NM_003235.4:missense:MODERATE:exon18/48:c.3935A>G:p.Asp1312Gly		rs2069556	0.3988	0.5697	21204/13133/123	0.5544	4.2890	T,T,T	T	B	T,T	0.75	188450 [TG (confirmed) Thyroid dyshormonogenesis 3,274700|Autoimmune thyroid disease,susceptibility to,3,608175];	RCV000241944.1 [benign]; RCV000280505.1 [likely benign]; 		COSM1454960	573	723					TG (inh=AR pLI=0.00)
chr8	133931748	133931748	T	C	hom	hom	het	gene_blacklist	QUAL=18648;DP=358,154,218;MQM=60	TG	synonymous	TG:NM_003235.4:synonymous:LOW:exon21/48:c.4506T>C:p.Ala1502Ala		rs853304	0.4738	0.5915	21933/13093/804	0.5820	-0.6180		T			0.02	188450 [TG (confirmed) Thyroid dyshormonogenesis 3,274700|Autoimmune thyroid disease,susceptibility to,3,608175];	RCV000244917.1 [benign]; RCV000267031.1 [likely benign]; 		COSM150549	575	714					TG (inh=AR pLI=0.00)
chr8	133975283	133975283	G	A	hom	hom	het	gene_blacklist;pred_pathogenic	QUAL=14137;DP=222,139,202;MQM=60	TG	missense	TG:NM_003235.4:missense:MODERATE:exon29/48:c.5512G>A:p.Asp1838Asn		rs2069561	0.3468	0.4846	15551/9018/67	0.4654	0.5280	T,T,D,T,.	T,T	B,B,.	T,T,T,.	3.74	188450 [TG (confirmed) Thyroid dyshormonogenesis 3,274700|Autoimmune thyroid disease,susceptibility to,3,608175];	RCV000242253.1 [benign]; RCV000305066.1 [likely benign]; 		COSM150550	403	723					TG (inh=AR pLI=0.00)
chr8	133984058	133984058	C	T	het	wt	het	gene_blacklist	QUAL=8440;DP=310,294,322;MQM=59	TG	missense	TG:NM_003235.4:missense:MODERATE:exon33/48:c.5995C>T:p.Arg1999Trp		rs2076740	0.3325	0.3226	6808/4063/1350	0.3198	0.0500	T,T,T,T,T,.	T,T	B,B,B,.	T,T,T,T,.	17.87	188450 [TG (confirmed) Thyroid dyshormonogenesis 3,274700|Autoimmune thyroid disease,susceptibility to,3,608175];	RCV000013533.3 [other]; RCV000251808.1 [benign]; RCV000277644.1 [likely benign]; 	CM035973 [CLASS=DP MUT=ALT PHEN="Autoimmune thyroid disease association with" GENE=TG]; 	COSM3982409	210	706					TG (inh=AR pLI=0.00)
chr8	134108453	134108453	C	T	wt	wt	het		QUAL=4564;DP=217,304,374;MQM=60	TG,SLA	synonymous,intron	TG:NM_003235.4:synonymous:LOW:exon43/48:c.7408C>T:p.Leu2470Leu,SLA:NM_001045556.2:intron:MODIFIER:exon1/8:c.-319+6344G>A:,SLA:NM_001045557.2:intron:MODIFIER:exon1/7:c.11+6344G>A:,SLA:NM_001282964.1:intron:MODIFIER:exon1/6:c.11+6344G>A:,SLA:NM_001282965.1:intron:MODIFIER:exon1/6:c.-264+6344G>A:		rs2069568	0.3446	0.4347	12009/7767/204	0.4287	1.5530		T			13.97	188450 [TG (confirmed) Thyroid dyshormonogenesis 3,274700|Autoimmune thyroid disease,susceptibility to,3,608175];	RCV000252113.1 [benign]; RCV000299677.1 [likely benign]; 			324	818					TG (inh=AR pLI=0.00), SLA (inh=n/a pLI=0.72)
chr8	134108546	134108546	T	C	wt	het	het		QUAL=13122;DP=377,451,548;MQM=60	TG,SLA	missense,intron	TG:NM_003235.4:missense:MODERATE:exon43/48:c.7501T>C:p.Trp2501Arg,SLA:NM_001045556.2:intron:MODIFIER:exon1/8:c.-319+6251A>G:,SLA:NM_001045557.2:intron:MODIFIER:exon1/7:c.11+6251A>G:,SLA:NM_001282964.1:intron:MODIFIER:exon1/6:c.11+6251A>G:,SLA:NM_001282965.1:intron:MODIFIER:exon1/6:c.-264+6251A>G:		rs2069569	0.5224	0.5024	16220/9542/3260	0.4984	-0.0180	.,T,T,T,T,T	T,T	.,B,B,B	.,T,T,T,T	0.01	188450 [TG (confirmed) Thyroid dyshormonogenesis 3,274700|Autoimmune thyroid disease,susceptibility to,3,608175];	RCV000244259.1 [benign]; RCV000354501.1 [benign]; 		COSM3763048	455	755					TG (inh=AR pLI=0.00), SLA (inh=n/a pLI=0.72)
chr8	134125682	134125682	G	A	wt	wt	het	gene_blacklist;pred_pathogenic	QUAL=1000;DP=172,91,126;MQM=60	TG	missense	TG:NM_003235.4:missense:MODERATE:exon44/48:c.7589G>A:p.Arg2530Gln		rs1133076	0.5373	0.4976	15712/7964/3181	0.4876	5.1390	T,T,T,T,T	T	B,B,B	T,T,T,T	19.72	188450 [TG (confirmed) Thyroid dyshormonogenesis 3,274700|Autoimmune thyroid disease,susceptibility to,3,608175];	RCV000249422.1 [benign]; RCV000329782.1 [benign]; 	CM045980 [CLASS=DP MUT=REF PHEN="Thyroid cancer increased risk association with" GENE=TG]; 	COSM4162677	358	819					TG (inh=AR pLI=0.00)
chr8	134144113	134144113	C	T	wt	het	wt	gene_blacklist	QUAL=2315;DP=195,186,233;MQM=60	TG	synonymous	TG:NM_003235.4:synonymous:LOW:exon46/48:c.7920C>T:p.Tyr2640Tyr		rs2294024	0.4054	0.4335	12299/8148/1823	0.4305	-0.0750					13.75	188450 [TG (confirmed) Thyroid dyshormonogenesis 3,274700|Autoimmune thyroid disease,susceptibility to,3,608175];	RCV000252575.1 [benign]; RCV000342038.1 [likely benign]; 		COSM150551	367	781					TG (inh=AR pLI=0.00)
chr8	134250165	134250165	A	G	het	het	wt		QUAL=4828;DP=215,175,236;MQM=59	NDRG1	3'UTR	NDRG1:NM_001135242.1:3'UTR:MODIFIER:exon16/16:c.*956T>C:,NDRG1:NM_001258432.1:3'UTR:MODIFIER:exon14/14:c.*956T>C:,NDRG1:NM_001258433.1:3'UTR:MODIFIER:exon15/15:c.*956T>C:,NDRG1:NM_006096.3:3'UTR:MODIFIER:exon16/16:c.*956T>C:		rs1049697	0.8303	0.0000	0/0/0	0.8020							605262 [NDRG1 (provisional) Charcot-Marie-Tooth disease,type 4D,601455];	RCV000270893.1 [benign]; 			146	75					NDRG1 (inh=AR pLI=0.05)
chr8	134250430	134250430	C	T	het	het	wt		QUAL=7645;DP=342,256,366;MQM=59	NDRG1	3'UTR	NDRG1:NM_001135242.1:3'UTR:MODIFIER:exon16/16:c.*691G>A:,NDRG1:NM_001258432.1:3'UTR:MODIFIER:exon14/14:c.*691G>A:,NDRG1:NM_001258433.1:3'UTR:MODIFIER:exon15/15:c.*691G>A:,NDRG1:NM_006096.3:3'UTR:MODIFIER:exon16/16:c.*691G>A:		rs1049694	0.2718	0.0000	0/0/0	0.2940							605262 [NDRG1 (provisional) Charcot-Marie-Tooth disease,type 4D,601455];	RCV000320327.1 [benign]; 			24	98					NDRG1 (inh=AR pLI=0.05)
chr8	134292516	134292516	A	G	hom	het	hom		QUAL=23790;DP=298,246,328;MQM=59	NDRG1	splice_region&intron,intron	NDRG1:NM_001135242.1:splice_region&intron:LOW:exon2/15:c.64-6T>C:,NDRG1:NM_001258433.1:splice_region&intron:LOW:exon2/14:c.-74-6T>C:,NDRG1:NM_006096.3:splice_region&intron:LOW:exon2/15:c.64-6T>C:,NDRG1:NM_001258432.1:intron:MODIFIER:exon1/13:c.-99-15621T>C:		rs2272653	0.6134	0.5635	20102/11176/3883	0.5584							605262 [NDRG1 (provisional) Charcot-Marie-Tooth disease,type 4D,601455];	RCV000254177.1 [benign]; RCV000380925.1 [benign]; 			510	741					NDRG1 (inh=AR pLI=0.05)
chr8	134309134	134309134	G	A	het	het	wt		QUAL=1462;DP=59,62,98;MQM=60	NDRG1	5'UTR,intron	NDRG1:NM_001135242.1:5'UTR:MODIFIER:exon1/16:c.-173C>T:,NDRG1:NM_001258432.1:intron:MODIFIER:exon1/13:c.-100+243C>T:,NDRG1:NM_001258433.1:intron:MODIFIER:exon1/14:c.-156+243C>T:,NDRG1:NM_006096.3:intron:MODIFIER:exon1/15:c.-19+243C>T:		rs10108354	0.0847	0.0000	0/0/0	0.0757							605262 [NDRG1 (provisional) Charcot-Marie-Tooth disease,type 4D,601455];				6	45					NDRG1 (inh=AR pLI=0.05)
chr8	140624798	140624798	-	G	hom	hom	hom		QUAL=27195;DP=228,283,363;MQM=59	KCNK9	non_coding_transcript_exon	KCNK9:NR_104210.1:non_coding_transcript_exon:MODIFIER:exon3/4:n.1308dupC:		rs386414214	1.0000	0.0000	0/0/0	0.9145							605874 [KCNK9 (confirmed) Birk-Barel mental retardation dysmorphism syndrome,612292];	RCV000285741.1 [benign]; 			230	0					KCNK9 (inh=AD pLI=0.13)
chr8	140630990	140630990	A	G	wt	het	het		QUAL=6290;DP=187,210,277;MQM=60	KCNK9	synonymous,non_coding_transcript_exon	KCNK9:NM_001282534.1:synonymous:LOW:exon2/2:c.636T>C:p.Gly212Gly,KCNK9:NR_104210.1:non_coding_transcript_exon:MODIFIER:exon2/4:n.700T>C:		rs2615374	0.7230	0.6586	26690/13289/3800	0.6377							605874 [KCNK9 (confirmed) Birk-Barel mental retardation dysmorphism syndrome,612292];				604	724					KCNK9 (inh=AD pLI=0.13)
chr8	140742772	140742772	C	T	wt	het	wt		QUAL=484;DP=34,47,61;MQM=60	TRAPPC9	3'UTR	TRAPPC9:NM_031466.7:3'UTR:MODIFIER:exon23/23:c.*532G>A:,TRAPPC9:NM_001160372.3:3'UTR:MODIFIER:exon23/23:c.*532G>A:,TRAPPC9:NM_001321646.1:3'UTR:MODIFIER:exon22/22:c.*532G>A:		rs187594197	0.0018	0.0000	0/0/0	0.0069							611966 [TRAPPC9 (provisional) Mental retardation,autosomal recessive 13,613192];	RCV000367806.1 [uncertain significance]; 			0	9					TRAPPC9 (inh=AR pLI=0.00)
chr8	140743200	140743200	G	A	hom	het	het		QUAL=6554;DP=91,132,174;MQM=59	TRAPPC9	3'UTR	TRAPPC9:NM_031466.7:3'UTR:MODIFIER:exon23/23:c.*104C>T:,TRAPPC9:NM_001160372.3:3'UTR:MODIFIER:exon23/23:c.*104C>T:,TRAPPC9:NM_001321646.1:3'UTR:MODIFIER:exon22/22:c.*104C>T:	GA-rich	rs199226	0.2007	0.0000	0/0/0	0.0277							611966 [TRAPPC9 (provisional) Mental retardation,autosomal recessive 13,613192];	RCV000327095.1 [benign]; 			6	61					TRAPPC9 (inh=AR pLI=0.00)
chr8	141310644	141310644	G	A	het	het	wt		QUAL=10928;DP=364,540,677;MQM=60	TRAPPC9	synonymous	TRAPPC9:NM_031466.7:synonymous:LOW:exon11/23:c.1986C>T:p.Asn662Asn,TRAPPC9:NM_001160372.3:synonymous:LOW:exon11/23:c.1692C>T:p.Asn564Asn,TRAPPC9:NM_001321646.1:synonymous:LOW:exon10/22:c.1665C>T:p.Asn555Asn		rs12549048	0.3558	0.2676	5520/1066/285	0.2629	0.2020		T			12.89	611966 [TRAPPC9 (provisional) Mental retardation,autosomal recessive 13,613192];	RCV000118668.3 [other]; RCV000319877.1 [benign]; 			80	445					TRAPPC9 (inh=AR pLI=0.00)
chr8	141381250	141381250	G	A	wt	wt	het	pred_pathogenic	QUAL=810;DP=244,71,74;MQM=60	TRAPPC9	synonymous	TRAPPC9:NM_031466.7:synonymous:LOW:exon8/23:c.1458C>T:p.Tyr486Tyr,TRAPPC9:NM_001160372.3:synonymous:LOW:exon8/23:c.1164C>T:p.Tyr388Tyr,TRAPPC9:NM_001321646.1:synonymous:LOW:exon7/22:c.1137C>T:p.Tyr379Tyr		rs148976893	0.0000	0.0013	0/0/0	0.0010	3.8420					0.49	611966 [TRAPPC9 (provisional) Mental retardation,autosomal recessive 13,613192];	RCV000193435.1 [likely benign]; RCV000397285.1 [uncertain significance]; 			0	10					TRAPPC9 (inh=AR pLI=0.00)
chr8	141445350	141445370	AGAAAACAAAAAACAAAAACC	-	het	het	het		QUAL=10485;DP=184,168,185;MQM=59	TRAPPC9	splice_region&intron	TRAPPC9:NM_031466.7:splice_region&intron:LOW:exon3/22:c.1025-31_1025-11delGGTTTTTGTTTTTTGTTTTCT:,TRAPPC9:NM_001160372.3:splice_region&intron:LOW:exon3/22:c.731-31_731-11delGGTTTTTGTTTTTTGTTTTCT:,TRAPPC9:NM_001321646.1:splice_region&intron:LOW:exon3/21:c.731-31_731-11delGGTTTTTGTTTTTTGTTTTCT:	(AAAACAA)n	rs11267571	0.7768	0.7332	27026/12824/1535	0.6880							611966 [TRAPPC9 (provisional) Mental retardation,autosomal recessive 13,613192];				176	1147					TRAPPC9 (inh=AR pLI=0.00)
chr8	141461062	141461062	G	A	het	het	hom		QUAL=16667;DP=332,241,303;MQM=60	TRAPPC9	synonymous	TRAPPC9:NM_031466.7:synonymous:LOW:exon2/23:c.705C>T:p.Asn235Asn,TRAPPC9:NM_001160372.3:synonymous:LOW:exon2/23:c.411C>T:p.Asn137Asn,TRAPPC9:NM_001321646.1:synonymous:LOW:exon2/22:c.411C>T:p.Asn137Asn		rs3735803	0.4667	0.4680	13536/7670/893	0.4644							611966 [TRAPPC9 (provisional) Mental retardation,autosomal recessive 13,613192];	RCV000118685.3 [other]; RCV000334004.1 [benign]; 			362	770					TRAPPC9 (inh=AR pLI=0.00)
chr8	141461185	141461185	A	G	het	het	hom		QUAL=13227;DP=182,217,271;MQM=60	TRAPPC9	synonymous	TRAPPC9:NM_031466.7:synonymous:LOW:exon2/23:c.582T>C:p.Phe194Phe,TRAPPC9:NM_001160372.3:synonymous:LOW:exon2/23:c.288T>C:p.Phe96Phe,TRAPPC9:NM_001321646.1:synonymous:LOW:exon2/22:c.288T>C:p.Phe96Phe		rs3735802	0.5389	0.5446	18260/10740/1545	0.5388							611966 [TRAPPC9 (provisional) Mental retardation,autosomal recessive 13,613192];	RCV000118681.3 [other]; RCV000384914.1 [benign]; 			509	747					TRAPPC9 (inh=AR pLI=0.00)
chr8	141461266	141461266	A	G	het	het	hom		QUAL=10353;DP=239,178,206;MQM=59	TRAPPC9	synonymous	TRAPPC9:NM_031466.7:synonymous:LOW:exon2/23:c.501T>C:p.Gly167Gly,TRAPPC9:NM_001160372.3:synonymous:LOW:exon2/23:c.207T>C:p.Gly69Gly,TRAPPC9:NM_001321646.1:synonymous:LOW:exon2/22:c.207T>C:p.Gly69Gly		rs3735801	0.5379	0.5439	18207/10738/1546	0.5239							611966 [TRAPPC9 (provisional) Mental retardation,autosomal recessive 13,613192];	RCV000118680.3 [other]; RCV000322051.1 [benign]; 			511	745					TRAPPC9 (inh=AR pLI=0.00)
chr8	143953937	143953937	A	C	het	het	het		QUAL=12017;DP=429,193,273;MQM=60	CYP11B1	3'UTR	CYP11B1:NM_000497.3:3'UTR:MODIFIER:exon9/9:c.*1852T>G:,CYP11B1:NM_001026213.1:3'UTR:MODIFIER:exon8/8:c.*1852T>G:	MLT1A0-int	rs4736312	0.6963	0.0000	0/0/0	0.1073							610613 [CYP11B1 (confirmed) Adrenal hyperplasia,congenital,due to 11-beta-hydroxylase deficiency,202010|Aldosteronism,glucocorticoid-remediable,103900];	RCV000265547.1 [benign]; RCV000364820.1 [benign]; 			69	72					CYP11B1 (inh=AR+AD pLI=0.00)
chr8	143954223	143954223	C	A	het	het	het		QUAL=12749;DP=412,240,270;MQM=60	CYP11B1	3'UTR	CYP11B1:NM_000497.3:3'UTR:MODIFIER:exon9/9:c.*1566G>T:,CYP11B1:NM_001026213.1:3'UTR:MODIFIER:exon8/8:c.*1566G>T:	MLT1A0	rs1134096	0.6961	0.0000	0/0/0	0.1073							610613 [CYP11B1 (confirmed) Adrenal hyperplasia,congenital,due to 11-beta-hydroxylase deficiency,202010|Aldosteronism,glucocorticoid-remediable,103900];	RCV000350010.1 [benign]; RCV000385918.1 [benign]; 			74	74					CYP11B1 (inh=AR+AD pLI=0.00)
chr8	143954290	143954290	G	A	het	het	het		QUAL=14300;DP=443,307,340;MQM=59	CYP11B1	3'UTR	CYP11B1:NM_000497.3:3'UTR:MODIFIER:exon9/9:c.*1499C>T:,CYP11B1:NM_001026213.1:3'UTR:MODIFIER:exon8/8:c.*1499C>T:	MLT1A0	rs1134095	0.6941	0.0000	0/0/0	0.1068							610613 [CYP11B1 (confirmed) Adrenal hyperplasia,congenital,due to 11-beta-hydroxylase deficiency,202010|Aldosteronism,glucocorticoid-remediable,103900];	RCV000347968.1 [benign]; RCV000400210.1 [benign]; 			74	76					CYP11B1 (inh=AR+AD pLI=0.00)
chr8	143954747	143954747	T	C	het	het	het		QUAL=12770;DP=390,263,308;MQM=59	CYP11B1	3'UTR	CYP11B1:NM_000497.3:3'UTR:MODIFIER:exon9/9:c.*1042A>G:,CYP11B1:NM_001026213.1:3'UTR:MODIFIER:exon8/8:c.*1042A>G:		rs7003319	0.6957	0.0000	0/0/0	0.1072							610613 [CYP11B1 (confirmed) Adrenal hyperplasia,congenital,due to 11-beta-hydroxylase deficiency,202010|Aldosteronism,glucocorticoid-remediable,103900];	RCV000343186.1 [benign]; RCV000401464.1 [benign]; 			94	106					CYP11B1 (inh=AR+AD pLI=0.00)
chr8	143954769	143954769	G	A	het	het	het		QUAL=12168;DP=391,270,316;MQM=57	CYP11B1	3'UTR	CYP11B1:NM_000497.3:3'UTR:MODIFIER:exon9/9:c.*1020C>T:,CYP11B1:NM_001026213.1:3'UTR:MODIFIER:exon8/8:c.*1020C>T:		rs5017238	0.6957	0.0000	0/0/0	0.6276							610613 [CYP11B1 (confirmed) Adrenal hyperplasia,congenital,due to 11-beta-hydroxylase deficiency,202010|Aldosteronism,glucocorticoid-remediable,103900];	RCV000297239.1 [benign]; RCV000356758.1 [benign]; 			94	106					CYP11B1 (inh=AR+AD pLI=0.00)
chr8	143955051	143955051	C	T	het	het	het		QUAL=21317;DP=311,628,781;MQM=59	CYP11B1	3'UTR	CYP11B1:NM_000497.3:3'UTR:MODIFIER:exon9/9:c.*738G>A:,CYP11B1:NM_001026213.1:3'UTR:MODIFIER:exon8/8:c.*738G>A:		rs5304	0.6957	0.0000	0/0/0	0.6221							610613 [CYP11B1 (confirmed) Adrenal hyperplasia,congenital,due to 11-beta-hydroxylase deficiency,202010|Aldosteronism,glucocorticoid-remediable,103900];	RCV000284379.1 [benign]; RCV000383461.1 [benign]; 			95	107					CYP11B1 (inh=AR+AD pLI=0.00)
chr8	143955095	143955095	A	G	het	het	het		QUAL=18874;DP=393,551,672;MQM=59	CYP11B1	3'UTR	CYP11B1:NM_000497.3:3'UTR:MODIFIER:exon9/9:c.*694T>C:,CYP11B1:NM_001026213.1:3'UTR:MODIFIER:exon8/8:c.*694T>C:		rs5303	0.7462	0.0000	0/0/0	0.1090							610613 [CYP11B1 (confirmed) Adrenal hyperplasia,congenital,due to 11-beta-hydroxylase deficiency,202010|Aldosteronism,glucocorticoid-remediable,103900];	RCV000282385.1 [benign]; RCV000394822.1 [benign]; 			95	107					CYP11B1 (inh=AR+AD pLI=0.00)
chr8	143955273	143955273	T	C	het	het	het		QUAL=20125;DP=453,525,655;MQM=59	CYP11B1	3'UTR	CYP11B1:NM_000497.3:3'UTR:MODIFIER:exon9/9:c.*516A>G:,CYP11B1:NM_001026213.1:3'UTR:MODIFIER:exon8/8:c.*516A>G:		rs5301	0.5745	0.0000	0/0/0	0.0907							610613 [CYP11B1 (confirmed) Adrenal hyperplasia,congenital,due to 11-beta-hydroxylase deficiency,202010|Aldosteronism,glucocorticoid-remediable,103900];	RCV000273065.1 [benign]; RCV000363072.1 [benign]; 			67	115					CYP11B1 (inh=AR+AD pLI=0.00)
chr8	143955318	143955318	T	G	het	het	het		QUAL=17586;DP=388,508,603;MQM=59	CYP11B1	3'UTR	CYP11B1:NM_000497.3:3'UTR:MODIFIER:exon9/9:c.*471A>C:,CYP11B1:NM_001026213.1:3'UTR:MODIFIER:exon8/8:c.*471A>C:		rs12543598	0.7512	0.0000	0/0/0	0.6429							610613 [CYP11B1 (confirmed) Adrenal hyperplasia,congenital,due to 11-beta-hydroxylase deficiency,202010|Aldosteronism,glucocorticoid-remediable,103900];	RCV000259195.1 [benign]; RCV000379427.1 [benign]; 			95	107					CYP11B1 (inh=AR+AD pLI=0.00)
chr8	143955471	143955471	T	C	het	het	het		QUAL=12469;DP=304,292,378;MQM=59	CYP11B1	3'UTR	CYP11B1:NM_000497.3:3'UTR:MODIFIER:exon9/9:c.*318A>G:,CYP11B1:NM_001026213.1:3'UTR:MODIFIER:exon8/8:c.*318A>G:		rs5299	0.6957	0.0000	0/0/0	0.1066							610613 [CYP11B1 (confirmed) Adrenal hyperplasia,congenital,due to 11-beta-hydroxylase deficiency,202010|Aldosteronism,glucocorticoid-remediable,103900];	RCV000296570.1 [benign]; RCV000388596.1 [benign]; 			95	107					CYP11B1 (inh=AR+AD pLI=0.00)
chr8	143960597	143960597	G	A	het	het	het		QUAL=10335;DP=127,302,410;MQM=59	CYP11B1	synonymous	CYP11B1:NM_000497.3:synonymous:LOW:exon2/9:c.246C>T:p.Asp82Asp,CYP11B1:NM_001026213.1:synonymous:LOW:exon2/8:c.246C>T:p.Asp82Asp		rs5283	0.3027	0.3979	10240/6426/64	0.3935							610613 [CYP11B1 (confirmed) Adrenal hyperplasia,congenital,due to 11-beta-hydroxylase deficiency,202010|Aldosteronism,glucocorticoid-remediable,103900];	RCV000293653.1 [benign]; RCV000385596.1 [benign]; 		COSM4162721	314	763					CYP11B1 (inh=AR+AD pLI=0.00)
chr8	143961005	143961005	T	C	het	het	het		QUAL=7892;DP=182,239,242;MQM=59	CYP11B1	synonymous	CYP11B1:NM_000497.3:synonymous:LOW:exon1/9:c.225A>G:p.Leu75Leu,CYP11B1:NM_001026213.1:synonymous:LOW:exon1/8:c.225A>G:p.Leu75Leu		rs6410	0.5841	0.5724	20338/9825/996	0.5663							610613 [CYP11B1 (confirmed) Adrenal hyperplasia,congenital,due to 11-beta-hydroxylase deficiency,202010|Aldosteronism,glucocorticoid-remediable,103900];	RCV000309802.1 [benign]; RCV000396739.1 [benign]; 			539	756					CYP11B1 (inh=AR+AD pLI=0.00)
chr8	143992218	143992218	A	G	het	het	het		QUAL=16719;DP=404,400,476;MQM=59	CYP11B2	3'UTR	CYP11B2:NM_000498.3:3'UTR:MODIFIER:exon9/9:c.*1178T>C:		rs3802228	0.5988	0.0000	0/0/0	0.5367							124080 [CYP11B2 (confirmed) Hypoaldosteronism,congenital,due to CMO II deficiency,610600|Hypoaldosteronism,congenital,due to CMO I deficiency,203400|Low renin hypertension,susceptibility to|Aldosterone to renin ratio raised];	RCV000263179.1 [benign]; RCV000330291.1 [benign]; RCV000387104.1 [benign]; 			86	109					CYP11B2 (inh=AR pLI=0.00)
chr8	143992661	143992661	C	T	het	het	het		QUAL=20623;DP=363,698,763;MQM=59	CYP11B2	3'UTR	CYP11B2:NM_000498.3:3'UTR:MODIFIER:exon9/9:c.*735G>A:		rs28491316	0.3099	0.0000	0/0/0	0.3790							124080 [CYP11B2 (confirmed) Hypoaldosteronism,congenital,due to CMO II deficiency,610600|Hypoaldosteronism,congenital,due to CMO I deficiency,203400|Low renin hypertension,susceptibility to|Aldosterone to renin ratio raised];	RCV000274392.1 [benign]; RCV000332815.1 [benign]; RCV000387341.1 [benign]; 			50	120					CYP11B2 (inh=AR pLI=0.00)
chr8	143992864	143992864	C	A	het	het	het		QUAL=20981;DP=463,572,694;MQM=59	CYP11B2	3'UTR	CYP11B2:NM_000498.3:3'UTR:MODIFIER:exon9/9:c.*532G>T:		rs3802230	0.5958	0.0000	0/0/0	0.0857							124080 [CYP11B2 (confirmed) Hypoaldosteronism,congenital,due to CMO II deficiency,610600|Hypoaldosteronism,congenital,due to CMO I deficiency,203400|Low renin hypertension,susceptibility to|Aldosterone to renin ratio raised];	RCV000306434.1 [benign]; RCV000346205.1 [benign]; RCV000394920.1 [benign]; 			86	109					CYP11B2 (inh=AR pLI=0.00)
chr8	143993101	143993101	-	GGA	het	het	het		QUAL=8624;DP=261,232,269;MQM=59	CYP11B2	3'UTR	CYP11B2:NM_000498.3:3'UTR:MODIFIER:exon9/9:c.*292_*294dupTCC:		rs377036717;rs3839864	0.7748	0.0000	0/0/0	0.5847							124080 [CYP11B2 (confirmed) Hypoaldosteronism,congenital,due to CMO II deficiency,610600|Hypoaldosteronism,congenital,due to CMO I deficiency,203400|Low renin hypertension,susceptibility to|Aldosterone to renin ratio raised];	RCV000284409.1 [benign]; RCV000320734.1 [benign]; RCV000378643.1 [benign]; 			97	105					CYP11B2 (inh=AR pLI=0.00)
chr8	143993157	143993157	A	G	hom	hom	hom		QUAL=22709;DP=217,264,250;MQM=59	CYP11B2	3'UTR	CYP11B2:NM_000498.3:3'UTR:MODIFIER:exon9/9:c.*239T>C:		rs9297975	0.9990	0.0000	0/0/0	0.1496							124080 [CYP11B2 (confirmed) Hypoaldosteronism,congenital,due to CMO II deficiency,610600|Hypoaldosteronism,congenital,due to CMO I deficiency,203400|Low renin hypertension,susceptibility to|Aldosterone to renin ratio raised];	RCV000289248.1 [benign]; RCV000344283.1 [benign]; RCV000384561.1 [benign]; 			230	0					CYP11B2 (inh=AR pLI=0.00)
chr8	143993315	143993315	C	T	wt	het	wt		QUAL=4759;DP=195,374,487;MQM=59	CYP11B2	3'UTR	CYP11B2:NM_000498.3:3'UTR:MODIFIER:exon9/9:c.*81G>A:		rs3097	0.1322	0.0000	0/0/0	0.0446							124080 [CYP11B2 (confirmed) Hypoaldosteronism,congenital,due to CMO II deficiency,610600|Hypoaldosteronism,congenital,due to CMO I deficiency,203400|Low renin hypertension,susceptibility to|Aldosterone to renin ratio raised];	RCV000301190.1 [benign]; RCV000356040.1 [benign]; RCV000393363.1 [benign]; 			11	79					CYP11B2 (inh=AR pLI=0.00)
chr8	143994702	143994702	G	T	het	het	het		QUAL=4466;DP=62,138,166;MQM=50	CYP11B2	splice_region&synonymous	CYP11B2:NM_000498.3:splice_region&synonymous:LOW:exon6/9:c.1120C>A:p.Arg374Arg		rs4538	0.6076	0.5922	21108/10299/1112	0.5363							124080 [CYP11B2 (confirmed) Hypoaldosteronism,congenital,due to CMO II deficiency,610600|Hypoaldosteronism,congenital,due to CMO I deficiency,203400|Low renin hypertension,susceptibility to|Aldosterone to renin ratio raised];	RCV000294441.1 [benign]; RCV000334245.1 [benign]; RCV000388744.1 [benign]; 		COSM454129	590	717					CYP11B2 (inh=AR pLI=0.00)
chr8	143995761	143995761	C	T	hom	hom	hom		QUAL=34663;DP=259,347,491;MQM=59	CYP11B2	synonymous	CYP11B2:NM_000498.3:synonymous:LOW:exon5/9:c.873G>A:p.Ala291Ala		rs4536	0.8235	0.9094	51128/31890/4646	0.8896							124080 [CYP11B2 (confirmed) Hypoaldosteronism,congenital,due to CMO II deficiency,610600|Hypoaldosteronism,congenital,due to CMO I deficiency,203400|Low renin hypertension,susceptibility to|Aldosterone to renin ratio raised];	RCV000263084.1 [benign]; RCV000315890.1 [benign]; RCV000354330.1 [benign]; 			1434	123					CYP11B2 (inh=AR pLI=0.00)
chr8	143996539	143996539	T	C	het	het	het		QUAL=10762;DP=166,320,422;MQM=54	CYP11B2	missense	CYP11B2:NM_000498.3:missense:MODERATE:exon3/9:c.518A>G:p.Lys173Arg		rs4539	0.3464	0.4189	10586/6607/276	0.3638	-0.6680	T	T	B	T	0.01	124080 [CYP11B2 (confirmed) Hypoaldosteronism,congenital,due to CMO II deficiency,610600|Hypoaldosteronism,congenital,due to CMO I deficiency,203400|Low renin hypertension,susceptibility to|Aldosterone to renin ratio raised];	RCV000269208.1 [benign]; RCV000307908.1 [benign]; RCV000366140.1 [benign]; 	CM962423 [CLASS=DP MUT=ALT PHEN="Low renin hypertension association with" GENE=CYP11B2]; 	COSM4006860	347	760					CYP11B2 (inh=AR pLI=0.00)
chr8	143996553	143996553	G	A	het	het	het		QUAL=11254;DP=196,315,424;MQM=55	CYP11B2	synonymous	CYP11B2:NM_000498.3:synonymous:LOW:exon3/9:c.504C>T:p.Phe168Phe		rs4546	0.3454	0.4189	10689/6665/273	0.3680							124080 [CYP11B2 (confirmed) Hypoaldosteronism,congenital,due to CMO II deficiency,610600|Hypoaldosteronism,congenital,due to CMO I deficiency,203400|Low renin hypertension,susceptibility to|Aldosterone to renin ratio raised];	RCV000273968.1 [benign]; RCV000331401.1 [benign]; RCV000370864.1 [benign]; 		COSM1569160	347	759					CYP11B2 (inh=AR pLI=0.00)
chr8	144989452	144989452	T	C	het	wt	het	gene_blacklist	QUAL=1198;DP=23,53,66;MQM=60	PLEC	3'UTR	PLEC:NM_201380.3:3'UTR:MODIFIER:exon32/32:c.*893A>G:,PLEC:NM_201384.2:3'UTR:MODIFIER:exon32/32:c.*893A>G:,PLEC:NM_201383.2:3'UTR:MODIFIER:exon32/32:c.*893A>G:,PLEC:NM_201382.3:3'UTR:MODIFIER:exon32/32:c.*893A>G:,PLEC:NM_201381.2:3'UTR:MODIFIER:exon32/32:c.*893A>G:,PLEC:NM_201379.2:3'UTR:MODIFIER:exon32/32:c.*893A>G:,PLEC:NM_201378.3:3'UTR:MODIFIER:exon32/32:c.*893A>G:,PLEC:NM_000445.4:3'UTR:MODIFIER:exon33/33:c.*893A>G:		rs189205952	0.0006	0.0000	0/0/0	0.0008							601282 [PLEC (confirmed) Epidermolysis bullosa simplex with muscular dystrophy,226670|Epidermolysis bullosa simplex,Ogna type,131950|Epidermolysis bullosa simplex with pyloric atresia,612138|Muscular dystrophy,limb-girdle,type 2Q,613723|Epidermolysis bullosa simplex with nail dystrophy,616487];				0	2					PLEC (inh=AR+AD pLI=0.02)
chr8	144992103	144992103	T	C	wt	het	wt	gene_blacklist	QUAL=1816;DP=65,163,228;MQM=60	PLEC	synonymous	PLEC:NM_201380.3:synonymous:LOW:exon32/32:c.12297A>G:p.Thr4099Thr,PLEC:NM_201384.2:synonymous:LOW:exon32/32:c.11886A>G:p.Thr3962Thr,PLEC:NM_201383.2:synonymous:LOW:exon32/32:c.11898A>G:p.Thr3966Thr,PLEC:NM_201382.3:synonymous:LOW:exon32/32:c.11886A>G:p.Thr3962Thr,PLEC:NM_201381.2:synonymous:LOW:exon32/32:c.11790A>G:p.Thr3930Thr,PLEC:NM_201379.2:synonymous:LOW:exon32/32:c.11820A>G:p.Thr3940Thr,PLEC:NM_201378.3:synonymous:LOW:exon32/32:c.11844A>G:p.Thr3948Thr,PLEC:NM_000445.4:synonymous:LOW:exon33/33:c.11967A>G:p.Thr3989Thr		rs6558406	0.4904	0.4343	12670/6447/3623	0.4262							601282 [PLEC (confirmed) Epidermolysis bullosa simplex with muscular dystrophy,226670|Epidermolysis bullosa simplex,Ogna type,131950|Epidermolysis bullosa simplex with pyloric atresia,612138|Muscular dystrophy,limb-girdle,type 2Q,613723|Epidermolysis bullosa simplex with nail dystrophy,616487];	RCV000078840.9 [other]; 		COSM3763120, COSM454175, COSM1489094, COSM3763121, COSM3763119, COSM454174	298	766					PLEC (inh=AR+AD pLI=0.02)
chr8	144995964	144995964	G	A	het	wt	het	gene_blacklist	QUAL=4193;DP=146,210,265;MQM=59	PLEC	synonymous	PLEC:NM_201380.3:synonymous:LOW:exon32/32:c.8436C>T:p.Gly2812Gly,PLEC:NM_201384.2:synonymous:LOW:exon32/32:c.8025C>T:p.Gly2675Gly,PLEC:NM_201383.2:synonymous:LOW:exon32/32:c.8037C>T:p.Gly2679Gly,PLEC:NM_201382.3:synonymous:LOW:exon32/32:c.8025C>T:p.Gly2675Gly,PLEC:NM_201381.2:synonymous:LOW:exon32/32:c.7929C>T:p.Gly2643Gly,PLEC:NM_201379.2:synonymous:LOW:exon32/32:c.7959C>T:p.Gly2653Gly,PLEC:NM_201378.3:synonymous:LOW:exon32/32:c.7983C>T:p.Gly2661Gly,PLEC:NM_000445.4:synonymous:LOW:exon33/33:c.8106C>T:p.Gly2702Gly		rs35139934	0.0276	0.0590	288/244/1	0.0556							601282 [PLEC (confirmed) Epidermolysis bullosa simplex with muscular dystrophy,226670|Epidermolysis bullosa simplex,Ogna type,131950|Epidermolysis bullosa simplex with pyloric atresia,612138|Muscular dystrophy,limb-girdle,type 2Q,613723|Epidermolysis bullosa simplex with nail dystrophy,616487];	RCV000117978.5 [other]; 		COSM4162792, COSM4162791, COSM4162789, COSM4162790, COSM4162793, COSM4162788	27	239					PLEC (inh=AR+AD pLI=0.02)
chr8	144997503	144997503	G	A	het	het	wt	gene_blacklist	QUAL=3304;DP=102,210,259;MQM=60	PLEC	synonymous	PLEC:NM_201380.3:synonymous:LOW:exon31/32:c.7005C>T:p.Thr2335Thr,PLEC:NM_201384.2:synonymous:LOW:exon31/32:c.6594C>T:p.Thr2198Thr,PLEC:NM_201383.2:synonymous:LOW:exon31/32:c.6606C>T:p.Thr2202Thr,PLEC:NM_201382.3:synonymous:LOW:exon31/32:c.6594C>T:p.Thr2198Thr,PLEC:NM_201381.2:synonymous:LOW:exon31/32:c.6498C>T:p.Thr2166Thr,PLEC:NM_201379.2:synonymous:LOW:exon31/32:c.6528C>T:p.Thr2176Thr,PLEC:NM_201378.3:synonymous:LOW:exon31/32:c.6552C>T:p.Thr2184Thr,PLEC:NM_000445.4:synonymous:LOW:exon32/33:c.6675C>T:p.Thr2225Thr		rs144242254	0.0016	0.0013	1/0/0	0.0012							601282 [PLEC (confirmed) Epidermolysis bullosa simplex with muscular dystrophy,226670|Epidermolysis bullosa simplex,Ogna type,131950|Epidermolysis bullosa simplex with pyloric atresia,612138|Muscular dystrophy,limb-girdle,type 2Q,613723|Epidermolysis bullosa simplex with nail dystrophy,616487];	RCV000177614.2 [uncertain significance]; 			1	10					PLEC (inh=AR+AD pLI=0.02)
chr8	145004546	145004546	G	A	hom	hom	hom	low_DP;gene_blacklist	QUAL=1003;DP=14,11,12;MQM=60	PLEC	splice_region&intron	PLEC:NM_201380.3:splice_region&intron:LOW:exon20/31:c.2868+6C>T:,PLEC:NM_201384.2:splice_region&intron:LOW:exon20/31:c.2457+6C>T:,PLEC:NM_201383.2:splice_region&intron:LOW:exon20/31:c.2469+6C>T:,PLEC:NM_201382.3:splice_region&intron:LOW:exon20/31:c.2457+6C>T:,PLEC:NM_201381.2:splice_region&intron:LOW:exon20/31:c.2361+6C>T:,PLEC:NM_201379.2:splice_region&intron:LOW:exon20/31:c.2391+6C>T:,PLEC:NM_201378.3:splice_region&intron:LOW:exon20/31:c.2415+6C>T:,PLEC:NM_000445.4:splice_region&intron:LOW:exon21/32:c.2538+6C>T:		rs11780911	0.5719	0.7411	15015/10543/338	0.5965							601282 [PLEC (confirmed) Epidermolysis bullosa simplex with muscular dystrophy,226670|Epidermolysis bullosa simplex,Ogna type,131950|Epidermolysis bullosa simplex with pyloric atresia,612138|Muscular dystrophy,limb-girdle,type 2Q,613723|Epidermolysis bullosa simplex with nail dystrophy,616487];	RCV000117959.7 [other]; 			964	513					PLEC (inh=AR+AD pLI=0.02)
chr8	145024450	145024450	C	T	het	het	wt	gene_blacklist;pred_pathogenic	QUAL=4700;DP=106,261,329;MQM=59	PLEC	missense,intron	PLEC:NM_201380.3:missense:MODERATE:exon1/32:c.425G>A:p.Arg142Gln,PLEC:NM_201379.2:intron:MODIFIER:exon1/31:c.46+3444G>A:,PLEC:NM_201378.3:intron:MODIFIER:exon1/31:c.71-11590G>A:,PLEC:NM_000445.4:intron:MODIFIER:exon2/32:c.194-11590G>A:		rs558227477	0.0000	0.0000	0/0/0	0.0001	2.5110	D	T	B	T	23.50	601282 [PLEC (confirmed) Epidermolysis bullosa simplex with muscular dystrophy,226670|Epidermolysis bullosa simplex,Ogna type,131950|Epidermolysis bullosa simplex with pyloric atresia,612138|Muscular dystrophy,limb-girdle,type 2Q,613723|Epidermolysis bullosa simplex with nail dystrophy,616487];				0	2					PLEC (inh=AR+AD pLI=0.02)
chr8	145699382	145699384	CTC	-	het	het	wt		QUAL=7327;DP=276,369,459;MQM=58	KIFC2,FOXH1	3'UTR	KIFC2:NM_145754.3:3'UTR:MODIFIER:exon17/17:c.*551_*553delCCT:,FOXH1:NM_003923.2:3'UTR:MODIFIER:exon3/3:c.*237_*239delGAG:		rs550365735	0.0012	0.0000	0/0/0	0.0006								RCV000283821.1 [uncertain significance]; 			0	2					KIFC2 (inh=n/a pLI=0.00), FOXH1 (inh=n/a pLI=0.01)
chr8	145699601	145699601	T	C	hom	hom	hom		QUAL=17184;DP=157,185,217;MQM=59	FOXH1	3'UTR	FOXH1:NM_003923.2:3'UTR:MODIFIER:exon3/3:c.*20A>G:		rs2721176	0.9457	0.9709	42177/25590/3618	0.8869								RCV000252700.2 [benign]; RCV000402838.1 [benign]; 			944	9					FOXH1 (inh=n/a pLI=0.01)
chr8	145700346	145700346	T	A	het	wt	het	pred_pathogenic	QUAL=1709;DP=64,122,116;MQM=60	FOXH1	missense	FOXH1:NM_003923.2:missense:MODERATE:exon3/3:c.373A>T:p.Thr125Ser		rs112028242	0.0266	0.0081	30/0/30	0.0066	2.3370	T,T	T	D	D	23.20		RCV000177182.2 [benign]; RCV000376248.1 [likely benign]; 			0	10					FOXH1 (inh=n/a pLI=0.01)
chr8	145701453	145701453	A	C	hom	hom	hom	low_DP	QUAL=2881;DP=44,17,34;MQM=59	FOXH1	5'UTR_premature_start_codon_gain,5'UTR	FOXH1:NM_003923.2:5'UTR_premature_start_codon_gain:LOW:exon1/3:c.-314T>G:,FOXH1:NM_003923.2:5'UTR:MODIFIER:exon1/3:c.-314T>G:		rs750472	0.4443	0.0000	0/0/0	0.4519								RCV000298563.1 [benign]; 			66	108					FOXH1 (inh=n/a pLI=0.01)
chr9	271638	271638	C	T	het	hom	wt	pred_pathogenic	QUAL=14394;DP=356,301,322;MQM=60	DOCK8	missense	DOCK8:NM_203447.3:missense:MODERATE:exon2/48:c.65C>T:p.Ala22Val		rs506121	0.3077	0.3245	1198/518/103	0.1090	1.4180	D,D	T	B	T	24.80	611432 [DOCK8 (provisional) Hyper-IgE recurrent infection syndrome,autosomal recessive,243700];	RCV000150504.3 [benign]; RCV000210052.1 [benign]; RCV000295061.1 [benign]; 		COSM3982814	164	689					DOCK8 (inh=AR pLI=0.00)
chr9	286491	286491	G	A	het	het	het	pred_pathogenic	QUAL=7367;DP=188,192,275;MQM=60	DOCK8	missense,5'UTR	DOCK8:NM_203447.3:missense:MODERATE:exon3/48:c.187G>A:p.Asp63Asn,DOCK8:NM_001190458.1:5'UTR:MODIFIER:exon2/46:c.-18G>A:,DOCK8:NM_001193536.1:5'UTR:MODIFIER:exon2/47:c.-18G>A:		rs3209441	0.0701	0.1234	1179/957/7	0.1237	9.4790	D,T	T	D	T	32.00	611432 [DOCK8 (provisional) Hyper-IgE recurrent infection syndrome,autosomal recessive,243700];	RCV000150505.3 [benign]; RCV000276708.1 [likely benign]; 			53	385					DOCK8 (inh=AR pLI=0.00)
chr9	286593	286593	C	A	het	het	het	pred_pathogenic	QUAL=11803;DP=277,228,321;MQM=60	DOCK8	missense	DOCK8:NM_203447.3:missense:MODERATE:exon3/48:c.289C>A:p.Pro97Thr,DOCK8:NM_001190458.1:missense:MODERATE:exon2/46:c.85C>A:p.Pro29Thr,DOCK8:NM_001193536.1:missense:MODERATE:exon2/47:c.85C>A:p.Pro29Thr		rs529208	0.5298	0.5206	16792/8156/852	0.5158	3.1490	D,D,D,T,T,D	T	D,P,P	T,T,T,T,T	23.60	611432 [DOCK8 (provisional) Hyper-IgE recurrent infection syndrome,autosomal recessive,243700];	RCV000155526.2 [benign]; RCV000210057.1 [benign]; RCV000273069.1 [benign]; 		COSM3763875, COSM3763874	384	750					DOCK8 (inh=AR pLI=0.00)
chr9	312124	312124	T	C	het	het	het		QUAL=8963;DP=142,267,282;MQM=59	DOCK8	synonymous	DOCK8:NM_203447.3:synonymous:LOW:exon6/48:c.699T>C:p.Asn233Asn,DOCK8:NM_001190458.1:synonymous:LOW:exon5/46:c.495T>C:p.Asn165Asn,DOCK8:NM_001193536.1:synonymous:LOW:exon5/47:c.495T>C:p.Asn165Asn		rs2039045	0.1643	0.1681	1905/1074/344	0.1667							611432 [DOCK8 (provisional) Hyper-IgE recurrent infection syndrome,autosomal recessive,243700];	RCV000150506.3 [benign]; RCV000314699.1 [benign]; 			56	471					DOCK8 (inh=AR pLI=0.00)
chr9	334337	334337	A	G	het	hom	het		QUAL=9217;DP=211,148,188;MQM=60	DOCK8	missense	DOCK8:NM_203447.3:missense:MODERATE:exon11/48:c.1238A>G:p.Asn413Ser,DOCK8:NM_001190458.1:missense:MODERATE:exon10/46:c.1034A>G:p.Asn345Ser,DOCK8:NM_001193536.1:missense:MODERATE:exon10/47:c.1034A>G:p.Asn345Ser		rs10970979	0.1997	0.2488	4204/3002/270	0.2316	0.4170	T,T,T,T	T	B,B	T,T,T	7.69	611432 [DOCK8 (provisional) Hyper-IgE recurrent infection syndrome,autosomal recessive,243700];	RCV000150508.2 [benign]; RCV000364547.1 [benign]; 		COSM3765452, COSM3765451	159	656					DOCK8 (inh=AR pLI=0.00)
chr9	370244	370244	A	G	het	hom	het		QUAL=20135;DP=406,301,408;MQM=60	DOCK8	synonymous	DOCK8:NM_203447.3:synonymous:LOW:exon16/48:c.1812A>G:p.Lys604Lys,DOCK8:NM_001190458.1:synonymous:LOW:exon15/46:c.1608A>G:p.Lys536Lys,DOCK8:NM_001193536.1:synonymous:LOW:exon15/47:c.1608A>G:p.Lys536Lys		rs913703	0.2159	0.2226	3228/1843/421	0.2196							611432 [DOCK8 (provisional) Hyper-IgE recurrent infection syndrome,autosomal recessive,243700];	RCV000155528.3 [benign]; RCV000377272.1 [benign]; 		COSM3763926, COSM3763925	104	569					DOCK8 (inh=AR pLI=0.00)
chr9	377111	377111	G	C	het	hom	het		QUAL=5599;DP=167,97,135;MQM=59	DOCK8	synonymous	DOCK8:NM_203447.3:synonymous:LOW:exon20/48:c.2340G>C:p.Leu780Leu,DOCK8:NM_001190458.1:synonymous:LOW:exon19/46:c.2136G>C:p.Leu712Leu,DOCK8:NM_001193536.1:synonymous:LOW:exon19/47:c.2136G>C:p.Leu712Leu		rs10814431	0.2286	0.2332	3272/1891/414	0.2273							611432 [DOCK8 (provisional) Hyper-IgE recurrent infection syndrome,autosomal recessive,243700];	RCV000150510.3 [benign]; RCV000296192.1 [benign]; 		COSM3763936, COSM3763935	112	576					DOCK8 (inh=AR pLI=0.00)
chr9	390512	390512	C	T	het	hom	het		QUAL=20055;DP=324,321,372;MQM=59	DOCK8	synonymous	DOCK8:NM_203447.3:synonymous:LOW:exon24/48:c.2916C>T:p.Thr972Thr,DOCK8:NM_001190458.1:synonymous:LOW:exon22/46:c.2616C>T:p.Thr872Thr,DOCK8:NM_001193536.1:synonymous:LOW:exon23/47:c.2712C>T:p.Thr904Thr		rs2297075	0.2550	0.2344	3600/1858/730	0.2318							611432 [DOCK8 (provisional) Hyper-IgE recurrent infection syndrome,autosomal recessive,243700];	RCV000155529.3 [benign]; RCV000379965.1 [benign]; 		COSM1179612, COSM1179613	105	567					DOCK8 (inh=AR pLI=0.00)
chr9	421032	421032	C	G	wt	wt	het		QUAL=4919;DP=206,333,397;MQM=60	DOCK8	synonymous	DOCK8:NM_203447.3:synonymous:LOW:exon32/48:c.4107C>G:p.Leu1369Leu,DOCK8:NM_001190458.1:synonymous:LOW:exon30/46:c.3807C>G:p.Leu1269Leu,DOCK8:NM_001193536.1:synonymous:LOW:exon31/47:c.3903C>G:p.Leu1301Leu		rs2297079	0.3918	0.5094	17056/12506/154	0.5112							611432 [DOCK8 (provisional) Hyper-IgE recurrent infection syndrome,autosomal recessive,243700];	RCV000155533.2 [benign]; RCV000210048.1 [benign]; RCV000342888.1 [benign]; 		COSM3763947, COSM3763946	555	710					DOCK8 (inh=AR pLI=0.00)
chr9	429719	429719	T	C	hom	hom	hom		QUAL=26415;DP=294,219,306;MQM=60	DOCK8	synonymous	DOCK8:NM_203447.3:synonymous:LOW:exon36/48:c.4491T>C:p.Phe1497Phe,DOCK8:NM_001190458.1:synonymous:LOW:exon34/46:c.4191T>C:p.Phe1397Phe,DOCK8:NM_001193536.1:synonymous:LOW:exon35/47:c.4287T>C:p.Phe1429Phe		rs7854035	0.9994	0.9978	60443/33169/5196	0.9661							611432 [DOCK8 (provisional) Hyper-IgE recurrent infection syndrome,autosomal recessive,243700];	RCV000155534.1 [benign]; 			1559	6					DOCK8 (inh=AR pLI=0.00)
chr9	432330	432330	C	G	hom	het	hom		QUAL=17048;DP=209,192,255;MQM=60	DOCK8	splice_region&intron	DOCK8:NM_203447.3:splice_region&intron:LOW:exon37/47:c.4785+6C>G:,DOCK8:NM_001190458.1:splice_region&intron:LOW:exon35/45:c.4485+6C>G:,DOCK8:NM_001193536.1:splice_region&intron:LOW:exon36/46:c.4581+6C>G:		rs7036567	0.7143	0.7577	35655/19625/1209	0.7405							611432 [DOCK8 (provisional) Hyper-IgE recurrent infection syndrome,autosomal recessive,243700];	RCV000150514.2 [benign]; RCV000403442.1 [benign]; 			889	557					DOCK8 (inh=AR pLI=0.00)
chr9	433978	433978	A	G	hom	het	hom		QUAL=20539;DP=261,216,299;MQM=60	DOCK8	splice_region&intron	DOCK8:NM_203447.3:splice_region&intron:LOW:exon38/47:c.4886+3A>G:,DOCK8:NM_001190458.1:splice_region&intron:LOW:exon36/45:c.4586+3A>G:,DOCK8:NM_001193536.1:splice_region&intron:LOW:exon37/46:c.4682+3A>G:		rs2360712	0.7210	0.7588	35664/19535/1311	0.7420							611432 [DOCK8 (provisional) Hyper-IgE recurrent infection syndrome,autosomal recessive,243700];	RCV000150515.2 [benign]; RCV000309557.1 [benign]; 			882	564					DOCK8 (inh=AR pLI=0.00)
chr9	441952	441952	G	A	het	wt	hom		QUAL=9539;DP=276,161,199;MQM=60	DOCK8	synonymous	DOCK8:NM_203447.3:synonymous:LOW:exon42/48:c.5433G>A:p.Glu1811Glu,DOCK8:NM_001190458.1:synonymous:LOW:exon40/46:c.5133G>A:p.Glu1711Glu,DOCK8:NM_001193536.1:synonymous:LOW:exon41/47:c.5229G>A:p.Glu1743Glu		rs1887957	0.8039	0.8201	41298/22413/1852	0.8018							611432 [DOCK8 (provisional) Hyper-IgE recurrent infection syndrome,autosomal recessive,243700];	RCV000155535.2 [benign]; RCV000210054.1 [benign]; RCV000262385.1 [benign]; 		COSM4163900, COSM4163899	1046	455					DOCK8 (inh=AR pLI=0.00)
chr9	449798	449798	G	A	het	wt	het		QUAL=4306;DP=159,125,213;MQM=60	DOCK8	synonymous	DOCK8:NM_203447.3:synonymous:LOW:exon45/48:c.5832G>A:p.Pro1944Pro,DOCK8:NM_001190458.1:synonymous:LOW:exon43/46:c.5532G>A:p.Pro1844Pro,DOCK8:NM_001193536.1:synonymous:LOW:exon44/47:c.5628G>A:p.Pro1876Pro		rs10491684	0.0717	0.0702	370/202/106	0.0687							611432 [DOCK8 (provisional) Hyper-IgE recurrent infection syndrome,autosomal recessive,243700];	RCV000150517.2 [benign]; RCV000298530.1 [likely benign]; 			8	191					DOCK8 (inh=AR pLI=0.00)
chr9	464920	464920	G	A	het	wt	hom		QUAL=12175;DP=442,164,211;MQM=59	DOCK8	3'UTR	DOCK8:NM_203447.3:3'UTR:MODIFIER:exon48/48:c.*701G>A:,DOCK8:NM_001190458.1:3'UTR:MODIFIER:exon46/46:c.*701G>A:,DOCK8:NM_001193536.1:3'UTR:MODIFIER:exon47/47:c.*701G>A:		rs3780338	0.8560	0.0000	0/0/0	0.1482							611432 [DOCK8 (provisional) Hyper-IgE recurrent infection syndrome,autosomal recessive,243700];	RCV000334208.1 [benign]; 			138	83					DOCK8 (inh=AR pLI=0.00)
chr9	470302	470302	T	C	het	wt	het		QUAL=4169;DP=254,84,114;MQM=59	KANK1	5'UTR	KANK1:NM_001256876.1:5'UTR:MODIFIER:exon1/16:c.-641T>C:		rs151242444	0.0130	0.0000	0/0/0	0.0045							607704 [KANK1 (confirmed) Cerebral palsy,spastic quadriplegic,2,612900];				0	4					KANK1 (inh=AD pLI=n/a)
chr9	549518	549518	A	G	wt	het	wt		QUAL=3404;DP=462,254,381;MQM=60	KANK1	5'UTR,intron	KANK1:NM_001256877.1:5'UTR:MODIFIER:exon2/13:c.-287A>G:,KANK1:NM_001256876.1:intron:MODIFIER:exon5/15:c.-84+8851A>G:,KANK1:NM_015158.3:intron:MODIFIER:exon1/11:c.-84+44764A>G:		rs2279619	0.2298	0.0000	0/0/0	0.2593							607704 [KANK1 (confirmed) Cerebral palsy,spastic quadriplegic,2,612900];				11	56					KANK1 (inh=AD pLI=n/a)
chr9	707077	707077	C	T	hom	hom	het		QUAL=15751;DP=178,221,331;MQM=60	KANK1	5'UTR_premature_start_codon_gain,5'UTR,intron	KANK1:NM_153186.4:5'UTR_premature_start_codon_gain:LOW:exon1/11:c.-608C>T:,KANK1:NM_153186.4:5'UTR:MODIFIER:exon1/11:c.-608C>T:,KANK1:NM_001256876.1:intron:MODIFIER:exon6/15:c.38-3727C>T:,KANK1:NM_001256877.1:intron:MODIFIER:exon3/12:c.38-3727C>T:,KANK1:NM_015158.3:intron:MODIFIER:exon2/11:c.38-3727C>T:		rs7871551	0.3676	0.0000	0/0/0	0.4134							607704 [KANK1 (confirmed) Cerebral palsy,spastic quadriplegic,2,612900];				56	115					KANK1 (inh=AD pLI=n/a)
chr9	712060	712060	G	C	hom	het	het	pred_pathogenic	QUAL=18655;DP=308,290,451;MQM=59	KANK1	missense	KANK1:NM_001256876.1:missense:MODERATE:exon7/16:c.1294G>C:p.Glu432Gln,KANK1:NM_001256877.1:missense:MODERATE:exon4/13:c.1294G>C:p.Glu432Gln,KANK1:NM_015158.3:missense:MODERATE:exon3/12:c.1294G>C:p.Glu432Gln,KANK1:NM_153186.4:missense:MODERATE:exon2/11:c.820G>C:p.Glu274Gln		rs4465020	0.2352	0.3392	8021/5294/32	0.3316	2.0530	T,T,T,T	T	B,B	T,T,T	0.17	607704 [KANK1 (confirmed) Cerebral palsy,spastic quadriplegic,2,612900];			COSM1132467, COSM1132465	299	679					KANK1 (inh=AD pLI=n/a)
chr9	712137	712137	G	C	wt	het	wt		QUAL=2550;DP=364,191,336;MQM=60	KANK1	synonymous	KANK1:NM_001256876.1:synonymous:LOW:exon7/16:c.1371G>C:p.Leu457Leu,KANK1:NM_001256877.1:synonymous:LOW:exon4/13:c.1371G>C:p.Leu457Leu,KANK1:NM_015158.3:synonymous:LOW:exon3/12:c.1371G>C:p.Leu457Leu,KANK1:NM_153186.4:synonymous:LOW:exon2/11:c.897G>C:p.Leu299Leu		rs912175	0.1833	0.2110	3116/1562/169	0.2099							607704 [KANK1 (confirmed) Cerebral palsy,spastic quadriplegic,2,612900];			COSM150569	76	467					KANK1 (inh=AD pLI=n/a)
chr9	712156	712156	T	G	wt	het	wt	pred_pathogenic	QUAL=2389;DP=386,193,325;MQM=60	KANK1	missense	KANK1:NM_001256876.1:missense:MODERATE:exon7/16:c.1390T>G:p.Ser464Ala,KANK1:NM_001256877.1:missense:MODERATE:exon4/13:c.1390T>G:p.Ser464Ala,KANK1:NM_015158.3:missense:MODERATE:exon3/12:c.1390T>G:p.Ser464Ala,KANK1:NM_153186.4:missense:MODERATE:exon2/11:c.916T>G:p.Ser306Ala		rs912174	0.2045	0.2189	3317/1609/305	0.2176	2.3580	T,T,T,T	T	B,B	T,T,T	9.26	607704 [KANK1 (confirmed) Cerebral palsy,spastic quadriplegic,2,612900];			COSM150570, COSM3927868, COSM3927869	80	468					KANK1 (inh=AD pLI=n/a)
chr9	712599	712599	C	T	hom	het	het		QUAL=36999;DP=543,592,815;MQM=60	KANK1	synonymous	KANK1:NM_001256876.1:synonymous:LOW:exon7/16:c.1833C>T:p.Asn611Asn,KANK1:NM_001256877.1:synonymous:LOW:exon4/13:c.1833C>T:p.Asn611Asn,KANK1:NM_015158.3:synonymous:LOW:exon3/12:c.1833C>T:p.Asn611Asn,KANK1:NM_153186.4:synonymous:LOW:exon2/11:c.1359C>T:p.Asn453Asn		rs11789987	0.2530	0.3486	8269/5478/89	0.3406							607704 [KANK1 (confirmed) Cerebral palsy,spastic quadriplegic,2,612900];			COSM1462713, COSM3750179, COSM1462714	303	684					KANK1 (inh=AD pLI=n/a)
chr9	732536	732536	T	C	wt	het	wt		QUAL=4515;DP=265,332,456;MQM=60	KANK1	missense	KANK1:NM_001256876.1:missense:MODERATE:exon10/16:c.3164T>C:p.Ile1055Thr,KANK1:NM_001256877.1:missense:MODERATE:exon7/13:c.3164T>C:p.Ile1055Thr,KANK1:NM_015158.3:missense:MODERATE:exon6/12:c.3164T>C:p.Ile1055Thr,KANK1:NM_153186.4:missense:MODERATE:exon5/11:c.2690T>C:p.Ile897Thr		rs34832656	0.1260	0.1539	1701/1008/192	0.1522	0.2140	T,T,T,T,T	T	B,B	T,T,T	0.16	607704 [KANK1 (confirmed) Cerebral palsy,spastic quadriplegic,2,612900];				53	385					KANK1 (inh=AD pLI=n/a)
chr9	740901	740901	C	T	wt	het	wt		QUAL=3803;DP=277,335,440;MQM=60	KANK1	synonymous	KANK1:NM_001256876.1:synonymous:LOW:exon13/16:c.3663C>T:p.Phe1221Phe,KANK1:NM_001256877.1:synonymous:LOW:exon10/13:c.3663C>T:p.Phe1221Phe,KANK1:NM_015158.3:synonymous:LOW:exon9/12:c.3663C>T:p.Phe1221Phe,KANK1:NM_153186.4:synonymous:LOW:exon8/11:c.3189C>T:p.Phe1063Phe		rs2296049	0.2660	0.2418	3935/1525/869	0.2366							607704 [KANK1 (confirmed) Cerebral palsy,spastic quadriplegic,2,612900];			COSM150572	90	461					KANK1 (inh=AD pLI=n/a)
chr9	742342	742342	A	G	hom	hom	hom	low_DP	QUAL=2904;DP=40,17,40;MQM=60	KANK1	synonymous	KANK1:NM_001256876.1:synonymous:LOW:exon14/16:c.3834A>G:p.Gly1278Gly,KANK1:NM_001256877.1:synonymous:LOW:exon11/13:c.3834A>G:p.Gly1278Gly,KANK1:NM_015158.3:synonymous:LOW:exon10/12:c.3834A>G:p.Gly1278Gly,KANK1:NM_153186.4:synonymous:LOW:exon9/11:c.3360A>G:p.Gly1120Gly		rs10733535	0.9976	0.9953	60119/32897/5192	0.9632							607704 [KANK1 (confirmed) Cerebral palsy,spastic quadriplegic,2,612900];			COSM3763986, COSM3763984, COSM3763985	1549	17					KANK1 (inh=AD pLI=n/a)
chr9	745289	745289	C	T	wt	het	wt		QUAL=2586;DP=239,238,306;MQM=60	KANK1	3'UTR	KANK1:NM_001256876.1:3'UTR:MODIFIER:exon16/16:c.*54C>T:,KANK1:NM_001256877.1:3'UTR:MODIFIER:exon13/13:c.*54C>T:,KANK1:NM_015158.3:3'UTR:MODIFIER:exon12/12:c.*54C>T:,KANK1:NM_153186.4:3'UTR:MODIFIER:exon11/11:c.*54C>T:		rs17369029	0.1142	0.0000	0/0/0	0.0326							607704 [KANK1 (confirmed) Cerebral palsy,spastic quadriplegic,2,612900];				40	254					KANK1 (inh=AD pLI=n/a)
chr9	745413	745413	A	G	wt	het	wt		QUAL=2379;DP=150,207,236;MQM=60	KANK1	3'UTR	KANK1:NM_001256876.1:3'UTR:MODIFIER:exon16/16:c.*178A>G:,KANK1:NM_001256877.1:3'UTR:MODIFIER:exon13/13:c.*178A>G:,KANK1:NM_015158.3:3'UTR:MODIFIER:exon12/12:c.*178A>G:,KANK1:NM_153186.4:3'UTR:MODIFIER:exon11/11:c.*178A>G:		rs3739586	0.6991	0.0000	0/0/0	0.1114							607704 [KANK1 (confirmed) Cerebral palsy,spastic quadriplegic,2,612900];				108	91					KANK1 (inh=AD pLI=n/a)
chr9	2039793	2039793	A	C	hom	het	het		QUAL=5241;DP=60,131,156;MQM=59	SMARCA2	missense	SMARCA2:NM_001289396.1:missense:MODERATE:exon4/34:c.683A>C:p.Gln228Pro,SMARCA2:NM_001289397.1:missense:MODERATE:exon4/33:c.683A>C:p.Gln228Pro,SMARCA2:NM_003070.4:missense:MODERATE:exon4/34:c.683A>C:p.Gln228Pro,SMARCA2:NM_139045.3:missense:MODERATE:exon4/33:c.683A>C:p.Gln228Pro	(GCA)n	rs62534884	0.0292	0.0390	82/70/0	0.0311	0.7910	T,T,T,T,T	T	B,B	T,T,T,T,T	5.29	600014 [SMARCA2 (provisional) Nicolaides-Baraitser syndrome,601358];	RCV000114294.1 [benign]; RCV000351026.1 [benign]; 		COSM1461691, COSM1461690	12	166					SMARCA2 (inh=AD pLI=1.00)
chr9	2116037	2116037	G	A	het	wt	het		QUAL=2800;DP=69,116,164;MQM=60	SMARCA2	synonymous	SMARCA2:NM_001289396.1:synonymous:LOW:exon25/34:c.3672G>A:p.Glu1224Glu,SMARCA2:NM_001289397.1:synonymous:LOW:exon25/33:c.3498G>A:p.Glu1166Glu,SMARCA2:NM_003070.4:synonymous:LOW:exon25/34:c.3672G>A:p.Glu1224Glu,SMARCA2:NM_139045.3:synonymous:LOW:exon25/33:c.3672G>A:p.Glu1224Glu		rs6601	0.2354	0.1380	2349/355/1832	0.1293							600014 [SMARCA2 (provisional) Nicolaides-Baraitser syndrome,601358];	RCV000114289.2 [likely benign]; RCV000360701.1 [benign]; 		COSM3763857, COSM3763856	20	301					SMARCA2 (inh=AD pLI=1.00)
chr9	2622121	2622121	A	G	hom	hom	hom	low_DP	QUAL=2093;DP=4,33,36;MQM=59	VLDLR,VLDLR-AS1	5'UTR,non_coding_transcript_exon	VLDLR:NM_003383.4:5'UTR:MODIFIER:exon1/19:c.-69A>G:,VLDLR:NM_001018056.2:5'UTR:MODIFIER:exon1/18:c.-69A>G:,VLDLR:NM_001322225.1:5'UTR:MODIFIER:exon1/18:c.-69A>G:,VLDLR:NM_001322226.1:5'UTR:MODIFIER:exon1/17:c.-69A>G:,VLDLR-AS1:NR_015375.2:non_coding_transcript_exon:MODIFIER:exon1/4:n.253T>C:		rs12379259	0.8123	0.0000	0/0/0	0.1402							192977 [VLDLR (confirmed) Cerebellar hypoplasia and mental retardation with or without quadrupedal locomotion 1,224050];	RCV000335588.1 [benign]; 			616	351					VLDLR (inh=AR pLI=0.00), VLDLR-AS1 (inh=n/a pLI=n/a)
chr9	2622146	2622146	-	CGG	hom	het	het	low_DP	QUAL=181;DP=1,26,25;MQM=59	VLDLR,VLDLR-AS1	5'UTR,non_coding_transcript_exon	VLDLR:NM_003383.4:5'UTR:MODIFIER:exon1/19:c.-21_-19dupGGC:,VLDLR:NM_001018056.2:5'UTR:MODIFIER:exon1/18:c.-21_-19dupGGC:,VLDLR:NM_001322225.1:5'UTR:MODIFIER:exon1/18:c.-21_-19dupGGC:,VLDLR:NM_001322226.1:5'UTR:MODIFIER:exon1/17:c.-21_-19dupGGC:,VLDLR-AS1:NR_015375.2:non_coding_transcript_exon:MODIFIER:exon1/4:n.225_227dupCCG:		rs555425887;rs770767853	0.0000	0.3376	178/42/2	0.0574							192977 [VLDLR (confirmed) Cerebellar hypoplasia and mental retardation with or without quadrupedal locomotion 1,224050];				111	367					VLDLR (inh=AR pLI=0.00), VLDLR-AS1 (inh=n/a pLI=n/a)
chr9	6532477	6532477	G	A	het	hom	het		QUAL=1928;DP=76,21,24;MQM=58	GLDC	3'UTR	GLDC:NM_000170.2:3'UTR:MODIFIER:exon25/25:c.*540C>T:		rs7848919	0.7712	0.0000	0/0/0	0.1121							238300 [GLDC (confirmed) Glycine encephalopathy,605899];	RCV000333967.1 [benign]; 			107	98					GLDC (inh=AR pLI=0.00)
chr9	6532511	6532512	AA	-	het	het	wt		QUAL=850;DP=82,26,34;MQM=50	GLDC	3'UTR	GLDC:NM_000170.2:3'UTR:MODIFIER:exon25/25:c.*505_*506delTT:		rs145481724	0.0000	0.0000	0/0/0	0.0452							238300 [GLDC (confirmed) Glycine encephalopathy,605899];	RCV000387900.1 [uncertain significance]; 			4	42					GLDC (inh=AR pLI=0.00)
chr9	6532511	6532511	A	-	wt	wt	het		QUAL=850;DP=82,26,34;MQM=55	GLDC	3'UTR	GLDC:NM_000170.2:3'UTR:MODIFIER:exon25/25:c.*506delT:		rs750981994;rs757228471	0.0000	0.0000	0/0/0	0.0346							238300 [GLDC (confirmed) Glycine encephalopathy,605899];				1	49					GLDC (inh=AR pLI=0.00)
chr9	6532544	6532544	G	A	het	hom	het	low_MQM	QUAL=3512;DP=129,50,61;MQM=41	GLDC	3'UTR	GLDC:NM_000170.2:3'UTR:MODIFIER:exon25/25:c.*473C>T:		rs1061407	0.7516	0.0000	0/0/0	0.6240							238300 [GLDC (confirmed) Glycine encephalopathy,605899];	RCV000274736.1 [benign]; 			96	107					GLDC (inh=AR pLI=0.00)
chr9	6533010	6533010	C	G	het	hom	het		QUAL=16809;DP=270,292,363;MQM=56	GLDC	3'UTR	GLDC:NM_000170.2:3'UTR:MODIFIER:exon25/25:c.*7G>C:		rs2228098	0.7552	0.6859	29234/12907/2674	0.6565							238300 [GLDC (confirmed) Glycine encephalopathy,605899];	RCV000251539.1 [benign]; RCV000286373.1 [benign]; 			828	883					GLDC (inh=AR pLI=0.00)
chr9	6553514	6553514	-	T	wt	het	het		QUAL=4749;DP=134,193,226;MQM=60	GLDC	splice_region&intron	GLDC:NM_000170.2:splice_region&intron:LOW:exon19/24:c.2316-6dupA:		rs3215923;rs369576748	0.2426	0.2957	5555/3213/140	0.2776							238300 [GLDC (confirmed) Glycine encephalopathy,605899];	RCV000253110.1 [benign]; RCV000318636.1 [benign]; 			165	826					GLDC (inh=AR pLI=0.00)
chr9	33001441	33001441	G	A	wt	het	wt		QUAL=6988;DP=338,545,668;MQM=60	APTX	5'UTR,intron,non_coding_transcript_exon	APTX:NM_001195249.1:5'UTR:MODIFIER:exon1/8:c.-115C>T:,APTX:NM_001195248.1:intron:MODIFIER:exon1/7:c.38+124C>T:,APTX:NM_001195254.1:intron:MODIFIER:exon1/6:c.-5+73C>T:,APTX:NR_036578.1:intron:MODIFIER:exon1/7:n.97+73C>T:,APTX:NM_001195250.1:intron:MODIFIER:exon1/6:c.38+124C>T:,APTX:NM_001195251.1:intron:MODIFIER:exon1/8:c.-111+124C>T:,APTX:NM_001195252.1:intron:MODIFIER:exon1/7:c.38+124C>T:,APTX:NM_175069.2:intron:MODIFIER:exon1/7:c.38+124C>T:,APTX:NM_175073.2:intron:MODIFIER:exon1/8:c.-111+124C>T:,APTX:NR_036576.1:intron:MODIFIER:exon1/7:n.75+124C>T:,APTX:NR_036577.1:intron:MODIFIER:exon1/7:n.75+124C>T:,APTX:NR_036579.1:non_coding_transcript_exon:MODIFIER:exon1/8:n.134C>T:		rs10813920	0.1605	0.2190	496/154/69	0.1101							606350 [APTX (confirmed) Ataxia,early-onset,with oculomotor apraxia and hypoalbuminemia,208920];				8	113					APTX (inh=AR pLI=0.00)
chr9	33001449	33001449	C	A	wt	het	wt		QUAL=7038;DP=292,569,686;MQM=60	APTX	5'UTR,intron,non_coding_transcript_exon	APTX:NM_001195249.1:5'UTR:MODIFIER:exon1/8:c.-123G>T:,APTX:NM_001195248.1:intron:MODIFIER:exon1/7:c.38+116G>T:,APTX:NM_001195254.1:intron:MODIFIER:exon1/6:c.-5+65G>T:,APTX:NR_036578.1:intron:MODIFIER:exon1/7:n.97+65G>T:,APTX:NM_001195250.1:intron:MODIFIER:exon1/6:c.38+116G>T:,APTX:NM_001195251.1:intron:MODIFIER:exon1/8:c.-111+116G>T:,APTX:NM_001195252.1:intron:MODIFIER:exon1/7:c.38+116G>T:,APTX:NM_175069.2:intron:MODIFIER:exon1/7:c.38+116G>T:,APTX:NM_175073.2:intron:MODIFIER:exon1/8:c.-111+116G>T:,APTX:NR_036576.1:intron:MODIFIER:exon1/7:n.75+116G>T:,APTX:NR_036577.1:intron:MODIFIER:exon1/7:n.75+116G>T:,APTX:NR_036579.1:non_coding_transcript_exon:MODIFIER:exon1/8:n.126G>T:		rs1197774	0.5933	0.5995	9688/5000/2032	0.4723							606350 [APTX (confirmed) Ataxia,early-onset,with oculomotor apraxia and hypoalbuminemia,208920];				154	278					APTX (inh=AR pLI=0.00)
chr9	33111277	33111277	C	A	wt	het	wt		QUAL=452;DP=131,54,128;MQM=54	B4GALT1	3'UTR	B4GALT1:NM_001497.3:3'UTR:MODIFIER:exon6/6:c.*2175G>T:	(A)n	rs7041909	0.0000	0.0000	0/0/0	0.0251							137060 [B4GALT1 (provisional) Congenital disorder of glycosylation,type IId,607091];	RCV000362838.1 [uncertain significance]; 			7	43					B4GALT1 (inh=AR pLI=0.49)
chr9	33112715	33112718	TTCT	-	het	wt	het		QUAL=5376;DP=310,110,162;MQM=59	B4GALT1	3'UTR	B4GALT1:NM_001497.3:3'UTR:MODIFIER:exon6/6:c.*734_*737delAGAA:		rs537888935	0.0046	0.0000	0/0/0	0.0113							137060 [B4GALT1 (provisional) Congenital disorder of glycosylation,type IId,607091];	RCV000323528.1 [uncertain significance]; 			0	7					B4GALT1 (inh=AR pLI=0.49)
chr9	33113121	33113121	G	A	wt	het	wt		QUAL=1002;DP=185,74,79;MQM=60	B4GALT1	3'UTR	B4GALT1:NM_001497.3:3'UTR:MODIFIER:exon6/6:c.*331C>T:		rs869	0.5535	0.0000	0/0/0	0.0809							137060 [B4GALT1 (provisional) Congenital disorder of glycosylation,type IId,607091];	RCV000330422.1 [benign]; 			45	106					B4GALT1 (inh=AR pLI=0.49)
chr9	33113196	33113196	G	T	hom	hom	hom		QUAL=15493;DP=244,114,125;MQM=60	B4GALT1	3'UTR	B4GALT1:NM_001497.3:3'UTR:MODIFIER:exon6/6:c.*256C>A:		rs7019896	0.9485	0.0000	0/0/0	0.8646							137060 [B4GALT1 (provisional) Congenital disorder of glycosylation,type IId,607091];	RCV000352521.1 [benign]; 			211	19					B4GALT1 (inh=AR pLI=0.49)
chr9	33113322	33113322	C	T	wt	het	wt		QUAL=2075;DP=252,170,189;MQM=60	B4GALT1	3'UTR	B4GALT1:NM_001497.3:3'UTR:MODIFIER:exon6/6:c.*130G>A:		rs7019909	0.2284	0.0000	0/0/0	0.0305							137060 [B4GALT1 (provisional) Congenital disorder of glycosylation,type IId,607091];	RCV000302832.1 [benign]; 			2	44					B4GALT1 (inh=AR pLI=0.49)
chr9	35060302	35060302	T	C	het	het	het		QUAL=3715;DP=154,53,67;MQM=60	VCP	splice_region&intron	VCP:NM_007126.3:splice_region&intron:LOW:exon13/16:c.1695+8A>G:		rs684562	0.4087	0.5865	22983/16416/378	0.5798							601023 [VCP (confirmed) Inclusion body myopathy with early-onset Paget disease and frontotemporal dementia 1,167320|Amyotrophic lateral sclerosis 14,with or without frontotemporal dementia,613954|Charcot-Marie-Tooth disease,type 2Y,616687];	RCV000254320.1 [benign]; RCV000367237.1 [benign]; RCV000393728.1 [benign]; 			729	791					VCP (inh=AD pLI=1.00)
chr9	35061693	35061693	-	ACAGTACACAA	het	het	het		QUAL=6691;DP=138,188,239;MQM=59	VCP	splice_region&intron	VCP:NM_007126.3:splice_region&intron:LOW:exon9/16:c.1082-18_1082-8dupTTGTGTACTGT:		rs11272867;rs6150985	0.4083	0.5805	22507/16066/365	0.0927							601023 [VCP (confirmed) Inclusion body myopathy with early-onset Paget disease and frontotemporal dementia 1,167320|Amyotrophic lateral sclerosis 14,with or without frontotemporal dementia,613954|Charcot-Marie-Tooth disease,type 2Y,616687];	RCV000243886.1 [benign]; RCV000321686.1 [benign]; RCV000383262.1 [benign]; 			708	772					VCP (inh=AD pLI=1.00)
chr9	35062972	35062972	C	T	het	het	het		QUAL=13221;DP=310,312,394;MQM=60	VCP	splice_region&intron,sequence_feature	VCP:NM_007126.3:splice_region&intron:LOW:exon7/16:c.811+3G>A:,VCP:NM_007126.3:sequence_feature:LOW::c.811+3G>A:		rs514492	0.7011	0.7442	34218/20040/2862	0.7371							601023 [VCP (confirmed) Inclusion body myopathy with early-onset Paget disease and frontotemporal dementia 1,167320|Amyotrophic lateral sclerosis 14,with or without frontotemporal dementia,613954|Charcot-Marie-Tooth disease,type 2Y,616687];	RCV000244946.1 [benign]; RCV000294534.1 [benign]; RCV000382040.1 [benign]; 		COSM150600	989	645					VCP (inh=AD pLI=1.00)
chr9	35074917	35074917	T	C	het	het	het		QUAL=7576;DP=208,141,223;MQM=59	FANCG	splice_region&intron	FANCG:NM_004629.1:splice_region&intron:LOW:exon12/13:c.1636+7A>G:		rs587118	0.2202	0.3957	11389/8269/33	0.3923							602956 [FANCG (confirmed) Fanconi anemia,complementation group G,614082];	RCV000247570.1 [benign]; RCV000275986.1 [benign]; RCV000367549.1 [benign]; RCV000394450.1 [benign]; 			766	1538	1	[1] Ilnaz Sepahi 29-03-2016 batch import			FANCG (inh=n/a pLI=0.00)
chr9	35657741	35657741	A	G	het	het	wt		QUAL=1252;DP=55,70,74;MQM=60	SIT1-RMRP	intergenic_region	SIT1-RMRP:SIT1-RMRP:intergenic_region:MODIFIER::n.35657741A>G:		rs71521283	0.1558	0.3695	225/69/0	0.0524							157660 [RMRP (confirmed) Cartilage-hair hypoplasia,250250|Metaphyseal dysplasia without hypotrichosis,250460|Anauxetic dysplasia,607095];				48	244					SIT1-RMRP (inh=n/a pLI=n/a)
chr9	35657838	35657838	G	A	wt	het	wt		QUAL=1383;DP=120,134,184;MQM=60	RMRP	non_coding_transcript_exon	RMRP:NR_003051.3:non_coding_transcript_exon:MODIFIER:exon1/1:n.178C>T:		rs7021642	0.1516	0.0991	78/18/13	0.0291							157660 [RMRP (confirmed) Cartilage-hair hypoplasia,250250|Metaphyseal dysplasia without hypotrichosis,250460|Anauxetic dysplasia,607095];	RCV000127794.1 [benign]; 			14	166					RMRP (inh=AR pLI=n/a)
chr9	35657859	35657859	C	G	wt	het	wt		QUAL=1664;DP=137,147,212;MQM=60	RMRP	non_coding_transcript_exon	RMRP:NR_003051.3:non_coding_transcript_exon:MODIFIER:exon1/1:n.157G>C:		rs7021463	0.1516	0.0988	77/18/12	0.0291							157660 [RMRP (confirmed) Cartilage-hair hypoplasia,250250|Metaphyseal dysplasia without hypotrichosis,250460|Anauxetic dysplasia,607095];	RCV000127793.1 [benign]; 			14	165					RMRP (inh=AR pLI=n/a)
chr9	35658020	35658020	C	T	wt	het	wt		QUAL=1034;DP=84,88,112;MQM=60	RMRP-CCDC107	intergenic_region	RMRP-CCDC107:RMRP-CCDC107:intergenic_region:MODIFIER::n.35658020C>T:		rs7024732	0.1468	0.1174	75/18/12	0.0287							157660 [RMRP (confirmed) Cartilage-hair hypoplasia,250250|Metaphyseal dysplasia without hypotrichosis,250460|Anauxetic dysplasia,607095];				14	169					RMRP-CCDC107 (inh=n/a pLI=n/a)
chr9	36214971	36214971	G	A	wt	het	het		QUAL=3193;DP=320,118,135;MQM=60	GNE	3'UTR	GNE:NM_001128227.2:3'UTR:MODIFIER:exon12/12:c.*2391C>T:,GNE:NM_001190383.1:3'UTR:MODIFIER:exon11/11:c.*2391C>T:,GNE:NM_001190384.1:3'UTR:MODIFIER:exon10/10:c.*2391C>T:,GNE:NM_005476.5:3'UTR:MODIFIER:exon12/12:c.*2391C>T:,GNE:NM_001190388.1:3'UTR:MODIFIER:exon11/11:c.*2391C>T:		rs1043313	0.5693	0.0000	0/0/0	0.1099							603824 [GNE (confirmed) Sialuria,269921|Nonaka myopathy,605820];	RCV000279225.1 [benign]; RCV000315865.1 [benign]; RCV000375084.1 [benign]; 			124	108					GNE (inh=AR+AD pLI=0.00)
chr9	36216426	36216426	G	A	wt	het	het		QUAL=499;DP=143,131,133;MQM=59	GNE	3'UTR	GNE:NM_001128227.2:3'UTR:MODIFIER:exon12/12:c.*936C>T:,GNE:NM_001190383.1:3'UTR:MODIFIER:exon11/11:c.*936C>T:,GNE:NM_001190384.1:3'UTR:MODIFIER:exon10/10:c.*936C>T:,GNE:NM_005476.5:3'UTR:MODIFIER:exon12/12:c.*936C>T:,GNE:NM_001190388.1:3'UTR:MODIFIER:exon11/11:c.*936C>T:	AluSx	rs56974443	0.3003	0.0000	0/0/0	0.3910							603824 [GNE (confirmed) Sialuria,269921|Nonaka myopathy,605820];	RCV000280341.1 [benign]; RCV000337734.1 [benign]; RCV000375784.1 [benign]; 			54	93					GNE (inh=AR+AD pLI=0.00)
chr9	71650752	71650752	A	G	hom	hom	hom		QUAL=4451;DP=23,57,78;MQM=60	FXN	synonymous	FXN:NM_000144.4:synonymous:LOW:exon1/5:c.54A>G:p.Pro18Pro,FXN:NM_181425.2:synonymous:LOW:exon1/5:c.54A>G:p.Pro18Pro,FXN:NM_001161706.1:synonymous:LOW:exon1/5:c.54A>G:p.Pro18Pro	(ACCCAG)n	rs2481598	0.9848	0.9993	5328/1350/99	0.2654							606829 [FXN (confirmed) Friedreich ataxia,229300|Friedreich ataxia with retained reflexes,229300];	RCV000117105.4 [other]; RCV000252378.1 [benign]; 			3217	2					FXN (inh=AR pLI=0.82)
chr9	71688476	71688476	T	G	het	het	het		QUAL=21108;DP=781,334,413;MQM=59	FXN	3'UTR,intron	FXN:NM_000144.4:3'UTR:MODIFIER:exon5/5:c.*798T>G:,FXN:NM_181425.2:3'UTR:MODIFIER:exon5/5:c.*848T>G:,FXN:NM_001161706.1:intron:MODIFIER:exon4/4:c.482+8525T>G:		rs11145043	0.3281	0.0000	0/0/0	0.0685							606829 [FXN (confirmed) Friedreich ataxia,229300|Friedreich ataxia with retained reflexes,229300];		CR132641 [CLASS=FP MUT=REF PHEN="Altered expression" GENE=FXN]; 		49	114					FXN (inh=AR pLI=0.82)
chr9	71689436	71689436	A	-	het	het	wt		QUAL=617;DP=107,53,65;MQM=59	FXN	3'UTR,intron	FXN:NM_000144.4:3'UTR:MODIFIER:exon5/5:c.*1771delA:,FXN:NM_181425.2:3'UTR:MODIFIER:exon5/5:c.*1821delA:,FXN:NM_001161706.1:intron:MODIFIER:exon4/4:c.482+9498delA:	AluSx	rs34933249	0.0000	0.0000	0/0/0	0.0035							606829 [FXN (confirmed) Friedreich ataxia,229300|Friedreich ataxia with retained reflexes,229300];				6	12					FXN (inh=AR pLI=0.82)
chr9	71690150	71690150	T	G	hom	hom	hom		QUAL=13268;DP=213,76,132;MQM=52	FXN	3'UTR,intron	FXN:NM_000144.4:3'UTR:MODIFIER:exon5/5:c.*2472T>G:,FXN:NM_181425.2:3'UTR:MODIFIER:exon5/5:c.*2522T>G:,FXN:NM_001161706.1:intron:MODIFIER:exon4/4:c.482+10199T>G:	AluSx	rs7875272	0.9916	0.0000	0/0/0	0.7322							606829 [FXN (confirmed) Friedreich ataxia,229300|Friedreich ataxia with retained reflexes,229300];				162	0					FXN (inh=AR pLI=0.82)
chr9	71690452	71690452	T	A	het	het	het		QUAL=12163;DP=395,255,352;MQM=60	FXN	3'UTR,intron	FXN:NM_000144.4:3'UTR:MODIFIER:exon5/5:c.*2774T>A:,FXN:NM_181425.2:3'UTR:MODIFIER:exon5/5:c.*2824T>A:,FXN:NM_001161706.1:intron:MODIFIER:exon4/4:c.482+10501T>A:		rs7875693	0.6617	0.0000	0/0/0	0.5608							606829 [FXN (confirmed) Friedreich ataxia,229300|Friedreich ataxia with retained reflexes,229300];				54	69					FXN (inh=AR pLI=0.82)
chr9	71690482	71690482	T	G	het	het	het		QUAL=11468;DP=344,277,386;MQM=60	FXN	3'UTR,intron	FXN:NM_000144.4:3'UTR:MODIFIER:exon5/5:c.*2804T>G:,FXN:NM_181425.2:3'UTR:MODIFIER:exon5/5:c.*2854T>G:,FXN:NM_001161706.1:intron:MODIFIER:exon4/4:c.482+10531T>G:		rs7849347	0.6643	0.0000	0/0/0	0.5629							606829 [FXN (confirmed) Friedreich ataxia,229300|Friedreich ataxia with retained reflexes,229300];				55	69					FXN (inh=AR pLI=0.82)
chr9	71690684	71690684	G	T	hom	hom	hom		QUAL=24918;DP=295,216,274;MQM=59	FXN	3'UTR,intron	FXN:NM_000144.4:3'UTR:MODIFIER:exon5/5:c.*3006G>T:,FXN:NM_181425.2:3'UTR:MODIFIER:exon5/5:c.*3056G>T:,FXN:NM_001161706.1:intron:MODIFIER:exon4/4:c.482+10733G>T:	AluJb	rs6560541	0.9898	0.0000	0/0/0	0.8768							606829 [FXN (confirmed) Friedreich ataxia,229300|Friedreich ataxia with retained reflexes,229300];				175	0					FXN (inh=AR pLI=0.82)
chr9	71690872	71690872	C	T	het	het	wt		QUAL=5322;DP=290,97,125;MQM=59	FXN	3'UTR,intron	FXN:NM_000144.4:3'UTR:MODIFIER:exon5/5:c.*3194C>T:,FXN:NM_181425.2:3'UTR:MODIFIER:exon5/5:c.*3244C>T:,FXN:NM_001161706.1:intron:MODIFIER:exon4/4:c.482+10921C>T:	AluJb	rs188391059	0.0010	0.0000	0/0/0	0.0030							606829 [FXN (confirmed) Friedreich ataxia,229300|Friedreich ataxia with retained reflexes,229300];				0	2					FXN (inh=AR pLI=0.82)
chr9	71691134	71691134	T	-	het	het	het		QUAL=1520;DP=135,55,73;MQM=59	FXN	3'UTR,intron	FXN:NM_000144.4:3'UTR:MODIFIER:exon5/5:c.*3469delT:,FXN:NM_181425.2:3'UTR:MODIFIER:exon5/5:c.*3519delT:,FXN:NM_001161706.1:intron:MODIFIER:exon4/4:c.482+11196delT:	MIRb	rs11310316	0.7163	0.0000	0/0/0	0.3357							606829 [FXN (confirmed) Friedreich ataxia,229300|Friedreich ataxia with retained reflexes,229300];				11	93					FXN (inh=AR pLI=0.82)
chr9	71692705	71692705	C	G	hom	hom	hom		QUAL=8777;DP=118,69,104;MQM=54	FXN	3'UTR,intron	FXN:NM_000144.4:3'UTR:MODIFIER:exon5/5:c.*5027C>G:,FXN:NM_181425.2:3'UTR:MODIFIER:exon5/5:c.*5077C>G:,FXN:NM_001161706.1:intron:MODIFIER:exon4/4:c.482+12754C>G:	AluSx	rs7848466	0.9898	0.0000	0/0/0	0.8759							606829 [FXN (confirmed) Friedreich ataxia,229300|Friedreich ataxia with retained reflexes,229300];				225	0					FXN (inh=AR pLI=0.82)
chr9	71693128	71693128	G	C	hom	hom	hom		QUAL=35198;DP=424,279,361;MQM=60	FXN	3'UTR,intron	FXN:NM_000144.4:3'UTR:MODIFIER:exon5/5:c.*5450G>C:,FXN:NM_181425.2:3'UTR:MODIFIER:exon5/5:c.*5500G>C:,FXN:NM_001161706.1:intron:MODIFIER:exon4/4:c.482+13177G>C:	MER91C	rs7866579	0.9920	0.0000	0/0/0	0.8778							606829 [FXN (confirmed) Friedreich ataxia,229300|Friedreich ataxia with retained reflexes,229300];				224	0					FXN (inh=AR pLI=0.82)
chr9	79792438	79792438	G	C	wt	het	wt	low_DP	QUAL=38;DP=10,10,14;MQM=60	VPS13A,VPS13A-AS1	5'UTR_premature_start_codon_gain,5'UTR,intron	VPS13A:NM_033305.2:5'UTR_premature_start_codon_gain:LOW:exon1/72:c.-183G>C:,VPS13A:NM_001018038.2:5'UTR_premature_start_codon_gain:LOW:exon1/69:c.-183G>C:,VPS13A:NM_015186.3:5'UTR_premature_start_codon_gain:LOW:exon1/69:c.-183G>C:,VPS13A:NM_001018037.1:5'UTR_premature_start_codon_gain:LOW:exon1/71:c.-183G>C:,VPS13A:NM_033305.2:5'UTR:MODIFIER:exon1/72:c.-183G>C:,VPS13A:NM_001018038.2:5'UTR:MODIFIER:exon1/69:c.-183G>C:,VPS13A:NM_015186.3:5'UTR:MODIFIER:exon1/69:c.-183G>C:,VPS13A:NM_001018037.1:5'UTR:MODIFIER:exon1/71:c.-183G>C:,VPS13A-AS1:NR_026668.2:intron:MODIFIER:exon1/1:n.291+105C>G:		rs12349389	0.0845	0.0000	0/0/0	0.0174							605978 [VPS13A (confirmed) Choreoacanthocytosis,200150];	RCV000277646.1 [likely benign]; 			4	43					VPS13A (inh=AR pLI=0.00), VPS13A-AS1 (inh=n/a pLI=n/a)
chr9	79792440	79792440	G	A	het	wt	het	low_DP	QUAL=186;DP=11,10,15;MQM=60	VPS13A,VPS13A-AS1	5'UTR,intron	VPS13A:NM_033305.2:5'UTR:MODIFIER:exon1/72:c.-181G>A:,VPS13A:NM_001018038.2:5'UTR:MODIFIER:exon1/69:c.-181G>A:,VPS13A:NM_015186.3:5'UTR:MODIFIER:exon1/69:c.-181G>A:,VPS13A:NM_001018037.1:5'UTR:MODIFIER:exon1/71:c.-181G>A:,VPS13A-AS1:NR_026668.2:intron:MODIFIER:exon1/1:n.291+103C>T:		rs117488726	0.0759	0.0000	0/0/0	0.0234							605978 [VPS13A (confirmed) Choreoacanthocytosis,200150];	RCV000316336.1 [likely benign]; 			7	43					VPS13A (inh=AR pLI=0.00), VPS13A-AS1 (inh=n/a pLI=n/a)
chr9	79897117	79897117	G	A	wt	het	wt		QUAL=1433;DP=229,94,134;MQM=60	VPS13A	synonymous	VPS13A:NM_033305.2:synonymous:LOW:exon29/72:c.3045G>A:p.Pro1015Pro,VPS13A:NM_001018038.2:synonymous:LOW:exon29/69:c.3045G>A:p.Pro1015Pro,VPS13A:NM_015186.3:synonymous:LOW:exon29/69:c.3045G>A:p.Pro1015Pro,VPS13A:NM_001018037.1:synonymous:LOW:exon29/71:c.3045G>A:p.Pro1015Pro		rs11145366	0.0839	0.0916	558/357/61	0.0897							605978 [VPS13A (confirmed) Choreoacanthocytosis,200150];	RCV000392188.1 [likely benign]; 			44	541					VPS13A (inh=AR pLI=0.00)
chr9	79936415	79936415	A	G	het	wt	het		QUAL=5102;DP=230,117,134;MQM=60	VPS13A	synonymous	VPS13A:NM_033305.2:synonymous:LOW:exon44/72:c.5583A>G:p.Thr1861Thr,VPS13A:NM_001018038.2:synonymous:LOW:exon44/69:c.5583A>G:p.Thr1861Thr,VPS13A:NM_015186.3:synonymous:LOW:exon44/69:c.5583A>G:p.Thr1861Thr,VPS13A:NM_001018037.1:synonymous:LOW:exon43/71:c.5466A>G:p.Thr1822Thr		rs17423984	0.0487	0.0758	422/243/3	0.0735	0.1070		T			1.42	605978 [VPS13A (confirmed) Choreoacanthocytosis,200150];	RCV000302242.1 [likely benign]; 		COSM3764012, COSM3764011, COSM3764010	20	471					VPS13A (inh=AR pLI=0.00)
chr9	79954425	79954425	A	T	het	wt	wt		QUAL=112;DP=112,36,37;MQM=54	VPS13A	splice_region&intron	VPS13A:NM_033305.2:splice_region&intron:LOW:exon47/71:c.6379-7A>T:,VPS13A:NM_001018038.2:splice_region&intron:LOW:exon47/68:c.6379-7A>T:,VPS13A:NM_015186.3:splice_region&intron:LOW:exon47/68:c.6379-7A>T:,VPS13A:NM_001018037.1:splice_region&intron:LOW:exon46/70:c.6262-7A>T:	(T)n	rs759586753	0.0000	0.1314	0/0/0	0.0121							605978 [VPS13A (confirmed) Choreoacanthocytosis,200150];				5	79					VPS13A (inh=AR pLI=0.00)
chr9	79954545	79954545	T	C	het	het	het		QUAL=9943;DP=321,229,285;MQM=60	VPS13A	synonymous	VPS13A:NM_033305.2:synonymous:LOW:exon48/72:c.6492T>C:p.Asp2164Asp,VPS13A:NM_001018038.2:synonymous:LOW:exon48/69:c.6492T>C:p.Asp2164Asp,VPS13A:NM_015186.3:synonymous:LOW:exon48/69:c.6492T>C:p.Asp2164Asp,VPS13A:NM_001018037.1:synonymous:LOW:exon47/71:c.6375T>C:p.Asp2125Asp		rs7025532	0.1627	0.1819	2013/1205/238	0.1718							605978 [VPS13A (confirmed) Choreoacanthocytosis,200150];	RCV000373807.1 [likely benign]; 		COSM3764013, COSM3764014, COSM3764015	134	888					VPS13A (inh=AR pLI=0.00)
chr9	79984232	79984232	T	C	het	wt	het		QUAL=8863;DP=342,163,281;MQM=60	VPS13A	synonymous	VPS13A:NM_033305.2:synonymous:LOW:exon63/72:c.8571T>C:p.Tyr2857Tyr,VPS13A:NM_001018038.2:synonymous:LOW:exon63/69:c.8571T>C:p.Tyr2857Tyr,VPS13A:NM_015186.3:synonymous:LOW:exon63/69:c.8571T>C:p.Tyr2857Tyr,VPS13A:NM_001018037.1:synonymous:LOW:exon62/71:c.8454T>C:p.Tyr2818Tyr		rs17340192	0.0517	0.0759	426/250/3	0.0741							605978 [VPS13A (confirmed) Choreoacanthocytosis,200150];	RCV000287482.1 [likely benign]; 		COSM3764016, COSM3764017, COSM3764018	18	424					VPS13A (inh=AR pLI=0.00)
chr9	79986057	79986057	A	G	het	het	het		QUAL=15260;DP=408,297,416;MQM=59	VPS13A	synonymous	VPS13A:NM_033305.2:synonymous:LOW:exon67/72:c.9069A>G:p.Gly3023Gly,VPS13A:NM_001018038.2:synonymous:LOW:exon67/69:c.9069A>G:p.Gly3023Gly,VPS13A:NM_015186.3:synonymous:LOW:exon67/69:c.9069A>G:p.Gly3023Gly,VPS13A:NM_001018037.1:synonymous:LOW:exon66/71:c.8952A>G:p.Gly2984Gly		rs3737289	0.4151	0.4505	12564/6158/517	0.4403							605978 [VPS13A (confirmed) Choreoacanthocytosis,200150];	RCV000393264.1 [benign]; 			549	1328					VPS13A (inh=AR pLI=0.00)
chr9	79997881	79997881	T	C	het	het	het		QUAL=11452;DP=368,197,277;MQM=60	VPS13A	3'UTR,intron	VPS13A:NM_001018038.2:3'UTR:MODIFIER:exon69/69:c.*666T>C:,VPS13A:NM_033305.2:intron:MODIFIER:exon68/71:c.9189+878T>C:,VPS13A:NM_015186.3:intron:MODIFIER:exon68/68:c.9189+878T>C:,VPS13A:NM_001018037.1:intron:MODIFIER:exon67/70:c.9072+878T>C:		rs10869921	0.3844	0.0000	0/0/0	0.4088							605978 [VPS13A (confirmed) Choreoacanthocytosis,200150];				47	134					VPS13A (inh=AR pLI=0.00)
chr9	79999783	79999783	A	G	wt	het	wt		QUAL=1687;DP=271,122,184;MQM=60	VPS13A	3'UTR,intron	VPS13A:NM_015186.3:3'UTR:MODIFIER:exon69/69:c.*184A>G:,VPS13A:NM_033305.2:intron:MODIFIER:exon68/71:c.9189+2780A>G:,VPS13A:NM_001018037.1:intron:MODIFIER:exon67/70:c.9072+2780A>G:		rs73451816	0.1653	0.0000	0/0/0	0.0227							605978 [VPS13A (confirmed) Choreoacanthocytosis,200150];				3	63					VPS13A (inh=AR pLI=0.00)
chr9	79999824	79999824	T	C	het	wt	het		QUAL=4925;DP=215,105,162;MQM=60	VPS13A	3'UTR,intron	VPS13A:NM_015186.3:3'UTR:MODIFIER:exon69/69:c.*225T>C:,VPS13A:NM_033305.2:intron:MODIFIER:exon68/71:c.9189+2821T>C:,VPS13A:NM_001018037.1:intron:MODIFIER:exon67/70:c.9072+2821T>C:		rs7872010	0.0731	0.0000	0/0/0	0.0130							605978 [VPS13A (confirmed) Choreoacanthocytosis,200150];				2	42					VPS13A (inh=AR pLI=0.00)
chr9	80000000	80000000	A	T	wt	het	wt		QUAL=342;DP=173,44,61;MQM=60	VPS13A	3'UTR,intron	VPS13A:NM_015186.3:3'UTR:MODIFIER:exon69/69:c.*401A>T:,VPS13A:NM_033305.2:intron:MODIFIER:exon68/71:c.9189+2997A>T:,VPS13A:NM_001018037.1:intron:MODIFIER:exon67/70:c.9072+2997A>T:		rs78198903	0.0847	0.0000	0/0/0	0.0134							605978 [VPS13A (confirmed) Choreoacanthocytosis,200150];				4	62					VPS13A (inh=AR pLI=0.00)
chr9	80031144	80031144	G	A	het	het	het		QUAL=4179;DP=168,58,68;MQM=60	VPS13A	3'UTR	VPS13A:NM_033305.2:3'UTR:MODIFIER:exon72/72:c.*222G>A:,VPS13A:NM_001018037.1:3'UTR:MODIFIER:exon71/71:c.*222G>A:		rs12343797	0.1653	0.0000	0/0/0	0.0290							605978 [VPS13A (confirmed) Choreoacanthocytosis,200150];	RCV000270493.1 [likely benign]; 			16	114					VPS13A (inh=AR pLI=0.00)
chr9	80031946	80031946	C	T	het	het	het		QUAL=7991;DP=243,151,194;MQM=60	VPS13A	3'UTR	VPS13A:NM_033305.2:3'UTR:MODIFIER:exon72/72:c.*1024C>T:,VPS13A:NM_001018037.1:3'UTR:MODIFIER:exon71/71:c.*1024C>T:		rs9186	0.5757	0.0000	0/0/0	0.0922							605978 [VPS13A (confirmed) Choreoacanthocytosis,200150];	RCV000373033.1 [benign]; 			61	148					VPS13A (inh=AR pLI=0.00)
chr9	80032300	80032300	C	A	het	het	het		QUAL=11116;DP=379,203,294;MQM=59	VPS13A	3'UTR	VPS13A:NM_033305.2:3'UTR:MODIFIER:exon72/72:c.*1378C>A:,VPS13A:NM_001018037.1:3'UTR:MODIFIER:exon71/71:c.*1378C>A:		rs13286867	0.2494	0.0000	0/0/0	0.0500							605978 [VPS13A (confirmed) Choreoacanthocytosis,200150];	RCV000293418.1 [benign]; 			37	123					VPS13A (inh=AR pLI=0.00)
chr9	94087622	94087622	T	G	het	wt	het		QUAL=7005;DP=329,126,154;MQM=60	AUH	synonymous,intron	AUH:NM_001698.2:synonymous:LOW:exon4/10:c.483A>C:p.Ile161Ile,AUH:NM_001306190.1:intron:MODIFIER:exon3/8:c.419-27264A>C:		rs7874056	0.0895	0.0866	593/331/183	0.0856							600529 [AUH (provisional) 3-methylglutaconic aciduria,type I,250950];	RCV000116490.3 [other]; RCV000369919.1 [likely benign]; 		COSM3764058	15	357					AUH (inh=AR pLI=0.01)
chr9	94118258	94118258	C	T	wt	het	wt		QUAL=1843;DP=385,166,189;MQM=60	AUH	splice_region&intron	AUH:NM_001698.2:splice_region&intron:LOW:exon2/9:c.331-6G>A:,AUH:NM_001306190.1:splice_region&intron:LOW:exon2/8:c.331-6G>A:		rs10991898	0.0958	0.1079	767/416/11	0.1068							600529 [AUH (provisional) 3-methylglutaconic aciduria,type I,250950];	RCV000253918.1 [benign]; RCV000330450.1 [likely benign]; 			27	480					AUH (inh=AR pLI=0.01)
chr9	94830356	94830356	C	A	het	wt	het	pred_pathogenic	QUAL=6680;DP=323,112,186;MQM=60	SPTLC1	missense	SPTLC1:NM_001281303.1:missense:MODERATE:exon6/15:c.452G>T:p.Arg151Leu,SPTLC1:NM_006415.3:missense:MODERATE:exon6/15:c.452G>T:p.Arg151Leu		rs45461899	0.0116	0.0220	51/42/0	0.0214	3.9190	D	T	B,B	D	33.00	605712 [SPTLC1 (provisional) Neuropathy,hereditary sensory and autonomic,type IA,162400];	RCV000313112.1 [likely benign]; 			2	67					SPTLC1 (inh=AD pLI=0.00)
chr9	97862118	97862118	C	T	het	het	het		QUAL=12662;DP=292,365,413;MQM=60	FANCC	3'UTR	FANCC:NM_000136.2:3'UTR:MODIFIER:exon15/15:c.*1871G>A:,FANCC:NM_001243743.1:3'UTR:MODIFIER:exon15/15:c.*1871G>A:		rs4647558	0.4135	0.0000	0/0/0	0.4334							613899 [FANCC (confirmed) Fanconi anemia,complementation group C,227645];	RCV000360013.1 [benign]; 			31	120					FANCC (inh=AR pLI=0.00)
chr9	97862701	97862701	A	G	het	het	het		QUAL=12121;DP=352,244,259;MQM=60	FANCC	3'UTR	FANCC:NM_000136.2:3'UTR:MODIFIER:exon15/15:c.*1288T>C:,FANCC:NM_001243743.1:3'UTR:MODIFIER:exon15/15:c.*1288T>C:		rs4647554	0.5028	0.0000	0/0/0	0.0786							613899 [FANCC (confirmed) Fanconi anemia,complementation group C,227645];	RCV000334241.1 [benign]; 			32	124					FANCC (inh=AR pLI=0.00)
chr9	97872712	97872712	C	T	hom	hom	hom		QUAL=10896;DP=215,55,64;MQM=60	FANCC	3'UTR,intron	FANCC:NM_001243744.1:3'UTR:MODIFIER:exon14/14:c.*766G>A:,FANCC:NM_000136.2:intron:MODIFIER:exon13/14:c.1329+1033G>A:,FANCC:NM_001243743.1:intron:MODIFIER:exon13/14:c.1329+1033G>A:		rs10429619	0.9980	0.0000	0/0/0	0.9128							613899 [FANCC (confirmed) Fanconi anemia,complementation group C,227645];				149	1					FANCC (inh=AR pLI=0.00)
chr9	97873004	97873007	TAAC	-	het	wt	het		QUAL=4053;DP=182,129,194;MQM=59	FANCC	3'UTR,intron	FANCC:NM_001243744.1:3'UTR:MODIFIER:exon14/14:c.*471_*474delGTTA:,FANCC:NM_000136.2:intron:MODIFIER:exon13/14:c.1329+738_1329+741delGTTA:,FANCC:NM_001243743.1:intron:MODIFIER:exon13/14:c.1329+738_1329+741delGTTA:		rs71934724	0.1350	0.0000	0/0/0	0.1392							613899 [FANCC (confirmed) Fanconi anemia,complementation group C,227645];				9	47					FANCC (inh=AR pLI=0.00)
chr9	97873339	97873339	G	A	het	het	het		QUAL=7688;DP=162,200,258;MQM=59	FANCC	3'UTR,intron	FANCC:NM_001243744.1:3'UTR:MODIFIER:exon14/14:c.*139C>T:,FANCC:NM_000136.2:intron:MODIFIER:exon13/14:c.1329+406C>T:,FANCC:NM_001243743.1:intron:MODIFIER:exon13/14:c.1329+406C>T:		rs879492	0.4167	0.0000	0/0/0	0.4342							613899 [FANCC (confirmed) Fanconi anemia,complementation group C,227645];				20	77					FANCC (inh=AR pLI=0.00)
chr9	97873435	97873435	G	A	het	het	het		QUAL=6382;DP=169,134,171;MQM=60	FANCC	3'UTR,intron	FANCC:NM_001243744.1:3'UTR:MODIFIER:exon14/14:c.*43C>T:,FANCC:NM_000136.2:intron:MODIFIER:exon13/14:c.1329+310C>T:,FANCC:NM_001243743.1:intron:MODIFIER:exon13/14:c.1329+310C>T:		rs2404457	0.4111	0.3979	994/244/20	0.1157							613899 [FANCC (confirmed) Fanconi anemia,complementation group C,227645];				144	410					FANCC (inh=AR pLI=0.00)
chr9	98205334	98205334	A	G	wt	het	wt		QUAL=4622;DP=363,328,376;MQM=60	PTCH1	3'UTR	PTCH1:NM_000264.3:3'UTR:MODIFIER:exon24/24:c.*3341T>C:,PTCH1:NM_001083607.1:3'UTR:MODIFIER:exon24/24:c.*3341T>C:,PTCH1:NM_001083606.1:3'UTR:MODIFIER:exon24/24:c.*3341T>C:,PTCH1:NM_001083604.1:3'UTR:MODIFIER:exon24/24:c.*3341T>C:,PTCH1:NM_001083605.1:3'UTR:MODIFIER:exon24/24:c.*3341T>C:,PTCH1:NM_001083602.1:3'UTR:MODIFIER:exon24/24:c.*3341T>C:,PTCH1:NM_001083603.1:3'UTR:MODIFIER:exon24/24:c.*3341T>C:		rs138499623	0.0036	0.0000	0/0/0	0.0067							601309 [PTCH1 (confirmed) Basal cell nevus syndrome,109400|Basal cell carcinoma,somatic,605462|Holoprosencephaly 7,610828];	RCV000267715.1 [likely benign]; RCV000360056.1 [likely benign]; 			0	4					PTCH1 (inh=AD pLI=1.00)
chr9	98205645	98205645	T	C	wt	wt	het		QUAL=3698;DP=463,180,267;MQM=60	PTCH1	3'UTR	PTCH1:NM_000264.3:3'UTR:MODIFIER:exon24/24:c.*3030A>G:,PTCH1:NM_001083607.1:3'UTR:MODIFIER:exon24/24:c.*3030A>G:,PTCH1:NM_001083606.1:3'UTR:MODIFIER:exon24/24:c.*3030A>G:,PTCH1:NM_001083604.1:3'UTR:MODIFIER:exon24/24:c.*3030A>G:,PTCH1:NM_001083605.1:3'UTR:MODIFIER:exon24/24:c.*3030A>G:,PTCH1:NM_001083602.1:3'UTR:MODIFIER:exon24/24:c.*3030A>G:,PTCH1:NM_001083603.1:3'UTR:MODIFIER:exon24/24:c.*3030A>G:		rs28485160	0.2129	0.0000	0/0/0	0.1297							601309 [PTCH1 (confirmed) Basal cell nevus syndrome,109400|Basal cell carcinoma,somatic,605462|Holoprosencephaly 7,610828];	RCV000304543.1 [benign]; RCV000361552.1 [benign]; 			2	33					PTCH1 (inh=AD pLI=1.00)
chr9	98206791	98206791	-	CA	wt	wt	het		QUAL=1143;DP=66,201,248;MQM=60	PTCH1	3'UTR	PTCH1:NM_000264.3:3'UTR:MODIFIER:exon24/24:c.*1882_*1883dupTG:,PTCH1:NM_001083607.1:3'UTR:MODIFIER:exon24/24:c.*1882_*1883dupTG:,PTCH1:NM_001083606.1:3'UTR:MODIFIER:exon24/24:c.*1882_*1883dupTG:,PTCH1:NM_001083604.1:3'UTR:MODIFIER:exon24/24:c.*1882_*1883dupTG:,PTCH1:NM_001083605.1:3'UTR:MODIFIER:exon24/24:c.*1882_*1883dupTG:,PTCH1:NM_001083602.1:3'UTR:MODIFIER:exon24/24:c.*1882_*1883dupTG:,PTCH1:NM_001083603.1:3'UTR:MODIFIER:exon24/24:c.*1882_*1883dupTG:	(AC)n	rs369387883;rs59205702;rs769003113	0.1328	0.0000	0/0/0	0.0526							601309 [PTCH1 (confirmed) Basal cell nevus syndrome,109400|Basal cell carcinoma,somatic,605462|Holoprosencephaly 7,610828];	RCV000273750.1 [uncertain significance]; RCV000319432.1,RCV000326712.1 [uncertain significance,likely benign]; RCV000383688.1 [likely benign]; 			0	24					PTCH1 (inh=AD pLI=1.00)
chr9	98207302	98207302	C	G	wt	wt	het		QUAL=4403;DP=278,243,319;MQM=60	PTCH1	3'UTR	PTCH1:NM_000264.3:3'UTR:MODIFIER:exon24/24:c.*1373G>C:,PTCH1:NM_001083607.1:3'UTR:MODIFIER:exon24/24:c.*1373G>C:,PTCH1:NM_001083606.1:3'UTR:MODIFIER:exon24/24:c.*1373G>C:,PTCH1:NM_001083604.1:3'UTR:MODIFIER:exon24/24:c.*1373G>C:,PTCH1:NM_001083605.1:3'UTR:MODIFIER:exon24/24:c.*1373G>C:,PTCH1:NM_001083602.1:3'UTR:MODIFIER:exon24/24:c.*1373G>C:,PTCH1:NM_001083603.1:3'UTR:MODIFIER:exon24/24:c.*1373G>C:		rs16909865	0.0519	0.0000	0/0/0	0.0691							601309 [PTCH1 (confirmed) Basal cell nevus syndrome,109400|Basal cell carcinoma,somatic,605462|Holoprosencephaly 7,610828];	RCV000317879.1 [likely benign]; RCV000353980.1 [likely benign]; 			1	31					PTCH1 (inh=AD pLI=1.00)
chr9	98207926	98207926	-	AAGT	wt	wt	het		QUAL=3843;DP=292,270,353;MQM=59	PTCH1	3'UTR	PTCH1:NM_000264.3:3'UTR:MODIFIER:exon24/24:c.*748_*749insACTT:,PTCH1:NM_001083607.1:3'UTR:MODIFIER:exon24/24:c.*748_*749insACTT:,PTCH1:NM_001083606.1:3'UTR:MODIFIER:exon24/24:c.*748_*749insACTT:,PTCH1:NM_001083604.1:3'UTR:MODIFIER:exon24/24:c.*748_*749insACTT:,PTCH1:NM_001083605.1:3'UTR:MODIFIER:exon24/24:c.*748_*749insACTT:,PTCH1:NM_001083602.1:3'UTR:MODIFIER:exon24/24:c.*748_*749insACTT:,PTCH1:NM_001083603.1:3'UTR:MODIFIER:exon24/24:c.*748_*749insACTT:		rs147342582;rs199573111	0.0545	0.0000	0/0/0	0.0634							601309 [PTCH1 (confirmed) Basal cell nevus syndrome,109400|Basal cell carcinoma,somatic,605462|Holoprosencephaly 7,610828];	RCV000297004.1 [likely benign]; RCV000393179.1 [likely benign]; RCV000266694.1 [likely benign]; RCV000361355.1 [likely benign]; 			2	31					PTCH1 (inh=AD pLI=1.00)
chr9	98229389	98229389	C	G	hom	hom	hom		QUAL=8503;DP=165,58,72;MQM=60	PTCH1,LOC100507346	splice_region&intron,non_coding_transcript_exon	PTCH1:NM_000264.3:splice_region&intron:LOW:exon15/23:c.2560+9G>C:,PTCH1:NM_001083607.1:splice_region&intron:LOW:exon15/23:c.2107+9G>C:,PTCH1:NM_001083606.1:splice_region&intron:LOW:exon15/23:c.2107+9G>C:,PTCH1:NM_001083604.1:splice_region&intron:LOW:exon15/23:c.2107+9G>C:,PTCH1:NM_001083605.1:splice_region&intron:LOW:exon15/23:c.2107+9G>C:,PTCH1:NM_001083602.1:splice_region&intron:LOW:exon15/23:c.2362+9G>C:,PTCH1:NM_001083603.1:splice_region&intron:LOW:exon15/23:c.2557+9G>C:,LOC100507346:NR_038982.1:non_coding_transcript_exon:MODIFIER:exon2/4:n.368C>G:		rs2066829	0.3906	0.3583	8491/4561/2155	0.3507							601309 [PTCH1 (confirmed) Basal cell nevus syndrome,109400|Basal cell carcinoma,somatic,605462|Holoprosencephaly 7,610828];	RCV000252294.1 [benign]; RCV000294663.1 [benign]; RCV000333289.1 [benign]; 			421	1466	1	[1] Ilnaz Sepahi 29-03-2016 batch import			PTCH1 (inh=AD pLI=1.00), LOC100507346 (inh=n/a pLI=n/a)
chr9	98238358	98238358	G	A	hom	hom	hom		QUAL=14352;DP=213,87,171;MQM=59	PTCH1	synonymous	PTCH1:NM_000264.3:synonymous:LOW:exon12/24:c.1686C>T:p.Ala562Ala,PTCH1:NM_001083607.1:synonymous:LOW:exon12/24:c.1233C>T:p.Ala411Ala,PTCH1:NM_001083606.1:synonymous:LOW:exon12/24:c.1233C>T:p.Ala411Ala,PTCH1:NM_001083604.1:synonymous:LOW:exon12/24:c.1233C>T:p.Ala411Ala,PTCH1:NM_001083605.1:synonymous:LOW:exon12/24:c.1233C>T:p.Ala411Ala,PTCH1:NM_001083602.1:synonymous:LOW:exon12/24:c.1488C>T:p.Ala496Ala,PTCH1:NM_001083603.1:synonymous:LOW:exon12/24:c.1683C>T:p.Ala561Ala		rs2066836	0.0919	0.1739	2070/1597/9	0.1698							601309 [PTCH1 (confirmed) Basal cell nevus syndrome,109400|Basal cell carcinoma,somatic,605462|Holoprosencephaly 7,610828];	RCV000250191.1 [benign]; RCV000342546.1 [likely benign]; RCV000376238.1 [likely benign]; 		COSM1756288, COSM1756290, COSM1756289, COSM1756287	154	1065	1	[1] Ilnaz Sepahi 29-03-2016 batch import			PTCH1 (inh=AD pLI=1.00)
chr9	98269419	98269419	G	-	hom	hom	hom		QUAL=19876;DP=173,218,304;MQM=59	PTCH1	5'UTR,intron	PTCH1:NM_001083607.1:5'UTR:MODIFIER:exon1/24:c.-453delC:,PTCH1:NM_000264.3:intron:MODIFIER:exon1/23:c.202-538delC:,PTCH1:NM_001083606.1:intron:MODIFIER:exon1/23:c.-253+92delC:,PTCH1:NM_001083604.1:intron:MODIFIER:exon1/23:c.-252-538delC:,PTCH1:NM_001083605.1:intron:MODIFIER:exon1/23:c.-252-538delC:,PTCH1:NM_001083602.1:intron:MODIFIER:exon1/23:c.4-538delC:,PTCH1:NM_001083603.1:intron:MODIFIER:exon1/23:c.199-538delC:		rs397728992	0.2228	0.0000	0/0/0	0.2045							601309 [PTCH1 (confirmed) Basal cell nevus syndrome,109400|Basal cell carcinoma,somatic,605462|Holoprosencephaly 7,610828];				14	75					PTCH1 (inh=AD pLI=1.00)
chr9	98270321	98270328	GTGAGTGT	-	hom	hom	hom		QUAL=17651;DP=78,254,373;MQM=59	PTCH1	5'UTR,intron,non_coding_transcript	PTCH1:NM_001083604.1:5'UTR:MODIFIER:exon1/24:c.-22231_-358delACACTCAC:,PTCH1:NM_001083605.1:5'UTR:MODIFIER:exon1/24:c.-22231_-341delACACTCAC:,PTCH1:NM_000264.3:intron:MODIFIER:exon1/23:c.201+115_201+122delACACTCAC:,PTCH1:NM_001083602.1:intron:MODIFIER:exon1/23:c.4-1447_4-1440delACACTCAC:,PTCH1:NM_001083603.1:intron:MODIFIER:exon1/23:c.199-1447_199-1440delACACTCAC:,PTCH1:NM_001083604.1:non_coding_transcript:MODIFIER:exon1/24:c.-22231_-358delACACTCAC:,PTCH1:NM_001083605.1:non_coding_transcript:MODIFIER:exon1/24:c.-22231_-341delACACTCAC:	(GT)n	rs148507954;rs71366292	0.0000	0.0000	0/0/0	0.1499							601309 [PTCH1 (confirmed) Basal cell nevus syndrome,109400|Basal cell carcinoma,somatic,605462|Holoprosencephaly 7,610828];				9	66					PTCH1 (inh=AD pLI=1.00)
chr9	98997810	98997810	C	T	wt	wt	het	pred_pathogenic	QUAL=1678;DP=85,92,169;MQM=60	HSD17B3	missense	HSD17B3:NM_000197.1:missense:MODERATE:exon11/11:c.865G>A:p.Gly289Ser		rs2066479	0.1190	0.0731	455/116/60	0.0738	-0.3970	T,T	T	B,B	D,D	0.55	605573 [HSD17B3 (provisional) Pseudohermaphroditism,male,with gynecomastia,264300];	RCV000249456.1 [likely benign]; RCV000334343.1 [likely benign]; 	CM023631 [CLASS=DP MUT=ALT PHEN="Prostate cancer susceptibility association with" GENE=HSD17B3]; 	COSM3764082	9	167					HSD17B3 (inh=AR pLI=0.00)
chr9	100459578	100459578	T	C	hom	het	hom		QUAL=6735;DP=63,104,150;MQM=59	XPA	5'UTR,non_coding_transcript_exon	XPA:NM_000380.3:5'UTR:MODIFIER:exon1/6:c.-4A>G:,XPA:NR_027302.1:non_coding_transcript_exon:MODIFIER:exon1/7:n.114A>G:		rs1800975	0.6464	0.6335	22195/12832/2430	0.5829							611153 [XPA (confirmed) Xeroderma pigmentosum,group A,278700];	RCV000170427.2 [benign]; RCV000286055.1 [benign]; 	CR044772 [CLASS=DP MUT=ALT PHEN="Lung adenocarcinoma risk association with" GENE=XPA]; 		1329	1201					XPA (inh=AR pLI=0.00)
chr9	100615553	100615553	A	G	het	wt	het	low_DP	QUAL=903;DP=4,48,86;MQM=59	FOXE1	5'UTR	FOXE1:NM_004473.3:5'UTR:MODIFIER:exon1/1:c.-644A>G:		rs13302470	0.6859	0.0000	0/0/0	0.1116							602617 [FOXE1 (confirmed) Bamforth-Lazarus syndrome,241850|Thyroid cancer,nonmedullary,4,616534];				73	80					FOXE1 (inh=AR pLI=n/a)
chr9	100615572	100615572	G	A	het	wt	het	low_DP	QUAL=1078;DP=7,62,105;MQM=59	FOXE1	5'UTR_premature_start_codon_gain,5'UTR	FOXE1:NM_004473.3:5'UTR_premature_start_codon_gain:LOW:exon1/1:c.-625G>A:,FOXE1:NM_004473.3:5'UTR:MODIFIER:exon1/1:c.-625G>A:			0.0000	0.0000	0/0/0	0.0000							602617 [FOXE1 (confirmed) Bamforth-Lazarus syndrome,241850|Thyroid cancer,nonmedullary,4,616534];				0	1					FOXE1 (inh=AR pLI=n/a)
chr9	100615660	100615660	G	C	hom	het	het		QUAL=5019;DP=31,152,194;MQM=59	FOXE1	5'UTR	FOXE1:NM_004473.3:5'UTR:MODIFIER:exon1/1:c.-537G>C:		rs7849497	0.8830	0.0000	0/0/0	0.1196							602617 [FOXE1 (confirmed) Bamforth-Lazarus syndrome,241850|Thyroid cancer,nonmedullary,4,616534];				136	74					FOXE1 (inh=AR pLI=n/a)
chr9	100615914	100615914	A	G	het	wt	het		QUAL=662;DP=22,26,51;MQM=60	FOXE1	5'UTR	FOXE1:NM_004473.3:5'UTR:MODIFIER:exon1/1:c.-283A>G:		rs1867277	0.6859	0.0000	0/0/0	0.0969							602617 [FOXE1 (confirmed) Bamforth-Lazarus syndrome,241850|Thyroid cancer,nonmedullary,4,616534];		CR095675 [CLASS=DFP MUT=REF PHEN="Thyroid cancer susceptibility association with" GENE=FOXE1]; 		82	106					FOXE1 (inh=AR pLI=n/a)
chr9	100615949	100615949	C	A	het	wt	het		QUAL=1434;DP=28,113,157;MQM=60	FOXE1	5'UTR	FOXE1:NM_004473.3:5'UTR:MODIFIER:exon1/1:c.-248C>A:		rs1867278	0.6859	0.0000	0/0/0	0.1096							602617 [FOXE1 (confirmed) Bamforth-Lazarus syndrome,241850|Thyroid cancer,nonmedullary,4,616534];				81	110					FOXE1 (inh=AR pLI=n/a)
chr9	100616041	100616041	T	C	hom	het	het	low_DP	QUAL=1277;DP=12,42,56;MQM=60	FOXE1	5'UTR	FOXE1:NM_004473.3:5'UTR:MODIFIER:exon1/1:c.-156T>C:		rs1867279	0.8830	0.0000	0/0/0	0.7029							602617 [FOXE1 (confirmed) Bamforth-Lazarus syndrome,241850|Thyroid cancer,nonmedullary,4,616534];				132	68					FOXE1 (inh=AR pLI=n/a)
chr9	100616066	100616066	G	C	het	wt	het	low_DP	QUAL=403;DP=12,25,30;MQM=60	FOXE1	5'UTR	FOXE1:NM_004473.3:5'UTR:MODIFIER:exon1/1:c.-131G>C:		rs1867280	0.6861	0.0000	0/0/0	0.1272							602617 [FOXE1 (confirmed) Bamforth-Lazarus syndrome,241850|Thyroid cancer,nonmedullary,4,616534];				74	89					FOXE1 (inh=AR pLI=n/a)
chr9	100616583	100616583	T	C	hom	het	het		QUAL=2544;DP=41,59,78;MQM=60	FOXE1	synonymous	FOXE1:NM_004473.3:synonymous:LOW:exon1/1:c.387T>C:p.Leu129Leu		rs3021523	0.8828	0.8005	38874/18153/4531	0.7715							602617 [FOXE1 (confirmed) Bamforth-Lazarus syndrome,241850|Thyroid cancer,nonmedullary,4,616534];	RCV000081101.5 [benign]; 		COSM4163149	920	536					FOXE1 (inh=AR pLI=n/a)
chr9	100616692	100616692	G	C	het	wt	wt	low_QUAL;low_DP;pred_pathogenic	QUAL=10;DP=10,4,13;MQM=55	FOXE1	missense	FOXE1:NM_004473.3:missense:MODERATE:exon1/1:c.496G>C:p.Ala166Pro			0.0000	0.0000	0/0/0	0.0000	1.2530	D	D	P	D	22.90	602617 [FOXE1 (confirmed) Bamforth-Lazarus syndrome,241850|Thyroid cancer,nonmedullary,4,616534];				0	1					FOXE1 (inh=AR pLI=n/a)
chr9	100617021	100617021	C	T	wt	wt	het	low_DP	QUAL=115;DP=1,4,9;MQM=60	FOXE1	synonymous	FOXE1:NM_004473.3:synonymous:LOW:exon1/1:c.825C>T:p.Ser275Ser		rs3021526	0.6861	0.6864	822/130/27	0.2724							602617 [FOXE1 (confirmed) Bamforth-Lazarus syndrome,241850|Thyroid cancer,nonmedullary,4,616534];	RCV000081103.5 [benign]; 			564	594					FOXE1 (inh=AR pLI=n/a)
chr9	100617375	100617375	T	C	hom	het	het		QUAL=18056;DP=258,416,514;MQM=59	FOXE1	3'UTR	FOXE1:NM_004473.3:3'UTR:MODIFIER:exon1/1:c.*57T>C:		rs7046645	0.8828	0.0000	0/0/0	0.1432							602617 [FOXE1 (confirmed) Bamforth-Lazarus syndrome,241850|Thyroid cancer,nonmedullary,4,616534];				453	252					FOXE1 (inh=AR pLI=n/a)
chr9	100617433	100617433	A	C	het	het	wt		QUAL=6611;DP=156,387,461;MQM=59	FOXE1	3'UTR	FOXE1:NM_004473.3:3'UTR:MODIFIER:exon1/1:c.*115A>C:		rs7043516	0.1813	0.0000	0/0/0	0.0233							602617 [FOXE1 (confirmed) Bamforth-Lazarus syndrome,241850|Thyroid cancer,nonmedullary,4,616534];				4	62					FOXE1 (inh=AR pLI=n/a)
chr9	100617479	100617479	G	T	het	wt	het		QUAL=6396;DP=173,306,424;MQM=59	FOXE1	3'UTR	FOXE1:NM_004473.3:3'UTR:MODIFIER:exon1/1:c.*161G>T:		rs1443434	0.6861	0.0000	0/0/0	0.1128							602617 [FOXE1 (confirmed) Bamforth-Lazarus syndrome,241850|Thyroid cancer,nonmedullary,4,616534];				83	111					FOXE1 (inh=AR pLI=n/a)
chr9	100617583	100617583	T	C	het	wt	het		QUAL=8372;DP=295,316,427;MQM=60	FOXE1	3'UTR	FOXE1:NM_004473.3:3'UTR:MODIFIER:exon1/1:c.*265T>C:		rs1443435	0.6861	0.0000	0/0/0	0.1118							602617 [FOXE1 (confirmed) Bamforth-Lazarus syndrome,241850|Thyroid cancer,nonmedullary,4,616534];				84	110					FOXE1 (inh=AR pLI=n/a)
chr9	100617649	100617649	A	G	het	wt	het		QUAL=9064;DP=373,280,363;MQM=60	FOXE1	3'UTR	FOXE1:NM_004473.3:3'UTR:MODIFIER:exon1/1:c.*331A>G:		rs41274258	0.0152	0.0000	0/0/0	0.0057							602617 [FOXE1 (confirmed) Bamforth-Lazarus syndrome,241850|Thyroid cancer,nonmedullary,4,616534];				0	20					FOXE1 (inh=AR pLI=n/a)
chr9	100618660	100618660	G	A	het	het	wt		QUAL=4027;DP=225,78,147;MQM=60	FOXE1	3'UTR	FOXE1:NM_004473.3:3'UTR:MODIFIER:exon1/1:c.*1342G>A:		rs10984009	0.0956	0.0000	0/0/0	0.0160							602617 [FOXE1 (confirmed) Bamforth-Lazarus syndrome,241850|Thyroid cancer,nonmedullary,4,616534];				1	46					FOXE1 (inh=AR pLI=n/a)
chr9	101911656	101911656	A	G	wt	wt	het		QUAL=1436;DP=283,100,119;MQM=60	TGFBR1	3'UTR	TGFBR1:NM_001306210.1:3'UTR:MODIFIER:exon9/9:c.*69A>G:,TGFBR1:NM_001130916.2:3'UTR:MODIFIER:exon8/8:c.*69A>G:,TGFBR1:NM_004612.3:3'UTR:MODIFIER:exon9/9:c.*69A>G:		rs868	0.1174	0.0000	0/0/0	0.0318							190181 [TGFBR1 (confirmed) Loeys-Dietz syndrome 1,609192|Multiple self-healing squamous epithelioma,susceptibility to,132800];	RCV000312076.1 [benign]; RCV000366670.1 [benign]; RCV000406058.1 [benign]; 	CR169005 [CLASS=DFP MUT=REF PHEN="Colorectal cancer risk microsatellite-stable association with" GENE=TGFBR1]; 		27	209					TGFBR1 (inh=AD pLI=0.95)
chr9	101912471	101912471	A	G	wt	wt	het		QUAL=676;DP=192,39,57;MQM=60	TGFBR1	3'UTR	TGFBR1:NM_001306210.1:3'UTR:MODIFIER:exon9/9:c.*884A>G:,TGFBR1:NM_001130916.2:3'UTR:MODIFIER:exon8/8:c.*884A>G:,TGFBR1:NM_004612.3:3'UTR:MODIFIER:exon9/9:c.*884A>G:		rs334348	0.3319	0.0000	0/0/0	0.0533							190181 [TGFBR1 (confirmed) Loeys-Dietz syndrome 1,609192|Multiple self-healing squamous epithelioma,susceptibility to,132800];	RCV000267995.1 [benign]; RCV000325466.1 [benign]; RCV000382288.1 [benign]; 	CR102176 [CLASS=DFP MUT=ALT PHEN="Breast cancer association with" GENE=TGFBR1]; 		16	89					TGFBR1 (inh=AD pLI=0.95)
chr9	101913690	101913690	T	G	het	het	hom	low_DP	QUAL=1636;DP=117,3,12;MQM=59	TGFBR1	3'UTR	TGFBR1:NM_001306210.1:3'UTR:MODIFIER:exon9/9:c.*2103T>G:,TGFBR1:NM_001130916.2:3'UTR:MODIFIER:exon8/8:c.*2103T>G:,TGFBR1:NM_004612.3:3'UTR:MODIFIER:exon9/9:c.*2103T>G:	(T)n	rs7871490	0.0000	0.0000	0/0/0	0.0967							190181 [TGFBR1 (confirmed) Loeys-Dietz syndrome 1,609192|Multiple self-healing squamous epithelioma,susceptibility to,132800];	RCV000266960.1 [uncertain significance]; RCV000307304.1 [uncertain significance]; RCV000361934.1 [uncertain significance]; 			6	74					TGFBR1 (inh=AD pLI=0.95)
chr9	101914387	101914387	G	A	wt	wt	het		QUAL=6997;DP=402,406,578;MQM=60	TGFBR1	3'UTR	TGFBR1:NM_001306210.1:3'UTR:MODIFIER:exon9/9:c.*2800G>A:,TGFBR1:NM_001130916.2:3'UTR:MODIFIER:exon8/8:c.*2800G>A:,TGFBR1:NM_004612.3:3'UTR:MODIFIER:exon9/9:c.*2800G>A:		rs334349	0.3259	0.0000	0/0/0	0.3115							190181 [TGFBR1 (confirmed) Loeys-Dietz syndrome 1,609192|Multiple self-healing squamous epithelioma,susceptibility to,132800];	RCV000280999.1 [benign]; RCV000319749.1 [benign]; RCV000372077.1 [benign]; 			16	90					TGFBR1 (inh=AD pLI=0.95)
chr9	101914873	101914873	G	C	wt	wt	het		QUAL=5075;DP=499,307,374;MQM=60	TGFBR1	3'UTR	TGFBR1:NM_001306210.1:3'UTR:MODIFIER:exon9/9:c.*3286G>C:,TGFBR1:NM_001130916.2:3'UTR:MODIFIER:exon8/8:c.*3286G>C:,TGFBR1:NM_004612.3:3'UTR:MODIFIER:exon9/9:c.*3286G>C:		rs420549	0.1082	0.0000	0/0/0	0.0257							190181 [TGFBR1 (confirmed) Loeys-Dietz syndrome 1,609192|Multiple self-healing squamous epithelioma,susceptibility to,132800];	RCV000301868.1 [benign]; RCV000341985.1 [benign]; RCV000392864.1 [benign]; 			8	64					TGFBR1 (inh=AD pLI=0.95)
chr9	101916076	101916076	T	C	wt	het	wt		QUAL=2288;DP=311,188,257;MQM=60	TGFBR1	3'UTR	TGFBR1:NM_001306210.1:3'UTR:MODIFIER:exon9/9:c.*4489T>C:,TGFBR1:NM_001130916.2:3'UTR:MODIFIER:exon8/8:c.*4489T>C:,TGFBR1:NM_004612.3:3'UTR:MODIFIER:exon9/9:c.*4489T>C:		rs7850895	0.0443	0.0000	0/0/0	0.0108							190181 [TGFBR1 (confirmed) Loeys-Dietz syndrome 1,609192|Multiple self-healing squamous epithelioma,susceptibility to,132800];	RCV000304946.1 [benign]; RCV000339851.1 [benign]; RCV000393552.1 [benign]; 			1	24					TGFBR1 (inh=AD pLI=0.95)
chr9	101916165	101916165	T	G	wt	wt	het		QUAL=3619;DP=239,168,266;MQM=60	TGFBR1	3'UTR	TGFBR1:NM_001306210.1:3'UTR:MODIFIER:exon9/9:c.*4578T>G:,TGFBR1:NM_001130916.2:3'UTR:MODIFIER:exon8/8:c.*4578T>G:,TGFBR1:NM_004612.3:3'UTR:MODIFIER:exon9/9:c.*4578T>G:		rs1590	0.3299	0.0000	0/0/0	0.0531							190181 [TGFBR1 (confirmed) Loeys-Dietz syndrome 1,609192|Multiple self-healing squamous epithelioma,susceptibility to,132800];	RCV000291169.1 [benign]; RCV000327431.1 [benign]; RCV000381609.1 [benign]; 			16	90					TGFBR1 (inh=AD pLI=0.95)
chr9	103015184	103015184	T	C	het	hom	wt		QUAL=4818;DP=123,100,142;MQM=60	INVS	splice_region&intron	INVS:NM_014425.4:splice_region&intron:LOW:exon9/16:c.1235-5T>C:,INVS:NM_001318381.1:splice_region&intron:LOW:exon10/17:c.947-5T>C:,INVS:NM_001318382.1:splice_region&intron:LOW:exon9/16:c.257-5T>C:,INVS:NR_134606.1:splice_region&intron:LOW:exon9/16:n.1491-5T>C:		rs2245216	0.2105	0.3224	6743/5428/109	0.3121							243305 [INVS (confirmed) Nephronophthisis 2,infantile,602088];	RCV000081626.5 [benign]; RCV000333501.1 [benign]; 		COSM150650	234	721					INVS (inh=AR pLI=0.00)
chr9	103054818	103054818	C	T	wt	wt	het	pred_pathogenic	QUAL=5506;DP=287,283,412;MQM=60	INVS	missense,non_coding_transcript_exon	INVS:NM_014425.4:missense:MODERATE:exon14/17:c.2279C>T:p.Ser760Phe,INVS:NM_001318381.1:missense:MODERATE:exon15/18:c.1991C>T:p.Ser664Phe,INVS:NM_001318382.1:missense:MODERATE:exon14/17:c.1301C>T:p.Ser434Phe,INVS:NR_134606.1:non_coding_transcript_exon:MODIFIER:exon14/17:n.2486C>T:			0.0000	0.0000	0/0/0	0.0000	0.2980	D,D	T	B,B	T,T	22.90	243305 [INVS (confirmed) Nephronophthisis 2,infantile,602088];				0	2					INVS (inh=AR pLI=0.00)
chr9	103054951	103054951	T	C	het	hom	het		QUAL=15678;DP=232,290,341;MQM=60	INVS	synonymous,non_coding_transcript_exon	INVS:NM_014425.4:synonymous:LOW:exon14/17:c.2412T>C:p.Ser804Ser,INVS:NM_001318381.1:synonymous:LOW:exon15/18:c.2124T>C:p.Ser708Ser,INVS:NM_001318382.1:synonymous:LOW:exon14/17:c.1434T>C:p.Ser478Ser,INVS:NR_134606.1:non_coding_transcript_exon:MODIFIER:exon14/17:n.2619T>C:		rs2787374	0.4073	0.4676	14861/10875/1792	0.4645							243305 [INVS (confirmed) Nephronophthisis 2,infantile,602088];	RCV000081629.5 [benign]; RCV000399311.1 [benign]; 		COSM3763489, COSM3763490	415	739					INVS (inh=AR pLI=0.00)
chr9	103063422	103063425	CACA	-	hom	hom	hom	low_DP	QUAL=525;DP=29,16,5;MQM=58	INVS	3'UTR,non_coding_transcript_exon	INVS:NM_014425.4:3'UTR:MODIFIER:exon17/17:c.*502_*505delCACA:,INVS:NM_001318381.1:3'UTR:MODIFIER:exon18/18:c.*502_*505delCACA:,INVS:NM_001318382.1:3'UTR:MODIFIER:exon17/17:c.*502_*505delCACA:,INVS:NR_134606.1:non_coding_transcript_exon:MODIFIER:exon17/17:n.3907_3910delCACA:	(CA)n		0.0000	0.0000	0/0/0	0.0000							243305 [INVS (confirmed) Nephronophthisis 2,infantile,602088];	RCV000317814.1 [uncertain significance]; 			2	4					INVS (inh=AR pLI=0.00)
chr9	104182940	104182940	T	C	wt	wt	het		QUAL=1621;DP=310,107,132;MQM=60	ALDOB	3'UTR	ALDOB:NM_000035.3:3'UTR:MODIFIER:exon9/9:c.*1151A>G:		rs491979	0.4978	0.0000	0/0/0	0.0769							612724 [ALDOB (confirmed) Fructose intolerance,229600];	RCV000402130.1 [benign]; 			40	113					ALDOB (inh=AR pLI=0.00)
chr9	104183194	104183194	C	T	het	hom	wt		QUAL=12616;DP=425,225,360;MQM=60	ALDOB	3'UTR	ALDOB:NM_000035.3:3'UTR:MODIFIER:exon9/9:c.*897G>A:	HAL1ME	rs17772839	0.0625	0.0000	0/0/0	0.0147							612724 [ALDOB (confirmed) Fructose intolerance,229600];	RCV000393044.1 [likely benign]; 			6	35					ALDOB (inh=AR pLI=0.00)
chr9	104183479	104183479	T	C	het	hom	wt		QUAL=7857;DP=237,144,130;MQM=60	ALDOB	3'UTR	ALDOB:NM_000035.3:3'UTR:MODIFIER:exon9/9:c.*612A>G:	MER5B	rs41296049	0.0625	0.0000	0/0/0	0.0147							612724 [ALDOB (confirmed) Fructose intolerance,229600];	RCV000358465.1 [likely benign]; 			6	34					ALDOB (inh=AR pLI=0.00)
chr9	104183539	104183539	A	T	het	hom	wt		QUAL=11018;DP=425,193,232;MQM=59	ALDOB	3'UTR	ALDOB:NM_000035.3:3'UTR:MODIFIER:exon9/9:c.*552T>A:	MER5B	rs41308902	0.0627	0.0000	0/0/0	0.0861							612724 [ALDOB (confirmed) Fructose intolerance,229600];	RCV000323875.1 [likely benign]; 			6	35					ALDOB (inh=AR pLI=0.00)
chr9	104183586	104183586	G	T	het	hom	wt		QUAL=11867;DP=466,194,255;MQM=60	ALDOB	3'UTR	ALDOB:NM_000035.3:3'UTR:MODIFIER:exon9/9:c.*505C>A:		rs17772845	0.0625	0.0000	0/0/0	0.0147							612724 [ALDOB (confirmed) Fructose intolerance,229600];	RCV000371488.1 [likely benign]; 			6	35					ALDOB (inh=AR pLI=0.00)
chr9	104183885	104183885	G	T	het	hom	wt		QUAL=8417;DP=362,127,162;MQM=60	ALDOB	3'UTR	ALDOB:NM_000035.3:3'UTR:MODIFIER:exon9/9:c.*206C>A:		rs17772869	0.0561	0.0000	0/0/0	0.0144							612724 [ALDOB (confirmed) Fructose intolerance,229600];	RCV000292298.1 [likely benign]; 			6	35					ALDOB (inh=AR pLI=0.00)
chr9	104183969	104183969	C	T	het	hom	wt		QUAL=5481;DP=192,98,119;MQM=60	ALDOB	3'UTR	ALDOB:NM_000035.3:3'UTR:MODIFIER:exon9/9:c.*122G>A:		rs41310087	0.0397	0.0000	0/0/0	0.0610							612724 [ALDOB (confirmed) Fructose intolerance,229600];	RCV000395004.1 [likely benign]; 			5	31					ALDOB (inh=AR pLI=0.00)
chr9	104184022	104184022	G	A	wt	wt	het		QUAL=996;DP=179,85,106;MQM=60	ALDOB	3'UTR	ALDOB:NM_000035.3:3'UTR:MODIFIER:exon9/9:c.*69C>T:		rs4577	0.4419	0.4466	9921/4377/610	0.4242							612724 [ALDOB (confirmed) Fructose intolerance,229600];	RCV000295978.1 [benign]; 			148	439					ALDOB (inh=AR pLI=0.00)
chr9	108335958	108335958	G	C	wt	het	wt		QUAL=2225;DP=311,224,273;MQM=60	FKTN	5'UTR,intron	FKTN:NM_001079802.1:5'UTR:MODIFIER:exon2/11:c.-158G>C:,FKTN:NM_001198963.1:5'UTR:MODIFIER:exon2/12:c.-158G>C:,FKTN:NM_006731.2:intron:MODIFIER:exon1/9:c.-88-1268G>C:	L1M7	rs4742953	0.1669	0.0000	0/0/0	0.2394							607440 [FKTN (confirmed) Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,4,253800|Muscular dystrophy-dystroglycanopathy (congenital without mental retardation),type B,4,613152|Cardiomyopathy,dilated,1X,611615|Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,4,611588];	RCV000281681.1 [likely benign]; RCV000338952.1 [likely benign]; 			12	69					FKTN (inh=AR pLI=0.00)
chr9	108366734	108366734	G	A	wt	het	wt	pred_pathogenic	QUAL=1368;DP=162,131,170;MQM=60	FKTN	missense	FKTN:NM_001079802.1:missense:MODERATE:exon6/11:c.608G>A:p.Arg203Gln,FKTN:NM_001198963.1:missense:MODERATE:exon6/12:c.608G>A:p.Arg203Gln,FKTN:NM_006731.2:missense:MODERATE:exon5/10:c.608G>A:p.Arg203Gln		rs34787999	0.1581	0.2446	4155/3146/135	0.2469	4.3990	T,T,T,T	T	B,B,B	D,D,D,D	23.30	607440 [FKTN (confirmed) Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,4,253800|Muscular dystrophy-dystroglycanopathy (congenital without mental retardation),type B,4,613152|Cardiomyopathy,dilated,1X,611615|Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,4,611588];	RCV000079437.10 [other]; RCV000322229.1 [likely benign]; RCV000379215.1 [likely benign]; 		COSM3763500, COSM3763499	105	629					FKTN (inh=AR pLI=0.00)
chr9	108380355	108380355	C	A	wt	het	wt		QUAL=791;DP=144,69,88;MQM=60	FKTN	synonymous	FKTN:NM_001079802.1:synonymous:LOW:exon9/11:c.1026C>A:p.Leu342Leu,FKTN:NM_001198963.1:synonymous:LOW:exon9/12:c.1026C>A:p.Leu342Leu,FKTN:NM_006731.2:synonymous:LOW:exon8/10:c.1026C>A:p.Leu342Leu	Penelope1_Vert	rs17309806	0.1783	0.2518	4258/3097/282	0.2525	0.6010					16.32	607440 [FKTN (confirmed) Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,4,253800|Muscular dystrophy-dystroglycanopathy (congenital without mental retardation),type B,4,613152|Cardiomyopathy,dilated,1X,611615|Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,4,611588];	RCV000079422.9 [other]; RCV000284002.1 [likely benign]; RCV000378499.1 [likely benign]; 		COSM4163187	103	637					FKTN (inh=AR pLI=0.00)
chr9	108398678	108398678	A	G	het	het	het		QUAL=13681;DP=248,327,398;MQM=60	FKTN	3'UTR,intron	FKTN:NM_001079802.1:3'UTR:MODIFIER:exon11/11:c.*1133A>G:,FKTN:NM_006731.2:3'UTR:MODIFIER:exon10/10:c.*1133A>G:,FKTN:NM_001198963.1:intron:MODIFIER:exon11/11:c.1270+1249A>G:		rs2768282	0.1354	0.0000	0/0/0	0.0264							607440 [FKTN (confirmed) Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,4,253800|Muscular dystrophy-dystroglycanopathy (congenital without mental retardation),type B,4,613152|Cardiomyopathy,dilated,1X,611615|Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,4,611588];	RCV000293508.1 [uncertain significance]; RCV000348334.1 [uncertain significance]; 			10	89					FKTN (inh=AR pLI=0.00)
chr9	108399825	108399825	T	C	het	het	het		QUAL=17626;DP=580,311,425;MQM=60	FKTN	3'UTR,intron	FKTN:NM_001079802.1:3'UTR:MODIFIER:exon11/11:c.*2280T>C:,FKTN:NM_006731.2:3'UTR:MODIFIER:exon10/10:c.*2280T>C:,FKTN:NM_001198963.1:intron:MODIFIER:exon11/11:c.1270+2396T>C:		rs1024366	0.1342	0.0000	0/0/0	0.0264							607440 [FKTN (confirmed) Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,4,253800|Muscular dystrophy-dystroglycanopathy (congenital without mental retardation),type B,4,613152|Cardiomyopathy,dilated,1X,611615|Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,4,611588];	RCV000405538.1 [benign]; 			10	88					FKTN (inh=AR pLI=0.00)
chr9	108402805	108402805	G	T	het	het	het	low_DP	QUAL=1511;DP=87,16,25;MQM=58	FKTN	3'UTR	FKTN:NM_001079802.1:3'UTR:MODIFIER:exon11/11:c.*5260G>T:,FKTN:NM_001198963.1:3'UTR:MODIFIER:exon12/12:c.*401G>T:,FKTN:NM_006731.2:3'UTR:MODIFIER:exon10/10:c.*5260G>T:	AluSz	rs2010861	0.1318	0.0000	0/0/0	0.1363							607440 [FKTN (confirmed) Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,4,253800|Muscular dystrophy-dystroglycanopathy (congenital without mental retardation),type B,4,613152|Cardiomyopathy,dilated,1X,611615|Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,4,611588];	RCV000317327.1 [uncertain significance]; RCV000371858.1 [uncertain significance]; 			10	86					FKTN (inh=AR pLI=0.00)
chr9	108402836	108402836	A	-	het	wt	wt		QUAL=131;DP=86,23,41;MQM=58	FKTN	3'UTR	FKTN:NM_001079802.1:3'UTR:MODIFIER:exon11/11:c.*5303delA:,FKTN:NM_001198963.1:3'UTR:MODIFIER:exon12/12:c.*444delA:,FKTN:NM_006731.2:3'UTR:MODIFIER:exon10/10:c.*5303delA:	AluSz	rs879263714	0.0000	0.0000	0/0/0	0.0014							607440 [FKTN (confirmed) Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,4,253800|Muscular dystrophy-dystroglycanopathy (congenital without mental retardation),type B,4,613152|Cardiomyopathy,dilated,1X,611615|Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,4,611588];				0	11					FKTN (inh=AR pLI=0.00)
chr9	111630324	111630324	C	T	wt	wt	het		QUAL=2837;DP=334,199,243;MQM=60	IKBKAP	3'UTR	IKBKAP:NM_003640.4:3'UTR:MODIFIER:exon37/37:c.*1071G>A:,IKBKAP:NM_001318360.1:3'UTR:MODIFIER:exon37/37:c.*1071G>A:	MSTB1	rs41305457	0.0751	0.0000	0/0/0	0.0159							603722 [IKBKAP (confirmed) Dysautonomia,familial,223900];	RCV000286241.1 [likely benign]; 			2	57					IKBKAP (inh=AR pLI=0.00)
chr9	111653574	111653574	C	G	hom	het	het		QUAL=13554;DP=258,202,282;MQM=60	IKBKAP	synonymous	IKBKAP:NM_003640.4:synonymous:LOW:exon28/37:c.3069G>C:p.Leu1023Leu,IKBKAP:NM_001318360.1:synonymous:LOW:exon28/37:c.2727G>C:p.Leu909Leu		rs1063110	0.3155	0.3913	10015/6650/72	0.3869							603722 [IKBKAP (confirmed) Dysautonomia,familial,223900];	RCV000245896.1 [benign]; RCV000338102.1 [likely benign]; 		COSM3763506	286	768					IKBKAP (inh=AR pLI=0.00)
chr9	111696389	111696389	G	C	het	het	wt		QUAL=1620;DP=41,105,166;MQM=59	IKBKAP	5'UTR	IKBKAP:NM_003640.4:5'UTR:MODIFIER:exon1/37:c.-301C>G:,IKBKAP:NM_001318360.1:5'UTR:MODIFIER:exon1/37:c.-498C>G:		rs2275641	0.3520	0.0000	0/0/0	0.3696							603722 [IKBKAP (confirmed) Dysautonomia,familial,223900];	RCV000368493.1 [likely benign]; 			29	100					IKBKAP (inh=AR pLI=0.00)
chr9	113457726	113457726	G	A	het	het	het		QUAL=8213;DP=220,170,233;MQM=60	MUSK	synonymous	MUSK:NM_005592.3:synonymous:LOW:exon4/14:c.402G>A:p.Glu134Glu,MUSK:NM_001166280.1:synonymous:LOW:exon4/13:c.402G>A:p.Glu134Glu,MUSK:NM_001166281.1:synonymous:LOW:exon4/12:c.402G>A:p.Glu134Glu		rs10980531	0.1701	0.2416	717/380/41	0.1380							601296 [MUSK (confirmed) Myasthenic syndrome,congenital,9,associated with acetylcholine receptor deficiency,616325|Fetal akinesia deformation sequence,208150];	RCV000117647.2 [benign]; RCV000348451.1 [benign]; 			56	444					MUSK (inh=AR pLI=0.00)
chr9	116023498	116023498	C	T	het	wt	het		QUAL=5709;DP=226,174,238;MQM=53	SLC31A1	3'UTR	SLC31A1:NM_001859.3:3'UTR:MODIFIER:exon5/5:c.*745C>T:	AluSq2	rs139028783	0.0096	0.0000	0/0/0	0.0108											0	6					SLC31A1 (inh=n/a pLI=0.52)
chr9	116023979	116023979	A	C	het	wt	het		QUAL=8036;DP=263,188,282;MQM=59	SLC31A1	3'UTR	SLC31A1:NM_001859.3:3'UTR:MODIFIER:exon5/5:c.*1226A>C:	MER5A	rs41280225	0.1384	0.0000	0/0/0	0.0227											3	42					SLC31A1 (inh=n/a pLI=0.52)
chr9	116025024	116025024	A	C	het	het	wt		QUAL=8842;DP=433,234,267;MQM=59	SLC31A1	3'UTR	SLC31A1:NM_001859.3:3'UTR:MODIFIER:exon5/5:c.*2271A>C:		rs10759637	0.5092	0.0000	0/0/0	0.0804											49	109					SLC31A1 (inh=n/a pLI=0.52)
chr9	116025982	116025982	A	C	wt	het	het	low_MQM	QUAL=7112;DP=637,287,391;MQM=48	SLC31A1	3'UTR	SLC31A1:NM_001859.3:3'UTR:MODIFIER:exon5/5:c.*3229A>C:		rs41280229	0.1352	0.0000	0/0/0	0.1829											17	76					SLC31A1 (inh=n/a pLI=0.52)
chr9	116026034	116026034	A	G	wt	het	het	low_MQM	QUAL=5958;DP=456,239,351;MQM=43	SLC31A1	3'UTR	SLC31A1:NM_001859.3:3'UTR:MODIFIER:exon5/5:c.*3281A>G:		rs10981707	0.1398	0.0000	0/0/0	0.1415											17	76					SLC31A1 (inh=n/a pLI=0.52)
chr9	116026040	116026040	C	T	wt	het	het	low_MQM	QUAL=5317;DP=391,227,336;MQM=42	SLC31A1	3'UTR	SLC31A1:NM_001859.3:3'UTR:MODIFIER:exon5/5:c.*3287C>T:		rs10981708	0.1368	0.0000	0/0/0	0.0291											15	76					SLC31A1 (inh=n/a pLI=0.52)
chr9	116026041	116026041	G	A	wt	het	het	low_MQM	QUAL=5317;DP=391,227,336;MQM=42	SLC31A1	3'UTR	SLC31A1:NM_001859.3:3'UTR:MODIFIER:exon5/5:c.*3288G>A:		rs10981709	0.1368	0.0000	0/0/0	0.0265											15	76					SLC31A1 (inh=n/a pLI=0.52)
chr9	116026255	116026255	G	C	het	het	wt		QUAL=7780;DP=355,189,250;MQM=59	SLC31A1	3'UTR	SLC31A1:NM_001859.3:3'UTR:MODIFIER:exon5/5:c.*3502G>C:		rs1143245	0.3185	0.0000	0/0/0	0.0404											11	75					SLC31A1 (inh=n/a pLI=0.52)
chr9	119462112	119462112	C	T	hom	hom	hom		QUAL=27330;DP=359,216,254;MQM=60	TRIM32,ASTN2	3'UTR,intron	TRIM32:NM_001099679.1:3'UTR:MODIFIER:exon2/2:c.*129C>T:,TRIM32:NM_012210.3:3'UTR:MODIFIER:exon2/2:c.*129C>T:,ASTN2:NM_014010.4:intron:MODIFIER:exon15/21:c.2653+25938G>A:		rs3019	0.9491	0.0000	0/0/0	0.1686							602290 [TRIM32 (confirmed) Muscular dystrophy,limb-girdle,type 2H,254110|Bardet-Biedl syndrome 11,615988];	RCV000284772.1 [benign]; RCV000339744.1 [benign]; 			205	25					TRIM32 (inh=AR pLI=0.10), ASTN2 (inh=n/a pLI=0.99)
chr9	119463189	119463189	T	C	het	wt	het		QUAL=9991;DP=356,326,327;MQM=60	TRIM32,ASTN2	3'UTR,intron	TRIM32:NM_001099679.1:3'UTR:MODIFIER:exon2/2:c.*1206T>C:,TRIM32:NM_012210.3:3'UTR:MODIFIER:exon2/2:c.*1206T>C:,ASTN2:NM_014010.4:intron:MODIFIER:exon15/21:c.2653+24861A>G:		rs2281627	0.2680	0.0000	0/0/0	0.0565							602290 [TRIM32 (confirmed) Muscular dystrophy,limb-girdle,type 2H,254110|Bardet-Biedl syndrome 11,615988];	RCV000304648.1 [likely benign]; RCV000407378.1 [likely benign]; 			27	122					TRIM32 (inh=AR pLI=0.10), ASTN2 (inh=n/a pLI=0.99)
chr9	123170733	123170733	C	G	hom	hom	hom		QUAL=29763;DP=361,275,338;MQM=59	CDK5RAP2	missense,non_coding_transcript_exon	CDK5RAP2:NM_018249.5:missense:MODERATE:exon31/38:c.4618G>C:p.Val1540Leu,CDK5RAP2:NM_001011649.2:missense:MODERATE:exon31/37:c.4618G>C:p.Val1540Leu,CDK5RAP2:NM_001272039.1:missense:MODERATE:exon28/35:c.3928G>C:p.Val1310Leu,CDK5RAP2:NR_073554.1:non_coding_transcript_exon:MODIFIER:exon31/38:n.4887G>C:,CDK5RAP2:NR_073555.1:non_coding_transcript_exon:MODIFIER:exon31/38:n.4810G>C:,CDK5RAP2:NR_073556.1:non_coding_transcript_exon:MODIFIER:exon32/39:n.5017G>C:,CDK5RAP2:NR_073557.1:non_coding_transcript_exon:MODIFIER:exon31/38:n.4890G>C:,CDK5RAP2:NR_073558.1:non_coding_transcript_exon:MODIFIER:exon31/38:n.4887G>C:		rs4837768	0.7532	0.7691	36224/18864/1789	0.7620	-0.0830	T,T,T,T,T,T,T	T	B,B,B,B,B	T,T,T,T,T,T	12.10	608201 [CDK5RAP2 (confirmed) Microcephaly 3,primary,autosomal recessive,604804];	RCV000020841.1 [benign]; RCV000145488.2 [other]; RCV000331745.1 [benign]; 			898	572					CDK5RAP2 (inh=AR pLI=0.00)
chr9	123215872	123215872	G	C	het	wt	het		QUAL=9842;DP=386,325,408;MQM=60	CDK5RAP2	missense,intron,non_coding_transcript_exon	CDK5RAP2:NM_018249.5:missense:MODERATE:exon21/38:c.2655C>G:p.Phe885Leu,CDK5RAP2:NM_001011649.2:missense:MODERATE:exon21/37:c.2655C>G:p.Phe885Leu,CDK5RAP2:NM_001272039.1:intron:MODIFIER:exon18/34:c.2104-5468C>G:,CDK5RAP2:NR_073554.1:non_coding_transcript_exon:MODIFIER:exon21/38:n.2924C>G:,CDK5RAP2:NR_073555.1:non_coding_transcript_exon:MODIFIER:exon21/38:n.2847C>G:,CDK5RAP2:NR_073556.1:non_coding_transcript_exon:MODIFIER:exon22/39:n.3054C>G:,CDK5RAP2:NR_073557.1:non_coding_transcript_exon:MODIFIER:exon21/38:n.2927C>G:,CDK5RAP2:NR_073558.1:non_coding_transcript_exon:MODIFIER:exon21/38:n.2924C>G:		rs112600265	0.0014	0.0040	0/0/0	0.0037	0.5100	T,T,T,T,T	T	B,B,B,B	T,T,T,T,T	9.02	608201 [CDK5RAP2 (confirmed) Microcephaly 3,primary,autosomal recessive,604804];	RCV000345743.1 [uncertain significance]; 			1	10	3	[3] Stephan Waldm?ller 12.08.2014			CDK5RAP2 (inh=AR pLI=0.00)
chr9	123291036	123291036	C	G	hom	hom	hom	pred_pathogenic	QUAL=34573;DP=329,332,385;MQM=60	CDK5RAP2	missense,non_coding_transcript_exon	CDK5RAP2:NM_018249.5:missense:MODERATE:exon9/38:c.865G>C:p.Glu289Gln,CDK5RAP2:NM_001011649.2:missense:MODERATE:exon9/37:c.865G>C:p.Glu289Gln,CDK5RAP2:NM_001272039.1:missense:MODERATE:exon9/35:c.865G>C:p.Glu289Gln,CDK5RAP2:NR_073554.1:non_coding_transcript_exon:MODIFIER:exon9/38:n.1057G>C:,CDK5RAP2:NR_073555.1:non_coding_transcript_exon:MODIFIER:exon9/38:n.1057G>C:,CDK5RAP2:NR_073556.1:non_coding_transcript_exon:MODIFIER:exon9/39:n.1054G>C:,CDK5RAP2:NR_073557.1:non_coding_transcript_exon:MODIFIER:exon9/38:n.1057G>C:,CDK5RAP2:NR_073558.1:non_coding_transcript_exon:MODIFIER:exon9/38:n.1054G>C:		rs4836822	0.8011	0.8772	47115/28550/2381	0.8694	2.5270	T,T,T,T,T,T	T	P,B,P	T,T,T,T,T	18.25	608201 [CDK5RAP2 (confirmed) Microcephaly 3,primary,autosomal recessive,604804];	RCV000020847.1 [benign]; RCV000145507.2 [other]; RCV000407188.1 [benign]; 			1273	276					CDK5RAP2 (inh=AR pLI=0.00)
chr9	123342259	123342259	C	A	hom	hom	hom		QUAL=6138;DP=91,41,69;MQM=60	CDK5RAP2	5'UTR,non_coding_transcript_exon	CDK5RAP2:NM_018249.5:5'UTR:MODIFIER:exon1/38:c.-3G>T:,CDK5RAP2:NM_001011649.2:5'UTR:MODIFIER:exon1/37:c.-3G>T:,CDK5RAP2:NM_001272039.1:5'UTR:MODIFIER:exon1/35:c.-3G>T:,CDK5RAP2:NR_073554.1:non_coding_transcript_exon:MODIFIER:exon1/38:n.190G>T:,CDK5RAP2:NR_073555.1:non_coding_transcript_exon:MODIFIER:exon1/38:n.190G>T:,CDK5RAP2:NR_073556.1:non_coding_transcript_exon:MODIFIER:exon1/39:n.190G>T:,CDK5RAP2:NR_073557.1:non_coding_transcript_exon:MODIFIER:exon1/38:n.190G>T:,CDK5RAP2:NR_073558.1:non_coding_transcript_exon:MODIFIER:exon1/38:n.190G>T:		rs932975	0.9804	0.9921	58644/32739/4293	0.9285							608201 [CDK5RAP2 (confirmed) Microcephaly 3,primary,autosomal recessive,604804];	RCV000081944.6 [benign]; RCV000387394.1 [benign]; RCV000281288.1 [uncertain significance]; 			1552	13					CDK5RAP2 (inh=AR pLI=0.00)
chr9	123342275	123342275	A	G	hom	hom	hom		QUAL=5221;DP=79,41,62;MQM=60	CDK5RAP2	5'UTR,non_coding_transcript_exon	CDK5RAP2:NM_018249.5:5'UTR:MODIFIER:exon1/38:c.-19T>C:,CDK5RAP2:NM_001011649.2:5'UTR:MODIFIER:exon1/37:c.-19T>C:,CDK5RAP2:NM_001272039.1:5'UTR:MODIFIER:exon1/35:c.-19T>C:,CDK5RAP2:NR_073554.1:non_coding_transcript_exon:MODIFIER:exon1/38:n.174T>C:,CDK5RAP2:NR_073555.1:non_coding_transcript_exon:MODIFIER:exon1/38:n.174T>C:,CDK5RAP2:NR_073556.1:non_coding_transcript_exon:MODIFIER:exon1/39:n.174T>C:,CDK5RAP2:NR_073557.1:non_coding_transcript_exon:MODIFIER:exon1/38:n.174T>C:,CDK5RAP2:NR_073558.1:non_coding_transcript_exon:MODIFIER:exon1/38:n.174T>C:		rs932974	0.9655	0.9878	56249/31622/3699	0.9215							608201 [CDK5RAP2 (confirmed) Microcephaly 3,primary,autosomal recessive,604804];	RCV000081943.5 [benign]; RCV000338769.1 [benign]; 			993	8					CDK5RAP2 (inh=AR pLI=0.00)
chr9	123714876	123714876	C	T	het	het	wt		QUAL=7325;DP=310,235,333;MQM=60	C5	3'UTR	C5:NM_001317163.1:3'UTR:MODIFIER:exon41/41:c.*141G>A:,C5:NM_001735.2:3'UTR:MODIFIER:exon41/41:c.*141G>A:			0.0000	0.0000	0/0/0	0.0000							120900 [C5 (confirmed) C5 deficiency,609536|Eculizumab,poor response to,615749];				0	2					C5 (inh=AR pLI=0.00)
chr9	123769200	123769200	C	T	hom	hom	hom		QUAL=23907;DP=282,187,250;MQM=60	C5	missense	C5:NM_001317163.1:missense:MODERATE:exon19/41:c.2422G>A:p.Val808Ile,C5:NM_001735.2:missense:MODERATE:exon19/41:c.2404G>A:p.Val802Ile,C5:NM_001317164.1:missense:MODERATE:exon19/21:c.2404G>A:p.Val802Ile		rs17611	0.4048	0.4586	13996/6618/45	0.4511	0.1000	T,T	T	B	T	18.88	120900 [C5 (confirmed) C5 deficiency,609536|Eculizumab,poor response to,615749];		CM093430 [CLASS=DP MUT=ALT PHEN="Ischemic stroke association with" GENE=C5]; 		345	776					C5 (inh=AR pLI=0.00)
chr9	123780005	123780005	G	A	hom	hom	hom		QUAL=28153;DP=396,202,246;MQM=60	C5	synonymous	C5:NM_001317163.1:synonymous:LOW:exon13/41:c.1650C>T:p.Tyr550Tyr,C5:NM_001735.2:synonymous:LOW:exon13/41:c.1632C>T:p.Tyr544Tyr,C5:NM_001317164.1:synonymous:LOW:exon13/21:c.1632C>T:p.Tyr544Tyr		rs25681	0.4058	0.4570	13895/6570/43	0.4496							120900 [C5 (confirmed) C5 deficiency,609536|Eculizumab,poor response to,615749];			COSM1459729	338	778					C5 (inh=AR pLI=0.00)
chr9	124083614	124083614	C	T	het	het	wt		QUAL=5903;DP=262,311,418;MQM=59	GSN	synonymous,sequence_feature	GSN:NM_000177.4:synonymous:LOW:exon10/17:c.1413C>T:p.Gly471Gly,GSN:NM_001127662.1:synonymous:LOW:exon10/17:c.1260C>T:p.Gly420Gly,GSN:NM_001127663.1:synonymous:LOW:exon12/19:c.1368C>T:p.Gly456Gly,GSN:NM_001127664.1:synonymous:LOW:exon12/19:c.1260C>T:p.Gly420Gly,GSN:NM_001127665.1:synonymous:LOW:exon12/19:c.1260C>T:p.Gly420Gly,GSN:NM_001127666.1:synonymous:LOW:exon12/19:c.1293C>T:p.Gly431Gly,GSN:NM_001127667.1:synonymous:LOW:exon12/19:c.1293C>T:p.Gly431Gly,GSN:NM_198252.2:synonymous:LOW:exon11/18:c.1260C>T:p.Gly420Gly,GSN:NM_001258029.1:synonymous:LOW:exon10/17:c.1311C>T:p.Gly437Gly,GSN:NM_001258030.1:synonymous:LOW:exon10/17:c.1284C>T:p.Gly428Gly,GSN:NM_000177.4:sequence_feature:LOW:exon10/17:c.1413C>T:,GSN:NM_001258030.1:sequence_feature:LOW:exon10/17:c.1284C>T:		rs2304393	0.0855	0.0625	355/103/37	0.0600							137350 [GSN (provisional) Amyloidosis,Finnish type,105120];	RCV000349867.1 [benign]; 			7	230					GSN (inh=AD pLI=0.00)
chr9	127244134	127244134	G	A	wt	wt	het		QUAL=3408;DP=334,244,287;MQM=60	NR5A1	3'UTR	NR5A1:NM_004959.4:3'UTR:MODIFIER:exon7/7:c.*903C>T:		rs10120967	0.6721	0.0000	0/0/0	0.0976							184757 [NR5A1 (confirmed) 46XY sex reversal 3,612965|Premature ovarian failure 7,612964|Adrenocortical insufficiency|Spermatogenic failure 8,613957];				54	107					NR5A1 (inh=AR pLI=0.95)
chr9	127244864	127244864	C	-	wt	wt	het		QUAL=286;DP=31,20,26;MQM=60	NR5A1	3'UTR	NR5A1:NM_004959.4:3'UTR:MODIFIER:exon7/7:c.*173delG:		rs796517206	0.0000	0.0000	0/0/0	0.3749							184757 [NR5A1 (confirmed) 46XY sex reversal 3,612965|Premature ovarian failure 7,612964|Adrenocortical insufficiency|Spermatogenic failure 8,613957];				53	108					NR5A1 (inh=AR pLI=0.95)
chr9	127244955	127244955	G	A	wt	wt	het	low_DP;anno_pathogenic_hgmd	QUAL=55;DP=9,2,6;MQM=60	NR5A1	3'UTR	NR5A1:NM_004959.4:3'UTR:MODIFIER:exon7/7:c.*82C>T:		rs915034	0.6567	0.0000	0/0/0	0.0977							184757 [NR5A1 (confirmed) 46XY sex reversal 3,612965|Premature ovarian failure 7,612964|Adrenocortical insufficiency|Spermatogenic failure 8,613957];		CR1212549 [CLASS=DM? MUT=ALT PHEN="Hypogonadotropic hypogonadism idiopathic" GENE=NR5A1]; 		55	85	2	[2] Ute Grasshoff 13.08.2014			NR5A1 (inh=AR pLI=0.95)
chr9	129377855	129377855	G	C	wt	wt	het	low_DP	QUAL=697;DP=9,36,63;MQM=60	LMX1B	splice_region&intron	LMX1B:NM_001174146.1:splice_region&intron:LOW:exon2/7:c.326+7G>C:,LMX1B:NM_001174147.1:splice_region&intron:LOW:exon2/7:c.326+7G>C:,LMX1B:NM_002316.3:splice_region&intron:LOW:exon2/7:c.326+7G>C:		rs1336980	0.2276	0.3403	5260/3666/98	0.2925							602575 [LMX1B (confirmed) Nail-patella syndrome,161200];	RCV000251085.1 [benign]; RCV000356108.1 [benign]; 			173	722					LMX1B (inh=AD pLI=0.82)
chr9	129453229	129453229	A	G	hom	het	hom		QUAL=8960;DP=110,105,131;MQM=59	LMX1B	synonymous	LMX1B:NM_001174146.1:synonymous:LOW:exon3/8:c.441A>G:p.Glu147Glu,LMX1B:NM_001174147.1:synonymous:LOW:exon3/8:c.441A>G:p.Glu147Glu,LMX1B:NM_002316.3:synonymous:LOW:exon3/8:c.441A>G:p.Glu147Glu		rs2277158	0.4800	0.4496	11975/5956/1445	0.4382							602575 [LMX1B (confirmed) Nail-patella syndrome,161200];	RCV000251599.1 [benign]; RCV000321575.1 [benign]; 		COSM3763642, COSM3763643, COSM3763641	290	774					LMX1B (inh=AD pLI=0.82)
chr9	129455587	129455587	G	C	hom	het	hom		QUAL=9114;DP=85,128,172;MQM=59	LMX1B	synonymous	LMX1B:NM_001174146.1:synonymous:LOW:exon4/8:c.726G>C:p.Ser242Ser,LMX1B:NM_001174147.1:synonymous:LOW:exon4/8:c.726G>C:p.Ser242Ser,LMX1B:NM_002316.3:synonymous:LOW:exon4/8:c.726G>C:p.Ser242Ser		rs13295990	0.4393	0.4702	8617/4539/644	0.4110							602575 [LMX1B (confirmed) Nail-patella syndrome,161200];	RCV000243969.2 [benign]; RCV000349276.1 [benign]; 			293	768					LMX1B (inh=AD pLI=0.82)
chr9	129459181	129459181	C	T	het	wt	het		QUAL=4899;DP=117,254,304;MQM=59	LMX1B	3'UTR	LMX1B:NM_001174146.1:3'UTR:MODIFIER:exon8/8:c.*451C>T:,LMX1B:NM_001174147.1:3'UTR:MODIFIER:exon8/8:c.*451C>T:,LMX1B:NM_002316.3:3'UTR:MODIFIER:exon8/8:c.*451C>T:		rs71497630	0.1516	0.0000	0/0/0	0.1362							602575 [LMX1B (confirmed) Nail-patella syndrome,161200];	RCV000303244.1 [benign]; 			2	51					LMX1B (inh=AD pLI=0.82)
chr9	129459314	129459314	C	T	het	het	het		QUAL=13134;DP=326,378,494;MQM=59	LMX1B	3'UTR	LMX1B:NM_001174146.1:3'UTR:MODIFIER:exon8/8:c.*584C>T:,LMX1B:NM_001174147.1:3'UTR:MODIFIER:exon8/8:c.*584C>T:,LMX1B:NM_002316.3:3'UTR:MODIFIER:exon8/8:c.*584C>T:		rs34200683	0.2181	0.0000	0/0/0	0.2694							602575 [LMX1B (confirmed) Nail-patella syndrome,161200];	RCV000363724.1 [benign]; 			20	125					LMX1B (inh=AD pLI=0.82)
chr9	129459438	129459438	G	A	het	het	het		QUAL=8308;DP=161,278,363;MQM=60	LMX1B	3'UTR	LMX1B:NM_001174146.1:3'UTR:MODIFIER:exon8/8:c.*708G>A:,LMX1B:NM_001174147.1:3'UTR:MODIFIER:exon8/8:c.*708G>A:,LMX1B:NM_002316.3:3'UTR:MODIFIER:exon8/8:c.*708G>A:		rs10987413	0.2057	0.0000	0/0/0	0.2636							602575 [LMX1B (confirmed) Nail-patella syndrome,161200];	RCV000368638.1 [benign]; 			17	123					LMX1B (inh=AD pLI=0.82)
chr9	129459478	129459478	C	T	het	het	het		QUAL=7256;DP=197,219,322;MQM=59	LMX1B	3'UTR	LMX1B:NM_001174146.1:3'UTR:MODIFIER:exon8/8:c.*748C>T:,LMX1B:NM_001174147.1:3'UTR:MODIFIER:exon8/8:c.*748C>T:,LMX1B:NM_002316.3:3'UTR:MODIFIER:exon8/8:c.*748C>T:		rs10987414	0.2340	0.0000	0/0/0	0.2662							602575 [LMX1B (confirmed) Nail-patella syndrome,161200];	RCV000276381.1 [benign]; 			20	126					LMX1B (inh=AD pLI=0.82)
chr9	129459662	129459662	G	T	het	wt	het		QUAL=9261;DP=458,229,266;MQM=59	LMX1B	3'UTR	LMX1B:NM_001174146.1:3'UTR:MODIFIER:exon8/8:c.*932G>T:,LMX1B:NM_001174147.1:3'UTR:MODIFIER:exon8/8:c.*932G>T:,LMX1B:NM_002316.3:3'UTR:MODIFIER:exon8/8:c.*932G>T:		rs28687510	0.2298	0.0000	0/0/0	0.1616							602575 [LMX1B (confirmed) Nail-patella syndrome,161200];	RCV000372190.1 [benign]; 			2	52					LMX1B (inh=AD pLI=0.82)
chr9	129459985	129459985	A	G	het	wt	het		QUAL=5786;DP=226,244,250;MQM=60	LMX1B	3'UTR	LMX1B:NM_001174146.1:3'UTR:MODIFIER:exon8/8:c.*1255A>G:,LMX1B:NM_001174147.1:3'UTR:MODIFIER:exon8/8:c.*1255A>G:,LMX1B:NM_002316.3:3'UTR:MODIFIER:exon8/8:c.*1255A>G:	L3b	rs16929236	0.2302	0.0000	0/0/0	0.1628							602575 [LMX1B (confirmed) Nail-patella syndrome,161200];	RCV000282993.1 [benign]; 			2	40					LMX1B (inh=AD pLI=0.82)
chr9	129460117	129460121	TGTTT	-	wt	wt	het		QUAL=4189;DP=34,95,68;MQM=59	LMX1B	3'UTR	LMX1B:NM_001174146.1:3'UTR:MODIFIER:exon8/8:c.*1437_*1441delTGTTT:,LMX1B:NM_001174147.1:3'UTR:MODIFIER:exon8/8:c.*1437_*1441delTGTTT:,LMX1B:NM_002316.3:3'UTR:MODIFIER:exon8/8:c.*1437_*1441delTGTTT:	L3b:(TGTTT)n	rs535437948;rs67078890	0.0000	0.0000	0/0/0	0.1678							602575 [LMX1B (confirmed) Nail-patella syndrome,161200];	RCV000343665.1 [uncertain significance]; 			25	13					LMX1B (inh=AD pLI=0.82)
chr9	129460119	129460119	T	G	hom	wt	het		QUAL=4189;DP=34,95,68;MQM=56	LMX1B	3'UTR	LMX1B:NM_001174146.1:3'UTR:MODIFIER:exon8/8:c.*1389T>G:,LMX1B:NM_001174147.1:3'UTR:MODIFIER:exon8/8:c.*1389T>G:,LMX1B:NM_002316.3:3'UTR:MODIFIER:exon8/8:c.*1389T>G:	(TGTTT)n	rs13300385	0.1641	0.0000	0/0/0	0.0774							602575 [LMX1B (confirmed) Nail-patella syndrome,161200];	RCV000394099.1 [benign]; 			3	32					LMX1B (inh=AD pLI=0.82)
chr9	129460123	129460123	G	T	hom	wt	het		QUAL=4189;DP=34,95,68;MQM=56	LMX1B	3'UTR	LMX1B:NM_001174146.1:3'UTR:MODIFIER:exon8/8:c.*1393G>T:,LMX1B:NM_001174147.1:3'UTR:MODIFIER:exon8/8:c.*1393G>T:,LMX1B:NM_002316.3:3'UTR:MODIFIER:exon8/8:c.*1393G>T:	(TGTTT)n	rs13299451	0.1613	0.0000	0/0/0	0.0517							602575 [LMX1B (confirmed) Nail-patella syndrome,161200];	RCV000313143.1 [benign]; 			3	32					LMX1B (inh=AD pLI=0.82)
chr9	129460203	129460203	G	A	het	wt	het	low_MQM	QUAL=2120;DP=133,133,99;MQM=48	LMX1B	3'UTR	LMX1B:NM_001174146.1:3'UTR:MODIFIER:exon8/8:c.*1473G>A:,LMX1B:NM_001174147.1:3'UTR:MODIFIER:exon8/8:c.*1473G>A:,LMX1B:NM_002316.3:3'UTR:MODIFIER:exon8/8:c.*1473G>A:	AluSp	rs13299609	0.1508	0.0000	0/0/0	0.1136							602575 [LMX1B (confirmed) Nail-patella syndrome,161200];	RCV000370211.1 [benign]; 			2	36					LMX1B (inh=AD pLI=0.82)
chr9	129460312	129460312	A	G	hom	het	hom		QUAL=11431;DP=164,143,166;MQM=56	LMX1B	3'UTR	LMX1B:NM_001174146.1:3'UTR:MODIFIER:exon8/8:c.*1582A>G:,LMX1B:NM_001174147.1:3'UTR:MODIFIER:exon8/8:c.*1582A>G:,LMX1B:NM_002316.3:3'UTR:MODIFIER:exon8/8:c.*1582A>G:	AluSp	rs10987415	0.4103	0.0000	0/0/0	0.3790							602575 [LMX1B (confirmed) Nail-patella syndrome,161200];	RCV000358180.1 [benign]; 			37	76					LMX1B (inh=AD pLI=0.82)
chr9	129460396	129460396	C	T	het	het	het		QUAL=11244;DP=248,288,370;MQM=56	LMX1B	3'UTR	LMX1B:NM_001174146.1:3'UTR:MODIFIER:exon8/8:c.*1666C>T:,LMX1B:NM_001174147.1:3'UTR:MODIFIER:exon8/8:c.*1666C>T:,LMX1B:NM_002316.3:3'UTR:MODIFIER:exon8/8:c.*1666C>T:	AluSp	rs10987416	0.2169	0.0000	0/0/0	0.2512							602575 [LMX1B (confirmed) Nail-patella syndrome,161200];	RCV000288172.1 [benign]; 			11	82					LMX1B (inh=AD pLI=0.82)
chr9	129460722	129460722	T	C	hom	het	het		QUAL=21495;DP=419,247,356;MQM=59	LMX1B	3'UTR	LMX1B:NM_001174146.1:3'UTR:MODIFIER:exon8/8:c.*1992T>C:,LMX1B:NM_001174147.1:3'UTR:MODIFIER:exon8/8:c.*1992T>C:,LMX1B:NM_002316.3:3'UTR:MODIFIER:exon8/8:c.*1992T>C:	L3	rs34776870	0.1955	0.0000	0/0/0	0.1508							602575 [LMX1B (confirmed) Nail-patella syndrome,161200];	RCV000397676.1 [benign]; 			3	42					LMX1B (inh=AD pLI=0.82)
chr9	129460727	129460727	G	A	hom	het	het		QUAL=20742;DP=419,253,352;MQM=59	LMX1B	3'UTR	LMX1B:NM_001174146.1:3'UTR:MODIFIER:exon8/8:c.*1997G>A:,LMX1B:NM_001174147.1:3'UTR:MODIFIER:exon8/8:c.*1997G>A:,LMX1B:NM_002316.3:3'UTR:MODIFIER:exon8/8:c.*1997G>A:	L3	rs35632228	0.1953	0.0000	0/0/0	0.1507							602575 [LMX1B (confirmed) Nail-patella syndrome,161200];	RCV000356475.1 [benign]; 			3	41					LMX1B (inh=AD pLI=0.82)
chr9	129460914	129460914	A	G	wt	het	wt		QUAL=764;DP=115,80,111;MQM=60	LMX1B	3'UTR	LMX1B:NM_001174146.1:3'UTR:MODIFIER:exon8/8:c.*2184A>G:,LMX1B:NM_001174147.1:3'UTR:MODIFIER:exon8/8:c.*2184A>G:,LMX1B:NM_002316.3:3'UTR:MODIFIER:exon8/8:c.*2184A>G:		rs10733682	0.4970	0.0000	0/0/0	0.4755							602575 [LMX1B (confirmed) Nail-patella syndrome,161200];	RCV000360275.1 [benign]; 			48	127					LMX1B (inh=AD pLI=0.82)
chr9	129461123	129461123	T	C	hom	hom	hom		QUAL=8085;DP=157,60,61;MQM=59	LMX1B	3'UTR	LMX1B:NM_001174146.1:3'UTR:MODIFIER:exon8/8:c.*2393T>C:,LMX1B:NM_001174147.1:3'UTR:MODIFIER:exon8/8:c.*2393T>C:,LMX1B:NM_002316.3:3'UTR:MODIFIER:exon8/8:c.*2393T>C:		rs10120414	0.8714	0.0000	0/0/0	0.7389							602575 [LMX1B (confirmed) Nail-patella syndrome,161200];	RCV000325189.1 [benign]; 			202	28					LMX1B (inh=AD pLI=0.82)
chr9	129461124	129461124	G	C	het	wt	het		QUAL=8085;DP=157,60,61;MQM=59	LMX1B	3'UTR	LMX1B:NM_001174146.1:3'UTR:MODIFIER:exon8/8:c.*2394G>C:,LMX1B:NM_001174147.1:3'UTR:MODIFIER:exon8/8:c.*2394G>C:,LMX1B:NM_002316.3:3'UTR:MODIFIER:exon8/8:c.*2394G>C:		rs10760451	0.4089	0.0000	0/0/0	0.2877							602575 [LMX1B (confirmed) Nail-patella syndrome,161200];	RCV000363812.1 [benign]; 			31	111					LMX1B (inh=AD pLI=0.82)
chr9	129461319	129461320	TT	-	het	het	het		QUAL=3786;DP=181,147,172;MQM=59	LMX1B	3'UTR	LMX1B:NM_001174146.1:3'UTR:MODIFIER:exon8/8:c.*2590_*2591delTT:,LMX1B:NM_001174147.1:3'UTR:MODIFIER:exon8/8:c.*2590_*2591delTT:,LMX1B:NM_002316.3:3'UTR:MODIFIER:exon8/8:c.*2590_*2591delTT:		rs560251761	0.3754	0.0000	0/0/0	0.3813							602575 [LMX1B (confirmed) Nail-patella syndrome,161200];	RCV000328842.1 [benign]; 			35	103					LMX1B (inh=AD pLI=0.82)
chr9	129461714	129461714	C	T	wt	wt	het		QUAL=838;DP=91,44,82;MQM=60	LMX1B	3'UTR	LMX1B:NM_001174146.1:3'UTR:MODIFIER:exon8/8:c.*2984C>T:,LMX1B:NM_001174147.1:3'UTR:MODIFIER:exon8/8:c.*2984C>T:,LMX1B:NM_002316.3:3'UTR:MODIFIER:exon8/8:c.*2984C>T:		rs4083644	0.2873	0.0000	0/0/0	0.2695							602575 [LMX1B (confirmed) Nail-patella syndrome,161200];	RCV000389476.1 [benign]; 			14	107					LMX1B (inh=AD pLI=0.82)
chr9	129461912	129461912	A	G	wt	wt	het		QUAL=4561;DP=195,244,376;MQM=60	LMX1B	3'UTR	LMX1B:NM_001174146.1:3'UTR:MODIFIER:exon8/8:c.*3182A>G:,LMX1B:NM_001174147.1:3'UTR:MODIFIER:exon8/8:c.*3182A>G:,LMX1B:NM_002316.3:3'UTR:MODIFIER:exon8/8:c.*3182A>G:		rs3861878	0.3015	0.0000	0/0/0	0.2700							602575 [LMX1B (confirmed) Nail-patella syndrome,161200];	RCV000374490.1 [benign]; 			14	102					LMX1B (inh=AD pLI=0.82)
chr9	129462072	129462072	T	C	wt	wt	het		QUAL=2842;DP=117,180,210;MQM=60	LMX1B	3'UTR	LMX1B:NM_001174146.1:3'UTR:MODIFIER:exon8/8:c.*3342T>C:,LMX1B:NM_001174147.1:3'UTR:MODIFIER:exon8/8:c.*3342T>C:,LMX1B:NM_002316.3:3'UTR:MODIFIER:exon8/8:c.*3342T>C:	MIR1_Amn	rs4083645	0.2792	0.0000	0/0/0	0.2646							602575 [LMX1B (confirmed) Nail-patella syndrome,161200];	RCV000395116.1 [benign]; 			15	104					LMX1B (inh=AD pLI=0.82)
chr9	129462076	129462076	G	A	wt	wt	het		QUAL=2842;DP=117,180,210;MQM=60	LMX1B	3'UTR	LMX1B:NM_001174146.1:3'UTR:MODIFIER:exon8/8:c.*3346G>A:,LMX1B:NM_001174147.1:3'UTR:MODIFIER:exon8/8:c.*3346G>A:,LMX1B:NM_002316.3:3'UTR:MODIFIER:exon8/8:c.*3346G>A:		rs7023938	0.2155	0.0000	0/0/0	0.2342							602575 [LMX1B (confirmed) Nail-patella syndrome,161200];	RCV000307697.1 [benign]; RCV000343746.1 [uncertain significance]; 			15	102					LMX1B (inh=AD pLI=0.82)
chr9	129462501	129462501	G	T	het	het	het		QUAL=12151;DP=317,272,375;MQM=60	LMX1B	3'UTR	LMX1B:NM_001174146.1:3'UTR:MODIFIER:exon8/8:c.*3771G>T:,LMX1B:NM_001174147.1:3'UTR:MODIFIER:exon8/8:c.*3771G>T:,LMX1B:NM_002316.3:3'UTR:MODIFIER:exon8/8:c.*3771G>T:		rs10987417	0.5407	0.0000	0/0/0	0.4961							602575 [LMX1B (confirmed) Nail-patella syndrome,161200];	RCV000275603.1 [benign]; 			53	111					LMX1B (inh=AD pLI=0.82)
chr9	129462563	129462563	A	G	het	het	het		QUAL=13475;DP=321,347,462;MQM=60	LMX1B	3'UTR	LMX1B:NM_001174146.1:3'UTR:MODIFIER:exon8/8:c.*3833A>G:,LMX1B:NM_001174147.1:3'UTR:MODIFIER:exon8/8:c.*3833A>G:,LMX1B:NM_002316.3:3'UTR:MODIFIER:exon8/8:c.*3833A>G:		rs10987418	0.5481	0.0000	0/0/0	0.4962							602575 [LMX1B (confirmed) Nail-patella syndrome,161200];	RCV000290870.1 [benign]; 			53	114					LMX1B (inh=AD pLI=0.82)
chr9	129462594	129462594	T	C	het	het	het		QUAL=14410;DP=284,399,533;MQM=59	LMX1B	3'UTR	LMX1B:NM_001174146.1:3'UTR:MODIFIER:exon8/8:c.*3864T>C:,LMX1B:NM_001174147.1:3'UTR:MODIFIER:exon8/8:c.*3864T>C:,LMX1B:NM_002316.3:3'UTR:MODIFIER:exon8/8:c.*3864T>C:		rs10987419	0.5483	0.0000	0/0/0	0.3616							602575 [LMX1B (confirmed) Nail-patella syndrome,161200];	RCV000345393.1 [benign]; 			53	114					LMX1B (inh=AD pLI=0.82)
chr9	129462687	129462687	C	A	het	het	het		QUAL=17614;DP=333,477,637;MQM=60	LMX1B	3'UTR	LMX1B:NM_001174146.1:3'UTR:MODIFIER:exon8/8:c.*3957C>A:,LMX1B:NM_001174147.1:3'UTR:MODIFIER:exon8/8:c.*3957C>A:,LMX1B:NM_002316.3:3'UTR:MODIFIER:exon8/8:c.*3957C>A:		rs10987422	0.5323	0.0000	0/0/0	0.5041							602575 [LMX1B (confirmed) Nail-patella syndrome,161200];	RCV000394311.1 [benign]; 			53	114					LMX1B (inh=AD pLI=0.82)
chr9	129462901	129462901	T	C	hom	het	hom		QUAL=21460;DP=227,280,362;MQM=59	LMX1B	3'UTR	LMX1B:NM_001174146.1:3'UTR:MODIFIER:exon8/8:c.*4171T>C:,LMX1B:NM_001174147.1:3'UTR:MODIFIER:exon8/8:c.*4171T>C:,LMX1B:NM_002316.3:3'UTR:MODIFIER:exon8/8:c.*4171T>C:	(CACGCA)n	rs3814119	0.5511	0.0000	0/0/0	0.5273							602575 [LMX1B (confirmed) Nail-patella syndrome,161200];	RCV000353178.1 [benign]; 			55	116					LMX1B (inh=AD pLI=0.82)
chr9	130629139	130629139	T	G	hom	hom	hom		QUAL=5420;DP=60,35,74;MQM=60	AK1	3'UTR	AK1:NM_001318122.1:3'UTR:MODIFIER:exon6/6:c.*1148A>C:,AK1:NM_000476.2:3'UTR:MODIFIER:exon7/7:c.*1148A>C:,AK1:NM_001318121.1:3'UTR:MODIFIER:exon7/7:c.*1148A>C:	LFSINE_Vert	rs913987	0.7087	0.0000	0/0/0	0.7214							103000 [AK1 (confirmed) Hemolytic anemia due to adenylate kinase deficiency,612631];				152	70					AK1 (inh=AR pLI=0.65)
chr9	130629527	130629527	G	T	hom	hom	hom		QUAL=7876;DP=91,79,103;MQM=57	AK1	3'UTR	AK1:NM_001318122.1:3'UTR:MODIFIER:exon6/6:c.*760C>A:,AK1:NM_000476.2:3'UTR:MODIFIER:exon7/7:c.*760C>A:,AK1:NM_001318121.1:3'UTR:MODIFIER:exon7/7:c.*760C>A:	AluSx	rs2249308	0.9181	0.0000	0/0/0	0.8322							103000 [AK1 (confirmed) Hemolytic anemia due to adenylate kinase deficiency,612631];				191	38					AK1 (inh=AR pLI=0.65)
chr9	130630233	130630233	G	T	hom	hom	hom		QUAL=39405;DP=187,482,614;MQM=59	AK1	3'UTR	AK1:NM_001318122.1:3'UTR:MODIFIER:exon6/6:c.*54C>A:,AK1:NM_000476.2:3'UTR:MODIFIER:exon7/7:c.*54C>A:,AK1:NM_001318121.1:3'UTR:MODIFIER:exon7/7:c.*54C>A:		rs4226	0.6817	0.0000	0/0/0	0.1600							103000 [AK1 (confirmed) Hemolytic anemia due to adenylate kinase deficiency,612631];				550	305					AK1 (inh=AR pLI=0.65)
chr9	130630639	130630639	A	G	hom	hom	hom		QUAL=24473;DP=259,250,273;MQM=59	AK1	synonymous	AK1:NM_001318122.1:synonymous:LOW:exon5/6:c.525T>C:p.Pro175Pro,AK1:NM_000476.2:synonymous:LOW:exon6/7:c.477T>C:p.Pro159Pro,AK1:NM_001318121.1:synonymous:LOW:exon6/7:c.477T>C:p.Pro159Pro		rs913986	0.9982	0.9995	56343/31274/4781	0.9439	-4.9500		T			13.82	103000 [AK1 (confirmed) Hemolytic anemia due to adenylate kinase deficiency,612631];				1566	0					AK1 (inh=AR pLI=0.65)
chr9	130698029	130698029	G	C	hom	hom	hom		QUAL=35788;DP=368,307,420;MQM=59	DPM2	missense	DPM2:NM_003863.3:missense:MODERATE:exon4/4:c.227C>G:p.Thr76Ser		rs7997	0.6835	0.7873	38367/24522/2292	0.7750	0.1410	T	T	B	T	0.13	603564 [DPM2 (provisional) Congenital disorder of glycosylation,type Iu,615042];	RCV000116901.1 [benign]; RCV000364982.1 [benign]; 		COSM3982740	782	311					DPM2 (inh=AR pLI=0.02)
chr9	130698043	130698043	A	G	hom	hom	hom		QUAL=33736;DP=334,309,392;MQM=60	DPM2	synonymous	DPM2:NM_003863.3:synonymous:LOW:exon4/4:c.213T>C:p.Tyr71Tyr		rs6781	0.7310	0.8139	40571/24672/2304	0.8057							603564 [DPM2 (provisional) Congenital disorder of glycosylation,type Iu,615042];	RCV000116900.4 [benign]; RCV000265670.1 [benign]; 			798	303					DPM2 (inh=AR pLI=0.02)
chr9	130700251	130700251	T	C	hom	hom	hom		QUAL=36008;DP=430,330,409;MQM=59	DPM2	5'UTR	DPM2:NM_003863.3:5'UTR:MODIFIER:exon1/4:c.-152A>G:		rs6478802	0.6839	0.0000	0/0/0	0.1310							603564 [DPM2 (provisional) Congenital disorder of glycosylation,type Iu,615042];	RCV000386486.1 [benign]; 			180	44					DPM2 (inh=AR pLI=0.02)
chr9	130700727	130700727	T	C	hom	hom	hom		QUAL=23385;DP=259,212,269;MQM=59	DPM2	5'UTR	DPM2:NM_003863.3:5'UTR:MODIFIER:exon1/4:c.-628A>G:		rs3758327	0.6839	0.0000	0/0/0	0.1301							603564 [DPM2 (provisional) Congenital disorder of glycosylation,type Iu,615042];	RCV000309328.1 [benign]; 			178	45					DPM2 (inh=AR pLI=0.02)
chr9	131285955	131285955	A	G	het	het	wt	pred_pathogenic	QUAL=758;DP=64,24,60;MQM=60	GLE1,MIR1268A	missense,intron	GLE1:NM_001003722.1:missense:MODERATE:exon6/16:c.727A>G:p.Ile243Val,GLE1:NM_001499.2:missense:MODERATE:exon6/14:c.727A>G:p.Ile243Val,MIR1268A:NR_031672.1.4:intron:MODIFIER:exon2/2:n.30-138438A>G:		rs2275260	0.3474	0.2679	4751/1439/746	0.2638	1.7440	T,T	T	B,B	T,T	0.01	603371 [GLE1 (confirmed) Lethal congenital contracture syndrome 1,253310|Arthrogryposis,lethal,with anterior horn cell disease,611890];	RCV000179351.2 [benign]; RCV000334555.1 [benign]; RCV000405131.1 [benign]; 	CM1310812 [CLASS=R MUT=ALT PHEN="Arthrogryposis & hypoplasia" GENE=GLE1]; 		108	583	2	[2] old entry - no details available			GLE1 (inh=AR pLI=0.00), MIR1268A (inh=n/a pLI=n/a)
chr9	131303522	131303522	G	A	het	het	wt		QUAL=4448;DP=191,155,163;MQM=60	GLE1,MIR1268A	3'UTR,intron	GLE1:NM_001003722.1:3'UTR:MODIFIER:exon16/16:c.*73G>A:,MIR1268A:NR_031672.1.4:intron:MODIFIER:exon2/2:n.30-120871G>A:		rs10760563	0.2660	0.0000	0/0/0	0.0457							603371 [GLE1 (confirmed) Lethal congenital contracture syndrome 1,253310|Arthrogryposis,lethal,with anterior horn cell disease,611890];	RCV000324283.1 [benign]; RCV000371900.1 [benign]; 			23	151					GLE1 (inh=AR pLI=0.00), MIR1268A (inh=n/a pLI=n/a)
chr9	131346218	131346218	A	C	hom	hom	hom		QUAL=37049;DP=247,398,532;MQM=59	SPTAN1,MIR1268A	synonymous,intron	SPTAN1:NM_001130438.2:synonymous:LOW:exon16/57:c.2163A>C:p.Ala721Ala,SPTAN1:NM_001195532.1:synonymous:LOW:exon16/55:c.2163A>C:p.Ala721Ala,SPTAN1:NM_003127.3:synonymous:LOW:exon16/56:c.2163A>C:p.Ala721Ala,MIR1268A:NR_031672.1.4:intron:MODIFIER:exon2/2:n.30-78175A>C:		rs10760566	0.9698	0.9914	59701/33359/4277	0.9361							182810 [SPTAN1 (confirmed) Epileptic encephalopathy,early infantile,5,613477];	RCV000128236.2 [benign]; RCV000233124.1 [likely benign]; 			1561	5					SPTAN1 (inh=AD pLI=1.00), MIR1268A (inh=n/a pLI=n/a)
chr9	131360750	131360750	C	T	hom	hom	hom		QUAL=16616;DP=225,133,160;MQM=59	SPTAN1,MIR1268A	synonymous,intron	SPTAN1:NM_001130438.2:synonymous:LOW:exon25/57:c.3486C>T:p.Leu1162Leu,SPTAN1:NM_001195532.1:synonymous:LOW:exon24/55:c.3426C>T:p.Leu1142Leu,SPTAN1:NM_003127.3:synonymous:LOW:exon25/56:c.3486C>T:p.Leu1162Leu,MIR1268A:NR_031672.1.4:intron:MODIFIER:exon2/2:n.30-63643C>T:		rs2227864	0.6428	0.8064	39037/26231/1134	0.7913							182810 [SPTAN1 (confirmed) Epileptic encephalopathy,early infantile,5,613477];	RCV000147625.1 [benign]; RCV000147626.2 [benign]; RCV000390746.1 [benign]; 			1191	336					SPTAN1 (inh=AD pLI=1.00), MIR1268A (inh=n/a pLI=n/a)
chr9	131375701	131375701	A	G	hom	hom	hom		QUAL=27141;DP=263,234,332;MQM=60	SPTAN1,MIR1268A	synonymous,intron	SPTAN1:NM_001130438.2:synonymous:LOW:exon40/57:c.5085A>G:p.Leu1695Leu,SPTAN1:NM_001195532.1:synonymous:LOW:exon38/55:c.5010A>G:p.Leu1670Leu,SPTAN1:NM_003127.3:synonymous:LOW:exon39/56:c.5070A>G:p.Leu1690Leu,MIR1268A:NR_031672.1.4:intron:MODIFIER:exon2/2:n.30-48692A>G:		rs1415568	0.9848	0.9959	60218/33367/4754	0.9314							182810 [SPTAN1 (confirmed) Epileptic encephalopathy,early infantile,5,613477];	RCV000128256.2 [benign]; 			1563	4					SPTAN1 (inh=AD pLI=1.00), MIR1268A (inh=n/a pLI=n/a)
chr9	131379967	131379967	C	T	hom	hom	hom		QUAL=28391;DP=283,252,377;MQM=59	SPTAN1,MIR1268A	synonymous,intron	SPTAN1:NM_001130438.2:synonymous:LOW:exon42/57:c.5406C>T:p.Thr1802Thr,SPTAN1:NM_001195532.1:synonymous:LOW:exon40/55:c.5331C>T:p.Thr1777Thr,SPTAN1:NM_003127.3:synonymous:LOW:exon41/56:c.5391C>T:p.Thr1797Thr,MIR1268A:NR_031672.1.4:intron:MODIFIER:exon2/2:n.30-44426C>T:		rs2227862	0.6170	0.7913	39713/26898/787	0.7850							182810 [SPTAN1 (confirmed) Epileptic encephalopathy,early infantile,5,613477];	RCV000147635.1 [benign]; RCV000147636.3 [benign]; RCV000406015.1 [benign]; 		COSM4163385, COSM4163386	1185	345					SPTAN1 (inh=AD pLI=1.00), MIR1268A (inh=n/a pLI=n/a)
chr9	131670457	131670457	T	C	wt	wt	het		QUAL=3219;DP=298,275,283;MQM=60	LRRC8A	synonymous	LRRC8A:NM_001127244.1:synonymous:LOW:exon3/4:c.1014T>C:p.Tyr338Tyr,LRRC8A:NM_001127245.1:synonymous:LOW:exon2/3:c.1014T>C:p.Tyr338Tyr,LRRC8A:NM_019594.3:synonymous:LOW:exon3/4:c.1014T>C:p.Tyr338Tyr		rs3750320	0.2644	0.2057	2924/1101/806	0.2018							608360 [LRRC8A (confirmed) Agammaglobulinemia 5,613506];				84	499					LRRC8A (inh=AD pLI=0.92)
chr9	131670919	131670919	T	C	hom	hom	het		QUAL=23089;DP=249,314,416;MQM=59	LRRC8A	synonymous	LRRC8A:NM_001127244.1:synonymous:LOW:exon3/4:c.1476T>C:p.Arg492Arg,LRRC8A:NM_001127245.1:synonymous:LOW:exon2/3:c.1476T>C:p.Arg492Arg,LRRC8A:NM_019594.3:synonymous:LOW:exon3/4:c.1476T>C:p.Arg492Arg		rs3750319	0.5711	0.6944	28974/16911/487	0.6811							608360 [LRRC8A (confirmed) Agammaglobulinemia 5,613506];				791	622					LRRC8A (inh=AD pLI=0.92)
chr9	131679892	131679892	C	T	hom	hom	het		QUAL=11683;DP=129,171,179;MQM=60	LRRC8A	3'UTR	LRRC8A:NM_001127244.1:3'UTR:MODIFIER:exon4/4:c.*1242C>T:,LRRC8A:NM_001127245.1:3'UTR:MODIFIER:exon3/3:c.*1242C>T:,LRRC8A:NM_019594.3:3'UTR:MODIFIER:exon4/4:c.*1242C>T:		rs9031	0.5118	0.0000	0/0/0	0.1102							608360 [LRRC8A (confirmed) Agammaglobulinemia 5,613506];				113	97					LRRC8A (inh=AD pLI=0.92)
chr9	131679897	131679897	A	G	hom	hom	hom		QUAL=15058;DP=130,171,182;MQM=60	LRRC8A	3'UTR	LRRC8A:NM_001127244.1:3'UTR:MODIFIER:exon4/4:c.*1247A>G:,LRRC8A:NM_001127245.1:3'UTR:MODIFIER:exon3/3:c.*1247A>G:,LRRC8A:NM_019594.3:3'UTR:MODIFIER:exon4/4:c.*1247A>G:		rs10819453	0.9974	0.0000	0/0/0	0.1493							608360 [LRRC8A (confirmed) Agammaglobulinemia 5,613506];				230	0					LRRC8A (inh=AD pLI=0.92)
chr9	131680177	131680177	G	T	het	het	wt		QUAL=8052;DP=296,335,429;MQM=59	LRRC8A	3'UTR	LRRC8A:NM_001127244.1:3'UTR:MODIFIER:exon4/4:c.*1527G>T:,LRRC8A:NM_001127245.1:3'UTR:MODIFIER:exon3/3:c.*1527G>T:,LRRC8A:NM_019594.3:3'UTR:MODIFIER:exon4/4:c.*1527G>T:		rs11542344	0.0262	0.0000	0/0/0	0.0079							608360 [LRRC8A (confirmed) Agammaglobulinemia 5,613506];				4	22					LRRC8A (inh=AD pLI=0.92)
chr9	132575797	132575797	A	T	het	wt	het		QUAL=5659;DP=258,167,211;MQM=60	TOR1A	3'UTR	TOR1A:NM_000113.2:3'UTR:MODIFIER:exon5/5:c.*454T>A:		rs1045441	0.0681	0.0000	0/0/0	0.0128							605204 [TOR1A (confirmed) Dystonia-1,torsion,128100|Dystonia-1,modifier of];	RCV000355909.1 [likely benign]; 			5	54					TOR1A (inh=AD pLI=0.17)
chr9	132575828	132575828	A	-	het	het	wt		QUAL=4153;DP=256,132,162;MQM=59	TOR1A	3'UTR	TOR1A:NM_000113.2:3'UTR:MODIFIER:exon5/5:c.*423delT:		rs573629050	0.0136	0.0000	0/0/0	0.0065							605204 [TOR1A (confirmed) Dystonia-1,torsion,128100|Dystonia-1,modifier of];	RCV000259565.1 [likely benign]; 			4	19					TOR1A (inh=AD pLI=0.17)
chr9	132576037	132576037	G	C	het	wt	het		QUAL=2975;DP=136,62,104;MQM=60	TOR1A	3'UTR	TOR1A:NM_000113.2:3'UTR:MODIFIER:exon5/5:c.*214C>G:		rs1183	0.0681	0.0000	0/0/0	0.0128							605204 [TOR1A (confirmed) Dystonia-1,torsion,128100|Dystonia-1,modifier of];	RCV000326607.1 [likely benign]; 			5	53					TOR1A (inh=AD pLI=0.17)
chr9	132585058	132585058	G	A	het	het	wt		QUAL=5796;DP=260,289,367;MQM=60	TOR1A	synonymous	TOR1A:NM_000113.2:synonymous:LOW:exon2/5:c.246C>T:p.Ala82Ala		rs2296793	0.2262	0.2275	3176/1911/254	0.2275							605204 [TOR1A (confirmed) Dystonia-1,torsion,128100|Dystonia-1,modifier of];	RCV000242539.1 [benign]; RCV000298379.1 [likely benign]; 		COSM150726	105	661					TOR1A (inh=AD pLI=0.17)
chr9	133364757	133364757	T	C	het	wt	het		QUAL=5532;DP=137,230,269;MQM=57	ASS1	synonymous	ASS1:NM_000050.4:synonymous:LOW:exon13/16:c.876T>C:p.His292His,ASS1:NM_054012.3:synonymous:LOW:exon12/15:c.876T>C:p.His292His		rs1057484	0.0767	0.0942	630/394/65	0.0902							603470 [ASS1 (confirmed) Citrullinemia,215700];	RCV000078028.6 [benign]; RCV000378731.1 [likely benign]; 			26	269					ASS1 (inh=AR pLI=0.00)
chr9	133376666	133376681	GTGTGTGTGTGTGTGT	-	hom	wt	wt		QUAL=831;DP=21,24,21;MQM=60	ASS1-LOC100272217	intergenic_region	ASS1-LOC100272217:ASS1-LOC100272217:intergenic_region:MODIFIER::n.133376666_133376681delGTGTGTGTGTGTGTGT:	(GT)n		0.0000	0.0000	0/0/0	0.0010							603470 [ASS1 (confirmed) Citrullinemia,215700];				0	3					ASS1-LOC100272217 (inh=n/a pLI=n/a)
chr9	133376666	133376679	GTGTGTGTGTGTGT	-	wt	hom	hom		QUAL=831;DP=21,24,21;MQM=59	ASS1-LOC100272217	intergenic_region	ASS1-LOC100272217:ASS1-LOC100272217:intergenic_region:MODIFIER::n.133376666_133376679delGTGTGTGTGTGTGT:	(GT)n	rs201793682;rs55743080	0.0000	0.0000	0/0/0	0.1760							603470 [ASS1 (confirmed) Citrullinemia,215700];				26	12					ASS1-LOC100272217 (inh=n/a pLI=n/a)
chr9	134385435	134385435	C	T	wt	wt	het	anno_high_impact;pred_pathogenic	QUAL=21086;DP=213,312,382;MQM=60	POMT1	stop_gained,intron	POMT1:NM_007171.3:stop_gained:HIGH:exon8/20:c.751C>T:p.Gln251*,POMT1:NM_001077365.1:intron:MODIFIER:exon8/19:c.699+52C>T:,POMT1:NM_001077366.1:intron:MODIFIER:exon7/18:c.537+52C>T:,POMT1:NM_001136113.1:intron:MODIFIER:exon8/19:c.699+52C>T:,POMT1:NM_001136114.1:intron:MODIFIER:exon6/17:c.348+52C>T:		rs3887873	0.0787	0.1035	796/609/66	0.0975	-0.0970					28.20	607423 [POMT1 (confirmed) Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,1,236670|Muscular dystrophy-dystroglycanopathy (congenital with mental retardation),type B,1,613155|Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,1,609308];	RCV000081492.10 [other]; RCV000326785.1 [likely benign]; 			14	273	2	[A] old entry - no details available [2] ute 27.11.2015: 140x gefunden, eher kein Artefakt, sondern Polymorph.			POMT1 (inh=AR pLI=0.00)
chr9	134385436	134385436	A	G	hom	het	hom	pred_pathogenic	QUAL=21086;DP=213,312,382;MQM=60	POMT1	missense,intron	POMT1:NM_007171.3:missense:MODERATE:exon8/20:c.752A>G:p.Gln251Arg,POMT1:NM_001077365.1:intron:MODIFIER:exon8/19:c.699+53A>G:,POMT1:NM_001077366.1:intron:MODIFIER:exon7/18:c.537+53A>G:,POMT1:NM_001136113.1:intron:MODIFIER:exon8/19:c.699+53A>G:,POMT1:NM_001136114.1:intron:MODIFIER:exon6/17:c.348+53A>G:		rs2296949	0.8706	0.9230	52010/30185/2838	0.9034	1.3280	T,T,T	T	B	T,D,T	0.02	607423 [POMT1 (confirmed) Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,1,236670|Muscular dystrophy-dystroglycanopathy (congenital with mental retardation),type B,1,613155|Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,1,609308];	RCV000081493.5 [benign]; RCV000216907.1 [benign]; 			1362	124					POMT1 (inh=AR pLI=0.00)
chr9	134386744	134386744	T	C	hom	het	hom	pred_pathogenic	QUAL=10758;DP=131,102,166;MQM=59	POMT1	synonymous	POMT1:NM_007171.3:synonymous:LOW:exon10/20:c.942T>C:p.Thr314Thr,POMT1:NM_001077365.1:synonymous:LOW:exon10/20:c.876T>C:p.Thr292Thr,POMT1:NM_001077366.1:synonymous:LOW:exon9/19:c.714T>C:p.Thr238Thr,POMT1:NM_001136113.1:synonymous:LOW:exon10/20:c.876T>C:p.Thr292Thr,POMT1:NM_001136114.1:synonymous:LOW:exon8/18:c.525T>C:p.Thr175Thr		rs10901065	0.8708	0.9231	52033/30195/2847	0.9071	-1.7260	D,D	T		D	5.99	607423 [POMT1 (confirmed) Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,1,236670|Muscular dystrophy-dystroglycanopathy (congenital with mental retardation),type B,1,613155|Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,1,609308];	RCV000153752.3 [benign]; 			1425	131					POMT1 (inh=AR pLI=0.00)
chr9	134386781	134386781	G	A	wt	het	wt	pred_pathogenic	QUAL=1279;DP=207,116,198;MQM=60	POMT1	missense	POMT1:NM_007171.3:missense:MODERATE:exon10/20:c.979G>A:p.Val327Ile,POMT1:NM_001077365.1:missense:MODERATE:exon10/20:c.913G>A:p.Val305Ile,POMT1:NM_001077366.1:missense:MODERATE:exon9/19:c.751G>A:p.Val251Ile,POMT1:NM_001136113.1:missense:MODERATE:exon10/20:c.913G>A:p.Val305Ile,POMT1:NM_001136114.1:missense:MODERATE:exon8/18:c.562G>A:p.Val188Ile		rs4740164	0.0525	0.0533	274/89/1	0.0526	4.8170	T,T,T,T,T,T,T,T,T,T,T	T,T	.,B,B,B,B,B	D,D,D,D,D,D,D,D,D,D	12.23	607423 [POMT1 (confirmed) Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,1,236670|Muscular dystrophy-dystroglycanopathy (congenital with mental retardation),type B,1,613155|Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,1,609308];	RCV000081497.9 [other]; RCV000296590.1 [likely benign]; 			6	114					POMT1 (inh=AR pLI=0.00)
chr9	134387488	134387488	T	C	hom	het	hom		QUAL=22363;DP=287,260,298;MQM=60	POMT1	synonymous	POMT1:NM_007171.3:synonymous:LOW:exon11/20:c.1113T>C:p.Asp371Asp,POMT1:NM_001077365.1:synonymous:LOW:exon11/20:c.1047T>C:p.Asp349Asp,POMT1:NM_001077366.1:synonymous:LOW:exon10/19:c.885T>C:p.Asp295Asp,POMT1:NM_001136113.1:synonymous:LOW:exon11/20:c.1047T>C:p.Asp349Asp,POMT1:NM_001136114.1:synonymous:LOW:exon9/18:c.696T>C:p.Asp232Asp		rs3739494	0.8708	0.9232	51995/30184/2844	0.9156							607423 [POMT1 (confirmed) Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,1,236670|Muscular dystrophy-dystroglycanopathy (congenital with mental retardation),type B,1,613155|Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,1,609308];	RCV000153753.4 [benign]; 			1426	131					POMT1 (inh=AR pLI=0.00)
chr9	134398534	134398534	T	C	hom	het	hom		QUAL=21150;DP=151,298,401;MQM=59	POMT1	3'UTR	POMT1:NM_007171.3:3'UTR:MODIFIER:exon20/20:c.*41T>C:,POMT1:NM_001077365.1:3'UTR:MODIFIER:exon20/20:c.*41T>C:,POMT1:NM_001077366.1:3'UTR:MODIFIER:exon19/19:c.*41T>C:,POMT1:NM_001136113.1:3'UTR:MODIFIER:exon20/20:c.*41T>C:,POMT1:NM_001136114.1:3'UTR:MODIFIER:exon18/18:c.*41T>C:		rs3739495	0.8704	0.9244	47097/27263/2415	0.9013							607423 [POMT1 (confirmed) Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,1,236670|Muscular dystrophy-dystroglycanopathy (congenital with mental retardation),type B,1,613155|Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,1,609308];	RCV000244228.1 [benign]; RCV000408356.1 [benign]; 			828	84					POMT1 (inh=AR pLI=0.00)
chr9	134398719	134398719	T	C	hom	het	hom		QUAL=28648;DP=365,310,418;MQM=59	POMT1	3'UTR	POMT1:NM_007171.3:3'UTR:MODIFIER:exon20/20:c.*226T>C:,POMT1:NM_001077365.1:3'UTR:MODIFIER:exon20/20:c.*226T>C:,POMT1:NM_001077366.1:3'UTR:MODIFIER:exon19/19:c.*226T>C:,POMT1:NM_001136113.1:3'UTR:MODIFIER:exon20/20:c.*226T>C:,POMT1:NM_001136114.1:3'UTR:MODIFIER:exon18/18:c.*226T>C:		rs3824395	0.8708	0.0000	0/0/0	0.1834							607423 [POMT1 (confirmed) Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,1,236670|Muscular dystrophy-dystroglycanopathy (congenital with mental retardation),type B,1,613155|Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,1,609308];	RCV000307484.1 [benign]; RCV000343623.1 [benign]; 			199	26					POMT1 (inh=AR pLI=0.00)
chr9	134398771	134398771	T	C	hom	het	hom		QUAL=28031;DP=284,334,444;MQM=59	POMT1	3'UTR	POMT1:NM_007171.3:3'UTR:MODIFIER:exon20/20:c.*278T>C:,POMT1:NM_001077365.1:3'UTR:MODIFIER:exon20/20:c.*278T>C:,POMT1:NM_001077366.1:3'UTR:MODIFIER:exon19/19:c.*278T>C:,POMT1:NM_001136113.1:3'UTR:MODIFIER:exon20/20:c.*278T>C:,POMT1:NM_001136114.1:3'UTR:MODIFIER:exon18/18:c.*278T>C:		rs10793885	0.8712	0.0000	0/0/0	0.1504							607423 [POMT1 (confirmed) Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,1,236670|Muscular dystrophy-dystroglycanopathy (congenital with mental retardation),type B,1,613155|Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,1,609308];	RCV000276888.1 [benign]; 			201	25					POMT1 (inh=AR pLI=0.00)
chr9	134398778	134398778	A	G	hom	hom	hom		QUAL=33140;DP=261,332,440;MQM=59	POMT1	3'UTR	POMT1:NM_007171.3:3'UTR:MODIFIER:exon20/20:c.*285A>G:,POMT1:NM_001077365.1:3'UTR:MODIFIER:exon20/20:c.*285A>G:,POMT1:NM_001077366.1:3'UTR:MODIFIER:exon19/19:c.*285A>G:,POMT1:NM_001136113.1:3'UTR:MODIFIER:exon20/20:c.*285A>G:,POMT1:NM_001136114.1:3'UTR:MODIFIER:exon18/18:c.*285A>G:		rs4740259	0.9812	0.0000	0/0/0	0.8392							607423 [POMT1 (confirmed) Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,1,236670|Muscular dystrophy-dystroglycanopathy (congenital with mental retardation),type B,1,613155|Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,1,609308];	RCV000311425.1 [benign]; 			229	1					POMT1 (inh=AR pLI=0.00)
chr9	134398841	134398841	C	T	hom	het	hom		QUAL=20370;DP=178,261,366;MQM=59	POMT1	3'UTR	POMT1:NM_007171.3:3'UTR:MODIFIER:exon20/20:c.*348C>T:,POMT1:NM_001077365.1:3'UTR:MODIFIER:exon20/20:c.*348C>T:,POMT1:NM_001077366.1:3'UTR:MODIFIER:exon19/19:c.*348C>T:,POMT1:NM_001136113.1:3'UTR:MODIFIER:exon20/20:c.*348C>T:,POMT1:NM_001136114.1:3'UTR:MODIFIER:exon18/18:c.*348C>T:		rs7857419	0.8664	0.0000	0/0/0	0.1549							607423 [POMT1 (confirmed) Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,1,236670|Muscular dystrophy-dystroglycanopathy (congenital with mental retardation),type B,1,613155|Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,1,609308];	RCV000262116.1 [benign]; 			190	35					POMT1 (inh=AR pLI=0.00)
chr9	134398914	134398914	G	A	wt	wt	het		QUAL=3227;DP=138,193,266;MQM=60	POMT1	3'UTR	POMT1:NM_007171.3:3'UTR:MODIFIER:exon20/20:c.*421G>A:,POMT1:NM_001077365.1:3'UTR:MODIFIER:exon20/20:c.*421G>A:,POMT1:NM_001077366.1:3'UTR:MODIFIER:exon19/19:c.*421G>A:,POMT1:NM_001136113.1:3'UTR:MODIFIER:exon20/20:c.*421G>A:,POMT1:NM_001136114.1:3'UTR:MODIFIER:exon18/18:c.*421G>A:		rs10257	0.0613	0.0000	0/0/0	0.0166							607423 [POMT1 (confirmed) Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,1,236670|Muscular dystrophy-dystroglycanopathy (congenital with mental retardation),type B,1,613155|Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,1,609308];	RCV000319591.1 [likely benign]; 			2	51					POMT1 (inh=AR pLI=0.00)
chr9	134398946	134398946	T	C	hom	het	het		QUAL=11520;DP=164,200,268;MQM=59	POMT1	3'UTR	POMT1:NM_007171.3:3'UTR:MODIFIER:exon20/20:c.*453T>C:,POMT1:NM_001077365.1:3'UTR:MODIFIER:exon20/20:c.*453T>C:,POMT1:NM_001077366.1:3'UTR:MODIFIER:exon19/19:c.*453T>C:,POMT1:NM_001136113.1:3'UTR:MODIFIER:exon20/20:c.*453T>C:,POMT1:NM_001136114.1:3'UTR:MODIFIER:exon18/18:c.*453T>C:		rs11005	0.7490	0.0000	0/0/0	0.1352							607423 [POMT1 (confirmed) Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,1,236670|Muscular dystrophy-dystroglycanopathy (congenital with mental retardation),type B,1,613155|Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,1,609308];	RCV000371769.1 [benign]; 			137	85					POMT1 (inh=AR pLI=0.00)
chr9	135138258	135138258	C	T	wt	het	wt		QUAL=2828;DP=407,205,287;MQM=60	SETX	3'UTR	SETX:NM_015046.5:3'UTR:MODIFIER:exon26/26:c.*1368G>A:		rs7025	0.1787	0.0000	0/0/0	0.0300							608465 [SETX (confirmed) Amyotrophic lateral sclerosis 4,juvenile,602433|Spinocerebellar ataxia,autosomal recessive 1,606002];	RCV000328543.1 [likely benign]; RCV000364540.1 [likely benign]; 			9	78					SETX (inh=AR+AD pLI=0.20)
chr9	135139000	135139000	G	A	wt	het	wt		QUAL=2322;DP=364,203,263;MQM=59	SETX	3'UTR	SETX:NM_015046.5:3'UTR:MODIFIER:exon26/26:c.*626C>T:		rs11795382	0.1785	0.0000	0/0/0	0.0300							608465 [SETX (confirmed) Amyotrophic lateral sclerosis 4,juvenile,602433|Spinocerebellar ataxia,autosomal recessive 1,606002];	RCV000259416.1 [likely benign]; RCV000319268.1 [likely benign]; 			9	79					SETX (inh=AR+AD pLI=0.20)
chr9	135139064	135139064	G	T	wt	het	wt		QUAL=1298;DP=255,137,170;MQM=59	SETX	3'UTR	SETX:NM_015046.5:3'UTR:MODIFIER:exon26/26:c.*562C>A:		rs11787894	0.1813	0.0000	0/0/0	0.0253							608465 [SETX (confirmed) Amyotrophic lateral sclerosis 4,juvenile,602433|Spinocerebellar ataxia,autosomal recessive 1,606002];	RCV000283999.1 [likely benign]; RCV000373909.1 [likely benign]; 			9	78					SETX (inh=AR+AD pLI=0.20)
chr9	135139901	135139901	T	C	wt	het	wt	pred_pathogenic	QUAL=3015;DP=221,244,280;MQM=60	SETX	missense	SETX:NM_015046.5:missense:MODERATE:exon26/26:c.7759A>G:p.Ile2587Val		rs1056899	0.5387	0.3926	11018/3090/2948	0.3846	-1.1110	T,T,T,T	T	B,B,B	D,D,D,D	0.01	608465 [SETX (confirmed) Amyotrophic lateral sclerosis 4,juvenile,602433|Spinocerebellar ataxia,autosomal recessive 1,606002];	RCV000081702.8 [other]; RCV000294610.1 [benign]; RCV000388921.1 [benign]; 		COSM3763694, COSM3763695	407	1358					SETX (inh=AR+AD pLI=0.20)
chr9	135202829	135202829	T	C	hom	hom	hom	pred_pathogenic	QUAL=23269;DP=326,171,205;MQM=60	SETX	missense	SETX:NM_015046.5:missense:MODERATE:exon10/26:c.4156A>G:p.Ile1386Val		rs543573	0.5561	0.7252	33935/23205/761	0.7203	-0.6580	T,T,T	T	B,B,B	D,D,D	0.01	608465 [SETX (confirmed) Amyotrophic lateral sclerosis 4,juvenile,602433|Spinocerebellar ataxia,autosomal recessive 1,606002];	RCV000081696.8 [other]; RCV000298134.1 [benign]; RCV000391406.1 [benign]; 		COSM3982759, COSM150732	2191	958					SETX (inh=AR+AD pLI=0.20)
chr9	135203231	135203231	C	T	hom	hom	hom	pred_pathogenic	QUAL=14736;DP=201,96,164;MQM=59	SETX	missense	SETX:NM_015046.5:missense:MODERATE:exon10/26:c.3754G>A:p.Gly1252Arg		rs1183768	0.5561	0.7251	33914/23192/758	0.6938	0.4900	T,T,T	T	B,B,B	D,D,D	17.34	608465 [SETX (confirmed) Amyotrophic lateral sclerosis 4,juvenile,602433|Spinocerebellar ataxia,autosomal recessive 1,606002];	RCV000081695.8 [other]; RCV000293963.1 [benign]; RCV000351274.1 [benign]; 		COSM3982760, COSM150733	2202	952					SETX (inh=AR+AD pLI=0.20)
chr9	135203409	135203409	A	C	hom	hom	hom	pred_pathogenic	QUAL=15430;DP=321,62,83;MQM=60	SETX	missense	SETX:NM_015046.5:missense:MODERATE:exon10/26:c.3576T>G:p.Asp1192Glu		rs1185193	0.6406	0.7635	36812/24117/2182	0.7563	-0.9950	T,T,T	T	B,B,B	D,D,D	0.01	608465 [SETX (confirmed) Amyotrophic lateral sclerosis 4,juvenile,602433|Spinocerebellar ataxia,autosomal recessive 1,606002];	RCV000081694.8 [other]; RCV000278408.1 [benign]; RCV000389540.1 [benign]; 			2293	879					SETX (inh=AR+AD pLI=0.20)
chr9	135206460	135206460	A	G	hom	hom	hom		QUAL=29150;DP=516,171,190;MQM=60	SETX	synonymous	SETX:NM_015046.5:synonymous:LOW:exon9/26:c.1077T>C:p.Tyr359Tyr		rs9411449	0.6266	0.7477	35321/23221/2007	0.7420							608465 [SETX (confirmed) Amyotrophic lateral sclerosis 4,juvenile,602433|Spinocerebellar ataxia,autosomal recessive 1,606002];	RCV000081691.8 [other]; RCV000324127.1 [benign]; RCV000381219.1 [benign]; 		COSM150734, COSM4163458	2212	949					SETX (inh=AR+AD pLI=0.20)
chr9	135767185	135767185	C	T	het	wt	het		QUAL=8687;DP=411,312,375;MQM=60	TSC1	3'UTR	TSC1:NM_000368.4:3'UTR:MODIFIER:exon23/23:c.*4437G>A:,TSC1:NM_001162426.1:3'UTR:MODIFIER:exon23/23:c.*4437G>A:,TSC1:NM_001162427.1:3'UTR:MODIFIER:exon22/22:c.*4437G>A:		rs11553763	0.1034	0.0000	0/0/0	0.0144							605284 [TSC1 (confirmed) Tuberous sclerosis-1,191100|Lymphangioleiomyomatosis,606690];	RCV000333342.1 [benign]; RCV000387639.1 [benign]; 			1	28					TSC1 (inh=AD pLI=1.00)
chr9	135767943	135767943	C	T	wt	het	het		QUAL=8723;DP=195,284,387;MQM=60	TSC1	3'UTR	TSC1:NM_000368.4:3'UTR:MODIFIER:exon23/23:c.*3679G>A:,TSC1:NM_001162426.1:3'UTR:MODIFIER:exon23/23:c.*3679G>A:,TSC1:NM_001162427.1:3'UTR:MODIFIER:exon22/22:c.*3679G>A:		rs1050700	0.7258	0.0000	0/0/0	0.1202							605284 [TSC1 (confirmed) Tuberous sclerosis-1,191100|Lymphangioleiomyomatosis,606690];	RCV000278209.1 [benign]; RCV000374675.1 [benign]; 			103	102					TSC1 (inh=AD pLI=1.00)
chr9	135770115	135770115	C	T	hom	hom	hom		QUAL=14553;DP=257,93,106;MQM=59	TSC1	3'UTR	TSC1:NM_000368.4:3'UTR:MODIFIER:exon23/23:c.*1507G>A:,TSC1:NM_001162426.1:3'UTR:MODIFIER:exon23/23:c.*1507G>A:,TSC1:NM_001162427.1:3'UTR:MODIFIER:exon22/22:c.*1507G>A:		rs739441	0.7734	0.0000	0/0/0	0.7171							605284 [TSC1 (confirmed) Tuberous sclerosis-1,191100|Lymphangioleiomyomatosis,606690];	RCV000293568.1 [benign]; RCV000373877.1 [benign]; 			116	72					TSC1 (inh=AD pLI=1.00)
chr9	135770134	135770134	G	A	het	wt	hom		QUAL=7494;DP=299,107,126;MQM=59	TSC1	3'UTR	TSC1:NM_000368.4:3'UTR:MODIFIER:exon23/23:c.*1488C>T:,TSC1:NM_001162426.1:3'UTR:MODIFIER:exon23/23:c.*1488C>T:,TSC1:NM_001162427.1:3'UTR:MODIFIER:exon22/22:c.*1488C>T:		rs739442	0.4507	0.0000	0/0/0	0.0889							605284 [TSC1 (confirmed) Tuberous sclerosis-1,191100|Lymphangioleiomyomatosis,606690];	RCV000348515.1 [benign]; RCV000393355.1 [benign]; 			54	103					TSC1 (inh=AD pLI=1.00)
chr9	135770250	135770250	A	C	het	het	het		QUAL=10462;DP=268,231,325;MQM=59	TSC1	3'UTR	TSC1:NM_000368.4:3'UTR:MODIFIER:exon23/23:c.*1372T>G:,TSC1:NM_001162426.1:3'UTR:MODIFIER:exon23/23:c.*1372T>G:,TSC1:NM_001162427.1:3'UTR:MODIFIER:exon22/22:c.*1372T>G:		rs58612431	0.2196	0.0000	0/0/0	0.0308							605284 [TSC1 (confirmed) Tuberous sclerosis-1,191100|Lymphangioleiomyomatosis,606690];	RCV000264627.1 [benign]; RCV000359363.1 [benign]; 			7	61					TSC1 (inh=AD pLI=1.00)
chr9	135770300	135770300	G	A	het	het	hom		QUAL=19647;DP=399,265,357;MQM=60	TSC1	3'UTR	TSC1:NM_000368.4:3'UTR:MODIFIER:exon23/23:c.*1322C>T:,TSC1:NM_001162426.1:3'UTR:MODIFIER:exon23/23:c.*1322C>T:,TSC1:NM_001162427.1:3'UTR:MODIFIER:exon22/22:c.*1322C>T:		rs2809243	0.5521	0.0000	0/0/0	0.1021							605284 [TSC1 (confirmed) Tuberous sclerosis-1,191100|Lymphangioleiomyomatosis,606690];	RCV000305720.1 [benign]; RCV000360906.1 [benign]; 			66	122					TSC1 (inh=AD pLI=1.00)
chr9	135770347	135770347	A	C	hom	hom	hom		QUAL=32149;DP=351,276,373;MQM=59	TSC1	3'UTR	TSC1:NM_000368.4:3'UTR:MODIFIER:exon23/23:c.*1275T>G:,TSC1:NM_001162426.1:3'UTR:MODIFIER:exon23/23:c.*1275T>G:,TSC1:NM_001162427.1:3'UTR:MODIFIER:exon22/22:c.*1275T>G:		rs2809244	0.7482	0.0000	0/0/0	0.7349							605284 [TSC1 (confirmed) Tuberous sclerosis-1,191100|Lymphangioleiomyomatosis,606690];	RCV000261435.1 [benign]; RCV000316720.1 [benign]; 			117	88					TSC1 (inh=AD pLI=1.00)
chr9	135771333	135771333	A	-	wt	wt	het		QUAL=2310;DP=292,222,246;MQM=59	TSC1	3'UTR	TSC1:NM_000368.4:3'UTR:MODIFIER:exon23/23:c.*289delT:,TSC1:NM_001162426.1:3'UTR:MODIFIER:exon23/23:c.*289delT:,TSC1:NM_001162427.1:3'UTR:MODIFIER:exon22/22:c.*289delT:		rs397819014	0.4391	0.0000	0/0/0	0.4292							605284 [TSC1 (confirmed) Tuberous sclerosis-1,191100|Lymphangioleiomyomatosis,606690];	RCV000293271.1 [benign]; RCV000352748.1 [benign]; 			44	110					TSC1 (inh=AD pLI=1.00)
chr9	135772717	135772717	G	A	het	het	het		QUAL=11310;DP=295,246,270;MQM=59	TSC1	synonymous	TSC1:NM_000368.4:synonymous:LOW:exon22/23:c.2829C>T:p.Ala943Ala,TSC1:NM_001162426.1:synonymous:LOW:exon22/23:c.2826C>T:p.Ala942Ala,TSC1:NM_001162427.1:synonymous:LOW:exon21/22:c.2676C>T:p.Ala892Ala		rs4962081	0.0621	0.0758	457/224/37	0.0752							605284 [TSC1 (confirmed) Tuberous sclerosis-1,191100|Lymphangioleiomyomatosis,606690];	RCV000042257.3 [benign]; RCV000054906.1 [not provided]; RCV000055028.1 [not provided]; RCV000055028.1 [not provided]; RCV000118693.8 [other]; RCV000162946.1 [benign]; RCV000370584.1 [benign]; 			7	237					TSC1 (inh=AD pLI=1.00)
chr9	135773001	135773001	A	-	hom	wt	wt		QUAL=1122;DP=45,21,26;MQM=59	TSC1	splice_region&intron	TSC1:NM_000368.4:splice_region&intron:LOW:exon20/22:c.2626-4delT:,TSC1:NM_001162426.1:splice_region&intron:LOW:exon20/22:c.2623-4delT:,TSC1:NM_001162427.1:splice_region&intron:LOW:exon19/21:c.2473-4delT:	(A)n	rs118203716	0.3427	0.2827	1/1/0	0.1961							605284 [TSC1 (confirmed) Tuberous sclerosis-1,191100|Lymphangioleiomyomatosis,606690];	RCV000042234.3 [benign]; RCV000313026.1 [benign]; 			14	115					TSC1 (inh=AD pLI=1.00)
chr9	135773000	135773000	G	AAA	wt	hom	hom		QUAL=1122;DP=45,21,26;MQM=51	TSC1	splice_region&intron	TSC1:NM_000368.4:splice_region&intron:LOW:exon20/22:c.2626-3delCinsTTT:,TSC1:NM_001162426.1:splice_region&intron:LOW:exon20/22:c.2623-3delCinsTTT:,TSC1:NM_001162427.1:splice_region&intron:LOW:exon19/21:c.2473-3delCinsTTT:			0.0000	0.0000	0/0/0	0.0000							605284 [TSC1 (confirmed) Tuberous sclerosis-1,191100|Lymphangioleiomyomatosis,606690];				9	2	2	[3] swoedl 18.03.2016 [2] ahbuchr1 10.05.2016 	n/a (1xTP, 0xFP)		TSC1 (inh=AD pLI=1.00)
chr9	135782221	135782221	T	C	het	het	wt		QUAL=3635;DP=178,99,140;MQM=60	TSC1	splice_region&synonymous	TSC1:NM_000368.4:splice_region&synonymous:LOW:exon14/23:c.1335A>G:p.Glu445Glu,TSC1:NM_001162426.1:splice_region&synonymous:LOW:exon14/23:c.1332A>G:p.Glu444Glu,TSC1:NM_001162427.1:splice_region&synonymous:LOW:exon13/22:c.1182A>G:p.Glu394Glu		rs7862221	0.1386	0.1371	1225/741/254	0.1350							605284 [TSC1 (confirmed) Tuberous sclerosis-1,191100|Lymphangioleiomyomatosis,606690];	RCV000042015.3 [benign]; RCV000118690.7 [other]; RCV000162953.1 [benign]; RCV000287833.1 [benign]; 		COSM3763712	43	509					TSC1 (inh=AD pLI=1.00)
chr9	135786904	135786904	A	G	het	het	wt	pred_pathogenic	QUAL=6103;DP=322,192,215;MQM=60	TSC1	missense	TSC1:NM_000368.4:missense:MODERATE:exon10/23:c.965T>C:p.Met322Thr,TSC1:NM_001162426.1:missense:MODERATE:exon10/23:c.965T>C:p.Met322Thr,TSC1:NM_001162427.1:missense:MODERATE:exon9/22:c.812T>C:p.Met271Thr		rs1073123	0.1352	0.1290	1104/639/250	0.1273	1.3780	T,T,T,T,T,T	T	B,B,B,B,B,B	D,D,D,D,D	6.71	605284 [TSC1 (confirmed) Tuberous sclerosis-1,191100|Lymphangioleiomyomatosis,606690];	RCV000034613.5 [benign]; RCV000054853.2 [benign]; RCV000054992.1 [not provided]; RCV000054997.1 [not provided]; RCV000054997.1 [not provided]; RCV000118695.8 [other]; RCV000162954.1 [benign]; RCV000355920.1 [benign]; 	CM131323 [CLASS=DP MUT=ALT PHEN="Respiratory disease aspirin-exacerbated association with" GENE=TSC1]; 	COSM3763713	40	483					TSC1 (inh=AD pLI=1.00)
chr9	135973678	135973678	C	T	wt	het	het		QUAL=4970;DP=156,219,267;MQM=60	RALGDS	3'UTR	RALGDS:NM_006266.3:3'UTR:MODIFIER:exon18/18:c.*296G>A:,RALGDS:NM_001271776.1:3'UTR:MODIFIER:exon18/18:c.*296G>A:,RALGDS:NM_001271775.1:3'UTR:MODIFIER:exon18/18:c.*296G>A:,RALGDS:NM_001271774.1:3'UTR:MODIFIER:exon18/18:c.*296G>A:,RALGDS:NM_001042368.2:3'UTR:MODIFIER:exon18/18:c.*296G>A:		rs3088274	0.1975	0.0000	0/0/0	0.0440											28	86					RALGDS (inh=n/a pLI=0.30)
chr9	135974079	135974079	G	C	het	hom	het		QUAL=12689;DP=236,201,323;MQM=59	RALGDS	synonymous	RALGDS:NM_006266.3:synonymous:LOW:exon18/18:c.2640C>G:p.Leu880Leu,RALGDS:NM_001271776.1:synonymous:LOW:exon18/18:c.2604C>G:p.Leu868Leu,RALGDS:NM_001271775.1:synonymous:LOW:exon18/18:c.2637C>G:p.Leu879Leu,RALGDS:NM_001271774.1:synonymous:LOW:exon18/18:c.2553C>G:p.Leu851Leu,RALGDS:NM_001042368.2:synonymous:LOW:exon18/18:c.2475C>G:p.Leu825Leu		rs1062356	0.8275	0.8416	43048/24211/3818	0.8337											1122	401					RALGDS (inh=n/a pLI=0.30)
chr9	135974100	135974100	G	A	het	het	wt		QUAL=4947;DP=221,215,337;MQM=60	RALGDS	synonymous	RALGDS:NM_006266.3:synonymous:LOW:exon18/18:c.2619C>T:p.Thr873Thr,RALGDS:NM_001271776.1:synonymous:LOW:exon18/18:c.2583C>T:p.Thr861Thr,RALGDS:NM_001271775.1:synonymous:LOW:exon18/18:c.2616C>T:p.Thr872Thr,RALGDS:NM_001271774.1:synonymous:LOW:exon18/18:c.2532C>T:p.Thr844Thr,RALGDS:NM_001042368.2:synonymous:LOW:exon18/18:c.2454C>T:p.Thr818Thr		rs886017	0.4916	0.5423	18396/9569/464	0.5337											475	749					RALGDS (inh=n/a pLI=0.30)
chr9	135982088	135982088	A	C	wt	het	het		QUAL=9203;DP=281,343,395;MQM=60	RALGDS	synonymous	RALGDS:NM_006266.3:synonymous:LOW:exon8/18:c.1461T>G:p.Ser487Ser,RALGDS:NM_001271776.1:synonymous:LOW:exon8/18:c.1425T>G:p.Ser475Ser,RALGDS:NM_001271775.1:synonymous:LOW:exon8/18:c.1458T>G:p.Ser486Ser,RALGDS:NM_001271774.1:synonymous:LOW:exon8/18:c.1374T>G:p.Ser458Ser,RALGDS:NM_001042368.2:synonymous:LOW:exon8/18:c.1296T>G:p.Ser432Ser		rs2073822	0.1945	0.2604	3985/2945/119	0.2498											144	635					RALGDS (inh=n/a pLI=0.30)
chr9	135983504	135983504	T	C	wt	het	het		QUAL=6678;DP=279,248,322;MQM=60	RALGDS	synonymous	RALGDS:NM_006266.3:synonymous:LOW:exon6/18:c.1068A>G:p.Ala356Ala,RALGDS:NM_001271776.1:synonymous:LOW:exon6/18:c.1032A>G:p.Ala344Ala,RALGDS:NM_001271775.1:synonymous:LOW:exon6/18:c.1065A>G:p.Ala355Ala,RALGDS:NM_001271774.1:synonymous:LOW:exon6/18:c.981A>G:p.Ala327Ala,RALGDS:NM_001042368.2:synonymous:LOW:exon6/18:c.903A>G:p.Ala301Ala		rs2285375	0.2889	0.2795	5255/3202/998	0.2782										COSM3763716, COSM3763715, COSM3763717, COSM3763714	155	644					RALGDS (inh=n/a pLI=0.30)
chr9	135985796	135985796	C	T	het	het	wt		QUAL=3891;DP=157,201,272;MQM=60	RALGDS	synonymous	RALGDS:NM_006266.3:synonymous:LOW:exon3/18:c.375G>A:p.Val125Val,RALGDS:NM_001271776.1:synonymous:LOW:exon3/18:c.375G>A:p.Val125Val,RALGDS:NM_001271775.1:synonymous:LOW:exon3/18:c.372G>A:p.Val124Val,RALGDS:NM_001271774.1:synonymous:LOW:exon3/18:c.324G>A:p.Val108Val,RALGDS:NM_001042368.2:synonymous:LOW:exon3/18:c.210G>A:p.Val70Val		rs3761824	0.2486	0.2853	5054/3159/113	0.2817										COSM4163476, COSM4163477, COSM4163475, COSM4163478	133	654					RALGDS (inh=n/a pLI=0.30)
chr9	136223366	136223366	G	A	hom	hom	hom	low_DP	QUAL=175;DP=3,1,2;MQM=60	SURF1-SURF2	intergenic_region	SURF1-SURF2:SURF1-SURF2:intergenic_region:MODIFIER::n.136223366G>A:		rs523304	0.5120	0.5354	992/273/15	0.1182							185620 [SURF1 (confirmed) Leigh syndrome,due to COX IV deficiency,256000|Charcot-Marie-Tooth disease,type 4K,616684];	RCV000128344.1 [benign]; RCV000286961.1 [benign]; 			169	342					SURF1-SURF2 (inh=n/a pLI=n/a)
chr9	136291063	136291063	C	T	hom	hom	hom		QUAL=32083;DP=343,326,388;MQM=59	ADAMTS13	synonymous,non_coding_transcript_exon	ADAMTS13:NM_139025.4:synonymous:LOW:exon5/29:c.420C>T:p.Ala140Ala,ADAMTS13:NM_139026.4:synonymous:LOW:exon5/29:c.420C>T:p.Ala140Ala,ADAMTS13:NM_139027.4:synonymous:LOW:exon5/29:c.420C>T:p.Ala140Ala,ADAMTS13:NR_024514.2:non_coding_transcript_exon:MODIFIER:exon5/18:n.621C>T:		rs3118667	0.5819	0.5504	18927/9627/1196	0.5450							604134 [ADAMTS13 (provisional) Thrombotic thrombocytopenic purpura,familial,274150];			COSM1460807	488	723					ADAMTS13 (inh=AR pLI=0.00)
chr9	136304497	136304497	A	G	hom	hom	hom		QUAL=31669;DP=268,333,390;MQM=59	ADAMTS13	synonymous,non_coding_transcript_exon	ADAMTS13:NM_139025.4:synonymous:LOW:exon15/29:c.1716A>G:p.Thr572Thr,ADAMTS13:NM_139026.4:synonymous:LOW:exon15/29:c.1623A>G:p.Thr541Thr,ADAMTS13:NM_139027.4:synonymous:LOW:exon15/29:c.1716A>G:p.Thr572Thr,ADAMTS13:NR_024514.2:non_coding_transcript_exon:MODIFIER:exon8/18:n.1003A>G:		rs3124768	0.5160	0.4718	14527/6664/695	0.4702							604134 [ADAMTS13 (provisional) Thrombotic thrombocytopenic purpura,familial,274150];		CM1213383 [CLASS=FP MUT=ALT PHEN="Reduced expression" GENE=ADAMTS13]; 	COSM4163494	351	739					ADAMTS13 (inh=AR pLI=0.00)
chr9	136397388	136397388	G	A	wt	wt	het	low_DP	QUAL=104;DP=17,2,7;MQM=60	ADAMTSL2	5'UTR	ADAMTSL2:NM_001145320.1:5'UTR:MODIFIER:exon1/19:c.-455G>A:	AluSx1	rs1985381	0.0347	0.0000	0/0/0	0.0576							612277 [ADAMTSL2 (provisional) Geleophysic dysplasia 1,231050];				0	10					ADAMTSL2 (inh=AR pLI=0.07)
chr9	136397443	136397443	C	T	wt	wt	het	low_DP	QUAL=166;DP=2,2,10;MQM=60	ADAMTSL2	5'UTR_premature_start_codon_gain,5'UTR	ADAMTSL2:NM_001145320.1:5'UTR_premature_start_codon_gain:LOW:exon1/19:c.-400C>T:,ADAMTSL2:NM_001145320.1:5'UTR:MODIFIER:exon1/19:c.-400C>T:	AluSx1	rs1985382	0.0587	0.0000	0/0/0	0.0641							612277 [ADAMTSL2 (provisional) Geleophysic dysplasia 1,231050];				2	3					ADAMTSL2 (inh=AR pLI=0.07)
chr9	136405809	136405809	G	A	wt	het	wt	pred_pathogenic	QUAL=3232;DP=177,238,277;MQM=60	ADAMTSL2	missense	ADAMTSL2:NM_001145320.1:missense:MODERATE:exon6/19:c.502G>A:p.Gly168Ser,ADAMTSL2:NM_014694.3:missense:MODERATE:exon6/19:c.502G>A:p.Gly168Ser		rs756311258	0.0000	0.0001	0/0/0	0.0001	9.4010	D,D,D	D	D	D,D,D	33.00	612277 [ADAMTSL2 (provisional) Geleophysic dysplasia 1,231050];				0	1					ADAMTSL2 (inh=AR pLI=0.07)
chr9	136412170	136412170	C	T	hom	het	hom		QUAL=23599;DP=140,372,479;MQM=60	ADAMTSL2	synonymous	ADAMTSL2:NM_001145320.1:synonymous:LOW:exon9/19:c.774C>T:p.Asp258Asp,ADAMTSL2:NM_014694.3:synonymous:LOW:exon9/19:c.774C>T:p.Asp258Asp		rs2073874	0.7240	0.8194	41810/27676/3235	0.8052							612277 [ADAMTSL2 (provisional) Geleophysic dysplasia 1,231050];	RCV000304229.1 [benign]; 			1200	328					ADAMTSL2 (inh=AR pLI=0.07)
chr9	136412236	136412236	A	T	hom	het	hom		QUAL=37057;DP=328,514,641;MQM=59	ADAMTSL2	synonymous	ADAMTSL2:NM_001145320.1:synonymous:LOW:exon9/19:c.840A>T:p.Ala280Ala,ADAMTSL2:NM_014694.3:synonymous:LOW:exon9/19:c.840A>T:p.Ala280Ala		rs2073875	0.7246	0.8197	41848/27706/3236	0.7824							612277 [ADAMTSL2 (provisional) Geleophysic dysplasia 1,231050];	RCV000361313.1 [benign]; 			1203	328					ADAMTSL2 (inh=AR pLI=0.07)
chr9	136412255	136412255	A	C	hom	het	hom		QUAL=36693;DP=288,520,639;MQM=59	ADAMTSL2	synonymous	ADAMTSL2:NM_001145320.1:synonymous:LOW:exon9/19:c.859A>C:p.Arg287Arg,ADAMTSL2:NM_014694.3:synonymous:LOW:exon9/19:c.859A>C:p.Arg287Arg		rs2073876	0.7246	0.8198	41848/27707/3236	0.7823							612277 [ADAMTSL2 (provisional) Geleophysic dysplasia 1,231050];	RCV000397418.1 [benign]; 			1203	328					ADAMTSL2 (inh=AR pLI=0.07)
chr9	136440078	136440078	G	A	wt	wt	het	low_MQM	QUAL=234;DP=288,26,34;MQM=47	ADAMTSL2	3'UTR	ADAMTSL2:NM_001145320.1:3'UTR:MODIFIER:exon19/19:c.*92G>A:,ADAMTSL2:NM_014694.3:3'UTR:MODIFIER:exon19/19:c.*92G>A:		rs62574238	0.0493	0.0000	0/0/0	0.0118							612277 [ADAMTSL2 (provisional) Geleophysic dysplasia 1,231050];	RCV000324853.1 [likely benign]; 			5	22					ADAMTSL2 (inh=AR pLI=0.07)
chr9	136440144	136440144	G	A	hom	het	hom	low_MQM	QUAL=5138;DP=66,76,95;MQM=46	ADAMTSL2	3'UTR	ADAMTSL2:NM_001145320.1:3'UTR:MODIFIER:exon19/19:c.*158G>A:,ADAMTSL2:NM_014694.3:3'UTR:MODIFIER:exon19/19:c.*158G>A:		rs1105952	0.4637	0.0000	0/0/0	0.0543							612277 [ADAMTSL2 (provisional) Geleophysic dysplasia 1,231050];	RCV000377166.1 [benign]; 			67	107					ADAMTSL2 (inh=AR pLI=0.07)
chr9	136440203	136440203	G	T	wt	wt	het	low_MQM	QUAL=879;DP=57,82,101;MQM=48	ADAMTSL2	3'UTR	ADAMTSL2:NM_001145320.1:3'UTR:MODIFIER:exon19/19:c.*217G>T:,ADAMTSL2:NM_014694.3:3'UTR:MODIFIER:exon19/19:c.*217G>T:		rs111717891	0.0327	0.0000	0/0/0	0.0063							612277 [ADAMTSL2 (provisional) Geleophysic dysplasia 1,231050];	RCV000285050.1 [likely benign]; 			1	36					ADAMTSL2 (inh=AR pLI=0.07)
chr9	136440272	136440272	C	-	wt	wt	het	low_MQM	QUAL=426;DP=24,50,66;MQM=42	ADAMTSL2	3'UTR	ADAMTSL2:NM_001145320.1:3'UTR:MODIFIER:exon19/19:c.*291delC:,ADAMTSL2:NM_014694.3:3'UTR:MODIFIER:exon19/19:c.*291delC:		rs3833705	0.2330	0.0000	0/0/0	0.1591							612277 [ADAMTSL2 (provisional) Geleophysic dysplasia 1,231050];				31	68					ADAMTSL2 (inh=AR pLI=0.07)
chr9	136440362	136440362	G	A	wt	wt	het	low_DP;low_MQM	QUAL=270;DP=8,35,38;MQM=38	ADAMTSL2	3'UTR	ADAMTSL2:NM_001145320.1:3'UTR:MODIFIER:exon19/19:c.*376G>A:,ADAMTSL2:NM_014694.3:3'UTR:MODIFIER:exon19/19:c.*376G>A:		rs113048552	0.0325	0.0000	0/0/0	0.0065							612277 [ADAMTSL2 (provisional) Geleophysic dysplasia 1,231050];	RCV000405159.1 [likely benign]; 			2	27					ADAMTSL2 (inh=AR pLI=0.07)
chr9	139089067	139089067	C	-	wt	het	wt		QUAL=373;DP=51,39,37;MQM=60	LHX3	3'UTR	LHX3:NM_014564.4:3'UTR:MODIFIER:exon6/6:c.*104delG:,LHX3:NM_178138.5:3'UTR:MODIFIER:exon6/6:c.*104delG:		rs146678449	0.1304	0.0000	0/0/0	0.1314							600577 [LHX3 (provisional) Pituitary hormone deficiency,combined,3,221750];	RCV000371868.1 [likely benign]; 			7	59					LHX3 (inh=AR pLI=0.16)
chr9	139258462	139258462	A	G	wt	wt	het		QUAL=1983;DP=35,122,142;MQM=60	CARD9	3'UTR	CARD9:NM_052813.4:3'UTR:MODIFIER:exon13/13:c.*292T>C:,CARD9:NM_052814.3:3'UTR:MODIFIER:exon13/13:c.*115T>C:		rs1135314	0.2542	0.3204	731/396/40	0.0915							607212 [CARD9 (provisional) Candidiasis,familial,2,autosomal recessive,212050];	RCV000331427.1 [benign]; 			95	411					CARD9 (inh=AR pLI=0.00)
chr9	139266405	139266405	G	A	wt	het	het		QUAL=923;DP=40,38,57;MQM=60	CARD9	synonymous	CARD9:NM_052813.4:synonymous:LOW:exon2/13:c.126C>T:p.Pro42Pro,CARD9:NM_052814.3:synonymous:LOW:exon2/13:c.126C>T:p.Pro42Pro		rs10781499	0.3662	0.4022	10140/6022/372	0.3986							607212 [CARD9 (provisional) Candidiasis,familial,2,autosomal recessive,212050];	RCV000351119.1 [benign]; 		COSM455593, COSM3763765	223	710					CARD9 (inh=AR pLI=0.00)
chr9	139266496	139266496	C	T	wt	het	het		QUAL=1037;DP=24,35,49;MQM=60	CARD9	missense	CARD9:NM_052813.4:missense:MODERATE:exon2/13:c.35G>A:p.Ser12Asn,CARD9:NM_052814.3:missense:MODERATE:exon2/13:c.35G>A:p.Ser12Asn		rs4077515	0.3666	0.4019	10028/5921/371	0.3973	-0.1340	T,T,T	T	B,B,B	T,T,T	0.07	607212 [CARD9 (provisional) Candidiasis,familial,2,autosomal recessive,212050];	RCV000408113.1 [benign]; 	CM1010097 [CLASS=DP MUT=ALT PHEN="Ankylosing spondylitis association with" GENE=CARD9]; 	COSM455594, COSM3736479	218	709					CARD9 (inh=AR pLI=0.00)
chr9	139323201	139323201	A	G	het	het	wt		QUAL=5771;DP=252,138,161;MQM=60	INPP5E	3'UTR	INPP5E:NM_019892.5:3'UTR:MODIFIER:exon10/10:c.*926T>C:,INPP5E:NM_001318502.1:3'UTR:MODIFIER:exon10/10:c.*926T>C:		rs1128877	0.1278	0.0000	0/0/0	0.0242							613037 [INPP5E (provisional) Mental retardation,truncal obesity,retinal dystrophy,and micropenis,610156|Joubert syndrome 1,213300];	RCV000361000.1 [likely benign]; 			4	60					INPP5E (inh=AR pLI=0.39)
chr9	139323311	139323311	T	C	het	hom	het		QUAL=11105;DP=186,188,233;MQM=59	INPP5E	3'UTR	INPP5E:NM_019892.5:3'UTR:MODIFIER:exon10/10:c.*816A>G:,INPP5E:NM_001318502.1:3'UTR:MODIFIER:exon10/10:c.*816A>G:		rs8413	0.3658	0.0000	0/0/0	0.0671							613037 [INPP5E (provisional) Mental retardation,truncal obesity,retinal dystrophy,and micropenis,610156|Joubert syndrome 1,213300];	RCV000321574.1 [benign]; 			48	110					INPP5E (inh=AR pLI=0.39)
chr9	139323424	139323424	T	C	het	hom	het		QUAL=8631;DP=159,140,146;MQM=59	INPP5E	3'UTR	INPP5E:NM_019892.5:3'UTR:MODIFIER:exon10/10:c.*703A>G:,INPP5E:NM_001318502.1:3'UTR:MODIFIER:exon10/10:c.*703A>G:		rs1128874	0.3776	0.0000	0/0/0	0.0717							613037 [INPP5E (provisional) Mental retardation,truncal obesity,retinal dystrophy,and micropenis,610156|Joubert syndrome 1,213300];	RCV000296422.1 [benign]; 			51	112					INPP5E (inh=AR pLI=0.39)
chr9	139323497	139323497	C	T	het	het	wt		QUAL=3322;DP=135,127,141;MQM=59	INPP5E	3'UTR	INPP5E:NM_019892.5:3'UTR:MODIFIER:exon10/10:c.*630G>A:,INPP5E:NM_001318502.1:3'UTR:MODIFIER:exon10/10:c.*630G>A:		rs539039743	0.0004	0.0000	0/0/0	0.0002							613037 [INPP5E (provisional) Mental retardation,truncal obesity,retinal dystrophy,and micropenis,610156|Joubert syndrome 1,213300];	RCV000348979.1 [uncertain significance]; 			0	2					INPP5E (inh=AR pLI=0.39)
chr9	139323799	139323799	A	G	het	hom	het		QUAL=9671;DP=134,186,229;MQM=59	INPP5E	3'UTR	INPP5E:NM_019892.5:3'UTR:MODIFIER:exon10/10:c.*328T>C:,INPP5E:NM_001318502.1:3'UTR:MODIFIER:exon10/10:c.*328T>C:		rs35763810	0.3828	0.0000	0/0/0	0.0686							613037 [INPP5E (provisional) Mental retardation,truncal obesity,retinal dystrophy,and micropenis,610156|Joubert syndrome 1,213300];	RCV000390164.1 [benign]; 			49	114					INPP5E (inh=AR pLI=0.39)
chr9	139324029	139324029	C	T	wt	het	het		QUAL=9854;DP=210,319,433;MQM=60	INPP5E	3'UTR	INPP5E:NM_019892.5:3'UTR:MODIFIER:exon10/10:c.*98G>A:,INPP5E:NM_001318502.1:3'UTR:MODIFIER:exon10/10:c.*98G>A:		rs35873563	0.1484	0.0000	0/0/0	0.0439							613037 [INPP5E (provisional) Mental retardation,truncal obesity,retinal dystrophy,and micropenis,610156|Joubert syndrome 1,213300];	RCV000347672.1 [likely benign]; 			19	87					INPP5E (inh=AR pLI=0.39)
chr9	139324737	139324737	C	A	wt	het	het		QUAL=4920;DP=92,194,264;MQM=60	INPP5E	synonymous	INPP5E:NM_019892.5:synonymous:LOW:exon9/10:c.1794G>T:p.Gly598Gly,INPP5E:NM_001318502.1:synonymous:LOW:exon9/10:c.1791G>T:p.Gly597Gly		rs33982662	0.1739	0.2047	454/304/19	0.1006							613037 [INPP5E (provisional) Mental retardation,truncal obesity,retinal dystrophy,and micropenis,610156|Joubert syndrome 1,213300];	RCV000117271.3 [other]; RCV000391288.1 [likely benign]; 			171	998					INPP5E (inh=AR pLI=0.39)
chr9	139324740	139324740	C	T	het	het	wt		QUAL=3799;DP=110,196,276;MQM=60	INPP5E	synonymous	INPP5E:NM_019892.5:synonymous:LOW:exon9/10:c.1791G>A:p.Pro597Pro,INPP5E:NM_001318502.1:synonymous:LOW:exon9/10:c.1788G>A:p.Pro596Pro		rs10870182	0.1284	0.1364	229/71/4	0.0592							613037 [INPP5E (provisional) Mental retardation,truncal obesity,retinal dystrophy,and micropenis,610156|Joubert syndrome 1,213300];	RCV000117270.2 [benign]; RCV000308485.1 [uncertain significance]; RCV000117269.4 [other]; RCV000360862.1 [likely benign]; 			46	581					INPP5E (inh=AR pLI=0.39)
chr9	139326304	139326304	G	A	het	het	wt		QUAL=807;DP=40,56,57;MQM=59	INPP5E	synonymous	INPP5E:NM_019892.5:synonymous:LOW:exon7/10:c.1521C>T:p.His507His,INPP5E:NM_001318502.1:synonymous:LOW:exon7/10:c.1518C>T:p.His506His		rs10870188	0.1214	0.1427	1288/510/7	0.1292							613037 [INPP5E (provisional) Mental retardation,truncal obesity,retinal dystrophy,and micropenis,610156|Joubert syndrome 1,213300];	RCV000117267.4 [other]; RCV000262680.1 [likely benign]; 		COSM1162712	47	574					INPP5E (inh=AR pLI=0.39)
chr9	139327034	139327034	A	G	het	hom	het		QUAL=7739;DP=114,132,143;MQM=59	INPP5E	splice_region&synonymous,synonymous	INPP5E:NM_001318502.1:splice_region&synonymous:LOW:exon6/10:c.1281T>C:p.Cys427Cys,INPP5E:NM_019892.5:synonymous:LOW:exon6/10:c.1284T>C:p.Gly428Gly		rs10870194	0.3778	0.4004	1662/879/204	0.1718							613037 [INPP5E (provisional) Mental retardation,truncal obesity,retinal dystrophy,and micropenis,610156|Joubert syndrome 1,213300];	RCV000117265.3 [other]; RCV000291204.1 [benign]; 		COSM3722170	468	1261					INPP5E (inh=AR pLI=0.39)
chr9	139327439	139327439	A	G	het	hom	het		QUAL=32677;DP=287,660,835;MQM=59	INPP5E	synonymous,sequence_feature	INPP5E:NM_019892.5:synonymous:LOW:exon5/10:c.1248T>C:p.Thr416Thr,INPP5E:NM_001318502.1:synonymous:LOW:exon5/10:c.1248T>C:p.Thr416Thr,INPP5E:NM_019892.5:sequence_feature:LOW:exon5/10:c.1248T>C:		rs10781542	0.3784	0.4194	10634/6412/754	0.4120							613037 [INPP5E (provisional) Mental retardation,truncal obesity,retinal dystrophy,and micropenis,610156|Joubert syndrome 1,213300];	RCV000117264.3 [other]; RCV000400377.1 [benign]; 			484	1306					INPP5E (inh=AR pLI=0.39)
chr9	139327599	139327599	-	CGCCCACCCCTCCAGCCA	wt	het	het		QUAL=3332;DP=137,381,465;MQM=59	INPP5E	splice_region&intron	INPP5E:NM_019892.5:splice_region&intron:LOW:exon4/9:c.1159+7_1159+8insTGGCTGGAGGGGTGGGCG:,INPP5E:NM_001318502.1:splice_region&intron:LOW:exon4/9:c.1159+7_1159+8insTGGCTGGAGGGGTGGGCG:		rs71269007;rs71384081	0.0000	0.2409	3630/2615/137	0.1963							613037 [INPP5E (provisional) Mental retardation,truncal obesity,retinal dystrophy,and micropenis,610156|Joubert syndrome 1,213300];	RCV000196392.4 [other]; RCV000242760.1 [likely benign]; 			202	748					INPP5E (inh=AR pLI=0.39)
chr9	139328551	139328551	T	C	het	het	wt		QUAL=2305;DP=97,129,165;MQM=60	INPP5E	synonymous	INPP5E:NM_019892.5:synonymous:LOW:exon3/10:c.972A>G:p.Pro324Pro,INPP5E:NM_001318502.1:synonymous:LOW:exon3/10:c.972A>G:p.Pro324Pro		rs10870199	0.1238	0.1596	1213/502/4	0.1319							613037 [INPP5E (provisional) Mental retardation,truncal obesity,retinal dystrophy,and micropenis,610156|Joubert syndrome 1,213300];	RCV000117276.4 [other]; RCV000297520.1 [likely benign]; 		COSM3763772	46	591					INPP5E (inh=AR pLI=0.39)
chr9	139726239	139726239	A	G	hom	hom	hom		QUAL=26466;DP=211,275,357;MQM=59	RABL6	synonymous	RABL6:NM_001173988.1:synonymous:LOW:exon6/15:c.525A>G:p.Gly175Gly,RABL6:NM_001173989.2:synonymous:LOW:exon6/8:c.525A>G:p.Gly175Gly,RABL6:NM_024718.4:synonymous:LOW:exon6/15:c.525A>G:p.Gly175Gly		rs2811748	0.8167	0.8475	43413/25653/3796	0.8240	-1.1310		T			9.25				COSM4163585, COSM4163586, COSM4163584	1138	384					RABL6 (inh=n/a pLI=0.97)
chr9	139731969	139731969	C	T	hom	hom	hom	low_DP	QUAL=856;DP=7,12,13;MQM=56	RABL6	synonymous	RABL6:NM_001173988.1:synonymous:LOW:exon9/15:c.984C>T:p.Ala328Ala,RABL6:NM_024718.4:synonymous:LOW:exon9/15:c.981C>T:p.Ala327Ala		rs2811742	0.7666	0.8049	6608/2900/359	0.5700										COSM3763796, COSM455622, COSM455621	972	438					RABL6 (inh=n/a pLI=0.97)
chr9	139732331	139732331	G	C	hom	hom	hom	pred_pathogenic	QUAL=12927;DP=100,159,183;MQM=59	RABL6	missense	RABL6:NM_001173988.1:missense:MODERATE:exon10/15:c.1147G>C:p.Glu383Gln,RABL6:NM_024718.4:missense:MODERATE:exon10/15:c.1144G>C:p.Glu382Gln		rs2811741	0.8055	0.8144	7251/3259/722	0.5115	3.6890	T,T,T,T,T	T	D,D,P	T,T,T,T,T	16.48					1022	474					RABL6 (inh=n/a pLI=0.97)
chr9	139735484	139735484	C	T	wt	het	wt		QUAL=768;DP=87,106,131;MQM=60	RABL6	3'UTR	RABL6:NM_001173988.1:3'UTR:MODIFIER:exon15/15:c.*510C>T:,RABL6:NM_024718.4:3'UTR:MODIFIER:exon15/15:c.*510C>T:		rs570494000	0.0000	0.0000	0/0/0	0.0001											0	1					RABL6 (inh=n/a pLI=0.97)
chr9	139981627	139981627	A	G	hom	hom	hom		QUAL=18102;DP=58,231,315;MQM=60	MAN1B1	missense,non_coding_transcript_exon	MAN1B1:NM_016219.4:missense:MODERATE:exon1/13:c.176A>G:p.Asn59Ser,MAN1B1:NR_045720.1:non_coding_transcript_exon:MODIFIER:exon1/13:n.249A>G:,MAN1B1:NR_045721.1:non_coding_transcript_exon:MODIFIER:exon1/14:n.249A>G:		rs968733	0.9054	0.9759	38578/22191/1633	0.8893	0.9110	T	T	B	T	0.02	604346 [MAN1B1 (provisional) Mental retardation,autosomal recessive 15,614202];	RCV000117582.2 [likely benign]; RCV000277681.1 [benign]; 		COSM4163617	1539	28					MAN1B1 (inh=AR pLI=0.00)
chr9	140002989	140002989	T	C	hom	hom	het		QUAL=20124;DP=155,341,441;MQM=59	MAN1B1	synonymous,non_coding_transcript_exon	MAN1B1:NM_016219.4:synonymous:LOW:exon13/13:c.2046T>C:p.Asp682Asp,MAN1B1:NR_045720.1:non_coding_transcript_exon:MODIFIER:exon13/13:n.2094T>C:,MAN1B1:NR_045721.1:non_coding_transcript_exon:MODIFIER:exon14/14:n.2250T>C:		rs4880091	0.8099	0.7663	35940/18905/4714	0.7513	1.0730		T,T			0.01	604346 [MAN1B1 (provisional) Mental retardation,autosomal recessive 15,614202];	RCV000117585.2 [likely benign]; RCV000318326.1 [benign]; 		COSM4138895	889	582					MAN1B1 (inh=AR pLI=0.00)
chr9	140003427	140003427	A	G	hom	hom	het		QUAL=8896;DP=141,102,107;MQM=59	MAN1B1	3'UTR,non_coding_transcript_exon	MAN1B1:NM_016219.4:3'UTR:MODIFIER:exon13/13:c.*384A>G:,MAN1B1:NR_045720.1:non_coding_transcript_exon:MODIFIER:exon13/13:n.2532A>G:,MAN1B1:NR_045721.1:non_coding_transcript_exon:MODIFIER:exon14/14:n.2688A>G:		rs4567	0.5519	0.4936	1497/416/73	0.1329	-3.1640		T			1.68	604346 [MAN1B1 (provisional) Mental retardation,autosomal recessive 15,614202];	RCV000384948.1 [benign]; 	CR094058 [CLASS=DFP MUT=REF PHEN="End-stage liver disease early onset association with" GENE=MAN1B1]; 		306	674					MAN1B1 (inh=AR pLI=0.00)
chr9	140003640	140003640	G	A	hom	hom	het		QUAL=15398;DP=196,211,248;MQM=60	MAN1B1-DPP7	intergenic_region	MAN1B1-DPP7:MAN1B1-DPP7:intergenic_region:MODIFIER::n.140003640G>A:		rs7853336	0.4040	0.2881	529/191/48	0.0858							604346 [MAN1B1 (provisional) Mental retardation,autosomal recessive 15,614202];	RCV000341912.1 [benign]; 			54	265					MAN1B1-DPP7 (inh=n/a pLI=n/a)
chr9	140611436	140611436	T	C	wt	wt	het		QUAL=1929;DP=264,129,179;MQM=60	EHMT1	synonymous	EHMT1:NM_024757.4:synonymous:LOW:exon3/27:c.444T>C:p.Pro148Pro,EHMT1:NM_001145527.1:synonymous:LOW:exon3/16:c.444T>C:p.Pro148Pro		rs3812497	0.2278	0.2791	5357/2598/66	0.2721							607001 [EHMT1 (confirmed) Kleefstra syndrome,610253];	RCV000082239.8 [other]; RCV000380419.1 [benign]; 		COSM3763829, COSM3763830	140	650					EHMT1 (inh=AD pLI=1.00)
chr9	140638461	140638461	T	C	wt	wt	het		QUAL=3781;DP=186,243,303;MQM=60	EHMT1	synonymous	EHMT1:NM_024757.4:synonymous:LOW:exon6/27:c.1089T>C:p.Gly363Gly,EHMT1:NM_001145527.1:synonymous:LOW:exon6/16:c.1089T>C:p.Gly363Gly		rs1129768	0.4689	0.3970	11202/4290/3332	0.3853							607001 [EHMT1 (confirmed) Kleefstra syndrome,610253];	RCV000082213.8 [other]; RCV000272550.1 [benign]; 		COSM3763833, COSM3763834	248	732					EHMT1 (inh=AD pLI=1.00)
chr9	140648742	140648742	C	T	wt	wt	het		QUAL=3938;DP=154,206,293;MQM=60	EHMT1	splice_region&synonymous	EHMT1:NM_024757.4:splice_region&synonymous:LOW:exon8/27:c.1368C>T:p.Leu456Leu,EHMT1:NM_001145527.1:splice_region&synonymous:LOW:exon8/16:c.1368C>T:p.Leu456Leu		rs45450992	0.0565	0.0714	382/271/19	0.0709							607001 [EHMT1 (confirmed) Kleefstra syndrome,610253];	RCV000082216.8 [other]; RCV000349834.1 [benign]; 			21	302					EHMT1 (inh=AD pLI=1.00)
chr9	140729844	140729844	G	C	het	het	wt		QUAL=4269;DP=196,162,238;MQM=59	EHMT1	3'UTR	EHMT1:NM_024757.4:3'UTR:MODIFIER:exon27/27:c.*439G>C:			0.0000	0.0000	0/0/0	0.0000							607001 [EHMT1 (confirmed) Kleefstra syndrome,610253];				0	2					EHMT1 (inh=AD pLI=1.00)
chr10	6053133	6053133	G	A	wt	wt	het		QUAL=3718;DP=389,309,319;MQM=60	IL2RA	3'UTR	IL2RA:NM_000417.2:3'UTR:MODIFIER:exon8/8:c.*1702C>T:,IL2RA:NM_001308242.1:3'UTR:MODIFIER:exon7/7:c.*1702C>T:,IL2RA:NM_001308243.1:3'UTR:MODIFIER:exon6/6:c.*1702C>T:		rs12722606	0.1112	0.0000	0/0/0	0.1715							147730 [IL2RA (confirmed) Immunodeficiency 41 with lymphoproliferation and autoimmunity,606367|Diabetes,mellitus,insulin-dependent,susceptibility to,10,601942];	RCV000265776.1 [benign]; 			12	60					IL2RA (inh=AR pLI=0.88)
chr10	6053374	6053374	A	G	het	hom	wt		QUAL=26947;DP=574,624,820;MQM=59	IL2RA	3'UTR	IL2RA:NM_000417.2:3'UTR:MODIFIER:exon8/8:c.*1461T>C:,IL2RA:NM_001308242.1:3'UTR:MODIFIER:exon7/7:c.*1461T>C:,IL2RA:NM_001308243.1:3'UTR:MODIFIER:exon6/6:c.*1461T>C:	MER5A	rs12244380	0.3548	0.0000	0/0/0	0.0657							147730 [IL2RA (confirmed) Immunodeficiency 41 with lymphoproliferation and autoimmunity,606367|Diabetes,mellitus,insulin-dependent,susceptibility to,10,601942];	RCV000332829.1 [benign]; 			24	77					IL2RA (inh=AR pLI=0.88)
chr10	6053568	6053568	C	T	hom	het	hom		QUAL=30049;DP=322,392,497;MQM=59	IL2RA	3'UTR	IL2RA:NM_000417.2:3'UTR:MODIFIER:exon8/8:c.*1267G>A:,IL2RA:NM_001308242.1:3'UTR:MODIFIER:exon7/7:c.*1267G>A:,IL2RA:NM_001308243.1:3'UTR:MODIFIER:exon6/6:c.*1267G>A:	AluJr	rs1570538	0.3760	0.0000	0/0/0	0.4195							147730 [IL2RA (confirmed) Immunodeficiency 41 with lymphoproliferation and autoimmunity,606367|Diabetes,mellitus,insulin-dependent,susceptibility to,10,601942];	RCV000281841.1 [benign]; 			42	84					IL2RA (inh=AR pLI=0.88)
chr10	6066200	6066200	C	G	hom	het	het		QUAL=12161;DP=102,314,399;MQM=60	IL2RA	splice_region&intron,sequence_feature	IL2RA:NM_000417.2:splice_region&intron:LOW:exon3/7:c.367+7G>C:,IL2RA:NM_001308242.1:splice_region&intron:LOW:exon3/6:c.367+7G>C:,IL2RA:NM_001308243.1:splice_region&intron:LOW:exon3/5:c.367+7G>C:,IL2RA:NM_000417.2:sequence_feature:LOW::c.367+7G>C:		rs11256369	0.1793	0.2126	3019/1778/41	0.2066							147730 [IL2RA (confirmed) Immunodeficiency 41 with lymphoproliferation and autoimmunity,606367|Diabetes,mellitus,insulin-dependent,susceptibility to,10,601942];	RCV000323644.1 [benign]; 			82	521					IL2RA (inh=AR pLI=0.88)
chr10	14949856	14949856	C	T	het	het	het	low_MQM	QUAL=640;DP=70,39,62;MQM=44	DCLRE1C	3'UTR,non_coding_transcript_exon	DCLRE1C:NM_001033855.2:3'UTR:MODIFIER:exon14/14:c.*551G>A:,DCLRE1C:NM_001033857.2:3'UTR:MODIFIER:exon15/15:c.*551G>A:,DCLRE1C:NM_001033858.2:3'UTR:MODIFIER:exon16/16:c.*551G>A:,DCLRE1C:NM_001289076.1:3'UTR:MODIFIER:exon12/12:c.*551G>A:,DCLRE1C:NM_001289077.1:3'UTR:MODIFIER:exon15/15:c.*551G>A:,DCLRE1C:NM_001289078.1:3'UTR:MODIFIER:exon12/12:c.*551G>A:,DCLRE1C:NM_001289079.1:3'UTR:MODIFIER:exon16/16:c.*551G>A:,DCLRE1C:NM_022487.3:3'UTR:MODIFIER:exon13/13:c.*551G>A:,DCLRE1C:NR_110297.1:non_coding_transcript_exon:MODIFIER:exon17/17:n.3405G>A:	AluSp	rs373280996	0.0000	0.0000	0/0/0	0.0030							605988 [DCLRE1C (confirmed) Severe combined immunodeficiency,Athabascan type,602450|Omenn syndrome,603554];				0	127					DCLRE1C (inh=AR pLI=0.00)
chr10	14976414	14976414	G	A	wt	het	wt		QUAL=2944;DP=278,222,271;MQM=59	DCLRE1C	synonymous,non_coding_transcript_exon	DCLRE1C:NM_001033855.2:synonymous:LOW:exon8/14:c.643C>T:p.Leu215Leu,DCLRE1C:NM_001033857.2:synonymous:LOW:exon9/15:c.283C>T:p.Leu95Leu,DCLRE1C:NM_001033858.2:synonymous:LOW:exon10/16:c.283C>T:p.Leu95Leu,DCLRE1C:NM_001289076.1:synonymous:LOW:exon6/12:c.298C>T:p.Leu100Leu,DCLRE1C:NM_001289077.1:synonymous:LOW:exon9/15:c.283C>T:p.Leu95Leu,DCLRE1C:NM_001289078.1:synonymous:LOW:exon6/12:c.298C>T:p.Leu100Leu,DCLRE1C:NM_001289079.1:synonymous:LOW:exon10/16:c.283C>T:p.Leu95Leu,DCLRE1C:NM_022487.3:synonymous:LOW:exon7/13:c.298C>T:p.Leu100Leu,DCLRE1C:NR_110297.1:non_coding_transcript_exon:MODIFIER:exon10/17:n.1277C>T:		rs7076862	0.5000	0.4187	11486/4281/2215	0.4003							605988 [DCLRE1C (confirmed) Severe combined immunodeficiency,Athabascan type,602450|Omenn syndrome,603554];	RCV000029658.1 [benign]; RCV000249874.1 [benign]; RCV000341516.1 [benign]; 			274	818					DCLRE1C (inh=AR pLI=0.00)
chr10	26993598	26993598	T	-	het	hom	het		QUAL=2622;DP=84,31,43;MQM=60	PDSS1	splice_region&intron	PDSS1:NM_014317.4:splice_region&intron:LOW:exon2/11:c.163-5delT:,PDSS1:NM_001321978.1:splice_region&intron:LOW:exon2/9:c.163-5delT:,PDSS1:NM_001321979.1:splice_region&intron:LOW:exon2/11:c.-431-5delT:		rs863224161	0.2374	0.3058	5907/3779/51	0.2831							607429 [PDSS1 (provisional) Coenzyme Q10 deficiency,primary,2,614651];	RCV000199022.1 [benign]; RCV000302465.1,RCV000199022.1 [likely benign,benign]; RCV000302465.1 [likely benign]; 			317	1200					PDSS1 (inh=AR pLI=0.26)
chr10	27035478	27035478	C	T	wt	wt	het		QUAL=1958;DP=345,145,171;MQM=59	PDSS1	3'UTR	PDSS1:NM_014317.4:3'UTR:MODIFIER:exon12/12:c.*76C>T:,PDSS1:NM_001321978.1:3'UTR:MODIFIER:exon10/10:c.*212C>T:,PDSS1:NM_001321979.1:3'UTR:MODIFIER:exon12/12:c.*76C>T:		rs12776877	0.0899	0.0000	0/0/0	0.0280							607429 [PDSS1 (provisional) Coenzyme Q10 deficiency,primary,2,614651];	RCV000372936.1 [likely benign]; 			3	64					PDSS1 (inh=AR pLI=0.26)
chr10	38344700	38344700	C	G	het	het	het	pred_pathogenic	QUAL=15695;DP=373,350,422;MQM=57	ZNF33A	missense,intron	ZNF33A:NM_001278177.1:missense:MODERATE:exon5/5:c.1711C>G:p.Gln571Glu,ZNF33A:NM_001278170.1:missense:MODERATE:exon4/4:c.1666C>G:p.Gln556Glu,ZNF33A:NM_001278171.1:missense:MODERATE:exon6/6:c.1312C>G:p.Gln438Glu,ZNF33A:NM_001278173.1:missense:MODERATE:exon6/6:c.1702C>G:p.Gln568Glu,ZNF33A:NM_001278174.1:missense:MODERATE:exon6/6:c.1312C>G:p.Gln438Glu,ZNF33A:NM_001278175.1:missense:MODERATE:exon6/6:c.1414C>G:p.Gln472Glu,ZNF33A:NM_001278176.1:missense:MODERATE:exon6/6:c.1519C>G:p.Gln507Glu,ZNF33A:NM_001278178.1:missense:MODERATE:exon5/5:c.1312C>G:p.Gln438Glu,ZNF33A:NM_001278179.1:missense:MODERATE:exon6/6:c.1312C>G:p.Gln438Glu,ZNF33A:NM_001324175.1:missense:MODERATE:exon6/6:c.1312C>G:p.Gln438Glu,ZNF33A:NM_001324176.1:missense:MODERATE:exon5/5:c.1312C>G:p.Gln438Glu,ZNF33A:NM_001324178.1:missense:MODERATE:exon4/4:c.1669C>G:p.Gln557Glu,ZNF33A:NM_006954.1:missense:MODERATE:exon5/5:c.1648C>G:p.Gln550Glu,ZNF33A:NM_006974.2:missense:MODERATE:exon5/5:c.1645C>G:p.Gln549Glu,ZNF33A:NM_001324177.1:missense:MODERATE:exon6/6:c.1312C>G:p.Gln438Glu,ZNF33A:NR_136709.1:intron:MODIFIER:exon5/5:n.533+1293C>G:,ZNF33A:NR_136710.1:intron:MODIFIER:exon4/4:n.429-8316C>G:		rs2505232	0.4770	0.4463	12613/7105/1354	0.4448	4.3420	T,T,T,T	T	B,B,B	T,T,T,T	0.01					243	573					ZNF33A (inh=n/a pLI=0.00)
chr10	38345465	38345465	G	C	wt	het	wt		QUAL=2868;DP=479,267,294;MQM=60	ZNF33A	missense,intron	ZNF33A:NM_001278177.1:missense:MODERATE:exon5/5:c.2476G>C:p.Asp826His,ZNF33A:NM_001278170.1:missense:MODERATE:exon4/4:c.2431G>C:p.Asp811His,ZNF33A:NM_001278171.1:missense:MODERATE:exon6/6:c.2077G>C:p.Asp693His,ZNF33A:NM_001278173.1:missense:MODERATE:exon6/6:c.2467G>C:p.Asp823His,ZNF33A:NM_001278174.1:missense:MODERATE:exon6/6:c.2077G>C:p.Asp693His,ZNF33A:NM_001278175.1:missense:MODERATE:exon6/6:c.2179G>C:p.Asp727His,ZNF33A:NM_001278176.1:missense:MODERATE:exon6/6:c.2284G>C:p.Asp762His,ZNF33A:NM_001278178.1:missense:MODERATE:exon5/5:c.2077G>C:p.Asp693His,ZNF33A:NM_001278179.1:missense:MODERATE:exon6/6:c.2077G>C:p.Asp693His,ZNF33A:NM_001324175.1:missense:MODERATE:exon6/6:c.2077G>C:p.Asp693His,ZNF33A:NM_001324176.1:missense:MODERATE:exon5/5:c.2077G>C:p.Asp693His,ZNF33A:NM_001324178.1:missense:MODERATE:exon4/4:c.2434G>C:p.Asp812His,ZNF33A:NM_006954.1:missense:MODERATE:exon5/5:c.2413G>C:p.Asp805His,ZNF33A:NM_006974.2:missense:MODERATE:exon5/5:c.2410G>C:p.Asp804His,ZNF33A:NM_001324177.1:missense:MODERATE:exon6/6:c.2077G>C:p.Asp693His,ZNF33A:NR_136709.1:intron:MODIFIER:exon5/5:n.533+2058G>C:,ZNF33A:NR_136710.1:intron:MODIFIER:exon4/4:n.429-7551G>C:		rs10508862	0.0317	0.0596	281/248/1	0.0577	-0.2290	T,T,T,T	T	B,B,B	T,T,T,T	0.01					13	152					ZNF33A (inh=n/a pLI=0.00)
chr10	38345856	38345856	C	A	wt	het	wt		QUAL=1005;DP=328,97,129;MQM=60	ZNF33A	3'UTR,intron	ZNF33A:NM_001278177.1:3'UTR:MODIFIER:exon5/5:c.*368C>A:,ZNF33A:NM_001278170.1:3'UTR:MODIFIER:exon4/4:c.*368C>A:,ZNF33A:NM_001278171.1:3'UTR:MODIFIER:exon6/6:c.*368C>A:,ZNF33A:NM_001278173.1:3'UTR:MODIFIER:exon6/6:c.*368C>A:,ZNF33A:NM_001278174.1:3'UTR:MODIFIER:exon6/6:c.*368C>A:,ZNF33A:NM_001278175.1:3'UTR:MODIFIER:exon6/6:c.*368C>A:,ZNF33A:NM_001278176.1:3'UTR:MODIFIER:exon6/6:c.*368C>A:,ZNF33A:NM_001278178.1:3'UTR:MODIFIER:exon5/5:c.*368C>A:,ZNF33A:NM_001278179.1:3'UTR:MODIFIER:exon6/6:c.*368C>A:,ZNF33A:NM_001324175.1:3'UTR:MODIFIER:exon6/6:c.*368C>A:,ZNF33A:NM_001324176.1:3'UTR:MODIFIER:exon5/5:c.*368C>A:,ZNF33A:NM_001324178.1:3'UTR:MODIFIER:exon4/4:c.*368C>A:,ZNF33A:NM_006954.1:3'UTR:MODIFIER:exon5/5:c.*368C>A:,ZNF33A:NM_006974.2:3'UTR:MODIFIER:exon5/5:c.*368C>A:,ZNF33A:NM_001324177.1:3'UTR:MODIFIER:exon6/6:c.*368C>A:,ZNF33A:NR_136709.1:intron:MODIFIER:exon5/5:n.533+2449C>A:,ZNF33A:NR_136710.1:intron:MODIFIER:exon4/4:n.429-7160C>A:		rs2505231	0.0317	0.0000	0/0/0	0.0101											2	24					ZNF33A (inh=n/a pLI=0.00)
chr10	38345877	38345877	C	T	wt	het	wt		QUAL=1248;DP=312,106,144;MQM=60	ZNF33A	3'UTR,intron	ZNF33A:NM_001278177.1:3'UTR:MODIFIER:exon5/5:c.*389C>T:,ZNF33A:NM_001278170.1:3'UTR:MODIFIER:exon4/4:c.*389C>T:,ZNF33A:NM_001278171.1:3'UTR:MODIFIER:exon6/6:c.*389C>T:,ZNF33A:NM_001278173.1:3'UTR:MODIFIER:exon6/6:c.*389C>T:,ZNF33A:NM_001278174.1:3'UTR:MODIFIER:exon6/6:c.*389C>T:,ZNF33A:NM_001278175.1:3'UTR:MODIFIER:exon6/6:c.*389C>T:,ZNF33A:NM_001278176.1:3'UTR:MODIFIER:exon6/6:c.*389C>T:,ZNF33A:NM_001278178.1:3'UTR:MODIFIER:exon5/5:c.*389C>T:,ZNF33A:NM_001278179.1:3'UTR:MODIFIER:exon6/6:c.*389C>T:,ZNF33A:NM_001324175.1:3'UTR:MODIFIER:exon6/6:c.*389C>T:,ZNF33A:NM_001324176.1:3'UTR:MODIFIER:exon5/5:c.*389C>T:,ZNF33A:NM_001324178.1:3'UTR:MODIFIER:exon4/4:c.*389C>T:,ZNF33A:NM_006954.1:3'UTR:MODIFIER:exon5/5:c.*389C>T:,ZNF33A:NM_006974.2:3'UTR:MODIFIER:exon5/5:c.*389C>T:,ZNF33A:NM_001324177.1:3'UTR:MODIFIER:exon6/6:c.*389C>T:,ZNF33A:NR_136709.1:intron:MODIFIER:exon5/5:n.533+2470C>T:,ZNF33A:NR_136710.1:intron:MODIFIER:exon4/4:n.429-7139C>T:		rs2505230	0.0319	0.0000	0/0/0	0.0102											2	24					ZNF33A (inh=n/a pLI=0.00)
chr10	38346092	38346092	C	T	het	het	wt		QUAL=6228;DP=300,153,213;MQM=60	ZNF33A	3'UTR,intron	ZNF33A:NM_001278177.1:3'UTR:MODIFIER:exon5/5:c.*604C>T:,ZNF33A:NM_001278170.1:3'UTR:MODIFIER:exon4/4:c.*604C>T:,ZNF33A:NM_001278171.1:3'UTR:MODIFIER:exon6/6:c.*604C>T:,ZNF33A:NM_001278173.1:3'UTR:MODIFIER:exon6/6:c.*604C>T:,ZNF33A:NM_001278174.1:3'UTR:MODIFIER:exon6/6:c.*604C>T:,ZNF33A:NM_001278175.1:3'UTR:MODIFIER:exon6/6:c.*604C>T:,ZNF33A:NM_001278176.1:3'UTR:MODIFIER:exon6/6:c.*604C>T:,ZNF33A:NM_001278178.1:3'UTR:MODIFIER:exon5/5:c.*604C>T:,ZNF33A:NM_001278179.1:3'UTR:MODIFIER:exon6/6:c.*604C>T:,ZNF33A:NM_001324175.1:3'UTR:MODIFIER:exon6/6:c.*604C>T:,ZNF33A:NM_001324176.1:3'UTR:MODIFIER:exon5/5:c.*604C>T:,ZNF33A:NM_001324178.1:3'UTR:MODIFIER:exon4/4:c.*604C>T:,ZNF33A:NM_006954.1:3'UTR:MODIFIER:exon5/5:c.*604C>T:,ZNF33A:NM_006974.2:3'UTR:MODIFIER:exon5/5:c.*604C>T:,ZNF33A:NM_001324177.1:3'UTR:MODIFIER:exon6/6:c.*604C>T:,ZNF33A:NR_136709.1:intron:MODIFIER:exon5/5:n.533+2685C>T:,ZNF33A:NR_136710.1:intron:MODIFIER:exon4/4:n.429-6924C>T:	L1MD2	rs2142349	0.0128	0.0000	0/0/0	0.0037											0	10					ZNF33A (inh=n/a pLI=0.00)
chr10	38346156	38346156	C	T	wt	het	wt		QUAL=1685;DP=338,127,156;MQM=59	ZNF33A	3'UTR,intron	ZNF33A:NM_001278177.1:3'UTR:MODIFIER:exon5/5:c.*668C>T:,ZNF33A:NM_001278170.1:3'UTR:MODIFIER:exon4/4:c.*668C>T:,ZNF33A:NM_001278171.1:3'UTR:MODIFIER:exon6/6:c.*668C>T:,ZNF33A:NM_001278173.1:3'UTR:MODIFIER:exon6/6:c.*668C>T:,ZNF33A:NM_001278174.1:3'UTR:MODIFIER:exon6/6:c.*668C>T:,ZNF33A:NM_001278175.1:3'UTR:MODIFIER:exon6/6:c.*668C>T:,ZNF33A:NM_001278176.1:3'UTR:MODIFIER:exon6/6:c.*668C>T:,ZNF33A:NM_001278178.1:3'UTR:MODIFIER:exon5/5:c.*668C>T:,ZNF33A:NM_001278179.1:3'UTR:MODIFIER:exon6/6:c.*668C>T:,ZNF33A:NM_001324175.1:3'UTR:MODIFIER:exon6/6:c.*668C>T:,ZNF33A:NM_001324176.1:3'UTR:MODIFIER:exon5/5:c.*668C>T:,ZNF33A:NM_001324178.1:3'UTR:MODIFIER:exon4/4:c.*668C>T:,ZNF33A:NM_006954.1:3'UTR:MODIFIER:exon5/5:c.*668C>T:,ZNF33A:NM_006974.2:3'UTR:MODIFIER:exon5/5:c.*668C>T:,ZNF33A:NM_001324177.1:3'UTR:MODIFIER:exon6/6:c.*668C>T:,ZNF33A:NR_136709.1:intron:MODIFIER:exon5/5:n.533+2749C>T:,ZNF33A:NR_136710.1:intron:MODIFIER:exon4/4:n.429-6860C>T:		rs2472161	0.0317	0.0000	0/0/0	0.0103											2	24					ZNF33A (inh=n/a pLI=0.00)
chr10	38346204	38346204	T	G	wt	het	wt		QUAL=1869;DP=374,126,145;MQM=59	ZNF33A	3'UTR,intron	ZNF33A:NM_001278177.1:3'UTR:MODIFIER:exon5/5:c.*716T>G:,ZNF33A:NM_001278170.1:3'UTR:MODIFIER:exon4/4:c.*716T>G:,ZNF33A:NM_001278171.1:3'UTR:MODIFIER:exon6/6:c.*716T>G:,ZNF33A:NM_001278173.1:3'UTR:MODIFIER:exon6/6:c.*716T>G:,ZNF33A:NM_001278174.1:3'UTR:MODIFIER:exon6/6:c.*716T>G:,ZNF33A:NM_001278175.1:3'UTR:MODIFIER:exon6/6:c.*716T>G:,ZNF33A:NM_001278176.1:3'UTR:MODIFIER:exon6/6:c.*716T>G:,ZNF33A:NM_001278178.1:3'UTR:MODIFIER:exon5/5:c.*716T>G:,ZNF33A:NM_001278179.1:3'UTR:MODIFIER:exon6/6:c.*716T>G:,ZNF33A:NM_001324175.1:3'UTR:MODIFIER:exon6/6:c.*716T>G:,ZNF33A:NM_001324176.1:3'UTR:MODIFIER:exon5/5:c.*716T>G:,ZNF33A:NM_001324178.1:3'UTR:MODIFIER:exon4/4:c.*716T>G:,ZNF33A:NM_006954.1:3'UTR:MODIFIER:exon5/5:c.*716T>G:,ZNF33A:NM_006974.2:3'UTR:MODIFIER:exon5/5:c.*716T>G:,ZNF33A:NM_001324177.1:3'UTR:MODIFIER:exon6/6:c.*716T>G:,ZNF33A:NR_136709.1:intron:MODIFIER:exon5/5:n.533+2797T>G:,ZNF33A:NR_136710.1:intron:MODIFIER:exon4/4:n.429-6812T>G:		rs2472162	0.0317	0.0000	0/0/0	0.0098											2	24					ZNF33A (inh=n/a pLI=0.00)
chr10	38346223	38346223	G	C	wt	het	wt		QUAL=1898;DP=364,128,143;MQM=59	ZNF33A	3'UTR,intron	ZNF33A:NM_001278177.1:3'UTR:MODIFIER:exon5/5:c.*735G>C:,ZNF33A:NM_001278170.1:3'UTR:MODIFIER:exon4/4:c.*735G>C:,ZNF33A:NM_001278171.1:3'UTR:MODIFIER:exon6/6:c.*735G>C:,ZNF33A:NM_001278173.1:3'UTR:MODIFIER:exon6/6:c.*735G>C:,ZNF33A:NM_001278174.1:3'UTR:MODIFIER:exon6/6:c.*735G>C:,ZNF33A:NM_001278175.1:3'UTR:MODIFIER:exon6/6:c.*735G>C:,ZNF33A:NM_001278176.1:3'UTR:MODIFIER:exon6/6:c.*735G>C:,ZNF33A:NM_001278178.1:3'UTR:MODIFIER:exon5/5:c.*735G>C:,ZNF33A:NM_001278179.1:3'UTR:MODIFIER:exon6/6:c.*735G>C:,ZNF33A:NM_001324175.1:3'UTR:MODIFIER:exon6/6:c.*735G>C:,ZNF33A:NM_001324176.1:3'UTR:MODIFIER:exon5/5:c.*735G>C:,ZNF33A:NM_001324178.1:3'UTR:MODIFIER:exon4/4:c.*735G>C:,ZNF33A:NM_006954.1:3'UTR:MODIFIER:exon5/5:c.*735G>C:,ZNF33A:NM_006974.2:3'UTR:MODIFIER:exon5/5:c.*735G>C:,ZNF33A:NM_001324177.1:3'UTR:MODIFIER:exon6/6:c.*735G>C:,ZNF33A:NR_136709.1:intron:MODIFIER:exon5/5:n.533+2816G>C:,ZNF33A:NR_136710.1:intron:MODIFIER:exon4/4:n.429-6793G>C:		rs2505229	0.0317	0.0000	0/0/0	0.0077											2	24					ZNF33A (inh=n/a pLI=0.00)
chr10	38346233	38346233	A	T	wt	het	wt		QUAL=2018;DP=351,135,153;MQM=59	ZNF33A	3'UTR,intron	ZNF33A:NM_001278177.1:3'UTR:MODIFIER:exon5/5:c.*745A>T:,ZNF33A:NM_001278170.1:3'UTR:MODIFIER:exon4/4:c.*745A>T:,ZNF33A:NM_001278171.1:3'UTR:MODIFIER:exon6/6:c.*745A>T:,ZNF33A:NM_001278173.1:3'UTR:MODIFIER:exon6/6:c.*745A>T:,ZNF33A:NM_001278174.1:3'UTR:MODIFIER:exon6/6:c.*745A>T:,ZNF33A:NM_001278175.1:3'UTR:MODIFIER:exon6/6:c.*745A>T:,ZNF33A:NM_001278176.1:3'UTR:MODIFIER:exon6/6:c.*745A>T:,ZNF33A:NM_001278178.1:3'UTR:MODIFIER:exon5/5:c.*745A>T:,ZNF33A:NM_001278179.1:3'UTR:MODIFIER:exon6/6:c.*745A>T:,ZNF33A:NM_001324175.1:3'UTR:MODIFIER:exon6/6:c.*745A>T:,ZNF33A:NM_001324176.1:3'UTR:MODIFIER:exon5/5:c.*745A>T:,ZNF33A:NM_001324178.1:3'UTR:MODIFIER:exon4/4:c.*745A>T:,ZNF33A:NM_006954.1:3'UTR:MODIFIER:exon5/5:c.*745A>T:,ZNF33A:NM_006974.2:3'UTR:MODIFIER:exon5/5:c.*745A>T:,ZNF33A:NM_001324177.1:3'UTR:MODIFIER:exon6/6:c.*745A>T:,ZNF33A:NR_136709.1:intron:MODIFIER:exon5/5:n.533+2826A>T:,ZNF33A:NR_136710.1:intron:MODIFIER:exon4/4:n.429-6783A>T:		rs2472163	0.0317	0.0000	0/0/0	0.0076											2	24					ZNF33A (inh=n/a pLI=0.00)
chr10	38346238	38346238	A	G	wt	het	wt		QUAL=2102;DP=355,135,150;MQM=59	ZNF33A	3'UTR,intron	ZNF33A:NM_001278177.1:3'UTR:MODIFIER:exon5/5:c.*750A>G:,ZNF33A:NM_001278170.1:3'UTR:MODIFIER:exon4/4:c.*750A>G:,ZNF33A:NM_001278171.1:3'UTR:MODIFIER:exon6/6:c.*750A>G:,ZNF33A:NM_001278173.1:3'UTR:MODIFIER:exon6/6:c.*750A>G:,ZNF33A:NM_001278174.1:3'UTR:MODIFIER:exon6/6:c.*750A>G:,ZNF33A:NM_001278175.1:3'UTR:MODIFIER:exon6/6:c.*750A>G:,ZNF33A:NM_001278176.1:3'UTR:MODIFIER:exon6/6:c.*750A>G:,ZNF33A:NM_001278178.1:3'UTR:MODIFIER:exon5/5:c.*750A>G:,ZNF33A:NM_001278179.1:3'UTR:MODIFIER:exon6/6:c.*750A>G:,ZNF33A:NM_001324175.1:3'UTR:MODIFIER:exon6/6:c.*750A>G:,ZNF33A:NM_001324176.1:3'UTR:MODIFIER:exon5/5:c.*750A>G:,ZNF33A:NM_001324178.1:3'UTR:MODIFIER:exon4/4:c.*750A>G:,ZNF33A:NM_006954.1:3'UTR:MODIFIER:exon5/5:c.*750A>G:,ZNF33A:NM_006974.2:3'UTR:MODIFIER:exon5/5:c.*750A>G:,ZNF33A:NM_001324177.1:3'UTR:MODIFIER:exon6/6:c.*750A>G:,ZNF33A:NR_136709.1:intron:MODIFIER:exon5/5:n.533+2831A>G:,ZNF33A:NR_136710.1:intron:MODIFIER:exon4/4:n.429-6778A>G:		rs2505228	0.0317	0.0000	0/0/0	0.0077											2	24					ZNF33A (inh=n/a pLI=0.00)
chr10	38346350	38346350	T	C	wt	het	wt		QUAL=2848;DP=365,189,199;MQM=59	ZNF33A	3'UTR,intron	ZNF33A:NM_001278177.1:3'UTR:MODIFIER:exon5/5:c.*862T>C:,ZNF33A:NM_001278170.1:3'UTR:MODIFIER:exon4/4:c.*862T>C:,ZNF33A:NM_001278171.1:3'UTR:MODIFIER:exon6/6:c.*862T>C:,ZNF33A:NM_001278173.1:3'UTR:MODIFIER:exon6/6:c.*862T>C:,ZNF33A:NM_001278174.1:3'UTR:MODIFIER:exon6/6:c.*862T>C:,ZNF33A:NM_001278175.1:3'UTR:MODIFIER:exon6/6:c.*862T>C:,ZNF33A:NM_001278176.1:3'UTR:MODIFIER:exon6/6:c.*862T>C:,ZNF33A:NM_001278178.1:3'UTR:MODIFIER:exon5/5:c.*862T>C:,ZNF33A:NM_001278179.1:3'UTR:MODIFIER:exon6/6:c.*862T>C:,ZNF33A:NM_001324175.1:3'UTR:MODIFIER:exon6/6:c.*862T>C:,ZNF33A:NM_001324176.1:3'UTR:MODIFIER:exon5/5:c.*862T>C:,ZNF33A:NM_001324178.1:3'UTR:MODIFIER:exon4/4:c.*862T>C:,ZNF33A:NM_006954.1:3'UTR:MODIFIER:exon5/5:c.*862T>C:,ZNF33A:NM_006974.2:3'UTR:MODIFIER:exon5/5:c.*862T>C:,ZNF33A:NM_001324177.1:3'UTR:MODIFIER:exon6/6:c.*862T>C:,ZNF33A:NR_136709.1:intron:MODIFIER:exon5/5:n.533+2943T>C:,ZNF33A:NR_136710.1:intron:MODIFIER:exon4/4:n.429-6666T>C:		rs2505227	0.0317	0.0000	0/0/0	0.0103											2	24					ZNF33A (inh=n/a pLI=0.00)
chr10	38346482	38346482	G	C	wt	het	wt		QUAL=1902;DP=387,138,154;MQM=60	ZNF33A	3'UTR,intron	ZNF33A:NM_001278177.1:3'UTR:MODIFIER:exon5/5:c.*994G>C:,ZNF33A:NM_001278170.1:3'UTR:MODIFIER:exon4/4:c.*994G>C:,ZNF33A:NM_001278171.1:3'UTR:MODIFIER:exon6/6:c.*994G>C:,ZNF33A:NM_001278173.1:3'UTR:MODIFIER:exon6/6:c.*994G>C:,ZNF33A:NM_001278174.1:3'UTR:MODIFIER:exon6/6:c.*994G>C:,ZNF33A:NM_001278175.1:3'UTR:MODIFIER:exon6/6:c.*994G>C:,ZNF33A:NM_001278176.1:3'UTR:MODIFIER:exon6/6:c.*994G>C:,ZNF33A:NM_001278178.1:3'UTR:MODIFIER:exon5/5:c.*994G>C:,ZNF33A:NM_001278179.1:3'UTR:MODIFIER:exon6/6:c.*994G>C:,ZNF33A:NM_001324175.1:3'UTR:MODIFIER:exon6/6:c.*994G>C:,ZNF33A:NM_001324176.1:3'UTR:MODIFIER:exon5/5:c.*994G>C:,ZNF33A:NM_001324178.1:3'UTR:MODIFIER:exon4/4:c.*994G>C:,ZNF33A:NM_006954.1:3'UTR:MODIFIER:exon5/5:c.*994G>C:,ZNF33A:NM_006974.2:3'UTR:MODIFIER:exon5/5:c.*994G>C:,ZNF33A:NM_001324177.1:3'UTR:MODIFIER:exon6/6:c.*994G>C:,ZNF33A:NR_136709.1:intron:MODIFIER:exon5/5:n.533+3075G>C:,ZNF33A:NR_136710.1:intron:MODIFIER:exon4/4:n.429-6534G>C:	Zaphod	rs2472164	0.0319	0.0000	0/0/0	0.0103											2	24					ZNF33A (inh=n/a pLI=0.00)
chr10	38347529	38347529	A	C	wt	het	wt	low_QUAL;low_DP	QUAL=10;DP=129,15,26;MQM=60	ZNF33A	3'UTR,intron	ZNF33A:NM_001278177.1:3'UTR:MODIFIER:exon5/5:c.*2041A>C:,ZNF33A:NM_001278170.1:3'UTR:MODIFIER:exon4/4:c.*2041A>C:,ZNF33A:NM_001278171.1:3'UTR:MODIFIER:exon6/6:c.*2041A>C:,ZNF33A:NM_001278173.1:3'UTR:MODIFIER:exon6/6:c.*2041A>C:,ZNF33A:NM_001278174.1:3'UTR:MODIFIER:exon6/6:c.*2041A>C:,ZNF33A:NM_001278175.1:3'UTR:MODIFIER:exon6/6:c.*2041A>C:,ZNF33A:NM_001278176.1:3'UTR:MODIFIER:exon6/6:c.*2041A>C:,ZNF33A:NM_001278178.1:3'UTR:MODIFIER:exon5/5:c.*2041A>C:,ZNF33A:NM_001278179.1:3'UTR:MODIFIER:exon6/6:c.*2041A>C:,ZNF33A:NM_001324175.1:3'UTR:MODIFIER:exon6/6:c.*2041A>C:,ZNF33A:NM_001324176.1:3'UTR:MODIFIER:exon5/5:c.*2041A>C:,ZNF33A:NM_001324178.1:3'UTR:MODIFIER:exon4/4:c.*2041A>C:,ZNF33A:NM_006954.1:3'UTR:MODIFIER:exon5/5:c.*2041A>C:,ZNF33A:NM_006974.2:3'UTR:MODIFIER:exon5/5:c.*2041A>C:,ZNF33A:NM_001324177.1:3'UTR:MODIFIER:exon6/6:c.*2041A>C:,ZNF33A:NR_136709.1:intron:MODIFIER:exon5/5:n.533+4122A>C:,ZNF33A:NR_136710.1:intron:MODIFIER:exon4/4:n.429-5487A>C:	AluSx3	rs2480524	0.0317	0.0000	0/0/0	0.0604											1	14					ZNF33A (inh=n/a pLI=0.00)
chr10	38347806	38347806	C	G	wt	het	wt		QUAL=1800;DP=423,180,189;MQM=60	ZNF33A	3'UTR,intron	ZNF33A:NM_001278177.1:3'UTR:MODIFIER:exon5/5:c.*2318C>G:,ZNF33A:NM_001278170.1:3'UTR:MODIFIER:exon4/4:c.*2318C>G:,ZNF33A:NM_001278171.1:3'UTR:MODIFIER:exon6/6:c.*2318C>G:,ZNF33A:NM_001278173.1:3'UTR:MODIFIER:exon6/6:c.*2318C>G:,ZNF33A:NM_001278174.1:3'UTR:MODIFIER:exon6/6:c.*2318C>G:,ZNF33A:NM_001278175.1:3'UTR:MODIFIER:exon6/6:c.*2318C>G:,ZNF33A:NM_001278176.1:3'UTR:MODIFIER:exon6/6:c.*2318C>G:,ZNF33A:NM_001278178.1:3'UTR:MODIFIER:exon5/5:c.*2318C>G:,ZNF33A:NM_001278179.1:3'UTR:MODIFIER:exon6/6:c.*2318C>G:,ZNF33A:NM_001324175.1:3'UTR:MODIFIER:exon6/6:c.*2318C>G:,ZNF33A:NM_001324176.1:3'UTR:MODIFIER:exon5/5:c.*2318C>G:,ZNF33A:NM_001324178.1:3'UTR:MODIFIER:exon4/4:c.*2318C>G:,ZNF33A:NM_006954.1:3'UTR:MODIFIER:exon5/5:c.*2318C>G:,ZNF33A:NM_006974.2:3'UTR:MODIFIER:exon5/5:c.*2318C>G:,ZNF33A:NM_001324177.1:3'UTR:MODIFIER:exon6/6:c.*2318C>G:,ZNF33A:NR_136709.1:intron:MODIFIER:exon5/5:n.533+4399C>G:,ZNF33A:NR_136710.1:intron:MODIFIER:exon4/4:n.429-5210C>G:	L1MC2	rs2472165	0.0315	0.0000	0/0/0	0.0103											1	14					ZNF33A (inh=n/a pLI=0.00)
chr10	38347850	38347850	G	C	wt	het	wt		QUAL=1391;DP=228,135,156;MQM=60	ZNF33A	3'UTR,intron	ZNF33A:NM_001278177.1:3'UTR:MODIFIER:exon5/5:c.*2362G>C:,ZNF33A:NM_001278170.1:3'UTR:MODIFIER:exon4/4:c.*2362G>C:,ZNF33A:NM_001278171.1:3'UTR:MODIFIER:exon6/6:c.*2362G>C:,ZNF33A:NM_001278173.1:3'UTR:MODIFIER:exon6/6:c.*2362G>C:,ZNF33A:NM_001278174.1:3'UTR:MODIFIER:exon6/6:c.*2362G>C:,ZNF33A:NM_001278175.1:3'UTR:MODIFIER:exon6/6:c.*2362G>C:,ZNF33A:NM_001278176.1:3'UTR:MODIFIER:exon6/6:c.*2362G>C:,ZNF33A:NM_001278178.1:3'UTR:MODIFIER:exon5/5:c.*2362G>C:,ZNF33A:NM_001278179.1:3'UTR:MODIFIER:exon6/6:c.*2362G>C:,ZNF33A:NM_001324175.1:3'UTR:MODIFIER:exon6/6:c.*2362G>C:,ZNF33A:NM_001324176.1:3'UTR:MODIFIER:exon5/5:c.*2362G>C:,ZNF33A:NM_001324178.1:3'UTR:MODIFIER:exon4/4:c.*2362G>C:,ZNF33A:NM_006954.1:3'UTR:MODIFIER:exon5/5:c.*2362G>C:,ZNF33A:NM_006974.2:3'UTR:MODIFIER:exon5/5:c.*2362G>C:,ZNF33A:NM_001324177.1:3'UTR:MODIFIER:exon6/6:c.*2362G>C:,ZNF33A:NR_136709.1:intron:MODIFIER:exon5/5:n.533+4443G>C:,ZNF33A:NR_136710.1:intron:MODIFIER:exon4/4:n.429-5166G>C:	L1MC2	rs2472166	0.0317	0.0000	0/0/0	0.0103											1	14					ZNF33A (inh=n/a pLI=0.00)
chr10	43595968	43595968	A	G	het	het	wt		QUAL=1504;DP=31,71,98;MQM=59	RET	synonymous	RET:NM_020975.4:synonymous:LOW:exon2/20:c.135A>G:p.Ala45Ala,RET:NM_020630.4:synonymous:LOW:exon2/19:c.135A>G:p.Ala45Ala		rs1800858	0.7536	0.7365	33200/17899/4676	0.7262							164761 [RET (confirmed) Multiple endocrine neoplasia IIA,171400|Medullary thyroid carcinoma,155240|Multiple endocrine neoplasia IIB,162300|Central hypoventilation syndrome,congenital,209880|Pheochromocytoma,171300|Hirschsprung disease,susceptibility to,1,142623];	RCV000014967.2 [other]; RCV000127776.1 [benign]; RCV000205827.1 [benign]; RCV000216697.1 [not provided]; RCV000153833.3 [benign]; 	CM020759 [CLASS=DP MUT=REF PHEN="Hirschsprung disease association with" GENE=RET]; 	COSM4144677, COSM4144678	1767	1238	1	[1] old entry - no details available			RET (inh=AR+AD pLI=1.00)
chr10	43606687	43606687	A	G	hom	hom	hom		QUAL=9839;DP=67,131,128;MQM=60	RET	synonymous	RET:NM_020975.4:synonymous:LOW:exon7/20:c.1296A>G:p.Ala432Ala,RET:NM_020630.4:synonymous:LOW:exon7/19:c.1296A>G:p.Ala432Ala		rs1800860	0.7752	0.7061	30695/15829/3890	0.6998							164761 [RET (confirmed) Multiple endocrine neoplasia IIA,171400|Medullary thyroid carcinoma,155240|Multiple endocrine neoplasia IIB,162300|Central hypoventilation syndrome,congenital,209880|Pheochromocytoma,171300|Hirschsprung disease,susceptibility to,1,142623];	RCV000082048.7 [benign]; RCV000131068.2 [benign]; RCV000265973.1 [benign]; RCV000285939.1 [benign]; RCV000321087.1 [benign]; RCV000380264.1 [benign]; 	CM033447 [CLASS=DP MUT=ALT PHEN="Hirschsprung disease association with" GENE=RET]; 		1571	1356	1	[1] Ilnaz Sepahi 29-03-2016 batch import			RET (inh=AR+AD pLI=1.00)
chr10	43613843	43613843	G	T	het	hom	het		QUAL=6292;DP=191,94,111;MQM=60	RET	synonymous	RET:NM_020975.4:synonymous:LOW:exon13/20:c.2307G>T:p.Leu769Leu,RET:NM_020630.4:synonymous:LOW:exon13/19:c.2307G>T:p.Leu769Leu		rs1800861	0.7125	0.7419	33769/19608/4074	0.7333							164761 [RET (confirmed) Multiple endocrine neoplasia IIA,171400|Medullary thyroid carcinoma,155240|Multiple endocrine neoplasia IIB,162300|Central hypoventilation syndrome,congenital,209880|Pheochromocytoma,171300|Hirschsprung disease,susceptibility to,1,142623];	RCV000021844.1 [benign]; RCV000127779.1 [benign]; RCV000154625.1 [benign]; RCV000203706.1 [benign]; RCV000153835.3 [benign]; 	CM014825 [CLASS=DP MUT=REF PHEN="Hirschsprung disease association with" GENE=RET]; 		1824	1204	1	[1] Ilnaz Sepahi 29-03-2016 batch import			RET (inh=AR+AD pLI=1.00)
chr10	43622217	43622217	T	C	het	hom	het		QUAL=11261;DP=205,158,258;MQM=59	RET	3'UTR,intron	RET:NM_020630.4:3'UTR:MODIFIER:exon19/19:c.*15T>C:,RET:NM_020975.4:intron:MODIFIER:exon19/19:c.3187+47T>C:		rs2075912	0.7550	0.8031	33460/19436/3910	0.7666							164761 [RET (confirmed) Multiple endocrine neoplasia IIA,171400|Medullary thyroid carcinoma,155240|Multiple endocrine neoplasia IIB,162300|Central hypoventilation syndrome,congenital,209880|Pheochromocytoma,171300|Hirschsprung disease,susceptibility to,1,142623];	RCV000151742.2 [benign]; 	CS032426 [CLASS=DP MUT=ALT PHEN="Hirschsprung disease association with" GENE=RET]; 		912	459					RET (inh=AR+AD pLI=1.00)
chr10	43622368	43622368	T	A	het	hom	het		QUAL=4430;DP=165,52,60;MQM=59	RET	3'UTR,intron	RET:NM_020630.4:3'UTR:MODIFIER:exon19/19:c.*166T>A:,RET:NM_020975.4:intron:MODIFIER:exon19/19:c.3187+198T>A:		rs2075913	0.6607	0.0000	0/0/0	0.1183							164761 [RET (confirmed) Multiple endocrine neoplasia IIA,171400|Medullary thyroid carcinoma,155240|Multiple endocrine neoplasia IIB,162300|Central hypoventilation syndrome,congenital,209880|Pheochromocytoma,171300|Hirschsprung disease,susceptibility to,1,142623];				83	53					RET (inh=AR+AD pLI=1.00)
chr10	43622933	43622933	T	C	het	hom	het		QUAL=26813;DP=414,439,533;MQM=60	RET	3'UTR,intron	RET:NM_020630.4:3'UTR:MODIFIER:exon19/19:c.*731T>C:,RET:NM_020975.4:intron:MODIFIER:exon19/19:c.3188-627T>C:		rs2565200	0.7654	0.0000	0/0/0	0.1531							164761 [RET (confirmed) Multiple endocrine neoplasia IIA,171400|Medullary thyroid carcinoma,155240|Multiple endocrine neoplasia IIB,162300|Central hypoventilation syndrome,congenital,209880|Pheochromocytoma,171300|Hirschsprung disease,susceptibility to,1,142623];				98	45					RET (inh=AR+AD pLI=1.00)
chr10	43623812	43623812	C	T	het	hom	het		QUAL=13119;DP=303,194,232;MQM=60	RET	3'UTR	RET:NM_020975.4:3'UTR:MODIFIER:exon20/20:c.*95C>T:		rs17028	0.1366	0.0000	0/0/0	0.0376							164761 [RET (confirmed) Multiple endocrine neoplasia IIA,171400|Medullary thyroid carcinoma,155240|Multiple endocrine neoplasia IIB,162300|Central hypoventilation syndrome,congenital,209880|Pheochromocytoma,171300|Hirschsprung disease,susceptibility to,1,142623];	RCV000276472.1 [likely benign]; RCV000311724.1 [likely benign]; RCV000333449.1 [likely benign]; RCV000368704.1 [likely benign]; 			8	83					RET (inh=AR+AD pLI=1.00)
chr10	43624317	43624317	A	T	het	hom	het		QUAL=6319;DP=182,81,114;MQM=59	RET	3'UTR	RET:NM_020975.4:3'UTR:MODIFIER:exon20/20:c.*600A>T:		rs2742240	0.7524	0.0000	0/0/0	0.1241							164761 [RET (confirmed) Multiple endocrine neoplasia IIA,171400|Medullary thyroid carcinoma,155240|Multiple endocrine neoplasia IIB,162300|Central hypoventilation syndrome,congenital,209880|Pheochromocytoma,171300|Hirschsprung disease,susceptibility to,1,142623];				153	67					RET (inh=AR+AD pLI=1.00)
chr10	43624833	43624833	T	C	het	hom	het		QUAL=19762;DP=364,346,341;MQM=60	RET	3'UTR	RET:NM_020975.4:3'UTR:MODIFIER:exon20/20:c.*1116T>C:		rs2435355	0.1899	0.0000	0/0/0	0.0369							164761 [RET (confirmed) Multiple endocrine neoplasia IIA,171400|Medullary thyroid carcinoma,155240|Multiple endocrine neoplasia IIB,162300|Central hypoventilation syndrome,congenital,209880|Pheochromocytoma,171300|Hirschsprung disease,susceptibility to,1,142623];	RCV000260152.1 [likely benign]; RCV000284603.1 [likely benign]; RCV000324757.1 [likely benign]; RCV000379318.1 [likely benign]; 			13	87					RET (inh=AR+AD pLI=1.00)
chr10	43625223	43625223	G	A	het	hom	het		QUAL=18009;DP=420,226,391;MQM=59	RET	3'UTR	RET:NM_020975.4:3'UTR:MODIFIER:exon20/20:c.*1506G>A:		rs2742241	0.7472	0.0000	0/0/0	0.1302							164761 [RET (confirmed) Multiple endocrine neoplasia IIA,171400|Medullary thyroid carcinoma,155240|Multiple endocrine neoplasia IIB,162300|Central hypoventilation syndrome,congenital,209880|Pheochromocytoma,171300|Hirschsprung disease,susceptibility to,1,142623];	RCV000271216.1 [benign]; RCV000326221.1 [benign]; RCV000362237.1 [benign]; RCV000366478.1 [benign]; 	CR032442 [CLASS=DP MUT=REF PHEN="Hirschsprung disease association with" GENE=RET]; 		152	68					RET (inh=AR+AD pLI=1.00)
chr10	50664895	50664897	AAT	-	het	het	wt		QUAL=7558;DP=341,286,339;MQM=59	ERCC6	3'UTR	ERCC6:NM_000124.3:3'UTR:MODIFIER:exon21/21:c.*1964_*1966delATT:		rs147228327	0.0349	0.0000	0/0/0	0.0601							609413 [ERCC6 (confirmed) Cockayne syndrome,type B,133540|Cerebrooculofacioskeletal syndrome 1,214150|De Sanctis-Cacchione syndrome,278800|Macular degeneration,age-related,susceptibility to,5,613761|UV-sensitive syndrome 1,600630|Lung cancer,susceptibility to,211980|Premature ovarian failure 11,616946];	RCV000271052.1 [benign]; RCV000309810.1 [benign]; RCV000362224.1 [benign]; 			5	30					ERCC6 (inh=AR+AD pLI=0.00)
chr10	50667105	50667105	T	C	het	het	hom	pred_pathogenic	QUAL=15915;DP=247,231,303;MQM=59	ERCC6	missense	ERCC6:NM_000124.3:missense:MODERATE:exon21/21:c.4238A>G:p.Gln1413Arg		rs2228529	0.1789	0.2178	3279/1699/83	0.2092	0.1010	T,T,T	T	B	D,T	0.06	609413 [ERCC6 (confirmed) Cockayne syndrome,type B,133540|Cerebrooculofacioskeletal syndrome 1,214150|De Sanctis-Cacchione syndrome,278800|Macular degeneration,age-related,susceptibility to,5,613761|UV-sensitive syndrome 1,600630|Lung cancer,susceptibility to,211980|Premature ovarian failure 11,616946];	RCV000117001.5 [other]; RCV000292311.1 [benign]; RCV000346112.1 [benign]; RCV000402619.1 [benign]; 		COSM427630	98	654					ERCC6 (inh=AR+AD pLI=0.00)
chr10	50678369	50678369	T	C	het	het	hom	pred_pathogenic	QUAL=12517;DP=230,203,209;MQM=59	ERCC6	missense	ERCC6:NM_000124.3:missense:MODERATE:exon18/21:c.3637A>G:p.Arg1213Gly		rs2228527	0.1847	0.2203	3325/1708/118	0.2041	1.7160	T,T,T	T	B	D,T	13.04	609413 [ERCC6 (confirmed) Cockayne syndrome,type B,133540|Cerebrooculofacioskeletal syndrome 1,214150|De Sanctis-Cacchione syndrome,278800|Macular degeneration,age-related,susceptibility to,5,613761|UV-sensitive syndrome 1,600630|Lung cancer,susceptibility to,211980|Premature ovarian failure 11,616946];	RCV000116998.6 [other]; RCV000272009.1 [benign]; RCV000329399.1 [benign]; RCV000367801.1 [benign]; 	CM980633 [CLASS=DP MUT=ALT PHEN="Colorectal cancer increased risk association with" GENE=ERCC6]; 	COSM3751836	103	656					ERCC6 (inh=AR+AD pLI=0.00)
chr10	50678717	50678717	T	C	het	het	hom	pred_pathogenic	QUAL=29118;DP=472,356,521;MQM=60	ERCC6	missense	ERCC6:NM_000124.3:missense:MODERATE:exon18/21:c.3289A>G:p.Met1097Val		rs2228526	0.1825	0.2186	3293/1702/93	0.2098	-0.2110	T,T,T	T	B	D,T	0.01	609413 [ERCC6 (confirmed) Cockayne syndrome,type B,133540|Cerebrooculofacioskeletal syndrome 1,214150|De Sanctis-Cacchione syndrome,278800|Macular degeneration,age-related,susceptibility to,5,613761|UV-sensitive syndrome 1,600630|Lung cancer,susceptibility to,211980|Premature ovarian failure 11,616946];	RCV000116997.6 [other]; RCV000287947.1 [benign]; RCV000322054.1 [benign]; RCV000378942.1 [benign]; 	CM076169 [CLASS=DP MUT=ALT PHEN="Reduced chromosomal damage in coke oven workers association with" GENE=ERCC6]; 	COSM3751837	100	653					ERCC6 (inh=AR+AD pLI=0.00)
chr10	50701156	50701156	G	A	het	het	hom		QUAL=10492;DP=205,146,190;MQM=60	ERCC6	splice_region&intron	ERCC6:NM_000124.3:splice_region&intron:LOW:exon8/20:c.1821+7C>T:		rs4253132	0.8770	0.8887	48044/25622/2737	0.8680							609413 [ERCC6 (confirmed) Cockayne syndrome,type B,133540|Cerebrooculofacioskeletal syndrome 1,214150|De Sanctis-Cacchione syndrome,278800|Macular degeneration,age-related,susceptibility to,5,613761|UV-sensitive syndrome 1,600630|Lung cancer,susceptibility to,211980|Premature ovarian failure 11,616946];	RCV000170371.2 [benign]; RCV000302397.1 [benign]; RCV000357202.1 [benign]; RCV000404616.1 [benign]; 			1384	345					ERCC6 (inh=AR+AD pLI=0.00)
chr10	50740876	50740876	G	C	het	het	hom		QUAL=13156;DP=175,228,280;MQM=59	ERCC6	synonymous	ERCC6:NM_000124.3:synonymous:LOW:exon2/21:c.135C>G:p.Leu45Leu,ERCC6:NM_001277058.1:synonymous:LOW:exon2/6:c.135C>G:p.Leu45Leu,ERCC6:NM_001277059.1:synonymous:LOW:exon2/6:c.135C>G:p.Leu45Leu		rs2228524	0.5909	0.6946	30180/18280/767	0.6793							609413 [ERCC6 (confirmed) Cockayne syndrome,type B,133540|Cerebrooculofacioskeletal syndrome 1,214150|De Sanctis-Cacchione syndrome,278800|Macular degeneration,age-related,susceptibility to,5,613761|UV-sensitive syndrome 1,600630|Lung cancer,susceptibility to,211980|Premature ovarian failure 11,616946];	RCV000116995.5 [other]; RCV000309121.1 [benign]; RCV000367258.1 [benign]; RCV000403290.1 [benign]; 			969	667					ERCC6 (inh=AR+AD pLI=0.00)
chr10	50821191	50821191	G	T	het	het	het		QUAL=10865;DP=252,282,326;MQM=59	CHAT	5'UTR,intron	CHAT:NM_020985.3:5'UTR:MODIFIER:exon1/16:c.-298G>T:,CHAT:NM_020986.3:5'UTR:MODIFIER:exon1/15:c.-126G>T:,CHAT:NM_020984.3:intron:MODIFIER:exon1/14:c.-68-3357G>T:		rs3729496	0.4307	0.0000	0/0/0	0.6145							118490 [CHAT (confirmed) Myasthenic syndrome,congenital,6,presynaptic,254210];				116	96					CHAT (inh=AR pLI=0.01)
chr10	50824588	50824588	G	A	wt	wt	het		QUAL=3855;DP=268,261,340;MQM=60	CHAT	synonymous,5'UTR	CHAT:NM_020549.4:synonymous:LOW:exon2/15:c.327G>A:p.Thr109Thr,CHAT:NM_001142933.1:synonymous:LOW:exon3/16:c.81G>A:p.Thr27Thr,CHAT:NM_020984.3:5'UTR:MODIFIER:exon2/15:c.-28G>A:,CHAT:NM_020985.3:5'UTR:MODIFIER:exon3/16:c.-28G>A:,CHAT:NM_020986.3:5'UTR:MODIFIER:exon2/15:c.-28G>A:,CHAT:NM_001142929.1:5'UTR:MODIFIER:exon2/15:c.-28G>A:,CHAT:NM_001142934.1:5'UTR:MODIFIER:exon3/16:c.-28G>A:		rs79914771	0.0014	0.0014	3/0/0	0.0011							118490 [CHAT (confirmed) Myasthenic syndrome,congenital,6,presynaptic,254210];	RCV000246018.1 [likely benign]; 			1	8					CHAT (inh=AR pLI=0.01)
chr10	50863147	50863147	T	C	hom	hom	hom		QUAL=14486;DP=229,118,129;MQM=59	CHAT	synonymous	CHAT:NM_020549.4:synonymous:LOW:exon12/15:c.1641T>C:p.His547His,CHAT:NM_020984.3:synonymous:LOW:exon12/15:c.1287T>C:p.His429His,CHAT:NM_020985.3:synonymous:LOW:exon13/16:c.1287T>C:p.His429His,CHAT:NM_020986.3:synonymous:LOW:exon12/15:c.1287T>C:p.His429His,CHAT:NM_001142929.1:synonymous:LOW:exon12/15:c.1287T>C:p.His429His,CHAT:NM_001142933.1:synonymous:LOW:exon13/16:c.1395T>C:p.His465His,CHAT:NM_001142934.1:synonymous:LOW:exon13/16:c.1287T>C:p.His429His		rs8178992	0.7935	0.8491	44227/27257/2476	0.8437							118490 [CHAT (confirmed) Myasthenic syndrome,congenital,6,presynaptic,254210];	RCV000116692.3 [benign]; 		COSM4144745, COSM4144746	1225	310					CHAT (inh=AR pLI=0.01)
chr10	64572038	64572038	T	-	hom	hom	hom		QUAL=18614;DP=254,170,181;MQM=59	EGR2	3'UTR	EGR2:NM_000399.4:3'UTR:MODIFIER:exon2/2:c.*929delA:,EGR2:NM_001136177.2:3'UTR:MODIFIER:exon3/3:c.*929delA:,EGR2:NM_001136179.2:3'UTR:MODIFIER:exon3/3:c.*929delA:,EGR2:NM_001321037.1:3'UTR:MODIFIER:exon3/3:c.*929delA:,EGR2:NM_001136178.1:3'UTR:MODIFIER:exon4/4:c.*929delA:		rs398013782	0.9944	0.0000	0/0/0	0.9094							129010 [EGR2 (provisional) Neuropathy,congenital hypomyelinating,1,605253|Charcot-Marie-Tooth disease,type 1D,607678|Dejerine-Sottas disease,145900];				230	0					EGR2 (inh=AR+AD pLI=0.62)
chr10	64573771	64573771	C	T	hom	hom	hom		QUAL=36295;DP=175,475,568;MQM=59	EGR2	synonymous	EGR2:NM_000399.4:synonymous:LOW:exon2/2:c.627G>A:p.Pro209Pro,EGR2:NM_001136177.2:synonymous:LOW:exon3/3:c.627G>A:p.Pro209Pro,EGR2:NM_001136179.2:synonymous:LOW:exon3/3:c.477G>A:p.Pro159Pro,EGR2:NM_001321037.1:synonymous:LOW:exon3/3:c.477G>A:p.Pro159Pro,EGR2:NM_001136178.1:synonymous:LOW:exon4/4:c.627G>A:p.Pro209Pro		rs224083	0.9860	0.9953	60144/33365/4686	0.9251							129010 [EGR2 (provisional) Neuropathy,congenital hypomyelinating,1,605253|Charcot-Marie-Tooth disease,type 1D,607678|Dejerine-Sottas disease,145900];	RCV000383101.1 [benign]; 			1565	0					EGR2 (inh=AR+AD pLI=0.62)
chr10	70748784	70748784	G	A	het	het	het		QUAL=6877;DP=190,186,251;MQM=59	KIAA1279	missense	KIAA1279:NM_015634.3:missense:MODERATE:exon1/7:c.196G>A:p.Gly66Ser		rs2255607	0.3538	0.4137	10594/7462/598	0.4102	0.2110	T	T	B	T	0.26	609367 [KIAA1279 (provisional) Goldberg-Shprintzen megacolon syndrome,609460];	RCV000146132.2 [benign]; 		COSM3751905	316	748					KIF1BP (inh=AR pLI=0.05)
chr10	70776594	70776594	A	C	het	het	het		QUAL=4926;DP=203,39,77;MQM=60	KIAA1279	3'UTR	KIAA1279:NM_015634.3:3'UTR:MODIFIER:exon7/7:c.*422A>C:		rs6864	0.3638	0.0000	0/0/0	0.4304							609367 [KIAA1279 (provisional) Goldberg-Shprintzen megacolon syndrome,609460];				40	116					KIF1BP (inh=AR pLI=0.05)
chr10	71332204	71332204	A	G	hom	hom	hom	pred_pathogenic	QUAL=10824;DP=105,100,143;MQM=59	NEUROG3	missense	NEUROG3:NM_020999.3:missense:MODERATE:exon2/2:c.596T>C:p.Phe199Ser		rs4536103	0.4299	0.5860	11362/7860/197	0.5069	1.4960	T	T	B	D	2.01	604882 [NEUROG3 (provisional) Diarrhea 4,malabsorptive,congenital,610370];	RCV000117780.2 [likely benign]; 	CM068025 [CLASS=DP MUT=ALT PHEN="Diabetes type 2 association with" GENE=NEUROG3]; 	COSM3749111	602	669					NEUROG3 (inh=AR pLI=0.00)
chr10	72357600	72357600	A	-	wt	hom	wt		QUAL=1527;DP=127,108,125;MQM=59	PRF1	3'UTR	PRF1:NM_001083116.1:3'UTR:MODIFIER:exon3/3:c.*209delT:,PRF1:NM_005041.4:3'UTR:MODIFIER:exon3/3:c.*209delT:	MER30	rs527442892;rs796359767	0.3638	0.0000	0/0/0	0.1007							170280 [PRF1 (confirmed) Hemophagocytic lymphohistiocytosis,familial,2,603553|Lymphoma,non-Hodgkin,605027|Aplastic anemia,609135];	RCV000388575.1 [benign]; 			0	109					PRF1 (inh=AR pLI=0.00)
chr10	72357713	72357713	C	T	hom	hom	hom		QUAL=38260;DP=545,300,408;MQM=59	PRF1	3'UTR	PRF1:NM_001083116.1:3'UTR:MODIFIER:exon3/3:c.*96G>A:,PRF1:NM_005041.4:3'UTR:MODIFIER:exon3/3:c.*96G>A:	MER30	rs1889490	0.5779	0.0000	0/0/0	0.0904							170280 [PRF1 (confirmed) Hemophagocytic lymphohistiocytosis,familial,2,603553|Lymphoma,non-Hodgkin,605027|Aplastic anemia,609135];	RCV000375811.1 [benign]; 			33	107					PRF1 (inh=AR pLI=0.00)
chr10	72358577	72358577	G	A	hom	hom	hom		QUAL=27545;DP=200,311,401;MQM=59	PRF1	synonymous	PRF1:NM_001083116.1:synonymous:LOW:exon3/3:c.900C>T:p.His300His,PRF1:NM_005041.4:synonymous:LOW:exon3/3:c.900C>T:p.His300His		rs885822	0.6959	0.6357	24936/11530/3341	0.6280							170280 [PRF1 (confirmed) Hemophagocytic lymphohistiocytosis,familial,2,603553|Lymphoma,non-Hodgkin,605027|Aplastic anemia,609135];	RCV000248849.1 [benign]; RCV000306406.1 [benign]; 		COSM3765513	580	738					PRF1 (inh=AR pLI=0.00)
chr10	73199588	73199588	C	T	wt	wt	het	low_DP;gene_blacklist	QUAL=263;DP=29,11,17;MQM=60	CDH23	5'UTR	CDH23:NM_022124.5:5'UTR:MODIFIER:exon2/68:c.-1C>T:,CDH23:NM_001171932.1:5'UTR:MODIFIER:exon2/11:c.-1C>T:,CDH23:NM_052836.3:5'UTR:MODIFIER:exon2/13:c.-1C>T:,CDH23:NM_001171931.1:5'UTR:MODIFIER:exon2/25:c.-1C>T:,CDH23:NM_001171930.1:5'UTR:MODIFIER:exon2/31:c.-1C>T:		rs41281302	0.0913	0.0708	101/7/77	0.0299							605516 [CDH23 (confirmed) Usher syndrome,type 1D,601067|Deafness,autosomal recessive 12,601386|Usher syndrome,type 1D/F digenic,601067];	RCV000150267.1 [benign]; RCV000309111.1 [likely benign]; RCV000365856.1 [likely benign]; 			6	99					CDH23 (inh=AR pLI=0.05)
chr10	73199595	73199595	C	T	wt	wt	het	low_DP;gene_blacklist	QUAL=227;DP=28,13,16;MQM=60	CDH23	missense	CDH23:NM_022124.5:missense:MODERATE:exon2/68:c.7C>T:p.Arg3Cys,CDH23:NM_001171932.1:missense:MODERATE:exon2/11:c.7C>T:p.Arg3Cys,CDH23:NM_052836.3:missense:MODERATE:exon2/13:c.7C>T:p.Arg3Cys,CDH23:NM_001171931.1:missense:MODERATE:exon2/25:c.7C>T:p.Arg3Cys,CDH23:NM_001171930.1:missense:MODERATE:exon2/31:c.7C>T:p.Arg3Cys		rs7902757	0.1370	0.0955	266/8/239	0.0392	-0.0530	T,T,T,T,T,T,T	T	B,B,B	T,T	18.96	605516 [CDH23 (confirmed) Usher syndrome,type 1D,601067|Deafness,autosomal recessive 12,601386|Usher syndrome,type 1D/F digenic,601067];	RCV000039278.2 [benign]; RCV000086977.1 [not provided]; RCV000273869.1 [likely benign]; RCV000331245.1 [likely benign]; 		COSM3751942, COSM3751940, COSM3751941, COSM3751943	8	101					CDH23 (inh=AR pLI=0.05)
chr10	73270906	73270906	T	C	hom	hom	hom		QUAL=40725;DP=329,419,547;MQM=59	CDH23,LOC102723377	synonymous,intron	CDH23:NM_022124.5:synonymous:LOW:exon6/68:c.366T>C:p.Val122Val,CDH23:NM_001171932.1:synonymous:LOW:exon6/11:c.366T>C:p.Val122Val,CDH23:NM_052836.3:synonymous:LOW:exon6/13:c.366T>C:p.Val122Val,CDH23:NM_001171931.1:synonymous:LOW:exon6/25:c.366T>C:p.Val122Val,CDH23:NM_001171930.1:synonymous:LOW:exon6/31:c.366T>C:p.Val122Val,LOC102723377:NR_120672.1:intron:MODIFIER:exon1/2:n.143+629A>G:		rs3802720	0.7346	0.6721	28139/14978/4298	0.6606							605516 [CDH23 (confirmed) Usher syndrome,type 1D,601067|Deafness,autosomal recessive 12,601386|Usher syndrome,type 1D/F digenic,601067];	RCV000150270.1 [benign]; RCV000039162.3 [benign]; RCV000288261.1 [likely benign]; RCV000380358.1 [likely benign]; 		COSM4144828, COSM4144829, COSM4144830, COSM4144827	663	716					CDH23 (inh=AR pLI=0.05), LOC102723377 (inh=n/a pLI=n/a)
chr10	73377314	73377314	C	G	hom	hom	hom	gene_blacklist	QUAL=25262;DP=237,248,344;MQM=60	CDH23	3'UTR,intron	CDH23:NM_001171932.1:3'UTR:MODIFIER:exon11/11:c.*77C>G:,CDH23:NM_022124.5:intron:MODIFIER:exon11/67:c.1134+164C>G:,CDH23:NM_052836.3:intron:MODIFIER:exon11/12:c.1134+164C>G:,CDH23:NM_001171931.1:intron:MODIFIER:exon11/24:c.1134+164C>G:,CDH23:NM_001171930.1:intron:MODIFIER:exon11/30:c.1134+164C>G:	Charlie7a	rs7903772	0.5495	0.0000	0/0/0	0.6312							605516 [CDH23 (confirmed) Usher syndrome,type 1D,601067|Deafness,autosomal recessive 12,601386|Usher syndrome,type 1D/F digenic,601067];				80	63					CDH23 (inh=AR pLI=0.05)
chr10	73406599	73406599	G	A	het	het	het	gene_blacklist	QUAL=10677;DP=210,242,358;MQM=60	CDH23	3'UTR,intron	CDH23:NM_052836.3:3'UTR:MODIFIER:exon13/13:c.*81G>A:,CDH23:NM_022124.5:intron:MODIFIER:exon13/67:c.1449+225G>A:,CDH23:NM_001171931.1:intron:MODIFIER:exon13/24:c.1449+225G>A:,CDH23:NM_001171930.1:intron:MODIFIER:exon13/30:c.1449+225G>A:		rs2305210	0.2592	0.0000	0/0/0	0.0478							605516 [CDH23 (confirmed) Usher syndrome,type 1D,601067|Deafness,autosomal recessive 12,601386|Usher syndrome,type 1D/F digenic,601067];				10	53					CDH23 (inh=AR pLI=0.05)
chr10	73406636	73406636	C	T	het	het	het	gene_blacklist	QUAL=7816;DP=221,194,272;MQM=60	CDH23	3'UTR,intron	CDH23:NM_052836.3:3'UTR:MODIFIER:exon13/13:c.*118C>T:,CDH23:NM_022124.5:intron:MODIFIER:exon13/67:c.1449+262C>T:,CDH23:NM_001171931.1:intron:MODIFIER:exon13/24:c.1449+262C>T:,CDH23:NM_001171930.1:intron:MODIFIER:exon13/30:c.1449+262C>T:		rs11598249	0.2368	0.0000	0/0/0	0.2760							605516 [CDH23 (confirmed) Usher syndrome,type 1D,601067|Deafness,autosomal recessive 12,601386|Usher syndrome,type 1D/F digenic,601067];				17	67					CDH23 (inh=AR pLI=0.05)
chr10	73407220	73407220	A	-	hom	hom	wt	low_DP;gene_blacklist	QUAL=279;DP=13,1,272;MQM=56	CDH23	intron	CDH23:NM_022124.5:intron:MODIFIER:exon13/67:c.1449+858delA:,CDH23:NM_001171931.1:intron:MODIFIER:exon13/24:c.1449+858delA:,CDH23:NM_001171930.1:intron:MODIFIER:exon13/30:c.1449+858delA:	AluSz	rs113373333;rs56367143	0.8317	0.0000	0/0/0	0.5641							605516 [CDH23 (confirmed) Usher syndrome,type 1D,601067|Deafness,autosomal recessive 12,601386|Usher syndrome,type 1D/F digenic,601067];				36	22					CDH23 (inh=AR pLI=0.05)
chr10	73434906	73434906	G	A	hom	hom	het	gene_blacklist	QUAL=25363;DP=401,258,383;MQM=59	CDH23	missense	CDH23:NM_022124.5:missense:MODERATE:exon14/68:c.1487G>A:p.Ser496Asn,CDH23:NM_001171931.1:missense:MODERATE:exon14/25:c.1487G>A:p.Ser496Asn,CDH23:NM_001171930.1:missense:MODERATE:exon14/31:c.1487G>A:p.Ser496Asn		rs10999947	0.2524	0.2724	4500/2314/301	0.2673	0.4000	T,T,T,T,T,T	T	B,B,B		10.40	605516 [CDH23 (confirmed) Usher syndrome,type 1D,601067|Deafness,autosomal recessive 12,601386|Usher syndrome,type 1D/F digenic,601067];	RCV000039108.3 [benign]; RCV000279658.1 [likely benign]; RCV000316088.1 [likely benign]; 			120	572					CDH23 (inh=AR pLI=0.05)
chr10	73455201	73455201	T	C	wt	het	het	gene_blacklist	QUAL=9246;DP=213,332,406;MQM=60	CDH23	synonymous	CDH23:NM_022124.5:synonymous:LOW:exon21/68:c.2316T>C:p.Asn772Asn,CDH23:NM_001171931.1:synonymous:LOW:exon21/25:c.2316T>C:p.Asn772Asn,CDH23:NM_001171930.1:synonymous:LOW:exon21/31:c.2316T>C:p.Asn772Asn		rs3752752	0.5545	0.6362	25114/16843/1372	0.6280							605516 [CDH23 (confirmed) Usher syndrome,type 1D,601067|Deafness,autosomal recessive 12,601386|Usher syndrome,type 1D/F digenic,601067];	RCV000154334.1 [benign]; RCV000039126.3 [benign]; RCV000349454.1 [likely benign]; RCV000394281.1 [likely benign]; 			800	616					CDH23 (inh=AR pLI=0.05)
chr10	73455273	73455273	T	C	wt	het	het	gene_blacklist	QUAL=8008;DP=216,312,355;MQM=60	CDH23	synonymous	CDH23:NM_022124.5:synonymous:LOW:exon21/68:c.2388T>C:p.Asp796Asp,CDH23:NM_001171931.1:synonymous:LOW:exon21/25:c.2388T>C:p.Asp796Asp,CDH23:NM_001171930.1:synonymous:LOW:exon21/31:c.2388T>C:p.Asp796Asp		rs3752751	0.5539	0.6363	25073/16824/1371	0.6277							605516 [CDH23 (confirmed) Usher syndrome,type 1D,601067|Deafness,autosomal recessive 12,601386|Usher syndrome,type 1D/F digenic,601067];	RCV000154335.1 [benign]; RCV000039129.3 [benign]; RCV000266647.1 [likely benign]; RCV000322204.1 [likely benign]; 		COSM4144837, COSM4144835, COSM4144836	800	616					CDH23 (inh=AR pLI=0.05)
chr10	73466670	73466670	C	T	wt	het	wt	low_DP;gene_blacklist	QUAL=102;DP=12,11,12;MQM=60	CDH23	synonymous	CDH23:NM_022124.5:synonymous:LOW:exon25/68:c.2970C>T:p.Asp990Asp,CDH23:NM_001171931.1:synonymous:LOW:exon25/25:c.2970C>T:p.Asp990Asp,CDH23:NM_001171930.1:synonymous:LOW:exon25/31:c.2970C>T:p.Asp990Asp		rs56216952	0.0016	0.0066	2/2/0	0.0034							605516 [CDH23 (confirmed) Usher syndrome,type 1D,601067|Deafness,autosomal recessive 12,601386|Usher syndrome,type 1D/F digenic,601067];	RCV000037086.3 [other]; RCV000329264.1 [uncertain significance]; RCV000381475.1 [uncertain significance]; 			0	7					CDH23 (inh=AR pLI=0.05)
chr10	73492079	73492079	A	G	het	het	hom	pred_pathogenic	QUAL=19200;DP=203,349,399;MQM=59	CDH23,C10orf105	missense,intron	CDH23:NM_022124.5:missense:MODERATE:exon31/68:c.4051A>G:p.Asn1351Asp,CDH23:NM_001171930.1:missense:MODERATE:exon31/31:c.4051A>G:p.Asn1351Asp,C10orf105:NM_001168390.1:intron:MODIFIER:exon1/1:c.-6+5406T>C:		rs1227065	0.7821	0.8159	31531/18061/2288	0.7833	7.6660	T,T,T,T	T	B		1.49	605516 [CDH23 (confirmed) Usher syndrome,type 1D,601067|Deafness,autosomal recessive 12,601386|Usher syndrome,type 1D/F digenic,601067];	RCV000154336.1 [benign]; RCV000039171.7 [benign]; RCV000345614.1 [likely benign]; RCV000397439.1 [likely benign]; 			1075	421					CDH23 (inh=AR pLI=0.05), C10orf105 (inh=n/a pLI=n/a)
chr10	73501556	73501556	G	A	het	het	hom	gene_blacklist;pred_pathogenic	QUAL=25178;DP=353,402,539;MQM=60	CDH23	missense	CDH23:NM_022124.5:missense:MODERATE:exon36/68:c.4723G>A:p.Ala1575Thr		rs1227051	0.7288	0.7752	34657/19701/1730	0.7579	6.2020	T,T,T,T	T	B		9.88	605516 [CDH23 (confirmed) Usher syndrome,type 1D,601067|Deafness,autosomal recessive 12,601386|Usher syndrome,type 1D/F digenic,601067];	RCV000154337.1 [benign]; RCV000039189.3 [benign]; RCV000275255.1 [likely benign]; RCV000328065.1 [likely benign]; 			987	487					CDH23 (inh=AR pLI=0.05)
chr10	73537614	73537614	G	A	het	het	wt	gene_blacklist	QUAL=932;DP=47,42,56;MQM=60	CDH23	missense	CDH23:NM_022124.5:missense:MODERATE:exon37/68:c.5023G>A:p.Val1675Ile		rs17712523	0.1322	0.1789	2098/1315/9	0.1758	0.1020	T,T,T	T	B		16.96	605516 [CDH23 (confirmed) Usher syndrome,type 1D,601067|Deafness,autosomal recessive 12,601386|Usher syndrome,type 1D/F digenic,601067];	RCV000039194.3 [benign]; RCV000086975.1 [not provided]; RCV000310492.1 [likely benign]; RCV000394559.1 [likely benign]; 		COSM146951	56	473					CDH23 (inh=AR pLI=0.05)
chr10	73537978	73537978	C	T	wt	het	wt	gene_blacklist	QUAL=3176;DP=219,264,413;MQM=60	CDH23	synonymous	CDH23:NM_022124.5:synonymous:LOW:exon38/68:c.5100C>T:p.Tyr1700Tyr		rs10762480	0.1793	0.1880	2230/1396/200	0.1869							605516 [CDH23 (confirmed) Usher syndrome,type 1D,601067|Deafness,autosomal recessive 12,601386|Usher syndrome,type 1D/F digenic,601067];	RCV000039199.5 [benign]; RCV000352137.1 [likely benign]; RCV000388097.1 [likely benign]; 		COSM427855	63	451					CDH23 (inh=AR pLI=0.05)
chr10	73544086	73544086	G	A	wt	het	wt	gene_blacklist;pred_pathogenic	QUAL=710;DP=50,69,120;MQM=60	CDH23	missense	CDH23:NM_022124.5:missense:MODERATE:exon40/68:c.5411G>A:p.Arg1804Gln		rs3802711	0.1390	0.1548	1578/995/27	0.1551	6.6760	T,T,T	T	D		26.40	605516 [CDH23 (confirmed) Usher syndrome,type 1D,601067|Deafness,autosomal recessive 12,601386|Usher syndrome,type 1D/F digenic,601067];	RCV000039213.4 [benign]; RCV000276508.1 [likely benign]; RCV000389376.1 [likely benign]; 		COSM3751945	43	381					CDH23 (inh=AR pLI=0.05)
chr10	73550117	73550117	C	G	het	het	het	gene_blacklist;pred_pathogenic	QUAL=7302;DP=153,232,313;MQM=60	CDH23	missense	CDH23:NM_022124.5:missense:MODERATE:exon44/68:c.5996C>G:p.Thr1999Ser		rs11592462	0.3452	0.4291	11548/7665/379	0.4188	1.6610	T,T,T	T	B		14.01	605516 [CDH23 (confirmed) Usher syndrome,type 1D,601067|Deafness,autosomal recessive 12,601386|Usher syndrome,type 1D/F digenic,601067];	RCV000039232.7 [benign]; RCV000338564.1 [likely benign]; RCV000405485.1 [likely benign]; 		COSM3751946	387	737					CDH23 (inh=AR pLI=0.05)
chr10	73569749	73569749	C	T	het	wt	het	gene_blacklist	QUAL=9699;DP=253,461,583;MQM=60	CDH23	synonymous	CDH23:NM_022124.5:synonymous:LOW:exon59/68:c.8895C>T:p.Pro2965Pro,CDH23:NM_001171933.1:synonymous:LOW:exon14/23:c.2175C>T:p.Pro725Pro,CDH23:NM_001171934.1:synonymous:LOW:exon14/22:c.2175C>T:p.Pro725Pro		rs11000009	0.0809	0.1141	924/627/48	0.1089							605516 [CDH23 (confirmed) Usher syndrome,type 1D,601067|Deafness,autosomal recessive 12,601386|Usher syndrome,type 1D/F digenic,601067];	RCV000039294.6 [benign]; RCV000290902.1 [likely benign]; RCV000348155.1 [likely benign]; 			44	415					CDH23 (inh=AR pLI=0.05)
chr10	73575384	73575384	A	G	het	hom	het	gene_blacklist	QUAL=12043;DP=186,225,242;MQM=60	CDH23	3'UTR	CDH23:NM_022124.5:3'UTR:MODIFIER:exon68/68:c.*349A>G:,CDH23:NM_001171933.1:3'UTR:MODIFIER:exon23/23:c.*349A>G:,CDH23:NM_001171934.1:3'UTR:MODIFIER:exon22/22:c.*349A>G:,CDH23:NM_001171935.1:3'UTR:MODIFIER:exon5/5:c.*349A>G:,CDH23:NM_001171936.1:3'UTR:MODIFIER:exon4/4:c.*349A>G:		rs1867978	0.7893	0.0000	0/0/0	0.1289							605516 [CDH23 (confirmed) Usher syndrome,type 1D,601067|Deafness,autosomal recessive 12,601386|Usher syndrome,type 1D/F digenic,601067];	RCV000277087.1 [benign]; RCV000301787.1 [likely benign]; RCV000311190.1 [benign]; RCV000368083.1 [benign]; RCV000369416.1 [benign]; RCV000407454.1 [likely benign]; 			115	100					CDH23 (inh=AR pLI=0.05)
chr10	75009977	75009977	A	-	het	hom	het	low_DP	QUAL=120;DP=31,4,6;MQM=54	MRPS16,DNAJC9-AS1	3'UTR,intron	MRPS16:NM_016065.3:3'UTR:MODIFIER:exon3/3:c.*633delT:,DNAJC9-AS1:NR_038373.1:intron:MODIFIER:exon2/3:n.175+1784delA:	AluY	rs555061429	0.0000	0.0000	0/0/0	0.0109							609204 [MRPS16 (confirmed) Combined oxidative phosphorylation deficiency 2,610498];				3	47					MRPS16 (inh=AR pLI=0.08), DNAJC9-AS1 (inh=n/a pLI=n/a)
chr10	75936611	75936611	C	T	hom	het	hom		QUAL=5205;DP=26,106,114;MQM=59	ADK	5'UTR_premature_start_codon_gain,5'UTR,intron	ADK:NM_001123.3:5'UTR_premature_start_codon_gain:LOW:exon1/11:c.-20C>T:,ADK:NM_001202449.1:5'UTR_premature_start_codon_gain:LOW:exon1/10:c.-20C>T:,ADK:NM_001123.3:5'UTR:MODIFIER:exon1/11:c.-20C>T:,ADK:NM_001202449.1:5'UTR:MODIFIER:exon1/10:c.-20C>T:,ADK:NM_006721.3:intron:MODIFIER:exon1/10:c.66-23911C>T:,ADK:NM_001202450.1:intron:MODIFIER:exon1/9:c.66-23911C>T:		rs10824095	0.6302	0.6812	27735/18112/3019	0.6523							102750 [ADK (confirmed) Hypermethioninemia due to adenosine kinase deficiency,614300];	RCV000293153.1 [benign]; 			579	347					ADK (inh=AR pLI=0.32)
chr10	76468851	76468851	C	T	het	hom	wt		QUAL=3986;DP=181,46,96;MQM=60	ADK	3'UTR	ADK:NM_006721.3:3'UTR:MODIFIER:exon11/11:c.*648C>T:,ADK:NM_001202450.1:3'UTR:MODIFIER:exon10/10:c.*648C>T:,ADK:NM_001123.3:3'UTR:MODIFIER:exon11/11:c.*648C>T:,ADK:NM_001202449.1:3'UTR:MODIFIER:exon10/10:c.*648C>T:		rs1189553	0.8500	0.0000	0/0/0	0.7920							102750 [ADK (confirmed) Hypermethioninemia due to adenosine kinase deficiency,614300];	RCV000307240.1 [benign]; 			144	75					ADK (inh=AR pLI=0.32)
chr10	82031937	82031937	-	CCAGCCTGAA	het	het	wt		QUAL=5057;DP=244,204,319;MQM=59	MAT1A	3'UTR	MAT1A:NM_000429.2:3'UTR:MODIFIER:exon9/9:c.*1599_*1600insTTCAGGCTGG:		rs145159688	0.4900	0.0000	0/0/0	0.3440							610550 [MAT1A (provisional) Hypermethioninemia,persistent,autosomal dominant,due to methionine adenosyltransferase I/III deficiency,250850|Methionine adenosyltransferase deficiency,autosomal recessive,250850];	RCV000301350.1 [benign]; 			32	104					MAT1A (inh=AR+AD pLI=0.75)
chr10	82032240	82032240	A	G	het	hom	wt		QUAL=9759;DP=267,247,284;MQM=60	MAT1A	3'UTR	MAT1A:NM_000429.2:3'UTR:MODIFIER:exon9/9:c.*1297T>C:		rs1985908	0.4982	0.0000	0/0/0	0.0693							610550 [MAT1A (provisional) Hypermethioninemia,persistent,autosomal dominant,due to methionine adenosyltransferase I/III deficiency,250850|Methionine adenosyltransferase deficiency,autosomal recessive,250850];	RCV000275391.1 [benign]; 			33	92					MAT1A (inh=AR+AD pLI=0.75)
chr10	82032445	82032445	G	C	wt	wt	het		QUAL=4837;DP=380,274,343;MQM=60	MAT1A	3'UTR	MAT1A:NM_000429.2:3'UTR:MODIFIER:exon9/9:c.*1092C>G:		rs41284062	0.0290	0.0000	0/0/0	0.0105							610550 [MAT1A (provisional) Hypermethioninemia,persistent,autosomal dominant,due to methionine adenosyltransferase I/III deficiency,250850|Methionine adenosyltransferase deficiency,autosomal recessive,250850];	RCV000327212.1 [likely benign]; 			1	44					MAT1A (inh=AR+AD pLI=0.75)
chr10	82033594	82033594	G	A	het	het	het		QUAL=18954;DP=486,419,544;MQM=59	MAT1A	synonymous	MAT1A:NM_000429.2:synonymous:LOW:exon9/9:c.1131C>T:p.Tyr377Tyr		rs2993763	0.5869	0.5124	16539/6889/2909	0.5024							610550 [MAT1A (provisional) Hypermethioninemia,persistent,autosomal dominant,due to methionine adenosyltransferase I/III deficiency,250850|Methionine adenosyltransferase deficiency,autosomal recessive,250850];	RCV000247170.1 [benign]; RCV000330172.1 [benign]; 		COSM3751998	377	758					MAT1A (inh=AR+AD pLI=0.75)
chr10	82034842	82034842	A	G	het	hom	het		QUAL=3648;DP=177,30,80;MQM=59	MAT1A	synonymous	MAT1A:NM_000429.2:synonymous:LOW:exon7/9:c.882T>C:p.Ala294Ala		rs10887711	0.8405	0.7441	20007/7937/2472	0.6787							610550 [MAT1A (provisional) Hypermethioninemia,persistent,autosomal dominant,due to methionine adenosyltransferase I/III deficiency,250850|Methionine adenosyltransferase deficiency,autosomal recessive,250850];	RCV000247603.2 [benign]; RCV000397356.1 [benign]; 		COSM428025	729	639					MAT1A (inh=AR+AD pLI=0.75)
chr10	82034854	82034854	T	C	het	hom	het		QUAL=3402;DP=152,31,78;MQM=59	MAT1A	synonymous,sequence_feature	MAT1A:NM_000429.2:synonymous:LOW:exon7/9:c.870A>G:p.Val290Val,MAT1A:NM_000429.2:sequence_feature:LOW:exon7/9:c.870A>G:		rs10788546	0.8409	0.7504	26294/10521/3162	0.6868							610550 [MAT1A (provisional) Hypermethioninemia,persistent,autosomal dominant,due to methionine adenosyltransferase I/III deficiency,250850|Methionine adenosyltransferase deficiency,autosomal recessive,250850];	RCV000243664.2 [benign]; RCV000289020.1 [benign]; 			731	641					MAT1A (inh=AR+AD pLI=0.75)
chr10	82040052	82040052	A	G	hom	hom	hom		QUAL=21601;DP=165,241,297;MQM=60	MAT1A	synonymous	MAT1A:NM_000429.2:synonymous:LOW:exon5/9:c.426T>C:p.Ala142Ala		rs1143694	0.8634	0.7543	35357/14968/4554	0.7439							610550 [MAT1A (provisional) Hypermethioninemia,persistent,autosomal dominant,due to methionine adenosyltransferase I/III deficiency,250850|Methionine adenosyltransferase deficiency,autosomal recessive,250850];	RCV000251869.1 [benign]; RCV000358819.1 [benign]; 		COSM4144914	813	601					MAT1A (inh=AR+AD pLI=0.75)
chr10	82045354	82045354	G	C	wt	wt	het		QUAL=3130;DP=259,157,219;MQM=60	MAT1A	splice_region&intron,sequence_feature	MAT1A:NM_000429.2:splice_region&intron:LOW:exon1/8:c.92-9C>G:,MAT1A:NM_000429.2:sequence_feature:LOW::c.92-9C>G:		rs10887721	0.1909	0.1467	1926/681/1046	0.1441							610550 [MAT1A (provisional) Hypermethioninemia,persistent,autosomal dominant,due to methionine adenosyltransferase I/III deficiency,250850|Methionine adenosyltransferase deficiency,autosomal recessive,250850];	RCV000252376.1 [benign]; RCV000260606.1 [benign]; 			33	387					MAT1A (inh=AR+AD pLI=0.75)
chr10	82049251	82049251	-	TTTTTC	wt	wt	het		QUAL=12518;DP=125,176,216;MQM=59	MAT1A	5'UTR	MAT1A:NM_000429.2:5'UTR:MODIFIER:exon1/9:c.-73_-72insGAAAAA:	(TTC)n		0.0423	0.0000	0/0/0	0.0265							610550 [MAT1A (provisional) Hypermethioninemia,persistent,autosomal dominant,due to methionine adenosyltransferase I/III deficiency,250850|Methionine adenosyltransferase deficiency,autosomal recessive,250850];	RCV000290891.1 [likely benign]; RCV000348217.1 [uncertain significance]; RCV000296617.1 [uncertain significance]; RCV000325963.1 [benign]; RCV000382851.1 [uncertain significance]; 			0	32					MAT1A (inh=AR+AD pLI=0.75)
chr10	82049251	82049251	-	TTCTTC	hom	hom	het		QUAL=12518;DP=125,176,216;MQM=59	MAT1A	5'UTR	MAT1A:NM_000429.2:5'UTR:MODIFIER:exon1/9:c.-78_-73dupGAAGAA:	(TTC)n	rs10694757;rs145126070	0.7696	0.0000	0/0/0	0.3409							610550 [MAT1A (provisional) Hypermethioninemia,persistent,autosomal dominant,due to methionine adenosyltransferase I/III deficiency,250850|Methionine adenosyltransferase deficiency,autosomal recessive,250850];	RCV000290891.1 [likely benign]; RCV000348217.1 [uncertain significance]; RCV000296617.1 [uncertain significance]; RCV000325963.1 [benign]; RCV000382851.1 [uncertain significance]; 			86	111					MAT1A (inh=AR+AD pLI=0.75)
chr10	83637775	83637775	C	G	het	wt	hom	pred_pathogenic	QUAL=8421;DP=288,136,166;MQM=60	NRG3	missense&splice_region,intron	NRG3:NM_001165973.1:missense&splice_region:MODERATE:exon1/11:c.59C>G:p.Thr20Arg,NRG3:NM_001010848.3:intron:MODIFIER:exon1/8:c.823+1856C>G:,NRG3:NM_001165972.1:intron:MODIFIER:exon1/8:c.823+1856C>G:		rs1884282	0.1394	0.1453	244/48/39	0.0405	-0.8040	D,T,D	T	B	T,T,T	2.95				COSM146979	23	272					NRG3 (inh=n/a pLI=0.21)
chr10	84745256	84745256	C	T	wt	wt	het		QUAL=5206;DP=558,364,432;MQM=60	NRG3	synonymous	NRG3:NM_001010848.3:synonymous:LOW:exon9/9:c.1986C>T:p.Ser662Ser,NRG3:NM_001165972.1:synonymous:LOW:exon9/9:c.1983C>T:p.Ser661Ser,NRG3:NM_001165973.1:synonymous:LOW:exon11/11:c.1395C>T:p.Ser465Ser		rs2295933	0.4696	0.3802	9535/3099/973	0.3755											197	687					NRG3 (inh=n/a pLI=0.21)
chr10	84745987	84745987	C	A	wt	wt	het		QUAL=210;DP=156,21,32;MQM=60	NRG3	3'UTR	NRG3:NM_001010848.3:3'UTR:MODIFIER:exon9/9:c.*626C>A:,NRG3:NM_001165972.1:3'UTR:MODIFIER:exon9/9:c.*626C>A:,NRG3:NM_001165973.1:3'UTR:MODIFIER:exon11/11:c.*626C>A:		rs1923547	0.4455	0.0000	0/0/0	0.0656											24	100					NRG3 (inh=n/a pLI=0.21)
chr10	84746576	84746576	C	T	hom	hom	hom		QUAL=24632;DP=284,208,253;MQM=59	NRG3	3'UTR	NRG3:NM_001010848.3:3'UTR:MODIFIER:exon9/9:c.*1215C>T:,NRG3:NM_001165972.1:3'UTR:MODIFIER:exon9/9:c.*1215C>T:,NRG3:NM_001165973.1:3'UTR:MODIFIER:exon11/11:c.*1215C>T:		rs3763704	0.9307	0.0000	0/0/0	0.1456											203	26					NRG3 (inh=n/a pLI=0.21)
chr10	84746621	84746621	A	G	hom	hom	het		QUAL=23542;DP=376,222,265;MQM=60	NRG3	3'UTR	NRG3:NM_001010848.3:3'UTR:MODIFIER:exon9/9:c.*1260A>G:,NRG3:NM_001165972.1:3'UTR:MODIFIER:exon9/9:c.*1260A>G:,NRG3:NM_001165973.1:3'UTR:MODIFIER:exon11/11:c.*1260A>G:		rs8421	0.3464	0.0000	0/0/0	0.0776											72	115					NRG3 (inh=n/a pLI=0.21)
chr10	87359561	87359561	T	A	hom	wt	het	low_DP	QUAL=107;DP=6,222,8;MQM=60	GRID1,GRID1-AS1	3'UTR,intron	GRID1:NM_017551.2:3'UTR:MODIFIER:exon16/16:c.*2469A>T:,GRID1-AS1:NR_038986.1:intron:MODIFIER:exon2/2:n.282-5591T>A:	(AT)n	rs200266031	0.0000	0.0000	0/0/0	0.0017											0	25					GRID1 (inh=n/a pLI=0.95), GRID1-AS1 (inh=n/a pLI=n/a)
chr10	87359563	87359563	T	A	het	wt	wt	low_DP	QUAL=107;DP=6,222,8;MQM=60	GRID1,GRID1-AS1	3'UTR,intron	GRID1:NM_017551.2:3'UTR:MODIFIER:exon16/16:c.*2467A>T:,GRID1-AS1:NR_038986.1:intron:MODIFIER:exon2/2:n.282-5589T>A:	(AT)n	rs866354599	0.0000	0.0000	0/0/0	0.0002											0	6					GRID1 (inh=n/a pLI=0.95), GRID1-AS1 (inh=n/a pLI=n/a)
chr10	87359567	87359567	T	C	wt	wt	het	low_DP	QUAL=39;DP=7,222,4;MQM=60	GRID1,GRID1-AS1	3'UTR,intron	GRID1:NM_017551.2:3'UTR:MODIFIER:exon16/16:c.*2463A>G:,GRID1-AS1:NR_038986.1:intron:MODIFIER:exon2/2:n.282-5585T>C:	(AT)n	rs4934124	0.0349	0.0000	0/0/0	0.0185											2	10					GRID1 (inh=n/a pLI=0.95), GRID1-AS1 (inh=n/a pLI=n/a)
chr10	87359672	87359672	T	A	wt	het	wt	low_DP	QUAL=227;DP=70,13,31;MQM=53	GRID1,GRID1-AS1	3'UTR,intron	GRID1:NM_017551.2:3'UTR:MODIFIER:exon16/16:c.*2358A>T:,GRID1-AS1:NR_038986.1:intron:MODIFIER:exon2/2:n.282-5480T>A:	(TC)n		0.0000	0.0000	0/0/0	0.0001											0	1					GRID1 (inh=n/a pLI=0.95), GRID1-AS1 (inh=n/a pLI=n/a)
chr10	87359674	87359674	T	A	wt	het	wt	low_DP	QUAL=227;DP=70,13,31;MQM=53	GRID1,GRID1-AS1	3'UTR,intron	GRID1:NM_017551.2:3'UTR:MODIFIER:exon16/16:c.*2356A>T:,GRID1-AS1:NR_038986.1:intron:MODIFIER:exon2/2:n.282-5478T>A:	(TC)n	rs201262498	0.0000	0.0000	0/0/0	0.0007											0	17					GRID1 (inh=n/a pLI=0.95), GRID1-AS1 (inh=n/a pLI=n/a)
chr10	87359676	87359676	T	A	het	hom	het	low_DP	QUAL=227;DP=70,13,31;MQM=53	GRID1,GRID1-AS1	3'UTR,intron	GRID1:NM_017551.2:3'UTR:MODIFIER:exon16/16:c.*2354A>T:,GRID1-AS1:NR_038986.1:intron:MODIFIER:exon2/2:n.282-5476T>A:	(TC)n	rs12253218	0.0000	0.0000	0/0/0	0.0056											5	98					GRID1 (inh=n/a pLI=0.95), GRID1-AS1 (inh=n/a pLI=n/a)
chr10	87359697	87359697	A	C	het	wt	wt		QUAL=61;DP=70,49,72;MQM=51	GRID1,GRID1-AS1	3'UTR,intron	GRID1:NM_017551.2:3'UTR:MODIFIER:exon16/16:c.*2333T>G:,GRID1-AS1:NR_038986.1:intron:MODIFIER:exon2/2:n.282-5455A>C:	(CA)n	rs201962779	0.0000	0.0000	0/0/0	0.0033											0	53					GRID1 (inh=n/a pLI=0.95), GRID1-AS1 (inh=n/a pLI=n/a)
chr10	87359826	87359826	A	G	hom	hom	het		QUAL=12310;DP=175,121,177;MQM=59	GRID1,GRID1-AS1	3'UTR,intron	GRID1:NM_017551.2:3'UTR:MODIFIER:exon16/16:c.*2204T>C:,GRID1-AS1:NR_038986.1:intron:MODIFIER:exon2/2:n.282-5326A>G:		rs2664405	0.6500	0.0000	0/0/0	0.1015											82	116					GRID1 (inh=n/a pLI=0.95), GRID1-AS1 (inh=n/a pLI=n/a)
chr10	87360712	87360712	G	C	hom	hom	het		QUAL=20210;DP=279,225,352;MQM=59	GRID1,GRID1-AS1	3'UTR,intron	GRID1:NM_017551.2:3'UTR:MODIFIER:exon16/16:c.*1318C>G:,GRID1-AS1:NR_038986.1:intron:MODIFIER:exon2/2:n.282-4440G>C:		rs2616672	0.6506	0.0000	0/0/0	0.5870											82	116					GRID1 (inh=n/a pLI=0.95), GRID1-AS1 (inh=n/a pLI=n/a)
chr10	87360723	87360723	A	G	hom	hom	het		QUAL=20900;DP=282,241,355;MQM=59	GRID1,GRID1-AS1	3'UTR,intron	GRID1:NM_017551.2:3'UTR:MODIFIER:exon16/16:c.*1307T>C:,GRID1-AS1:NR_038986.1:intron:MODIFIER:exon2/2:n.282-4429A>G:		rs2664404	0.6506	0.0000	0/0/0	0.5926											82	116					GRID1 (inh=n/a pLI=0.95), GRID1-AS1 (inh=n/a pLI=n/a)
chr10	87361961	87361961	G	A	hom	het	het		QUAL=1983;DP=44,31,41;MQM=59	GRID1,GRID1-AS1	3'UTR,intron	GRID1:NM_017551.2:3'UTR:MODIFIER:exon16/16:c.*69C>T:,GRID1-AS1:NR_038986.1:intron:MODIFIER:exon2/2:n.282-3191G>A:	(TG)n	rs1054979	0.3618	0.0000	0/0/0	0.0588											105	227					GRID1 (inh=n/a pLI=0.95), GRID1-AS1 (inh=n/a pLI=n/a)
chr10	87675994	87675994	G	A	wt	wt	het		QUAL=5007;DP=273,247,317;MQM=60	GRID1	splice_region&synonymous	GRID1:NM_017551.2:splice_region&synonymous:LOW:exon5/16:c.729C>T:p.Ala243Ala		rs35815235	0.0315	0.0382	119/48/0	0.0364											9	151					GRID1 (inh=n/a pLI=0.95)
chr10	87898729	87898729	G	A	hom	het	het		QUAL=15879;DP=208,364,458;MQM=59	GRID1	synonymous	GRID1:NM_017551.2:synonymous:LOW:exon4/16:c.573C>T:p.Asp191Asp		rs17106320	0.1809	0.1483	1594/765/326	0.1456											44	461					GRID1 (inh=n/a pLI=0.95)
chr10	88428303	88428303	G	A	het	wt	het		QUAL=7589;DP=240,271,360;MQM=59	LDB3	5'UTR	LDB3:NM_001171610.1:5'UTR:MODIFIER:exon1/14:c.-48G>A:		rs2803556	0.0597	0.0000	0/0/0	0.0966							605906 [LDB3 (confirmed) Myopathy,myofibrillar,4,609452|Cardiomyopathy,dilated,1C,with or without LVNC,601493|Cardiomyopathy,hypertrophic,24,601493|Left ventricular noncompaction 3,601493];	RCV000126610.3 [benign]; 			1	34					LDB3 (inh=AD pLI=0.00)
chr10	88428335	88428335	T	C	hom	hom	hom		QUAL=25960;DP=143,322,388;MQM=59	LDB3	splice_region&intron,5'UTR	LDB3:NM_001171610.1:splice_region&intron:LOW:exon1/13:c.-24+8T>C:,LDB3:NM_001080116.1:5'UTR:MODIFIER:exon1/8:c.-114T>C:		rs2803558	0.7522	0.0000	0/0/0	0.6847							605906 [LDB3 (confirmed) Myopathy,myofibrillar,4,609452|Cardiomyopathy,dilated,1C,with or without LVNC,601493|Cardiomyopathy,hypertrophic,24,601493|Left ventricular noncompaction 3,601493];	RCV000126612.2 [benign]; RCV000308499.1 [likely benign]; RCV000370149.1 [likely benign]; RCV000393181.1 [likely benign]; RCV000393189.1 [likely benign]; 			119	93					LDB3 (inh=AD pLI=0.00)
chr10	88494752	88494752	A	-	hom	hom	hom		QUAL=2860;DP=102,28,45;MQM=59	LDB3	3'UTR	LDB3:NM_001171610.1:3'UTR:MODIFIER:exon14/14:c.*2033delA:,LDB3:NM_001080114.1:3'UTR:MODIFIER:exon13/13:c.*2033delA:,LDB3:NM_007078.2:3'UTR:MODIFIER:exon13/13:c.*2033delA:		rs11314847;rs571839799;rs753169910	0.8584	0.0000	0/0/0	0.4180							605906 [LDB3 (confirmed) Myopathy,myofibrillar,4,609452|Cardiomyopathy,dilated,1C,with or without LVNC,601493|Cardiomyopathy,hypertrophic,24,601493|Left ventricular noncompaction 3,601493];				19	190					LDB3 (inh=AD pLI=0.00)
chr10	88494809	88494809	-	AC	hom	hom	hom	low_DP	QUAL=396;DP=21,3,7;MQM=57	LDB3	3'UTR	LDB3:NM_001171610.1:3'UTR:MODIFIER:exon14/14:c.*2123_*2124dupAC:,LDB3:NM_001080114.1:3'UTR:MODIFIER:exon13/13:c.*2123_*2124dupAC:,LDB3:NM_007078.2:3'UTR:MODIFIER:exon13/13:c.*2123_*2124dupAC:			0.0000	0.0000	0/0/0	0.0001							605906 [LDB3 (confirmed) Myopathy,myofibrillar,4,609452|Cardiomyopathy,dilated,1C,with or without LVNC,601493|Cardiomyopathy,hypertrophic,24,601493|Left ventricular noncompaction 3,601493];				0	2					LDB3 (inh=AD pLI=0.00)
chr10	89623716	89623716	G	A	het	wt	het	low_DP	QUAL=125;DP=3,10,11;MQM=60	PTEN	missense,5'UTR	PTEN:NM_001304717.2:missense:MODERATE:exon1/10:c.10G>A:p.Gly4Arg,PTEN:NM_000314.6:5'UTR:MODIFIER:exon1/9:c.-511G>A:,PTEN:NM_001304718.1:5'UTR:MODIFIER:exon1/9:c.-1216G>A:	(GGC)n	rs12573787	0.1603	0.0000	0/0/0	0.1632							601728 [PTEN (confirmed) Cowden syndrome 1,158350|Lhermitte-Duclos syndrome,158350|Bannayan-Riley-Ruvalcaba syndrome,153480|Meningioma,607174|Glioma susceptibility 2,613028|Macrocephaly/autism syndrome,605309|PTEN hamartoma tumor syndrome|VATER association with macrocephaly and ventriculomegaly,276950|Prostate cancer,somatic,176807|Malignant melanoma,somatic,155600|Endometrial carcinoma,somatic,608089|Squamous cell carcinoma,head and neck,somatic,275355];				2	27					PTEN (inh=AD pLI=0.98)
chr10	89623861	89623861	T	-	hom	hom	hom	low_DP;anno_high_impact	QUAL=1192;DP=4,16,22;MQM=58	PTEN	splice_acceptor&splice_donor,5'UTR	PTEN:NM_001304717.2:splice_acceptor&splice_donor:HIGH:exon1/9:c.154+1delT:,PTEN:NM_000314.6:5'UTR:MODIFIER:exon1/9:c.-366delT:,PTEN:NM_001304718.1:5'UTR:MODIFIER:exon1/9:c.-1071delT:	(CGG)n	rs71022512	1.0000	0.0000	0/0/0	0.4537							601728 [PTEN (confirmed) Cowden syndrome 1,158350|Lhermitte-Duclos syndrome,158350|Bannayan-Riley-Ruvalcaba syndrome,153480|Meningioma,607174|Glioma susceptibility 2,613028|Macrocephaly/autism syndrome,605309|PTEN hamartoma tumor syndrome|VATER association with macrocephaly and ventriculomegaly,276950|Prostate cancer,somatic,176807|Malignant melanoma,somatic,155600|Endometrial carcinoma,somatic,608089|Squamous cell carcinoma,head and neck,somatic,275355];				211	7	1	[1] auto-classification 16.06.2016  			PTEN (inh=AD pLI=0.98)
chr10	89623901	89623901	G	C	hom	hom	hom	low_DP	QUAL=1757;DP=25,16,22;MQM=50	PTEN	missense,5'UTR	PTEN:NM_001304717.2:missense:MODERATE:exon2/10:c.194G>C:p.Cys65Ser,PTEN:NM_000314.6:5'UTR:MODIFIER:exon1/9:c.-326G>C:,PTEN:NM_001304718.1:5'UTR:MODIFIER:exon1/9:c.-1031G>C:		rs2943772	1.0000	0.0000	0/0/0	0.5228							601728 [PTEN (confirmed) Cowden syndrome 1,158350|Lhermitte-Duclos syndrome,158350|Bannayan-Riley-Ruvalcaba syndrome,153480|Meningioma,607174|Glioma susceptibility 2,613028|Macrocephaly/autism syndrome,605309|PTEN hamartoma tumor syndrome|VATER association with macrocephaly and ventriculomegaly,276950|Prostate cancer,somatic,176807|Malignant melanoma,somatic,155600|Endometrial carcinoma,somatic,608089|Squamous cell carcinoma,head and neck,somatic,275355];				235	2					PTEN (inh=AD pLI=0.98)
chr10	89726745	89726745	T	C	wt	het	wt		QUAL=446;DP=340,56,78;MQM=60	PTEN	3'UTR	PTEN:NM_001304717.2:3'UTR:MODIFIER:exon10/10:c.*1516T>C:,PTEN:NM_000314.6:3'UTR:MODIFIER:exon9/9:c.*1516T>C:,PTEN:NM_001304718.1:3'UTR:MODIFIER:exon9/9:c.*1516T>C:		rs701848	0.3734	0.0000	0/0/0	0.0658							601728 [PTEN (confirmed) Cowden syndrome 1,158350|Lhermitte-Duclos syndrome,158350|Bannayan-Riley-Ruvalcaba syndrome,153480|Meningioma,607174|Glioma susceptibility 2,613028|Macrocephaly/autism syndrome,605309|PTEN hamartoma tumor syndrome|VATER association with macrocephaly and ventriculomegaly,276950|Prostate cancer,somatic,176807|Malignant melanoma,somatic,155600|Endometrial carcinoma,somatic,608089|Squamous cell carcinoma,head and neck,somatic,275355];	RCV000301364.1 [benign]; 			42	117					PTEN (inh=AD pLI=0.98)
chr10	90771829	90771829	T	C	het	hom	wt		QUAL=9521;DP=300,154,234;MQM=60	FAS	sequence_feature,synonymous,intron,non_coding_transcript_exon	FAS:NM_000043.5:sequence_feature:MODERATE:exon7/9:c.642T>C:,FAS:NM_152871.3:sequence_feature:MODERATE:exon6/8:c.579T>C:,FAS:NM_152872.3:sequence_feature:MODERATE:exon7/8:c.642T>C:,FAS:NM_000043.5:synonymous:LOW:exon7/9:c.642T>C:p.Thr214Thr,FAS:NM_152871.3:synonymous:LOW:exon6/8:c.579T>C:p.Thr193Thr,FAS:NM_152872.3:synonymous:LOW:exon7/8:c.642T>C:p.Thr214Thr,FAS:NM_001320619.1:intron:MODIFIER:exon6/7:c.568+1257T>C:,FAS:NR_135313.1:intron:MODIFIER:exon5/6:n.777+1257T>C:,FAS:NR_028033.3:non_coding_transcript_exon:MODIFIER:exon5/7:n.788T>C:,FAS:NR_028034.3:non_coding_transcript_exon:MODIFIER:exon4/6:n.650T>C:,FAS:NR_028035.3:non_coding_transcript_exon:MODIFIER:exon5/7:n.713T>C:,FAS:NR_028036.3:non_coding_transcript_exon:MODIFIER:exon6/8:n.851T>C:,FAS:NR_135314.1:non_coding_transcript_exon:MODIFIER:exon7/9:n.951T>C:,FAS:NR_135315.1:non_coding_transcript_exon:MODIFIER:exon5/7:n.704T>C:		rs2234978	0.7754	0.7561	35133/16231/2363	0.7408							134637 [FAS (confirmed) Autoimmune lymphoproliferative syndrome,601859|Squamous cell carcinoma,burn scar-related,somatic|Autoimmune lymphoproliferative syndrome,type IA,601859];	RCV000244361.1 [benign]; RCV000284596.1 [benign]; 	CM045201 [CLASS=DP MUT=REF PHEN="Thyroid carcinoma association with" GENE=FAS]; 		833	599					FAS (inh=AD pLI=0.73)
chr10	95552653	95552653	T	C	hom	hom	hom		QUAL=20561;DP=264,165,212;MQM=60	LGI1	synonymous,non_coding_transcript_exon	LGI1:NM_005097.3:synonymous:LOW:exon6/8:c.657T>C:p.Phe219Phe,LGI1:NM_001308275.1:synonymous:LOW:exon6/8:c.657T>C:p.Phe219Phe,LGI1:NM_001308276.1:synonymous:LOW:exon4/6:c.513T>C:p.Phe171Phe,LGI1:NR_131777.1:non_coding_transcript_exon:MODIFIER:exon4/6:n.921T>C:		rs1111820	0.9774	0.9928	59851/33261/4529	0.9551							604619 [LGI1 (confirmed) Epilepsy,familial temporal lobe,1,600512];	RCV000232651.1 [likely benign]; 			1560	5					LGI1 (inh=AD pLI=1.00)
chr10	95753822	95753822	A	G	wt	het	wt	low_DP	QUAL=184;DP=8,29,30;MQM=60	PLCE1	5'UTR_premature_start_codon_gain,5'UTR	PLCE1:NM_016341.3:5'UTR_premature_start_codon_gain:LOW:exon1/33:c.-558A>G:,PLCE1:NM_001288989.1:5'UTR_premature_start_codon_gain:LOW:exon1/33:c.-558A>G:,PLCE1:NM_016341.3:5'UTR:MODIFIER:exon1/33:c.-558A>G:,PLCE1:NM_001288989.1:5'UTR:MODIFIER:exon1/33:c.-558A>G:		rs2911857	0.5525	0.0000	0/0/0	0.3182							608414 [PLCE1 (confirmed) Nephrotic syndrome,type 3,610725];	RCV000316756.1 [benign]; 			15	63					PLCE1 (inh=AR pLI=0.20)
chr10	95892129	95892129	T	A	het	het	wt	pred_pathogenic	QUAL=15012;DP=609,658,768;MQM=60	PLCE1	missense	PLCE1:NM_016341.3:missense:MODERATE:exon3/33:c.1405T>A:p.Ser469Thr,PLCE1:NM_001288989.1:missense:MODERATE:exon3/33:c.1405T>A:p.Ser469Thr,PLCE1:NM_001165979.2:missense:MODERATE:exon2/32:c.481T>A:p.Ser161Thr		rs17508082	0.0172	0.0313	85/74/0	0.0309	3.4920	D,D,D,D	T	B,B,B	T,T,T,T	21.60	608414 [PLCE1 (confirmed) Nephrotic syndrome,type 3,610725];	RCV000250368.1 [benign]; RCV000302907.1 [likely benign]; 			9	153					PLCE1 (inh=AR pLI=0.20)
chr10	95931087	95931087	G	T	wt	wt	het	pred_pathogenic;anno_pathogenic_hgmd	QUAL=8463;DP=457,606,695;MQM=60	PLCE1	missense	PLCE1:NM_016341.3:missense:MODERATE:exon4/33:c.1643G>T:p.Arg548Leu,PLCE1:NM_001288989.1:missense:MODERATE:exon4/33:c.1643G>T:p.Arg548Leu,PLCE1:NM_001165979.2:missense:MODERATE:exon3/32:c.719G>T:p.Arg240Leu		rs17417407	0.2011	0.1782	2283/983/189	0.1752	4.6710	D,D,T,T	T	D,P,D	T,T,T,T	28.80	608414 [PLCE1 (confirmed) Nephrotic syndrome,type 3,610725];	RCV000242119.1 [benign]; RCV000269488.1 [benign]; 	CM1512225 [CLASS=DM? MUT=ALT PHEN="Nephrotic syndrome steroid resistant" GENE=PLCE1]; 	COSM3752063, COSM3752065, COSM3752064	83	443					PLCE1 (inh=AR pLI=0.20)
chr10	96039597	96039597	G	C	het	het	wt		QUAL=7484;DP=306,336,490;MQM=59	PLCE1,PLCE1-AS1	missense,non_coding_transcript_exon	PLCE1:NM_016341.3:missense:MODERATE:exon20/33:c.4724G>C:p.Arg1575Pro,PLCE1:NM_001288989.1:missense:MODERATE:exon20/33:c.4676G>C:p.Arg1559Pro,PLCE1:NM_001165979.2:missense:MODERATE:exon19/32:c.3800G>C:p.Arg1267Pro,PLCE1-AS1:NR_033969.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.858C>G:		rs2274224	0.4862	0.4378	11866/6347/1515	0.4156	0.7950	T,T,T,T	T	B,B,B	T,T,T,T	13.37	608414 [PLCE1 (confirmed) Nephrotic syndrome,type 3,610725];	RCV000254331.1 [benign]; RCV000394591.1 [benign]; 	CM1314035 [CLASS=DP MUT=REF PHEN="Oesophageal squamous cell carcinoma reduced risk" GENE=PLCE1]; 		383	774					PLCE1 (inh=AR pLI=0.20), PLCE1-AS1 (inh=n/a pLI=n/a)
chr10	96058298	96058298	C	T	het	het	wt	pred_pathogenic	QUAL=8558;DP=408,306,398;MQM=60	PLCE1	missense	PLCE1:NM_016341.3:missense:MODERATE:exon24/33:c.5330C>T:p.Thr1777Ile,PLCE1:NM_001288989.1:missense:MODERATE:exon24/33:c.5282C>T:p.Thr1761Ile,PLCE1:NM_001165979.2:missense:MODERATE:exon23/32:c.4406C>T:p.Thr1469Ile		rs3765524	0.3079	0.2711	4911/2783/909	0.2686	5.1480	T,T,T,T	T	B,B,B	T,T,T,T	13.94	608414 [PLCE1 (confirmed) Nephrotic syndrome,type 3,610725];	RCV000245651.1 [benign]; RCV000354149.1 [benign]; 	CM105437 [CLASS=DP MUT=ALT PHEN="Gastric adenocarcinoma and oesophageal SCC association with" GENE=PLCE1]; 		188	688					PLCE1 (inh=AR pLI=0.20)
chr10	96058433	96058433	G	A	het	het	wt		QUAL=5680;DP=231,239,300;MQM=60	PLCE1	splice_region&intron	PLCE1:NM_016341.3:splice_region&intron:LOW:exon24/32:c.5458+7G>A:,PLCE1:NM_001288989.1:splice_region&intron:LOW:exon24/32:c.5410+7G>A:,PLCE1:NM_001165979.2:splice_region&intron:LOW:exon23/31:c.4534+7G>A:		rs17516758	0.1068	0.1372	1360/876/45	0.1332							608414 [PLCE1 (confirmed) Nephrotic syndrome,type 3,610725];	RCV000250395.1 [benign]; RCV000266326.1 [likely benign]; 			60	481					PLCE1 (inh=AR pLI=0.20)
chr10	96066341	96066341	A	G	het	het	wt	pred_pathogenic	QUAL=8447;DP=355,281,366;MQM=60	PLCE1	missense	PLCE1:NM_016341.3:missense:MODERATE:exon26/33:c.5780A>G:p.His1927Arg,PLCE1:NM_001288989.1:missense:MODERATE:exon26/33:c.5732A>G:p.His1911Arg,PLCE1:NM_001165979.2:missense:MODERATE:exon25/32:c.4856A>G:p.His1619Arg		rs2274223	0.2985	0.2846	5213/3247/609	0.2829	3.0200	T,T,T,T	T	B,B,B	T,T,T,T	4.78	608414 [PLCE1 (confirmed) Nephrotic syndrome,type 3,610725];	RCV000250112.1 [benign]; RCV000376111.1 [benign]; 	CM105436 [CLASS=DP MUT=ALT PHEN="Gastric adenocarcinoma and oesophageal SCC association with" GENE=PLCE1]; 		208	716					PLCE1 (inh=AR pLI=0.20)
chr10	96087728	96087728	A	G	het	het	wt	pred_pathogenic	QUAL=3905;DP=247,78,95;MQM=60	PLCE1	3'UTR	PLCE1:NM_016341.3:3'UTR:MODIFIER:exon33/33:c.*28A>G:,PLCE1:NM_001288989.1:3'UTR:MODIFIER:exon33/33:c.*28A>G:,PLCE1:NM_001165979.2:3'UTR:MODIFIER:exon32/32:c.*28A>G:		rs3203713	0.1054	0.1453	1214/780/45	0.1273	2.1340	T	T			13.74	608414 [PLCE1 (confirmed) Nephrotic syndrome,type 3,610725];	RCV000292908.1 [likely benign]; 			43	352					PLCE1 (inh=AR pLI=0.20)
chr10	97365820	97365820	G	A	het	het	het		QUAL=5482;DP=219,75,109;MQM=60	ALDH18A1	3'UTR	ALDH18A1:NM_001323413.1:3'UTR:MODIFIER:exon18/18:c.*699C>T:,ALDH18A1:NM_001323414.1:3'UTR:MODIFIER:exon18/18:c.*699C>T:,ALDH18A1:NM_001017423.1:3'UTR:MODIFIER:exon18/18:c.*699C>T:,ALDH18A1:NM_001323412.1:3'UTR:MODIFIER:exon17/17:c.*699C>T:,ALDH18A1:NM_001323415.1:3'UTR:MODIFIER:exon18/18:c.*699C>T:,ALDH18A1:NM_001323416.1:3'UTR:MODIFIER:exon17/17:c.*699C>T:,ALDH18A1:NM_001323417.1:3'UTR:MODIFIER:exon17/17:c.*699C>T:,ALDH18A1:NM_001323418.1:3'UTR:MODIFIER:exon17/17:c.*699C>T:,ALDH18A1:NM_001323419.1:3'UTR:MODIFIER:exon15/15:c.*699C>T:,ALDH18A1:NM_002860.3:3'UTR:MODIFIER:exon18/18:c.*699C>T:		rs4037	0.2005	0.0000	0/0/0	0.0498							138250 [ALDH18A1 (confirmed) Cutis laxa,autosomal recessive,type IIIA,219150|Spastic paraplegia 9A,autosomal dominant,601162|Spastic paraplegia 9B,autosomal recessive,616586|Cutis laxa,autosomal dominant 3,616603];	RCV000273322.1 [benign]; 			24	108					ALDH18A1 (inh=AR+AD pLI=0.86)
chr10	97366107	97366107	A	G	wt	het	wt		QUAL=421;DP=108,49,55;MQM=60	ALDH18A1	3'UTR	ALDH18A1:NM_001323413.1:3'UTR:MODIFIER:exon18/18:c.*412T>C:,ALDH18A1:NM_001323414.1:3'UTR:MODIFIER:exon18/18:c.*412T>C:,ALDH18A1:NM_001017423.1:3'UTR:MODIFIER:exon18/18:c.*412T>C:,ALDH18A1:NM_001323412.1:3'UTR:MODIFIER:exon17/17:c.*412T>C:,ALDH18A1:NM_001323415.1:3'UTR:MODIFIER:exon18/18:c.*412T>C:,ALDH18A1:NM_001323416.1:3'UTR:MODIFIER:exon17/17:c.*412T>C:,ALDH18A1:NM_001323417.1:3'UTR:MODIFIER:exon17/17:c.*412T>C:,ALDH18A1:NM_001323418.1:3'UTR:MODIFIER:exon17/17:c.*412T>C:,ALDH18A1:NM_001323419.1:3'UTR:MODIFIER:exon15/15:c.*412T>C:,ALDH18A1:NM_002860.3:3'UTR:MODIFIER:exon18/18:c.*412T>C:		rs8758	0.2001	0.0000	0/0/0	0.0500							138250 [ALDH18A1 (confirmed) Cutis laxa,autosomal recessive,type IIIA,219150|Spastic paraplegia 9A,autosomal dominant,601162|Spastic paraplegia 9B,autosomal recessive,616586|Cutis laxa,autosomal dominant 3,616603];	RCV000275740.1 [benign]; 			23	105					ALDH18A1 (inh=AR+AD pLI=0.86)
chr10	97366364	97366364	C	T	het	het	hom		QUAL=6119;DP=208,63,86;MQM=60	ALDH18A1	3'UTR	ALDH18A1:NM_001323413.1:3'UTR:MODIFIER:exon18/18:c.*155G>A:,ALDH18A1:NM_001323414.1:3'UTR:MODIFIER:exon18/18:c.*155G>A:,ALDH18A1:NM_001017423.1:3'UTR:MODIFIER:exon18/18:c.*155G>A:,ALDH18A1:NM_001323412.1:3'UTR:MODIFIER:exon17/17:c.*155G>A:,ALDH18A1:NM_001323415.1:3'UTR:MODIFIER:exon18/18:c.*155G>A:,ALDH18A1:NM_001323416.1:3'UTR:MODIFIER:exon17/17:c.*155G>A:,ALDH18A1:NM_001323417.1:3'UTR:MODIFIER:exon17/17:c.*155G>A:,ALDH18A1:NM_001323418.1:3'UTR:MODIFIER:exon17/17:c.*155G>A:,ALDH18A1:NM_001323419.1:3'UTR:MODIFIER:exon15/15:c.*155G>A:,ALDH18A1:NM_002860.3:3'UTR:MODIFIER:exon18/18:c.*155G>A:		rs1053905	0.2979	0.0000	0/0/0	0.0874							138250 [ALDH18A1 (confirmed) Cutis laxa,autosomal recessive,type IIIA,219150|Spastic paraplegia 9A,autosomal dominant,601162|Spastic paraplegia 9B,autosomal recessive,616586|Cutis laxa,autosomal dominant 3,616603];	RCV000336778.1 [benign]; 			64	124					ALDH18A1 (inh=AR+AD pLI=0.86)
chr10	97388162	97388162	G	A	het	wt	hom	pred_pathogenic	QUAL=11993;DP=284,227,265;MQM=60	ALDH18A1	missense	ALDH18A1:NM_001323413.1:missense:MODERATE:exon8/18:c.896C>T:p.Thr299Ile,ALDH18A1:NM_001323414.1:missense:MODERATE:exon8/18:c.896C>T:p.Thr299Ile,ALDH18A1:NM_001017423.1:missense:MODERATE:exon8/18:c.890C>T:p.Thr297Ile,ALDH18A1:NM_001323412.1:missense:MODERATE:exon7/17:c.563C>T:p.Thr188Ile,ALDH18A1:NM_001323415.1:missense:MODERATE:exon8/18:c.890C>T:p.Thr297Ile,ALDH18A1:NM_001323416.1:missense:MODERATE:exon7/17:c.563C>T:p.Thr188Ile,ALDH18A1:NM_001323417.1:missense:MODERATE:exon7/17:c.791C>T:p.Thr264Ile,ALDH18A1:NM_001323418.1:missense:MODERATE:exon7/17:c.557C>T:p.Thr186Ile,ALDH18A1:NM_001323419.1:missense:MODERATE:exon5/15:c.260C>T:p.Thr87Ile,ALDH18A1:NM_002860.3:missense:MODERATE:exon8/18:c.896C>T:p.Thr299Ile		rs2275272	0.0717	0.1030	782/603/10	0.1021	6.1520	T,D	T	B,B	T,T	25.40	138250 [ALDH18A1 (confirmed) Cutis laxa,autosomal recessive,type IIIA,219150|Spastic paraplegia 9A,autosomal dominant,601162|Spastic paraplegia 9B,autosomal recessive,616586|Cutis laxa,autosomal dominant 3,616603];	RCV000243312.1 [benign]; RCV000346020.1 [likely benign]; 			39	386					ALDH18A1 (inh=AR+AD pLI=0.86)
chr10	97515949	97515949	G	T	het	wt	het		QUAL=7343;DP=357,208,242;MQM=60	ENTPD1,ENTPD1-AS1	5'UTR_premature_start_codon_gain,5'UTR,intron,non_coding_transcript_exon	ENTPD1:NM_001164179.1:5'UTR_premature_start_codon_gain:LOW:exon1/10:c.-48G>T:,ENTPD1:NM_001164182.1:5'UTR_premature_start_codon_gain:LOW:exon1/9:c.-311G>T:,ENTPD1:NM_001164183.1:5'UTR_premature_start_codon_gain:LOW:exon1/8:c.-193G>T:,ENTPD1:NM_001776.5:5'UTR_premature_start_codon_gain:LOW:exon1/10:c.-48G>T:,ENTPD1:NM_001164179.1:5'UTR:MODIFIER:exon1/10:c.-48G>T:,ENTPD1:NM_001164182.1:5'UTR:MODIFIER:exon1/9:c.-311G>T:,ENTPD1:NM_001164183.1:5'UTR:MODIFIER:exon1/8:c.-193G>T:,ENTPD1:NM_001776.5:5'UTR:MODIFIER:exon1/10:c.-48G>T:,ENTPD1:NM_001164178.1:intron:MODIFIER:exon1/9:c.52+426G>T:,ENTPD1:NM_001098175.1:intron:MODIFIER:exon1/9:c.37+44199G>T:,ENTPD1:NM_001164181.1:intron:MODIFIER:exon1/8:c.-181+426G>T:,ENTPD1:NM_001312654.1:intron:MODIFIER:exon1/9:c.-355+426G>T:,ENTPD1:NM_001320916.1:intron:MODIFIER:exon1/9:c.52+426G>T:,ENTPD1-AS1:NR_038444.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.1276C>A:		rs200451742	0.0004	0.0013	0/0/0	0.0005							601752 [ENTPD1 (provisional) Spastic paraplegia 64,autosomal recessive,615683];				0	4					ENTPD1 (inh=AR pLI=0.52), ENTPD1-AS1 (inh=n/a pLI=n/a)
chr10	97628170	97628170	T	C	het	wt	hom		QUAL=18965;DP=469,287,385;MQM=59	ENTPD1,ENTPD1-AS1	3'UTR,intron	ENTPD1:NM_001164178.1:3'UTR:MODIFIER:exon10/10:c.*2030T>C:,ENTPD1:NM_001098175.1:3'UTR:MODIFIER:exon10/10:c.*2030T>C:,ENTPD1:NM_001164181.1:3'UTR:MODIFIER:exon9/9:c.*2030T>C:,ENTPD1:NM_001312654.1:3'UTR:MODIFIER:exon10/10:c.*2030T>C:,ENTPD1:NM_001164179.1:3'UTR:MODIFIER:exon10/10:c.*2030T>C:,ENTPD1:NM_001164182.1:3'UTR:MODIFIER:exon9/9:c.*2030T>C:,ENTPD1:NM_001164183.1:3'UTR:MODIFIER:exon8/8:c.*2030T>C:,ENTPD1:NM_001776.5:3'UTR:MODIFIER:exon10/10:c.*2030T>C:,ENTPD1-AS1:NR_038444.1:intron:MODIFIER:exon3/5:n.439+8105A>G:,ENTPD1:NM_001320916.1:intron:MODIFIER:exon9/9:c.1362+3552T>C:		rs3181115	0.0499	0.0000	0/0/0	0.0133							601752 [ENTPD1 (provisional) Spastic paraplegia 64,autosomal recessive,615683];				4	54					ENTPD1 (inh=AR pLI=0.52), ENTPD1-AS1 (inh=n/a pLI=n/a)
chr10	97628994	97628994	A	G	wt	het	wt	low_DP	QUAL=117;DP=45,11,13;MQM=60	ENTPD1,ENTPD1-AS1	3'UTR,intron	ENTPD1:NM_001164178.1:3'UTR:MODIFIER:exon10/10:c.*2854A>G:,ENTPD1:NM_001098175.1:3'UTR:MODIFIER:exon10/10:c.*2854A>G:,ENTPD1:NM_001164181.1:3'UTR:MODIFIER:exon9/9:c.*2854A>G:,ENTPD1:NM_001312654.1:3'UTR:MODIFIER:exon10/10:c.*2854A>G:,ENTPD1:NM_001164179.1:3'UTR:MODIFIER:exon10/10:c.*2854A>G:,ENTPD1:NM_001164182.1:3'UTR:MODIFIER:exon9/9:c.*2854A>G:,ENTPD1:NM_001164183.1:3'UTR:MODIFIER:exon8/8:c.*2854A>G:,ENTPD1:NM_001776.5:3'UTR:MODIFIER:exon10/10:c.*2854A>G:,ENTPD1-AS1:NR_038444.1:intron:MODIFIER:exon3/5:n.439+7281T>C:,ENTPD1:NM_001320916.1:intron:MODIFIER:exon9/9:c.1362+4376A>G:		rs2226163	0.4756	0.0000	0/0/0	0.2443							601752 [ENTPD1 (provisional) Spastic paraplegia 64,autosomal recessive,615683];				36	71					ENTPD1 (inh=AR pLI=0.52), ENTPD1-AS1 (inh=n/a pLI=n/a)
chr10	97630523	97630523	C	T	het	het	hom		QUAL=18962;DP=400,250,336;MQM=60	ENTPD1,ENTPD1-AS1	3'UTR,intron	ENTPD1:NM_001164178.1:3'UTR:MODIFIER:exon10/10:c.*4383C>T:,ENTPD1:NM_001098175.1:3'UTR:MODIFIER:exon10/10:c.*4383C>T:,ENTPD1:NM_001164181.1:3'UTR:MODIFIER:exon9/9:c.*4383C>T:,ENTPD1:NM_001312654.1:3'UTR:MODIFIER:exon10/10:c.*4383C>T:,ENTPD1:NM_001164179.1:3'UTR:MODIFIER:exon10/10:c.*4383C>T:,ENTPD1:NM_001164182.1:3'UTR:MODIFIER:exon9/9:c.*4383C>T:,ENTPD1:NM_001164183.1:3'UTR:MODIFIER:exon8/8:c.*4383C>T:,ENTPD1:NM_001776.5:3'UTR:MODIFIER:exon10/10:c.*4383C>T:,ENTPD1-AS1:NR_038444.1:intron:MODIFIER:exon3/5:n.439+5752G>A:,ENTPD1:NM_001320916.1:intron:MODIFIER:exon9/9:c.1363-5763C>T:		rs10736094	0.5841	0.0000	0/0/0	0.6183							601752 [ENTPD1 (provisional) Spastic paraplegia 64,autosomal recessive,615683];				98	99					ENTPD1 (inh=AR pLI=0.52), ENTPD1-AS1 (inh=n/a pLI=n/a)
chr10	97631051	97631051	T	C	het	het	hom		QUAL=12960;DP=411,131,171;MQM=59	ENTPD1,ENTPD1-AS1	3'UTR,intron	ENTPD1:NM_001164178.1:3'UTR:MODIFIER:exon10/10:c.*4911T>C:,ENTPD1:NM_001098175.1:3'UTR:MODIFIER:exon10/10:c.*4911T>C:,ENTPD1:NM_001164181.1:3'UTR:MODIFIER:exon9/9:c.*4911T>C:,ENTPD1:NM_001312654.1:3'UTR:MODIFIER:exon10/10:c.*4911T>C:,ENTPD1:NM_001164179.1:3'UTR:MODIFIER:exon10/10:c.*4911T>C:,ENTPD1:NM_001164182.1:3'UTR:MODIFIER:exon9/9:c.*4911T>C:,ENTPD1:NM_001164183.1:3'UTR:MODIFIER:exon8/8:c.*4911T>C:,ENTPD1:NM_001776.5:3'UTR:MODIFIER:exon10/10:c.*4911T>C:,ENTPD1-AS1:NR_038444.1:intron:MODIFIER:exon3/5:n.439+5224A>G:,ENTPD1:NM_001320916.1:intron:MODIFIER:exon9/9:c.1363-5235T>C:		rs2153914	0.5865	0.0000	0/0/0	0.6182							601752 [ENTPD1 (provisional) Spastic paraplegia 64,autosomal recessive,615683];				98	100					ENTPD1 (inh=AR pLI=0.52), ENTPD1-AS1 (inh=n/a pLI=n/a)
chr10	97631172	97631172	A	C	het	wt	hom		QUAL=11223;DP=361,150,208;MQM=60	ENTPD1,ENTPD1-AS1	3'UTR,intron	ENTPD1:NM_001164178.1:3'UTR:MODIFIER:exon10/10:c.*5032A>C:,ENTPD1:NM_001098175.1:3'UTR:MODIFIER:exon10/10:c.*5032A>C:,ENTPD1:NM_001164181.1:3'UTR:MODIFIER:exon9/9:c.*5032A>C:,ENTPD1:NM_001312654.1:3'UTR:MODIFIER:exon10/10:c.*5032A>C:,ENTPD1:NM_001164179.1:3'UTR:MODIFIER:exon10/10:c.*5032A>C:,ENTPD1:NM_001164182.1:3'UTR:MODIFIER:exon9/9:c.*5032A>C:,ENTPD1:NM_001164183.1:3'UTR:MODIFIER:exon8/8:c.*5032A>C:,ENTPD1:NM_001776.5:3'UTR:MODIFIER:exon10/10:c.*5032A>C:,ENTPD1-AS1:NR_038444.1:intron:MODIFIER:exon3/5:n.439+5103T>G:,ENTPD1:NM_001320916.1:intron:MODIFIER:exon9/9:c.1363-5114A>C:		rs34630379	0.0541	0.0000	0/0/0	0.0829							601752 [ENTPD1 (provisional) Spastic paraplegia 64,autosomal recessive,615683];				4	54					ENTPD1 (inh=AR pLI=0.52), ENTPD1-AS1 (inh=n/a pLI=n/a)
chr10	97631492	97631492	T	A	wt	het	wt		QUAL=2242;DP=455,161,217;MQM=60	ENTPD1,ENTPD1-AS1	3'UTR,intron	ENTPD1:NM_001164178.1:3'UTR:MODIFIER:exon10/10:c.*5352T>A:,ENTPD1:NM_001098175.1:3'UTR:MODIFIER:exon10/10:c.*5352T>A:,ENTPD1:NM_001164181.1:3'UTR:MODIFIER:exon9/9:c.*5352T>A:,ENTPD1:NM_001312654.1:3'UTR:MODIFIER:exon10/10:c.*5352T>A:,ENTPD1:NM_001164179.1:3'UTR:MODIFIER:exon10/10:c.*5352T>A:,ENTPD1:NM_001164182.1:3'UTR:MODIFIER:exon9/9:c.*5352T>A:,ENTPD1:NM_001164183.1:3'UTR:MODIFIER:exon8/8:c.*5352T>A:,ENTPD1:NM_001776.5:3'UTR:MODIFIER:exon10/10:c.*5352T>A:,ENTPD1-AS1:NR_038444.1:intron:MODIFIER:exon3/5:n.439+4783A>T:,ENTPD1:NM_001320916.1:intron:MODIFIER:exon9/9:c.1363-4794T>A:		rs1935815	0.1933	0.0000	0/0/0	0.2855							601752 [ENTPD1 (provisional) Spastic paraplegia 64,autosomal recessive,615683];				24	108					ENTPD1 (inh=AR pLI=0.52), ENTPD1-AS1 (inh=n/a pLI=n/a)
chr10	97632082	97632082	C	T	wt	het	wt		QUAL=4622;DP=514,344,533;MQM=60	ENTPD1,ENTPD1-AS1	3'UTR,intron	ENTPD1:NM_001164178.1:3'UTR:MODIFIER:exon10/10:c.*5942C>T:,ENTPD1:NM_001098175.1:3'UTR:MODIFIER:exon10/10:c.*5942C>T:,ENTPD1:NM_001164181.1:3'UTR:MODIFIER:exon9/9:c.*5942C>T:,ENTPD1:NM_001312654.1:3'UTR:MODIFIER:exon10/10:c.*5942C>T:,ENTPD1:NM_001164179.1:3'UTR:MODIFIER:exon10/10:c.*5942C>T:,ENTPD1:NM_001164182.1:3'UTR:MODIFIER:exon9/9:c.*5942C>T:,ENTPD1:NM_001164183.1:3'UTR:MODIFIER:exon8/8:c.*5942C>T:,ENTPD1:NM_001776.5:3'UTR:MODIFIER:exon10/10:c.*5942C>T:,ENTPD1-AS1:NR_038444.1:intron:MODIFIER:exon3/5:n.439+4193G>A:,ENTPD1:NM_001320916.1:intron:MODIFIER:exon9/9:c.1363-4204C>T:	L2c	rs2051052	0.4972	0.0000	0/0/0	0.0901							601752 [ENTPD1 (provisional) Spastic paraplegia 64,autosomal recessive,615683];				60	101					ENTPD1 (inh=AR pLI=0.52), ENTPD1-AS1 (inh=n/a pLI=n/a)
chr10	97632435	97632435	-	A	wt	het	wt		QUAL=2634;DP=278,202,276;MQM=60	ENTPD1,ENTPD1-AS1	3'UTR,intron	ENTPD1:NM_001164178.1:3'UTR:MODIFIER:exon10/10:c.*6295_*6296insA:,ENTPD1:NM_001098175.1:3'UTR:MODIFIER:exon10/10:c.*6295_*6296insA:,ENTPD1:NM_001164181.1:3'UTR:MODIFIER:exon9/9:c.*6295_*6296insA:,ENTPD1:NM_001312654.1:3'UTR:MODIFIER:exon10/10:c.*6295_*6296insA:,ENTPD1:NM_001164179.1:3'UTR:MODIFIER:exon10/10:c.*6295_*6296insA:,ENTPD1:NM_001164182.1:3'UTR:MODIFIER:exon9/9:c.*6295_*6296insA:,ENTPD1:NM_001164183.1:3'UTR:MODIFIER:exon8/8:c.*6295_*6296insA:,ENTPD1:NM_001776.5:3'UTR:MODIFIER:exon10/10:c.*6295_*6296insA:,ENTPD1-AS1:NR_038444.1:intron:MODIFIER:exon3/5:n.439+3839_439+3840insT:,ENTPD1:NM_001320916.1:intron:MODIFIER:exon9/9:c.1363-3851_1363-3850insA:		rs34980533	0.4972	0.0000	0/0/0	0.3289							601752 [ENTPD1 (provisional) Spastic paraplegia 64,autosomal recessive,615683];				61	107					ENTPD1 (inh=AR pLI=0.52), ENTPD1-AS1 (inh=n/a pLI=n/a)
chr10	97632808	97632808	A	C	wt	het	wt		QUAL=739;DP=80,39,21;MQM=60	ENTPD1,ENTPD1-AS1	3'UTR,intron	ENTPD1:NM_001164178.1:3'UTR:MODIFIER:exon10/10:c.*6668A>C:,ENTPD1:NM_001098175.1:3'UTR:MODIFIER:exon10/10:c.*6668A>C:,ENTPD1:NM_001164181.1:3'UTR:MODIFIER:exon9/9:c.*6668A>C:,ENTPD1:NM_001312654.1:3'UTR:MODIFIER:exon10/10:c.*6668A>C:,ENTPD1:NM_001164179.1:3'UTR:MODIFIER:exon10/10:c.*6668A>C:,ENTPD1:NM_001164182.1:3'UTR:MODIFIER:exon9/9:c.*6668A>C:,ENTPD1:NM_001164183.1:3'UTR:MODIFIER:exon8/8:c.*6668A>C:,ENTPD1:NM_001776.5:3'UTR:MODIFIER:exon10/10:c.*6668A>C:,ENTPD1-AS1:NR_038444.1:intron:MODIFIER:exon3/5:n.439+3467T>G:,ENTPD1:NM_001320916.1:intron:MODIFIER:exon9/9:c.1363-3478A>C:	MER5A1	rs3192654	0.1933	0.0000	0/0/0	0.2725							601752 [ENTPD1 (provisional) Spastic paraplegia 64,autosomal recessive,615683];				24	104					ENTPD1 (inh=AR pLI=0.52), ENTPD1-AS1 (inh=n/a pLI=n/a)
chr10	97633021	97633021	C	T	het	het	hom		QUAL=18297;DP=328,260,345;MQM=59	ENTPD1,ENTPD1-AS1	3'UTR,intron	ENTPD1:NM_001164178.1:3'UTR:MODIFIER:exon10/10:c.*6881C>T:,ENTPD1:NM_001098175.1:3'UTR:MODIFIER:exon10/10:c.*6881C>T:,ENTPD1:NM_001164181.1:3'UTR:MODIFIER:exon9/9:c.*6881C>T:,ENTPD1:NM_001312654.1:3'UTR:MODIFIER:exon10/10:c.*6881C>T:,ENTPD1:NM_001164179.1:3'UTR:MODIFIER:exon10/10:c.*6881C>T:,ENTPD1:NM_001164182.1:3'UTR:MODIFIER:exon9/9:c.*6881C>T:,ENTPD1:NM_001164183.1:3'UTR:MODIFIER:exon8/8:c.*6881C>T:,ENTPD1:NM_001776.5:3'UTR:MODIFIER:exon10/10:c.*6881C>T:,ENTPD1-AS1:NR_038444.1:intron:MODIFIER:exon3/5:n.439+3254G>A:,ENTPD1:NM_001320916.1:intron:MODIFIER:exon9/9:c.1363-3265C>T:	L3	rs11188513	0.5839	0.0000	0/0/0	0.6176							601752 [ENTPD1 (provisional) Spastic paraplegia 64,autosomal recessive,615683];				96	100					ENTPD1 (inh=AR pLI=0.52), ENTPD1-AS1 (inh=n/a pLI=n/a)
chr10	97633470	97633470	T	C	het	wt	hom		QUAL=12915;DP=310,239,263;MQM=59	ENTPD1,ENTPD1-AS1	3'UTR,intron	ENTPD1:NM_001164178.1:3'UTR:MODIFIER:exon10/10:c.*7330T>C:,ENTPD1:NM_001098175.1:3'UTR:MODIFIER:exon10/10:c.*7330T>C:,ENTPD1:NM_001164181.1:3'UTR:MODIFIER:exon9/9:c.*7330T>C:,ENTPD1:NM_001312654.1:3'UTR:MODIFIER:exon10/10:c.*7330T>C:,ENTPD1:NM_001164179.1:3'UTR:MODIFIER:exon10/10:c.*7330T>C:,ENTPD1:NM_001164182.1:3'UTR:MODIFIER:exon9/9:c.*7330T>C:,ENTPD1:NM_001164183.1:3'UTR:MODIFIER:exon8/8:c.*7330T>C:,ENTPD1:NM_001776.5:3'UTR:MODIFIER:exon10/10:c.*7330T>C:,ENTPD1-AS1:NR_038444.1:intron:MODIFIER:exon3/5:n.439+2805A>G:,ENTPD1:NM_001320916.1:intron:MODIFIER:exon9/9:c.1363-2816T>C:	THE1A	rs11592937	0.0497	0.0000	0/0/0	0.0790							601752 [ENTPD1 (provisional) Spastic paraplegia 64,autosomal recessive,615683];				5	36					ENTPD1 (inh=AR pLI=0.52), ENTPD1-AS1 (inh=n/a pLI=n/a)
chr10	97635516	97635516	C	T	wt	het	wt	low_DP	QUAL=204;DP=116,17,20;MQM=60	ENTPD1,ENTPD1-AS1	3'UTR,intron	ENTPD1:NM_001164178.1:3'UTR:MODIFIER:exon10/10:c.*9376C>T:,ENTPD1:NM_001098175.1:3'UTR:MODIFIER:exon10/10:c.*9376C>T:,ENTPD1:NM_001164181.1:3'UTR:MODIFIER:exon9/9:c.*9376C>T:,ENTPD1:NM_001312654.1:3'UTR:MODIFIER:exon10/10:c.*9376C>T:,ENTPD1:NM_001164179.1:3'UTR:MODIFIER:exon10/10:c.*9376C>T:,ENTPD1:NM_001164182.1:3'UTR:MODIFIER:exon9/9:c.*9376C>T:,ENTPD1:NM_001164183.1:3'UTR:MODIFIER:exon8/8:c.*9376C>T:,ENTPD1:NM_001776.5:3'UTR:MODIFIER:exon10/10:c.*9376C>T:,ENTPD1-AS1:NR_038444.1:intron:MODIFIER:exon3/5:n.439+759G>A:,ENTPD1:NM_001320916.1:intron:MODIFIER:exon9/9:c.1363-770C>T:	THE1A	rs2096219	0.4265	0.0000	0/0/0	0.4525							601752 [ENTPD1 (provisional) Spastic paraplegia 64,autosomal recessive,615683];				49	90					ENTPD1 (inh=AR pLI=0.52), ENTPD1-AS1 (inh=n/a pLI=n/a)
chr10	97976495	97976495	C	G	wt	wt	het		QUAL=1347;DP=263,124,136;MQM=60	BLNK	splice_region&intron,intron	BLNK:NM_013314.3:splice_region&intron:LOW:exon6/16:c.526-5G>C:,BLNK:NM_001258440.1:splice_region&intron:LOW:exon6/15:c.526-5G>C:,BLNK:NM_001258441.1:splice_region&intron:LOW:exon6/14:c.526-5G>C:,BLNK:NR_047680.1:splice_region&intron:LOW:exon5/15:n.468-5G>C:,BLNK:NR_047681.1:splice_region&intron:LOW:exon5/14:n.485-5G>C:,BLNK:NR_047682.1:splice_region&intron:LOW:exon5/14:n.480-5G>C:,BLNK:NR_047683.1:splice_region&intron:LOW:exon6/13:n.644-5G>C:,BLNK:NM_001114094.1:splice_region&intron:LOW:exon6/15:c.526-5G>C:,BLNK:NM_001258442.1:intron:MODIFIER:exon5/13:c.350-1407G>C:		rs17111459	0.0144	0.0077	12/8/3	0.0076							604515 [BLNK (provisional) Agammaglobulinemia 4,613502];				2	19					BLNK (inh=AR pLI=0.99)
chr10	97990583	97990583	A	G	hom	hom	het		QUAL=14500;DP=202,158,198;MQM=60	BLNK	synonymous,non_coding_transcript_exon	BLNK:NM_013314.3:synonymous:LOW:exon4/17:c.171T>C:p.Pro57Pro,BLNK:NM_001258440.1:synonymous:LOW:exon4/16:c.171T>C:p.Pro57Pro,BLNK:NM_001258441.1:synonymous:LOW:exon4/15:c.171T>C:p.Pro57Pro,BLNK:NM_001258442.1:synonymous:LOW:exon4/14:c.171T>C:p.Pro57Pro,BLNK:NM_001114094.1:synonymous:LOW:exon4/16:c.171T>C:p.Pro57Pro,BLNK:NR_047680.1:non_coding_transcript_exon:MODIFIER:exon4/16:n.289T>C:,BLNK:NR_047681.1:non_coding_transcript_exon:MODIFIER:exon4/15:n.294T>C:,BLNK:NR_047682.1:non_coding_transcript_exon:MODIFIER:exon4/15:n.289T>C:,BLNK:NR_047683.1:non_coding_transcript_exon:MODIFIER:exon4/14:n.289T>C:		rs727852	0.4613	0.6384	23363/15833/277	0.6135							604515 [BLNK (provisional) Agammaglobulinemia 4,613502];			COSM147002	745	630					BLNK (inh=AR pLI=0.99)
chr10	101469605	101469605	G	A	hom	het	hom		QUAL=38982;DP=520,402,508;MQM=60	ENTPD7,COX15	3'UTR,intron	ENTPD7:NM_020354.3:3'UTR:MODIFIER:exon13/13:c.*5165G>A:,COX15:NM_001320974.1:intron:MODIFIER:exon8/8:c.1101+6500C>T:		rs2300983	0.8263	0.0000	0/0/0	0.8566							603646 [COX15 (confirmed) Leigh syndrome due to cytochrome c oxidase deficiency,256000|Cardioencephalomyopathy,fatal infantile,due to cytochrome c oxidase deficiency 2,615119];	RCV000289074.1 [benign]; 			111	35					ENTPD7 (inh=n/a pLI=0.00), COX15 (inh=AR pLI=0.00)
chr10	101469903	101469903	T	G	wt	het	wt		QUAL=2005;DP=398,188,198;MQM=60	ENTPD7,COX15	3'UTR,intron	ENTPD7:NM_020354.3:3'UTR:MODIFIER:exon13/13:c.*5463T>G:,COX15:NM_001320974.1:intron:MODIFIER:exon8/8:c.1101+6202A>C:		rs1056844	0.1064	0.0000	0/0/0	0.1203							603646 [COX15 (confirmed) Leigh syndrome due to cytochrome c oxidase deficiency,256000|Cardioencephalomyopathy,fatal infantile,due to cytochrome c oxidase deficiency 2,615119];	RCV000389345.1 [likely benign]; 			4	35					ENTPD7 (inh=n/a pLI=0.00), COX15 (inh=AR pLI=0.00)
chr10	101470858	101470858	-	A	hom	het	hom		QUAL=10597;DP=243,54,78;MQM=59	ENTPD7,COX15	3'UTR,intron	ENTPD7:NM_020354.3:3'UTR:MODIFIER:exon13/13:c.*6426dupA:,COX15:NM_078470.5:3'UTR:MODIFIER:exon9/9:c.*3485dupT:,COX15:NM_001320975.1:3'UTR:MODIFIER:exon8/8:c.*3666dupT:,COX15:NM_001320976.1:3'UTR:MODIFIER:exon9/9:c.*3485dupT:,COX15:NM_004376.6:3'UTR:MODIFIER:exon9/9:c.*2312dupT:,COX15:NM_001320974.1:intron:MODIFIER:exon8/8:c.1101+5246dupT:		rs397764905	0.8227	0.0000	0/0/0	0.7346							603646 [COX15 (confirmed) Leigh syndrome due to cytochrome c oxidase deficiency,256000|Cardioencephalomyopathy,fatal infantile,due to cytochrome c oxidase deficiency 2,615119];	RCV000264324.1,RCV000361237.1 [uncertain significance,benign]; 			110	36					ENTPD7 (inh=n/a pLI=0.00), COX15 (inh=AR pLI=0.00)
chr10	101470927	101470927	A	G	hom	het	het		QUAL=10632;DP=266,77,92;MQM=59	ENTPD7,COX15	3'UTR,intron	ENTPD7:NM_020354.3:3'UTR:MODIFIER:exon13/13:c.*6487A>G:,COX15:NM_078470.5:3'UTR:MODIFIER:exon9/9:c.*3417T>C:,COX15:NM_001320975.1:3'UTR:MODIFIER:exon8/8:c.*3598T>C:,COX15:NM_001320976.1:3'UTR:MODIFIER:exon9/9:c.*3417T>C:,COX15:NM_004376.6:3'UTR:MODIFIER:exon9/9:c.*2244T>C:,COX15:NM_001320974.1:intron:MODIFIER:exon8/8:c.1101+5178T>C:		rs10883407	0.1264	0.0000	0/0/0	0.1325							603646 [COX15 (confirmed) Leigh syndrome due to cytochrome c oxidase deficiency,256000|Cardioencephalomyopathy,fatal infantile,due to cytochrome c oxidase deficiency 2,615119];	RCV000303474.1 [likely benign]; 			3	25					ENTPD7 (inh=n/a pLI=0.00), COX15 (inh=AR pLI=0.00)
chr10	101471695	101471695	C	T	wt	wt	het		QUAL=1569;DP=200,106,145;MQM=60	COX15	3'UTR,intron	COX15:NM_078470.5:3'UTR:MODIFIER:exon9/9:c.*2649G>A:,COX15:NM_001320975.1:3'UTR:MODIFIER:exon8/8:c.*2830G>A:,COX15:NM_001320976.1:3'UTR:MODIFIER:exon9/9:c.*2649G>A:,COX15:NM_004376.6:3'UTR:MODIFIER:exon9/9:c.*1476G>A:,COX15:NM_001320974.1:intron:MODIFIER:exon8/8:c.1101+4410G>A:	MSTB	rs1128642	0.2518	0.0000	0/0/0	0.2734							603646 [COX15 (confirmed) Leigh syndrome due to cytochrome c oxidase deficiency,256000|Cardioencephalomyopathy,fatal infantile,due to cytochrome c oxidase deficiency 2,615119];	RCV000386007.1 [likely benign]; 			9	61					COX15 (inh=AR pLI=0.00)
chr10	101473218	101473218	A	G	hom	het	hom		QUAL=18289;DP=250,183,231;MQM=60	COX15	missense,3'UTR,intron	COX15:NM_004376.6:missense:MODERATE:exon9/9:c.1120T>C:p.Phe374Leu,COX15:NM_078470.5:3'UTR:MODIFIER:exon9/9:c.*1126T>C:,COX15:NM_001320975.1:3'UTR:MODIFIER:exon8/8:c.*1307T>C:,COX15:NM_001320976.1:3'UTR:MODIFIER:exon9/9:c.*1126T>C:,COX15:NM_001320974.1:intron:MODIFIER:exon8/8:c.1101+2887T>C:	L3	rs2231687	0.8271	0.8610	44825/25308/2970	0.8438	0.2480	T	T	B		10.16	603646 [COX15 (confirmed) Leigh syndrome due to cytochrome c oxidase deficiency,256000|Cardioencephalomyopathy,fatal infantile,due to cytochrome c oxidase deficiency 2,615119];	RCV000116814.2 [other]; RCV000259999.1 [benign]; 			1200	324					COX15 (inh=AR pLI=0.00)
chr10	101473535	101473535	C	T	hom	het	hom		QUAL=17617;DP=296,141,195;MQM=56	COX15	3'UTR,intron	COX15:NM_078470.5:3'UTR:MODIFIER:exon9/9:c.*809G>A:,COX15:NM_001320975.1:3'UTR:MODIFIER:exon8/8:c.*990G>A:,COX15:NM_001320976.1:3'UTR:MODIFIER:exon9/9:c.*809G>A:,COX15:NM_001320974.1:intron:MODIFIER:exon8/8:c.1101+2570G>A:,COX15:NM_004376.6:intron:MODIFIER:exon8/8:c.1102-299G>A:	AluSq2	rs7073616	0.8518	0.0000	0/0/0	0.7976							603646 [COX15 (confirmed) Leigh syndrome due to cytochrome c oxidase deficiency,256000|Cardioencephalomyopathy,fatal infantile,due to cytochrome c oxidase deficiency 2,615119];				111	35					COX15 (inh=AR pLI=0.00)
chr10	101492241	101492241	G	A	wt	het	wt		QUAL=42;DP=123,43,62;MQM=60	COX15,CUTC	5'UTR,intron	COX15:NM_078470.5:5'UTR:MODIFIER:exon1/9:c.-435C>T:,COX15:NM_001320974.1:5'UTR:MODIFIER:exon1/9:c.-435C>T:,COX15:NM_001320975.1:5'UTR:MODIFIER:exon1/8:c.-435C>T:,COX15:NM_001320976.1:5'UTR:MODIFIER:exon1/9:c.-889C>T:,COX15:NM_004376.6:5'UTR:MODIFIER:exon1/9:c.-435C>T:,CUTC:NM_015960.2:intron:MODIFIER:exon1/8:c.61+75G>A:		rs2231675	0.5387	0.0000	0/0/0	0.5176							603646 [COX15 (confirmed) Leigh syndrome due to cytochrome c oxidase deficiency,256000|Cardioencephalomyopathy,fatal infantile,due to cytochrome c oxidase deficiency 2,615119];	RCV000288170.1 [likely benign]; 			97	109					COX15 (inh=AR pLI=0.00), CUTC (inh=n/a pLI=0.02)
chr10	101492403	101492403	T	G	wt	het	wt		QUAL=1404;DP=129,124,205;MQM=60	COX15,CUTC	5'UTR_premature_start_codon_gain,5'UTR,intron	COX15:NM_078470.5:5'UTR_premature_start_codon_gain:LOW:exon1/9:c.-597A>C:,COX15:NM_001320974.1:5'UTR_premature_start_codon_gain:LOW:exon1/9:c.-597A>C:,COX15:NM_001320975.1:5'UTR_premature_start_codon_gain:LOW:exon1/8:c.-597A>C:,COX15:NM_001320976.1:5'UTR_premature_start_codon_gain:LOW:exon1/9:c.-1051A>C:,COX15:NM_004376.6:5'UTR_premature_start_codon_gain:LOW:exon1/9:c.-597A>C:,COX15:NM_078470.5:5'UTR:MODIFIER:exon1/9:c.-597A>C:,COX15:NM_001320974.1:5'UTR:MODIFIER:exon1/9:c.-597A>C:,COX15:NM_001320975.1:5'UTR:MODIFIER:exon1/8:c.-597A>C:,COX15:NM_001320976.1:5'UTR:MODIFIER:exon1/9:c.-1051A>C:,COX15:NM_004376.6:5'UTR:MODIFIER:exon1/9:c.-597A>C:,CUTC:NM_015960.2:intron:MODIFIER:exon1/8:c.61+237T>G:	MIRb	rs2281636	0.5401	0.0000	0/0/0	0.5624							603646 [COX15 (confirmed) Leigh syndrome due to cytochrome c oxidase deficiency,256000|Cardioencephalomyopathy,fatal infantile,due to cytochrome c oxidase deficiency 2,615119];	RCV000383808.1 [likely benign]; 			96	109					COX15 (inh=AR pLI=0.00), CUTC (inh=n/a pLI=0.02)
chr10	102747363	102747363	G	T	het	het	het		QUAL=16033;DP=534,370,487;MQM=60	C10orf2	5'UTR	C10orf2:NM_021830.4:5'UTR:MODIFIER:exon1/5:c.-605G>T:,C10orf2:NM_001163812.1:5'UTR:MODIFIER:exon1/5:c.-605G>T:,C10orf2:NM_001163813.1:5'UTR:MODIFIER:exon1/5:c.-127G>T:,C10orf2:NM_001163814.1:5'UTR:MODIFIER:exon1/5:c.-127G>T:		rs3740484	0.4121	0.0000	0/0/0	0.3752								RCV000124045.1 [benign]; RCV000269417.1 [benign]; RCV000304511.1 [benign]; RCV000326884.1 [benign]; RCV000361730.1 [benign]; 			23	114					TWNK (inh=AR+AD pLI=0.99)
chr10	102750621	102750621	C	T	het	het	wt		QUAL=5407;DP=282,220,298;MQM=60	C10orf2	splice_region&intron	C10orf2:NM_021830.4:splice_region&intron:LOW:exon3/4:c.1593-5C>T:,C10orf2:NM_001163812.1:splice_region&intron:LOW:exon3/4:c.1593-5C>T:,C10orf2:NM_001163813.1:splice_region&intron:LOW:exon3/4:c.231-5C>T:,C10orf2:NM_001163814.1:splice_region&intron:LOW:exon3/4:c.231-5C>T:		rs3740485	0.3760	0.2751	5495/1347/1029	0.0402								RCV000124041.2 [benign]; RCV000273221.1 [benign]; RCV000328346.1 [benign]; RCV000331870.1 [benign]; RCV000386399.1 [benign]; 			117	879					TWNK (inh=AR+AD pLI=0.99)
chr10	102750623	102750623	T	C	het	het	wt		QUAL=5407;DP=282,220,298;MQM=60	C10orf2	splice_region&intron	C10orf2:NM_021830.4:splice_region&intron:LOW:exon3/4:c.1593-3T>C:,C10orf2:NM_001163812.1:splice_region&intron:LOW:exon3/4:c.1593-3T>C:,C10orf2:NM_001163813.1:splice_region&intron:LOW:exon3/4:c.231-3T>C:,C10orf2:NM_001163814.1:splice_region&intron:LOW:exon3/4:c.231-3T>C:		rs3740486	0.3760	0.2752	5496/1346/1029	0.2532								RCV000124042.2 [benign]; RCV000288050.1 [benign]; RCV000343097.1 [benign]; RCV000379002.1 [benign]; RCV000382498.1 [benign]; 			117	879					TWNK (inh=AR+AD pLI=0.99)
chr10	102750783	102750783	C	A	het	het	wt		QUAL=6242;DP=217,276,340;MQM=60	C10orf2	splice_region&intron,3'UTR	C10orf2:NM_021830.4:splice_region&intron:LOW:exon4/4:c.1734+16C>A:,C10orf2:NM_001163813.1:splice_region&intron:LOW:exon4/4:c.372+16C>A:,C10orf2:NM_001163812.1:3'UTR:MODIFIER:exon4/5:c.*1C>A:,C10orf2:NM_001163814.1:3'UTR:MODIFIER:exon4/5:c.*1C>A:		rs3740487	0.3758	0.2755	5487/1344/1027	0.2720								RCV000124043.2 [benign]; 			117	872					TWNK (inh=AR+AD pLI=0.99)
chr10	102753788	102753788	C	G	wt	wt	het		QUAL=6932;DP=477,397,525;MQM=60	C10orf2	3'UTR	C10orf2:NM_021830.4:3'UTR:MODIFIER:exon5/5:c.*521C>G:,C10orf2:NM_001163812.1:3'UTR:MODIFIER:exon5/5:c.*871C>G:,C10orf2:NM_001163813.1:3'UTR:MODIFIER:exon5/5:c.*521C>G:,C10orf2:NM_001163814.1:3'UTR:MODIFIER:exon5/5:c.*871C>G:	L2a	rs11542131	0.0575	0.0000	0/0/0	0.0151								RCV000289850.1 [benign]; RCV000326146.1 [benign]; RCV000380788.1 [benign]; RCV000384190.1 [benign]; 			5	44					TWNK (inh=AR+AD pLI=0.99)
chr10	102754033	102754033	A	T	het	het	wt		QUAL=8136;DP=342,270,387;MQM=60	C10orf2	3'UTR	C10orf2:NM_021830.4:3'UTR:MODIFIER:exon5/5:c.*766A>T:,C10orf2:NM_001163812.1:3'UTR:MODIFIER:exon5/5:c.*1116A>T:,C10orf2:NM_001163813.1:3'UTR:MODIFIER:exon5/5:c.*766A>T:,C10orf2:NM_001163814.1:3'UTR:MODIFIER:exon5/5:c.*1116A>T:		rs3740488	0.3748	0.0000	0/0/0	0.0502								RCV000312968.1 [benign]; RCV000346808.1 [benign]; RCV000352677.1 [benign]; RCV000406316.1 [benign]; 			11	81					TWNK (inh=AR+AD pLI=0.99)
chr10	104596924	104596924	C	A	hom	het	hom		QUAL=4722;DP=94,61,54;MQM=59	CYP17A1	synonymous	CYP17A1:NM_000102.3:synonymous:LOW:exon1/8:c.195G>T:p.Ser65Ser		rs6163	0.4103	0.3974	9728/5086/683	0.3951							609300 [CYP17A1 (confirmed) 17-alpha-hydroxylase/17,20-lyase deficiency,202110|17,20-lyase deficiency,isolated,202110];	RCV000366126.1 [benign]; 		COSM3751499	293	725					CYP17A1 (inh=AR pLI=0.04)
chr10	104596981	104596981	G	A	hom	het	hom		QUAL=8546;DP=152,103,111;MQM=59	CYP17A1	synonymous	CYP17A1:NM_000102.3:synonymous:LOW:exon1/8:c.138C>T:p.His46His		rs6162	0.4425	0.4248	11081/5549/693	0.4204							609300 [CYP17A1 (confirmed) 17-alpha-hydroxylase/17,20-lyase deficiency,202110|17,20-lyase deficiency,isolated,202110];	RCV000403468.1 [benign]; 		COSM3751500	342	736					CYP17A1 (inh=AR pLI=0.04)
chr10	104597152	104597152	A	G	hom	het	hom		QUAL=18487;DP=251,213,242;MQM=59	CYP17A1	5'UTR	CYP17A1:NM_000102.3:5'UTR:MODIFIER:exon1/8:c.-34T>C:		rs743572	0.4105	0.4001	9368/4905/624	0.3883							609300 [CYP17A1 (confirmed) 17-alpha-hydroxylase/17,20-lyase deficiency,202110|17,20-lyase deficiency,isolated,202110];	RCV000354477.1 [benign]; 	CR942079 [CLASS=DP MUT=ALT PHEN="Polycystic ovaries association with" GENE=CYP17A1]; 		143	342					CYP17A1 (inh=AR pLI=0.04)
chr10	105791355	105791355	C	T	het	het	het		QUAL=9980;DP=370,157,232;MQM=60	COL17A1	3'UTR	COL17A1:NM_000494.3:3'UTR:MODIFIER:exon56/56:c.*638G>A:		rs9425	0.1885	0.0000	0/0/0	0.1694							113811 [COL17A1 (confirmed) Epidermolysis bullosa,junctional,non-Herlitz type,226650|Epidermolysis bullosa,junctional,localisata variant,226650|Epithelial recurrent erosion dystrophy,122400];	RCV000376614.1 [benign]; 			7	64					COL17A1 (inh=AR+AD pLI=0.00)
chr10	105791630	105791630	A	-	het	het	het		QUAL=13642;DP=345,330,429;MQM=59	COL17A1	3'UTR	COL17A1:NM_000494.3:3'UTR:MODIFIER:exon56/56:c.*363delT:		rs113786874	0.2466	0.0000	0/0/0	0.1849							113811 [COL17A1 (confirmed) Epidermolysis bullosa,junctional,non-Herlitz type,226650|Epidermolysis bullosa,junctional,localisata variant,226650|Epithelial recurrent erosion dystrophy,122400];	RCV000379845.1 [benign]; 			12	65					COL17A1 (inh=AR+AD pLI=0.00)
chr10	105791929	105791929	C	G	het	het	het		QUAL=12027;DP=364,239,358;MQM=59	COL17A1	3'UTR	COL17A1:NM_000494.3:3'UTR:MODIFIER:exon56/56:c.*64G>C:		rs805687	0.2288	0.0000	0/0/0	0.0357							113811 [COL17A1 (confirmed) Epidermolysis bullosa,junctional,non-Herlitz type,226650|Epidermolysis bullosa,junctional,localisata variant,226650|Epithelial recurrent erosion dystrophy,122400];	RCV000317208.1 [benign]; 			28	198					COL17A1 (inh=AR+AD pLI=0.00)
chr10	105796399	105796399	G	C	het	het	het		QUAL=3985;DP=69,93,140;MQM=60	COL17A1	splice_region&intron	COL17A1:NM_000494.3:splice_region&intron:LOW:exon47/55:c.3278-9C>G:		rs2274098	0.6915	0.7804	37104/22537/1286	0.7642							113811 [COL17A1 (confirmed) Epidermolysis bullosa,junctional,non-Herlitz type,226650|Epidermolysis bullosa,junctional,localisata variant,226650|Epithelial recurrent erosion dystrophy,122400];	RCV000244046.1 [benign]; RCV000333063.1 [benign]; 			1032	451					COL17A1 (inh=AR+AD pLI=0.00)
chr10	105796819	105796819	A	G	hom	hom	hom		QUAL=32186;DP=239,338,435;MQM=60	COL17A1	synonymous	COL17A1:NM_000494.3:synonymous:LOW:exon47/56:c.3261T>C:p.Ile1087Ile		rs2476958	0.9860	0.9964	55550/31287/4211	0.9409							113811 [COL17A1 (confirmed) Epidermolysis bullosa,junctional,non-Herlitz type,226650|Epidermolysis bullosa,junctional,localisata variant,226650|Epithelial recurrent erosion dystrophy,122400];	RCV000252056.1 [benign]; RCV000288544.1 [benign]; 			1559	0					COL17A1 (inh=AR+AD pLI=0.00)
chr10	105798872	105798872	T	C	het	het	het		QUAL=12251;DP=396,329,406;MQM=60	COL17A1	synonymous	COL17A1:NM_000494.3:synonymous:LOW:exon44/56:c.2904A>G:p.Pro968Pro		rs2274100	0.6815	0.7768	37240/22857/1302	0.7728							113811 [COL17A1 (confirmed) Epidermolysis bullosa,junctional,non-Herlitz type,226650|Epidermolysis bullosa,junctional,localisata variant,226650|Epithelial recurrent erosion dystrophy,122400];	RCV000242121.1 [benign]; RCV000339063.1 [benign]; 		COSM3751514	1032	455					COL17A1 (inh=AR+AD pLI=0.00)
chr10	105799216	105799216	G	T	het	het	het		QUAL=9298;DP=244,199,265;MQM=59	COL17A1	synonymous	COL17A1:NM_000494.3:synonymous:LOW:exon43/56:c.2883C>A:p.Pro961Pro		rs2296219	0.6835	0.7769	37320/22756/1206	0.7568							113811 [COL17A1 (confirmed) Epidermolysis bullosa,junctional,non-Herlitz type,226650|Epidermolysis bullosa,junctional,localisata variant,226650|Epithelial recurrent erosion dystrophy,122400];	RCV000250170.1 [benign]; RCV000393118.1 [benign]; 		COSM3751515	1032	450					COL17A1 (inh=AR+AD pLI=0.00)
chr10	105801253	105801253	G	A	het	het	het		QUAL=4997;DP=151,113,137;MQM=59	COL17A1	synonymous	COL17A1:NM_000494.3:synonymous:LOW:exon37/56:c.2595C>T:p.Arg865Arg		rs4918079	0.6739	0.7725	36341/22479/1244	0.7573							113811 [COL17A1 (confirmed) Epidermolysis bullosa,junctional,non-Herlitz type,226650|Epidermolysis bullosa,junctional,localisata variant,226650|Epithelial recurrent erosion dystrophy,122400];	RCV000246830.1 [benign]; RCV000276483.1 [benign]; 	CM144867 [CLASS=DP MUT=ALT PHEN="Ossification of posterior longitudinal ligament association with" GENE=COL17A1]; 	COSM3751516	1021	463					COL17A1 (inh=AR+AD pLI=0.00)
chr10	105810400	105810400	T	C	het	hom	het	pred_pathogenic	QUAL=28202;DP=426,456,586;MQM=60	COL17A1	missense	COL17A1:NM_000494.3:missense:MODERATE:exon27/56:c.2107A>G:p.Met703Val		rs805722	0.6937	0.7803	37505/22415/1454	0.7754	-0.2220	T,T	T	B	D,D	0.01	113811 [COL17A1 (confirmed) Epidermolysis bullosa,junctional,non-Herlitz type,226650|Epidermolysis bullosa,junctional,localisata variant,226650|Epithelial recurrent erosion dystrophy,122400];	RCV000249875.1 [benign]; RCV000390866.1 [benign]; 		COSM1178415	1009	494					COL17A1 (inh=AR+AD pLI=0.00)
chr10	105816916	105816916	C	T	hom	hom	hom	pred_pathogenic	QUAL=25000;DP=117,292,370;MQM=59	COL17A1	missense	COL17A1:NM_000494.3:missense:MODERATE:exon17/56:c.1282G>A:p.Gly428Ser		rs805698	0.8185	0.9357	53798/32795/1593	0.9252	0.8810	T,T,T	T	B,B	D,D	6.68	113811 [COL17A1 (confirmed) Epidermolysis bullosa,junctional,non-Herlitz type,226650|Epidermolysis bullosa,junctional,localisata variant,226650|Epithelial recurrent erosion dystrophy,122400];	RCV000244902.1 [benign]; RCV000344715.1 [benign]; 	CM144866 [CLASS=DP MUT=ALT PHEN="Ossification of posterior longitudinal ligament association with" GENE=COL17A1]; 		1497	58					COL17A1 (inh=AR+AD pLI=0.00)
chr10	105819956	105819956	G	A	het	hom	het		QUAL=27562;DP=420,465,572;MQM=59	COL17A1	synonymous	COL17A1:NM_000494.3:synonymous:LOW:exon14/56:c.1062C>T:p.Ala354Ala		rs805701	0.5525	0.6473	26225/15108/512	0.6435							113811 [COL17A1 (confirmed) Epidermolysis bullosa,junctional,non-Herlitz type,226650|Epidermolysis bullosa,junctional,localisata variant,226650|Epithelial recurrent erosion dystrophy,122400];	RCV000246164.1 [benign]; RCV000265171.1 [benign]; 			698	690					COL17A1 (inh=AR+AD pLI=0.00)
chr10	105824333	105824333	G	A	het	hom	het	pred_pathogenic	QUAL=1983;DP=50,39,23;MQM=60	COL17A1	missense	COL17A1:NM_000494.3:missense:MODERATE:exon10/56:c.629C>T:p.Thr210Met		rs805708	0.5649	0.6739	27226/16148/617	0.6626	6.8340	T,T,T,T	T	D,D,P	T,T,T	23.20	113811 [COL17A1 (confirmed) Epidermolysis bullosa,junctional,non-Herlitz type,226650|Epidermolysis bullosa,junctional,localisata variant,226650|Epithelial recurrent erosion dystrophy,122400];	RCV000252360.1 [benign]; RCV000264886.1 [benign]; 			736	665					COL17A1 (inh=AR+AD pLI=0.00)
chr10	112343591	112343591	G	A	wt	het	wt		QUAL=1001;DP=216,99,127;MQM=60	SMC3	splice_region&intron	SMC3:NM_005445.3:splice_region&intron:LOW:exon11/28:c.970-8G>A:		rs11195199	0.1482	0.1490	1594/445/33	0.1436							606062 [SMC3 (provisional) Cornelia de Lange syndrome 3,610759];	RCV000147602.2 [benign]; RCV000280036.1 [benign]; 			27	363					SMC3 (inh=AD pLI=1.00)
chr10	112361870	112361870	A	G	hom	hom	hom		QUAL=17448;DP=230,129,170;MQM=58	SMC3	sequence_feature,synonymous	SMC3:NM_005445.3:sequence_feature:MODERATE:exon25/29:c.3039A>G:,SMC3:NM_005445.3:synonymous:LOW:exon25/29:c.3039A>G:p.Ser1013Ser		rs2419565	0.9868	0.9963	60202/33298/4794	0.9645							606062 [SMC3 (provisional) Cornelia de Lange syndrome 3,610759];	RCV000147595.2 [benign]; RCV000323853.1 [benign]; 			1562	3					SMC3 (inh=AD pLI=1.00)
chr10	112773063	112773063	G	-	het	wt	het		QUAL=1928;DP=201,47,80;MQM=59	SHOC2	3'UTR,non_coding_transcript_exon	SHOC2:NM_001324336.1:3'UTR:MODIFIER:exon9/9:c.*1487delG:,SHOC2:NM_001269039.2:3'UTR:MODIFIER:exon8/8:c.*1487delG:,SHOC2:NM_001324337.1:3'UTR:MODIFIER:exon10/10:c.*1487delG:,SHOC2:NM_007373.3:3'UTR:MODIFIER:exon9/9:c.*1487delG:,SHOC2:NR_136749.1:non_coding_transcript_exon:MODIFIER:exon8/8:n.2648delG:		rs143768227	0.0525	0.0000	0/0/0	0.0348							602775 [SHOC2 (provisional) Noonan-like syndrome with loose anagen hair,607721];	RCV000352708.1 [benign]; 			0	21					SHOC2 (inh=AD pLI=0.99)
chr10	119302341	119302341	-	T	hom	hom	hom		QUAL=2081;DP=66,71,123;MQM=59	EMX2,EMX2OS	5'UTR,intron	EMX2:NM_004098.3:5'UTR:MODIFIER:exon1/3:c.-424dupT:,EMX2:NM_001165924.1:5'UTR:MODIFIER:exon1/2:c.-424dupT:,EMX2OS:NR_002791.2:intron:MODIFIER:exon2/3:n.574+1475dupA:			0.5284	0.0000	0/0/0	0.3523							600035 [EMX2 (provisional) Schizencephaly,269160];				4	136					EMX2 (inh=n/a pLI=0.94), EMX2OS (inh=n/a pLI=n/a)
chr10	119302449	119302449	G	A	het	het	het	low_DP	QUAL=411;DP=76,17,21;MQM=52	EMX2,EMX2OS	5'UTR,intron	EMX2:NM_004098.3:5'UTR:MODIFIER:exon1/3:c.-330G>A:,EMX2:NM_001165924.1:5'UTR:MODIFIER:exon1/2:c.-330G>A:,EMX2OS:NR_002791.2:intron:MODIFIER:exon2/3:n.574+1368C>T:	(A)n	rs879001240	0.0000	0.0000	0/0/0	0.0008							600035 [EMX2 (provisional) Schizencephaly,269160];				1	133					EMX2 (inh=n/a pLI=0.94), EMX2OS (inh=n/a pLI=n/a)
chr10	119302459	119302459	G	A	het	het	wt	low_QUAL;low_DP;low_MQM	QUAL=19;DP=68,13,23;MQM=44	EMX2,EMX2OS	5'UTR,intron	EMX2:NM_004098.3:5'UTR:MODIFIER:exon1/3:c.-320G>A:,EMX2:NM_001165924.1:5'UTR:MODIFIER:exon1/2:c.-320G>A:,EMX2OS:NR_002791.2:intron:MODIFIER:exon2/3:n.574+1358C>T:	(A)n	rs878875506	0.0000	0.0000	0/0/0	0.0004							600035 [EMX2 (provisional) Schizencephaly,269160];				0	108					EMX2 (inh=n/a pLI=0.94), EMX2OS (inh=n/a pLI=n/a)
chr10	119308060	119308063	AGAG	-	hom	hom	hom		QUAL=11167;DP=94,143,187;MQM=59	EMX2	3'UTR	EMX2:NM_004098.3:3'UTR:MODIFIER:exon3/3:c.*338_*341delGAGA:,EMX2:NM_001165924.1:3'UTR:MODIFIER:exon2/2:c.*402_*405delGAGA:	(GAGA)n	rs34929200;rs66710107	0.9497	0.0000	0/0/0	0.6184							600035 [EMX2 (provisional) Schizencephaly,269160];				203	25					EMX2 (inh=n/a pLI=0.94)
chr10	119308944	119308944	T	C	wt	wt	het		QUAL=1188;DP=137,84,126;MQM=60	EMX2	3'UTR	EMX2:NM_004098.3:3'UTR:MODIFIER:exon3/3:c.*1201T>C:,EMX2:NM_001165924.1:3'UTR:MODIFIER:exon2/2:c.*1265T>C:		rs41284394	0.0300	0.0000	0/0/0	0.0053							600035 [EMX2 (provisional) Schizencephaly,269160];				0	17					EMX2 (inh=n/a pLI=0.94)
chr10	121429633	121429633	T	C	wt	het	wt	pred_pathogenic	QUAL=3477;DP=132,315,422;MQM=60	BAG3	missense	BAG3:NM_004281.3:missense:MODERATE:exon2/4:c.451T>C:p.Cys151Arg		rs2234962	0.0964	0.1767	2215/1572/10	0.1713	0.5660	D,D	T	B	T,T	23.80	603883 [BAG3 (provisional) Myopathy,myofibrillar,6,612954|Cardiomyopathy,dilated,1HH,613881];	RCV000037893.9 [benign]; RCV000243456.1 [benign]; RCV000276835.1 [benign]; RCV000369042.1 [benign]; 	CM1111343 [CLASS=DP MUT=ALT PHEN="Cardiomyopathy dilated reduced risk" GENE=BAG3]; 	COSM3733958	82	522					BAG3 (inh=AD pLI=0.53)
chr10	121436362	121436362	A	G	het	het	het		QUAL=10002;DP=385,153,234;MQM=59	BAG3	synonymous	BAG3:NM_004281.3:synonymous:LOW:exon4/4:c.1296A>G:p.Val432Val		rs196295	0.7065	0.7409	33720/20379/2977	0.7374							603883 [BAG3 (provisional) Myopathy,myofibrillar,6,612954|Cardiomyopathy,dilated,1HH,613881];	RCV000037886.8 [benign]; RCV000243961.1 [benign]; RCV000280713.1 [benign]; RCV000399004.1 [benign]; 			1043	508					BAG3 (inh=AD pLI=0.53)
chr10	121437012	121437012	G	C	wt	het	wt		QUAL=3503;DP=440,275,373;MQM=60	BAG3	3'UTR	BAG3:NM_004281.3:3'UTR:MODIFIER:exon4/4:c.*218G>C:		rs8946	0.3544	0.0000	0/0/0	0.0620							603883 [BAG3 (provisional) Myopathy,myofibrillar,6,612954|Cardiomyopathy,dilated,1HH,613881];	RCV000285835.1 [benign]; RCV000395345.1 [benign]; 	CR1511374 [CLASS=DFP MUT=ALT PHEN="Cardiomyopathy tako-tsubo increased risk" GENE=BAG3]; 		28	117					BAG3 (inh=AD pLI=0.53)
chr10	121437032	121437034	TTG	-	het	wt	het		QUAL=9345;DP=390,276,386;MQM=59	BAG3	3'UTR	BAG3:NM_004281.3:3'UTR:MODIFIER:exon4/4:c.*243_*245delGTT:		rs71758126	0.4585	0.0000	0/0/0	0.5259							603883 [BAG3 (provisional) Myopathy,myofibrillar,6,612954|Cardiomyopathy,dilated,1HH,613881];	RCV000343159.1 [benign]; RCV000395361.1 [benign]; 			87	101					BAG3 (inh=AD pLI=0.53)
chr10	123239112	123239112	G	A	het	hom	het		QUAL=12951;DP=198,238,288;MQM=59	FGFR2	synonymous,3'UTR,non_coding_transcript_exon	FGFR2:NM_001144915.1:synonymous:LOW:exon17/17:c.2107C>T:p.Leu703Leu,FGFR2:NM_022970.3:3'UTR:MODIFIER:exon18/18:c.*259C>T:,FGFR2:NM_001320654.1:3'UTR:MODIFIER:exon17/17:c.*259C>T:,FGFR2:NM_001144914.1:3'UTR:MODIFIER:exon15/15:c.*259C>T:,FGFR2:NM_023029.2:3'UTR:MODIFIER:exon16/16:c.*259C>T:,FGFR2:NM_001144916.1:3'UTR:MODIFIER:exon15/15:c.*259C>T:,FGFR2:NM_000141.4:3'UTR:MODIFIER:exon18/18:c.*259C>T:,FGFR2:NM_001144917.1:3'UTR:MODIFIER:exon16/16:c.*259C>T:,FGFR2:NM_001144918.1:3'UTR:MODIFIER:exon16/16:c.*259C>T:,FGFR2:NM_001320658.1:3'UTR:MODIFIER:exon18/18:c.*259C>T:,FGFR2:NR_073009.1:non_coding_transcript_exon:MODIFIER:exon17/17:n.3175C>T:		rs1047057	0.4143	0.5311	3140/1421/27	0.1985							176943 [FGFR2 (confirmed) Crouzon syndrome,123500|Jackson-Weiss syndrome,123150|Beare-Stevenson cutis gyrata syndrome,123790|Pfeiffer syndrome,101600|Apert syndrome,101200|Saethre-Chotzen syndrome,101400|Craniosynostosis,nonspecific|Gastric cancer,somatic,613659|Craniofacial-skeletal-dermatologic dysplasia,101600|Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis,207410|Scaphocephaly and Axenfeld-Rieger anomaly|LADD syndrome,149730|Scaphocephaly,maxillary retrusion,and mental retardation,609579|Bent bone dysplasia syndrome,614592];	RCV000264030.1 [benign]; RCV000302746.1 [benign]; RCV000304323.1 [benign]; RCV000310102.1 [benign]; RCV000343896.1 [benign]; RCV000355233.1 [benign]; RCV000361106.1 [benign]; RCV000398132.1 [benign]; RCV000398152.1 [benign]; 		COSM147070	516	777					FGFR2 (inh=AR+AD pLI=1.00)
chr10	123298158	123298158	T	C	hom	het	hom		QUAL=40379;DP=412,469,618;MQM=59	FGFR2	synonymous,non_coding_transcript_exon	FGFR2:NM_022970.3:synonymous:LOW:exon6/18:c.696A>G:p.Val232Val,FGFR2:NM_001144914.1:synonymous:LOW:exon5/15:c.696A>G:p.Val232Val,FGFR2:NM_023029.2:synonymous:LOW:exon4/16:c.429A>G:p.Val143Val,FGFR2:NM_001144916.1:synonymous:LOW:exon3/15:c.351A>G:p.Val117Val,FGFR2:NM_001144915.1:synonymous:LOW:exon5/17:c.429A>G:p.Val143Val,FGFR2:NM_000141.4:synonymous:LOW:exon6/18:c.696A>G:p.Val232Val,FGFR2:NM_001144917.1:synonymous:LOW:exon6/16:c.696A>G:p.Val232Val,FGFR2:NM_001144918.1:synonymous:LOW:exon4/16:c.351A>G:p.Val117Val,FGFR2:NM_001320658.1:synonymous:LOW:exon6/18:c.696A>G:p.Val232Val,FGFR2:NM_001144913.1:synonymous:LOW:exon5/17:c.696A>G:p.Val232Val,FGFR2:NM_001144919.1:synonymous:LOW:exon5/17:c.429A>G:p.Val143Val,FGFR2:NR_073009.1:non_coding_transcript_exon:MODIFIER:exon4/17:n.998A>G:		rs1047100	0.7953	0.7797	37171/19910/2915	0.7745							176943 [FGFR2 (confirmed) Crouzon syndrome,123500|Jackson-Weiss syndrome,123150|Beare-Stevenson cutis gyrata syndrome,123790|Pfeiffer syndrome,101600|Apert syndrome,101200|Saethre-Chotzen syndrome,101400|Craniosynostosis,nonspecific|Gastric cancer,somatic,613659|Craniofacial-skeletal-dermatologic dysplasia,101600|Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis,207410|Scaphocephaly and Axenfeld-Rieger anomaly|LADD syndrome,149730|Scaphocephaly,maxillary retrusion,and mental retardation,609579|Bent bone dysplasia syndrome,614592];	RCV000250550.1 [benign]; RCV000264031.1 [benign]; RCV000268420.1 [benign]; RCV000270961.1 [benign]; RCV000308616.1 [benign]; RCV000316516.1 [benign]; RCV000321550.1 [benign]; RCV000363146.1 [benign]; RCV000365600.1 [benign]; RCV000378516.1 [benign]; 			1020	531					FGFR2 (inh=AR+AD pLI=1.00)
chr10	123325034	123325034	C	T	wt	het	wt		QUAL=1168;DP=102,133,194;MQM=60	FGFR2	synonymous,intron	FGFR2:NM_022970.3:synonymous:LOW:exon3/18:c.294G>A:p.Thr98Thr,FGFR2:NM_001144914.1:synonymous:LOW:exon2/15:c.294G>A:p.Thr98Thr,FGFR2:NM_000141.4:synonymous:LOW:exon3/18:c.294G>A:p.Thr98Thr,FGFR2:NM_001144917.1:synonymous:LOW:exon3/16:c.294G>A:p.Thr98Thr,FGFR2:NM_001320658.1:synonymous:LOW:exon3/18:c.294G>A:p.Thr98Thr,FGFR2:NM_001144913.1:synonymous:LOW:exon2/17:c.294G>A:p.Thr98Thr,FGFR2:NM_023029.2:intron:MODIFIER:exon1/15:c.110-941G>A:,FGFR2:NM_001144916.1:intron:MODIFIER:exon1/14:c.110-14061G>A:,FGFR2:NM_001144915.1:intron:MODIFIER:exon2/16:c.110-941G>A:,FGFR2:NM_001144918.1:intron:MODIFIER:exon2/15:c.110-14061G>A:,FGFR2:NR_073009.1:intron:MODIFIER:exon2/16:n.757-14061G>A:,FGFR2:NM_001144919.1:intron:MODIFIER:exon2/16:c.110-941G>A:		rs1047101	0.0034	0.0080	6/4/0	0.0076							176943 [FGFR2 (confirmed) Crouzon syndrome,123500|Jackson-Weiss syndrome,123150|Beare-Stevenson cutis gyrata syndrome,123790|Pfeiffer syndrome,101600|Apert syndrome,101200|Saethre-Chotzen syndrome,101400|Craniosynostosis,nonspecific|Gastric cancer,somatic,613659|Craniofacial-skeletal-dermatologic dysplasia,101600|Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis,207410|Scaphocephaly and Axenfeld-Rieger anomaly|LADD syndrome,149730|Scaphocephaly,maxillary retrusion,and mental retardation,609579|Bent bone dysplasia syndrome,614592];	RCV000176990.2 [benign]; RCV000284750.1 [likely benign]; RCV000290130.1 [likely benign]; RCV000296060.1 [likely benign]; RCV000325276.1 [likely benign]; RCV000330827.1 [likely benign]; RCV000347878.1 [likely benign]; RCV000382173.1 [likely benign]; RCV000387738.1 [likely benign]; RCV000407171.1 [likely benign]; 			0	26	1	[1] Frequenz >1% karins 10.10.2016			FGFR2 (inh=AR+AD pLI=1.00)
chr10	123357561	123357561	C	T	hom	het	hom	low_DP	QUAL=1869;DP=12,29,52;MQM=60	FGFR2	5'UTR,non_coding_transcript_exon	FGFR2:NM_022970.3:5'UTR:MODIFIER:exon1/18:c.-236G>A:,FGFR2:NM_000141.4:5'UTR:MODIFIER:exon1/18:c.-236G>A:,FGFR2:NM_001144917.1:5'UTR:MODIFIER:exon1/16:c.-236G>A:,FGFR2:NM_001144918.1:5'UTR:MODIFIER:exon1/16:c.-236G>A:,FGFR2:NM_001320658.1:5'UTR:MODIFIER:exon1/18:c.-236G>A:,FGFR2:NM_001144919.1:5'UTR:MODIFIER:exon1/17:c.-236G>A:,FGFR2:NR_073009.1:non_coding_transcript_exon:MODIFIER:exon1/17:n.412G>A:		rs1047111	0.7103	0.0000	0/0/0	0.6842							176943 [FGFR2 (confirmed) Crouzon syndrome,123500|Jackson-Weiss syndrome,123150|Beare-Stevenson cutis gyrata syndrome,123790|Pfeiffer syndrome,101600|Apert syndrome,101200|Saethre-Chotzen syndrome,101400|Craniosynostosis,nonspecific|Gastric cancer,somatic,613659|Craniofacial-skeletal-dermatologic dysplasia,101600|Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis,207410|Scaphocephaly and Axenfeld-Rieger anomaly|LADD syndrome,149730|Scaphocephaly,maxillary retrusion,and mental retardation,609579|Bent bone dysplasia syndrome,614592];	RCV000279553.1 [benign]; RCV000281215.1 [benign]; RCV000296302.1 [benign]; RCV000326787.1 [benign]; RCV000338502.1 [benign]; RCV000348831.1 [benign]; RCV000387274.1 [benign]; RCV000388393.1 [benign]; RCV000393727.1 [benign]; RCV000270363.1 [benign]; RCV000301938.1 [benign]; RCV000309774.1 [benign]; RCV000332515.1 [benign]; RCV000341554.1 [benign]; RCV000359107.1 [benign]; RCV000362123.1 [benign]; RCV000404795.1 [benign]; RCV000405669.1 [benign]; 			152	62					FGFR2 (inh=AR+AD pLI=1.00)
chr10	126089434	126089434	G	A	wt	het	het		QUAL=3873;DP=140,119,187;MQM=60	OAT	synonymous	OAT:NM_000274.3:synonymous:LOW:exon9/10:c.1134C>T:p.Asn378Asn,OAT:NM_001171814.1:synonymous:LOW:exon8/9:c.720C>T:p.Asn240Asn,OAT:NM_001322965.1:synonymous:LOW:exon9/10:c.1134C>T:p.Asn378Asn,OAT:NM_001322966.1:synonymous:LOW:exon10/11:c.1134C>T:p.Asn378Asn,OAT:NM_001322967.1:synonymous:LOW:exon10/11:c.1134C>T:p.Asn378Asn,OAT:NM_001322968.1:synonymous:LOW:exon11/12:c.1134C>T:p.Asn378Asn,OAT:NM_001322969.1:synonymous:LOW:exon10/11:c.1134C>T:p.Asn378Asn,OAT:NM_001322970.1:synonymous:LOW:exon11/12:c.1134C>T:p.Asn378Asn,OAT:NM_001322971.1:synonymous:LOW:exon7/8:c.813C>T:p.Asn271Asn,OAT:NM_001322974.1:synonymous:LOW:exon9/10:c.534C>T:p.Asn178Asn		rs11461	0.4099	0.4180	11274/5069/136	0.4118							613349 [OAT (confirmed) Gyrate atrophy of choroid and retina with or without ornithinemia,258870];	RCV000000184.2 [benign]; RCV000380778.1 [benign]; 		COSM3751589	290	650					OAT (inh=AR pLI=0.00)
chr10	126107434	126107434	G	A	wt	het	wt	low_DP	QUAL=1096;DP=15,88,114;MQM=60	OAT	splice_region&intron	OAT:NM_000274.3:splice_region&intron:LOW:exon1/9:c.-30+8C>T:,OAT:NM_001171814.1:splice_region&intron:LOW:exon1/8:c.-216+8C>T:,OAT:NM_001322965.1:splice_region&intron:LOW:exon1/9:c.-30+13C>T:,OAT:NM_001322966.1:splice_region&intron:LOW:exon1/10:c.-345+8C>T:,OAT:NM_001322967.1:splice_region&intron:LOW:exon1/10:c.-150+8C>T:,OAT:NM_001322968.1:splice_region&intron:LOW:exon1/11:c.-237+8C>T:,OAT:NM_001322969.1:splice_region&intron:LOW:exon1/10:c.-117+8C>T:,OAT:NM_001322970.1:splice_region&intron:LOW:exon1/11:c.-333+8C>T:,OAT:NM_001322971.1:splice_region&intron:LOW:exon1/7:c.-30+8C>T:,OAT:NM_001322974.1:splice_region&intron:LOW:exon1/9:c.-516+8C>T:		rs552799531	0.0012	0.0000	0/0/0	0.0053							613349 [OAT (confirmed) Gyrate atrophy of choroid and retina with or without ornithinemia,258870];	RCV000357000.1 [uncertain significance]; 			0	2					OAT (inh=AR pLI=0.00)
chr10	126107506	126107506	A	C	het	hom	het		QUAL=8062;DP=148,126,186;MQM=60	OAT	5'UTR	OAT:NM_000274.3:5'UTR:MODIFIER:exon1/10:c.-94T>G:,OAT:NM_001171814.1:5'UTR:MODIFIER:exon1/9:c.-280T>G:,OAT:NM_001322965.1:5'UTR:MODIFIER:exon1/10:c.-89T>G:,OAT:NM_001322966.1:5'UTR:MODIFIER:exon1/11:c.-409T>G:,OAT:NM_001322967.1:5'UTR:MODIFIER:exon1/11:c.-214T>G:,OAT:NM_001322968.1:5'UTR:MODIFIER:exon1/12:c.-301T>G:,OAT:NM_001322969.1:5'UTR:MODIFIER:exon1/11:c.-181T>G:,OAT:NM_001322970.1:5'UTR:MODIFIER:exon1/12:c.-397T>G:,OAT:NM_001322971.1:5'UTR:MODIFIER:exon1/8:c.-94T>G:,OAT:NM_001322974.1:5'UTR:MODIFIER:exon1/10:c.-580T>G:		rs4144117	0.8630	0.0000	0/0/0	0.7491							613349 [OAT (confirmed) Gyrate atrophy of choroid and retina with or without ornithinemia,258870];	RCV000268468.1 [benign]; 			154	71					OAT (inh=AR pLI=0.00)
chr11	534332	534332	G	A	wt	wt	het		QUAL=2921;DP=81,211,258;MQM=60	HRAS	5'UTR_premature_start_codon_gain,5'UTR	HRAS:NM_001130442.2:5'UTR_premature_start_codon_gain:LOW:exon2/5:c.-10C>T:,HRAS:NM_001318054.1:5'UTR_premature_start_codon_gain:LOW:exon2/7:c.-329C>T:,HRAS:NM_005343.3:5'UTR_premature_start_codon_gain:LOW:exon2/6:c.-10C>T:,HRAS:NM_176795.4:5'UTR_premature_start_codon_gain:LOW:exon2/6:c.-10C>T:,HRAS:NM_001130442.2:5'UTR:MODIFIER:exon2/5:c.-10C>T:,HRAS:NM_001318054.1:5'UTR:MODIFIER:exon2/7:c.-329C>T:,HRAS:NM_005343.3:5'UTR:MODIFIER:exon2/6:c.-10C>T:,HRAS:NM_176795.4:5'UTR:MODIFIER:exon2/6:c.-10C>T:		rs41294870	0.0357	0.0475	157/96/4	0.0424							190020 [HRAS (confirmed) Bladder cancer,somatic,109800|Costello syndrome,218040|Thyroid carcinoma,follicular,somatic,188470|Congenital myopathy with excess of muscle spindles,218040|Nevus sebaceous or woolly hair nevus,somatic,162900|Schimmelpenning-Feuerstein-Mims syndrome,somatic mosaic,163200|Spitz nevus or nevus spilus,somatic,137550];	RCV000154268.3 [benign]; 			5	169					HRAS (inh=AD pLI=0.01)
chr11	791169	791169	C	G	wt	wt	het		QUAL=4398;DP=121,346,413;MQM=60	SLC25A22	3'UTR	SLC25A22:NM_001191060.1:3'UTR:MODIFIER:exon10/10:c.*746G>C:,SLC25A22:NM_024698.5:3'UTR:MODIFIER:exon10/10:c.*746G>C:,SLC25A22:NM_001191061.1:3'UTR:MODIFIER:exon10/10:c.*746G>C:		rs576938612	0.0002	0.0000	0/0/0	0.0004							609302 [SLC25A22 (provisional) Epileptic encephalopathy,early infantile,3,609304];				0	1					SLC25A22 (inh=AR pLI=0.57)
chr11	791462	791462	G	A	het	wt	het		QUAL=4079;DP=132,117,208;MQM=60	SLC25A22	3'UTR	SLC25A22:NM_001191060.1:3'UTR:MODIFIER:exon10/10:c.*453C>T:,SLC25A22:NM_024698.5:3'UTR:MODIFIER:exon10/10:c.*453C>T:,SLC25A22:NM_001191061.1:3'UTR:MODIFIER:exon10/10:c.*453C>T:		rs4963153	0.2993	0.0000	0/0/0	0.0706							609302 [SLC25A22 (provisional) Epileptic encephalopathy,early infantile,3,609304];	RCV000401091.1 [benign]; 			47	111					SLC25A22 (inh=AR pLI=0.57)
chr11	792735	792735	C	G	wt	wt	het		QUAL=597;DP=21,20,51;MQM=60	SLC25A22	splice_region&intron	SLC25A22:NM_001191060.1:splice_region&intron:LOW:exon6/9:c.413-8G>C:,SLC25A22:NM_024698.5:splice_region&intron:LOW:exon6/9:c.413-8G>C:,SLC25A22:NM_001191061.1:splice_region&intron:LOW:exon6/9:c.413-8G>C:		rs376015598	0.0002	0.0004	0/0/0	0.0002							609302 [SLC25A22 (provisional) Epileptic encephalopathy,early infantile,3,609304];	RCV000128081.2 [other]; RCV000147509.1 [uncertain significance]; RCV000391935.1 [uncertain significance]; 			0	1					SLC25A22 (inh=AR pLI=0.57)
chr11	1861760	1861760	T	C	hom	hom	hom		QUAL=21630;DP=176,227,329;MQM=59	TNNI2	splice_region&synonymous	TNNI2:NM_001145829.1:splice_region&synonymous:LOW:exon4/7:c.60T>C:p.Ser20Ser,TNNI2:NM_003282.3:splice_region&synonymous:LOW:exon4/7:c.60T>C:p.Ser20Ser,TNNI2:NM_001145841.1:splice_region&synonymous:LOW:exon3/6:c.60T>C:p.Ser20Ser		rs907610	0.8277	0.8760	44552/24284/2076	0.8203							191043 [TNNI2 (confirmed) Arthrogryposis multiplex congenita,distal,type 2B,601680];	RCV000080081.9 [other]; RCV000128669.1 [not provided]; RCV000320562.1 [likely benign]; RCV000361293.1 [likely benign]; 		COSM4145619	1211	329					TNNI2 (inh=AD pLI=0.09)
chr11	1959707	1959707	C	T	het	het	het		QUAL=836;DP=32,26,41;MQM=59	TNNT3	synonymous	TNNT3:NM_006757.3:synonymous:LOW:exon16/16:c.762C>T:p.Gly254Gly,TNNT3:NM_001042780.2:synonymous:LOW:exon15/15:c.738C>T:p.Gly246Gly,TNNT3:NM_001042781.2:synonymous:LOW:exon16/16:c.756C>T:p.Gly252Gly,TNNT3:NM_001042782.2:synonymous:LOW:exon15/15:c.738C>T:p.Gly246Gly,TNNT3:NM_001297646.1:synonymous:LOW:exon16/16:c.738C>T:p.Gly246Gly		rs4727	0.1370	0.1452	1645/842/7	0.1441							600692 [TNNT3 (confirmed) Arthyrgryposis,distal,type 2B,601680];	RCV000024568.1 [not provided]; RCV000118647.2 [benign]; RCV000334912.1 [likely benign]; RCV000373168.1 [likely benign]; 		COSM3752283, COSM3752285, COSM3752284	53	402					TNNT3 (inh=AD pLI=0.00)
chr11	2187855	2187855	G	C	het	wt	het	low_DP	QUAL=2184;DP=16,127,158;MQM=60	TH	splice_region&intron	TH:NM_199292.2:splice_region&intron:LOW:exon9/13:c.1070+8C>G:,TH:NM_000360.3:splice_region&intron:LOW:exon8/12:c.977+8C>G:,TH:NM_199293.2:splice_region&intron:LOW:exon9/13:c.1058+8C>G:		rs12419447	0.1799	0.3690	2558/2162/34	0.2279							191290 [TH (confirmed) Segawa syndrome,recessive,605407];	RCV000250457.2 [benign]; RCV000278788.1 [benign]; 			234	946					TH (inh=AR pLI=0.00)
chr11	2188238	2188238	C	T	het	wt	het		QUAL=1472;DP=35,72,94;MQM=60	TH	synonymous	TH:NM_199292.2:synonymous:LOW:exon8/14:c.813G>A:p.Lys271Lys,TH:NM_000360.3:synonymous:LOW:exon7/13:c.720G>A:p.Lys240Lys,TH:NM_199293.2:synonymous:LOW:exon8/14:c.801G>A:p.Lys267Lys		rs6357	0.1546	0.3060	2044/1694/44	0.2007							191290 [TH (confirmed) Segawa syndrome,recessive,605407];	RCV000252592.1 [benign]; RCV000287153.1 [benign]; 		COSM3752293	180	937					TH (inh=AR pLI=0.00)
chr11	2189718	2189718	C	T	wt	wt	het		QUAL=604;DP=53,30,44;MQM=60	TH	splice_region&intron	TH:NM_199292.2:splice_region&intron:LOW:exon4/13:c.580+3G>A:,TH:NM_000360.3:splice_region&intron:LOW:exon3/12:c.487+3G>A:,TH:NM_199293.2:splice_region&intron:LOW:exon4/13:c.568+3G>A:		rs11042950	0.0054	0.0106	12/9/0	0.0093							191290 [TH (confirmed) Segawa syndrome,recessive,605407];	RCV000229985.1 [benign]; 			4	67	1	[1] old entry - no details available	n/a (1xTP, 0xFP)		TH (inh=AR pLI=0.00)
chr11	2190951	2190951	C	T	wt	het	het	pred_pathogenic	QUAL=1576;DP=77,56,102;MQM=60	TH	missense	TH:NM_199292.2:missense:MODERATE:exon3/14:c.334G>A:p.Val112Met,TH:NM_000360.3:missense:MODERATE:exon2/13:c.241G>A:p.Val81Met,TH:NM_199293.2:missense:MODERATE:exon3/14:c.322G>A:p.Val108Met		rs6356	0.4305	0.4249	12086/4741/97	0.4149	-0.3270	T,T,T,T	T	B,B,B,B,B	D,D,D,D	14.34	191290 [TH (confirmed) Segawa syndrome,recessive,605407];	RCV000021078.2 [benign]; RCV000241867.1 [benign]; 	CM1213128 [CLASS=DP MUT=REF PHEN="Alcoholism association with" GENE=TH]; 	COSM3752294	383	1140	1	[1] old entry - no details available			TH (inh=AR pLI=0.00)
chr11	2416705	2416705	T	C	wt	wt	het		QUAL=3146;DP=230,193,268;MQM=60	CD81	synonymous	CD81:NM_004356.3:synonymous:LOW:exon5/8:c.414T>C:p.Asp138Asp,CD81:NM_001297649.1:synonymous:LOW:exon5/8:c.201T>C:p.Asp67Asp		rs143644902	0.0010	0.0023	0/0/0	0.0022	-3.0440		T			0.92	186845 [CD81 (provisional) Immunodeficiency,common variable,6,613496];				0	8					CD81 (inh=AR pLI=0.95)
chr11	3877074	3877074	C	T	wt	het	wt		QUAL=315;DP=25,69,69;MQM=60	STIM1	5'UTR_premature_start_codon_gain,5'UTR	STIM1:NM_001277961.1:5'UTR_premature_start_codon_gain:LOW:exon1/12:c.-427C>T:,STIM1:NM_001277962.1:5'UTR_premature_start_codon_gain:LOW:exon1/13:c.-427C>T:,STIM1:NM_003156.3:5'UTR_premature_start_codon_gain:LOW:exon1/12:c.-427C>T:,STIM1:NM_001277961.1:5'UTR:MODIFIER:exon1/12:c.-427C>T:,STIM1:NM_001277962.1:5'UTR:MODIFIER:exon1/13:c.-427C>T:,STIM1:NM_003156.3:5'UTR:MODIFIER:exon1/12:c.-427C>T:		rs10835206	0.4461	0.0000	0/0/0	0.0662							605921 [STIM1 (provisional) Immunodeficiency 10,612783|Myopathy,tubular aggregate,1 160565|Stormorken syndrome,185070];				42	103					STIM1 (inh=AR+AD pLI=0.93)
chr11	3877114	3877118	TCTCT	-	het	het	hom		QUAL=2916;DP=78,78,79;MQM=59	STIM1	5'UTR	STIM1:NM_001277961.1:5'UTR:MODIFIER:exon1/12:c.-370_-366delTCTTC:,STIM1:NM_001277962.1:5'UTR:MODIFIER:exon1/13:c.-370_-366delTCTTC:,STIM1:NM_003156.3:5'UTR:MODIFIER:exon1/12:c.-370_-366delTCTTC:	(TCTCT)n	rs147711952	0.2688	0.0000	0/0/0	0.3058							605921 [STIM1 (provisional) Immunodeficiency 10,612783|Myopathy,tubular aggregate,1 160565|Stormorken syndrome,185070];				27	107					STIM1 (inh=AR+AD pLI=0.93)
chr11	4103524	4103524	A	G	hom	het	hom	pred_pathogenic	QUAL=16507;DP=217,179,244;MQM=60	STIM1	synonymous	STIM1:NM_001277961.1:synonymous:LOW:exon8/12:c.1080A>G:p.Gln360Gln,STIM1:NM_001277962.1:synonymous:LOW:exon8/13:c.1080A>G:p.Gln360Gln,STIM1:NM_003156.3:synonymous:LOW:exon8/12:c.1080A>G:p.Gln360Gln		rs2304891	0.3890	0.4996	15744/10562/190	0.4993	1.7940		T			5.98	605921 [STIM1 (provisional) Immunodeficiency 10,612783|Myopathy,tubular aggregate,1 160565|Stormorken syndrome,185070];	RCV000250516.1 [benign]; 		COSM428967	461	725					STIM1 (inh=AR+AD pLI=0.93)
chr11	4113395	4113395	G	A	hom	het	hom		QUAL=22561;DP=311,252,293;MQM=59	STIM1	3'UTR	STIM1:NM_001277961.1:3'UTR:MODIFIER:exon12/12:c.*367G>A:,STIM1:NM_001277962.1:3'UTR:MODIFIER:exon13/13:c.*839G>A:,STIM1:NM_003156.3:3'UTR:MODIFIER:exon12/12:c.*367G>A:		rs1561876	0.6941	0.0000	0/0/0	0.1389							605921 [STIM1 (provisional) Immunodeficiency 10,612783|Myopathy,tubular aggregate,1 160565|Stormorken syndrome,185070];				172	49					STIM1 (inh=AR+AD pLI=0.93)
chr11	4113471	4113471	G	A	het	het	het		QUAL=13495;DP=361,305,358;MQM=59	STIM1	3'UTR	STIM1:NM_001277961.1:3'UTR:MODIFIER:exon12/12:c.*443G>A:,STIM1:NM_001277962.1:3'UTR:MODIFIER:exon13/13:c.*915G>A:,STIM1:NM_003156.3:3'UTR:MODIFIER:exon12/12:c.*443G>A:		rs76833585	0.0397	0.0000	0/0/0	0.0117							605921 [STIM1 (provisional) Immunodeficiency 10,612783|Myopathy,tubular aggregate,1 160565|Stormorken syndrome,185070];				3	23					STIM1 (inh=AR+AD pLI=0.93)
chr11	5248243	5248243	A	G	het	het	hom		QUAL=23335;DP=418,367,425;MQM=59	HBB	synonymous,sequence_feature	HBB:NM_000518.4:synonymous:LOW:exon1/3:c.9T>C:p.His3His,HBB:NM_000518.4:sequence_feature:LOW:exon1/3:c.9T>C:		rs713040	0.7143	0.7671	36531/23436/3939	0.7564							141900 [HBB (confirmed) Sickle cell anemia,603903|Thalassemias,beta-,613985|Erythremias,beta-|Methemoglobinemias,beta-|Heinz body anemias,beta-,140700|Thalassemia-beta,dominant inclusion-body,603902|Hereditary persistence of fetal hemoglobin,141749|Delta-beta thalassemia,141749|Malaria,resistance to,611162];	RCV000173144.2 [benign]; RCV000271089.1 [benign]; RCV000328523.1 [benign]; RCV000362141.1 [benign]; RCV000016529.2 [other]; 			1058	448					HBB (inh=AR+AD pLI=0.00)
chr11	6411936	6411941	GCTGGC	-	het	hom	wt		QUAL=3986;DP=53,36,47;MQM=59	SMPD1	disruptive_inframe_deletion,5'UTR,non_coding_transcript_exon	SMPD1:NM_000543.4:disruptive_inframe_deletion:MODERATE:exon1/6:c.138_143delGCTGGC:p.Leu47_Ala48del,SMPD1:NM_001007593.2:disruptive_inframe_deletion:MODERATE:exon1/6:c.138_143delGCTGGC:p.Leu47_Ala48del,SMPD1:NM_001318087.1:disruptive_inframe_deletion:MODERATE:exon1/6:c.138_143delGCTGGC:p.Leu47_Ala48del,SMPD1:NM_001318088.1:5'UTR:MODIFIER:exon1/6:c.-824_-819delGCTGGC:,SMPD1:NR_027400.2:non_coding_transcript_exon:MODIFIER:exon1/5:n.323_328delGCTGGC:,SMPD1:NR_134502.1:non_coding_transcript_exon:MODIFIER:exon1/6:n.323_328delGCTGGC:	(CTGGCG)n	rs3838786;rs558809956	0.0000	0.2239	6066/4023/610	0.1941							607608 [SMPD1 (confirmed) Niemann-Pick disease,type A,257200|Niemann-Pick disease,type B,607616];	RCV000248934.2,RCV000248934.2 [benign,benign]; 		COSM930080, COSM930081	245	727					SMPD1 (inh=AR pLI=0.00)
chr11	6411935	6411935	T	C	het	wt	hom		QUAL=3986;DP=53,36,47;MQM=60	SMPD1	missense,5'UTR,non_coding_transcript_exon	SMPD1:NM_000543.4:missense:MODERATE:exon1/6:c.107T>C:p.Val36Ala,SMPD1:NM_001007593.2:missense:MODERATE:exon1/6:c.107T>C:p.Val36Ala,SMPD1:NM_001318087.1:missense:MODERATE:exon1/6:c.107T>C:p.Val36Ala,SMPD1:NM_001318088.1:5'UTR:MODIFIER:exon1/6:c.-855T>C:,SMPD1:NR_027400.2:non_coding_transcript_exon:MODIFIER:exon1/5:n.292T>C:,SMPD1:NR_134502.1:non_coding_transcript_exon:MODIFIER:exon1/6:n.292T>C:	(CTGGCG)n	rs1050228	0.5613	0.5580	18416/8580/254	0.4869	0.5000	T,T,T,T	T	B,B	T,T,T,T	0.02	607608 [SMPD1 (confirmed) Niemann-Pick disease,type A,257200|Niemann-Pick disease,type B,607616];	RCV000079189.5 [benign]; RCV000315171.1 [benign]; 	CM154141 [CLASS=R MUT=ALT PHEN="Niemann-Pick disease" GENE=SMPD1]; 	COSM1561696, COSM1561695	509	765	2	[2] Ute Grasshoff 28.10.2015			SMPD1 (inh=AR pLI=0.00)
chr11	6415463	6415463	G	A	het	hom	wt	pred_pathogenic	QUAL=13168;DP=363,265,342;MQM=59	SMPD1	missense,3'UTR,non_coding_transcript_exon	SMPD1:NM_000543.4:missense:MODERATE:exon6/6:c.1522G>A:p.Gly508Arg,SMPD1:NM_001007593.2:missense:MODERATE:exon6/6:c.1519G>A:p.Gly507Arg,SMPD1:NM_001318088.1:missense:MODERATE:exon6/6:c.601G>A:p.Gly201Arg,SMPD1:NM_001318087.1:3'UTR:MODIFIER:exon6/6:c.*15G>A:,SMPD1:NR_027400.2:non_coding_transcript_exon:MODIFIER:exon5/5:n.1535G>A:,SMPD1:NR_134502.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.1074G>A:		rs1050239	0.1500	0.1917	2401/1754/95	0.1927	6.2260	T,T,T,T	T	P,P,P	D,D,D,D	22.60	607608 [SMPD1 (confirmed) Niemann-Pick disease,type A,257200|Niemann-Pick disease,type B,607616];	RCV000079195.5 [benign]; RCV000336908.1 [likely benign]; RCV000192218.1 [benign]; 	CM1415110 [CLASS=DP MUT=ALT PHEN="Allergy self-reported association with" GENE=SMPD1]; 	COSM3752608, COSM3752609	63	524					SMPD1 (inh=AR pLI=0.00)
chr11	6634149	6634149	C	T	het	hom	het		QUAL=19952;DP=358,313,395;MQM=59	TPP1	3'UTR	TPP1:NM_000391.3:3'UTR:MODIFIER:exon13/13:c.*1628G>A:	L2c	rs7488	0.8103	0.0000	0/0/0	0.1332							607998 [TPP1 (confirmed) Ceroid lipofuscinosis,neuronal,2,204500|Spinocerebellar ataxia,autosomal recessive 7,609270];	RCV000363243.1 [benign]; 			120	68					TPP1 (inh=AR pLI=0.03)
chr11	6634189	6634189	G	A	het	het	het		QUAL=14138;DP=437,289,340;MQM=59	TPP1	3'UTR	TPP1:NM_000391.3:3'UTR:MODIFIER:exon13/13:c.*1588C>T:	L2c	rs7487	0.4489	0.0000	0/0/0	0.0893							607998 [TPP1 (confirmed) Ceroid lipofuscinosis,neuronal,2,204500|Spinocerebellar ataxia,autosomal recessive 7,609270];	RCV000273317.1 [benign]; 			71	92					TPP1 (inh=AR pLI=0.03)
chr11	6634659	6634659	C	G	wt	het	wt		QUAL=1230;DP=304,104,125;MQM=60	TPP1	3'UTR	TPP1:NM_000391.3:3'UTR:MODIFIER:exon13/13:c.*1118G>C:		rs1045450	0.3351	0.0000	0/0/0	0.0395							607998 [TPP1 (confirmed) Ceroid lipofuscinosis,neuronal,2,204500|Spinocerebellar ataxia,autosomal recessive 7,609270];	RCV000316562.1 [benign]; 			11	68					TPP1 (inh=AR pLI=0.03)
chr11	6636106	6636106	T	A	wt	het	wt		QUAL=1286;DP=137,124,182;MQM=60	TPP1	synonymous	TPP1:NM_000391.3:synonymous:LOW:exon12/13:c.1542A>T:p.Gly514Gly		rs1128396	0.2312	0.1933	2381/1086/247	0.1860							607998 [TPP1 (confirmed) Ceroid lipofuscinosis,neuronal,2,204500|Spinocerebellar ataxia,autosomal recessive 7,609270];	RCV000118652.3 [other]; RCV000395501.1 [benign]; 		COSM3752668	82	702					TPP1 (inh=AR pLI=0.03)
chr11	6637740	6637743	TTTT	-	hom	hom	hom		QUAL=1108;DP=49,44,53;MQM=59	TPP1	splice_region&intron	TPP1:NM_000391.3:splice_region&intron:LOW:exon7/12:c.887-9_887-6delAAAA:	(T)n	rs769864650	0.0000	0.0272	0/0/0	0.0057							607998 [TPP1 (confirmed) Ceroid lipofuscinosis,neuronal,2,204500|Spinocerebellar ataxia,autosomal recessive 7,609270];				28	7					TPP1 (inh=AR pLI=0.03)
chr11	9800601	9800601	G	A	het	het	hom		QUAL=6576;DP=189,66,88;MQM=60	SBF2,SBF2-AS1	3'UTR,intron	SBF2:NM_030962.3:3'UTR:MODIFIER:exon40/40:c.*1364C>T:,SBF2-AS1:NR_036485.1:intron:MODIFIER:exon1/2:n.211+20551G>A:		rs10118	0.6108	0.0000	0/0/0	0.1228							607697 [SBF2 (confirmed) Charcot-Marie-Tooth disease,type 4B2,604563];	RCV000278813.1 [benign]; 			97	111					SBF2 (inh=AR pLI=0.38), SBF2-AS1 (inh=n/a pLI=n/a)
chr11	9801925	9801925	T	G	het	het	hom		QUAL=20468;DP=272,304,414;MQM=60	SBF2,SBF2-AS1	3'UTR,intron	SBF2:NM_030962.3:3'UTR:MODIFIER:exon40/40:c.*40A>C:,SBF2-AS1:NR_036485.1:intron:MODIFIER:exon1/2:n.211+21875T>G:		rs3751000	0.3275	0.3090	5548/2156/529	0.2912							607697 [SBF2 (confirmed) Charcot-Marie-Tooth disease,type 4B2,604563];	RCV000299034.1 [benign]; 			67	312					SBF2 (inh=AR pLI=0.38), SBF2-AS1 (inh=n/a pLI=n/a)
chr11	9812236	9812236	G	A	hom	hom	hom		QUAL=9387;DP=145,58,82;MQM=59	SBF2,SBF2-AS1	splice_region&intron,intron	SBF2:NM_030962.3:splice_region&intron:LOW:exon33/39:c.4571-6C>T:,SBF2-AS1:NR_036485.1:intron:MODIFIER:exon1/2:n.212-17159G>A:		rs2645029	0.8027	0.8584	44419/26489/3513	0.8256							607697 [SBF2 (confirmed) Charcot-Marie-Tooth disease,type 4B2,604563];	RCV000249680.1 [benign]; RCV000349837.1 [benign]; 			1186	317					SBF2 (inh=AR pLI=0.38), SBF2-AS1 (inh=n/a pLI=n/a)
chr11	10019879	10019879	G	A	wt	het	het		QUAL=3587;DP=236,104,156;MQM=60	SBF2	synonymous	SBF2:NM_030962.3:synonymous:LOW:exon9/40:c.909C>T:p.Pro303Pro		rs16907355	0.0637	0.0760	508/238/4	0.0727							607697 [SBF2 (confirmed) Charcot-Marie-Tooth disease,type 4B2,604563];	RCV000127863.1 [benign]; RCV000397057.1 [likely benign]; 			24	271					SBF2 (inh=AR pLI=0.38)
chr11	13514053	13514053	G	T	wt	het	wt	anno_pathogenic_clinvar	QUAL=3661;DP=426,267,323;MQM=60	PTH	synonymous	PTH:NM_001316352.1:synonymous:LOW:exon3/3:c.343C>A:p.Arg115Arg,PTH:NM_000315.3:synonymous:LOW:exon3/3:c.247C>A:p.Arg83Arg		rs6256	0.1514	0.1611	1978/845/24	0.1560							168450 [PTH (confirmed) Hypoparathyroidism,autosomal dominant,146200|Hypoparathyroidism,autosomal recessive,146200];	RCV000014767.25 [pathogenic]; RCV000245073.1 [benign]; RCV000334070.1 [benign]; 		COSM3998350	68	438	1	[1] Ute Grasshoff 13.08.2014			PTH (inh=AD pLI=0.27)
chr11	13514417	13514417	C	T	het	het	hom		QUAL=9272;DP=233,133,139;MQM=60	PTH	splice_region&intron	PTH:NM_001316352.1:splice_region&intron:LOW:exon1/2:c.92-10G>A:,PTH:NM_000315.3:splice_region&intron:LOW:exon1/2:c.-5-10G>A:		rs694	0.4177	0.5579	19191/13468/337	0.5370							168450 [PTH (confirmed) Hypoparathyroidism,autosomal dominant,146200|Hypoparathyroidism,autosomal recessive,146200];	RCV000254294.1 [benign]; RCV000289575.1 [benign]; 			391	444					PTH (inh=AD pLI=0.27)
chr11	17408025	17408025	A	G	het	het	wt		QUAL=4454;DP=177,231,267;MQM=60	KCNJ11	3'UTR	KCNJ11:NM_000525.3:3'UTR:MODIFIER:exon1/1:c.*441T>C:,KCNJ11:NM_001166290.1:3'UTR:MODIFIER:exon2/2:c.*441T>C:		rs2285676	0.4689	0.0000	0/0/0	0.0709							600937 [KCNJ11 (confirmed) Hyperinsulinemic hypoglycemia,familial,2,601820|Diabetes,permanent neonatal,606176|Diabetes mellitus,permanent neonatal,with neurologic features,606176|Diabetes mellitus,type 2,susceptibility to,125853|Diabetes mellitus,transient neonatal,3,610582|Maturity-onset diabetes of the young,type 13,616329];	RCV000301359.1 [likely benign]; RCV000356199.1 [likely benign]; RCV000400519.1 [likely benign]; 			20	118					KCNJ11 (inh=AR+AD pLI=0.31)
chr11	17408251	17408251	G	A	het	het	wt		QUAL=5891;DP=260,299,422;MQM=59	KCNJ11	3'UTR	KCNJ11:NM_000525.3:3'UTR:MODIFIER:exon1/1:c.*215C>T:,KCNJ11:NM_001166290.1:3'UTR:MODIFIER:exon2/2:c.*215C>T:		rs5210	0.4677	0.0000	0/0/0	0.0708							600937 [KCNJ11 (confirmed) Hyperinsulinemic hypoglycemia,familial,2,601820|Diabetes,permanent neonatal,606176|Diabetes mellitus,permanent neonatal,with neurologic features,606176|Diabetes mellitus,type 2,susceptibility to,125853|Diabetes mellitus,transient neonatal,3,610582|Maturity-onset diabetes of the young,type 13,616329];	RCV000293997.1 [likely benign]; RCV000348877.1 [likely benign]; RCV000395953.1 [likely benign]; 	CS035715 [CLASS=DFP MUT=ALT PHEN="Diabetes type 2 association with" GENE=KCNJ11]; 		20	118					KCNJ11 (inh=AR+AD pLI=0.31)
chr11	17408404	17408404	C	T	hom	hom	het		QUAL=27272;DP=218,450,620;MQM=59	KCNJ11	3'UTR	KCNJ11:NM_000525.3:3'UTR:MODIFIER:exon1/1:c.*62G>A:,KCNJ11:NM_001166290.1:3'UTR:MODIFIER:exon2/2:c.*62G>A:		rs5213	0.7358	0.0000	0/0/0	0.1333							600937 [KCNJ11 (confirmed) Hyperinsulinemic hypoglycemia,familial,2,601820|Diabetes,permanent neonatal,606176|Diabetes mellitus,permanent neonatal,with neurologic features,606176|Diabetes mellitus,type 2,susceptibility to,125853|Diabetes mellitus,transient neonatal,3,610582|Maturity-onset diabetes of the young,type 13,616329];	RCV000275742.1 [likely benign]; RCV000324987.1 [likely benign]; RCV000370291.1 [likely benign]; 			318	371					KCNJ11 (inh=AR+AD pLI=0.31)
chr11	17408630	17408630	C	T	hom	hom	het	pred_pathogenic	QUAL=39002;DP=337,617,763;MQM=59	KCNJ11	missense	KCNJ11:NM_000525.3:missense:MODERATE:exon1/1:c.1009G>A:p.Val337Ile,KCNJ11:NM_001166290.1:missense:MODERATE:exon2/2:c.748G>A:p.Val250Ile		rs5215	0.7306	0.6448	25728/13093/4355	0.6426	-0.1400	T,T	T	B	D,D	12.36	600937 [KCNJ11 (confirmed) Hyperinsulinemic hypoglycemia,familial,2,601820|Diabetes,permanent neonatal,606176|Diabetes mellitus,permanent neonatal,with neurologic features,606176|Diabetes mellitus,type 2,susceptibility to,125853|Diabetes mellitus,transient neonatal,3,610582|Maturity-onset diabetes of the young,type 13,616329];	RCV000146099.2 [benign]; RCV000262909.1 [likely benign]; RCV000315713.1 [likely benign]; RCV000357357.1 [likely benign]; 	CM078157 [CLASS=DP MUT=REF PHEN="Diabetes mellitus 2 association with" GENE=KCNJ11]; 		670	755					KCNJ11 (inh=AR+AD pLI=0.31)
chr11	17408838	17408838	G	C	het	wt	het		QUAL=9816;DP=276,413,495;MQM=59	KCNJ11	synonymous	KCNJ11:NM_000525.3:synonymous:LOW:exon1/1:c.801C>G:p.Leu267Leu,KCNJ11:NM_001166290.1:synonymous:LOW:exon2/2:c.540C>G:p.Leu180Leu		rs5216	0.0134	0.0174	26/12/0	0.0178							600937 [KCNJ11 (confirmed) Hyperinsulinemic hypoglycemia,familial,2,601820|Diabetes,permanent neonatal,606176|Diabetes mellitus,permanent neonatal,with neurologic features,606176|Diabetes mellitus,type 2,susceptibility to,125853|Diabetes mellitus,transient neonatal,3,610582|Maturity-onset diabetes of the young,type 13,616329];	RCV000146118.3 [benign]; RCV000289500.1 [likely benign]; RCV000351492.1 [likely benign]; RCV000381795.1 [likely benign]; 	CM156016 [CLASS=R MUT=ALT PHEN="Hyperinsulinaemic hypoglycaemia" GENE=KCNJ11]; 		1	70					KCNJ11 (inh=AR+AD pLI=0.31)
chr11	17409069	17409069	G	A	het	het	wt		QUAL=6285;DP=215,313,384;MQM=60	KCNJ11	synonymous	KCNJ11:NM_000525.3:synonymous:LOW:exon1/1:c.570C>T:p.Ala190Ala,KCNJ11:NM_001166290.1:synonymous:LOW:exon2/2:c.309C>T:p.Ala103Ala		rs5218	0.2274	0.2582	4538/2773/34	0.2600							600937 [KCNJ11 (confirmed) Hyperinsulinemic hypoglycemia,familial,2,601820|Diabetes,permanent neonatal,606176|Diabetes mellitus,permanent neonatal,with neurologic features,606176|Diabetes mellitus,type 2,susceptibility to,125853|Diabetes mellitus,transient neonatal,3,610582|Maturity-onset diabetes of the young,type 13,616329];	RCV000146111.2 [benign]; RCV000300958.1 [likely benign]; RCV000353536.1 [likely benign]; RCV000398496.1 [likely benign]; 	CM035697 [CLASS=DFP MUT=REF PHEN="Diabetes type 2 association with" GENE=KCNJ11]; 	COSM3752262	102	592					KCNJ11 (inh=AR+AD pLI=0.31)
chr11	17409572	17409572	T	C	hom	hom	het	pred_pathogenic	QUAL=22496;DP=234,377,439;MQM=59	KCNJ11	missense,intron	KCNJ11:NM_000525.3:missense:MODERATE:exon1/1:c.67A>G:p.Lys23Glu,KCNJ11:NM_001166290.1:intron:MODIFIER:exon1/1:c.-16-179A>G:		rs5219	0.7370	0.6471	25897/13054/4555	0.6432	2.0650	T	T	B	D	0.13	600937 [KCNJ11 (confirmed) Hyperinsulinemic hypoglycemia,familial,2,601820|Diabetes,permanent neonatal,606176|Diabetes mellitus,permanent neonatal,with neurologic features,606176|Diabetes mellitus,type 2,susceptibility to,125853|Diabetes mellitus,transient neonatal,3,610582|Maturity-onset diabetes of the young,type 13,616329];	RCV000009214.4 [other]; RCV000009215.4 [drug response]; RCV000020356.2 [benign]; RCV000146116.3 [benign]; RCV000281825.1 [other]; RCV000294608.1 [other]; RCV000385348.1 [likely benign]; 	CM981121 [CLASS=DFP MUT=REF PHEN="Diabetes mellitus 2 association with" GENE=KCNJ11]; 	COSM3765554	669	756					KCNJ11 (inh=AR+AD pLI=0.31)
chr11	17410136	17410136	A	G	het	wt	het		QUAL=619;DP=57,24,39;MQM=55	KCNJ11	5'UTR,intron	KCNJ11:NM_000525.3:5'UTR:MODIFIER:exon1/1:c.-498T>C:,KCNJ11:NM_001166290.1:intron:MODIFIER:exon1/1:c.-17+585T>C:	AluSg	rs529946415	0.0030	0.0000	0/0/0	0.0027							600937 [KCNJ11 (confirmed) Hyperinsulinemic hypoglycemia,familial,2,601820|Diabetes,permanent neonatal,606176|Diabetes mellitus,permanent neonatal,with neurologic features,606176|Diabetes mellitus,type 2,susceptibility to,125853|Diabetes mellitus,transient neonatal,3,610582|Maturity-onset diabetes of the young,type 13,616329];	RCV000270522.1 [other]; RCV000307819.1 [other]; RCV000310444.1 [uncertain significance]; RCV000404230.1 [likely benign]; 			0	1					KCNJ11 (inh=AR+AD pLI=0.31)
chr11	17410145	17410145	A	-	het	het	wt	low_DP	QUAL=752;DP=46,19,31;MQM=57	KCNJ11	5'UTR,intron	KCNJ11:NM_000525.3:5'UTR:MODIFIER:exon1/1:c.-507delT:,KCNJ11:NM_001166290.1:intron:MODIFIER:exon1/1:c.-17+576delT:	AluSg	rs397808534	0.0000	0.0000	0/0/0	0.2678							600937 [KCNJ11 (confirmed) Hyperinsulinemic hypoglycemia,familial,2,601820|Diabetes,permanent neonatal,606176|Diabetes mellitus,permanent neonatal,with neurologic features,606176|Diabetes mellitus,type 2,susceptibility to,125853|Diabetes mellitus,transient neonatal,3,610582|Maturity-onset diabetes of the young,type 13,616329];				17	86					KCNJ11 (inh=AR+AD pLI=0.31)
chr11	17414570	17414570	C	T	wt	het	wt	pred_pathogenic	QUAL=3615;DP=176,277,386;MQM=60	ABCC8	missense	ABCC8:NM_001287174.1:missense:MODERATE:exon39/39:c.4717G>A:p.Val1573Ile,ABCC8:NM_000352.4:missense:MODERATE:exon39/39:c.4714G>A:p.Val1572Ile		rs8192690	0.0312	0.0562	265/187/6	0.0545	0.6630	T,T	T	B	D,D	12.72	600509 [ABCC8 (confirmed) Hyperinsulinemic hypoglycemia,familial,1,256450|Hypoglycemia of infancy,leucine-sensitive,240800|Diabetes mellitus,transient neonatal 2,610374|Diabetes mellitus,noninsulin-dependent,125853|Diabetes mellitus,permanent neonatal,606176];	RCV000145003.2 [benign]; RCV000293707.1 [other]; RCV000348648.1 [likely benign]; RCV000364373.1 [benign]; RCV000389101.1 [other]; 			18	237					ABCC8 (inh=AR+AD pLI=0.00)
chr11	17418477	17418477	C	A	hom	hom	het	pred_pathogenic	QUAL=12018;DP=118,198,331;MQM=60	ABCC8	missense	ABCC8:NM_001287174.1:missense:MODERATE:exon33/39:c.4108G>T:p.Ala1370Ser,ABCC8:NM_000352.4:missense:MODERATE:exon33/39:c.4105G>T:p.Ala1369Ser		rs757110	0.7264	0.6431	25565/12982/4579	0.6402	0.1700	T,T,.	T,T	B,.	D,D,.	10.25	600509 [ABCC8 (confirmed) Hyperinsulinemic hypoglycemia,familial,1,256450|Hypoglycemia of infancy,leucine-sensitive,240800|Diabetes mellitus,transient neonatal 2,610374|Diabetes mellitus,noninsulin-dependent,125853|Diabetes mellitus,permanent neonatal,606176];	RCV000144996.2 [other]; RCV000269263.1 [benign]; RCV000326750.1 [benign]; RCV000388290.1 [benign]; 	CM004821 [CLASS=DFP MUT=REF PHEN="Enhanced insulin secretion in pregnancy association" GENE=ABCC8]; 		645	744					ABCC8 (inh=AR+AD pLI=0.00)
chr11	17419279	17419279	C	T	het	wt	het		QUAL=5196;DP=126,131,218;MQM=59	ABCC8	synonymous,sequence_feature	ABCC8:NM_001287174.1:synonymous:LOW:exon31/39:c.3822G>A:p.Arg1274Arg,ABCC8:NM_000352.4:synonymous:LOW:exon31/39:c.3819G>A:p.Arg1273Arg,ABCC8:NM_001287174.1:sequence_feature:LOW:exon31/39:c.3822G>A:,ABCC8:NM_000352.4:sequence_feature:LOW:exon31/39:c.3819G>A:		rs1799859	0.3910	0.2962	6572/2174/2599	0.2933	0.3110		T			16.01	600509 [ABCC8 (confirmed) Hyperinsulinemic hypoglycemia,familial,1,256450|Hypoglycemia of infancy,leucine-sensitive,240800|Diabetes mellitus,transient neonatal 2,610374|Diabetes mellitus,noninsulin-dependent,125853|Diabetes mellitus,permanent neonatal,606176];	RCV000144994.3 [other]; RCV000276828.1 [benign]; RCV000330489.1 [benign]; RCV000389902.1 [benign]; 	CM981881 [CLASS=DP MUT=ALT PHEN="Hyperinsulinaemia association with" GENE=ABCC8]; 	COSM3752264	146	665					ABCC8 (inh=AR+AD pLI=0.00)
chr11	17434284	17434284	G	A	wt	het	wt		QUAL=2208;DP=206,151,168;MQM=60	ABCC8	synonymous	ABCC8:NM_001287174.1:synonymous:LOW:exon21/39:c.2488C>T:p.Leu830Leu,ABCC8:NM_000352.4:synonymous:LOW:exon21/39:c.2485C>T:p.Leu829Leu		rs1805036	0.1202	0.1251	696/253/299	0.0961							600509 [ABCC8 (confirmed) Hyperinsulinemic hypoglycemia,familial,1,256450|Hypoglycemia of infancy,leucine-sensitive,240800|Diabetes mellitus,transient neonatal 2,610374|Diabetes mellitus,noninsulin-dependent,125853|Diabetes mellitus,permanent neonatal,606176];	RCV000144986.2 [other]; RCV000269562.1 [benign]; RCV000304886.1 [benign]; RCV000364184.1 [benign]; 			14	276					ABCC8 (inh=AR+AD pLI=0.00)
chr11	17448704	17448704	G	A	het	het	wt		QUAL=3423;DP=141,225,340;MQM=60	ABCC8	splice_region&intron	ABCC8:NM_001287174.1:splice_region&intron:LOW:exon15/38:c.2117-3C>T:,ABCC8:NM_000352.4:splice_region&intron:LOW:exon15/38:c.2117-3C>T:		rs1799854	0.3684	0.4346	11790/6320/135	0.4215							600509 [ABCC8 (confirmed) Hyperinsulinemic hypoglycemia,familial,1,256450|Hypoglycemia of infancy,leucine-sensitive,240800|Diabetes mellitus,transient neonatal 2,610374|Diabetes mellitus,noninsulin-dependent,125853|Diabetes mellitus,permanent neonatal,606176];	RCV000144983.3 [other]; RCV000306691.1 [benign]; RCV000341582.1 [benign]; RCV000396912.1 [benign]; 	CS991507 [CLASS=DP MUT=ALT PHEN="Diabetes mellitus 2 association with" GENE=ABCC8]; 		295	735					ABCC8 (inh=AR+AD pLI=0.00)
chr11	17449929	17449929	C	T	wt	wt	het		QUAL=2874;DP=180,155,209;MQM=60	ABCC8	synonymous	ABCC8:NM_001287174.1:synonymous:LOW:exon14/39:c.1947G>A:p.Lys649Lys,ABCC8:NM_000352.4:synonymous:LOW:exon14/39:c.1947G>A:p.Lys649Lys		rs1799858	0.2021	0.1785	2157/833/178	0.1740							600509 [ABCC8 (confirmed) Hyperinsulinemic hypoglycemia,familial,1,256450|Hypoglycemia of infancy,leucine-sensitive,240800|Diabetes mellitus,transient neonatal 2,610374|Diabetes mellitus,noninsulin-dependent,125853|Diabetes mellitus,permanent neonatal,606176];	RCV000144981.3 [other]; RCV000286519.1 [benign]; RCV000343598.1 [benign]; RCV000378609.1 [benign]; 	CM035686 [CLASS=DP MUT=ALT PHEN="Diabetes type 2 association with" GENE=ABCC8]; 	COSM3752265	40	382					ABCC8 (inh=AR+AD pLI=0.00)
chr11	17452492	17452492	G	A	wt	het	het		QUAL=760;DP=39,38,48;MQM=60	ABCC8	synonymous	ABCC8:NM_001287174.1:synonymous:LOW:exon12/39:c.1686C>T:p.His562His,ABCC8:NM_000352.4:synonymous:LOW:exon12/39:c.1686C>T:p.His562His		rs1799857	0.4299	0.4311	11353/6511/1165	0.4250							600509 [ABCC8 (confirmed) Hyperinsulinemic hypoglycemia,familial,1,256450|Hypoglycemia of infancy,leucine-sensitive,240800|Diabetes mellitus,transient neonatal 2,610374|Diabetes mellitus,noninsulin-dependent,125853|Diabetes mellitus,permanent neonatal,606176];	RCV000144979.2 [other]; RCV000302706.1 [benign]; RCV000359236.1 [benign]; RCV000402117.1 [benign]; 		COSM4145596	337	736					ABCC8 (inh=AR+AD pLI=0.00)
chr11	17496516	17496516	A	G	het	het	wt		QUAL=8988;DP=331,407,532;MQM=59	ABCC8	synonymous	ABCC8:NM_001287174.1:synonymous:LOW:exon2/39:c.207T>C:p.Pro69Pro,ABCC8:NM_000352.4:synonymous:LOW:exon2/39:c.207T>C:p.Pro69Pro		rs1048099	0.4393	0.4740	13970/8522/818	0.4705							600509 [ABCC8 (confirmed) Hyperinsulinemic hypoglycemia,familial,1,256450|Hypoglycemia of infancy,leucine-sensitive,240800|Diabetes mellitus,transient neonatal 2,610374|Diabetes mellitus,noninsulin-dependent,125853|Diabetes mellitus,permanent neonatal,606176];	RCV000144982.3 [other]; RCV000314568.1 [benign]; RCV000334473.1 [benign]; RCV000405380.1 [benign]; 	CM129527 [CLASS=DFP MUT=ALT PHEN="Diabetes mellitus protection against" GENE=ABCC8]; 	COSM3752266	419	758					ABCC8 (inh=AR+AD pLI=0.00)
chr11	17515459	17515459	-	TGTT	hom	hom	het		QUAL=8861;DP=150,71,81;MQM=59	USH1C	3'UTR,non_coding_transcript_exon	USH1C:NM_153676.3:3'UTR:MODIFIER:exon27/27:c.*419_*420insAACA:,USH1C:NM_001297764.1:3'UTR:MODIFIER:exon20/20:c.*451_*452insAACA:,USH1C:NM_005709.3:3'UTR:MODIFIER:exon21/21:c.*451_*452insAACA:,USH1C:NR_123738.1:non_coding_transcript_exon:MODIFIER:exon20/20:n.2145_2146insAACA:		rs10649542	0.9453	0.0000	0/0/0	0.8462							605242 [USH1C (confirmed) Usher syndrome,type 1C,276904|Deafness,autosomal recessive 18A,602092];	RCV000292469.1 [benign]; RCV000347392.1 [benign]; 			219	11					USH1C (inh=AR pLI=0.00)
chr11	17515668	17515668	T	C	het	het	wt		QUAL=8900;DP=324,430,575;MQM=59	USH1C	3'UTR,non_coding_transcript_exon	USH1C:NM_153676.3:3'UTR:MODIFIER:exon27/27:c.*211A>G:,USH1C:NM_001297764.1:3'UTR:MODIFIER:exon20/20:c.*243A>G:,USH1C:NM_005709.3:3'UTR:MODIFIER:exon21/21:c.*243A>G:,USH1C:NR_123738.1:non_coding_transcript_exon:MODIFIER:exon20/20:n.1937A>G:		rs1055581	0.3826	0.0000	0/0/0	0.0713							605242 [USH1C (confirmed) Usher syndrome,type 1C,276904|Deafness,autosomal recessive 18A,602092];	RCV000303954.1 [likely benign]; RCV000358662.1 [likely benign]; 			54	113					USH1C (inh=AR pLI=0.00)
chr11	17515693	17515693	G	A	het	het	wt		QUAL=9016;DP=324,434,584;MQM=59	USH1C	3'UTR,non_coding_transcript_exon	USH1C:NM_153676.3:3'UTR:MODIFIER:exon27/27:c.*186C>T:,USH1C:NM_001297764.1:3'UTR:MODIFIER:exon20/20:c.*218C>T:,USH1C:NM_005709.3:3'UTR:MODIFIER:exon21/21:c.*218C>T:,USH1C:NR_123738.1:non_coding_transcript_exon:MODIFIER:exon20/20:n.1912C>T:		rs1055577	0.3666	0.0000	0/0/0	0.0705							605242 [USH1C (confirmed) Usher syndrome,type 1C,276904|Deafness,autosomal recessive 18A,602092];	RCV000264175.1 [likely benign]; RCV000319324.1 [likely benign]; 			53	113					USH1C (inh=AR pLI=0.00)
chr11	17515833	17515833	A	G	het	het	wt		QUAL=7290;DP=284,308,441;MQM=59	USH1C	3'UTR,non_coding_transcript_exon	USH1C:NM_153676.3:3'UTR:MODIFIER:exon27/27:c.*46T>C:,USH1C:NM_001297764.1:3'UTR:MODIFIER:exon20/20:c.*78T>C:,USH1C:NM_005709.3:3'UTR:MODIFIER:exon21/21:c.*78T>C:,USH1C:NR_123738.1:non_coding_transcript_exon:MODIFIER:exon20/20:n.1772T>C:		rs1055574	0.3704	0.4536	8142/5336/674	0.4005							605242 [USH1C (confirmed) Usher syndrome,type 1C,276904|Deafness,autosomal recessive 18A,602092];	RCV000244578.1 [benign]; RCV000294252.1 [likely benign]; RCV000330604.1 [likely benign]; 			186	455					USH1C (inh=AR pLI=0.00)
chr11	17519742	17519742	C	G	het	het	wt	pred_pathogenic	QUAL=8770;DP=370,365,584;MQM=59	USH1C	missense,non_coding_transcript_exon	USH1C:NM_153676.3:missense:MODERATE:exon24/27:c.2457G>C:p.Glu819Asp,USH1C:NM_001297764.1:missense:MODERATE:exon18/20:c.1500G>C:p.Glu500Asp,USH1C:NM_005709.3:missense:MODERATE:exon19/21:c.1557G>C:p.Glu519Asp,USH1C:NR_123738.1:non_coding_transcript_exon:MODIFIER:exon18/20:n.1592G>C:		rs1064074	0.4209	0.4875	14857/10035/925	0.4840	0.6000	T,T,D,D	T	B,B,B	T,T,T,T	24.40	605242 [USH1C (confirmed) Usher syndrome,type 1C,276904|Deafness,autosomal recessive 18A,602092];	RCV000041279.3 [benign]; RCV000302668.1 [likely benign]; RCV000390848.1 [likely benign]; 		COSM3736036, COSM3736035	434	756					USH1C (inh=AR pLI=0.00)
chr11	17522638	17522638	G	A	wt	het	wt		QUAL=2071;DP=106,182,256;MQM=60	USH1C	synonymous,non_coding_transcript_exon	USH1C:NM_153676.3:synonymous:LOW:exon23/27:c.2340C>T:p.Val780Val,USH1C:NM_001297764.1:synonymous:LOW:exon17/20:c.1383C>T:p.Val461Val,USH1C:NM_005709.3:synonymous:LOW:exon18/21:c.1440C>T:p.Val480Val,USH1C:NR_123738.1:non_coding_transcript_exon:MODIFIER:exon17/20:n.1475C>T:		rs10832796	0.1905	0.2520	4052/2801/19	0.2504							605242 [USH1C (confirmed) Usher syndrome,type 1C,276904|Deafness,autosomal recessive 18A,602092];	RCV000041273.3 [benign]; RCV000276982.1 [likely benign]; RCV000331988.1 [likely benign]; 			131	588					USH1C (inh=AR pLI=0.00)
chr11	17542439	17542439	T	C	hom	het	hom		QUAL=20959;DP=222,255,348;MQM=59	USH1C	synonymous,non_coding_transcript_exon	USH1C:NM_153676.3:synonymous:LOW:exon14/27:c.1188A>G:p.Pro396Pro,USH1C:NM_001297764.1:synonymous:LOW:exon13/20:c.1131A>G:p.Pro377Pro,USH1C:NM_005709.3:synonymous:LOW:exon14/21:c.1188A>G:p.Pro396Pro,USH1C:NR_123738.1:non_coding_transcript_exon:MODIFIER:exon14/20:n.1297A>G:		rs2240487	0.5164	0.5689	20210/11477/602	0.5607							605242 [USH1C (confirmed) Usher syndrome,type 1C,276904|Deafness,autosomal recessive 18A,602092];	RCV000041251.3 [benign]; RCV000351095.1 [likely benign]; RCV000395027.1 [likely benign]; 		COSM4145600, COSM4145599	497	761					USH1C (inh=AR pLI=0.00)
chr11	22214877	22214877	-	AGGAGGAGGGGAATGAGGAGGAGG	het	wt	hom		QUAL=6989;DP=78,296,251;MQM=59	ANO5	5'UTR	ANO5:NM_213599.2:5'UTR:MODIFIER:exon1/22:c.-156_-155insAGGGGAATGAGGAGGAGGAGGAGG:,ANO5:NM_001142649.1:5'UTR:MODIFIER:exon1/22:c.-156_-155insAGGGGAATGAGGAGGAGGAGGAGG:	GA-rich	rs139514865;rs71034576	0.7814	0.0000	0/0/0	0.3097							608662 [ANO5 (confirmed) Gnathodiaphyseal dysplasia,166260|Muscular dystrophy,limb-girdle,type 2L,611307|Miyoshi muscular dystrophy 3,613319];				131	91					ANO5 (inh=AR+AD pLI=0.00)
chr11	22214903	22214903	G	C	het	wt	hom		QUAL=9448;DP=67,289,299;MQM=59	ANO5	5'UTR	ANO5:NM_213599.2:5'UTR:MODIFIER:exon1/22:c.-136G>C:,ANO5:NM_001142649.1:5'UTR:MODIFIER:exon1/22:c.-136G>C:	GA-rich	rs12792259	0.7899	0.0000	0/0/0	0.0890							608662 [ANO5 (confirmed) Gnathodiaphyseal dysplasia,166260|Muscular dystrophy,limb-girdle,type 2L,611307|Miyoshi muscular dystrophy 3,613319];	RCV000128763.1 [not provided]; RCV000267576.1 [benign]; RCV000301651.1 [benign]; RCV000406447.1 [benign]; 			167	62					ANO5 (inh=AR+AD pLI=0.00)
chr11	22242729	22242729	T	C	het	wt	hom		QUAL=13430;DP=368,203,230;MQM=60	ANO5	synonymous	ANO5:NM_213599.2:synonymous:LOW:exon5/22:c.267T>C:p.Asp89Asp,ANO5:NM_001142649.1:synonymous:LOW:exon5/22:c.264T>C:p.Asp88Asp		rs4312063	0.7899	0.7772	37046/21355/4526	0.7670							608662 [ANO5 (confirmed) Gnathodiaphyseal dysplasia,166260|Muscular dystrophy,limb-girdle,type 2L,611307|Miyoshi muscular dystrophy 3,613319];	RCV000082848.7 [benign]; RCV000128783.1 [not provided]; RCV000282244.1 [benign]; RCV000334993.1 [benign]; 		COSM3998372	1024	489					ANO5 (inh=AR+AD pLI=0.00)
chr11	22271870	22271870	A	T	het	wt	hom		QUAL=7567;DP=188,146,161;MQM=60	ANO5	missense	ANO5:NM_213599.2:missense:MODERATE:exon10/22:c.966A>T:p.Leu322Phe,ANO5:NM_001142649.1:missense:MODERATE:exon10/22:c.963A>T:p.Leu321Phe		rs7481951	0.0000	0.4835	15551/11314/142	0.4645	-0.0010	T	T	B	T	13.12	608662 [ANO5 (confirmed) Gnathodiaphyseal dysplasia,166260|Muscular dystrophy,limb-girdle,type 2L,611307|Miyoshi muscular dystrophy 3,613319];	RCV000082855.8 [benign]; RCV000128791.1 [not provided]; RCV000261985.1 [likely benign]; RCV000386589.1 [likely benign]; 		COSM3998373	511	749					ANO5 (inh=AR+AD pLI=0.00)
chr11	22301411	22301412	TT	-	hom	wt	hom		QUAL=3247;DP=131,33,51;MQM=59	ANO5	3'UTR	ANO5:NM_213599.2:3'UTR:MODIFIER:exon22/22:c.*112_*113delTT:,ANO5:NM_001142649.1:3'UTR:MODIFIER:exon22/22:c.*112_*113delTT:	(T)n	rs398015551;rs67178076	0.0000	0.0000	0/0/0	0.2375							608662 [ANO5 (confirmed) Gnathodiaphyseal dysplasia,166260|Muscular dystrophy,limb-girdle,type 2L,611307|Miyoshi muscular dystrophy 3,613319];	RCV000268860.1 [uncertain significance]; RCV000364161.1 [uncertain significance]; 			90	107					ANO5 (inh=AR+AD pLI=0.00)
chr11	22301411	22301411	T	-	wt	hom	wt		QUAL=3247;DP=131,33,51;MQM=60	ANO5	3'UTR	ANO5:NM_213599.2:3'UTR:MODIFIER:exon22/22:c.*113delT:,ANO5:NM_001142649.1:3'UTR:MODIFIER:exon22/22:c.*113delT:	(T)n	rs778938921;rs796159112	0.0000	0.0000	0/0/0	0.1471							608662 [ANO5 (confirmed) Gnathodiaphyseal dysplasia,166260|Muscular dystrophy,limb-girdle,type 2L,611307|Miyoshi muscular dystrophy 3,613319];				12	116					ANO5 (inh=AR+AD pLI=0.00)
chr11	22301807	22301807	A	G	het	wt	hom		QUAL=11079;DP=321,136,182;MQM=60	ANO5	3'UTR	ANO5:NM_213599.2:3'UTR:MODIFIER:exon22/22:c.*496A>G:,ANO5:NM_001142649.1:3'UTR:MODIFIER:exon22/22:c.*496A>G:		rs10766930	0.4441	0.0000	0/0/0	0.0929							608662 [ANO5 (confirmed) Gnathodiaphyseal dysplasia,166260|Muscular dystrophy,limb-girdle,type 2L,611307|Miyoshi muscular dystrophy 3,613319];	RCV000307969.1 [likely benign]; RCV000366171.1 [likely benign]; 			89	114					ANO5 (inh=AR+AD pLI=0.00)
chr11	22302597	22302597	G	T	het	wt	hom		QUAL=7443;DP=223,116,144;MQM=60	ANO5	3'UTR	ANO5:NM_213599.2:3'UTR:MODIFIER:exon22/22:c.*1286G>T:,ANO5:NM_001142649.1:3'UTR:MODIFIER:exon22/22:c.*1286G>T:		rs7925081	0.5675	0.0000	0/0/0	0.0982							608662 [ANO5 (confirmed) Gnathodiaphyseal dysplasia,166260|Muscular dystrophy,limb-girdle,type 2L,611307|Miyoshi muscular dystrophy 3,613319];	RCV000346894.1 [likely benign]; RCV000402414.1 [likely benign]; 			92	109					ANO5 (inh=AR+AD pLI=0.00)
chr11	22303068	22303068	A	-	het	wt	hom		QUAL=12520;DP=245,226,303;MQM=60	ANO5	3'UTR	ANO5:NM_213599.2:3'UTR:MODIFIER:exon22/22:c.*1762delA:,ANO5:NM_001142649.1:3'UTR:MODIFIER:exon22/22:c.*1762delA:		rs398015552	0.4702	0.0000	0/0/0	0.5224							608662 [ANO5 (confirmed) Gnathodiaphyseal dysplasia,166260|Muscular dystrophy,limb-girdle,type 2L,611307|Miyoshi muscular dystrophy 3,613319];	RCV000335659.1 [likely benign]; RCV000400689.1 [likely benign]; 			88	114					ANO5 (inh=AR+AD pLI=0.00)
chr11	22303201	22303204	AAGA	-	het	wt	hom		QUAL=13829;DP=277,226,322;MQM=59	ANO5	3'UTR	ANO5:NM_213599.2:3'UTR:MODIFIER:exon22/22:c.*1894_*1897delAAGA:,ANO5:NM_001142649.1:3'UTR:MODIFIER:exon22/22:c.*1894_*1897delAAGA:		rs397786204	0.4527	0.0000	0/0/0	0.5201							608662 [ANO5 (confirmed) Gnathodiaphyseal dysplasia,166260|Muscular dystrophy,limb-girdle,type 2L,611307|Miyoshi muscular dystrophy 3,613319];	RCV000301948.1 [likely benign]; RCV000401485.1 [likely benign]; 			88	114					ANO5 (inh=AR+AD pLI=0.00)
chr11	22303406	22303406	G	A	het	hom	wt		QUAL=8189;DP=398,76,119;MQM=60	ANO5	3'UTR	ANO5:NM_213599.2:3'UTR:MODIFIER:exon22/22:c.*2095G>A:,ANO5:NM_001142649.1:3'UTR:MODIFIER:exon22/22:c.*2095G>A:		rs142192440	0.0052	0.0000	0/0/0	0.0021							608662 [ANO5 (confirmed) Gnathodiaphyseal dysplasia,166260|Muscular dystrophy,limb-girdle,type 2L,611307|Miyoshi muscular dystrophy 3,613319];	RCV000271617.1 [uncertain significance]; RCV000328962.1 [uncertain significance]; 			1	9					ANO5 (inh=AR+AD pLI=0.00)
chr11	22304489	22304489	C	G	het	wt	hom		QUAL=7759;DP=219,94,148;MQM=60	ANO5	3'UTR	ANO5:NM_213599.2:3'UTR:MODIFIER:exon22/22:c.*3178C>G:,ANO5:NM_001142649.1:3'UTR:MODIFIER:exon22/22:c.*3178C>G:		rs6483841	0.6929	0.0000	0/0/0	0.1099							608662 [ANO5 (confirmed) Gnathodiaphyseal dysplasia,166260|Muscular dystrophy,limb-girdle,type 2L,611307|Miyoshi muscular dystrophy 3,613319];	RCV000259448.1 [benign]; RCV000370241.1 [benign]; 			103	102					ANO5 (inh=AR+AD pLI=0.00)
chr11	22644893	22644893	-	T	hom	hom	hom		QUAL=7748;DP=181,31,28;MQM=59	FANCF	3'UTR	FANCF:NM_022725.3:3'UTR:MODIFIER:exon1/1:c.*1338dupA:		rs45554234	0.0000	0.0000	0/0/0	0.6714							613897 [FANCF (provisional) Fanconi anemia,complementation group F,603467];	RCV000329822.1 [uncertain significance]; 			227	3					FANCF (inh=AR pLI=0.00)
chr11	22645413	22645413	G	A	hom	hom	hom		QUAL=5736;DP=101,55,64;MQM=59	FANCF	3'UTR	FANCF:NM_022725.3:3'UTR:MODIFIER:exon1/1:c.*819C>T:	AluSx3	rs450946	0.9491	0.0000	0/0/0	0.8624							613897 [FANCF (provisional) Fanconi anemia,complementation group F,603467];	RCV000372401.1 [benign]; 			191	2					FANCF (inh=AR pLI=0.00)
chr11	22645600	22645600	C	T	hom	hom	hom		QUAL=9065;DP=174,46,63;MQM=60	FANCF	3'UTR	FANCF:NM_022725.3:3'UTR:MODIFIER:exon1/1:c.*632G>A:		rs444923	0.9714	0.0000	0/0/0	0.1482							613897 [FANCF (provisional) Fanconi anemia,complementation group F,603467];	RCV000341199.1 [benign]; 			230	0					FANCF (inh=AR pLI=0.00)
chr11	22646025	22646025	G	A	hom	hom	hom		QUAL=26262;DP=383,194,215;MQM=59	FANCF	3'UTR	FANCF:NM_022725.3:3'UTR:MODIFIER:exon1/1:c.*207C>T:		rs4447177	0.7037	0.0000	0/0/0	0.1364							613897 [FANCF (provisional) Fanconi anemia,complementation group F,603467];	RCV000274375.1 [benign]; 			153	63					FANCF (inh=AR pLI=0.00)
chr11	30344725	30344725	C	T	wt	het	wt		QUAL=3612;DP=147,258,367;MQM=60	ARL14EP	5'UTR_premature_start_codon_gain,5'UTR	ARL14EP:NM_152316.2:5'UTR_premature_start_codon_gain:LOW:exon1/4:c.-88C>T:,ARL14EP:NM_152316.2:5'UTR:MODIFIER:exon1/4:c.-88C>T:		rs4071559	0.0869	0.0000	0/0/0	0.1187											3	62					ARL14EP (inh=n/a pLI=0.15)
chr11	30352473	30352473	-	AG	hom	hom	hom		QUAL=13795;DP=217,105,131;MQM=59	ARL14EP	5'UTR	ARL14EP:NM_152316.2:5'UTR:MODIFIER:exon2/4:c.-23_-22insAG:		rs35824273	0.0000	0.6882	28383/13960/3255	0.6156											413	400					ARL14EP (inh=n/a pLI=0.15)
chr11	30358475	30358475	A	T	hom	hom	hom		QUAL=19051;DP=316,128,135;MQM=59	ARL14EP	3'UTR	ARL14EP:NM_152316.2:3'UTR:MODIFIER:exon4/4:c.*133A>T:		rs1222206	1.0000	0.0000	0/0/0	0.1496											229	2					ARL14EP (inh=n/a pLI=0.15)
chr11	31807524	31807524	C	T	hom	hom	hom		QUAL=19723;DP=270,133,182;MQM=60	PAX6	3'UTR	PAX6:NM_001258462.1:3'UTR:MODIFIER:exon14/14:c.*3958G>A:,PAX6:NM_001310160.1:3'UTR:MODIFIER:exon10/10:c.*3958G>A:,PAX6:NM_001310161.1:3'UTR:MODIFIER:exon11/11:c.*3958G>A:,PAX6:NM_001258465.1:3'UTR:MODIFIER:exon12/12:c.*3958G>A:,PAX6:NM_000280.4:3'UTR:MODIFIER:exon13/13:c.*3958G>A:,PAX6:NM_001258464.1:3'UTR:MODIFIER:exon13/13:c.*3958G>A:,PAX6:NM_001604.5:3'UTR:MODIFIER:exon14/14:c.*3958G>A:,PAX6:NM_001258463.1:3'UTR:MODIFIER:exon14/14:c.*3958G>A:,PAX6:NM_001310158.1:3'UTR:MODIFIER:exon14/14:c.*3958G>A:,PAX6:NM_001127612.1:3'UTR:MODIFIER:exon13/13:c.*3958G>A:		rs3026401	0.6432	0.0000	0/0/0	0.1198							607108 [PAX6 (confirmed) Aniridia,106210|Cataract with late-onset corneal dystrophy,106210|Anterior segment dysgenesis 5,multiple subtypes,604229|Foveal hypoplasia 1,136520|Keratitis,148190|Optic nerve hypoplasia,165550|Morning glory disc anomaly,120430|Coloboma of optic nerve,120430|Coloboma,ocular,120200];	RCV000272675.1 [benign]; RCV000273772.1 [benign]; RCV000307913.1 [benign]; RCV000327646.1 [benign]; RCV000333466.1 [benign]; RCV000362607.1 [benign]; RCV000386873.1 [benign]; 			149	91					PAX6 (inh=AR+AD pLI=1.00)
chr11	31808235	31808235	-	AAAA	hom	hom	hom		QUAL=16640;DP=196,141,183;MQM=59	PAX6	3'UTR	PAX6:NM_001258462.1:3'UTR:MODIFIER:exon14/14:c.*3246_*3247insTTTT:,PAX6:NM_001310160.1:3'UTR:MODIFIER:exon10/10:c.*3246_*3247insTTTT:,PAX6:NM_001310161.1:3'UTR:MODIFIER:exon11/11:c.*3246_*3247insTTTT:,PAX6:NM_001258465.1:3'UTR:MODIFIER:exon12/12:c.*3246_*3247insTTTT:,PAX6:NM_000280.4:3'UTR:MODIFIER:exon13/13:c.*3246_*3247insTTTT:,PAX6:NM_001258464.1:3'UTR:MODIFIER:exon13/13:c.*3246_*3247insTTTT:,PAX6:NM_001604.5:3'UTR:MODIFIER:exon14/14:c.*3246_*3247insTTTT:,PAX6:NM_001258463.1:3'UTR:MODIFIER:exon14/14:c.*3246_*3247insTTTT:,PAX6:NM_001310158.1:3'UTR:MODIFIER:exon14/14:c.*3246_*3247insTTTT:,PAX6:NM_001127612.1:3'UTR:MODIFIER:exon13/13:c.*3246_*3247insTTTT:		rs34919147;rs397768344	0.4946	0.0000	0/0/0	0.6047							607108 [PAX6 (confirmed) Aniridia,106210|Cataract with late-onset corneal dystrophy,106210|Anterior segment dysgenesis 5,multiple subtypes,604229|Foveal hypoplasia 1,136520|Keratitis,148190|Optic nerve hypoplasia,165550|Morning glory disc anomaly,120430|Coloboma of optic nerve,120430|Coloboma,ocular,120200];	RCV000270087.1 [benign]; RCV000299243.1 [benign]; RCV000305344.1 [benign]; RCV000358681.1 [benign]; RCV000359957.1 [benign]; RCV000392032.1 [benign]; RCV000392047.1 [benign]; 			141	97					PAX6 (inh=AR+AD pLI=1.00)
chr11	31808280	31808280	C	T	hom	hom	hom		QUAL=18260;DP=226,150,184;MQM=59	PAX6	3'UTR	PAX6:NM_001258462.1:3'UTR:MODIFIER:exon14/14:c.*3202G>A:,PAX6:NM_001310160.1:3'UTR:MODIFIER:exon10/10:c.*3202G>A:,PAX6:NM_001310161.1:3'UTR:MODIFIER:exon11/11:c.*3202G>A:,PAX6:NM_001258465.1:3'UTR:MODIFIER:exon12/12:c.*3202G>A:,PAX6:NM_000280.4:3'UTR:MODIFIER:exon13/13:c.*3202G>A:,PAX6:NM_001258464.1:3'UTR:MODIFIER:exon13/13:c.*3202G>A:,PAX6:NM_001604.5:3'UTR:MODIFIER:exon14/14:c.*3202G>A:,PAX6:NM_001258463.1:3'UTR:MODIFIER:exon14/14:c.*3202G>A:,PAX6:NM_001310158.1:3'UTR:MODIFIER:exon14/14:c.*3202G>A:,PAX6:NM_001127612.1:3'UTR:MODIFIER:exon13/13:c.*3202G>A:		rs608293	0.8498	0.0000	0/0/0	0.1407							607108 [PAX6 (confirmed) Aniridia,106210|Cataract with late-onset corneal dystrophy,106210|Anterior segment dysgenesis 5,multiple subtypes,604229|Foveal hypoplasia 1,136520|Keratitis,148190|Optic nerve hypoplasia,165550|Morning glory disc anomaly,120430|Coloboma of optic nerve,120430|Coloboma,ocular,120200];	RCV000271960.1 [benign]; RCV000277532.1 [benign]; RCV000325808.1 [benign]; RCV000331769.1 [benign]; RCV000332589.1 [benign]; RCV000366442.1 [benign]; RCV000386337.1 [benign]; 			186	65					PAX6 (inh=AR+AD pLI=1.00)
chr11	31808585	31808585	-	AAAT	hom	hom	hom		QUAL=15487;DP=224,108,151;MQM=59	PAX6	3'UTR	PAX6:NM_001258462.1:3'UTR:MODIFIER:exon14/14:c.*2893_*2896dupATTT:,PAX6:NM_001310160.1:3'UTR:MODIFIER:exon10/10:c.*2893_*2896dupATTT:,PAX6:NM_001310161.1:3'UTR:MODIFIER:exon11/11:c.*2893_*2896dupATTT:,PAX6:NM_001258465.1:3'UTR:MODIFIER:exon12/12:c.*2893_*2896dupATTT:,PAX6:NM_000280.4:3'UTR:MODIFIER:exon13/13:c.*2893_*2896dupATTT:,PAX6:NM_001258464.1:3'UTR:MODIFIER:exon13/13:c.*2893_*2896dupATTT:,PAX6:NM_001604.5:3'UTR:MODIFIER:exon14/14:c.*2893_*2896dupATTT:,PAX6:NM_001258463.1:3'UTR:MODIFIER:exon14/14:c.*2893_*2896dupATTT:,PAX6:NM_001310158.1:3'UTR:MODIFIER:exon14/14:c.*2893_*2896dupATTT:,PAX6:NM_001127612.1:3'UTR:MODIFIER:exon13/13:c.*2893_*2896dupATTT:	(ATAA)n	rs10623053;rs397795797	0.8478	0.0000	0/0/0	0.7499							607108 [PAX6 (confirmed) Aniridia,106210|Cataract with late-onset corneal dystrophy,106210|Anterior segment dysgenesis 5,multiple subtypes,604229|Foveal hypoplasia 1,136520|Keratitis,148190|Optic nerve hypoplasia,165550|Morning glory disc anomaly,120430|Coloboma of optic nerve,120430|Coloboma,ocular,120200];	RCV000279797.1 [benign]; RCV000295258.1 [benign]; RCV000330541.1 [benign]; RCV000337230.1 [benign]; RCV000352420.1 [benign]; RCV000387389.1 [benign]; RCV000401427.1 [benign]; 			182	63					PAX6 (inh=AR+AD pLI=1.00)
chr11	31808775	31808775	G	A	het	hom	wt		QUAL=11224;DP=299,246,285;MQM=59	PAX6	3'UTR	PAX6:NM_001258462.1:3'UTR:MODIFIER:exon14/14:c.*2707C>T:,PAX6:NM_001310160.1:3'UTR:MODIFIER:exon10/10:c.*2707C>T:,PAX6:NM_001310161.1:3'UTR:MODIFIER:exon11/11:c.*2707C>T:,PAX6:NM_001258465.1:3'UTR:MODIFIER:exon12/12:c.*2707C>T:,PAX6:NM_000280.4:3'UTR:MODIFIER:exon13/13:c.*2707C>T:,PAX6:NM_001258464.1:3'UTR:MODIFIER:exon13/13:c.*2707C>T:,PAX6:NM_001604.5:3'UTR:MODIFIER:exon14/14:c.*2707C>T:,PAX6:NM_001258463.1:3'UTR:MODIFIER:exon14/14:c.*2707C>T:,PAX6:NM_001310158.1:3'UTR:MODIFIER:exon14/14:c.*2707C>T:,PAX6:NM_001127612.1:3'UTR:MODIFIER:exon13/13:c.*2707C>T:		rs3026398	0.1540	0.0000	0/0/0	0.2145							607108 [PAX6 (confirmed) Aniridia,106210|Cataract with late-onset corneal dystrophy,106210|Anterior segment dysgenesis 5,multiple subtypes,604229|Foveal hypoplasia 1,136520|Keratitis,148190|Optic nerve hypoplasia,165550|Morning glory disc anomaly,120430|Coloboma of optic nerve,120430|Coloboma,ocular,120200];	RCV000276213.1 [benign]; RCV000306938.1 [benign]; RCV000311393.1 [benign]; RCV000314986.1 [benign]; RCV000363855.1 [benign]; RCV000368371.1 [benign]; RCV000392121.1 [benign]; 			18	93					PAX6 (inh=AR+AD pLI=1.00)
chr11	31809322	31809322	C	T	het	wt	hom		QUAL=10656;DP=276,166,208;MQM=60	PAX6	3'UTR	PAX6:NM_001258462.1:3'UTR:MODIFIER:exon14/14:c.*2160G>A:,PAX6:NM_001310160.1:3'UTR:MODIFIER:exon10/10:c.*2160G>A:,PAX6:NM_001310161.1:3'UTR:MODIFIER:exon11/11:c.*2160G>A:,PAX6:NM_001258465.1:3'UTR:MODIFIER:exon12/12:c.*2160G>A:,PAX6:NM_000280.4:3'UTR:MODIFIER:exon13/13:c.*2160G>A:,PAX6:NM_001258464.1:3'UTR:MODIFIER:exon13/13:c.*2160G>A:,PAX6:NM_001604.5:3'UTR:MODIFIER:exon14/14:c.*2160G>A:,PAX6:NM_001258463.1:3'UTR:MODIFIER:exon14/14:c.*2160G>A:,PAX6:NM_001310158.1:3'UTR:MODIFIER:exon14/14:c.*2160G>A:,PAX6:NM_001127612.1:3'UTR:MODIFIER:exon13/13:c.*2160G>A:		rs12421026	0.4479	0.0000	0/0/0	0.0806							607108 [PAX6 (confirmed) Aniridia,106210|Cataract with late-onset corneal dystrophy,106210|Anterior segment dysgenesis 5,multiple subtypes,604229|Foveal hypoplasia 1,136520|Keratitis,148190|Optic nerve hypoplasia,165550|Morning glory disc anomaly,120430|Coloboma of optic nerve,120430|Coloboma,ocular,120200];	RCV000267117.1 [benign]; RCV000270682.1 [benign]; RCV000282254.1 [benign]; RCV000322069.1 [benign]; RCV000325742.1 [benign]; RCV000376648.1 [benign]; RCV000380270.1 [benign]; 			63	129					PAX6 (inh=AR+AD pLI=1.00)
chr11	31810298	31810298	T	A	hom	hom	hom		QUAL=28875;DP=397,201,281;MQM=60	PAX6	3'UTR	PAX6:NM_001258462.1:3'UTR:MODIFIER:exon14/14:c.*1184A>T:,PAX6:NM_001310160.1:3'UTR:MODIFIER:exon10/10:c.*1184A>T:,PAX6:NM_001310161.1:3'UTR:MODIFIER:exon11/11:c.*1184A>T:,PAX6:NM_001258465.1:3'UTR:MODIFIER:exon12/12:c.*1184A>T:,PAX6:NM_000280.4:3'UTR:MODIFIER:exon13/13:c.*1184A>T:,PAX6:NM_001258464.1:3'UTR:MODIFIER:exon13/13:c.*1184A>T:,PAX6:NM_001604.5:3'UTR:MODIFIER:exon14/14:c.*1184A>T:,PAX6:NM_001258463.1:3'UTR:MODIFIER:exon14/14:c.*1184A>T:,PAX6:NM_001310158.1:3'UTR:MODIFIER:exon14/14:c.*1184A>T:,PAX6:NM_001127612.1:3'UTR:MODIFIER:exon13/13:c.*1184A>T:		rs1506	0.6609	0.0000	0/0/0	0.1493							607108 [PAX6 (confirmed) Aniridia,106210|Cataract with late-onset corneal dystrophy,106210|Anterior segment dysgenesis 5,multiple subtypes,604229|Foveal hypoplasia 1,136520|Keratitis,148190|Optic nerve hypoplasia,165550|Morning glory disc anomaly,120430|Coloboma of optic nerve,120430|Coloboma,ocular,120200];	RCV000280988.1 [benign]; RCV000286998.1 [benign]; RCV000298746.1 [benign]; RCV000338402.1 [benign]; RCV000339784.1 [benign]; RCV000398435.1 [benign]; RCV000399005.1 [benign]; 			149	89					PAX6 (inh=AR+AD pLI=1.00)
chr11	31832367	31832367	C	T	wt	het	wt	anno_pathogenic_hgmd	QUAL=2504;DP=167,206,288;MQM=60	PAX6	splice_region&intron	PAX6:NM_001258462.1:splice_region&intron:LOW:exon2/13:c.-129+9G>A:,PAX6:NM_001258465.1:splice_region&intron:LOW:exon1/11:c.-129+9G>A:,PAX6:NM_000280.4:splice_region&intron:LOW:exon2/12:c.-129+9G>A:,PAX6:NM_001258464.1:splice_region&intron:LOW:exon2/12:c.-129+9G>A:,PAX6:NM_001604.5:splice_region&intron:LOW:exon2/13:c.-129+9G>A:,PAX6:NM_001258463.1:splice_region&intron:LOW:exon2/13:c.-129+9G>A:,PAX6:NM_001310158.1:splice_region&intron:LOW:exon2/13:c.-129+9G>A:,PAX6:NM_001127612.1:splice_region&intron:LOW:exon2/12:c.-129+9G>A:		rs56139994	0.0154	0.0000	0/0/0	0.0053							607108 [PAX6 (confirmed) Aniridia,106210|Cataract with late-onset corneal dystrophy,106210|Anterior segment dysgenesis 5,multiple subtypes,604229|Foveal hypoplasia 1,136520|Keratitis,148190|Optic nerve hypoplasia,165550|Morning glory disc anomaly,120430|Coloboma of optic nerve,120430|Coloboma,ocular,120200];	RCV000202974.2 [benign]; RCV000290390.1 [likely benign]; RCV000305825.1 [likely benign]; RCV000340726.1 [likely benign]; RCV000342099.1 [likely benign]; RCV000395429.1 [likely benign]; RCV000395452.1 [likely benign]; RCV000401317.1 [likely benign]; 	CS072275 [CLASS=DM? MUT=ALT PHEN="Bilateral microphthalmia" GENE=PAX6]; 		0	26					PAX6 (inh=AR+AD pLI=1.00)
chr11	32456298	32456298	G	A	het	het	wt		QUAL=2439;DP=75,170,234;MQM=60	WT1	synonymous	WT1:NM_024426.4:synonymous:LOW:exon1/10:c.594C>T:p.Asn198Asn,WT1:NM_000378.4:synonymous:LOW:exon1/9:c.594C>T:p.Asn198Asn,WT1:NM_024424.3:synonymous:LOW:exon1/10:c.594C>T:p.Asn198Asn		rs2234583	0.1212	0.0806	598/148/366	0.0765							607102 [WT1 (confirmed) Wilms tumor,type 1,194070|Denys-Drash syndrome,194080|Nephrotic syndrome,type 4,256370|Frasier syndrome,136680|Meacham syndrome,608978|Mesothelioma,somatic,156240];	RCV000247609.2 [benign]; RCV000293694.1 [likely benign]; RCV000348640.1 [likely benign]; RCV000393785.1 [likely benign]; RCV000403336.1 [likely benign]; 			19	258					WT1 (inh=AR+AD pLI=n/a)
chr11	32456694	32456694	C	A	het	het	wt	low_DP	QUAL=193;DP=9,11,11;MQM=60	WT1	synonymous	WT1:NM_024426.4:synonymous:LOW:exon1/10:c.198G>T:p.Pro66Pro,WT1:NM_000378.4:synonymous:LOW:exon1/9:c.198G>T:p.Pro66Pro,WT1:NM_024424.3:synonymous:LOW:exon1/10:c.198G>T:p.Pro66Pro		rs2234582	0.3017	0.3299	520/108/51	0.1000							607102 [WT1 (confirmed) Wilms tumor,type 1,194070|Denys-Drash syndrome,194080|Nephrotic syndrome,type 4,256370|Frasier syndrome,136680|Meacham syndrome,608978|Mesothelioma,somatic,156240];	RCV000254527.2 [benign]; RCV000277367.1 [benign]; RCV000313693.1 [benign]; RCV000354183.1 [benign]; RCV000367093.1 [benign]; 		COSM4145655	110	521					WT1 (inh=AR+AD pLI=n/a)
chr11	33724780	33724780	T	C	hom	het	het		QUAL=18464;DP=359,218,293;MQM=59	CD59	3'UTR	CD59:NM_000611.5:3'UTR:MODIFIER:exon4/4:c.*6892A>G:,CD59:NM_001127223.1:3'UTR:MODIFIER:exon3/3:c.*6892A>G:,CD59:NM_001127225.1:3'UTR:MODIFIER:exon4/4:c.*6892A>G:,CD59:NM_001127226.1:3'UTR:MODIFIER:exon4/4:c.*6892A>G:,CD59:NM_001127227.1:3'UTR:MODIFIER:exon4/4:c.*6892A>G:,CD59:NM_203329.2:3'UTR:MODIFIER:exon5/5:c.*6892A>G:,CD59:NM_203330.2:3'UTR:MODIFIER:exon6/6:c.*6892A>G:,CD59:NM_203331.2:3'UTR:MODIFIER:exon5/5:c.*6892A>G:		rs704697	0.5096	0.0000	0/0/0	0.5102							107271 [CD59 (confirmed) Hemolytic anemia,CD59-mediated,with or without immune-mediated polyneuropathy,612300];				66	119					CD59 (inh=AR pLI=0.07)
chr11	33724885	33724885	C	T	wt	het	wt		QUAL=3253;DP=334,250,305;MQM=60	CD59	3'UTR	CD59:NM_000611.5:3'UTR:MODIFIER:exon4/4:c.*6787G>A:,CD59:NM_001127223.1:3'UTR:MODIFIER:exon3/3:c.*6787G>A:,CD59:NM_001127225.1:3'UTR:MODIFIER:exon4/4:c.*6787G>A:,CD59:NM_001127226.1:3'UTR:MODIFIER:exon4/4:c.*6787G>A:,CD59:NM_001127227.1:3'UTR:MODIFIER:exon4/4:c.*6787G>A:,CD59:NM_203329.2:3'UTR:MODIFIER:exon5/5:c.*6787G>A:,CD59:NM_203330.2:3'UTR:MODIFIER:exon6/6:c.*6787G>A:,CD59:NM_203331.2:3'UTR:MODIFIER:exon5/5:c.*6787G>A:		rs79094033	0.0441	0.0000	0/0/0	0.0227							107271 [CD59 (confirmed) Hemolytic anemia,CD59-mediated,with or without immune-mediated polyneuropathy,612300];				0	9					CD59 (inh=AR pLI=0.07)
chr11	33724992	33724992	T	C	hom	het	het		QUAL=16971;DP=334,222,290;MQM=59	CD59	3'UTR	CD59:NM_000611.5:3'UTR:MODIFIER:exon4/4:c.*6680A>G:,CD59:NM_001127223.1:3'UTR:MODIFIER:exon3/3:c.*6680A>G:,CD59:NM_001127225.1:3'UTR:MODIFIER:exon4/4:c.*6680A>G:,CD59:NM_001127226.1:3'UTR:MODIFIER:exon4/4:c.*6680A>G:,CD59:NM_001127227.1:3'UTR:MODIFIER:exon4/4:c.*6680A>G:,CD59:NM_203329.2:3'UTR:MODIFIER:exon5/5:c.*6680A>G:,CD59:NM_203330.2:3'UTR:MODIFIER:exon6/6:c.*6680A>G:,CD59:NM_203331.2:3'UTR:MODIFIER:exon5/5:c.*6680A>G:		rs1047581	0.2103	0.0000	0/0/0	0.2332							107271 [CD59 (confirmed) Hemolytic anemia,CD59-mediated,with or without immune-mediated polyneuropathy,612300];				23	99					CD59 (inh=AR pLI=0.07)
chr11	33725052	33725052	G	A	wt	het	wt		QUAL=3295;DP=643,293,362;MQM=60	CD59	3'UTR	CD59:NM_000611.5:3'UTR:MODIFIER:exon4/4:c.*6620C>T:,CD59:NM_001127223.1:3'UTR:MODIFIER:exon3/3:c.*6620C>T:,CD59:NM_001127225.1:3'UTR:MODIFIER:exon4/4:c.*6620C>T:,CD59:NM_001127226.1:3'UTR:MODIFIER:exon4/4:c.*6620C>T:,CD59:NM_001127227.1:3'UTR:MODIFIER:exon4/4:c.*6620C>T:,CD59:NM_203329.2:3'UTR:MODIFIER:exon5/5:c.*6620C>T:,CD59:NM_203330.2:3'UTR:MODIFIER:exon6/6:c.*6620C>T:,CD59:NM_203331.2:3'UTR:MODIFIER:exon5/5:c.*6620C>T:		rs77354123	0.0573	0.0000	0/0/0	0.0314							107271 [CD59 (confirmed) Hemolytic anemia,CD59-mediated,with or without immune-mediated polyneuropathy,612300];				0	12					CD59 (inh=AR pLI=0.07)
chr11	33725757	33725760	CTCT	-	wt	het	wt		QUAL=2857;DP=333,234,295;MQM=60	CD59	3'UTR	CD59:NM_000611.5:3'UTR:MODIFIER:exon4/4:c.*5912_*5915delAGAG:,CD59:NM_001127223.1:3'UTR:MODIFIER:exon3/3:c.*5912_*5915delAGAG:,CD59:NM_001127225.1:3'UTR:MODIFIER:exon4/4:c.*5912_*5915delAGAG:,CD59:NM_001127226.1:3'UTR:MODIFIER:exon4/4:c.*5912_*5915delAGAG:,CD59:NM_001127227.1:3'UTR:MODIFIER:exon4/4:c.*5912_*5915delAGAG:,CD59:NM_203329.2:3'UTR:MODIFIER:exon5/5:c.*5912_*5915delAGAG:,CD59:NM_203330.2:3'UTR:MODIFIER:exon6/6:c.*5912_*5915delAGAG:,CD59:NM_203331.2:3'UTR:MODIFIER:exon5/5:c.*5912_*5915delAGAG:	MIRb	rs143165441	0.0471	0.0000	0/0/0	0.0234							107271 [CD59 (confirmed) Hemolytic anemia,CD59-mediated,with or without immune-mediated polyneuropathy,612300];				0	9					CD59 (inh=AR pLI=0.07)
chr11	33726222	33726222	G	A	hom	het	het		QUAL=18874;DP=381,248,312;MQM=60	CD59	3'UTR	CD59:NM_000611.5:3'UTR:MODIFIER:exon4/4:c.*5450C>T:,CD59:NM_001127223.1:3'UTR:MODIFIER:exon3/3:c.*5450C>T:,CD59:NM_001127225.1:3'UTR:MODIFIER:exon4/4:c.*5450C>T:,CD59:NM_001127226.1:3'UTR:MODIFIER:exon4/4:c.*5450C>T:,CD59:NM_001127227.1:3'UTR:MODIFIER:exon4/4:c.*5450C>T:,CD59:NM_203329.2:3'UTR:MODIFIER:exon5/5:c.*5450C>T:,CD59:NM_203330.2:3'UTR:MODIFIER:exon6/6:c.*5450C>T:,CD59:NM_203331.2:3'UTR:MODIFIER:exon5/5:c.*5450C>T:	MIR	rs1546727	0.1589	0.0000	0/0/0	0.2172							107271 [CD59 (confirmed) Hemolytic anemia,CD59-mediated,with or without immune-mediated polyneuropathy,612300];				23	93					CD59 (inh=AR pLI=0.07)
chr11	33726290	33726290	C	A	hom	het	het		QUAL=12935;DP=241,209,266;MQM=59	CD59	3'UTR	CD59:NM_000611.5:3'UTR:MODIFIER:exon4/4:c.*5382G>T:,CD59:NM_001127223.1:3'UTR:MODIFIER:exon3/3:c.*5382G>T:,CD59:NM_001127225.1:3'UTR:MODIFIER:exon4/4:c.*5382G>T:,CD59:NM_001127226.1:3'UTR:MODIFIER:exon4/4:c.*5382G>T:,CD59:NM_001127227.1:3'UTR:MODIFIER:exon4/4:c.*5382G>T:,CD59:NM_203329.2:3'UTR:MODIFIER:exon5/5:c.*5382G>T:,CD59:NM_203330.2:3'UTR:MODIFIER:exon6/6:c.*5382G>T:,CD59:NM_203331.2:3'UTR:MODIFIER:exon5/5:c.*5382G>T:		rs36093484	0.1863	0.0000	0/0/0	0.0386							107271 [CD59 (confirmed) Hemolytic anemia,CD59-mediated,with or without immune-mediated polyneuropathy,612300];				23	97					CD59 (inh=AR pLI=0.07)
chr11	33726544	33726544	C	G	hom	het	het		QUAL=12829;DP=257,144,177;MQM=60	CD59	3'UTR	CD59:NM_000611.5:3'UTR:MODIFIER:exon4/4:c.*5128G>C:,CD59:NM_001127223.1:3'UTR:MODIFIER:exon3/3:c.*5128G>C:,CD59:NM_001127225.1:3'UTR:MODIFIER:exon4/4:c.*5128G>C:,CD59:NM_001127226.1:3'UTR:MODIFIER:exon4/4:c.*5128G>C:,CD59:NM_001127227.1:3'UTR:MODIFIER:exon4/4:c.*5128G>C:,CD59:NM_203329.2:3'UTR:MODIFIER:exon5/5:c.*5128G>C:,CD59:NM_203330.2:3'UTR:MODIFIER:exon6/6:c.*5128G>C:,CD59:NM_203331.2:3'UTR:MODIFIER:exon5/5:c.*5128G>C:		rs12364970	0.1571	0.0000	0/0/0	0.2167							107271 [CD59 (confirmed) Hemolytic anemia,CD59-mediated,with or without immune-mediated polyneuropathy,612300];				23	97					CD59 (inh=AR pLI=0.07)
chr11	33726980	33726980	A	G	hom	hom	het		QUAL=22961;DP=345,233,337;MQM=59	CD59	3'UTR	CD59:NM_000611.5:3'UTR:MODIFIER:exon4/4:c.*4692T>C:,CD59:NM_001127223.1:3'UTR:MODIFIER:exon3/3:c.*4692T>C:,CD59:NM_001127225.1:3'UTR:MODIFIER:exon4/4:c.*4692T>C:,CD59:NM_001127226.1:3'UTR:MODIFIER:exon4/4:c.*4692T>C:,CD59:NM_001127227.1:3'UTR:MODIFIER:exon4/4:c.*4692T>C:,CD59:NM_203329.2:3'UTR:MODIFIER:exon5/5:c.*4692T>C:,CD59:NM_203330.2:3'UTR:MODIFIER:exon6/6:c.*4692T>C:,CD59:NM_203331.2:3'UTR:MODIFIER:exon5/5:c.*4692T>C:		rs7046	0.6410	0.0000	0/0/0	0.5832							107271 [CD59 (confirmed) Hemolytic anemia,CD59-mediated,with or without immune-mediated polyneuropathy,612300];				82	110					CD59 (inh=AR pLI=0.07)
chr11	33727515	33727515	T	C	wt	het	wt		QUAL=3021;DP=250,219,289;MQM=60	CD59	3'UTR	CD59:NM_000611.5:3'UTR:MODIFIER:exon4/4:c.*4157A>G:,CD59:NM_001127223.1:3'UTR:MODIFIER:exon3/3:c.*4157A>G:,CD59:NM_001127225.1:3'UTR:MODIFIER:exon4/4:c.*4157A>G:,CD59:NM_001127226.1:3'UTR:MODIFIER:exon4/4:c.*4157A>G:,CD59:NM_001127227.1:3'UTR:MODIFIER:exon4/4:c.*4157A>G:,CD59:NM_203329.2:3'UTR:MODIFIER:exon5/5:c.*4157A>G:,CD59:NM_203330.2:3'UTR:MODIFIER:exon6/6:c.*4157A>G:,CD59:NM_203331.2:3'UTR:MODIFIER:exon5/5:c.*4157A>G:		rs12272660	0.0443	0.0000	0/0/0	0.0226							107271 [CD59 (confirmed) Hemolytic anemia,CD59-mediated,with or without immune-mediated polyneuropathy,612300];				0	9					CD59 (inh=AR pLI=0.07)
chr11	33728170	33728170	T	C	wt	het	wt		QUAL=357;DP=295,49,97;MQM=60	CD59	3'UTR	CD59:NM_000611.5:3'UTR:MODIFIER:exon4/4:c.*3502A>G:,CD59:NM_001127223.1:3'UTR:MODIFIER:exon3/3:c.*3502A>G:,CD59:NM_001127225.1:3'UTR:MODIFIER:exon4/4:c.*3502A>G:,CD59:NM_001127226.1:3'UTR:MODIFIER:exon4/4:c.*3502A>G:,CD59:NM_001127227.1:3'UTR:MODIFIER:exon4/4:c.*3502A>G:,CD59:NM_203329.2:3'UTR:MODIFIER:exon5/5:c.*3502A>G:,CD59:NM_203330.2:3'UTR:MODIFIER:exon6/6:c.*3502A>G:,CD59:NM_203331.2:3'UTR:MODIFIER:exon5/5:c.*3502A>G:	MIRb	rs74580548	0.0479	0.0000	0/0/0	0.0242							107271 [CD59 (confirmed) Hemolytic anemia,CD59-mediated,with or without immune-mediated polyneuropathy,612300];				0	9					CD59 (inh=AR pLI=0.07)
chr11	33728614	33728614	T	G	hom	het	het		QUAL=15620;DP=358,146,199;MQM=60	CD59	3'UTR	CD59:NM_000611.5:3'UTR:MODIFIER:exon4/4:c.*3058A>C:,CD59:NM_001127223.1:3'UTR:MODIFIER:exon3/3:c.*3058A>C:,CD59:NM_001127225.1:3'UTR:MODIFIER:exon4/4:c.*3058A>C:,CD59:NM_001127226.1:3'UTR:MODIFIER:exon4/4:c.*3058A>C:,CD59:NM_001127227.1:3'UTR:MODIFIER:exon4/4:c.*3058A>C:,CD59:NM_203329.2:3'UTR:MODIFIER:exon5/5:c.*3058A>C:,CD59:NM_203330.2:3'UTR:MODIFIER:exon6/6:c.*3058A>C:,CD59:NM_203331.2:3'UTR:MODIFIER:exon5/5:c.*3058A>C:		rs831618	0.5092	0.0000	0/0/0	0.5107							107271 [CD59 (confirmed) Hemolytic anemia,CD59-mediated,with or without immune-mediated polyneuropathy,612300];				66	119					CD59 (inh=AR pLI=0.07)
chr11	33730060	33730060	A	C	hom	het	het		QUAL=4099;DP=95,46,50;MQM=60	CD59	3'UTR	CD59:NM_000611.5:3'UTR:MODIFIER:exon4/4:c.*1612T>G:,CD59:NM_001127223.1:3'UTR:MODIFIER:exon3/3:c.*1612T>G:,CD59:NM_001127225.1:3'UTR:MODIFIER:exon4/4:c.*1612T>G:,CD59:NM_001127226.1:3'UTR:MODIFIER:exon4/4:c.*1612T>G:,CD59:NM_001127227.1:3'UTR:MODIFIER:exon4/4:c.*1612T>G:,CD59:NM_203329.2:3'UTR:MODIFIER:exon5/5:c.*1612T>G:,CD59:NM_203330.2:3'UTR:MODIFIER:exon6/6:c.*1612T>G:,CD59:NM_203331.2:3'UTR:MODIFIER:exon5/5:c.*1612T>G:		rs11032350	0.1583	0.0000	0/0/0	0.2163							107271 [CD59 (confirmed) Hemolytic anemia,CD59-mediated,with or without immune-mediated polyneuropathy,612300];				23	93					CD59 (inh=AR pLI=0.07)
chr11	33730261	33730261	G	T	hom	het	het		QUAL=13859;DP=198,243,318;MQM=59	CD59	3'UTR	CD59:NM_000611.5:3'UTR:MODIFIER:exon4/4:c.*1411C>A:,CD59:NM_001127223.1:3'UTR:MODIFIER:exon3/3:c.*1411C>A:,CD59:NM_001127225.1:3'UTR:MODIFIER:exon4/4:c.*1411C>A:,CD59:NM_001127226.1:3'UTR:MODIFIER:exon4/4:c.*1411C>A:,CD59:NM_001127227.1:3'UTR:MODIFIER:exon4/4:c.*1411C>A:,CD59:NM_203329.2:3'UTR:MODIFIER:exon5/5:c.*1411C>A:,CD59:NM_203330.2:3'UTR:MODIFIER:exon6/6:c.*1411C>A:,CD59:NM_203331.2:3'UTR:MODIFIER:exon5/5:c.*1411C>A:		rs7357	0.1867	0.0000	0/0/0	0.2249							107271 [CD59 (confirmed) Hemolytic anemia,CD59-mediated,with or without immune-mediated polyneuropathy,612300];				23	98					CD59 (inh=AR pLI=0.07)
chr11	33731406	33731406	C	T	hom	het	het		QUAL=13732;DP=274,169,215;MQM=60	CD59	3'UTR	CD59:NM_000611.5:3'UTR:MODIFIER:exon4/4:c.*266G>A:,CD59:NM_001127223.1:3'UTR:MODIFIER:exon3/3:c.*266G>A:,CD59:NM_001127225.1:3'UTR:MODIFIER:exon4/4:c.*266G>A:,CD59:NM_001127226.1:3'UTR:MODIFIER:exon4/4:c.*266G>A:,CD59:NM_001127227.1:3'UTR:MODIFIER:exon4/4:c.*266G>A:,CD59:NM_203329.2:3'UTR:MODIFIER:exon5/5:c.*266G>A:,CD59:NM_203330.2:3'UTR:MODIFIER:exon6/6:c.*266G>A:,CD59:NM_203331.2:3'UTR:MODIFIER:exon5/5:c.*266G>A:		rs842	0.1863	0.0000	0/0/0	0.0382							107271 [CD59 (confirmed) Hemolytic anemia,CD59-mediated,with or without immune-mediated polyneuropathy,612300];				24	98					CD59 (inh=AR pLI=0.07)
chr11	33757941	33757941	A	G	hom	hom	het		QUAL=4502;DP=33,77,106;MQM=60	CD59	5'UTR_premature_start_codon_gain,5'UTR	CD59:NM_000611.5:5'UTR_premature_start_codon_gain:LOW:exon1/4:c.-32T>C:,CD59:NM_203329.2:5'UTR_premature_start_codon_gain:LOW:exon1/5:c.-148T>C:,CD59:NM_203330.2:5'UTR_premature_start_codon_gain:LOW:exon1/6:c.-193T>C:,CD59:NM_203331.2:5'UTR_premature_start_codon_gain:LOW:exon1/5:c.-77T>C:,CD59:NM_000611.5:5'UTR:MODIFIER:exon1/4:c.-32T>C:,CD59:NM_203329.2:5'UTR:MODIFIER:exon1/5:c.-148T>C:,CD59:NM_203330.2:5'UTR:MODIFIER:exon1/6:c.-193T>C:,CD59:NM_203331.2:5'UTR:MODIFIER:exon1/5:c.-77T>C:		rs13614	0.6468	0.0000	0/0/0	0.5768							107271 [CD59 (confirmed) Hemolytic anemia,CD59-mediated,with or without immune-mediated polyneuropathy,612300];				93	112					CD59 (inh=AR pLI=0.07)
chr11	34937697	34937697	T	C	hom	het	hom		QUAL=2015;DP=29,41,35;MQM=59	PDHX,APIP	5'UTR,intron	PDHX:NM_003477.2:5'UTR:MODIFIER:exon1/11:c.-506T>C:,PDHX:NM_001135024.1:5'UTR:MODIFIER:exon1/11:c.-222T>C:,PDHX:NM_001166158.1:5'UTR:MODIFIER:exon1/6:c.-506T>C:,APIP:NM_015957.3:intron:MODIFIER:exon1/6:c.57+78A>G:		rs2016814	0.7722	0.0000	0/0/0	0.1449							608769 [PDHX (confirmed) Lacticacidemia due to PDX1 deficiency,245349];	RCV000290955.1 [benign]; 			135	78					PDHX (inh=AR pLI=0.00), APIP (inh=n/a pLI=0.00)
chr11	34937698	34937698	G	A	het	wt	hom		QUAL=2015;DP=29,41,35;MQM=59	PDHX,APIP	5'UTR,intron	PDHX:NM_003477.2:5'UTR:MODIFIER:exon1/11:c.-505G>A:,PDHX:NM_001135024.1:5'UTR:MODIFIER:exon1/11:c.-221G>A:,PDHX:NM_001166158.1:5'UTR:MODIFIER:exon1/6:c.-505G>A:,APIP:NM_015957.3:intron:MODIFIER:exon1/6:c.57+77C>T:		rs16926448	0.1927	0.0000	0/0/0	0.0157							608769 [PDHX (confirmed) Lacticacidemia due to PDX1 deficiency,245349];	RCV000348341.1 [benign]; 			10	38					PDHX (inh=AR pLI=0.00), APIP (inh=n/a pLI=0.00)
chr11	34937901	34937901	A	G	hom	het	hom		QUAL=3895;DP=46,56,65;MQM=59	PDHX,APIP	5'UTR_premature_start_codon_gain,5'UTR	PDHX:NM_003477.2:5'UTR_premature_start_codon_gain:LOW:exon1/11:c.-302A>G:,PDHX:NM_001135024.1:5'UTR_premature_start_codon_gain:LOW:exon1/11:c.-18A>G:,PDHX:NM_001166158.1:5'UTR_premature_start_codon_gain:LOW:exon1/6:c.-302A>G:,APIP:NM_015957.3:5'UTR:MODIFIER:exon1/7:c.-70T>C:,PDHX:NM_003477.2:5'UTR:MODIFIER:exon1/11:c.-302A>G:,PDHX:NM_001135024.1:5'UTR:MODIFIER:exon1/11:c.-18A>G:,PDHX:NM_001166158.1:5'UTR:MODIFIER:exon1/6:c.-302A>G:		rs2956112	0.7626	0.7921	20446/11997/1396	0.6960							608769 [PDHX (confirmed) Lacticacidemia due to PDX1 deficiency,245349];	RCV000356024.1 [benign]; 			1258	623					PDHX (inh=AR pLI=0.00), APIP (inh=n/a pLI=0.00)
chr11	34938001	34938001	A	G	het	wt	hom	low_DP	QUAL=1138;DP=19,17,30;MQM=59	PDHX	missense,5'UTR	PDHX:NM_001135024.1:missense:MODERATE:exon1/11:c.83A>G:p.Glu28Gly,PDHX:NM_003477.2:5'UTR:MODIFIER:exon1/11:c.-202A>G:,PDHX:NM_001166158.1:5'UTR:MODIFIER:exon1/6:c.-202A>G:		rs113073242	0.1927	0.2306	33/1/30	0.0397	0.1540	T	T	B	T	5.61	608769 [PDHX (confirmed) Lacticacidemia due to PDX1 deficiency,245349];	RCV000266950.1 [benign]; 		COSM3749158	61	527					PDHX (inh=AR pLI=0.00)
chr11	34938072	34938074	GGC	-	het	wt	hom	low_DP	QUAL=1628;DP=23,19,46;MQM=59	PDHX	5'UTR,intron	PDHX:NM_003477.2:5'UTR:MODIFIER:exon1/11:c.-129_-127delCGG:,PDHX:NM_001166158.1:5'UTR:MODIFIER:exon1/6:c.-129_-127delCGG:,PDHX:NM_001135024.1:intron:MODIFIER:exon1/10:c.115+41_115+43delCGG:		rs371074122	0.0000	0.2302	57/6/43	0.0409							608769 [PDHX (confirmed) Lacticacidemia due to PDX1 deficiency,245349];	RCV000362815.1 [benign]; 			28	163					PDHX (inh=AR pLI=0.00)
chr11	34938074	34938074	C	T	het	het	wt	low_DP	QUAL=1628;DP=23,19,46;MQM=60	PDHX	5'UTR,intron	PDHX:NM_003477.2:5'UTR:MODIFIER:exon1/11:c.-129C>T:,PDHX:NM_001166158.1:5'UTR:MODIFIER:exon1/6:c.-129C>T:,PDHX:NM_001135024.1:intron:MODIFIER:exon1/10:c.115+41C>T:		rs112032820	0.1206	0.3263	74/62/4	0.0777							608769 [PDHX (confirmed) Lacticacidemia due to PDX1 deficiency,245349];	RCV000270554.1 [benign]; 			79	355					PDHX (inh=AR pLI=0.00)
chr11	34938079	34938079	G	C	het	wt	hom		QUAL=1246;DP=37,27,44;MQM=59	PDHX	5'UTR,intron	PDHX:NM_003477.2:5'UTR:MODIFIER:exon1/11:c.-124G>C:,PDHX:NM_001166158.1:5'UTR:MODIFIER:exon1/6:c.-124G>C:,PDHX:NM_001135024.1:intron:MODIFIER:exon1/10:c.115+46G>C:		rs375130125	0.1925	0.1761	66/9/49	0.0388							608769 [PDHX (confirmed) Lacticacidemia due to PDX1 deficiency,245349];	RCV000328825.1 [benign]; 			27	159					PDHX (inh=AR pLI=0.00)
chr11	34938115	34938115	C	A	het	het	wt		QUAL=1929;DP=131,65,87;MQM=60	PDHX	5'UTR_premature_start_codon_gain,5'UTR,intron	PDHX:NM_003477.2:5'UTR_premature_start_codon_gain:LOW:exon1/11:c.-88C>A:,PDHX:NM_001166158.1:5'UTR_premature_start_codon_gain:LOW:exon1/6:c.-88C>A:,PDHX:NM_003477.2:5'UTR:MODIFIER:exon1/11:c.-88C>A:,PDHX:NM_001166158.1:5'UTR:MODIFIER:exon1/6:c.-88C>A:,PDHX:NM_001135024.1:intron:MODIFIER:exon1/10:c.115+82C>A:		rs2956110	0.5719	0.0000	0/0/0	0.6381							608769 [PDHX (confirmed) Lacticacidemia due to PDX1 deficiency,245349];	RCV000385759.1 [benign]; 			103	108					PDHX (inh=AR pLI=0.00)
chr11	34938199	34938199	C	G	het	wt	hom		QUAL=6751;DP=108,124,175;MQM=59	PDHX	5'UTR,intron	PDHX:NM_003477.2:5'UTR:MODIFIER:exon1/11:c.-4C>G:,PDHX:NM_001166158.1:5'UTR:MODIFIER:exon1/6:c.-4C>G:,PDHX:NM_001135024.1:intron:MODIFIER:exon1/10:c.115+166C>G:		rs3818401	0.1925	0.1381	1459/449/764	0.1303							608769 [PDHX (confirmed) Lacticacidemia due to PDX1 deficiency,245349];	RCV000284713.1 [benign]; RCV000389336.1 [benign]; 			61	567					PDHX (inh=AR pLI=0.00)
chr11	34938265	34938265	C	T	hom	het	hom		QUAL=9483;DP=77,132,199;MQM=59	PDHX	synonymous,intron	PDHX:NM_003477.2:synonymous:LOW:exon1/11:c.63C>T:p.Pro21Pro,PDHX:NM_001166158.1:synonymous:LOW:exon1/6:c.63C>T:p.Pro21Pro,PDHX:NM_001135024.1:intron:MODIFIER:exon1/10:c.115+232C>T:		rs2956109	0.7646	0.7744	35869/21045/3058	0.7574							608769 [PDHX (confirmed) Lacticacidemia due to PDX1 deficiency,245349];	RCV000335880.1 [benign]; RCV000376293.1 [benign]; 			1715	854					PDHX (inh=AR pLI=0.00)
chr11	34938269	34938269	C	T	het	wt	hom		QUAL=9483;DP=77,132,199;MQM=60	PDHX	missense,intron	PDHX:NM_003477.2:missense:MODERATE:exon1/11:c.67C>T:p.Arg23Cys,PDHX:NM_001166158.1:missense:MODERATE:exon1/6:c.67C>T:p.Arg23Cys,PDHX:NM_001135024.1:intron:MODIFIER:exon1/10:c.115+236C>T:		rs1049306	0.1925	0.1384	1438/445/743	0.1285	-0.0800	T,T,T	T	B,B	T,T,T	12.06	608769 [PDHX (confirmed) Lacticacidemia due to PDX1 deficiency,245349];	RCV000342110.1 [benign]; RCV000406992.1 [benign]; 			60	572					PDHX (inh=AR pLI=0.00)
chr11	34938272	34938272	C	G	wt	het	wt	pred_pathogenic	QUAL=1611;DP=80,133,209;MQM=60	PDHX	missense,intron	PDHX:NM_003477.2:missense:MODERATE:exon1/11:c.70C>G:p.Arg24Gly,PDHX:NM_001166158.1:missense:MODERATE:exon1/6:c.70C>G:p.Arg24Gly,PDHX:NM_001135024.1:intron:MODIFIER:exon1/10:c.115+239C>G:		rs11539201	0.0154	0.0303	77/44/0	0.0276	0.2710	D,D,T	T	D,D	T,T,T	15.80	608769 [PDHX (confirmed) Lacticacidemia due to PDX1 deficiency,245349];	RCV000127408.3 [benign]; RCV000281607.1 [likely benign]; 			1	193					PDHX (inh=AR pLI=0.00)
chr11	34938310	34938310	T	C	het	wt	hom		QUAL=8801;DP=139,158,230;MQM=59	PDHX	synonymous,intron	PDHX:NM_003477.2:synonymous:LOW:exon1/11:c.108T>C:p.Ser36Ser,PDHX:NM_001166158.1:synonymous:LOW:exon1/6:c.108T>C:p.Ser36Ser,PDHX:NM_001135024.1:intron:MODIFIER:exon1/10:c.115+277T>C:		rs1049307	0.1927	0.1677	1207/357/631	0.1257							608769 [PDHX (confirmed) Lacticacidemia due to PDX1 deficiency,245349];	RCV000297676.1 [benign]; RCV000338943.1 [benign]; 			60	572					PDHX (inh=AR pLI=0.00)
chr11	34969112	34969112	A	G	het	het	wt	pred_pathogenic	QUAL=5287;DP=233,163,244;MQM=60	PDHX	missense	PDHX:NM_003477.2:missense:MODERATE:exon3/11:c.301A>G:p.Thr101Ala,PDHX:NM_001135024.1:missense:MODERATE:exon3/11:c.256A>G:p.Thr86Ala,PDHX:NM_001166158.1:missense:MODERATE:exon3/6:c.301A>G:p.Thr101Ala		rs11539202	0.1088	0.2197	3654/3176/27	0.2211	8.1290	T,T,T,T,T	T	D,B,B	T,T,T,T,T	23.50	608769 [PDHX (confirmed) Lacticacidemia due to PDX1 deficiency,245349];	RCV000361091.1 [benign]; 		COSM3752346	216	1077					PDHX (inh=AR pLI=0.00)
chr11	34979095	34979095	C	T	wt	wt	het		QUAL=2765;DP=269,216,224;MQM=60	PDHX	synonymous,intron	PDHX:NM_003477.2:synonymous:LOW:exon4/11:c.507C>T:p.Ile169Ile,PDHX:NM_001135024.1:synonymous:LOW:exon4/11:c.462C>T:p.Ile154Ile,PDHX:NM_001166158.1:intron:MODIFIER:exon3/5:c.342+9942C>T:		rs79170416	0.0323	0.0367	124/48/2	0.0348							608769 [PDHX (confirmed) Lacticacidemia due to PDX1 deficiency,245349];	RCV000127413.1 [benign]; RCV000330463.1 [likely benign]; 			12	213					PDHX (inh=AR pLI=0.00)
chr11	34988343	34988343	T	C	wt	wt	het		QUAL=2770;DP=215,176,223;MQM=60	PDHX	synonymous,intron	PDHX:NM_003477.2:synonymous:LOW:exon6/11:c.798T>C:p.Pro266Pro,PDHX:NM_001135024.1:synonymous:LOW:exon6/11:c.753T>C:p.Pro251Pro,PDHX:NM_001166158.1:intron:MODIFIER:exon3/5:c.343-17774T>C:		rs61760973	0.1170	0.0619	524/50/387	0.0584							608769 [PDHX (confirmed) Lacticacidemia due to PDX1 deficiency,245349];	RCV000127416.2 [benign]; RCV000408410.1 [benign]; 			21	242					PDHX (inh=AR pLI=0.00)
chr11	34991727	34991727	T	C	het	het	wt		QUAL=5750;DP=248,187,199;MQM=60	PDHX	synonymous,intron	PDHX:NM_003477.2:synonymous:LOW:exon7/11:c.858T>C:p.Val286Val,PDHX:NM_001135024.1:synonymous:LOW:exon7/11:c.813T>C:p.Val271Val,PDHX:NM_001166158.1:intron:MODIFIER:exon3/5:c.343-14390T>C:		rs497582	0.5705	0.6438	25844/16343/746	0.6417							608769 [PDHX (confirmed) Lacticacidemia due to PDX1 deficiency,245349];	RCV000344720.1 [benign]; 		COSM4145675, COSM4145674	1253	1127					PDHX (inh=AR pLI=0.00)
chr11	35017205	35017205	G	T	het	het	wt		QUAL=7911;DP=357,200,238;MQM=59	PDHX	3'UTR	PDHX:NM_003477.2:3'UTR:MODIFIER:exon11/11:c.*486G>T:,PDHX:NM_001135024.1:3'UTR:MODIFIER:exon11/11:c.*486G>T:,PDHX:NM_001166158.1:3'UTR:MODIFIER:exon6/6:c.*486G>T:		rs9326	0.6248	0.0000	0/0/0	0.1338							608769 [PDHX (confirmed) Lacticacidemia due to PDX1 deficiency,245349];	RCV000383839.1 [benign]; 			98	103					PDHX (inh=AR pLI=0.00)
chr11	35017363	35017363	C	A	hom	het	hom		QUAL=22371;DP=439,176,180;MQM=59	PDHX	3'UTR	PDHX:NM_003477.2:3'UTR:MODIFIER:exon11/11:c.*644C>A:,PDHX:NM_001135024.1:3'UTR:MODIFIER:exon11/11:c.*644C>A:,PDHX:NM_001166158.1:3'UTR:MODIFIER:exon6/6:c.*644C>A:		rs7808	0.7816	0.0000	0/0/0	0.1556							608769 [PDHX (confirmed) Lacticacidemia due to PDX1 deficiency,245349];	RCV000270716.1 [benign]; 			137	79					PDHX (inh=AR pLI=0.00)
chr11	35017609	35017609	T	C	wt	wt	het		QUAL=672;DP=198,34,50;MQM=60	PDHX	3'UTR	PDHX:NM_003477.2:3'UTR:MODIFIER:exon11/11:c.*890T>C:,PDHX:NM_001135024.1:3'UTR:MODIFIER:exon11/11:c.*890T>C:,PDHX:NM_001166158.1:3'UTR:MODIFIER:exon6/6:c.*890T>C:		rs1049333	0.0563	0.0000	0/0/0	0.0365							608769 [PDHX (confirmed) Lacticacidemia due to PDX1 deficiency,245349];	RCV000340754.1 [likely benign]; 			0	10					PDHX (inh=AR pLI=0.00)
chr11	36595600	36595600	A	G	het	wt	het	anno_pathogenic_clinvar	QUAL=7408;DP=283,262,313;MQM=59	RAG1	missense	RAG1:NM_000448.2:missense:MODERATE:exon2/2:c.746A>G:p.His249Arg		rs3740955	0.6134	0.4470	13935/3540/2722	0.4424	0.1690	T,T	T	B	T,T	0.01	179615 [RAG1 (confirmed) Severe combined immunodeficiency,B cell-negative,601457|Omenn syndrome,603554|Alpha/beta T-cell lymphopenia with gamma/delta T-cell expansion,severe cytomegalovirus infection,and autoimmunity,609889|Combined cellular and humoral immune defects with granulomas,233650];	RCV000389898.1,RCV000127709.1 [pathogenic,benign]; 	CM122460 [CLASS=R MUT=ALT PHEN="Immunodeficiency severe combined" GENE=RAG1]; 		224	726	2	[2] old entry - no details available			RAG1 (inh=AR pLI=0.00)
chr11	36601170	36601170	G	A	het	wt	het		QUAL=2486;DP=171,30,51;MQM=59	RAG1	3'UTR	RAG1:NM_000448.2:3'UTR:MODIFIER:exon2/2:c.*3184G>A:		rs1056403	0.6126	0.0000	0/0/0	0.0800							179615 [RAG1 (confirmed) Severe combined immunodeficiency,B cell-negative,601457|Omenn syndrome,603554|Alpha/beta T-cell lymphopenia with gamma/delta T-cell expansion,severe cytomegalovirus infection,and autoimmunity,609889|Combined cellular and humoral immune defects with granulomas,233650];	RCV000331349.1 [benign]; RCV000365249.1 [benign]; 			34	109					RAG1 (inh=AR pLI=0.00)
chr11	36613807	36613807	T	C	het	wt	het		QUAL=4907;DP=211,115,130;MQM=60	RAG2	3'UTR	RAG2:NM_000536.3:3'UTR:MODIFIER:exon2/2:c.*328A>G:,RAG2:NM_001243785.1:3'UTR:MODIFIER:exon3/3:c.*328A>G:,RAG2:NM_001243786.1:3'UTR:MODIFIER:exon3/3:c.*328A>G:		rs10836573	0.6132	0.0000	0/0/0	0.0765							179615 [RAG1 (confirmed) Severe combined immunodeficiency,B cell-negative,601457|Omenn syndrome,603554|Alpha/beta T-cell lymphopenia with gamma/delta T-cell expansion,severe cytomegalovirus infection,and autoimmunity,609889|Combined cellular and humoral immune defects with granulomas,233650]:179616 [RAG2 (confirmed) Severe combined immunodeficiency,B cell-negative,601457|Omenn syndrome,603554|Combined cellular and humoral immune defects with granulomas,233650];	RCV000286048.1 [benign]; RCV000382631.1 [benign]; 			32	111					RAG2 (inh=AR pLI=0.01)
chr11	36615697	36615697	C	T	wt	wt	het	pred_pathogenic	QUAL=2522;DP=497,197,219;MQM=60	RAG2	missense	RAG2:NM_000536.3:missense:MODERATE:exon2/2:c.22G>A:p.Val8Ile,RAG2:NM_001243785.1:missense:MODERATE:exon3/3:c.22G>A:p.Val8Ile,RAG2:NM_001243786.1:missense:MODERATE:exon3/3:c.22G>A:p.Val8Ile		rs150762709	0.0008	0.0032	2/2/0	0.0033	1.0720	T,T,T	D	B	D,D,D	20.20	179616 [RAG2 (confirmed) Severe combined immunodeficiency,B cell-negative,601457|Omenn syndrome,603554|Combined cellular and humoral immune defects with granulomas,233650];	RCV000127712.1 [benign]; RCV000277572.1 [uncertain significance]; RCV000388047.1 [uncertain significance]; 		COSM328290	0	5					RAG2 (inh=AR pLI=0.01)
chr11	44117102	44117102	T	C	het	hom	wt		QUAL=12731;DP=443,206,291;MQM=60	EXT2	5'UTR	EXT2:NM_001178083.1:5'UTR:MODIFIER:exon1/15:c.-331T>C:,EXT2:NM_207122.1:5'UTR:MODIFIER:exon1/14:c.-331T>C:		rs10458911	0.3061	0.0000	0/0/0	0.3302							608210 [EXT2 (confirmed) Exostoses,multiple,type 2,133701|Seizures,scoliosis,and macrocephaly syndrome,616682];	RCV000342075.1 [benign]; 			18	77					EXT2 (inh=AD pLI=0.00)
chr11	44117122	44117122	G	A	hom	hom	het		QUAL=20974;DP=400,202,292;MQM=59	EXT2	5'UTR	EXT2:NM_001178083.1:5'UTR:MODIFIER:exon1/15:c.-311G>A:,EXT2:NM_207122.1:5'UTR:MODIFIER:exon1/14:c.-311G>A:		rs3923808	0.5208	0.0000	0/0/0	0.5873							608210 [EXT2 (confirmed) Exostoses,multiple,type 2,133701|Seizures,scoliosis,and macrocephaly syndrome,616682];	RCV000400767.1 [benign]; 			70	103					EXT2 (inh=AD pLI=0.00)
chr11	44283238	44283238	G	A	wt	het	wt		QUAL=4347;DP=300,346,451;MQM=60	ALX4	3'UTR	ALX4:NM_021926.3:3'UTR:MODIFIER:exon4/4:c.*3166C>T:		rs7116335	0.2935	0.0000	0/0/0	0.3099							605420 [ALX4 (provisional) Parietal foramina 2,609597|Frontonasal dysplasia 2,613451|Craniosynostosis 5,susceptibility to,615529];	RCV000371090.1 [benign]; 			15	87					ALX4 (inh=AD pLI=0.23)
chr11	44283297	44283297	T	C	hom	hom	hom		QUAL=43895;DP=309,450,605;MQM=59	ALX4	3'UTR	ALX4:NM_021926.3:3'UTR:MODIFIER:exon4/4:c.*3107A>G:		rs4755239	0.9073	0.0000	0/0/0	0.8343							605420 [ALX4 (provisional) Parietal foramina 2,609597|Frontonasal dysplasia 2,613451|Craniosynostosis 5,susceptibility to,615529];	RCV000325133.1 [benign]; 			182	43					ALX4 (inh=AD pLI=0.23)
chr11	44283572	44283572	T	G	wt	het	wt		QUAL=2439;DP=257,194,264;MQM=60	ALX4	3'UTR	ALX4:NM_021926.3:3'UTR:MODIFIER:exon4/4:c.*2832A>C:		rs1840254	0.2997	0.0000	0/0/0	0.0535							605420 [ALX4 (provisional) Parietal foramina 2,609597|Frontonasal dysplasia 2,613451|Craniosynostosis 5,susceptibility to,615529];	RCV000278525.1 [benign]; 			15	90					ALX4 (inh=AD pLI=0.23)
chr11	44283722	44283722	G	A	het	hom	het		QUAL=20423;DP=295,353,435;MQM=59	ALX4	3'UTR	ALX4:NM_021926.3:3'UTR:MODIFIER:exon4/4:c.*2682C>T:		rs897005	0.7326	0.0000	0/0/0	0.7134							605420 [ALX4 (provisional) Parietal foramina 2,609597|Frontonasal dysplasia 2,613451|Craniosynostosis 5,susceptibility to,615529];	RCV000401847.1 [benign]; 			97	109					ALX4 (inh=AD pLI=0.23)
chr11	44283925	44283925	A	G	wt	het	wt		QUAL=4907;DP=198,382,452;MQM=60	ALX4	3'UTR	ALX4:NM_021926.3:3'UTR:MODIFIER:exon4/4:c.*2479T>C:		rs897004	0.3115	0.0000	0/0/0	0.0555							605420 [ALX4 (provisional) Parietal foramina 2,609597|Frontonasal dysplasia 2,613451|Craniosynostosis 5,susceptibility to,615529];	RCV000363921.1 [benign]; 			18	93					ALX4 (inh=AD pLI=0.23)
chr11	44284178	44284178	C	T	wt	het	wt		QUAL=1988;DP=246,182,220;MQM=60	ALX4	3'UTR	ALX4:NM_021926.3:3'UTR:MODIFIER:exon4/4:c.*2226G>A:		rs78607024	0.0248	0.0000	0/0/0	0.0045							605420 [ALX4 (provisional) Parietal foramina 2,609597|Frontonasal dysplasia 2,613451|Craniosynostosis 5,susceptibility to,615529];	RCV000321021.1 [likely benign]; 			0	12					ALX4 (inh=AD pLI=0.23)
chr11	44284294	44284294	T	C	hom	hom	hom		QUAL=17791;DP=288,115,148;MQM=59	ALX4	3'UTR	ALX4:NM_021926.3:3'UTR:MODIFIER:exon4/4:c.*2110A>G:		rs7105993	0.9918	0.0000	0/0/0	0.1493							605420 [ALX4 (provisional) Parietal foramina 2,609597|Frontonasal dysplasia 2,613451|Craniosynostosis 5,susceptibility to,615529];	RCV000361732.1 [benign]; 			230	0					ALX4 (inh=AD pLI=0.23)
chr11	44284705	44284705	C	A	wt	wt	het		QUAL=646;DP=89,38,65;MQM=60	ALX4	3'UTR	ALX4:NM_021926.3:3'UTR:MODIFIER:exon4/4:c.*1699G>T:		rs7942612	0.1392	0.0000	0/0/0	0.1122							605420 [ALX4 (provisional) Parietal foramina 2,609597|Frontonasal dysplasia 2,613451|Craniosynostosis 5,susceptibility to,615529];	RCV000350705.1 [benign]; 			4	29					ALX4 (inh=AD pLI=0.23)
chr11	44285431	44285431	C	T	wt	wt	het		QUAL=1640;DP=110,77,110;MQM=60	ALX4	3'UTR	ALX4:NM_021926.3:3'UTR:MODIFIER:exon4/4:c.*973G>A:		rs117526668	0.0919	0.0000	0/0/0	0.0140							605420 [ALX4 (provisional) Parietal foramina 2,609597|Frontonasal dysplasia 2,613451|Craniosynostosis 5,susceptibility to,615529];	RCV000397352.1 [likely benign]; 			3	26					ALX4 (inh=AD pLI=0.23)
chr11	44285857	44285857	T	C	hom	hom	hom		QUAL=21833;DP=148,258,315;MQM=59	ALX4	3'UTR	ALX4:NM_021926.3:3'UTR:MODIFIER:exon4/4:c.*547A>G:		rs4755796	0.8848	0.0000	0/0/0	0.1409							605420 [ALX4 (provisional) Parietal foramina 2,609597|Frontonasal dysplasia 2,613451|Craniosynostosis 5,susceptibility to,615529];	RCV000327880.1 [benign]; 			149	73					ALX4 (inh=AD pLI=0.23)
chr11	44285887	44285887	G	A	hom	hom	hom		QUAL=23222;DP=159,263,324;MQM=59	ALX4	3'UTR	ALX4:NM_021926.3:3'UTR:MODIFIER:exon4/4:c.*517C>T:		rs4755797	0.7560	0.0000	0/0/0	0.1285							605420 [ALX4 (provisional) Parietal foramina 2,609597|Frontonasal dysplasia 2,613451|Craniosynostosis 5,susceptibility to,615529];	RCV000264610.1 [benign]; 			116	93					ALX4 (inh=AD pLI=0.23)
chr11	44286176	44286176	G	A	hom	het	het		QUAL=6206;DP=80,142,177;MQM=59	ALX4	3'UTR	ALX4:NM_021926.3:3'UTR:MODIFIER:exon4/4:c.*228C>T:		rs4755798	0.1991	0.0000	0/0/0	0.0388							605420 [ALX4 (provisional) Parietal foramina 2,609597|Frontonasal dysplasia 2,613451|Craniosynostosis 5,susceptibility to,615529];	RCV000280630.1 [likely benign]; 			15	92					ALX4 (inh=AD pLI=0.23)
chr11	44286566	44286566	G	A	wt	het	het		QUAL=1199;DP=34,50,74;MQM=60	ALX4	synonymous	ALX4:NM_021926.3:synonymous:LOW:exon4/4:c.1074C>T:p.His358His		rs3802805	0.3584	0.3618	8603/3405/134	0.3575							605420 [ALX4 (provisional) Parietal foramina 2,609597|Frontonasal dysplasia 2,613451|Craniosynostosis 5,susceptibility to,615529];	RCV000363369.1 [benign]; 		COSM1178421	173	654					ALX4 (inh=AD pLI=0.23)
chr11	44289071	44289071	G	A	hom	het	het		QUAL=8111;DP=125,135,195;MQM=60	ALX4	synonymous	ALX4:NM_021926.3:synonymous:LOW:exon3/4:c.879C>T:p.Leu293Leu		rs12419361	0.1036	0.1097	752/394/17	0.1091							605420 [ALX4 (provisional) Parietal foramina 2,609597|Frontonasal dysplasia 2,613451|Craniosynostosis 5,susceptibility to,615529];	RCV000272001.1 [likely benign]; 			34	317					ALX4 (inh=AD pLI=0.23)
chr11	44297054	44297054	T	C	hom	hom	hom		QUAL=8585;DP=59,107,110;MQM=60	ALX4	synonymous	ALX4:NM_021926.3:synonymous:LOW:exon2/4:c.621A>G:p.Ser207Ser		rs10769028	0.9916	0.9975	60402/33362/4920	0.9690							605420 [ALX4 (provisional) Parietal foramina 2,609597|Frontonasal dysplasia 2,613451|Craniosynostosis 5,susceptibility to,615529];	RCV000323653.1 [benign]; 		COSM4145711	1564	1					ALX4 (inh=AD pLI=0.23)
chr11	44331309	44331309	G	A	het	het	het	low_DP;pred_pathogenic	QUAL=1705;DP=5,63,90;MQM=60	ALX4	missense	ALX4:NM_021926.3:missense:MODERATE:exon1/4:c.304C>T:p.Pro102Ser	(GCGGCT)n	rs12421995	0.3720	0.6028	2981/913/8	0.2672		D	T	B	T	5.21	605420 [ALX4 (provisional) Parietal foramina 2,609597|Frontonasal dysplasia 2,613451|Craniosynostosis 5,susceptibility to,615529];	RCV000282185.1 [benign]; 		COSM3749161	327	723					ALX4 (inh=AD pLI=0.23)
chr11	44331509	44331509	C	G	het	het	het	pred_pathogenic	QUAL=5741;DP=58,185,239;MQM=60	ALX4	missense	ALX4:NM_021926.3:missense:MODERATE:exon1/4:c.104G>C:p.Arg35Thr		rs3824915	0.4726	0.5914	11196/5385/291	0.4588	5.2690	D	T	B	D	28.50	605420 [ALX4 (provisional) Parietal foramina 2,609597|Frontonasal dysplasia 2,613451|Craniosynostosis 5,susceptibility to,615529];	RCV000352665.1 [benign]; 		COSM3752366	419	769					ALX4 (inh=AD pLI=0.23)
chr11	45827050	45827050	G	C	wt	wt	het		QUAL=767;DP=33,76,69;MQM=60	SLC35C1	5'UTR,intron	SLC35C1:NM_018389.4:5'UTR:MODIFIER:exon1/2:c.-303G>C:,SLC35C1:NM_001145265.1:intron:MODIFIER:exon1/2:c.-31-311G>C:,SLC35C1:NM_001145266.1:intron:MODIFIER:exon1/2:c.-31-311G>C:		rs12289963	0.1466	0.0000	0/0/0	0.0150							605881 [SLC35C1 (confirmed) Congenital disorder of glycosylation,type IIc,266265];	RCV000287881.1 [likely benign]; 			1	32					SLC35C1 (inh=AR pLI=0.15)
chr11	45827350	45827350	A	G	wt	wt	het		QUAL=1422;DP=153,65,111;MQM=59	SLC35C1	splice_region&intron,5'UTR_premature_start_codon_gain,5'UTR	SLC35C1:NM_001145265.1:splice_region&intron:LOW:exon1/2:c.-31-11A>G:,SLC35C1:NM_001145266.1:splice_region&intron:LOW:exon1/2:c.-31-11A>G:,SLC35C1:NM_018389.4:5'UTR_premature_start_codon_gain:LOW:exon1/2:c.-3A>G:,SLC35C1:NM_018389.4:5'UTR:MODIFIER:exon1/2:c.-3A>G:		rs3808976	0.2500	0.2114	3075/1572/880	0.2081							605881 [SLC35C1 (confirmed) Congenital disorder of glycosylation,type IIc,266265];	RCV000081951.5 [benign]; RCV000397142.1 [likely benign]; 			67	474					SLC35C1 (inh=AR pLI=0.15)
chr11	45832509	45832509	A	G	wt	wt	het		QUAL=2077;DP=179,143,179;MQM=60	SLC35C1	missense	SLC35C1:NM_018389.4:missense:MODERATE:exon2/2:c.718A>G:p.Ile240Val,SLC35C1:NM_001145265.1:missense:MODERATE:exon3/3:c.679A>G:p.Ile227Val,SLC35C1:NM_001145266.1:missense:MODERATE:exon3/3:c.679A>G:p.Ile227Val	(CCTGCT)n	rs7130656	0.1028	0.0942	715/425/202	0.0943	0.5510	T,T,T,T,T	T	B	T,T,T	0.01	605881 [SLC35C1 (confirmed) Congenital disorder of glycosylation,type IIc,266265];	RCV000081953.4 [benign]; RCV000398854.1 [likely benign]; 		COSM428995	17	271					SLC35C1 (inh=AR pLI=0.15)
chr11	45832935	45832935	G	A	hom	het	het		QUAL=15267;DP=186,292,427;MQM=59	SLC35C1	3'UTR	SLC35C1:NM_018389.4:3'UTR:MODIFIER:exon2/2:c.*49G>A:,SLC35C1:NM_001145265.1:3'UTR:MODIFIER:exon3/3:c.*49G>A:,SLC35C1:NM_001145266.1:3'UTR:MODIFIER:exon3/3:c.*49G>A:		rs1139266	0.4513	0.6741	2211/1758/25	0.4493							605881 [SLC35C1 (confirmed) Congenital disorder of glycosylation,type IIc,266265];	RCV000243982.1 [benign]; RCV000330911.1 [benign]; 			453	301					SLC35C1 (inh=AR pLI=0.15)
chr11	45834044	45834044	C	T	hom	hom	hom		QUAL=18675;DP=206,188,220;MQM=60	SLC35C1	3'UTR	SLC35C1:NM_018389.4:3'UTR:MODIFIER:exon2/2:c.*1158C>T:,SLC35C1:NM_001145265.1:3'UTR:MODIFIER:exon3/3:c.*1158C>T:,SLC35C1:NM_001145266.1:3'UTR:MODIFIER:exon3/3:c.*1158C>T:	MLT1A0	rs4756027	0.7206	0.0000	0/0/0	0.1347							605881 [SLC35C1 (confirmed) Congenital disorder of glycosylation,type IIc,266265];	RCV000344613.1 [benign]; 			284	94					SLC35C1 (inh=AR pLI=0.15)
chr11	45834198	45834198	T	C	hom	hom	hom		QUAL=18808;DP=235,157,210;MQM=59	SLC35C1	3'UTR	SLC35C1:NM_018389.4:3'UTR:MODIFIER:exon2/2:c.*1312T>C:,SLC35C1:NM_001145265.1:3'UTR:MODIFIER:exon3/3:c.*1312T>C:,SLC35C1:NM_001145266.1:3'UTR:MODIFIER:exon3/3:c.*1312T>C:	MLT1A0	rs7943306	0.6538	0.7743	3296/1095/39	0.1954							605881 [SLC35C1 (confirmed) Congenital disorder of glycosylation,type IIc,266265];	RCV000314257.1 [benign]; 			729	269					SLC35C1 (inh=AR pLI=0.15)
chr11	45834466	45834466	C	T	wt	het	wt		QUAL=381;DP=103,29,48;MQM=60	SLC35C1	3'UTR	SLC35C1:NM_018389.4:3'UTR:MODIFIER:exon2/2:c.*1580C>T:,SLC35C1:NM_001145265.1:3'UTR:MODIFIER:exon3/3:c.*1580C>T:,SLC35C1:NM_001145266.1:3'UTR:MODIFIER:exon3/3:c.*1580C>T:		rs10838518	0.0996	0.0000	0/0/0	0.0089							605881 [SLC35C1 (confirmed) Congenital disorder of glycosylation,type IIc,266265];	RCV000321594.1 [likely benign]; 			0	11					SLC35C1 (inh=AR pLI=0.15)
chr11	45931502	45931502	G	A	hom	het	hom		QUAL=19327;DP=177,248,361;MQM=60	PEX16	3'UTR	PEX16:NM_057174.2:3'UTR:MODIFIER:exon11/11:c.*138C>T:,PEX16:NM_004813.2:3'UTR:MODIFIER:exon11/11:c.*303C>T:		rs10838529	0.3936	0.0000	0/0/0	0.0961							603360 [PEX16 (provisional) Peroxisome biogenesis disorder 8A (Zellweger),614876|Peroxisome biogenesis disorder 8B,614877];	RCV000267975.1 [benign]; 			117	83					PEX16 (inh=AR pLI=0.00)
chr11	45935384	45935384	A	G	hom	het	hom		QUAL=21005;DP=184,255,393;MQM=59	PEX16	synonymous	PEX16:NM_057174.2:synonymous:LOW:exon9/11:c.873T>C:p.Tyr291Tyr,PEX16:NM_004813.2:synonymous:LOW:exon9/11:c.873T>C:p.Tyr291Tyr		rs1132349	0.6891	0.8155	42019/27922/1802	0.8018							603360 [PEX16 (provisional) Peroxisome biogenesis disorder 8A (Zellweger),614876|Peroxisome biogenesis disorder 8B,614877];	RCV000248969.1 [benign]; RCV000389065.1 [benign]; 		COSM4145722, COSM4145721	1236	302					PEX16 (inh=AR pLI=0.00)
chr11	45937267	45937267	C	T	hom	hom	hom	pred_pathogenic	QUAL=30239;DP=244,304,451;MQM=60	PEX16	missense	PEX16:NM_057174.2:missense:MODERATE:exon4/11:c.346G>A:p.Val116Ile,PEX16:NM_004813.2:missense:MODERATE:exon4/11:c.346G>A:p.Val116Ile		rs10742772	1.0000	1.0000	60695/33362/5202	0.9362	3.7850	T,T,T,T	T	B,B	T,T,T,T	16.46	603360 [PEX16 (provisional) Peroxisome biogenesis disorder 8A (Zellweger),614876|Peroxisome biogenesis disorder 8B,614877];				1565	0					PEX16 (inh=AR pLI=0.00)
chr11	47238522	47238522	T	C	hom	hom	hom	low_DP	QUAL=1242;DP=20,10,10;MQM=60	DDB2	synonymous	DDB2:NM_000107.2:synonymous:LOW:exon3/10:c.378T>C:p.Thr126Thr,DDB2:NM_001300734.1:synonymous:LOW:exon3/6:c.378T>C:p.Thr126Thr		rs326212	0.9942	0.9987	60550/33369/5055	0.9443							600811 [DDB2 (provisional) Xeroderma pigmentosum,group E,DDB-negative subtype,278740];				2923	1					DDB2 (inh=AR pLI=0.01)
chr11	47460306	47460306	A	G	hom	het	hom	low_DP	QUAL=1604;DP=17,21,28;MQM=60	RAPSN	synonymous	RAPSN:NM_005055.4:synonymous:LOW:exon7/8:c.1143T>C:p.Pro381Pro,RAPSN:NM_032645.4:synonymous:LOW:exon5/6:c.966T>C:p.Pro322Pro		rs7126210	0.6248	0.6837	10399/5850/425	0.5710							601592 [RAPSN (provisional) Myasthenic syndrome,congenital,11,associated with acetylcholine receptor deficiency,616326|Fetal akinesia deformation sequence,208150];	RCV000118117.3 [other]; RCV000292191.1 [benign]; RCV000347078.1 [benign]; 		COSM3931321	866	580					RAPSN (inh=AR pLI=0.03)
chr11	47463484	47463484	G	-	hom	het	hom		QUAL=2246;DP=23,49,53;MQM=59	RAPSN	splice_region&intron	RAPSN:NM_005055.4:splice_region&intron:LOW:exon3/7:c.691-11delC:,RAPSN:NM_032645.4:splice_region&intron:LOW:exon3/5:c.691-11delC:		rs397825047	0.6108	0.7106	10475/5999/322	0.5567							601592 [RAPSN (provisional) Myasthenic syndrome,congenital,11,associated with acetylcholine receptor deficiency,616326|Fetal akinesia deformation sequence,208150];	RCV000178237.2 [benign]; RCV000288381.1 [benign]; RCV000382725.1 [benign]; 			819	493					RAPSN (inh=AR pLI=0.03)
chr11	47469439	47469439	A	G	hom	het	hom		QUAL=29279;DP=289,422,522;MQM=59	RAPSN	synonymous	RAPSN:NM_005055.4:synonymous:LOW:exon2/8:c.456T>C:p.Tyr152Tyr,RAPSN:NM_032645.4:synonymous:LOW:exon2/6:c.456T>C:p.Tyr152Tyr		rs7111873	0.6256	0.6847	27963/16859/899	0.6731							601592 [RAPSN (provisional) Myasthenic syndrome,congenital,11,associated with acetylcholine receptor deficiency,616326|Fetal akinesia deformation sequence,208150];	RCV000118119.3 [other]; RCV000315533.1 [benign]; RCV000367686.1 [benign]; 			871	582					RAPSN (inh=AR pLI=0.03)
chr11	60236272	60236272	A	G	het	hom	wt		QUAL=13559;DP=347,268,327;MQM=60	MS4A1	3'UTR	MS4A1:NM_021950.3:3'UTR:MODIFIER:exon7/7:c.*331A>G:,MS4A1:NM_152866.2:3'UTR:MODIFIER:exon8/8:c.*331A>G:		rs1051756	0.6380	0.0000	0/0/0	0.0994							112210 [MS4A1 (confirmed) Immunodeficiency,common variable,5,613495];				81	109					MS4A1 (inh=AR pLI=0.02)
chr11	60237028	60237028	T	A	wt	het	wt		QUAL=322;DP=178,31,30;MQM=60	MS4A1	3'UTR	MS4A1:NM_021950.3:3'UTR:MODIFIER:exon7/7:c.*1087T>A:,MS4A1:NM_152866.2:3'UTR:MODIFIER:exon8/8:c.*1087T>A:		rs12287265	0.0789	0.0000	0/0/0	0.0091							112210 [MS4A1 (confirmed) Immunodeficiency,common variable,5,613495];				1	30					MS4A1 (inh=AR pLI=0.02)
chr11	60237234	60237234	T	C	het	het	wt		QUAL=4996;DP=239,141,187;MQM=60	MS4A1	3'UTR	MS4A1:NM_021950.3:3'UTR:MODIFIER:exon7/7:c.*1293T>C:,MS4A1:NM_152866.2:3'UTR:MODIFIER:exon8/8:c.*1293T>C:		rs1051461	0.2228	0.0000	0/0/0	0.0512							112210 [MS4A1 (confirmed) Immunodeficiency,common variable,5,613495];				26	105					MS4A1 (inh=AR pLI=0.02)
chr11	60237991	60237991	T	C	het	hom	wt		QUAL=7828;DP=351,81,105;MQM=60	MS4A1	3'UTR	MS4A1:NM_021950.3:3'UTR:MODIFIER:exon7/7:c.*2050T>C:,MS4A1:NM_152866.2:3'UTR:MODIFIER:exon8/8:c.*2050T>C:		rs1051593	0.4756	0.0000	0/0/0	0.0783							112210 [MS4A1 (confirmed) Immunodeficiency,common variable,5,613495];				56	120					MS4A1 (inh=AR pLI=0.02)
chr11	60238054	60238054	C	T	het	hom	wt		QUAL=6663;DP=272,94,123;MQM=60	MS4A1	3'UTR	MS4A1:NM_021950.3:3'UTR:MODIFIER:exon7/7:c.*2113C>T:,MS4A1:NM_152866.2:3'UTR:MODIFIER:exon8/8:c.*2113C>T:		rs1051594	0.4742	0.0000	0/0/0	0.4566							112210 [MS4A1 (confirmed) Immunodeficiency,common variable,5,613495];				57	118					MS4A1 (inh=AR pLI=0.02)
chr11	61165280	61165280	G	A	het	het	hom		QUAL=4496;DP=136,65,82;MQM=59	TMEM216	synonymous	TMEM216:NM_001173991.2:synonymous:LOW:exon4/5:c.264G>A:p.Pro88Pro,TMEM216:NM_001173990.2:synonymous:LOW:exon4/5:c.264G>A:p.Pro88Pro,TMEM216:NM_016499.5:synonymous:LOW:exon4/5:c.81G>A:p.Pro27Pro		rs3741265	0.8558	0.8659	45445/24981/2828	0.8337							613277 [TMEM216 (confirmed) Joubert syndrome 2,608091|Meckel syndrome 2,603194];	RCV000114238.3 [other]; RCV000361073.1 [benign]; RCV000405990.1 [benign]; 			2071	572					TMEM216 (inh=AR pLI=0.00)
chr11	61165731	61165731	-	A	het	het	hom	anno_high_impact	QUAL=7846;DP=189,103,126;MQM=59	TMEM216	splice_acceptor,splice_region&intron	TMEM216:NM_001173991.2:splice_acceptor:HIGH:exon4/4:c.432-2_432-1insA:,TMEM216:NM_016499.5:splice_acceptor:HIGH:exon4/4:c.249-2_249-1insA:,TMEM216:NM_001173990.2:splice_region&intron:LOW:exon4/4:c.432-11_432-10insA:		rs11382548	0.8558	0.8593	43189/23691/2710	0.8032							613277 [TMEM216 (confirmed) Joubert syndrome 2,608091|Meckel syndrome 2,603194];	RCV000154006.3 [benign]; RCV000270481.1 [benign]; RCV000325554.1 [benign]; 			1898	527	1	[1] auto-classification 16.06.2016  [2] Ute Grasshoff 09.04.2015			TMEM216 (inh=AR pLI=0.00)
chr11	61165741	61165741	G	C	het	het	hom	anno_high_impact;pred_pathogenic	QUAL=8618;DP=187,121,143;MQM=59	TMEM216	splice_acceptor,missense	TMEM216:NM_001173990.2:splice_acceptor:HIGH:exon4/4:c.432-1G>C:,TMEM216:NM_001173991.2:missense:MODERATE:exon5/5:c.440G>C:p.Arg147Thr,TMEM216:NM_016499.5:missense:MODERATE:exon5/5:c.257G>C:p.Arg86Thr		rs10897158	0.7196	0.8153	40102/23265/640	0.7371	0.7930	.,.,T	.,T		.,D	23.80	613277 [TMEM216 (confirmed) Joubert syndrome 2,608091|Meckel syndrome 2,603194];	RCV000114239.5 [benign]; RCV000200066.4 [benign]; RCV000291379.1 [benign]; 		COSM1582850	1983	647	1	[1] auto-classification 16.06.2016  [2] Ute Grasshoff 09.04.2015			TMEM216 (inh=AR pLI=0.00)
chr11	61166306	61166306	G	A	het	wt	hom	low_DP	QUAL=919;DP=112,4,7;MQM=60	TMEM216	3'UTR	TMEM216:NM_001173991.2:3'UTR:MODIFIER:exon5/5:c.*558G>A:,TMEM216:NM_001173990.2:3'UTR:MODIFIER:exon5/5:c.*558G>A:,TMEM216:NM_016499.5:3'UTR:MODIFIER:exon5/5:c.*558G>A:		rs7607	0.7196	0.0000	0/0/0	0.1181							613277 [TMEM216 (confirmed) Joubert syndrome 2,608091|Meckel syndrome 2,603194];	RCV000329368.1 [benign]; RCV000377140.1 [benign]; 			173	49					TMEM216 (inh=AR pLI=0.00)
chr11	61717607	61717607	C	T	het	wt	het		QUAL=7597;DP=297,349,395;MQM=60	BEST1	5'UTR,non_coding_transcript_exon	BEST1:NM_001139443.1:5'UTR:MODIFIER:exon1/9:c.-321C>T:,BEST1:NM_001300786.1:5'UTR:MODIFIER:exon1/9:c.-321C>T:,BEST1:NM_001300787.1:5'UTR:MODIFIER:exon1/10:c.-321C>T:,BEST1:NM_004183.3:5'UTR:MODIFIER:exon1/11:c.-329C>T:,BEST1:NR_134580.1:non_coding_transcript_exon:MODIFIER:exon1/11:n.252C>T:		rs972354	0.3490	0.0000	0/0/0	0.2440							607854 [BEST1 (confirmed) Macular dystrophy,vitelliform,2,153700|Bestrophinopathy,autosomal recessive,611809|Vitreoretinochoroidopathy,193220|Microcornea,rod-cone dystrophy,cataract,and posterior staphyloma,193220|Retinitis pigmentosa-50,613194|Retinitis pigmentosa,concentric,613194];	RCV000304307.1 [benign]; RCV000361256.1 [benign]; RCV000392337.1 [benign]; 			5	48					BEST1 (inh=AR+AD pLI=0.00)
chr11	61717715	61717715	T	C	het	het	het		QUAL=12101;DP=352,285,313;MQM=60	BEST1	5'UTR,non_coding_transcript_exon	BEST1:NM_001139443.1:5'UTR:MODIFIER:exon1/9:c.-213T>C:,BEST1:NM_001300786.1:5'UTR:MODIFIER:exon1/9:c.-213T>C:,BEST1:NM_001300787.1:5'UTR:MODIFIER:exon1/10:c.-213T>C:,BEST1:NM_004183.3:5'UTR:MODIFIER:exon1/11:c.-221T>C:,BEST1:NR_134580.1:non_coding_transcript_exon:MODIFIER:exon1/11:n.360T>C:		rs972353	0.6793	0.0000	0/0/0	0.4136							607854 [BEST1 (confirmed) Macular dystrophy,vitelliform,2,153700|Bestrophinopathy,autosomal recessive,611809|Vitreoretinochoroidopathy,193220|Microcornea,rod-cone dystrophy,cataract,and posterior staphyloma,193220|Retinitis pigmentosa-50,613194|Retinitis pigmentosa,concentric,613194];	RCV000298197.1 [benign]; RCV000355356.1 [benign]; RCV000392227.1 [benign]; 			31	107					BEST1 (inh=AR+AD pLI=0.00)
chr11	61719387	61719387	T	C	het	het	het	low_DP	QUAL=462;DP=34,8,12;MQM=60	BEST1	synonymous,intron,non_coding_transcript_exon	BEST1:NM_004183.3:synonymous:LOW:exon2/11:c.109T>C:p.Leu37Leu,BEST1:NM_001139443.1:intron:MODIFIER:exon1/8:c.-29+1488T>C:,BEST1:NM_001300786.1:intron:MODIFIER:exon1/8:c.-29+1488T>C:,BEST1:NM_001300787.1:intron:MODIFIER:exon1/9:c.-29+1488T>C:,BEST1:NR_134580.1:non_coding_transcript_exon:MODIFIER:exon2/11:n.689T>C:		rs1800007	0.6805	0.4847	17100/3272/2778	0.4613							607854 [BEST1 (confirmed) Macular dystrophy,vitelliform,2,153700|Bestrophinopathy,autosomal recessive,611809|Vitreoretinochoroidopathy,193220|Microcornea,rod-cone dystrophy,cataract,and posterior staphyloma,193220|Retinitis pigmentosa-50,613194|Retinitis pigmentosa,concentric,613194];	RCV000086084.1 [not provided]; RCV000152861.4 [benign]; RCV000283689.1 [benign]; RCV000341149.1 [benign]; RCV000398665.1 [benign]; 		COSM3752558	228	673					BEST1 (inh=AR+AD pLI=0.00)
chr11	61727438	61727438	C	T	het	wt	het	pred_pathogenic	QUAL=6090;DP=244,163,246;MQM=60	BEST1	synonymous,non_coding_transcript_exon	BEST1:NM_001139443.1:synonymous:LOW:exon8/9:c.843C>T:p.Pro281Pro,BEST1:NM_001300786.1:synonymous:LOW:exon7/9:c.762C>T:p.Pro254Pro,BEST1:NM_001300787.1:synonymous:LOW:exon8/10:c.843C>T:p.Pro281Pro,BEST1:NM_004183.3:synonymous:LOW:exon9/11:c.1023C>T:p.Pro341Pro,BEST1:NR_134580.1:non_coding_transcript_exon:MODIFIER:exon9/11:n.1806C>T:		rs1801390	0.0140	0.0249	40/22/7	0.0213	-3.4650	D	D	B,B	D	6.49	607854 [BEST1 (confirmed) Macular dystrophy,vitelliform,2,153700|Bestrophinopathy,autosomal recessive,611809|Vitreoretinochoroidopathy,193220|Microcornea,rod-cone dystrophy,cataract,and posterior staphyloma,193220|Retinitis pigmentosa-50,613194|Retinitis pigmentosa,concentric,613194];	RCV000086082.1 [not provided]; RCV000303310.1 [benign]; RCV000342198.1 [benign]; RCV000358637.1 [benign]; RCV000392142.1 [benign]; 			1	66					BEST1 (inh=AR+AD pLI=0.00)
chr11	61730036	61730036	G	A	het	het	het		QUAL=8556;DP=293,213,252;MQM=59	BEST1	synonymous,non_coding_transcript_exon	BEST1:NM_001139443.1:synonymous:LOW:exon9/9:c.1230G>A:p.Thr410Thr,BEST1:NM_001300786.1:synonymous:LOW:exon8/9:c.1149G>A:p.Thr383Thr,BEST1:NM_001300787.1:synonymous:LOW:exon9/10:c.1230G>A:p.Thr410Thr,BEST1:NM_004183.3:synonymous:LOW:exon10/11:c.1410G>A:p.Thr470Thr,BEST1:NR_134580.1:non_coding_transcript_exon:MODIFIER:exon10/11:n.2193G>A:		rs149698	0.1122	0.2271	3986/3382/31	0.2275							607854 [BEST1 (confirmed) Macular dystrophy,vitelliform,2,153700|Bestrophinopathy,autosomal recessive,611809|Vitreoretinochoroidopathy,193220|Microcornea,rod-cone dystrophy,cataract,and posterior staphyloma,193220|Retinitis pigmentosa-50,613194|Retinitis pigmentosa,concentric,613194];	RCV000173795.2 [benign]; RCV000301873.1 [benign]; RCV000365872.1 [benign]; RCV000392906.1 [benign]; RCV000401921.1 [benign]; 		COSM3752559, COSM3752560	133	609					BEST1 (inh=AR+AD pLI=0.00)
chr11	63988102	63988102	C	T	wt	het	wt	low_QUAL;low_DP;pred_pathogenic	QUAL=26;DP=22,7,4;MQM=60	FERMT3	synonymous	FERMT3:NM_178443.2:synonymous:LOW:exon12/15:c.1518C>T:p.Leu506Leu,FERMT3:NM_031471.5:synonymous:LOW:exon12/15:c.1506C>T:p.Leu502Leu		rs3802933	0.1629	0.1899	1696/837/76	0.1681	-1.6890	D	T		T	11.81	607901 [FERMT3 (confirmed) Leukocyte adhesion deficiency,type III,612840];			COSM3931384, COSM3931385	46	382					FERMT3 (inh=AR pLI=0.26)
chr11	63990997	63990997	C	-	het	het	het		QUAL=5728;DP=157,172,240;MQM=59	FERMT3	3'UTR	FERMT3:NM_178443.2:3'UTR:MODIFIER:exon15/15:c.*35delC:,FERMT3:NM_031471.5:3'UTR:MODIFIER:exon15/15:c.*35delC:		rs5792315	0.0000	0.5153	9066/3303/1610	0.3899							607901 [FERMT3 (confirmed) Leukocyte adhesion deficiency,type III,612840];				169	351					FERMT3 (inh=AR pLI=0.26)
chr11	65485727	65485727	T	G	hom	het	hom		QUAL=30748;DP=387,348,445;MQM=59	RNASEH2C,KAT5	3'UTR,intron	RNASEH2C:NM_032193.3:3'UTR:MODIFIER:exon4/4:c.*1527A>C:,KAT5:NM_182710.2:intron:MODIFIER:exon10/12:c.1265-334T>G:,KAT5:NM_001206833.1:intron:MODIFIER:exon9/11:c.1109-334T>G:,KAT5:NM_006388.3:intron:MODIFIER:exon11/13:c.1166-334T>G:,KAT5:NM_182709.2:intron:MODIFIER:exon10/12:c.1010-334T>G:		rs521678	0.8249	0.0000	0/0/0	0.1501							610330 [RNASEH2C (provisional) Aicardi-Goutieres syndrome 3,610329];	RCV000363567.1 [benign]; 			194	34					RNASEH2C (inh=AR pLI=0.51), KAT5 (inh=n/a pLI=0.47)
chr11	65488386	65488386	G	T	wt	het	wt		QUAL=610;DP=25,47,43;MQM=60	RNASEH2C	5'UTR	RNASEH2C:NM_032193.3:5'UTR:MODIFIER:exon1/4:c.-157C>A:		rs535406222	0.0028	0.0000	0/0/0	0.0056							610330 [RNASEH2C (provisional) Aicardi-Goutieres syndrome 3,610329];	RCV000336949.1 [uncertain significance]; 			1	2					RNASEH2C (inh=AR pLI=0.51)
chr11	65636053	65636053	T	C	hom	hom	hom	pred_pathogenic	QUAL=27488;DP=338,245,308;MQM=59	EFEMP2	missense,non_coding_transcript_exon	EFEMP2:NM_016938.4:missense:MODERATE:exon8/11:c.775A>G:p.Ile259Val,EFEMP2:NR_037718.1:non_coding_transcript_exon:MODIFIER:exon8/12:n.1034A>G:		rs601314	0.8946	0.9695	57465/33186/2374	0.9323	0.5430	T,T	T	B,B	T,D	0.39	604633 [EFEMP2 (provisional) Cutis laxa,autosomal recessive,type IB,614437];	RCV000032273.1 [benign]; RCV000155538.2 [benign]; RCV000378680.1 [benign]; 			1583	29					EFEMP2 (inh=AR pLI=0.03)
chr11	65638719	65638719	G	A	hom	het	hom		QUAL=15870;DP=113,266,327;MQM=60	EFEMP2	synonymous,non_coding_transcript_exon	EFEMP2:NM_016938.4:synonymous:LOW:exon4/11:c.276C>T:p.His92His,EFEMP2:NR_037718.1:non_coding_transcript_exon:MODIFIER:exon4/12:n.535C>T:		rs633800	0.3211	0.4503	13690/8944/130	0.4423							604633 [EFEMP2 (provisional) Cutis laxa,autosomal recessive,type IB,614437];	RCV000150612.2 [benign]; RCV000375568.1 [benign]; 		COSM3752644	437	792					EFEMP2 (inh=AR pLI=0.03)
chr11	66282095	66282095	G	A	het	wt	hom	pred_pathogenic	QUAL=6493;DP=140,96,169;MQM=60	BBS1	synonymous	BBS1:NM_024649.4:synonymous:LOW:exon4/17:c.378G>A:p.Leu126Leu		rs2298806	0.2117	0.2233	3285/1868/79	0.2212	1.1130	T	T		D	7.29	209901 [BBS1 (confirmed) Bardet-Biedl syndrome 1,209900];	RCV000247494.1 [benign]; RCV000262515.1 [benign]; 		COSM147274, COSM3998544	68	538					BBS1 (inh=AR pLI=0.00)
chr11	66288733	66288733	G	C	het	wt	hom		QUAL=4205;DP=105,69,99;MQM=60	BBS1	splice_region&intron	BBS1:NM_024649.4:splice_region&intron:LOW:exon8/16:c.724-8G>C:		rs10896125	0.2426	0.2321	3458/1862/251	0.2297							209901 [BBS1 (confirmed) Bardet-Biedl syndrome 1,209900];	RCV000082204.5 [benign]; RCV000385461.1 [benign]; 		COSM3998545, COSM147275	69	540					BBS1 (inh=AR pLI=0.00)
chr11	66297363	66297363	C	T	het	wt	hom		QUAL=11063;DP=206,189,274;MQM=59	BBS1	synonymous	BBS1:NM_024649.4:synonymous:LOW:exon14/17:c.1413C>T:p.Leu471Leu		rs3816492	0.1434	0.2089	2812/1803/11	0.1982							209901 [BBS1 (confirmed) Bardet-Biedl syndrome 1,209900];	RCV000243070.1 [benign]; RCV000369667.1 [benign]; 		COSM3752663, COSM3752662	67	528					BBS1 (inh=AR pLI=0.00)
chr11	66299515	66299515	A	G	hom	het	hom		QUAL=11302;DP=175,104,155;MQM=59	BBS1	3'UTR	BBS1:NM_024649.4:3'UTR:MODIFIER:exon17/17:c.*7A>G:		rs8432	0.6128	0.5894	13682/8183/2600	0.5219							209901 [BBS1 (confirmed) Bardet-Biedl syndrome 1,209900];	RCV000241930.1 [benign]; RCV000270220.1 [benign]; 			531	702					BBS1 (inh=AR pLI=0.00)
chr11	66300348	66300348	A	G	het	wt	hom		QUAL=1902;DP=57,33,42;MQM=60	BBS1	3'UTR	BBS1:NM_024649.4:3'UTR:MODIFIER:exon17/17:c.*840A>G:		rs3741360	0.2358	0.0000	0/0/0	0.2283							209901 [BBS1 (confirmed) Bardet-Biedl syndrome 1,209900];	RCV000406652.1 [likely benign]; 			8	84					BBS1 (inh=AR pLI=0.00)
chr11	66300463	66300463	G	A	wt	het	wt	low_QUAL;low_DP	QUAL=27;DP=93,14,18;MQM=60	BBS1	3'UTR	BBS1:NM_024649.4:3'UTR:MODIFIER:exon17/17:c.*955G>A:		rs1791686	0.3846	0.0000	0/0/0	0.0713							209901 [BBS1 (confirmed) Bardet-Biedl syndrome 1,209900];	RCV000337876.1 [benign]; 			51	101					BBS1 (inh=AR pLI=0.00)
chr11	66452849	66452849	T	G	wt	het	het	low_QUAL	QUAL=17;DP=89,57,70;MQM=59	SPTBN2	3'UTR	SPTBN2:NM_006946.2:3'UTR:MODIFIER:exon37/37:c.*493A>C:			0.0000	0.0000	0/0/0	0.0000							604985 [SPTBN2 (confirmed) Spinocerebellar ataxia 5,600224|Spinocerebellar ataxia,autosomal recessive 14,615386];				0	5					SPTBN2 (inh=AR+AD pLI=1.00)
chr11	66458980	66458980	G	A	het	wt	hom		QUAL=7340;DP=96,117,205;MQM=59	SPTBN2	synonymous	SPTBN2:NM_006946.2:synonymous:LOW:exon26/37:c.5340C>T:p.Asn1780Asn		rs623022	0.0631	0.0659	366/173/1	0.0627							604985 [SPTBN2 (confirmed) Spinocerebellar ataxia 5,600224|Spinocerebellar ataxia,autosomal recessive 14,615386];	RCV000319541.1 [likely benign]; 			9	244					SPTBN2 (inh=AR+AD pLI=1.00)
chr11	66460527	66460527	C	T	het	wt	hom		QUAL=4377;DP=97,74,98;MQM=59	SPTBN2	synonymous	SPTBN2:NM_006946.2:synonymous:LOW:exon24/37:c.4899G>A:p.Leu1633Leu		rs639938	0.0777	0.0694	378/171/13	0.0666							604985 [SPTBN2 (confirmed) Spinocerebellar ataxia 5,600224|Spinocerebellar ataxia,autosomal recessive 14,615386];	RCV000404452.1 [likely benign]; 		COSM3998546, COSM3998547	11	245					SPTBN2 (inh=AR+AD pLI=1.00)
chr11	66468469	66468469	A	G	het	wt	hom		QUAL=4644;DP=97,128,118;MQM=60	SPTBN2	missense	SPTBN2:NM_006946.2:missense:MODERATE:exon16/37:c.3101T>C:p.Val1034Ala		rs506028	0.2057	0.1335	1312/375/379	0.1284	-0.1020	T,T,T	T	B	T,T,T	0.01	604985 [SPTBN2 (confirmed) Spinocerebellar ataxia 5,600224|Spinocerebellar ataxia,autosomal recessive 14,615386];	RCV000118411.2 [likely benign]; RCV000390858.1 [benign]; 		COSM3752672, COSM3752673	29	501					SPTBN2 (inh=AR+AD pLI=1.00)
chr11	66472274	66472274	T	C	hom	hom	hom	pred_pathogenic	QUAL=5420;DP=28,74,72;MQM=60	SPTBN2	missense	SPTBN2:NM_006946.2:missense:MODERATE:exon14/37:c.2473A>G:p.Ser825Gly		rs4930388	0.9878	0.9969	56199/30704/4050	0.9306	2.0170	T,T,T	T	B	T,T,T	6.02	604985 [SPTBN2 (confirmed) Spinocerebellar ataxia 5,600224|Spinocerebellar ataxia,autosomal recessive 14,615386];	RCV000336627.1 [benign]; 		COSM3752675, COSM3752674	2686	6					SPTBN2 (inh=AR+AD pLI=1.00)
chr11	66481633	66481633	G	A	het	het	wt		QUAL=12361;DP=418,528,634;MQM=60	SPTBN2	synonymous	SPTBN2:NM_006946.2:synonymous:LOW:exon6/37:c.585C>T:p.Asn195Asn		rs34775878	0.0407	0.0818	586/514/2	0.0832							604985 [SPTBN2 (confirmed) Spinocerebellar ataxia 5,600224|Spinocerebellar ataxia,autosomal recessive 14,615386];	RCV000118412.2 [likely benign]; RCV000321710.1 [likely benign]; 			37	550					SPTBN2 (inh=AR+AD pLI=1.00)
chr11	67758895	67758895	G	C	het	hom	wt	low_DP;low_MQM	QUAL=247;DP=14,7,14;MQM=43	UNC93B1	3'UTR	UNC93B1:NM_030930.3:3'UTR:MODIFIER:exon11/11:c.*122C>G:		rs7932	0.2302	0.0000	0/0/0	0.1751							608204 [UNC93B1 (confirmed) Herpes simplex encephalitis,susceptibility to,1,610551];				17	79					UNC93B1 (inh=n/a pLI=0.51)
chr11	67759196	67759196	A	C	wt	het	het	low_QUAL;low_DP;low_MQM;pred_pathogenic	QUAL=22;DP=15,49,49;MQM=29	UNC93B1	missense	UNC93B1:NM_030930.3:missense:MODERATE:exon11/11:c.1612T>G:p.Tyr538Asp		rs2375178	0.0000	0.0017	0/0/0	0.0001	8.0290	D	T	D	T	25.20	608204 [UNC93B1 (confirmed) Herpes simplex encephalitis,susceptibility to,1,610551];			COSM132779	0	48					UNC93B1 (inh=n/a pLI=0.51)
chr11	67759254	67759254	G	C	het	hom	het	low_MQM	QUAL=2164;DP=22,78,97;MQM=35	UNC93B1	synonymous	UNC93B1:NM_030930.3:synonymous:LOW:exon11/11:c.1554C>G:p.Arg518Arg		rs7149	0.2566	0.0564	32/9/6	0.0147							608204 [UNC93B1 (confirmed) Herpes simplex encephalitis,susceptibility to,1,610551];			COSM1288831	67	284					UNC93B1 (inh=n/a pLI=0.51)
chr11	67759316	67759316	C	T	wt	het	het	low_MQM;pred_pathogenic	QUAL=708;DP=58,135,157;MQM=42	UNC93B1	missense	UNC93B1:NM_030930.3:missense:MODERATE:exon11/11:c.1492G>A:p.Val498Met		rs4014596	0.0000	0.0486	0/0/0	0.0002	1.9730	D	T	B	D	27.50	608204 [UNC93B1 (confirmed) Herpes simplex encephalitis,susceptibility to,1,610551];			COSM227082	2	85					UNC93B1 (inh=n/a pLI=0.51)
chr11	67765163	67765163	-	G	hom	hom	hom	anno_high_impact	QUAL=14494;DP=74,175,251;MQM=59	UNC93B1	frameshift	UNC93B1:NM_030930.3:frameshift:HIGH:exon7/11:c.887dupC:p.Ser297fs		rs5792426	1.0000	1.0000	60061/33107/4866	0.9364							608204 [UNC93B1 (confirmed) Herpes simplex encephalitis,susceptibility to,1,610551];			COSM1356479	1573	0	1	[1] auto-classification 16.06.2016  [2] Ute Grasshoff 24.11.2015			UNC93B1 (inh=n/a pLI=0.51)
chr11	67804074	67804074	C	T	het	hom	wt		QUAL=12374;DP=195,337,384;MQM=59	NDUFS8	3'UTR	NDUFS8:NM_002496.3:3'UTR:MODIFIER:exon7/7:c.*14C>T:		rs1051806	0.1699	0.1545	1549/1008/286	0.1557							602141 [NDUFS8 (confirmed) Leigh syndrome due to mitochondrial complex I deficiency,256000];	RCV000285968.1 [likely benign]; RCV000313524.1 [benign]; RCV000326666.1 [likely benign]; 			38	255					NDUFS8 (inh=AR pLI=0.01)
chr11	67814979	67814979	G	C	hom	hom	hom		QUAL=18974;DP=146,199,264;MQM=59	TCIRG1	synonymous	TCIRG1:NM_006019.3:synonymous:LOW:exon11/20:c.1245G>C:p.Leu415Leu,TCIRG1:NM_006053.3:synonymous:LOW:exon6/15:c.597G>C:p.Leu199Leu		rs2471829	0.9698	0.9927	59623/33159/4404	0.9290	0.4660		T			10.60	604592 [TCIRG1 (confirmed) Osteopetrosis,autosomal recessive 1,259700];	RCV000224273.1 [benign]; 			1558	7					TCIRG1 (inh=AR pLI=0.00)
chr11	68133035	68133035	T	C	het	het	wt		QUAL=2030;DP=59,133,200;MQM=57	LRP5	splice_region&intron,sequence_feature	LRP5:NM_002335.3:splice_region&intron:LOW:exon4/22:c.884-4T>C:,LRP5:NM_001291902.1:splice_region&intron:LOW:exon4/22:c.-882-4T>C:,LRP5:NM_002335.3:sequence_feature:LOW::c.884-4T>C:		rs314776	0.4032	0.3765	10142/5257/2532	0.3691							603506 [LRP5 (confirmed) Osteoporosis-pseudoglioma syndrome,259770|Bone mineral density variability 1,601884|Hyperostosis,endosteal,144750|van Buchem disease,type 2,607636|Osteosclerosis,144750|Osteoporosis,166710|Exudative vitreoretinopathy 4,601813|Osteopetrosis,autosomal dominant 1,607634];	RCV000252412.2 [benign]; 		COSM3765595	246	762					LRP5 (inh=AR+AD pLI=1.00)
chr11	68171013	68171013	T	C	hom	hom	hom		QUAL=7263;DP=66,76,91;MQM=59	LRP5	synonymous,5'UTR	LRP5:NM_002335.3:synonymous:LOW:exon8/23:c.1647T>C:p.Phe549Phe,LRP5:NM_001291902.1:5'UTR:MODIFIER:exon7/23:c.-291T>C:		rs545382	0.8415	0.9001	49650/27709/2102	0.8789							603506 [LRP5 (confirmed) Osteoporosis-pseudoglioma syndrome,259770|Bone mineral density variability 1,601884|Hyperostosis,endosteal,144750|van Buchem disease,type 2,607636|Osteosclerosis,144750|Osteoporosis,166710|Exudative vitreoretinopathy 4,601813|Osteopetrosis,autosomal dominant 1,607634];	RCV000253993.1 [benign]; 		COSM4146219	1256	290					LRP5 (inh=AR+AD pLI=1.00)
chr11	68174122	68174122	G	A	het	het	wt		QUAL=9828;DP=293,443,544;MQM=59	LRP5	synonymous,sequence_feature	LRP5:NM_002335.3:synonymous:LOW:exon9/23:c.1932G>A:p.Glu644Glu,LRP5:NM_001291902.1:synonymous:LOW:exon9/23:c.189G>A:p.Glu63Glu,LRP5:NM_002335.3:sequence_feature:LOW:exon9/23:c.1932G>A:		rs2277268	0.0559	0.0598	227/155/20	0.0597							603506 [LRP5 (confirmed) Osteoporosis-pseudoglioma syndrome,259770|Bone mineral density variability 1,601884|Hyperostosis,endosteal,144750|van Buchem disease,type 2,607636|Osteosclerosis,144750|Osteoporosis,166710|Exudative vitreoretinopathy 4,601813|Osteopetrosis,autosomal dominant 1,607634];	RCV000246217.1 [benign]; 			6	204					LRP5 (inh=AR+AD pLI=1.00)
chr11	68177614	68177614	T	C	het	het	wt		QUAL=3358;DP=146,188,228;MQM=59	LRP5	splice_region&intron,sequence_feature	LRP5:NM_002335.3:splice_region&intron:LOW:exon10/22:c.2318+6T>C:,LRP5:NM_001291902.1:splice_region&intron:LOW:exon10/22:c.575+6T>C:,LRP5:NM_002335.3:sequence_feature:LOW::c.2318+6T>C:		rs4988322	0.0559	0.0667	219/152/18	0.0583							603506 [LRP5 (confirmed) Osteoporosis-pseudoglioma syndrome,259770|Bone mineral density variability 1,601884|Hyperostosis,endosteal,144750|van Buchem disease,type 2,607636|Osteosclerosis,144750|Osteoporosis,166710|Exudative vitreoretinopathy 4,601813|Osteopetrosis,autosomal dominant 1,607634];	RCV000246341.1 [benign]; 			6	208					LRP5 (inh=AR+AD pLI=1.00)
chr11	68192690	68192690	G	A	het	wt	hom		QUAL=8939;DP=192,170,218;MQM=60	LRP5	synonymous	LRP5:NM_002335.3:synonymous:LOW:exon15/23:c.3357G>A:p.Val1119Val,LRP5:NM_001291902.1:synonymous:LOW:exon15/23:c.1614G>A:p.Val538Val		rs556442	0.5793	0.6755	29005/15721/282	0.6631							603506 [LRP5 (confirmed) Osteoporosis-pseudoglioma syndrome,259770|Bone mineral density variability 1,601884|Hyperostosis,endosteal,144750|van Buchem disease,type 2,607636|Osteosclerosis,144750|Osteoporosis,166710|Exudative vitreoretinopathy 4,601813|Osteopetrosis,autosomal dominant 1,607634];	RCV000246826.1 [benign]; 		COSM3752692	676	705					LRP5 (inh=AR+AD pLI=1.00)
chr11	68201295	68201295	C	T	wt	het	wt	pred_pathogenic	QUAL=699;DP=78,66,60;MQM=60	LRP5	missense	LRP5:NM_002335.3:missense:MODERATE:exon18/23:c.3989C>T:p.Ala1330Val,LRP5:NM_001291902.1:missense:MODERATE:exon18/23:c.2246C>T:p.Ala749Val		rs3736228	0.1160	0.1392	1139/564/8	0.1299	0.6750	T	T	B,B	D	20.90	603506 [LRP5 (confirmed) Osteoporosis-pseudoglioma syndrome,259770|Bone mineral density variability 1,601884|Hyperostosis,endosteal,144750|van Buchem disease,type 2,607636|Osteosclerosis,144750|Osteoporosis,166710|Exudative vitreoretinopathy 4,601813|Osteopetrosis,autosomal dominant 1,607634];	RCV000242123.2 [benign]; 	CM067428 [CLASS=DFP MUT=ALT PHEN="Lumbar spine bone-mineral content association with" GENE=LRP5]; 		31	385					LRP5 (inh=AR+AD pLI=1.00)
chr11	68522216	68522216	T	C	het	het	wt		QUAL=10787;DP=490,312,392;MQM=60	CPT1A	3'UTR	CPT1A:NM_001031847.2:3'UTR:MODIFIER:exon19/19:c.*68A>G:		rs75022915	0.0104	0.0000	0/0/0	0.0049							600528 [CPT1A (confirmed) CPT deficiency,hepatic,type IA,255120];				0	73					CPT1A (inh=AR pLI=0.94)
chr11	68523179	68523179	T	-	wt	wt	hom	low_DP	QUAL=51;DP=36,18,12;MQM=59	CPT1A	3'UTR,intron	CPT1A:NM_001876.3:3'UTR:MODIFIER:exon19/19:c.*1933delA:,CPT1A:NM_001031847.2:intron:MODIFIER:exon18/18:c.2236-860delA:	(T)n		0.0000	0.0000	0/0/0	0.0069							600528 [CPT1A (confirmed) CPT deficiency,hepatic,type IA,255120];				0	2					CPT1A (inh=AR pLI=0.94)
chr11	68523910	68523910	T	C	het	het	hom		QUAL=10879;DP=292,135,139;MQM=59	CPT1A	3'UTR,intron	CPT1A:NM_001876.3:3'UTR:MODIFIER:exon19/19:c.*1202A>G:,CPT1A:NM_001031847.2:intron:MODIFIER:exon18/18:c.2236-1591A>G:		rs2278908	0.6488	0.0000	0/0/0	0.6562							600528 [CPT1A (confirmed) CPT deficiency,hepatic,type IA,255120];				120	113					CPT1A (inh=AR pLI=0.94)
chr11	68524053	68524053	G	A	het	het	hom		QUAL=4188;DP=148,53,59;MQM=59	CPT1A	3'UTR,intron	CPT1A:NM_001876.3:3'UTR:MODIFIER:exon19/19:c.*1059C>T:,CPT1A:NM_001031847.2:intron:MODIFIER:exon18/18:c.2236-1734C>T:		rs2278907	0.5625	0.0000	0/0/0	0.5606							600528 [CPT1A (confirmed) CPT deficiency,hepatic,type IA,255120];				90	137					CPT1A (inh=AR pLI=0.94)
chr11	68549340	68549340	A	G	hom	hom	hom		QUAL=37439;DP=324,341,492;MQM=60	CPT1A	synonymous	CPT1A:NM_001876.3:synonymous:LOW:exon11/19:c.1251T>C:p.Phe417Phe,CPT1A:NM_001031847.2:synonymous:LOW:exon11/19:c.1251T>C:p.Phe417Phe	L3	rs2228502	0.8926	0.9313	52771/30243/3693	0.9236							600528 [CPT1A (confirmed) CPT deficiency,hepatic,type IA,255120];	RCV000124600.2 [benign]; RCV000153103.4 [benign]; 			1333	205					CPT1A (inh=AR pLI=0.94)
chr11	68560787	68560787	C	T	het	het	wt		QUAL=3290;DP=140,93,111;MQM=60	CPT1A	synonymous	CPT1A:NM_001876.3:synonymous:LOW:exon9/19:c.963G>A:p.Glu321Glu,CPT1A:NM_001031847.2:synonymous:LOW:exon9/19:c.963G>A:p.Glu321Glu		rs2229737	0.0509	0.1036	557/444/11	0.0868							600528 [CPT1A (confirmed) CPT deficiency,hepatic,type IA,255120];	RCV000079919.6 [benign]; 		COSM3752694, COSM3752695	14	262					CPT1A (inh=AR pLI=0.94)
chr11	68562328	68562328	C	T	het	wt	het	pred_pathogenic;anno_pathogenic_clinvar;anno_pathogenic_hgmd	QUAL=9826;DP=418,338,401;MQM=60	CPT1A	missense	CPT1A:NM_001876.3:missense:MODERATE:exon8/19:c.823G>A:p.Ala275Thr,CPT1A:NM_001031847.2:missense:MODERATE:exon8/19:c.823G>A:p.Ala275Thr		rs2229738	0.0238	0.0647	388/297/2	0.0619	0.2480	T,T,T,T,T	T	B,B,B	D,D,D,D	12.21	600528 [CPT1A (confirmed) CPT deficiency,hepatic,type IA,255120];	RCV000055868.1 [pathogenic]; RCV000180224.2 [benign]; 	CM033597 [CLASS=DM? MUT=ALT PHEN="Carnitine palmitoyltransferase 1 deficiency" GENE=CPT1A]; 		9	214	2	[2] Peter Bauer 05.08.2014			CPT1A (inh=AR pLI=0.94)
chr11	68671419	68671419	C	T	het	hom	wt		QUAL=1697;DP=65,50,105;MQM=60	IGHMBP2	5'UTR	IGHMBP2:NM_002180.2:5'UTR:MODIFIER:exon1/15:c.-2C>T:		rs4930624	0.1160	0.2481	1037/900/20	0.1465							600502 [IGHMBP2 (provisional) Neuronopathy,distal hereditary motor,type VI,604320|Charcot-Marie-Tooth disease,axonal,type 2S,616155];	RCV000251714.2 [benign]; RCV000349227.1 [benign]; 			71	550					IGHMBP2 (inh=AR pLI=0.00)
chr11	68671477	68671477	T	C	het	hom	het	low_DP	QUAL=2470;DP=17,55,91;MQM=60	IGHMBP2	synonymous	IGHMBP2:NM_002180.2:synonymous:LOW:exon1/15:c.57T>C:p.Leu19Leu		rs1249463	0.6751	0.7589	5684/2673/466	0.4110							600502 [IGHMBP2 (provisional) Neuronopathy,distal hereditary motor,type VI,604320|Charcot-Marie-Tooth disease,axonal,type 2S,616155];	RCV000246174.2 [benign]; RCV000400134.1 [benign]; 			1061	452					IGHMBP2 (inh=AR pLI=0.00)
chr11	68678962	68678962	T	C	het	hom	het	pred_pathogenic	QUAL=18544;DP=273,316,457;MQM=60	IGHMBP2	missense	IGHMBP2:NM_002180.2:missense:MODERATE:exon5/15:c.602T>C:p.Leu201Ser		rs560096	0.6805	0.7719	36809/23109/2139	0.7681	-0.0700	T	T	B	D	0.07	600502 [IGHMBP2 (provisional) Neuronopathy,distal hereditary motor,type VI,604320|Charcot-Marie-Tooth disease,axonal,type 2S,616155];	RCV000248264.1 [benign]; RCV000324070.1 [benign]; 		COSM4146225	1064	455					IGHMBP2 (inh=AR pLI=0.00)
chr11	68682402	68682402	A	G	het	hom	wt		QUAL=4997;DP=166,96,113;MQM=60	IGHMBP2	missense	IGHMBP2:NM_002180.2:missense:MODERATE:exon6/15:c.823A>G:p.Ile275Val		rs10896380	0.1198	0.1819	2378/1979/70	0.1837	1.5760	T	T	B	T	8.17	600502 [IGHMBP2 (provisional) Neuronopathy,distal hereditary motor,type VI,604320|Charcot-Marie-Tooth disease,axonal,type 2S,616155];	RCV000244835.1 [benign]; RCV000388182.1 [benign]; 		COSM1178425	73	547					IGHMBP2 (inh=AR pLI=0.00)
chr11	68701948	68701948	C	T	het	hom	wt		QUAL=12471;DP=202,325,451;MQM=60	IGHMBP2	synonymous	IGHMBP2:NM_002180.2:synonymous:LOW:exon11/15:c.1554C>T:p.Val518Val		rs11228413	0.1328	0.2299	2103/1685/134	0.1861							600502 [IGHMBP2 (provisional) Neuronopathy,distal hereditary motor,type VI,604320|Charcot-Marie-Tooth disease,axonal,type 2S,616155];	RCV000254390.1 [benign]; RCV000276501.1 [benign]; 		COSM429749	73	550					IGHMBP2 (inh=AR pLI=0.00)
chr11	68704028	68704028	C	T	het	hom	wt	pred_pathogenic	QUAL=5643;DP=117,152,170;MQM=59	IGHMBP2	missense	IGHMBP2:NM_002180.2:missense:MODERATE:exon13/15:c.2080C>T:p.Arg694Trp		rs2236654	0.1330	0.1896	2409/1934/147	0.1889	0.1980	D	T	B	D	23.40	600502 [IGHMBP2 (provisional) Neuronopathy,distal hereditary motor,type VI,604320|Charcot-Marie-Tooth disease,axonal,type 2S,616155];	RCV000247088.2 [benign]; RCV000340149.1 [benign]; 		COSM3722147	73	551					IGHMBP2 (inh=AR pLI=0.00)
chr11	68707454	68707454	T	C	het	hom	het		QUAL=3523;DP=115,45,73;MQM=59	IGHMBP2	3'UTR	IGHMBP2:NM_002180.2:3'UTR:MODIFIER:exon15/15:c.*255T>C:		rs564244	0.6709	0.0000	0/0/0	0.7581							600502 [IGHMBP2 (provisional) Neuronopathy,distal hereditary motor,type VI,604320|Charcot-Marie-Tooth disease,axonal,type 2S,616155];	RCV000303046.1 [benign]; 			149	74					IGHMBP2 (inh=AR pLI=0.00)
chr11	68707626	68707626	C	T	wt	wt	het		QUAL=2818;DP=196,176,253;MQM=60	IGHMBP2	3'UTR	IGHMBP2:NM_002180.2:3'UTR:MODIFIER:exon15/15:c.*427C>T:		rs3750980	0.1967	0.0000	0/0/0	0.2741							600502 [IGHMBP2 (provisional) Neuronopathy,distal hereditary motor,type VI,604320|Charcot-Marie-Tooth disease,axonal,type 2S,616155];	RCV000382495.1 [benign]; 			13	84					IGHMBP2 (inh=AR pLI=0.00)
chr11	68707864	68707864	C	T	wt	het	wt		QUAL=1121;DP=159,101,120;MQM=60	IGHMBP2	3'UTR	IGHMBP2:NM_002180.2:3'UTR:MODIFIER:exon15/15:c.*665C>T:		rs9769	0.0773	0.0000	0/0/0	0.1485							600502 [IGHMBP2 (provisional) Neuronopathy,distal hereditary motor,type VI,604320|Charcot-Marie-Tooth disease,axonal,type 2S,616155];	RCV000294061.1 [likely benign]; 			11	88					IGHMBP2 (inh=AR pLI=0.00)
chr11	68707880	68707880	T	C	het	hom	wt		QUAL=4916;DP=146,103,119;MQM=59	IGHMBP2	3'UTR	IGHMBP2:NM_002180.2:3'UTR:MODIFIER:exon15/15:c.*681T>C:		rs9095	0.1536	0.0000	0/0/0	0.1949							600502 [IGHMBP2 (provisional) Neuronopathy,distal hereditary motor,type VI,604320|Charcot-Marie-Tooth disease,axonal,type 2S,616155];	RCV000332785.1 [benign]; 			13	100					IGHMBP2 (inh=AR pLI=0.00)
chr11	70049523	70049523	A	G	het	hom	wt	low_DP	QUAL=1236;DP=15,39,57;MQM=60	FADD	5'UTR	FADD:NM_003824.3:5'UTR:MODIFIER:exon1/2:c.-43A>G:		rs1131677	0.5327	0.5124	2231/1103/134	0.3280							602457 [FADD (confirmed) Infections,recurrent,with encephalopathy,hepatic dysfunction,and cardiovasuclar malformations,613759];				222	371					FADD (inh=AR pLI=0.67)
chr11	70053123	70053123	-	TGT	het	hom	wt		QUAL=2575;DP=80,63,102;MQM=59	FADD	3'UTR	FADD:NM_003824.3:3'UTR:MODIFIER:exon2/2:c.*545_*547dupTGT:	G-rich	rs397720848	0.4653	0.0000	0/0/0	0.4657							602457 [FADD (confirmed) Infections,recurrent,with encephalopathy,hepatic dysfunction,and cardiovasuclar malformations,613759];				65	117					FADD (inh=AR pLI=0.67)
chr11	70053487	70053487	C	T	het	hom	wt		QUAL=10131;DP=325,204,280;MQM=60	FADD	3'UTR	FADD:NM_003824.3:3'UTR:MODIFIER:exon2/2:c.*908C>T:		rs1131715	0.5405	0.0000	0/0/0	0.5594							602457 [FADD (confirmed) Infections,recurrent,with encephalopathy,hepatic dysfunction,and cardiovasuclar malformations,613759];				72	112					FADD (inh=AR pLI=0.67)
chr11	70314597	70314597	T	A	hom	hom	hom		QUAL=29450;DP=385,216,301;MQM=60	SHANK2	3'UTR,non_coding_transcript_exon	SHANK2:NM_012309.4:3'UTR:MODIFIER:exon23/23:c.*4377A>T:,SHANK2:NM_133266.4:3'UTR:MODIFIER:exon11/11:c.*4377A>T:,SHANK2:NR_110766.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.5781A>T:		rs513996	0.9635	0.0000	0/0/0	0.8695							603290 [SHANK2 (provisional) Autism susceptibility 17,613436];				258	1					SHANK2 (inh=AD pLI=1.00)
chr11	70316391	70316391	A	G	het	het	hom		QUAL=17026;DP=399,280,272;MQM=59	SHANK2	3'UTR,non_coding_transcript_exon	SHANK2:NM_012309.4:3'UTR:MODIFIER:exon23/23:c.*2583T>C:,SHANK2:NM_133266.4:3'UTR:MODIFIER:exon11/11:c.*2583T>C:,SHANK2:NR_110766.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.3987T>C:		rs55678639	0.2173	0.0000	0/0/0	0.0508							603290 [SHANK2 (provisional) Autism susceptibility 17,613436];				21	129					SHANK2 (inh=AD pLI=1.00)
chr11	70318714	70318714	A	G	hom	hom	hom		QUAL=25930;DP=249,260,306;MQM=59	SHANK2	3'UTR,non_coding_transcript_exon	SHANK2:NM_012309.4:3'UTR:MODIFIER:exon23/23:c.*260T>C:,SHANK2:NM_133266.4:3'UTR:MODIFIER:exon11/11:c.*260T>C:,SHANK2:NR_110766.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.1664T>C:		rs578657	0.9683	0.0000	0/0/0	0.8705							603290 [SHANK2 (provisional) Autism susceptibility 17,613436];				303	1					SHANK2 (inh=AD pLI=1.00)
chr11	70666765	70666765	C	T	het	het	wt		QUAL=471;DP=20,32,54;MQM=60	SHANK2	synonymous	SHANK2:NM_012309.4:synonymous:LOW:exon9/23:c.1005G>A:p.Ala335Ala		rs11237599	0.0931	0.1511	89/71/0	0.0401							603290 [SHANK2 (provisional) Autism susceptibility 17,613436];				51	432					SHANK2 (inh=AD pLI=1.00)
chr11	70935766	70935766	T	C	het	hom	het		QUAL=15957;DP=315,263,373;MQM=60	SHANK2	5'UTR	SHANK2:NM_012309.4:5'UTR:MODIFIER:exon1/23:c.-36A>G:		rs3020047	0.7468	0.0000	0/0/0	0.5742							603290 [SHANK2 (provisional) Autism susceptibility 17,613436];	RCV000307493.1 [likely benign]; 			55	104					SHANK2 (inh=AD pLI=1.00)
chr11	71145687	71145687	T	C	hom	hom	hom		QUAL=18606;DP=214,164,201;MQM=59	DHCR7	3'UTR	DHCR7:NM_001163817.1:3'UTR:MODIFIER:exon9/9:c.*734A>G:,DHCR7:NM_001360.2:3'UTR:MODIFIER:exon9/9:c.*734A>G:	LTR41B	rs7690	0.7736	0.0000	0/0/0	0.8822							602858 [DHCR7 (confirmed) Smith-Lemli-Opitz syndrome,270400];	RCV000265019.1 [benign]; 			210	19					DHCR7 (inh=AR pLI=0.00)
chr11	71145778	71145778	G	A	hom	hom	hom		QUAL=22902;DP=200,234,299;MQM=59	DHCR7	3'UTR	DHCR7:NM_001163817.1:3'UTR:MODIFIER:exon9/9:c.*643C>T:,DHCR7:NM_001360.2:3'UTR:MODIFIER:exon9/9:c.*643C>T:		rs1044535	0.7436	0.0000	0/0/0	0.1472							602858 [DHCR7 (confirmed) Smith-Lemli-Opitz syndrome,270400];	RCV000335396.1 [benign]; 			205	21					DHCR7 (inh=AR pLI=0.00)
chr11	71145941	71145941	G	A	het	het	hom		QUAL=17450;DP=209,290,388;MQM=60	DHCR7	3'UTR	DHCR7:NM_001163817.1:3'UTR:MODIFIER:exon9/9:c.*480C>T:,DHCR7:NM_001360.2:3'UTR:MODIFIER:exon9/9:c.*480C>T:	LTR41B	rs1790345	0.3594	0.0000	0/0/0	0.0468							602858 [DHCR7 (confirmed) Smith-Lemli-Opitz syndrome,270400];	RCV000389863.1 [likely benign]; 			20	104					DHCR7 (inh=AR pLI=0.00)
chr11	71146249	71146260	AGCAAGGAACAG	-	het	het	hom		QUAL=19666;DP=236,372,480;MQM=59	DHCR7	3'UTR	DHCR7:NM_001163817.1:3'UTR:MODIFIER:exon9/9:c.*161_*172delCTGTTCCTTGCT:,DHCR7:NM_001360.2:3'UTR:MODIFIER:exon9/9:c.*161_*172delCTGTTCCTTGCT:		rs368755383	0.3544	0.4544	1513/287/69	0.0393							602858 [DHCR7 (confirmed) Smith-Lemli-Opitz syndrome,270400];	RCV000307027.1 [likely benign]; 			77	408					DHCR7 (inh=AR pLI=0.00)
chr11	71146577	71146577	G	A	het	het	wt		QUAL=3677;DP=116,299,428;MQM=59	DHCR7	synonymous	DHCR7:NM_001163817.1:synonymous:LOW:exon9/9:c.1272C>T:p.Gly424Gly,DHCR7:NM_001360.2:synonymous:LOW:exon9/9:c.1272C>T:p.Gly424Gly		rs909217	0.3820	0.5499	19688/15390/493	0.5202							602858 [DHCR7 (confirmed) Smith-Lemli-Opitz syndrome,270400];	RCV000079641.6 [benign]; RCV000352975.1 [likely benign]; 		COSM329305	682	620					DHCR7 (inh=AR pLI=0.00)
chr11	71146691	71146691	A	G	hom	hom	hom	pred_pathogenic	QUAL=13139;DP=104,172,172;MQM=59	DHCR7	synonymous	DHCR7:NM_001163817.1:synonymous:LOW:exon9/9:c.1158T>C:p.Asp386Asp,DHCR7:NM_001360.2:synonymous:LOW:exon9/9:c.1158T>C:p.Asp386Asp		rs760241	0.7564	0.8531	44219/28936/2543	0.8492	-0.7980	D	T		D	0.01	602858 [DHCR7 (confirmed) Smith-Lemli-Opitz syndrome,270400];	RCV000079639.6 [benign]; RCV000276871.1 [benign]; 		COSM429787, COSM1475860	1267	269					DHCR7 (inh=AR pLI=0.00)
chr11	71152461	71152461	A	G	hom	hom	hom		QUAL=31128;DP=249,307,436;MQM=60	DHCR7	synonymous	DHCR7:NM_001163817.1:synonymous:LOW:exon6/9:c.438T>C:p.Asn146Asn,DHCR7:NM_001360.2:synonymous:LOW:exon6/9:c.438T>C:p.Asn146Asn		rs949177	0.8073	0.8747	46425/29488/3574	0.8706							602858 [DHCR7 (confirmed) Smith-Lemli-Opitz syndrome,270400];	RCV000079654.6 [benign]; RCV000355894.1 [benign]; 			1280	248					DHCR7 (inh=AR pLI=0.00)
chr11	71155129	71155129	G	A	wt	wt	het		QUAL=4176;DP=144,248,335;MQM=60	DHCR7	synonymous	DHCR7:NM_001163817.1:synonymous:LOW:exon4/9:c.231C>T:p.Thr77Thr,DHCR7:NM_001360.2:synonymous:LOW:exon4/9:c.231C>T:p.Thr77Thr		rs4316537	0.1052	0.0844	456/148/85	0.0789							602858 [DHCR7 (confirmed) Smith-Lemli-Opitz syndrome,270400];	RCV000079650.5 [benign]; RCV000329907.1 [likely benign]; 		COSM3752710, COSM3752709	13	176					DHCR7 (inh=AR pLI=0.00)
chr11	71155153	71155153	A	G	hom	hom	hom		QUAL=28422;DP=248,270,371;MQM=59	DHCR7	synonymous	DHCR7:NM_001163817.1:synonymous:LOW:exon4/9:c.207T>C:p.Thr69Thr,DHCR7:NM_001360.2:synonymous:LOW:exon4/9:c.207T>C:p.Thr69Thr		rs1790334	0.8101	0.8755	45276/28900/3465	0.8693							602858 [DHCR7 (confirmed) Smith-Lemli-Opitz syndrome,270400];	RCV000079649.6 [benign]; RCV000368185.1 [benign]; 		COSM4146259, COSM4146260	1284	252					DHCR7 (inh=AR pLI=0.00)
chr11	71155171	71155171	C	T	het	het	wt		QUAL=6706;DP=256,285,374;MQM=59	DHCR7	synonymous	DHCR7:NM_001163817.1:synonymous:LOW:exon4/9:c.189G>A:p.Gln63Gln,DHCR7:NM_001360.2:synonymous:LOW:exon4/9:c.189G>A:p.Gln63Gln		rs1044482	0.4010	0.5718	19162/15003/756	0.5574							602858 [DHCR7 (confirmed) Smith-Lemli-Opitz syndrome,270400];	RCV000079647.6 [benign]; RCV000271282.1 [likely benign]; 		COSM3931425, COSM3931426	688	607					DHCR7 (inh=AR pLI=0.00)
chr11	71158672	71158672	A	G	wt	wt	het		QUAL=4505;DP=182,268,322;MQM=60	DHCR7	5'UTR_premature_start_codon_gain,5'UTR	DHCR7:NM_001163817.1:5'UTR_premature_start_codon_gain:LOW:exon2/9:c.-23T>C:,DHCR7:NM_001360.2:5'UTR_premature_start_codon_gain:LOW:exon2/9:c.-23T>C:,DHCR7:NM_001163817.1:5'UTR:MODIFIER:exon2/9:c.-23T>C:,DHCR7:NM_001360.2:5'UTR:MODIFIER:exon2/9:c.-23T>C:		rs12573951	0.0439	0.0000	0/0/0	0.0452							602858 [DHCR7 (confirmed) Smith-Lemli-Opitz syndrome,270400];	RCV000322582.1 [likely benign]; 			2	28					DHCR7 (inh=AR pLI=0.00)
chr11	71159429	71159429	G	A	hom	het	het		QUAL=3481;DP=37,81,97;MQM=59	DHCR7	5'UTR	DHCR7:NM_001163817.1:5'UTR:MODIFIER:exon1/9:c.-202C>T:,DHCR7:NM_001360.2:5'UTR:MODIFIER:exon1/9:c.-225C>T:		rs4944946	0.3534	0.0000	0/0/0	0.5805							602858 [DHCR7 (confirmed) Smith-Lemli-Opitz syndrome,270400];	RCV000402332.1 [likely benign]; RCV000315551.1 [likely benign]; 			120	91					DHCR7 (inh=AR pLI=0.00)
chr11	71900964	71900964	G	A	wt	het	wt		QUAL=4091;DP=398,370,490;MQM=60	FOLR1	5'UTR,intron	FOLR1:NM_000802.3:5'UTR:MODIFIER:exon1/5:c.-20G>A:,FOLR1:NM_016724.2:intron:MODIFIER:exon1/5:c.-75+161G>A:,FOLR1:NM_016725.2:intron:MODIFIER:exon1/4:c.-9+161G>A:	MIR3	rs2071010	0.0984	0.0000	0/0/0	0.0850							136430 [FOLR1 (confirmed) Neurodegeneration due to cerebral folate transport deficiency,613068];	RCV000144917.1 [uncertain significance]; 			0	18					FOLR1 (inh=AR pLI=0.01)
chr11	74165954	74165954	G	C	het	het	wt		QUAL=10086;DP=410,407,503;MQM=60	KCNE3	3'UTR	KCNE3:NM_005472.4:3'UTR:MODIFIER:exon3/3:c.*2343C>G:		rs34315739	0.1677	0.0000	0/0/0	0.0223							604433 [KCNE3 (provisional) Brugada syndrome 6,613119];	RCV000270258.1 [likely benign]; 			3	55					KCNE3 (inh=AD pLI=0.44)
chr11	74166278	74166278	G	A	hom	hom	hom		QUAL=19111;DP=321,113,145;MQM=60	KCNE3	3'UTR	KCNE3:NM_005472.4:3'UTR:MODIFIER:exon3/3:c.*2019C>T:		rs9516	0.5960	0.0000	0/0/0	0.0960							604433 [KCNE3 (provisional) Brugada syndrome 6,613119];	RCV000374272.1 [likely benign]; 			60	126					KCNE3 (inh=AD pLI=0.44)
chr11	74166320	74166320	T	G	hom	hom	hom		QUAL=20899;DP=285,153,201;MQM=59	KCNE3	3'UTR	KCNE3:NM_005472.4:3'UTR:MODIFIER:exon3/3:c.*1977A>C:		rs7789	0.4247	0.0000	0/0/0	0.0787							604433 [KCNE3 (provisional) Brugada syndrome 6,613119];	RCV000282115.1 [likely benign]; 			45	116					KCNE3 (inh=AD pLI=0.44)
chr11	74166781	74166781	-	T	het	het	wt		QUAL=2040;DP=193,94,140;MQM=56	KCNE3	3'UTR	KCNE3:NM_005472.4:3'UTR:MODIFIER:exon3/3:c.*1515dupA:	AluSx1	rs141878274	0.2863	0.0000	0/0/0	0.1167							604433 [KCNE3 (provisional) Brugada syndrome 6,613119];	RCV000294920.1 [likely benign]; RCV000395884.1 [likely benign]; 			2	47					KCNE3 (inh=AD pLI=0.44)
chr11	74166859	74166859	A	G	hom	hom	hom		QUAL=11391;DP=167,86,126;MQM=51	KCNE3	3'UTR	KCNE3:NM_005472.4:3'UTR:MODIFIER:exon3/3:c.*1438T>C:	AluSx1	rs35833816	0.5956	0.0000	0/0/0	0.4085							604433 [KCNE3 (provisional) Brugada syndrome 6,613119];	RCV000346048.1 [likely benign]; 			34	82					KCNE3 (inh=AD pLI=0.44)
chr11	74166866	74166866	G	A	hom	hom	hom		QUAL=11466;DP=162,87,124;MQM=52	KCNE3	3'UTR	KCNE3:NM_005472.4:3'UTR:MODIFIER:exon3/3:c.*1431C>T:	AluSx1	rs28705219	0.5671	0.0000	0/0/0	0.4238							604433 [KCNE3 (provisional) Brugada syndrome 6,613119];	RCV000389926.1 [likely benign]; 			34	79					KCNE3 (inh=AD pLI=0.44)
chr11	74167201	74167206	ATATAT	-	hom	wt	wt	low_DP	QUAL=173;DP=6,29,32;MQM=60	KCNE3	3'UTR	KCNE3:NM_005472.4:3'UTR:MODIFIER:exon3/3:c.*1091_*1096delATATAT:	AluSx1:(AT)n	rs113583236;rs56871652;rs773139324	0.0000	0.0000	0/0/0	0.2817							604433 [KCNE3 (provisional) Brugada syndrome 6,613119];	RCV000386156.1 [uncertain significance]; 			16	1					KCNE3 (inh=AD pLI=0.44)
chr11	74167387	74167388	AG	-	wt	wt	het		QUAL=5424;DP=175,99,155;MQM=59	KCNE3	3'UTR	KCNE3:NM_005472.4:3'UTR:MODIFIER:exon3/3:c.*909_*910delCT:	AluSx1	rs796367392	0.2410	0.0000	0/0/0	0.1712							604433 [KCNE3 (provisional) Brugada syndrome 6,613119];	RCV000304883.1 [likely benign]; 			0	22					KCNE3 (inh=AD pLI=0.44)
chr11	74167388	74167388	G	A	het	het	het		QUAL=5424;DP=175,99,155;MQM=55	KCNE3	3'UTR	KCNE3:NM_005472.4:3'UTR:MODIFIER:exon3/3:c.*909C>T:	AluSx1	rs41258394	0.0000	0.0000	0/0/0	0.0073							604433 [KCNE3 (provisional) Brugada syndrome 6,613119];	RCV000336440.1 [uncertain significance]; 			0	49					KCNE3 (inh=AD pLI=0.44)
chr11	74167409	74167409	T	C	hom	hom	hom		QUAL=15881;DP=193,129,213;MQM=59	KCNE3	3'UTR	KCNE3:NM_005472.4:3'UTR:MODIFIER:exon3/3:c.*888A>G:		rs12272502	0.5667	0.0000	0/0/0	0.3470							604433 [KCNE3 (provisional) Brugada syndrome 6,613119];	RCV000399322.1 [likely benign]; 			41	77					KCNE3 (inh=AD pLI=0.44)
chr11	74167630	74167630	A	G	hom	hom	hom		QUAL=22404;DP=239,193,246;MQM=60	KCNE3	3'UTR	KCNE3:NM_005472.4:3'UTR:MODIFIER:exon3/3:c.*667T>C:	Arthur1B	rs12271177	0.5733	0.0000	0/0/0	0.0849							604433 [KCNE3 (provisional) Brugada syndrome 6,613119];	RCV000311159.1 [likely benign]; 			52	114					KCNE3 (inh=AD pLI=0.44)
chr11	74168411	74168411	A	G	het	het	wt		QUAL=4218;DP=162,166,267;MQM=60	KCNE3	synonymous	KCNE3:NM_005472.4:synonymous:LOW:exon3/3:c.198T>C:p.Phe66Phe		rs2270676	0.1412	0.1336	1245/458/90	0.1289							604433 [KCNE3 (provisional) Brugada syndrome 6,613119];	RCV000245979.1 [benign]; RCV000250331.1 [benign]; RCV000399032.1 [likely benign]; 	CM057459 [CLASS=DP MUT=ALT PHEN="Meniere's disease association with" GENE=KCNE3]; 		21	312					KCNE3 (inh=AD pLI=0.44)
chr11	74178491	74178491	C	T	wt	wt	het		QUAL=1051;DP=49,65,83;MQM=60	KCNE3	5'UTR	KCNE3:NM_005472.4:5'UTR:MODIFIER:exon1/3:c.-238G>A:		rs118022255	0.0308	0.0000	0/0/0	0.0105							604433 [KCNE3 (provisional) Brugada syndrome 6,613119];	RCV000348771.1 [likely benign]; 			0	32					KCNE3 (inh=AD pLI=0.44)
chr11	76853783	76853783	T	C	het	wt	hom	pred_pathogenic	QUAL=9836;DP=139,136,263;MQM=59	MYO7A	missense	MYO7A:NM_000260.3:missense:MODERATE:exon3/49:c.47T>C:p.Leu16Ser,MYO7A:NM_001127179.2:missense:MODERATE:exon3/27:c.47T>C:p.Leu16Ser,MYO7A:NM_001127180.1:missense:MODERATE:exon3/49:c.47T>C:p.Leu16Ser		rs1052030	0.5136	0.4348	9797/3817/2689	0.3901	4.4690	T,T,T,T,T,T,T,T	T	B,B,B	D,D,D,D	8.79	276903 [MYO7A (confirmed) Usher syndrome,type 1B,276900|Deafness,autosomal recessive 2,600060|Deafness,autosomal dominant 11,601317];	RCV000036163.4 [benign]; RCV000132571.1 [likely benign]; RCV000261128.1 [benign]; RCV000318604.1 [benign]; RCV000353260.1 [benign]; 		COSM4146342	243	709					MYO7A (inh=AR+AD pLI=0.00)
chr11	76868392	76868392	A	G	het	wt	het	pred_pathogenic;anno_pathogenic_hgmd	QUAL=8814;DP=272,284,367;MQM=60	MYO7A	missense	MYO7A:NM_000260.3:missense:MODERATE:exon8/49:c.803A>G:p.Lys268Arg,MYO7A:NM_001127179.2:missense:MODERATE:exon8/27:c.803A>G:p.Lys268Arg,MYO7A:NM_001127180.1:missense:MODERATE:exon8/49:c.803A>G:p.Lys268Arg		rs184866544	0.0006	0.0011	0/0/0	0.0010	0.6210	T,T,T,T,T,T,T,T	D	B,B,B	D,D,D,D	15.69	276903 [MYO7A (confirmed) Usher syndrome,type 1B,276900|Deafness,autosomal recessive 2,600060|Deafness,autosomal dominant 11,601317];	RCV000155225.3 [other]; 	CM112920 [CLASS=DM? MUT=ALT PHEN="Usher syndrome 2" GENE=MYO7A]; 		0	3					MYO7A (inh=AR+AD pLI=0.00)
chr11	76895855	76895855	C	G	het	het	wt	pred_pathogenic	QUAL=10477;DP=348,472,558;MQM=60	MYO7A	3'UTR,intron	MYO7A:NM_001127179.2:3'UTR:MODIFIER:exon27/27:c.*61C>G:,MYO7A:NM_000260.3:intron:MODIFIER:exon27/48:c.3503+95C>G:,MYO7A:NM_001127180.1:intron:MODIFIER:exon27/48:c.3503+95C>G:	MIRb	rs576982361	0.0010	0.0027	0/0/0	0.0012	-0.0160	D	T			3.41	276903 [MYO7A (confirmed) Usher syndrome,type 1B,276900|Deafness,autosomal recessive 2,600060|Deafness,autosomal dominant 11,601317];				0	7					MYO7A (inh=AR+AD pLI=0.00)
chr11	76910766	76910766	C	T	wt	het	wt		QUAL=5976;DP=392,533,712;MQM=60	MYO7A	synonymous	MYO7A:NM_000260.3:synonymous:LOW:exon35/49:c.4755C>T:p.Ser1585Ser,MYO7A:NM_001127180.1:synonymous:LOW:exon35/49:c.4641C>T:p.Ser1547Ser		rs7927472	0.4325	0.5083	15707/9342/516	0.4968							276903 [MYO7A (confirmed) Usher syndrome,type 1B,276900|Deafness,autosomal recessive 2,600060|Deafness,autosomal dominant 11,601317];	RCV000036162.4 [benign]; RCV000296516.1 [benign]; RCV000351371.1 [benign]; RCV000403200.1 [benign]; 		COSM3752746	427	734					MYO7A (inh=AR+AD pLI=0.00)
chr11	76912636	76912636	A	T	wt	het	wt	pred_pathogenic	QUAL=2578;DP=226,238,326;MQM=60	MYO7A	missense	MYO7A:NM_000260.3:missense:MODERATE:exon36/49:c.4996A>T:p.Ser1666Cys,MYO7A:NM_001127180.1:missense:MODERATE:exon36/49:c.4882A>T:p.Ser1628Cys		rs2276288	0.5517	0.5440	18473/9951/2308	0.5367	2.9200	T,T,T,T,T,T,T,T,T	T	B,B	T,T,T,T	0.76	276903 [MYO7A (confirmed) Usher syndrome,type 1B,276900|Deafness,autosomal recessive 2,600060|Deafness,autosomal dominant 11,601317];	RCV000036174.4 [benign]; RCV000294774.1 [benign]; RCV000335830.1 [benign]; RCV000389186.1 [benign]; 	CM097878 [CLASS=DP MUT=ALT PHEN="Malignant melanoma association with" GENE=MYO7A]; 	COSM3752747	461	742					MYO7A (inh=AR+AD pLI=0.00)
chr11	76917220	76917220	A	G	wt	het	wt		QUAL=5135;DP=204,415,510;MQM=60	MYO7A	synonymous	MYO7A:NM_000260.3:synonymous:LOW:exon41/49:c.5715A>G:p.Lys1905Lys,MYO7A:NM_001127180.1:synonymous:LOW:exon41/49:c.5601A>G:p.Lys1867Lys		rs2276293	0.5549	0.5232	15809/7508/2363	0.5010							276903 [MYO7A (confirmed) Usher syndrome,type 1B,276900|Deafness,autosomal recessive 2,600060|Deafness,autosomal dominant 11,601317];	RCV000036201.3 [benign]; RCV000266939.1 [benign]; RCV000326880.1 [benign]; RCV000361573.1 [benign]; 		COSM3752748	403	728					MYO7A (inh=AR+AD pLI=0.00)
chr11	76919468	76919468	A	T	wt	het	wt		QUAL=2677;DP=292,251,348;MQM=60	MYO7A	splice_region&intron	MYO7A:NM_000260.3:splice_region&intron:LOW:exon42/48:c.5857-7A>T:,MYO7A:NM_001127180.1:splice_region&intron:LOW:exon42/48:c.5743-7A>T:		rs1320703	0.5130	0.5675	17512/10002/1234	0.5393							276903 [MYO7A (confirmed) Usher syndrome,type 1B,276900|Deafness,autosomal recessive 2,600060|Deafness,autosomal dominant 11,601317];	RCV000036208.4 [benign]; RCV000306203.1 [benign]; RCV000344672.1 [benign]; RCV000404086.1 [benign]; 		COSM3739294	542	740					MYO7A (inh=AR+AD pLI=0.00)
chr11	76919484	76919484	G	A	wt	het	wt	pred_pathogenic	QUAL=3182;DP=328,283,388;MQM=60	MYO7A	missense	MYO7A:NM_000260.3:missense:MODERATE:exon43/49:c.5866G>A:p.Val1956Ile,MYO7A:NM_001127180.1:missense:MODERATE:exon43/49:c.5752G>A:p.Val1918Ile		rs142293185	0.0016	0.0045	5/4/0	0.0042	5.2390	T,T,T,T,T,T,T,T,T	T	B,P	T,T,T,T	23.90	276903 [MYO7A (confirmed) Usher syndrome,type 1B,276900|Deafness,autosomal recessive 2,600060|Deafness,autosomal dominant 11,601317];	RCV000036210.3 [benign]; RCV000277461.1 [likely benign]; RCV000312785.1 [likely benign]; RCV000369786.1 [likely benign]; 			0	14					MYO7A (inh=AR+AD pLI=0.00)
chr11	76926245	76926245	C	T	het	het	het		QUAL=6869;DP=268,134,174;MQM=60	MYO7A	3'UTR	MYO7A:NM_000260.3:3'UTR:MODIFIER:exon49/49:c.*504C>T:,MYO7A:NM_001127180.1:3'UTR:MODIFIER:exon49/49:c.*504C>T:		rs34765389	0.0339	0.0000	0/0/0	0.0131							276903 [MYO7A (confirmed) Usher syndrome,type 1B,276900|Deafness,autosomal recessive 2,600060|Deafness,autosomal dominant 11,601317];	RCV000282133.1 [likely benign]; RCV000320801.1 [likely benign]; RCV000374295.1 [likely benign]; 			0	38					MYO7A (inh=AR+AD pLI=0.00)
chr11	77811990	77811990	T	C	hom	hom	hom		QUAL=14759;DP=121,154,187;MQM=59	ALG8	splice_region,3'UTR	ALG8:NM_024079.4:splice_region:LOW:exon13/13:c.*20A>G:,ALG8:NM_001007027.2:splice_region:LOW:exon14/14:c.*272A>G:,ALG8:NM_024079.4:3'UTR:MODIFIER:exon13/13:c.*20A>G:,ALG8:NM_001007027.2:3'UTR:MODIFIER:exon14/14:c.*272A>G:		rs1263505	0.8327	0.8319	42282/24157/4541	0.8202							608103 [ALG8 (provisional) Congenital disorder of glycosylation,type Ih,608104];	RCV000082154.5 [benign]; RCV000377689.1 [benign]; 			707	229					ALG8 (inh=n/a pLI=0.00)
chr11	77825320	77825320	T	C	hom	hom	het	pred_pathogenic	QUAL=19441;DP=248,223,351;MQM=60	ALG8	missense	ALG8:NM_024079.4:missense:MODERATE:exon6/13:c.665A>G:p.Asn222Ser,ALG8:NM_001007027.2:missense:MODERATE:exon6/14:c.665A>G:p.Asn222Ser		rs665278	0.1464	0.1991	2626/1804/18	0.1968	0.5410	.,.,T,T,T,T,T,T,T	T,T	.,B,B,B	.,D,D,D,D,D,D,D	0.99	608103 [ALG8 (provisional) Congenital disorder of glycosylation,type Ih,608104];	RCV000082158.5 [other]; RCV000312261.1 [likely benign]; 		COSM3752755	104	524					ALG8 (inh=n/a pLI=0.00)
chr11	77838439	77838439	T	G	wt	het	wt	pred_pathogenic;anno_pathogenic_hgmd	QUAL=1590;DP=306,126,187;MQM=60	ALG8	missense	ALG8:NM_024079.4:missense:MODERATE:exon2/13:c.139A>C:p.Thr47Pro,ALG8:NM_001007027.2:missense:MODERATE:exon2/14:c.139A>C:p.Thr47Pro		rs121908293	0.0000	0.0001	0/0/0	0.0001	7.3510	D,D,D,D,D	D	D,D	D,D,D,D,D	28.40	608103 [ALG8 (provisional) Congenital disorder of glycosylation,type Ih,608104];		CM041671 [CLASS=DM MUT=ALT PHEN="Congenital disorder of glycosylation 1h" GENE=ALG8]; 		0	1					ALG8 (inh=n/a pLI=0.00)
chr11	87013438	87013438	G	A	hom	hom	hom	pred_pathogenic	QUAL=19888;DP=225,146,233;MQM=60	TMEM135	missense,non_coding_transcript_exon	TMEM135:NM_022918.3:missense:MODERATE:exon8/15:c.652G>A:p.Gly218Arg,TMEM135:NM_001168724.1:missense:MODERATE:exon7/14:c.586G>A:p.Gly196Arg,TMEM135:NR_033149.1:non_coding_transcript_exon:MODIFIER:exon7/14:n.820G>A:		rs2276102	0.5829	0.6239	24141/14924/1951	0.6211	2.4950	T,T,T,T,T	T	B,B	T,T,T,T	11.02					707	697					TMEM135 (inh=n/a pLI=0.88)
chr11	87036784	87036784	T	C	hom	hom	hom		QUAL=23599;DP=350,167,202;MQM=60	TMEM135	3'UTR,non_coding_transcript_exon	TMEM135:NM_022918.3:3'UTR:MODIFIER:exon15/15:c.*4409T>C:,TMEM135:NM_001168724.1:3'UTR:MODIFIER:exon14/14:c.*4409T>C:,TMEM135:NR_033149.1:non_coding_transcript_exon:MODIFIER:exon14/14:n.5954T>C:		rs10898669	0.2306	0.3313	627/245/3	0.0759											71	279					TMEM135 (inh=n/a pLI=0.88)
chr11	87037129	87037129	-	T	wt	het	wt		QUAL=6485;DP=262,117,179;MQM=59	TMEM135	3'UTR,non_coding_transcript_exon	TMEM135:NM_022918.3:3'UTR:MODIFIER:exon15/15:c.*4768dupT:,TMEM135:NM_001168724.1:3'UTR:MODIFIER:exon14/14:c.*4768dupT:,TMEM135:NR_033149.1:non_coding_transcript_exon:MODIFIER:exon14/14:n.6313dupT:		rs199909607;rs762006965	0.0000	0.4884	0/0/0	0.0004											0	36					TMEM135 (inh=n/a pLI=0.88)
chr11	87037139	87037139	T	A	het	wt	het		QUAL=6485;DP=262,117,179;MQM=60	TMEM135	3'UTR,non_coding_transcript_exon	TMEM135:NM_022918.3:3'UTR:MODIFIER:exon15/15:c.*4764T>A:,TMEM135:NM_001168724.1:3'UTR:MODIFIER:exon14/14:c.*4764T>A:,TMEM135:NR_033149.1:non_coding_transcript_exon:MODIFIER:exon14/14:n.6309T>A:		rs551809652	0.0006	0.0000	0/0/0	0.0001											0	2					TMEM135 (inh=n/a pLI=0.88)
chr11	87037202	87037202	T	C	hom	hom	hom		QUAL=24302;DP=301,181,289;MQM=59	TMEM135	3'UTR,non_coding_transcript_exon	TMEM135:NM_022918.3:3'UTR:MODIFIER:exon15/15:c.*4827T>C:,TMEM135:NM_001168724.1:3'UTR:MODIFIER:exon14/14:c.*4827T>C:,TMEM135:NR_033149.1:non_coding_transcript_exon:MODIFIER:exon14/14:n.6372T>C:		rs12276145	0.2151	0.3310	626/249/3	0.0759											71	278					TMEM135 (inh=n/a pLI=0.88)
chr11	87037565	87037565	T	C	hom	hom	hom		QUAL=35015;DP=482,228,348;MQM=60	TMEM135	3'UTR,non_coding_transcript_exon	TMEM135:NM_022918.3:3'UTR:MODIFIER:exon15/15:c.*5190T>C:,TMEM135:NM_001168724.1:3'UTR:MODIFIER:exon14/14:c.*5190T>C:,TMEM135:NR_033149.1:non_coding_transcript_exon:MODIFIER:exon14/14:n.6735T>C:		rs7926724	0.4461	0.5730	1775/570/19	0.1351											215	278					TMEM135 (inh=n/a pLI=0.88)
chr11	87037680	87037680	A	G	hom	hom	hom		QUAL=14545;DP=216,113,167;MQM=59	TMEM135	3'UTR,non_coding_transcript_exon	TMEM135:NM_022918.3:3'UTR:MODIFIER:exon15/15:c.*5305A>G:,TMEM135:NM_001168724.1:3'UTR:MODIFIER:exon14/14:c.*5305A>G:,TMEM135:NR_033149.1:non_coding_transcript_exon:MODIFIER:exon14/14:n.6850A>G:	(TCCTT)n	rs12282551	0.3502	0.4716	1222/401/16	0.1057											150	289					TMEM135 (inh=n/a pLI=0.88)
chr11	87037743	87037743	G	A	hom	hom	hom		QUAL=13879;DP=193,105,123;MQM=59	TMEM135	3'UTR,non_coding_transcript_exon	TMEM135:NM_022918.3:3'UTR:MODIFIER:exon15/15:c.*5368G>A:,TMEM135:NM_001168724.1:3'UTR:MODIFIER:exon14/14:c.*5368G>A:,TMEM135:NR_033149.1:non_coding_transcript_exon:MODIFIER:exon14/14:n.6913G>A:		rs10898670	0.3385	0.4709	1220/402/13	0.1078											151	288					TMEM135 (inh=n/a pLI=0.88)
chr11	87037954	87037956	TTT	-	wt	wt	hom		QUAL=2248;DP=88,43,42;MQM=59	TMEM135	3'UTR,non_coding_transcript_exon	TMEM135:NM_022918.3:3'UTR:MODIFIER:exon15/15:c.*5595_*5597delTTT:,TMEM135:NM_001168724.1:3'UTR:MODIFIER:exon14/14:c.*5595_*5597delTTT:,TMEM135:NR_033149.1:non_coding_transcript_exon:MODIFIER:exon14/14:n.7140_7142delTTT:	(T)n	rs751903466	0.0000	0.1249	0/0/0	0.0177											2	40					TMEM135 (inh=n/a pLI=0.88)
chr11	87037954	87037955	TT	-	hom	hom	wt		QUAL=2248;DP=88,43,42;MQM=59	TMEM135	3'UTR,non_coding_transcript_exon	TMEM135:NM_022918.3:3'UTR:MODIFIER:exon15/15:c.*5596_*5597delTT:,TMEM135:NM_001168724.1:3'UTR:MODIFIER:exon14/14:c.*5596_*5597delTT:,TMEM135:NR_033149.1:non_coding_transcript_exon:MODIFIER:exon14/14:n.7141_7142delTT:	(T)n	rs756445728	0.0000	0.2815	5/1/0	0.0621											17	135					TMEM135 (inh=n/a pLI=0.88)
chr11	87039402	87039402	G	A	hom	hom	hom		QUAL=19340;DP=277,136,188;MQM=59	TMEM135	3'UTR,non_coding_transcript_exon	TMEM135:NM_022918.3:3'UTR:MODIFIER:exon15/15:c.*7027G>A:,TMEM135:NM_001168724.1:3'UTR:MODIFIER:exon14/14:c.*7027G>A:,TMEM135:NR_033149.1:non_coding_transcript_exon:MODIFIER:exon14/14:n.8572G>A:		rs4480563	0.3411	0.4620	1171/399/12	0.1068											150	289					TMEM135 (inh=n/a pLI=0.88)
chr11	87039467	87039467	T	G	hom	hom	hom		QUAL=20642;DP=299,143,175;MQM=58	TMEM135	3'UTR,non_coding_transcript_exon	TMEM135:NM_022918.3:3'UTR:MODIFIER:exon15/15:c.*7092T>G:,TMEM135:NM_001168724.1:3'UTR:MODIFIER:exon14/14:c.*7092T>G:,TMEM135:NR_033149.1:non_coding_transcript_exon:MODIFIER:exon14/14:n.8637T>G:	L1PB3	rs4644661	0.3413	0.4601	1163/397/12	0.1071											150	289					TMEM135 (inh=n/a pLI=0.88)
chr11	87039532	87039532	C	T	hom	hom	hom		QUAL=21042;DP=295,148,196;MQM=60	TMEM135	3'UTR,non_coding_transcript_exon	TMEM135:NM_022918.3:3'UTR:MODIFIER:exon15/15:c.*7157C>T:,TMEM135:NM_001168724.1:3'UTR:MODIFIER:exon14/14:c.*7157C>T:,TMEM135:NR_033149.1:non_coding_transcript_exon:MODIFIER:exon14/14:n.8702C>T:	L1PB3	rs4318005	0.3411	0.4612	1168/397/12	0.1069											150	289					TMEM135 (inh=n/a pLI=0.88)
chr11	88045583	88045583	A	G	het	hom	het	anno_pathogenic_hgmd	QUAL=12386;DP=249,212,255;MQM=60	CTSC	missense	CTSC:NM_001814.5:missense:MODERATE:exon3/7:c.458T>C:p.Ile153Thr		rs217086	0.9309	0.8861	47848/23928/4334	0.8631	-0.6170	T,T,.	T,.	B,.	T,.	0.01	602365 [CTSC (confirmed) Papillon-Lefevre syndrome,245000|Haim-Munk syndrome,245010|Periodontitis 1,juvenile,170650];		CM002936 [CLASS=DM? MUT=REF PHEN="Papillon-Lefevre syndrome" GENE=CTSC]; 	COSM3752799	1156	375	2	[2] old entry - no details available			CTSC (inh=AR pLI=0.00)
chr11	88053979	88053979	T	C	het	hom	het		QUAL=5870;DP=130,77,106;MQM=60	CTSC	splice_region,3'UTR,intron	CTSC:NM_001114173.2:splice_region:LOW:exon4/4:c.*5566A>G:,CTSC:NM_148170.4:splice_region:LOW:exon4/4:c.*5622A>G:,CTSC:NM_001114173.2:3'UTR:MODIFIER:exon4/4:c.*5566A>G:,CTSC:NM_148170.4:3'UTR:MODIFIER:exon4/4:c.*5622A>G:,CTSC:NM_001814.5:intron:MODIFIER:exon2/6:c.319-8257A>G:		rs217053	0.8239	0.0000	0/0/0	0.1411							602365 [CTSC (confirmed) Papillon-Lefevre syndrome,245000|Haim-Munk syndrome,245010|Periodontitis 1,juvenile,170650];				106	54					CTSC (inh=AR pLI=0.00)
chr11	88054346	88054346	G	C	het	hom	het	low_DP	QUAL=959;DP=59,7,9;MQM=60	CTSC	3'UTR,intron	CTSC:NM_001114173.2:3'UTR:MODIFIER:exon4/4:c.*5199C>G:,CTSC:NM_148170.4:3'UTR:MODIFIER:exon4/4:c.*5255C>G:,CTSC:NM_001814.5:intron:MODIFIER:exon2/6:c.319-8624C>G:	L1PA10	rs217054	0.8516	0.0000	0/0/0	0.7118							602365 [CTSC (confirmed) Papillon-Lefevre syndrome,245000|Haim-Munk syndrome,245010|Periodontitis 1,juvenile,170650];				97	55					CTSC (inh=AR pLI=0.00)
chr11	88054571	88054571	G	A	het	hom	het	low_DP	QUAL=819;DP=46,7,12;MQM=59	CTSC	3'UTR,intron	CTSC:NM_001114173.2:3'UTR:MODIFIER:exon4/4:c.*4974C>T:,CTSC:NM_148170.4:3'UTR:MODIFIER:exon4/4:c.*5030C>T:,CTSC:NM_001814.5:intron:MODIFIER:exon2/6:c.319-8849C>T:	L1PA10	rs10830669	0.1861	0.0000	0/0/0	0.0517							602365 [CTSC (confirmed) Papillon-Lefevre syndrome,245000|Haim-Munk syndrome,245010|Periodontitis 1,juvenile,170650];				36	70					CTSC (inh=AR pLI=0.00)
chr11	88055089	88055089	C	T	het	hom	het		QUAL=6241;DP=207,76,78;MQM=60	CTSC	3'UTR,intron	CTSC:NM_001114173.2:3'UTR:MODIFIER:exon4/4:c.*4456G>A:,CTSC:NM_148170.4:3'UTR:MODIFIER:exon4/4:c.*4512G>A:,CTSC:NM_001814.5:intron:MODIFIER:exon2/6:c.319-9367G>A:	L1PA10	rs217055	0.9311	0.0000	0/0/0	0.8034							602365 [CTSC (confirmed) Papillon-Lefevre syndrome,245000|Haim-Munk syndrome,245010|Periodontitis 1,juvenile,170650];				111	45					CTSC (inh=AR pLI=0.00)
chr11	88055170	88055170	G	A	het	hom	het		QUAL=4462;DP=110,68,55;MQM=60	CTSC	3'UTR,intron	CTSC:NM_001114173.2:3'UTR:MODIFIER:exon4/4:c.*4375C>T:,CTSC:NM_148170.4:3'UTR:MODIFIER:exon4/4:c.*4431C>T:,CTSC:NM_001814.5:intron:MODIFIER:exon2/6:c.319-9448C>T:	L1PA10	rs596261	0.3456	0.0000	0/0/0	0.0763							602365 [CTSC (confirmed) Papillon-Lefevre syndrome,245000|Haim-Munk syndrome,245010|Periodontitis 1,juvenile,170650];				48	77					CTSC (inh=AR pLI=0.00)
chr11	88055291	88055291	T	C	het	hom	het		QUAL=2904;DP=141,27,30;MQM=60	CTSC	3'UTR,intron	CTSC:NM_001114173.2:3'UTR:MODIFIER:exon4/4:c.*4254A>G:,CTSC:NM_148170.4:3'UTR:MODIFIER:exon4/4:c.*4310A>G:,CTSC:NM_001814.5:intron:MODIFIER:exon2/6:c.319-9569A>G:	L1PA10	rs12288615	0.2037	0.0000	0/0/0	0.3112							602365 [CTSC (confirmed) Papillon-Lefevre syndrome,245000|Haim-Munk syndrome,245010|Periodontitis 1,juvenile,170650];				35	73					CTSC (inh=AR pLI=0.00)
chr11	88055789	88055789	A	T	het	hom	het	low_DP	QUAL=1617;DP=70,12,14;MQM=54	CTSC	3'UTR,intron	CTSC:NM_001114173.2:3'UTR:MODIFIER:exon4/4:c.*3756T>A:,CTSC:NM_148170.4:3'UTR:MODIFIER:exon4/4:c.*3812T>A:,CTSC:NM_001814.5:intron:MODIFIER:exon2/6:c.319-10067T>A:	L1P3	rs452648	0.8650	0.0000	0/0/0	0.7296							602365 [CTSC (confirmed) Papillon-Lefevre syndrome,245000|Haim-Munk syndrome,245010|Periodontitis 1,juvenile,170650];				98	52					CTSC (inh=AR pLI=0.00)
chr11	88055794	88055794	A	G	het	hom	het	low_DP	QUAL=1714;DP=69,12,15;MQM=53	CTSC	3'UTR,intron	CTSC:NM_001114173.2:3'UTR:MODIFIER:exon4/4:c.*3751T>C:,CTSC:NM_148170.4:3'UTR:MODIFIER:exon4/4:c.*3807T>C:,CTSC:NM_001814.5:intron:MODIFIER:exon2/6:c.319-10072T>C:	L1P3	rs442528	0.8650	0.0000	0/0/0	0.7295							602365 [CTSC (confirmed) Papillon-Lefevre syndrome,245000|Haim-Munk syndrome,245010|Periodontitis 1,juvenile,170650];				98	51					CTSC (inh=AR pLI=0.00)
chr11	88056130	88056130	A	G	het	hom	het	low_DP	QUAL=1830;DP=71,17,27;MQM=58	CTSC	3'UTR,intron	CTSC:NM_001114173.2:3'UTR:MODIFIER:exon4/4:c.*3415T>C:,CTSC:NM_148170.4:3'UTR:MODIFIER:exon4/4:c.*3471T>C:,CTSC:NM_001814.5:intron:MODIFIER:exon2/6:c.319-10408T>C:	L1P3	rs217056	0.7899	0.0000	0/0/0	0.7428							602365 [CTSC (confirmed) Papillon-Lefevre syndrome,245000|Haim-Munk syndrome,245010|Periodontitis 1,juvenile,170650];				89	62					CTSC (inh=AR pLI=0.00)
chr11	88056396	88056396	T	G	het	hom	het	low_DP	QUAL=1376;DP=47,15,12;MQM=59	CTSC	3'UTR,intron	CTSC:NM_001114173.2:3'UTR:MODIFIER:exon4/4:c.*3149A>C:,CTSC:NM_148170.4:3'UTR:MODIFIER:exon4/4:c.*3205A>C:,CTSC:NM_001814.5:intron:MODIFIER:exon2/6:c.319-10674A>C:	L1P3	rs217057	0.7895	0.0000	0/0/0	0.7405							602365 [CTSC (confirmed) Papillon-Lefevre syndrome,245000|Haim-Munk syndrome,245010|Periodontitis 1,juvenile,170650];				91	60					CTSC (inh=AR pLI=0.00)
chr11	88056942	88056942	G	A	het	hom	het	low_DP	QUAL=312;DP=19,5,7;MQM=59	CTSC	3'UTR,intron	CTSC:NM_001114173.2:3'UTR:MODIFIER:exon4/4:c.*2603C>T:,CTSC:NM_148170.4:3'UTR:MODIFIER:exon4/4:c.*2659C>T:,CTSC:NM_001814.5:intron:MODIFIER:exon2/6:c.318+11163C>T:	L1P3	rs217058	0.9083	0.0000	0/0/0	0.7966							602365 [CTSC (confirmed) Papillon-Lefevre syndrome,245000|Haim-Munk syndrome,245010|Periodontitis 1,juvenile,170650];				98	20					CTSC (inh=AR pLI=0.00)
chr11	94151547	94151547	-	T	het	het	wt		QUAL=3341;DP=244,188,268;MQM=59	MRE11A	3'UTR	MRE11A:NM_005591.3:3'UTR:MODIFIER:exon20/20:c.*1743dupA:,MRE11A:NM_005590.3:3'UTR:MODIFIER:exon19/19:c.*1743dupA:		rs200848216	0.1270	0.0000	0/0/0	0.1080							600814 [MRE11A (provisional) Ataxia-telangiectasia-like disorder,604391];	RCV000282301.1 [likely benign]; 			1	80					MRE11 (inh=AR+AD pLI=0.00)
chr11	94152631	94152631	-	GAGA	wt	wt	hom	low_DP	QUAL=1523;DP=74,15,36;MQM=57	MRE11A	3'UTR	MRE11A:NM_005591.3:3'UTR:MODIFIER:exon20/20:c.*656_*659dupTCTC:,MRE11A:NM_005590.3:3'UTR:MODIFIER:exon19/19:c.*656_*659dupTCTC:	(GA)n	rs201800515;rs373002609	0.0000	0.0000	0/0/0	0.0009							600814 [MRE11A (provisional) Ataxia-telangiectasia-like disorder,604391];	RCV000332757.1 [uncertain significance]; RCV000389620.1 [uncertain significance]; RCV000288194.1 [uncertain significance]; RCV000261725.1 [uncertain significance]; RCV000319260.1 [uncertain significance]; RCV000385521.1 [uncertain significance]; RCV000293610.1 [uncertain significance]; 			2	32					MRE11 (inh=AR+AD pLI=0.00)
chr11	94152631	94152631	-	GGGAGAGAGAGAGA	hom	hom	wt	low_DP	QUAL=1523;DP=74,15,36;MQM=60	MRE11A	3'UTR	MRE11A:NM_005591.3:3'UTR:MODIFIER:exon20/20:c.*659_*660insTCTCTCTCTCTCCC:,MRE11A:NM_005590.3:3'UTR:MODIFIER:exon19/19:c.*659_*660insTCTCTCTCTCTCCC:	(GA)n		0.0000	0.0000	0/0/0	0.0006							600814 [MRE11A (provisional) Ataxia-telangiectasia-like disorder,604391];	RCV000332757.1 [uncertain significance]; RCV000389620.1 [uncertain significance]; RCV000288194.1 [uncertain significance]; RCV000261725.1 [uncertain significance]; RCV000319260.1 [uncertain significance]; RCV000385521.1 [uncertain significance]; RCV000293610.1 [uncertain significance]; 			1	2					MRE11 (inh=AR+AD pLI=0.00)
chr11	94204763	94204763	A	G	wt	wt	het		QUAL=2492;DP=168,146,189;MQM=60	MRE11A	synonymous	MRE11A:NM_005591.3:synonymous:LOW:exon8/20:c.822T>C:p.Leu274Leu,MRE11A:NM_005590.3:synonymous:LOW:exon8/19:c.822T>C:p.Leu274Leu		rs137868143	0.0004	0.0015	2/2/0	0.0014							600814 [MRE11A (provisional) Ataxia-telangiectasia-like disorder,604391];	RCV000160572.7 [other]; RCV000212561.2 [other]; RCV000396829.1 [other]; 			1	26					MRE11 (inh=AR+AD pLI=0.00)
chr11	94212048	94212048	C	T	het	wt	hom		QUAL=7179;DP=156,149,173;MQM=60	MRE11A	splice_region&intron	MRE11A:NM_005591.3:splice_region&intron:LOW:exon5/19:c.403-6G>A:,MRE11A:NM_005590.3:splice_region&intron:LOW:exon5/18:c.403-6G>A:		rs535801	0.3131	0.3252	6588/3086/210	0.3209							600814 [MRE11A (provisional) Ataxia-telangiectasia-like disorder,604391];	RCV000117634.3 [other]; RCV000277270.1 [benign]; 			497	1999	1	[1] Ilnaz Sepahi 29-03-2016 batch import			MRE11 (inh=AR+AD pLI=0.00)
chr11	95566048	95566048	G	A	het	het	wt		QUAL=2941;DP=146,72,136;MQM=60	MTMR2	3'UTR	MTMR2:NM_016156.5:3'UTR:MODIFIER:exon15/15:c.*2406C>T:,MTMR2:NM_001243571.1:3'UTR:MODIFIER:exon18/18:c.*2406C>T:,MTMR2:NM_201278.2:3'UTR:MODIFIER:exon17/17:c.*2406C>T:,MTMR2:NM_201281.2:3'UTR:MODIFIER:exon16/16:c.*2406C>T:		rs16922613	0.0298	0.0000	0/0/0	0.0232							603557 [MTMR2 (confirmed) Charcot-Marie-Tooth disease,type 4B1,601382];	RCV000260908.1 [likely benign]; 			0	11					MTMR2 (inh=AR pLI=0.21)
chr11	95566520	95566520	A	G	wt	het	wt		QUAL=2275;DP=296,189,236;MQM=60	MTMR2	3'UTR	MTMR2:NM_016156.5:3'UTR:MODIFIER:exon15/15:c.*1934T>C:,MTMR2:NM_001243571.1:3'UTR:MODIFIER:exon18/18:c.*1934T>C:,MTMR2:NM_201278.2:3'UTR:MODIFIER:exon17/17:c.*1934T>C:,MTMR2:NM_201281.2:3'UTR:MODIFIER:exon16/16:c.*1934T>C:		rs525404	0.2035	0.0000	0/0/0	0.0531							603557 [MTMR2 (confirmed) Charcot-Marie-Tooth disease,type 4B1,601382];	RCV000291350.1 [benign]; 			37	90					MTMR2 (inh=AR pLI=0.21)
chr11	95566886	95566886	G	A	wt	het	wt		QUAL=1316;DP=315,99,147;MQM=60	MTMR2	3'UTR	MTMR2:NM_016156.5:3'UTR:MODIFIER:exon15/15:c.*1568C>T:,MTMR2:NM_001243571.1:3'UTR:MODIFIER:exon18/18:c.*1568C>T:,MTMR2:NM_201278.2:3'UTR:MODIFIER:exon17/17:c.*1568C>T:,MTMR2:NM_201281.2:3'UTR:MODIFIER:exon16/16:c.*1568C>T:		rs596277	0.2025	0.0000	0/0/0	0.0531							603557 [MTMR2 (confirmed) Charcot-Marie-Tooth disease,type 4B1,601382];	RCV000398568.1 [benign]; 			38	89					MTMR2 (inh=AR pLI=0.21)
chr11	95567035	95567035	C	T	wt	het	wt		QUAL=1909;DP=372,145,209;MQM=60	MTMR2	3'UTR	MTMR2:NM_016156.5:3'UTR:MODIFIER:exon15/15:c.*1419G>A:,MTMR2:NM_001243571.1:3'UTR:MODIFIER:exon18/18:c.*1419G>A:,MTMR2:NM_201278.2:3'UTR:MODIFIER:exon17/17:c.*1419G>A:,MTMR2:NM_201281.2:3'UTR:MODIFIER:exon16/16:c.*1419G>A:	X4b_DNA	rs496305	0.2035	0.0000	0/0/0	0.0531							603557 [MTMR2 (confirmed) Charcot-Marie-Tooth disease,type 4B1,601382];	RCV000262209.1 [benign]; 			38	89					MTMR2 (inh=AR pLI=0.21)
chr11	95567905	95567905	C	T	wt	het	wt		QUAL=2043;DP=276,142,212;MQM=60	MTMR2	3'UTR	MTMR2:NM_016156.5:3'UTR:MODIFIER:exon15/15:c.*549G>A:,MTMR2:NM_001243571.1:3'UTR:MODIFIER:exon18/18:c.*549G>A:,MTMR2:NM_201278.2:3'UTR:MODIFIER:exon17/17:c.*549G>A:,MTMR2:NM_201281.2:3'UTR:MODIFIER:exon16/16:c.*549G>A:		rs611020	0.2021	0.0000	0/0/0	0.0530							603557 [MTMR2 (confirmed) Charcot-Marie-Tooth disease,type 4B1,601382];	RCV000349494.1 [benign]; 			38	89					MTMR2 (inh=AR pLI=0.21)
chr11	95580926	95580926	G	A	wt	het	wt		QUAL=2158;DP=351,215,329;MQM=60	MTMR2	synonymous	MTMR2:NM_016156.5:synonymous:LOW:exon10/15:c.1131C>T:p.Thr377Thr,MTMR2:NM_001243571.1:synonymous:LOW:exon13/18:c.915C>T:p.Thr305Thr,MTMR2:NM_201278.2:synonymous:LOW:exon12/17:c.915C>T:p.Thr305Thr,MTMR2:NM_201281.2:synonymous:LOW:exon11/16:c.915C>T:p.Thr305Thr		rs566204	0.2093	0.2980	6108/4932/98	0.3017							603557 [MTMR2 (confirmed) Charcot-Marie-Tooth disease,type 4B1,601382];	RCV000250417.1 [benign]; RCV000374263.1 [benign]; 		COSM3752824, COSM3752825	185	667					MTMR2 (inh=AR pLI=0.21)
chr11	102980324	102980324	C	T	hom	het	het		QUAL=12477;DP=207,234,352;MQM=59	DYNC2H1	synonymous	DYNC2H1:NM_001080463.1:synonymous:LOW:exon1/90:c.21C>T:p.Asp7Asp,DYNC2H1:NM_001377.2:synonymous:LOW:exon1/89:c.21C>T:p.Asp7Asp		rs17301028	0.0411	0.0761	407/302/3	0.0719							603297 [DYNC2H1 (provisional) Short-rib thoracic dysplasia 3 with or without polydactyly,613091];	RCV000319173.1 [likely benign]; RCV000373826.1 [likely benign]; 			19	269					DYNC2H1 (inh=n/a pLI=0.00)
chr11	103006557	103006557	G	A	wt	het	wt		QUAL=2671;DP=398,221,276;MQM=60	DYNC2H1	synonymous	DYNC2H1:NM_001080463.1:synonymous:LOW:exon17/90:c.2454G>A:p.Glu818Glu,DYNC2H1:NM_001377.2:synonymous:LOW:exon17/89:c.2454G>A:p.Glu818Glu		rs77738279	0.0415	0.0431	125/54/0	0.0424							603297 [DYNC2H1 (provisional) Short-rib thoracic dysplasia 3 with or without polydactyly,613091];	RCV000294863.1 [likely benign]; RCV000373006.1 [likely benign]; 			4	150					DYNC2H1 (inh=n/a pLI=0.00)
chr11	103029516	103029516	A	G	hom	hom	hom	pred_pathogenic	QUAL=9808;DP=171,48,73;MQM=60	DYNC2H1	missense	DYNC2H1:NM_001080463.1:missense:MODERATE:exon27/90:c.4238A>G:p.Lys1413Arg,DYNC2H1:NM_001377.2:missense:MODERATE:exon27/89:c.4238A>G:p.Lys1413Arg		rs688906	0.6683	0.7126	5704/2722/293	0.4542	4.1300	T,T	T	B,B	T,T	20.30	603297 [DYNC2H1 (provisional) Short-rib thoracic dysplasia 3 with or without polydactyly,613091];	RCV000176721.1 [benign]; RCV000281569.1 [benign]; RCV000334296.1 [benign]; 			865	580					DYNC2H1 (inh=n/a pLI=0.00)
chr11	103047007	103047007	C	A	hom	hom	hom		QUAL=12900;DP=192,76,127;MQM=60	DYNC2H1	synonymous	DYNC2H1:NM_001080463.1:synonymous:LOW:exon37/90:c.5718C>A:p.Thr1906Thr,DYNC2H1:NM_001377.2:synonymous:LOW:exon37/89:c.5718C>A:p.Thr1906Thr		rs585692	0.9313	0.9178	10622/4998/1304	0.7405							603297 [DYNC2H1 (provisional) Short-rib thoracic dysplasia 3 with or without polydactyly,613091];	RCV000153168.3 [benign]; RCV000275629.1 [benign]; RCV000330716.1 [benign]; 			1296	250	2	[2] Stephan Waldm?ller 19.10.2015			DYNC2H1 (inh=n/a pLI=0.00)
chr11	103057048	103057048	A	G	hom	hom	hom		QUAL=20027;DP=226,183,223;MQM=60	DYNC2H1	synonymous	DYNC2H1:NM_001080463.1:synonymous:LOW:exon42/90:c.6711A>G:p.Arg2237Arg,DYNC2H1:NM_001377.2:synonymous:LOW:exon42/89:c.6711A>G:p.Arg2237Arg		rs658804	0.5715	0.6204	23424/13354/1323	0.6067							603297 [DYNC2H1 (provisional) Short-rib thoracic dysplasia 3 with or without polydactyly,613091];	RCV000273552.1 [benign]; RCV000368121.1 [benign]; 			651	702					DYNC2H1 (inh=n/a pLI=0.00)
chr11	103058126	103058126	C	T	hom	hom	hom		QUAL=14047;DP=198,103,138;MQM=60	DYNC2H1	synonymous	DYNC2H1:NM_001080463.1:synonymous:LOW:exon43/90:c.6951C>T:p.His2317His,DYNC2H1:NM_001377.2:synonymous:LOW:exon43/89:c.6951C>T:p.His2317His		rs586592	0.6170	0.6330	24445/13441/2150	0.6203							603297 [DYNC2H1 (provisional) Short-rib thoracic dysplasia 3 with or without polydactyly,613091];	RCV000079444.4 [benign]; RCV000290279.1 [benign]; RCV000384618.1 [benign]; 			659	702					DYNC2H1 (inh=n/a pLI=0.00)
chr11	103082590	103082590	G	A	hom	hom	hom	pred_pathogenic	QUAL=13998;DP=230,83,105;MQM=60	DYNC2H1	missense	DYNC2H1:NM_001080463.1:missense:MODERATE:exon54/90:c.8612G>A:p.Arg2871Gln,DYNC2H1:NM_001377.2:missense:MODERATE:exon54/89:c.8612G>A:p.Arg2871Gln		rs589623	0.7384	0.7873	8800/4453/565	0.6169	4.3360	T,T	T	B,B	T,T	23.30	603297 [DYNC2H1 (provisional) Short-rib thoracic dysplasia 3 with or without polydactyly,613091];	RCV000303608.1 [benign]; RCV000403673.1 [benign]; 		COSM147316	1018	484					DYNC2H1 (inh=n/a pLI=0.00)
chr11	103153788	103153788	C	A	het	het	wt		QUAL=5176;DP=322,93,163;MQM=60	DYNC2H1	synonymous	DYNC2H1:NM_001080463.1:synonymous:LOW:exon74/90:c.10885C>A:p.Arg3629Arg,DYNC2H1:NM_001377.2:synonymous:LOW:exon73/89:c.10864C>A:p.Arg3622Arg		rs117178504	0.0042	0.0074	3/3/0	0.0074							603297 [DYNC2H1 (provisional) Short-rib thoracic dysplasia 3 with or without polydactyly,613091];	RCV000205607.1 [benign]; 			0	22					DYNC2H1 (inh=n/a pLI=0.00)
chr11	103158278	103158278	C	T	het	wt	het	pred_pathogenic	QUAL=6218;DP=285,159,230;MQM=60	DYNC2H1	missense	DYNC2H1:NM_001080463.1:missense:MODERATE:exon76/90:c.11060C>T:p.Ala3687Val,DYNC2H1:NM_001377.2:missense:MODERATE:exon75/89:c.11039C>T:p.Ala3680Val		rs10895391	0.2863	0.3329	6544/3984/170	0.3221	6.1230	T,T	T	B,B	T,T	25.00	603297 [DYNC2H1 (provisional) Short-rib thoracic dysplasia 3 with or without polydactyly,613091];	RCV000294784.1 [benign]; RCV000333401.1 [benign]; 			179	697	2	[2] Stephan Waldm?ller 19.10.2015			DYNC2H1 (inh=n/a pLI=0.00)
chr11	103229027	103229027	T	C	het	hom	het		QUAL=10430;DP=253,141,168;MQM=60	DYNC2H1	synonymous	DYNC2H1:NM_001080463.1:synonymous:LOW:exon84/90:c.12117T>C:p.Asp4039Asp,DYNC2H1:NM_001377.2:synonymous:LOW:exon83/89:c.12096T>C:p.Asp4032Asp		rs2566913	0.4950	0.6589	16885/10514/341	0.5820							603297 [DYNC2H1 (provisional) Short-rib thoracic dysplasia 3 with or without polydactyly,613091];	RCV000279105.1 [benign]; RCV000336461.1 [benign]; 			645	716					DYNC2H1 (inh=n/a pLI=0.00)
chr11	103270607	103270607	G	A	het	wt	hom		QUAL=5738;DP=158,76,124;MQM=60	DYNC2H1	splice_region&intron	DYNC2H1:NM_001080463.1:splice_region&intron:LOW:exon85/89:c.12387+7G>A:,DYNC2H1:NM_001377.2:splice_region&intron:LOW:exon84/88:c.12366+7G>A:		rs10895417	0.5377	0.4912	14633/6500/1858	0.4807							603297 [DYNC2H1 (provisional) Short-rib thoracic dysplasia 3 with or without polydactyly,613091];	RCV000314601.1 [benign]; RCV000362268.1 [benign]; 			342	772	2	[2] Stephan Waldm?ller 19.10.2015			DYNC2H1 (inh=n/a pLI=0.00)
chr11	107992312	107992312	C	G	het	het	wt		QUAL=2502;DP=81,103,110;MQM=59	ACAT1	5'UTR	ACAT1:NM_000019.3:5'UTR:MODIFIER:exon1/12:c.-22C>G:		rs3741054	0.0954	0.1672	240/93/10	0.0749							607809 [ACAT1 (confirmed) Alpha-methylacetoacetic aciduria,203750];	RCV000337537.1 [likely benign]; RCV000391640.1 [uncertain significance]; 			19	239					ACAT1 (inh=AR pLI=0.00)
chr11	107992325	107992325	T	A	het	wt	hom		QUAL=4348;DP=136,95,110;MQM=59	ACAT1	5'UTR	ACAT1:NM_000019.3:5'UTR:MODIFIER:exon1/12:c.-9T>A:		rs3741055	0.3137	0.3881	1348/357/8	0.1634							607809 [ACAT1 (confirmed) Alpha-methylacetoacetic aciduria,203750];	RCV000077928.5 [benign]; RCV000336276.1 [benign]; 			251	688					ACAT1 (inh=AR pLI=0.00)
chr11	107992346	107992346	G	C	het	wt	hom	pred_pathogenic	QUAL=3958;DP=127,86,100;MQM=59	ACAT1	missense	ACAT1:NM_000019.3:missense:MODERATE:exon1/12:c.13G>C:p.Ala5Pro		rs3741056	0.3319	0.4014	1372/362/18	0.1727	-0.1180	D,T	T	B,B	D,D	17.60	607809 [ACAT1 (confirmed) Alpha-methylacetoacetic aciduria,203750];	RCV000077929.5 [benign]; RCV000391653.1 [benign]; 		COSM3752118	253	686					ACAT1 (inh=AR pLI=0.00)
chr11	108009660	108009660	C	A	het	het	wt		QUAL=5557;DP=202,308,395;MQM=60	ACAT1	synonymous	ACAT1:NM_000019.3:synonymous:LOW:exon6/12:c.471C>A:p.Ser157Ser		rs35188041	0.1270	0.1555	1659/997/206	0.1525	0.1580		T			16.92	607809 [ACAT1 (confirmed) Alpha-methylacetoacetic aciduria,203750];	RCV000077930.4 [benign]; RCV000366294.1 [likely benign]; 		COSM1350699	32	379					ACAT1 (inh=AR pLI=0.00)
chr11	108018716	108018716	A	C	wt	het	wt		QUAL=1638;DP=156,142,193;MQM=60	ACAT1	3'UTR	ACAT1:NM_000019.3:3'UTR:MODIFIER:exon12/12:c.*599A>C:		rs2280332	0.3988	0.0000	0/0/0	0.2992							607809 [ACAT1 (confirmed) Alpha-methylacetoacetic aciduria,203750];	RCV000348219.1 [benign]; 			7	72					ACAT1 (inh=AR pLI=0.00)
chr11	108018894	108018897	AATT	-	het	het	wt		QUAL=5426;DP=271,211,270;MQM=59	ACAT1-NPAT	intergenic_region	ACAT1-NPAT:ACAT1-NPAT:intergenic_region:MODIFIER::n.108018894_108018897delAATT:		rs112801981;rs577109182	0.2039	0.0000	0/0/0	0.2592							607809 [ACAT1 (confirmed) Alpha-methylacetoacetic aciduria,203750];	RCV000345943.1 [benign]; 			30	84					ACAT1-NPAT (inh=n/a pLI=n/a)
chr11	108093833	108093833	G	A	het	wt	hom		QUAL=17303;DP=341,397,501;MQM=60	ATM	5'UTR	ATM:NM_000051.3:5'UTR:MODIFIER:exon1/63:c.-111G>A:		rs189037	0.4760	0.0000	0/0/0	0.5334							607585 [ATM (confirmed) Ataxia-telangiectasia,208900|Lymphoma,B-cell non-Hodgkin,somatic|Breast cancer,susceptibility to,114480|Lymphoma,mantle cell,somatic|T-cell prolymphocytic leukemia,somatic];	RCV000304644.1 [benign]; 	CR109394 [CLASS=DFP MUT=ALT PHEN="Longevity association with" GENE=ATM]; 		95	94					ATM (inh=AR+AD pLI=0.00)
chr11	108163487	108163487	C	T	wt	het	wt	anno_pathogenic_hgmd	QUAL=1177;DP=239,144,169;MQM=60	ATM	synonymous	ATM:NM_000051.3:synonymous:LOW:exon30/63:c.4578C>T:p.Pro1526Pro		rs1800889	0.0154	0.0333	114/103/0	0.0338							607585 [ATM (confirmed) Ataxia-telangiectasia,208900|Lymphoma,B-cell non-Hodgkin,somatic|Breast cancer,susceptibility to,114480|Lymphoma,mantle cell,somatic|T-cell prolymphocytic leukemia,somatic];	RCV000116426.3 [other]; RCV000119133.3 [other]; RCV000162381.1 [benign]; 	CM1610819 [CLASS=DM? MUT=ALT PHEN="Breast cancer" GENE=ATM]; 		7	398	1	[1] Ilnaz Sepahi 29-03-2016 batch import			ATM (inh=AR+AD pLI=0.00)
chr11	108183167	108183167	A	G	hom	hom	hom		QUAL=14951;DP=213,92,142;MQM=60	ATM	missense	ATM:NM_000051.3:missense:MODERATE:exon40/63:c.5948A>G:p.Asn1983Ser		rs659243	1.0000	1.0000	60654/33353/5170	0.9355	-1.0580	T,T	T	B,B	T,T	0.01	607585 [ATM (confirmed) Ataxia-telangiectasia,208900|Lymphoma,B-cell non-Hodgkin,somatic|Breast cancer,susceptibility to,114480|Lymphoma,mantle cell,somatic|T-cell prolymphocytic leukemia,somatic];	RCV000128947.1 [benign]; RCV000120149.2 [benign]; 			4824	0	1	[3] Ilnaz Sepahi 29-03-2016 batch import [1] ahdoeha1 31.03.2016: GC-HBOC class 1 [n/a] harmuth 02.09.2016; observed base G is the wildtype base (hg38) which means that we sequenced the wildtype 			ATM (inh=AR+AD pLI=0.00)
chr11	108224615	108224615	A	C	wt	wt	het		QUAL=1562;DP=114,107,99;MQM=60	ATM	splice_region&intron	ATM:NM_000051.3:splice_region&intron:LOW:exon60/62:c.8786+8A>C:		rs4986839	0.0124	0.0250	78/69/0	0.0259							607585 [ATM (confirmed) Ataxia-telangiectasia,208900|Lymphoma,B-cell non-Hodgkin,somatic|Breast cancer,susceptibility to,114480|Lymphoma,mantle cell,somatic|T-cell prolymphocytic leukemia,somatic];	RCV000119125.3 [other]; RCV000128889.2 [benign]; RCV000250207.1 [benign]; 			4	353	1	[1] Ilnaz Sepahi 29-03-2016 batch import			ATM (inh=AR+AD pLI=0.00)
chr11	108236783	108236783	G	T	het	wt	hom	low_DP	QUAL=1517;DP=72,19,25;MQM=58	ATM	3'UTR	ATM:NM_000051.3:3'UTR:MODIFIER:exon63/63:c.*548G>T:		rs227092	0.5184	0.0000	0/0/0	0.4976							607585 [ATM (confirmed) Ataxia-telangiectasia,208900|Lymphoma,B-cell non-Hodgkin,somatic|Breast cancer,susceptibility to,114480|Lymphoma,mantle cell,somatic|T-cell prolymphocytic leukemia,somatic];	RCV000291267.1 [benign]; 			77	63					ATM (inh=AR+AD pLI=0.00)
chr11	108237839	108237839	C	T	het	wt	hom		QUAL=1686;DP=93,37,34;MQM=52	ATM	3'UTR	ATM:NM_000051.3:3'UTR:MODIFIER:exon63/63:c.*1604C>T:	AluSc8	rs227091	0.5182	0.0000	0/0/0	0.5093							607585 [ATM (confirmed) Ataxia-telangiectasia,208900|Lymphoma,B-cell non-Hodgkin,somatic|Breast cancer,susceptibility to,114480|Lymphoma,mantle cell,somatic|T-cell prolymphocytic leukemia,somatic];	RCV000338616.1 [benign]; 			77	71					ATM (inh=AR+AD pLI=0.00)
chr11	108239628	108239628	G	T	het	wt	hom		QUAL=7099;DP=332,88,83;MQM=60	ATM	3'UTR	ATM:NM_000051.3:3'UTR:MODIFIER:exon63/63:c.*3393G>T:		rs4585	0.5345	0.0000	0/0/0	0.1098							607585 [ATM (confirmed) Ataxia-telangiectasia,208900|Lymphoma,B-cell non-Hodgkin,somatic|Breast cancer,susceptibility to,114480|Lymphoma,mantle cell,somatic|T-cell prolymphocytic leukemia,somatic];	RCV000274160.1 [benign]; 			99	98					ATM (inh=AR+AD pLI=0.00)
chr11	111654621	111654625	TATAT	-	het	het	wt		QUAL=2854;DP=196,83,125;MQM=59	ALG9	3'UTR	ALG9:NM_024740.2:3'UTR:MODIFIER:exon16/16:c.*2496_*2500delATATA:,ALG9:NM_001077691.1:3'UTR:MODIFIER:exon15/15:c.*2496_*2500delATATA:,ALG9:NM_001077692.1:3'UTR:MODIFIER:exon15/15:c.*2496_*2500delATATA:,ALG9:NM_001077690.1:3'UTR:MODIFIER:exon16/16:c.*2496_*2500delATATA:		rs66517706	0.2372	0.0000	0/0/0	0.2440							606941 [ALG9 (confirmed) Congenital disorder of glycosylation,type Il,608776|Gillessen-Kaesbach-Nishimura syndrome,263210];				22	103					ALG9 (inh=AR pLI=0.00)
chr11	111654647	111654647	-	A	het	het	wt		QUAL=6246;DP=215,56,72;MQM=59	ALG9	3'UTR	ALG9:NM_024740.2:3'UTR:MODIFIER:exon16/16:c.*2473_*2474insT:,ALG9:NM_001077691.1:3'UTR:MODIFIER:exon15/15:c.*2473_*2474insT:,ALG9:NM_001077692.1:3'UTR:MODIFIER:exon15/15:c.*2473_*2474insT:,ALG9:NM_001077690.1:3'UTR:MODIFIER:exon16/16:c.*2473_*2474insT:			0.0000	0.0000	0/0/0	0.0102							606941 [ALG9 (confirmed) Congenital disorder of glycosylation,type Il,608776|Gillessen-Kaesbach-Nishimura syndrome,263210];	RCV000363122.1 [uncertain significance]; 			0	53					ALG9 (inh=AR pLI=0.00)
chr11	111654648	111654648	T	A	hom	hom	het		QUAL=6246;DP=215,56,72;MQM=59	ALG9	3'UTR	ALG9:NM_024740.2:3'UTR:MODIFIER:exon16/16:c.*2473A>T:,ALG9:NM_001077691.1:3'UTR:MODIFIER:exon15/15:c.*2473A>T:,ALG9:NM_001077692.1:3'UTR:MODIFIER:exon15/15:c.*2473A>T:,ALG9:NM_001077690.1:3'UTR:MODIFIER:exon16/16:c.*2473A>T:		rs2554994	0.0000	0.0000	0/0/0	0.0760							606941 [ALG9 (confirmed) Congenital disorder of glycosylation,type Il,608776|Gillessen-Kaesbach-Nishimura syndrome,263210];	RCV000270520.1 [uncertain significance]; 			66	157					ALG9 (inh=AR pLI=0.00)
chr11	111654670	111654678	GACAAAACA	-	het	het	wt		QUAL=2623;DP=200,62,69;MQM=58	ALG9	3'UTR	ALG9:NM_024740.2:3'UTR:MODIFIER:exon16/16:c.*2443_*2451delTGTTTTGTC:,ALG9:NM_001077691.1:3'UTR:MODIFIER:exon15/15:c.*2443_*2451delTGTTTTGTC:,ALG9:NM_001077692.1:3'UTR:MODIFIER:exon15/15:c.*2443_*2451delTGTTTTGTC:,ALG9:NM_001077690.1:3'UTR:MODIFIER:exon16/16:c.*2443_*2451delTGTTTTGTC:	GA-rich	rs72428193	0.0000	0.0000	0/0/0	0.0838							606941 [ALG9 (confirmed) Congenital disorder of glycosylation,type Il,608776|Gillessen-Kaesbach-Nishimura syndrome,263210];				26	102					ALG9 (inh=AR pLI=0.00)
chr11	111656221	111656221	-	A	wt	wt	het		QUAL=2493;DP=336,229,250;MQM=60	ALG9	3'UTR	ALG9:NM_024740.2:3'UTR:MODIFIER:exon16/16:c.*899dupT:,ALG9:NM_001077691.1:3'UTR:MODIFIER:exon15/15:c.*899dupT:,ALG9:NM_001077692.1:3'UTR:MODIFIER:exon15/15:c.*899dupT:,ALG9:NM_001077690.1:3'UTR:MODIFIER:exon16/16:c.*899dupT:			0.0000	0.0000	0/0/0	0.0011							606941 [ALG9 (confirmed) Congenital disorder of glycosylation,type Il,608776|Gillessen-Kaesbach-Nishimura syndrome,263210];				0	3					ALG9 (inh=AR pLI=0.00)
chr11	111724133	111724133	C	T	het	het	het	pred_pathogenic	QUAL=9187;DP=316,224,251;MQM=60	ALG9	missense	ALG9:NM_024740.2:missense:MODERATE:exon9/16:c.865G>A:p.Val289Ile,ALG9:NM_001077691.1:missense:MODERATE:exon8/15:c.352G>A:p.Val118Ile,ALG9:NM_001077692.1:missense:MODERATE:exon8/15:c.352G>A:p.Val118Ile,ALG9:NM_001077690.1:missense:MODERATE:exon9/16:c.865G>A:p.Val289Ile		rs10502151	0.3265	0.3510	7918/3581/92	0.3448	6.0710	T,T,T	T	P,B,P	T,T	22.20	606941 [ALG9 (confirmed) Congenital disorder of glycosylation,type Il,608776|Gillessen-Kaesbach-Nishimura syndrome,263210];			COSM3998221, COSM3998222, COSM3998223	198	688					ALG9 (inh=AR pLI=0.00)
chr11	111741724	111741724	G	A	wt	het	wt		QUAL=3371;DP=350,300,401;MQM=60	ALG9	5'UTR_premature_start_codon_gain,5'UTR,intron	ALG9:NM_001077691.1:5'UTR_premature_start_codon_gain:LOW:exon1/15:c.-609C>T:,ALG9:NM_001077692.1:5'UTR_premature_start_codon_gain:LOW:exon1/15:c.-609C>T:,ALG9:NM_001077691.1:5'UTR:MODIFIER:exon1/15:c.-609C>T:,ALG9:NM_001077692.1:5'UTR:MODIFIER:exon1/15:c.-609C>T:,ALG9:NM_024740.2:intron:MODIFIER:exon2/15:c.131+351C>T:,ALG9:NM_001077690.1:intron:MODIFIER:exon2/15:c.131+351C>T:		rs371129231	0.0020	0.0000	0/0/0	0.0004							606941 [ALG9 (confirmed) Congenital disorder of glycosylation,type Il,608776|Gillessen-Kaesbach-Nishimura syndrome,263210];				0	1					ALG9 (inh=AR pLI=0.00)
chr11	111742146	111742146	G	-	hom	hom	hom	anno_high_impact	QUAL=10671;DP=28,125,221;MQM=59	ALG9	splice_acceptor&splice_donor	ALG9:NM_024740.2:splice_acceptor&splice_donor:HIGH:exon1/15:c.60+1delC:,ALG9:NM_001077690.1:splice_acceptor&splice_donor:HIGH:exon1/15:c.60+1delC:		rs10708475	1.0000	1.0000	6194/1836/287	0.2542							606941 [ALG9 (confirmed) Congenital disorder of glycosylation,type Il,608776|Gillessen-Kaesbach-Nishimura syndrome,263210];				1531	0	1	[1] auto-classification 16.06.2016  [2] Ute Grasshoff 24.11.2015			ALG9 (inh=AR pLI=0.00)
chr11	111781047	111781047	A	C	het	het	wt	pred_pathogenic	QUAL=4806;DP=213,182,267;MQM=60	CRYAB	splice_region&intron	CRYAB:NM_001289807.1:splice_region&intron:LOW:exon3/3:c.324+4T>G:,CRYAB:NM_001289808.1:splice_region&intron:LOW:exon2/2:c.324+4T>G:,CRYAB:NM_001885.2:splice_region&intron:LOW:exon3/3:c.324+4T>G:		rs11603779	0.2398	0.2695	4615/2908/218	0.2692		T	T	B	D	0.09	123590 [CRYAB (confirmed) Myopathy,myofibrillar,2,608810|Cataract 16,multiple types,613763|Myopathy,myofibrillar,fatal infantile hypertrophy,alpha-B crystallin-related,613869|Cardiomyopathy,dilated,1II,615184];	RCV000037213.4 [benign]; RCV000252961.1 [benign]; RCV000268709.1 [benign]; RCV000308725.1 [benign]; RCV000363435.1 [benign]; 		COSM3998232	158	688					CRYAB (inh=AR+AD pLI=0.01)
chr11	114121292	114121292	C	T	wt	wt	het		QUAL=3861;DP=248,233,333;MQM=59	ZBTB16	3'UTR	ZBTB16:NM_001018011.1:3'UTR:MODIFIER:exon7/7:c.*15C>T:,ZBTB16:NM_006006.4:3'UTR:MODIFIER:exon7/7:c.*15C>T:		rs3088357	0.0050	0.0068	4/4/0	0.0067							176797 [ZBTB16 (confirmed) Leukemia,acute promyelocytic,PL2F/RARA type|Skeletal defects,genital hypoplasia,and mental retardation,612447];				1	12					ZBTB16 (inh=AR pLI=0.98)
chr11	118175439	118175439	G	A	het	het	het		QUAL=3974;DP=213,62,85;MQM=60	CD3E	5'UTR	CD3E:NM_000733.3:5'UTR:MODIFIER:exon1/9:c.-112G>A:		rs2231440	0.2290	0.0000	0/0/0	0.3006							186830 [CD3E (provisional) Immunodeficiency 18,615615|Immunodeficiency 18,SCID variant,615615];	RCV000370695.1 [benign]; 			20	104					CD3E (inh=AR+AD pLI=0.30)
chr11	118178007	118178007	C	T	het	het	het		QUAL=4651;DP=153,107,125;MQM=60	CD3E	synonymous	CD3E:NM_000733.3:synonymous:LOW:exon3/9:c.54C>T:p.Gly18Gly		rs1126924	0.2254	0.3061	6374/3322/39	0.3032							186830 [CD3E (provisional) Immunodeficiency 18,615615|Immunodeficiency 18,SCID variant,615615];	RCV000330794.1 [benign]; 		COSM147335	146	675					CD3E (inh=AR+AD pLI=0.30)
chr11	118215076	118215079	GGCT	-	het	het	wt		QUAL=3500;DP=158,193,240;MQM=59	CD3G	5'UTR	CD3G:NM_000073.2:5'UTR:MODIFIER:exon1/7:c.-46_-43delGCTG:	(CTGG)n	rs68070310	0.4026	0.0000	0/0/0	0.2976							186740 [CD3G (confirmed) Immunodeficiency 17,CD3 gamma deficient,615607];	RCV000267460.1 [likely benign]; RCV000342221.1,RCV000267460.1 [benign,likely benign]; RCV000342221.1 [benign]; 			98	338					CD3G (inh=AR pLI=0.03)
chr11	118221349	118221349	T	C	het	het	wt		QUAL=752;DP=70,24,47;MQM=60	CD3G	synonymous	CD3G:NM_000073.2:synonymous:LOW:exon4/7:c.390T>C:p.Ala130Ala		rs3753059	0.2963	0.2189	3926/848/115	0.1923							186740 [CD3G (confirmed) Immunodeficiency 17,CD3 gamma deficient,615607];	RCV000288417.1 [likely benign]; 		COSM3998253	101	508					CD3G (inh=AR pLI=0.03)
chr11	118221350	118221350	G	T	het	het	wt	pred_pathogenic	QUAL=752;DP=70,24,47;MQM=60	CD3G	missense	CD3G:NM_000073.2:missense:MODERATE:exon4/7:c.391G>T:p.Val131Phe		rs3753058	0.2975	0.2189	3923/846/115	0.2003	0.3220	D	T	P	T	25.90	186740 [CD3G (confirmed) Immunodeficiency 17,CD3 gamma deficient,615607];	RCV000352643.1 [likely benign]; 		COSM3931231	101	508					CD3G (inh=AR pLI=0.03)
chr11	118224059	118224059	A	G	het	wt	het		QUAL=4090;DP=252,20,48;MQM=60	CD3G	3'UTR	CD3G:NM_000073.2:3'UTR:MODIFIER:exon7/7:c.*244A>G:		rs45508093	0.0721	0.0000	0/0/0	0.1323							186740 [CD3G (confirmed) Immunodeficiency 17,CD3 gamma deficient,615607];	RCV000349036.1 [likely benign]; 			7	64					CD3G (inh=AR pLI=0.03)
chr11	118224268	118224268	G	T	het	het	wt		QUAL=1147;DP=116,21,25;MQM=54	CD3G	3'UTR	CD3G:NM_000073.2:3'UTR:MODIFIER:exon7/7:c.*453G>T:	AluSz	rs45477194	0.2977	0.0000	0/0/0	0.1264							186740 [CD3G (confirmed) Immunodeficiency 17,CD3 gamma deficient,615607];	RCV000305705.1 [likely benign]; 			9	57					CD3G (inh=AR pLI=0.03)
chr11	118895202	118895202	A	G	wt	het	wt		QUAL=5774;DP=328,444,578;MQM=60	SLC37A4	3'UTR	SLC37A4:NM_001164278.1:3'UTR:MODIFIER:exon12/12:c.*418T>C:,SLC37A4:NM_001164280.1:3'UTR:MODIFIER:exon9/9:c.*418T>C:,SLC37A4:NM_001164277.1:3'UTR:MODIFIER:exon11/11:c.*418T>C:,SLC37A4:NM_001164279.1:3'UTR:MODIFIER:exon11/11:c.*418T>C:,SLC37A4:NM_001467.5:3'UTR:MODIFIER:exon10/10:c.*418T>C:		rs11006	0.1819	0.0000	0/0/0	0.1843							602671 [SLC37A4 (confirmed) Glycogen storage disease Ib,232220|Glycogen storage disease Ic,232240];	RCV000265891.1 [benign]; 			12	72					SLC37A4 (inh=AR pLI=0.00)
chr11	118895495	118895495	C	G	wt	het	wt		QUAL=1380;DP=223,154,179;MQM=60	SLC37A4	3'UTR	SLC37A4:NM_001164278.1:3'UTR:MODIFIER:exon12/12:c.*125G>C:,SLC37A4:NM_001164280.1:3'UTR:MODIFIER:exon9/9:c.*125G>C:,SLC37A4:NM_001164277.1:3'UTR:MODIFIER:exon11/11:c.*125G>C:,SLC37A4:NM_001164279.1:3'UTR:MODIFIER:exon11/11:c.*125G>C:,SLC37A4:NM_001467.5:3'UTR:MODIFIER:exon10/10:c.*125G>C:		rs8301	0.2835	0.0000	0/0/0	0.2601							602671 [SLC37A4 (confirmed) Glycogen storage disease Ib,232220|Glycogen storage disease Ic,232240];	RCV000294933.1 [benign]; 			23	133					SLC37A4 (inh=AR pLI=0.00)
chr11	118895686	118895686	C	T	wt	het	wt	pred_pathogenic	QUAL=1171;DP=201,103,165;MQM=60	SLC37A4	synonymous	SLC37A4:NM_001164278.1:synonymous:LOW:exon12/12:c.1290G>A:p.Thr430Thr,SLC37A4:NM_001164280.1:synonymous:LOW:exon9/9:c.1224G>A:p.Thr408Thr,SLC37A4:NM_001164277.1:synonymous:LOW:exon11/11:c.1224G>A:p.Thr408Thr,SLC37A4:NM_001164279.1:synonymous:LOW:exon11/11:c.1005G>A:p.Thr335Thr,SLC37A4:NM_001467.5:synonymous:LOW:exon10/10:c.1224G>A:p.Thr408Thr		rs8192696	0.2478	0.2187	3200/1473/626	0.2140	-1.1460	D	T		T	15.93	602671 [SLC37A4 (confirmed) Glycogen storage disease Ib,232220|Glycogen storage disease Ic,232240];	RCV000128142.2 [benign]; 		COSM3752170	74	544					SLC37A4 (inh=AR pLI=0.00)
chr11	118898436	118898436	C	-	hom	hom	hom	anno_high_impact	QUAL=54851;DP=295,679,852;MQM=59	SLC37A4	splice_acceptor&splice_donor	SLC37A4:NM_001164278.1:splice_acceptor&splice_donor:HIGH:exon5/11:c.527+1delG:,SLC37A4:NM_001164280.1:splice_acceptor&splice_donor:HIGH:exon3/8:c.527+1delG:,SLC37A4:NM_001164277.1:splice_acceptor&splice_donor:HIGH:exon5/10:c.527+1delG:,SLC37A4:NM_001164279.1:splice_acceptor&splice_donor:HIGH:exon5/10:c.308+1delG:,SLC37A4:NM_001467.5:splice_acceptor&splice_donor:HIGH:exon4/9:c.527+1delG:		rs547203028	1.0000	1.0000	60059/33162/4885	0.9338							602671 [SLC37A4 (confirmed) Glycogen storage disease Ib,232220|Glycogen storage disease Ic,232240];				1565	0	1	[1] auto-classification 16.06.2016  [2] Ute Grasshoff 24.11.2015			SLC37A4 (inh=AR pLI=0.00)
chr11	118901166	118901166	C	G	het	het	hom		QUAL=7627;DP=89,126,178;MQM=59	SLC37A4	5'UTR_premature_start_codon_gain,5'UTR,intron	SLC37A4:NM_001164277.1:5'UTR_premature_start_codon_gain:LOW:exon2/11:c.-420G>C:,SLC37A4:NM_001164277.1:5'UTR:MODIFIER:exon2/11:c.-420G>C:,SLC37A4:NM_001164278.1:intron:MODIFIER:exon2/11:c.-196+92G>C:,SLC37A4:NM_001164279.1:intron:MODIFIER:exon1/10:c.-345+393G>C:,SLC37A4:NM_001467.5:intron:MODIFIER:exon1/9:c.-196+393G>C:		rs2846281	0.8496	0.0000	0/0/0	0.7904							602671 [SLC37A4 (confirmed) Glycogen storage disease Ib,232220|Glycogen storage disease Ic,232240];	RCV000281378.1 [benign]; 			151	71					SLC37A4 (inh=AR pLI=0.00)
chr11	118901262	118901262	C	T	wt	het	wt		QUAL=1380;DP=49,108,145;MQM=60	SLC37A4	5'UTR,intron	SLC37A4:NM_001164278.1:5'UTR:MODIFIER:exon2/12:c.-200G>A:,SLC37A4:NM_001164277.1:5'UTR:MODIFIER:exon2/11:c.-516G>A:,SLC37A4:NM_001164279.1:intron:MODIFIER:exon1/10:c.-345+297G>A:,SLC37A4:NM_001467.5:intron:MODIFIER:exon1/9:c.-196+297G>A:		rs3759012	0.5262	0.0000	0/0/0	0.3906							602671 [SLC37A4 (confirmed) Glycogen storage disease Ib,232220|Glycogen storage disease Ic,232240];	RCV000128145.1 [benign]; RCV000317647.1 [benign]; 			43	109					SLC37A4 (inh=AR pLI=0.00)
chr11	118967291	118967291	A	G	wt	het	het		QUAL=2279;DP=147,74,116;MQM=60	DPAGT1	3'UTR	DPAGT1:NM_001382.3:3'UTR:MODIFIER:exon9/9:c.*417T>C:		rs7759	0.2726	0.0000	0/0/0	0.0597							191350 [DPAGT1 (confirmed) Congenital disorder of glycosylation,type Ij,608093|Myasthenic syndrome,congenital,13,with tubular aggregates,614750];	RCV000352190.1 [benign]; RCV000357296.1 [benign]; 			25	101					DPAGT1 (inh=AR pLI=0.00)
chr11	118967524	118967524	C	T	het	het	hom		QUAL=17357;DP=251,272,338;MQM=60	DPAGT1	3'UTR	DPAGT1:NM_001382.3:3'UTR:MODIFIER:exon9/9:c.*184G>A:		rs8551	0.4367	0.0000	0/0/0	0.0744							191350 [DPAGT1 (confirmed) Congenital disorder of glycosylation,type Ij,608093|Myasthenic syndrome,congenital,13,with tubular aggregates,614750];	RCV000313130.1 [benign]; RCV000404523.1 [benign]; 			44	104					DPAGT1 (inh=AR pLI=0.00)
chr11	118967758	118967758	T	C	het	het	hom	pred_pathogenic	QUAL=20347;DP=372,276,352;MQM=59	DPAGT1	missense	DPAGT1:NM_001382.3:missense:MODERATE:exon9/9:c.1177A>G:p.Ile393Val		rs643788	0.4333	0.4215	11492/6311/443	0.4211	-0.3200	T,T,T	T	B,B	D,D,D	0.01	191350 [DPAGT1 (confirmed) Congenital disorder of glycosylation,type Ij,608093|Myasthenic syndrome,congenital,13,with tubular aggregates,614750];	RCV000079665.6 [benign]; RCV000277995.1 [benign]; RCV000354528.1 [benign]; 			321	728					DPAGT1 (inh=AR pLI=0.00)
chr11	119209979	119209979	T	A	het	het	wt		QUAL=2849;DP=124,162,243;MQM=60	C1QTNF5,MFRP	3'UTR	C1QTNF5:NM_001278431.1:3'UTR:MODIFIER:exon3/3:c.*62A>T:,MFRP:NM_031433.3:3'UTR:MODIFIER:exon15/15:c.*1690A>T:,C1QTNF5:NM_015645.4:3'UTR:MODIFIER:exon15/15:c.*62A>T:		rs9640	0.1378	0.0000	0/0/0	0.0255							606227 [MFRP (provisional) Microphthalmia,isolated 5,611040|Nanophthalmos 2,609549];	RCV000332420.1 [likely benign]; RCV000372083.1 [likely benign]; 	CR080754 [CLASS=DP MUT=REF PHEN="Increased BMI association with" GENE=C1QTNF5]; 		6	135					C1QTNF5 (inh=AD pLI=0.83), MFRP (inh=AR pLI=0.00)
chr11	119213303	119213303	C	T	wt	het	wt		QUAL=2548;DP=154,206,223;MQM=60	MFRP,C1QTNF5	splice_region&intron	MFRP:NM_031433.3:splice_region&intron:LOW:exon11/14:c.1387+3G>A:,C1QTNF5:NM_015645.4:splice_region&intron:LOW:exon11/14:c.-1250+3G>A:		rs11217241	0.2400	0.1683	2850/160/37	0.1531							606227 [MFRP (provisional) Microphthalmia,isolated 5,611040|Nanophthalmos 2,609549];	RCV000244406.1 [benign]; RCV000267815.1 [likely benign]; RCV000322794.1 [likely benign]; 			36	271					MFRP (inh=AR pLI=0.00), C1QTNF5 (inh=AD pLI=0.83)
chr11	119215046	119215046	C	T	wt	het	wt		QUAL=2194;DP=345,172,207;MQM=60	MFRP,C1QTNF5	synonymous,5'UTR	MFRP:NM_031433.3:synonymous:LOW:exon8/15:c.954G>A:p.Leu318Leu,C1QTNF5:NM_015645.4:5'UTR:MODIFIER:exon8/15:c.-1683G>A:		rs35885438	0.0573	0.0551	282/84/3	0.0524							606227 [MFRP (provisional) Microphthalmia,isolated 5,611040|Nanophthalmos 2,609549];	RCV000306213.1 [likely benign]; RCV000360922.1 [likely benign]; 			4	163					MFRP (inh=AR pLI=0.00), C1QTNF5 (inh=AD pLI=0.83)
chr11	119216231	119216231	A	G	hom	hom	hom		QUAL=6365;DP=100,43,55;MQM=60	MFRP,C1QTNF5	synonymous,5'UTR	MFRP:NM_031433.3:synonymous:LOW:exon5/15:c.540T>C:p.His180His,C1QTNF5:NM_015645.4:5'UTR:MODIFIER:exon5/15:c.-2097T>C:		rs2510143	0.9020	0.9364	53245/30591/4010	0.9276							606227 [MFRP (provisional) Microphthalmia,isolated 5,611040|Nanophthalmos 2,609549];	RCV000153496.3 [benign]; RCV000276256.1 [likely benign]; RCV000311491.1 [benign]; 		COSM4145393	1376	107					MFRP (inh=AR pLI=0.00), C1QTNF5 (inh=AD pLI=0.83)
chr11	119216279	119216279	G	A	wt	wt	het		QUAL=521;DP=106,39,49;MQM=60	MFRP,C1QTNF5	synonymous,5'UTR	MFRP:NM_031433.3:synonymous:LOW:exon5/15:c.492C>T:p.Tyr164Tyr,C1QTNF5:NM_015645.4:5'UTR:MODIFIER:exon5/15:c.-2145C>T:		rs36015759	0.2015	0.2136	2977/1879/280	0.2016							606227 [MFRP (provisional) Microphthalmia,isolated 5,611040|Nanophthalmos 2,609549];	RCV000132684.1 [likely benign]; RCV000153497.3 [benign]; RCV000267889.1 [likely benign]; RCV000381081.1 [likely benign]; 		COSM4145394	68	441					MFRP (inh=AR pLI=0.00), C1QTNF5 (inh=AD pLI=0.83)
chr11	119216504	119216504	C	T	het	hom	wt		QUAL=1596;DP=86,24,38;MQM=59	MFRP,C1QTNF5	missense,5'UTR_premature_start_codon_gain,5'UTR	MFRP:NM_031433.3:missense:MODERATE:exon4/15:c.406G>A:p.Val136Met,C1QTNF5:NM_015645.4:5'UTR_premature_start_codon_gain:LOW:exon4/15:c.-2231G>A:,C1QTNF5:NM_015645.4:5'UTR:MODIFIER:exon4/15:c.-2231G>A:		rs3814762	0.1821	0.2664	4745/3585/43	0.2651	-1.8680	T,T,T	T	B,B	T,T,T	0.24	606227 [MFRP (provisional) Microphthalmia,isolated 5,611040|Nanophthalmos 2,609549];	RCV000153499.5 [benign]; RCV000279501.1 [likely benign]; RCV000374001.1 [likely benign]; 			168	621					MFRP (inh=AR pLI=0.00), C1QTNF5 (inh=AD pLI=0.83)
chr11	119217254	119217254	C	T	het	hom	wt		QUAL=9480;DP=259,207,323;MQM=59	MFRP,C1QTNF5	5'UTR	MFRP:NM_031433.3:5'UTR:MODIFIER:exon1/15:c.-31G>A:,C1QTNF5:NM_015645.4:5'UTR:MODIFIER:exon1/15:c.-2667G>A:		rs883247	0.6356	0.5951	21471/11104/1496	0.5865							606227 [MFRP (provisional) Microphthalmia,isolated 5,611040|Nanophthalmos 2,609549];	RCV000347276.1 [likely benign]; RCV000400633.1 [likely benign]; 			324	308					MFRP (inh=AR pLI=0.00), C1QTNF5 (inh=AD pLI=0.83)
chr11	119217311	119217311	G	A	het	hom	wt		QUAL=7836;DP=208,171,276;MQM=60	MFRP,C1QTNF5	5'UTR_premature_start_codon_gain,5'UTR	MFRP:NM_031433.3:5'UTR_premature_start_codon_gain:LOW:exon1/15:c.-88C>T:,C1QTNF5:NM_015645.4:5'UTR_premature_start_codon_gain:LOW:exon1/15:c.-2724C>T:,MFRP:NM_031433.3:5'UTR:MODIFIER:exon1/15:c.-88C>T:,C1QTNF5:NM_015645.4:5'UTR:MODIFIER:exon1/15:c.-2724C>T:		rs883245	0.5839	0.0000	0/0/0	0.0938							606227 [MFRP (provisional) Microphthalmia,isolated 5,611040|Nanophthalmos 2,609549];	RCV000300755.1 [likely benign]; RCV000355624.1 [likely benign]; 			56	66					MFRP (inh=AR pLI=0.00), C1QTNF5 (inh=AD pLI=0.83)
chr11	119510644	119510644	A	C	hom	hom	hom		QUAL=23199;DP=227,196,313;MQM=59	NECTIN1	missense	NECTIN1:NM_203285.1:missense:MODERATE:exon6/8:c.1082T>G:p.Val361Gly		rs7940667	0.8728	0.9164	51183/28172/2686	0.9070	0.0680	T	T	B	T	1.20	600644 [PVRL1 (confirmed) Cleft lip/palate-ectodermal dysplasia syndrome,225060|Orofacial cleft 7,225060];		CM066206 [CLASS=DP MUT=ALT PHEN="Cleft lip / palate association with" GENE=PVRL1]; 		1387	172					NECTIN1 (inh=AR pLI=0.50)
chr11	119545224	119545224	-	G	het	hom	wt		QUAL=3997;DP=112,114,156;MQM=59	NECTIN1	3'UTR,intron	NECTIN1:NM_203286.1:3'UTR:MODIFIER:exon6/6:c.*77dupC:,NECTIN1:NM_002855.4:intron:MODIFIER:exon5/5:c.1003+644dupC:,NECTIN1:NM_203285.1:intron:MODIFIER:exon5/7:c.1003+644dupC:		rs113705862;rs534319501;rs763447380	0.1040	0.0000	0/0/0	0.0354							600644 [PVRL1 (confirmed) Cleft lip/palate-ectodermal dysplasia syndrome,225060|Orofacial cleft 7,225060];				2	39					NECTIN1 (inh=AR pLI=0.50)
chr11	121178302	121178302	A	C	het	het	hom		QUAL=14865;DP=274,195,273;MQM=60	SC5D	3'UTR	SC5D:NM_001024956.2:3'UTR:MODIFIER:exon5/5:c.*81A>C:,SC5D:NM_006918.4:3'UTR:MODIFIER:exon5/5:c.*81A>C:		rs1061332	0.7246	0.0000	0/0/0	0.1395							602286 [SC5D (confirmed) Lathosterolosis,607330];	RCV000314437.1 [benign]; 			109	96					SC5D (inh=AR pLI=0.10)
chr11	121179847	121179847	A	T	het	het	hom		QUAL=18253;DP=325,234,323;MQM=60	SC5D	3'UTR	SC5D:NM_001024956.2:3'UTR:MODIFIER:exon5/5:c.*1626A>T:,SC5D:NM_006918.4:3'UTR:MODIFIER:exon5/5:c.*1626A>T:	MLT1J2	rs2060008	0.4221	0.0000	0/0/0	0.4887							602286 [SC5D (confirmed) Lathosterolosis,607330];	RCV000397918.1 [benign]; 			59	109					SC5D (inh=AR pLI=0.10)
chr11	121181184	121181184	G	T	hom	hom	hom		QUAL=3701;DP=110,28,64;MQM=60	SC5D	3'UTR	SC5D:NM_001024956.2:3'UTR:MODIFIER:exon5/5:c.*2963G>T:,SC5D:NM_006918.4:3'UTR:MODIFIER:exon5/5:c.*2963G>T:	AluY		0.0000	0.0000	0/0/0	0.0001							602286 [SC5D (confirmed) Lathosterolosis,607330];				0	0					SC5D (inh=AR pLI=0.10)
chr11	121183145	121183145	T	C	het	het	hom		QUAL=6409;DP=192,69,80;MQM=59	SC5D	3'UTR	SC5D:NM_001024956.2:3'UTR:MODIFIER:exon5/5:c.*4924T>C:,SC5D:NM_006918.4:3'UTR:MODIFIER:exon5/5:c.*4924T>C:		rs35288685	0.3934	0.0000	0/0/0	0.4671							602286 [SC5D (confirmed) Lathosterolosis,607330];	RCV000283126.1 [benign]; 			59	112					SC5D (inh=AR pLI=0.10)
chr11	126139100	126139100	T	C	hom	hom	hom		QUAL=24943;DP=182,285,347;MQM=60	FOXRED1	5'UTR,non_coding_transcript_exon	FOXRED1:NM_017547.3:5'UTR:MODIFIER:exon1/11:c.-2T>C:,FOXRED1:NR_037647.1:non_coding_transcript_exon:MODIFIER:exon1/10:n.166T>C:,FOXRED1:NR_037648.1:non_coding_transcript_exon:MODIFIER:exon1/11:n.61T>C:		rs1786702	0.7861	0.7891	38033/19007/1620	0.7422							613622 [FOXRED1 (provisional) Leigh syndrome due to mitochondrial complex I deficiency,256000|Mitochondrial complex I deficiency,252010];	RCV000381743.1 [benign]; 			927	532					FOXRED1 (inh=AR pLI=0.00)
chr11	126146290	126146290	T	G	het	wt	wt	pred_pathogenic	QUAL=281;DP=48,62,82;MQM=59	FOXRED1	missense&splice_region,splice_region&non_coding_transcript_exon	FOXRED1:NM_017547.3:missense&splice_region:MODERATE:exon9/11:c.973T>G:p.Tyr325Asp,FOXRED1:NR_037647.1:splice_region&non_coding_transcript_exon:LOW:exon8/10:n.919T>G:,FOXRED1:NR_037648.1:splice_region&non_coding_transcript_exon:LOW:exon9/11:n.1159T>G:		rs201062084	0.2644	0.4552	0/0/0	0.0086	7.1660	D,D,D	D	B,P,B	D,D,D	24.00	613622 [FOXRED1 (provisional) Leigh syndrome due to mitochondrial complex I deficiency,256000|Mitochondrial complex I deficiency,252010];			COSM3746238	0	82					FOXRED1 (inh=AR pLI=0.00)
chr11	126147697	126147697	G	A	het	het	het		QUAL=6022;DP=196,157,225;MQM=60	FOXRED1	3'UTR,non_coding_transcript_exon	FOXRED1:NM_017547.3:3'UTR:MODIFIER:exon11/11:c.*113G>A:,FOXRED1:NR_037647.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1520G>A:,FOXRED1:NR_037648.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.1760G>A:		rs667627	0.1314	0.2138	1917/1466/51	0.1760							613622 [FOXRED1 (provisional) Leigh syndrome due to mitochondrial complex I deficiency,256000|Mitochondrial complex I deficiency,252010];	RCV000371864.1 [likely benign]; 			29	225					FOXRED1 (inh=AR pLI=0.00)
chr11	126293799	126293799	C	G	het	hom	wt		QUAL=2156;DP=78,50,61;MQM=59	KIRREL3	3'UTR	KIRREL3:NM_032531.3:3'UTR:MODIFIER:exon17/17:c.*676G>C:,KIRREL3:NM_001301097.1:3'UTR:MODIFIER:exon16/16:c.*676G>C:		rs948053	0.5783	0.0000	0/0/0	0.0935							607761 [KIRREL3 (provisional) Mental retardation,autosomal dominant 4,612581];				69	111					KIRREL3 (inh=AD pLI=0.98)
chr11	126294080	126294080	C	G	hom	hom	hom		QUAL=12747;DP=135,125,147;MQM=59	KIRREL3	3'UTR	KIRREL3:NM_032531.3:3'UTR:MODIFIER:exon17/17:c.*395G>C:,KIRREL3:NM_001301097.1:3'UTR:MODIFIER:exon16/16:c.*395G>C:		rs7113456	0.7179	0.0000	0/0/0	0.6457							607761 [KIRREL3 (provisional) Mental retardation,autosomal dominant 4,612581];				85	121					KIRREL3 (inh=AD pLI=0.98)
chr11	126294237	126294237	G	A	het	wt	het		QUAL=3821;DP=138,159,200;MQM=59	KIRREL3	3'UTR	KIRREL3:NM_032531.3:3'UTR:MODIFIER:exon17/17:c.*238C>T:,KIRREL3:NM_001301097.1:3'UTR:MODIFIER:exon16/16:c.*238C>T:		rs34642230	0.1190	0.0000	0/0/0	0.0195							607761 [KIRREL3 (provisional) Mental retardation,autosomal dominant 4,612581];				2	52					KIRREL3 (inh=AD pLI=0.98)
chr11	126294261	126294261	T	C	het	wt	hom		QUAL=8927;DP=172,180,230;MQM=60	KIRREL3	3'UTR	KIRREL3:NM_032531.3:3'UTR:MODIFIER:exon17/17:c.*214A>G:,KIRREL3:NM_001301097.1:3'UTR:MODIFIER:exon16/16:c.*214A>G:		rs3802815	0.3874	0.0000	0/0/0	0.0634							607761 [KIRREL3 (provisional) Mental retardation,autosomal dominant 4,612581];				40	95					KIRREL3 (inh=AD pLI=0.98)
chr11	126294817	126294817	G	A	hom	hom	hom		QUAL=10398;DP=64,146,189;MQM=59	KIRREL3	synonymous	KIRREL3:NM_032531.3:synonymous:LOW:exon17/17:c.1995C>T:p.Gly665Gly,KIRREL3:NM_001301097.1:synonymous:LOW:exon16/16:c.1959C>T:p.Gly653Gly		rs948052	0.7037	0.6713	26534/13761/2444	0.6536							607761 [KIRREL3 (provisional) Mental retardation,autosomal dominant 4,612581];	RCV000117432.2 [likely benign]; 			680	696					KIRREL3 (inh=AD pLI=0.98)
chr11	128708423	128708423	G	A	het	het	wt		QUAL=8161;DP=420,231,268;MQM=60	KCNJ1	3'UTR	KCNJ1:NM_000220.4:3'UTR:MODIFIER:exon2/2:c.*597C>T:,KCNJ1:NM_153764.2:3'UTR:MODIFIER:exon2/2:c.*597C>T:,KCNJ1:NM_153765.2:3'UTR:MODIFIER:exon3/3:c.*597C>T:,KCNJ1:NM_153766.2:3'UTR:MODIFIER:exon3/3:c.*597C>T:,KCNJ1:NM_153767.3:3'UTR:MODIFIER:exon4/4:c.*597C>T:		rs117189807	0.0108	0.0000	0/0/0	0.0031							600359 [KCNJ1 (confirmed) Bartter syndrome,type 2,241200];	RCV000357906.1 [uncertain significance]; 			0	8					KCNJ1 (inh=AR pLI=0.00)
chr11	128737188	128737188	A	G	hom	hom	hom		QUAL=30920;DP=378,222,338;MQM=59	KCNJ1	5'UTR	KCNJ1:NM_153764.2:5'UTR:MODIFIER:exon1/2:c.-142T>C:,KCNJ1:NM_153765.2:5'UTR:MODIFIER:exon1/3:c.-224T>C:,KCNJ1:NM_153766.2:5'UTR:MODIFIER:exon1/3:c.-312T>C:,KCNJ1:NM_153767.3:5'UTR:MODIFIER:exon1/4:c.-445T>C:		rs2855790	0.8185	0.0000	0/0/0	0.8297							600359 [KCNJ1 (confirmed) Bartter syndrome,type 2,241200];				172	53					KCNJ1 (inh=AR pLI=0.00)
chr12	392977	392977	T	-	wt	wt	het		QUAL=1419;DP=271,106,125;MQM=60	KDM5A	3'UTR	KDM5A:NM_001042603.2:3'UTR:MODIFIER:exon28/28:c.*1645delA:		rs796795200	0.3730	0.0000	0/0/0	0.1866											14	92					KDM5A (inh=n/a pLI=1.00)
chr12	406292	406292	G	A	wt	wt	het		QUAL=1291;DP=305,149,152;MQM=60	KDM5A	synonymous	KDM5A:NM_001042603.2:synonymous:LOW:exon25/28:c.4149C>T:p.Ser1383Ser		rs2229351	0.3526	0.3104	6149/2257/526	0.3045											116	633					KDM5A (inh=n/a pLI=1.00)
chr12	427575	427575	A	G	wt	wt	het	pred_pathogenic	QUAL=4752;DP=429,302,362;MQM=60	KDM5A	missense	KDM5A:NM_001042603.2:missense:MODERATE:exon19/28:c.2594T>C:p.Met865Thr		rs11062385	0.3530	0.3102	6227/2289/530	0.3050	3.9080	T,T,T,T,T	T	B,B,B	T,T,T	10.70					117	606					KDM5A (inh=n/a pLI=1.00)
chr12	431586	431586	T	A	het	wt	het	pred_pathogenic	QUAL=3006;DP=105,110,154;MQM=60	KDM5A	missense	KDM5A:NM_001042603.2:missense:MODERATE:exon17/28:c.2423A>T:p.His808Leu		rs74894801	0.0084	0.0164	22/17/0	0.0169	5.8510	T,T,T,T,T	T	B,B,B	T,T,T	18.26					1	52					KDM5A (inh=n/a pLI=1.00)
chr12	498282	498283	GT	-	hom	wt	hom	low_DP	QUAL=1201;DP=5,15,71;MQM=51	KDM5A	5'UTR	KDM5A:NM_001042603.2:5'UTR:MODIFIER:exon1/28:c.-26_-25delAC:		rs796202342	0.0000	0.0109	0/0/0	0.0002											2	4					KDM5A (inh=n/a pLI=1.00)
chr12	862641	862641	T	G	het	wt	het		QUAL=1290;DP=36,68,79;MQM=59	WNK1	5'UTR	WNK1:NM_001184985.1:5'UTR:MODIFIER:exon1/28:c.-91T>G:,WNK1:NM_014823.2:5'UTR:MODIFIER:exon1/26:c.-91T>G:,WNK1:NM_018979.3:5'UTR:MODIFIER:exon1/28:c.-91T>G:,WNK1:NM_213655.4:5'UTR:MODIFIER:exon1/28:c.-91T>G:		rs3088353	0.3399	0.0000	0/0/0	0.0689							605232 [WNK1 (confirmed) Pseudohypoaldosteronism,type IIC,614492|Neuropathy,hereditary sensory and autonomic,type II,201300];	RCV000265340.1 [benign]; RCV000320343.1 [benign]; 			45	112					WNK1 (inh=AR+AD pLI=1.00)
chr12	862989	862989	T	C	hom	hom	hom		QUAL=10318;DP=118,98,116;MQM=59	WNK1	synonymous	WNK1:NM_001184985.1:synonymous:LOW:exon1/28:c.258T>C:p.Cys86Cys,WNK1:NM_014823.2:synonymous:LOW:exon1/26:c.258T>C:p.Cys86Cys,WNK1:NM_018979.3:synonymous:LOW:exon1/28:c.258T>C:p.Cys86Cys,WNK1:NM_213655.4:synonymous:LOW:exon1/28:c.258T>C:p.Cys86Cys		rs3168640	0.9756	0.9924	58554/32517/4124	0.9257							605232 [WNK1 (confirmed) Pseudohypoaldosteronism,type IIC,614492|Neuropathy,hereditary sensory and autonomic,type II,201300];	RCV000246196.2 [benign]; RCV000304597.1 [benign]; RCV000391424.1 [benign]; 			1565	0					WNK1 (inh=AR+AD pLI=1.00)
chr12	863152	863152	G	A	het	wt	het	pred_pathogenic	QUAL=3792;DP=153,112,207;MQM=59	WNK1	missense	WNK1:NM_001184985.1:missense:MODERATE:exon1/28:c.421G>A:p.Ala141Thr,WNK1:NM_014823.2:missense:MODERATE:exon1/26:c.421G>A:p.Ala141Thr,WNK1:NM_018979.3:missense:MODERATE:exon1/28:c.421G>A:p.Ala141Thr,WNK1:NM_213655.4:missense:MODERATE:exon1/28:c.421G>A:p.Ala141Thr		rs11554421	0.0745	0.1633	689/375/6	0.0989	2.0540	D,D,D,D,D	T	B,B,B	T,T,T,T,T	11.74	605232 [WNK1 (confirmed) Pseudohypoaldosteronism,type IIC,614492|Neuropathy,hereditary sensory and autonomic,type II,201300];	RCV000126341.2 [benign]; RCV000274665.1 [benign]; RCV000369345.1 [benign]; 		COSM3753517, COSM3753516	36	329					WNK1 (inh=AR+AD pLI=1.00)
chr12	939302	939302	A	G	hom	hom	hom		QUAL=33876;DP=255,395,412;MQM=60	WNK1	synonymous	WNK1:NM_001184985.1:synonymous:LOW:exon4/28:c.1287A>G:p.Ala429Ala,WNK1:NM_014823.2:synonymous:LOW:exon4/26:c.1287A>G:p.Ala429Ala,WNK1:NM_018979.3:synonymous:LOW:exon4/28:c.1287A>G:p.Ala429Ala,WNK1:NM_213655.4:synonymous:LOW:exon4/28:c.1287A>G:p.Ala429Ala		rs10774466	0.6935	0.7451	34121/19376/1544	0.7283							605232 [WNK1 (confirmed) Pseudohypoaldosteronism,type IIC,614492|Neuropathy,hereditary sensory and autonomic,type II,201300];	RCV000243912.1 [benign]; RCV000338242.1 [benign]; RCV000374093.1 [benign]; 		COSM3753538	845	604					WNK1 (inh=AR+AD pLI=1.00)
chr12	968489	968489	T	C	het	wt	het		QUAL=4595;DP=250,172,210;MQM=60	WNK1	synonymous	WNK1:NM_001184985.1:synonymous:LOW:exon6/28:c.1479T>C:p.Asp493Asp,WNK1:NM_014823.2:synonymous:LOW:exon6/26:c.1479T>C:p.Asp493Asp,WNK1:NM_018979.3:synonymous:LOW:exon6/28:c.1479T>C:p.Asp493Asp,WNK1:NM_213655.4:synonymous:LOW:exon6/28:c.1479T>C:p.Asp493Asp		rs2286006	0.0935	0.1488	1643/1002/17	0.1418							605232 [WNK1 (confirmed) Pseudohypoaldosteronism,type IIC,614492|Neuropathy,hereditary sensory and autonomic,type II,201300];	RCV000126337.2 [benign]; RCV000312056.1 [benign]; RCV000369034.1 [benign]; 		COSM3753547, COSM3753546	54	418					WNK1 (inh=AR+AD pLI=1.00)
chr12	974308	974308	-	C	wt	het	het	anno_high_impact	QUAL=3482;DP=199,122,183;MQM=59	WNK1	frameshift,intron	WNK1:NM_213655.4:frameshift:HIGH:exon9/28:c.2175dupC:p.Ile726fs,WNK1:NM_001184985.1:intron:MODIFIER:exon8/27:c.2140-2721dupC:,WNK1:NM_014823.2:intron:MODIFIER:exon8/25:c.2139+2875dupC:,WNK1:NM_018979.3:intron:MODIFIER:exon8/27:c.2139+2875dupC:		rs141823469;rs35706572	0.0000	0.3039	528/268/13	0.0456							605232 [WNK1 (confirmed) Pseudohypoaldosteronism,type IIC,614492|Neuropathy,hereditary sensory and autonomic,type II,201300];				165	624	1	[1] old entry - no details available			WNK1 (inh=AR+AD pLI=1.00)
chr12	974355	974355	-	C	hom	het	hom	anno_high_impact	QUAL=11265;DP=145,135,199;MQM=59	WNK1	frameshift,intron	WNK1:NM_213655.4:frameshift:HIGH:exon9/28:c.2220dupC:p.Phe741fs,WNK1:NM_001184985.1:intron:MODIFIER:exon8/27:c.2140-2676dupC:,WNK1:NM_014823.2:intron:MODIFIER:exon8/25:c.2139+2920dupC:,WNK1:NM_018979.3:intron:MODIFIER:exon8/27:c.2139+2920dupC:		rs397768556	0.5184	0.5445	1852/575/64	0.1412							605232 [WNK1 (confirmed) Pseudohypoaldosteronism,type IIC,614492|Neuropathy,hereditary sensory and autonomic,type II,201300];				519	656	1	[1] auto-classification 16.06.2016  [2] old entry - no details available			WNK1 (inh=AR+AD pLI=1.00)
chr12	974404	974404	T	C	hom	hom	het		QUAL=17910;DP=227,227,363;MQM=59	WNK1	synonymous,intron	WNK1:NM_213655.4:synonymous:LOW:exon9/28:c.2268T>C:p.Pro756Pro,WNK1:NM_001184985.1:intron:MODIFIER:exon8/27:c.2140-2628T>C:,WNK1:NM_014823.2:intron:MODIFIER:exon8/25:c.2139+2968T>C:,WNK1:NM_018979.3:intron:MODIFIER:exon8/27:c.2139+2968T>C:		rs7300829	0.6540	0.6031	2301/609/144	0.1660							605232 [WNK1 (confirmed) Pseudohypoaldosteronism,type IIC,614492|Neuropathy,hereditary sensory and autonomic,type II,201300];				474	665					WNK1 (inh=AR+AD pLI=1.00)
chr12	987482	987482	G	A	hom	hom	hom		QUAL=10681;DP=172,66,101;MQM=59	WNK1	synonymous	WNK1:NM_001184985.1:synonymous:LOW:exon11/28:c.3567G>A:p.Gln1189Gln,WNK1:NM_014823.2:synonymous:LOW:exon10/26:c.2325G>A:p.Gln775Gln,WNK1:NM_018979.3:synonymous:LOW:exon10/28:c.2328G>A:p.Gln776Gln,WNK1:NM_213655.4:synonymous:LOW:exon12/28:c.3822G>A:p.Gln1274Gln		rs1012729	0.6795	0.7340	33053/19022/1583	0.7206	-0.8680		T			4.22	605232 [WNK1 (confirmed) Pseudohypoaldosteronism,type IIC,614492|Neuropathy,hereditary sensory and autonomic,type II,201300];	RCV000249177.1 [benign]; RCV000265691.1 [benign]; RCV000358053.1 [benign]; 		COSM3753549, COSM3753548	815	625					WNK1 (inh=AR+AD pLI=1.00)
chr12	987533	987533	-	T	het	hom	hom		QUAL=1393;DP=111,25,42;MQM=59	WNK1	intron	WNK1:NM_001184985.1:intron:MODIFIER:exon11/27:c.3612+21dupT:,WNK1:NM_014823.2:intron:MODIFIER:exon10/25:c.2370+21dupT:,WNK1:NM_018979.3:intron:MODIFIER:exon10/27:c.2373+21dupT:,WNK1:NM_213655.4:intron:MODIFIER:exon12/27:c.3867+21dupT:		rs398116010;rs570861980;rs5795952	0.4421	0.4607	481/279/35	0.0640							605232 [WNK1 (confirmed) Pseudohypoaldosteronism,type IIC,614492|Neuropathy,hereditary sensory and autonomic,type II,201300];	RCV000202746.1,RCV000202746.1 [benign,benign]; 			235	822					WNK1 (inh=AR+AD pLI=1.00)
chr12	990912	990912	A	C	het	hom	het		QUAL=19731;DP=400,286,374;MQM=60	WNK1	missense	WNK1:NM_001184985.1:missense:MODERATE:exon13/28:c.3946A>C:p.Thr1316Pro,WNK1:NM_014823.2:missense:MODERATE:exon11/26:c.2425A>C:p.Thr809Pro,WNK1:NM_018979.3:missense:MODERATE:exon13/28:c.3166A>C:p.Thr1056Pro,WNK1:NM_213655.4:missense:MODERATE:exon13/28:c.3922A>C:p.Thr1308Pro		rs956868	0.8528	0.8314	42059/23307/3857	0.8287	0.0100	.,T,T,T,T,T,T	T,T	.,B,B,B	.,T,T,T,T,T	0.06	605232 [WNK1 (confirmed) Pseudohypoaldosteronism,type IIC,614492|Neuropathy,hereditary sensory and autonomic,type II,201300];	RCV000251124.1 [benign]; RCV000332623.1 [benign]; RCV000368653.1 [benign]; 	CM065520 [CLASS=DP MUT=REF PHEN="Colorectal cancer increased risk association with" GENE=WNK1]; 		1090	416					WNK1 (inh=AR+AD pLI=1.00)
chr12	993930	993930	C	T	het	hom	het		QUAL=14198;DP=317,215,262;MQM=60	WNK1	synonymous	WNK1:NM_001184985.1:synonymous:LOW:exon19/28:c.4740C>T:p.Asn1580Asn,WNK1:NM_014823.2:synonymous:LOW:exon17/26:c.3219C>T:p.Asn1073Asn,WNK1:NM_018979.3:synonymous:LOW:exon19/28:c.3960C>T:p.Asn1320Asn,WNK1:NM_213655.4:synonymous:LOW:exon19/28:c.4716C>T:p.Asn1572Asn		rs7300444	0.3990	0.4192	10950/6561/457	0.4188							605232 [WNK1 (confirmed) Pseudohypoaldosteronism,type IIC,614492|Neuropathy,hereditary sensory and autonomic,type II,201300];	RCV000126339.2 [benign]; RCV000294740.1 [benign]; RCV000389073.1 [benign]; 		COSM3753553, COSM3753554	274	700					WNK1 (inh=AR+AD pLI=1.00)
chr12	994014	994014	C	T	het	wt	het		QUAL=6000;DP=257,180,223;MQM=59	WNK1	synonymous	WNK1:NM_001184985.1:synonymous:LOW:exon19/28:c.4824C>T:p.Thr1608Thr,WNK1:NM_014823.2:synonymous:LOW:exon17/26:c.3303C>T:p.Thr1101Thr,WNK1:NM_018979.3:synonymous:LOW:exon19/28:c.4044C>T:p.Thr1348Thr,WNK1:NM_213655.4:synonymous:LOW:exon19/28:c.4800C>T:p.Thr1600Thr		rs10849577	0.1158	0.1554	1649/900/14	0.1486							605232 [WNK1 (confirmed) Pseudohypoaldosteronism,type IIC,614492|Neuropathy,hereditary sensory and autonomic,type II,201300];	RCV000126340.2 [benign]; RCV000349618.1 [benign]; RCV000403645.1 [benign]; 		COSM3998995, COSM3998996	53	401					WNK1 (inh=AR+AD pLI=1.00)
chr12	994487	994487	G	C	hom	hom	hom		QUAL=30159;DP=470,190,255;MQM=59	WNK1	missense	WNK1:NM_001184985.1:missense:MODERATE:exon19/28:c.5297G>C:p.Cys1766Ser,WNK1:NM_014823.2:missense:MODERATE:exon17/26:c.3776G>C:p.Cys1259Ser,WNK1:NM_018979.3:missense:MODERATE:exon19/28:c.4517G>C:p.Cys1506Ser,WNK1:NM_213655.4:missense:MODERATE:exon19/28:c.5273G>C:p.Cys1758Ser		rs7955371	0.9868	0.9963	60269/33358/4809	0.9326	0.1530	T,T,T,T,T,T	T	B,B,B	T,T,T,T,T	0.01	605232 [WNK1 (confirmed) Pseudohypoaldosteronism,type IIC,614492|Neuropathy,hereditary sensory and autonomic,type II,201300];	RCV000246878.1 [benign]; RCV000263201.1 [benign]; RCV000318455.1 [benign]; 			1564	2					WNK1 (inh=AR+AD pLI=1.00)
chr12	999638	999638	C	T	wt	het	het	pred_pathogenic	QUAL=5502;DP=324,242,305;MQM=60	WNK1	missense	WNK1:NM_001184985.1:missense:MODERATE:exon22/28:c.6248C>T:p.Pro2083Leu,WNK1:NM_014823.2:missense:MODERATE:exon20/26:c.4727C>T:p.Pro1576Leu,WNK1:NM_018979.3:missense:MODERATE:exon22/28:c.5468C>T:p.Pro1823Leu,WNK1:NM_213655.4:missense:MODERATE:exon22/28:c.6224C>T:p.Pro2075Leu		rs17755373	0.0220	0.0167	42/17/0	0.0156	3.7020	D,D,D,D,D,D	T	P,B,B	T,T,T,T,T	19.30	605232 [WNK1 (confirmed) Pseudohypoaldosteronism,type IIC,614492|Neuropathy,hereditary sensory and autonomic,type II,201300];	RCV000297008.1 [benign]; RCV000370115.1 [benign]; 			4	58					WNK1 (inh=AR+AD pLI=1.00)
chr12	1003758	1003766	CAACTAGTT	-	wt	het	wt		QUAL=1617;DP=280,123,135;MQM=60	WNK1	conservative_inframe_deletion	WNK1:NM_001184985.1:conservative_inframe_deletion:MODERATE:exon23/28:c.6322_6330delACTAGTTCA:p.Thr2108_Ser2110del,WNK1:NM_014823.2:conservative_inframe_deletion:MODERATE:exon21/26:c.4798_4806delACTAGTTCA:p.Thr1600_Ser1602del,WNK1:NM_018979.3:conservative_inframe_deletion:MODERATE:exon23/28:c.5542_5550delACTAGTTCA:p.Thr1848_Ser1850del,WNK1:NM_213655.4:conservative_inframe_deletion:MODERATE:exon23/28:c.6298_6306delACTAGTTCA:p.Thr2100_Ser2102del		rs544395150	0.0032	0.0033	2/1/0	0.0029							605232 [WNK1 (confirmed) Pseudohypoaldosteronism,type IIC,614492|Neuropathy,hereditary sensory and autonomic,type II,201300];				1	13					WNK1 (inh=AR+AD pLI=1.00)
chr12	1017197	1017197	C	T	hom	hom	hom		QUAL=26695;DP=206,274,373;MQM=60	WNK1	sequence_feature,synonymous	WNK1:NM_001184985.1:sequence_feature:MODERATE:exon27/28:c.7608C>T:,WNK1:NM_018979.3:sequence_feature:MODERATE:exon27/28:c.6828C>T:,WNK1:NM_213655.4:sequence_feature:MODERATE:exon27/28:c.7584C>T:,WNK1:NM_001184985.1:synonymous:LOW:exon27/28:c.7608C>T:p.Tyr2536Tyr,WNK1:NM_014823.2:synonymous:LOW:exon25/26:c.6084C>T:p.Tyr2028Tyr,WNK1:NM_018979.3:synonymous:LOW:exon27/28:c.6828C>T:p.Tyr2276Tyr,WNK1:NM_213655.4:synonymous:LOW:exon27/28:c.7584C>T:p.Tyr2528Tyr		rs4766334	0.9870	0.9964	59903/33156/4714	0.9392							605232 [WNK1 (confirmed) Pseudohypoaldosteronism,type IIC,614492|Neuropathy,hereditary sensory and autonomic,type II,201300];	RCV000242168.1 [benign]; RCV000267038.1 [benign]; RCV000326897.1 [benign]; 		COSM4146468, COSM4146469	1562	3					WNK1 (inh=AR+AD pLI=1.00)
chr12	1019453	1019453	-	ATC	het	hom	het		QUAL=12313;DP=353,150,239;MQM=59	WNK1	3'UTR	WNK1:NM_001184985.1:3'UTR:MODIFIER:exon28/28:c.*1496_*1498dupATC:,WNK1:NM_014823.2:3'UTR:MODIFIER:exon26/26:c.*1496_*1498dupATC:,WNK1:NM_018979.3:3'UTR:MODIFIER:exon28/28:c.*1496_*1498dupATC:,WNK1:NM_213655.4:3'UTR:MODIFIER:exon28/28:c.*1496_*1498dupATC:		rs3072752;rs397783428	0.0000	0.0000	0/0/0	0.2928							605232 [WNK1 (confirmed) Pseudohypoaldosteronism,type IIC,614492|Neuropathy,hereditary sensory and autonomic,type II,201300];				24	99					WNK1 (inh=AR+AD pLI=1.00)
chr12	1019944	1019944	G	A	hom	hom	hom		QUAL=25808;DP=339,203,244;MQM=60	WNK1	3'UTR	WNK1:NM_001184985.1:3'UTR:MODIFIER:exon28/28:c.*1986G>A:,WNK1:NM_014823.2:3'UTR:MODIFIER:exon26/26:c.*1986G>A:,WNK1:NM_018979.3:3'UTR:MODIFIER:exon28/28:c.*1986G>A:,WNK1:NM_213655.4:3'UTR:MODIFIER:exon28/28:c.*1986G>A:		rs2023944	0.9872	0.0000	0/0/0	0.1488							605232 [WNK1 (confirmed) Pseudohypoaldosteronism,type IIC,614492|Neuropathy,hereditary sensory and autonomic,type II,201300];	RCV000285694.1 [benign]; RCV000406509.1 [benign]; 			230	0					WNK1 (inh=AR+AD pLI=1.00)
chr12	1020266	1020266	T	C	het	wt	het		QUAL=8066;DP=391,149,213;MQM=60	WNK1	3'UTR	WNK1:NM_001184985.1:3'UTR:MODIFIER:exon28/28:c.*2308T>C:,WNK1:NM_014823.2:3'UTR:MODIFIER:exon26/26:c.*2308T>C:,WNK1:NM_018979.3:3'UTR:MODIFIER:exon28/28:c.*2308T>C:,WNK1:NM_213655.4:3'UTR:MODIFIER:exon28/28:c.*2308T>C:		rs1060499	0.1192	0.0000	0/0/0	0.0233							605232 [WNK1 (confirmed) Pseudohypoaldosteronism,type IIC,614492|Neuropathy,hereditary sensory and autonomic,type II,201300];	RCV000290908.1 [benign]; RCV000382968.1 [benign]; 			9	69					WNK1 (inh=AR+AD pLI=1.00)
chr12	1020371	1020371	G	T	wt	het	het		QUAL=2990;DP=242,95,145;MQM=60	WNK1	3'UTR	WNK1:NM_001184985.1:3'UTR:MODIFIER:exon28/28:c.*2413G>T:,WNK1:NM_014823.2:3'UTR:MODIFIER:exon26/26:c.*2413G>T:,WNK1:NM_018979.3:3'UTR:MODIFIER:exon28/28:c.*2413G>T:,WNK1:NM_213655.4:3'UTR:MODIFIER:exon28/28:c.*2413G>T:		rs11571497	0.0214	0.0000	0/0/0	0.0121							605232 [WNK1 (confirmed) Pseudohypoaldosteronism,type IIC,614492|Neuropathy,hereditary sensory and autonomic,type II,201300];	RCV000266532.1 [likely benign]; RCV000358406.1 [likely benign]; 			0	4					WNK1 (inh=AR+AD pLI=1.00)
chr12	5020435	5020435	G	A	het	het	wt		QUAL=1067;DP=59,49,86;MQM=60	KCNA1	5'UTR	KCNA1:NM_000217.2:5'UTR:MODIFIER:exon2/2:c.-110G>A:		rs35678382	0.1583	0.0000	0/0/0	0.1309							176260 [KCNA1 (confirmed) Episodic ataxia/myokymia syndrome,160120];	RCV000331891.1 [benign]; RCV000367845.1 [benign]; 			6	50					KCNA1 (inh=AD pLI=0.05)
chr12	5021348	5021348	G	C	wt	het	wt		QUAL=3926;DP=221,280,383;MQM=60	KCNA1	synonymous	KCNA1:NM_000217.2:synonymous:LOW:exon2/2:c.804G>C:p.Thr268Thr		rs2227910	0.5333	0.5256	16995/8876/1081	0.5217							176260 [KCNA1 (confirmed) Episodic ataxia/myokymia syndrome,160120];	RCV000020222.1 [benign]; RCV000117316.2 [likely benign]; RCV000343851.1 [benign]; RCV000391589.1 [benign]; 			713	1326	1	[1] Julia Bickmann 23.09.2014	n/a (1xTP, 0xFP)		KCNA1 (inh=AD pLI=0.05)
chr12	5021984	5021984	T	A	het	hom	wt		QUAL=14967;DP=262,360,427;MQM=60	KCNA1	synonymous	KCNA1:NM_000217.2:synonymous:LOW:exon2/2:c.1440T>A:p.Thr480Thr		rs4766309	0.8205	0.7385	33542/15798/3831	0.7071							176260 [KCNA1 (confirmed) Episodic ataxia/myokymia syndrome,160120];	RCV000117314.4 [other]; RCV000297286.1 [benign]; RCV000361409.1 [benign]; 			1269	1174	1	[1] Julia Bickmann 23.09.2014	n/a (1xTP, 0xFP)		KCNA1 (inh=AD pLI=0.05)
chr12	5023556	5023556	A	G	wt	het	wt		QUAL=1899;DP=284,135,169;MQM=60	KCNA1	3'UTR	KCNA1:NM_000217.2:3'UTR:MODIFIER:exon2/2:c.*1524A>G:		rs79357862	0.0495	0.0000	0/0/0	0.0430							176260 [KCNA1 (confirmed) Episodic ataxia/myokymia syndrome,160120];	RCV000289171.1 [benign]; RCV000351088.1 [benign]; 			1	21					KCNA1 (inh=AD pLI=0.05)
chr12	5024365	5024365	G	A	wt	het	wt		QUAL=1968;DP=189,171,251;MQM=60	KCNA1	3'UTR	KCNA1:NM_000217.2:3'UTR:MODIFIER:exon2/2:c.*2333G>A:		rs2109420	0.0723	0.0000	0/0/0	0.0086							176260 [KCNA1 (confirmed) Episodic ataxia/myokymia syndrome,160120];	RCV000331933.1 [benign]; RCV000388826.1 [benign]; 			1	20					KCNA1 (inh=AD pLI=0.05)
chr12	5026471	5026471	C	T	het	hom	wt		QUAL=13343;DP=356,269,339;MQM=60	KCNA1	3'UTR	KCNA1:NM_000217.2:3'UTR:MODIFIER:exon2/2:c.*4439C>T:		rs12424292	0.2438	0.0000	0/0/0	0.2186							176260 [KCNA1 (confirmed) Episodic ataxia/myokymia syndrome,160120];	RCV000292257.1 [benign]; RCV000351825.1 [benign]; 			11	73					KCNA1 (inh=AD pLI=0.05)
chr12	5027173	5027173	G	A	wt	het	wt		QUAL=1876;DP=362,175,197;MQM=60	KCNA1	3'UTR	KCNA1:NM_000217.2:3'UTR:MODIFIER:exon2/2:c.*5141G>A:		rs41482147	0.0605	0.0000	0/0/0	0.0470							176260 [KCNA1 (confirmed) Episodic ataxia/myokymia syndrome,160120];	RCV000282033.1 [benign]; RCV000337102.1 [benign]; 			1	23					KCNA1 (inh=AD pLI=0.05)
chr12	6450945	6450945	T	C	wt	het	wt		QUAL=862;DP=214,102,131;MQM=60	TNFRSF1A	synonymous	TNFRSF1A:NM_001065.3:synonymous:LOW:exon1/10:c.36A>G:p.Pro12Pro		rs767455	0.3015	0.3755	9032/6117/652	0.3646							191190 [TNFRSF1A (confirmed) Periodic fever,familial,142680|Multiple sclerosis,susceptibility to,5,614810];	RCV000252192.1 [benign]; RCV000402234.1 [likely benign]; 		COSM431654	283	760					TNFRSF1A (inh=AD pLI=0.99)
chr12	6457062	6457062	T	C	hom	hom	het		QUAL=8153;DP=107,113,131;MQM=59	SCNN1A	missense	SCNN1A:NM_001159576.1:missense:MODERATE:exon12/12:c.2164A>G:p.Thr722Ala,SCNN1A:NM_001038.5:missense:MODERATE:exon13/13:c.1987A>G:p.Thr663Ala,SCNN1A:NM_001159575.1:missense:MODERATE:exon13/13:c.2056A>G:p.Thr686Ala		rs2228576	0.7406	0.7133	22085/10769/2783	0.6427	-0.5860	T,T,T,T,T	T	B,B,B	T,T,T,T,T	0.01	600228 [SCNN1A (confirmed) Pseudohypoaldosteronism,type I,264350|Bronchiectasis with or without elevated sweat chloride 2,613021];	RCV000151811.3 [benign]; RCV000295920.1 [benign]; RCV000325126.1 [benign]; 	CM994637 [CLASS=DFP MUT=ALT PHEN="Hypertension reduced risk association with" GENE=SCNN1A]; 	COSM1747194	789	586					SCNN1A (inh=AR+AD pLI=0.00)
chr12	6472752	6472752	G	A	wt	wt	het	low_DP;pred_pathogenic;anno_pathogenic_hgmd	QUAL=142;DP=9,12,19;MQM=60	SCNN1A	missense	SCNN1A:NM_001159576.1:missense:MODERATE:exon2/12:c.718C>T:p.Arg240Trp,SCNN1A:NM_001038.5:missense:MODERATE:exon3/13:c.541C>T:p.Arg181Trp,SCNN1A:NM_001159575.1:missense:MODERATE:exon3/13:c.610C>T:p.Arg204Trp		rs55797039	0.0072	0.0202	20/14/0	0.0166	-1.8330	D,D,D,D,D	T	P,P,P	T,T,T,T,T	24.80	600228 [SCNN1A (confirmed) Pseudohypoaldosteronism,type I,264350|Bronchiectasis with or without elevated sweat chloride 2,613021];	RCV000177108.1 [benign]; RCV000303655.1 [likely benign]; RCV000360696.1 [likely benign]; 	CM055536 [CLASS=DM? MUT=ALT PHEN="Cystic fibrosis non-classic" GENE=SCNN1A]; 		2	71					SCNN1A (inh=AR+AD pLI=0.00)
chr12	6472753	6472753	C	A	wt	wt	het	low_DP	QUAL=142;DP=9,12,19;MQM=60	SCNN1A	synonymous	SCNN1A:NM_001159576.1:synonymous:LOW:exon2/12:c.717G>T:p.Leu239Leu,SCNN1A:NM_001038.5:synonymous:LOW:exon3/13:c.540G>T:p.Leu180Leu,SCNN1A:NM_001159575.1:synonymous:LOW:exon3/13:c.609G>T:p.Leu203Leu		rs55859427	0.0072	0.0202	20/14/0	0.0166							600228 [SCNN1A (confirmed) Pseudohypoaldosteronism,type I,264350|Bronchiectasis with or without elevated sweat chloride 2,613021];	RCV000177107.1 [benign]; RCV000297832.1 [likely benign]; RCV000390365.1 [likely benign]; 			2	71					SCNN1A (inh=AR+AD pLI=0.00)
chr12	6484709	6484709	T	C	het	wt	hom		QUAL=1098;DP=22,30,29;MQM=60	SCNN1A,LTBR	5'UTR,intron	SCNN1A:NM_001038.5:5'UTR:MODIFIER:exon1/13:c.-93A>G:,LTBR:NM_001270987.1:5'UTR:MODIFIER:exon1/10:c.-13T>C:,SCNN1A:NM_001159575.1:intron:MODIFIER:exon1/12:c.16-706A>G:		rs10849447	0.7568	0.5820	1920/204/73	0.1404							600228 [SCNN1A (confirmed) Pseudohypoaldosteronism,type I,264350|Bronchiectasis with or without elevated sweat chloride 2,613021];	RCV000299434.1 [benign]; RCV000356647.1 [benign]; 			261	452					SCNN1A (inh=AR+AD pLI=0.00), LTBR (inh=n/a pLI=0.43)
chr12	6976650	6976650	C	T	wt	het	wt	low_QUAL;low_DP	QUAL=27;DP=13,13,20;MQM=60	TPI1	missense	TPI1:NM_001159287.1:missense:MODERATE:exon1/7:c.31C>T:p.His11Tyr		rs781949460	0.0006	0.0028	1/1/0	0.0008	-0.1440	T	T			7.97	190450 [TPI1 (confirmed) Hemolytic anemia due to triosephosphate isomerase deficiency,615512];				0	5					TPI1 (inh=n/a pLI=0.58)
chr12	7045178	7045178	G	A	het	het	wt	pred_pathogenic	QUAL=918;DP=29,55,69;MQM=60	ATN1	missense	ATN1:NM_001007026.1:missense:MODERATE:exon5/10:c.748G>A:p.Gly250Ser,ATN1:NM_001940.3:missense:MODERATE:exon5/10:c.748G>A:p.Gly250Ser		rs148694613	0.0030	0.0067	5/5/0	0.0065	2.6350	D,D,D	T	B,B	T,T,T	18.73	607462 [ATN1 (confirmed) Dentatorubro-pallidoluysian atrophy,125370];				0	22					ATN1 (inh=AD pLI=1.00)
chr12	7045892	7045912	CAGCAGCAGCAGCAGCAGCAG	-	wt	het	wt	low_DP	QUAL=3133;DP=4,184,234;MQM=59	ATN1	disruptive_inframe_deletion	ATN1:NM_001007026.1:disruptive_inframe_deletion:MODERATE:exon5/10:c.1488_1508delGCAGCAGCAGCAGCAGCAGCA:p.Gln496_Gln502del,ATN1:NM_001940.3:disruptive_inframe_deletion:MODERATE:exon5/10:c.1488_1508delGCAGCAGCAGCAGCAGCAGCA:p.Gln496_Gln502del	(CAG)n		0.0000	0.0000	0/0/0	0.0025							607462 [ATN1 (confirmed) Dentatorubro-pallidoluysian atrophy,125370];			COSM1476884	99	221	2	[2] Stefanie Beck-Woedl 04.12.2014			ATN1 (inh=AD pLI=1.00)
chr12	7045892	7045894	CAG	-	wt	het	wt	low_DP	QUAL=3133;DP=4,184,234;MQM=60	ATN1	disruptive_inframe_deletion	ATN1:NM_001007026.1:disruptive_inframe_deletion:MODERATE:exon5/10:c.1506_1508delGCA:p.Gln502del,ATN1:NM_001940.3:disruptive_inframe_deletion:MODERATE:exon5/10:c.1506_1508delGCA:p.Gln502del	(CAG)n		0.0000	0.0000	0/0/0	0.0006							607462 [ATN1 (confirmed) Dentatorubro-pallidoluysian atrophy,125370];			COSM431782	39	74					ATN1 (inh=AD pLI=1.00)
chr12	7048292	7048292	C	T	het	wt	wt	pred_pathogenic	QUAL=2234;DP=215,303,420;MQM=60	ATN1	missense	ATN1:NM_001007026.1:missense:MODERATE:exon7/10:c.3166C>T:p.His1056Tyr,ATN1:NM_001940.3:missense:MODERATE:exon7/10:c.3166C>T:p.His1056Tyr	(CACCAG)n		0.0000	0.0000	0/0/0	0.0000	7.6510	D,D,D,D	D	P	D,D,D	28.60	607462 [ATN1 (confirmed) Dentatorubro-pallidoluysian atrophy,125370];				0	1					ATN1 (inh=AD pLI=1.00)
chr12	7242204	7242204	C	T	het	hom	wt	pred_pathogenic	QUAL=3000;DP=121,69,94;MQM=60	C1R	missense	C1R:NM_001733.4:missense:MODERATE:exon4/9:c.550G>A:p.Glu184Lys		rs1126605	0.1749	0.1174	1215/265/109	0.1168	-0.4440	T,T,T,T,T,T	T	B,B,B	D,D	0.01	613785 [C1R (confirmed) Ehlers-Danlos syndrome,periodontal type,1,130080];				20	256					C1R (inh=AR pLI=n/a)
chr12	7242299	7242299	G	A	het	wt	het	pred_pathogenic	QUAL=2242;DP=125,61,74;MQM=59	C1R	missense	C1R:NM_001733.4:missense:MODERATE:exon4/9:c.455C>T:p.Ser152Leu		rs1801046	0.2392	0.2337	3593/1941/159	0.2303	0.0160	T,T,T,T,T,T,T,T,T	T	B,B,B	D,D,D,T,T	8.17	613785 [C1R (confirmed) Ehlers-Danlos syndrome,periodontal type,1,130080];				80	552					C1R (inh=AR pLI=n/a)
chr12	7343109	7343153	GCCTCTGAGGCAGTGAGTGTTCTTGAGGTGGAAAGCCCAGGTGCA	-	wt	het	het		QUAL=213;DP=22,38,54;MQM=59	PEX5	sequence_feature,intron	PEX5:NM_001131023.1:sequence_feature:MODERATE:exon2/16:c.136_180delGCCTCTGAGGCAGTGAGTGTTCTTGAGGTGGAAAGCCCAGGTGCA:,PEX5:NM_001300789.1:intron:MODIFIER:exon2/15:c.210+77_210+121delCAGCCTCTGAGGCAGTGAGTGTTCTTGAGGTGGAAAGCCCAGGTG:,PEX5:NM_001131026.1:intron:MODIFIER:exon3/17:c.147+77_147+121delCAGCCTCTGAGGCAGTGAGTGTTCTTGAGGTGGAAAGCCCAGGTG:,PEX5:NM_001131023.1:intron:MODIFIER:exon2/15:c.192+32_192+76delCAGCCTCTGAGGCAGTGAGTGTTCTTGAGGTGGAAAGCCCAGGTG:,PEX5:NM_001131024.1:intron:MODIFIER:exon2/14:c.147+77_147+121delCAGCCTCTGAGGCAGTGAGTGTTCTTGAGGTGGAAAGCCCAGGTG:,PEX5:NM_001131025.1:intron:MODIFIER:exon2/15:c.147+77_147+121delCAGCCTCTGAGGCAGTGAGTGTTCTTGAGGTGGAAAGCCCAGGTG:,PEX5:NM_000319.4:intron:MODIFIER:exon1/14:c.147+77_147+121delCAGCCTCTGAGGCAGTGAGTGTTCTTGAGGTGGAAAGCCCAGGTG:		rs757612863	0.0000	0.0001	0/0/0	0.0001							600414 [PEX5 (confirmed) Peroxisome biogenesis disorder 2A (Zellweger),214110|Peroxisome biogenesis disorder 2B,202370|Rhizomelic chondrodysplasia punctata,type 5,616716];				0	223	2	[2] Ute Grasshoff 22.04.2015			PEX5 (inh=AR pLI=0.40)
chr12	7363447	7363447	G	A	wt	wt	het		QUAL=4244;DP=200,307,326;MQM=60	PEX5	3'UTR,intron	PEX5:NM_001300789.1:3'UTR:MODIFIER:exon16/16:c.*628G>A:,PEX5:NM_001131023.1:3'UTR:MODIFIER:exon16/16:c.*628G>A:,PEX5:NM_001131024.1:3'UTR:MODIFIER:exon15/15:c.*628G>A:,PEX5:NM_001131025.1:3'UTR:MODIFIER:exon16/16:c.*628G>A:,PEX5:NM_000319.4:3'UTR:MODIFIER:exon15/15:c.*628G>A:,PEX5:NM_001131026.1:intron:MODIFIER:exon17/17:c.*19+609G>A:		rs12316371	0.0925	0.0000	0/0/0	0.0788							600414 [PEX5 (confirmed) Peroxisome biogenesis disorder 2A (Zellweger),214110|Peroxisome biogenesis disorder 2B,202370|Rhizomelic chondrodysplasia punctata,type 5,616716];	RCV000370847.1 [likely benign]; 			1	28					PEX5 (inh=AR pLI=0.40)
chr12	7363574	7363574	C	G	het	hom	wt		QUAL=11760;DP=280,261,270;MQM=59	PEX5	3'UTR,intron	PEX5:NM_001300789.1:3'UTR:MODIFIER:exon16/16:c.*755C>G:,PEX5:NM_001131023.1:3'UTR:MODIFIER:exon16/16:c.*755C>G:,PEX5:NM_001131024.1:3'UTR:MODIFIER:exon15/15:c.*755C>G:,PEX5:NM_001131025.1:3'UTR:MODIFIER:exon16/16:c.*755C>G:,PEX5:NM_000319.4:3'UTR:MODIFIER:exon15/15:c.*755C>G:,PEX5:NM_001131026.1:intron:MODIFIER:exon17/17:c.*19+736C>G:		rs1057225	0.4321	0.0000	0/0/0	0.4912							600414 [PEX5 (confirmed) Peroxisome biogenesis disorder 2A (Zellweger),214110|Peroxisome biogenesis disorder 2B,202370|Rhizomelic chondrodysplasia punctata,type 5,616716];	RCV000374463.1 [benign]; 			39	70					PEX5 (inh=AR pLI=0.40)
chr12	7363943	7363943	-	T	wt	wt	het		QUAL=815;DP=202,54,79;MQM=60	PEX5	3'UTR,intron	PEX5:NM_001300789.1:3'UTR:MODIFIER:exon16/16:c.*1134dupT:,PEX5:NM_001131023.1:3'UTR:MODIFIER:exon16/16:c.*1134dupT:,PEX5:NM_001131024.1:3'UTR:MODIFIER:exon15/15:c.*1134dupT:,PEX5:NM_001131025.1:3'UTR:MODIFIER:exon16/16:c.*1134dupT:,PEX5:NM_000319.4:3'UTR:MODIFIER:exon15/15:c.*1134dupT:,PEX5:NM_001131026.1:intron:MODIFIER:exon17/17:c.*19+1115dupT:		rs11448434	0.3169	0.0000	0/0/0	0.1979							600414 [PEX5 (confirmed) Peroxisome biogenesis disorder 2A (Zellweger),214110|Peroxisome biogenesis disorder 2B,202370|Rhizomelic chondrodysplasia punctata,type 5,616716];	RCV000288679.1 [benign]; 			10	61					PEX5 (inh=AR pLI=0.40)
chr12	8755737	8755737	C	T	hom	hom	hom	low_DP	QUAL=3179;DP=24,15,27;MQM=60	AICDA	3'UTR	AICDA:NM_020661.2:3'UTR:MODIFIER:exon5/5:c.*1143G>A:	(TTCTCT)n		0.0000	0.0000	0/0/0	0.0001							605257 [AICDA (confirmed) Immunodeficiency with hyper-IgM,type 2,605258];				0	0					AICDA (inh=AR pLI=0.00)
chr12	8756791	8756791	T	G	wt	wt	het		QUAL=3803;DP=322,220,310;MQM=60	AICDA	3'UTR	AICDA:NM_020661.2:3'UTR:MODIFIER:exon5/5:c.*89A>C:		rs11046349	0.2302	0.0000	0/0/0	0.0219							605257 [AICDA (confirmed) Immunodeficiency with hyper-IgM,type 2,605258];	RCV000375584.1 [benign]; 			5	28					AICDA (inh=AR pLI=0.00)
chr12	8757481	8757481	G	A	het	het	het		QUAL=2804;DP=195,31,70;MQM=59	AICDA	synonymous	AICDA:NM_020661.2:synonymous:LOW:exon4/5:c.465C>T:p.His155His		rs2028373	0.4842	0.5904	21560/13501/541	0.5602	-0.1680		T			2.15	605257 [AICDA (confirmed) Immunodeficiency with hyper-IgM,type 2,605258];	RCV000242942.2 [benign]; RCV000317701.1 [benign]; 			594	688					AICDA (inh=AR pLI=0.00)
chr12	8757522	8757522	-	A	hom	hom	hom	low_DP	QUAL=911;DP=36,11,30;MQM=59	AICDA	splice_region&intron	AICDA:NM_020661.2:splice_region&intron:LOW:exon3/4:c.428-5dupT:		rs397718057;rs5796316	0.6424	0.5635	6110/3495/306	0.0883							605257 [AICDA (confirmed) Immunodeficiency with hyper-IgM,type 2,605258];	RCV000348506.1 [uncertain significance]; RCV000295883.1 [benign]; 			398	623	1	[1] old entry - no details available			AICDA (inh=AR pLI=0.00)
chr12	8765447	8765447	T	C	hom	hom	hom		QUAL=34885;DP=384,284,413;MQM=60	AICDA-MFAP5	intergenic_region	AICDA-MFAP5:AICDA-MFAP5:intergenic_region:MODIFIER::n.8765447T>C:		rs1345004	0.9954	0.0000	0/0/0	0.1526							605257 [AICDA (confirmed) Immunodeficiency with hyper-IgM,type 2,605258];	RCV000269201.1 [benign]; 			398	0					AICDA-MFAP5 (inh=n/a pLI=n/a)
chr12	13714729	13714729	T	C	hom	hom	hom		QUAL=28867;DP=407,205,270;MQM=59	GRIN2B	3'UTR	GRIN2B:NM_000834.3:3'UTR:MODIFIER:exon13/13:c.*988A>G:		rs1805477	0.8914	0.0000	0/0/0	0.1446							138252 [GRIN2B (provisional) Mental retardation,autosomal dominant 6,613970|Epileptic encephalopathy,early infantile,27,616139];	RCV000389607.1 [likely benign]; 			423	3					GRIN2B (inh=AD pLI=1.00)
chr12	13715308	13715308	A	C	het	het	wt		QUAL=8140;DP=414,203,308;MQM=60	GRIN2B	3'UTR	GRIN2B:NM_000834.3:3'UTR:MODIFIER:exon13/13:c.*409T>G:		rs890	0.2750	0.0000	0/0/0	0.0719							138252 [GRIN2B (provisional) Mental retardation,autosomal dominant 6,613970|Epileptic encephalopathy,early infantile,27,616139];	RCV000339902.1 [likely benign]; 			98	222					GRIN2B (inh=AD pLI=1.00)
chr12	13716638	13716638	G	A	het	wt	het		QUAL=6448;DP=238,306,350;MQM=59	GRIN2B	synonymous	GRIN2B:NM_000834.3:synonymous:LOW:exon13/13:c.3534C>T:p.His1178His		rs1806191	0.2476	0.3915	10739/8298/201	0.3914							138252 [GRIN2B (provisional) Mental retardation,autosomal dominant 6,613970|Epileptic encephalopathy,early infantile,27,616139];	RCV000117197.2 [likely benign]; RCV000313654.1 [likely benign]; 		COSM4146926	402	854					GRIN2B (inh=AD pLI=1.00)
chr12	13717508	13717508	G	A	wt	het	het		QUAL=5480;DP=222,198,291;MQM=60	GRIN2B	synonymous	GRIN2B:NM_000834.3:synonymous:LOW:exon13/13:c.2664C>T:p.Thr888Thr		rs1806201	0.3033	0.3102	6410/2495/62	0.3038							138252 [GRIN2B (provisional) Mental retardation,autosomal dominant 6,613970|Epileptic encephalopathy,early infantile,27,616139];	RCV000084728.1 [not provided]; RCV000117194.2 [likely benign]; RCV000377659.1 [likely benign]; 	CM074898 [CLASS=DP MUT=ALT PHEN="Huntington disease earlier onset in females association with" GENE=GRIN2B]; 	COSM430806	155	667					GRIN2B (inh=AD pLI=1.00)
chr12	14018777	14018777	G	C	wt	het	het		QUAL=4409;DP=197,163,223;MQM=60	GRIN2B	synonymous	GRIN2B:NM_000834.3:synonymous:LOW:exon2/13:c.366C>G:p.Pro122Pro		rs7301328	0.4415	0.4172	10950/5277/1331	0.4113							138252 [GRIN2B (provisional) Mental retardation,autosomal dominant 6,613970|Epileptic encephalopathy,early infantile,27,616139];	RCV000117198.3 [other]; RCV000259325.1 [likely benign]; 	CM014358 [CLASS=DP MUT=ALT PHEN="Schizophrenia association with" GENE=GRIN2B]; 		319	797					GRIN2B (inh=AD pLI=1.00)
chr12	14019157	14019157	C	T	het	wt	het		QUAL=1380;DP=79,47,54;MQM=59	GRIN2B	5'UTR	GRIN2B:NM_000834.3:5'UTR:MODIFIER:exon2/13:c.-15G>A:		rs12818068	0.0379	0.0820	509/440/1	0.0792							138252 [GRIN2B (provisional) Mental retardation,autosomal dominant 6,613970|Epileptic encephalopathy,early infantile,27,616139];	RCV000125318.2 [benign]; RCV000289774.1 [likely benign]; 			13	203					GRIN2B (inh=AD pLI=1.00)
chr12	25358650	25358650	A	T	hom	hom	het		QUAL=10937;DP=265,47,64;MQM=57	KRAS	3'UTR	KRAS:NM_033360.3:3'UTR:MODIFIER:exon6/6:c.*4200T>A:,KRAS:NM_004985.4:3'UTR:MODIFIER:exon5/5:c.*4079T>A:		rs12245	0.5483	0.0000	0/0/0	0.5422							190070 [KRAS (confirmed) Lung cancer,somatic,211980|Bladder cancer,somatic,109800|Pancreatic carcinoma,somatic,260350|Gastric cancer,somatic,137215|Leukemia,acute myeloid,601626|Noonan syndrome 3,609942|Cardiofaciocutaneous syndrome 2,615278|Breast cancer,somatic,114480|Schimmelpenning-Feuerstein-Mims syndrome,somatic mosaic,163200|RAS-associated autoimmune leukoproliferative disorder,614470];	RCV000333232.1 [likely benign]; RCV000366899.1 [likely benign]; 	CR1010511 [CLASS=DP MUT=ALT PHEN="Ovarian cancer increased risk association with" GENE=KRAS]; 		72	128					KRAS (inh=AD pLI=0.00)
chr12	25358663	25358664	TT	-	hom	hom	het		QUAL=8471;DP=235,37,53;MQM=56	KRAS	3'UTR	KRAS:NM_033360.3:3'UTR:MODIFIER:exon6/6:c.*4186_*4187delAA:,KRAS:NM_004985.4:3'UTR:MODIFIER:exon5/5:c.*4065_*4066delAA:		rs57698689;rs796922820	0.5435	0.0000	0/0/0	0.4391							190070 [KRAS (confirmed) Lung cancer,somatic,211980|Bladder cancer,somatic,109800|Pancreatic carcinoma,somatic,260350|Gastric cancer,somatic,137215|Leukemia,acute myeloid,601626|Noonan syndrome 3,609942|Cardiofaciocutaneous syndrome 2,615278|Breast cancer,somatic,114480|Schimmelpenning-Feuerstein-Mims syndrome,somatic mosaic,163200|RAS-associated autoimmune leukoproliferative disorder,614470];	RCV000323439.1 [likely benign]; RCV000380266.1 [likely benign]; 			69	126					KRAS (inh=AD pLI=0.00)
chr12	25358828	25358828	T	G	hom	hom	het		QUAL=7935;DP=143,61,74;MQM=60	KRAS	3'UTR	KRAS:NM_033360.3:3'UTR:MODIFIER:exon6/6:c.*4022A>C:,KRAS:NM_004985.4:3'UTR:MODIFIER:exon5/5:c.*3901A>C:		rs12587	0.5483	0.0000	0/0/0	0.5650							190070 [KRAS (confirmed) Lung cancer,somatic,211980|Bladder cancer,somatic,109800|Pancreatic carcinoma,somatic,260350|Gastric cancer,somatic,137215|Leukemia,acute myeloid,601626|Noonan syndrome 3,609942|Cardiofaciocutaneous syndrome 2,615278|Breast cancer,somatic,114480|Schimmelpenning-Feuerstein-Mims syndrome,somatic mosaic,163200|RAS-associated autoimmune leukoproliferative disorder,614470];	RCV000282245.1 [likely benign]; RCV000401125.1 [likely benign]; 			67	128					KRAS (inh=AD pLI=0.00)
chr12	25358943	25358943	T	C	hom	hom	het		QUAL=15667;DP=367,77,102;MQM=59	KRAS	3'UTR	KRAS:NM_033360.3:3'UTR:MODIFIER:exon6/6:c.*3907A>G:,KRAS:NM_004985.4:3'UTR:MODIFIER:exon5/5:c.*3786A>G:		rs8720	0.5485	0.0000	0/0/0	0.5578							190070 [KRAS (confirmed) Lung cancer,somatic,211980|Bladder cancer,somatic,109800|Pancreatic carcinoma,somatic,260350|Gastric cancer,somatic,137215|Leukemia,acute myeloid,601626|Noonan syndrome 3,609942|Cardiofaciocutaneous syndrome 2,615278|Breast cancer,somatic,114480|Schimmelpenning-Feuerstein-Mims syndrome,somatic mosaic,163200|RAS-associated autoimmune leukoproliferative disorder,614470];	RCV000334990.1 [likely benign]; RCV000401993.1 [likely benign]; 			67	126					KRAS (inh=AD pLI=0.00)
chr12	25358969	25358969	T	G	hom	hom	het		QUAL=12878;DP=297,63,93;MQM=59	KRAS	3'UTR	KRAS:NM_033360.3:3'UTR:MODIFIER:exon6/6:c.*3881A>C:,KRAS:NM_004985.4:3'UTR:MODIFIER:exon5/5:c.*3760A>C:		rs1137196	0.4333	0.0000	0/0/0	0.4646							190070 [KRAS (confirmed) Lung cancer,somatic,211980|Bladder cancer,somatic,109800|Pancreatic carcinoma,somatic,260350|Gastric cancer,somatic,137215|Leukemia,acute myeloid,601626|Noonan syndrome 3,609942|Cardiofaciocutaneous syndrome 2,615278|Breast cancer,somatic,114480|Schimmelpenning-Feuerstein-Mims syndrome,somatic mosaic,163200|RAS-associated autoimmune leukoproliferative disorder,614470];	RCV000314184.1 [likely benign]; RCV000371183.1 [likely benign]; 			53	115					KRAS (inh=AD pLI=0.00)
chr12	25359328	25359328	A	T	hom	hom	het		QUAL=11447;DP=199,93,153;MQM=59	KRAS	3'UTR	KRAS:NM_033360.3:3'UTR:MODIFIER:exon6/6:c.*3522T>A:,KRAS:NM_004985.4:3'UTR:MODIFIER:exon5/5:c.*3401T>A:		rs1137189	0.5481	0.0000	0/0/0	0.0770							190070 [KRAS (confirmed) Lung cancer,somatic,211980|Bladder cancer,somatic,109800|Pancreatic carcinoma,somatic,260350|Gastric cancer,somatic,137215|Leukemia,acute myeloid,601626|Noonan syndrome 3,609942|Cardiofaciocutaneous syndrome 2,615278|Breast cancer,somatic,114480|Schimmelpenning-Feuerstein-Mims syndrome,somatic mosaic,163200|RAS-associated autoimmune leukoproliferative disorder,614470];	RCV000349055.1 [likely benign]; RCV000400744.1 [likely benign]; 			67	128					KRAS (inh=AD pLI=0.00)
chr12	25359352	25359352	G	A	hom	hom	het		QUAL=11558;DP=222,76,136;MQM=59	KRAS	3'UTR	KRAS:NM_033360.3:3'UTR:MODIFIER:exon6/6:c.*3498C>T:,KRAS:NM_004985.4:3'UTR:MODIFIER:exon5/5:c.*3377C>T:		rs1137188	0.5485	0.0000	0/0/0	0.5418							190070 [KRAS (confirmed) Lung cancer,somatic,211980|Bladder cancer,somatic,109800|Pancreatic carcinoma,somatic,260350|Gastric cancer,somatic,137215|Leukemia,acute myeloid,601626|Noonan syndrome 3,609942|Cardiofaciocutaneous syndrome 2,615278|Breast cancer,somatic,114480|Schimmelpenning-Feuerstein-Mims syndrome,somatic mosaic,163200|RAS-associated autoimmune leukoproliferative disorder,614470];	RCV000309178.1 [likely benign]; RCV000347746.1 [likely benign]; 			67	128					KRAS (inh=AD pLI=0.00)
chr12	25359465	25359465	A	-	hom	hom	het		QUAL=14928;DP=310,105,172;MQM=59	KRAS	3'UTR	KRAS:NM_033360.3:3'UTR:MODIFIER:exon6/6:c.*3385delT:,KRAS:NM_004985.4:3'UTR:MODIFIER:exon5/5:c.*3264delT:		rs796285705	0.5485	0.0000	0/0/0	0.4990							190070 [KRAS (confirmed) Lung cancer,somatic,211980|Bladder cancer,somatic,109800|Pancreatic carcinoma,somatic,260350|Gastric cancer,somatic,137215|Leukemia,acute myeloid,601626|Noonan syndrome 3,609942|Cardiofaciocutaneous syndrome 2,615278|Breast cancer,somatic,114480|Schimmelpenning-Feuerstein-Mims syndrome,somatic mosaic,163200|RAS-associated autoimmune leukoproliferative disorder,614470];	RCV000304310.1 [likely benign]; RCV000393670.1 [likely benign]; 			68	128					KRAS (inh=AD pLI=0.00)
chr12	25359841	25359841	T	C	hom	hom	het	low_DP	QUAL=6843;DP=174,18,38;MQM=60	KRAS	3'UTR	KRAS:NM_033360.3:3'UTR:MODIFIER:exon6/6:c.*3009A>G:,KRAS:NM_004985.4:3'UTR:MODIFIER:exon5/5:c.*2888A>G:		rs13096	0.5256	0.0000	0/0/0	0.5579							190070 [KRAS (confirmed) Lung cancer,somatic,211980|Bladder cancer,somatic,109800|Pancreatic carcinoma,somatic,260350|Gastric cancer,somatic,137215|Leukemia,acute myeloid,601626|Noonan syndrome 3,609942|Cardiofaciocutaneous syndrome 2,615278|Breast cancer,somatic,114480|Schimmelpenning-Feuerstein-Mims syndrome,somatic mosaic,163200|RAS-associated autoimmune leukoproliferative disorder,614470];	RCV000333153.1 [likely benign]; RCV000385382.1 [likely benign]; 			66	128					KRAS (inh=AD pLI=0.00)
chr12	25360138	25360138	T	C	hom	hom	hom		QUAL=31421;DP=309,263,405;MQM=59	KRAS	3'UTR	KRAS:NM_033360.3:3'UTR:MODIFIER:exon6/6:c.*2712A>G:,KRAS:NM_004985.4:3'UTR:MODIFIER:exon5/5:c.*2591A>G:	L2a	rs4963858	0.9886	0.0000	0/0/0	0.8760							190070 [KRAS (confirmed) Lung cancer,somatic,211980|Bladder cancer,somatic,109800|Pancreatic carcinoma,somatic,260350|Gastric cancer,somatic,137215|Leukemia,acute myeloid,601626|Noonan syndrome 3,609942|Cardiofaciocutaneous syndrome 2,615278|Breast cancer,somatic,114480|Schimmelpenning-Feuerstein-Mims syndrome,somatic mosaic,163200|RAS-associated autoimmune leukoproliferative disorder,614470];				256	1					KRAS (inh=AD pLI=0.00)
chr12	25360449	25360449	-	A	het	hom	hom		QUAL=4164;DP=136,38,41;MQM=59	KRAS	3'UTR	KRAS:NM_033360.3:3'UTR:MODIFIER:exon6/6:c.*2400dupT:,KRAS:NM_004985.4:3'UTR:MODIFIER:exon5/5:c.*2279dupT:	AluSz	rs397747594	0.8788	0.0000	0/0/0	0.6037							190070 [KRAS (confirmed) Lung cancer,somatic,211980|Bladder cancer,somatic,109800|Pancreatic carcinoma,somatic,260350|Gastric cancer,somatic,137215|Leukemia,acute myeloid,601626|Noonan syndrome 3,609942|Cardiofaciocutaneous syndrome 2,615278|Breast cancer,somatic,114480|Schimmelpenning-Feuerstein-Mims syndrome,somatic mosaic,163200|RAS-associated autoimmune leukoproliferative disorder,614470];	RCV000298757.1 [likely benign]; RCV000370101.1 [likely benign]; 			36	214					KRAS (inh=AD pLI=0.00)
chr12	25361074	25361074	G	A	wt	wt	het		QUAL=1800;DP=325,127,170;MQM=60	KRAS	3'UTR	KRAS:NM_033360.3:3'UTR:MODIFIER:exon6/6:c.*1776C>T:,KRAS:NM_004985.4:3'UTR:MODIFIER:exon5/5:c.*1655C>T:		rs7973623	0.1583	0.0000	0/0/0	0.0325							190070 [KRAS (confirmed) Lung cancer,somatic,211980|Bladder cancer,somatic,109800|Pancreatic carcinoma,somatic,260350|Gastric cancer,somatic,137215|Leukemia,acute myeloid,601626|Noonan syndrome 3,609942|Cardiofaciocutaneous syndrome 2,615278|Breast cancer,somatic,114480|Schimmelpenning-Feuerstein-Mims syndrome,somatic mosaic,163200|RAS-associated autoimmune leukoproliferative disorder,614470];	RCV000272996.1 [likely benign]; RCV000328055.1 [likely benign]; 			12	90					KRAS (inh=AD pLI=0.00)
chr12	25361091	25361091	T	C	hom	hom	hom		QUAL=17642;DP=287,120,157;MQM=59	KRAS	3'UTR	KRAS:NM_033360.3:3'UTR:MODIFIER:exon6/6:c.*1759A>G:,KRAS:NM_004985.4:3'UTR:MODIFIER:exon5/5:c.*1638A>G:		rs4597149	0.9974	0.0000	0/0/0	0.5453							190070 [KRAS (confirmed) Lung cancer,somatic,211980|Bladder cancer,somatic,109800|Pancreatic carcinoma,somatic,260350|Gastric cancer,somatic,137215|Leukemia,acute myeloid,601626|Noonan syndrome 3,609942|Cardiofaciocutaneous syndrome 2,615278|Breast cancer,somatic,114480|Schimmelpenning-Feuerstein-Mims syndrome,somatic mosaic,163200|RAS-associated autoimmune leukoproliferative disorder,614470];	RCV000324189.1 [likely benign]; RCV000378636.1 [likely benign]; 			257	0					KRAS (inh=AD pLI=0.00)
chr12	25361101	25361101	-	A	het	hom	het		QUAL=8155;DP=240,92,129;MQM=59	KRAS	3'UTR	KRAS:NM_033360.3:3'UTR:MODIFIER:exon6/6:c.*1748dupT:,KRAS:NM_004985.4:3'UTR:MODIFIER:exon5/5:c.*1627dupT:		rs398116239	0.5711	0.0000	0/0/0	0.3700							190070 [KRAS (confirmed) Lung cancer,somatic,211980|Bladder cancer,somatic,109800|Pancreatic carcinoma,somatic,260350|Gastric cancer,somatic,137215|Leukemia,acute myeloid,601626|Noonan syndrome 3,609942|Cardiofaciocutaneous syndrome 2,615278|Breast cancer,somatic,114480|Schimmelpenning-Feuerstein-Mims syndrome,somatic mosaic,163200|RAS-associated autoimmune leukoproliferative disorder,614470];	RCV000280925.1 [likely benign]; RCV000375331.1 [likely benign]; 			36	167					KRAS (inh=AD pLI=0.00)
chr12	25361142	25361142	A	G	wt	wt	het		QUAL=1710;DP=372,129,172;MQM=60	KRAS	3'UTR	KRAS:NM_033360.3:3'UTR:MODIFIER:exon6/6:c.*1708T>C:,KRAS:NM_004985.4:3'UTR:MODIFIER:exon5/5:c.*1587T>C:		rs7973450	0.1753	0.0000	0/0/0	0.0335							190070 [KRAS (confirmed) Lung cancer,somatic,211980|Bladder cancer,somatic,109800|Pancreatic carcinoma,somatic,260350|Gastric cancer,somatic,137215|Leukemia,acute myeloid,601626|Noonan syndrome 3,609942|Cardiofaciocutaneous syndrome 2,615278|Breast cancer,somatic,114480|Schimmelpenning-Feuerstein-Mims syndrome,somatic mosaic,163200|RAS-associated autoimmune leukoproliferative disorder,614470];	RCV000349968.1 [likely benign]; RCV000394209.1 [likely benign]; 			12	91					KRAS (inh=AD pLI=0.00)
chr12	25361646	25361646	T	C	wt	wt	het		QUAL=2655;DP=313,196,214;MQM=60	KRAS	3'UTR	KRAS:NM_033360.3:3'UTR:MODIFIER:exon6/6:c.*1204A>G:,KRAS:NM_004985.4:3'UTR:MODIFIER:exon5/5:c.*1083A>G:	MamSINE1	rs7960917	0.1599	0.0000	0/0/0	0.1888							190070 [KRAS (confirmed) Lung cancer,somatic,211980|Bladder cancer,somatic,109800|Pancreatic carcinoma,somatic,260350|Gastric cancer,somatic,137215|Leukemia,acute myeloid,601626|Noonan syndrome 3,609942|Cardiofaciocutaneous syndrome 2,615278|Breast cancer,somatic,114480|Schimmelpenning-Feuerstein-Mims syndrome,somatic mosaic,163200|RAS-associated autoimmune leukoproliferative disorder,614470];	RCV000267082.1 [likely benign]; RCV000317588.1 [likely benign]; 			11	91					KRAS (inh=AD pLI=0.00)
chr12	25362217	25362217	A	G	hom	hom	het		QUAL=14119;DP=266,103,149;MQM=60	KRAS	3'UTR	KRAS:NM_033360.3:3'UTR:MODIFIER:exon6/6:c.*633T>C:,KRAS:NM_004985.4:3'UTR:MODIFIER:exon5/5:c.*512T>C:		rs9266	0.5491	0.6359	2234/513/17	0.1501							190070 [KRAS (confirmed) Lung cancer,somatic,211980|Bladder cancer,somatic,109800|Pancreatic carcinoma,somatic,260350|Gastric cancer,somatic,137215|Leukemia,acute myeloid,601626|Noonan syndrome 3,609942|Cardiofaciocutaneous syndrome 2,615278|Breast cancer,somatic,114480|Schimmelpenning-Feuerstein-Mims syndrome,somatic mosaic,163200|RAS-associated autoimmune leukoproliferative disorder,614470];	RCV000342340.1 [likely benign]; RCV000398489.1 [likely benign]; 	CR1415243 [CLASS=FP MUT=ALT PHEN="Reduced promoter activity" GENE=KRAS]; 		312	523					KRAS (inh=AD pLI=0.00)
chr12	25362465	25362465	G	A	hom	hom	hom		QUAL=19026;DP=324,114,163;MQM=58	KRAS	3'UTR	KRAS:NM_033360.3:3'UTR:MODIFIER:exon6/6:c.*385C>T:,KRAS:NM_004985.4:3'UTR:MODIFIER:exon5/5:c.*264C>T:		rs4285970	0.9972	0.0000	0/0/0	0.1502							190070 [KRAS (confirmed) Lung cancer,somatic,211980|Bladder cancer,somatic,109800|Pancreatic carcinoma,somatic,260350|Gastric cancer,somatic,137215|Leukemia,acute myeloid,601626|Noonan syndrome 3,609942|Cardiofaciocutaneous syndrome 2,615278|Breast cancer,somatic,114480|Schimmelpenning-Feuerstein-Mims syndrome,somatic mosaic,163200|RAS-associated autoimmune leukoproliferative disorder,614470];				306	0					KRAS (inh=AD pLI=0.00)
chr12	25362552	25362552	A	C	hom	hom	het		QUAL=14601;DP=266,109,171;MQM=60	KRAS	3'UTR	KRAS:NM_033360.3:3'UTR:MODIFIER:exon6/6:c.*298T>G:,KRAS:NM_004985.4:3'UTR:MODIFIER:exon5/5:c.*177T>G:		rs712	0.5206	0.0000	0/0/0	0.5578							190070 [KRAS (confirmed) Lung cancer,somatic,211980|Bladder cancer,somatic,109800|Pancreatic carcinoma,somatic,260350|Gastric cancer,somatic,137215|Leukemia,acute myeloid,601626|Noonan syndrome 3,609942|Cardiofaciocutaneous syndrome 2,615278|Breast cancer,somatic,114480|Schimmelpenning-Feuerstein-Mims syndrome,somatic mosaic,163200|RAS-associated autoimmune leukoproliferative disorder,614470];	RCV000332687.1 [likely benign]; RCV000382642.1 [likely benign]; 	CR1415242 [CLASS=FP MUT=ALT PHEN="Reduced promoter activity" GENE=KRAS]; 		70	129					KRAS (inh=AD pLI=0.00)
chr12	25362777	25362777	A	G	wt	wt	het		QUAL=2116;DP=381,175,203;MQM=60	KRAS	synonymous,3'UTR	KRAS:NM_004985.4:synonymous:LOW:exon5/5:c.519T>C:p.Asp173Asp,KRAS:NM_033360.3:3'UTR:MODIFIER:exon6/6:c.*73T>C:		rs1137282	0.1755	0.1969	2325/1536/171	0.1941							190070 [KRAS (confirmed) Lung cancer,somatic,211980|Bladder cancer,somatic,109800|Pancreatic carcinoma,somatic,260350|Gastric cancer,somatic,137215|Leukemia,acute myeloid,601626|Noonan syndrome 3,609942|Cardiofaciocutaneous syndrome 2,615278|Breast cancer,somatic,114480|Schimmelpenning-Feuerstein-Mims syndrome,somatic mosaic,163200|RAS-associated autoimmune leukoproliferative disorder,614470];	RCV000038277.9 [benign]; RCV000339718.1 [likely benign]; RCV000378737.1 [likely benign]; 		COSM3753105	90	583					KRAS (inh=AD pLI=0.00)
chr12	25368462	25368462	C	T	hom	hom	hom		QUAL=14340;DP=205,93,146;MQM=60	KRAS	synonymous,intron	KRAS:NM_033360.3:synonymous:LOW:exon5/6:c.483G>A:p.Arg161Arg,KRAS:NM_004985.4:intron:MODIFIER:exon4/4:c.451-5617G>A:		rs4362222	0.9976	0.9995	60632/33359/5147	0.9349							190070 [KRAS (confirmed) Lung cancer,somatic,211980|Bladder cancer,somatic,109800|Pancreatic carcinoma,somatic,260350|Gastric cancer,somatic,137215|Leukemia,acute myeloid,601626|Noonan syndrome 3,609942|Cardiofaciocutaneous syndrome 2,615278|Breast cancer,somatic,114480|Schimmelpenning-Feuerstein-Mims syndrome,somatic mosaic,163200|RAS-associated autoimmune leukoproliferative disorder,614470];	RCV000150886.1 [benign]; RCV000039808.3 [benign]; RCV000149847.3 [benign]; 			1702	0					KRAS (inh=AD pLI=0.00)
chr12	31226795	31226795	T	G	wt	het	het		QUAL=41;DP=33,38,47;MQM=58	DDX11	5'UTR	DDX11:NM_001257144.1:5'UTR:MODIFIER:exon1/27:c.-113T>G:,DDX11:NM_001257145.1:5'UTR:MODIFIER:exon1/27:c.-118T>G:,DDX11:NM_004399.2:5'UTR:MODIFIER:exon1/26:c.-235T>G:,DDX11:NM_030653.3:5'UTR:MODIFIER:exon1/27:c.-235T>G:,DDX11:NM_152438.1:5'UTR:MODIFIER:exon1/27:c.-235T>G:			0.0000	0.0000	0/0/0	0.0001							601150 [DDX11 (provisional) Warsaw breakage syndrome,613398];				0	2					DDX11 (inh=AR pLI=n/a)
chr12	31226835	31226835	T	A	wt	wt	het	low_MQM	QUAL=1408;DP=312,126,153;MQM=47	DDX11	5'UTR	DDX11:NM_001257144.1:5'UTR:MODIFIER:exon1/27:c.-73T>A:,DDX11:NM_001257145.1:5'UTR:MODIFIER:exon1/27:c.-78T>A:,DDX11:NM_004399.2:5'UTR:MODIFIER:exon1/26:c.-195T>A:,DDX11:NM_030653.3:5'UTR:MODIFIER:exon1/27:c.-195T>A:,DDX11:NM_152438.1:5'UTR:MODIFIER:exon1/27:c.-195T>A:		rs7953706	0.6266	0.0000	0/0/0	0.4320							601150 [DDX11 (provisional) Warsaw breakage syndrome,613398];				61	113					DDX11 (inh=AR pLI=n/a)
chr12	31226934	31226934	C	T	het	wt	wt	low_MQM	QUAL=52;DP=85,211,258;MQM=44	DDX11	5'UTR,intron	DDX11:NM_004399.2:5'UTR:MODIFIER:exon1/26:c.-96C>T:,DDX11:NM_030653.3:5'UTR:MODIFIER:exon1/27:c.-96C>T:,DDX11:NM_152438.1:5'UTR:MODIFIER:exon1/27:c.-96C>T:,DDX11:NM_001257144.1:intron:MODIFIER:exon1/26:c.-5+31C>T:,DDX11:NM_001257145.1:intron:MODIFIER:exon1/26:c.-10+31C>T:		rs74087917	0.0000	0.0000	0/0/0	0.0007							601150 [DDX11 (provisional) Warsaw breakage syndrome,613398];				0	76					DDX11 (inh=AR pLI=n/a)
chr12	31240925	31240925	A	G	wt	wt	het		QUAL=3972;DP=187,253,333;MQM=52	DDX11	splice_region&intron	DDX11:NM_001257144.1:splice_region&intron:LOW:exon6/26:c.684+8A>G:,DDX11:NM_001257145.1:splice_region&intron:LOW:exon6/26:c.606+8A>G:,DDX11:NM_004399.2:splice_region&intron:LOW:exon6/25:c.684+8A>G:,DDX11:NM_030653.3:splice_region&intron:LOW:exon6/26:c.684+8A>G:,DDX11:NM_152438.1:splice_region&intron:LOW:exon6/26:c.684+8A>G:		rs7308773	0.6330	0.5076	15059/5311/2057	0.5019							601150 [DDX11 (provisional) Warsaw breakage syndrome,613398];				345	761					DDX11 (inh=AR pLI=n/a)
chr12	31242399	31242399	T	C	wt	wt	het		QUAL=3311;DP=237,224,285;MQM=55	DDX11	synonymous,sequence_feature	DDX11:NM_001257144.1:synonymous:LOW:exon8/27:c.855T>C:p.Cys285Cys,DDX11:NM_001257145.1:synonymous:LOW:exon8/27:c.777T>C:p.Cys259Cys,DDX11:NM_004399.2:synonymous:LOW:exon8/26:c.855T>C:p.Cys285Cys,DDX11:NM_030653.3:synonymous:LOW:exon8/27:c.855T>C:p.Cys285Cys,DDX11:NM_152438.1:synonymous:LOW:exon8/27:c.855T>C:p.Cys285Cys,DDX11:NM_001257145.1:sequence_feature:LOW:exon8/27:c.777T>C:,DDX11:NM_004399.2:sequence_feature:LOW:exon8/26:c.855T>C:,DDX11:NM_030653.3:sequence_feature:LOW:exon8/27:c.855T>C:,DDX11:NM_152438.1:sequence_feature:LOW:exon8/27:c.855T>C:		rs3881298	0.6456	0.5214	16923/6068/2372	0.4632							601150 [DDX11 (provisional) Warsaw breakage syndrome,613398];			COSM4146994, COSM4146993	342	764					DDX11 (inh=AR pLI=n/a)
chr12	31249861	31249861	C	G	wt	wt	het	pred_pathogenic	QUAL=6466;DP=275,488,532;MQM=55	DDX11	missense	DDX11:NM_001257144.1:missense:MODERATE:exon17/27:c.1699C>G:p.Gln567Glu,DDX11:NM_001257145.1:missense:MODERATE:exon17/27:c.1621C>G:p.Gln541Glu,DDX11:NM_004399.2:missense:MODERATE:exon17/26:c.1699C>G:p.Gln567Glu,DDX11:NM_030653.3:missense:MODERATE:exon17/27:c.1699C>G:p.Gln567Glu,DDX11:NM_152438.1:missense:MODERATE:exon17/27:c.1699C>G:p.Gln567Glu		rs2075322	0.6412	0.5273	17935/6205/2397	0.5054	5.3440	T,T,T,T,T,T	T	B,B,B,B	T,T,T,T,T	1.71	601150 [DDX11 (provisional) Warsaw breakage syndrome,613398];			COSM3753167, COSM3753168	349	754					DDX11 (inh=AR pLI=n/a)
chr12	31253995	31253995	C	T	wt	wt	het		QUAL=3167;DP=153,202,305;MQM=59	DDX11	synonymous	DDX11:NM_001257144.1:synonymous:LOW:exon20/27:c.1983C>T:p.Leu661Leu,DDX11:NM_001257145.1:synonymous:LOW:exon20/27:c.1905C>T:p.Leu635Leu,DDX11:NM_004399.2:synonymous:LOW:exon20/26:c.1983C>T:p.Leu661Leu,DDX11:NM_030653.3:synonymous:LOW:exon20/27:c.1983C>T:p.Leu661Leu,DDX11:NM_152438.1:synonymous:LOW:exon20/27:c.1983C>T:p.Leu661Leu		rs1046456	0.6284	0.5259	17890/6539/2288	0.4886							601150 [DDX11 (provisional) Warsaw breakage syndrome,613398];				345	763					DDX11 (inh=AR pLI=n/a)
chr12	31256546	31256546	G	A	wt	wt	het	low_MQM;pred_pathogenic	QUAL=2804;DP=181,234,266;MQM=49	DDX11	missense	DDX11:NM_001257144.1:missense:MODERATE:exon26/27:c.2567G>A:p.Arg856His,DDX11:NM_001257145.1:missense:MODERATE:exon26/27:c.2494G>A:p.Val832Ile,DDX11:NM_004399.2:missense:MODERATE:exon25/26:c.2422G>A:p.Val808Ile,DDX11:NM_030653.3:missense:MODERATE:exon26/27:c.2572G>A:p.Val858Ile,DDX11:NM_152438.1:missense:MODERATE:exon26/27:c.2567G>A:p.Arg856His		rs1046457	0.6342	0.5095	15900/5560/2106	0.4583	2.7960	T,T,T,T,T	T,T	B,B,B,B	T,T,D,D,D	23.50	601150 [DDX11 (provisional) Warsaw breakage syndrome,613398];			COSM3753169, COSM3753170	345	761					DDX11 (inh=AR pLI=n/a)
chr12	31256905	31256905	T	C	wt	wt	het	low_MQM	QUAL=2593;DP=250,208,255;MQM=49	DDX11	missense,3'UTR	DDX11:NM_001257144.1:missense:MODERATE:exon27/27:c.2851T>C:p.Cys951Arg,DDX11:NM_152438.1:missense:MODERATE:exon27/27:c.2851T>C:p.Cys951Arg,DDX11:NM_001257145.1:3'UTR:MODIFIER:exon27/27:c.*135T>C:,DDX11:NM_004399.2:3'UTR:MODIFIER:exon26/26:c.*135T>C:,DDX11:NM_030653.3:3'UTR:MODIFIER:exon27/27:c.*135T>C:		rs1046458	0.6384	0.4082	3661/1186/552	0.3364	-0.8760	T,T	T	B	T,T	0.03	601150 [DDX11 (provisional) Warsaw breakage syndrome,613398];				380	744					DDX11 (inh=AR pLI=n/a)
chr12	31256995	31256995	G	A	hom	hom	het		QUAL=12123;DP=181,142,197;MQM=50	DDX11	3'UTR	DDX11:NM_001257144.1:3'UTR:MODIFIER:exon27/27:c.*28G>A:,DDX11:NM_001257145.1:3'UTR:MODIFIER:exon27/27:c.*225G>A:,DDX11:NM_004399.2:3'UTR:MODIFIER:exon26/26:c.*225G>A:,DDX11:NM_030653.3:3'UTR:MODIFIER:exon27/27:c.*225G>A:,DDX11:NM_152438.1:3'UTR:MODIFIER:exon27/27:c.*28G>A:		rs11545332	0.1546	0.2505	530/274/6	0.0768							601150 [DDX11 (provisional) Warsaw breakage syndrome,613398];				39	268					DDX11 (inh=AR pLI=n/a)
chr12	31257327	31257327	T	C	wt	wt	het		QUAL=996;DP=80,70,82;MQM=52	DDX11	3'UTR	DDX11:NM_001257144.1:3'UTR:MODIFIER:exon27/27:c.*360T>C:,DDX11:NM_001257145.1:3'UTR:MODIFIER:exon27/27:c.*557T>C:,DDX11:NM_004399.2:3'UTR:MODIFIER:exon26/26:c.*557T>C:,DDX11:NM_030653.3:3'UTR:MODIFIER:exon27/27:c.*557T>C:,DDX11:NM_152438.1:3'UTR:MODIFIER:exon27/27:c.*360T>C:		rs1046467	0.6304	0.0000	0/0/0	0.2377							601150 [DDX11 (provisional) Warsaw breakage syndrome,613398];				60	111					DDX11 (inh=AR pLI=n/a)
chr12	31257464	31257464	G	A	wt	wt	het	low_DP;low_MQM	QUAL=82;DP=89,18,24;MQM=48	DDX11	3'UTR	DDX11:NM_001257144.1:3'UTR:MODIFIER:exon27/27:c.*497G>A:,DDX11:NM_001257145.1:3'UTR:MODIFIER:exon27/27:c.*694G>A:,DDX11:NM_004399.2:3'UTR:MODIFIER:exon26/26:c.*694G>A:,DDX11:NM_030653.3:3'UTR:MODIFIER:exon27/27:c.*694G>A:,DDX11:NM_152438.1:3'UTR:MODIFIER:exon27/27:c.*497G>A:		rs9750	0.6348	0.0000	0/0/0	0.3007							601150 [DDX11 (provisional) Warsaw breakage syndrome,613398];				62	108					DDX11 (inh=AR pLI=n/a)
chr12	31257695	31257695	T	C	wt	wt	hom	low_DP	QUAL=201;DP=14,3,8;MQM=59	DDX11	3'UTR	DDX11:NM_001257144.1:3'UTR:MODIFIER:exon27/27:c.*728T>C:,DDX11:NM_001257145.1:3'UTR:MODIFIER:exon27/27:c.*925T>C:,DDX11:NM_004399.2:3'UTR:MODIFIER:exon26/26:c.*925T>C:,DDX11:NM_030653.3:3'UTR:MODIFIER:exon27/27:c.*925T>C:,DDX11:NM_152438.1:3'UTR:MODIFIER:exon27/27:c.*728T>C:		rs11219	0.6346	0.0000	0/0/0	0.3811							601150 [DDX11 (provisional) Warsaw breakage syndrome,613398];				58	91					DDX11 (inh=AR pLI=n/a)
chr12	32735236	32735236	C	T	het	wt	het		QUAL=11852;DP=543,342,455;MQM=60	FGD4	synonymous,5'UTR	FGD4:NM_001304480.1:synonymous:LOW:exon4/17:c.771C>T:p.Asp257Asp,FGD4:NM_001304481.1:synonymous:LOW:exon4/17:c.690C>T:p.Asp230Asp,FGD4:NM_139241.3:synonymous:LOW:exon4/17:c.435C>T:p.Asp145Asp,FGD4:NM_001304483.1:5'UTR:MODIFIER:exon4/17:c.-410C>T:,FGD4:NM_001304484.1:5'UTR:MODIFIER:exon4/18:c.-717C>T:		rs904582	0.4671	0.4107	10927/4889/2424	0.4017							611104 [FGD4 (confirmed) Charcot-Marie-Tooth disease,type 4H,609311];	RCV000178387.1 [benign]; RCV000330497.1 [uncertain significance]; RCV000368855.1 [benign]; 			278	721					FGD4 (inh=AR pLI=0.34)
chr12	32755259	32755259	G	A	wt	het	wt		QUAL=889;DP=185,73,121;MQM=60	FGD4	splice_region&intron	FGD4:NM_001304480.1:splice_region&intron:LOW:exon7/16:c.1329+8G>A:,FGD4:NM_001304481.1:splice_region&intron:LOW:exon7/16:c.1248+8G>A:,FGD4:NM_001304483.1:splice_region&intron:LOW:exon8/16:c.249+8G>A:,FGD4:NM_001304484.1:splice_region&intron:LOW:exon8/17:c.-59+8G>A:,FGD4:NM_139241.3:splice_region&intron:LOW:exon7/16:c.993+8G>A:		rs12823621	0.0383	0.0782	513/402/1	0.0778							611104 [FGD4 (confirmed) Charcot-Marie-Tooth disease,type 4H,609311];	RCV000374914.1 [likely benign]; 			16	248					FGD4 (inh=AR pLI=0.34)
chr12	32778581	32778581	T	C	het	wt	het		QUAL=4518;DP=185,109,173;MQM=60	FGD4	splice_region&intron	FGD4:NM_001304480.1:splice_region&intron:LOW:exon13/16:c.1972-7T>C:,FGD4:NM_001304481.1:splice_region&intron:LOW:exon13/16:c.1891-7T>C:,FGD4:NM_001304483.1:splice_region&intron:LOW:exon14/16:c.892-7T>C:,FGD4:NM_001304484.1:splice_region&intron:LOW:exon14/17:c.604-7T>C:,FGD4:NM_139241.3:splice_region&intron:LOW:exon13/16:c.1636-7T>C:		rs11052113	0.1402	0.1318	1264/523/258	0.1260							611104 [FGD4 (confirmed) Charcot-Marie-Tooth disease,type 4H,609311];	RCV000277525.1 [likely benign]; 			28	385					FGD4 (inh=AR pLI=0.34)
chr12	32794600	32794600	A	C	het	wt	het		QUAL=6019;DP=288,167,185;MQM=60	FGD4	3'UTR	FGD4:NM_001304480.1:3'UTR:MODIFIER:exon17/17:c.*1133A>C:,FGD4:NM_001304481.1:3'UTR:MODIFIER:exon17/17:c.*1133A>C:,FGD4:NM_001304484.1:3'UTR:MODIFIER:exon18/18:c.*1133A>C:,FGD4:NM_139241.3:3'UTR:MODIFIER:exon17/17:c.*1133A>C:		rs10844268	0.3616	0.0000	0/0/0	0.0540							611104 [FGD4 (confirmed) Charcot-Marie-Tooth disease,type 4H,609311];	RCV000334527.1 [benign]; 			30	104					FGD4 (inh=AR pLI=0.34)
chr12	32794921	32794921	A	G	het	wt	het		QUAL=6481;DP=295,118,131;MQM=59	FGD4	3'UTR	FGD4:NM_001304480.1:3'UTR:MODIFIER:exon17/17:c.*1454A>G:,FGD4:NM_001304481.1:3'UTR:MODIFIER:exon17/17:c.*1454A>G:,FGD4:NM_001304484.1:3'UTR:MODIFIER:exon18/18:c.*1454A>G:,FGD4:NM_139241.3:3'UTR:MODIFIER:exon17/17:c.*1454A>G:		rs7964947	0.3171	0.0000	0/0/0	0.0506							611104 [FGD4 (confirmed) Charcot-Marie-Tooth disease,type 4H,609311];	RCV000360536.1 [benign]; 			26	102					FGD4 (inh=AR pLI=0.34)
chr12	32794959	32794959	T	G	het	wt	het		QUAL=6215;DP=278,143,153;MQM=59	FGD4	3'UTR	FGD4:NM_001304480.1:3'UTR:MODIFIER:exon17/17:c.*1492T>G:,FGD4:NM_001304481.1:3'UTR:MODIFIER:exon17/17:c.*1492T>G:,FGD4:NM_001304484.1:3'UTR:MODIFIER:exon18/18:c.*1492T>G:,FGD4:NM_139241.3:3'UTR:MODIFIER:exon17/17:c.*1492T>G:		rs7980205	0.3618	0.0000	0/0/0	0.0540							611104 [FGD4 (confirmed) Charcot-Marie-Tooth disease,type 4H,609311];	RCV000325578.1 [benign]; 			30	104					FGD4 (inh=AR pLI=0.34)
chr12	32795421	32795421	A	G	het	wt	het	low_DP	QUAL=2479;DP=152,16,32;MQM=60	FGD4	3'UTR	FGD4:NM_001304480.1:3'UTR:MODIFIER:exon17/17:c.*1954A>G:,FGD4:NM_001304481.1:3'UTR:MODIFIER:exon17/17:c.*1954A>G:,FGD4:NM_001304484.1:3'UTR:MODIFIER:exon18/18:c.*1954A>G:,FGD4:NM_139241.3:3'UTR:MODIFIER:exon17/17:c.*1954A>G:		rs1239829	0.7418	0.0000	0/0/0	0.0995							611104 [FGD4 (confirmed) Charcot-Marie-Tooth disease,type 4H,609311];	RCV000389845.1 [benign]; 			67	100					FGD4 (inh=AR pLI=0.34)
chr12	32796394	32796397	CTAT	-	wt	het	wt		QUAL=1133;DP=171,95,115;MQM=60	FGD4	3'UTR	FGD4:NM_001304480.1:3'UTR:MODIFIER:exon17/17:c.*2928_*2931delTATC:,FGD4:NM_001304481.1:3'UTR:MODIFIER:exon17/17:c.*2928_*2931delTATC:,FGD4:NM_001304484.1:3'UTR:MODIFIER:exon18/18:c.*2928_*2931delTATC:,FGD4:NM_139241.3:3'UTR:MODIFIER:exon17/17:c.*2928_*2931delTATC:		rs549931906	0.0813	0.0000	0/0/0	0.1571							611104 [FGD4 (confirmed) Charcot-Marie-Tooth disease,type 4H,609311];	RCV000390748.1 [benign]; 			13	69					FGD4 (inh=AR pLI=0.34)
chr12	32796604	32796604	T	-	het	wt	het		QUAL=2414;DP=164,27,29;MQM=59	FGD4	3'UTR	FGD4:NM_001304480.1:3'UTR:MODIFIER:exon17/17:c.*3148delT:,FGD4:NM_001304481.1:3'UTR:MODIFIER:exon17/17:c.*3148delT:,FGD4:NM_001304484.1:3'UTR:MODIFIER:exon18/18:c.*3148delT:,FGD4:NM_139241.3:3'UTR:MODIFIER:exon17/17:c.*3148delT:		rs797002948	0.3351	0.0000	0/0/0	0.2159							611104 [FGD4 (confirmed) Charcot-Marie-Tooth disease,type 4H,609311];	RCV000333825.1 [benign]; 			26	106					FGD4 (inh=AR pLI=0.34)
chr12	32797237	32797237	G	T	het	wt	het		QUAL=4856;DP=237,135,167;MQM=60	FGD4	3'UTR	FGD4:NM_001304480.1:3'UTR:MODIFIER:exon17/17:c.*3770G>T:,FGD4:NM_001304481.1:3'UTR:MODIFIER:exon17/17:c.*3770G>T:,FGD4:NM_001304484.1:3'UTR:MODIFIER:exon18/18:c.*3770G>T:,FGD4:NM_139241.3:3'UTR:MODIFIER:exon17/17:c.*3770G>T:		rs11052123	0.4337	0.0000	0/0/0	0.4234							611104 [FGD4 (confirmed) Charcot-Marie-Tooth disease,type 4H,609311];	RCV000286713.1 [benign]; 			59	103					FGD4 (inh=AR pLI=0.34)
chr12	32797822	32797822	-	A	het	wt	het		QUAL=769;DP=195,79,78;MQM=59	FGD4	3'UTR	FGD4:NM_001304480.1:3'UTR:MODIFIER:exon17/17:c.*4369dupA:,FGD4:NM_001304481.1:3'UTR:MODIFIER:exon17/17:c.*4369dupA:,FGD4:NM_001304484.1:3'UTR:MODIFIER:exon18/18:c.*4369dupA:,FGD4:NM_139241.3:3'UTR:MODIFIER:exon17/17:c.*4369dupA:		rs35874340;rs397713417;rs59282238	0.2957	0.0000	0/0/0	0.0745							611104 [FGD4 (confirmed) Charcot-Marie-Tooth disease,type 4H,609311];	RCV000332236.1 [benign]; 			1	72					FGD4 (inh=AR pLI=0.34)
chr12	32797905	32797905	A	G	het	wt	het		QUAL=6330;DP=312,140,156;MQM=60	FGD4	3'UTR	FGD4:NM_001304480.1:3'UTR:MODIFIER:exon17/17:c.*4438A>G:,FGD4:NM_001304481.1:3'UTR:MODIFIER:exon17/17:c.*4438A>G:,FGD4:NM_001304484.1:3'UTR:MODIFIER:exon18/18:c.*4438A>G:,FGD4:NM_139241.3:3'UTR:MODIFIER:exon17/17:c.*4438A>G:		rs11052124	0.4966	0.0000	0/0/0	0.0757							611104 [FGD4 (confirmed) Charcot-Marie-Tooth disease,type 4H,609311];	RCV000367614.1 [benign]; 			60	102					FGD4 (inh=AR pLI=0.34)
chr12	32798458	32798458	A	G	hom	hom	hom		QUAL=6497;DP=144,26,35;MQM=59	FGD4	3'UTR	FGD4:NM_001304480.1:3'UTR:MODIFIER:exon17/17:c.*4991A>G:,FGD4:NM_001304481.1:3'UTR:MODIFIER:exon17/17:c.*4991A>G:,FGD4:NM_001304484.1:3'UTR:MODIFIER:exon18/18:c.*4991A>G:,FGD4:NM_139241.3:3'UTR:MODIFIER:exon17/17:c.*4991A>G:	AluSg	rs1239830	0.9902	0.0000	0/0/0	0.8762							611104 [FGD4 (confirmed) Charcot-Marie-Tooth disease,type 4H,609311];	RCV000336307.1 [benign]; 			201	0					FGD4 (inh=AR pLI=0.34)
chr12	32798665	32798665	G	A	het	wt	het		QUAL=3742;DP=158,114,166;MQM=56	FGD4	3'UTR	FGD4:NM_001304480.1:3'UTR:MODIFIER:exon17/17:c.*5198G>A:,FGD4:NM_001304481.1:3'UTR:MODIFIER:exon17/17:c.*5198G>A:,FGD4:NM_001304484.1:3'UTR:MODIFIER:exon18/18:c.*5198G>A:,FGD4:NM_139241.3:3'UTR:MODIFIER:exon17/17:c.*5198G>A:	AluSg	rs1133509	0.4677	0.0000	0/0/0	0.4216							611104 [FGD4 (confirmed) Charcot-Marie-Tooth disease,type 4H,609311];	RCV000310944.1 [benign]; 			59	102					FGD4 (inh=AR pLI=0.34)
chr12	32899495	32899495	C	T	het	wt	het	low_DP	QUAL=217;DP=27,11,10;MQM=60	YARS2	3'UTR	YARS2:NM_001040436.2:3'UTR:MODIFIER:exon5/5:c.*643G>A:	AluSz6	rs11052214	0.1266	0.0000	0/0/0	0.1179							610957 [YARS2 (provisional) Myopathy,lactic acidosis,and sideroblastic anemia 2,613561];	RCV000319068.1 [likely benign]; RCV000371457.1 [likely benign]; RCV000406313.1 [benign]; 			9	35					YARS2 (inh=AR pLI=0.00)
chr12	32899929	32899929	C	G	het	wt	het		QUAL=5695;DP=289,124,182;MQM=60	YARS2	3'UTR	YARS2:NM_001040436.2:3'UTR:MODIFIER:exon5/5:c.*209G>C:		rs10844337	0.1438	0.0000	0/0/0	0.1297							610957 [YARS2 (provisional) Myopathy,lactic acidosis,and sideroblastic anemia 2,613561];	RCV000305932.1 [likely benign]; RCV000322564.1 [benign]; RCV000392192.1 [likely benign]; 			9	57					YARS2 (inh=AR pLI=0.00)
chr12	32908237	32908237	C	A	het	wt	het	pred_pathogenic;anno_pathogenic_clinvar	QUAL=3547;DP=229,105,158;MQM=59	YARS2	missense	YARS2:NM_001040436.2:missense:MODERATE:exon1/5:c.572G>T:p.Gly191Val		rs11539445	0.1266	0.1259	1011/648/149	0.1197	4.2110	T	T	B	T	23.00	610957 [YARS2 (provisional) Myopathy,lactic acidosis,and sideroblastic anemia 2,613561];	RCV000280875.1 [likely benign]; RCV000377688.1 [likely benign]; RCV000088672.3 [pathogenic]; 	CM1312757 [CLASS=FP MUT=ALT PHEN="Reduced catalytic efficiency" GENE=YARS2]; 	COSM3753192	45	344					YARS2 (inh=AR pLI=0.00)
chr12	32908518	32908518	G	A	het	wt	het		QUAL=9548;DP=407,278,379;MQM=59	YARS2	synonymous	YARS2:NM_001040436.2:synonymous:LOW:exon1/5:c.291C>T:p.Gly97Gly		rs11539444	0.1270	0.1264	1018/651/152	0.1244							610957 [YARS2 (provisional) Myopathy,lactic acidosis,and sideroblastic anemia 2,613561];	RCV000126351.1 [benign]; RCV000310151.1 [likely benign]; RCV000362476.1 [likely benign]; 		COSM3753193	45	343					YARS2 (inh=AR pLI=0.00)
chr12	41337435	41337435	C	T	wt	wt	het		QUAL=2537;DP=247,157,200;MQM=60	CNTN1	synonymous	CNTN1:NM_001843.3:synonymous:LOW:exon13/24:c.1416C>T:p.Asn472Asn,CNTN1:NM_001256063.1:synonymous:LOW:exon13/16:c.1416C>T:p.Asn472Asn,CNTN1:NM_001256064.1:synonymous:LOW:exon13/16:c.1416C>T:p.Asn472Asn,CNTN1:NM_175038.2:synonymous:LOW:exon11/22:c.1383C>T:p.Asn461Asn		rs1056019	0.5715	0.6193	23449/13834/1779	0.6103							600016 [CNTN1 (provisional) Myopathy,congenital,Compton-North,612540];	RCV000116765.2 [benign]; 		COSM3753220, COSM431076	635	717					CNTN1 (inh=AR pLI=1.00)
chr12	41366042	41366042	G	T	wt	wt	het		QUAL=480;DP=135,37,48;MQM=60	CNTN1	sequence_feature,3'UTR,intron	CNTN1:NM_175038.2:sequence_feature:LOW::c.1772-8669G>T:,CNTN1:NM_001256063.1:3'UTR:MODIFIER:exon16/16:c.*727G>T:,CNTN1:NM_001256064.1:3'UTR:MODIFIER:exon16/16:c.*727G>T:,CNTN1:NM_001843.3:intron:MODIFIER:exon15/23:c.1805-8669G>T:,CNTN1:NM_175038.2:intron:MODIFIER:exon13/21:c.1772-8669G>T:		rs10879442	0.5815	0.0000	0/0/0	0.6122							600016 [CNTN1 (provisional) Myopathy,congenital,Compton-North,612540];				55	76					CNTN1 (inh=AR pLI=1.00)
chr12	41366155	41366155	A	G	wt	wt	het	low_DP	QUAL=150;DP=103,15,23;MQM=60	CNTN1	sequence_feature,3'UTR,intron	CNTN1:NM_175038.2:sequence_feature:LOW::c.1772-8556A>G:,CNTN1:NM_001256063.1:3'UTR:MODIFIER:exon16/16:c.*840A>G:,CNTN1:NM_001256064.1:3'UTR:MODIFIER:exon16/16:c.*840A>G:,CNTN1:NM_001843.3:intron:MODIFIER:exon15/23:c.1805-8556A>G:,CNTN1:NM_175038.2:intron:MODIFIER:exon13/21:c.1772-8556A>G:		rs10879443	0.6122	0.0000	0/0/0	0.6228							600016 [CNTN1 (provisional) Myopathy,congenital,Compton-North,612540];				56	74					CNTN1 (inh=AR pLI=1.00)
chr12	41464003	41464003	G	A	wt	wt	het		QUAL=3391;DP=349,214,252;MQM=60	CNTN1	3'UTR	CNTN1:NM_001843.3:3'UTR:MODIFIER:exon24/24:c.*166G>A:,CNTN1:NM_175038.2:3'UTR:MODIFIER:exon22/22:c.*166G>A:		rs444927	0.5325	0.0000	0/0/0	0.0882							600016 [CNTN1 (provisional) Myopathy,congenital,Compton-North,612540];				57	121					CNTN1 (inh=AR pLI=1.00)
chr12	41464848	41464848	G	T	wt	wt	het		QUAL=665;DP=172,61,85;MQM=60	CNTN1	3'UTR	CNTN1:NM_001843.3:3'UTR:MODIFIER:exon24/24:c.*1011G>T:,CNTN1:NM_175038.2:3'UTR:MODIFIER:exon22/22:c.*1011G>T:		rs17624585	0.0659	0.0000	0/0/0	0.1077							600016 [CNTN1 (provisional) Myopathy,congenital,Compton-North,612540];				4	28					CNTN1 (inh=AR pLI=1.00)
chr12	44182361	44182361	G	T	wt	hom	hom	low_QUAL;low_DP	QUAL=21;DP=31,7,11;MQM=60	IRAK4	3'UTR	IRAK4:NM_001114182.2:3'UTR:MODIFIER:exon13/13:c.*1843G>T:,IRAK4:NM_001145256.1:3'UTR:MODIFIER:exon12/12:c.*1843G>T:,IRAK4:NM_001145257.1:3'UTR:MODIFIER:exon11/11:c.*1843G>T:,IRAK4:NM_001145258.1:3'UTR:MODIFIER:exon10/10:c.*1843G>T:,IRAK4:NM_016123.3:3'UTR:MODIFIER:exon12/12:c.*1843G>T:	AluY		0.0000	0.0000	0/0/0	0.0001							606883 [IRAK4 (provisional) IRAK4 deficiency,607676|Invasive pneumococcal disease,recurrent isolated,1,610799];				0	3					IRAK4 (inh=AR pLI=0.00)
chr12	44182706	44182706	A	G	het	het	wt		QUAL=3945;DP=180,106,150;MQM=60	IRAK4	3'UTR	IRAK4:NM_001114182.2:3'UTR:MODIFIER:exon13/13:c.*2188A>G:,IRAK4:NM_001145256.1:3'UTR:MODIFIER:exon12/12:c.*2188A>G:,IRAK4:NM_001145257.1:3'UTR:MODIFIER:exon11/11:c.*2188A>G:,IRAK4:NM_001145258.1:3'UTR:MODIFIER:exon10/10:c.*2188A>G:,IRAK4:NM_016123.3:3'UTR:MODIFIER:exon12/12:c.*2188A>G:	MSTB-int	rs1141168	0.4225	0.0000	0/0/0	0.4654							606883 [IRAK4 (provisional) IRAK4 deficiency,607676|Invasive pneumococcal disease,recurrent isolated,1,610799];	RCV000395832.1 [benign]; 			55	81					IRAK4 (inh=AR pLI=0.00)
chr12	48235555	48235555	T	A	wt	wt	het		QUAL=4418;DP=368,247,339;MQM=60	VDR	3'UTR	VDR:NM_001017536.1:3'UTR:MODIFIER:exon10/10:c.*2974A>T:,VDR:NM_000376.2:3'UTR:MODIFIER:exon10/10:c.*2974A>T:,VDR:NM_001017535.1:3'UTR:MODIFIER:exon11/11:c.*2974A>T:		rs11574139	0.0304	0.0000	0/0/0	0.0306							601769 [VDR (provisional) Rickets,vitamin D-resistant,type IIA,277440|Osteoporosis,involutional,166710];	RCV000355805.1 [uncertain significance]; 			0	14					VDR (inh=AR+AD pLI=0.39)
chr12	48235738	48235738	C	T	wt	wt	het		QUAL=2783;DP=329,129,210;MQM=60	VDR	3'UTR	VDR:NM_001017536.1:3'UTR:MODIFIER:exon10/10:c.*2791G>A:,VDR:NM_000376.2:3'UTR:MODIFIER:exon10/10:c.*2791G>A:,VDR:NM_001017535.1:3'UTR:MODIFIER:exon11/11:c.*2791G>A:		rs2853563	0.0807	0.0000	0/0/0	0.0450							601769 [VDR (provisional) Rickets,vitamin D-resistant,type IIA,277440|Osteoporosis,involutional,166710];	RCV000327185.1 [likely benign]; 			0	14					VDR (inh=AR+AD pLI=0.39)
chr12	48236386	48236386	T	A	het	hom	wt	low_DP;low_MQM	QUAL=1275;DP=75,19,26;MQM=49	VDR	3'UTR	VDR:NM_001017536.1:3'UTR:MODIFIER:exon10/10:c.*2143A>T:,VDR:NM_000376.2:3'UTR:MODIFIER:exon10/10:c.*2143A>T:,VDR:NM_001017535.1:3'UTR:MODIFIER:exon11/11:c.*2143A>T:	AluSp	rs2853562	0.5433	0.0000	0/0/0	0.4743							601769 [VDR (provisional) Rickets,vitamin D-resistant,type IIA,277440|Osteoporosis,involutional,166710];	RCV000339222.1 [likely benign]; 			47	73					VDR (inh=AR+AD pLI=0.39)
chr12	48236407	48236412	TTTTTT	-	wt	hom	wt	low_DP	QUAL=204;DP=25,20,5;MQM=54	VDR	3'UTR	VDR:NM_001017536.1:3'UTR:MODIFIER:exon10/10:c.*2117_*2122delAAAAAA:,VDR:NM_000376.2:3'UTR:MODIFIER:exon10/10:c.*2117_*2122delAAAAAA:,VDR:NM_001017535.1:3'UTR:MODIFIER:exon11/11:c.*2117_*2122delAAAAAA:	AluSp	rs534479904;rs541331784;rs776780383	0.7738	0.0000	0/0/0	0.4180							601769 [VDR (provisional) Rickets,vitamin D-resistant,type IIA,277440|Osteoporosis,involutional,166710];	RCV000394229.1 [benign]; 			36	36					VDR (inh=AR+AD pLI=0.39)
chr12	48236550	48236550	G	C	hom	hom	hom		QUAL=22719;DP=329,206,206;MQM=59	VDR	3'UTR	VDR:NM_001017536.1:3'UTR:MODIFIER:exon10/10:c.*1979C>G:,VDR:NM_000376.2:3'UTR:MODIFIER:exon10/10:c.*1979C>G:,VDR:NM_001017535.1:3'UTR:MODIFIER:exon11/11:c.*1979C>G:	AluSp	rs2544043	0.9782	0.0000	0/0/0	0.8690							601769 [VDR (provisional) Rickets,vitamin D-resistant,type IIA,277440|Osteoporosis,involutional,166710];	RCV000373120.1 [benign]; 			142	22					VDR (inh=AR+AD pLI=0.39)
chr12	48236623	48236623	G	T	het	hom	wt		QUAL=14045;DP=237,314,306;MQM=60	VDR	3'UTR	VDR:NM_001017536.1:3'UTR:MODIFIER:exon10/10:c.*1906C>A:,VDR:NM_000376.2:3'UTR:MODIFIER:exon10/10:c.*1906C>A:,VDR:NM_001017535.1:3'UTR:MODIFIER:exon11/11:c.*1906C>A:	MIRc	rs9729	0.5026	0.0000	0/0/0	0.4969							601769 [VDR (provisional) Rickets,vitamin D-resistant,type IIA,277440|Osteoporosis,involutional,166710];	RCV000262137.1 [likely benign]; 			49	77					VDR (inh=AR+AD pLI=0.39)
chr12	48237279	48237279	-	GCTGG	wt	wt	het		QUAL=5160;DP=231,356,497;MQM=60	VDR	3'UTR	VDR:NM_001017536.1:3'UTR:MODIFIER:exon10/10:c.*1245_*1249dupCCAGC:,VDR:NM_000376.2:3'UTR:MODIFIER:exon10/10:c.*1245_*1249dupCCAGC:,VDR:NM_001017535.1:3'UTR:MODIFIER:exon11/11:c.*1245_*1249dupCCAGC:		rs11574130	0.0296	0.0000	0/0/0	0.0298							601769 [VDR (provisional) Rickets,vitamin D-resistant,type IIA,277440|Osteoporosis,involutional,166710];	RCV000309957.1 [uncertain significance]; 			0	14					VDR (inh=AR+AD pLI=0.39)
chr12	48237736	48237736	A	-	het	hom	wt		QUAL=8380;DP=216,207,287;MQM=59	VDR	3'UTR	VDR:NM_001017536.1:3'UTR:MODIFIER:exon10/10:c.*793delT:,VDR:NM_000376.2:3'UTR:MODIFIER:exon10/10:c.*793delT:,VDR:NM_001017535.1:3'UTR:MODIFIER:exon11/11:c.*793delT:		rs78783628	0.0000	0.0000	0/0/0	0.3669							601769 [VDR (provisional) Rickets,vitamin D-resistant,type IIA,277440|Osteoporosis,involutional,166710];				61	119					VDR (inh=AR+AD pLI=0.39)
chr12	48237967	48237967	T	G	wt	wt	het		QUAL=1648;DP=153,125,144;MQM=60	VDR	3'UTR	VDR:NM_001017536.1:3'UTR:MODIFIER:exon10/10:c.*562A>C:,VDR:NM_000376.2:3'UTR:MODIFIER:exon10/10:c.*562A>C:,VDR:NM_001017535.1:3'UTR:MODIFIER:exon11/11:c.*562A>C:		rs3858733	0.0302	0.0000	0/0/0	0.0306							601769 [VDR (provisional) Rickets,vitamin D-resistant,type IIA,277440|Osteoporosis,involutional,166710];				0	14					VDR (inh=AR+AD pLI=0.39)
chr12	48238092	48238092	G	C	wt	wt	het		QUAL=752;DP=81,59,61;MQM=60	VDR	3'UTR	VDR:NM_001017536.1:3'UTR:MODIFIER:exon10/10:c.*437C>G:,VDR:NM_000376.2:3'UTR:MODIFIER:exon10/10:c.*437C>G:,VDR:NM_001017535.1:3'UTR:MODIFIER:exon11/11:c.*437C>G:		rs11574119	0.0315	0.0000	0/0/0	0.0057							601769 [VDR (provisional) Rickets,vitamin D-resistant,type IIA,277440|Osteoporosis,involutional,166710];	RCV000382943.1 [uncertain significance]; 			0	14					VDR (inh=AR+AD pLI=0.39)
chr12	48238221	48238221	G	T	het	hom	wt		QUAL=6431;DP=209,122,130;MQM=59	VDR	3'UTR	VDR:NM_001017536.1:3'UTR:MODIFIER:exon10/10:c.*308C>A:,VDR:NM_000376.2:3'UTR:MODIFIER:exon10/10:c.*308C>A:,VDR:NM_001017535.1:3'UTR:MODIFIER:exon11/11:c.*308C>A:		rs739837	0.4942	0.0000	0/0/0	0.0848							601769 [VDR (provisional) Rickets,vitamin D-resistant,type IIA,277440|Osteoporosis,involutional,166710];	RCV000351615.1 [likely benign]; 			61	120					VDR (inh=AR+AD pLI=0.39)
chr12	48238757	48238757	A	G	het	hom	wt		QUAL=14273;DP=254,400,547;MQM=59	VDR	synonymous	VDR:NM_001017536.1:synonymous:LOW:exon10/10:c.1206T>C:p.Ile402Ile,VDR:NM_000376.2:synonymous:LOW:exon10/10:c.1056T>C:p.Ile352Ile,VDR:NM_001017535.1:synonymous:LOW:exon11/11:c.1056T>C:p.Ile352Ile		rs731236	0.2766	0.3338	7505/5336/418	0.3310							601769 [VDR (provisional) Rickets,vitamin D-resistant,type IIA,277440|Osteoporosis,involutional,166710];	RCV000361773.1 [likely benign]; 		COSM431157, COSM3753247	267	748					VDR (inh=AR+AD pLI=0.39)
chr12	48272895	48272895	A	G	hom	hom	hom	anno_high_impact;pred_pathogenic	QUAL=4369;DP=48,48,48;MQM=60	VDR	start_lost,missense	VDR:NM_000376.2:start_lost:HIGH:exon3/10:c.2T>C:p.Met1?,VDR:NM_001017535.1:start_lost:HIGH:exon4/11:c.2T>C:p.Met1?,VDR:NM_001017536.1:missense:MODERATE:exon3/10:c.152T>C:p.Met51Thr		rs2228570	0.6715	0.6376	25052/12547/3235	0.6232	4.2980	D,D,D,D,D,D,D	T	B,P	D,D,D,D,D,D,D	23.00	601769 [VDR (provisional) Rickets,vitamin D-resistant,type IIA,277440|Osteoporosis,involutional,166710];	RCV000280730.1 [benign]; 	CM972826 [CLASS=DFP MUT=ALT PHEN="Higher bone mineral density association with" GENE=VDR]; 	COSM3753248	745	656	1	[1] auto-classification 16.06.2016  [2] Ute Grasshoff 24.11.2015			VDR (inh=AR+AD pLI=0.39)
chr12	48293716	48293716	G	T	het	wt	hom		QUAL=16795;DP=313,341,407;MQM=60	VDR	5'UTR,intron	VDR:NM_001017535.1:5'UTR:MODIFIER:exon2/11:c.-180C>A:,VDR:NM_001017536.1:intron:MODIFIER:exon1/9:c.67+4631C>A:,VDR:NM_000376.2:intron:MODIFIER:exon1/9:c.-84+5022C>A:		rs11168293	0.1661	0.0000	0/0/0	0.2512							601769 [VDR (provisional) Rickets,vitamin D-resistant,type IIA,277440|Osteoporosis,involutional,166710];	RCV000341708.1 [likely benign]; 			16	57					VDR (inh=AR+AD pLI=0.39)
chr12	48375568	48375568	A	G	het	hom	het		QUAL=20953;DP=232,397,525;MQM=59	COL2A1	synonymous	COL2A1:NM_001844.4:synonymous:LOW:exon36/54:c.2400T>C:p.Asn800Asn,COL2A1:NM_033150.2:synonymous:LOW:exon35/53:c.2193T>C:p.Asn731Asn		rs1635553	0.4828	0.4896	2790/1189/317	0.3003							120140 [COL2A1 (confirmed) Stickler syndrome,type I,108300|Kniest dysplasia,156550|Achondrogenesis,type II or hypochondrogenesis,200610|SED congenita,183900|SMED Strudwick type,184250|Epiphyseal dysplasia,multiple,with myopia and deafness,132450|Spondyloperipheral dysplasia,271700|Osteoarthritis with mild chondrodysplasia,604864|Vitreoretinopathy with phalangeal epiphyseal dysplasia|Platyspondylic skeletal dysplasia,Torrance type,151210|Otospondylomegaepiphyseal dysplasia,215150|Avascular necrosis of the femoral head,608805|Legg-Calve-Perthes disease,150600|Stickler sydrome,type I,nonsyndromic ocular,609508|Czech dysplasia,609162|Spondyloepiphyseal dysplasia,Stanescu type,616583];	RCV000079724.6 [benign]; RCV000316658.1 [likely benign]; RCV000371359.1 [likely benign]; 		COSM1606169, COSM1606168	311	799					COL2A1 (inh=AR+AD pLI=1.00)
chr12	48376291	48376291	G	A	het	hom	het		QUAL=15820;DP=296,266,313;MQM=59	COL2A1	synonymous	COL2A1:NM_001844.4:synonymous:LOW:exon34/54:c.2295C>T:p.Gly765Gly,COL2A1:NM_033150.2:synonymous:LOW:exon33/53:c.2088C>T:p.Gly696Gly		rs2276454	0.4297	0.3958	9914/5059/631	0.3931							120140 [COL2A1 (confirmed) Stickler syndrome,type I,108300|Kniest dysplasia,156550|Achondrogenesis,type II or hypochondrogenesis,200610|SED congenita,183900|SMED Strudwick type,184250|Epiphyseal dysplasia,multiple,with myopia and deafness,132450|Spondyloperipheral dysplasia,271700|Osteoarthritis with mild chondrodysplasia,604864|Vitreoretinopathy with phalangeal epiphyseal dysplasia|Platyspondylic skeletal dysplasia,Torrance type,151210|Otospondylomegaepiphyseal dysplasia,215150|Avascular necrosis of the femoral head,608805|Legg-Calve-Perthes disease,150600|Stickler sydrome,type I,nonsyndromic ocular,609508|Czech dysplasia,609162|Spondyloepiphyseal dysplasia,Stanescu type,616583];	RCV000249196.1 [benign]; RCV000292068.1 [likely benign]; RCV000385327.1 [likely benign]; 			242	776					COL2A1 (inh=AR+AD pLI=1.00)
chr12	48391416	48391416	G	T	het	hom	wt		QUAL=7844;DP=195,197,249;MQM=59	COL2A1	synonymous	COL2A1:NM_001844.4:synonymous:LOW:exon7/54:c.504C>A:p.Gly168Gly,COL2A1:NM_033150.2:synonymous:LOW:exon6/53:c.297C>A:p.Gly99Gly	(GACCAGGGG)n	rs3737548	0.2192	0.2052	2642/1526/119	0.2022							120140 [COL2A1 (confirmed) Stickler syndrome,type I,108300|Kniest dysplasia,156550|Achondrogenesis,type II or hypochondrogenesis,200610|SED congenita,183900|SMED Strudwick type,184250|Epiphyseal dysplasia,multiple,with myopia and deafness,132450|Spondyloperipheral dysplasia,271700|Osteoarthritis with mild chondrodysplasia,604864|Vitreoretinopathy with phalangeal epiphyseal dysplasia|Platyspondylic skeletal dysplasia,Torrance type,151210|Otospondylomegaepiphyseal dysplasia,215150|Avascular necrosis of the femoral head,608805|Legg-Calve-Perthes disease,150600|Stickler sydrome,type I,nonsyndromic ocular,609508|Czech dysplasia,609162|Spondyloepiphyseal dysplasia,Stanescu type,616583];	RCV000179829.3 [benign]; RCV000260987.1 [likely benign]; RCV000332793.1 [likely benign]; 		COSM3753254, COSM3753255	51	473					COL2A1 (inh=AR+AD pLI=1.00)
chr12	48391657	48391657	T	A	het	het	wt	pred_pathogenic	QUAL=11112;DP=513,364,481;MQM=60	COL2A1	missense	COL2A1:NM_001844.4:missense:MODERATE:exon6/54:c.426A>T:p.Glu142Asp,COL2A1:NM_033150.2:missense:MODERATE:exon5/53:c.219A>T:p.Glu73Asp		rs34392760	0.0180	0.0381	117/108/0	0.0381	0.5040	T,T,T	T	B,B	D,D	14.60	120140 [COL2A1 (confirmed) Stickler syndrome,type I,108300|Kniest dysplasia,156550|Achondrogenesis,type II or hypochondrogenesis,200610|SED congenita,183900|SMED Strudwick type,184250|Epiphyseal dysplasia,multiple,with myopia and deafness,132450|Spondyloperipheral dysplasia,271700|Osteoarthritis with mild chondrodysplasia,604864|Vitreoretinopathy with phalangeal epiphyseal dysplasia|Platyspondylic skeletal dysplasia,Torrance type,151210|Otospondylomegaepiphyseal dysplasia,215150|Avascular necrosis of the femoral head,608805|Legg-Calve-Perthes disease,150600|Stickler sydrome,type I,nonsyndromic ocular,609508|Czech dysplasia,609162|Spondyloepiphyseal dysplasia,Stanescu type,616583];	RCV000252660.1 [benign]; RCV000274081.1 [likely benign]; RCV000371064.1 [likely benign]; 			1	139					COL2A1 (inh=AR+AD pLI=1.00)
chr12	48398080	48398080	T	A	wt	hom	hom	low_DP;pred_pathogenic	QUAL=192;DP=513,8,1;MQM=60	COL2A1	missense	COL2A1:NM_001844.4:missense:MODERATE:exon1/54:c.25A>T:p.Thr9Ser,COL2A1:NM_033150.2:missense:MODERATE:exon1/53:c.25A>T:p.Thr9Ser		rs3803183	0.6853	0.7726	6024/2819/562	0.2779	1.8880	T,T,T	T	B,B	D,D	16.71	120140 [COL2A1 (confirmed) Stickler syndrome,type I,108300|Kniest dysplasia,156550|Achondrogenesis,type II or hypochondrogenesis,200610|SED congenita,183900|SMED Strudwick type,184250|Epiphyseal dysplasia,multiple,with myopia and deafness,132450|Spondyloperipheral dysplasia,271700|Osteoarthritis with mild chondrodysplasia,604864|Vitreoretinopathy with phalangeal epiphyseal dysplasia|Platyspondylic skeletal dysplasia,Torrance type,151210|Otospondylomegaepiphyseal dysplasia,215150|Avascular necrosis of the femoral head,608805|Legg-Calve-Perthes disease,150600|Stickler sydrome,type I,nonsyndromic ocular,609508|Czech dysplasia,609162|Spondyloepiphyseal dysplasia,Stanescu type,616583];	RCV000079725.5 [benign]; RCV000342882.1 [likely benign]; RCV000406531.1 [likely benign]; 		COSM3753256, COSM3753257	990	390					COL2A1 (inh=AR+AD pLI=1.00)
chr12	48398223	48398223	G	A	wt	hom	hom	low_DP	QUAL=200;DP=513,6,2;MQM=60	COL2A1	5'UTR	COL2A1:NM_001844.4:5'UTR:MODIFIER:exon1/54:c.-119C>T:,COL2A1:NM_033150.2:5'UTR:MODIFIER:exon1/53:c.-119C>T:		rs3803182	0.7276	0.0000	0/0/0	0.7678							120140 [COL2A1 (confirmed) Stickler syndrome,type I,108300|Kniest dysplasia,156550|Achondrogenesis,type II or hypochondrogenesis,200610|SED congenita,183900|SMED Strudwick type,184250|Epiphyseal dysplasia,multiple,with myopia and deafness,132450|Spondyloperipheral dysplasia,271700|Osteoarthritis with mild chondrodysplasia,604864|Vitreoretinopathy with phalangeal epiphyseal dysplasia|Platyspondylic skeletal dysplasia,Torrance type,151210|Otospondylomegaepiphyseal dysplasia,215150|Avascular necrosis of the femoral head,608805|Legg-Calve-Perthes disease,150600|Stickler sydrome,type I,nonsyndromic ocular,609508|Czech dysplasia,609162|Spondyloepiphyseal dysplasia,Stanescu type,616583];	RCV000314719.1 [likely benign]; RCV000367182.1 [likely benign]; 			86	27					COL2A1 (inh=AR+AD pLI=1.00)
chr12	49413486	49413486	C	T	wt	het	wt		QUAL=1463;DP=271,132,221;MQM=60	KMT2D	3'UTR	KMT2D:NM_003482.3:3'UTR:MODIFIER:exon54/54:c.*2077G>A:		rs7975791	0.0102	0.0000	0/0/0	0.0042							602113 [KMT2D (provisional) Kabuki syndrome 1,147920];	RCV000302791.1 [likely benign]; 			1	15					KMT2D (inh=AD pLI=1.00)
chr12	49418435	49418435	A	C	het	het	wt		QUAL=2479;DP=113,106,144;MQM=60	KMT2D	synonymous	KMT2D:NM_003482.3:synonymous:LOW:exon50/54:c.15978T>G:p.Leu5326Leu		rs55776396	0.0174	0.0273	66/43/1	0.0261							602113 [KMT2D (provisional) Kabuki syndrome 1,147920];	RCV000080152.6 [benign]; RCV000365512.1 [likely benign]; 			4	131					KMT2D (inh=AD pLI=1.00)
chr12	49424534	49424534	G	A	het	wt	het		QUAL=1799;DP=87,53,65;MQM=60	KMT2D	synonymous	KMT2D:NM_003482.3:synonymous:LOW:exon41/54:c.13689C>T:p.Pro4563Pro		rs11168830	0.1228	0.0946	1243/47/12	0.0878							602113 [KMT2D (provisional) Kabuki syndrome 1,147920];	RCV000080132.7 [benign]; RCV000264135.1 [benign]; 		COSM3753293, COSM3753292	9	133					KMT2D (inh=AD pLI=1.00)
chr12	49425978	49425978	T	C	wt	wt	het		QUAL=3357;DP=162,221,335;MQM=60	KMT2D	synonymous	KMT2D:NM_003482.3:synonymous:LOW:exon39/54:c.12510A>G:p.Pro4170Pro		rs3741622	0.2754	0.3192	6750/3740/32	0.3140							602113 [KMT2D (provisional) Kabuki syndrome 1,147920];	RCV000080121.7 [benign]; RCV000405693.1 [benign]; 		COSM147495, COSM3998819	181	688					KMT2D (inh=AD pLI=1.00)
chr12	49426460	49426460	A	G	het	het	wt	pred_pathogenic	QUAL=6875;DP=210,358,454;MQM=59	KMT2D	missense	KMT2D:NM_003482.3:missense:MODERATE:exon39/54:c.12028T>C:p.Ser4010Pro		rs80132640	0.0172	0.0288	56/35/1	0.0256	1.4120	D	T	B	T	1.10	602113 [KMT2D (provisional) Kabuki syndrome 1,147920];	RCV000080117.8 [benign]; RCV000353616.1 [likely benign]; 			4	130					KMT2D (inh=AD pLI=1.00)
chr12	49427652	49427652	C	T	het	het	het		QUAL=13869;DP=308,388,515;MQM=59	KMT2D	synonymous	KMT2D:NM_003482.3:synonymous:LOW:exon39/54:c.10836G>A:p.Gln3612Gln	(TGC)n	rs3782357	0.4435	0.4616	3953/1823/660	0.3110							602113 [KMT2D (provisional) Kabuki syndrome 1,147920];	RCV000080105.7 [benign]; RCV000287333.1 [benign]; 		COSM431202, COSM431203	231	731					KMT2D (inh=AD pLI=1.00)
chr12	49434074	49434074	C	A	het	het	het	low_DP	QUAL=649;DP=26,19,24;MQM=59	KMT2D	synonymous	KMT2D:NM_003482.3:synonymous:LOW:exon31/54:c.7479G>T:p.Gly2493Gly		rs10747559	0.4355	0.4197	9996/5433/993	0.3929							602113 [KMT2D (provisional) Kabuki syndrome 1,147920];	RCV000080211.7 [benign]; RCV000404970.1 [benign]; 		COSM3722550, COSM3722551	288	782					KMT2D (inh=AD pLI=1.00)
chr12	49442562	49442563	AG	-	het	het	wt		QUAL=7161;DP=294,334,437;MQM=59	KMT2D	splice_region&intron	KMT2D:NM_003482.3:splice_region&intron:LOW:exon12/53:c.4021-11_4021-10delCT:		rs55776244	0.0539	0.0384	138/37/78	0.0350							602113 [KMT2D (provisional) Kabuki syndrome 1,147920];	RCV000080177.7 [benign]; RCV000363557.1 [benign]; 			4	135					KMT2D (inh=AD pLI=1.00)
chr12	49444545	49444545	G	A	het	het	het		QUAL=1097;DP=54,25,25;MQM=59	KMT2D	synonymous	KMT2D:NM_003482.3:synonymous:LOW:exon11/54:c.2826C>T:p.Ile942Ile		rs2241726	0.4036	0.3796	8821/4499/894	0.3702							602113 [KMT2D (provisional) Kabuki syndrome 1,147920];	RCV000080169.7 [benign]; RCV000302786.1 [benign]; 		COSM147497, COSM3753294	240	723					KMT2D (inh=AD pLI=1.00)
chr12	49445028	49445028	G	A	wt	wt	het	low_DP	QUAL=44;DP=33,7,8;MQM=60	KMT2D	missense	KMT2D:NM_003482.3:missense:MODERATE:exon10/54:c.2438C>T:p.Pro813Leu		rs75226229	0.0160	0.0427	155/113/0	0.0381	-0.5870	T	T	B	T	2.76	602113 [KMT2D (provisional) Kabuki syndrome 1,147920];	RCV000080165.8 [benign]; RCV000262518.1 [benign]; 		COSM3753295	5	134					KMT2D (inh=AD pLI=1.00)
chr12	49448463	49448463	C	T	het	het	wt	anno_pathogenic_hgmd	QUAL=2811;DP=130,101,136;MQM=59	KMT2D	missense	KMT2D:NM_003482.3:missense:MODERATE:exon3/54:c.248G>A:p.Arg83Gln		rs55865069	0.0164	0.0277	53/34/1	0.0250	0.6130	T,T	T	B	T	19.80	602113 [KMT2D (provisional) Kabuki syndrome 1,147920];	RCV000080166.7 [benign]; RCV000328729.1 [likely benign]; 	CM165012 [CLASS=DM? MUT=ALT PHEN="Atrioventricular septum defect" GENE=KMT2D]; 	COSM3773643, COSM3773644	4	125					KMT2D (inh=AD pLI=1.00)
chr12	50898784	50898784	-	GGC	wt	wt	hom	low_DP	QUAL=698;DP=1,46,31;MQM=60	DIP2B	5'UTR	DIP2B:NM_173602.2:5'UTR:MODIFIER:exon1/38:c.-119_-117dupCGG:		rs574938327	0.0000	0.0000	0/0/0	0.0111							611379 [DIP2B (provisional) Mental retardation,FRA12A type,136630];				2	7					DIP2B (inh=n/a pLI=1.00)
chr12	51135275	51135275	T	C	hom	hom	hom		QUAL=47585;DP=460,465,546;MQM=60	DIP2B	synonymous	DIP2B:NM_173602.2:synonymous:LOW:exon37/38:c.4431T>C:p.Ile1477Ile		rs1866422	0.9599	0.9884	59362/33338/3978	0.9509							611379 [DIP2B (provisional) Mental retardation,FRA12A type,136630];				1563	4					DIP2B (inh=n/a pLI=1.00)
chr12	51139279	51139279	A	G	hom	het	het		QUAL=10730;DP=181,147,210;MQM=60	DIP2B	3'UTR	DIP2B:NM_173602.2:3'UTR:MODIFIER:exon38/38:c.*657A>G:		rs4768914	0.2905	0.0000	0/0/0	0.3022							611379 [DIP2B (provisional) Mental retardation,FRA12A type,136630];				16	95					DIP2B (inh=n/a pLI=1.00)
chr12	51139692	51139692	T	G	hom	het	het		QUAL=12555;DP=310,99,133;MQM=60	DIP2B	3'UTR	DIP2B:NM_173602.2:3'UTR:MODIFIER:exon38/38:c.*1070T>G:		rs35845404	0.2907	0.0000	0/0/0	0.3019							611379 [DIP2B (provisional) Mental retardation,FRA12A type,136630];				15	96					DIP2B (inh=n/a pLI=1.00)
chr12	51139803	51139803	C	A	hom	het	het		QUAL=9694;DP=195,108,171;MQM=60	DIP2B	3'UTR	DIP2B:NM_173602.2:3'UTR:MODIFIER:exon38/38:c.*1181C>A:		rs3742063	0.2534	0.0000	0/0/0	0.2908							611379 [DIP2B (provisional) Mental retardation,FRA12A type,136630];				15	96					DIP2B (inh=n/a pLI=1.00)
chr12	51139892	51139892	C	T	hom	het	het		QUAL=12200;DP=262,146,214;MQM=60	DIP2B	3'UTR	DIP2B:NM_173602.2:3'UTR:MODIFIER:exon38/38:c.*1270C>T:		rs3742064	0.2740	0.0000	0/0/0	0.2973							611379 [DIP2B (provisional) Mental retardation,FRA12A type,136630];				15	96					DIP2B (inh=n/a pLI=1.00)
chr12	51140410	51140410	C	G	hom	hom	hom		QUAL=28644;DP=389,225,271;MQM=60	DIP2B	3'UTR	DIP2B:NM_173602.2:3'UTR:MODIFIER:exon38/38:c.*1788C>G:		rs7303202	0.8389	0.0000	0/0/0	0.8966							611379 [DIP2B (provisional) Mental retardation,FRA12A type,136630];				212	18					DIP2B (inh=n/a pLI=1.00)
chr12	51141883	51141883	A	G	hom	hom	hom		QUAL=29929;DP=373,253,305;MQM=60	DIP2B	3'UTR	DIP2B:NM_173602.2:3'UTR:MODIFIER:exon38/38:c.*3261A>G:		rs4768915	0.7953	0.0000	0/0/0	0.1792							611379 [DIP2B (provisional) Mental retardation,FRA12A type,136630];				212	18					DIP2B (inh=n/a pLI=1.00)
chr12	53703021	53703021	G	A	hom	hom	hom		QUAL=9602;DP=148,71,98;MQM=60	AAAS	synonymous	AAAS:NM_015665.5:synonymous:LOW:exon9/16:c.855C>T:p.Phe285Phe,AAAS:NM_001173466.1:synonymous:LOW:exon8/15:c.756C>T:p.Phe252Phe		rs1546808	0.9153	0.9745	57989/33276/2750	0.9058							605378 [AAAS (confirmed) Achalasia-addisonianism-alacrimia syndrome,231550];	RCV000116212.2 [likely benign]; RCV000378616.1 [benign]; 			1549	16					AAAS (inh=AR pLI=0.00)
chr12	56082025	56082025	G	C	het	het	wt		QUAL=14845;DP=612,495,656;MQM=60	ITGA7	synonymous	ITGA7:NM_001144996.1:synonymous:LOW:exon23/25:c.3030C>G:p.Ser1010Ser,ITGA7:NM_002206.2:synonymous:LOW:exon23/25:c.3018C>G:p.Ser1006Ser,ITGA7:NM_001144997.1:synonymous:LOW:exon23/25:c.2739C>G:p.Ser913Ser		rs17117883	0.0443	0.0416	134/77/17	0.0416							600536 [ITGA7 (provisional) Muscular dystrophy,congenital,due to ITGA7 deficiency,613204];	RCV000117295.3 [other]; RCV000368589.1 [uncertain significance]; 		COSM1128538, COSM1128539	8	172					ITGA7 (inh=AR pLI=0.00)
chr12	56087806	56087806	G	A	wt	het	wt	pred_pathogenic	QUAL=4668;DP=232,363,389;MQM=60	ITGA7	missense&splice_region	ITGA7:NM_001144996.1:missense&splice_region:MODERATE:exon19/25:c.2546C>T:p.Thr849Met,ITGA7:NM_002206.2:missense&splice_region:MODERATE:exon19/25:c.2534C>T:p.Thr845Met,ITGA7:NM_001144997.1:missense&splice_region:MODERATE:exon19/25:c.2255C>T:p.Thr752Met		rs55654066	0.0000	0.0001	0/0/0	0.0001	1.3890	D,D,D,D,D,D,D,T,D	T	P,P,B,P	T,T,T,T,T,T,T,T	26.30	600536 [ITGA7 (provisional) Muscular dystrophy,congenital,due to ITGA7 deficiency,613204];				0	2					ITGA7 (inh=AR pLI=0.00)
chr12	56089344	56089344	A	G	het	wt	het		QUAL=2330;DP=107,129,136;MQM=59	ITGA7	synonymous	ITGA7:NM_001144996.1:synonymous:LOW:exon14/25:c.1977T>C:p.Cys659Cys,ITGA7:NM_002206.2:synonymous:LOW:exon14/25:c.1965T>C:p.Cys655Cys,ITGA7:NM_001144997.1:synonymous:LOW:exon14/25:c.1686T>C:p.Cys562Cys		rs7971022	0.0098	0.0164	24/15/0	0.0166							600536 [ITGA7 (provisional) Muscular dystrophy,congenital,due to ITGA7 deficiency,613204];	RCV000079980.8 [other]; RCV000287455.1 [uncertain significance]; 			1	66					ITGA7 (inh=AR pLI=0.00)
chr12	56089357	56089357	C	T	het	het	hom		QUAL=7536;DP=166,149,151;MQM=59	ITGA7	missense	ITGA7:NM_001144996.1:missense:MODERATE:exon14/25:c.1964G>A:p.Arg655His,ITGA7:NM_002206.2:missense:MODERATE:exon14/25:c.1952G>A:p.Arg651His,ITGA7:NM_001144997.1:missense:MODERATE:exon14/25:c.1673G>A:p.Arg558His		rs1800974	0.5994	0.5854	22147/8870/590	0.5764	0.2040	T,T,T,T,T,T,T,T	T	B,B,B,B	T,T,T,T,T,T,T,T	18.52	600536 [ITGA7 (provisional) Muscular dystrophy,congenital,due to ITGA7 deficiency,613204];	RCV000079979.6 [benign]; RCV000392154.1 [benign]; 	CM067685 [CLASS=DP MUT=ALT PHEN="Lung cancer susceptibility to association with" GENE=ITGA7]; 	COSM4147273, COSM4147274, COSM4147272, COSM4147275	441	770					ITGA7 (inh=AR pLI=0.00)
chr12	56398454	56398454	G	C	hom	hom	hom		QUAL=23432;DP=261,210,283;MQM=60	SUOX	synonymous	SUOX:NM_000456.2:synonymous:LOW:exon6/6:c.1281G>C:p.Ser427Ser,SUOX:NM_001032386.1:synonymous:LOW:exon5/5:c.1281G>C:p.Ser427Ser,SUOX:NM_001032387.1:synonymous:LOW:exon4/4:c.1281G>C:p.Ser427Ser		rs773115	0.7522	0.8730	47850/27916/655	0.8421							606887 [SUOX (provisional) Sulfite oxidase deficiency,272300];	RCV000118423.3 [other]; RCV000363638.1 [benign]; RCV000268966.1 [likely benign]; 			1331	219					SUOX (inh=AR pLI=0.00)
chr12	56473808	56473808	T	C	het	het	het		QUAL=1499;DP=35,37,52;MQM=59	RPS26-ERBB3	intergenic_region	RPS26-ERBB3:RPS26-ERBB3:intergenic_region:MODIFIER::n.56473808T>C:		rs7297175	0.6508	0.0000	0/0/0	0.5476							190151 [ERBB3 (confirmed) Lethal congenital contractural syndrome 2,607598];				66	69					RPS26-ERBB3 (inh=n/a pLI=n/a)
chr12	56477694	56477694	A	T	het	het	het		QUAL=12299;DP=205,356,482;MQM=59	ERBB3	splice_region&intron	ERBB3:NM_001982.3:splice_region&intron:LOW:exon2/27:c.234+8A>T:,ERBB3:NM_001005915.1:splice_region&intron:LOW:exon2/2:c.234+8A>T:		rs2271194	0.5923	0.6173	24096/11601/525	0.6014							190151 [ERBB3 (confirmed) Lethal congenital contractural syndrome 2,607598];				656	747					ERBB3 (inh=AR pLI=0.00)
chr12	56493822	56493822	A	C	het	het	het		QUAL=15969;DP=417,342,442;MQM=59	ERBB3	splice_region&intron	ERBB3:NM_001982.3:splice_region&intron:LOW:exon25/27:c.3129+9A>C:		rs2292238	0.2951	0.3612	8237/5447/198	0.3603							190151 [ERBB3 (confirmed) Lethal congenital contractural syndrome 2,607598];			COSM3998886, COSM3998887	200	755					ERBB3 (inh=AR pLI=0.00)
chr12	56494991	56494991	G	A	het	het	het		QUAL=7856;DP=193,198,252;MQM=60	ERBB3	synonymous	ERBB3:NM_001982.3:synonymous:LOW:exon27/28:c.3348G>A:p.Arg1116Arg		rs2271189	0.2522	0.3417	7518/5186/93	0.3369							190151 [ERBB3 (confirmed) Lethal congenital contractural syndrome 2,607598];				189	749					ERBB3 (inh=AR pLI=0.00)
chr12	65108160	65108160	G	C	het	hom	wt		QUAL=16111;DP=573,284,371;MQM=60	GNS	3'UTR	GNS:NM_002076.3:3'UTR:MODIFIER:exon14/14:c.*2361C>G:		rs1061743	0.6064	0.0000	0/0/0	0.6114							607664 [GNS (provisional) Mucopolysaccharidosis type IIID,252940];	RCV000307546.1 [benign]; 			79	134					GNS (inh=AR pLI=0.08)
chr12	65108586	65108586	G	C	het	wt	het		QUAL=5333;DP=251,116,166;MQM=60	GNS	3'UTR	GNS:NM_002076.3:3'UTR:MODIFIER:exon14/14:c.*1935C>G:			0.0000	0.0000	0/0/0	0.0000							607664 [GNS (provisional) Mucopolysaccharidosis type IIID,252940];				0	2					GNS (inh=AR pLI=0.08)
chr12	65109168	65109168	C	T	het	hom	wt		QUAL=5596;DP=203,107,129;MQM=56	GNS	3'UTR	GNS:NM_002076.3:3'UTR:MODIFIER:exon14/14:c.*1353G>A:	AluSx3	rs1269548	0.5939	0.0000	0/0/0	0.5368							607664 [GNS (provisional) Mucopolysaccharidosis type IIID,252940];	RCV000324716.1 [benign]; 			101	133					GNS (inh=AR pLI=0.08)
chr12	65110141	65110141	G	A	het	hom	wt		QUAL=11986;DP=483,182,306;MQM=60	GNS	3'UTR	GNS:NM_002076.3:3'UTR:MODIFIER:exon14/14:c.*380C>T:	(GT)n	rs674	0.7157	0.0000	0/0/0	0.6438							607664 [GNS (provisional) Mucopolysaccharidosis type IIID,252940];	RCV000299072.1 [benign]; 			82	136					GNS (inh=AR pLI=0.08)
chr12	65110252	65110252	G	A	het	hom	wt		QUAL=13124;DP=520,206,337;MQM=60	GNS	3'UTR	GNS:NM_002076.3:3'UTR:MODIFIER:exon14/14:c.*269C>T:		rs2279597	0.1953	0.0000	0/0/0	0.2582							607664 [GNS (provisional) Mucopolysaccharidosis type IIID,252940];	RCV000358700.1 [likely benign]; 			16	112					GNS (inh=AR pLI=0.08)
chr12	65146532	65146532	C	T	het	hom	wt		QUAL=7720;DP=352,125,175;MQM=60	GNS	synonymous	GNS:NM_002076.3:synonymous:LOW:exon2/14:c.198G>A:p.Pro66Pro		rs1147096	0.0000	0.6550	25120/11214/3804	0.6181							607664 [GNS (provisional) Mucopolysaccharidosis type IIID,252940];	RCV000079972.5 [benign]; RCV000337177.1 [benign]; 			566	751					GNS (inh=AR pLI=0.08)
chr12	66218494	66218513	TCTCTCTCTCTCTCTCTCTC	-	wt	wt	hom	low_DP	QUAL=3401;DP=1,42,92;MQM=59	HMGA2,RPSAP52	5'UTR,intron	HMGA2:NM_001300919.1:5'UTR:MODIFIER:exon1/4:c.-521_-502delTCTCTCTCTCTCTCTCTCTC:,HMGA2:NM_003484.1:5'UTR:MODIFIER:exon1/4:c.-521_-502delTCTCTCTCTCTCTCTCTCTC:,HMGA2:NM_001300918.1:5'UTR:MODIFIER:exon1/5:c.-521_-502delTCTCTCTCTCTCTCTCTCTC:,HMGA2:NM_003483.4:5'UTR:MODIFIER:exon1/5:c.-521_-502delTCTCTCTCTCTCTCTCTCTC:,RPSAP52:NR_026825.2:intron:MODIFIER:exon1/1:n.132+2110_132+2129delGAGAGAGAGAGAGAGAGAGA:	(TC)n		0.0000	0.0000	0/0/0	0.0000							600698 [HMGA2 (confirmed) Leiomyoma,uterine,somatic,150699];				1	0					HMGA2 (inh=AD pLI=0.73), RPSAP52 (inh=n/a pLI=n/a)
chr12	66218507	66218507	-	TCTCTG	hom	hom	wt	low_DP	QUAL=3401;DP=1,42,92;MQM=60	HMGA2,RPSAP52	5'UTR,intron	HMGA2:NM_001300919.1:5'UTR:MODIFIER:exon1/4:c.-539_-538insGTCTCT:,HMGA2:NM_003484.1:5'UTR:MODIFIER:exon1/4:c.-539_-538insGTCTCT:,HMGA2:NM_001300918.1:5'UTR:MODIFIER:exon1/5:c.-539_-538insGTCTCT:,HMGA2:NM_003483.4:5'UTR:MODIFIER:exon1/5:c.-539_-538insGTCTCT:,RPSAP52:NR_026825.2:intron:MODIFIER:exon1/1:n.132+2115_132+2116insCAGAGA:	(TC)n		0.0000	0.0000	0/0/0	0.0003							600698 [HMGA2 (confirmed) Leiomyoma,uterine,somatic,150699];				0	0					HMGA2 (inh=AD pLI=0.73), RPSAP52 (inh=n/a pLI=n/a)
chr12	66309196	66309196	-	T	wt	wt	het		QUAL=3428;DP=453,212,294;MQM=60	HMGA2	3'UTR,intron	HMGA2:NM_001300919.1:3'UTR:MODIFIER:exon4/4:c.*503dupT:,HMGA2:NM_003484.1:3'UTR:MODIFIER:exon4/4:c.*287dupT:,HMGA2:NM_001300918.1:intron:MODIFIER:exon3/4:c.250-35966dupT:,HMGA2:NM_003483.4:intron:MODIFIER:exon3/4:c.250-35966dupT:	MER91A	rs397693908	0.1302	0.0000	0/0/0	0.1291							600698 [HMGA2 (confirmed) Leiomyoma,uterine,somatic,150699];				3	39					HMGA2 (inh=AD pLI=0.73)
chr12	66357946	66357946	A	T	wt	het	wt		QUAL=1665;DP=345,127,130;MQM=60	HMGA2	3'UTR	HMGA2:NM_003483.4:3'UTR:MODIFIER:exon5/5:c.*874A>T:		rs80299335	0.0164	0.0000	0/0/0	0.0334							600698 [HMGA2 (confirmed) Leiomyoma,uterine,somatic,150699];				2	26					HMGA2 (inh=AD pLI=0.73)
chr12	66358120	66358121	TT	-	het	het	wt		QUAL=4137;DP=287,62,117;MQM=59	HMGA2	3'UTR	HMGA2:NM_003483.4:3'UTR:MODIFIER:exon5/5:c.*1048_*1049delTT:	(TC)n	rs10573247	0.3327	0.0000	0/0/0	0.2350							600698 [HMGA2 (confirmed) Leiomyoma,uterine,somatic,150699];				5	78					HMGA2 (inh=AD pLI=0.73)
chr12	66358347	66358347	C	T	het	hom	wt		QUAL=6508;DP=188,107,174;MQM=60	HMGA2	3'UTR	HMGA2:NM_003483.4:3'UTR:MODIFIER:exon5/5:c.*1275C>T:		rs1042725	0.5825	0.0000	0/0/0	0.0945							600698 [HMGA2 (confirmed) Leiomyoma,uterine,somatic,150699];		CR078543 [CLASS=DFP MUT=REF PHEN="Increased height association with" GENE=HMGA2]; 		66	114					HMGA2 (inh=AD pLI=0.73)
chr12	66358571	66358571	C	A	het	het	wt		QUAL=3224;DP=194,48,47;MQM=60	HMGA2	3'UTR	HMGA2:NM_003483.4:3'UTR:MODIFIER:exon5/5:c.*1499C>A:		rs1042729	0.0176	0.0000	0/0/0	0.0071							600698 [HMGA2 (confirmed) Leiomyoma,uterine,somatic,150699];				1	26					HMGA2 (inh=AD pLI=0.73)
chr12	66359752	66359752	C	A	het	hom	wt		QUAL=9267;DP=397,129,188;MQM=60	HMGA2	3'UTR	HMGA2:NM_003483.4:3'UTR:MODIFIER:exon5/5:c.*2680C>A:		rs8756	0.6919	0.0000	0/0/0	0.6109							600698 [HMGA2 (confirmed) Leiomyoma,uterine,somatic,150699];				73	111					HMGA2 (inh=AD pLI=0.73)
chr12	66360068	66360068	C	T	het	het	wt		QUAL=8874;DP=367,328,473;MQM=60	HMGA2	3'UTR	HMGA2:NM_003483.4:3'UTR:MODIFIER:exon5/5:c.*2996C>T:		rs11175982	0.3325	0.0000	0/0/0	0.2897							600698 [HMGA2 (confirmed) Leiomyoma,uterine,somatic,150699];				5	78					HMGA2 (inh=AD pLI=0.73)
chr12	66741538	66741538	T	-	het	het	het		QUAL=4146;DP=203,63,89;MQM=59	GRIP1	3'UTR	GRIP1:NM_021150.3:3'UTR:MODIFIER:exon24/24:c.*1261delA:,GRIP1:NM_001178074.1:3'UTR:MODIFIER:exon23/23:c.*1261delA:		rs397850337	0.4770	0.0000	0/0/0	0.2970							604597 [GRIP1 (provisional) Fraser syndrome,219000];	RCV000308024.1 [benign]; 			49	116					GRIP1 (inh=AR pLI=0.92)
chr12	66742183	66742183	A	G	het	het	het		QUAL=15616;DP=529,296,378;MQM=60	GRIP1	3'UTR	GRIP1:NM_021150.3:3'UTR:MODIFIER:exon24/24:c.*616T>C:,GRIP1:NM_001178074.1:3'UTR:MODIFIER:exon23/23:c.*616T>C:		rs1168308	0.5038	0.0000	0/0/0	0.4863							604597 [GRIP1 (provisional) Fraser syndrome,219000];	RCV000291068.1 [benign]; 			47	118					GRIP1 (inh=AR pLI=0.92)
chr12	66786091	66786091	G	C	hom	hom	hom	pred_pathogenic	QUAL=13465;DP=139,134,152;MQM=60	GRIP1	missense	GRIP1:NM_021150.3:missense:MODERATE:exon18/24:c.2305C>G:p.Gln769Glu,GRIP1:NM_001178074.1:missense:MODERATE:exon18/23:c.2305C>G:p.Gln769Glu		rs13277	0.8437	0.9494	55143/33228/1967	0.9296	7.3090	T,T,T,T,T,T	T	B,B,B,B	T,T,T,T,T,T	5.74	604597 [GRIP1 (provisional) Fraser syndrome,219000];	RCV000247437.1 [benign]; RCV000328734.1 [benign]; 			1526	28					GRIP1 (inh=AR pLI=0.92)
chr12	66786171	66786171	A	C	het	wt	het	anno_pathogenic_hgmd	QUAL=8180;DP=381,182,219;MQM=59	GRIP1	missense	GRIP1:NM_021150.3:missense:MODERATE:exon18/24:c.2225T>G:p.Met742Arg,GRIP1:NM_001178074.1:missense:MODERATE:exon18/23:c.2225T>G:p.Met742Arg		rs144494437	0.0014	0.0018	2/1/0	0.0016	1.3260	.,T,T,T,T,T,T	T,T	.,B,B,B,B	.,T,T,T,T,T,T	0.06	604597 [GRIP1 (provisional) Fraser syndrome,219000];	RCV000216399.1 [likely benign]; 	CM112031 [CLASS=DM MUT=ALT PHEN="Autism" GENE=GRIP1]; 		0	21	3	[3] Stephan Waldm?ller 13.08.2014 [n/a] comment imported from detected variant: Nur 1 Bericht mit Assoziation			GRIP1 (inh=AR pLI=0.92)
chr12	81102891	81102891	C	A	het	het	het		QUAL=14036;DP=379,308,449;MQM=60	MYF6	3'UTR	MYF6:NM_002469.2:3'UTR:MODIFIER:exon3/3:c.*152C>A:		rs3120	0.1064	0.0000	0/0/0	0.0346							159991 [MYF6 (confirmed) Myopathy,centronuclear,3,614408];	RCV000386200.1 [likely benign]; 			16	79					MYF6 (inh=AD pLI=0.08)
chr12	81102921	81102921	T	C	het	het	hom		QUAL=20318;DP=341,260,419;MQM=59	MYF6	3'UTR	MYF6:NM_002469.2:3'UTR:MODIFIER:exon3/3:c.*182T>C:		rs3121	0.4585	0.0000	0/0/0	0.3895							159991 [MYF6 (confirmed) Myopathy,centronuclear,3,614408];	RCV000292087.1 [benign]; 			35	101					MYF6 (inh=AD pLI=0.08)
chr12	81103085	81103085	A	G	het	het	het		QUAL=8522;DP=484,83,132;MQM=60	MYF6	3'UTR	MYF6:NM_002469.2:3'UTR:MODIFIER:exon3/3:c.*346A>G:		rs1047183	0.1056	0.0000	0/0/0	0.0289							159991 [MYF6 (confirmed) Myopathy,centronuclear,3,614408];	RCV000288148.1 [uncertain significance]; RCV000342986.1 [likely benign]; 			16	79					MYF6 (inh=AD pLI=0.08)
chr12	81103144	81103144	A	G	het	het	hom		QUAL=3987;DP=125,39,64;MQM=60	MYF6	3'UTR	MYF6:NM_002469.2:3'UTR:MODIFIER:exon3/3:c.*405A>G:		rs1047185	0.4585	0.0000	0/0/0	0.0770							159991 [MYF6 (confirmed) Myopathy,centronuclear,3,614408];	RCV000406980.1 [benign]; 			34	101					MYF6 (inh=AD pLI=0.08)
chr12	88483273	88483273	A	-	hom	hom	hom		QUAL=8604;DP=145,67,71;MQM=59	CEP290	splice_region&intron	CEP290:NM_025114.3:splice_region&intron:LOW:exon30/53:c.3574-9delT:		rs398020484	0.8736	0.9161	6265/3194/382	0.5248							610142 [CEP290 (confirmed) Joubert syndrome 5,610188|Senior-Loken syndrome 6,610189|Leber congenital amaurosis 10,611755|Meckel syndrome 4,611134|Bardet-Biedl syndrome 14,615991];	RCV000082247.5 [benign]; RCV000196108.3 [benign]; RCV000196108.3 [benign]; RCV000196108.3 [benign]; RCV000268851.1 [benign]; RCV000307583.1 [benign]; RCV000313246.1 [benign]; RCV000364690.1 [benign]; RCV000370292.1 [benign]; 			2414	288					CEP290 (inh=AR pLI=0.00)
chr12	88505078	88505078	T	C	hom	hom	hom		QUAL=13777;DP=207,85,120;MQM=60	CEP290	synonymous	CEP290:NM_025114.3:synonymous:LOW:exon22/54:c.2268A>G:p.Ser756Ser		rs2468255	0.7646	0.8888	28347/16074/567	0.8494							610142 [CEP290 (confirmed) Joubert syndrome 5,610188|Senior-Loken syndrome 6,610189|Leber congenital amaurosis 10,611755|Meckel syndrome 4,611134|Bardet-Biedl syndrome 14,615991];	RCV000124245.1 [benign]; RCV000231629.1 [benign]; RCV000231629.1 [benign]; RCV000231629.1 [benign]; RCV000114186.2 [likely benign]; 			2359	384					CEP290 (inh=AR pLI=0.00)
chr12	102154900	102154900	A	G	het	wt	het		QUAL=5242;DP=244,148,167;MQM=60	GNPTAB	splice_region&intron	GNPTAB:NM_024312.4:splice_region&intron:LOW:exon15/20:c.3135+5T>C:		rs759935	0.6905	0.6015	22256/9352/2819	0.5890							607840 [GNPTAB (confirmed) Mucolipidosis III alpha/beta,252600|Mucolipidosis II alpha/beta,252500];	RCV000082191.5 [benign]; RCV000270011.1 [benign]; RCV000362355.1 [benign]; 			499	751					GNPTAB (inh=AR pLI=0.00)
chr12	102158763	102158763	T	C	het	wt	het		QUAL=8992;DP=439,210,302;MQM=60	GNPTAB	synonymous	GNPTAB:NM_024312.4:synonymous:LOW:exon13/21:c.1932A>G:p.Thr644Thr		rs10778148	0.6514	0.5885	21589/9378/2161	0.5811							607840 [GNPTAB (confirmed) Mucolipidosis III alpha/beta,252600|Mucolipidosis II alpha/beta,252500];	RCV000082189.5 [benign]; RCV000268458.1 [benign]; RCV000301696.1 [benign]; 		COSM1127589	492	751					GNPTAB (inh=AR pLI=0.00)
chr12	102224492	102224494	GCC	-	wt	wt	het	low_QUAL;low_DP	QUAL=18;DP=6,15,45;MQM=58	GNPTAB	5'UTR	GNPTAB:NM_024312.4:5'UTR:MODIFIER:exon1/21:c.-41_-39delGGC:		rs76300806;rs766382404	0.7023	0.4186	5157/2335/386	0.3564							607840 [GNPTAB (confirmed) Mucolipidosis III alpha/beta,252600|Mucolipidosis II alpha/beta,252500];	RCV000245561.1 [benign]; RCV000267238.1 [benign]; RCV000364177.1 [benign]; 			196	313					GNPTAB (inh=AR pLI=0.00)
chr12	102224610	102224610	G	T	wt	wt	hom	low_DP	QUAL=98;DP=6,15,4;MQM=60	GNPTAB	5'UTR	GNPTAB:NM_024312.4:5'UTR:MODIFIER:exon1/21:c.-157C>A:		rs140600142	0.0695	0.0000	0/0/0	0.0863							607840 [GNPTAB (confirmed) Mucolipidosis III alpha/beta,252600|Mucolipidosis II alpha/beta,252500];	RCV000280513.1 [likely benign]; RCV000319137.1 [likely benign]; 			1	14					GNPTAB (inh=AR pLI=0.00)
chr12	102789901	102789901	G	A	het	wt	het		QUAL=7375;DP=350,143,230;MQM=60	IGF1	3'UTR	IGF1:NM_001111284.1:3'UTR:MODIFIER:exon4/4:c.*6384C>T:,IGF1:NM_000618.4:3'UTR:MODIFIER:exon4/4:c.*6384C>T:,IGF1:NM_001111283.2:3'UTR:MODIFIER:exon5/5:c.*6418C>T:		rs6222	0.0202	0.0000	0/0/0	0.0029							147440 [IGF1 (confirmed) Growth retardation with deafness and mental retardation due to IGF1 deficiency,608747];	RCV000292383.1 [likely benign]; 			0	8					IGF1 (inh=AR pLI=0.47)
chr12	102790780	102790780	A	T	het	het	hom	low_DP	QUAL=1769;DP=102,11,4;MQM=59	IGF1	3'UTR	IGF1:NM_001111284.1:3'UTR:MODIFIER:exon4/4:c.*5505T>A:,IGF1:NM_000618.4:3'UTR:MODIFIER:exon4/4:c.*5505T>A:,IGF1:NM_001111283.2:3'UTR:MODIFIER:exon5/5:c.*5539T>A:	AluSx3	rs1140655	0.6190	0.0000	0/0/0	0.6076							147440 [IGF1 (confirmed) Growth retardation with deafness and mental retardation due to IGF1 deficiency,608747];	RCV000304519.1 [benign]; 			113	68					IGF1 (inh=AR pLI=0.47)
chr12	102791801	102791801	A	-	het	wt	het		QUAL=2529;DP=148,21,28;MQM=60	IGF1	3'UTR	IGF1:NM_001111284.1:3'UTR:MODIFIER:exon4/4:c.*4484delT:,IGF1:NM_000618.4:3'UTR:MODIFIER:exon4/4:c.*4484delT:,IGF1:NM_001111283.2:3'UTR:MODIFIER:exon5/5:c.*4518delT:		rs397844200	0.0204	0.0000	0/0/0	0.0173							147440 [IGF1 (confirmed) Growth retardation with deafness and mental retardation due to IGF1 deficiency,608747];	RCV000392650.1 [likely benign]; 			0	9					IGF1 (inh=AR pLI=0.47)
chr12	102791881	102791881	C	A	het	wt	wt	low_DP	QUAL=161;DP=56,6,17;MQM=50	IGF1	3'UTR	IGF1:NM_001111284.1:3'UTR:MODIFIER:exon4/4:c.*4404G>T:,IGF1:NM_000618.4:3'UTR:MODIFIER:exon4/4:c.*4404G>T:,IGF1:NM_001111283.2:3'UTR:MODIFIER:exon5/5:c.*4438G>T:	(A)n	rs201936984	0.0000	0.0000	0/0/0	0.0005							147440 [IGF1 (confirmed) Growth retardation with deafness and mental retardation due to IGF1 deficiency,608747];	RCV000357290.1 [uncertain significance]; 			1	19					IGF1 (inh=AR pLI=0.47)
chr12	102792897	102792897	G	A	hom	wt	hom		QUAL=3286;DP=112,83,139;MQM=59	IGF1	3'UTR	IGF1:NM_001111284.1:3'UTR:MODIFIER:exon4/4:c.*3388C>T:,IGF1:NM_000618.4:3'UTR:MODIFIER:exon4/4:c.*3388C>T:,IGF1:NM_001111283.2:3'UTR:MODIFIER:exon5/5:c.*3422C>T:	(TG)n	rs5742705	0.0208	0.0000	0/0/0	0.0141							147440 [IGF1 (confirmed) Growth retardation with deafness and mental retardation due to IGF1 deficiency,608747];	RCV000392965.1 [likely benign]; 			0	9					IGF1 (inh=AR pLI=0.47)
chr12	102793569	102793569	C	T	het	wt	hom		QUAL=12575;DP=367,191,231;MQM=60	IGF1	3'UTR	IGF1:NM_001111284.1:3'UTR:MODIFIER:exon4/4:c.*2716G>A:,IGF1:NM_000618.4:3'UTR:MODIFIER:exon4/4:c.*2716G>A:,IGF1:NM_001111283.2:3'UTR:MODIFIER:exon5/5:c.*2750G>A:		rs6214	0.4269	0.0000	0/0/0	0.0829							147440 [IGF1 (confirmed) Growth retardation with deafness and mental retardation due to IGF1 deficiency,608747];	RCV000307677.1 [benign]; 			39	124					IGF1 (inh=AR pLI=0.47)
chr12	102793921	102793921	T	C	het	wt	hom		QUAL=2771;DP=158,29,52;MQM=60	IGF1	3'UTR	IGF1:NM_001111284.1:3'UTR:MODIFIER:exon4/4:c.*2364A>G:,IGF1:NM_000618.4:3'UTR:MODIFIER:exon4/4:c.*2364A>G:,IGF1:NM_001111283.2:3'UTR:MODIFIER:exon5/5:c.*2398A>G:		rs5742704	0.0208	0.0000	0/0/0	0.0030							147440 [IGF1 (confirmed) Growth retardation with deafness and mental retardation due to IGF1 deficiency,608747];	RCV000378960.1 [likely benign]; 			0	9					IGF1 (inh=AR pLI=0.47)
chr12	102794515	102794515	G	A	wt	het	het		QUAL=2882;DP=377,107,105;MQM=60	IGF1	3'UTR	IGF1:NM_001111284.1:3'UTR:MODIFIER:exon4/4:c.*1770C>T:,IGF1:NM_000618.4:3'UTR:MODIFIER:exon4/4:c.*1770C>T:,IGF1:NM_001111283.2:3'UTR:MODIFIER:exon5/5:c.*1804C>T:		rs6220	0.6386	0.0000	0/0/0	0.1293							147440 [IGF1 (confirmed) Growth retardation with deafness and mental retardation due to IGF1 deficiency,608747];	RCV000348790.1 [benign]; 			113	89					IGF1 (inh=AR pLI=0.47)
chr12	103237468	103237468	G	C	hom	hom	hom	low_DP	QUAL=2175;DP=46,8,14;MQM=60	PAH	synonymous	PAH:NM_000277.1:synonymous:LOW:exon11/13:c.1155C>G:p.Leu385Leu		rs772897	0.8403	0.8582	44804/24014/3307	0.8486							612349 [PAH (confirmed) Phenylketonuria,261600|Hyperphenylalaninemia,non-PKU mild,261600];	RCV000088769.1 [not provided]; RCV000153631.2 [benign]; 			1089	437					PAH (inh=AR pLI=0.00)
chr12	103248924	103248924	C	T	hom	hom	hom		QUAL=22067;DP=160,216,331;MQM=59	PAH	synonymous	PAH:NM_000277.1:synonymous:LOW:exon6/13:c.696G>A:p.Gln232Gln		rs1126758	0.5465	0.5785	21720/11666/3117	0.5695							612349 [PAH (confirmed) Phenylketonuria,261600|Hyperphenylalaninemia,non-PKU mild,261600];	RCV000089040.1 [not provided]; RCV000153637.2 [benign]; 			511	751					PAH (inh=AR pLI=0.00)
chr12	103351826	103351826	T	C	het	hom	wt		QUAL=5207;DP=123,119,189;MQM=60	ASCL1	5'UTR	ASCL1:NM_004316.3:5'UTR:MODIFIER:exon1/2:c.-197T>C:		rs9782	0.3001	0.0000	0/0/0	0.2868							100790 [ASCL1 (confirmed) Central hypoventilation syndrome,congenital,209880|Haddad syndrome,209880];				17	113					ASCL1 (inh=AD pLI=0.36)
chr12	103352171	103352171	-	GCA	wt	het	wt	low_DP	QUAL=62;DP=123,8,12;MQM=60	ASCL1	conservative_inframe_insertion	ASCL1:NM_004316.3:conservative_inframe_insertion:MODERATE:exon1/2:c.184_186dupCAG:p.Gln62dup	(GCA)n	rs3832799;rs71438488;rs764970999	0.0000	0.2074	23/11/0	0.0494							100790 [ASCL1 (confirmed) Central hypoventilation syndrome,congenital,209880|Haddad syndrome,209880];	RCV000150165.3 [benign]; 			124	443					ASCL1 (inh=AD pLI=0.36)
chr12	103353209	103353209	A	-	hom	hom	hom		QUAL=11469;DP=144,111,135;MQM=59	ASCL1	3'UTR	ASCL1:NM_004316.3:3'UTR:MODIFIER:exon2/2:c.*126delA:	(AAAAGA)n	rs398020887	0.9760	0.0000	0/0/0	0.7104							100790 [ASCL1 (confirmed) Central hypoventilation syndrome,congenital,209880|Haddad syndrome,209880];				178	16					ASCL1 (inh=AD pLI=0.36)
chr12	103353525	103353525	T	C	hom	hom	hom		QUAL=16460;DP=160,145,218;MQM=60	ASCL1	3'UTR	ASCL1:NM_004316.3:3'UTR:MODIFIER:exon2/2:c.*433T>C:		rs1391682	0.9764	0.0000	0/0/0	0.8875							100790 [ASCL1 (confirmed) Central hypoventilation syndrome,congenital,209880|Haddad syndrome,209880];				212	17					ASCL1 (inh=AD pLI=0.36)
chr12	103353538	103353538	A	G	hom	hom	hom		QUAL=17302;DP=182,153,214;MQM=60	ASCL1	3'UTR	ASCL1:NM_004316.3:3'UTR:MODIFIER:exon2/2:c.*446A>G:		rs2291854	0.8215	0.0000	0/0/0	0.8278							100790 [ASCL1 (confirmed) Central hypoventilation syndrome,congenital,209880|Haddad syndrome,209880];				152	72					ASCL1 (inh=AD pLI=0.36)
chr12	103354187	103354187	T	-	hom	hom	hom		QUAL=8773;DP=174,47,61;MQM=59	ASCL1	3'UTR	ASCL1:NM_004316.3:3'UTR:MODIFIER:exon2/2:c.*1103delT:		rs34660835	0.8494	0.0000	0/0/0	0.6386							100790 [ASCL1 (confirmed) Central hypoventilation syndrome,congenital,209880|Haddad syndrome,209880];				176	50					ASCL1 (inh=AD pLI=0.36)
chr12	106751657	106751657	C	T	wt	het	wt		QUAL=3358;DP=134,304,448;MQM=60	POLR3B	5'UTR	POLR3B:NM_018082.5:5'UTR:MODIFIER:exon1/28:c.-1C>T:		rs117873765	0.0036	0.0076	5/4/0	0.0070							614366 [POLR3B (provisional) Leukodystrophy,hypomyelinating,8,with or without oligodontia and/or hypogonadotropic hypogonadism,614381];	RCV000393105.1 [uncertain significance]; 			0	44					POLR3B (inh=AR pLI=0.00)
chr12	106751875	106751875	C	T	wt	het	wt		QUAL=1585;DP=179,125,124;MQM=59	POLR3B	5'UTR,intron	POLR3B:NM_001160708.1:5'UTR:MODIFIER:exon1/28:c.-228C>T:,POLR3B:NM_018082.5:intron:MODIFIER:exon1/27:c.72+146C>T:		rs17285274	0.1546	0.0000	0/0/0	0.1841							614366 [POLR3B (provisional) Leukodystrophy,hypomyelinating,8,with or without oligodontia and/or hypogonadotropic hypogonadism,614381];				12	70					POLR3B (inh=AR pLI=0.00)
chr12	106751911	106751915	AGTGA	-	wt	het	wt		QUAL=609;DP=58,64,53;MQM=59	POLR3B	5'UTR,intron	POLR3B:NM_001160708.1:5'UTR:MODIFIER:exon1/28:c.-190_-186delTGAAG:,POLR3B:NM_018082.5:intron:MODIFIER:exon1/27:c.72+184_72+188delTGAAG:		rs780018048	0.2192	0.0000	0/0/0	0.2041							614366 [POLR3B (provisional) Leukodystrophy,hypomyelinating,8,with or without oligodontia and/or hypogonadotropic hypogonadism,614381];				11	73					POLR3B (inh=AR pLI=0.00)
chr12	106838340	106838340	T	C	het	het	wt		QUAL=7998;DP=369,267,299;MQM=59	POLR3B	synonymous	POLR3B:NM_018082.5:synonymous:LOW:exon19/28:c.2055T>C:p.Tyr685Tyr,POLR3B:NM_001160708.1:synonymous:LOW:exon19/28:c.1881T>C:p.Tyr627Tyr		rs10861607	0.3179	0.3143	7200/2541/16	0.3020							614366 [POLR3B (provisional) Leukodystrophy,hypomyelinating,8,with or without oligodontia and/or hypogonadotropic hypogonadism,614381];	RCV000118025.2 [likely benign]; RCV000294165.1 [benign]; 		COSM1358426	236	1211					POLR3B (inh=AR pLI=0.00)
chr12	106848414	106848414	A	G	het	wt	het	pred_pathogenic	QUAL=5181;DP=267,143,167;MQM=60	POLR3B	missense	POLR3B:NM_018082.5:missense:MODERATE:exon20/28:c.2218A>G:p.Thr740Ala,POLR3B:NM_001160708.1:missense:MODERATE:exon20/28:c.2044A>G:p.Thr682Ala		rs17038460	0.0266	0.0470	160/134/0	0.0477	9.3000	D,D	T	B	T,T	23.60	614366 [POLR3B (provisional) Leukodystrophy,hypomyelinating,8,with or without oligodontia and/or hypogonadotropic hypogonadism,614381];	RCV000118026.2 [likely benign]; RCV000288077.1 [likely benign]; 			24	408					POLR3B (inh=AR pLI=0.00)
chr12	106903321	106903321	T	C	het	het	wt		QUAL=7302;DP=322,210,279;MQM=60	POLR3B,LOC100287944	synonymous,intron	POLR3B:NM_018082.5:synonymous:LOW:exon28/28:c.3396T>C:p.Asn1132Asn,POLR3B:NM_001160708.1:synonymous:LOW:exon28/28:c.3222T>C:p.Asn1074Asn,LOC100287944:NR_040246.1:intron:MODIFIER:exon1/3:n.143-1733A>G:		rs13561	0.3249	0.3241	7398/2815/34	0.3218							614366 [POLR3B (provisional) Leukodystrophy,hypomyelinating,8,with or without oligodontia and/or hypogonadotropic hypogonadism,614381];	RCV000118027.2 [likely benign]; RCV000329648.1 [benign]; 		COSM3752870	252	1269					POLR3B (inh=AR pLI=0.00), LOC100287944 (inh=n/a pLI=n/a)
chr12	106903674	106903674	A	G	het	het	wt		QUAL=4366;DP=270,81,140;MQM=60	POLR3B,LOC100287944	3'UTR,intron	POLR3B:NM_018082.5:3'UTR:MODIFIER:exon28/28:c.*347A>G:,POLR3B:NM_001160708.1:3'UTR:MODIFIER:exon28/28:c.*347A>G:,LOC100287944:NR_040246.1:intron:MODIFIER:exon1/3:n.143-2086T>C:		rs2288266	0.3249	0.0000	0/0/0	0.3362							614366 [POLR3B (provisional) Leukodystrophy,hypomyelinating,8,with or without oligodontia and/or hypogonadotropic hypogonadism,614381];	RCV000294586.1 [benign]; 			15	89					POLR3B (inh=AR pLI=0.00), LOC100287944 (inh=n/a pLI=n/a)
chr12	109991998	109991998	A	G	wt	het	wt		QUAL=2547;DP=400,195,299;MQM=60	MMAB	3'UTR,non_coding_transcript_exon	MMAB:NM_052845.3:3'UTR:MODIFIER:exon9/9:c.*2835T>C:,MMAB:NR_038118.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.3748T>C:	MIRb	rs12817689	0.1611	0.1478	118/39/6	0.0411							607568 [MMAB (provisional) Methylmalonic aciduria,vitamin B12-responsive,due to defect in synthesis of adenosylcobalamin,cblB complementation type,251110];	RCV000301254.1 [likely benign]; 			25	190					MMAB (inh=AR pLI=0.00)
chr12	109992132	109992132	C	G	wt	het	het		QUAL=9269;DP=567,302,458;MQM=60	MMAB	3'UTR,non_coding_transcript_exon	MMAB:NM_052845.3:3'UTR:MODIFIER:exon9/9:c.*2701G>C:,MMAB:NR_038118.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.3614G>C:		rs2241201	0.3163	0.2198	297/91/32	0.0669							607568 [MMAB (provisional) Methylmalonic aciduria,vitamin B12-responsive,due to defect in synthesis of adenosylcobalamin,cblB complementation type,251110];	RCV000261158.1 [benign]; 			60	262					MMAB (inh=AR pLI=0.00)
chr12	109992149	109992149	C	G	wt	het	wt		QUAL=3137;DP=521,314,469;MQM=60	MMAB	3'UTR,non_coding_transcript_exon	MMAB:NM_052845.3:3'UTR:MODIFIER:exon9/9:c.*2684G>C:,MMAB:NR_038118.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.3597G>C:		rs35145546	0.1589	0.1476	119/40/6	0.0408							607568 [MMAB (provisional) Methylmalonic aciduria,vitamin B12-responsive,due to defect in synthesis of adenosylcobalamin,cblB complementation type,251110];	RCV000297595.1 [likely benign]; 			25	190					MMAB (inh=AR pLI=0.00)
chr12	109993081	109993091	TTTTTTTTTTT	-	wt	wt	hom	low_DP	QUAL=373;DP=21,3,62;MQM=60	MMAB	3'UTR,non_coding_transcript_exon	MMAB:NM_052845.3:3'UTR:MODIFIER:exon9/9:c.*1742_*1752delAAAAAAAAAAA:,MMAB:NR_038118.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.2655_2665delAAAAAAAAAAA:	AluSx1	rs776867529	0.0000	0.0580	11/6/0	0.0047							607568 [MMAB (provisional) Methylmalonic aciduria,vitamin B12-responsive,due to defect in synthesis of adenosylcobalamin,cblB complementation type,251110];				40	45					MMAB (inh=AR pLI=0.00)
chr12	109993104	109993104	T	G	wt	wt	hom	low_DP	QUAL=373;DP=21,3,62;MQM=60	MMAB	3'UTR,non_coding_transcript_exon	MMAB:NM_052845.3:3'UTR:MODIFIER:exon9/9:c.*1729A>C:,MMAB:NR_038118.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.2642A>C:	AluSx1	rs559163901	0.0000	0.0533	20/9/1	0.0020							607568 [MMAB (provisional) Methylmalonic aciduria,vitamin B12-responsive,due to defect in synthesis of adenosylcobalamin,cblB complementation type,251110];	RCV000398858.1 [likely benign]; 			43	53					MMAB (inh=AR pLI=0.00)
chr12	109993255	109993255	T	A	hom	hom	hom	low_DP	QUAL=6208;DP=15,33,50;MQM=60	MMAB	3'UTR,non_coding_transcript_exon	MMAB:NM_052845.3:3'UTR:MODIFIER:exon9/9:c.*1578A>T:,MMAB:NR_038118.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.2491A>T:	AluSx1		0.0000	0.0000	0/0/0	0.0001							607568 [MMAB (provisional) Methylmalonic aciduria,vitamin B12-responsive,due to defect in synthesis of adenosylcobalamin,cblB complementation type,251110];				0	0					MMAB (inh=AR pLI=0.00)
chr12	109993298	109993298	C	T	wt	het	wt		QUAL=1170;DP=174,121,194;MQM=59	MMAB	3'UTR,non_coding_transcript_exon	MMAB:NM_052845.3:3'UTR:MODIFIER:exon9/9:c.*1535G>A:,MMAB:NR_038118.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.2448G>A:	AluSx1	rs34921355	0.1611	0.1484	49/17/4	0.0349							607568 [MMAB (provisional) Methylmalonic aciduria,vitamin B12-responsive,due to defect in synthesis of adenosylcobalamin,cblB complementation type,251110];	RCV000276503.1 [likely benign]; 			26	186					MMAB (inh=AR pLI=0.00)
chr12	109993603	109993603	C	A	wt	het	het		QUAL=12647;DP=303,398,553;MQM=60	MMAB	3'UTR,non_coding_transcript_exon	MMAB:NM_052845.3:3'UTR:MODIFIER:exon9/9:c.*1230G>T:,MMAB:NR_038118.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.2143G>T:		rs11067231	0.5134	0.4644	1240/404/56	0.1241							607568 [MMAB (provisional) Methylmalonic aciduria,vitamin B12-responsive,due to defect in synthesis of adenosylcobalamin,cblB complementation type,251110];	RCV000318722.1 [benign]; 	CR1510569 [CLASS=DP MUT=REF PHEN="Total cholesterol levels association with" GENE=MMAB]; 		196	330					MMAB (inh=AR pLI=0.00)
chr12	109993828	109993828	T	C	wt	wt	het		QUAL=4827;DP=432,310,377;MQM=60	MMAB	3'UTR,non_coding_transcript_exon	MMAB:NM_052845.3:3'UTR:MODIFIER:exon9/9:c.*1005A>G:,MMAB:NR_038118.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1918A>G:		rs67432283	0.0268	0.0522	21/10/1	0.0138							607568 [MMAB (provisional) Methylmalonic aciduria,vitamin B12-responsive,due to defect in synthesis of adenosylcobalamin,cblB complementation type,251110];	RCV000284869.1 [likely benign]; 			5	100					MMAB (inh=AR pLI=0.00)
chr12	109993976	109993976	C	G	wt	het	het		QUAL=12697;DP=442,433,572;MQM=60	MMAB	3'UTR,non_coding_transcript_exon	MMAB:NM_052845.3:3'UTR:MODIFIER:exon9/9:c.*857G>C:,MMAB:NR_038118.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1770G>C:		rs877710	0.5134	0.4666	1240/401/59	0.1242							607568 [MMAB (provisional) Methylmalonic aciduria,vitamin B12-responsive,due to defect in synthesis of adenosylcobalamin,cblB complementation type,251110];	RCV000309656.1 [benign]; 	CR1510602 [CLASS=DP MUT=REF PHEN="HDL cholesterol association with" GENE=MMAB]; 		196	330					MMAB (inh=AR pLI=0.00)
chr12	109994454	109994463	CACACACACA	-	hom	wt	hom		QUAL=2880;DP=55,38,120;MQM=59	MMAB	3'UTR,non_coding_transcript_exon	MMAB:NM_052845.3:3'UTR:MODIFIER:exon9/9:c.*370_*379delTGTGTGTGTG:,MMAB:NR_038118.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1283_1292delTGTGTGTGTG:	(CA)n	rs762567631	0.0000	0.0495	3/0/0	0.0033							607568 [MMAB (provisional) Methylmalonic aciduria,vitamin B12-responsive,due to defect in synthesis of adenosylcobalamin,cblB complementation type,251110];				3	40					MMAB (inh=AR pLI=0.00)
chr12	109994454	109994457	CACA	-	wt	hom	wt		QUAL=2880;DP=55,38,120;MQM=59	MMAB	3'UTR,non_coding_transcript_exon	MMAB:NM_052845.3:3'UTR:MODIFIER:exon9/9:c.*376_*379delTGTG:,MMAB:NR_038118.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1289_1292delTGTG:	(CA)n	rs772758985	0.0000	0.1331	3/1/0	0.0071							607568 [MMAB (provisional) Methylmalonic aciduria,vitamin B12-responsive,due to defect in synthesis of adenosylcobalamin,cblB complementation type,251110];	RCV000352087.1 [uncertain significance]; 			4	6					MMAB (inh=AR pLI=0.00)
chr12	109994455	109994455	A	T	hom	wt	hom		QUAL=2880;DP=55,38,120;MQM=59	MMAB	3'UTR,non_coding_transcript_exon	MMAB:NM_052845.3:3'UTR:MODIFIER:exon9/9:c.*378T>A:,MMAB:NR_038118.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1291T>A:	(CA)n	rs66497319	0.0000	0.0574	1/0/0	0.0013							607568 [MMAB (provisional) Methylmalonic aciduria,vitamin B12-responsive,due to defect in synthesis of adenosylcobalamin,cblB complementation type,251110];	RCV000354578.1 [likely benign]; 			0	93					MMAB (inh=AR pLI=0.00)
chr12	109994457	109994457	A	T	hom	wt	hom		QUAL=2880;DP=55,38,120;MQM=59	MMAB	3'UTR,non_coding_transcript_exon	MMAB:NM_052845.3:3'UTR:MODIFIER:exon9/9:c.*376T>A:,MMAB:NR_038118.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1289T>A:	(CA)n	rs527861371	0.1494	0.0277	1/0/0	0.0057							607568 [MMAB (provisional) Methylmalonic aciduria,vitamin B12-responsive,due to defect in synthesis of adenosylcobalamin,cblB complementation type,251110];	RCV000259215.1 [likely benign]; 			0	82					MMAB (inh=AR pLI=0.00)
chr12	109994870	109994870	A	T	wt	het	het	pred_pathogenic	QUAL=4472;DP=289,187,205;MQM=60	MMAB	missense,non_coding_transcript_exon	MMAB:NM_052845.3:missense:MODERATE:exon9/9:c.716T>A:p.Met239Lys,MMAB:NR_038118.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.876T>A:		rs9593	0.5134	0.5095	16355/9685/2725	0.5047	-0.1190	T,T	T	B	D,D	0.53	607568 [MMAB (provisional) Methylmalonic aciduria,vitamin B12-responsive,due to defect in synthesis of adenosylcobalamin,cblB complementation type,251110];	RCV000082328.7 [benign]; RCV000320735.1 [benign]; 		COSM3752888	502	765	1	hohe Frequenz [1] swoedl 28.06.2016			MMAB (inh=AR pLI=0.00)
chr12	110017759	110017759	C	T	wt	wt	het		QUAL=1242;DP=148,126,136;MQM=60	MVK	splice_region&intron	MVK:NM_000431.3:splice_region&intron:LOW:exon4/10:c.371+8C>T:,MVK:NM_001114185.2:splice_region&intron:LOW:exon4/10:c.371+8C>T:,MVK:NM_001301182.1:splice_region&intron:LOW:exon4/9:c.371+8C>T:		rs67886029	0.0268	0.0605	277/235/1	0.0595							251170 [MVK (confirmed) Mevalonic aciduria,610377|Hyper-IgD syndrome,260920|Porokeratosis 3,multiple types,175900];	RCV000250476.1 [benign]; RCV000314746.1 [likely benign]; RCV000391679.1 [likely benign]; 			14	234					MVK (inh=AR+AD pLI=0.04)
chr12	110019338	110019338	C	T	wt	het	wt	anno_pathogenic_hgmd	QUAL=3751;DP=257,310,364;MQM=60	MVK	synonymous,intron	MVK:NM_000431.3:synonymous:LOW:exon5/11:c.510C>T:p.Asp170Asp,MVK:NM_001114185.2:synonymous:LOW:exon5/11:c.510C>T:p.Asp170Asp,MVK:NM_001301182.1:intron:MODIFIER:exon4/9:c.371+1587C>T:		rs2287218	0.1633	0.1618	1619/972/215	0.1631							251170 [MVK (confirmed) Mevalonic aciduria,610377|Hyper-IgD syndrome,260920|Porokeratosis 3,multiple types,175900];	RCV000117652.3 [other]; RCV000286775.1 [likely benign]; RCV000378359.1 [likely benign]; 	CM166277 [CLASS=DM MUT=ALT PHEN="Hyperimmunoglobulin D syndrome" GENE=MVK]; 		52	449					MVK (inh=AR+AD pLI=0.04)
chr12	110034435	110034435	-	G	wt	het	wt		QUAL=578;DP=67,54,68;MQM=60	MVK	3'UTR	MVK:NM_000431.3:3'UTR:MODIFIER:exon11/11:c.*58dupG:,MVK:NM_001114185.2:3'UTR:MODIFIER:exon11/11:c.*58dupG:,MVK:NM_001301182.1:3'UTR:MODIFIER:exon10/10:c.*58dupG:		rs397714540	0.1579	0.0000	0/0/0	0.1480							251170 [MVK (confirmed) Mevalonic aciduria,610377|Hyper-IgD syndrome,260920|Porokeratosis 3,multiple types,175900];	RCV000268790.1 [likely benign]; RCV000385099.1 [likely benign]; 			24	209					MVK (inh=AR+AD pLI=0.04)
chr12	110238487	110238487	A	G	wt	wt	het		QUAL=2115;DP=161,181,200;MQM=60	TRPV4	synonymous,intron	TRPV4:NM_021625.4:synonymous:LOW:exon5/16:c.789T>C:p.Asp263Asp,TRPV4:NM_001177431.1:synonymous:LOW:exon5/16:c.687T>C:p.Asp229Asp,TRPV4:NM_147204.2:synonymous:LOW:exon4/14:c.789T>C:p.Asp263Asp,TRPV4:NM_001177428.1:intron:MODIFIER:exon3/13:c.713-1770T>C:,TRPV4:NM_001177433.1:intron:MODIFIER:exon3/12:c.713-1770T>C:		rs3742034	0.1564	0.1135	974/255/275	0.1093							605427 [TRPV4 (confirmed) Brachyolmia type 3,113500|Spondylometaphyseal dysplasia,Kozlowski type,184252|Metatropic dysplasia,156530|Hereditary motor and sensory neuropathy,type IIc,606071|Scapuloperoneal spinal muscular atrophy,181405|Sodium serum level QTL 1,613508|Parastremmatic dwarfism,168400|SED,Maroteaux type,184095|Spinal muscular atrophy,distal,congenital nonprogressive,600175|Digital arthropathy-brachydactyly,familial,606835];	RCV000125614.2 [benign]; RCV000272462.1 [benign]; RCV000288351.1 [benign]; RCV000324677.1 [benign]; RCV000327414.1 [benign]; RCV000379327.1 [benign]; RCV000382023.1 [benign]; 		COSM3752894	36	403					TRPV4 (inh=AD pLI=0.00)
chr12	110240838	110240838	T	G	het	het	het		QUAL=10306;DP=240,203,341;MQM=60	TRPV4	synonymous	TRPV4:NM_021625.4:synonymous:LOW:exon4/16:c.670A>C:p.Arg224Arg,TRPV4:NM_001177431.1:synonymous:LOW:exon4/16:c.568A>C:p.Arg190Arg,TRPV4:NM_001177428.1:synonymous:LOW:exon3/14:c.670A>C:p.Arg224Arg,TRPV4:NM_001177433.1:synonymous:LOW:exon3/13:c.670A>C:p.Arg224Arg,TRPV4:NM_147204.2:synonymous:LOW:exon3/14:c.670A>C:p.Arg224Arg		rs3825394	0.7544	0.6340	25572/9130/2574	0.6123							605427 [TRPV4 (confirmed) Brachyolmia type 3,113500|Spondylometaphyseal dysplasia,Kozlowski type,184252|Metatropic dysplasia,156530|Hereditary motor and sensory neuropathy,type IIc,606071|Scapuloperoneal spinal muscular atrophy,181405|Sodium serum level QTL 1,613508|Parastremmatic dwarfism,168400|SED,Maroteaux type,184095|Spinal muscular atrophy,distal,congenital nonprogressive,600175|Digital arthropathy-brachydactyly,familial,606835];	RCV000248184.1 [benign]; RCV000278253.1 [benign]; RCV000293693.1 [benign]; RCV000318188.1 [benign]; RCV000352038.1 [benign]; RCV000372711.1 [benign]; RCV000387910.1 [benign]; 		COSM3752895	686	1029					TRPV4 (inh=AD pLI=0.00)
chr12	110240908	110240908	C	T	wt	het	wt		QUAL=2247;DP=337,198,315;MQM=60	TRPV4	synonymous	TRPV4:NM_021625.4:synonymous:LOW:exon4/16:c.600G>A:p.Leu200Leu,TRPV4:NM_001177431.1:synonymous:LOW:exon4/16:c.498G>A:p.Leu166Leu,TRPV4:NM_001177428.1:synonymous:LOW:exon3/14:c.600G>A:p.Leu200Leu,TRPV4:NM_001177433.1:synonymous:LOW:exon3/13:c.600G>A:p.Leu200Leu,TRPV4:NM_147204.2:synonymous:LOW:exon3/14:c.600G>A:p.Leu200Leu			0.0000	0.0000	0/0/0	0.0000							605427 [TRPV4 (confirmed) Brachyolmia type 3,113500|Spondylometaphyseal dysplasia,Kozlowski type,184252|Metatropic dysplasia,156530|Hereditary motor and sensory neuropathy,type IIc,606071|Scapuloperoneal spinal muscular atrophy,181405|Sodium serum level QTL 1,613508|Parastremmatic dwarfism,168400|SED,Maroteaux type,184095|Spinal muscular atrophy,distal,congenital nonprogressive,600175|Digital arthropathy-brachydactyly,familial,606835];				0	1					TRPV4 (inh=AD pLI=0.00)
chr12	110784907	110784907	-	ATCA	het	het	wt		QUAL=3137;DP=189,96,120;MQM=56	ATP2A2	3'UTR,intron	ATP2A2:NM_170665.3:3'UTR:MODIFIER:exon20/20:c.*633_*636dupATCA:,ATP2A2:NM_001681.3:intron:MODIFIER:exon20/20:c.2980+782_2980+785dupATCA:		rs112750891	0.1378	0.0000	0/0/0	0.0877							108740 [ATP2A2 (confirmed) Darier disease,124200|Acrokeratosis verruciformis,101900];				1	35					ATP2A2 (inh=AD pLI=1.00)
chr12	112036754	112036756	GCT	-	wt	hom	hom	low_DP	QUAL=930;DP=101,15,22;MQM=60	ATXN2	disruptive_inframe_deletion,intron,non_coding_transcript_exon	ATXN2:NM_002973.3:disruptive_inframe_deletion:MODERATE:exon1/25:c.563_565delAGC:p.Gln188del,ATXN2:NM_001310121.1:intron:MODIFIER:exon1/25:c.-65+623_-65+625delAGC:,ATXN2:NM_001310123.1:intron:MODIFIER:exon1/21:c.-28+623_-28+625delAGC:,ATXN2:NR_132311.1:non_coding_transcript_exon:MODIFIER:exon1/24:n.725_727delAGC:	(GCT)n	rs10560189;rs67658094	0.9511	0.5912	751/163/4	0.1336							601517 [ATXN2 (confirmed) Spinocerebellar ataxia 2,183090|Amyotrophic lateral sclerosis,susceptibility to,13,183090|Parkinson disease,late-onset,susceptibility to,168600];			COSM404975	1428	246					ATXN2 (inh=AD pLI=1.00)
chr12	112036797	112036797	C	T	wt	het	het	low_DP	QUAL=701;DP=101,19,27;MQM=60	ATXN2	synonymous,intron,non_coding_transcript_exon	ATXN2:NM_002973.3:synonymous:LOW:exon1/25:c.522G>A:p.Gln174Gln,ATXN2:NM_001310121.1:intron:MODIFIER:exon1/25:c.-65+582G>A:,ATXN2:NM_001310123.1:intron:MODIFIER:exon1/21:c.-28+582G>A:,ATXN2:NR_132311.1:non_coding_transcript_exon:MODIFIER:exon1/24:n.684G>A:	(GCT)n	rs4098854	0.6567	0.6209	1637/565/20	0.0398							601517 [ATXN2 (confirmed) Spinocerebellar ataxia 2,183090|Amyotrophic lateral sclerosis,susceptibility to,13,183090|Parkinson disease,late-onset,susceptibility to,168600];	RCV000116479.2 [likely benign]; 		COSM3752917	523	455					ATXN2 (inh=AD pLI=1.00)
chr12	112036929	112036929	G	A	wt	hom	hom	low_DP	QUAL=162;DP=101,3,5;MQM=60	ATXN2	synonymous,intron,non_coding_transcript_exon	ATXN2:NM_002973.3:synonymous:LOW:exon1/25:c.390C>T:p.Arg130Arg,ATXN2:NM_001310121.1:intron:MODIFIER:exon1/25:c.-65+450C>T:,ATXN2:NM_001310123.1:intron:MODIFIER:exon1/21:c.-28+450C>T:,ATXN2:NR_132311.1:non_coding_transcript_exon:MODIFIER:exon1/24:n.552C>T:		rs695872	0.4443	0.7186	106/15/0	0.0604							601517 [ATXN2 (confirmed) Spinocerebellar ataxia 2,183090|Amyotrophic lateral sclerosis,susceptibility to,13,183090|Parkinson disease,late-onset,susceptibility to,168600];	RCV000116478.2 [likely benign]; 			489	311					ATXN2 (inh=AD pLI=1.00)
chr12	112944602	112944602	G	-	het	het	wt		QUAL=4477;DP=230,157,233;MQM=58	PTPN11	3'UTR	PTPN11:NM_002834.3:3'UTR:MODIFIER:exon16/16:c.*1006delG:	MLT1H	rs146940557	0.0351	0.0000	0/0/0	0.0622							176876 [PTPN11 (confirmed) Noonan syndrome 1,163950|LEOPARD syndrome 1,151100|Leukemia,juvenile myelomonocytic,somatic,607785|Metachondromatosis,156250];	RCV000296025.1 [likely benign]; RCV000349825.1 [likely benign]; RCV000387928.1 [likely benign]; 			3	31					PTPN11 (inh=AD pLI=1.00)
chr12	112944751	112944753	TGA	-	wt	het	wt		QUAL=270;DP=44,72,106;MQM=60	PTPN11	3'UTR	PTPN11:NM_002834.3:3'UTR:MODIFIER:exon16/16:c.*1199_*1201delATG:	MLT1H:(TGA)n	rs148422684;rs80269561	0.6370	0.0000	0/0/0	0.2606							176876 [PTPN11 (confirmed) Noonan syndrome 1,163950|LEOPARD syndrome 1,151100|Leukemia,juvenile myelomonocytic,somatic,607785|Metachondromatosis,156250];	RCV000261988.1 [likely benign]; RCV000319453.1 [likely benign]; RCV000354481.1 [likely benign]; 			18	51					PTPN11 (inh=AD pLI=1.00)
chr12	116397088	116397088	A	T	het	wt	wt	low_DP	QUAL=565;DP=47,72,4;MQM=59	MED13L	3'UTR	MED13L:NM_015335.4:3'UTR:MODIFIER:exon31/31:c.*1983T>A:	(TT)n	rs12423578	0.1745	0.0000	0/0/0	0.0351							608771 [MED13L (provisional) Transposition of the great arteries,dextro-looped 1,608808|Mental retardation and distinctive facial features with or without cardiac defects,616789];				11	59					MED13L (inh=AD pLI=1.00)
chr12	116398626	116398626	A	C	het	wt	hom		QUAL=14359;DP=397,238,279;MQM=60	MED13L	3'UTR	MED13L:NM_015335.4:3'UTR:MODIFIER:exon31/31:c.*445T>G:		rs66898998	0.1324	0.0000	0/0/0	0.2672							608771 [MED13L (provisional) Transposition of the great arteries,dextro-looped 1,608808|Mental retardation and distinctive facial features with or without cardiac defects,616789];				31	108					MED13L (inh=AD pLI=1.00)
chr12	116406910	116406910	G	A	het	het	wt		QUAL=4903;DP=191,183,188;MQM=59	MED13L	splice_region&intron	MED13L:NM_015335.4:splice_region&intron:LOW:exon27/30:c.6068-8C>T:		rs61936939	0.0046	0.0110	10/7/0	0.0103							608771 [MED13L (provisional) Transposition of the great arteries,dextro-looped 1,608808|Mental retardation and distinctive facial features with or without cardiac defects,616789];	RCV000226253.1 [benign]; 			2	32					MED13L (inh=AD pLI=1.00)
chr12	116408538	116408538	A	G	het	het	wt		QUAL=5899;DP=271,190,265;MQM=60	MED13L	synonymous	MED13L:NM_015335.4:synonymous:LOW:exon27/31:c.5928T>C:p.Thr1976Thr		rs2304460	0.1528	0.1694	1863/1117/43	0.1689	0.4130		T			9.63	608771 [MED13L (provisional) Transposition of the great arteries,dextro-looped 1,608808|Mental retardation and distinctive facial features with or without cardiac defects,616789];			COSM147620	57	451					MED13L (inh=AD pLI=1.00)
chr12	116429689	116429689	A	G	het	het	wt		QUAL=8726;DP=307,387,552;MQM=59	MED13L	synonymous	MED13L:NM_015335.4:synonymous:LOW:exon17/31:c.3070T>C:p.Leu1024Leu		rs1865787	0.1558	0.1732	1904/1165/30	0.1716							608771 [MED13L (provisional) Transposition of the great arteries,dextro-looped 1,608808|Mental retardation and distinctive facial features with or without cardiac defects,616789];				53	459					MED13L (inh=AD pLI=1.00)
chr12	116445448	116445448	G	A	het	het	het		QUAL=908;DP=49,35,69;MQM=55	MED13L	splice_region&intron	MED13L:NM_015335.4:splice_region&intron:LOW:exon10/30:c.2013-7C>T:	(A)n	rs199749418	0.0000	0.0492	0/0/0	0.0014							608771 [MED13L (provisional) Transposition of the great arteries,dextro-looped 1,608808|Mental retardation and distinctive facial features with or without cardiac defects,616789];			COSM3746277	9	155	2	Prima Vista kein Anhalt f?r Splice-Defekt; 160704 In 151162_01 vermutlich Artefakt [2] ahwalds1 05.07.2016			MED13L (inh=AD pLI=1.00)
chr12	116445450	116445450	C	A	het	het	het		QUAL=908;DP=49,35,69;MQM=55	MED13L	splice_region&intron	MED13L:NM_015335.4:splice_region&intron:LOW:exon10/30:c.2013-9G>T:	(A)n	rs200367922	0.0000	0.0553	0/0/0	0.0036							608771 [MED13L (provisional) Transposition of the great arteries,dextro-looped 1,608808|Mental retardation and distinctive facial features with or without cardiac defects,616789];			COSM3746278	22	288	2	Prima Vista kein Anhalt f?r Splice-Defekt; 160704 In 151162_01 vermutlich Artefakt [2] ahwalds1 05.07.2016			MED13L (inh=AD pLI=1.00)
chr12	116446445	116446445	C	T	het	het	wt		QUAL=6597;DP=260,235,323;MQM=60	MED13L	synonymous	MED13L:NM_015335.4:synonymous:LOW:exon10/31:c.1773G>A:p.Gln591Gln		rs3741768	0.1434	0.1638	1764/1083/21	0.1638							608771 [MED13L (provisional) Transposition of the great arteries,dextro-looped 1,608808|Mental retardation and distinctive facial features with or without cardiac defects,616789];			COSM3752943	52	445					MED13L (inh=AD pLI=1.00)
chr12	116457090	116457090	C	T	het	het	wt		QUAL=7654;DP=352,249,348;MQM=60	MED13L	synonymous	MED13L:NM_015335.4:synonymous:LOW:exon7/31:c.948G>A:p.Lys316Lys		rs61748072	0.0044	0.0105	11/8/0	0.0103							608771 [MED13L (provisional) Transposition of the great arteries,dextro-looped 1,608808|Mental retardation and distinctive facial features with or without cardiac defects,616789];	RCV000230147.1 [benign]; 			1	32					MED13L (inh=AD pLI=1.00)
chr12	119632307	119632307	A	G	het	wt	het		QUAL=2876;DP=127,99,97;MQM=60	HSPB8	3'UTR	HSPB8:NM_014365.2:3'UTR:MODIFIER:exon3/3:c.*644A>G:		rs11038	0.3802	0.0000	0/0/0	0.3057							608014 [HSPB8 (confirmed) Neuropathy,distal hereditary motor,type IIA,158590|Charcot-Marie-Tooth disease,axonal,type 2L,608673];	RCV000277778.1 [likely benign]; RCV000332840.1 [likely benign]; 			17	99					HSPB8 (inh=AD pLI=0.03)
chr12	119632347	119632347	G	A	het	wt	het		QUAL=2513;DP=99,70,74;MQM=60	HSPB8	3'UTR	HSPB8:NM_014365.2:3'UTR:MODIFIER:exon3/3:c.*684G>A:		rs1133026	0.1370	0.0000	0/0/0	0.1816							608014 [HSPB8 (confirmed) Neuropathy,distal hereditary motor,type IIA,158590|Charcot-Marie-Tooth disease,axonal,type 2L,608673];	RCV000318196.1 [likely benign]; RCV000377443.1 [likely benign]; 			8	81					HSPB8 (inh=AD pLI=0.03)
chr12	119632511	119632516	TAATAA	-	het	wt	hom	low_DP	QUAL=1684;DP=49,3,36;MQM=59	HSPB8	3'UTR	HSPB8:NM_014365.2:3'UTR:MODIFIER:exon3/3:c.*866_*871delTAATAA:	(AAT)n	rs112223147;rs555638888	0.0000	0.0000	0/0/0	0.1252							608014 [HSPB8 (confirmed) Neuropathy,distal hereditary motor,type IIA,158590|Charcot-Marie-Tooth disease,axonal,type 2L,608673];				47	51					HSPB8 (inh=AD pLI=0.03)
chr12	120941215	120941215	T	C	het	het	wt		QUAL=5130;DP=257,138,219;MQM=59	COQ5	3'UTR	COQ5:NM_032314.3:3'UTR:MODIFIER:exon7/7:c.*372A>G:		rs7471	0.2646	0.0000	0/0/0	0.3220											22	94					COQ5 (inh=n/a pLI=0.00)
chr12	120941444	120941444	T	C	wt	het	wt		QUAL=4524;DP=493,284,391;MQM=60	COQ5	3'UTR	COQ5:NM_032314.3:3'UTR:MODIFIER:exon7/7:c.*143A>G:		rs14017	0.0407	0.0865	83/21/0	0.0296											7	91					COQ5 (inh=n/a pLI=0.00)
chr12	120966921	120966921	A	G	het	het	wt		QUAL=4057;DP=282,95,145;MQM=59	COQ5	synonymous	COQ5:NM_032314.3:synonymous:LOW:exon1/7:c.24T>C:p.Ala8Ala		rs3742052	0.2646	0.3070	5778/2926/49	0.2969										COSM3752963	137	585					COQ5 (inh=n/a pLI=0.00)
chr12	121416622	121416622	C	G	wt	het	het		QUAL=4599;DP=79,155,248;MQM=60	HNF1A	synonymous	HNF1A:NM_001306179.1:synonymous:LOW:exon1/10:c.51C>G:p.Leu17Leu,HNF1A:NM_000545.6:synonymous:LOW:exon1/10:c.51C>G:p.Leu17Leu		rs1169289	0.4285	0.4722	13325/7330/522	0.4534							142410 [HNF1A (confirmed) MODY,type III,600496|Diabetes mellitus,noninsulin-dependent,2,125853|Diabetes mellitus,insulin-dependent,222100|Hepatic adenoma,somatic,142330|Renal cell carcinoma,144700|Diabetes mellitus,insulin-dependent,20,612520];	RCV000117231.4 [other]; RCV000340336.1 [benign]; 		COSM430521	442	776					HNF1A (inh=AD pLI=0.97)
chr12	121416650	121416650	A	C	wt	het	het	pred_pathogenic	QUAL=4313;DP=76,156,253;MQM=60	HNF1A	missense	HNF1A:NM_001306179.1:missense:MODERATE:exon1/10:c.79A>C:p.Ile27Leu,HNF1A:NM_000545.6:missense:MODERATE:exon1/10:c.79A>C:p.Ile27Leu		rs1169288	0.2985	0.3533	7738/4027/68	0.3397	3.1350	T,T,T,T,T,T,T,T,T,T,T	T	B,B,B,B	D,D,D	25.60	142410 [HNF1A (confirmed) MODY,type III,600496|Diabetes mellitus,noninsulin-dependent,2,125853|Diabetes mellitus,insulin-dependent,222100|Hepatic adenoma,somatic,142330|Renal cell carcinoma,144700|Diabetes mellitus,insulin-dependent,20,612520];	RCV000016074.3 [other]; RCV000016075.27 [other]; RCV000117233.6 [other]; RCV000401319.1 [benign]; 	CM001349 [CLASS=DP MUT=ALT PHEN="Insulin resistance association with" GENE=HNF1A]; 	COSM430522	245	743	2	[2] old entry - no details available			HNF1A (inh=AD pLI=0.97)
chr12	121432117	121432117	G	C	hom	het	het		QUAL=11738;DP=131,276,370;MQM=59	HNF1A	synonymous	HNF1A:NM_001306179.1:synonymous:LOW:exon4/10:c.864G>C:p.Gly288Gly,HNF1A:NM_000545.6:synonymous:LOW:exon4/10:c.864G>C:p.Gly288Gly		rs56348580	0.1811	0.2788	3183/2067/136	0.2354							142410 [HNF1A (confirmed) MODY,type III,600496|Diabetes mellitus,noninsulin-dependent,2,125853|Diabetes mellitus,insulin-dependent,222100|Hepatic adenoma,somatic,142330|Renal cell carcinoma,144700|Diabetes mellitus,insulin-dependent,20,612520];	RCV000117234.4 [benign]; RCV000331151.1 [benign]; 	CM067044 [CLASS=DP MUT=ALT PHEN="Diabetes type 2 association with" GENE=HNF1A]; 		144	630	2	[2] old entry - no details available			HNF1A (inh=AD pLI=0.97)
chr12	121435342	121435342	C	T	wt	wt	het		QUAL=3626;DP=130,172,261;MQM=60	HNF1A	synonymous	HNF1A:NM_001306179.1:synonymous:LOW:exon7/10:c.1375C>T:p.Leu459Leu,HNF1A:NM_000545.6:synonymous:LOW:exon7/10:c.1375C>T:p.Leu459Leu		rs2259820	0.3167	0.3368	7133/3424/80	0.3279							142410 [HNF1A (confirmed) MODY,type III,600496|Diabetes mellitus,noninsulin-dependent,2,125853|Diabetes mellitus,insulin-dependent,222100|Hepatic adenoma,somatic,142330|Renal cell carcinoma,144700|Diabetes mellitus,insulin-dependent,20,612520];	RCV000117226.4 [other]; RCV000373115.1 [benign]; 		COSM3931546	209	749					HNF1A (inh=AD pLI=0.97)
chr12	121435427	121435427	G	A	wt	wt	het	pred_pathogenic	QUAL=3329;DP=115,132,242;MQM=60	HNF1A	missense	HNF1A:NM_001306179.1:missense:MODERATE:exon7/10:c.1460G>A:p.Ser487Asn,HNF1A:NM_000545.6:missense:MODERATE:exon7/10:c.1460G>A:p.Ser487Asn		rs2464196	0.3177	0.3465	6789/3256/77	0.3265	1.5270	T,T,T,T,T,T,T	T	B,B,B	D,D,D	15.32	142410 [HNF1A (confirmed) MODY,type III,600496|Diabetes mellitus,noninsulin-dependent,2,125853|Diabetes mellitus,insulin-dependent,222100|Hepatic adenoma,somatic,142330|Renal cell carcinoma,144700|Diabetes mellitus,insulin-dependent,20,612520];	RCV000117227.6 [other]; RCV000320780.1 [benign]; 	CM067474 [CLASS=DP MUT=ALT PHEN="Cadiovascular disease increased risk association with" GENE=HNF1A]; 		209	748					HNF1A (inh=AD pLI=0.97)
chr12	121435475	121435475	G	A	wt	wt	het		QUAL=2439;DP=81,98,186;MQM=60	HNF1A	splice_region&intron	HNF1A:NM_001306179.1:splice_region&intron:LOW:exon7/9:c.1501+7G>A:,HNF1A:NM_000545.6:splice_region&intron:LOW:exon7/9:c.1501+7G>A:		rs2464195	0.3596	0.4347	7698/3772/85	0.3656	-0.2400	T	T	B		0.08	142410 [HNF1A (confirmed) MODY,type III,600496|Diabetes mellitus,noninsulin-dependent,2,125853|Diabetes mellitus,insulin-dependent,222100|Hepatic adenoma,somatic,142330|Renal cell carcinoma,144700|Diabetes mellitus,insulin-dependent,20,612520];	RCV000117228.5 [other]; RCV000377703.1 [benign]; 			306	763					HNF1A (inh=AD pLI=0.97)
chr12	121437382	121437382	A	G	hom	hom	hom	pred_pathogenic;anno_pathogenic_clinvar	QUAL=13894;DP=76,165,215;MQM=59	HNF1A	missense	HNF1A:NM_001306179.1:missense:MODERATE:exon9/10:c.1741A>G:p.Ser581Gly,HNF1A:NM_000545.6:missense:MODERATE:exon9/10:c.1720A>G:p.Ser574Gly	(CCAG)n	rs1169305	0.9852	0.9958	57820/31915/4361	0.9294	0.3180	T,T,T,T,T,T	T	B	D,D,D	5.41	142410 [HNF1A (confirmed) MODY,type III,600496|Diabetes mellitus,noninsulin-dependent,2,125853|Diabetes mellitus,insulin-dependent,222100|Hepatic adenoma,somatic,142330|Renal cell carcinoma,144700|Diabetes mellitus,insulin-dependent,20,612520];	RCV000016077.25 [pathogenic]; RCV000030490.2 [not provided]; RCV000121200.1 [not provided]; 	CM020516 [CLASS=DFP MUT=REF PHEN="Diabetes type 2 association with" GENE=HNF1A]; 		1650	2	2	[2] old entry - no details available			HNF1A (inh=AD pLI=0.97)
chr12	121439192	121439192	G	T	wt	wt	het		QUAL=5288;DP=228,339,440;MQM=60	HNF1A	3'UTR	HNF1A:NM_001306179.1:3'UTR:MODIFIER:exon10/10:c.*197G>T:,HNF1A:NM_000545.6:3'UTR:MODIFIER:exon10/10:c.*197G>T:		rs1169309	0.3598	0.0000	0/0/0	0.0640							142410 [HNF1A (confirmed) MODY,type III,600496|Diabetes mellitus,noninsulin-dependent,2,125853|Diabetes mellitus,insulin-dependent,222100|Hepatic adenoma,somatic,142330|Renal cell carcinoma,144700|Diabetes mellitus,insulin-dependent,20,612520];	RCV000346267.1 [benign]; 			76	151					HNF1A (inh=AD pLI=0.97)
chr12	121439433	121439433	G	A	wt	wt	het		QUAL=6651;DP=206,435,517;MQM=60	HNF1A	3'UTR	HNF1A:NM_001306179.1:3'UTR:MODIFIER:exon10/10:c.*438G>A:,HNF1A:NM_000545.6:3'UTR:MODIFIER:exon10/10:c.*438G>A:		rs1169310	0.3600	0.0000	0/0/0	0.0643							142410 [HNF1A (confirmed) MODY,type III,600496|Diabetes mellitus,noninsulin-dependent,2,125853|Diabetes mellitus,insulin-dependent,222100|Hepatic adenoma,somatic,142330|Renal cell carcinoma,144700|Diabetes mellitus,insulin-dependent,20,612520];	RCV000402135.1 [benign]; 			81	175					HNF1A (inh=AD pLI=0.97)
chr12	121440039	121440039	G	A	wt	wt	het		QUAL=694;DP=103,70,68;MQM=60	HNF1A	3'UTR	HNF1A:NM_001306179.1:3'UTR:MODIFIER:exon10/10:c.*1044G>A:,HNF1A:NM_000545.6:3'UTR:MODIFIER:exon10/10:c.*1044G>A:			0.0000	0.0000	0/0/0	0.0000							142410 [HNF1A (confirmed) MODY,type III,600496|Diabetes mellitus,noninsulin-dependent,2,125853|Diabetes mellitus,insulin-dependent,222100|Hepatic adenoma,somatic,142330|Renal cell carcinoma,144700|Diabetes mellitus,insulin-dependent,20,612520];				0	1					HNF1A (inh=AD pLI=0.97)
chr12	121440263	121440263	G	A	hom	het	het	pred_pathogenic	QUAL=9074;DP=164,144,178;MQM=59	HNF1A,C12orf43	3'UTR,non_coding_transcript_exon	HNF1A:NM_001306179.1:3'UTR:MODIFIER:exon10/10:c.*1268G>A:,C12orf43:NM_001286191.1:3'UTR:MODIFIER:exon6/6:c.*1693C>T:,HNF1A:NM_000545.6:3'UTR:MODIFIER:exon10/10:c.*1268G>A:,C12orf43:NM_001286192.1:3'UTR:MODIFIER:exon6/6:c.*1693C>T:,C12orf43:NM_001286195.1:3'UTR:MODIFIER:exon6/6:c.*1693C>T:,C12orf43:NM_001286196.1:3'UTR:MODIFIER:exon6/6:c.*1693C>T:,C12orf43:NM_001286197.1:3'UTR:MODIFIER:exon5/5:c.*1693C>T:,C12orf43:NM_001286198.1:3'UTR:MODIFIER:exon7/7:c.*1693C>T:,C12orf43:NM_022895.2:3'UTR:MODIFIER:exon6/6:c.*1693C>T:,C12orf43:NR_104409.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.2523C>T:		rs41279096	0.1054	0.0859	48/8/1	0.0270	0.2980	D	T			3.34	142410 [HNF1A (confirmed) MODY,type III,600496|Diabetes mellitus,noninsulin-dependent,2,125853|Diabetes mellitus,insulin-dependent,222100|Hepatic adenoma,somatic,142330|Renal cell carcinoma,144700|Diabetes mellitus,insulin-dependent,20,612520];	RCV000322383.1 [benign]; 			19	191					HNF1A (inh=AD pLI=0.97), C12orf43 (inh=n/a pLI=0.00)
chr12	122064774	122064779	CCGCCA	-	hom	hom	hom	low_DP	QUAL=622;DP=11,6,13;MQM=59	ORAI1	disruptive_inframe_deletion	ORAI1:NM_032790.3:disruptive_inframe_deletion:MODERATE:exon1/2:c.138_143delACCGCC:p.Pro47_Pro48del	(GCCACC)n	rs141919534;rs531278468	0.9998	0.9941	50849/27505/3399	0.8785							610277 [ORAI1 (provisional) Immunodeficiency 9,612782|Myopathy,tubular aggregate,2,615883];	RCV000173541.1 [benign]; 		COSM430547	1456	42					ORAI1 (inh=AR pLI=0.00)
chr12	122295335	122295335	T	C	hom	hom	hom	pred_pathogenic;anno_pathogenic_clinvar;anno_pathogenic_hgmd	QUAL=21457;DP=184,204,292;MQM=59	HPD	missense,5'UTR	HPD:NM_002150.2:missense:MODERATE:exon4/14:c.97A>G:p.Thr33Ala,HPD:NM_001171993.1:5'UTR:MODIFIER:exon6/16:c.-21A>G:		rs1154510	0.8764	0.8502	44159/24898/4816	0.8345	3.8970	T,T	T		T	1.00	609695 [HPD (confirmed) Tyrosinemia,type III,276710|Hawkinsinuria,140350];	RCV000001643.2 [pathogenic]; 	CM003889 [CLASS=DM? MUT=REF PHEN="Hawkinsinuria" GENE=HPD]; 	COSM3736057	1171	371	2	[2] old entry - no details available			HPD (inh=AR+AD pLI=0.01)
chr12	122756470	122756470	C	A	het	wt	het		QUAL=4279;DP=231,93,143;MQM=60	CLIP1	3'UTR	CLIP1:NM_001247997.1:3'UTR:MODIFIER:exon26/26:c.*952G>T:,CLIP1:NM_002956.2:3'UTR:MODIFIER:exon25/25:c.*952G>T:,CLIP1:NM_198240.1:3'UTR:MODIFIER:exon24/24:c.*952G>T:		rs112052364	0.0012	0.0000	0/0/0	0.0022											0	7					CLIP1 (inh=n/a pLI=0.97)
chr12	122812503	122812503	G	C	hom	het	hom		QUAL=18678;DP=198,250,313;MQM=59	CLIP1	missense	CLIP1:NM_001247997.1:missense:MODERATE:exon17/26:c.3240C>G:p.Asp1080Glu,CLIP1:NM_002956.2:missense:MODERATE:exon16/25:c.3207C>G:p.Asp1069Glu,CLIP1:NM_198240.1:missense:MODERATE:exon15/24:c.3102C>G:p.Asp1034Glu		rs1129167	0.4066	0.5625	20626/13576/125	0.5454	0.2800	T,T,T,T,T,T,T	T	B,B,B	T,T,T,T,T	0.15					523	669					CLIP1 (inh=n/a pLI=0.97)
chr12	122817580	122817580	A	G	het	het	wt	pred_pathogenic	QUAL=4918;DP=231,132,185;MQM=60	CLIP1	missense	CLIP1:NM_001247997.1:missense:MODERATE:exon15/26:c.2821T>C:p.Ser941Pro,CLIP1:NM_002956.2:missense:MODERATE:exon14/25:c.2788T>C:p.Ser930Pro,CLIP1:NM_198240.1:missense:MODERATE:exon13/24:c.2683T>C:p.Ser895Pro		rs17883517	0.0313	0.0631	311/284/4	0.0633	8.6630	D,D,D,D,D,D,D	T	D,D,D	T,T,T,T,T,T	31.00				COSM3752995, COSM3752996	8	204					CLIP1 (inh=n/a pLI=0.97)
chr12	122865029	122865029	T	C	wt	het	wt		QUAL=782;DP=109,70,73;MQM=60	CLIP1	5'UTR	CLIP1:NM_001247997.1:5'UTR:MODIFIER:exon2/26:c.-30A>G:,CLIP1:NM_002956.2:5'UTR:MODIFIER:exon2/25:c.-30A>G:,CLIP1:NM_198240.1:5'UTR:MODIFIER:exon2/24:c.-30A>G:		rs1803290	0.1815	0.2252	3038/1975/126	0.2169											46	321					CLIP1 (inh=n/a pLI=0.97)
chr12	122956772	122956772	G	T	hom	hom	hom		QUAL=3568;DP=81,23,35;MQM=60	ZCCHC8	3'UTR	ZCCHC8:NM_017612.4:3'UTR:MODIFIER:exon14/14:c.*1272C>A:	AluSp		0.0000	0.0000	0/0/0	0.0001											0	0					ZCCHC8 (inh=n/a pLI=0.78)
chr12	122956842	122956842	A	C	hom	het	hom		QUAL=3797;DP=79,38,52;MQM=52	ZCCHC8	3'UTR	ZCCHC8:NM_017612.4:3'UTR:MODIFIER:exon14/14:c.*1202T>G:	AluSp	rs11608711	0.5791	0.0000	0/0/0	0.4785											60	85					ZCCHC8 (inh=n/a pLI=0.78)
chr12	122957085	122957085	G	A	hom	hom	hom	low_DP	QUAL=238;DP=7,1,1;MQM=59	ZCCHC8	3'UTR	ZCCHC8:NM_017612.4:3'UTR:MODIFIER:exon14/14:c.*959C>T:		rs7132830	0.5789	0.0000	0/0/0	0.5331											48	41					ZCCHC8 (inh=n/a pLI=0.78)
chr12	123718301	123718301	C	T	het	hom	het		QUAL=9125;DP=215,150,169;MQM=60	C12orf65	5'UTR,intron	C12orf65:NM_001143905.2:5'UTR:MODIFIER:exon1/3:c.-169C>T:,C12orf65:NM_001194995.1:5'UTR:MODIFIER:exon1/3:c.-199C>T:,C12orf65:NM_152269.4:intron:MODIFIER:exon1/2:c.-29+223C>T:		rs1727332	0.5569	0.0000	0/0/0	0.6906							613541 [C12ORF65 (provisional) Combined oxidative phosphorylation deficiency 7,613559|Spastic paraplegia 55,autosomal recessive,615035];				111	93					C12orf65 (inh=AR pLI=0.17)
chr12	123738494	123738494	C	T	het	wt	het		QUAL=6428;DP=264,155,217;MQM=60	C12orf65	synonymous	C12orf65:NM_001143905.2:synonymous:LOW:exon2/3:c.273C>T:p.Ile91Ile,C12orf65:NM_152269.4:synonymous:LOW:exon2/3:c.273C>T:p.Ile91Ile,C12orf65:NM_001194995.1:synonymous:LOW:exon2/3:c.273C>T:p.Ile91Ile		rs2280424	0.0909	0.0569	410/57/10	0.0572							613541 [C12ORF65 (provisional) Combined oxidative phosphorylation deficiency 7,613559|Spastic paraplegia 55,autosomal recessive,615035];	RCV000249717.1 [benign]; RCV000277121.1 [likely benign]; 		COSM3998691	8	193					C12orf65 (inh=AR pLI=0.17)
chr12	123741706	123741706	C	A	het	wt	het		QUAL=2423;DP=139,70,71;MQM=60	C12orf65	3'UTR	C12orf65:NM_001143905.2:3'UTR:MODIFIER:exon3/3:c.*128C>A:,C12orf65:NM_152269.4:3'UTR:MODIFIER:exon3/3:c.*128C>A:,C12orf65:NM_001194995.1:3'UTR:MODIFIER:exon3/3:c.*128C>A:		rs11554169	0.0935	0.0000	0/0/0	0.0125							613541 [C12ORF65 (provisional) Combined oxidative phosphorylation deficiency 7,613559|Spastic paraplegia 55,autosomal recessive,615035];	RCV000386593.1 [likely benign]; 			0	36					C12orf65 (inh=AR pLI=0.17)
chr12	123741776	123741776	T	C	hom	hom	hom		QUAL=14250;DP=222,104,123;MQM=59	C12orf65	3'UTR	C12orf65:NM_001143905.2:3'UTR:MODIFIER:exon3/3:c.*198T>C:,C12orf65:NM_152269.4:3'UTR:MODIFIER:exon3/3:c.*198T>C:,C12orf65:NM_001194995.1:3'UTR:MODIFIER:exon3/3:c.*198T>C:	AluSx1	rs1969354	0.6514	0.0000	0/0/0	0.6764							613541 [C12ORF65 (provisional) Combined oxidative phosphorylation deficiency 7,613559|Spastic paraplegia 55,autosomal recessive,615035];	RCV000382713.1 [benign]; 			136	79					C12orf65 (inh=AR pLI=0.17)
chr12	123742032	123742032	A	C	het	wt	het		QUAL=4174;DP=194,71,113;MQM=57	C12orf65	3'UTR	C12orf65:NM_001143905.2:3'UTR:MODIFIER:exon3/3:c.*454A>C:,C12orf65:NM_152269.4:3'UTR:MODIFIER:exon3/3:c.*454A>C:,C12orf65:NM_001194995.1:3'UTR:MODIFIER:exon3/3:c.*454A>C:	AluSx1	rs76029248	0.0933	0.0000	0/0/0	0.0519							613541 [C12ORF65 (provisional) Combined oxidative phosphorylation deficiency 7,613559|Spastic paraplegia 55,autosomal recessive,615035];	RCV000394629.1 [likely benign]; 			1	26					C12orf65 (inh=AR pLI=0.17)
chr12	123742061	123742061	G	A	het	hom	het		QUAL=6284;DP=220,75,127;MQM=59	C12orf65	3'UTR	C12orf65:NM_001143905.2:3'UTR:MODIFIER:exon3/3:c.*483G>A:,C12orf65:NM_152269.4:3'UTR:MODIFIER:exon3/3:c.*483G>A:,C12orf65:NM_001194995.1:3'UTR:MODIFIER:exon3/3:c.*483G>A:	AluSx1	rs1969355	0.5573	0.0000	0/0/0	0.6277							613541 [C12ORF65 (provisional) Combined oxidative phosphorylation deficiency 7,613559|Spastic paraplegia 55,autosomal recessive,615035];	RCV000339566.1 [benign]; 			89	69					C12orf65 (inh=AR pLI=0.17)
chr12	123742093	123742093	T	G	hom	hom	hom		QUAL=14962;DP=258,83,140;MQM=59	C12orf65	3'UTR	C12orf65:NM_001143905.2:3'UTR:MODIFIER:exon3/3:c.*515T>G:,C12orf65:NM_152269.4:3'UTR:MODIFIER:exon3/3:c.*515T>G:,C12orf65:NM_001194995.1:3'UTR:MODIFIER:exon3/3:c.*515T>G:		rs1533703	0.6506	0.0000	0/0/0	0.6816							613541 [C12ORF65 (provisional) Combined oxidative phosphorylation deficiency 7,613559|Spastic paraplegia 55,autosomal recessive,615035];	RCV000398841.1 [benign]; 			112	57					C12orf65 (inh=AR pLI=0.17)
chr12	123742271	123742274	AAAG	-	het	wt	het		QUAL=2401;DP=125,23,53;MQM=59	C12orf65	3'UTR	C12orf65:NM_001143905.2:3'UTR:MODIFIER:exon3/3:c.*696_*699delGAAA:,C12orf65:NM_152269.4:3'UTR:MODIFIER:exon3/3:c.*696_*699delGAAA:,C12orf65:NM_001194995.1:3'UTR:MODIFIER:exon3/3:c.*696_*699delGAAA:	L1ME3B	rs202152701	0.0933	0.0000	0/0/0	0.0399							613541 [C12ORF65 (provisional) Combined oxidative phosphorylation deficiency 7,613559|Spastic paraplegia 55,autosomal recessive,615035];	RCV000336587.1 [likely benign]; 			0	22					C12orf65 (inh=AR pLI=0.17)
chr12	123742287	123742289	TAC	-	het	wt	het		QUAL=2815;DP=135,28,57;MQM=59	C12orf65	3'UTR	C12orf65:NM_001143905.2:3'UTR:MODIFIER:exon3/3:c.*711_*713delCTA:,C12orf65:NM_152269.4:3'UTR:MODIFIER:exon3/3:c.*711_*713delCTA:,C12orf65:NM_001194995.1:3'UTR:MODIFIER:exon3/3:c.*711_*713delCTA:	L1ME3B	rs148010033	0.0933	0.0000	0/0/0	0.0417							613541 [C12ORF65 (provisional) Combined oxidative phosphorylation deficiency 7,613559|Spastic paraplegia 55,autosomal recessive,615035];	RCV000315504.1 [likely benign]; 			0	22					C12orf65 (inh=AR pLI=0.17)
chr12	124105848	124105848	A	G	hom	hom	hom		QUAL=32887;DP=354,264,404;MQM=60	EIF2B1	3'UTR	EIF2B1:NM_001414.3:3'UTR:MODIFIER:exon9/9:c.*455T>C:		rs7137332	0.9972	0.0000	0/0/0	0.9100							606686 [EIF2B1 (provisional) Leukoencephalopathy with vanishing white matter,603896];				228	2					EIF2B1 (inh=AR pLI=0.10)
chr12	124197099	124197099	C	T	het	het	het	low_DP	QUAL=288;DP=7,6,19;MQM=60	ATP6V0A2	5'UTR	ATP6V0A2:NM_012463.3:5'UTR:MODIFIER:exon1/20:c.-14C>T:		rs1139320	0.2722	0.4825	3200/2075/284	0.2537							611716 [ATP6V0A2 (confirmed) Cutis laxa,autosomal recessive,type IIA,219200|Wrinkly skin syndrome,278250];	RCV000081542.5 [other]; RCV000305731.1 [likely benign]; RCV000339426.1 [benign]; RCV000407551.1 [likely benign]; 			121	385					ATP6V0A2 (inh=AR pLI=0.00)
chr12	124209332	124209332	T	C	het	het	het		QUAL=6780;DP=217,141,159;MQM=60	ATP6V0A2	synonymous	ATP6V0A2:NM_012463.3:synonymous:LOW:exon4/20:c.426T>C:p.Asn142Asn		rs1139789	0.7510	0.6792	28565/12919/2481	0.6544							611716 [ATP6V0A2 (confirmed) Cutis laxa,autosomal recessive,type IIA,219200|Wrinkly skin syndrome,278250];	RCV000081551.6 [benign]; RCV000394212.1 [benign]; 		COSM3753015	630	714					ATP6V0A2 (inh=AR pLI=0.00)
chr12	124210782	124210782	T	C	het	het	het		QUAL=9892;DP=287,218,262;MQM=60	ATP6V0A2	synonymous	ATP6V0A2:NM_012463.3:synonymous:LOW:exon5/20:c.471T>C:p.Ser157Ser		rs1399961	0.7498	0.6756	28301/12692/2473	0.6580							611716 [ATP6V0A2 (confirmed) Cutis laxa,autosomal recessive,type IIA,219200|Wrinkly skin syndrome,278250];	RCV000081553.5 [benign]; RCV000369580.1 [benign]; 		COSM3753016	626	714					ATP6V0A2 (inh=AR pLI=0.00)
chr12	124229429	124229429	T	C	het	het	het		QUAL=18224;DP=324,479,591;MQM=59	ATP6V0A2	sequence_feature,splice_region&synonymous	ATP6V0A2:NM_012463.3:sequence_feature:MODERATE:exon13/20:c.1515T>C:,ATP6V0A2:NM_012463.3:splice_region&synonymous:LOW:exon13/20:c.1515T>C:p.Asn505Asn		rs7135542	0.7995	0.6934	29854/12976/3617	0.6753							611716 [ATP6V0A2 (confirmed) Cutis laxa,autosomal recessive,type IIA,219200|Wrinkly skin syndrome,278250];	RCV000081547.5 [benign]; RCV000374481.1 [benign]; 		COSM1127520	634	714					ATP6V0A2 (inh=AR pLI=0.00)
chr12	124243707	124243707	T	C	het	het	het		QUAL=8074;DP=260,147,201;MQM=60	ATP6V0A2	3'UTR	ATP6V0A2:NM_012463.3:3'UTR:MODIFIER:exon20/20:c.*1128T>C:		rs10744162	0.6176	0.0000	0/0/0	0.5632							611716 [ATP6V0A2 (confirmed) Cutis laxa,autosomal recessive,type IIA,219200|Wrinkly skin syndrome,278250];	RCV000339651.1 [benign]; 			81	100					ATP6V0A2 (inh=AR pLI=0.00)
chr12	124244272	124244272	C	G	het	het	het		QUAL=12643;DP=355,264,347;MQM=60	ATP6V0A2	3'UTR	ATP6V0A2:NM_012463.3:3'UTR:MODIFIER:exon20/20:c.*1693C>G:		rs10846553	0.7915	0.0000	0/0/0	0.6323							611716 [ATP6V0A2 (confirmed) Cutis laxa,autosomal recessive,type IIA,219200|Wrinkly skin syndrome,278250];	RCV000330111.1 [benign]; 			88	105					ATP6V0A2 (inh=AR pLI=0.00)
chr12	124245579	124245579	G	A	wt	wt	het	low_DP	QUAL=93;DP=65,5,10;MQM=60	ATP6V0A2	3'UTR	ATP6V0A2:NM_012463.3:3'UTR:MODIFIER:exon20/20:c.*3000G>A:	AluSx1	rs183891010	0.0088	0.0000	0/0/0	0.0084							611716 [ATP6V0A2 (confirmed) Cutis laxa,autosomal recessive,type IIA,219200|Wrinkly skin syndrome,278250];	RCV000314254.1 [likely benign]; 			0	6					ATP6V0A2 (inh=AR pLI=0.00)
chr12	124246004	124246004	G	A	het	het	het		QUAL=16881;DP=461,363,445;MQM=60	ATP6V0A2	3'UTR	ATP6V0A2:NM_012463.3:3'UTR:MODIFIER:exon20/20:c.*3425G>A:		rs2333834	0.6066	0.0000	0/0/0	0.5612							611716 [ATP6V0A2 (confirmed) Cutis laxa,autosomal recessive,type IIA,219200|Wrinkly skin syndrome,278250];	RCV000380607.1 [benign]; 			79	103					ATP6V0A2 (inh=AR pLI=0.00)
chr13	20761763	20761763	A	G	hom	hom	hom		QUAL=22115;DP=286,159,230;MQM=59	GJB2	3'UTR	GJB2:NM_004004.5:3'UTR:MODIFIER:exon2/2:c.*1277T>C:		rs7988691	0.9972	0.0000	0/0/0	0.8762							121011 [GJB2 (confirmed) Deafness,autosomal recessive 1A,220290|Deafness,autosomal dominant 3A,601544|Vohwinkel syndrome,124500|Keratoderma,palmoplantar,with deafness,148350|Keratitis-ichthyosis-deafness syndrome,148210|Hystrix-like ichthyosis with deafness,602540|Bart-Pumphrey syndrome,149200];	RCV000276545.1 [benign]; RCV000326865.1 [benign]; RCV000329812.1 [benign]; RCV000381445.1 [benign]; RCV000389084.1 [benign]; 			230	0					GJB2 (inh=n/a pLI=0.00)
chr13	20761888	20761888	C	T	hom	hom	hom		QUAL=20406;DP=246,157,207;MQM=60	GJB2	3'UTR	GJB2:NM_004004.5:3'UTR:MODIFIER:exon2/2:c.*1152G>A:		rs7623	0.8934	0.0000	0/0/0	0.1462							121011 [GJB2 (confirmed) Deafness,autosomal recessive 1A,220290|Deafness,autosomal dominant 3A,601544|Vohwinkel syndrome,124500|Keratoderma,palmoplantar,with deafness,148350|Keratitis-ichthyosis-deafness syndrome,148210|Hystrix-like ichthyosis with deafness,602540|Bart-Pumphrey syndrome,149200];	RCV000268670.1 [benign]; RCV000274368.1 [benign]; RCV000315488.1 [benign]; RCV000363347.1 [benign]; RCV000369038.1 [benign]; 			209	21					GJB2 (inh=n/a pLI=0.00)
chr13	20761973	20761973	C	A	hom	hom	hom		QUAL=30430;DP=477,189,265;MQM=59	GJB2	3'UTR	GJB2:NM_004004.5:3'UTR:MODIFIER:exon2/2:c.*1067G>T:		rs9237	0.8702	0.0000	0/0/0	0.0981							121011 [GJB2 (confirmed) Deafness,autosomal recessive 1A,220290|Deafness,autosomal dominant 3A,601544|Vohwinkel syndrome,124500|Keratoderma,palmoplantar,with deafness,148350|Keratitis-ichthyosis-deafness syndrome,148210|Hystrix-like ichthyosis with deafness,602540|Bart-Pumphrey syndrome,149200];	RCV000265290.1 [benign]; RCV000320457.1 [benign]; RCV000328529.1 [benign]; RCV000379737.1 [benign]; RCV000383076.1 [benign]; 			190	40					GJB2 (inh=n/a pLI=0.00)
chr13	20762956	20762956	A	G	hom	hom	hom		QUAL=35620;DP=468,279,359;MQM=60	GJB2	3'UTR	GJB2:NM_004004.5:3'UTR:MODIFIER:exon2/2:c.*84T>C:		rs3751385	0.6867	0.0000	0/0/0	0.1097							121011 [GJB2 (confirmed) Deafness,autosomal recessive 1A,220290|Deafness,autosomal dominant 3A,601544|Vohwinkel syndrome,124500|Keratoderma,palmoplantar,with deafness,148350|Keratitis-ichthyosis-deafness syndrome,148210|Hystrix-like ichthyosis with deafness,602540|Bart-Pumphrey syndrome,149200];	RCV000029940.1 [benign]; RCV000266913.1 [benign]; RCV000302407.1 [benign]; RCV000324393.1 [benign]; RCV000359458.1 [benign]; RCV000372078.1 [benign]; 			159	71					GJB2 (inh=n/a pLI=0.00)
chr13	20978006	20978006	A	G	hom	hom	hom		QUAL=33137;DP=385,294,372;MQM=59	CRYL1	3'UTR	CRYL1:NM_015974.2:3'UTR:MODIFIER:exon8/8:c.*262T>C:		rs7165	0.6903	0.0000	0/0/0	0.1222											125	93					CRYL1 (inh=n/a pLI=0.00)
chr13	21063524	21063524	A	G	het	wt	hom		QUAL=9586;DP=240,196,219;MQM=60	CRYL1	synonymous	CRYL1:NM_015974.2:synonymous:LOW:exon3/8:c.261T>C:p.Gly87Gly		rs14236	0.2704	0.2292	3587/1867/990	0.2232										COSM3753610	64	407					CRYL1 (inh=n/a pLI=0.00)
chr13	23824783	23824783	T	G	hom	hom	het		QUAL=9039;DP=128,91,122;MQM=60	SGCG	synonymous	SGCG:NM_000231.2:synonymous:LOW:exon4/8:c.312T>G:p.Leu104Leu		rs1800351	0.5248	0.4343	11651/4678/2403	0.4236							608896 [SGCG (confirmed) Muscular dystrophy,limb-girdle,type 2C,253700];	RCV000078404.7 [benign]; RCV000302440.1 [benign]; RCV000360063.1 [benign]; 		COSM3753619	232	694					SGCG (inh=AR pLI=0.01)
chr13	23824818	23824818	G	A	wt	wt	het	pred_pathogenic	QUAL=1468;DP=187,118,137;MQM=60	SGCG	missense	SGCG:NM_000231.2:missense:MODERATE:exon4/8:c.347G>A:p.Arg116His		rs17314986	0.0775	0.1104	832/543/6	0.1081	2.6790	D,D,D	T	P	D,D,D	23.90	608896 [SGCG (confirmed) Muscular dystrophy,limb-girdle,type 2C,253700];	RCV000078405.10 [other]; RCV000270116.1 [likely benign]; RCV000325049.1 [likely benign]; 	CM078792 [CLASS=R MUT=ALT PHEN="Muscular dystrophy limb girdle" GENE=SGCG]; 		38	360					SGCG (inh=AR pLI=0.01)
chr13	23898509	23898509	T	C	het	wt	hom		QUAL=7196;DP=153,89,169;MQM=60	SGCG	splice_region&synonymous	SGCG:NM_000231.2:splice_region&synonymous:LOW:exon8/8:c.705T>C:p.Leu235Leu		rs1800353	0.6298	0.6744	28194/14968/836	0.6690							608896 [SGCG (confirmed) Muscular dystrophy,limb-girdle,type 2C,253700];	RCV000078407.7 [benign]; RCV000278365.1 [benign]; RCV000293880.1 [likely benign]; RCV000373060.1 [benign]; 			773	653					SGCG (inh=AR pLI=0.01)
chr13	23898664	23898664	A	G	hom	hom	hom	pred_pathogenic	QUAL=13522;DP=172,94,166;MQM=59	SGCG	missense	SGCG:NM_000231.2:missense:MODERATE:exon8/8:c.860A>G:p.Asn287Ser		rs1800354	0.8778	0.8817	47373/25293/2853	0.8478	4.0170	T,T,T	T	B	D,D,D	4.80	608896 [SGCG (confirmed) Muscular dystrophy,limb-girdle,type 2C,253700];	RCV000245291.1 [benign]; RCV000153942.4 [benign]; RCV000348757.1 [benign]; 	CM1414776 [CLASS=R MUT=REF PHEN="Muscular dystrophy limb girdle 2C" GENE=SGCG]; 	COSM4147635	1202	368	2	[2] Ute Grasshoff 24.11.2015			SGCG (inh=AR pLI=0.01)
chr13	23898934	23898934	G	A	het	hom	wt		QUAL=16094;DP=484,299,443;MQM=60	SGCG	3'UTR	SGCG:NM_000231.2:3'UTR:MODIFIER:exon8/8:c.*254G>A:		rs3751371	0.3502	0.0000	0/0/0	0.0653							608896 [SGCG (confirmed) Muscular dystrophy,limb-girdle,type 2C,253700];	RCV000315861.1 [benign]; RCV000354144.1 [likely benign]; RCV000372732.1 [benign]; RCV000394244.1 [benign]; 			54	100					SGCG (inh=AR pLI=0.01)
chr13	23898975	23898975	T	C	het	wt	hom		QUAL=19551;DP=421,340,444;MQM=60	SGCG	3'UTR	SGCG:NM_000231.2:3'UTR:MODIFIER:exon8/8:c.*295T>C:		rs3829352	0.3480	0.0000	0/0/0	0.0717							608896 [SGCG (confirmed) Muscular dystrophy,limb-girdle,type 2C,253700];	RCV000261794.1 [likely benign]; RCV000319133.1 [likely benign]; RCV000391543.1 [likely benign]; 			45	92					SGCG (inh=AR pLI=0.01)
chr13	23899226	23899226	T	C	wt	wt	het		QUAL=1518;DP=245,106,154;MQM=60	SGCG	3'UTR	SGCG:NM_000231.2:3'UTR:MODIFIER:exon8/8:c.*546T>C:		rs41283956	0.0056	0.0000	0/0/0	0.0020							608896 [SGCG (confirmed) Muscular dystrophy,limb-girdle,type 2C,253700];				0	4					SGCG (inh=AR pLI=0.01)
chr13	23903220	23903224	TAAAG	-	het	wt	het		QUAL=6118;DP=238,131,221;MQM=59	SACS	3'UTR	SACS:NM_014363.5:3'UTR:MODIFIER:exon10/10:c.*1051_*1055delCTTTA:,SACS:NM_001278055.1:3'UTR:MODIFIER:exon8/8:c.*1051_*1055delCTTTA:		rs66920661	0.0345	0.0000	0/0/0	0.0761							604490 [SACS (provisional) Spastic ataxia,Charlevoix-Saguenay type,270550];	RCV000305184.1 [likely benign]; RCV000359875.1 [likely benign]; RCV000400201.1 [likely benign]; 			5	34					SACS (inh=AR pLI=0.00)
chr13	23903791	23903791	A	G	het	wt	hom		QUAL=13471;DP=471,195,221;MQM=60	SACS	3'UTR	SACS:NM_014363.5:3'UTR:MODIFIER:exon10/10:c.*484T>C:,SACS:NM_001278055.1:3'UTR:MODIFIER:exon8/8:c.*484T>C:		rs4770433	0.3444	0.0000	0/0/0	0.0715							604490 [SACS (provisional) Spastic ataxia,Charlevoix-Saguenay type,270550];	RCV000271293.1 [likely benign]; RCV000315525.1 [likely benign]; RCV000365800.1 [likely benign]; 			52	104					SACS (inh=AR pLI=0.00)
chr13	23907677	23907677	C	T	hom	hom	hom		QUAL=25269;DP=361,176,222;MQM=60	SACS	synonymous	SACS:NM_014363.5:synonymous:LOW:exon10/10:c.10338G>A:p.Gln3446Gln,SACS:NM_001278055.1:synonymous:LOW:exon8/8:c.9897G>A:p.Gln3299Gln		rs2737701	0.9854	0.9957	60154/33342/4714	0.9318							604490 [SACS (provisional) Spastic ataxia,Charlevoix-Saguenay type,270550];	RCV000118229.3 [other]; RCV000270430.1 [benign]; 			3234	6					SACS (inh=AR pLI=0.00)
chr13	23908034	23908034	A	G	het	wt	hom		QUAL=14080;DP=403,198,259;MQM=60	SACS	synonymous	SACS:NM_014363.5:synonymous:LOW:exon10/10:c.9981T>C:p.Ala3327Ala,SACS:NM_001278055.1:synonymous:LOW:exon8/8:c.9540T>C:p.Ala3180Ala		rs2737700	0.3387	0.4061	10250/6340/153	0.4055							604490 [SACS (provisional) Spastic ataxia,Charlevoix-Saguenay type,270550];	RCV000118235.3 [other]; RCV000331174.1 [likely benign]; 		COSM3999043	574	1540					SACS (inh=AR pLI=0.00)
chr13	23929095	23929095	T	C	het	hom	wt		QUAL=9491;DP=327,164,249;MQM=60	SACS	synonymous	SACS:NM_014363.5:synonymous:LOW:exon8/10:c.1656A>G:p.Leu552Leu,SACS:NM_001278055.1:synonymous:LOW:exon6/8:c.1215A>G:p.Leu405Leu		rs1536365	0.0867	0.1140	873/525/2	0.1118	-0.2340		T			0.63	604490 [SACS (provisional) Spastic ataxia,Charlevoix-Saguenay type,270550];	RCV000118231.3 [other]; RCV000321187.1 [likely benign]; 		COSM3753620, COSM3753621	54	688					SACS (inh=AR pLI=0.00)
chr13	23930055	23930055	A	T	het	hom	wt	pred_pathogenic	QUAL=9434;DP=392,155,249;MQM=60	SACS	missense	SACS:NM_014363.5:missense:MODERATE:exon8/10:c.696T>A:p.Asn232Lys,SACS:NM_001278055.1:missense:MODERATE:exon6/8:c.255T>A:p.Asn85Lys		rs2031640	0.0865	0.1144	871/522/2	0.1120	0.5360	T,T,.	T,T	P,P,B,.	D,D,.	22.80	604490 [SACS (provisional) Spastic ataxia,Charlevoix-Saguenay type,270550];	RCV000118233.3 [other]; RCV000304888.1 [likely benign]; 		COSM3753622, COSM3753623	52	692					SACS (inh=AR pLI=0.00)
chr13	23949252	23949252	G	A	het	wt	het	low_DP	QUAL=677;DP=15,33,62;MQM=60	SACS	splice_region&intron	SACS:NM_014363.5:splice_region&intron:LOW:exon3/9:c.171+6C>T:,SACS:NM_001278055.1:splice_region&intron:LOW:exon2/7:c.-183+6C>T:		rs3751368	0.0895	0.1047	69/30/1	0.0384							604490 [SACS (provisional) Spastic ataxia,Charlevoix-Saguenay type,270550];	RCV000242640.1 [benign]; RCV000300554.1 [likely benign]; 			87	870					SACS (inh=AR pLI=0.00)
chr13	24007783	24007783	C	T	het	het	wt		QUAL=3459;DP=142,133,178;MQM=60	SACS	5'UTR	SACS:NM_014363.5:5'UTR:MODIFIER:exon1/10:c.-531G>A:		rs73154650	0.0300	0.0000	0/0/0	0.0326							604490 [SACS (provisional) Spastic ataxia,Charlevoix-Saguenay type,270550];	RCV000342904.1 [uncertain significance]; 			0	15					SACS (inh=AR pLI=0.00)
chr13	25456631	25456631	-	T	het	wt	het		QUAL=8249;DP=403,307,351;MQM=59	CENPJ	3'UTR,non_coding_transcript_exon	CENPJ:NM_018451.4:3'UTR:MODIFIER:exon17/17:c.*683dupA:,CENPJ:NR_047594.1:non_coding_transcript_exon:MODIFIER:exon18/18:n.5012dupA:,CENPJ:NR_047595.1:non_coding_transcript_exon:MODIFIER:exon16/16:n.4810dupA:		rs397718122;rs58955593	0.3239	0.0000	0/0/0	0.2335							609279 [CENPJ (confirmed) Microcephaly 6,primary,autosomal recessive,608393|Seckel syndrome 4,613676];	RCV000273764.1 [benign]; RCV000368335.1 [benign]; 			30	112					CENPJ (inh=AR pLI=0.00)
chr13	25456911	25456911	G	A	wt	het	wt		QUAL=2100;DP=338,190,215;MQM=60	CENPJ	3'UTR,non_coding_transcript_exon	CENPJ:NM_018451.4:3'UTR:MODIFIER:exon17/17:c.*404C>T:,CENPJ:NR_047594.1:non_coding_transcript_exon:MODIFIER:exon18/18:n.4733C>T:,CENPJ:NR_047595.1:non_coding_transcript_exon:MODIFIER:exon16/16:n.4531C>T:		rs77868928	0.1544	0.0000	0/0/0	0.1310							609279 [CENPJ (confirmed) Microcephaly 6,primary,autosomal recessive,608393|Seckel syndrome 4,613676];	RCV000309693.1 [benign]; RCV000401197.1 [benign]; 			4	46					CENPJ (inh=AR pLI=0.00)
chr13	25456917	25456917	T	C	wt	het	wt		QUAL=2198;DP=383,195,216;MQM=60	CENPJ	3'UTR,non_coding_transcript_exon	CENPJ:NM_018451.4:3'UTR:MODIFIER:exon17/17:c.*398A>G:,CENPJ:NR_047594.1:non_coding_transcript_exon:MODIFIER:exon18/18:n.4727A>G:,CENPJ:NR_047595.1:non_coding_transcript_exon:MODIFIER:exon16/16:n.4525A>G:		rs11620289	0.1350	0.0000	0/0/0	0.1438							609279 [CENPJ (confirmed) Microcephaly 6,primary,autosomal recessive,608393|Seckel syndrome 4,613676];	RCV000269776.1 [benign]; RCV000364280.1 [benign]; 			4	46					CENPJ (inh=AR pLI=0.00)
chr13	25457005	25457007	CTT	-	het	het	wt		QUAL=5832;DP=319,171,186;MQM=59	CENPJ	3'UTR,non_coding_transcript_exon	CENPJ:NM_018451.4:3'UTR:MODIFIER:exon17/17:c.*308_*310delAAG:,CENPJ:NR_047594.1:non_coding_transcript_exon:MODIFIER:exon18/18:n.4637_4639delAAG:,CENPJ:NR_047595.1:non_coding_transcript_exon:MODIFIER:exon16/16:n.4435_4437delAAG:		rs796638364	0.1587	0.0000	0/0/0	0.2145							609279 [CENPJ (confirmed) Microcephaly 6,primary,autosomal recessive,608393|Seckel syndrome 4,613676];	RCV000306011.1 [benign]; RCV000360685.1 [benign]; 			27	84					CENPJ (inh=AR pLI=0.00)
chr13	25457013	25457013	T	-	wt	wt	het		QUAL=2299;DP=301,154,172;MQM=59	CENPJ	3'UTR,non_coding_transcript_exon	CENPJ:NM_018451.4:3'UTR:MODIFIER:exon17/17:c.*302delA:,CENPJ:NR_047594.1:non_coding_transcript_exon:MODIFIER:exon18/18:n.4631delA:,CENPJ:NR_047595.1:non_coding_transcript_exon:MODIFIER:exon16/16:n.4429delA:		rs138938177	0.2185	0.0000	0/0/0	0.0883							609279 [CENPJ (confirmed) Microcephaly 6,primary,autosomal recessive,608393|Seckel syndrome 4,613676];	RCV000260457.1 [benign]; RCV000373910.1 [benign]; 			6	78					CENPJ (inh=AR pLI=0.00)
chr13	25457207	25457207	T	C	hom	hom	hom		QUAL=18779;DP=270,124,180;MQM=60	CENPJ	3'UTR,non_coding_transcript_exon	CENPJ:NM_018451.4:3'UTR:MODIFIER:exon17/17:c.*108A>G:,CENPJ:NR_047594.1:non_coding_transcript_exon:MODIFIER:exon18/18:n.4437A>G:,CENPJ:NR_047595.1:non_coding_transcript_exon:MODIFIER:exon16/16:n.4235A>G:		rs9318911	0.9667	0.0000	0/0/0	0.1755							609279 [CENPJ (confirmed) Microcephaly 6,primary,autosomal recessive,608393|Seckel syndrome 4,613676];				230	1					CENPJ (inh=AR pLI=0.00)
chr13	25466774	25466774	T	C	hom	hom	het		QUAL=7049;DP=88,88,121;MQM=59	CENPJ	splice_region&intron	CENPJ:NM_018451.4:splice_region&intron:LOW:exon10/16:c.3216+7A>G:,CENPJ:NR_047594.1:splice_region&intron:LOW:exon10/17:n.3411+7A>G:,CENPJ:NR_047595.1:splice_region&intron:LOW:exon10/15:n.3411+7A>G:		rs9318917	0.7372	0.8036	39655/23064/2190	0.7804							609279 [CENPJ (confirmed) Microcephaly 6,primary,autosomal recessive,608393|Seckel syndrome 4,613676];	RCV000145574.5 [benign]; RCV000342658.1 [benign]; RCV000395412.1 [benign]; 			977	497					CENPJ (inh=AR pLI=0.00)
chr13	25466955	25466955	T	C	het	het	het		QUAL=6907;DP=226,148,190;MQM=60	CENPJ	synonymous,non_coding_transcript_exon	CENPJ:NM_018451.4:synonymous:LOW:exon10/17:c.3042A>G:p.Glu1014Glu,CENPJ:NR_047594.1:non_coding_transcript_exon:MODIFIER:exon10/18:n.3237A>G:,CENPJ:NR_047595.1:non_coding_transcript_exon:MODIFIER:exon10/16:n.3237A>G:		rs3742165	0.4840	0.5395	18371/9675/435	0.5357	0.1810		T			3.16	609279 [CENPJ (confirmed) Microcephaly 6,primary,autosomal recessive,608393|Seckel syndrome 4,613676];	RCV000145573.3 [benign]; RCV000298966.1 [benign]; RCV000402333.1 [benign]; 		COSM4147658	427	776					CENPJ (inh=AR pLI=0.00)
chr13	25487103	25487103	T	C	wt	het	wt	pred_pathogenic	QUAL=2791;DP=324,239,305;MQM=60	CENPJ	missense,non_coding_transcript_exon	CENPJ:NM_018451.4:missense:MODERATE:exon2/17:c.61A>G:p.Met21Val,CENPJ:NR_047594.1:non_coding_transcript_exon:MODIFIER:exon2/18:n.256A>G:,CENPJ:NR_047595.1:non_coding_transcript_exon:MODIFIER:exon2/16:n.256A>G:		rs35498994	0.1552	0.1450	1560/651/53	0.1393	2.6310	D,D,D	T	B	T,T	21.20	609279 [CENPJ (confirmed) Microcephaly 6,primary,autosomal recessive,608393|Seckel syndrome 4,613676];	RCV000145583.3 [benign]; RCV000152967.2 [uncertain significance]; RCV000309037.1 [likely benign]; RCV000401419.1 [likely benign]; RCV000020856.1 [benign]; RCV000081958.6 [benign]; RCV000263946.1 [benign]; RCV000358738.1 [benign]; 		COSM3999057	25	296					CENPJ (inh=AR pLI=0.00)
chr13	32676114	32676114	A	G	het	het	wt		QUAL=6562;DP=292,186,252;MQM=60	FRY	synonymous	FRY:NM_023037.2:synonymous:LOW:exon3/61:c.285A>G:p.Thr95Thr		rs364995	0.5815	0.6047	22418/13360/1665	0.5960										COSM3753642, COSM3753641	610	711					FRY (inh=n/a pLI=1.00)
chr13	32758834	32758834	A	G	het	hom	wt		QUAL=5146;DP=201,80,111;MQM=60	FRY	splice_region&intron	FRY:NM_023037.2:splice_region&intron:LOW:exon25/60:c.3146+6A>G:		rs798971	0.8217	0.7885	37731/18675/2948	0.7637											907	564					FRY (inh=n/a pLI=1.00)
chr13	32776603	32776603	T	C	het	het	wt		QUAL=5456;DP=242,181,249;MQM=59	FRY	synonymous	FRY:NM_023037.2:synonymous:LOW:exon31/61:c.3957T>C:p.Leu1319Leu		rs2428249	0.3458	0.3848	9423/5682/866	0.3763										COSM3765691	199	729					FRY (inh=n/a pLI=1.00)
chr13	32811607	32811607	G	A	hom	hom	het	pred_pathogenic	QUAL=16321;DP=177,231,302;MQM=60	FRY	missense	FRY:NM_023037.2:missense:MODERATE:exon44/61:c.5902G>A:p.Gly1968Ser		rs2806639	0.2159	0.2811	5441/3587/546	0.2744	1.8580	T,T	T	B	T	15.05					143	662					FRY (inh=n/a pLI=1.00)
chr13	32870750	32870750	-	A	wt	wt	het		QUAL=147;DP=37,31,58;MQM=59	FRY	3'UTR	FRY:NM_023037.2:3'UTR:MODIFIER:exon61/61:c.*1168dupA:		rs565605441	0.4924	0.0000	0/0/0	0.3962											2	137					FRY (inh=n/a pLI=1.00)
chr13	32890572	32890572	G	A	het	het	wt		QUAL=6867;DP=301,200,239;MQM=60	BRCA2	5'UTR	BRCA2:NM_000059.3:5'UTR:MODIFIER:exon2/27:c.-26G>A:		rs1799943	0.2093	0.2465	3755/2063/51	0.2438							600185 [BRCA2 (confirmed) Breast-ovarian cancer,familial,2,612555|Fanconi anemia,complementation group D1,605724|Prostate cancer,176807|Breast cancer,male,susceptibility to,114480|Wilms tumor,194070|Medulloblastoma,155255|Glioblastoma 3,613029|Pancreatic cancer 2,613347];	RCV000112977.3 [benign]; RCV000114981.1 [not provided]; RCV000246798.1 [benign]; RCV000312794.1 [benign]; RCV000397056.1 [benign]; RCV000112978.1 [benign]; RCV000112979.1 [benign]; 	CR068211 [CLASS=DFP MUT=ALT PHEN="Breast cancer sporadic protection against" GENE=BRCA2]; 		88	553					BRCA2 (inh=AR+AD pLI=0.00)
chr13	32893271	32893271	A	G	wt	wt	het	anno_pathogenic_hgmd	QUAL=1434;DP=137,54,86;MQM=60	BRCA2	missense	BRCA2:NM_000059.3:missense:MODERATE:exon3/27:c.125A>G:p.Tyr42Cys		rs4987046	0.0008	0.0017	0/0/0	0.0016	0.7770	T,T,T	T	B	T,T	0.51	600185 [BRCA2 (confirmed) Breast-ovarian cancer,familial,2,612555|Fanconi anemia,complementation group D1,605724|Prostate cancer,176807|Breast cancer,male,susceptibility to,114480|Wilms tumor,194070|Medulloblastoma,155255|Glioblastoma 3,613029|Pancreatic cancer 2,613347];	RCV000034429.3 [uncertain significance]; RCV000113161.5 [benign]; RCV000120379.6 [other]; RCV000162523.1 [benign]; RCV000257910.2 [other]; 	CM970178 [CLASS=DM? MUT=ALT PHEN="Breast cancer" GENE=BRCA2]; 		0	6	1	[1] old entry - no details available			BRCA2 (inh=AR+AD pLI=0.00)
chr13	32906729	32906729	A	C	het	het	het		QUAL=10264;DP=395,133,193;MQM=60	BRCA2	missense	BRCA2:NM_000059.3:missense:MODERATE:exon10/27:c.1114A>C:p.Asn372His		rs144848	0.2494	0.2779	4939/2667/82	0.2666	0.7570	T,T,T	T		T,T	0.01	600185 [BRCA2 (confirmed) Breast-ovarian cancer,familial,2,612555|Fanconi anemia,complementation group D1,605724|Prostate cancer,176807|Breast cancer,male,susceptibility to,114480|Wilms tumor,194070|Medulloblastoma,155255|Glioblastoma 3,613029|Pancreatic cancer 2,613347];	RCV000112880.1 [not provided]; RCV000009916.7 [benign]; RCV000034427.1 [benign]; RCV000120303.6 [benign]; RCV000130720.3 [benign]; RCV000207052.1 [uncertain significance]; RCV000260146.1 [benign]; RCV000320173.1 [benign]; 	CM002750 [CLASS=DFP MUT=ALT PHEN="Breast cancer association with" GENE=BRCA2]; 	COSM147663, COSM3753646	301	1402	1	[1] old entry - no details available			BRCA2 (inh=AR+AD pLI=0.00)
chr13	32911888	32911888	A	G	het	het	wt		QUAL=6648;DP=349,118,158;MQM=59	BRCA2	synonymous	BRCA2:NM_000059.3:synonymous:LOW:exon11/27:c.3396A>G:p.Lys1132Lys		rs1801406	0.2668	0.2945	5391/3115/273	0.2927							600185 [BRCA2 (confirmed) Breast-ovarian cancer,familial,2,612555|Fanconi anemia,complementation group D1,605724|Prostate cancer,176807|Breast cancer,male,susceptibility to,114480|Wilms tumor,194070|Medulloblastoma,155255|Glioblastoma 3,613029|Pancreatic cancer 2,613347];	RCV000113169.1 [benign]; RCV000113170.4 [benign]; RCV000114982.2 [benign]; RCV000130987.2 [benign]; RCV000152873.5 [benign]; RCV000337515.1 [benign]; RCV000375777.1 [benign]; 			336	1535	1	[1] Ulrike Faust 13.06.2015			BRCA2 (inh=AR+AD pLI=0.00)
chr13	32912299	32912299	T	C	wt	wt	het		QUAL=1831;DP=277,108,126;MQM=60	BRCA2	synonymous	BRCA2:NM_000059.3:synonymous:LOW:exon11/27:c.3807T>C:p.Val1269Val		rs543304	0.1681	0.1898	1862/1174/181	0.1743							600185 [BRCA2 (confirmed) Breast-ovarian cancer,familial,2,612555|Fanconi anemia,complementation group D1,605724|Prostate cancer,176807|Breast cancer,male,susceptibility to,114480|Wilms tumor,194070|Medulloblastoma,155255|Glioblastoma 3,613029|Pancreatic cancer 2,613347];	RCV000113220.4 [benign]; RCV000123965.2 [benign]; RCV000130362.2 [benign]; RCV000152874.5 [benign]; RCV000316398.1 [benign]; RCV000354795.1 [benign]; RCV000113221.1 [benign]; 			124	1124	1	[1] Ulrike Faust 13.06.2015			BRCA2 (inh=AR+AD pLI=0.00)
chr13	32913055	32913055	A	G	hom	hom	hom		QUAL=17062;DP=273,115,123;MQM=60	BRCA2	synonymous	BRCA2:NM_000059.3:synonymous:LOW:exon11/27:c.4563A>G:p.Leu1521Leu		rs206075	0.9740	0.9931	59672/33182/4417	0.9551							600185 [BRCA2 (confirmed) Breast-ovarian cancer,familial,2,612555|Fanconi anemia,complementation group D1,605724|Prostate cancer,176807|Breast cancer,male,susceptibility to,114480|Wilms tumor,194070|Medulloblastoma,155255|Glioblastoma 3,613029|Pancreatic cancer 2,613347];	RCV000113321.1 [benign]; RCV000160224.1 [benign]; RCV000164515.2 [likely benign]; RCV000198429.1 [likely benign]; RCV000412372.1 [likely benign]; RCV000119245.2 [benign]; RCV000132170.2 [benign]; RCV000152875.8 [benign]; RCV000257902.2 [benign]; RCV000340564.1 [benign]; 			3560	11	1	[1] Ulrike Faust 13.06.2015			BRCA2 (inh=AR+AD pLI=0.00)
chr13	32915005	32915005	G	C	hom	hom	hom		QUAL=26943;DP=415,165,228;MQM=59	BRCA2	synonymous	BRCA2:NM_000059.3:synonymous:LOW:exon11/27:c.6513G>C:p.Val2171Val		rs206076	0.9736	0.9930	59677/33272/4398	0.9628							600185 [BRCA2 (confirmed) Breast-ovarian cancer,familial,2,612555|Fanconi anemia,complementation group D1,605724|Prostate cancer,176807|Breast cancer,male,susceptibility to,114480|Wilms tumor,194070|Medulloblastoma,155255|Glioblastoma 3,613029|Pancreatic cancer 2,613347];	RCV000113602.1 [not provided]; RCV000119246.2 [benign]; RCV000152878.8 [benign]; RCV000162377.1 [benign]; RCV000257903.2 [benign]; RCV000261979.1 [benign]; RCV000163332.1 [likely benign]; RCV000168590.4 [other]; RCV000195987.2 [other]; 		COSM4147690, COSM4147689	3560	14	1	[1] old entry - no details available			BRCA2 (inh=AR+AD pLI=0.00)
chr13	32929232	32929232	A	G	het	het	wt		QUAL=10727;DP=475,387,505;MQM=60	BRCA2	synonymous	BRCA2:NM_000059.3:synonymous:LOW:exon14/27:c.7242A>G:p.Ser2414Ser		rs1799955	0.2326	0.2244	3228/1556/231	0.2239							600185 [BRCA2 (confirmed) Breast-ovarian cancer,familial,2,612555|Fanconi anemia,complementation group D1,605724|Prostate cancer,176807|Breast cancer,male,susceptibility to,114480|Wilms tumor,194070|Medulloblastoma,155255|Glioblastoma 3,613029|Pancreatic cancer 2,613347];	RCV000113739.4 [benign]; RCV000123992.2 [benign]; RCV000130994.2 [benign]; RCV000152882.5 [benign]; RCV000336026.1 [benign]; RCV000394273.1 [benign]; 			164	1268	1	[1] Ulrike Faust 13.06.2015			BRCA2 (inh=AR+AD pLI=0.00)
chr13	32929387	32929387	T	C	hom	hom	hom	pred_pathogenic;anno_pathogenic_hgmd	QUAL=25309;DP=291,219,281;MQM=60	BRCA2	missense	BRCA2:NM_000059.3:missense:MODERATE:exon14/27:c.7397T>C:p.Val2466Ala		rs169547	0.9758	0.9937	59912/33304/4522	0.9638	2.3530	T,T	T		T,T	0.37	600185 [BRCA2 (confirmed) Breast-ovarian cancer,familial,2,612555|Fanconi anemia,complementation group D1,605724|Prostate cancer,176807|Breast cancer,male,susceptibility to,114480|Wilms tumor,194070|Medulloblastoma,155255|Glioblastoma 3,613029|Pancreatic cancer 2,613347];	RCV000045197.4 [benign]; RCV000113751.2 [benign]; RCV000168597.1 [benign]; RCV000203672.1 [benign]; RCV000120357.6 [benign]; RCV000207137.1 [uncertain significance]; 	CM960194 [CLASS=DM? MUT=REF PHEN="Breast cancer" GENE=BRCA2]; 		3571	11	2	[2] old entry - no details available			BRCA2 (inh=AR+AD pLI=0.00)
chr13	32972760	32972760	G	A	wt	wt	het		QUAL=2552;DP=448,156,217;MQM=60	BRCA2	synonymous	BRCA2:NM_000059.3:synonymous:LOW:exon27/27:c.10110G>A:p.Arg3370Arg		rs28897762	0.0008	0.0015	0/0/0	0.0014							600185 [BRCA2 (confirmed) Breast-ovarian cancer,familial,2,612555|Fanconi anemia,complementation group D1,605724|Prostate cancer,176807|Breast cancer,male,susceptibility to,114480|Wilms tumor,194070|Medulloblastoma,155255|Glioblastoma 3,613029|Pancreatic cancer 2,613347];	RCV000043713.7 [other]; RCV000112841.1 [other]; RCV000162524.1 [likely benign]; RCV000168619.3 [benign]; RCV000260989.1 [likely benign]; 			0	4					BRCA2 (inh=AR+AD pLI=0.00)
chr13	32973012	32973012	A	C	wt	wt	het		QUAL=1422;DP=247,87,131;MQM=60	BRCA2	3'UTR	BRCA2:NM_000059.3:3'UTR:MODIFIER:exon27/27:c.*105A>C:		rs15869	0.1607	0.0000	0/0/0	0.0371							600185 [BRCA2 (confirmed) Breast-ovarian cancer,familial,2,612555|Fanconi anemia,complementation group D1,605724|Prostate cancer,176807|Breast cancer,male,susceptibility to,114480|Wilms tumor,194070|Medulloblastoma,155255|Glioblastoma 3,613029|Pancreatic cancer 2,613347];	RCV000112856.2 [benign]; RCV000273093.1 [benign]; RCV000328172.1 [benign]; 			14	109					BRCA2 (inh=AR+AD pLI=0.00)
chr13	32973439	32973439	A	G	het	het	wt		QUAL=5679;DP=295,154,195;MQM=60	BRCA2	3'UTR	BRCA2:NM_000059.3:3'UTR:MODIFIER:exon27/27:c.*532A>G:		rs11571836	0.1975	0.0000	0/0/0	0.2279							600185 [BRCA2 (confirmed) Breast-ovarian cancer,familial,2,612555|Fanconi anemia,complementation group D1,605724|Prostate cancer,176807|Breast cancer,male,susceptibility to,114480|Wilms tumor,194070|Medulloblastoma,155255|Glioblastoma 3,613029|Pancreatic cancer 2,613347];	RCV000191876.1 [benign]; RCV000279399.1 [benign]; RCV000341382.1 [benign]; 			13	109					BRCA2 (inh=AR+AD pLI=0.00)
chr13	32973737	32973737	T	-	het	het	wt		QUAL=2483;DP=210,45,86;MQM=59	BRCA2	3'UTR	BRCA2:NM_000059.3:3'UTR:MODIFIER:exon27/27:c.*839delT:		rs139813105	0.2310	0.0000	0/0/0	0.1505							600185 [BRCA2 (confirmed) Breast-ovarian cancer,familial,2,612555|Fanconi anemia,complementation group D1,605724|Prostate cancer,176807|Breast cancer,male,susceptibility to,114480|Wilms tumor,194070|Medulloblastoma,155255|Glioblastoma 3,613029|Pancreatic cancer 2,613347];	RCV000254751.1 [benign]; RCV000273874.1 [benign]; RCV000370559.1 [benign]; 			13	110					BRCA2 (inh=AR+AD pLI=0.00)
chr13	36876372	36876375	TATC	-	wt	het	het		QUAL=2551;DP=176,66,86;MQM=59	SPG20	3'UTR	SPG20:NM_001142294.1:3'UTR:MODIFIER:exon9/9:c.*2127_*2130delGATA:,SPG20:NM_001142296.1:3'UTR:MODIFIER:exon10/10:c.*2127_*2130delGATA:,SPG20:NM_015087.4:3'UTR:MODIFIER:exon9/9:c.*2127_*2130delGATA:,SPG20:NM_001142295.1:3'UTR:MODIFIER:exon9/9:c.*2127_*2130delGATA:		rs150662490	0.2869	0.0000	0/0/0	0.1980							607111 [SPG20 (provisional) Troyer syndrome,275900];	RCV000348114.1 [likely benign]; 			14	72					SPG20 (inh=AR pLI=0.00)
chr13	36876379	36876379	A	G	wt	het	het		QUAL=2852;DP=183,68,92;MQM=59	SPG20	3'UTR	SPG20:NM_001142294.1:3'UTR:MODIFIER:exon9/9:c.*2123T>C:,SPG20:NM_001142296.1:3'UTR:MODIFIER:exon10/10:c.*2123T>C:,SPG20:NM_015087.4:3'UTR:MODIFIER:exon9/9:c.*2123T>C:,SPG20:NM_001142295.1:3'UTR:MODIFIER:exon9/9:c.*2123T>C:		rs78129833	0.2867	0.0000	0/0/0	0.1028							607111 [SPG20 (provisional) Troyer syndrome,275900];	RCV000408422.1 [likely benign]; 			14	72					SPG20 (inh=AR pLI=0.00)
chr13	36876655	36876655	C	G	wt	het	wt		QUAL=1992;DP=245,141,195;MQM=60	SPG20	3'UTR	SPG20:NM_001142294.1:3'UTR:MODIFIER:exon9/9:c.*1847G>C:,SPG20:NM_001142296.1:3'UTR:MODIFIER:exon10/10:c.*1847G>C:,SPG20:NM_015087.4:3'UTR:MODIFIER:exon9/9:c.*1847G>C:,SPG20:NM_001142295.1:3'UTR:MODIFIER:exon9/9:c.*1847G>C:	MER58A	rs540414622	0.0000	0.0000	0/0/0	0.0001							607111 [SPG20 (provisional) Troyer syndrome,275900];				0	1					SPG20 (inh=AR pLI=0.00)
chr13	36876703	36876703	C	T	wt	het	het		QUAL=3734;DP=249,127,170;MQM=60	SPG20	3'UTR	SPG20:NM_001142294.1:3'UTR:MODIFIER:exon9/9:c.*1799G>A:,SPG20:NM_001142296.1:3'UTR:MODIFIER:exon10/10:c.*1799G>A:,SPG20:NM_015087.4:3'UTR:MODIFIER:exon9/9:c.*1799G>A:,SPG20:NM_001142295.1:3'UTR:MODIFIER:exon9/9:c.*1799G>A:		rs9547190	0.2867	0.0000	0/0/0	0.0504							607111 [SPG20 (provisional) Troyer syndrome,275900];	RCV000403783.1 [likely benign]; 			14	58					SPG20 (inh=AR pLI=0.00)
chr13	36877519	36877519	-	ATA	het	het	wt		QUAL=4900;DP=309,90,147;MQM=59	SPG20	3'UTR	SPG20:NM_001142294.1:3'UTR:MODIFIER:exon9/9:c.*980_*982dupTAT:,SPG20:NM_001142296.1:3'UTR:MODIFIER:exon10/10:c.*980_*982dupTAT:,SPG20:NM_015087.4:3'UTR:MODIFIER:exon9/9:c.*980_*982dupTAT:,SPG20:NM_001142295.1:3'UTR:MODIFIER:exon9/9:c.*980_*982dupTAT:		rs200142976	0.0040	0.0000	0/0/0	0.0047							607111 [SPG20 (provisional) Troyer syndrome,275900];				0	8					SPG20 (inh=AR pLI=0.00)
chr13	36877578	36877578	G	T	wt	het	het		QUAL=2245;DP=264,63,101;MQM=60	SPG20	3'UTR	SPG20:NM_001142294.1:3'UTR:MODIFIER:exon9/9:c.*924C>A:,SPG20:NM_001142296.1:3'UTR:MODIFIER:exon10/10:c.*924C>A:,SPG20:NM_015087.4:3'UTR:MODIFIER:exon9/9:c.*924C>A:,SPG20:NM_001142295.1:3'UTR:MODIFIER:exon9/9:c.*924C>A:		rs7333861	0.2839	0.0000	0/0/0	0.0500							607111 [SPG20 (provisional) Troyer syndrome,275900];	RCV000356091.1 [likely benign]; 			14	72					SPG20 (inh=AR pLI=0.00)
chr13	36877656	36877656	C	T	het	wt	het		QUAL=1731;DP=116,22,28;MQM=59	SPG20	3'UTR	SPG20:NM_001142294.1:3'UTR:MODIFIER:exon9/9:c.*846G>A:,SPG20:NM_001142296.1:3'UTR:MODIFIER:exon10/10:c.*846G>A:,SPG20:NM_015087.4:3'UTR:MODIFIER:exon9/9:c.*846G>A:,SPG20:NM_001142295.1:3'UTR:MODIFIER:exon9/9:c.*846G>A:		rs1054152	0.1382	0.0000	0/0/0	0.0298							607111 [SPG20 (provisional) Troyer syndrome,275900];	RCV000265378.1 [likely benign]; 			9	71					SPG20 (inh=AR pLI=0.00)
chr13	36877878	36877878	T	C	hom	hom	hom		QUAL=12135;DP=165,100,102;MQM=60	SPG20	3'UTR	SPG20:NM_001142294.1:3'UTR:MODIFIER:exon9/9:c.*624A>G:,SPG20:NM_001142296.1:3'UTR:MODIFIER:exon10/10:c.*624A>G:,SPG20:NM_015087.4:3'UTR:MODIFIER:exon9/9:c.*624A>G:,SPG20:NM_001142295.1:3'UTR:MODIFIER:exon9/9:c.*624A>G:		rs2148049	0.9890	0.0000	0/0/0	0.8522							607111 [SPG20 (provisional) Troyer syndrome,275900];	RCV000380694.1 [benign]; 			230	0					SPG20 (inh=AR pLI=0.00)
chr13	36877894	36877894	G	A	wt	het	het		QUAL=2721;DP=191,108,110;MQM=60	SPG20	3'UTR	SPG20:NM_001142294.1:3'UTR:MODIFIER:exon9/9:c.*608C>T:,SPG20:NM_001142296.1:3'UTR:MODIFIER:exon10/10:c.*608C>T:,SPG20:NM_015087.4:3'UTR:MODIFIER:exon9/9:c.*608C>T:,SPG20:NM_001142295.1:3'UTR:MODIFIER:exon9/9:c.*608C>T:		rs1054144	0.2869	0.0000	0/0/0	0.0568							607111 [SPG20 (provisional) Troyer syndrome,275900];	RCV000291046.1 [likely benign]; 			14	72					SPG20 (inh=AR pLI=0.00)
chr13	36877978	36877978	T	C	wt	het	het		QUAL=2931;DP=184,98,128;MQM=60	SPG20	3'UTR	SPG20:NM_001142294.1:3'UTR:MODIFIER:exon9/9:c.*524A>G:,SPG20:NM_001142296.1:3'UTR:MODIFIER:exon10/10:c.*524A>G:,SPG20:NM_015087.4:3'UTR:MODIFIER:exon9/9:c.*524A>G:,SPG20:NM_001142295.1:3'UTR:MODIFIER:exon9/9:c.*524A>G:		rs1054141	0.2887	0.0000	0/0/0	0.0502							607111 [SPG20 (provisional) Troyer syndrome,275900];	RCV000327395.1 [likely benign]; 			14	72					SPG20 (inh=AR pLI=0.00)
chr13	36886469	36886469	T	C	wt	het	het		QUAL=5096;DP=342,176,233;MQM=60	SPG20	synonymous	SPG20:NM_001142294.1:synonymous:LOW:exon7/9:c.1629A>G:p.Ala543Ala,SPG20:NM_001142296.1:synonymous:LOW:exon8/10:c.1629A>G:p.Ala543Ala,SPG20:NM_015087.4:synonymous:LOW:exon7/9:c.1629A>G:p.Ala543Ala,SPG20:NM_001142295.1:synonymous:LOW:exon7/9:c.1629A>G:p.Ala543Ala		rs2274293	0.2891	0.2821	5346/2317/111	0.2742							607111 [SPG20 (provisional) Troyer syndrome,275900];	RCV000118408.2 [likely benign]; RCV000405815.1 [likely benign]; 		COSM3753671	155	778					SPG20 (inh=AR pLI=0.00)
chr13	36920504	36920504	C	T	wt	het	het	low_DP	QUAL=503;DP=1,17,20;MQM=60	SPG20	5'UTR,intron	SPG20:NM_001142296.1:5'UTR:MODIFIER:exon1/10:c.-128G>A:,SPG20:NM_015087.4:5'UTR:MODIFIER:exon1/9:c.-145G>A:,SPG20:NM_001142294.1:intron:MODIFIER:exon1/8:c.-2-10535G>A:,SPG20:NM_001142295.1:intron:MODIFIER:exon1/8:c.-3+215G>A:		rs9566108	0.2877	0.0000	0/0/0	0.3031							607111 [SPG20 (provisional) Troyer syndrome,275900];	RCV000275963.1 [likely benign]; 			13	62					SPG20 (inh=AR pLI=0.00)
chr13	36920612	36920612	C	T	wt	het	het		QUAL=2029;DP=24,98,140;MQM=59	SPG20,SPG20-AS1	5'UTR,intron,non_coding_transcript_exon	SPG20:NM_001142296.1:5'UTR:MODIFIER:exon1/10:c.-236G>A:,SPG20:NM_015087.4:5'UTR:MODIFIER:exon1/9:c.-253G>A:,SPG20:NM_001142294.1:intron:MODIFIER:exon1/8:c.-2-10643G>A:,SPG20:NM_001142295.1:intron:MODIFIER:exon1/8:c.-3+107G>A:,SPG20-AS1:NR_045180.1:non_coding_transcript_exon:MODIFIER:exon1/6:n.45C>T:,SPG20-AS1:NR_045181.1:non_coding_transcript_exon:MODIFIER:exon1/5:n.45C>T:	(CGC)n	rs2281864	0.2875	0.0000	0/0/0	0.2882							607111 [SPG20 (provisional) Troyer syndrome,275900];	RCV000371465.1 [likely benign]; 			15	72					SPG20 (inh=AR pLI=0.00), SPG20-AS1 (inh=n/a pLI=n/a)
chr13	36920849	36920849	-	C	het	wt	het		QUAL=1899;DP=48,199,235;MQM=60	SPG20,SPG20-AS1	5'UTR,intron	SPG20:NM_001142295.1:5'UTR:MODIFIER:exon1/9:c.-134dupG:,SPG20:NM_001142294.1:intron:MODIFIER:exon1/8:c.-2-10881dupG:,SPG20-AS1:NR_045180.1:intron:MODIFIER:exon1/5:n.77+212dupC:,SPG20-AS1:NR_045181.1:intron:MODIFIER:exon1/4:n.77+212dupC:		rs146524559	0.2800	0.0000	0/0/0	0.3243							607111 [SPG20 (provisional) Troyer syndrome,275900];				39	96					SPG20 (inh=AR pLI=0.00), SPG20-AS1 (inh=n/a pLI=n/a)
chr13	36920890	36920890	G	C	hom	hom	hom		QUAL=12961;DP=44,164,217;MQM=59	SPG20,SPG20-AS1	5'UTR,intron	SPG20:NM_001142295.1:5'UTR:MODIFIER:exon1/9:c.-174C>G:,SPG20:NM_001142294.1:intron:MODIFIER:exon1/8:c.-2-10921C>G:,SPG20-AS1:NR_045180.1:intron:MODIFIER:exon1/5:n.77+246G>C:,SPG20-AS1:NR_045181.1:intron:MODIFIER:exon1/4:n.77+246G>C:		rs4943362	1.0000	0.0000	0/0/0	0.8487							607111 [SPG20 (provisional) Troyer syndrome,275900];				230	0					SPG20 (inh=AR pLI=0.00), SPG20-AS1 (inh=n/a pLI=n/a)
chr13	36920918	36920918	C	G	wt	het	het		QUAL=3344;DP=52,119,161;MQM=60	SPG20,SPG20-AS1	5'UTR,intron	SPG20:NM_001142295.1:5'UTR:MODIFIER:exon1/9:c.-202G>C:,SPG20:NM_001142294.1:intron:MODIFIER:exon1/8:c.-2-10949G>C:,SPG20-AS1:NR_045180.1:intron:MODIFIER:exon1/5:n.77+274C>G:,SPG20-AS1:NR_045181.1:intron:MODIFIER:exon1/4:n.77+274C>G:		rs9531842	0.2877	0.0000	0/0/0	0.3052							607111 [SPG20 (provisional) Troyer syndrome,275900];				15	73					SPG20 (inh=AR pLI=0.00), SPG20-AS1 (inh=n/a pLI=n/a)
chr13	36944274	36944274	C	T	het	hom	hom	low_DP	QUAL=145;DP=13,1,1;MQM=60	SPG20	5'UTR	SPG20:NM_001142294.1:5'UTR:MODIFIER:exon1/9:c.-51G>A:		rs4287440	0.7476	0.0000	0/0/0	0.7084							607111 [SPG20 (provisional) Troyer syndrome,275900];				87	76					SPG20 (inh=AR pLI=0.00)
chr13	37401918	37401918	T	-	hom	hom	hom		QUAL=21338;DP=228,186,264;MQM=59	RFXAP	3'UTR	RFXAP:NM_000538.3:3'UTR:MODIFIER:exon3/3:c.*33delT:		rs398022347	0.8011	0.8784	45811/27682/2680	0.8210							601861 [RFXAP (provisional) Bare lymphocyte syndrome,type II,complementation group D,209920];	RCV000375835.1 [benign]; 			732	169					RFXAP (inh=AR+AD pLI=0.44)
chr13	37402369	37402369	G	A	wt	het	wt		QUAL=1106;DP=231,126,169;MQM=60	RFXAP	3'UTR	RFXAP:NM_000538.3:3'UTR:MODIFIER:exon3/3:c.*479G>A:	MER20	rs117112761	0.0014	0.0000	0/0/0	0.0004							601861 [RFXAP (provisional) Bare lymphocyte syndrome,type II,complementation group D,209920];				0	3					RFXAP (inh=AR+AD pLI=0.44)
chr13	37402440	37402440	T	C	hom	hom	hom		QUAL=19274;DP=297,123,156;MQM=59	RFXAP	3'UTR	RFXAP:NM_000538.3:3'UTR:MODIFIER:exon3/3:c.*550T>C:		rs9547679	0.7961	0.0000	0/0/0	0.1471							601861 [RFXAP (provisional) Bare lymphocyte syndrome,type II,complementation group D,209920];	RCV000285256.1 [benign]; 			177	50					RFXAP (inh=AR+AD pLI=0.44)
chr13	37403084	37403084	A	G	wt	wt	het		QUAL=2672;DP=255,163,205;MQM=60	RFXAP	3'UTR	RFXAP:NM_000538.3:3'UTR:MODIFIER:exon3/3:c.*1194A>G:		rs11539183	0.0016	0.0000	0/0/0	0.0016							601861 [RFXAP (provisional) Bare lymphocyte syndrome,type II,complementation group D,209920];	RCV000290954.1 [uncertain significance]; 			0	1					RFXAP (inh=AR+AD pLI=0.44)
chr13	37403143	37403143	G	A	het	wt	het		QUAL=8686;DP=349,202,313;MQM=59	RFXAP	3'UTR	RFXAP:NM_000538.3:3'UTR:MODIFIER:exon3/3:c.*1253G>A:		rs10976	0.1414	0.0000	0/0/0	0.0230							601861 [RFXAP (provisional) Bare lymphocyte syndrome,type II,complementation group D,209920];	RCV000408366.1 [likely benign]; 			10	68					RFXAP (inh=AR+AD pLI=0.44)
chr13	39262057	39262057	G	A	hom	hom	hom		QUAL=15525;DP=93,181,231;MQM=60	FREM2	synonymous	FREM2:NM_207361.5:synonymous:LOW:exon1/24:c.576G>A:p.Glu192Glu		rs1868464	1.0000	1.0000	45999/24829/3896	0.9379							608945 [FREM2 (provisional) Fraser syndrome,219000];	RCV000250281.1 [benign]; RCV000347448.1 [benign]; 		COSM4147704	1566	0					FREM2 (inh=AR pLI=0.00)
chr13	39263714	39263714	T	C	hom	hom	hom	pred_pathogenic	QUAL=33208;DP=333,325,416;MQM=59	FREM2	missense	FREM2:NM_207361.5:missense:MODERATE:exon1/24:c.2233T>C:p.Ser745Pro		rs2496423	1.0000	1.0000	60494/33299/5198	0.9453	3.1680	T	T	B	T	5.98	608945 [FREM2 (provisional) Fraser syndrome,219000];	RCV000173610.2 [benign]; RCV000357309.1 [benign]; 			1564	0					FREM2 (inh=AR pLI=0.00)
chr13	39263731	39263731	C	T	wt	wt	het		QUAL=4812;DP=335,309,401;MQM=60	FREM2	synonymous	FREM2:NM_207361.5:synonymous:LOW:exon1/24:c.2250C>T:p.Asp750Asp		rs41292755	0.0998	0.1039	787/324/3	0.1021							608945 [FREM2 (provisional) Fraser syndrome,219000];	RCV000173611.2 [benign]; RCV000405344.1 [likely benign]; 			20	304					FREM2 (inh=AR pLI=0.00)
chr13	39264690	39264690	T	C	het	het	het		QUAL=12315;DP=398,214,282;MQM=59	FREM2	missense	FREM2:NM_207361.5:missense:MODERATE:exon1/24:c.3209T>C:p.Phe1070Ser		rs2496425	0.4812	0.3473	8569/2562/3014	0.3410	0.9280	T	T	B	T	6.48	608945 [FREM2 (provisional) Fraser syndrome,219000];	RCV000173599.1 [benign]; RCV000380412.1 [benign]; 	CM065186 [CLASS=DP MUT=ALT PHEN="Colorectal cancer increased risk association with" GENE=FREM2]; 	COSM1366801	142	619					FREM2 (inh=AR pLI=0.00)
chr13	39343822	39343822	C	T	het	het	het	pred_pathogenic	QUAL=9392;DP=318,178,297;MQM=60	FREM2	missense	FREM2:NM_207361.5:missense:MODERATE:exon4/24:c.5518C>T:p.Arg1840Trp		rs9603422	0.1418	0.1215	1023/437/259	0.1206	0.8450	D	T	D	T	24.10	608945 [FREM2 (provisional) Fraser syndrome,219000];	RCV000301753.1 [likely benign]; 			41	334					FREM2 (inh=AR pLI=0.00)
chr13	39422624	39422624	C	T	het	wt	het	pred_pathogenic	QUAL=3261;DP=136,126,124;MQM=60	FREM2	missense	FREM2:NM_207361.5:missense:MODERATE:exon8/24:c.6196C>T:p.Arg2066Cys		rs9548505	0.1096	0.1224	1333/348/104	0.1201	4.8040	D	T	P,D	T	35.00	608945 [FREM2 (provisional) Fraser syndrome,219000];	RCV000288508.1 [benign]; 		COSM3753678	24	294					FREM2 (inh=AR pLI=0.00)
chr13	39424253	39424253	C	G	het	wt	het	pred_pathogenic	QUAL=3222;DP=225,60,66;MQM=60	FREM2	missense	FREM2:NM_207361.5:missense:MODERATE:exon9/24:c.6458C>G:p.Thr2153Ser		rs9548506	0.0919	0.1172	1225/338/35	0.1093	3.4960	T	T	B,B	T	0.46	608945 [FREM2 (provisional) Fraser syndrome,219000];	RCV000391684.1 [benign]; 		COSM3753679	24	289					FREM2 (inh=AR pLI=0.00)
chr13	39424254	39424254	T	C	het	wt	het		QUAL=3222;DP=225,60,66;MQM=60	FREM2	synonymous	FREM2:NM_207361.5:synonymous:LOW:exon9/24:c.6459T>C:p.Thr2153Thr		rs9548507	0.0919	0.1172	1223/337/35	0.1093							608945 [FREM2 (provisional) Fraser syndrome,219000];	RCV000300256.1 [benign]; 		COSM3753680	24	289					FREM2 (inh=AR pLI=0.00)
chr13	39430314	39430314	C	T	het	het	hom	pred_pathogenic	QUAL=15444;DP=264,191,292;MQM=60	FREM2	missense,sequence_feature	FREM2:NM_207361.5:missense:MODERATE:exon12/24:c.6977C>T:p.Thr2326Ile,FREM2:NM_207361.5:sequence_feature:LOW:exon12/24:c.6977C>T:		rs9548509	0.7720	0.7398	33703/16210/2911	0.7216	6.1370	T	T	B,B	T	14.53	608945 [FREM2 (provisional) Fraser syndrome,219000];	RCV000241670.1 [benign]; RCV000369162.1 [benign]; 		COSM432379	765	665					FREM2 (inh=AR pLI=0.00)
chr13	39433606	39433606	A	G	het	wt	hom		QUAL=27482;DP=416,496,709;MQM=60	FREM2	synonymous	FREM2:NM_207361.5:synonymous:LOW:exon14/24:c.7398A>G:p.Thr2466Thr		rs9532292	0.4367	0.3734	9063/3345/1621	0.3672							608945 [FREM2 (provisional) Fraser syndrome,219000];	RCV000244828.1 [benign]; RCV000381500.1 [benign]; 		COSM3753681	200	710					FREM2 (inh=AR pLI=0.00)
chr13	39455266	39455266	G	A	wt	het	wt		QUAL=2691;DP=414,206,275;MQM=60	FREM2	3'UTR	FREM2:NM_207361.5:3'UTR:MODIFIER:exon24/24:c.*342G>A:		rs9603463	0.3263	0.0000	0/0/0	0.0633							608945 [FREM2 (provisional) Fraser syndrome,219000];	RCV000344602.1 [benign]; 			31	113					FREM2 (inh=AR pLI=0.00)
chr13	39455916	39455916	T	C	het	wt	het		QUAL=10901;DP=472,191,325;MQM=60	FREM2	3'UTR	FREM2:NM_207361.5:3'UTR:MODIFIER:exon24/24:c.*992T>C:		rs9532297	0.0845	0.0000	0/0/0	0.0189							608945 [FREM2 (provisional) Fraser syndrome,219000];	RCV000407772.1 [benign]; 			4	42					FREM2 (inh=AR pLI=0.00)
chr13	39455965	39455965	C	T	het	wt	het		QUAL=10593;DP=491,232,349;MQM=60	FREM2	3'UTR	FREM2:NM_207361.5:3'UTR:MODIFIER:exon24/24:c.*1041C>T:		rs9548521	0.0675	0.0000	0/0/0	0.0158							608945 [FREM2 (provisional) Fraser syndrome,219000];	RCV000304836.1 [likely benign]; 			3	31					FREM2 (inh=AR pLI=0.00)
chr13	39456352	39456352	A	G	het	het	het		QUAL=9492;DP=408,165,176;MQM=59	FREM2	3'UTR	FREM2:NM_207361.5:3'UTR:MODIFIER:exon24/24:c.*1428A>G:		rs9548522	0.4339	0.0000	0/0/0	0.0848							608945 [FREM2 (provisional) Fraser syndrome,219000];	RCV000263845.1 [benign]; 			50	124					FREM2 (inh=AR pLI=0.00)
chr13	39456391	39456391	G	A	het	wt	het		QUAL=7839;DP=443,165,177;MQM=60	FREM2	3'UTR	FREM2:NM_207361.5:3'UTR:MODIFIER:exon24/24:c.*1467G>A:		rs9548523	0.0675	0.0000	0/0/0	0.0158							608945 [FREM2 (provisional) Fraser syndrome,219000];	RCV000316827.1 [likely benign]; 			3	31					FREM2 (inh=AR pLI=0.00)
chr13	39457064	39457064	C	G	het	het	het		QUAL=18088;DP=627,298,416;MQM=60	FREM2	3'UTR	FREM2:NM_207361.5:3'UTR:MODIFIER:exon24/24:c.*2140C>G:		rs7324632	0.4339	0.0000	0/0/0	0.4991							608945 [FREM2 (provisional) Fraser syndrome,219000];	RCV000341891.1 [benign]; 			51	123					FREM2 (inh=AR pLI=0.00)
chr13	39457850	39457850	G	A	wt	wt	het		QUAL=3402;DP=348,180,234;MQM=60	FREM2	3'UTR	FREM2:NM_207361.5:3'UTR:MODIFIER:exon24/24:c.*2926G>A:		rs1945508	0.2987	0.0000	0/0/0	0.0382							608945 [FREM2 (provisional) Fraser syndrome,219000];	RCV000269221.1 [benign]; 			3	71					FREM2 (inh=AR pLI=0.00)
chr13	39458116	39458116	T	C	wt	wt	het		QUAL=2036;DP=393,115,151;MQM=60	FREM2	3'UTR	FREM2:NM_207361.5:3'UTR:MODIFIER:exon24/24:c.*3192T>C:		rs7337135	0.3037	0.0000	0/0/0	0.0385							608945 [FREM2 (provisional) Fraser syndrome,219000];	RCV000283966.1 [benign]; 			3	71					FREM2 (inh=AR pLI=0.00)
chr13	39458405	39458405	G	A	wt	wt	het		QUAL=2265;DP=388,168,212;MQM=60	FREM2	3'UTR	FREM2:NM_207361.5:3'UTR:MODIFIER:exon24/24:c.*3481G>A:		rs2184141	0.3037	0.0000	0/0/0	0.0385							608945 [FREM2 (provisional) Fraser syndrome,219000];	RCV000379656.1 [benign]; 			3	72					FREM2 (inh=AR pLI=0.00)
chr13	39459389	39459389	C	T	het	het	hom		QUAL=6613;DP=194,96,100;MQM=59	FREM2	3'UTR	FREM2:NM_207361.5:3'UTR:MODIFIER:exon24/24:c.*4465C>T:		rs2027770	0.7474	0.0000	0/0/0	0.1419							608945 [FREM2 (provisional) Fraser syndrome,219000];	RCV000315258.1 [benign]; 			97	110					FREM2 (inh=AR pLI=0.00)
chr13	39459484	39459484	G	A	wt	wt	het		QUAL=2121;DP=314,154,173;MQM=60	FREM2	3'UTR	FREM2:NM_207361.5:3'UTR:MODIFIER:exon24/24:c.*4560G>A:		rs2225623	0.2987	0.0000	0/0/0	0.0382							608945 [FREM2 (provisional) Fraser syndrome,219000];	RCV000406839.1 [benign]; 			3	71					FREM2 (inh=AR pLI=0.00)
chr13	39459694	39459694	C	T	wt	wt	het		QUAL=963;DP=255,76,95;MQM=60	FREM2	3'UTR	FREM2:NM_207361.5:3'UTR:MODIFIER:exon24/24:c.*4770C>T:		rs6563648	0.3087	0.0000	0/0/0	0.0386							608945 [FREM2 (provisional) Fraser syndrome,219000];	RCV000322382.1 [benign]; 			3	71					FREM2 (inh=AR pLI=0.00)
chr13	39460259	39460259	A	G	het	wt	het		QUAL=4047;DP=224,78,93;MQM=60	FREM2	3'UTR	FREM2:NM_207361.5:3'UTR:MODIFIER:exon24/24:c.*5335A>G:		rs9548524	0.0843	0.0000	0/0/0	0.1110							608945 [FREM2 (provisional) Fraser syndrome,219000];	RCV000279086.1 [benign]; 			4	42					FREM2 (inh=AR pLI=0.00)
chr13	39460415	39460415	G	A	het	het	hom		QUAL=13061;DP=353,133,201;MQM=59	FREM2	3'UTR	FREM2:NM_207361.5:3'UTR:MODIFIER:exon24/24:c.*5491G>A:		rs2226913	0.7504	0.0000	0/0/0	0.7284							608945 [FREM2 (provisional) Fraser syndrome,219000];	RCV000320239.1 [benign]; 			96	109					FREM2 (inh=AR pLI=0.00)
chr13	39460466	39460466	T	A	wt	wt	het		QUAL=1925;DP=440,147,205;MQM=59	FREM2	3'UTR	FREM2:NM_207361.5:3'UTR:MODIFIER:exon24/24:c.*5542T>A:	(ATAC)n	rs7327529	0.3085	0.0000	0/0/0	0.1971							608945 [FREM2 (provisional) Fraser syndrome,219000];	RCV000293330.1 [benign]; 			3	71					FREM2 (inh=AR pLI=0.00)
chr13	39460486	39460486	C	G	het	het	het		QUAL=8979;DP=276,148,203;MQM=59	FREM2	3'UTR	FREM2:NM_207361.5:3'UTR:MODIFIER:exon24/24:c.*5562C>G:	(ATAC)n	rs1945507	0.4341	0.0000	0/0/0	0.4322							608945 [FREM2 (provisional) Fraser syndrome,219000];	RCV000295552.1 [benign]; 			51	121					FREM2 (inh=AR pLI=0.00)
chr13	39460522	39460522	-	AG	wt	wt	het		QUAL=2120;DP=115,107,127;MQM=59	FREM2	3'UTR	FREM2:NM_207361.5:3'UTR:MODIFIER:exon24/24:c.*5610_*5611dupGA:	(ATAC)n	rs5802960	0.0000	0.0000	0/0/0	0.0154							608945 [FREM2 (provisional) Fraser syndrome,219000];	RCV000267139.1 [uncertain significance]; 			1	37					FREM2 (inh=AR pLI=0.00)
chr13	39460522	39460522	T	G	wt	het	wt		QUAL=2120;DP=115,107,127;MQM=59	FREM2	3'UTR	FREM2:NM_207361.5:3'UTR:MODIFIER:exon24/24:c.*5598T>G:	(ATAC)n	rs1945506	0.4645	0.0000	0/0/0	0.3217							608945 [FREM2 (provisional) Fraser syndrome,219000];	RCV000310607.1 [benign]; 			23	80					FREM2 (inh=AR pLI=0.00)
chr13	39460540	39460540	T	-	het	het	hom		QUAL=4247;DP=114,89,101;MQM=59	FREM2	3'UTR	FREM2:NM_207361.5:3'UTR:MODIFIER:exon24/24:c.*5627delT:	AluSp	rs5802961	0.7486	0.0000	0/0/0	0.2855							608945 [FREM2 (provisional) Fraser syndrome,219000];	RCV000385673.1 [benign]; 			63	98					FREM2 (inh=AR pLI=0.00)
chr13	39460657	39460657	C	T	het	het	het		QUAL=3444;DP=153,41,61;MQM=59	FREM2	3'UTR	FREM2:NM_207361.5:3'UTR:MODIFIER:exon24/24:c.*5733C>T:	AluSp	rs1945505	0.4343	0.0000	0/0/0	0.4515							608945 [FREM2 (provisional) Fraser syndrome,219000];	RCV000382194.1 [benign]; 			39	94					FREM2 (inh=AR pLI=0.00)
chr13	39460823	39460823	C	T	wt	het	wt		QUAL=1144;DP=120,121,131;MQM=60	FREM2	3'UTR	FREM2:NM_207361.5:3'UTR:MODIFIER:exon24/24:c.*5899C>T:	AluSp	rs1945504	0.2572	0.0000	0/0/0	0.3123							608945 [FREM2 (provisional) Fraser syndrome,219000];	RCV000383553.1 [benign]; 			31	103					FREM2 (inh=AR pLI=0.00)
chr13	41382711	41382711	A	T	het	wt	het		QUAL=4536;DP=166,153,185;MQM=55	SLC25A15,TPTE2P5	missense,intron	SLC25A15:NM_014252.3:missense:MODERATE:exon6/7:c.760A>T:p.Ile254Leu,TPTE2P5:NR_038258.1:intron:MODIFIER:exon7/7:n.623-7851T>A:,TPTE2P5:NR_038259.1:intron:MODIFIER:exon5/5:n.452-7851T>A:		rs17849654	0.3227	0.3725	8648/5828/193	0.3632	1.3490	T,T	T	B,B	T	0.01	603861 [SLC25A15 (confirmed) Hyperornithinemia-hyperammonemia-homocitrullinemia syndrome,238970];	RCV000128071.2 [benign]; RCV000273122.1 [benign]; 		COSM3753692	468	1234					SLC25A15 (inh=AR pLI=0.00), TPTE2P5 (inh=n/a pLI=n/a)
chr13	41384156	41384156	A	G	het	wt	het		QUAL=6076;DP=241,165,213;MQM=59	SLC25A15,TPTE2P5	3'UTR,intron	SLC25A15:NM_014252.3:3'UTR:MODIFIER:exon7/7:c.*353A>G:,TPTE2P5:NR_038258.1:intron:MODIFIER:exon7/7:n.623-9296T>C:,TPTE2P5:NR_038259.1:intron:MODIFIER:exon5/5:n.452-9296T>C:		rs9549293	0.4237	0.0000	0/0/0	0.0723							603861 [SLC25A15 (confirmed) Hyperornithinemia-hyperammonemia-homocitrullinemia syndrome,238970];	RCV000372205.1 [benign]; 			54	129					SLC25A15 (inh=AR pLI=0.00), TPTE2P5 (inh=n/a pLI=n/a)
chr13	41384318	41384318	A	G	het	wt	het		QUAL=1988;DP=122,23,28;MQM=58	SLC25A15,TPTE2P5	3'UTR,intron	SLC25A15:NM_014252.3:3'UTR:MODIFIER:exon7/7:c.*515A>G:,TPTE2P5:NR_038258.1:intron:MODIFIER:exon7/7:n.623-9458T>C:,TPTE2P5:NR_038259.1:intron:MODIFIER:exon5/5:n.452-9458T>C:	AluSz	rs7322603	0.4237	0.0000	0/0/0	0.3827							603861 [SLC25A15 (confirmed) Hyperornithinemia-hyperammonemia-homocitrullinemia syndrome,238970];	RCV000337207.1 [benign]; 			52	117					SLC25A15 (inh=AR pLI=0.00), TPTE2P5 (inh=n/a pLI=n/a)
chr13	41384382	41384382	C	T	het	wt	het	low_DP	QUAL=2071;DP=145,12,28;MQM=51	SLC25A15,TPTE2P5	3'UTR,intron	SLC25A15:NM_014252.3:3'UTR:MODIFIER:exon7/7:c.*579C>T:,TPTE2P5:NR_038258.1:intron:MODIFIER:exon7/7:n.623-9522G>A:,TPTE2P5:NR_038259.1:intron:MODIFIER:exon5/5:n.452-9522G>A:	AluSz	rs7321976	0.4237	0.0000	0/0/0	0.3824							603861 [SLC25A15 (confirmed) Hyperornithinemia-hyperammonemia-homocitrullinemia syndrome,238970];	RCV000398781.1 [benign]; 			46	105					SLC25A15 (inh=AR pLI=0.00), TPTE2P5 (inh=n/a pLI=n/a)
chr13	48517289	48517289	A	G	hom	hom	hom		QUAL=30309;DP=439,213,267;MQM=60	SUCLA2	3'UTR	SUCLA2:NM_003850.2:3'UTR:MODIFIER:exon11/11:c.*217T>C:		rs4941618	0.9419	0.0000	0/0/0	0.1460							603921 [SUCLA2 (confirmed) Mitochondrial DNA depletion syndrome 5 (encephalomyopathic with or without methylmalonic aciduria),612073];	RCV000322278.1 [benign]; 			195	32					SUCLA2 (inh=AR pLI=0.03)
chr13	48547467	48547467	A	T	hom	het	hom	pred_pathogenic	QUAL=12839;DP=205,124,140;MQM=59	SUCLA2	missense	SUCLA2:NM_003850.2:missense:MODERATE:exon5/11:c.595T>A:p.Ser199Thr		rs7320366	0.6835	0.7515	34944/22378/1754	0.7436	4.7410	T,T,T,T,T,T,T,T,T,T	T	B	T,T,T,T,T,T	14.64	603921 [SUCLA2 (confirmed) Mitochondrial DNA depletion syndrome 5 (encephalomyopathic with or without methylmalonic aciduria),612073];	RCV000128327.3 [benign]; RCV000300356.1 [benign]; 			933	544					SUCLA2 (inh=AR pLI=0.03)
chr13	48563008	48563008	G	A	hom	het	hom		QUAL=17856;DP=277,162,207;MQM=60	SUCLA2	splice_region&intron	SUCLA2:NM_003850.2:splice_region&intron:LOW:exon3/10:c.371+9C>T:		rs6561424	0.6835	0.7515	34812/22285/1738	0.7448							603921 [SUCLA2 (confirmed) Mitochondrial DNA depletion syndrome 5 (encephalomyopathic with or without methylmalonic aciduria),612073];	RCV000177179.3 [benign]; RCV000360855.1 [benign]; 			926	528					SUCLA2 (inh=AR pLI=0.03)
chr13	52507110	52507110	G	C	wt	het	het		QUAL=6977;DP=225,221,324;MQM=60	ATP7B	3'UTR	ATP7B:NM_000053.3:3'UTR:MODIFIER:exon21/21:c.*1782C>G:,ATP7B:NM_001005918.2:3'UTR:MODIFIER:exon17/17:c.*1782C>G:,ATP7B:NM_001243182.1:3'UTR:MODIFIER:exon22/22:c.*1782C>G:		rs928169	0.5240	0.0000	0/0/0	0.0946							606882 [ATP7B (confirmed) Wilson disease,277900];	RCV000336343.1 [benign]; 			75	134					ATP7B (inh=AR pLI=0.00)
chr13	52507720	52507720	C	T	wt	het	het		QUAL=7628;DP=349,266,316;MQM=60	ATP7B	3'UTR	ATP7B:NM_000053.3:3'UTR:MODIFIER:exon21/21:c.*1172G>A:,ATP7B:NM_001005918.2:3'UTR:MODIFIER:exon17/17:c.*1172G>A:,ATP7B:NM_001243182.1:3'UTR:MODIFIER:exon22/22:c.*1172G>A:		rs1051332	0.3069	0.0000	0/0/0	0.0702							606882 [ATP7B (confirmed) Wilson disease,277900];	RCV000315820.1 [likely benign]; 			55	124					ATP7B (inh=AR pLI=0.00)
chr13	52511606	52511606	G	A	wt	het	het		QUAL=9573;DP=236,345,468;MQM=60	ATP7B	splice_region&intron	ATP7B:NM_000053.3:splice_region&intron:LOW:exon18/20:c.3903+6C>T:,ATP7B:NM_001005918.2:splice_region&intron:LOW:exon14/16:c.3282+6C>T:,ATP7B:NM_001243182.1:splice_region&intron:LOW:exon19/21:c.3570+6C>T:		rs2282057	0.5018	0.5374	17624/10914/1090	0.5260							606882 [ATP7B (confirmed) Wilson disease,277900];	RCV000029376.2 [benign]; RCV000078054.7 [benign]; 			936	1378	1	[1] old entry - no details available			ATP7B (inh=AR pLI=0.00)
chr13	52515354	52515354	A	G	wt	het	het	pred_pathogenic	QUAL=1797;DP=187,63,98;MQM=60	ATP7B	missense	ATP7B:NM_000053.3:missense:MODERATE:exon16/21:c.3419T>C:p.Val1140Ala,ATP7B:NM_001005918.2:missense:MODERATE:exon12/17:c.2798T>C:p.Val933Ala,ATP7B:NM_001243182.1:missense:MODERATE:exon17/22:c.3086T>C:p.Val1029Ala		rs1801249	0.5405	0.5653	19526/11248/1479	0.5583	0.1100	T,T,T,T,T,T,T	T	B,B,B,B,B,B,B,B	D,D,D,D,D,D,D	0.05	606882 [ATP7B (confirmed) Wilson disease,277900];	RCV000029369.2 [benign]; RCV000078051.8 [other]; 	CM044579 [CLASS=DP MUT=ALT PHEN="Wilson disease" GENE=ATP7B]; 	COSM3765712	964	1373	1	[1] old entry - no details available			ATP7B (inh=AR pLI=0.00)
chr13	52523808	52523808	C	T	wt	het	het	pred_pathogenic	QUAL=6354;DP=207,194,244;MQM=60	ATP7B	missense,intron	ATP7B:NM_000053.3:missense:MODERATE:exon12/21:c.2855G>A:p.Arg952Lys,ATP7B:NM_001243182.1:missense:MODERATE:exon13/22:c.2522G>A:p.Arg841Lys,ATP7B:NM_001005918.2:intron:MODIFIER:exon8/16:c.2244+335G>A:		rs732774	0.5310	0.5627	19321/11227/1313	0.5519	2.7810	T,T,T,T,T,T	T	B,B,B,B,B,B,B	D,D,D,D,D,D	17.00	606882 [ATP7B (confirmed) Wilson disease,277900];	RCV000029357.2 [benign]; RCV000078044.8 [other]; 	CM127927 [CLASS=DP MUT=ALT PHEN="Alzheimer disease association with" GENE=ATP7B]; 	COSM147691	973	1363	1	[1] old entry - no details available			ATP7B (inh=AR pLI=0.00)
chr13	52524488	52524488	T	C	wt	het	het	pred_pathogenic	QUAL=10548;DP=499,365,534;MQM=60	ATP7B	missense	ATP7B:NM_000053.3:missense:MODERATE:exon10/21:c.2495A>G:p.Lys832Arg,ATP7B:NM_001005918.2:missense:MODERATE:exon7/17:c.2009A>G:p.Lys670Arg,ATP7B:NM_001243182.1:missense:MODERATE:exon11/22:c.2162A>G:p.Lys721Arg		rs1061472	0.5024	0.5384	17668/10915/1140	0.5286	6.2060	T,T,T,T,T,T	T	B,P,P,B,B,P,B	D,D,D,D,D,D	22.20	606882 [ATP7B (confirmed) Wilson disease,277900];	RCV000029356.2 [benign]; RCV000078043.7 [benign]; 	CM116966 [CLASS=DP MUT=ALT PHEN="Alzheimer disease association with" GENE=ATP7B]; 	COSM3753723	950	1366	1	[1] old entry - no details available			ATP7B (inh=AR pLI=0.00)
chr13	52548140	52548140	A	C	wt	het	het	pred_pathogenic	QUAL=12046;DP=478,402,483;MQM=60	ATP7B	missense	ATP7B:NM_000053.3:missense:MODERATE:exon2/21:c.1216T>G:p.Ser406Ala,ATP7B:NM_001005918.2:missense:MODERATE:exon2/17:c.1216T>G:p.Ser406Ala,ATP7B:NM_001243182.1:missense:MODERATE:exon3/22:c.883T>G:p.Ser295Ala		rs1801243	0.3762	0.4388	12197/7804/166	0.4390	-0.6690	T,T,T,T,T,T,T	T	B,B,B,B,B,B,B,B	D,D,D,D,D,D,D	0.16	606882 [ATP7B (confirmed) Wilson disease,277900];	RCV000029350.2 [other]; RCV000078038.7 [benign]; 	CM129458 [CLASS=FP MUT=ALT PHEN="Reduced copper accumulation" GENE=ATP7B]; 	COSM3753725	677	1402	1	[1] old entry - no details available			ATP7B (inh=AR pLI=0.00)
chr13	52585548	52585548	G	T	wt	het	het	anno_pathogenic_hgmd	QUAL=777;DP=92,39,36;MQM=60	ATP7B	5'UTR	ATP7B:NM_000053.3:5'UTR:MODIFIER:exon1/21:c.-75C>A:,ATP7B:NM_001005918.2:5'UTR:MODIFIER:exon1/17:c.-75C>A:,ATP7B:NM_001243182.1:5'UTR:MODIFIER:exon1/22:c.-75C>A:		rs2277448	0.5168	0.0000	0/0/0	0.1281							606882 [ATP7B (confirmed) Wilson disease,277900];	RCV000296384.1 [benign]; RCV000384429.1 [benign]; 	CR129463 [CLASS=DM? MUT=ALT PHEN="Wilson disease" GENE=ATP7B]; 		253	222	2	[2] old entry - no details available			ATP7B (inh=AR pLI=0.00)
chr13	52585591	52585591	-	CGGCG	wt	het	het	low_DP	QUAL=306;DP=42,29,19;MQM=60	ATP7B	5'UTR	ATP7B:NM_000053.3:5'UTR:MODIFIER:exon1/21:c.-123_-119dupCGCCG:,ATP7B:NM_001005918.2:5'UTR:MODIFIER:exon1/17:c.-123_-119dupCGCCG:,ATP7B:NM_001243182.1:5'UTR:MODIFIER:exon1/22:c.-123_-119dupCGCCG:		rs148013251;rs3832920	0.3704	0.0000	0/0/0	0.4243							606882 [ATP7B (confirmed) Wilson disease,277900];	RCV000029348.2 [other]; RCV000332700.1 [benign]; 			54	147					ATP7B (inh=AR pLI=0.00)
chr13	78470350	78470350	A	G	hom	hom	hom		QUAL=7356;DP=160,38,36;MQM=60	EDNRB,EDNRB-AS1	3'UTR,intron	EDNRB:NM_001201397.1:3'UTR:MODIFIER:exon8/8:c.*1985T>C:,EDNRB:NM_001122659.2:3'UTR:MODIFIER:exon7/7:c.*1985T>C:,EDNRB:NM_003991.3:3'UTR:MODIFIER:exon7/7:c.*227T>C:,EDNRB:NM_000115.3:3'UTR:MODIFIER:exon8/8:c.*1985T>C:,EDNRB-AS1:NR_103853.1:intron:MODIFIER:exon6/6:n.1695-11477A>G:		rs4885491	0.9255	0.0000	0/0/0	0.1342							131244 [EDNRB (confirmed) Hirschsprung disease,susceptibility to,2,600155|ABCD syndrome,600501|Waardenburg syndrome,type 4A,277580];				159	67					EDNRB (inh=AR+AD pLI=0.02), EDNRB-AS1 (inh=n/a pLI=n/a)
chr13	78470568	78470568	G	A	het	wt	het		QUAL=3341;DP=213,64,60;MQM=60	EDNRB,EDNRB-AS1	3'UTR,intron	EDNRB:NM_001201397.1:3'UTR:MODIFIER:exon8/8:c.*1767C>T:,EDNRB:NM_001122659.2:3'UTR:MODIFIER:exon7/7:c.*1767C>T:,EDNRB:NM_003991.3:3'UTR:MODIFIER:exon7/7:c.*9C>T:,EDNRB:NM_000115.3:3'UTR:MODIFIER:exon8/8:c.*1767C>T:,EDNRB-AS1:NR_103853.1:intron:MODIFIER:exon6/6:n.1695-11259G>A:		rs3027092	0.0146	0.0228	7/4/0	0.0104							131244 [EDNRB (confirmed) Hirschsprung disease,susceptibility to,2,600155|ABCD syndrome,600501|Waardenburg syndrome,type 4A,277580];	RCV000217389.1 [benign]; RCV000267567.1 [likely benign]; RCV000324935.1 [likely benign]; 			0	43					EDNRB (inh=AR+AD pLI=0.02), EDNRB-AS1 (inh=n/a pLI=n/a)
chr13	78475313	78475313	T	C	wt	het	het		QUAL=3417;DP=111,90,141;MQM=60	EDNRB,EDNRB-AS1	synonymous,intron	EDNRB:NM_001201397.1:synonymous:LOW:exon5/8:c.1101A>G:p.Leu367Leu,EDNRB:NM_001122659.2:synonymous:LOW:exon4/7:c.831A>G:p.Leu277Leu,EDNRB:NM_003991.3:synonymous:LOW:exon4/7:c.831A>G:p.Leu277Leu,EDNRB:NM_000115.3:synonymous:LOW:exon5/8:c.831A>G:p.Leu277Leu,EDNRB-AS1:NR_103853.1:intron:MODIFIER:exon6/6:n.1695-6514T>C:		rs5351	0.5447	0.5799	20667/12737/1588	0.5752							131244 [EDNRB (confirmed) Hirschsprung disease,susceptibility to,2,600155|ABCD syndrome,600501|Waardenburg syndrome,type 4A,277580];	RCV000219248.2 [benign]; RCV000263642.1 [benign]; RCV000321151.1 [benign]; 		COSM3753748, COSM3753750, COSM3753749	654	857					EDNRB (inh=AR+AD pLI=0.02), EDNRB-AS1 (inh=n/a pLI=n/a)
chr13	78477674	78477674	A	G	hom	hom	hom		QUAL=24512;DP=334,183,226;MQM=59	EDNRB,EDNRB-AS1	synonymous,intron	EDNRB:NM_001201397.1:synonymous:LOW:exon3/8:c.822T>C:p.Ser274Ser,EDNRB:NM_001122659.2:synonymous:LOW:exon2/7:c.552T>C:p.Ser184Ser,EDNRB:NM_003991.3:synonymous:LOW:exon2/7:c.552T>C:p.Ser184Ser,EDNRB:NM_000115.3:synonymous:LOW:exon3/8:c.552T>C:p.Ser184Ser,EDNRB-AS1:NR_103853.1:intron:MODIFIER:exon6/6:n.1695-4153A>G:		rs5348	0.9838	0.9949	59991/33323/4723	0.9405							131244 [EDNRB (confirmed) Hirschsprung disease,susceptibility to,2,600155|ABCD syndrome,600501|Waardenburg syndrome,type 4A,277580];	RCV000220746.1 [benign]; 			1564	1					EDNRB (inh=AR+AD pLI=0.02), EDNRB-AS1 (inh=n/a pLI=n/a)
chr13	78549635	78549635	C	T	het	wt	het	low_DP	QUAL=139;DP=9,7,6;MQM=60	EDNRB	5'UTR	EDNRB:NM_000115.3:5'UTR:MODIFIER:exon1/8:c.-205G>A:	HERVE_a-int	rs12720104	0.0146	0.0000	0/0/0	0.0121							131244 [EDNRB (confirmed) Hirschsprung disease,susceptibility to,2,600155|ABCD syndrome,600501|Waardenburg syndrome,type 4A,277580];				0	3					EDNRB (inh=AR+AD pLI=0.02)
chr13	100635377	100635377	C	T	het	wt	het		QUAL=7505;DP=233,385,462;MQM=59	ZIC2	synonymous	ZIC2:NM_007129.3:synonymous:LOW:exon1/3:c.1059C>T:p.His353His		rs1831992	0.0417	0.0799	549/492/3	0.0801							603073 [ZIC2 (provisional) Holoprosencephaly 5,609637];	RCV000081471.5 [benign]; 			23	270					ZIC2 (inh=AD pLI=n/a)
chr13	100638392	100638392	G	A	hom	het	hom		QUAL=27395;DP=553,170,288;MQM=59	ZIC2	3'UTR	ZIC2:NM_007129.3:3'UTR:MODIFIER:exon3/3:c.*456G>A:		rs13542	0.3105	0.0000	0/0/0	0.2696							603073 [ZIC2 (provisional) Holoprosencephaly 5,609637];				29	147					ZIC2 (inh=AD pLI=n/a)
chr13	100888122	100888122	A	G	wt	wt	het		QUAL=3882;DP=446,241,273;MQM=60	PCCA	synonymous	PCCA:NM_000282.3:synonymous:LOW:exon8/24:c.627A>G:p.Ala209Ala,PCCA:NM_001127692.2:synonymous:LOW:exon7/23:c.549A>G:p.Ala183Ala,PCCA:NM_001178004.1:synonymous:LOW:exon8/23:c.627A>G:p.Ala209Ala		rs538229	0.1030	0.1475	1483/1038/51	0.1463							232000 [PCCA (confirmed) Propionicacidemia,606054];	RCV000180126.2 [benign]; RCV000392647.1 [likely benign]; 			66	468					PCCA (inh=AR pLI=0.00)
chr13	101101556	101101556	A	G	wt	het	wt		QUAL=2961;DP=318,218,332;MQM=60	PCCA	synonymous	PCCA:NM_000282.3:synonymous:LOW:exon21/24:c.1896A>G:p.Thr632Thr,PCCA:NM_001127692.2:synonymous:LOW:exon20/23:c.1818A>G:p.Thr606Thr,PCCA:NM_001178004.1:synonymous:LOW:exon21/23:c.1896A>G:p.Thr632Thr		rs61760965	0.0002	0.0002	0/0/0	0.0001	0.4580		T			2.06	232000 [PCCA (confirmed) Propionicacidemia,606054];				0	3					PCCA (inh=AR pLI=0.00)
chr13	102373515	102373517	GAG	-	wt	het	wt		QUAL=1394;DP=321,134,169;MQM=59	FGF14	3'UTR	FGF14:NM_175929.2:3'UTR:MODIFIER:exon5/5:c.*1664_*1666delCTC:,FGF14:NM_004115.3:3'UTR:MODIFIER:exon5/5:c.*1664_*1666delCTC:,FGF14:NM_001321931.1:3'UTR:MODIFIER:exon6/6:c.*1664_*1666delCTC:,FGF14:NM_001321932.1:3'UTR:MODIFIER:exon6/6:c.*1664_*1666delCTC:,FGF14:NM_001321933.1:3'UTR:MODIFIER:exon6/6:c.*1664_*1666delCTC:,FGF14:NM_001321934.1:3'UTR:MODIFIER:exon5/5:c.*1664_*1666delCTC:,FGF14:NM_001321935.1:3'UTR:MODIFIER:exon5/5:c.*1664_*1666delCTC:,FGF14:NM_001321936.1:3'UTR:MODIFIER:exon6/6:c.*1664_*1666delCTC:,FGF14:NM_001321938.1:3'UTR:MODIFIER:exon7/7:c.*1664_*1666delCTC:,FGF14:NM_001321939.1:3'UTR:MODIFIER:exon4/4:c.*1664_*1666delCTC:,FGF14:NM_001321940.1:3'UTR:MODIFIER:exon6/6:c.*1664_*1666delCTC:,FGF14:NM_001321941.1:3'UTR:MODIFIER:exon6/6:c.*1664_*1666delCTC:,FGF14:NM_001321942.1:3'UTR:MODIFIER:exon6/6:c.*1664_*1666delCTC:,FGF14:NM_001321943.1:3'UTR:MODIFIER:exon6/6:c.*1664_*1666delCTC:,FGF14:NM_001321944.1:3'UTR:MODIFIER:exon6/6:c.*1664_*1666delCTC:,FGF14:NM_001321945.1:3'UTR:MODIFIER:exon6/6:c.*1664_*1666delCTC:,FGF14:NM_001321946.1:3'UTR:MODIFIER:exon7/7:c.*1664_*1666delCTC:,FGF14:NM_001321947.1:3'UTR:MODIFIER:exon6/6:c.*1664_*1666delCTC:,FGF14:NM_001321948.1:3'UTR:MODIFIER:exon6/6:c.*1664_*1666delCTC:,FGF14:NM_001321949.1:3'UTR:MODIFIER:exon6/6:c.*1664_*1666delCTC:		rs141424596	0.0509	0.0000	0/0/0	0.0517							601515 [FGF14 (confirmed) Spinocerebellar ataxia 27,609307];	RCV000349896.1 [likely benign]; 			2	26					FGF14 (inh=AD pLI=0.72)
chr13	102373563	102373563	A	T	hom	hom	hom		QUAL=25448;DP=327,168,261;MQM=60	FGF14	3'UTR	FGF14:NM_175929.2:3'UTR:MODIFIER:exon5/5:c.*1618T>A:,FGF14:NM_004115.3:3'UTR:MODIFIER:exon5/5:c.*1618T>A:,FGF14:NM_001321931.1:3'UTR:MODIFIER:exon6/6:c.*1618T>A:,FGF14:NM_001321932.1:3'UTR:MODIFIER:exon6/6:c.*1618T>A:,FGF14:NM_001321933.1:3'UTR:MODIFIER:exon6/6:c.*1618T>A:,FGF14:NM_001321934.1:3'UTR:MODIFIER:exon5/5:c.*1618T>A:,FGF14:NM_001321935.1:3'UTR:MODIFIER:exon5/5:c.*1618T>A:,FGF14:NM_001321936.1:3'UTR:MODIFIER:exon6/6:c.*1618T>A:,FGF14:NM_001321938.1:3'UTR:MODIFIER:exon7/7:c.*1618T>A:,FGF14:NM_001321939.1:3'UTR:MODIFIER:exon4/4:c.*1618T>A:,FGF14:NM_001321940.1:3'UTR:MODIFIER:exon6/6:c.*1618T>A:,FGF14:NM_001321941.1:3'UTR:MODIFIER:exon6/6:c.*1618T>A:,FGF14:NM_001321942.1:3'UTR:MODIFIER:exon6/6:c.*1618T>A:,FGF14:NM_001321943.1:3'UTR:MODIFIER:exon6/6:c.*1618T>A:,FGF14:NM_001321944.1:3'UTR:MODIFIER:exon6/6:c.*1618T>A:,FGF14:NM_001321945.1:3'UTR:MODIFIER:exon6/6:c.*1618T>A:,FGF14:NM_001321946.1:3'UTR:MODIFIER:exon7/7:c.*1618T>A:,FGF14:NM_001321947.1:3'UTR:MODIFIER:exon6/6:c.*1618T>A:,FGF14:NM_001321948.1:3'UTR:MODIFIER:exon6/6:c.*1618T>A:,FGF14:NM_001321949.1:3'UTR:MODIFIER:exon6/6:c.*1618T>A:		rs15608	0.8325	0.0000	0/0/0	0.7843							601515 [FGF14 (confirmed) Spinocerebellar ataxia 27,609307];	RCV000404703.1 [benign]; 			141	105					FGF14 (inh=AD pLI=0.72)
chr13	102373569	102373569	C	A	het	hom	wt		QUAL=9563;DP=322,178,273;MQM=60	FGF14	3'UTR	FGF14:NM_175929.2:3'UTR:MODIFIER:exon5/5:c.*1612G>T:,FGF14:NM_004115.3:3'UTR:MODIFIER:exon5/5:c.*1612G>T:,FGF14:NM_001321931.1:3'UTR:MODIFIER:exon6/6:c.*1612G>T:,FGF14:NM_001321932.1:3'UTR:MODIFIER:exon6/6:c.*1612G>T:,FGF14:NM_001321933.1:3'UTR:MODIFIER:exon6/6:c.*1612G>T:,FGF14:NM_001321934.1:3'UTR:MODIFIER:exon5/5:c.*1612G>T:,FGF14:NM_001321935.1:3'UTR:MODIFIER:exon5/5:c.*1612G>T:,FGF14:NM_001321936.1:3'UTR:MODIFIER:exon6/6:c.*1612G>T:,FGF14:NM_001321938.1:3'UTR:MODIFIER:exon7/7:c.*1612G>T:,FGF14:NM_001321939.1:3'UTR:MODIFIER:exon4/4:c.*1612G>T:,FGF14:NM_001321940.1:3'UTR:MODIFIER:exon6/6:c.*1612G>T:,FGF14:NM_001321941.1:3'UTR:MODIFIER:exon6/6:c.*1612G>T:,FGF14:NM_001321942.1:3'UTR:MODIFIER:exon6/6:c.*1612G>T:,FGF14:NM_001321943.1:3'UTR:MODIFIER:exon6/6:c.*1612G>T:,FGF14:NM_001321944.1:3'UTR:MODIFIER:exon6/6:c.*1612G>T:,FGF14:NM_001321945.1:3'UTR:MODIFIER:exon6/6:c.*1612G>T:,FGF14:NM_001321946.1:3'UTR:MODIFIER:exon7/7:c.*1612G>T:,FGF14:NM_001321947.1:3'UTR:MODIFIER:exon6/6:c.*1612G>T:,FGF14:NM_001321948.1:3'UTR:MODIFIER:exon6/6:c.*1612G>T:,FGF14:NM_001321949.1:3'UTR:MODIFIER:exon6/6:c.*1612G>T:		rs1046197	0.3431	0.0000	0/0/0	0.3412							601515 [FGF14 (confirmed) Spinocerebellar ataxia 27,609307];	RCV000343974.1 [benign]; 			25	136					FGF14 (inh=AD pLI=0.72)
chr13	102373790	102373790	-	TTTA	hom	hom	hom		QUAL=24827;DP=406,159,201;MQM=59	FGF14	3'UTR	FGF14:NM_175929.2:3'UTR:MODIFIER:exon5/5:c.*1387_*1390dupTAAA:,FGF14:NM_004115.3:3'UTR:MODIFIER:exon5/5:c.*1387_*1390dupTAAA:,FGF14:NM_001321931.1:3'UTR:MODIFIER:exon6/6:c.*1387_*1390dupTAAA:,FGF14:NM_001321932.1:3'UTR:MODIFIER:exon6/6:c.*1387_*1390dupTAAA:,FGF14:NM_001321933.1:3'UTR:MODIFIER:exon6/6:c.*1387_*1390dupTAAA:,FGF14:NM_001321934.1:3'UTR:MODIFIER:exon5/5:c.*1387_*1390dupTAAA:,FGF14:NM_001321935.1:3'UTR:MODIFIER:exon5/5:c.*1387_*1390dupTAAA:,FGF14:NM_001321936.1:3'UTR:MODIFIER:exon6/6:c.*1387_*1390dupTAAA:,FGF14:NM_001321938.1:3'UTR:MODIFIER:exon7/7:c.*1387_*1390dupTAAA:,FGF14:NM_001321939.1:3'UTR:MODIFIER:exon4/4:c.*1387_*1390dupTAAA:,FGF14:NM_001321940.1:3'UTR:MODIFIER:exon6/6:c.*1387_*1390dupTAAA:,FGF14:NM_001321941.1:3'UTR:MODIFIER:exon6/6:c.*1387_*1390dupTAAA:,FGF14:NM_001321942.1:3'UTR:MODIFIER:exon6/6:c.*1387_*1390dupTAAA:,FGF14:NM_001321943.1:3'UTR:MODIFIER:exon6/6:c.*1387_*1390dupTAAA:,FGF14:NM_001321944.1:3'UTR:MODIFIER:exon6/6:c.*1387_*1390dupTAAA:,FGF14:NM_001321945.1:3'UTR:MODIFIER:exon6/6:c.*1387_*1390dupTAAA:,FGF14:NM_001321946.1:3'UTR:MODIFIER:exon7/7:c.*1387_*1390dupTAAA:,FGF14:NM_001321947.1:3'UTR:MODIFIER:exon6/6:c.*1387_*1390dupTAAA:,FGF14:NM_001321948.1:3'UTR:MODIFIER:exon6/6:c.*1387_*1390dupTAAA:,FGF14:NM_001321949.1:3'UTR:MODIFIER:exon6/6:c.*1387_*1390dupTAAA:		rs10626847;rs5806245	0.4169	0.0000	0/0/0	0.2646							601515 [FGF14 (confirmed) Spinocerebellar ataxia 27,609307];	RCV000304271.1 [benign]; 			45	139					FGF14 (inh=AD pLI=0.72)
chr13	102373957	102373957	-	TAAT	wt	het	wt		QUAL=604;DP=273,77,111;MQM=60	FGF14	3'UTR	FGF14:NM_175929.2:3'UTR:MODIFIER:exon5/5:c.*1220_*1223dupATTA:,FGF14:NM_004115.3:3'UTR:MODIFIER:exon5/5:c.*1220_*1223dupATTA:,FGF14:NM_001321931.1:3'UTR:MODIFIER:exon6/6:c.*1220_*1223dupATTA:,FGF14:NM_001321932.1:3'UTR:MODIFIER:exon6/6:c.*1220_*1223dupATTA:,FGF14:NM_001321933.1:3'UTR:MODIFIER:exon6/6:c.*1220_*1223dupATTA:,FGF14:NM_001321934.1:3'UTR:MODIFIER:exon5/5:c.*1220_*1223dupATTA:,FGF14:NM_001321935.1:3'UTR:MODIFIER:exon5/5:c.*1220_*1223dupATTA:,FGF14:NM_001321936.1:3'UTR:MODIFIER:exon6/6:c.*1220_*1223dupATTA:,FGF14:NM_001321938.1:3'UTR:MODIFIER:exon7/7:c.*1220_*1223dupATTA:,FGF14:NM_001321939.1:3'UTR:MODIFIER:exon4/4:c.*1220_*1223dupATTA:,FGF14:NM_001321940.1:3'UTR:MODIFIER:exon6/6:c.*1220_*1223dupATTA:,FGF14:NM_001321941.1:3'UTR:MODIFIER:exon6/6:c.*1220_*1223dupATTA:,FGF14:NM_001321942.1:3'UTR:MODIFIER:exon6/6:c.*1220_*1223dupATTA:,FGF14:NM_001321943.1:3'UTR:MODIFIER:exon6/6:c.*1220_*1223dupATTA:,FGF14:NM_001321944.1:3'UTR:MODIFIER:exon6/6:c.*1220_*1223dupATTA:,FGF14:NM_001321945.1:3'UTR:MODIFIER:exon6/6:c.*1220_*1223dupATTA:,FGF14:NM_001321946.1:3'UTR:MODIFIER:exon7/7:c.*1220_*1223dupATTA:,FGF14:NM_001321947.1:3'UTR:MODIFIER:exon6/6:c.*1220_*1223dupATTA:,FGF14:NM_001321948.1:3'UTR:MODIFIER:exon6/6:c.*1220_*1223dupATTA:,FGF14:NM_001321949.1:3'UTR:MODIFIER:exon6/6:c.*1220_*1223dupATTA:		rs546246953	0.0000	0.0000	0/0/0	0.0005							601515 [FGF14 (confirmed) Spinocerebellar ataxia 27,609307];	RCV000264126.1 [uncertain significance]; 			0	1					FGF14 (inh=AD pLI=0.72)
chr13	102374208	102374208	-	T	hom	hom	hom		QUAL=3478;DP=117,80,101;MQM=59	FGF14	3'UTR	FGF14:NM_175929.2:3'UTR:MODIFIER:exon5/5:c.*972dupA:,FGF14:NM_004115.3:3'UTR:MODIFIER:exon5/5:c.*972dupA:,FGF14:NM_001321931.1:3'UTR:MODIFIER:exon6/6:c.*972dupA:,FGF14:NM_001321932.1:3'UTR:MODIFIER:exon6/6:c.*972dupA:,FGF14:NM_001321933.1:3'UTR:MODIFIER:exon6/6:c.*972dupA:,FGF14:NM_001321934.1:3'UTR:MODIFIER:exon5/5:c.*972dupA:,FGF14:NM_001321935.1:3'UTR:MODIFIER:exon5/5:c.*972dupA:,FGF14:NM_001321936.1:3'UTR:MODIFIER:exon6/6:c.*972dupA:,FGF14:NM_001321938.1:3'UTR:MODIFIER:exon7/7:c.*972dupA:,FGF14:NM_001321939.1:3'UTR:MODIFIER:exon4/4:c.*972dupA:,FGF14:NM_001321940.1:3'UTR:MODIFIER:exon6/6:c.*972dupA:,FGF14:NM_001321941.1:3'UTR:MODIFIER:exon6/6:c.*972dupA:,FGF14:NM_001321942.1:3'UTR:MODIFIER:exon6/6:c.*972dupA:,FGF14:NM_001321943.1:3'UTR:MODIFIER:exon6/6:c.*972dupA:,FGF14:NM_001321944.1:3'UTR:MODIFIER:exon6/6:c.*972dupA:,FGF14:NM_001321945.1:3'UTR:MODIFIER:exon6/6:c.*972dupA:,FGF14:NM_001321946.1:3'UTR:MODIFIER:exon7/7:c.*972dupA:,FGF14:NM_001321947.1:3'UTR:MODIFIER:exon6/6:c.*972dupA:,FGF14:NM_001321948.1:3'UTR:MODIFIER:exon6/6:c.*972dupA:,FGF14:NM_001321949.1:3'UTR:MODIFIER:exon6/6:c.*972dupA:		rs397768294;rs557319654	0.3570	0.0000	0/0/0	0.2348							601515 [FGF14 (confirmed) Spinocerebellar ataxia 27,609307];	RCV000294304.1,RCV000386280.1 [uncertain significance,benign]; 			5	169					FGF14 (inh=AD pLI=0.72)
chr13	103498198	103498198	A	G	het	het	hom		QUAL=3289;DP=110,53,64;MQM=59	ERCC5,BIVM-ERCC5	5'UTR,intron	ERCC5:NM_000123.3:5'UTR:MODIFIER:exon1/15:c.-419A>G:,BIVM-ERCC5:NM_001204425.1:intron:MODIFIER:exon9/22:c.1450+6045A>G:		rs751402	0.6889	0.0000	0/0/0	0.1265							133530 [ERCC5 (confirmed) Xeroderma pigmentosum,group G,278780|Xeroderma pigmentosum,group G/Cockayne syndrome,278780|Cerebrooculofacioskeletal syndrome 3,616570];	RCV000392824.1 [benign]; 	CR1510212 [CLASS=DFP MUT=REF PHEN="Oral squamous cell carcinoma increased risk" GENE=ERCC5]; 		137	78					ERCC5 (inh=AR pLI=0.00), BIVM-ERCC5 (inh=n/a pLI=n/a)
chr13	103498375	103498375	T	C	het	het	hom		QUAL=15543;DP=268,254,317;MQM=60	ERCC5,BIVM-ERCC5	5'UTR,intron	ERCC5:NM_000123.3:5'UTR:MODIFIER:exon1/15:c.-242T>C:,BIVM-ERCC5:NM_001204425.1:intron:MODIFIER:exon9/22:c.1451-6093T>C:		rs2296147	0.2979	0.0000	0/0/0	0.0652							133530 [ERCC5 (confirmed) Xeroderma pigmentosum,group G,278780|Xeroderma pigmentosum,group G/Cockayne syndrome,278780|Cerebrooculofacioskeletal syndrome 3,616570];	RCV000278463.1 [benign]; 			47	111					ERCC5 (inh=AR pLI=0.00), BIVM-ERCC5 (inh=n/a pLI=n/a)
chr13	103504517	103504517	T	C	het	het	hom		QUAL=8021;DP=158,113,129;MQM=60	BIVM-ERCC5,ERCC5	synonymous	BIVM-ERCC5:NM_001204425.1:synonymous:LOW:exon10/23:c.1500T>C:p.His500His,ERCC5:NM_000123.3:synonymous:LOW:exon2/15:c.138T>C:p.His46His		rs1047768	0.4930	0.5291	18075/11535/2239	0.5227							133530 [ERCC5 (confirmed) Xeroderma pigmentosum,group G,278780|Xeroderma pigmentosum,group G/Cockayne syndrome,278780|Cerebrooculofacioskeletal syndrome 3,616570];	RCV000116990.3 [other]; RCV000272532.1 [benign]; 		COSM3753565	929	1431					BIVM-ERCC5 (inh=n/a pLI=n/a), ERCC5 (inh=AR pLI=0.00)
chr13	103527849	103527849	G	C	hom	hom	hom	pred_pathogenic	QUAL=17138;DP=245,118,156;MQM=60	BIVM-ERCC5,ERCC5	missense	BIVM-ERCC5:NM_001204425.1:missense:MODERATE:exon23/23:c.4519G>C:p.Gly1507Arg,ERCC5:NM_000123.3:missense:MODERATE:exon15/15:c.3157G>C:p.Gly1053Arg		rs9514066	0.9982	0.9994	60603/33354/5133	0.9353	3.2550	T,D,D,T	T	P	T,T	23.00	133530 [ERCC5 (confirmed) Xeroderma pigmentosum,group G,278780|Xeroderma pigmentosum,group G/Cockayne syndrome,278780|Cerebrooculofacioskeletal syndrome 3,616570];	RCV000120845.1 [not provided]; 			2927	1					BIVM-ERCC5 (inh=n/a pLI=n/a), ERCC5 (inh=AR pLI=0.00)
chr13	103527930	103527930	G	C	hom	hom	hom	anno_pathogenic_clinvar	QUAL=16156;DP=255,108,130;MQM=60	BIVM-ERCC5,ERCC5	missense	BIVM-ERCC5:NM_001204425.1:missense:MODERATE:exon23/23:c.4600G>C:p.Gly1534Arg,ERCC5:NM_000123.3:missense:MODERATE:exon15/15:c.3238G>C:p.Gly1080Arg		rs9514067	0.9972	0.9993	60574/33341/5128	0.9354	-0.3730	T,T,T,T	T	B	T,T	0.04	133530 [ERCC5 (confirmed) Xeroderma pigmentosum,group G,278780|Xeroderma pigmentosum,group G/Cockayne syndrome,278780|Cerebrooculofacioskeletal syndrome 3,616570];	RCV000120846.1 [not provided]; RCV000190581.1 [likely pathogenic]; 			2924	2	1	[1] harmuth 11.02.2016; bei 1700 homo Beobachtungen in unser db ist es sicher der Wildtyp			BIVM-ERCC5 (inh=n/a pLI=n/a), ERCC5 (inh=AR pLI=0.00)
chr13	103528337	103528337	G	A	hom	hom	hom		QUAL=25215;DP=335,186,259;MQM=60	BIVM-ERCC5,ERCC5	3'UTR	BIVM-ERCC5:NM_001204425.1:3'UTR:MODIFIER:exon23/23:c.*84G>A:,ERCC5:NM_000123.3:3'UTR:MODIFIER:exon15/15:c.*84G>A:		rs873601	0.5495	0.0000	0/0/0	0.1295							133530 [ERCC5 (confirmed) Xeroderma pigmentosum,group G,278780|Xeroderma pigmentosum,group G/Cockayne syndrome,278780|Cerebrooculofacioskeletal syndrome 3,616570];	RCV000342790.1 [benign]; 			120	90					BIVM-ERCC5 (inh=n/a pLI=n/a), ERCC5 (inh=AR pLI=0.00)
chr13	108860204	108860204	T	C	wt	het	wt		QUAL=688;DP=278,53,75;MQM=60	LIG4	3'UTR	LIG4:NM_001098268.1:3'UTR:MODIFIER:exon2/2:c.*677A>G:,LIG4:NM_002312.3:3'UTR:MODIFIER:exon2/2:c.*677A>G:,LIG4:NM_206937.1:3'UTR:MODIFIER:exon3/3:c.*677A>G:		rs3093772	0.0711	0.0000	0/0/0	0.0918							601837 [LIG4 (provisional) LIG4 syndrome,606593|Multiple myeloma,resistance to,254500];	RCV000268077.1 [likely benign]; RCV000323207.1 [likely benign]; 			1	46					LIG4 (inh=n/a pLI=0.00)
chr13	108870616	108870616	A	C	wt	het	wt		QUAL=430;DP=40,40,46;MQM=60	LIG4	5'UTR	LIG4:NM_001098268.1:5'UTR:MODIFIER:exon1/2:c.-135T>G:		rs12868340	0.1771	0.0000	0/0/0	0.1964							601837 [LIG4 (provisional) LIG4 syndrome,606593|Multiple myeloma,resistance to,254500];				13	83					LIG4 (inh=n/a pLI=0.00)
chr13	110818598	110818598	T	G	het	het	het	pred_pathogenic	QUAL=9472;DP=306,218,259;MQM=60	COL4A1	missense	COL4A1:NM_001845.5:missense:MODERATE:exon45/52:c.4002A>C:p.Gln1334His		rs3742207	0.2883	0.3098	6036/3924/420	0.3093	0.4600	T,T,T	T	B	D	8.70	120130 [COL4A1 (confirmed) Porencephaly 1,175780|Brain small vessel disease with or without ocular anomalies,607595|Angiopathy,hereditary,with nephropathy,aneurysms,and muscle cramps,611773|Hemorrhage,intracerebral,susceptibility to,614519|Retinal arteries,tortuosity of,180000];	RCV000178573.2 [benign]; RCV000269625.1 [benign]; RCV000326846.1 [benign]; RCV000388359.1 [benign]; 	CM083606 [CLASS=DP MUT=ALT PHEN="Myocardial infarction protection association with" GENE=COL4A1]; 	COSM3736082, COSM3736081	172	704					COL4A1 (inh=AD pLI=1.00)
chr13	110819586	110819586	G	A	het	het	het		QUAL=8372;DP=160,219,284;MQM=60	COL4A1	splice_region&intron	COL4A1:NM_001845.5:splice_region&intron:LOW:exon43/51:c.3877-9C>T:		rs589985	0.6554	0.6728	27659/14576/1577	0.6640							120130 [COL4A1 (confirmed) Porencephaly 1,175780|Brain small vessel disease with or without ocular anomalies,607595|Angiopathy,hereditary,with nephropathy,aneurysms,and muscle cramps,611773|Hemorrhage,intracerebral,susceptibility to,614519|Retinal arteries,tortuosity of,180000];	RCV000246560.1 [benign]; RCV000270389.1 [benign]; RCV000310269.1 [benign]; RCV000362657.1 [benign]; 			698	700					COL4A1 (inh=AD pLI=1.00)
chr13	110827574	110827574	T	A	hom	het	hom		QUAL=15280;DP=184,183,247;MQM=60	COL4A1	synonymous	COL4A1:NM_001845.5:synonymous:LOW:exon37/52:c.3189A>T:p.Arg1063Arg		rs874203	0.3179	0.3515	7525/4271/388	0.3451							120130 [COL4A1 (confirmed) Porencephaly 1,175780|Brain small vessel disease with or without ocular anomalies,607595|Angiopathy,hereditary,with nephropathy,aneurysms,and muscle cramps,611773|Hemorrhage,intracerebral,susceptibility to,614519|Retinal arteries,tortuosity of,180000];	RCV000252826.1 [benign]; RCV000295246.1 [benign]; RCV000352486.1 [benign]; RCV000402267.1 [benign]; 			194	662					COL4A1 (inh=AD pLI=1.00)
chr13	110827580	110827580	C	T	hom	het	hom		QUAL=14700;DP=171,189,256;MQM=60	COL4A1	synonymous	COL4A1:NM_001845.5:synonymous:LOW:exon37/52:c.3183G>A:p.Gly1061Gly		rs874204	0.3181	0.3515	7529/4277/386	0.3428							120130 [COL4A1 (confirmed) Porencephaly 1,175780|Brain small vessel disease with or without ocular anomalies,607595|Angiopathy,hereditary,with nephropathy,aneurysms,and muscle cramps,611773|Hemorrhage,intracerebral,susceptibility to,614519|Retinal arteries,tortuosity of,180000];	RCV000247662.1 [benign]; RCV000312646.1 [benign]; RCV000356008.1 [benign]; RCV000401840.1 [benign]; 			194	663					COL4A1 (inh=AD pLI=1.00)
chr13	110833702	110833702	C	T	hom	het	hom		QUAL=10751;DP=171,143,153;MQM=59	COL4A1	synonymous	COL4A1:NM_001845.5:synonymous:LOW:exon29/52:c.2130G>A:p.Pro710Pro		rs16975492	0.3071	0.3477	7309/4163/299	0.3391							120130 [COL4A1 (confirmed) Porencephaly 1,175780|Brain small vessel disease with or without ocular anomalies,607595|Angiopathy,hereditary,with nephropathy,aneurysms,and muscle cramps,611773|Hemorrhage,intracerebral,susceptibility to,614519|Retinal arteries,tortuosity of,180000];	RCV000250703.1 [benign]; RCV000307335.1 [benign]; RCV000342375.1 [benign]; RCV000398706.1 [benign]; 		COSM4147573	190	664					COL4A1 (inh=AD pLI=1.00)
chr13	110839550	110839550	T	G	hom	hom	hom	pred_pathogenic	QUAL=17149;DP=148,172,233;MQM=59	COL4A1	missense	COL4A1:NM_001845.5:missense:MODERATE:exon25/52:c.1663A>C:p.Thr555Pro		rs536174	1.0000	1.0000	60706/33370/5203	0.9362	5.9870	T	T	B	D	3.98	120130 [COL4A1 (confirmed) Porencephaly 1,175780|Brain small vessel disease with or without ocular anomalies,607595|Angiopathy,hereditary,with nephropathy,aneurysms,and muscle cramps,611773|Hemorrhage,intracerebral,susceptibility to,614519|Retinal arteries,tortuosity of,180000];	RCV000245629.2 [benign]; RCV000299532.1 [benign]; RCV000359055.1 [benign]; RCV000391710.1 [benign]; 			1564	1					COL4A1 (inh=AD pLI=1.00)
chr13	110857895	110857895	A	G	hom	hom	hom		QUAL=33307;DP=486,231,318;MQM=59	COL4A1	splice_region&intron	COL4A1:NM_001845.5:splice_region&intron:LOW:exon15/51:c.859-10T>C:,COL4A1:NM_001303110.1:splice_region&intron:LOW:exon15/24:c.859-10T>C:		rs677877	0.5964	0.6222	24081/13926/913	0.6189							120130 [COL4A1 (confirmed) Porencephaly 1,175780|Brain small vessel disease with or without ocular anomalies,607595|Angiopathy,hereditary,with nephropathy,aneurysms,and muscle cramps,611773|Hemorrhage,intracerebral,susceptibility to,614519|Retinal arteries,tortuosity of,180000];	RCV000246292.1 [benign]; RCV000287138.1 [benign]; RCV000340823.1 [benign]; RCV000376905.1 [benign]; 			689	697					COL4A1 (inh=AD pLI=1.00)
chr13	110859743	110859743	C	T	hom	hom	hom		QUAL=15099;DP=201,101,162;MQM=60	COL4A1	splice_region&intron	COL4A1:NM_001845.5:splice_region&intron:LOW:exon13/51:c.780+7G>A:,COL4A1:NM_001303110.1:splice_region&intron:LOW:exon13/24:c.780+7G>A:		rs598893	0.5960	0.6210	24010/13898/910	0.6181							120130 [COL4A1 (confirmed) Porencephaly 1,175780|Brain small vessel disease with or without ocular anomalies,607595|Angiopathy,hereditary,with nephropathy,aneurysms,and muscle cramps,611773|Hemorrhage,intracerebral,susceptibility to,614519|Retinal arteries,tortuosity of,180000];	RCV000245991.1 [benign]; RCV000263276.1 [benign]; RCV000318467.1 [benign]; RCV000353343.1 [benign]; 			688	697					COL4A1 (inh=AD pLI=1.00)
chr13	110864225	110864225	A	T	wt	het	wt		QUAL=1555;DP=200,130,178;MQM=60	COL4A1	synonymous	COL4A1:NM_001845.5:synonymous:LOW:exon7/52:c.432T>A:p.Ala144Ala,COL4A1:NM_001303110.1:synonymous:LOW:exon7/25:c.432T>A:p.Ala144Ala		rs532625	0.4728	0.4672	13577/7306/713	0.4627							120130 [COL4A1 (confirmed) Porencephaly 1,175780|Brain small vessel disease with or without ocular anomalies,607595|Angiopathy,hereditary,with nephropathy,aneurysms,and muscle cramps,611773|Hemorrhage,intracerebral,susceptibility to,614519|Retinal arteries,tortuosity of,180000];	RCV000248410.1 [benign]; RCV000294435.1 [benign]; RCV000333020.1 [benign]; RCV000389866.1 [benign]; 		COSM3753575, COSM3753576	411	765					COL4A1 (inh=AD pLI=1.00)
chr13	110866265	110866265	G	A	hom	het	het		QUAL=12910;DP=224,195,309;MQM=59	COL4A1	splice_region&intron	COL4A1:NM_001845.5:splice_region&intron:LOW:exon3/51:c.234+8C>T:,COL4A1:NM_001303110.1:splice_region&intron:LOW:exon3/24:c.234+8C>T:		rs9521650	0.1304	0.1429	1412/888/35	0.1440							120130 [COL4A1 (confirmed) Porencephaly 1,175780|Brain small vessel disease with or without ocular anomalies,607595|Angiopathy,hereditary,with nephropathy,aneurysms,and muscle cramps,611773|Hemorrhage,intracerebral,susceptibility to,614519|Retinal arteries,tortuosity of,180000];	RCV000177133.2 [benign]; RCV000283020.1 [benign]; RCV000318401.1 [benign]; RCV000375383.1 [benign]; 			48	367					COL4A1 (inh=AD pLI=1.00)
chr13	110959643	110959643	A	C	wt	wt	hom	low_DP	QUAL=97;DP=224,195,4;MQM=60	COL4A2	5'UTR	COL4A2:NM_001846.3:5'UTR:MODIFIER:exon1/48:c.-277A>C:		rs7989823	0.6150	0.0000	0/0/0	0.5745							120090 [COL4A2 (confirmed) Porencephaly 2,614483|Hemorrhage,intracerebral,susceptibility to,614519];	RCV000270652.1 [benign]; RCV000307011.1 [benign]; RCV000365296.1 [benign]; 			2	3					COL4A2 (inh=AD pLI=0.00)
chr13	110959705	110959705	C	T	wt	wt	hom	low_DP	QUAL=51;DP=224,1,3;MQM=60	COL4A2	5'UTR_premature_start_codon_gain,5'UTR	COL4A2:NM_001846.3:5'UTR_premature_start_codon_gain:LOW:exon1/48:c.-215C>T:,COL4A2:NM_001846.3:5'UTR:MODIFIER:exon1/48:c.-215C>T:		rs7990017	0.5094	0.0000	0/0/0	0.4262							120090 [COL4A2 (confirmed) Porencephaly 2,614483|Hemorrhage,intracerebral,susceptibility to,614519];	RCV000263402.1 [benign]; RCV000319008.1 [benign]; RCV000385884.1 [benign]; 			6	12					COL4A2 (inh=AD pLI=0.00)
chr13	110959787	110959787	A	G	wt	wt	het	low_DP	QUAL=49;DP=224,3,7;MQM=60	COL4A2	5'UTR	COL4A2:NM_001846.3:5'UTR:MODIFIER:exon1/48:c.-133A>G:		rs35466678	0.1843	0.0000	0/0/0	0.1757							120090 [COL4A2 (confirmed) Porencephaly 2,614483|Hemorrhage,intracerebral,susceptibility to,614519];	RCV000285021.1 [benign]; RCV000303409.1 [benign]; RCV000339993.1 [benign]; 			1	12					COL4A2 (inh=AD pLI=0.00)
chr13	111077197	111077197	G	A	het	het	hom		QUAL=14518;DP=256,242,260;MQM=60	COL4A2	synonymous	COL4A2:NM_001846.3:synonymous:LOW:exon5/48:c.297G>A:p.Thr99Thr		rs4238272	0.9427	0.9614	55860/30956/3576	0.9357							120090 [COL4A2 (confirmed) Porencephaly 2,614483|Hemorrhage,intracerebral,susceptibility to,614519];	RCV000325831.1 [benign]; 			1433	131					COL4A2 (inh=AD pLI=0.00)
chr13	111098226	111098226	C	T	het	wt	het		QUAL=2639;DP=136,75,90;MQM=60	COL4A2	synonymous	COL4A2:NM_001846.3:synonymous:LOW:exon17/48:c.1008C>T:p.Pro336Pro		rs4103	0.4828	0.5137	16167/9407/779	0.5093							120090 [COL4A2 (confirmed) Porencephaly 2,614483|Hemorrhage,intracerebral,susceptibility to,614519];	RCV000369813.1 [benign]; 		COSM1365445	393	771					COL4A2 (inh=AD pLI=0.00)
chr13	111111173	111111173	G	A	het	hom	het		QUAL=16779;DP=368,249,317;MQM=59	COL4A2,COL4A2-AS2	synonymous,intron	COL4A2:NM_001846.3:synonymous:LOW:exon22/48:c.1488G>A:p.Pro496Pro,COL4A2-AS2:NM_001267044.1:intron:MODIFIER:exon1/4:c.73-540C>T:		rs7990214	0.4914	0.5288	17896/12114/1962	0.5239							120090 [COL4A2 (confirmed) Porencephaly 2,614483|Hemorrhage,intracerebral,susceptibility to,614519];	RCV000341336.1 [benign]; 		COSM3999021	553	738					COL4A2 (inh=AD pLI=0.00), COL4A2-AS2 (inh=n/a pLI=n/a)
chr13	111111235	111111235	G	A	het	hom	het	pred_pathogenic	QUAL=10915;DP=143,210,268;MQM=59	COL4A2,COL4A2-AS2	missense,intron	COL4A2:NM_001846.3:missense:MODERATE:exon22/48:c.1550G>A:p.Arg517Lys,COL4A2-AS2:NM_001267044.1:intron:MODIFIER:exon1/4:c.73-602C>T:		rs7990383	0.5092	0.5390	17979/11948/2311	0.5265	-1.2950	T,T	T	B	D	0.01	120090 [COL4A2 (confirmed) Porencephaly 2,614483|Hemorrhage,intracerebral,susceptibility to,614519];	RCV000394894.1 [benign]; 		COSM3931786	551	741					COL4A2 (inh=AD pLI=0.00), COL4A2-AS2 (inh=n/a pLI=n/a)
chr13	111117745	111117745	C	T	het	hom	wt		QUAL=4020;DP=136,67,92;MQM=60	COL4A2	splice_region&intron	COL4A2:NM_001846.3:splice_region&intron:LOW:exon24/47:c.1777-7C>T:		rs3803236	0.5140	0.5383	17734/11700/1981	0.5294							120090 [COL4A2 (confirmed) Porencephaly 2,614483|Hemorrhage,intracerebral,susceptibility to,614519];	RCV000371352.1 [benign]; 			549	722					COL4A2 (inh=AD pLI=0.00)
chr13	111119396	111119396	G	C	wt	het	wt	pred_pathogenic	QUAL=987;DP=200,104,173;MQM=60	COL4A2	missense	COL4A2:NM_001846.3:missense:MODERATE:exon27/48:c.2048G>C:p.Gly683Ala		rs3803230	0.1038	0.1061	768/408/60	0.1036	0.4870	T,T	T	B	D	12.72	120090 [COL4A2 (confirmed) Porencephaly 2,614483|Hemorrhage,intracerebral,susceptibility to,614519];	RCV000379310.1 [benign]; 		COSM3753580	23	321					COL4A2 (inh=AD pLI=0.00)
chr13	111121620	111121620	C	T	het	het	wt	pred_pathogenic	QUAL=2521;DP=195,99,150;MQM=59	COL4A2	missense	COL4A2:NM_001846.3:missense:MODERATE:exon28/48:c.2152C>T:p.Pro718Ser		rs9583500	0.1909	0.2554	1736/1173/364	0.1663	1.2810	T,T	T	B	D	8.81	120090 [COL4A2 (confirmed) Porencephaly 2,614483|Hemorrhage,intracerebral,susceptibility to,614519];	RCV000375113.1 [benign]; 			90	493					COL4A2 (inh=AD pLI=0.00)
chr13	111130519	111130519	C	T	het	hom	wt		QUAL=2459;DP=79,54,68;MQM=59	COL4A2	splice_region&intron	COL4A2:NM_001846.3:splice_region&intron:LOW:exon30/47:c.2587+8C>T:		rs2281974	0.4691	0.4087	7042/2486/1156	0.3488							120090 [COL4A2 (confirmed) Porencephaly 2,614483|Hemorrhage,intracerebral,susceptibility to,614519];	RCV000350640.1 [benign]; 			191	634					COL4A2 (inh=AD pLI=0.00)
chr13	111154058	111154058	T	A	hom	hom	hom	low_DP	QUAL=657;DP=11,4,5;MQM=60	COL4A2	synonymous	COL4A2:NM_001846.3:synonymous:LOW:exon41/48:c.3804T>A:p.Pro1268Pro		rs439831	0.9395	0.9839	58581/33264/3312	0.9360							120090 [COL4A2 (confirmed) Porencephaly 2,614483|Hemorrhage,intracerebral,susceptibility to,614519];				1493	6					COL4A2 (inh=AD pLI=0.00)
chr13	111154061	111154061	T	C	hom	hom	hom	low_DP	QUAL=657;DP=11,4,5;MQM=60	COL4A2	synonymous	COL4A2:NM_001846.3:synonymous:LOW:exon41/48:c.3807T>C:p.Gly1269Gly		rs409858	0.9395	0.9839	58579/33262/3310	0.9360							120090 [COL4A2 (confirmed) Porencephaly 2,614483|Hemorrhage,intracerebral,susceptibility to,614519];				1497	6					COL4A2 (inh=AD pLI=0.00)
chr13	111155773	111155773	T	C	hom	hom	hom		QUAL=3656;DP=69,25,32;MQM=59	COL4A2,COL4A2-AS1	synonymous,sequence_feature,intron	COL4A2:NM_001846.3:synonymous:LOW:exon43/48:c.4083T>C:p.Thr1361Thr,COL4A2:NM_001846.3:sequence_feature:LOW:exon43/48:c.4083T>C:,COL4A2-AS1:NR_046583.1:intron:MODIFIER:exon2/2:n.187-498A>G:		rs438758	0.9802	0.9934	41431/23365/3096	0.9105							120090 [COL4A2 (confirmed) Porencephaly 2,614483|Hemorrhage,intracerebral,susceptibility to,614519];				1560	5					COL4A2 (inh=AD pLI=0.00), COL4A2-AS1 (inh=n/a pLI=n/a)
chr13	111155779	111155779	G	A	wt	wt	het		QUAL=251;DP=80,21,28;MQM=60	COL4A2,COL4A2-AS1	synonymous,intron	COL4A2:NM_001846.3:synonymous:LOW:exon43/48:c.4089G>A:p.Ala1363Ala,COL4A2-AS1:NR_046583.1:intron:MODIFIER:exon2/2:n.187-504C>T:		rs4773199	0.1863	0.2775	2079/1270/313	0.1856							120090 [COL4A2 (confirmed) Porencephaly 2,614483|Hemorrhage,intracerebral,susceptibility to,614519];	RCV000359805.1 [benign]; 		COSM1606855	56	550					COL4A2 (inh=AD pLI=0.00), COL4A2-AS1 (inh=n/a pLI=n/a)
chr13	111156250	111156250	G	A	het	hom	wt	low_DP;pred_pathogenic	QUAL=171;DP=17,1,5;MQM=60	COL4A2,COL4A2-AS1	missense,intron	COL4A2:NM_001846.3:missense:MODERATE:exon44/48:c.4195G>A:p.Val1399Ile,COL4A2-AS1:NR_046583.1:intron:MODIFIER:exon2/2:n.187-975C>T:		rs45520539	0.0144	0.0307	77/64/0	0.0304	-0.5270	T,T	T	B	D	1.51	120090 [COL4A2 (confirmed) Porencephaly 2,614483|Hemorrhage,intracerebral,susceptibility to,614519];	RCV000356521.1 [likely benign]; 			1	120					COL4A2 (inh=AD pLI=0.00), COL4A2-AS1 (inh=n/a pLI=n/a)
chr13	111156499	111156499	C	T	hom	hom	hom		QUAL=18090;DP=109,225,250;MQM=60	COL4A2,COL4A2-AS1	synonymous,intron	COL4A2:NM_001846.3:synonymous:LOW:exon45/48:c.4290C>T:p.Phe1430Phe,COL4A2-AS1:NR_046583.1:intron:MODIFIER:exon2/2:n.187-1224G>A:		rs4771683	0.9359	0.9833	58522/33267/3251	0.9409							120090 [COL4A2 (confirmed) Porencephaly 2,614483|Hemorrhage,intracerebral,susceptibility to,614519];			COSM4147578	1558	7					COL4A2 (inh=AD pLI=0.00), COL4A2-AS1 (inh=n/a pLI=n/a)
chr13	111158874	111158874	A	G	hom	hom	hom		QUAL=21638;DP=195,197,290;MQM=59	COL4A2,COL4A2-AS1	synonymous,intron	COL4A2:NM_001846.3:synonymous:LOW:exon46/48:c.4515A>G:p.Pro1505Pro,COL4A2-AS1:NR_046583.1:intron:MODIFIER:exon2/2:n.186+1120T>C:		rs445348	0.7520	0.8329	40861/26131/2866	0.7979							120090 [COL4A2 (confirmed) Porencephaly 2,614483|Hemorrhage,intracerebral,susceptibility to,614519];	RCV000387441.1 [benign]; 			1286	258					COL4A2 (inh=AD pLI=0.00), COL4A2-AS1 (inh=n/a pLI=n/a)
chr13	111160304	111160304	G	A	het	wt	het		QUAL=8224;DP=261,366,469;MQM=59	COL4A2,COL4A2-AS1	synonymous,intron	COL4A2:NM_001846.3:synonymous:LOW:exon47/48:c.4617G>A:p.Ala1539Ala,COL4A2-AS1:NR_046583.1:intron:MODIFIER:exon1/2:n.81+142C>T:		rs391859	0.1008	0.1010	775/314/37	0.0985							120090 [COL4A2 (confirmed) Porencephaly 2,614483|Hemorrhage,intracerebral,susceptibility to,614519];	RCV000383562.1 [benign]; 			23	297					COL4A2 (inh=AD pLI=0.00), COL4A2-AS1 (inh=n/a pLI=n/a)
chr13	111164614	111164614	T	C	het	wt	hom		QUAL=8708;DP=279,88,151;MQM=59	COL4A2	3'UTR	COL4A2:NM_001846.3:3'UTR:MODIFIER:exon48/48:c.*76T>C:		rs422733	0.4663	0.0000	0/0/0	0.1047							120090 [COL4A2 (confirmed) Porencephaly 2,614483|Hemorrhage,intracerebral,susceptibility to,614519];	RCV000286656.1 [benign]; 			137	186					COL4A2 (inh=AD pLI=0.00)
chr13	111164629	111164630	AA	-	het	wt	hom		QUAL=6058;DP=196,70,141;MQM=59	COL4A2	3'UTR	COL4A2:NM_001846.3:3'UTR:MODIFIER:exon48/48:c.*101_*102delAA:		rs397838577	0.4677	0.0000	0/0/0	0.3720							120090 [COL4A2 (confirmed) Porencephaly 2,614483|Hemorrhage,intracerebral,susceptibility to,614519];	RCV000322953.1 [benign]; 			89	108					COL4A2 (inh=AD pLI=0.00)
chr13	111164955	111164955	C	G	het	hom	het		QUAL=11639;DP=188,194,270;MQM=59	COL4A2	3'UTR	COL4A2:NM_001846.3:3'UTR:MODIFIER:exon48/48:c.*417C>G:		rs10509	0.8868	0.0000	0/0/0	0.8961							120090 [COL4A2 (confirmed) Porencephaly 2,614483|Hemorrhage,intracerebral,susceptibility to,614519];	RCV000404461.1 [benign]; 			190	34					COL4A2 (inh=AD pLI=0.00)
chr13	111165079	111165079	C	T	het	hom	wt		QUAL=10656;DP=269,242,270;MQM=60	COL4A2	3'UTR	COL4A2:NM_001846.3:3'UTR:MODIFIER:exon48/48:c.*541C>T:		rs1049906	0.5054	0.0000	0/0/0	0.0824							120090 [COL4A2 (confirmed) Porencephaly 2,614483|Hemorrhage,intracerebral,susceptibility to,614519];	RCV000397445.1 [benign]; 			42	104					COL4A2 (inh=AD pLI=0.00)
chr13	111165095	111165095	A	G	wt	wt	het		QUAL=3493;DP=246,218,255;MQM=60	COL4A2	3'UTR	COL4A2:NM_001846.3:3'UTR:MODIFIER:exon48/48:c.*557A>G:		rs1049931	0.3371	0.0000	0/0/0	0.0699							120090 [COL4A2 (confirmed) Porencephaly 2,614483|Hemorrhage,intracerebral,susceptibility to,614519];	RCV000314922.1 [benign]; 			58	112					COL4A2 (inh=AD pLI=0.00)
chr13	111165188	111165188	T	C	wt	wt	het		QUAL=2114;DP=225,120,149;MQM=60	COL4A2	3'UTR	COL4A2:NM_001846.3:3'UTR:MODIFIER:exon48/48:c.*650T>C:		rs1049977	0.3361	0.0000	0/0/0	0.0697							120090 [COL4A2 (confirmed) Porencephaly 2,614483|Hemorrhage,intracerebral,susceptibility to,614519];	RCV000397455.1 [benign]; 			58	110					COL4A2 (inh=AD pLI=0.00)
chr13	111165201	111165201	T	C	wt	wt	het		QUAL=2172;DP=192,106,149;MQM=60	COL4A2	3'UTR	COL4A2:NM_001846.3:3'UTR:MODIFIER:exon48/48:c.*663T>C:		rs7711	0.3750	0.0000	0/0/0	0.0717							120090 [COL4A2 (confirmed) Porencephaly 2,614483|Hemorrhage,intracerebral,susceptibility to,614519];	RCV000308964.1 [benign]; 			58	110					COL4A2 (inh=AD pLI=0.00)
chr13	111165265	111165265	G	C	het	hom	wt		QUAL=4711;DP=146,91,113;MQM=59	COL4A2	3'UTR	COL4A2:NM_001846.3:3'UTR:MODIFIER:exon48/48:c.*727G>C:		rs15457	0.5108	0.0000	0/0/0	0.0826							120090 [COL4A2 (confirmed) Porencephaly 2,614483|Hemorrhage,intracerebral,susceptibility to,614519];	RCV000268815.1 [benign]; 			43	104					COL4A2 (inh=AD pLI=0.00)
chr14	20757383	20757383	A	G	het	het	wt		QUAL=2597;DP=148,52,49;MQM=60	TTC5	3'UTR	TTC5:NM_138376.2:3'UTR:MODIFIER:exon10/10:c.*403T>C:	A-rich	rs74596138	0.1140	0.0000	0/0/0	0.0107											0	26					TTC5 (inh=n/a pLI=0.00)
chr14	20764585	20764585	A	C	het	het	hom		QUAL=20752;DP=395,285,356;MQM=60	TTC5	synonymous	TTC5:NM_138376.2:synonymous:LOW:exon6/10:c.660T>G:p.Ala220Ala		rs1953552	0.4012	0.4585	13125/8312/359	0.4422	-0.0430		T			5.74				COSM1128303	258	579					TTC5 (inh=n/a pLI=0.00)
chr14	20770036	20770036	T	C	hom	hom	hom		QUAL=41162;DP=427,326,513;MQM=59	TTC5	missense	TTC5:NM_138376.2:missense:MODERATE:exon2/10:c.140A>G:p.Gln47Arg		rs3742945	0.7456	0.7368	33266/18133/2884	0.7285	-0.3360	T	T	B	T	0.34				COSM1179594	633	440					TTC5 (inh=n/a pLI=0.00)
chr14	20937588	20937588	G	A	het	het	wt		QUAL=8993;DP=437,274,416;MQM=59	PNP	5'UTR	PNP:NM_000270.3:5'UTR:MODIFIER:exon1/6:c.-96G>A:		rs17881206	0.0058	0.0000	0/0/0	0.0039							164050 [PNP (confirmed) Immunodeficiency due to purine nucleoside phosphorylase deficiency,613179];	RCV000291266.1 [uncertain significance]; 			0	7					PNP (inh=AR pLI=0.07)
chr14	20942744	20942744	A	G	het	hom	wt		QUAL=13749;DP=259,337,418;MQM=60	PNP	splice_region&intron	PNP:NM_000270.3:splice_region&intron:LOW:exon3/5:c.285+10A>G:		rs1713420	0.2023	0.1943	2549/1492/528	0.1911							164050 [PNP (confirmed) Immunodeficiency due to purine nucleoside phosphorylase deficiency,613179];	RCV000317230.1 [benign]; 			65	456					PNP (inh=AR pLI=0.07)
chr14	20945355	20945355	C	T	het	het	wt		QUAL=5281;DP=263,192,221;MQM=60	PNP	3'UTR	PNP:NM_000270.3:3'UTR:MODIFIER:exon6/6:c.*595C>T:		rs17878900	0.0647	0.0000	0/0/0	0.0363							164050 [PNP (confirmed) Immunodeficiency due to purine nucleoside phosphorylase deficiency,613179];	RCV000301354.1 [likely benign]; 			0	12					PNP (inh=AR pLI=0.07)
chr14	20945488	20945488	T	C	hom	hom	hom		QUAL=47450;DP=619,417,442;MQM=59	PNP	3'UTR	PNP:NM_000270.3:3'UTR:MODIFIER:exon6/6:c.*728T>C:		rs1760933	0.9774	0.0000	0/0/0	0.8747							164050 [PNP (confirmed) Immunodeficiency due to purine nucleoside phosphorylase deficiency,613179];	RCV000335164.1 [benign]; 			137	13					PNP (inh=AR pLI=0.07)
chr14	20945864	20945864	-	G	wt	het	wt		QUAL=5680;DP=588,450,627;MQM=59	PNP	3'UTR	PNP:NM_000270.3:3'UTR:MODIFIER:exon6/6:c.*1105dupG:		rs397807669	0.1703	0.0000	0/0/0	0.1424							164050 [PNP (confirmed) Immunodeficiency due to purine nucleoside phosphorylase deficiency,613179];	RCV000303873.1 [likely benign]; 			4	46					PNP (inh=AR pLI=0.07)
chr14	20945906	20945906	A	C	wt	het	wt		QUAL=5937;DP=333,420,560;MQM=60	PNP	3'UTR	PNP:NM_000270.3:3'UTR:MODIFIER:exon6/6:c.*1146A>C:		rs56141845	0.2053	0.0000	0/0/0	0.1983							164050 [PNP (confirmed) Immunodeficiency due to purine nucleoside phosphorylase deficiency,613179];	RCV000365018.1 [likely benign]; 			8	56					PNP (inh=AR pLI=0.07)
chr14	20945993	20945993	T	C	wt	het	wt		QUAL=3956;DP=464,273,316;MQM=60	PNP	3'UTR	PNP:NM_000270.3:3'UTR:MODIFIER:exon6/6:c.*1233T>C:		rs1079376	0.1284	0.0000	0/0/0	0.1429							164050 [PNP (confirmed) Immunodeficiency due to purine nucleoside phosphorylase deficiency,613179];	RCV000382857.1 [likely benign]; 			4	45					PNP (inh=AR pLI=0.07)
chr14	20946151	20946151	T	C	wt	het	wt		QUAL=1311;DP=321,95,121;MQM=59	PNP	3'UTR	PNP:NM_000270.3:3'UTR:MODIFIER:exon6/6:c.*1391T>C:		rs1079375	0.3223	0.0000	0/0/0	0.2619							164050 [PNP (confirmed) Immunodeficiency due to purine nucleoside phosphorylase deficiency,613179];	RCV000294273.1 [benign]; 			14	66					PNP (inh=AR pLI=0.07)
chr14	21152604	21152604	C	A	wt	het	wt		QUAL=1419;DP=183,145,211;MQM=60	RNASE4,ANG	5'UTR	RNASE4:NM_001282192.1:5'UTR:MODIFIER:exon1/3:c.-435C>A:,ANG:NM_001145.4:5'UTR:MODIFIER:exon1/2:c.-332C>A:,RNASE4:NM_001282193.1:5'UTR:MODIFIER:exon1/2:c.-269C>A:,RNASE4:NM_002937.4:5'UTR:MODIFIER:exon1/2:c.-331C>A:		rs28589501	0.0978	0.0000	0/0/0	0.0995							105850 [ANG (confirmed) Amyotrophic lateral sclerosis 9,611895];	RCV000362504.1 [likely benign]; 			5	37					RNASE4 (inh=n/a pLI=0.01), ANG (inh=AD pLI=0.22)
chr14	23242828	23242828	T	C	hom	hom	hom		QUAL=12854;DP=178,112,125;MQM=60	SLC7A7	synonymous,non_coding_transcript_exon	SLC7A7:NM_001126105.2:synonymous:LOW:exon11/11:c.1527A>G:p.Lys509Lys,SLC7A7:NM_001126106.2:synonymous:LOW:exon11/11:c.1527A>G:p.Lys509Lys,SLC7A7:NR_040448.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.2142A>G:		rs1061040	0.7855	0.8651	46223/26587/1361	0.8591							603593 [SLC7A7 (confirmed) Lysinuric protein intolerance,222700];	RCV000128147.2 [benign]; RCV000398235.1 [benign]; 			1277	274					SLC7A7 (inh=AR pLI=0.00)
chr14	23282110	23282110	A	G	het	hom	wt		QUAL=2667;DP=79,73,83;MQM=59	SLC7A7	splice_region&synonymous,splice_region&non_coding_transcript_exon	SLC7A7:NM_001126105.2:splice_region&synonymous:LOW:exon3/11:c.498T>C:p.Ile166Ile,SLC7A7:NR_040448.1:splice_region&non_coding_transcript_exon:LOW:exon2/10:n.1113T>C:,SLC7A7:NM_001126106.2:splice_region&synonymous:LOW:exon3/11:c.498T>C:p.Ile166Ile		rs8018462	0.5821	0.5603	19314/9431/1158	0.5492							603593 [SLC7A7 (confirmed) Lysinuric protein intolerance,222700];	RCV000128149.2 [benign]; RCV000333159.1 [benign]; 			401	789					SLC7A7 (inh=AR pLI=0.00)
chr14	23282449	23282449	C	T	het	hom	wt		QUAL=7646;DP=281,128,142;MQM=59	SLC7A7	synonymous,non_coding_transcript_exon	SLC7A7:NM_001126105.2:synonymous:LOW:exon3/11:c.159G>A:p.Ser53Ser,SLC7A7:NM_001126106.2:synonymous:LOW:exon3/11:c.159G>A:p.Ser53Ser,SLC7A7:NR_040448.1:non_coding_transcript_exon:MODIFIER:exon2/10:n.774G>A:		rs1805059	0.6060	0.6073	22980/12266/1276	0.5866							603593 [SLC7A7 (confirmed) Lysinuric protein intolerance,222700];	RCV000128148.2 [benign]; RCV000396503.1 [benign]; 		COSM3753883	530	787					SLC7A7 (inh=AR pLI=0.00)
chr14	23284572	23284572	A	G	het	hom	wt		QUAL=7856;DP=231,175,264;MQM=59	SLC7A7	5'UTR,non_coding_transcript_exon	SLC7A7:NM_001126105.2:5'UTR:MODIFIER:exon2/11:c.-86T>C:,SLC7A7:NM_001126106.2:5'UTR:MODIFIER:exon2/11:c.-86T>C:,SLC7A7:NR_040448.1:non_coding_transcript_exon:MODIFIER:exon1/10:n.530T>C:		rs2281677	0.5781	0.5294	1992/691/83	0.1633							603593 [SLC7A7 (confirmed) Lysinuric protein intolerance,222700];	RCV000367365.1 [benign]; 			207	340					SLC7A7 (inh=AR pLI=0.00)
chr14	23288935	23288935	C	G	wt	wt	het		QUAL=3231;DP=240,295,303;MQM=60	SLC7A7	5'UTR	SLC7A7:NM_001126106.2:5'UTR:MODIFIER:exon1/11:c.-263G>C:		rs17122772	0.1170	0.0000	0/0/0	0.1696							603593 [SLC7A7 (confirmed) Lysinuric protein intolerance,222700];	RCV000371386.1 [likely benign]; RCV000260359.1 [uncertain significance]; 			12	86					SLC7A7 (inh=AR pLI=0.00)
chr14	23288953	23288953	A	G	wt	wt	het		QUAL=3188;DP=297,309,311;MQM=60	SLC7A7	5'UTR_premature_start_codon_gain,5'UTR	SLC7A7:NM_001126106.2:5'UTR_premature_start_codon_gain:LOW:exon1/11:c.-281T>C:,SLC7A7:NM_001126106.2:5'UTR:MODIFIER:exon1/11:c.-281T>C:		rs17122776	0.1170	0.0000	0/0/0	0.1740							603593 [SLC7A7 (confirmed) Lysinuric protein intolerance,222700];	RCV000374625.1 [likely benign]; 			12	87					SLC7A7 (inh=AR pLI=0.00)
chr14	23588642	23588642	G	A	het	het	hom		QUAL=16509;DP=263,270,315;MQM=59	CEBPE	5'UTR	CEBPE:NM_001805.3:5'UTR:MODIFIER:exon1/2:c.-342C>T:		rs12434881	0.3231	0.0000	0/0/0	0.4011							600749 [CEBPE (provisional) Specific granule deficiency,245480];				30	73					CEBPE (inh=AR pLI=0.00)
chr14	23588731	23588731	G	C	het	het	hom		QUAL=15139;DP=198,247,327;MQM=59	CEBPE	5'UTR	CEBPE:NM_001805.3:5'UTR:MODIFIER:exon1/2:c.-431C>G:		rs2239635	0.6643	0.0000	0/0/0	0.6806							600749 [CEBPE (provisional) Specific granule deficiency,245480];				63	78					CEBPE (inh=AR pLI=0.00)
chr14	23884889	23884889	C	T	wt	wt	het		QUAL=6025;DP=192,312,468;MQM=59	MYH7,MHRT	synonymous,non_coding_transcript_exon	MYH7:NM_000257.3:synonymous:LOW:exon35/40:c.5106G>A:p.Ala1702Ala,MHRT:NR_126491.1:non_coding_transcript_exon:MODIFIER:exon2/6:n.112C>T:		rs3729830	0.1176	0.1070	903/493/297	0.1065							160760 [MYH7 (confirmed) Cardiomyopathy,hypertrophic,1,192600|Cardiomyopathy,dilated,1S,613426|Myopathy,myosin storage,autosomal dominant,608358|Laing distal myopathy,160500|Scapuloperoneal syndrome,myopathic type,181430|Left ventricular noncompaction 5,613426|Myopathy,myosin storage,autosomal recessive,255160];	RCV000035950.4 [benign]; RCV000192199.1 [benign]; RCV000248510.1 [benign]; RCV000265247.1 [benign]; RCV000304358.1 [benign]; RCV000309741.1 [benign]; RCV000344972.1 [benign]; RCV000357626.1 [benign]; RCV000405836.1 [benign]; 			31	348					MYH7 (inh=AD pLI=0.00), MHRT (inh=n/a pLI=n/a)
chr14	23892888	23892888	A	G	wt	wt	het		QUAL=3898;DP=166,209,332;MQM=60	MYH7	synonymous	MYH7:NM_000257.3:synonymous:LOW:exon24/40:c.2967T>C:p.Ile989Ile		rs7157716	0.3764	0.3212	7390/3538/2697	0.3179							160760 [MYH7 (confirmed) Cardiomyopathy,hypertrophic,1,192600|Cardiomyopathy,dilated,1S,613426|Myopathy,myosin storage,autosomal dominant,608358|Laing distal myopathy,160500|Scapuloperoneal syndrome,myopathic type,181430|Left ventricular noncompaction 5,613426|Myopathy,myosin storage,autosomal recessive,255160];	RCV000035835.5 [benign]; RCV000246682.1 [benign]; RCV000266522.1 [benign]; RCV000296884.1 [benign]; RCV000324042.1 [benign]; RCV000354060.1 [benign]; RCV000355361.1 [benign]; RCV000392400.1 [benign]; 		COSM147748	197	714					MYH7 (inh=AD pLI=0.00)
chr14	23898994	23898994	G	A	wt	wt	het		QUAL=2610;DP=133,184,247;MQM=60	MYH7	synonymous	MYH7:NM_000257.3:synonymous:LOW:exon12/40:c.1128C>T:p.Asp376Asp		rs2231126	0.1562	0.0961	1084/212/777	0.0928							160760 [MYH7 (confirmed) Cardiomyopathy,hypertrophic,1,192600|Cardiomyopathy,dilated,1S,613426|Myopathy,myosin storage,autosomal dominant,608358|Laing distal myopathy,160500|Scapuloperoneal syndrome,myopathic type,181430|Left ventricular noncompaction 5,613426|Myopathy,myosin storage,autosomal recessive,255160];	RCV000035699.4 [benign]; RCV000253836.1 [benign]; RCV000302714.1 [benign]; RCV000306387.1 [benign]; RCV000359932.1 [benign]; RCV000363434.1 [benign]; RCV000393760.1 [benign]; RCV000401862.1 [benign]; RCV000158503.1 [likely benign]; 		COSM1562687	14	265					MYH7 (inh=AD pLI=0.00)
chr14	23900794	23900794	G	A	wt	wt	het		QUAL=8723;DP=457,630,744;MQM=59	MYH7	splice_region&synonymous,sequence_feature	MYH7:NM_000257.3:splice_region&synonymous:LOW:exon8/40:c.732C>T:p.Phe244Phe,MYH7:NM_000257.3:sequence_feature:LOW:exon8/40:c.732C>T:		rs2069542	0.2638	0.1836	2981/907/1579	0.1800							160760 [MYH7 (confirmed) Cardiomyopathy,hypertrophic,1,192600|Cardiomyopathy,dilated,1S,613426|Myopathy,myosin storage,autosomal dominant,608358|Laing distal myopathy,160500|Scapuloperoneal syndrome,myopathic type,181430|Left ventricular noncompaction 5,613426|Myopathy,myosin storage,autosomal recessive,255160];	RCV000035998.5 [benign]; RCV000251626.1 [benign]; RCV000307808.1 [benign]; RCV000311518.1 [benign]; RCV000347751.1 [benign]; RCV000362465.1 [benign]; RCV000390522.1 [benign]; RCV000394459.1 [benign]; 		COSM4148016	62	504					MYH7 (inh=AD pLI=0.00)
chr14	23902753	23902753	G	A	het	wt	hom		QUAL=7033;DP=141,118,181;MQM=59	MYH7	synonymous	MYH7:NM_000257.3:synonymous:LOW:exon3/40:c.189C>T:p.Thr63Thr		rs2069540	0.5204	0.4888	14779/7595/2050	0.4827							160760 [MYH7 (confirmed) Cardiomyopathy,hypertrophic,1,192600|Cardiomyopathy,dilated,1S,613426|Myopathy,myosin storage,autosomal dominant,608358|Laing distal myopathy,160500|Scapuloperoneal syndrome,myopathic type,181430|Left ventricular noncompaction 5,613426|Myopathy,myosin storage,autosomal recessive,255160];	RCV000154237.1 [benign]; RCV000035752.5 [benign]; RCV000248228.1 [benign]; RCV000297610.1 [benign]; RCV000312955.1 [benign]; RCV000337511.1 [benign]; RCV000352455.1 [benign]; RCV000399650.1 [benign]; RCV000400497.1 [benign]; 		COSM3753910	434	797					MYH7 (inh=AD pLI=0.00)
chr14	24718380	24718401	CTCCGGGAGCCCTGGACTCCCC	-	het	hom	hom		QUAL=11379;DP=153,159,206;MQM=59	TGM1	3'UTR	TGM1:NM_000359.2:3'UTR:MODIFIER:exon15/15:c.*118_*139delGGGGAGTCCAGGGCTCCCGGAG:		rs531264904	0.9914	0.0000	0/0/0	0.8322							190195 [TGM1 (confirmed) Ichthyosis,congenital,autosomal recessive 1,242300];				198	33					TGM1 (inh=AR pLI=0.00)
chr14	24718515	24718515	G	A	hom	hom	het		QUAL=25620;DP=294,343,446;MQM=59	TGM1	3'UTR	TGM1:NM_000359.2:3'UTR:MODIFIER:exon15/15:c.*4C>T:		rs2229463	0.7163	0.7913	38491/24275/2501	0.7865							190195 [TGM1 (confirmed) Ichthyosis,congenital,autosomal recessive 1,242300];				1132	395					TGM1 (inh=AR pLI=0.00)
chr14	29238048	29238048	C	-	het	wt	het		QUAL=2766;DP=182,81,113;MQM=59	FOXG1	3'UTR	FOXG1:NM_005249.4:3'UTR:MODIFIER:exon1/1:c.*100delC:		rs397788971	0.0737	0.0000	0/0/0	0.0590							164874 [FOXG1 (confirmed) Rett syndrome,congenital variant,613454];				0	26					FOXG1 (inh=AD pLI=n/a)
chr14	29238429	29238433	CTTTT	-	wt	het	wt		QUAL=1726;DP=227,108,136;MQM=59	FOXG1	3'UTR	FOXG1:NM_005249.4:3'UTR:MODIFIER:exon1/1:c.*478_*482delTCTTT:		rs138317321	0.1693	0.0000	0/0/0	0.1849							164874 [FOXG1 (confirmed) Rett syndrome,congenital variant,613454];				8	66					FOXG1 (inh=AD pLI=n/a)
chr14	32047217	32047217	T	C	het	het	wt		QUAL=8895;DP=360,360,353;MQM=60	NUBPL	5'UTR,intron	NUBPL:NM_001201573.1:5'UTR:MODIFIER:exon1/9:c.-12T>C:,NUBPL:NM_025152.2:intron:MODIFIER:exon3/10:c.291+12963T>C:,NUBPL:NR_120408.1:intron:MODIFIER:exon3/9:n.346+12963T>C:	L2c	rs7142098	0.3041	0.3886	864/169/6	0.0890							613621 [NUBPL (provisional) Mitochondrial complex I deficiency,252010];				146	481					NUBPL (inh=AR pLI=0.00)
chr14	32183848	32183848	C	T	het	het	wt		QUAL=16210;DP=249,136,166;MQM=59	NUBPL	5'UTR,intron	NUBPL:NM_001201574.1:5'UTR:MODIFIER:exon1/6:c.-198C>T:,NUBPL:NM_025152.2:intron:MODIFIER:exon6/10:c.513+41068C>T:,NUBPL:NR_120408.1:intron:MODIFIER:exon6/9:n.568+41068C>T:,NUBPL:NM_001201573.1:intron:MODIFIER:exon4/8:c.225+41068C>T:	MSTB	rs11623835	0.2829	0.0000	0/0/0	0.2247							613621 [NUBPL (provisional) Mitochondrial complex I deficiency,252010];				26	65					NUBPL (inh=AR pLI=0.00)
chr14	32183849	32183849	A	G	hom	hom	hom		QUAL=16210;DP=249,136,166;MQM=59	NUBPL	5'UTR,intron	NUBPL:NM_001201574.1:5'UTR:MODIFIER:exon1/6:c.-197A>G:,NUBPL:NM_025152.2:intron:MODIFIER:exon6/10:c.513+41069A>G:,NUBPL:NR_120408.1:intron:MODIFIER:exon6/9:n.568+41069A>G:,NUBPL:NM_001201573.1:intron:MODIFIER:exon4/8:c.225+41069A>G:	MSTB	rs11156699	0.7063	0.0000	0/0/0	0.7132							613621 [NUBPL (provisional) Mitochondrial complex I deficiency,252010];				140	9					NUBPL (inh=AR pLI=0.00)
chr14	32183970	32183970	A	T	het	het	wt		QUAL=4632;DP=252,101,105;MQM=59	NUBPL	5'UTR,intron	NUBPL:NM_001201574.1:5'UTR:MODIFIER:exon1/6:c.-76A>T:,NUBPL:NM_025152.2:intron:MODIFIER:exon6/10:c.513+41190A>T:,NUBPL:NR_120408.1:intron:MODIFIER:exon6/9:n.568+41190A>T:,NUBPL:NM_001201573.1:intron:MODIFIER:exon4/8:c.225+41190A>T:	MLT1L	rs11624772	0.2829	0.0000	0/0/0	0.3368							613621 [NUBPL (provisional) Mitochondrial complex I deficiency,252010];				26	65					NUBPL (inh=AR pLI=0.00)
chr14	32328659	32328659	C	T	wt	wt	het		QUAL=3197;DP=483,220,272;MQM=60	NUBPL	3'UTR,non_coding_transcript_exon	NUBPL:NM_025152.2:3'UTR:MODIFIER:exon11/11:c.*273C>T:,NUBPL:NM_001201573.1:3'UTR:MODIFIER:exon9/9:c.*273C>T:,NUBPL:NM_001201574.1:3'UTR:MODIFIER:exon6/6:c.*273C>T:,NUBPL:NR_120408.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1194C>T:		rs76188062	0.0583	0.0000	0/0/0	0.1040							613621 [NUBPL (provisional) Mitochondrial complex I deficiency,252010];	RCV000288716.1 [likely benign]; 			10	44					NUBPL (inh=AR pLI=0.00)
chr14	32328922	32328922	-	A	wt	wt	het		QUAL=3951;DP=477,232,299;MQM=60	NUBPL	3'UTR,non_coding_transcript_exon	NUBPL:NM_025152.2:3'UTR:MODIFIER:exon11/11:c.*537dupA:,NUBPL:NM_001201573.1:3'UTR:MODIFIER:exon9/9:c.*537dupA:,NUBPL:NM_001201574.1:3'UTR:MODIFIER:exon6/6:c.*537dupA:,NUBPL:NR_120408.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1458dupA:	MER5A	rs200626091	0.0581	0.0000	0/0/0	0.1032							613621 [NUBPL (provisional) Mitochondrial complex I deficiency,252010];	RCV000305637.1 [likely benign]; 			7	30					NUBPL (inh=AR pLI=0.00)
chr14	32329381	32329381	T	C	wt	wt	het		QUAL=972;DP=128,81,93;MQM=59	NUBPL	3'UTR,non_coding_transcript_exon	NUBPL:NM_025152.2:3'UTR:MODIFIER:exon11/11:c.*995T>C:,NUBPL:NM_001201573.1:3'UTR:MODIFIER:exon9/9:c.*995T>C:,NUBPL:NM_001201574.1:3'UTR:MODIFIER:exon6/6:c.*995T>C:,NUBPL:NR_120408.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1916T>C:	AluSg	rs10136892	0.6050	0.0000	0/0/0	0.4632							613621 [NUBPL (provisional) Mitochondrial complex I deficiency,252010];	RCV000262171.1 [benign]; 			34	75					NUBPL (inh=AR pLI=0.00)
chr14	35180389	35180389	T	A	het	hom	het		QUAL=7032;DP=233,78,115;MQM=59	CFL2	3'UTR,non_coding_transcript_exon	CFL2:NM_021914.7:3'UTR:MODIFIER:exon4/4:c.*1682A>T:,CFL2:NM_001243645.1:3'UTR:MODIFIER:exon4/4:c.*1682A>T:,CFL2:NM_138638.4:3'UTR:MODIFIER:exon4/4:c.*1682A>T:,CFL2:NR_028130.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.2323A>T:,CFL2:NR_028131.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.2212A>T:		rs712301	0.3421	0.4130	972/410/20	0.1002							601443 [CFL2 (confirmed) Nemaline myopathy 7,autosomal recessive,610687];	RCV000269932.1 [benign]; 			177	293					CFL2 (inh=AR pLI=0.16)
chr14	35180678	35180678	T	-	het	hom	het		QUAL=15673;DP=297,222,293;MQM=59	CFL2	3'UTR,non_coding_transcript_exon	CFL2:NM_021914.7:3'UTR:MODIFIER:exon4/4:c.*1393delA:,CFL2:NM_001243645.1:3'UTR:MODIFIER:exon4/4:c.*1393delA:,CFL2:NM_138638.4:3'UTR:MODIFIER:exon4/4:c.*1393delA:,CFL2:NR_028130.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.2034delA:,CFL2:NR_028131.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.1923delA:		rs398024763	0.6595	0.7591	3602/1221/187	0.1785							601443 [CFL2 (confirmed) Nemaline myopathy 7,autosomal recessive,610687];	RCV000308670.1 [benign]; 			401	219					CFL2 (inh=AR pLI=0.16)
chr14	36986023	36986023	A	-	hom	het	wt		QUAL=837;DP=102,89,132;MQM=59	NKX2-1	3'UTR	NKX2-1:NM_001079668.2:3'UTR:MODIFIER:exon3/3:c.*460delT:,NKX2-1:NM_003317.3:3'UTR:MODIFIER:exon2/2:c.*460delT:		rs5807883	0.0000	0.0000	0/0/0	0.0192							600635 [NKX2-1 (provisional) Thyroid cancer,monmedullary,1,188550|Chorea,hereditary benign,118700|Choreoathetosis,hypothyroidism,and neonatal respiratory distress,610978];	RCV000286589.1 [uncertain significance]; RCV000334608.1 [uncertain significance]; 			0	54					NKX2-1 (inh=AD pLI=0.08)
chr14	36986022	36986022	-	A	wt	het	wt		QUAL=837;DP=102,89,132;MQM=60	NKX2-1	3'UTR	NKX2-1:NM_001079668.2:3'UTR:MODIFIER:exon3/3:c.*460dupT:,NKX2-1:NM_003317.3:3'UTR:MODIFIER:exon2/2:c.*460dupT:		rs878907370	0.0000	0.0000	0/0/0	0.0343							600635 [NKX2-1 (provisional) Thyroid cancer,monmedullary,1,188550|Chorea,hereditary benign,118700|Choreoathetosis,hypothyroidism,and neonatal respiratory distress,610978];	RCV000321812.1 [uncertain significance]; RCV000378715.1,RCV000280837.1 [uncertain significance,uncertain significance]; RCV000373071.1 [uncertain significance]; 			2	115					NKX2-1 (inh=AD pLI=0.08)
chr14	36986190	36986190	-	C	wt	het	wt		QUAL=531;DP=168,85,157;MQM=60	NKX2-1	3'UTR	NKX2-1:NM_001079668.2:3'UTR:MODIFIER:exon3/3:c.*292dupG:,NKX2-1:NM_003317.3:3'UTR:MODIFIER:exon2/2:c.*292dupG:		rs398118058	0.1338	0.0000	0/0/0	0.2090							600635 [NKX2-1 (provisional) Thyroid cancer,monmedullary,1,188550|Chorea,hereditary benign,118700|Choreoathetosis,hypothyroidism,and neonatal respiratory distress,610978];	RCV000312649.1 [benign]; RCV000351206.1 [benign]; 			14	93					NKX2-1 (inh=AD pLI=0.08)
chr14	36986265	36986265	-	T	wt	het	wt		QUAL=4795;DP=100,30,39;MQM=60	NKX2-1	3'UTR	NKX2-1:NM_001079668.2:3'UTR:MODIFIER:exon3/3:c.*217dupA:,NKX2-1:NM_003317.3:3'UTR:MODIFIER:exon2/2:c.*217dupA:		rs71124756	0.0000	0.0000	0/0/0	0.1951							600635 [NKX2-1 (provisional) Thyroid cancer,monmedullary,1,188550|Chorea,hereditary benign,118700|Choreoathetosis,hypothyroidism,and neonatal respiratory distress,610978];				23	80					NKX2-1 (inh=AD pLI=0.08)
chr14	36986273	36986273	A	T	hom	het	hom		QUAL=4795;DP=100,30,39;MQM=60	NKX2-1	3'UTR	NKX2-1:NM_001079668.2:3'UTR:MODIFIER:exon3/3:c.*210T>A:,NKX2-1:NM_003317.3:3'UTR:MODIFIER:exon2/2:c.*210T>A:		rs10139625	0.6218	0.0000	0/0/0	0.2975							600635 [NKX2-1 (provisional) Thyroid cancer,monmedullary,1,188550|Chorea,hereditary benign,118700|Choreoathetosis,hypothyroidism,and neonatal respiratory distress,610978];	RCV000274909.1 [benign]; RCV000369541.1 [benign]; 			89	113					NKX2-1 (inh=AD pLI=0.08)
chr14	36986296	36986296	-	GGGTGG	wt	het	wt		QUAL=215;DP=55,26,37;MQM=60	NKX2-1	3'UTR	NKX2-1:NM_001079668.2:3'UTR:MODIFIER:exon3/3:c.*186_*187insCCACCC:,NKX2-1:NM_003317.3:3'UTR:MODIFIER:exon2/2:c.*186_*187insCCACCC:		rs141117763	0.0000	0.0000	0/0/0	0.0001							600635 [NKX2-1 (provisional) Thyroid cancer,monmedullary,1,188550|Chorea,hereditary benign,118700|Choreoathetosis,hypothyroidism,and neonatal respiratory distress,610978];	RCV000267741.1 [uncertain significance]; RCV000371682.1 [uncertain significance]; RCV000261766.1 [uncertain significance]; RCV000316953.1 [uncertain significance]; 			13	76					NKX2-1 (inh=AD pLI=0.08)
chr14	36986304	36986307	AAAA	-	wt	het	wt		QUAL=266;DP=50,27,36;MQM=60	NKX2-1	3'UTR	NKX2-1:NM_001079668.2:3'UTR:MODIFIER:exon3/3:c.*176_*179delTTTT:,NKX2-1:NM_003317.3:3'UTR:MODIFIER:exon2/2:c.*176_*179delTTTT:		rs200848675	0.0000	0.0000	0/0/0	0.0001							600635 [NKX2-1 (provisional) Thyroid cancer,monmedullary,1,188550|Chorea,hereditary benign,118700|Choreoathetosis,hypothyroidism,and neonatal respiratory distress,610978];				21	76					NKX2-1 (inh=AD pLI=0.08)
chr14	36988623	36988623	G	A	wt	wt	het		QUAL=2959;DP=108,174,231;MQM=60	NKX2-1,NKX2-1-AS1	5'UTR_premature_start_codon_gain,5'UTR,intron,non_coding_transcript_exon	NKX2-1:NM_003317.3:5'UTR_premature_start_codon_gain:LOW:exon1/2:c.-61C>T:,NKX2-1:NM_003317.3:5'UTR:MODIFIER:exon1/2:c.-61C>T:,NKX2-1:NM_001079668.2:intron:MODIFIER:exon1/2:c.78-48C>T:,NKX2-1-AS1:NR_103710.1:non_coding_transcript_exon:MODIFIER:exon1/2:n.141G>A:	GA-rich	rs147791173	0.0032	0.0069	6/3/0	0.0058							600635 [NKX2-1 (provisional) Thyroid cancer,monmedullary,1,188550|Chorea,hereditary benign,118700|Choreoathetosis,hypothyroidism,and neonatal respiratory distress,610978];				0	11					NKX2-1 (inh=AD pLI=0.08), NKX2-1-AS1 (inh=n/a pLI=n/a)
chr14	50087753	50087753	T	C	het	het	hom		QUAL=8353;DP=50,130,234;MQM=60	MGAT2	5'UTR	MGAT2:NM_002408.3:5'UTR:MODIFIER:exon1/1:c.-234T>C:		rs7519	0.2953	0.4935	1352/444/4	0.1105							602616 [MGAT2 (provisional) Congenital disorder of glycosylation,type IIa,212066];	RCV000329751.1 [benign]; RCV000389040.1 [benign]; 			283	500					MGAT2 (inh=AR pLI=0.96)
chr14	50712569	50712569	A	G	hom	hom	het		QUAL=15904;DP=221,197,233;MQM=59	L2HGDH	3'UTR	L2HGDH:NM_024884.2:3'UTR:MODIFIER:exon10/10:c.*1207T>C:	AluSq2	rs7157035	0.8377	0.0000	0/0/0	0.8033							609584 [L2HGDH (confirmed) L-2-hydroxyglutaric aciduria,236792];				166	61					L2HGDH (inh=AR pLI=0.31)
chr14	50712797	50712797	T	C	hom	hom	het		QUAL=8504;DP=153,74,141;MQM=54	L2HGDH	3'UTR	L2HGDH:NM_024884.2:3'UTR:MODIFIER:exon10/10:c.*979A>G:	AluSq2	rs1964845	0.8902	0.0000	0/0/0	0.7934							609584 [L2HGDH (confirmed) L-2-hydroxyglutaric aciduria,236792];				156	45					L2HGDH (inh=AR pLI=0.31)
chr14	50712852	50712852	T	A	hom	hom	het		QUAL=8940;DP=189,89,166;MQM=57	L2HGDH	3'UTR	L2HGDH:NM_024884.2:3'UTR:MODIFIER:exon10/10:c.*924A>T:	AluSq2	rs6572652	0.8377	0.0000	0/0/0	0.6728							609584 [L2HGDH (confirmed) L-2-hydroxyglutaric aciduria,236792];				117	53					L2HGDH (inh=AR pLI=0.31)
chr14	50712980	50712980	A	G	het	hom	wt		QUAL=5125;DP=196,88,150;MQM=59	L2HGDH	3'UTR	L2HGDH:NM_024884.2:3'UTR:MODIFIER:exon10/10:c.*796T>C:	AluJb	rs74541550	0.2756	0.0000	0/0/0	0.0340							609584 [L2HGDH (confirmed) L-2-hydroxyglutaric aciduria,236792];				10	56					L2HGDH (inh=AR pLI=0.31)
chr14	50713679	50713679	T	G	hom	hom	hom		QUAL=10438;DP=185,62,78;MQM=59	L2HGDH	3'UTR	L2HGDH:NM_024884.2:3'UTR:MODIFIER:exon10/10:c.*97A>C:		rs7143186	0.9990	0.0000	0/0/0	0.2044							609584 [L2HGDH (confirmed) L-2-hydroxyglutaric aciduria,236792];				227	2					L2HGDH (inh=AR pLI=0.31)
chr14	50769717	50769717	G	A	hom	hom	het		QUAL=21683;DP=381,201,220;MQM=60	L2HGDH	synonymous	L2HGDH:NM_024884.2:synonymous:LOW:exon2/10:c.159C>T:p.Ile53Ile		rs2297995	0.5966	0.5701	19824/10678/1970	0.5608							609584 [L2HGDH (confirmed) L-2-hydroxyglutaric aciduria,236792];	RCV000146249.1 [likely benign]; 		COSM4150800, COSM4150799	872	1311					L2HGDH (inh=AR pLI=0.31)
chr14	50778816	50778816	A	C	hom	hom	het	pred_pathogenic	QUAL=5287;DP=44,84,117;MQM=59	L2HGDH	missense	L2HGDH:NM_024884.2:missense:MODERATE:exon1/10:c.53T>G:p.Leu18Arg		rs2275591	0.5727	0.5999	16174/9166/1257	0.5346	-4.0100	T,T,T,T,T,T	T	B,B	D,D,D,D,D	0.01	609584 [L2HGDH (confirmed) L-2-hydroxyglutaric aciduria,236792];	RCV000146250.1 [likely benign]; 		COSM3753977, COSM433105	894	1329					L2HGDH (inh=AR pLI=0.31)
chr14	51054598	51054598	A	G	het	wt	het		QUAL=7700;DP=213,229,363;MQM=60	ATL1	synonymous	ATL1:NM_015915.4:synonymous:LOW:exon2/14:c.84A>G:p.Pro28Pro,ATL1:NM_001127713.1:synonymous:LOW:exon3/14:c.84A>G:p.Pro28Pro,ATL1:NM_181598.3:synonymous:LOW:exon2/13:c.84A>G:p.Pro28Pro		rs35014209	0.1641	0.1359	1425/664/552	0.1347							606439 [ATL1 (confirmed) Spastic paraplegia 3A,autosomal dominant,182600|Neuropathy,hereditary sensory,type ID,613708];	RCV000020724.1 [benign]; RCV000116421.3 [other]; RCV000335510.1 [benign]; 		COSM3753981	40	501					ATL1 (inh=AD pLI=0.99)
chr14	51057727	51057727	G	A	hom	het	het		QUAL=15292;DP=293,213,245;MQM=60	ATL1	synonymous	ATL1:NM_015915.4:synonymous:LOW:exon3/14:c.351G>A:p.Glu117Glu,ATL1:NM_001127713.1:synonymous:LOW:exon4/14:c.351G>A:p.Glu117Glu,ATL1:NM_181598.3:synonymous:LOW:exon3/13:c.351G>A:p.Glu117Glu		rs1060197	0.8215	0.7633	35571/17438/4515	0.7550							606439 [ATL1 (confirmed) Spastic paraplegia 3A,autosomal dominant,182600|Neuropathy,hereditary sensory,type ID,613708];	RCV000020720.1 [benign]; RCV000116420.2 [likely benign]; RCV000392328.1 [benign]; 			1083	828	1	[1] old entry - no details available	n/a (2xTP, 0xFP)		ATL1 (inh=AD pLI=0.99)
chr14	51062357	51062357	G	A	het	wt	het		QUAL=5485;DP=205,165,230;MQM=59	ATL1	splice_region&intron	ATL1:NM_015915.4:splice_region&intron:LOW:exon6/13:c.630+7G>A:,ATL1:NM_001127713.1:splice_region&intron:LOW:exon7/13:c.630+7G>A:,ATL1:NM_181598.3:splice_region&intron:LOW:exon6/12:c.630+7G>A:		rs3759588	0.1494	0.1331	1300/692/398	0.1319							606439 [ATL1 (confirmed) Spastic paraplegia 3A,autosomal dominant,182600|Neuropathy,hereditary sensory,type ID,613708];	RCV000123709.1 [benign]; RCV000362910.1 [benign]; 		COSM3999276	40	501					ATL1 (inh=AD pLI=0.99)
chr14	54417522	54417522	A	G	wt	het	het	pred_pathogenic	QUAL=9758;DP=349,344,434;MQM=60	BMP4	missense	BMP4:NM_001202.4:missense:MODERATE:exon4/4:c.455T>C:p.Val152Ala,BMP4:NM_130850.3:missense:MODERATE:exon4/4:c.455T>C:p.Val152Ala		rs17563	0.3257	0.4570	13614/10193/313	0.4529	5.0630	T,T	T	B	T,T	9.34	112262 [BMP4 (confirmed) Microphthalmia,syndromic 6,607932|Orofacial cleft 11,600625];	RCV000178157.2 [benign]; RCV000274304.1 [likely benign]; RCV000309331.1 [likely benign]; RCV000366338.1 [likely benign]; RCV000405370.1 [likely benign]; 	CM096386 [CLASS=DFP MUT=ALT PHEN="Cutaneous melanoma susceptibility to association with" GENE=BMP4]; 	COSM3754009	395	774					BMP4 (inh=AD pLI=0.97)
chr14	55308770	55308770	C	A	hom	hom	hom		QUAL=8146;DP=154,48,59;MQM=60	GCH1	3'UTR	GCH1:NM_000161.2:3'UTR:MODIFIER:exon6/6:c.*1965G>T:,GCH1:NM_001024024.1:3'UTR:MODIFIER:exon7/7:c.*1019G>T:,GCH1:NM_001024070.1:3'UTR:MODIFIER:exon7/7:c.*1015G>T:,GCH1:NM_001024071.1:3'UTR:MODIFIER:exon6/6:c.*987G>T:		rs6572984	0.9900	0.0000	0/0/0	0.8749							600225 [GCH1 (provisional) Dystonia,DOPA-responsive,with or without hyperphenylalaninemia,128230|Hyperphenylalaninemia,BH4-deficient,B,233910];				259	0					GCH1 (inh=AD pLI=0.94)
chr14	55309107	55309107	T	G	wt	het	wt		QUAL=1589;DP=285,112,116;MQM=60	GCH1	3'UTR	GCH1:NM_000161.2:3'UTR:MODIFIER:exon6/6:c.*1628A>C:,GCH1:NM_001024024.1:3'UTR:MODIFIER:exon7/7:c.*682A>C:,GCH1:NM_001024070.1:3'UTR:MODIFIER:exon7/7:c.*678A>C:,GCH1:NM_001024071.1:3'UTR:MODIFIER:exon6/6:c.*650A>C:		rs185031007	0.0002	0.0000	0/0/0	0.0010							600225 [GCH1 (provisional) Dystonia,DOPA-responsive,with or without hyperphenylalaninemia,128230|Hyperphenylalaninemia,BH4-deficient,B,233910];	RCV000335964.1 [likely benign]; RCV000407257.1 [likely benign]; 			0	1					GCH1 (inh=AD pLI=0.94)
chr14	55369502	55369502	A	G	hom	hom	hom	low_DP	QUAL=1272;DP=9,14,21;MQM=59	GCH1	5'UTR	GCH1:NM_000161.2:5'UTR:MODIFIER:exon1/6:c.-121T>C:,GCH1:NM_001024024.1:5'UTR:MODIFIER:exon1/7:c.-121T>C:,GCH1:NM_001024070.1:5'UTR:MODIFIER:exon1/7:c.-121T>C:,GCH1:NM_001024071.1:5'UTR:MODIFIER:exon1/6:c.-121T>C:		rs1753589	0.9457	0.0000	0/0/0	0.1505							600225 [GCH1 (provisional) Dystonia,DOPA-responsive,with or without hyperphenylalaninemia,128230|Hyperphenylalaninemia,BH4-deficient,B,233910];	RCV000265291.1 [benign]; RCV000357872.1 [benign]; 			261	6					GCH1 (inh=AD pLI=0.94)
chr14	57268443	57268443	C	T	het	het	wt		QUAL=5031;DP=279,144,193;MQM=59	OTX2	3'UTR,non_coding_transcript_exon	OTX2:NM_001270525.1:3'UTR:MODIFIER:exon3/3:c.*10G>A:,OTX2:NM_172337.2:3'UTR:MODIFIER:exon3/3:c.*10G>A:,OTX2:NM_001270523.1:3'UTR:MODIFIER:exon5/5:c.*10G>A:,OTX2:NM_001270524.1:3'UTR:MODIFIER:exon4/4:c.*10G>A:,OTX2:NM_021728.3:3'UTR:MODIFIER:exon5/5:c.*10G>A:,OTX2:NR_073036.1:non_coding_transcript_exon:MODIFIER:exon2/2:n.935G>A:,OTX2:NR_073034.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.1012G>A:		rs171978	0.0315	0.0662	338/303/3	0.0658							600037 [OTX2 (confirmed) Microphthalmia,syndromic 5,610125|Pituitary hormone deficiency,combined,6,613986|Retinal dystrophy,early-onset,with or without pituitary dysfunction,610125];	RCV000265380.1 [likely benign]; RCV000318117.1 [likely benign]; RCV000357798.1 [likely benign]; RCV000364347.1 [benign]; RCV000375013.1 [likely benign]; 			19	240					OTX2 (inh=AD pLI=0.74)
chr14	64408852	64408852	G	C	wt	het	wt	gene_blacklist	QUAL=1559;DP=492,126,192;MQM=60	SYNE2	synonymous	SYNE2:NM_182914.2:synonymous:LOW:exon6/116:c.399G>C:p.Leu133Leu,SYNE2:NM_015180.4:synonymous:LOW:exon6/115:c.399G>C:p.Leu133Leu		rs33976862	0.1090	0.0840	607/169/239	0.0820							608442 [SYNE2 (provisional) Emery-Dreifuss muscular dystrophy 5,autosomal dominant,612999];	RCV000118536.1 [benign]; RCV000296672.1 [benign]; 		COSM147791	9	162					SYNE2 (inh=AD pLI=0.00)
chr14	64469828	64469828	C	T	wt	het	wt	gene_blacklist	QUAL=1951;DP=484,159,247;MQM=60	SYNE2	missense	SYNE2:NM_182914.2:missense:MODERATE:exon30/116:c.4177C>T:p.Arg1393Trp,SYNE2:NM_015180.4:missense:MODERATE:exon30/115:c.4177C>T:p.Arg1393Trp		rs17751301	0.0256	0.0564	295/163/0	0.0552	-1.0530	T,T,T,T	T	B,B	T,T,T	10.05	608442 [SYNE2 (provisional) Emery-Dreifuss muscular dystrophy 5,autosomal dominant,612999];	RCV000118537.1 [benign]; RCV000278257.1 [benign]; 		COSM3754037	8	138					SYNE2 (inh=AD pLI=0.00)
chr14	64476680	64476680	T	A	wt	het	wt	gene_blacklist	QUAL=1014;DP=145,87,95;MQM=60	SYNE2	splice_region&intron	SYNE2:NM_182914.2:splice_region&intron:LOW:exon31/115:c.4578-4T>A:,SYNE2:NM_015180.4:splice_region&intron:LOW:exon31/114:c.4578-4T>A:		rs7146588	0.3502	0.2425	4302/1144/1711	0.2347							608442 [SYNE2 (provisional) Emery-Dreifuss muscular dystrophy 5,autosomal dominant,612999];	RCV000118539.1 [benign]; RCV000397115.1 [benign]; 			84	501					SYNE2 (inh=AD pLI=0.00)
chr14	64491695	64491695	T	C	hom	hom	hom	gene_blacklist	QUAL=28525;DP=395,231,253;MQM=59	SYNE2	missense	SYNE2:NM_182914.2:missense:MODERATE:exon40/116:c.5906T>C:p.Met1969Thr,SYNE2:NM_015180.4:missense:MODERATE:exon40/115:c.5906T>C:p.Met1969Thr		rs4902264	0.6789	0.8118	40789/25249/878	0.8027	0.1190	T,T,T,T	T	B,B	T,T,T	0.19	608442 [SYNE2 (provisional) Emery-Dreifuss muscular dystrophy 5,autosomal dominant,612999];	RCV000118541.1 [benign]; RCV000350785.1 [benign]; 			1206	406					SYNE2 (inh=AD pLI=0.00)
chr14	64494278	64494278	C	T	hom	hom	hom	gene_blacklist	QUAL=16646;DP=287,96,119;MQM=60	SYNE2	synonymous	SYNE2:NM_182914.2:synonymous:LOW:exon43/116:c.6481C>T:p.Leu2161Leu,SYNE2:NM_015180.4:synonymous:LOW:exon43/115:c.6481C>T:p.Leu2161Leu		rs10151127	0.7520	0.8692	46325/27862/1488	0.8591							608442 [SYNE2 (provisional) Emery-Dreifuss muscular dystrophy 5,autosomal dominant,612999];	RCV000118543.2 [benign]; RCV000339334.1 [benign]; 			1315	330					SYNE2 (inh=AD pLI=0.00)
chr14	64496749	64496749	C	T	hom	hom	hom	gene_blacklist	QUAL=12599;DP=218,85,97;MQM=60	SYNE2	missense	SYNE2:NM_182914.2:missense:MODERATE:exon44/116:c.6851C>T:p.Ala2284Val,SYNE2:NM_015180.4:missense:MODERATE:exon44/115:c.6851C>T:p.Ala2284Val		rs4027402	0.6719	0.8122	40858/25441/856	0.8031	0.3380	T,T,T,T	T	B,B	T,T,T	11.46	608442 [SYNE2 (provisional) Emery-Dreifuss muscular dystrophy 5,autosomal dominant,612999];	RCV000118544.1 [benign]; RCV000364940.1 [benign]; 			1203	409					SYNE2 (inh=AD pLI=0.00)
chr14	64497930	64497930	G	A	hom	hom	hom	gene_blacklist	QUAL=33185;DP=485,230,308;MQM=60	SYNE2	missense	SYNE2:NM_182914.2:missense:MODERATE:exon45/116:c.7076G>A:p.Ser2359Asn,SYNE2:NM_015180.4:missense:MODERATE:exon45/115:c.7076G>A:p.Ser2359Asn		rs4027404	0.7025	0.8209	41396/25465/1249	0.8113	0.9820	T,T,T,T	T	B,B	T,T,T	5.52	608442 [SYNE2 (provisional) Emery-Dreifuss muscular dystrophy 5,autosomal dominant,612999];	RCV000118548.1 [benign]; RCV000281736.1 [benign]; 			1217	406					SYNE2 (inh=AD pLI=0.00)
chr14	64498037	64498037	G	A	hom	hom	hom	gene_blacklist;pred_pathogenic	QUAL=23671;DP=284,190,274;MQM=59	SYNE2	missense	SYNE2:NM_182914.2:missense:MODERATE:exon45/116:c.7183G>A:p.Ala2395Thr,SYNE2:NM_015180.4:missense:MODERATE:exon45/115:c.7183G>A:p.Ala2395Thr		rs4027405	0.8373	0.8924	48092/27760/2937	0.8825	1.8170	T,T,T,T	T	B,B	T,T,T	22.90	608442 [SYNE2 (provisional) Emery-Dreifuss muscular dystrophy 5,autosomal dominant,612999];	RCV000118551.1 [benign]; RCV000393202.1 [benign]; 			1339	320					SYNE2 (inh=AD pLI=0.00)
chr14	64519035	64519035	A	G	hom	hom	hom	gene_blacklist	QUAL=25977;DP=298,234,262;MQM=60	SYNE2	missense	SYNE2:NM_182914.2:missense:MODERATE:exon48/116:c.8404A>G:p.Ser2802Gly,SYNE2:NM_015180.4:missense:MODERATE:exon48/115:c.8404A>G:p.Ser2802Gly		rs1890908	0.8618	0.9068	49811/28871/3670	0.8970	-1.6090	T,T,T,T	T	B,B	T,T,T	0.01	608442 [SYNE2 (provisional) Emery-Dreifuss muscular dystrophy 5,autosomal dominant,612999];	RCV000118553.1 [benign]; RCV000280345.1 [benign]; 			1404	255					SYNE2 (inh=AD pLI=0.00)
chr14	64519455	64519455	A	G	hom	hom	hom	gene_blacklist	QUAL=31160;DP=407,231,315;MQM=59	SYNE2	missense	SYNE2:NM_182914.2:missense:MODERATE:exon48/116:c.8824A>G:p.Ile2942Val,SYNE2:NM_015180.4:missense:MODERATE:exon48/115:c.8824A>G:p.Ile2942Val		rs3829767	0.6651	0.8031	39757/24554/758	0.7932	-0.8420	T,T,T,T	T	B,B	T,T,T	0.01	608442 [SYNE2 (provisional) Emery-Dreifuss muscular dystrophy 5,autosomal dominant,612999];	RCV000118556.1 [benign]; RCV000377044.1 [benign]; 			1197	422					SYNE2 (inh=AD pLI=0.00)
chr14	64522674	64522674	G	C	hom	hom	hom	gene_blacklist;pred_pathogenic	QUAL=21764;DP=285,180,224;MQM=59	SYNE2	missense	SYNE2:NM_182914.2:missense:MODERATE:exon49/116:c.9757G>C:p.Asp3253His,SYNE2:NM_015180.4:missense:MODERATE:exon49/115:c.9757G>C:p.Asp3253His		rs8010911	0.6813	0.8076	40017/24574/972	0.7970	2.7620	T,T,T,T	T	B,B	T,T,T	24.40	608442 [SYNE2 (provisional) Emery-Dreifuss muscular dystrophy 5,autosomal dominant,612999];	RCV000118560.1 [benign]; RCV000384721.1 [benign]; 			1187	417					SYNE2 (inh=AD pLI=0.00)
chr14	64522843	64522843	A	G	hom	hom	hom	gene_blacklist;pred_pathogenic	QUAL=40103;DP=430,367,451;MQM=60	SYNE2	missense	SYNE2:NM_182914.2:missense:MODERATE:exon49/116:c.9926A>G:p.His3309Arg,SYNE2:NM_015180.4:missense:MODERATE:exon49/115:c.9926A>G:p.His3309Arg		rs8010699	0.6823	0.8074	40218/24698/987	0.7955	1.1020	D,D,T,T	T	B,B	T,T,T	0.57	608442 [SYNE2 (provisional) Emery-Dreifuss muscular dystrophy 5,autosomal dominant,612999];	RCV000118561.1 [benign]; RCV000344125.1 [benign]; RCV000393944.1 [uncertain significance]; 			1190	426					SYNE2 (inh=AD pLI=0.00)
chr14	64565536	64565536	C	T	het	wt	het	gene_blacklist	QUAL=8560;DP=377,247,316;MQM=60	SYNE2	synonymous	SYNE2:NM_182914.2:synonymous:LOW:exon63/116:c.12378C>T:p.Ser4126Ser,SYNE2:NM_015180.4:synonymous:LOW:exon63/115:c.12378C>T:p.Ser4126Ser		rs36007735	0.0024	0.0056	3/3/0	0.0053							608442 [SYNE2 (provisional) Emery-Dreifuss muscular dystrophy 5,autosomal dominant,612999];	RCV000179624.1 [benign]; RCV000278335.1 [likely benign]; 		COSM1240354	0	33					SYNE2 (inh=AD pLI=0.00)
chr14	64604595	64604595	G	A	wt	het	wt	gene_blacklist;pred_pathogenic	QUAL=2781;DP=292,217,316;MQM=60	SYNE2	missense	SYNE2:NM_182914.2:missense:MODERATE:exon79/116:c.14737G>A:p.Glu4913Lys,SYNE2:NM_015180.4:missense:MODERATE:exon79/115:c.14737G>A:p.Glu4913Lys		rs12881815	0.0194	0.0408	159/95/0	0.0407	3.5790	T,T,T,T,T,T,T	T	B,B,B	T,T,T,T,T,T	25.20	608442 [SYNE2 (provisional) Emery-Dreifuss muscular dystrophy 5,autosomal dominant,612999];	RCV000118516.2 [likely benign]; RCV000385288.1 [benign]; 		COSM3754038, COSM3754039	3	93					SYNE2 (inh=AD pLI=0.00)
chr14	64612845	64612845	C	T	het	wt	het	gene_blacklist	QUAL=7498;DP=259,157,240;MQM=60	SYNE2	synonymous	SYNE2:NM_182914.2:synonymous:LOW:exon84/116:c.15543C>T:p.Ile5181Ile,SYNE2:NM_015180.4:synonymous:LOW:exon84/115:c.15543C>T:p.Ile5181Ile		rs11629287	0.4419	0.3709	8457/3585/1500	0.3661							608442 [SYNE2 (provisional) Emery-Dreifuss muscular dystrophy 5,autosomal dominant,612999];	RCV000118519.1 [benign]; RCV000273835.1 [benign]; 		COSM1128227	184	725					SYNE2 (inh=AD pLI=0.00)
chr14	64612858	64612858	C	A	het	wt	het	gene_blacklist	QUAL=8063;DP=264,177,268;MQM=60	SYNE2	missense	SYNE2:NM_182914.2:missense:MODERATE:exon84/116:c.15556C>A:p.Leu5186Met,SYNE2:NM_015180.4:missense:MODERATE:exon84/115:c.15556C>A:p.Leu5186Met		rs10151658	0.6318	0.5031	16305/6360/3881	0.4952	-0.5950	T,T,T,T,T,T,T	T	B,B,B,B	T,T,T,T,T,T	1.26	608442 [SYNE2 (provisional) Emery-Dreifuss muscular dystrophy 5,autosomal dominant,612999];	RCV000118520.1 [benign]; RCV000331267.1 [benign]; 		COSM1128226	373	794					SYNE2 (inh=AD pLI=0.00)
chr14	64637147	64637147	C	A	het	wt	het	gene_blacklist	QUAL=7273;DP=202,286,388;MQM=60	SYNE2	synonymous	SYNE2:NM_182914.2:synonymous:LOW:exon94/116:c.17202C>A:p.Leu5734Leu,SYNE2:NM_015180.4:synonymous:LOW:exon94/115:c.17202C>A:p.Leu5734Leu		rs7161192	0.3658	0.3510	6653/3213/668	0.3293							608442 [SYNE2 (provisional) Emery-Dreifuss muscular dystrophy 5,autosomal dominant,612999];	RCV000118525.1 [benign]; RCV000390655.1 [benign]; 			168	729					SYNE2 (inh=AD pLI=0.00)
chr14	64656855	64656855	T	C	het	wt	het	gene_blacklist	QUAL=5887;DP=227,138,210;MQM=60	SYNE2	synonymous	SYNE2:NM_182914.2:synonymous:LOW:exon99/116:c.17938T>C:p.Leu5980Leu,SYNE2:NM_015180.4:synonymous:LOW:exon99/115:c.17938T>C:p.Leu5980Leu		rs2256191	0.4870	0.3943	10411/4412/2967	0.3887							608442 [SYNE2 (provisional) Emery-Dreifuss muscular dystrophy 5,autosomal dominant,612999];	RCV000118528.1 [benign]; RCV000272822.1 [benign]; 		COSM3999320, COSM3999321	280	758					SYNE2 (inh=AD pLI=0.00)
chr14	64681193	64681193	C	T	het	wt	hom	gene_blacklist	QUAL=4326;DP=189,51,73;MQM=60	SYNE2	splice_region&intron	SYNE2:NM_182914.2:splice_region&intron:LOW:exon106/115:c.19333+5C>T:,SYNE2:NM_015180.4:splice_region&intron:LOW:exon106/114:c.19333+5C>T:,SYNE2:NM_182913.2:splice_region&intron:LOW:exon1/10:c.235+5C>T:		rs1152590	0.5833	0.4702	12006/4538/2895	0.4347							608442 [SYNE2 (provisional) Emery-Dreifuss muscular dystrophy 5,autosomal dominant,612999];	RCV000118529.2 [benign]; RCV000372153.1 [benign]; 			304	725					SYNE2 (inh=AD pLI=0.00)
chr14	64686125	64686125	G	T	het	wt	hom	gene_blacklist	QUAL=5745;DP=115,110,156;MQM=60	SYNE2	synonymous	SYNE2:NM_182914.2:synonymous:LOW:exon110/116:c.19857G>T:p.Leu6619Leu,SYNE2:NM_015180.4:synonymous:LOW:exon109/115:c.19788G>T:p.Leu6596Leu,SYNE2:NM_182913.2:synonymous:LOW:exon5/11:c.759G>T:p.Leu253Leu,SYNE2:NM_182910.2:synonymous:LOW:exon3/9:c.381G>T:p.Leu127Leu		rs35648226	0.2097	0.2409	3759/2615/223	0.2398							608442 [SYNE2 (provisional) Emery-Dreifuss muscular dystrophy 5,autosomal dominant,612999];	RCV000118530.1 [benign]; RCV000289541.1 [benign]; 			145	671					SYNE2 (inh=AD pLI=0.00)
chr14	64692630	64692630	G	C	het	wt	hom	gene_blacklist	QUAL=7140;DP=229,118,134;MQM=60	SYNE2	3'UTR	SYNE2:NM_182914.2:3'UTR:MODIFIER:exon116/116:c.*386G>C:,SYNE2:NM_015180.4:3'UTR:MODIFIER:exon115/115:c.*386G>C:,SYNE2:NM_182913.2:3'UTR:MODIFIER:exon11/11:c.*386G>C:,SYNE2:NM_182910.2:3'UTR:MODIFIER:exon9/9:c.*386G>C:		rs1152582	0.6895	0.0000	0/0/0	0.5974							608442 [SYNE2 (provisional) Emery-Dreifuss muscular dystrophy 5,autosomal dominant,612999];	RCV000385648.1 [benign]; 			77	109					SYNE2 (inh=AD pLI=0.00)
chr14	64692825	64692825	G	A	het	wt	hom	gene_blacklist	QUAL=5936;DP=177,114,128;MQM=60	SYNE2	3'UTR	SYNE2:NM_182914.2:3'UTR:MODIFIER:exon116/116:c.*581G>A:,SYNE2:NM_015180.4:3'UTR:MODIFIER:exon115/115:c.*581G>A:,SYNE2:NM_182913.2:3'UTR:MODIFIER:exon11/11:c.*581G>A:,SYNE2:NM_182910.2:3'UTR:MODIFIER:exon9/9:c.*581G>A:		rs7229	0.6909	0.0000	0/0/0	0.1158							608442 [SYNE2 (provisional) Emery-Dreifuss muscular dystrophy 5,autosomal dominant,612999];	RCV000373373.1 [benign]; 			76	108					SYNE2 (inh=AD pLI=0.00)
chr14	64693064	64693064	T	G	wt	het	het	low_DP;gene_blacklist	QUAL=138;DP=87,10,24;MQM=60	SYNE2	3'UTR	SYNE2:NM_182914.2:3'UTR:MODIFIER:exon116/116:c.*820T>G:,SYNE2:NM_015180.4:3'UTR:MODIFIER:exon115/115:c.*820T>G:,SYNE2:NM_182913.2:3'UTR:MODIFIER:exon11/11:c.*820T>G:,SYNE2:NM_182910.2:3'UTR:MODIFIER:exon9/9:c.*820T>G:			0.0000	0.0000	0/0/0	0.0001							608442 [SYNE2 (provisional) Emery-Dreifuss muscular dystrophy 5,autosomal dominant,612999];				1	7					SYNE2 (inh=AD pLI=0.00)
chr14	66974474	66974474	T	C	het	wt	het		QUAL=3493;DP=150,124,164;MQM=59	GPHN	5'UTR	GPHN:NM_020806.4:5'UTR:MODIFIER:exon1/23:c.-772T>C:,GPHN:NM_001024218.1:5'UTR:MODIFIER:exon1/22:c.-772T>C:		rs928553	0.4507	0.2890	607/100/118	0.0705							603930 [GPHN (confirmed) Molybdenum cofactor deficiency C,615501];				55	299					GPHN (inh=n/a pLI=1.00)
chr14	67147816	67147816	T	C	het	wt	het		QUAL=3322;DP=175,75,87;MQM=60	GPHN	splice_region&intron	GPHN:NM_020806.4:splice_region&intron:LOW:exon1/22:c.65-9T>C:,GPHN:NM_001024218.1:splice_region&intron:LOW:exon1/21:c.65-9T>C:		rs3759753	0.4503	0.2661	6113/784/2292	0.2589							603930 [GPHN (confirmed) Molybdenum cofactor deficiency C,615501];	RCV000252877.1 [benign]; 		COSM147798, COSM3999345	88	454					GPHN (inh=n/a pLI=1.00)
chr14	68213571	68213571	C	T	hom	hom	hom		QUAL=44420;DP=555,333,471;MQM=60	ZFYVE26	3'UTR	ZFYVE26:NM_015346.3:3'UTR:MODIFIER:exon42/42:c.*1582G>A:		rs8017209	0.9501	0.0000	0/0/0	0.1542							612012 [ZFYVE26 (confirmed) Spastic paraplegia 15,autosomal recessive,270700];	RCV000388011.1 [benign]; 			226	4					ZFYVE26 (inh=AR pLI=0.00)
chr14	68213744	68213744	G	A	hom	hom	hom		QUAL=24824;DP=364,177,213;MQM=59	ZFYVE26	3'UTR	ZFYVE26:NM_015346.3:3'UTR:MODIFIER:exon42/42:c.*1409C>T:		rs10288	0.9501	0.0000	0/0/0	0.1542							612012 [ZFYVE26 (confirmed) Spastic paraplegia 15,autosomal recessive,270700];	RCV000270156.1 [benign]; 			225	5					ZFYVE26 (inh=AR pLI=0.00)
chr14	68213792	68213792	A	G	hom	hom	hom		QUAL=28149;DP=369,223,291;MQM=59	ZFYVE26	3'UTR	ZFYVE26:NM_015346.3:3'UTR:MODIFIER:exon42/42:c.*1361T>C:		rs1044126	0.3135	0.0000	0/0/0	0.0804							612012 [ZFYVE26 (confirmed) Spastic paraplegia 15,autosomal recessive,270700];	RCV000325247.1 [benign]; 			72	106					ZFYVE26 (inh=AR pLI=0.00)
chr14	68234539	68234539	T	C	hom	hom	hom		QUAL=35153;DP=312,304,476;MQM=60	ZFYVE26	missense	ZFYVE26:NM_015346.3:missense:MODERATE:exon31/42:c.5672A>G:p.Asn1891Ser		rs3742883	0.9032	0.9546	55500/32425/3741	0.9365	-0.3940	T,T,T	T	B	T,T	0.01	612012 [ZFYVE26 (confirmed) Spastic paraplegia 15,autosomal recessive,270700];	RCV000118901.2 [likely benign]; RCV000318199.1 [benign]; 			2094	64					ZFYVE26 (inh=AR pLI=0.00)
chr14	68249499	68249499	C	T	hom	het	het	pred_pathogenic	QUAL=11258;DP=238,136,159;MQM=59	ZFYVE26	missense&splice_region	ZFYVE26:NM_015346.3:missense&splice_region:MODERATE:exon21/42:c.4370G>A:p.Cys1457Tyr		rs2235967	0.1601	0.2632	5052/4072/40	0.2544	2.5290	T,T,T	T	B,B	T,T	13.79	612012 [ZFYVE26 (confirmed) Spastic paraplegia 15,autosomal recessive,270700];	RCV000118900.3 [other]; RCV000360357.1 [likely benign]; 		COSM3754058	276	925					ZFYVE26 (inh=AR pLI=0.00)
chr14	68257352	68257352	T	A	wt	wt	het		QUAL=2758;DP=195,206,235;MQM=60	ZFYVE26	missense	ZFYVE26:NM_015346.3:missense:MODERATE:exon15/42:c.2692A>T:p.Thr898Ser		rs17192170	0.0429	0.0903	653/500/5	0.0904	1.2560	T,T,T	T	B,B	T,T	13.08	612012 [ZFYVE26 (confirmed) Spastic paraplegia 15,autosomal recessive,270700];	RCV000392341.1 [likely benign]; 			37	391					ZFYVE26 (inh=AR pLI=0.00)
chr14	68257485	68257485	C	T	hom	het	het		QUAL=7472;DP=104,154,213;MQM=60	ZFYVE26	synonymous	ZFYVE26:NM_015346.3:synonymous:LOW:exon15/42:c.2559G>A:p.Leu853Leu		rs7143196	0.0747	0.1456	1669/1409/8	0.1471							612012 [ZFYVE26 (confirmed) Spastic paraplegia 15,autosomal recessive,270700];	RCV000118895.2 [likely benign]; RCV000314307.1 [likely benign]; 			84	653					ZFYVE26 (inh=AR pLI=0.00)
chr14	68264867	68264867	A	G	wt	het	het		QUAL=3961;DP=162,150,194;MQM=59	ZFYVE26	synonymous	ZFYVE26:NM_015346.3:synonymous:LOW:exon11/42:c.2112T>C:p.Pro704Pro		rs12891164	0.7712	0.7112	31292/13929/2449	0.6893							612012 [ZFYVE26 (confirmed) Spastic paraplegia 15,autosomal recessive,270700];	RCV000206048.2 [benign]; 			914	960					ZFYVE26 (inh=AR pLI=0.00)
chr14	75476071	75476071	G	C	hom	het	hom		QUAL=37658;DP=442,431,571;MQM=59	EIF2B2	3'UTR	EIF2B2:NM_014239.3:3'UTR:MODIFIER:exon8/8:c.*180G>C:		rs4556	0.5176	0.0000	0/0/0	0.0970							606454 [EIF2B2 (provisional) Leukoencephalopathy with vanishing white matter,603896|Ovarioleukodystrophy,603896];	RCV000295805.1 [benign]; RCV000299748.1 [likely benign]; 			64	129					EIF2B2 (inh=AR pLI=0.00)
chr14	76045388	76045405	CCCAGCGTCTCGGTCCAT	-	wt	wt	het	anno_pathogenic_hgmd	QUAL=1687;DP=177,150,219;MQM=59	FLVCR2,LOC102724153	disruptive_inframe_deletion,sequence_feature,non_coding_transcript_exon	FLVCR2:NM_017791.2:disruptive_inframe_deletion:MODERATE:exon1/10:c.102_119delGGTCCATCCCAGCGTCTC:p.Val35_Ser40del,FLVCR2:NM_017791.2:sequence_feature:LOW:exon1/10:c.73_90delCCCAGCGTCTCGGTCCAT:,FLVCR2:NM_017791.2:sequence_feature:LOW:exon1/10:c.73_90delCCCAGCGTCTCGGTCCAT:,LOC102724153:NR_110552.1:non_coding_transcript_exon:MODIFIER:exon1/3:n.527_544delATGGACCGAGACGCTGGG:		rs548569935	0.0016	0.0029	0/0/0	0.0002							610865 [FLVCR2 (provisional) Proliferative vasculopathy and hydraencephaly-hydrocephaly syndrome,225790];		CD148840 [CLASS=DM MUT=ALT PHEN="Hydraencephaly" GENE=FLVCR2]; 	COSM1371174	0	7					FLVCR2 (inh=AR pLI=0.00), LOC102724153 (inh=n/a pLI=n/a)
chr14	77741394	77741394	T	C	hom	het	hom		QUAL=9414;DP=201,71,81;MQM=59	POMT2	3'UTR	POMT2:NM_013382.5:3'UTR:MODIFIER:exon21/21:c.*2325A>G:		rs11547793	0.2913	0.0000	0/0/0	0.2835							607439 [POMT2 (confirmed) Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,2,613150|Muscular dystrophy-dystroglycanopathy (congenital with mental retardation),type B,2,613156|Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,2,613158];	RCV000405359.1 [likely benign]; 			20	87					POMT2 (inh=AR pLI=0.00)
chr14	77741977	77741977	C	T	hom	het	hom		QUAL=20064;DP=312,210,254;MQM=59	POMT2	3'UTR	POMT2:NM_013382.5:3'UTR:MODIFIER:exon21/21:c.*1742G>A:		rs12894594	0.8522	0.0000	0/0/0	0.7411							607439 [POMT2 (confirmed) Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,2,613150|Muscular dystrophy-dystroglycanopathy (congenital with mental retardation),type B,2,613156|Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,2,613158];	RCV000342374.1 [benign]; 			163	56					POMT2 (inh=AR pLI=0.00)
chr14	77742218	77742218	C	T	hom	het	hom		QUAL=18940;DP=232,245,280;MQM=60	POMT2	3'UTR	POMT2:NM_013382.5:3'UTR:MODIFIER:exon21/21:c.*1501G>A:		rs4141640	0.8558	0.0000	0/0/0	0.1282							607439 [POMT2 (confirmed) Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,2,613150|Muscular dystrophy-dystroglycanopathy (congenital with mental retardation),type B,2,613156|Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,2,613158];	RCV000370357.1 [benign]; 			163	58					POMT2 (inh=AR pLI=0.00)
chr14	77743644	77743644	G	A	hom	het	hom		QUAL=10214;DP=141,92,151;MQM=60	POMT2	3'UTR	POMT2:NM_013382.5:3'UTR:MODIFIER:exon21/21:c.*75C>T:		rs1055592	0.2686	0.0000	0/0/0	0.0506							607439 [POMT2 (confirmed) Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,2,613150|Muscular dystrophy-dystroglycanopathy (congenital with mental retardation),type B,2,613156|Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,2,613158];	RCV000357869.1 [likely benign]; 			20	81					POMT2 (inh=AR pLI=0.00)
chr14	77745193	77745193	A	C	hom	het	hom		QUAL=23108;DP=126,339,480;MQM=59	POMT2	synonymous	POMT2:NM_013382.5:synonymous:LOW:exon19/21:c.1911T>G:p.Leu637Leu		rs3209079	0.8470	0.8176	40497/22244/3618	0.7953	-0.7790		T			1.69	607439 [POMT2 (confirmed) Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,2,613150|Muscular dystrophy-dystroglycanopathy (congenital with mental retardation),type B,2,613156|Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,2,613158];	RCV000118038.2 [benign]; RCV000153051.3 [benign]; 		COSM4148271	1095	417					POMT2 (inh=AR pLI=0.00)
chr14	77751925	77751925	C	T	hom	het	hom		QUAL=16953;DP=186,194,257;MQM=60	POMT2	synonymous	POMT2:NM_013382.5:synonymous:LOW:exon13/21:c.1383G>A:p.Arg461Arg		rs2270419	0.8582	0.8208	41097/22217/3920	0.7728							607439 [POMT2 (confirmed) Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,2,613150|Muscular dystrophy-dystroglycanopathy (congenital with mental retardation),type B,2,613156|Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,2,613158];	RCV000127577.2 [benign]; RCV000153056.3 [benign]; 		COSM4148272	1090	423					POMT2 (inh=AR pLI=0.00)
chr14	77893276	77893276	G	A	het	het	het		QUAL=10822;DP=339,270,341;MQM=60	VIPAS39	3'UTR	VIPAS39:NM_001193314.1:3'UTR:MODIFIER:exon20/20:c.*683C>T:,VIPAS39:NM_001193315.1:3'UTR:MODIFIER:exon20/20:c.*683C>T:,VIPAS39:NM_001193316.1:3'UTR:MODIFIER:exon19/19:c.*683C>T:,VIPAS39:NM_001193317.1:3'UTR:MODIFIER:exon20/20:c.*683C>T:,VIPAS39:NM_022067.3:3'UTR:MODIFIER:exon21/21:c.*683C>T:		rs4223	0.4896	0.0000	0/0/0	0.4777							613401 [VIPAS39 (provisional) Arthrogryposis,renal dysfunction,and cholestasis 2,613404];				58	110					VIPAS39 (inh=AR pLI=0.00)
chr14	77893431	77893431	A	G	hom	hom	hom		QUAL=28179;DP=346,245,267;MQM=59	VIPAS39	3'UTR	VIPAS39:NM_001193314.1:3'UTR:MODIFIER:exon20/20:c.*528T>C:,VIPAS39:NM_001193315.1:3'UTR:MODIFIER:exon20/20:c.*528T>C:,VIPAS39:NM_001193316.1:3'UTR:MODIFIER:exon19/19:c.*528T>C:,VIPAS39:NM_001193317.1:3'UTR:MODIFIER:exon20/20:c.*528T>C:,VIPAS39:NM_022067.3:3'UTR:MODIFIER:exon21/21:c.*528T>C:		rs8009177	0.9764	0.0000	0/0/0	0.8722							613401 [VIPAS39 (provisional) Arthrogryposis,renal dysfunction,and cholestasis 2,613404];				230	0					VIPAS39 (inh=AR pLI=0.00)
chr14	77923783	77923783	C	T	het	het	het		QUAL=12548;DP=376,332,426;MQM=60	VIPAS39	5'UTR,intron	VIPAS39:NM_001193314.1:5'UTR:MODIFIER:exon1/20:c.-346G>A:,VIPAS39:NM_001193317.1:5'UTR:MODIFIER:exon1/20:c.-123G>A:,VIPAS39:NM_001193315.1:intron:MODIFIER:exon1/19:c.-1+55G>A:,VIPAS39:NM_001193316.1:intron:MODIFIER:exon1/18:c.-1+55G>A:,VIPAS39:NM_022067.3:intron:MODIFIER:exon1/20:c.-272+55G>A:		rs11845345	0.1396	0.2265	285/37/0	0.0463							613401 [VIPAS39 (provisional) Arthrogryposis,renal dysfunction,and cholestasis 2,613404];				41	303					VIPAS39 (inh=AR pLI=0.00)
chr14	77973953	77973953	-	CA	hom	hom	hom		QUAL=14258;DP=206,132,128;MQM=58	SPTLC2	3'UTR	SPTLC2:NM_004863.3:3'UTR:MODIFIER:exon12/12:c.*4673_*4674insTG:	AluSz6	rs58831828	0.8512	0.0000	0/0/0	0.8270							605713 [SPTLC2 (provisional) Neuropathy,hereditary sensory and autonomic,type IC,613640];	RCV000263277.1 [benign]; 			183	41					SPTLC2 (inh=AD pLI=0.82)
chr14	77973982	77973982	T	C	hom	hom	hom		QUAL=19233;DP=312,133,144;MQM=59	SPTLC2	3'UTR	SPTLC2:NM_004863.3:3'UTR:MODIFIER:exon12/12:c.*4645A>G:		rs10132095	0.9451	0.0000	0/0/0	0.8985							605713 [SPTLC2 (provisional) Neuropathy,hereditary sensory and autonomic,type IC,613640];	RCV000316158.1 [benign]; 			225	3					SPTLC2 (inh=AD pLI=0.82)
chr14	77974181	77974181	C	A	hom	hom	hom		QUAL=9626;DP=178,55,62;MQM=59	SPTLC2	3'UTR	SPTLC2:NM_004863.3:3'UTR:MODIFIER:exon12/12:c.*4446G>T:		rs11159268	0.5962	0.0000	0/0/0	0.5989							605713 [SPTLC2 (provisional) Neuropathy,hereditary sensory and autonomic,type IC,613640];	RCV000376513.1 [benign]; 			88	111					SPTLC2 (inh=AD pLI=0.82)
chr14	77974990	77974990	C	T	hom	hom	hom		QUAL=27089;DP=409,215,219;MQM=60	SPTLC2	3'UTR	SPTLC2:NM_004863.3:3'UTR:MODIFIER:exon12/12:c.*3637G>A:		rs1063271	0.7690	0.0000	0/0/0	0.7442							605713 [SPTLC2 (provisional) Neuropathy,hereditary sensory and autonomic,type IC,613640];	RCV000360818.1 [benign]; 			151	72					SPTLC2 (inh=AD pLI=0.82)
chr14	77975015	77975015	A	T	hom	hom	hom		QUAL=23646;DP=343,169,200;MQM=60	SPTLC2	3'UTR	SPTLC2:NM_004863.3:3'UTR:MODIFIER:exon12/12:c.*3612T>A:		rs2364160	0.9475	0.0000	0/0/0	0.8645							605713 [SPTLC2 (provisional) Neuropathy,hereditary sensory and autonomic,type IC,613640];	RCV000268443.1 [benign]; 			230	0					SPTLC2 (inh=AD pLI=0.82)
chr14	77975103	77975103	T	G	hom	hom	hom		QUAL=18932;DP=285,131,160;MQM=60	SPTLC2	3'UTR	SPTLC2:NM_004863.3:3'UTR:MODIFIER:exon12/12:c.*3524A>C:		rs1063270	0.7762	0.0000	0/0/0	0.7446							605713 [SPTLC2 (provisional) Neuropathy,hereditary sensory and autonomic,type IC,613640];	RCV000359692.1 [benign]; 			150	73					SPTLC2 (inh=AD pLI=0.82)
chr14	77976325	77976325	T	C	hom	hom	hom		QUAL=21897;DP=320,144,192;MQM=60	SPTLC2	3'UTR	SPTLC2:NM_004863.3:3'UTR:MODIFIER:exon12/12:c.*2302A>G:		rs11159269	0.7606	0.0000	0/0/0	0.7418							605713 [SPTLC2 (provisional) Neuropathy,hereditary sensory and autonomic,type IC,613640];	RCV000333490.1 [benign]; 			151	72					SPTLC2 (inh=AD pLI=0.82)
chr14	78028803	78028803	A	G	hom	hom	hom		QUAL=12515;DP=167,91,123;MQM=60	SPTLC2	synonymous	SPTLC2:NM_004863.3:synonymous:LOW:exon6/12:c.786T>C:p.Asn262Asn		rs2364602	0.8375	0.9029	50110/29097/2098	0.8821	1.1100		T			5.32	605713 [SPTLC2 (provisional) Neuropathy,hereditary sensory and autonomic,type IC,613640];	RCV000294134.1 [benign]; 			1385	170					SPTLC2 (inh=AD pLI=0.82)
chr14	81562998	81562998	T	C	het	het	wt		QUAL=5322;DP=204,224,284;MQM=60	TSHR	synonymous	TSHR:NM_000369.2:synonymous:LOW:exon7/10:c.561T>C:p.Asn187Asn,TSHR:NM_001018036.2:synonymous:LOW:exon7/9:c.561T>C:p.Asn187Asn,TSHR:NM_001142626.2:synonymous:LOW:exon7/9:c.561T>C:p.Asn187Asn		rs2075179	0.3001	0.1913	3097/654/1528	0.1875							603372 [TSHR (confirmed) Hypothyroidism,congenital,nongoitrous,1 275200|Thyroid adenoma,hyperfunctioning,somatic|Hyperthyroidism,nonautoimmune,609152|Thyroid carcinoma with thyrotoxicosis|Hyperthyroidism,familial gestational,603373];	RCV000248392.1 [benign]; RCV000312123.1 [likely benign]; RCV000371329.1 [likely benign]; 		COSM147826, COSM3754139	44	392					TSHR (inh=AR+AD pLI=0.00)
chr14	81574959	81574959	A	G	het	het	het		QUAL=11607;DP=400,292,365;MQM=59	TSHR	synonymous,intron	TSHR:NM_001018036.2:synonymous:LOW:exon9/9:c.696A>G:p.Leu232Leu,TSHR:NM_001142626.2:synonymous:LOW:exon9/9:c.759A>G:p.Leu253Leu,TSHR:NM_000369.2:intron:MODIFIER:exon8/9:c.692+163A>G:		rs3783942	0.6112	0.6468	25939/14472/2079	0.6356							603372 [TSHR (confirmed) Hypothyroidism,congenital,nongoitrous,1 275200|Thyroid adenoma,hyperfunctioning,somatic|Hyperthyroidism,nonautoimmune,609152|Thyroid carcinoma with thyrotoxicosis|Hyperthyroidism,familial gestational,603373];				714	715					TSHR (inh=AR+AD pLI=0.00)
chr14	81575005	81575005	C	A	het	het	het		QUAL=16713;DP=600,383,508;MQM=60	TSHR	missense,intron	TSHR:NM_001018036.2:missense:MODERATE:exon9/9:c.742C>A:p.Arg248Ser,TSHR:NM_001142626.2:missense:MODERATE:exon9/9:c.805C>A:p.Arg269Ser,TSHR:NM_000369.2:intron:MODIFIER:exon8/9:c.692+209C>A:		rs3783941	0.6102	0.6465	25847/14428/2044	0.6299	-0.9880	T,T	T	B,B	T,T	3.45	603372 [TSHR (confirmed) Hypothyroidism,congenital,nongoitrous,1 275200|Thyroid adenoma,hyperfunctioning,somatic|Hyperthyroidism,nonautoimmune,609152|Thyroid carcinoma with thyrotoxicosis|Hyperthyroidism,familial gestational,603373];	RCV000122257.1 [not provided]; 			714	713					TSHR (inh=AR+AD pLI=0.00)
chr14	81610583	81610583	G	C	hom	hom	hom		QUAL=16098;DP=186,147,165;MQM=60	TSHR	missense	TSHR:NM_000369.2:missense:MODERATE:exon10/10:c.2181G>C:p.Glu727Asp		rs1991517	0.8968	0.9004	49233/27565/4600	0.8936	-0.1250	T,T,T	T	B	T,T	0.01	603372 [TSHR (confirmed) Hypothyroidism,congenital,nongoitrous,1 275200|Thyroid adenoma,hyperfunctioning,somatic|Hyperthyroidism,nonautoimmune,609152|Thyroid carcinoma with thyrotoxicosis|Hyperthyroidism,familial gestational,603373];	RCV000122254.2 [benign]; RCV000302729.1 [likely benign]; RCV000392451.1 [likely benign]; 	CM994612 [CLASS=DFP MUT=REF PHEN="Toxic multinodular goitre association with" GENE=TSHR]; 		1308	206					TSHR (inh=AR+AD pLI=0.00)
chr14	81610869	81610869	C	A	wt	het	wt		QUAL=1798;DP=308,188,320;MQM=60	TSHR	3'UTR	TSHR:NM_000369.2:3'UTR:MODIFIER:exon10/10:c.*172C>A:		rs2268477	0.2432	0.0000	0/0/0	0.1584							603372 [TSHR (confirmed) Hypothyroidism,congenital,nongoitrous,1 275200|Thyroid adenoma,hyperfunctioning,somatic|Hyperthyroidism,nonautoimmune,609152|Thyroid carcinoma with thyrotoxicosis|Hyperthyroidism,familial gestational,603373];	RCV000279898.1 [likely benign]; RCV000337203.1 [likely benign]; 			2	35					TSHR (inh=AR+AD pLI=0.00)
chr14	81610942	81610942	C	T	het	hom	het		QUAL=13161;DP=304,159,269;MQM=59	TSHR	3'UTR	TSHR:NM_000369.2:3'UTR:MODIFIER:exon10/10:c.*245C>T:		rs7144481	0.8433	0.0000	0/0/0	0.8596							603372 [TSHR (confirmed) Hypothyroidism,congenital,nongoitrous,1 275200|Thyroid adenoma,hyperfunctioning,somatic|Hyperthyroidism,nonautoimmune,609152|Thyroid carcinoma with thyrotoxicosis|Hyperthyroidism,familial gestational,603373];	RCV000340818.1 [likely benign]; RCV000398726.1 [likely benign]; 			176	51					TSHR (inh=AR+AD pLI=0.00)
chr14	81611849	81611849	T	A	het	hom	het		QUAL=12124;DP=331,135,189;MQM=59	TSHR	3'UTR	TSHR:NM_000369.2:3'UTR:MODIFIER:exon10/10:c.*1152T>A:		rs2288494	0.8472	0.0000	0/0/0	0.3084							603372 [TSHR (confirmed) Hypothyroidism,congenital,nongoitrous,1 275200|Thyroid adenoma,hyperfunctioning,somatic|Hyperthyroidism,nonautoimmune,609152|Thyroid carcinoma with thyrotoxicosis|Hyperthyroidism,familial gestational,603373];	RCV000288117.1 [likely benign]; RCV000396098.1 [likely benign]; 			176	51					TSHR (inh=AR+AD pLI=0.00)
chr14	81611850	81611850	-	T	het	hom	het		QUAL=12124;DP=331,135,189;MQM=59	TSHR	3'UTR	TSHR:NM_000369.2:3'UTR:MODIFIER:exon10/10:c.*1154dupT:		rs3214569	0.8476	0.0000	0/0/0	0.5683							603372 [TSHR (confirmed) Hypothyroidism,congenital,nongoitrous,1 275200|Thyroid adenoma,hyperfunctioning,somatic|Hyperthyroidism,nonautoimmune,609152|Thyroid carcinoma with thyrotoxicosis|Hyperthyroidism,familial gestational,603373];	RCV000345465.1 [likely benign]; RCV000400446.1 [likely benign]; 			176	51					TSHR (inh=AR+AD pLI=0.00)
chr14	81611919	81611919	G	C	het	het	het		QUAL=12577;DP=429,203,256;MQM=59	TSHR	3'UTR	TSHR:NM_000369.2:3'UTR:MODIFIER:exon10/10:c.*1222G>C:		rs2288495	0.2931	0.0000	0/0/0	0.4147							603372 [TSHR (confirmed) Hypothyroidism,congenital,nongoitrous,1 275200|Thyroid adenoma,hyperfunctioning,somatic|Hyperthyroidism,nonautoimmune,609152|Thyroid carcinoma with thyrotoxicosis|Hyperthyroidism,familial gestational,603373];	RCV000310384.1 [likely benign]; RCV000349021.1 [likely benign]; 			66	107					TSHR (inh=AR+AD pLI=0.00)
chr14	81612114	81612114	T	C	het	het	het		QUAL=9036;DP=241,178,210;MQM=60	TSHR	3'UTR	TSHR:NM_000369.2:3'UTR:MODIFIER:exon10/10:c.*1417T>C:		rs2288496	0.2935	0.0000	0/0/0	0.4150							603372 [TSHR (confirmed) Hypothyroidism,congenital,nongoitrous,1 275200|Thyroid adenoma,hyperfunctioning,somatic|Hyperthyroidism,nonautoimmune,609152|Thyroid carcinoma with thyrotoxicosis|Hyperthyroidism,familial gestational,603373];	RCV000299426.1 [likely benign]; RCV000356567.1 [likely benign]; 			66	106					TSHR (inh=AR+AD pLI=0.00)
chr14	88399488	88399488	A	C	wt	het	wt		QUAL=959;DP=220,76,99;MQM=60	GALC	3'UTR	GALC:NM_000153.3:3'UTR:MODIFIER:exon17/17:c.*1588T>G:,GALC:NM_001201401.1:3'UTR:MODIFIER:exon16/16:c.*1588T>G:,GALC:NM_001201402.1:3'UTR:MODIFIER:exon17/17:c.*1588T>G:	L1ME2	rs17198	0.4886	0.0000	0/0/0	0.0919							606890 [GALC (confirmed) Krabbe disease,245200];	RCV000400503.1 [benign]; 			66	86					GALC (inh=AR pLI=0.00)
chr14	88399623	88399623	T	C	hom	het	hom		QUAL=19205;DP=265,160,258;MQM=60	GALC	3'UTR	GALC:NM_000153.3:3'UTR:MODIFIER:exon17/17:c.*1453A>G:,GALC:NM_001201401.1:3'UTR:MODIFIER:exon16/16:c.*1453A>G:,GALC:NM_001201402.1:3'UTR:MODIFIER:exon17/17:c.*1453A>G:	L1ME2	rs405567	0.4479	0.0000	0/0/0	0.0744							606890 [GALC (confirmed) Krabbe disease,245200];	RCV000358158.1 [benign]; 			56	102					GALC (inh=AR pLI=0.00)
chr14	88399801	88399801	C	T	wt	het	wt		QUAL=478;DP=314,57,101;MQM=60	GALC	3'UTR	GALC:NM_000153.3:3'UTR:MODIFIER:exon17/17:c.*1275G>A:,GALC:NM_001201401.1:3'UTR:MODIFIER:exon16/16:c.*1275G>A:,GALC:NM_001201402.1:3'UTR:MODIFIER:exon17/17:c.*1275G>A:	L1ME2	rs1042042	0.4888	0.0000	0/0/0	0.1029							606890 [GALC (confirmed) Krabbe disease,245200];	RCV000304690.1 [benign]; 			81	116					GALC (inh=AR pLI=0.00)
chr14	88399888	88399890	ATC	-	wt	het	wt		QUAL=697;DP=316,66,81;MQM=60	GALC	3'UTR	GALC:NM_000153.3:3'UTR:MODIFIER:exon17/17:c.*1186_*1188delGAT:,GALC:NM_001201401.1:3'UTR:MODIFIER:exon16/16:c.*1186_*1188delGAT:,GALC:NM_001201402.1:3'UTR:MODIFIER:exon17/17:c.*1186_*1188delGAT:		rs141199615	0.4934	0.0000	0/0/0	0.4779							606890 [GALC (confirmed) Krabbe disease,245200];	RCV000361752.1 [benign]; 			80	117					GALC (inh=AR pLI=0.00)
chr14	88399950	88399950	C	T	wt	het	wt		QUAL=955;DP=301,83,81;MQM=60	GALC	3'UTR	GALC:NM_000153.3:3'UTR:MODIFIER:exon17/17:c.*1126G>A:,GALC:NM_001201401.1:3'UTR:MODIFIER:exon16/16:c.*1126G>A:,GALC:NM_001201402.1:3'UTR:MODIFIER:exon17/17:c.*1126G>A:		rs1042035	0.0763	0.0000	0/0/0	0.0197							606890 [GALC (confirmed) Krabbe disease,245200];	RCV000267767.1 [likely benign]; 			1	57					GALC (inh=AR pLI=0.00)
chr14	88400087	88400087	C	T	hom	hom	hom		QUAL=27201;DP=512,144,179;MQM=60	GALC	3'UTR	GALC:NM_000153.3:3'UTR:MODIFIER:exon17/17:c.*989G>A:,GALC:NM_001201401.1:3'UTR:MODIFIER:exon16/16:c.*989G>A:,GALC:NM_001201402.1:3'UTR:MODIFIER:exon17/17:c.*989G>A:		rs370559	0.9409	0.0000	0/0/0	0.1455							606890 [GALC (confirmed) Krabbe disease,245200];	RCV000322846.1 [benign]; 			353	3					GALC (inh=AR pLI=0.00)
chr14	88400353	88400353	C	T	hom	het	hom		QUAL=36486;DP=571,311,432;MQM=60	GALC	3'UTR	GALC:NM_000153.3:3'UTR:MODIFIER:exon17/17:c.*723G>A:,GALC:NM_001201401.1:3'UTR:MODIFIER:exon16/16:c.*723G>A:,GALC:NM_001201402.1:3'UTR:MODIFIER:exon17/17:c.*723G>A:		rs412915	0.4475	0.4363	1083/333/34	0.1101							606890 [GALC (confirmed) Krabbe disease,245200];	RCV000264088.1 [benign]; 			583	1280					GALC (inh=AR pLI=0.00)
chr14	88400449	88400449	T	C	hom	hom	hom		QUAL=26941;DP=543,141,179;MQM=60	GALC	3'UTR	GALC:NM_000153.3:3'UTR:MODIFIER:exon17/17:c.*627A>G:,GALC:NM_001201401.1:3'UTR:MODIFIER:exon16/16:c.*627A>G:,GALC:NM_001201402.1:3'UTR:MODIFIER:exon17/17:c.*627A>G:		rs413750	0.9409	0.0000	0/0/0	0.1796							606890 [GALC (confirmed) Krabbe disease,245200];	RCV000373804.1 [benign]; 			378	5					GALC (inh=AR pLI=0.00)
chr14	88400450	88400450	G	A	hom	het	hom		QUAL=26941;DP=543,141,179;MQM=60	GALC	3'UTR	GALC:NM_000153.3:3'UTR:MODIFIER:exon17/17:c.*626C>T:,GALC:NM_001201401.1:3'UTR:MODIFIER:exon16/16:c.*626C>T:,GALC:NM_001201402.1:3'UTR:MODIFIER:exon17/17:c.*626C>T:		rs432946	0.4475	0.0000	0/0/0	0.3097							606890 [GALC (confirmed) Krabbe disease,245200];	RCV000279227.1 [benign]; 			94	171					GALC (inh=AR pLI=0.00)
chr14	88400486	88400486	A	G	wt	het	wt		QUAL=1635;DP=553,120,165;MQM=60	GALC	3'UTR	GALC:NM_000153.3:3'UTR:MODIFIER:exon17/17:c.*590T>C:,GALC:NM_001201401.1:3'UTR:MODIFIER:exon16/16:c.*590T>C:,GALC:NM_001201402.1:3'UTR:MODIFIER:exon17/17:c.*590T>C:		rs1042029	0.4934	0.0000	0/0/0	0.0919							606890 [GALC (confirmed) Krabbe disease,245200];	RCV000388884.1 [benign]; 			112	164					GALC (inh=AR pLI=0.00)
chr14	88401213	88401213	T	C	hom	hom	hom	pred_pathogenic;anno_pathogenic_hgmd	QUAL=28141;DP=326,243,312;MQM=59	GALC	missense	GALC:NM_000153.3:missense:MODERATE:exon17/17:c.1921A>G:p.Thr641Ala,GALC:NM_001201401.1:missense:MODERATE:exon16/16:c.1852A>G:p.Thr618Ala,GALC:NM_001201402.1:missense:MODERATE:exon17/17:c.1843A>G:p.Thr615Ala		rs421262	0.9407	0.9828	58239/33275/3619	0.9489	0.5190	T,T,T,T	T	B	D,D,D	0.01	606890 [GALC (confirmed) Krabbe disease,245200];	RCV000078197.6 [benign]; RCV000290698.1 [benign]; 	CM950521 [CLASS=DM? MUT=REF PHEN="Krabbe disease" GENE=GALC]; 		3215	18	2	[2] old entry - no details available			GALC (inh=AR pLI=0.00)
chr14	88407734	88407734	G	C	hom	hom	hom		QUAL=8703;DP=185,57,82;MQM=59	GALC	splice_region&intron	GALC:NM_000153.3:splice_region&intron:LOW:exon15/16:c.1834+5C>G:,GALC:NM_001201401.1:splice_region&intron:LOW:exon14/15:c.1765+5C>G:,GALC:NM_001201402.1:splice_region&intron:LOW:exon15/16:c.1756+5C>G:		rs448805	0.9409	0.9830	57978/33136/3573	0.9009							606890 [GALC (confirmed) Krabbe disease,245200];	RCV000078196.6 [benign]; RCV000398764.1 [benign]; 			3211	20					GALC (inh=AR pLI=0.00)
chr14	88407875	88407875	T	A	hom	hom	hom		QUAL=21043;DP=308,134,197;MQM=60	GALC	synonymous	GALC:NM_000153.3:synonymous:LOW:exon15/17:c.1698A>T:p.Val566Val,GALC:NM_001201401.1:synonymous:LOW:exon14/16:c.1629A>T:p.Val543Val,GALC:NM_001201402.1:synonymous:LOW:exon15/17:c.1620A>T:p.Val540Val		rs421466	0.9409	0.9828	58347/33328/3624	0.9247							606890 [GALC (confirmed) Krabbe disease,245200];	RCV000078195.6 [benign]; RCV000360908.1 [benign]; 			3211	18					GALC (inh=AR pLI=0.00)
chr14	88407888	88407888	A	G	hom	het	hom	pred_pathogenic	QUAL=16485;DP=277,122,182;MQM=60	GALC	missense	GALC:NM_000153.3:missense:MODERATE:exon15/17:c.1685T>C:p.Ile562Thr,GALC:NM_001201401.1:missense:MODERATE:exon14/16:c.1616T>C:p.Ile539Thr,GALC:NM_001201402.1:missense:MODERATE:exon15/17:c.1607T>C:p.Ile536Thr		rs398607	0.4475	0.4406	12358/7521/1838	0.4319	9.2700	D,D,T,D,D	T	B,B,B,B	D,D,D,D	22.90	606890 [GALC (confirmed) Krabbe disease,245200];	RCV000078194.6 [benign]; RCV000399633.1 [benign]; 	CM140252 [CLASS=DFP MUT=ALT PHEN="Krabbe disease late-onset" GENE=GALC]; 	COSM3754140	713	1574					GALC (inh=AR pLI=0.00)
chr14	88411947	88411947	T	C	hom	hom	hom		QUAL=9979;DP=186,62,86;MQM=59	GALC	synonymous	GALC:NM_000153.3:synonymous:LOW:exon14/17:c.1620A>G:p.Thr540Thr,GALC:NM_001201401.1:synonymous:LOW:exon13/16:c.1551A>G:p.Thr517Thr,GALC:NM_001201402.1:synonymous:LOW:exon14/17:c.1542A>G:p.Thr514Thr		rs367327	0.9427	0.9832	58378/33309/3665	0.9156							606890 [GALC (confirmed) Krabbe disease,245200];	RCV000153295.2 [benign]; 			3218	18					GALC (inh=AR pLI=0.00)
chr14	88414211	88414211	G	A	hom	het	het		QUAL=13369;DP=218,221,303;MQM=60	GALC	synonymous	GALC:NM_000153.3:synonymous:LOW:exon13/17:c.1350C>T:p.Ser450Ser,GALC:NM_001201401.1:synonymous:LOW:exon12/16:c.1281C>T:p.Ser427Ser,GALC:NM_001201402.1:synonymous:LOW:exon13/17:c.1272C>T:p.Ser424Ser		rs398076	0.3666	0.3734	8642/5333/905	0.3678							606890 [GALC (confirmed) Krabbe disease,245200];	RCV000078191.6 [benign]; RCV000277817.1 [benign]; 		COSM3999388	497	1510					GALC (inh=AR pLI=0.00)
chr14	88417096	88417096	A	-	hom	hom	hom		QUAL=12020;DP=186,87,160;MQM=59	GALC	splice_region&intron	GALC:NM_000153.3:splice_region&intron:LOW:exon10/16:c.1162-4delT:,GALC:NM_001201401.1:splice_region&intron:LOW:exon9/15:c.1093-4delT:,GALC:NM_001201402.1:splice_region&intron:LOW:exon10/16:c.1084-4delT:		rs11300320;rs398099546	0.9483	0.9775	50900/28362/3134	0.8639							606890 [GALC (confirmed) Krabbe disease,245200];	RCV000078190.4 [benign]; RCV000292380.1 [benign]; 			2950	245	2	[2] Peter Bauer 27.08.2014			GALC (inh=AR pLI=0.00)
chr14	88442712	88442712	C	T	wt	het	wt	pred_pathogenic	QUAL=2959;DP=215,255,359;MQM=60	GALC	missense	GALC:NM_000153.3:missense:MODERATE:exon7/17:c.742G>A:p.Asp248Asn,GALC:NM_001201401.1:missense:MODERATE:exon6/16:c.673G>A:p.Asp225Asn,GALC:NM_001201402.1:missense:MODERATE:exon7/17:c.664G>A:p.Asp222Asn		rs34362748	0.0795	0.1244	1066/749/4	0.1226	5.2960	D,D,D,D,T,.	T	B,P,B,B,B	D,D,D,D	27.80	606890 [GALC (confirmed) Krabbe disease,245200];	RCV000078206.5 [benign]; RCV000340530.1 [likely benign]; 		COSM3765774	72	804					GALC (inh=AR pLI=0.00)
chr14	88459434	88459434	G	T	wt	het	wt		QUAL=492;DP=41,49,67;MQM=60	GALC	synonymous,intron	GALC:NM_000153.3:synonymous:LOW:exon1/17:c.75C>A:p.Gly25Gly,GALC:NM_001201401.1:synonymous:LOW:exon1/16:c.75C>A:p.Gly25Gly,GALC:NM_001201402.1:intron:MODIFIER:exon1/16:c.117+293C>A:		rs111976362	0.0785	0.1427	167/104/1	0.0797							606890 [GALC (confirmed) Krabbe disease,245200];	RCV000078207.5 [benign]; RCV000286631.1 [likely benign]; 		COSM1128184	67	791					GALC (inh=AR pLI=0.00)
chr14	88459448	88459448	C	G	wt	het	wt	pred_pathogenic	QUAL=657;DP=21,62,86;MQM=60	GALC	missense,intron	GALC:NM_000153.3:missense:MODERATE:exon1/17:c.61G>C:p.Ala21Pro,GALC:NM_001201401.1:missense:MODERATE:exon1/16:c.61G>C:p.Ala21Pro,GALC:NM_001201402.1:intron:MODIFIER:exon1/16:c.117+279G>C:		rs111887056	0.0789	0.1661	311/208/1	0.0839	0.6530	T,D,.	T	D,D,D	D,D	29.90	606890 [GALC (confirmed) Krabbe disease,245200];	RCV000078205.5 [benign]; RCV000322914.1 [likely benign]; 		COSM3754142	68	798					GALC (inh=AR pLI=0.00)
chr14	88459467	88459467	C	G	wt	het	wt		QUAL=710;DP=38,73,100;MQM=60	GALC	synonymous,intron	GALC:NM_000153.3:synonymous:LOW:exon1/17:c.42G>C:p.Ala14Ala,GALC:NM_001201401.1:synonymous:LOW:exon1/16:c.42G>C:p.Ala14Ala,GALC:NM_001201402.1:intron:MODIFIER:exon1/16:c.117+260G>C:		rs112992946	0.0787	0.1644	316/227/1	0.0867							606890 [GALC (confirmed) Krabbe disease,245200];	RCV000078202.5 [benign]; RCV000282939.1 [likely benign]; 			70	799					GALC (inh=AR pLI=0.00)
chr14	88459795	88459795	C	T	wt	wt	het		QUAL=5305;DP=573,286,414;MQM=60	GALC	missense	GALC:NM_001201402.1:missense:MODERATE:exon1/17:c.49G>A:p.Ala17Thr		rs73312836	0.0767	0.0474	19/5/3	0.0171	-0.4220	T	T		T	8.20	606890 [GALC (confirmed) Krabbe disease,245200];				17	451					GALC (inh=AR pLI=0.00)
chr14	89042180	89042180	T	G	hom	het	hom		QUAL=12496;DP=187,137,146;MQM=59	ZC3H14	splice_region&intron	ZC3H14:NM_024824.4:splice_region&intron:LOW:exon7/16:c.1023-4T>G:,ZC3H14:NM_001160103.1:splice_region&intron:LOW:exon7/16:c.1023-4T>G:,ZC3H14:NM_001160104.1:splice_region&intron:LOW:exon7/16:c.1023-4T>G:,ZC3H14:NM_001326295.1:splice_region&intron:LOW:exon7/14:c.1023-4T>G:,ZC3H14:NM_001326296.1:splice_region&intron:LOW:exon7/15:c.1023-4T>G:,ZC3H14:NM_001326297.1:splice_region&intron:LOW:exon7/16:c.921-4T>G:,ZC3H14:NM_001326298.1:splice_region&intron:LOW:exon7/13:c.1023-4T>G:,ZC3H14:NM_001326299.1:splice_region&intron:LOW:exon7/15:c.1023-4T>G:,ZC3H14:NM_001326300.1:splice_region&intron:LOW:exon6/15:c.558-4T>G:,ZC3H14:NM_001326301.1:splice_region&intron:LOW:exon7/15:c.921-4T>G:,ZC3H14:NM_001326302.1:splice_region&intron:LOW:exon6/15:c.558-4T>G:,ZC3H14:NM_001326303.1:splice_region&intron:LOW:exon7/13:c.921-4T>G:,ZC3H14:NM_001326304.1:splice_region&intron:LOW:exon6/13:c.558-4T>G:,ZC3H14:NM_001326305.1:splice_region&intron:LOW:exon6/14:c.558-4T>G:,ZC3H14:NM_001326306.1:splice_region&intron:LOW:exon7/12:c.1023-4T>G:,ZC3H14:NM_001326307.1:splice_region&intron:LOW:exon7/15:c.1023-4T>G:,ZC3H14:NM_001326308.1:splice_region&intron:LOW:exon6/13:c.558-4T>G:,ZC3H14:NM_001326309.1:splice_region&intron:LOW:exon6/12:c.558-4T>G:,ZC3H14:NM_001326310.1:splice_region&intron:LOW:exon7/16:c.1023-4T>G:,ZC3H14:NM_001326311.1:splice_region&intron:LOW:exon6/12:c.558-4T>G:,ZC3H14:NM_001326312.1:splice_region&intron:LOW:exon7/15:c.1023-4T>G:,ZC3H14:NM_001326313.1:splice_region&intron:LOW:exon7/12:c.1023-4T>G:,ZC3H14:NM_001326314.1:splice_region&intron:LOW:exon6/14:c.558-4T>G:,ZC3H14:NM_001326315.1:splice_region&intron:LOW:exon7/16:c.921-4T>G:,ZC3H14:NM_207660.3:splice_region&intron:LOW:exon7/13:c.1023-4T>G:,ZC3H14:NR_136936.1:splice_region&intron:LOW:exon7/15:n.1248-4T>G:,ZC3H14:NM_001326316.1:splice_region&intron:LOW:exon7/16:c.921-4T>G:,ZC3H14:NM_207661.2:splice_region&intron:LOW:exon7/14:c.921-4T>G:		rs1469602	0.4858	0.6188	24782/17739/560	0.6151							613279 [ZC3H14 (provisional) Mental retardation,autosomal recessive 56,617125];	RCV000118883.2 [likely benign]; 		COSM3999396	754	640					ZC3H14 (inh=n/a pLI=1.00)
chr14	89078927	89078927	A	G	hom	hom	hom		QUAL=10975;DP=182,65,73;MQM=60	ZC3H14	3'UTR,non_coding_transcript_exon	ZC3H14:NM_024824.4:3'UTR:MODIFIER:exon17/17:c.*832A>G:,ZC3H14:NM_001160103.1:3'UTR:MODIFIER:exon17/17:c.*832A>G:,ZC3H14:NM_001160104.1:3'UTR:MODIFIER:exon17/17:c.*832A>G:,ZC3H14:NM_001326295.1:3'UTR:MODIFIER:exon15/15:c.*832A>G:,ZC3H14:NM_001326296.1:3'UTR:MODIFIER:exon16/16:c.*832A>G:,ZC3H14:NM_001326297.1:3'UTR:MODIFIER:exon17/17:c.*832A>G:,ZC3H14:NM_001326298.1:3'UTR:MODIFIER:exon14/14:c.*832A>G:,ZC3H14:NM_001326299.1:3'UTR:MODIFIER:exon16/16:c.*832A>G:,ZC3H14:NM_001326300.1:3'UTR:MODIFIER:exon16/16:c.*832A>G:,ZC3H14:NM_001326301.1:3'UTR:MODIFIER:exon16/16:c.*832A>G:,ZC3H14:NM_001326302.1:3'UTR:MODIFIER:exon16/16:c.*832A>G:,ZC3H14:NM_001326303.1:3'UTR:MODIFIER:exon14/14:c.*832A>G:,ZC3H14:NM_001326304.1:3'UTR:MODIFIER:exon14/14:c.*832A>G:,ZC3H14:NM_001326305.1:3'UTR:MODIFIER:exon15/15:c.*832A>G:,ZC3H14:NM_001326306.1:3'UTR:MODIFIER:exon13/13:c.*832A>G:,ZC3H14:NM_001326307.1:3'UTR:MODIFIER:exon16/16:c.*832A>G:,ZC3H14:NM_001326308.1:3'UTR:MODIFIER:exon14/14:c.*832A>G:,ZC3H14:NM_001326309.1:3'UTR:MODIFIER:exon13/13:c.*832A>G:,ZC3H14:NM_001326310.1:3'UTR:MODIFIER:exon17/17:c.*832A>G:,ZC3H14:NM_001326311.1:3'UTR:MODIFIER:exon13/13:c.*832A>G:,ZC3H14:NM_001326312.1:3'UTR:MODIFIER:exon16/16:c.*832A>G:,ZC3H14:NM_001326313.1:3'UTR:MODIFIER:exon13/13:c.*832A>G:,ZC3H14:NM_001326314.1:3'UTR:MODIFIER:exon15/15:c.*832A>G:,ZC3H14:NM_001326315.1:3'UTR:MODIFIER:exon17/17:c.*832A>G:,ZC3H14:NM_207660.3:3'UTR:MODIFIER:exon14/14:c.*832A>G:,ZC3H14:NM_001326316.1:3'UTR:MODIFIER:exon17/17:c.*832A>G:,ZC3H14:NM_207661.2:3'UTR:MODIFIER:exon15/15:c.*832A>G:,ZC3H14:NM_207662.3:3'UTR:MODIFIER:exon7/7:c.*832A>G:,ZC3H14:NR_136936.1:non_coding_transcript_exon:MODIFIER:exon16/16:n.3108A>G:		rs8008847	0.9103	0.0000	0/0/0	0.1773							613279 [ZC3H14 (provisional) Mental retardation,autosomal recessive 56,617125];				223	7					ZC3H14 (inh=n/a pLI=1.00)
chr14	89079324	89079324	A	-	wt	het	wt		QUAL=263;DP=179,74,95;MQM=59	ZC3H14	3'UTR,non_coding_transcript_exon	ZC3H14:NM_024824.4:3'UTR:MODIFIER:exon17/17:c.*1243delA:,ZC3H14:NM_001160103.1:3'UTR:MODIFIER:exon17/17:c.*1243delA:,ZC3H14:NM_001160104.1:3'UTR:MODIFIER:exon17/17:c.*1243delA:,ZC3H14:NM_001326295.1:3'UTR:MODIFIER:exon15/15:c.*1243delA:,ZC3H14:NM_001326296.1:3'UTR:MODIFIER:exon16/16:c.*1243delA:,ZC3H14:NM_001326297.1:3'UTR:MODIFIER:exon17/17:c.*1243delA:,ZC3H14:NM_001326298.1:3'UTR:MODIFIER:exon14/14:c.*1243delA:,ZC3H14:NM_001326299.1:3'UTR:MODIFIER:exon16/16:c.*1243delA:,ZC3H14:NM_001326300.1:3'UTR:MODIFIER:exon16/16:c.*1243delA:,ZC3H14:NM_001326301.1:3'UTR:MODIFIER:exon16/16:c.*1243delA:,ZC3H14:NM_001326302.1:3'UTR:MODIFIER:exon16/16:c.*1243delA:,ZC3H14:NM_001326303.1:3'UTR:MODIFIER:exon14/14:c.*1243delA:,ZC3H14:NM_001326304.1:3'UTR:MODIFIER:exon14/14:c.*1243delA:,ZC3H14:NM_001326305.1:3'UTR:MODIFIER:exon15/15:c.*1243delA:,ZC3H14:NM_001326306.1:3'UTR:MODIFIER:exon13/13:c.*1243delA:,ZC3H14:NM_001326307.1:3'UTR:MODIFIER:exon16/16:c.*1243delA:,ZC3H14:NM_001326308.1:3'UTR:MODIFIER:exon14/14:c.*1243delA:,ZC3H14:NM_001326309.1:3'UTR:MODIFIER:exon13/13:c.*1243delA:,ZC3H14:NM_001326310.1:3'UTR:MODIFIER:exon17/17:c.*1243delA:,ZC3H14:NM_001326311.1:3'UTR:MODIFIER:exon13/13:c.*1243delA:,ZC3H14:NM_001326312.1:3'UTR:MODIFIER:exon16/16:c.*1243delA:,ZC3H14:NM_001326313.1:3'UTR:MODIFIER:exon13/13:c.*1243delA:,ZC3H14:NM_001326314.1:3'UTR:MODIFIER:exon15/15:c.*1243delA:,ZC3H14:NM_001326315.1:3'UTR:MODIFIER:exon17/17:c.*1243delA:,ZC3H14:NM_207660.3:3'UTR:MODIFIER:exon14/14:c.*1243delA:,ZC3H14:NM_001326316.1:3'UTR:MODIFIER:exon17/17:c.*1243delA:,ZC3H14:NM_207661.2:3'UTR:MODIFIER:exon15/15:c.*1243delA:,ZC3H14:NM_207662.3:3'UTR:MODIFIER:exon7/7:c.*1243delA:,ZC3H14:NR_136936.1:non_coding_transcript_exon:MODIFIER:exon16/16:n.3519delA:		rs35822845;rs67812081	0.4209	0.0000	0/0/0	0.1237							613279 [ZC3H14 (provisional) Mental retardation,autosomal recessive 56,617125];				10	105					ZC3H14 (inh=n/a pLI=1.00)
chr14	89079323	89079323	-	A	wt	wt	het		QUAL=263;DP=179,74,95;MQM=59	ZC3H14	3'UTR,non_coding_transcript_exon	ZC3H14:NM_024824.4:3'UTR:MODIFIER:exon17/17:c.*1243dupA:,ZC3H14:NM_001160103.1:3'UTR:MODIFIER:exon17/17:c.*1243dupA:,ZC3H14:NM_001160104.1:3'UTR:MODIFIER:exon17/17:c.*1243dupA:,ZC3H14:NM_001326295.1:3'UTR:MODIFIER:exon15/15:c.*1243dupA:,ZC3H14:NM_001326296.1:3'UTR:MODIFIER:exon16/16:c.*1243dupA:,ZC3H14:NM_001326297.1:3'UTR:MODIFIER:exon17/17:c.*1243dupA:,ZC3H14:NM_001326298.1:3'UTR:MODIFIER:exon14/14:c.*1243dupA:,ZC3H14:NM_001326299.1:3'UTR:MODIFIER:exon16/16:c.*1243dupA:,ZC3H14:NM_001326300.1:3'UTR:MODIFIER:exon16/16:c.*1243dupA:,ZC3H14:NM_001326301.1:3'UTR:MODIFIER:exon16/16:c.*1243dupA:,ZC3H14:NM_001326302.1:3'UTR:MODIFIER:exon16/16:c.*1243dupA:,ZC3H14:NM_001326303.1:3'UTR:MODIFIER:exon14/14:c.*1243dupA:,ZC3H14:NM_001326304.1:3'UTR:MODIFIER:exon14/14:c.*1243dupA:,ZC3H14:NM_001326305.1:3'UTR:MODIFIER:exon15/15:c.*1243dupA:,ZC3H14:NM_001326306.1:3'UTR:MODIFIER:exon13/13:c.*1243dupA:,ZC3H14:NM_001326307.1:3'UTR:MODIFIER:exon16/16:c.*1243dupA:,ZC3H14:NM_001326308.1:3'UTR:MODIFIER:exon14/14:c.*1243dupA:,ZC3H14:NM_001326309.1:3'UTR:MODIFIER:exon13/13:c.*1243dupA:,ZC3H14:NM_001326310.1:3'UTR:MODIFIER:exon17/17:c.*1243dupA:,ZC3H14:NM_001326311.1:3'UTR:MODIFIER:exon13/13:c.*1243dupA:,ZC3H14:NM_001326312.1:3'UTR:MODIFIER:exon16/16:c.*1243dupA:,ZC3H14:NM_001326313.1:3'UTR:MODIFIER:exon13/13:c.*1243dupA:,ZC3H14:NM_001326314.1:3'UTR:MODIFIER:exon15/15:c.*1243dupA:,ZC3H14:NM_001326315.1:3'UTR:MODIFIER:exon17/17:c.*1243dupA:,ZC3H14:NM_207660.3:3'UTR:MODIFIER:exon14/14:c.*1243dupA:,ZC3H14:NM_001326316.1:3'UTR:MODIFIER:exon17/17:c.*1243dupA:,ZC3H14:NM_207661.2:3'UTR:MODIFIER:exon15/15:c.*1243dupA:,ZC3H14:NM_207662.3:3'UTR:MODIFIER:exon7/7:c.*1243dupA:,ZC3H14:NR_136936.1:non_coding_transcript_exon:MODIFIER:exon16/16:n.3519dupA:			0.0000	0.0000	0/0/0	0.0194							613279 [ZC3H14 (provisional) Mental retardation,autosomal recessive 56,617125];				1	45					ZC3H14 (inh=n/a pLI=1.00)
chr14	92347680	92347680	A	G	hom	hom	het		QUAL=25913;DP=322,304,457;MQM=59	FBLN5	synonymous	FBLN5:NM_006329.3:synonymous:LOW:exon9/11:c.945T>C:p.Ile315Ile		rs2430347	0.7849	0.7609	35359/17889/3216	0.7554							604580 [FBLN5 (confirmed) Cutis laxa,autosomal recessive,type IA,219100|Cutis laxa,autosomal dominant 2,614434|Macular degeneration,age-related,3,608895|Neuropathy,hereditary,with or without age-related macular degeneration,608895];	RCV000150685.3 [benign]; RCV000336959.1 [benign]; RCV000403489.1 [benign]; 			840	599					FBLN5 (inh=AR+AD pLI=1.00)
chr14	92413987	92413987	G	A	het	het	het		QUAL=6101;DP=277,99,167;MQM=59	FBLN5	5'UTR	FBLN5:NM_006329.3:5'UTR:MODIFIER:exon1/11:c.-414C>T:		rs7149187	0.2508	0.0000	0/0/0	0.2816							604580 [FBLN5 (confirmed) Cutis laxa,autosomal recessive,type IA,219100|Cutis laxa,autosomal dominant 2,614434|Macular degeneration,age-related,3,608895|Neuropathy,hereditary,with or without age-related macular degeneration,608895];	RCV000342843.1 [benign]; RCV000404509.1 [benign]; 			30	90					FBLN5 (inh=AR+AD pLI=1.00)
chr14	92525145	92525145	A	G	het	het	het		QUAL=8556;DP=324,173,228;MQM=59	ATXN3	3'UTR,non_coding_transcript_exon	ATXN3:NM_004993.5:3'UTR:MODIFIER:exon11/11:c.*5519T>C:,ATXN3:NM_001127696.1:3'UTR:MODIFIER:exon10/10:c.*5519T>C:,ATXN3:NM_001127697.2:3'UTR:MODIFIER:exon9/9:c.*5519T>C:,ATXN3:NM_001164774.1:3'UTR:MODIFIER:exon4/4:c.*5655T>C:,ATXN3:NM_001164776.1:3'UTR:MODIFIER:exon5/5:c.*5655T>C:,ATXN3:NM_001164777.1:3'UTR:MODIFIER:exon4/4:c.*5655T>C:,ATXN3:NM_001164778.1:3'UTR:MODIFIER:exon7/7:c.*5655T>C:,ATXN3:NM_001164779.1:3'UTR:MODIFIER:exon7/7:c.*5519T>C:,ATXN3:NM_001164780.1:3'UTR:MODIFIER:exon8/8:c.*5519T>C:,ATXN3:NM_001164781.1:3'UTR:MODIFIER:exon9/9:c.*5519T>C:,ATXN3:NM_001164782.1:3'UTR:MODIFIER:exon3/3:c.*5655T>C:,ATXN3:NM_030660.4:3'UTR:MODIFIER:exon10/10:c.*5519T>C:,ATXN3:NR_028453.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.6588T>C:,ATXN3:NR_028454.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.6423T>C:,ATXN3:NR_028455.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.6642T>C:,ATXN3:NR_028456.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.6477T>C:,ATXN3:NR_028457.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.6733T>C:,ATXN3:NR_028458.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.6577T>C:,ATXN3:NR_028459.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.6728T>C:,ATXN3:NR_028460.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.6103T>C:,ATXN3:NR_028461.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.6586T>C:,ATXN3:NR_028462.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.6565T>C:,ATXN3:NR_028463.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.6277T>C:,ATXN3:NR_028464.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.6575T>C:,ATXN3:NR_028465.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.6597T>C:,ATXN3:NR_028466.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.6223T>C:,ATXN3:NR_028467.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.6589T>C:,ATXN3:NR_028468.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.6421T>C:,ATXN3:NR_028469.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.6435T>C:,ATXN3:NR_028470.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.5893T>C:,ATXN3:NR_031765.1:non_coding_transcript_exon:MODIFIER:exon5/5:n.6090T>C:		rs1047795	0.3007	0.0000	0/0/0	0.2696							607047 [ATXN3 (confirmed) Machado-Joseph disease,109150];				14	83					ATXN3 (inh=AD pLI=0.18)
chr14	92525290	92525290	A	-	het	het	wt		QUAL=103;DP=135,25,30;MQM=59	ATXN3	3'UTR,non_coding_transcript_exon	ATXN3:NM_004993.5:3'UTR:MODIFIER:exon11/11:c.*5374delT:,ATXN3:NM_001127696.1:3'UTR:MODIFIER:exon10/10:c.*5374delT:,ATXN3:NM_001127697.2:3'UTR:MODIFIER:exon9/9:c.*5374delT:,ATXN3:NM_001164774.1:3'UTR:MODIFIER:exon4/4:c.*5510delT:,ATXN3:NM_001164776.1:3'UTR:MODIFIER:exon5/5:c.*5510delT:,ATXN3:NM_001164777.1:3'UTR:MODIFIER:exon4/4:c.*5510delT:,ATXN3:NM_001164778.1:3'UTR:MODIFIER:exon7/7:c.*5510delT:,ATXN3:NM_001164779.1:3'UTR:MODIFIER:exon7/7:c.*5374delT:,ATXN3:NM_001164780.1:3'UTR:MODIFIER:exon8/8:c.*5374delT:,ATXN3:NM_001164781.1:3'UTR:MODIFIER:exon9/9:c.*5374delT:,ATXN3:NM_001164782.1:3'UTR:MODIFIER:exon3/3:c.*5510delT:,ATXN3:NM_030660.4:3'UTR:MODIFIER:exon10/10:c.*5374delT:,ATXN3:NR_028453.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.6443delT:,ATXN3:NR_028454.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.6278delT:,ATXN3:NR_028455.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.6497delT:,ATXN3:NR_028456.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.6332delT:,ATXN3:NR_028457.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.6588delT:,ATXN3:NR_028458.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.6432delT:,ATXN3:NR_028459.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.6583delT:,ATXN3:NR_028460.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.5958delT:,ATXN3:NR_028461.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.6441delT:,ATXN3:NR_028462.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.6420delT:,ATXN3:NR_028463.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.6132delT:,ATXN3:NR_028464.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.6430delT:,ATXN3:NR_028465.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.6452delT:,ATXN3:NR_028466.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.6078delT:,ATXN3:NR_028467.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.6444delT:,ATXN3:NR_028468.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.6276delT:,ATXN3:NR_028469.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.6290delT:,ATXN3:NR_028470.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.5748delT:,ATXN3:NR_031765.1:non_coding_transcript_exon:MODIFIER:exon5/5:n.5945delT:		rs762458117	0.0000	0.0000	0/0/0	0.0018							607047 [ATXN3 (confirmed) Machado-Joseph disease,109150];				0	38					ATXN3 (inh=AD pLI=0.18)
chr14	92525471	92525471	C	T	hom	hom	hom		QUAL=10510;DP=117,89,117;MQM=60	ATXN3	3'UTR,non_coding_transcript_exon	ATXN3:NM_004993.5:3'UTR:MODIFIER:exon11/11:c.*5193G>A:,ATXN3:NM_001127696.1:3'UTR:MODIFIER:exon10/10:c.*5193G>A:,ATXN3:NM_001127697.2:3'UTR:MODIFIER:exon9/9:c.*5193G>A:,ATXN3:NM_001164774.1:3'UTR:MODIFIER:exon4/4:c.*5329G>A:,ATXN3:NM_001164776.1:3'UTR:MODIFIER:exon5/5:c.*5329G>A:,ATXN3:NM_001164777.1:3'UTR:MODIFIER:exon4/4:c.*5329G>A:,ATXN3:NM_001164778.1:3'UTR:MODIFIER:exon7/7:c.*5329G>A:,ATXN3:NM_001164779.1:3'UTR:MODIFIER:exon7/7:c.*5193G>A:,ATXN3:NM_001164780.1:3'UTR:MODIFIER:exon8/8:c.*5193G>A:,ATXN3:NM_001164781.1:3'UTR:MODIFIER:exon9/9:c.*5193G>A:,ATXN3:NM_001164782.1:3'UTR:MODIFIER:exon3/3:c.*5329G>A:,ATXN3:NM_030660.4:3'UTR:MODIFIER:exon10/10:c.*5193G>A:,ATXN3:NR_028453.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.6262G>A:,ATXN3:NR_028454.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.6097G>A:,ATXN3:NR_028455.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.6316G>A:,ATXN3:NR_028456.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.6151G>A:,ATXN3:NR_028457.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.6407G>A:,ATXN3:NR_028458.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.6251G>A:,ATXN3:NR_028459.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.6402G>A:,ATXN3:NR_028460.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.5777G>A:,ATXN3:NR_028461.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.6260G>A:,ATXN3:NR_028462.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.6239G>A:,ATXN3:NR_028463.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.5951G>A:,ATXN3:NR_028464.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.6249G>A:,ATXN3:NR_028465.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.6271G>A:,ATXN3:NR_028466.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.5897G>A:,ATXN3:NR_028467.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.6263G>A:,ATXN3:NR_028468.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.6095G>A:,ATXN3:NR_028469.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.6109G>A:,ATXN3:NR_028470.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.5567G>A:,ATXN3:NR_031765.1:non_coding_transcript_exon:MODIFIER:exon5/5:n.5764G>A:		rs8022758	0.7508	0.0000	0/0/0	0.7487							607047 [ATXN3 (confirmed) Machado-Joseph disease,109150];				127	89					ATXN3 (inh=AD pLI=0.18)
chr14	92525613	92525613	C	T	het	het	het		QUAL=2733;DP=131,38,55;MQM=59	ATXN3	3'UTR,non_coding_transcript_exon	ATXN3:NM_004993.5:3'UTR:MODIFIER:exon11/11:c.*5051G>A:,ATXN3:NM_001127696.1:3'UTR:MODIFIER:exon10/10:c.*5051G>A:,ATXN3:NM_001127697.2:3'UTR:MODIFIER:exon9/9:c.*5051G>A:,ATXN3:NM_001164774.1:3'UTR:MODIFIER:exon4/4:c.*5187G>A:,ATXN3:NM_001164776.1:3'UTR:MODIFIER:exon5/5:c.*5187G>A:,ATXN3:NM_001164777.1:3'UTR:MODIFIER:exon4/4:c.*5187G>A:,ATXN3:NM_001164778.1:3'UTR:MODIFIER:exon7/7:c.*5187G>A:,ATXN3:NM_001164779.1:3'UTR:MODIFIER:exon7/7:c.*5051G>A:,ATXN3:NM_001164780.1:3'UTR:MODIFIER:exon8/8:c.*5051G>A:,ATXN3:NM_001164781.1:3'UTR:MODIFIER:exon9/9:c.*5051G>A:,ATXN3:NM_001164782.1:3'UTR:MODIFIER:exon3/3:c.*5187G>A:,ATXN3:NM_030660.4:3'UTR:MODIFIER:exon10/10:c.*5051G>A:,ATXN3:NR_028453.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.6120G>A:,ATXN3:NR_028454.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.5955G>A:,ATXN3:NR_028455.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.6174G>A:,ATXN3:NR_028456.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.6009G>A:,ATXN3:NR_028457.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.6265G>A:,ATXN3:NR_028458.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.6109G>A:,ATXN3:NR_028459.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.6260G>A:,ATXN3:NR_028460.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.5635G>A:,ATXN3:NR_028461.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.6118G>A:,ATXN3:NR_028462.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.6097G>A:,ATXN3:NR_028463.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.5809G>A:,ATXN3:NR_028464.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.6107G>A:,ATXN3:NR_028465.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.6129G>A:,ATXN3:NR_028466.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.5755G>A:,ATXN3:NR_028467.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.6121G>A:,ATXN3:NR_028468.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.5953G>A:,ATXN3:NR_028469.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.5967G>A:,ATXN3:NR_028470.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.5425G>A:,ATXN3:NR_031765.1:non_coding_transcript_exon:MODIFIER:exon5/5:n.5622G>A:		rs10151945	0.4706	0.0000	0/0/0	0.4054							607047 [ATXN3 (confirmed) Machado-Joseph disease,109150];				32	105					ATXN3 (inh=AD pLI=0.18)
chr14	92525998	92525998	-	A	het	het	het		QUAL=1923;DP=105,33,40;MQM=59	ATXN3	3'UTR,non_coding_transcript_exon	ATXN3:NM_004993.5:3'UTR:MODIFIER:exon11/11:c.*4665dupT:,ATXN3:NM_001127696.1:3'UTR:MODIFIER:exon10/10:c.*4665dupT:,ATXN3:NM_001127697.2:3'UTR:MODIFIER:exon9/9:c.*4665dupT:,ATXN3:NM_001164774.1:3'UTR:MODIFIER:exon4/4:c.*4801dupT:,ATXN3:NM_001164776.1:3'UTR:MODIFIER:exon5/5:c.*4801dupT:,ATXN3:NM_001164777.1:3'UTR:MODIFIER:exon4/4:c.*4801dupT:,ATXN3:NM_001164778.1:3'UTR:MODIFIER:exon7/7:c.*4801dupT:,ATXN3:NM_001164779.1:3'UTR:MODIFIER:exon7/7:c.*4665dupT:,ATXN3:NM_001164780.1:3'UTR:MODIFIER:exon8/8:c.*4665dupT:,ATXN3:NM_001164781.1:3'UTR:MODIFIER:exon9/9:c.*4665dupT:,ATXN3:NM_001164782.1:3'UTR:MODIFIER:exon3/3:c.*4801dupT:,ATXN3:NM_030660.4:3'UTR:MODIFIER:exon10/10:c.*4665dupT:,ATXN3:NR_028453.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5734dupT:,ATXN3:NR_028454.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.5569dupT:,ATXN3:NR_028455.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.5788dupT:,ATXN3:NR_028456.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5623dupT:,ATXN3:NR_028457.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.5879dupT:,ATXN3:NR_028458.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5723dupT:,ATXN3:NR_028459.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.5874dupT:,ATXN3:NR_028460.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.5249dupT:,ATXN3:NR_028461.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5732dupT:,ATXN3:NR_028462.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5711dupT:,ATXN3:NR_028463.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.5423dupT:,ATXN3:NR_028464.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5721dupT:,ATXN3:NR_028465.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5743dupT:,ATXN3:NR_028466.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.5369dupT:,ATXN3:NR_028467.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5735dupT:,ATXN3:NR_028468.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.5567dupT:,ATXN3:NR_028469.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.5581dupT:,ATXN3:NR_028470.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.5039dupT:,ATXN3:NR_031765.1:non_coding_transcript_exon:MODIFIER:exon5/5:n.5236dupT:	AluSx1	rs552780970	0.3085	0.0000	0/0/0	0.1543							607047 [ATXN3 (confirmed) Machado-Joseph disease,109150];				9	64					ATXN3 (inh=AD pLI=0.18)
chr14	92526157	92526157	G	A	het	het	het		QUAL=2831;DP=174,42,57;MQM=58	ATXN3	3'UTR,non_coding_transcript_exon	ATXN3:NM_004993.5:3'UTR:MODIFIER:exon11/11:c.*4507C>T:,ATXN3:NM_001127696.1:3'UTR:MODIFIER:exon10/10:c.*4507C>T:,ATXN3:NM_001127697.2:3'UTR:MODIFIER:exon9/9:c.*4507C>T:,ATXN3:NM_001164774.1:3'UTR:MODIFIER:exon4/4:c.*4643C>T:,ATXN3:NM_001164776.1:3'UTR:MODIFIER:exon5/5:c.*4643C>T:,ATXN3:NM_001164777.1:3'UTR:MODIFIER:exon4/4:c.*4643C>T:,ATXN3:NM_001164778.1:3'UTR:MODIFIER:exon7/7:c.*4643C>T:,ATXN3:NM_001164779.1:3'UTR:MODIFIER:exon7/7:c.*4507C>T:,ATXN3:NM_001164780.1:3'UTR:MODIFIER:exon8/8:c.*4507C>T:,ATXN3:NM_001164781.1:3'UTR:MODIFIER:exon9/9:c.*4507C>T:,ATXN3:NM_001164782.1:3'UTR:MODIFIER:exon3/3:c.*4643C>T:,ATXN3:NM_030660.4:3'UTR:MODIFIER:exon10/10:c.*4507C>T:,ATXN3:NR_028453.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5576C>T:,ATXN3:NR_028454.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.5411C>T:,ATXN3:NR_028455.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.5630C>T:,ATXN3:NR_028456.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5465C>T:,ATXN3:NR_028457.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.5721C>T:,ATXN3:NR_028458.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5565C>T:,ATXN3:NR_028459.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.5716C>T:,ATXN3:NR_028460.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.5091C>T:,ATXN3:NR_028461.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5574C>T:,ATXN3:NR_028462.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5553C>T:,ATXN3:NR_028463.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.5265C>T:,ATXN3:NR_028464.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5563C>T:,ATXN3:NR_028465.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5585C>T:,ATXN3:NR_028466.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.5211C>T:,ATXN3:NR_028467.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5577C>T:,ATXN3:NR_028468.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.5409C>T:,ATXN3:NR_028469.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.5423C>T:,ATXN3:NR_028470.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.4881C>T:,ATXN3:NR_031765.1:non_coding_transcript_exon:MODIFIER:exon5/5:n.5078C>T:	AluSx1	rs112733683	0.3143	0.0000	0/0/0	0.2008							607047 [ATXN3 (confirmed) Machado-Joseph disease,109150];				11	59					ATXN3 (inh=AD pLI=0.18)
chr14	92526240	92526240	A	C	het	het	het		QUAL=1459;DP=99,27,34;MQM=59	ATXN3	3'UTR,non_coding_transcript_exon	ATXN3:NM_004993.5:3'UTR:MODIFIER:exon11/11:c.*4424T>G:,ATXN3:NM_001127696.1:3'UTR:MODIFIER:exon10/10:c.*4424T>G:,ATXN3:NM_001127697.2:3'UTR:MODIFIER:exon9/9:c.*4424T>G:,ATXN3:NM_001164774.1:3'UTR:MODIFIER:exon4/4:c.*4560T>G:,ATXN3:NM_001164776.1:3'UTR:MODIFIER:exon5/5:c.*4560T>G:,ATXN3:NM_001164777.1:3'UTR:MODIFIER:exon4/4:c.*4560T>G:,ATXN3:NM_001164778.1:3'UTR:MODIFIER:exon7/7:c.*4560T>G:,ATXN3:NM_001164779.1:3'UTR:MODIFIER:exon7/7:c.*4424T>G:,ATXN3:NM_001164780.1:3'UTR:MODIFIER:exon8/8:c.*4424T>G:,ATXN3:NM_001164781.1:3'UTR:MODIFIER:exon9/9:c.*4424T>G:,ATXN3:NM_001164782.1:3'UTR:MODIFIER:exon3/3:c.*4560T>G:,ATXN3:NM_030660.4:3'UTR:MODIFIER:exon10/10:c.*4424T>G:,ATXN3:NR_028453.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5493T>G:,ATXN3:NR_028454.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.5328T>G:,ATXN3:NR_028455.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.5547T>G:,ATXN3:NR_028456.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5382T>G:,ATXN3:NR_028457.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.5638T>G:,ATXN3:NR_028458.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5482T>G:,ATXN3:NR_028459.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.5633T>G:,ATXN3:NR_028460.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.5008T>G:,ATXN3:NR_028461.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5491T>G:,ATXN3:NR_028462.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5470T>G:,ATXN3:NR_028463.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.5182T>G:,ATXN3:NR_028464.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5480T>G:,ATXN3:NR_028465.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5502T>G:,ATXN3:NR_028466.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.5128T>G:,ATXN3:NR_028467.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5494T>G:,ATXN3:NR_028468.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.5326T>G:,ATXN3:NR_028469.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.5340T>G:,ATXN3:NR_028470.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.4798T>G:,ATXN3:NR_031765.1:non_coding_transcript_exon:MODIFIER:exon5/5:n.4995T>G:		rs67089639	0.3007	0.0000	0/0/0	0.2327							607047 [ATXN3 (confirmed) Machado-Joseph disease,109150];				9	63					ATXN3 (inh=AD pLI=0.18)
chr14	92526429	92526429	T	G	het	hom	het	low_DP	QUAL=312;DP=29,1,2;MQM=56	ATXN3	3'UTR,non_coding_transcript_exon	ATXN3:NM_004993.5:3'UTR:MODIFIER:exon11/11:c.*4235A>C:,ATXN3:NM_001127696.1:3'UTR:MODIFIER:exon10/10:c.*4235A>C:,ATXN3:NM_001127697.2:3'UTR:MODIFIER:exon9/9:c.*4235A>C:,ATXN3:NM_001164774.1:3'UTR:MODIFIER:exon4/4:c.*4371A>C:,ATXN3:NM_001164776.1:3'UTR:MODIFIER:exon5/5:c.*4371A>C:,ATXN3:NM_001164777.1:3'UTR:MODIFIER:exon4/4:c.*4371A>C:,ATXN3:NM_001164778.1:3'UTR:MODIFIER:exon7/7:c.*4371A>C:,ATXN3:NM_001164779.1:3'UTR:MODIFIER:exon7/7:c.*4235A>C:,ATXN3:NM_001164780.1:3'UTR:MODIFIER:exon8/8:c.*4235A>C:,ATXN3:NM_001164781.1:3'UTR:MODIFIER:exon9/9:c.*4235A>C:,ATXN3:NM_001164782.1:3'UTR:MODIFIER:exon3/3:c.*4371A>C:,ATXN3:NM_030660.4:3'UTR:MODIFIER:exon10/10:c.*4235A>C:,ATXN3:NR_028453.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5304A>C:,ATXN3:NR_028454.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.5139A>C:,ATXN3:NR_028455.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.5358A>C:,ATXN3:NR_028456.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5193A>C:,ATXN3:NR_028457.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.5449A>C:,ATXN3:NR_028458.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5293A>C:,ATXN3:NR_028459.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.5444A>C:,ATXN3:NR_028460.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.4819A>C:,ATXN3:NR_028461.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5302A>C:,ATXN3:NR_028462.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5281A>C:,ATXN3:NR_028463.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.4993A>C:,ATXN3:NR_028464.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5291A>C:,ATXN3:NR_028465.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5313A>C:,ATXN3:NR_028466.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.4939A>C:,ATXN3:NR_028467.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5305A>C:,ATXN3:NR_028468.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.5137A>C:,ATXN3:NR_028469.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.5151A>C:,ATXN3:NR_028470.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.4609A>C:,ATXN3:NR_031765.1:non_coding_transcript_exon:MODIFIER:exon5/5:n.4806A>C:	AluSq2	rs8009456	0.3143	0.0000	0/0/0	0.1955							607047 [ATXN3 (confirmed) Machado-Joseph disease,109150];				8	21					ATXN3 (inh=AD pLI=0.18)
chr14	92526630	92526630	A	G	het	wt	het	low_DP	QUAL=33;DP=7,1,2;MQM=60	ATXN3	3'UTR,non_coding_transcript_exon	ATXN3:NM_004993.5:3'UTR:MODIFIER:exon11/11:c.*4034T>C:,ATXN3:NM_001127696.1:3'UTR:MODIFIER:exon10/10:c.*4034T>C:,ATXN3:NM_001127697.2:3'UTR:MODIFIER:exon9/9:c.*4034T>C:,ATXN3:NM_001164774.1:3'UTR:MODIFIER:exon4/4:c.*4170T>C:,ATXN3:NM_001164776.1:3'UTR:MODIFIER:exon5/5:c.*4170T>C:,ATXN3:NM_001164777.1:3'UTR:MODIFIER:exon4/4:c.*4170T>C:,ATXN3:NM_001164778.1:3'UTR:MODIFIER:exon7/7:c.*4170T>C:,ATXN3:NM_001164779.1:3'UTR:MODIFIER:exon7/7:c.*4034T>C:,ATXN3:NM_001164780.1:3'UTR:MODIFIER:exon8/8:c.*4034T>C:,ATXN3:NM_001164781.1:3'UTR:MODIFIER:exon9/9:c.*4034T>C:,ATXN3:NM_001164782.1:3'UTR:MODIFIER:exon3/3:c.*4170T>C:,ATXN3:NM_030660.4:3'UTR:MODIFIER:exon10/10:c.*4034T>C:,ATXN3:NR_028453.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5103T>C:,ATXN3:NR_028454.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.4938T>C:,ATXN3:NR_028455.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.5157T>C:,ATXN3:NR_028456.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4992T>C:,ATXN3:NR_028457.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.5248T>C:,ATXN3:NR_028458.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5092T>C:,ATXN3:NR_028459.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.5243T>C:,ATXN3:NR_028460.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.4618T>C:,ATXN3:NR_028461.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5101T>C:,ATXN3:NR_028462.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5080T>C:,ATXN3:NR_028463.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.4792T>C:,ATXN3:NR_028464.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5090T>C:,ATXN3:NR_028465.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5112T>C:,ATXN3:NR_028466.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.4738T>C:,ATXN3:NR_028467.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5104T>C:,ATXN3:NR_028468.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.4936T>C:,ATXN3:NR_028469.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.4950T>C:,ATXN3:NR_028470.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.4408T>C:,ATXN3:NR_031765.1:non_coding_transcript_exon:MODIFIER:exon5/5:n.4605T>C:	AluSz	rs8008405	0.3139	0.0000	0/0/0	0.2088							607047 [ATXN3 (confirmed) Machado-Joseph disease,109150];				5	30					ATXN3 (inh=AD pLI=0.18)
chr14	92527078	92527078	-	T	wt	hom	wt		QUAL=70;DP=119,34,67;MQM=58	ATXN3	3'UTR,non_coding_transcript_exon	ATXN3:NM_004993.5:3'UTR:MODIFIER:exon11/11:c.*3585dupA:,ATXN3:NM_001127696.1:3'UTR:MODIFIER:exon10/10:c.*3585dupA:,ATXN3:NM_001127697.2:3'UTR:MODIFIER:exon9/9:c.*3585dupA:,ATXN3:NM_001164774.1:3'UTR:MODIFIER:exon4/4:c.*3721dupA:,ATXN3:NM_001164776.1:3'UTR:MODIFIER:exon5/5:c.*3721dupA:,ATXN3:NM_001164777.1:3'UTR:MODIFIER:exon4/4:c.*3721dupA:,ATXN3:NM_001164778.1:3'UTR:MODIFIER:exon7/7:c.*3721dupA:,ATXN3:NM_001164779.1:3'UTR:MODIFIER:exon7/7:c.*3585dupA:,ATXN3:NM_001164780.1:3'UTR:MODIFIER:exon8/8:c.*3585dupA:,ATXN3:NM_001164781.1:3'UTR:MODIFIER:exon9/9:c.*3585dupA:,ATXN3:NM_001164782.1:3'UTR:MODIFIER:exon3/3:c.*3721dupA:,ATXN3:NM_030660.4:3'UTR:MODIFIER:exon10/10:c.*3585dupA:,ATXN3:NR_028453.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4654dupA:,ATXN3:NR_028454.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.4489dupA:,ATXN3:NR_028455.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.4708dupA:,ATXN3:NR_028456.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4543dupA:,ATXN3:NR_028457.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.4799dupA:,ATXN3:NR_028458.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4643dupA:,ATXN3:NR_028459.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.4794dupA:,ATXN3:NR_028460.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.4169dupA:,ATXN3:NR_028461.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4652dupA:,ATXN3:NR_028462.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4631dupA:,ATXN3:NR_028463.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.4343dupA:,ATXN3:NR_028464.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4641dupA:,ATXN3:NR_028465.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4663dupA:,ATXN3:NR_028466.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.4289dupA:,ATXN3:NR_028467.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4655dupA:,ATXN3:NR_028468.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.4487dupA:,ATXN3:NR_028469.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.4501dupA:,ATXN3:NR_028470.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.3959dupA:,ATXN3:NR_031765.1:non_coding_transcript_exon:MODIFIER:exon5/5:n.4156dupA:			0.0000	0.0000	0/0/0	0.0082							607047 [ATXN3 (confirmed) Machado-Joseph disease,109150];				0	21					ATXN3 (inh=AD pLI=0.18)
chr14	92527145	92527145	T	C	het	het	het		QUAL=4098;DP=147,61,104;MQM=59	ATXN3	3'UTR,non_coding_transcript_exon	ATXN3:NM_004993.5:3'UTR:MODIFIER:exon11/11:c.*3519A>G:,ATXN3:NM_001127696.1:3'UTR:MODIFIER:exon10/10:c.*3519A>G:,ATXN3:NM_001127697.2:3'UTR:MODIFIER:exon9/9:c.*3519A>G:,ATXN3:NM_001164774.1:3'UTR:MODIFIER:exon4/4:c.*3655A>G:,ATXN3:NM_001164776.1:3'UTR:MODIFIER:exon5/5:c.*3655A>G:,ATXN3:NM_001164777.1:3'UTR:MODIFIER:exon4/4:c.*3655A>G:,ATXN3:NM_001164778.1:3'UTR:MODIFIER:exon7/7:c.*3655A>G:,ATXN3:NM_001164779.1:3'UTR:MODIFIER:exon7/7:c.*3519A>G:,ATXN3:NM_001164780.1:3'UTR:MODIFIER:exon8/8:c.*3519A>G:,ATXN3:NM_001164781.1:3'UTR:MODIFIER:exon9/9:c.*3519A>G:,ATXN3:NM_001164782.1:3'UTR:MODIFIER:exon3/3:c.*3655A>G:,ATXN3:NM_030660.4:3'UTR:MODIFIER:exon10/10:c.*3519A>G:,ATXN3:NR_028453.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4588A>G:,ATXN3:NR_028454.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.4423A>G:,ATXN3:NR_028455.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.4642A>G:,ATXN3:NR_028456.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4477A>G:,ATXN3:NR_028457.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.4733A>G:,ATXN3:NR_028458.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4577A>G:,ATXN3:NR_028459.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.4728A>G:,ATXN3:NR_028460.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.4103A>G:,ATXN3:NR_028461.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4586A>G:,ATXN3:NR_028462.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4565A>G:,ATXN3:NR_028463.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.4277A>G:,ATXN3:NR_028464.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4575A>G:,ATXN3:NR_028465.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4597A>G:,ATXN3:NR_028466.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.4223A>G:,ATXN3:NR_028467.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4589A>G:,ATXN3:NR_028468.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.4421A>G:,ATXN3:NR_028469.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.4435A>G:,ATXN3:NR_028470.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.3893A>G:,ATXN3:NR_031765.1:non_coding_transcript_exon:MODIFIER:exon5/5:n.4090A>G:	AluSg4	rs1134378	0.3149	0.0000	0/0/0	0.2316							607047 [ATXN3 (confirmed) Machado-Joseph disease,109150];				14	83					ATXN3 (inh=AD pLI=0.18)
chr14	92527164	92527164	T	C	het	het	het		QUAL=4438;DP=186,59,100;MQM=59	ATXN3	3'UTR,non_coding_transcript_exon	ATXN3:NM_004993.5:3'UTR:MODIFIER:exon11/11:c.*3500A>G:,ATXN3:NM_001127696.1:3'UTR:MODIFIER:exon10/10:c.*3500A>G:,ATXN3:NM_001127697.2:3'UTR:MODIFIER:exon9/9:c.*3500A>G:,ATXN3:NM_001164774.1:3'UTR:MODIFIER:exon4/4:c.*3636A>G:,ATXN3:NM_001164776.1:3'UTR:MODIFIER:exon5/5:c.*3636A>G:,ATXN3:NM_001164777.1:3'UTR:MODIFIER:exon4/4:c.*3636A>G:,ATXN3:NM_001164778.1:3'UTR:MODIFIER:exon7/7:c.*3636A>G:,ATXN3:NM_001164779.1:3'UTR:MODIFIER:exon7/7:c.*3500A>G:,ATXN3:NM_001164780.1:3'UTR:MODIFIER:exon8/8:c.*3500A>G:,ATXN3:NM_001164781.1:3'UTR:MODIFIER:exon9/9:c.*3500A>G:,ATXN3:NM_001164782.1:3'UTR:MODIFIER:exon3/3:c.*3636A>G:,ATXN3:NM_030660.4:3'UTR:MODIFIER:exon10/10:c.*3500A>G:,ATXN3:NR_028453.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4569A>G:,ATXN3:NR_028454.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.4404A>G:,ATXN3:NR_028455.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.4623A>G:,ATXN3:NR_028456.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4458A>G:,ATXN3:NR_028457.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.4714A>G:,ATXN3:NR_028458.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4558A>G:,ATXN3:NR_028459.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.4709A>G:,ATXN3:NR_028460.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.4084A>G:,ATXN3:NR_028461.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4567A>G:,ATXN3:NR_028462.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4546A>G:,ATXN3:NR_028463.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.4258A>G:,ATXN3:NR_028464.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4556A>G:,ATXN3:NR_028465.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4578A>G:,ATXN3:NR_028466.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.4204A>G:,ATXN3:NR_028467.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4570A>G:,ATXN3:NR_028468.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.4402A>G:,ATXN3:NR_028469.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.4416A>G:,ATXN3:NR_028470.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.3874A>G:,ATXN3:NR_031765.1:non_coding_transcript_exon:MODIFIER:exon5/5:n.4071A>G:	AluSg4	rs1134377	0.3141	0.0000	0/0/0	0.2339							607047 [ATXN3 (confirmed) Machado-Joseph disease,109150];				14	79					ATXN3 (inh=AD pLI=0.18)
chr14	92527399	92527399	A	G	het	het	het		QUAL=7526;DP=312,86,169;MQM=59	ATXN3	3'UTR,non_coding_transcript_exon	ATXN3:NM_004993.5:3'UTR:MODIFIER:exon11/11:c.*3265T>C:,ATXN3:NM_001127696.1:3'UTR:MODIFIER:exon10/10:c.*3265T>C:,ATXN3:NM_001127697.2:3'UTR:MODIFIER:exon9/9:c.*3265T>C:,ATXN3:NM_001164774.1:3'UTR:MODIFIER:exon4/4:c.*3401T>C:,ATXN3:NM_001164776.1:3'UTR:MODIFIER:exon5/5:c.*3401T>C:,ATXN3:NM_001164777.1:3'UTR:MODIFIER:exon4/4:c.*3401T>C:,ATXN3:NM_001164778.1:3'UTR:MODIFIER:exon7/7:c.*3401T>C:,ATXN3:NM_001164779.1:3'UTR:MODIFIER:exon7/7:c.*3265T>C:,ATXN3:NM_001164780.1:3'UTR:MODIFIER:exon8/8:c.*3265T>C:,ATXN3:NM_001164781.1:3'UTR:MODIFIER:exon9/9:c.*3265T>C:,ATXN3:NM_001164782.1:3'UTR:MODIFIER:exon3/3:c.*3401T>C:,ATXN3:NM_030660.4:3'UTR:MODIFIER:exon10/10:c.*3265T>C:,ATXN3:NR_028453.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4334T>C:,ATXN3:NR_028454.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.4169T>C:,ATXN3:NR_028455.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.4388T>C:,ATXN3:NR_028456.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4223T>C:,ATXN3:NR_028457.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.4479T>C:,ATXN3:NR_028458.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4323T>C:,ATXN3:NR_028459.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.4474T>C:,ATXN3:NR_028460.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.3849T>C:,ATXN3:NR_028461.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4332T>C:,ATXN3:NR_028462.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4311T>C:,ATXN3:NR_028463.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.4023T>C:,ATXN3:NR_028464.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4321T>C:,ATXN3:NR_028465.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4343T>C:,ATXN3:NR_028466.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.3969T>C:,ATXN3:NR_028467.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.4335T>C:,ATXN3:NR_028468.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.4167T>C:,ATXN3:NR_028469.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.4181T>C:,ATXN3:NR_028470.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.3639T>C:,ATXN3:NR_031765.1:non_coding_transcript_exon:MODIFIER:exon5/5:n.3836T>C:		rs1055996	0.2406	0.0000	0/0/0	0.2498							607047 [ATXN3 (confirmed) Machado-Joseph disease,109150];				14	79					ATXN3 (inh=AD pLI=0.18)
chr14	92527977	92527977	T	C	het	het	het		QUAL=13012;DP=449,239,261;MQM=60	ATXN3	3'UTR,non_coding_transcript_exon	ATXN3:NM_004993.5:3'UTR:MODIFIER:exon11/11:c.*2687A>G:,ATXN3:NM_001127696.1:3'UTR:MODIFIER:exon10/10:c.*2687A>G:,ATXN3:NM_001127697.2:3'UTR:MODIFIER:exon9/9:c.*2687A>G:,ATXN3:NM_001164774.1:3'UTR:MODIFIER:exon4/4:c.*2823A>G:,ATXN3:NM_001164776.1:3'UTR:MODIFIER:exon5/5:c.*2823A>G:,ATXN3:NM_001164777.1:3'UTR:MODIFIER:exon4/4:c.*2823A>G:,ATXN3:NM_001164778.1:3'UTR:MODIFIER:exon7/7:c.*2823A>G:,ATXN3:NM_001164779.1:3'UTR:MODIFIER:exon7/7:c.*2687A>G:,ATXN3:NM_001164780.1:3'UTR:MODIFIER:exon8/8:c.*2687A>G:,ATXN3:NM_001164781.1:3'UTR:MODIFIER:exon9/9:c.*2687A>G:,ATXN3:NM_001164782.1:3'UTR:MODIFIER:exon3/3:c.*2823A>G:,ATXN3:NM_030660.4:3'UTR:MODIFIER:exon10/10:c.*2687A>G:,ATXN3:NR_028453.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.3756A>G:,ATXN3:NR_028454.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.3591A>G:,ATXN3:NR_028455.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.3810A>G:,ATXN3:NR_028456.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.3645A>G:,ATXN3:NR_028457.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.3901A>G:,ATXN3:NR_028458.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.3745A>G:,ATXN3:NR_028459.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.3896A>G:,ATXN3:NR_028460.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.3271A>G:,ATXN3:NR_028461.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.3754A>G:,ATXN3:NR_028462.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.3733A>G:,ATXN3:NR_028463.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.3445A>G:,ATXN3:NR_028464.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.3743A>G:,ATXN3:NR_028465.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.3765A>G:,ATXN3:NR_028466.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.3391A>G:,ATXN3:NR_028467.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.3757A>G:,ATXN3:NR_028468.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.3589A>G:,ATXN3:NR_028469.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.3603A>G:,ATXN3:NR_028470.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.3061A>G:,ATXN3:NR_031765.1:non_coding_transcript_exon:MODIFIER:exon5/5:n.3258A>G:		rs11628764	0.1761	0.0000	0/0/0	0.2419							607047 [ATXN3 (confirmed) Machado-Joseph disease,109150];				17	91					ATXN3 (inh=AD pLI=0.18)
chr14	92528429	92528429	C	T	het	het	het		QUAL=5287;DP=175,98,169;MQM=59	ATXN3	3'UTR,non_coding_transcript_exon	ATXN3:NM_004993.5:3'UTR:MODIFIER:exon11/11:c.*2235G>A:,ATXN3:NM_001127696.1:3'UTR:MODIFIER:exon10/10:c.*2235G>A:,ATXN3:NM_001127697.2:3'UTR:MODIFIER:exon9/9:c.*2235G>A:,ATXN3:NM_001164774.1:3'UTR:MODIFIER:exon4/4:c.*2371G>A:,ATXN3:NM_001164776.1:3'UTR:MODIFIER:exon5/5:c.*2371G>A:,ATXN3:NM_001164777.1:3'UTR:MODIFIER:exon4/4:c.*2371G>A:,ATXN3:NM_001164778.1:3'UTR:MODIFIER:exon7/7:c.*2371G>A:,ATXN3:NM_001164779.1:3'UTR:MODIFIER:exon7/7:c.*2235G>A:,ATXN3:NM_001164780.1:3'UTR:MODIFIER:exon8/8:c.*2235G>A:,ATXN3:NM_001164781.1:3'UTR:MODIFIER:exon9/9:c.*2235G>A:,ATXN3:NM_001164782.1:3'UTR:MODIFIER:exon3/3:c.*2371G>A:,ATXN3:NM_030660.4:3'UTR:MODIFIER:exon10/10:c.*2235G>A:,ATXN3:NR_028453.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.3304G>A:,ATXN3:NR_028454.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.3139G>A:,ATXN3:NR_028455.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.3358G>A:,ATXN3:NR_028456.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.3193G>A:,ATXN3:NR_028457.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.3449G>A:,ATXN3:NR_028458.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.3293G>A:,ATXN3:NR_028459.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.3444G>A:,ATXN3:NR_028460.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.2819G>A:,ATXN3:NR_028461.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.3302G>A:,ATXN3:NR_028462.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.3281G>A:,ATXN3:NR_028463.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.2993G>A:,ATXN3:NR_028464.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.3291G>A:,ATXN3:NR_028465.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.3313G>A:,ATXN3:NR_028466.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.2939G>A:,ATXN3:NR_028467.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.3305G>A:,ATXN3:NR_028468.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.3137G>A:,ATXN3:NR_028469.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.3151G>A:,ATXN3:NR_028470.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.2609G>A:,ATXN3:NR_031765.1:non_coding_transcript_exon:MODIFIER:exon5/5:n.2806G>A:	AluSx1	rs8019545	0.3165	0.0000	0/0/0	0.2389							607047 [ATXN3 (confirmed) Machado-Joseph disease,109150];				14	78					ATXN3 (inh=AD pLI=0.18)
chr14	92530282	92530282	C	A	het	het	het		QUAL=8597;DP=302,156,154;MQM=59	ATXN3	3'UTR,non_coding_transcript_exon	ATXN3:NM_004993.5:3'UTR:MODIFIER:exon11/11:c.*382G>T:,ATXN3:NM_001127696.1:3'UTR:MODIFIER:exon10/10:c.*382G>T:,ATXN3:NM_001127697.2:3'UTR:MODIFIER:exon9/9:c.*382G>T:,ATXN3:NM_001164774.1:3'UTR:MODIFIER:exon4/4:c.*518G>T:,ATXN3:NM_001164776.1:3'UTR:MODIFIER:exon5/5:c.*518G>T:,ATXN3:NM_001164777.1:3'UTR:MODIFIER:exon4/4:c.*518G>T:,ATXN3:NM_001164778.1:3'UTR:MODIFIER:exon7/7:c.*518G>T:,ATXN3:NM_001164779.1:3'UTR:MODIFIER:exon7/7:c.*382G>T:,ATXN3:NM_001164780.1:3'UTR:MODIFIER:exon8/8:c.*382G>T:,ATXN3:NM_001164781.1:3'UTR:MODIFIER:exon9/9:c.*382G>T:,ATXN3:NM_001164782.1:3'UTR:MODIFIER:exon3/3:c.*518G>T:,ATXN3:NM_030660.4:3'UTR:MODIFIER:exon10/10:c.*382G>T:,ATXN3:NR_028453.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1451G>T:,ATXN3:NR_028454.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.1286G>T:,ATXN3:NR_028455.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.1505G>T:,ATXN3:NR_028456.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1340G>T:,ATXN3:NR_028457.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.1596G>T:,ATXN3:NR_028458.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1440G>T:,ATXN3:NR_028459.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.1591G>T:,ATXN3:NR_028460.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.966G>T:,ATXN3:NR_028461.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1449G>T:,ATXN3:NR_028462.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1428G>T:,ATXN3:NR_028463.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.1140G>T:,ATXN3:NR_028464.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1438G>T:,ATXN3:NR_028465.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1460G>T:,ATXN3:NR_028466.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.1086G>T:,ATXN3:NR_028467.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1452G>T:,ATXN3:NR_028468.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.1284G>T:,ATXN3:NR_028469.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.1298G>T:,ATXN3:NR_028470.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.756G>T:,ATXN3:NR_031765.1:non_coding_transcript_exon:MODIFIER:exon5/5:n.953G>T:		rs910369	0.2877	0.0000	0/0/0	0.0453							607047 [ATXN3 (confirmed) Machado-Joseph disease,109150];				14	83					ATXN3 (inh=AD pLI=0.18)
chr14	92530513	92530513	C	T	het	het	het		QUAL=4455;DP=229,64,69;MQM=60	ATXN3	3'UTR,non_coding_transcript_exon	ATXN3:NM_004993.5:3'UTR:MODIFIER:exon11/11:c.*151G>A:,ATXN3:NM_001127696.1:3'UTR:MODIFIER:exon10/10:c.*151G>A:,ATXN3:NM_001127697.2:3'UTR:MODIFIER:exon9/9:c.*151G>A:,ATXN3:NM_001164774.1:3'UTR:MODIFIER:exon4/4:c.*287G>A:,ATXN3:NM_001164776.1:3'UTR:MODIFIER:exon5/5:c.*287G>A:,ATXN3:NM_001164777.1:3'UTR:MODIFIER:exon4/4:c.*287G>A:,ATXN3:NM_001164778.1:3'UTR:MODIFIER:exon7/7:c.*287G>A:,ATXN3:NM_001164779.1:3'UTR:MODIFIER:exon7/7:c.*151G>A:,ATXN3:NM_001164780.1:3'UTR:MODIFIER:exon8/8:c.*151G>A:,ATXN3:NM_001164781.1:3'UTR:MODIFIER:exon9/9:c.*151G>A:,ATXN3:NM_001164782.1:3'UTR:MODIFIER:exon3/3:c.*287G>A:,ATXN3:NM_030660.4:3'UTR:MODIFIER:exon10/10:c.*151G>A:,ATXN3:NR_028453.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1220G>A:,ATXN3:NR_028454.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.1055G>A:,ATXN3:NR_028455.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.1274G>A:,ATXN3:NR_028456.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1109G>A:,ATXN3:NR_028457.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.1365G>A:,ATXN3:NR_028458.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1209G>A:,ATXN3:NR_028459.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.1360G>A:,ATXN3:NR_028460.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.735G>A:,ATXN3:NR_028461.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1218G>A:,ATXN3:NR_028462.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1197G>A:,ATXN3:NR_028463.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.909G>A:,ATXN3:NR_028464.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1207G>A:,ATXN3:NR_028465.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1229G>A:,ATXN3:NR_028466.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.855G>A:,ATXN3:NR_028467.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1221G>A:,ATXN3:NR_028468.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.1053G>A:,ATXN3:NR_028469.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.1067G>A:,ATXN3:NR_028470.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.525G>A:,ATXN3:NR_031765.1:non_coding_transcript_exon:MODIFIER:exon5/5:n.722G>A:		rs709930	0.2819	0.0000	0/0/0	0.0454							607047 [ATXN3 (confirmed) Machado-Joseph disease,109150];				14	83					ATXN3 (inh=AD pLI=0.18)
chr14	92537353	92537353	-	GCTGCTGCTGCTGCTGCTG	wt	het	wt	low_DP;anno_high_impact	QUAL=66;DP=8,21,17;MQM=60	ATXN3	frameshift,non_coding_transcript_exon	ATXN3:NM_004993.5:frameshift:HIGH:exon10/11:c.916_917insCAGCAGCAGCAGCAGCAGC:p.Gly306fs,ATXN3:NM_001127696.1:frameshift:HIGH:exon9/10:c.871_872insCAGCAGCAGCAGCAGCAGC:p.Gly291fs,ATXN3:NM_001127697.2:frameshift:HIGH:exon8/9:c.763_764insCAGCAGCAGCAGCAGCAGC:p.Gly255fs,ATXN3:NM_001164774.1:frameshift:HIGH:exon3/4:c.233_234insCAGCAGCAGCAGCAGCAGC:p.Gly79fs,ATXN3:NM_001164776.1:frameshift:HIGH:exon4/5:c.278_279insCAGCAGCAGCAGCAGCAGC:p.Gly94fs,ATXN3:NM_001164777.1:frameshift:HIGH:exon3/4:c.113_114insCAGCAGCAGCAGCAGCAGC:p.Gly39fs,ATXN3:NM_001164778.1:frameshift:HIGH:exon6/7:c.431_432insCAGCAGCAGCAGCAGCAGC:p.Gly145fs,ATXN3:NM_001164779.1:frameshift:HIGH:exon6/7:c.553_554insCAGCAGCAGCAGCAGCAGC:p.Gly185fs,ATXN3:NM_001164780.1:frameshift:HIGH:exon7/8:c.379_380insCAGCAGCAGCAGCAGCAGC:p.Gly127fs,ATXN3:NM_001164781.1:frameshift:HIGH:exon8/9:c.706_707insCAGCAGCAGCAGCAGCAGC:p.Gly236fs,ATXN3:NM_001164782.1:frameshift:HIGH:exon2/3:c.68_69insCAGCAGCAGCAGCAGCAGC:p.Gly24fs,ATXN3:NM_030660.4:frameshift:HIGH:exon9/10:c.751_752insCAGCAGCAGCAGCAGCAGC:p.Gly251fs,ATXN3:NR_028453.1:non_coding_transcript_exon:MODIFIER:exon9/10:n.899_900insCAGCAGCAGCAGCAGCAGC:,ATXN3:NR_028454.1:non_coding_transcript_exon:MODIFIER:exon8/9:n.734_735insCAGCAGCAGCAGCAGCAGC:,ATXN3:NR_028455.1:non_coding_transcript_exon:MODIFIER:exon10/11:n.953_954insCAGCAGCAGCAGCAGCAGC:,ATXN3:NR_028456.1:non_coding_transcript_exon:MODIFIER:exon9/10:n.788_789insCAGCAGCAGCAGCAGCAGC:,ATXN3:NR_028457.1:non_coding_transcript_exon:MODIFIER:exon11/12:n.1044_1045insCAGCAGCAGCAGCAGCAGC:,ATXN3:NR_028458.1:non_coding_transcript_exon:MODIFIER:exon9/10:n.888_889insCAGCAGCAGCAGCAGCAGC:,ATXN3:NR_028459.1:non_coding_transcript_exon:MODIFIER:exon11/12:n.1039_1040insCAGCAGCAGCAGCAGCAGC:,ATXN3:NR_028460.1:non_coding_transcript_exon:MODIFIER:exon5/6:n.414_415insCAGCAGCAGCAGCAGCAGC:,ATXN3:NR_028461.1:non_coding_transcript_exon:MODIFIER:exon9/10:n.897_898insCAGCAGCAGCAGCAGCAGC:,ATXN3:NR_028462.1:non_coding_transcript_exon:MODIFIER:exon9/10:n.876_877insCAGCAGCAGCAGCAGCAGC:,ATXN3:NR_028463.1:non_coding_transcript_exon:MODIFIER:exon6/7:n.588_589insCAGCAGCAGCAGCAGCAGC:,ATXN3:NR_028464.1:non_coding_transcript_exon:MODIFIER:exon9/10:n.886_887insCAGCAGCAGCAGCAGCAGC:,ATXN3:NR_028465.1:non_coding_transcript_exon:MODIFIER:exon9/10:n.908_909insCAGCAGCAGCAGCAGCAGC:,ATXN3:NR_028466.1:non_coding_transcript_exon:MODIFIER:exon5/6:n.534_535insCAGCAGCAGCAGCAGCAGC:,ATXN3:NR_028467.1:non_coding_transcript_exon:MODIFIER:exon9/10:n.900_901insCAGCAGCAGCAGCAGCAGC:,ATXN3:NR_028468.1:non_coding_transcript_exon:MODIFIER:exon8/9:n.732_733insCAGCAGCAGCAGCAGCAGC:,ATXN3:NR_028469.1:non_coding_transcript_exon:MODIFIER:exon8/9:n.746_747insCAGCAGCAGCAGCAGCAGC:,ATXN3:NR_028470.1:non_coding_transcript_exon:MODIFIER:exon3/4:n.204_205insCAGCAGCAGCAGCAGCAGC:,ATXN3:NR_031765.1:non_coding_transcript_exon:MODIFIER:exon4/5:n.401_402insCAGCAGCAGCAGCAGCAGC:			0.0000	0.0000	0/0/0	0.0000							607047 [ATXN3 (confirmed) Machado-Joseph disease,109150];				10	65					ATXN3 (inh=AD pLI=0.18)
chr14	92537353	92537353	-	GCTGCTGCTGCTGCTG	wt	wt	het	low_DP;anno_high_impact	QUAL=66;DP=8,21,17;MQM=60	ATXN3	frameshift,non_coding_transcript_exon	ATXN3:NM_004993.5:frameshift:HIGH:exon10/11:c.916_917insCAGCAGCAGCAGCAGC:p.Gly306fs,ATXN3:NM_001127696.1:frameshift:HIGH:exon9/10:c.871_872insCAGCAGCAGCAGCAGC:p.Gly291fs,ATXN3:NM_001127697.2:frameshift:HIGH:exon8/9:c.763_764insCAGCAGCAGCAGCAGC:p.Gly255fs,ATXN3:NM_001164774.1:frameshift:HIGH:exon3/4:c.233_234insCAGCAGCAGCAGCAGC:p.Gly79fs,ATXN3:NM_001164776.1:frameshift:HIGH:exon4/5:c.278_279insCAGCAGCAGCAGCAGC:p.Gly94fs,ATXN3:NM_001164777.1:frameshift:HIGH:exon3/4:c.113_114insCAGCAGCAGCAGCAGC:p.Gly39fs,ATXN3:NM_001164778.1:frameshift:HIGH:exon6/7:c.431_432insCAGCAGCAGCAGCAGC:p.Gly145fs,ATXN3:NM_001164779.1:frameshift:HIGH:exon6/7:c.553_554insCAGCAGCAGCAGCAGC:p.Gly185fs,ATXN3:NM_001164780.1:frameshift:HIGH:exon7/8:c.379_380insCAGCAGCAGCAGCAGC:p.Gly127fs,ATXN3:NM_001164781.1:frameshift:HIGH:exon8/9:c.706_707insCAGCAGCAGCAGCAGC:p.Gly236fs,ATXN3:NM_001164782.1:frameshift:HIGH:exon2/3:c.68_69insCAGCAGCAGCAGCAGC:p.Gly24fs,ATXN3:NM_030660.4:frameshift:HIGH:exon9/10:c.751_752insCAGCAGCAGCAGCAGC:p.Gly251fs,ATXN3:NR_028453.1:non_coding_transcript_exon:MODIFIER:exon9/10:n.899_900insCAGCAGCAGCAGCAGC:,ATXN3:NR_028454.1:non_coding_transcript_exon:MODIFIER:exon8/9:n.734_735insCAGCAGCAGCAGCAGC:,ATXN3:NR_028455.1:non_coding_transcript_exon:MODIFIER:exon10/11:n.953_954insCAGCAGCAGCAGCAGC:,ATXN3:NR_028456.1:non_coding_transcript_exon:MODIFIER:exon9/10:n.788_789insCAGCAGCAGCAGCAGC:,ATXN3:NR_028457.1:non_coding_transcript_exon:MODIFIER:exon11/12:n.1044_1045insCAGCAGCAGCAGCAGC:,ATXN3:NR_028458.1:non_coding_transcript_exon:MODIFIER:exon9/10:n.888_889insCAGCAGCAGCAGCAGC:,ATXN3:NR_028459.1:non_coding_transcript_exon:MODIFIER:exon11/12:n.1039_1040insCAGCAGCAGCAGCAGC:,ATXN3:NR_028460.1:non_coding_transcript_exon:MODIFIER:exon5/6:n.414_415insCAGCAGCAGCAGCAGC:,ATXN3:NR_028461.1:non_coding_transcript_exon:MODIFIER:exon9/10:n.897_898insCAGCAGCAGCAGCAGC:,ATXN3:NR_028462.1:non_coding_transcript_exon:MODIFIER:exon9/10:n.876_877insCAGCAGCAGCAGCAGC:,ATXN3:NR_028463.1:non_coding_transcript_exon:MODIFIER:exon6/7:n.588_589insCAGCAGCAGCAGCAGC:,ATXN3:NR_028464.1:non_coding_transcript_exon:MODIFIER:exon9/10:n.886_887insCAGCAGCAGCAGCAGC:,ATXN3:NR_028465.1:non_coding_transcript_exon:MODIFIER:exon9/10:n.908_909insCAGCAGCAGCAGCAGC:,ATXN3:NR_028466.1:non_coding_transcript_exon:MODIFIER:exon5/6:n.534_535insCAGCAGCAGCAGCAGC:,ATXN3:NR_028467.1:non_coding_transcript_exon:MODIFIER:exon9/10:n.900_901insCAGCAGCAGCAGCAGC:,ATXN3:NR_028468.1:non_coding_transcript_exon:MODIFIER:exon8/9:n.732_733insCAGCAGCAGCAGCAGC:,ATXN3:NR_028469.1:non_coding_transcript_exon:MODIFIER:exon8/9:n.746_747insCAGCAGCAGCAGCAGC:,ATXN3:NR_028470.1:non_coding_transcript_exon:MODIFIER:exon3/4:n.204_205insCAGCAGCAGCAGCAGC:,ATXN3:NR_031765.1:non_coding_transcript_exon:MODIFIER:exon4/5:n.401_402insCAGCAGCAGCAGCAGC:			0.0000	0.0000	0/0/0	0.0000							607047 [ATXN3 (confirmed) Machado-Joseph disease,109150];				4	43					ATXN3 (inh=AD pLI=0.18)
chr14	92537354	92537354	-	TG	wt	het	het	low_DP;anno_high_impact	QUAL=66;DP=8,21,17;MQM=60	ATXN3	frameshift,non_coding_transcript_exon	ATXN3:NM_004993.5:frameshift:HIGH:exon10/11:c.915_916insCA:p.Gly306fs,ATXN3:NM_001127696.1:frameshift:HIGH:exon9/10:c.870_871insCA:p.Gly291fs,ATXN3:NM_001127697.2:frameshift:HIGH:exon8/9:c.762_763insCA:p.Gly255fs,ATXN3:NM_001164774.1:frameshift:HIGH:exon3/4:c.232_233insCA:p.Gly78fs,ATXN3:NM_001164776.1:frameshift:HIGH:exon4/5:c.277_278insCA:p.Gly93fs,ATXN3:NM_001164777.1:frameshift:HIGH:exon3/4:c.112_113insCA:p.Gly38fs,ATXN3:NM_001164778.1:frameshift:HIGH:exon6/7:c.430_431insCA:p.Gly144fs,ATXN3:NM_001164779.1:frameshift:HIGH:exon6/7:c.552_553insCA:p.Gly185fs,ATXN3:NM_001164780.1:frameshift:HIGH:exon7/8:c.378_379insCA:p.Gly127fs,ATXN3:NM_001164781.1:frameshift:HIGH:exon8/9:c.705_706insCA:p.Gly236fs,ATXN3:NM_001164782.1:frameshift:HIGH:exon2/3:c.67_68insCA:p.Gly23fs,ATXN3:NM_030660.4:frameshift:HIGH:exon9/10:c.750_751insCA:p.Gly251fs,ATXN3:NR_028453.1:non_coding_transcript_exon:MODIFIER:exon9/10:n.898_899insCA:,ATXN3:NR_028454.1:non_coding_transcript_exon:MODIFIER:exon8/9:n.733_734insCA:,ATXN3:NR_028455.1:non_coding_transcript_exon:MODIFIER:exon10/11:n.952_953insCA:,ATXN3:NR_028456.1:non_coding_transcript_exon:MODIFIER:exon9/10:n.787_788insCA:,ATXN3:NR_028457.1:non_coding_transcript_exon:MODIFIER:exon11/12:n.1043_1044insCA:,ATXN3:NR_028458.1:non_coding_transcript_exon:MODIFIER:exon9/10:n.887_888insCA:,ATXN3:NR_028459.1:non_coding_transcript_exon:MODIFIER:exon11/12:n.1038_1039insCA:,ATXN3:NR_028460.1:non_coding_transcript_exon:MODIFIER:exon5/6:n.413_414insCA:,ATXN3:NR_028461.1:non_coding_transcript_exon:MODIFIER:exon9/10:n.896_897insCA:,ATXN3:NR_028462.1:non_coding_transcript_exon:MODIFIER:exon9/10:n.875_876insCA:,ATXN3:NR_028463.1:non_coding_transcript_exon:MODIFIER:exon6/7:n.587_588insCA:,ATXN3:NR_028464.1:non_coding_transcript_exon:MODIFIER:exon9/10:n.885_886insCA:,ATXN3:NR_028465.1:non_coding_transcript_exon:MODIFIER:exon9/10:n.907_908insCA:,ATXN3:NR_028466.1:non_coding_transcript_exon:MODIFIER:exon5/6:n.533_534insCA:,ATXN3:NR_028467.1:non_coding_transcript_exon:MODIFIER:exon9/10:n.899_900insCA:,ATXN3:NR_028468.1:non_coding_transcript_exon:MODIFIER:exon8/9:n.731_732insCA:,ATXN3:NR_028469.1:non_coding_transcript_exon:MODIFIER:exon8/9:n.745_746insCA:,ATXN3:NR_028470.1:non_coding_transcript_exon:MODIFIER:exon3/4:n.203_204insCA:,ATXN3:NR_031765.1:non_coding_transcript_exon:MODIFIER:exon4/5:n.400_401insCA:			0.0000	0.0000	0/0/0	0.0000							607047 [ATXN3 (confirmed) Machado-Joseph disease,109150];				30	91					ATXN3 (inh=AD pLI=0.18)
chr14	92537379	92537379	T	C	het	het	het	low_DP	QUAL=291;DP=8,35,32;MQM=58	ATXN3	missense,synonymous,non_coding_transcript_exon	ATXN3:NM_001164774.1:missense:MODERATE:exon3/4:c.208A>G:p.Thr70Ala,ATXN3:NM_001164776.1:missense:MODERATE:exon4/5:c.253A>G:p.Thr85Ala,ATXN3:NM_001164777.1:missense:MODERATE:exon3/4:c.88A>G:p.Thr30Ala,ATXN3:NM_001164778.1:missense:MODERATE:exon6/7:c.406A>G:p.Thr136Ala,ATXN3:NM_001164782.1:missense:MODERATE:exon2/3:c.43A>G:p.Thr15Ala,ATXN3:NM_004993.5:synonymous:LOW:exon10/11:c.891A>G:p.Gln297Gln,ATXN3:NM_001127696.1:synonymous:LOW:exon9/10:c.846A>G:p.Gln282Gln,ATXN3:NM_001127697.2:synonymous:LOW:exon8/9:c.738A>G:p.Gln246Gln,ATXN3:NM_001164779.1:synonymous:LOW:exon6/7:c.528A>G:p.Gln176Gln,ATXN3:NM_001164780.1:synonymous:LOW:exon7/8:c.354A>G:p.Gln118Gln,ATXN3:NM_001164781.1:synonymous:LOW:exon8/9:c.681A>G:p.Gln227Gln,ATXN3:NM_030660.4:synonymous:LOW:exon9/10:c.726A>G:p.Gln242Gln,ATXN3:NR_028453.1:non_coding_transcript_exon:MODIFIER:exon9/10:n.874A>G:,ATXN3:NR_028454.1:non_coding_transcript_exon:MODIFIER:exon8/9:n.709A>G:,ATXN3:NR_028455.1:non_coding_transcript_exon:MODIFIER:exon10/11:n.928A>G:,ATXN3:NR_028456.1:non_coding_transcript_exon:MODIFIER:exon9/10:n.763A>G:,ATXN3:NR_028457.1:non_coding_transcript_exon:MODIFIER:exon11/12:n.1019A>G:,ATXN3:NR_028458.1:non_coding_transcript_exon:MODIFIER:exon9/10:n.863A>G:,ATXN3:NR_028459.1:non_coding_transcript_exon:MODIFIER:exon11/12:n.1014A>G:,ATXN3:NR_028460.1:non_coding_transcript_exon:MODIFIER:exon5/6:n.389A>G:,ATXN3:NR_028461.1:non_coding_transcript_exon:MODIFIER:exon9/10:n.872A>G:,ATXN3:NR_028462.1:non_coding_transcript_exon:MODIFIER:exon9/10:n.851A>G:,ATXN3:NR_028463.1:non_coding_transcript_exon:MODIFIER:exon6/7:n.563A>G:,ATXN3:NR_028464.1:non_coding_transcript_exon:MODIFIER:exon9/10:n.861A>G:,ATXN3:NR_028465.1:non_coding_transcript_exon:MODIFIER:exon9/10:n.883A>G:,ATXN3:NR_028466.1:non_coding_transcript_exon:MODIFIER:exon5/6:n.509A>G:,ATXN3:NR_028467.1:non_coding_transcript_exon:MODIFIER:exon9/10:n.875A>G:,ATXN3:NR_028468.1:non_coding_transcript_exon:MODIFIER:exon8/9:n.707A>G:,ATXN3:NR_028469.1:non_coding_transcript_exon:MODIFIER:exon8/9:n.721A>G:,ATXN3:NR_028470.1:non_coding_transcript_exon:MODIFIER:exon3/4:n.179A>G:,ATXN3:NR_031765.1:non_coding_transcript_exon:MODIFIER:exon4/5:n.376A>G:	(CTG)n	rs12896583	0.0000	0.3342	136/60/40	0.0012							607047 [ATXN3 (confirmed) Machado-Joseph disease,109150];	RCV000116484.2 [likely benign]; 		COSM3749284, COSM3749285, COSM433493	4	578					ATXN3 (inh=AD pLI=0.18)
chr14	92548785	92548785	C	T	het	het	het	pred_pathogenic	QUAL=9368;DP=218,227,279;MQM=60	ATXN3	missense,intron,non_coding_transcript_exon	ATXN3:NM_004993.5:missense:MODERATE:exon8/11:c.634G>A:p.Val212Met,ATXN3:NM_001127696.1:missense:MODERATE:exon7/10:c.589G>A:p.Val197Met,ATXN3:NM_001127697.2:missense:MODERATE:exon6/9:c.481G>A:p.Val161Met,ATXN3:NM_001164779.1:missense:MODERATE:exon4/7:c.271G>A:p.Val91Met,ATXN3:NM_001164780.1:missense:MODERATE:exon5/8:c.97G>A:p.Val33Met,ATXN3:NM_001164781.1:missense:MODERATE:exon6/9:c.424G>A:p.Val142Met,ATXN3:NM_030660.4:missense:MODERATE:exon7/10:c.469G>A:p.Val157Met,ATXN3:NM_001164774.1:intron:MODIFIER:exon2/3:c.190-11388G>A:,ATXN3:NM_001164776.1:intron:MODIFIER:exon3/4:c.235-11388G>A:,ATXN3:NM_001164777.1:intron:MODIFIER:exon2/3:c.70-11388G>A:,ATXN3:NM_001164778.1:intron:MODIFIER:exon5/6:c.387+10811G>A:,ATXN3:NM_001164782.1:intron:MODIFIER:exon1/2:c.25-11388G>A:,ATXN3:NR_028460.1:intron:MODIFIER:exon4/5:n.370+10811G>A:,ATXN3:NR_028468.1:intron:MODIFIER:exon6/8:n.591+685G>A:,ATXN3:NR_028470.1:intron:MODIFIER:exon2/3:n.160+10811G>A:,ATXN3:NR_028453.1:non_coding_transcript_exon:MODIFIER:exon7/10:n.617G>A:,ATXN3:NR_028454.1:non_coding_transcript_exon:MODIFIER:exon6/9:n.452G>A:,ATXN3:NR_028455.1:non_coding_transcript_exon:MODIFIER:exon7/11:n.617G>A:,ATXN3:NR_028456.1:non_coding_transcript_exon:MODIFIER:exon6/10:n.452G>A:,ATXN3:NR_028457.1:non_coding_transcript_exon:MODIFIER:exon8/12:n.708G>A:,ATXN3:NR_028458.1:non_coding_transcript_exon:MODIFIER:exon7/10:n.594G>A:,ATXN3:NR_028459.1:non_coding_transcript_exon:MODIFIER:exon8/12:n.703G>A:,ATXN3:NR_028461.1:non_coding_transcript_exon:MODIFIER:exon7/10:n.615G>A:,ATXN3:NR_028462.1:non_coding_transcript_exon:MODIFIER:exon7/10:n.594G>A:,ATXN3:NR_028463.1:non_coding_transcript_exon:MODIFIER:exon3/7:n.252G>A:,ATXN3:NR_028464.1:non_coding_transcript_exon:MODIFIER:exon6/10:n.550G>A:,ATXN3:NR_028465.1:non_coding_transcript_exon:MODIFIER:exon6/10:n.572G>A:,ATXN3:NR_028466.1:non_coding_transcript_exon:MODIFIER:exon3/6:n.252G>A:,ATXN3:NR_028467.1:non_coding_transcript_exon:MODIFIER:exon7/10:n.618G>A:,ATXN3:NR_028469.1:non_coding_transcript_exon:MODIFIER:exon6/9:n.452G>A:,ATXN3:NR_031765.1:non_coding_transcript_exon:MODIFIER:exon2/5:n.119G>A:		rs1048755	0.3251	0.2714	4838/2011/615	0.2699	2.2370	T,T,T,T,T,T,T,T,T,T,T,T,T,T,T,T,T,T,T,T,T	T	B,B,B,B,B	T,T,T,T,T,T,T,T,T,T,T,T,T,T	21.20	607047 [ATXN3 (confirmed) Machado-Joseph disease,109150];	RCV000116481.2 [likely benign]; 		COSM3754168, COSM3754167, COSM3754169	109	588					ATXN3 (inh=AD pLI=0.18)
chr14	92549586	92549586	G	A	het	het	het		QUAL=6481;DP=307,103,149;MQM=59	ATXN3	splice_region&intron,synonymous,5'UTR_premature_start_codon_gain,5'UTR,intron,non_coding_transcript_exon	ATXN3:NR_028458.1:splice_region&intron:LOW:exon5/9:n.459-7C>T:,ATXN3:NR_028462.1:splice_region&intron:LOW:exon5/9:n.459-7C>T:,ATXN3:NR_028467.1:splice_region&intron:LOW:exon5/9:n.483-7C>T:,ATXN3:NM_004993.5:synonymous:LOW:exon7/11:c.492C>T:p.Val164Val,ATXN3:NM_001127696.1:synonymous:LOW:exon6/10:c.447C>T:p.Val149Val,ATXN3:NM_001127697.2:synonymous:LOW:exon5/9:c.339C>T:p.Val113Val,ATXN3:NM_001164779.1:synonymous:LOW:exon3/7:c.129C>T:p.Val43Val,ATXN3:NM_001164781.1:synonymous:LOW:exon5/9:c.282C>T:p.Val94Val,ATXN3:NM_030660.4:synonymous:LOW:exon6/10:c.327C>T:p.Val109Val,ATXN3:NM_001164780.1:5'UTR_premature_start_codon_gain:LOW:exon4/8:c.-46C>T:,ATXN3:NM_001164780.1:5'UTR:MODIFIER:exon4/8:c.-46C>T:,ATXN3:NM_001164774.1:intron:MODIFIER:exon2/3:c.190-12189C>T:,ATXN3:NM_001164776.1:intron:MODIFIER:exon3/4:c.235-12189C>T:,ATXN3:NM_001164777.1:intron:MODIFIER:exon2/3:c.70-12189C>T:,ATXN3:NM_001164778.1:intron:MODIFIER:exon5/6:c.387+10010C>T:,ATXN3:NM_001164782.1:intron:MODIFIER:exon1/2:c.25-12189C>T:,ATXN3:NR_028460.1:intron:MODIFIER:exon4/5:n.370+10010C>T:,ATXN3:NR_028470.1:intron:MODIFIER:exon2/3:n.160+10010C>T:,ATXN3:NR_031765.1:intron:MODIFIER:exon1/4:n.94-776C>T:,ATXN3:NR_028453.1:non_coding_transcript_exon:MODIFIER:exon6/10:n.475C>T:,ATXN3:NR_028454.1:non_coding_transcript_exon:MODIFIER:exon5/9:n.310C>T:,ATXN3:NR_028455.1:non_coding_transcript_exon:MODIFIER:exon6/11:n.475C>T:,ATXN3:NR_028456.1:non_coding_transcript_exon:MODIFIER:exon5/10:n.310C>T:,ATXN3:NR_028457.1:non_coding_transcript_exon:MODIFIER:exon7/12:n.566C>T:,ATXN3:NR_028459.1:non_coding_transcript_exon:MODIFIER:exon7/12:n.561C>T:,ATXN3:NR_028461.1:non_coding_transcript_exon:MODIFIER:exon6/10:n.473C>T:,ATXN3:NR_028463.1:non_coding_transcript_exon:MODIFIER:exon2/7:n.110C>T:,ATXN3:NR_028464.1:non_coding_transcript_exon:MODIFIER:exon5/10:n.408C>T:,ATXN3:NR_028465.1:non_coding_transcript_exon:MODIFIER:exon5/10:n.430C>T:,ATXN3:NR_028466.1:non_coding_transcript_exon:MODIFIER:exon2/6:n.110C>T:,ATXN3:NR_028468.1:non_coding_transcript_exon:MODIFIER:exon6/9:n.475C>T:,ATXN3:NR_028469.1:non_coding_transcript_exon:MODIFIER:exon5/9:n.310C>T:		rs16999141	0.5667	0.5028	15770/7814/2396	0.4915							607047 [ATXN3 (confirmed) Machado-Joseph disease,109150];	RCV000116480.2 [likely benign]; 		COSM147835	377	800					ATXN3 (inh=AD pLI=0.18)
chr14	93673580	93673580	A	G	het	wt	het		QUAL=2422;DP=87,148,190;MQM=59	UBR7	5'UTR,non_coding_transcript_exon	UBR7:NM_175748.3:5'UTR:MODIFIER:exon1/11:c.-57A>G:,UBR7:NR_038150.1:non_coding_transcript_exon:MODIFIER:exon1/10:n.180A>G:		rs2255370	0.3622	0.4092	1351/321/145	0.1541											136	531					UBR7 (inh=n/a pLI=0.43)
chr14	93693422	93693422	C	T	het	het	het		QUAL=13827;DP=392,286,385;MQM=59	UBR7	3'UTR,non_coding_transcript_exon	UBR7:NM_175748.3:3'UTR:MODIFIER:exon11/11:c.*41C>T:,UBR7:NR_038150.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1421C>T:		rs2905	0.1945	0.2996	4801/3511/16	0.2705											143	603					UBR7 (inh=n/a pLI=0.43)
chr14	93693604	93693604	T	G	het	het	het		QUAL=15362;DP=366,370,505;MQM=60	UBR7	3'UTR,non_coding_transcript_exon	UBR7:NM_175748.3:3'UTR:MODIFIER:exon11/11:c.*223T>G:,UBR7:NR_038150.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1603T>G:		rs10144530	0.3878	0.3776	975/500/30	0.1405											167	318					UBR7 (inh=n/a pLI=0.43)
chr14	93693831	93693831	C	T	het	het	het		QUAL=12044;DP=358,221,285;MQM=60	UBR7	3'UTR,non_coding_transcript_exon	UBR7:NM_175748.3:3'UTR:MODIFIER:exon11/11:c.*450C>T:,UBR7:NR_038150.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1830C>T:		rs11621915	0.1939	0.2190	378/224/1	0.0689											74	293					UBR7 (inh=n/a pLI=0.43)
chr14	97321689	97321689	C	T	het	het	het		QUAL=8859;DP=190,192,274;MQM=60	VRK1	synonymous	VRK1:NM_003384.2:synonymous:LOW:exon8/13:c.705C>T:p.Gly235Gly		rs2230532	0.4167	0.3892	10581/4415/157	0.3865	-0.6900		T			17.47	602168 [VRK1 (provisional) Pontocerebellar hypoplasia type 1A,607596];	RCV000118848.3 [other]; RCV000262267.1 [benign]; 			349	1201					VRK1 (inh=AR pLI=0.04)
chr14	106321590	106321590	C	A	hom	hom	hom		QUAL=21838;DP=279,215,268;MQM=59	ELK2AP-MIR4507	intergenic_region	ELK2AP-MIR4507:ELK2AP-MIR4507:intergenic_region:MODIFIER::n.106321590C>A:		rs12365	0.9149	0.9744	53543/31053/2148	0.9343											1309	23					ELK2AP-MIR4507 (inh=n/a pLI=n/a)
chr14	106321913	106321913	G	A	hom	hom	hom		QUAL=23027;DP=305,199,246;MQM=59	ELK2AP-MIR4507	intergenic_region	ELK2AP-MIR4507:ELK2AP-MIR4507:intergenic_region:MODIFIER::n.106321913G>A:		rs1136534	0.5631	0.5279	16813/8406/2257	0.5077											397	695					ELK2AP-MIR4507 (inh=n/a pLI=n/a)
chr15	23043896	23043896	G	A	hom	hom	hom		QUAL=22297;DP=379,123,169;MQM=60	NIPA1	3'UTR	NIPA1:NM_144599.4:3'UTR:MODIFIER:exon5/5:c.*4933C>T:,NIPA1:NM_001142275.1:3'UTR:MODIFIER:exon5/5:c.*4933C>T:		rs7181789	0.5557	0.0000	0/0/0	0.0965							608145 [NIPA1 (confirmed) Spastic paraplegia 6,autosomal dominant,600363];	RCV000401961.1 [benign]; 			60	121					NIPA1 (inh=AD pLI=0.21)
chr15	23046770	23046770	-	AA	het	hom	wt		QUAL=10432;DP=383,173,233;MQM=59	NIPA1	3'UTR	NIPA1:NM_144599.4:3'UTR:MODIFIER:exon5/5:c.*2058_*2059insTT:,NIPA1:NM_001142275.1:3'UTR:MODIFIER:exon5/5:c.*2058_*2059insTT:		rs3057642	0.7214	0.0000	0/0/0	0.6452							608145 [NIPA1 (confirmed) Spastic paraplegia 6,autosomal dominant,600363];	RCV000266600.1 [benign]; 			125	86					NIPA1 (inh=AD pLI=0.21)
chr15	23046848	23046848	T	C	hom	hom	hom		QUAL=30589;DP=472,199,238;MQM=59	NIPA1	3'UTR	NIPA1:NM_144599.4:3'UTR:MODIFIER:exon5/5:c.*1981A>G:,NIPA1:NM_001142275.1:3'UTR:MODIFIER:exon5/5:c.*1981A>G:		rs6606822	1.0000	0.0000	0/0/0	0.8794							608145 [NIPA1 (confirmed) Spastic paraplegia 6,autosomal dominant,600363];	RCV000357863.1 [benign]; 			230	0					NIPA1 (inh=AD pLI=0.21)
chr15	23046855	23046855	G	T	hom	hom	hom		QUAL=27198;DP=398,185,228;MQM=59	NIPA1	3'UTR	NIPA1:NM_144599.4:3'UTR:MODIFIER:exon5/5:c.*1974C>A:,NIPA1:NM_001142275.1:3'UTR:MODIFIER:exon5/5:c.*1974C>A:		rs6606823	0.9639	0.0000	0/0/0	0.1469							608145 [NIPA1 (confirmed) Spastic paraplegia 6,autosomal dominant,600363];	RCV000265292.1 [benign]; 			196	34					NIPA1 (inh=AD pLI=0.21)
chr15	23046902	23046902	T	C	het	hom	wt		QUAL=10778;DP=344,186,217;MQM=59	NIPA1	3'UTR	NIPA1:NM_144599.4:3'UTR:MODIFIER:exon5/5:c.*1927A>G:,NIPA1:NM_001142275.1:3'UTR:MODIFIER:exon5/5:c.*1927A>G:		rs17807140	0.2558	0.0000	0/0/0	0.0487							608145 [NIPA1 (confirmed) Spastic paraplegia 6,autosomal dominant,600363];	RCV000375079.1 [benign]; 			24	91					NIPA1 (inh=AD pLI=0.21)
chr15	23046982	23046982	-	T	het	hom	wt		QUAL=9285;DP=275,191,194;MQM=59	NIPA1	3'UTR	NIPA1:NM_144599.4:3'UTR:MODIFIER:exon5/5:c.*1846dupA:,NIPA1:NM_001142275.1:3'UTR:MODIFIER:exon5/5:c.*1846dupA:		rs113532349	0.2722	0.0000	0/0/0	0.2688							608145 [NIPA1 (confirmed) Spastic paraplegia 6,autosomal dominant,600363];	RCV000387862.1 [uncertain significance]; RCV000317044.1 [benign]; 			24	91					NIPA1 (inh=AD pLI=0.21)
chr15	23047857	23047857	G	A	het	hom	wt		QUAL=8939;DP=251,178,245;MQM=59	NIPA1	3'UTR	NIPA1:NM_144599.4:3'UTR:MODIFIER:exon5/5:c.*972C>T:,NIPA1:NM_001142275.1:3'UTR:MODIFIER:exon5/5:c.*972C>T:	Tigger3a	rs8025849	0.6879	0.0000	0/0/0	0.1235							608145 [NIPA1 (confirmed) Spastic paraplegia 6,autosomal dominant,600363];	RCV000276623.1 [benign]; 			122	86					NIPA1 (inh=AD pLI=0.21)
chr15	23048542	23048542	A	G	het	hom	wt		QUAL=12873;DP=343,250,312;MQM=60	NIPA1	3'UTR	NIPA1:NM_144599.4:3'UTR:MODIFIER:exon5/5:c.*287T>C:,NIPA1:NM_001142275.1:3'UTR:MODIFIER:exon5/5:c.*287T>C:		rs3812924	0.1893	0.0000	0/0/0	0.0453							608145 [NIPA1 (confirmed) Spastic paraplegia 6,autosomal dominant,600363];	RCV000326090.1 [benign]; 			24	92					NIPA1 (inh=AD pLI=0.21)
chr15	23052632	23052632	T	C	het	hom	wt		QUAL=6668;DP=193,147,224;MQM=60	NIPA1	synonymous	NIPA1:NM_144599.4:synonymous:LOW:exon4/5:c.441A>G:p.Thr147Thr,NIPA1:NM_001142275.1:synonymous:LOW:exon4/5:c.216A>G:p.Thr72Thr		rs11263683	0.7041	0.7359	33561/17397/1324	0.7290							608145 [NIPA1 (confirmed) Spastic paraplegia 6,autosomal dominant,600363];	RCV000117820.2 [likely benign]; RCV000298408.1 [benign]; 		COSM3999473	1118	834					NIPA1 (inh=AD pLI=0.21)
chr15	23931507	23931507	G	A	hom	het	het		QUAL=7973;DP=176,87,126;MQM=59	NDN	synonymous	NDN:NM_002487.2:synonymous:LOW:exon1/1:c.858C>T:p.Asp286Asp		rs2192206	0.1895	0.2268	3136/1558/9	0.2155							602117 [NDN (confirmed) Prader-Willi syndrome,176270];			COSM3754246	92	538					NDN (inh=n/a pLI=0.47)
chr15	25219512	25219512	T	C	hom	hom	hom		QUAL=35242;DP=308,343,440;MQM=60	SNRPN,SNURF	5'UTR,3'UTR	SNRPN:NM_003097.4:5'UTR:MODIFIER:exon4/10:c.-89T>C:,SNRPN:NM_022806.3:5'UTR:MODIFIER:exon6/12:c.-89T>C:,SNRPN:NM_022807.3:5'UTR:MODIFIER:exon7/13:c.-89T>C:,SNRPN:NM_022808.3:5'UTR:MODIFIER:exon6/12:c.-89T>C:,SNRPN:NM_022805.3:5'UTR:MODIFIER:exon6/12:c.-89T>C:,SNURF:NM_005678.4:3'UTR:MODIFIER:exon4/10:c.*100T>C:		rs705	0.5218	0.0000	0/0/0	0.0975							182279 [SNRPN (provisional) Prader-Willi syndrome,176270];	RCV000302218.1 [likely benign]; 			62	140					SNRPN (inh=AD pLI=0.85), SNURF (inh=n/a pLI=0.78)
chr15	32322929	32322929	G	A	wt	wt	het	low_QUAL;low_DP	QUAL=27;DP=2,1,16;MQM=60	CHRNA7	synonymous,intron	CHRNA7:NM_001190455.2:synonymous:LOW:exon1/10:c.132G>A:p.Ala44Ala,CHRNA7:NM_000746.5:intron:MODIFIER:exon1/9:c.55+77G>A:,CHRNA7:NR_046324.1:intron:MODIFIER:exon1/7:n.167+77G>A:		rs2292571	0.0913	0.1512	112/34/0	0.0463							118511 [CHRNA7 (confirmed) Schizophrenia,neurophysiologic defect in];			COSM4148627	28	245					CHRNA7 (inh=n/a pLI=n/a)
chr15	32450704	32450704	G	A	wt	het	wt	low_MQM	QUAL=867;DP=99,199,192;MQM=33	CHRNA7	synonymous,non_coding_transcript_exon	CHRNA7:NM_001190455.2:synonymous:LOW:exon7/10:c.777G>A:p.Thr259Thr,CHRNA7:NM_000746.5:synonymous:LOW:exon7/10:c.690G>A:p.Thr230Thr,CHRNA7:NR_046324.1:non_coding_transcript_exon:MODIFIER:exon5/8:n.612G>A:		rs1042722	0.0000	0.2613	269/60/17	0.0070							118511 [CHRNA7 (confirmed) Schizophrenia,neurophysiologic defect in];			COSM118928, COSM118929	2	766					CHRNA7 (inh=n/a pLI=n/a)
chr15	32460419	32460419	C	T	het	het	het	low_DP;low_MQM	QUAL=326;DP=4,73,117;MQM=26	CHRNA7	synonymous,non_coding_transcript_exon	CHRNA7:NM_001190455.2:synonymous:LOW:exon10/10:c.1356C>T:p.Gly452Gly,CHRNA7:NM_000746.5:synonymous:LOW:exon10/10:c.1269C>T:p.Gly423Gly,CHRNA7:NR_046324.1:non_coding_transcript_exon:MODIFIER:exon8/8:n.1191C>T:		rs1042724	0.0000	0.4590	119/82/9	0.1263							118511 [CHRNA7 (confirmed) Schizophrenia,neurophysiologic defect in];			COSM4148629, COSM4148628	34	830					CHRNA7 (inh=n/a pLI=n/a)
chr15	32461233	32461233	T	C	hom	wt	hom	low_MQM	QUAL=993;DP=25,50,26;MQM=32	CHRNA7	3'UTR,non_coding_transcript_exon	CHRNA7:NM_001190455.2:3'UTR:MODIFIER:exon10/10:c.*574T>C:,CHRNA7:NM_000746.5:3'UTR:MODIFIER:exon10/10:c.*574T>C:,CHRNA7:NR_046324.1:non_coding_transcript_exon:MODIFIER:exon8/8:n.2005T>C:		rs67960669	0.0000	0.0000	0/0/0	0.0004							118511 [CHRNA7 (confirmed) Schizophrenia,neurophysiologic defect in];				0	9					CHRNA7 (inh=n/a pLI=n/a)
chr15	34522679	34522679	C	T	hom	het	hom		QUAL=11998;DP=157,134,169;MQM=59	SLC12A6	3'UTR	SLC12A6:NM_133647.1:3'UTR:MODIFIER:exon25/25:c.*3403G>A:,SLC12A6:NM_005135.2:3'UTR:MODIFIER:exon25/25:c.*3403G>A:,SLC12A6:NM_001042497.1:3'UTR:MODIFIER:exon24/24:c.*3403G>A:,SLC12A6:NM_001042494.1:3'UTR:MODIFIER:exon26/26:c.*3403G>A:,SLC12A6:NM_001042496.1:3'UTR:MODIFIER:exon26/26:c.*3403G>A:,SLC12A6:NM_001042495.1:3'UTR:MODIFIER:exon26/26:c.*3403G>A:		rs4530104	0.5449	0.0000	0/0/0	0.1103							604878 [SLC12A6 (confirmed) Agenesis of the corpus callosum with peripheral neuropathy,218000];	RCV000267812.1 [benign]; 			94	104					SLC12A6 (inh=AR pLI=0.98)
chr15	34522985	34522985	C	G	hom	hom	hom		QUAL=21793;DP=253,199,208;MQM=60	SLC12A6	3'UTR	SLC12A6:NM_133647.1:3'UTR:MODIFIER:exon25/25:c.*3097G>C:,SLC12A6:NM_005135.2:3'UTR:MODIFIER:exon25/25:c.*3097G>C:,SLC12A6:NM_001042497.1:3'UTR:MODIFIER:exon24/24:c.*3097G>C:,SLC12A6:NM_001042494.1:3'UTR:MODIFIER:exon26/26:c.*3097G>C:,SLC12A6:NM_001042496.1:3'UTR:MODIFIER:exon26/26:c.*3097G>C:,SLC12A6:NM_001042495.1:3'UTR:MODIFIER:exon26/26:c.*3097G>C:		rs4238571	0.9671	0.0000	0/0/0	0.8691							604878 [SLC12A6 (confirmed) Agenesis of the corpus callosum with peripheral neuropathy,218000];	RCV000293353.1 [benign]; 			229	1					SLC12A6 (inh=AR pLI=0.98)
chr15	34524357	34524357	C	T	wt	het	wt		QUAL=875;DP=307,77,171;MQM=60	SLC12A6	3'UTR	SLC12A6:NM_133647.1:3'UTR:MODIFIER:exon25/25:c.*1725G>A:,SLC12A6:NM_005135.2:3'UTR:MODIFIER:exon25/25:c.*1725G>A:,SLC12A6:NM_001042497.1:3'UTR:MODIFIER:exon24/24:c.*1725G>A:,SLC12A6:NM_001042494.1:3'UTR:MODIFIER:exon26/26:c.*1725G>A:,SLC12A6:NM_001042496.1:3'UTR:MODIFIER:exon26/26:c.*1725G>A:,SLC12A6:NM_001042495.1:3'UTR:MODIFIER:exon26/26:c.*1725G>A:		rs76243307	0.0086	0.0000	0/0/0	0.0029							604878 [SLC12A6 (confirmed) Agenesis of the corpus callosum with peripheral neuropathy,218000];				0	10					SLC12A6 (inh=AR pLI=0.98)
chr15	34524590	34524590	A	G	hom	hom	hom		QUAL=15754;DP=221,112,152;MQM=59	SLC12A6	3'UTR	SLC12A6:NM_133647.1:3'UTR:MODIFIER:exon25/25:c.*1492T>C:,SLC12A6:NM_005135.2:3'UTR:MODIFIER:exon25/25:c.*1492T>C:,SLC12A6:NM_001042497.1:3'UTR:MODIFIER:exon24/24:c.*1492T>C:,SLC12A6:NM_001042494.1:3'UTR:MODIFIER:exon26/26:c.*1492T>C:,SLC12A6:NM_001042496.1:3'UTR:MODIFIER:exon26/26:c.*1492T>C:,SLC12A6:NM_001042495.1:3'UTR:MODIFIER:exon26/26:c.*1492T>C:	AluSz	rs6495640	0.9457	0.0000	0/0/0	0.8628							604878 [SLC12A6 (confirmed) Agenesis of the corpus callosum with peripheral neuropathy,218000];	RCV000390176.1 [benign]; 			192	1					SLC12A6 (inh=AR pLI=0.98)
chr15	34524995	34524995	G	T	hom	het	hom		QUAL=26473;DP=336,274,377;MQM=59	SLC12A6	3'UTR	SLC12A6:NM_133647.1:3'UTR:MODIFIER:exon25/25:c.*1087C>A:,SLC12A6:NM_005135.2:3'UTR:MODIFIER:exon25/25:c.*1087C>A:,SLC12A6:NM_001042497.1:3'UTR:MODIFIER:exon24/24:c.*1087C>A:,SLC12A6:NM_001042494.1:3'UTR:MODIFIER:exon26/26:c.*1087C>A:,SLC12A6:NM_001042496.1:3'UTR:MODIFIER:exon26/26:c.*1087C>A:,SLC12A6:NM_001042495.1:3'UTR:MODIFIER:exon26/26:c.*1087C>A:		rs4779660	0.7895	0.0000	0/0/0	0.1310							604878 [SLC12A6 (confirmed) Agenesis of the corpus callosum with peripheral neuropathy,218000];	RCV000377910.1 [benign]; 			157	68					SLC12A6 (inh=AR pLI=0.98)
chr15	34525035	34525035	T	C	hom	het	hom		QUAL=30096;DP=404,295,395;MQM=59	SLC12A6	3'UTR	SLC12A6:NM_133647.1:3'UTR:MODIFIER:exon25/25:c.*1047A>G:,SLC12A6:NM_005135.2:3'UTR:MODIFIER:exon25/25:c.*1047A>G:,SLC12A6:NM_001042497.1:3'UTR:MODIFIER:exon24/24:c.*1047A>G:,SLC12A6:NM_001042494.1:3'UTR:MODIFIER:exon26/26:c.*1047A>G:,SLC12A6:NM_001042496.1:3'UTR:MODIFIER:exon26/26:c.*1047A>G:,SLC12A6:NM_001042495.1:3'UTR:MODIFIER:exon26/26:c.*1047A>G:		rs4780233	0.5861	0.0000	0/0/0	0.1130							604878 [SLC12A6 (confirmed) Agenesis of the corpus callosum with peripheral neuropathy,218000];	RCV000267883.1 [benign]; 			94	108					SLC12A6 (inh=AR pLI=0.98)
chr15	34525170	34525170	T	G	wt	het	het		QUAL=1006;DP=150,119,190;MQM=57	SLC12A6	3'UTR	SLC12A6:NM_133647.1:3'UTR:MODIFIER:exon25/25:c.*912A>C:,SLC12A6:NM_005135.2:3'UTR:MODIFIER:exon25/25:c.*912A>C:,SLC12A6:NM_001042497.1:3'UTR:MODIFIER:exon24/24:c.*912A>C:,SLC12A6:NM_001042494.1:3'UTR:MODIFIER:exon26/26:c.*912A>C:,SLC12A6:NM_001042496.1:3'UTR:MODIFIER:exon26/26:c.*912A>C:,SLC12A6:NM_001042495.1:3'UTR:MODIFIER:exon26/26:c.*912A>C:			0.0000	0.0000	0/0/0	0.0001							604878 [SLC12A6 (confirmed) Agenesis of the corpus callosum with peripheral neuropathy,218000];				0	87					SLC12A6 (inh=AR pLI=0.98)
chr15	34525176	34525176	C	G	wt	het	het		QUAL=235;DP=173,98,160;MQM=57	SLC12A6	3'UTR	SLC12A6:NM_133647.1:3'UTR:MODIFIER:exon25/25:c.*906G>C:,SLC12A6:NM_005135.2:3'UTR:MODIFIER:exon25/25:c.*906G>C:,SLC12A6:NM_001042497.1:3'UTR:MODIFIER:exon24/24:c.*906G>C:,SLC12A6:NM_001042494.1:3'UTR:MODIFIER:exon26/26:c.*906G>C:,SLC12A6:NM_001042496.1:3'UTR:MODIFIER:exon26/26:c.*906G>C:,SLC12A6:NM_001042495.1:3'UTR:MODIFIER:exon26/26:c.*906G>C:		rs879186866	0.0000	0.0000	0/0/0	0.0000							604878 [SLC12A6 (confirmed) Agenesis of the corpus callosum with peripheral neuropathy,218000];				0	28					SLC12A6 (inh=AR pLI=0.98)
chr15	34525258	34525258	A	G	het	het	wt		QUAL=5560;DP=341,95,168;MQM=60	SLC12A6	3'UTR	SLC12A6:NM_133647.1:3'UTR:MODIFIER:exon25/25:c.*824T>C:,SLC12A6:NM_005135.2:3'UTR:MODIFIER:exon25/25:c.*824T>C:,SLC12A6:NM_001042497.1:3'UTR:MODIFIER:exon24/24:c.*824T>C:,SLC12A6:NM_001042494.1:3'UTR:MODIFIER:exon26/26:c.*824T>C:,SLC12A6:NM_001042496.1:3'UTR:MODIFIER:exon26/26:c.*824T>C:,SLC12A6:NM_001042495.1:3'UTR:MODIFIER:exon26/26:c.*824T>C:		rs75307067	0.0421	0.0000	0/0/0	0.0099							604878 [SLC12A6 (confirmed) Agenesis of the corpus callosum with peripheral neuropathy,218000];	RCV000372915.1 [likely benign]; 			0	37					SLC12A6 (inh=AR pLI=0.98)
chr15	34528948	34528948	G	A	hom	het	hom		QUAL=29103;DP=351,307,429;MQM=60	SLC12A6	synonymous	SLC12A6:NM_133647.1:synonymous:LOW:exon22/25:c.3003C>T:p.Leu1001Leu,SLC12A6:NM_005135.2:synonymous:LOW:exon22/25:c.2850C>T:p.Leu950Leu,SLC12A6:NM_001042497.1:synonymous:LOW:exon21/24:c.2958C>T:p.Leu986Leu,SLC12A6:NM_001042494.1:synonymous:LOW:exon23/26:c.2826C>T:p.Leu942Leu,SLC12A6:NM_001042496.1:synonymous:LOW:exon23/26:c.2976C>T:p.Leu992Leu,SLC12A6:NM_001042495.1:synonymous:LOW:exon23/26:c.2826C>T:p.Leu942Leu		rs4577050	0.5721	0.6510	26234/15441/995	0.6484							604878 [SLC12A6 (confirmed) Agenesis of the corpus callosum with peripheral neuropathy,218000];	RCV000147486.2 [benign]; RCV000265452.1 [benign]; 		COSM3754266, COSM3754264, COSM3754265	669	684					SLC12A6 (inh=AR pLI=0.98)
chr15	34551082	34551082	G	A	het	het	wt		QUAL=9292;DP=381,348,427;MQM=60	SLC12A6	synonymous	SLC12A6:NM_133647.1:synonymous:LOW:exon4/25:c.475C>T:p.Leu159Leu,SLC12A6:NM_005135.2:synonymous:LOW:exon4/25:c.322C>T:p.Leu108Leu,SLC12A6:NM_001042497.1:synonymous:LOW:exon3/24:c.430C>T:p.Leu144Leu,SLC12A6:NM_001042494.1:synonymous:LOW:exon5/26:c.298C>T:p.Leu100Leu,SLC12A6:NM_001042496.1:synonymous:LOW:exon5/26:c.448C>T:p.Leu150Leu,SLC12A6:NM_001042495.1:synonymous:LOW:exon5/26:c.298C>T:p.Leu100Leu		rs7164902	0.2768	0.2511	4022/1945/240	0.2486							604878 [SLC12A6 (confirmed) Agenesis of the corpus callosum with peripheral neuropathy,218000];	RCV000147488.2 [benign]; RCV000271997.1 [benign]; 		COSM3754270, COSM3754271, COSM3754272	127	571					SLC12A6 (inh=AR pLI=0.98)
chr15	34610964	34610964	G	C	het	het	wt		QUAL=8053;DP=569,184,240;MQM=59	SLC12A6	5'UTR,intron	SLC12A6:NM_005135.2:5'UTR:MODIFIER:exon1/25:c.-85C>G:,SLC12A6:NM_133647.1:intron:MODIFIER:exon1/24:c.271+17647C>G:,SLC12A6:NM_001042497.1:intron:MODIFIER:exon1/23:c.271+17647C>G:,SLC12A6:NM_001042494.1:intron:MODIFIER:exon2/25:c.94+17647C>G:,SLC12A6:NM_001042496.1:intron:MODIFIER:exon2/25:c.244+17647C>G:,SLC12A6:NM_001042495.1:intron:MODIFIER:exon2/25:c.94+17647C>G:		rs347867	0.4515	0.0000	0/0/0	0.0609							604878 [SLC12A6 (confirmed) Agenesis of the corpus callosum with peripheral neuropathy,218000];				26	85					SLC12A6 (inh=AR pLI=0.98)
chr15	34629024	34629024	C	T	het	het	wt		QUAL=3904;DP=261,85,115;MQM=60	SLC12A6	5'UTR,intron	SLC12A6:NM_133647.1:5'UTR:MODIFIER:exon1/25:c.-143G>A:,SLC12A6:NM_001042497.1:5'UTR:MODIFIER:exon1/24:c.-143G>A:,SLC12A6:NM_001042494.1:intron:MODIFIER:exon1/25:c.-98-222G>A:,SLC12A6:NM_001042496.1:intron:MODIFIER:exon1/25:c.-14-156G>A:,SLC12A6:NM_001042495.1:intron:MODIFIER:exon1/25:c.-98-222G>A:		rs73374490	0.2107	0.0000	0/0/0	0.0398							604878 [SLC12A6 (confirmed) Agenesis of the corpus callosum with peripheral neuropathy,218000];	RCV000290170.1 [benign]; RCV000319657.1 [likely benign]; 			5	58					SLC12A6 (inh=AR pLI=0.98)
chr15	40705225	40705225	C	T	wt	wt	het		QUAL=1374;DP=140,107,157;MQM=60	IVD	synonymous	IVD:NM_002225.3:synonymous:LOW:exon7/12:c.732C>T:p.Asp244Asp,IVD:NM_001159508.1:synonymous:LOW:exon6/11:c.642C>T:p.Asp214Asp		rs2229312	0.0791	0.1164	960/676/28	0.1137	0.4200		T			14.11	607036 [IVD (provisional) Isovaleric acidemia,243500];	RCV000080001.5 [benign]; RCV000315524.1 [likely benign]; 			22	346					IVD (inh=AR pLI=0.00)
chr15	40710723	40710723	G	A	hom	het	het		QUAL=28457;DP=517,455,556;MQM=60	IVD	3'UTR	IVD:NM_002225.3:3'UTR:MODIFIER:exon12/12:c.*261G>A:,IVD:NM_001159508.1:3'UTR:MODIFIER:exon11/11:c.*261G>A:		rs2075624	0.3578	0.0000	0/0/0	0.0549							607036 [IVD (provisional) Isovaleric acidemia,243500];	RCV000319888.1 [benign]; 			22	99					IVD (inh=AR pLI=0.00)
chr15	40710762	40710799	GCCCACCTCCCAGGGTAGGCACCTGGGGGCATGCAGGT	-	wt	wt	het		QUAL=2544;DP=105,301,357;MQM=59	IVD	3'UTR	IVD:NM_002225.3:3'UTR:MODIFIER:exon12/12:c.*338_*375delGCCCACCTCCCAGGGTAGGCACCTGGGGGCATGCAGGT:,IVD:NM_001159508.1:3'UTR:MODIFIER:exon11/11:c.*338_*375delGCCCACCTCCCAGGGTAGGCACCTGGGGGCATGCAGGT:		rs368025013	0.0793	0.0000	0/0/0	0.0319							607036 [IVD (provisional) Isovaleric acidemia,243500];				4	10					IVD (inh=AR pLI=0.00)
chr15	40711270	40711270	C	G	hom	hom	het		QUAL=9415;DP=147,102,155;MQM=57	IVD	3'UTR	IVD:NM_002225.3:3'UTR:MODIFIER:exon12/12:c.*808C>G:,IVD:NM_001159508.1:3'UTR:MODIFIER:exon11/11:c.*808C>G:	AluSq2	rs2075625	0.5074	0.0000	0/0/0	0.4814							607036 [IVD (provisional) Isovaleric acidemia,243500];	RCV000310233.1 [benign]; 			253	425					IVD (inh=AR pLI=0.00)
chr15	40711933	40711933	G	A	hom	hom	hom	low_DP;low_MQM	QUAL=2268;DP=59,7,13;MQM=48	IVD	3'UTR	IVD:NM_002225.3:3'UTR:MODIFIER:exon12/12:c.*1471G>A:,IVD:NM_001159508.1:3'UTR:MODIFIER:exon11/11:c.*1471G>A:	AluSg7	rs4923865	0.5869	0.0000	0/0/0	0.5735							607036 [IVD (provisional) Isovaleric acidemia,243500];	RCV000266746.1 [benign]; 			93	72					IVD (inh=AR pLI=0.00)
chr15	40712039	40712039	C	G	hom	hom	het	low_DP	QUAL=1268;DP=40,3,3;MQM=55	IVD	3'UTR	IVD:NM_002225.3:3'UTR:MODIFIER:exon12/12:c.*1577C>G:,IVD:NM_001159508.1:3'UTR:MODIFIER:exon11/11:c.*1577C>G:	AluSg	rs11630850	0.5068	0.0000	0/0/0	0.4713							607036 [IVD (provisional) Isovaleric acidemia,243500];	RCV000298491.1 [benign]; 			60	73					IVD (inh=AR pLI=0.00)
chr15	40712072	40712072	C	T	hom	hom	het	low_DP	QUAL=1142;DP=37,5,4;MQM=52	IVD	3'UTR	IVD:NM_002225.3:3'UTR:MODIFIER:exon12/12:c.*1610C>T:,IVD:NM_001159508.1:3'UTR:MODIFIER:exon11/11:c.*1610C>T:	AluSg	rs11630878	0.5070	0.0000	0/0/0	0.4262							607036 [IVD (provisional) Isovaleric acidemia,243500];	RCV000352977.1 [benign]; 			57	84					IVD (inh=AR pLI=0.00)
chr15	40712349	40712349	G	-	hom	hom	het		QUAL=18434;DP=219,178,247;MQM=59	IVD	3'UTR	IVD:NM_002225.3:3'UTR:MODIFIER:exon12/12:c.*1893delG:,IVD:NM_001159508.1:3'UTR:MODIFIER:exon11/11:c.*1893delG:		rs398026948	0.5070	0.0000	0/0/0	0.4808							607036 [IVD (provisional) Isovaleric acidemia,243500];	RCV000262767.1 [benign]; 			92	155					IVD (inh=AR pLI=0.00)
chr15	40712352	40712352	G	C	wt	wt	het		QUAL=18434;DP=219,178,247;MQM=60	IVD	3'UTR	IVD:NM_002225.3:3'UTR:MODIFIER:exon12/12:c.*1890G>C:,IVD:NM_001159508.1:3'UTR:MODIFIER:exon11/11:c.*1890G>C:		rs12185076	0.0805	0.0000	0/0/0	0.0640							607036 [IVD (provisional) Isovaleric acidemia,243500];	RCV000318067.1 [likely benign]; 			5	71					IVD (inh=AR pLI=0.00)
chr15	40712737	40712737	T	C	hom	hom	hom		QUAL=20211;DP=193,191,258;MQM=60	IVD	3'UTR	IVD:NM_002225.3:3'UTR:MODIFIER:exon12/12:c.*2275T>C:,IVD:NM_001159508.1:3'UTR:MODIFIER:exon11/11:c.*2275T>C:		rs11790	0.6112	0.0000	0/0/0	0.1122							607036 [IVD (provisional) Isovaleric acidemia,243500];	RCV000387858.1 [benign]; 			467	494					IVD (inh=AR pLI=0.00)
chr15	40713306	40713306	T	C	hom	hom	het		QUAL=22519;DP=356,205,308;MQM=59	IVD	3'UTR	IVD:NM_002225.3:3'UTR:MODIFIER:exon12/12:c.*2844T>C:,IVD:NM_001159508.1:3'UTR:MODIFIER:exon11/11:c.*2844T>C:		rs7207	0.5072	0.0000	0/0/0	0.0936							607036 [IVD (provisional) Isovaleric acidemia,243500];	RCV000401680.1 [benign]; 			70	130					IVD (inh=AR pLI=0.00)
chr15	40713491	40713491	A	-	hom	hom	het		QUAL=13402;DP=218,160,207;MQM=59	IVD	3'UTR	IVD:NM_002225.3:3'UTR:MODIFIER:exon12/12:c.*3036delA:,IVD:NM_001159508.1:3'UTR:MODIFIER:exon11/11:c.*3036delA:		rs5812161	0.5072	0.0000	0/0/0	0.4799							607036 [IVD (provisional) Isovaleric acidemia,243500];	RCV000407960.1 [benign]; 			68	131					IVD (inh=AR pLI=0.00)
chr15	42704105	42704105	C	T	hom	hom	hom		QUAL=35856;DP=376,363,429;MQM=59	CAPN3	3'UTR	CAPN3:NM_000070.2:3'UTR:MODIFIER:exon24/24:c.*134C>T:,CAPN3:NM_024344.1:3'UTR:MODIFIER:exon23/23:c.*134C>T:,CAPN3:NM_173087.1:3'UTR:MODIFIER:exon21/21:c.*134C>T:,CAPN3:NM_173088.1:3'UTR:MODIFIER:exon13/13:c.*134C>T:,CAPN3:NM_173089.1:3'UTR:MODIFIER:exon9/9:c.*134C>T:,CAPN3:NM_173090.1:3'UTR:MODIFIER:exon10/10:c.*134C>T:		rs3098423	0.9912	0.0000	0/0/0	0.1807							114240 [CAPN3 (confirmed) Muscular dystrophy,limb-girdle,type 2A,253600];	RCV000259632.1 [benign]; RCV000312848.1 [benign]; RCV000401564.1 [benign]; 			534	11					CAPN3 (inh=AR pLI=0.00)
chr15	43212707	43212707	T	G	wt	hom	het	low_QUAL;low_DP	QUAL=16;DP=1,2,8;MQM=60	TTBK2	5'UTR	TTBK2:NM_173500.3:5'UTR:MODIFIER:exon1/15:c.-139A>C:			0.0000	0.0000	0/0/0	0.0000							611695 [TTBK2 (confirmed) Spinocerebellar ataxia 11,604432];				0	0					TTBK2 (inh=AD pLI=1.00)
chr15	43212818	43212818	C	G	hom	hom	hom	low_DP	QUAL=888;DP=4,5,23;MQM=58	TTBK2	5'UTR	TTBK2:NM_173500.3:5'UTR:MODIFIER:exon1/15:c.-250G>C:		rs12437637	0.5387	0.0000	0/0/0	0.0956							611695 [TTBK2 (confirmed) Spinocerebellar ataxia 11,604432];	RCV000262105.1 [benign]; 			92	46					TTBK2 (inh=AD pLI=1.00)
chr15	43236612	43236612	C	T	hom	hom	hom		QUAL=18226;DP=257,119,174;MQM=60	UBR1	3'UTR	UBR1:NM_174916.2:3'UTR:MODIFIER:exon47/47:c.*915G>A:		rs7178567	0.8442	0.0000	0/0/0	0.1464							605981 [UBR1 (confirmed) Johanson-Blizzard syndrome,243800];				190	38					UBR1 (inh=AR pLI=0.32)
chr15	43237203	43237203	T	C	hom	hom	hom		QUAL=11867;DP=202,67,86;MQM=60	UBR1	3'UTR	UBR1:NM_174916.2:3'UTR:MODIFIER:exon47/47:c.*324A>G:		rs3803341	0.7869	0.0000	0/0/0	0.1444							605981 [UBR1 (confirmed) Johanson-Blizzard syndrome,243800];				188	39					UBR1 (inh=AR pLI=0.32)
chr15	43237414	43237414	C	T	het	het	wt		QUAL=9199;DP=390,297,381;MQM=60	UBR1	3'UTR	UBR1:NM_174916.2:3'UTR:MODIFIER:exon47/47:c.*113G>A:		rs62020698	0.0347	0.0000	0/0/0	0.0129							605981 [UBR1 (confirmed) Johanson-Blizzard syndrome,243800];				2	40					UBR1 (inh=AR pLI=0.32)
chr15	44943757	44943757	A	G	het	hom	het	pred_pathogenic	QUAL=21575;DP=339,374,464;MQM=59	SPG11	missense	SPG11:NM_025137.3:missense:MODERATE:exon6/40:c.1388T>C:p.Phe463Ser,SPG11:NM_001160227.1:missense:MODERATE:exon6/38:c.1388T>C:p.Phe463Ser		rs3759871	0.4748	0.4659	13393/7070/1456	0.4628	1.2260	T,T,T	T	B,B,B,B	T,T,T	23.10	610844 [SPG11 (confirmed) Spastic paraplegia 11,autosomal recessive,604360|Amyotrophic lateral sclerosis 5,juvenile,602099|Charcot-Marie-Tooth disease,axonal,type 2X,616668];	RCV000034172.2 [benign]; RCV000118403.2 [likely benign]; RCV000377866.1 [benign]; 		COSM147894	420	977	1	[1] old entry - no details available			SPG11 (inh=AR pLI=0.00)
chr15	45385496	45385496	A	T	het	hom	wt		QUAL=9616;DP=337,192,305;MQM=60	DUOX2	3'UTR	DUOX2:NM_014080.4:3'UTR:MODIFIER:exon34/34:c.*852T>A:		rs4775744	0.2302	0.0000	0/0/0	0.0206							606759 [DUOX2 (confirmed) Thryoid dyshormonogenesis 6,607200];	RCV000327846.1 [likely benign]; 			3	39					DUOX2 (inh=AR pLI=0.00)
chr15	45385626	45385626	C	T	wt	het	wt		QUAL=2156;DP=207,172,263;MQM=60	DUOX2	3'UTR	DUOX2:NM_014080.4:3'UTR:MODIFIER:exon34/34:c.*722G>A:		rs8024922	0.1032	0.0000	0/0/0	0.0126							606759 [DUOX2 (confirmed) Thryoid dyshormonogenesis 6,607200];	RCV000387062.1 [likely benign]; 			2	31					DUOX2 (inh=AR pLI=0.00)
chr15	45385895	45385895	A	G	wt	het	wt		QUAL=3168;DP=403,227,300;MQM=60	DUOX2	3'UTR	DUOX2:NM_014080.4:3'UTR:MODIFIER:exon34/34:c.*453T>C:		rs3743222	0.0968	0.0000	0/0/0	0.0119							606759 [DUOX2 (confirmed) Thryoid dyshormonogenesis 6,607200];	RCV000389205.1 [likely benign]; 			2	28					DUOX2 (inh=AR pLI=0.00)
chr15	45385916	45385916	C	T	wt	het	wt		QUAL=3247;DP=423,226,285;MQM=60	DUOX2	3'UTR	DUOX2:NM_014080.4:3'UTR:MODIFIER:exon34/34:c.*432G>A:		rs10851420	0.2252	0.0000	0/0/0	0.0185							606759 [DUOX2 (confirmed) Thryoid dyshormonogenesis 6,607200];	RCV000278434.1 [likely benign]; 			2	32					DUOX2 (inh=AR pLI=0.00)
chr15	45386806	45386806	G	C	wt	het	wt		QUAL=1273;DP=139,96,130;MQM=60	DUOX2	synonymous	DUOX2:NM_014080.4:synonymous:LOW:exon33/34:c.4479C>G:p.Pro1493Pro		rs56323146	0.0705	0.0684	321/156/80	0.0641							606759 [DUOX2 (confirmed) Thryoid dyshormonogenesis 6,607200];	RCV000243583.1 [benign]; RCV000304172.1 [likely benign]; 			4	174					DUOX2 (inh=AR pLI=0.00)
chr15	45392075	45392075	G	A	hom	het	hom	pred_pathogenic;anno_pathogenic_hgmd	QUAL=18718;DP=123,313,359;MQM=59	DUOX2	missense	DUOX2:NM_014080.4:missense:MODERATE:exon25/34:c.3200C>T:p.Ser1067Leu		rs269868	0.7202	0.8644	47538/28550/377	0.8378	7.9340	D	T	B		23.00	606759 [DUOX2 (confirmed) Thryoid dyshormonogenesis 6,607200];	RCV000252016.1 [benign]; RCV000394986.1 [benign]; 	CM085371 [CLASS=DM? MUT=REF PHEN="Hypothyroidism transient" GENE=DUOX2]; 	COSM4148787	1330	215	2	[2] old entry - no details available			DUOX2 (inh=AR pLI=0.00)
chr15	45393014	45393014	G	C	wt	het	wt		QUAL=201;DP=51,26,38;MQM=60	DUOX2	missense	DUOX2:NM_014080.4:missense:MODERATE:exon23/34:c.2944C>G:p.Pro982Ala		rs61730030	0.0313	0.0480	194/116/7	0.0468	-0.5420	T	T	B		0.01	606759 [DUOX2 (confirmed) Thryoid dyshormonogenesis 6,607200];	RCV000247053.1 [benign]; 		COSM4148788	4	145					DUOX2 (inh=AR pLI=0.00)
chr15	45397889	45397889	C	T	wt	het	wt		QUAL=2762;DP=247,203,290;MQM=60	DUOX2	synonymous	DUOX2:NM_014080.4:synonymous:LOW:exon18/34:c.2286G>A:p.Gln762Gln		rs73406334	0.0629	0.0673	347/189/51	0.0660							606759 [DUOX2 (confirmed) Thryoid dyshormonogenesis 6,607200];	RCV000250509.1 [benign]; RCV000390536.1 [likely benign]; 			7	192					DUOX2 (inh=AR pLI=0.00)
chr15	45398314	45398314	G	A	wt	het	wt		QUAL=134;DP=36,21,22;MQM=60	DUOX2	splice_region&intron	DUOX2:NM_014080.4:splice_region&intron:LOW:exon17/33:c.2148+9C>T:		rs73406337	0.0631	0.0673	333/181/51	0.0648							606759 [DUOX2 (confirmed) Thryoid dyshormonogenesis 6,607200];	RCV000245946.1 [benign]; RCV000300795.1 [likely benign]; 			7	191					DUOX2 (inh=AR pLI=0.00)
chr15	45398369	45398369	C	T	wt	het	wt		QUAL=360;DP=27,29,27;MQM=60	DUOX2	missense	DUOX2:NM_014080.4:missense:MODERATE:exon17/34:c.2102G>A:p.Arg701Gln		rs113400262	0.0331	0.0505	212/123/7	0.0493	-1.3890	T	T	B,B		19.78	606759 [DUOX2 (confirmed) Thryoid dyshormonogenesis 6,607200];	RCV000242564.1 [benign]; RCV000357885.1 [likely benign]; 			5	162					DUOX2 (inh=AR pLI=0.00)
chr15	45398438	45398438	T	C	wt	het	wt		QUAL=315;DP=58,24,32;MQM=60	DUOX2	missense	DUOX2:NM_014080.4:missense:MODERATE:exon17/34:c.2033A>G:p.His678Arg		rs57659670	0.1649	0.1021	1185/201/800	0.0988	-0.0730	T	T	B,B		0.01	606759 [DUOX2 (confirmed) Thryoid dyshormonogenesis 6,607200];	RCV000251004.1 [benign]; RCV000265293.1 [likely benign]; 	CM085365 [CLASS=DFP MUT=ALT PHEN="Hypothyroidism transient" GENE=DUOX2]; 		12	213	2	[2] old entry - no details available			DUOX2 (inh=AR pLI=0.00)
chr15	45400358	45400358	C	G	hom	hom	hom		QUAL=15127;DP=147,126,219;MQM=59	DUOX2	synonymous	DUOX2:NM_014080.4:synonymous:LOW:exon13/34:c.1461G>C:p.Gly487Gly		rs269860	0.8614	0.9410	54417/31502/1980	0.9115							606759 [DUOX2 (confirmed) Thryoid dyshormonogenesis 6,607200];	RCV000254488.1 [benign]; RCV000364666.1 [benign]; 		COSM4148789	1493	68					DUOX2 (inh=AR pLI=0.00)
chr15	45404066	45404066	G	A	hom	het	hom	low_DP;pred_pathogenic	QUAL=1615;DP=16,19,33;MQM=59	DUOX2	missense	DUOX2:NM_014080.4:missense:MODERATE:exon5/34:c.413C>T:p.Pro138Leu		rs2001616	0.7600	0.8624	45622/26862/943	0.8538	2.4090	T	T	B		16.34	606759 [DUOX2 (confirmed) Thryoid dyshormonogenesis 6,607200];	RCV000251571.1 [benign]; RCV000396025.1 [benign]; 		COSM4148790	1273	265					DUOX2 (inh=AR pLI=0.00)
chr15	45406718	45406718	C	T	wt	wt	het		QUAL=5534;DP=245,464,502;MQM=60	DUOXA2	5'UTR	DUOXA2:NM_207581.3:5'UTR:MODIFIER:exon1/6:c.-86C>T:		rs187290	0.0361	0.0000	0/0/0	0.0120							612772 [DUOXA2 (provisional) Thyroid dyshormonogenesis 5,274900];				3	30					DUOXA2 (inh=AR pLI=0.00)
chr15	45408414	45408414	C	G	hom	hom	hom	pred_pathogenic	QUAL=28364;DP=219,301,398;MQM=59	DUOXA2	missense	DUOXA2:NM_207581.3:missense:MODERATE:exon3/6:c.298C>G:p.Arg100Gly		rs2576090	0.8584	0.9621	56765/33327/1497	0.9217	7.3630	T	T	B	T	12.32	612772 [DUOXA2 (provisional) Thyroid dyshormonogenesis 5,274900];	RCV000250029.1 [benign]; 			1552	8					DUOXA2 (inh=AR pLI=0.00)
chr15	45408710	45408710	A	G	hom	hom	hom		QUAL=11425;DP=106,122,151;MQM=59	DUOXA2	splice_region&intron	DUOXA2:NM_207581.3:splice_region&intron:LOW:exon3/5:c.341-4A>G:		rs2554459	0.9203	0.9819	58282/33236/3025	0.8969							612772 [DUOXA2 (provisional) Thyroid dyshormonogenesis 5,274900];	RCV000247778.1 [benign]; 			1553	11					DUOXA2 (inh=AR pLI=0.00)
chr15	45408933	45408933	T	C	hom	het	hom		QUAL=10075;DP=104,124,183;MQM=59	DUOXA2	splice_region&intron	DUOXA2:NM_207581.3:splice_region&intron:LOW:exon4/5:c.554+6T>C:		rs2576092	0.7642	0.8765	46739/27701/817	0.8572							612772 [DUOXA2 (provisional) Thyroid dyshormonogenesis 5,274900];	RCV000252536.1 [benign]; 			1301	240					DUOXA2 (inh=AR pLI=0.00)
chr15	45653367	45653367	G	A	wt	het	wt		QUAL=210;DP=115,37,55;MQM=60	GATM	3'UTR	GATM:NM_001482.2:3'UTR:MODIFIER:exon9/9:c.*940C>T:,GATM:NM_001321015.1:3'UTR:MODIFIER:exon12/12:c.*940C>T:		rs1049518	0.7177	0.0000	0/0/0	0.0922							602360 [GATM (confirmed) Cerebral creatine deficiency syndrome 3,612718];	RCV000320405.1 [benign]; 			58	98					GATM (inh=AR pLI=0.87)
chr15	45653394	45653394	C	T	wt	het	wt		QUAL=413;DP=157,57,87;MQM=60	GATM	3'UTR	GATM:NM_001482.2:3'UTR:MODIFIER:exon9/9:c.*913G>A:,GATM:NM_001321015.1:3'UTR:MODIFIER:exon12/12:c.*913G>A:		rs17618637	0.0553	0.0000	0/0/0	0.0148							602360 [GATM (confirmed) Cerebral creatine deficiency syndrome 3,612718];	RCV000377389.1 [likely benign]; 			5	47					GATM (inh=AR pLI=0.87)
chr15	45653572	45653572	-	TG	wt	het	wt		QUAL=1329;DP=191,126,167;MQM=60	GATM	3'UTR	GATM:NM_001482.2:3'UTR:MODIFIER:exon9/9:c.*734_*735insCA:,GATM:NM_001321015.1:3'UTR:MODIFIER:exon12/12:c.*734_*735insCA:		rs35410548;rs56259861	0.7177	0.0000	0/0/0	0.4689							602360 [GATM (confirmed) Cerebral creatine deficiency syndrome 3,612718];	RCV000342700.1 [benign]; 			58	101					GATM (inh=AR pLI=0.87)
chr15	45653592	45653592	A	G	wt	het	wt		QUAL=1323;DP=178,126,163;MQM=60	GATM	3'UTR	GATM:NM_001482.2:3'UTR:MODIFIER:exon9/9:c.*715T>C:,GATM:NM_001321015.1:3'UTR:MODIFIER:exon12/12:c.*715T>C:		rs1049508	0.6178	0.0000	0/0/0	0.4363							602360 [GATM (confirmed) Cerebral creatine deficiency syndrome 3,612718];	RCV000403631.1 [benign]; 			34	90					GATM (inh=AR pLI=0.87)
chr15	45653707	45653707	T	C	wt	het	wt		QUAL=559;DP=177,43,55;MQM=59	GATM	3'UTR	GATM:NM_001482.2:3'UTR:MODIFIER:exon9/9:c.*600A>G:,GATM:NM_001321015.1:3'UTR:MODIFIER:exon12/12:c.*600A>G:		rs1049503	0.4507	0.0000	0/0/0	0.0735							602360 [GATM (confirmed) Cerebral creatine deficiency syndrome 3,612718];	RCV000346317.1 [benign]; 			33	90					GATM (inh=AR pLI=0.87)
chr15	45654327	45654327	A	G	wt	het	wt		QUAL=5354;DP=346,432,519;MQM=60	GATM	synonymous	GATM:NM_001482.2:synonymous:LOW:exon9/9:c.1252T>C:p.Leu418Leu,GATM:NM_001321015.1:synonymous:LOW:exon12/12:c.865T>C:p.Leu289Leu		rs1145086	0.7177	0.5329	19400/5340/3721	0.5252							602360 [GATM (confirmed) Cerebral creatine deficiency syndrome 3,612718];	RCV000117124.3 [other]; RCV000395145.1 [benign]; 			347	689					GATM (inh=AR pLI=0.87)
chr15	45661678	45661678	T	A	wt	het	wt	pred_pathogenic	QUAL=2133;DP=192,162,260;MQM=60	GATM	missense,5'UTR_premature_start_codon_gain,5'UTR	GATM:NM_001482.2:missense:MODERATE:exon3/9:c.330A>T:p.Gln110His,GATM:NM_001321015.1:5'UTR_premature_start_codon_gain:LOW:exon6/12:c.-58A>T:,GATM:NM_001321015.1:5'UTR:MODIFIER:exon6/12:c.-58A>T:		rs1288775	0.6186	0.4185	13301/2567/3222	0.4126	1.9470	T	T	B,B	T	12.24	602360 [GATM (confirmed) Cerebral creatine deficiency syndrome 3,612718];	RCV000117125.5 [other]; RCV000312436.1 [benign]; 			175	616					GATM (inh=AR pLI=0.87)
chr15	48580713	48580713	T	C	hom	hom	hom	pred_pathogenic	QUAL=23445;DP=335,151,238;MQM=60	SLC12A1	missense&splice_region	SLC12A1:NM_000338.2:missense&splice_region:MODERATE:exon23/27:c.2873T>C:p.Val958Ala,SLC12A1:NM_001184832.1:missense&splice_region:MODERATE:exon23/27:c.2873T>C:p.Val958Ala		rs1552311	0.9978	0.9992	13825/6167/1679	0.7480	1.0800	T,T	T	B,B	D,D	0.54	600839 [SLC12A1 (confirmed) Bartter syndrome,type 1,601678];	RCV000248948.1 [benign]; RCV000323585.1 [benign]; 			1561	0					SLC12A1 (inh=AR pLI=0.00)
chr15	48595192	48595192	G	T	hom	het	hom		QUAL=19221;DP=330,150,193;MQM=60	SLC12A1	3'UTR	SLC12A1:NM_000338.2:3'UTR:MODIFIER:exon27/27:c.*110G>T:,SLC12A1:NM_001184832.1:3'UTR:MODIFIER:exon27/27:c.*110G>T:		rs8025278	0.7352	0.0000	0/0/0	0.1721							600839 [SLC12A1 (confirmed) Bartter syndrome,type 1,601678];	RCV000348266.1 [benign]; 			209	22					SLC12A1 (inh=AR pLI=0.00)
chr15	48595366	48595366	A	G	hom	het	hom		QUAL=18065;DP=278,143,218;MQM=60	SLC12A1	3'UTR	SLC12A1:NM_000338.2:3'UTR:MODIFIER:exon27/27:c.*284A>G:,SLC12A1:NM_001184832.1:3'UTR:MODIFIER:exon27/27:c.*284A>G:		rs12902028	0.6961	0.0000	0/0/0	0.1456							600839 [SLC12A1 (confirmed) Bartter syndrome,type 1,601678];	RCV000305368.1 [benign]; 			211	18					SLC12A1 (inh=AR pLI=0.00)
chr15	48596166	48596166	A	T	hom	hom	hom		QUAL=13630;DP=205,96,128;MQM=60	SLC12A1	3'UTR	SLC12A1:NM_000338.2:3'UTR:MODIFIER:exon27/27:c.*1084A>T:,SLC12A1:NM_001184832.1:3'UTR:MODIFIER:exon27/27:c.*1084A>T:		rs12438818	0.8207	0.0000	0/0/0	0.1527							600839 [SLC12A1 (confirmed) Bartter syndrome,type 1,601678];	RCV000374469.1 [benign]; 			218	12					SLC12A1 (inh=AR pLI=0.00)
chr15	48701029	48701029	C	T	hom	hom	hom		QUAL=26474;DP=399,183,221;MQM=59	FBN1	3'UTR	FBN1:NM_000138.4:3'UTR:MODIFIER:exon66/66:c.*2158G>A:		rs11070641	0.7823	0.0000	0/0/0	0.7994							134797 [FBN1 (confirmed) Marfan syndrome,154700|Marfan lipodystrophy syndrome,616914|Ectopia lentis,familial,129600|MASS syndrome,604308|Weill-Marchesani syndrome 2,dominant,608328|Aortic aneurysm,ascending,and dissection|Stiff skin syndrome,184900|Acromicric dysplasia,102370|Geleophysic dysplasia 2,614185];	RCV000264532.1 [benign]; RCV000309412.1 [benign]; RCV000313560.1 [benign]; RCV000348604.1 [benign]; RCV000359463.1 [benign]; RCV000362911.1 [benign]; RCV000402950.1 [benign]; RCV000406604.1 [benign]; 			141	74					FBN1 (inh=AD pLI=1.00)
chr15	48701096	48701096	C	T	wt	wt	het		QUAL=2048;DP=258,155,182;MQM=60	FBN1	3'UTR	FBN1:NM_000138.4:3'UTR:MODIFIER:exon66/66:c.*2091G>A:		rs575922741	0.0000	0.0000	0/0/0	0.0006							134797 [FBN1 (confirmed) Marfan syndrome,154700|Marfan lipodystrophy syndrome,616914|Ectopia lentis,familial,129600|MASS syndrome,604308|Weill-Marchesani syndrome 2,dominant,608328|Aortic aneurysm,ascending,and dissection|Stiff skin syndrome,184900|Acromicric dysplasia,102370|Geleophysic dysplasia 2,614185];	RCV000259997.1 [uncertain significance]; RCV000275353.1 [uncertain significance]; RCV000304791.1 [uncertain significance]; RCV000319804.1 [uncertain significance]; RCV000330197.1 [uncertain significance]; RCV000354953.1 [uncertain significance]; RCV000356041.1 [uncertain significance]; RCV000403277.1 [uncertain significance]; 			0	1					FBN1 (inh=AD pLI=1.00)
chr15	48701612	48701612	A	C	hom	hom	hom		QUAL=31868;DP=416,254,324;MQM=60	FBN1	3'UTR	FBN1:NM_000138.4:3'UTR:MODIFIER:exon66/66:c.*1575T>G:		rs4775760	0.6569	0.0000	0/0/0	0.7346							134797 [FBN1 (confirmed) Marfan syndrome,154700|Marfan lipodystrophy syndrome,616914|Ectopia lentis,familial,129600|MASS syndrome,604308|Weill-Marchesani syndrome 2,dominant,608328|Aortic aneurysm,ascending,and dissection|Stiff skin syndrome,184900|Acromicric dysplasia,102370|Geleophysic dysplasia 2,614185];	RCV000263577.1 [benign]; RCV000276624.1 [benign]; RCV000294620.1 [benign]; RCV000330398.1 [benign]; RCV000334072.1 [benign]; RCV000356014.1 [benign]; RCV000368857.1 [benign]; RCV000381682.1 [benign]; 			139	76					FBN1 (inh=AD pLI=1.00)
chr15	48702457	48702457	C	A	hom	hom	hom		QUAL=37677;DP=408,323,408;MQM=59	FBN1	3'UTR	FBN1:NM_000138.4:3'UTR:MODIFIER:exon66/66:c.*730G>T:		rs13598	0.9193	0.0000	0/0/0	0.1412							134797 [FBN1 (confirmed) Marfan syndrome,154700|Marfan lipodystrophy syndrome,616914|Ectopia lentis,familial,129600|MASS syndrome,604308|Weill-Marchesani syndrome 2,dominant,608328|Aortic aneurysm,ascending,and dissection|Stiff skin syndrome,184900|Acromicric dysplasia,102370|Geleophysic dysplasia 2,614185];	RCV000293740.1 [benign]; RCV000294541.1 [benign]; RCV000297172.1 [benign]; RCV000336986.1 [benign]; RCV000351824.1 [benign]; RCV000354587.1 [benign]; RCV000394077.1 [benign]; RCV000401006.1 [benign]; 			184	44					FBN1 (inh=AD pLI=1.00)
chr15	48702873	48702873	G	A	hom	hom	hom		QUAL=52448;DP=607,437,555;MQM=59	FBN1	3'UTR	FBN1:NM_000138.4:3'UTR:MODIFIER:exon66/66:c.*314C>T:		rs1042078	0.6000	0.0000	0/0/0	0.6823							134797 [FBN1 (confirmed) Marfan syndrome,154700|Marfan lipodystrophy syndrome,616914|Ectopia lentis,familial,129600|MASS syndrome,604308|Weill-Marchesani syndrome 2,dominant,608328|Aortic aneurysm,ascending,and dissection|Stiff skin syndrome,184900|Acromicric dysplasia,102370|Geleophysic dysplasia 2,614185];	RCV000275580.1 [benign]; RCV000305212.1 [benign]; RCV000310625.1 [benign]; RCV000340144.1 [benign]; RCV000345741.1 [benign]; RCV000365337.1 [benign]; RCV000399351.1 [benign]; RCV000401289.1 [benign]; 			118	93					FBN1 (inh=AD pLI=1.00)
chr15	48807637	48807637	C	T	hom	hom	hom	pred_pathogenic	QUAL=34238;DP=399,299,396;MQM=59	FBN1	missense	FBN1:NM_000138.4:missense:MODERATE:exon12/66:c.1415G>A:p.Cys472Tyr		rs4775765	1.0000	1.0000	60683/33360/5200	0.9362	5.9640	T	T	B	D	15.61	134797 [FBN1 (confirmed) Marfan syndrome,154700|Marfan lipodystrophy syndrome,616914|Ectopia lentis,familial,129600|MASS syndrome,604308|Weill-Marchesani syndrome 2,dominant,608328|Aortic aneurysm,ascending,and dissection|Stiff skin syndrome,184900|Acromicric dysplasia,102370|Geleophysic dysplasia 2,614185];	RCV000223162.1 [not provided]; 			1611	0					FBN1 (inh=AD pLI=1.00)
chr15	48902965	48902965	G	A	het	wt	het		QUAL=7462;DP=364,187,238;MQM=60	FBN1	sequence_feature,synonymous	FBN1:NM_000138.4:sequence_feature:MODERATE:exon4/66:c.306C>T:,FBN1:NM_000138.4:synonymous:LOW:exon4/66:c.306C>T:p.Cys102Cys		rs25388	0.0008	0.0041	2/2/0	0.0039							134797 [FBN1 (confirmed) Marfan syndrome,154700|Marfan lipodystrophy syndrome,616914|Ectopia lentis,familial,129600|MASS syndrome,604308|Weill-Marchesani syndrome 2,dominant,608328|Aortic aneurysm,ascending,and dissection|Stiff skin syndrome,184900|Acromicric dysplasia,102370|Geleophysic dysplasia 2,614185];	RCV000154417.4 [benign]; RCV000230637.1 [benign]; RCV000230637.1 [benign]; RCV000253616.2 [likely benign]; RCV000287932.1 [likely benign]; RCV000293746.1 [likely benign]; RCV000313423.1 [likely benign]; RCV000347453.1 [likely benign]; RCV000348609.1 [likely benign]; RCV000382318.1 [likely benign]; RCV000407439.1 [likely benign]; 			0	8					FBN1 (inh=AD pLI=1.00)
chr15	49044538	49044538	C	G	hom	het	het		QUAL=11290;DP=183,176,215;MQM=60	CEP152	splice_region&intron	CEP152:NM_001194998.1:splice_region&intron:LOW:exon21/26:c.3466+8G>C:,CEP152:NM_014985.3:splice_region&intron:LOW:exon21/25:c.3466+8G>C:		rs2306187	0.3247	0.1989	3511/562/1308	0.1967							613529 [CEP152 (provisional) Microcephaly 9,primary,autosomal recessive,614852|Seckel syndrome 5,613823];	RCV000081686.7 [benign]; RCV000281663.1 [benign]; RCV000339078.1 [benign]; 			35	351					CEP152 (inh=AR pLI=0.00)
chr15	49048705	49048705	G	C	wt	wt	het		QUAL=2799;DP=330,191,213;MQM=59	CEP152	missense	CEP152:NM_001194998.1:missense:MODERATE:exon20/27:c.2740C>G:p.Leu914Val,CEP152:NM_014985.3:missense:MODERATE:exon20/26:c.2740C>G:p.Leu914Val		rs16961560	0.0505	0.0733	351/225/0	0.0697	0.7850	T,T,T	T	B,B,B	T,T,T	6.81	613529 [CEP152 (provisional) Microcephaly 9,primary,autosomal recessive,614852|Seckel syndrome 5,613823];	RCV000145616.2 [benign]; RCV000309624.1 [likely benign]; RCV000399120.1 [likely benign]; 			15	201					CEP152 (inh=AR pLI=0.00)
chr15	49083577	49083577	C	T	wt	het	het		QUAL=1393;DP=142,77,74;MQM=60	CEP152	splice_region&intron	CEP152:NM_001194998.1:splice_region&intron:LOW:exon7/26:c.833-4G>A:,CEP152:NM_014985.3:splice_region&intron:LOW:exon7/25:c.833-4G>A:		rs58156069	0.3446	0.3975	9903/6650/471	0.3963							613529 [CEP152 (provisional) Microcephaly 9,primary,autosomal recessive,614852|Seckel syndrome 5,613823];	RCV000145648.2 [benign]; RCV000280082.1 [benign]; RCV000374581.1 [benign]; 			296	791					CEP152 (inh=AR pLI=0.00)
chr15	49103174	49103174	T	A	wt	het	wt		QUAL=704;DP=49,88,122;MQM=60	CEP152	5'UTR_premature_start_codon_gain,5'UTR	CEP152:NM_001194998.1:5'UTR_premature_start_codon_gain:LOW:exon1/27:c.-24A>T:,CEP152:NM_014985.3:5'UTR_premature_start_codon_gain:LOW:exon1/26:c.-24A>T:,CEP152:NM_001194998.1:5'UTR:MODIFIER:exon1/27:c.-24A>T:,CEP152:NM_014985.3:5'UTR:MODIFIER:exon1/26:c.-24A>T:		rs62621137	0.0669	0.0000	0/0/0	0.0127							613529 [CEP152 (provisional) Microcephaly 9,primary,autosomal recessive,614852|Seckel syndrome 5,613823];	RCV000124243.1 [benign]; 			8	72					CEP152 (inh=AR pLI=0.00)
chr15	49103175	49103175	G	T	wt	het	wt		QUAL=704;DP=49,88,122;MQM=60	CEP152	5'UTR	CEP152:NM_001194998.1:5'UTR:MODIFIER:exon1/27:c.-25C>A:,CEP152:NM_014985.3:5'UTR:MODIFIER:exon1/26:c.-25C>A:		rs185424999	0.0669	0.0000	0/0/0	0.0127							613529 [CEP152 (provisional) Microcephaly 9,primary,autosomal recessive,614852|Seckel syndrome 5,613823];	RCV000124242.1 [benign]; 			8	72					CEP152 (inh=AR pLI=0.00)
chr15	49103176	49103176	T	A	wt	het	wt		QUAL=704;DP=49,88,122;MQM=60	CEP152	5'UTR	CEP152:NM_001194998.1:5'UTR:MODIFIER:exon1/27:c.-26A>T:,CEP152:NM_014985.3:5'UTR:MODIFIER:exon1/26:c.-26A>T:		rs35871801	0.0669	0.0000	0/0/0	0.0127							613529 [CEP152 (provisional) Microcephaly 9,primary,autosomal recessive,614852|Seckel syndrome 5,613823];	RCV000124241.1 [benign]; 			8	72					CEP152 (inh=AR pLI=0.00)
chr15	49103244	49103244	T	C	hom	het	het		QUAL=9220;DP=172,133,177;MQM=59	CEP152	5'UTR	CEP152:NM_001194998.1:5'UTR:MODIFIER:exon1/27:c.-94A>G:,CEP152:NM_014985.3:5'UTR:MODIFIER:exon1/26:c.-94A>G:		rs2304546	0.1971	0.0000	0/0/0	0.1476							613529 [CEP152 (provisional) Microcephaly 9,primary,autosomal recessive,614852|Seckel syndrome 5,613823];	RCV000330536.1 [benign]; RCV000385024.1 [benign]; 			1	24					CEP152 (inh=AR pLI=0.00)
chr15	51296015	51296015	G	A	het	wt	het		QUAL=6371;DP=300,117,184;MQM=60	AP4E1	3'UTR	AP4E1:NM_007347.4:3'UTR:MODIFIER:exon21/21:c.*1156G>A:,AP4E1:NM_001252127.1:3'UTR:MODIFIER:exon21/21:c.*1156G>A:		rs2619685	0.1566	0.0000	0/0/0	0.0270							607244 [AP4E1 (provisional) Spastic paraplegia 51,autosomal recessive,613744|Stuttering,familial persistent,1,184450];				4	66					AP4E1 (inh=AR pLI=0.98)
chr15	52601189	52601189	C	T	wt	wt	het		QUAL=6947;DP=497,443,563;MQM=60	MYO5A	3'UTR	MYO5A:NM_000259.3:3'UTR:MODIFIER:exon41/41:c.*4704G>A:,MYO5A:NM_001142495.1:3'UTR:MODIFIER:exon40/40:c.*4704G>A:		rs1045700	0.2494	0.0000	0/0/0	0.0473							160777 [MYO5A (confirmed) Griscelli syndrome,type 1,214450];				29	103					MYO5A (inh=AR pLI=0.99)
chr15	52601220	52601220	G	A	wt	wt	het		QUAL=6884;DP=401,425,537;MQM=60	MYO5A	3'UTR	MYO5A:NM_000259.3:3'UTR:MODIFIER:exon41/41:c.*4673C>T:,MYO5A:NM_001142495.1:3'UTR:MODIFIER:exon40/40:c.*4673C>T:		rs1045699	0.4942	0.0000	0/0/0	0.1055							160777 [MYO5A (confirmed) Griscelli syndrome,type 1,214450];				132	76					MYO5A (inh=AR pLI=0.99)
chr15	52601570	52601570	G	T	wt	wt	het		QUAL=4219;DP=351,256,335;MQM=60	MYO5A	3'UTR	MYO5A:NM_000259.3:3'UTR:MODIFIER:exon41/41:c.*4323C>A:,MYO5A:NM_001142495.1:3'UTR:MODIFIER:exon40/40:c.*4323C>A:		rs3751620	0.2814	0.0000	0/0/0	0.0332							160777 [MYO5A (confirmed) Griscelli syndrome,type 1,214450];				11	59					MYO5A (inh=AR pLI=0.99)
chr15	52601591	52601591	C	A	wt	wt	het		QUAL=4405;DP=355,280,338;MQM=60	MYO5A	3'UTR	MYO5A:NM_000259.3:3'UTR:MODIFIER:exon41/41:c.*4302G>T:,MYO5A:NM_001142495.1:3'UTR:MODIFIER:exon40/40:c.*4302G>T:		rs3751619	0.1504	0.0000	0/0/0	0.0261							160777 [MYO5A (confirmed) Griscelli syndrome,type 1,214450];				8	59					MYO5A (inh=AR pLI=0.99)
chr15	52601750	52601750	A	G	hom	hom	hom		QUAL=38808;DP=377,396,436;MQM=59	MYO5A	3'UTR	MYO5A:NM_000259.3:3'UTR:MODIFIER:exon41/41:c.*4143T>C:,MYO5A:NM_001142495.1:3'UTR:MODIFIER:exon40/40:c.*4143T>C:		rs2414136	0.9770	0.0000	0/0/0	0.1485							160777 [MYO5A (confirmed) Griscelli syndrome,type 1,214450];				224	1					MYO5A (inh=AR pLI=0.99)
chr15	52602693	52602693	G	A	wt	het	wt		QUAL=2312;DP=350,186,221;MQM=59	MYO5A	3'UTR	MYO5A:NM_000259.3:3'UTR:MODIFIER:exon41/41:c.*3200C>T:,MYO5A:NM_001142495.1:3'UTR:MODIFIER:exon40/40:c.*3200C>T:		rs11633035	0.0589	0.0000	0/0/0	0.0101							160777 [MYO5A (confirmed) Griscelli syndrome,type 1,214450];				1	25					MYO5A (inh=AR pLI=0.99)
chr15	52602752	52602754	AAC	-	wt	wt	het		QUAL=3503;DP=320,219,267;MQM=59	MYO5A	3'UTR	MYO5A:NM_000259.3:3'UTR:MODIFIER:exon41/41:c.*3139_*3141delGTT:,MYO5A:NM_001142495.1:3'UTR:MODIFIER:exon40/40:c.*3139_*3141delGTT:		rs34647073	0.1500	0.0000	0/0/0	0.1465							160777 [MYO5A (confirmed) Griscelli syndrome,type 1,214450];				8	61					MYO5A (inh=AR pLI=0.99)
chr15	52603363	52603363	G	A	hom	het	het		QUAL=25234;DP=487,347,452;MQM=59	MYO5A	3'UTR	MYO5A:NM_000259.3:3'UTR:MODIFIER:exon41/41:c.*2530C>T:,MYO5A:NM_001142495.1:3'UTR:MODIFIER:exon40/40:c.*2530C>T:		rs7176482	0.3063	0.0000	0/0/0	0.0817							160777 [MYO5A (confirmed) Griscelli syndrome,type 1,214450];				76	106					MYO5A (inh=AR pLI=0.99)
chr15	52604136	52604136	-	TTTGTCATT	hom	hom	hom		QUAL=11039;DP=229,41,62;MQM=59	MYO5A	3'UTR	MYO5A:NM_000259.3:3'UTR:MODIFIER:exon41/41:c.*1756_*1757insAATGACAAA:,MYO5A:NM_001142495.1:3'UTR:MODIFIER:exon40/40:c.*1756_*1757insAATGACAAA:		rs11282676	0.9766	0.0000	0/0/0	0.8231							160777 [MYO5A (confirmed) Griscelli syndrome,type 1,214450];				220	10					MYO5A (inh=AR pLI=0.99)
chr15	52604533	52604533	T	A	wt	het	wt		QUAL=2219;DP=276,151,205;MQM=60	MYO5A	3'UTR	MYO5A:NM_000259.3:3'UTR:MODIFIER:exon41/41:c.*1360A>T:,MYO5A:NM_001142495.1:3'UTR:MODIFIER:exon40/40:c.*1360A>T:		rs62015995	0.0591	0.0000	0/0/0	0.0109							160777 [MYO5A (confirmed) Griscelli syndrome,type 1,214450];				2	24					MYO5A (inh=AR pLI=0.99)
chr15	52643564	52643564	G	A	wt	wt	het	pred_pathogenic	QUAL=3655;DP=313,226,327;MQM=60	MYO5A	missense	MYO5A:NM_000259.3:missense:MODERATE:exon28/41:c.3736C>T:p.Arg1246Cys,MYO5A:NM_001142495.1:missense:MODERATE:exon28/40:c.3736C>T:p.Arg1246Cys		rs1058219	0.1486	0.1543	1506/918/55	0.1534	2.5030	D,.,D,D,D,D,D,D	T	B,P	T,T,T,T,T,T	25.40	160777 [MYO5A (confirmed) Griscelli syndrome,type 1,214450];	RCV000247971.1 [benign]; 			53	440					MYO5A (inh=AR pLI=0.99)
chr15	52667552	52667552	G	A	hom	hom	hom		QUAL=30002;DP=395,237,285;MQM=59	MYO5A	synonymous	MYO5A:NM_000259.3:synonymous:LOW:exon20/41:c.2526C>T:p.Ile842Ile,MYO5A:NM_001142495.1:synonymous:LOW:exon20/40:c.2526C>T:p.Ile842Ile		rs2414145	0.8446	0.9518	55390/33103/1738	0.9188							160777 [MYO5A (confirmed) Griscelli syndrome,type 1,214450];				1504	59					MYO5A (inh=AR pLI=0.99)
chr15	52689526	52689526	T	C	hom	hom	hom		QUAL=34585;DP=389,287,389;MQM=59	MYO5A	synonymous	MYO5A:NM_000259.3:synonymous:LOW:exon10/41:c.1191A>G:p.Thr397Thr,MYO5A:NM_001142495.1:synonymous:LOW:exon10/40:c.1191A>G:p.Thr397Thr		rs2924130	0.9617	0.9896	59189/33361/3794	0.9229							160777 [MYO5A (confirmed) Griscelli syndrome,type 1,214450];				1567	1					MYO5A (inh=AR pLI=0.99)
chr15	52689631	52689631	T	G	hom	hom	hom	pred_pathogenic	QUAL=22056;DP=168,214,309;MQM=59	MYO5A	missense	MYO5A:NM_000259.3:missense:MODERATE:exon10/41:c.1086A>C:p.Glu362Asp,MYO5A:NM_001142495.1:missense:MODERATE:exon10/40:c.1086A>C:p.Glu362Asp		rs1724577	0.8868	0.9629	56334/33115/2483	0.9298	-0.1140	T,T,T,T,T	T	B,B	D,D,D,D,D	1.04	160777 [MYO5A (confirmed) Griscelli syndrome,type 1,214450];			COSM4128296, COSM4128297	1516	49					MYO5A (inh=AR pLI=0.99)
chr15	55495545	55495545	T	C	het	wt	het		QUAL=8724;DP=396,193,247;MQM=59	RAB27A	3'UTR	RAB27A:NM_004580.4:3'UTR:MODIFIER:exon6/6:c.*2160A>G:,RAB27A:NM_183234.2:3'UTR:MODIFIER:exon7/7:c.*2160A>G:,RAB27A:NM_183236.2:3'UTR:MODIFIER:exon7/7:c.*2160A>G:,RAB27A:NM_183235.2:3'UTR:MODIFIER:exon7/7:c.*2160A>G:		rs62020099	0.0036	0.0000	0/0/0	0.0015							603868 [RAB27A (provisional) Griscelli syndrome,type 2,607624];				0	4					RAB27A (inh=AR pLI=0.00)
chr15	55495698	55495698	C	T	het	het	wt	low_MQM	QUAL=2225;DP=143,70,128;MQM=43	RAB27A	3'UTR	RAB27A:NM_004580.4:3'UTR:MODIFIER:exon6/6:c.*2007G>A:,RAB27A:NM_183234.2:3'UTR:MODIFIER:exon7/7:c.*2007G>A:,RAB27A:NM_183236.2:3'UTR:MODIFIER:exon7/7:c.*2007G>A:,RAB27A:NM_183235.2:3'UTR:MODIFIER:exon7/7:c.*2007G>A:	AluY	rs6493769	0.2654	0.0000	0/0/0	0.1887							603868 [RAB27A (provisional) Griscelli syndrome,type 2,607624];	RCV000382963.1 [benign]; 			6	44					RAB27A (inh=AR pLI=0.00)
chr15	55495774	55495774	A	G	het	het	wt		QUAL=1105;DP=84,53,90;MQM=51	RAB27A	3'UTR	RAB27A:NM_004580.4:3'UTR:MODIFIER:exon6/6:c.*1931T>C:,RAB27A:NM_183234.2:3'UTR:MODIFIER:exon7/7:c.*1931T>C:,RAB27A:NM_183236.2:3'UTR:MODIFIER:exon7/7:c.*1931T>C:,RAB27A:NM_183235.2:3'UTR:MODIFIER:exon7/7:c.*1931T>C:	AluY	rs6493770	0.2652	0.0000	0/0/0	0.1014							603868 [RAB27A (provisional) Griscelli syndrome,type 2,607624];	RCV000288579.1 [benign]; 			6	44					RAB27A (inh=AR pLI=0.00)
chr15	55495779	55495779	A	T	het	het	wt		QUAL=1168;DP=59,38,72;MQM=54	RAB27A	3'UTR	RAB27A:NM_004580.4:3'UTR:MODIFIER:exon6/6:c.*1926T>A:,RAB27A:NM_183234.2:3'UTR:MODIFIER:exon7/7:c.*1926T>A:,RAB27A:NM_183236.2:3'UTR:MODIFIER:exon7/7:c.*1926T>A:,RAB27A:NM_183235.2:3'UTR:MODIFIER:exon7/7:c.*1926T>A:	AluY	rs8028801	0.2656	0.0000	0/0/0	0.0867							603868 [RAB27A (provisional) Griscelli syndrome,type 2,607624];	RCV000348181.1 [benign]; 			6	44					RAB27A (inh=AR pLI=0.00)
chr15	55495782	55495782	-	TTA	het	het	wt		QUAL=1168;DP=59,38,72;MQM=54	RAB27A	3'UTR	RAB27A:NM_004580.4:3'UTR:MODIFIER:exon6/6:c.*1922_*1923insTAA:,RAB27A:NM_183234.2:3'UTR:MODIFIER:exon7/7:c.*1922_*1923insTAA:,RAB27A:NM_183236.2:3'UTR:MODIFIER:exon7/7:c.*1922_*1923insTAA:,RAB27A:NM_183235.2:3'UTR:MODIFIER:exon7/7:c.*1922_*1923insTAA:	AluY	rs555244731	0.0000	0.0000	0/0/0	0.0270							603868 [RAB27A (provisional) Griscelli syndrome,type 2,607624];	RCV000383908.1 [uncertain significance]; 			3	39					RAB27A (inh=AR pLI=0.00)
chr15	55495786	55495786	T	A	het	het	wt		QUAL=1161;DP=89,61,81;MQM=54	RAB27A	3'UTR	RAB27A:NM_004580.4:3'UTR:MODIFIER:exon6/6:c.*1919A>T:,RAB27A:NM_183234.2:3'UTR:MODIFIER:exon7/7:c.*1919A>T:,RAB27A:NM_183236.2:3'UTR:MODIFIER:exon7/7:c.*1919A>T:,RAB27A:NM_183235.2:3'UTR:MODIFIER:exon7/7:c.*1919A>T:	AluY	rs867969605	0.0000	0.0000	0/0/0	0.0002							603868 [RAB27A (provisional) Griscelli syndrome,type 2,607624];				3	43					RAB27A (inh=AR pLI=0.00)
chr15	55495790	55495790	T	A	het	het	wt		QUAL=1161;DP=89,61,81;MQM=54	RAB27A	3'UTR	RAB27A:NM_004580.4:3'UTR:MODIFIER:exon6/6:c.*1915A>T:,RAB27A:NM_183234.2:3'UTR:MODIFIER:exon7/7:c.*1915A>T:,RAB27A:NM_183236.2:3'UTR:MODIFIER:exon7/7:c.*1915A>T:,RAB27A:NM_183235.2:3'UTR:MODIFIER:exon7/7:c.*1915A>T:	AluY		0.0000	0.0000	0/0/0	0.0002							603868 [RAB27A (provisional) Griscelli syndrome,type 2,607624];				2	39					RAB27A (inh=AR pLI=0.00)
chr15	55495801	55495801	T	A	het	het	wt		QUAL=1668;DP=95,60,69;MQM=51	RAB27A	3'UTR	RAB27A:NM_004580.4:3'UTR:MODIFIER:exon6/6:c.*1904A>T:,RAB27A:NM_183234.2:3'UTR:MODIFIER:exon7/7:c.*1904A>T:,RAB27A:NM_183236.2:3'UTR:MODIFIER:exon7/7:c.*1904A>T:,RAB27A:NM_183235.2:3'UTR:MODIFIER:exon7/7:c.*1904A>T:	AluY	rs28620827	0.0000	0.0000	0/0/0	0.0259							603868 [RAB27A (provisional) Griscelli syndrome,type 2,607624];				4	46					RAB27A (inh=AR pLI=0.00)
chr15	55495963	55495963	T	C	het	het	wt		QUAL=5457;DP=288,174,269;MQM=59	RAB27A	3'UTR	RAB27A:NM_004580.4:3'UTR:MODIFIER:exon6/6:c.*1742A>G:,RAB27A:NM_183234.2:3'UTR:MODIFIER:exon7/7:c.*1742A>G:,RAB27A:NM_183236.2:3'UTR:MODIFIER:exon7/7:c.*1742A>G:,RAB27A:NM_183235.2:3'UTR:MODIFIER:exon7/7:c.*1742A>G:		rs1061824	0.2652	0.0000	0/0/0	0.0334							603868 [RAB27A (provisional) Griscelli syndrome,type 2,607624];	RCV000304619.1 [benign]; 			9	45					RAB27A (inh=AR pLI=0.00)
chr15	55496043	55496043	T	A	het	het	wt		QUAL=3034;DP=138,122,176;MQM=60	RAB27A	3'UTR	RAB27A:NM_004580.4:3'UTR:MODIFIER:exon6/6:c.*1662A>T:,RAB27A:NM_183234.2:3'UTR:MODIFIER:exon7/7:c.*1662A>T:,RAB27A:NM_183236.2:3'UTR:MODIFIER:exon7/7:c.*1662A>T:,RAB27A:NM_183235.2:3'UTR:MODIFIER:exon7/7:c.*1662A>T:		rs1061823	0.2654	0.0000	0/0/0	0.0314							603868 [RAB27A (provisional) Griscelli syndrome,type 2,607624];	RCV000301016.1 [benign]; 			9	46					RAB27A (inh=AR pLI=0.00)
chr15	55496058	55496058	A	C	het	het	wt		QUAL=2922;DP=141,112,161;MQM=60	RAB27A	3'UTR	RAB27A:NM_004580.4:3'UTR:MODIFIER:exon6/6:c.*1647T>G:,RAB27A:NM_183234.2:3'UTR:MODIFIER:exon7/7:c.*1647T>G:,RAB27A:NM_183236.2:3'UTR:MODIFIER:exon7/7:c.*1647T>G:,RAB27A:NM_183235.2:3'UTR:MODIFIER:exon7/7:c.*1647T>G:		rs1061822	0.2654	0.0000	0/0/0	0.0332							603868 [RAB27A (provisional) Griscelli syndrome,type 2,607624];	RCV000355996.1 [benign]; 			10	45					RAB27A (inh=AR pLI=0.00)
chr15	55496111	55496111	T	C	het	het	wt		QUAL=2898;DP=196,66,91;MQM=60	RAB27A	3'UTR	RAB27A:NM_004580.4:3'UTR:MODIFIER:exon6/6:c.*1594A>G:,RAB27A:NM_183234.2:3'UTR:MODIFIER:exon7/7:c.*1594A>G:,RAB27A:NM_183236.2:3'UTR:MODIFIER:exon7/7:c.*1594A>G:,RAB27A:NM_183235.2:3'UTR:MODIFIER:exon7/7:c.*1594A>G:		rs1061821	0.2652	0.0000	0/0/0	0.0327							603868 [RAB27A (provisional) Griscelli syndrome,type 2,607624];	RCV000311768.1 [benign]; 			7	46					RAB27A (inh=AR pLI=0.00)
chr15	55496278	55496278	C	T	het	het	wt		QUAL=3459;DP=205,44,60;MQM=59	RAB27A	3'UTR	RAB27A:NM_004580.4:3'UTR:MODIFIER:exon6/6:c.*1427G>A:,RAB27A:NM_183234.2:3'UTR:MODIFIER:exon7/7:c.*1427G>A:,RAB27A:NM_183236.2:3'UTR:MODIFIER:exon7/7:c.*1427G>A:,RAB27A:NM_183235.2:3'UTR:MODIFIER:exon7/7:c.*1427G>A:		rs1061875	0.2652	0.0000	0/0/0	0.0320							603868 [RAB27A (provisional) Griscelli syndrome,type 2,607624];	RCV000325244.1 [benign]; 			9	64					RAB27A (inh=AR pLI=0.00)
chr15	55496287	55496287	A	T	het	het	wt		QUAL=3189;DP=186,46,58;MQM=59	RAB27A	3'UTR	RAB27A:NM_004580.4:3'UTR:MODIFIER:exon6/6:c.*1418T>A:,RAB27A:NM_183234.2:3'UTR:MODIFIER:exon7/7:c.*1418T>A:,RAB27A:NM_183236.2:3'UTR:MODIFIER:exon7/7:c.*1418T>A:,RAB27A:NM_183235.2:3'UTR:MODIFIER:exon7/7:c.*1418T>A:		rs1061874	0.2654	0.0000	0/0/0	0.0322							603868 [RAB27A (provisional) Griscelli syndrome,type 2,607624];	RCV000384508.1 [benign]; 			9	64					RAB27A (inh=AR pLI=0.00)
chr15	55496313	55496313	T	G	wt	het	het		QUAL=1273;DP=186,41,61;MQM=60	RAB27A	3'UTR	RAB27A:NM_004580.4:3'UTR:MODIFIER:exon6/6:c.*1392A>C:,RAB27A:NM_183234.2:3'UTR:MODIFIER:exon7/7:c.*1392A>C:,RAB27A:NM_183236.2:3'UTR:MODIFIER:exon7/7:c.*1392A>C:,RAB27A:NM_183235.2:3'UTR:MODIFIER:exon7/7:c.*1392A>C:		rs12907749	0.0779	0.0000	0/0/0	0.0183							603868 [RAB27A (provisional) Griscelli syndrome,type 2,607624];	RCV000271160.1 [likely benign]; 			6	78					RAB27A (inh=AR pLI=0.00)
chr15	55496756	55496756	T	C	het	het	wt		QUAL=6441;DP=344,178,247;MQM=60	RAB27A	3'UTR	RAB27A:NM_004580.4:3'UTR:MODIFIER:exon6/6:c.*949A>G:,RAB27A:NM_183234.2:3'UTR:MODIFIER:exon7/7:c.*949A>G:,RAB27A:NM_183236.2:3'UTR:MODIFIER:exon7/7:c.*949A>G:,RAB27A:NM_183235.2:3'UTR:MODIFIER:exon7/7:c.*949A>G:		rs1061873	0.2650	0.0000	0/0/0	0.0334							603868 [RAB27A (provisional) Griscelli syndrome,type 2,607624];	RCV000341280.1 [benign]; 			9	64					RAB27A (inh=AR pLI=0.00)
chr15	55496769	55496769	G	T	het	het	wt		QUAL=6403;DP=335,176,265;MQM=60	RAB27A	3'UTR	RAB27A:NM_004580.4:3'UTR:MODIFIER:exon6/6:c.*936C>A:,RAB27A:NM_183234.2:3'UTR:MODIFIER:exon7/7:c.*936C>A:,RAB27A:NM_183236.2:3'UTR:MODIFIER:exon7/7:c.*936C>A:,RAB27A:NM_183235.2:3'UTR:MODIFIER:exon7/7:c.*936C>A:		rs1061870	0.2652	0.0000	0/0/0	0.0334							603868 [RAB27A (provisional) Griscelli syndrome,type 2,607624];	RCV000373109.1 [benign]; 			9	64					RAB27A (inh=AR pLI=0.00)
chr15	55496853	55496853	G	A	het	het	wt		QUAL=4364;DP=264,112,204;MQM=60	RAB27A	3'UTR	RAB27A:NM_004580.4:3'UTR:MODIFIER:exon6/6:c.*852C>T:,RAB27A:NM_183234.2:3'UTR:MODIFIER:exon7/7:c.*852C>T:,RAB27A:NM_183236.2:3'UTR:MODIFIER:exon7/7:c.*852C>T:,RAB27A:NM_183235.2:3'UTR:MODIFIER:exon7/7:c.*852C>T:		rs3179664	0.3267	0.0000	0/0/0	0.0365							603868 [RAB27A (provisional) Griscelli syndrome,type 2,607624];	RCV000338342.1 [benign]; 			10	64					RAB27A (inh=AR pLI=0.00)
chr15	55497691	55497691	G	A	het	het	wt		QUAL=10480;DP=537,358,399;MQM=60	RAB27A	3'UTR	RAB27A:NM_004580.4:3'UTR:MODIFIER:exon6/6:c.*14C>T:,RAB27A:NM_183234.2:3'UTR:MODIFIER:exon7/7:c.*14C>T:,RAB27A:NM_183236.2:3'UTR:MODIFIER:exon7/7:c.*14C>T:,RAB27A:NM_183235.2:3'UTR:MODIFIER:exon7/7:c.*14C>T:		rs1050931	0.2648	0.2007	3129/1157/1301	0.1965							603868 [RAB27A (provisional) Griscelli syndrome,type 2,607624];	RCV000253078.1 [benign]; RCV000320993.1 [benign]; 		COSN164951	52	284					RAB27A (inh=AR pLI=0.00)
chr15	65369395	65369395	C	T	hom	hom	wt	low_DP;pred_pathogenic	QUAL=293;DP=2,11,14;MQM=60	KBTBD13	missense	KBTBD13:NM_001101362.2:missense:MODERATE:exon1/1:c.242C>T:p.Ala81Val		rs2919358	0.5218	0.4003	814/220/49	0.1895	7.2510	T	T	P	T	28.30	613727 [KBTBD13 (provisional) Nemaline myopathy 6,autosomal dominant,609273];	RCV000117309.2 [benign]; RCV000368854.1 [benign]; 		COSM3749303	257	638					KBTBD13 (inh=AD pLI=0.00)
chr15	65369531	65369531	G	T	het	hom	wt	low_DP	QUAL=472;DP=2,17,14;MQM=60	KBTBD13	synonymous	KBTBD13:NM_001101362.2:synonymous:LOW:exon1/1:c.378G>T:p.Ala126Ala		rs2946642	0.5016	0.4024	763/201/35	0.1697							613727 [KBTBD13 (provisional) Nemaline myopathy 6,autosomal dominant,609273];	RCV000117310.2 [benign]; RCV000315819.1 [benign]; 		COSM3754413	262	645					KBTBD13 (inh=AD pLI=0.00)
chr15	65369951	65369951	A	G	hom	hom	hom		QUAL=3542;DP=21,43,54;MQM=59	KBTBD13	synonymous	KBTBD13:NM_001101362.2:synonymous:LOW:exon1/1:c.798A>G:p.Glu266Glu		rs2919359	0.9038	0.8853	30318/15899/1992	0.7621							613727 [KBTBD13 (provisional) Nemaline myopathy 6,autosomal dominant,609273];	RCV000117312.2 [benign]; RCV000287772.1 [benign]; 		COSM3749304	1170	336					KBTBD13 (inh=AD pLI=0.00)
chr15	65370353	65370353	T	C	hom	hom	hom		QUAL=16649;DP=113,183,257;MQM=59	KBTBD13	synonymous	KBTBD13:NM_001101362.2:synonymous:LOW:exon1/1:c.1200T>C:p.Gly400Gly		rs2919360	0.9894	0.9961	55898/30708/3823	0.9146							613727 [KBTBD13 (provisional) Nemaline myopathy 6,autosomal dominant,609273];	RCV000117308.2 [benign]; RCV000359041.1 [benign]; 		COSM3754414	1543	11					KBTBD13 (inh=AD pLI=0.00)
chr15	65370652	65370652	T	C	het	wt	hom		QUAL=14467;DP=352,284,329;MQM=59	KBTBD13	3'UTR	KBTBD13:NM_001101362.2:3'UTR:MODIFIER:exon1/1:c.*122T>C:		rs12901617	0.3908	0.0000	0/0/0	0.4272							613727 [KBTBD13 (provisional) Nemaline myopathy 6,autosomal dominant,609273];	RCV000389026.1 [benign]; 			35	78					KBTBD13 (inh=AD pLI=0.00)
chr15	65370835	65370835	C	T	hom	hom	hom		QUAL=23617;DP=305,192,270;MQM=59	KBTBD13	3'UTR	KBTBD13:NM_001101362.2:3'UTR:MODIFIER:exon1/1:c.*305C>T:		rs2946643	0.8894	0.0000	0/0/0	0.7833							613727 [KBTBD13 (provisional) Nemaline myopathy 6,autosomal dominant,609273];	RCV000294476.1 [benign]; 			121	23					KBTBD13 (inh=AD pLI=0.00)
chr15	65371050	65371050	A	G	het	wt	hom		QUAL=14560;DP=420,157,281;MQM=60	KBTBD13	3'UTR	KBTBD13:NM_001101362.2:3'UTR:MODIFIER:exon1/1:c.*520A>G:		rs12904843	0.3433	0.0000	0/0/0	0.3896							613727 [KBTBD13 (provisional) Nemaline myopathy 6,autosomal dominant,609273];	RCV000385367.1 [benign]; 			28	84					KBTBD13 (inh=AD pLI=0.00)
chr15	65371427	65371427	A	G	het	wt	hom		QUAL=16453;DP=287,304,419;MQM=60	KBTBD13	3'UTR	KBTBD13:NM_001101362.2:3'UTR:MODIFIER:exon1/1:c.*897A>G:		rs12905499	0.3832	0.0000	0/0/0	0.4069							613727 [KBTBD13 (provisional) Nemaline myopathy 6,autosomal dominant,609273];	RCV000343355.1 [benign]; 			30	82					KBTBD13 (inh=AD pLI=0.00)
chr15	66729107	66729107	C	T	wt	het	wt		QUAL=2157;DP=138,220,275;MQM=60	MAP2K1	synonymous,sequence_feature	MAP2K1:NM_002755.3:synonymous:LOW:exon3/11:c.315C>T:p.Pro105Pro,MAP2K1:NM_002755.3:sequence_feature:LOW:exon3/11:c.315C>T:		rs144166521	0.0004	0.0006	0/0/0	0.0006	-2.5190		T			17.13	176872 [MAP2K1 (confirmed) Cardiofaciocutaneous syndrome 3,615279];	RCV000037594.4 [other]; RCV000227559.1 [benign]; 			0	7					MAP2K1 (inh=AD pLI=0.99)
chr15	66782048	66782048	C	T	wt	het	wt		QUAL=2126;DP=277,177,281;MQM=60	MAP2K1	splice_region&intron	MAP2K1:NM_002755.3:splice_region&intron:LOW:exon9/10:c.1023-8C>T:		rs41306345	0.0893	0.0843	420/220/55	0.0818							176872 [MAP2K1 (confirmed) Cardiofaciocutaneous syndrome 3,615279];	RCV000037587.4 [benign]; RCV000345322.1 [likely benign]; RCV000406966.1 [likely benign]; 		COSM3999588	11	259					MAP2K1 (inh=AD pLI=0.99)
chr15	68499321	68499321	T	C	het	hom	het		QUAL=1317;DP=39,21,28;MQM=60	CALML4-CLN6	intergenic_region	CALML4-CLN6:CALML4-CLN6:intergenic_region:MODIFIER::n.68499321T>C:		rs8028241	0.4842	0.0000	0/0/0	0.4951							606725 [CLN6 (confirmed) Ceroid lipofuscinosis,neuronal,6,601780|Ceroid lipofuscinosis,neuronal,Kufs type,adult onset,204300];	RCV000328369.1 [benign]; 			66	115					CALML4-CLN6 (inh=n/a pLI=n/a)
chr15	68499661	68499661	G	A	het	hom	wt	low_DP	QUAL=353;DP=16,7,2;MQM=60	CLN6	3'UTR	CLN6:NM_017882.2:3'UTR:MODIFIER:exon7/7:c.*817C>T:		rs8142	0.4050	0.0000	0/0/0	0.0793							606725 [CLN6 (confirmed) Ceroid lipofuscinosis,neuronal,6,601780|Ceroid lipofuscinosis,neuronal,Kufs type,adult onset,204300];	RCV000355138.1 [benign]; 			62	102					CLN6 (inh=AR pLI=0.38)
chr15	68500318	68500321	ACAC	-	het	hom	het		QUAL=6602;DP=98,106,157;MQM=59	CLN6	3'UTR	CLN6:NM_017882.2:3'UTR:MODIFIER:exon7/7:c.*157_*160delGTGT:	(CA)n	rs141886537;rs748086627;rs780072735	0.0000	0.0000	0/0/0	0.2620							606725 [CLN6 (confirmed) Ceroid lipofuscinosis,neuronal,6,601780|Ceroid lipofuscinosis,neuronal,Kufs type,adult onset,204300];	RCV000350982.1 [uncertain significance]; 			77	107					CLN6 (inh=AR pLI=0.38)
chr15	68500317	68500317	-	AC	het	wt	het		QUAL=6602;DP=98,106,157;MQM=59	CLN6	3'UTR	CLN6:NM_017882.2:3'UTR:MODIFIER:exon7/7:c.*159_*160dupGT:	(CA)n	rs138882836;rs201282122;rs765543395;rs780072735	0.3345	0.0000	0/0/0	0.2518							606725 [CLN6 (confirmed) Ceroid lipofuscinosis,neuronal,6,601780|Ceroid lipofuscinosis,neuronal,Kufs type,adult onset,204300];	RCV000338546.1 [other]; RCV000390333.1 [uncertain significance]; RCV000279536.1 [likely benign]; 			16	128					CLN6 (inh=AR pLI=0.38)
chr15	72635829	72635829	A	C	hom	hom	hom		QUAL=8020;DP=136,53,61;MQM=59	HEXA	3'UTR	HEXA:NM_001318825.1:3'UTR:MODIFIER:exon14/14:c.*589T>G:,HEXA:NM_000520.5:3'UTR:MODIFIER:exon14/14:c.*589T>G:		rs11629508	0.6933	0.0000	0/0/0	0.1426							606869 [HEXA (confirmed) Tay-Sachs disease,272800|GM2-gangliosidosis,several forms,272800|Hex A pseudodeficiency,272800];	RCV000301101.1 [benign]; 			200	30					HEXA (inh=AR pLI=0.00)
chr15	72635903	72635903	C	T	hom	hom	hom		QUAL=9523;DP=122,85,101;MQM=60	HEXA	3'UTR	HEXA:NM_001318825.1:3'UTR:MODIFIER:exon14/14:c.*515G>A:,HEXA:NM_000520.5:3'UTR:MODIFIER:exon14/14:c.*515G>A:		rs3087652	0.6929	0.0000	0/0/0	0.1428							606869 [HEXA (confirmed) Tay-Sachs disease,272800|GM2-gangliosidosis,several forms,272800|Hex A pseudodeficiency,272800];	RCV000275354.1 [benign]; 			200	30					HEXA (inh=AR pLI=0.00)
chr15	72637795	72637795	T	C	hom	hom	hom		QUAL=21227;DP=246,205,216;MQM=60	HEXA	synonymous,non_coding_transcript_exon	HEXA:NM_001318825.1:synonymous:LOW:exon13/14:c.1551A>G:p.Glu517Glu,HEXA:NM_000520.5:synonymous:LOW:exon13/14:c.1518A>G:p.Glu506Glu,HEXA:NR_134869.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.1762A>G:		rs4777502	0.8770	0.9641	57123/33251/1969	0.9432							606869 [HEXA (confirmed) Tay-Sachs disease,272800|GM2-gangliosidosis,several forms,272800|Hex A pseudodeficiency,272800];	RCV000079051.9 [other]; RCV000291094.1 [benign]; 			3311	41					HEXA (inh=AR pLI=0.00)
chr15	72638892	72638892	T	C	hom	hom	hom	pred_pathogenic	QUAL=7793;DP=88,58,93;MQM=60	HEXA	missense,intron	HEXA:NM_001318825.1:missense:MODERATE:exon11/14:c.1339A>G:p.Ile447Val,HEXA:NM_000520.5:missense:MODERATE:exon11/14:c.1306A>G:p.Ile436Val,HEXA:NR_134869.1:intron:MODIFIER:exon9/10:n.1575-226A>G:		rs1800431	0.8764	0.9643	57089/33227/1971	0.9339	-0.2020	T,T	T	B,B	D,D	13.21	606869 [HEXA (confirmed) Tay-Sachs disease,272800|GM2-gangliosidosis,several forms,272800|Hex A pseudodeficiency,272800];	RCV000079049.9 [other]; RCV000283218.1 [benign]; 			3308	43					HEXA (inh=AR pLI=0.00)
chr15	72668304	72668304	A	G	het	wt	het	pred_pathogenic;anno_pathogenic_hgmd	QUAL=4138;DP=126,183,227;MQM=59	HEXA	missense,non_coding_transcript_exon	HEXA:NM_001318825.1:missense:MODERATE:exon1/14:c.10T>C:p.Ser4Pro,HEXA:NM_000520.5:missense:MODERATE:exon1/14:c.10T>C:p.Ser4Pro,HEXA:NR_134869.1:non_coding_transcript_exon:MODIFIER:exon1/11:n.511T>C:		rs146938346	0.0000	0.0001	0/0/0	0.0001	-0.1370	T	D	B,B	D	17.79	606869 [HEXA (confirmed) Tay-Sachs disease,272800|GM2-gangliosidosis,several forms,272800|Hex A pseudodeficiency,272800];		CM045965 [CLASS=DM? MUT=ALT PHEN="Beta-hexosaminidase pseudodeficiency" GENE=HEXA]; 		0	8					HEXA (inh=AR pLI=0.00)
chr15	72978552	72978552	C	T	het	het	het		QUAL=2373;DP=121,82,81;MQM=60	BBS4	5'UTR,non_coding_transcript_exon	BBS4:NM_033028.4:5'UTR:MODIFIER:exon1/16:c.-17C>T:,BBS4:NM_001252678.1:5'UTR:MODIFIER:exon1/15:c.-486C>T:,BBS4:NM_001320665.1:5'UTR:MODIFIER:exon1/15:c.-17C>T:,BBS4:NR_045565.1:non_coding_transcript_exon:MODIFIER:exon1/17:n.33C>T:,BBS4:NR_045566.1:non_coding_transcript_exon:MODIFIER:exon1/16:n.33C>T:		rs56368716	0.0375	0.0839	94/83/0	0.0402							600374 [BBS4 (confirmed) Bardet-Biedl syndrome 4,615982];	RCV000020935.2 [benign]; RCV000173544.2 [benign]; RCV000371581.1 [likely benign]; 			10	232					BBS4 (inh=AR pLI=0.00)
chr15	73002035	73002035	G	A	hom	hom	hom		QUAL=24132;DP=294,208,244;MQM=59	BBS4	splice_region&intron	BBS4:NM_033028.4:splice_region&intron:LOW:exon2/15:c.77-6G>A:,BBS4:NM_001252678.1:splice_region&intron:LOW:exon1/14:c.-445-6G>A:,BBS4:NM_001320665.1:splice_region&intron:LOW:exon2/14:c.77-6G>A:,BBS4:NR_045565.1:splice_region&intron:LOW:exon3/16:n.184-6G>A:,BBS4:NR_045566.1:splice_region&intron:LOW:exon2/15:n.439-6G>A:		rs8033604	0.9421	0.9831	58833/33340/3448	0.9549							600374 [BBS4 (confirmed) Bardet-Biedl syndrome 4,615982];	RCV000252464.1 [benign]; RCV000292222.1 [benign]; 			1553	12					BBS4 (inh=AR pLI=0.00)
chr15	73023937	73023937	T	C	hom	hom	hom		QUAL=40926;DP=372,388,482;MQM=60	BBS4	synonymous,non_coding_transcript_exon	BBS4:NM_033028.4:synonymous:LOW:exon12/16:c.906T>C:p.Phe302Phe,BBS4:NM_001252678.1:synonymous:LOW:exon11/15:c.390T>C:p.Phe130Phe,BBS4:NM_001320665.1:synonymous:LOW:exon11/15:c.837T>C:p.Phe279Phe,BBS4:NR_045565.1:non_coding_transcript_exon:MODIFIER:exon13/17:n.1013T>C:,BBS4:NR_045566.1:non_coding_transcript_exon:MODIFIER:exon12/16:n.1268T>C:		rs12914333	0.9605	0.9875	59279/33354/3854	0.9501							600374 [BBS4 (confirmed) Bardet-Biedl syndrome 4,615982];	RCV000152839.3 [benign]; 			1556	8					BBS4 (inh=AR pLI=0.00)
chr15	73027478	73027478	T	C	hom	het	hom		QUAL=31562;DP=376,345,430;MQM=59	BBS4	missense,non_coding_transcript_exon	BBS4:NM_033028.4:missense:MODERATE:exon13/16:c.1061T>C:p.Ile354Thr,BBS4:NM_001252678.1:missense:MODERATE:exon12/15:c.545T>C:p.Ile182Thr,BBS4:NM_001320665.1:missense:MODERATE:exon12/15:c.992T>C:p.Ile331Thr,BBS4:NR_045565.1:non_coding_transcript_exon:MODIFIER:exon14/17:n.1168T>C:,BBS4:NR_045566.1:non_coding_transcript_exon:MODIFIER:exon13/16:n.1423T>C:		rs2277598	0.4289	0.5743	21186/14353/508	0.5651	-0.2460	T,T,T,T	T	B,B,B,B	T,T,T,T	3.05	600374 [BBS4 (confirmed) Bardet-Biedl syndrome 4,615982];	RCV000020938.3 [benign]; RCV000132688.1 [likely benign]; RCV000152842.4 [benign]; 	CM1010466 [CLASS=FP MUT=REF PHEN="Altered function" GENE=BBS4]; 	COSM3999597, COSM3999596	649	700					BBS4 (inh=AR pLI=0.00)
chr15	74472199	74472199	C	T	hom	hom	het		QUAL=20115;DP=265,234,330;MQM=59	STRA6	3'UTR	STRA6:NM_001199042.1:3'UTR:MODIFIER:exon19/19:c.*222G>A:,STRA6:NM_022369.3:3'UTR:MODIFIER:exon19/19:c.*222G>A:,STRA6:NM_001142618.1:3'UTR:MODIFIER:exon19/19:c.*222G>A:,STRA6:NM_001199041.1:3'UTR:MODIFIER:exon19/19:c.*222G>A:,STRA6:NM_001142617.1:3'UTR:MODIFIER:exon19/19:c.*222G>A:,STRA6:NM_001142619.1:3'UTR:MODIFIER:exon19/19:c.*222G>A:,STRA6:NM_001199040.1:3'UTR:MODIFIER:exon19/19:c.*222G>A:		rs10910	0.5327	0.0000	0/0/0	0.6346							610745 [STRA6 (provisional) Microphthalmia,syndromic 9,601186|Microphthalmia,isolated,with coloboma 8,601186];	RCV000318472.1 [benign]; 			121	95					STRA6 (inh=AR pLI=0.00)
chr15	74473739	74473739	C	T	wt	wt	het		QUAL=1394;DP=105,109,119;MQM=60	STRA6	missense	STRA6:NM_001199042.1:missense:MODERATE:exon17/19:c.1698G>A:p.Met566Ile,STRA6:NM_022369.3:missense:MODERATE:exon17/19:c.1581G>A:p.Met527Ile,STRA6:NM_001142618.1:missense:MODERATE:exon17/19:c.1581G>A:p.Met527Ile,STRA6:NM_001199041.1:missense:MODERATE:exon17/19:c.1626G>A:p.Met542Ile,STRA6:NM_001142617.1:missense:MODERATE:exon17/19:c.1581G>A:p.Met527Ile,STRA6:NM_001142619.1:missense:MODERATE:exon17/19:c.1554G>A:p.Met518Ile,STRA6:NM_001199040.1:missense:MODERATE:exon17/19:c.1692G>A:p.Met564Ile		rs736118	0.1995	0.1583	2113/257/38	0.1474	0.3200	T,T,T,.,T,T,T,T	T	B,B,B,B,B,B	T,T,T,T	16.00	610745 [STRA6 (provisional) Microphthalmia,syndromic 9,601186|Microphthalmia,isolated,with coloboma 8,601186];	RCV000253939.1 [benign]; RCV000401354.1 [benign]; 		COSM147950	23	294					STRA6 (inh=AR pLI=0.00)
chr15	74476340	74476340	G	C	het	wt	hom		QUAL=5824;DP=70,134,174;MQM=60	STRA6	splice_region&intron	STRA6:NM_001199042.1:splice_region&intron:LOW:exon13/18:c.1284-10C>G:,STRA6:NM_022369.3:splice_region&intron:LOW:exon13/18:c.1167-10C>G:,STRA6:NM_001142618.1:splice_region&intron:LOW:exon13/18:c.1167-10C>G:,STRA6:NM_001199041.1:splice_region&intron:LOW:exon13/18:c.1212-10C>G:,STRA6:NM_001142617.1:splice_region&intron:LOW:exon13/18:c.1167-10C>G:,STRA6:NM_001142619.1:splice_region&intron:LOW:exon13/18:c.1140-10C>G:,STRA6:NM_001199040.1:splice_region&intron:LOW:exon13/18:c.1278-10C>G:		rs2277608	0.2081	0.1953	2696/770/44	0.1899							610745 [STRA6 (provisional) Microphthalmia,syndromic 9,601186|Microphthalmia,isolated,with coloboma 8,601186];	RCV000248979.1 [benign]; RCV000329298.1 [benign]; 		COSM147951	61	426					STRA6 (inh=AR pLI=0.00)
chr15	74487024	74487024	A	G	het	wt	hom		QUAL=19397;DP=386,324,449;MQM=60	STRA6	3'UTR,intron	STRA6:NM_001142620.1:3'UTR:MODIFIER:exon6/6:c.*919T>C:,STRA6:NM_001199042.1:intron:MODIFIER:exon7/18:c.714+619T>C:,STRA6:NM_022369.3:intron:MODIFIER:exon7/18:c.597+619T>C:,STRA6:NM_001142618.1:intron:MODIFIER:exon7/18:c.597+619T>C:,STRA6:NM_001199041.1:intron:MODIFIER:exon7/18:c.642+619T>C:,STRA6:NM_001142617.1:intron:MODIFIER:exon7/18:c.597+619T>C:,STRA6:NM_001142619.1:intron:MODIFIER:exon7/18:c.570+619T>C:,STRA6:NM_001199040.1:intron:MODIFIER:exon7/18:c.708+619T>C:	L2a	rs58138979	0.0531	0.0000	0/0/0	0.0928							610745 [STRA6 (provisional) Microphthalmia,syndromic 9,601186|Microphthalmia,isolated,with coloboma 8,601186];				5	37					STRA6 (inh=AR pLI=0.00)
chr15	74487036	74487036	T	A	het	wt	hom		QUAL=20211;DP=377,322,474;MQM=59	STRA6	3'UTR,intron	STRA6:NM_001142620.1:3'UTR:MODIFIER:exon6/6:c.*907A>T:,STRA6:NM_001199042.1:intron:MODIFIER:exon7/18:c.714+607A>T:,STRA6:NM_022369.3:intron:MODIFIER:exon7/18:c.597+607A>T:,STRA6:NM_001142618.1:intron:MODIFIER:exon7/18:c.597+607A>T:,STRA6:NM_001199041.1:intron:MODIFIER:exon7/18:c.642+607A>T:,STRA6:NM_001142617.1:intron:MODIFIER:exon7/18:c.597+607A>T:,STRA6:NM_001142619.1:intron:MODIFIER:exon7/18:c.570+607A>T:,STRA6:NM_001199040.1:intron:MODIFIER:exon7/18:c.708+607A>T:	L2a	rs351224	0.4922	0.0000	0/0/0	0.4899							610745 [STRA6 (provisional) Microphthalmia,syndromic 9,601186|Microphthalmia,isolated,with coloboma 8,601186];				45	96					STRA6 (inh=AR pLI=0.00)
chr15	74495556	74495557	TG	-	het	hom	wt	low_DP	QUAL=698;DP=52,10,11;MQM=60	STRA6	5'UTR,intron,non_coding_transcript	STRA6:NM_001142618.1:5'UTR:MODIFIER:exon1/19:c.-949_-228delCA:,STRA6:NM_001199041.1:intron:MODIFIER:exon1/18:c.31-934_31-933delCA:,STRA6:NM_001142617.1:intron:MODIFIER:exon1/18:c.-15-934_-15-933delCA:,STRA6:NM_001142619.1:intron:MODIFIER:exon1/18:c.-15-934_-15-933delCA:,STRA6:NM_001199040.1:intron:MODIFIER:exon1/18:c.97-934_97-933delCA:,STRA6:NM_001142620.1:intron:MODIFIER:exon1/5:c.-15-934_-15-933delCA:,STRA6:NM_001142618.1:non_coding_transcript:MODIFIER:exon1/19:c.-949_-228delCA:		rs372268345	0.2927	0.0000	0/0/0	0.2738							610745 [STRA6 (provisional) Microphthalmia,syndromic 9,601186|Microphthalmia,isolated,with coloboma 8,601186];				26	104					STRA6 (inh=AR pLI=0.00)
chr15	74500105	74500105	G	A	het	het	wt		QUAL=7501;DP=268,363,426;MQM=59	STRA6	5'UTR_premature_start_codon_gain,5'UTR,intron	STRA6:NM_001199041.1:5'UTR_premature_start_codon_gain:LOW:exon1/19:c.-38C>T:,STRA6:NM_001199041.1:5'UTR:MODIFIER:exon1/19:c.-38C>T:,STRA6:NM_001142617.1:intron:MODIFIER:exon1/18:c.-16+1036C>T:,STRA6:NM_001142619.1:intron:MODIFIER:exon1/18:c.-16+1036C>T:,STRA6:NM_001199040.1:intron:MODIFIER:exon1/18:c.96+1595C>T:,STRA6:NM_001142620.1:intron:MODIFIER:exon1/5:c.-16+1036C>T:		rs12915846	0.1999	0.2198	269/71/2	0.0586							610745 [STRA6 (provisional) Microphthalmia,syndromic 9,601186|Microphthalmia,isolated,with coloboma 8,601186];				46	260					STRA6 (inh=AR pLI=0.00)
chr15	74500238	74500238	C	T	het	het	wt		QUAL=10287;DP=262,609,686;MQM=59	STRA6	5'UTR,intron	STRA6:NM_001199041.1:5'UTR:MODIFIER:exon1/19:c.-171G>A:,STRA6:NM_001142617.1:intron:MODIFIER:exon1/18:c.-16+903G>A:,STRA6:NM_001142619.1:intron:MODIFIER:exon1/18:c.-16+903G>A:,STRA6:NM_001199040.1:intron:MODIFIER:exon1/18:c.96+1462G>A:,STRA6:NM_001142620.1:intron:MODIFIER:exon1/5:c.-16+903G>A:		rs10152959	0.2260	0.0000	0/0/0	0.2443							610745 [STRA6 (provisional) Microphthalmia,syndromic 9,601186|Microphthalmia,isolated,with coloboma 8,601186];				11	76					STRA6 (inh=AR pLI=0.00)
chr15	74658315	74658315	-	A	hom	hom	hom	low_DP	QUAL=2609;DP=12,42,48;MQM=60	CYP11A1	5'UTR,intron	CYP11A1:NM_001099773.1:5'UTR:MODIFIER:exon1/9:c.-465dupT:,CYP11A1:NM_000781.2:intron:MODIFIER:exon1/8:c.269+1342dupT:		rs386383486;rs79534403	0.9998	0.0000	0/0/0	0.9136							118485 [CYP11A1 (confirmed) Adrenal insufficiency,congenital,with 46XY sex reversal,partial or complete,613743];				221	2					CYP11A1 (inh=n/a pLI=0.00)
chr15	75185670	75185670	A	G	het	hom	wt		QUAL=6205;DP=104,162,189;MQM=60	MPI	splice_region&intron,intron	MPI:NM_002435.2:splice_region&intron:LOW:exon5/7:c.670+9A>G:,MPI:NM_001289155.1:splice_region&intron:LOW:exon5/6:c.670+9A>G:,MPI:NM_001289156.1:splice_region&intron:LOW:exon4/6:c.520+9A>G:,MPI:NM_001289157.1:intron:MODIFIER:exon4/6:c.487+527A>G:		rs7495739	0.3383	0.4375	12640/9238/543	0.4431							154550 [MPI (confirmed) Congenital disorder of glycosylation,type Ib,602579];	RCV000080014.5 [benign]; RCV000298232.1 [benign]; 		COSM4128400	321	755					MPI (inh=AR pLI=0.00)
chr15	75189930	75189930	A	G	het	hom	wt		QUAL=5925;DP=182,124,195;MQM=60	MPI	synonymous,3'UTR	MPI:NM_002435.2:synonymous:LOW:exon8/8:c.1131A>G:p.Val377Val,MPI:NM_001289156.1:synonymous:LOW:exon7/7:c.981A>G:p.Val327Val,MPI:NM_001289157.1:synonymous:LOW:exon7/7:c.948A>G:p.Val316Val,MPI:NM_001289155.1:3'UTR:MODIFIER:exon7/7:c.*58A>G:		rs1130741	0.3387	0.4376	12747/9315/548	0.4438							154550 [MPI (confirmed) Congenital disorder of glycosylation,type Ib,602579];	RCV000080011.5 [benign]; RCV000328204.1 [benign]; 			322	755					MPI (inh=AR pLI=0.00)
chr15	76508684	76508684	T	A	hom	hom	hom		QUAL=14989;DP=221,107,137;MQM=60	ETFA	3'UTR	ETFA:NM_000126.3:3'UTR:MODIFIER:exon12/12:c.*216A>T:,ETFA:NM_001127716.1:3'UTR:MODIFIER:exon11/11:c.*216A>T:		rs1803550	0.9742	0.0000	0/0/0	0.9005							608053 [ETFA (confirmed) Glutaric acidemia IIA,231680];	RCV000313076.1 [benign]; 			229	0					ETFA (inh=AR pLI=0.01)
chr15	76673716	76673716	T	C	het	hom	wt		QUAL=6918;DP=189,145,186;MQM=60	SCAPER	splice_region&intron	SCAPER:NM_020843.2:splice_region&intron:LOW:exon27/30:c.3705+3A>G:,SCAPER:NM_001145923.1:splice_region&intron:LOW:exon28/31:c.2967+3A>G:		rs3765115	0.4157	0.4249	8160/3189/383	0.3609											165	496					SCAPER (inh=n/a pLI=0.04)
chr15	76726465	76726465	G	T	het	hom	wt		QUAL=5853;DP=228,115,202;MQM=60	SCAPER	missense	SCAPER:NM_020843.2:missense:MODERATE:exon25/31:c.3265C>A:p.Pro1089Thr,SCAPER:NM_001145923.1:missense:MODERATE:exon26/32:c.2527C>A:p.Pro843Thr		rs1607017	0.3560	0.3504	8098/3389/78	0.3452	0.6870	T,T,.	T	B,B	T,T	6.65					154	489					SCAPER (inh=n/a pLI=0.04)
chr15	77085740	77085740	C	A	hom	hom	hom		QUAL=14755;DP=104,175,196;MQM=60	SCAPER	splice_region&intron,intron	SCAPER:NM_001145923.1:splice_region&intron:LOW:exon7/31:c.-125-8G>T:,SCAPER:NM_020843.2:intron:MODIFIER:exon7/30:c.772+1881G>T:	MER21B	rs3102707	0.9673	0.0000	0/0/0	0.9065											150	0					SCAPER (inh=n/a pLI=0.04)
chr15	77087785	77087785	T	C	het	hom	wt		QUAL=2918;DP=109,55,66;MQM=60	SCAPER	splice_region&intron	SCAPER:NM_020843.2:splice_region&intron:LOW:exon6/30:c.612-4A>G:,SCAPER:NM_001145923.1:splice_region&intron:LOW:exon6/31:c.-286-4A>G:		rs11852395	0.3532	0.3546	7222/2797/110	0.3273											135	469					SCAPER (inh=n/a pLI=0.04)
chr15	77176158	77176158	T	C	het	hom	wt	anno_high_impact;pred_pathogenic	QUAL=4564;DP=159,96,124;MQM=60	SCAPER	start_lost	SCAPER:NM_020843.2:start_lost:HIGH:exon1/31:c.1A>G:p.Met1?		rs3812908	0.4177	0.4036	4526/1605/337	0.3126	2.6450	T,.	T,T	P,.	T,.	11.99					145	487	1	[1] auto-classification 16.06.2016  			SCAPER (inh=n/a pLI=0.04)
chr15	77176200	77176200	A	T	het	hom	wt		QUAL=5090;DP=202,100,136;MQM=60	SCAPER	5'UTR	SCAPER:NM_020843.2:5'UTR:MODIFIER:exon1/31:c.-42T>A:		rs3812909	0.4169	0.3859	3539/1191/276	0.2983	0.4960		T			1.87					123	425					SCAPER (inh=n/a pLI=0.04)
chr15	80445292	80445292	G	C	wt	het	het	low_DP	QUAL=201;DP=5,7,8;MQM=60	FAH	5'UTR	FAH:NM_000137.2:5'UTR:MODIFIER:exon1/14:c.-105G>C:		rs112474268	0.1865	0.0000	0/0/0	0.2204							613871 [FAH (confirmed) Tyrosinemia,type I,276700];	RCV000332455.1 [likely benign]; 			19	42					FAH (inh=AR pLI=0.00)
chr15	80445363	80445363	C	T	wt	het	wt		QUAL=284;DP=97,22,32;MQM=60	FAH	5'UTR	FAH:NM_000137.2:5'UTR:MODIFIER:exon1/14:c.-34C>T:		rs142522569	0.0030	0.0121	19/18/0	0.0120							613871 [FAH (confirmed) Tyrosinemia,type I,276700];	RCV000373041.1 [uncertain significance]; 			0	26					FAH (inh=AR pLI=0.00)
chr15	80452172	80452172	G	C	wt	het	wt		QUAL=2665;DP=267,212,352;MQM=60	FAH	synonymous	FAH:NM_000137.2:synonymous:LOW:exon3/14:c.267G>C:p.Leu89Leu		rs33929922	0.0597	0.0748	353/195/24	0.0737							613871 [FAH (confirmed) Tyrosinemia,type I,276700];	RCV000078136.5 [benign]; RCV000398694.1 [likely benign]; 		COSM3999621	17	240					FAH (inh=AR pLI=0.00)
chr15	80478588	80478591	CACC	-	wt	het	wt		QUAL=3342;DP=293,316,413;MQM=59	FAH	3'UTR	FAH:NM_000137.2:3'UTR:MODIFIER:exon14/14:c.*38_*41delACCC:		rs369845634	0.0000	0.1348	1018/525/20	0.1057							613871 [FAH (confirmed) Tyrosinemia,type I,276700];				19	237					FAH (inh=AR pLI=0.00)
chr15	80478593	80478593	-	TTTG	wt	het	wt		QUAL=3297;DP=355,322,418;MQM=59	FAH	3'UTR	FAH:NM_000137.2:3'UTR:MODIFIER:exon14/14:c.*45_*46insGTTT:		rs751787251	0.0000	0.1352	1012/523/20	0.0004							613871 [FAH (confirmed) Tyrosinemia,type I,276700];				19	237					FAH (inh=AR pLI=0.00)
chr15	80478600	80478600	C	-	wt	het	wt		QUAL=3584;DP=365,342,422;MQM=59	FAH	3'UTR	FAH:NM_000137.2:3'UTR:MODIFIER:exon14/14:c.*51delC:		rs200464452	0.1124	0.1347	999/514/20	0.0128							613871 [FAH (confirmed) Tyrosinemia,type I,276700];	RCV000389756.1 [likely benign]; 			19	237					FAH (inh=AR pLI=0.00)
chr15	80478645	80478645	T	C	wt	het	wt		QUAL=5344;DP=445,468,554;MQM=59	FAH	3'UTR	FAH:NM_000137.2:3'UTR:MODIFIER:exon14/14:c.*94T>C:		rs1049194	0.1126	0.0000	0/0/0	0.0252							613871 [FAH (confirmed) Tyrosinemia,type I,276700];	RCV000350427.1 [likely benign]; 			10	108					FAH (inh=AR pLI=0.00)
chr15	80478835	80478835	C	G	wt	het	wt		QUAL=3193;DP=173,248,294;MQM=60	FAH	3'UTR	FAH:NM_000137.2:3'UTR:MODIFIER:exon14/14:c.*284C>G:		rs79203348	0.0511	0.0000	0/0/0	0.0124							613871 [FAH (confirmed) Tyrosinemia,type I,276700];	RCV000299361.1 [likely benign]; 			1	38					FAH (inh=AR pLI=0.00)
chr15	80478861	80478861	T	A	wt	het	wt		QUAL=2472;DP=209,196,238;MQM=60	FAH	3'UTR	FAH:NM_000137.2:3'UTR:MODIFIER:exon14/14:c.*310T>A:		rs75212096	0.1126	0.0000	0/0/0	0.0220							613871 [FAH (confirmed) Tyrosinemia,type I,276700];	RCV000335637.1 [likely benign]; 			4	40					FAH (inh=AR pLI=0.00)
chr15	85326955	85326955	G	A	het	wt	het	pred_pathogenic	QUAL=5783;DP=229,191,213;MQM=59	ZNF592	missense	ZNF592:NM_014630.2:missense:MODERATE:exon4/11:c.1049G>A:p.Arg350His		rs61737677	0.0138	0.0084	7/1/3	0.0086	4.6240	D	T	D	T	25.30					0	47					ZNF592 (inh=AR pLI=0.95)
chr15	85333953	85333953	A	G	wt	het	het		QUAL=5721;DP=124,208,261;MQM=60	ZNF592	synonymous	ZNF592:NM_014630.2:synonymous:LOW:exon5/11:c.2238A>G:p.Gln746Gln		rs2241645	0.7839	0.7501	34415/18001/3368	0.7441								RCV000118955.2 [likely benign]; 		COSM4128497	1488	1045					ZNF592 (inh=AR pLI=0.95)
chr15	85347114	85347114	T	C	hom	hom	hom		QUAL=23059;DP=261,190,284;MQM=59	ZNF592	3'UTR	ZNF592:NM_014630.2:3'UTR:MODIFIER:exon11/11:c.*1490T>C:		rs9806315	0.8670	0.0000	0/0/0	0.7334											139	81					ZNF592 (inh=AR pLI=0.95)
chr15	85347673	85347673	T	C	het	wt	het		QUAL=5005;DP=192,175,204;MQM=60	ZNF592	3'UTR	ZNF592:NM_014630.2:3'UTR:MODIFIER:exon11/11:c.*2049T>C:		rs114257982	0.0280	0.0000	0/0/0	0.0141											0	4					ZNF592 (inh=AR pLI=0.95)
chr15	85348172	85348172	G	T	het	het	wt		QUAL=9076;DP=370,286,399;MQM=60	ZNF592	3'UTR	ZNF592:NM_014630.2:3'UTR:MODIFIER:exon11/11:c.*2548G>T:	MIRb	rs1719	0.0585	0.0000	0/0/0	0.0517											2	28					ZNF592 (inh=AR pLI=0.95)
chr15	85348551	85348551	G	C	het	wt	het		QUAL=5778;DP=268,106,157;MQM=60	ZNF592	3'UTR	ZNF592:NM_014630.2:3'UTR:MODIFIER:exon11/11:c.*2927G>C:		rs117658444	0.0142	0.0000	0/0/0	0.0099											0	4					ZNF592 (inh=AR pLI=0.95)
chr15	89804043	89804043	C	T	wt	het	het	pred_pathogenic	QUAL=2042;DP=109,63,91;MQM=60	FANCI	missense	FANCI:NM_001113378.1:missense:MODERATE:exon4/38:c.257C>T:p.Ala86Val,FANCI:NM_018193.2:missense:MODERATE:exon4/37:c.257C>T:p.Ala86Val		rs17803620	0.2598	0.3569	8307/4961/45	0.3495	1.9700	T,T,T	T	B,B	T,T,T	23.40	611360 [FANCI (provisional) Fanconi anemia,complementation group I,609053];	RCV000247561.1 [benign]; RCV000262235.1 [benign]; 		COSM3754557, COSM3754558	259	816					FANCI (inh=AR pLI=0.00)
chr15	89835937	89835937	A	G	het	het	wt		QUAL=7547;DP=289,255,291;MQM=59	FANCI	missense	FANCI:NM_001113378.1:missense:MODERATE:exon21/38:c.2011A>G:p.Ile671Val,FANCI:NM_018193.2:missense:MODERATE:exon21/37:c.2011A>G:p.Ile671Val		rs139814895	0.0038	0.0039	3/0/0	0.0033	1.0600	T,T,T	T	B,B,B	T,T,T	14.58	611360 [FANCI (provisional) Fanconi anemia,complementation group I,609053];	RCV000228217.2 [other]; 			0	13					FANCI (inh=AR pLI=0.00)
chr15	89836228	89836228	G	C	wt	het	het	pred_pathogenic	QUAL=3757;DP=320,126,190;MQM=60	FANCI	missense	FANCI:NM_001113378.1:missense:MODERATE:exon22/38:c.2225G>C:p.Cys742Ser,FANCI:NM_018193.2:missense:MODERATE:exon22/37:c.2225G>C:p.Cys742Ser		rs2283432	0.2650	0.3623	8539/5091/46	0.3540	4.9320	T,T,T	T	B,B,B	T,T,T	15.87	611360 [FANCI (provisional) Fanconi anemia,complementation group I,609053];	RCV000250359.1 [benign]; RCV000339014.1 [benign]; 		COSM1179764, COSM1179763	271	824					FANCI (inh=AR pLI=0.00)
chr15	89837139	89837139	G	T	het	het	wt		QUAL=3724;DP=218,117,154;MQM=60	FANCI	synonymous	FANCI:NM_001113378.1:synonymous:LOW:exon23/38:c.2367G>T:p.Ala789Ala,FANCI:NM_018193.2:synonymous:LOW:exon23/37:c.2367G>T:p.Ala789Ala		rs11857960	0.0789	0.0280	301/2/291	0.0265							611360 [FANCI (provisional) Fanconi anemia,complementation group I,609053];	RCV000242536.1 [benign]; RCV000397172.1 [likely benign]; 			1	32					FANCI (inh=AR pLI=0.00)
chr15	89838236	89838236	G	A	hom	hom	hom		QUAL=29395;DP=417,181,293;MQM=60	FANCI	sequence_feature,synonymous,intron	FANCI:NM_001113378.1:sequence_feature:MODERATE:exon24/38:c.2547G>A:,FANCI:NM_001113378.1:synonymous:LOW:exon24/38:c.2547G>A:p.Lys849Lys,FANCI:NM_018193.2:intron:MODIFIER:exon23/36:c.2456+1008G>A:		rs7183618	0.9808	0.9593	11000/4586/1263	0.3080							611360 [FANCI (provisional) Fanconi anemia,complementation group I,609053];	RCV000226449.1 [benign]; 			1649	162					FANCI (inh=AR pLI=0.00)
chr15	89838293	89838293	A	C	het	het	wt		QUAL=5454;DP=266,154,247;MQM=60	FANCI	missense,intron	FANCI:NM_001113378.1:missense:MODERATE:exon24/38:c.2604A>C:p.Glu868Asp,FANCI:NM_018193.2:intron:MODIFIER:exon23/36:c.2456+1065A>C:		rs118031800	0.0038	0.0045	2/0/0	0.0009	-0.0490	T	T	B	T	8.04	611360 [FANCI (provisional) Fanconi anemia,complementation group I,609053];	RCV000230137.2 [other]; 			0	13					FANCI (inh=AR pLI=0.00)
chr15	89838318	89838318	A	T	wt	wt	het	pred_pathogenic	QUAL=2135;DP=204,140,217;MQM=60	FANCI	missense,intron	FANCI:NM_001113378.1:missense:MODERATE:exon24/38:c.2629A>T:p.Ile877Leu,FANCI:NM_018193.2:intron:MODIFIER:exon23/36:c.2456+1090A>T:		rs35875311	0.0595	0.0947	126/50/1	0.0289	4.1290	T	T	B	T	22.60	611360 [FANCI (provisional) Fanconi anemia,complementation group I,609053];	RCV000252318.1 [benign]; RCV000397179.1 [likely benign]; 		COSM3754559	16	318					FANCI (inh=AR pLI=0.00)
chr15	89848645	89848645	-	T	het	het	wt		QUAL=14030;DP=634,519,668;MQM=59	FANCI	splice_region&intron	FANCI:NM_001113378.1:splice_region&intron:LOW:exon30/37:c.3255+6dupT:,FANCI:NM_018193.2:splice_region&intron:LOW:exon29/36:c.3075+6dupT:		rs878854178	0.0036	0.0039	3/0/0	0.0033							611360 [FANCI (provisional) Fanconi anemia,complementation group I,609053];	RCV000227226.1 [benign]; 			0	13					FANCI (inh=AR pLI=0.00)
chr15	89858602	89858602	T	C	het	hom	het		QUAL=11685;DP=204,178,298;MQM=60	FANCI	synonymous	FANCI:NM_001113378.1:synonymous:LOW:exon37/38:c.3906T>C:p.Gly1302Gly,FANCI:NM_018193.2:synonymous:LOW:exon36/37:c.3726T>C:p.Gly1242Gly		rs1138465	0.4123	0.4123	10413/5346/1018	0.4032							611360 [FANCI (provisional) Fanconi anemia,complementation group I,609053];	RCV000251297.1 [benign]; RCV000329693.1 [likely benign]; RCV000348737.1 [benign]; 		COSM3754561, COSM3754560	297	841					FANCI (inh=AR pLI=0.00)
chr15	89859932	89859932	-	C	wt	het	het		QUAL=3178;DP=188,112,165;MQM=60	FANCI,POLG	3'UTR	FANCI:NM_001113378.1:3'UTR:MODIFIER:exon38/38:c.*244dupC:,POLG:NM_001126131.1:3'UTR:MODIFIER:exon23/23:c.*49dupG:,FANCI:NM_018193.2:3'UTR:MODIFIER:exon37/37:c.*244dupC:,POLG:NM_002693.2:3'UTR:MODIFIER:exon23/23:c.*49dupG:		rs3087377	0.2893	0.3708	8715/5159/123	0.3427							611360 [FANCI (provisional) Fanconi anemia,complementation group I,609053]:174763 [POLG (provisional) Progressive external ophthalmoplegia,autosomal recessive 1,258450|Progressive external ophthalmoplegia,autosomal dominant 1,157640|Mitochondrial DNA depletion syndrome 4B (MNGIE type),613662|Mitochondrial DNA depletion syndrome 4A (Alpers type),203700|Mitochondrial recessive ataxia syndrome (includes SANDO and SCAE),607459];	RCV000320567.1,RCV000265494.1 [likely benign,benign]; 			104	362					FANCI (inh=AR pLI=0.00), POLG (inh=AR+AD pLI=0.00)
chr15	89860350	89860350	A	C	het	hom	het		QUAL=3570;DP=164,21,54;MQM=60	FANCI,POLG	3'UTR,intron	FANCI:NM_001113378.1:3'UTR:MODIFIER:exon38/38:c.*660A>C:,FANCI:NM_018193.2:3'UTR:MODIFIER:exon37/37:c.*660A>C:,POLG:NM_001126131.1:intron:MODIFIER:exon22/22:c.3643+257T>G:,POLG:NM_002693.2:intron:MODIFIER:exon22/22:c.3643+257T>G:		rs1061316	0.4459	0.0000	0/0/0	0.0785							611360 [FANCI (provisional) Fanconi anemia,complementation group I,609053]:174763 [POLG (provisional) Progressive external ophthalmoplegia,autosomal recessive 1,258450|Progressive external ophthalmoplegia,autosomal dominant 1,157640|Mitochondrial DNA depletion syndrome 4B (MNGIE type),613662|Mitochondrial DNA depletion syndrome 4A (Alpers type),203700|Mitochondrial recessive ataxia syndrome (includes SANDO and SCAE),607459];	RCV000274297.1 [benign]; RCV000331693.1 [benign]; 			24	102					FANCI (inh=AR pLI=0.00), POLG (inh=AR+AD pLI=0.00)
chr15	89867380	89867380	C	T	het	het	wt		QUAL=4087;DP=258,158,235;MQM=60	POLG	synonymous	POLG:NM_001126131.1:synonymous:LOW:exon11/23:c.2028G>A:p.Ala676Ala,POLG:NM_002693.2:synonymous:LOW:exon11/23:c.2028G>A:p.Ala676Ala		rs373550219	0.0000	0.0004	0/0/0	0.0003							174763 [POLG (provisional) Progressive external ophthalmoplegia,autosomal recessive 1,258450|Progressive external ophthalmoplegia,autosomal dominant 1,157640|Mitochondrial DNA depletion syndrome 4B (MNGIE type),613662|Mitochondrial DNA depletion syndrome 4A (Alpers type),203700|Mitochondrial recessive ataxia syndrome (includes SANDO and SCAE),607459];	RCV000127516.2 [other]; RCV000263177.1 [uncertain significance]; 			0	11					POLG (inh=AR+AD pLI=0.00)
chr15	89872249	89872249	C	T	het	het	wt	anno_pathogenic_hgmd	QUAL=3930;DP=203,138,162;MQM=59	POLG	synonymous	POLG:NM_001126131.1:synonymous:LOW:exon4/23:c.948G>A:p.Lys316Lys,POLG:NM_002693.2:synonymous:LOW:exon4/23:c.948G>A:p.Lys316Lys		rs61756401	0.0036	0.0039	3/0/0	0.0033							174763 [POLG (provisional) Progressive external ophthalmoplegia,autosomal recessive 1,258450|Progressive external ophthalmoplegia,autosomal dominant 1,157640|Mitochondrial DNA depletion syndrome 4B (MNGIE type),613662|Mitochondrial DNA depletion syndrome 4A (Alpers type),203700|Mitochondrial recessive ataxia syndrome (includes SANDO and SCAE),607459];	RCV000118023.4 [other]; 	CM133443 [CLASS=DM? MUT=ALT PHEN="SANDO" GENE=POLG]; 		0	16	2	[2] Stephan Waldm?ller 13.08.2014			POLG (inh=AR+AD pLI=0.00)
chr15	90171306	90171306	A	G	het	wt	het		QUAL=9630;DP=383,282,369;MQM=59	KIF7	3'UTR	KIF7:NM_198525.2:3'UTR:MODIFIER:exon19/19:c.*344T>C:		rs1054435	0.4485	0.0000	0/0/0	0.3664							611254 [KIF7 (provisional) Hydrolethalus syndrome 2,614120|Acrocallosal syndrome,200990|Joubert syndrome 12,200990|Al-Gazali-Bakalinova syndrome,607131];	RCV000383066.1 [benign]; 			39	109					KIF7 (inh=AR pLI=0.00)
chr15	90172600	90172600	G	A	het	wt	het		QUAL=1277;DP=60,33,53;MQM=59	KIF7	splice_region&intron	KIF7:NM_198525.2:splice_region&intron:LOW:exon17/18:c.3517+6C>T:		rs74251725	0.2752	0.3199	5557/3286/56	0.2913							611254 [KIF7 (provisional) Hydrolethalus syndrome 2,614120|Acrocallosal syndrome,200990|Joubert syndrome 12,200990|Al-Gazali-Bakalinova syndrome,607131];	RCV000117423.4 [other]; RCV000396714.1 [benign]; 			206	675					KIF7 (inh=AR pLI=0.00)
chr15	90173734	90173734	-	AG	het	hom	het		QUAL=6988;DP=118,138,188;MQM=59	KIF7	splice_region&intron	KIF7:NM_198525.2:splice_region&intron:LOW:exon15/18:c.3112-11_3112-10insCT:		rs35820949	0.4922	0.5473	3268/1570/505	0.3005							611254 [KIF7 (provisional) Hydrolethalus syndrome 2,614120|Acrocallosal syndrome,200990|Joubert syndrome 12,200990|Al-Gazali-Bakalinova syndrome,607131];	RCV000252342.2 [benign]; RCV000328696.1 [benign]; 			439	762					KIF7 (inh=AR pLI=0.00)
chr15	90174789	90174789	C	T	het	het	het		QUAL=1125;DP=54,25,47;MQM=60	KIF7	synonymous	KIF7:NM_198525.2:synonymous:LOW:exon15/19:c.3048G>A:p.Ser1016Ser		rs9672286	0.4511	0.5270	5814/3549/539	0.4280							611254 [KIF7 (provisional) Hydrolethalus syndrome 2,614120|Acrocallosal syndrome,200990|Joubert syndrome 12,200990|Al-Gazali-Bakalinova syndrome,607131];	RCV000082817.8 [other]; RCV000274985.1 [benign]; 		COSM3932192, COSM3932193	430	766					KIF7 (inh=AR pLI=0.00)
chr15	90174824	90174824	C	T	het	het	het		QUAL=1375;DP=59,22,50;MQM=60	KIF7	missense	KIF7:NM_198525.2:missense:MODERATE:exon15/19:c.3013G>A:p.Gly1005Arg		rs12900805	0.4393	0.5128	3876/2157/361	0.3791	1.1430	T	T	B,B	T	12.42	611254 [KIF7 (provisional) Hydrolethalus syndrome 2,614120|Acrocallosal syndrome,200990|Joubert syndrome 12,200990|Al-Gazali-Bakalinova syndrome,607131];	RCV000082815.8 [other]; RCV000332349.1 [benign]; 			431	769					KIF7 (inh=AR pLI=0.00)
chr15	90176073	90176073	C	A	het	hom	het	low_DP;pred_pathogenic	QUAL=710;DP=18,17,32;MQM=60	KIF7	missense	KIF7:NM_198525.2:missense:MODERATE:exon14/19:c.2873G>T:p.Ser958Ile		rs3803530	0.4383	0.5255	16267/10811/1038	0.4930	1.1000	T	T	B,B	T	22.50	611254 [KIF7 (provisional) Hydrolethalus syndrome 2,614120|Acrocallosal syndrome,200990|Joubert syndrome 12,200990|Al-Gazali-Bakalinova syndrome,607131];	RCV000082813.8 [other]; RCV000316792.1 [benign]; 			430	732					KIF7 (inh=AR pLI=0.00)
chr15	90176432	90176432	T	G	hom	hom	hom		QUAL=10444;DP=86,88,153;MQM=60	KIF7	synonymous	KIF7:NM_198525.2:synonymous:LOW:exon13/19:c.2658A>C:p.Ala886Ala		rs3803531	0.7945	0.8618	40722/25357/2898	0.8169							611254 [KIF7 (provisional) Hydrolethalus syndrome 2,614120|Acrocallosal syndrome,200990|Joubert syndrome 12,200990|Al-Gazali-Bakalinova syndrome,607131];	RCV000117420.4 [other]; RCV000373784.1 [benign]; 		COSM147979	1256	295					KIF7 (inh=AR pLI=0.00)
chr15	90191827	90191827	T	C	hom	hom	hom	low_DP	QUAL=709;DP=15,5,6;MQM=60	KIF7	missense	KIF7:NM_198525.2:missense:MODERATE:exon5/19:c.1102A>G:p.Thr368Ala	(CCGCTCG)n	rs8037349	0.8614	0.8912	5930/2140/604	0.2337	-0.4760	T	T	B	T	0.01	611254 [KIF7 (provisional) Hydrolethalus syndrome 2,614120|Acrocallosal syndrome,200990|Joubert syndrome 12,200990|Al-Gazali-Bakalinova syndrome,607131];	RCV000082811.9 [other]; RCV000394862.1 [benign]; 		COSM4128555	1241	281					KIF7 (inh=AR pLI=0.00)
chr15	90195967	90195967	C	G	hom	hom	hom		QUAL=27263;DP=234,298,367;MQM=60	KIF7	synonymous	KIF7:NM_198525.2:synonymous:LOW:exon2/19:c.195G>C:p.Ala65Ala		rs8179066	0.8602	0.8937	8050/3473/1003	0.3219							611254 [KIF7 (provisional) Hydrolethalus syndrome 2,614120|Acrocallosal syndrome,200990|Joubert syndrome 12,200990|Al-Gazali-Bakalinova syndrome,607131];	RCV000117415.7 [other]; RCV000373043.1 [benign]; 			1256	291					KIF7 (inh=AR pLI=0.00)
chr15	90196008	90196008	C	T	het	wt	het	pred_pathogenic	QUAL=5839;DP=173,286,348;MQM=59	KIF7	missense	KIF7:NM_198525.2:missense:MODERATE:exon2/19:c.154G>A:p.Asp52Asn		rs8179065	0.2424	0.2697	779/303/4	0.0862	0.7100	T	T	B	T	22.80	611254 [KIF7 (provisional) Hydrolethalus syndrome 2,614120|Acrocallosal syndrome,200990|Joubert syndrome 12,200990|Al-Gazali-Bakalinova syndrome,607131];	RCV000117413.4 [other]; RCV000278498.1 [benign]; 		COSM3754564	136	643					KIF7 (inh=AR pLI=0.00)
chr15	91312823	91312823	T	C	hom	het	het	low_DP	QUAL=1935;DP=56,10,8;MQM=60	BLM	splice_region&intron	BLM:NM_000057.3:splice_region&intron:LOW:exon12/21:c.2555+7T>C:,BLM:NM_001287246.1:splice_region&intron:LOW:exon13/22:c.2555+7T>C:,BLM:NM_001287247.1:splice_region&intron:LOW:exon12/19:c.2555+7T>C:,BLM:NM_001287248.1:splice_region&intron:LOW:exon12/21:c.1430+7T>C:		rs3815003	0.3666	0.2956	5554/2506/1864	0.2830							604610 [BLM (confirmed) Bloom syndrome,210900];	RCV000078057.8 [other]; RCV000297248.1 [benign]; 			255	1178	1	[1] Ilnaz Sepahi 29-03-2016 batch import			BLM (inh=AR pLI=0.00)
chr15	91337479	91337479	G	A	het	wt	het		QUAL=3535;DP=150,111,128;MQM=60	BLM	synonymous	BLM:NM_000057.3:synonymous:LOW:exon16/22:c.3102G>A:p.Thr1034Thr,BLM:NM_001287246.1:synonymous:LOW:exon17/23:c.3102G>A:p.Thr1034Thr,BLM:NM_001287247.1:synonymous:LOW:exon16/20:c.3102G>A:p.Thr1034Thr,BLM:NM_001287248.1:synonymous:LOW:exon16/22:c.1977G>A:p.Thr659Thr		rs2227933	0.1512	0.1611	1682/1159/184	0.1599							604610 [BLM (confirmed) Bloom syndrome,210900];	RCV000078059.8 [other]; RCV000123848.2 [benign]; RCV000366766.1 [likely benign]; 			102	930	1	[1] Ilnaz Sepahi 29-03-2016 batch import			BLM (inh=AR pLI=0.00)
chr15	91346923	91346923	C	A	het	wt	het		QUAL=6620;DP=263,195,246;MQM=60	BLM	synonymous,intron	BLM:NM_000057.3:synonymous:LOW:exon18/22:c.3531C>A:p.Ala1177Ala,BLM:NM_001287246.1:synonymous:LOW:exon19/23:c.3531C>A:p.Ala1177Ala,BLM:NM_001287248.1:synonymous:LOW:exon18/22:c.2406C>A:p.Ala802Ala,BLM:NM_001287247.1:intron:MODIFIER:exon17/19:c.3358+5356C>A:		rs2227934	0.1332	0.1553	1569/1157/68	0.1557							604610 [BLM (confirmed) Bloom syndrome,210900];	RCV000078060.8 [other]; RCV000363720.1 [likely benign]; 			102	920	1	[1] Ilnaz Sepahi 29-03-2016 batch import			BLM (inh=AR pLI=0.00)
chr15	91354505	91354505	C	T	het	wt	het		QUAL=8301;DP=258,216,341;MQM=59	BLM	synonymous	BLM:NM_000057.3:synonymous:LOW:exon21/22:c.3945C>T:p.Leu1315Leu,BLM:NM_001287246.1:synonymous:LOW:exon22/23:c.3945C>T:p.Leu1315Leu,BLM:NM_001287247.1:synonymous:LOW:exon19/20:c.3552C>T:p.Leu1184Leu,BLM:NM_001287248.1:synonymous:LOW:exon21/22:c.2820C>T:p.Leu940Leu		rs1063147	0.1328	0.1557	1589/1170/81	0.1556							604610 [BLM (confirmed) Bloom syndrome,210900];	RCV000078061.8 [other]; RCV000320678.1 [likely benign]; 			106	929	1	[1] Ilnaz Sepahi 29-03-2016 batch import			BLM (inh=AR pLI=0.00)
chr15	91354521	91354521	G	A	het	hom	wt		QUAL=11068;DP=281,233,354;MQM=60	BLM	missense	BLM:NM_000057.3:missense:MODERATE:exon21/22:c.3961G>A:p.Val1321Ile,BLM:NM_001287246.1:missense:MODERATE:exon22/23:c.3961G>A:p.Val1321Ile,BLM:NM_001287247.1:missense:MODERATE:exon19/20:c.3568G>A:p.Val1190Ile,BLM:NM_001287248.1:missense:MODERATE:exon21/22:c.2836G>A:p.Val946Ile		rs7167216	0.0671	0.0663	309/164/35	0.0647	-0.6680	T,T,T	T	B,B	T	0.60	604610 [BLM (confirmed) Bloom syndrome,210900];	RCV000116501.4 [other]; RCV000281046.1 [likely benign]; 			14	354	1	[1] Ilnaz Sepahi 29-03-2016 batch import			BLM (inh=AR pLI=0.00)
chr15	91543761	91543761	C	T	het	hom	het	pred_pathogenic	QUAL=20759;DP=414,312,429;MQM=60	VPS33B	missense	VPS33B:NM_018668.4:missense:MODERATE:exon20/23:c.1540G>A:p.Gly514Ser,VPS33B:NM_001289148.1:missense:MODERATE:exon19/22:c.1459G>A:p.Gly487Ser,VPS33B:NM_001289149.1:missense:MODERATE:exon19/22:c.1267G>A:p.Gly423Ser		rs11073964	0.7678	0.5629	21914/5394/4150	0.5408	4.2670	T,T,T,T	T	B,B	T,T,T	20.90	608552 [VPS33B (provisional) Arthrogryposis,renal dysfunction,and cholestasis 1,208085];	RCV000253189.1 [benign]; RCV000305164.1 [benign]; 		COSM3754589	339	772					VPS33B (inh=AR pLI=0.00)
chr15	91548601	91548601	G	A	het	hom	het		QUAL=18207;DP=292,298,387;MQM=59	VPS33B	splice_region&intron	VPS33B:NM_018668.4:splice_region&intron:LOW:exon14/22:c.1105+9C>T:,VPS33B:NM_001289148.1:splice_region&intron:LOW:exon13/21:c.1024+9C>T:,VPS33B:NM_001289149.1:splice_region&intron:LOW:exon13/21:c.832+9C>T:		rs3826033	0.2081	0.1797	2808/595/2	0.1767							608552 [VPS33B (provisional) Arthrogryposis,renal dysfunction,and cholestasis 1,208085];	RCV000249496.1 [benign]; RCV000261543.1 [benign]; 		COSM3999688	37	342					VPS33B (inh=AR pLI=0.00)
chr15	91565804	91565804	A	G	het	hom	het		QUAL=13244;DP=455,187,206;MQM=59	VPS33B	5'UTR	VPS33B:NM_018668.4:5'UTR:MODIFIER:exon1/23:c.-325T>C:,VPS33B:NM_001289148.1:5'UTR:MODIFIER:exon1/22:c.-325T>C:,VPS33B:NM_001289149.1:5'UTR:MODIFIER:exon1/22:c.-536T>C:		rs11073967	0.7566	0.0000	0/0/0	0.4870							608552 [VPS33B (provisional) Arthrogryposis,renal dysfunction,and cholestasis 1,208085];	RCV000327280.1 [benign]; 			44	119					VPS33B (inh=AR pLI=0.00)
chr15	97347632	97347632	C	T	het	hom	wt		QUAL=7034;DP=234,128,300;MQM=60	SPATA8-LOC101927286	intergenic_region	SPATA8-LOC101927286:SPATA8-LOC101927286:intergenic_region:MODIFIER::n.97347632C>T:		rs12902162	0.2879	0.0000	0/0/0	0.3108											20	68					SPATA8-LOC101927286 (inh=n/a pLI=n/a)
chr15	101109677	101109677	C	A	hom	het	het		QUAL=9270;DP=149,135,181;MQM=60	LINS1	missense	LINS1:NM_001040616.2:missense:MODERATE:exon7/7:c.2040G>T:p.Arg680Ser		rs8451	0.3115	0.3850	9739/7089/359	0.3856	-0.3100	T	T	B	T	9.49				COSM147993	332	739					LINS1 (inh=AR pLI=0.00)
chr15	101109794	101109794	C	G	hom	het	het		QUAL=8183;DP=178,68,92;MQM=60	LINS1	missense	LINS1:NM_001040616.2:missense:MODERATE:exon7/7:c.1923G>C:p.Glu641Asp		rs12157	0.3115	0.3848	9733/7085/359	0.3856	0.0660	T	T	B	T	0.23				COSM3999451	332	740					LINS1 (inh=AR pLI=0.00)
chr15	101109818	101109818	G	A	hom	het	het		QUAL=8847;DP=204,75,90;MQM=59	LINS1	synonymous	LINS1:NM_001040616.2:synonymous:LOW:exon7/7:c.1899C>T:p.Asp633Asp		rs12460	0.4563	0.5056	15889/10248/746	0.5057										COSM4148339	509	720					LINS1 (inh=AR pLI=0.00)
chr15	101109893	101109893	C	A	hom	het	het		QUAL=8560;DP=195,118,110;MQM=60	LINS1	synonymous	LINS1:NM_001040616.2:synonymous:LOW:exon7/7:c.1824G>T:p.Gly608Gly		rs6598356	0.3117	0.3848	9709/7071/356	0.3733										COSM3999452	328	744					LINS1 (inh=AR pLI=0.00)
chr15	101110265	101110265	T	A	hom	het	het		QUAL=14328;DP=336,114,144;MQM=60	LINS1	synonymous	LINS1:NM_001040616.2:synonymous:LOW:exon7/7:c.1452A>T:p.Thr484Thr		rs2411836	0.3115	0.3860	9286/6832/342	0.3816										COSM147994	330	721					LINS1 (inh=AR pLI=0.00)
chr15	101110302	101110302	C	G	hom	het	het		QUAL=17335;DP=429,97,139;MQM=59	LINS1	missense	LINS1:NM_001040616.2:missense:MODERATE:exon7/7:c.1415G>C:p.Ser472Thr		rs2411837	0.2548	0.3438	7753/5790/123	0.3407	-0.1740	T	T	B	T	8.76				COSM147995	265	679					LINS1 (inh=AR pLI=0.00)
chr15	101113862	101113862	C	T	hom	hom	hom	pred_pathogenic	QUAL=9828;DP=192,62,67;MQM=60	LINS1	missense	LINS1:NM_001040616.2:missense:MODERATE:exon5/7:c.1216G>A:p.Val406Met		rs12719734	0.8952	0.9542	55343/32548/4654	0.9428	2.0920	T	T	B,B	T	8.46					1533	27					LINS1 (inh=AR pLI=0.00)
chr15	101113950	101113950	A	G	hom	het	het		QUAL=12849;DP=281,164,207;MQM=60	LINS1	synonymous	LINS1:NM_001040616.2:synonymous:LOW:exon5/7:c.1128T>C:p.Ser376Ser		rs12592868	0.3275	0.3885	9876/7092/488	0.3898										COSM147996, COSM3999453	330	744					LINS1 (inh=AR pLI=0.00)
chr15	101114418	101114418	G	A	hom	het	het		QUAL=5208;DP=140,33,37;MQM=60	LINS1	synonymous	LINS1:NM_001040616.2:synonymous:LOW:exon5/7:c.660C>T:p.Phe220Phe		rs8039437	0.3143	0.3867	9596/6970/340	0.3846										COSM3722370, COSM3722371	323	726					LINS1 (inh=AR pLI=0.00)
chr15	101120963	101120963	T	C	hom	het	het		QUAL=29635;DP=568,332,461;MQM=59	LINS1	missense	LINS1:NM_001040616.2:missense:MODERATE:exon2/7:c.85A>G:p.Ile29Val		rs11247226	0.2985	0.3836	9489/6974/237	0.3817	-2.6700	T	T	B,B	T	0.01				COSM3936696, COSM3936697	328	730					LINS1 (inh=AR pLI=0.00)
chr15	101142449	101142449	G	T	hom	het	het		QUAL=6482;DP=117,131,188;MQM=59	LINS1-ASB7	intergenic_region	LINS1-ASB7:LINS1-ASB7:intergenic_region:MODIFIER::n.101142449G>T:		rs7166822	0.3448	0.0000	0/0/0	0.4161											30	72					LINS1-ASB7 (inh=n/a pLI=n/a)
chr16	1250559	1250559	T	C	hom	het	het		QUAL=11079;DP=85,338,399;MQM=59	CACNA1H	synonymous	CACNA1H:NM_021098.2:synonymous:LOW:exon7/35:c.1107T>C:p.Ile369Ile,CACNA1H:NM_001005407.1:synonymous:LOW:exon7/34:c.1107T>C:p.Ile369Ile		rs8044363	0.3327	0.3774	9204/5909/1130	0.3693							607904 [CACNA1H (provisional) Epilepsy,idiopathic generalized,susceptibility to,6,611942|Epilepsy,childhood absence,susceptibility to,6,611942|Hyperaldosteronism,familial,type IV,617027];	RCV000152871.3 [benign]; 	CM071580 [CLASS=DP MUT=ALT PHEN="Epilepsy childhood absence association with" GENE=CACNA1H]; 	COSM3999710, COSM3999709, COSM3999711	214	683					CACNA1H (inh=n/a pLI=0.76)
chr16	1252259	1252259	A	G	hom	het	het	low_DP	QUAL=286;DP=2,10,9;MQM=60	CACNA1H	synonymous	CACNA1H:NM_021098.2:synonymous:LOW:exon9/35:c.1809A>G:p.Arg603Arg,CACNA1H:NM_001005407.1:synonymous:LOW:exon9/34:c.1809A>G:p.Arg603Arg		rs9934839	0.3966	0.5185	4284/2879/466	0.3406							607904 [CACNA1H (provisional) Epilepsy,idiopathic generalized,susceptibility to,6,611942|Epilepsy,childhood absence,susceptibility to,6,611942|Hyperaldosteronism,familial,type IV,617027];	RCV000082063.4 [benign]; 	CM071579 [CLASS=DP MUT=REF PHEN="Epilepsy childhood absence association with" GENE=CACNA1H]; 	COSM3754631, COSM3754630, COSM3754629	286	680					CACNA1H (inh=n/a pLI=0.76)
chr16	1260481	1260481	T	C	het	hom	het		QUAL=13561;DP=109,273,368;MQM=59	CACNA1H	synonymous	CACNA1H:NM_021098.2:synonymous:LOW:exon19/35:c.3957T>C:p.Asp1319Asp,CACNA1H:NM_001005407.1:synonymous:LOW:exon19/34:c.3957T>C:p.Asp1319Asp		rs8063574	0.9199	0.8601	44276/21587/4008	0.8151							607904 [CACNA1H (provisional) Epilepsy,idiopathic generalized,susceptibility to,6,611942|Epilepsy,childhood absence,susceptibility to,6,611942|Hyperaldosteronism,familial,type IV,617027];	RCV000082071.4 [benign]; 		COSM4128659, COSM4128661, COSM4128660	1085	436					CACNA1H (inh=n/a pLI=0.76)
chr16	1261219	1261219	A	G	het	hom	het		QUAL=15495;DP=90,300,393;MQM=59	CACNA1H	synonymous	CACNA1H:NM_021098.2:synonymous:LOW:exon22/35:c.4275A>G:p.Ser1425Ser,CACNA1H:NM_001005407.1:synonymous:LOW:exon22/34:c.4275A>G:p.Ser1425Ser		rs2753326	0.7097	0.6431	25385/11745/2618	0.6300							607904 [CACNA1H (provisional) Epilepsy,idiopathic generalized,susceptibility to,6,611942|Epilepsy,childhood absence,susceptibility to,6,611942|Hyperaldosteronism,familial,type IV,617027];			COSM3765849, COSM3765850, COSM3765851	558	749					CACNA1H (inh=n/a pLI=0.76)
chr16	1261222	1261222	A	G	het	hom	het		QUAL=15495;DP=90,300,393;MQM=59	CACNA1H	synonymous	CACNA1H:NM_021098.2:synonymous:LOW:exon22/35:c.4278A>G:p.Ser1426Ser,CACNA1H:NM_001005407.1:synonymous:LOW:exon22/34:c.4278A>G:p.Ser1426Ser		rs2753325	0.7097	0.6432	25402/11754/2624	0.6335							607904 [CACNA1H (provisional) Epilepsy,idiopathic generalized,susceptibility to,6,611942|Epilepsy,childhood absence,susceptibility to,6,611942|Hyperaldosteronism,familial,type IV,617027];			COSM3765854, COSM3765852, COSM3765853	558	749					CACNA1H (inh=n/a pLI=0.76)
chr16	1261282	1261282	T	C	het	hom	het		QUAL=15583;DP=74,316,382;MQM=59	CACNA1H	synonymous	CACNA1H:NM_021098.2:synonymous:LOW:exon22/35:c.4338T>C:p.Ile1446Ile,CACNA1H:NM_001005407.1:synonymous:LOW:exon22/34:c.4338T>C:p.Ile1446Ile		rs4984637	0.9177	0.8597	44695/21924/4005	0.8252							607904 [CACNA1H (provisional) Epilepsy,idiopathic generalized,susceptibility to,6,611942|Epilepsy,childhood absence,susceptibility to,6,611942|Hyperaldosteronism,familial,type IV,617027];			COSM3765857, COSM3765855, COSM3765856	1088	435					CACNA1H (inh=n/a pLI=0.76)
chr16	1265600	1265600	G	A	wt	het	het		QUAL=1990;DP=80,107,168;MQM=60	CACNA1H	splice_region&intron	CACNA1H:NM_021098.2:splice_region&intron:LOW:exon30/34:c.5244+7G>A:,CACNA1H:NM_001005407.1:splice_region&intron:LOW:exon29/33:c.5226+7G>A:		rs2235634	0.1294	0.1559	1217/683/1	0.1343							607904 [CACNA1H (provisional) Epilepsy,idiopathic generalized,susceptibility to,6,611942|Epilepsy,childhood absence,susceptibility to,6,611942|Hyperaldosteronism,familial,type IV,617027];				30	434					CACNA1H (inh=n/a pLI=0.76)
chr16	1268494	1268494	C	T	het	hom	het		QUAL=20503;DP=194,424,512;MQM=60	CACNA1H	synonymous	CACNA1H:NM_021098.2:synonymous:LOW:exon33/35:c.5730C>T:p.Asp1910Asp,CACNA1H:NM_001005407.1:synonymous:LOW:exon32/34:c.5712C>T:p.Asp1904Asp		rs2745136	0.6991	0.6224	4475/2095/539	0.4512							607904 [CACNA1H (provisional) Epilepsy,idiopathic generalized,susceptibility to,6,611942|Epilepsy,childhood absence,susceptibility to,6,611942|Hyperaldosteronism,familial,type IV,617027];			COSM434641, COSM434640, COSM3754639	555	754					CACNA1H (inh=n/a pLI=0.76)
chr16	1269029	1269029	T	C	het	hom	het		QUAL=2003;DP=26,47,62;MQM=60	CACNA1H	synonymous	CACNA1H:NM_021098.2:synonymous:LOW:exon34/35:c.5947T>C:p.Leu1983Leu,CACNA1H:NM_001005407.1:synonymous:LOW:exon33/34:c.5929T>C:p.Leu1977Leu		rs2738893	0.6917	0.6104	3593/1506/397	0.2399							607904 [CACNA1H (provisional) Epilepsy,idiopathic generalized,susceptibility to,6,611942|Epilepsy,childhood absence,susceptibility to,6,611942|Hyperaldosteronism,familial,type IV,617027];				549	751					CACNA1H (inh=n/a pLI=0.76)
chr16	1270162	1270162	G	A	het	hom	het		QUAL=4330;DP=47,86,133;MQM=60	CACNA1H	missense	CACNA1H:NM_021098.2:missense:MODERATE:exon35/35:c.6230G>A:p.Arg2077His,CACNA1H:NM_001005407.1:missense:MODERATE:exon34/34:c.6212G>A:p.Arg2071His		rs1054645	0.7007	0.6628	20660/9821/1832	0.5942	-0.6630	T,T	T	B,B	T,T	10.19	607904 [CACNA1H (provisional) Epilepsy,idiopathic generalized,susceptibility to,6,611942|Epilepsy,childhood absence,susceptibility to,6,611942|Hyperaldosteronism,familial,type IV,617027];	RCV000082076.4 [benign]; 		COSM3754643, COSM434644, COSM434645	551	735					CACNA1H (inh=n/a pLI=0.76)
chr16	1270349	1270349	T	C	het	hom	het		QUAL=2349;DP=59,42,52;MQM=60	CACNA1H	synonymous	CACNA1H:NM_021098.2:synonymous:LOW:exon35/35:c.6417T>C:p.Asp2139Asp,CACNA1H:NM_001005407.1:synonymous:LOW:exon34/34:c.6399T>C:p.Asp2133Asp		rs4247094	0.9139	0.8583	35348/17568/2683	0.7500							607904 [CACNA1H (provisional) Epilepsy,idiopathic generalized,susceptibility to,6,611942|Epilepsy,childhood absence,susceptibility to,6,611942|Hyperaldosteronism,familial,type IV,617027];	RCV000082078.4 [benign]; 		COSM3749326, COSM3749327, COSM3749328	1049	377					CACNA1H (inh=n/a pLI=0.76)
chr16	1271189	1271189	G	A	het	hom	het		QUAL=10720;DP=128,201,260;MQM=59	CACNA1H	3'UTR	CACNA1H:NM_021098.2:3'UTR:MODIFIER:exon35/35:c.*195G>A:,CACNA1H:NM_001005407.1:3'UTR:MODIFIER:exon34/34:c.*195G>A:		rs2248457	0.6933	0.0000	0/0/0	0.6490							607904 [CACNA1H (provisional) Epilepsy,idiopathic generalized,susceptibility to,6,611942|Epilepsy,childhood absence,susceptibility to,6,611942|Hyperaldosteronism,familial,type IV,617027];				76	120					CACNA1H (inh=n/a pLI=0.76)
chr16	1495006	1495006	C	G	wt	wt	het		QUAL=2086;DP=159,128,198;MQM=60	CLCN7	3'UTR	CLCN7:NM_001287.5:3'UTR:MODIFIER:exon25/25:c.*1626G>C:,CLCN7:NM_001114331.2:3'UTR:MODIFIER:exon24/24:c.*1626G>C:	MER33	rs8767	0.6613	0.0000	0/0/0	0.6109							602727 [CLCN7 (confirmed) Osteopetrosis,autosomal recessive 4,611490|Osteopetrosis,autosomal dominant 2,166600];	RCV000260830.1 [benign]; 			82	102					CLCN7 (inh=AR+AD pLI=0.98)
chr16	1495243	1495243	T	G	hom	het	hom		QUAL=3454;DP=53,37,44;MQM=60	CLCN7	3'UTR	CLCN7:NM_001287.5:3'UTR:MODIFIER:exon25/25:c.*1389A>C:,CLCN7:NM_001114331.2:3'UTR:MODIFIER:exon24/24:c.*1389A>C:		rs710900	0.9189	0.0000	0/0/0	0.8173							602727 [CLCN7 (confirmed) Osteopetrosis,autosomal recessive 4,611490|Osteopetrosis,autosomal dominant 2,166600];	RCV000396092.1 [benign]; 			189	38					CLCN7 (inh=AR+AD pLI=0.98)
chr16	1495300	1495300	G	A	wt	wt	het		QUAL=592;DP=35,41,58;MQM=60	CLCN7	3'UTR	CLCN7:NM_001287.5:3'UTR:MODIFIER:exon25/25:c.*1332C>T:,CLCN7:NM_001114331.2:3'UTR:MODIFIER:exon24/24:c.*1332C>T:		rs941439	0.4696	0.0000	0/0/0	0.0786							602727 [CLCN7 (confirmed) Osteopetrosis,autosomal recessive 4,611490|Osteopetrosis,autosomal dominant 2,166600];	RCV000306818.1 [benign]; 			40	101					CLCN7 (inh=AR+AD pLI=0.98)
chr16	1495745	1495745	G	A	hom	het	hom	low_DP	QUAL=1892;DP=24,15,40;MQM=59	CLCN7	3'UTR	CLCN7:NM_001287.5:3'UTR:MODIFIER:exon25/25:c.*887C>T:,CLCN7:NM_001114331.2:3'UTR:MODIFIER:exon24/24:c.*887C>T:		rs6600146	0.9066	0.0000	0/0/0	0.0984							602727 [CLCN7 (confirmed) Osteopetrosis,autosomal recessive 4,611490|Osteopetrosis,autosomal dominant 2,166600];	RCV000374837.1 [benign]; 			164	58					CLCN7 (inh=AR+AD pLI=0.98)
chr16	1495746	1495746	G	A	hom	het	hom	low_DP	QUAL=1892;DP=24,15,40;MQM=59	CLCN7	3'UTR	CLCN7:NM_001287.5:3'UTR:MODIFIER:exon25/25:c.*886C>T:,CLCN7:NM_001114331.2:3'UTR:MODIFIER:exon24/24:c.*886C>T:		rs1050834	0.9066	0.0000	0/0/0	0.5819							602727 [CLCN7 (confirmed) Osteopetrosis,autosomal recessive 4,611490|Osteopetrosis,autosomal dominant 2,166600];	RCV000266296.1 [benign]; 			164	58					CLCN7 (inh=AR+AD pLI=0.98)
chr16	1495897	1495897	G	A	wt	wt	het		QUAL=1597;DP=61,105,143;MQM=60	CLCN7	3'UTR	CLCN7:NM_001287.5:3'UTR:MODIFIER:exon25/25:c.*735C>T:,CLCN7:NM_001114331.2:3'UTR:MODIFIER:exon24/24:c.*735C>T:		rs2294542	0.5871	0.0000	0/0/0	0.0917							602727 [CLCN7 (confirmed) Osteopetrosis,autosomal recessive 4,611490|Osteopetrosis,autosomal dominant 2,166600];	RCV000378392.1 [benign]; 			53	115					CLCN7 (inh=AR+AD pLI=0.98)
chr16	1496005	1496005	T	C	wt	het	wt		QUAL=2632;DP=124,182,219;MQM=60	CLCN7	3'UTR	CLCN7:NM_001287.5:3'UTR:MODIFIER:exon25/25:c.*627A>G:,CLCN7:NM_001114331.2:3'UTR:MODIFIER:exon24/24:c.*627A>G:		rs10903009	0.0895	0.0000	0/0/0	0.0140							602727 [CLCN7 (confirmed) Osteopetrosis,autosomal recessive 4,611490|Osteopetrosis,autosomal dominant 2,166600];	RCV000345757.1 [likely benign]; 			4	45					CLCN7 (inh=AR+AD pLI=0.98)
chr16	1503879	1503879	T	A	het	het	het		QUAL=8668;DP=226,189,252;MQM=60	CLCN7	synonymous	CLCN7:NM_001287.5:synonymous:LOW:exon14/25:c.1170A>T:p.Ala390Ala,CLCN7:NM_001114331.2:synonymous:LOW:exon13/24:c.1098A>T:p.Ala366Ala		rs2235579	0.5559	0.5335	17293/8469/1355	0.5164							602727 [CLCN7 (confirmed) Osteopetrosis,autosomal recessive 4,611490|Osteopetrosis,autosomal dominant 2,166600];	RCV000241746.1 [benign]; RCV000303073.1 [benign]; 		COSM3754669	404	813					CLCN7 (inh=AR+AD pLI=0.98)
chr16	2139320	2139320	G	A	wt	het	wt	gene_blacklist	QUAL=3104;DP=247,227,328;MQM=60	PKD1	3'UTR	PKD1:NM_001009944.2:3'UTR:MODIFIER:exon46/46:c.*408C>T:,PKD1:NM_000296.3:3'UTR:MODIFIER:exon46/46:c.*408C>T:		rs181780746	0.0002	0.0000	0/0/0	0.0001							601313 [PKD1 (confirmed) Polycystic kidney disease,adult type I,173900];				0	1					PKD1 (inh=AD pLI=1.00)
chr16	2150466	2150466	T	A	het	het	wt	low_MQM;gene_blacklist;pred_pathogenic;anno_pathogenic_hgmd	QUAL=4004;DP=161,266,346;MQM=48	PKD1	missense	PKD1:NM_001009944.2:missense:MODERATE:exon27/46:c.9499A>T:p.Ile3167Phe,PKD1:NM_000296.3:missense:MODERATE:exon27/46:c.9499A>T:p.Ile3167Phe		rs139945204	0.0002	0.0011	2/2/0	0.0009	1.3330	D,D,D	T	P,D	T,T	26.00	601313 [PKD1 (confirmed) Polycystic kidney disease,adult type I,173900];		CM022663 [CLASS=DM MUT=ALT PHEN="Polycystic kidney disease 1" GENE=PKD1]; 	COSM3754779	0	5					PKD1 (inh=AD pLI=1.00)
chr16	2160251	2160251	G	A	wt	het	wt	gene_blacklist	QUAL=609;DP=67,105,161;MQM=58	PKD1	synonymous	PKD1:NM_001009944.2:synonymous:LOW:exon15/46:c.4917C>T:p.Gly1639Gly,PKD1:NM_000296.3:synonymous:LOW:exon15/46:c.4917C>T:p.Gly1639Gly		rs148852027	0.0006	0.0014	0/0/0	0.0012							601313 [PKD1 (confirmed) Polycystic kidney disease,adult type I,173900];	RCV000246928.1 [likely benign]; 			0	14					PKD1 (inh=AD pLI=1.00)
chr16	2160494	2160494	C	T	het	het	wt	gene_blacklist	QUAL=4601;DP=250,120,151;MQM=59	PKD1	synonymous	PKD1:NM_001009944.2:synonymous:LOW:exon15/46:c.4674G>A:p.Thr1558Thr,PKD1:NM_000296.3:synonymous:LOW:exon15/46:c.4674G>A:p.Thr1558Thr		rs79884128	0.0711	0.0757	424/194/0	0.0751							601313 [PKD1 (confirmed) Polycystic kidney disease,adult type I,173900];	RCV000249784.1 [benign]; 		COSM3754780	12	211					PKD1 (inh=AD pLI=1.00)
chr16	2164808	2164808	C	T	het	hom	het	low_DP;low_MQM;gene_blacklist	QUAL=3112;DP=10,90,153;MQM=31	PKD1	missense	PKD1:NM_001009944.2:missense:MODERATE:exon11/46:c.2216G>A:p.Arg739Gln,PKD1:NM_000296.3:missense:MODERATE:exon11/46:c.2216G>A:p.Arg739Gln		rs40433	0.9792	0.9586	4288/1221/255	0.1506	0.0910	T,T	T	B,B	T,T	0.16	601313 [PKD1 (confirmed) Polycystic kidney disease,adult type I,173900];			COSM4128808	706	76					PKD1 (inh=AD pLI=1.00)
chr16	2167874	2167874	G	A	het	hom	het	low_MQM;gene_blacklist	QUAL=5445;DP=78,118,122;MQM=30	PKD1	synonymous	PKD1:NM_001009944.2:synonymous:LOW:exon5/46:c.1119C>T:p.Leu373Leu,PKD1:NM_000296.3:synonymous:LOW:exon5/46:c.1119C>T:p.Leu373Leu		rs35842	0.9443	0.9051	1062/323/151	0.1336							601313 [PKD1 (confirmed) Polycystic kidney disease,adult type I,173900];			COSM4128810	409	288					PKD1 (inh=AD pLI=1.00)
chr16	2167970	2167970	G	A	het	wt	het	low_DP;low_MQM;gene_blacklist	QUAL=615;DP=19,89,83;MQM=29	PKD1	synonymous	PKD1:NM_001009944.2:synonymous:LOW:exon5/46:c.1023C>T:p.Ala341Ala,PKD1:NM_000296.3:synonymous:LOW:exon5/46:c.1023C>T:p.Ala341Ala		rs11643513	0.0260	0.0273	7/3/0	0.0026							601313 [PKD1 (confirmed) Polycystic kidney disease,adult type I,173900];	RCV000242828.1 [benign]; 			3	63					PKD1 (inh=AD pLI=1.00)
chr16	2331430	2331430	A	G	hom	hom	hom		QUAL=25801;DP=287,229,307;MQM=59	ABCA3	synonymous	ABCA3:NM_001089.2:synonymous:LOW:exon27/33:c.4116T>C:p.Ser1372Ser		rs149532	0.9010	0.9192	51391/27749/3132	0.8966							601615 [ABCA3 (provisional) Surfactant metabolism dysfunction,pulmonary,3,610921];	RCV000150112.1 [benign]; 		COSM4128822	1266	280					ABCA3 (inh=AR pLI=0.00)
chr16	2348528	2348528	G	C	het	het	wt		QUAL=2519;DP=121,139,204;MQM=60	ABCA3	synonymous	ABCA3:NM_001089.2:synonymous:LOW:exon15/33:c.1755C>G:p.Pro585Pro		rs323043	0.0817	0.1434	1572/1299/28	0.1407							601615 [ABCA3 (provisional) Surfactant metabolism dysfunction,pulmonary,3,610921];	RCV000155454.1 [benign]; RCV000365741.1 [likely benign]; 		COSM3754801	45	424					ABCA3 (inh=AR pLI=0.00)
chr16	2550292	2550292	C	T	wt	het	wt		QUAL=713;DP=74,76,83;MQM=60	TBC1D24	synonymous	TBC1D24:NM_001199107.1:synonymous:LOW:exon7/8:c.1326C>T:p.Tyr442Tyr,TBC1D24:NM_020705.2:synonymous:LOW:exon6/7:c.1308C>T:p.Tyr436Tyr		rs184639841	0.0012	0.0041	0/0/0	0.0028							613577 [TBC1D24 (provisional) Myoclonic epilepsy,infantile,familial,605021|Epileptic encephalopathy,early infantile,16,615338|DOOR syndrome,220500|Deafness,autosomal recessive 86,614617|Deafness,autosomal dominant 65,616044];	RCV000118575.4 [other]; RCV000268514.1 [uncertain significance]; 			0	15	2	[2] ahschak1 11.10.2016			TBC1D24 (inh=AR pLI=0.00)
chr16	2551147	2551147	C	T	het	het	wt		QUAL=4290;DP=179,195,223;MQM=59	TBC1D24	3'UTR	TBC1D24:NM_001199107.1:3'UTR:MODIFIER:exon8/8:c.*188C>T:,TBC1D24:NM_020705.2:3'UTR:MODIFIER:exon7/7:c.*188C>T:		rs62040717	0.0284	0.0000	0/0/0	0.0575							613577 [TBC1D24 (provisional) Myoclonic epilepsy,infantile,familial,605021|Epileptic encephalopathy,early infantile,16,615338|DOOR syndrome,220500|Deafness,autosomal recessive 86,614617|Deafness,autosomal dominant 65,616044];	RCV000403871.1 [likely benign]; 			2	45					TBC1D24 (inh=AR pLI=0.00)
chr16	2553869	2553869	A	T	wt	het	het	low_DP	QUAL=499;DP=88,19,24;MQM=60	TBC1D24	3'UTR	TBC1D24:NM_001199107.1:3'UTR:MODIFIER:exon8/8:c.*2910A>T:,TBC1D24:NM_020705.2:3'UTR:MODIFIER:exon7/7:c.*2910A>T:		rs4786287	0.4555	0.0000	0/0/0	0.3992							613577 [TBC1D24 (provisional) Myoclonic epilepsy,infantile,familial,605021|Epileptic encephalopathy,early infantile,16,615338|DOOR syndrome,220500|Deafness,autosomal recessive 86,614617|Deafness,autosomal dominant 65,616044];	RCV000268374.1 [benign]; 			26	63					TBC1D24 (inh=AR pLI=0.00)
chr16	3292398	3292398	A	G	het	hom	wt	low_DP;low_MQM	QUAL=300;DP=20,3,4;MQM=45	MEFV	3'UTR	MEFV:NM_000243.2:3'UTR:MODIFIER:exon10/10:c.*743T>C:,MEFV:NM_001198536.1:3'UTR:MODIFIER:exon9/9:c.*1293T>C:	AluSx	rs170387	0.6943	0.0000	0/0/0	0.5033							608107 [MEFV (confirmed) Familial Mediterranean fever,AR,249100|Familial Mediterranean fever,AD,134610];	RCV000293660.1 [likely benign]; 			39	54					MEFV (inh=AR+AD pLI=0.00)
chr16	3292666	3292666	T	C	het	hom	wt		QUAL=7979;DP=149,222,239;MQM=55	MEFV	3'UTR	MEFV:NM_000243.2:3'UTR:MODIFIER:exon10/10:c.*475A>G:,MEFV:NM_001198536.1:3'UTR:MODIFIER:exon9/9:c.*1025A>G:	AluSx	rs11466052	0.6514	0.0000	0/0/0	0.1267							608107 [MEFV (confirmed) Familial Mediterranean fever,AR,249100|Familial Mediterranean fever,AD,134610];	RCV000291003.1 [likely benign]; 			54	104					MEFV (inh=AR+AD pLI=0.00)
chr16	3292667	3292667	G	C	het	hom	wt		QUAL=7979;DP=149,222,239;MQM=55	MEFV	3'UTR	MEFV:NM_000243.2:3'UTR:MODIFIER:exon10/10:c.*474C>G:,MEFV:NM_001198536.1:3'UTR:MODIFIER:exon9/9:c.*1024C>G:	AluSx	rs11466051	0.6512	0.0000	0/0/0	0.1267							608107 [MEFV (confirmed) Familial Mediterranean fever,AR,249100|Familial Mediterranean fever,AD,134610];	RCV000345914.1 [likely benign]; 			54	104					MEFV (inh=AR+AD pLI=0.00)
chr16	3292673	3292675	AAA	-	hom	hom	wt		QUAL=3946;DP=86,179,157;MQM=57	MEFV	3'UTR	MEFV:NM_000243.2:3'UTR:MODIFIER:exon10/10:c.*466_*468delTTT:,MEFV:NM_001198536.1:3'UTR:MODIFIER:exon9/9:c.*1016_*1018delTTT:	AluSx	rs61379197;rs796294754	0.6571	0.0000	0/0/0	0.3617							608107 [MEFV (confirmed) Familial Mediterranean fever,AR,249100|Familial Mediterranean fever,AD,134610];	RCV000301778.1 [likely benign]; 			41	93					MEFV (inh=AR+AD pLI=0.00)
chr16	3292874	3292874	C	T	het	hom	wt		QUAL=15013;DP=229,376,432;MQM=60	MEFV	3'UTR	MEFV:NM_000243.2:3'UTR:MODIFIER:exon10/10:c.*267G>A:,MEFV:NM_001198536.1:3'UTR:MODIFIER:exon9/9:c.*817G>A:		rs2741918	0.6462	0.0000	0/0/0	0.0998							608107 [MEFV (confirmed) Familial Mediterranean fever,AR,249100|Familial Mediterranean fever,AD,134610];	RCV000209906.2 [likely benign]; 			54	116					MEFV (inh=AR+AD pLI=0.00)
chr16	3292896	3292896	C	T	het	hom	wt		QUAL=16212;DP=303,374,401;MQM=60	MEFV	3'UTR	MEFV:NM_000243.2:3'UTR:MODIFIER:exon10/10:c.*245G>A:,MEFV:NM_001198536.1:3'UTR:MODIFIER:exon9/9:c.*795G>A:		rs2741919	0.6398	0.0000	0/0/0	0.0996							608107 [MEFV (confirmed) Familial Mediterranean fever,AR,249100|Familial Mediterranean fever,AD,134610];	RCV000209870.2 [likely benign]; 			54	116					MEFV (inh=AR+AD pLI=0.00)
chr16	3293888	3293888	C	T	het	wt	hom		QUAL=16280;DP=300,327,384;MQM=59	MEFV	missense,synonymous	MEFV:NM_001198536.1:missense:MODERATE:exon8/9:c.1306G>A:p.Gly436Arg,MEFV:NM_000243.2:synonymous:LOW:exon9/10:c.1764G>A:p.Pro588Pro		rs1231122	0.3536	0.3967	9774/6909/594	0.3946	0.1690	T	T		T	9.74	608107 [MEFV (confirmed) Familial Mediterranean fever,AR,249100|Familial Mediterranean fever,AD,134610];	RCV000126738.1 [benign]; RCV000030177.2 [benign]; RCV000266471.1 [benign]; 		COSM3754866, COSM3754867	337	743					MEFV (inh=AR+AD pLI=0.00)
chr16	3293922	3293922	A	T	het	wt	hom	pred_pathogenic	QUAL=17940;DP=303,365,434;MQM=60	MEFV	missense,intron	MEFV:NM_001198536.1:missense:MODERATE:exon8/9:c.1272T>A:p.Asp424Glu,MEFV:NM_000243.2:intron:MODIFIER:exon8/9:c.1760-30T>A:		rs1231123	0.3113	0.3949	8787/6520/449	0.3610	-0.0680	D	T		T	1.92	608107 [MEFV (confirmed) Familial Mediterranean fever,AR,249100|Familial Mediterranean fever,AD,134610];				305	703					MEFV (inh=AR+AD pLI=0.00)
chr16	3297073	3297073	A	G	het	hom	wt		QUAL=11631;DP=147,323,366;MQM=60	MEFV	synonymous	MEFV:NM_000243.2:synonymous:LOW:exon5/10:c.1530T>C:p.Asp510Asp,MEFV:NM_001198536.1:synonymous:LOW:exon4/9:c.897T>C:p.Asp299Asp		rs224206	0.6631	0.6104	23159/9953/2456	0.5952							608107 [MEFV (confirmed) Familial Mediterranean fever,AR,249100|Familial Mediterranean fever,AD,134610];	RCV000030175.2 [other]; RCV000254381.1 [benign]; 			484	744					MEFV (inh=AR+AD pLI=0.00)
chr16	3297175	3297175	T	C	het	hom	wt		QUAL=13298;DP=280,315,376;MQM=59	MEFV	synonymous	MEFV:NM_000243.2:synonymous:LOW:exon5/10:c.1428A>G:p.Gln476Gln,MEFV:NM_001198536.1:synonymous:LOW:exon4/9:c.795A>G:p.Gln265Gln		rs224207	0.6506	0.6057	22800/9899/2177	0.5907							608107 [MEFV (confirmed) Familial Mediterranean fever,AR,249100|Familial Mediterranean fever,AD,134610];	RCV000244842.1 [benign]; RCV000399975.1 [likely benign]; 			481	743					MEFV (inh=AR+AD pLI=0.00)
chr16	3297181	3297181	C	T	het	hom	wt		QUAL=12085;DP=249,303,361;MQM=59	MEFV	synonymous	MEFV:NM_000243.2:synonymous:LOW:exon5/10:c.1422G>A:p.Glu474Glu,MEFV:NM_001198536.1:synonymous:LOW:exon4/9:c.789G>A:p.Glu263Glu		rs224208	0.6390	0.6027	22578/9895/2139	0.5876							608107 [MEFV (confirmed) Familial Mediterranean fever,AR,249100|Familial Mediterranean fever,AD,134610];	RCV000030172.2 [other]; RCV000253062.1 [benign]; 			479	742					MEFV (inh=AR+AD pLI=0.00)
chr16	3299749	3299749	G	A	het	hom	wt		QUAL=2449;DP=86,57,59;MQM=59	MEFV	synonymous	MEFV:NM_000243.2:synonymous:LOW:exon3/10:c.942C>T:p.Arg314Arg,MEFV:NM_001198536.1:synonymous:LOW:exon2/9:c.309C>T:p.Arg103Arg		rs224213	0.6907	0.6283	24123/10133/2666	0.6148							608107 [MEFV (confirmed) Familial Mediterranean fever,AR,249100|Familial Mediterranean fever,AD,134610];	RCV000030188.2 [other]; RCV000243663.1 [benign]; 		COSM3754869, COSM3754868	508	714					MEFV (inh=AR+AD pLI=0.00)
chr16	3304463	3304463	C	T	wt	het	wt		QUAL=429;DP=28,43,48;MQM=60	MEFV	missense,intron	MEFV:NM_000243.2:missense:MODERATE:exon2/10:c.605G>A:p.Arg202Gln,MEFV:NM_001198536.1:intron:MODIFIER:exon1/8:c.277+1848G>A:		rs224222	0.1360	0.2555	3138/1982/18	0.2108	-2.4200	T,T	T	B	T	0.10	608107 [MEFV (confirmed) Familial Mediterranean fever,AR,249100|Familial Mediterranean fever,AD,134610];	RCV000030185.2 [other]; RCV000175564.3 [benign]; 	CM044663 [CLASS=DP MUT=ALT PHEN="Mediterranean fever familial" GENE=MEFV]; 	COSM3749364	104	496					MEFV (inh=AR+AD pLI=0.00)
chr16	3304573	3304573	G	T	hom	hom	het		QUAL=2511;DP=56,21,35;MQM=59	MEFV	synonymous,intron	MEFV:NM_000243.2:synonymous:LOW:exon2/10:c.495C>A:p.Ala165Ala,MEFV:NM_001198536.1:intron:MODIFIER:exon1/8:c.277+1738C>A:		rs224223	0.3864	0.4907	6129/3819/562	0.3662							608107 [MEFV (confirmed) Familial Mediterranean fever,AR,249100|Familial Mediterranean fever,AD,134610];	RCV000030184.2 [other]; RCV000242316.2 [benign]; 		COSM1128970	304	706					MEFV (inh=AR+AD pLI=0.00)
chr16	3304654	3304654	T	C	hom	hom	het	low_DP	QUAL=937;DP=7,10,31;MQM=59	MEFV	synonymous,intron	MEFV:NM_000243.2:synonymous:LOW:exon2/10:c.414A>G:p.Gly138Gly,MEFV:NM_001198536.1:intron:MODIFIER:exon1/8:c.277+1657A>G:		rs224224	0.3866	0.4375	11379/6808/1066	0.4011							608107 [MEFV (confirmed) Familial Mediterranean fever,AR,249100|Familial Mediterranean fever,AD,134610];	RCV000030183.2 [other]; RCV000126740.3 [benign]; 		COSM3754870	297	685					MEFV (inh=AR+AD pLI=0.00)
chr16	3304762	3304762	A	G	hom	hom	het	low_DP	QUAL=984;DP=25,3,10;MQM=59	MEFV	synonymous,intron	MEFV:NM_000243.2:synonymous:LOW:exon2/10:c.306T>C:p.Asp102Asp,MEFV:NM_001198536.1:intron:MODIFIER:exon1/8:c.277+1549T>C:		rs224225	0.3894	0.4382	12231/7333/1175	0.4282							608107 [MEFV (confirmed) Familial Mediterranean fever,AR,249100|Familial Mediterranean fever,AD,134610];	RCV000030182.2 [other]; RCV000242621.2 [benign]; 		COSM435205	305	695					MEFV (inh=AR+AD pLI=0.00)
chr16	3775717	3775717	C	T	hom	hom	hom		QUAL=17917;DP=271,117,162;MQM=59	CREBBP	3'UTR	CREBBP:NM_004380.2:3'UTR:MODIFIER:exon31/31:c.*2002G>A:,CREBBP:NM_001079846.1:3'UTR:MODIFIER:exon30/30:c.*2002G>A:		rs1635400	0.9808	0.0000	0/0/0	0.1551							600140 [CREBBP (confirmed) Rubinstein-Taybi syndrome,180849];				227	3					CREBBP (inh=AD pLI=1.00)
chr16	3776414	3776426	CGCCCACCTCAGT	-	het	het	het		QUAL=10255;DP=92,188,294;MQM=59	CREBBP	3'UTR	CREBBP:NM_004380.2:3'UTR:MODIFIER:exon31/31:c.*1293_*1305delACTGAGGTGGGCG:,CREBBP:NM_001079846.1:3'UTR:MODIFIER:exon30/30:c.*1293_*1305delACTGAGGTGGGCG:		rs113182995	0.9790	0.0000	0/0/0	0.5463							600140 [CREBBP (confirmed) Rubinstein-Taybi syndrome,180849];				149	81					CREBBP (inh=AD pLI=1.00)
chr16	5128001	5128001	C	T	wt	wt	het		QUAL=2271;DP=92,146,192;MQM=59	ALG1	synonymous	ALG1:NM_019109.4:synonymous:LOW:exon6/13:c.723C>T:p.His241His		rs7195893	0.0925	0.0695	367/95/68	0.0674							605907 [ALG1 (provisional) Congenital disorder of glycosylation,type Ik,608540];	RCV000179507.2 [benign]; 		COSM3754926	9	128					ALG1 (inh=AR pLI=0.00)
chr16	5128857	5128857	G	C	wt	het	wt		QUAL=2443;DP=109,180,253;MQM=60	ALG1	synonymous	ALG1:NM_019109.4:synonymous:LOW:exon7/13:c.840G>C:p.Leu280Leu		rs12921879	0.0302	0.0382	121/92/17	0.0372							605907 [ALG1 (provisional) Congenital disorder of glycosylation,type Ik,608540];	RCV000081988.5 [benign]; 			8	107					ALG1 (inh=AR pLI=0.00)
chr16	5132636	5132636	C	T	hom	het	het		QUAL=15311;DP=188,348,412;MQM=57	ALG1	synonymous	ALG1:NM_019109.4:synonymous:LOW:exon11/13:c.1149C>T:p.Phe383Phe		rs1047732	0.5198	0.5243	17005/8740/793	0.5047							605907 [ALG1 (provisional) Congenital disorder of glycosylation,type Ik,608540];	RCV000081982.5 [benign]; 		COSM3754927	356	596					ALG1 (inh=AR pLI=0.00)
chr16	5134774	5134774	T	A	wt	wt	het		QUAL=285;DP=67,50,44;MQM=54	ALG1,EEF2KMT	missense,3'UTR	ALG1:NM_019109.4:missense:MODERATE:exon13/13:c.1287T>A:p.Asp429Glu,EEF2KMT:NM_201400.3:3'UTR:MODIFIER:exon8/8:c.*859A>T:,EEF2KMT:NM_001289029.1:3'UTR:MODIFIER:exon6/6:c.*859A>T:,EEF2KMT:NM_201598.3:3'UTR:MODIFIER:exon7/7:c.*859A>T:		rs9745522	0.1270	0.1174	814/341/84	0.1062	-0.0460	T,T	T	B,B	T,T	6.73	605907 [ALG1 (provisional) Congenital disorder of glycosylation,type Ik,608540];	RCV000174584.2 [benign]; 			21	122					ALG1 (inh=AR pLI=0.00), EEF2KMT (inh=n/a pLI=0.00)
chr16	5134898	5134898	-	TA	wt	het	wt		QUAL=1932;DP=98,184,238;MQM=57	ALG1,EEF2KMT	3'UTR	ALG1:NM_019109.4:3'UTR:MODIFIER:exon13/13:c.*17_*18dupTA:,EEF2KMT:NM_201400.3:3'UTR:MODIFIER:exon8/8:c.*733_*734dupTA:,EEF2KMT:NM_001289029.1:3'UTR:MODIFIER:exon6/6:c.*733_*734dupTA:,EEF2KMT:NM_201598.3:3'UTR:MODIFIER:exon7/7:c.*733_*734dupTA:		rs397714567	0.0000	0.3098	5568/3539/212	0.0324							605907 [ALG1 (provisional) Congenital disorder of glycosylation,type Ik,608540];	RCV000152770.2,RCV000152770.2 [benign,benign]; 			67	189					ALG1 (inh=AR pLI=0.00), EEF2KMT (inh=n/a pLI=0.00)
chr16	5135380	5135380	A	G	hom	het	het	low_MQM	QUAL=15810;DP=317,193,259;MQM=47	ALG1,EEF2KMT	3'UTR	ALG1:NM_019109.4:3'UTR:MODIFIER:exon13/13:c.*498A>G:,EEF2KMT:NM_201400.3:3'UTR:MODIFIER:exon8/8:c.*253T>C:,EEF2KMT:NM_001289029.1:3'UTR:MODIFIER:exon6/6:c.*253T>C:,EEF2KMT:NM_201598.3:3'UTR:MODIFIER:exon7/7:c.*253T>C:		rs6775	0.5595	0.0000	0/0/0	0.5243							605907 [ALG1 (provisional) Congenital disorder of glycosylation,type Ik,608540];				29	102					ALG1 (inh=AR pLI=0.00), EEF2KMT (inh=n/a pLI=0.00)
chr16	5135947	5135947	C	G	hom	het	het		QUAL=11357;DP=187,168,250;MQM=56	ALG1,EEF2KMT	3'UTR,intron	ALG1:NM_019109.4:3'UTR:MODIFIER:exon13/13:c.*1065C>G:,EEF2KMT:NM_201400.3:intron:MODIFIER:exon7/7:c.893-214G>C:,EEF2KMT:NM_001289029.1:intron:MODIFIER:exon5/5:c.710-214G>C:,EEF2KMT:NM_201598.3:intron:MODIFIER:exon6/6:c.791-214G>C:		rs4483845	0.5687	0.0000	0/0/0	0.5063							605907 [ALG1 (provisional) Congenital disorder of glycosylation,type Ik,608540];				75	109					ALG1 (inh=AR pLI=0.00), EEF2KMT (inh=n/a pLI=0.00)
chr16	5135956	5135956	G	T	wt	het	wt		QUAL=1921;DP=221,176,272;MQM=59	ALG1,EEF2KMT	3'UTR,intron	ALG1:NM_019109.4:3'UTR:MODIFIER:exon13/13:c.*1074G>T:,EEF2KMT:NM_201400.3:intron:MODIFIER:exon7/7:c.893-223C>A:,EEF2KMT:NM_001289029.1:intron:MODIFIER:exon5/5:c.710-223C>A:,EEF2KMT:NM_201598.3:intron:MODIFIER:exon6/6:c.791-223C>A:		rs4786593	0.2624	0.0000	0/0/0	0.2826							605907 [ALG1 (provisional) Congenital disorder of glycosylation,type Ik,608540];				24	96					ALG1 (inh=AR pLI=0.00), EEF2KMT (inh=n/a pLI=0.00)
chr16	5135979	5135979	T	C	hom	hom	hom		QUAL=20920;DP=235,173,260;MQM=59	ALG1,EEF2KMT	3'UTR,intron	ALG1:NM_019109.4:3'UTR:MODIFIER:exon13/13:c.*1097T>C:,EEF2KMT:NM_201400.3:intron:MODIFIER:exon7/7:c.893-246A>G:,EEF2KMT:NM_001289029.1:intron:MODIFIER:exon5/5:c.710-246A>G:,EEF2KMT:NM_201598.3:intron:MODIFIER:exon6/6:c.791-246A>G:		rs4238853	0.9852	0.0000	0/0/0	0.8444							605907 [ALG1 (provisional) Congenital disorder of glycosylation,type Ik,608540];				230	0					ALG1 (inh=AR pLI=0.00), EEF2KMT (inh=n/a pLI=0.00)
chr16	5136085	5136085	C	A	wt	het	wt		QUAL=1424;DP=175,169,225;MQM=59	ALG1,EEF2KMT	3'UTR,intron	ALG1:NM_019109.4:3'UTR:MODIFIER:exon13/13:c.*1203C>A:,EEF2KMT:NM_201400.3:intron:MODIFIER:exon7/7:c.893-352G>T:,EEF2KMT:NM_001289029.1:intron:MODIFIER:exon5/5:c.710-352G>T:,EEF2KMT:NM_201598.3:intron:MODIFIER:exon6/6:c.791-352G>T:	AluSz	rs4786594	0.1929	0.0000	0/0/0	0.2511							605907 [ALG1 (provisional) Congenital disorder of glycosylation,type Ik,608540];				17	87					ALG1 (inh=AR pLI=0.00), EEF2KMT (inh=n/a pLI=0.00)
chr16	5136294	5136294	C	T	wt	wt	het		QUAL=1271;DP=103,83,99;MQM=59	ALG1,EEF2KMT	3'UTR,intron	ALG1:NM_019109.4:3'UTR:MODIFIER:exon13/13:c.*1412C>T:,EEF2KMT:NM_201400.3:intron:MODIFIER:exon7/7:c.893-561G>A:,EEF2KMT:NM_001289029.1:intron:MODIFIER:exon5/5:c.710-561G>A:,EEF2KMT:NM_201598.3:intron:MODIFIER:exon6/6:c.791-561G>A:	AluSz	rs111263245	0.1138	0.0000	0/0/0	0.0888							605907 [ALG1 (provisional) Congenital disorder of glycosylation,type Ik,608540];				2	34					ALG1 (inh=AR pLI=0.00), EEF2KMT (inh=n/a pLI=0.00)
chr16	5136320	5136320	G	A	hom	hom	hom		QUAL=8497;DP=112,84,101;MQM=54	ALG1,EEF2KMT	3'UTR,intron	ALG1:NM_019109.4:3'UTR:MODIFIER:exon13/13:c.*1438G>A:,EEF2KMT:NM_201400.3:intron:MODIFIER:exon7/7:c.893-587C>T:,EEF2KMT:NM_001289029.1:intron:MODIFIER:exon5/5:c.710-587C>T:,EEF2KMT:NM_201598.3:intron:MODIFIER:exon6/6:c.791-587C>T:	AluSz	rs12922304	0.9599	0.0000	0/0/0	0.4693							605907 [ALG1 (provisional) Congenital disorder of glycosylation,type Ik,608540];				179	0					ALG1 (inh=AR pLI=0.00), EEF2KMT (inh=n/a pLI=0.00)
chr16	5136336	5136339	AAAA	-	hom	hom	hom		QUAL=3060;DP=81,55,68;MQM=58	ALG1,EEF2KMT	3'UTR,intron	ALG1:NM_019109.4:3'UTR:MODIFIER:exon13/13:c.*1468_*1471delAAAA:,EEF2KMT:NM_201400.3:intron:MODIFIER:exon7/7:c.893-606_893-603delTTTT:,EEF2KMT:NM_001289029.1:intron:MODIFIER:exon5/5:c.710-606_710-603delTTTT:,EEF2KMT:NM_201598.3:intron:MODIFIER:exon6/6:c.791-606_791-603delTTTT:	AluSz	rs556079793	0.7480	0.0000	0/0/0	0.4468							605907 [ALG1 (provisional) Congenital disorder of glycosylation,type Ik,608540];				52	64					ALG1 (inh=AR pLI=0.00), EEF2KMT (inh=n/a pLI=0.00)
chr16	5136900	5136900	C	A	hom	hom	hom		QUAL=18076;DP=162,163,253;MQM=56	ALG1,EEF2KMT	3'UTR,intron	ALG1:NM_019109.4:3'UTR:MODIFIER:exon13/13:c.*2018C>A:,EEF2KMT:NM_201400.3:intron:MODIFIER:exon7/7:c.893-1167G>T:,EEF2KMT:NM_001289029.1:intron:MODIFIER:exon5/5:c.710-1167G>T:,EEF2KMT:NM_201598.3:intron:MODIFIER:exon6/6:c.791-1167G>T:	AluSg	rs4786595	0.9599	0.0000	0/0/0	0.6495							605907 [ALG1 (provisional) Congenital disorder of glycosylation,type Ik,608540];				230	0					ALG1 (inh=AR pLI=0.00), EEF2KMT (inh=n/a pLI=0.00)
chr16	5136901	5136901	C	G	hom	hom	hom		QUAL=18076;DP=162,163,253;MQM=56	ALG1,EEF2KMT	3'UTR,intron	ALG1:NM_019109.4:3'UTR:MODIFIER:exon13/13:c.*2019C>G:,EEF2KMT:NM_201400.3:intron:MODIFIER:exon7/7:c.893-1168G>C:,EEF2KMT:NM_001289029.1:intron:MODIFIER:exon5/5:c.710-1168G>C:,EEF2KMT:NM_201598.3:intron:MODIFIER:exon6/6:c.791-1168G>C:	AluSg	rs4786596	0.9599	0.0000	0/0/0	0.6875							605907 [ALG1 (provisional) Congenital disorder of glycosylation,type Ik,608540];				230	0					ALG1 (inh=AR pLI=0.00), EEF2KMT (inh=n/a pLI=0.00)
chr16	5137069	5137069	C	G	hom	het	het		QUAL=15265;DP=262,233,279;MQM=58	ALG1,EEF2KMT	3'UTR,intron	ALG1:NM_019109.4:3'UTR:MODIFIER:exon13/13:c.*2187C>G:,EEF2KMT:NM_201400.3:intron:MODIFIER:exon7/7:c.893-1336G>C:,EEF2KMT:NM_001289029.1:intron:MODIFIER:exon5/5:c.710-1336G>C:,EEF2KMT:NM_201598.3:intron:MODIFIER:exon6/6:c.791-1336G>C:		rs12928220	0.3704	0.0000	0/0/0	0.3970							605907 [ALG1 (provisional) Congenital disorder of glycosylation,type Ik,608540];				47	107					ALG1 (inh=AR pLI=0.00), EEF2KMT (inh=n/a pLI=0.00)
chr16	5137285	5137285	A	G	hom	hom	hom		QUAL=30180;DP=441,218,260;MQM=59	ALG1,EEF2KMT	3'UTR,intron	ALG1:NM_019109.4:3'UTR:MODIFIER:exon13/13:c.*2403A>G:,EEF2KMT:NM_201400.3:intron:MODIFIER:exon7/7:c.893-1552T>C:,EEF2KMT:NM_001289029.1:intron:MODIFIER:exon5/5:c.710-1552T>C:,EEF2KMT:NM_201598.3:intron:MODIFIER:exon6/6:c.791-1552T>C:		rs4786597	0.9619	0.0000	0/0/0	0.8641							605907 [ALG1 (provisional) Congenital disorder of glycosylation,type Ik,608540];				230	0					ALG1 (inh=AR pLI=0.00), EEF2KMT (inh=n/a pLI=0.00)
chr16	8807100	8807100	G	T	wt	het	het		QUAL=356;DP=61,21,26;MQM=59	ABAT	5'UTR_premature_start_codon_gain,5'UTR,intron	ABAT:NM_000663.4:5'UTR_premature_start_codon_gain:LOW:exon1/16:c.-664G>T:,ABAT:NM_000663.4:5'UTR:MODIFIER:exon1/16:c.-664G>T:,ABAT:NM_020686.5:intron:MODIFIER:exon1/15:c.-41-22456G>T:		rs1060784	0.7284	0.0000	0/0/0	0.7571							137150 [ABAT (provisional) GABA-transaminase deficiency,613163];				153	91					ABAT (inh=AR pLI=0.37)
chr16	8807140	8807140	-	A	wt	het	het		QUAL=135;DP=33,27,34;MQM=60	ABAT	5'UTR,intron	ABAT:NM_000663.4:5'UTR:MODIFIER:exon1/16:c.-609dupA:,ABAT:NM_020686.5:intron:MODIFIER:exon1/15:c.-41-22401dupA:		rs554719618	0.4525	0.0000	0/0/0	0.1629							137150 [ABAT (provisional) GABA-transaminase deficiency,613163];				10	155					ABAT (inh=AR pLI=0.37)
chr16	8807315	8807315	C	T	wt	het	het		QUAL=2013;DP=68,92,82;MQM=60	ABAT	5'UTR,intron	ABAT:NM_000663.4:5'UTR:MODIFIER:exon1/16:c.-449C>T:,ABAT:NM_020686.5:intron:MODIFIER:exon1/15:c.-41-22241C>T:		rs7188782	0.6889	0.0000	0/0/0	0.6936							137150 [ABAT (provisional) GABA-transaminase deficiency,613163];				121	124					ABAT (inh=AR pLI=0.37)
chr16	8839954	8839954	A	G	wt	het	wt		QUAL=3477;DP=300,249,273;MQM=60	ABAT	missense&splice_region	ABAT:NM_000663.4:missense&splice_region:MODERATE:exon3/16:c.167A>G:p.Gln56Arg,ABAT:NM_020686.5:missense&splice_region:MODERATE:exon3/16:c.167A>G:p.Gln56Arg,ABAT:NM_001127448.1:missense&splice_region:MODERATE:exon3/16:c.167A>G:p.Gln56Arg		rs1731017	0.5008	0.5841	21150/12411/553	0.5771	0.4020	T,T,T	T	B	T,T,T	0.31	137150 [ABAT (provisional) GABA-transaminase deficiency,613163];	RCV000342704.1 [benign]; 			549	737					ABAT (inh=AR pLI=0.37)
chr16	8841960	8841960	T	C	wt	het	wt		QUAL=1943;DP=279,143,238;MQM=60	ABAT	splice_region&intron	ABAT:NM_000663.4:splice_region&intron:LOW:exon3/15:c.169-5T>C:,ABAT:NM_020686.5:splice_region&intron:LOW:exon3/15:c.169-5T>C:,ABAT:NM_001127448.1:splice_region&intron:LOW:exon3/15:c.169-5T>C:		rs1641010	0.4694	0.5704	20656/12259/251	0.5690							137150 [ABAT (provisional) GABA-transaminase deficiency,613163];	RCV000284451.1 [benign]; 			540	740					ABAT (inh=AR pLI=0.37)
chr16	8844389	8844389	C	T	wt	wt	het		QUAL=3018;DP=200,198,229;MQM=60	ABAT	synonymous	ABAT:NM_000663.4:synonymous:LOW:exon5/16:c.309C>T:p.Val103Val,ABAT:NM_020686.5:synonymous:LOW:exon5/16:c.309C>T:p.Val103Val,ABAT:NM_001127448.1:synonymous:LOW:exon5/16:c.309C>T:p.Val103Val		rs2229157	0.1048	0.1210	974/482/17	0.1167							137150 [ABAT (provisional) GABA-transaminase deficiency,613163];	RCV000404270.1 [likely benign]; 		COSM3755186	28	284					ABAT (inh=AR pLI=0.37)
chr16	8860130	8860130	G	A	wt	wt	het		QUAL=3467;DP=136,163,270;MQM=60	ABAT	splice_region&intron	ABAT:NM_000663.4:splice_region&intron:LOW:exon9/15:c.603+3G>A:,ABAT:NM_020686.5:splice_region&intron:LOW:exon9/15:c.603+3G>A:,ABAT:NM_001127448.1:splice_region&intron:LOW:exon9/15:c.603+3G>A:		rs41312254	0.0100	0.0080	12/8/2	0.0079							137150 [ABAT (provisional) GABA-transaminase deficiency,613163];	RCV000224546.1 [likely benign]; RCV000324489.1 [uncertain significance]; 			1	36					ABAT (inh=AR pLI=0.37)
chr16	8868776	8868776	C	A	wt	het	wt		QUAL=2118;DP=105,174,235;MQM=60	ABAT	synonymous	ABAT:NM_000663.4:synonymous:LOW:exon13/16:c.984C>A:p.Val328Val,ABAT:NM_020686.5:synonymous:LOW:exon13/16:c.984C>A:p.Val328Val,ABAT:NM_001127448.1:synonymous:LOW:exon13/16:c.984C>A:p.Val328Val		rs1641022	0.3175	0.3856	9520/5937/69	0.3788							137150 [ABAT (provisional) GABA-transaminase deficiency,613163];	RCV000398799.1 [benign]; 			276	738					ABAT (inh=AR pLI=0.37)
chr16	8873456	8873456	T	C	het	het	het		QUAL=8502;DP=151,267,324;MQM=60	ABAT	splice_region&intron	ABAT:NM_000663.4:splice_region&intron:LOW:exon15/15:c.1381+9T>C:,ABAT:NM_020686.5:splice_region&intron:LOW:exon15/15:c.1381+9T>C:,ABAT:NM_001127448.1:splice_region&intron:LOW:exon15/15:c.1381+9T>C:		rs1079348	0.3500	0.3065	5670/2655/1003	0.2969							137150 [ABAT (provisional) GABA-transaminase deficiency,613163];	RCV000362298.1 [benign]; 			173	612					ABAT (inh=AR pLI=0.37)
chr16	8875529	8875529	G	T	het	het	het		QUAL=1449;DP=104,27,24;MQM=59	ABAT	3'UTR	ABAT:NM_000663.4:3'UTR:MODIFIER:exon16/16:c.*242G>T:,ABAT:NM_020686.5:3'UTR:MODIFIER:exon16/16:c.*242G>T:,ABAT:NM_001127448.1:3'UTR:MODIFIER:exon16/16:c.*242G>T:		rs2270288	0.3738	0.0000	0/0/0	0.0731							137150 [ABAT (provisional) GABA-transaminase deficiency,613163];	RCV000264800.1 [benign]; 			57	98					ABAT (inh=AR pLI=0.37)
chr16	8875545	8875545	G	C	het	het	het	low_DP	QUAL=2021;DP=106,26,17;MQM=60	ABAT	3'UTR	ABAT:NM_000663.4:3'UTR:MODIFIER:exon16/16:c.*258G>C:,ABAT:NM_020686.5:3'UTR:MODIFIER:exon16/16:c.*258G>C:,ABAT:NM_001127448.1:3'UTR:MODIFIER:exon16/16:c.*258G>C:		rs737695	0.3239	0.0000	0/0/0	0.0555							137150 [ABAT (provisional) GABA-transaminase deficiency,613163];	RCV000374511.1 [benign]; 			23	94					ABAT (inh=AR pLI=0.37)
chr16	8875763	8875763	T	C	het	het	het		QUAL=2513;DP=75,58,77;MQM=59	ABAT	3'UTR	ABAT:NM_000663.4:3'UTR:MODIFIER:exon16/16:c.*476T>C:,ABAT:NM_020686.5:3'UTR:MODIFIER:exon16/16:c.*476T>C:,ABAT:NM_001127448.1:3'UTR:MODIFIER:exon16/16:c.*476T>C:		rs1731071	0.3902	0.0000	0/0/0	0.3586							137150 [ABAT (provisional) GABA-transaminase deficiency,613163];	RCV000350077.1 [benign]; 			28	95					ABAT (inh=AR pLI=0.37)
chr16	8875799	8875799	G	A	het	het	het		QUAL=3906;DP=112,76,106;MQM=60	ABAT	3'UTR	ABAT:NM_000663.4:3'UTR:MODIFIER:exon16/16:c.*512G>A:,ABAT:NM_020686.5:3'UTR:MODIFIER:exon16/16:c.*512G>A:,ABAT:NM_001127448.1:3'UTR:MODIFIER:exon16/16:c.*512G>A:		rs3743798	0.3712	0.0000	0/0/0	0.0728							137150 [ABAT (provisional) GABA-transaminase deficiency,613163];	RCV000345259.1 [benign]; 			58	97					ABAT (inh=AR pLI=0.37)
chr16	8875858	8875858	A	C	het	het	het		QUAL=5088;DP=222,100,149;MQM=60	ABAT	3'UTR	ABAT:NM_000663.4:3'UTR:MODIFIER:exon16/16:c.*571A>C:,ABAT:NM_020686.5:3'UTR:MODIFIER:exon16/16:c.*571A>C:,ABAT:NM_001127448.1:3'UTR:MODIFIER:exon16/16:c.*571A>C:		rs1641031	0.3928	0.0000	0/0/0	0.3566							137150 [ABAT (provisional) GABA-transaminase deficiency,613163];	RCV000392956.1 [benign]; 			28	94					ABAT (inh=AR pLI=0.37)
chr16	8875861	8875861	A	G	het	het	het		QUAL=5088;DP=222,100,149;MQM=60	ABAT	3'UTR	ABAT:NM_000663.4:3'UTR:MODIFIER:exon16/16:c.*574A>G:,ABAT:NM_020686.5:3'UTR:MODIFIER:exon16/16:c.*574A>G:,ABAT:NM_001127448.1:3'UTR:MODIFIER:exon16/16:c.*574A>G:		rs1641032	0.3932	0.0000	0/0/0	0.3568							137150 [ABAT (provisional) GABA-transaminase deficiency,613163];	RCV000305624.1 [benign]; 			28	94					ABAT (inh=AR pLI=0.37)
chr16	8876202	8876202	C	G	het	het	het		QUAL=11629;DP=319,247,341;MQM=59	ABAT	3'UTR	ABAT:NM_000663.4:3'UTR:MODIFIER:exon16/16:c.*915C>G:,ABAT:NM_020686.5:3'UTR:MODIFIER:exon16/16:c.*915C>G:,ABAT:NM_001127448.1:3'UTR:MODIFIER:exon16/16:c.*915C>G:		rs3743801	0.3850	0.0000	0/0/0	0.0732							137150 [ABAT (provisional) GABA-transaminase deficiency,613163];	RCV000360321.1 [benign]; 			59	95					ABAT (inh=AR pLI=0.37)
chr16	8876277	8876277	G	C	het	het	het		QUAL=12284;DP=302,298,371;MQM=60	ABAT	3'UTR	ABAT:NM_000663.4:3'UTR:MODIFIER:exon16/16:c.*990G>C:,ABAT:NM_020686.5:3'UTR:MODIFIER:exon16/16:c.*990G>C:,ABAT:NM_001127448.1:3'UTR:MODIFIER:exon16/16:c.*990G>C:		rs4985000	0.6064	0.0000	0/0/0	0.1086							137150 [ABAT (provisional) GABA-transaminase deficiency,613163];	RCV000302021.1 [benign]; 			109	92					ABAT (inh=AR pLI=0.37)
chr16	8876418	8876418	G	A	het	het	het		QUAL=15828;DP=375,337,463;MQM=59	ABAT	3'UTR	ABAT:NM_000663.4:3'UTR:MODIFIER:exon16/16:c.*1131G>A:,ABAT:NM_020686.5:3'UTR:MODIFIER:exon16/16:c.*1131G>A:,ABAT:NM_001127448.1:3'UTR:MODIFIER:exon16/16:c.*1131G>A:		rs7205816	0.5503	0.0000	0/0/0	0.0991							137150 [ABAT (provisional) GABA-transaminase deficiency,613163];	RCV000261569.1 [benign]; 			89	101					ABAT (inh=AR pLI=0.37)
chr16	8876692	8876692	C	T	het	het	het		QUAL=15445;DP=462,301,329;MQM=60	ABAT	3'UTR	ABAT:NM_000663.4:3'UTR:MODIFIER:exon16/16:c.*1405C>T:,ABAT:NM_020686.5:3'UTR:MODIFIER:exon16/16:c.*1405C>T:,ABAT:NM_001127448.1:3'UTR:MODIFIER:exon16/16:c.*1405C>T:		rs7201586	0.2788	0.0000	0/0/0	0.0462							137150 [ABAT (provisional) GABA-transaminase deficiency,613163];	RCV000329279.1 [benign]; 			12	86					ABAT (inh=AR pLI=0.37)
chr16	8876880	8876880	T	A	het	het	het		QUAL=11397;DP=249,251,337;MQM=60	ABAT	3'UTR	ABAT:NM_000663.4:3'UTR:MODIFIER:exon16/16:c.*1593T>A:,ABAT:NM_020686.5:3'UTR:MODIFIER:exon16/16:c.*1593T>A:,ABAT:NM_001127448.1:3'UTR:MODIFIER:exon16/16:c.*1593T>A:		rs1061842	0.3862	0.0000	0/0/0	0.0734							137150 [ABAT (provisional) GABA-transaminase deficiency,613163];	RCV000301413.1 [benign]; 			56	98					ABAT (inh=AR pLI=0.37)
chr16	8877220	8877220	T	C	hom	hom	hom		QUAL=45031;DP=367,484,532;MQM=60	ABAT	3'UTR	ABAT:NM_000663.4:3'UTR:MODIFIER:exon16/16:c.*1933T>C:,ABAT:NM_020686.5:3'UTR:MODIFIER:exon16/16:c.*1933T>C:,ABAT:NM_001127448.1:3'UTR:MODIFIER:exon16/16:c.*1933T>C:	L2c	rs4985036	0.9081	0.0000	0/0/0	0.1714							137150 [ABAT (provisional) GABA-transaminase deficiency,613163];	RCV000271048.1 [benign]; 			176	18					ABAT (inh=AR pLI=0.37)
chr16	8877401	8877401	G	A	het	het	het		QUAL=18966;DP=423,432,516;MQM=60	ABAT	3'UTR	ABAT:NM_000663.4:3'UTR:MODIFIER:exon16/16:c.*2114G>A:,ABAT:NM_020686.5:3'UTR:MODIFIER:exon16/16:c.*2114G>A:,ABAT:NM_001127448.1:3'UTR:MODIFIER:exon16/16:c.*2114G>A:		rs11648372	0.6068	0.0000	0/0/0	0.6388							137150 [ABAT (provisional) GABA-transaminase deficiency,613163];	RCV000377409.1 [benign]; 			107	87					ABAT (inh=AR pLI=0.37)
chr16	8877854	8877854	C	G	het	het	het		QUAL=5980;DP=248,95,141;MQM=59	ABAT	3'UTR	ABAT:NM_000663.4:3'UTR:MODIFIER:exon16/16:c.*2567C>G:,ABAT:NM_020686.5:3'UTR:MODIFIER:exon16/16:c.*2567C>G:,ABAT:NM_001127448.1:3'UTR:MODIFIER:exon16/16:c.*2567C>G:		rs12597124	0.6054	0.0000	0/0/0	0.1086							137150 [ABAT (provisional) GABA-transaminase deficiency,613163];	RCV000398947.1 [benign]; 			109	92					ABAT (inh=AR pLI=0.37)
chr16	8900241	8900241	G	A	het	wt	het	low_DP	QUAL=540;DP=33,7,8;MQM=60	PMM2	synonymous	PMM2:NM_000303.2:synonymous:LOW:exon4/8:c.324G>A:p.Ala108Ala		rs62031146	0.0148	0.0176	40/22/0	0.0169							601785 [PMM2 (confirmed) Congenital disorder of glycosylation,type Ia,212065];	RCV000117997.3 [other]; RCV000262546.1 [uncertain significance]; 			4	124					PMM2 (inh=AR pLI=0.00)
chr16	8905010	8905010	G	A	wt	wt	het	pred_pathogenic;anno_pathogenic_clinvar;anno_pathogenic_hgmd	QUAL=5738;DP=412,293,410;MQM=59	PMM2	missense,sequence_feature	PMM2:NM_000303.2:missense:MODERATE:exon5/8:c.422G>A:p.Arg141His,PMM2:NM_000303.2:sequence_feature:LOW:exon5/8:c.422G>A:		rs28936415	0.0036	0.0066	0/0/0	0.0031	9.1690	D,D,D	D	B,P	D,D,D	34.00	601785 [PMM2 (confirmed) Congenital disorder of glycosylation,type Ia,212065];	RCV000008145.6 [pathogenic]; RCV000078590.4 [pathogenic]; RCV000277720.1 [pathogenic]; 	CM971228 [CLASS=DM MUT=ALT PHEN="Congenital disorder of glycosylation 1a" GENE=PMM2]; 		0	26	5	[5] 06.06.2014  Florian Harmuth  HGMD: DM; Vega et al. 2011, Bell et al. 2011; 06.06.2014; FH 18.05.2016; ClinVar with 4 entries of 4 different submitters [import GPD] Julia Bickmann 2015-04-01 17:39:00 -type: mutation details -link: http://www.ncbi.nlm.nih.gov/books/NBK1110/table/cdg-1a.T.selected_pmm2_pathogenic_varian/?report=objectonly <p><strong>Matthijs et al., 1997 (Nature Genetics):</strong> First idenfication of R141H in patients with a documented phosphomannomutase deficiency: - patient 16: Belgian, genotype: R141H/Y106C- patient 17: Belgian, genotype: R141H/P113L - patient 35: British, genotype: R141H/F119L - patient 38: German, genotype: R141H/P113L - patient 40: French, genotype: R141H/P113L</p> <p><strong>Kjaergaard et al., 2001 (Arch Dis Child):</strong> Clinical study of 13 female and 12 male Danish CDG patients from 19 unrelated families with the genotype R141H/F119L (diagnosis made on the basis IEF of Serum TF, PMM activity measurement in fibroblasts, mutation analysis) - normal birth weight and length - three preterm neonates with appropriate birth weight and length - six had APGAR - 21 neonates were hospitalised due to cyanosis, respiratory distress, hypoglycaemia, dysmorphic features, oedema, lethargy, feeding problems and/or failure to thrive - two neonates died (rupture of the tentorium cerebellum; thrombemboli of the abdominal aorta and common iliac artery) - 23 had severe feeding problems in the first two years of life (nasogastric tube in 11 children, gastrotomy in 1). Failure to thrive, vomiting and diarrhoea prominent in early life - 23 had severe developmental delay before 6 months of age; hypotonia, ataxia, peripheral muscular atrophy, lack of deep tendon reflexes in all patients; cerebellar atrophy in 18 children after 3 months of age, supratentorial atrophy in 10 children (cortical and/or central); MRI findings were progressive in all; afebrile seizures (simple focal, complex partial focal, tonic-clonic, atonic, absence) in 13 children (8 relapsed several times), 3 children with relapsing migraine-like headaches - stroke-like episodes with hemiplegia and/or coma for &gt;24h in 52% of the patients (mostly associated with fever and seizures); hemiplegia was permanent in 1 child, and disappeared after 2 days to 6 months in the others - 48% had hepatomegaly and hepatic failure of varying extent - pericardial effusions in 10/19 patients; ascites in 6 patients - all had dysmorphic features: inverted nipples (23 children), subcutaneous suprapubic, perineal and/or gluteal fat pads (91%), almond-shaped, upslanting palpebral fissures, prominent maxilla with widely-spaced teeth, microcephaly and insufficient head growth in all patients; limited range of joint movements in 52% of neonates, congenital clubfeet in 1 child; hydroceles, inguinal hernias and/or non-descended testes in most male patients - esotropia (in all patients), severe neurogenic hearing impairment in 3/9 patients, recurrent otitis media in 11 children, 3 with permanent perforation of the tympanic membrane - kyphoscoliosis in 48% above age 3; pectus carinatum or excavatum in all patients &gt; 2 years; pathological fractures in 2 boys and 4 girls - 2 had thromboembolic events as neonates (1 died) - none of the girls had spontaneous onset of puberty due to hypergonadotropic hypogonadism and hypoplastic internal genitalia - 14 children could sit freely at 20 months to 5 years of age; 5 children (&gt; 4 years) failed to sit freely; 2 children walked with the aid of a rolator; the majority were mobile in a wheelchair or gait trainer; 2 patients were non-ambulatory at age 9 - all patients but 2 had to be fed (at the age of 9?), only one patient was toilet-trained, one patient had comprehensible speech, 10 patients had active vocabulary of 10-50 words with better passive vocabulary - functional outcome variable even among sibs and identical twins - mortality: 7 patients died (at 15 y. after car accident, at neonate stage due to thromboemboli or rupture of tentorium cerebelli; pneumonia at 4.3 and 6 y., septic shock at 1.8 y., infectious disease at 9.9 years) </p> <p>viele weitere Artikel zu dieser Mutation in der Literatur</p> <p><strong>Laut Gene Reviews findet sich bei 40% der CDG-Syndrom Patientin die Mutation R141H; sie liegt niemals homozygot vor.</strong></p> <p> </p>		n/a (erneut zur Validierung angesto??en, JKB 15.06.2015 (war aus NGSD gel??scht))	PMM2 (inh=AR pLI=0.00)
chr16	8941818	8941818	A	C	het	het	wt		QUAL=2768;DP=129,144,173;MQM=60	PMM2	3'UTR	PMM2:NM_000303.2:3'UTR:MODIFIER:exon8/8:c.*136A>C:		rs2075827	0.2590	0.0000	0/0/0	0.2313							601785 [PMM2 (confirmed) Congenital disorder of glycosylation,type Ia,212065];	RCV000311429.1 [likely benign]; 			13	85					PMM2 (inh=AR pLI=0.00)
chr16	8941857	8941857	G	A	het	het	wt		QUAL=3552;DP=217,139,164;MQM=59	PMM2	3'UTR	PMM2:NM_000303.2:3'UTR:MODIFIER:exon8/8:c.*175G>A:		rs2072688	0.2694	0.0000	0/0/0	0.0442							601785 [PMM2 (confirmed) Congenital disorder of glycosylation,type Ia,212065];	RCV000276181.1 [likely benign]; 			13	85					PMM2 (inh=AR pLI=0.00)
chr16	8941934	8941934	C	A	het	het	het		QUAL=3219;DP=85,70,67;MQM=60	PMM2	3'UTR	PMM2:NM_000303.2:3'UTR:MODIFIER:exon8/8:c.*252C>A:		rs2075828	0.3962	0.0000	0/0/0	0.4493							601785 [PMM2 (confirmed) Congenital disorder of glycosylation,type Ia,212065];	RCV000326434.1 [likely benign]; 			55	108					PMM2 (inh=AR pLI=0.00)
chr16	8942473	8942473	G	C	hom	hom	hom		QUAL=18697;DP=293,129,173;MQM=59	PMM2	3'UTR	PMM2:NM_000303.2:3'UTR:MODIFIER:exon8/8:c.*791G>C:		rs2437722	0.9209	0.0000	0/0/0	0.8460							601785 [PMM2 (confirmed) Congenital disorder of glycosylation,type Ia,212065];	RCV000390225.1 [benign]; 			199	25					PMM2 (inh=AR pLI=0.00)
chr16	8942679	8942679	A	G	het	het	wt		QUAL=4064;DP=157,112,151;MQM=60	PMM2	3'UTR	PMM2:NM_000303.2:3'UTR:MODIFIER:exon8/8:c.*997A>G:		rs1056898	0.2905	0.0000	0/0/0	0.2679							601785 [PMM2 (confirmed) Congenital disorder of glycosylation,type Ia,212065];	RCV000317823.1 [likely benign]; 			13	84					PMM2 (inh=AR pLI=0.00)
chr16	9848471	9848471	T	G	hom	hom	hom		QUAL=10929;DP=200,70,59;MQM=60	GRIN2A	3'UTR	GRIN2A:NM_000833.4:3'UTR:MODIFIER:exon14/14:c.*8535A>C:,GRIN2A:NM_001134408.2:3'UTR:MODIFIER:exon14/14:c.*8741A>C:,GRIN2A:NM_001134407.2:3'UTR:MODIFIER:exon13/13:c.*8535A>C:		rs767749	0.7506	0.0000	0/0/0	0.1343							138253 [GRIN2A (provisional) Epilepsy,focal,with speech disorder and with or without mental retardation,245570];	RCV000372002.1 [benign]; 			307	105					GRIN2A (inh=AD pLI=1.00)
chr16	9850397	9850397	A	G	hom	hom	hom		QUAL=28034;DP=325,240,280;MQM=59	GRIN2A	3'UTR	GRIN2A:NM_000833.4:3'UTR:MODIFIER:exon14/14:c.*6609T>C:,GRIN2A:NM_001134408.2:3'UTR:MODIFIER:exon14/14:c.*6815T>C:,GRIN2A:NM_001134407.2:3'UTR:MODIFIER:exon13/13:c.*6609T>C:		rs1420040	0.4233	0.0000	0/0/0	0.0736							138253 [GRIN2A (provisional) Epilepsy,focal,with speech disorder and with or without mental retardation,245570];	RCV000297274.1 [benign]; 			85	211					GRIN2A (inh=AD pLI=1.00)
chr16	9850857	9850857	G	C	hom	hom	hom		QUAL=36387;DP=441,298,372;MQM=60	GRIN2A	3'UTR	GRIN2A:NM_000833.4:3'UTR:MODIFIER:exon14/14:c.*6149C>G:,GRIN2A:NM_001134408.2:3'UTR:MODIFIER:exon14/14:c.*6355C>G:,GRIN2A:NM_001134407.2:3'UTR:MODIFIER:exon13/13:c.*6149C>G:		rs9940680	0.4163	0.0000	0/0/0	0.0729							138253 [GRIN2A (provisional) Epilepsy,focal,with speech disorder and with or without mental retardation,245570];	RCV000388572.1 [benign]; 			85	209					GRIN2A (inh=AD pLI=1.00)
chr16	9850878	9850878	T	C	hom	hom	hom		QUAL=29746;DP=312,267,339;MQM=59	GRIN2A	3'UTR	GRIN2A:NM_000833.4:3'UTR:MODIFIER:exon14/14:c.*6128A>G:,GRIN2A:NM_001134408.2:3'UTR:MODIFIER:exon14/14:c.*6334A>G:,GRIN2A:NM_001134407.2:3'UTR:MODIFIER:exon13/13:c.*6128A>G:		rs9933624	0.4173	0.0000	0/0/0	0.0732							138253 [GRIN2A (provisional) Epilepsy,focal,with speech disorder and with or without mental retardation,245570];	RCV000280250.1 [benign]; 			87	210					GRIN2A (inh=AD pLI=1.00)
chr16	9851122	9851122	C	T	hom	hom	hom		QUAL=24520;DP=414,156,184;MQM=60	GRIN2A	3'UTR	GRIN2A:NM_000833.4:3'UTR:MODIFIER:exon14/14:c.*5884G>A:,GRIN2A:NM_001134408.2:3'UTR:MODIFIER:exon14/14:c.*6090G>A:,GRIN2A:NM_001134407.2:3'UTR:MODIFIER:exon13/13:c.*5884G>A:		rs8045712	0.3676	0.0000	0/0/0	0.0691							138253 [GRIN2A (provisional) Epilepsy,focal,with speech disorder and with or without mental retardation,245570];	RCV000341214.1 [benign]; 			81	208					GRIN2A (inh=AD pLI=1.00)
chr16	9851188	9851188	G	A	hom	hom	hom		QUAL=13168;DP=256,71,96;MQM=59	GRIN2A	3'UTR	GRIN2A:NM_000833.4:3'UTR:MODIFIER:exon14/14:c.*5818C>T:,GRIN2A:NM_001134408.2:3'UTR:MODIFIER:exon14/14:c.*6024C>T:,GRIN2A:NM_001134407.2:3'UTR:MODIFIER:exon13/13:c.*5818C>T:		rs8044472	0.7522	0.0000	0/0/0	0.1340							138253 [GRIN2A (provisional) Epilepsy,focal,with speech disorder and with or without mental retardation,245570];	RCV000403854.1 [benign]; 			306	103					GRIN2A (inh=AD pLI=1.00)
chr16	9854389	9854389	C	G	hom	hom	hom		QUAL=30624;DP=462,233,255;MQM=59	GRIN2A	3'UTR	GRIN2A:NM_000833.4:3'UTR:MODIFIER:exon14/14:c.*2617G>C:,GRIN2A:NM_001134408.2:3'UTR:MODIFIER:exon14/14:c.*2823G>C:,GRIN2A:NM_001134407.2:3'UTR:MODIFIER:exon13/13:c.*2617G>C:		rs62034910	0.3740	0.0000	0/0/0	0.0699							138253 [GRIN2A (provisional) Epilepsy,focal,with speech disorder and with or without mental retardation,245570];	RCV000355830.1 [benign]; 			80	206					GRIN2A (inh=AD pLI=1.00)
chr16	9854796	9854796	T	A	wt	het	wt		QUAL=3727;DP=165,282,326;MQM=60	GRIN2A	3'UTR	GRIN2A:NM_000833.4:3'UTR:MODIFIER:exon14/14:c.*2210A>T:,GRIN2A:NM_001134408.2:3'UTR:MODIFIER:exon14/14:c.*2416A>T:,GRIN2A:NM_001134407.2:3'UTR:MODIFIER:exon13/13:c.*2210A>T:		rs148482120	0.0026	0.0000	0/0/0	0.0045							138253 [GRIN2A (provisional) Epilepsy,focal,with speech disorder and with or without mental retardation,245570];	RCV000363034.1 [likely benign]; 			0	9					GRIN2A (inh=AD pLI=1.00)
chr16	10995933	10995933	A	G	hom	hom	hom	pred_pathogenic	QUAL=12974;DP=131,114,176;MQM=60	CIITA	missense,intron,non_coding_transcript_exon	CIITA:NM_001286402.1:missense:MODERATE:exon7/20:c.523A>G:p.Arg175Gly,CIITA:NM_000246.3:missense:MODERATE:exon7/20:c.520A>G:p.Arg174Gly,CIITA:NM_001286403.1:intron:MODIFIER:exon6/17:c.481+518A>G:,CIITA:NR_104444.1:non_coding_transcript_exon:MODIFIER:exon7/18:n.653A>G:		rs8046121	0.9872	0.9959	60198/33353/4741	0.9321	1.7160	T,T	T	B,B	T	10.50	600005 [CIITA (provisional) Bare lymphocyte syndrome,type II,complementation group A,209920|Rheumatoid arthritis,susceptibility to,180300];			COSM4128622	1562	3					CIITA (inh=AR+AD pLI=0.00)
chr16	11000848	11000848	G	C	het	wt	het		QUAL=1857;DP=83,55,46;MQM=60	CIITA	missense,intron	CIITA:NM_001286402.1:missense:MODERATE:exon11/20:c.1502G>C:p.Gly501Ala,CIITA:NM_000246.3:missense:MODERATE:exon11/20:c.1499G>C:p.Gly500Ala,CIITA:NM_001286403.1:intron:MODIFIER:exon9/17:c.860-1992G>C:,CIITA:NR_104444.1:intron:MODIFIER:exon10/17:n.1139+2179G>C:		rs4774	0.2590	0.2932	5522/2877/353	0.2882	0.7060	T,T	T	B,B,B	T	0.01	600005 [CIITA (provisional) Bare lymphocyte syndrome,type II,complementation group A,209920|Rheumatoid arthritis,susceptibility to,180300];	RCV000378352.1 [benign]; 	CM102885 [CLASS=DP MUT=ALT PHEN="Multiple sclerosis increased risk association with" GENE=CIITA]; 	COSM434601	144	620					CIITA (inh=AR+AD pLI=0.00)
chr16	11001691	11001691	C	T	het	wt	het		QUAL=4716;DP=154,194,246;MQM=59	CIITA	missense,intron	CIITA:NM_001286402.1:missense:MODERATE:exon11/20:c.2345C>T:p.Ser782Leu,CIITA:NM_000246.3:missense:MODERATE:exon11/20:c.2342C>T:p.Ser781Leu,CIITA:NM_001286403.1:intron:MODIFIER:exon9/17:c.860-1149C>T:,CIITA:NR_104444.1:intron:MODIFIER:exon10/17:n.1140-2354C>T:		rs13330686	0.0397	0.0637	277/221/5	0.0613	-0.2870	T,T	T	B,B,B,B	T	0.02	600005 [CIITA (provisional) Bare lymphocyte syndrome,type II,complementation group A,209920|Rheumatoid arthritis,susceptibility to,180300];	RCV000361096.1 [likely benign]; 			17	246					CIITA (inh=AR+AD pLI=0.00)
chr16	11001694	11001694	T	C	het	wt	het		QUAL=4716;DP=154,194,246;MQM=59	CIITA	missense,intron	CIITA:NM_001286402.1:missense:MODERATE:exon11/20:c.2348T>C:p.Val783Ala,CIITA:NM_000246.3:missense:MODERATE:exon11/20:c.2345T>C:p.Val782Ala,CIITA:NM_001286403.1:intron:MODIFIER:exon9/17:c.860-1146T>C:,CIITA:NR_104444.1:intron:MODIFIER:exon10/17:n.1140-2351T>C:		rs13336804	0.0399	0.0638	275/219/5	0.0616	0.4060	T,T	T	B,B,B,B	T	0.01	600005 [CIITA (provisional) Bare lymphocyte syndrome,type II,complementation group A,209920|Rheumatoid arthritis,susceptibility to,180300];	RCV000266523.1 [likely benign]; 		COSM3754601	17	245					CIITA (inh=AR+AD pLI=0.00)
chr16	11001743	11001743	G	A	het	het	wt		QUAL=2525;DP=119,115,141;MQM=59	CIITA	synonymous,intron	CIITA:NM_001286402.1:synonymous:LOW:exon11/20:c.2397G>A:p.Pro799Pro,CIITA:NM_000246.3:synonymous:LOW:exon11/20:c.2394G>A:p.Pro798Pro,CIITA:NM_001286403.1:intron:MODIFIER:exon9/17:c.860-1097G>A:,CIITA:NR_104444.1:intron:MODIFIER:exon10/17:n.1140-2302G>A:		rs2229320	0.1893	0.2122	2804/1448/12	0.2018							600005 [CIITA (provisional) Bare lymphocyte syndrome,type II,complementation group A,209920|Rheumatoid arthritis,susceptibility to,180300];	RCV000321727.1 [benign]; 		COSM3754602	78	542					CIITA (inh=AR+AD pLI=0.00)
chr16	11001914	11001914	G	A	het	wt	het		QUAL=1853;DP=89,50,61;MQM=59	CIITA	synonymous,intron	CIITA:NM_001286402.1:synonymous:LOW:exon11/20:c.2568G>A:p.Ala856Ala,CIITA:NM_000246.3:synonymous:LOW:exon11/20:c.2565G>A:p.Ala855Ala,CIITA:NM_001286403.1:intron:MODIFIER:exon9/17:c.860-926G>A:,CIITA:NR_104444.1:intron:MODIFIER:exon10/17:n.1140-2131G>A:		rs2229321	0.0397	0.0758	290/232/5	0.0624							600005 [CIITA (provisional) Bare lymphocyte syndrome,type II,complementation group A,209920|Rheumatoid arthritis,susceptibility to,180300];	RCV000382292.1 [likely benign]; 		COSM3754603	17	245					CIITA (inh=AR+AD pLI=0.00)
chr16	11002904	11002904	G	A	het	hom	het		QUAL=16957;DP=139,326,451;MQM=59	CIITA	synonymous,intron	CIITA:NM_001286402.1:synonymous:LOW:exon12/20:c.2679G>A:p.Thr893Thr,CIITA:NM_000246.3:synonymous:LOW:exon12/20:c.2676G>A:p.Thr892Thr,CIITA:NM_001286403.1:synonymous:LOW:exon10/18:c.924G>A:p.Thr308Thr,CIITA:NR_104444.1:intron:MODIFIER:exon10/17:n.1140-1141G>A:		rs2228238	0.6631	0.6840	28826/16292/1325	0.6763							600005 [CIITA (provisional) Bare lymphocyte syndrome,type II,complementation group A,209920|Rheumatoid arthritis,susceptibility to,180300];	RCV000388213.1 [benign]; 			761	643					CIITA (inh=AR+AD pLI=0.00)
chr16	11002927	11002927	A	G	hom	hom	hom		QUAL=36313;DP=270,375,513;MQM=59	CIITA	missense,intron	CIITA:NM_001286402.1:missense:MODERATE:exon12/20:c.2702A>G:p.Gln901Arg,CIITA:NM_000246.3:missense:MODERATE:exon12/20:c.2699A>G:p.Gln900Arg,CIITA:NM_001286403.1:missense:MODERATE:exon10/18:c.947A>G:p.Gln316Arg,CIITA:NR_104444.1:intron:MODIFIER:exon10/17:n.1140-1118A>G:		rs7197779	0.9287	0.9787	58319/33286/3054	0.9252	0.8840	T,T	T	B,B	T,T	0.50	600005 [CIITA (provisional) Bare lymphocyte syndrome,type II,complementation group A,209920|Rheumatoid arthritis,susceptibility to,180300];	RCV000292677.1 [benign]; 			1549	13					CIITA (inh=AR+AD pLI=0.00)
chr16	11016045	11016045	C	T	het	wt	het		QUAL=5588;DP=233,181,261;MQM=59	CIITA	synonymous,non_coding_transcript_exon	CIITA:NM_001286402.1:synonymous:LOW:exon17/20:c.3174C>T:p.Cys1058Cys,CIITA:NM_000246.3:synonymous:LOW:exon17/20:c.3171C>T:p.Cys1057Cys,CIITA:NM_001286403.1:synonymous:LOW:exon15/18:c.1419C>T:p.Cys473Cys,CIITA:NR_104444.1:non_coding_transcript_exon:MODIFIER:exon15/18:n.1494C>T:		rs2229322	0.1048	0.1009	674/369/22	0.1017							600005 [CIITA (provisional) Bare lymphocyte syndrome,type II,complementation group A,209920|Rheumatoid arthritis,susceptibility to,180300];	RCV000359080.1 [likely benign]; 		COSM3754604, COSM148019	26	283					CIITA (inh=AR+AD pLI=0.00)
chr16	11018622	11018622	T	C	het	het	wt		QUAL=5541;DP=222,205,247;MQM=60	CIITA	3'UTR,non_coding_transcript_exon	CIITA:NM_001286402.1:3'UTR:MODIFIER:exon20/20:c.*910T>C:,CIITA:NM_000246.3:3'UTR:MODIFIER:exon20/20:c.*910T>C:,CIITA:NM_001286403.1:3'UTR:MODIFIER:exon18/18:c.*910T>C:,CIITA:NR_104444.1:non_coding_transcript_exon:MODIFIER:exon18/18:n.2626T>C:		rs1139564	0.6917	0.0000	0/0/0	0.7563							600005 [CIITA (provisional) Bare lymphocyte syndrome,type II,complementation group A,209920|Rheumatoid arthritis,susceptibility to,180300];	RCV000315324.1 [benign]; 			147	74					CIITA (inh=AR+AD pLI=0.00)
chr16	11642242	11642242	T	C	hom	hom	het		QUAL=14602;DP=212,152,192;MQM=60	LITAF	3'UTR,non_coding_transcript_exon	LITAF:NM_001136472.1:3'UTR:MODIFIER:exon4/4:c.*1251A>G:,LITAF:NM_004862.3:3'UTR:MODIFIER:exon4/4:c.*1251A>G:,LITAF:NM_001136473.1:3'UTR:MODIFIER:exon5/5:c.*1376A>G:,LITAF:NR_024320.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.1871A>G:		rs7102	0.4105	0.4049	916/193/16	0.0968							603795 [LITAF (confirmed) Charcot-Marie-Tooth disease,type 1C,601098];	RCV000376300.1 [benign]; 			88	303					LITAF (inh=AD pLI=0.31)
chr16	11642445	11642445	T	-	het	het	wt		QUAL=2375;DP=287,122,131;MQM=59	LITAF	3'UTR,non_coding_transcript_exon	LITAF:NM_001136472.1:3'UTR:MODIFIER:exon4/4:c.*1048delA:,LITAF:NM_004862.3:3'UTR:MODIFIER:exon4/4:c.*1048delA:,LITAF:NM_001136473.1:3'UTR:MODIFIER:exon5/5:c.*1173delA:,LITAF:NR_024320.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.1668delA:	(T)n	rs71778957	0.0000	0.4720	0/0/0	0.0149							603795 [LITAF (confirmed) Charcot-Marie-Tooth disease,type 1C,601098];				5	266					LITAF (inh=AD pLI=0.31)
chr16	11642910	11642910	-	A	hom	hom	het		QUAL=11573;DP=211,136,165;MQM=59	LITAF	3'UTR,non_coding_transcript_exon	LITAF:NM_001136472.1:3'UTR:MODIFIER:exon4/4:c.*582dupT:,LITAF:NM_004862.3:3'UTR:MODIFIER:exon4/4:c.*582dupT:,LITAF:NM_001136473.1:3'UTR:MODIFIER:exon5/5:c.*707dupT:,LITAF:NR_024320.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.1202dupT:		rs398119229;rs71406254	0.3732	0.3353	378/99/12	0.0657							603795 [LITAF (confirmed) Charcot-Marie-Tooth disease,type 1C,601098];	RCV000304204.1 [benign]; 			46	318					LITAF (inh=AD pLI=0.31)
chr16	11647492	11647492	T	C	het	wt	hom	pred_pathogenic	QUAL=16068;DP=339,392,395;MQM=60	LITAF	missense,non_coding_transcript_exon	LITAF:NM_001136472.1:missense:MODERATE:exon3/4:c.274A>G:p.Ile92Val,LITAF:NM_004862.3:missense:MODERATE:exon3/4:c.274A>G:p.Ile92Val,LITAF:NM_001136473.1:missense:MODERATE:exon3/5:c.274A>G:p.Ile92Val,LITAF:NR_024320.1:non_coding_transcript_exon:MODIFIER:exon3/4:n.408A>G:		rs4280262	0.1026	0.1624	1860/1469/25	0.1623	0.2440	T,T,T	T	B,B	D,D,D	0.01	603795 [LITAF (confirmed) Charcot-Marie-Tooth disease,type 1C,601098];	RCV000398802.1 [benign]; 	CM1410967 [CLASS=DFP MUT=ALT PHEN="Charcot-Marie-Tooth disease 1a/Neuropathy with liability to pressure palsies earlier onset association with" GENE=LITAF]; 		74	461					LITAF (inh=AD pLI=0.31)
chr16	14026007	14026007	G	A	hom	hom	hom		QUAL=26920;DP=302,242,284;MQM=60	ERCC4	splice_region&intron	ERCC4:NM_005236.2:splice_region&intron:LOW:exon5/10:c.974-7G>A:		rs254942	0.9465	0.9661	56802/32023/5142	0.9567							133520 [ERCC4 (confirmed) Xeroderma pigmentosum,group F,278760|XFE progeroid syndrome,610965|Fanconi anemia,complementation group Q,615272|Xeroderma pigmentosum,type F/Cockayne syndrome,278760];	RCV000246561.1 [benign]; RCV000318579.1 [benign]; 			2778	150					ERCC4 (inh=AR pLI=0.00)
chr16	14041958	14041958	T	C	het	wt	het		QUAL=8506;DP=268,317,387;MQM=59	ERCC4	synonymous,sequence_feature	ERCC4:NM_005236.2:synonymous:LOW:exon11/11:c.2505T>C:p.Ser835Ser,ERCC4:NM_005236.2:sequence_feature:LOW:exon11/11:c.2505T>C:		rs1799801	0.2412	0.2723	4606/2859/175	0.2717							133520 [ERCC4 (confirmed) Xeroderma pigmentosum,group F,278760|XFE progeroid syndrome,610965|Fanconi anemia,complementation group Q,615272|Xeroderma pigmentosum,type F/Cockayne syndrome,278760];	RCV000116988.3 [other]; RCV000265728.1 [benign]; 			299	1189					ERCC4 (inh=AR pLI=0.00)
chr16	14042108	14042108	G	A	het	wt	het		QUAL=13845;DP=577,407,481;MQM=59	ERCC4	synonymous	ERCC4:NM_005236.2:synonymous:LOW:exon11/11:c.2655G>A:p.Thr885Thr		rs16963255	0.0046	0.0109	10/7/0	0.0104							133520 [ERCC4 (confirmed) Xeroderma pigmentosum,group F,278760|XFE progeroid syndrome,610965|Fanconi anemia,complementation group Q,615272|Xeroderma pigmentosum,type F/Cockayne syndrome,278760];	RCV000242822.1 [benign]; RCV000384807.1 [likely benign]; 			0	89					ERCC4 (inh=AR pLI=0.00)
chr16	14042688	14042688	G	T	het	wt	het		QUAL=10690;DP=331,431,535;MQM=60	ERCC4	3'UTR	ERCC4:NM_005236.2:3'UTR:MODIFIER:exon11/11:c.*484G>T:		rs3743538	0.3496	0.0000	0/0/0	0.3433							133520 [ERCC4 (confirmed) Xeroderma pigmentosum,group F,278760|XFE progeroid syndrome,610965|Fanconi anemia,complementation group Q,615272|Xeroderma pigmentosum,type F/Cockayne syndrome,278760];	RCV000338839.1 [benign]; 			29	102					ERCC4 (inh=AR pLI=0.00)
chr16	14042930	14042930	G	C	het	wt	het		QUAL=5307;DP=283,101,137;MQM=60	ERCC4	3'UTR	ERCC4:NM_005236.2:3'UTR:MODIFIER:exon11/11:c.*726G>C:		rs2276464	0.2376	0.0000	0/0/0	0.2722							133520 [ERCC4 (confirmed) Xeroderma pigmentosum,group F,278760|XFE progeroid syndrome,610965|Fanconi anemia,complementation group Q,615272|Xeroderma pigmentosum,type F/Cockayne syndrome,278760];	RCV000302862.1 [benign]; 			23	95					ERCC4 (inh=AR pLI=0.00)
chr16	14043014	14043014	G	A	het	wt	het		QUAL=6709;DP=327,124,189;MQM=59	ERCC4	3'UTR	ERCC4:NM_005236.2:3'UTR:MODIFIER:exon11/11:c.*810G>A:		rs2276465	0.2592	0.0000	0/0/0	0.3083							133520 [ERCC4 (confirmed) Xeroderma pigmentosum,group F,278760|XFE progeroid syndrome,610965|Fanconi anemia,complementation group Q,615272|Xeroderma pigmentosum,type F/Cockayne syndrome,278760];	RCV000269593.1 [benign]; 			23	103					ERCC4 (inh=AR pLI=0.00)
chr16	14043175	14043175	C	G	het	wt	het		QUAL=6077;DP=187,190,269;MQM=60	ERCC4	3'UTR	ERCC4:NM_005236.2:3'UTR:MODIFIER:exon11/11:c.*971C>G:		rs2276466	0.2372	0.0000	0/0/0	0.2717							133520 [ERCC4 (confirmed) Xeroderma pigmentosum,group F,278760|XFE progeroid syndrome,610965|Fanconi anemia,complementation group Q,615272|Xeroderma pigmentosum,type F/Cockayne syndrome,278760];	RCV000330321.1 [benign]; 			23	95					ERCC4 (inh=AR pLI=0.00)
chr16	14044717	14044717	C	A	het	wt	het		QUAL=6305;DP=205,131,220;MQM=59	ERCC4	3'UTR	ERCC4:NM_005236.2:3'UTR:MODIFIER:exon11/11:c.*2513C>A:		rs11075223	0.2592	0.0000	0/0/0	0.3064							133520 [ERCC4 (confirmed) Xeroderma pigmentosum,group F,278760|XFE progeroid syndrome,610965|Fanconi anemia,complementation group Q,615272|Xeroderma pigmentosum,type F/Cockayne syndrome,278760];	RCV000273445.1 [benign]; 			22	103					ERCC4 (inh=AR pLI=0.00)
chr16	14044776	14044776	C	-	het	wt	het		QUAL=5367;DP=154,155,230;MQM=59	ERCC4	3'UTR	ERCC4:NM_005236.2:3'UTR:MODIFIER:exon11/11:c.*2577delC:		rs796908123	0.2596	0.0000	0/0/0	0.2316							133520 [ERCC4 (confirmed) Xeroderma pigmentosum,group F,278760|XFE progeroid syndrome,610965|Fanconi anemia,complementation group Q,615272|Xeroderma pigmentosum,type F/Cockayne syndrome,278760];	RCV000192706.1 [likely benign]; RCV000314550.1 [benign]; 			22	104					ERCC4 (inh=AR pLI=0.00)
chr16	14044781	14044781	C	A	het	wt	het		QUAL=5367;DP=154,155,230;MQM=59	ERCC4	3'UTR	ERCC4:NM_005236.2:3'UTR:MODIFIER:exon11/11:c.*2577C>A:		rs56012340	0.2133	0.0000	0/0/0	0.0831							133520 [ERCC4 (confirmed) Xeroderma pigmentosum,group F,278760|XFE progeroid syndrome,610965|Fanconi anemia,complementation group Q,615272|Xeroderma pigmentosum,type F/Cockayne syndrome,278760];	RCV000194891.1 [likely benign]; RCV000369259.1 [benign]; 			17	94					ERCC4 (inh=AR pLI=0.00)
chr16	14045236	14045236	G	T	het	wt	het		QUAL=4012;DP=218,85,91;MQM=60	ERCC4	3'UTR	ERCC4:NM_005236.2:3'UTR:MODIFIER:exon11/11:c.*3032G>T:		rs4781562	0.2574	0.0000	0/0/0	0.2648							133520 [ERCC4 (confirmed) Xeroderma pigmentosum,group F,278760|XFE progeroid syndrome,610965|Fanconi anemia,complementation group Q,615272|Xeroderma pigmentosum,type F/Cockayne syndrome,278760];	RCV000380253.1 [benign]; 			17	91					ERCC4 (inh=AR pLI=0.00)
chr16	14045399	14045399	G	A	het	wt	het		QUAL=8717;DP=389,233,281;MQM=60	ERCC4	3'UTR	ERCC4:NM_005236.2:3'UTR:MODIFIER:exon11/11:c.*3195G>A:		rs4781563	0.2139	0.0000	0/0/0	0.2521							133520 [ERCC4 (confirmed) Xeroderma pigmentosum,group F,278760|XFE progeroid syndrome,610965|Fanconi anemia,complementation group Q,615272|Xeroderma pigmentosum,type F/Cockayne syndrome,278760];	RCV000346605.1 [benign]; 			17	94					ERCC4 (inh=AR pLI=0.00)
chr16	14046150	14046150	T	-	het	wt	het		QUAL=6298;DP=378,68,127;MQM=59	ERCC4	3'UTR	ERCC4:NM_005236.2:3'UTR:MODIFIER:exon11/11:c.*3953delT:		rs397778750	0.2133	0.0000	0/0/0	0.2252							133520 [ERCC4 (confirmed) Xeroderma pigmentosum,group F,278760|XFE progeroid syndrome,610965|Fanconi anemia,complementation group Q,615272|Xeroderma pigmentosum,type F/Cockayne syndrome,278760];	RCV000359931.1 [benign]; 			17	93					ERCC4 (inh=AR pLI=0.00)
chr16	20360101	20360101	G	A	hom	hom	hom		QUAL=6919;DP=73,75,84;MQM=59	UMOD	synonymous	UMOD:NM_001278614.1:synonymous:LOW:exon4/12:c.621C>T:p.Cys207Cys,UMOD:NM_001008389.2:synonymous:LOW:exon3/11:c.522C>T:p.Cys174Cys,UMOD:NM_003361.3:synonymous:LOW:exon3/11:c.522C>T:p.Cys174Cys		rs7193058	0.5439	0.6040	2858/1456/352	0.3382							191845 [UMOD (confirmed) Hyperuricemic nephropathy,familial juvenile 1,162000|Medullary cystic kidney disease 2,603860|Glomerulocystic kidney disease with hyperuricemia and isosthenuria,609886];	RCV000080093.6 [benign]; RCV000335513.1 [benign]; 		COSM3749349, COSM3749348	748	626					UMOD (inh=AD pLI=0.00)
chr16	23197545	23197545	C	G	het	wt	het		QUAL=3883;DP=130,144,194;MQM=60	SCNN1G	splice_region&intron	SCNN1G:NM_001039.3:splice_region&intron:LOW:exon1/12:c.-44-4C>G:		rs5731	0.1969	0.2354	3475/1719/66	0.2284							600761 [SCNN1G (confirmed) Liddle syndrome,177200|Pseudohypoaldosteronism,type I,264350|Bronchiectasis with or without elevated sweat chloride 3,613071];	RCV000321774.1 [benign]; RCV000376481.1 [benign]; 			45	273					SCNN1G (inh=AR+AD pLI=0.37)
chr16	23197562	23197562	A	G	het	wt	het		QUAL=3951;DP=111,180,231;MQM=60	SCNN1G	5'UTR	SCNN1G:NM_001039.3:5'UTR:MODIFIER:exon2/13:c.-31A>G:		rs5732	0.1969	0.2378	3674/1818/71	0.2309							600761 [SCNN1G (confirmed) Liddle syndrome,177200|Pseudohypoaldosteronism,type I,264350|Bronchiectasis with or without elevated sweat chloride 3,613071];	RCV000267876.1 [benign]; RCV000322965.1 [benign]; 			56	324					SCNN1G (inh=AR+AD pLI=0.37)
chr16	23200761	23200761	T	C	het	wt	het		QUAL=8899;DP=380,264,357;MQM=59	SCNN1G	synonymous	SCNN1G:NM_001039.3:synonymous:LOW:exon3/13:c.387T>C:p.Tyr129Tyr		rs5734	0.2390	0.3023	5980/3366/136	0.2963							600761 [SCNN1G (confirmed) Liddle syndrome,177200|Pseudohypoaldosteronism,type I,264350|Bronchiectasis with or without elevated sweat chloride 3,613071];	RCV000151819.2 [benign]; RCV000328934.1 [benign]; RCV000383542.1 [benign]; 			158	639					SCNN1G (inh=AR+AD pLI=0.37)
chr16	23200848	23200848	T	C	het	wt	het		QUAL=9807;DP=311,336,479;MQM=60	SCNN1G	synonymous	SCNN1G:NM_001039.3:synonymous:LOW:exon3/13:c.474T>C:p.Ile158Ile		rs5735	0.2392	0.3018	5991/3371/136	0.2937							600761 [SCNN1G (confirmed) Liddle syndrome,177200|Pseudohypoaldosteronism,type I,264350|Bronchiectasis with or without elevated sweat chloride 3,613071];	RCV000151820.2 [benign]; RCV000300778.1 [benign]; RCV000355585.1 [benign]; 		COSM4128821	158	638					SCNN1G (inh=AR+AD pLI=0.37)
chr16	23224416	23224416	G	A	wt	wt	het		QUAL=3619;DP=282,237,338;MQM=60	SCNN1G	splice_region&intron	SCNN1G:NM_001039.3:splice_region&intron:LOW:exon10/12:c.1432-7G>A:		rs13306653	0.1554	0.1782	2315/1657/322	0.1772							600761 [SCNN1G (confirmed) Liddle syndrome,177200|Pseudohypoaldosteronism,type I,264350|Bronchiectasis with or without elevated sweat chloride 3,613071];	RCV000151822.2 [benign]; RCV000277495.1 [benign]; RCV000316196.1 [benign]; 			80	438					SCNN1G (inh=AR+AD pLI=0.37)
chr16	23226787	23226787	C	G	wt	wt	het		QUAL=5353;DP=316,386,459;MQM=60	SCNN1G	synonymous	SCNN1G:NM_001039.3:synonymous:LOW:exon13/13:c.1947C>G:p.Leu649Leu		rs5723	0.1550	0.1789	2284/1632/316	0.1753							600761 [SCNN1G (confirmed) Liddle syndrome,177200|Pseudohypoaldosteronism,type I,264350|Bronchiectasis with or without elevated sweat chloride 3,613071];	RCV000151824.2 [benign]; RCV000309769.1 [benign]; RCV000348242.1 [benign]; 			80	437					SCNN1G (inh=AR+AD pLI=0.37)
chr16	23226949	23226949	T	G	wt	wt	het		QUAL=4599;DP=309,304,383;MQM=60	SCNN1G	3'UTR	SCNN1G:NM_001039.3:3'UTR:MODIFIER:exon13/13:c.*159T>G:		rs3026	0.1554	0.0000	0/0/0	0.1740							600761 [SCNN1G (confirmed) Liddle syndrome,177200|Pseudohypoaldosteronism,type I,264350|Bronchiectasis with or without elevated sweat chloride 3,613071];	RCV000298351.1 [benign]; RCV000355503.1 [benign]; 			8	63					SCNN1G (inh=AR+AD pLI=0.37)
chr16	23227026	23227026	C	T	wt	wt	het		QUAL=5400;DP=391,358,445;MQM=60	SCNN1G	3'UTR	SCNN1G:NM_001039.3:3'UTR:MODIFIER:exon13/13:c.*236C>T:		rs5726	0.1550	0.0000	0/0/0	0.1740							600761 [SCNN1G (confirmed) Liddle syndrome,177200|Pseudohypoaldosteronism,type I,264350|Bronchiectasis with or without elevated sweat chloride 3,613071];	RCV000263142.1 [benign]; RCV000320650.1 [benign]; 			8	63					SCNN1G (inh=AR+AD pLI=0.37)
chr16	23227058	23227058	G	A	wt	wt	het		QUAL=4090;DP=288,319,349;MQM=60	SCNN1G	3'UTR	SCNN1G:NM_001039.3:3'UTR:MODIFIER:exon13/13:c.*268G>A:		rs5727	0.1550	0.0000	0/0/0	0.1740							600761 [SCNN1G (confirmed) Liddle syndrome,177200|Pseudohypoaldosteronism,type I,264350|Bronchiectasis with or without elevated sweat chloride 3,613071];	RCV000268141.1 [benign]; RCV000379066.1 [benign]; 			9	62					SCNN1G (inh=AR+AD pLI=0.37)
chr16	23227362	23227362	A	G	het	het	hom		QUAL=16593;DP=340,240,295;MQM=60	SCNN1G	3'UTR	SCNN1G:NM_001039.3:3'UTR:MODIFIER:exon13/13:c.*572A>G:		rs5728	0.3395	0.0000	0/0/0	0.0659							600761 [SCNN1G (confirmed) Liddle syndrome,177200|Pseudohypoaldosteronism,type I,264350|Bronchiectasis with or without elevated sweat chloride 3,613071];	RCV000290607.1 [benign]; RCV000347941.1 [benign]; 			50	102					SCNN1G (inh=AR+AD pLI=0.37)
chr16	23227396	23227396	T	A	wt	wt	het		QUAL=3543;DP=237,228,283;MQM=60	SCNN1G	3'UTR	SCNN1G:NM_001039.3:3'UTR:MODIFIER:exon13/13:c.*606T>A:		rs5729	0.1550	0.0000	0/0/0	0.1740							600761 [SCNN1G (confirmed) Liddle syndrome,177200|Pseudohypoaldosteronism,type I,264350|Bronchiectasis with or without elevated sweat chloride 3,613071];	RCV000297822.1 [benign]; RCV000336441.1 [benign]; 			8	61					SCNN1G (inh=AR+AD pLI=0.37)
chr16	23227449	23227449	T	C	het	het	hom		QUAL=12903;DP=318,186,219;MQM=60	SCNN1G	3'UTR	SCNN1G:NM_001039.3:3'UTR:MODIFIER:exon13/13:c.*659T>C:		rs9922851	0.3395	0.0000	0/0/0	0.0659							600761 [SCNN1G (confirmed) Liddle syndrome,177200|Pseudohypoaldosteronism,type I,264350|Bronchiectasis with or without elevated sweat chloride 3,613071];	RCV000300448.1 [benign]; RCV000398594.1 [benign]; 			48	92					SCNN1G (inh=AR+AD pLI=0.37)
chr16	23227465	23227465	A	G	wt	wt	het		QUAL=3252;DP=361,183,230;MQM=60	SCNN1G	3'UTR	SCNN1G:NM_001039.3:3'UTR:MODIFIER:exon13/13:c.*675A>G:	MIR	rs5730	0.1550	0.0000	0/0/0	0.0296							600761 [SCNN1G (confirmed) Liddle syndrome,177200|Pseudohypoaldosteronism,type I,264350|Bronchiectasis with or without elevated sweat chloride 3,613071];	RCV000265167.1 [benign]; RCV000357562.1 [benign]; 			9	54					SCNN1G (inh=AR+AD pLI=0.37)
chr16	23227579	23227579	T	C	het	het	hom		QUAL=21112;DP=436,294,431;MQM=59	SCNN1G	3'UTR	SCNN1G:NM_001039.3:3'UTR:MODIFIER:exon13/13:c.*789T>C:	MIR	rs9923016	0.3389	0.0000	0/0/0	0.0479							600761 [SCNN1G (confirmed) Liddle syndrome,177200|Pseudohypoaldosteronism,type I,264350|Bronchiectasis with or without elevated sweat chloride 3,613071];	RCV000305014.1 [benign]; RCV000362088.1 [benign]; 			50	99					SCNN1G (inh=AR+AD pLI=0.37)
chr16	23227580	23227580	C	T	wt	wt	het		QUAL=21112;DP=436,294,431;MQM=59	SCNN1G	3'UTR	SCNN1G:NM_001039.3:3'UTR:MODIFIER:exon13/13:c.*790C>T:	MIR	rs9932505	0.1506	0.0000	0/0/0	0.0203							600761 [SCNN1G (confirmed) Liddle syndrome,177200|Pseudohypoaldosteronism,type I,264350|Bronchiectasis with or without elevated sweat chloride 3,613071];	RCV000273125.1 [benign]; RCV000365324.1 [benign]; 			9	57					SCNN1G (inh=AR+AD pLI=0.37)
chr16	23360199	23360199	T	C	het	het	wt		QUAL=6271;DP=311,270,396;MQM=59	SCNN1B	synonymous	SCNN1B:NM_000336.2:synonymous:LOW:exon2/13:c.279T>C:p.Pro93Pro		rs238547	0.7885	0.6355	26254/10387/4313	0.6109							600760 [SCNN1B (confirmed) Liddle syndrome,177200|Pseudohypoaldosteronism,type I,264350|Bronchiectasis with or without elevated sweat chloride 1,211400];	RCV000151814.3 [benign]; RCV000266524.1 [benign]; RCV000307100.1 [benign]; RCV000361247.1 [benign]; 			609	714					SCNN1B (inh=AR+AD pLI=0.00)
chr16	23399964	23399964	G	T	hom	hom	hom	low_DP	QUAL=210;DP=28,6,15;MQM=60	COG7	3'UTR	COG7:NM_153603.3:3'UTR:MODIFIER:exon17/17:c.*277C>A:	Alu		0.0000	0.0000	0/0/0	0.0000							606978 [COG7 (confirmed) Congenital disorder of glycosylation,type IIe,608779];				0	1					COG7 (inh=n/a pLI=0.00)
chr16	23400054	23400054	T	C	het	het	het		QUAL=6299;DP=227,166,201;MQM=57	COG7	3'UTR	COG7:NM_153603.3:3'UTR:MODIFIER:exon17/17:c.*187A>G:	AluSg	rs250588	0.3610	0.0000	0/0/0	0.2286							606978 [COG7 (confirmed) Congenital disorder of glycosylation,type IIe,608779];	RCV000364633.1 [benign]; 			13	78					COG7 (inh=n/a pLI=0.00)
chr16	23400194	23400194	G	A	het	het	het		QUAL=13345;DP=299,328,439;MQM=59	COG7	3'UTR	COG7:NM_153603.3:3'UTR:MODIFIER:exon17/17:c.*47C>T:		rs250587	0.2436	0.2030	2715/1088/411	0.1887							606978 [COG7 (confirmed) Congenital disorder of glycosylation,type IIe,608779];	RCV000398954.1 [likely benign]; 			22	224					COG7 (inh=n/a pLI=0.00)
chr16	23457291	23457291	A	-	wt	het	het		QUAL=804;DP=55,77,133;MQM=59	COG7	splice_region&intron	COG7:NM_153603.3:splice_region&intron:LOW:exon1/16:c.170-9delT:	(A)n	rs34368657;rs71379679	0.0000	0.3899	29/13/1	0.0038							606978 [COG7 (confirmed) Congenital disorder of glycosylation,type IIe,608779];	RCV000339395.1 [uncertain significance]; 			14	230					COG7 (inh=n/a pLI=0.00)
chr16	23646191	23646191	T	C	het	wt	het		QUAL=5941;DP=153,242,272;MQM=60	PALB2	missense	PALB2:NM_024675.3:missense:MODERATE:exon4/13:c.1676A>G:p.Gln559Arg		rs152451	0.1508	0.1176	771/232/252	0.1046	0.4010	T	T	B	T	0.01	610355 [PALB2 (provisional) Fanconi anemia,complementation group N,610832|Breast cancer,susceptibility to,114480|Pancreatic cancer,susceptibility to,3,613348];	RCV000114486.2 [other]; RCV000121747.3 [benign]; RCV000128962.4 [benign]; RCV000395533.1 [benign]; 	CM1312156 [CLASS=DP MUT=ALT PHEN="Breast cancer association with" GENE=PALB2]; 		30	633	1	[1] Christopher Schroeder 27.04.2015			PALB2 (inh=AR+AD pLI=0.00)
chr16	28488943	28488943	T	C	wt	het	wt	pred_pathogenic	QUAL=3015;DP=140,236,324;MQM=60	CLN3	missense	CLN3:NM_000086.2:missense:MODERATE:exon15/15:c.1211A>G:p.His404Arg,CLN3:NM_001286109.1:missense:MODERATE:exon13/14:c.977A>G:p.His326Arg,CLN3:NM_001042432.1:missense:MODERATE:exon16/16:c.1211A>G:p.His404Arg,CLN3:NM_001286105.1:missense:MODERATE:exon13/13:c.911A>G:p.His304Arg,CLN3:NM_001286110.1:missense:MODERATE:exon14/14:c.1049A>G:p.His350Arg,CLN3:NM_001286104.1:missense:MODERATE:exon15/15:c.1139A>G:p.His380Arg		rs77595156	0.1558	0.0807	774/36/427	0.0761	4.7440	T,T,T,T,T,T,T,T	T	D,D,D,D,D,D,D,D	D,D,D,D,D,D,D,D	23.20	607042 [CLN3 (confirmed) Ceroid lipofuscinosis,neuronal,3,204200];	RCV000116749.4 [other]; RCV000371392.1 [benign]; 			5	148					CLN3 (inh=AR pLI=0.00)
chr16	28853996	28853996	A	C	wt	wt	het		QUAL=5617;DP=368,387,469;MQM=60	TUFM	3'UTR	TUFM:NM_003321.4:3'UTR:MODIFIER:exon10/10:c.*300T>G:		rs3088215	0.2616	0.0000	0/0/0	0.0576							602389 [TUFM (confirmed) Combined oxidative phosphorylation deficiency 4,610678];	RCV000352107.1 [benign]; 			35	96					TUFM (inh=AR pLI=0.65)
chr16	28857645	28857645	A	G	wt	wt	het		QUAL=493;DP=176,34,46;MQM=60	TUFM	5'UTR	TUFM:NM_003321.4:5'UTR:MODIFIER:exon1/10:c.-55T>C:		rs7187776	0.3492	0.0000	0/0/0	0.0648							602389 [TUFM (confirmed) Combined oxidative phosphorylation deficiency 4,610678];	RCV000304891.1 [benign]; 			116	375					TUFM (inh=AR pLI=0.65)
chr16	28944396	28944396	C	G	hom	hom	hom		QUAL=10112;DP=104,90,134;MQM=59	CD19	missense	CD19:NM_001178098.1:missense:MODERATE:exon3/15:c.520C>G:p.Leu174Val,CD19:NM_001770.5:missense:MODERATE:exon3/15:c.520C>G:p.Leu174Val		rs2904880	0.8303	0.7293	33026/15765/4563	0.7190	0.0920	T,T,T	T	B,B	T,T	1.94	107265 [CD19 (provisional) Immunodeficiency,common variable,3,613493];	RCV000325903.1 [benign]; 			865	584					CD19 (inh=AR pLI=0.85)
chr16	28944700	28944700	G	T	wt	het	het		QUAL=6206;DP=221,220,274;MQM=60	CD19	synonymous	CD19:NM_001178098.1:synonymous:LOW:exon4/15:c.705G>T:p.Pro235Pro,CD19:NM_001770.5:synonymous:LOW:exon4/15:c.705G>T:p.Pro235Pro		rs35979293	0.1871	0.2935	6018/4608/63	0.2933							107265 [CD19 (provisional) Immunodeficiency,common variable,3,613493];	RCV000271669.1 [benign]; 		COSM3754835	201	666					CD19 (inh=AR pLI=0.85)
chr16	28950051	28950051	G	A	het	het	wt	pred_pathogenic	QUAL=3273;DP=134,163,181;MQM=60	CD19	missense	CD19:NM_001178098.1:missense:MODERATE:exon13/15:c.1544G>A:p.Arg515His,CD19:NM_001770.5:missense:MODERATE:exon13/15:c.1541G>A:p.Arg514His		rs34763945	0.0182	0.0398	130/97/3	0.0403	0.2880	T,T,T,T	T	B,B	T,T	21.10	107265 [CD19 (provisional) Immunodeficiency,common variable,3,613493];	RCV000278853.1 [likely benign]; 			4	157					CD19 (inh=AR pLI=0.85)
chr16	29825126	29825126	T	C	hom	hom	hom		QUAL=21222;DP=118,243,341;MQM=59	PRRT2	synonymous	PRRT2:NM_001256442.1:synonymous:LOW:exon2/3:c.751T>C:p.Leu251Leu,PRRT2:NM_001256443.1:synonymous:LOW:exon2/2:c.751T>C:p.Leu251Leu,PRRT2:NM_145239.2:synonymous:LOW:exon2/4:c.751T>C:p.Leu251Leu		rs11150573	0.9918	0.9980	59929/33124/4804	0.9333							614386 [PRRT2 (provisional) Episodic kinesigenic dyskinesia 1,128200|Seizures,benign familial infantile,2,605751|Convulsions,familial infantile,with paroxysmal choreoathetosis,602066];	RCV000127623.2 [benign]; RCV000153784.2 [benign]; 			2495	2					PRRT2 (inh=AD pLI=0.30)
chr16	29826538	29826538	T	C	hom	hom	hom		QUAL=20237;DP=203,185,250;MQM=59	PRRT2	3'UTR	PRRT2:NM_001256442.1:3'UTR:MODIFIER:exon3/3:c.*579T>C:,PRRT2:NM_001256443.1:3'UTR:MODIFIER:exon2/2:c.*1263T>C:,PRRT2:NM_145239.2:3'UTR:MODIFIER:exon4/4:c.*579T>C:		rs10204	0.7816	0.0000	0/0/0	0.1321							614386 [PRRT2 (provisional) Episodic kinesigenic dyskinesia 1,128200|Seizures,benign familial infantile,2,605751|Convulsions,familial infantile,with paroxysmal choreoathetosis,602066];				173	51					PRRT2 (inh=AD pLI=0.30)
chr16	30194840	30194840	A	G	het	het	het		QUAL=4124;DP=110,136,162;MQM=60	CORO1A	5'UTR	CORO1A:NM_001193333.2:5'UTR:MODIFIER:exon1/12:c.-326A>G:,CORO1A:NM_007074.3:5'UTR:MODIFIER:exon1/11:c.-208A>G:		rs930392	0.7911	0.0000	0/0/0	0.5790							605000 [CORO1A (provisional) Immunodeficiency 8,615401];				54	72					CORO1A (inh=AR pLI=0.95)
chr16	30198151	30198151	A	G	het	het	het		QUAL=5983;DP=160,154,181;MQM=59	CORO1A	synonymous	CORO1A:NM_001193333.2:synonymous:LOW:exon5/12:c.336A>G:p.Pro112Pro,CORO1A:NM_007074.3:synonymous:LOW:exon4/11:c.336A>G:p.Pro112Pro		rs1132812	0.7941	0.6540	26673/10035/4050	0.6416							605000 [CORO1A (provisional) Immunodeficiency 8,615401];			COSM3721331	596	699					CORO1A (inh=AR pLI=0.95)
chr16	31191482	31191482	A	G	hom	hom	hom		QUAL=21607;DP=243,200,282;MQM=59	FUS	5'UTR,non_coding_transcript_exon	FUS:NM_004960.3:5'UTR:MODIFIER:exon1/15:c.-54A>G:,FUS:NM_001170634.1:5'UTR:MODIFIER:exon1/15:c.-54A>G:,FUS:NM_001170937.1:5'UTR:MODIFIER:exon1/15:c.-54A>G:,FUS:NR_028388.2:non_coding_transcript_exon:MODIFIER:exon1/14:n.52A>G:		rs929867	0.9391	0.9846	44807/25930/2605	0.9101							137070 [FUS (confirmed) Amyotrophic lateral sclerosis 6,with or without frontotemporal dementia,608030|Tremor,hereditary essential,4,614782];	RCV000307180.1 [benign]; 			1385	5					FUS (inh=AR+AD pLI=1.00)
chr16	31193942	31193942	C	A	het	wt	het		QUAL=11576;DP=416,334,438;MQM=60	FUS	synonymous,non_coding_transcript_exon	FUS:NM_004960.3:synonymous:LOW:exon3/15:c.147C>A:p.Gly49Gly,FUS:NM_001170634.1:synonymous:LOW:exon3/15:c.147C>A:p.Gly49Gly,FUS:NM_001170937.1:synonymous:LOW:exon3/15:c.147C>A:p.Gly49Gly,FUS:NR_028388.2:non_coding_transcript_exon:MODIFIER:exon3/14:n.252C>A:		rs741810	0.2790	0.3221	7130/3180/26	0.3143							137070 [FUS (confirmed) Amyotrophic lateral sclerosis 6,with or without frontotemporal dementia,608030|Tremor,hereditary essential,4,614782];	RCV000251286.1 [benign]; RCV000356600.1 [benign]; 		COSM1377614, COSM3754865	210	828					FUS (inh=AR+AD pLI=1.00)
chr16	31195279	31195279	C	T	het	het	wt		QUAL=3808;DP=239,111,158;MQM=60	FUS	synonymous,non_coding_transcript_exon	FUS:NM_004960.3:synonymous:LOW:exon4/15:c.291C>T:p.Tyr97Tyr,FUS:NM_001170634.1:synonymous:LOW:exon4/15:c.288C>T:p.Tyr96Tyr,FUS:NM_001170937.1:synonymous:LOW:exon4/15:c.291C>T:p.Tyr97Tyr,FUS:NR_028388.2:non_coding_transcript_exon:MODIFIER:exon4/14:n.396C>T:		rs1052352	0.4738	0.5186	17189/10275/360	0.4883							137070 [FUS (confirmed) Amyotrophic lateral sclerosis 6,with or without frontotemporal dementia,608030|Tremor,hereditary essential,4,614782];	RCV000244413.1 [benign]; RCV000277026.1 [benign]; 			731	956					FUS (inh=AR+AD pLI=1.00)
chr16	31202800	31202800	G	A	het	wt	het	anno_pathogenic_hgmd	QUAL=6944;DP=374,178,218;MQM=59	FUS	3'UTR,non_coding_transcript_exon	FUS:NM_004960.3:3'UTR:MODIFIER:exon15/15:c.*41G>A:,FUS:NM_001170634.1:3'UTR:MODIFIER:exon15/15:c.*41G>A:,FUS:NM_001170937.1:3'UTR:MODIFIER:exon15/15:c.*41G>A:,FUS:NR_028388.2:non_coding_transcript_exon:MODIFIER:exon14/14:n.1692G>A:		rs80301724	0.0044	0.0069	6/1/0	0.0063							137070 [FUS (confirmed) Amyotrophic lateral sclerosis 6,with or without frontotemporal dementia,608030|Tremor,hereditary essential,4,614782];	RCV000340713.1 [likely benign]; 	CR121643 [CLASS=DM MUT=ALT PHEN="Amyotrophic lateral sclerosis" GENE=FUS]; 		2	32					FUS (inh=AR+AD pLI=1.00)
chr16	31203529	31203529	G	C	het	wt	het		QUAL=7269;DP=381,185,223;MQM=60	FUS	3'UTR,non_coding_transcript_exon	FUS:NM_004960.3:3'UTR:MODIFIER:exon15/15:c.*770G>C:,FUS:NM_001170634.1:3'UTR:MODIFIER:exon15/15:c.*770G>C:,FUS:NM_001170937.1:3'UTR:MODIFIER:exon15/15:c.*770G>C:,FUS:NR_028388.2:non_coding_transcript_exon:MODIFIER:exon14/14:n.2421G>C:		rs4889537	0.2817	0.4227	1066/89/2	0.0831							137070 [FUS (confirmed) Amyotrophic lateral sclerosis 6,with or without frontotemporal dementia,608030|Tremor,hereditary essential,4,614782];	RCV000328414.1 [benign]; 			55	233					FUS (inh=AR+AD pLI=1.00)
chr16	31204235	31204235	T	C	hom	hom	hom		QUAL=40393;DP=452,335,435;MQM=60	FUS	3'UTR,non_coding_transcript_exon	FUS:NM_004960.3:3'UTR:MODIFIER:exon15/15:c.*1476T>C:,FUS:NM_001170634.1:3'UTR:MODIFIER:exon15/15:c.*1476T>C:,FUS:NM_001170937.1:3'UTR:MODIFIER:exon15/15:c.*1476T>C:,FUS:NR_028388.2:non_coding_transcript_exon:MODIFIER:exon14/14:n.3127T>C:		rs11860134	0.9910	0.9994	5389/1374/89	0.2328							137070 [FUS (confirmed) Amyotrophic lateral sclerosis 6,with or without frontotemporal dementia,608030|Tremor,hereditary essential,4,614782];	RCV000390213.1 [benign]; 			573	1					FUS (inh=AR+AD pLI=1.00)
chr16	56545175	56545175	T	C	het	hom	wt	pred_pathogenic	QUAL=12550;DP=337,264,388;MQM=60	BBS2	missense	BBS2:NM_031885.3:missense:MODERATE:exon3/17:c.367A>G:p.Ile123Val		rs11373	0.2636	0.2092	2948/1009/273	0.2089	0.4020	T	T	B,B	D	0.23	606151 [BBS2 (confirmed) Bardet-Biedl syndrome 2,615981|Retinitis pigmentosa 74,616562];	RCV000241605.1 [benign]; RCV000261972.1 [benign]; 	CM144738 [CLASS=DFP MUT=ALT PHEN="Bardet-Biedl syndrome" GENE=BBS2]; 		62	470					BBS2 (inh=AR pLI=0.00)
chr16	56548501	56548501	C	T	hom	hom	hom	pred_pathogenic;anno_pathogenic_clinvar;anno_pathogenic_hgmd	QUAL=19343;DP=248,161,202;MQM=60	BBS2	missense	BBS2:NM_031885.3:missense:MODERATE:exon2/17:c.209G>A:p.Ser70Asn		rs4784677	0.9964	0.9938	59947/32858/5179	0.9713	5.0110	T	T		T	12.57	606151 [BBS2 (confirmed) Bardet-Biedl syndrome 2,615981|Retinitis pigmentosa 74,616562];	RCV000004838.3 [pathogenic]; RCV000301991.1 [benign]; 	CM012900 [CLASS=DM MUT=REF PHEN="Bardet-Biedl syndrome" GENE=BBS2]; 		1529	34	2	[2] old entry - no details available [n/a] comment imported from detected variant: Wirkt falsch annotiert; 30.03.14, PB			BBS2 (inh=AR pLI=0.00)
chr16	56554016	56554016	A	G	hom	hom	hom		QUAL=8283;DP=100,65,119;MQM=59	BBS2-MT4	intergenic_region	BBS2-MT4:BBS2-MT4:intergenic_region:MODIFIER::n.56554016A>G:		rs12446354	0.9970	0.0000	0/0/0	0.8581							606151 [BBS2 (confirmed) Bardet-Biedl syndrome 2,615981|Retinitis pigmentosa 74,616562];	RCV000317329.1 [benign]; 			217	0					BBS2-MT4 (inh=n/a pLI=n/a)
chr16	57495026	57495026	T	C	hom	hom	hom		QUAL=25237;DP=280,229,298;MQM=59	COQ9	3'UTR	COQ9:NM_020312.3:3'UTR:MODIFIER:exon9/9:c.*490T>C:		rs223870	0.9926	0.0000	0/0/0	0.8911							612837 [COQ9 (provisional) Coenzyme Q10 deficiency,primary,5,614654];	RCV000359269.1 [benign]; 			848	52					COQ9 (inh=AR pLI=0.00)
chr16	66514962	66514962	C	T	het	hom	wt		QUAL=13035;DP=226,335,460;MQM=59	BEAN1	3'UTR,intron	BEAN1:NM_001178020.2:3'UTR:MODIFIER:exon5/5:c.*134C>T:,BEAN1:NM_001136106.4:3'UTR:MODIFIER:exon4/4:c.*134C>T:,BEAN1:NM_001197224.3:intron:MODIFIER:exon3/4:c.114-1819C>T:,BEAN1:NM_001197225.3:intron:MODIFIER:exon3/4:c.114-1823C>T:	(CA)n	rs3743709	0.1110	0.0000	0/0/0	0.0768							612051 [BEAN1 (provisional) Spinocerebellar ataxia 31,117210]:188250 [TK2 (confirmed) Mitochondrial DNA depletion syndrome 2 (myopathic type),609560|Progressive external ophthalmoplegia with mitochondrial DNA deletions,autosomal recessive 3,617069];				5	24					BEAN1 (inh=AD pLI=n/a)
chr16	66527192	66527192	G	A	het	hom	wt		QUAL=5772;DP=97,160,184;MQM=59	BEAN1	missense,3'UTR	BEAN1:NM_001197225.3:missense:MODERATE:exon5/5:c.475G>A:p.Gly159Arg,BEAN1:NM_001197224.3:3'UTR:MODIFIER:exon5/5:c.*224G>A:		rs58468753	0.1114	0.0525	27/6/5	0.0194							612051 [BEAN1 (provisional) Spinocerebellar ataxia 31,117210]:188250 [TK2 (confirmed) Mitochondrial DNA depletion syndrome 2 (myopathic type),609560|Progressive external ophthalmoplegia with mitochondrial DNA deletions,autosomal recessive 3,617069];				14	169					BEAN1 (inh=AD pLI=n/a)
chr16	66584002	66584002	T	C	het	hom	het	pred_pathogenic	QUAL=8403;DP=259,112,156;MQM=60	TK2	5'UTR,intron,non_coding_transcript_exon	TK2:NM_004614.4:5'UTR:MODIFIER:exon1/10:c.-38A>G:,TK2:NM_001172644.1:5'UTR:MODIFIER:exon1/9:c.-38A>G:,TK2:NM_001172645.1:5'UTR:MODIFIER:exon1/9:c.-38A>G:,TK2:NM_001271934.1:5'UTR:MODIFIER:exon1/11:c.-280A>G:,TK2:NM_001172643.1:intron:MODIFIER:exon1/9:c.31+154A>G:,TK2:NM_001271935.1:intron:MODIFIER:exon1/7:c.31+154A>G:,TK2:NR_073520.1:non_coding_transcript_exon:MODIFIER:exon1/9:n.314A>G:		rs3743716	0.3259	0.2681	2735/378/1059	0.1863	0.3800	T	T	B	D	6.44	188250 [TK2 (confirmed) Mitochondrial DNA depletion syndrome 2 (myopathic type),609560|Progressive external ophthalmoplegia with mitochondrial DNA deletions,autosomal recessive 3,617069];	RCV000125522.1 [benign]; RCV000338994.1 [benign]; 		COSM435490	34	259					TK2 (inh=AR pLI=0.00)
chr16	67311767	67311767	G	A	het	het	wt		QUAL=6161;DP=278,306,450;MQM=59	SLC9A5-PLEKHG4	intergenic_region	SLC9A5-PLEKHG4:SLC9A5-PLEKHG4:intergenic_region:MODIFIER::n.67311767G>A:		rs8050745	0.2410	0.0000	0/0/0	0.1124											6	108					SLC9A5-PLEKHG4 (inh=n/a pLI=n/a)
chr16	67313805	67313805	G	A	het	het	wt		QUAL=3344;DP=187,102,156;MQM=59	PLEKHG4	5'UTR	PLEKHG4:NM_001129727.2:5'UTR:MODIFIER:exon3/23:c.-143G>A:,PLEKHG4:NM_001129728.1:5'UTR:MODIFIER:exon2/22:c.-143G>A:,PLEKHG4:NM_001129729.2:5'UTR:MODIFIER:exon2/22:c.-143G>A:,PLEKHG4:NM_001129731.2:5'UTR:MODIFIER:exon1/20:c.-143G>A:		rs141261466	0.0062	0.0000	0/0/0	0.0116											0	15					PLEKHG4 (inh=AD pLI=0.00)
chr16	67316234	67316234	C	T	het	het	wt	pred_pathogenic	QUAL=2675;DP=125,107,102;MQM=59	PLEKHG4	missense	PLEKHG4:NM_001129727.2:missense:MODERATE:exon10/23:c.1235C>T:p.Thr412Ile,PLEKHG4:NM_001129728.1:missense:MODERATE:exon9/22:c.1235C>T:p.Thr412Ile,PLEKHG4:NM_001129729.2:missense:MODERATE:exon9/22:c.1235C>T:p.Thr412Ile,PLEKHG4:NM_001129731.2:missense:MODERATE:exon7/20:c.992C>T:p.Thr331Ile		rs11860295	0.2440	0.1343	2240/217/1724	0.1237	0.0090	T,T,T,T	T	P,B	T,T,T,T	20.70		RCV000117985.2 [likely benign]; 			47	383					PLEKHG4 (inh=AD pLI=0.00)
chr16	67318242	67318242	A	G	het	het	wt		QUAL=1432;DP=94,82,124;MQM=60	PLEKHG4	missense	PLEKHG4:NM_001129727.2:missense:MODERATE:exon13/23:c.1574A>G:p.Asp525Gly,PLEKHG4:NM_001129728.1:missense:MODERATE:exon12/22:c.1574A>G:p.Asp525Gly,PLEKHG4:NM_001129729.2:missense:MODERATE:exon12/22:c.1574A>G:p.Asp525Gly,PLEKHG4:NM_001129731.2:missense:MODERATE:exon10/20:c.1331A>G:p.Asp444Gly		rs8044843	0.2816	0.1641	2920/433/2029	0.1550	0.6240	T,T,T,T	T	B,B	T,T,T,T	5.62		RCV000117986.2 [likely benign]; 		COSM3765919	67	500					PLEKHG4 (inh=AD pLI=0.00)
chr16	67320223	67320223	G	A	het	het	wt	low_DP;pred_pathogenic	QUAL=184;DP=15,11,24;MQM=60	PLEKHG4	missense	PLEKHG4:NM_001129727.2:missense:MODERATE:exon16/23:c.2489G>A:p.Arg830His,PLEKHG4:NM_001129728.1:missense:MODERATE:exon15/22:c.2489G>A:p.Arg830His,PLEKHG4:NM_001129729.2:missense:MODERATE:exon15/22:c.2489G>A:p.Arg830His,PLEKHG4:NM_001129731.2:missense:MODERATE:exon13/20:c.2246G>A:p.Arg749His		rs3868142	0.2414	0.1289	2253/234/1716	0.1233	2.0690	D,D,D,D	T	B,B	T,T,T,T	23.60		RCV000117987.2 [likely benign]; 		COSM4129187	47	375					PLEKHG4 (inh=AD pLI=0.00)
chr16	67469733	67469733	C	A	het	het	wt		QUAL=5923;DP=157,311,353;MQM=59	HSD11B2	synonymous	HSD11B2:NM_000196.3:synonymous:LOW:exon2/5:c.468C>A:p.Thr156Thr		rs5479	0.0927	0.0587	357/76/202	0.0563							614232 [HSD11B2 (confirmed) Apparent mineralocorticoid excess,218030];		CM057710 [CLASS=DP MUT=ALT PHEN="Hypertension association with" GENE=HSD11B2]; 	COSM4129203	19	161					HSD11B2 (inh=AR pLI=0.24)
chr16	67469915	67469915	G	A	het	het	wt		QUAL=7862;DP=368,341,385;MQM=59	HSD11B2	synonymous	HSD11B2:NM_000196.3:synonymous:LOW:exon3/5:c.534G>A:p.Glu178Glu		rs45483293	0.0144	0.0311	87/74/0	0.0308							614232 [HSD11B2 (confirmed) Apparent mineralocorticoid excess,218030];				7	121					HSD11B2 (inh=AR pLI=0.24)
chr16	69373414	69373414	T	C	hom	het	het		QUAL=3355;DP=59,48,87;MQM=60	COG8	synonymous	COG8:NM_032382.4:synonymous:LOW:exon1/6:c.42A>G:p.Thr14Thr		rs11542583	0.2576	0.2968	5104/2940/519	0.2712							606979 [COG8 (confirmed) Congenital disorder of glycosylation,type IIh,611182];	RCV000082299.4 [benign]; RCV000338035.1 [likely benign]; 		COSM4129245	152	615					COG8 (inh=AR pLI=0.00)
chr16	70287177	70287177	A	G	hom	hom	hom		QUAL=21255;DP=147,226,305;MQM=59	AARS	synonymous	AARS:NM_001605.2:synonymous:LOW:exon20/21:c.2715T>C:p.Val905Val		rs4081753	0.8812	0.8241	41311/20791/4840	0.8013							601065 [AARS (confirmed) Charcot-Marie-Tooth disease,axonal,type 2N,613287|Epileptic encephalopathy,early infantile,29,616339];	RCV000364752.1 [benign]; 		COSM435653	1019	475					AARS (inh=AR+AD pLI=0.00)
chr16	70303580	70303580	G	A	het	het	hom		QUAL=20552;DP=189,313,456;MQM=60	AARS	synonymous	AARS:NM_001605.2:synonymous:LOW:exon7/21:c.903C>T:p.His301His		rs2070203	0.4253	0.4659	13572/8545/1128	0.4574							601065 [AARS (confirmed) Charcot-Marie-Tooth disease,axonal,type 2N,613287|Epileptic encephalopathy,early infantile,29,616339];	RCV000374249.1 [benign]; RCV000382444.1 [benign]; 	CM995271 [CLASS=FP MUT=ALT PHEN="Altered mRNA folding" GENE=AARS]; 		361	754					AARS (inh=AR+AD pLI=0.00)
chr16	74747267	74747267	G	C	het	wt	het		QUAL=3730;DP=241,97,102;MQM=59	FA2H	3'UTR	FA2H:NM_024306.4:3'UTR:MODIFIER:exon7/7:c.*821C>G:		rs573058036	0.0014	0.0000	0/0/0	0.0021							611026 [FA2H (provisional) Spastic paraplegia 35,autosomal recessive,612319];	RCV000328142.1 [uncertain significance]; 			0	4					FA2H (inh=AR pLI=0.73)
chr16	74747451	74747451	C	G	het	hom	wt	low_DP	QUAL=1405;DP=67,18,34;MQM=59	FA2H	3'UTR	FA2H:NM_024306.4:3'UTR:MODIFIER:exon7/7:c.*637G>C:		rs56033857	0.2378	0.0000	0/0/0	0.0506							611026 [FA2H (provisional) Spastic paraplegia 35,autosomal recessive,612319];	RCV000375512.1 [benign]; 			30	102					FA2H (inh=AR pLI=0.73)
chr16	74750396	74750396	T	C	wt	het	wt		QUAL=4091;DP=176,347,458;MQM=60	FA2H	synonymous	FA2H:NM_024306.4:synonymous:LOW:exon6/7:c.888A>G:p.Val296Val		rs11554621	0.1160	0.1195	1034/702/239	0.1196							611026 [FA2H (provisional) Spastic paraplegia 35,autosomal recessive,612319];	RCV000117013.1 [benign]; RCV000389521.1 [likely benign]; 		COSM3755071	45	516					FA2H (inh=AR pLI=0.73)
chr16	74750405	74750405	G	A	het	hom	het		QUAL=18154;DP=162,338,425;MQM=60	FA2H	synonymous	FA2H:NM_024306.4:synonymous:LOW:exon6/7:c.879C>T:p.Pro293Pro		rs2301865	0.7252	0.7732	35691/21638/2641	0.7629							611026 [FA2H (provisional) Spastic paraplegia 35,autosomal recessive,612319];	RCV000117012.1 [benign]; RCV000292801.1 [benign]; 			1330	697					FA2H (inh=AR pLI=0.73)
chr16	74808425	74808425	G	A	wt	wt	het	low_QUAL;low_DP	QUAL=29;DP=130,152,5;MQM=60	FA2H	synonymous	FA2H:NM_024306.4:synonymous:LOW:exon1/7:c.229C>T:p.Leu77Leu		rs929881	0.2490	0.3587	3343/2296/547	0.2322							611026 [FA2H (provisional) Spastic paraplegia 35,autosomal recessive,612319];	RCV000117009.2 [benign]; RCV000355693.1 [benign]; 		COSM3749377	177	777					FA2H (inh=AR pLI=0.73)
chr16	81398635	81398635	C	T	wt	wt	het		QUAL=3896;DP=305,250,306;MQM=60	GAN	synonymous	GAN:NM_022041.3:synonymous:LOW:exon8/11:c.1293C>T:p.Tyr431Tyr		rs2608555	0.1512	0.1954	2601/1997/175	0.1952							605379 [GAN (confirmed) Giant axonal neuropathy-1,256850];	RCV000117118.3 [other]; RCV000396998.1 [benign]; 		COSM3755118	117	796					GAN (inh=AR pLI=0.04)
chr16	81399026	81399026	C	T	het	wt	het	pred_pathogenic	QUAL=4104;DP=167,142,178;MQM=60	GAN	missense	GAN:NM_022041.3:missense:MODERATE:exon9/11:c.1445C>T:p.Ala482Val		rs146576740	0.0008	0.0016	0/0/0	0.0016	1.8290	T	T	B	T	17.04	605379 [GAN (confirmed) Giant axonal neuropathy-1,256850];	RCV000255353.1 [uncertain significance]; 			1	20	3	[3] Stephan Waldm?ller 13.08.2014			GAN (inh=AR pLI=0.04)
chr16	81411448	81411448	G	A	hom	hom	het		QUAL=21087;DP=328,220,298;MQM=60	GAN	3'UTR	GAN:NM_022041.3:3'UTR:MODIFIER:exon11/11:c.*247G>A:		rs2216769	0.6276	0.0000	0/0/0	0.1038							605379 [GAN (confirmed) Giant axonal neuropathy-1,256850];	RCV000346692.1 [benign]; 			91	107					GAN (inh=AR pLI=0.04)
chr16	81411673	81411673	C	G	hom	hom	het		QUAL=31887;DP=451,368,431;MQM=59	GAN	3'UTR	GAN:NM_022041.3:3'UTR:MODIFIER:exon11/11:c.*472C>G:		rs1816122	0.6711	0.0000	0/0/0	0.1110							605379 [GAN (confirmed) Giant axonal neuropathy-1,256850];	RCV000353280.1 [benign]; 			100	106					GAN (inh=AR pLI=0.04)
chr16	81411793	81411793	T	A	hom	hom	het		QUAL=19915;DP=291,211,264;MQM=60	GAN	3'UTR	GAN:NM_022041.3:3'UTR:MODIFIER:exon11/11:c.*592T>A:		rs1345895	0.6418	0.0000	0/0/0	0.1073							605379 [GAN (confirmed) Giant axonal neuropathy-1,256850];	RCV000273804.1 [benign]; 			100	104					GAN (inh=AR pLI=0.04)
chr16	81412168	81412168	G	A	hom	hom	het		QUAL=14455;DP=272,87,168;MQM=60	GAN	3'UTR	GAN:NM_022041.3:3'UTR:MODIFIER:exon11/11:c.*967G>A:		rs12920236	0.3055	0.0000	0/0/0	0.0701							605379 [GAN (confirmed) Giant axonal neuropathy-1,256850];	RCV000382338.1 [benign]; 			71	102					GAN (inh=AR pLI=0.04)
chr16	83941726	83941726	C	T	het	het	wt	anno_pathogenic_hgmd	QUAL=2568;DP=107,133,174;MQM=60	MLYCD	splice_region&intron	MLYCD:NM_012213.2:splice_region&intron:LOW:exon2/4:c.642-5C>T:		rs2278037	0.0773	0.0642	320/84/54	0.0647							606761 [MLYCD (provisional) Malonyl-CoA decarboxylase deficiency,248360];	RCV000081530.5 [benign]; RCV000347623.1 [likely benign]; 	CS016047 [CLASS=DM? MUT=ALT PHEN="Malonyl-CoA decarboxylase deficiency" GENE=MLYCD]; 		7	125	2	[2] old entry - no details available			MLYCD (inh=AR pLI=0.00)
chr16	83941821	83941821	G	A	het	het	wt		QUAL=4937;DP=258,159,213;MQM=59	MLYCD	synonymous	MLYCD:NM_012213.2:synonymous:LOW:exon3/5:c.732G>A:p.Ser244Ser		rs2278038	0.0481	0.0560	283/89/2	0.0568							606761 [MLYCD (provisional) Malonyl-CoA decarboxylase deficiency,248360];	RCV000126785.2 [benign]; RCV000406258.1 [likely benign]; 		COSM3755130	7	121					MLYCD (inh=AR pLI=0.00)
chr16	83949506	83949506	T	C	het	het	wt		QUAL=9360;DP=444,303,349;MQM=60	MLYCD	3'UTR	MLYCD:NM_012213.2:3'UTR:MODIFIER:exon5/5:c.*412T>C:		rs1127382	0.1556	0.0000	0/0/0	0.1113							606761 [MLYCD (provisional) Malonyl-CoA decarboxylase deficiency,248360];	RCV000370065.1 [benign]; 			3	40					MLYCD (inh=AR pLI=0.00)
chr16	85945231	85945231	C	T	het	het	wt		QUAL=5656;DP=220,237,240;MQM=60	IRF8	synonymous	IRF8:NM_002163.2:synonymous:LOW:exon4/9:c.414C>T:p.Cys138Cys		rs8052064	0.0875	0.1236	980/614/84	0.1206							601565 [IRF8 (provisional) Immunodeficiency 32A,mycobacteriosis,autosomal dominant,614893|Immunodeficiency 32B,monocyte and dendritic cell deficiency,autosomal recessive,614894];				30	346					IRF8 (inh=AR pLI=0.93)
chr16	85955242	85955242	C	T	hom	het	het		QUAL=9855;DP=180,159,168;MQM=60	IRF8	3'UTR	IRF8:NM_002163.2:3'UTR:MODIFIER:exon9/9:c.*354C>T:		rs10514611	0.1905	0.0000	0/0/0	0.0361							601565 [IRF8 (provisional) Immunodeficiency 32A,mycobacteriosis,autosomal dominant,614893|Immunodeficiency 32B,monocyte and dendritic cell deficiency,autosomal recessive,614894];		CR127264 [CLASS=DFP MUT=ALT PHEN="Tuberculosis association with" GENE=IRF8]; 		18	71					IRF8 (inh=AR pLI=0.93)
chr16	85955304	85955304	G	T	hom	hom	hom		QUAL=11969;DP=221,79,78;MQM=60	IRF8	3'UTR	IRF8:NM_002163.2:3'UTR:MODIFIER:exon9/9:c.*416G>T:		rs1568391	0.6751	0.0000	0/0/0	0.0790							601565 [IRF8 (provisional) Immunodeficiency 32A,mycobacteriosis,autosomal dominant,614893|Immunodeficiency 32B,monocyte and dendritic cell deficiency,autosomal recessive,614894];				80	104					IRF8 (inh=AR pLI=0.93)
chr16	85955671	85955671	C	T	hom	hom	hom		QUAL=31120;DP=374,270,305;MQM=59	IRF8	3'UTR	IRF8:NM_002163.2:3'UTR:MODIFIER:exon9/9:c.*783C>T:		rs1044873	0.3548	0.0000	0/0/0	0.0441							601565 [IRF8 (provisional) Immunodeficiency 32A,mycobacteriosis,autosomal dominant,614893|Immunodeficiency 32B,monocyte and dendritic cell deficiency,autosomal recessive,614894];				39	107					IRF8 (inh=AR pLI=0.93)
chr16	85955730	85955730	A	-	hom	hom	hom		QUAL=30986;DP=333,311,359;MQM=59	IRF8	3'UTR	IRF8:NM_002163.2:3'UTR:MODIFIER:exon9/9:c.*843delA:		rs397844297	0.7362	0.0000	0/0/0	0.4127							601565 [IRF8 (provisional) Immunodeficiency 32A,mycobacteriosis,autosomal dominant,614893|Immunodeficiency 32B,monocyte and dendritic cell deficiency,autosomal recessive,614894];				82	103					IRF8 (inh=AR pLI=0.93)
chr16	85956044	85956044	A	T	hom	hom	hom	low_DP	QUAL=4631;DP=118,16,16;MQM=60	IRF8	3'UTR	IRF8:NM_002163.2:3'UTR:MODIFIER:exon9/9:c.*1156A>T:		rs6638	0.6538	0.0000	0/0/0	0.0785							601565 [IRF8 (provisional) Immunodeficiency 32A,mycobacteriosis,autosomal dominant,614893|Immunodeficiency 32B,monocyte and dendritic cell deficiency,autosomal recessive,614894];				80	101					IRF8 (inh=AR pLI=0.93)
chr16	88494947	88494947	T	C	hom	hom	hom	gene_blacklist	QUAL=11401;DP=72,113,190;MQM=59	ZNF469	missense	ZNF469:NM_001127464.2:missense:MODERATE:exon1/2:c.1069T>C:p.Ser357Pro		rs11648572	0.9890	0.9827	7497/2594/595	0.2947	-0.4430	T	T	B	T	0.01	612078 [ZNF469 (confirmed) Brittle cornea syndrome 1,229200];	RCV000173223.1 [benign]; RCV000352613.1 [benign]; 		COSM4129466	1453	86					ZNF469 (inh=AR pLI=n/a)
chr16	88494976	88494976	A	C	hom	hom	hom	gene_blacklist	QUAL=12663;DP=108,122,185;MQM=59	ZNF469	missense	ZNF469:NM_001127464.2:missense:MODERATE:exon1/2:c.1098A>C:p.Arg366Ser		rs11640794	0.8550	0.9341	6850/2497/245	0.2848	0.5620	T	T	B	T	0.01	612078 [ZNF469 (confirmed) Brittle cornea syndrome 1,229200];	RCV000173224.1 [benign]; RCV000402834.1 [benign]; 			1358	175					ZNF469 (inh=AR pLI=n/a)
chr16	88495367	88495367	G	A	wt	het	wt	gene_blacklist	QUAL=455;DP=51,43,53;MQM=60	ZNF469	missense	ZNF469:NM_001127464.2:missense:MODERATE:exon1/2:c.1489G>A:p.Gly497Arg		rs28723506	0.0807	0.0970	64/26/2	0.0292	-0.3650	T	T	B	T	0.01	612078 [ZNF469 (confirmed) Brittle cornea syndrome 1,229200];	RCV000297953.1 [likely benign]; 			18	334					ZNF469 (inh=AR pLI=n/a)
chr16	88495407	88495407	G	C	hom	hom	hom	gene_blacklist	QUAL=5351;DP=45,50,90;MQM=59	ZNF469	missense	ZNF469:NM_001127464.2:missense:MODERATE:exon1/2:c.1529G>C:p.Gly510Ala		rs7199961	0.9916	0.9996	6667/2144/323	0.2560	0.1520	T	T	B	T	0.01	612078 [ZNF469 (confirmed) Brittle cornea syndrome 1,229200];	RCV000266943.1 [benign]; 		COSM3755187	1542	4					ZNF469 (inh=AR pLI=n/a)
chr16	88495654	88495654	A	G	hom	hom	hom	gene_blacklist	QUAL=6047;DP=51,61,100;MQM=59	ZNF469	synonymous	ZNF469:NM_001127464.2:synonymous:LOW:exon1/2:c.1776A>G:p.Pro592Pro		rs12927001	0.8748	0.9444	6586/2406/265	0.2707							612078 [ZNF469 (confirmed) Brittle cornea syndrome 1,229200];	RCV000332131.1 [benign]; 		COSM4129467	1375	174					ZNF469 (inh=AR pLI=n/a)
chr16	88496008	88496008	T	C	het	het	hom	gene_blacklist	QUAL=2465;DP=30,32,70;MQM=59	ZNF469	synonymous	ZNF469:NM_001127464.2:synonymous:LOW:exon1/2:c.2130T>C:p.Pro710Pro		rs12918876	0.6044	0.7420	3871/1356/50	0.1846							612078 [ZNF469 (confirmed) Brittle cornea syndrome 1,229200];	RCV000303039.1 [benign]; 		COSM4129468	832	583					ZNF469 (inh=AR pLI=n/a)
chr16	88497031	88497031	T	C	hom	hom	hom	low_DP;gene_blacklist	QUAL=1997;DP=4,22,40;MQM=60	ZNF469	synonymous	ZNF469:NM_001127464.2:synonymous:LOW:exon1/2:c.3153T>C:p.Ile1051Ile		rs9924504	1.0000	1.0000	5554/1442/164	0.2465							612078 [ZNF469 (confirmed) Brittle cornea syndrome 1,229200];	RCV000173219.2 [benign]; RCV000260279.1 [benign]; 			1523	1					ZNF469 (inh=AR pLI=n/a)
chr16	88497394	88497394	T	C	het	wt	het	gene_blacklist	QUAL=1597;DP=57,76,78;MQM=59	ZNF469	synonymous	ZNF469:NM_001127464.2:synonymous:LOW:exon2/2:c.3432T>C:p.Arg1144Arg		rs111557381	0.0381	0.0556	25/5/4	0.0138							612078 [ZNF469 (confirmed) Brittle cornea syndrome 1,229200];	RCV000361351.1 [benign]; RCV000381675.1 [likely benign]; 		COSM3755188	10	143					ZNF469 (inh=AR pLI=n/a)
chr16	88497400	88497400	G	A	hom	hom	hom	gene_blacklist	QUAL=6012;DP=50,76,76;MQM=59	ZNF469	synonymous	ZNF469:NM_001127464.2:synonymous:LOW:exon2/2:c.3438G>A:p.Pro1146Pro		rs9938800	0.9026	0.9603	6472/2108/248	0.2137							612078 [ZNF469 (confirmed) Brittle cornea syndrome 1,229200];	RCV000264366.1 [benign]; RCV000291992.1 [benign]; 		COSM3755189	1432	94					ZNF469 (inh=AR pLI=n/a)
chr16	88497446	88497446	A	G	het	hom	het	gene_blacklist	QUAL=4954;DP=65,86,105;MQM=59	ZNF469	missense	ZNF469:NM_001127464.2:missense:MODERATE:exon2/2:c.3484A>G:p.Lys1162Glu		rs7197071	0.8189	0.9022	6438/2480/172	0.2691	-0.3040	T	T	B	T	3.02	612078 [ZNF469 (confirmed) Brittle cornea syndrome 1,229200];	RCV000303459.1 [benign]; RCV000393906.1 [benign]; 		COSM3755190	1309	224					ZNF469 (inh=AR pLI=n/a)
chr16	88498221	88498221	C	T	hom	hom	hom	gene_blacklist;pred_pathogenic	QUAL=13563;DP=125,147,182;MQM=59	ZNF469	missense	ZNF469:NM_001127464.2:missense:MODERATE:exon2/2:c.4259C>T:p.Pro1420Leu		rs4782300	0.8442	0.8748	7440/3382/649	0.2616	2.7110	T	T	B	T	11.71	612078 [ZNF469 (confirmed) Brittle cornea syndrome 1,229200];	RCV000335231.1 [benign]; RCV000360108.1 [benign]; 		COSM3755191	1233	296					ZNF469 (inh=AR pLI=n/a)
chr16	88498297	88498297	T	G	hom	hom	hom	gene_blacklist	QUAL=19052;DP=145,239,251;MQM=59	ZNF469	synonymous	ZNF469:NM_001127464.2:synonymous:LOW:exon2/2:c.4335T>G:p.Ser1445Ser		rs12445417	0.8464	0.9278	8616/3898/311	0.2852							612078 [ZNF469 (confirmed) Brittle cornea syndrome 1,229200];	RCV000290308.1 [benign]; RCV000332940.1 [benign]; 		COSM4129472	1470	90					ZNF469 (inh=AR pLI=n/a)
chr16	88499539	88499539	C	G	hom	hom	hom	gene_blacklist	QUAL=18190;DP=252,151,190;MQM=59	ZNF469	synonymous	ZNF469:NM_001127464.2:synonymous:LOW:exon2/2:c.5577C>G:p.Thr1859Thr		rs9931465	0.7796	0.8648	7264/3417/329	0.2598							612078 [ZNF469 (confirmed) Brittle cornea syndrome 1,229200];	RCV000341186.1 [benign]; 		COSM435898	1261	274					ZNF469 (inh=AR pLI=n/a)
chr16	88501034	88501034	G	C	het	het	het	low_DP;gene_blacklist	QUAL=727;DP=47,17,10;MQM=60	ZNF469	missense	ZNF469:NM_001127464.2:missense:MODERATE:exon2/2:c.7072G>C:p.Gly2358Arg		rs12598474	0.2951	0.3093	896/513/69	0.1077	-1.1320	T	T	B	T	1.28	612078 [ZNF469 (confirmed) Brittle cornea syndrome 1,229200];	RCV000393479.1 [benign]; 		COSM472205	194	680					ZNF469 (inh=AR pLI=n/a)
chr16	88501971	88501971	T	A	het	het	het	gene_blacklist	QUAL=3792;DP=74,98,131;MQM=60	ZNF469	missense	ZNF469:NM_001127464.2:missense:MODERATE:exon2/2:c.8009T>A:p.Leu2670Gln		rs3812956	0.2943	0.3062	895/509/53	0.1063	-1.0570	T	T	B	T	0.01	612078 [ZNF469 (confirmed) Brittle cornea syndrome 1,229200];	RCV000286597.1 [benign]; RCV000330898.1 [benign]; 		COSM3755192	191	690					ZNF469 (inh=AR pLI=n/a)
chr16	88502482	88502482	C	T	het	het	het	gene_blacklist	QUAL=6290;DP=182,125,160;MQM=59	ZNF469	synonymous	ZNF469:NM_001127464.2:synonymous:LOW:exon2/2:c.8520C>T:p.Arg2840Arg		rs3812953	0.4700	0.5345	2564/900/138	0.1508							612078 [ZNF469 (confirmed) Brittle cornea syndrome 1,229200];	RCV000334561.1 [benign]; RCV000361549.1 [benign]; 		COSM435901	355	791					ZNF469 (inh=AR pLI=n/a)
chr16	88502505	88502505	A	G	hom	hom	hom	gene_blacklist;pred_pathogenic	QUAL=11651;DP=118,114,146;MQM=59	ZNF469	missense	ZNF469:NM_001127464.2:missense:MODERATE:exon2/2:c.8543A>G:p.His2848Arg		rs1983014	0.9962	0.9983	9014/3586/897	0.2909	4.7990	T	T	B	T	0.01	612078 [ZNF469 (confirmed) Brittle cornea syndrome 1,229200];	RCV000175671.1 [benign]; RCV000308538.1 [benign]; 			1563	0					ZNF469 (inh=AR pLI=n/a)
chr16	88504206	88504206	G	C	het	het	wt	gene_blacklist	QUAL=2431;DP=55,215,294;MQM=59	ZNF469	missense	ZNF469:NM_001127464.2:missense:MODERATE:exon2/2:c.10244G>C:p.Gly3415Ala		rs140056980	0.0000	0.0018	0/0/0	0.0003	0.5390	T	T	B	T	0.01	612078 [ZNF469 (confirmed) Brittle cornea syndrome 1,229200];	RCV000263311.1 [likely benign]; 			0	5					ZNF469 (inh=AR pLI=n/a)
chr16	88504850	88504850	G	C	het	het	het	gene_blacklist;pred_pathogenic	QUAL=6778;DP=130,175,230;MQM=59	ZNF469	missense	ZNF469:NM_001127464.2:missense:MODERATE:exon2/2:c.10888G>C:p.Glu3630Gln		rs1105066	0.3910	0.3255	845/368/169	0.1117	-0.5190	D	T	B	T	7.15	612078 [ZNF469 (confirmed) Brittle cornea syndrome 1,229200];	RCV000384193.1 [benign]; 			236	688					ZNF469 (inh=AR pLI=n/a)
chr16	88504868	88504868	A	G	hom	hom	hom	gene_blacklist	QUAL=14955;DP=100,168,234;MQM=59	ZNF469	missense	ZNF469:NM_001127464.2:missense:MODERATE:exon2/2:c.10906A>G:p.Thr3636Ala		rs904783	0.9992	0.9998	7998/2965/661	0.2799	-1.3970	T	T	B	T	0.03	612078 [ZNF469 (confirmed) Brittle cornea syndrome 1,229200];	RCV000175660.1 [benign]; RCV000349645.1 [benign]; 		COSM4129476	1567	0					ZNF469 (inh=AR pLI=n/a)
chr16	88505635	88505635	A	G	het	het	hom	gene_blacklist	QUAL=10113;DP=132,183,206;MQM=59	ZNF469	synonymous	ZNF469:NM_001127464.2:synonymous:LOW:exon2/2:c.11673A>G:p.Pro3891Pro		rs4782301	0.7963	0.7885	5981/2403/638	0.2412							612078 [ZNF469 (confirmed) Brittle cornea syndrome 1,229200];	RCV000325525.1 [benign]; 			970	507					ZNF469 (inh=AR pLI=n/a)
chr16	88505734	88505734	C	T	hom	hom	hom	gene_blacklist	QUAL=21675;DP=210,207,255;MQM=59	ZNF469	synonymous	ZNF469:NM_001127464.2:synonymous:LOW:exon2/2:c.11772C>T:p.Ser3924Ser		rs4782362	0.9872	0.9957	9082/3711/856	0.2868							612078 [ZNF469 (confirmed) Brittle cornea syndrome 1,229200];	RCV000329575.1 [benign]; 			1556	2					ZNF469 (inh=AR pLI=n/a)
chr16	88505748	88505748	G	A	het	het	wt	gene_blacklist	QUAL=3772;DP=176,194,234;MQM=59	ZNF469	3'UTR	ZNF469:NM_001127464.2:3'UTR:MODIFIER:exon2/2:c.*8G>A:		rs45504291	0.2214	0.2282	418/209/37	0.0700							612078 [ZNF469 (confirmed) Brittle cornea syndrome 1,229200];	RCV000386403.1 [benign]; 			105	551					ZNF469 (inh=AR pLI=n/a)
chr16	88506287	88506287	-	GCCTCCTCCCTCTGACCACAGGGTCAT	wt	het	hom	gene_blacklist	QUAL=8689;DP=70,228,242;MQM=59	ZNF469	3'UTR	ZNF469:NM_001127464.2:3'UTR:MODIFIER:exon2/2:c.*578_*604dupTCCTCCCTCTGACCACAGGGTCATGCC:		rs3838248;rs6145934	0.3968	0.0000	0/0/0	0.2448							612078 [ZNF469 (confirmed) Brittle cornea syndrome 1,229200];	RCV000406907.1 [benign]; 			5	44					ZNF469 (inh=AR pLI=n/a)
chr16	88506358	88506358	T	G	hom	hom	hom	gene_blacklist	QUAL=33589;DP=288,350,423;MQM=59	ZNF469	3'UTR	ZNF469:NM_001127464.2:3'UTR:MODIFIER:exon2/2:c.*618T>G:		rs3859020	0.9473	0.0000	0/0/0	0.8699							612078 [ZNF469 (confirmed) Brittle cornea syndrome 1,229200];	RCV000318656.1 [benign]; 			219	11					ZNF469 (inh=AR pLI=n/a)
chr16	88506528	88506528	G	A	hom	hom	hom	gene_blacklist	QUAL=21422;DP=206,214,303;MQM=59	ZNF469	3'UTR	ZNF469:NM_001127464.2:3'UTR:MODIFIER:exon2/2:c.*788G>A:		rs3894713	0.9862	0.0000	0/0/0	0.8741							612078 [ZNF469 (confirmed) Brittle cornea syndrome 1,229200];	RCV000293816.1 [benign]; 			230	0					ZNF469 (inh=AR pLI=n/a)
chr16	88506600	88506600	T	-	het	het	hom	gene_blacklist	QUAL=10381;DP=184,199,248;MQM=59	ZNF469	3'UTR	ZNF469:NM_001127464.2:3'UTR:MODIFIER:exon2/2:c.*870delT:		rs35684712	0.5501	0.0000	0/0/0	0.4404							612078 [ZNF469 (confirmed) Brittle cornea syndrome 1,229200];	RCV000290346.1 [benign]; 			87	108					ZNF469 (inh=AR pLI=n/a)
chr16	88506741	88506741	A	G	hom	hom	hom	gene_blacklist	QUAL=12053;DP=120,135,130;MQM=59	ZNF469	3'UTR	ZNF469:NM_001127464.2:3'UTR:MODIFIER:exon2/2:c.*1001A>G:		rs3848234	0.8409	0.0000	0/0/0	0.8364							612078 [ZNF469 (confirmed) Brittle cornea syndrome 1,229200];	RCV000408283.1 [benign]; 			165	60					ZNF469 (inh=AR pLI=n/a)
chr16	88709712	88709712	A	G	wt	het	wt	low_DP	QUAL=112;DP=5,10,11;MQM=60	CYBA	3'UTR	CYBA:NM_000101.3:3'UTR:MODIFIER:exon6/6:c.*49T>C:		rs7195830	0.7396	0.6718	1619/372/82	0.2985							608508 [CYBA (confirmed) Chronic granulomatous disease,autosomal,due to deficiency of CYBA,233690];				428	426					CYBA (inh=AR pLI=0.00)
chr16	88709737	88709737	C	T	wt	het	wt	low_DP	QUAL=67;DP=7,9,9;MQM=60	CYBA	3'UTR	CYBA:NM_000101.3:3'UTR:MODIFIER:exon6/6:c.*24G>A:		rs1049255	0.4692	0.5601	1482/483/39	0.2580							608508 [CYBA (confirmed) Chronic granulomatous disease,autosomal,due to deficiency of CYBA,233690];		CR995275 [CLASS=DFP MUT=ALT PHEN="Coronary artery disease increased risk association with" GENE=CYBA]; 		277	494					CYBA (inh=AR pLI=0.00)
chr16	88709828	88709828	A	G	wt	hom	wt	low_DP;pred_pathogenic	QUAL=58;DP=7,4,8;MQM=60	CYBA	missense	CYBA:NM_000101.3:missense:MODERATE:exon6/6:c.521T>C:p.Val174Ala		rs1049254	0.7374	0.6892	2750/674/136	0.2742	-1.1690	T	T	B	D	0.01	608508 [CYBA (confirmed) Chronic granulomatous disease,autosomal,due to deficiency of CYBA,233690];	RCV000179254.3 [benign]; 		COSM3749388	610	612					CYBA (inh=AR pLI=0.00)
chr16	88713236	88713236	A	G	hom	het	hom	pred_pathogenic	QUAL=21552;DP=203,328,396;MQM=59	CYBA	missense	CYBA:NM_000101.3:missense:MODERATE:exon4/6:c.214T>C:p.Tyr72His		rs4673	0.6643	0.6908	29452/14998/1554	0.6757	4.4150	T	T	D	D	11.69	608508 [CYBA (confirmed) Chronic granulomatous disease,autosomal,due to deficiency of CYBA,233690];	RCV000002351.2 [benign]; RCV000249071.1 [benign]; 	CM983302 [CLASS=DFP MUT=REF PHEN="Coronary artery disease lower risk association" GENE=CYBA]; 	COSM3755197	645	701					CYBA (inh=AR pLI=0.00)
chr16	88713501	88713501	A	G	hom	het	hom		QUAL=5378;DP=97,55,62;MQM=59	CYBA	splice_region&intron	CYBA:NM_000101.3:splice_region&intron:LOW:exon3/5:c.203+8T>C:		rs4782393	0.3660	0.4821	12972/8034/427	0.4564							608508 [CYBA (confirmed) Chronic granulomatous disease,autosomal,due to deficiency of CYBA,233690];	RCV000176978.2 [benign]; 			360	718					CYBA (inh=AR pLI=0.00)
chr16	88717386	88717386	T	C	hom	hom	hom	low_DP	QUAL=1528;DP=21,12,21;MQM=60	CYBA	synonymous	CYBA:NM_000101.3:synonymous:LOW:exon1/6:c.36A>G:p.Glu12Glu		rs8053867	0.9956	0.9991	44806/25040/3395	0.9239							608508 [CYBA (confirmed) Chronic granulomatous disease,autosomal,due to deficiency of CYBA,233690];			COSM4129484	1557	0					CYBA (inh=AR pLI=0.00)
chr16	89238190	89238190	G	A	hom	hom	het		QUAL=6483;DP=92,114,94;MQM=59	CDH15	5'UTR	CDH15:NM_004933.2:5'UTR:MODIFIER:exon1/14:c.-50G>A:		rs12927793	0.2510	0.4180	1657/1248/11	0.2741							114019 [CDH15 (provisional) Mental retardation,autosomal dominant 3,612580];				255	434					CDH15 (inh=AD pLI=0.00)
chr16	89245890	89245890	G	T	wt	wt	het		QUAL=1022;DP=47,93,99;MQM=60	CDH15	missense	CDH15:NM_004933.2:missense:MODERATE:exon2/14:c.109G>T:p.Ala37Ser		rs2287359	0.1687	0.1132	1529/138/12	0.1128	-0.4470	T	T	B	T	0.01	114019 [CDH15 (provisional) Mental retardation,autosomal dominant 3,612580];	RCV000116614.2 [likely benign]; 		COSM4129509	26	266					CDH15 (inh=AD pLI=0.00)
chr16	89246670	89246670	T	C	wt	wt	het		QUAL=2887;DP=175,191,243;MQM=60	CDH15	synonymous	CDH15:NM_004933.2:synonymous:LOW:exon3/14:c.264T>C:p.Asp88Asp		rs59865771	0.4309	0.3565	7238/2026/391	0.3298							114019 [CDH15 (provisional) Mental retardation,autosomal dominant 3,612580];	RCV000116623.2 [likely benign]; 		COSM3773766	159	598					CDH15 (inh=AD pLI=0.00)
chr16	89256695	89256695	G	A	wt	wt	het		QUAL=2250;DP=101,135,195;MQM=60	CDH15	synonymous	CDH15:NM_004933.2:synonymous:LOW:exon8/14:c.1023G>A:p.Ser341Ser		rs72819366	0.1755	0.1939	2125/1150/26	0.1844							114019 [CDH15 (provisional) Mental retardation,autosomal dominant 3,612580];	RCV000116613.2 [likely benign]; 			76	496					CDH15 (inh=AD pLI=0.00)
chr16	89259993	89259993	A	G	wt	wt	het		QUAL=996;DP=38,60,82;MQM=60	CDH15	synonymous	CDH15:NM_004933.2:synonymous:LOW:exon12/14:c.1971A>G:p.Gln657Gln		rs3815615	0.4998	0.5074	11482/5264/516	0.4175							114019 [CDH15 (provisional) Mental retardation,autosomal dominant 3,612580];	RCV000116619.2 [likely benign]; 		COSM3755229	356	691					CDH15 (inh=AD pLI=0.00)
chr16	89597221	89597221	A	G	het	hom	het		QUAL=18013;DP=143,367,451;MQM=59	SPG7	splice_region&intron	SPG7:NM_003119.3:splice_region&intron:LOW:exon7/16:c.987+5A>G:,SPG7:NM_199367.2:splice_region&intron:LOW:exon7/9:c.987+5A>G:		rs4785691	0.5294	0.4731	14027/6950/910	0.4472							602783 [SPG7 (provisional) Spastic paraplegia 7,autosomal recessive,607259];	RCV000251593.1 [benign]; RCV000298634.1 [benign]; 			744	1437					SPG7 (inh=AR+AD pLI=0.00)
chr16	89603586	89603586	A	G	het	hom	het		QUAL=6304;DP=147,101,140;MQM=59	SPG7	3'UTR,intron	SPG7:NM_199367.2:3'UTR:MODIFIER:exon10/10:c.*268A>G:,SPG7:NM_003119.3:intron:MODIFIER:exon9/16:c.1324+4542A>G:		rs382745	0.5387	0.0000	0/0/0	0.3659							602783 [SPG7 (provisional) Spastic paraplegia 7,autosomal recessive,607259];				53	119					SPG7 (inh=AR+AD pLI=0.00)
chr16	89603698	89603698	-	T	het	wt	het		QUAL=2982;DP=132,84,116;MQM=60	SPG7	3'UTR,intron	SPG7:NM_199367.2:3'UTR:MODIFIER:exon10/10:c.*380_*381insT:,SPG7:NM_003119.3:intron:MODIFIER:exon9/16:c.1324+4654_1324+4655insT:		rs3833827	0.4359	0.0000	0/0/0	0.4776							602783 [SPG7 (provisional) Spastic paraplegia 7,autosomal recessive,607259];				58	120					SPG7 (inh=AR+AD pLI=0.00)
chr16	89623746	89623746	G	T	het	wt	het		QUAL=4168;DP=221,121,141;MQM=60	SPG7	3'UTR	SPG7:NM_003119.3:3'UTR:MODIFIER:exon17/17:c.*245G>T:		rs780776019	0.0000	0.0000	0/0/0	0.0001							602783 [SPG7 (provisional) Spastic paraplegia 7,autosomal recessive,607259];				0	2					SPG7 (inh=AR+AD pLI=0.00)
chr16	89804336	89804336	T	-	het	wt	het		QUAL=5699;DP=227,234,298;MQM=59	FANCA,ZNF276	3'UTR,intron	FANCA:NM_000135.2:3'UTR:MODIFIER:exon43/43:c.*673delA:,FANCA:NM_001286167.1:3'UTR:MODIFIER:exon43/43:c.*770delA:,ZNF276:NM_001113525.1:intron:MODIFIER:exon10/10:c.1574+23delT:,ZNF276:NR_110128.1:intron:MODIFIER:exon10/10:n.1552+23delT:,ZNF276:NR_110122.1:intron:MODIFIER:exon10/10:n.1746+23delT:,ZNF276:NR_110126.1:intron:MODIFIER:exon10/10:n.1629+23delT:,ZNF276:NM_152287.3:intron:MODIFIER:exon10/10:c.1349+23delT:,ZNF276:NR_110129.1:intron:MODIFIER:exon10/10:n.1641+23delT:		rs17233826	0.0000	0.4862	16320/4399/2087	0.4356							607139 [FANCA (confirmed) Fanconi anemia,complementation group A,227650];	RCV000297540.1 [benign]; 			179	354					FANCA (inh=AR pLI=0.00), ZNF276 (inh=n/a pLI=0.00)
chr16	89804855	89804855	C	T	het	wt	het		QUAL=9522;DP=319,332,447;MQM=60	ZNF276,FANCA	3'UTR,non_coding_transcript_exon	ZNF276:NM_001113525.1:3'UTR:MODIFIER:exon11/11:c.*201C>T:,FANCA:NM_000135.2:3'UTR:MODIFIER:exon43/43:c.*154G>A:,ZNF276:NM_152287.3:3'UTR:MODIFIER:exon11/11:c.*201C>T:,FANCA:NM_001286167.1:3'UTR:MODIFIER:exon43/43:c.*251G>A:,ZNF276:NR_110128.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.2024C>T:,ZNF276:NR_110122.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.2218C>T:,ZNF276:NR_110126.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.2101C>T:,ZNF276:NR_110129.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.2113C>T:		rs1230	0.6977	0.0000	0/0/0	0.0804							607139 [FANCA (confirmed) Fanconi anemia,complementation group A,227650];	RCV000339087.1 [benign]; 			25	69					ZNF276 (inh=n/a pLI=0.00), FANCA (inh=AR pLI=0.00)
chr16	89836323	89836323	C	T	het	wt	het	pred_pathogenic	QUAL=6396;DP=219,203,270;MQM=59	FANCA	missense	FANCA:NM_000135.2:missense:MODERATE:exon26/43:c.2426G>A:p.Gly809Asp,FANCA:NM_001286167.1:missense:MODERATE:exon26/43:c.2426G>A:p.Gly809Asp		rs7195066	0.6667	0.4690	16070/3144/2387	0.4485	0.3050	T	T	B,B	D	3.27	607139 [FANCA (confirmed) Fanconi anemia,complementation group A,227650];	RCV000120927.2 [benign]; RCV000292806.1 [benign]; 	CM137288 [CLASS=R MUT=ALT PHEN="Fanconi anaemia A" GENE=FANCA]; 	COSM435949	437	1430	2	[2] old entry - no details available			FANCA (inh=AR pLI=0.00)
chr16	89838078	89838078	A	G	het	wt	het		QUAL=4280;DP=134,197,251;MQM=59	FANCA	splice_region&intron	FANCA:NM_000135.2:splice_region&intron:LOW:exon23/42:c.2151+8T>C:,FANCA:NM_001286167.1:splice_region&intron:LOW:exon23/42:c.2151+8T>C:		rs1800340	0.5599	0.4315	12977/3039/1411	0.4236							607139 [FANCA (confirmed) Fanconi anemia,complementation group A,227650];	RCV000244957.1 [benign]; RCV000398159.1 [benign]; 			377	1424	1	[1] Ilnaz Sepahi 29-03-2016 batch import			FANCA (inh=AR pLI=0.00)
chr16	89849480	89849480	C	T	het	wt	het	pred_pathogenic	QUAL=7910;DP=244,273,319;MQM=60	FANCA	missense	FANCA:NM_000135.2:missense:MODERATE:exon16/43:c.1501G>A:p.Gly501Ser,FANCA:NM_001286167.1:missense:MODERATE:exon16/43:c.1501G>A:p.Gly501Ser		rs2239359	0.6240	0.4995	16447/5298/2452	0.4917	-0.0380	T	T	B,B	D	0.07	607139 [FANCA (confirmed) Fanconi anemia,complementation group A,227650];	RCV000120917.3 [benign]; RCV000389853.1 [benign]; 	CM137880 [CLASS=DP MUT=ALT PHEN="Breast cancer association with" GENE=FANCA]; 		584	1595	1	[1] Ilnaz Sepahi 29-03-2016 batch import			FANCA (inh=AR pLI=0.00)
chr16	89865103	89865103	T	A	het	wt	het		QUAL=10095;DP=416,318,411;MQM=60	FANCA	3'UTR,intron	FANCA:NM_001018112.1:3'UTR:MODIFIER:exon11/11:c.*384A>T:,FANCA:NM_000135.2:intron:MODIFIER:exon10/42:c.893+471A>T:,FANCA:NM_001286167.1:intron:MODIFIER:exon10/42:c.893+471A>T:		rs11076626	0.6913	0.0000	0/0/0	0.4746							607139 [FANCA (confirmed) Fanconi anemia,complementation group A,227650];				49	98					FANCA (inh=AR pLI=0.00)
chr16	89865242	89865242	T	C	het	wt	het		QUAL=5611;DP=230,193,249;MQM=60	FANCA	3'UTR,intron	FANCA:NM_001018112.1:3'UTR:MODIFIER:exon11/11:c.*245A>G:,FANCA:NM_000135.2:intron:MODIFIER:exon10/42:c.893+332A>G:,FANCA:NM_001286167.1:intron:MODIFIER:exon10/42:c.893+332A>G:		rs10852623	0.6871	0.0000	0/0/0	0.4734							607139 [FANCA (confirmed) Fanconi anemia,complementation group A,227650];				48	99					FANCA (inh=AR pLI=0.00)
chr16	89866043	89866043	T	C	het	wt	het		QUAL=8225;DP=305,244,334;MQM=59	FANCA	missense	FANCA:NM_000135.2:missense:MODERATE:exon9/43:c.796A>G:p.Thr266Ala,FANCA:NM_001286167.1:missense:MODERATE:exon9/43:c.796A>G:p.Thr266Ala,FANCA:NM_001018112.1:missense:MODERATE:exon9/11:c.796A>G:p.Thr266Ala		rs7190823	0.6905	0.5166	18422/4824/2761	0.4992	0.4020	T,T,T,T	T	B,B,B,B,B,B	T,T,T,T	0.01	607139 [FANCA (confirmed) Fanconi anemia,complementation group A,227650];	RCV000120967.2 [benign]; RCV000308742.1 [benign]; 	CM137879 [CLASS=DP MUT=ALT PHEN="Breast cancer association with" GENE=FANCA]; 		577	1538	1	[1] Ilnaz Sepahi 29-03-2016 batch import			FANCA (inh=AR pLI=0.00)
chr17	1247850	1247851	AG	-	het	het	wt		QUAL=3405;DP=240,108,132;MQM=59	YWHAE	3'UTR,non_coding_transcript_exon	YWHAE:NM_006761.4:3'UTR:MODIFIER:exon6/6:c.*890_*891delCT:,YWHAE:NR_024058.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.1843_1844delCT:	(TTTAAG)n	rs147204530	0.0379	0.0000	0/0/0	0.0513											3	26					YWHAE (inh=n/a pLI=0.96)
chr17	1248392	1248392	A	G	wt	het	wt		QUAL=2368;DP=261,153,181;MQM=60	YWHAE	3'UTR,non_coding_transcript_exon	YWHAE:NM_006761.4:3'UTR:MODIFIER:exon6/6:c.*349T>C:,YWHAE:NR_024058.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.1302T>C:		rs9393	0.1540	0.0000	0/0/0	0.0230											1	47					YWHAE (inh=n/a pLI=0.96)
chr17	1248466	1248466	C	T	het	het	wt		QUAL=4907;DP=355,118,160;MQM=60	YWHAE	3'UTR,non_coding_transcript_exon	YWHAE:NM_006761.4:3'UTR:MODIFIER:exon6/6:c.*275G>A:,YWHAE:NR_024058.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.1228G>A:		rs7266	0.0379	0.0000	0/0/0	0.0089											3	26					YWHAE (inh=n/a pLI=0.96)
chr17	2586229	2586229	A	G	het	het	hom		QUAL=25193;DP=581,323,418;MQM=60	PAFAH1B1	3'UTR	PAFAH1B1:NM_000430.3:3'UTR:MODIFIER:exon11/11:c.*1133A>G:		rs4790356	0.8367	0.0000	0/0/0	0.8885							601545 [PAFAH1B1 (confirmed) Lissencephaly 1,607432|Subcortical laminar heterotopia,607432];	RCV000365404.1 [benign]; 			193	37					PAFAH1B1 (inh=AR+AD pLI=1.00)
chr17	2588917	2588931	TTTTTTTTTTTTTTT	-	hom	het	hom	low_DP	QUAL=393;DP=20,11,9;MQM=59	PAFAH1B1-CLUH	intergenic_region	PAFAH1B1-CLUH:PAFAH1B1-CLUH:intergenic_region:MODIFIER::n.2588917_2588931delTTTTTTTTTTTTTTT:	(T)n	rs200593896;rs749202525;rs780861755	0.9982	0.0000	0/0/0	0.4472							601545 [PAFAH1B1 (confirmed) Lissencephaly 1,607432|Subcortical laminar heterotopia,607432];				53	15					PAFAH1B1-CLUH (inh=n/a pLI=n/a)
chr17	3377396	3377396	C	G	hom	het	hom		QUAL=12534;DP=210,108,132;MQM=60	SPATA22	intron	SPATA22:NM_001321336.1:intron:MODIFIER:exon1/8:c.-73-4704G>C:,SPATA22:NM_001321337.1:intron:MODIFIER:exon1/8:c.-73-4704G>C:		rs11078450	0.1945	0.0000	0/0/0	0.2096							608034 [ASPA (confirmed) Canavan disease,271900];				56	93					SPATA22 (inh=n/a pLI=0.00)
chr17	3402521	3402521	C	A	hom	hom	hom		QUAL=12679;DP=205,88,108;MQM=59	ASPA,SPATA22	3'UTR,intron	ASPA:NM_000049.2:3'UTR:MODIFIER:exon6/6:c.*139C>A:,ASPA:NM_001128085.1:3'UTR:MODIFIER:exon7/7:c.*139C>A:,SPATA22:NM_001321336.1:intron:MODIFIER:exon1/8:c.-74+14185G>T:,SPATA22:NM_001321337.1:intron:MODIFIER:exon1/8:c.-74+14185G>T:	L2d2	rs1552830	0.9992	0.0000	0/0/0	0.1419							608034 [ASPA (confirmed) Canavan disease,271900];				230	0					ASPA (inh=AR pLI=0.01), SPATA22 (inh=n/a pLI=0.00)
chr17	3540042	3540042	G	A	het	het	wt		QUAL=3120;DP=145,111,121;MQM=59	CTNS	5'UTR,intron	CTNS:NM_004937.2:5'UTR:MODIFIER:exon1/12:c.-313G>A:,CTNS:NM_001031681.2:intron:MODIFIER:exon1/12:c.-230+40G>A:		rs17707869	0.1540	0.0000	0/0/0	0.1721							606272 [CTNS (confirmed) Cystinosis,nephropathic,219800|Cystinosis,ocular nonnephropathic,219750|Cystinosis,late-onset juvenile or adolescent nephropathic,219900|Cystinosis,atypical nephropathic,219800];	RCV000370497.1 [likely benign]; RCV000401897.1 [likely benign]; 			8	62					CTNS (inh=AR pLI=0.03)
chr17	3559823	3559823	G	A	het	het	wt		QUAL=5371;DP=196,303,423;MQM=60	CTNS	synonymous	CTNS:NM_001031681.2:synonymous:LOW:exon8/13:c.504G>A:p.Thr168Thr,CTNS:NM_004937.2:synonymous:LOW:exon8/12:c.504G>A:p.Thr168Thr		rs1800528	0.1506	0.1864	2052/1095/9	0.1743							606272 [CTNS (confirmed) Cystinosis,nephropathic,219800|Cystinosis,ocular nonnephropathic,219750|Cystinosis,late-onset juvenile or adolescent nephropathic,219900|Cystinosis,atypical nephropathic,219800];	RCV000246446.1 [benign]; RCV000277810.1 [likely benign]; RCV000370416.1 [likely benign]; 			60	439					CTNS (inh=AR pLI=0.03)
chr17	3561396	3561396	C	T	hom	hom	hom	pred_pathogenic	QUAL=32296;DP=251,325,470;MQM=59	CTNS	missense	CTNS:NM_001031681.2:missense:MODERATE:exon10/13:c.779C>T:p.Thr260Ile,CTNS:NM_004937.2:missense:MODERATE:exon10/12:c.779C>T:p.Thr260Ile		rs161400	0.8183	0.9183	51792/30388/1763	0.9114	2.3950	T,T,T,T	T	B,B,B	D,D,D,D	11.82	606272 [CTNS (confirmed) Cystinosis,nephropathic,219800|Cystinosis,ocular nonnephropathic,219750|Cystinosis,late-onset juvenile or adolescent nephropathic,219900|Cystinosis,atypical nephropathic,219800];	RCV000248355.1 [benign]; RCV000339531.1 [benign]; RCV000380229.1 [benign]; 			1373	178					CTNS (inh=AR pLI=0.03)
chr17	3563963	3563963	C	G	wt	het	wt	pred_pathogenic	QUAL=357;DP=190,46,61;MQM=60	CTNS	missense,3'UTR	CTNS:NM_001031681.2:missense:MODERATE:exon13/13:c.1138C>G:p.Pro380Ala,CTNS:NM_004937.2:3'UTR:MODIFIER:exon12/12:c.*300C>G:		rs2873624	0.2286	0.2514	4367/2008/10	0.2483	0.3280	T,T	T	B,B	D,D	0.01	606272 [CTNS (confirmed) Cystinosis,nephropathic,219800|Cystinosis,ocular nonnephropathic,219750|Cystinosis,late-onset juvenile or adolescent nephropathic,219900|Cystinosis,atypical nephropathic,219800];	RCV000252728.1 [benign]; RCV000294120.1 [benign]; RCV000348863.1 [benign]; 		COSM3721369	105	548					CTNS (inh=AR pLI=0.03)
chr17	3564068	3564068	G	A	het	het	wt		QUAL=2368;DP=161,71,87;MQM=59	CTNS	3'UTR	CTNS:NM_001031681.2:3'UTR:MODIFIER:exon13/13:c.*40G>A:,CTNS:NM_004937.2:3'UTR:MODIFIER:exon12/12:c.*405G>A:		rs760273	0.1973	0.2117	2562/1313/86	0.2011							606272 [CTNS (confirmed) Cystinosis,nephropathic,219800|Cystinosis,ocular nonnephropathic,219750|Cystinosis,late-onset juvenile or adolescent nephropathic,219900|Cystinosis,atypical nephropathic,219800];	RCV000295137.1 [likely benign]; RCV000399422.1 [likely benign]; 			41	282					CTNS (inh=AR pLI=0.03)
chr17	3564073	3564073	A	G	het	het	wt		QUAL=2522;DP=166,71,89;MQM=59	CTNS	3'UTR	CTNS:NM_001031681.2:3'UTR:MODIFIER:exon13/13:c.*45A>G:,CTNS:NM_004937.2:3'UTR:MODIFIER:exon12/12:c.*410A>G:		rs3826496	0.1977	0.2118	2543/1297/85	0.2010							606272 [CTNS (confirmed) Cystinosis,nephropathic,219800|Cystinosis,ocular nonnephropathic,219750|Cystinosis,late-onset juvenile or adolescent nephropathic,219900|Cystinosis,atypical nephropathic,219800];	RCV000336136.1 [likely benign]; RCV000394000.1 [likely benign]; 			41	283					CTNS (inh=AR pLI=0.03)
chr17	3564084	3564084	T	C	het	het	wt		QUAL=2312;DP=158,71,96;MQM=59	CTNS	3'UTR	CTNS:NM_001031681.2:3'UTR:MODIFIER:exon13/13:c.*56T>C:,CTNS:NM_004937.2:3'UTR:MODIFIER:exon12/12:c.*421T>C:		rs760274	0.1973	0.0000	0/0/0	0.0373							606272 [CTNS (confirmed) Cystinosis,nephropathic,219800|Cystinosis,ocular nonnephropathic,219750|Cystinosis,late-onset juvenile or adolescent nephropathic,219900|Cystinosis,atypical nephropathic,219800];	RCV000301323.1 [likely benign]; RCV000356111.1 [likely benign]; 			41	282					CTNS (inh=AR pLI=0.03)
chr17	3564218	3564218	T	C	het	het	wt		QUAL=4072;DP=258,187,276;MQM=60	CTNS	3'UTR	CTNS:NM_001031681.2:3'UTR:MODIFIER:exon13/13:c.*190T>C:,CTNS:NM_004937.2:3'UTR:MODIFIER:exon12/12:c.*555T>C:		rs1048646	0.1983	0.0000	0/0/0	0.2124							606272 [CTNS (confirmed) Cystinosis,nephropathic,219800|Cystinosis,ocular nonnephropathic,219750|Cystinosis,late-onset juvenile or adolescent nephropathic,219900|Cystinosis,atypical nephropathic,219800];	RCV000327154.1 [likely benign]; RCV000362176.1 [likely benign]; 			10	79					CTNS (inh=AR pLI=0.03)
chr17	3564235	3564235	A	G	het	het	wt		QUAL=5451;DP=325,209,302;MQM=60	CTNS	3'UTR	CTNS:NM_001031681.2:3'UTR:MODIFIER:exon13/13:c.*207A>G:,CTNS:NM_004937.2:3'UTR:MODIFIER:exon12/12:c.*572A>G:		rs3826493	0.2053	0.0000	0/0/0	0.0365							606272 [CTNS (confirmed) Cystinosis,nephropathic,219800|Cystinosis,ocular nonnephropathic,219750|Cystinosis,late-onset juvenile or adolescent nephropathic,219900|Cystinosis,atypical nephropathic,219800];	RCV000272228.1 [likely benign]; RCV000327354.1 [likely benign]; 			10	78					CTNS (inh=AR pLI=0.03)
chr17	3564290	3564290	T	C	het	het	wt		QUAL=6664;DP=348,203,294;MQM=59	CTNS	3'UTR	CTNS:NM_001031681.2:3'UTR:MODIFIER:exon13/13:c.*262T>C:,CTNS:NM_004937.2:3'UTR:MODIFIER:exon12/12:c.*627T>C:	L3	rs1048647	0.1983	0.0000	0/0/0	0.0361							606272 [CTNS (confirmed) Cystinosis,nephropathic,219800|Cystinosis,ocular nonnephropathic,219750|Cystinosis,late-onset juvenile or adolescent nephropathic,219900|Cystinosis,atypical nephropathic,219800];	RCV000334075.1 [likely benign]; RCV000388542.1 [likely benign]; 			10	75					CTNS (inh=AR pLI=0.03)
chr17	3564294	3564294	T	C	het	het	wt		QUAL=6664;DP=348,203,294;MQM=59	CTNS	3'UTR	CTNS:NM_001031681.2:3'UTR:MODIFIER:exon13/13:c.*266T>C:,CTNS:NM_004937.2:3'UTR:MODIFIER:exon12/12:c.*631T>C:	L3	rs1048648	0.1981	0.0000	0/0/0	0.0361							606272 [CTNS (confirmed) Cystinosis,nephropathic,219800|Cystinosis,ocular nonnephropathic,219750|Cystinosis,late-onset juvenile or adolescent nephropathic,219900|Cystinosis,atypical nephropathic,219800];	RCV000280141.1 [likely benign]; RCV000335091.1 [likely benign]; 			10	76					CTNS (inh=AR pLI=0.03)
chr17	3564378	3564378	C	T	het	het	wt		QUAL=6133;DP=261,184,245;MQM=59	CTNS	3'UTR	CTNS:NM_001031681.2:3'UTR:MODIFIER:exon13/13:c.*350C>T:,CTNS:NM_004937.2:3'UTR:MODIFIER:exon12/12:c.*715C>T:		rs1048649	0.1967	0.0000	0/0/0	0.2117							606272 [CTNS (confirmed) Cystinosis,nephropathic,219800|Cystinosis,ocular nonnephropathic,219750|Cystinosis,late-onset juvenile or adolescent nephropathic,219900|Cystinosis,atypical nephropathic,219800];	RCV000340873.1 [likely benign]; RCV000407349.1 [likely benign]; 			10	73					CTNS (inh=AR pLI=0.03)
chr17	3564400	3564400	T	A	wt	het	wt		QUAL=22530;DP=274,176,260;MQM=60	CTNS	3'UTR	CTNS:NM_001031681.2:3'UTR:MODIFIER:exon13/13:c.*372T>A:,CTNS:NM_004937.2:3'UTR:MODIFIER:exon12/12:c.*737T>A:		rs222754	0.2903	0.0000	0/0/0	0.2030							606272 [CTNS (confirmed) Cystinosis,nephropathic,219800|Cystinosis,ocular nonnephropathic,219750|Cystinosis,late-onset juvenile or adolescent nephropathic,219900|Cystinosis,atypical nephropathic,219800];	RCV000305693.1 [benign]; RCV000341913.1 [benign]; 			23	83					CTNS (inh=AR pLI=0.03)
chr17	3564401	3564401	T	G	hom	hom	hom		QUAL=22530;DP=274,176,260;MQM=60	CTNS	3'UTR	CTNS:NM_001031681.2:3'UTR:MODIFIER:exon13/13:c.*373T>G:,CTNS:NM_004937.2:3'UTR:MODIFIER:exon12/12:c.*738T>G:		rs224562	0.9954	0.0000	0/0/0	0.1925							606272 [CTNS (confirmed) Cystinosis,nephropathic,219800|Cystinosis,ocular nonnephropathic,219750|Cystinosis,late-onset juvenile or adolescent nephropathic,219900|Cystinosis,atypical nephropathic,219800];	RCV000310153.1 [benign]; RCV000407354.1 [benign]; 			229	1					CTNS (inh=AR pLI=0.03)
chr17	3564510	3564510	C	T	wt	het	wt		QUAL=3498;DP=190,341,457;MQM=60	CTNS	3'UTR	CTNS:NM_001031681.2:3'UTR:MODIFIER:exon13/13:c.*482C>T:,CTNS:NM_004937.2:3'UTR:MODIFIER:exon12/12:c.*847C>T:		rs146131305	0.0046	0.0000	0/0/0	0.0016							606272 [CTNS (confirmed) Cystinosis,nephropathic,219800|Cystinosis,ocular nonnephropathic,219750|Cystinosis,late-onset juvenile or adolescent nephropathic,219900|Cystinosis,atypical nephropathic,219800];	RCV000274790.1 [uncertain significance]; RCV000364784.1 [uncertain significance]; 			0	5					CTNS (inh=AR pLI=0.03)
chr17	3564687	3564687	C	T	het	het	wt		QUAL=4156;DP=174,298,492;MQM=59	CTNS	3'UTR	CTNS:NM_001031681.2:3'UTR:MODIFIER:exon13/13:c.*659C>T:,CTNS:NM_004937.2:3'UTR:MODIFIER:exon12/12:c.*1024C>T:		rs1048673	0.1947	0.0000	0/0/0	0.0593							606272 [CTNS (confirmed) Cystinosis,nephropathic,219800|Cystinosis,ocular nonnephropathic,219750|Cystinosis,late-onset juvenile or adolescent nephropathic,219900|Cystinosis,atypical nephropathic,219800];	RCV000283184.1 [likely benign]; RCV000342825.1 [likely benign]; 			12	76					CTNS (inh=AR pLI=0.03)
chr17	3564688	3564688	A	G	het	het	wt		QUAL=4156;DP=174,298,492;MQM=59	CTNS	3'UTR	CTNS:NM_001031681.2:3'UTR:MODIFIER:exon13/13:c.*660A>G:,CTNS:NM_004937.2:3'UTR:MODIFIER:exon12/12:c.*1025A>G:		rs1048674	0.1939	0.0000	0/0/0	0.0598							606272 [CTNS (confirmed) Cystinosis,nephropathic,219800|Cystinosis,ocular nonnephropathic,219750|Cystinosis,late-onset juvenile or adolescent nephropathic,219900|Cystinosis,atypical nephropathic,219800];	RCV000288903.1 [likely benign]; RCV000378727.1 [likely benign]; 			12	76					CTNS (inh=AR pLI=0.03)
chr17	3564693	3564693	-	GTC	het	het	wt		QUAL=2232;DP=158,261,481;MQM=59	CTNS	3'UTR	CTNS:NM_001031681.2:3'UTR:MODIFIER:exon13/13:c.*666_*668dupGTC:,CTNS:NM_004937.2:3'UTR:MODIFIER:exon12/12:c.*1031_*1033dupGTC:		rs397831765	0.1923	0.0000	0/0/0	0.1196							606272 [CTNS (confirmed) Cystinosis,nephropathic,219800|Cystinosis,ocular nonnephropathic,219750|Cystinosis,late-onset juvenile or adolescent nephropathic,219900|Cystinosis,atypical nephropathic,219800];				12	73					CTNS (inh=AR pLI=0.03)
chr17	3564711	3564711	-	G	wt	het	wt		QUAL=385;DP=170,252,436;MQM=59	CTNS	3'UTR	CTNS:NM_001031681.2:3'UTR:MODIFIER:exon13/13:c.*687dupG:,CTNS:NM_004937.2:3'UTR:MODIFIER:exon12/12:c.*1052dupG:		rs71379527	0.0000	0.0000	0/0/0	0.0182							606272 [CTNS (confirmed) Cystinosis,nephropathic,219800|Cystinosis,ocular nonnephropathic,219750|Cystinosis,late-onset juvenile or adolescent nephropathic,219900|Cystinosis,atypical nephropathic,219800];				0	26					CTNS (inh=AR pLI=0.03)
chr17	3564716	3564716	T	G	het	het	wt		QUAL=4836;DP=198,252,417;MQM=59	CTNS	3'UTR	CTNS:NM_001031681.2:3'UTR:MODIFIER:exon13/13:c.*688T>G:,CTNS:NM_004937.2:3'UTR:MODIFIER:exon12/12:c.*1053T>G:		rs1048677	0.0000	0.0000	0/0/0	0.0070							606272 [CTNS (confirmed) Cystinosis,nephropathic,219800|Cystinosis,ocular nonnephropathic,219750|Cystinosis,late-onset juvenile or adolescent nephropathic,219900|Cystinosis,atypical nephropathic,219800];	RCV000297583.1 [uncertain significance]; RCV000357390.1 [uncertain significance]; 			12	76					CTNS (inh=AR pLI=0.03)
chr17	3564779	3564779	C	T	het	het	wt		QUAL=3635;DP=220,202,343;MQM=59	CTNS	3'UTR	CTNS:NM_001031681.2:3'UTR:MODIFIER:exon13/13:c.*751C>T:,CTNS:NM_004937.2:3'UTR:MODIFIER:exon12/12:c.*1116C>T:		rs1048682	0.1929	0.0000	0/0/0	0.0349							606272 [CTNS (confirmed) Cystinosis,nephropathic,219800|Cystinosis,ocular nonnephropathic,219750|Cystinosis,late-onset juvenile or adolescent nephropathic,219900|Cystinosis,atypical nephropathic,219800];	RCV000262579.1 [likely benign]; RCV000322275.1 [likely benign]; 			11	76					CTNS (inh=AR pLI=0.03)
chr17	3564815	3564815	A	G	het	het	wt		QUAL=3392;DP=233,158,287;MQM=59	CTNS	3'UTR	CTNS:NM_001031681.2:3'UTR:MODIFIER:exon13/13:c.*787A>G:,CTNS:NM_004937.2:3'UTR:MODIFIER:exon12/12:c.*1152A>G:		rs2235104	0.1871	0.0000	0/0/0	0.0348							606272 [CTNS (confirmed) Cystinosis,nephropathic,219800|Cystinosis,ocular nonnephropathic,219750|Cystinosis,late-onset juvenile or adolescent nephropathic,219900|Cystinosis,atypical nephropathic,219800];	RCV000288599.1 [likely benign]; RCV000345907.1 [likely benign]; 			12	75					CTNS (inh=AR pLI=0.03)
chr17	3564837	3564838	CT	-	het	het	wt		QUAL=3439;DP=287,140,255;MQM=59	CTNS	3'UTR	CTNS:NM_001031681.2:3'UTR:MODIFIER:exon13/13:c.*811_*812delCT:,CTNS:NM_004937.2:3'UTR:MODIFIER:exon12/12:c.*1176_*1177delCT:		rs397857879	0.1931	0.0000	0/0/0	0.1885							606272 [CTNS (confirmed) Cystinosis,nephropathic,219800|Cystinosis,ocular nonnephropathic,219750|Cystinosis,late-onset juvenile or adolescent nephropathic,219900|Cystinosis,atypical nephropathic,219800];	RCV000351600.1 [likely benign]; RCV000399291.1 [likely benign]; 			12	75					CTNS (inh=AR pLI=0.03)
chr17	3565103	3565103	A	G	het	hom	wt		QUAL=5089;DP=146,109,159;MQM=59	CTNS	3'UTR	CTNS:NM_001031681.2:3'UTR:MODIFIER:exon13/13:c.*1075A>G:,CTNS:NM_004937.2:3'UTR:MODIFIER:exon12/12:c.*1440A>G:		rs161398	0.7420	0.0000	0/0/0	0.6885							606272 [CTNS (confirmed) Cystinosis,nephropathic,219800|Cystinosis,ocular nonnephropathic,219750|Cystinosis,late-onset juvenile or adolescent nephropathic,219900|Cystinosis,atypical nephropathic,219800];	RCV000279748.1 [benign]; RCV000371865.1 [benign]; 			104	98					CTNS (inh=AR pLI=0.03)
chr17	3565606	3565606	A	-	hom	hom	hom		QUAL=8480;DP=156,101,164;MQM=58	CTNS	3'UTR	CTNS:NM_001031681.2:3'UTR:MODIFIER:exon13/13:c.*1592delA:,CTNS:NM_004937.2:3'UTR:MODIFIER:exon12/12:c.*1957delA:	AluSq2	rs397856854	0.4742	0.0000	0/0/0	0.4643							606272 [CTNS (confirmed) Cystinosis,nephropathic,219800|Cystinosis,ocular nonnephropathic,219750|Cystinosis,late-onset juvenile or adolescent nephropathic,219900|Cystinosis,atypical nephropathic,219800];	RCV000312044.1 [benign]; RCV000389998.1 [benign]; 			31	193					CTNS (inh=AR pLI=0.03)
chr17	3565969	3565969	T	C	hom	hom	hom		QUAL=21427;DP=210,219,261;MQM=59	CTNS	3'UTR	CTNS:NM_001031681.2:3'UTR:MODIFIER:exon13/13:c.*1941T>C:,CTNS:NM_004937.2:3'UTR:MODIFIER:exon12/12:c.*2306T>C:		rs161397	0.6384	0.0000	0/0/0	0.7702							606272 [CTNS (confirmed) Cystinosis,nephropathic,219800|Cystinosis,ocular nonnephropathic,219750|Cystinosis,late-onset juvenile or adolescent nephropathic,219900|Cystinosis,atypical nephropathic,219800];	RCV000347864.1 [benign]; RCV000386826.1 [benign]; 			156	67					CTNS (inh=AR pLI=0.03)
chr17	3566045	3566045	-	C	hom	hom	hom		QUAL=12318;DP=125,136,154;MQM=59	CTNS	3'UTR	CTNS:NM_001031681.2:3'UTR:MODIFIER:exon13/13:c.*2018dupC:,CTNS:NM_004937.2:3'UTR:MODIFIER:exon12/12:c.*2383dupC:		rs397702352	0.7676	0.0000	0/0/0	0.7613							606272 [CTNS (confirmed) Cystinosis,nephropathic,219800|Cystinosis,ocular nonnephropathic,219750|Cystinosis,late-onset juvenile or adolescent nephropathic,219900|Cystinosis,atypical nephropathic,219800];				166	59					CTNS (inh=AR pLI=0.03)
chr17	3566232	3566232	C	T	het	hom	wt		QUAL=6203;DP=252,113,126;MQM=59	CTNS,TAX1BP3,P2RX5-TAX1BP3	3'UTR,non_coding_transcript_exon	CTNS:NM_001031681.2:3'UTR:MODIFIER:exon13/13:c.*2204C>T:,TAX1BP3:NM_014604.3:3'UTR:MODIFIER:exon4/4:c.*810G>A:,CTNS:NM_004937.2:3'UTR:MODIFIER:exon12/12:c.*2569C>T:,TAX1BP3:NM_001204698.1:3'UTR:MODIFIER:exon3/3:c.*810G>A:,P2RX5-TAX1BP3:NR_037928.1:non_coding_transcript_exon:MODIFIER:exon15/15:n.6240G>A:		rs7093	0.3616	0.0000	0/0/0	0.0657							606272 [CTNS (confirmed) Cystinosis,nephropathic,219800|Cystinosis,ocular nonnephropathic,219750|Cystinosis,late-onset juvenile or adolescent nephropathic,219900|Cystinosis,atypical nephropathic,219800];	RCV000327551.1 [benign]; RCV000384559.1 [benign]; 			24	63					CTNS (inh=AR pLI=0.03), TAX1BP3 (inh=n/a pLI=0.00), P2RX5-TAX1BP3 (inh=n/a pLI=n/a)
chr17	4801125	4801125	C	G	het	het	wt		QUAL=593;DP=26,28,33;MQM=59	MINK1,CHRNE	3'UTR	MINK1:NM_153827.4:3'UTR:MODIFIER:exon32/32:c.*543C>G:,CHRNE:NM_000080.3:3'UTR:MODIFIER:exon12/12:c.*906G>C:,MINK1:NM_001024937.3:3'UTR:MODIFIER:exon32/32:c.*543C>G:,MINK1:NM_001321236.1:3'UTR:MODIFIER:exon32/32:c.*543C>G:,MINK1:NM_015716.4:3'UTR:MODIFIER:exon31/31:c.*543C>G:,MINK1:NM_170663.4:3'UTR:MODIFIER:exon32/32:c.*543C>G:		rs9914357	0.2153	0.0000	0/0/0	0.0171							100725 [CHRNE (confirmed) Myasthenic syndrome,congenital,4A,slow-channel,605809|Myasthenic syndrome,congenital,4B,fast-channel,616324|Myasthenic syndrome,congenital,4C,associated with acetylcholine receptor deficiency,608931];	RCV000344016.1 [benign]; 			0	23					MINK1 (inh=n/a pLI=1.00), CHRNE (inh=AR pLI=0.00)
chr17	4801163	4801163	C	A	wt	wt	het	low_DP	QUAL=166;DP=12,20,27;MQM=60	MINK1,CHRNE	3'UTR	MINK1:NM_153827.4:3'UTR:MODIFIER:exon32/32:c.*581C>A:,CHRNE:NM_000080.3:3'UTR:MODIFIER:exon12/12:c.*868G>T:,MINK1:NM_001024937.3:3'UTR:MODIFIER:exon32/32:c.*581C>A:,MINK1:NM_001321236.1:3'UTR:MODIFIER:exon32/32:c.*581C>A:,MINK1:NM_015716.4:3'UTR:MODIFIER:exon31/31:c.*581C>A:,MINK1:NM_170663.4:3'UTR:MODIFIER:exon32/32:c.*581C>A:		rs7774	0.4788	0.0000	0/0/0	0.3740							100725 [CHRNE (confirmed) Myasthenic syndrome,congenital,4A,slow-channel,605809|Myasthenic syndrome,congenital,4B,fast-channel,616324|Myasthenic syndrome,congenital,4C,associated with acetylcholine receptor deficiency,608931];	RCV000314040.1 [benign]; 			9	73					MINK1 (inh=n/a pLI=1.00), CHRNE (inh=AR pLI=0.00)
chr17	4801194	4801194	T	C	wt	wt	het	low_DP	QUAL=349;DP=14,20,27;MQM=60	MINK1,CHRNE	3'UTR	MINK1:NM_153827.4:3'UTR:MODIFIER:exon32/32:c.*612T>C:,CHRNE:NM_000080.3:3'UTR:MODIFIER:exon12/12:c.*837A>G:,MINK1:NM_001024937.3:3'UTR:MODIFIER:exon32/32:c.*612T>C:,MINK1:NM_001321236.1:3'UTR:MODIFIER:exon32/32:c.*612T>C:,MINK1:NM_015716.4:3'UTR:MODIFIER:exon31/31:c.*612T>C:,MINK1:NM_170663.4:3'UTR:MODIFIER:exon32/32:c.*612T>C:		rs8834	0.4477	0.0000	0/0/0	0.0562							100725 [CHRNE (confirmed) Myasthenic syndrome,congenital,4A,slow-channel,605809|Myasthenic syndrome,congenital,4B,fast-channel,616324|Myasthenic syndrome,congenital,4C,associated with acetylcholine receptor deficiency,608931];	RCV000298853.1 [benign]; 			22	64					MINK1 (inh=n/a pLI=1.00), CHRNE (inh=AR pLI=0.00)
chr17	4801273	4801273	-	CTC	hom	hom	hom		QUAL=2426;DP=30,23,43;MQM=58	MINK1,CHRNE	3'UTR	MINK1:NM_153827.4:3'UTR:MODIFIER:exon32/32:c.*693_*695dupTCC:,CHRNE:NM_000080.3:3'UTR:MODIFIER:exon12/12:c.*755_*757dupGAG:,MINK1:NM_001024937.3:3'UTR:MODIFIER:exon32/32:c.*693_*695dupTCC:,MINK1:NM_001321236.1:3'UTR:MODIFIER:exon32/32:c.*693_*695dupTCC:,MINK1:NM_015716.4:3'UTR:MODIFIER:exon31/31:c.*693_*695dupTCC:,MINK1:NM_170663.4:3'UTR:MODIFIER:exon32/32:c.*693_*695dupTCC:		rs538982347	0.0000	0.0000	0/0/0	0.5897							100725 [CHRNE (confirmed) Myasthenic syndrome,congenital,4A,slow-channel,605809|Myasthenic syndrome,congenital,4B,fast-channel,616324|Myasthenic syndrome,congenital,4C,associated with acetylcholine receptor deficiency,608931];				89	53					MINK1 (inh=n/a pLI=1.00), CHRNE (inh=AR pLI=0.00)
chr17	4801286	4801286	C	T	hom	hom	hom		QUAL=2449;DP=33,28,44;MQM=60	MINK1,CHRNE	3'UTR	MINK1:NM_153827.4:3'UTR:MODIFIER:exon32/32:c.*704C>T:,CHRNE:NM_000080.3:3'UTR:MODIFIER:exon12/12:c.*745G>A:,MINK1:NM_001024937.3:3'UTR:MODIFIER:exon32/32:c.*704C>T:,MINK1:NM_001321236.1:3'UTR:MODIFIER:exon32/32:c.*704C>T:,MINK1:NM_015716.4:3'UTR:MODIFIER:exon31/31:c.*704C>T:,MINK1:NM_170663.4:3'UTR:MODIFIER:exon32/32:c.*704C>T:		rs1053751	0.7712	0.0000	0/0/0	0.2560							100725 [CHRNE (confirmed) Myasthenic syndrome,congenital,4A,slow-channel,605809|Myasthenic syndrome,congenital,4B,fast-channel,616324|Myasthenic syndrome,congenital,4C,associated with acetylcholine receptor deficiency,608931];	RCV000380686.1 [benign]; 			108	34					MINK1 (inh=n/a pLI=1.00), CHRNE (inh=AR pLI=0.00)
chr17	4801288	4801288	A	C	hom	hom	het		QUAL=2449;DP=33,28,44;MQM=58	MINK1,CHRNE	3'UTR	MINK1:NM_153827.4:3'UTR:MODIFIER:exon32/32:c.*706A>C:,CHRNE:NM_000080.3:3'UTR:MODIFIER:exon12/12:c.*743T>G:,MINK1:NM_001024937.3:3'UTR:MODIFIER:exon32/32:c.*706A>C:,MINK1:NM_001321236.1:3'UTR:MODIFIER:exon32/32:c.*706A>C:,MINK1:NM_015716.4:3'UTR:MODIFIER:exon31/31:c.*706A>C:,MINK1:NM_170663.4:3'UTR:MODIFIER:exon32/32:c.*706A>C:		rs1053754	0.3662	0.0000	0/0/0	0.0797							100725 [CHRNE (confirmed) Myasthenic syndrome,congenital,4A,slow-channel,605809|Myasthenic syndrome,congenital,4B,fast-channel,616324|Myasthenic syndrome,congenital,4C,associated with acetylcholine receptor deficiency,608931];	RCV000288680.1 [benign]; 			53	68					MINK1 (inh=n/a pLI=1.00), CHRNE (inh=AR pLI=0.00)
chr17	4801594	4801594	C	G	wt	wt	het		QUAL=1729;DP=143,126,163;MQM=60	CHRNE	3'UTR	CHRNE:NM_000080.3:3'UTR:MODIFIER:exon12/12:c.*437G>C:		rs3514	0.2005	0.0000	0/0/0	0.1579							100725 [CHRNE (confirmed) Myasthenic syndrome,congenital,4A,slow-channel,605809|Myasthenic syndrome,congenital,4B,fast-channel,616324|Myasthenic syndrome,congenital,4C,associated with acetylcholine receptor deficiency,608931];	RCV000335329.1 [benign]; 			5	70					CHRNE (inh=AR pLI=0.00)
chr17	4801887	4801887	A	G	wt	wt	het		QUAL=4558;DP=245,280,334;MQM=59	CHRNE	3'UTR	CHRNE:NM_000080.3:3'UTR:MODIFIER:exon12/12:c.*144T>C:		rs12936083	0.5841	0.0000	0/0/0	0.0738							100725 [CHRNE (confirmed) Myasthenic syndrome,congenital,4A,slow-channel,605809|Myasthenic syndrome,congenital,4B,fast-channel,616324|Myasthenic syndrome,congenital,4C,associated with acetylcholine receptor deficiency,608931];	RCV000360573.1 [benign]; 			22	115					CHRNE (inh=AR pLI=0.00)
chr17	4801970	4801970	G	A	wt	wt	het		QUAL=3875;DP=269,234,299;MQM=60	CHRNE	3'UTR	CHRNE:NM_000080.3:3'UTR:MODIFIER:exon12/12:c.*61C>T:		rs12940036	0.1877	0.0000	0/0/0	0.1505							100725 [CHRNE (confirmed) Myasthenic syndrome,congenital,4A,slow-channel,605809|Myasthenic syndrome,congenital,4B,fast-channel,616324|Myasthenic syndrome,congenital,4C,associated with acetylcholine receptor deficiency,608931];	RCV000382689.1 [benign]; 			17	206					CHRNE (inh=AR pLI=0.00)
chr17	4802329	4802329	G	A	wt	wt	het		QUAL=5068;DP=140,309,366;MQM=60	CHRNE	synonymous	CHRNE:NM_000080.3:synonymous:LOW:exon11/12:c.1293C>T:p.Ala431Ala		rs33978919	0.1913	0.1804	1362/549/404	0.1401							100725 [CHRNE (confirmed) Myasthenic syndrome,congenital,4A,slow-channel,605809|Myasthenic syndrome,congenital,4B,fast-channel,616324|Myasthenic syndrome,congenital,4C,associated with acetylcholine receptor deficiency,608931];	RCV000116735.2 [benign]; RCV000340615.1 [benign]; 		COSM3755643	36	404					CHRNE (inh=AR pLI=0.00)
chr17	4802685	4802685	G	A	het	het	wt		QUAL=2365;DP=110,58,84;MQM=59	CHRNE	splice_region&intron	CHRNE:NM_000080.3:splice_region&intron:LOW:exon9/11:c.1033-6C>T:		rs2075763	0.1062	0.1205	86/14/1	0.0476							100725 [CHRNE (confirmed) Myasthenic syndrome,congenital,4A,slow-channel,605809|Myasthenic syndrome,congenital,4B,fast-channel,616324|Myasthenic syndrome,congenital,4C,associated with acetylcholine receptor deficiency,608931];	RCV000116734.3 [other]; RCV000273943.1 [benign]; 			8	205					CHRNE (inh=AR pLI=0.00)
chr17	7123240	7123240	-	GGGCGTGCAGGACGC	wt	het	wt	low_DP	QUAL=136;DP=7,14,10;MQM=60	DLG4,ACADVL	5'UTR,intron,non_coding_transcript_exon	DLG4:NM_001365.4:5'UTR:MODIFIER:exon1/22:c.-1087_-1073dupGCGTCCTGCACGCCC:,DLG4:NM_001321074.1:5'UTR:MODIFIER:exon1/22:c.-1087_-1073dupGCGTCCTGCACGCCC:,ACADVL:NM_000018.3:5'UTR:MODIFIER:exon1/20:c.-63_-49dupGGGCGTGCAGGACGC:,ACADVL:NM_001033859.2:5'UTR:MODIFIER:exon1/19:c.-63_-49dupGGGCGTGCAGGACGC:,ACADVL:NM_001270448.1:5'UTR:MODIFIER:exon1/19:c.-366_-352dupGGGCGTGCAGGACGC:,ACADVL:NM_001270447.1:intron:MODIFIER:exon2/20:c.132-200_132-186dupGGGCGTGCAGGACGC:,DLG4:NR_135527.1:non_coding_transcript_exon:MODIFIER:exon1/21:n.115_129dupGCGTCCTGCACGCCC:		rs139223575;rs6145976	0.4679	0.5996	5518/3034/150	0.0478							609575 [ACADVL (confirmed) VLCAD deficiency,201475];				314	353					DLG4 (inh=n/a pLI=1.00), ACADVL (inh=AR pLI=0.00)
chr17	7127718	7127718	T	C	het	het	wt		QUAL=5916;DP=292,244,273;MQM=59	ACADVL	splice_region&intron	ACADVL:NM_001270447.1:splice_region&intron:LOW:exon17/20:c.1674+6T>C:,ACADVL:NM_000018.3:splice_region&intron:LOW:exon16/19:c.1605+6T>C:,ACADVL:NM_001033859.2:splice_region&intron:LOW:exon15/18:c.1539+6T>C:,ACADVL:NM_001270448.1:splice_region&intron:LOW:exon15/18:c.1377+6T>C:		rs17671352	0.5198	0.6000	21852/13466/920	0.5818							609575 [ACADVL (confirmed) VLCAD deficiency,201475];	RCV000077908.7 [benign]; RCV000169539.2 [benign]; 			705	674					ACADVL (inh=AR pLI=0.00)
chr17	7360110	7360110	T	C	het	wt	het		QUAL=9935;DP=355,266,364;MQM=59	CHRNB1	3'UTR	CHRNB1:NM_000747.2:3'UTR:MODIFIER:exon11/11:c.*68T>C:		rs2302764	0.3057	0.0000	0/0/0	0.0483							100710 [CHRNB1 (confirmed) Myasthenic syndrome,congenital,2A,slow-channel,616313|Myasthenic syndrome,congenital,2C,associated with acetylcholine receptor deficiency,616314];	RCV000274455.1 [benign]; 			37	241					CHRNB1 (inh=n/a pLI=0.00)
chr17	7490810	7490810	G	A	het	hom	wt	pred_pathogenic	QUAL=9223;DP=339,175,156;MQM=59	MPDU1	missense,3'UTR,non_coding_transcript_exon	MPDU1:NM_004870.3:missense:MODERATE:exon7/7:c.685G>A:p.Ala229Thr,MPDU1:NM_001330073.1:3'UTR:MODIFIER:exon6/6:c.*48G>A:,MPDU1:NR_024603.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.896G>A:		rs10852891	0.1562	0.1540	1582/983/164	0.1520	0.8700	T,D	T,T	B,.	T,.	20.90	604041 [MPDU1 (confirmed) Congenital disorder of glycosylation,type If,609180];	RCV000081188.5 [benign]; RCV000379507.1 [likely benign]; 		COSM3766188	36	375					MPDU1 (inh=n/a pLI=0.14)
chr17	7491177	7491177	G	T	hom	hom	hom		QUAL=36340;DP=370,306,447;MQM=59	MPDU1	3'UTR,non_coding_transcript_exon	MPDU1:NM_004870.3:3'UTR:MODIFIER:exon7/7:c.*308G>T:,MPDU1:NM_001330073.1:3'UTR:MODIFIER:exon6/6:c.*415G>T:,MPDU1:NR_024603.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.1263G>T:		rs4227	0.6819	0.8095	3712/912/51	0.2145							604041 [MPDU1 (confirmed) Congenital disorder of glycosylation,type If,609180];	RCV000299242.1 [benign]; 			378	232					MPDU1 (inh=n/a pLI=0.14)
chr17	7750010	7750010	G	C	wt	het	wt	low_DP;pred_pathogenic	QUAL=133;DP=18,14,16;MQM=60	KDM6B	missense	KDM6B:NM_001080424.1:missense:MODERATE:exon8/22:c.663G>C:p.Glu221Asp		rs79548905	0.0068	0.0191	40/37/0	0.0175	2.0760	D,D	T	P	T,T	13.27					5	72					KDM6B (inh=AR pLI=1.00)
chr17	7750177	7750177	-	ACCACC	wt	wt	hom	low_DP	QUAL=172;DP=1,7,6;MQM=60	KDM6B	disruptive_inframe_insertion	KDM6B:NM_001080424.1:disruptive_inframe_insertion:MODERATE:exon9/22:c.786_791dupACCACC:p.Pro263_Pro264dup	(CCA)n	rs61462443;rs765463905;rs768799563;rs771743551;rs779500270	0.0000	0.2223	2474/1113/110	0.3082										COSM985377	581	56					KDM6B (inh=AR pLI=1.00)
chr17	7750177	7750177	-	ACC	hom	hom	wt	low_DP	QUAL=172;DP=1,7,6;MQM=60	KDM6B	disruptive_inframe_insertion	KDM6B:NM_001080424.1:disruptive_inframe_insertion:MODERATE:exon9/22:c.789_791dupACC:p.Pro264dup	(CCA)n	rs771743551;rs779500270	0.0000	0.0308	38/17/8	0.0213											15	22					KDM6B (inh=AR pLI=1.00)
chr17	7754993	7754993	G	A	wt	het	wt		QUAL=2081;DP=217,159,186;MQM=60	KDM6B	synonymous	KDM6B:NM_001080424.1:synonymous:LOW:exon17/22:c.4044G>A:p.Leu1348Leu		rs12939056	0.1871	0.4529	6071/5412/27	0.3427										COSM3755970	439	674					KDM6B (inh=AR pLI=1.00)
chr17	7757146	7757146	G	A	wt	wt	het		QUAL=1493;DP=56,88,128;MQM=60	KDM6B	3'UTR	KDM6B:NM_001080424.1:3'UTR:MODIFIER:exon22/22:c.*307G>A:		rs11553166	0.0962	0.0000	0/0/0	0.1045											2	38					KDM6B (inh=AR pLI=1.00)
chr17	10297658	10297658	A	G	het	wt	het		QUAL=12506;DP=454,521,612;MQM=55	MYH8,MYHAS	missense,intron	MYH8:NM_002472.2:missense:MODERATE:exon35/40:c.5074T>C:p.Trp1692Arg,MYHAS:NR_125367.1:intron:MODIFIER:exon1/10:n.76+11134A>G:		rs8069834	0.4854	0.5096	17218/11431/2748	0.5024	0.9480	T,T	T	B	T	7.97	160741 [MYH8 (confirmed) Carney complex variant,608837|Trismus-pseudocamptodactyly syndrome,158300];	RCV000117692.2 [benign]; RCV000341726.1 [likely benign]; 		COSM3765969	528	696					MYH8 (inh=AD pLI=0.00), MYHAS (inh=n/a pLI=n/a)
chr17	10304500	10304500	C	T	het	wt	het		QUAL=6565;DP=321,111,167;MQM=60	MYH8,MYHAS	synonymous,intron	MYH8:NM_002472.2:synonymous:LOW:exon25/40:c.3117G>A:p.Gly1039Gly,MYHAS:NR_125367.1:intron:MODIFIER:exon1/10:n.77-4965C>T:		rs3744553	0.0505	0.0586	286/135/1	0.0559							160741 [MYH8 (confirmed) Carney complex variant,608837|Trismus-pseudocamptodactyly syndrome,158300];	RCV000117687.2 [benign]; RCV000289687.1 [likely benign]; 		COSM3999995	8	157					MYH8 (inh=AD pLI=0.00), MYHAS (inh=n/a pLI=n/a)
chr17	10318636	10318636	A	G	het	hom	het		QUAL=28920;DP=590,427,519;MQM=59	MYH8,MYHAS	synonymous,intron	MYH8:NM_002472.2:synonymous:LOW:exon8/40:c.714T>C:p.Thr238Thr,MYHAS:NR_125367.1:intron:MODIFIER:exon2/10:n.167+9081A>G:		rs8068729	0.8624	0.9224	52039/29586/2290	0.8959							160741 [MYH8 (confirmed) Carney complex variant,608837|Trismus-pseudocamptodactyly syndrome,158300];	RCV000117694.2 [benign]; RCV000283465.1 [likely benign]; 			1319	231					MYH8 (inh=AD pLI=0.00), MYHAS (inh=n/a pLI=n/a)
chr17	10324980	10324980	C	T	het	hom	het		QUAL=7813;DP=260,87,150;MQM=60	MYH8,MYHAS	splice_region,5'UTR,intron	MYH8:NM_002472.2:splice_region:LOW:exon2/40:c.-31G>A:,MYH8:NM_002472.2:5'UTR:MODIFIER:exon2/40:c.-31G>A:,MYHAS:NR_125367.1:intron:MODIFIER:exon2/10:n.167+15425C>T:		rs2277648	0.4365	0.0000	0/0/0	0.4004							160741 [MYH8 (confirmed) Carney complex variant,608837|Trismus-pseudocamptodactyly syndrome,158300];	RCV000349915.1 [likely benign]; 			31	98					MYH8 (inh=AD pLI=0.00), MYHAS (inh=n/a pLI=n/a)
chr17	10427924	10427924	G	A	het	het	het	low_MQM	QUAL=17043;DP=391,493,602;MQM=47	MYH2,MYHAS	synonymous,intron	MYH2:NM_001100112.1:synonymous:LOW:exon35/40:c.5034C>T:p.Ala1678Ala,MYH2:NM_017534.5:synonymous:LOW:exon35/40:c.5034C>T:p.Ala1678Ala,MYHAS:NR_125367.1:intron:MODIFIER:exon2/10:n.168-42930G>A:		rs1042236	0.3189	0.2561	5940/882/52	0.2433							160740 [MYH2 (confirmed) Proximal myopathy and ophthalmoplegia,605637];	RCV000252048.2 [benign]; RCV000306693.1 [benign]; 		COSM3765976	43	426					MYH2 (inh=AR pLI=0.00), MYHAS (inh=n/a pLI=n/a)
chr17	10448769	10448769	A	T	het	hom	het		QUAL=13996;DP=278,228,304;MQM=59	MYH2,MYHAS	synonymous,intron	MYH2:NM_001100112.1:synonymous:LOW:exon5/40:c.399T>A:p.Pro133Pro,MYH2:NM_017534.5:synonymous:LOW:exon5/40:c.399T>A:p.Pro133Pro,MYHAS:NR_125367.1:intron:MODIFIER:exon2/10:n.168-22085A>T:		rs11078850	0.5168	0.4808	15288/5671/517	0.4708							160740 [MYH2 (confirmed) Proximal myopathy and ophthalmoplegia,605637];	RCV000243742.2 [benign]; RCV000354660.1 [benign]; 			313	738					MYH2 (inh=AR pLI=0.00), MYHAS (inh=n/a pLI=n/a)
chr17	10450816	10450816	T	C	het	hom	het		QUAL=20351;DP=291,356,439;MQM=59	MYH2,MYHAS	synonymous,intron	MYH2:NM_001100112.1:synonymous:LOW:exon4/40:c.324A>G:p.Glu108Glu,MYH2:NM_017534.5:synonymous:LOW:exon4/40:c.324A>G:p.Glu108Glu,MYHAS:NR_125367.1:intron:MODIFIER:exon2/10:n.168-20038T>C:		rs12600539	0.5435	0.4922	15912/5811/779	0.4796							160740 [MYH2 (confirmed) Proximal myopathy and ophthalmoplegia,605637];	RCV000250668.2 [benign]; RCV000390577.1 [benign]; 		COSM3765977	327	737					MYH2 (inh=AR pLI=0.00), MYHAS (inh=n/a pLI=n/a)
chr17	10453015	10453015	T	C	het	het	wt		QUAL=7036;DP=427,254,346;MQM=60	MYH2,MYHAS	5'UTR_premature_start_codon_gain,5'UTR,intron	MYH2:NM_017534.5:5'UTR_premature_start_codon_gain:LOW:exon1/40:c.-126A>G:,MYH2:NM_017534.5:5'UTR:MODIFIER:exon1/40:c.-126A>G:,MYHAS:NR_125367.1:intron:MODIFIER:exon2/10:n.168-17839T>C:		rs74967762	0.0765	0.0000	0/0/0	0.0722							160740 [MYH2 (confirmed) Proximal myopathy and ophthalmoplegia,605637];	RCV000285665.1 [likely benign]; 			0	11					MYH2 (inh=AR pLI=0.00), MYHAS (inh=n/a pLI=n/a)
chr17	10536018	10536018	G	A	het	wt	hom		QUAL=20145;DP=311,365,504;MQM=60	MYH3	synonymous	MYH3:NM_002470.3:synonymous:LOW:exon34/41:c.4731C>T:p.Ile1577Ile		rs2285479	0.4696	0.6089	24040/17495/504	0.5892							160720 [MYH3 (confirmed) Arthrogryposis,distal,type 2A,193700|Arthrogryposis,distal,type 2B,601680|Arthrogryposis,distal,type 8,178110];	RCV000117675.2 [benign]; RCV000285592.1 [likely benign]; RCV000382183.1 [likely benign]; 		COSM4000000	748	640					MYH3 (inh=AD pLI=0.00)
chr17	10541515	10541515	C	T	het	wt	hom		QUAL=23212;DP=270,478,651;MQM=59	MYH3	missense	MYH3:NM_002470.3:missense:MODERATE:exon27/41:c.3574G>A:p.Ala1192Thr		rs2285477	0.5865	0.6902	29937/20587/1707	0.6816	-0.4290	T	T	B	T	14.03	160720 [MYH3 (confirmed) Arthrogryposis,distal,type 2A,193700|Arthrogryposis,distal,type 2B,601680|Arthrogryposis,distal,type 8,178110];	RCV000117670.2 [benign]; RCV000259987.1 [likely benign]; RCV000317596.1 [likely benign]; 		COSM4000001	883	571					MYH3 (inh=AD pLI=0.00)
chr17	10541741	10541741	A	G	het	hom	wt		QUAL=3334;DP=69,106,192;MQM=59	MYH3	synonymous	MYH3:NM_002470.3:synonymous:LOW:exon27/41:c.3348T>C:p.Ile1116Ile		rs201626	0.2610	0.1888	3362/355/79	0.1821							160720 [MYH3 (confirmed) Arthrogryposis,distal,type 2A,193700|Arthrogryposis,distal,type 2B,601680|Arthrogryposis,distal,type 8,178110];	RCV000117669.2 [benign]; RCV000303204.1 [likely benign]; RCV000355718.1 [likely benign]; 		COSM1749857	36	318					MYH3 (inh=AD pLI=0.00)
chr17	10542471	10542471	T	G	het	wt	hom		QUAL=9848;DP=274,142,171;MQM=59	MYH3	synonymous	MYH3:NM_002470.3:synonymous:LOW:exon25/41:c.3138A>C:p.Arg1046Arg		rs2285475	0.4665	0.6085	24022/17511/486	0.6077							160720 [MYH3 (confirmed) Arthrogryposis,distal,type 2A,193700|Arthrogryposis,distal,type 2B,601680|Arthrogryposis,distal,type 8,178110];	RCV000117668.2 [benign]; RCV000333596.1 [likely benign]; RCV000385658.1 [likely benign]; 		COSM4000003	748	640					MYH3 (inh=AD pLI=0.00)
chr17	10542765	10542765	A	G	het	wt	hom		QUAL=9317;DP=206,158,202;MQM=60	MYH3	synonymous	MYH3:NM_002470.3:synonymous:LOW:exon24/41:c.2952T>C:p.Ser984Ser		rs2285474	0.4665	0.6094	23991/17489/485	0.6075							160720 [MYH3 (confirmed) Arthrogryposis,distal,type 2A,193700|Arthrogryposis,distal,type 2B,601680|Arthrogryposis,distal,type 8,178110];	RCV000117665.2 [benign]; RCV000299935.1 [likely benign]; RCV000400223.1 [likely benign]; 		COSM4000004	750	640					MYH3 (inh=AD pLI=0.00)
chr17	10542886	10542886	T	C	het	wt	hom		QUAL=12561;DP=232,242,297;MQM=59	MYH3	synonymous	MYH3:NM_002470.3:synonymous:LOW:exon23/41:c.2916A>G:p.Thr972Thr		rs2285472	0.4663	0.6085	24022/17513/486	0.5778							160720 [MYH3 (confirmed) Arthrogryposis,distal,type 2A,193700|Arthrogryposis,distal,type 2B,601680|Arthrogryposis,distal,type 8,178110];	RCV000117664.2 [benign]; RCV000277869.1 [likely benign]; RCV000311920.1 [likely benign]; 		COSM4000005	748	642					MYH3 (inh=AD pLI=0.00)
chr17	10543463	10543463	T	C	het	wt	hom		QUAL=17678;DP=262,365,441;MQM=59	MYH3	synonymous	MYH3:NM_002470.3:synonymous:LOW:exon22/41:c.2532A>G:p.Ala844Ala		rs2285469	0.4665	0.6085	24025/17513/486	0.5967							160720 [MYH3 (confirmed) Arthrogryposis,distal,type 2A,193700|Arthrogryposis,distal,type 2B,601680|Arthrogryposis,distal,type 8,178110];	RCV000117662.2 [benign]; RCV000282605.1 [likely benign]; RCV000337349.1 [likely benign]; 		COSM4000006	750	640					MYH3 (inh=AD pLI=0.00)
chr17	10544416	10544416	G	T	het	wt	hom		QUAL=14953;DP=290,279,358;MQM=60	MYH3	synonymous	MYH3:NM_002470.3:synonymous:LOW:exon19/41:c.2151C>A:p.Gly717Gly		rs876657	0.0000	0.6092	23980/17489/479	0.5864							160720 [MYH3 (confirmed) Arthrogryposis,distal,type 2A,193700|Arthrogryposis,distal,type 2B,601680|Arthrogryposis,distal,type 8,178110];	RCV000117661.2 [benign]; RCV000324188.1 [likely benign]; RCV000360244.1 [likely benign]; 		COSM4000007	750	628					MYH3 (inh=AD pLI=0.00)
chr17	10544697	10544697	A	-	het	wt	hom		QUAL=11033;DP=243,201,267;MQM=59	MYH3	splice_region&intron	MYH3:NM_002470.3:splice_region&intron:LOW:exon17/40:c.1960-8delT:		rs397857823	0.4673	0.6242	23904/17389/472	0.5513							160720 [MYH3 (confirmed) Arthrogryposis,distal,type 2A,193700|Arthrogryposis,distal,type 2B,601680|Arthrogryposis,distal,type 8,178110];	RCV000331324.1 [likely benign]; RCV000385731.1 [likely benign]; 			741	640					MYH3 (inh=AD pLI=0.00)
chr17	10555833	10555833	C	T	wt	het	wt		QUAL=1010;DP=44,69,89;MQM=60	MYH3	synonymous	MYH3:NM_002470.3:synonymous:LOW:exon4/41:c.252G>A:p.Lys84Lys		rs147410236	0.0002	0.0013	2/2/0	0.0012							160720 [MYH3 (confirmed) Arthrogryposis,distal,type 2A,193700|Arthrogryposis,distal,type 2B,601680|Arthrogryposis,distal,type 8,178110];	RCV000306539.1 [uncertain significance]; RCV000365909.1 [uncertain significance]; 		COSM705051	0	5	2	Prima vista kein Anhalt f?r Splice Defekt, swal, 160309 [2] ahwalds1 09.03.2016			MYH3 (inh=AD pLI=0.00)
chr17	10583714	10583714	G	C	hom	het	het		QUAL=13159;DP=235,175,202;MQM=60	SCO1	3'UTR	SCO1:NM_004589.3:3'UTR:MODIFIER:exon6/6:c.*722C>G:		rs7512	0.4778	0.0000	0/0/0	0.0762							603644 [SCO1 (provisional) Mitochondrial complex IV deficiency,220110];	RCV000304976.1 [benign]; RCV000347088.1 [benign]; RCV000398310.1 [benign]; 			42	112					SCO1 (inh=AR pLI=0.51)
chr17	10584116	10584116	C	T	hom	hom	hom		QUAL=15078;DP=148,155,220;MQM=59	SCO1	3'UTR	SCO1:NM_004589.3:3'UTR:MODIFIER:exon6/6:c.*320G>A:		rs2040570	1.0000	0.0000	0/0/0	0.1480							603644 [SCO1 (provisional) Mitochondrial complex IV deficiency,220110];	RCV000283552.1 [benign]; RCV000340923.1 [benign]; RCV000384875.1 [benign]; 			230	0					SCO1 (inh=AR pLI=0.51)
chr17	13972811	13972811	G	A	hom	hom	hom	low_DP	QUAL=467;DP=4,2,10;MQM=60	COX10	5'UTR	COX10:NM_001303.3:5'UTR:MODIFIER:exon1/7:c.-112G>A:		rs6502330	0.9956	0.0000	0/0/0	0.8663							602125 [COX10 (confirmed) Mitochondrial complex IV deficiency,220110|Leigh syndrome due to mitochondrial COX4 deficiency,256000];	RCV000336039.1 [benign]; RCV000390210.1 [benign]; 			187	6					COX10 (inh=AR pLI=0.65)
chr17	13980058	13980058	A	T	het	wt	het	pred_pathogenic	QUAL=9024;DP=434,230,295;MQM=60	COX10	missense	COX10:NM_001303.3:missense:MODERATE:exon3/7:c.184A>T:p.Thr62Ser		rs2230351	0.0615	0.0765	415/204/2	0.0748	6.0420	.,T	T,T	.,B	.,T	17.10	602125 [COX10 (confirmed) Mitochondrial complex IV deficiency,220110|Leigh syndrome due to mitochondrial COX4 deficiency,256000];	RCV000124571.1 [benign]; RCV000311575.1 [likely benign]; RCV000401023.1 [likely benign]; 		COSM4000018	7	157					COX10 (inh=AR pLI=0.65)
chr17	13980350	13980350	G	A	het	hom	het	pred_pathogenic	QUAL=19869;DP=406,277,385;MQM=60	COX10	missense	COX10:NM_001303.3:missense:MODERATE:exon3/7:c.476G>A:p.Arg159Gln		rs2072279	0.4639	0.4945	14893/8373/1058	0.4890	7.1630	T,T	T,T	B,B	T,T	27.00	602125 [COX10 (confirmed) Mitochondrial complex IV deficiency,220110|Leigh syndrome due to mitochondrial COX4 deficiency,256000];	RCV000124574.1 [benign]; RCV000268376.1 [benign]; RCV000322790.1 [benign]; 			437	751					COX10 (inh=AR pLI=0.65)
chr17	14005439	14005439	G	A	wt	het	het		QUAL=1783;DP=150,66,100;MQM=60	COX10	synonymous	COX10:NM_001303.3:synonymous:LOW:exon4/7:c.504G>A:p.Leu168Leu		rs2159132	0.4918	0.5223	17031/10825/1334	0.5199							602125 [COX10 (confirmed) Mitochondrial complex IV deficiency,220110|Leigh syndrome due to mitochondrial COX4 deficiency,256000];	RCV000124568.1 [benign]; RCV000264198.1 [benign]; RCV000377462.1 [benign]; 		COSM4000019	510	779					COX10 (inh=AR pLI=0.65)
chr17	14095309	14095309	A	G	het	hom	het		QUAL=6582;DP=185,105,156;MQM=52	COX10	synonymous	COX10:NM_001303.3:synonymous:LOW:exon6/7:c.699A>G:p.Pro233Pro		rs2230354	0.5483	0.5850	20957/11887/1153	0.5297							602125 [COX10 (confirmed) Mitochondrial complex IV deficiency,220110|Leigh syndrome due to mitochondrial COX4 deficiency,256000];	RCV000124560.2 [benign]; RCV000294930.1 [benign]; RCV000388928.1 [benign]; 		COSM3765989	557	738					COX10 (inh=AR pLI=0.65)
chr17	14110669	14110670	TT	-	het	het	wt		QUAL=1904;DP=181,116,131;MQM=59	COX10	3'UTR	COX10:NM_001303.3:3'UTR:MODIFIER:exon7/7:c.*151_*152delTT:		rs200239586	0.2021	0.0000	0/0/0	0.1075							602125 [COX10 (confirmed) Mitochondrial complex IV deficiency,220110|Leigh syndrome due to mitochondrial COX4 deficiency,256000];	RCV000332249.1 [benign]; RCV000386652.1 [benign]; 			6	52					COX10 (inh=AR pLI=0.65)
chr17	14110827	14110827	G	A	wt	het	het		QUAL=8620;DP=241,293,410;MQM=60	COX10	3'UTR	COX10:NM_001303.3:3'UTR:MODIFIER:exon7/7:c.*297G>A:		rs8076247	0.2017	0.0000	0/0/0	0.2736							602125 [COX10 (confirmed) Mitochondrial complex IV deficiency,220110|Leigh syndrome due to mitochondrial COX4 deficiency,256000];	RCV000334328.1 [likely benign]; RCV000396612.1 [likely benign]; 			11	115					COX10 (inh=AR pLI=0.65)
chr17	14110852	14110852	T	C	het	het	wt		QUAL=5974;DP=218,275,396;MQM=60	COX10	3'UTR	COX10:NM_001303.3:3'UTR:MODIFIER:exon7/7:c.*322T>C:		rs11078233	0.1991	0.0000	0/0/0	0.0307							602125 [COX10 (confirmed) Mitochondrial complex IV deficiency,220110|Leigh syndrome due to mitochondrial COX4 deficiency,256000];	RCV000285265.1 [benign]; RCV000341057.1 [benign]; 			6	58					COX10 (inh=AR pLI=0.65)
chr17	14110901	14110901	A	G	het	het	wt		QUAL=5242;DP=230,241,342;MQM=60	COX10	3'UTR	COX10:NM_001303.3:3'UTR:MODIFIER:exon7/7:c.*371A>G:		rs11078234	0.2206	0.0000	0/0/0	0.1876							602125 [COX10 (confirmed) Mitochondrial complex IV deficiency,220110|Leigh syndrome due to mitochondrial COX4 deficiency,256000];	RCV000310611.1 [benign]; RCV000389973.1 [benign]; 			6	60					COX10 (inh=AR pLI=0.65)
chr17	14111176	14111176	C	A	het	het	wt		QUAL=6349;DP=257,261,321;MQM=59	COX10	3'UTR	COX10:NM_001303.3:3'UTR:MODIFIER:exon7/7:c.*646C>A:		rs7214082	0.1995	0.0000	0/0/0	0.1725							602125 [COX10 (confirmed) Mitochondrial complex IV deficiency,220110|Leigh syndrome due to mitochondrial COX4 deficiency,256000];	RCV000282929.1 [benign]; RCV000379280.1 [benign]; RCV000347246.1 [uncertain significance]; RCV000395029.1 [uncertain significance]; 			6	60					COX10 (inh=AR pLI=0.65)
chr17	14111287	14111287	T	C	het	het	wt		QUAL=8350;DP=366,261,309;MQM=60	COX10	3'UTR	COX10:NM_001303.3:3'UTR:MODIFIER:exon7/7:c.*757T>C:		rs1802618	0.2001	0.0000	0/0/0	0.0310							602125 [COX10 (confirmed) Mitochondrial complex IV deficiency,220110|Leigh syndrome due to mitochondrial COX4 deficiency,256000];	RCV000313440.1 [benign]; RCV000390456.1 [benign]; 			6	60					COX10 (inh=AR pLI=0.65)
chr17	14111361	14111362	CT	-	het	het	wt		QUAL=7158;DP=330,312,375;MQM=59	COX10	3'UTR	COX10:NM_001303.3:3'UTR:MODIFIER:exon7/7:c.*833_*834delCT:		rs397763766	0.1999	0.0000	0/0/0	0.1580							602125 [COX10 (confirmed) Mitochondrial complex IV deficiency,220110|Leigh syndrome due to mitochondrial COX4 deficiency,256000];	RCV000300799.1 [benign]; RCV000355513.1 [benign]; 			6	60					COX10 (inh=AR pLI=0.65)
chr17	14111606	14111606	T	C	het	het	wt		QUAL=7928;DP=421,176,208;MQM=59	COX10	3'UTR	COX10:NM_001303.3:3'UTR:MODIFIER:exon7/7:c.*1076T>C:		rs1050216	0.2133	0.0000	0/0/0	0.1857							602125 [COX10 (confirmed) Mitochondrial complex IV deficiency,220110|Leigh syndrome due to mitochondrial COX4 deficiency,256000];	RCV000266831.1 [benign]; RCV000361388.1 [benign]; 			6	60					COX10 (inh=AR pLI=0.65)
chr17	14111608	14111608	C	T	wt	het	het		QUAL=4374;DP=422,177,207;MQM=59	COX10	3'UTR	COX10:NM_001303.3:3'UTR:MODIFIER:exon7/7:c.*1078C>T:		rs13183	0.2019	0.0000	0/0/0	0.2738							602125 [COX10 (confirmed) Mitochondrial complex IV deficiency,220110|Leigh syndrome due to mitochondrial COX4 deficiency,256000];	RCV000321981.1 [likely benign]; RCV000376624.1 [likely benign]; 			11	116					COX10 (inh=AR pLI=0.65)
chr17	14111797	14111797	A	G	het	het	wt		QUAL=6314;DP=322,139,170;MQM=60	COX10	3'UTR	COX10:NM_001303.3:3'UTR:MODIFIER:exon7/7:c.*1267A>G:		rs75844637	0.0086	0.0000	0/0/0	0.0024							602125 [COX10 (confirmed) Mitochondrial complex IV deficiency,220110|Leigh syndrome due to mitochondrial COX4 deficiency,256000];				0	8					COX10 (inh=AR pLI=0.65)
chr17	14111915	14111915	C	T	het	wt	het		QUAL=7095;DP=303,158,224;MQM=60	COX10	3'UTR	COX10:NM_001303.3:3'UTR:MODIFIER:exon7/7:c.*1385C>T:		rs1050223	0.2266	0.0000	0/0/0	0.0490							602125 [COX10 (confirmed) Mitochondrial complex IV deficiency,220110|Leigh syndrome due to mitochondrial COX4 deficiency,256000];	RCV000292528.1 [likely benign]; RCV000349607.1 [likely benign]; 			30	85					COX10 (inh=AR pLI=0.65)
chr17	15133406	15133406	C	T	wt	het	wt		QUAL=2004;DP=342,163,226;MQM=60	PMP22	3'UTR,non_coding_transcript_exon	PMP22:NM_000304.3:3'UTR:MODIFIER:exon5/5:c.*828G>A:,PMP22:NM_153322.2:3'UTR:MODIFIER:exon4/4:c.*828G>A:,PMP22:NM_001281455.1:3'UTR:MODIFIER:exon5/5:c.*828G>A:,PMP22:NM_153321.2:3'UTR:MODIFIER:exon5/5:c.*828G>A:,PMP22:NM_001281456.1:3'UTR:MODIFIER:exon5/5:c.*828G>A:,PMP22:NR_104017.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.1437G>A:,PMP22:NR_104018.1:non_coding_transcript_exon:MODIFIER:exon3/3:n.1337G>A:		rs13027	0.0869	0.0000	0/0/0	0.0152							601097 [PMP22 (confirmed) Charcot-Marie-Tooth disease,type 1A,118220|Dejerine-Sottas disease,145900|Neuropathy,recurrent,with pressure palsies,162500|Charcot-Marie-Tooth disease,type 1E,118300|Roussy-Levy syndrome,180800|Neuropathy,inflammatory demyelinating,139393];	RCV000277968.1 [likely benign]; RCV000330696.1 [likely benign]; 			1	36					PMP22 (inh=AR+AD pLI=0.83)
chr17	15133657	15133657	A	G	wt	wt	het		QUAL=2926;DP=252,179,252;MQM=60	PMP22	3'UTR,non_coding_transcript_exon	PMP22:NM_000304.3:3'UTR:MODIFIER:exon5/5:c.*577T>C:,PMP22:NM_153322.2:3'UTR:MODIFIER:exon4/4:c.*577T>C:,PMP22:NM_001281455.1:3'UTR:MODIFIER:exon5/5:c.*577T>C:,PMP22:NM_153321.2:3'UTR:MODIFIER:exon5/5:c.*577T>C:,PMP22:NM_001281456.1:3'UTR:MODIFIER:exon5/5:c.*577T>C:,PMP22:NR_104017.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.1186T>C:,PMP22:NR_104018.1:non_coding_transcript_exon:MODIFIER:exon3/3:n.1086T>C:		rs7538	0.1302	0.0000	0/0/0	0.0360							601097 [PMP22 (confirmed) Charcot-Marie-Tooth disease,type 1A,118220|Dejerine-Sottas disease,145900|Neuropathy,recurrent,with pressure palsies,162500|Charcot-Marie-Tooth disease,type 1E,118300|Roussy-Levy syndrome,180800|Neuropathy,inflammatory demyelinating,139393];	RCV000281530.1 [likely benign]; RCV000387609.1 [likely benign]; 			19	95					PMP22 (inh=AR+AD pLI=0.83)
chr17	15133706	15133707	AG	-	hom	het	het		QUAL=10971;DP=260,130,170;MQM=59	PMP22	3'UTR,non_coding_transcript_exon	PMP22:NM_000304.3:3'UTR:MODIFIER:exon5/5:c.*527_*528delCT:,PMP22:NM_153322.2:3'UTR:MODIFIER:exon4/4:c.*527_*528delCT:,PMP22:NM_001281455.1:3'UTR:MODIFIER:exon5/5:c.*527_*528delCT:,PMP22:NM_153321.2:3'UTR:MODIFIER:exon5/5:c.*527_*528delCT:,PMP22:NM_001281456.1:3'UTR:MODIFIER:exon5/5:c.*527_*528delCT:,PMP22:NR_104017.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.1136_1137delCT:,PMP22:NR_104018.1:non_coding_transcript_exon:MODIFIER:exon3/3:n.1036_1037delCT:		rs869161943	0.3193	0.0000	0/0/0	0.3481							601097 [PMP22 (confirmed) Charcot-Marie-Tooth disease,type 1A,118220|Dejerine-Sottas disease,145900|Neuropathy,recurrent,with pressure palsies,162500|Charcot-Marie-Tooth disease,type 1E,118300|Roussy-Levy syndrome,180800|Neuropathy,inflammatory demyelinating,139393];	RCV000280289.1 [likely benign]; RCV000342212.1 [likely benign]; 			35	118					PMP22 (inh=AR+AD pLI=0.83)
chr17	15134175	15134175	T	G	hom	hom	het		QUAL=24063;DP=309,301,387;MQM=60	PMP22	3'UTR,non_coding_transcript_exon	PMP22:NM_000304.3:3'UTR:MODIFIER:exon5/5:c.*59A>C:,PMP22:NM_153322.2:3'UTR:MODIFIER:exon4/4:c.*59A>C:,PMP22:NM_001281455.1:3'UTR:MODIFIER:exon5/5:c.*59A>C:,PMP22:NM_153321.2:3'UTR:MODIFIER:exon5/5:c.*59A>C:,PMP22:NM_001281456.1:3'UTR:MODIFIER:exon5/5:c.*59A>C:,PMP22:NR_104017.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.668A>C:,PMP22:NR_104018.1:non_coding_transcript_exon:MODIFIER:exon3/3:n.568A>C:		rs13422	0.5954	0.5351	17161/8416/2590	0.5257							601097 [PMP22 (confirmed) Charcot-Marie-Tooth disease,type 1A,118220|Dejerine-Sottas disease,145900|Neuropathy,recurrent,with pressure palsies,162500|Charcot-Marie-Tooth disease,type 1E,118300|Roussy-Levy syndrome,180800|Neuropathy,inflammatory demyelinating,139393];	RCV000330964.1 [benign]; RCV000355581.1 [benign]; 			252	488					PMP22 (inh=AR+AD pLI=0.83)
chr17	15931693	15931693	G	A	het	het	het		QUAL=9885;DP=293,202,249;MQM=60	TTC19	3'UTR	TTC19:NM_017775.3:3'UTR:MODIFIER:exon10/10:c.*857G>A:,TTC19:NM_001271420.1:3'UTR:MODIFIER:exon10/10:c.*857G>A:		rs72821769	0.0327	0.0570	27/20/0	0.0139							613814 [TTC19 (provisional) Mitochondrial complex III deficiency,nuclear type 2,615157];	RCV000322473.1 [likely benign]; 			5	121					TTC19 (inh=AR pLI=0.00)
chr17	15932071	15932071	-	TT	hom	hom	het		QUAL=6737;DP=123,62,75;MQM=59	TTC19	3'UTR	TTC19:NM_017775.3:3'UTR:MODIFIER:exon10/10:c.*1236_*1237dupTT:,TTC19:NM_001271420.1:3'UTR:MODIFIER:exon10/10:c.*1236_*1237dupTT:		rs386385756;rs61349729	0.4944	0.4930	1380/555/31	0.1190							613814 [TTC19 (provisional) Mitochondrial complex III deficiency,nuclear type 2,615157];	RCV000288534.1 [likely benign]; 			237	319					TTC19 (inh=AR pLI=0.00)
chr17	15932420	15932420	-	GAG	het	wt	het		QUAL=1937;DP=88,47,95;MQM=59	TTC19	3'UTR	TTC19:NM_017775.3:3'UTR:MODIFIER:exon10/10:c.*1584_*1585insGAG:,TTC19:NM_001271420.1:3'UTR:MODIFIER:exon10/10:c.*1584_*1585insGAG:		rs758709551	0.0000	0.0139	3/3/0	0.0004							613814 [TTC19 (provisional) Mitochondrial complex III deficiency,nuclear type 2,615157];				0	28					TTC19 (inh=AR pLI=0.00)
chr17	15932422	15932422	-	AGTAAAAA	het	wt	het		QUAL=1716;DP=85,43,91;MQM=59	TTC19	3'UTR	TTC19:NM_017775.3:3'UTR:MODIFIER:exon10/10:c.*1586_*1587insAGTAAAAA:,TTC19:NM_001271420.1:3'UTR:MODIFIER:exon10/10:c.*1586_*1587insAGTAAAAA:		rs778157002	0.0000	0.0139	3/3/0	0.0004							613814 [TTC19 (provisional) Mitochondrial complex III deficiency,nuclear type 2,615157];				0	27					TTC19 (inh=AR pLI=0.00)
chr17	15932627	15932627	T	C	hom	hom	het		QUAL=9314;DP=200,53,84;MQM=59	TTC19	3'UTR	TTC19:NM_017775.3:3'UTR:MODIFIER:exon10/10:c.*1791T>C:,TTC19:NM_001271420.1:3'UTR:MODIFIER:exon10/10:c.*1791T>C:		rs9890012	0.3674	0.4462	1112/483/8	0.1086							613814 [TTC19 (provisional) Mitochondrial complex III deficiency,nuclear type 2,615157];	RCV000383682.1 [likely benign]; 			187	293					TTC19 (inh=AR pLI=0.00)
chr17	16842912	16842912	A	G	het	het	wt		QUAL=874;DP=48,59,66;MQM=59	TNFRSF13B	synonymous	TNFRSF13B:NM_012452.2:synonymous:LOW:exon5/5:c.831T>C:p.Ser277Ser		rs11078355	0.5952	0.4943	15663/5421/1951	0.4748							604907 [TNFRSF13B (provisional) Immunoglobulin A deficiency 2,609529|Immunodeficiency,common variable,2,240500];	RCV000249157.1 [benign]; RCV000347652.1 [benign]; 		COSM3766008	391	731					TNFRSF13B (inh=AR+AD pLI=0.00)
chr17	16852206	16852206	A	C	het	het	wt		QUAL=6336;DP=242,284,346;MQM=60	TNFRSF13B	synonymous	TNFRSF13B:NM_012452.2:synonymous:LOW:exon3/5:c.291T>G:p.Pro97Pro		rs35062843	0.0485	0.0424	165/56/3	0.0414							604907 [TNFRSF13B (provisional) Immunoglobulin A deficiency 2,609529|Immunodeficiency,common variable,2,240500];	RCV000252622.1 [benign]; RCV000359099.1 [likely benign]; 			2	137					TNFRSF13B (inh=AR+AD pLI=0.00)
chr17	16855878	16855878	C	T	hom	hom	hom		QUAL=18887;DP=173,190,266;MQM=59	TNFRSF13B	synonymous	TNFRSF13B:NM_012452.2:synonymous:LOW:exon2/5:c.81G>A:p.Thr27Thr		rs8072293	0.8996	0.8112	40369/18884/4689	0.7824							604907 [TNFRSF13B (provisional) Immunoglobulin A deficiency 2,609529|Immunodeficiency,common variable,2,240500];	RCV000030561.1 [benign]; RCV000244388.1 [benign]; RCV000327385.1 [benign]; 			896	551					TNFRSF13B (inh=AR+AD pLI=0.00)
chr17	17697094	17697096	CAG	-	hom	het	wt		QUAL=2690;DP=47,303,362;MQM=60	RAI1	disruptive_inframe_deletion,sequence_feature	RAI1:NM_030665.3:disruptive_inframe_deletion:MODERATE:exon3/6:c.870_872delGCA:p.Gln291del,RAI1:NM_030665.3:sequence_feature:LOW:exon3/6:c.832_834delCAG:	(CAG)n	rs371983878;rs794727527;rs794727528;rs879071724	0.0000	0.2141	48/16/27	0.1382							607642 [RAI1 (confirmed) Smith-Magenis syndrome,182290];	RCV000177381.5,RCV000177381.5 [benign,benign]; 		COSM1479304	15	105	1	[1] Ute Grasshoff 04.07.2014			RAI1 (inh=AD pLI=1.00)
chr17	17697404	17697404	C	T	wt	het	wt	pred_pathogenic	QUAL=3075;DP=182,318,363;MQM=60	RAI1	missense	RAI1:NM_030665.3:missense:MODERATE:exon3/6:c.1142C>T:p.Ala381Val		rs113208290	0.0030	0.0036	1/1/0	0.0035	3.1410	D,D,D,D,D,D	T	P	T,T,T	21.40	607642 [RAI1 (confirmed) Smith-Magenis syndrome,182290];	RCV000082255.8 [other]; 			0	14					RAI1 (inh=AD pLI=1.00)
chr17	17698254	17698254	G	A	hom	hom	hom		QUAL=8161;DP=142,56,79;MQM=59	RAI1	synonymous	RAI1:NM_030665.3:synonymous:LOW:exon3/6:c.1992G>A:p.Pro664Pro		rs8067439	0.3998	0.5069	17240/12958/1675	0.5075							607642 [RAI1 (confirmed) Smith-Magenis syndrome,182290];	RCV000082257.8 [other]; 		COSM3766017, COSM3766018	526	724					RAI1 (inh=AD pLI=1.00)
chr17	17700573	17700573	T	C	het	het	wt		QUAL=2518;DP=185,56,106;MQM=59	RAI1	synonymous	RAI1:NM_030665.3:synonymous:LOW:exon3/6:c.4311T>C:p.Pro1437Pro		rs4925112	0.0946	0.0646	505/128/339	0.0625							607642 [RAI1 (confirmed) Smith-Magenis syndrome,182290];	RCV000082268.8 [other]; 			9	160					RAI1 (inh=AD pLI=1.00)
chr17	17700792	17700792	C	T	het	het	wt		QUAL=2837;DP=86,176,227;MQM=60	RAI1	synonymous	RAI1:NM_030665.3:synonymous:LOW:exon3/6:c.4530C>T:p.Pro1510Pro		rs35686634	0.0731	0.0579	340/125/178	0.0557							607642 [RAI1 (confirmed) Smith-Magenis syndrome,182290];	RCV000082270.8 [other]; 			8	153					RAI1 (inh=AD pLI=1.00)
chr17	17707105	17707105	T	C	het	het	hom		QUAL=13511;DP=195,212,251;MQM=59	RAI1	synonymous	RAI1:NM_030665.3:synonymous:LOW:exon4/6:c.5601T>C:p.Ile1867Ile		rs3818717	0.2406	0.4214	12779/10732/166	0.4193	-1.2000	T,T	T			7.67	607642 [RAI1 (confirmed) Smith-Magenis syndrome,182290];	RCV000082273.8 [other]; 		COSM3766019	414	740					RAI1 (inh=AD pLI=1.00)
chr17	17714717	17714717	G	A	hom	hom	hom	low_DP	QUAL=1212;DP=40,11,7;MQM=60	RAI1,SREBF1	3'UTR	RAI1:NM_030665.3:3'UTR:MODIFIER:exon6/6:c.*1422G>A:,SREBF1:NM_001005291.2:3'UTR:MODIFIER:exon20/20:c.*1219C>T:,SREBF1:NM_004176.4:3'UTR:MODIFIER:exon19/19:c.*1219C>T:			0.0000	0.0000	0/0/0	0.0001							607642 [RAI1 (confirmed) Smith-Magenis syndrome,182290];				0	26					RAI1 (inh=AD pLI=1.00), SREBF1 (inh=n/a pLI=0.99)
chr17	19578873	19578873	A	T	hom	het	het		QUAL=18056;DP=331,239,308;MQM=60	ALDH3A2	splice_region,splice_region&synonymous,3'UTR	ALDH3A2:NM_001031806.1:splice_region:LOW:exon11/11:c.*44A>T:,ALDH3A2:NM_000382.2:splice_region&synonymous:LOW:exon10/10:c.1446A>T:p.Ala482Ala,ALDH3A2:NM_001031806.1:3'UTR:MODIFIER:exon11/11:c.*44A>T:		rs7216	0.6785	0.6154	24079/10338/1460	0.5986							609523 [ALDH3A2 (confirmed) Sjogren-Larsson syndrome,270200];	RCV000283231.1 [benign]; 		COSM3766033	681	998					ALDH3A2 (inh=AR pLI=0.01)
chr17	19580494	19580494	A	G	hom	het	het		QUAL=23112;DP=528,237,288;MQM=60	ALDH3A2	3'UTR	ALDH3A2:NM_001031806.1:3'UTR:MODIFIER:exon11/11:c.*1665A>G:,ALDH3A2:NM_000382.2:3'UTR:MODIFIER:exon10/10:c.*1609A>G:		rs7215	0.6042	0.0000	0/0/0	0.1016							609523 [ALDH3A2 (confirmed) Sjogren-Larsson syndrome,270200];	RCV000343374.1 [benign]; 			82	98					ALDH3A2 (inh=AR pLI=0.01)
chr17	19580761	19580762	AC	-	hom	het	het		QUAL=6063;DP=176,58,84;MQM=59	ALDH3A2	3'UTR	ALDH3A2:NM_001031806.1:3'UTR:MODIFIER:exon11/11:c.*1935_*1936delCA:,ALDH3A2:NM_000382.2:3'UTR:MODIFIER:exon10/10:c.*1879_*1880delCA:		rs4646805	0.3273	0.0000	0/0/0	0.2855							609523 [ALDH3A2 (confirmed) Sjogren-Larsson syndrome,270200];	RCV000337707.1 [benign]; 			34	102					ALDH3A2 (inh=AR pLI=0.01)
chr17	26864302	26864302	G	C	het	hom	het	pred_pathogenic	QUAL=10785;DP=116,191,243;MQM=59	FOXN1	missense	FOXN1:NM_003593.2:missense:MODERATE:exon8/8:c.1795G>C:p.Ala599Pro		rs532648	0.3928	0.3229	6785/2847/1780	0.3164	0.5980	T	T	B	D	0.01	600838 [FOXN1 (provisional) T-cell immunodeficiency,congenital alopecia,and nail dystrophy,601705];	RCV000399481.1 [benign]; 		COSM4000076	146	656					FOXN1 (inh=AR pLI=0.97)
chr17	26864708	26864708	G	A	wt	wt	het		QUAL=2563;DP=180,135,182;MQM=60	FOXN1	3'UTR	FOXN1:NM_003593.2:3'UTR:MODIFIER:exon8/8:c.*254G>A:		rs3744635	0.1196	0.0000	0/0/0	0.0141							600838 [FOXN1 (provisional) T-cell immunodeficiency,congenital alopecia,and nail dystrophy,601705];	RCV000356658.1 [benign]; 			1	36					FOXN1 (inh=AR pLI=0.97)
chr17	29483108	29483108	C	T	het	wt	het		QUAL=4729;DP=242,191,211;MQM=60	NF1	synonymous	NF1:NM_001042492.2:synonymous:LOW:exon2/58:c.168C>T:p.Ser56Ser,NF1:NM_001128147.2:synonymous:LOW:exon2/15:c.168C>T:p.Ser56Ser,NF1:NM_000267.3:synonymous:LOW:exon2/57:c.168C>T:p.Ser56Ser		rs17881168	0.0046	0.0119	14/11/1	0.0129							613113 [NF1 (confirmed) Neurofibromatosis,type 1,162200|Leukemia,juvenile myelomonocytic,607785|Neurofibromatosis,familial spinal,162210|Neurofibromatosis-Noonan syndrome,601321|Watson syndrome,193520];	RCV000163256.1 [benign]; RCV000205406.2 [other]; RCV000215995.2 [benign]; RCV000289551.1 [likely benign]; RCV000324800.1 [likely benign]; RCV000381546.1 [likely benign]; 			2	116					NF1 (inh=AD pLI=1.00)
chr17	29508775	29508775	G	A	het	wt	het		QUAL=6185;DP=330,146,190;MQM=59	NF1	synonymous	NF1:NM_001042492.2:synonymous:LOW:exon7/58:c.702G>A:p.Leu234Leu,NF1:NM_001128147.2:synonymous:LOW:exon7/15:c.702G>A:p.Leu234Leu,NF1:NM_000267.3:synonymous:LOW:exon7/57:c.702G>A:p.Leu234Leu		rs1801052	0.5118	0.6228	24613/16345/471	0.6200							613113 [NF1 (confirmed) Neurofibromatosis,type 1,162200|Leukemia,juvenile myelomonocytic,607785|Neurofibromatosis,familial spinal,162210|Neurofibromatosis-Noonan syndrome,601321|Watson syndrome,193520];	RCV000162647.1 [benign]; RCV000218671.2 [benign]; RCV000279983.1 [likely benign]; RCV000319858.1 [likely benign]; RCV000334631.1 [likely benign]; RCV000374483.1 [likely benign]; 		COSM3755377, COSM3755378	1520	1285					NF1 (inh=AD pLI=1.00)
chr17	29553485	29553485	G	A	het	hom	het		QUAL=6887;DP=133,113,141;MQM=59	NF1	synonymous	NF1:NM_001042492.2:synonymous:LOW:exon18/58:c.2034G>A:p.Pro678Pro,NF1:NM_000267.3:synonymous:LOW:exon18/57:c.2034G>A:p.Pro678Pro		rs2285892	0.4968	0.3827	9925/3078/2462	0.3658							613113 [NF1 (confirmed) Neurofibromatosis,type 1,162200|Leukemia,juvenile myelomonocytic,607785|Neurofibromatosis,familial spinal,162210|Neurofibromatosis-Noonan syndrome,601321|Watson syndrome,193520];	RCV000162648.1 [benign]; RCV000219876.2 [benign]; RCV000296834.1 [likely benign]; RCV000356219.1 [likely benign]; RCV000371357.1 [likely benign]; RCV000400800.1 [likely benign]; 			273	1285					NF1 (inh=AD pLI=1.00)
chr17	29559088	29559088	C	T	het	wt	wt		QUAL=71;DP=66,25,45;MQM=51	NF1	splice_region&intron	NF1:NM_001042492.2:splice_region&intron:LOW:exon24/57:c.3198-3C>T:,NF1:NM_000267.3:splice_region&intron:LOW:exon24/56:c.3198-3C>T:		rs777759972	0.0000	0.0004	0/0/0	0.0001							613113 [NF1 (confirmed) Neurofibromatosis,type 1,162200|Leukemia,juvenile myelomonocytic,607785|Neurofibromatosis,familial spinal,162210|Neurofibromatosis-Noonan syndrome,601321|Watson syndrome,193520];				2	67	2	[2] Stefanie Beck-Woedl 29.03.2015			NF1 (inh=AD pLI=1.00)
chr17	29702031	29702032	TA	-	hom	hom	wt	low_DP	QUAL=149;DP=6,1,45;MQM=60	NF1	3'UTR	NF1:NM_001042492.2:3'UTR:MODIFIER:exon58/58:c.*873_*874delAT:,NF1:NM_000267.3:3'UTR:MODIFIER:exon57/57:c.*873_*874delAT:	(TA)n	rs34207771;rs369548314	0.5551	0.0000	0/0/0	0.2688							613113 [NF1 (confirmed) Neurofibromatosis,type 1,162200|Leukemia,juvenile myelomonocytic,607785|Neurofibromatosis,familial spinal,162210|Neurofibromatosis-Noonan syndrome,601321|Watson syndrome,193520];	RCV000285167.1 [benign]; RCV000291178.1 [benign]; RCV000343788.1 [benign]; RCV000381987.1 [benign]; 			21	62					NF1 (inh=AD pLI=1.00)
chr17	29703374	29703374	G	A	het	hom	het		QUAL=12801;DP=278,185,207;MQM=60	NF1	3'UTR	NF1:NM_001042492.2:3'UTR:MODIFIER:exon58/58:c.*2201G>A:,NF1:NM_000267.3:3'UTR:MODIFIER:exon57/57:c.*2201G>A:		rs7406983	0.5306	0.0000	0/0/0	0.0684							613113 [NF1 (confirmed) Neurofibromatosis,type 1,162200|Leukemia,juvenile myelomonocytic,607785|Neurofibromatosis,familial spinal,162210|Neurofibromatosis-Noonan syndrome,601321|Watson syndrome,193520];	RCV000261900.1 [likely benign]; RCV000331091.1 [likely benign]; RCV000356839.1 [likely benign]; RCV000385830.1 [likely benign]; 			25	95					NF1 (inh=AD pLI=1.00)
chr17	29703438	29703438	C	G	het	hom	het		QUAL=10318;DP=332,124,135;MQM=60	NF1	3'UTR	NF1:NM_001042492.2:3'UTR:MODIFIER:exon58/58:c.*2265C>G:,NF1:NM_000267.3:3'UTR:MODIFIER:exon57/57:c.*2265C>G:		rs1800845	0.5587	0.0000	0/0/0	0.0699							613113 [NF1 (confirmed) Neurofibromatosis,type 1,162200|Leukemia,juvenile myelomonocytic,607785|Neurofibromatosis,familial spinal,162210|Neurofibromatosis-Noonan syndrome,601321|Watson syndrome,193520];	RCV000283413.1 [benign]; RCV000343161.1 [benign]; RCV000346501.1 [benign]; RCV000377894.1 [benign]; 			25	96					NF1 (inh=AD pLI=1.00)
chr17	29704002	29704002	T	C	het	wt	het		QUAL=10917;DP=424,340,432;MQM=60	NF1	3'UTR	NF1:NM_001042492.2:3'UTR:MODIFIER:exon58/58:c.*2829T>C:,NF1:NM_000267.3:3'UTR:MODIFIER:exon57/57:c.*2829T>C:		rs1048317	0.6126	0.0000	0/0/0	0.1199							613113 [NF1 (confirmed) Neurofibromatosis,type 1,162200|Leukemia,juvenile myelomonocytic,607785|Neurofibromatosis,familial spinal,162210|Neurofibromatosis-Noonan syndrome,601321|Watson syndrome,193520];	RCV000271959.1 [likely benign]; RCV000287335.1 [likely benign]; RCV000322312.1 [likely benign]; RCV000376914.1 [likely benign]; 			93	104					NF1 (inh=AD pLI=1.00)
chr17	33901918	33901921	TAAG	-	het	het	wt		QUAL=1871;DP=136,32,41;MQM=59	PEX12	3'UTR	PEX12:NM_000286.2:3'UTR:MODIFIER:exon3/3:c.*880_*883delCTTA:		rs35050283	0.4465	0.0000	0/0/0	0.4390							601758 [PEX12 (provisional) Peroxisome biogenesis disorder 3A (Zellweger),614859|Peroxisome biogenesis disorder 3B,266510];	RCV000264131.1 [benign]; 			50	119					PEX12 (inh=AR pLI=0.00)
chr17	33901965	33901965	C	G	het	het	het		QUAL=4812;DP=197,69,91;MQM=60	PEX12	3'UTR	PEX12:NM_000286.2:3'UTR:MODIFIER:exon3/3:c.*836G>C:		rs10068	0.4010	0.0000	0/0/0	0.0649							601758 [PEX12 (provisional) Peroxisome biogenesis disorder 3A (Zellweger),614859|Peroxisome biogenesis disorder 3B,266510];	RCV000321572.1 [benign]; 			31	114					PEX12 (inh=AR pLI=0.00)
chr17	33904933	33904933	A	-	wt	het	wt	anno_high_impact	QUAL=2976;DP=336,210,317;MQM=59	PEX12	frameshift	PEX12:NM_000286.2:frameshift:HIGH:exon1/3:c.108delT:p.Leu37fs			0.0000	0.0000	0/0/0	0.0000							601758 [PEX12 (provisional) Peroxisome biogenesis disorder 3A (Zellweger),614859|Peroxisome biogenesis disorder 3B,266510];				0	1					PEX12 (inh=AR pLI=0.00)
chr17	33905468	33905468	A	G	hom	hom	het		QUAL=13338;DP=185,167,233;MQM=60	PEX12	5'UTR	PEX12:NM_000286.2:5'UTR:MODIFIER:exon1/3:c.-428T>C:		rs321600	0.8774	0.0000	0/0/0	0.1393							601758 [PEX12 (provisional) Peroxisome biogenesis disorder 3A (Zellweger),614859|Peroxisome biogenesis disorder 3B,266510];	RCV000347251.1 [benign]; 			146	75					PEX12 (inh=AR pLI=0.00)
chr17	37822311	37822311	A	C	het	wt	hom		QUAL=9785;DP=201,230,238;MQM=59	TCAP	synonymous	TCAP:NM_003673.3:synonymous:LOW:exon2/2:c.453A>C:p.Ala151Ala		rs1053651	0.5497	0.6706	27830/17324/955	0.6617							604488 [TCAP (confirmed) Muscular dystrophy,limb-girdle,type 2G,601954|Cardiomyopathy,hypertrophic,25,607487];	RCV000154431.1 [benign]; RCV000037796.10 [benign]; RCV000251363.1 [benign]; RCV000299362.1 [likely benign]; RCV000337974.1 [likely benign]; RCV000395204.1 [likely benign]; 		COSM436493	843	681					TCAP (inh=AR+AD pLI=0.08)
chr17	38783971	38783972	TT	-	hom	hom	hom	low_DP	QUAL=4530;DP=118,16,23;MQM=59	CCR7-SMARCE1	intergenic_region	CCR7-SMARCE1:CCR7-SMARCE1:intergenic_region:MODIFIER::n.38783971_38783972delTT:		rs59835738;rs869254366	0.0000	0.0000	0/0/0	0.2492							603111 [SMARCE1 (provisional) Meningioma,familial,susceptibility to,607174|Coffin-Siris syndrome 5,616938];				54	102					CCR7-SMARCE1 (inh=n/a pLI=n/a)
chr17	40465420	40465420	G	A	het	wt	het		QUAL=203;DP=65,39,52;MQM=51	STAT3	3'UTR	STAT3:NM_139276.2:3'UTR:MODIFIER:exon24/24:c.*2343C>T:,STAT3:NM_213662.1:3'UTR:MODIFIER:exon24/24:c.*2437C>T:,STAT3:NM_003150.3:3'UTR:MODIFIER:exon24/24:c.*2343C>T:	(A)n	rs200029754	0.0000	0.0000	0/0/0	0.0004							102582 [STAT3 (provisional) Hyper-IgE recurrent infection syndrome,147060|Autoimmune disease,multisystem,infantile-onset,1,615952];				0	56					STAT3 (inh=AD pLI=1.00)
chr17	40465422	40465422	C	A	het	wt	het		QUAL=203;DP=65,39,52;MQM=51	STAT3	3'UTR	STAT3:NM_139276.2:3'UTR:MODIFIER:exon24/24:c.*2341G>T:,STAT3:NM_213662.1:3'UTR:MODIFIER:exon24/24:c.*2435G>T:,STAT3:NM_003150.3:3'UTR:MODIFIER:exon24/24:c.*2341G>T:	(A)n		0.0000	0.0000	0/0/0	0.0006							102582 [STAT3 (provisional) Hyper-IgE recurrent infection syndrome,147060|Autoimmune disease,multisystem,infantile-onset,1,615952];				0	38					STAT3 (inh=AD pLI=1.00)
chr17	40466092	40466092	G	A	het	het	hom		QUAL=9468;DP=175,137,165;MQM=60	STAT3	3'UTR	STAT3:NM_139276.2:3'UTR:MODIFIER:exon24/24:c.*1671C>T:,STAT3:NM_213662.1:3'UTR:MODIFIER:exon24/24:c.*1765C>T:,STAT3:NM_003150.3:3'UTR:MODIFIER:exon24/24:c.*1671C>T:		rs1053004	0.4499	0.0000	0/0/0	0.0988							102582 [STAT3 (provisional) Hyper-IgE recurrent infection syndrome,147060|Autoimmune disease,multisystem,infantile-onset,1,615952];	RCV000323761.1 [benign]; 			90	115					STAT3 (inh=AD pLI=1.00)
chr17	40466869	40466869	C	T	het	het	het		QUAL=353;DP=181,54,70;MQM=56	STAT3	3'UTR	STAT3:NM_139276.2:3'UTR:MODIFIER:exon24/24:c.*894G>A:,STAT3:NM_213662.1:3'UTR:MODIFIER:exon24/24:c.*988G>A:,STAT3:NM_003150.3:3'UTR:MODIFIER:exon24/24:c.*894G>A:	AluSc8		0.0000	0.0000	0/0/0	0.0003							102582 [STAT3 (provisional) Hyper-IgE recurrent infection syndrome,147060|Autoimmune disease,multisystem,infantile-onset,1,615952];				9	48					STAT3 (inh=AD pLI=1.00)
chr17	40689455	40689455	T	C	hom	hom	hom		QUAL=21766;DP=200,198,295;MQM=59	NAGLU	synonymous	NAGLU:NM_000263.3:synonymous:LOW:exon2/6:c.423T>C:p.Ser141Ser		rs659497	0.9976	0.9947	60052/32838/5192	0.9721							609701 [NAGLU (confirmed) Mucopolysaccharidosis type IIIB (Sanfilippo B),252920|Charcot-Marie-Tooth disease,axonal,type 2V,616491];	RCV000078458.5 [benign]; RCV000295179.1 [benign]; 			1554	11					NAGLU (inh=AR+AD pLI=0.00)
chr17	40696233	40696233	C	G	hom	hom	hom	low_DP;pred_pathogenic	QUAL=2856;DP=46,17,30;MQM=59	NAGLU	missense	NAGLU:NM_000263.3:missense:MODERATE:exon6/6:c.2209C>G:p.Arg737Gly		rs86312	0.8592	0.9055	49702/28044/2166	0.8676	0.8780	D,T	T	B	D	23.70	609701 [NAGLU (confirmed) Mucopolysaccharidosis type IIIB (Sanfilippo B),252920|Charcot-Marie-Tooth disease,axonal,type 2V,616491];	RCV000078456.4 [benign]; RCV000326969.1 [uncertain significance]; RCV000078457.5 [benign]; RCV000388513.1 [benign]; 		COSM4130095	1311	245					NAGLU (inh=AR+AD pLI=0.00)
chr17	42084067	42084067	T	C	wt	wt	het		QUAL=239;DP=25,22,37;MQM=60	NAGS	synonymous	NAGS:NM_153006.2:synonymous:LOW:exon4/7:c.1086T>C:p.Phe362Phe		rs55708447	0.1068	0.1678	1637/1221/42	0.1493							608300 [NAGS (confirmed) N-acetylglutamate synthase deficiency,237310];	RCV000186064.2 [other]; RCV000275672.1 [benign]; 			45	400					NAGS (inh=AR pLI=0.00)
chr17	42085150	42085150	T	C	hom	hom	hom	low_DP	QUAL=337;DP=7,4,2;MQM=59	NAGS	splice_region&intron	NAGS:NM_153006.2:splice_region&intron:LOW:exon6/6:c.1451+9T>C:		rs228773	0.9603	0.9432	24550/11656/1857	0.7860							608300 [NAGS (confirmed) N-acetylglutamate synthase deficiency,237310];	RCV000250494.1 [benign]; RCV000282299.1 [benign]; 			1363	141					NAGS (inh=AR pLI=0.00)
chr17	42085972	42085972	C	T	hom	hom	het		QUAL=15950;DP=286,146,227;MQM=59	NAGS	3'UTR	NAGS:NM_153006.2:3'UTR:MODIFIER:exon7/7:c.*3C>T:		rs186636	0.4756	0.5660	20389/13970/861	0.5506							608300 [NAGS (confirmed) N-acetylglutamate synthase deficiency,237310];	RCV000250223.1 [benign]; RCV000339592.1 [benign]; 			657	693					NAGS (inh=AR pLI=0.00)
chr17	42086180	42086180	C	T	hom	hom	hom		QUAL=32772;DP=365,282,386;MQM=59	NAGS	3'UTR	NAGS:NM_153006.2:3'UTR:MODIFIER:exon7/7:c.*211C>T:		rs640631	0.8948	0.0000	0/0/0	0.8553							608300 [NAGS (confirmed) N-acetylglutamate synthase deficiency,237310];	RCV000406871.1 [benign]; 			209	21					NAGS (inh=AR pLI=0.00)
chr17	42148205	42148205	C	T	het	hom	wt		QUAL=1286;DP=56,25,39;MQM=58	G6PC3	5'UTR_premature_start_codon_gain,5'UTR,non_coding_transcript_exon	G6PC3:NM_138387.3:5'UTR_premature_start_codon_gain:LOW:exon1/6:c.-129C>T:,G6PC3:NM_001319945.1:5'UTR_premature_start_codon_gain:LOW:exon1/5:c.-129C>T:,G6PC3:NM_138387.3:5'UTR:MODIFIER:exon1/6:c.-129C>T:,G6PC3:NM_001319945.1:5'UTR:MODIFIER:exon1/5:c.-129C>T:,G6PC3:NR_028581.1:non_coding_transcript_exon:MODIFIER:exon1/7:n.108C>T:,G6PC3:NR_028582.1:non_coding_transcript_exon:MODIFIER:exon1/6:n.108C>T:		rs228758	0.3231	0.5670	1438/377/1	0.1066							611045 [G6PC3 (provisional) Neutropenia,severe congenital 4,autosomal recessive,612541|Dursun syndrome,612541];	RCV000312411.1 [benign]; 			183	318					G6PC3 (inh=AR pLI=0.00)
chr17	42153562	42153562	G	C	wt	wt	het		QUAL=926;DP=87,41,66;MQM=60	G6PC3	3'UTR,non_coding_transcript_exon	G6PC3:NM_138387.3:3'UTR:MODIFIER:exon6/6:c.*151G>C:,G6PC3:NM_001319945.1:3'UTR:MODIFIER:exon5/5:c.*485G>C:,G6PC3:NR_028581.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.1622G>C:,G6PC3:NR_028582.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.1487G>C:		rs1046770	0.1002	0.1826	1643/1128/8	0.1529							611045 [G6PC3 (provisional) Neutropenia,severe congenital 4,autosomal recessive,612541|Dursun syndrome,612541];	RCV000348935.1 [benign]; 			19	190					G6PC3 (inh=AR pLI=0.00)
chr17	42983193	42983193	A	G	het	het	het		QUAL=6361;DP=170,158,177;MQM=59	GFAP	3'UTR	GFAP:NM_002055.4:3'UTR:MODIFIER:exon9/9:c.*1522T>C:		rs17027	0.2438	0.0000	0/0/0	0.2478							137780 [GFAP (confirmed) Alexander disease,203450];	RCV000331184.1 [benign]; RCV000331524.1 [likely benign]; 			22	100					GFAP (inh=AD pLI=0.00)
chr17	42984085	42984085	C	T	het	wt	het		QUAL=7716;DP=325,253,325;MQM=59	GFAP	3'UTR	GFAP:NM_002055.4:3'UTR:MODIFIER:exon9/9:c.*630G>A:	FLAM_A	rs72828813	0.0036	0.0000	0/0/0	0.0085							137780 [GFAP (confirmed) Alexander disease,203450];	RCV000390405.1 [likely benign]; 			0	5					GFAP (inh=AD pLI=0.00)
chr17	42984687	42984687	G	C	het	het	het		QUAL=3909;DP=119,68,100;MQM=59	GFAP	3'UTR	GFAP:NM_002055.4:3'UTR:MODIFIER:exon9/9:c.*28C>G:		rs11558961	0.2438	0.2670	4378/2546/281	0.2599							137780 [GFAP (confirmed) Alexander disease,203450];	RCV000056816.1 [not provided]; RCV000305452.1 [benign]; RCV000401615.1 [likely benign]; 			65	369					GFAP (inh=AD pLI=0.00)
chr17	42987523	42987523	G	A	het	het	het	pred_pathogenic	QUAL=9188;DP=223,228,355;MQM=59	GFAP	missense,3'UTR,intron	GFAP:NM_001131019.2:missense:MODERATE:exon8/8:c.1277C>T:p.Thr426Met,GFAP:NM_001242376.1:3'UTR:MODIFIER:exon7/7:c.*314C>T:,GFAP:NM_002055.4:intron:MODIFIER:exon7/8:c.1171+460C>T:		rs9908084	0.1056	0.1375	1356/952/36	0.1265	1.9410	D	T	B	D	9.57	137780 [GFAP (confirmed) Alexander disease,203450];			COSM3755582	99	845					GFAP (inh=AD pLI=0.00)
chr17	42987524	42987524	T	C	het	het	het	pred_pathogenic	QUAL=9188;DP=223,228,355;MQM=59	GFAP	missense,3'UTR,intron	GFAP:NM_001131019.2:missense:MODERATE:exon8/8:c.1276A>G:p.Thr426Ala,GFAP:NM_001242376.1:3'UTR:MODIFIER:exon7/7:c.*313A>G:,GFAP:NM_002055.4:intron:MODIFIER:exon7/8:c.1171+459A>G:		rs9916491	0.2436	0.2675	4424/2575/266	0.2521	0.7530	T	T	B	D	6.79	137780 [GFAP (confirmed) Alexander disease,203450];			COSM4000176	259	1168					GFAP (inh=AD pLI=0.00)
chr17	45195850	45195850	G	A	wt	wt	het	gene_blacklist	QUAL=2884;DP=297,237,275;MQM=60	CDC27	3'UTR	CDC27:NM_001114091.2:3'UTR:MODIFIER:exon19/19:c.*2451C>T:,CDC27:NM_001256.4:3'UTR:MODIFIER:exon19/19:c.*2451C>T:,CDC27:NM_001293089.1:3'UTR:MODIFIER:exon19/19:c.*2451C>T:,CDC27:NM_001293091.1:3'UTR:MODIFIER:exon18/18:c.*2451C>T:		rs11079757	0.1975	0.0000	0/0/0	0.0335											13	63					CDC27 (inh=n/a pLI=0.49)
chr17	45196190	45196190	T	C	het	het	het	gene_blacklist	QUAL=8090;DP=277,132,166;MQM=59	CDC27	3'UTR	CDC27:NM_001114091.2:3'UTR:MODIFIER:exon19/19:c.*2111A>G:,CDC27:NM_001256.4:3'UTR:MODIFIER:exon19/19:c.*2111A>G:,CDC27:NM_001293089.1:3'UTR:MODIFIER:exon19/19:c.*2111A>G:,CDC27:NM_001293091.1:3'UTR:MODIFIER:exon18/18:c.*2111A>G:		rs1713494	0.2808	0.0000	0/0/0	0.0616											34	105					CDC27 (inh=n/a pLI=0.49)
chr17	45197296	45197296	C	T	wt	wt	het	gene_blacklist	QUAL=1586;DP=281,143,164;MQM=60	CDC27	3'UTR	CDC27:NM_001114091.2:3'UTR:MODIFIER:exon19/19:c.*1005G>A:,CDC27:NM_001256.4:3'UTR:MODIFIER:exon19/19:c.*1005G>A:,CDC27:NM_001293089.1:3'UTR:MODIFIER:exon19/19:c.*1005G>A:,CDC27:NM_001293091.1:3'UTR:MODIFIER:exon18/18:c.*1005G>A:		rs11570579	0.1214	0.0000	0/0/0	0.0202											6	49					CDC27 (inh=n/a pLI=0.49)
chr17	45214558	45214558	G	A	het	wt	wt	low_MQM;gene_blacklist;anno_high_impact;pred_pathogenic	QUAL=72;DP=143,80,122;MQM=37	CDC27	stop_gained	CDC27:NM_001114091.2:stop_gained:HIGH:exon14/19:c.1891C>T:p.Arg631*,CDC27:NM_001256.4:stop_gained:HIGH:exon14/19:c.1873C>T:p.Arg625*,CDC27:NM_001293089.1:stop_gained:HIGH:exon14/19:c.1870C>T:p.Arg624*,CDC27:NM_001293091.1:stop_gained:HIGH:exon13/18:c.1690C>T:p.Arg564*		rs77685276	0.0000	0.4968	0/0/0	0.0196	2.0410					41.00					0	474	2	[2] old entry - no details available			CDC27 (inh=n/a pLI=0.49)
chr17	45214682	45214682	A	G	het	wt	wt	low_MQM;gene_blacklist	QUAL=59;DP=169,81,126;MQM=39	CDC27	synonymous,sequence_feature	CDC27:NM_001114091.2:synonymous:LOW:exon14/19:c.1767T>C:p.His589His,CDC27:NM_001256.4:synonymous:LOW:exon14/19:c.1749T>C:p.His583His,CDC27:NM_001293089.1:synonymous:LOW:exon14/19:c.1746T>C:p.His582His,CDC27:NM_001293091.1:synonymous:LOW:exon13/18:c.1566T>C:p.His522His,CDC27:NM_001114091.2:sequence_feature:LOW:exon14/19:c.1767T>C:,CDC27:NM_001256.4:sequence_feature:LOW:exon14/19:c.1749T>C:		rs62075622	0.0000	0.4919	0/0/0	0.0149										COSM4130203, COSM4130204	1	289					CDC27 (inh=n/a pLI=0.49)
chr17	45219669	45219669	G	A	het	wt	wt	low_MQM;gene_blacklist;pred_pathogenic	QUAL=87;DP=102,25,34;MQM=26	CDC27	missense,sequence_feature	CDC27:NM_001114091.2:missense:MODERATE:exon11/19:c.1322C>T:p.Ser441Phe,CDC27:NM_001256.4:missense:MODERATE:exon11/19:c.1304C>T:p.Ser435Phe,CDC27:NM_001293089.1:missense:MODERATE:exon11/19:c.1304C>T:p.Ser435Phe,CDC27:NM_001293091.1:missense:MODERATE:exon10/18:c.1121C>T:p.Ser374Phe,CDC27:NM_001114091.2:sequence_feature:MODERATE:exon11/19:c.1322C>T:,CDC27:NM_001256.4:sequence_feature:MODERATE:exon11/19:c.1304C>T:		rs11491191	0.0000	0.0348	0/0/0	0.0005	4.9730	D,D,D,D	T	P,P,P,P	T,T,T,T	23.00				COSM3932634, COSM3932635	0	136					CDC27 (inh=n/a pLI=0.49)
chr17	45221351	45221351	A	-	wt	wt	het	gene_blacklist	QUAL=460;DP=40,25,41;MQM=60	CDC27	splice_region&intron	CDC27:NM_001114091.2:splice_region&intron:LOW:exon9/18:c.1089-3delT:,CDC27:NM_001256.4:splice_region&intron:LOW:exon9/18:c.1071-3delT:,CDC27:NM_001293089.1:splice_region&intron:LOW:exon9/18:c.1071-3delT:,CDC27:NM_001293091.1:splice_region&intron:LOW:exon8/17:c.888-3delT:		rs11570517	0.1088	0.1382	554/207/6	0.0860											14	177					CDC27 (inh=n/a pLI=0.49)
chr17	45232137	45232137	T	C	wt	het	wt	gene_blacklist	QUAL=1655;DP=232,135,150;MQM=60	CDC27	synonymous	CDC27:NM_001114091.2:synonymous:LOW:exon8/19:c.858A>G:p.Pro286Pro,CDC27:NM_001256.4:synonymous:LOW:exon8/19:c.858A>G:p.Pro286Pro,CDC27:NM_001293089.1:synonymous:LOW:exon8/19:c.858A>G:p.Pro286Pro,CDC27:NM_001293091.1:synonymous:LOW:exon7/18:c.675A>G:p.Pro225Pro		rs61749925	0.0008	0.0038	3/2/0	0.0028										COSM243573, COSM243574	1	26					CDC27 (inh=n/a pLI=0.49)
chr17	45234303	45234303	G	C	het	het	het	low_MQM;gene_blacklist;pred_pathogenic	QUAL=453;DP=131,41,44;MQM=34	CDC27	missense	CDC27:NM_001114091.2:missense:MODERATE:exon7/19:c.818C>G:p.Ala273Gly,CDC27:NM_001256.4:missense:MODERATE:exon7/19:c.818C>G:p.Ala273Gly,CDC27:NM_001293089.1:missense:MODERATE:exon7/19:c.818C>G:p.Ala273Gly,CDC27:NM_001293091.1:missense:MODERATE:exon6/18:c.635C>G:p.Ala212Gly		rs200611688	0.0000	0.4774	0/0/0	0.0050	9.2600	D,D,D,D,D	T	B,B,B,B	T,T,T,T,T	21.70				COSM1178872, COSM1178871	1	356					CDC27 (inh=n/a pLI=0.49)
chr17	45234407	45234407	A	-	het	het	het	low_MQM;gene_blacklist;anno_high_impact	QUAL=1934;DP=223,81,107;MQM=34	CDC27	frameshift	CDC27:NM_001114091.2:frameshift:HIGH:exon7/19:c.714delT:p.Val239fs,CDC27:NM_001256.4:frameshift:HIGH:exon7/19:c.714delT:p.Val239fs,CDC27:NM_001293089.1:frameshift:HIGH:exon7/19:c.714delT:p.Val239fs,CDC27:NM_001293091.1:frameshift:HIGH:exon6/18:c.531delT:p.Val178fs		rs112848754	0.0000	0.4952	0/0/0	0.0132											1	603	1	[1] old entry - no details available			CDC27 (inh=n/a pLI=0.49)
chr17	45234417	45234417	A	G	het	het	het	low_MQM;gene_blacklist;pred_pathogenic	QUAL=1728;DP=208,75,107;MQM=34	CDC27	missense	CDC27:NM_001114091.2:missense:MODERATE:exon7/19:c.704T>C:p.Ile235Thr,CDC27:NM_001256.4:missense:MODERATE:exon7/19:c.704T>C:p.Ile235Thr,CDC27:NM_001293089.1:missense:MODERATE:exon7/19:c.704T>C:p.Ile235Thr,CDC27:NM_001293091.1:missense:MODERATE:exon6/18:c.521T>C:p.Ile174Thr		rs193061947	0.0000	0.4881	0/0/0	0.0003	8.7540	T,T,T,T,T	T	B,B,B,B	T,T,T,T,T	18.40				COSM4130263, COSM4130264	1	506					CDC27 (inh=n/a pLI=0.49)
chr17	45234420	45234420	T	G	het	het	het	low_MQM;gene_blacklist;pred_pathogenic	QUAL=1728;DP=208,75,107;MQM=34	CDC27	missense	CDC27:NM_001114091.2:missense:MODERATE:exon7/19:c.701A>C:p.Tyr234Ser,CDC27:NM_001256.4:missense:MODERATE:exon7/19:c.701A>C:p.Tyr234Ser,CDC27:NM_001293089.1:missense:MODERATE:exon7/19:c.701A>C:p.Tyr234Ser,CDC27:NM_001293091.1:missense:MODERATE:exon6/18:c.518A>C:p.Tyr173Ser		rs78493795	0.0000	0.4898	0/0/0	0.0005	7.5220	T,T,T,T,T	T	B,B,B,B	T,T,T,T,T	19.07				COSM3734971, COSM3734972	1	503					CDC27 (inh=n/a pLI=0.49)
chr17	45234449	45234449	G	A	het	het	het	low_MQM;gene_blacklist	QUAL=451;DP=179,76,105;MQM=35	CDC27	synonymous	CDC27:NM_001114091.2:synonymous:LOW:exon7/19:c.672C>T:p.Tyr224Tyr,CDC27:NM_001256.4:synonymous:LOW:exon7/19:c.672C>T:p.Tyr224Tyr,CDC27:NM_001293089.1:synonymous:LOW:exon7/19:c.672C>T:p.Tyr224Tyr,CDC27:NM_001293091.1:synonymous:LOW:exon6/18:c.489C>T:p.Tyr163Tyr		rs112216339	0.0000	0.4217	0/0/0	0.0003										COSM1383886, COSM1383887	0	316					CDC27 (inh=n/a pLI=0.49)
chr17	45234707	45234707	T	A	het	wt	wt	low_MQM;gene_blacklist;pred_pathogenic	QUAL=682;DP=365,149,149;MQM=36	CDC27	missense	CDC27:NM_001114091.2:missense:MODERATE:exon6/19:c.519A>T:p.Leu173Phe,CDC27:NM_001256.4:missense:MODERATE:exon6/19:c.519A>T:p.Leu173Phe,CDC27:NM_001293089.1:missense:MODERATE:exon6/19:c.519A>T:p.Leu173Phe,CDC27:NM_001293091.1:missense:MODERATE:exon5/18:c.336A>T:p.Leu112Phe		rs75353677	0.0000	0.4633	0/0/0	0.0029	0.5090	D,D,D,D,D	T	B,B,P,B	T,T,T,T,T	11.09				COSM1737257, COSM1737258	0	288					CDC27 (inh=n/a pLI=0.49)
chr17	45234710	45234710	A	C	het	wt	wt	low_MQM;gene_blacklist	QUAL=682;DP=365,149,149;MQM=36	CDC27	synonymous	CDC27:NM_001114091.2:synonymous:LOW:exon6/19:c.516T>G:p.Ser172Ser,CDC27:NM_001256.4:synonymous:LOW:exon6/19:c.516T>G:p.Ser172Ser,CDC27:NM_001293089.1:synonymous:LOW:exon6/19:c.516T>G:p.Ser172Ser,CDC27:NM_001293091.1:synonymous:LOW:exon5/18:c.333T>G:p.Ser111Ser		rs78395997	0.0000	0.3447	0/0/0	0.0007										COSM4130284, COSM4130283	0	242					CDC27 (inh=n/a pLI=0.49)
chr17	45234713	45234713	T	C	het	wt	wt	low_MQM;gene_blacklist	QUAL=439;DP=360,143,141;MQM=32	CDC27	synonymous	CDC27:NM_001114091.2:synonymous:LOW:exon6/19:c.513A>G:p.Thr171Thr,CDC27:NM_001256.4:synonymous:LOW:exon6/19:c.513A>G:p.Thr171Thr,CDC27:NM_001293089.1:synonymous:LOW:exon6/19:c.513A>G:p.Thr171Thr,CDC27:NM_001293091.1:synonymous:LOW:exon5/18:c.330A>G:p.Thr110Thr		rs139751753	0.0000	0.0401	0/0/0	0.0376										COSM1130261, COSM1130260	0	39					CDC27 (inh=n/a pLI=0.49)
chr17	45234760	45234760	-	A	het	het	het	gene_blacklist	QUAL=823;DP=103,59,67;MQM=59	CDC27	splice_region&intron	CDC27:NM_001114091.2:splice_region&intron:LOW:exon5/18:c.476-11dupT:,CDC27:NM_001256.4:splice_region&intron:LOW:exon5/18:c.476-11dupT:,CDC27:NM_001293089.1:splice_region&intron:LOW:exon5/18:c.476-11dupT:,CDC27:NM_001293091.1:splice_region&intron:LOW:exon4/17:c.293-11dupT:		rs11372544;rs577503859	0.2694	0.4021	560/341/43	0.0495											132	423					CDC27 (inh=n/a pLI=0.49)
chr17	45360730	45360730	T	C	wt	wt	het	pred_pathogenic;anno_pathogenic_clinvar	QUAL=3655;DP=101,232,301;MQM=60	ITGB3	missense,sequence_feature	ITGB3:NM_000212.2:missense:MODERATE:exon3/15:c.176T>C:p.Leu59Pro,ITGB3:NM_000212.2:sequence_feature:LOW:exon3/15:c.176T>C:		rs5918	0.0889	0.1235	1050/794/57	0.1228	-1.3820	T,T	T	B	D	0.01	173470 [ITGB3 (confirmed) Glanzmann thrombasthenia,273800|Thrombocytopenia,neonatal alloimmune|Myocardial infarction,susceptibility to,608446|Purpura,posttransfusion|Bleeding disorder,platelet-type,16,autosomal dominant,187800];	RCV000014519.4 [benign]; RCV000014520.21 [pathogenic]; RCV000014521.27 [pathogenic]; RCV000014522.4 [other]; RCV000014524.4 [other]; RCV000246922.1 [benign]; RCV000383813.1 [likely benign]; 	CM890078 [CLASS=DFP MUT=ALT PHEN="Neonatal alloimmune thrombocytopenic purpura association with" GENE=ITGB3]; 		33	369	2	[2] old entry - no details available			ITGB3 (inh=AR+AD pLI=0.14)
chr17	45364540	45364540	T	C	wt	het	wt		QUAL=1894;DP=266,182,266;MQM=60	ITGB3	synonymous	ITGB3:NM_000212.2:synonymous:LOW:exon6/15:c.882T>C:p.Pro294Pro		rs5919	0.1440	0.1029	874/216/124	0.1011							173470 [ITGB3 (confirmed) Glanzmann thrombasthenia,273800|Thrombocytopenia,neonatal alloimmune|Myocardial infarction,susceptibility to,608446|Purpura,posttransfusion|Bleeding disorder,platelet-type,16,autosomal dominant,187800];	RCV000252166.1 [benign]; RCV000389557.1 [benign]; 			21	272					ITGB3 (inh=AR+AD pLI=0.14)
chr17	45368337	45368337	A	C	het	het	hom		QUAL=18417;DP=235,298,349;MQM=60	ITGB3	synonymous,sequence_feature	ITGB3:NM_000212.2:synonymous:LOW:exon9/15:c.1143A>C:p.Val381Val,ITGB3:NM_000212.2:sequence_feature:LOW:exon9/15:c.1143A>C:		rs15908	0.4311	0.3902	9633/4589/970	0.3807							173470 [ITGB3 (confirmed) Glanzmann thrombasthenia,273800|Thrombocytopenia,neonatal alloimmune|Myocardial infarction,susceptibility to,608446|Purpura,posttransfusion|Bleeding disorder,platelet-type,16,autosomal dominant,187800];	RCV000245014.1 [benign]; RCV000336334.1 [benign]; 			258	755					ITGB3 (inh=AR+AD pLI=0.14)
chr17	45369777	45369777	A	G	het	wt	hom		QUAL=5610;DP=105,103,147;MQM=59	ITGB3	synonymous	ITGB3:NM_000212.2:synonymous:LOW:exon10/15:c.1533A>G:p.Glu511Glu		rs4642	0.2873	0.2871	5006/2824/359	0.2842							173470 [ITGB3 (confirmed) Glanzmann thrombasthenia,273800|Thrombocytopenia,neonatal alloimmune|Myocardial infarction,susceptibility to,608446|Purpura,posttransfusion|Bleeding disorder,platelet-type,16,autosomal dominant,187800];	RCV000249975.1 [benign]; RCV000337655.1 [benign]; 		COSM1383908, COSM1383909, COSM4000179	153	644					ITGB3 (inh=AR+AD pLI=0.14)
chr17	45369789	45369789	G	A	het	wt	hom		QUAL=4968;DP=115,91,132;MQM=59	ITGB3	synonymous	ITGB3:NM_000212.2:synonymous:LOW:exon10/15:c.1545G>A:p.Arg515Arg		rs4634	0.2873	0.2873	5006/2822/359	0.2841							173470 [ITGB3 (confirmed) Glanzmann thrombasthenia,273800|Thrombocytopenia,neonatal alloimmune|Myocardial infarction,susceptibility to,608446|Purpura,posttransfusion|Bleeding disorder,platelet-type,16,autosomal dominant,187800];	RCV000241947.1 [benign]; RCV000394843.1 [benign]; 		COSM4000180, COSM1383912, COSM1383913	153	644					ITGB3 (inh=AR+AD pLI=0.14)
chr17	45385012	45385012	C	T	het	het	wt		QUAL=6444;DP=184,357,377;MQM=60	ITGB3,THCAT158	splice_region&intron,intron	ITGB3:NM_000212.2:splice_region&intron:LOW:exon14/14:c.2301+9C>T:,THCAT158:NR_110880.1:intron:MODIFIER:exon2/2:n.363-3864G>A:,THCAT158:NR_110881.1:intron:MODIFIER:exon2/2:n.227-3864G>A:		rs3809863	0.3990	0.4383	11551/7186/1198	0.4288							173470 [ITGB3 (confirmed) Glanzmann thrombasthenia,273800|Thrombocytopenia,neonatal alloimmune|Myocardial infarction,susceptibility to,608446|Purpura,posttransfusion|Bleeding disorder,platelet-type,16,autosomal dominant,187800];	RCV000242227.1 [benign]; RCV000328155.1 [benign]; 			304	771					ITGB3 (inh=AR+AD pLI=0.14), THCAT158 (inh=n/a pLI=n/a)
chr17	45388209	45388209	G	A	wt	wt	het		QUAL=6582;DP=501,397,517;MQM=60	ITGB3,THCAT158	3'UTR,intron	ITGB3:NM_000212.2:3'UTR:MODIFIER:exon15/15:c.*639G>A:,THCAT158:NR_110880.1:intron:MODIFIER:exon2/2:n.363-7061C>T:,THCAT158:NR_110881.1:intron:MODIFIER:exon2/2:n.227-7061C>T:		rs17225109	0.0154	0.0000	0/0/0	0.0062							173470 [ITGB3 (confirmed) Glanzmann thrombasthenia,273800|Thrombocytopenia,neonatal alloimmune|Myocardial infarction,susceptibility to,608446|Purpura,posttransfusion|Bleeding disorder,platelet-type,16,autosomal dominant,187800];	RCV000376795.1 [likely benign]; 			0	15					ITGB3 (inh=AR+AD pLI=0.14), THCAT158 (inh=n/a pLI=n/a)
chr17	45388241	45388241	C	T	wt	het	wt		QUAL=5330;DP=433,385,514;MQM=60	ITGB3,THCAT158	3'UTR,intron	ITGB3:NM_000212.2:3'UTR:MODIFIER:exon15/15:c.*671C>T:,THCAT158:NR_110880.1:intron:MODIFIER:exon2/2:n.363-7093G>A:,THCAT158:NR_110881.1:intron:MODIFIER:exon2/2:n.227-7093G>A:		rs16941864	0.0236	0.0000	0/0/0	0.0069							173470 [ITGB3 (confirmed) Glanzmann thrombasthenia,273800|Thrombocytopenia,neonatal alloimmune|Myocardial infarction,susceptibility to,608446|Purpura,posttransfusion|Bleeding disorder,platelet-type,16,autosomal dominant,187800];	RCV000287057.1 [likely benign]; 			2	31					ITGB3 (inh=AR+AD pLI=0.14), THCAT158 (inh=n/a pLI=n/a)
chr17	45388283	45388283	A	G	wt	het	wt		QUAL=5100;DP=394,375,534;MQM=60	ITGB3,THCAT158	3'UTR,intron	ITGB3:NM_000212.2:3'UTR:MODIFIER:exon15/15:c.*713A>G:,THCAT158:NR_110880.1:intron:MODIFIER:exon2/2:n.363-7135T>C:,THCAT158:NR_110881.1:intron:MODIFIER:exon2/2:n.227-7135T>C:		rs2317676	0.1232	0.0000	0/0/0	0.0160							173470 [ITGB3 (confirmed) Glanzmann thrombasthenia,273800|Thrombocytopenia,neonatal alloimmune|Myocardial infarction,susceptibility to,608446|Purpura,posttransfusion|Bleeding disorder,platelet-type,16,autosomal dominant,187800];	RCV000310133.1 [likely benign]; 			4	40					ITGB3 (inh=AR+AD pLI=0.14), THCAT158 (inh=n/a pLI=n/a)
chr17	45388586	45388586	T	A	het	hom	wt		QUAL=7951;DP=292,174,271;MQM=60	ITGB3,THCAT158	3'UTR,intron	ITGB3:NM_000212.2:3'UTR:MODIFIER:exon15/15:c.*1016T>A:,THCAT158:NR_110880.1:intron:MODIFIER:exon2/2:n.362+7252A>T:,THCAT158:NR_110881.1:intron:MODIFIER:exon2/2:n.226+7252A>T:		rs3809865	0.7234	0.0000	0/0/0	0.1193							173470 [ITGB3 (confirmed) Glanzmann thrombasthenia,273800|Thrombocytopenia,neonatal alloimmune|Myocardial infarction,susceptibility to,608446|Purpura,posttransfusion|Bleeding disorder,platelet-type,16,autosomal dominant,187800];	RCV000370303.1 [benign]; 			128	88					ITGB3 (inh=AR+AD pLI=0.14), THCAT158 (inh=n/a pLI=n/a)
chr17	46020698	46020698	C	T	het	het	wt		QUAL=6571;DP=261,233,343;MQM=60	PNPO	synonymous	PNPO:NM_018129.3:synonymous:LOW:exon2/7:c.165C>T:p.Ser55Ser		rs11079804	0.1625	0.1822	2276/900/33	0.1789							603287 [PNPO (provisional) Pyridoxamine 5'-phosphate oxidase deficiency,610090];	RCV000118001.3 [other]; RCV000297776.1 [benign]; 		COSM1179771	59	456					PNPO (inh=AR pLI=0.00)
chr17	46024660	46024660	A	C	wt	het	het		QUAL=8004;DP=251,233,323;MQM=59	PNPO	3'UTR	PNPO:NM_018129.3:3'UTR:MODIFIER:exon7/7:c.*512A>C:		rs7220104	0.4255	0.0000	0/0/0	0.3981							603287 [PNPO (provisional) Pyridoxamine 5'-phosphate oxidase deficiency,610090];	RCV000389748.1 [benign]; 			30	110					PNPO (inh=AR pLI=0.00)
chr17	46025052	46025052	A	G	wt	het	het	low_DP	QUAL=276;DP=59,14,20;MQM=59	PNPO	3'UTR	PNPO:NM_018129.3:3'UTR:MODIFIER:exon7/7:c.*904A>G:	AluSc	rs1962201	0.6877	0.0000	0/0/0	0.6373							603287 [PNPO (provisional) Pyridoxamine 5'-phosphate oxidase deficiency,610090];	RCV000394753.1 [benign]; 			102	84					PNPO (inh=AR pLI=0.00)
chr17	46026031	46026031	G	C	het	het	wt		QUAL=10136;DP=396,427,579;MQM=59	PNPO	3'UTR	PNPO:NM_018129.3:3'UTR:MODIFIER:exon7/7:c.*1883G>C:	MER5A1	rs1986694	0.1132	0.0000	0/0/0	0.1094							603287 [PNPO (provisional) Pyridoxamine 5'-phosphate oxidase deficiency,610090];	RCV000283286.1 [likely benign]; 			0	46					PNPO (inh=AR pLI=0.00)
chr17	46026156	46026156	A	G	het	hom	het		QUAL=18611;DP=264,316,427;MQM=59	PNPO	3'UTR	PNPO:NM_018129.3:3'UTR:MODIFIER:exon7/7:c.*2008A>G:	Tigger19a	rs1986693	0.8079	0.0000	0/0/0	0.7384							603287 [PNPO (provisional) Pyridoxamine 5'-phosphate oxidase deficiency,610090];	RCV000340353.1 [benign]; 			152	70					PNPO (inh=AR pLI=0.00)
chr17	48252804	48252804	T	C	hom	hom	hom	low_DP	QUAL=869;DP=10,4,15;MQM=60	SGCA	3'UTR,non_coding_transcript_exon	SGCA:NM_000023.3:3'UTR:MODIFIER:exon9/10:c.*6T>C:,SGCA:NM_001135697.2:3'UTR:MODIFIER:exon7/8:c.*6T>C:,SGCA:NR_135553.1:non_coding_transcript_exon:MODIFIER:exon8/9:n.1017T>C:		rs2696288	0.9219	0.9566	54006/29806/3068	0.9221							600119 [SGCA (confirmed) Muscular dystrophy,limb-girdle,type 2D,608099];	RCV000153940.3 [benign]; 			1442	95					SGCA (inh=AR pLI=0.19)
chr17	48261852	48261852	A	G	het	het	wt		QUAL=2922;DP=185,52,71;MQM=58	COL1A1	3'UTR	COL1A1:NM_000088.3:3'UTR:MODIFIER:exon51/51:c.*1011T>C:	A-rich	rs1061970	0.0000	0.0000	0/0/0	0.0644							120150 [COL1A1 (confirmed) Osteogenesis imperfecta,type I,166200|Osteogenesis imperfecta,type II,166210|Osteogenesis imperfecta,type III,259420|Osteogenesis imperfecta,type IV,166220|Ehlers-Danlos syndrome,classic,130000|Ehlers-Danlos syndrome,type VIIA,130060|Caffey disease,114000|Bone mineral density variation QTL,osteoporosis,166710];				2	42					COL1A1 (inh=AR+AD pLI=1.00)
chr17	48261852	48261852	-	G	wt	het	wt		QUAL=2922;DP=185,52,71;MQM=56	COL1A1	3'UTR	COL1A1:NM_000088.3:3'UTR:MODIFIER:exon51/51:c.*1010_*1011insC:	A-rich		0.0000	0.0000	0/0/0	0.0020							120150 [COL1A1 (confirmed) Osteogenesis imperfecta,type I,166200|Osteogenesis imperfecta,type II,166210|Osteogenesis imperfecta,type III,259420|Osteogenesis imperfecta,type IV,166220|Ehlers-Danlos syndrome,classic,130000|Ehlers-Danlos syndrome,type VIIA,130060|Caffey disease,114000|Bone mineral density variation QTL,osteoporosis,166710];				0	0					COL1A1 (inh=AR+AD pLI=1.00)
chr17	48262163	48262163	C	T	wt	wt	het		QUAL=2851;DP=71,153,201;MQM=59	COL1A1	3'UTR	COL1A1:NM_000088.3:3'UTR:MODIFIER:exon51/51:c.*700G>A:			0.0000	0.0000	0/0/0	0.0000							120150 [COL1A1 (confirmed) Osteogenesis imperfecta,type I,166200|Osteogenesis imperfecta,type II,166210|Osteogenesis imperfecta,type III,259420|Osteogenesis imperfecta,type IV,166220|Ehlers-Danlos syndrome,classic,130000|Ehlers-Danlos syndrome,type VIIA,130060|Caffey disease,114000|Bone mineral density variation QTL,osteoporosis,166710];				0	1					COL1A1 (inh=AR+AD pLI=1.00)
chr17	48262181	48262181	-	TGCT	het	wt	hom		QUAL=5040;DP=50,136,164;MQM=59	COL1A1	3'UTR	COL1A1:NM_000088.3:3'UTR:MODIFIER:exon51/51:c.*681_*682insAGCA:		rs112626388;rs35521741;rs3840870	0.5803	0.0000	0/0/0	0.5860							120150 [COL1A1 (confirmed) Osteogenesis imperfecta,type I,166200|Osteogenesis imperfecta,type II,166210|Osteogenesis imperfecta,type III,259420|Osteogenesis imperfecta,type IV,166220|Ehlers-Danlos syndrome,classic,130000|Ehlers-Danlos syndrome,type VIIA,130060|Caffey disease,114000|Bone mineral density variation QTL,osteoporosis,166710];	RCV000311883.1 [likely benign]; RCV000351512.1 [likely benign]; RCV000403912.1 [likely benign]; 			95	113					COL1A1 (inh=AR+AD pLI=1.00)
chr17	48262619	48262619	T	-	hom	hom	hom	low_DP	QUAL=597;DP=31,6,20;MQM=59	COL1A1	3'UTR	COL1A1:NM_000088.3:3'UTR:MODIFIER:exon51/51:c.*244delA:	(T)n		0.0000	0.0000	0/0/0	0.0000							120150 [COL1A1 (confirmed) Osteogenesis imperfecta,type I,166200|Osteogenesis imperfecta,type II,166210|Osteogenesis imperfecta,type III,259420|Osteogenesis imperfecta,type IV,166220|Ehlers-Danlos syndrome,classic,130000|Ehlers-Danlos syndrome,type VIIA,130060|Caffey disease,114000|Bone mineral density variation QTL,osteoporosis,166710];				0	0					COL1A1 (inh=AR+AD pLI=1.00)
chr17	48262775	48262775	A	G	het	hom	wt		QUAL=4489;DP=85,128,171;MQM=59	COL1A1	3'UTR	COL1A1:NM_000088.3:3'UTR:MODIFIER:exon51/51:c.*88T>C:		rs1061237	0.3786	0.0000	0/0/0	0.0528							120150 [COL1A1 (confirmed) Osteogenesis imperfecta,type I,166200|Osteogenesis imperfecta,type II,166210|Osteogenesis imperfecta,type III,259420|Osteogenesis imperfecta,type IV,166220|Ehlers-Danlos syndrome,classic,130000|Ehlers-Danlos syndrome,type VIIA,130060|Caffey disease,114000|Bone mineral density variation QTL,osteoporosis,166710];	RCV000287367.1 [likely benign]; RCV000322041.1 [likely benign]; RCV000376642.1 [likely benign]; 			19	89					COL1A1 (inh=AR+AD pLI=1.00)
chr17	48265475	48265475	A	G	het	het	wt		QUAL=3233;DP=73,204,283;MQM=59	COL1A1	synonymous	COL1A1:NM_000088.3:synonymous:LOW:exon44/51:c.3243T>C:p.Val1081Val		rs1800217	0.0040	0.0092	7/4/0	0.0055							120150 [COL1A1 (confirmed) Osteogenesis imperfecta,type I,166200|Osteogenesis imperfecta,type II,166210|Osteogenesis imperfecta,type III,259420|Osteogenesis imperfecta,type IV,166220|Ehlers-Danlos syndrome,classic,130000|Ehlers-Danlos syndrome,type VIIA,130060|Caffey disease,114000|Bone mineral density variation QTL,osteoporosis,166710];	RCV000178543.1 [benign]; 			0	31					COL1A1 (inh=AR+AD pLI=1.00)
chr17	48265495	48265495	T	C	hom	hom	hom	pred_pathogenic	QUAL=14663;DP=67,175,246;MQM=59	COL1A1	missense	COL1A1:NM_000088.3:missense:MODERATE:exon44/51:c.3223A>G:p.Thr1075Ala		rs1800215	0.9788	0.9848	23381/11926/2154	0.8885	0.5710	T	T	B	D	4.59	120150 [COL1A1 (confirmed) Osteogenesis imperfecta,type I,166200|Osteogenesis imperfecta,type II,166210|Osteogenesis imperfecta,type III,259420|Osteogenesis imperfecta,type IV,166220|Ehlers-Danlos syndrome,classic,130000|Ehlers-Danlos syndrome,type VIIA,130060|Caffey disease,114000|Bone mineral density variation QTL,osteoporosis,166710];	RCV000341625.1 [benign]; 		COSM4130378	1532	33					COL1A1 (inh=AR+AD pLI=1.00)
chr17	48268223	48268223	A	G	hom	hom	hom		QUAL=44290;DP=198,482,726;MQM=59	COL1A1	synonymous	COL1A1:NM_000088.3:synonymous:LOW:exon33/51:c.2298T>C:p.Thr766Thr		rs2734272	0.9998	0.9998	60645/33352/5192	0.9451							120150 [COL1A1 (confirmed) Osteogenesis imperfecta,type I,166200|Osteogenesis imperfecta,type II,166210|Osteogenesis imperfecta,type III,259420|Osteogenesis imperfecta,type IV,166220|Ehlers-Danlos syndrome,classic,130000|Ehlers-Danlos syndrome,type VIIA,130060|Caffey disease,114000|Bone mineral density variation QTL,osteoporosis,166710];	RCV000247058.1 [benign]; RCV000265335.1 [likely benign]; RCV000328440.1 [likely benign]; RCV000383040.1 [likely benign]; 		COSM4130379	1564	1					COL1A1 (inh=AR+AD pLI=1.00)
chr17	48646376	48646376	-	GTGTGTGTGTTG	wt	hom	wt		QUAL=74;DP=41,32,99;MQM=59	CACNA1G	intron	CACNA1G:NM_018896.4:intron:MODIFIER:exon2/37:c.354+34_354+35insGTGTGTGTGTTG:,CACNA1G:NM_001256324.1:intron:MODIFIER:exon2/35:c.354+34_354+35insGTGTGTGTGTTG:,CACNA1G:NM_001256325.1:intron:MODIFIER:exon2/35:c.354+34_354+35insGTGTGTGTGTTG:,CACNA1G:NM_001256326.1:intron:MODIFIER:exon2/35:c.354+34_354+35insGTGTGTGTGTTG:,CACNA1G:NM_001256327.1:intron:MODIFIER:exon2/35:c.354+34_354+35insGTGTGTGTGTTG:,CACNA1G:NM_001256328.1:intron:MODIFIER:exon2/34:c.354+34_354+35insGTGTGTGTGTTG:,CACNA1G:NM_001256329.1:intron:MODIFIER:exon2/35:c.354+34_354+35insGTGTGTGTGTTG:,CACNA1G:NM_001256330.1:intron:MODIFIER:exon2/34:c.354+34_354+35insGTGTGTGTGTTG:,CACNA1G:NM_001256331.1:intron:MODIFIER:exon2/34:c.354+34_354+35insGTGTGTGTGTTG:,CACNA1G:NM_001256332.1:intron:MODIFIER:exon2/34:c.354+34_354+35insGTGTGTGTGTTG:,CACNA1G:NM_001256333.1:intron:MODIFIER:exon2/36:c.354+34_354+35insGTGTGTGTGTTG:,CACNA1G:NM_001256334.1:intron:MODIFIER:exon2/35:c.354+34_354+35insGTGTGTGTGTTG:,CACNA1G:NM_001256359.1:intron:MODIFIER:exon2/35:c.354+34_354+35insGTGTGTGTGTTG:,CACNA1G:NM_001256360.1:intron:MODIFIER:exon2/34:c.354+34_354+35insGTGTGTGTGTTG:,CACNA1G:NM_001256361.1:intron:MODIFIER:exon2/34:c.354+34_354+35insGTGTGTGTGTTG:,CACNA1G:NM_198376.2:intron:MODIFIER:exon2/34:c.354+34_354+35insGTGTGTGTGTTG:,CACNA1G:NM_198377.2:intron:MODIFIER:exon2/36:c.354+34_354+35insGTGTGTGTGTTG:,CACNA1G:NM_198378.2:intron:MODIFIER:exon2/34:c.354+34_354+35insGTGTGTGTGTTG:,CACNA1G:NM_198379.2:intron:MODIFIER:exon2/34:c.354+34_354+35insGTGTGTGTGTTG:,CACNA1G:NM_198380.2:intron:MODIFIER:exon2/35:c.354+34_354+35insGTGTGTGTGTTG:,CACNA1G:NM_198382.2:intron:MODIFIER:exon2/34:c.354+34_354+35insGTGTGTGTGTTG:,CACNA1G:NM_198383.2:intron:MODIFIER:exon2/35:c.354+34_354+35insGTGTGTGTGTTG:,CACNA1G:NM_198384.2:intron:MODIFIER:exon2/35:c.354+34_354+35insGTGTGTGTGTTG:,CACNA1G:NM_198385.2:intron:MODIFIER:exon2/36:c.354+34_354+35insGTGTGTGTGTTG:,CACNA1G:NM_198386.2:intron:MODIFIER:exon2/34:c.354+34_354+35insGTGTGTGTGTTG:,CACNA1G:NM_198387.2:intron:MODIFIER:exon2/33:c.354+34_354+35insGTGTGTGTGTTG:,CACNA1G:NM_198388.2:intron:MODIFIER:exon2/33:c.354+34_354+35insGTGTGTGTGTTG:,CACNA1G:NM_198396.2:intron:MODIFIER:exon2/35:c.354+34_354+35insGTGTGTGTGTTG:,CACNA1G:NR_046054.1:intron:MODIFIER:exon2/35:n.746+34_746+35insGTGTGTGTGTTG:,CACNA1G:NR_046055.1:intron:MODIFIER:exon2/34:n.746+34_746+35insGTGTGTGTGTTG:,CACNA1G:NR_046056.1:intron:MODIFIER:exon2/34:n.746+34_746+35insGTGTGTGTGTTG:,CACNA1G:NR_046057.1:intron:MODIFIER:exon2/34:n.746+34_746+35insGTGTGTGTGTTG:,CACNA1G:NR_046058.1:intron:MODIFIER:exon2/33:n.746+34_746+35insGTGTGTGTGTTG:	(GT)n	rs58450142	0.4689	0.0000	0/0/0	0.0195							604065 [CACNA1G (provisional) Spinocerebellar ataxia 42,616795];				21	61					CACNA1G (inh=AD pLI=1.00)
chr17	48653354	48653354	C	A	het	het	hom		QUAL=9926;DP=99,165,236;MQM=60	CACNA1G	synonymous,non_coding_transcript_exon	CACNA1G:NM_018896.4:synonymous:LOW:exon8/38:c.1591C>A:p.Arg531Arg,CACNA1G:NM_001256324.1:synonymous:LOW:exon8/36:c.1591C>A:p.Arg531Arg,CACNA1G:NM_001256325.1:synonymous:LOW:exon8/36:c.1591C>A:p.Arg531Arg,CACNA1G:NM_001256326.1:synonymous:LOW:exon8/36:c.1591C>A:p.Arg531Arg,CACNA1G:NM_001256327.1:synonymous:LOW:exon8/36:c.1591C>A:p.Arg531Arg,CACNA1G:NM_001256328.1:synonymous:LOW:exon8/35:c.1591C>A:p.Arg531Arg,CACNA1G:NM_001256329.1:synonymous:LOW:exon8/36:c.1591C>A:p.Arg531Arg,CACNA1G:NM_001256330.1:synonymous:LOW:exon8/35:c.1591C>A:p.Arg531Arg,CACNA1G:NM_001256331.1:synonymous:LOW:exon8/35:c.1591C>A:p.Arg531Arg,CACNA1G:NM_001256332.1:synonymous:LOW:exon8/35:c.1591C>A:p.Arg531Arg,CACNA1G:NM_001256333.1:synonymous:LOW:exon8/37:c.1591C>A:p.Arg531Arg,CACNA1G:NM_001256334.1:synonymous:LOW:exon8/36:c.1591C>A:p.Arg531Arg,CACNA1G:NM_001256359.1:synonymous:LOW:exon8/36:c.1591C>A:p.Arg531Arg,CACNA1G:NM_001256360.1:synonymous:LOW:exon8/35:c.1591C>A:p.Arg531Arg,CACNA1G:NM_001256361.1:synonymous:LOW:exon8/35:c.1591C>A:p.Arg531Arg,CACNA1G:NM_198376.2:synonymous:LOW:exon8/35:c.1591C>A:p.Arg531Arg,CACNA1G:NM_198377.2:synonymous:LOW:exon8/37:c.1591C>A:p.Arg531Arg,CACNA1G:NM_198378.2:synonymous:LOW:exon8/35:c.1591C>A:p.Arg531Arg,CACNA1G:NM_198379.2:synonymous:LOW:exon8/35:c.1591C>A:p.Arg531Arg,CACNA1G:NM_198380.2:synonymous:LOW:exon8/36:c.1591C>A:p.Arg531Arg,CACNA1G:NM_198382.2:synonymous:LOW:exon8/35:c.1591C>A:p.Arg531Arg,CACNA1G:NM_198383.2:synonymous:LOW:exon8/36:c.1591C>A:p.Arg531Arg,CACNA1G:NM_198384.2:synonymous:LOW:exon8/36:c.1591C>A:p.Arg531Arg,CACNA1G:NM_198385.2:synonymous:LOW:exon8/37:c.1591C>A:p.Arg531Arg,CACNA1G:NM_198386.2:synonymous:LOW:exon8/35:c.1591C>A:p.Arg531Arg,CACNA1G:NM_198387.2:synonymous:LOW:exon8/34:c.1591C>A:p.Arg531Arg,CACNA1G:NM_198388.2:synonymous:LOW:exon8/34:c.1591C>A:p.Arg531Arg,CACNA1G:NM_198396.2:synonymous:LOW:exon8/36:c.1591C>A:p.Arg531Arg,CACNA1G:NR_046054.1:non_coding_transcript_exon:MODIFIER:exon8/36:n.1983C>A:,CACNA1G:NR_046055.1:non_coding_transcript_exon:MODIFIER:exon8/35:n.1983C>A:,CACNA1G:NR_046056.1:non_coding_transcript_exon:MODIFIER:exon8/35:n.1983C>A:,CACNA1G:NR_046057.1:non_coding_transcript_exon:MODIFIER:exon8/35:n.1983C>A:,CACNA1G:NR_046058.1:non_coding_transcript_exon:MODIFIER:exon8/34:n.1983C>A:		rs12449998	0.5240	0.5554	3740/1310/44	0.3873							604065 [CACNA1G (provisional) Spinocerebellar ataxia 42,616795];			COSM436875, COSM436878, COSM436877, COSM436876	392	922					CACNA1G (inh=AD pLI=1.00)
chr17	48655672	48655672	G	A	wt	het	wt	pred_pathogenic	QUAL=3622;DP=220,303,401;MQM=60	CACNA1G	missense,non_coding_transcript_exon	CACNA1G:NM_018896.4:missense:MODERATE:exon9/38:c.2048G>A:p.Arg683His,CACNA1G:NM_001256324.1:missense:MODERATE:exon9/36:c.2048G>A:p.Arg683His,CACNA1G:NM_001256325.1:missense:MODERATE:exon9/36:c.2048G>A:p.Arg683His,CACNA1G:NM_001256326.1:missense:MODERATE:exon9/36:c.2048G>A:p.Arg683His,CACNA1G:NM_001256327.1:missense:MODERATE:exon9/36:c.2048G>A:p.Arg683His,CACNA1G:NM_001256328.1:missense:MODERATE:exon9/35:c.2048G>A:p.Arg683His,CACNA1G:NM_001256329.1:missense:MODERATE:exon9/36:c.2048G>A:p.Arg683His,CACNA1G:NM_001256330.1:missense:MODERATE:exon9/35:c.2048G>A:p.Arg683His,CACNA1G:NM_001256331.1:missense:MODERATE:exon9/35:c.2048G>A:p.Arg683His,CACNA1G:NM_001256332.1:missense:MODERATE:exon9/35:c.2048G>A:p.Arg683His,CACNA1G:NM_001256333.1:missense:MODERATE:exon9/37:c.2048G>A:p.Arg683His,CACNA1G:NM_001256334.1:missense:MODERATE:exon9/36:c.2048G>A:p.Arg683His,CACNA1G:NM_001256359.1:missense:MODERATE:exon9/36:c.2048G>A:p.Arg683His,CACNA1G:NM_001256360.1:missense:MODERATE:exon9/35:c.2048G>A:p.Arg683His,CACNA1G:NM_001256361.1:missense:MODERATE:exon9/35:c.2048G>A:p.Arg683His,CACNA1G:NM_198376.2:missense:MODERATE:exon9/35:c.2048G>A:p.Arg683His,CACNA1G:NM_198377.2:missense:MODERATE:exon9/37:c.2048G>A:p.Arg683His,CACNA1G:NM_198378.2:missense:MODERATE:exon9/35:c.2048G>A:p.Arg683His,CACNA1G:NM_198379.2:missense:MODERATE:exon9/35:c.2048G>A:p.Arg683His,CACNA1G:NM_198380.2:missense:MODERATE:exon9/36:c.2048G>A:p.Arg683His,CACNA1G:NM_198382.2:missense:MODERATE:exon9/35:c.2048G>A:p.Arg683His,CACNA1G:NM_198383.2:missense:MODERATE:exon9/36:c.2048G>A:p.Arg683His,CACNA1G:NM_198384.2:missense:MODERATE:exon9/36:c.2048G>A:p.Arg683His,CACNA1G:NM_198385.2:missense:MODERATE:exon9/37:c.2048G>A:p.Arg683His,CACNA1G:NM_198386.2:missense:MODERATE:exon9/35:c.2048G>A:p.Arg683His,CACNA1G:NM_198387.2:missense:MODERATE:exon9/34:c.2048G>A:p.Arg683His,CACNA1G:NM_198388.2:missense:MODERATE:exon9/34:c.2048G>A:p.Arg683His,CACNA1G:NM_198396.2:missense:MODERATE:exon9/36:c.2048G>A:p.Arg683His,CACNA1G:NR_046054.1:non_coding_transcript_exon:MODIFIER:exon9/36:n.2440G>A:,CACNA1G:NR_046055.1:non_coding_transcript_exon:MODIFIER:exon9/35:n.2440G>A:,CACNA1G:NR_046056.1:non_coding_transcript_exon:MODIFIER:exon9/35:n.2440G>A:,CACNA1G:NR_046057.1:non_coding_transcript_exon:MODIFIER:exon9/35:n.2440G>A:,CACNA1G:NR_046058.1:non_coding_transcript_exon:MODIFIER:exon9/34:n.2440G>A:		rs539364383	0.0002	0.0001	0/0/0	0.0001	0.3920	T,T,T,T,T,T,T,T,T,T,T,T,T,T,T,T,T,T,T,T,T,T,T,T,T,T	D	B,B,B,B,B,B,B,B,B,B,B,B,B,B,B,B,B,B,B,B,B,B,B,B,B,B	D,D,D,D,D,D,D,D,D,D,D,D,D,D,D,D,D,D,D,D,D,D,D,D,D,D	0.11	604065 [CACNA1G (provisional) Spinocerebellar ataxia 42,616795];				0	1					CACNA1G (inh=AD pLI=1.00)
chr17	48692881	48692881	C	T	het	hom	wt		QUAL=5304;DP=33,191,214;MQM=59	CACNA1G	splice_region&intron	CACNA1G:NM_018896.4:splice_region&intron:LOW:exon27/37:c.4911+8C>T:,CACNA1G:NM_001256324.1:splice_region&intron:LOW:exon26/35:c.4857+8C>T:,CACNA1G:NM_001256325.1:splice_region&intron:LOW:exon27/35:c.4932+8C>T:,CACNA1G:NM_001256326.1:splice_region&intron:LOW:exon26/35:c.4776+8C>T:,CACNA1G:NM_001256327.1:splice_region&intron:LOW:exon27/35:c.4911+8C>T:,CACNA1G:NM_001256328.1:splice_region&intron:LOW:exon26/34:c.4857+8C>T:,CACNA1G:NM_001256329.1:splice_region&intron:LOW:exon27/35:c.4809+8C>T:,CACNA1G:NM_001256330.1:splice_region&intron:LOW:exon26/34:c.4776+8C>T:,CACNA1G:NM_001256331.1:splice_region&intron:LOW:exon26/34:c.4755+8C>T:,CACNA1G:NM_001256332.1:splice_region&intron:LOW:exon26/34:c.4740+8C>T:,CACNA1G:NM_001256333.1:splice_region&intron:LOW:exon27/36:c.4911+8C>T:,CACNA1G:NM_001256334.1:splice_region&intron:LOW:exon26/35:c.4878+8C>T:,CACNA1G:NM_001256359.1:splice_region&intron:LOW:exon27/35:c.4830+8C>T:,CACNA1G:NM_001256360.1:splice_region&intron:LOW:exon26/34:c.4803+8C>T:,CACNA1G:NM_001256361.1:splice_region&intron:LOW:exon26/34:c.4797+8C>T:,CACNA1G:NM_198376.2:splice_region&intron:LOW:exon25/34:c.4809+8C>T:,CACNA1G:NM_198377.2:splice_region&intron:LOW:exon26/36:c.4878+8C>T:,CACNA1G:NM_198378.2:splice_region&intron:LOW:exon26/34:c.4878+8C>T:,CACNA1G:NM_198379.2:splice_region&intron:LOW:exon25/34:c.4809+8C>T:,CACNA1G:NM_198380.2:splice_region&intron:LOW:exon26/35:c.4878+8C>T:,CACNA1G:NM_198382.2:splice_region&intron:LOW:exon26/34:c.4842+8C>T:,CACNA1G:NM_198383.2:splice_region&intron:LOW:exon26/35:c.4842+8C>T:,CACNA1G:NM_198384.2:splice_region&intron:LOW:exon27/35:c.4911+8C>T:,CACNA1G:NM_198385.2:splice_region&intron:LOW:exon27/36:c.4911+8C>T:,CACNA1G:NM_198386.2:splice_region&intron:LOW:exon26/34:c.4857+8C>T:,CACNA1G:NM_198387.2:splice_region&intron:LOW:exon25/33:c.4809+8C>T:,CACNA1G:NM_198388.2:splice_region&intron:LOW:exon25/33:c.4788+8C>T:,CACNA1G:NM_198396.2:splice_region&intron:LOW:exon25/35:c.4809+8C>T:,CACNA1G:NR_046054.1:splice_region&intron:LOW:exon27/35:n.5303+8C>T:,CACNA1G:NR_046055.1:splice_region&intron:LOW:exon26/34:n.5270+8C>T:,CACNA1G:NR_046056.1:splice_region&intron:LOW:exon26/34:n.5249+8C>T:,CACNA1G:NR_046057.1:splice_region&intron:LOW:exon26/34:n.5234+8C>T:,CACNA1G:NR_046058.1:splice_region&intron:LOW:exon25/33:n.5180+8C>T:		rs8066527	0.2001	0.2842	4983/3686/296	0.2748							604065 [CACNA1G (provisional) Spinocerebellar ataxia 42,616795];				201	737					CACNA1G (inh=AD pLI=1.00)
chr17	48703752	48703752	T	C	het	hom	wt		QUAL=4626;DP=156,73,94;MQM=59	CACNA1G	synonymous,non_coding_transcript_exon	CACNA1G:NM_018896.4:synonymous:LOW:exon38/38:c.6774T>C:p.Pro2258Pro,CACNA1G:NM_001256324.1:synonymous:LOW:exon36/36:c.6585T>C:p.Pro2195Pro,CACNA1G:NM_001256325.1:synonymous:LOW:exon36/36:c.6516T>C:p.Pro2172Pro,CACNA1G:NM_001256326.1:synonymous:LOW:exon36/36:c.6504T>C:p.Pro2168Pro,CACNA1G:NM_001256327.1:synonymous:LOW:exon36/36:c.6474T>C:p.Pro2158Pro,CACNA1G:NM_001256328.1:synonymous:LOW:exon35/35:c.6420T>C:p.Pro2140Pro,CACNA1G:NM_001256329.1:synonymous:LOW:exon36/36:c.6393T>C:p.Pro2131Pro,CACNA1G:NM_001256330.1:synonymous:LOW:exon35/35:c.6360T>C:p.Pro2120Pro,CACNA1G:NM_001256331.1:synonymous:LOW:exon35/35:c.6339T>C:p.Pro2113Pro,CACNA1G:NM_001256332.1:synonymous:LOW:exon35/35:c.6324T>C:p.Pro2108Pro,CACNA1G:NM_001256333.1:synonymous:LOW:exon37/37:c.6258T>C:p.Pro2086Pro,CACNA1G:NM_001256334.1:synonymous:LOW:exon36/36:c.6225T>C:p.Pro2075Pro,CACNA1G:NM_001256359.1:synonymous:LOW:exon36/36:c.6414T>C:p.Pro2138Pro,CACNA1G:NM_001256360.1:synonymous:LOW:exon35/35:c.6387T>C:p.Pro2129Pro,CACNA1G:NM_001256361.1:synonymous:LOW:exon35/35:c.6381T>C:p.Pro2127Pro,CACNA1G:NM_198376.2:synonymous:LOW:exon35/35:c.6156T>C:p.Pro2052Pro,CACNA1G:NM_198377.2:synonymous:LOW:exon37/37:c.6741T>C:p.Pro2247Pro,CACNA1G:NM_198378.2:synonymous:LOW:exon35/35:c.6462T>C:p.Pro2154Pro,CACNA1G:NM_198379.2:synonymous:LOW:exon35/35:c.6537T>C:p.Pro2179Pro,CACNA1G:NM_198380.2:synonymous:LOW:exon36/36:c.6606T>C:p.Pro2202Pro,CACNA1G:NM_198382.2:synonymous:LOW:exon35/35:c.6426T>C:p.Pro2142Pro,CACNA1G:NM_198383.2:synonymous:LOW:exon36/36:c.6561T>C:p.Pro2187Pro,CACNA1G:NM_198384.2:synonymous:LOW:exon36/36:c.6495T>C:p.Pro2165Pro,CACNA1G:NM_198385.2:synonymous:LOW:exon37/37:c.6639T>C:p.Pro2213Pro,CACNA1G:NM_198386.2:synonymous:LOW:exon35/35:c.6441T>C:p.Pro2147Pro,CACNA1G:NM_198387.2:synonymous:LOW:exon34/34:c.6393T>C:p.Pro2131Pro,CACNA1G:NM_198388.2:synonymous:LOW:exon34/34:c.6372T>C:p.Pro2124Pro,CACNA1G:NM_198396.2:synonymous:LOW:exon36/36:c.6672T>C:p.Pro2224Pro,CACNA1G:NR_046054.1:non_coding_transcript_exon:MODIFIER:exon36/36:n.6838T>C:,CACNA1G:NR_046055.1:non_coding_transcript_exon:MODIFIER:exon35/35:n.6805T>C:,CACNA1G:NR_046056.1:non_coding_transcript_exon:MODIFIER:exon35/35:n.6784T>C:,CACNA1G:NR_046057.1:non_coding_transcript_exon:MODIFIER:exon35/35:n.6769T>C:,CACNA1G:NR_046058.1:non_coding_transcript_exon:MODIFIER:exon34/34:n.6715T>C:		rs739925	0.3672	0.4165	9847/6278/1230	0.3892							604065 [CACNA1G (provisional) Spinocerebellar ataxia 42,616795];			COSM4130401, COSM4130402, COSM4130403	350	868					CACNA1G (inh=AD pLI=1.00)
chr17	48703986	48703986	G	A	het	wt	het		QUAL=1621;DP=61,61,85;MQM=59	CACNA1G	synonymous,non_coding_transcript_exon	CACNA1G:NM_018896.4:synonymous:LOW:exon38/38:c.7008G>A:p.Pro2336Pro,CACNA1G:NM_001256324.1:synonymous:LOW:exon36/36:c.6819G>A:p.Pro2273Pro,CACNA1G:NM_001256325.1:synonymous:LOW:exon36/36:c.6750G>A:p.Pro2250Pro,CACNA1G:NM_001256326.1:synonymous:LOW:exon36/36:c.6738G>A:p.Pro2246Pro,CACNA1G:NM_001256327.1:synonymous:LOW:exon36/36:c.6708G>A:p.Pro2236Pro,CACNA1G:NM_001256328.1:synonymous:LOW:exon35/35:c.6654G>A:p.Pro2218Pro,CACNA1G:NM_001256329.1:synonymous:LOW:exon36/36:c.6627G>A:p.Pro2209Pro,CACNA1G:NM_001256330.1:synonymous:LOW:exon35/35:c.6594G>A:p.Pro2198Pro,CACNA1G:NM_001256331.1:synonymous:LOW:exon35/35:c.6573G>A:p.Pro2191Pro,CACNA1G:NM_001256332.1:synonymous:LOW:exon35/35:c.6558G>A:p.Pro2186Pro,CACNA1G:NM_001256333.1:synonymous:LOW:exon37/37:c.6492G>A:p.Pro2164Pro,CACNA1G:NM_001256334.1:synonymous:LOW:exon36/36:c.6459G>A:p.Pro2153Pro,CACNA1G:NM_001256359.1:synonymous:LOW:exon36/36:c.6648G>A:p.Pro2216Pro,CACNA1G:NM_001256360.1:synonymous:LOW:exon35/35:c.6621G>A:p.Pro2207Pro,CACNA1G:NM_001256361.1:synonymous:LOW:exon35/35:c.6615G>A:p.Pro2205Pro,CACNA1G:NM_198376.2:synonymous:LOW:exon35/35:c.6390G>A:p.Pro2130Pro,CACNA1G:NM_198377.2:synonymous:LOW:exon37/37:c.6975G>A:p.Pro2325Pro,CACNA1G:NM_198378.2:synonymous:LOW:exon35/35:c.6696G>A:p.Pro2232Pro,CACNA1G:NM_198379.2:synonymous:LOW:exon35/35:c.6771G>A:p.Pro2257Pro,CACNA1G:NM_198380.2:synonymous:LOW:exon36/36:c.6840G>A:p.Pro2280Pro,CACNA1G:NM_198382.2:synonymous:LOW:exon35/35:c.6660G>A:p.Pro2220Pro,CACNA1G:NM_198383.2:synonymous:LOW:exon36/36:c.6795G>A:p.Pro2265Pro,CACNA1G:NM_198384.2:synonymous:LOW:exon36/36:c.6729G>A:p.Pro2243Pro,CACNA1G:NM_198385.2:synonymous:LOW:exon37/37:c.6873G>A:p.Pro2291Pro,CACNA1G:NM_198386.2:synonymous:LOW:exon35/35:c.6675G>A:p.Pro2225Pro,CACNA1G:NM_198387.2:synonymous:LOW:exon34/34:c.6627G>A:p.Pro2209Pro,CACNA1G:NM_198388.2:synonymous:LOW:exon34/34:c.6606G>A:p.Pro2202Pro,CACNA1G:NM_198396.2:synonymous:LOW:exon36/36:c.6906G>A:p.Pro2302Pro,CACNA1G:NR_046054.1:non_coding_transcript_exon:MODIFIER:exon36/36:n.7072G>A:,CACNA1G:NR_046055.1:non_coding_transcript_exon:MODIFIER:exon35/35:n.7039G>A:,CACNA1G:NR_046056.1:non_coding_transcript_exon:MODIFIER:exon35/35:n.7018G>A:,CACNA1G:NR_046057.1:non_coding_transcript_exon:MODIFIER:exon35/35:n.7003G>A:,CACNA1G:NR_046058.1:non_coding_transcript_exon:MODIFIER:exon34/34:n.6949G>A:		rs9893223	0.1927	0.1181	1359/126/600	0.1095							604065 [CACNA1G (provisional) Spinocerebellar ataxia 42,616795];			COSM436909, COSM436907, COSM436908	14	238					CACNA1G (inh=AD pLI=1.00)
chr17	48704800	48704800	A	C	het	hom	wt	low_DP	QUAL=1609;DP=64,11,7;MQM=60	CACNA1G	3'UTR,non_coding_transcript_exon	CACNA1G:NM_018896.4:3'UTR:MODIFIER:exon38/38:c.*688A>C:,CACNA1G:NM_001256324.1:3'UTR:MODIFIER:exon36/36:c.*688A>C:,CACNA1G:NM_001256325.1:3'UTR:MODIFIER:exon36/36:c.*688A>C:,CACNA1G:NM_001256326.1:3'UTR:MODIFIER:exon36/36:c.*688A>C:,CACNA1G:NM_001256327.1:3'UTR:MODIFIER:exon36/36:c.*688A>C:,CACNA1G:NM_001256328.1:3'UTR:MODIFIER:exon35/35:c.*688A>C:,CACNA1G:NM_001256329.1:3'UTR:MODIFIER:exon36/36:c.*688A>C:,CACNA1G:NM_001256330.1:3'UTR:MODIFIER:exon35/35:c.*688A>C:,CACNA1G:NM_001256331.1:3'UTR:MODIFIER:exon35/35:c.*688A>C:,CACNA1G:NM_001256332.1:3'UTR:MODIFIER:exon35/35:c.*688A>C:,CACNA1G:NM_001256333.1:3'UTR:MODIFIER:exon37/37:c.*688A>C:,CACNA1G:NM_001256334.1:3'UTR:MODIFIER:exon36/36:c.*688A>C:,CACNA1G:NM_001256359.1:3'UTR:MODIFIER:exon36/36:c.*688A>C:,CACNA1G:NM_001256360.1:3'UTR:MODIFIER:exon35/35:c.*688A>C:,CACNA1G:NM_001256361.1:3'UTR:MODIFIER:exon35/35:c.*688A>C:,CACNA1G:NM_198376.2:3'UTR:MODIFIER:exon35/35:c.*688A>C:,CACNA1G:NM_198377.2:3'UTR:MODIFIER:exon37/37:c.*688A>C:,CACNA1G:NM_198378.2:3'UTR:MODIFIER:exon35/35:c.*688A>C:,CACNA1G:NM_198379.2:3'UTR:MODIFIER:exon35/35:c.*688A>C:,CACNA1G:NM_198380.2:3'UTR:MODIFIER:exon36/36:c.*688A>C:,CACNA1G:NM_198382.2:3'UTR:MODIFIER:exon35/35:c.*688A>C:,CACNA1G:NM_198383.2:3'UTR:MODIFIER:exon36/36:c.*688A>C:,CACNA1G:NM_198384.2:3'UTR:MODIFIER:exon36/36:c.*688A>C:,CACNA1G:NM_198385.2:3'UTR:MODIFIER:exon37/37:c.*688A>C:,CACNA1G:NM_198386.2:3'UTR:MODIFIER:exon35/35:c.*688A>C:,CACNA1G:NM_198387.2:3'UTR:MODIFIER:exon34/34:c.*688A>C:,CACNA1G:NM_198388.2:3'UTR:MODIFIER:exon34/34:c.*688A>C:,CACNA1G:NM_198396.2:3'UTR:MODIFIER:exon36/36:c.*688A>C:,CACNA1G:NR_046054.1:non_coding_transcript_exon:MODIFIER:exon36/36:n.7886A>C:,CACNA1G:NR_046055.1:non_coding_transcript_exon:MODIFIER:exon35/35:n.7853A>C:,CACNA1G:NR_046056.1:non_coding_transcript_exon:MODIFIER:exon35/35:n.7832A>C:,CACNA1G:NR_046057.1:non_coding_transcript_exon:MODIFIER:exon35/35:n.7817A>C:,CACNA1G:NR_046058.1:non_coding_transcript_exon:MODIFIER:exon34/34:n.7763A>C:	(TATA)n	rs34036927	0.1348	0.0000	3/1/0	0.0367							604065 [CACNA1G (provisional) Spinocerebellar ataxia 42,616795];				39	218					CACNA1G (inh=AD pLI=1.00)
chr17	56283026	56283026	G	A	wt	wt	het		QUAL=3364;DP=279,221,291;MQM=60	MKS1	3'UTR	MKS1:NM_001321269.1:3'UTR:MODIFIER:exon17/17:c.*325C>T:,MKS1:NM_001321268.1:3'UTR:MODIFIER:exon17/17:c.*414C>T:,MKS1:NM_017777.3:3'UTR:MODIFIER:exon18/18:c.*414C>T:,MKS1:NM_001165927.1:3'UTR:MODIFIER:exon18/18:c.*414C>T:		rs2302313	0.0863	0.1028	84/31/2	0.0291							609883 [MKS1 (confirmed) Meckel syndrome 1,249000|Bardet-Biedl syndrome 13,615990|Joubert syndrome 28,617121];	RCV000342948.1 [likely benign]; RCV000392540.1 [likely benign]; 		COSM4000227	9	201					MKS1 (inh=AR pLI=0.00)
chr17	56283089	56283089	C	-	hom	het	het		QUAL=15383;DP=342,200,238;MQM=59	MKS1	3'UTR	MKS1:NM_001321269.1:3'UTR:MODIFIER:exon17/17:c.*262delG:,MKS1:NM_001321268.1:3'UTR:MODIFIER:exon17/17:c.*351delG:,MKS1:NM_017777.3:3'UTR:MODIFIER:exon18/18:c.*351delG:,MKS1:NM_001165927.1:3'UTR:MODIFIER:exon18/18:c.*351delG:		rs35298266	0.0152	0.0219	7/4/0	0.0096							609883 [MKS1 (confirmed) Meckel syndrome 1,249000|Bardet-Biedl syndrome 13,615990|Joubert syndrome 28,617121];				1	70					MKS1 (inh=AR pLI=0.00)
chr17	56283365	56283365	G	A	wt	wt	het		QUAL=763;DP=158,60,65;MQM=60	MKS1	missense,3'UTR	MKS1:NM_001321269.1:missense:MODERATE:exon17/17:c.1672C>T:p.Arg558Cys,MKS1:NM_001321268.1:3'UTR:MODIFIER:exon17/17:c.*75C>T:,MKS1:NM_017777.3:3'UTR:MODIFIER:exon18/18:c.*75C>T:,MKS1:NM_001165927.1:3'UTR:MODIFIER:exon18/18:c.*75C>T:		rs35184412	0.0863	0.0000	0/0/0	0.0160							609883 [MKS1 (confirmed) Meckel syndrome 1,249000|Bardet-Biedl syndrome 13,615990|Joubert syndrome 28,617121];	RCV000269059.1 [likely benign]; RCV000363357.1 [likely benign]; 			2	74					MKS1 (inh=AR pLI=0.00)
chr17	56290334	56290334	T	C	hom	hom	hom		QUAL=11582;DP=143,98,125;MQM=60	MKS1	splice_region&intron	MKS1:NM_001321269.1:splice_region&intron:LOW:exon8/16:c.858+9A>G:,MKS1:NM_001321268.1:splice_region&intron:LOW:exon7/16:c.249+9A>G:,MKS1:NM_017777.3:splice_region&intron:LOW:exon8/17:c.858+9A>G:,MKS1:NM_001165927.1:splice_region&intron:LOW:exon8/17:c.828+9A>G:		rs3826300	0.4808	0.4466	13147/6816/3120	0.4355							609883 [MKS1 (confirmed) Meckel syndrome 1,249000|Bardet-Biedl syndrome 13,615990|Joubert syndrome 28,617121];	RCV000114214.3 [other]; RCV000313219.1 [benign]; RCV000367861.1 [benign]; 		COSM4000229, COSM4000228	302	773					MKS1 (inh=AR pLI=0.00)
chr17	57076104	57076104	T	A	het	het	hom		QUAL=3794;DP=179,28,37;MQM=60	TRIM37	3'UTR,intron	TRIM37:NM_001320987.1:3'UTR:MODIFIER:exon23/23:c.*634A>T:,TRIM37:NM_001320988.1:3'UTR:MODIFIER:exon23/23:c.*634A>T:,TRIM37:NM_001320990.1:3'UTR:MODIFIER:exon24/24:c.*634A>T:,TRIM37:NM_015294.4:3'UTR:MODIFIER:exon24/24:c.*634A>T:,TRIM37:NM_001005207.3:intron:MODIFIER:exon24/24:c.2891+638A>T:,TRIM37:NM_001320989.1:intron:MODIFIER:exon23/23:c.2774+638A>T:		rs28475409	0.3277	0.0000	0/0/0	0.3325							605073 [TRIM37 (confirmed) Mulibrey nanism,253250];	RCV000372594.1 [benign]; 			35	105					TRIM37 (inh=AR pLI=0.17)
chr17	57184162	57184162	A	C	het	het	hom	low_DP	QUAL=1031;DP=15,17,29;MQM=59	TRIM37	5'UTR	TRIM37:NM_001005207.3:5'UTR:MODIFIER:exon1/25:c.-340T>G:,TRIM37:NM_001320989.1:5'UTR:MODIFIER:exon1/24:c.-340T>G:,TRIM37:NM_001320987.1:5'UTR:MODIFIER:exon1/23:c.-340T>G:,TRIM37:NM_001320988.1:5'UTR:MODIFIER:exon1/23:c.-340T>G:,TRIM37:NM_001320990.1:5'UTR:MODIFIER:exon1/24:c.-782T>G:,TRIM37:NM_015294.4:5'UTR:MODIFIER:exon1/24:c.-340T>G:		rs7503190	0.6118	0.0000	0/0/0	0.1008							605073 [TRIM37 (confirmed) Mulibrey nanism,253250];	RCV000276584.1 [benign]; 			77	89					TRIM37 (inh=AR pLI=0.17)
chr17	59757143	59757143	A	C	wt	het	het		QUAL=1952;DP=223,41,104;MQM=60	BRIP1	3'UTR	BRIP1:NM_032043.2:3'UTR:MODIFIER:exon20/20:c.*3514T>G:	MIR	rs10744996	0.7622	0.0000	0/0/0	0.7157							605882 [BRIP1 (confirmed) Breast cancer,early-onset,114480|Fanconi anemia,complementation group J,609054];	RCV000259510.1 [likely benign]; RCV000319405.1 [likely benign]; 			74	60					BRIP1 (inh=AR+AD pLI=0.00)
chr17	59757169	59757169	T	A	wt	het	wt		QUAL=408;DP=190,36,86;MQM=60	BRIP1	3'UTR	BRIP1:NM_032043.2:3'UTR:MODIFIER:exon20/20:c.*3488A>T:		rs11079454	0.3423	0.0000	0/0/0	0.3473							605882 [BRIP1 (confirmed) Breast cancer,early-onset,114480|Fanconi anemia,complementation group J,609054];	RCV000343111.1 [likely benign]; RCV000379026.1 [likely benign]; 			16	64					BRIP1 (inh=AR+AD pLI=0.00)
chr17	59758567	59758567	C	G	wt	het	wt		QUAL=1477;DP=296,120,151;MQM=60	BRIP1	3'UTR	BRIP1:NM_032043.2:3'UTR:MODIFIER:exon20/20:c.*2090G>C:	THE1C	rs60657820	0.3922	0.0000	0/0/0	0.2454							605882 [BRIP1 (confirmed) Breast cancer,early-onset,114480|Fanconi anemia,complementation group J,609054];	RCV000194841.1 [likely benign]; RCV000330408.1 [likely benign]; RCV000371096.1 [likely benign]; 			16	65					BRIP1 (inh=AR+AD pLI=0.00)
chr17	59758572	59758575	GACA	-	wt	het	wt		QUAL=1255;DP=274,126,148;MQM=60	BRIP1	3'UTR	BRIP1:NM_032043.2:3'UTR:MODIFIER:exon20/20:c.*2082_*2085delTGTC:	THE1C	rs10601136	0.3880	0.0000	0/0/0	0.3253							605882 [BRIP1 (confirmed) Breast cancer,early-onset,114480|Fanconi anemia,complementation group J,609054];	RCV000277157.1 [likely benign]; RCV000315840.1 [likely benign]; 			16	65					BRIP1 (inh=AR+AD pLI=0.00)
chr17	59760174	59760174	G	A	wt	het	het		QUAL=8110;DP=457,263,323;MQM=60	BRIP1	3'UTR	BRIP1:NM_032043.2:3'UTR:MODIFIER:exon20/20:c.*483C>T:		rs7213430	0.6260	0.0000	0/0/0	0.6301							605882 [BRIP1 (confirmed) Breast cancer,early-onset,114480|Fanconi anemia,complementation group J,609054];	RCV000289915.1 [likely benign]; RCV000347253.1 [likely benign]; 			86	107					BRIP1 (inh=AR+AD pLI=0.00)
chr17	59760499	59760499	A	G	wt	het	het		QUAL=3977;DP=272,122,150;MQM=60	BRIP1	3'UTR	BRIP1:NM_032043.2:3'UTR:MODIFIER:exon20/20:c.*158T>C:	AluSg	rs1978111	0.6218	0.0000	0/0/0	0.5643							605882 [BRIP1 (confirmed) Breast cancer,early-onset,114480|Fanconi anemia,complementation group J,609054];	RCV000331494.1 [likely benign]; RCV000388380.1 [likely benign]; 			86	108					BRIP1 (inh=AR+AD pLI=0.00)
chr17	59760996	59760996	A	G	wt	het	het		QUAL=4659;DP=438,137,183;MQM=60	BRIP1	synonymous	BRIP1:NM_032043.2:synonymous:LOW:exon20/20:c.3411T>C:p.Tyr1137Tyr		rs4986763	0.6208	0.5941	22043/11338/2201	0.5943							605882 [BRIP1 (confirmed) Breast cancer,early-onset,114480|Fanconi anemia,complementation group J,609054];	RCV000162378.1 [benign]; RCV000251677.1 [benign]; RCV000283962.1 [likely benign]; RCV000341269.1 [likely benign]; RCV000410144.1 [benign]; RCV000411217.1 [benign]; 			1188	1641	1	[1] Ilnaz Sepahi 29-03-2016 batch import			BRIP1 (inh=AR+AD pLI=0.00)
chr17	59763347	59763347	A	G	wt	het	het		QUAL=8494;DP=412,295,402;MQM=60	BRIP1	missense	BRIP1:NM_032043.2:missense:MODERATE:exon19/20:c.2755T>C:p.Ser919Pro		rs4986764	0.6278	0.5972	22365/11454/2344	0.5828	0.1360	T	T	B	T	0.20	605882 [BRIP1 (confirmed) Breast cancer,early-onset,114480|Fanconi anemia,complementation group J,609054];	RCV000120400.2 [benign]; RCV000132148.2 [benign]; RCV000286073.1 [likely benign]; RCV000377937.1 [likely benign]; RCV000410195.1 [benign]; RCV000412161.1 [benign]; 	CM046104 [CLASS=DP MUT=REF PHEN="Breast cancer association with" GENE=BRIP1]; 		1193	1642	1	[1] Ilnaz Sepahi 29-03-2016 batch import			BRIP1 (inh=AR+AD pLI=0.00)
chr17	59763465	59763465	T	C	wt	het	het		QUAL=6549;DP=446,249,329;MQM=60	BRIP1	synonymous	BRIP1:NM_032043.2:synonymous:LOW:exon19/20:c.2637A>G:p.Glu879Glu		rs4986765	0.8151	0.7188	32088/14734/4248	0.7134							605882 [BRIP1 (confirmed) Breast cancer,early-onset,114480|Fanconi anemia,complementation group J,609054];	RCV000162379.1 [benign]; RCV000242120.1 [benign]; RCV000290016.1 [likely benign]; RCV000347348.1 [likely benign]; RCV000410880.1 [benign]; RCV000412411.1 [benign]; 		COSM437064, COSM1479821	1616	1484	1	[1] Ilnaz Sepahi 29-03-2016 batch import			BRIP1 (inh=AR+AD pLI=0.00)
chr17	59940819	59940819	C	T	wt	wt	het		QUAL=601;DP=56,42,50;MQM=60	BRIP1	5'UTR	BRIP1:NM_032043.2:5'UTR:MODIFIER:exon1/20:c.-205G>A:		rs2048718	0.5230	0.0000	0/0/0	0.4436							605882 [BRIP1 (confirmed) Breast cancer,early-onset,114480|Fanconi anemia,complementation group J,609054];	RCV000262472.1 [likely benign]; RCV000317692.1 [likely benign]; 			38	76					BRIP1 (inh=AR+AD pLI=0.00)
chr17	61996204	61996204	T	C	wt	het	het		QUAL=2603;DP=128,70,114;MQM=59	GH1	5'UTR	GH1:NM_000515.4:5'UTR:MODIFIER:exon1/5:c.-68A>G:,GH1:NM_022559.3:5'UTR:MODIFIER:exon1/5:c.-68A>G:,GH1:NM_022560.3:5'UTR:MODIFIER:exon1/4:c.-68A>G:		rs6171	0.3634	0.0000	0/0/0	0.0750							139250 [GH1 (confirmed) Growth hormone deficiency,isolated,type IA,262400|Growth hormone deficiency,isolated,type IB,612781|Growth hormone deficiency,isolated,type II,173100|Kowarski syndrome,262650];	RCV000399451.1 [likely benign]; 	CR031006 [CLASS=FP MUT=ALT PHEN="Altered gene expression" GENE=GH1]; 		167	430					GH1 (inh=AR+AD pLI=0.02)
chr17	62006129	62006129	-	G	het	wt	het		QUAL=965;DP=62,34,37;MQM=59	CD79B	3'UTR	CD79B:NM_001039933.2:3'UTR:MODIFIER:exon6/6:c.*456dupC:,CD79B:NM_000626.3:3'UTR:MODIFIER:exon6/6:c.*456dupC:,CD79B:NM_001329050.1:3'UTR:MODIFIER:exon5/5:c.*456dupC:,CD79B:NM_021602.3:3'UTR:MODIFIER:exon5/5:c.*456dupC:		rs554643850	0.0014	0.0000	0/0/0	0.0017							147245 [CD79B (provisional) Agammaglobulinemia 6,612692];				0	3					CD79B (inh=AR pLI=0.95)
chr17	62006406	62006406	A	G	het	het	wt		QUAL=1848;DP=101,65,127;MQM=60	CD79B	3'UTR	CD79B:NM_001039933.2:3'UTR:MODIFIER:exon6/6:c.*180T>C:,CD79B:NM_000626.3:3'UTR:MODIFIER:exon6/6:c.*180T>C:,CD79B:NM_001329050.1:3'UTR:MODIFIER:exon5/5:c.*180T>C:,CD79B:NM_021602.3:3'UTR:MODIFIER:exon5/5:c.*180T>C:		rs147717759	0.0030	0.0000	0/0/0	0.0015							147245 [CD79B (provisional) Agammaglobulinemia 6,612692];				0	7					CD79B (inh=AR pLI=0.95)
chr17	62006432	62006432	G	A	wt	het	het		QUAL=1557;DP=88,46,88;MQM=60	CD79B	3'UTR	CD79B:NM_001039933.2:3'UTR:MODIFIER:exon6/6:c.*154C>T:,CD79B:NM_000626.3:3'UTR:MODIFIER:exon6/6:c.*154C>T:,CD79B:NM_001329050.1:3'UTR:MODIFIER:exon5/5:c.*154C>T:,CD79B:NM_021602.3:3'UTR:MODIFIER:exon5/5:c.*154C>T:		rs12603821	0.2837	0.0000	0/0/0	0.0406							147245 [CD79B (provisional) Agammaglobulinemia 6,612692];				38	114					CD79B (inh=AR pLI=0.95)
chr17	62006433	62006433	G	C	wt	het	het		QUAL=1557;DP=88,46,88;MQM=60	CD79B	3'UTR	CD79B:NM_001039933.2:3'UTR:MODIFIER:exon6/6:c.*153C>G:,CD79B:NM_000626.3:3'UTR:MODIFIER:exon6/6:c.*153C>G:,CD79B:NM_001329050.1:3'UTR:MODIFIER:exon5/5:c.*153C>G:,CD79B:NM_021602.3:3'UTR:MODIFIER:exon5/5:c.*153C>G:		rs1051688	0.2837	0.0000	0/0/0	0.0411							147245 [CD79B (provisional) Agammaglobulinemia 6,612692];				38	114					CD79B (inh=AR pLI=0.95)
chr17	62006497	62006497	A	G	wt	het	het		QUAL=1217;DP=64,32,65;MQM=60	CD79B	3'UTR	CD79B:NM_001039933.2:3'UTR:MODIFIER:exon6/6:c.*89T>C:,CD79B:NM_000626.3:3'UTR:MODIFIER:exon6/6:c.*89T>C:,CD79B:NM_001329050.1:3'UTR:MODIFIER:exon5/5:c.*89T>C:,CD79B:NM_021602.3:3'UTR:MODIFIER:exon5/5:c.*89T>C:		rs1051684	0.5619	0.0000	0/0/0	0.1192							147245 [CD79B (provisional) Agammaglobulinemia 6,612692];				90	116					CD79B (inh=AR pLI=0.95)
chr17	62007498	62007498	A	G	wt	het	het		QUAL=13224;DP=351,464,584;MQM=60	CD79B	synonymous,intron	CD79B:NM_001039933.2:synonymous:LOW:exon3/6:c.369T>C:p.Cys123Cys,CD79B:NM_000626.3:synonymous:LOW:exon3/6:c.366T>C:p.Cys122Cys,CD79B:NM_001329050.1:intron:MODIFIER:exon2/4:c.122-250T>C:,CD79B:NM_021602.3:intron:MODIFIER:exon2/4:c.119-250T>C:		rs2070776	0.5617	0.5952	21810/14146/2345	0.5920							147245 [CD79B (provisional) Agammaglobulinemia 6,612692];			COSM148316	699	722					CD79B (inh=AR pLI=0.95)
chr17	62016440	62016440	-	CA	wt	het	het		QUAL=7195;DP=283,296,374;MQM=59	SCN4A	3'UTR	SCN4A:NM_000334.4:3'UTR:MODIFIER:exon24/24:c.*1689_*1690dupTG:		rs397797581;rs66908473;rs752948504;rs79824884	0.6078	0.0000	0/0/0	0.5166							603967 [SCN4A (confirmed) Hyperkalemic periodic paralysis,type 2,170500|Paramyotonia congenita,168300|Myotonia congenita,atypical,acetazolamide-responsive,608390|Myasthenic syndrome,congenital,16,614198|Hypokalemic periodic paralysis,type 2,613345];	RCV000264045.1 [benign]; RCV000309028.1 [benign]; RCV000323743.1 [benign]; RCV000358810.1 [benign]; RCV000398112.1 [benign]; 			44	164					SCN4A (inh=AR+AD pLI=0.01)
chr17	62016727	62016727	-	ACACATATAT	wt	het	het		QUAL=8715;DP=413,399,526;MQM=59	SCN4A	3'UTR	SCN4A:NM_000334.4:3'UTR:MODIFIER:exon24/24:c.*1394_*1403dupATATATGTGT:		rs58550342	0.3746	0.0000	0/0/0	0.3963							603967 [SCN4A (confirmed) Hyperkalemic periodic paralysis,type 2,170500|Paramyotonia congenita,168300|Myotonia congenita,atypical,acetazolamide-responsive,608390|Myasthenic syndrome,congenital,16,614198|Hypokalemic periodic paralysis,type 2,613345];	RCV000269915.1 [benign]; RCV000273435.1 [benign]; RCV000333260.1 [benign]; RCV000368947.1 [benign]; RCV000387625.1 [benign]; 			52	91					SCN4A (inh=AR+AD pLI=0.01)
chr17	62017421	62017421	A	G	wt	het	het		QUAL=10941;DP=394,334,466;MQM=59	SCN4A	3'UTR	SCN4A:NM_000334.4:3'UTR:MODIFIER:exon24/24:c.*710T>C:		rs2532111	0.5960	0.0000	0/0/0	0.6002							603967 [SCN4A (confirmed) Hyperkalemic periodic paralysis,type 2,170500|Paramyotonia congenita,168300|Myotonia congenita,atypical,acetazolamide-responsive,608390|Myasthenic syndrome,congenital,16,614198|Hypokalemic periodic paralysis,type 2,613345];	RCV000299310.1 [benign]; RCV000312427.1 [benign]; RCV000337946.1 [benign]; RCV000404348.1 [benign]; RCV000406453.1 [benign]; 			85	121					SCN4A (inh=AR+AD pLI=0.01)
chr17	62018002	62018002	C	A	het	wt	het		QUAL=5440;DP=199,212,242;MQM=60	SCN4A	3'UTR	SCN4A:NM_000334.4:3'UTR:MODIFIER:exon24/24:c.*129G>T:		rs140026321	0.0016	0.0000	0/0/0	0.0033							603967 [SCN4A (confirmed) Hyperkalemic periodic paralysis,type 2,170500|Paramyotonia congenita,168300|Myotonia congenita,atypical,acetazolamide-responsive,608390|Myasthenic syndrome,congenital,16,614198|Hypokalemic periodic paralysis,type 2,613345];	RCV000289000.1 [likely benign]; RCV000293949.1 [likely benign]; RCV000346264.1 [likely benign]; RCV000351216.1 [likely benign]; RCV000389473.1 [likely benign]; 			0	3					SCN4A (inh=AR+AD pLI=0.01)
chr17	62018773	62018773	T	C	wt	het	het		QUAL=4052;DP=166,152,180;MQM=60	SCN4A	synonymous	SCN4A:NM_000334.4:synonymous:LOW:exon24/24:c.4869A>G:p.Thr1623Thr		rs2070720	0.4189	0.3703	8742/4288/1730	0.3653							603967 [SCN4A (confirmed) Hyperkalemic periodic paralysis,type 2,170500|Paramyotonia congenita,168300|Myotonia congenita,atypical,acetazolamide-responsive,608390|Myasthenic syndrome,congenital,16,614198|Hypokalemic periodic paralysis,type 2,613345];	RCV000078662.6 [benign]; RCV000271992.1 [benign]; RCV000302506.1 [benign]; RCV000327021.1 [benign]; RCV000363176.1 [benign]; RCV000366604.1 [benign]; 			227	692					SCN4A (inh=AR+AD pLI=0.01)
chr17	62020348	62020348	T	C	wt	het	het	pred_pathogenic	QUAL=11403;DP=231,379,522;MQM=60	SCN4A	missense	SCN4A:NM_000334.4:missense:MODERATE:exon23/24:c.4126A>G:p.Asn1376Asp		rs2058194	0.5615	0.5237	17134/9529/2801	0.5157	4.7990	T	T	B	D	12.24	603967 [SCN4A (confirmed) Hyperkalemic periodic paralysis,type 2,170500|Paramyotonia congenita,168300|Myotonia congenita,atypical,acetazolamide-responsive,608390|Myasthenic syndrome,congenital,16,614198|Hypokalemic periodic paralysis,type 2,613345];	RCV000118272.5 [benign]; RCV000266121.1 [benign]; RCV000306001.1 [benign]; RCV000309565.1 [benign]; RCV000358378.1 [benign]; RCV000366334.1 [benign]; 		COSM148318	500	750					SCN4A (inh=AR+AD pLI=0.01)
chr17	62028920	62028920	C	G	het	het	wt	pred_pathogenic	QUAL=4329;DP=194,170,193;MQM=59	SCN4A	missense	SCN4A:NM_000334.4:missense:MODERATE:exon14/24:c.2717G>C:p.Ser906Thr		rs41280102	0.0050	0.0095	8/6/0	0.0095	0.5540	T	T	B	D	7.54	603967 [SCN4A (confirmed) Hyperkalemic periodic paralysis,type 2,170500|Paramyotonia congenita,168300|Myotonia congenita,atypical,acetazolamide-responsive,608390|Myasthenic syndrome,congenital,16,614198|Hypokalemic periodic paralysis,type 2,613345];	RCV000020269.1 [benign]; RCV000078659.8 [other]; RCV000288548.1 [likely benign]; RCV000342369.1 [likely benign]; RCV000348143.1 [likely benign]; RCV000382734.1 [likely benign]; RCV000398742.1 [likely benign]; 	CM034679 [CLASS=FP MUT=ALT PHEN="Impaired slow inactivation" GENE=SCN4A]; 		0	45	2	[2] Stefanie Beck-Woedl 11.12.2014			SCN4A (inh=AR+AD pLI=0.01)
chr17	62041068	62041068	T	C	hom	hom	hom	pred_pathogenic	QUAL=7750;DP=107,63,83;MQM=60	SCN4A	missense	SCN4A:NM_000334.4:missense:MODERATE:exon10/24:c.1570A>G:p.Ser524Gly		rs6504191	0.9443	0.9288	50207/26766/3789	0.8993	1.3430	T	T	B	D	0.03	603967 [SCN4A (confirmed) Hyperkalemic periodic paralysis,type 2,170500|Paramyotonia congenita,168300|Myotonia congenita,atypical,acetazolamide-responsive,608390|Myasthenic syndrome,congenital,16,614198|Hypokalemic periodic paralysis,type 2,613345];	RCV000118264.5 [benign]; RCV000279460.1 [benign]; RCV000294720.1 [benign]; RCV000336656.1 [benign]; RCV000351978.1 [benign]; RCV000400214.1 [benign]; 		COSM4130494	1344	212					SCN4A (inh=AR+AD pLI=0.01)
chr17	71197323	71197323	G	C	het	wt	het	pred_pathogenic	QUAL=8285;DP=382,289,377;MQM=59	COG1	missense	COG1:NM_018714.2:missense:MODERATE:exon7/14:c.1357G>C:p.Glu453Gln		rs62621249	0.0503	0.0670	359/255/8	0.0671	4.1400	T,T	T	B,B,B	T,T	22.20	606973 [COG1 (confirmed) Congenital disorder of glycosylation,type IIg,611209];	RCV000081961.4 [benign]; RCV000275253.1 [likely benign]; 		COSM3755789	20	247					COG1 (inh=AR pLI=0.10)
chr17	72912265	72912265	C	G	hom	hom	het		QUAL=9057;DP=94,132,144;MQM=59	USH1G	3'UTR	USH1G:NM_173477.4:3'UTR:MODIFIER:exon3/3:c.*1903G>C:,USH1G:NM_001282489.2:3'UTR:MODIFIER:exon3/3:c.*1903G>C:		rs1568448	0.3540	0.0000	0/0/0	0.4056							607696 [USH1G (confirmed) Usher syndrome,type 1G,606943];	RCV000280705.1 [benign]; 			42	104					USH1G (inh=AR pLI=0.00)
chr17	72912862	72912862	G	A	wt	wt	het		QUAL=2499;DP=102,173,219;MQM=60	USH1G	3'UTR	USH1G:NM_173477.4:3'UTR:MODIFIER:exon3/3:c.*1306C>T:,USH1G:NM_001282489.2:3'UTR:MODIFIER:exon3/3:c.*1306C>T:		rs1013013	0.2037	0.0000	0/0/0	0.2096							607696 [USH1G (confirmed) Usher syndrome,type 1G,606943];	RCV000352489.1 [likely benign]; 			11	77					USH1G (inh=AR pLI=0.00)
chr17	72913797	72913797	T	-	hom	hom	hom		QUAL=16403;DP=145,185,250;MQM=59	USH1G	3'UTR	USH1G:NM_173477.4:3'UTR:MODIFIER:exon3/3:c.*371delA:,USH1G:NM_001282489.2:3'UTR:MODIFIER:exon3/3:c.*371delA:		rs55654382	1.0000	0.0000	0/0/0	0.9157							607696 [USH1G (confirmed) Usher syndrome,type 1G,606943];				230	0					USH1G (inh=AR pLI=0.00)
chr17	73269258	73269258	G	C	hom	hom	hom		QUAL=42827;DP=274,465,598;MQM=59	SLC25A19,LOC100287042	3'UTR,non_coding_transcript_exon	SLC25A19:NM_001126121.1:3'UTR:MODIFIER:exon8/8:c.*274C>G:,SLC25A19:NM_001126122.1:3'UTR:MODIFIER:exon7/7:c.*274C>G:,SLC25A19:NM_021734.4:3'UTR:MODIFIER:exon8/8:c.*274C>G:,LOC100287042:NR_036520.1:non_coding_transcript_exon:MODIFIER:exon1/1:n.1879G>C:		rs7198	0.5365	0.0000	0/0/0	0.6635							606521 [SLC25A19 (confirmed) Microcephaly,Amish type,607196|Thiamine metabolism dysfunction syndrome 4 (progressive polyneuropathy type),613710];	RCV000333409.1 [likely benign]; 			128	105					SLC25A19 (inh=AR pLI=0.93), LOC100287042 (inh=n/a pLI=n/a)
chr17	73269530	73269530	A	G	hom	hom	hom		QUAL=34421;DP=301,319,441;MQM=60	SLC25A19,LOC100287042	3'UTR,non_coding_transcript_exon	SLC25A19:NM_001126121.1:3'UTR:MODIFIER:exon8/8:c.*2T>C:,SLC25A19:NM_001126122.1:3'UTR:MODIFIER:exon7/7:c.*2T>C:,SLC25A19:NM_021734.4:3'UTR:MODIFIER:exon8/8:c.*2T>C:,LOC100287042:NR_036520.1:non_coding_transcript_exon:MODIFIER:exon1/1:n.2151A>G:		rs1809352	0.9002	0.9290	51858/28159/3027	0.9060							606521 [SLC25A19 (confirmed) Microcephaly,Amish type,607196|Thiamine metabolism dysfunction syndrome 4 (progressive polyneuropathy type),613710];	RCV000118365.1 [benign]; RCV000327662.1 [likely benign]; 			1340	208					SLC25A19 (inh=AR pLI=0.93), LOC100287042 (inh=n/a pLI=n/a)
chr17	73269676	73269676	C	T	hom	hom	hom		QUAL=32496;DP=306,294,430;MQM=59	SLC25A19,LOC100287042	synonymous,non_coding_transcript_exon	SLC25A19:NM_001126121.1:synonymous:LOW:exon8/8:c.819G>A:p.Leu273Leu,SLC25A19:NM_001126122.1:synonymous:LOW:exon7/7:c.819G>A:p.Leu273Leu,SLC25A19:NM_021734.4:synonymous:LOW:exon8/8:c.819G>A:p.Leu273Leu,LOC100287042:NR_036520.1:non_coding_transcript_exon:MODIFIER:exon1/1:n.2297C>T:		rs4789164	0.5302	0.6517	27604/15403/119	0.6449							606521 [SLC25A19 (confirmed) Microcephaly,Amish type,607196|Thiamine metabolism dysfunction syndrome 4 (progressive polyneuropathy type),613710];	RCV000118371.2 [likely benign]; RCV000282825.1 [likely benign]; 			639	708					SLC25A19 (inh=AR pLI=0.93), LOC100287042 (inh=n/a pLI=n/a)
chr17	73279624	73279624	A	G	hom	hom	hom		QUAL=10216;DP=91,100,132;MQM=60	SLC25A19	synonymous	SLC25A19:NM_001126121.1:synonymous:LOW:exon5/8:c.339T>C:p.Tyr113Tyr,SLC25A19:NM_001126122.1:synonymous:LOW:exon4/7:c.339T>C:p.Tyr113Tyr,SLC25A19:NM_021734.4:synonymous:LOW:exon5/8:c.339T>C:p.Tyr113Tyr		rs7213318	0.8896	0.9617	55939/33017/3409	0.9403							606521 [SLC25A19 (confirmed) Microcephaly,Amish type,607196|Thiamine metabolism dysfunction syndrome 4 (progressive polyneuropathy type),613710];	RCV000118368.2 [likely benign]; RCV000334842.1 [likely benign]; 		COSM4130610	1530	33					SLC25A19 (inh=AR pLI=0.93)
chr17	73285461	73285461	A	C	hom	hom	hom		QUAL=7895;DP=90,75,100;MQM=59	SLC25A19	5'UTR	SLC25A19:NM_001126121.1:5'UTR:MODIFIER:exon1/8:c.-155T>G:,SLC25A19:NM_001126122.1:5'UTR:MODIFIER:exon1/7:c.-65T>G:,SLC25A19:NM_021734.4:5'UTR:MODIFIER:exon1/8:c.-139T>G:		rs2291033	0.8612	0.0000	0/0/0	0.8551							606521 [SLC25A19 (confirmed) Microcephaly,Amish type,607196|Thiamine metabolism dysfunction syndrome 4 (progressive polyneuropathy type),613710];	RCV000312441.1 [likely benign]; 			223	6					SLC25A19 (inh=AR pLI=0.93)
chr17	73518203	73518203	G	C	hom	hom	hom	pred_pathogenic	QUAL=21643;DP=189,221,295;MQM=59	TSEN54	missense	TSEN54:NM_207346.2:missense:MODERATE:exon8/11:c.1041G>C:p.Lys347Asn		rs9911502	0.4447	0.6414	10356/6865/111	0.5181	3.6300	D	T	P	T	26.10	608755 [TSEN54 (provisional) Pontocerebellar hypoplasia type 2A,277470|Pontocerebellar hypoplasia type 4,225753|Pontocerebellar hypoplasia type 5,610204];	RCV000147767.5 [benign]; RCV000295979.1 [benign]; 		COSM437385	1132	1179					TSEN54 (inh=AR pLI=0.00)
chr17	73518284	73518284	G	C	hom	hom	hom		QUAL=15916;DP=112,186,229;MQM=59	TSEN54	synonymous	TSEN54:NM_207346.2:synonymous:LOW:exon8/11:c.1122G>C:p.Arg374Arg		rs6501820	0.8143	0.8717	8961/4099/1218	0.6336							608755 [TSEN54 (provisional) Pontocerebellar hypoplasia type 2A,277470|Pontocerebellar hypoplasia type 4,225753|Pontocerebellar hypoplasia type 5,610204];	RCV000082834.6 [benign]; RCV000400655.1 [benign]; 			2173	458					TSEN54 (inh=AR pLI=0.00)
chr17	73519413	73519413	C	T	hom	hom	hom	pred_pathogenic	QUAL=33493;DP=358,355,431;MQM=59	TSEN54	missense	TSEN54:NM_207346.2:missense:MODERATE:exon9/11:c.1310C>T:p.Ala437Val		rs8064529	0.5613	0.6241	24545/15568/1756	0.6146	0.3350	T	T	B	T	23.00	608755 [TSEN54 (provisional) Pontocerebellar hypoplasia type 2A,277470|Pontocerebellar hypoplasia type 4,225753|Pontocerebellar hypoplasia type 5,610204];	RCV000147771.2 [benign]; RCV000304359.1 [benign]; 			1146	1177					TSEN54 (inh=AR pLI=0.00)
chr17	73750859	73750859	C	G	hom	hom	het		QUAL=22693;DP=189,398,503;MQM=59	ITGB4	synonymous	ITGB4:NM_000213.4:synonymous:LOW:exon34/40:c.4521C>G:p.Pro1507Pro,ITGB4:NM_001005731.2:synonymous:LOW:exon33/39:c.4311C>G:p.Pro1437Pro,ITGB4:NM_001321123.1:synonymous:LOW:exon33/39:c.4311C>G:p.Pro1437Pro,ITGB4:NM_001005619.1:synonymous:LOW:exon32/39:c.4311C>G:p.Pro1437Pro		rs8669	0.3772	0.4520	13004/8106/94	0.4429							147557 [ITGB4 (confirmed) Epidermolysis bullosa,junctional,with pyloric atresia,226730|Epidermolysis bullosa,junctional,non-Herlitz type,226650|Epidermolysis bullosa of hands and feet,131800];	RCV000244157.1 [benign]; RCV000289992.1 [benign]; RCV000375888.1 [benign]; 		COSM3755857, COSM3755858	321	779					ITGB4 (inh=AR+AD pLI=0.00)
chr17	73753503	73753503	T	C	hom	hom	hom	pred_pathogenic	QUAL=31656;DP=162,398,467;MQM=59	ITGB4	missense	ITGB4:NM_000213.4:missense:MODERATE:exon40/40:c.5336T>C:p.Leu1779Pro,ITGB4:NM_001005731.2:missense:MODERATE:exon39/39:c.5126T>C:p.Leu1709Pro,ITGB4:NM_001321123.1:missense:MODERATE:exon39/39:c.5126T>C:p.Leu1709Pro,ITGB4:NM_001005619.1:missense:MODERATE:exon39/39:c.5285T>C:p.Leu1762Pro		rs871443	0.5715	0.7144	32047/19478/324	0.7067	4.7950	T,T,T	T	D,P,P	T,T,T	26.10	147557 [ITGB4 (confirmed) Epidermolysis bullosa,junctional,with pyloric atresia,226730|Epidermolysis bullosa,junctional,non-Herlitz type,226650|Epidermolysis bullosa of hands and feet,131800];	RCV000247515.1 [benign]; RCV000294224.1 [benign]; RCV000322321.1 [benign]; 		COSM3722197, COSM3722198	865	602					ITGB4 (inh=AR+AD pLI=0.00)
chr17	73753661	73753661	C	T	hom	hom	hom		QUAL=23988;DP=172,289,390;MQM=59	ITGB4	3'UTR	ITGB4:NM_000213.4:3'UTR:MODIFIER:exon40/40:c.*25C>T:,ITGB4:NM_001005731.2:3'UTR:MODIFIER:exon39/39:c.*25C>T:,ITGB4:NM_001321123.1:3'UTR:MODIFIER:exon39/39:c.*25C>T:,ITGB4:NM_001005619.1:3'UTR:MODIFIER:exon39/39:c.*25C>T:		rs9367	0.6530	0.7379	33375/20646/1478	0.7104							147557 [ITGB4 (confirmed) Epidermolysis bullosa,junctional,with pyloric atresia,226730|Epidermolysis bullosa,junctional,non-Herlitz type,226650|Epidermolysis bullosa of hands and feet,131800];	RCV000279492.1 [benign]; RCV000287232.1 [benign]; 			438	272					ITGB4 (inh=AR+AD pLI=0.00)
chr17	73942196	73942196	C	G	het	het	wt		QUAL=2292;DP=115,92,117;MQM=60	ACOX1	3'UTR	ACOX1:NM_004035.6:3'UTR:MODIFIER:exon14/14:c.*633G>C:,ACOX1:NM_001185039.1:3'UTR:MODIFIER:exon14/14:c.*633G>C:,ACOX1:NM_007292.5:3'UTR:MODIFIER:exon14/14:c.*633G>C:		rs71382188	0.0266	0.0000	0/0/0	0.0480							609751 [ACOX1 (confirmed) Peroxisomal acyl-CoA oxidase deficiency,264470];	RCV000298055.1 [likely benign]; 			0	32					ACOX1 (inh=AR pLI=0.09)
chr17	73949540	73949540	G	C	hom	hom	hom		QUAL=19540;DP=164,198,256;MQM=60	ACOX1	missense	ACOX1:NM_004035.6:missense:MODERATE:exon7/14:c.936C>G:p.Ile312Met,ACOX1:NM_001185039.1:missense:MODERATE:exon7/14:c.822C>G:p.Ile274Met,ACOX1:NM_007292.5:missense:MODERATE:exon7/14:c.936C>G:p.Ile312Met		rs1135640	0.5507	0.6424	26247/14634/252	0.6323	1.0860	T,T,T,T,T	T	B,B,B,B	T,T,T	17.91	609751 [ACOX1 (confirmed) Peroxisomal acyl-CoA oxidase deficiency,264470];	RCV000253358.1 [benign]; RCV000405630.1 [benign]; 		COSM3755874, COSM3755875	646	697					ACOX1 (inh=AR pLI=0.09)
chr17	75316009	75316009	G	T	wt	wt	het		QUAL=413;DP=50,32,42;MQM=60	SEPT9	5'UTR,intron	SEPT9:NM_006640.4:5'UTR:MODIFIER:exon1/11:c.-400G>T:,SEPT9:NM_001113491.1:intron:MODIFIER:exon2/11:c.76+12730G>T:,SEPT9:NM_001293695.1:intron:MODIFIER:exon1/10:c.19+38373G>T:,SEPT9:NM_001113492.1:intron:MODIFIER:exon2/11:c.-417+12730G>T:		rs138208028	0.0170	0.0000	0/0/0	0.0083							604061 [SEPT9 (confirmed) Leukemia,acute myeloid,therapy-related|Ovarian carcinoma|Amyotrophy,hereditary neuralgic,162100];	RCV000311820.1 [benign]; 			0	3					SEPT9 (inh=AD pLI=0.89)
chr17	75372339	75372339	C	T	het	het	hom		QUAL=6849;DP=96,113,153;MQM=59	SEPT9	5'UTR,intron	SEPT9:NM_001113494.1:5'UTR:MODIFIER:exon1/11:c.-558C>T:,SEPT9:NM_001113491.1:intron:MODIFIER:exon2/11:c.77-25802C>T:,SEPT9:NM_001293695.1:intron:MODIFIER:exon1/10:c.20-25802C>T:,SEPT9:NM_001113492.1:intron:MODIFIER:exon2/11:c.-416-25802C>T:,SEPT9:NM_006640.4:intron:MODIFIER:exon1/10:c.23-25802C>T:,SEPT9:NM_001113493.1:intron:MODIFIER:exon1/10:c.55+2705C>T:		rs312826	0.6066	0.0000	0/0/0	0.5936							604061 [SEPT9 (confirmed) Leukemia,acute myeloid,therapy-related|Ovarian carcinoma|Amyotrophy,hereditary neuralgic,162100];				87	102					SEPT9 (inh=AD pLI=0.89)
chr17	75372447	75372447	G	A	wt	het	wt		QUAL=683;DP=215,65,90;MQM=60	SEPT9	5'UTR,intron	SEPT9:NM_001113494.1:5'UTR:MODIFIER:exon1/11:c.-450G>A:,SEPT9:NM_001113491.1:intron:MODIFIER:exon2/11:c.77-25694G>A:,SEPT9:NM_001293695.1:intron:MODIFIER:exon1/10:c.20-25694G>A:,SEPT9:NM_001113492.1:intron:MODIFIER:exon2/11:c.-416-25694G>A:,SEPT9:NM_006640.4:intron:MODIFIER:exon1/10:c.23-25694G>A:,SEPT9:NM_001113493.1:intron:MODIFIER:exon1/10:c.55+2813G>A:		rs140282527	0.0058	0.0000	0/0/0	0.0161							604061 [SEPT9 (confirmed) Leukemia,acute myeloid,therapy-related|Ovarian carcinoma|Amyotrophy,hereditary neuralgic,162100];				0	12					SEPT9 (inh=AD pLI=0.89)
chr17	75398498	75398498	C	T	wt	het	wt	pred_pathogenic	QUAL=947;DP=50,94,130;MQM=60	SEPT9	missense,5'UTR_premature_start_codon_gain,5'UTR	SEPT9:NM_001113491.1:missense:MODERATE:exon3/12:c.434C>T:p.Pro145Leu,SEPT9:NM_001293695.1:missense:MODERATE:exon2/11:c.377C>T:p.Pro126Leu,SEPT9:NM_006640.4:missense:MODERATE:exon2/11:c.380C>T:p.Pro127Leu,SEPT9:NM_001113493.1:missense:MODERATE:exon2/11:c.413C>T:p.Pro138Leu,SEPT9:NM_001113492.1:5'UTR_premature_start_codon_gain:LOW:exon3/12:c.-59C>T:,SEPT9:NM_001113494.1:5'UTR_premature_start_codon_gain:LOW:exon2/11:c.-59C>T:,SEPT9:NM_001113492.1:5'UTR:MODIFIER:exon3/12:c.-59C>T:,SEPT9:NM_001113494.1:5'UTR:MODIFIER:exon2/11:c.-59C>T:		rs34587622	0.0497	0.0928	447/353/4	0.0791	2.1520	D,D,D	T	B,B,B,B	T,T,T	14.82	604061 [SEPT9 (confirmed) Leukemia,acute myeloid,therapy-related|Ovarian carcinoma|Amyotrophy,hereditary neuralgic,162100];	RCV000406676.1 [benign]; 		COSM3755914, COSM3755912, COSM3755915, COSM3755913	33	302					SEPT9 (inh=AD pLI=0.89)
chr17	75494705	75494705	A	G	hom	hom	hom		QUAL=3637;DP=27,39,54;MQM=59	SEPT9	missense	SEPT9:NM_001113491.1:missense:MODERATE:exon12/12:c.1726A>G:p.Met576Val,SEPT9:NM_001293695.1:missense:MODERATE:exon11/11:c.1669A>G:p.Met557Val,SEPT9:NM_001113492.1:missense:MODERATE:exon12/12:c.1234A>G:p.Met412Val,SEPT9:NM_006640.4:missense:MODERATE:exon11/11:c.1672A>G:p.Met558Val,SEPT9:NM_001113493.1:missense:MODERATE:exon11/11:c.1705A>G:p.Met569Val,SEPT9:NM_001113494.1:missense:MODERATE:exon11/11:c.1234A>G:p.Met412Val,SEPT9:NM_001293696.1:missense:MODERATE:exon10/10:c.1054A>G:p.Met352Val,SEPT9:NM_001113496.1:missense:MODERATE:exon10/10:c.973A>G:p.Met325Val,SEPT9:NM_001293697.1:missense:MODERATE:exon10/10:c.973A>G:p.Met325Val,SEPT9:NM_001293698.1:missense:MODERATE:exon10/10:c.973A>G:p.Met325Val,SEPT9:NM_001113495.1:missense:MODERATE:exon10/10:c.1390A>G:p.Met464Val		rs2627223	0.9066	0.9371	50761/28109/2740	0.8450	0.0380	T,T,T,T,T,T,T,T	T	B,B,B,B,B,B	T,T,T,T,T,T	0.03	604061 [SEPT9 (confirmed) Leukemia,acute myeloid,therapy-related|Ovarian carcinoma|Amyotrophy,hereditary neuralgic,162100];	RCV000343437.1 [benign]; 		COSM4130688, COSM4130689, COSM4130691, COSM4130690, COSM4130692	1398	161					SEPT9 (inh=AD pLI=0.89)
chr17	75494746	75494746	A	G	wt	het	het	low_DP	QUAL=631;DP=7,25,38;MQM=60	SEPT9	3'UTR	SEPT9:NM_001113491.1:3'UTR:MODIFIER:exon12/12:c.*6A>G:,SEPT9:NM_001293695.1:3'UTR:MODIFIER:exon11/11:c.*6A>G:,SEPT9:NM_001113492.1:3'UTR:MODIFIER:exon12/12:c.*6A>G:,SEPT9:NM_006640.4:3'UTR:MODIFIER:exon11/11:c.*6A>G:,SEPT9:NM_001113493.1:3'UTR:MODIFIER:exon11/11:c.*6A>G:,SEPT9:NM_001113494.1:3'UTR:MODIFIER:exon11/11:c.*6A>G:,SEPT9:NM_001293696.1:3'UTR:MODIFIER:exon10/10:c.*6A>G:,SEPT9:NM_001113496.1:3'UTR:MODIFIER:exon10/10:c.*6A>G:,SEPT9:NM_001293697.1:3'UTR:MODIFIER:exon10/10:c.*6A>G:,SEPT9:NM_001293698.1:3'UTR:MODIFIER:exon10/10:c.*6A>G:,SEPT9:NM_001113495.1:3'UTR:MODIFIER:exon10/10:c.*6A>G:		rs1059485	0.5617	0.5267	15418/5466/412	0.4431							604061 [SEPT9 (confirmed) Leukemia,acute myeloid,therapy-related|Ovarian carcinoma|Amyotrophy,hereditary neuralgic,162100];	RCV000300249.1 [benign]; 			363	708					SEPT9 (inh=AD pLI=0.89)
chr17	75494780	75494780	A	T	wt	het	wt	low_DP	QUAL=124;DP=7,16,26;MQM=60	SEPT9	3'UTR	SEPT9:NM_001113491.1:3'UTR:MODIFIER:exon12/12:c.*40A>T:,SEPT9:NM_001293695.1:3'UTR:MODIFIER:exon11/11:c.*40A>T:,SEPT9:NM_001113492.1:3'UTR:MODIFIER:exon12/12:c.*40A>T:,SEPT9:NM_006640.4:3'UTR:MODIFIER:exon11/11:c.*40A>T:,SEPT9:NM_001113493.1:3'UTR:MODIFIER:exon11/11:c.*40A>T:,SEPT9:NM_001113494.1:3'UTR:MODIFIER:exon11/11:c.*40A>T:,SEPT9:NM_001293696.1:3'UTR:MODIFIER:exon10/10:c.*40A>T:,SEPT9:NM_001113496.1:3'UTR:MODIFIER:exon10/10:c.*40A>T:,SEPT9:NM_001293697.1:3'UTR:MODIFIER:exon10/10:c.*40A>T:,SEPT9:NM_001293698.1:3'UTR:MODIFIER:exon10/10:c.*40A>T:,SEPT9:NM_001113495.1:3'UTR:MODIFIER:exon10/10:c.*40A>T:		rs11537705	0.2071	0.3396	769/142/359	0.0931							604061 [SEPT9 (confirmed) Leukemia,acute myeloid,therapy-related|Ovarian carcinoma|Amyotrophy,hereditary neuralgic,162100];	RCV000384864.1 [benign]; 			18	188					SEPT9 (inh=AD pLI=0.89)
chr17	75494787	75494787	-	C	hom	hom	hom	low_DP	QUAL=911;DP=6,11,26;MQM=59	SEPT9	3'UTR	SEPT9:NM_001113491.1:3'UTR:MODIFIER:exon12/12:c.*55dupC:,SEPT9:NM_001293695.1:3'UTR:MODIFIER:exon11/11:c.*55dupC:,SEPT9:NM_001113492.1:3'UTR:MODIFIER:exon12/12:c.*55dupC:,SEPT9:NM_006640.4:3'UTR:MODIFIER:exon11/11:c.*55dupC:,SEPT9:NM_001113493.1:3'UTR:MODIFIER:exon11/11:c.*55dupC:,SEPT9:NM_001113494.1:3'UTR:MODIFIER:exon11/11:c.*55dupC:,SEPT9:NM_001293696.1:3'UTR:MODIFIER:exon10/10:c.*55dupC:,SEPT9:NM_001113496.1:3'UTR:MODIFIER:exon10/10:c.*55dupC:,SEPT9:NM_001293697.1:3'UTR:MODIFIER:exon10/10:c.*55dupC:,SEPT9:NM_001293698.1:3'UTR:MODIFIER:exon10/10:c.*55dupC:,SEPT9:NM_001113495.1:3'UTR:MODIFIER:exon10/10:c.*55dupC:		rs5822173	0.9363	0.9067	8612/3906/601	0.6319							604061 [SEPT9 (confirmed) Leukemia,acute myeloid,therapy-related|Ovarian carcinoma|Amyotrophy,hereditary neuralgic,162100];	RCV000376645.1 [likely benign]; RCV000340911.1 [benign]; 			843	127					SEPT9 (inh=AD pLI=0.89)
chr17	75495065	75495065	T	C	wt	wt	het		QUAL=1580;DP=55,97,96;MQM=60	SEPT9	3'UTR	SEPT9:NM_001113491.1:3'UTR:MODIFIER:exon12/12:c.*325T>C:,SEPT9:NM_001293695.1:3'UTR:MODIFIER:exon11/11:c.*325T>C:,SEPT9:NM_001113492.1:3'UTR:MODIFIER:exon12/12:c.*325T>C:,SEPT9:NM_006640.4:3'UTR:MODIFIER:exon11/11:c.*325T>C:,SEPT9:NM_001113493.1:3'UTR:MODIFIER:exon11/11:c.*325T>C:,SEPT9:NM_001113494.1:3'UTR:MODIFIER:exon11/11:c.*325T>C:,SEPT9:NM_001293696.1:3'UTR:MODIFIER:exon10/10:c.*325T>C:,SEPT9:NM_001113496.1:3'UTR:MODIFIER:exon10/10:c.*325T>C:,SEPT9:NM_001293697.1:3'UTR:MODIFIER:exon10/10:c.*325T>C:,SEPT9:NM_001293698.1:3'UTR:MODIFIER:exon10/10:c.*325T>C:,SEPT9:NM_001113495.1:3'UTR:MODIFIER:exon10/10:c.*325T>C:		rs448203	0.6993	0.6119	2140/257/34	0.1354	-5.2790					4.66	604061 [SEPT9 (confirmed) Leukemia,acute myeloid,therapy-related|Ovarian carcinoma|Amyotrophy,hereditary neuralgic,162100];	RCV000297232.1 [benign]; 			257	506					SEPT9 (inh=AD pLI=0.89)
chr17	75495397	75495397	T	C	wt	wt	het		QUAL=1301;DP=109,68,120;MQM=60	SEPT9	3'UTR	SEPT9:NM_001113491.1:3'UTR:MODIFIER:exon12/12:c.*657T>C:,SEPT9:NM_001293695.1:3'UTR:MODIFIER:exon11/11:c.*657T>C:,SEPT9:NM_001113492.1:3'UTR:MODIFIER:exon12/12:c.*657T>C:,SEPT9:NM_006640.4:3'UTR:MODIFIER:exon11/11:c.*657T>C:,SEPT9:NM_001113493.1:3'UTR:MODIFIER:exon11/11:c.*657T>C:,SEPT9:NM_001113494.1:3'UTR:MODIFIER:exon11/11:c.*657T>C:,SEPT9:NM_001293696.1:3'UTR:MODIFIER:exon10/10:c.*657T>C:,SEPT9:NM_001113496.1:3'UTR:MODIFIER:exon10/10:c.*657T>C:,SEPT9:NM_001293697.1:3'UTR:MODIFIER:exon10/10:c.*657T>C:,SEPT9:NM_001293698.1:3'UTR:MODIFIER:exon10/10:c.*657T>C:,SEPT9:NM_001113495.1:3'UTR:MODIFIER:exon10/10:c.*657T>C:		rs9038	0.6294	0.5501	15815/4221/945	0.4790	-0.0380	.,T,.	.,T,T			3.93	604061 [SEPT9 (confirmed) Leukemia,acute myeloid,therapy-related|Ovarian carcinoma|Amyotrophy,hereditary neuralgic,162100];	RCV000363814.1 [benign]; 			228	511					SEPT9 (inh=AD pLI=0.89)
chr17	75495840	75495840	T	C	hom	hom	hom		QUAL=8584;DP=69,90,126;MQM=59	SEPT9	3'UTR	SEPT9:NM_001113491.1:3'UTR:MODIFIER:exon12/12:c.*1100T>C:,SEPT9:NM_001293695.1:3'UTR:MODIFIER:exon11/11:c.*1100T>C:,SEPT9:NM_001113492.1:3'UTR:MODIFIER:exon12/12:c.*1100T>C:,SEPT9:NM_006640.4:3'UTR:MODIFIER:exon11/11:c.*1100T>C:,SEPT9:NM_001113493.1:3'UTR:MODIFIER:exon11/11:c.*1100T>C:,SEPT9:NM_001113494.1:3'UTR:MODIFIER:exon11/11:c.*1100T>C:,SEPT9:NM_001293696.1:3'UTR:MODIFIER:exon10/10:c.*1100T>C:,SEPT9:NM_001113496.1:3'UTR:MODIFIER:exon10/10:c.*1100T>C:,SEPT9:NM_001293697.1:3'UTR:MODIFIER:exon10/10:c.*1100T>C:,SEPT9:NM_001293698.1:3'UTR:MODIFIER:exon10/10:c.*1100T>C:,SEPT9:NM_001113495.1:3'UTR:MODIFIER:exon10/10:c.*1100T>C:		rs407525	0.9876	0.0000	0/0/0	0.8986							604061 [SEPT9 (confirmed) Leukemia,acute myeloid,therapy-related|Ovarian carcinoma|Amyotrophy,hereditary neuralgic,162100];				294	7					SEPT9 (inh=AD pLI=0.89)
chr17	75496342	75496342	T	C	hom	hom	hom		QUAL=17249;DP=139,183,222;MQM=59	SEPT9	3'UTR	SEPT9:NM_001113491.1:3'UTR:MODIFIER:exon12/12:c.*1602T>C:,SEPT9:NM_001293695.1:3'UTR:MODIFIER:exon11/11:c.*1602T>C:,SEPT9:NM_001113492.1:3'UTR:MODIFIER:exon12/12:c.*1602T>C:,SEPT9:NM_006640.4:3'UTR:MODIFIER:exon11/11:c.*1602T>C:,SEPT9:NM_001113493.1:3'UTR:MODIFIER:exon11/11:c.*1602T>C:,SEPT9:NM_001113494.1:3'UTR:MODIFIER:exon11/11:c.*1602T>C:,SEPT9:NM_001293696.1:3'UTR:MODIFIER:exon10/10:c.*1602T>C:,SEPT9:NM_001113496.1:3'UTR:MODIFIER:exon10/10:c.*1602T>C:,SEPT9:NM_001293697.1:3'UTR:MODIFIER:exon10/10:c.*1602T>C:,SEPT9:NM_001293698.1:3'UTR:MODIFIER:exon10/10:c.*1602T>C:,SEPT9:NM_001113495.1:3'UTR:MODIFIER:exon10/10:c.*1602T>C:		rs448767	0.9864	0.0000	0/0/0	0.1529							604061 [SEPT9 (confirmed) Leukemia,acute myeloid,therapy-related|Ovarian carcinoma|Amyotrophy,hereditary neuralgic,162100];				263	7					SEPT9 (inh=AD pLI=0.89)
chr17	75496361	75496361	A	G	hom	hom	hom		QUAL=20859;DP=193,212,251;MQM=60	SEPT9	3'UTR	SEPT9:NM_001113491.1:3'UTR:MODIFIER:exon12/12:c.*1621A>G:,SEPT9:NM_001293695.1:3'UTR:MODIFIER:exon11/11:c.*1621A>G:,SEPT9:NM_001113492.1:3'UTR:MODIFIER:exon12/12:c.*1621A>G:,SEPT9:NM_006640.4:3'UTR:MODIFIER:exon11/11:c.*1621A>G:,SEPT9:NM_001113493.1:3'UTR:MODIFIER:exon11/11:c.*1621A>G:,SEPT9:NM_001113494.1:3'UTR:MODIFIER:exon11/11:c.*1621A>G:,SEPT9:NM_001293696.1:3'UTR:MODIFIER:exon10/10:c.*1621A>G:,SEPT9:NM_001113496.1:3'UTR:MODIFIER:exon10/10:c.*1621A>G:,SEPT9:NM_001293697.1:3'UTR:MODIFIER:exon10/10:c.*1621A>G:,SEPT9:NM_001293698.1:3'UTR:MODIFIER:exon10/10:c.*1621A>G:,SEPT9:NM_001113495.1:3'UTR:MODIFIER:exon10/10:c.*1621A>G:		rs2627222	0.9864	0.0000	0/0/0	0.1535							604061 [SEPT9 (confirmed) Leukemia,acute myeloid,therapy-related|Ovarian carcinoma|Amyotrophy,hereditary neuralgic,162100];				261	7					SEPT9 (inh=AD pLI=0.89)
chr17	75496460	75496460	T	C	hom	het	het		QUAL=5556;DP=78,142,154;MQM=59	SEPT9	3'UTR	SEPT9:NM_001113491.1:3'UTR:MODIFIER:exon12/12:c.*1720T>C:,SEPT9:NM_001293695.1:3'UTR:MODIFIER:exon11/11:c.*1720T>C:,SEPT9:NM_001113492.1:3'UTR:MODIFIER:exon12/12:c.*1720T>C:,SEPT9:NM_006640.4:3'UTR:MODIFIER:exon11/11:c.*1720T>C:,SEPT9:NM_001113493.1:3'UTR:MODIFIER:exon11/11:c.*1720T>C:,SEPT9:NM_001113494.1:3'UTR:MODIFIER:exon11/11:c.*1720T>C:,SEPT9:NM_001293696.1:3'UTR:MODIFIER:exon10/10:c.*1720T>C:,SEPT9:NM_001113496.1:3'UTR:MODIFIER:exon10/10:c.*1720T>C:,SEPT9:NM_001293697.1:3'UTR:MODIFIER:exon10/10:c.*1720T>C:,SEPT9:NM_001293698.1:3'UTR:MODIFIER:exon10/10:c.*1720T>C:,SEPT9:NM_001113495.1:3'UTR:MODIFIER:exon10/10:c.*1720T>C:		rs445507	0.4321	0.0000	0/0/0	0.4311							604061 [SEPT9 (confirmed) Leukemia,acute myeloid,therapy-related|Ovarian carcinoma|Amyotrophy,hereditary neuralgic,162100];	RCV000323614.1 [benign]; 			70	111					SEPT9 (inh=AD pLI=0.89)
chr17	76109073	76109073	C	T	wt	het	wt		QUAL=3841;DP=230,277,469;MQM=60	TMC6	3'UTR	TMC6:NM_001127198.2:3'UTR:MODIFIER:exon20/20:c.*156G>A:,TMC6:NM_001321185.1:3'UTR:MODIFIER:exon20/20:c.*156G>A:,TMC6:NM_007267.7:3'UTR:MODIFIER:exon20/20:c.*156G>A:		rs2253277	0.0825	0.0000	0/0/0	0.0801							605828 [TMC6 (confirmed) Epidermodysplasia verruciformis,226400];				1	39					TMC6 (inh=n/a pLI=0.00)
chr17	76118834	76118834	G	C	wt	het	wt		QUAL=1113;DP=49,109,136;MQM=60	TMC6	splice_region&intron	TMC6:NM_001127198.2:splice_region&intron:LOW:exon9/19:c.1083-4C>G:,TMC6:NM_001321185.1:splice_region&intron:LOW:exon9/19:c.1083-4C>G:,TMC6:NM_007267.7:splice_region&intron:LOW:exon9/19:c.1083-4C>G:		rs2057188	0.0859	0.1018	457/272/7	0.0882							605828 [TMC6 (confirmed) Epidermodysplasia verruciformis,226400];				15	223					TMC6 (inh=n/a pLI=0.00)
chr17	76120065	76120065	A	G	wt	het	wt		QUAL=2963;DP=153,253,308;MQM=60	TMC6	splice_region&intron	TMC6:NM_001127198.2:splice_region&intron:LOW:exon9/19:c.1082+5T>C:,TMC6:NM_001321185.1:splice_region&intron:LOW:exon9/19:c.1082+5T>C:,TMC6:NM_007267.7:splice_region&intron:LOW:exon9/19:c.1082+5T>C:		rs2613522	0.4736	0.3484	8113/2657/1940	0.3406							605828 [TMC6 (confirmed) Epidermodysplasia verruciformis,226400];				144	630					TMC6 (inh=n/a pLI=0.00)
chr17	76121864	76121864	A	G	wt	het	wt	pred_pathogenic	QUAL=1350;DP=76,140,173;MQM=60	TMC6	missense	TMC6:NM_001127198.2:missense:MODERATE:exon5/20:c.373T>C:p.Trp125Arg,TMC6:NM_001321185.1:missense:MODERATE:exon5/20:c.373T>C:p.Trp125Arg,TMC6:NM_007267.7:missense:MODERATE:exon5/20:c.373T>C:p.Trp125Arg		rs2748427	0.3349	0.3212	1158/332/350	0.1697	2.0220	T,T,T	T	B,B	T,T,T	0.30	605828 [TMC6 (confirmed) Epidermodysplasia verruciformis,226400];			COSM3755918	63	491					TMC6 (inh=n/a pLI=0.00)
chr17	76127431	76127431	G	C	hom	hom	hom		QUAL=10661;DP=98,102,153;MQM=59	TMC8,TMC6	5'UTR,intron	TMC8:NM_152468.4:5'UTR:MODIFIER:exon2/16:c.-239G>C:,TMC6:NM_007267.7:intron:MODIFIER:exon1/19:c.-75+991C>G:	MIRb	rs383603	0.6987	0.0000	0/0/0	0.6726							605828 [TMC6 (confirmed) Epidermodysplasia verruciformis,226400]:605829 [TMC8 (confirmed) Epidermodysplasia verruciformis,226400];				134	84					TMC8 (inh=n/a pLI=0.00), TMC6 (inh=n/a pLI=0.00)
chr17	76127483	76127483	C	T	wt	het	wt		QUAL=1571;DP=146,128,195;MQM=60	TMC8,TMC6	5'UTR,intron	TMC8:NM_152468.4:5'UTR:MODIFIER:exon2/16:c.-187C>T:,TMC6:NM_007267.7:intron:MODIFIER:exon1/19:c.-75+939G>A:		rs452483	0.0827	0.0000	0/0/0	0.0877							605828 [TMC6 (confirmed) Epidermodysplasia verruciformis,226400]:605829 [TMC8 (confirmed) Epidermodysplasia verruciformis,226400];				7	29					TMC8 (inh=n/a pLI=0.00), TMC6 (inh=n/a pLI=0.00)
chr17	76130575	76130575	A	T	hom	het	hom		QUAL=10259;DP=84,155,200;MQM=59	TMC8	missense	TMC8:NM_152468.4:missense:MODERATE:exon8/16:c.917A>T:p.Asn306Ile		rs7208422	0.5523	0.5148	16335/8279/2409	0.5070	1.3510	T	T	B,B	T	5.51	605829 [TMC8 (confirmed) Epidermodysplasia verruciformis,226400];		CM091876 [CLASS=DP MUT=ALT PHEN="Epidermodysplasia verruciformis susceptibility in HIV association" GENE=TMC8]; 		480	720					TMC8 (inh=n/a pLI=0.00)
chr17	76130947	76130947	G	T	het	het	het		QUAL=7515;DP=60,257,283;MQM=59	TMC8	splice_region&intron	TMC8:NM_152468.4:splice_region&intron:LOW:exon8/15:c.988-4G>T:		rs62079073	0.0777	0.0783	413/265/32	0.0750							605829 [TMC8 (confirmed) Epidermodysplasia verruciformis,226400];				19	266					TMC8 (inh=n/a pLI=0.00)
chr17	76131070	76131070	G	A	het	het	hom		QUAL=20535;DP=144,374,446;MQM=59	TMC8	synonymous	TMC8:NM_152468.4:synonymous:LOW:exon9/16:c.1107G>A:p.Glu369Glu		rs12452890	0.5403	0.5343	17787/9533/2491	0.5259							605829 [TMC8 (confirmed) Epidermodysplasia verruciformis,226400];				532	726					TMC8 (inh=n/a pLI=0.00)
chr17	76137198	76137198	T	G	hom	hom	hom		QUAL=3388;DP=47,32,36;MQM=59	TMC8	3'UTR	TMC8:NM_152468.4:3'UTR:MODIFIER:exon16/16:c.*5T>G:		rs369764	0.9986	0.9955	49659/27823/3664	0.9259							605829 [TMC8 (confirmed) Epidermodysplasia verruciformis,226400];				1481	15					TMC8 (inh=n/a pLI=0.00)
chr17	76137337	76137337	C	G	het	het	hom		QUAL=4847;DP=95,62,89;MQM=59	TMC8	3'UTR	TMC8:NM_152468.4:3'UTR:MODIFIER:exon16/16:c.*144C>G:		rs454138	0.6569	0.0000	0/0/0	0.5989							605829 [TMC8 (confirmed) Epidermodysplasia verruciformis,226400];				107	99					TMC8 (inh=n/a pLI=0.00)
chr17	76137477	76137477	T	G	het	het	het		QUAL=1839;DP=86,22,38;MQM=60	TMC8	3'UTR	TMC8:NM_152468.4:3'UTR:MODIFIER:exon16/16:c.*284T>G:		rs2871647	0.1296	0.0000	0/0/0	0.1188							605829 [TMC8 (confirmed) Epidermodysplasia verruciformis,226400];				5	59					TMC8 (inh=n/a pLI=0.00)
chr17	76138158	76138158	G	C	wt	wt	het		QUAL=3095;DP=181,168,231;MQM=60	TMC8	3'UTR	TMC8:NM_152468.4:3'UTR:MODIFIER:exon16/16:c.*965G>C:		rs118166247	0.0128	0.0000	0/0/0	0.0366							605829 [TMC8 (confirmed) Epidermodysplasia verruciformis,226400];				1	30					TMC8 (inh=n/a pLI=0.00)
chr17	76138577	76138577	A	G	het	het	hom		QUAL=14163;DP=234,214,276;MQM=59	TMC8	3'UTR	TMC8:NM_152468.4:3'UTR:MODIFIER:exon16/16:c.*1384A>G:		rs4789015	0.5795	0.0000	0/0/0	0.5494							605829 [TMC8 (confirmed) Epidermodysplasia verruciformis,226400];				88	106					TMC8 (inh=n/a pLI=0.00)
chr17	76139060	76139060	T	-	wt	wt	hom	low_DP	QUAL=507;DP=39,18,49;MQM=60	TMC8-C17orf99	intergenic_region	TMC8-C17orf99:TMC8-C17orf99:intergenic_region:MODIFIER::n.76139060delT:	AluSx1	rs750433708	0.1915	0.0000	0/0/0	0.1214							605829 [TMC8 (confirmed) Epidermodysplasia verruciformis,226400];				5	48					TMC8-C17orf99 (inh=n/a pLI=n/a)
chr17	78075462	78075462	G	C	het	wt	het		QUAL=1496;DP=95,21,36;MQM=59	GAA	5'UTR,intron	GAA:NM_000152.4:5'UTR:MODIFIER:exon1/20:c.-260G>C:,GAA:NR_134848.1:intron:MODIFIER:exon1/1:n.100+38G>C:,GAA:NM_001079803.2:intron:MODIFIER:exon1/20:c.-113+38G>C:,GAA:NM_001079804.2:intron:MODIFIER:exon1/19:c.-33+38G>C:		rs2304849	0.1180	0.0000	0/0/0	0.1841							606800 [GAA (confirmed) Glycogen storage disease II,232300];	RCV000352096.1 [likely benign]; RCV000381550.1 [likely benign]; 			10	73					GAA (inh=AR pLI=0.00)
chr17	78078709	78078709	T	C	hom	hom	het		QUAL=3656;DP=53,38,58;MQM=59	GAA	synonymous	GAA:NM_000152.4:synonymous:LOW:exon2/20:c.324T>C:p.Cys108Cys,GAA:NM_001079803.2:synonymous:LOW:exon3/21:c.324T>C:p.Cys108Cys,GAA:NM_001079804.2:synonymous:LOW:exon2/20:c.324T>C:p.Cys108Cys		rs1800300	0.7145	0.7367	32095/18688/2459	0.7198							606800 [GAA (confirmed) Glycogen storage disease II,232300];	RCV000078180.6 [benign]; RCV000284275.1 [benign]; RCV000299885.1 [benign]; 		COSM3755978	960	566					GAA (inh=AR pLI=0.00)
chr17	78079544	78079544	C	G	hom	hom	het		QUAL=20803;DP=226,270,379;MQM=60	GAA	splice_region&intron	GAA:NM_000152.4:splice_region&intron:LOW:exon2/19:c.547-4C>G:,GAA:NM_001079803.2:splice_region&intron:LOW:exon3/20:c.547-4C>G:,GAA:NM_001079804.2:splice_region&intron:LOW:exon2/19:c.547-4C>G:		rs3816256	0.6028	0.6759	28330/18491/1489	0.6631							606800 [GAA (confirmed) Glycogen storage disease II,232300];	RCV000078182.6 [benign]; RCV000369731.1 [benign]; 			893	603					GAA (inh=AR pLI=0.00)
chr17	78079597	78079597	A	G	hom	hom	het	pred_pathogenic	QUAL=15938;DP=167,245,344;MQM=59	GAA	missense	GAA:NM_000152.4:missense:MODERATE:exon3/20:c.596A>G:p.His199Arg,GAA:NM_001079803.2:missense:MODERATE:exon4/21:c.596A>G:p.His199Arg,GAA:NM_001079804.2:missense:MODERATE:exon3/20:c.596A>G:p.His199Arg		rs1042393	0.6008	0.6746	28199/18465/1486	0.6691	-0.2170	T,T	T	B	D,D	0.01	606800 [GAA (confirmed) Glycogen storage disease II,232300];	RCV000078183.6 [benign]; RCV000275148.1 [benign]; 		COSM3755979	893	602					GAA (inh=AR pLI=0.00)
chr17	78079643	78079643	C	T	het	hom	wt		QUAL=8107;DP=138,212,286;MQM=60	GAA	synonymous	GAA:NM_000152.4:synonymous:LOW:exon3/20:c.642C>T:p.Ser214Ser,GAA:NM_001079803.2:synonymous:LOW:exon4/21:c.642C>T:p.Ser214Ser,GAA:NM_001079804.2:synonymous:LOW:exon3/20:c.642C>T:p.Ser214Ser		rs1800301	0.1060	0.1802	2343/1763/29	0.1761							606800 [GAA (confirmed) Glycogen storage disease II,232300];	RCV000078184.6 [benign]; RCV000330247.1 [likely benign]; 		COSM3755980	102	523					GAA (inh=AR pLI=0.00)
chr17	78079669	78079669	G	A	hom	hom	het	pred_pathogenic	QUAL=10107;DP=121,184,243;MQM=59	GAA	missense	GAA:NM_000152.4:missense:MODERATE:exon3/20:c.668G>A:p.Arg223His,GAA:NM_001079803.2:missense:MODERATE:exon4/21:c.668G>A:p.Arg223His,GAA:NM_001079804.2:missense:MODERATE:exon3/20:c.668G>A:p.Arg223His		rs1042395	0.6024	0.6760	28120/18333/1473	0.6642	-0.0440	T,T	T	B	D,D	11.39	606800 [GAA (confirmed) Glycogen storage disease II,232300];	RCV000078185.6 [benign]; RCV000169616.2 [other]; 		COSM3721877	893	600					GAA (inh=AR pLI=0.00)
chr17	78081526	78081526	-	GCAGCGG	hom	hom	het		QUAL=9090;DP=30,198,238;MQM=59	GAA	splice_region&intron	GAA:NM_000152.4:splice_region&intron:LOW:exon4/19:c.858+7_858+8insAGCGGGC:,GAA:NM_001079803.2:splice_region&intron:LOW:exon5/20:c.858+7_858+8insAGCGGGC:,GAA:NM_001079804.2:splice_region&intron:LOW:exon4/19:c.858+7_858+8insAGCGGGC:		rs3071247;rs372331052	0.5929	0.6724	26638/17376/1313	0.0935							606800 [GAA (confirmed) Glycogen storage disease II,232300];	RCV000078186.6 [benign]; 			691	755					GAA (inh=AR pLI=0.00)
chr17	78082504	78082504	G	A	hom	hom	het		QUAL=11662;DP=131,161,215;MQM=59	GAA	synonymous	GAA:NM_000152.4:synonymous:LOW:exon8/20:c.1203G>A:p.Gln401Gln,GAA:NM_001079803.2:synonymous:LOW:exon9/21:c.1203G>A:p.Gln401Gln,GAA:NM_001079804.2:synonymous:LOW:exon8/20:c.1203G>A:p.Gln401Gln		rs1800304	0.6028	0.6784	27460/17905/1391	0.6674							606800 [GAA (confirmed) Glycogen storage disease II,232300];	RCV000078155.6 [benign]; RCV000344845.1 [benign]; 		COSM3755981	897	596					GAA (inh=AR pLI=0.00)
chr17	78084769	78084769	G	A	het	wt	het		QUAL=5763;DP=203,282,316;MQM=60	GAA	synonymous	GAA:NM_000152.4:synonymous:LOW:exon11/20:c.1581G>A:p.Arg527Arg,GAA:NM_001079803.2:synonymous:LOW:exon12/21:c.1581G>A:p.Arg527Arg,GAA:NM_001079804.2:synonymous:LOW:exon11/20:c.1581G>A:p.Arg527Arg		rs1042396	0.1595	0.2309	3584/2541/27	0.2303							606800 [GAA (confirmed) Glycogen storage disease II,232300];	RCV000078160.6 [benign]; RCV000301295.1 [likely benign]; 		COSM148357	127	612					GAA (inh=AR pLI=0.00)
chr17	78087109	78087109	A	G	wt	het	wt		QUAL=321;DP=82,29,63;MQM=60	GAA	synonymous	GAA:NM_000152.4:synonymous:LOW:exon15/20:c.2133A>G:p.Thr711Thr,GAA:NM_001079803.2:synonymous:LOW:exon16/21:c.2133A>G:p.Thr711Thr,GAA:NM_001079804.2:synonymous:LOW:exon15/20:c.2133A>G:p.Thr711Thr		rs1800310	0.2416	0.3423	3212/1948/53	0.2472							606800 [GAA (confirmed) Glycogen storage disease II,232300];	RCV000078168.6 [benign]; RCV000292038.1 [likely benign]; 		COSM1162489	161	662					GAA (inh=AR pLI=0.00)
chr17	78091405	78091405	G	A	hom	hom	het	low_DP;pred_pathogenic	QUAL=1008;DP=16,15,15;MQM=59	GAA	missense	GAA:NM_000152.4:missense:MODERATE:exon17/20:c.2338G>A:p.Val780Ile,GAA:NM_001079803.2:missense:MODERATE:exon18/21:c.2338G>A:p.Val780Ile,GAA:NM_001079804.2:missense:MODERATE:exon17/20:c.2338G>A:p.Val780Ile		rs1126690	0.7119	0.7296	32675/19277/2490	0.7210	-0.3890	T,T	T	B	D,D	0.40	606800 [GAA (confirmed) Glycogen storage disease II,232300];	RCV000078171.6 [benign]; RCV000336875.1 [benign]; 		COSM3755982	960	554					GAA (inh=AR pLI=0.00)
chr17	78092063	78092063	G	A	hom	hom	het		QUAL=6629;DP=58,116,139;MQM=59	GAA	synonymous	GAA:NM_000152.4:synonymous:LOW:exon18/20:c.2553G>A:p.Gly851Gly,GAA:NM_001079803.2:synonymous:LOW:exon19/21:c.2553G>A:p.Gly851Gly,GAA:NM_001079804.2:synonymous:LOW:exon18/20:c.2553G>A:p.Gly851Gly		rs1042397	0.5094	0.5805	20899/13839/1484	0.5703							606800 [GAA (confirmed) Glycogen storage disease II,232300];	RCV000078176.6 [benign]; RCV000399277.1 [benign]; 		COSM3766205	695	693					GAA (inh=AR pLI=0.00)
chr17	78093353	78093353	C	T	wt	het	wt		QUAL=1304;DP=49,107,112;MQM=60	GAA	3'UTR	GAA:NM_000152.4:3'UTR:MODIFIER:exon20/20:c.*223C>T:,GAA:NM_001079803.2:3'UTR:MODIFIER:exon21/21:c.*223C>T:,GAA:NM_001079804.2:3'UTR:MODIFIER:exon20/20:c.*223C>T:		rs8132	0.1795	0.0000	0/0/0	0.2272							606800 [GAA (confirmed) Glycogen storage disease II,232300];	RCV000334735.1 [likely benign]; 			21	94					GAA (inh=AR pLI=0.00)
chr17	78093549	78093549	G	T	hom	het	het	low_DP	QUAL=882;DP=35,9,17;MQM=60	GAA	3'UTR	GAA:NM_000152.4:3'UTR:MODIFIER:exon20/20:c.*419G>T:,GAA:NM_001079803.2:3'UTR:MODIFIER:exon21/21:c.*419G>T:,GAA:NM_001079804.2:3'UTR:MODIFIER:exon20/20:c.*419G>T:		rs7567	0.1560	0.0000	0/0/0	0.2179							606800 [GAA (confirmed) Glycogen storage disease II,232300];	RCV000342723.1 [likely benign]; 			16	78					GAA (inh=AR pLI=0.00)
chr17	78183396	78183396	A	G	het	het	hom		QUAL=33545;DP=274,814,851;MQM=58	SGSH	3'UTR	SGSH:NM_000199.3:3'UTR:MODIFIER:exon8/8:c.*855T>C:		rs1046832	0.4507	0.0000	0/0/0	0.2794							605270 [SGSH (confirmed) Mucopolysaccharidosis type IIIA (Sanfilippo A),252900];	RCV000275910.1 [benign]; 			52	127					SGSH (inh=AR pLI=0.00)
chr17	78183403	78183403	G	C	het	het	hom		QUAL=41641;DP=264,844,979;MQM=58	SGSH	3'UTR	SGSH:NM_000199.3:3'UTR:MODIFIER:exon8/8:c.*848C>G:		rs709677	0.6542	0.0000	0/0/0	0.3617							605270 [SGSH (confirmed) Mucopolysaccharidosis type IIIA (Sanfilippo A),252900];	RCV000314605.1 [benign]; 			118	82					SGSH (inh=AR pLI=0.00)
chr17	78183411	78183411	T	C	het	het	hom		QUAL=41950;DP=269,822,991;MQM=58	SGSH	3'UTR	SGSH:NM_000199.3:3'UTR:MODIFIER:exon8/8:c.*840A>G:		rs709678	0.6470	0.0000	0/0/0	0.4118							605270 [SGSH (confirmed) Mucopolysaccharidosis type IIIA (Sanfilippo A),252900];	RCV000366910.1 [benign]; 			116	85					SGSH (inh=AR pLI=0.00)
chr17	78183936	78183936	G	A	het	het	hom		QUAL=8167;DP=126,151,172;MQM=60	SGSH	3'UTR	SGSH:NM_000199.3:3'UTR:MODIFIER:exon8/8:c.*315C>T:		rs2071148	0.4483	0.0000	0/0/0	0.5359							605270 [SGSH (confirmed) Mucopolysaccharidosis type IIIA (Sanfilippo A),252900];	RCV000379351.1 [benign]; 			83	96					SGSH (inh=AR pLI=0.00)
chr17	78184393	78184393	C	T	het	het	wt		QUAL=4300;DP=160,229,304;MQM=60	SGSH	missense	SGSH:NM_000199.3:missense:MODERATE:exon8/8:c.1367G>A:p.Arg456His		rs7503034	0.3458	0.3592	7750/3342/233	0.3465	-0.3080	T,T	T	B	T,T	3.78	605270 [SGSH (confirmed) Mucopolysaccharidosis type IIIA (Sanfilippo A),252900];	RCV000078352.5 [benign]; RCV000289567.1 [benign]; 		COSM3755983	198	653					SGSH (inh=AR pLI=0.00)
chr17	79478007	79478007	G	A	wt	wt	het		QUAL=6356;DP=338,332,477;MQM=59	ACTG1	synonymous,non_coding_transcript_exon	ACTG1:NM_001199954.1:synonymous:LOW:exon5/6:c.930C>T:p.Ala310Ala,ACTG1:NM_001614.3:synonymous:LOW:exon5/6:c.930C>T:p.Ala310Ala,ACTG1:NR_037688.1:non_coding_transcript_exon:MODIFIER:exon5/7:n.1069C>T:		rs1135989	0.1853	0.2882	6100/4817/185	0.2806							102560 [ACTG1 (confirmed) Deafness,autosomal dominant 20/26,604717|Baraitser-Winter syndrome 2,614583];	RCV000037127.5 [other]; 			163	676					ACTG1 (inh=AD pLI=0.22)
chr17	79478019	79478019	G	A	hom	hom	hom		QUAL=35479;DP=356,331,484;MQM=59	ACTG1	synonymous,non_coding_transcript_exon	ACTG1:NM_001199954.1:synonymous:LOW:exon5/6:c.918C>T:p.Tyr306Tyr,ACTG1:NM_001614.3:synonymous:LOW:exon5/6:c.918C>T:p.Tyr306Tyr,ACTG1:NR_037688.1:non_coding_transcript_exon:MODIFIER:exon5/7:n.1057C>T:		rs1139405	0.7562	0.7902	38122/22217/2075	0.7765							102560 [ACTG1 (confirmed) Deafness,autosomal dominant 20/26,604717|Baraitser-Winter syndrome 2,614583];	RCV000037126.5 [other]; 		COSM1387303	1026	474					ACTG1 (inh=AD pLI=0.22)
chr17	79479808	79479808	C	T	hom	het	hom	low_DP	QUAL=226;DP=1,7,7;MQM=60	ACTG1	5'UTR,non_coding_transcript_exon	ACTG1:NM_001199954.1:5'UTR:MODIFIER:exon1/6:c.-174G>A:,ACTG1:NM_001614.3:5'UTR:MODIFIER:exon1/6:c.-55G>A:,ACTG1:NR_037688.1:non_coding_transcript_exon:MODIFIER:exon1/7:n.85G>A:		rs7503278	0.7344	0.7934	3217/820/35	0.1410							102560 [ACTG1 (confirmed) Deafness,autosomal dominant 20/26,604717|Baraitser-Winter syndrome 2,614583];				390	162					ACTG1 (inh=AD pLI=0.22)
chr17	79479843	79479843	C	G	hom	wt	het	low_DP	QUAL=55;DP=1,4,11;MQM=60	ACTG1	5'UTR,non_coding_transcript_exon	ACTG1:NM_001199954.1:5'UTR:MODIFIER:exon1/6:c.-209G>C:,ACTG1:NM_001614.3:5'UTR:MODIFIER:exon1/6:c.-90G>C:,ACTG1:NR_037688.1:non_coding_transcript_exon:MODIFIER:exon1/7:n.50G>C:		rs542961891	0.0034	0.0154	3/0/0	0.0003							102560 [ACTG1 (confirmed) Deafness,autosomal dominant 20/26,604717|Baraitser-Winter syndrome 2,614583];				1	10					ACTG1 (inh=AD pLI=0.22)
chr17	79891147	79891147	T	C	hom	hom	hom		QUAL=30092;DP=185,349,451;MQM=60	PYCR1	sequence_feature,synonymous,intron	PYCR1:NM_001282281.1:sequence_feature:MODERATE:exon8/8:c.984A>G:,PYCR1:NM_006907.3:sequence_feature:MODERATE:exon7/7:c.903A>G:,PYCR1:NM_001282281.1:synonymous:LOW:exon8/8:c.984A>G:p.Ser328Ser,PYCR1:NM_006907.3:synonymous:LOW:exon7/7:c.903A>G:p.Ser301Ser,PYCR1:NM_001282279.1:synonymous:LOW:exon7/7:c.810A>G:p.Ser270Ser,PYCR1:NM_001282280.1:synonymous:LOW:exon8/8:c.903A>G:p.Ser301Ser,PYCR1:NM_153824.2:intron:MODIFIER:exon7/7:c.867+36A>G:		rs61747618	0.9860	0.9951	59613/32948/4604	0.9363							179035 [PYCR1 (provisional) Cutis laxa,autosomal recessive,type IIB,612940|Cutis laxa,autosomal recessive,type IIIB,614438];			COSM4130834	1563	1					PYCR1 (inh=AR pLI=0.00)
chr17	80036877	80036877	A	G	het	het	het		QUAL=1584;DP=31,59,79;MQM=59	FASN	3'UTR	FASN:NM_004104.4:3'UTR:MODIFIER:exon43/43:c.*142T>C:		rs11550611	0.5885	0.0000	0/0/0	0.5375											117	91					FASN (inh=n/a pLI=1.00)
chr17	80039481	80039481	G	A	wt	wt	het		QUAL=1285;DP=47,97,113;MQM=60	FASN	synonymous	FASN:NM_004104.4:synonymous:LOW:exon37/43:c.6402C>T:p.Ile2134Ile		rs1140616	0.3039	0.4254	11824/8977/224	0.4095										COSM3766217	334	738					FASN (inh=n/a pLI=1.00)
chr17	80041466	80041466	G	A	wt	wt	het		QUAL=4888;DP=224,308,403;MQM=60	FASN	synonymous	FASN:NM_004104.4:synonymous:LOW:exon31/43:c.5268C>T:p.Ser1756Ser		rs2229425	0.0471	0.1147	936/824/6	0.1046										COSM3756036	24	310					FASN (inh=n/a pLI=1.00)
chr17	80043349	80043349	C	T	wt	wt	het	low_DP	QUAL=334;DP=6,18,33;MQM=60	FASN	splice_region&intron	FASN:NM_004104.4:splice_region&intron:LOW:exon23/42:c.4122+9G>A:		rs17848939	0.4221	0.5105	8026/5550/661	0.4000											357	728					FASN (inh=n/a pLI=1.00)
chr17	80043739	80043739	A	G	wt	wt	het	low_DP	QUAL=95;DP=15,7,16;MQM=60	FASN	synonymous,sequence_feature	FASN:NM_004104.4:synonymous:LOW:exon23/43:c.3741T>C:p.Ala1247Ala,FASN:NM_004104.4:sequence_feature:LOW:exon23/43:c.3741T>C:		rs2229422	0.2360	0.3675	1096/781/62	0.1965										COSM437819	119	579					FASN (inh=n/a pLI=1.00)
chr17	80045086	80045086	G	C	het	het	wt		QUAL=2064;DP=70,111,126;MQM=59	FASN	synonymous	FASN:NM_004104.4:synonymous:LOW:exon21/43:c.3267C>G:p.Ala1089Ala		rs4485435	0.2230	0.2016	2331/851/383	0.1668										COSM4130849	61	475					FASN (inh=n/a pLI=1.00)
chr17	80051183	80051183	A	G	het	wt	hom		QUAL=5891;DP=158,154,136;MQM=59	FASN	synonymous	FASN:NM_004104.4:synonymous:LOW:exon5/43:c.567T>C:p.Asn189Asn		rs2228309	0.3918	0.5373	10895/7835/893	0.4004										COSM3756037	400	752					FASN (inh=n/a pLI=1.00)
chr17	80572628	80572628	A	G	het	wt	het		QUAL=5105;DP=270,117,162;MQM=59	WDR45B	3'UTR	WDR45B:NM_019613.3:3'UTR:MODIFIER:exon10/10:c.*1167T>C:		rs1059672	0.6310	0.0000	0/0/0	0.0862											78	109					WDR45B (inh=n/a pLI=0.64)
chr17	80573272	80573272	A	G	hom	het	het		QUAL=9647;DP=181,140,175;MQM=58	WDR45B	3'UTR	WDR45B:NM_019613.3:3'UTR:MODIFIER:exon10/10:c.*523T>C:		rs9271	0.8634	0.0000	0/0/0	0.1210											162	63					WDR45B (inh=n/a pLI=0.64)
chr17	80579609	80579609	T	C	het	wt	het	pred_pathogenic	QUAL=4538;DP=222,148,180;MQM=60	WDR45B	missense	WDR45B:NM_019613.3:missense:MODERATE:exon6/10:c.494A>G:p.His165Arg		rs74895287	0.0132	0.0132	21/14/4	0.0129	7.5030	T,T	T	B	T	18.85				COSM3756047	4	60					WDR45B (inh=n/a pLI=0.64)
chr17	80585094	80585094	C	T	het	het	wt		QUAL=5074;DP=196,202,215;MQM=57	WDR45B	synonymous	WDR45B:NM_019613.3:synonymous:LOW:exon4/10:c.318G>A:p.Lys106Lys		rs2291393	0.2007	0.2315	3485/2039/65	0.2159										COSM3756048	109	545					WDR45B (inh=n/a pLI=0.64)
chr18	2917152	2917152	T	C	het	het	wt		QUAL=7986;DP=339,243,340;MQM=60	LPIN2	3'UTR	LPIN2:NM_014646.2:3'UTR:MODIFIER:exon20/20:c.*3139A>G:		rs1164	0.1420	0.0000	0/0/0	0.0300							605519 [LPIN2 (provisional) Majeed syndrome,609628];	RCV000373518.1 [benign]; 			12	72					LPIN2 (inh=n/a pLI=0.67)
chr18	2917357	2917357	G	A	het	het	hom		QUAL=19697;DP=652,191,226;MQM=60	LPIN2	3'UTR	LPIN2:NM_014646.2:3'UTR:MODIFIER:exon20/20:c.*2934C>T:		rs7980	0.5455	0.0000	0/0/0	0.0995							605519 [LPIN2 (provisional) Majeed syndrome,609628];	RCV000306995.1 [benign]; 			83	111					LPIN2 (inh=n/a pLI=0.67)
chr18	2919343	2919343	-	T	hom	het	het		QUAL=15953;DP=375,174,222;MQM=59	LPIN2	3'UTR	LPIN2:NM_014646.2:3'UTR:MODIFIER:exon20/20:c.*947dupA:		rs3840906	0.3265	0.0000	0/0/0	0.3498							605519 [LPIN2 (provisional) Majeed syndrome,609628];	RCV000323381.1 [benign]; 			37	109					LPIN2 (inh=n/a pLI=0.67)
chr18	2919606	2919606	A	T	het	hom	het		QUAL=11329;DP=292,185,260;MQM=60	LPIN2	3'UTR	LPIN2:NM_014646.2:3'UTR:MODIFIER:exon20/20:c.*685T>A:		rs607549	0.6913	0.0000	0/0/0	0.1169							605519 [LPIN2 (provisional) Majeed syndrome,609628];	RCV000360188.1 [benign]; 			125	86					LPIN2 (inh=n/a pLI=0.67)
chr18	2919790	2919790	A	G	wt	wt	het		QUAL=2904;DP=228,172,249;MQM=60	LPIN2	3'UTR	LPIN2:NM_014646.2:3'UTR:MODIFIER:exon20/20:c.*501T>C:		rs35176958	0.0224	0.0000	0/0/0	0.0091							605519 [LPIN2 (provisional) Majeed syndrome,609628];	RCV000261113.1 [likely benign]; 			4	37					LPIN2 (inh=n/a pLI=0.67)
chr18	2920288	2920288	G	A	wt	het	het		QUAL=7168;DP=259,269,345;MQM=60	LPIN2	3'UTR	LPIN2:NM_014646.2:3'UTR:MODIFIER:exon20/20:c.*3C>T:		rs3745012	0.3622	0.3131	6641/2201/295	0.3080							605519 [LPIN2 (provisional) Majeed syndrome,609628];	RCV000249293.1 [benign]; RCV000335425.1 [benign]; 	CR076713 [CLASS=DP MUT=REF PHEN="Diabetes type 2 association with" GENE=LPIN2]; 		125	638					LPIN2 (inh=n/a pLI=0.67)
chr18	3412167	3412167	C	T	hom	het	hom		QUAL=1818;DP=49,20,21;MQM=59	TGIF1	5'UTR	TGIF1:NM_174886.2:5'UTR:MODIFIER:exon1/4:c.-203C>T:		rs11571505	0.6166	0.0000	0/0/0	0.5401							602630 [TGIF1 (confirmed) Holoprosencephaly 4,142946];				70	113					TGIF1 (inh=AD pLI=0.09)
chr18	3447725	3447725	C	T	het	het	wt		QUAL=8899;DP=597,215,295;MQM=60	TGIF1	5'UTR,intron	TGIF1:NM_173207.2:5'UTR:MODIFIER:exon1/3:c.-13C>T:,TGIF1:NM_174886.2:intron:MODIFIER:exon2/3:c.-44-8627C>T:,TGIF1:NM_001278686.1:intron:MODIFIER:exon2/3:c.-44-8627C>T:		rs238137	0.0837	0.0481	220/41/104	0.0477							602630 [TGIF1 (confirmed) Holoprosencephaly 4,142946];				0	66					TGIF1 (inh=AD pLI=0.09)
chr18	3450455	3450455	C	A	het	hom	wt		QUAL=8859;DP=146,246,292;MQM=59	TGIF1	5'UTR,intron	TGIF1:NM_001278684.1:5'UTR:MODIFIER:exon2/4:c.-33C>A:,TGIF1:NM_173208.2:5'UTR:MODIFIER:exon2/4:c.-33C>A:,TGIF1:NM_003244.3:5'UTR:MODIFIER:exon1/3:c.-33C>A:,TGIF1:NM_174886.2:intron:MODIFIER:exon2/3:c.-44-5897C>A:,TGIF1:NM_001278686.1:intron:MODIFIER:exon2/3:c.-44-5897C>A:,TGIF1:NM_173207.2:intron:MODIFIER:exon1/2:c.58+2660C>A:,TGIF1:NM_001278682.1:intron:MODIFIER:exon1/2:c.25+801C>A:,TGIF1:NM_173209.2:intron:MODIFIER:exon1/2:c.-45+387C>A:		rs238132	0.2839	0.2158	668/96/430	0.0988							602630 [TGIF1 (confirmed) Holoprosencephaly 4,142946];	RCV000245689.1 [benign]; RCV000259321.1 [benign]; 			38	247					TGIF1 (inh=AD pLI=0.09)
chr18	3451762	3451762	C	T	wt	het	wt		QUAL=2329;DP=222,181,278;MQM=60	TGIF1	5'UTR,intron	TGIF1:NM_170695.3:5'UTR:MODIFIER:exon1/3:c.-216C>T:,TGIF1:NM_173210.2:5'UTR:MODIFIER:exon1/3:c.-56C>T:,TGIF1:NM_174886.2:intron:MODIFIER:exon2/3:c.-44-4590C>T:,TGIF1:NM_001278686.1:intron:MODIFIER:exon2/3:c.-44-4590C>T:,TGIF1:NM_173207.2:intron:MODIFIER:exon1/2:c.58+3967C>T:,TGIF1:NM_001278682.1:intron:MODIFIER:exon1/2:c.25+2108C>T:,TGIF1:NM_001278684.1:intron:MODIFIER:exon2/3:c.16+1259C>T:,TGIF1:NM_173208.2:intron:MODIFIER:exon2/3:c.16+1259C>T:,TGIF1:NM_173209.2:intron:MODIFIER:exon1/2:c.-45+1694C>T:,TGIF1:NM_003244.3:intron:MODIFIER:exon1/2:c.16+1259C>T:		rs238533	0.1957	0.0000	0/0/0	0.1340							602630 [TGIF1 (confirmed) Holoprosencephaly 4,142946];				8	42					TGIF1 (inh=AD pLI=0.09)
chr18	3451896	3451896	G	A	wt	het	wt		QUAL=1699;DP=330,154,233;MQM=60	TGIF1	5'UTR,intron	TGIF1:NM_170695.3:5'UTR:MODIFIER:exon1/3:c.-82G>A:,TGIF1:NM_174886.2:intron:MODIFIER:exon2/3:c.-44-4456G>A:,TGIF1:NM_001278686.1:intron:MODIFIER:exon2/3:c.-44-4456G>A:,TGIF1:NM_173207.2:intron:MODIFIER:exon1/2:c.58+4101G>A:,TGIF1:NM_001278682.1:intron:MODIFIER:exon1/2:c.25+2242G>A:,TGIF1:NM_001278684.1:intron:MODIFIER:exon2/3:c.16+1393G>A:,TGIF1:NM_173208.2:intron:MODIFIER:exon2/3:c.16+1393G>A:,TGIF1:NM_173209.2:intron:MODIFIER:exon1/2:c.-45+1828G>A:,TGIF1:NM_003244.3:intron:MODIFIER:exon1/2:c.16+1393G>A:,TGIF1:NM_173210.2:intron:MODIFIER:exon1/2:c.-45+123G>A:		rs11571508	0.0847	0.0000	0/0/0	0.0138							602630 [TGIF1 (confirmed) Holoprosencephaly 4,142946];				3	20					TGIF1 (inh=AD pLI=0.09)
chr18	3452223	3452223	T	-	het	wt	het	anno_high_impact	QUAL=468;DP=22,33,43;MQM=59	TGIF1	frameshift,intron	TGIF1:NM_170695.3:frameshift:HIGH:exon1/3:c.246delT:p.Pro83fs,TGIF1:NM_174886.2:intron:MODIFIER:exon2/3:c.-44-4129delT:,TGIF1:NM_001278686.1:intron:MODIFIER:exon2/3:c.-44-4129delT:,TGIF1:NM_173207.2:intron:MODIFIER:exon1/2:c.59-4129delT:,TGIF1:NM_001278682.1:intron:MODIFIER:exon1/2:c.25+2569delT:,TGIF1:NM_001278684.1:intron:MODIFIER:exon2/3:c.16+1720delT:,TGIF1:NM_173208.2:intron:MODIFIER:exon2/3:c.16+1720delT:,TGIF1:NM_173209.2:intron:MODIFIER:exon1/2:c.-45+2155delT:,TGIF1:NM_003244.3:intron:MODIFIER:exon1/2:c.16+1720delT:,TGIF1:NM_173210.2:intron:MODIFIER:exon1/2:c.-45+450delT:		rs11571510	0.2556	0.3296	6049/4473/371	0.2965							602630 [TGIF1 (confirmed) Holoprosencephaly 4,142946];			COSM296436	173	471	1	[1] old entry - no details available			TGIF1 (inh=AD pLI=0.09)
chr18	3457539	3457539	A	G	wt	het	wt		QUAL=2247;DP=223,176,263;MQM=59	TGIF1	synonymous	TGIF1:NM_170695.3:synonymous:LOW:exon3/3:c.807A>G:p.Pro269Pro,TGIF1:NM_174886.2:synonymous:LOW:exon4/4:c.360A>G:p.Pro120Pro,TGIF1:NM_001278686.1:synonymous:LOW:exon4/4:c.360A>G:p.Pro120Pro,TGIF1:NM_173207.2:synonymous:LOW:exon3/3:c.462A>G:p.Pro154Pro,TGIF1:NM_001278682.1:synonymous:LOW:exon3/3:c.429A>G:p.Pro143Pro,TGIF1:NM_001278684.1:synonymous:LOW:exon4/4:c.420A>G:p.Pro140Pro,TGIF1:NM_173208.2:synonymous:LOW:exon4/4:c.420A>G:p.Pro140Pro,TGIF1:NM_173209.2:synonymous:LOW:exon3/3:c.360A>G:p.Pro120Pro,TGIF1:NM_003244.3:synonymous:LOW:exon3/3:c.420A>G:p.Pro140Pro,TGIF1:NM_173210.2:synonymous:LOW:exon3/3:c.360A>G:p.Pro120Pro,TGIF1:NM_173211.1:synonymous:LOW:exon3/3:c.360A>G:p.Pro120Pro		rs2229337	0.1915	0.1072	1064/157/437	0.1067							602630 [TGIF1 (confirmed) Holoprosencephaly 4,142946];	RCV000253985.1 [benign]; RCV000375922.1 [likely benign]; 			14	239					TGIF1 (inh=AD pLI=0.09)
chr18	3457606	3457606	C	T	het	het	wt	pred_pathogenic	QUAL=6456;DP=241,237,315;MQM=59	TGIF1	missense	TGIF1:NM_170695.3:missense:MODERATE:exon3/3:c.874C>T:p.Pro292Ser,TGIF1:NM_174886.2:missense:MODERATE:exon4/4:c.427C>T:p.Pro143Ser,TGIF1:NM_001278686.1:missense:MODERATE:exon4/4:c.427C>T:p.Pro143Ser,TGIF1:NM_173207.2:missense:MODERATE:exon3/3:c.529C>T:p.Pro177Ser,TGIF1:NM_001278682.1:missense:MODERATE:exon3/3:c.496C>T:p.Pro166Ser,TGIF1:NM_001278684.1:missense:MODERATE:exon4/4:c.487C>T:p.Pro163Ser,TGIF1:NM_173208.2:missense:MODERATE:exon4/4:c.487C>T:p.Pro163Ser,TGIF1:NM_173209.2:missense:MODERATE:exon3/3:c.427C>T:p.Pro143Ser,TGIF1:NM_003244.3:missense:MODERATE:exon3/3:c.487C>T:p.Pro163Ser,TGIF1:NM_173210.2:missense:MODERATE:exon3/3:c.427C>T:p.Pro143Ser,TGIF1:NM_173211.1:missense:MODERATE:exon3/3:c.427C>T:p.Pro143Ser		rs4468717	0.0313	0.0602	302/211/0	0.0582	3.6330	D,T,T,D,T,T,T,T,T,T,T,T,T	T	B,B,B	T,T,T,T,T,T,T,T,T,T,T,T,T	12.27	602630 [TGIF1 (confirmed) Holoprosencephaly 4,142946];	RCV000246246.1 [benign]; RCV000293052.1 [likely benign]; 	CM1411534 [CLASS=DP MUT=ALT PHEN="Myopia high-grade association with" GENE=TGIF1]; 		11	227					TGIF1 (inh=AD pLI=0.09)
chr18	3457607	3457607	C	T	wt	het	wt	pred_pathogenic	QUAL=2685;DP=242,241,316;MQM=59	TGIF1	missense	TGIF1:NM_170695.3:missense:MODERATE:exon3/3:c.875C>T:p.Pro292Leu,TGIF1:NM_174886.2:missense:MODERATE:exon4/4:c.428C>T:p.Pro143Leu,TGIF1:NM_001278686.1:missense:MODERATE:exon4/4:c.428C>T:p.Pro143Leu,TGIF1:NM_173207.2:missense:MODERATE:exon3/3:c.530C>T:p.Pro177Leu,TGIF1:NM_001278682.1:missense:MODERATE:exon3/3:c.497C>T:p.Pro166Leu,TGIF1:NM_001278684.1:missense:MODERATE:exon4/4:c.488C>T:p.Pro163Leu,TGIF1:NM_173208.2:missense:MODERATE:exon4/4:c.488C>T:p.Pro163Leu,TGIF1:NM_173209.2:missense:MODERATE:exon3/3:c.428C>T:p.Pro143Leu,TGIF1:NM_003244.3:missense:MODERATE:exon3/3:c.488C>T:p.Pro163Leu,TGIF1:NM_173210.2:missense:MODERATE:exon3/3:c.428C>T:p.Pro143Leu,TGIF1:NM_173211.1:missense:MODERATE:exon3/3:c.428C>T:p.Pro143Leu		rs2229333	0.0777	0.0627	331/98/1	0.0620	7.3010	D,D,D,D,D,D,D,D,D,D,D,D,D	T	P,P,D	T,T,T,T,T,T,T,T,T,T,T,T,T	24.20	602630 [TGIF1 (confirmed) Holoprosencephaly 4,142946];	RCV000250978.1 [likely benign]; RCV000331659.1 [likely benign]; 	CM1411535 [CLASS=DP MUT=ALT PHEN="Myopia high-grade association with" GENE=TGIF1]; 	COSM4000401, COSM4000402	6	187					TGIF1 (inh=AD pLI=0.09)
chr18	6943264	6943264	G	A	hom	hom	hom		QUAL=28838;DP=288,275,337;MQM=60	LAMA1	synonymous	LAMA1:NM_005559.3:synonymous:LOW:exon62/63:c.8982C>T:p.Asp2994Asp		rs2016639	0.2861	0.3307	7376/3447/31	0.3242							150320 [LAMA1 (provisional) Poretti-Boltshauser syndrome,615960];			COSM148377	170	654					LAMA1 (inh=AR pLI=0.00)
chr18	6980523	6980523	T	C	hom	hom	het		QUAL=19935;DP=232,258,292;MQM=59	LAMA1	missense	LAMA1:NM_005559.3:missense:MODERATE:exon42/63:c.6004A>G:p.Lys2002Glu		rs607230	0.6937	0.7278	32332/17088/1629	0.7198	1.4670	T	T	B	T	17.60	150320 [LAMA1 (provisional) Poretti-Boltshauser syndrome,615960];				825	626					LAMA1 (inh=AR pLI=0.00)
chr18	6985631	6985631	C	T	hom	hom	het		QUAL=26754;DP=389,310,367;MQM=60	LAMA1	synonymous	LAMA1:NM_005559.3:synonymous:LOW:exon38/63:c.5391G>A:p.Leu1797Leu		rs617206	0.5521	0.5151	16844/6495/1378	0.5003							150320 [LAMA1 (provisional) Poretti-Boltshauser syndrome,615960];			COSM3756200	295	769					LAMA1 (inh=AR pLI=0.00)
chr18	6986227	6986227	G	A	wt	wt	het		QUAL=2337;DP=274,202,242;MQM=60	LAMA1	missense	LAMA1:NM_005559.3:missense:MODERATE:exon37/63:c.5288C>T:p.Ala1763Val		rs12607841	0.1416	0.1360	1177/689/106	0.1338	0.4730	T	T	B	T	6.42	150320 [LAMA1 (provisional) Poretti-Boltshauser syndrome,615960];				41	430					LAMA1 (inh=AR pLI=0.00)
chr18	6999628	6999628	T	C	wt	het	het		QUAL=2906;DP=189,107,136;MQM=60	LAMA1	synonymous	LAMA1:NM_005559.3:synonymous:LOW:exon32/63:c.4479A>G:p.Ser1493Ser		rs625106	0.4663	0.4507	10695/5714/2455	0.4080							150320 [LAMA1 (provisional) Poretti-Boltshauser syndrome,615960];			COSM3756203	304	754					LAMA1 (inh=AR pLI=0.00)
chr18	6999963	6999963	G	A	wt	het	wt		QUAL=2172;DP=419,212,301;MQM=60	LAMA1	synonymous	LAMA1:NM_005559.3:synonymous:LOW:exon31/63:c.4416C>T:p.His1472His		rs12970643	0.0805	0.0831	518/299/113	0.0826							150320 [LAMA1 (provisional) Poretti-Boltshauser syndrome,615960];			COSM3756204	21	270					LAMA1 (inh=AR pLI=0.00)
chr18	7008591	7008591	T	C	het	het	wt	pred_pathogenic	QUAL=6657;DP=310,172,242;MQM=60	LAMA1	missense	LAMA1:NM_005559.3:missense:MODERATE:exon28/63:c.4018A>G:p.Met1340Val		rs662471	0.1871	0.2384	3959/2876/287	0.2343	-0.0350	D	T	B	T	9.36	150320 [LAMA1 (provisional) Poretti-Boltshauser syndrome,615960];				125	615					LAMA1 (inh=AR pLI=0.00)
chr18	7011338	7011338	C	T	wt	het	wt		QUAL=490;DP=45,47,60;MQM=60	LAMA1	synonymous	LAMA1:NM_005559.3:synonymous:LOW:exon25/63:c.3648G>A:p.Pro1216Pro		rs12969598	0.0176	0.0382	77/66/4	0.0325							150320 [LAMA1 (provisional) Poretti-Boltshauser syndrome,615960];			COSM3742687	5	129					LAMA1 (inh=AR pLI=0.00)
chr18	7011413	7011413	G	A	wt	het	wt		QUAL=793;DP=117,68,107;MQM=60	LAMA1	synonymous	LAMA1:NM_005559.3:synonymous:LOW:exon25/63:c.3573C>T:p.Thr1191Thr		rs619106	0.3646	0.3366	5512/2448/1919	0.2927							150320 [LAMA1 (provisional) Poretti-Boltshauser syndrome,615960];			COSM148383	141	631					LAMA1 (inh=AR pLI=0.00)
chr18	7012123	7012123	A	G	het	hom	wt		QUAL=9426;DP=238,219,341;MQM=60	LAMA1	synonymous	LAMA1:NM_005559.3:synonymous:LOW:exon24/63:c.3378T>C:p.Gly1126Gly		rs9946794	0.4201	0.3774	9575/4683/3020	0.3682							150320 [LAMA1 (provisional) Poretti-Boltshauser syndrome,615960];			COSM438362	228	724					LAMA1 (inh=AR pLI=0.00)
chr18	7017322	7017322	A	G	het	hom	wt		QUAL=18258;DP=440,397,564;MQM=59	LAMA1	synonymous	LAMA1:NM_005559.3:synonymous:LOW:exon20/63:c.2763T>C:p.Cys921Cys		rs539713	0.5475	0.5194	17510/9437/3769	0.5090							150320 [LAMA1 (provisional) Poretti-Boltshauser syndrome,615960];			COSM4131076	477	763					LAMA1 (inh=AR pLI=0.00)
chr18	7023371	7023371	A	G	het	het	wt		QUAL=1440;DP=54,53,60;MQM=60	LAMA1	sequence_feature,synonymous	LAMA1:NM_005559.3:sequence_feature:MODERATE:exon19/63:c.2493T>C:,LAMA1:NM_005559.3:synonymous:LOW:exon19/63:c.2493T>C:p.Cys831Cys		rs684634	0.4373	0.3801	9955/4884/3110	0.3756							150320 [LAMA1 (provisional) Poretti-Boltshauser syndrome,615960];			COSM1179774	193	716					LAMA1 (inh=AR pLI=0.00)
chr18	7033037	7033037	G	A	het	hom	wt		QUAL=8169;DP=284,157,225;MQM=59	LAMA1	synonymous	LAMA1:NM_005559.3:synonymous:LOW:exon15/63:c.2109C>T:p.Ala703Ala		rs621993	0.4066	0.4057	9166/5102/2046	0.3770							150320 [LAMA1 (provisional) Poretti-Boltshauser syndrome,615960];				221	751					LAMA1 (inh=AR pLI=0.00)
chr18	7034508	7034508	T	G	wt	het	wt		QUAL=2618;DP=270,184,265;MQM=60	LAMA1	missense	LAMA1:NM_005559.3:missense:MODERATE:exon14/63:c.2021A>C:p.Asn674Thr		rs566655	0.1502	0.1928	2497/1744/162	0.1930	0.2560	T	T	B	T	14.64	150320 [LAMA1 (provisional) Poretti-Boltshauser syndrome,615960];			COSM3756205	85	501					LAMA1 (inh=AR pLI=0.00)
chr18	7117782	7117782	A	G	wt	het	hom	low_DP	QUAL=397;DP=2,16,8;MQM=60	LAMA1	5'UTR	LAMA1:NM_005559.3:5'UTR:MODIFIER:exon1/63:c.-63T>C:		rs334407	0.5182	0.0000	0/0/0	0.0775							150320 [LAMA1 (provisional) Poretti-Boltshauser syndrome,615960];				275	401					LAMA1 (inh=AR pLI=0.00)
chr18	9117867	9117867	T	C	hom	hom	hom		QUAL=11262;DP=239,42,54;MQM=60	NDUFV2	missense	NDUFV2:NM_021074.4:missense:MODERATE:exon2/8:c.86T>C:p.Val29Ala		rs906807	0.7790	0.8001	39013/22176/2993	0.7909	1.5370	T,T	T	B	T,T	9.71	600532 [NDUFV2 (confirmed) Mitochondrial complex I deficiency,252010];	RCV000009621.2 [uncertain significance]; RCV000117718.3 [other]; RCV000312272.1 [benign]; 	CM983407 [CLASS=DP MUT=REF PHEN="Parkinson disease susceptibility to association" GENE=NDUFV2]; 	COSM3773839	1073	453					NDUFV2 (inh=AR pLI=0.01)
chr18	9119489	9119489	A	T	het	het	wt		QUAL=8746;DP=402,247,299;MQM=55	NDUFV2	synonymous	NDUFV2:NM_021074.4:synonymous:LOW:exon4/8:c.201A>T:p.Val67Val		rs41274300	0.0751	0.0850	542/368/110	0.0845							600532 [NDUFV2 (confirmed) Mitochondrial complex I deficiency,252010];	RCV000117717.2 [likely benign]; RCV000366995.1 [likely benign]; 		COSM4131120	20	301					NDUFV2 (inh=AR pLI=0.01)
chr18	9134344	9134344	T	C	het	het	wt		QUAL=2987;DP=117,118,143;MQM=60	NDUFV2-AS1	intron	NDUFV2-AS1:NR_110771.1:intron:MODIFIER:exon1/3:n.358-836A>G:,NDUFV2-AS1:NR_110772.1:intron:MODIFIER:exon1/2:n.358-836A>G:		rs62088771	0.0034	0.0000	0/0/0	0.0016							600532 [NDUFV2 (confirmed) Mitochondrial complex I deficiency,252010];				0	10					NDUFV2-AS1 (inh=n/a pLI=n/a)
chr18	12329536	12329536	C	G	wt	het	wt		QUAL=2049;DP=296,160,241;MQM=60	AFG3L2,TUBB6	3'UTR	AFG3L2:NM_006796.2:3'UTR:MODIFIER:exon17/17:c.*28G>C:,TUBB6:NM_001303525.1:3'UTR:MODIFIER:exon4/4:c.*354C>G:		rs1129115	0.3359	0.2631	4650/1611/820	0.2582							604581 [AFG3L2 (confirmed) Spinocerebellar ataxia 28,610246|Spastic ataxia 5,autosomal recessive,614487];	RCV000357421.1 [benign]; 			61	362					AFG3L2 (inh=AR+AD pLI=0.01), TUBB6 (inh=n/a pLI=0.00)
chr18	12348285	12348285	T	C	hom	het	hom		QUAL=15844;DP=215,184,213;MQM=60	AFG3L2	synonymous	AFG3L2:NM_006796.2:synonymous:LOW:exon13/17:c.1650A>G:p.Glu550Glu		rs11553521	0.7099	0.7492	34444/20351/3067	0.7403							604581 [AFG3L2 (confirmed) Spinocerebellar ataxia 28,610246|Spastic ataxia 5,autosomal recessive,614487];	RCV000116249.3 [other]; RCV000329004.1 [benign]; 		COSM148398	2021	1119					AFG3L2 (inh=AR+AD pLI=0.01)
chr18	12351342	12351342	C	T	hom	het	hom		QUAL=16470;DP=202,194,252;MQM=59	AFG3L2	synonymous	AFG3L2:NM_006796.2:synonymous:LOW:exon11/17:c.1389G>A:p.Leu463Leu		rs11080572	0.6232	0.7205	32215/20238/1251	0.7140							604581 [AFG3L2 (confirmed) Spinocerebellar ataxia 28,610246|Spastic ataxia 5,autosomal recessive,614487];	RCV000116248.4 [other]; RCV000323296.1 [benign]; 		COSM148399	2005	1123					AFG3L2 (inh=AR+AD pLI=0.01)
chr18	12359920	12359920	G	A	hom	het	hom		QUAL=14167;DP=179,146,202;MQM=59	AFG3L2	splice_region&intron,sequence_feature	AFG3L2:NM_006796.2:splice_region&intron:LOW:exon7/16:c.752+6C>T:,AFG3L2:NM_006796.2:sequence_feature:LOW::c.752+6C>T:		rs8097342	0.6196	0.7177	31953/20115/1248	0.7050							604581 [AFG3L2 (confirmed) Spinocerebellar ataxia 28,610246|Spastic ataxia 5,autosomal recessive,614487];	RCV000179927.2 [benign]; RCV000340354.1 [benign]; 		COSM148400	1978	1088					AFG3L2 (inh=AR+AD pLI=0.01)
chr18	21119777	21119777	G	A	hom	het	hom		QUAL=14838;DP=201,207,209;MQM=59	NPC1	splice_region&synonymous	NPC1:NM_000271.4:splice_region&synonymous:LOW:exon18/25:c.2793C>T:p.Asn931Asn		rs1140458	0.4840	0.4902	15043/7063/759	0.4859							607623 [NPC1 (confirmed) Niemann-Pick disease,type C1,257220|Niemann-Pick disease,type D,257220];	RCV000020228.2 [benign]; RCV000078475.9 [other]; RCV000348906.1 [benign]; 		COSM437978	595	1347					NPC1 (inh=AR pLI=0.00)
chr18	21120444	21120444	T	C	hom	het	hom	pred_pathogenic	QUAL=28222;DP=561,198,223;MQM=59	NPC1	missense	NPC1:NM_000271.4:missense:MODERATE:exon17/25:c.2572A>G:p.Ile858Val		rs1805082	0.4858	0.4947	15014/7024/758	0.4897	4.9470	T,T,T	T	B,B	D,D	20.90	607623 [NPC1 (confirmed) Niemann-Pick disease,type C1,257220|Niemann-Pick disease,type D,257220];	RCV000020227.2 [benign]; RCV000078474.9 [other]; RCV000391750.1 [benign]; 			599	1355	1	[1] old entry - no details available			NPC1 (inh=AR pLI=0.00)
chr18	21123537	21123538	AA	-	wt	het	wt		QUAL=845;DP=60,64,49;MQM=59	NPC1	splice_region&intron	NPC1:NM_000271.4:splice_region&intron:LOW:exon13/24:c.2131-5_2131-4delTT:	(A)n	rs201618643;rs574145826	0.1947	0.3011	5/0/4	0.2233							607623 [NPC1 (confirmed) Niemann-Pick disease,type C1,257220|Niemann-Pick disease,type D,257220];				32	459					NPC1 (inh=AR pLI=0.00)
chr18	21123537	21123537	A	-	hom	het	wt		QUAL=845;DP=60,64,49;MQM=59	NPC1	splice_region&intron	NPC1:NM_000271.4:splice_region&intron:LOW:exon13/24:c.2131-4delT:	(A)n	rs11299077;rs533551695;rs796757567	0.5022	0.4575	165/73/30	0.3868							607623 [NPC1 (confirmed) Niemann-Pick disease,type C1,257220|Niemann-Pick disease,type D,257220];				264	1683	2	[2] Stephan Waldm?ller 13.11.2014			NPC1 (inh=AR pLI=0.00)
chr18	21124917	21124917	G	C	het	wt	het	low_DP;low_MQM	QUAL=870;DP=4,83,73;MQM=49	NPC1	splice_region&intron	NPC1:NM_000271.4:splice_region&intron:LOW:exon12/24:c.1947+7C>G:		rs56394541	0.0000	0.0001	0/0/0	0.0001							607623 [NPC1 (confirmed) Niemann-Pick disease,type C1,257220|Niemann-Pick disease,type D,257220];				43	97	2	[2] Stefanie Beck-Woedl 20.03.2015			NPC1 (inh=AR pLI=0.00)
chr18	21124918	21124918	G	C	het	wt	het	low_DP;low_MQM	QUAL=870;DP=4,83,73;MQM=49	NPC1	splice_region&intron	NPC1:NM_000271.4:splice_region&intron:LOW:exon12/24:c.1947+6C>G:		rs745432812	0.0000	0.0001	0/0/0	0.0001							607623 [NPC1 (confirmed) Niemann-Pick disease,type C1,257220|Niemann-Pick disease,type D,257220];	RCV000290784.1 [uncertain significance]; 			0	55					NPC1 (inh=AR pLI=0.00)
chr18	21124945	21124945	C	G	hom	het	hom	pred_pathogenic	QUAL=5168;DP=51,110,113;MQM=59	NPC1	missense,sequence_feature	NPC1:NM_000271.4:missense:MODERATE:exon12/25:c.1926G>C:p.Met642Ile,NPC1:NM_000271.4:sequence_feature:LOW:exon12/25:c.1926G>C:		rs1788799	0.8317	0.7177	32007/13600/4398	0.6903	3.3010	T,T,T	T	B,B	D,D	12.77	607623 [NPC1 (confirmed) Niemann-Pick disease,type C1,257220|Niemann-Pick disease,type D,257220];	RCV000020225.2 [benign]; RCV000078467.9 [other]; RCV000348137.1 [benign]; 			1200	1230					NPC1 (inh=AR pLI=0.00)
chr18	21134786	21134786	G	A	het	wt	het	pred_pathogenic	QUAL=7443;DP=217,247,361;MQM=60	NPC1	missense	NPC1:NM_000271.4:missense:MODERATE:exon9/25:c.1489C>T:p.His497Tyr		rs770838112	0.0000	0.0001	0/0/0	0.0001	6.4200	T,T,T	T	B,B	T,T	14.29	607623 [NPC1 (confirmed) Niemann-Pick disease,type C1,257220|Niemann-Pick disease,type D,257220];				0	2	3	[3] Stephan Waldm?ller 13.08.2014			NPC1 (inh=AR pLI=0.00)
chr18	21140432	21140432	T	C	hom	het	hom	pred_pathogenic	QUAL=2361;DP=42,31,29;MQM=59	NPC1	missense	NPC1:NM_000271.4:missense:MODERATE:exon6/25:c.644A>G:p.His215Arg		rs1805081	0.2187	0.3287	7279/5277/37	0.3285	0.5890	T,T	T	B	D	1.52	607623 [NPC1 (confirmed) Niemann-Pick disease,type C1,257220|Niemann-Pick disease,type D,257220];	RCV000078484.9 [other]; RCV000158944.1 [benign]; RCV000405719.1 [benign]; 	CM1515430 [CLASS=DP MUT=REF PHEN="Obesity extreme association with" GENE=NPC1]; 		372	1240					NPC1 (inh=AR pLI=0.00)
chr18	21413869	21413869	T	C	het	het	hom		QUAL=19977;DP=347,326,370;MQM=59	LAMA3	synonymous	LAMA3:NM_198129.2:synonymous:LOW:exon24/75:c.2901T>C:p.Ala967Ala,LAMA3:NM_001127717.2:synonymous:LOW:exon24/74:c.2901T>C:p.Ala967Ala		rs9962023	0.6244	0.6631	27016/16761/1443	0.6569							600805 [LAMA3 (provisional) Epidermolysis bullosa,junctional,Herlitz type,226700|Epidermolysis bullosa,generalized atrophic benign,226650|Laryngoonychocutaneous syndrome,245660];			COSM4130939	750	679					LAMA3 (inh=AR pLI=0.00)
chr18	21437931	21437931	G	C	het	het	hom		QUAL=25123;DP=355,392,525;MQM=60	LAMA3	synonymous	LAMA3:NM_198129.2:synonymous:LOW:exon33/75:c.4260G>C:p.Gly1420Gly,LAMA3:NM_001127717.2:synonymous:LOW:exon33/74:c.4260G>C:p.Gly1420Gly		rs867449	0.3437	0.4962	16492/12782/336	0.4860							600805 [LAMA3 (provisional) Epidermolysis bullosa,junctional,Herlitz type,226700|Epidermolysis bullosa,generalized atrophic benign,226650|Laryngoonychocutaneous syndrome,245660];				515	752					LAMA3 (inh=AR pLI=0.00)
chr18	21441717	21441717	C	T	het	het	hom		QUAL=10335;DP=134,141,222;MQM=60	LAMA3	synonymous	LAMA3:NM_198129.2:synonymous:LOW:exon35/75:c.4530C>T:p.Pro1510Pro,LAMA3:NM_001127717.2:synonymous:LOW:exon35/74:c.4530C>T:p.Pro1510Pro		rs12965685	0.3407	0.4995	16084/12519/296	0.4880							600805 [LAMA3 (provisional) Epidermolysis bullosa,junctional,Herlitz type,226700|Epidermolysis bullosa,generalized atrophic benign,226650|Laryngoonychocutaneous syndrome,245660];				515	754					LAMA3 (inh=AR pLI=0.00)
chr18	21481233	21481233	C	G	het	het	wt		QUAL=4344;DP=246,96,138;MQM=60	LAMA3	synonymous	LAMA3:NM_198129.2:synonymous:LOW:exon48/75:c.6147C>G:p.Ala2049Ala,LAMA3:NM_001127717.2:synonymous:LOW:exon47/74:c.5979C>G:p.Ala1993Ala,LAMA3:NM_000227.4:synonymous:LOW:exon11/38:c.1320C>G:p.Ala440Ala,LAMA3:NM_001127718.2:synonymous:LOW:exon10/37:c.1152C>G:p.Ala384Ala		rs1154226	0.1683	0.2343	3696/2434/17	0.2339							600805 [LAMA3 (provisional) Epidermolysis bullosa,junctional,Herlitz type,226700|Epidermolysis bullosa,generalized atrophic benign,226650|Laryngoonychocutaneous syndrome,245660];	RCV000241986.1 [benign]; RCV000350792.1 [benign]; RCV000386499.1 [benign]; 		COSM1179775, COSM1179776	103	606					LAMA3 (inh=AR pLI=0.00)
chr18	21511034	21511034	C	A	het	het	wt		QUAL=5183;DP=215,132,197;MQM=60	LAMA3	missense	LAMA3:NM_198129.2:missense:MODERATE:exon65/75:c.8445C>A:p.Asn2815Lys,LAMA3:NM_001127717.2:missense:MODERATE:exon64/74:c.8277C>A:p.Asn2759Lys,LAMA3:NM_000227.4:missense:MODERATE:exon28/38:c.3618C>A:p.Asn1206Lys,LAMA3:NM_001127718.2:missense:MODERATE:exon27/37:c.3450C>A:p.Asn1150Lys		rs1154232	0.1567	0.1889	2374/1348/18	0.1874	-0.0070	T,T,T	T	B,B,B,B	T,T,T	9.00	600805 [LAMA3 (provisional) Epidermolysis bullosa,junctional,Herlitz type,226700|Epidermolysis bullosa,generalized atrophic benign,226650|Laryngoonychocutaneous syndrome,245660];	RCV000250312.1 [benign]; RCV000264313.1 [benign]; RCV000328887.1 [benign]; 			70	507					LAMA3 (inh=AR pLI=0.00)
chr18	21511089	21511089	A	G	hom	hom	hom		QUAL=22691;DP=272,177,249;MQM=60	LAMA3	missense	LAMA3:NM_198129.2:missense:MODERATE:exon65/75:c.8500A>G:p.Ser2834Gly,LAMA3:NM_001127717.2:missense:MODERATE:exon64/74:c.8332A>G:p.Ser2778Gly,LAMA3:NM_000227.4:missense:MODERATE:exon28/38:c.3673A>G:p.Ser1225Gly,LAMA3:NM_001127718.2:missense:MODERATE:exon27/37:c.3505A>G:p.Ser1169Gly		rs1154233	1.0000	1.0000	60703/33370/5202	0.9419	-1.2560	T,T,T	T	B,B,B,B	T,T,T	0.01	600805 [LAMA3 (provisional) Epidermolysis bullosa,junctional,Herlitz type,226700|Epidermolysis bullosa,generalized atrophic benign,226650|Laryngoonychocutaneous syndrome,245660];	RCV000242248.1 [benign]; RCV000270352.1 [benign]; RCV000383453.1 [benign]; 			1581	0					LAMA3 (inh=AR pLI=0.00)
chr18	21511172	21511172	G	C	hom	hom	hom		QUAL=17370;DP=193,154,201;MQM=60	LAMA3	splice_region&intron	LAMA3:NM_198129.2:splice_region&intron:LOW:exon65/74:c.8576+7G>C:,LAMA3:NM_001127717.2:splice_region&intron:LOW:exon64/73:c.8408+7G>C:,LAMA3:NM_000227.4:splice_region&intron:LOW:exon28/37:c.3749+7G>C:,LAMA3:NM_001127718.2:splice_region&intron:LOW:exon27/36:c.3581+7G>C:		rs1258107	0.9489	0.9732	57551/32496/4160	0.9305							600805 [LAMA3 (provisional) Epidermolysis bullosa,junctional,Herlitz type,226700|Epidermolysis bullosa,generalized atrophic benign,226650|Laryngoonychocutaneous syndrome,245660];	RCV000247245.1 [benign]; RCV000325474.1 [benign]; RCV000389378.1 [benign]; RCV000296169.1 [uncertain significance]; RCV000348726.1 [uncertain significance]; 			1508	70					LAMA3 (inh=AR pLI=0.00)
chr18	21513768	21513768	C	T	het	het	wt		QUAL=2822;DP=135,89,105;MQM=60	LAMA3	synonymous	LAMA3:NM_198129.2:synonymous:LOW:exon67/75:c.8731C>T:p.Leu2911Leu,LAMA3:NM_001127717.2:synonymous:LOW:exon66/74:c.8563C>T:p.Leu2855Leu,LAMA3:NM_000227.4:synonymous:LOW:exon30/38:c.3904C>T:p.Leu1302Leu,LAMA3:NM_001127718.2:synonymous:LOW:exon29/37:c.3736C>T:p.Leu1246Leu		rs1131521	0.1484	0.1860	2331/1334/11	0.1850							600805 [LAMA3 (provisional) Epidermolysis bullosa,junctional,Herlitz type,226700|Epidermolysis bullosa,generalized atrophic benign,226650|Laryngoonychocutaneous syndrome,245660];	RCV000252202.1 [benign]; RCV000309977.1 [benign]; RCV000362299.1 [benign]; 		COSM3756099, COSM3756100	70	505					LAMA3 (inh=AR pLI=0.00)
chr18	21529722	21529722	G	A	het	het	hom		QUAL=10922;DP=225,178,190;MQM=60	LAMA3	splice_region&intron	LAMA3:NM_198129.2:splice_region&intron:LOW:exon70/74:c.9352-7G>A:,LAMA3:NM_001127717.2:splice_region&intron:LOW:exon69/73:c.9184-7G>A:,LAMA3:NM_000227.4:splice_region&intron:LOW:exon33/37:c.4525-7G>A:,LAMA3:NM_001127718.2:splice_region&intron:LOW:exon32/36:c.4357-7G>A:		rs2241643	0.3590	0.5377	19668/15371/360	0.5302							600805 [LAMA3 (provisional) Epidermolysis bullosa,junctional,Herlitz type,226700|Epidermolysis bullosa,generalized atrophic benign,226650|Laryngoonychocutaneous syndrome,245660];	RCV000247590.1 [benign]; RCV000290820.1 [benign]; RCV000348031.1 [benign]; 			611	715					LAMA3 (inh=AR pLI=0.00)
chr18	21534701	21534701	C	A	het	het	hom		QUAL=17672;DP=279,258,346;MQM=60	LAMA3	3'UTR	LAMA3:NM_198129.2:3'UTR:MODIFIER:exon75/75:c.*89C>A:,LAMA3:NM_001127717.2:3'UTR:MODIFIER:exon74/74:c.*89C>A:,LAMA3:NM_000227.4:3'UTR:MODIFIER:exon38/38:c.*89C>A:,LAMA3:NM_001127718.2:3'UTR:MODIFIER:exon37/37:c.*89C>A:		rs1051149	0.3596	0.0000	0/0/0	0.0830							600805 [LAMA3 (provisional) Epidermolysis bullosa,junctional,Herlitz type,226700|Epidermolysis bullosa,generalized atrophic benign,226650|Laryngoonychocutaneous syndrome,245660];	RCV000344067.1 [benign]; RCV000399433.1 [benign]; 			87	111					LAMA3 (inh=AR pLI=0.00)
chr18	21534703	21534703	C	T	het	het	hom		QUAL=17672;DP=279,258,346;MQM=60	LAMA3	3'UTR	LAMA3:NM_198129.2:3'UTR:MODIFIER:exon75/75:c.*91C>T:,LAMA3:NM_001127717.2:3'UTR:MODIFIER:exon74/74:c.*91C>T:,LAMA3:NM_000227.4:3'UTR:MODIFIER:exon38/38:c.*91C>T:,LAMA3:NM_001127718.2:3'UTR:MODIFIER:exon37/37:c.*91C>T:		rs1051150	0.3596	0.0000	0/0/0	0.0830							600805 [LAMA3 (provisional) Epidermolysis bullosa,junctional,Herlitz type,226700|Epidermolysis bullosa,generalized atrophic benign,226650|Laryngoonychocutaneous syndrome,245660];	RCV000295082.1 [benign]; RCV000348785.1 [benign]; 			87	111					LAMA3 (inh=AR pLI=0.00)
chr18	29178899	29178899	C	T	wt	wt	het		QUAL=2125;DP=265,149,184;MQM=60	TTR	3'UTR	TTR:NM_000371.3:3'UTR:MODIFIER:exon4/4:c.*261C>T:		rs62093482	0.0100	0.0000	0/0/0	0.0035							176300 [TTR (confirmed) Amyloidosis,hereditary,transthyretin-related,105210|Dystransthyretinemic hyperthyroxinemia,145680|Carpal tunnel syndrome,familial,115430];				0	17					TTR (inh=AD pLI=0.13)
chr18	31320229	31320229	A	G	het	het	het		QUAL=11713;DP=370,224,265;MQM=60	ASXL3	missense	ASXL3:NM_030632.2:missense:MODERATE:exon11/12:c.2861A>G:p.Asn954Ser		rs2282632	0.7033	0.6029	22038/8392/2969	0.5850	0.4050	T	T	B	T	1.54	615115 [ASXL3 (provisional) Bainbridge-Ropers syndrome,615485];				290	558					ASXL3 (inh=AD pLI=1.00)
chr18	31323848	31323848	A	G	het	wt	het	pred_pathogenic	QUAL=9221;DP=383,303,421;MQM=60	ASXL3	missense	ASXL3:NM_030632.2:missense:MODERATE:exon12/12:c.4036A>G:p.Ile1346Val		rs61995734	0.0246	0.0164	39/10/24	0.0160	0.4170	D	T	B	T	8.26	615115 [ASXL3 (provisional) Bainbridge-Ropers syndrome,615485];				0	30					ASXL3 (inh=AD pLI=1.00)
chr18	31324934	31324934	A	G	het	het	het		QUAL=15392;DP=356,350,506;MQM=59	ASXL3	missense	ASXL3:NM_030632.2:missense:MODERATE:exon12/12:c.5122A>G:p.Met1708Val		rs7232237	0.6791	0.5863	21888/8534/2669	0.5773	-1.4340	T	T	B	T	0.01	615115 [ASXL3 (provisional) Bainbridge-Ropers syndrome,615485];				289	556					ASXL3 (inh=AD pLI=1.00)
chr18	31326012	31326012	T	G	wt	wt	het	pred_pathogenic	QUAL=1687;DP=230,107,120;MQM=60	ASXL3	missense	ASXL3:NM_030632.2:missense:MODERATE:exon12/12:c.6200T>G:p.Leu2067Arg		rs144534810	0.0024	0.0063	5/5/0	0.0062	4.1970	D	T	P	T	23.10	615115 [ASXL3 (provisional) Bainbridge-Ropers syndrome,615485];	RCV000203181.1 [benign]; 		COSM3756131	0	15					ASXL3 (inh=AD pLI=1.00)
chr18	31327296	31327296	A	C	het	wt	het		QUAL=7616;DP=415,176,221;MQM=60	ASXL3	3'UTR	ASXL3:NM_030632.2:3'UTR:MODIFIER:exon12/12:c.*737A>C:		rs7243541	0.2169	0.0000	0/0/0	0.1578							615115 [ASXL3 (provisional) Bainbridge-Ropers syndrome,615485];				2	53					ASXL3 (inh=AD pLI=1.00)
chr18	33713287	33713287	T	A	het	het	het		QUAL=12045;DP=383,272,315;MQM=60	ELP2	splice_region&intron,intron	ELP2:NM_001242875.2:splice_region&intron:LOW:exon2/22:c.217+8T>A:,ELP2:NM_001242876.2:splice_region&intron:LOW:exon2/20:c.217+8T>A:,ELP2:NM_001242877.2:splice_region&intron:LOW:exon2/20:c.217+8T>A:,ELP2:NM_001242878.2:splice_region&intron:LOW:exon2/19:c.217+8T>A:,ELP2:NM_001242879.2:splice_region&intron:LOW:exon2/18:c.217+8T>A:,ELP2:NM_001324465.1:splice_region&intron:LOW:exon2/20:c.217+8T>A:,ELP2:NM_001324466.1:splice_region&intron:LOW:exon2/21:c.217+8T>A:,ELP2:NM_001324467.1:splice_region&intron:LOW:exon2/20:c.217+8T>A:,ELP2:NM_018255.3:splice_region&intron:LOW:exon2/21:c.217+8T>A:,ELP2:NR_040110.2:splice_region&intron:LOW:exon2/21:n.277+8T>A:,ELP2:NR_136897.1:splice_region&intron:LOW:exon2/20:n.277+8T>A:,ELP2:NR_136898.1:splice_region&intron:LOW:exon2/21:n.277+8T>A:,ELP2:NR_137173.1:splice_region&intron:LOW:exon2/20:n.277+8T>A:,ELP2:NM_001324468.1:intron:MODIFIER:exon1/20:c.-230-2983T>A:		rs1785905	0.3205	0.3443	7387/4583/754	0.3392							616054 [ELP2 (provisional) Mental retardation,autosomal recessive 58,617270];				213	715					ELP2 (inh=n/a pLI=0.00)
chr18	33718326	33718326	A	C	het	het	het		QUAL=7291;DP=266,171,150;MQM=60	ELP2	missense,5'UTR,non_coding_transcript_exon	ELP2:NM_001242875.2:missense:MODERATE:exon4/23:c.382A>C:p.Thr128Pro,ELP2:NM_001242876.2:missense:MODERATE:exon4/21:c.382A>C:p.Thr128Pro,ELP2:NM_001242877.2:missense:MODERATE:exon4/21:c.382A>C:p.Thr128Pro,ELP2:NM_001242878.2:missense:MODERATE:exon4/20:c.382A>C:p.Thr128Pro,ELP2:NM_001242879.2:missense:MODERATE:exon4/19:c.382A>C:p.Thr128Pro,ELP2:NM_001324465.1:missense:MODERATE:exon4/21:c.382A>C:p.Thr128Pro,ELP2:NM_001324466.1:missense:MODERATE:exon4/22:c.382A>C:p.Thr128Pro,ELP2:NM_001324467.1:missense:MODERATE:exon4/21:c.382A>C:p.Thr128Pro,ELP2:NM_018255.3:missense:MODERATE:exon4/22:c.382A>C:p.Thr128Pro,ELP2:NM_001324468.1:5'UTR:MODIFIER:exon3/21:c.-66A>C:,ELP2:NR_040110.2:non_coding_transcript_exon:MODIFIER:exon4/22:n.442A>C:,ELP2:NR_136897.1:non_coding_transcript_exon:MODIFIER:exon4/21:n.442A>C:,ELP2:NR_136898.1:non_coding_transcript_exon:MODIFIER:exon4/22:n.442A>C:,ELP2:NR_137173.1:non_coding_transcript_exon:MODIFIER:exon4/21:n.442A>C:		rs1785934	0.3205	0.3427	7445/4635/756	0.3395	0.6540	T,T,T,T,T,T	T	B,B,B,B,B,B	T,T,T,T,T,T	5.90	616054 [ELP2 (provisional) Mental retardation,autosomal recessive 58,617270];				212	719					ELP2 (inh=n/a pLI=0.00)
chr18	33719434	33719434	C	T	het	het	het		QUAL=6371;DP=155,133,216;MQM=60	ELP2	synonymous,intron	ELP2:NM_001242875.2:synonymous:LOW:exon6/23:c.576C>T:p.Ala192Ala,ELP2:NM_001242876.2:synonymous:LOW:exon5/21:c.498C>T:p.Ala166Ala,ELP2:NM_001324466.1:synonymous:LOW:exon5/22:c.498C>T:p.Ala166Ala,ELP2:NM_001242877.2:intron:MODIFIER:exon4/20:c.445+1045C>T:,ELP2:NM_001242878.2:intron:MODIFIER:exon4/19:c.445+1045C>T:,ELP2:NM_001242879.2:intron:MODIFIER:exon4/18:c.445+1045C>T:,ELP2:NM_001324465.1:intron:MODIFIER:exon5/20:c.523+599C>T:,ELP2:NM_001324467.1:intron:MODIFIER:exon5/20:c.523+599C>T:,ELP2:NM_001324468.1:intron:MODIFIER:exon4/20:c.76+599C>T:,ELP2:NM_018255.3:intron:MODIFIER:exon5/21:c.523+599C>T:,ELP2:NR_040110.2:intron:MODIFIER:exon5/21:n.583+599C>T:,ELP2:NR_136897.1:intron:MODIFIER:exon5/20:n.583+599C>T:,ELP2:NR_136898.1:intron:MODIFIER:exon5/21:n.583+599C>T:,ELP2:NR_137173.1:intron:MODIFIER:exon5/20:n.583+599C>T:		rs1785932	0.2452	0.2372	348/189/3	0.0725							616054 [ELP2 (provisional) Mental retardation,autosomal recessive 58,617270];				187	648					ELP2 (inh=n/a pLI=0.00)
chr18	33725931	33725931	G	A	het	het	het		QUAL=9142;DP=325,177,251;MQM=59	ELP2	missense,non_coding_transcript_exon	ELP2:NM_001242875.2:missense:MODERATE:exon11/23:c.1108G>A:p.Val370Met,ELP2:NM_001242876.2:missense:MODERATE:exon10/21:c.1030G>A:p.Val344Met,ELP2:NM_001242877.2:missense:MODERATE:exon9/21:c.835G>A:p.Val279Met,ELP2:NM_001242878.2:missense:MODERATE:exon9/20:c.835G>A:p.Val279Met,ELP2:NM_001242879.2:missense:MODERATE:exon7/19:c.703G>A:p.Val235Met,ELP2:NM_001324465.1:missense:MODERATE:exon10/21:c.913G>A:p.Val305Met,ELP2:NM_001324466.1:missense:MODERATE:exon10/22:c.1030G>A:p.Val344Met,ELP2:NM_001324467.1:missense:MODERATE:exon10/21:c.913G>A:p.Val305Met,ELP2:NM_001324468.1:missense:MODERATE:exon9/21:c.466G>A:p.Val156Met,ELP2:NM_018255.3:missense:MODERATE:exon10/22:c.913G>A:p.Val305Met,ELP2:NR_040110.2:non_coding_transcript_exon:MODIFIER:exon10/22:n.973G>A:,ELP2:NR_136897.1:non_coding_transcript_exon:MODIFIER:exon9/21:n.906G>A:,ELP2:NR_136898.1:non_coding_transcript_exon:MODIFIER:exon10/22:n.973G>A:,ELP2:NR_137173.1:non_coding_transcript_exon:MODIFIER:exon10/21:n.973G>A:		rs1785928	0.3217	0.3427	7458/4632/762	0.3302	0.2480	T,T,T,T,T,T	T	B,B,B,B,B,B	T,T,T,T,T,T	3.76	616054 [ELP2 (provisional) Mental retardation,autosomal recessive 58,617270];			COSM1388588	212	721					ELP2 (inh=n/a pLI=0.00)
chr18	33750046	33750046	C	T	het	het	het		QUAL=5337;DP=121,120,159;MQM=60	ELP2	synonymous,intron,non_coding_transcript_exon	ELP2:NM_001242875.2:synonymous:LOW:exon21/23:c.2292C>T:p.Cys764Cys,ELP2:NM_001242876.2:synonymous:LOW:exon19/21:c.2082C>T:p.Cys694Cys,ELP2:NM_001242877.2:synonymous:LOW:exon19/21:c.2019C>T:p.Cys673Cys,ELP2:NM_001242878.2:synonymous:LOW:exon18/20:c.1887C>T:p.Cys629Cys,ELP2:NM_001242879.2:synonymous:LOW:exon17/19:c.1887C>T:p.Cys629Cys,ELP2:NM_001324465.1:synonymous:LOW:exon19/21:c.1965C>T:p.Cys655Cys,ELP2:NM_001324466.1:synonymous:LOW:exon20/22:c.2214C>T:p.Cys738Cys,ELP2:NM_001324467.1:synonymous:LOW:exon19/21:c.1947C>T:p.Cys649Cys,ELP2:NM_001324468.1:synonymous:LOW:exon19/21:c.1650C>T:p.Cys550Cys,ELP2:NM_018255.3:synonymous:LOW:exon20/22:c.2097C>T:p.Cys699Cys,ELP2:NR_137173.1:intron:MODIFIER:exon19/20:n.2137-964C>T:,ELP2:NR_040110.2:non_coding_transcript_exon:MODIFIER:exon20/22:n.2105C>T:,ELP2:NR_136897.1:non_coding_transcript_exon:MODIFIER:exon19/21:n.2038C>T:,ELP2:NR_136898.1:non_coding_transcript_exon:MODIFIER:exon20/22:n.2102C>T:		rs8299	0.3237	0.3507	7827/4961/762	0.3481							616054 [ELP2 (provisional) Mental retardation,autosomal recessive 58,617270];			COSM1388592	229	733					ELP2 (inh=n/a pLI=0.00)
chr18	42260911	42260911	G	T	het	het	wt		QUAL=2047;DP=110,71,109;MQM=59	SETBP1	5'UTR_premature_start_codon_gain,5'UTR,intron	SETBP1:NM_015559.2:5'UTR_premature_start_codon_gain:LOW:exon1/6:c.-248G>T:,SETBP1:NM_015559.2:5'UTR:MODIFIER:exon1/6:c.-248G>T:,SETBP1:NM_001130110.1:intron:MODIFIER:exon1/3:c.-173+551G>T:		rs563748893	0.0018	0.0000	0/0/0	0.0069							611060 [SETBP1 (confirmed) Schinzel-Giedion midface retraction syndrome,269150|Mental retardation,autosomal dominant 29,616078];	RCV000319325.1 [likely benign]; 		COSN148355	0	10					SETBP1 (inh=AD pLI=1.00)
chr18	42456653	42456653	G	A	hom	het	het	pred_pathogenic	QUAL=7046;DP=143,91,134;MQM=59	SETBP1	missense,intron	SETBP1:NM_001130110.1:missense:MODERATE:exon4/4:c.664G>A:p.Ala222Thr,SETBP1:NM_015559.2:intron:MODIFIER:exon3/5:c.540+7405G>A:		rs663651	0.4930	0.5073	2819/1389/305	0.1671	-0.9690	D	T	B		2.67	611060 [SETBP1 (confirmed) Schinzel-Giedion midface retraction syndrome,269150|Mental retardation,autosomal dominant 29,616078];	RCV000147471.1 [likely benign]; 			468	743					SETBP1 (inh=AD pLI=1.00)
chr18	42456670	42456670	-	TCTT	hom	het	het	anno_high_impact	QUAL=6204;DP=145,80,119;MQM=59	SETBP1	frameshift,intron	SETBP1:NM_001130110.1:frameshift:HIGH:exon4/4:c.681_682insTCTT:p.Thr228fs,SETBP1:NM_015559.2:intron:MODIFIER:exon3/5:c.540+7422_540+7423insTCTT:		rs3085861	0.4938	0.5146	2765/1366/302	0.0840							611060 [SETBP1 (confirmed) Schinzel-Giedion midface retraction syndrome,269150|Mental retardation,autosomal dominant 29,616078];	RCV000326176.1 [benign]; 		COSM1480329	467	741	1	[1] auto-classification 16.06.2016  [2] old entry - no details available			SETBP1 (inh=AD pLI=1.00)
chr18	42529996	42529996	G	C	het	het	wt	pred_pathogenic	QUAL=5410;DP=191,251,328;MQM=60	SETBP1	missense	SETBP1:NM_015559.2:missense:MODERATE:exon4/6:c.691G>C:p.Val231Leu		rs11082414	0.1567	0.1934	2511/1430/123	0.1880	-0.1230	D	T	B	T	0.01	611060 [SETBP1 (confirmed) Schinzel-Giedion midface retraction syndrome,269150|Mental retardation,autosomal dominant 29,616078];	RCV000147472.1 [benign]; RCV000291334.1 [benign]; 			82	457					SETBP1 (inh=AD pLI=1.00)
chr18	42532606	42532606	G	A	wt	wt	het		QUAL=5927;DP=403,360,435;MQM=60	SETBP1	missense	SETBP1:NM_015559.2:missense:MODERATE:exon4/6:c.3301G>A:p.Val1101Ile		rs3744825	0.1248	0.1212	1063/520/13	0.1239	1.2060	T	T	B	T	0.22	611060 [SETBP1 (confirmed) Schinzel-Giedion midface retraction syndrome,269150|Mental retardation,autosomal dominant 29,616078];	RCV000147459.1 [benign]; RCV000395670.1 [benign]; 		COSM148423	24	323					SETBP1 (inh=AD pLI=1.00)
chr18	42532693	42532693	C	A	wt	het	wt	pred_pathogenic	QUAL=4611;DP=498,366,528;MQM=60	SETBP1	missense	SETBP1:NM_015559.2:missense:MODERATE:exon4/6:c.3388C>A:p.Pro1130Thr		rs1064204	0.1186	0.1288	1406/395/10	0.1273	1.8730	T	T	B	T	11.20	611060 [SETBP1 (confirmed) Schinzel-Giedion midface retraction syndrome,269150|Mental retardation,autosomal dominant 29,616078];	RCV000147460.1 [benign]; RCV000308554.1 [benign]; 			33	328					SETBP1 (inh=AD pLI=1.00)
chr18	42533130	42533130	A	G	hom	hom	hom		QUAL=18632;DP=291,126,177;MQM=59	SETBP1	synonymous	SETBP1:NM_015559.2:synonymous:LOW:exon4/6:c.3825A>G:p.Ser1275Ser		rs8096662	0.9069	0.8775	46900/24556/4935	0.8514							611060 [SETBP1 (confirmed) Schinzel-Giedion midface retraction syndrome,269150|Mental retardation,autosomal dominant 29,616078];	RCV000147461.1 [uncertain significance]; RCV000147462.1 [benign]; RCV000324790.1 [benign]; RCV000147463.1 [uncertain significance]; 			1162	339					SETBP1 (inh=AD pLI=1.00)
chr18	42533315	42533315	T	A	wt	het	wt		QUAL=1644;DP=193,123,156;MQM=60	SETBP1	splice_region&intron	SETBP1:NM_015559.2:splice_region&intron:LOW:exon4/5:c.4000+10T>A:		rs3786177	0.1186	0.1390	1327/371/13	0.1265							611060 [SETBP1 (confirmed) Schinzel-Giedion midface retraction syndrome,269150|Mental retardation,autosomal dominant 29,616078];	RCV000147464.1 [benign]; RCV000261259.1 [benign]; 			33	280					SETBP1 (inh=AD pLI=1.00)
chr18	42646635	42646635	T	-	het	wt	hom		QUAL=519;DP=115,24,21;MQM=59	SETBP1	3'UTR	SETBP1:NM_015559.2:3'UTR:MODIFIER:exon6/6:c.*2987delT:		rs34125334	0.3756	0.0000	0/0/0	0.1125							611060 [SETBP1 (confirmed) Schinzel-Giedion midface retraction syndrome,269150|Mental retardation,autosomal dominant 29,616078];	RCV000316690.1 [benign]; 			4	152					SETBP1 (inh=AD pLI=1.00)
chr18	46987023	46987023	C	G	het	het	wt		QUAL=2411;DP=59,138,165;MQM=59	DYM	5'UTR	DYM:NM_017653.3:5'UTR:MODIFIER:exon1/17:c.-309G>C:		rs28364579	0.1194	0.0000	0/0/0	0.1197							607461 [DYM (confirmed) Dyggve-Melchior-Clausen disease,223800|Smith-McCort dysplasia,607326];	RCV000268340.1 [benign]; RCV000323440.1 [benign]; 			2	34					DYM (inh=AR pLI=0.00)
chr18	52889712	52889712	-	A	het	wt	het		QUAL=420;DP=108,26,25;MQM=59	TCF4	3'UTR	TCF4:NM_001243226.2:3'UTR:MODIFIER:exon21/21:c.*5553dupT:,TCF4:NM_001243236.1:3'UTR:MODIFIER:exon13/13:c.*5553dupT:,TCF4:NM_001243234.1:3'UTR:MODIFIER:exon13/13:c.*5553dupT:,TCF4:NM_001243235.1:3'UTR:MODIFIER:exon13/13:c.*5553dupT:,TCF4:NM_001243232.1:3'UTR:MODIFIER:exon16/16:c.*5553dupT:,TCF4:NM_001306208.1:3'UTR:MODIFIER:exon16/16:c.*5553dupT:,TCF4:NM_001243233.1:3'UTR:MODIFIER:exon16/16:c.*5553dupT:,TCF4:NM_001243231.1:3'UTR:MODIFIER:exon18/18:c.*5553dupT:,TCF4:NM_001306207.1:3'UTR:MODIFIER:exon19/19:c.*5553dupT:,TCF4:NM_001083962.1:3'UTR:MODIFIER:exon20/20:c.*5553dupT:,TCF4:NM_001243230.1:3'UTR:MODIFIER:exon19/19:c.*5553dupT:,TCF4:NM_003199.2:3'UTR:MODIFIER:exon20/20:c.*5553dupT:,TCF4:NM_001243227.1:3'UTR:MODIFIER:exon19/19:c.*5553dupT:,TCF4:NM_001243228.1:3'UTR:MODIFIER:exon20/20:c.*5553dupT:		rs71670792	0.2208	0.0000	0/0/0	0.1693							602272 [TCF4 (confirmed) Pitt-Hopkins syndrome,610954|Corneal dystrophy,Fuchs endothelial,3,613267];	RCV000282991.1 [benign]; 			1	110					TCF4 (inh=AD pLI=1.00)
chr18	52889967	52889967	T	C	het	wt	hom		QUAL=8118;DP=280,89,135;MQM=60	TCF4	3'UTR	TCF4:NM_001243226.2:3'UTR:MODIFIER:exon21/21:c.*5299A>G:,TCF4:NM_001243236.1:3'UTR:MODIFIER:exon13/13:c.*5299A>G:,TCF4:NM_001243234.1:3'UTR:MODIFIER:exon13/13:c.*5299A>G:,TCF4:NM_001243235.1:3'UTR:MODIFIER:exon13/13:c.*5299A>G:,TCF4:NM_001243232.1:3'UTR:MODIFIER:exon16/16:c.*5299A>G:,TCF4:NM_001306208.1:3'UTR:MODIFIER:exon16/16:c.*5299A>G:,TCF4:NM_001243233.1:3'UTR:MODIFIER:exon16/16:c.*5299A>G:,TCF4:NM_001243231.1:3'UTR:MODIFIER:exon18/18:c.*5299A>G:,TCF4:NM_001306207.1:3'UTR:MODIFIER:exon19/19:c.*5299A>G:,TCF4:NM_001083962.1:3'UTR:MODIFIER:exon20/20:c.*5299A>G:,TCF4:NM_001243230.1:3'UTR:MODIFIER:exon19/19:c.*5299A>G:,TCF4:NM_003199.2:3'UTR:MODIFIER:exon20/20:c.*5299A>G:,TCF4:NM_001243227.1:3'UTR:MODIFIER:exon19/19:c.*5299A>G:,TCF4:NM_001243228.1:3'UTR:MODIFIER:exon20/20:c.*5299A>G:		rs1261085	0.3974	0.0000	0/0/0	0.0642							602272 [TCF4 (confirmed) Pitt-Hopkins syndrome,610954|Corneal dystrophy,Fuchs endothelial,3,613267];	RCV000397336.1 [benign]; 			42	116					TCF4 (inh=AD pLI=1.00)
chr18	52890160	52890160	A	G	het	wt	hom		QUAL=6287;DP=280,100,96;MQM=60	TCF4	3'UTR	TCF4:NM_001243226.2:3'UTR:MODIFIER:exon21/21:c.*5106T>C:,TCF4:NM_001243236.1:3'UTR:MODIFIER:exon13/13:c.*5106T>C:,TCF4:NM_001243234.1:3'UTR:MODIFIER:exon13/13:c.*5106T>C:,TCF4:NM_001243235.1:3'UTR:MODIFIER:exon13/13:c.*5106T>C:,TCF4:NM_001243232.1:3'UTR:MODIFIER:exon16/16:c.*5106T>C:,TCF4:NM_001306208.1:3'UTR:MODIFIER:exon16/16:c.*5106T>C:,TCF4:NM_001243233.1:3'UTR:MODIFIER:exon16/16:c.*5106T>C:,TCF4:NM_001243231.1:3'UTR:MODIFIER:exon18/18:c.*5106T>C:,TCF4:NM_001306207.1:3'UTR:MODIFIER:exon19/19:c.*5106T>C:,TCF4:NM_001083962.1:3'UTR:MODIFIER:exon20/20:c.*5106T>C:,TCF4:NM_001243230.1:3'UTR:MODIFIER:exon19/19:c.*5106T>C:,TCF4:NM_003199.2:3'UTR:MODIFIER:exon20/20:c.*5106T>C:,TCF4:NM_001243227.1:3'UTR:MODIFIER:exon19/19:c.*5106T>C:,TCF4:NM_001243228.1:3'UTR:MODIFIER:exon20/20:c.*5106T>C:		rs1261084	0.4437	0.0000	0/0/0	0.0720							602272 [TCF4 (confirmed) Pitt-Hopkins syndrome,610954|Corneal dystrophy,Fuchs endothelial,3,613267];	RCV000261417.1 [benign]; 			51	111					TCF4 (inh=AD pLI=1.00)
chr18	52890913	52890914	TT	-	het	wt	hom		QUAL=2294;DP=164,25,70;MQM=59	TCF4	3'UTR	TCF4:NM_001243226.2:3'UTR:MODIFIER:exon21/21:c.*4352_*4353delAA:,TCF4:NM_001243236.1:3'UTR:MODIFIER:exon13/13:c.*4352_*4353delAA:,TCF4:NM_001243234.1:3'UTR:MODIFIER:exon13/13:c.*4352_*4353delAA:,TCF4:NM_001243235.1:3'UTR:MODIFIER:exon13/13:c.*4352_*4353delAA:,TCF4:NM_001243232.1:3'UTR:MODIFIER:exon16/16:c.*4352_*4353delAA:,TCF4:NM_001306208.1:3'UTR:MODIFIER:exon16/16:c.*4352_*4353delAA:,TCF4:NM_001243233.1:3'UTR:MODIFIER:exon16/16:c.*4352_*4353delAA:,TCF4:NM_001243231.1:3'UTR:MODIFIER:exon18/18:c.*4352_*4353delAA:,TCF4:NM_001306207.1:3'UTR:MODIFIER:exon19/19:c.*4352_*4353delAA:,TCF4:NM_001083962.1:3'UTR:MODIFIER:exon20/20:c.*4352_*4353delAA:,TCF4:NM_001243230.1:3'UTR:MODIFIER:exon19/19:c.*4352_*4353delAA:,TCF4:NM_003199.2:3'UTR:MODIFIER:exon20/20:c.*4352_*4353delAA:,TCF4:NM_001243227.1:3'UTR:MODIFIER:exon19/19:c.*4352_*4353delAA:,TCF4:NM_001243228.1:3'UTR:MODIFIER:exon20/20:c.*4352_*4353delAA:		rs11431395;rs773076214	0.5080	0.0000	0/0/0	0.2628							602272 [TCF4 (confirmed) Pitt-Hopkins syndrome,610954|Corneal dystrophy,Fuchs endothelial,3,613267];	RCV000273208.1 [benign]; 			38	82					TCF4 (inh=AD pLI=1.00)
chr18	52890946	52890946	-	TC	het	wt	hom		QUAL=3981;DP=202,33,73;MQM=59	TCF4	3'UTR	TCF4:NM_001243226.2:3'UTR:MODIFIER:exon21/21:c.*4319_*4320insGA:,TCF4:NM_001243236.1:3'UTR:MODIFIER:exon13/13:c.*4319_*4320insGA:,TCF4:NM_001243234.1:3'UTR:MODIFIER:exon13/13:c.*4319_*4320insGA:,TCF4:NM_001243235.1:3'UTR:MODIFIER:exon13/13:c.*4319_*4320insGA:,TCF4:NM_001243232.1:3'UTR:MODIFIER:exon16/16:c.*4319_*4320insGA:,TCF4:NM_001306208.1:3'UTR:MODIFIER:exon16/16:c.*4319_*4320insGA:,TCF4:NM_001243233.1:3'UTR:MODIFIER:exon16/16:c.*4319_*4320insGA:,TCF4:NM_001243231.1:3'UTR:MODIFIER:exon18/18:c.*4319_*4320insGA:,TCF4:NM_001306207.1:3'UTR:MODIFIER:exon19/19:c.*4319_*4320insGA:,TCF4:NM_001083962.1:3'UTR:MODIFIER:exon20/20:c.*4319_*4320insGA:,TCF4:NM_001243230.1:3'UTR:MODIFIER:exon19/19:c.*4319_*4320insGA:,TCF4:NM_003199.2:3'UTR:MODIFIER:exon20/20:c.*4319_*4320insGA:,TCF4:NM_001243227.1:3'UTR:MODIFIER:exon19/19:c.*4319_*4320insGA:,TCF4:NM_001243228.1:3'UTR:MODIFIER:exon20/20:c.*4319_*4320insGA:		rs373174214;rs61382440	0.4145	0.0000	0/0/0	0.3797							602272 [TCF4 (confirmed) Pitt-Hopkins syndrome,610954|Corneal dystrophy,Fuchs endothelial,3,613267];	RCV000394708.1 [benign]; 			20	105					TCF4 (inh=AD pLI=1.00)
chr18	52890958	52890958	-	T	wt	wt	het		QUAL=405;DP=160,28,62;MQM=60	TCF4	3'UTR	TCF4:NM_001243226.2:3'UTR:MODIFIER:exon21/21:c.*4307dupA:,TCF4:NM_001243236.1:3'UTR:MODIFIER:exon13/13:c.*4307dupA:,TCF4:NM_001243234.1:3'UTR:MODIFIER:exon13/13:c.*4307dupA:,TCF4:NM_001243235.1:3'UTR:MODIFIER:exon13/13:c.*4307dupA:,TCF4:NM_001243232.1:3'UTR:MODIFIER:exon16/16:c.*4307dupA:,TCF4:NM_001306208.1:3'UTR:MODIFIER:exon16/16:c.*4307dupA:,TCF4:NM_001243233.1:3'UTR:MODIFIER:exon16/16:c.*4307dupA:,TCF4:NM_001243231.1:3'UTR:MODIFIER:exon18/18:c.*4307dupA:,TCF4:NM_001306207.1:3'UTR:MODIFIER:exon19/19:c.*4307dupA:,TCF4:NM_001083962.1:3'UTR:MODIFIER:exon20/20:c.*4307dupA:,TCF4:NM_001243230.1:3'UTR:MODIFIER:exon19/19:c.*4307dupA:,TCF4:NM_003199.2:3'UTR:MODIFIER:exon20/20:c.*4307dupA:,TCF4:NM_001243227.1:3'UTR:MODIFIER:exon19/19:c.*4307dupA:,TCF4:NM_001243228.1:3'UTR:MODIFIER:exon20/20:c.*4307dupA:		rs144800392	0.0000	0.0000	0/0/0	0.0422							602272 [TCF4 (confirmed) Pitt-Hopkins syndrome,610954|Corneal dystrophy,Fuchs endothelial,3,613267];				2	50					TCF4 (inh=AD pLI=1.00)
chr18	52891284	52891284	T	-	het	wt	het	low_DP	QUAL=1817;DP=125,19,43;MQM=60	TCF4	3'UTR	TCF4:NM_001243226.2:3'UTR:MODIFIER:exon21/21:c.*3982delA:,TCF4:NM_001243236.1:3'UTR:MODIFIER:exon13/13:c.*3982delA:,TCF4:NM_001243234.1:3'UTR:MODIFIER:exon13/13:c.*3982delA:,TCF4:NM_001243235.1:3'UTR:MODIFIER:exon13/13:c.*3982delA:,TCF4:NM_001243232.1:3'UTR:MODIFIER:exon16/16:c.*3982delA:,TCF4:NM_001306208.1:3'UTR:MODIFIER:exon16/16:c.*3982delA:,TCF4:NM_001243233.1:3'UTR:MODIFIER:exon16/16:c.*3982delA:,TCF4:NM_001243231.1:3'UTR:MODIFIER:exon18/18:c.*3982delA:,TCF4:NM_001306207.1:3'UTR:MODIFIER:exon19/19:c.*3982delA:,TCF4:NM_001083962.1:3'UTR:MODIFIER:exon20/20:c.*3982delA:,TCF4:NM_001243230.1:3'UTR:MODIFIER:exon19/19:c.*3982delA:,TCF4:NM_003199.2:3'UTR:MODIFIER:exon20/20:c.*3982delA:,TCF4:NM_001243227.1:3'UTR:MODIFIER:exon19/19:c.*3982delA:,TCF4:NM_001243228.1:3'UTR:MODIFIER:exon20/20:c.*3982delA:	(T)n	rs35555522	0.2376	0.0000	0/0/0	0.1621							602272 [TCF4 (confirmed) Pitt-Hopkins syndrome,610954|Corneal dystrophy,Fuchs endothelial,3,613267];	RCV000265839.1 [benign]; 			8	101					TCF4 (inh=AD pLI=1.00)
chr18	52891396	52891396	T	-	wt	wt	hom		QUAL=1458;DP=103,47,77;MQM=59	TCF4	3'UTR	TCF4:NM_001243226.2:3'UTR:MODIFIER:exon21/21:c.*3870delA:,TCF4:NM_001243236.1:3'UTR:MODIFIER:exon13/13:c.*3870delA:,TCF4:NM_001243234.1:3'UTR:MODIFIER:exon13/13:c.*3870delA:,TCF4:NM_001243235.1:3'UTR:MODIFIER:exon13/13:c.*3870delA:,TCF4:NM_001243232.1:3'UTR:MODIFIER:exon16/16:c.*3870delA:,TCF4:NM_001306208.1:3'UTR:MODIFIER:exon16/16:c.*3870delA:,TCF4:NM_001243233.1:3'UTR:MODIFIER:exon16/16:c.*3870delA:,TCF4:NM_001243231.1:3'UTR:MODIFIER:exon18/18:c.*3870delA:,TCF4:NM_001306207.1:3'UTR:MODIFIER:exon19/19:c.*3870delA:,TCF4:NM_001083962.1:3'UTR:MODIFIER:exon20/20:c.*3870delA:,TCF4:NM_001243230.1:3'UTR:MODIFIER:exon19/19:c.*3870delA:,TCF4:NM_003199.2:3'UTR:MODIFIER:exon20/20:c.*3870delA:,TCF4:NM_001243227.1:3'UTR:MODIFIER:exon19/19:c.*3870delA:,TCF4:NM_001243228.1:3'UTR:MODIFIER:exon20/20:c.*3870delA:		rs550931998;rs66807288	0.2790	0.0000	0/0/0	0.1985							602272 [TCF4 (confirmed) Pitt-Hopkins syndrome,610954|Corneal dystrophy,Fuchs endothelial,3,613267];	RCV000366190.1 [uncertain significance]; 			6	135					TCF4 (inh=AD pLI=1.00)
chr18	52892562	52892564	ACT	-	wt	wt	het		QUAL=1709;DP=255,130,141;MQM=60	TCF4	3'UTR	TCF4:NM_001243226.2:3'UTR:MODIFIER:exon21/21:c.*2702_*2704delAGT:,TCF4:NM_001243236.1:3'UTR:MODIFIER:exon13/13:c.*2702_*2704delAGT:,TCF4:NM_001243234.1:3'UTR:MODIFIER:exon13/13:c.*2702_*2704delAGT:,TCF4:NM_001243235.1:3'UTR:MODIFIER:exon13/13:c.*2702_*2704delAGT:,TCF4:NM_001243232.1:3'UTR:MODIFIER:exon16/16:c.*2702_*2704delAGT:,TCF4:NM_001306208.1:3'UTR:MODIFIER:exon16/16:c.*2702_*2704delAGT:,TCF4:NM_001243233.1:3'UTR:MODIFIER:exon16/16:c.*2702_*2704delAGT:,TCF4:NM_001243231.1:3'UTR:MODIFIER:exon18/18:c.*2702_*2704delAGT:,TCF4:NM_001306207.1:3'UTR:MODIFIER:exon19/19:c.*2702_*2704delAGT:,TCF4:NM_001083962.1:3'UTR:MODIFIER:exon20/20:c.*2702_*2704delAGT:,TCF4:NM_001243230.1:3'UTR:MODIFIER:exon19/19:c.*2702_*2704delAGT:,TCF4:NM_003199.2:3'UTR:MODIFIER:exon20/20:c.*2702_*2704delAGT:,TCF4:NM_001243227.1:3'UTR:MODIFIER:exon19/19:c.*2702_*2704delAGT:,TCF4:NM_001243228.1:3'UTR:MODIFIER:exon20/20:c.*2702_*2704delAGT:		rs150498725	0.0158	0.0000	0/0/0	0.0350							602272 [TCF4 (confirmed) Pitt-Hopkins syndrome,610954|Corneal dystrophy,Fuchs endothelial,3,613267];	RCV000310029.1 [likely benign]; 			0	24					TCF4 (inh=AD pLI=1.00)
chr18	52893255	52893255	-	A	het	wt	het		QUAL=3220;DP=268,63,58;MQM=59	TCF4	3'UTR	TCF4:NM_001243226.2:3'UTR:MODIFIER:exon21/21:c.*2010dupT:,TCF4:NM_001243236.1:3'UTR:MODIFIER:exon13/13:c.*2010dupT:,TCF4:NM_001243234.1:3'UTR:MODIFIER:exon13/13:c.*2010dupT:,TCF4:NM_001243235.1:3'UTR:MODIFIER:exon13/13:c.*2010dupT:,TCF4:NM_001243232.1:3'UTR:MODIFIER:exon16/16:c.*2010dupT:,TCF4:NM_001306208.1:3'UTR:MODIFIER:exon16/16:c.*2010dupT:,TCF4:NM_001243233.1:3'UTR:MODIFIER:exon16/16:c.*2010dupT:,TCF4:NM_001243231.1:3'UTR:MODIFIER:exon18/18:c.*2010dupT:,TCF4:NM_001306207.1:3'UTR:MODIFIER:exon19/19:c.*2010dupT:,TCF4:NM_001083962.1:3'UTR:MODIFIER:exon20/20:c.*2010dupT:,TCF4:NM_001243230.1:3'UTR:MODIFIER:exon19/19:c.*2010dupT:,TCF4:NM_003199.2:3'UTR:MODIFIER:exon20/20:c.*2010dupT:,TCF4:NM_001243227.1:3'UTR:MODIFIER:exon19/19:c.*2010dupT:,TCF4:NM_001243228.1:3'UTR:MODIFIER:exon20/20:c.*2010dupT:		rs550740474	0.2240	0.0000	0/0/0	0.1603							602272 [TCF4 (confirmed) Pitt-Hopkins syndrome,610954|Corneal dystrophy,Fuchs endothelial,3,613267];	RCV000259881.1 [benign]; 			19	93					TCF4 (inh=AD pLI=1.00)
chr18	52893505	52893505	T	-	het	wt	hom		QUAL=9984;DP=384,147,206;MQM=59	TCF4	3'UTR	TCF4:NM_001243226.2:3'UTR:MODIFIER:exon21/21:c.*1761delA:,TCF4:NM_001243236.1:3'UTR:MODIFIER:exon13/13:c.*1761delA:,TCF4:NM_001243234.1:3'UTR:MODIFIER:exon13/13:c.*1761delA:,TCF4:NM_001243235.1:3'UTR:MODIFIER:exon13/13:c.*1761delA:,TCF4:NM_001243232.1:3'UTR:MODIFIER:exon16/16:c.*1761delA:,TCF4:NM_001306208.1:3'UTR:MODIFIER:exon16/16:c.*1761delA:,TCF4:NM_001243233.1:3'UTR:MODIFIER:exon16/16:c.*1761delA:,TCF4:NM_001243231.1:3'UTR:MODIFIER:exon18/18:c.*1761delA:,TCF4:NM_001306207.1:3'UTR:MODIFIER:exon19/19:c.*1761delA:,TCF4:NM_001083962.1:3'UTR:MODIFIER:exon20/20:c.*1761delA:,TCF4:NM_001243230.1:3'UTR:MODIFIER:exon19/19:c.*1761delA:,TCF4:NM_003199.2:3'UTR:MODIFIER:exon20/20:c.*1761delA:,TCF4:NM_001243227.1:3'UTR:MODIFIER:exon19/19:c.*1761delA:,TCF4:NM_001243228.1:3'UTR:MODIFIER:exon20/20:c.*1761delA:		rs71674214	0.3460	0.0000	0/0/0	0.2427							602272 [TCF4 (confirmed) Pitt-Hopkins syndrome,610954|Corneal dystrophy,Fuchs endothelial,3,613267];	RCV000288677.1 [benign]; 			33	110					TCF4 (inh=AD pLI=1.00)
chr18	52893926	52893926	-	A	wt	wt	het		QUAL=1522;DP=293,148,173;MQM=60	TCF4	3'UTR	TCF4:NM_001243226.2:3'UTR:MODIFIER:exon21/21:c.*1339dupT:,TCF4:NM_001243236.1:3'UTR:MODIFIER:exon13/13:c.*1339dupT:,TCF4:NM_001243234.1:3'UTR:MODIFIER:exon13/13:c.*1339dupT:,TCF4:NM_001243235.1:3'UTR:MODIFIER:exon13/13:c.*1339dupT:,TCF4:NM_001243232.1:3'UTR:MODIFIER:exon16/16:c.*1339dupT:,TCF4:NM_001306208.1:3'UTR:MODIFIER:exon16/16:c.*1339dupT:,TCF4:NM_001243233.1:3'UTR:MODIFIER:exon16/16:c.*1339dupT:,TCF4:NM_001243231.1:3'UTR:MODIFIER:exon18/18:c.*1339dupT:,TCF4:NM_001306207.1:3'UTR:MODIFIER:exon19/19:c.*1339dupT:,TCF4:NM_001083962.1:3'UTR:MODIFIER:exon20/20:c.*1339dupT:,TCF4:NM_001243230.1:3'UTR:MODIFIER:exon19/19:c.*1339dupT:,TCF4:NM_003199.2:3'UTR:MODIFIER:exon20/20:c.*1339dupT:,TCF4:NM_001243227.1:3'UTR:MODIFIER:exon19/19:c.*1339dupT:,TCF4:NM_001243228.1:3'UTR:MODIFIER:exon20/20:c.*1339dupT:		rs145712320	0.0929	0.0000	0/0/0	0.0776							602272 [TCF4 (confirmed) Pitt-Hopkins syndrome,610954|Corneal dystrophy,Fuchs endothelial,3,613267];	RCV000397291.1 [benign]; 			0	41					TCF4 (inh=AD pLI=1.00)
chr18	52894479	52894479	-	AA	wt	wt	het		QUAL=162;DP=186,77,82;MQM=60	TCF4	3'UTR	TCF4:NM_001243226.2:3'UTR:MODIFIER:exon21/21:c.*785_*786dupTT:,TCF4:NM_001243236.1:3'UTR:MODIFIER:exon13/13:c.*785_*786dupTT:,TCF4:NM_001243234.1:3'UTR:MODIFIER:exon13/13:c.*785_*786dupTT:,TCF4:NM_001243235.1:3'UTR:MODIFIER:exon13/13:c.*785_*786dupTT:,TCF4:NM_001243232.1:3'UTR:MODIFIER:exon16/16:c.*785_*786dupTT:,TCF4:NM_001306208.1:3'UTR:MODIFIER:exon16/16:c.*785_*786dupTT:,TCF4:NM_001243233.1:3'UTR:MODIFIER:exon16/16:c.*785_*786dupTT:,TCF4:NM_001243231.1:3'UTR:MODIFIER:exon18/18:c.*785_*786dupTT:,TCF4:NM_001306207.1:3'UTR:MODIFIER:exon19/19:c.*785_*786dupTT:,TCF4:NM_001083962.1:3'UTR:MODIFIER:exon20/20:c.*785_*786dupTT:,TCF4:NM_001243230.1:3'UTR:MODIFIER:exon19/19:c.*785_*786dupTT:,TCF4:NM_003199.2:3'UTR:MODIFIER:exon20/20:c.*785_*786dupTT:,TCF4:NM_001243227.1:3'UTR:MODIFIER:exon19/19:c.*785_*786dupTT:,TCF4:NM_001243228.1:3'UTR:MODIFIER:exon20/20:c.*785_*786dupTT:		rs375140529	0.0913	0.0000	0/0/0	0.0257							602272 [TCF4 (confirmed) Pitt-Hopkins syndrome,610954|Corneal dystrophy,Fuchs endothelial,3,613267];	RCV000261228.1 [benign]; 			1	19					TCF4 (inh=AD pLI=1.00)
chr18	52895531	52895531	T	C	het	wt	hom		QUAL=6755;DP=241,89,116;MQM=60	TCF4	synonymous	TCF4:NM_001243226.2:synonymous:LOW:exon20/21:c.2247A>G:p.Ser749Ser,TCF4:NM_001243236.1:synonymous:LOW:exon12/13:c.1449A>G:p.Ser483Ser,TCF4:NM_001243234.1:synonymous:LOW:exon12/13:c.1461A>G:p.Ser487Ser,TCF4:NM_001243235.1:synonymous:LOW:exon12/13:c.1449A>G:p.Ser483Ser,TCF4:NM_001243232.1:synonymous:LOW:exon15/16:c.1728A>G:p.Ser576Ser,TCF4:NM_001306208.1:synonymous:LOW:exon15/16:c.1716A>G:p.Ser572Ser,TCF4:NM_001243233.1:synonymous:LOW:exon15/16:c.1539A>G:p.Ser513Ser,TCF4:NM_001243231.1:synonymous:LOW:exon17/18:c.1803A>G:p.Ser601Ser,TCF4:NM_001306207.1:synonymous:LOW:exon18/19:c.1857A>G:p.Ser619Ser,TCF4:NM_001083962.1:synonymous:LOW:exon19/20:c.1941A>G:p.Ser647Ser,TCF4:NM_001243230.1:synonymous:LOW:exon18/19:c.1920A>G:p.Ser640Ser,TCF4:NM_003199.2:synonymous:LOW:exon19/20:c.1929A>G:p.Ser643Ser,TCF4:NM_001243227.1:synonymous:LOW:exon18/19:c.1869A>G:p.Ser623Ser,TCF4:NM_001243228.1:synonymous:LOW:exon19/20:c.1959A>G:p.Ser653Ser		rs8766	0.3425	0.3714	8710/5314/549	0.3700							602272 [TCF4 (confirmed) Pitt-Hopkins syndrome,610954|Corneal dystrophy,Fuchs endothelial,3,613267];	RCV000079460.8 [benign]; RCV000405030.1 [benign]; 			226	738					TCF4 (inh=AD pLI=1.00)
chr18	53070914	53070914	G	A	het	wt	hom	pred_pathogenic	QUAL=20870;DP=521,308,416;MQM=60	TCF4	missense,intron	TCF4:NM_001243232.1:missense:MODERATE:exon1/16:c.32C>T:p.Ala11Val,TCF4:NM_001306208.1:missense:MODERATE:exon1/16:c.32C>T:p.Ala11Val,TCF4:NM_001243226.2:intron:MODIFIER:exon6/20:c.611-165C>T:,TCF4:NM_001243233.1:intron:MODIFIER:exon1/15:c.-86-165C>T:,TCF4:NM_001243231.1:intron:MODIFIER:exon3/17:c.179-165C>T:,TCF4:NM_001306207.1:intron:MODIFIER:exon4/18:c.233-165C>T:,TCF4:NM_001083962.1:intron:MODIFIER:exon5/19:c.305-165C>T:,TCF4:NM_001243230.1:intron:MODIFIER:exon4/18:c.299-165C>T:,TCF4:NM_003199.2:intron:MODIFIER:exon5/19:c.305-165C>T:,TCF4:NM_001243227.1:intron:MODIFIER:exon4/18:c.233-165C>T:,TCF4:NM_001243228.1:intron:MODIFIER:exon5/19:c.305-165C>T:		rs17522826	0.1923	0.2173	695/261/8	0.1434	2.9740	D	T	B	T	14.22	602272 [TCF4 (confirmed) Pitt-Hopkins syndrome,610954|Corneal dystrophy,Fuchs endothelial,3,613267];	RCV000147721.1 [likely benign]; 			66	449					TCF4 (inh=AD pLI=1.00)
chr18	53303101	53303101	C	G	hom	hom	hom		QUAL=14562;DP=180,106,164;MQM=59	TCF4	missense	TCF4:NM_001243226.2:missense:MODERATE:exon1/21:c.28G>C:p.Ala10Pro		rs611326	0.9968	0.9994	23663/11825/1809	0.8732	1.4190	T	T	B	T	2.45	602272 [TCF4 (confirmed) Pitt-Hopkins syndrome,610954|Corneal dystrophy,Fuchs endothelial,3,613267];				1439	0	2	[2] Stefanie Beck-Woedl 30.07.2015			TCF4 (inh=AD pLI=1.00)
chr18	53303150	53303150	T	C	het	wt	het		QUAL=3390;DP=124,91,129;MQM=60	TCF4	5'UTR_premature_start_codon_gain,5'UTR	TCF4:NM_001243226.2:5'UTR_premature_start_codon_gain:LOW:exon1/21:c.-22A>G:,TCF4:NM_001243226.2:5'UTR:MODIFIER:exon1/21:c.-22A>G:	OldhAT1	rs77891683	0.0048	0.0167	4/4/0	0.0100							602272 [TCF4 (confirmed) Pitt-Hopkins syndrome,610954|Corneal dystrophy,Fuchs endothelial,3,613267];				0	14					TCF4 (inh=AD pLI=1.00)
chr18	55313705	55313705	T	-	het	wt	het	low_DP	QUAL=1262;DP=99,19,40;MQM=60	ATP8B1,LOC100505549	3'UTR,intron	ATP8B1:NM_005603.4:3'UTR:MODIFIER:exon28/28:c.*2015delA:,LOC100505549:NM_001242804.1:intron:MODIFIER:exon2/2:c.139+4427delT:		rs35833803	0.1753	0.0000	0/0/0	0.1320							602397 [ATP8B1 (provisional) Cholestasis,progressive familial intrahepatic 1,211600|Cholestasis,benign recurrent intrahepatic,243300|Cholestasis,intrahepatic,of pregnancy,1,147480];	RCV000403606.1 [benign]; 			3	49					ATP8B1 (inh=AR+AD pLI=0.00), LOC100505549 (inh=n/a pLI=n/a)
chr18	55314211	55314211	T	C	het	wt	het		QUAL=2550;DP=143,34,60;MQM=60	ATP8B1,LOC100505549	3'UTR,intron	ATP8B1:NM_005603.4:3'UTR:MODIFIER:exon28/28:c.*1509A>G:,LOC100505549:NM_001242804.1:intron:MODIFIER:exon2/2:c.139+4927T>C:		rs1968274	0.3085	0.0000	0/0/0	0.0463							602397 [ATP8B1 (provisional) Cholestasis,progressive familial intrahepatic 1,211600|Cholestasis,benign recurrent intrahepatic,243300|Cholestasis,intrahepatic,of pregnancy,1,147480];	RCV000262371.1 [benign]; 			15	78					ATP8B1 (inh=AR+AD pLI=0.00), LOC100505549 (inh=n/a pLI=n/a)
chr18	55314820	55314820	C	A	het	wt	het		QUAL=6789;DP=310,167,216;MQM=60	ATP8B1,LOC100505549	3'UTR,intron	ATP8B1:NM_005603.4:3'UTR:MODIFIER:exon28/28:c.*900G>T:,LOC100505549:NM_001242804.1:intron:MODIFIER:exon2/2:c.139+5536C>A:		rs4940950	0.4661	0.0000	0/0/0	0.0831							602397 [ATP8B1 (provisional) Cholestasis,progressive familial intrahepatic 1,211600|Cholestasis,benign recurrent intrahepatic,243300|Cholestasis,intrahepatic,of pregnancy,1,147480];	RCV000380280.1 [benign]; 			60	111					ATP8B1 (inh=AR+AD pLI=0.00), LOC100505549 (inh=n/a pLI=n/a)
chr18	55315133	55315133	C	T	wt	het	het	low_DP	QUAL=353;DP=88,17,10;MQM=60	ATP8B1,LOC100505549	3'UTR,intron	ATP8B1:NM_005603.4:3'UTR:MODIFIER:exon28/28:c.*587G>A:,LOC100505549:NM_001242804.1:intron:MODIFIER:exon2/2:c.139+5849C>T:	AluSz	rs317822	0.3389	0.0000	0/0/0	0.2706							602397 [ATP8B1 (provisional) Cholestasis,progressive familial intrahepatic 1,211600|Cholestasis,benign recurrent intrahepatic,243300|Cholestasis,intrahepatic,of pregnancy,1,147480];	RCV000352794.1 [benign]; 			11	62					ATP8B1 (inh=AR+AD pLI=0.00), LOC100505549 (inh=n/a pLI=n/a)
chr18	55317676	55317676	C	T	hom	hom	hom	pred_pathogenic	QUAL=32297;DP=351,298,377;MQM=60	ATP8B1,LOC100505549	missense,intron	ATP8B1:NM_005603.4:missense:MODERATE:exon27/28:c.3454G>A:p.Ala1152Thr,LOC100505549:NM_001242804.1:intron:MODIFIER:exon2/2:c.139+8392C>T:		rs222581	0.9998	0.9997	60671/33368/5171	0.9360	2.0100	T,T	T	B	T,T	8.37	602397 [ATP8B1 (provisional) Cholestasis,progressive familial intrahepatic 1,211600|Cholestasis,benign recurrent intrahepatic,243300|Cholestasis,intrahepatic,of pregnancy,1,147480];				1564	0					ATP8B1 (inh=AR+AD pLI=0.00), LOC100505549 (inh=n/a pLI=n/a)
chr18	55362532	55362532	T	G	hom	hom	hom		QUAL=16478;DP=252,94,148;MQM=60	ATP8B1	synonymous	ATP8B1:NM_005603.4:synonymous:LOW:exon10/28:c.811A>C:p.Arg271Arg		rs319443	0.9926	0.9972	60322/33323/4892	0.9429							602397 [ATP8B1 (provisional) Cholestasis,progressive familial intrahepatic 1,211600|Cholestasis,benign recurrent intrahepatic,243300|Cholestasis,intrahepatic,of pregnancy,1,147480];	RCV000252875.1 [benign]; RCV000366441.1 [benign]; 			1564	1					ATP8B1 (inh=AR+AD pLI=0.00)
chr18	55364852	55364852	A	G	hom	hom	hom		QUAL=32554;DP=443,253,338;MQM=59	ATP8B1	splice_region&synonymous	ATP8B1:NM_005603.4:splice_region&synonymous:LOW:exon8/28:c.696T>C:p.Asp232Asp		rs319438	0.9946	0.9980	60416/33333/4978	0.9303							602397 [ATP8B1 (provisional) Cholestasis,progressive familial intrahepatic 1,211600|Cholestasis,benign recurrent intrahepatic,243300|Cholestasis,intrahepatic,of pregnancy,1,147480];	RCV000243388.1 [benign]; RCV000313084.1 [benign]; 			1563	2					ATP8B1 (inh=AR+AD pLI=0.00)
chr18	77441442	77441442	C	A	wt	het	wt		QUAL=3824;DP=233,286,349;MQM=60	CTDP1	5'UTR,intron	CTDP1:NM_001202504.1:5'UTR:MODIFIER:exon1/13:c.-119C>A:,CTDP1:NM_004715.4:intron:MODIFIER:exon1/12:c.314+1181C>A:,CTDP1:NM_001318511.1:intron:MODIFIER:exon1/11:c.314+1181C>A:,CTDP1:NM_048368.3:intron:MODIFIER:exon1/11:c.314+1181C>A:		rs520874	0.1745	0.0000	0/0/0	0.1651							604927 [CTDP1 (provisional) Congenital cataracts,facial dysmorphism,and neuropathy,604168];				4	44					CTDP1 (inh=AR pLI=0.92)
chr18	77473086	77473086	G	A	wt	het	wt		QUAL=2918;DP=258,226,280;MQM=60	CTDP1	synonymous	CTDP1:NM_004715.4:synonymous:LOW:exon7/13:c.978G>A:p.Thr326Thr,CTDP1:NM_001318511.1:synonymous:LOW:exon7/12:c.978G>A:p.Thr326Thr,CTDP1:NM_048368.3:synonymous:LOW:exon7/12:c.978G>A:p.Thr326Thr,CTDP1:NM_001202504.1:synonymous:LOW:exon7/13:c.621G>A:p.Thr207Thr		rs599554	0.2089	0.1837	2215/1046/464	0.1804							604927 [CTDP1 (provisional) Congenital cataracts,facial dysmorphism,and neuropathy,604168];			COSM4131105	59	405					CTDP1 (inh=AR pLI=0.92)
chr18	77473127	77473127	C	T	hom	het	het		QUAL=11794;DP=188,192,232;MQM=59	CTDP1	missense	CTDP1:NM_004715.4:missense:MODERATE:exon7/13:c.1019C>T:p.Thr340Met,CTDP1:NM_001318511.1:missense:MODERATE:exon7/12:c.1019C>T:p.Thr340Met,CTDP1:NM_048368.3:missense:MODERATE:exon7/12:c.1019C>T:p.Thr340Met,CTDP1:NM_001202504.1:missense:MODERATE:exon7/13:c.662C>T:p.Thr221Met		rs2279103	0.0827	0.1397	1387/1090/9	0.1375	0.0990	T,T	T	B,B,B	T,T	10.18	604927 [CTDP1 (provisional) Congenital cataracts,facial dysmorphism,and neuropathy,604168];	RCV000246925.1 [benign]; 			27	365					CTDP1 (inh=AR pLI=0.92)
chr18	77474921	77474921	G	A	wt	het	wt		QUAL=2204;DP=121,168,232;MQM=60	CTDP1	synonymous	CTDP1:NM_004715.4:synonymous:LOW:exon8/13:c.1461G>A:p.Pro487Pro,CTDP1:NM_001318511.1:synonymous:LOW:exon8/12:c.1461G>A:p.Pro487Pro,CTDP1:NM_048368.3:synonymous:LOW:exon8/12:c.1461G>A:p.Pro487Pro,CTDP1:NM_001202504.1:synonymous:LOW:exon8/13:c.1104G>A:p.Pro368Pro		rs2126082	0.1851	0.2330	584/305/67	0.1271							604927 [CTDP1 (provisional) Congenital cataracts,facial dysmorphism,and neuropathy,604168];	RCV000401492.1 [benign]; 		COSM4131106	50	407					CTDP1 (inh=AR pLI=0.92)
chr18	77513721	77513721	T	C	hom	hom	hom		QUAL=37390;DP=267,397,549;MQM=59	CTDP1	synonymous,3'UTR	CTDP1:NM_004715.4:synonymous:LOW:exon13/13:c.2817T>C:p.Asp939Asp,CTDP1:NM_001202504.1:synonymous:LOW:exon13/13:c.2460T>C:p.Asp820Asp,CTDP1:NM_001318511.1:3'UTR:MODIFIER:exon12/12:c.*46T>C:,CTDP1:NM_048368.3:3'UTR:MODIFIER:exon12/12:c.*50T>C:		rs626169	0.8952	0.9666	56942/32743/2566	0.9433							604927 [CTDP1 (provisional) Congenital cataracts,facial dysmorphism,and neuropathy,604168];	RCV000116845.3 [other]; 		COSM4131107	1523	39					CTDP1 (inh=AR pLI=0.92)
chr18	77513841	77513841	G	A	hom	het	het		QUAL=15305;DP=276,252,343;MQM=59	CTDP1	3'UTR	CTDP1:NM_004715.4:3'UTR:MODIFIER:exon13/13:c.*51G>A:,CTDP1:NM_001318511.1:3'UTR:MODIFIER:exon12/12:c.*166G>A:,CTDP1:NM_048368.3:3'UTR:MODIFIER:exon12/12:c.*170G>A:,CTDP1:NM_001202504.1:3'UTR:MODIFIER:exon13/13:c.*51G>A:		rs76088733	0.1306	0.2104	1814/1267/30	0.1678							604927 [CTDP1 (provisional) Congenital cataracts,facial dysmorphism,and neuropathy,604168];				30	260					CTDP1 (inh=AR pLI=0.92)
chr19	860852	860852	G	C	wt	het	het	low_DP	QUAL=1116;DP=18,38,46;MQM=60	CFD	splice_region&intron	CFD:NM_001317335.1:splice_region&intron:LOW:exon2/4:c.234-9G>C:,CFD:NM_001928.3:splice_region&intron:LOW:exon2/4:c.213-9G>C:		rs1629038	0.4409	0.5914	6723/4141/250	0.4317							134350 [CFD (confirmed) Complement factor D deficiency,613912];			COSM3766470	414	768					CFD (inh=AR pLI=0.02)
chr19	863356	863356	C	T	het	het	wt		QUAL=10057;DP=318,449,568;MQM=59	CFD	3'UTR	CFD:NM_001317335.1:3'UTR:MODIFIER:exon5/5:c.*118C>T:,CFD:NM_001928.3:3'UTR:MODIFIER:exon5/5:c.*118C>T:	AluJr	rs10506	0.2754	0.0000	0/0/0	0.1599							134350 [CFD (confirmed) Complement factor D deficiency,613912];				6	59					CFD (inh=AR pLI=0.02)
chr19	863388	863388	C	G	wt	het	wt		QUAL=5054;DP=208,410,508;MQM=60	CFD	3'UTR	CFD:NM_001317335.1:3'UTR:MODIFIER:exon5/5:c.*150C>G:,CFD:NM_001928.3:3'UTR:MODIFIER:exon5/5:c.*150C>G:	AluJr	rs1135146	0.1208	0.0000	0/0/0	0.1894							134350 [CFD (confirmed) Complement factor D deficiency,613912];				8	86					CFD (inh=AR pLI=0.02)
chr19	863436	863436	A	-	wt	het	wt		QUAL=3288;DP=193,304,312;MQM=60	CFD	3'UTR	CFD:NM_001317335.1:3'UTR:MODIFIER:exon5/5:c.*203delA:,CFD:NM_001928.3:3'UTR:MODIFIER:exon5/5:c.*203delA:	AluJr	rs756801764	0.1591	0.0000	0/0/0	0.1993							134350 [CFD (confirmed) Complement factor D deficiency,613912];				8	80					CFD (inh=AR pLI=0.02)
chr19	863471	863471	G	C	wt	het	wt		QUAL=3412;DP=226,269,307;MQM=60	CFD	3'UTR	CFD:NM_001317335.1:3'UTR:MODIFIER:exon5/5:c.*233G>C:,CFD:NM_001928.3:3'UTR:MODIFIER:exon5/5:c.*233G>C:	AluJr	rs187211507	0.0024	0.0000	0/0/0	0.0077							134350 [CFD (confirmed) Complement factor D deficiency,613912];				0	2					CFD (inh=AR pLI=0.02)
chr19	1388538	1388538	C	T	het	hom	het		QUAL=3508;DP=69,52,72;MQM=59	NDUFS7	missense	NDUFS7:NM_024407.4:missense:MODERATE:exon3/8:c.68C>T:p.Pro23Leu		rs1142530	0.4557	0.5502	17944/11720/688	0.5139	0.8850	T,T,T,T,T,T,T	T	B,B,B	T,T,T,T,T	4.17	601825 [NDUFS7 (provisional) Leigh syndrome,256000];	RCV000117716.2 [likely benign]; RCV000342300.1 [likely benign]; RCV000407392.1 [likely benign]; 		COSM4131259	594	752					NDUFS7 (inh=AR pLI=0.75)
chr19	1398750	1398750	C	T	het	wt	het		QUAL=8871;DP=308,350,408;MQM=59	GAMT	synonymous,intron	GAMT:NM_138924.2:synonymous:LOW:exon5/5:c.735G>A:p.Ala245Ala,GAMT:NM_000156.5:intron:MODIFIER:exon5/5:c.570+165G>A:		rs74253480	0.0114	0.0101	2/1/0	0.0037							601240 [GAMT (provisional) Cerebral creatine deficiency syndrome 2,612736];	RCV000125193.2 [benign]; 			0	27					GAMT (inh=AR pLI=0.00)
chr19	3631036	3631036	A	G	hom	hom	hom		QUAL=25253;DP=288,211,293;MQM=59	PIP5K1C	3'UTR	PIP5K1C:NM_001195733.1:3'UTR:MODIFIER:exon17/17:c.*2129T>C:,PIP5K1C:NM_012398.2:3'UTR:MODIFIER:exon18/18:c.*2129T>C:		rs4807493	0.8508	0.0000	0/0/0	0.7485							606102 [PIP5K1C (provisional) Lethal congenital contractural syndrome 3,611369];				163	60					PIP5K1C (inh=AR pLI=0.86)
chr19	3631569	3631569	C	G	hom	het	hom	low_DP	QUAL=1069;DP=33,5,5;MQM=59	PIP5K1C	3'UTR	PIP5K1C:NM_001195733.1:3'UTR:MODIFIER:exon17/17:c.*1596G>C:,PIP5K1C:NM_012398.2:3'UTR:MODIFIER:exon18/18:c.*1596G>C:		rs4807494	0.8452	0.0000	0/0/0	0.8136							606102 [PIP5K1C (provisional) Lethal congenital contractural syndrome 3,611369];				147	61					PIP5K1C (inh=AR pLI=0.86)
chr19	3631694	3631694	G	A	hom	het	hom		QUAL=2851;DP=66,29,26;MQM=59	PIP5K1C	3'UTR	PIP5K1C:NM_001195733.1:3'UTR:MODIFIER:exon17/17:c.*1471C>T:,PIP5K1C:NM_012398.2:3'UTR:MODIFIER:exon18/18:c.*1471C>T:		rs4806946	0.3980	0.0000	0/0/0	0.4688							606102 [PIP5K1C (provisional) Lethal congenital contractural syndrome 3,611369];				98	97					PIP5K1C (inh=AR pLI=0.86)
chr19	3653525	3653525	C	T	het	het	hom		QUAL=28340;DP=177,487,642;MQM=59	PIP5K1C	synonymous	PIP5K1C:NM_001300849.1:synonymous:LOW:exon7/17:c.684G>A:p.Ser228Ser,PIP5K1C:NM_001195733.1:synonymous:LOW:exon7/17:c.684G>A:p.Ser228Ser,PIP5K1C:NM_012398.2:synonymous:LOW:exon7/18:c.684G>A:p.Ser228Ser		rs2074957	0.5429	0.5603	19550/10423/1113	0.5569							606102 [PIP5K1C (provisional) Lethal congenital contractural syndrome 3,611369];			COSM4131725	488	765					PIP5K1C (inh=AR pLI=0.86)
chr19	4090422	4090422	G	T	het	het	wt		QUAL=4652;DP=119,278,363;MQM=59	MAP2K2	3'UTR	MAP2K2:NM_030662.3:3'UTR:MODIFIER:exon11/11:c.*174C>A:		rs6630	0.1717	0.0000	0/0/0	0.0960							601263 [MAP2K2 (provisional) Cardiofaciocutaneous syndrome 4,615280];				1	32					MAP2K2 (inh=AD pLI=0.86)
chr19	4101062	4101062	G	T	het	hom	wt		QUAL=3999;DP=104,94,147;MQM=53	MAP2K2	synonymous	MAP2K2:NM_030662.3:synonymous:LOW:exon6/11:c.660C>A:p.Ile220Ile		rs10250	0.4333	0.5472	8097/4588/241	0.4267							601263 [MAP2K2 (provisional) Cardiofaciocutaneous syndrome 4,615280];	RCV000039490.3 [benign]; RCV000149846.1 [benign]; 		COSM439538, COSM1481088	343	791					MAP2K2 (inh=AD pLI=0.86)
chr19	4102449	4102449	G	A	het	wt	het		QUAL=6916;DP=138,322,435;MQM=59	MAP2K2	splice_region&synonymous	MAP2K2:NM_030662.3:splice_region&synonymous:LOW:exon4/11:c.453C>T:p.Asp151Asp		rs17851657	0.1112	0.2315	1446/1006/11	0.1491							601263 [MAP2K2 (provisional) Cardiofaciocutaneous syndrome 4,615280];	RCV000039484.3 [benign]; RCV000149845.3 [benign]; 		COSM4131862, COSM1129849	62	541					MAP2K2 (inh=AD pLI=0.86)
chr19	4117528	4117528	G	A	het	het	wt		QUAL=4190;DP=181,176,236;MQM=57	MAP2K2	synonymous	MAP2K2:NM_030662.3:synonymous:LOW:exon2/11:c.192C>T:p.Val64Val		rs8157	0.0583	0.0619	294/157/25	0.0588							601263 [MAP2K2 (provisional) Cardiofaciocutaneous syndrome 4,615280];	RCV000039473.3 [benign]; 			7	174					MAP2K2 (inh=AD pLI=0.86)
chr19	5891299	5891299	C	T	het	wt	hom		QUAL=935;DP=41,21,22;MQM=59	NDUFA11	3'UTR	NDUFA11:NM_001193375.1:3'UTR:MODIFIER:exon4/4:c.*1629G>A:	AluSx1	rs1674158	0.4750	0.0000	0/0/0	0.4335							612638 [NDUFA11 (provisional) Mitochondrial complex I deficiency,252010];				26	69					NDUFA11 (inh=n/a pLI=0.54)
chr19	5891746	5891746	G	C	hom	het	hom		QUAL=15158;DP=143,229,268;MQM=59	NDUFA11	3'UTR	NDUFA11:NM_001193375.1:3'UTR:MODIFIER:exon4/4:c.*1182C>G:	L2b	rs1678866	0.6272	0.0000	0/0/0	0.6737							612638 [NDUFA11 (provisional) Mitochondrial complex I deficiency,252010];				62	67					NDUFA11 (inh=n/a pLI=0.54)
chr19	5892267	5892267	G	T	het	het	wt		QUAL=2609;DP=119,104,170;MQM=59	NDUFA11	3'UTR	NDUFA11:NM_001193375.1:3'UTR:MODIFIER:exon4/4:c.*661C>A:		rs74500071	0.0980	0.0000	0/0/0	0.1302							612638 [NDUFA11 (provisional) Mitochondrial complex I deficiency,252010];				3	28					NDUFA11 (inh=n/a pLI=0.54)
chr19	5892317	5892317	C	T	hom	het	hom		QUAL=8557;DP=79,86,173;MQM=60	NDUFA11	3'UTR	NDUFA11:NM_001193375.1:3'UTR:MODIFIER:exon4/4:c.*611G>A:		rs1626918	0.6410	0.0000	0/0/0	0.1196							612638 [NDUFA11 (provisional) Mitochondrial complex I deficiency,252010];				252	316					NDUFA11 (inh=n/a pLI=0.54)
chr19	5892382	5892382	C	T	hom	het	hom		QUAL=7545;DP=70,65,151;MQM=60	NDUFA11	3'UTR	NDUFA11:NM_001193375.1:3'UTR:MODIFIER:exon4/4:c.*546G>A:		rs1678867	0.7272	0.0000	0/0/0	0.7148							612638 [NDUFA11 (provisional) Mitochondrial complex I deficiency,252010];				311	312					NDUFA11 (inh=n/a pLI=0.54)
chr19	5892433	5892433	C	T	het	wt	hom		QUAL=4248;DP=84,51,114;MQM=60	NDUFA11	3'UTR	NDUFA11:NM_001193375.1:3'UTR:MODIFIER:exon4/4:c.*495G>A:		rs1627779	0.4742	0.0000	0/0/0	0.0883							612638 [NDUFA11 (provisional) Mitochondrial complex I deficiency,252010];				139	401					NDUFA11 (inh=n/a pLI=0.54)
chr19	5892486	5892486	C	T	hom	het	hom		QUAL=7001;DP=80,68,119;MQM=59	NDUFA11	3'UTR	NDUFA11:NM_001193375.1:3'UTR:MODIFIER:exon4/4:c.*442G>A:		rs1628564	0.5839	0.0000	0/0/0	0.1100							612638 [NDUFA11 (provisional) Mitochondrial complex I deficiency,252010];				257	431					NDUFA11 (inh=n/a pLI=0.54)
chr19	5892568	5892568	G	T	hom	het	hom		QUAL=8458;DP=121,85,116;MQM=59	NDUFA11	3'UTR	NDUFA11:NM_001193375.1:3'UTR:MODIFIER:exon4/4:c.*360C>A:		rs1629368	0.5759	0.0000	0/0/0	0.1100							612638 [NDUFA11 (provisional) Mitochondrial complex I deficiency,252010];				254	431					NDUFA11 (inh=n/a pLI=0.54)
chr19	5892585	5892585	G	A	het	het	wt		QUAL=2268;DP=128,84,126;MQM=59	NDUFA11	3'UTR	NDUFA11:NM_001193375.1:3'UTR:MODIFIER:exon4/4:c.*343C>T:		rs60236148	0.0891	0.0000	0/0/0	0.0193							612638 [NDUFA11 (provisional) Mitochondrial complex I deficiency,252010];				25	174					NDUFA11 (inh=n/a pLI=0.54)
chr19	5892743	5892743	C	T	het	wt	hom		QUAL=6632;DP=112,124,182;MQM=59	NDUFA11	3'UTR	NDUFA11:NM_001193375.1:3'UTR:MODIFIER:exon4/4:c.*185G>A:		rs10432306	0.4127	0.0000	0/0/0	0.0842							612638 [NDUFA11 (provisional) Mitochondrial complex I deficiency,252010];				139	393					NDUFA11 (inh=n/a pLI=0.54)
chr19	5892770	5892770	C	T	hom	het	hom		QUAL=12453;DP=107,143,234;MQM=59	NDUFA11	3'UTR	NDUFA11:NM_001193375.1:3'UTR:MODIFIER:exon4/4:c.*158G>A:		rs1631032	0.5859	0.0000	0/0/0	0.1110							612638 [NDUFA11 (provisional) Mitochondrial complex I deficiency,252010];				254	434					NDUFA11 (inh=n/a pLI=0.54)
chr19	5892954	5892954	T	C	het	wt	hom	pred_pathogenic	QUAL=12720;DP=174,272,352;MQM=60	NDUFA11	missense	NDUFA11:NM_001193375.1:missense:MODERATE:exon4/4:c.661A>G:p.Thr221Ala	MIR	rs1678868	0.4770	0.5216	417/145/19	0.1227	-0.0270	D	T	B		0.02	612638 [NDUFA11 (provisional) Mitochondrial complex I deficiency,252010];				258	660					NDUFA11 (inh=n/a pLI=0.54)
chr19	5903807	5903807	G	T	hom	het	hom		QUAL=26139;DP=194,375,560;MQM=59	NDUFA11	5'UTR,non_coding_transcript_exon	NDUFA11:NM_001193375.1:5'UTR:MODIFIER:exon1/4:c.-88C>A:,NDUFA11:NM_175614.4:5'UTR:MODIFIER:exon1/4:c.-88C>A:,NDUFA11:NR_034166.2:non_coding_transcript_exon:MODIFIER:exon1/5:n.218C>A:		rs8108064	0.6815	0.6750	4379/1717/478	0.2050							612638 [NDUFA11 (provisional) Mitochondrial complex I deficiency,252010];	RCV000294085.1 [likely benign]; 			284	298					NDUFA11 (inh=n/a pLI=0.54)
chr19	5903936	5903936	T	C	hom	het	hom		QUAL=14537;DP=79,204,312;MQM=59	NDUFA11	5'UTR,non_coding_transcript_exon	NDUFA11:NM_001193375.1:5'UTR:MODIFIER:exon1/4:c.-217A>G:,NDUFA11:NM_175614.4:5'UTR:MODIFIER:exon1/4:c.-217A>G:,NDUFA11:NR_034166.2:non_coding_transcript_exon:MODIFIER:exon1/5:n.89A>G:		rs1056987	0.7266	0.7489	3262/674/101	0.1990							612638 [NDUFA11 (provisional) Mitochondrial complex I deficiency,252010];	RCV000336107.1 [likely benign]; 			314	269					NDUFA11 (inh=n/a pLI=0.54)
chr19	6677989	6677989	G	A	het	hom	het		QUAL=22178;DP=302,390,461;MQM=59	C3	synonymous	C3:NM_000064.3:synonymous:LOW:exon41/41:c.4896C>T:p.Pro1632Pro		rs17030	0.5329	0.5241	16781/8886/1266	0.5175							120700 [C3 (confirmed) C3 deficiency,613779|Hemolytic uremic syndrome,atypical,susceptibility to,5,612925|Macular degeneration,age-related,9,611378];	RCV000283840.1 [benign]; RCV000323725.1 [benign]; RCV000378258.1 [benign]; 		COSM3766459	460	731					C3 (inh=AR pLI=1.00)
chr19	6679511	6679511	C	T	het	hom	het		QUAL=19508;DP=352,319,381;MQM=59	C3	splice_region&intron	C3:NM_000064.3:splice_region&intron:LOW:exon36/40:c.4457-4G>A:		rs2277984	0.5244	0.5215	16622/8906/1034	0.5104							120700 [C3 (confirmed) C3 deficiency,613779|Hemolytic uremic syndrome,atypical,susceptibility to,5,612925|Macular degeneration,age-related,9,611378];	RCV000261116.1 [benign]; RCV000316465.1 [benign]; RCV000389627.1 [benign]; 			460	732					C3 (inh=AR pLI=1.00)
chr19	6696597	6696597	G	A	hom	hom	hom		QUAL=37916;DP=282,472,524;MQM=59	C3	splice_region&intron	C3:NM_000064.3:splice_region&intron:LOW:exon22/40:c.2863+7C>T:		rs2287845	0.7324	0.6666	27443/12486/2543	0.6191							120700 [C3 (confirmed) C3 deficiency,613779|Hemolytic uremic syndrome,atypical,susceptibility to,5,612925|Macular degeneration,age-related,9,611378];	RCV000281934.1 [benign]; RCV000317538.1 [benign]; RCV000374021.1 [benign]; 			645	717					C3 (inh=AR pLI=1.00)
chr19	6697406	6697406	A	G	hom	hom	hom		QUAL=14949;DP=208,140,138;MQM=59	C3	synonymous	C3:NM_000064.3:synonymous:LOW:exon21/41:c.2745T>C:p.Ala915Ala		rs423490	0.8149	0.7889	37958/19091/2952	0.7804							120700 [C3 (confirmed) C3 deficiency,613779|Hemolytic uremic syndrome,atypical,susceptibility to,5,612925|Macular degeneration,age-related,9,611378];	RCV000308367.1 [benign]; RCV000342250.1 [benign]; RCV000394673.1 [benign]; 			920	554					C3 (inh=AR pLI=1.00)
chr19	6702157	6702157	C	G	hom	hom	hom		QUAL=22860;DP=239,205,270;MQM=59	C3	synonymous	C3:NM_000064.3:synonymous:LOW:exon19/41:c.2421G>C:p.Val807Val		rs428453	0.7324	0.6664	27406/12467/2524	0.6610							120700 [C3 (confirmed) C3 deficiency,613779|Hemolytic uremic syndrome,atypical,susceptibility to,5,612925|Macular degeneration,age-related,9,611378];	RCV000291985.1 [benign]; RCV000344527.1 [benign]; RCV000382623.1 [benign]; 		COSM3757394	645	717					C3 (inh=AR pLI=1.00)
chr19	6702598	6702598	G	A	hom	hom	hom		QUAL=20082;DP=187,193,265;MQM=60	C3	splice_region&intron	C3:NM_000064.3:splice_region&intron:LOW:exon17/40:c.2246-8C>T:		rs406514	0.8149	0.7888	37935/19094/2939	0.7717							120700 [C3 (confirmed) C3 deficiency,613779|Hemolytic uremic syndrome,atypical,susceptibility to,5,612925|Macular degeneration,age-related,9,611378];	RCV000277187.1 [benign]; RCV000297613.1 [benign]; RCV000369463.1 [benign]; 			917	555					C3 (inh=AR pLI=1.00)
chr19	6709848	6709848	C	T	wt	het	het		QUAL=3365;DP=86,103,158;MQM=60	C3	synonymous	C3:NM_000064.3:synonymous:LOW:exon14/41:c.1692G>A:p.Val564Val		rs2230204	0.4353	0.3520	7992/2646/1472	0.3366							120700 [C3 (confirmed) C3 deficiency,613779|Hemolytic uremic syndrome,atypical,susceptibility to,5,612925|Macular degeneration,age-related,9,611378];	RCV000303712.1 [benign]; RCV000358237.1 [benign]; RCV000395652.1 [benign]; 		COSM4001040	138	651					C3 (inh=AR pLI=1.00)
chr19	7112265	7112265	G	A	het	wt	hom	low_DP	QUAL=201;DP=26,3,1;MQM=60	ZNF557-INSR	intergenic_region	ZNF557-INSR:ZNF557-INSR:intergenic_region:MODIFIER::n.7112265G>A:		rs12150997	0.3019	0.0000	0/0/0	0.2208							147670 [INSR (confirmed) Leprechaunism,246200|Rabson-Mendenhall syndrome,262190|Diabetes mellitus,insulin-resistant,with acanthosis nigricans,610549|Hyperinsulinemic hypoglycemia,familial,5,609968];	RCV000313887.1 [benign]; RCV000370897.1 [benign]; RCV000395881.1 [benign]; 			10	58					ZNF557-INSR (inh=n/a pLI=n/a)
chr19	7112593	7112593	G	A	het	wt	hom		QUAL=9762;DP=316,138,190;MQM=59	INSR	3'UTR	INSR:NM_000208.3:3'UTR:MODIFIER:exon22/22:c.*4474C>T:,INSR:NM_001079817.2:3'UTR:MODIFIER:exon21/21:c.*4474C>T:		rs1052371	0.3075	0.0000	0/0/0	0.2234							147670 [INSR (confirmed) Leprechaunism,246200|Rabson-Mendenhall syndrome,262190|Diabetes mellitus,insulin-resistant,with acanthosis nigricans,610549|Hyperinsulinemic hypoglycemia,familial,5,609968];	RCV000311008.1 [benign]; RCV000355368.1 [benign]; RCV000398125.1 [benign]; 			12	82					INSR (inh=AR+AD pLI=0.19)
chr19	7112645	7112645	C	A	het	wt	het		QUAL=6610;DP=240,181,265;MQM=60	INSR	3'UTR	INSR:NM_000208.3:3'UTR:MODIFIER:exon22/22:c.*4422G>T:,INSR:NM_001079817.2:3'UTR:MODIFIER:exon21/21:c.*4422G>T:		rs12642	0.1248	0.0000	0/0/0	0.1363							147670 [INSR (confirmed) Leprechaunism,246200|Rabson-Mendenhall syndrome,262190|Diabetes mellitus,insulin-resistant,with acanthosis nigricans,610549|Hyperinsulinemic hypoglycemia,familial,5,609968];	RCV000275766.1 [benign]; RCV000307297.1 [benign]; RCV000367915.1 [benign]; 			8	75					INSR (inh=AR+AD pLI=0.19)
chr19	7113444	7113444	T	C	wt	wt	het		QUAL=4103;DP=303,306,324;MQM=60	INSR	3'UTR	INSR:NM_000208.3:3'UTR:MODIFIER:exon22/22:c.*3623A>G:,INSR:NM_001079817.2:3'UTR:MODIFIER:exon21/21:c.*3623A>G:		rs77859571	0.0685	0.0000	0/0/0	0.0392							147670 [INSR (confirmed) Leprechaunism,246200|Rabson-Mendenhall syndrome,262190|Diabetes mellitus,insulin-resistant,with acanthosis nigricans,610549|Hyperinsulinemic hypoglycemia,familial,5,609968];	RCV000262896.1 [benign]; RCV000298288.1 [benign]; RCV000355417.1 [benign]; 			0	14					INSR (inh=AR+AD pLI=0.19)
chr19	7114213	7114213	C	A	het	wt	het		QUAL=7488;DP=338,265,347;MQM=60	INSR	3'UTR	INSR:NM_000208.3:3'UTR:MODIFIER:exon22/22:c.*2854G>T:,INSR:NM_001079817.2:3'UTR:MODIFIER:exon21/21:c.*2854G>T:		rs1864193	0.1282	0.0000	0/0/0	0.1379							147670 [INSR (confirmed) Leprechaunism,246200|Rabson-Mendenhall syndrome,262190|Diabetes mellitus,insulin-resistant,with acanthosis nigricans,610549|Hyperinsulinemic hypoglycemia,familial,5,609968];	RCV000264599.1 [benign]; RCV000303410.1 [benign]; RCV000360541.1 [benign]; 			8	73					INSR (inh=AR+AD pLI=0.19)
chr19	7114288	7114288	C	T	het	hom	het		QUAL=19256;DP=375,311,416;MQM=60	INSR	3'UTR	INSR:NM_000208.3:3'UTR:MODIFIER:exon22/22:c.*2779G>A:,INSR:NM_001079817.2:3'UTR:MODIFIER:exon21/21:c.*2779G>A:		rs3745551	0.7177	0.0000	0/0/0	0.6713							147670 [INSR (confirmed) Leprechaunism,246200|Rabson-Mendenhall syndrome,262190|Diabetes mellitus,insulin-resistant,with acanthosis nigricans,610549|Hyperinsulinemic hypoglycemia,familial,5,609968];	RCV000295734.1 [benign]; RCV000350686.1 [benign]; RCV000404280.1 [benign]; 			90	101					INSR (inh=AR+AD pLI=0.19)
chr19	7114920	7114920	-	T	het	hom	het		QUAL=2038;DP=90,28,43;MQM=59	INSR	3'UTR	INSR:NM_000208.3:3'UTR:MODIFIER:exon22/22:c.*2146dupA:,INSR:NM_001079817.2:3'UTR:MODIFIER:exon21/21:c.*2146dupA:		rs57473640;rs71915849	0.0000	0.0000	0/0/0	0.3140							147670 [INSR (confirmed) Leprechaunism,246200|Rabson-Mendenhall syndrome,262190|Diabetes mellitus,insulin-resistant,with acanthosis nigricans,610549|Hyperinsulinemic hypoglycemia,familial,5,609968];	RCV000289911.1 [uncertain significance]; RCV000345006.1 [uncertain significance]; RCV000405681.1 [uncertain significance]; 			34	162					INSR (inh=AR+AD pLI=0.19)
chr19	7115057	7115057	C	T	het	wt	het	low_DP	QUAL=862;DP=64,14,15;MQM=60	INSR	3'UTR	INSR:NM_000208.3:3'UTR:MODIFIER:exon22/22:c.*2010G>A:,INSR:NM_001079817.2:3'UTR:MODIFIER:exon21/21:c.*2010G>A:		rs55972112	0.1250	0.0000	0/0/0	0.1350							147670 [INSR (confirmed) Leprechaunism,246200|Rabson-Mendenhall syndrome,262190|Diabetes mellitus,insulin-resistant,with acanthosis nigricans,610549|Hyperinsulinemic hypoglycemia,familial,5,609968];	RCV000262572.1 [benign]; RCV000317649.1 [benign]; RCV000353795.1 [benign]; 			8	69					INSR (inh=AR+AD pLI=0.19)
chr19	7115573	7115573	C	T	wt	wt	het		QUAL=4816;DP=455,271,404;MQM=59	INSR	3'UTR	INSR:NM_000208.3:3'UTR:MODIFIER:exon22/22:c.*1494G>A:,INSR:NM_001079817.2:3'UTR:MODIFIER:exon21/21:c.*1494G>A:		rs3745550	0.3151	0.0000	0/0/0	0.2281							147670 [INSR (confirmed) Leprechaunism,246200|Rabson-Mendenhall syndrome,262190|Diabetes mellitus,insulin-resistant,with acanthosis nigricans,610549|Hyperinsulinemic hypoglycemia,familial,5,609968];	RCV000271381.1 [benign]; RCV000301737.1 [benign]; RCV000365726.1 [benign]; 			10	76					INSR (inh=AR+AD pLI=0.19)
chr19	7115651	7115651	T	-	het	wt	hom		QUAL=18968;DP=342,328,504;MQM=59	INSR	3'UTR	INSR:NM_000208.3:3'UTR:MODIFIER:exon22/22:c.*1416delA:,INSR:NM_001079817.2:3'UTR:MODIFIER:exon21/21:c.*1416delA:		rs3833238	0.3325	0.0000	0/0/0	0.2221							147670 [INSR (confirmed) Leprechaunism,246200|Rabson-Mendenhall syndrome,262190|Diabetes mellitus,insulin-resistant,with acanthosis nigricans,610549|Hyperinsulinemic hypoglycemia,familial,5,609968];	RCV000292651.1 [benign]; RCV000332408.1 [benign]; RCV000386880.1 [benign]; 			20	88					INSR (inh=AR+AD pLI=0.19)
chr19	7116136	7116136	-	T	hom	hom	hom		QUAL=1352;DP=115,27,30;MQM=59	INSR	3'UTR	INSR:NM_000208.3:3'UTR:MODIFIER:exon22/22:c.*930dupA:,INSR:NM_001079817.2:3'UTR:MODIFIER:exon21/21:c.*930dupA:	(T)n	rs34045095;rs397813616	0.8291	0.0000	0/0/0	0.5179							147670 [INSR (confirmed) Leprechaunism,246200|Rabson-Mendenhall syndrome,262190|Diabetes mellitus,insulin-resistant,with acanthosis nigricans,610549|Hyperinsulinemic hypoglycemia,familial,5,609968];	RCV000284982.1 [benign]; RCV000346999.1 [benign]; RCV000377088.1 [benign]; 			2	152					INSR (inh=AR+AD pLI=0.19)
chr19	7116283	7116283	G	C	het	wt	het		QUAL=6231;DP=243,186,246;MQM=60	INSR	3'UTR	INSR:NM_000208.3:3'UTR:MODIFIER:exon22/22:c.*784C>G:,INSR:NM_001079817.2:3'UTR:MODIFIER:exon21/21:c.*784C>G:		rs1051651	0.2959	0.0000	0/0/0	0.2089							147670 [INSR (confirmed) Leprechaunism,246200|Rabson-Mendenhall syndrome,262190|Diabetes mellitus,insulin-resistant,with acanthosis nigricans,610549|Hyperinsulinemic hypoglycemia,familial,5,609968];	RCV000259352.1 [benign]; RCV000316958.1 [benign]; RCV000360026.1 [benign]; 			20	75					INSR (inh=AR+AD pLI=0.19)
chr19	7116779	7116779	G	-	wt	het	wt		QUAL=116;DP=119,38,29;MQM=60	INSR	3'UTR	INSR:NM_000208.3:3'UTR:MODIFIER:exon22/22:c.*288delC:,INSR:NM_001079817.2:3'UTR:MODIFIER:exon21/21:c.*288delC:		rs397859480	0.4395	0.0000	0/0/0	0.3029							147670 [INSR (confirmed) Leprechaunism,246200|Rabson-Mendenhall syndrome,262190|Diabetes mellitus,insulin-resistant,with acanthosis nigricans,610549|Hyperinsulinemic hypoglycemia,familial,5,609968];	RCV000286344.1 [benign]; RCV000290009.1 [benign]; RCV000338986.1 [benign]; 			51	121					INSR (inh=AR+AD pLI=0.19)
chr19	7116963	7116963	T	C	het	het	hom		QUAL=6681;DP=173,98,113;MQM=60	INSR	3'UTR	INSR:NM_000208.3:3'UTR:MODIFIER:exon22/22:c.*104A>G:,INSR:NM_001079817.2:3'UTR:MODIFIER:exon21/21:c.*104A>G:		rs1051690	0.8774	0.0000	0/0/0	0.1541							147670 [INSR (confirmed) Leprechaunism,246200|Rabson-Mendenhall syndrome,262190|Diabetes mellitus,insulin-resistant,with acanthosis nigricans,610549|Hyperinsulinemic hypoglycemia,familial,5,609968];	RCV000297534.1 [benign]; RCV000357012.1 [benign]; RCV000397487.1 [benign]; 	CR082021 [CLASS=DFP MUT=REF PHEN="Colorectal cancer increased risk association with" GENE=INSR]; 		161	64					INSR (inh=AR+AD pLI=0.19)
chr19	7125297	7125297	G	A	het	wt	het		QUAL=3431;DP=95,149,222;MQM=59	INSR	synonymous	INSR:NM_000208.3:synonymous:LOW:exon17/22:c.3255C>T:p.His1085His,INSR:NM_001079817.2:synonymous:LOW:exon16/21:c.3219C>T:p.His1073His		rs1799817	0.2925	0.2273	3491/1057/268	0.2215							147670 [INSR (confirmed) Leprechaunism,246200|Rabson-Mendenhall syndrome,262190|Diabetes mellitus,insulin-resistant,with acanthosis nigricans,610549|Hyperinsulinemic hypoglycemia,familial,5,609968];	RCV000175129.1 [benign]; RCV000278910.1 [benign]; RCV000333104.1 [benign]; RCV000373687.1 [benign]; 	CM092295 [CLASS=DP MUT=ALT PHEN="Polycystic ovary syndrome in lean women association with" GENE=INSR]; 	COSM4001047, COSM4001048	90	528					INSR (inh=AR+AD pLI=0.19)
chr19	7141775	7141775	G	A	het	wt	hom		QUAL=1531;DP=50,36,32;MQM=60	INSR	synonymous	INSR:NM_000208.3:synonymous:LOW:exon13/22:c.2595C>T:p.Asn865Asn,INSR:NM_001079817.2:synonymous:LOW:exon12/21:c.2559C>T:p.Asn853Asn		rs2229431	0.0869	0.0615	307/80/134	0.0609							147670 [INSR (confirmed) Leprechaunism,246200|Rabson-Mendenhall syndrome,262190|Diabetes mellitus,insulin-resistant,with acanthosis nigricans,610549|Hyperinsulinemic hypoglycemia,familial,5,609968];	RCV000265366.1 [benign]; RCV000300575.1 [benign]; RCV000355369.1 [benign]; 			5	167					INSR (inh=AR+AD pLI=0.19)
chr19	7166376	7166376	C	T	het	het	wt		QUAL=2869;DP=160,94,119;MQM=60	INSR	synonymous	INSR:NM_000208.3:synonymous:LOW:exon8/22:c.1650G>A:p.Ala550Ala,INSR:NM_001079817.2:synonymous:LOW:exon8/21:c.1650G>A:p.Ala550Ala		rs2059806	0.2448	0.2549	3909/2174/194	0.2487							147670 [INSR (confirmed) Leprechaunism,246200|Rabson-Mendenhall syndrome,262190|Diabetes mellitus,insulin-resistant,with acanthosis nigricans,610549|Hyperinsulinemic hypoglycemia,familial,5,609968];	RCV000180111.1 [benign]; RCV000290514.1 [benign]; RCV000347847.1 [benign]; RCV000393623.1 [benign]; 	CM004252 [CLASS=DP MUT=ALT PHEN="Reduced diastolic blood pressure association with" GENE=INSR]; 	COSM148469, COSM4132751	102	598					INSR (inh=AR+AD pLI=0.19)
chr19	7166388	7166388	G	A	wt	het	wt		QUAL=954;DP=166,81,104;MQM=60	INSR	synonymous	INSR:NM_000208.3:synonymous:LOW:exon8/22:c.1638C>T:p.Asp546Asp,INSR:NM_001079817.2:synonymous:LOW:exon8/21:c.1638C>T:p.Asp546Asp		rs2229429	0.2566	0.2075	3059/1217/991	0.2011							147670 [INSR (confirmed) Leprechaunism,246200|Rabson-Mendenhall syndrome,262190|Diabetes mellitus,insulin-resistant,with acanthosis nigricans,610549|Hyperinsulinemic hypoglycemia,familial,5,609968];	RCV000312658.1 [benign]; RCV000351255.1 [benign]; RCV000406047.1 [benign]; 		COSM4132752, COSM4132753	90	548					INSR (inh=AR+AD pLI=0.19)
chr19	7593589	7593589	C	T	het	hom	het		QUAL=24726;DP=182,498,630;MQM=59	MCOLN1	splice_region&synonymous	MCOLN1:NM_020533.2:splice_region&synonymous:LOW:exon8/14:c.984C>T:p.Asn328Asn		rs612862	0.2556	0.2875	5504/3980/301	0.2835							605248 [MCOLN1 (confirmed) Mucolipidosis IV,252650];	RCV000254195.1 [benign]; RCV000380192.1 [likely benign]; 		COSM4132764	200	688					MCOLN1 (inh=AR pLI=0.04)
chr19	7703605	7703605	C	T	het	het	wt	low_DP	QUAL=543;DP=36,19,19;MQM=60	STXBP2	sequence_feature,splice_region&intron	STXBP2:NM_001272034.1:sequence_feature:MODERATE::c.38-7C>T:,STXBP2:NM_001127396.2:sequence_feature:MODERATE::c.38-7C>T:,STXBP2:NM_006949.3:sequence_feature:MODERATE::c.38-7C>T:,STXBP2:NM_001272034.1:splice_region&intron:LOW:exon1/18:c.38-7C>T:,STXBP2:NM_001127396.2:splice_region&intron:LOW:exon1/18:c.38-7C>T:,STXBP2:NM_006949.3:splice_region&intron:LOW:exon1/18:c.38-7C>T:,STXBP2:NR_073560.1:splice_region&intron:LOW:exon1/18:n.87-7C>T:		rs8104339	0.4824	0.4044	10443/4768/1346	0.4058							601717 [STXBP2 (provisional) Hemophagocytic lymphohistiocytosis,familial,5,613101];	RCV000244568.1 [benign]; RCV000367298.1 [benign]; 			252	698					STXBP2 (inh=AR pLI=0.00)
chr19	7711221	7711221	T	C	het	het	wt		QUAL=3411;DP=95,194,326;MQM=59	STXBP2	synonymous,non_coding_transcript_exon	STXBP2:NM_001272034.1:synonymous:LOW:exon16/19:c.1476T>C:p.Asp492Asp,STXBP2:NM_001127396.2:synonymous:LOW:exon16/19:c.1434T>C:p.Asp478Asp,STXBP2:NM_006949.3:synonymous:LOW:exon16/19:c.1443T>C:p.Asp481Asp,STXBP2:NR_073560.1:non_coding_transcript_exon:MODIFIER:exon16/19:n.1467T>C:		rs10001	0.5042	0.4626	8932/3784/1061	0.3943							601717 [STXBP2 (provisional) Hemophagocytic lymphohistiocytosis,familial,5,613101];	RCV000253160.1 [benign]; RCV000311684.1 [benign]; 		COSM1178455	244	699					STXBP2 (inh=AR pLI=0.00)
chr19	7712277	7712277	A	G	het	het	wt	low_DP	QUAL=201;DP=12,17,26;MQM=60	STXBP2	missense,non_coding_transcript_exon	STXBP2:NM_001272034.1:missense:MODERATE:exon18/19:c.1609A>G:p.Ile537Val,STXBP2:NM_001127396.2:missense:MODERATE:exon18/19:c.1567A>G:p.Ile523Val,STXBP2:NM_006949.3:missense:MODERATE:exon18/19:c.1576A>G:p.Ile526Val,STXBP2:NR_073560.1:non_coding_transcript_exon:MODIFIER:exon18/19:n.1600A>G:		rs6791	0.7061	0.6352	24381/12303/2856	0.6314	-0.1760	T,T,T,T	T	B,B,B,B	T,T,T	0.01	601717 [STXBP2 (provisional) Hemophagocytic lymphohistiocytosis,familial,5,613101];	RCV000250426.1 [benign]; RCV000308412.1 [benign]; 		COSM440643	566	735					STXBP2 (inh=AR pLI=0.00)
chr19	8376204	8376204	G	A	wt	wt	het		QUAL=2194;DP=168,160,157;MQM=59	NDUFA7	intron	NDUFA7:NR_135539.1:intron:MODIFIER:exon4/4:n.490+92C>T:	AluJr	rs35669830	0.0100	0.0000	0/0/0	0.0134											0	3					NDUFA7 (inh=n/a pLI=0.00)
chr19	8376431	8376431	G	A	het	het	wt		QUAL=8811;DP=318,459,579;MQM=60	NDUFA7	synonymous,non_coding_transcript_exon	NDUFA7:NM_005001.4:synonymous:LOW:exon4/4:c.300C>T:p.Pro100Pro,NDUFA7:NR_135539.1:non_coding_transcript_exon:MODIFIER:exon4/5:n.355C>T:		rs561	0.1382	0.1750	2182/1197/10	0.1735											40	410					NDUFA7 (inh=n/a pLI=0.00)
chr19	8381489	8381489	T	G	wt	wt	het	pred_pathogenic	QUAL=1179;DP=64,95,107;MQM=60	NDUFA7	missense,non_coding_transcript_exon	NDUFA7:NM_005001.4:missense:MODERATE:exon3/4:c.142A>C:p.Lys48Gln,NDUFA7:NR_135539.1:non_coding_transcript_exon:MODIFIER:exon3/5:n.197A>C:		rs12986323	0.0066	0.0120	22/8/0	0.0118	4.6900	T	T	D	T	22.30					1	36					NDUFA7 (inh=n/a pLI=0.00)
chr19	10265312	10265312	T	C	hom	hom	hom		QUAL=16586;DP=200,161,168;MQM=59	DNMT1	synonymous	DNMT1:NM_001130823.2:synonymous:LOW:exon21/41:c.1782A>G:p.Thr594Thr,DNMT1:NM_001318730.1:synonymous:LOW:exon20/40:c.1734A>G:p.Thr578Thr,DNMT1:NM_001318731.1:synonymous:LOW:exon21/41:c.1419A>G:p.Thr473Thr,DNMT1:NM_001379.3:synonymous:LOW:exon20/40:c.1734A>G:p.Thr578Thr		rs721186	0.9958	0.9910	59584/32465/5165	0.9416							126375 [DNMT1 (confirmed) Neuropathy,hereditary sensory,type IE,614116|Cerebellar ataxia,deafness,and narcolepsy,autosomal dominant,604121];	RCV000247150.1 [benign]; RCV000306290.1 [benign]; 			1582	29					DNMT1 (inh=AD pLI=1.00)
chr19	10267077	10267077	T	C	het	het	het		QUAL=7805;DP=225,186,229;MQM=59	DNMT1	synonymous	DNMT1:NM_001130823.2:synonymous:LOW:exon18/41:c.1389A>G:p.Pro463Pro,DNMT1:NM_001318730.1:synonymous:LOW:exon17/40:c.1341A>G:p.Pro447Pro,DNMT1:NM_001318731.1:synonymous:LOW:exon18/41:c.1026A>G:p.Pro342Pro,DNMT1:NM_001379.3:synonymous:LOW:exon17/40:c.1341A>G:p.Pro447Pro		rs2228611	0.5339	0.5188	16554/8241/1413	0.5129							126375 [DNMT1 (confirmed) Neuropathy,hereditary sensory,type IE,614116|Cerebellar ataxia,deafness,and narcolepsy,autosomal dominant,604121];	RCV000245855.1 [benign]; RCV000385434.1 [benign]; 			409	775					DNMT1 (inh=AD pLI=1.00)
chr19	10270747	10270747	A	-	het	het	het		QUAL=7924;DP=270,181,249;MQM=59	DNMT1	splice_region&intron	DNMT1:NM_001130823.2:splice_region&intron:LOW:exon14/40:c.1044-8delT:,DNMT1:NM_001318730.1:splice_region&intron:LOW:exon13/39:c.996-8delT:,DNMT1:NM_001318731.1:splice_region&intron:LOW:exon14/40:c.681-8delT:,DNMT1:NM_001379.3:splice_region&intron:LOW:exon13/39:c.996-8delT:		rs3079962;rs397859148;rs59599980;rs796846833	0.5795	0.6388	23788/14795/2955	0.5306							126375 [DNMT1 (confirmed) Neuropathy,hereditary sensory,type IE,614116|Cerebellar ataxia,deafness,and narcolepsy,autosomal dominant,604121];	RCV000278836.1 [benign]; 			715	716					DNMT1 (inh=AD pLI=1.00)
chr19	10472933	10472933	A	G	wt	het	het		QUAL=4064;DP=91,148,183;MQM=60	TYK2	splice_region&intron	TYK2:NM_003331.4:splice_region&intron:LOW:exon11/24:c.1669+7T>C:		rs280519	0.5331	0.5082	16043/8969/1640	0.4959							176941 [TYK2 (confirmed) Immunodeficiency 35,611521];	RCV000245301.1 [benign]; RCV000394899.1 [benign]; 			406	753					TYK2 (inh=AR pLI=0.00)
chr19	10473138	10473138	A	G	wt	het	het		QUAL=2672;DP=83,128,133;MQM=60	TYK2	splice_region&intron	TYK2:NM_003331.4:splice_region&intron:LOW:exon10/24:c.1477-6T>C:		rs280520	0.3299	0.3217	3005/1101/509	0.2344							176941 [TYK2 (confirmed) Immunodeficiency 35,611521];	RCV000126191.2 [benign]; RCV000398417.1 [benign]; 			95	537					TYK2 (inh=AR pLI=0.00)
chr19	10477206	10477206	G	A	wt	het	het		QUAL=9646;DP=262,293,394;MQM=60	TYK2	synonymous	TYK2:NM_003331.4:synonymous:LOW:exon6/25:c.516C>T:p.Thr172Thr		rs280523	0.0833	0.0728	412/158/149	0.0711							176941 [TYK2 (confirmed) Immunodeficiency 35,611521];	RCV000126189.1 [benign]; RCV000280944.1 [likely benign]; 			9	169					TYK2 (inh=AR pLI=0.00)
chr19	10939792	10939792	T	C	het	wt	het		QUAL=3918;DP=163,149,179;MQM=59	DNM2	synonymous	DNM2:NM_001005360.2:synonymous:LOW:exon19/21:c.2139T>C:p.Ala713Ala,DNM2:NM_001005361.2:synonymous:LOW:exon19/21:c.2139T>C:p.Ala713Ala,DNM2:NM_001005362.2:synonymous:LOW:exon18/20:c.2127T>C:p.Ala709Ala,DNM2:NM_001190716.1:synonymous:LOW:exon19/21:c.2139T>C:p.Ala713Ala,DNM2:NM_004945.3:synonymous:LOW:exon18/20:c.2127T>C:p.Ala709Ala		rs2229920	0.3383	0.3115	6082/2703/408	0.3090							602378 [DNM2 (confirmed) Charcot-Marie-Tooth disease,dominant intermediate B,606482|Myopathy,centronuclear,160150|Charcot-Marie-Tooth disease,axonal,type 2M,606482|Lethal congenital contracture syndrome 5,615368];	RCV000145914.3 [other]; RCV000312099.1 [benign]; RCV000371358.1 [benign]; 		COSM3766266, COSM3766265, COSM3766264	142	686					DNM2 (inh=AR+AD pLI=1.00)
chr19	11105608	11105608	T	C	het	wt	het		QUAL=7091;DP=207,293,377;MQM=60	SMARCA4	synonymous	SMARCA4:NM_001128849.1:synonymous:LOW:exon9/36:c.1524T>C:p.His508His,SMARCA4:NM_001128844.1:synonymous:LOW:exon10/36:c.1524T>C:p.His508His,SMARCA4:NM_003072.3:synonymous:LOW:exon9/35:c.1524T>C:p.His508His,SMARCA4:NM_001128845.1:synonymous:LOW:exon8/33:c.1524T>C:p.His508His,SMARCA4:NM_001128846.1:synonymous:LOW:exon8/33:c.1524T>C:p.His508His,SMARCA4:NM_001128847.1:synonymous:LOW:exon8/33:c.1524T>C:p.His508His,SMARCA4:NM_001128848.1:synonymous:LOW:exon8/33:c.1524T>C:p.His508His		rs7935	0.3115	0.3353	6930/3973/490	0.3275							603254 [SMARCA4 (provisional) Rhabdoid tumor predisposition syndrome 2,613325|Coffin-Siris syndrome 4,614609];	RCV000114302.2 [benign]; RCV000264120.1 [benign]; 		COSM4131184, COSM4131185	341	1268					SMARCA4 (inh=AD pLI=1.00)
chr19	11123622	11123622	C	A	wt	het	wt		QUAL=4578;DP=165,372,482;MQM=60	SMARCA4	splice_region&intron	SMARCA4:NM_001128849.1:splice_region&intron:LOW:exon15/35:c.2275-3C>A:,SMARCA4:NM_001128844.1:splice_region&intron:LOW:exon16/35:c.2275-3C>A:,SMARCA4:NM_003072.3:splice_region&intron:LOW:exon15/34:c.2275-3C>A:,SMARCA4:NM_001128845.1:splice_region&intron:LOW:exon14/32:c.2275-3C>A:,SMARCA4:NM_001128846.1:splice_region&intron:LOW:exon14/32:c.2275-3C>A:,SMARCA4:NM_001128847.1:splice_region&intron:LOW:exon14/32:c.2275-3C>A:,SMARCA4:NM_001128848.1:splice_region&intron:LOW:exon14/32:c.2275-3C>A:		rs117611401	0.0010	0.0028	1/1/0	0.0028							603254 [SMARCA4 (provisional) Rhabdoid tumor predisposition syndrome 2,613325|Coffin-Siris syndrome 4,614609];	RCV000193996.2 [other]; RCV000204957.2 [likely benign]; RCV000345652.1 [likely benign]; RCV000226002.1 [uncertain significance]; 			0	33	2	[2] old entry - no details available			SMARCA4 (inh=AD pLI=1.00)
chr19	11170839	11170839	T	C	wt	het	wt	low_DP	QUAL=208;DP=19,14,34;MQM=60	SMARCA4	synonymous	SMARCA4:NM_001128849.1:synonymous:LOW:exon35/36:c.4983T>C:p.Asp1661Asp,SMARCA4:NM_001128844.1:synonymous:LOW:exon35/36:c.4887T>C:p.Asp1629Asp,SMARCA4:NM_003072.3:synonymous:LOW:exon34/35:c.4887T>C:p.Asp1629Asp,SMARCA4:NM_001128845.1:synonymous:LOW:exon32/33:c.4797T>C:p.Asp1599Asp,SMARCA4:NM_001128846.1:synonymous:LOW:exon32/33:c.4794T>C:p.Asp1598Asp,SMARCA4:NM_001128847.1:synonymous:LOW:exon32/33:c.4788T>C:p.Asp1596Asp,SMARCA4:NM_001128848.1:synonymous:LOW:exon32/33:c.4785T>C:p.Asp1595Asp		rs7275	0.2498	0.3090	981/342/119	0.1108							603254 [SMARCA4 (provisional) Rhabdoid tumor predisposition syndrome 2,613325|Coffin-Siris syndrome 4,614609];	RCV000114308.2 [benign]; RCV000287003.1 [benign]; 		COSM1390290, COSM1390291	249	1101					SMARCA4 (inh=AD pLI=1.00)
chr19	12767448	12767448	C	T	wt	het	wt		QUAL=4196;DP=384,310,336;MQM=60	MAN2B1	synonymous	MAN2B1:NM_000528.3:synonymous:LOW:exon13/24:c.1581G>A:p.Arg527Arg,MAN2B1:NM_001173498.1:synonymous:LOW:exon13/24:c.1578G>A:p.Arg526Arg		rs149613968	0.0016	0.0042	5/5/0	0.0040	0.2190		T			18.59	609458 [MAN2B1 (confirmed) Mannosidosis,alpha-,types I and II,248500];				0	12	2	[2] ahschak1 11.10.2016			MAN2B1 (inh=AR pLI=0.00)
chr19	12768948	12768948	T	C	wt	het	wt	pred_pathogenic	QUAL=1233;DP=88,117,173;MQM=59	MAN2B1	missense	MAN2B1:NM_000528.3:missense:MODERATE:exon10/24:c.1238A>G:p.Asn413Ser,MAN2B1:NM_001173498.1:missense:MODERATE:exon10/24:c.1235A>G:p.Asn412Ser		rs35836657	0.0385	0.0912	733/595/4	0.0884	2.0600	D,D,D	T	B,B	T,T	14.61	609458 [MAN2B1 (confirmed) Mannosidosis,alpha-,types I and II,248500];	RCV000117592.7 [other]; RCV000392754.1 [likely benign]; 		COSM438614	26	252					MAN2B1 (inh=AR pLI=0.00)
chr19	12772090	12772090	C	T	het	het	wt		QUAL=8883;DP=221,485,577;MQM=60	MAN2B1	missense	MAN2B1:NM_000528.3:missense:MODERATE:exon7/24:c.1010G>A:p.Arg337Gln,MAN2B1:NM_001173498.1:missense:MODERATE:exon7/24:c.1010G>A:p.Arg337Gln		rs1133330	0.2484	0.3104	6628/4984/557	0.3093	-0.0410	T,T,T	T	B,B	T,T	18.09	609458 [MAN2B1 (confirmed) Mannosidosis,alpha-,types I and II,248500];	RCV000079070.8 [other]; RCV000298455.1 [benign]; 		COSM1582962	247	724					MAN2B1 (inh=AR pLI=0.00)
chr19	12772165	12772165	G	A	het	het	wt	pred_pathogenic	QUAL=8580;DP=240,540,661;MQM=60	MAN2B1	missense	MAN2B1:NM_000528.3:missense:MODERATE:exon7/24:c.935C>T:p.Thr312Ile,MAN2B1:NM_001173498.1:missense:MODERATE:exon7/24:c.935C>T:p.Thr312Ile		rs1054487	0.3279	0.3398	8097/5345/1594	0.3382	1.9380	T,T,T	T	B,B	T,T	0.01	609458 [MAN2B1 (confirmed) Mannosidosis,alpha-,types I and II,248500];	RCV000079081.8 [other]; RCV000355741.1 [benign]; RCV000224033.1 [likely benign]; 		COSM1178457	271	719					MAN2B1 (inh=AR pLI=0.00)
chr19	12774208	12774208	G	C	het	wt	het		QUAL=9143;DP=333,345,433;MQM=59	MAN2B1	missense	MAN2B1:NM_000528.3:missense:MODERATE:exon6/24:c.832C>G:p.Leu278Val,MAN2B1:NM_001173498.1:missense:MODERATE:exon6/24:c.832C>G:p.Leu278Val		rs1054486	0.2394	0.2567	4512/2834/779	0.2516	-0.4280	T,T,T	T	B,B	T,T	0.01	609458 [MAN2B1 (confirmed) Mannosidosis,alpha-,types I and II,248500];	RCV000079080.8 [other]; RCV000368270.1 [benign]; 			137	601					MAN2B1 (inh=AR pLI=0.00)
chr19	12917472	12917472	T	C	wt	het	wt		QUAL=2735;DP=205,200,244;MQM=60	RNASEH2A	5'UTR	RNASEH2A:NM_006397.2:5'UTR:MODIFIER:exon1/8:c.-16T>C:		rs1046220	0.0126	0.0389	23/20/0	0.0222							606034 [RNASEH2A (confirmed) Aicardi-Goutieres syndrome 4,610333];	RCV000299981.1 [likely benign]; 			0	56					RNASEH2A (inh=AR pLI=0.05)
chr19	13008607	13008607	G	T	wt	wt	het	low_DP	QUAL=41;DP=32,8,7;MQM=60	GCDH	synonymous,non_coding_transcript_exon	GCDH:NM_000159.3:synonymous:LOW:exon11/12:c.1173G>T:p.Gly391Gly,GCDH:NM_013976.3:synonymous:LOW:exon11/12:c.1173G>T:p.Gly391Gly,GCDH:NR_102316.1:non_coding_transcript_exon:MODIFIER:exon11/12:n.1336G>T:,GCDH:NR_102317.1:non_coding_transcript_exon:MODIFIER:exon10/11:n.1554G>T:		rs1060218	0.2504	0.3245	6834/4395/196	0.3033							608801 [GCDH (confirmed) Glutaricaciduria,type I,231670];	RCV000078250.6 [benign]; RCV000269249.1 [benign]; 		COSM3756352, COSM3756353, COSM3756351	383	1263					GCDH (inh=AR pLI=0.34)
chr19	13010520	13010520	A	G	wt	wt	het	pred_pathogenic;anno_pathogenic_clinvar	QUAL=4920;DP=238,318,396;MQM=60	GCDH,SYCE2	missense,3'UTR,intron,non_coding_transcript_exon	GCDH:NM_013976.3:missense:MODERATE:exon12/12:c.1250A>G:p.Gln417Arg,GCDH:NM_000159.3:3'UTR:MODIFIER:exon12/12:c.*165A>G:,SYCE2:NM_001105578.1:intron:MODIFIER:exon5/5:c.612+298T>C:,GCDH:NR_102316.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.1645A>G:,GCDH:NR_102317.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.1863A>G:		rs8012	0.7204	0.6130	23435/9944/3352	0.6030	0.3260	T	T	B	D	0.30	608801 [GCDH (confirmed) Glutaricaciduria,type I,231670];	RCV000190518.1 [likely pathogenic]; RCV000281284.1 [benign]; 			959	1332	2	[2] bauer 26.02.2016			GCDH (inh=AR pLI=0.34), SYCE2 (inh=n/a pLI=0.42)
chr19	13010643	13010643	G	T	wt	wt	het	anno_pathogenic_clinvar	QUAL=4275;DP=400,279,320;MQM=60	GCDH,SYCE2	3'UTR,intron,non_coding_transcript_exon	GCDH:NM_000159.3:3'UTR:MODIFIER:exon12/12:c.*288G>T:,GCDH:NM_013976.3:3'UTR:MODIFIER:exon12/12:c.*86G>T:,SYCE2:NM_001105578.1:intron:MODIFIER:exon5/5:c.612+175C>A:,GCDH:NR_102316.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.1768G>T:,GCDH:NR_102317.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.1986G>T:		rs9384	0.2780	0.0000	0/0/0	0.0662							608801 [GCDH (confirmed) Glutaricaciduria,type I,231670];	RCV000190519.1 [likely pathogenic]; RCV000336585.1 [benign]; 			87	287					GCDH (inh=AR pLI=0.34), SYCE2 (inh=n/a pLI=0.42)
chr19	13227354	13227354	G	A	het	wt	het		QUAL=3910;DP=177,113,158;MQM=60	TRMT1	5'UTR_premature_start_codon_gain,5'UTR,intron	TRMT1:NM_001142554.1:5'UTR_premature_start_codon_gain:LOW:exon1/15:c.-141C>T:,TRMT1:NM_017722.3:5'UTR_premature_start_codon_gain:LOW:exon1/16:c.-141C>T:,TRMT1:NM_001142554.1:5'UTR:MODIFIER:exon1/15:c.-141C>T:,TRMT1:NM_017722.3:5'UTR:MODIFIER:exon1/16:c.-141C>T:,TRMT1:NM_001136035.2:intron:MODIFIER:exon1/16:c.-32-109C>T:		rs2302159	0.0980	0.0000	0/0/0	0.0793											1	39					TRMT1 (inh=n/a pLI=0.00)
chr19	13317491	13317493	TTA	-	hom	hom	het		QUAL=7687;DP=147,64,85;MQM=59	CACNA1A	3'UTR	CACNA1A:NM_023035.2:3'UTR:MODIFIER:exon47/47:c.*634_*636delTAA:,CACNA1A:NM_000068.3:3'UTR:MODIFIER:exon47/47:c.*1367_*1369delTAA:,CACNA1A:NM_001127221.1:3'UTR:MODIFIER:exon47/47:c.*1367_*1369delTAA:,CACNA1A:NM_001127222.1:3'UTR:MODIFIER:exon47/47:c.*634_*636delTAA:,CACNA1A:NM_001174080.1:3'UTR:MODIFIER:exon47/47:c.*1367_*1369delTAA:	(ATT)n	rs143342886;rs869287699	0.5569	0.0000	0/0/0	0.1065							601011 [CACNA1A (confirmed) Migraine,familial hemiplegic,1,141500|Episodic ataxia,type 2,108500|Spinocerebellar ataxia 6,183086|Migraine,familial hemiplegic,1,with progressive cerebellar ataxia,141500|Epileptic encephalopathy,early infantile,42,617106];				304	492					CACNA1A (inh=AD pLI=1.00)
chr19	13317759	13317770	TTTTTTTTTTTT	-	hom	wt	hom	low_DP	QUAL=246;DP=17,9,5;MQM=60	CACNA1A	3'UTR	CACNA1A:NM_023035.2:3'UTR:MODIFIER:exon47/47:c.*357_*368delAAAAAAAAAAAA:,CACNA1A:NM_000068.3:3'UTR:MODIFIER:exon47/47:c.*1090_*1101delAAAAAAAAAAAA:,CACNA1A:NM_001127221.1:3'UTR:MODIFIER:exon47/47:c.*1090_*1101delAAAAAAAAAAAA:,CACNA1A:NM_001127222.1:3'UTR:MODIFIER:exon47/47:c.*357_*368delAAAAAAAAAAAA:,CACNA1A:NM_001174080.1:3'UTR:MODIFIER:exon47/47:c.*1090_*1101delAAAAAAAAAAAA:	(T)n		0.0000	0.0000	0/0/0	0.0000							601011 [CACNA1A (confirmed) Migraine,familial hemiplegic,1,141500|Episodic ataxia,type 2,108500|Spinocerebellar ataxia 6,183086|Migraine,familial hemiplegic,1,with progressive cerebellar ataxia,141500|Epileptic encephalopathy,early infantile,42,617106];				0	0					CACNA1A (inh=AD pLI=1.00)
chr19	13317980	13317980	G	T	hom	hom	het		QUAL=3501;DP=41,52,67;MQM=59	CACNA1A	3'UTR	CACNA1A:NM_023035.2:3'UTR:MODIFIER:exon47/47:c.*147C>A:,CACNA1A:NM_000068.3:3'UTR:MODIFIER:exon47/47:c.*880C>A:,CACNA1A:NM_001127221.1:3'UTR:MODIFIER:exon47/47:c.*880C>A:,CACNA1A:NM_001127222.1:3'UTR:MODIFIER:exon47/47:c.*147C>A:,CACNA1A:NM_001174080.1:3'UTR:MODIFIER:exon47/47:c.*880C>A:		rs7254351	0.5080	0.0000	0/0/0	0.4214							601011 [CACNA1A (confirmed) Migraine,familial hemiplegic,1,141500|Episodic ataxia,type 2,108500|Spinocerebellar ataxia 6,183086|Migraine,familial hemiplegic,1,with progressive cerebellar ataxia,141500|Epileptic encephalopathy,early infantile,42,617106];				88	168					CACNA1A (inh=AD pLI=1.00)
chr19	13319693	13319693	A	G	wt	wt	het	low_DP	QUAL=35;DP=3,4,10;MQM=60	CACNA1A	synonymous	CACNA1A:NM_023035.2:synonymous:LOW:exon46/47:c.6669T>C:p.His2223His,CACNA1A:NM_000068.3:synonymous:LOW:exon46/47:c.6669T>C:p.His2223His,CACNA1A:NM_001127221.1:synonymous:LOW:exon46/47:c.6660T>C:p.His2220His,CACNA1A:NM_001127222.1:synonymous:LOW:exon46/47:c.6657T>C:p.His2219His,CACNA1A:NM_001174080.1:synonymous:LOW:exon46/47:c.6660T>C:p.His2220His		rs16051	0.6869	0.6160	2501/798/253	0.2463							601011 [CACNA1A (confirmed) Migraine,familial hemiplegic,1,141500|Episodic ataxia,type 2,108500|Spinocerebellar ataxia 6,183086|Migraine,familial hemiplegic,1,with progressive cerebellar ataxia,141500|Epileptic encephalopathy,early infantile,42,617106];	RCV000079479.9 [other]; 		COSM3756360, COSM3756359, COSM3756358, COSM3756357	894	1110	1	[1] Julia Bickmann 23.09.2014	n/a (2xTP, 0xFP)		CACNA1A (inh=AD pLI=1.00)
chr19	13445208	13445208	C	T	het	het	wt		QUAL=3163;DP=139,140,138;MQM=60	CACNA1A	synonymous	CACNA1A:NM_023035.2:synonymous:LOW:exon8/47:c.1182G>A:p.Glu394Glu,CACNA1A:NM_000068.3:synonymous:LOW:exon8/47:c.1182G>A:p.Glu394Glu,CACNA1A:NM_001127221.1:synonymous:LOW:exon8/47:c.1182G>A:p.Glu394Glu,CACNA1A:NM_001127222.1:synonymous:LOW:exon8/47:c.1182G>A:p.Glu394Glu,CACNA1A:NM_001174080.1:synonymous:LOW:exon8/47:c.1182G>A:p.Glu394Glu		rs2248069	0.6412	0.6857	28664/15595/1344	0.6738							601011 [CACNA1A (confirmed) Migraine,familial hemiplegic,1,141500|Episodic ataxia,type 2,108500|Spinocerebellar ataxia 6,183086|Migraine,familial hemiplegic,1,with progressive cerebellar ataxia,141500|Epileptic encephalopathy,early infantile,42,617106];	RCV000079475.8 [other]; 			1233	1126	1	[1] Julia Bickmann 23.09.2014	n/a (2xTP, 0xFP)		CACNA1A (inh=AD pLI=1.00)
chr19	14038791	14038791	C	T	hom	het	het	pred_pathogenic	QUAL=11525;DP=211,212,242;MQM=59	CC2D1A	missense	CC2D1A:NM_017721.4:missense:MODERATE:exon23/29:c.2402C>T:p.Thr801Met		rs2305777	0.1250	0.2104	3013/2348/12	0.2082	3.9450	T,T	T	B,D,D	T	26.50	610055 [CC2D1A (provisional) Mental retardation,autosomal recessive 3,608443];	RCV000116591.2 [likely benign]; 		COSM4000530	112	518					CC2D1A (inh=AR pLI=0.00)
chr19	14040896	14040896	G	A	het	het	wt		QUAL=2244;DP=84,99,139;MQM=59	CC2D1A	missense	CC2D1A:NM_017721.4:missense:MODERATE:exon27/29:c.2716G>A:p.Ala906Thr		rs11669628	0.1332	0.1385	1154/558/11	0.1276	-2.5760	T,T	T	B,B,B	T	5.17	610055 [CC2D1A (provisional) Mental retardation,autosomal recessive 3,608443];	RCV000116594.2 [likely benign]; 		COSM1750675	30	382					CC2D1A (inh=AR pLI=0.00)
chr19	15270583	15270583	G	A	hom	hom	het		QUAL=23983;DP=322,269,377;MQM=59	NOTCH3	3'UTR	NOTCH3:NM_000435.2:3'UTR:MODIFIER:exon33/33:c.*890C>T:		rs1044123	0.6238	0.0000	0/0/0	0.6973							600276 [NOTCH3 (confirmed) Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy 1,125310|Myofibromatosis,infantile 2,615293|Lateral meningocele syndrome,130720];	RCV000337524.1 [benign]; 			110	90					NOTCH3 (inh=AD pLI=0.21)
chr19	15270665	15270665	C	T	hom	hom	het		QUAL=22329;DP=270,270,382;MQM=60	NOTCH3	3'UTR	NOTCH3:NM_000435.2:3'UTR:MODIFIER:exon33/33:c.*808G>A:		rs1044116	0.6238	0.0000	0/0/0	0.6973							600276 [NOTCH3 (confirmed) Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy 1,125310|Myofibromatosis,infantile 2,615293|Lateral meningocele syndrome,130720];	RCV000362084.1 [benign]; 			110	90					NOTCH3 (inh=AD pLI=0.21)
chr19	15270805	15270805	C	A	hom	hom	het		QUAL=8812;DP=134,100,143;MQM=59	NOTCH3	3'UTR	NOTCH3:NM_000435.2:3'UTR:MODIFIER:exon33/33:c.*668G>T:		rs1044055	0.6234	0.0000	0/0/0	0.1186							600276 [NOTCH3 (confirmed) Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy 1,125310|Myofibromatosis,infantile 2,615293|Lateral meningocele syndrome,130720];	RCV000267443.1 [benign]; 			110	90					NOTCH3 (inh=AD pLI=0.21)
chr19	15270910	15270910	A	G	hom	het	het		QUAL=5077;DP=125,57,68;MQM=59	NOTCH3	3'UTR	NOTCH3:NM_000435.2:3'UTR:MODIFIER:exon33/33:c.*563T>C:		rs77669983	0.0110	0.0000	0/0/0	0.0318							600276 [NOTCH3 (confirmed) Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy 1,125310|Myofibromatosis,infantile 2,615293|Lateral meningocele syndrome,130720];	RCV000365612.1 [likely benign]; 			1	26					NOTCH3 (inh=AD pLI=0.21)
chr19	15271135	15271135	T	G	hom	hom	hom		QUAL=4660;DP=67,36,54;MQM=59	NOTCH3	3'UTR	NOTCH3:NM_000435.2:3'UTR:MODIFIER:exon33/33:c.*338A>C:	(TAAAAA)n	rs7247906	0.8708	0.0000	0/0/0	0.8430							600276 [NOTCH3 (confirmed) Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy 1,125310|Myofibromatosis,infantile 2,615293|Lateral meningocele syndrome,130720];	RCV000334074.1 [benign]; 			142	46					NOTCH3 (inh=AD pLI=0.21)
chr19	15271771	15271771	G	A	hom	hom	het		QUAL=3362;DP=25,62,74;MQM=59	NOTCH3	missense	NOTCH3:NM_000435.2:missense:MODERATE:exon33/33:c.6668C>T:p.Ala2223Val		rs1044009	0.6294	0.7591	19791/12817/819	0.6543	1.1220	T	T	B	T	9.60	600276 [NOTCH3 (confirmed) Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy 1,125310|Myofibromatosis,infantile 2,615293|Lateral meningocele syndrome,130720];	RCV000249070.2 [benign]; RCV000278901.1 [benign]; 		COSM3756389, COSM3756390	934	566					NOTCH3 (inh=AD pLI=0.21)
chr19	15273381	15273381	A	G	hom	hom	hom		QUAL=23110;DP=205,231,312;MQM=60	NOTCH3	splice_region&intron	NOTCH3:NM_000435.2:splice_region&intron:LOW:exon31/32:c.5816-8T>C:		rs4809030	0.8690	0.8745	46287/26814/4941	0.8661							600276 [NOTCH3 (confirmed) Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy 1,125310|Myofibromatosis,infantile 2,615293|Lateral meningocele syndrome,130720];	RCV000241820.1 [benign]; RCV000277327.1 [benign]; 			1289	301					NOTCH3 (inh=AD pLI=0.21)
chr19	15278057	15278057	A	G	hom	hom	hom		QUAL=9842;DP=135,83,111;MQM=59	NOTCH3	splice_region&intron	NOTCH3:NM_000435.2:splice_region&intron:LOW:exon29/32:c.5362+3T>C:		rs1548555	0.8700	0.8741	46647/26964/4975	0.8678							600276 [NOTCH3 (confirmed) Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy 1,125310|Myofibromatosis,infantile 2,615293|Lateral meningocele syndrome,130720];	RCV000246404.1 [benign]; RCV000288178.1 [benign]; 			1289	302					NOTCH3 (inh=AD pLI=0.21)
chr19	15284924	15284924	C	T	wt	wt	het	pred_pathogenic	QUAL=3342;DP=106,158,270;MQM=60	NOTCH3	missense	NOTCH3:NM_000435.2:missense:MODERATE:exon25/33:c.4691G>A:p.Gly1564Asp		rs746928836	0.0000	0.0001	0/0/0	0.0001	0.2230	T	T	B	D	6.17	600276 [NOTCH3 (confirmed) Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy 1,125310|Myofibromatosis,infantile 2,615293|Lateral meningocele syndrome,130720];				0	1					NOTCH3 (inh=AD pLI=0.21)
chr19	15285052	15285052	T	C	hom	hom	hom		QUAL=22803;DP=181,219,348;MQM=59	NOTCH3	synonymous,sequence_feature	NOTCH3:NM_000435.2:synonymous:LOW:exon25/33:c.4563A>G:p.Pro1521Pro,NOTCH3:NM_000435.2:sequence_feature:LOW:exon25/33:c.4563A>G:		rs1044006	0.8718	0.8812	34152/19607/3360	0.8146							600276 [NOTCH3 (confirmed) Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy 1,125310|Myofibromatosis,infantile 2,615293|Lateral meningocele syndrome,130720];	RCV000249034.1 [benign]; RCV000315021.1 [benign]; 		COSM438775, COSM1480700	1285	300					NOTCH3 (inh=AD pLI=0.21)
chr19	15292437	15292437	T	C	hom	hom	hom		QUAL=8496;DP=66,87,128;MQM=59	NOTCH3	synonymous	NOTCH3:NM_000435.2:synonymous:LOW:exon17/33:c.2742A>G:p.Pro914Pro		rs1043997	0.7390	0.8019	6280/2876/430	0.4975							600276 [NOTCH3 (confirmed) Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy 1,125310|Myofibromatosis,infantile 2,615293|Lateral meningocele syndrome,130720];	RCV000246643.1 [benign]; RCV000304759.1 [benign]; 		COSM4131310, COSM4131309	1165	404					NOTCH3 (inh=AD pLI=0.21)
chr19	15295134	15295134	G	A	hom	hom	het		QUAL=13277;DP=125,212,277;MQM=60	NOTCH3	synonymous	NOTCH3:NM_000435.2:synonymous:LOW:exon16/33:c.2538C>T:p.Cys846Cys		rs1043996	0.5200	0.6427	26200/17147/378	0.6382							600276 [NOTCH3 (confirmed) Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy 1,125310|Myofibromatosis,infantile 2,615293|Lateral meningocele syndrome,130720];	RCV000241854.1 [benign]; RCV000269025.1 [benign]; 		COSM4131311, COSM4131312	769	685					NOTCH3 (inh=AD pLI=0.21)
chr19	15299051	15299051	G	A	het	het	wt	pred_pathogenic;anno_pathogenic_hgmd	QUAL=2578;DP=127,88,85;MQM=59	NOTCH3	missense	NOTCH3:NM_000435.2:missense:MODERATE:exon9/33:c.1487C>T:p.Pro496Leu		rs11670799	0.0036	0.0207	16/16/0	0.0101	4.5180	D,D	D	P,P	D	25.10	600276 [NOTCH3 (confirmed) Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy 1,125310|Myofibromatosis,infantile 2,615293|Lateral meningocele syndrome,130720];	RCV000253366.1 [benign]; RCV000301926.1 [likely benign]; 	CM162093 [CLASS=DM? MUT=ALT PHEN="Pulmonary arterial hypertension" GENE=NOTCH3]; 		1	56					NOTCH3 (inh=AD pLI=0.21)
chr19	15300136	15300136	A	G	het	het	wt		QUAL=5245;DP=200,261,292;MQM=59	NOTCH3	synonymous	NOTCH3:NM_000435.2:synonymous:LOW:exon7/33:c.1140T>C:p.Pro380Pro		rs61749020	0.0152	0.0256	62/54/2	0.0249							600276 [NOTCH3 (confirmed) Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy 1,125310|Myofibromatosis,infantile 2,615293|Lateral meningocele syndrome,130720];	RCV000252960.1 [benign]; RCV000362891.1 [likely benign]; 		COSM3773842, COSM3773843	2	135					NOTCH3 (inh=AD pLI=0.21)
chr19	15302844	15302844	T	C	hom	hom	hom		QUAL=37951;DP=211,462,555;MQM=59	NOTCH3	synonymous	NOTCH3:NM_000435.2:synonymous:LOW:exon4/33:c.606A>G:p.Ala202Ala		rs1043994	0.8558	0.8581	44532/25552/4278	0.8278							600276 [NOTCH3 (confirmed) Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy 1,125310|Myofibromatosis,infantile 2,615293|Lateral meningocele syndrome,130720];	RCV000242339.1 [benign]; RCV000374496.1 [benign]; 			1216	369					NOTCH3 (inh=AD pLI=0.21)
chr19	15303225	15303225	G	A	wt	wt	het		QUAL=2994;DP=130,136,193;MQM=60	NOTCH3	synonymous	NOTCH3:NM_000435.2:synonymous:LOW:exon3/33:c.303C>T:p.Thr101Thr		rs3815188	0.2240	0.1822	2021/697/323	0.1738							600276 [NOTCH3 (confirmed) Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy 1,125310|Myofibromatosis,infantile 2,615293|Lateral meningocele syndrome,130720];	RCV000251392.1 [benign]; RCV000373577.1 [benign]; 			36	426					NOTCH3 (inh=AD pLI=0.21)
chr19	17935585	17935586	AA	-	het	het	wt		QUAL=4025;DP=97,62,124;MQM=59	INSL3-JAK3	intergenic_region	INSL3-JAK3:INSL3-JAK3:intergenic_region:MODIFIER::n.17935585_17935586delAA:		rs796392933	0.3197	0.0000	0/0/0	0.2350							600173 [JAK3 (provisional) SCID,autosomal recessive,T-negative/B-positive type,600802];	RCV000333875.1 [benign]; 			12	64					INSL3-JAK3 (inh=n/a pLI=n/a)
chr19	17935586	17935586	-	AC	wt	het	het		QUAL=4025;DP=97,62,124;MQM=60	INSL3-JAK3	intergenic_region	INSL3-JAK3:INSL3-JAK3:intergenic_region:MODIFIER::n.17935586_17935587insAC:		rs10672762;rs34291897	0.3878	0.0000	0/0/0	0.2178							600173 [JAK3 (provisional) SCID,autosomal recessive,T-negative/B-positive type,600802];	RCV000261213.1 [benign]; 			21	70					INSL3-JAK3 (inh=n/a pLI=n/a)
chr19	17935626	17935626	T	C	het	hom	het		QUAL=6482;DP=188,80,154;MQM=59	JAK3	3'UTR	JAK3:NM_000215.3:3'UTR:MODIFIER:exon24/24:c.*1926A>G:	L2c	rs11888	0.3980	0.0000	0/0/0	0.3754							600173 [JAK3 (provisional) SCID,autosomal recessive,T-negative/B-positive type,600802];	RCV000278899.1 [benign]; 			25	73					JAK3 (inh=AR pLI=1.00)
chr19	17936259	17936259	G	A	het	hom	wt		QUAL=3670;DP=146,64,64;MQM=60	JAK3	3'UTR	JAK3:NM_000215.3:3'UTR:MODIFIER:exon24/24:c.*1293C>T:		rs73014967	0.1591	0.0000	0/0/0	0.1875							600173 [JAK3 (provisional) SCID,autosomal recessive,T-negative/B-positive type,600802];	RCV000309786.1 [likely benign]; 			15	87					JAK3 (inh=AR pLI=1.00)
chr19	17936898	17936898	T	A	het	het	wt	low_DP	QUAL=87;DP=18,4,12;MQM=59	JAK3	3'UTR	JAK3:NM_000215.3:3'UTR:MODIFIER:exon24/24:c.*654A>T:		rs71332114	0.2077	0.0000	0/0/0	0.0441							600173 [JAK3 (provisional) SCID,autosomal recessive,T-negative/B-positive type,600802];	RCV000343033.1 [benign]; 			5	21					JAK3 (inh=AR pLI=1.00)
chr19	17937104	17937104	G	T	het	het	wt	low_DP	QUAL=478;DP=31,4,7;MQM=50	JAK3	3'UTR	JAK3:NM_000215.3:3'UTR:MODIFIER:exon24/24:c.*448C>A:	AluSz	rs3212802	0.2194	0.0000	0/0/0	0.1661							600173 [JAK3 (provisional) SCID,autosomal recessive,T-negative/B-positive type,600802];	RCV000309394.1 [benign]; 			3	27					JAK3 (inh=AR pLI=1.00)
chr19	17937429	17937429	A	G	het	hom	wt		QUAL=5338;DP=112,122,177;MQM=60	JAK3	3'UTR	JAK3:NM_000215.3:3'UTR:MODIFIER:exon24/24:c.*123T>C:		rs3008	0.5401	0.0000	0/0/0	0.0956							600173 [JAK3 (provisional) SCID,autosomal recessive,T-negative/B-positive type,600802];	RCV000355256.1 [benign]; 			39	88					JAK3 (inh=AR pLI=1.00)
chr19	17945696	17945696	C	T	het	het	wt	pred_pathogenic;anno_pathogenic_hgmd	QUAL=3841;DP=237,102,150;MQM=60	JAK3	missense	JAK3:NM_000215.3:missense:MODERATE:exon16/24:c.2164G>A:p.Val722Ile		rs3213409	0.0036	0.0086	11/9/0	0.0085	1.5240	D,D,D	T	B,B	T,T,T	16.20	600173 [JAK3 (provisional) SCID,autosomal recessive,T-negative/B-positive type,600802];	RCV000121262.1 [not provided]; 	CM000172 [CLASS=DM? MUT=ALT PHEN="Immunodeficiency severe combined" GENE=JAK3]; 	COSM34213	0	52					JAK3 (inh=AR pLI=1.00)
chr19	17983059	17983059	C	T	wt	wt	het	low_DP	QUAL=304;DP=17,12,17;MQM=60	SLC5A5	5'UTR	SLC5A5:NM_000453.2:5'UTR:MODIFIER:exon1/15:c.-70C>T:		rs118133504	0.0260	0.0000	0/0/0	0.0059							601843 [SLC5A5 (provisional) Thyroid dyshormonogenesis 1,274400];	RCV000370579.1 [uncertain significance]; 			2	54					SLC5A5 (inh=AR pLI=0.74)
chr19	17999239	17999239	C	T	wt	het	het		QUAL=5447;DP=290,193,238;MQM=60	SLC5A5	synonymous	SLC5A5:NM_000453.2:synonymous:LOW:exon13/15:c.1626C>T:p.Cys542Cys		rs45602038	0.0132	0.0255	58/34/1	0.0248							601843 [SLC5A5 (provisional) Thyroid dyshormonogenesis 1,274400];	RCV000390236.1 [uncertain significance]; 			3	107					SLC5A5 (inh=AR pLI=0.74)
chr19	18001686	18001686	G	A	het	wt	het		QUAL=4007;DP=120,174,231;MQM=60	SLC5A5	splice_region&intron	SLC5A5:NM_000453.2:splice_region&intron:LOW:exon13/14:c.1652-9G>A:		rs4808708	0.1246	0.1795	2297/1742/64	0.1762							601843 [SLC5A5 (provisional) Thyroid dyshormonogenesis 1,274400];	RCV000248822.1 [benign]; RCV000354638.1 [likely benign]; 			83	550					SLC5A5 (inh=AR pLI=0.74)
chr19	18004912	18004912	T	C	het	wt	het		QUAL=3270;DP=203,116,154;MQM=59	SLC5A5	3'UTR	SLC5A5:NM_000453.2:3'UTR:MODIFIER:exon15/15:c.*226T>C:		rs12327843	0.1520	0.0000	0/0/0	0.1910							601843 [SLC5A5 (provisional) Thyroid dyshormonogenesis 1,274400];	RCV000323427.1 [likely benign]; 			7	80					SLC5A5 (inh=AR pLI=0.74)
chr19	18004959	18004959	-	TTTC	wt	wt	het		QUAL=494;DP=138,85,107;MQM=58	SLC5A5	3'UTR	SLC5A5:NM_000453.2:3'UTR:MODIFIER:exon15/15:c.*276_*277insCTTT:	AluSx1	rs201684511	0.1214	0.0000	0/0/0	0.0617							601843 [SLC5A5 (provisional) Thyroid dyshormonogenesis 1,274400];				0	10					SLC5A5 (inh=AR pLI=0.74)
chr19	18180413	18180413	C	G	het	het	het		QUAL=10016;DP=108,320,399;MQM=60	IL12RB1	missense	IL12RB1:NM_001290024.1:missense:MODERATE:exon11/18:c.1252G>C:p.Gly418Arg,IL12RB1:NM_001290023.1:missense:MODERATE:exon10/17:c.1132G>C:p.Gly378Arg,IL12RB1:NM_005535.2:missense:MODERATE:exon10/17:c.1132G>C:p.Gly378Arg		rs401502	0.2516	0.2841	5086/3432/190	0.2828	-1.8560	T	T	B,B	T	1.88	601604 [IL12RB1 (provisional) Immunodeficiency 30,614891];	RCV000333588.1 [benign]; 	CM030471 [CLASS=DP MUT=ALT PHEN="Tuberculosis susceptibility to association with" GENE=IL12RB1]; 		168	652					IL12RB1 (inh=AR pLI=0.00)
chr19	18180451	18180451	A	G	het	het	het		QUAL=12484;DP=189,367,474;MQM=59	IL12RB1	missense	IL12RB1:NM_001290024.1:missense:MODERATE:exon11/18:c.1214T>C:p.Met405Thr,IL12RB1:NM_001290023.1:missense:MODERATE:exon10/17:c.1094T>C:p.Met365Thr,IL12RB1:NM_005535.2:missense:MODERATE:exon10/17:c.1094T>C:p.Met365Thr		rs375947	0.2686	0.2894	5295/3473/331	0.2881	-0.9480	T	T	B,B	T	0.01	601604 [IL12RB1 (provisional) Immunodeficiency 30,614891];	RCV000353556.1 [benign]; 	CM030470 [CLASS=DP MUT=ALT PHEN="Tuberculosis susceptibility to association with" GENE=IL12RB1]; 	COSM4000563, COSM4000562	168	653					IL12RB1 (inh=AR pLI=0.00)
chr19	18181569	18181569	A	G	het	het	het		QUAL=5324;DP=120,168,194;MQM=59	IL12RB1	3'UTR,intron	IL12RB1:NM_153701.2:3'UTR:MODIFIER:exon10/10:c.*450T>C:,IL12RB1:NM_001290024.1:intron:MODIFIER:exon10/17:c.1142-1046T>C:,IL12RB1:NM_001290023.1:intron:MODIFIER:exon9/16:c.1022-1046T>C:,IL12RB1:NM_005535.2:intron:MODIFIER:exon9/16:c.1022-1046T>C:	AluJr	rs845380	0.6585	0.0000	0/0/0	0.6312							601604 [IL12RB1 (provisional) Immunodeficiency 30,614891];				80	63					IL12RB1 (inh=AR pLI=0.00)
chr19	18186575	18186575	G	A	het	het	het		QUAL=6615;DP=148,192,227;MQM=60	IL12RB1	synonymous	IL12RB1:NM_001290024.1:synonymous:LOW:exon8/18:c.804C>T:p.Pro268Pro,IL12RB1:NM_001290023.1:synonymous:LOW:exon7/17:c.684C>T:p.Pro228Pro,IL12RB1:NM_005535.2:synonymous:LOW:exon7/17:c.684C>T:p.Pro228Pro,IL12RB1:NM_153701.2:synonymous:LOW:exon7/10:c.684C>T:p.Pro228Pro		rs17852635	0.2298	0.2772	4994/3457/68	0.2784							601604 [IL12RB1 (provisional) Immunodeficiency 30,614891];	RCV000342695.1 [benign]; 		COSM4000566, COSM4000564, COSM4000565	168	651					IL12RB1 (inh=AR pLI=0.00)
chr19	18186618	18186618	T	C	het	het	het	pred_pathogenic;anno_pathogenic_hgmd	QUAL=7824;DP=144,218,261;MQM=59	IL12RB1	missense	IL12RB1:NM_001290024.1:missense:MODERATE:exon8/18:c.761A>G:p.Gln254Arg,IL12RB1:NM_001290023.1:missense:MODERATE:exon7/17:c.641A>G:p.Gln214Arg,IL12RB1:NM_005535.2:missense:MODERATE:exon7/17:c.641A>G:p.Gln214Arg,IL12RB1:NM_153701.2:missense:MODERATE:exon7/10:c.641A>G:p.Gln214Arg		rs11575934	0.2294	0.2771	4992/3459/64	0.2732	-0.2090	T,.	T	B,B,B	T,D	0.01	601604 [IL12RB1 (provisional) Immunodeficiency 30,614891];	RCV000395252.1 [benign]; 	CM984025 [CLASS=DM? MUT=ALT PHEN="Mycobacterial infection" GENE=IL12RB1]; 	COSM4131454, COSM4131452, COSM4131453	167	651	2	[2] old entry - no details available			IL12RB1 (inh=AR pLI=0.00)
chr19	18191664	18191664	C	G	het	het	het		QUAL=5030;DP=131,159,194;MQM=59	IL12RB1	synonymous	IL12RB1:NM_001290024.1:synonymous:LOW:exon5/18:c.507G>C:p.Val169Val,IL12RB1:NM_001290023.1:synonymous:LOW:exon4/17:c.387G>C:p.Val129Val,IL12RB1:NM_005535.2:synonymous:LOW:exon4/17:c.387G>C:p.Val129Val,IL12RB1:NM_153701.2:synonymous:LOW:exon4/10:c.387G>C:p.Val129Val		rs11086087	0.1300	0.1185	998/494/11	0.1186							601604 [IL12RB1 (provisional) Immunodeficiency 30,614891];	RCV000339160.1 [benign]; 		COSM4000567, COSM4000569, COSM4000568	31	312					IL12RB1 (inh=AR pLI=0.00)
chr19	33878071	33878071	-	TAAT	wt	het	het		QUAL=3453;DP=413,163,218;MQM=60	PEPD	3'UTR	PEPD:NM_000285.3:3'UTR:MODIFIER:exon15/15:c.*175_*178dupATTA:,PEPD:NM_001166056.1:3'UTR:MODIFIER:exon13/13:c.*175_*178dupATTA:,PEPD:NM_001166057.1:3'UTR:MODIFIER:exon13/13:c.*175_*178dupATTA:		rs79486519	0.0883	0.0000	0/0/0	0.1375							613230 [PEPD (confirmed) Prolidase deficiency,170100];	RCV000403368.1 [benign]; 			10	57					PEPD (inh=AR pLI=0.01)
chr19	33882222	33882222	G	A	het	het	wt		QUAL=900;DP=34,52,79;MQM=60	PEPD	synonymous	PEPD:NM_000285.3:synonymous:LOW:exon13/15:c.1131C>T:p.His377His,PEPD:NM_001166056.1:synonymous:LOW:exon11/13:c.1008C>T:p.His336His,PEPD:NM_001166057.1:synonymous:LOW:exon11/13:c.939C>T:p.His313His		rs17569	0.0984	0.1484	1115/692/3	0.1307							613230 [PEPD (confirmed) Prolidase deficiency,170100];	RCV000285859.1 [benign]; 			22	391					PEPD (inh=AR pLI=0.01)
chr19	33953912	33953912	A	G	het	het	wt		QUAL=8399;DP=301,313,436;MQM=60	PEPD	synonymous,intron	PEPD:NM_000285.3:synonymous:LOW:exon9/15:c.660T>C:p.Tyr220Tyr,PEPD:NM_001166057.1:synonymous:LOW:exon7/13:c.468T>C:p.Tyr156Tyr,PEPD:NM_001166056.1:intron:MODIFIER:exon7/12:c.548+15040T>C:		rs3745969	0.0298	0.0378	159/51/1	0.0375							613230 [PEPD (confirmed) Prolidase deficiency,170100];	RCV000376172.1 [likely benign]; 			4	88					PEPD (inh=AR pLI=0.01)
chr19	34872382	34872382	G	A	het	wt	het		QUAL=9051;DP=241,451,560;MQM=60	GPI	synonymous	GPI:NM_001289789.1:synonymous:LOW:exon10/19:c.879G>A:p.Lys293Lys,GPI:NM_001184722.1:synonymous:LOW:exon9/18:c.795G>A:p.Lys265Lys,GPI:NM_001329909.1:synonymous:LOW:exon10/19:c.762G>A:p.Lys254Lys,GPI:NM_001329910.1:synonymous:LOW:exon10/19:c.762G>A:p.Lys254Lys,GPI:NM_000175.4:synonymous:LOW:exon9/18:c.762G>A:p.Lys254Lys,GPI:NM_001289790.2:synonymous:LOW:exon8/17:c.678G>A:p.Lys226Lys,GPI:NM_001329911.1:synonymous:LOW:exon9/18:c.762G>A:p.Lys254Lys		rs1864139	0.1200	0.0806	700/126/261	0.0746							172400 [GPI (confirmed) Hemolytic anemia,nonspherocytic,due to glucose phosphate isomerase deficiency,613470];				15	241					GPI (inh=AR pLI=0.00)
chr19	34891482	34891482	C	G	het	hom	het		QUAL=32356;DP=459,548,717;MQM=60	GPI	3'UTR	GPI:NM_001289789.1:3'UTR:MODIFIER:exon19/19:c.*541C>G:,GPI:NM_001184722.1:3'UTR:MODIFIER:exon18/18:c.*541C>G:,GPI:NM_001329909.1:3'UTR:MODIFIER:exon19/19:c.*541C>G:,GPI:NM_001329910.1:3'UTR:MODIFIER:exon19/19:c.*541C>G:,GPI:NM_000175.4:3'UTR:MODIFIER:exon18/18:c.*541C>G:,GPI:NM_001289790.2:3'UTR:MODIFIER:exon17/17:c.*541C>G:,GPI:NM_001329911.1:3'UTR:MODIFIER:exon18/18:c.*541C>G:		rs4619515	0.8826	0.0000	11/6/3	0.1603							172400 [GPI (confirmed) Hemolytic anemia,nonspherocytic,due to glucose phosphate isomerase deficiency,613470];				131	18					GPI (inh=AR pLI=0.00)
chr19	35524824	35524824	T	C	het	wt	het	pred_pathogenic	QUAL=7370;DP=176,267,397;MQM=60	SCN1B	missense,intron	SCN1B:NM_199037.4:missense:MODERATE:exon3/3:c.629T>C:p.Leu210Pro,SCN1B:NM_001037.4:intron:MODIFIER:exon3/5:c.448+181T>C:,SCN1B:NM_001321605.1:intron:MODIFIER:exon3/5:c.349+181T>C:		rs55742440	0.3776	0.4262	3359/1869/617	0.2947	0.0050	D	T	B	D	0.12	600235 [SCN1B (confirmed) Epilepsy,generalized,with febrile seizures plus,type 1,604233|Brugada syndrome 5,612838|Cardiac conduction defect,nonspecific,612838|Atrial fibrillation,familial,13,615377];	RCV000127905.4 [benign]; 		COSM4131651	275	737					SCN1B (inh=AR+AD pLI=0.21)
chr19	36139172	36139172	G	A	hom	het	het		QUAL=6853;DP=64,178,251;MQM=59	COX6B1	5'UTR	COX6B1:NM_001863.4:5'UTR:MODIFIER:exon1/4:c.-145G>A:		rs10420252	0.1148	0.0000	0/0/0	0.1049							124089 [COX6B1 (provisional) Mitochondrial complex IV deficiency,220110];	RCV000269405.1 [likely benign]; 			4	42					COX6B1 (inh=AR pLI=0.08)
chr19	36316710	36316710	T	C	hom	hom	het		QUAL=14464;DP=225,147,196;MQM=60	NPHS1	3'UTR	NPHS1:NM_004646.3:3'UTR:MODIFIER:exon29/29:c.*706A>G:		rs80296922	0.0162	0.0000	0/0/0	0.0267							602716 [NPHS1 (provisional) Nephrotic syndrome,type 1,256300];	RCV000385786.1 [uncertain significance]; 			2	21					NPHS1 (inh=AR pLI=0.00)
chr19	36317556	36317556	C	A	hom	hom	het		QUAL=18795;DP=240,266,275;MQM=60	NPHS1	splice_region&intron	NPHS1:NM_004646.3:splice_region&intron:LOW:exon28/28:c.3595-9G>T:		rs77309273	0.0198	0.0407	148/96/1	0.0397							602716 [NPHS1 (provisional) Nephrotic syndrome,type 1,256300];	RCV000252812.1 [benign]; RCV000309915.1 [likely benign]; 			5	119					NPHS1 (inh=AR pLI=0.00)
chr19	36322270	36322270	C	T	hom	hom	hom		QUAL=42098;DP=291,469,611;MQM=59	NPHS1	sequence_feature,synonymous	NPHS1:NM_004646.3:sequence_feature:MODERATE:exon26/29:c.3315G>A:,NPHS1:NM_004646.3:synonymous:LOW:exon26/29:c.3315G>A:p.Ser1105Ser		rs2071327	0.3676	0.3923	10277/5006/51	0.3812							602716 [NPHS1 (provisional) Nephrotic syndrome,type 1,256300];	RCV000246751.1 [benign]; RCV000361802.1 [likely benign]; 			209	694					NPHS1 (inh=AR pLI=0.00)
chr19	36339247	36339247	C	T	wt	wt	het	pred_pathogenic;anno_pathogenic_hgmd	QUAL=5248;DP=295,314,458;MQM=60	NPHS1	missense	NPHS1:NM_004646.3:missense:MODERATE:exon10/29:c.1223G>A:p.Arg408Gln		rs33950747	0.0206	0.0473	185/126/0	0.0472	5.5060	T,T	T	D	T,T	32.00	602716 [NPHS1 (provisional) Nephrotic syndrome,type 1,256300];	RCV000251573.1 [benign]; RCV000277714.1 [likely benign]; 	CM990958 [CLASS=DM? MUT=ALT PHEN="Congenital nephrotic syndrome Finnish type" GENE=NPHS1]; 		3	122					NPHS1 (inh=AR pLI=0.00)
chr19	36342212	36342212	C	T	het	hom	wt	pred_pathogenic	QUAL=8700;DP=296,170,268;MQM=60	NPHS1	missense	NPHS1:NM_004646.3:missense:MODERATE:exon3/29:c.349G>A:p.Glu117Lys		rs3814995	0.2919	0.3148	6569/2984/40	0.3109	2.5550	T,T	T	D	T,T	26.60	602716 [NPHS1 (provisional) Nephrotic syndrome,type 1,256300];	RCV000249474.1 [benign]; RCV000364963.1 [likely benign]; 		COSM3756680	135	615					NPHS1 (inh=AR pLI=0.00)
chr19	36487146	36487146	A	G	het	wt	het		QUAL=3772;DP=171,106,132;MQM=60	SDHAF1	3'UTR	SDHAF1:NM_001042631.2:3'UTR:MODIFIER:exon1/1:c.*622A>G:		rs7925	0.0948	0.0000	0/0/0	0.1207							612848 [SDHAF1 (provisional) Mitochondrial complex II deficiency,252011];	RCV000261418.1 [likely benign]; 			15	46					SDHAF1 (inh=AR pLI=0.11)
chr19	36549690	36549690	C	T	wt	het	wt		QUAL=2362;DP=211,196,239;MQM=60	WDR62	synonymous	WDR62:NM_001083961.1:synonymous:LOW:exon2/32:c.186C>T:p.Leu62Leu,WDR62:NM_173636.4:synonymous:LOW:exon2/32:c.186C>T:p.Leu62Leu		rs11538454	0.1256	0.1795	2083/1400/11	0.1748							613583 [WDR62 (confirmed) Microcephaly 2,primary,autosomal recessive,with or without cortical malformations,604317];	RCV000147926.1 [benign]; RCV000147927.3 [benign]; RCV000321480.1 [likely benign]; 		COSM148599	66	482					WDR62 (inh=AR pLI=0.00)
chr19	36575645	36575645	G	A	wt	het	wt		QUAL=2075;DP=173,200,301;MQM=60	WDR62	splice_region&synonymous	WDR62:NM_001083961.1:splice_region&synonymous:LOW:exon12/32:c.1641G>A:p.Thr547Thr,WDR62:NM_173636.4:splice_region&synonymous:LOW:exon12/32:c.1641G>A:p.Thr547Thr		rs2301734	0.1250	0.1789	2120/1426/12	0.1761							613583 [WDR62 (confirmed) Microcephaly 2,primary,autosomal recessive,with or without cortical malformations,604317];	RCV000147918.3 [benign]; RCV000364762.1 [likely benign]; RCV000174279.2 [other]; 		COSM148600	65	481					WDR62 (inh=AR pLI=0.00)
chr19	36583651	36583651	G	A	het	wt	het		QUAL=8944;DP=267,294,429;MQM=59	WDR62	synonymous	WDR62:NM_001083961.1:synonymous:LOW:exon19/32:c.2271G>A:p.Leu757Leu,WDR62:NM_173636.4:synonymous:LOW:exon19/32:c.2271G>A:p.Leu757Leu		rs61494900	0.1228	0.1064	880/422/273	0.1051							613583 [WDR62 (confirmed) Microcephaly 2,primary,autosomal recessive,with or without cortical malformations,604317];	RCV000147931.2 [benign]; RCV000337058.1 [likely benign]; 			42	330					WDR62 (inh=AR pLI=0.00)
chr19	36590329	36590329	T	C	hom	het	hom		QUAL=11753;DP=109,184,216;MQM=59	WDR62	missense	WDR62:NM_001083961.1:missense:MODERATE:exon22/32:c.2549T>C:p.Leu850Ser,WDR62:NM_173636.4:missense:MODERATE:exon22/32:c.2549T>C:p.Leu850Ser		rs2285745	0.6542	0.6426	24832/13944/2641	0.6157	0.7020	T,T	T	B,B	T,T	1.48	613583 [WDR62 (confirmed) Microcephaly 2,primary,autosomal recessive,with or without cortical malformations,604317];	RCV000147938.2 [benign]; RCV000407227.1 [likely benign]; 		COSM4131728	645	706					WDR62 (inh=AR pLI=0.00)
chr19	36594063	36594063	C	T	het	wt	het		QUAL=6694;DP=217,201,307;MQM=59	WDR62	synonymous	WDR62:NM_001083961.1:synonymous:LOW:exon29/32:c.3468C>T:p.Leu1156Leu,WDR62:NM_173636.4:synonymous:LOW:exon29/32:c.3453C>T:p.Leu1151Leu		rs17851502	0.1212	0.1060	860/422/257	0.1044							613583 [WDR62 (confirmed) Microcephaly 2,primary,autosomal recessive,with or without cortical malformations,604317];	RCV000147957.2 [benign]; RCV000372454.1 [likely benign]; 			42	329					WDR62 (inh=AR pLI=0.00)
chr19	36594659	36594659	A	T	hom	het	het		QUAL=15292;DP=232,285,347;MQM=59	WDR62	missense	WDR62:NM_001083961.1:missense:MODERATE:exon30/32:c.3929A>T:p.Gln1310Leu,WDR62:NM_173636.4:missense:MODERATE:exon30/32:c.3914A>T:p.Gln1305Leu		rs2074435	0.7296	0.6536	26222/12268/3229	0.6479	0.5110	T,T	T	B,B	T,T	1.71	613583 [WDR62 (confirmed) Microcephaly 2,primary,autosomal recessive,with or without cortical malformations,604317];	RCV000079454.6 [benign]; RCV000403416.1 [benign]; 		COSM3756682	612	722					WDR62 (inh=AR pLI=0.00)
chr19	36595436	36595436	A	C	hom	hom	het		QUAL=2150;DP=33,25,46;MQM=59	WDR62	missense	WDR62:NM_001083961.1:missense:MODERATE:exon31/32:c.4170A>C:p.Leu1390Phe,WDR62:NM_173636.4:missense:MODERATE:exon31/32:c.4155A>C:p.Leu1385Phe		rs1008328	0.7163	0.7428	33744/19823/2495	0.7322	0.3220	T,T	T	B,B	T,T	1.35	613583 [WDR62 (confirmed) Microcephaly 2,primary,autosomal recessive,with or without cortical malformations,604317];	RCV000147972.5 [benign]; RCV000353726.1 [benign]; 		COSM1129883	915	558					WDR62 (inh=AR pLI=0.00)
chr19	38935280	38935280	A	G	het	wt	het		QUAL=5140;DP=143,170,238;MQM=59	RYR1	synonymous	RYR1:NM_000540.2:synonymous:LOW:exon7/106:c.594A>G:p.Leu198Leu,RYR1:NM_001042723.1:synonymous:LOW:exon7/105:c.594A>G:p.Leu198Leu		rs2229139	0.5433	0.6074	22424/13822/1384	0.5922							180901 [RYR1 (confirmed) Malignant hyperthermia susceptibility 1,145600|Central core disease,117000|Minicore myopathy with external ophthalmoplegia,255320|Neuromuscular disease,congenital,with uniform type 1 fiber,117000|King-Denborough syndrome,145600];	RCV000079154.8 [other]; RCV000119644.1 [not provided]; RCV000259980.1 [benign]; RCV000277554.1 [benign]; RCV000313910.1 [benign]; RCV000354818.1 [benign]; 			622	708					RYR1 (inh=AR+AD pLI=0.00)
chr19	38939408	38939408	T	C	het	het	hom		QUAL=10388;DP=233,191,201;MQM=59	RYR1	synonymous	RYR1:NM_000540.2:synonymous:LOW:exon11/106:c.1077T>C:p.Ala359Ala,RYR1:NM_001042723.1:synonymous:LOW:exon11/105:c.1077T>C:p.Ala359Ala		rs10406027	0.9040	0.8844	47713/26148/4496	0.8600							180901 [RYR1 (confirmed) Malignant hyperthermia susceptibility 1,145600|Central core disease,117000|Minicore myopathy with external ophthalmoplegia,255320|Neuromuscular disease,congenital,with uniform type 1 fiber,117000|King-Denborough syndrome,145600];	RCV000079119.8 [benign]; RCV000119418.1 [not provided]; RCV000293044.1 [benign]; RCV000349685.1 [benign]; RCV000384950.1 [benign]; RCV000387851.1 [benign]; 		COSM4131781	1203	356					RYR1 (inh=AR+AD pLI=0.00)
chr19	38946182	38946182	G	A	het	het	hom		QUAL=22412;DP=281,346,484;MQM=59	RYR1	synonymous	RYR1:NM_000540.2:synonymous:LOW:exon15/106:c.1668G>A:p.Ser556Ser,RYR1:NM_001042723.1:synonymous:LOW:exon15/105:c.1668G>A:p.Ser556Ser		rs2288888	0.5713	0.6366	25034/15457/1561	0.6226							180901 [RYR1 (confirmed) Malignant hyperthermia susceptibility 1,145600|Central core disease,117000|Minicore myopathy with external ophthalmoplegia,255320|Neuromuscular disease,congenital,with uniform type 1 fiber,117000|King-Denborough syndrome,145600];	RCV000079135.7 [benign]; RCV000119582.1 [not provided]; RCV000283069.1 [benign]; RCV000286535.1 [benign]; RCV000340367.1 [benign]; RCV000390356.1 [benign]; 			696	689					RYR1 (inh=AR+AD pLI=0.00)
chr19	38949904	38949904	C	T	het	het	hom		QUAL=10920;DP=218,145,194;MQM=59	RYR1	synonymous	RYR1:NM_000540.2:synonymous:LOW:exon19/106:c.2286C>T:p.Pro762Pro,RYR1:NM_001042723.1:synonymous:LOW:exon19/105:c.2286C>T:p.Pro762Pro		rs3745847	0.5541	0.6211	23949/14881/1456	0.6179							180901 [RYR1 (confirmed) Malignant hyperthermia susceptibility 1,145600|Central core disease,117000|Minicore myopathy with external ophthalmoplegia,255320|Neuromuscular disease,congenital,with uniform type 1 fiber,117000|King-Denborough syndrome,145600];	RCV000079136.7 [benign]; RCV000119595.1 [not provided]; RCV000267870.1 [benign]; RCV000302784.1 [benign]; RCV000325270.1 [benign]; RCV000359922.1 [benign]; 		COSM4131782	667	687					RYR1 (inh=AR+AD pLI=0.00)
chr19	38956726	38956726	C	T	wt	wt	het	anno_pathogenic_hgmd	QUAL=2575;DP=104,132,180;MQM=60	RYR1	splice_region&intron	RYR1:NM_000540.2:splice_region&intron:LOW:exon23/105:c.2871-5C>T:,RYR1:NM_001042723.1:splice_region&intron:LOW:exon23/104:c.2871-5C>T:		rs45585535	0.0148	0.0448	72/44/0	0.0269							180901 [RYR1 (confirmed) Malignant hyperthermia susceptibility 1,145600|Central core disease,117000|Minicore myopathy with external ophthalmoplegia,255320|Neuromuscular disease,congenital,with uniform type 1 fiber,117000|King-Denborough syndrome,145600];	RCV000079137.6 [benign]; RCV000282057.1 [benign]; RCV000337065.1 [benign]; RCV000401147.1 [benign]; RCV000402108.1 [benign]; 	CS105864 [CLASS=DM? MUT=ALT PHEN="Myopathy congenital" GENE=RYR1]; 		5	100	2	[2] old entry - no details available			RYR1 (inh=AR+AD pLI=0.00)
chr19	38956803	38956803	G	A	wt	het	wt		QUAL=3070;DP=254,242,318;MQM=60	RYR1	synonymous	RYR1:NM_000540.2:synonymous:LOW:exon24/106:c.2943G>A:p.Thr981Thr,RYR1:NM_001042723.1:synonymous:LOW:exon24/105:c.2943G>A:p.Thr981Thr		rs2228069	0.5455	0.5962	20947/12574/1606	0.5680							180901 [RYR1 (confirmed) Malignant hyperthermia susceptibility 1,145600|Central core disease,117000|Minicore myopathy with external ophthalmoplegia,255320|Neuromuscular disease,congenital,with uniform type 1 fiber,117000|King-Denborough syndrome,145600];	RCV000079138.7 [benign]; RCV000119602.1 [not provided]; RCV000264161.1 [benign]; RCV000267837.1 [benign]; RCV000322762.1 [benign]; RCV000377343.1 [benign]; RCV000119603.1 [not provided]; 		COSM3756752	629	700					RYR1 (inh=AR+AD pLI=0.00)
chr19	38956839	38956839	C	T	wt	wt	het		QUAL=5007;DP=294,274,392;MQM=60	RYR1	synonymous	RYR1:NM_000540.2:synonymous:LOW:exon24/106:c.2979C>T:p.Asn993Asn,RYR1:NM_001042723.1:synonymous:LOW:exon24/105:c.2979C>T:p.Asn993Asn		rs2228070	0.2440	0.2410	3828/1800/47	0.2359							180901 [RYR1 (confirmed) Malignant hyperthermia susceptibility 1,145600|Central core disease,117000|Minicore myopathy with external ophthalmoplegia,255320|Neuromuscular disease,congenital,with uniform type 1 fiber,117000|King-Denborough syndrome,145600];	RCV000079139.7 [benign]; RCV000119604.1 [not provided]; RCV000279466.1 [benign]; RCV000319352.1 [benign]; RCV000334468.1 [benign]; RCV000373768.1 [benign]; 		COSM3756753	77	523					RYR1 (inh=AR+AD pLI=0.00)
chr19	38959680	38959680	C	T	hom	het	hom		QUAL=29070;DP=199,451,528;MQM=60	RYR1	synonymous	RYR1:NM_000540.2:synonymous:LOW:exon26/106:c.3456C>T:p.Ile1152Ile,RYR1:NM_001042723.1:synonymous:LOW:exon26/105:c.3456C>T:p.Ile1152Ile		rs11083462	0.4493	0.3956	9943/4353/1022	0.3855							180901 [RYR1 (confirmed) Malignant hyperthermia susceptibility 1,145600|Central core disease,117000|Minicore myopathy with external ophthalmoplegia,255320|Neuromuscular disease,congenital,with uniform type 1 fiber,117000|King-Denborough syndrome,145600];	RCV000079140.7 [benign]; RCV000119611.1 [not provided]; RCV000268115.1 [benign]; RCV000269655.1 [benign]; RCV000327094.1 [benign]; RCV000360884.1 [benign]; 		COSM148605	255	688					RYR1 (inh=AR+AD pLI=0.00)
chr19	38965952	38965952	T	C	het	het	wt		QUAL=2738;DP=111,137,175;MQM=60	RYR1	splice_region&intron	RYR1:NM_000540.2:splice_region&intron:LOW:exon28/105:c.4161-6T>C:,RYR1:NM_001042723.1:splice_region&intron:LOW:exon28/104:c.4161-6T>C:		rs55845760	0.2171	0.2427	860/188/418	0.1177							180901 [RYR1 (confirmed) Malignant hyperthermia susceptibility 1,145600|Central core disease,117000|Minicore myopathy with external ophthalmoplegia,255320|Neuromuscular disease,congenital,with uniform type 1 fiber,117000|King-Denborough syndrome,145600];	RCV000079145.6 [benign]; RCV000264083.1 [benign]; RCV000281857.1 [benign]; RCV000321657.1 [benign]; RCV000373955.1 [benign]; 			43	363					RYR1 (inh=AR+AD pLI=0.00)
chr19	38976655	38976655	C	T	wt	het	wt	pred_pathogenic	QUAL=1397;DP=69,158,216;MQM=60	RYR1	missense	RYR1:NM_000540.2:missense:MODERATE:exon34/106:c.5360C>T:p.Pro1787Leu,RYR1:NM_001042723.1:missense:MODERATE:exon34/105:c.5360C>T:p.Pro1787Leu		rs34934920	0.0170	0.0196	46/23/0	0.0194	0.7450	T,T,T	T	B,B	T,T,T	22.70	180901 [RYR1 (confirmed) Malignant hyperthermia susceptibility 1,145600|Central core disease,117000|Minicore myopathy with external ophthalmoplegia,255320|Neuromuscular disease,congenital,with uniform type 1 fiber,117000|King-Denborough syndrome,145600];	RCV000119638.1 [not provided]; RCV000147431.2 [benign]; RCV000203058.1 [benign]; RCV000210010.1 [benign]; RCV000282227.1 [likely benign]; RCV000348925.1 [likely benign]; RCV000374303.1 [likely benign]; RCV000387436.1 [likely benign]; 			1	65					RYR1 (inh=AR+AD pLI=0.00)
chr19	38981284	38981284	A	G	het	hom	wt		QUAL=12334;DP=284,251,251;MQM=60	RYR1	synonymous	RYR1:NM_000540.2:synonymous:LOW:exon37/106:c.6039A>G:p.Lys2013Lys,RYR1:NM_001042723.1:synonymous:LOW:exon37/105:c.6039A>G:p.Lys2013Lys		rs2228068	0.0751	0.0919	695/321/6	0.0894							180901 [RYR1 (confirmed) Malignant hyperthermia susceptibility 1,145600|Central core disease,117000|Minicore myopathy with external ophthalmoplegia,255320|Neuromuscular disease,congenital,with uniform type 1 fiber,117000|King-Denborough syndrome,145600];	RCV000079155.7 [benign]; RCV000119646.1 [not provided]; RCV000266290.1 [benign]; RCV000310744.1 [benign]; RCV000323764.1 [benign]; RCV000358631.1 [benign]; 		COSM4131783	31	306					RYR1 (inh=AR+AD pLI=0.00)
chr19	38983180	38983180	G	T	het	hom	wt	pred_pathogenic	QUAL=7646;DP=206,190,231;MQM=59	RYR1	missense	RYR1:NM_000540.2:missense:MODERATE:exon38/106:c.6178G>T:p.Gly2060Cys,RYR1:NM_001042723.1:missense:MODERATE:exon38/105:c.6178G>T:p.Gly2060Cys		rs35364374	0.0549	0.0694	447/176/1	0.0670	0.6150	T,T,T	T	P,B	T,T,T	21.20	180901 [RYR1 (confirmed) Malignant hyperthermia susceptibility 1,145600|Central core disease,117000|Minicore myopathy with external ophthalmoplegia,255320|Neuromuscular disease,congenital,with uniform type 1 fiber,117000|King-Denborough syndrome,145600];	RCV000056058.2 [benign]; RCV000079156.7 [benign]; RCV000119647.1 [not provided]; RCV000209979.1 [benign]; RCV000259584.1 [benign]; RCV000299979.1 [benign]; RCV000395150.1 [benign]; 			22	229					RYR1 (inh=AR+AD pLI=0.00)
chr19	38990336	38990336	C	T	wt	wt	het		QUAL=2382;DP=130,111,192;MQM=60	RYR1	synonymous	RYR1:NM_000540.2:synonymous:LOW:exon44/106:c.7089C>T:p.Cys2363Cys,RYR1:NM_001042723.1:synonymous:LOW:exon44/105:c.7089C>T:p.Cys2363Cys		rs2228071	0.0845	0.0719	309/130/18	0.0662							180901 [RYR1 (confirmed) Malignant hyperthermia susceptibility 1,145600|Central core disease,117000|Minicore myopathy with external ophthalmoplegia,255320|Neuromuscular disease,congenital,with uniform type 1 fiber,117000|King-Denborough syndrome,145600];	RCV000079161.6 [benign]; RCV000119684.1 [not provided]; RCV000303882.1 [benign]; RCV000341260.1 [benign]; RCV000365420.1 [benign]; RCV000393391.1 [benign]; 		COSM3756754	11	193					RYR1 (inh=AR+AD pLI=0.00)
chr19	38990345	38990345	C	T	wt	wt	het		QUAL=2552;DP=143,121,195;MQM=60	RYR1	synonymous	RYR1:NM_000540.2:synonymous:LOW:exon44/106:c.7098C>T:p.Pro2366Pro,RYR1:NM_001042723.1:synonymous:LOW:exon44/105:c.7098C>T:p.Pro2366Pro		rs2229147	0.1218	0.0835	454/130/158	0.0764							180901 [RYR1 (confirmed) Malignant hyperthermia susceptibility 1,145600|Central core disease,117000|Minicore myopathy with external ophthalmoplegia,255320|Neuromuscular disease,congenital,with uniform type 1 fiber,117000|King-Denborough syndrome,145600];	RCV000079162.6 [benign]; RCV000119687.1 [not provided]; RCV000273264.1 [benign]; RCV000276659.1 [benign]; RCV000307181.1 [benign]; RCV000364149.1 [benign]; 		COSM3756755	11	195					RYR1 (inh=AR+AD pLI=0.00)
chr19	38991516	38991516	G	A	het	wt	het		QUAL=9443;DP=230,310,458;MQM=59	RYR1	synonymous	RYR1:NM_000540.2:synonymous:LOW:exon47/106:c.7500G>A:p.Ala2500Ala,RYR1:NM_001042723.1:synonymous:LOW:exon47/105:c.7500G>A:p.Ala2500Ala		rs2228072	0.1508	0.1140	937/252/66	0.1115							180901 [RYR1 (confirmed) Malignant hyperthermia susceptibility 1,145600|Central core disease,117000|Minicore myopathy with external ophthalmoplegia,255320|Neuromuscular disease,congenital,with uniform type 1 fiber,117000|King-Denborough syndrome,145600];	RCV000079165.7 [benign]; RCV000300125.1 [benign]; RCV000349039.1 [benign]; RCV000357373.1 [benign]; RCV000403681.1 [benign]; RCV000119716.1 [not provided]; 			20	298					RYR1 (inh=AR+AD pLI=0.00)
chr19	38991543	38991543	G	A	het	wt	het		QUAL=10854;DP=297,342,509;MQM=59	RYR1	synonymous	RYR1:NM_000540.2:synonymous:LOW:exon47/106:c.7527G>A:p.Val2509Val,RYR1:NM_001042723.1:synonymous:LOW:exon47/105:c.7527G>A:p.Val2509Val		rs2071088	0.1360	0.1116	913/253/41	0.1087							180901 [RYR1 (confirmed) Malignant hyperthermia susceptibility 1,145600|Central core disease,117000|Minicore myopathy with external ophthalmoplegia,255320|Neuromuscular disease,congenital,with uniform type 1 fiber,117000|King-Denborough syndrome,145600];	RCV000079166.7 [benign]; RCV000119720.1 [not provided]; RCV000267498.1 [benign]; RCV000298144.1 [benign]; RCV000359902.1 [benign]; RCV000397086.1 [benign]; 			20	294					RYR1 (inh=AR+AD pLI=0.00)
chr19	38991640	38991640	C	G	wt	wt	het		QUAL=4134;DP=92,269,390;MQM=60	RYR1	splice_region&intron	RYR1:NM_000540.2:splice_region&intron:LOW:exon47/105:c.7614+10C>G:,RYR1:NM_001042723.1:splice_region&intron:LOW:exon47/104:c.7614+10C>G:		rs2960323	0.2604	0.2221	2743/902/558	0.2017							180901 [RYR1 (confirmed) Malignant hyperthermia susceptibility 1,145600|Central core disease,117000|Minicore myopathy with external ophthalmoplegia,255320|Neuromuscular disease,congenital,with uniform type 1 fiber,117000|King-Denborough syndrome,145600];	RCV000079167.7 [benign]; RCV000119723.1 [not provided]; RCV000282148.1 [benign]; RCV000293169.1 [benign]; RCV000350105.1 [benign]; RCV000374379.1 [benign]; 		COSM148608	52	463					RYR1 (inh=AR+AD pLI=0.00)
chr19	38993372	38993372	A	G	het	wt	hom	low_DP	QUAL=707;DP=13,22,26;MQM=60	RYR1	splice_region&intron	RYR1:NM_000540.2:splice_region&intron:LOW:exon48/105:c.7835+5A>G:,RYR1:NM_001042723.1:splice_region&intron:LOW:exon48/104:c.7835+5A>G:		rs1469695	0.4219	0.3366	6386/2083/965	0.3043							180901 [RYR1 (confirmed) Malignant hyperthermia susceptibility 1,145600|Central core disease,117000|Minicore myopathy with external ophthalmoplegia,255320|Neuromuscular disease,congenital,with uniform type 1 fiber,117000|King-Denborough syndrome,145600];	RCV000079170.7 [benign]; RCV000119729.1 [not provided]; RCV000274147.1 [benign]; RCV000314041.1 [benign]; RCV000370968.1 [benign]; RCV000404387.1 [benign]; 			136	637					RYR1 (inh=AR+AD pLI=0.00)
chr19	38993547	38993547	C	T	het	wt	hom		QUAL=4909;DP=164,78,107;MQM=59	RYR1	synonymous	RYR1:NM_000540.2:synonymous:LOW:exon49/106:c.7863C>T:p.His2621His,RYR1:NM_001042723.1:synonymous:LOW:exon49/105:c.7863C>T:p.His2621His		rs2229142	0.2378	0.1821	2233/752/190	0.1721							180901 [RYR1 (confirmed) Malignant hyperthermia susceptibility 1,145600|Central core disease,117000|Minicore myopathy with external ophthalmoplegia,255320|Neuromuscular disease,congenital,with uniform type 1 fiber,117000|King-Denborough syndrome,145600];	RCV000079172.7 [benign]; RCV000119732.1 [not provided]; RCV000296738.1 [benign]; RCV000350558.1 [benign]; RCV000351618.1 [benign]; RCV000390814.1 [benign]; 		COSM148609	53	452					RYR1 (inh=AR+AD pLI=0.00)
chr19	38994910	38994910	G	A	het	wt	hom		QUAL=9306;DP=263,163,195;MQM=59	RYR1	synonymous	RYR1:NM_000540.2:synonymous:LOW:exon50/106:c.7977G>A:p.Thr2659Thr,RYR1:NM_001042723.1:synonymous:LOW:exon50/105:c.7977G>A:p.Thr2659Thr		rs2229144	0.4123	0.3261	6847/2252/1130	0.3167							180901 [RYR1 (confirmed) Malignant hyperthermia susceptibility 1,145600|Central core disease,117000|Minicore myopathy with external ophthalmoplegia,255320|Neuromuscular disease,congenital,with uniform type 1 fiber,117000|King-Denborough syndrome,145600];	RCV000079174.8 [benign]; RCV000119736.1 [not provided]; RCV000271603.1 [benign]; RCV000307899.1 [benign]; RCV000312792.1 [benign]; RCV000366261.1 [benign]; 		COSM148610	135	648					RYR1 (inh=AR+AD pLI=0.00)
chr19	38995438	38995438	T	C	het	wt	hom		QUAL=9122;DP=173,184,224;MQM=59	RYR1	synonymous	RYR1:NM_000540.2:synonymous:LOW:exon51/106:c.8118T>C:p.Ile2706Ile,RYR1:NM_001042723.1:synonymous:LOW:exon51/105:c.8118T>C:p.Ile2706Ile		rs2960340	0.4151	0.3264	6973/2271/1133	0.3133							180901 [RYR1 (confirmed) Malignant hyperthermia susceptibility 1,145600|Central core disease,117000|Minicore myopathy with external ophthalmoplegia,255320|Neuromuscular disease,congenital,with uniform type 1 fiber,117000|King-Denborough syndrome,145600];	RCV000079175.7 [benign]; RCV000119738.1 [not provided]; RCV000310752.1 [benign]; RCV000346944.1 [benign]; RCV000405618.1 [benign]; RCV000406007.1 [benign]; 		COSM148611	136	649					RYR1 (inh=AR+AD pLI=0.00)
chr19	38995510	38995510	T	C	het	wt	hom		QUAL=13993;DP=319,277,317;MQM=59	RYR1	synonymous	RYR1:NM_000540.2:synonymous:LOW:exon51/106:c.8190T>C:p.Asp2730Asp,RYR1:NM_001042723.1:synonymous:LOW:exon51/105:c.8190T>C:p.Asp2730Asp		rs2915951	0.4171	0.3294	7072/2345/1136	0.3216							180901 [RYR1 (confirmed) Malignant hyperthermia susceptibility 1,145600|Central core disease,117000|Minicore myopathy with external ophthalmoplegia,255320|Neuromuscular disease,congenital,with uniform type 1 fiber,117000|King-Denborough syndrome,145600];	RCV000079176.7 [benign]; RCV000119741.1 [not provided]; RCV000276810.1 [benign]; RCV000299073.1 [benign]; RCV000311779.1 [benign]; RCV000371398.1 [benign]; 		COSM148612	138	655					RYR1 (inh=AR+AD pLI=0.00)
chr19	38995975	38995975	G	A	het	wt	hom		QUAL=4727;DP=153,76,93;MQM=60	RYR1	synonymous	RYR1:NM_000540.2:synonymous:LOW:exon53/106:c.8337G>A:p.Glu2779Glu,RYR1:NM_001042723.1:synonymous:LOW:exon53/105:c.8337G>A:p.Glu2779Glu		rs2915952	0.4060	0.3294	6270/2046/892	0.3125							180901 [RYR1 (confirmed) Malignant hyperthermia susceptibility 1,145600|Central core disease,117000|Minicore myopathy with external ophthalmoplegia,255320|Neuromuscular disease,congenital,with uniform type 1 fiber,117000|King-Denborough syndrome,145600];	RCV000079177.7 [benign]; RCV000119745.1 [not provided]; RCV000293580.1 [benign]; RCV000344459.1 [benign]; RCV000348376.1 [benign]; RCV000383245.1 [benign]; 		COSM148613	136	647					RYR1 (inh=AR+AD pLI=0.00)
chr19	38996990	38996990	T	C	het	wt	hom		QUAL=13469;DP=249,268,330;MQM=59	RYR1	synonymous	RYR1:NM_000540.2:synonymous:LOW:exon55/106:c.8589T>C:p.Ser2863Ser,RYR1:NM_001042723.1:synonymous:LOW:exon55/105:c.8589T>C:p.Ser2863Ser		rs2229146	0.4081	0.3265	6923/2338/1002	0.3139							180901 [RYR1 (confirmed) Malignant hyperthermia susceptibility 1,145600|Central core disease,117000|Minicore myopathy with external ophthalmoplegia,255320|Neuromuscular disease,congenital,with uniform type 1 fiber,117000|King-Denborough syndrome,145600];	RCV000079178.7 [benign]; RCV000119753.1 [not provided]; RCV000281789.1 [benign]; RCV000304127.1 [benign]; RCV000339193.1 [benign]; RCV000403926.1 [benign]; 		COSM148614	138	653					RYR1 (inh=AR+AD pLI=0.00)
chr19	39002725	39002725	A	G	het	wt	hom		QUAL=3647;DP=101,110,89;MQM=60	RYR1	synonymous	RYR1:NM_000540.2:synonymous:LOW:exon62/106:c.9186A>G:p.Pro3062Pro,RYR1:NM_001042723.1:synonymous:LOW:exon62/105:c.9186A>G:p.Pro3062Pro		rs2071089	0.4069	0.3251	6688/2227/977	0.3142							180901 [RYR1 (confirmed) Malignant hyperthermia susceptibility 1,145600|Central core disease,117000|Minicore myopathy with external ophthalmoplegia,255320|Neuromuscular disease,congenital,with uniform type 1 fiber,117000|King-Denborough syndrome,145600];	RCV000079184.7 [benign]; RCV000119767.1 [not provided]; RCV000293902.1 [benign]; RCV000297297.1 [benign]; RCV000351185.1 [benign]; RCV000406849.1 [benign]; 		COSM3756756	136	650					RYR1 (inh=AR+AD pLI=0.00)
chr19	39010053	39010053	C	T	het	wt	het	low_DP	QUAL=216;DP=7,7,8;MQM=60	RYR1	synonymous	RYR1:NM_000540.2:synonymous:LOW:exon67/106:c.10218C>T:p.Tyr3406Tyr,RYR1:NM_001042723.1:synonymous:LOW:exon67/105:c.10218C>T:p.Tyr3406Tyr		rs41274330	0.1022	0.1055	516/56/1	0.0688							180901 [RYR1 (confirmed) Malignant hyperthermia susceptibility 1,145600|Central core disease,117000|Minicore myopathy with external ophthalmoplegia,255320|Neuromuscular disease,congenital,with uniform type 1 fiber,117000|King-Denborough syndrome,145600];	RCV000079116.7 [benign]; RCV000119405.1 [not provided]; RCV000262204.1 [benign]; RCV000301982.1 [benign]; RCV000317374.1 [benign]; RCV000356845.1 [benign]; 			18	196					RYR1 (inh=AR+AD pLI=0.00)
chr19	39018280	39018280	C	T	wt	wt	het		QUAL=334;DP=25,36,57;MQM=60	RYR1	splice_region&intron	RYR1:NM_000540.2:splice_region&intron:LOW:exon72/105:c.10687-7C>T:,RYR1:NM_001042723.1:splice_region&intron:LOW:exon71/104:c.10672-7C>T:		rs2960354	0.1242	0.0729	585/116/391	0.0686							180901 [RYR1 (confirmed) Malignant hyperthermia susceptibility 1,145600|Central core disease,117000|Minicore myopathy with external ophthalmoplegia,255320|Neuromuscular disease,congenital,with uniform type 1 fiber,117000|King-Denborough syndrome,145600];	RCV000147400.1 [uncertain significance]; RCV000079118.8 [other]; RCV000119416.1 [not provided]; RCV000268917.1 [benign]; RCV000308788.1 [benign]; RCV000324000.1 [benign]; RCV000363502.1 [benign]; 			15	181					RYR1 (inh=AR+AD pLI=0.00)
chr19	39061258	39061258	C	G	wt	wt	het		QUAL=1238;DP=157,104,112;MQM=60	RYR1	synonymous	RYR1:NM_000540.2:synonymous:LOW:exon94/106:c.13671C>G:p.Ser4557Ser,RYR1:NM_001042723.1:synonymous:LOW:exon93/105:c.13656C>G:p.Ser4552Ser		rs35959206	0.0335	0.0460	172/100/0	0.0437							180901 [RYR1 (confirmed) Malignant hyperthermia susceptibility 1,145600|Central core disease,117000|Minicore myopathy with external ophthalmoplegia,255320|Neuromuscular disease,congenital,with uniform type 1 fiber,117000|King-Denborough syndrome,145600];	RCV000079130.6 [benign]; RCV000119482.1 [not provided]; RCV000277839.1 [benign]; RCV000313093.1 [benign]; RCV000369977.1 [benign]; RCV000391147.1 [benign]; 		COSM3756759	12	173					RYR1 (inh=AR+AD pLI=0.00)
chr19	40900865	40900865	C	T	hom	hom	hom		QUAL=12699;DP=116,125,181;MQM=59	PRX	missense,3'UTR	PRX:NM_181882.2:missense:MODERATE:exon7/7:c.3394G>A:p.Gly1132Arg,PRX:NM_020956.2:3'UTR:MODIFIER:exon6/6:c.*3599G>A:		rs268674	0.9655	0.9469	54288/29495/5083	0.9253	-0.1040	T,T	T	B	T	2.77	605725 [PRX (provisional) Dejerine-Sottas disease,145900|Charcot-Marie-Tooth disease,type 4F,614895];	RCV000118080.3 [other]; RCV000293783.1 [benign]; 		COSM3756794	1331	220					PRX (inh=AR+AD pLI=0.00)
chr19	40901011	40901011	G	C	wt	het	wt	pred_pathogenic	QUAL=1362;DP=107,122,206;MQM=60	PRX	missense,3'UTR	PRX:NM_181882.2:missense:MODERATE:exon7/7:c.3248C>G:p.Pro1083Arg,PRX:NM_020956.2:3'UTR:MODIFIER:exon6/6:c.*3453C>G:		rs3745202	0.0992	0.1411	1426/1038/12	0.1405	0.4320	T	T	D	T	13.56	605725 [PRX (provisional) Dejerine-Sottas disease,145900|Charcot-Marie-Tooth disease,type 4F,614895];	RCV000118079.3 [other]; RCV000396987.1 [likely benign]; 			46	426					PRX (inh=AR+AD pLI=0.00)
chr19	40901496	40901496	T	C	wt	het	wt		QUAL=2452;DP=264,224,346;MQM=60	PRX	missense,3'UTR	PRX:NM_181882.2:missense:MODERATE:exon7/7:c.2763A>G:p.Ile921Met,PRX:NM_020956.2:3'UTR:MODIFIER:exon6/6:c.*2968A>G:		rs268673	0.2967	0.3504	7856/5118/554	0.3476	-2.7630	T,T	T	B	T	0.01	605725 [PRX (provisional) Dejerine-Sottas disease,145900|Charcot-Marie-Tooth disease,type 4F,614895];	RCV000118077.2 [likely benign]; RCV000265764.1 [benign]; 		COSM3756795	192	678					PRX (inh=AR+AD pLI=0.00)
chr19	40901604	40901604	A	G	het	hom	wt		QUAL=8452;DP=195,203,288;MQM=59	PRX	synonymous,3'UTR	PRX:NM_181882.2:synonymous:LOW:exon7/7:c.2655T>C:p.Pro885Pro,PRX:NM_020956.2:3'UTR:MODIFIER:exon6/6:c.*2860T>C:		rs268672	0.5319	0.5070	16573/8832/3336	0.5004							605725 [PRX (provisional) Dejerine-Sottas disease,145900|Charcot-Marie-Tooth disease,type 4F,614895];	RCV000118076.2 [likely benign]; RCV000326806.1 [benign]; 		COSM4131847	411	749					PRX (inh=AR+AD pLI=0.00)
chr19	40901614	40901614	A	G	het	hom	wt	pred_pathogenic	QUAL=8298;DP=210,202,272;MQM=59	PRX	missense,3'UTR	PRX:NM_181882.2:missense:MODERATE:exon7/7:c.2645T>C:p.Val882Ala,PRX:NM_020956.2:3'UTR:MODIFIER:exon6/6:c.*2850T>C:		rs268671	0.5319	0.5069	16557/8815/3340	0.4859	2.6800	T,T	T	B	T	0.01	605725 [PRX (provisional) Dejerine-Sottas disease,145900|Charcot-Marie-Tooth disease,type 4F,614895];	RCV000118075.2 [likely benign]; RCV000388381.1 [benign]; 		COSM4000733	409	751					PRX (inh=AR+AD pLI=0.00)
chr19	40904602	40904602	G	A	wt	het	wt		QUAL=1824;DP=76,168,214;MQM=60	PRX	synonymous	PRX:NM_181882.2:synonymous:LOW:exon6/7:c.306C>T:p.Thr102Thr,PRX:NM_020956.2:synonymous:LOW:exon6/6:c.306C>T:p.Thr102Thr		rs744389	0.1022	0.1455	1480/1046/12	0.1437							605725 [PRX (provisional) Dejerine-Sottas disease,145900|Charcot-Marie-Tooth disease,type 4F,614895];	RCV000118078.3 [other]; RCV000369236.1 [likely benign]; 		COSM4131851, COSM4131850	50	433					PRX (inh=AR+AD pLI=0.00)
chr19	41892269	41892269	C	T	hom	hom	hom		QUAL=5873;DP=56,64,71;MQM=60	TMEM91-EXOSC5	intergenic_region	TMEM91-EXOSC5:TMEM91-EXOSC5:intergenic_region:MODIFIER::n.41892269C>T:	L2b	rs3826713	0.5044	0.0000	0/0/0	0.5499							608348 [BCKDHA (confirmed) Maple syrup urine disease,type Ia,248600];				74	106					TMEM91-EXOSC5 (inh=n/a pLI=n/a)
chr19	41903220	41903220	G	A	hom	hom	hom		QUAL=29155;DP=249,293,400;MQM=60	EXOSC5	missense	EXOSC5:NM_020158.3:missense:MODERATE:exon1/6:c.14C>T:p.Thr5Met		rs10853751	0.6144	0.5954	22014/11928/3534	0.5876	-0.0950	T	T	B	T	8.76	608348 [BCKDHA (confirmed) Maple syrup urine disease,type Ia,248600];				457	518					EXOSC5 (inh=n/a pLI=0.00)
chr19	41903261	41903261	T	A	wt	wt	het		QUAL=3949;DP=95,252,377;MQM=60	EXOSC5-BCKDHA	intergenic_region	EXOSC5-BCKDHA:EXOSC5-BCKDHA:intergenic_region:MODIFIER::n.41903261T>A:		rs112381655	0.0070	0.0208	35/30/1	0.0204							608348 [BCKDHA (confirmed) Maple syrup urine disease,type Ia,248600];				0	32					EXOSC5-BCKDHA (inh=n/a pLI=n/a)
chr19	41903699	41903699	T	G	het	het	wt		QUAL=754;DP=67,26,40;MQM=60	BCKDHA	5'UTR	BCKDHA:NM_000709.3:5'UTR:MODIFIER:exon1/9:c.-34T>G:,BCKDHA:NM_001164783.1:5'UTR:MODIFIER:exon1/9:c.-34T>G:		rs45500792	0.0825	0.1172	899/589/1	0.1127							608348 [BCKDHA (confirmed) Maple syrup urine disease,type Ia,248600];	RCV000079215.5 [other]; RCV000337766.1 [likely benign]; 			9	203					BCKDHA (inh=AR pLI=0.00)
chr19	41916549	41916549	C	A	het	het	wt	pred_pathogenic	QUAL=2294;DP=67,140,178;MQM=59	BCKDHA	missense	BCKDHA:NM_000709.3:missense:MODERATE:exon2/9:c.116C>A:p.Pro39His,BCKDHA:NM_001164783.1:missense:MODERATE:exon2/9:c.116C>A:p.Pro39His		rs11549936	0.0553	0.0985	711/538/1	0.0943	-1.4150	T,T,T,T	T	B,B,B	D,D,D	2.13	608348 [BCKDHA (confirmed) Maple syrup urine disease,type Ia,248600];	RCV000079222.9 [other]; RCV000396713.1 [likely benign]; 		COSM4131898	28	373					BCKDHA (inh=AR pLI=0.00)
chr19	41920030	41920030	C	T	wt	het	wt	pred_pathogenic;anno_pathogenic_hgmd	QUAL=735;DP=147,80,106;MQM=60	BCKDHA	missense	BCKDHA:NM_000709.3:missense:MODERATE:exon4/9:c.452C>T:p.Thr151Met,BCKDHA:NM_001164783.1:missense:MODERATE:exon4/9:c.452C>T:p.Thr151Met		rs34442879	0.0042	0.0108	9/8/0	0.0100	1.7550	.,D,D,D,D,D	D,D	.,P,P,P,P	.,D,D,D,D	30.00	608348 [BCKDHA (confirmed) Maple syrup urine disease,type Ia,248600];	RCV000079243.6 [other]; RCV000295914.1 [likely benign]; 	CM021497 [CLASS=DM? MUT=ALT PHEN="Maple syrup urine disease" GENE=BCKDHA]; 	COSM3692790	0	50	1	[1] Stefanie Beck-Woedl 07.07.2014			BCKDHA (inh=AR pLI=0.00)
chr19	41928652	41928652	C	T	hom	hom	hom		QUAL=16688;DP=129,186,247;MQM=59	BCKDHA	synonymous	BCKDHA:NM_000709.3:synonymous:LOW:exon7/9:c.972C>T:p.Phe324Phe,BCKDHA:NM_001164783.1:synonymous:LOW:exon7/9:c.969C>T:p.Phe323Phe		rs284652	0.6164	0.5994	22181/12060/3531	0.5894							608348 [BCKDHA (confirmed) Maple syrup urine disease,type Ia,248600];	RCV000079266.9 [other]; RCV000284317.1 [benign]; 		COSM3933055	607	706					BCKDHA (inh=AR pLI=0.00)
chr19	41930396	41930396	A	G	hom	hom	hom		QUAL=4690;DP=74,43,52;MQM=59	BCKDHA	synonymous	BCKDHA:NM_000709.3:synonymous:LOW:exon9/9:c.1221A>G:p.Leu407Leu,BCKDHA:NM_001164783.1:synonymous:LOW:exon9/9:c.1218A>G:p.Leu406Leu		rs4674	0.6170	0.6000	22302/12132/3540	0.5924							608348 [BCKDHA (confirmed) Maple syrup urine disease,type Ia,248600];	RCV000079224.8 [other]; RCV000394945.1 [benign]; 			607	708					BCKDHA (inh=AR pLI=0.00)
chr19	44031324	44031324	C	T	wt	wt	het		QUAL=462;DP=41,22,37;MQM=60	ETHE1	synonymous,5'UTR	ETHE1:NM_014297.4:synonymous:LOW:exon1/7:c.6G>A:p.Ala2Ala,ETHE1:NM_001320867.1:synonymous:LOW:exon1/7:c.6G>A:p.Ala2Ala,ETHE1:NM_001320869.1:synonymous:LOW:exon1/5:c.6G>A:p.Ala2Ala,ETHE1:NM_001320868.1:5'UTR:MODIFIER:exon1/6:c.-215G>A:		rs3810381	0.1524	0.1907	243/88/9	0.0942							608451 [ETHE1 (provisional) Ethylmalonic encephalopathy,602473];	RCV000251048.1 [benign]; RCV000379794.1 [benign]; 		COSM3749515	48	441					ETHE1 (inh=AR pLI=0.02)
chr19	45854919	45854919	T	G	hom	het	hom	pred_pathogenic	QUAL=20147;DP=138,334,412;MQM=59	ERCC2	missense	ERCC2:NM_000400.3:missense:MODERATE:exon23/23:c.2251A>C:p.Lys751Gln		rs13181	0.2366	0.3308	7354/5029/253	0.3182	1.1980	T,T,T,T	T	B,B	T,D	10.56	126340 [ERCC2 (confirmed) Xeroderma pigmentosum,group D,278730|Trichothiodystrophy 1,photosensitive,601675|Cerebrooculofacioskeletal syndrome 2,610756];	RCV000120777.2 [benign]; RCV000282755.1 [benign]; 	CM004814 [CLASS=DFP MUT=ALT PHEN="Basal cell carcinoma reduced risk association with" GENE=ERCC2]; 	COSM4132125	654	1879					ERCC2 (inh=AR pLI=0.00)
chr19	45855524	45855524	G	A	hom	het	hom		QUAL=7015;DP=136,45,77;MQM=60	ERCC2	synonymous	ERCC2:NM_000400.3:synonymous:LOW:exon22/23:c.2133C>T:p.Asp711Asp		rs1052555	0.1823	0.2859	5793/4062/58	0.2780							126340 [ERCC2 (confirmed) Xeroderma pigmentosum,group D,278730|Trichothiodystrophy 1,photosensitive,601675|Cerebrooculofacioskeletal syndrome 2,610756];	RCV000249244.1 [benign]; RCV000334441.1 [benign]; 	CM052870 [CLASS=DP MUT=ALT PHEN="Reduced risk oligodendroglioma development association" GENE=ERCC2]; 	COSM3756953	552	1799					ERCC2 (inh=AR pLI=0.00)
chr19	45867259	45867259	C	T	hom	het	hom	pred_pathogenic	QUAL=5146;DP=45,70,99;MQM=60	ERCC2	missense	ERCC2:NM_000400.3:missense:MODERATE:exon10/23:c.934G>A:p.Asp312Asn,ERCC2:NM_001130867.1:missense:MODERATE:exon9/12:c.862G>A:p.Asp288Asn		rs1799793	0.1945	0.3788	1102/479/9	0.1892	7.1920	T,T,T,T,T	T	B,B,B	T,T,T	24.00	126340 [ERCC2 (confirmed) Xeroderma pigmentosum,group D,278730|Trichothiodystrophy 1,photosensitive,601675|Cerebrooculofacioskeletal syndrome 2,610756];	RCV000120789.2 [benign]; RCV000393523.1 [benign]; 	CM015299 [CLASS=DFP MUT=ALT PHEN="Increased response to UV association with" GENE=ERCC2]; 	COSM3749518, COSM3749519	633	1845					ERCC2 (inh=AR pLI=0.00)
chr19	45868309	45868309	T	G	hom	het	hom		QUAL=23228;DP=138,364,475;MQM=59	ERCC2	synonymous	ERCC2:NM_000400.3:synonymous:LOW:exon6/23:c.468A>C:p.Arg156Arg,ERCC2:NM_001130867.1:synonymous:LOW:exon5/12:c.396A>C:p.Arg132Arg		rs238406	0.6362	0.5898	21339/10481/3987	0.5765							126340 [ERCC2 (confirmed) Xeroderma pigmentosum,group D,278730|Trichothiodystrophy 1,photosensitive,601675|Cerebrooculofacioskeletal syndrome 2,610756];	RCV000242247.1 [benign]; RCV000323397.1 [benign]; 	CM057545 [CLASS=DP MUT=REF PHEN="Lung adenocarcinoma increased risk association with" GENE=ERCC2]; 		1366	2024					ERCC2 (inh=AR pLI=0.00)
chr19	45910672	45910672	A	G	hom	hom	het		QUAL=9194;DP=201,56,95;MQM=60	ERCC1,CD3EAP	3'UTR,intron	ERCC1:NM_001166049.1:3'UTR:MODIFIER:exon9/9:c.*2261T>C:,ERCC1:NM_001983.3:3'UTR:MODIFIER:exon10/10:c.*2261T>C:,CD3EAP:NM_001297590.1:intron:MODIFIER:exon2/2:c.170+179A>G:,CD3EAP:NM_012099.1:intron:MODIFIER:exon2/2:c.164+179A>G:	MER41D	rs1046282	0.3249	0.0000	0/0/0	0.2845							126380 [ERCC1 (confirmed) Cerebrooculofacioskeletal syndrome 4,610758];				20	80					ERCC1 (inh=AR pLI=0.00), CD3EAP (inh=n/a pLI=0.00)
chr19	45911320	45911320	A	-	hom	hom	het		QUAL=21151;DP=212,328,447;MQM=59	ERCC1,CD3EAP	3'UTR,intron	ERCC1:NM_001166049.1:3'UTR:MODIFIER:exon9/9:c.*1613delT:,ERCC1:NM_001983.3:3'UTR:MODIFIER:exon10/10:c.*1613delT:,CD3EAP:NM_001297590.1:intron:MODIFIER:exon2/2:c.171-62delA:,CD3EAP:NM_012099.1:intron:MODIFIER:exon2/2:c.165-62delA:	AluSx1	rs11314106	0.0000	0.0000	0/0/0	0.0284							126380 [ERCC1 (confirmed) Cerebrooculofacioskeletal syndrome 4,610758];				35	110					ERCC1 (inh=AR pLI=0.00), CD3EAP (inh=n/a pLI=0.00)
chr19	45912490	45912492	AAG	-	hom	hom	het		QUAL=13792;DP=178,212,233;MQM=59	CD3EAP,ERCC1	disruptive_inframe_deletion,sequence_feature,3'UTR	CD3EAP:NM_001297590.1:disruptive_inframe_deletion:MODERATE:exon3/3:c.1287_1289delGAA:p.Lys430del,CD3EAP:NM_012099.1:disruptive_inframe_deletion:MODERATE:exon3/3:c.1281_1283delGAA:p.Lys428del,CD3EAP:NM_001297590.1:sequence_feature:LOW:exon3/3:c.1270_1272delAAG:,CD3EAP:NM_012099.1:sequence_feature:LOW:exon3/3:c.1264_1266delAAG:,ERCC1:NM_001166049.1:3'UTR:MODIFIER:exon9/9:c.*441_*443delCTT:,ERCC1:NM_001983.3:3'UTR:MODIFIER:exon10/10:c.*441_*443delCTT:	(AAG)n	rs35729377;rs374686338	0.0000	0.2366	1707/1238/29	0.1949							126380 [ERCC1 (confirmed) Cerebrooculofacioskeletal syndrome 4,610758];			COSM1481223	90	485					CD3EAP (inh=n/a pLI=0.00), ERCC1 (inh=AR pLI=0.00)
chr19	45912736	45912736	C	A	hom	hom	het		QUAL=11258;DP=133,170,180;MQM=59	CD3EAP,ERCC1	missense,sequence_feature,3'UTR	CD3EAP:NM_001297590.1:missense:MODERATE:exon3/3:c.1516C>A:p.Gln506Lys,CD3EAP:NM_012099.1:missense:MODERATE:exon3/3:c.1510C>A:p.Gln504Lys,CD3EAP:NM_001297590.1:sequence_feature:LOW:exon3/3:c.1516C>A:,CD3EAP:NM_012099.1:sequence_feature:LOW:exon3/3:c.1510C>A:,ERCC1:NM_001166049.1:3'UTR:MODIFIER:exon9/9:c.*197G>T:,ERCC1:NM_001983.3:3'UTR:MODIFIER:exon10/10:c.*197G>T:	(AGC)n	rs3212986	0.2951	0.3237	4297/1703/385	0.2625	-1.3970	T	T	B,B	T	0.01	126380 [ERCC1 (confirmed) Cerebrooculofacioskeletal syndrome 4,610758];	RCV000211219.1 [drug response]; RCV000211315.1 [drug response]; RCV000211398.1 [drug response]; 	CM005461 [CLASS=DP MUT=REF PHEN="Glioma adult-onset association with" GENE=CD3EAP]; 		120	534					CD3EAP (inh=n/a pLI=0.00), ERCC1 (inh=AR pLI=0.00)
chr19	45923653	45923653	A	G	hom	hom	het		QUAL=22904;DP=179,357,456;MQM=60	ERCC1	synonymous	ERCC1:NM_202001.2:synonymous:LOW:exon3/8:c.354T>C:p.Asn118Asn,ERCC1:NM_001166049.1:synonymous:LOW:exon4/9:c.354T>C:p.Asn118Asn,ERCC1:NM_001983.3:synonymous:LOW:exon4/10:c.354T>C:p.Asn118Asn		rs11615	0.6689	0.5085	16939/4659/4049	0.4918							126380 [ERCC1 (confirmed) Cerebrooculofacioskeletal syndrome 4,610758];	RCV000211176.1 [drug response]; RCV000211179.1 [drug response]; RCV000211295.1 [drug response]; RCV000211304.1 [drug response]; RCV000211427.1 [drug response]; RCV000407425.1 [benign]; 			344	763					ERCC1 (inh=AR pLI=0.00)
chr19	45927050	45927050	G	T	wt	het	wt		QUAL=657;DP=81,60,81;MQM=60	ERCC1	5'UTR	ERCC1:NM_001166049.1:5'UTR:MODIFIER:exon1/9:c.-19C>A:,ERCC1:NM_001983.3:5'UTR:MODIFIER:exon1/10:c.-19C>A:		rs41559012	0.0058	0.0000	0/0/0	0.0103							126380 [ERCC1 (confirmed) Cerebrooculofacioskeletal syndrome 4,610758];				0	5					ERCC1 (inh=AR pLI=0.00)
chr19	45998346	45998346	C	A	hom	het	het		QUAL=13652;DP=244,208,330;MQM=59	RTN2	splice_region&intron	RTN2:NM_005619.4:splice_region&intron:LOW:exon2/10:c.79+7G>T:,RTN2:NM_206900.2:splice_region&intron:LOW:exon2/9:c.79+7G>T:		rs2298887	0.1494	0.1569	1716/873/163	0.1519							603183 [RTN2 (provisional) Spastic paraplegia 12,autosomal dominant,604805];				72	602					RTN2 (inh=AD pLI=0.64)
chr19	46031606	46031606	T	C	hom	hom	hom		QUAL=25304;DP=282,257,278;MQM=59	OPA3	3'UTR	OPA3:NM_001017989.2:3'UTR:MODIFIER:exon2/2:c.*708A>G:		rs7259834	0.9888	0.0000	0/0/0	0.8909							606580 [OPA3 (confirmed) 3-methylglutaconic aciduria,type III,258501|Optic atrophy 3 with cataract,165300];				221	9					OPA3 (inh=AR pLI=0.00)
chr19	46049982	46049982	A	G	hom	hom	hom	low_DP	QUAL=853;DP=22,7,1;MQM=60	OPA3	3'UTR,intron	OPA3:NM_025136.3:3'UTR:MODIFIER:exon2/2:c.*6790T>C:,OPA3:NM_001017989.2:intron:MODIFIER:exon1/1:c.143-17268T>C:	AluSz	rs10422253	0.7754	0.0000	0/0/0	0.7131							606580 [OPA3 (confirmed) 3-methylglutaconic aciduria,type III,258501|Optic atrophy 3 with cataract,165300];	RCV000311918.1 [benign]; RCV000401947.1 [benign]; 			126	48					OPA3 (inh=AR pLI=0.00)
chr19	46050760	46050760	T	C	het	het	het		QUAL=17543;DP=384,395,484;MQM=59	OPA3	3'UTR,intron	OPA3:NM_025136.3:3'UTR:MODIFIER:exon2/2:c.*6012A>G:,OPA3:NM_001017989.2:intron:MODIFIER:exon1/1:c.143-18046A>G:	L2b	rs11083772	0.6380	0.0000	0/0/0	0.6388							606580 [OPA3 (confirmed) 3-methylglutaconic aciduria,type III,258501|Optic atrophy 3 with cataract,165300];	RCV000344363.1 [benign]; RCV000407518.1 [benign]; 			72	70					OPA3 (inh=AR pLI=0.00)
chr19	46051915	46051915	T	A	het	hom	wt		QUAL=2467;DP=135,46,60;MQM=59	OPA3	3'UTR,intron	OPA3:NM_025136.3:3'UTR:MODIFIER:exon2/2:c.*4857A>T:,OPA3:NM_001017989.2:intron:MODIFIER:exon1/1:c.143-19201A>T:	(T)n	rs4803833	0.7610	0.0000	0/0/0	0.3638							606580 [OPA3 (confirmed) 3-methylglutaconic aciduria,type III,258501|Optic atrophy 3 with cataract,165300];	RCV000337162.1 [benign]; RCV000375401.1 [benign]; 			55	105					OPA3 (inh=AR pLI=0.00)
chr19	46051920	46051922	TTT	-	het	hom	wt		QUAL=1189;DP=101,33,37;MQM=59	OPA3	3'UTR,intron	OPA3:NM_025136.3:3'UTR:MODIFIER:exon2/2:c.*4850_*4852delAAA:,OPA3:NM_001017989.2:intron:MODIFIER:exon1/1:c.143-19208_143-19206delAAA:	(T)n	rs761676585	0.7610	0.0000	0/0/0	0.4274							606580 [OPA3 (confirmed) 3-methylglutaconic aciduria,type III,258501|Optic atrophy 3 with cataract,165300];	RCV000314705.1 [benign]; RCV000392404.1 [benign]; 			70	82					OPA3 (inh=AR pLI=0.00)
chr19	46052454	46052454	A	G	het	hom	wt		QUAL=18559;DP=392,389,530;MQM=60	OPA3	3'UTR,intron	OPA3:NM_025136.3:3'UTR:MODIFIER:exon2/2:c.*4318T>C:,OPA3:NM_001017989.2:intron:MODIFIER:exon1/1:c.143-19740T>C:		rs4802261	0.7584	0.0000	0/0/0	0.7016							606580 [OPA3 (confirmed) 3-methylglutaconic aciduria,type III,258501|Optic atrophy 3 with cataract,165300];	RCV000331372.1 [benign]; RCV000369693.1 [benign]; 			89	110					OPA3 (inh=AR pLI=0.00)
chr19	46052621	46052625	CAGGG	-	het	hom	wt		QUAL=11254;DP=178,335,403;MQM=59	OPA3	3'UTR,intron	OPA3:NM_025136.3:3'UTR:MODIFIER:exon2/2:c.*4147_*4151delCCCTG:,OPA3:NM_001017989.2:intron:MODIFIER:exon1/1:c.143-19911_143-19907delCCCTG:		rs774875450	0.7584	0.0000	0/0/0	0.6262							606580 [OPA3 (confirmed) 3-methylglutaconic aciduria,type III,258501|Optic atrophy 3 with cataract,165300];	RCV000277715.1 [benign]; RCV000325765.1 [benign]; 			90	109					OPA3 (inh=AR pLI=0.00)
chr19	46052898	46052898	C	T	het	het	wt		QUAL=4822;DP=191,187,213;MQM=55	OPA3	3'UTR,intron	OPA3:NM_025136.3:3'UTR:MODIFIER:exon2/2:c.*3874G>A:,OPA3:NM_001017989.2:intron:MODIFIER:exon1/1:c.143-20184G>A:	AluSz6	rs62109650	0.1546	0.0000	0/0/0	0.2137							606580 [OPA3 (confirmed) 3-methylglutaconic aciduria,type III,258501|Optic atrophy 3 with cataract,165300];	RCV000314945.1 [likely benign]; RCV000407934.1 [likely benign]; 			14	72					OPA3 (inh=AR pLI=0.00)
chr19	46053385	46053385	C	T	het	hom	wt	low_DP	QUAL=1792;DP=96,18,21;MQM=59	OPA3	3'UTR,intron	OPA3:NM_025136.3:3'UTR:MODIFIER:exon2/2:c.*3387G>A:,OPA3:NM_001017989.2:intron:MODIFIER:exon1/1:c.143-20671G>A:	AluSx1	rs3760844	0.7602	0.0000	0/0/0	0.6370							606580 [OPA3 (confirmed) 3-methylglutaconic aciduria,type III,258501|Optic atrophy 3 with cataract,165300];	RCV000294229.1 [benign]; RCV000386198.1 [benign]; 			89	102					OPA3 (inh=AR pLI=0.00)
chr19	46053655	46053655	-	GCT	het	hom	wt		QUAL=10780;DP=277,268,336;MQM=59	OPA3	3'UTR,intron	OPA3:NM_025136.3:3'UTR:MODIFIER:exon2/2:c.*3114_*3116dupAGC:,OPA3:NM_001017989.2:intron:MODIFIER:exon1/1:c.143-20944_143-20942dupAGC:		rs10650481;rs542311224	0.7574	0.0000	0/0/0	0.4477							606580 [OPA3 (confirmed) 3-methylglutaconic aciduria,type III,258501|Optic atrophy 3 with cataract,165300];	RCV000273210.1 [benign]; RCV000377006.1 [benign]; 			89	110					OPA3 (inh=AR pLI=0.00)
chr19	46054822	46054822	C	T	het	hom	wt		QUAL=16321;DP=477,374,424;MQM=59	OPA3	3'UTR,intron	OPA3:NM_025136.3:3'UTR:MODIFIER:exon2/2:c.*1950G>A:,OPA3:NM_001017989.2:intron:MODIFIER:exon1/1:c.143-22108G>A:	MLT1B	rs4404183	0.7568	0.0000	0/0/0	0.6967							606580 [OPA3 (confirmed) 3-methylglutaconic aciduria,type III,258501|Optic atrophy 3 with cataract,165300];	RCV000309414.1 [benign]; RCV000407759.1 [benign]; 			78	75					OPA3 (inh=AR pLI=0.00)
chr19	46055477	46055477	-	T	het	het	wt		QUAL=1647;DP=179,46,74;MQM=60	OPA3	3'UTR,intron	OPA3:NM_025136.3:3'UTR:MODIFIER:exon2/2:c.*1294dupA:,OPA3:NM_001017989.2:intron:MODIFIER:exon1/1:c.143-22764dupA:		rs74313320	0.3183	0.0000	0/0/0	0.3478							606580 [OPA3 (confirmed) 3-methylglutaconic aciduria,type III,258501|Optic atrophy 3 with cataract,165300];	RCV000313908.1 [benign]; RCV000401562.1 [benign]; 			32	104					OPA3 (inh=AR pLI=0.00)
chr19	46055786	46055786	T	-	hom	hom	wt		QUAL=1174;DP=53,52,52;MQM=59	OPA3	3'UTR,intron	OPA3:NM_025136.3:3'UTR:MODIFIER:exon2/2:c.*986delA:,OPA3:NM_001017989.2:intron:MODIFIER:exon1/1:c.143-23072delA:	AluSg4	rs377547137	0.6052	0.0000	0/0/0	0.1758							606580 [OPA3 (confirmed) 3-methylglutaconic aciduria,type III,258501|Optic atrophy 3 with cataract,165300];	RCV000351099.1 [benign]; RCV000387008.1 [benign]; 			4	124					OPA3 (inh=AR pLI=0.00)
chr19	46056134	46056134	A	T	wt	het	wt		QUAL=1075;DP=77,102,132;MQM=59	OPA3	3'UTR,intron	OPA3:NM_025136.3:3'UTR:MODIFIER:exon2/2:c.*638T>A:,OPA3:NM_001017989.2:intron:MODIFIER:exon1/1:c.143-23420T>A:	AluSz	rs150575877	0.1478	0.0000	0/0/0	0.1441							606580 [OPA3 (confirmed) 3-methylglutaconic aciduria,type III,258501|Optic atrophy 3 with cataract,165300];	RCV000268949.1 [likely benign]; RCV000365216.1 [likely benign]; 			6	59					OPA3 (inh=AR pLI=0.00)
chr19	46056620	46056620	C	T	het	hom	wt		QUAL=13551;DP=228,356,380;MQM=59	OPA3	3'UTR,intron	OPA3:NM_025136.3:3'UTR:MODIFIER:exon2/2:c.*152G>A:,OPA3:NM_001017989.2:intron:MODIFIER:exon1/1:c.143-23906G>A:		rs3826861	0.7107	0.0000	0/0/0	0.6736							606580 [OPA3 (confirmed) 3-methylglutaconic aciduria,type III,258501|Optic atrophy 3 with cataract,165300];	RCV000318662.1 [benign]; RCV000357168.1 [benign]; 			91	109					OPA3 (inh=AR pLI=0.00)
chr19	46057081	46057081	A	G	het	hom	wt		QUAL=5140;DP=135,113,162;MQM=60	OPA3	synonymous,intron	OPA3:NM_025136.3:synonymous:LOW:exon2/2:c.231T>C:p.Ala77Ala,OPA3:NM_001017989.2:intron:MODIFIER:exon1/1:c.143-24367T>C:		rs3826860	0.7670	0.7076	29591/13637/2757	0.6871							606580 [OPA3 (confirmed) 3-methylglutaconic aciduria,type III,258501|Optic atrophy 3 with cataract,165300];	RCV000020908.1 [benign]; RCV000082252.9 [other]; RCV000132683.1 [likely benign]; RCV000288721.1 [benign]; RCV000400863.1 [benign]; 		COSM439792	1352	1474	1	[1] old entry - no details available			OPA3 (inh=AR pLI=0.00)
chr19	46273463	46273507	CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG	-	wt	het	het		QUAL=2041;DP=135,72,104;MQM=59	DMPK	3'UTR	DMPK:NM_001288764.1:3'UTR:MODIFIER:exon16/16:c.*239_*283delCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG:,DMPK:NM_001288765.1:3'UTR:MODIFIER:exon13/13:c.*232_*276delCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG:,DMPK:NM_001081563.2:3'UTR:MODIFIER:exon14/14:c.*239_*283delCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG:,DMPK:NM_001081560.2:3'UTR:MODIFIER:exon15/15:c.*239_*283delCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG:,DMPK:NM_001081562.2:3'UTR:MODIFIER:exon15/15:c.*232_*276delCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG:,DMPK:NM_001288766.1:3'UTR:MODIFIER:exon13/13:c.*384_*428delCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG:,DMPK:NM_004409.4:3'UTR:MODIFIER:exon15/15:c.*239_*283delCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG:	(CAG)n	rs144131694;rs796909571	0.0000	0.0000	0/0/0	0.0979							605377 [DMPK (confirmed) Myotonic dystrophy 1,160900];				26	38					DMPK (inh=AD pLI=0.03)
chr19	46273463	46273483	CAGCAGCAGCAGCAGCAGCAG	-	wt	wt	het		QUAL=2041;DP=135,72,104;MQM=59	DMPK	3'UTR	DMPK:NM_001288764.1:3'UTR:MODIFIER:exon16/16:c.*263_*283delCTGCTGCTGCTGCTGCTGCTG:,DMPK:NM_001288765.1:3'UTR:MODIFIER:exon13/13:c.*256_*276delCTGCTGCTGCTGCTGCTGCTG:,DMPK:NM_001081563.2:3'UTR:MODIFIER:exon14/14:c.*263_*283delCTGCTGCTGCTGCTGCTGCTG:,DMPK:NM_001081560.2:3'UTR:MODIFIER:exon15/15:c.*263_*283delCTGCTGCTGCTGCTGCTGCTG:,DMPK:NM_001081562.2:3'UTR:MODIFIER:exon15/15:c.*256_*276delCTGCTGCTGCTGCTGCTGCTG:,DMPK:NM_001288766.1:3'UTR:MODIFIER:exon13/13:c.*408_*428delCTGCTGCTGCTGCTGCTGCTG:,DMPK:NM_004409.4:3'UTR:MODIFIER:exon15/15:c.*263_*283delCTGCTGCTGCTGCTGCTGCTG:	(CAG)n		0.0000	0.0000	0/0/0	0.0173							605377 [DMPK (confirmed) Myotonic dystrophy 1,160900];				13	17					DMPK (inh=AD pLI=0.03)
chr19	46281745	46281745	A	G	wt	wt	het		QUAL=3927;DP=89,183,311;MQM=60	DMPK	splice_region&intron	DMPK:NM_001288764.1:splice_region&intron:LOW:exon6/15:c.659+6T>C:,DMPK:NM_001288765.1:splice_region&intron:LOW:exon3/12:c.314+6T>C:,DMPK:NM_001081563.2:splice_region&intron:LOW:exon4/13:c.611+6T>C:,DMPK:NM_001081560.2:splice_region&intron:LOW:exon5/14:c.581+6T>C:,DMPK:NM_001081562.2:splice_region&intron:LOW:exon5/14:c.581+6T>C:,DMPK:NM_001288766.1:splice_region&intron:LOW:exon5/12:c.581+6T>C:,DMPK:NM_004409.4:splice_region&intron:LOW:exon5/14:c.581+6T>C:		rs1799894	0.0000	0.5351	17774/7031/2228	0.4857							605377 [DMPK (confirmed) Myotonic dystrophy 1,160900];	RCV000116882.1 [benign]; 			345	742					DMPK (inh=AD pLI=0.03)
chr19	47258674	47258674	C	T	het	wt	het	low_DP	QUAL=158;DP=18,8,9;MQM=60	FKRP	5'UTR	FKRP:NM_001039885.2:5'UTR:MODIFIER:exon4/4:c.-34C>T:,FKRP:NM_024301.4:5'UTR:MODIFIER:exon4/4:c.-34C>T:		rs3201779	0.1038	0.2286	1810/1393/16	0.1663							606596 [FKRP (confirmed) Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,5,613153|Muscular dystrophy-dystroglycanopathy (congenital with or without mental retardation),type B,5,606612|Muscular dystrophy-dystroglycanopathy (limb-girdle),type C,5,607155];	RCV000082170.6 [benign]; 			49	247					FKRP (inh=AR pLI=0.00)
chr19	50410273	50410273	T	C	wt	het	wt		QUAL=5331;DP=340,424,482;MQM=60	NUP62,IL4I1	3'UTR,intron	NUP62:NM_001193357.1:3'UTR:MODIFIER:exon2/2:c.*1223A>G:,NUP62:NM_012346.4:3'UTR:MODIFIER:exon2/2:c.*1223A>G:,NUP62:NM_153718.3:3'UTR:MODIFIER:exon2/2:c.*1223A>G:,NUP62:NM_153719.3:3'UTR:MODIFIER:exon3/3:c.*1223A>G:,NUP62:NM_016553.4:3'UTR:MODIFIER:exon3/3:c.*1223A>G:,IL4I1:NM_001258017.1:intron:MODIFIER:exon2/9:c.-227-2695A>G:,IL4I1:NM_001258018.1:intron:MODIFIER:exon2/9:c.-285-2695A>G:,IL4I1:NM_172374.2:intron:MODIFIER:exon2/9:c.-227-2695A>G:,IL4I1:NR_047577.1:intron:MODIFIER:exon2/10:n.337-2695A>G:		rs62126289	0.0114	0.0000	0/0/0	0.0174							605815 [NUP62 (confirmed) Striatonigral degeneration,infantile,271930];				0	11					NUP62 (inh=AR pLI=0.80), IL4I1 (inh=n/a pLI=0.26)
chr19	50410550	50410550	G	A	wt	wt	het		QUAL=4569;DP=241,362,412;MQM=60	NUP62,IL4I1	3'UTR,intron	NUP62:NM_001193357.1:3'UTR:MODIFIER:exon2/2:c.*946C>T:,NUP62:NM_012346.4:3'UTR:MODIFIER:exon2/2:c.*946C>T:,NUP62:NM_153718.3:3'UTR:MODIFIER:exon2/2:c.*946C>T:,NUP62:NM_153719.3:3'UTR:MODIFIER:exon3/3:c.*946C>T:,NUP62:NM_016553.4:3'UTR:MODIFIER:exon3/3:c.*946C>T:,IL4I1:NM_001258017.1:intron:MODIFIER:exon2/9:c.-227-2972C>T:,IL4I1:NM_001258018.1:intron:MODIFIER:exon2/9:c.-285-2972C>T:,IL4I1:NM_172374.2:intron:MODIFIER:exon2/9:c.-227-2972C>T:,IL4I1:NR_047577.1:intron:MODIFIER:exon2/10:n.337-2972C>T:	L2c	rs8429	0.3093	0.0000	0/0/0	0.3489							605815 [NUP62 (confirmed) Striatonigral degeneration,infantile,271930];				37	111					NUP62 (inh=AR pLI=0.80), IL4I1 (inh=n/a pLI=0.26)
chr19	50411012	50411012	C	T	het	wt	het		QUAL=4872;DP=185,128,170;MQM=53	NUP62,IL4I1	3'UTR,intron	NUP62:NM_001193357.1:3'UTR:MODIFIER:exon2/2:c.*484G>A:,NUP62:NM_012346.4:3'UTR:MODIFIER:exon2/2:c.*484G>A:,NUP62:NM_153718.3:3'UTR:MODIFIER:exon2/2:c.*484G>A:,NUP62:NM_153719.3:3'UTR:MODIFIER:exon3/3:c.*484G>A:,NUP62:NM_016553.4:3'UTR:MODIFIER:exon3/3:c.*484G>A:,IL4I1:NM_001258017.1:intron:MODIFIER:exon2/9:c.-227-3434G>A:,IL4I1:NM_001258018.1:intron:MODIFIER:exon2/9:c.-285-3434G>A:,IL4I1:NM_172374.2:intron:MODIFIER:exon2/9:c.-227-3434G>A:,IL4I1:NR_047577.1:intron:MODIFIER:exon2/10:n.337-3434G>A:	AluSz	rs1127729	0.0677	0.0000	0/0/0	0.0858							605815 [NUP62 (confirmed) Striatonigral degeneration,infantile,271930];				6	55					NUP62 (inh=AR pLI=0.80), IL4I1 (inh=n/a pLI=0.26)
chr19	50411132	50411132	T	C	wt	wt	het		QUAL=4137;DP=300,242,320;MQM=60	NUP62,IL4I1	3'UTR,intron	NUP62:NM_001193357.1:3'UTR:MODIFIER:exon2/2:c.*364A>G:,NUP62:NM_012346.4:3'UTR:MODIFIER:exon2/2:c.*364A>G:,NUP62:NM_153718.3:3'UTR:MODIFIER:exon2/2:c.*364A>G:,NUP62:NM_153719.3:3'UTR:MODIFIER:exon3/3:c.*364A>G:,NUP62:NM_016553.4:3'UTR:MODIFIER:exon3/3:c.*364A>G:,IL4I1:NM_001258017.1:intron:MODIFIER:exon2/9:c.-227-3554A>G:,IL4I1:NM_001258018.1:intron:MODIFIER:exon2/9:c.-285-3554A>G:,IL4I1:NM_172374.2:intron:MODIFIER:exon2/9:c.-227-3554A>G:,IL4I1:NR_047577.1:intron:MODIFIER:exon2/10:n.337-3554A>G:		rs9523	0.3165	0.0000	0/0/0	0.3223							605815 [NUP62 (confirmed) Striatonigral degeneration,infantile,271930];				39	133					NUP62 (inh=AR pLI=0.80), IL4I1 (inh=n/a pLI=0.26)
chr19	50411742	50411742	A	G	het	het	hom		QUAL=29880;DP=294,483,640;MQM=59	NUP62,IL4I1	synonymous,intron	NUP62:NM_001193357.1:synonymous:LOW:exon2/2:c.1323T>C:p.Asp441Asp,NUP62:NM_012346.4:synonymous:LOW:exon2/2:c.1323T>C:p.Asp441Asp,NUP62:NM_153718.3:synonymous:LOW:exon2/2:c.1323T>C:p.Asp441Asp,NUP62:NM_153719.3:synonymous:LOW:exon3/3:c.1323T>C:p.Asp441Asp,NUP62:NM_016553.4:synonymous:LOW:exon3/3:c.1323T>C:p.Asp441Asp,IL4I1:NM_001258017.1:intron:MODIFIER:exon2/9:c.-227-4164T>C:,IL4I1:NM_001258018.1:intron:MODIFIER:exon2/9:c.-285-4164T>C:,IL4I1:NM_172374.2:intron:MODIFIER:exon2/9:c.-227-4164T>C:,IL4I1:NR_047577.1:intron:MODIFIER:exon2/10:n.337-4164T>C:		rs892028	0.9740	0.9444	54164/28535/5072	0.9210							605815 [NUP62 (confirmed) Striatonigral degeneration,infantile,271930];	RCV000117863.2 [likely benign]; 			1369	188					NUP62 (inh=AR pLI=0.80), IL4I1 (inh=n/a pLI=0.26)
chr19	50412217	50412217	C	G	wt	wt	het		QUAL=891;DP=65,96,111;MQM=59	NUP62,IL4I1	missense,intron	NUP62:NM_001193357.1:missense:MODERATE:exon2/2:c.848G>C:p.Ser283Thr,NUP62:NM_012346.4:missense:MODERATE:exon2/2:c.848G>C:p.Ser283Thr,NUP62:NM_153718.3:missense:MODERATE:exon2/2:c.848G>C:p.Ser283Thr,NUP62:NM_153719.3:missense:MODERATE:exon3/3:c.848G>C:p.Ser283Thr,NUP62:NM_016553.4:missense:MODERATE:exon3/3:c.848G>C:p.Ser283Thr,IL4I1:NM_001258017.1:intron:MODIFIER:exon2/9:c.-227-4639G>C:,IL4I1:NM_001258018.1:intron:MODIFIER:exon2/9:c.-285-4639G>C:,IL4I1:NM_172374.2:intron:MODIFIER:exon2/9:c.-227-4639G>C:,IL4I1:NR_047577.1:intron:MODIFIER:exon2/10:n.337-4639G>C:	(GGT)n	rs1062798	0.3163	0.3518	7229/4370/254	0.3399	1.2210	T,T,T	T	B	T,T,T	0.01	605815 [NUP62 (confirmed) Striatonigral degeneration,infantile,271930];	RCV000117866.2 [likely benign]; 		COSM1325120	189	588					NUP62 (inh=AR pLI=0.80), IL4I1 (inh=n/a pLI=0.26)
chr19	50412417	50412417	G	A	het	wt	hom		QUAL=5682;DP=64,147,167;MQM=60	NUP62,IL4I1	synonymous,intron	NUP62:NM_001193357.1:synonymous:LOW:exon2/2:c.648C>T:p.Ser216Ser,NUP62:NM_012346.4:synonymous:LOW:exon2/2:c.648C>T:p.Ser216Ser,NUP62:NM_153718.3:synonymous:LOW:exon2/2:c.648C>T:p.Ser216Ser,NUP62:NM_153719.3:synonymous:LOW:exon3/3:c.648C>T:p.Ser216Ser,NUP62:NM_016553.4:synonymous:LOW:exon3/3:c.648C>T:p.Ser216Ser,IL4I1:NM_001258017.1:intron:MODIFIER:exon2/9:c.-227-4839C>T:,IL4I1:NM_001258018.1:intron:MODIFIER:exon2/9:c.-285-4839C>T:,IL4I1:NM_172374.2:intron:MODIFIER:exon2/9:c.-227-4839C>T:,IL4I1:NR_047577.1:intron:MODIFIER:exon2/10:n.337-4839C>T:		rs999583	0.8604	0.7919	38333/18884/4313	0.7831							605815 [NUP62 (confirmed) Striatonigral degeneration,infantile,271930];	RCV000117865.2 [likely benign]; 		COSM3757052	946	496					NUP62 (inh=AR pLI=0.80), IL4I1 (inh=n/a pLI=0.26)
chr19	50432789	50432789	G	C	wt	wt	het		QUAL=3562;DP=81,300,316;MQM=60	IL4I1,NUP62,ATF5	5'UTR,intron,non_coding_transcript_exon	IL4I1:NM_001258017.1:5'UTR:MODIFIER:exon1/10:c.-532C>G:,NUP62:NM_001193357.1:5'UTR:MODIFIER:exon1/2:c.-193C>G:,IL4I1:NM_001258018.1:5'UTR:MODIFIER:exon1/10:c.-614C>G:,IL4I1:NM_172374.2:5'UTR:MODIFIER:exon1/10:c.-556C>G:,NUP62:NM_016553.4:5'UTR:MODIFIER:exon1/3:c.-406C>G:,ATF5:NM_001193646.1:intron:MODIFIER:exon1/2:c.-120+132G>C:,ATF5:NM_012068.5:intron:MODIFIER:exon2/3:c.-120+132G>C:,IL4I1:NR_047577.1:non_coding_transcript_exon:MODIFIER:exon1/11:n.8C>G:		rs76858107	0.0110	0.0000	0/0/0	0.0235							605815 [NUP62 (confirmed) Striatonigral degeneration,infantile,271930];				0	22					IL4I1 (inh=n/a pLI=0.26), NUP62 (inh=AR pLI=0.80), ATF5 (inh=n/a pLI=0.02)
chr19	51850290	51850290	G	A	het	hom	het	pred_pathogenic	QUAL=5301;DP=80,90,133;MQM=60	ETFB	missense	ETFB:NM_001014763.1:missense:MODERATE:exon4/5:c.734C>T:p.Thr245Met,ETFB:NM_001985.2:missense:MODERATE:exon5/6:c.461C>T:p.Thr154Met		rs1130426	0.4197	0.4980	15226/10649/1277	0.4881	3.6820	D,D	T	P,P	D,D	32.00	130410 [ETFB (confirmed) Glutaric acidemia IIB,231680];	RCV000079961.4 [benign]; 		COSM3721676, COSM3721677	620	952					ETFB (inh=AR pLI=0.00)
chr19	54385820	54385820	C	T	hom	hom	hom		QUAL=5629;DP=43,64,89;MQM=59	PRKCG	synonymous	PRKCG:NM_001316329.1:synonymous:LOW:exon1/19:c.72C>T:p.Ala24Ala,PRKCG:NM_002739.4:synonymous:LOW:exon1/18:c.72C>T:p.Ala24Ala		rs2547362	0.8964	0.9463	54518/30486/2768	0.9210							176980 [PRKCG (confirmed) Spinocerebellar ataxia 14,605361];	RCV000118063.3 [other]; RCV000379683.1 [benign]; 			2393	173	2	[2] Julia Bickmann 18.09.2014	n/a (2xTP, 0xFP)		PRKCG (inh=AD pLI=1.00)
chr19	54394965	54394965	T	C	het	het	het		QUAL=9523;DP=175,253,359;MQM=60	PRKCG	synonymous	PRKCG:NM_001316329.1:synonymous:LOW:exon6/19:c.567T>C:p.Asn189Asn,PRKCG:NM_002739.4:synonymous:LOW:exon6/18:c.567T>C:p.Asn189Asn		rs3745406	0.3295	0.3977	9824/5601/233	0.3927							176980 [PRKCG (confirmed) Spinocerebellar ataxia 14,605361];	RCV000118062.2 [likely benign]; RCV000407374.1 [benign]; 		COSM148736	447	1314	2	[2] Julia Bickmann 18.09.2014	n/a (1xTP, 0xFP)		PRKCG (inh=AD pLI=1.00)
chr19	54695163	54695163	T	C	het	wt	hom	low_DP	QUAL=185;DP=5,2,7;MQM=60	TSEN34	5'UTR,intron	TSEN34:NM_001077446.3:5'UTR:MODIFIER:exon1/4:c.-53T>C:,TSEN34:NM_001282333.1:intron:MODIFIER:exon1/5:c.6-49T>C:,TSEN34:NM_024075.4:intron:MODIFIER:exon1/4:c.-4-49T>C:,TSEN34:NM_001282332.1:intron:MODIFIER:exon1/4:c.-4-49T>C:		rs593073	0.7418	0.7937	4870/1825/381	0.3350							608754 [TSEN34 (provisional) Pontocerebellar hypoplasia type 2C,612390];				480	217					TSEN34 (inh=AR pLI=0.40)
chr19	54697079	54697079	C	T	het	het	hom		QUAL=17624;DP=179,268,360;MQM=60	TSEN34	synonymous	TSEN34:NM_001282333.1:synonymous:LOW:exon5/6:c.804C>T:p.Pro268Pro,TSEN34:NM_024075.4:synonymous:LOW:exon5/5:c.795C>T:p.Pro265Pro,TSEN34:NM_001282332.1:synonymous:LOW:exon5/5:c.795C>T:p.Pro265Pro,TSEN34:NM_001077446.3:synonymous:LOW:exon4/4:c.795C>T:p.Pro265Pro		rs7595	0.7482	0.7722	36753/22253/3502	0.7517							608754 [TSEN34 (provisional) Pontocerebellar hypoplasia type 2C,612390];	RCV000147766.1 [benign]; RCV000284876.1 [benign]; 			1709	873					TSEN34 (inh=AR pLI=0.40)
chr19	54697602	54697602	G	A	het	het	hom		QUAL=4750;DP=128,40,62;MQM=59	TSEN34	3'UTR	TSEN34:NM_001282333.1:3'UTR:MODIFIER:exon6/6:c.*76G>A:,TSEN34:NM_024075.4:3'UTR:MODIFIER:exon5/5:c.*385G>A:,TSEN34:NM_001282332.1:3'UTR:MODIFIER:exon5/5:c.*385G>A:,TSEN34:NM_001077446.3:3'UTR:MODIFIER:exon4/4:c.*385G>A:	MIRb	rs36622	0.7482	0.0000	0/0/0	0.7088							608754 [TSEN34 (provisional) Pontocerebellar hypoplasia type 2C,612390];	RCV000296732.1 [benign]; 			221	112					TSEN34 (inh=AR pLI=0.40)
chr19	54697714	54697714	C	T	het	het	hom		QUAL=6082;DP=184,65,77;MQM=60	TSEN34	3'UTR	TSEN34:NM_001282333.1:3'UTR:MODIFIER:exon6/6:c.*188C>T:,TSEN34:NM_024075.4:3'UTR:MODIFIER:exon5/5:c.*497C>T:,TSEN34:NM_001282332.1:3'UTR:MODIFIER:exon5/5:c.*497C>T:,TSEN34:NM_001077446.3:3'UTR:MODIFIER:exon4/4:c.*497C>T:	MIRb	rs36621	0.7488	0.0000	0/0/0	0.7528							608754 [TSEN34 (provisional) Pontocerebellar hypoplasia type 2C,612390];	RCV000391988.1 [benign]; 			197	99					TSEN34 (inh=AR pLI=0.40)
chr19	54698196	54698198	GGA	-	het	het	hom		QUAL=9669;DP=296,115,165;MQM=60	TSEN34	3'UTR	TSEN34:NM_001282333.1:3'UTR:MODIFIER:exon6/6:c.*671_*673delGAG:,TSEN34:NM_024075.4:3'UTR:MODIFIER:exon5/5:c.*980_*982delGAG:,TSEN34:NM_001282332.1:3'UTR:MODIFIER:exon5/5:c.*980_*982delGAG:,TSEN34:NM_001077446.3:3'UTR:MODIFIER:exon4/4:c.*980_*982delGAG:		rs879960569	0.0000	0.0000	0/0/0	0.3139							608754 [TSEN34 (provisional) Pontocerebellar hypoplasia type 2C,612390];				70	129					TSEN34 (inh=AR pLI=0.40)
chr19	55644325	55644325	A	C	hom	hom	wt	low_DP	QUAL=250;DP=7,1,165;MQM=60	TNNT1	synonymous	TNNT1:NM_003283.5:synonymous:LOW:exon14/14:c.795T>G:p.Arg265Arg,TNNT1:NM_001126132.2:synonymous:LOW:exon14/14:c.747T>G:p.Arg249Arg,TNNT1:NM_001126133.2:synonymous:LOW:exon13/13:c.714T>G:p.Arg238Arg,TNNT1:NM_001291774.1:synonymous:LOW:exon14/14:c.714T>G:p.Arg238Arg		rs890868	0.9804	0.9892	48080/27722/4166	0.9379							191041 [TNNT1 (confirmed) Nemaline myopathy 5,Amish type,605355];	RCV000024552.1 [not provided]; RCV000154008.3 [benign]; 			1459	0					TNNT1 (inh=AR pLI=0.00)
chr19	55658387	55658387	T	C	het	wt	het	pred_pathogenic	QUAL=900;DP=20,54,64;MQM=59	TNNT1	missense&splice_region	TNNT1:NM_003283.5:missense&splice_region:MODERATE:exon3/14:c.35A>G:p.Glu12Gly,TNNT1:NM_001126132.2:missense&splice_region:MODERATE:exon3/14:c.35A>G:p.Glu12Gly,TNNT1:NM_001126133.2:missense&splice_region:MODERATE:exon3/13:c.35A>G:p.Glu12Gly,TNNT1:NM_001291774.1:missense&splice_region:MODERATE:exon4/14:c.35A>G:p.Glu12Gly		rs112562759	0.0359	0.0815	348/282/1	0.0681	2.0130	D,T,D,D	T	B,B,B,B	D,D,D	18.28	191041 [TNNT1 (confirmed) Nemaline myopathy 5,Amish type,605355];	RCV000024560.1 [not provided]; RCV000080082.7 [benign]; RCV000259493.1 [likely benign]; RCV000263178.1 [likely benign]; RCV000299675.1 [likely benign]; RCV000354576.1 [likely benign]; 			20	236					TNNT1 (inh=AR pLI=0.00)
chr19	55660537	55660537	T	C	hom	hom	hom		QUAL=17327;DP=142,178,234;MQM=59	TNNT1	5'UTR	TNNT1:NM_003283.5:5'UTR:MODIFIER:exon1/14:c.-20A>G:,TNNT1:NM_001126132.2:5'UTR:MODIFIER:exon1/14:c.-20A>G:,TNNT1:NM_001126133.2:5'UTR:MODIFIER:exon1/13:c.-20A>G:,TNNT1:NM_001291774.1:5'UTR:MODIFIER:exon1/14:c.-115A>G:		rs9636153	0.8101	0.8315	3817/1005/70	0.2328	-0.9490	T	T			0.51	191041 [TNNT1 (confirmed) Nemaline myopathy 5,Amish type,605355];	RCV000024550.1 [not provided]; RCV000272701.1 [likely benign]; RCV000289192.1 [likely benign]; RCV000344273.1 [likely benign]; RCV000380170.1 [likely benign]; RCV000383640.1 [likely benign]; 			826	240					TNNT1 (inh=AR pLI=0.00)
chr20	3209083	3209083	G	A	wt	het	wt		QUAL=2428;DP=158,240,361;MQM=60	SLC4A11	splice_region&intron	SLC4A11:NM_001174090.1:splice_region&intron:LOW:exon18/19:c.2518-9C>T:,SLC4A11:NM_032034.3:splice_region&intron:LOW:exon17/18:c.2437-9C>T:,SLC4A11:NR_135000.1:splice_region&intron:LOW:exon18/19:n.2487-9C>T:,SLC4A11:NM_001174089.1:splice_region&intron:LOW:exon18/19:c.2389-9C>T:		rs41281858	0.1591	0.1296	1183/548/401	0.1294							610206 [SLC4A11 (confirmed) Corneal endothelial dystrophy,autosomal recessive,217700|Corneal endothelial dystrophy and perceptive deafness,217400|Corneal dystrophy,Fuchs endothelial,4,613268];	RCV000250950.1 [benign]; RCV000405544.1 [likely benign]; 		COSM3740088, COSM3740087	17	339					SLC4A11 (inh=AR+AD pLI=0.00)
chr20	3210301	3210301	G	A	wt	het	wt		QUAL=5356;DP=150,439,551;MQM=60	SLC4A11	synonymous,non_coding_transcript_exon	SLC4A11:NM_001174090.1:synonymous:LOW:exon14/20:c.1740C>T:p.Asn580Asn,SLC4A11:NM_032034.3:synonymous:LOW:exon13/19:c.1659C>T:p.Asn553Asn,SLC4A11:NM_001174089.1:synonymous:LOW:exon14/20:c.1611C>T:p.Asn537Asn,SLC4A11:NR_135000.1:non_coding_transcript_exon:MODIFIER:exon14/20:n.1709C>T:		rs41281860	0.0485	0.0916	631/507/5	0.0912							610206 [SLC4A11 (confirmed) Corneal endothelial dystrophy,autosomal recessive,217700|Corneal endothelial dystrophy and perceptive deafness,217400|Corneal dystrophy,Fuchs endothelial,4,613268];	RCV000254477.1 [benign]; RCV000375014.1 [likely benign]; 		COSM3773984, COSM3773985	9	311					SLC4A11 (inh=AR+AD pLI=0.00)
chr20	3211235	3211235	C	T	wt	het	wt		QUAL=4575;DP=341,354,500;MQM=60	SLC4A11	synonymous,non_coding_transcript_exon	SLC4A11:NM_001174090.1:synonymous:LOW:exon12/20:c.1470G>A:p.Thr490Thr,SLC4A11:NM_032034.3:synonymous:LOW:exon11/19:c.1389G>A:p.Thr463Thr,SLC4A11:NM_001174089.1:synonymous:LOW:exon12/20:c.1341G>A:p.Thr447Thr,SLC4A11:NR_135000.1:non_coding_transcript_exon:MODIFIER:exon12/20:n.1509G>A:		rs6084312	0.0451	0.0851	581/481/7	0.0854							610206 [SLC4A11 (confirmed) Corneal endothelial dystrophy,autosomal recessive,217700|Corneal endothelial dystrophy and perceptive deafness,217400|Corneal dystrophy,Fuchs endothelial,4,613268];	RCV000248066.1 [benign]; RCV000288238.1 [likely benign]; 			10	292					SLC4A11 (inh=AR+AD pLI=0.00)
chr20	3214819	3214819	T	G	het	wt	het		QUAL=8624;DP=189,405,523;MQM=60	SLC4A11	synonymous,non_coding_transcript_exon	SLC4A11:NM_001174090.1:synonymous:LOW:exon5/20:c.562A>C:p.Arg188Arg,SLC4A11:NM_032034.3:synonymous:LOW:exon4/19:c.481A>C:p.Arg161Arg,SLC4A11:NM_001174089.1:synonymous:LOW:exon5/20:c.433A>C:p.Arg145Arg,SLC4A11:NR_135000.1:non_coding_transcript_exon:MODIFIER:exon5/20:n.601A>C:		rs3827075	0.4798	0.4365	12113/5554/2180	0.4320							610206 [SLC4A11 (confirmed) Corneal endothelial dystrophy,autosomal recessive,217700|Corneal endothelial dystrophy and perceptive deafness,217400|Corneal dystrophy,Fuchs endothelial,4,613268];	RCV000245921.1 [benign]; RCV000384700.1 [likely benign]; 			222	754					SLC4A11 (inh=AR+AD pLI=0.00)
chr20	3215548	3215548	C	A	het	wt	het		QUAL=7604;DP=350,235,338;MQM=59	SLC4A11	splice_region&intron	SLC4A11:NM_001174090.1:splice_region&intron:LOW:exon2/19:c.218-8G>T:,SLC4A11:NM_032034.3:splice_region&intron:LOW:exon1/18:c.137-8G>T:,SLC4A11:NR_135000.1:splice_region&intron:LOW:exon2/19:n.257-8G>T:,SLC4A11:NM_001174089.1:splice_region&intron:LOW:exon2/19:c.89-8G>T:		rs3803957	0.2724	0.2999	5646/2851/232	0.2930							610206 [SLC4A11 (confirmed) Corneal endothelial dystrophy,autosomal recessive,217700|Corneal endothelial dystrophy and perceptive deafness,217400|Corneal dystrophy,Fuchs endothelial,4,613268];	RCV000243306.1 [benign]; RCV000386561.1 [likely benign]; 		COSM4001879, COSM4001880	106	625					SLC4A11 (inh=AR+AD pLI=0.00)
chr20	3218355	3218355	C	G	het	wt	het		QUAL=5535;DP=147,207,305;MQM=59	SLC4A11	5'UTR_premature_start_codon_gain,5'UTR,intron	SLC4A11:NM_032034.3:5'UTR_premature_start_codon_gain:LOW:exon1/19:c.-30G>C:,SLC4A11:NM_032034.3:5'UTR:MODIFIER:exon1/19:c.-30G>C:,SLC4A11:NM_001174090.1:intron:MODIFIER:exon1/19:c.173-121G>C:,SLC4A11:NR_135000.1:intron:MODIFIER:exon1/19:n.212-121G>C:,SLC4A11:NM_001174089.1:intron:MODIFIER:exon1/19:c.44-121G>C:		rs3827076	0.4503	0.4119	10717/4934/1649	0.4017							610206 [SLC4A11 (confirmed) Corneal endothelial dystrophy,autosomal recessive,217700|Corneal endothelial dystrophy and perceptive deafness,217400|Corneal dystrophy,Fuchs endothelial,4,613268];	RCV000338145.1 [likely benign]; 			97	343					SLC4A11 (inh=AR+AD pLI=0.00)
chr20	3218634	3218634	G	C	het	wt	het		QUAL=3772;DP=116,107,187;MQM=59	SLC4A11	missense,intron	SLC4A11:NM_001174090.1:missense:MODERATE:exon1/20:c.77C>G:p.Pro26Arg,SLC4A11:NR_135000.1:intron:MODIFIER:exon1/19:n.212-400C>G:,SLC4A11:NM_001174089.1:intron:MODIFIER:exon1/19:c.44-400C>G:		rs3810562	0.6416	0.5711	2540/825/282	0.1850	-0.8580	T	T	B	T	0.01	610206 [SLC4A11 (confirmed) Corneal endothelial dystrophy,autosomal recessive,217700|Corneal endothelial dystrophy and perceptive deafness,217400|Corneal dystrophy,Fuchs endothelial,4,613268];			COSM330384	439	725					SLC4A11 (inh=AR+AD pLI=0.00)
chr20	3870124	3870124	G	C	hom	hom	hom	low_DP;pred_pathogenic	QUAL=454;DP=2,11,4;MQM=59	PANK2	missense,5'UTR,intron,non_coding_transcript_exon	PANK2:NM_153638.3:missense:MODERATE:exon1/7:c.377G>C:p.Gly126Ala,PANK2:NM_001324192.1:missense:MODERATE:exon1/2:c.377G>C:p.Gly126Ala,PANK2:NM_001324191.1:5'UTR:MODIFIER:exon1/8:c.-665G>C:,PANK2:NM_024960.5:intron:MODIFIER:exon1/6:c.-246+573G>C:,PANK2:NR_136715.1:non_coding_transcript_exon:MODIFIER:exon1/7:n.544G>C:		rs3737084	0.8792	0.8654	10763/6307/798	0.6936	1.0190	T	T	B	D	9.54	606157 [PANK2 (provisional) Neurodegeneration with brain iron accumulation 1,234200|HARP syndrome,607236];	RCV000082679.4 [benign]; RCV000313320.1 [benign]; 		COSM4134538	1635	490					PANK2 (inh=AR pLI=0.01)
chr20	3891347	3891347	T	G	het	wt	het	pred_pathogenic	QUAL=8779;DP=358,257,341;MQM=60	PANK2	missense,5'UTR_premature_start_codon_gain,5'UTR,non_coding_transcript_exon	PANK2:NM_153638.3:missense:MODERATE:exon3/7:c.1105T>G:p.Ser369Ala,PANK2:NM_024960.5:missense:MODERATE:exon3/7:c.232T>G:p.Ser78Ala,PANK2:NM_001324191.1:missense:MODERATE:exon4/8:c.232T>G:p.Ser78Ala,PANK2:NM_153640.3:missense:MODERATE:exon3/7:c.232T>G:p.Ser78Ala,PANK2:NM_001324193.1:5'UTR_premature_start_codon_gain:LOW:exon3/7:c.-204T>G:,PANK2:NM_001324193.1:5'UTR:MODIFIER:exon3/7:c.-204T>G:,PANK2:NR_136715.1:non_coding_transcript_exon:MODIFIER:exon3/7:n.1129T>G:			0.0000	0.0000	0/0/0	0.0000	0.9130	T,T,T	D	B	D,D	7.60	606157 [PANK2 (provisional) Neurodegeneration with brain iron accumulation 1,234200|HARP syndrome,607236];				0	2	3	[3] Stephan Waldm?ller 13.08.2014			PANK2 (inh=AR pLI=0.01)
chr20	10618574	10618574	T	C	het	hom	wt		QUAL=6102;DP=217,96,117;MQM=60	JAG1	3'UTR	JAG1:NM_000214.2:3'UTR:MODIFIER:exon26/26:c.*1572A>G:		rs8708	0.4742	0.0000	0/0/0	0.0867							601920 [JAG1 (confirmed) Alagille syndrome 1,118450|Tetralogy of Fallot,187500|Deafness,congenital heart defects,and posterior embryotoxon];	RCV000300443.1 [benign]; RCV000366943.1 [benign]; 			76	107					JAG1 (inh=AD pLI=1.00)
chr20	10618940	10618940	A	-	wt	het	wt		QUAL=1970;DP=231,196,244;MQM=60	JAG1	3'UTR	JAG1:NM_000214.2:3'UTR:MODIFIER:exon26/26:c.*1206delT:		rs34134142	0.3149	0.0000	0/0/0	0.2195							601920 [JAG1 (confirmed) Alagille syndrome 1,118450|Tetralogy of Fallot,187500|Deafness,congenital heart defects,and posterior embryotoxon];	RCV000334952.1 [benign]; RCV000401970.1 [benign]; 			29	115					JAG1 (inh=AD pLI=1.00)
chr20	10619014	10619014	A	C	wt	het	wt		QUAL=2753;DP=485,234,275;MQM=60	JAG1	3'UTR	JAG1:NM_000214.2:3'UTR:MODIFIER:exon26/26:c.*1132T>G:		rs7828	0.2216	0.0000	0/0/0	0.0497							601920 [JAG1 (confirmed) Alagille syndrome 1,118450|Tetralogy of Fallot,187500|Deafness,congenital heart defects,and posterior embryotoxon];	RCV000310295.1 [benign]; RCV000408215.1 [benign]; 			26	109					JAG1 (inh=AD pLI=1.00)
chr20	10619289	10619289	-	A	wt	het	wt		QUAL=1344;DP=484,123,185;MQM=60	JAG1	3'UTR	JAG1:NM_000214.2:3'UTR:MODIFIER:exon26/26:c.*856dupT:		rs397823621	0.2524	0.0000	0/0/0	0.2549							601920 [JAG1 (confirmed) Alagille syndrome 1,118450|Tetralogy of Fallot,187500|Deafness,congenital heart defects,and posterior embryotoxon];	RCV000278346.1 [benign]; RCV000323447.1 [benign]; 			21	109					JAG1 (inh=AD pLI=1.00)
chr20	10619660	10619660	A	-	wt	het	wt		QUAL=1307;DP=197,110,118;MQM=59	JAG1	3'UTR	JAG1:NM_000214.2:3'UTR:MODIFIER:exon26/26:c.*486delT:		rs397701055	0.1801	0.0000	0/0/0	0.2131							601920 [JAG1 (confirmed) Alagille syndrome 1,118450|Tetralogy of Fallot,187500|Deafness,congenital heart defects,and posterior embryotoxon];	RCV000301259.1 [benign]; RCV000356320.1 [benign]; 			17	105					JAG1 (inh=AD pLI=1.00)
chr20	10620275	10620275	G	A	wt	het	wt		QUAL=1259;DP=224,127,159;MQM=60	JAG1	synonymous	JAG1:NM_000214.2:synonymous:LOW:exon26/26:c.3528C>T:p.Tyr1176Tyr		rs1051421	0.1801	0.2383	3736/2590/59	0.2385							601920 [JAG1 (confirmed) Alagille syndrome 1,118450|Tetralogy of Fallot,187500|Deafness,congenital heart defects,and posterior embryotoxon];	RCV000035333.5 [benign]; RCV000245407.1 [benign]; RCV000305764.1 [benign]; RCV000359120.1 [benign]; 		COSM149139, COSM3758425	129	659					JAG1 (inh=AD pLI=1.00)
chr20	10620386	10620386	A	G	het	hom	wt		QUAL=7947;DP=264,141,182;MQM=60	JAG1	synonymous	JAG1:NM_000214.2:synonymous:LOW:exon26/26:c.3417T>C:p.Tyr1139Tyr		rs1051419	0.7127	0.6592	27182/13748/4203	0.6490							601920 [JAG1 (confirmed) Alagille syndrome 1,118450|Tetralogy of Fallot,187500|Deafness,congenital heart defects,and posterior embryotoxon];	RCV000150844.2 [benign]; RCV000125430.3 [benign]; RCV000250727.1 [benign]; RCV000270345.1 [benign]; RCV000364728.1 [benign]; 		COSM149140, COSM3758426	719	738					JAG1 (inh=AD pLI=1.00)
chr20	10633237	10633237	G	A	het	hom	wt	anno_pathogenic_clinvar	QUAL=3252;DP=88,65,91;MQM=59	JAG1	synonymous	JAG1:NM_000214.2:synonymous:LOW:exon6/26:c.765C>T:p.Tyr255Tyr		rs1131695	0.4233	0.4541	12652/7312/620	0.4460							601920 [JAG1 (confirmed) Alagille syndrome 1,118450|Tetralogy of Fallot,187500|Deafness,congenital heart defects,and posterior embryotoxon];	RCV000150845.2 [benign]; RCV000132569.1 [likely benign]; RCV000199026.2 [benign]; RCV000254531.1 [benign]; RCV000293317.1 [benign]; RCV000398702.1 [benign]; RCV000214085.1 [pathogenic]; 		COSM3758428, COSM3758427	442	789	1	hohe Frequenz, keine splice site Ver?nderung[1] swoedl 28.06.2016			JAG1 (inh=AD pLI=1.00)
chr20	10653469	10653469	C	T	het	het	wt		QUAL=6558;DP=247,343,475;MQM=59	JAG1	synonymous	JAG1:NM_000214.2:synonymous:LOW:exon2/26:c.267G>A:p.Gly89Gly		rs1051415	0.0653	0.0940	658/447/8	0.0929							601920 [JAG1 (confirmed) Alagille syndrome 1,118450|Tetralogy of Fallot,187500|Deafness,congenital heart defects,and posterior embryotoxon];	RCV000035331.4 [benign]; RCV000343444.1 [likely benign]; RCV000398297.1 [likely benign]; 			13	246					JAG1 (inh=AD pLI=1.00)
chr20	10654563	10654563	A	C	het	het	het		QUAL=3157;DP=96,94,122;MQM=59	JAG1	5'UTR	JAG1:NM_000214.2:5'UTR:MODIFIER:exon1/26:c.-385T>G:		rs1051412	0.5545	0.0000	0/0/0	0.4532							601920 [JAG1 (confirmed) Alagille syndrome 1,118450|Tetralogy of Fallot,187500|Deafness,congenital heart defects,and posterior embryotoxon];	RCV000312591.1 [benign]; RCV000401777.1 [benign]; 			66	106					JAG1 (inh=AD pLI=1.00)
chr20	13765943	13765950	CCGCGGGG	-	wt	het	wt		QUAL=379;DP=20,49,50;MQM=59	NDUFAF5	splice_region&intron	NDUFAF5:NM_024120.4:splice_region&intron:LOW:exon1/10:c.222+8_222+15delCGCGGGGC:,NDUFAF5:NM_001039375.2:splice_region&intron:LOW:exon1/9:c.222+8_222+15delCGCGGGGC:,NDUFAF5:NR_029377.1:splice_region&intron:LOW:exon1/11:n.265+8_265+15delCGCGGGGC:	G-rich	rs56363401	0.1252	0.2193	2041/1505/4	0.1677							612360 [NDUFAF5 (provisional) Mitochondrial complex 1 deficiency,252010];	RCV000195552.1,RCV000195552.1 [benign,benign]; 			71	439					NDUFAF5 (inh=AR pLI=0.00)
chr20	13798449	13798470	ACAGTCATCAGTTTATTGTTAA	-	hom	het	het		QUAL=8851;DP=204,117,124;MQM=59	NDUFAF5	3'UTR,non_coding_transcript_exon	NDUFAF5:NM_024120.4:3'UTR:MODIFIER:exon11/11:c.*593_*614delACAGTCATCAGTTTATTGTTAA:,NDUFAF5:NM_001039375.2:3'UTR:MODIFIER:exon10/10:c.*593_*614delACAGTCATCAGTTTATTGTTAA:,NDUFAF5:NR_029377.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.1772_1793delACAGTCATCAGTTTATTGTTAA:		rs35624053	0.2426	0.3269	632/254/5	0.0466							612360 [NDUFAF5 (provisional) Mitochondrial complex 1 deficiency,252010];				41	103					NDUFAF5 (inh=AR pLI=0.00)
chr20	13798549	13798549	C	T	wt	wt	het		QUAL=1767;DP=259,152,169;MQM=60	NDUFAF5	3'UTR,non_coding_transcript_exon	NDUFAF5:NM_024120.4:3'UTR:MODIFIER:exon11/11:c.*693C>T:,NDUFAF5:NM_001039375.2:3'UTR:MODIFIER:exon10/10:c.*693C>T:,NDUFAF5:NR_029377.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.1872C>T:		rs10485768	0.0413	0.0402	20/16/0	0.0143							612360 [NDUFAF5 (provisional) Mitochondrial complex 1 deficiency,252010];				4	18					NDUFAF5 (inh=AR pLI=0.00)
chr20	13798676	13798676	C	T	wt	het	wt		QUAL=3400;DP=374,293,341;MQM=59	NDUFAF5	3'UTR,non_coding_transcript_exon	NDUFAF5:NM_024120.4:3'UTR:MODIFIER:exon11/11:c.*820C>T:,NDUFAF5:NM_001039375.2:3'UTR:MODIFIER:exon10/10:c.*820C>T:,NDUFAF5:NR_029377.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.1999C>T:		rs2423751	0.4507	0.3846	851/129/23	0.0997							612360 [NDUFAF5 (provisional) Mitochondrial complex 1 deficiency,252010];				38	102					NDUFAF5 (inh=AR pLI=0.00)
chr20	13798693	13798706	AACCTGGGCACTGC	-	wt	het	wt		QUAL=3088;DP=451,295,312;MQM=59	NDUFAF5	3'UTR,non_coding_transcript_exon	NDUFAF5:NM_024120.4:3'UTR:MODIFIER:exon11/11:c.*837_*850delAACCTGGGCACTGC:,NDUFAF5:NM_001039375.2:3'UTR:MODIFIER:exon10/10:c.*837_*850delAACCTGGGCACTGC:,NDUFAF5:NR_029377.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.2016_2029delAACCTGGGCACTGC:		rs71334159	0.1216	0.1713	177/43/1	0.0254							612360 [NDUFAF5 (provisional) Mitochondrial complex 1 deficiency,252010];				14	80					NDUFAF5 (inh=AR pLI=0.00)
chr20	13798776	13798776	T	C	hom	hom	hom		QUAL=24056;DP=229,256,269;MQM=59	NDUFAF5	3'UTR,non_coding_transcript_exon	NDUFAF5:NM_024120.4:3'UTR:MODIFIER:exon11/11:c.*920T>C:,NDUFAF5:NM_001039375.2:3'UTR:MODIFIER:exon10/10:c.*920T>C:,NDUFAF5:NR_029377.1:non_coding_transcript_exon:MODIFIER:exon12/12:n.2099T>C:		rs2423752	0.8872	0.8569	4016/1283/93	0.2350							612360 [NDUFAF5 (provisional) Mitochondrial complex 1 deficiency,252010];				207	24					NDUFAF5 (inh=AR pLI=0.00)
chr20	25275554	25275559	TTAGTT	-	wt	wt	het		QUAL=8975;DP=331,532,765;MQM=59	ABHD12,PYGB	3'UTR,intron	ABHD12:NM_015600.4:3'UTR:MODIFIER:exon13/13:c.*50_*55delAACTAA:,PYGB:NM_002862.3:intron:MODIFIER:exon18/19:c.2312+634_2312+639delAGTTTT:		rs748791257	0.6088	0.0000	0/0/0	0.0772							613599 [ABHD12 (provisional) Polyneuropathy,hearing loss,ataxia,retinitis pigmentosa,and cataract,612674];				239	415					ABHD12 (inh=AR pLI=0.00), PYGB (inh=n/a pLI=0.00)
chr20	25281027	25281027	C	T	het	wt	het		QUAL=4550;DP=142,178,246;MQM=60	ABHD12	3'UTR,intron	ABHD12:NM_001042472.2:3'UTR:MODIFIER:exon13/13:c.*454G>A:,ABHD12:NM_015600.4:intron:MODIFIER:exon12/12:c.1157+1828G>A:		rs41309917	0.0194	0.0000	0/0/0	0.0045							613599 [ABHD12 (provisional) Polyneuropathy,hearing loss,ataxia,retinitis pigmentosa,and cataract,612674];	RCV000332184.1 [likely benign]; 			0	16					ABHD12 (inh=AR pLI=0.00)
chr20	25281184	25281184	G	C	wt	wt	het		QUAL=808;DP=49,50,73;MQM=60	ABHD12	3'UTR,intron	ABHD12:NM_001042472.2:3'UTR:MODIFIER:exon13/13:c.*297C>G:,ABHD12:NM_015600.4:intron:MODIFIER:exon12/12:c.1157+1671C>G:		rs11100	0.5363	0.0000	0/0/0	0.0848							613599 [ABHD12 (provisional) Polyneuropathy,hearing loss,ataxia,retinitis pigmentosa,and cataract,612674];	RCV000325016.1 [benign]; 			42	104					ABHD12 (inh=AR pLI=0.00)
chr20	25281333	25281333	G	A	wt	wt	het		QUAL=2083;DP=77,101,160;MQM=60	ABHD12	3'UTR,intron	ABHD12:NM_001042472.2:3'UTR:MODIFIER:exon13/13:c.*148C>T:,ABHD12:NM_015600.4:intron:MODIFIER:exon12/12:c.1157+1522C>T:		rs1046073	0.5359	0.0000	0/0/0	0.0846							613599 [ABHD12 (provisional) Polyneuropathy,hearing loss,ataxia,retinitis pigmentosa,and cataract,612674];	RCV000379946.1 [benign]; 			43	105					ABHD12 (inh=AR pLI=0.00)
chr20	25281398	25281398	C	T	wt	wt	het		QUAL=3368;DP=158,173,247;MQM=60	ABHD12	3'UTR,intron	ABHD12:NM_001042472.2:3'UTR:MODIFIER:exon13/13:c.*83G>A:,ABHD12:NM_015600.4:intron:MODIFIER:exon12/12:c.1157+1457G>A:		rs2424708	0.4517	0.0000	0/0/0	0.0928							613599 [ABHD12 (provisional) Polyneuropathy,hearing loss,ataxia,retinitis pigmentosa,and cataract,612674];	RCV000285470.1 [benign]; 			43	104					ABHD12 (inh=AR pLI=0.00)
chr20	25282944	25282944	A	G	wt	wt	het		QUAL=3646;DP=284,182,260;MQM=60	ABHD12	synonymous	ABHD12:NM_015600.4:synonymous:LOW:exon12/13:c.1068T>C:p.Asp356Asp,ABHD12:NM_001042472.2:synonymous:LOW:exon12/13:c.1068T>C:p.Asp356Asp		rs10966	0.5415	0.4632	14195/6306/1022	0.4648							613599 [ABHD12 (provisional) Polyneuropathy,hearing loss,ataxia,retinitis pigmentosa,and cataract,612674];	RCV000116214.3 [other]; RCV000282089.1 [benign]; 		COSM3758500, COSM3758499	614	1514					ABHD12 (inh=AR pLI=0.00)
chr20	25288632	25288632	G	A	hom	hom	het		QUAL=10403;DP=164,124,155;MQM=59	ABHD12	synonymous	ABHD12:NM_015600.4:synonymous:LOW:exon9/13:c.837C>T:p.Arg279Arg,ABHD12:NM_001042472.2:synonymous:LOW:exon9/13:c.837C>T:p.Arg279Arg		rs6107027	0.3361	0.4696	14984/9197/355	0.4603							613599 [ABHD12 (provisional) Polyneuropathy,hearing loss,ataxia,retinitis pigmentosa,and cataract,612674];	RCV000116215.2 [likely benign]; RCV000369740.1 [benign]; 		COSM4134339, COSM4134340	926	1560					ABHD12 (inh=AR pLI=0.00)
chr20	31022959	31022959	T	C	hom	hom	hom		QUAL=35809;DP=389,300,402;MQM=59	ASXL1	missense	ASXL1:NM_015338.5:missense:MODERATE:exon12/12:c.2444T>C:p.Leu815Pro		rs6058694	1.0000	1.0000	60464/33254/5131	0.9362	-0.1360	T,T,T,T,T	T	B,B	T,T	0.09	612990 [ASXL1 (provisional) Bohring-Opitz syndrome,605039|Myelodysplastic syndrome,somatic,614286];	RCV000120112.1 [not provided]; 			1607	0					ASXL1 (inh=AD pLI=0.00)
chr20	31024274	31024274	T	C	hom	hom	het		QUAL=14470;DP=317,84,123;MQM=59	ASXL1	synonymous	ASXL1:NM_015338.5:synonymous:LOW:exon12/12:c.3759T>C:p.Ser1253Ser		rs4911231	0.4058	0.4183	11590/5178/192	0.4130							612990 [ASXL1 (provisional) Bohring-Opitz syndrome,605039|Myelodysplastic syndrome,somatic,614286];	RCV000397795.1 [benign]; 		COSM4134436, COSM4134435	224	730					ASXL1 (inh=AD pLI=0.00)
chr20	31025163	31025163	A	G	hom	hom	het		QUAL=36544;DP=394,499,534;MQM=60	ASXL1	3'UTR	ASXL1:NM_015338.5:3'UTR:MODIFIER:exon12/12:c.*22A>G:		rs2295764	0.4000	0.4065	11069/4730/184	0.4009							612990 [ASXL1 (provisional) Bohring-Opitz syndrome,605039|Myelodysplastic syndrome,somatic,614286];	RCV000386449.1 [benign]; 			122	433					ASXL1 (inh=AD pLI=0.00)
chr20	31025231	31025231	T	C	hom	hom	het		QUAL=30497;DP=356,391,441;MQM=60	ASXL1	3'UTR	ASXL1:NM_015338.5:3'UTR:MODIFIER:exon12/12:c.*90T>C:		rs2295763	0.3998	0.0000	0/0/0	0.0793							612990 [ASXL1 (provisional) Bohring-Opitz syndrome,605039|Myelodysplastic syndrome,somatic,614286];	RCV000387762.1 [benign]; 			29	107					ASXL1 (inh=AD pLI=0.00)
chr20	31025535	31025535	A	G	hom	hom	het		QUAL=22744;DP=368,232,274;MQM=59	ASXL1	3'UTR	ASXL1:NM_015338.5:3'UTR:MODIFIER:exon12/12:c.*394A>G:		rs2295762	0.4289	0.0000	0/0/0	0.4125							612990 [ASXL1 (provisional) Bohring-Opitz syndrome,605039|Myelodysplastic syndrome,somatic,614286];	RCV000404106.1 [benign]; 			29	106					ASXL1 (inh=AD pLI=0.00)
chr20	31386347	31386347	T	C	hom	hom	het		QUAL=6729;DP=150,42,72;MQM=59	DNMT3B	synonymous	DNMT3B:NM_006892.3:synonymous:LOW:exon15/23:c.1572T>C:p.Cys524Cys,DNMT3B:NM_001207055.1:synonymous:LOW:exon13/19:c.1386T>C:p.Cys462Cys,DNMT3B:NM_001207056.1:synonymous:LOW:exon12/18:c.1284T>C:p.Cys428Cys,DNMT3B:NM_175848.1:synonymous:LOW:exon14/22:c.1512T>C:p.Cys504Cys,DNMT3B:NM_175849.1:synonymous:LOW:exon14/20:c.1512T>C:p.Cys504Cys,DNMT3B:NM_175850.2:synonymous:LOW:exon14/22:c.1548T>C:p.Cys516Cys		rs6058891	0.7558	0.5806	22601/6622/3879	0.5595							602900 [DNMT3B (confirmed) Immunodeficiency-centromeric instability-facial anomalies syndrome 1,242860];	RCV000307572.1 [benign]; 		COSM4134441, COSM4134442	364	742					DNMT3B (inh=AR pLI=1.00)
chr20	31386449	31386449	T	C	hom	hom	het	low_DP	QUAL=1172;DP=26,11,20;MQM=59	DNMT3B	splice_region&synonymous	DNMT3B:NM_006892.3:splice_region&synonymous:LOW:exon15/23:c.1674T>C:p.Tyr558Tyr,DNMT3B:NM_001207055.1:splice_region&synonymous:LOW:exon13/19:c.1488T>C:p.Tyr496Tyr,DNMT3B:NM_001207056.1:splice_region&synonymous:LOW:exon12/18:c.1386T>C:p.Tyr462Tyr,DNMT3B:NM_175848.1:splice_region&synonymous:LOW:exon14/22:c.1614T>C:p.Tyr538Tyr,DNMT3B:NM_175849.1:splice_region&synonymous:LOW:exon14/20:c.1614T>C:p.Tyr538Tyr,DNMT3B:NM_175850.2:splice_region&synonymous:LOW:exon14/22:c.1650T>C:p.Tyr550Tyr		rs2424922	0.7558	0.5792	22012/6451/3616	0.5545							602900 [DNMT3B (confirmed) Immunodeficiency-centromeric instability-facial anomalies syndrome 1,242860];	RCV000343834.1 [benign]; 		COSM4134443, COSM4134444	358	742					DNMT3B (inh=AR pLI=1.00)
chr20	31387954	31387954	C	G	hom	hom	het		QUAL=18395;DP=173,274,352;MQM=59	DNMT3B	splice_region&intron	DNMT3B:NM_006892.3:splice_region&intron:LOW:exon16/22:c.1760-5C>G:,DNMT3B:NM_001207055.1:splice_region&intron:LOW:exon14/18:c.1574-5C>G:,DNMT3B:NM_001207056.1:splice_region&intron:LOW:exon13/17:c.1472-5C>G:,DNMT3B:NM_175848.1:splice_region&intron:LOW:exon15/21:c.1700-5C>G:,DNMT3B:NM_175849.1:splice_region&intron:LOW:exon15/19:c.1700-5C>G:,DNMT3B:NM_175850.2:splice_region&intron:LOW:exon15/21:c.1736-5C>G:		rs1997797	0.7141	0.5663	21416/6619/2755	0.5434							602900 [DNMT3B (confirmed) Immunodeficiency-centromeric instability-facial anomalies syndrome 1,242860];	RCV000394272.1 [benign]; 			352	751					DNMT3B (inh=AR pLI=1.00)
chr20	31388636	31388636	T	C	hom	hom	het		QUAL=18738;DP=202,252,348;MQM=59	DNMT3B	splice_region&intron	DNMT3B:NM_006892.3:splice_region&intron:LOW:exon17/22:c.1906-5T>C:,DNMT3B:NM_001207055.1:splice_region&intron:LOW:exon15/18:c.1720-5T>C:,DNMT3B:NM_001207056.1:splice_region&intron:LOW:exon14/17:c.1618-5T>C:,DNMT3B:NM_175848.1:splice_region&intron:LOW:exon16/21:c.1846-5T>C:,DNMT3B:NM_175849.1:splice_region&intron:LOW:exon16/19:c.1846-5T>C:,DNMT3B:NM_175850.2:splice_region&intron:LOW:exon16/21:c.1882-5T>C:	(CTCTCT)n	rs2424928	0.7426	0.5737	22080/6633/3366	0.5429							602900 [DNMT3B (confirmed) Immunodeficiency-centromeric instability-facial anomalies syndrome 1,242860];	RCV000356980.1 [benign]; 			364	743					DNMT3B (inh=AR pLI=1.00)
chr20	31396536	31396536	A	G	hom	hom	het		QUAL=25677;DP=524,201,242;MQM=59	DNMT3B	3'UTR	DNMT3B:NM_006892.3:3'UTR:MODIFIER:exon23/23:c.*827A>G:,DNMT3B:NM_001207055.1:3'UTR:MODIFIER:exon19/19:c.*827A>G:,DNMT3B:NM_001207056.1:3'UTR:MODIFIER:exon18/18:c.*827A>G:,DNMT3B:NM_175848.1:3'UTR:MODIFIER:exon22/22:c.*827A>G:,DNMT3B:NM_175849.1:3'UTR:MODIFIER:exon20/20:c.*827A>G:,DNMT3B:NM_175850.2:3'UTR:MODIFIER:exon22/22:c.*827A>G:		rs2424932	0.8047	0.0000	0/0/0	0.1191							602900 [DNMT3B (confirmed) Immunodeficiency-centromeric instability-facial anomalies syndrome 1,242860];	RCV000368232.1 [benign]; 			88	104					DNMT3B (inh=AR pLI=1.00)
chr20	31397020	31397020	T	-	hom	hom	het		QUAL=9076;DP=197,75,84;MQM=53	DNMT3B	3'UTR	DNMT3B:NM_006892.3:3'UTR:MODIFIER:exon23/23:c.*1318delT:,DNMT3B:NM_001207055.1:3'UTR:MODIFIER:exon19/19:c.*1318delT:,DNMT3B:NM_001207056.1:3'UTR:MODIFIER:exon18/18:c.*1318delT:,DNMT3B:NM_175848.1:3'UTR:MODIFIER:exon22/22:c.*1318delT:,DNMT3B:NM_175849.1:3'UTR:MODIFIER:exon20/20:c.*1318delT:,DNMT3B:NM_175850.2:3'UTR:MODIFIER:exon22/22:c.*1318delT:		rs398088406	0.7093	0.0000	0/0/0	0.4773							602900 [DNMT3B (confirmed) Immunodeficiency-centromeric instability-facial anomalies syndrome 1,242860];	RCV000269320.1 [benign]; 			48	109					DNMT3B (inh=AR pLI=1.00)
chr20	43034693	43034693	C	T	het	wt	het		QUAL=1853;DP=90,89,107;MQM=60	HNF4A	splice_region&intron	HNF4A:NM_000457.4:splice_region&intron:LOW:exon1/9:c.116-5C>T:,HNF4A:NM_001030004.2:splice_region&intron:LOW:exon1/7:c.50-5C>T:,HNF4A:NM_001287184.1:splice_region&intron:LOW:exon2/8:c.41-5C>T:,HNF4A:NM_001030003.2:splice_region&intron:LOW:exon1/9:c.50-5C>T:,HNF4A:NM_001287182.1:splice_region&intron:LOW:exon2/10:c.41-5C>T:,HNF4A:NM_001287183.1:splice_region&intron:LOW:exon2/10:c.41-5C>T:,HNF4A:NM_175914.4:splice_region&intron:LOW:exon1/9:c.50-5C>T:,HNF4A:NM_178850.2:splice_region&intron:LOW:exon1/7:c.116-5C>T:,HNF4A:NM_001258355.1:splice_region&intron:LOW:exon2/10:c.95-5C>T:,HNF4A:NM_178849.2:splice_region&intron:LOW:exon1/9:c.116-5C>T:		rs745975	0.1687	0.2008	2690/1802/55	0.1967							600281 [HNF4A (confirmed) MODY,type I,125850|Diabetes mellitus,noninsulin-dependent,125853|Fanconi renotubular syndrome 4,with maturity-onset diabetes of the young,616026];	RCV000117237.3 [other]; RCV000268875.1 [likely benign]; RCV000361090.1 [likely benign]; 	CS004500 [CLASS=DP MUT=ALT PHEN="Diabetes type 2 association with" GENE=HNF4A]; 		69	490					HNF4A (inh=AD pLI=0.92)
chr20	43034783	43034783	C	T	het	wt	het		QUAL=4710;DP=195,170,206;MQM=59	HNF4A	synonymous	HNF4A:NM_000457.4:synonymous:LOW:exon2/10:c.201C>T:p.Ala67Ala,HNF4A:NM_001030004.2:synonymous:LOW:exon2/8:c.135C>T:p.Ala45Ala,HNF4A:NM_001287184.1:synonymous:LOW:exon3/9:c.126C>T:p.Ala42Ala,HNF4A:NM_001030003.2:synonymous:LOW:exon2/10:c.135C>T:p.Ala45Ala,HNF4A:NM_001287182.1:synonymous:LOW:exon3/11:c.126C>T:p.Ala42Ala,HNF4A:NM_001287183.1:synonymous:LOW:exon3/11:c.126C>T:p.Ala42Ala,HNF4A:NM_175914.4:synonymous:LOW:exon2/10:c.135C>T:p.Ala45Ala,HNF4A:NM_178850.2:synonymous:LOW:exon2/8:c.201C>T:p.Ala67Ala,HNF4A:NM_001258355.1:synonymous:LOW:exon3/11:c.180C>T:p.Ala60Ala,HNF4A:NM_178849.2:synonymous:LOW:exon2/10:c.201C>T:p.Ala67Ala		rs736823	0.0146	0.0335	115/101/2	0.0342							600281 [HNF4A (confirmed) MODY,type I,125850|Diabetes mellitus,noninsulin-dependent,125853|Fanconi renotubular syndrome 4,with maturity-onset diabetes of the young,616026];	RCV000117236.3 [benign]; RCV000272263.1 [likely benign]; RCV000329726.1 [likely benign]; 			4	84					HNF4A (inh=AD pLI=0.92)
chr20	43059211	43059211	A	C	het	hom	het		QUAL=24190;DP=447,360,487;MQM=59	HNF4A	3'UTR	HNF4A:NM_000457.4:3'UTR:MODIFIER:exon10/10:c.*906A>C:,HNF4A:NM_001030003.2:3'UTR:MODIFIER:exon10/10:c.*906A>C:,HNF4A:NM_001287182.1:3'UTR:MODIFIER:exon11/11:c.*906A>C:,HNF4A:NM_001287183.1:3'UTR:MODIFIER:exon11/11:c.*906A>C:,HNF4A:NM_175914.4:3'UTR:MODIFIER:exon10/10:c.*906A>C:,HNF4A:NM_001258355.1:3'UTR:MODIFIER:exon11/11:c.*906A>C:,HNF4A:NM_178849.2:3'UTR:MODIFIER:exon10/10:c.*906A>C:	L2d2	rs3212210	0.5713	0.0000	0/0/0	0.5503							600281 [HNF4A (confirmed) MODY,type I,125850|Diabetes mellitus,noninsulin-dependent,125853|Fanconi renotubular syndrome 4,with maturity-onset diabetes of the young,616026];	RCV000270968.1 [likely benign]; RCV000365535.1 [likely benign]; RCV000306835.1 [likely benign]; RCV000361574.1 [likely benign]; 			110	100					HNF4A (inh=AD pLI=0.92)
chr20	43059238	43059256	GAGGAAGAATGGTGTGGGA	-	het	hom	wt		QUAL=11965;DP=290,332,391;MQM=59	HNF4A	3'UTR	HNF4A:NM_000457.4:3'UTR:MODIFIER:exon10/10:c.*937_*955delAAGAATGGTGTGGGAGAGG:,HNF4A:NM_001030003.2:3'UTR:MODIFIER:exon10/10:c.*937_*955delAAGAATGGTGTGGGAGAGG:,HNF4A:NM_001287182.1:3'UTR:MODIFIER:exon11/11:c.*937_*955delAAGAATGGTGTGGGAGAGG:,HNF4A:NM_001287183.1:3'UTR:MODIFIER:exon11/11:c.*937_*955delAAGAATGGTGTGGGAGAGG:,HNF4A:NM_175914.4:3'UTR:MODIFIER:exon10/10:c.*937_*955delAAGAATGGTGTGGGAGAGG:,HNF4A:NM_001258355.1:3'UTR:MODIFIER:exon11/11:c.*937_*955delAAGAATGGTGTGGGAGAGG:,HNF4A:NM_178849.2:3'UTR:MODIFIER:exon10/10:c.*937_*955delAAGAATGGTGTGGGAGAGG:	L2d2	rs72137187	0.1881	0.0000	0/0/0	0.1283							600281 [HNF4A (confirmed) MODY,type I,125850|Diabetes mellitus,noninsulin-dependent,125853|Fanconi renotubular syndrome 4,with maturity-onset diabetes of the young,616026];				8	65					HNF4A (inh=AD pLI=0.92)
chr20	43059596	43059603	TCCTCCCT	-	het	wt	het		QUAL=5107;DP=170,218,327;MQM=59	HNF4A	3'UTR	HNF4A:NM_000457.4:3'UTR:MODIFIER:exon10/10:c.*1299_*1306delTCCTCCCT:,HNF4A:NM_001030003.2:3'UTR:MODIFIER:exon10/10:c.*1299_*1306delTCCTCCCT:,HNF4A:NM_001287182.1:3'UTR:MODIFIER:exon11/11:c.*1299_*1306delTCCTCCCT:,HNF4A:NM_001287183.1:3'UTR:MODIFIER:exon11/11:c.*1299_*1306delTCCTCCCT:,HNF4A:NM_175914.4:3'UTR:MODIFIER:exon10/10:c.*1299_*1306delTCCTCCCT:,HNF4A:NM_001258355.1:3'UTR:MODIFIER:exon11/11:c.*1299_*1306delTCCTCCCT:,HNF4A:NM_178849.2:3'UTR:MODIFIER:exon10/10:c.*1299_*1306delTCCTCCCT:	MIRb:MIR	rs868132750	0.0517	0.0000	0/0/0	0.0639							600281 [HNF4A (confirmed) MODY,type I,125850|Diabetes mellitus,noninsulin-dependent,125853|Fanconi renotubular syndrome 4,with maturity-onset diabetes of the young,616026];	RCV000302022.1 [likely benign]; RCV000356823.1 [likely benign]; 			0	28					HNF4A (inh=AD pLI=0.92)
chr20	43264927	43264927	C	T	hom	hom	hom		QUAL=16063;DP=247,125,149;MQM=59	ADA	splice_region&synonymous,splice_region,splice_region&non_coding_transcript_exon,5'UTR	ADA:NM_000022.3:splice_region&synonymous:LOW:exon2/12:c.36G>A:p.Val12Val,ADA:NM_001322050.1:splice_region:LOW:exon2/11:c.-254G>A:,ADA:NM_001322051.1:splice_region&synonymous:LOW:exon2/11:c.36G>A:p.Val12Val,ADA:NR_136160.1:splice_region&non_coding_transcript_exon:LOW:exon2/11:n.187G>A:,ADA:NM_001322050.1:5'UTR:MODIFIER:exon2/11:c.-254G>A:		rs394105	0.9822	0.9955	53996/30140/4118	0.9400							608958 [ADA (confirmed) Severe combined immunodeficiency due to ADA deficiency,102700|Adenosine deaminase deficiency,partial,102700];	RCV000029300.1 [benign]; 			1562	2					ADA (inh=AR pLI=0.00)
chr20	44519643	44519643	G	A	het	het	hom		QUAL=4131;DP=55,69,97;MQM=60	NEURL2,CTSA	5'UTR,non_coding_transcript_exon	NEURL2:NM_080749.3:5'UTR:MODIFIER:exon1/2:c.-13C>T:,CTSA:NM_000308.3:5'UTR:MODIFIER:exon1/15:c.-322G>A:,NEURL2:NM_001278535.1:5'UTR:MODIFIER:exon1/2:c.-13C>T:,CTSA:NM_001127695.2:5'UTR:MODIFIER:exon1/15:c.-422G>A:,CTSA:NM_001167594.2:5'UTR:MODIFIER:exon1/14:c.-322G>A:,CTSA:NR_133656.1:non_coding_transcript_exon:MODIFIER:exon1/15:n.861G>A:		rs2868362	0.3842	0.5824	2477/1828/34	0.3506							613111 [CTSA (confirmed) Galactosialidosis,256540];	RCV000364953.1 [benign]; 			238	415					NEURL2 (inh=n/a pLI=0.00), CTSA (inh=AR pLI=0.00)
chr20	44520238	44520240	CTG	-	hom	het	hom	anno_pathogenic_hgmd	QUAL=2584;DP=22,69,63;MQM=60	CTSA	disruptive_inframe_deletion,non_coding_transcript_exon	CTSA:NM_000308.3:disruptive_inframe_deletion:MODERATE:exon2/15:c.108_110delGCT:p.Leu37del,CTSA:NM_001127695.2:disruptive_inframe_deletion:MODERATE:exon2/15:c.54_56delGCT:p.Leu19del,CTSA:NM_001167594.2:disruptive_inframe_deletion:MODERATE:exon2/14:c.108_110delGCT:p.Leu37del,CTSA:NR_133656.1:non_coding_transcript_exon:MODIFIER:exon2/15:n.1290_1292delGCT:	(CTG)n	rs3080212;rs397784956	0.6494	0.6432	19878/10192/1647	0.5456							613111 [CTSA (confirmed) Galactosialidosis,256540];	RCV000175578.1 [benign]; RCV000317016.1 [benign]; 	CD1413773 [CLASS=DM? MUT=ALT PHEN="Galactosialidosis" GENE=CTSA]; 	COSM443915	637	677	2	[2] Ute Grasshoff 28.10.2015			CTSA (inh=AR pLI=0.00)
chr20	44523547	44523547	G	A	het	het	hom		QUAL=24393;DP=217,449,508;MQM=59	CTSA	splice_region&intron	CTSA:NM_000308.3:splice_region&intron:LOW:exon10/14:c.1002+7G>A:,CTSA:NM_001127695.2:splice_region&intron:LOW:exon10/14:c.948+7G>A:,CTSA:NM_001167594.2:splice_region&intron:LOW:exon9/13:c.951+7G>A:,CTSA:NR_133656.1:splice_region&intron:LOW:exon10/14:n.2191+7G>A:		rs2075961	0.6783	0.6602	26737/13039/2302	0.6485							613111 [CTSA (confirmed) Galactosialidosis,256540];	RCV000262630.1 [benign]; 			644	718					CTSA (inh=AR pLI=0.00)
chr20	44523782	44523782	C	T	het	het	hom		QUAL=13927;DP=91,266,318;MQM=60	CTSA	splice_region&intron	CTSA:NM_000308.3:splice_region&intron:LOW:exon11/14:c.1142+10C>T:,CTSA:NM_001127695.2:splice_region&intron:LOW:exon11/14:c.1088+10C>T:,CTSA:NM_001167594.2:splice_region&intron:LOW:exon10/13:c.1091+10C>T:,CTSA:NR_133656.1:splice_region&intron:LOW:exon11/14:n.2331+10C>T:		rs4608591	0.6799	0.6608	26736/13016/2338	0.6537							613111 [CTSA (confirmed) Galactosialidosis,256540];	RCV000261253.1 [benign]; 			645	716					CTSA (inh=AR pLI=0.00)
chr20	44746982	44746982	T	C	hom	hom	hom		QUAL=3938;DP=62,27,38;MQM=60	CD40	5'UTR,non_coding_transcript_exon	CD40:NM_001322421.1:5'UTR:MODIFIER:exon1/9:c.-1T>C:,CD40:NM_001250.5:5'UTR:MODIFIER:exon1/9:c.-1T>C:,CD40:NM_001302753.1:5'UTR:MODIFIER:exon1/9:c.-1T>C:,CD40:NM_001322422.1:5'UTR:MODIFIER:exon1/7:c.-1T>C:,CD40:NM_152854.3:5'UTR:MODIFIER:exon1/8:c.-1T>C:,CD40:NR_126502.1:non_coding_transcript_exon:MODIFIER:exon1/7:n.90T>C:,CD40:NR_136327.1:non_coding_transcript_exon:MODIFIER:exon1/8:n.90T>C:		rs1883832	0.7712	0.7527	34693/18125/4613	0.7452							109535 [CD40 (confirmed) Immunodeficiency with hyper-IgM,type 3,606843];	RCV000348388.1 [benign]; 	CR052074 [CLASS=DFP MUT=REF PHEN="Graves' disease association with" GENE=CD40]; 		858	597					CD40 (inh=AR pLI=0.66)
chr20	47626847	47626847	T	C	het	het	het		QUAL=10589;DP=310,225,332;MQM=59	ARFGEF2	synonymous	ARFGEF2:NM_006420.2:synonymous:LOW:exon27/39:c.3663T>C:p.Gly1221Gly		rs2295580	0.3542	0.3195	6571/3519/1513	0.3165							605371 [ARFGEF2 (confirmed) Periventricular heterotopia with microcephaly,608097];	RCV000116402.4 [other]; RCV000406191.1 [likely benign]; 		COSM1412311	176	677					ARFGEF2 (inh=AR pLI=1.00)
chr20	47651492	47651492	G	A	het	het	het		QUAL=13041;DP=359,286,340;MQM=59	ARFGEF2	3'UTR	ARFGEF2:NM_006420.2:3'UTR:MODIFIER:exon39/39:c.*1756G>A:		rs6019602	0.3462	0.0000	0/0/0	0.0518							605371 [ARFGEF2 (confirmed) Periventricular heterotopia with microcephaly,608097];	RCV000323371.1 [likely benign]; 			15	99					ARFGEF2 (inh=AR pLI=1.00)
chr20	47652254	47652254	A	G	het	het	het		QUAL=6619;DP=171,128,199;MQM=60	ARFGEF2	3'UTR	ARFGEF2:NM_006420.2:3'UTR:MODIFIER:exon39/39:c.*2518A>G:		rs707533	0.3462	0.0000	0/0/0	0.0519							605371 [ARFGEF2 (confirmed) Periventricular heterotopia with microcephaly,608097];	RCV000403352.1 [likely benign]; 			15	99					ARFGEF2 (inh=AR pLI=1.00)
chr20	47652338	47652338	A	G	het	het	het		QUAL=5564;DP=233,87,126;MQM=60	ARFGEF2	3'UTR	ARFGEF2:NM_006420.2:3'UTR:MODIFIER:exon39/39:c.*2602A>G:		rs707534	0.3462	0.0000	0/0/0	0.0517							605371 [ARFGEF2 (confirmed) Periventricular heterotopia with microcephaly,608097];	RCV000337719.1 [likely benign]; 			15	99					ARFGEF2 (inh=AR pLI=1.00)
chr20	47652530	47652530	-	A	het	het	het		QUAL=248;DP=98,42,48;MQM=59	ARFGEF2	3'UTR	ARFGEF2:NM_006420.2:3'UTR:MODIFIER:exon39/39:c.*2806dupA:		rs397957165	0.3411	0.0000	0/0/0	0.1853							605371 [ARFGEF2 (confirmed) Periventricular heterotopia with microcephaly,608097];	RCV000267324.1 [uncertain significance]; RCV000362044.1 [likely benign]; 			0	94					ARFGEF2 (inh=AR pLI=1.00)
chr20	49551780	49551780	-	A	het	wt	het		QUAL=1620;DP=159,45,63;MQM=59	DPM1,ADNP-AS1	splice_region&intron,intron	DPM1:NM_001317034.1:splice_region&intron:LOW:exon9/9:c.784-8dupT:,DPM1:NM_001317035.1:splice_region&intron:LOW:exon9/9:c.760-8dupT:,DPM1:NM_001317036.1:splice_region&intron:LOW:exon7/7:c.610-8dupT:,DPM1:NM_003859.2:splice_region&intron:LOW:exon8/8:c.679-8dupT:,DPM1:NR_133648.1:splice_region&intron:LOW:exon8/8:n.742-8dupT:,ADNP-AS1:NR_110007.1:intron:MODIFIER:exon3/3:n.250+1428dupA:,ADNP-AS1:NR_110008.1:intron:MODIFIER:exon2/2:n.149+3806dupA:,ADNP-AS1:NR_110009.1:intron:MODIFIER:exon2/2:n.146+3806dupA:		rs11483542;rs397978438;rs560680352	0.3059	0.3342	2658/1234/630	0.2769							603503 [DPM1 (provisional) Congenital disorder of glycosylation,type Ie,608799];				98	673					DPM1 (inh=AR pLI=0.54), ADNP-AS1 (inh=n/a pLI=n/a)
chr20	57019491	57019492	AT	-	het	wt	het		QUAL=6958;DP=347,232,332;MQM=59	VAPB	3'UTR,non_coding_transcript_exon	VAPB:NM_004738.4:3'UTR:MODIFIER:exon6/6:c.*200_*201delAT:,VAPB:NM_001195677.1:3'UTR:MODIFIER:exon3/3:c.*270_*271delAT:,VAPB:NR_036633.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.1088_1089delAT:		rs571412501	0.0300	0.0406	9/0/0	0.0010							605704 [VAPB (confirmed) Amyotrophic lateral sclerosis 8,608627|Spinal muscular atrophy,late-onset,Finkel type,182980];				4	70					VAPB (inh=AD pLI=0.74)
chr20	57019495	57019495	A	T	het	wt	het		QUAL=6836;DP=232,216,293;MQM=59	VAPB	3'UTR,non_coding_transcript_exon	VAPB:NM_004738.4:3'UTR:MODIFIER:exon6/6:c.*204A>T:,VAPB:NM_001195677.1:3'UTR:MODIFIER:exon3/3:c.*274A>T:,VAPB:NR_036633.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.1092A>T:			0.0000	0.0000	0/0/0	0.0001							605704 [VAPB (confirmed) Amyotrophic lateral sclerosis 8,608627|Spinal muscular atrophy,late-onset,Finkel type,182980];				4	70					VAPB (inh=AD pLI=0.74)
chr20	57019496	57019496	T	G	het	wt	het		QUAL=6836;DP=232,216,293;MQM=59	VAPB	3'UTR,non_coding_transcript_exon	VAPB:NM_004738.4:3'UTR:MODIFIER:exon6/6:c.*205T>G:,VAPB:NM_001195677.1:3'UTR:MODIFIER:exon3/3:c.*275T>G:,VAPB:NR_036633.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.1093T>G:			0.0000	0.0000	0/0/0	0.0001							605704 [VAPB (confirmed) Amyotrophic lateral sclerosis 8,608627|Spinal muscular atrophy,late-onset,Finkel type,182980];				4	70					VAPB (inh=AD pLI=0.74)
chr20	57019497	57019497	-	GGGG	het	wt	het		QUAL=6836;DP=232,216,293;MQM=59	VAPB	3'UTR,non_coding_transcript_exon	VAPB:NM_004738.4:3'UTR:MODIFIER:exon6/6:c.*207_*208insGGGG:,VAPB:NM_001195677.1:3'UTR:MODIFIER:exon3/3:c.*277_*278insGGGG:,VAPB:NR_036633.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.1095_1096insGGGG:		rs777453383	0.0000	0.0000	0/0/0	0.0001							605704 [VAPB (confirmed) Amyotrophic lateral sclerosis 8,608627|Spinal muscular atrophy,late-onset,Finkel type,182980];				4	70					VAPB (inh=AD pLI=0.74)
chr20	57019499	57019499	T	A	het	wt	het		QUAL=6836;DP=232,216,293;MQM=59	VAPB	3'UTR,non_coding_transcript_exon	VAPB:NM_004738.4:3'UTR:MODIFIER:exon6/6:c.*208T>A:,VAPB:NM_001195677.1:3'UTR:MODIFIER:exon3/3:c.*278T>A:,VAPB:NR_036633.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.1096T>A:		rs577029630	0.0300	0.0000	0/0/0	0.0010							605704 [VAPB (confirmed) Amyotrophic lateral sclerosis 8,608627|Spinal muscular atrophy,late-onset,Finkel type,182980];				4	70					VAPB (inh=AD pLI=0.74)
chr20	57019502	57019502	-	AT	het	wt	het		QUAL=6836;DP=232,216,293;MQM=59	VAPB	3'UTR,non_coding_transcript_exon	VAPB:NM_004738.4:3'UTR:MODIFIER:exon6/6:c.*211_*212insAT:,VAPB:NM_001195677.1:3'UTR:MODIFIER:exon3/3:c.*281_*282insAT:,VAPB:NR_036633.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.1099_1100insAT:			0.0000	0.0000	0/0/0	0.0000							605704 [VAPB (confirmed) Amyotrophic lateral sclerosis 8,608627|Spinal muscular atrophy,late-onset,Finkel type,182980];				4	70					VAPB (inh=AD pLI=0.74)
chr20	57019504	57019504	G	A	het	wt	het		QUAL=6836;DP=232,216,293;MQM=59	VAPB	3'UTR,non_coding_transcript_exon	VAPB:NM_004738.4:3'UTR:MODIFIER:exon6/6:c.*213G>A:,VAPB:NM_001195677.1:3'UTR:MODIFIER:exon3/3:c.*283G>A:,VAPB:NR_036633.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.1101G>A:		rs202245892	0.0000	0.0000	0/0/0	0.0001							605704 [VAPB (confirmed) Amyotrophic lateral sclerosis 8,608627|Spinal muscular atrophy,late-onset,Finkel type,182980];				4	70					VAPB (inh=AD pLI=0.74)
chr20	57019505	57019505	-	AAG	het	wt	het		QUAL=6836;DP=232,216,293;MQM=59	VAPB	3'UTR,non_coding_transcript_exon	VAPB:NM_004738.4:3'UTR:MODIFIER:exon6/6:c.*214_*215insAAG:,VAPB:NM_001195677.1:3'UTR:MODIFIER:exon3/3:c.*284_*285insAAG:,VAPB:NR_036633.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.1102_1103insAAG:			0.0000	0.0000	0/0/0	0.0000							605704 [VAPB (confirmed) Amyotrophic lateral sclerosis 8,608627|Spinal muscular atrophy,late-onset,Finkel type,182980];				4	70					VAPB (inh=AD pLI=0.74)
chr20	57020741	57020758	TGTGTGTGTGTGTGTGTG	-	het	het	wt		QUAL=3312;DP=271,143,173;MQM=59	VAPB	3'UTR,non_coding_transcript_exon	VAPB:NM_004738.4:3'UTR:MODIFIER:exon6/6:c.*1469_*1486delGTGTGTGTGTGTGTGTGT:,VAPB:NM_001195677.1:3'UTR:MODIFIER:exon3/3:c.*1539_*1556delGTGTGTGTGTGTGTGTGT:,VAPB:NR_036633.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.2357_2374delGTGTGTGTGTGTGTGTGT:	(TG)n	rs138225455	0.0000	0.2978	137/51/10	0.0211							605704 [VAPB (confirmed) Amyotrophic lateral sclerosis 8,608627|Spinal muscular atrophy,late-onset,Finkel type,182980];				70	108					VAPB (inh=AD pLI=0.74)
chr20	57022713	57022720	TGTGTGCA	-	hom	hom	hom		QUAL=12275;DP=143,164,158;MQM=59	VAPB	3'UTR,non_coding_transcript_exon	VAPB:NM_004738.4:3'UTR:MODIFIER:exon6/6:c.*3444_*3451delCATGTGTG:,VAPB:NM_001195677.1:3'UTR:MODIFIER:exon3/3:c.*3514_*3521delCATGTGTG:,VAPB:NR_036633.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.4332_4339delCATGTGTG:	(TGTGTGCA)n	rs201983028	0.9091	0.9145	4487/1101/76	0.1964							605704 [VAPB (confirmed) Amyotrophic lateral sclerosis 8,608627|Spinal muscular atrophy,late-onset,Finkel type,182980];	RCV000271475.1 [benign]; RCV000363767.1 [benign]; 			468	83					VAPB (inh=AD pLI=0.74)
chr20	57023343	57023343	C	T	het	het	wt		QUAL=7841;DP=425,263,345;MQM=60	VAPB	3'UTR,non_coding_transcript_exon	VAPB:NM_004738.4:3'UTR:MODIFIER:exon6/6:c.*4052C>T:,VAPB:NM_001195677.1:3'UTR:MODIFIER:exon3/3:c.*4122C>T:,VAPB:NR_036633.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.4940C>T:		rs76295834	0.0210	0.0222	5/2/0	0.0102							605704 [VAPB (confirmed) Amyotrophic lateral sclerosis 8,608627|Spinal muscular atrophy,late-onset,Finkel type,182980];	RCV000334124.1 [likely benign]; RCV000370068.1 [likely benign]; 			2	66					VAPB (inh=AD pLI=0.74)
chr20	57023737	57023737	G	A	het	het	wt		QUAL=5562;DP=312,116,164;MQM=60	VAPB	3'UTR,non_coding_transcript_exon	VAPB:NM_004738.4:3'UTR:MODIFIER:exon6/6:c.*4446G>A:,VAPB:NM_001195677.1:3'UTR:MODIFIER:exon3/3:c.*4516G>A:,VAPB:NR_036633.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.5334G>A:		rs79623348	0.0270	0.0260	6/2/0	0.0107							605704 [VAPB (confirmed) Amyotrophic lateral sclerosis 8,608627|Spinal muscular atrophy,late-onset,Finkel type,182980];	RCV000273605.1 [likely benign]; RCV000368174.1 [likely benign]; 			2	66					VAPB (inh=AD pLI=0.74)
chr20	57024159	57024159	C	T	het	het	wt		QUAL=3314;DP=170,75,119;MQM=59	VAPB	3'UTR,non_coding_transcript_exon	VAPB:NM_004738.4:3'UTR:MODIFIER:exon6/6:c.*4868C>T:,VAPB:NM_001195677.1:3'UTR:MODIFIER:exon3/3:c.*4938C>T:,VAPB:NR_036633.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.5756C>T:		rs74748993	0.0212	0.0220	5/2/0	0.0102							605704 [VAPB (confirmed) Amyotrophic lateral sclerosis 8,608627|Spinal muscular atrophy,late-onset,Finkel type,182980];	RCV000321832.1 [likely benign]; RCV000376542.1 [likely benign]; 			2	66					VAPB (inh=AD pLI=0.74)
chr20	57024541	57024541	T	C	het	het	wt		QUAL=4802;DP=319,154,171;MQM=60	VAPB	3'UTR,non_coding_transcript_exon	VAPB:NM_004738.4:3'UTR:MODIFIER:exon6/6:c.*5250T>C:,VAPB:NM_001195677.1:3'UTR:MODIFIER:exon3/3:c.*5320T>C:,VAPB:NR_036633.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.6138T>C:		rs6015274	0.4832	0.4272	1026/252/26	0.1124							605704 [VAPB (confirmed) Amyotrophic lateral sclerosis 8,608627|Spinal muscular atrophy,late-onset,Finkel type,182980];	RCV000303935.1 [benign]; RCV000358667.1 [benign]; 			121	288					VAPB (inh=AD pLI=0.74)
chr20	57024589	57024589	C	T	het	het	wt		QUAL=6082;DP=368,171,220;MQM=60	VAPB	3'UTR,non_coding_transcript_exon	VAPB:NM_004738.4:3'UTR:MODIFIER:exon6/6:c.*5298C>T:,VAPB:NM_001195677.1:3'UTR:MODIFIER:exon3/3:c.*5368C>T:,VAPB:NR_036633.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.6186C>T:		rs6015275	0.2091	0.2547	375/69/3	0.0564							605704 [VAPB (confirmed) Amyotrophic lateral sclerosis 8,608627|Spinal muscular atrophy,late-onset,Finkel type,182980];	RCV000264156.1 [benign]; RCV000319356.1 [benign]; 			31	214					VAPB (inh=AD pLI=0.74)
chr20	57025407	57025410	TCTG	-	het	het	wt		QUAL=9433;DP=420,320,416;MQM=59	VAPB	3'UTR,non_coding_transcript_exon	VAPB:NM_004738.4:3'UTR:MODIFIER:exon6/6:c.*6121_*6124delCTGT:,VAPB:NM_001195677.1:3'UTR:MODIFIER:exon3/3:c.*6191_*6194delCTGT:,VAPB:NR_036633.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.7009_7012delCTGT:		rs143261907	0.0214	0.0223	5/2/0	0.0100							605704 [VAPB (confirmed) Amyotrophic lateral sclerosis 8,608627|Spinal muscular atrophy,late-onset,Finkel type,182980];	RCV000328637.1 [likely benign]; RCV000383258.1 [likely benign]; 			2	66					VAPB (inh=AD pLI=0.74)
chr20	57415110	57415110	A	G	hom	hom	het		QUAL=15038;DP=131,240,294;MQM=59	GNAS,GNAS-AS1	5'UTR,intron	GNAS:NM_016592.3:5'UTR:MODIFIER:exon1/13:c.-52A>G:,GNAS-AS1:NR_002785.2:intron:MODIFIER:exon4/4:n.819+1882T>C:		rs1800900	0.5976	0.0000	0/0/0	0.1298							610540 [GNAS-AS1 (provisional) Pseudohypoparathyroidism,type IB,603233]:139320 [GNAS (confirmed) Pseudohypoparathyroidism Ia,103580|McCune-Albright syndrome,somatic,mosaic 174800|Pseudohypoparathyroidism Ic,612462|Osseous heteroplasia,progressive,166350|Pseudohypoparathyroidism Ib,603233|Acromegaly,somatic,102200|Pseudopseudohypoparathyroidism,612463|ACTH-independent macronodular adrenal hyperplasia,219080];				302	344					GNAS (inh=AD pLI=1.00), GNAS-AS1 (inh=AD pLI=n/a)
chr20	57429447	57429447	C	T	wt	wt	het	pred_pathogenic	QUAL=2141;DP=51,153,209;MQM=60	GNAS	missense,intron	GNAS:NM_080425.3:missense:MODERATE:exon1/13:c.1127C>T:p.Pro376Leu,GNAS:NM_001309883.1:missense:MODERATE:exon1/6:c.940C>T:p.Arg314Trp,GNAS:NM_001077490.2:missense:MODERATE:exon1/13:c.940C>T:p.Arg314Trp,GNAS:NM_016592.3:intron:MODIFIER:exon1/12:c.*42+13506C>T:,GNAS:NM_001309861.1:intron:MODIFIER:exon1/12:c.-39+12517C>T:		rs61749697	0.0182	0.0306	8/7/0	0.0156	0.6910	T,T,T,D	T,T	B,.	D,D,.	22.20	139320 [GNAS (confirmed) Pseudohypoparathyroidism Ia,103580|McCune-Albright syndrome,somatic,mosaic 174800|Pseudohypoparathyroidism Ic,612462|Osseous heteroplasia,progressive,166350|Pseudohypoparathyroidism Ib,603233|Acromegaly,somatic,102200|Pseudopseudohypoparathyroidism,612463|ACTH-independent macronodular adrenal hyperplasia,219080];	RCV000121165.1 [not provided]; 		COSM3758659	4	85					GNAS (inh=AD pLI=1.00)
chr20	57478807	57478807	C	T	het	wt	hom		QUAL=32990;DP=596,577,796;MQM=60	GNAS	synonymous,3'UTR	GNAS:NM_080425.3:synonymous:LOW:exon5/13:c.2322C>T:p.Ile774Ile,GNAS:NM_001309861.1:synonymous:LOW:exon5/13:c.216C>T:p.Ile72Ile,GNAS:NM_001309840.1:synonymous:LOW:exon5/13:c.216C>T:p.Ile72Ile,GNAS:NM_000516.5:synonymous:LOW:exon5/13:c.393C>T:p.Ile131Ile,GNAS:NM_001077488.3:synonymous:LOW:exon5/13:c.396C>T:p.Ile132Ile,GNAS:NM_001077489.3:synonymous:LOW:exon4/12:c.348C>T:p.Ile116Ile,GNAS:NM_080426.3:synonymous:LOW:exon4/12:c.351C>T:p.Ile117Ile,GNAS:NM_016592.3:3'UTR:MODIFIER:exon5/13:c.*299C>T:,GNAS:NM_001077490.2:3'UTR:MODIFIER:exon5/13:c.*254C>T:		rs7121	0.6444	0.5473	18875/8501/2997	0.5393	-0.3130		T			15.17	139320 [GNAS (confirmed) Pseudohypoparathyroidism Ia,103580|McCune-Albright syndrome,somatic,mosaic 174800|Pseudohypoparathyroidism Ic,612462|Osseous heteroplasia,progressive,166350|Pseudohypoparathyroidism Ib,603233|Acromegaly,somatic,102200|Pseudopseudohypoparathyroidism,612463|ACTH-independent macronodular adrenal hyperplasia,219080];	RCV000178784.1 [benign]; 	CM023931 [CLASS=DP MUT=REF PHEN="Essential hypertension association with" GENE=GNAS]; 	COSM3758661, COSM3758662	479	778					GNAS (inh=AD pLI=1.00)
chr20	57899654	57899654	C	-	het	het	wt		QUAL=2597;DP=152,93,106;MQM=59	EDN3	3'UTR	EDN3:NM_207034.2:3'UTR:MODIFIER:exon5/5:c.*149delC:,EDN3:NM_001302455.1:3'UTR:MODIFIER:exon5/5:c.*273delC:,EDN3:NM_001302456.1:3'UTR:MODIFIER:exon4/4:c.*241delC:,EDN3:NM_207032.2:3'UTR:MODIFIER:exon5/5:c.*241delC:,EDN3:NM_207033.2:3'UTR:MODIFIER:exon4/4:c.*149delC:		rs11475273;rs754876648	0.0000	0.0000	0/0/0	0.1017							131242 [EDN3 (confirmed) Waardenburg syndrome,type 4B,613265|Central hypoventilation syndrome,congenital,209880|Hirschsprung disease,susceptibility to,4,613712];				9	84					EDN3 (inh=AR+AD pLI=0.07)
chr20	61974862	61974862	C	T	het	wt	het		QUAL=8475;DP=152,393,523;MQM=59	CHRNA4	3'UTR,non_coding_transcript_exon	CHRNA4:NM_000744.6:3'UTR:MODIFIER:exon6/6:c.*3228G>A:,CHRNA4:NM_001256573.1:3'UTR:MODIFIER:exon6/6:c.*3228G>A:,CHRNA4:NR_046317.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.5368G>A:		rs45601435	0.0262	0.0609	33/18/0	0.0089							118504 [CHRNA4 (confirmed) Epilepsy,nocturnal frontal lobe,1,600513|Nicotine addiction,susceptibility to,188890];				3	80					CHRNA4 (inh=AD pLI=0.02)
chr20	61974929	61974929	-	AT	het	wt	het		QUAL=6694;DP=215,305,399;MQM=59	CHRNA4	3'UTR,non_coding_transcript_exon	CHRNA4:NM_000744.6:3'UTR:MODIFIER:exon6/6:c.*3160_*3161insAT:,CHRNA4:NM_001256573.1:3'UTR:MODIFIER:exon6/6:c.*3160_*3161insAT:,CHRNA4:NR_046317.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.5300_5301insAT:	MER74A	rs79237427	0.1134	0.1922	228/33/1	0.0296							118504 [CHRNA4 (confirmed) Epilepsy,nocturnal frontal lobe,1,600513|Nicotine addiction,susceptibility to,188890];				10	140					CHRNA4 (inh=AD pLI=0.02)
chr20	61974986	61974986	C	A	het	wt	het		QUAL=4399;DP=111,202,272;MQM=59	CHRNA4	3'UTR,non_coding_transcript_exon	CHRNA4:NM_000744.6:3'UTR:MODIFIER:exon6/6:c.*3104G>T:,CHRNA4:NM_001256573.1:3'UTR:MODIFIER:exon6/6:c.*3104G>T:,CHRNA4:NR_046317.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.5244G>T:	MER74A	rs45543134	0.0789	0.1560	150/31/0	0.0248							118504 [CHRNA4 (confirmed) Epilepsy,nocturnal frontal lobe,1,600513|Nicotine addiction,susceptibility to,188890];				10	128					CHRNA4 (inh=AD pLI=0.02)
chr20	61974991	61974991	-	G	het	wt	het		QUAL=4203;DP=104,194,257;MQM=59	CHRNA4	3'UTR,non_coding_transcript_exon	CHRNA4:NM_000744.6:3'UTR:MODIFIER:exon6/6:c.*3098dupC:,CHRNA4:NM_001256573.1:3'UTR:MODIFIER:exon6/6:c.*3098dupC:,CHRNA4:NR_046317.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.5238dupC:	MER74A	rs148816386	0.0292	0.0634	32/16/0	0.0092							118504 [CHRNA4 (confirmed) Epilepsy,nocturnal frontal lobe,1,600513|Nicotine addiction,susceptibility to,188890];				3	73					CHRNA4 (inh=AD pLI=0.02)
chr20	61975084	61975084	A	G	het	wt	het		QUAL=2452;DP=90,84,121;MQM=59	CHRNA4	3'UTR,non_coding_transcript_exon	CHRNA4:NM_000744.6:3'UTR:MODIFIER:exon6/6:c.*3006T>C:,CHRNA4:NM_001256573.1:3'UTR:MODIFIER:exon6/6:c.*3006T>C:,CHRNA4:NR_046317.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.5146T>C:	MER74A	rs45620536	0.0835	0.1605	143/31/0	0.0247							118504 [CHRNA4 (confirmed) Epilepsy,nocturnal frontal lobe,1,600513|Nicotine addiction,susceptibility to,188890];				13	121					CHRNA4 (inh=AD pLI=0.02)
chr20	61975091	61975091	A	G	het	wt	het		QUAL=2082;DP=84,82,108;MQM=59	CHRNA4	3'UTR,non_coding_transcript_exon	CHRNA4:NM_000744.6:3'UTR:MODIFIER:exon6/6:c.*2999T>C:,CHRNA4:NM_001256573.1:3'UTR:MODIFIER:exon6/6:c.*2999T>C:,CHRNA4:NR_046317.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.5139T>C:	MER74A	rs45600338	0.0771	0.1559	140/32/0	0.0242							118504 [CHRNA4 (confirmed) Epilepsy,nocturnal frontal lobe,1,600513|Nicotine addiction,susceptibility to,188890];				13	119					CHRNA4 (inh=AD pLI=0.02)
chr20	61975378	61975378	A	G	het	wt	het		QUAL=4978;DP=200,186,251;MQM=59	CHRNA4	3'UTR,non_coding_transcript_exon	CHRNA4:NM_000744.6:3'UTR:MODIFIER:exon6/6:c.*2712T>C:,CHRNA4:NM_001256573.1:3'UTR:MODIFIER:exon6/6:c.*2712T>C:,CHRNA4:NR_046317.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.4852T>C:	L1ME3	rs6090378	0.0677	0.1067	78/18/0	0.0143							118504 [CHRNA4 (confirmed) Epilepsy,nocturnal frontal lobe,1,600513|Nicotine addiction,susceptibility to,188890];				4	73					CHRNA4 (inh=AD pLI=0.02)
chr20	61975624	61975624	G	C	het	wt	het		QUAL=7365;DP=261,325,334;MQM=60	CHRNA4	3'UTR,non_coding_transcript_exon	CHRNA4:NM_000744.6:3'UTR:MODIFIER:exon6/6:c.*2466C>G:,CHRNA4:NM_001256573.1:3'UTR:MODIFIER:exon6/6:c.*2466C>G:,CHRNA4:NR_046317.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.4606C>G:	L1ME3	rs45494793	0.0296	0.0614	34/18/0	0.0093							118504 [CHRNA4 (confirmed) Epilepsy,nocturnal frontal lobe,1,600513|Nicotine addiction,susceptibility to,188890];				3	78					CHRNA4 (inh=AD pLI=0.02)
chr20	61975829	61975829	-	T	het	wt	het		QUAL=1818;DP=131,134,145;MQM=59	CHRNA4	3'UTR,non_coding_transcript_exon	CHRNA4:NM_000744.6:3'UTR:MODIFIER:exon6/6:c.*2260dupA:,CHRNA4:NM_001256573.1:3'UTR:MODIFIER:exon6/6:c.*2260dupA:,CHRNA4:NR_046317.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.4400dupA:		rs11480478;rs568329035	0.2746	0.2015	39/8/0	0.0277							118504 [CHRNA4 (confirmed) Epilepsy,nocturnal frontal lobe,1,600513|Nicotine addiction,susceptibility to,188890];				13	225					CHRNA4 (inh=AD pLI=0.02)
chr20	61975846	61975846	-	A	het	wt	het		QUAL=1249;DP=144,116,122;MQM=59	CHRNA4	3'UTR,non_coding_transcript_exon	CHRNA4:NM_000744.6:3'UTR:MODIFIER:exon6/6:c.*2243dupT:,CHRNA4:NM_001256573.1:3'UTR:MODIFIER:exon6/6:c.*2243dupT:,CHRNA4:NR_046317.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.4383dupT:		rs551959449	0.2885	0.4044	2/0/0	0.0175							118504 [CHRNA4 (confirmed) Epilepsy,nocturnal frontal lobe,1,600513|Nicotine addiction,susceptibility to,188890];				12	273					CHRNA4 (inh=AD pLI=0.02)
chr20	61976028	61976028	G	A	het	wt	het		QUAL=4541;DP=115,168,210;MQM=59	CHRNA4	3'UTR,non_coding_transcript_exon	CHRNA4:NM_000744.6:3'UTR:MODIFIER:exon6/6:c.*2062C>T:,CHRNA4:NM_001256573.1:3'UTR:MODIFIER:exon6/6:c.*2062C>T:,CHRNA4:NR_046317.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.4202C>T:		rs45536037	0.0296	0.0610	34/18/0	0.0091							118504 [CHRNA4 (confirmed) Epilepsy,nocturnal frontal lobe,1,600513|Nicotine addiction,susceptibility to,188890];				3	80					CHRNA4 (inh=AD pLI=0.02)
chr20	61976032	61976032	A	G	het	wt	het		QUAL=4541;DP=115,168,210;MQM=59	CHRNA4	3'UTR,non_coding_transcript_exon	CHRNA4:NM_000744.6:3'UTR:MODIFIER:exon6/6:c.*2058T>C:,CHRNA4:NM_001256573.1:3'UTR:MODIFIER:exon6/6:c.*2058T>C:,CHRNA4:NR_046317.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.4198T>C:		rs45523232	0.0296	0.0610	34/18/0	0.0092							118504 [CHRNA4 (confirmed) Epilepsy,nocturnal frontal lobe,1,600513|Nicotine addiction,susceptibility to,188890];				3	80					CHRNA4 (inh=AD pLI=0.02)
chr20	61976530	61976530	C	T	het	wt	het		QUAL=2407;DP=76,78,129;MQM=60	CHRNA4	3'UTR,non_coding_transcript_exon	CHRNA4:NM_000744.6:3'UTR:MODIFIER:exon6/6:c.*1560G>A:,CHRNA4:NM_001256573.1:3'UTR:MODIFIER:exon6/6:c.*1560G>A:,CHRNA4:NR_046317.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.3700G>A:		rs45476096	0.0262	0.0589	27/17/0	0.0087							118504 [CHRNA4 (confirmed) Epilepsy,nocturnal frontal lobe,1,600513|Nicotine addiction,susceptibility to,188890];				3	78					CHRNA4 (inh=AD pLI=0.02)
chr20	61976920	61976920	T	C	het	wt	het		QUAL=1199;DP=80,53,48;MQM=60	CHRNA4	3'UTR,non_coding_transcript_exon	CHRNA4:NM_000744.6:3'UTR:MODIFIER:exon6/6:c.*1170A>G:,CHRNA4:NM_001256573.1:3'UTR:MODIFIER:exon6/6:c.*1170A>G:,CHRNA4:NR_046317.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.3310A>G:		rs41283006	0.0487	0.1247	60/10/0	0.0126							118504 [CHRNA4 (confirmed) Epilepsy,nocturnal frontal lobe,1,600513|Nicotine addiction,susceptibility to,188890];				3	79					CHRNA4 (inh=AD pLI=0.02)
chr20	61977015	61977015	C	T	het	wt	het	low_DP	QUAL=327;DP=35,17,14;MQM=59	CHRNA4	3'UTR,non_coding_transcript_exon	CHRNA4:NM_000744.6:3'UTR:MODIFIER:exon6/6:c.*1075G>A:,CHRNA4:NM_001256573.1:3'UTR:MODIFIER:exon6/6:c.*1075G>A:,CHRNA4:NR_046317.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.3215G>A:		rs41283008	0.0302	0.0614	34/18/0	0.0092							118504 [CHRNA4 (confirmed) Epilepsy,nocturnal frontal lobe,1,600513|Nicotine addiction,susceptibility to,188890];				2	81					CHRNA4 (inh=AD pLI=0.02)
chr20	61977049	61977049	G	C	het	wt	het	low_DP	QUAL=335;DP=44,15,13;MQM=59	CHRNA4	3'UTR,non_coding_transcript_exon	CHRNA4:NM_000744.6:3'UTR:MODIFIER:exon6/6:c.*1041C>G:,CHRNA4:NM_001256573.1:3'UTR:MODIFIER:exon6/6:c.*1041C>G:,CHRNA4:NR_046317.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.3181C>G:		rs41283010	0.0302	0.0617	34/18/0	0.0093							118504 [CHRNA4 (confirmed) Epilepsy,nocturnal frontal lobe,1,600513|Nicotine addiction,susceptibility to,188890];				3	80					CHRNA4 (inh=AD pLI=0.02)
chr20	61977335	61977335	A	G	het	wt	het		QUAL=550;DP=42,22,29;MQM=59	CHRNA4	3'UTR,non_coding_transcript_exon	CHRNA4:NM_000744.6:3'UTR:MODIFIER:exon6/6:c.*755T>C:,CHRNA4:NM_001256573.1:3'UTR:MODIFIER:exon6/6:c.*755T>C:,CHRNA4:NR_046317.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.2895T>C:		rs45624232	0.0751	0.1491	147/34/0	0.0244							118504 [CHRNA4 (confirmed) Epilepsy,nocturnal frontal lobe,1,600513|Nicotine addiction,susceptibility to,188890];				10	138					CHRNA4 (inh=AD pLI=0.02)
chr20	61977373	61977373	G	A	het	wt	het		QUAL=562;DP=38,32,35;MQM=59	CHRNA4	3'UTR,non_coding_transcript_exon	CHRNA4:NM_000744.6:3'UTR:MODIFIER:exon6/6:c.*717C>T:,CHRNA4:NM_001256573.1:3'UTR:MODIFIER:exon6/6:c.*717C>T:,CHRNA4:NR_046317.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.2857C>T:		rs45556643	0.0304	0.0614	34/18/0	0.0089							118504 [CHRNA4 (confirmed) Epilepsy,nocturnal frontal lobe,1,600513|Nicotine addiction,susceptibility to,188890];				3	79					CHRNA4 (inh=AD pLI=0.02)
chr20	61977556	61977556	G	A	het	het	het		QUAL=9544;DP=161,282,310;MQM=60	CHRNA4	3'UTR,non_coding_transcript_exon	CHRNA4:NM_000744.6:3'UTR:MODIFIER:exon6/6:c.*534C>T:,CHRNA4:NM_001256573.1:3'UTR:MODIFIER:exon6/6:c.*534C>T:,CHRNA4:NR_046317.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.2674C>T:		rs2236196	0.6142	0.6256	2122/541/16	0.1777							118504 [CHRNA4 (confirmed) Epilepsy,nocturnal frontal lobe,1,600513|Nicotine addiction,susceptibility to,188890];		CR077876 [CLASS=DFP MUT=REF PHEN="Nicotine dependence association with" GENE=CHRNA4]; 		327	267					CHRNA4 (inh=AD pLI=0.02)
chr20	61981104	61981104	C	T	het	het	het		QUAL=3933;DP=49,163,226;MQM=60	CHRNA4	synonymous,non_coding_transcript_exon	CHRNA4:NM_000744.6:synonymous:LOW:exon5/6:c.1659G>A:p.Ala553Ala,CHRNA4:NM_001256573.1:synonymous:LOW:exon5/6:c.1131G>A:p.Ala377Ala,CHRNA4:NR_046317.1:non_coding_transcript_exon:MODIFIER:exon5/6:n.1915G>A:		rs1044397	0.3518	0.4750	14137/9170/80	0.4603							118504 [CHRNA4 (confirmed) Epilepsy,nocturnal frontal lobe,1,600513|Nicotine addiction,susceptibility to,188890];	RCV000079314.9 [other]; 		COSM3758737	304	567					CHRNA4 (inh=AD pLI=0.02)
chr20	61981134	61981134	G	A	het	het	het		QUAL=6113;DP=103,189,258;MQM=60	CHRNA4	synonymous,non_coding_transcript_exon	CHRNA4:NM_000744.6:synonymous:LOW:exon5/6:c.1629C>T:p.Ser543Ser,CHRNA4:NM_001256573.1:synonymous:LOW:exon5/6:c.1101C>T:p.Ser367Ser,CHRNA4:NR_046317.1:non_coding_transcript_exon:MODIFIER:exon5/6:n.1885C>T:		rs1044396	0.3235	0.4659	13598/9089/75	0.4511							118504 [CHRNA4 (confirmed) Epilepsy,nocturnal frontal lobe,1,600513|Nicotine addiction,susceptibility to,188890];	RCV000079313.9 [other]; 		COSM3758738	301	560					CHRNA4 (inh=AD pLI=0.02)
chr20	61981536	61981536	A	G	hom	het	hom		QUAL=14911;DP=110,214,286;MQM=59	CHRNA4	synonymous,non_coding_transcript_exon	CHRNA4:NM_000744.6:synonymous:LOW:exon5/6:c.1227T>C:p.Cys409Cys,CHRNA4:NM_001256573.1:synonymous:LOW:exon5/6:c.699T>C:p.Cys233Cys,CHRNA4:NR_046317.1:non_coding_transcript_exon:MODIFIER:exon5/6:n.1483T>C:		rs2229960	0.8708	0.9357	40678/23296/1633	0.8704							118504 [CHRNA4 (confirmed) Epilepsy,nocturnal frontal lobe,1,600513|Nicotine addiction,susceptibility to,188890];	RCV000079311.9 [other]; 		COSM4134782	1369	163					CHRNA4 (inh=AD pLI=0.02)
chr20	61981554	61981554	C	A	hom	het	hom		QUAL=14161;DP=105,231,299;MQM=59	CHRNA4	synonymous,non_coding_transcript_exon	CHRNA4:NM_000744.6:synonymous:LOW:exon5/6:c.1209G>T:p.Pro403Pro,CHRNA4:NM_001256573.1:synonymous:LOW:exon5/6:c.681G>T:p.Pro227Pro,CHRNA4:NR_046317.1:non_coding_transcript_exon:MODIFIER:exon5/6:n.1465G>T:		rs2229959	0.7338	0.8354	35239/21198/881	0.7850							118504 [CHRNA4 (confirmed) Epilepsy,nocturnal frontal lobe,1,600513|Nicotine addiction,susceptibility to,188890];	RCV000079310.9 [other]; 		COSM4134783	1101	388					CHRNA4 (inh=AD pLI=0.02)
chr20	61982085	61982085	A	G	hom	het	hom		QUAL=68729;DP=415,1118,1336;MQM=59	CHRNA4	synonymous,non_coding_transcript_exon	CHRNA4:NM_000744.6:synonymous:LOW:exon5/6:c.678T>C:p.Cys226Cys,CHRNA4:NM_001256573.1:synonymous:LOW:exon5/6:c.150T>C:p.Cys50Cys,CHRNA4:NR_046317.1:non_coding_transcript_exon:MODIFIER:exon5/6:n.934T>C:		rs1044394	0.8636	0.9196	51602/28961/2215	0.8980							118504 [CHRNA4 (confirmed) Epilepsy,nocturnal frontal lobe,1,600513|Nicotine addiction,susceptibility to,188890];	RCV000116723.4 [other]; 			1362	192					CHRNA4 (inh=AD pLI=0.02)
chr20	61982124	61982124	A	G	hom	het	hom		QUAL=61752;DP=469,987,1172;MQM=59	CHRNA4	synonymous,non_coding_transcript_exon	CHRNA4:NM_000744.6:synonymous:LOW:exon5/6:c.639T>C:p.Asp213Asp,CHRNA4:NM_001256573.1:synonymous:LOW:exon5/6:c.111T>C:p.Asp37Asp,CHRNA4:NR_046317.1:non_coding_transcript_exon:MODIFIER:exon5/6:n.895T>C:		rs1044393	0.7572	0.8353	42869/25323/1471	0.8109							118504 [CHRNA4 (confirmed) Epilepsy,nocturnal frontal lobe,1,600513|Nicotine addiction,susceptibility to,188890];	RCV000116722.4 [other]; 			1107	405					CHRNA4 (inh=AD pLI=0.02)
chr20	62037879	62037879	A	C	het	wt	het	low_QUAL	QUAL=21;DP=29,20,48;MQM=59	KCNQ2	3'UTR	KCNQ2:NM_172107.3:3'UTR:MODIFIER:exon17/17:c.*118T>G:,KCNQ2:NM_004518.5:3'UTR:MODIFIER:exon15/15:c.*118T>G:,KCNQ2:NM_172106.2:3'UTR:MODIFIER:exon16/16:c.*118T>G:,KCNQ2:NM_172108.4:3'UTR:MODIFIER:exon16/16:c.*118T>G:			0.0000	0.0000	0/0/0	0.0002							602235 [KCNQ2 (confirmed) Seizures,benign neonatal,1,121200|Myokymia,121200|Epileptic encephalopathy,early infantile,7,613720];				0	7					KCNQ2 (inh=AD pLI=1.00)
chr20	62038277	62038277	T	G	het	het	wt	pred_pathogenic	QUAL=1090;DP=50,61,105;MQM=60	KCNQ2	missense	KCNQ2:NM_172107.3:missense:MODERATE:exon17/17:c.2339A>C:p.Asn780Thr,KCNQ2:NM_004518.5:missense:MODERATE:exon15/15:c.2255A>C:p.Asn752Thr,KCNQ2:NM_172106.2:missense:MODERATE:exon16/16:c.2285A>C:p.Asn762Thr,KCNQ2:NM_172108.4:missense:MODERATE:exon16/16:c.2246A>C:p.Asn749Thr		rs1801475	0.5905	0.6372	19837/12061/1048	0.5794	1.8720	T,T,T,T,T,T,T,T,T	T	B,B,B,B	T,T,T,T,T,T,T,T,T	0.01	602235 [KCNQ2 (confirmed) Seizures,benign neonatal,1,121200|Myokymia,121200|Epileptic encephalopathy,early infantile,7,613720];	RCV000020987.1 [benign]; RCV000082686.9 [benign]; RCV000348446.1 [benign]; 		COSM3758740, COSM3758739, COSM3758741	621	698					KCNQ2 (inh=AD pLI=1.00)
chr20	62046278	62046278	G	C	wt	het	wt		QUAL=393;DP=28,28,57;MQM=60	KCNQ2	synonymous	KCNQ2:NM_172107.3:synonymous:LOW:exon13/17:c.1503C>G:p.Ala501Ala,KCNQ2:NM_004518.5:synonymous:LOW:exon11/15:c.1419C>G:p.Ala473Ala,KCNQ2:NM_172106.2:synonymous:LOW:exon12/16:c.1449C>G:p.Ala483Ala,KCNQ2:NM_172108.4:synonymous:LOW:exon12/16:c.1413C>G:p.Ala471Ala		rs1801545	0.0693	0.0746	425/246/116	0.0716							602235 [KCNQ2 (confirmed) Seizures,benign neonatal,1,121200|Myokymia,121200|Epileptic encephalopathy,early infantile,7,613720];	RCV000174619.1 [uncertain significance]; RCV000117340.3 [other]; RCV000270863.1 [benign]; 			17	248					KCNQ2 (inh=AD pLI=1.00)
chr20	62564027	62564027	T	G	wt	het	wt		QUAL=2465;DP=318,168,242;MQM=60	DNAJC5	3'UTR	DNAJC5:NM_025219.2:3'UTR:MODIFIER:exon5/5:c.*1106T>G:		rs11554629	0.0881	0.0000	0/0/0	0.0147							611203 [DNAJC5 (provisional) Ceroid lipofuscinosis,neuronal,4,Parry type,162350];	RCV000371743.1 [benign]; 			0	36					DNAJC5 (inh=AD pLI=0.86)
chr20	62565622	62565622	C	T	wt	het	wt		QUAL=1083;DP=91,87,129;MQM=60	DNAJC5	3'UTR	DNAJC5:NM_025219.2:3'UTR:MODIFIER:exon5/5:c.*2701C>T:		rs3206771	0.0875	0.0000	0/0/0	0.0147							611203 [DNAJC5 (provisional) Ceroid lipofuscinosis,neuronal,4,Parry type,162350];	RCV000352876.1 [benign]; 			0	25					DNAJC5 (inh=AD pLI=0.86)
chr20	62565646	62565646	G	A	het	wt	het		QUAL=2701;DP=128,68,100;MQM=59	DNAJC5	3'UTR	DNAJC5:NM_025219.2:3'UTR:MODIFIER:exon5/5:c.*2725G>A:		rs11554628	0.0310	0.0000	0/0/0	0.0120							611203 [DNAJC5 (provisional) Ceroid lipofuscinosis,neuronal,4,Parry type,162350];	RCV000353528.1 [likely benign]; 			0	26					DNAJC5 (inh=AD pLI=0.86)
chr20	62566991	62566991	C	G	wt	het	wt		QUAL=2738;DP=239,245,281;MQM=60	DNAJC5	3'UTR	DNAJC5:NM_025219.2:3'UTR:MODIFIER:exon5/5:c.*4070C>G:		rs3810500	0.0877	0.0000	0/0/0	0.0147							611203 [DNAJC5 (provisional) Ceroid lipofuscinosis,neuronal,4,Parry type,162350];	RCV000332327.1 [benign]; RCV000389099.1 [uncertain significance]; 			0	25					DNAJC5 (inh=AD pLI=0.86)
chr21	34787312	34787312	A	G	het	het	wt		QUAL=5157;DP=230,188,314;MQM=59	IFNGR2	missense	IFNGR2:NM_001329128.1:missense:MODERATE:exon3/8:c.248A>G:p.Gln83Arg,IFNGR2:NM_005534.3:missense:MODERATE:exon2/7:c.191A>G:p.Gln64Arg		rs9808753	0.2720	0.1963	2951/574/275	0.1943	0.1630	T,T	T	B,B	T,T	0.01	147569 [IFNGR2 (confirmed) Immunodeficiency 28,mycobacteriosis,614889];		CM1111763 [CLASS=DP MUT=REF PHEN="Non-Hodgkin lymphoma increased risk association with" GENE=IFNGR2]; 	COSM3758854	46	379					IFNGR2 (inh=AR pLI=0.88)
chr21	34809693	34809693	C	T	het	hom	het		QUAL=5611;DP=99,88,102;MQM=59	IFNGR2,TMEM50B	3'UTR,intron	IFNGR2:NM_001329128.1:3'UTR:MODIFIER:exon8/8:c.*424C>T:,IFNGR2:NM_005534.3:3'UTR:MODIFIER:exon7/7:c.*424C>T:,TMEM50B:NR_040016.1:intron:MODIFIER:exon8/8:n.2810+1828G>A:		rs1059293	0.6807	0.0000	0/0/0	0.0963							147569 [IFNGR2 (confirmed) Immunodeficiency 28,mycobacteriosis,614889];				49	110					IFNGR2 (inh=AR pLI=0.88), TMEM50B (inh=n/a pLI=0.30)
chr21	38123320	38123320	-	A	het	wt	het		QUAL=2184;DP=219,74,92;MQM=59	HLCS	3'UTR	HLCS:NM_000411.6:3'UTR:MODIFIER:exon12/12:c.*3226dupT:,HLCS:NM_001242784.1:3'UTR:MODIFIER:exon12/12:c.*3226dupT:,HLCS:NM_001242785.1:3'UTR:MODIFIER:exon12/12:c.*3226dupT:		rs762985167	0.0000	0.0000	0/0/0	0.0142							609018 [HLCS (confirmed) Holocarboxylase synthetase deficiency,253270];	RCV000333447.1 [uncertain significance]; 			0	35					HLCS (inh=AR pLI=0.49)
chr21	38123404	38123404	-	AT	het	wt	het		QUAL=4099;DP=275,80,112;MQM=59	HLCS	3'UTR	HLCS:NM_000411.6:3'UTR:MODIFIER:exon12/12:c.*3141_*3142dupAT:,HLCS:NM_001242784.1:3'UTR:MODIFIER:exon12/12:c.*3141_*3142dupAT:,HLCS:NM_001242785.1:3'UTR:MODIFIER:exon12/12:c.*3141_*3142dupAT:		rs3031056;rs5843777	0.3524	0.0000	0/0/0	0.3626							609018 [HLCS (confirmed) Holocarboxylase synthetase deficiency,253270];	RCV000280668.1 [benign]; 			46	106					HLCS (inh=AR pLI=0.49)
chr21	38123925	38123925	C	T	het	wt	het		QUAL=11779;DP=371,357,452;MQM=59	HLCS	3'UTR	HLCS:NM_000411.6:3'UTR:MODIFIER:exon12/12:c.*2622G>A:,HLCS:NM_001242784.1:3'UTR:MODIFIER:exon12/12:c.*2622G>A:,HLCS:NM_001242785.1:3'UTR:MODIFIER:exon12/12:c.*2622G>A:		rs14407	0.4465	0.0000	0/0/0	0.0757							609018 [HLCS (confirmed) Holocarboxylase synthetase deficiency,253270];	RCV000389959.1 [benign]; 			51	103					HLCS (inh=AR pLI=0.49)
chr21	38308774	38308774	C	T	het	het	wt	pred_pathogenic	QUAL=8708;DP=320,380,446;MQM=60	HLCS	missense	HLCS:NM_000411.6:missense:MODERATE:exon5/12:c.971G>A:p.Arg324His,HLCS:NM_001242784.1:missense:MODERATE:exon5/12:c.971G>A:p.Arg324His,HLCS:NM_001242785.1:missense:MODERATE:exon5/12:c.971G>A:p.Arg324His		rs61732501	0.0070	0.0097	10/8/0	0.0094	-2.1740	T,T	D	B,B	D,D	4.57	609018 [HLCS (confirmed) Holocarboxylase synthetase deficiency,253270];	RCV000125363.2 [benign]; 			0	31					HLCS (inh=AR pLI=0.49)
chr21	38320006	38320006	C	G	het	het	het		QUAL=15822;DP=586,284,336;MQM=60	HLCS	5'UTR,intron	HLCS:NM_001242784.1:5'UTR:MODIFIER:exon3/12:c.-485G>C:,HLCS:NM_000411.6:intron:MODIFIER:exon2/11:c.-257-1552G>C:,HLCS:NM_001242785.1:intron:MODIFIER:exon2/11:c.-257-1552G>C:		rs13047776	0.4940	0.0000	0/0/0	0.3797							609018 [HLCS (confirmed) Holocarboxylase synthetase deficiency,253270];				49	71					HLCS (inh=AR pLI=0.49)
chr21	38320007	38320007	T	G	het	het	het		QUAL=15822;DP=586,284,336;MQM=60	HLCS	5'UTR,intron	HLCS:NM_001242784.1:5'UTR:MODIFIER:exon3/12:c.-486A>C:,HLCS:NM_000411.6:intron:MODIFIER:exon2/11:c.-257-1553A>C:,HLCS:NM_001242785.1:intron:MODIFIER:exon2/11:c.-257-1553A>C:		rs13048613	0.4948	0.0000	0/0/0	0.3780							609018 [HLCS (confirmed) Holocarboxylase synthetase deficiency,253270];				49	71					HLCS (inh=AR pLI=0.49)
chr21	38320591	38320591	G	A	hom	hom	hom	low_DP	QUAL=876;DP=26,9,3;MQM=58	HLCS	splice_region&intron,intron	HLCS:NM_001242784.1:splice_region&intron:LOW:exon2/11:c.-1066-4C>T:,HLCS:NM_000411.6:intron:MODIFIER:exon2/11:c.-257-2137C>T:,HLCS:NM_001242785.1:intron:MODIFIER:exon2/11:c.-257-2137C>T:	AluSg		0.0000	0.0000	0/0/0	0.0001							609018 [HLCS (confirmed) Holocarboxylase synthetase deficiency,253270];				0	5					HLCS (inh=AR pLI=0.49)
chr21	38353268	38353268	-	TCCG	het	het	wt	low_DP	QUAL=363;DP=9,37,53;MQM=59	HLCS	intron	HLCS:NM_000411.6:intron:MODIFIER:exon1/11:c.-393+9186_-393+9189dupCGGA:		rs35269254;rs71328533	0.3405	0.0000	0/0/0	0.3532							609018 [HLCS (confirmed) Holocarboxylase synthetase deficiency,253270];				15	53					HLCS (inh=AR pLI=0.49)
chr21	38782911	38782911	T	C	het	wt	het		QUAL=6622;DP=278,223,228;MQM=59	DYRK1A	5'UTR	DYRK1A:NM_101395.2:5'UTR:MODIFIER:exon2/13:c.-138T>C:	FRAM	rs9981736	0.5543	0.0000	0/0/0	0.4639							600855 [DYRK1A (confirmed) Mental retardation,autosomal dominant 7,614104];				34	80					DYRK1A (inh=AD pLI=1.00)
chr21	38791581	38791581	A	C	het	wt	het		QUAL=14186;DP=662,328,412;MQM=60	DYRK1A	5'UTR,intron	DYRK1A:NM_130436.2:5'UTR:MODIFIER:exon1/11:c.-1096A>C:,DYRK1A:NM_101395.2:intron:MODIFIER:exon2/12:c.-76-1020A>C:		rs2835726	0.5000	0.0000	0/0/0	0.0758							600855 [DYRK1A (confirmed) Mental retardation,autosomal dominant 7,614104];				55	112					DYRK1A (inh=AD pLI=1.00)
chr21	38792131	38792131	T	C	het	wt	het		QUAL=4963;DP=241,102,137;MQM=60	DYRK1A	5'UTR,intron	DYRK1A:NM_130436.2:5'UTR:MODIFIER:exon1/11:c.-546T>C:,DYRK1A:NM_101395.2:intron:MODIFIER:exon2/12:c.-76-470T>C:		rs13049514	0.0996	0.0000	0/0/0	0.0206							600855 [DYRK1A (confirmed) Mental retardation,autosomal dominant 7,614104];				4	65					DYRK1A (inh=AD pLI=1.00)
chr21	44473425	44473425	G	A	hom	het	hom		QUAL=21708;DP=276,271,299;MQM=59	CBS,CBSL	3'UTR	CBS:NM_000071.2:3'UTR:MODIFIER:exon17/17:c.*565C>T:,CBSL:NM_001321073.1:3'UTR:MODIFIER:exon18/18:c.*351C>T:,CBS:NM_001321072.1:3'UTR:MODIFIER:exon14/14:c.*565C>T:,CBS:NM_001178008.2:3'UTR:MODIFIER:exon17/17:c.*565C>T:,CBS:NM_001178009.2:3'UTR:MODIFIER:exon18/18:c.*351C>T:,CBS:NM_001320298.1:3'UTR:MODIFIER:exon18/18:c.*565C>T:	L1MB5	rs706209	0.3654	0.0000	0/0/0	0.0709							613381 [CBS (confirmed) Homocystinuria,B6-responsive and nonresponsive types,236200|Thrombosis,hyperhomocysteinemic,236200];	RCV000261214.1 [benign]; 			56	91					CBS (inh=AR pLI=0.01), CBSL (inh=n/a pLI=n/a)
chr21	44473446	44473446	A	G	hom	het	hom		QUAL=22057;DP=302,244,283;MQM=59	CBS,CBSL	3'UTR	CBS:NM_000071.2:3'UTR:MODIFIER:exon17/17:c.*544T>C:,CBSL:NM_001321073.1:3'UTR:MODIFIER:exon18/18:c.*330T>C:,CBS:NM_001321072.1:3'UTR:MODIFIER:exon14/14:c.*544T>C:,CBS:NM_001178008.2:3'UTR:MODIFIER:exon17/17:c.*544T>C:,CBS:NM_001178009.2:3'UTR:MODIFIER:exon18/18:c.*330T>C:,CBS:NM_001320298.1:3'UTR:MODIFIER:exon18/18:c.*544T>C:	L1MB5	rs706208	0.3662	0.0000	0/0/0	0.0710							613381 [CBS (confirmed) Homocystinuria,B6-responsive and nonresponsive types,236200|Thrombosis,hyperhomocysteinemic,236200];	RCV000316354.1 [benign]; 			53	95					CBS (inh=AR pLI=0.01), CBSL (inh=n/a pLI=n/a)
chr21	44480616	44480616	G	A	hom	het	hom		QUAL=12928;DP=116,186,248;MQM=60	CBS,CBSL	synonymous	CBS:NM_000071.2:synonymous:LOW:exon12/17:c.1080C>T:p.Ala360Ala,CBSL:NM_001321073.1:synonymous:LOW:exon12/18:c.1080C>T:p.Ala360Ala,CBS:NM_001321072.1:synonymous:LOW:exon9/14:c.765C>T:p.Ala255Ala,CBS:NM_001178008.2:synonymous:LOW:exon12/17:c.1080C>T:p.Ala360Ala,CBS:NM_001178009.2:synonymous:LOW:exon12/18:c.1080C>T:p.Ala360Ala,CBS:NM_001320298.1:synonymous:LOW:exon13/18:c.1080C>T:p.Ala360Ala		rs1801181	0.2955	0.3382	7601/4195/25	0.3295	-2.6190		T			10.45	613381 [CBS (confirmed) Homocystinuria,B6-responsive and nonresponsive types,236200|Thrombosis,hyperhomocysteinemic,236200];	RCV000078107.7 [benign]; RCV000244095.1 [benign]; RCV000313339.1 [benign]; 		COSM3758919, COSM3758920	228	665					CBS (inh=AR pLI=0.01), CBSL (inh=n/a pLI=n/a)
chr21	44485350	44485350	G	A	wt	het	wt		QUAL=1496;DP=275,140,160;MQM=60	CBS,CBSL	synonymous	CBS:NM_000071.2:synonymous:LOW:exon8/17:c.699C>T:p.Tyr233Tyr,CBSL:NM_001321073.1:synonymous:LOW:exon8/18:c.699C>T:p.Tyr233Tyr,CBS:NM_001321072.1:synonymous:LOW:exon5/14:c.384C>T:p.Tyr128Tyr,CBS:NM_001178008.2:synonymous:LOW:exon8/17:c.699C>T:p.Tyr233Tyr,CBS:NM_001178009.2:synonymous:LOW:exon8/18:c.699C>T:p.Tyr233Tyr,CBS:NM_001320298.1:synonymous:LOW:exon9/18:c.699C>T:p.Tyr233Tyr		rs234706	0.1965	0.2763	5228/3928/274	0.2750							613381 [CBS (confirmed) Homocystinuria,B6-responsive and nonresponsive types,236200|Thrombosis,hyperhomocysteinemic,236200];	RCV000078110.7 [benign]; RCV000247442.1 [benign]; RCV000377779.1 [benign]; 	CM074081 [CLASS=DFP MUT=ALT PHEN="Altered one-carbon metabolism" GENE=CBS]; 	COSM1414310, COSM1414309	185	644					CBS (inh=AR pLI=0.01), CBSL (inh=n/a pLI=n/a)
chr21	45193728	45193728	G	C	het	het	wt		QUAL=5827;DP=241,199,281;MQM=60	CSTB	3'UTR	CSTB:NM_000100.3:3'UTR:MODIFIER:exon3/3:c.*355C>G:	MIR	rs143062585	0.0070	0.0000	0/0/0	0.0065							601145 [CSTB (provisional) Epilepsy,progressive myoclonic 1A (Unverricht and Lundborg),254800];	RCV000388869.1 [uncertain significance]; 			0	6					CSTB (inh=AR pLI=0.00)
chr21	45708277	45708277	C	T	wt	het	het		QUAL=7465;DP=210,217,343;MQM=60	AIRE	synonymous	AIRE:NM_000383.3:synonymous:LOW:exon5/14:c.588C>T:p.Ser196Ser		rs878081	0.1332	0.2080	2946/2158/15	0.2071							607358 [AIRE (confirmed) Autoimmune polyendocrinopathy syndrome,type I,with or without reversible metaphyseal dysplasia,240300];	RCV000116301.3 [other]; 		COSM4002050	111	515					AIRE (inh=AR+AD pLI=0.00)
chr21	45709568	45709568	C	T	het	wt	het		QUAL=3784;DP=115,150,208;MQM=60	AIRE	synonymous	AIRE:NM_000383.3:synonymous:LOW:exon6/14:c.681C>T:p.Gly227Gly		rs1055311	0.1176	0.2222	3552/2538/16	0.2184							607358 [AIRE (confirmed) Autoimmune polyendocrinopathy syndrome,type I,with or without reversible metaphyseal dysplasia,240300];	RCV000116302.3 [other]; 		COSM3758929	82	572					AIRE (inh=AR+AD pLI=0.00)
chr21	45710410	45710410	C	G	wt	het	het		QUAL=1569;DP=68,47,70;MQM=60	AIRE	intron	AIRE:NM_000383.3:intron:MODIFIER:exon7/13:c.879+459C>G:		rs941405	0.4069	0.0000	0/0/0	0.3946							607358 [AIRE (confirmed) Autoimmune polyendocrinopathy syndrome,type I,with or without reversible metaphyseal dysplasia,240300];				109	329					AIRE (inh=AR+AD pLI=0.00)
chr21	45712290	45712290	G	A	het	het	wt	anno_pathogenic_hgmd	QUAL=1572;DP=98,106,144;MQM=59	AIRE	splice_region&intron	AIRE:NM_000383.3:splice_region&intron:LOW:exon9/13:c.1095+6G>A:		rs1800525	0.1496	0.1321	166/43/15	0.0603							607358 [AIRE (confirmed) Autoimmune polyendocrinopathy syndrome,type I,with or without reversible metaphyseal dysplasia,240300];	RCV000116292.4 [other]; 	CS1412655 [CLASS=DM? MUT=ALT PHEN="Autoimmune polyglandular syndrome type 2" GENE=AIRE]; 		23	316					AIRE (inh=AR+AD pLI=0.00)
chr21	45712977	45712977	T	C	het	hom	het		QUAL=1990;DP=32,36,84;MQM=60	AIRE	synonymous	AIRE:NM_000383.3:synonymous:LOW:exon10/14:c.1197T>C:p.Ala399Ala		rs1800521	0.3562	0.3780	6924/3950/1081	0.3372							607358 [AIRE (confirmed) Autoimmune polyendocrinopathy syndrome,type I,with or without reversible metaphyseal dysplasia,240300];	RCV000116299.3 [other]; 		COSM1483985, COSM444569	206	729					AIRE (inh=AR+AD pLI=0.00)
chr21	45714294	45714294	C	T	het	het	wt	low_DP;pred_pathogenic;anno_pathogenic_hgmd	QUAL=332;DP=17,13,12;MQM=60	AIRE	missense	AIRE:NM_000383.3:missense:MODERATE:exon12/14:c.1411C>T:p.Arg471Cys		rs74203920	0.0044	0.0214	7/5/0	0.0081	0.0570	D,D,D,D	D	P,P	D,D	22.70	607358 [AIRE (confirmed) Autoimmune polyendocrinopathy syndrome,type I,with or without reversible metaphyseal dysplasia,240300];	RCV000116295.3 [other]; 	CM109490 [CLASS=DM? MUT=ALT PHEN="Hypoparathyroidism without APECED" GENE=AIRE]; 		0	33					AIRE (inh=AR+AD pLI=0.00)
chr21	45717550	45717550	T	C	wt	het	wt	low_DP	QUAL=100;DP=29,13,8;MQM=60	AIRE	synonymous	AIRE:NM_000383.3:synonymous:LOW:exon14/14:c.1578T>C:p.Asp526Asp		rs1133779	0.5304	0.4611	13128/5546/2153	0.4427							607358 [AIRE (confirmed) Autoimmune polyendocrinopathy syndrome,type I,with or without reversible metaphyseal dysplasia,240300];	RCV000116300.3 [other]; 		COSM329123, COSM3773998	330	693					AIRE (inh=AR+AD pLI=0.00)
chr21	46311813	46311813	A	G	het	wt	hom		QUAL=10702;DP=113,222,298;MQM=59	ITGB2	synonymous	ITGB2:NM_000211.4:synonymous:LOW:exon11/16:c.1323T>C:p.Val441Val,ITGB2:NM_001303238.1:synonymous:LOW:exon11/16:c.1116T>C:p.Val372Val,ITGB2:NM_001127491.2:synonymous:LOW:exon11/16:c.1323T>C:p.Val441Val		rs235326	0.7630	0.6888	29127/14797/4422	0.6819							600065 [ITGB2 (confirmed) Leukocyte adhesion deficiency,116920];	RCV000279131.1 [benign]; 		COSM3766671	695	734					ITGB2 (inh=AR pLI=0.00)
chr21	46314907	46314907	T	A	hom	hom	hom	pred_pathogenic	QUAL=27322;DP=228,303,332;MQM=60	ITGB2	missense	ITGB2:NM_000211.4:missense:MODERATE:exon9/16:c.1062A>T:p.Gln354His,ITGB2:NM_001303238.1:missense:MODERATE:exon9/16:c.855A>T:p.Gln285His,ITGB2:NM_001127491.2:missense:MODERATE:exon9/16:c.1062A>T:p.Gln354His		rs235330	1.0000	0.9999	60689/33355/5203	0.9520	-0.9340	D,D,T,D,D,D,T	T	B,P	D,D,D,D,D,D	15.04	600065 [ITGB2 (confirmed) Leukocyte adhesion deficiency,116920];	RCV000087107.1 [not provided]; RCV000405921.1 [benign]; 		COSM4135040	1565	0					ITGB2 (inh=AR pLI=0.00)
chr21	46320313	46320313	C	T	het	het	het		QUAL=2594;DP=64,75,90;MQM=59	ITGB2	synonymous	ITGB2:NM_000211.4:synonymous:LOW:exon7/16:c.819G>A:p.Gly273Gly,ITGB2:NM_001303238.1:synonymous:LOW:exon7/16:c.612G>A:p.Gly204Gly,ITGB2:NM_001127491.2:synonymous:LOW:exon7/16:c.819G>A:p.Gly273Gly		rs2230528	0.2230	0.2428	3830/1944/132	0.2373							600065 [ITGB2 (confirmed) Leukocyte adhesion deficiency,116920];	RCV000087125.1 [not provided]; RCV000354913.1 [benign]; 			103	588					ITGB2 (inh=AR pLI=0.00)
chr21	46340843	46340843	A	G	wt	het	wt		QUAL=1986;DP=316,265,400;MQM=60	ITGB2	5'UTR,intron	ITGB2:NM_000211.4:5'UTR:MODIFIER:exon1/16:c.-111T>C:,ITGB2:NM_001303238.1:5'UTR:MODIFIER:exon1/16:c.-361T>C:,ITGB2:NM_001127491.2:intron:MODIFIER:exon1/15:c.-4+7726T>C:		rs2070947	0.1643	0.0000	0/0/0	0.2579							600065 [ITGB2 (confirmed) Leukocyte adhesion deficiency,116920];	RCV000285974.1 [benign]; 			13	99					ITGB2 (inh=AR pLI=0.00)
chr21	46348700	46348700	T	G	hom	hom	hom		QUAL=12753;DP=132,135,139;MQM=60	ITGB2,ITGB2-AS1	5'UTR,non_coding_transcript_exon	ITGB2:NM_001127491.2:5'UTR:MODIFIER:exon1/16:c.-135A>C:,ITGB2-AS1:NR_038311.1:non_coding_transcript_exon:MODIFIER:exon5/5:n.1500T>G:,ITGB2-AS1:NR_038312.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.1457T>G:,ITGB2-AS1:NR_038313.1:non_coding_transcript_exon:MODIFIER:exon5/5:n.1476T>G:,ITGB2-AS1:NR_038314.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.1405T>G:,ITGB2-AS1:NR_038315.1:non_coding_transcript_exon:MODIFIER:exon4/4:n.1401T>G:,ITGB2-AS1:NR_038316.1:non_coding_transcript_exon:MODIFIER:exon3/3:n.1362T>G:		rs9982872	0.9884	0.0000	0/0/0	0.8964							600065 [ITGB2 (confirmed) Leukocyte adhesion deficiency,116920];				227	3					ITGB2 (inh=AR pLI=0.00), ITGB2-AS1 (inh=n/a pLI=n/a)
chr21	46875564	46875564	T	C	het	hom	het		QUAL=16418;DP=215,287,387;MQM=59	COL18A1	synonymous,intron	COL18A1:NM_130444.2:synonymous:LOW:exon1/42:c.120T>C:p.His40His,COL18A1:NM_030582.3:synonymous:LOW:exon1/42:c.120T>C:p.His40His,COL18A1:NM_130445.3:intron:MODIFIER:exon2/42:c.107-12592T>C:		rs914230	0.9884	0.9705	56851/30556/4837	0.9454							120328 [COL18A1 (confirmed) Knobloch syndrome,type 1,267750];				1461	100					COL18A1 (inh=AR pLI=0.00)
chr21	46876083	46876083	A	G	het	het	het		QUAL=3841;DP=69,110,135;MQM=59	COL18A1	synonymous,intron	COL18A1:NM_130444.2:synonymous:LOW:exon1/42:c.639A>G:p.Pro213Pro,COL18A1:NM_030582.3:synonymous:LOW:exon1/42:c.639A>G:p.Pro213Pro,COL18A1:NM_130445.3:intron:MODIFIER:exon2/42:c.107-12073A>G:		rs2236451	0.3756	0.3437	6980/3629/1394	0.3262							120328 [COL18A1 (confirmed) Knobloch syndrome,type 1,267750];	RCV000245572.1 [benign]; 		COSM4004829, COSM4004828	192	645					COL18A1 (inh=AR pLI=0.00)
chr21	46896303	46896303	C	G	wt	wt	het		QUAL=4323;DP=150,274,345;MQM=59	COL18A1	synonymous	COL18A1:NM_130444.2:synonymous:LOW:exon5/42:c.2082C>G:p.Pro694Pro,COL18A1:NM_130445.3:synonymous:LOW:exon6/43:c.837C>G:p.Pro279Pro,COL18A1:NM_030582.3:synonymous:LOW:exon5/42:c.1377C>G:p.Pro459Pro		rs2230687	0.2454	0.1526	1776/297/734	0.1468							120328 [COL18A1 (confirmed) Knobloch syndrome,type 1,267750];	RCV000246654.1 [benign]; RCV000350136.1 [benign]; 			17	326					COL18A1 (inh=AR pLI=0.00)
chr21	46896312	46896312	G	T	wt	wt	het		QUAL=4526;DP=177,289,360;MQM=59	COL18A1	synonymous	COL18A1:NM_130444.2:synonymous:LOW:exon5/42:c.2091G>T:p.Thr697Thr,COL18A1:NM_130445.3:synonymous:LOW:exon6/43:c.846G>T:p.Thr282Thr,COL18A1:NM_030582.3:synonymous:LOW:exon5/42:c.1386G>T:p.Thr462Thr		rs2230688	0.2278	0.1474	1572/298/536	0.1403							120328 [COL18A1 (confirmed) Knobloch syndrome,type 1,267750];	RCV000251805.1 [benign]; RCV000386040.1 [benign]; 		COSM3758949, COSM3758948	17	325					COL18A1 (inh=AR pLI=0.00)
chr21	46908355	46908355	T	C	het	het	wt		QUAL=6050;DP=233,241,295;MQM=59	COL18A1	synonymous	COL18A1:NM_130444.2:synonymous:LOW:exon17/42:c.3165T>C:p.Leu1055Leu,COL18A1:NM_130445.3:synonymous:LOW:exon18/43:c.1920T>C:p.Leu640Leu,COL18A1:NM_030582.3:synonymous:LOW:exon17/42:c.2460T>C:p.Leu820Leu		rs11702425	0.3199	0.3052	5764/3096/691	0.2972							120328 [COL18A1 (confirmed) Knobloch syndrome,type 1,267750];	RCV000249339.1 [benign]; RCV000342153.1 [benign]; 		COSM3758950, COSM3758951	162	637					COL18A1 (inh=AR pLI=0.00)
chr21	46924426	46924434	GGCCCCCCA	-	hom	hom	hom	low_DP	QUAL=782;DP=11,13,14;MQM=59	COL18A1	disruptive_inframe_deletion	COL18A1:NM_130444.2:disruptive_inframe_deletion:MODERATE:exon34/42:c.4074_4082delCCCAGGCCC:p.Pro1359_Pro1361del,COL18A1:NM_130445.3:disruptive_inframe_deletion:MODERATE:exon35/43:c.2829_2837delCCCAGGCCC:p.Pro944_Pro946del,COL18A1:NM_030582.3:disruptive_inframe_deletion:MODERATE:exon34/42:c.3369_3377delCCCAGGCCC:p.Pro1124_Pro1126del		rs149296338;rs78227997	0.0000	0.9693	29713/15968/1807	0.0525							120328 [COL18A1 (confirmed) Knobloch syndrome,type 1,267750];			COSM1031439	1340	133	2	[2] old entry - no details available			COL18A1 (inh=AR pLI=0.00)
chr21	46927489	46927489	A	G	het	het	wt		QUAL=2314;DP=124,150,226;MQM=60	COL18A1	synonymous	COL18A1:NM_130444.2:synonymous:LOW:exon38/42:c.4467A>G:p.Thr1489Thr,COL18A1:NM_130445.3:synonymous:LOW:exon39/43:c.3222A>G:p.Thr1074Thr,COL18A1:NM_030582.3:synonymous:LOW:exon38/42:c.3762A>G:p.Thr1254Thr		rs12483761	0.1184	0.1241	882/503/85	0.1181							120328 [COL18A1 (confirmed) Knobloch syndrome,type 1,267750];	RCV000242753.1 [benign]; 			23	334					COL18A1 (inh=AR pLI=0.00)
chr21	46929467	46929467	G	A	wt	het	het	low_DP	QUAL=174;DP=2,6,12;MQM=60	COL18A1	synonymous	COL18A1:NM_130444.2:synonymous:LOW:exon39/42:c.4683G>A:p.Ala1561Ala,COL18A1:NM_130445.3:synonymous:LOW:exon40/43:c.3438G>A:p.Ala1146Ala,COL18A1:NM_030582.3:synonymous:LOW:exon39/42:c.3978G>A:p.Ala1326Ala		rs1050351	0.5036	0.5110	2170/731/118	0.2988	-2.9700		T			6.15	120328 [COL18A1 (confirmed) Knobloch syndrome,type 1,267750];	RCV000252618.1 [benign]; 		COSM3749754, COSM3749755	277	692					COL18A1 (inh=AR pLI=0.00)
chr21	46929523	46929523	C	-	wt	het	het	low_DP	QUAL=82;DP=1,4,7;MQM=60	COL18A1	splice_region&intron	COL18A1:NM_130444.2:splice_region&intron:LOW:exon39/41:c.4731+14delC:,COL18A1:NM_130445.3:splice_region&intron:LOW:exon40/42:c.3486+14delC:,COL18A1:NM_030582.3:splice_region&intron:LOW:exon39/41:c.4026+14delC:		rs397867928	0.5549	0.4859	1457/316/77	0.2367							120328 [COL18A1 (confirmed) Knobloch syndrome,type 1,267750];				305	680					COL18A1 (inh=AR pLI=0.00)
chr21	46931109	46931109	G	A	het	het	wt	pred_pathogenic;anno_pathogenic_clinvar	QUAL=2039;DP=80,94,145;MQM=60	COL18A1	missense	COL18A1:NM_130444.2:missense:MODERATE:exon41/42:c.5014G>A:p.Asp1672Asn,COL18A1:NM_130445.3:missense:MODERATE:exon42/43:c.3769G>A:p.Asp1257Asn,COL18A1:NM_030582.3:missense:MODERATE:exon41/42:c.4309G>A:p.Asp1437Asn		rs12483377	0.0443	0.1125	186/157/4	0.0576	5.7980	T,T,T,T,D,T	T	D,D,D,D	T,T,T,T	27.70	120328 [COL18A1 (confirmed) Knobloch syndrome,type 1,267750];	RCV000018655.28 [pathogenic]; RCV000248578.1 [benign]; 		COSM1579620	9	252	2	[2] old entry - no details available			COL18A1 (inh=AR pLI=0.00)
chr21	46932328	46932328	G	A	wt	het	het		QUAL=7614;DP=228,291,393;MQM=60	COL18A1	3'UTR	COL18A1:NM_130444.2:3'UTR:MODIFIER:exon42/42:c.*16G>A:,COL18A1:NM_130445.3:3'UTR:MODIFIER:exon43/43:c.*16G>A:,COL18A1:NM_030582.3:3'UTR:MODIFIER:exon42/42:c.*16G>A:		rs7499	0.4673	0.4461	9777/4663/909	0.3959							120328 [COL18A1 (confirmed) Knobloch syndrome,type 1,267750];	RCV000249700.1 [benign]; RCV000368050.1 [benign]; 			165	473					COL18A1 (inh=AR pLI=0.00)
chr21	46932383	46932383	G	A	wt	het	het		QUAL=7631;DP=116,301,399;MQM=60	COL18A1	3'UTR	COL18A1:NM_130444.2:3'UTR:MODIFIER:exon42/42:c.*71G>A:,COL18A1:NM_130445.3:3'UTR:MODIFIER:exon43/43:c.*71G>A:,COL18A1:NM_030582.3:3'UTR:MODIFIER:exon42/42:c.*71G>A:		rs8199	0.5094	0.0000	0/0/0	0.0722							120328 [COL18A1 (confirmed) Knobloch syndrome,type 1,267750];	RCV000333113.1 [benign]; 			43	106					COL18A1 (inh=AR pLI=0.00)
chr21	46932618	46932618	G	C	het	het	wt		QUAL=4605;DP=203,165,177;MQM=59	COL18A1	3'UTR	COL18A1:NM_130444.2:3'UTR:MODIFIER:exon42/42:c.*306G>C:,COL18A1:NM_130445.3:3'UTR:MODIFIER:exon43/43:c.*306G>C:,COL18A1:NM_030582.3:3'UTR:MODIFIER:exon42/42:c.*306G>C:		rs17004785	0.1036	0.0000	0/0/0	0.1051							120328 [COL18A1 (confirmed) Knobloch syndrome,type 1,267750];	RCV000340934.1 [likely benign]; 			2	48					COL18A1 (inh=AR pLI=0.00)
chr21	46932652	46932652	G	A	wt	het	het		QUAL=4171;DP=206,182,190;MQM=60	COL18A1	3'UTR	COL18A1:NM_130444.2:3'UTR:MODIFIER:exon42/42:c.*340G>A:,COL18A1:NM_130445.3:3'UTR:MODIFIER:exon43/43:c.*340G>A:,COL18A1:NM_030582.3:3'UTR:MODIFIER:exon42/42:c.*340G>A:		rs7867	0.5180	0.0000	0/0/0	0.4687							120328 [COL18A1 (confirmed) Knobloch syndrome,type 1,267750];	RCV000407365.1 [benign]; 			45	107					COL18A1 (inh=AR pLI=0.00)
chr21	46933460	46933460	-	CA	wt	het	het		QUAL=9182;DP=270,316,423;MQM=59	COL18A1	3'UTR	COL18A1:NM_130444.2:3'UTR:MODIFIER:exon42/42:c.*1148_*1149insCA:,COL18A1:NM_130445.3:3'UTR:MODIFIER:exon43/43:c.*1148_*1149insCA:,COL18A1:NM_030582.3:3'UTR:MODIFIER:exon42/42:c.*1148_*1149insCA:		rs78063943	0.5697	0.0000	0/0/0	0.4218							120328 [COL18A1 (confirmed) Knobloch syndrome,type 1,267750];	RCV000279292.1 [benign]; 			46	108					COL18A1 (inh=AR pLI=0.00)
chr21	47401760	47401760	C	G	wt	het	het	low_DP	QUAL=372;DP=17,12,19;MQM=60	COL6A1	5'UTR	COL6A1:NM_001848.2:5'UTR:MODIFIER:exon1/35:c.-5C>G:		rs7671	0.5365	0.6132	9093/4449/162	0.4439							120220 [COL6A1 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090];	RCV000079729.7 [benign]; RCV000314940.1 [benign]; 			484	741					COL6A1 (inh=AD pLI=1.00)
chr21	47410931	47410931	T	C	hom	het	het		QUAL=6012;DP=121,90,136;MQM=60	COL6A1	synonymous	COL6A1:NM_001848.2:synonymous:LOW:exon15/35:c.1095T>C:p.Gly365Gly		rs1980982	0.5449	0.5315	17619/10012/2922	0.5227							120220 [COL6A1 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090];	RCV000079742.6 [benign]; RCV000358186.1 [benign]; 		COSM3758956	461	777					COL6A1 (inh=AD pLI=1.00)
chr21	47423389	47423389	G	A	hom	het	het	pred_pathogenic	QUAL=6589;DP=89,154,184;MQM=59	COL6A1	missense	COL6A1:NM_001848.2:missense:MODERATE:exon35/35:c.2549G>A:p.Arg850His		rs1053312	0.2702	0.2888	4969/2844/771	0.2789	-0.0010	T	T	B	D	22.30	120220 [COL6A1 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090];	RCV000079798.6 [benign]; RCV000305303.1 [benign]; 		COSM3758957	141	631					COL6A1 (inh=AD pLI=1.00)
chr21	47423507	47423507	G	A	hom	het	het		QUAL=3249;DP=43,79,93;MQM=59	COL6A1	synonymous	COL6A1:NM_001848.2:synonymous:LOW:exon35/35:c.2667G>A:p.Ala889Ala		rs1053315;rs71336107	0.2682	0.2859	5021/2870/764	0.2765							120220 [COL6A1 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090];	RCV000079801.8 [other]; RCV000381032.1 [benign]; 		COSM329269	139	627					COL6A1 (inh=AD pLI=1.00)
chr21	47423636	47423636	C	T	hom	het	het		QUAL=2636;DP=75,45,27;MQM=59	COL6A1	synonymous	COL6A1:NM_001848.2:synonymous:LOW:exon35/35:c.2796C>T:p.Ser932Ser		rs1053320	0.2642	0.2715	4530/2543/809	0.2639							120220 [COL6A1 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090];	RCV000079807.6 [benign]; RCV000374356.1 [benign]; 		COSM444608	122	584					COL6A1 (inh=AD pLI=1.00)
chr21	47424187	47424187	A	G	hom	hom	het		QUAL=8431;DP=139,87,127;MQM=59	COL6A1	3'UTR	COL6A1:NM_001848.2:3'UTR:MODIFIER:exon35/35:c.*260A>G:		rs1053331	0.8704	0.0000	0/0/0	0.8401							120220 [COL6A1 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090];	RCV000261714.1 [benign]; 			235	63					COL6A1 (inh=AD pLI=1.00)
chr21	47424275	47424287	CTCCTGCCCTGCC	-	het	het	het		QUAL=3219;DP=56,92,140;MQM=59	COL6A1	3'UTR	COL6A1:NM_001848.2:3'UTR:MODIFIER:exon35/35:c.*357_*369delTGCCCTCCTGCCC:	(GCCCT)n	rs752193493	0.0469	0.0000	0/0/0	0.0758							120220 [COL6A1 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090];				5	43					COL6A1 (inh=AD pLI=1.00)
chr21	47424346	47424346	A	G	hom	hom	het		QUAL=11974;DP=98,178,277;MQM=59	COL6A1	3'UTR	COL6A1:NM_001848.2:3'UTR:MODIFIER:exon35/35:c.*419A>G:		rs9254	0.8820	0.0000	0/0/0	0.8740							120220 [COL6A1 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090];	RCV000284968.1 [benign]; 			278	81					COL6A1 (inh=AD pLI=1.00)
chr21	47532500	47532500	C	T	wt	wt	het		QUAL=563;DP=48,43,68;MQM=60	COL6A2	splice_region&intron	COL6A2:NM_001849.3:splice_region&intron:LOW:exon3/27:c.714+9C>T:,COL6A2:NM_058174.2:splice_region&intron:LOW:exon3/27:c.714+9C>T:,COL6A2:NM_058175.2:splice_region&intron:LOW:exon3/27:c.714+9C>T:		rs78822624	0.0162	0.0400	132/98/0	0.0382							120240 [COL6A2 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090|Myosclerosis,congenital,255600];	RCV000079898.8 [other]; RCV000263753.1 [likely benign]; RCV000374715.1 [likely benign]; 			4	115					COL6A2 (inh=AR+AD pLI=0.00)
chr21	47538960	47538960	G	A	hom	hom	hom	pred_pathogenic	QUAL=24132;DP=209,243,315;MQM=59	COL6A2	missense	COL6A2:NM_001849.3:missense:MODERATE:exon14/28:c.1196G>A:p.Ser399Asn,COL6A2:NM_058174.2:missense:MODERATE:exon14/28:c.1196G>A:p.Ser399Asn,COL6A2:NM_058175.2:missense:MODERATE:exon14/28:c.1196G>A:p.Ser399Asn		rs2839110	0.7053	0.7734	36591/21934/1479	0.7586	0.3610	T,T,T,T,T	T	B,B,B	D,D,D,D,D	8.06	120240 [COL6A2 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090|Myosclerosis,congenital,255600];	RCV000079842.6 [benign]; RCV000323060.1 [benign]; RCV000382221.1 [benign]; 		COSM3758958, COSM3758960, COSM3758959	977	510					COL6A2 (inh=AR+AD pLI=0.00)
chr21	47542861	47542861	A	G	hom	hom	hom		QUAL=20931;DP=139,234,315;MQM=59	COL6A2	splice_region&intron	COL6A2:NM_001849.3:splice_region&intron:LOW:exon21/27:c.1671+10A>G:,COL6A2:NM_058174.2:splice_region&intron:LOW:exon21/27:c.1671+10A>G:,COL6A2:NM_058175.2:splice_region&intron:LOW:exon21/27:c.1671+10A>G:		rs915786	0.8474	0.8122	40202/21592/4615	0.7715							120240 [COL6A2 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090|Myosclerosis,congenital,255600];	RCV000079853.8 [other]; RCV000284926.1 [benign]; RCV000339110.1 [benign]; 			990	502					COL6A2 (inh=AR+AD pLI=0.00)
chr21	47545768	47545768	G	A	hom	hom	hom	pred_pathogenic	QUAL=24899;DP=238,243,361;MQM=59	COL6A2	missense	COL6A2:NM_001849.3:missense:MODERATE:exon26/28:c.2039G>A:p.Arg680His,COL6A2:NM_058174.2:missense:MODERATE:exon26/28:c.2039G>A:p.Arg680His,COL6A2:NM_058175.2:missense:MODERATE:exon26/28:c.2039G>A:p.Arg680His		rs1042917	0.3940	0.4784	14691/8634/318	0.4742	4.7640	T,D,T,T,D,T	T	D,P,P	T,T,T,T,T,T	25.80	120240 [COL6A2 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090|Myosclerosis,congenital,255600];	RCV000079868.6 [benign]; RCV000320471.1 [benign]; RCV000380396.1 [benign]; 		COSM3758963, COSM3758961, COSM3758962	344	767					COL6A2 (inh=AR+AD pLI=0.00)
chr21	47545823	47545823	G	A	hom	hom	hom		QUAL=28429;DP=235,311,441;MQM=59	COL6A2	synonymous	COL6A2:NM_001849.3:synonymous:LOW:exon26/28:c.2094G>A:p.Ala698Ala,COL6A2:NM_058174.2:synonymous:LOW:exon26/28:c.2094G>A:p.Ala698Ala,COL6A2:NM_058175.2:synonymous:LOW:exon26/28:c.2094G>A:p.Ala698Ala		rs13052956	0.3942	0.4755	14468/8494/320	0.4716							120240 [COL6A2 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090|Myosclerosis,congenital,255600];	RCV000079869.6 [benign]; RCV000267217.1 [benign]; RCV000327020.1 [benign]; 		COSM3758965, COSM3758964, COSM3758966	342	768					COL6A2 (inh=AR+AD pLI=0.00)
chr21	47545826	47545826	C	T	hom	hom	hom		QUAL=28429;DP=235,311,441;MQM=59	COL6A2	synonymous	COL6A2:NM_001849.3:synonymous:LOW:exon26/28:c.2097C>T:p.Gly699Gly,COL6A2:NM_058174.2:synonymous:LOW:exon26/28:c.2097C>T:p.Gly699Gly,COL6A2:NM_058175.2:synonymous:LOW:exon26/28:c.2097C>T:p.Gly699Gly		rs13046639	0.3940	0.4755	14471/8495/317	0.4650							120240 [COL6A2 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090|Myosclerosis,congenital,255600];	RCV000079870.6 [benign]; RCV000291715.1 [benign]; RCV000381689.1 [benign]; 		COSM3758968, COSM3758969, COSM3758967	342	768					COL6A2 (inh=AR+AD pLI=0.00)
chr21	47545913	47545913	G	A	het	het	het		QUAL=12986;DP=175,408,546;MQM=59	COL6A2	synonymous	COL6A2:NM_001849.3:synonymous:LOW:exon26/28:c.2184G>A:p.Val728Val,COL6A2:NM_058174.2:synonymous:LOW:exon26/28:c.2184G>A:p.Val728Val,COL6A2:NM_058175.2:synonymous:LOW:exon26/28:c.2184G>A:p.Val728Val		rs2839114	0.3221	0.3748	9378/4800/96	0.3712							120240 [COL6A2 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090|Myosclerosis,congenital,255600];	RCV000079875.6 [benign]; RCV000264972.1 [benign]; RCV000304018.1 [benign]; 		COSM3758972, COSM3758971, COSM3758970	195	690					COL6A2 (inh=AR+AD pLI=0.00)
chr21	47549629	47549629	T	A	hom	hom	hom		QUAL=19716;DP=217,193,254;MQM=59	COL6A2	3'UTR,intron	COL6A2:NM_058174.2:3'UTR:MODIFIER:exon28/28:c.*224T>A:,COL6A2:NM_058175.2:3'UTR:MODIFIER:exon28/28:c.*787T>A:,COL6A2:NM_001849.3:intron:MODIFIER:exon27/27:c.2462-2239T>A:	MLT1C2	rs1044598	0.3868	0.0000	0/0/0	0.4675							120240 [COL6A2 (confirmed) Bethlem myopathy 1,158810|Ullrich congenital muscular dystrophy 1,254090|Myosclerosis,congenital,255600];				39	121					COL6A2 (inh=AR+AD pLI=0.00)
chr21	47744038	47744038	G	-	hom	hom	hom		QUAL=6744;DP=33,102,108;MQM=59	PCNT	5'UTR	PCNT:NM_006031.5:5'UTR:MODIFIER:exon1/47:c.-100delG:		rs397802954	0.7672	0.0000	0/0/0	0.4779							605925 [PCNT (confirmed) Microcephalic osteodysplastic primordial dwarfism,type II,210720];	RCV000336290.1 [benign]; 			537	223					PCNT (inh=AR pLI=0.00)
chr21	47754471	47754471	-	TGGGATGTTCACAGTCAGTGACCACCCACCAGAACAGCA	wt	het	wt		QUAL=355;DP=277,548,817;MQM=59	PCNT	disruptive_inframe_insertion	PCNT:NM_006031.5:disruptive_inframe_insertion:MODERATE:exon3/47:c.467_505dupATGGGATGTTCACAGTCAGTGACCACCCACCAGAACAGC:p.His156_Gln168dup,PCNT:NM_001315529.1:disruptive_inframe_insertion:MODERATE:exon3/47:c.113_151dupATGGGATGTTCACAGTCAGTGACCACCCACCAGAACAGC:p.His38_Gln50dup		rs797045878	0.0000	0.0011	32/19/11	0.0001							605925 [PCNT (confirmed) Microcephalic osteodysplastic primordial dwarfism,type II,210720];	RCV000194880.1 [likely benign]; 			1	4					PCNT (inh=AR pLI=0.00)
chr21	47766650	47766650	G	A	hom	hom	het		QUAL=8877;DP=82,173,164;MQM=59	PCNT	splice_region&intron	PCNT:NM_006031.5:splice_region&intron:LOW:exon4/46:c.721-7G>A:,PCNT:NM_001315529.1:splice_region&intron:LOW:exon4/46:c.367-7G>A:		rs2839217	0.2999	0.4134	4846/3264/144	0.3115							605925 [PCNT (confirmed) Microcephalic osteodysplastic primordial dwarfism,type II,210720];	RCV000147195.2 [benign]; RCV000317940.1 [benign]; RCV000372635.1 [uncertain significance]; 			266	712					PCNT (inh=AR pLI=0.00)
chr21	47773103	47773103	C	A	hom	hom	het		QUAL=25357;DP=225,353,478;MQM=60	PCNT	synonymous	PCNT:NM_006031.5:synonymous:LOW:exon10/47:c.1542C>A:p.Ser514Ser,PCNT:NM_001315529.1:synonymous:LOW:exon10/47:c.1188C>A:p.Ser396Ser		rs2249057	0.2895	0.3201	6428/3931/272	0.3172							605925 [PCNT (confirmed) Microcephalic osteodysplastic primordial dwarfism,type II,210720];	RCV000147090.1 [benign]; RCV000402281.1 [benign]; 		COSM1130514	208	715					PCNT (inh=AR pLI=0.00)
chr21	47777063	47777063	G	A	hom	hom	hom	pred_pathogenic	QUAL=20878;DP=197,191,273;MQM=60	PCNT	missense	PCNT:NM_006031.5:missense:MODERATE:exon13/47:c.2111G>A:p.Gly704Glu,PCNT:NM_001315529.1:missense:MODERATE:exon13/47:c.1757G>A:p.Gly586Glu		rs2839223	0.8486	0.8559	44630/25532/4423	0.8488	3.8370	T,T	T	B,B	T	3.39	605925 [PCNT (confirmed) Microcephalic osteodysplastic primordial dwarfism,type II,210720];	RCV000147093.1 [benign]; RCV000276066.1 [benign]; 		COSM4135102	1128	401					PCNT (inh=AR pLI=0.00)
chr21	47783796	47783796	T	C	hom	hom	hom		QUAL=10135;DP=135,91,117;MQM=60	PCNT	synonymous	PCNT:NM_006031.5:synonymous:LOW:exon14/47:c.2556T>C:p.Ala852Ala,PCNT:NM_001315529.1:synonymous:LOW:exon14/47:c.2202T>C:p.Ala734Ala		rs8131546	0.8470	0.8548	43091/24499/4074	0.8342							605925 [PCNT (confirmed) Microcephalic osteodysplastic primordial dwarfism,type II,210720];	RCV000147097.1 [benign]; RCV000327808.1 [benign]; 		COSM444637	1118	399					PCNT (inh=AR pLI=0.00)
chr21	47786494	47786494	C	T	hom	hom	hom	low_DP	QUAL=2503;DP=57,10,20;MQM=59	PCNT	splice_region&intron	PCNT:NM_006031.5:splice_region&intron:LOW:exon14/46:c.2610-5C>T:,PCNT:NM_001315529.1:splice_region&intron:LOW:exon14/46:c.2256-5C>T:		rs2839226	0.6577	0.7487	34455/21052/1003	0.7359							605925 [PCNT (confirmed) Microcephalic osteodysplastic primordial dwarfism,type II,210720];	RCV000147099.1 [benign]; RCV000345207.1 [benign]; 			945	535					PCNT (inh=AR pLI=0.00)
chr21	47786817	47786817	C	G	hom	hom	hom		QUAL=32471;DP=158,361,507;MQM=60	PCNT	synonymous	PCNT:NM_006031.5:synonymous:LOW:exon15/47:c.2928C>G:p.Leu976Leu,PCNT:NM_001315529.1:synonymous:LOW:exon15/47:c.2574C>G:p.Leu858Leu		rs2839228	0.8389	0.8527	44245/25455/4136	0.8456							605925 [PCNT (confirmed) Microcephalic osteodysplastic primordial dwarfism,type II,210720];	RCV000147104.2 [benign]; RCV000335049.1 [benign]; 		COSM1414625	1121	410					PCNT (inh=AR pLI=0.00)
chr21	47787002	47787002	T	C	hom	hom	hom		QUAL=22537;DP=115,251,383;MQM=60	PCNT	missense	PCNT:NM_006031.5:missense:MODERATE:exon15/47:c.3113T>C:p.Val1038Ala,PCNT:NM_001315529.1:missense:MODERATE:exon15/47:c.2759T>C:p.Val920Ala		rs6518289	0.8377	0.8530	43999/25340/4085	0.8314	-0.9870	T	T	B,B	T	0.01	605925 [PCNT (confirmed) Microcephalic osteodysplastic primordial dwarfism,type II,210720];	RCV000147106.2 [benign]; RCV000399320.1 [benign]; 			1121	410					PCNT (inh=AR pLI=0.00)
chr21	47805773	47805773	T	C	wt	wt	het		QUAL=3884;DP=247,277,334;MQM=60	PCNT	synonymous	PCNT:NM_006031.5:synonymous:LOW:exon17/47:c.3339T>C:p.Ser1113Ser,PCNT:NM_001315529.1:synonymous:LOW:exon17/47:c.2985T>C:p.Ser995Ser		rs61735805	0.0156	0.0367	115/92/0	0.0362							605925 [PCNT (confirmed) Microcephalic osteodysplastic primordial dwarfism,type II,210720];	RCV000147110.1 [benign]; RCV000371071.1 [likely benign]; 			4	106					PCNT (inh=AR pLI=0.00)
chr21	47811272	47811272	C	T	hom	hom	het		QUAL=5639;DP=61,98,114;MQM=59	PCNT	synonymous	PCNT:NM_006031.5:synonymous:LOW:exon21/47:c.4197C>T:p.Asp1399Asp,PCNT:NM_001315529.1:synonymous:LOW:exon21/47:c.3843C>T:p.Asp1281Asp		rs3737438	0.3015	0.3658	1224/677/52	0.2170							605925 [PCNT (confirmed) Microcephalic osteodysplastic primordial dwarfism,type II,210720];	RCV000147122.2 [benign]; RCV000279190.1 [benign]; 		COSM444639	262	713					PCNT (inh=AR pLI=0.00)
chr21	47832836	47832836	A	G	het	wt	het	pred_pathogenic	QUAL=5968;DP=158,286,361;MQM=59	PCNT	missense	PCNT:NM_006031.5:missense:MODERATE:exon29/47:c.6080A>G:p.Gln2027Arg,PCNT:NM_001315529.1:missense:MODERATE:exon29/47:c.5726A>G:p.Gln1909Arg		rs147189224	0.0008	0.0019	0/0/0	0.0019	4.5150	T	T	D,D	T	21.70	605925 [PCNT (confirmed) Microcephalic osteodysplastic primordial dwarfism,type II,210720];	RCV000192953.1 [uncertain significance]; 			0	5	3	[3] Stephan Waldm?ller 13.08.2014			PCNT (inh=AR pLI=0.00)
chr21	47836403	47836403	T	C	wt	wt	het		QUAL=2339;DP=245,136,215;MQM=60	PCNT	missense	PCNT:NM_006031.5:missense:MODERATE:exon30/47:c.6571T>C:p.Ser2191Pro,PCNT:NM_001315529.1:missense:MODERATE:exon30/47:c.6217T>C:p.Ser2073Pro		rs34151633	0.0212	0.0361	134/120/2	0.0357	0.2020	T	T	B,P	T	13.93	605925 [PCNT (confirmed) Microcephalic osteodysplastic primordial dwarfism,type II,210720];	RCV000147168.1 [benign]; RCV000362982.1 [likely benign]; 		COSM3758999	4	143					PCNT (inh=AR pLI=0.00)
chr21	47836653	47836653	C	T	het	het	het		QUAL=2792;DP=100,61,74;MQM=59	PCNT	missense	PCNT:NM_006031.5:missense:MODERATE:exon30/47:c.6821C>T:p.Pro2274Leu,PCNT:NM_001315529.1:missense:MODERATE:exon30/47:c.6467C>T:p.Pro2156Leu		rs2070425	0.2496	0.2811	4341/2592/126	0.2635	0.0390	T	T	B,B	T	0.10	605925 [PCNT (confirmed) Microcephalic osteodysplastic primordial dwarfism,type II,210720];	RCV000147179.1 [benign]; RCV000350993.1 [benign]; 		COSM3759001	153	627					PCNT (inh=AR pLI=0.00)
chr21	47836750	47836750	T	C	wt	wt	het		QUAL=999;DP=98,71,94;MQM=60	PCNT	synonymous	PCNT:NM_006031.5:synonymous:LOW:exon30/47:c.6918T>C:p.Ala2306Ala,PCNT:NM_001315529.1:synonymous:LOW:exon30/47:c.6564T>C:p.Ala2188Ala		rs61738290	0.0228	0.0365	119/104/4	0.0338							605925 [PCNT (confirmed) Microcephalic osteodysplastic primordial dwarfism,type II,210720];	RCV000147180.1 [benign]; RCV000365607.1 [likely benign]; 			5	129					PCNT (inh=AR pLI=0.00)
chr21	47850484	47850484	G	C	hom	hom	hom		QUAL=21158;DP=159,225,311;MQM=59	PCNT	missense	PCNT:NM_006031.5:missense:MODERATE:exon37/47:c.7977G>C:p.Gln2659His,PCNT:NM_001315529.1:missense:MODERATE:exon37/47:c.7623G>C:p.Gln2541His		rs2070426	0.4882	0.5774	5215/3037/211	0.4282	-3.2770	T	T	B,B	T	18.05	605925 [PCNT (confirmed) Microcephalic osteodysplastic primordial dwarfism,type II,210720];	RCV000147219.2 [benign]; RCV000367854.1 [benign]; 		COSM3759003	568	727					PCNT (inh=AR pLI=0.00)
chr21	47851753	47851753	A	G	hom	hom	hom		QUAL=19184;DP=213,174,216;MQM=59	PCNT	missense	PCNT:NM_006031.5:missense:MODERATE:exon38/47:c.8375A>G:p.Gln2792Arg,PCNT:NM_001315529.1:missense:MODERATE:exon38/47:c.8021A>G:p.Gln2674Arg		rs2073376	0.6699	0.6397	25038/14058/3257	0.6326	0.2460	T	T	B,B	T	0.01	605925 [PCNT (confirmed) Microcephalic osteodysplastic primordial dwarfism,type II,210720];	RCV000147222.4 [benign]; RCV000329338.1 [benign]; 		COSM4135105	707	682					PCNT (inh=AR pLI=0.00)
chr21	47852085	47852085	G	A	het	het	wt	pred_pathogenic	QUAL=5734;DP=281,264,357;MQM=59	PCNT	missense,intron	PCNT:NM_006031.5:missense:MODERATE:exon38/47:c.8707G>A:p.Ala2903Thr,PCNT:NM_001315529.1:intron:MODIFIER:exon38/46:c.8160+193G>A:		rs35147998	0.0385	0.0635	286/228/0	0.0603	3.8120	T	T	B	T	16.89	605925 [PCNT (confirmed) Microcephalic osteodysplastic primordial dwarfism,type II,210720];	RCV000147227.1 [likely benign]; RCV000336085.1 [likely benign]; RCV000147228.1 [benign]; 			6	225					PCNT (inh=AR pLI=0.00)
chr21	47860764	47860764	T	C	het	het	wt		QUAL=2903;DP=132,33,73;MQM=60	PCNT	splice_region&intron	PCNT:NM_006031.5:splice_region&intron:LOW:exon42/46:c.9394-4T>C:,PCNT:NM_001315529.1:splice_region&intron:LOW:exon42/46:c.8803-4T>C:		rs2839260	0.1058	0.1277	1151/905/102	0.1261							605925 [PCNT (confirmed) Microcephalic osteodysplastic primordial dwarfism,type II,210720];	RCV000147245.1 [benign]; RCV000338053.1 [likely benign]; 			41	418					PCNT (inh=AR pLI=0.00)
chr21	47863757	47863757	A	C	het	wt	het		QUAL=1975;DP=93,67,98;MQM=59	PCNT	missense	PCNT:NM_006031.5:missense:MODERATE:exon45/47:c.9735A>C:p.Arg3245Ser,PCNT:NM_001315529.1:missense:MODERATE:exon45/47:c.9144A>C:p.Arg3048Ser		rs2073380	0.2063	0.2289	3506/1775/23	0.2260	-0.0160	T	T	B,B	T	13.29	605925 [PCNT (confirmed) Microcephalic osteodysplastic primordial dwarfism,type II,210720];	RCV000147250.1 [benign]; RCV000348673.1 [benign]; 		COSM1751704	94	573					PCNT (inh=AR pLI=0.00)
chr22	17565888	17565888	C	A	hom	het	hom		QUAL=5776;DP=30,106,111;MQM=60	IL17RA	5'UTR	IL17RA:NM_014339.6:5'UTR:MODIFIER:exon1/13:c.-94C>A:,IL17RA:NM_001289905.1:5'UTR:MODIFIER:exon1/12:c.-94C>A:		rs13053694	0.3195	0.0000	0/0/0	0.0870							605461 [IL17RA (provisional) Immunodeficiency 51,613953];	RCV000315798.1 [benign]; 			73	107					IL17RA (inh=AR pLI=0.12)
chr22	17565932	17565932	T	C	hom	hom	hom		QUAL=5607;DP=24,82,85;MQM=60	IL17RA	5'UTR	IL17RA:NM_014339.6:5'UTR:MODIFIER:exon1/13:c.-50T>C:,IL17RA:NM_001289905.1:5'UTR:MODIFIER:exon1/12:c.-50T>C:		rs917864	0.7750	0.0000	11/8/1	0.1496							605461 [IL17RA (provisional) Immunodeficiency 51,613953];	RCV000372717.1 [benign]; 			623	253					IL17RA (inh=AR pLI=0.12)
chr22	17565974	17565974	G	C	hom	hom	hom	low_DP	QUAL=3124;DP=9,47,54;MQM=59	IL17RA	5'UTR	IL17RA:NM_014339.6:5'UTR:MODIFIER:exon1/13:c.-8G>C:,IL17RA:NM_001289905.1:5'UTR:MODIFIER:exon1/12:c.-8G>C:		rs917865	0.7748	0.8066	85/11/4	0.1888							605461 [IL17RA (provisional) Immunodeficiency 51,613953];	RCV000293416.1 [benign]; 			1037	416					IL17RA (inh=AR pLI=0.12)
chr22	17591089	17591089	G	A	het	hom	het		QUAL=12189;DP=249,236,268;MQM=59	IL17RA	3'UTR	IL17RA:NM_014339.6:3'UTR:MODIFIER:exon13/13:c.*379G>A:,IL17RA:NM_001289905.1:3'UTR:MODIFIER:exon12/12:c.*379G>A:	L2c	rs2895332	0.7310	0.0000	0/0/0	0.6933							605461 [IL17RA (provisional) Immunodeficiency 51,613953];	RCV000330329.1 [benign]; 			84	70					IL17RA (inh=AR pLI=0.12)
chr22	17591144	17591144	C	T	het	hom	wt		QUAL=6614;DP=187,149,166;MQM=58	IL17RA	3'UTR	IL17RA:NM_014339.6:3'UTR:MODIFIER:exon13/13:c.*434C>T:,IL17RA:NM_001289905.1:3'UTR:MODIFIER:exon12/12:c.*434C>T:	AluSz	rs3179921	0.5397	0.0000	0/0/0	0.5250							605461 [IL17RA (provisional) Immunodeficiency 51,613953];	RCV000295393.1 [benign]; 			56	77					IL17RA (inh=AR pLI=0.12)
chr22	17591388	17591388	A	-	wt	hom	wt	low_DP	QUAL=71;DP=22,10,6;MQM=58	IL17RA	3'UTR	IL17RA:NM_014339.6:3'UTR:MODIFIER:exon13/13:c.*696delA:,IL17RA:NM_001289905.1:3'UTR:MODIFIER:exon12/12:c.*696delA:	AluSz	rs35219112;rs55885138;rs746289220	0.5020	0.0000	0/0/0	0.2188							605461 [IL17RA (provisional) Immunodeficiency 51,613953];	RCV000290041.1 [benign]; 			5	39					IL17RA (inh=AR pLI=0.12)
chr22	17591697	17591697	G	A	het	hom	wt		QUAL=5070;DP=146,111,149;MQM=59	IL17RA	3'UTR	IL17RA:NM_014339.6:3'UTR:MODIFIER:exon13/13:c.*987G>A:,IL17RA:NM_001289905.1:3'UTR:MODIFIER:exon12/12:c.*987G>A:	AluJo	rs882644	0.5555	0.0000	0/0/0	0.5295							605461 [IL17RA (provisional) Immunodeficiency 51,613953];	RCV000296969.1 [benign]; 			47	79					IL17RA (inh=AR pLI=0.12)
chr22	17591973	17591973	G	T	het	hom	het		QUAL=3470;DP=45,66,82;MQM=59	IL17RA	3'UTR	IL17RA:NM_014339.6:3'UTR:MODIFIER:exon13/13:c.*1263G>T:,IL17RA:NM_001289905.1:3'UTR:MODIFIER:exon12/12:c.*1263G>T:	L2c	rs887795	0.0000	0.0000	0/0/0	0.4753							605461 [IL17RA (provisional) Immunodeficiency 51,613953];				86	57					IL17RA (inh=AR pLI=0.12)
chr22	17593048	17593049	AT	-	het	het	wt		QUAL=10433;DP=423,433,582;MQM=59	IL17RA	3'UTR	IL17RA:NM_014339.6:3'UTR:MODIFIER:exon13/13:c.*2338_*2339delAT:,IL17RA:NM_001289905.1:3'UTR:MODIFIER:exon12/12:c.*2338_*2339delAT:		rs57380532	0.1152	0.0000	0/0/0	0.0949							605461 [IL17RA (provisional) Immunodeficiency 51,613953];	RCV000397733.1 [likely benign]; 			2	32					IL17RA (inh=AR pLI=0.12)
chr22	17593685	17593685	G	A	het	hom	het		QUAL=15314;DP=338,221,293;MQM=60	IL17RA	3'UTR	IL17RA:NM_014339.6:3'UTR:MODIFIER:exon13/13:c.*2975G>A:,IL17RA:NM_001289905.1:3'UTR:MODIFIER:exon12/12:c.*2975G>A:		rs887796	0.8367	0.0000	0/0/0	0.1404							605461 [IL17RA (provisional) Immunodeficiency 51,613953];	RCV000344523.1 [benign]; 			101	41					IL17RA (inh=AR pLI=0.12)
chr22	17593880	17593880	T	-	wt	hom	wt		QUAL=1230;DP=173,46,102;MQM=60	IL17RA	3'UTR	IL17RA:NM_014339.6:3'UTR:MODIFIER:exon13/13:c.*3179delT:,IL17RA:NM_001289905.1:3'UTR:MODIFIER:exon12/12:c.*3179delT:	(T)n	rs111392920;rs796607473	0.0000	0.0000	0/0/0	0.2139							605461 [IL17RA (provisional) Immunodeficiency 51,613953];	RCV000396995.1 [uncertain significance]; 			44	77					IL17RA (inh=AR pLI=0.12)
chr22	17593891	17593891	T	G	het	het	wt		QUAL=4872;DP=369,192,172;MQM=59	IL17RA	3'UTR	IL17RA:NM_014339.6:3'UTR:MODIFIER:exon13/13:c.*3181T>G:,IL17RA:NM_001289905.1:3'UTR:MODIFIER:exon12/12:c.*3181T>G:	(T)n	rs73876645	0.0000	0.0000	0/0/0	0.0323							605461 [IL17RA (provisional) Immunodeficiency 51,613953];	RCV000321823.1 [uncertain significance]; 			0	7					IL17RA (inh=AR pLI=0.12)
chr22	17593929	17593929	A	G	wt	wt	het		QUAL=1370;DP=259,214,175;MQM=59	IL17RA	3'UTR	IL17RA:NM_014339.6:3'UTR:MODIFIER:exon13/13:c.*3219A>G:,IL17RA:NM_001289905.1:3'UTR:MODIFIER:exon12/12:c.*3219A>G:		rs5746995	0.1621	0.0000	0/0/0	0.1314							605461 [IL17RA (provisional) Immunodeficiency 51,613953];	RCV000272479.1 [benign]; 			1	27					IL17RA (inh=AR pLI=0.12)
chr22	17593973	17593973	G	-	wt	wt	het		QUAL=2296;DP=376,248,248;MQM=59	IL17RA	3'UTR	IL17RA:NM_014339.6:3'UTR:MODIFIER:exon13/13:c.*3265delG:,IL17RA:NM_001289905.1:3'UTR:MODIFIER:exon12/12:c.*3265delG:		rs398040433	0.1627	0.0000	0/0/0	0.1109							605461 [IL17RA (provisional) Immunodeficiency 51,613953];	RCV000327594.1 [benign]; 			1	27					IL17RA (inh=AR pLI=0.12)
chr22	17594623	17594623	C	T	het	het	wt		QUAL=6390;DP=233,232,352;MQM=59	IL17RA	3'UTR	IL17RA:NM_014339.6:3'UTR:MODIFIER:exon13/13:c.*3913C>T:,IL17RA:NM_001289905.1:3'UTR:MODIFIER:exon12/12:c.*3913C>T:		rs11702918	0.1134	0.0000	0/0/0	0.0158							605461 [IL17RA (provisional) Immunodeficiency 51,613953];	RCV000304211.1 [uncertain significance]; RCV000359024.1 [likely benign]; 			2	32					IL17RA (inh=AR pLI=0.12)
chr22	17594755	17594755	G	A	het	het	wt		QUAL=5496;DP=226,272,362;MQM=59	IL17RA	3'UTR	IL17RA:NM_014339.6:3'UTR:MODIFIER:exon13/13:c.*4045G>A:,IL17RA:NM_001289905.1:3'UTR:MODIFIER:exon12/12:c.*4045G>A:	MIR	rs11703539	0.0984	0.0000	0/0/0	0.0151							605461 [IL17RA (provisional) Immunodeficiency 51,613953];	RCV000275875.1 [likely benign]; 			1	31					IL17RA (inh=AR pLI=0.12)
chr22	17594772	17594772	T	A	wt	wt	het		QUAL=3791;DP=284,249,333;MQM=60	IL17RA	3'UTR	IL17RA:NM_014339.6:3'UTR:MODIFIER:exon13/13:c.*4062T>A:,IL17RA:NM_001289905.1:3'UTR:MODIFIER:exon12/12:c.*4062T>A:	MIR	rs12484781	0.1627	0.0000	0/0/0	0.0226							605461 [IL17RA (provisional) Immunodeficiency 51,613953];	RCV000386266.1 [benign]; 			1	27					IL17RA (inh=AR pLI=0.12)
chr22	17594886	17594886	T	C	het	hom	wt		QUAL=16638;DP=420,341,454;MQM=60	IL17RA	3'UTR	IL17RA:NM_014339.6:3'UTR:MODIFIER:exon13/13:c.*4176T>C:,IL17RA:NM_001289905.1:3'UTR:MODIFIER:exon12/12:c.*4176T>C:		rs738035	0.4874	0.0000	0/0/0	0.5276							605461 [IL17RA (provisional) Immunodeficiency 51,613953];	RCV000282593.1 [benign]; 			45	81					IL17RA (inh=AR pLI=0.12)
chr22	17594915	17594915	G	A	het	hom	wt		QUAL=18854;DP=433,374,471;MQM=60	IL17RA	3'UTR	IL17RA:NM_014339.6:3'UTR:MODIFIER:exon13/13:c.*4205G>A:,IL17RA:NM_001289905.1:3'UTR:MODIFIER:exon12/12:c.*4205G>A:		rs738034	0.4864	0.0000	0/0/0	0.5259							605461 [IL17RA (provisional) Immunodeficiency 51,613953];	RCV000337488.1 [benign]; 			45	81					IL17RA (inh=AR pLI=0.12)
chr22	17595070	17595070	T	G	het	hom	wt		QUAL=16981;DP=472,348,380;MQM=59	IL17RA	3'UTR	IL17RA:NM_014339.6:3'UTR:MODIFIER:exon13/13:c.*4360T>G:,IL17RA:NM_001289905.1:3'UTR:MODIFIER:exon12/12:c.*4360T>G:		rs5992628	0.4860	0.0000	0/0/0	0.5267							605461 [IL17RA (provisional) Immunodeficiency 51,613953];	RCV000343453.1 [benign]; 			45	81					IL17RA (inh=AR pLI=0.12)
chr22	17595175	17595175	C	T	wt	wt	het		QUAL=7014;DP=355,417,562;MQM=60	IL17RA	3'UTR	IL17RA:NM_014339.6:3'UTR:MODIFIER:exon13/13:c.*4465C>T:,IL17RA:NM_001289905.1:3'UTR:MODIFIER:exon12/12:c.*4465C>T:		rs62623403	0.0244	0.0000	0/0/0	0.0450							605461 [IL17RA (provisional) Immunodeficiency 51,613953];	RCV000405866.1 [likely benign]; 			1	21					IL17RA (inh=AR pLI=0.12)
chr22	17595226	17595226	C	T	wt	het	wt		QUAL=7159;DP=374,495,601;MQM=60	IL17RA	3'UTR	IL17RA:NM_014339.6:3'UTR:MODIFIER:exon13/13:c.*4516C>T:,IL17RA:NM_001289905.1:3'UTR:MODIFIER:exon12/12:c.*4516C>T:		rs180834857	0.0016	0.0000	0/0/0	0.0047							605461 [IL17RA (provisional) Immunodeficiency 51,613953];	RCV000339543.1 [uncertain significance]; 			0	4					IL17RA (inh=AR pLI=0.12)
chr22	17595915	17595915	C	A	wt	het	wt		QUAL=3261;DP=342,234,335;MQM=60	IL17RA	3'UTR	IL17RA:NM_014339.6:3'UTR:MODIFIER:exon13/13:c.*5205C>A:,IL17RA:NM_001289905.1:3'UTR:MODIFIER:exon12/12:c.*5205C>A:		rs3827278	0.1715	0.0000	0/0/0	0.0259							605461 [IL17RA (provisional) Immunodeficiency 51,613953];	RCV000379537.1 [benign]; 			6	52					IL17RA (inh=AR pLI=0.12)
chr22	17595929	17595929	G	C	wt	het	wt		QUAL=3304;DP=349,244,379;MQM=60	IL17RA	3'UTR	IL17RA:NM_014339.6:3'UTR:MODIFIER:exon13/13:c.*5219G>C:,IL17RA:NM_001289905.1:3'UTR:MODIFIER:exon12/12:c.*5219G>C:		rs3827279	0.1719	0.0000	0/0/0	0.1513							605461 [IL17RA (provisional) Immunodeficiency 51,613953];	RCV000285318.1 [benign]; 			6	53					IL17RA (inh=AR pLI=0.12)
chr22	17596178	17596178	T	C	het	hom	het		QUAL=14101;DP=425,162,221;MQM=60	IL17RA	3'UTR	IL17RA:NM_014339.6:3'UTR:MODIFIER:exon13/13:c.*5468T>C:,IL17RA:NM_001289905.1:3'UTR:MODIFIER:exon12/12:c.*5468T>C:	MIRc	rs4819962	0.6186	0.0000	0/0/0	0.1125							605461 [IL17RA (provisional) Immunodeficiency 51,613953];	RCV000346293.1 [benign]; 			74	63					IL17RA (inh=AR pLI=0.12)
chr22	17596322	17596322	A	G	wt	het	wt		QUAL=1965;DP=442,166,200;MQM=59	IL17RA	3'UTR	IL17RA:NM_014339.6:3'UTR:MODIFIER:exon13/13:c.*5612A>G:,IL17RA:NM_001289905.1:3'UTR:MODIFIER:exon12/12:c.*5612A>G:	MIRc	rs1656	0.1715	0.0000	0/0/0	0.0368							605461 [IL17RA (provisional) Immunodeficiency 51,613953];	RCV000352179.1 [benign]; 			6	53					IL17RA (inh=AR pLI=0.12)
chr22	17596388	17596388	G	C	het	hom	het		QUAL=11335;DP=320,132,153;MQM=60	IL17RA	3'UTR	IL17RA:NM_014339.6:3'UTR:MODIFIER:exon13/13:c.*5678G>C:,IL17RA:NM_001289905.1:3'UTR:MODIFIER:exon12/12:c.*5678G>C:		rs1654	0.8369	0.0000	0/0/0	0.8257							605461 [IL17RA (provisional) Immunodeficiency 51,613953];	RCV000367325.1 [benign]; 			100	43					IL17RA (inh=AR pLI=0.12)
chr22	17596477	17596477	-	A	wt	wt	het		QUAL=1468;DP=259,127,159;MQM=60	IL17RA	3'UTR	IL17RA:NM_014339.6:3'UTR:MODIFIER:exon13/13:c.*5779dupA:,IL17RA:NM_001289905.1:3'UTR:MODIFIER:exon12/12:c.*5779dupA:		rs11389817;rs5844288	0.4535	0.0000	0/0/0	0.2759							605461 [IL17RA (provisional) Immunodeficiency 51,613953];	RCV000353396.1 [uncertain significance]; RCV000300909.1 [uncertain significance]; RCV000396848.1 [benign]; 			3	90					IL17RA (inh=AR pLI=0.12)
chr22	18560873	18560873	G	A	wt	wt	het		QUAL=632;DP=55,37,64;MQM=60	PEX26	5'UTR,intron	PEX26:NM_001127649.2:5'UTR:MODIFIER:exon1/5:c.-270G>A:,PEX26:NM_001199319.1:intron:MODIFIER:exon1/4:c.-82+60G>A:,PEX26:NM_017929.5:intron:MODIFIER:exon1/5:c.-82+60G>A:			0.0000	0.0000	0/0/0	0.0000							608666 [PEX26 (confirmed) Peroxisome biogenesis disorder 7A (Zellweger),614872|Peroxisome biogenesis disorder 7B,614873];				0	1					PEX26 (inh=AR pLI=0.44)
chr22	18570974	18570974	C	T	het	wt	het		QUAL=6537;DP=255,212,286;MQM=59	PEX26	3'UTR	PEX26:NM_001127649.2:3'UTR:MODIFIER:exon5/5:c.*133C>T:,PEX26:NM_001199319.1:3'UTR:MODIFIER:exon5/5:c.*133C>T:,PEX26:NM_017929.5:3'UTR:MODIFIER:exon6/6:c.*133C>T:		rs200243782	0.0010	0.0021	0/0/0	0.0012							608666 [PEX26 (confirmed) Peroxisome biogenesis disorder 7A (Zellweger),614872|Peroxisome biogenesis disorder 7B,614873];	RCV000274220.1 [uncertain significance]; 			0	8					PEX26 (inh=AR pLI=0.44)
chr22	18571008	18571008	G	A	hom	het	hom	pred_pathogenic	QUAL=22698;DP=292,248,343;MQM=59	PEX26	3'UTR	PEX26:NM_001127649.2:3'UTR:MODIFIER:exon5/5:c.*167G>A:,PEX26:NM_001199319.1:3'UTR:MODIFIER:exon5/5:c.*167G>A:,PEX26:NM_017929.5:3'UTR:MODIFIER:exon6/6:c.*167G>A:		rs464385	0.4227	0.6133	5812/3358/143	0.4018	-0.0230	D	T			6.64	608666 [PEX26 (confirmed) Peroxisome biogenesis disorder 7A (Zellweger),614872|Peroxisome biogenesis disorder 7B,614873];	RCV000331781.1 [benign]; 			356	434					PEX26 (inh=AR pLI=0.44)
chr22	18571670	18571670	A	G	hom	hom	hom		QUAL=33052;DP=302,321,397;MQM=59	PEX26	3'UTR	PEX26:NM_001127649.2:3'UTR:MODIFIER:exon5/5:c.*829A>G:,PEX26:NM_001199319.1:3'UTR:MODIFIER:exon5/5:c.*829A>G:,PEX26:NM_017929.5:3'UTR:MODIFIER:exon6/6:c.*829A>G:		rs362057	0.9958	0.0000	0/0/0	0.1826							608666 [PEX26 (confirmed) Peroxisome biogenesis disorder 7A (Zellweger),614872|Peroxisome biogenesis disorder 7B,614873];	RCV000306534.1 [benign]; 			226	4					PEX26 (inh=AR pLI=0.44)
chr22	18571758	18571758	C	T	wt	het	wt		QUAL=3776;DP=272,320,412;MQM=60	PEX26	3'UTR	PEX26:NM_001127649.2:3'UTR:MODIFIER:exon5/5:c.*917C>T:,PEX26:NM_001199319.1:3'UTR:MODIFIER:exon5/5:c.*917C>T:,PEX26:NM_017929.5:3'UTR:MODIFIER:exon6/6:c.*917C>T:		rs9605518	0.0713	0.0000	0/0/0	0.0106							608666 [PEX26 (confirmed) Peroxisome biogenesis disorder 7A (Zellweger),614872|Peroxisome biogenesis disorder 7B,614873];	RCV000276104.1 [likely benign]; 			0	18					PEX26 (inh=AR pLI=0.44)
chr22	18571828	18571828	T	C	hom	hom	hom		QUAL=33097;DP=395,287,379;MQM=59	PEX26	3'UTR	PEX26:NM_001127649.2:3'UTR:MODIFIER:exon5/5:c.*987T>C:,PEX26:NM_001199319.1:3'UTR:MODIFIER:exon5/5:c.*987T>C:,PEX26:NM_017929.5:3'UTR:MODIFIER:exon6/6:c.*987T>C:		rs361807	0.8734	0.0000	0/0/0	0.8826							608666 [PEX26 (confirmed) Peroxisome biogenesis disorder 7A (Zellweger),614872|Peroxisome biogenesis disorder 7B,614873];	RCV000260942.1 [benign]; 			182	43					PEX26 (inh=AR pLI=0.44)
chr22	18572106	18572106	T	A	hom	het	hom		QUAL=13214;DP=204,171,166;MQM=59	PEX26	3'UTR	PEX26:NM_001127649.2:3'UTR:MODIFIER:exon5/5:c.*1265T>A:,PEX26:NM_001199319.1:3'UTR:MODIFIER:exon5/5:c.*1265T>A:,PEX26:NM_017929.5:3'UTR:MODIFIER:exon6/6:c.*1265T>A:		rs456551	0.4231	0.0000	0/0/0	0.0615							608666 [PEX26 (confirmed) Peroxisome biogenesis disorder 7A (Zellweger),614872|Peroxisome biogenesis disorder 7B,614873];	RCV000291367.1 [benign]; 			92	103					PEX26 (inh=AR pLI=0.44)
chr22	18572371	18572371	-	TTGG	hom	hom	hom		QUAL=29834;DP=264,333,419;MQM=59	PEX26	3'UTR	PEX26:NM_001127649.2:3'UTR:MODIFIER:exon5/5:c.*1532_*1535dupTGGT:,PEX26:NM_001199319.1:3'UTR:MODIFIER:exon5/5:c.*1532_*1535dupTGGT:,PEX26:NM_017929.5:3'UTR:MODIFIER:exon6/6:c.*1532_*1535dupTGGT:		rs361782;rs397708785;rs5844350	0.8680	0.0000	0/0/0	0.8058							608666 [PEX26 (confirmed) Peroxisome biogenesis disorder 7A (Zellweger),614872|Peroxisome biogenesis disorder 7B,614873];	RCV000406809.1 [benign]; 			118	29					PEX26 (inh=AR pLI=0.44)
chr22	18572499	18572499	-	CTCA	hom	hom	hom		QUAL=14678;DP=169,181,216;MQM=54	PEX26	3'UTR	PEX26:NM_001127649.2:3'UTR:MODIFIER:exon5/5:c.*1661_*1662insACTC:,PEX26:NM_001199319.1:3'UTR:MODIFIER:exon5/5:c.*1661_*1662insACTC:,PEX26:NM_017929.5:3'UTR:MODIFIER:exon6/6:c.*1661_*1662insACTC:	AluYf1	rs10629935;rs772261665	0.9952	0.0000	0/0/0	0.8529							608666 [PEX26 (confirmed) Peroxisome biogenesis disorder 7A (Zellweger),614872|Peroxisome biogenesis disorder 7B,614873];	RCV000297780.1 [benign]; 			148	2					PEX26 (inh=AR pLI=0.44)
chr22	18572892	18572892	A	G	hom	hom	hom		QUAL=10531;DP=168,71,83;MQM=60	PEX26	3'UTR	PEX26:NM_001127649.2:3'UTR:MODIFIER:exon5/5:c.*2051A>G:,PEX26:NM_001199319.1:3'UTR:MODIFIER:exon5/5:c.*2051A>G:,PEX26:NM_017929.5:3'UTR:MODIFIER:exon6/6:c.*2051A>G:		rs361946	0.8734	0.0000	0/0/0	0.1510							608666 [PEX26 (confirmed) Peroxisome biogenesis disorder 7A (Zellweger),614872|Peroxisome biogenesis disorder 7B,614873];	RCV000288555.1 [benign]; 			119	28					PEX26 (inh=AR pLI=0.44)
chr22	18573122	18573122	T	C	hom	hom	hom		QUAL=23816;DP=264,193,284;MQM=59	PEX26	3'UTR	PEX26:NM_001127649.2:3'UTR:MODIFIER:exon5/5:c.*2281T>C:,PEX26:NM_001199319.1:3'UTR:MODIFIER:exon5/5:c.*2281T>C:,PEX26:NM_017929.5:3'UTR:MODIFIER:exon6/6:c.*2281T>C:	L2b	rs362209	0.9960	0.0000	0/0/0	0.1545							608666 [PEX26 (confirmed) Peroxisome biogenesis disorder 7A (Zellweger),614872|Peroxisome biogenesis disorder 7B,614873];	RCV000349159.1 [benign]; 			148	2					PEX26 (inh=AR pLI=0.44)
chr22	18573544	18573544	G	A	wt	wt	het		QUAL=4087;DP=80,103,233;MQM=60	PEX26	3'UTR	PEX26:NM_001127649.2:3'UTR:MODIFIER:exon5/5:c.*2703G>A:,PEX26:NM_001199319.1:3'UTR:MODIFIER:exon5/5:c.*2703G>A:,PEX26:NM_017929.5:3'UTR:MODIFIER:exon6/6:c.*2703G>A:		rs186314626	0.0028	0.0000	0/0/0	0.0012							608666 [PEX26 (confirmed) Peroxisome biogenesis disorder 7A (Zellweger),614872|Peroxisome biogenesis disorder 7B,614873];				0	1					PEX26 (inh=AR pLI=0.44)
chr22	21213380	21213380	C	T	hom	hom	hom		QUAL=14514;DP=166,130,217;MQM=59	SNAP29	5'UTR_premature_start_codon_gain,5'UTR	SNAP29:NM_004782.3:5'UTR_premature_start_codon_gain:LOW:exon1/5:c.-19C>T:,SNAP29:NM_004782.3:5'UTR:MODIFIER:exon1/5:c.-19C>T:		rs1061063	0.4639	0.5473	12802/7587/536	0.4767							604202 [SNAP29 (provisional) Cerebral dysgenesis,neuropathy,ichthyosis,and palmoplantar keratoderma syndrome,609528];	RCV000282177.1 [benign]; 			263	461					SNAP29 (inh=AR pLI=0.15)
chr22	21213416	21213416	A	G	hom	hom	hom		QUAL=21139;DP=199,206,303;MQM=59	SNAP29	synonymous	SNAP29:NM_004782.3:synonymous:LOW:exon1/5:c.18A>G:p.Lys6Lys		rs1061064	0.4036	0.5358	14180/8596/164	0.4765							604202 [SNAP29 (provisional) Cerebral dysgenesis,neuropathy,ichthyosis,and palmoplantar keratoderma syndrome,609528];	RCV000342922.1 [benign]; 		COSM444738	432	742					SNAP29 (inh=AR pLI=0.15)
chr22	21242600	21242603	CACA	-	hom	hom	wt		QUAL=2069;DP=94,89,118;MQM=59	SNAP29	3'UTR	SNAP29:NM_004782.3:3'UTR:MODIFIER:exon5/5:c.*517_*520delACAC:	(CA)n	rs575240461;rs760058624	0.0000	0.0000	0/0/0	0.1234							604202 [SNAP29 (provisional) Cerebral dysgenesis,neuropathy,ichthyosis,and palmoplantar keratoderma syndrome,609528];	RCV000381344.1 [uncertain significance]; 			3	9					SNAP29 (inh=AR pLI=0.15)
chr22	21244940	21244940	A	G	hom	hom	het	low_DP;low_MQM	QUAL=330;DP=10,1,4;MQM=47	SNAP29	3'UTR	SNAP29:NM_004782.3:3'UTR:MODIFIER:exon5/5:c.*2816A>G:	AluYk3	rs165739	0.8321	0.0000	0/0/0	0.7231							604202 [SNAP29 (provisional) Cerebral dysgenesis,neuropathy,ichthyosis,and palmoplantar keratoderma syndrome,609528];	RCV000306894.1 [benign]; 			102	23					SNAP29 (inh=AR pLI=0.15)
chr22	23915370	23915370	G	A	het	het	wt		QUAL=2069;DP=101,73,83;MQM=59	IGLL1	3'UTR	IGLL1:NM_020070.3:3'UTR:MODIFIER:exon3/3:c.*83C>T:,IGLL1:NM_152855.2:3'UTR:MODIFIER:exon2/2:c.*354C>T:		rs8141940	0.1204	0.0000	0/0/0	0.0106							146770 [IGLL1 (confirmed) Agammaglobulinemia 2,613500];				2	21					IGLL1 (inh=AR pLI=0.02)
chr22	23915610	23915610	A	T	het	het	wt	pred_pathogenic	QUAL=4835;DP=193,245,300;MQM=55	IGLL1	missense,3'UTR	IGLL1:NM_020070.3:missense:MODERATE:exon3/3:c.485T>A:p.Met162Lys,IGLL1:NM_152855.2:3'UTR:MODIFIER:exon2/2:c.*114T>A:		rs111903752	0.0383	0.0312	65/41/11	0.0286	2.2680	D,D	T	B	T,T	0.35	146770 [IGLL1 (confirmed) Agammaglobulinemia 2,613500];			COSM228749	3	93					IGLL1 (inh=AR pLI=0.02)
chr22	23915652	23915652	G	A	het	wt	het		QUAL=5837;DP=238,223,256;MQM=56	IGLL1	missense,3'UTR	IGLL1:NM_020070.3:missense:MODERATE:exon3/3:c.443C>T:p.Thr148Ile,IGLL1:NM_152855.2:3'UTR:MODIFIER:exon2/2:c.*72C>T:		rs73157031	0.1388	0.1500	1679/537/8	0.1442	0.2820	T,T	T	B	T,T	1.71	146770 [IGLL1 (confirmed) Agammaglobulinemia 2,613500];			COSM149263	32	308					IGLL1 (inh=AR pLI=0.02)
chr22	24891292	24891292	C	G	hom	hom	het		QUAL=11035;DP=96,180,217;MQM=59	UPB1	5'UTR	UPB1:NM_016327.2:5'UTR:MODIFIER:exon1/10:c.-80C>G:		rs2070474	0.5327	0.0000	0/0/0	0.1059							606673 [UPB1 (provisional) Beta-ureidopropionase deficiency,613161];	RCV000086537.1 [not provided]; RCV000323244.1 [benign]; 			79	119					UPB1 (inh=AR pLI=0.00)
chr22	24891355	24891355	A	T	wt	wt	het		QUAL=3664;DP=111,255,349;MQM=60	UPB1	5'UTR	UPB1:NM_016327.2:5'UTR:MODIFIER:exon1/10:c.-17A>T:		rs2070475	0.1560	0.1541	1615/839/5	0.1481							606673 [UPB1 (provisional) Beta-ureidopropionase deficiency,613161];	RCV000086538.1 [not provided]; RCV000402048.1 [benign]; 			17	197					UPB1 (inh=AR pLI=0.00)
chr22	31003138	31003138	A	G	hom	hom	hom		QUAL=6543;DP=76,61,92;MQM=59	TCN2	5'UTR	TCN2:NM_000355.3:5'UTR:MODIFIER:exon1/9:c.-181A>G:,TCN2:NM_001184726.1:5'UTR:MODIFIER:exon1/9:c.-181A>G:		rs2240433	0.5545	0.0000	0/0/0	0.4920							613441 [TCN2 (confirmed) Transcobalamin II deficiency,275350];	RCV000377487.1 [uncertain significance]; RCV000285374.1 [benign]; 			46	80					TCN2 (inh=AR pLI=0.02)
chr22	31006860	31006860	A	G	wt	wt	het		QUAL=4301;DP=206,250,317;MQM=60	TCN2	missense&splice_region	TCN2:NM_000355.3:missense&splice_region:MODERATE:exon2/9:c.67A>G:p.Ile23Val,TCN2:NM_001184726.1:missense&splice_region:MODERATE:exon2/9:c.67A>G:p.Ile23Val		rs9606756	0.1130	0.1165	972/474/142	0.1146	0.1820	T,T,T,T	T	B,B,B	T,T,T,T	1.80	613441 [TCN2 (confirmed) Transcobalamin II deficiency,275350];	RCV000398328.1 [likely benign]; 	CM114813 [CLASS=FP MUT=ALT PHEN="Lower total-TC concentrations" GENE=TCN2]; 		20	294					TCN2 (inh=AR pLI=0.02)
chr22	31008867	31008867	T	C	wt	het	wt		QUAL=644;DP=60,47,64;MQM=60	TCN2	missense	TCN2:NM_000355.3:missense:MODERATE:exon3/9:c.265T>C:p.Phe89Leu,TCN2:NM_001184726.1:missense:MODERATE:exon3/9:c.265T>C:p.Phe89Leu		rs35915865	0.0082	0.0140	25/18/0	0.0140	-2.5930	T,T	T	B,B	T,T	0.01	613441 [TCN2 (confirmed) Transcobalamin II deficiency,275350];	RCV000389989.1 [uncertain significance]; 			0	53					TCN2 (inh=AR pLI=0.02)
chr22	31011610	31011610	G	C	hom	het	het		QUAL=15750;DP=220,310,359;MQM=59	TCN2	missense	TCN2:NM_000355.3:missense:MODERATE:exon6/9:c.776G>C:p.Arg259Pro,TCN2:NM_001184726.1:missense:MODERATE:exon6/9:c.695G>C:p.Arg232Pro		rs1801198	0.5797	0.5673	20120/10854/3008	0.5604	0.1460	T,T,T	T	B,B,B	T,T,T	4.51	613441 [TCN2 (confirmed) Transcobalamin II deficiency,275350];	RCV000000117.2 [benign]; RCV000374451.1 [benign]; 	CM022466 [CLASS=DFP MUT=REF PHEN="Decreased holo TCII levels association with" GENE=TCN2]; 	COSM4002151	480	754					TCN2 (inh=AR pLI=0.02)
chr22	31019044	31019044	G	A	wt	het	wt		QUAL=2197;DP=217,175,217;MQM=60	TCN2	missense	TCN2:NM_000355.3:missense:MODERATE:exon8/9:c.1196G>A:p.Arg399Gln,TCN2:NM_001184726.1:missense:MODERATE:exon8/9:c.1115G>A:p.Arg372Gln		rs4820889	0.0565	0.0351	143/34/70	0.0345	-0.5000	T,T,T	T	B,B,B	T,T,T	16.16	613441 [TCN2 (confirmed) Transcobalamin II deficiency,275350];	RCV000353236.1 [likely benign]; 	CM025996 [CLASS=FP MUT=ALT PHEN="Increased total-TC concentrations" GENE=TCN2]; 		5	92					TCN2 (inh=AR pLI=0.02)
chr22	31022635	31022635	C	T	hom	het	het		QUAL=15920;DP=256,225,337;MQM=59	TCN2	3'UTR	TCN2:NM_000355.3:3'UTR:MODIFIER:exon9/9:c.*127C>T:,TCN2:NM_001184726.1:3'UTR:MODIFIER:exon9/9:c.*127C>T:		rs12160073	0.0675	0.0000	0/0/0	0.0261							613441 [TCN2 (confirmed) Transcobalamin II deficiency,275350];	RCV000273895.1 [likely benign]; 			6	60					TCN2 (inh=AR pLI=0.02)
chr22	31022890	31022890	C	T	wt	het	wt		QUAL=2854;DP=207,226,327;MQM=60	TCN2	3'UTR	TCN2:NM_000355.3:3'UTR:MODIFIER:exon9/9:c.*382C>T:,TCN2:NM_001184726.1:3'UTR:MODIFIER:exon9/9:c.*382C>T:		rs56076607	0.0138	0.0000	0/0/0	0.0155							613441 [TCN2 (confirmed) Transcobalamin II deficiency,275350];	RCV000291397.1 [uncertain significance]; 			0	7					TCN2 (inh=AR pLI=0.02)
chr22	33669492	33669492	G	C	het	het	wt		QUAL=8345;DP=398,235,322;MQM=59	LARGE1	3'UTR	LARGE1:NM_004737.4:3'UTR:MODIFIER:exon16/16:c.*921C>G:,LARGE1:NM_133642.3:3'UTR:MODIFIER:exon15/15:c.*921C>G:		rs16992034	0.0543	0.0000	0/0/0	0.0093							603590 [LARGE (confirmed) Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,6,613154|Muscular dystrophy-dystroglycanopathy (congenital with mental retardation),type B,6,608840];	RCV000268769.1 [likely benign]; RCV000365682.1 [likely benign]; 			1	23					LARGE1 (inh=AR pLI=0.96)
chr22	33670584	33670584	G	A	het	het	wt		QUAL=4251;DP=172,160,176;MQM=60	LARGE1	synonymous	LARGE1:NM_004737.4:synonymous:LOW:exon16/16:c.2100C>T:p.Asn700Asn,LARGE1:NM_133642.3:synonymous:LOW:exon15/15:c.2100C>T:p.Asn700Asn		rs17722172	0.0210	0.0472	178/163/0	0.0472							603590 [LARGE (confirmed) Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,6,613154|Muscular dystrophy-dystroglycanopathy (congenital with mental retardation),type B,6,608840];	RCV000081178.8 [other]; RCV000296322.1 [likely benign]; RCV000351281.1 [likely benign]; 			9	157					LARGE1 (inh=AR pLI=0.96)
chr22	34022284	34022284	G	A	het	het	het		QUAL=15377;DP=340,366,489;MQM=60	LARGE1	synonymous	LARGE1:NM_004737.4:synonymous:LOW:exon5/16:c.435C>T:p.Ala145Ala,LARGE1:NM_133642.3:synonymous:LOW:exon4/15:c.435C>T:p.Ala145Ala		rs86487	0.4129	0.4771	14434/7968/126	0.4745							603590 [LARGE (confirmed) Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies),type A,6,613154|Muscular dystrophy-dystroglycanopathy (congenital with mental retardation),type B,6,608840];	RCV000081181.7 [other]; RCV000333062.1 [benign]; RCV000373679.1 [benign]; 		COSM4156187	419	767					LARGE1 (inh=AR pLI=0.96)
chr22	37271882	37271882	T	C	hom	hom	hom	pred_pathogenic	QUAL=15839;DP=114,184,229;MQM=59	NCF4	missense,intron	NCF4:NM_013416.3:missense:MODERATE:exon8/9:c.815T>C:p.Leu272Pro,NCF4:NM_000631.4:intron:MODIFIER:exon8/9:c.758+57T>C:		rs2075939	0.8281	0.8337	42411/23351/4665	0.8159	0.2940	D	T	B	T	13.63	601488 [NCF4 (provisional) Granulomatous disease,chronic,autosomal recessive,cytochrome b-positive,type III,613960];	RCV000253146.1 [benign]; RCV000375140.1 [benign]; 		COSM4156206	1095	414					NCF4 (inh=AR pLI=0.00)
chr22	38369027	38369027	C	T	het	hom	het		QUAL=8649;DP=173,149,192;MQM=60	SOX10,POLR2F	3'UTR,intron	SOX10:NM_006941.3:3'UTR:MODIFIER:exon4/4:c.*475G>A:,POLR2F:NM_001301130.1:intron:MODIFIER:exon4/5:c.293+5850C>T:,POLR2F:NM_001301131.1:intron:MODIFIER:exon4/4:c.293+5850C>T:		rs139883	0.6084	0.0000	0/0/0	0.1069							602229 [SOX10 (confirmed) Waardenburg syndrome,type 4C,613266|Waardenburg syndrome,type 2E,with or without neurologic involvement,611584|PCWH syndrome,609136];	RCV000296837.1 [benign]; RCV000354094.1 [benign]; 			104	122					SOX10 (inh=AD pLI=0.91), POLR2F (inh=n/a pLI=0.65)
chr22	38369976	38369976	A	G	het	hom	het		QUAL=3406;DP=95,46,72;MQM=60	SOX10,POLR2F	synonymous,intron	SOX10:NM_006941.3:synonymous:LOW:exon4/4:c.927T>C:p.His309His,POLR2F:NM_001301130.1:intron:MODIFIER:exon4/5:c.293+6799A>G:,POLR2F:NM_001301131.1:intron:MODIFIER:exon4/4:c.293+6799A>G:		rs139884	0.7133	0.6537	26127/13186/3510	0.6486							602229 [SOX10 (confirmed) Waardenburg syndrome,type 4C,613266|Waardenburg syndrome,type 2E,with or without neurologic involvement,611584|PCWH syndrome,609136];	RCV000218215.2 [benign]; RCV000276693.1 [benign]; RCV000368913.1 [benign]; 		COSM4156245	854	1000					SOX10 (inh=AD pLI=0.91), POLR2F (inh=n/a pLI=0.65)
chr22	38507818	38507818	G	T	wt	wt	het	low_DP	QUAL=264;DP=28,16,28;MQM=60	PLA2G6	3'UTR	PLA2G6:NM_003560.2:3'UTR:MODIFIER:exon17/17:c.*350C>A:,PLA2G6:NM_001004426.1:3'UTR:MODIFIER:exon16/16:c.*350C>A:,PLA2G6:NM_001199562.1:3'UTR:MODIFIER:exon16/16:c.*350C>A:	G-rich	rs11570770	0.1184	0.0000	0/0/0	0.0162							603604 [PLA2G6 (confirmed) Infantile neuroaxonal dystrophy 1,256600|Neurodegeneration with brain iron accumulation 2B,610217|Parkinson disease 14,autosomal recessive,612953];	RCV000400315.1 [likely benign]; 			2	53					PLA2G6 (inh=AR pLI=0.00)
chr22	41256802	41256802	A	G	wt	wt	het		QUAL=402;DP=58,22,24;MQM=60	XPNPEP3,DNAJB7	splice_region&intron,3'UTR,intron	XPNPEP3:NM_001204827.1:splice_region&intron:LOW:exon2/2:c.*12+5A>G:,DNAJB7:NM_145174.1:3'UTR:MODIFIER:exon1/1:c.*267T>C:,XPNPEP3:NM_022098.3:intron:MODIFIER:exon1/9:c.64+3553A>G:	AluJb	rs103197	0.6118	0.6375	317/100/27	0.1367							613553 [XPNPEP3 (confirmed) Nephronophthisis-like nephropathy 1,613159];				348	505					XPNPEP3 (inh=AR pLI=0.00), DNAJB7 (inh=n/a pLI=0.00)
chr22	41323879	41323879	A	-	wt	wt	hom	low_DP;low_MQM	QUAL=524;DP=84,19,19;MQM=47	XPNPEP3	3'UTR	XPNPEP3:NM_022098.3:3'UTR:MODIFIER:exon10/10:c.*1457delA:	AluYm1	rs573345765	0.0288	0.0000	0/0/0	0.0059							613553 [XPNPEP3 (confirmed) Nephronophthisis-like nephropathy 1,613159];				0	32					XPNPEP3 (inh=AR pLI=0.00)
chr22	41323897	41323897	G	A	het	wt	wt	low_DP;low_MQM	QUAL=524;DP=84,19,19;MQM=37	XPNPEP3	3'UTR	XPNPEP3:NM_022098.3:3'UTR:MODIFIER:exon10/10:c.*1458G>A:	AluYm1		0.0000	0.0000	0/0/0	0.0008							613553 [XPNPEP3 (confirmed) Nephronophthisis-like nephropathy 1,613159];	RCV000297081.1 [uncertain significance]; 			1	82					XPNPEP3 (inh=AR pLI=0.00)
chr22	41324205	41324205	C	T	hom	hom	hom		QUAL=1473;DP=34,21,28;MQM=56	XPNPEP3	3'UTR	XPNPEP3:NM_022098.3:3'UTR:MODIFIER:exon10/10:c.*1766C>T:	AluSx3	rs371229000	0.0000	0.0000	0/0/0	0.0002							613553 [XPNPEP3 (confirmed) Nephronophthisis-like nephropathy 1,613159];				0	23					XPNPEP3 (inh=AR pLI=0.00)
chr22	41324315	41324315	A	G	wt	het	wt		QUAL=143;DP=161,27,30;MQM=58	XPNPEP3	3'UTR	XPNPEP3:NM_022098.3:3'UTR:MODIFIER:exon10/10:c.*1876A>G:	AluSx3	rs555560884	0.0004	0.0000	0/0/0	0.0011							613553 [XPNPEP3 (confirmed) Nephronophthisis-like nephropathy 1,613159];	RCV000382457.1 [uncertain significance]; 			0	4					XPNPEP3 (inh=AR pLI=0.00)
chr22	41325068	41325068	G	A	hom	hom	het		QUAL=16964;DP=239,227,268;MQM=60	XPNPEP3	3'UTR	XPNPEP3:NM_022098.3:3'UTR:MODIFIER:exon10/10:c.*2629G>A:		rs2899341	0.5946	0.0000	0/0/0	0.0952							613553 [XPNPEP3 (confirmed) Nephronophthisis-like nephropathy 1,613159];	RCV000374085.1 [benign]; 			41	68					XPNPEP3 (inh=AR pLI=0.00)
chr22	41325196	41325196	C	T	hom	hom	hom		QUAL=2365;DP=93,37,58;MQM=54	XPNPEP3	3'UTR	XPNPEP3:NM_022098.3:3'UTR:MODIFIER:exon10/10:c.*2757C>T:	AluSx3	rs201927557	0.0000	0.0000	0/0/0	0.0004							613553 [XPNPEP3 (confirmed) Nephronophthisis-like nephropathy 1,613159];				0	32					XPNPEP3 (inh=AR pLI=0.00)
chr22	42454354	42454354	G	A	hom	het	het		QUAL=19175;DP=317,291,346;MQM=59	NAGA	3'UTR	NAGA:NM_000262.2:3'UTR:MODIFIER:exon9/9:c.*1929C>T:	L1MC5a	rs5758566	0.6476	0.0000	0/0/0	0.1161							104170 [NAGA (confirmed) Schindler disease,type I,609241|Kanzaki disease,609242|Schindler disease,type III,609241];	RCV000288226.1 [benign]; RCV000382486.1 [benign]; 			105	100					NAGA (inh=AR pLI=0.00)
chr22	42454494	42454494	A	-	hom	hom	hom		QUAL=21013;DP=308,205,215;MQM=59	NAGA	3'UTR	NAGA:NM_000262.2:3'UTR:MODIFIER:exon9/9:c.*1789delT:		rs796216027	0.8966	0.0000	0/0/0	0.3680							104170 [NAGA (confirmed) Schindler disease,type I,609241|Kanzaki disease,609242|Schindler disease,type III,609241];	RCV000313100.1 [uncertain significance]; RCV000349138.1 [uncertain significance]; 			198	29					NAGA (inh=AR pLI=0.00)
chr22	42454950	42454950	A	G	het	het	wt		QUAL=11053;DP=450,381,449;MQM=60	NAGA	3'UTR	NAGA:NM_000262.2:3'UTR:MODIFIER:exon9/9:c.*1333T>C:		rs1063392	0.4595	0.0000	0/0/0	0.0869							104170 [NAGA (confirmed) Schindler disease,type I,609241|Kanzaki disease,609242|Schindler disease,type III,609241];	RCV000266251.1 [benign]; RCV000323621.1 [benign]; 			55	114					NAGA (inh=AR pLI=0.00)
chr22	42455248	42455248	C	T	het	wt	het		QUAL=10862;DP=368,344,470;MQM=60	NAGA	3'UTR	NAGA:NM_000262.2:3'UTR:MODIFIER:exon9/9:c.*1035G>A:		rs62238588	0.0306	0.0000	0/0/0	0.0107							104170 [NAGA (confirmed) Schindler disease,type I,609241|Kanzaki disease,609242|Schindler disease,type III,609241];	RCV000295309.1 [likely benign]; RCV000387189.1 [likely benign]; 			0	28					NAGA (inh=AR pLI=0.00)
chr22	42458827	42458827	G	C	het	wt	het	low_DP	QUAL=53;DP=9,7,4;MQM=60	NAGA	splice_region&intron	NAGA:NM_000262.2:splice_region&intron:LOW:exon7/8:c.957+4C>G:		rs55715427	0.0298	0.0577	280/249/0	0.0585							104170 [NAGA (confirmed) Schindler disease,type I,609241|Kanzaki disease,609242|Schindler disease,type III,609241];	RCV000338134.1 [likely benign]; RCV000396099.1 [likely benign]; 			7	181					NAGA (inh=AR pLI=0.00)
chr22	42463814	42463814	C	T	hom	het	het		QUAL=13517;DP=186,278,384;MQM=59	NAGA	synonymous	NAGA:NM_000262.2:synonymous:LOW:exon3/9:c.279G>A:p.Pro93Pro		rs133369	0.6769	0.6728	27836/14900/1773	0.6700							104170 [NAGA (confirmed) Schindler disease,type I,609241|Kanzaki disease,609242|Schindler disease,type III,609241];	RCV000177025.1 [benign]; RCV000282713.1 [benign]; RCV000322543.1 [benign]; 		COSM3759227	655	716					NAGA (inh=AR pLI=0.00)
chr22	42466509	42466509	C	G	hom	het	het		QUAL=18767;DP=324,294,377;MQM=59	NAGA	5'UTR	NAGA:NM_000262.2:5'UTR:MODIFIER:exon1/9:c.-208G>C:		rs133375	0.6424	0.0000	0/0/0	0.1156							104170 [NAGA (confirmed) Schindler disease,type I,609241|Kanzaki disease,609242|Schindler disease,type III,609241];	RCV000369898.1 [benign]; RCV000399431.1 [benign]; 			105	101					NAGA (inh=AR pLI=0.00)
chr22	42522550	42522550	G	A	het	wt	wt	low_QUAL;low_DP;low_MQM	QUAL=17;DP=7,1,1;MQM=42	CYP2D6,LOC101929829	3'UTR,non_coding_transcript_exon	CYP2D6:NM_000106.5:3'UTR:MODIFIER:exon9/9:c.*26C>T:,CYP2D6:NM_001025161.2:3'UTR:MODIFIER:exon8/8:c.*26C>T:,LOC101929829:NR_111920.1:non_coding_transcript_exon:MODIFIER:exon9/9:n.1609C>T:		rs201759814	0.0000	0.0221	0/0/0	0.0011							124030 [CYP2D6 (confirmed) Debrisoquine sensitivity,608902|Codeine sensitivity,608902];				2	29					CYP2D6 (inh=n/a pLI=0.00), LOC101929829 (inh=n/a pLI=n/a)
chr22	42523003	42523003	A	G	hom	wt	het	low_DP;low_MQM	QUAL=286;DP=9,110,157;MQM=31	CYP2D6,LOC101929829	splice_region&intron	CYP2D6:NM_000106.5:splice_region&intron:LOW:exon7/8:c.1174-9T>C:,LOC101929829:NR_111920.1:splice_region&intron:LOW:exon7/8:n.1263-9T>C:,CYP2D6:NM_001025161.2:splice_region&intron:LOW:exon6/7:c.1021-9T>C:		rs4987144	0.0000	0.0598	1097/562/98	0.0958							124030 [CYP2D6 (confirmed) Debrisoquine sensitivity,608902|Codeine sensitivity,608902];				661	475					CYP2D6 (inh=n/a pLI=0.00), LOC101929829 (inh=n/a pLI=n/a)
chr22	42523528	42523528	C	T	het	wt	het	pred_pathogenic	QUAL=2573;DP=175,137,465;MQM=52	CYP2D6,LOC101929829	missense,non_coding_transcript_exon	CYP2D6:NM_000106.5:missense:MODERATE:exon7/9:c.1094G>A:p.Arg365His,CYP2D6:NM_001025161.2:missense:MODERATE:exon6/8:c.941G>A:p.Arg314His,LOC101929829:NR_111920.1:non_coding_transcript_exon:MODIFIER:exon7/9:n.1183G>A:		rs1058172	0.0000	0.1211	10/6/0	0.0989	7.6100	D,D,D,D,D	T	D,D,D	D,D,D	35.00	124030 [CYP2D6 (confirmed) Debrisoquine sensitivity,608902|Codeine sensitivity,608902];			COSM445068, COSM445067	0	324					CYP2D6 (inh=n/a pLI=0.00), LOC101929829 (inh=n/a pLI=n/a)
chr22	42523636	42523636	C	A	het	wt	wt	low_MQM;pred_pathogenic	QUAL=371;DP=116,105,330;MQM=40	CYP2D6,LOC101929829	missense&splice_region,splice_region&non_coding_transcript_exon	CYP2D6:NM_000106.5:missense&splice_region:MODERATE:exon7/9:c.986G>T:p.Arg329Leu,CYP2D6:NM_001025161.2:missense&splice_region:MODERATE:exon6/8:c.833G>T:p.Arg278Leu,LOC101929829:NR_111920.1:splice_region&non_coding_transcript_exon:LOW:exon7/9:n.1075G>T:		rs3915951	0.0000	0.0756	1/1/0	0.0010	0.4480	D,D,D,D,D	T	B,B,B	T,T,T	23.40	124030 [CYP2D6 (confirmed) Debrisoquine sensitivity,608902|Codeine sensitivity,608902];			COSM304740, COSM225813	0	88					CYP2D6 (inh=n/a pLI=0.00), LOC101929829 (inh=n/a pLI=n/a)
chr22	42523943	42523943	A	G	hom	wt	het		QUAL=14082;DP=187,245,671;MQM=56	CYP2D6,LOC101929829	missense,non_coding_transcript_exon	CYP2D6:NM_000106.5:missense:MODERATE:exon6/9:c.886T>C:p.Cys296Arg,CYP2D6:NM_001025161.2:missense:MODERATE:exon5/8:c.733T>C:p.Cys245Arg,LOC101929829:NR_111920.1:non_coding_transcript_exon:MODIFIER:exon6/9:n.975T>C:		rs16947	0.6408	0.6567	27465/14944/1310	0.6417	-1.2000	T,T,T,T,T	T	B,B	T,T,T	0.04	124030 [CYP2D6 (confirmed) Debrisoquine sensitivity,608902|Codeine sensitivity,608902];	RCV000018391.27 [drug response]; 	CM930187 [CLASS=DFP MUT=REF PHEN="Parkinson disease association with" GENE=CYP2D6]; 	COSM1130423, COSM1130422	670	694					CYP2D6 (inh=n/a pLI=0.00), LOC101929829 (inh=n/a pLI=n/a)
chr22	42524795	42524795	A	G	het	het	wt		QUAL=1101;DP=110,327,270;MQM=55	CYP2D6,LOC101929829	synonymous,non_coding_transcript_exon	CYP2D6:NM_000106.5:synonymous:LOW:exon4/9:c.657T>C:p.Phe219Phe,CYP2D6:NM_001025161.2:synonymous:LOW:exon3/8:c.504T>C:p.Phe168Phe,LOC101929829:NR_111920.1:non_coding_transcript_exon:MODIFIER:exon4/9:n.746T>C:		rs28371713	0.0000	0.3434	35/17/7	0.0098							124030 [CYP2D6 (confirmed) Debrisoquine sensitivity,608902|Codeine sensitivity,608902];			COSM1632628, COSM1632629	2	990					CYP2D6 (inh=n/a pLI=0.00), LOC101929829 (inh=n/a pLI=n/a)
chr22	42524947	42524947	C	T	hom	wt	het	low_MQM;anno_high_impact;pred_pathogenic	QUAL=4903;DP=68,145,303;MQM=48	CYP2D6,LOC101929829	splice_acceptor	CYP2D6:NM_000106.5:splice_acceptor:HIGH:exon3/8:c.506-1G>A:,LOC101929829:NR_111920.1:splice_acceptor:HIGH:exon3/8:n.596-2G>A:,CYP2D6:NM_001025161.2:splice_acceptor:HIGH:exon2/7:c.353-1G>A:		rs3892097	0.0931	0.1708	530/393/37	0.1080	5.1840					23.00	124030 [CYP2D6 (confirmed) Debrisoquine sensitivity,608902|Codeine sensitivity,608902];	RCV000018385.23 [drug response]; RCV000211167.1 [drug response]; RCV000211174.1 [drug response]; RCV000211232.1 [drug response]; RCV000211292.1 [drug response]; RCV000211293.1 [drug response]; RCV000211307.1 [drug response]; RCV000211390.1 [drug response]; RCV000211415.1 [drug response]; RCV000211422.1 [drug response]; RCV000342450.1 [other]; 	CS900241 [CLASS=FP MUT=ALT PHEN="Poor metaboliser" GENE=CYP2D6]; 		57	402	1	[1] auto-classification 16.06.2016  [2] Peter Bauer 05.08.2014			CYP2D6 (inh=n/a pLI=0.00), LOC101929829 (inh=n/a pLI=n/a)
chr22	42525811	42525811	T	C	wt	wt	het	low_QUAL;low_DP	QUAL=11;DP=68,6,18;MQM=54	CYP2D6,LOC101929829	missense,non_coding_transcript_exon	CYP2D6:NM_000106.5:missense:MODERATE:exon2/9:c.281A>G:p.His94Arg,CYP2D6:NM_001025161.2:missense:MODERATE:exon2/8:c.281A>G:p.His94Arg,LOC101929829:NR_111920.1:non_coding_transcript_exon:MODIFIER:exon2/9:n.371A>G:		rs28371704	0.0693	0.1156	828/682/8	0.0095	0.1190	T,T,T,T,T	T	B,B	T,T,T	0.01	124030 [CYP2D6 (confirmed) Debrisoquine sensitivity,608902|Codeine sensitivity,608902];		CM994690 [CLASS=FP MUT=ALT PHEN="Poor metaboliser" GENE=CYP2D6]; 		37	238					CYP2D6 (inh=n/a pLI=0.00), LOC101929829 (inh=n/a pLI=n/a)
chr22	42526694	42526694	G	A	hom	wt	het	pred_pathogenic	QUAL=2290;DP=39,44,109;MQM=59	CYP2D6,LOC101929829	missense,non_coding_transcript_exon	CYP2D6:NM_000106.5:missense:MODERATE:exon1/9:c.100C>T:p.Pro34Ser,CYP2D6:NM_001025161.2:missense:MODERATE:exon1/8:c.100C>T:p.Pro34Ser,LOC101929829:NR_111920.1:non_coding_transcript_exon:MODIFIER:exon1/9:n.190C>T:		rs1065852	0.2380	0.2467	3570/1648/121	0.1838	7.1060	D,D,D,D	T	D,P	D,D,D	24.90	124030 [CYP2D6 (confirmed) Debrisoquine sensitivity,608902|Codeine sensitivity,608902];	RCV000018389.23 [drug response]; 	CM900081 [CLASS=FP MUT=ALT PHEN="Poor metaboliser" GENE=CYP2D6]; 		76	450	1	[1] auto-classification 16.06.2016  [2] old entry - no details available			CYP2D6 (inh=n/a pLI=0.00), LOC101929829 (inh=n/a pLI=n/a)
chr22	43014351	43014351	G	A	wt	het	wt		QUAL=373;DP=43,33,31;MQM=53	CYB5R3	3'UTR	CYB5R3:NM_001171660.1:3'UTR:MODIFIER:exon9/9:c.*1428C>T:,CYB5R3:NM_001129819.2:3'UTR:MODIFIER:exon9/9:c.*1428C>T:,CYB5R3:NM_001171661.1:3'UTR:MODIFIER:exon10/10:c.*1428C>T:,CYB5R3:NM_007326.4:3'UTR:MODIFIER:exon9/9:c.*1428C>T:,CYB5R3:NM_000398.6:3'UTR:MODIFIER:exon9/9:c.*1428C>T:	AluYa5	rs8190475	0.1090	0.0000	0/0/0	0.0825							613213 [CYB5R3 (confirmed) Methemoglobinemia,type I,250800|Methemoglobinemia,type II,250800];				1	30					CYB5R3 (inh=AR pLI=0.21)
chr22	43014714	43014714	A	-	het	wt	wt		QUAL=61;DP=74,23,30;MQM=58	CYB5R3	3'UTR	CYB5R3:NM_001171660.1:3'UTR:MODIFIER:exon9/9:c.*1065delT:,CYB5R3:NM_001129819.2:3'UTR:MODIFIER:exon9/9:c.*1065delT:,CYB5R3:NM_001171661.1:3'UTR:MODIFIER:exon10/10:c.*1065delT:,CYB5R3:NM_007326.4:3'UTR:MODIFIER:exon9/9:c.*1065delT:,CYB5R3:NM_000398.6:3'UTR:MODIFIER:exon9/9:c.*1065delT:	AluSg4	rs36011098;rs796931131	0.0000	0.0000	0/0/0	0.0113							613213 [CYB5R3 (confirmed) Methemoglobinemia,type I,250800|Methemoglobinemia,type II,250800];				3	61					CYB5R3 (inh=AR pLI=0.21)
chr22	43032742	43032742	C	T	het	het	wt		QUAL=5138;DP=151,317,419;MQM=60	CYB5R3	synonymous	CYB5R3:NM_001171660.1:synonymous:LOW:exon2/9:c.231G>A:p.Pro77Pro,CYB5R3:NM_001129819.2:synonymous:LOW:exon2/9:c.63G>A:p.Pro21Pro,CYB5R3:NM_001171661.1:synonymous:LOW:exon3/10:c.63G>A:p.Pro21Pro,CYB5R3:NM_007326.4:synonymous:LOW:exon2/9:c.63G>A:p.Pro21Pro,CYB5R3:NM_000398.6:synonymous:LOW:exon2/9:c.132G>A:p.Pro44Pro		rs5996200	0.0737	0.1179	889/725/59	0.1112							613213 [CYB5R3 (confirmed) Methemoglobinemia,type I,250800|Methemoglobinemia,type II,250800];	RCV000251674.1 [benign]; 			46	386					CYB5R3 (inh=AR pLI=0.21)
chr22	46067693	46067693	C	T	wt	het	wt	low_QUAL;low_DP	QUAL=25;DP=1,6,8;MQM=60	ATXN10	5'UTR_premature_start_codon_gain,5'UTR	ATXN10:NM_013236.3:5'UTR_premature_start_codon_gain:LOW:exon1/12:c.-251C>T:,ATXN10:NM_001167621.1:5'UTR_premature_start_codon_gain:LOW:exon1/11:c.-251C>T:,ATXN10:NM_013236.3:5'UTR:MODIFIER:exon1/12:c.-251C>T:,ATXN10:NM_001167621.1:5'UTR:MODIFIER:exon1/11:c.-251C>T:		rs144270457	0.0180	0.0000	0/0/0	0.0040							611150 [ATXN10 (confirmed) Spinocerebellar ataxia 10,603516];				1	8					ATXN10 (inh=AD pLI=0.75)
chr22	46239934	46239934	C	T	het	het	wt		QUAL=8567;DP=408,242,333;MQM=60	ATXN10	3'UTR	ATXN10:NM_013236.3:3'UTR:MODIFIER:exon12/12:c.*383C>T:,ATXN10:NM_001167621.1:3'UTR:MODIFIER:exon11/11:c.*383C>T:		rs9614791	0.0200	0.0000	0/0/0	0.0074							611150 [ATXN10 (confirmed) Spinocerebellar ataxia 10,603516];				2	30					ATXN10 (inh=AD pLI=0.75)
chr22	46753179	46753179	G	A	wt	wt	het		QUAL=569;DP=86,26,46;MQM=60	TRMU	3'UTR,non_coding_transcript_exon	TRMU:NM_018006.4:3'UTR:MODIFIER:exon11/11:c.*276G>A:,TRMU:NM_001282782.1:3'UTR:MODIFIER:exon10/10:c.*276G>A:,TRMU:NM_001282783.1:3'UTR:MODIFIER:exon10/10:c.*276G>A:,TRMU:NM_001282784.1:3'UTR:MODIFIER:exon9/9:c.*328G>A:,TRMU:NM_001282785.1:3'UTR:MODIFIER:exon10/10:c.*328G>A:,TRMU:NR_104240.1:non_coding_transcript_exon:MODIFIER:exon11/11:n.1851G>A:,TRMU:NR_104241.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.1744G>A:		rs13585	0.1933	0.0000	0/0/0	0.0265							610230 [TRMU (provisional) Deafness,mitochondrial,modifier of,580000|Liver failure,transient infantile,613070];	RCV000271191.1 [benign]; 			11	68					TRMU (inh=AR pLI=0.00)
chr22	50297591	50297591	G	A	het	het	wt		QUAL=5676;DP=205,299,428;MQM=59	ALG12	synonymous	ALG12:NM_024105.3:synonymous:LOW:exon10/10:c.1362C>T:p.Val454Val		rs12163163	0.0012	0.0010	1/0/0	0.0009	0.0060		T			7.30	607144 [ALG12 (confirmed) Congenital disorder of glycosylation,type Ig,607143];	RCV000405148.1 [uncertain significance]; 			0	4					ALG12 (inh=n/a pLI=0.01)
chr22	50298118	50298118	C	T	wt	wt	het		QUAL=4645;DP=320,284,363;MQM=60	ALG12	synonymous	ALG12:NM_024105.3:synonymous:LOW:exon8/10:c.1029G>A:p.Ala343Ala		rs62233155	0.0104	0.0320	115/93/0	0.0310	-0.3450		T			13.05	607144 [ALG12 (confirmed) Congenital disorder of glycosylation,type Ig,607143];	RCV000308206.1 [likely benign]; 		COSM3759280	4	70					ALG12 (inh=n/a pLI=0.01)
chr22	50498030	50498030	-	C	het	het	wt		QUAL=2977;DP=166,173,175;MQM=59	MLC1	3'UTR	MLC1:NM_015166.3:3'UTR:MODIFIER:exon12/12:c.*1981dupG:,MLC1:NM_139202.2:3'UTR:MODIFIER:exon12/12:c.*1981dupG:		rs145385166	0.1322	0.0000	0/0/0	0.1364							605908 [MLC1 (confirmed) Megalencephalic leukoencephalopathy with subcortical cysts,604004];	RCV000379634.1 [likely benign]; 			1	59					MLC1 (inh=AR pLI=0.00)
chr22	50498176	50498176	C	T	het	het	het		QUAL=4789;DP=151,132,138;MQM=60	MLC1	3'UTR	MLC1:NM_015166.3:3'UTR:MODIFIER:exon12/12:c.*1836G>A:,MLC1:NM_139202.2:3'UTR:MODIFIER:exon12/12:c.*1836G>A:		rs11703598	0.0563	0.0000	0/0/0	0.0157							605908 [MLC1 (confirmed) Megalencephalic leukoencephalopathy with subcortical cysts,604004];	RCV000341072.1 [likely benign]; 			5	54					MLC1 (inh=AR pLI=0.00)
chr22	50498389	50498389	C	A	het	het	het		QUAL=4808;DP=156,89,123;MQM=59	MLC1	3'UTR	MLC1:NM_015166.3:3'UTR:MODIFIER:exon12/12:c.*1623G>T:,MLC1:NM_139202.2:3'UTR:MODIFIER:exon12/12:c.*1623G>T:		rs35730155	0.1510	0.0000	0/0/0	0.0247							605908 [MLC1 (confirmed) Megalencephalic leukoencephalopathy with subcortical cysts,604004];	RCV000335142.1 [likely benign]; 			6	55					MLC1 (inh=AR pLI=0.00)
chr22	50499021	50499021	A	C	het	het	wt		QUAL=7318;DP=195,445,565;MQM=59	MLC1	3'UTR	MLC1:NM_015166.3:3'UTR:MODIFIER:exon12/12:c.*991T>G:,MLC1:NM_139202.2:3'UTR:MODIFIER:exon12/12:c.*991T>G:		rs11704648	0.1304	0.0000	0/0/0	0.0239							605908 [MLC1 (confirmed) Megalencephalic leukoencephalopathy with subcortical cysts,604004];	RCV000325587.1 [likely benign]; 			5	56					MLC1 (inh=AR pLI=0.00)
chr22	50499075	50499075	G	A	het	het	wt		QUAL=5237;DP=221,338,457;MQM=59	MLC1	3'UTR	MLC1:NM_015166.3:3'UTR:MODIFIER:exon12/12:c.*937C>T:,MLC1:NM_139202.2:3'UTR:MODIFIER:exon12/12:c.*937C>T:		rs41283491	0.1306	0.0000	0/0/0	0.1392							605908 [MLC1 (confirmed) Megalencephalic leukoencephalopathy with subcortical cysts,604004];	RCV000267260.1 [likely benign]; 			5	56					MLC1 (inh=AR pLI=0.00)
chr22	50499127	50499228	GCAGCGGCCACGTGGCACTCCAAGCTGGGCATGACAGTGCCCGGGACGTGGGCAGCGGCCATGTGGCACTCCAAGCTGGGCATGACAGTGCCCGGGACGTGG	-	wt	het	wt		QUAL=422;DP=221,61,46;MQM=59	MLC1	3'UTR	MLC1:NM_015166.3:3'UTR:MODIFIER:exon12/12:c.*784_*885del:,MLC1:NM_139202.2:3'UTR:MODIFIER:exon12/12:c.*784_*885del:			0.0000	0.0000	0/0/0	0.0009							605908 [MLC1 (confirmed) Megalencephalic leukoencephalopathy with subcortical cysts,604004];				1	2					MLC1 (inh=AR pLI=0.00)
chr22	50499239	50499239	C	T	het	wt	wt		QUAL=741;DP=90,92,168;MQM=54	MLC1	3'UTR	MLC1:NM_015166.3:3'UTR:MODIFIER:exon12/12:c.*773G>A:,MLC1:NM_139202.2:3'UTR:MODIFIER:exon12/12:c.*773G>A:		rs4838880	0.1793	0.0000	0/0/0	0.1414							605908 [MLC1 (confirmed) Megalencephalic leukoencephalopathy with subcortical cysts,604004];	RCV000319349.1 [likely benign]; 			5	58					MLC1 (inh=AR pLI=0.00)
chr22	50499634	50499634	-	GACCCCC	het	het	wt		QUAL=2902;DP=196,183,286;MQM=59	MLC1	3'UTR	MLC1:NM_015166.3:3'UTR:MODIFIER:exon12/12:c.*377_*378insGGGGGTC:,MLC1:NM_139202.2:3'UTR:MODIFIER:exon12/12:c.*377_*378insGGGGGTC:		rs368794754	0.1304	0.0000	0/0/0	0.1256							605908 [MLC1 (confirmed) Megalencephalic leukoencephalopathy with subcortical cysts,604004];	RCV000402457.1 [likely benign]; 			4	55					MLC1 (inh=AR pLI=0.00)
chr22	50499964	50499964	T	C	het	het	het		QUAL=8616;DP=178,266,327;MQM=60	MLC1	3'UTR	MLC1:NM_015166.3:3'UTR:MODIFIER:exon12/12:c.*48A>G:,MLC1:NM_139202.2:3'UTR:MODIFIER:exon12/12:c.*48A>G:		rs137919	0.2829	0.2974	5755/2771/78	0.2915							605908 [MLC1 (confirmed) Megalencephalic leukoencephalopathy with subcortical cysts,604004];	RCV000246160.1 [benign]; RCV000362458.1 [benign]; 			92	344					MLC1 (inh=AR pLI=0.00)
chr22	50499967	50499967	T	C	het	het	het		QUAL=10516;DP=166,258,327;MQM=60	MLC1	3'UTR	MLC1:NM_015166.3:3'UTR:MODIFIER:exon12/12:c.*45A>G:,MLC1:NM_139202.2:3'UTR:MODIFIER:exon12/12:c.*45A>G:		rs2072873	0.1504	0.1460	1336/617/181	0.1419							605908 [MLC1 (confirmed) Megalencephalic leukoencephalopathy with subcortical cysts,604004];	RCV000252122.1 [benign]; RCV000394298.1 [likely benign]; 			17	189					MLC1 (inh=AR pLI=0.00)
chr22	50502469	50502469	-	GCACCCCCACCCCACAGGCCACTCACCTCCCCG	wt	het	wt		QUAL=184;DP=26,46,90;MQM=58	MLC1	disruptive_inframe_insertion	MLC1:NM_015166.3:disruptive_inframe_insertion:MODERATE:exon11/12:c.1052_1053insCGGGGAGGTGAGTGGCCTGTGGGGTGGGGGTGC:p.Ala351_Gly352insGlyGluValSerGlyLeuTrpGlyGlyGlyAla,MLC1:NM_139202.2:disruptive_inframe_insertion:MODERATE:exon11/12:c.1052_1053insCGGGGAGGTGAGTGGCCTGTGGGGTGGGGGTGC:p.Ala351_Gly352insGlyGluValSerGlyLeuTrpGlyGlyGlyAla		rs11568189;rs745656804	0.0000	0.0681	579/233/11	0.0002							605908 [MLC1 (confirmed) Megalencephalic leukoencephalopathy with subcortical cysts,604004];				12	25					MLC1 (inh=AR pLI=0.00)
chr22	50502491	50502491	T	C	het	het	wt	pred_pathogenic	QUAL=1472;DP=72,90,122;MQM=59	MLC1	missense	MLC1:NM_015166.3:missense:MODERATE:exon11/12:c.1031A>G:p.Asn344Ser,MLC1:NM_139202.2:missense:MODERATE:exon11/12:c.1031A>G:p.Asn344Ser		rs11568188	0.1312	0.0907	670/280/17	0.0800	0.6210	T,T,T,T,T,T	T	B,B,B	D,D,D,D,D,D	0.01	605908 [MLC1 (confirmed) Megalencephalic leukoencephalopathy with subcortical cysts,604004];	RCV000020711.2 [benign]; RCV000117622.3 [other]; RCV000321929.1 [likely benign]; 		COSM1416980	49	521					MLC1 (inh=AR pLI=0.00)
chr22	50502526	50502526	A	G	het	het	wt		QUAL=2707;DP=133,132,174;MQM=59	MLC1	synonymous	MLC1:NM_015166.3:synonymous:LOW:exon11/12:c.996T>C:p.Ser332Ser,MLC1:NM_139202.2:synonymous:LOW:exon11/12:c.996T>C:p.Ser332Ser		rs11568187	0.1312	0.1303	1030/499/31	0.1233							605908 [MLC1 (confirmed) Megalencephalic leukoencephalopathy with subcortical cysts,604004];	RCV000117629.3 [other]; RCV000355808.1 [likely benign]; 		COSM3722537	47	510					MLC1 (inh=AR pLI=0.00)
chr22	50502544	50502544	G	A	het	het	wt		QUAL=3549;DP=171,153,180;MQM=59	MLC1	synonymous	MLC1:NM_015166.3:synonymous:LOW:exon11/12:c.978C>T:p.Cys326Cys,MLC1:NM_139202.2:synonymous:LOW:exon11/12:c.978C>T:p.Cys326Cys		rs11568186	0.1312	0.1311	1027/493/29	0.1249							605908 [MLC1 (confirmed) Megalencephalic leukoencephalopathy with subcortical cysts,604004];	RCV000117628.3 [other]; RCV000263376.1 [likely benign]; 			43	499					MLC1 (inh=AR pLI=0.00)
chr22	50502636	50502636	G	A	het	het	wt		QUAL=1725;DP=58,136,191;MQM=59	MLC1	splice_region&intron	MLC1:NM_015166.3:splice_region&intron:LOW:exon10/11:c.895-9C>T:,MLC1:NM_139202.2:splice_region&intron:LOW:exon10/11:c.895-9C>T:		rs11568185	0.1316	0.1386	584/234/18	0.1074							605908 [MLC1 (confirmed) Megalencephalic leukoencephalopathy with subcortical cysts,604004];	RCV000117627.3 [other]; RCV000316264.1 [likely benign]; 			49	621					MLC1 (inh=AR pLI=0.00)
chr22	50515270	50515270	T	C	het	het	wt		QUAL=8752;DP=241,407,443;MQM=59	MLC1	splice_region&synonymous,sequence_feature	MLC1:NM_015166.3:splice_region&synonymous:LOW:exon7/12:c.597A>G:p.Ser199Ser,MLC1:NM_139202.2:splice_region&synonymous:LOW:exon7/12:c.597A>G:p.Ser199Ser,MLC1:NM_139202.2:sequence_feature:LOW:exon7/12:c.597A>G:		rs6010164	0.1306	0.1270	1096/468/66	0.1259							605908 [MLC1 (confirmed) Megalencephalic leukoencephalopathy with subcortical cysts,604004];	RCV000117626.3 [other]; RCV000389139.1 [likely benign]; 		COSM4002217	43	568					MLC1 (inh=AR pLI=0.00)
chr22	50515273	50515273	G	A	het	het	wt		QUAL=8752;DP=241,407,443;MQM=59	MLC1	synonymous	MLC1:NM_015166.3:synonymous:LOW:exon7/12:c.594C>T:p.Tyr198Tyr,MLC1:NM_139202.2:synonymous:LOW:exon7/12:c.594C>T:p.Tyr198Tyr		rs6010165	0.1306	0.1270	1096/468/66	0.1258							605908 [MLC1 (confirmed) Megalencephalic leukoencephalopathy with subcortical cysts,604004];	RCV000117625.3 [other]; RCV000294810.1 [likely benign]; 		COSM4002218	43	568					MLC1 (inh=AR pLI=0.00)
chr22	50515843	50515843	C	A	het	het	wt	pred_pathogenic	QUAL=2287;DP=99,111,153;MQM=60	MLC1	missense	MLC1:NM_015166.3:missense:MODERATE:exon6/12:c.512G>T:p.Cys171Phe,MLC1:NM_139202.2:missense:MODERATE:exon6/12:c.512G>T:p.Cys171Phe		rs6010260	0.1216	0.1242	1025/444/27	0.1226	2.1120	D,D,D,D,D,D,D	T	B,B,B,B	D,D,D,D,D,D,D	24.40	605908 [MLC1 (confirmed) Megalencephalic leukoencephalopathy with subcortical cysts,604004];	RCV000020714.2 [benign]; RCV000117624.3 [other]; RCV000392609.1 [likely benign]; 			42	567					MLC1 (inh=AR pLI=0.00)
chr22	50524250	50524250	-	C	hom	hom	hom		QUAL=12325;DP=133,130,187;MQM=59	MLC1	5'UTR	MLC1:NM_015166.3:5'UTR:MODIFIER:exon1/12:c.-527dupG:		rs137931	0.6719	0.0000	0/0/0	0.6744							605908 [MLC1 (confirmed) Megalencephalic leukoencephalopathy with subcortical cysts,604004];	RCV000333064.1 [benign]; 			121	99					MLC1 (inh=AR pLI=0.00)
chr22	50524285	50524285	C	T	het	het	het		QUAL=3720;DP=162,89,142;MQM=59	MLC1	5'UTR	MLC1:NM_015166.3:5'UTR:MODIFIER:exon1/12:c.-561G>A:		rs4838883	0.1494	0.0000	0/0/0	0.1540							605908 [MLC1 (confirmed) Megalencephalic leukoencephalopathy with subcortical cysts,604004];	RCV000269244.1 [likely benign]; 			6	59					MLC1 (inh=AR pLI=0.00)
chr22	50962208	50962208	T	G	het	wt	het		QUAL=2899;DP=145,86,80;MQM=60	SCO2,NCAPH2	synonymous,3'UTR	SCO2:NM_001169109.1:synonymous:LOW:exon2/2:c.633A>C:p.Ala211Ala,SCO2:NM_001169111.1:synonymous:LOW:exon2/2:c.633A>C:p.Ala211Ala,SCO2:NM_005138.2:synonymous:LOW:exon2/2:c.633A>C:p.Ala211Ala,SCO2:NM_001169110.1:synonymous:LOW:exon2/2:c.633A>C:p.Ala211Ala,NCAPH2:NM_001185011.1:3'UTR:MODIFIER:exon20/20:c.*404T>G:,NCAPH2:NM_152299.3:3'UTR:MODIFIER:exon20/20:c.*404T>G:		rs12148	0.6556	0.6383	24848/12588/2265	0.6312							604272 [SCO2 (confirmed) Cardioencephalomyopathy,fatal infantile,due to cytochrome c oxidase deficiency 1,604377|Myopia 6,608908];	RCV000128016.1 [benign]; RCV000269901.1 [benign]; RCV000300513.1 [benign]; RCV000404245.1 [benign]; 			642	739					SCO2 (inh=AR+AD pLI=0.00), NCAPH2 (inh=n/a pLI=0.65)
chr22	50962259	50962259	G	A	wt	wt	het		QUAL=1304;DP=122,85,107;MQM=60	SCO2,NCAPH2	synonymous,3'UTR	SCO2:NM_001169109.1:synonymous:LOW:exon2/2:c.582C>T:p.Ser194Ser,SCO2:NM_001169111.1:synonymous:LOW:exon2/2:c.582C>T:p.Ser194Ser,SCO2:NM_005138.2:synonymous:LOW:exon2/2:c.582C>T:p.Ser194Ser,SCO2:NM_001169110.1:synonymous:LOW:exon2/2:c.582C>T:p.Ser194Ser,NCAPH2:NM_001185011.1:3'UTR:MODIFIER:exon20/20:c.*455G>A:,NCAPH2:NM_152299.3:3'UTR:MODIFIER:exon20/20:c.*455G>A:		rs131811	0.0258	0.0519	239/206/2	0.0522							604272 [SCO2 (confirmed) Cardioencephalomyopathy,fatal infantile,due to cytochrome c oxidase deficiency 1,604377|Myopia 6,608908];	RCV000128015.1 [benign]; RCV000324968.1 [likely benign]; RCV000336884.1 [likely benign]; RCV000406575.1 [likely benign]; 			3	194					SCO2 (inh=AR+AD pLI=0.00), NCAPH2 (inh=n/a pLI=0.65)
chr22	50962782	50962782	C	G	het	wt	het	pred_pathogenic	QUAL=1851;DP=96,45,75;MQM=60	SCO2,NCAPH2	missense,3'UTR	SCO2:NM_001169109.1:missense:MODERATE:exon2/2:c.59G>C:p.Arg20Pro,SCO2:NM_001169111.1:missense:MODERATE:exon2/2:c.59G>C:p.Arg20Pro,SCO2:NM_005138.2:missense:MODERATE:exon2/2:c.59G>C:p.Arg20Pro,SCO2:NM_001169110.1:missense:MODERATE:exon2/2:c.59G>C:p.Arg20Pro,NCAPH2:NM_001185011.1:3'UTR:MODIFIER:exon20/20:c.*978C>G:,NCAPH2:NM_152299.3:3'UTR:MODIFIER:exon20/20:c.*978C>G:		rs140523	0.6516	0.6393	23621/11904/1889	0.6245	-3.5700	T,T,T,T,T,T	T	B	D,D,D,D,T,T	4.15	604272 [SCO2 (confirmed) Cardioencephalomyopathy,fatal infantile,due to cytochrome c oxidase deficiency 1,604377|Myopia 6,608908];	RCV000128012.1 [benign]; RCV000271220.1 [benign]; RCV000338357.1 [benign]; RCV000374348.1 [benign]; 		COSM445183, COSM1484348	644	732					SCO2 (inh=AR+AD pLI=0.00), NCAPH2 (inh=n/a pLI=0.65)
chr22	50963965	50963965	C	G	het	wt	het		QUAL=1567;DP=53,51,78;MQM=60	SCO2	5'UTR,intron	SCO2:NM_001169111.1:5'UTR:MODIFIER:exon1/2:c.-108G>C:,SCO2:NM_005138.2:5'UTR:MODIFIER:exon1/2:c.-78G>C:,SCO2:NM_001169109.1:intron:MODIFIER:exon1/1:c.-14+710G>C:,SCO2:NM_001169110.1:intron:MODIFIER:exon1/1:c.-14+465G>C:		rs131806	0.5339	0.0000	0/0/0	0.5079							604272 [SCO2 (confirmed) Cardioencephalomyopathy,fatal infantile,due to cytochrome c oxidase deficiency 1,604377|Myopia 6,608908];	RCV000309935.1 [benign]; RCV000364567.1 [benign]; RCV000376198.1 [benign]; 			72	109					SCO2 (inh=AR+AD pLI=0.00)
chr22	50964862	50964862	G	A	hom	wt	wt	low_DP	QUAL=47;DP=4,8,3;MQM=60	TYMP,SCO2	synonymous,5'UTR	TYMP:NM_001257989.1:synonymous:LOW:exon8/10:c.972C>T:p.Ala324Ala,TYMP:NM_001113755.2:synonymous:LOW:exon8/10:c.972C>T:p.Ala324Ala,TYMP:NM_001113756.2:synonymous:LOW:exon7/9:c.972C>T:p.Ala324Ala,TYMP:NM_001257988.1:synonymous:LOW:exon8/10:c.972C>T:p.Ala324Ala,TYMP:NM_001953.4:synonymous:LOW:exon8/10:c.972C>T:p.Ala324Ala,SCO2:NM_001169109.1:5'UTR:MODIFIER:exon1/2:c.-201C>T:		rs131804	0.5329	0.6721	3624/1538/63	0.3645							604272 [SCO2 (confirmed) Cardioencephalomyopathy,fatal infantile,due to cytochrome c oxidase deficiency 1,604377|Myopia 6,608908]:131222 [TYMP (confirmed) Mitochondrial DNA depletion syndrome 1 (MNGIE type),603041];	RCV000118808.5 [other]; RCV000278985.1 [benign]; RCV000279726.1 [benign]; RCV000338776.1 [benign]; 			470	679					TYMP (inh=AR pLI=0.00), SCO2 (inh=AR+AD pLI=0.00)
chr22	51061827	51061827	C	T	wt	wt	het		QUAL=5038;DP=362,324,390;MQM=60	ARSA	3'UTR	ARSA:NM_000487.5:3'UTR:MODIFIER:exon8/8:c.*1746G>A:,ARSA:NM_001085425.2:3'UTR:MODIFIER:exon9/9:c.*1746G>A:,ARSA:NM_001085426.2:3'UTR:MODIFIER:exon9/9:c.*1746G>A:,ARSA:NM_001085427.2:3'UTR:MODIFIER:exon9/9:c.*1746G>A:,ARSA:NM_001085428.2:3'UTR:MODIFIER:exon8/8:c.*1746G>A:	L2	rs73172277	0.0306	0.0000	0/0/0	0.0315							607574 [ARSA (confirmed) Metachromatic leukodystrophy,250100];	RCV000320648.1 [likely benign]; 			0	13					ARSA (inh=AR pLI=0.00)
chr22	51062051	51062051	G	T	het	wt	hom		QUAL=3136;DP=170,52,53;MQM=58	ARSA	3'UTR	ARSA:NM_000487.5:3'UTR:MODIFIER:exon8/8:c.*1522C>A:,ARSA:NM_001085425.2:3'UTR:MODIFIER:exon9/9:c.*1522C>A:,ARSA:NM_001085426.2:3'UTR:MODIFIER:exon9/9:c.*1522C>A:,ARSA:NM_001085427.2:3'UTR:MODIFIER:exon9/9:c.*1522C>A:,ARSA:NM_001085428.2:3'UTR:MODIFIER:exon8/8:c.*1522C>A:	AluSx	rs6009939	0.3321	0.0000	0/0/0	0.2131							607574 [ARSA (confirmed) Metachromatic leukodystrophy,250100];	RCV000336859.1 [benign]; 			4	49					ARSA (inh=AR pLI=0.00)
chr22	51062222	51062222	G	C	het	wt	wt	low_DP	QUAL=119;DP=14,1,53;MQM=51	ARSA	3'UTR	ARSA:NM_000487.5:3'UTR:MODIFIER:exon8/8:c.*1351C>G:,ARSA:NM_001085425.2:3'UTR:MODIFIER:exon9/9:c.*1351C>G:,ARSA:NM_001085426.2:3'UTR:MODIFIER:exon9/9:c.*1351C>G:,ARSA:NM_001085427.2:3'UTR:MODIFIER:exon9/9:c.*1351C>G:,ARSA:NM_001085428.2:3'UTR:MODIFIER:exon8/8:c.*1351C>G:	AluSx	rs131717	0.4762	0.0000	0/0/0	0.4178							607574 [ARSA (confirmed) Metachromatic leukodystrophy,250100];	RCV000270537.1 [benign]; 			46	41					ARSA (inh=AR pLI=0.00)
chr22	51062327	51062358	AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	-	wt	wt	hom	low_DP	QUAL=181;DP=14,1,8;MQM=60	ARSA	3'UTR	ARSA:NM_000487.5:3'UTR:MODIFIER:exon8/8:c.*1215_*1246delTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT:,ARSA:NM_001085425.2:3'UTR:MODIFIER:exon9/9:c.*1215_*1246delTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT:,ARSA:NM_001085426.2:3'UTR:MODIFIER:exon9/9:c.*1215_*1246delTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT:,ARSA:NM_001085427.2:3'UTR:MODIFIER:exon9/9:c.*1215_*1246delTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT:,ARSA:NM_001085428.2:3'UTR:MODIFIER:exon8/8:c.*1215_*1246delTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT:	AluSx:AluJr	rs131716	0.9990	0.0000	0/0/0	0.0456							607574 [ARSA (confirmed) Metachromatic leukodystrophy,250100];				5	1					ARSA (inh=AR pLI=0.00)
chr22	51062654	51062654	T	C	hom	het	hom		QUAL=5566;DP=79,57,88;MQM=55	ARSA	3'UTR	ARSA:NM_000487.5:3'UTR:MODIFIER:exon8/8:c.*919A>G:,ARSA:NM_001085425.2:3'UTR:MODIFIER:exon9/9:c.*919A>G:,ARSA:NM_001085426.2:3'UTR:MODIFIER:exon9/9:c.*919A>G:,ARSA:NM_001085427.2:3'UTR:MODIFIER:exon9/9:c.*919A>G:,ARSA:NM_001085428.2:3'UTR:MODIFIER:exon8/8:c.*919A>G:	AluSp	rs5770805	0.8349	0.0000	0/0/0	0.6361							607574 [ARSA (confirmed) Metachromatic leukodystrophy,250100];	RCV000281321.1 [benign]; 			85	58					ARSA (inh=AR pLI=0.00)
chr22	51062718	51062718	C	T	het	het	wt		QUAL=2003;DP=89,105,144;MQM=50	ARSA	3'UTR	ARSA:NM_000487.5:3'UTR:MODIFIER:exon8/8:c.*855G>A:,ARSA:NM_001085425.2:3'UTR:MODIFIER:exon9/9:c.*855G>A:,ARSA:NM_001085426.2:3'UTR:MODIFIER:exon9/9:c.*855G>A:,ARSA:NM_001085427.2:3'UTR:MODIFIER:exon9/9:c.*855G>A:,ARSA:NM_001085428.2:3'UTR:MODIFIER:exon8/8:c.*855G>A:	AluSp	rs7288050	0.3490	0.0000	0/0/0	0.2005							607574 [ARSA (confirmed) Metachromatic leukodystrophy,250100];	RCV000407866.1 [benign]; 			30	79					ARSA (inh=AR pLI=0.00)
chr22	51062832	51062832	G	A	het	wt	het		QUAL=8738;DP=305,268,386;MQM=59	ARSA	3'UTR	ARSA:NM_000487.5:3'UTR:MODIFIER:exon8/8:c.*741C>T:,ARSA:NM_001085425.2:3'UTR:MODIFIER:exon9/9:c.*741C>T:,ARSA:NM_001085426.2:3'UTR:MODIFIER:exon9/9:c.*741C>T:,ARSA:NM_001085427.2:3'UTR:MODIFIER:exon9/9:c.*741C>T:,ARSA:NM_001085428.2:3'UTR:MODIFIER:exon8/8:c.*741C>T:	L2	rs8142033	0.1773	0.0000	0/0/0	0.1096							607574 [ARSA (confirmed) Metachromatic leukodystrophy,250100];	RCV000407824.1 [likely benign]; 			0	32					ARSA (inh=AR pLI=0.00)
chr22	51062891	51062891	C	G	het	het	wt		QUAL=4813;DP=177,227,336;MQM=60	ARSA	3'UTR	ARSA:NM_000487.5:3'UTR:MODIFIER:exon8/8:c.*682G>C:,ARSA:NM_001085425.2:3'UTR:MODIFIER:exon9/9:c.*682G>C:,ARSA:NM_001085426.2:3'UTR:MODIFIER:exon9/9:c.*682G>C:,ARSA:NM_001085427.2:3'UTR:MODIFIER:exon9/9:c.*682G>C:,ARSA:NM_001085428.2:3'UTR:MODIFIER:exon8/8:c.*682G>C:		rs7288338	0.3510	0.0000	0/0/0	0.3790							607574 [ARSA (confirmed) Metachromatic leukodystrophy,250100];	RCV000346142.1 [benign]; 			32	78					ARSA (inh=AR pLI=0.00)
chr22	51062938	51062938	C	T	het	wt	hom		QUAL=8993;DP=131,198,252;MQM=59	ARSA	3'UTR	ARSA:NM_000487.5:3'UTR:MODIFIER:exon8/8:c.*635G>A:,ARSA:NM_001085425.2:3'UTR:MODIFIER:exon9/9:c.*635G>A:,ARSA:NM_001085426.2:3'UTR:MODIFIER:exon9/9:c.*635G>A:,ARSA:NM_001085427.2:3'UTR:MODIFIER:exon9/9:c.*635G>A:,ARSA:NM_001085428.2:3'UTR:MODIFIER:exon8/8:c.*635G>A:		rs5770953	0.3588	0.0000	0/0/0	0.2397							607574 [ARSA (confirmed) Metachromatic leukodystrophy,250100];	RCV000301794.1 [benign]; 			4	49					ARSA (inh=AR pLI=0.00)
chr22	51063477	51063477	T	C	het	wt	het	anno_pathogenic_clinvar	QUAL=11488;DP=210,582,740;MQM=59	ARSA	3'UTR	ARSA:NM_000487.5:3'UTR:MODIFIER:exon8/8:c.*96A>G:,ARSA:NM_001085425.2:3'UTR:MODIFIER:exon9/9:c.*96A>G:,ARSA:NM_001085426.2:3'UTR:MODIFIER:exon9/9:c.*96A>G:,ARSA:NM_001085427.2:3'UTR:MODIFIER:exon9/9:c.*96A>G:,ARSA:NM_001085428.2:3'UTR:MODIFIER:exon8/8:c.*96A>G:		rs6151429	0.0499	0.0000	0/0/0	0.0092							607574 [ARSA (confirmed) Metachromatic leukodystrophy,250100];	RCV000003190.2 [pathogenic]; RCV000020309.2 [other]; RCV000180167.2 [other]; RCV000246300.1 [benign]; 	CR890137 [CLASS=DP MUT=ALT PHEN="Arylsulphatase A pseudodeficiency association" GENE=ARSA]; 		1	48	2	[2] old entry - no details available			ARSA (inh=AR pLI=0.00)
chr22	51064039	51064039	G	C	het	het	het	pred_pathogenic	QUAL=9971;DP=201,206,290;MQM=59	ARSA	missense	ARSA:NM_000487.5:missense:MODERATE:exon7/8:c.1178C>G:p.Thr393Ser,ARSA:NM_001085425.2:missense:MODERATE:exon8/9:c.1178C>G:p.Thr393Ser,ARSA:NM_001085426.2:missense:MODERATE:exon8/9:c.1178C>G:p.Thr393Ser,ARSA:NM_001085427.2:missense:MODERATE:exon8/9:c.1178C>G:p.Thr393Ser,ARSA:NM_001085428.2:missense:MODERATE:exon7/8:c.920C>G:p.Thr307Ser		rs743616	0.4056	0.4843	14735/9758/824	0.4707	0.1030	T,T,T,T,T,T,T	T	B	D,D,D,D,D,D,D	7.55	607574 [ARSA (confirmed) Metachromatic leukodystrophy,250100];	RCV000020311.2 [other]; RCV000078937.5 [benign]; 	CM910052 [CLASS=DP MUT=ALT PHEN="Phenotype modifier association with" GENE=ARSA]; 		701	1363	2	[2] old entry - no details available			ARSA (inh=AR pLI=0.00)
chr22	51064416	51064416	T	C	het	wt	het	pred_pathogenic	QUAL=6149;DP=166,283,303;MQM=59	ARSA	missense	ARSA:NM_000487.5:missense:MODERATE:exon6/8:c.1055A>G:p.Asn352Ser,ARSA:NM_001085425.2:missense:MODERATE:exon7/9:c.1055A>G:p.Asn352Ser,ARSA:NM_001085426.2:missense:MODERATE:exon7/9:c.1055A>G:p.Asn352Ser,ARSA:NM_001085427.2:missense:MODERATE:exon7/9:c.1055A>G:p.Asn352Ser,ARSA:NM_001085428.2:missense:MODERATE:exon6/8:c.797A>G:p.Asn266Ser		rs2071421	0.2248	0.2166	839/252/316	0.1258	1.7670	T,T,T,T,T,T,T	T	B	D,D,D,D,D,D,D	15.45	607574 [ARSA (confirmed) Metachromatic leukodystrophy,250100];	RCV000003191.2 [benign]; RCV000020310.2 [other]; RCV000078931.5 [other]; RCV000249834.1 [benign]; 	CM890013 [CLASS=DP MUT=ALT PHEN="Arylsulphatase A pseudodeficiency association" GENE=ARSA]; 	COSM4004968	50	654	2	[2] old entry - no details available			ARSA (inh=AR pLI=0.00)
chr22	51066537	51066537	G	A	wt	wt	het		QUAL=849;DP=153,60,76;MQM=60	ARSA	5'UTR	ARSA:NM_000487.5:5'UTR:MODIFIER:exon1/8:c.-330C>T:,ARSA:NM_001085425.2:5'UTR:MODIFIER:exon1/9:c.-225C>T:,ARSA:NM_001085426.2:5'UTR:MODIFIER:exon1/9:c.-177C>T:,ARSA:NM_001085427.2:5'UTR:MODIFIER:exon1/9:c.-132C>T:,ARSA:NM_001085428.2:5'UTR:MODIFIER:exon1/8:c.-198C>T:		rs558023516	0.0012	0.0000	0/0/0	0.0021							607574 [ARSA (confirmed) Metachromatic leukodystrophy,250100];	RCV000339802.1 [uncertain significance]; 			0	6					ARSA (inh=AR pLI=0.00)
chrX	2852951	2852951	G	A	wt	het	hom		QUAL=10824;DP=120,343,223;MQM=57	ARSE	synonymous	ARSE:NM_001282628.1:synonymous:LOW:exon12/12:c.1767C>T:p.Asn589Asn,ARSE:NM_000047.2:synonymous:LOW:exon11/11:c.1692C>T:p.Asn564Asn,ARSE:NM_001282631.1:synonymous:LOW:exon10/10:c.1557C>T:p.Asn519Asn		rs11222	0.5658	0.6260	10823/5901/89	0.5833							300180 [ARSE (confirmed) Chondrodysplasia punctata,X-linked recessive,302950];	RCV000145028.2 [benign]; RCV000224622.1 [benign]; 			998	268					ARSE (inh=XLR pLI=0.12)
chrX	2856155	2856155	C	T	hom	hom	hom	pred_pathogenic	QUAL=5926;DP=75,69,58;MQM=59	ARSE	missense	ARSE:NM_001282628.1:missense:MODERATE:exon10/12:c.1345G>A:p.Gly449Ser,ARSE:NM_000047.2:missense:MODERATE:exon9/11:c.1270G>A:p.Gly424Ser,ARSE:NM_001282631.1:missense:MODERATE:exon8/10:c.1135G>A:p.Gly379Ser		rs35143646	0.5746	0.6593	11756/6675/93	0.6127	6.3350	T,T,T	T	P,B,P	D,D,D	24.20	300180 [ARSE (confirmed) Chondrodysplasia punctata,X-linked recessive,302950];	RCV000145026.2 [benign]; RCV000224630.1 [benign]; 			1064	250					ARSE (inh=XLR pLI=0.12)
chrX	5808426	5808426	A	G	wt	wt	hom		QUAL=1566;DP=151,104,60;MQM=60	NLGN4X	3'UTR	NLGN4X:NM_001282145.1:3'UTR:MODIFIER:exon7/7:c.*2432T>C:,NLGN4X:NM_001282146.1:3'UTR:MODIFIER:exon6/6:c.*2432T>C:,NLGN4X:NM_020742.3:3'UTR:MODIFIER:exon6/6:c.*2432T>C:,NLGN4X:NM_181332.2:3'UTR:MODIFIER:exon6/6:c.*2432T>C:			0.0000	0.0000	0/0/0	0.0000							300427 [NLGN4X (provisional) Autism susceptibility,X-linked 2,300495|Asperger syndrome susceptibility,X-linked 2,300497|Mental retardation,X-linked,300495];				1	0					NLGN4X (inh=n/a pLI=0.93)
chrX	5808861	5808861	G	A	hom	het	hom		QUAL=12150;DP=196,150,113;MQM=60	NLGN4X	3'UTR	NLGN4X:NM_001282145.1:3'UTR:MODIFIER:exon7/7:c.*1997C>T:,NLGN4X:NM_001282146.1:3'UTR:MODIFIER:exon6/6:c.*1997C>T:,NLGN4X:NM_020742.3:3'UTR:MODIFIER:exon6/6:c.*1997C>T:,NLGN4X:NM_181332.2:3'UTR:MODIFIER:exon6/6:c.*1997C>T:		rs1882260	0.7083	0.0000	0/0/0	0.4939							300427 [NLGN4X (provisional) Autism susceptibility,X-linked 2,300495|Asperger syndrome susceptibility,X-linked 2,300497|Mental retardation,X-linked,300495];				234	44					NLGN4X (inh=n/a pLI=0.93)
chrX	5808871	5808871	A	C	wt	wt	hom		QUAL=3347;DP=179,149,105;MQM=60	NLGN4X	3'UTR	NLGN4X:NM_001282145.1:3'UTR:MODIFIER:exon7/7:c.*1987T>G:,NLGN4X:NM_001282146.1:3'UTR:MODIFIER:exon6/6:c.*1987T>G:,NLGN4X:NM_020742.3:3'UTR:MODIFIER:exon6/6:c.*1987T>G:,NLGN4X:NM_181332.2:3'UTR:MODIFIER:exon6/6:c.*1987T>G:		rs16983882	0.1785	0.0000	0/0/0	0.1257							300427 [NLGN4X (provisional) Autism susceptibility,X-linked 2,300495|Asperger syndrome susceptibility,X-linked 2,300497|Mental retardation,X-linked,300495];				47	31					NLGN4X (inh=n/a pLI=0.93)
chrX	5810090	5810090	A	G	hom	het	wt		QUAL=3648;DP=98,58,27;MQM=60	NLGN4X	3'UTR	NLGN4X:NM_001282145.1:3'UTR:MODIFIER:exon7/7:c.*768T>C:,NLGN4X:NM_001282146.1:3'UTR:MODIFIER:exon6/6:c.*768T>C:,NLGN4X:NM_020742.3:3'UTR:MODIFIER:exon6/6:c.*768T>C:,NLGN4X:NM_181332.2:3'UTR:MODIFIER:exon6/6:c.*768T>C:	(TA)n	rs3810685	0.3687	0.0000	0/0/0	0.2203							300427 [NLGN4X (provisional) Autism susceptibility,X-linked 2,300495|Asperger syndrome susceptibility,X-linked 2,300497|Mental retardation,X-linked,300495];				130	63					NLGN4X (inh=n/a pLI=0.93)
chrX	5810574	5810574	C	T	hom	het	wt		QUAL=9755;DP=209,252,176;MQM=60	NLGN4X	3'UTR	NLGN4X:NM_001282145.1:3'UTR:MODIFIER:exon7/7:c.*284G>A:,NLGN4X:NM_001282146.1:3'UTR:MODIFIER:exon6/6:c.*284G>A:,NLGN4X:NM_020742.3:3'UTR:MODIFIER:exon6/6:c.*284G>A:,NLGN4X:NM_181332.2:3'UTR:MODIFIER:exon6/6:c.*284G>A:		rs3810686	0.3674	0.0000	0/0/0	0.0476							300427 [NLGN4X (provisional) Autism susceptibility,X-linked 2,300495|Asperger syndrome susceptibility,X-linked 2,300497|Mental retardation,X-linked,300495];				130	60					NLGN4X (inh=n/a pLI=0.93)
chrX	5810756	5810756	C	T	wt	wt	hom		QUAL=5353;DP=166,258,172;MQM=60	NLGN4X	3'UTR	NLGN4X:NM_001282145.1:3'UTR:MODIFIER:exon7/7:c.*102G>A:,NLGN4X:NM_001282146.1:3'UTR:MODIFIER:exon6/6:c.*102G>A:,NLGN4X:NM_020742.3:3'UTR:MODIFIER:exon6/6:c.*102G>A:,NLGN4X:NM_181332.2:3'UTR:MODIFIER:exon6/6:c.*102G>A:		rs3810688	0.3430	0.0000	0/0/0	0.0443							300427 [NLGN4X (provisional) Autism susceptibility,X-linked 2,300495|Asperger syndrome susceptibility,X-linked 2,300497|Mental retardation,X-linked,300495];				70	51					NLGN4X (inh=n/a pLI=0.93)
chrX	6145855	6145855	C	G	wt	het	wt		QUAL=2081;DP=89,215,150;MQM=60	NLGN4X,LOC105373156	5'UTR,intron,non_coding_transcript_exon	NLGN4X:NM_020742.3:5'UTR:MODIFIER:exon1/6:c.-431G>C:,NLGN4X:NM_001282145.1:intron:MODIFIER:exon1/6:c.-613+727G>C:,NLGN4X:NM_181332.2:intron:MODIFIER:exon1/5:c.-306+727G>C:,LOC105373156:NR_136577.1:non_coding_transcript_exon:MODIFIER:exon1/1:n.1457C>G:		rs2290488	0.2747	0.0000	0/0/0	0.2372							300427 [NLGN4X (provisional) Autism susceptibility,X-linked 2,300495|Asperger syndrome susceptibility,X-linked 2,300497|Mental retardation,X-linked,300495];				107	50					NLGN4X (inh=n/a pLI=0.93), LOC105373156 (inh=n/a pLI=n/a)
chrX	10126431	10126431	C	T	wt	wt	hom	low_DP	QUAL=201;DP=4,5,9;MQM=60	CLCN4	5'UTR	CLCN4:NM_001830.3:5'UTR:MODIFIER:exon2/13:c.-172C>T:,CLCN4:NM_001256944.1:5'UTR:MODIFIER:exon2/11:c.-199C>T:		rs1061287	0.0201	0.0000	0/0/0	0.0383							302910 [CLCN4 (provisional) Mental retardation,X-linked 49/15,300114];				10	7					CLCN4 (inh=n/a pLI=0.99)
chrX	10201780	10201780	A	G	wt	wt	hom		QUAL=2464;DP=145,130,84;MQM=60	CLCN4	3'UTR	CLCN4:NM_001830.3:3'UTR:MODIFIER:exon13/13:c.*156A>G:,CLCN4:NM_001256944.1:3'UTR:MODIFIER:exon11/11:c.*156A>G:		rs5933825	0.6003	0.0000	0/0/0	0.0662							302910 [CLCN4 (provisional) Mental retardation,X-linked 49/15,300114];				114	43					CLCN4 (inh=n/a pLI=0.99)
chrX	10202343	10202343	C	T	wt	wt	hom		QUAL=10989;DP=429,573,344;MQM=60	CLCN4	3'UTR	CLCN4:NM_001830.3:3'UTR:MODIFIER:exon13/13:c.*719C>T:,CLCN4:NM_001256944.1:3'UTR:MODIFIER:exon11/11:c.*719C>T:		rs2269815	0.5897	0.0000	0/0/0	0.0557							302910 [CLCN4 (provisional) Mental retardation,X-linked 49/15,300114];				110	47					CLCN4 (inh=n/a pLI=0.99)
chrX	10203077	10203077	G	T	wt	het	wt		QUAL=3051;DP=181,251,177;MQM=60	CLCN4	3'UTR	CLCN4:NM_001830.3:3'UTR:MODIFIER:exon13/13:c.*1453G>T:,CLCN4:NM_001256944.1:3'UTR:MODIFIER:exon11/11:c.*1453G>T:	MLT1J	rs55847247	0.0013	0.0000	0/0/0	0.0035							302910 [CLCN4 (provisional) Mental retardation,X-linked 49/15,300114];				1	2					CLCN4 (inh=n/a pLI=0.99)
chrX	10203395	10203395	A	C	wt	wt	hom		QUAL=6151;DP=168,300,199;MQM=60	CLCN4	3'UTR	CLCN4:NM_001830.3:3'UTR:MODIFIER:exon13/13:c.*1771A>C:,CLCN4:NM_001256944.1:3'UTR:MODIFIER:exon11/11:c.*1771A>C:	MLT1J	rs2269814	0.4132	0.0000	0/0/0	0.0448							302910 [CLCN4 (provisional) Mental retardation,X-linked 49/15,300114];				90	48					CLCN4 (inh=n/a pLI=0.99)
chrX	10204267	10204267	T	A	wt	wt	hom		QUAL=3684;DP=109,198,123;MQM=60	CLCN4	3'UTR	CLCN4:NM_001830.3:3'UTR:MODIFIER:exon13/13:c.*2643T>A:,CLCN4:NM_001256944.1:3'UTR:MODIFIER:exon11/11:c.*2643T>A:		rs4830442	0.5812	0.0000	0/0/0	0.0604							302910 [CLCN4 (provisional) Mental retardation,X-linked 49/15,300114];				91	57					CLCN4 (inh=n/a pLI=0.99)
chrX	10413758	10413758	A	G	wt	wt	hom		QUAL=3859;DP=214,252,125;MQM=60	MID1	3'UTR	MID1:NM_000381.3:3'UTR:MODIFIER:exon10/10:c.*3650T>C:,MID1:NM_001193277.1:3'UTR:MODIFIER:exon10/10:c.*3650T>C:,MID1:NM_033289.1:3'UTR:MODIFIER:exon10/10:c.*3650T>C:,MID1:NM_001098624.2:3'UTR:MODIFIER:exon10/10:c.*3650T>C:,MID1:NM_033290.3:3'UTR:MODIFIER:exon10/10:c.*3650T>C:		rs183965210	0.0032	0.0000	0/0/0	0.0044							300552 [MID1 (confirmed) Opitz GBBB syndrome,type I,300000];				2	3					MID1 (inh=XLR pLI=0.50)
chrX	10588431	10588431	C	A	hom	het	wt		QUAL=13531;DP=281,441,236;MQM=59	MID1	5'UTR,intron	MID1:NM_000381.3:5'UTR:MODIFIER:exon1/10:c.-158G>T:,MID1:NM_033289.1:5'UTR:MODIFIER:exon1/10:c.-158G>T:,MID1:NM_001098624.2:intron:MODIFIER:exon1/9:c.-56-52788G>T:,MID1:NM_033290.3:intron:MODIFIER:exon1/9:c.-56-52788G>T:		rs147326498	0.0037	0.0000	0/0/0	0.0095							300552 [MID1 (confirmed) Opitz GBBB syndrome,type I,300000];				6	1					MID1 (inh=XLR pLI=0.50)
chrX	12725042	12725042	C	T	hom	wt	wt	low_QUAL;low_DP	QUAL=20;DP=11,16,13;MQM=57	FRMPD4	splice_region&intron	FRMPD4:NM_014728.3:splice_region&intron:LOW:exon12/16:c.1287+8C>T:	(T)n	rs201309783	0.0000	0.1156	0/0/0	0.0529							300838 [FRMPD4 (provisional) Mental retardation,X-linked 104,300983];				2	236					FRMPD4 (inh=n/a pLI=1.00)
chrX	12739294	12739294	A	G	hom	het	wt		QUAL=8278;DP=167,284,188;MQM=59	FRMPD4	3'UTR	FRMPD4:NM_014728.3:3'UTR:MODIFIER:exon17/17:c.*642A>G:		rs3827468	0.2662	0.0000	0/0/0	0.0338							300838 [FRMPD4 (provisional) Mental retardation,X-linked 104,300983];				255	203					FRMPD4 (inh=n/a pLI=1.00)
chrX	12739359	12739359	G	C	hom	het	wt		QUAL=7871;DP=146,314,184;MQM=59	FRMPD4	3'UTR	FRMPD4:NM_014728.3:3'UTR:MODIFIER:exon17/17:c.*707G>C:		rs5979716	0.0885	0.0000	0/0/0	0.0057							300838 [FRMPD4 (provisional) Mental retardation,X-linked 104,300983];				29	23					FRMPD4 (inh=n/a pLI=1.00)
chrX	12740371	12740371	A	G	hom	hom	wt		QUAL=6742;DP=118,93,55;MQM=60	FRMPD4	3'UTR	FRMPD4:NM_014728.3:3'UTR:MODIFIER:exon17/17:c.*1719A>G:	GA-rich	rs5978572	0.5089	0.0000	0/0/0	0.0455							300838 [FRMPD4 (provisional) Mental retardation,X-linked 104,300983];				99	51					FRMPD4 (inh=n/a pLI=1.00)
chrX	12741502	12741502	T	G	hom	hom	wt		QUAL=13505;DP=175,249,184;MQM=59	FRMPD4	3'UTR	FRMPD4:NM_014728.3:3'UTR:MODIFIER:exon17/17:c.*2850T>G:		rs5979717	0.6310	0.0000	0/0/0	0.0701							300838 [FRMPD4 (provisional) Mental retardation,X-linked 104,300983];				97	33					FRMPD4 (inh=n/a pLI=1.00)
chrX	13752895	13752895	G	T	hom	het	wt		QUAL=3278;DP=93,82,57;MQM=59	OFD1	5'UTR	OFD1:NM_003611.2:5'UTR:MODIFIER:exon1/23:c.-296G>T:,OFD1:NM_001330209.1:5'UTR:MODIFIER:exon1/22:c.-296G>T:,OFD1:NM_001330210.1:5'UTR:MODIFIER:exon1/24:c.-841G>T:		rs2285635	0.3767	0.0000	0/0/0	0.0370							300170 [OFD1 (confirmed) Orofaciodigital syndrome I,311200|Simpson-Golabi-Behmel syndrome,type 2,300209|Joubert syndrome 10,300804|Retinitis pigmentosa 23,300424];	RCV000034056.2 [benign]; 			63	42					OFD1 (inh=XLR+XLD pLI=0.98)
chrX	14868806	14868806	A	G	hom	het	wt	low_DP	QUAL=75;DP=3,2,1;MQM=60	FANCB	splice_region&intron	FANCB:NM_001018113.2:splice_region&intron:LOW:exon6/9:c.1327-10T>C:,FANCB:NM_001324162.1:splice_region&intron:LOW:exon6/9:c.1327-10T>C:,FANCB:NM_152633.3:splice_region&intron:LOW:exon5/8:c.1327-10T>C:		rs2905223	0.4336	0.5638	6784/4686/666	0.4555							300515 [FANCB (confirmed) Fanconi anemia,complementation group B,300514];	RCV000079364.5 [benign]; RCV000348663.1 [benign]; RCV000394031.1 [benign]; 			816	391					FANCB (inh=XLR pLI=0.99)
chrX	14877404	14877404	C	T	wt	wt	hom	pred_pathogenic	QUAL=1680;DP=93,107,55;MQM=60	FANCB	missense	FANCB:NM_001018113.2:missense:MODERATE:exon4/10:c.1004G>A:p.Gly335Glu,FANCB:NM_001324162.1:missense:MODERATE:exon4/10:c.1004G>A:p.Gly335Glu,FANCB:NM_152633.3:missense:MODERATE:exon3/9:c.1004G>A:p.Gly335Glu		rs41309679	0.0366	0.0640	136/108/1	0.0614	4.2310	D,D,D	T	D		24.70	300515 [FANCB (confirmed) Fanconi anemia,complementation group B,300514];	RCV000241904.1 [benign]; RCV000301775.1 [benign]; RCV000365780.1 [benign]; 			117	120					FANCB (inh=XLR pLI=0.99)
chrX	14887147	14887147	C	G	hom	het	wt		QUAL=8719;DP=175,236,164;MQM=60	FANCB	5'UTR,intron,non_coding_transcript_exon	FANCB:NM_001018113.2:5'UTR:MODIFIER:exon2/10:c.-173G>C:,FANCB:NM_001324162.1:5'UTR:MODIFIER:exon2/10:c.-173G>C:,FANCB:NM_152633.3:intron:MODIFIER:exon1/8:c.-70-3445G>C:,FANCB:NR_136707.1:non_coding_transcript_exon:MODIFIER:exon2/3:n.103G>C:		rs2188383	0.5256	0.0000	0/0/0	0.3993							300515 [FANCB (confirmed) Fanconi anemia,complementation group B,300514];	RCV000268796.1 [benign]; RCV000364217.1 [benign]; 			172	48					FANCB (inh=XLR pLI=0.99)
chrX	15337614	15337614	T	C	hom	het	wt		QUAL=2299;DP=63,40,32;MQM=60	PIGA	3'UTR,non_coding_transcript_exon	PIGA:NM_002641.3:3'UTR:MODIFIER:exon6/6:c.*2014A>G:,PIGA:NM_020473.3:3'UTR:MODIFIER:exon5/5:c.*2014A>G:,PIGA:NR_033835.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.3211A>G:,PIGA:NR_033836.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.2927A>G:		rs3434	0.3608	0.0000	0/0/0	0.2642							311770 [PIGA (provisional) Paroxysmal nocturnal hemoglobinuria,somatic,300818|Multiple congenital anomalies-hypotonia-seizures syndrome 2,300868];				111	49					PIGA (inh=XLR pLI=0.92)
chrX	15337849	15337849	-	A	hom	hom	wt		QUAL=5572;DP=92,86,57;MQM=60	PIGA	3'UTR,non_coding_transcript_exon	PIGA:NM_002641.3:3'UTR:MODIFIER:exon6/6:c.*1778dupT:,PIGA:NM_020473.3:3'UTR:MODIFIER:exon5/5:c.*1778dupT:,PIGA:NR_033835.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.2975dupT:,PIGA:NR_033836.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.2691dupT:		rs397950456	0.5783	0.0000	0/0/0	0.3293							311770 [PIGA (provisional) Paroxysmal nocturnal hemoglobinuria,somatic,300818|Multiple congenital anomalies-hypotonia-seizures syndrome 2,300868];				139	51					PIGA (inh=XLR pLI=0.92)
chrX	15337882	15337882	A	T	hom	het	wt		QUAL=5005;DP=124,81,54;MQM=59	PIGA	3'UTR,non_coding_transcript_exon	PIGA:NM_002641.3:3'UTR:MODIFIER:exon6/6:c.*1746T>A:,PIGA:NM_020473.3:3'UTR:MODIFIER:exon5/5:c.*1746T>A:,PIGA:NR_033835.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.2943T>A:,PIGA:NR_033836.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.2659T>A:		rs3087965	0.3793	0.0000	0/0/0	0.0457							311770 [PIGA (provisional) Paroxysmal nocturnal hemoglobinuria,somatic,300818|Multiple congenital anomalies-hypotonia-seizures syndrome 2,300868];				114	46					PIGA (inh=XLR pLI=0.92)
chrX	15338002	15338002	A	G	hom	het	wt		QUAL=4585;DP=111,81,61;MQM=59	PIGA	3'UTR,non_coding_transcript_exon	PIGA:NM_002641.3:3'UTR:MODIFIER:exon6/6:c.*1626T>C:,PIGA:NM_020473.3:3'UTR:MODIFIER:exon5/5:c.*1626T>C:,PIGA:NR_033835.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.2823T>C:,PIGA:NR_033836.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.2539T>C:		rs3661	0.4146	0.0000	0/0/0	0.0470							311770 [PIGA (provisional) Paroxysmal nocturnal hemoglobinuria,somatic,300818|Multiple congenital anomalies-hypotonia-seizures syndrome 2,300868];				115	46					PIGA (inh=XLR pLI=0.92)
chrX	15349998	15349998	G	A	wt	het	wt		QUAL=4440;DP=251,320,209;MQM=60	PIGA	missense,splice_region&non_coding_transcript_exon,intron,non_coding_transcript_exon	PIGA:NM_002641.3:missense:MODERATE:exon2/6:c.55C>T:p.Arg19Trp,PIGA:NR_033836.1:splice_region&non_coding_transcript_exon:LOW:exon2/6:n.171C>T:,PIGA:NM_020473.3:intron:MODIFIER:exon1/4:c.13+3625C>T:,PIGA:NR_033835.1:non_coding_transcript_exon:MODIFIER:exon2/6:n.171C>T:		rs34422225	0.0246	0.0317	45/36/4	0.0293	0.2770	T	T	B,B,B		6.87	311770 [PIGA (provisional) Paroxysmal nocturnal hemoglobinuria,somatic,300818|Multiple congenital anomalies-hypotonia-seizures syndrome 2,300868];			COSM3759421	48	47					PIGA (inh=XLR pLI=0.92)
chrX	15844899	15844899	A	-	hom	hom	wt	low_DP	QUAL=666;DP=48,26,7;MQM=59	AP1S2	3'UTR	AP1S2:NM_001272071.1:3'UTR:MODIFIER:exon6/6:c.*549delT:,AP1S2:NM_003916.4:3'UTR:MODIFIER:exon5/5:c.*549delT:		rs201939651	0.0000	0.0000	0/0/0	0.0126							300629 [AP1S2 (confirmed) Mental retardation,X-linked syndromic 5,304340];				7	90					AP1S2 (inh=n/a pLI=0.79)
chrX	17753436	17753436	A	T	hom	hom	hom		QUAL=18798;DP=182,225,167;MQM=60	NHS	3'UTR	NHS:NM_001291867.1:3'UTR:MODIFIER:exon9/9:c.*2852A>T:,NHS:NM_198270.3:3'UTR:MODIFIER:exon8/8:c.*2852A>T:,NHS:NM_001136024.3:3'UTR:MODIFIER:exon9/9:c.*2852A>T:,NHS:NM_001291868.1:3'UTR:MODIFIER:exon8/8:c.*2852A>T:		rs5909331	1.0000	0.0000	0/0/0	0.1205							300457 [NHS (confirmed) Nance-Horan syndrome,302350|Cataract 40,X-linked,302200];				335	0					NHS (inh=XLD pLI=1.00)
chrX	20170527	20170527	C	T	wt	wt	hom		QUAL=1970;DP=220,129,66;MQM=60	RPS6KA3	3'UTR	RPS6KA3:NM_004586.2:3'UTR:MODIFIER:exon22/22:c.*2989G>A:		rs12010722	0.3219	0.0000	0/0/0	0.0249							300075 [RPS6KA3 (confirmed) Coffin-Lowry syndrome,303600|Mental retardation,X-linked 19,300844];				41	26					RPS6KA3 (inh=n/a pLI=1.00)
chrX	20170908	20170908	T	A	wt	wt	hom		QUAL=4319;DP=195,203,139;MQM=60	RPS6KA3	3'UTR	RPS6KA3:NM_004586.2:3'UTR:MODIFIER:exon22/22:c.*2608A>T:		rs7051161	0.2501	0.0000	0/0/0	0.0205							300075 [RPS6KA3 (confirmed) Coffin-Lowry syndrome,303600|Mental retardation,X-linked 19,300844];				32	24					RPS6KA3 (inh=n/a pLI=1.00)
chrX	20171056	20171056	G	T	wt	wt	hom		QUAL=5538;DP=259,296,179;MQM=60	RPS6KA3	3'UTR	RPS6KA3:NM_004586.2:3'UTR:MODIFIER:exon22/22:c.*2460C>A:		rs7064020	0.3346	0.0000	0/0/0	0.0253							300075 [RPS6KA3 (confirmed) Coffin-Lowry syndrome,303600|Mental retardation,X-linked 19,300844];				41	25					RPS6KA3 (inh=n/a pLI=1.00)
chrX	20204461	20204461	G	T	wt	wt	hom		QUAL=1567;DP=179,128,58;MQM=60	RPS6KA3	synonymous	RPS6KA3:NM_004586.2:synonymous:LOW:exon10/22:c.798C>A:p.Leu266Leu		rs2230488	0.2299	0.1812	1425/452/805	0.1652							300075 [RPS6KA3 (confirmed) Coffin-Lowry syndrome,303600|Mental retardation,X-linked 19,300844];	RCV000081158.8 [other]; RCV000127812.1 [benign]; 		COSM3759447	181	159					RPS6KA3 (inh=n/a pLI=1.00)
chrX	21392713	21392715	GCA	-	hom	het	hom	low_DP	QUAL=3726;DP=4,192,124;MQM=59	CNKSR2	5'UTR	CNKSR2:NM_014927.3:5'UTR:MODIFIER:exon1/22:c.-268_-266delAGC:,CNKSR2:NM_001168648.1:5'UTR:MODIFIER:exon1/21:c.-268_-266delAGC:,CNKSR2:NM_001168649.1:5'UTR:MODIFIER:exon1/20:c.-268_-266delAGC:,CNKSR2:NM_001168647.1:5'UTR:MODIFIER:exon1/21:c.-268_-266delAGC:	(GCA)n	rs3217648	0.0000	0.0000	0/0/0	0.0542											13	8					CNKSR2 (inh=XLR+XLD pLI=1.00)
chrX	21672413	21672413	C	A	het	het	het		QUAL=948;DP=104,27,23;MQM=51	CNKSR2	3'UTR	CNKSR2:NM_014927.3:3'UTR:MODIFIER:exon22/22:c.*1774C>A:,CNKSR2:NM_001168647.1:3'UTR:MODIFIER:exon21/21:c.*1774C>A:	(A)n	rs202179371	0.0000	0.0000	0/0/0	0.0022										COSN200730	2	122					CNKSR2 (inh=XLR+XLD pLI=1.00)
chrX	21861434	21861434	A	G	hom	het	hom		QUAL=11502;DP=96,250,167;MQM=60	MBTPS2	splice_region&synonymous	MBTPS2:NM_015884.3:splice_region&synonymous:LOW:exon2/11:c.222A>G:p.Gln74Gln		rs3213451	0.4577	0.4214	5335/2120/750	0.3857							300294 [MBTPS2 (provisional) IFAP syndrome with or without BRESHECK syndrome,308205|Keratosis follicularis spinulosa decalvans,X-linked,308800|Olmsted syndrome,X-linked,300918];	RCV000081783.4 [benign]; 		COSM3759449, COSM3759448	523	316					MBTPS2 (inh=XLR pLI=0.94)
chrX	21901814	21901814	C	G	wt	het	wt		QUAL=4182;DP=293,335,228;MQM=60	MBTPS2	3'UTR	MBTPS2:NM_015884.3:3'UTR:MODIFIER:exon11/11:c.*1041C>G:		rs56079719	0.0156	0.0000	0/0/0	0.0219							300294 [MBTPS2 (provisional) IFAP syndrome with or without BRESHECK syndrome,308205|Keratosis follicularis spinulosa decalvans,X-linked,308800|Olmsted syndrome,X-linked,300918];				4	11					MBTPS2 (inh=XLR pLI=0.94)
chrX	21901903	21901903	G	A	hom	het	hom		QUAL=13902;DP=162,251,166;MQM=59	MBTPS2	3'UTR	MBTPS2:NM_015884.3:3'UTR:MODIFIER:exon11/11:c.*1130G>A:		rs5951476	0.4281	0.0000	0/0/0	0.0513							300294 [MBTPS2 (provisional) IFAP syndrome with or without BRESHECK syndrome,308205|Keratosis follicularis spinulosa decalvans,X-linked,308800|Olmsted syndrome,X-linked,300918];				115	54					MBTPS2 (inh=XLR pLI=0.94)
chrX	21958768	21958768	-	G	wt	hom	hom	low_DP	QUAL=123;DP=162,3,2;MQM=60	SMS	5'UTR	SMS:NM_004595.4:5'UTR:MODIFIER:exon1/11:c.-174dupG:,SMS:NM_001258423.1:5'UTR:MODIFIER:exon1/9:c.-174dupG:		rs35504508;rs398121977	1.0000	0.0000	0/0/0	0.4089							300105 [SMS (confirmed) Mental retardation,X-linked,Snyder-Robinson type,309583];				16	0					SMS (inh=XLR pLI=0.92)
chrX	22012913	22012913	A	-	wt	het	wt		QUAL=378;DP=37,36,27;MQM=59	SMS	3'UTR	SMS:NM_004595.4:3'UTR:MODIFIER:exon11/11:c.*452delA:,SMS:NM_001258423.1:3'UTR:MODIFIER:exon9/9:c.*452delA:		rs397840302	0.2925	0.0000	0/0/0	0.0708							300105 [SMS (confirmed) Mental retardation,X-linked,Snyder-Robinson type,309583];				59	37					SMS (inh=XLR pLI=0.92)
chrX	23398214	23398214	T	C	wt	het	hom		QUAL=14131;DP=127,394,290;MQM=60	PTCHD1	synonymous	PTCHD1:NM_173495.2:synonymous:LOW:exon2/3:c.858T>C:p.Cys286Cys		rs5926304	0.6355	0.5943	10230/5303/2604	0.5475							300828 [PTCHD1 (provisional) Autism,susceptibility to,X-linked 4,300830];	RCV000082701.7 [other]; 		COSM3812430	900	295					PTCHD1 (inh=XLR pLI=0.95)
chrX	23412685	23412685	T	C	hom	het	hom		QUAL=8760;DP=119,121,103;MQM=59	PTCHD1	3'UTR	PTCHD1:NM_173495.2:3'UTR:MODIFIER:exon3/3:c.*383T>C:		rs5926307	0.5513	0.0000	0/0/0	0.0586							300828 [PTCHD1 (provisional) Autism,susceptibility to,X-linked 4,300830];				95	54					PTCHD1 (inh=XLR pLI=0.95)
chrX	23412936	23412936	T	C	hom	het	hom		QUAL=17721;DP=213,310,201;MQM=60	PTCHD1	3'UTR	PTCHD1:NM_173495.2:3'UTR:MODIFIER:exon3/3:c.*634T>C:		rs1317583	0.6302	0.0000	0/0/0	0.0623							300828 [PTCHD1 (provisional) Autism,susceptibility to,X-linked 4,300830];				97	54					PTCHD1 (inh=XLR pLI=0.95)
chrX	24004216	24004216	-	T	wt	het	wt		QUAL=409;DP=147,48,30;MQM=60	KLHL15	3'UTR	KLHL15:NM_030624.2:3'UTR:MODIFIER:exon4/4:c.*1821dupA:		rs202211933	0.0395	0.0000	0/0/0	0.0703							300980 [KLHL15 (confirmed) Mental retardation,X-linked 103,300982];				37	33					KLHL15 (inh=n/a pLI=0.95)
chrX	24073761	24073761	C	T	hom	hom	hom		QUAL=14974;DP=181,207,126;MQM=59	EIF2S3	synonymous	EIF2S3:NM_001415.3:synonymous:LOW:exon2/12:c.99C>T:p.His33His		rs36018672	0.3632	0.5496	9349/6732/120	0.5130	0.0700					17.12	300161 [EIF2S3 (provisional) Mental retardation,X-linked,syndromic,Borck type,300987];	RCV000116975.2 [likely benign]; 		COSM3759453, COSM3759454	673	229					EIF2S3 (inh=n/a pLI=0.92)
chrX	24095043	24095043	C	T	hom	hom	hom		QUAL=4759;DP=112,56,36;MQM=57	EIF2S3	3'UTR	EIF2S3:NM_001415.3:3'UTR:MODIFIER:exon12/12:c.*141C>T:	(T)n	rs5949273	0.3650	0.0000	0/0/0	0.0953							300161 [EIF2S3 (provisional) Mental retardation,X-linked,syndromic,Borck type,300987];				130	113					EIF2S3 (inh=n/a pLI=0.92)
chrX	25022104	25022104	T	-	hom	hom	wt		QUAL=405;DP=45,72,51;MQM=59	ARX	3'UTR	ARX:NM_139058.2:3'UTR:MODIFIER:exon5/5:c.*683delA:	(T)n	rs67950419	0.4731	0.0000	0/0/0	0.2470							300382 [ARX (confirmed) Epileptic encephalopathy,early infantile,1,308350|Lissencephaly,X-linked 2,300215|Mental retardation,X-linked 29 and others,300419|Proud syndrome,300004|Partington syndrome,309510|Hydranencephaly with abnormal genitalia,300215];				6	107					ARX (inh=XLR pLI=0.75)
chrX	25022751	25022751	G	A	wt	het	wt		QUAL=3794;DP=21,281,181;MQM=60	ARX	3'UTR	ARX:NM_139058.2:3'UTR:MODIFIER:exon5/5:c.*36C>T:			0.0000	0.0000	0/0/0	0.0001							300382 [ARX (confirmed) Epileptic encephalopathy,early infantile,1,308350|Lissencephaly,X-linked 2,300215|Mental retardation,X-linked 29 and others,300419|Proud syndrome,300004|Partington syndrome,309510|Hydranencephaly with abnormal genitalia,300215];				0	1					ARX (inh=XLR pLI=0.75)
chrX	28605877	28605877	T	-	wt	het	wt		QUAL=2479;DP=122,206,133;MQM=60	IL1RAPL1	5'UTR	IL1RAPL1:NM_014271.3:5'UTR:MODIFIER:exon1/11:c.-302delT:		rs796538341	0.6135	0.0000	0/0/0	0.2920							300206 [IL1RAPL1 (confirmed) Mental retardation,X-linked 21/34,300143];	RCV000267990.1 [benign]; 			102	99					IL1RAPL1 (inh=XLR pLI=1.00)
chrX	28807442	28807442	G	A	hom	hom	hom		QUAL=7681;DP=86,85,67;MQM=60	IL1RAPL1	5'UTR	IL1RAPL1:NM_014271.3:5'UTR:MODIFIER:exon2/11:c.-19G>A:		rs6526806	0.7351	0.6013	10243/3559/2751	0.5379							300206 [IL1RAPL1 (confirmed) Mental retardation,X-linked 21/34,300143];	RCV000289385.1 [benign]; RCV000382997.1 [benign]; 			590	185					IL1RAPL1 (inh=XLR pLI=1.00)
chrX	30686141	30686141	G	A	hom	het	wt		QUAL=5724;DP=131,113,94;MQM=57	GK	synonymous	GK:NM_001205019.1:synonymous:LOW:exon3/21:c.165G>A:p.Gln55Gln,GK:NM_000167.5:synonymous:LOW:exon3/19:c.165G>A:p.Gln55Gln,GK:NM_001128127.2:synonymous:LOW:exon3/20:c.165G>A:p.Gln55Gln,GK:NM_203391.3:synonymous:LOW:exon3/20:c.165G>A:p.Gln55Gln		rs34795481	0.0313	0.0524	91/78/1	0.0502							300474 [GK (confirmed) Glycerol kinase deficiency,307030];				72	70					GK (inh=XLR+XLD pLI=0.90)
chrX	30747060	30747060	T	-	wt	wt	hom	low_MQM	QUAL=721;DP=61,55,38;MQM=35	GK	3'UTR	GK:NM_001205019.1:3'UTR:MODIFIER:exon21/21:c.*214delT:,GK:NM_000167.5:3'UTR:MODIFIER:exon19/19:c.*214delT:,GK:NM_001128127.2:3'UTR:MODIFIER:exon20/20:c.*214delT:,GK:NM_203391.3:3'UTR:MODIFIER:exon20/20:c.*214delT:		rs34867477	0.3552	0.0000	0/0/0	0.0715							300474 [GK (confirmed) Glycerol kinase deficiency,307030];				3	94					GK (inh=XLR+XLD pLI=0.90)
chrX	30747199	30747199	C	T	hom	het	wt	low_MQM	QUAL=5585;DP=148,161,107;MQM=37	GK	3'UTR	GK:NM_001205019.1:3'UTR:MODIFIER:exon21/21:c.*340C>T:,GK:NM_000167.5:3'UTR:MODIFIER:exon19/19:c.*340C>T:,GK:NM_001128127.2:3'UTR:MODIFIER:exon20/20:c.*340C>T:,GK:NM_203391.3:3'UTR:MODIFIER:exon20/20:c.*340C>T:		rs3931219	0.0318	0.0000	0/0/0	0.0201							300474 [GK (confirmed) Glycerol kinase deficiency,307030];				18	14					GK (inh=XLR+XLD pLI=0.90)
chrX	30748284	30748284	T	C	wt	het	hom		QUAL=1505;DP=100,54,27;MQM=59	GK	3'UTR	GK:NM_001205019.1:3'UTR:MODIFIER:exon21/21:c.*1425T>C:,GK:NM_000167.5:3'UTR:MODIFIER:exon19/19:c.*1425T>C:,GK:NM_001128127.2:3'UTR:MODIFIER:exon20/20:c.*1425T>C:,GK:NM_203391.3:3'UTR:MODIFIER:exon20/20:c.*1425T>C:		rs5926945	0.7168	0.0000	0/0/0	0.0836							300474 [GK (confirmed) Glycerol kinase deficiency,307030];				210	42					GK (inh=XLR+XLD pLI=0.90)
chrX	30749081	30749081	T	C	hom	hom	hom		QUAL=23152;DP=232,287,187;MQM=60	GK	3'UTR	GK:NM_001205019.1:3'UTR:MODIFIER:exon21/21:c.*2222T>C:,GK:NM_000167.5:3'UTR:MODIFIER:exon19/19:c.*2222T>C:,GK:NM_001128127.2:3'UTR:MODIFIER:exon20/20:c.*2222T>C:,GK:NM_203391.3:3'UTR:MODIFIER:exon20/20:c.*2222T>C:		rs2170611	0.8011	0.0000	0/0/0	0.5399							300474 [GK (confirmed) Glycerol kinase deficiency,307030];				107	21					GK (inh=XLR+XLD pLI=0.90)
chrX	30749142	30749142	T	G	hom	hom	hom		QUAL=21663;DP=175,303,184;MQM=60	GK	3'UTR	GK:NM_001205019.1:3'UTR:MODIFIER:exon21/21:c.*2283T>G:,GK:NM_000167.5:3'UTR:MODIFIER:exon19/19:c.*2283T>G:,GK:NM_001128127.2:3'UTR:MODIFIER:exon20/20:c.*2283T>G:,GK:NM_203391.3:3'UTR:MODIFIER:exon20/20:c.*2283T>G:		rs5927599	0.7581	0.0000	0/0/0	0.5332							300474 [GK (confirmed) Glycerol kinase deficiency,307030];				107	21					GK (inh=XLR+XLD pLI=0.90)
chrX	31138589	31138589	T	C	hom	het	hom		QUAL=9228;DP=153,114,75;MQM=60	DMD	3'UTR	DMD:NM_004006.2:3'UTR:MODIFIER:exon79/79:c.*1447A>G:,DMD:NM_004015.2:3'UTR:MODIFIER:exon18/18:c.*1447A>G:,DMD:NM_004016.2:3'UTR:MODIFIER:exon17/17:c.*1361A>G:,DMD:NM_004017.2:3'UTR:MODIFIER:exon17/17:c.*1447A>G:,DMD:NM_004018.2:3'UTR:MODIFIER:exon16/16:c.*1361A>G:,DMD:NM_004014.2:3'UTR:MODIFIER:exon25/25:c.*1447A>G:,DMD:NM_004013.2:3'UTR:MODIFIER:exon36/36:c.*1447A>G:,DMD:NM_004020.3:3'UTR:MODIFIER:exon32/32:c.*1447A>G:,DMD:NM_004021.2:3'UTR:MODIFIER:exon35/35:c.*1361A>G:,DMD:NM_004022.2:3'UTR:MODIFIER:exon34/34:c.*1361A>G:,DMD:NM_004023.2:3'UTR:MODIFIER:exon31/31:c.*1361A>G:,DMD:NM_004011.3:3'UTR:MODIFIER:exon51/51:c.*1447A>G:,DMD:NM_004012.3:3'UTR:MODIFIER:exon51/51:c.*1447A>G:,DMD:NM_004010.3:3'UTR:MODIFIER:exon79/79:c.*1447A>G:,DMD:NM_004009.3:3'UTR:MODIFIER:exon79/79:c.*1447A>G:,DMD:NM_000109.3:3'UTR:MODIFIER:exon79/79:c.*1447A>G:		rs3361	0.3542	0.0000	0/0/0	0.0317							300377 [DMD (confirmed) Duchenne muscular dystrophy,310200|Becker muscular dystrophy,300376|Cardiomyopathy,dilated,3B,302045];	RCV000287236.1 [likely benign]; 			54	48					DMD (inh=XLR pLI=1.00)
chrX	31138983	31138983	-	ATCA	wt	wt	hom		QUAL=3565;DP=150,234,121;MQM=59	DMD	3'UTR	DMD:NM_004006.2:3'UTR:MODIFIER:exon79/79:c.*1049_*1052dupTGAT:,DMD:NM_004015.2:3'UTR:MODIFIER:exon18/18:c.*1049_*1052dupTGAT:,DMD:NM_004016.2:3'UTR:MODIFIER:exon17/17:c.*963_*966dupTGAT:,DMD:NM_004017.2:3'UTR:MODIFIER:exon17/17:c.*1049_*1052dupTGAT:,DMD:NM_004018.2:3'UTR:MODIFIER:exon16/16:c.*963_*966dupTGAT:,DMD:NM_004014.2:3'UTR:MODIFIER:exon25/25:c.*1049_*1052dupTGAT:,DMD:NM_004013.2:3'UTR:MODIFIER:exon36/36:c.*1049_*1052dupTGAT:,DMD:NM_004020.3:3'UTR:MODIFIER:exon32/32:c.*1049_*1052dupTGAT:,DMD:NM_004021.2:3'UTR:MODIFIER:exon35/35:c.*963_*966dupTGAT:,DMD:NM_004022.2:3'UTR:MODIFIER:exon34/34:c.*963_*966dupTGAT:,DMD:NM_004023.2:3'UTR:MODIFIER:exon31/31:c.*963_*966dupTGAT:,DMD:NM_004011.3:3'UTR:MODIFIER:exon51/51:c.*1049_*1052dupTGAT:,DMD:NM_004012.3:3'UTR:MODIFIER:exon51/51:c.*1049_*1052dupTGAT:,DMD:NM_004010.3:3'UTR:MODIFIER:exon79/79:c.*1049_*1052dupTGAT:,DMD:NM_004009.3:3'UTR:MODIFIER:exon79/79:c.*1049_*1052dupTGAT:,DMD:NM_000109.3:3'UTR:MODIFIER:exon79/79:c.*1049_*1052dupTGAT:		rs111646375;rs397977802;rs59846267;rs71860126	0.0000	0.0000	0/0/0	0.0709							300377 [DMD (confirmed) Duchenne muscular dystrophy,310200|Becker muscular dystrophy,300376|Cardiomyopathy,dilated,3B,302045];				17	53					DMD (inh=XLR pLI=1.00)
chrX	31139555	31139555	-	TGTA	wt	wt	hom		QUAL=1027;DP=98,74,47;MQM=60	DMD	3'UTR	DMD:NM_004006.2:3'UTR:MODIFIER:exon79/79:c.*477_*480dupTACA:,DMD:NM_004015.2:3'UTR:MODIFIER:exon18/18:c.*477_*480dupTACA:,DMD:NM_004016.2:3'UTR:MODIFIER:exon17/17:c.*391_*394dupTACA:,DMD:NM_004017.2:3'UTR:MODIFIER:exon17/17:c.*477_*480dupTACA:,DMD:NM_004018.2:3'UTR:MODIFIER:exon16/16:c.*391_*394dupTACA:,DMD:NM_004014.2:3'UTR:MODIFIER:exon25/25:c.*477_*480dupTACA:,DMD:NM_004013.2:3'UTR:MODIFIER:exon36/36:c.*477_*480dupTACA:,DMD:NM_004020.3:3'UTR:MODIFIER:exon32/32:c.*477_*480dupTACA:,DMD:NM_004021.2:3'UTR:MODIFIER:exon35/35:c.*391_*394dupTACA:,DMD:NM_004022.2:3'UTR:MODIFIER:exon34/34:c.*391_*394dupTACA:,DMD:NM_004023.2:3'UTR:MODIFIER:exon31/31:c.*391_*394dupTACA:,DMD:NM_004011.3:3'UTR:MODIFIER:exon51/51:c.*477_*480dupTACA:,DMD:NM_004012.3:3'UTR:MODIFIER:exon51/51:c.*477_*480dupTACA:,DMD:NM_004010.3:3'UTR:MODIFIER:exon79/79:c.*477_*480dupTACA:,DMD:NM_004009.3:3'UTR:MODIFIER:exon79/79:c.*477_*480dupTACA:,DMD:NM_000109.3:3'UTR:MODIFIER:exon79/79:c.*477_*480dupTACA:	(TG)n	rs3833413;rs763785200	0.0000	0.0000	0/0/0	0.0711							300377 [DMD (confirmed) Duchenne muscular dystrophy,310200|Becker muscular dystrophy,300376|Cardiomyopathy,dilated,3B,302045];				25	44					DMD (inh=XLR pLI=1.00)
chrX	31196550	31196550	T	-	wt	wt	hom		QUAL=2244;DP=193,138,115;MQM=59	DMD	sequence_feature,3'UTR,intron	DMD:NM_004017.2:sequence_feature:MODERATE::c.1019+236delA:,DMD:NM_004018.2:sequence_feature:MODERATE::c.1019+236delA:,DMD:NM_004019.2:3'UTR:MODIFIER:exon9/9:c.*232delA:,DMD:NM_004006.2:intron:MODIFIER:exon70/78:c.10223+236delA:,DMD:NM_004015.2:intron:MODIFIER:exon9/17:c.1019+236delA:,DMD:NM_004016.2:intron:MODIFIER:exon9/16:c.1019+236delA:,DMD:NM_004017.2:intron:MODIFIER:exon9/16:c.1019+236delA:,DMD:NM_004018.2:intron:MODIFIER:exon9/15:c.1019+236delA:,DMD:NM_004014.2:intron:MODIFIER:exon16/24:c.2036+236delA:,DMD:NM_004013.2:intron:MODIFIER:exon27/35:c.2843+236delA:,DMD:NM_004020.3:intron:MODIFIER:exon27/31:c.2843+236delA:,DMD:NM_004021.2:intron:MODIFIER:exon27/34:c.2843+236delA:,DMD:NM_004022.2:intron:MODIFIER:exon27/33:c.2843+236delA:,DMD:NM_004023.2:intron:MODIFIER:exon27/30:c.2843+236delA:,DMD:NM_004011.3:intron:MODIFIER:exon42/50:c.6200+236delA:,DMD:NM_004012.3:intron:MODIFIER:exon42/50:c.6191+236delA:,DMD:NM_004010.3:intron:MODIFIER:exon70/78:c.9854+236delA:,DMD:NM_004009.3:intron:MODIFIER:exon70/78:c.10211+236delA:,DMD:NM_000109.3:intron:MODIFIER:exon70/78:c.10199+236delA:		rs11333372	0.4111	0.0000	0/0/0	0.1859							300377 [DMD (confirmed) Duchenne muscular dystrophy,310200|Becker muscular dystrophy,300376|Cardiomyopathy,dilated,3B,302045];				7	139					DMD (inh=XLR pLI=1.00)
chrX	31496350	31496350	C	T	hom	hom	hom		QUAL=9207;DP=116,96,77;MQM=60	DMD	missense	DMD:NM_004006.2:missense:MODERATE:exon59/79:c.8810G>A:p.Arg2937Gln,DMD:NM_004014.2:missense:MODERATE:exon5/25:c.623G>A:p.Arg208Gln,DMD:NM_004013.2:missense:MODERATE:exon16/36:c.1430G>A:p.Arg477Gln,DMD:NM_004020.3:missense:MODERATE:exon16/32:c.1430G>A:p.Arg477Gln,DMD:NM_004021.2:missense:MODERATE:exon16/35:c.1430G>A:p.Arg477Gln,DMD:NM_004022.2:missense:MODERATE:exon16/34:c.1430G>A:p.Arg477Gln,DMD:NM_004023.2:missense:MODERATE:exon16/31:c.1430G>A:p.Arg477Gln,DMD:NM_004011.3:missense:MODERATE:exon31/51:c.4787G>A:p.Arg1596Gln,DMD:NM_004012.3:missense:MODERATE:exon31/51:c.4778G>A:p.Arg1593Gln,DMD:NM_004010.3:missense:MODERATE:exon59/79:c.8441G>A:p.Arg2814Gln,DMD:NM_004009.3:missense:MODERATE:exon59/79:c.8798G>A:p.Arg2933Gln,DMD:NM_000109.3:missense:MODERATE:exon59/79:c.8786G>A:p.Arg2929Gln		rs1800280	0.8819	0.9045	22571/13029/3238	0.8399	0.8710	T,T,T,T,T,T,T,T,T,T,T,T,T	T	B,B,B,B,B,B,B,B,B	T,T,T,T,T,T,T,T	17.10	300377 [DMD (confirmed) Duchenne muscular dystrophy,310200|Becker muscular dystrophy,300376|Cardiomyopathy,dilated,3B,302045];	RCV000124712.2 [benign]; RCV000206630.2 [benign]; RCV000152765.5 [benign]; 	CM135605 [CLASS=R MUT=REF PHEN="Muscular dystrophy Duchenne" GENE=DMD]; 		1659	74	2	[2] old entry - no details available			DMD (inh=XLR pLI=1.00)
chrX	31697636	31697636	A	G	hom	het	hom		QUAL=9151;DP=87,172,131;MQM=60	DMD	synonymous	DMD:NM_004006.2:synonymous:LOW:exon53/79:c.7728T>C:p.Asn2576Asn,DMD:NM_004013.2:synonymous:LOW:exon10/36:c.348T>C:p.Asn116Asn,DMD:NM_004020.3:synonymous:LOW:exon10/32:c.348T>C:p.Asn116Asn,DMD:NM_004021.2:synonymous:LOW:exon10/35:c.348T>C:p.Asn116Asn,DMD:NM_004022.2:synonymous:LOW:exon10/34:c.348T>C:p.Asn116Asn,DMD:NM_004023.2:synonymous:LOW:exon10/31:c.348T>C:p.Asn116Asn,DMD:NM_004011.3:synonymous:LOW:exon25/51:c.3705T>C:p.Asn1235Asn,DMD:NM_004012.3:synonymous:LOW:exon25/51:c.3696T>C:p.Asn1232Asn,DMD:NM_004010.3:synonymous:LOW:exon53/79:c.7359T>C:p.Asn2453Asn,DMD:NM_004009.3:synonymous:LOW:exon53/79:c.7716T>C:p.Asn2572Asn,DMD:NM_000109.3:synonymous:LOW:exon53/79:c.7704T>C:p.Asn2568Asn		rs1801188	0.1812	0.1713	915/514/34	0.1636	1.0650					7.02	300377 [DMD (confirmed) Duchenne muscular dystrophy,310200|Becker muscular dystrophy,300376|Cardiomyopathy,dilated,3B,302045];	RCV000080769.8 [benign]; RCV000252250.1 [benign]; RCV000382472.1 [likely benign]; 		COSM3759470, COSM3759467, COSM3759469, COSM3759468, COSM3759471	257	204					DMD (inh=XLR pLI=1.00)
chrX	31893307	31893307	T	G	hom	het	wt	anno_high_impact;pred_pathogenic	QUAL=3434;DP=64,118,68;MQM=60	DMD	splice_donor	DMD:NM_004006.2:splice_donor:HIGH:exon48/78:c.7095+1A>C:,DMD:NM_004013.2:splice_donor:HIGH:exon5/35:c.-286+1A>C:,DMD:NM_004020.3:splice_donor:HIGH:exon5/31:c.-286+1A>C:,DMD:NM_004021.2:splice_donor:HIGH:exon5/34:c.-286+1A>C:,DMD:NM_004022.2:splice_donor:HIGH:exon5/33:c.-286+1A>C:,DMD:NM_004023.2:splice_donor:HIGH:exon5/30:c.-286+1A>C:,DMD:NM_004011.3:splice_donor:HIGH:exon20/50:c.3072+1A>C:,DMD:NM_004012.3:splice_donor:HIGH:exon20/50:c.3063+1A>C:,DMD:NM_004010.3:splice_donor:HIGH:exon48/78:c.6726+1A>C:,DMD:NM_004009.3:splice_donor:HIGH:exon48/78:c.7083+1A>C:,DMD:NM_000109.3:splice_donor:HIGH:exon48/78:c.7071+1A>C:		rs1800275	0.1833	0.2781	1898/640/111	0.2051	2.4550	T,T,T,T,T,T,T,T,.	T,.	D,D,D,D,D,.	T,T,T,.	15.62	300377 [DMD (confirmed) Duchenne muscular dystrophy,310200|Becker muscular dystrophy,300376|Cardiomyopathy,dilated,3B,302045];	RCV000124703.2 [benign]; RCV000204283.1 [benign]; RCV000152810.3 [benign]; 		COSM3759475, COSM3759474, COSM3759473, COSM3759472	256	217	1	[1] auto-classification 16.06.2016  [2] Ute Grasshoff 09.04.2015			DMD (inh=XLR pLI=1.00)
chrX	32380996	32380996	C	T	wt	het	wt	pred_pathogenic	QUAL=5137;DP=216,428,221;MQM=60	DMD	missense	DMD:NM_004006.2:missense:MODERATE:exon37/79:c.5234G>A:p.Arg1745His,DMD:NM_004011.3:missense:MODERATE:exon9/51:c.1211G>A:p.Arg404His,DMD:NM_004012.3:missense:MODERATE:exon9/51:c.1202G>A:p.Arg401His,DMD:NM_004010.3:missense:MODERATE:exon37/79:c.4865G>A:p.Arg1622His,DMD:NM_004009.3:missense:MODERATE:exon37/79:c.5222G>A:p.Arg1741His,DMD:NM_000109.3:missense:MODERATE:exon37/79:c.5210G>A:p.Arg1737His		rs1801187	0.4652	0.5142	7919/3449/33	0.4769	4.0050	D,D,D,D,D,D,D	T	D,D,D,D,D	T,T	32.00	300377 [DMD (confirmed) Duchenne muscular dystrophy,310200|Becker muscular dystrophy,300376|Cardiomyopathy,dilated,3B,302045];	RCV000080647.8 [benign]; RCV000251070.1 [benign]; RCV000365312.1 [likely benign]; 			738	328					DMD (inh=XLR pLI=1.00)
chrX	32503194	32503194	T	C	wt	het	wt		QUAL=2503;DP=131,226,143;MQM=60	DMD	missense	DMD:NM_004006.2:missense:MODERATE:exon21/79:c.2645A>G:p.Asp882Gly,DMD:NM_004010.3:missense:MODERATE:exon21/79:c.2276A>G:p.Asp759Gly,DMD:NM_004009.3:missense:MODERATE:exon21/79:c.2633A>G:p.Asp878Gly,DMD:NM_000109.3:missense:MODERATE:exon21/79:c.2621A>G:p.Asp874Gly		rs228406	0.7483	0.7211	14412/6520/1343	0.6671	0.8990	T,T,T,T,T	T	B,B,B	T,T	8.37	300377 [DMD (confirmed) Duchenne muscular dystrophy,310200|Becker muscular dystrophy,300376|Cardiomyopathy,dilated,3B,302045];	RCV000124736.2 [benign]; RCV000206108.1 [benign]; RCV000152984.3 [benign]; 		COSM4156808, COSM4156807, COSM4156809	1118	297	1	[1] Peter Bauer 16.12.2014			DMD (inh=XLR pLI=1.00)
chrX	37670729	37670729	T	G	wt	wt	hom		QUAL=4415;DP=204,257,140;MQM=60	CYBB	3'UTR	CYBB:NM_000397.3:3'UTR:MODIFIER:exon13/13:c.*559T>G:		rs5964151	0.2040	0.0000	0/0/0	0.0205							300481 [CYBB (confirmed) Chronic granulomatous disease,X-linked,306400|Immunodeficiency 34,mycobacteriosis,X-linked,300645];				43	21					CYBB (inh=XLR pLI=1.00)
chrX	38547308	38547308	C	A	hom	hom	wt		QUAL=17599;DP=220,410,297;MQM=60	TSPAN7	3'UTR	TSPAN7:NM_004615.3:3'UTR:MODIFIER:exon8/8:c.*123C>A:		rs15765	0.7115	0.0000	0/0/0	0.0739							300096 [TSPAN7 (confirmed) Mental retardation,X-linked 58,300210];				197	44					TSPAN7 (inh=n/a pLI=0.87)
chrX	38547862	38547862	G	A	hom	hom	wt		QUAL=13506;DP=176,246,168;MQM=60	TSPAN7	3'UTR	TSPAN7:NM_004615.3:3'UTR:MODIFIER:exon8/8:c.*677G>A:		rs10333	0.7229	0.0000	0/0/0	0.4601							300096 [TSPAN7 (confirmed) Mental retardation,X-linked 58,300210];				197	44					TSPAN7 (inh=n/a pLI=0.87)
chrX	38548083	38548083	G	A	hom	hom	wt		QUAL=6009;DP=130,58,48;MQM=60	TSPAN7	3'UTR	TSPAN7:NM_004615.3:3'UTR:MODIFIER:exon8/8:c.*898G>A:		rs3269	0.7200	0.0000	0/0/0	0.4593							300096 [TSPAN7 (confirmed) Mental retardation,X-linked 58,300210];				197	44					TSPAN7 (inh=n/a pLI=0.87)
chrX	39911629	39911629	C	T	hom	het	wt		QUAL=8966;DP=212,199,138;MQM=60	BCOR	synonymous	BCOR:NM_001123385.1:synonymous:LOW:exon15/15:c.5001G>A:p.Ser1667Ser,BCOR:NM_017745.5:synonymous:LOW:exon15/15:c.4899G>A:p.Ser1633Ser,BCOR:NM_001123383.1:synonymous:LOW:exon15/15:c.4899G>A:p.Ser1633Ser,BCOR:NM_001123384.1:synonymous:LOW:exon14/14:c.4845G>A:p.Ser1615Ser		rs375878497	0.0000	0.0001	0/0/0	0.0001	-1.5110		T			7.58	300485 [BCOR (confirmed) Microphthalmia,syndromic 2,300166];				1	1					BCOR (inh=XLD pLI=1.00)
chrX	39932907	39932907	T	C	wt	het	wt		QUAL=3709;DP=131,336,200;MQM=60	BCOR	synonymous	BCOR:NM_001123385.1:synonymous:LOW:exon4/15:c.1692A>G:p.Ala564Ala,BCOR:NM_017745.5:synonymous:LOW:exon4/15:c.1692A>G:p.Ala564Ala,BCOR:NM_001123383.1:synonymous:LOW:exon4/15:c.1692A>G:p.Ala564Ala,BCOR:NM_001123384.1:synonymous:LOW:exon4/14:c.1692A>G:p.Ala564Ala		rs6520618	0.5240	0.2671	4014/188/2157	0.2368							300485 [BCOR (confirmed) Microphthalmia,syndromic 2,300166];	RCV000081811.8 [other]; 			217	169					BCOR (inh=XLD pLI=1.00)
chrX	39933339	39933339	A	G	hom	hom	hom		QUAL=15685;DP=115,237,145;MQM=60	BCOR	synonymous	BCOR:NM_001123385.1:synonymous:LOW:exon4/15:c.1260T>C:p.Asp420Asp,BCOR:NM_017745.5:synonymous:LOW:exon4/15:c.1260T>C:p.Asp420Asp,BCOR:NM_001123383.1:synonymous:LOW:exon4/15:c.1260T>C:p.Asp420Asp,BCOR:NM_001123384.1:synonymous:LOW:exon4/14:c.1260T>C:p.Asp420Asp		rs5917933	0.9030	0.8952	22091/11549/2805	0.8251							300485 [BCOR (confirmed) Microphthalmia,syndromic 2,300166];	RCV000081809.8 [other]; 		COSM4156839, COSM4156840	1468	156					BCOR (inh=XLD pLI=1.00)
chrX	41374941	41374941	-	A	wt	wt	hom		QUAL=3192;DP=115,232,132;MQM=59	CASK	3'UTR	CASK:NM_003688.3:3'UTR:MODIFIER:exon27/27:c.*4731dupT:,CASK:NM_001126054.2:3'UTR:MODIFIER:exon26/26:c.*4731dupT:,CASK:NM_001126055.2:3'UTR:MODIFIER:exon25/25:c.*4731dupT:			0.0000	0.0000	0/0/0	0.0008							300172 [CASK (confirmed) Mental retardation and microcephaly with pontine and cerebellar hypoplasia,300749|FG syndrome 4,300422|Mental retardation,with or without nystagmus,300422];				0	1					CASK (inh=XLD pLI=1.00)
chrX	43571197	43571197	A	C	hom	het	wt		QUAL=7055;DP=143,205,150;MQM=60	MAOA	synonymous,5'UTR	MAOA:NM_000240.3:synonymous:LOW:exon4/15:c.385A>C:p.Arg129Arg,MAOA:NM_001270458.1:5'UTR:MODIFIER:exon5/16:c.-15A>C:		rs1800464	0.1571	0.0785	843/21/816	0.0690							309850 [MAOA (confirmed) Brunner syndrome,300615|Antisocial behavior,300615];	RCV000117593.3 [other]; 			69	84					MAOA (inh=n/a pLI=0.99)
chrX	43591036	43591036	G	T	hom	hom	hom		QUAL=20763;DP=194,291,169;MQM=60	MAOA	synonymous	MAOA:NM_000240.3:synonymous:LOW:exon8/15:c.891G>T:p.Arg297Arg,MAOA:NM_001270458.1:synonymous:LOW:exon9/16:c.492G>T:p.Arg164Arg		rs6323	0.6249	0.6529	12444/7177/2388	0.6045							309850 [MAOA (confirmed) Brunner syndrome,300615|Antisocial behavior,300615];	RCV000078415.8 [other]; 	CM073190 [CLASS=DP MUT=REF PHEN="Bipolar disorder association with" GENE=MAOA]; 	COSM4156846	1160	297					MAOA (inh=n/a pLI=0.99)
chrX	43603391	43603391	T	C	hom	hom	hom		QUAL=27885;DP=320,293,229;MQM=59	MAOA	synonymous	MAOA:NM_000240.3:synonymous:LOW:exon14/15:c.1410T>C:p.Asp470Asp,MAOA:NM_001270458.1:synonymous:LOW:exon15/16:c.1011T>C:p.Asp337Asp		rs1137070	0.5518	0.6260	10989/7170/1286	0.5797							309850 [MAOA (confirmed) Brunner syndrome,300615|Antisocial behavior,300615];	RCV000078414.8 [other]; 			1154	298					MAOA (inh=n/a pLI=0.99)
chrX	43604841	43604841	A	G	hom	hom	hom		QUAL=6805;DP=126,41,34;MQM=60	MAOA	3'UTR	MAOA:NM_000240.3:3'UTR:MODIFIER:exon15/15:c.*1081A>G:,MAOA:NM_001270458.1:3'UTR:MODIFIER:exon16/16:c.*1081A>G:		rs3027407	0.5510	0.0000	0/0/0	0.0766							309850 [MAOA (confirmed) Brunner syndrome,300615|Antisocial behavior,300615];				335	79					MAOA (inh=n/a pLI=0.99)
chrX	43605100	43605100	A	-	hom	het	wt		QUAL=4913;DP=138,61,50;MQM=59	MAOA	3'UTR	MAOA:NM_000240.3:3'UTR:MODIFIER:exon15/15:c.*1341delA:,MAOA:NM_001270458.1:3'UTR:MODIFIER:exon16/16:c.*1341delA:			0.0000	0.0000	0/0/0	0.0000							309850 [MAOA (confirmed) Brunner syndrome,300615|Antisocial behavior,300615];				1	1					MAOA (inh=n/a pLI=0.99)
chrX	43818002	43818002	C	A	hom	het	wt		QUAL=17680;DP=403,388,210;MQM=60	NDP	5'UTR	NDP:NM_000266.3:5'UTR:MODIFIER:exon2/3:c.-111G>T:		rs45501198	0.0132	0.0000	0/0/0	0.0021							300658 [NDP (confirmed) Norrie disease,310600|Exudative vitreoretinopathy 2,X-linked,305390];				9	7					NDP (inh=XLR pLI=0.64)
chrX	44938563	44938563	G	A	hom	het	wt	pred_pathogenic	QUAL=4296;DP=95,139,93;MQM=60	KDM6A	synonymous,non_coding_transcript_exon	KDM6A:NM_001291415.1:synonymous:LOW:exon21/30:c.3267G>A:p.Gln1089Gln,KDM6A:NM_001291416.1:synonymous:LOW:exon20/29:c.3132G>A:p.Gln1044Gln,KDM6A:NM_001291417.1:synonymous:LOW:exon19/28:c.2976G>A:p.Gln992Gln,KDM6A:NM_001291418.1:synonymous:LOW:exon18/27:c.2874G>A:p.Gln958Gln,KDM6A:NM_001291421.1:synonymous:LOW:exon18/27:c.2223G>A:p.Gln741Gln,KDM6A:NM_021140.3:synonymous:LOW:exon20/29:c.3111G>A:p.Gln1037Gln,KDM6A:NR_111960.1:non_coding_transcript_exon:MODIFIER:exon19/28:n.3407G>A:		rs20539	0.2217	0.2384	2158/492/8	0.2140	1.8190		T			4.68	300128 [KDM6A (provisional) Kabuki syndrome 2,300867];	RCV000146125.7 [benign]; 		COSM1179848	305	209					KDM6A (inh=XLD pLI=1.00)
chrX	47061018	47061018	C	G	hom	hom	hom		QUAL=16955;DP=87,279,175;MQM=60	UBA1	splice_region&intron,sequence_feature	UBA1:NM_003334.3:splice_region&intron:LOW:exon8/25:c.811+9C>G:,UBA1:NM_153280.2:splice_region&intron:LOW:exon8/25:c.811+9C>G:,UBA1:NM_003334.3:sequence_feature:LOW::c.811+9C>G:		rs4239964	0.9711	0.9795	26029/14170/3253	0.9158							314370 [UBA1 (confirmed) Spinal muscular atrophy,X-linked 2,infantile,301830];	RCV000317636.1 [benign]; 			1625	25					UBA1 (inh=XLR pLI=1.00)
chrX	47466361	47466361	A	G	hom	hom	hom		QUAL=21026;DP=176,311,180;MQM=60	SYN1	synonymous	SYN1:NM_006950.3:synonymous:LOW:exon3/13:c.510T>C:p.Asn170Asn,SYN1:NM_133499.2:synonymous:LOW:exon3/13:c.510T>C:p.Asn170Asn		rs1142636	0.3687	0.3808	4055/2291/610	0.3447							313440 [SYN1 (confirmed) Epilepsy,X-linked,with variable learning disabilities and behavior disorders,300491];	RCV000082513.7 [other]; 			529	270					SYN1 (inh=XLR+XLD pLI=0.88)
chrX	47483800	47483800	G	A	wt	het	hom		QUAL=4849;DP=39,141,109;MQM=60	CFP	synonymous,sequence_feature	CFP:NM_001145252.1:synonymous:LOW:exon9/9:c.1284C>T:p.Asn428Asn,CFP:NM_002621.2:synonymous:LOW:exon10/10:c.1284C>T:p.Asn428Asn,CFP:NM_002621.2:sequence_feature:LOW:exon10/10:c.1284C>T:		rs1048118	0.2069	0.2287	1639/973/189	0.2128							300383 [CFP (confirmed) Properdin deficiency,X-linked,312060];			COSM3759503	299	233					CFP (inh=XLR pLI=0.94)
chrX	48759204	48759204	C	T	hom	hom	wt		QUAL=9350;DP=56,256,162;MQM=60	PQBP1	splice_region&intron	PQBP1:NM_001032381.1:splice_region&intron:LOW:exon3/6:c.180-3C>T:,PQBP1:NM_001032382.1:splice_region&intron:LOW:exon3/6:c.180-3C>T:,PQBP1:NM_001032383.1:splice_region&intron:LOW:exon3/6:c.180-3C>T:,PQBP1:NM_144495.2:splice_region&intron:LOW:exon3/5:c.180-3C>T:,PQBP1:NM_001167989.1:splice_region&intron:LOW:exon3/6:c.180-3C>T:,PQBP1:NM_001167990.1:splice_region&intron:LOW:exon3/6:c.156-3C>T:,PQBP1:NM_001032384.1:splice_region&intron:LOW:exon3/6:c.180-3C>T:,PQBP1:NM_005710.2:splice_region&intron:LOW:exon2/5:c.180-3C>T:,PQBP1:NM_001167992.1:splice_region&intron:LOW:exon2/5:c.180-3C>T:		rs741932	0.6254	0.6124	10022/5244/980	0.5647							300463 [PQBP1 (confirmed) Renpenning syndrome,309500];	RCV000081326.7 [other]; RCV000407634.1 [benign]; 			937	301					PQBP1 (inh=XLR pLI=0.59)
chrX	49071964	49071964	A	G	wt	het	wt		QUAL=5934;DP=175,517,327;MQM=60	CACNA1F	synonymous	CACNA1F:NM_005183.3:synonymous:LOW:exon28/48:c.3309T>C:p.His1103His,CACNA1F:NM_001256789.2:synonymous:LOW:exon28/48:c.3276T>C:p.His1092His,CACNA1F:NM_001256790.2:synonymous:LOW:exon28/48:c.3114T>C:p.His1038His		rs2075866	0.5521	0.4349	5929/1306/1867	0.3678							300110 [CACNA1F (confirmed) Night blindness,congenital stationary (incomplete),2A,X-linked,300071|Cone-rod dystrophy,X-linked,3,300476|Aland Island eye disease,300600];				387	275					CACNA1F (inh=n/a pLI=0.87)
chrX	49081291	49081291	G	A	wt	het	wt		QUAL=2778;DP=96,281,149;MQM=60	CACNA1F	synonymous	CACNA1F:NM_005183.3:synonymous:LOW:exon14/48:c.1842C>T:p.Gly614Gly,CACNA1F:NM_001256789.2:synonymous:LOW:exon14/48:c.1809C>T:p.Gly603Gly,CACNA1F:NM_001256790.2:synonymous:LOW:exon14/48:c.1647C>T:p.Gly549Gly		rs2235127	0.4405	0.4461	3675/1050/577	0.3147							300110 [CACNA1F (confirmed) Night blindness,congenital stationary (incomplete),2A,X-linked,300071|Cone-rod dystrophy,X-linked,3,300476|Aland Island eye disease,300600];			COSM1468350	357	274					CACNA1F (inh=n/a pLI=0.87)
chrX	49084492	49084492	C	T	wt	het	wt		QUAL=5126;DP=164,442,303;MQM=60	CACNA1F	splice_region&intron,sequence_feature	CACNA1F:NM_005183.3:splice_region&intron:LOW:exon8/47:c.1118+6G>A:,CACNA1F:NM_001256789.2:splice_region&intron:LOW:exon8/47:c.1118+6G>A:,CACNA1F:NM_001256790.2:splice_region&intron:LOW:exon8/47:c.923+6G>A:,CACNA1F:NM_005183.3:sequence_feature:LOW::c.1118+6G>A:,CACNA1F:NM_001256790.2:sequence_feature:LOW::c.923+6G>A:	L2c	rs6609854	0.3568	0.3625	3566/1143/128	0.3009							300110 [CACNA1F (confirmed) Night blindness,congenital stationary (incomplete),2A,X-linked,300071|Cone-rod dystrophy,X-linked,3,300476|Aland Island eye disease,300600];				350	271					CACNA1F (inh=n/a pLI=0.87)
chrX	49646968	49646968	G	A	het	het	wt	low_DP	QUAL=164;DP=27,4,2;MQM=57	USP27X	3'UTR	USP27X:NM_001145073.2:3'UTR:MODIFIER:exon1/1:c.*741G>A:	(A)n	rs199555442	0.0000	0.0000	0/0/0	0.0022							300975 [USP27X (provisional) Mental retardation 105,300984];				0	60					USP27X (inh=n/a pLI=0.59)
chrX	50334695	50334698	TTTC	-	hom	hom	wt	low_DP;low_MQM	QUAL=255;DP=12,1,2;MQM=46	SHROOM4	3'UTR,non_coding_transcript_exon	SHROOM4:NM_020717.3:3'UTR:MODIFIER:exon9/9:c.*4997_*5000delGAAA:,SHROOM4:NR_027121.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5952_5955delGAAA:	(TTTC)n	rs782605261	0.0000	0.1568	37/21/1	0.0127							300579 [SHROOM4 (confirmed) Stocco dos Santos X-linked mental retardation syndrome,300434];				117	60					SHROOM4 (inh=n/a pLI=1.00)
chrX	50334780	50334780	T	C	wt	wt	hom	low_DP	QUAL=76;DP=16,11,5;MQM=60	SHROOM4	3'UTR,non_coding_transcript_exon	SHROOM4:NM_020717.3:3'UTR:MODIFIER:exon9/9:c.*4915A>G:,SHROOM4:NR_027121.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5870A>G:	AluSc8	rs5915276	0.7563	0.8209	794/276/22	0.1446							300579 [SHROOM4 (confirmed) Stocco dos Santos X-linked mental retardation syndrome,300434];				362	83					SHROOM4 (inh=n/a pLI=1.00)
chrX	50335008	50335008	T	C	wt	wt	hom		QUAL=3529;DP=102,168,122;MQM=60	SHROOM4	3'UTR,non_coding_transcript_exon	SHROOM4:NM_020717.3:3'UTR:MODIFIER:exon9/9:c.*4687A>G:,SHROOM4:NR_027121.1:non_coding_transcript_exon:MODIFIER:exon10/10:n.5642A>G:	AluSc8	rs2873098	0.7200	0.7838	836/273/17	0.1430							300579 [SHROOM4 (confirmed) Stocco dos Santos X-linked mental retardation syndrome,300434];				355	80					SHROOM4 (inh=n/a pLI=1.00)
chrX	50336022	50336022	A	T	wt	wt	hom		QUAL=5730;DP=140,303,183;MQM=60	SHROOM4	3'UTR,intron	SHROOM4:NM_020717.3:3'UTR:MODIFIER:exon9/9:c.*3673T>A:,SHROOM4:NR_027121.1:intron:MODIFIER:exon9/9:n.5506-878T>A:		rs5915277	0.6633	0.0000	0/0/0	0.4889							300579 [SHROOM4 (confirmed) Stocco dos Santos X-linked mental retardation syndrome,300434];				216	40					SHROOM4 (inh=n/a pLI=1.00)
chrX	50336529	50336529	-	C	wt	wt	hom	low_DP	QUAL=63;DP=30,32,7;MQM=60	SHROOM4	3'UTR,intron	SHROOM4:NM_020717.3:3'UTR:MODIFIER:exon9/9:c.*3165dupG:,SHROOM4:NR_027121.1:intron:MODIFIER:exon9/9:n.5506-1386dupG:		rs201053201;rs3215652;rs71728121	0.7213	0.0000	0/0/0	0.4930							300579 [SHROOM4 (confirmed) Stocco dos Santos X-linked mental retardation syndrome,300434];				204	50					SHROOM4 (inh=n/a pLI=1.00)
chrX	50337240	50337240	G	A	wt	het	wt		QUAL=3106;DP=161,235,142;MQM=60	SHROOM4	3'UTR,intron	SHROOM4:NM_020717.3:3'UTR:MODIFIER:exon9/9:c.*2455C>T:,SHROOM4:NR_027121.1:intron:MODIFIER:exon9/9:n.5505+1458C>T:		rs112959631	0.0140	0.0000	0/0/0	0.0241							300579 [SHROOM4 (confirmed) Stocco dos Santos X-linked mental retardation syndrome,300434];				6	3					SHROOM4 (inh=n/a pLI=1.00)
chrX	50350674	50350674	T	C	wt	wt	hom		QUAL=1513;DP=52,79,53;MQM=59	SHROOM4	synonymous,non_coding_transcript_exon	SHROOM4:NM_020717.3:synonymous:LOW:exon6/9:c.3468A>G:p.Glu1156Glu,SHROOM4:NR_027121.1:non_coding_transcript_exon:MODIFIER:exon6/10:n.3494A>G:	(CTC)n	rs3747282	0.2999	0.3140	2344/1450/212	0.2839							300579 [SHROOM4 (confirmed) Stocco dos Santos X-linked mental retardation syndrome,300434];	RCV000082027.8 [other]; 		COSM235350	489	283					SHROOM4 (inh=n/a pLI=1.00)
chrX	50350728	50350728	-	TCC	wt	wt	hom		QUAL=1807;DP=25,102,62;MQM=59	SHROOM4	disruptive_inframe_insertion,non_coding_transcript_exon	SHROOM4:NM_020717.3:disruptive_inframe_insertion:MODERATE:exon6/9:c.3411_3413dupGGA:p.Glu1138dup,SHROOM4:NR_027121.1:non_coding_transcript_exon:MODIFIER:exon6/10:n.3437_3439dupGGA:	(CTC)n	rs143151534	0.2564	0.2466	1220/793/65	0.2121							300579 [SHROOM4 (confirmed) Stocco dos Santos X-linked mental retardation syndrome,300434];	RCV000082025.5 [benign]; 		COSM1491057	350	303					SHROOM4 (inh=n/a pLI=1.00)
chrX	50350758	50350758	-	TGCTGCTGCTGT	wt	wt	hom		QUAL=2754;DP=34,151,84;MQM=59	SHROOM4	disruptive_inframe_insertion,non_coding_transcript_exon	SHROOM4:NM_020717.3:disruptive_inframe_insertion:MODERATE:exon6/9:c.3372_3383dupACAGCAGCAGCA:p.Gln1125_Gln1128dup,SHROOM4:NR_027121.1:non_coding_transcript_exon:MODIFIER:exon6/10:n.3398_3409dupACAGCAGCAGCA:	(CTC)n:(CTG)n	rs201922875	0.0000	0.3491	2887/1422/738	0.2645							300579 [SHROOM4 (confirmed) Stocco dos Santos X-linked mental retardation syndrome,300434];	RCV000082024.4 [benign]; 		COSM1468432	432	308					SHROOM4 (inh=n/a pLI=1.00)
chrX	53220836	53220836	G	T	hom	hom	hom		QUAL=18788;DP=173,238,157;MQM=60	KDM5C	3'UTR	KDM5C:NM_004187.3:3'UTR:MODIFIER:exon26/26:c.*1313C>A:,KDM5C:NM_001146702.1:3'UTR:MODIFIER:exon24/24:c.*1090C>A:,KDM5C:NM_001282622.1:3'UTR:MODIFIER:exon26/26:c.*1313C>A:		rs1886889	0.8072	0.0000	0/0/0	0.6428							314690 [KDM5C (confirmed) Mental retardation,X-linked,syndromic,Claes-Jensen type,300534];				319	6					KDM5C (inh=XLR pLI=1.00)
chrX	53220927	53220927	T	C	wt	wt	hom		QUAL=2940;DP=82,168,99;MQM=60	KDM5C	3'UTR	KDM5C:NM_004187.3:3'UTR:MODIFIER:exon26/26:c.*1222A>G:,KDM5C:NM_001146702.1:3'UTR:MODIFIER:exon24/24:c.*999A>G:,KDM5C:NM_001282622.1:3'UTR:MODIFIER:exon26/26:c.*1222A>G:		rs185115468	0.0005	0.0000	0/0/0	0.0011							314690 [KDM5C (confirmed) Mental retardation,X-linked,syndromic,Claes-Jensen type,300534];				3	0					KDM5C (inh=XLR pLI=1.00)
chrX	53221259	53221259	-	G	hom	hom	hom		QUAL=4903;DP=73,71,23;MQM=59	KDM5C	3'UTR	KDM5C:NM_004187.3:3'UTR:MODIFIER:exon26/26:c.*889dupC:,KDM5C:NM_001146702.1:3'UTR:MODIFIER:exon24/24:c.*666dupC:,KDM5C:NM_001282622.1:3'UTR:MODIFIER:exon26/26:c.*889dupC:	MIRb	rs66463350;rs75167298	0.7650	0.0000	0/0/0	0.6296							314690 [KDM5C (confirmed) Mental retardation,X-linked,syndromic,Claes-Jensen type,300534];				238	5					KDM5C (inh=XLR pLI=1.00)
chrX	53222043	53222043	-	C	het	hom	het	low_DP	QUAL=121;DP=2,6,4;MQM=60	KDM5C	3'UTR,intron	KDM5C:NM_004187.3:3'UTR:MODIFIER:exon26/26:c.*105dupG:,KDM5C:NM_001282622.1:3'UTR:MODIFIER:exon26/26:c.*105dupG:,KDM5C:NM_001146702.1:intron:MODIFIER:exon23/23:c.4047-25dupG:		rs146836963;rs150558161	0.7759	0.9040	6720/4012/257	0.6426							314690 [KDM5C (confirmed) Mental retardation,X-linked,syndromic,Claes-Jensen type,300534];				1000	30					KDM5C (inh=XLR pLI=1.00)
chrX	53262303	53262303	G	A	wt	wt	hom		QUAL=778;DP=40,36,27;MQM=60	IQSEC2	3'UTR	IQSEC2:NM_001111125.2:3'UTR:MODIFIER:exon15/15:c.*1098C>T:,IQSEC2:NM_015075.1:3'UTR:MODIFIER:exon14/14:c.*2050C>T:		rs12851791	0.0328	0.0000	0/0/0	0.0086							300522 [IQSEC2 (provisional) Mental retardation,X-linked 1/78,309530];				20	21					IQSEC2 (inh=XLR+XLD pLI=0.98)
chrX	53449568	53449568	G	A	hom	hom	hom		QUAL=15947;DP=186,233,140;MQM=60	SMC1A	5'UTR_premature_start_codon_gain,5'UTR	SMC1A:NM_006306.3:5'UTR_premature_start_codon_gain:LOW:exon1/25:c.-19C>T:,SMC1A:NM_001281463.1:5'UTR_premature_start_codon_gain:LOW:exon1/26:c.-231C>T:,SMC1A:NM_006306.3:5'UTR:MODIFIER:exon1/25:c.-19C>T:,SMC1A:NM_001281463.1:5'UTR:MODIFIER:exon1/26:c.-231C>T:		rs1264011	0.3984	0.5163	7564/4983/34	0.4778							300040 [SMC1A (provisional) Cornelia de Lange syndrome 2,300590];	RCV000081383.5 [benign]; RCV000260444.1 [benign]; 			576	188					SMC1A (inh=XLR pLI=1.00)
chrX	53559668	53559668	C	A	hom	hom	wt		QUAL=9849;DP=118,195,109;MQM=60	HUWE1	3'UTR	HUWE1:NM_031407.6:3'UTR:MODIFIER:exon84/84:c.*602G>T:		rs12836234	0.0570	0.0000	0/0/0	0.0846							300697 [HUWE1 (provisional) Mental retardation,X-linked syndromic,Turner type,300706];				15	18					HUWE1 (inh=XLR+XLD pLI=1.00)
chrX	53563589	53563589	A	G	hom	hom	hom		QUAL=19956;DP=160,316,170;MQM=59	HUWE1	synonymous	HUWE1:NM_031407.6:synonymous:LOW:exon79/84:c.12177T>C:p.Gly4059Gly		rs426298	0.9950	0.9973	26877/14624/3158	0.9080	-0.3880		T			11.76	300697 [HUWE1 (provisional) Mental retardation,X-linked syndromic,Turner type,300706];	RCV000082281.7 [other]; 			1766	0	1	[1] Peter Bauer 07.08.2014			HUWE1 (inh=XLR+XLD pLI=1.00)
chrX	53641647	53641647	T	C	hom	hom	wt		QUAL=4778;DP=66,91,70;MQM=60	HUWE1	synonymous	HUWE1:NM_031407.6:synonymous:LOW:exon23/84:c.2109A>G:p.Ser703Ser		rs6638360	0.3897	0.4895	6721/4208/32	0.4559							300697 [HUWE1 (provisional) Mental retardation,X-linked syndromic,Turner type,300706];	RCV000117252.2 [likely benign]; 			792	311					HUWE1 (inh=XLR+XLD pLI=1.00)
chrX	53713581	53713581	-	GCCCTGCTTCA	wt	hom	wt	low_DP	QUAL=3996;DP=14,98,65;MQM=59	HUWE1	5'UTR	HUWE1:NM_031407.6:5'UTR:MODIFIER:exon1/84:c.-321_-311dupTGAAGCAGGGC:		rs201999836	0.3634	0.0000	0/0/0	0.0520							300697 [HUWE1 (provisional) Mental retardation,X-linked syndromic,Turner type,300706];				18	31					HUWE1 (inh=XLR+XLD pLI=1.00)
chrX	53713590	53713590	-	CAGCCCTGCTC	wt	wt	het	low_DP	QUAL=3996;DP=14,98,65;MQM=59	HUWE1	5'UTR	HUWE1:NM_031407.6:5'UTR:MODIFIER:exon1/84:c.-330_-320dupGAGCAGGGCTG:			0.0000	0.0000	0/0/0	0.0000							300697 [HUWE1 (provisional) Mental retardation,X-linked syndromic,Turner type,300706];				0	5					HUWE1 (inh=XLR+XLD pLI=1.00)
chrX	53713601	53713601	C	T	het	wt	wt		QUAL=39;DP=52,129,81;MQM=60	HUWE1	5'UTR	HUWE1:NM_031407.6:5'UTR:MODIFIER:exon1/84:c.-330G>A:		rs5978184	0.1881	0.0000	0/0/0	0.1159							300697 [HUWE1 (provisional) Mental retardation,X-linked syndromic,Turner type,300706];				10	43					HUWE1 (inh=XLR+XLD pLI=1.00)
chrX	53713640	53713640	G	C	hom	hom	hom		QUAL=8807;DP=76,131,83;MQM=59	HUWE1	5'UTR	HUWE1:NM_031407.6:5'UTR:MODIFIER:exon1/84:c.-369C>G:		rs2333864	1.0000	0.0000	0/0/0	0.4018							300697 [HUWE1 (provisional) Mental retardation,X-linked syndromic,Turner type,300706];				212	1					HUWE1 (inh=XLR+XLD pLI=1.00)
chrX	53963378	53963378	A	G	wt	het	wt		QUAL=510;DP=59,40,28;MQM=60	PHF8	3'UTR	PHF8:NM_001184896.1:3'UTR:MODIFIER:exon22/22:c.*2213T>C:,PHF8:NM_001184897.1:3'UTR:MODIFIER:exon22/22:c.*1036T>C:,PHF8:NM_015107.2:3'UTR:MODIFIER:exon22/22:c.*2213T>C:		rs185305171	0.0021	0.0000	0/0/0	0.0017							300560 [PHF8 (confirmed) Mental retardation syndrome,X-linked,Siderius type,300263];				0	1					PHF8 (inh=XLR pLI=1.00)
chrX	53964403	53964403	G	-	wt	wt	hom		QUAL=8530;DP=222,549,295;MQM=59	PHF8	3'UTR	PHF8:NM_001184896.1:3'UTR:MODIFIER:exon22/22:c.*1188delC:,PHF8:NM_001184897.1:3'UTR:MODIFIER:exon22/22:c.*11delC:,PHF8:NM_015107.2:3'UTR:MODIFIER:exon22/22:c.*1188delC:		rs200973089	0.0114	0.0217	4/2/0	0.0050							300560 [PHF8 (confirmed) Mental retardation syndrome,X-linked,Siderius type,300263];				21	19					PHF8 (inh=XLR pLI=1.00)
chrX	54069535	54069535	A	G	wt	het	wt		QUAL=501;DP=37,45,41;MQM=60	PHF8	splice_region&intron,intron	PHF8:NM_001184898.1:splice_region&intron:LOW:exon1/21:c.-93+9T>C:,PHF8:NM_001184896.1:intron:MODIFIER:exon1/21:c.17-282T>C:,PHF8:NM_001184897.1:intron:MODIFIER:exon1/21:c.-92-282T>C:,PHF8:NM_015107.2:intron:MODIFIER:exon1/21:c.-92-282T>C:		rs782493145	0.0000	0.0000	0/0/0	0.0003							300560 [PHF8 (confirmed) Mental retardation syndrome,X-linked,Siderius type,300263];				0	1					PHF8 (inh=XLR pLI=1.00)
chrX	56312422	56312422	T	C	wt	wt	hom		QUAL=2599;DP=103,96,82;MQM=60	KLF8	3'UTR,non_coding_transcript_exon	KLF8:NM_001324104.1:3'UTR:MODIFIER:exon7/7:c.*1495T>C:,KLF8:NM_001324105.1:3'UTR:MODIFIER:exon6/6:c.*1495T>C:,KLF8:NM_001159296.2:3'UTR:MODIFIER:exon6/6:c.*1661T>C:,KLF8:NM_001324102.1:3'UTR:MODIFIER:exon7/7:c.*1495T>C:,KLF8:NM_007250.5:3'UTR:MODIFIER:exon6/6:c.*1495T>C:,KLF8:NM_001324099.1:3'UTR:MODIFIER:exon4/4:c.*1661T>C:,KLF8:NM_001324100.1:3'UTR:MODIFIER:exon4/4:c.*1495T>C:,KLF8:NR_136705.1:non_coding_transcript_exon:MODIFIER:exon5/5:n.7187T>C:,KLF8:NR_136704.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.2831T>C:		rs145489310	0.0056	0.0000	0/0/0	0.0096											2	1					KLF8 (inh=n/a pLI=0.03)
chrX	62857726	62857726	C	G	wt	het	wt	low_DP	QUAL=53;DP=27,19,11;MQM=60	ARHGEF9	3'UTR	ARHGEF9:NM_015185.2:3'UTR:MODIFIER:exon10/10:c.*182G>C:,ARHGEF9:NM_001173480.1:3'UTR:MODIFIER:exon9/9:c.*182G>C:,ARHGEF9:NM_001173479.1:3'UTR:MODIFIER:exon9/9:c.*182G>C:		rs782785419	0.0106	0.0000	0/0/0	0.0018							300429 [ARHGEF9 (confirmed) Epileptic encephalopathy,early infantile,8,300607];				2	3					ARHGEF9 (inh=XLR pLI=0.98)
chrX	62975023	62975023	T	G	wt	wt	hom		QUAL=3126;DP=125,257,109;MQM=60	ARHGEF9	5'UTR,intron	ARHGEF9:NM_015185.2:5'UTR:MODIFIER:exon1/10:c.-831A>C:,ARHGEF9:NM_001173480.1:5'UTR:MODIFIER:exon1/9:c.-946A>C:,ARHGEF9:NM_001173479.1:intron:MODIFIER:exon1/8:c.30+29973A>C:		rs782129950	0.0029	0.0000	0/0/0	0.0041							300429 [ARHGEF9 (confirmed) Epileptic encephalopathy,early infantile,8,300607];				2	4					ARHGEF9 (inh=XLR pLI=0.98)
chrX	64136374	64136374	G	A	wt	wt	hom		QUAL=3880;DP=185,184,122;MQM=60	ZC4H2	3'UTR,non_coding_transcript_exon	ZC4H2:NM_018684.3:3'UTR:MODIFIER:exon5/5:c.*1289C>T:,ZC4H2:NM_001178033.2:3'UTR:MODIFIER:exon4/4:c.*1270C>T:,ZC4H2:NM_001178032.2:3'UTR:MODIFIER:exon5/5:c.*1289C>T:,ZC4H2:NM_001243804.1:3'UTR:MODIFIER:exon5/5:c.*1289C>T:,ZC4H2:NR_045044.1:non_coding_transcript_exon:MODIFIER:exon5/5:n.2375C>T:		rs17301297	0.0114	0.0000	0/0/0	0.0028							300897 [ZC4H2 (confirmed) Wieacker-Wolff syndrome,314580];				6	7					ZC4H2 (inh=XLR pLI=0.83)
chrX	66765159	66765161	GCA	-	wt	wt	hom	low_DP;anno_pathogenic_hgmd	QUAL=423;DP=185,28,18;MQM=58	AR	disruptive_inframe_deletion,sequence_feature	AR:NM_000044.3:disruptive_inframe_deletion:MODERATE:exon1/8:c.237_239delGCA:p.Gln80del,AR:NM_000044.3:sequence_feature:LOW:exon1/8:c.171_173delGCA:,AR:NM_000044.3:sequence_feature:LOW:exon1/8:c.171_173delGCA:	(GCA)n	rs778920072	0.0000	0.0031	6/5/1	0.0073							313700 [AR (confirmed) Androgen insensitivity,300068|Spinal and bulbar muscular atrophy of Kennedy,313200|Androgen insensitivity,partial,with or without breast cancer,312300|Prostate cancer,susceptibility to,176807|Hypospadias 1,X-linked,300633];		CD1510117 [CLASS=DM? MUT=ALT PHEN="Androgen insensitivity syndrome" GENE=AR]; 		154	29	2	[2] old entry - no details available			AR (inh=n/a pLI=0.99)
chrX	66765627	66765627	G	A	wt	het	hom		QUAL=10566;DP=139,331,195;MQM=59	AR	synonymous	AR:NM_000044.3:synonymous:LOW:exon1/8:c.639G>A:p.Glu213Glu		rs6152	0.2387	0.1747	1670/325/1285	0.1508							313700 [AR (confirmed) Androgen insensitivity,300068|Spinal and bulbar muscular atrophy of Kennedy,313200|Androgen insensitivity,partial,with or without breast cancer,312300|Prostate cancer,susceptibility to,176807|Hypospadias 1,X-linked,300633];	RCV000244696.1 [benign]; 	CM051843 [CLASS=DP MUT=ALT PHEN="Androgenetic alopecia reduced risk association with" GENE=AR]; 		191	183					AR (inh=n/a pLI=0.99)
chrX	66944120	66944120	A	-	hom	het	het		QUAL=2053;DP=48,76,69;MQM=60	AR	3'UTR	AR:NM_000044.3:3'UTR:MODIFIER:exon8/8:c.*447delA:,AR:NM_001011645.2:3'UTR:MODIFIER:exon8/8:c.*447delA:	A-rich	rs11351755	0.6805	0.0000	0/0/0	0.4152							313700 [AR (confirmed) Androgen insensitivity,300068|Spinal and bulbar muscular atrophy of Kennedy,313200|Androgen insensitivity,partial,with or without breast cancer,312300|Prostate cancer,susceptibility to,176807|Hypospadias 1,X-linked,300633];				206	36					AR (inh=n/a pLI=0.99)
chrX	66945740	66945740	T	C	hom	hom	hom		QUAL=23221;DP=172,342,194;MQM=60	AR	3'UTR	AR:NM_000044.3:3'UTR:MODIFIER:exon8/8:c.*2057T>C:,AR:NM_001011645.2:3'UTR:MODIFIER:exon8/8:c.*2057T>C:		rs5919413	0.8593	0.0000	0/0/0	0.1140							313700 [AR (confirmed) Androgen insensitivity,300068|Spinal and bulbar muscular atrophy of Kennedy,313200|Androgen insensitivity,partial,with or without breast cancer,312300|Prostate cancer,susceptibility to,176807|Hypospadias 1,X-linked,300633];				150	0					AR (inh=n/a pLI=0.99)
chrX	66946851	66946851	T	C	hom	hom	hom		QUAL=15014;DP=177,189,110;MQM=60	AR	3'UTR	AR:NM_000044.3:3'UTR:MODIFIER:exon8/8:c.*3168T>C:,AR:NM_001011645.2:3'UTR:MODIFIER:exon8/8:c.*3168T>C:		rs1931537	0.8593	0.0000	0/0/0	0.1368							313700 [AR (confirmed) Androgen insensitivity,300068|Spinal and bulbar muscular atrophy of Kennedy,313200|Androgen insensitivity,partial,with or without breast cancer,312300|Prostate cancer,susceptibility to,176807|Hypospadias 1,X-linked,300633];				150	0					AR (inh=n/a pLI=0.99)
chrX	66948019	66948019	-	T	hom	hom	hom		QUAL=5168;DP=137,39,23;MQM=59	AR	3'UTR	AR:NM_000044.3:3'UTR:MODIFIER:exon8/8:c.*4345dupT:,AR:NM_001011645.2:3'UTR:MODIFIER:exon8/8:c.*4345dupT:		rs397737842	0.8416	0.0000	0/0/0	0.5158							313700 [AR (confirmed) Androgen insensitivity,300068|Spinal and bulbar muscular atrophy of Kennedy,313200|Androgen insensitivity,partial,with or without breast cancer,312300|Prostate cancer,susceptibility to,176807|Hypospadias 1,X-linked,300633];				100	49					AR (inh=n/a pLI=0.99)
chrX	66949722	66949722	C	T	hom	hom	hom		QUAL=10081;DP=136,119,75;MQM=60	AR	3'UTR	AR:NM_000044.3:3'UTR:MODIFIER:exon8/8:c.*6039C>T:,AR:NM_001011645.2:3'UTR:MODIFIER:exon8/8:c.*6039C>T:		rs7440	0.8585	0.0000	0/0/0	0.1133							313700 [AR (confirmed) Androgen insensitivity,300068|Spinal and bulbar muscular atrophy of Kennedy,313200|Androgen insensitivity,partial,with or without breast cancer,312300|Prostate cancer,susceptibility to,176807|Hypospadias 1,X-linked,300633];				150	0					AR (inh=n/a pLI=0.99)
chrX	66950023	66950025	AAG	-	hom	hom	hom		QUAL=3735;DP=32,58,32;MQM=60	AR	3'UTR	AR:NM_000044.3:3'UTR:MODIFIER:exon8/8:c.*6344_*6346delAGA:,AR:NM_001011645.2:3'UTR:MODIFIER:exon8/8:c.*6344_*6346delAGA:	A-rich	rs878967261	0.0000	0.0000	0/0/0	0.4732							313700 [AR (confirmed) Androgen insensitivity,300068|Spinal and bulbar muscular atrophy of Kennedy,313200|Androgen insensitivity,partial,with or without breast cancer,312300|Prostate cancer,susceptibility to,176807|Hypospadias 1,X-linked,300633];				149	0					AR (inh=n/a pLI=0.99)
chrX	66950105	66950105	C	T	hom	hom	hom		QUAL=9656;DP=123,113,60;MQM=59	AR	3'UTR	AR:NM_000044.3:3'UTR:MODIFIER:exon8/8:c.*6422C>T:,AR:NM_001011645.2:3'UTR:MODIFIER:exon8/8:c.*6422C>T:		rs2362520	0.8583	0.0000	0/0/0	0.1140							313700 [AR (confirmed) Androgen insensitivity,300068|Spinal and bulbar muscular atrophy of Kennedy,313200|Androgen insensitivity,partial,with or without breast cancer,312300|Prostate cancer,susceptibility to,176807|Hypospadias 1,X-linked,300633];				150	0					AR (inh=n/a pLI=0.99)
chrX	67263222	67263222	G	A	hom	hom	hom	low_DP;low_MQM	QUAL=336;DP=6,3,4;MQM=47	OPHN1	3'UTR	OPHN1:NM_002547.2:3'UTR:MODIFIER:exon25/25:c.*3792C>T:	L1HS	rs7883184	0.1195	0.0000	0/0/0	0.0514							300127 [OPHN1 (provisional) Mental retardation,X-linked,with cerebellar hypoplasia and distinctive facial appearance,300486];				58	50					OPHN1 (inh=XLR pLI=1.00)
chrX	67263229	67263229	A	G	het	hom	hom	low_DP	QUAL=133;DP=6,2,2;MQM=51	OPHN1	3'UTR	OPHN1:NM_002547.2:3'UTR:MODIFIER:exon25/25:c.*3785T>C:		rs184510922	0.1788	0.0000	0/0/0	0.0401							300127 [OPHN1 (provisional) Mental retardation,X-linked,with cerebellar hypoplasia and distinctive facial appearance,300486];				9	54					OPHN1 (inh=XLR pLI=1.00)
chrX	67263293	67263293	A	G	hom	hom	hom	low_DP	QUAL=1023;DP=16,11,5;MQM=60	OPHN1	3'UTR	OPHN1:NM_002547.2:3'UTR:MODIFIER:exon25/25:c.*3721T>C:	Arthur2	rs7888212	0.5189	0.0000	0/0/0	0.2618							300127 [OPHN1 (provisional) Mental retardation,X-linked,with cerebellar hypoplasia and distinctive facial appearance,300486];				90	42					OPHN1 (inh=XLR pLI=1.00)
chrX	67263844	67263844	C	T	hom	hom	hom		QUAL=15569;DP=196,165,122;MQM=60	OPHN1	3'UTR	OPHN1:NM_002547.2:3'UTR:MODIFIER:exon25/25:c.*3170G>A:		rs492933	0.5094	0.0000	0/0/0	0.2671							300127 [OPHN1 (provisional) Mental retardation,X-linked,with cerebellar hypoplasia and distinctive facial appearance,300486];				94	46					OPHN1 (inh=XLR pLI=1.00)
chrX	67265417	67265417	G	T	hom	hom	hom		QUAL=11604;DP=105,149,108;MQM=60	OPHN1	3'UTR	OPHN1:NM_002547.2:3'UTR:MODIFIER:exon25/25:c.*1597C>A:		rs2254886	0.4297	0.0000	0/0/0	0.2490							300127 [OPHN1 (provisional) Mental retardation,X-linked,with cerebellar hypoplasia and distinctive facial appearance,300486];				92	47					OPHN1 (inh=XLR pLI=1.00)
chrX	67265915	67265915	-	T	hom	hom	hom		QUAL=5146;DP=79,47,37;MQM=60	OPHN1	3'UTR	OPHN1:NM_002547.2:3'UTR:MODIFIER:exon25/25:c.*1098dupA:	Charlie4z	rs397698299	0.1823	0.0000	0/0/0	0.1498							300127 [OPHN1 (provisional) Mental retardation,X-linked,with cerebellar hypoplasia and distinctive facial appearance,300486];				62	41					OPHN1 (inh=XLR pLI=1.00)
chrX	68060503	68060503	C	T	wt	het	wt		QUAL=1728;DP=46,146,113;MQM=60	EFNB1	3'UTR	EFNB1:NM_004429.4:3'UTR:MODIFIER:exon5/5:c.*6C>T:		rs2230423	0.0895	0.1241	267/185/22	0.0875							300035 [EFNB1 (confirmed) Craniofrontonasal dysplasia,304110];				109	108					EFNB1 (inh=XLD pLI=0.78)
chrX	68061228	68061228	-	CACAC	wt	het	wt		QUAL=366;DP=44,77,64;MQM=59	EFNB1	3'UTR	EFNB1:NM_004429.4:3'UTR:MODIFIER:exon5/5:c.*731_*732insCACAC:	(CA)n	rs61387446	0.0000	0.0000	0/0/0	0.0429							300035 [EFNB1 (confirmed) Craniofrontonasal dysplasia,304110];				3	3					EFNB1 (inh=XLD pLI=0.78)
chrX	68061229	68061229	-	C	wt	het	wt		QUAL=366;DP=44,77,64;MQM=59	EFNB1	3'UTR	EFNB1:NM_004429.4:3'UTR:MODIFIER:exon5/5:c.*732_*733insC:		rs58007755	0.5203	0.0000	0/0/0	0.0746							300035 [EFNB1 (confirmed) Craniofrontonasal dysplasia,304110];				98	37					EFNB1 (inh=XLD pLI=0.78)
chrX	68061231	68061231	A	C	wt	het	wt		QUAL=828;DP=123,117,91;MQM=59	EFNB1	3'UTR	EFNB1:NM_004429.4:3'UTR:MODIFIER:exon5/5:c.*734A>C:		rs688969	0.5494	0.0000	0/0/0	0.1286							300035 [EFNB1 (confirmed) Craniofrontonasal dysplasia,304110];				109	72					EFNB1 (inh=XLD pLI=0.78)
chrX	68836358	68836358	G	T	wt	het	wt	pred_pathogenic;anno_pathogenic_clinvar;anno_pathogenic_hgmd	QUAL=1721;DP=54,148,121;MQM=60	EDA	missense	EDA:NM_001399.4:missense:MODERATE:exon1/8:c.206G>T:p.Arg69Leu,EDA:NM_001005610.3:missense:MODERATE:exon1/2:c.206G>T:p.Arg69Leu,EDA:NM_001005613.3:missense:MODERATE:exon1/3:c.206G>T:p.Arg69Leu,EDA:NM_001005609.1:missense:MODERATE:exon1/8:c.206G>T:p.Arg69Leu,EDA:NM_001005612.2:missense:MODERATE:exon1/8:c.206G>T:p.Arg69Leu		rs132630309	0.0013	0.0031	1/1/0	0.0030	3.0250	.,T,.,D,T,T,.	D	B,B,B,P,D,D,B,D	D,D,D,D,D,D	24.00	300451 [EDA (confirmed) Ectodermal dysplasia 1,hypohidrotic,X-linked,305100|Tooth agenesis,selective,X-linked 1,313500];	RCV000011779.3 [pathogenic]; RCV000218834.1 [benign]; 	CM960503 [CLASS=DM MUT=ALT PHEN="Ectodermal dysplasia" GENE=EDA]; 	COSM3914162, COSM3914160, COSM3914161	4	7					EDA (inh=XLR+XLD pLI=0.92)
chrX	69080840	69080840	G	A	hom	hom	hom		QUAL=13353;DP=145,169,102;MQM=60	EDA	3'UTR,intron	EDA:NM_001005610.3:3'UTR:MODIFIER:exon2/2:c.*141G>A:,EDA:NM_001005613.3:3'UTR:MODIFIER:exon3/3:c.*186G>A:,EDA:NM_001399.4:intron:MODIFIER:exon1/7:c.397-96037G>A:,EDA:NM_001005609.1:intron:MODIFIER:exon1/7:c.397-96037G>A:,EDA:NM_001005612.2:intron:MODIFIER:exon1/7:c.397-96037G>A:	L1MEd	rs1203003	1.0000	0.0000	0/0/0	0.1227							300451 [EDA (confirmed) Ectodermal dysplasia 1,hypohidrotic,X-linked,305100|Tooth agenesis,selective,X-linked 1,313500];				467	0					EDA (inh=XLR+XLD pLI=0.92)
chrX	69258515	69258515	T	G	hom	het	hom		QUAL=11138;DP=183,144,91;MQM=60	EDA	3'UTR	EDA:NM_001399.4:3'UTR:MODIFIER:exon8/8:c.*3056T>G:,EDA:NM_001005609.1:3'UTR:MODIFIER:exon8/8:c.*3056T>G:,EDA:NM_001005612.2:3'UTR:MODIFIER:exon8/8:c.*3056T>G:		rs3795170	0.3939	0.0000	0/0/0	0.2767							300451 [EDA (confirmed) Ectodermal dysplasia 1,hypohidrotic,X-linked,305100|Tooth agenesis,selective,X-linked 1,313500];				105	48					EDA (inh=XLR+XLD pLI=0.92)
chrX	69510335	69510335	C	T	wt	het	hom		QUAL=10536;DP=297,322,199;MQM=59	KIF4A	synonymous,sequence_feature	KIF4A:NM_012310.4:synonymous:LOW:exon2/31:c.27C>T:p.Pro9Pro,KIF4A:NM_012310.4:sequence_feature:LOW:exon2/31:c.27C>T:		rs1199470	0.9952	0.9927	26646/14273/3303	0.9179							300521 [KIF4A (provisional) Mental retardation,X-linked 100,300923];				1230	17					KIF4A (inh=n/a pLI=1.00)
chrX	69550098	69550098	T	C	wt	wt	hom		QUAL=2249;DP=151,136,74;MQM=59	KIF4A	synonymous	KIF4A:NM_012310.4:synonymous:LOW:exon9/31:c.987T>C:p.Tyr329Tyr		rs41305391	0.1028	0.0768	202/35/7	0.0701							300521 [KIF4A (provisional) Mental retardation,X-linked 100,300923];				44	57					KIF4A (inh=n/a pLI=1.00)
chrX	69626739	69626739	C	T	hom	het	wt		QUAL=5022;DP=102,150,102;MQM=59	KIF4A	splice_region&intron	KIF4A:NM_012310.4:splice_region&intron:LOW:exon27/30:c.3073-4C>T:		rs10482161	0.0601	0.0689	180/118/52	0.0638							300521 [KIF4A (provisional) Mental retardation,X-linked 100,300923];				54	72					KIF4A (inh=n/a pLI=1.00)
chrX	69640700	69640700	C	T	hom	het	wt		QUAL=8407;DP=192,172,118;MQM=60	KIF4A	3'UTR	KIF4A:NM_012310.4:3'UTR:MODIFIER:exon31/31:c.*585C>T:		rs1063088	0.0257	0.0000	0/0/0	0.0446							300521 [KIF4A (provisional) Mental retardation,X-linked 100,300923];				20	20					KIF4A (inh=n/a pLI=1.00)
chrX	69724731	69724731	G	T	hom	het	wt		QUAL=12644;DP=265,363,253;MQM=59	DLG3	3'UTR	DLG3:NM_021120.3:3'UTR:MODIFIER:exon19/19:c.*2612G>T:,DLG3:NM_020730.2:3'UTR:MODIFIER:exon14/14:c.*2612G>T:,DLG3:NM_001166278.1:3'UTR:MODIFIER:exon12/12:c.*2612G>T:		rs3828017	0.5592	0.0000	0/0/0	0.3416							300189 [DLG3 (provisional) Mental retardation,X-linked 90,300850];				123	58					DLG3 (inh=XLR pLI=1.00)
chrX	70390007	70390007	-	CACA	hom	het	wt		QUAL=494;DP=33,93,58;MQM=58	NLGN3	3'UTR	NLGN3:NM_181303.1:3'UTR:MODIFIER:exon8/8:c.*78_*81dupACAC:,NLGN3:NM_001166660.1:3'UTR:MODIFIER:exon6/6:c.*78_*81dupACAC:,NLGN3:NM_001321276.1:3'UTR:MODIFIER:exon7/7:c.*78_*81dupACAC:,NLGN3:NM_018977.3:3'UTR:MODIFIER:exon7/7:c.*78_*81dupACAC:		rs112095862;rs35156036	0.0000	0.0000	0/0/0	0.0013							300336 [NLGN3 (provisional) Autism susceptibility,X-linked 1,300425|Asperger syndrome susceptibility,X-linked 1,300494];				1	10					NLGN3 (inh=n/a pLI=0.90)
chrX	70390207	70390207	A	C	wt	wt	hom		QUAL=3215;DP=115,163,108;MQM=60	NLGN3	3'UTR	NLGN3:NM_181303.1:3'UTR:MODIFIER:exon8/8:c.*260A>C:,NLGN3:NM_001166660.1:3'UTR:MODIFIER:exon6/6:c.*260A>C:,NLGN3:NM_001321276.1:3'UTR:MODIFIER:exon7/7:c.*260A>C:,NLGN3:NM_018977.3:3'UTR:MODIFIER:exon7/7:c.*260A>C:			0.0000	0.0000	0/0/0	0.0000							300336 [NLGN3 (provisional) Autism susceptibility,X-linked 1,300425|Asperger syndrome susceptibility,X-linked 1,300494];				1	0					NLGN3 (inh=n/a pLI=0.90)
chrX	70465331	70465331	A	C	wt	het	wt		QUAL=3860;DP=142,300,179;MQM=60	ZMYM3,BCYRN1	synonymous,intron	ZMYM3:NM_005096.3:synonymous:LOW:exon18/25:c.2865T>G:p.Leu955Leu,ZMYM3:NM_201599.2:synonymous:LOW:exon18/25:c.2865T>G:p.Leu955Leu,ZMYM3:NM_001171162.1:synonymous:LOW:exon18/25:c.2829T>G:p.Leu943Leu,BCYRN1:NR_001568.1:intron:MODIFIER:exon3/3:n.173-35278T>G:		rs374745868	0.0000	0.0002	0/0/0	0.0002											0	1					ZMYM3 (inh=n/a pLI=1.00), BCYRN1 (inh=n/a pLI=n/a)
chrX	70469182	70469182	G	A	hom	hom	hom		QUAL=18021;DP=171,217,164;MQM=60	ZMYM3,BCYRN1	3'UTR,intron	ZMYM3:NM_001171163.1:3'UTR:MODIFIER:exon7/7:c.*111C>T:,BCYRN1:NR_001568.1:intron:MODIFIER:exon3/3:n.173-39129C>T:,ZMYM3:NM_005096.3:intron:MODIFIER:exon7/24:c.1470+129C>T:,ZMYM3:NM_201599.2:intron:MODIFIER:exon7/24:c.1470+129C>T:,ZMYM3:NM_001171162.1:intron:MODIFIER:exon7/24:c.1470+129C>T:	L1ME3Cz	rs2341539	0.9992	0.0000	0/0/0	0.6958											268	0					ZMYM3 (inh=n/a pLI=1.00), BCYRN1 (inh=n/a pLI=n/a)
chrX	70684777	70684777	A	G	wt	wt	hom		QUAL=1164;DP=71,59,43;MQM=60	TAF1,BCYRN1	3'UTR,intron	TAF1:NM_001286074.1:3'UTR:MODIFIER:exon38/38:c.*881A>G:,TAF1:NM_004606.4:3'UTR:MODIFIER:exon38/38:c.*881A>G:,TAF1:NM_138923.3:3'UTR:MODIFIER:exon38/38:c.*881A>G:,BCYRN1:NR_001568.1:intron:MODIFIER:exon2/3:n.161+119078T>C:,TAF1:NR_104387.1:intron:MODIFIER:exon38/39:n.5637+4124A>G:,TAF1:NR_104388.1:intron:MODIFIER:exon38/39:n.5628+4124A>G:,TAF1:NR_104389.1:intron:MODIFIER:exon37/38:n.5535+4124A>G:,TAF1:NR_104390.1:intron:MODIFIER:exon37/38:n.5541+4124A>G:,TAF1:NR_104391.1:intron:MODIFIER:exon38/39:n.5563+4124A>G:,TAF1:NR_104392.1:intron:MODIFIER:exon38/39:n.5557+4124A>G:,TAF1:NR_104393.1:intron:MODIFIER:exon38/39:n.5643+4124A>G:,TAF1:NR_104394.1:intron:MODIFIER:exon38/39:n.5514+4124A>G:,TAF1:NR_104395.1:intron:MODIFIER:exon37/38:n.5566+4124A>G:		rs113203261	0.0466	0.0000	0/0/0	0.0100							313650 [TAF1 (confirmed) Dystonia-Parkinsonism,X-linked,314250|Mental retardation,X-linked,syndromic 33,300966];				19	19					TAF1 (inh=XLR pLI=1.00), BCYRN1 (inh=n/a pLI=n/a)
chrX	73641569	73641569	T	C	wt	het	wt		QUAL=470;DP=29,37,31;MQM=60	SLC16A2	missense	SLC16A2:NM_006517.4:missense:MODERATE:exon1/6:c.97T>C:p.Ser33Pro	(AGCCGG)n	rs6647476	0.6638	0.5610	2686/858/487	0.3531	-0.3900	T	T	B	T	0.27	300095 [SLC16A2 (confirmed) Allan-Herndon-Dudley syndrome,300523];	RCV000020650.1 [benign]; RCV000081443.6 [benign]; 		COSM458039	758	395	1	[1] old entry - no details available			SLC16A2 (inh=XLD pLI=0.93)
chrX	73803082	73803082	C	T	wt	wt	het	low_MQM	QUAL=50;DP=256,279,236;MQM=40	RLIM	3'UTR	RLIM:NM_016120.3:3'UTR:MODIFIER:exon4/4:c.*8193G>A:,RLIM:NM_183353.2:3'UTR:MODIFIER:exon5/5:c.*8193G>A:		rs868820973	0.0000	0.0000	0/0/0	0.0001							300379 [RLIM (provisional) Mental retardation,X-linked 61,300978];				0	75					RLIM (inh=n/a pLI=0.99)
chrX	73803084	73803084	C	T	wt	wt	het	low_MQM	QUAL=50;DP=256,279,236;MQM=40	RLIM	3'UTR	RLIM:NM_016120.3:3'UTR:MODIFIER:exon4/4:c.*8191G>A:,RLIM:NM_183353.2:3'UTR:MODIFIER:exon5/5:c.*8191G>A:		rs866155402	0.0000	0.0000	0/0/0	0.0001							300379 [RLIM (provisional) Mental retardation,X-linked 61,300978];				0	73					RLIM (inh=n/a pLI=0.99)
chrX	73803099	73803099	C	T	wt	wt	het	low_MQM	QUAL=563;DP=251,293,225;MQM=41	RLIM	3'UTR	RLIM:NM_016120.3:3'UTR:MODIFIER:exon4/4:c.*8176G>A:,RLIM:NM_183353.2:3'UTR:MODIFIER:exon5/5:c.*8176G>A:		rs866650596	0.0000	0.0000	0/0/0	0.0001							300379 [RLIM (provisional) Mental retardation,X-linked 61,300978];				0	174					RLIM (inh=n/a pLI=0.99)
chrX	73803100	73803100	G	A	wt	wt	het	low_MQM	QUAL=563;DP=251,293,225;MQM=41	RLIM	3'UTR	RLIM:NM_016120.3:3'UTR:MODIFIER:exon4/4:c.*8175C>T:,RLIM:NM_183353.2:3'UTR:MODIFIER:exon5/5:c.*8175C>T:		rs868576827	0.0000	0.0000	0/0/0	0.0001							300379 [RLIM (provisional) Mental retardation,X-linked 61,300978];				0	175					RLIM (inh=n/a pLI=0.99)
chrX	73803117	73803117	T	A	wt	wt	het	low_MQM	QUAL=898;DP=224,314,246;MQM=41	RLIM	3'UTR	RLIM:NM_016120.3:3'UTR:MODIFIER:exon4/4:c.*8158A>T:,RLIM:NM_183353.2:3'UTR:MODIFIER:exon5/5:c.*8158A>T:		rs866011482	0.0000	0.0000	0/0/0	0.0002							300379 [RLIM (provisional) Mental retardation,X-linked 61,300978];				0	247					RLIM (inh=n/a pLI=0.99)
chrX	73803129	73803129	G	A	wt	wt	het	low_MQM	QUAL=978;DP=217,329,274;MQM=41	RLIM	3'UTR	RLIM:NM_016120.3:3'UTR:MODIFIER:exon4/4:c.*8146C>T:,RLIM:NM_183353.2:3'UTR:MODIFIER:exon5/5:c.*8146C>T:		rs867642028	0.0000	0.0000	0/0/0	0.0002							300379 [RLIM (provisional) Mental retardation,X-linked 61,300978];				0	265					RLIM (inh=n/a pLI=0.99)
chrX	73803149	73803149	A	G	wt	wt	het	low_MQM	QUAL=1187;DP=247,360,297;MQM=41	RLIM	3'UTR	RLIM:NM_016120.3:3'UTR:MODIFIER:exon4/4:c.*8126T>C:,RLIM:NM_183353.2:3'UTR:MODIFIER:exon5/5:c.*8126T>C:		rs867999880	0.0000	0.0000	0/0/0	0.0001							300379 [RLIM (provisional) Mental retardation,X-linked 61,300978];				0	264					RLIM (inh=n/a pLI=0.99)
chrX	73803162	73803162	G	C	wt	wt	het	low_MQM	QUAL=1100;DP=264,355,300;MQM=40	RLIM	3'UTR	RLIM:NM_016120.3:3'UTR:MODIFIER:exon4/4:c.*8113C>G:,RLIM:NM_183353.2:3'UTR:MODIFIER:exon5/5:c.*8113C>G:			0.0000	0.0000	0/0/0	0.0001							300379 [RLIM (provisional) Mental retardation,X-linked 61,300978];				0	237					RLIM (inh=n/a pLI=0.99)
chrX	73803167	73803167	-	GAG	wt	wt	het	low_MQM	QUAL=870;DP=264,359,305;MQM=41	RLIM	3'UTR	RLIM:NM_016120.3:3'UTR:MODIFIER:exon4/4:c.*8105_*8107dupCTC:,RLIM:NM_183353.2:3'UTR:MODIFIER:exon5/5:c.*8105_*8107dupCTC:		rs776858201	0.0000	0.0000	0/0/0	0.0019							300379 [RLIM (provisional) Mental retardation,X-linked 61,300978];				0	140					RLIM (inh=n/a pLI=0.99)
chrX	73803191	73803191	A	G	wt	wt	het	low_MQM	QUAL=741;DP=283,381,312;MQM=40	RLIM	3'UTR	RLIM:NM_016120.3:3'UTR:MODIFIER:exon4/4:c.*8084T>C:,RLIM:NM_183353.2:3'UTR:MODIFIER:exon5/5:c.*8084T>C:		rs77921515	0.0000	0.0000	0/0/0	0.0001							300379 [RLIM (provisional) Mental retardation,X-linked 61,300978];				0	85					RLIM (inh=n/a pLI=0.99)
chrX	73803222	73803222	T	C	wt	wt	het	low_MQM	QUAL=590;DP=297,396,329;MQM=39	RLIM	3'UTR	RLIM:NM_016120.3:3'UTR:MODIFIER:exon4/4:c.*8053A>G:,RLIM:NM_183353.2:3'UTR:MODIFIER:exon5/5:c.*8053A>G:		rs78118824	0.0000	0.0000	0/0/0	0.0001							300379 [RLIM (provisional) Mental retardation,X-linked 61,300978];				0	35					RLIM (inh=n/a pLI=0.99)
chrX	73803237	73803237	C	T	wt	wt	het	low_MQM	QUAL=137;DP=307,404,320;MQM=39	RLIM	3'UTR	RLIM:NM_016120.3:3'UTR:MODIFIER:exon4/4:c.*8038G>A:,RLIM:NM_183353.2:3'UTR:MODIFIER:exon5/5:c.*8038G>A:		rs77407345	0.0000	0.0000	0/0/0	0.0001							300379 [RLIM (provisional) Mental retardation,X-linked 61,300978];				0	16					RLIM (inh=n/a pLI=0.99)
chrX	73956893	73956893	T	G	het	wt	wt		QUAL=428;DP=83,49,31;MQM=60	KIAA2022	3'UTR	KIAA2022:NM_001008537.2:3'UTR:MODIFIER:exon4/4:c.*2347A>C:		rs199521894	0.0000	0.0000	0/0/0	0.0002							300524 [KIAA2022 (provisional) Mental retardation,X-linked 98,300912];				0	146					KIAA2022 (inh=XLR pLI=0.95)
chrX	73958629	73958629	G	A	hom	hom	hom		QUAL=9364;DP=115,105,62;MQM=59	KIAA2022	3'UTR	KIAA2022:NM_001008537.2:3'UTR:MODIFIER:exon4/4:c.*611C>T:		rs2209549	0.4095	0.0000	0/0/0	0.0836							300524 [KIAA2022 (provisional) Mental retardation,X-linked 98,300912];				263	33					KIAA2022 (inh=XLR pLI=0.95)
chrX	74589117	74589117	C	T	hom	hom	hom		QUAL=16413;DP=176,205,130;MQM=59	ZDHHC15	3'UTR	ZDHHC15:NM_144969.2:3'UTR:MODIFIER:exon12/12:c.*3696G>A:,ZDHHC15:NM_001146256.1:3'UTR:MODIFIER:exon11/11:c.*3696G>A:		rs7052314	0.4199	0.0000	0/0/0	0.4704							300576 [ZDHHC15 (provisional) Mental retardation,X-linked 91,300577];				164	38					ZDHHC15 (inh=n/a pLI=0.90)
chrX	74589151	74589154	TGTG	-	hom	hom	wt		QUAL=10249;DP=113,203,125;MQM=59	ZDHHC15	3'UTR	ZDHHC15:NM_144969.2:3'UTR:MODIFIER:exon12/12:c.*3659_*3662delCACA:,ZDHHC15:NM_001146256.1:3'UTR:MODIFIER:exon11/11:c.*3659_*3662delCACA:	(TG)n	rs752312995	0.0000	0.0000	0/0/0	0.1817							300576 [ZDHHC15 (provisional) Mental retardation,X-linked 91,300577];				78	65					ZDHHC15 (inh=n/a pLI=0.90)
chrX	74589151	74589152	TG	-	wt	wt	hom		QUAL=10249;DP=113,203,125;MQM=59	ZDHHC15	3'UTR	ZDHHC15:NM_144969.2:3'UTR:MODIFIER:exon12/12:c.*3661_*3662delCA:,ZDHHC15:NM_001146256.1:3'UTR:MODIFIER:exon11/11:c.*3661_*3662delCA:	(TG)n	rs757030488	0.0000	0.0000	0/0/0	0.0237							300576 [ZDHHC15 (provisional) Mental retardation,X-linked 91,300577];				10	16					ZDHHC15 (inh=n/a pLI=0.90)
chrX	74590136	74590136	G	C	hom	hom	hom		QUAL=13807;DP=124,180,115;MQM=60	ZDHHC15	3'UTR	ZDHHC15:NM_144969.2:3'UTR:MODIFIER:exon12/12:c.*2677C>G:,ZDHHC15:NM_001146256.1:3'UTR:MODIFIER:exon11/11:c.*2677C>G:		rs1998494	0.8127	0.0000	0/0/0	0.6448							300576 [ZDHHC15 (provisional) Mental retardation,X-linked 91,300577];				214	11					ZDHHC15 (inh=n/a pLI=0.90)
chrX	74590180	74590180	G	A	hom	hom	hom		QUAL=13482;DP=172,150,81;MQM=60	ZDHHC15	3'UTR	ZDHHC15:NM_144969.2:3'UTR:MODIFIER:exon12/12:c.*2633C>T:,ZDHHC15:NM_001146256.1:3'UTR:MODIFIER:exon11/11:c.*2633C>T:		rs1998493	0.8127	0.0000	0/0/0	0.6405							300576 [ZDHHC15 (provisional) Mental retardation,X-linked 91,300577];				214	11					ZDHHC15 (inh=n/a pLI=0.90)
chrX	74590258	74590258	G	T	hom	hom	hom		QUAL=13889;DP=195,167,83;MQM=60	ZDHHC15	3'UTR	ZDHHC15:NM_144969.2:3'UTR:MODIFIER:exon12/12:c.*2555C>A:,ZDHHC15:NM_001146256.1:3'UTR:MODIFIER:exon11/11:c.*2555C>A:		rs1998492	0.8130	0.0000	0/0/0	0.6443							300576 [ZDHHC15 (provisional) Mental retardation,X-linked 91,300577];				214	11					ZDHHC15 (inh=n/a pLI=0.90)
chrX	74590359	74590368	TTTTTTTTTT	-	hom	hom	hom		QUAL=3144;DP=63,77,40;MQM=58	ZDHHC15	3'UTR	ZDHHC15:NM_144969.2:3'UTR:MODIFIER:exon12/12:c.*2445_*2454delAAAAAAAAAA:,ZDHHC15:NM_001146256.1:3'UTR:MODIFIER:exon11/11:c.*2445_*2454delAAAAAAAAAA:	AluSp	rs367924484;rs747471622;rs775337620	0.9065	0.0000	0/0/0	0.3612							300576 [ZDHHC15 (provisional) Mental retardation,X-linked 91,300577];				78	68					ZDHHC15 (inh=n/a pLI=0.90)
chrX	74591706	74591706	T	C	hom	hom	hom		QUAL=11075;DP=151,114,68;MQM=60	ZDHHC15	3'UTR	ZDHHC15:NM_144969.2:3'UTR:MODIFIER:exon12/12:c.*1107A>G:,ZDHHC15:NM_001146256.1:3'UTR:MODIFIER:exon11/11:c.*1107A>G:		rs2146770	0.9253	0.0000	0/0/0	0.6823							300576 [ZDHHC15 (provisional) Mental retardation,X-linked 91,300577];				228	0					ZDHHC15 (inh=n/a pLI=0.90)
chrX	74743194	74743194	C	G	hom	hom	hom		QUAL=6533;DP=71,99,43;MQM=60	ZDHHC15	5'UTR	ZDHHC15:NM_144969.2:5'UTR:MODIFIER:exon1/12:c.-335G>C:,ZDHHC15:NM_001146256.1:5'UTR:MODIFIER:exon1/11:c.-335G>C:,ZDHHC15:NM_001146257.1:5'UTR:MODIFIER:exon1/3:c.-335G>C:		rs11796028	0.3846	0.0000	0/0/0	0.4576							300576 [ZDHHC15 (provisional) Mental retardation,X-linked 91,300577];				161	39					ZDHHC15 (inh=n/a pLI=0.90)
chrX	76762375	76762375	C	T	het	wt	wt	low_DP	QUAL=84;DP=53,14,8;MQM=53	ATRX	3'UTR	ATRX:NM_000489.4:3'UTR:MODIFIER:exon35/35:c.*1454G>A:,ATRX:NM_138270.3:3'UTR:MODIFIER:exon34/34:c.*1454G>A:	(T)n	rs782665097	0.3462	0.0000	0/0/0	0.0502							300032 [ATRX (confirmed) Alpha-thalassemia/mental retardation syndrome,301040|Alpha-thalassemia myelodysplasia syndrome,somatic,300448|Mental retardation-hypotonic facies syndrome,X-linked,309580];				0	153					ATRX (inh=XLR pLI=1.00)
chrX	77298857	77298857	G	A	hom	hom	hom	pred_pathogenic	QUAL=15672;DP=104,237,131;MQM=60	ATP7A	missense,non_coding_transcript_exon	ATP7A:NM_000052.6:missense:MODERATE:exon21/23:c.4048G>A:p.Glu1350Lys,ATP7A:NM_001282224.1:missense:MODERATE:exon20/22:c.3814G>A:p.Glu1272Lys,ATP7A:NR_104109.1:non_coding_transcript_exon:MODIFIER:exon8/10:n.1258G>A:		rs4826245	1.0000	1.0000	27055/14628/3310	0.9028	7.0780	T,T,T	T	B	D,D,D	10.98	300011 [ATP7A (confirmed) Menkes disease,309400|Occipital horn syndrome,304150|Spinal muscular atrophy,distal,X-linked 3,300489];	RCV000078036.6 [benign]; 			1751	0					ATP7A (inh=XLR pLI=1.00)
chrX	79925246	79925246	A	G	hom	hom	hom	low_DP	QUAL=2458;DP=45,15,14;MQM=60	BRWD3	3'UTR	BRWD3:NM_153252.4:3'UTR:MODIFIER:exon41/41:c.*6862T>C:		rs2063579	0.5211	0.0000	0/0/0	0.4593							300553 [BRWD3 (provisional) Mental retardation,X-linked 93,300659];	RCV000341194.1 [benign]; 			90	32					BRWD3 (inh=XLR pLI=1.00)
chrX	79926082	79926082	-	A	wt	wt	hom		QUAL=1493;DP=99,115,58;MQM=59	BRWD3	3'UTR	BRWD3:NM_153252.4:3'UTR:MODIFIER:exon41/41:c.*6025dupT:	AluJb	rs201004001	0.0090	0.0000	0/0/0	0.0050							300553 [BRWD3 (provisional) Mental retardation,X-linked 93,300659];	RCV000370337.1 [likely benign]; 			3	0					BRWD3 (inh=XLR pLI=1.00)
chrX	79931832	79931835	GTGT	-	hom	hom	hom		QUAL=16579;DP=128,257,176;MQM=59	BRWD3	3'UTR	BRWD3:NM_153252.4:3'UTR:MODIFIER:exon41/41:c.*273_*276delACAC:	(GT)n	rs397895620	0.5136	0.0000	0/0/0	0.4064							300553 [BRWD3 (provisional) Mental retardation,X-linked 93,300659];	RCV000337357.1 [benign]; 			211	49					BRWD3 (inh=XLR pLI=1.00)
chrX	79943569	79943569	T	C	hom	hom	hom		QUAL=14390;DP=116,208,115;MQM=60	BRWD3	missense&splice_region	BRWD3:NM_153252.4:missense&splice_region:MODERATE:exon34/41:c.3863A>G:p.Lys1288Arg		rs3122407	0.9897	0.9972	26864/14624/3144	0.8998	0.1700	T	T	B	T	7.36	300553 [BRWD3 (provisional) Mental retardation,X-linked 93,300659];	RCV000371280.1 [benign]; 			1762	2					BRWD3 (inh=XLR pLI=1.00)
chrX	80065236	80065237	AG	-	hom	hom	hom	low_DP	QUAL=1686;DP=7,36,33;MQM=59	BRWD3-HMGN5	intergenic_region	BRWD3-HMGN5:BRWD3-HMGN5:intergenic_region:MODIFIER::n.80065236_80065237delAG:	GA-rich	rs762475206	0.8167	0.0000	0/0/0	0.3676							300553 [BRWD3 (provisional) Mental retardation,X-linked 93,300659];	RCV000303458.1 [benign]; 			253	8					BRWD3-HMGN5 (inh=n/a pLI=n/a)
chrX	99550883	99550883	G	A	hom	het	wt	low_DP	QUAL=873;DP=26,15,12;MQM=60	PCDH19	3'UTR	PCDH19:NM_001184880.1:3'UTR:MODIFIER:exon6/6:c.*392C>T:,PCDH19:NM_001105243.1:3'UTR:MODIFIER:exon5/5:c.*392C>T:,PCDH19:NM_020766.2:3'UTR:MODIFIER:exon5/5:c.*392C>T:		rs1335268	0.2299	0.0000	0/0/0	0.0377							300460 [PCDH19 (confirmed) Epileptic encephalopathy,early infantile,9,300088];				80	44					PCDH19 (inh=AR+AD pLI=0.98)
chrX	99661969	99661969	G	A	hom	het	wt		QUAL=9210;DP=127,448,280;MQM=59	PCDH19	synonymous	PCDH19:NM_001184880.1:synonymous:LOW:exon1/6:c.1627C>T:p.Leu543Leu,PCDH19:NM_001105243.1:synonymous:LOW:exon1/5:c.1627C>T:p.Leu543Leu,PCDH19:NM_020766.2:synonymous:LOW:exon1/5:c.1627C>T:p.Leu543Leu		rs1953337	0.0861	0.2067	1550/1211/14	0.1932							300460 [PCDH19 (confirmed) Epileptic encephalopathy,early infantile,9,300088];	RCV000079603.6 [benign]; 		COSM3759554	278	230					PCDH19 (inh=AR+AD pLI=0.98)
chrX	99664018	99664018	G	A	wt	wt	hom	low_DP	QUAL=136;DP=1,1,7;MQM=60	PCDH19	5'UTR	PCDH19:NM_001184880.1:5'UTR:MODIFIER:exon1/6:c.-423C>T:,PCDH19:NM_001105243.1:5'UTR:MODIFIER:exon1/5:c.-423C>T:,PCDH19:NM_020766.2:5'UTR:MODIFIER:exon1/5:c.-423C>T:		rs111823340	0.3870	0.0000	0/0/0	0.0447							300460 [PCDH19 (confirmed) Epileptic encephalopathy,early infantile,9,300088];				33	16					PCDH19 (inh=AR+AD pLI=0.98)
chrX	99926122	99926122	G	A	hom	hom	hom		QUAL=31706;DP=271,415,291;MQM=60	SRPX2	3'UTR	SRPX2:NM_014467.2:3'UTR:MODIFIER:exon11/11:c.*138G>A:		rs5967163	0.9656	0.0000	0/0/0	0.1175							300642 [SRPX2 (provisional) Rolandic epilepsy,mental retardation,and speech dyspraxia,300643];				336	0					SRPX2 (inh=AD pLI=0.96)
chrX	100532621	100532621	T	C	hom	het	wt	pred_pathogenic	QUAL=6398;DP=188,91,70;MQM=60	TAF7L	missense	TAF7L:NM_024885.3:missense:MODERATE:exon9/13:c.922A>G:p.Ser308Gly,TAF7L:NM_001168474.1:missense:MODERATE:exon9/13:c.664A>G:p.Ser222Gly		rs35899692	0.1804	0.1482	733/263/194	0.1313	2.3940	T,T,T,T	T	B,B	T,T,T,T	0.01				COSM3759316	165	172					TAF7L (inh=n/a pLI=0.84)
chrX	100547933	100547933	A	G	hom	hom	hom		QUAL=28125;DP=205,424,259;MQM=60	TAF7L	missense	TAF7L:NM_024885.3:missense:MODERATE:exon1/13:c.101T>C:p.Leu34Pro		rs5951328	0.9950	0.9905	26499/14215/3284	0.8939	-1.2920	T	T	B	T	0.03					1642	15					TAF7L (inh=n/a pLI=0.84)
chrX	100600981	100600981	-	ATC	wt	het	wt		QUAL=1940;DP=146,161,100;MQM=58	TIMM8A	3'UTR	TIMM8A:NM_004085.3:3'UTR:MODIFIER:exon2/2:c.*503_*505dupGAT:		rs80356558	0.4845	0.0000	0/0/0	0.1812							300356 [TIMM8A (confirmed) Mohr-Tranebjaerg syndrome,304700];	RCV000020580.1,RCV000020580.1 [benign,benign]; 			36	33					TIMM8A (inh=n/a pLI=0.61)
chrX	100603363	100603363	T	C	wt	wt	hom		QUAL=3678;DP=113,217,127;MQM=60	TIMM8A	3'UTR,intron	TIMM8A:NM_001145951.1:3'UTR:MODIFIER:exon2/2:c.*12A>G:,TIMM8A:NM_004085.3:intron:MODIFIER:exon1/1:c.132+158A>G:		rs41309506	0.0069	0.0198	2/2/0	0.0098							300356 [TIMM8A (confirmed) Mohr-Tranebjaerg syndrome,304700];	RCV000037058.3 [benign]; 			11	14					TIMM8A (inh=n/a pLI=0.61)
chrX	100604681	100604681	C	T	wt	het	wt		QUAL=3386;DP=121,239,154;MQM=60	BTK	3'UTR	BTK:NM_001287344.1:3'UTR:MODIFIER:exon19/19:c.*192G>A:,BTK:NM_000061.2:3'UTR:MODIFIER:exon19/19:c.*192G>A:,BTK:NM_001287345.1:3'UTR:MODIFIER:exon17/17:c.*192G>A:		rs1057403	0.4562	0.0000	0/0/0	0.0318							300300 [BTK (confirmed) Agammaglobulinemia,X-linked 1,300755|Agammaglobulinemia and isolated hormone deficiency,307200];	RCV000283042.1 [benign]; RCV000342738.1 [benign]; 			36	33					BTK (inh=XLR pLI=1.00)
chrX	100604757	100604757	T	G	wt	wt	hom		QUAL=4398;DP=144,203,136;MQM=60	BTK	3'UTR	BTK:NM_001287344.1:3'UTR:MODIFIER:exon19/19:c.*116A>C:,BTK:NM_000061.2:3'UTR:MODIFIER:exon19/19:c.*116A>C:,BTK:NM_001287345.1:3'UTR:MODIFIER:exon17/17:c.*116A>C:		rs700	0.2689	0.0000	0/0/0	0.0589							300300 [BTK (confirmed) Agammaglobulinemia,X-linked 1,300755|Agammaglobulinemia and isolated hormone deficiency,307200];	RCV000289032.1 [benign]; RCV000407071.1 [benign]; 		COSN168778	143	59					BTK (inh=XLR pLI=1.00)
chrX	100608191	100608191	G	A	wt	het	wt	pred_pathogenic	QUAL=1592;DP=90,131,72;MQM=60	BTK	synonymous	BTK:NM_001287344.1:synonymous:LOW:exon18/19:c.2001C>T:p.Cys667Cys,BTK:NM_000061.2:synonymous:LOW:exon18/19:c.1899C>T:p.Cys633Cys,BTK:NM_001287345.1:synonymous:LOW:exon16/17:c.1371C>T:p.Cys457Cys		rs1135363	0.5081	0.3208	4702/405/2194	0.2828	2.4440	D	T			2.27	300300 [BTK (confirmed) Agammaglobulinemia,X-linked 1,300755|Agammaglobulinemia and isolated hormone deficiency,307200];	RCV000254181.1 [benign]; RCV000343690.1 [benign]; RCV000407074.1 [benign]; 			246	187					BTK (inh=XLR pLI=1.00)
chrX	103042882	103042882	T	C	wt	het	wt		QUAL=4094;DP=141,320,227;MQM=60	PLP1	synonymous	PLP1:NM_000533.4:synonymous:LOW:exon4/7:c.609T>C:p.Asp203Asp,PLP1:NM_001128834.2:synonymous:LOW:exon5/8:c.609T>C:p.Asp203Asp,PLP1:NM_199478.2:synonymous:LOW:exon4/7:c.504T>C:p.Asp168Asp,PLP1:NM_001305004.1:synonymous:LOW:exon4/7:c.444T>C:p.Asp148Asp		rs1126707	0.2066	0.2789	2356/1352/65	0.2587							300401 [PLP1 (confirmed) Pelizaeus-Merzbacher disease,312080|Spastic paraplegia 2,X-linked,312920];	RCV000079098.8 [other]; 		COSM1464568	504	361					PLP1 (inh=XLR pLI=0.90)
chrX	103046527	103046527	G	-	hom	hom	hom		QUAL=17487;DP=213,191,133;MQM=59	PLP1	3'UTR	PLP1:NM_000533.4:3'UTR:MODIFIER:exon7/7:c.*1005delG:,PLP1:NM_001128834.2:3'UTR:MODIFIER:exon8/8:c.*1005delG:,PLP1:NM_199478.2:3'UTR:MODIFIER:exon7/7:c.*1005delG:,PLP1:NM_001305004.1:3'UTR:MODIFIER:exon7/7:c.*1005delG:		rs796941012	1.0000	0.0000	0/0/0	0.6272							300401 [PLP1 (confirmed) Pelizaeus-Merzbacher disease,312080|Spastic paraplegia 2,X-linked,312920];				335	0					PLP1 (inh=XLR pLI=0.90)
chrX	107834411	107834411	C	A	wt	wt	hom	pred_pathogenic	QUAL=2404;DP=95,120,80;MQM=60	COL4A5	missense	COL4A5:NM_033380.2:missense:MODERATE:exon20/51:c.1289C>A:p.Ala430Asp,COL4A5:NM_000495.4:missense:MODERATE:exon20/51:c.1289C>A:p.Ala430Asp		rs142883891	0.0024	0.0047	0/0/0	0.0046	1.0580	T,T,T	D	B,B,B	D,D	18.97	303630 [COL4A5 (confirmed) Alport syndrome,301050];	RCV000249325.1 [likely benign]; 			8	11					COL4A5 (inh=XLD pLI=1.00)
chrX	110537061	110537061	T	C	wt	het	wt		QUAL=1753;DP=117,133,76;MQM=60	DCX	3'UTR	DCX:NM_000555.3:3'UTR:MODIFIER:exon7/7:c.*7854A>G:,DCX:NM_178151.2:3'UTR:MODIFIER:exon7/7:c.*7854A>G:,DCX:NM_001195553.1:3'UTR:MODIFIER:exon7/7:c.*7854A>G:,DCX:NM_178152.2:3'UTR:MODIFIER:exon7/7:c.*7854A>G:,DCX:NM_178153.2:3'UTR:MODIFIER:exon7/7:c.*7854A>G:		rs41300894	0.0048	0.0000	0/0/0	0.0011							300121 [DCX (confirmed) Lissencephaly,X-linked,300067|Subcortical laminal heteropia,X-linked,300067];				1	1					DCX (inh=XLR+XLD pLI=0.86)
chrX	110540014	110540014	G	A	hom	hom	hom		QUAL=1469;DP=36,33,21;MQM=59	DCX	3'UTR	DCX:NM_000555.3:3'UTR:MODIFIER:exon7/7:c.*4901C>T:,DCX:NM_178151.2:3'UTR:MODIFIER:exon7/7:c.*4901C>T:,DCX:NM_001195553.1:3'UTR:MODIFIER:exon7/7:c.*4901C>T:,DCX:NM_178152.2:3'UTR:MODIFIER:exon7/7:c.*4901C>T:,DCX:NM_178153.2:3'UTR:MODIFIER:exon7/7:c.*4901C>T:			0.0000	0.0000	0/0/0	0.0000							300121 [DCX (confirmed) Lissencephaly,X-linked,300067|Subcortical laminal heteropia,X-linked,300067];				0	6					DCX (inh=XLR+XLD pLI=0.86)
chrX	110541090	110541090	C	G	wt	het	wt		QUAL=4123;DP=193,329,206;MQM=60	DCX	3'UTR	DCX:NM_000555.3:3'UTR:MODIFIER:exon7/7:c.*3825G>C:,DCX:NM_178151.2:3'UTR:MODIFIER:exon7/7:c.*3825G>C:,DCX:NM_001195553.1:3'UTR:MODIFIER:exon7/7:c.*3825G>C:,DCX:NM_178152.2:3'UTR:MODIFIER:exon7/7:c.*3825G>C:,DCX:NM_178153.2:3'UTR:MODIFIER:exon7/7:c.*3825G>C:		rs145764957	0.0034	0.0000	0/0/0	0.0049							300121 [DCX (confirmed) Lissencephaly,X-linked,300067|Subcortical laminal heteropia,X-linked,300067];				1	1					DCX (inh=XLR+XLD pLI=0.86)
chrX	119560140	119560140	T	C	wt	wt	hom		QUAL=4982;DP=266,278,162;MQM=60	LAMP2	3'UTR	LAMP2:NM_001122606.1:3'UTR:MODIFIER:exon9/9:c.*2199A>G:,LAMP2:NM_002294.2:3'UTR:MODIFIER:exon9/9:c.*5038A>G:		rs2748	0.2985	0.0000	0/0/0	0.2462							309060 [LAMP2 (confirmed) Danon disease,300257];	RCV000319063.1 [likely benign]; RCV000375907.1 [likely benign]; 			111	52					LAMP2 (inh=XLD pLI=0.95)
chrX	119560599	119560599	T	C	hom	het	hom		QUAL=9284;DP=154,111,80;MQM=60	LAMP2	3'UTR	LAMP2:NM_001122606.1:3'UTR:MODIFIER:exon9/9:c.*1740A>G:,LAMP2:NM_002294.2:3'UTR:MODIFIER:exon9/9:c.*4579A>G:		rs42885	0.7097	0.0000	0/0/0	0.4471							309060 [LAMP2 (confirmed) Danon disease,300257];	RCV000369947.1 [likely benign]; RCV000404849.1 [likely benign]; 			161	55					LAMP2 (inh=XLD pLI=0.95)
chrX	119561929	119561929	A	G	hom	het	wt		QUAL=6634;DP=135,160,82;MQM=60	LAMP2	3'UTR	LAMP2:NM_001122606.1:3'UTR:MODIFIER:exon9/9:c.*410T>C:,LAMP2:NM_002294.2:3'UTR:MODIFIER:exon9/9:c.*3249T>C:		rs41300908	0.0032	0.0000	0/0/0	0.0018							309060 [LAMP2 (confirmed) Danon disease,300257];	RCV000349932.1 [uncertain significance]; RCV000399713.1 [uncertain significance]; 			3	3					LAMP2 (inh=XLD pLI=0.95)
chrX	119563765	119563765	T	C	wt	wt	hom		QUAL=4351;DP=203,242,135;MQM=60	LAMP2	3'UTR,intron	LAMP2:NM_002294.2:3'UTR:MODIFIER:exon9/9:c.*1413A>G:,LAMP2:NM_001122606.1:intron:MODIFIER:exon8/8:c.1094-1284A>G:	(ACTTTT)n	rs773379092	0.0000	0.0000	0/0/0	0.0003							309060 [LAMP2 (confirmed) Danon disease,300257];				1	0					LAMP2 (inh=XLD pLI=0.95)
chrX	119571073	119571073	G	A	wt	wt	hom		QUAL=1592;DP=90,77,53;MQM=60	LAMP2	3'UTR,intron	LAMP2:NM_013995.2:3'UTR:MODIFIER:exon9/9:c.*1936C>T:,LAMP2:NM_001122606.1:intron:MODIFIER:exon8/8:c.1093+4512C>T:,LAMP2:NM_002294.2:intron:MODIFIER:exon8/8:c.1093+4512C>T:		rs14410	0.2715	0.0000	0/0/0	0.0490							309060 [LAMP2 (confirmed) Danon disease,300257];				108	53					LAMP2 (inh=XLD pLI=0.95)
chrX	119571157	119571157	-	AT	hom	het	wt		QUAL=1946;DP=64,34,26;MQM=59	LAMP2	3'UTR,intron	LAMP2:NM_013995.2:3'UTR:MODIFIER:exon9/9:c.*1850_*1851dupAT:,LAMP2:NM_001122606.1:intron:MODIFIER:exon8/8:c.1093+4426_1093+4427dupAT:,LAMP2:NM_002294.2:intron:MODIFIER:exon8/8:c.1093+4426_1093+4427dupAT:	(TA)n	rs755523524;rs765735586	0.3033	0.0000	0/0/0	0.1275							309060 [LAMP2 (confirmed) Danon disease,300257];				19	48					LAMP2 (inh=XLD pLI=0.95)
chrX	119571268	119571269	AA	-	wt	wt	hom		QUAL=1185;DP=52,24,20;MQM=60	LAMP2	3'UTR,intron	LAMP2:NM_013995.2:3'UTR:MODIFIER:exon9/9:c.*1740_*1741delTT:,LAMP2:NM_001122606.1:intron:MODIFIER:exon8/8:c.1093+4316_1093+4317delTT:,LAMP2:NM_002294.2:intron:MODIFIER:exon8/8:c.1093+4316_1093+4317delTT:	A-rich	rs201938539	0.0000	0.0000	0/0/0	0.0287							309060 [LAMP2 (confirmed) Danon disease,300257];				75	71					LAMP2 (inh=XLD pLI=0.95)
chrX	119571268	119571268	A	-	hom	hom	wt		QUAL=1185;DP=52,24,20;MQM=59	LAMP2	3'UTR,intron	LAMP2:NM_013995.2:3'UTR:MODIFIER:exon9/9:c.*1741delT:,LAMP2:NM_001122606.1:intron:MODIFIER:exon8/8:c.1093+4317delT:,LAMP2:NM_002294.2:intron:MODIFIER:exon8/8:c.1093+4317delT:	A-rich	rs10565432;rs879252777	0.0000	0.0000	0/0/0	0.0176							309060 [LAMP2 (confirmed) Danon disease,300257];				6	65					LAMP2 (inh=XLD pLI=0.95)
chrX	119571541	119571541	T	C	hom	hom	hom		QUAL=8117;DP=94,84,67;MQM=60	LAMP2	3'UTR,intron	LAMP2:NM_013995.2:3'UTR:MODIFIER:exon9/9:c.*1468A>G:,LAMP2:NM_001122606.1:intron:MODIFIER:exon8/8:c.1093+4044A>G:,LAMP2:NM_002294.2:intron:MODIFIER:exon8/8:c.1093+4044A>G:		rs42889	0.7889	0.0000	0/0/0	0.0809							309060 [LAMP2 (confirmed) Danon disease,300257];				168	52					LAMP2 (inh=XLD pLI=0.95)
chrX	119572548	119572553	CACACA	-	hom	het	wt	low_DP	QUAL=2592;DP=41,74,19;MQM=59	LAMP2	3'UTR,intron	LAMP2:NM_013995.2:3'UTR:MODIFIER:exon9/9:c.*456_*461delTGTGTG:,LAMP2:NM_001122606.1:intron:MODIFIER:exon8/8:c.1093+3032_1093+3037delTGTGTG:,LAMP2:NM_002294.2:intron:MODIFIER:exon8/8:c.1093+3032_1093+3037delTGTGTG:	(CA)n	rs767342235	0.0000	0.0000	0/0/0	0.0333							309060 [LAMP2 (confirmed) Danon disease,300257];				16	9					LAMP2 (inh=XLD pLI=0.95)
chrX	119572584	119572584	C	-	wt	het	wt	low_DP	QUAL=2592;DP=41,74,19;MQM=59	LAMP2	3'UTR,intron	LAMP2:NM_013995.2:3'UTR:MODIFIER:exon9/9:c.*425delG:,LAMP2:NM_001122606.1:intron:MODIFIER:exon8/8:c.1093+3001delG:,LAMP2:NM_002294.2:intron:MODIFIER:exon8/8:c.1093+3001delG:	(CA)n	rs774013302	0.0005	0.0000	0/0/0	0.0001							309060 [LAMP2 (confirmed) Danon disease,300257];				3	2					LAMP2 (inh=XLD pLI=0.95)
chrX	119572586	119572586	C	-	wt	het	wt	low_DP	QUAL=2592;DP=41,74,19;MQM=59	LAMP2	3'UTR,intron	LAMP2:NM_013995.2:3'UTR:MODIFIER:exon9/9:c.*423delG:,LAMP2:NM_001122606.1:intron:MODIFIER:exon8/8:c.1093+2999delG:,LAMP2:NM_002294.2:intron:MODIFIER:exon8/8:c.1093+2999delG:	(CA)n	rs60325643	0.0000	0.0000	0/0/0	0.0000							309060 [LAMP2 (confirmed) Danon disease,300257];				3	2					LAMP2 (inh=XLD pLI=0.95)
chrX	119572586	119572586	-	ACAAAA	wt	wt	hom	low_DP	QUAL=2592;DP=41,74,19;MQM=58	LAMP2	3'UTR,intron	LAMP2:NM_013995.2:3'UTR:MODIFIER:exon9/9:c.*422_*423insTTTTGT:,LAMP2:NM_001122606.1:intron:MODIFIER:exon8/8:c.1093+2998_1093+2999insTTTTGT:,LAMP2:NM_002294.2:intron:MODIFIER:exon8/8:c.1093+2998_1093+2999insTTTTGT:	(CA)n	rs576233822	0.0000	0.0000	0/0/0	0.0859							309060 [LAMP2 (confirmed) Danon disease,300257];				29	18					LAMP2 (inh=XLD pLI=0.95)
chrX	119576455	119576455	G	A	wt	wt	hom		QUAL=3380;DP=176,194,107;MQM=60	LAMP2	splice_region&synonymous	LAMP2:NM_001122606.1:splice_region&synonymous:LOW:exon7/9:c.927C>T:p.Ser309Ser,LAMP2:NM_002294.2:splice_region&synonymous:LOW:exon7/9:c.927C>T:p.Ser309Ser,LAMP2:NM_013995.2:splice_region&synonymous:LOW:exon7/9:c.927C>T:p.Ser309Ser		rs73219144	0.0132	0.0275	27/20/0	0.0255							309060 [LAMP2 (confirmed) Danon disease,300257];	RCV000037435.4 [benign]; RCV000242368.1 [benign]; RCV000280231.1 [likely benign]; RCV000374719.1 [likely benign]; 			53	47					LAMP2 (inh=XLD pLI=0.95)
chrX	119590533	119590533	T	A	hom	het	hom		QUAL=3226;DP=53,37,36;MQM=60	LAMP2	synonymous	LAMP2:NM_001122606.1:synonymous:LOW:exon2/9:c.156A>T:p.Val52Val,LAMP2:NM_002294.2:synonymous:LOW:exon2/9:c.156A>T:p.Val52Val,LAMP2:NM_013995.2:synonymous:LOW:exon2/9:c.156A>T:p.Val52Val		rs12097	0.3809	0.4280	4103/2443/431	0.3689							309060 [LAMP2 (confirmed) Danon disease,300257];	RCV000037405.9 [benign]; RCV000253949.1 [benign]; RCV000346704.1 [likely benign]; RCV000399625.1 [likely benign]; 		COSM4156558, COSM4156557, COSM4156559	610	323					LAMP2 (inh=XLD pLI=0.95)
chrX	122318386	122318386	-	G	hom	hom	hom		QUAL=7216;DP=67,96,78;MQM=59	GRIA3	5'UTR	GRIA3:NM_000828.4:5'UTR:MODIFIER:exon1/16:c.-2_-1insG:,GRIA3:NM_001256743.1:5'UTR:MODIFIER:exon1/4:c.-2_-1insG:,GRIA3:NM_007325.4:5'UTR:MODIFIER:exon1/16:c.-2_-1insG:		rs58044961	1.0000	1.0000	27060/14630/3313	0.9018							305915 [GRIA3 (confirmed) Mental retardation,X-linked 94,300699];				1751	0					GRIA3 (inh=XLR pLI=1.00)
chrX	122336600	122336600	-	G	hom	hom	hom	anno_high_impact	QUAL=17088;DP=94,332,192;MQM=59	GRIA3	frameshift,intron	GRIA3:NM_001256743.1:frameshift:HIGH:exon3/4:c.384dupG:p.Pro129fs,GRIA3:NM_000828.4:intron:MODIFIER:exon2/15:c.268+16761dupG:,GRIA3:NM_007325.4:intron:MODIFIER:exon2/15:c.268+16761dupG:		rs11452643	0.9995	1.0000	3156/1449/286	0.2340							305915 [GRIA3 (confirmed) Mental retardation,X-linked 94,300699];				1530	95	1	[1] auto-classification 16.06.2016  [2] old entry - no details available		n/a (14.10.13, UG)	GRIA3 (inh=XLR pLI=1.00)
chrX	122622934	122622937	ACAC	-	hom	hom	wt	low_DP	QUAL=2886;DP=86,33,18;MQM=59	GRIA3	3'UTR	GRIA3:NM_000828.4:3'UTR:MODIFIER:exon16/16:c.*404_*407delCACA:,GRIA3:NM_007325.4:3'UTR:MODIFIER:exon16/16:c.*404_*407delCACA:	(AC)n	rs201935330	0.0000	0.0000	0/0/0	0.0416							305915 [GRIA3 (confirmed) Mental retardation,X-linked 94,300699];				13	13					GRIA3 (inh=XLR pLI=1.00)
chrX	122622933	122622933	-	AC	wt	wt	hom	low_DP	QUAL=2886;DP=86,33,18;MQM=60	GRIA3	3'UTR	GRIA3:NM_000828.4:3'UTR:MODIFIER:exon16/16:c.*406_*407dupCA:,GRIA3:NM_007325.4:3'UTR:MODIFIER:exon16/16:c.*406_*407dupCA:		rs34745333;rs764125150	0.0000	0.0000	0/0/0	0.1550							305915 [GRIA3 (confirmed) Mental retardation,X-linked 94,300699];				19	104					GRIA3 (inh=XLR pLI=1.00)
chrX	122993745	122993745	C	T	wt	wt	hom	low_DP	QUAL=333;DP=5,19,13;MQM=60	XIAP	5'UTR_premature_start_codon_gain,5'UTR	XIAP:NM_001204401.1:5'UTR_premature_start_codon_gain:LOW:exon1/7:c.-43C>T:,XIAP:NM_001204401.1:5'UTR:MODIFIER:exon1/7:c.-43C>T:		rs28382701	0.0286	0.0000	0/0/0	0.0432							300079 [XIAP (confirmed) Lymphoproliferative syndrome,X-linked,2,300635];				9	10					XIAP (inh=n/a pLI=0.98)
chrX	123034511	123034511	A	C	hom	hom	hom	pred_pathogenic	QUAL=10416;DP=76,145,103;MQM=60	XIAP	missense,non_coding_transcript_exon	XIAP:NM_001167.3:missense:MODERATE:exon6/7:c.1268A>C:p.Gln423Pro,XIAP:NM_001204401.1:missense:MODERATE:exon6/7:c.1268A>C:p.Gln423Pro,XIAP:NR_037916.1:non_coding_transcript_exon:MODIFIER:exon5/6:n.518A>C:		rs5956583	0.3036	0.3334	3387/1917/724	0.3084	2.0790	D,D,D	T	B	T,T,T	6.08	300079 [XIAP (confirmed) Lymphoproliferative syndrome,X-linked,2,300635];	RCV000249776.1 [benign]; RCV000328885.1 [benign]; 	CM097066 [CLASS=DFP MUT=REF PHEN="Periodic fever idiopathic association with" GENE=XIAP]; 	COSM3759346	464	294					XIAP (inh=n/a pLI=0.98)
chrX	123041111	123041111	G	C	wt	wt	hom		QUAL=3404;DP=175,195,116;MQM=56	XIAP	3'UTR,non_coding_transcript_exon	XIAP:NM_001167.3:3'UTR:MODIFIER:exon7/7:c.*80G>C:,XIAP:NM_001204401.1:3'UTR:MODIFIER:exon7/7:c.*80G>C:,XIAP:NR_037916.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.824G>C:		rs12838858	0.0297	0.0868	91/71/0	0.0533							300079 [XIAP (confirmed) Lymphoproliferative syndrome,X-linked,2,300635];	RCV000288875.1 [benign]; 			57	38					XIAP (inh=n/a pLI=0.98)
chrX	123042989	123042989	G	A	wt	wt	hom	low_DP	QUAL=171;DP=59,9,8;MQM=60	XIAP	3'UTR,non_coding_transcript_exon	XIAP:NM_001167.3:3'UTR:MODIFIER:exon7/7:c.*1958G>A:,XIAP:NM_001204401.1:3'UTR:MODIFIER:exon7/7:c.*1958G>A:,XIAP:NR_037916.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.2702G>A:	AluSz	rs41309540	0.0228	0.0000	0/0/0	0.0074							300079 [XIAP (confirmed) Lymphoproliferative syndrome,X-linked,2,300635];	RCV000276604.1 [benign]; 			40	26					XIAP (inh=n/a pLI=0.98)
chrX	123044718	123044718	A	-	het	wt	het	low_QUAL;low_DP	QUAL=9;DP=37,12,12;MQM=51	XIAP	3'UTR,non_coding_transcript_exon	XIAP:NM_001167.3:3'UTR:MODIFIER:exon7/7:c.*3702delA:,XIAP:NM_001204401.1:3'UTR:MODIFIER:exon7/7:c.*3702delA:,XIAP:NR_037916.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.4446delA:	AluY	rs762891006	0.0000	0.2248	0/0/0	0.0001							300079 [XIAP (confirmed) Lymphoproliferative syndrome,X-linked,2,300635];				0	90					XIAP (inh=n/a pLI=0.98)
chrX	123045327	123045327	-	A	hom	hom	het	low_DP	QUAL=303;DP=7,9,3;MQM=57	XIAP	3'UTR,non_coding_transcript_exon	XIAP:NM_001167.3:3'UTR:MODIFIER:exon7/7:c.*4309dupA:,XIAP:NM_001204401.1:3'UTR:MODIFIER:exon7/7:c.*4309dupA:,XIAP:NR_037916.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.5053dupA:	AluSp	rs34868593;rs397713705;rs748304435	0.3038	0.2433	7/1/0	0.0385							300079 [XIAP (confirmed) Lymphoproliferative syndrome,X-linked,2,300635];	RCV000319477.1 [uncertain significance]; RCV000261920.1 [benign]; 			25	200					XIAP (inh=n/a pLI=0.98)
chrX	123045641	123045641	C	T	hom	hom	hom		QUAL=8498;DP=94,93,76;MQM=59	XIAP	3'UTR,non_coding_transcript_exon	XIAP:NM_001167.3:3'UTR:MODIFIER:exon7/7:c.*4610C>T:,XIAP:NM_001204401.1:3'UTR:MODIFIER:exon7/7:c.*4610C>T:,XIAP:NR_037916.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.5354C>T:		rs9856	0.5844	0.5800	488/185/19	0.1102							300079 [XIAP (confirmed) Lymphoproliferative syndrome,X-linked,2,300635];	RCV000279320.1 [benign]; 			282	106					XIAP (inh=n/a pLI=0.98)
chrX	123046272	123046272	A	T	hom	hom	hom		QUAL=10487;DP=169,105,57;MQM=59	XIAP	3'UTR,non_coding_transcript_exon	XIAP:NM_001167.3:3'UTR:MODIFIER:exon7/7:c.*5241A>T:,XIAP:NM_001204401.1:3'UTR:MODIFIER:exon7/7:c.*5241A>T:,XIAP:NR_037916.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.5985A>T:	MER2	rs5958343	0.5846	0.5797	487/184/19	0.1099							300079 [XIAP (confirmed) Lymphoproliferative syndrome,X-linked,2,300635];	RCV000299858.1 [benign]; 			288	107					XIAP (inh=n/a pLI=0.98)
chrX	123046537	123046537	T	-	hom	hom	hom		QUAL=2729;DP=93,40,25;MQM=59	XIAP	3'UTR,non_coding_transcript_exon	XIAP:NM_001167.3:3'UTR:MODIFIER:exon7/7:c.*5519delT:,XIAP:NM_001204401.1:3'UTR:MODIFIER:exon7/7:c.*5519delT:,XIAP:NR_037916.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.6263delT:	AluSz	rs374013599	0.2490	0.3974	4/4/0	0.0281							300079 [XIAP (confirmed) Lymphoproliferative syndrome,X-linked,2,300635];	RCV000330402.1 [benign]; 			38	229					XIAP (inh=n/a pLI=0.98)
chrX	123046923	123046923	T	G	hom	hom	hom		QUAL=5354;DP=53,74,47;MQM=59	XIAP	3'UTR,non_coding_transcript_exon	XIAP:NM_001167.3:3'UTR:MODIFIER:exon7/7:c.*5892T>G:,XIAP:NM_001204401.1:3'UTR:MODIFIER:exon7/7:c.*5892T>G:,XIAP:NR_037916.1:non_coding_transcript_exon:MODIFIER:exon6/6:n.6636T>G:	AluSx	rs6648556	0.6212	0.6683	480/173/24	0.1100							300079 [XIAP (confirmed) Lymphoproliferative syndrome,X-linked,2,300635];	RCV000381680.1 [benign]; 			277	109					XIAP (inh=n/a pLI=0.98)
chrX	123480147	123480147	C	T	wt	wt	hom		QUAL=3943;DP=127,244,132;MQM=60	SH2D1A	5'UTR_premature_start_codon_gain,5'UTR	SH2D1A:NM_002351.4:5'UTR_premature_start_codon_gain:LOW:exon1/4:c.-346C>T:,SH2D1A:NM_001114937.2:5'UTR_premature_start_codon_gain:LOW:exon1/4:c.-346C>T:,SH2D1A:NM_002351.4:5'UTR:MODIFIER:exon1/4:c.-346C>T:,SH2D1A:NM_001114937.2:5'UTR:MODIFIER:exon1/4:c.-346C>T:		rs12164382	0.5211	0.0000	0/0/0	0.0566							300490 [SH2D1A (confirmed) Lymphoproliferative syndrome,X-linked,1,308240];	RCV000314167.1 [benign]; 	CR126383 [CLASS=DFP MUT=ALT PHEN="Lymphoproliferative syndrome in males association with" GENE=SH2D1A]; 		117	57					SH2D1A (inh=XLR pLI=0.08)
chrX	123505440	123505440	A	-	wt	wt	hom		QUAL=2040;DP=123,104,67;MQM=60	SH2D1A	3'UTR	SH2D1A:NM_002351.4:3'UTR:MODIFIER:exon4/4:c.*203delA:,SH2D1A:NM_001114937.2:3'UTR:MODIFIER:exon4/4:c.*203delA:		rs398087910	0.1348	0.0000	0/0/0	0.0894							300490 [SH2D1A (confirmed) Lymphoproliferative syndrome,X-linked,1,308240];	RCV000324639.1 [benign]; 			25	23					SH2D1A (inh=XLR pLI=0.08)
chrX	123506104	123506104	T	A	hom	hom	wt		QUAL=6225;DP=102,87,57;MQM=60	SH2D1A	3'UTR	SH2D1A:NM_002351.4:3'UTR:MODIFIER:exon4/4:c.*863T>A:,SH2D1A:NM_001114937.2:3'UTR:MODIFIER:exon4/4:c.*863T>A:		rs7876065	0.8140	0.0000	0/0/0	0.1043							300490 [SH2D1A (confirmed) Lymphoproliferative syndrome,X-linked,1,308240];	RCV000398926.1 [benign]; 			269	30					SH2D1A (inh=XLR pLI=0.08)
chrX	123506562	123506562	A	G	wt	wt	hom		QUAL=12044;DP=318,547,378;MQM=60	SH2D1A	3'UTR	SH2D1A:NM_002351.4:3'UTR:MODIFIER:exon4/4:c.*1321A>G:,SH2D1A:NM_001114937.2:3'UTR:MODIFIER:exon4/4:c.*1321A>G:	MamRep605	rs6649207	0.1886	0.0000	0/0/0	0.0195							300490 [SH2D1A (confirmed) Lymphoproliferative syndrome,X-linked,1,308240];	RCV000399159.1 [benign]; 			22	23					SH2D1A (inh=XLR pLI=0.08)
chrX	128724525	128724525	G	A	wt	het	wt		QUAL=4005;DP=226,287,205;MQM=60	OCRL	3'UTR	OCRL:NM_001318784.1:3'UTR:MODIFIER:exon24/24:c.*278G>A:,OCRL:NM_000276.3:3'UTR:MODIFIER:exon24/24:c.*278G>A:,OCRL:NM_001587.3:3'UTR:MODIFIER:exon23/23:c.*278G>A:		rs2071706	0.1661	0.0000	0/0/0	0.1487							300535 [OCRL (confirmed) Lowe syndrome,309000|Dent disease 2,300555];				63	42					OCRL (inh=XLR pLI=1.00)
chrX	128938958	128938958	T	C	hom	hom	hom		QUAL=15207;DP=218,156,106;MQM=59	ZDHHC9	3'UTR	ZDHHC9:NM_001008222.2:3'UTR:MODIFIER:exon10/10:c.*1388A>G:,ZDHHC9:NM_016032.3:3'UTR:MODIFIER:exon11/11:c.*1388A>G:		rs1053486	0.6196	0.0000	0/0/0	0.1025							300646 [ZDHHC9 (confirmed) Mental retardation,X-linked syndromic,Raymond type,300799];				314	10					ZDHHC9 (inh=n/a pLI=0.89)
chrX	128939695	128939695	T	C	wt	wt	hom		QUAL=3729;DP=136,178,119;MQM=60	ZDHHC9	3'UTR	ZDHHC9:NM_001008222.2:3'UTR:MODIFIER:exon10/10:c.*651A>G:,ZDHHC9:NM_016032.3:3'UTR:MODIFIER:exon11/11:c.*651A>G:		rs11990	0.0482	0.0000	0/0/0	0.0749							300646 [ZDHHC9 (confirmed) Mental retardation,X-linked syndromic,Raymond type,300799];				40	22					ZDHHC9 (inh=n/a pLI=0.89)
chrX	129283520	129283520	A	G	hom	hom	hom		QUAL=16470;DP=180,204,134;MQM=60	AIFM1	synonymous,non_coding_transcript_exon	AIFM1:NM_004208.3:synonymous:LOW:exon3/16:c.273T>C:p.Asp91Asp,AIFM1:NM_001130847.3:synonymous:LOW:exon3/17:c.273T>C:p.Asp91Asp,AIFM1:NM_145812.2:synonymous:LOW:exon3/16:c.261T>C:p.Asp87Asp,AIFM1:NR_132647.1:non_coding_transcript_exon:MODIFIER:exon2/16:n.361T>C:		rs1139851	0.4911	0.4329	5607/2478/1687	0.4003							300169 [AIFM1 (confirmed) Combined oxidative phosphorylation deficiency 6,300816|Cowchock syndrome,310490|Deafness,X-linked 5,300614];	RCV000373191.1 [benign]; 		COSM1465605, COSM1465604	597	313					AIFM1 (inh=XLR pLI=0.98)
chrX	132838306	132838306	A	-	het	wt	het		QUAL=139;DP=71,71,67;MQM=59	GPC3	splice_region&intron,intron	GPC3:NM_001164617.1:splice_region&intron:LOW:exon3/8:c.1033-5delT:,GPC3:NM_001164618.1:intron:MODIFIER:exon3/7:c.985-4250delT:,GPC3:NM_001164619.1:intron:MODIFIER:exon2/6:c.871-4250delT:,GPC3:NM_004484.3:intron:MODIFIER:exon3/7:c.1033-4250delT:		rs374169314	0.0000	0.3076	0/0/0	0.0321							300037 [GPC3 (confirmed) Simpson-Golabi-Behmel syndrome,type 1,312870|Wilms tumor,somatic,194070];			COSM1625536	5	232					GPC3 (inh=XLR pLI=0.99)
chrX	132888208	132888208	A	-	wt	het	wt		QUAL=242;DP=48,49,22;MQM=59	GPC3	splice_region&intron	GPC3:NM_001164617.1:splice_region&intron:LOW:exon2/8:c.338-5delT:,GPC3:NM_001164618.1:splice_region&intron:LOW:exon2/7:c.290-5delT:,GPC3:NM_001164619.1:splice_region&intron:LOW:exon1/6:c.176-5delT:,GPC3:NM_004484.3:splice_region&intron:LOW:exon2/7:c.338-5delT:	A-rich	rs370737647	0.0000	0.3293	5/0/0	0.0010							300037 [GPC3 (confirmed) Simpson-Golabi-Behmel syndrome,type 1,312870|Wilms tumor,somatic,194070];	RCV000202708.1 [benign]; 			12	197				n/a (02.03.2015, TCB: Poly A, Position nicht auswertbar, auch in Kontrolle.)	GPC3 (inh=XLR pLI=0.99)
chrX	133560121	133560121	-	T	wt	het	wt		QUAL=1461;DP=174,139,89;MQM=60	PHF6	3'UTR	PHF6:NM_001015877.1:3'UTR:MODIFIER:exon11/11:c.*440dupT:,PHF6:NM_032458.2:3'UTR:MODIFIER:exon10/10:c.*770dupT:		rs771886074	0.4609	0.0000	0/0/0	0.1896							300414 [PHF6 (confirmed) Borjeson-Forssman-Lehmann syndrome,301900];				59	47					PHF6 (inh=XLR pLI=0.97)
chrX	133561092	133561092	-	T	wt	het	wt		QUAL=664;DP=134,72,57;MQM=60	PHF6	3'UTR	PHF6:NM_001015877.1:3'UTR:MODIFIER:exon11/11:c.*1411dupT:,PHF6:NM_032458.2:3'UTR:MODIFIER:exon10/10:c.*1741dupT:		rs397894938	0.4225	0.0000	0/0/0	0.1582							300414 [PHF6 (confirmed) Borjeson-Forssman-Lehmann syndrome,301900];				55	44					PHF6 (inh=XLR pLI=0.97)
chrX	133561242	133561242	G	A	wt	het	wt		QUAL=864;DP=113,82,50;MQM=60	PHF6	3'UTR	PHF6:NM_001015877.1:3'UTR:MODIFIER:exon11/11:c.*1552G>A:,PHF6:NM_032458.2:3'UTR:MODIFIER:exon10/10:c.*1882G>A:		rs6638230	0.4246	0.0000	0/0/0	0.0364							300414 [PHF6 (confirmed) Borjeson-Forssman-Lehmann syndrome,301900];				61	39					PHF6 (inh=XLR pLI=0.97)
chrX	133594186	133594186	C	G	wt	hom	wt	low_DP	QUAL=50;DP=113,3,1;MQM=60	HPRT1	5'UTR	HPRT1:NM_000194.2:5'UTR:MODIFIER:exon1/9:c.-156C>G:		rs193054558	0.2413	0.0000	0/0/0	0.0183							308000 [HPRT1 (confirmed) Lesch-Nyhan syndrome,300322|HPRT-related gout,300323];				8	12					HPRT1 (inh=XLR pLI=0.92)
chrX	135251679	135251679	-	A	hom	hom	wt		QUAL=4123;DP=104,56,39;MQM=59	FHL1	5'UTR,intron	FHL1:NM_001159704.1:5'UTR:MODIFIER:exon1/6:c.-478dupA:,FHL1:NM_001159702.2:intron:MODIFIER:exon1/7:c.-100-378dupA:,FHL1:NR_027621.1:intron:MODIFIER:exon1/6:n.312-378dupA:,FHL1:NM_001159703.1:intron:MODIFIER:exon1/5:c.-100-378dupA:,FHL1:NM_001449.4:intron:MODIFIER:exon1/6:c.-100-378dupA:,FHL1:NM_001159700.1:intron:MODIFIER:exon1/6:c.-100-378dupA:		rs397710404;rs760593394	0.0000	0.0000	0/0/0	0.3150							300163 [FHL1 (confirmed) Scapuloperoneal myopathy,X-linked dominant,300695|Myopathy,X-linked,with postural muscle atrophy,300696|Reducing body myopathy,X-linked 1a,severe,infantile or early childhood onset,300717|Reducing body myopathy,X-linked 1b,with late childhood or adult onset,300718|Emery-Dreifuss muscular dystrophy 6,X-linked,300696];				162	126					FHL1 (inh=n/a pLI=0.92)
chrX	135292022	135292022	C	T	hom	hom	hom		QUAL=11269;DP=96,140,133;MQM=59	FHL1	splice_region&intron	FHL1:NM_001159702.2:splice_region&intron:LOW:exon7/7:c.889-8C>T:,FHL1:NR_027621.1:splice_region&intron:LOW:exon6/6:n.1100-8C>T:,FHL1:NM_001159703.1:splice_region&intron:LOW:exon5/5:c.502-8C>T:,FHL1:NM_001449.4:splice_region&intron:LOW:exon6/6:c.689-8C>T:,FHL1:NM_001159700.1:splice_region&intron:LOW:exon6/6:c.689-8C>T:,FHL1:NM_001159704.1:splice_region&intron:LOW:exon5/5:c.689-8C>T:,FHL1:NM_001167819.1:splice_region&intron:LOW:exon6/6:c.689-8C>T:,FHL1:NM_001159701.1:splice_region&intron:LOW:exon5/5:c.776-8C>T:,FHL1:NM_001159699.1:splice_region&intron:LOW:exon5/5:c.737-8C>T:	(TTTCT)n	rs2076705	0.5197	0.4945	6087/3308/376	0.4202							300163 [FHL1 (confirmed) Scapuloperoneal myopathy,X-linked dominant,300695|Myopathy,X-linked,with postural muscle atrophy,300696|Reducing body myopathy,X-linked 1a,severe,infantile or early childhood onset,300717|Reducing body myopathy,X-linked 1b,with late childhood or adult onset,300718|Emery-Dreifuss muscular dystrophy 6,X-linked,300696];	RCV000179824.3 [benign]; 			688	324					FHL1 (inh=n/a pLI=0.92)
chrX	135292164	135292164	G	A	hom	het	wt	pred_pathogenic	QUAL=8223;DP=187,205,149;MQM=59	FHL1	missense,3'UTR,non_coding_transcript_exon	FHL1:NM_001449.4:missense:MODERATE:exon7/7:c.823G>A:p.Asp275Asn,FHL1:NM_001159700.1:missense:MODERATE:exon7/7:c.823G>A:p.Asp275Asn,FHL1:NM_001159704.1:missense:MODERATE:exon6/6:c.823G>A:p.Asp275Asn,FHL1:NM_001167819.1:missense:MODERATE:exon7/7:c.823G>A:p.Asp275Asn,FHL1:NM_001159701.1:missense:MODERATE:exon6/6:c.910G>A:p.Asp304Asn,FHL1:NM_001159699.1:missense:MODERATE:exon6/6:c.871G>A:p.Asp291Asn,FHL1:NM_001159702.2:3'UTR:MODIFIER:exon8/8:c.*51G>A:,FHL1:NM_001159703.1:3'UTR:MODIFIER:exon6/6:c.*51G>A:,FHL1:NR_027621.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.1234G>A:		rs151315725	0.0048	0.0113	10/10/0	0.0105	6.2260	D,D,D,D,D,D,D,D,D	T	B,B	D,D,D,D,D,D	15.77	300163 [FHL1 (confirmed) Scapuloperoneal myopathy,X-linked dominant,300695|Myopathy,X-linked,with postural muscle atrophy,300696|Reducing body myopathy,X-linked 1a,severe,infantile or early childhood onset,300717|Reducing body myopathy,X-linked 1b,with late childhood or adult onset,300718|Emery-Dreifuss muscular dystrophy 6,X-linked,300696];	RCV000228514.1 [benign]; RCV000296313.1 [benign]; 			13	14					FHL1 (inh=n/a pLI=0.92)
chrX	135293082	135293082	G	A	hom	hom	hom		QUAL=18935;DP=226,214,141;MQM=60	FHL1	3'UTR,non_coding_transcript_exon	FHL1:NM_001159702.2:3'UTR:MODIFIER:exon8/8:c.*969G>A:,FHL1:NM_001159703.1:3'UTR:MODIFIER:exon6/6:c.*969G>A:,FHL1:NM_001449.4:3'UTR:MODIFIER:exon7/7:c.*898G>A:,FHL1:NM_001159700.1:3'UTR:MODIFIER:exon7/7:c.*898G>A:,FHL1:NM_001159704.1:3'UTR:MODIFIER:exon6/6:c.*898G>A:,FHL1:NM_001167819.1:3'UTR:MODIFIER:exon7/7:c.*898G>A:,FHL1:NM_001159701.1:3'UTR:MODIFIER:exon6/6:c.*898G>A:,FHL1:NM_001159699.1:3'UTR:MODIFIER:exon6/6:c.*898G>A:,FHL1:NR_027621.1:non_coding_transcript_exon:MODIFIER:exon7/7:n.2152G>A:		rs9018	0.5068	0.4787	353/142/6	0.0967							300163 [FHL1 (confirmed) Scapuloperoneal myopathy,X-linked dominant,300695|Myopathy,X-linked,with postural muscle atrophy,300696|Reducing body myopathy,X-linked 1a,severe,infantile or early childhood onset,300717|Reducing body myopathy,X-linked 1b,with late childhood or adult onset,300718|Emery-Dreifuss muscular dystrophy 6,X-linked,300696];				303	121					FHL1 (inh=n/a pLI=0.92)
chrX	135742076	135742076	G	C	het	wt	wt		QUAL=396;DP=50,28,20;MQM=52	CD40LG	3'UTR	CD40LG:NM_000074.2:3'UTR:MODIFIER:exon5/5:c.*502G>C:			0.0000	0.0000	0/0/0	0.0000							300386 [CD40LG (confirmed) Immunodeficiency,X-linked,with hyper-IgM,308230];				0	5					CD40LG (inh=XLR pLI=0.86)
chrX	135742096	135742096	G	C	hom	hom	hom	low_DP	QUAL=362;DP=19,10,6;MQM=52	CD40LG	3'UTR	CD40LG:NM_000074.2:3'UTR:MODIFIER:exon5/5:c.*522G>C:	(C)n	rs867476242	0.0000	0.0000	0/0/0	0.0002							300386 [CD40LG (confirmed) Immunodeficiency,X-linked,with hyper-IgM,308230];				0	17					CD40LG (inh=XLR pLI=0.86)
chrX	135742258	135742258	C	T	hom	het	wt		QUAL=2129;DP=61,44,35;MQM=58	CD40LG	3'UTR	CD40LG:NM_000074.2:3'UTR:MODIFIER:exon5/5:c.*684C>T:	(TC)n	rs779484195	0.0029	0.0000	0/0/0	0.0030							300386 [CD40LG (confirmed) Immunodeficiency,X-linked,with hyper-IgM,308230];				1	2					CD40LG (inh=XLR pLI=0.86)
chrX	138644836	138644836	G	A	wt	wt	hom		QUAL=2686;DP=85,121,86;MQM=60	F9	3'UTR	F9:NM_000133.3:3'UTR:MODIFIER:exon8/8:c.*606G>A:,F9:NM_001313913.1:3'UTR:MODIFIER:exon7/7:c.*606G>A:		rs191483077	0.0011	0.0000	0/0/0	0.0026							300746 [F9 (confirmed) Hemophilia B,306900|Warfarin sensitivity,122700|Thrombophilia,X-linked,due to factor IX defect,300807|Deep venous thrombosis,protection against,300807];	RCV000366729.1 [likely benign]; 			1	0					F9 (inh=n/a pLI=0.99)
chrX	139586494	139586494	T	G	wt	het	wt	low_QUAL;low_DP	QUAL=12;DP=6,12,10;MQM=60	SOX3	synonymous	SOX3:NM_005634.2:synonymous:LOW:exon1/1:c.732A>C:p.Ala244Ala	(GGC)n	rs45451393	0.0217	0.0186	4/0/0	0.0046							313430 [SOX3 (confirmed) Mental retardation,X-linked,with isolated growth hormone deficiency,300123|Panhypopituitarism,X-linked,312000];	RCV000081320.4 [benign]; 		COSM1559871	13	24					SOX3 (inh=XLR pLI=n/a)
chrX	139586617	139586617	A	G	wt	het	wt		QUAL=3453;DP=81,306,182;MQM=60	SOX3	synonymous	SOX3:NM_005634.2:synonymous:LOW:exon1/1:c.609T>C:p.Tyr203Tyr		rs45586631	0.0220	0.0331	68/14/0	0.0296							313430 [SOX3 (confirmed) Mental retardation,X-linked,with isolated growth hormone deficiency,300123|Panhypopituitarism,X-linked,312000];	RCV000081319.4 [benign]; 		COSM456868	18	27					SOX3 (inh=XLR pLI=n/a)
chrX	147010320	147010320	G	A	wt	het	wt		QUAL=1421;DP=137,97,64;MQM=60	FMR1	synonymous,non_coding_transcript_exon	FMR1:NM_002024.5:synonymous:LOW:exon5/17:c.414G>A:p.Arg138Arg,FMR1:NM_001185075.1:synonymous:LOW:exon5/16:c.414G>A:p.Arg138Arg,FMR1:NM_001185076.1:synonymous:LOW:exon5/16:c.414G>A:p.Arg138Arg,FMR1:NM_001185081.1:synonymous:LOW:exon5/15:c.414G>A:p.Arg138Arg,FMR1:NM_001185082.1:synonymous:LOW:exon5/16:c.414G>A:p.Arg138Arg,FMR1:NR_033699.1:non_coding_transcript_exon:MODIFIER:exon5/16:n.643G>A:,FMR1:NR_033700.1:non_coding_transcript_exon:MODIFIER:exon5/15:n.643G>A:		rs25707	0.0996	0.0868	298/131/122	0.0808							309550 [FMR1 (confirmed) Fragile X syndrome,300624|Fragile X tremor/ataxia syndrome,300623|Premature ovarian failure 1,311360];	RCV000079966.7 [other]; 		COSM3759387, COSM3759386	105	110					FMR1 (inh=XLD pLI=0.13)
chrX	147031538	147031538	C	T	hom	hom	hom		QUAL=4529;DP=70,40,30;MQM=60	FMR1	3'UTR,non_coding_transcript_exon	FMR1:NM_002024.5:3'UTR:MODIFIER:exon17/17:c.*1174C>T:,FMR1:NM_001185075.1:3'UTR:MODIFIER:exon16/16:c.*1188C>T:,FMR1:NM_001185076.1:3'UTR:MODIFIER:exon16/16:c.*1174C>T:,FMR1:NM_001185081.1:3'UTR:MODIFIER:exon15/15:c.*1188C>T:,FMR1:NM_001185082.1:3'UTR:MODIFIER:exon16/16:c.*1174C>T:,FMR1:NR_033699.1:non_coding_transcript_exon:MODIFIER:exon16/16:n.3106C>T:,FMR1:NR_033700.1:non_coding_transcript_exon:MODIFIER:exon15/15:n.3043C>T:		rs25704	0.4956	0.2834	228/49/73	0.0628							309550 [FMR1 (confirmed) Fragile X syndrome,300624|Fragile X tremor/ataxia syndrome,300623|Premature ovarian failure 1,311360];		CR114249 [CLASS=DP MUT=ALT PHEN="Epithelial ovarian cancer increased risk association" GENE=FMR1]; 		160	90					FMR1 (inh=XLD pLI=0.13)
chrX	147800748	147800748	A	G	wt	wt	hom		QUAL=5882;DP=136,339,190;MQM=60	AFF2	missense,intron	AFF2:NM_001170628.1:missense:MODERATE:exon1/18:c.44A>G:p.Lys15Arg,AFF2:NM_002025.3:intron:MODIFIER:exon3/20:c.1041+56459A>G:,AFF2:NM_001169122.1:intron:MODIFIER:exon3/19:c.1029+56459A>G:,AFF2:NM_001169123.1:intron:MODIFIER:exon3/20:c.1029+56459A>G:,AFF2:NM_001169124.1:intron:MODIFIER:exon3/19:c.1041+56459A>G:,AFF2:NM_001169125.1:intron:MODIFIER:exon3/19:c.1029+56459A>G:		rs241084	0.2811	0.2526	376/129/209	0.0594	-0.1730	T	T	B	T	1.09	300806 [AFF2 (provisional) Mental retardation,X-linked,FRAXE type,309548];			COSM3843803	265	222					AFF2 (inh=XLR pLI=1.00)
chrX	148035200	148035200	G	A	wt	wt	hom		QUAL=4368;DP=171,271,145;MQM=60	AFF2	synonymous	AFF2:NM_002025.3:synonymous:LOW:exon10/21:c.1488G>A:p.Ser496Ser,AFF2:NM_001169122.1:synonymous:LOW:exon9/20:c.1389G>A:p.Ser463Ser,AFF2:NM_001169123.1:synonymous:LOW:exon10/21:c.1458G>A:p.Ser486Ser,AFF2:NM_001169124.1:synonymous:LOW:exon9/20:c.1383G>A:p.Ser461Ser,AFF2:NM_001169125.1:synonymous:LOW:exon9/20:c.1371G>A:p.Ser457Ser,AFF2:NM_001170628.1:synonymous:LOW:exon7/18:c.411G>A:p.Ser137Ser		rs12011040	0.1420	0.0735	591/26/542	0.0635							300806 [AFF2 (provisional) Mental retardation,X-linked,FRAXE type,309548];	RCV000116243.2 [benign]; 			53	59					AFF2 (inh=XLR pLI=1.00)
chrX	148055144	148055144	A	G	hom	hom	hom		QUAL=15818;DP=88,256,160;MQM=60	AFF2	splice_region&intron	AFF2:NM_002025.3:splice_region&intron:LOW:exon16/20:c.3404+7A>G:,AFF2:NM_001169122.1:splice_region&intron:LOW:exon15/19:c.3299+7A>G:,AFF2:NM_001169123.1:splice_region&intron:LOW:exon16/20:c.3374+7A>G:,AFF2:NM_001169124.1:splice_region&intron:LOW:exon15/19:c.3299+7A>G:,AFF2:NM_001169125.1:splice_region&intron:LOW:exon15/19:c.3287+7A>G:,AFF2:NM_001170628.1:splice_region&intron:LOW:exon13/17:c.2327+7A>G:		rs5980615	0.9542	0.9829	25940/14606/2279	0.8886							300806 [AFF2 (provisional) Mental retardation,X-linked,FRAXE type,309548];	RCV000079971.10 [other]; 			1734	4					AFF2 (inh=XLR pLI=1.00)
chrX	148079639	148079639	A	C	hom	hom	hom		QUAL=12505;DP=141,139,98;MQM=60	AFF2	3'UTR	AFF2:NM_002025.3:3'UTR:MODIFIER:exon21/21:c.*6777A>C:,AFF2:NM_001169122.1:3'UTR:MODIFIER:exon20/20:c.*6777A>C:,AFF2:NM_001169123.1:3'UTR:MODIFIER:exon21/21:c.*6777A>C:,AFF2:NM_001169124.1:3'UTR:MODIFIER:exon20/20:c.*6777A>C:,AFF2:NM_001169125.1:3'UTR:MODIFIER:exon20/20:c.*6777A>C:,AFF2:NM_001170628.1:3'UTR:MODIFIER:exon18/18:c.*6777A>C:		rs16994920	0.8760	0.0000	0/0/0	0.1080							300806 [AFF2 (provisional) Mental retardation,X-linked,FRAXE type,309548];				305	13					AFF2 (inh=XLR pLI=1.00)
chrX	148079740	148079740	A	C	hom	hom	hom		QUAL=18890;DP=161,265,160;MQM=60	AFF2	3'UTR	AFF2:NM_002025.3:3'UTR:MODIFIER:exon21/21:c.*6878A>C:,AFF2:NM_001169122.1:3'UTR:MODIFIER:exon20/20:c.*6878A>C:,AFF2:NM_001169123.1:3'UTR:MODIFIER:exon21/21:c.*6878A>C:,AFF2:NM_001169124.1:3'UTR:MODIFIER:exon20/20:c.*6878A>C:,AFF2:NM_001169125.1:3'UTR:MODIFIER:exon20/20:c.*6878A>C:,AFF2:NM_001170628.1:3'UTR:MODIFIER:exon18/18:c.*6878A>C:		rs58901446	0.8707	0.0000	0/0/0	0.6319							300806 [AFF2 (provisional) Mental retardation,X-linked,FRAXE type,309548];				307	12					AFF2 (inh=XLR pLI=1.00)
chrX	148079877	148079877	T	C	hom	hom	hom		QUAL=18325;DP=163,238,164;MQM=60	AFF2	3'UTR	AFF2:NM_002025.3:3'UTR:MODIFIER:exon21/21:c.*7015T>C:,AFF2:NM_001169122.1:3'UTR:MODIFIER:exon20/20:c.*7015T>C:,AFF2:NM_001169123.1:3'UTR:MODIFIER:exon21/21:c.*7015T>C:,AFF2:NM_001169124.1:3'UTR:MODIFIER:exon20/20:c.*7015T>C:,AFF2:NM_001169125.1:3'UTR:MODIFIER:exon20/20:c.*7015T>C:,AFF2:NM_001170628.1:3'UTR:MODIFIER:exon18/18:c.*7015T>C:		rs16994922	0.8302	0.0000	0/0/0	0.6235							300806 [AFF2 (provisional) Mental retardation,X-linked,FRAXE type,309548];				308	12					AFF2 (inh=XLR pLI=1.00)
chrX	148080095	148080095	A	G	wt	wt	hom		QUAL=4886;DP=170,187,155;MQM=60	AFF2	3'UTR	AFF2:NM_002025.3:3'UTR:MODIFIER:exon21/21:c.*7233A>G:,AFF2:NM_001169122.1:3'UTR:MODIFIER:exon20/20:c.*7233A>G:,AFF2:NM_001169123.1:3'UTR:MODIFIER:exon21/21:c.*7233A>G:,AFF2:NM_001169124.1:3'UTR:MODIFIER:exon20/20:c.*7233A>G:,AFF2:NM_001169125.1:3'UTR:MODIFIER:exon20/20:c.*7233A>G:,AFF2:NM_001170628.1:3'UTR:MODIFIER:exon18/18:c.*7233A>G:		rs6641482	0.1062	0.0000	0/0/0	0.0116							300806 [AFF2 (provisional) Mental retardation,X-linked,FRAXE type,309548];				15	27					AFF2 (inh=XLR pLI=1.00)
chrX	148081140	148081140	A	G	hom	hom	hom		QUAL=21607;DP=150,319,215;MQM=59	AFF2	3'UTR	AFF2:NM_002025.3:3'UTR:MODIFIER:exon21/21:c.*8278A>G:,AFF2:NM_001169122.1:3'UTR:MODIFIER:exon20/20:c.*8278A>G:,AFF2:NM_001169123.1:3'UTR:MODIFIER:exon21/21:c.*8278A>G:,AFF2:NM_001169124.1:3'UTR:MODIFIER:exon20/20:c.*8278A>G:,AFF2:NM_001169125.1:3'UTR:MODIFIER:exon20/20:c.*8278A>G:,AFF2:NM_001170628.1:3'UTR:MODIFIER:exon18/18:c.*8278A>G:	(GT)n	rs184050542	0.9966	0.0000	0/0/0	0.6029							300806 [AFF2 (provisional) Mental retardation,X-linked,FRAXE type,309548];				325	1					AFF2 (inh=XLR pLI=1.00)
chrX	148081451	148081451	A	G	hom	hom	hom		QUAL=13091;DP=180,139,77;MQM=60	AFF2	3'UTR	AFF2:NM_002025.3:3'UTR:MODIFIER:exon21/21:c.*8589A>G:,AFF2:NM_001169122.1:3'UTR:MODIFIER:exon20/20:c.*8589A>G:,AFF2:NM_001169123.1:3'UTR:MODIFIER:exon21/21:c.*8589A>G:,AFF2:NM_001169124.1:3'UTR:MODIFIER:exon20/20:c.*8589A>G:,AFF2:NM_001169125.1:3'UTR:MODIFIER:exon20/20:c.*8589A>G:,AFF2:NM_001170628.1:3'UTR:MODIFIER:exon18/18:c.*8589A>G:		rs141776682	1.0000	0.0000	0/0/0	0.1189							300806 [AFF2 (provisional) Mental retardation,X-linked,FRAXE type,309548];				334	0					AFF2 (inh=XLR pLI=1.00)
chrX	148560581	148560581	G	A	wt	het	wt		QUAL=858;DP=94,84,80;MQM=60	IDS	3'UTR	IDS:NM_000202.7:3'UTR:MODIFIER:exon9/9:c.*3696C>T:,IDS:NM_001166550.3:3'UTR:MODIFIER:exon9/9:c.*3696C>T:	AluSg7	rs1141636	0.1732	0.0000	0/0/0	0.2030							300823 [IDS (confirmed) Mucopolysaccharidosis II,309900];				82	53					IDS (inh=XLR pLI=0.98)
chrX	148561332	148561332	C	T	wt	het	wt		QUAL=747;DP=76,57,43;MQM=60	IDS	3'UTR	IDS:NM_000202.7:3'UTR:MODIFIER:exon9/9:c.*2945G>A:,IDS:NM_001166550.3:3'UTR:MODIFIER:exon9/9:c.*2945G>A:		rs8965	0.3865	0.0000	0/0/0	0.0588							300823 [IDS (confirmed) Mucopolysaccharidosis II,309900];				160	56					IDS (inh=XLR pLI=0.98)
chrX	148562167	148562167	C	T	wt	het	wt		QUAL=2157;DP=170,177,115;MQM=59	IDS	3'UTR	IDS:NM_000202.7:3'UTR:MODIFIER:exon9/9:c.*2110G>A:,IDS:NM_001166550.3:3'UTR:MODIFIER:exon9/9:c.*2110G>A:	AluSz	rs5936293	0.2633	0.0000	0/0/0	0.2449							300823 [IDS (confirmed) Mucopolysaccharidosis II,309900];				91	56					IDS (inh=XLR pLI=0.98)
chrX	148563150	148563150	C	T	wt	het	wt		QUAL=1584;DP=191,137,89;MQM=60	IDS	3'UTR	IDS:NM_000202.7:3'UTR:MODIFIER:exon9/9:c.*1127G>A:,IDS:NM_001166550.3:3'UTR:MODIFIER:exon9/9:c.*1127G>A:		rs4844025	0.3338	0.0000	0/0/0	0.3314							300823 [IDS (confirmed) Mucopolysaccharidosis II,309900];				156	58					IDS (inh=XLR pLI=0.98)
chrX	148564053	148564053	A	-	wt	het	wt		QUAL=1786;DP=100,130,75;MQM=60	IDS	3'UTR	IDS:NM_000202.7:3'UTR:MODIFIER:exon9/9:c.*224delT:,IDS:NM_001166550.3:3'UTR:MODIFIER:exon9/9:c.*224delT:		rs376528035;rs71753099	0.2546	0.0000	0/0/0	0.1841							300823 [IDS (confirmed) Mucopolysaccharidosis II,309900];				94	58					IDS (inh=XLR pLI=0.98)
chrX	148582549	148582549	G	A	wt	het	wt		QUAL=2062;DP=143,186,149;MQM=60	IDS	synonymous,non_coding_transcript_exon	IDS:NM_000202.7:synonymous:LOW:exon4/9:c.438C>T:p.Thr146Thr,IDS:NM_001166550.3:synonymous:LOW:exon4/9:c.168C>T:p.Thr56Thr,IDS:NM_006123.4:synonymous:LOW:exon4/8:c.438C>T:p.Thr146Thr,IDS:NR_104128.1:non_coding_transcript_exon:MODIFIER:exon4/9:n.655C>T:		rs1141608	0.1926	0.2783	2605/2118/233	0.2648							300823 [IDS (confirmed) Mucopolysaccharidosis II,309900];	RCV000078365.5 [benign]; RCV000206047.1 [benign]; 		COSM3759390, COSM3759388, COSM3759389	488	284					IDS (inh=XLR pLI=0.98)
chrX	149826503	149826503	G	A	hom	hom	wt		QUAL=3747;DP=64,57,35;MQM=60	MTM1	splice_region&intron	MTM1:NM_000252.2:splice_region&intron:LOW:exon11/14:c.1260+3G>A:		rs222410	0.6570	0.5797	8850/3658/2570	0.5198							300415 [MTM1 (confirmed) Myotubular myopathy,X-linked,310400];	RCV000078428.9 [other]; 			819	298					MTM1 (inh=XLR pLI=1.00)
chrX	152018832	152018832	T	G	wt	het	hom		QUAL=5239;DP=70,168,108;MQM=60	NSDHL	synonymous	NSDHL:NM_001129765.1:synonymous:LOW:exon4/9:c.132T>G:p.Gly44Gly,NSDHL:NM_015922.2:synonymous:LOW:exon3/8:c.132T>G:p.Gly44Gly		rs5969919	0.8615	0.8764	20749/11112/1872	0.8144							300275 [NSDHL (provisional) CHILD syndrome,308050|CK syndrome,300831];	RCV000146961.5 [benign]; 			1442	147					NSDHL (inh=XLR+XLD pLI=0.94)
chrX	152961140	152961140	A	G	wt	wt	hom		QUAL=1447;DP=44,112,54;MQM=60	SLC6A8	3'UTR	SLC6A8:NM_005629.3:3'UTR:MODIFIER:exon13/13:c.*471A>G:,SLC6A8:NM_001142805.1:3'UTR:MODIFIER:exon13/13:c.*471A>G:,SLC6A8:NM_001142806.1:3'UTR:MODIFIER:exon13/13:c.*471A>G:		rs4532754	0.1815	0.0000	0/0/0	0.0080							300036 [SLC6A8 (confirmed) Cerebral creatine deficiency syndrome 1,300352];				4	6					SLC6A8 (inh=XLR pLI=0.99)
chrX	152990663	152990663	C	T	wt	wt	hom		QUAL=5194;DP=124,289,176;MQM=60	ABCD1	5'UTR	ABCD1:NM_000033.3:5'UTR:MODIFIER:exon1/10:c.-59C>T:	(CCAGCC)n	rs4148030	0.0943	0.0000	0/0/0	0.0127							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];	RCV000286561.1 [benign]; 			93	86					ABCD1 (inh=XLR pLI=0.98)
chrX	153005605	153005605	G	A	wt	wt	hom		QUAL=583;DP=24,40,21;MQM=60	ABCD1	synonymous	ABCD1:NM_000033.3:synonymous:LOW:exon6/10:c.1548G>A:p.Leu516Leu		rs41314153	0.0856	0.0992	270/158/10	0.0939	0.0740		T			8.37	300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];	RCV000077953.6 [benign]; RCV000402140.1 [benign]; 		COSM4156701	212	224					ABCD1 (inh=XLR pLI=0.98)
chrX	153008675	153008675	G	A	het	wt	wt	low_MQM	QUAL=369;DP=98,362,208;MQM=34	ABCD1	splice_region&synonymous	ABCD1:NM_000033.3:splice_region&synonymous:LOW:exon9/10:c.1866G>A:p.Arg622Arg		rs201197921	0.0000	0.0000	0/0/0	0.0002							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];			COSM1636441	0	174					ABCD1 (inh=XLR pLI=0.98)
chrX	153008984	153008984	G	A	het	wt	wt	low_MQM;pred_pathogenic	QUAL=380;DP=77,288,180;MQM=32	ABCD1	missense	ABCD1:NM_000033.3:missense:MODERATE:exon10/10:c.2033G>A:p.Gly678Asp		rs75125350	0.0000	0.0001	0/0/0	0.0005	9.4050	D	D	D	D	26.90	300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];				0	139					ABCD1 (inh=XLR pLI=0.98)
chrX	153009017	153009017	G	A	het	wt	wt	low_MQM;pred_pathogenic	QUAL=179;DP=76,260,168;MQM=31	ABCD1	missense	ABCD1:NM_000033.3:missense:MODERATE:exon10/10:c.2066G>A:p.Arg689His		rs781952886	0.0000	0.0001	0/0/0	0.0001	7.5710	D	D	D	D	32.00	300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];				0	145					ABCD1 (inh=XLR pLI=0.98)
chrX	153009140	153009140	C	T	het	wt	wt	low_MQM;pred_pathogenic	QUAL=42;DP=49,78,62;MQM=39	ABCD1	missense	ABCD1:NM_000033.3:missense:MODERATE:exon10/10:c.2189C>T:p.Pro730Leu		rs375489051	0.0000	0.0001	0/0/0	0.0001	-0.2740	T	D	B	D	8.52	300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];				0	59					ABCD1 (inh=XLR pLI=0.98)
chrX	153009197	153009197	G	C	wt	het	hom	low_DP	QUAL=1123;DP=11,44,29;MQM=59	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*8G>C:		rs2229539	0.7404	0.7197	2607/1342/307	0.4221							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];	RCV000077949.6 [benign]; RCV000360011.1 [benign]; 			1371	464					ABCD1 (inh=XLR pLI=0.98)
chrX	153009289	153009289	C	A	het	wt	wt		QUAL=88;DP=45,39,31;MQM=51	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*100C>A:		rs182735515	0.0000	0.0000	0/0/0	0.0001							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];				0	83					ABCD1 (inh=XLR pLI=0.98)
chrX	153009303	153009303	A	G	het	wt	wt	low_MQM	QUAL=56;DP=42,43,38;MQM=47	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*114A>G:			0.0000	0.0000	0/0/0	0.0000							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];				0	81					ABCD1 (inh=XLR pLI=0.98)
chrX	153009304	153009304	A	G	het	wt	wt	low_MQM	QUAL=56;DP=42,43,38;MQM=47	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*115A>G:			0.0000	0.0000	0/0/0	0.0000							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];				0	77					ABCD1 (inh=XLR pLI=0.98)
chrX	153009314	153009314	C	A	het	wt	wt	low_QUAL;low_MQM	QUAL=14;DP=56,51,39;MQM=43	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*125C>A:			0.0000	0.0000	0/0/0	0.0000							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];				0	120					ABCD1 (inh=XLR pLI=0.98)
chrX	153009342	153009342	C	T	het	wt	wt	low_MQM	QUAL=102;DP=73,58,48;MQM=38	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*153C>T:			0.0000	0.0000	0/0/0	0.0000							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];				1	148					ABCD1 (inh=XLR pLI=0.98)
chrX	153009350	153009350	G	A	het	wt	wt	low_MQM	QUAL=186;DP=67,64,54;MQM=38	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*161G>A:			0.0000	0.0000	0/0/0	0.0000							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];				1	157					ABCD1 (inh=XLR pLI=0.98)
chrX	153009352	153009352	A	G	het	wt	wt	low_MQM	QUAL=186;DP=67,64,54;MQM=38	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*163A>G:		rs191015436	0.0000	0.0000	0/0/0	0.0001							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];				1	154					ABCD1 (inh=XLR pLI=0.98)
chrX	153009364	153009364	G	A	het	wt	wt	low_MQM	QUAL=375;DP=86,64,53;MQM=36	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*175G>A:			0.0000	0.0000	0/0/0	0.0001							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];				1	159					ABCD1 (inh=XLR pLI=0.98)
chrX	153009385	153009385	C	G	het	wt	wt	low_MQM	QUAL=155;DP=63,73,55;MQM=31	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*196C>G:		rs367591611	0.0000	0.0000	0/0/0	0.0001							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];	RCV000384405.1 [uncertain significance]; 			0	77					ABCD1 (inh=XLR pLI=0.98)
chrX	153009386	153009386	G	T	het	wt	wt	low_MQM	QUAL=155;DP=63,73,55;MQM=31	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*197G>T:		rs371380320	0.0000	0.0000	0/0/0	0.0001							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];				0	73					ABCD1 (inh=XLR pLI=0.98)
chrX	153009448	153009448	A	G	het	wt	wt	low_MQM	QUAL=362;DP=54,76,54;MQM=36	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*259A>G:		rs374092960	0.0000	0.0000	0/0/0	0.0013							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];	RCV000290033.1 [uncertain significance]; 			0	221					ABCD1 (inh=XLR pLI=0.98)
chrX	153009488	153009488	C	T	het	wt	wt	low_MQM	QUAL=86;DP=68,77,55;MQM=34	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*299C>T:		rs201959080	0.0000	0.0000	0/0/0	0.0004							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];				0	130					ABCD1 (inh=XLR pLI=0.98)
chrX	153009665	153009665	A	G	het	wt	wt	low_MQM	QUAL=464;DP=131,165,91;MQM=36	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*476A>G:		rs372234126	0.0000	0.0000	0/0/0	0.0066							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];				0	239					ABCD1 (inh=XLR pLI=0.98)
chrX	153009670	153009670	G	T	het	wt	wt	low_MQM	QUAL=1145;DP=154,161,91;MQM=38	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*481G>T:		rs199942817	0.0000	0.0000	0/0/0	0.0067							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];	RCV000296588.1 [uncertain significance]; 			0	243					ABCD1 (inh=XLR pLI=0.98)
chrX	153009719	153009719	G	A	het	wt	wt	low_MQM	QUAL=2164;DP=164,163,93;MQM=40	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*530G>A:		rs67211405	0.0000	0.0000	0/0/0	0.0122							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];	RCV000351429.1 [uncertain significance]; 			0	272					ABCD1 (inh=XLR pLI=0.98)
chrX	153009769	153009769	C	G	het	wt	wt	low_MQM	QUAL=218;DP=83,195,96;MQM=45	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*580C>G:			0.0000	0.0000	0/0/0	0.0000							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];				0	10					ABCD1 (inh=XLR pLI=0.98)
chrX	153009770	153009770	A	G	het	wt	wt	low_MQM	QUAL=218;DP=83,195,96;MQM=45	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*581A>G:			0.0000	0.0000	0/0/0	0.0000							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];				0	9					ABCD1 (inh=XLR pLI=0.98)
chrX	153009774	153009774	G	A	het	wt	wt	low_MQM	QUAL=218;DP=83,195,96;MQM=45	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*585G>A:			0.0000	0.0000	0/0/0	0.0001							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];				0	9					ABCD1 (inh=XLR pLI=0.98)
chrX	153009797	153009797	G	A	wt	wt	hom		QUAL=3524;DP=123,218,134;MQM=60	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*608G>A:		rs73640819	0.2066	0.0000	0/0/0	0.0829							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];	RCV000338821.1 [benign]; 			13	57					ABCD1 (inh=XLR pLI=0.98)
chrX	153009808	153009808	A	T	het	wt	het	low_MQM	QUAL=56;DP=127,229,154;MQM=38	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*619A>T:			0.0000	0.0000	0/0/0	0.0002							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];				0	51					ABCD1 (inh=XLR pLI=0.98)
chrX	153009810	153009810	C	G	het	wt	het	low_MQM	QUAL=56;DP=127,229,154;MQM=38	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*621C>G:			0.0000	0.0000	0/0/0	0.0002							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];				0	47					ABCD1 (inh=XLR pLI=0.98)
chrX	153009818	153009818	A	G	het	wt	het	low_MQM	QUAL=276;DP=138,248,169;MQM=36	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*629A>G:			0.0000	0.0000	0/0/0	0.0003							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];				0	84					ABCD1 (inh=XLR pLI=0.98)
chrX	153009838	153009838	C	A	het	wt	het	low_MQM	QUAL=667;DP=165,259,183;MQM=35	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*649C>A:		rs372449563	0.0000	0.0000	0/0/0	0.0026							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];				0	120					ABCD1 (inh=XLR pLI=0.98)
chrX	153009876	153009876	G	C	het	wt	het	low_MQM	QUAL=960;DP=104,247,186;MQM=34	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*687G>C:		rs377207559	0.0000	0.0000	0/0/0	0.0036							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];				0	215					ABCD1 (inh=XLR pLI=0.98)
chrX	153009912	153009912	G	C	het	wt	het	low_MQM	QUAL=443;DP=40,217,171;MQM=35	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*723G>C:		rs369704281	0.0000	0.0000	0/0/0	0.0027							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];				0	235					ABCD1 (inh=XLR pLI=0.98)
chrX	153009914	153009914	G	T	het	wt	het	low_MQM	QUAL=443;DP=40,217,171;MQM=35	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*725G>T:		rs202120253	0.0000	0.0000	0/0/0	0.0025							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];				0	216					ABCD1 (inh=XLR pLI=0.98)
chrX	153009949	153009949	C	T	wt	wt	het	low_MQM	QUAL=129;DP=27,177,122;MQM=34	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*760C>T:		rs376897282	0.0000	0.0000	0/0/0	0.0003							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];				0	193					ABCD1 (inh=XLR pLI=0.98)
chrX	153009952	153009952	C	T	wt	wt	het	low_MQM	QUAL=129;DP=27,177,122;MQM=34	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*763C>T:		rs369150301	0.0000	0.0000	0/0/0	0.0002							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];				0	186					ABCD1 (inh=XLR pLI=0.98)
chrX	153009964	153009964	C	A	wt	wt	het	low_MQM	QUAL=70;DP=37,172,112;MQM=33	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*775C>A:		rs782438948	0.0000	0.0000	0/0/0	0.0002							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];				0	157					ABCD1 (inh=XLR pLI=0.98)
chrX	153010014	153010014	C	T	wt	het	het	low_MQM	QUAL=770;DP=37,137,123;MQM=39	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*825C>T:			0.0000	0.0000	0/0/0	0.0001							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];				1	142					ABCD1 (inh=XLR pLI=0.98)
chrX	153010019	153010019	A	G	het	het	het	low_MQM	QUAL=764;DP=37,130,122;MQM=39	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*830A>G:			0.0000	0.0000	0/0/0	0.0002							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];				1	142					ABCD1 (inh=XLR pLI=0.98)
chrX	153010020	153010020	G	T	het	het	het	low_MQM	QUAL=764;DP=37,130,122;MQM=39	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*831G>T:		rs879964075	0.0000	0.0000	0/0/0	0.0002							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];				1	138					ABCD1 (inh=XLR pLI=0.98)
chrX	153010059	153010059	G	T	het	het	het	low_MQM	QUAL=3041;DP=104,122,136;MQM=37	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*870G>T:		rs72616452	0.0000	0.0000	0/0/0	0.0041							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];	RCV000353490.1 [uncertain significance]; 			2	333					ABCD1 (inh=XLR pLI=0.98)
chrX	153010066	153010066	C	T	wt	het	het		QUAL=2493;DP=119,131,143;MQM=60	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*877C>T:		rs11803	0.7311	0.0000	0/0/0	0.1554							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];	RCV000394962.1 [benign]; 			1	238					ABCD1 (inh=XLR pLI=0.98)
chrX	153010083	153010083	G	A	wt	het	wt		QUAL=836;DP=135,134,148;MQM=60	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*894G>A:		rs1055847	0.4599	0.0000	0/0/0	0.1078							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];	RCV000305050.1 [benign]; 			1	166					ABCD1 (inh=XLR pLI=0.98)
chrX	153010090	153010090	G	A	het	het	het	low_MQM	QUAL=2848;DP=117,138,144;MQM=38	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*901G>A:		rs75637470	0.0000	0.0000	0/0/0	0.0051							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];				3	332					ABCD1 (inh=XLR pLI=0.98)
chrX	153010092	153010092	G	A	het	het	het	low_MQM	QUAL=2848;DP=117,138,144;MQM=38	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*903G>A:		rs78155328	0.0000	0.0000	0/0/0	0.0044							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];	RCV000359653.1 [uncertain significance]; 			3	332					ABCD1 (inh=XLR pLI=0.98)
chrX	153010137	153010137	C	T	het	het	het	low_MQM	QUAL=889;DP=91,161,126;MQM=38	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*948C>T:		rs112109783	0.0000	0.0000	0/0/0	0.0022							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];				0	305					ABCD1 (inh=XLR pLI=0.98)
chrX	153010149	153010149	G	A	wt	wt	het	low_MQM	QUAL=121;DP=87,151,105;MQM=33	ABCD1	3'UTR	ABCD1:NM_000033.3:3'UTR:MODIFIER:exon10/10:c.*960G>A:		rs192271038	0.0003	0.0000	0/0/0	0.0001							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];				0	139					ABCD1 (inh=XLR pLI=0.98)
chrX	153010224	153010224	C	T	wt	het	hom		QUAL=4569;DP=23,145,100;MQM=59	ABCD1-PLXNB3	intergenic_region	ABCD1-PLXNB3:ABCD1-PLXNB3:intergenic_region:MODIFIER::n.153010224C>T:		rs6643782	0.7385	0.0000	0/0/0	0.3855							300371 [ABCD1 (confirmed) Adrenoleukodystrophy,300100|Adrenomyeloneuropathy,adult,300100];	RCV000406870.1 [benign]; 			121	50					ABCD1-PLXNB3 (inh=n/a pLI=n/a)
chrX	153127735	153127735	G	A	hom	het	wt		QUAL=1988;DP=32,133,96;MQM=60	L1CAM	3'UTR	L1CAM:NM_000425.4:3'UTR:MODIFIER:exon28/28:c.*383C>T:,L1CAM:NM_001143963.2:3'UTR:MODIFIER:exon26/26:c.*383C>T:,L1CAM:NM_024003.3:3'UTR:MODIFIER:exon27/27:c.*383C>T:,L1CAM:NM_001278116.1:3'UTR:MODIFIER:exon29/29:c.*383C>T:		rs41311708	0.0207	0.0000	0/0/0	0.0048							308840 [L1CAM (confirmed) Hydrocephalus due to aqueductal stenosis,307000|MASA syndrome,303350|CRASH syndrome,303350|Hydrocephalus with Hirschsprung disease,307000|Hydrocephalus with congenital idiopathic intestinal pseudoobstruction,307000|Corpus callosum,partial agenesis of,304100];				12	11					L1CAM (inh=XLR pLI=1.00)
chrX	153170980	153170980	T	G	hom	hom	hom	low_DP	QUAL=2223;DP=38,25,18;MQM=59	AVPR2	splice_region&intron,intron	AVPR2:NM_000054.4:splice_region&intron:LOW:exon1/2:c.26-6T>G:,AVPR2:NM_001146151.1:splice_region&intron:LOW:exon1/1:c.26-6T>G:,AVPR2:NR_027419.1:intron:MODIFIER:exon2/3:n.559+356T>G:		rs56689668	0.9992	0.9993	14332/7851/1445	0.8146							300538 [AVPR2 (confirmed) Diabetes insipidus,nephrogenic,304800|Nephrogenic syndrome of inappropriate antidiuresis,300539];	RCV000242524.1 [benign]; RCV000325895.1 [benign]; 			1628	2					AVPR2 (inh=XLR pLI=0.12)
chrX	153214721	153214721	T	G	wt	het	het		QUAL=42;DP=30,46,27;MQM=60	HCFC1	3'UTR	HCFC1:NM_005334.2:3'UTR:MODIFIER:exon26/26:c.*77A>C:		rs782735671	0.0003	0.0000	0/0/0	0.0001							300019 [HCFC1 (confirmed) Mental retardation,X-linked 3 (methylmalonic acidemia and homocysteinemia,cblX type ),309541];				0	7					HCFC1 (inh=n/a pLI=1.00)
chrX	153214725	153214725	A	G	wt	het	het		QUAL=42;DP=30,46,27;MQM=60	HCFC1	3'UTR	HCFC1:NM_005334.2:3'UTR:MODIFIER:exon26/26:c.*73T>C:		rs781953961	0.0019	0.0000	0/0/0	0.0003							300019 [HCFC1 (confirmed) Mental retardation,X-linked 3 (methylmalonic acidemia and homocysteinemia,cblX type ),309541];				0	4					HCFC1 (inh=n/a pLI=1.00)
chrX	153215839	153215839	G	A	hom	hom	hom		QUAL=4672;DP=31,77,59;MQM=59	HCFC1	synonymous	HCFC1:NM_005334.2:synonymous:LOW:exon24/26:c.5859C>T:p.Cys1953Cys		rs3027875	0.1913	0.4320	6497/5802/27	0.4102	-0.6000		T			11.37	300019 [HCFC1 (confirmed) Mental retardation,X-linked 3 (methylmalonic acidemia and homocysteinemia,cblX type ),309541];	RCV000081294.7 [other]; 		COSM457075, COSM457076	587	224					HCFC1 (inh=n/a pLI=1.00)
chrX	153287325	153287325	T	G	het	het	wt	low_DP	QUAL=44;DP=39,3,7;MQM=58	MECP2	3'UTR	MECP2:NM_004992.3:3'UTR:MODIFIER:exon4/4:c.*8493A>C:		rs868980743	0.0000	0.0000	0/0/0	0.0001							300005 [MECP2 (confirmed) Rett syndrome,312750|Mental retardation,X-linked,syndromic 13,300055|Rett syndrome,preserved speech variant,312750|Encephalopathy,neonatal severe,300673|Autism susceptibility,X-linked 3,300496|Mental retardation,X-linked syndromic,Lubs type,300260|Rett syndrome,atypical,312750];				0	23					MECP2 (inh=XLR+XLD pLI=0.70)
chrX	153292180	153292180	T	C	hom	hom	hom		QUAL=16671;DP=170,223,131;MQM=60	MECP2	3'UTR	MECP2:NM_004992.3:3'UTR:MODIFIER:exon4/4:c.*3638A>G:		rs2734647	0.6262	0.0000	0/0/0	0.5229							300005 [MECP2 (confirmed) Rett syndrome,312750|Mental retardation,X-linked,syndromic 13,300055|Rett syndrome,preserved speech variant,312750|Encephalopathy,neonatal severe,300673|Autism susceptibility,X-linked 3,300496|Mental retardation,X-linked syndromic,Lubs type,300260|Rett syndrome,atypical,312750];				257	30					MECP2 (inh=XLR+XLD pLI=0.70)
chrX	153294542	153294542	T	C	hom	hom	hom		QUAL=16172;DP=133,241,154;MQM=60	MECP2	3'UTR	MECP2:NM_004992.3:3'UTR:MODIFIER:exon4/4:c.*1276A>G:		rs2853337	0.9936	0.0000	0/0/0	0.1183							300005 [MECP2 (confirmed) Rett syndrome,312750|Mental retardation,X-linked,syndromic 13,300055|Rett syndrome,preserved speech variant,312750|Encephalopathy,neonatal severe,300673|Autism susceptibility,X-linked 3,300496|Mental retardation,X-linked syndromic,Lubs type,300260|Rett syndrome,atypical,312750];				335	0					MECP2 (inh=XLR+XLD pLI=0.70)
chrX	153294998	153294998	C	G	wt	wt	hom		QUAL=4945;DP=121,265,169;MQM=60	MECP2	3'UTR	MECP2:NM_004992.3:3'UTR:MODIFIER:exon4/4:c.*820G>C:		rs185146054	0.0032	0.0000	0/0/0	0.0048							300005 [MECP2 (confirmed) Rett syndrome,312750|Mental retardation,X-linked,syndromic 13,300055|Rett syndrome,preserved speech variant,312750|Encephalopathy,neonatal severe,300673|Autism susceptibility,X-linked 3,300496|Mental retardation,X-linked syndromic,Lubs type,300260|Rett syndrome,atypical,312750];				5	4					MECP2 (inh=XLR+XLD pLI=0.70)
chrX	153629155	153629155	A	G	hom	hom	hom	low_MQM	QUAL=12907;DP=185,156,93;MQM=44	RPL10	missense,3'UTR	RPL10:NM_001256577.2:missense:MODERATE:exon6/6:c.442A>G:p.Ile148Val,RPL10:NM_001256580.2:missense:MODERATE:exon6/6:c.497A>G:p.Asn166Ser,RPL10:NM_001303625.1:missense:MODERATE:exon7/7:c.605A>G:p.Asn202Ser,RPL10:NM_006013.4:missense:MODERATE:exon7/7:c.605A>G:p.Asn202Ser,RPL10:NM_001303624.1:missense:MODERATE:exon6/6:c.605A>G:p.Asn202Ser,RPL10:NM_001303626.1:3'UTR:MODIFIER:exon6/6:c.*156A>G:		rs12012747	0.6689	0.8261	17974/11413/162	0.6914	1.2780	T,T,T,T,T	T,T	B,B	.,T,T,T,T	10.99	312173 [RPL10 (confirmed) Autism,susceptibility to,X-linked 5,300847];	RCV000081344.7 [other]; 			1442	175					RPL10 (inh=n/a pLI=0.90)
chrX	153630255	153630255	G	C	hom	hom	hom		QUAL=21658;DP=193,301,178;MQM=59	RPL10,DNASE1L1	3'UTR	RPL10:NM_001256577.2:3'UTR:MODIFIER:exon6/6:c.*891G>C:,DNASE1L1:NM_001009932.2:3'UTR:MODIFIER:exon10/10:c.*793C>G:,RPL10:NM_001256580.2:3'UTR:MODIFIER:exon6/6:c.*1060G>C:,RPL10:NM_001303625.1:3'UTR:MODIFIER:exon7/7:c.*1060G>C:,RPL10:NM_006013.4:3'UTR:MODIFIER:exon7/7:c.*1060G>C:,RPL10:NM_001303624.1:3'UTR:MODIFIER:exon6/6:c.*1060G>C:,RPL10:NM_001303626.1:3'UTR:MODIFIER:exon6/6:c.*1256G>C:,DNASE1L1:NM_001303620.1:3'UTR:MODIFIER:exon8/8:c.*793C>G:,DNASE1L1:NM_006730.3:3'UTR:MODIFIER:exon8/8:c.*793C>G:,DNASE1L1:NM_001009933.2:3'UTR:MODIFIER:exon9/9:c.*793C>G:,DNASE1L1:NM_001009934.2:3'UTR:MODIFIER:exon8/8:c.*793C>G:		rs12877	0.6678	0.0000	0/0/0	0.0967							312173 [RPL10 (confirmed) Autism,susceptibility to,X-linked 5,300847];				241	18					RPL10 (inh=n/a pLI=0.90), DNASE1L1 (inh=n/a pLI=0.06)
chrX	153630293	153630293	C	T	hom	hom	hom		QUAL=20341;DP=188,305,161;MQM=59	RPL10,DNASE1L1	3'UTR	RPL10:NM_001256577.2:3'UTR:MODIFIER:exon6/6:c.*929C>T:,DNASE1L1:NM_001009932.2:3'UTR:MODIFIER:exon10/10:c.*755G>A:,RPL10:NM_001256580.2:3'UTR:MODIFIER:exon6/6:c.*1098C>T:,RPL10:NM_001303625.1:3'UTR:MODIFIER:exon7/7:c.*1098C>T:,RPL10:NM_006013.4:3'UTR:MODIFIER:exon7/7:c.*1098C>T:,RPL10:NM_001303624.1:3'UTR:MODIFIER:exon6/6:c.*1098C>T:,RPL10:NM_001303626.1:3'UTR:MODIFIER:exon6/6:c.*1294C>T:,DNASE1L1:NM_001303620.1:3'UTR:MODIFIER:exon8/8:c.*755G>A:,DNASE1L1:NM_006730.3:3'UTR:MODIFIER:exon8/8:c.*755G>A:,DNASE1L1:NM_001009933.2:3'UTR:MODIFIER:exon9/9:c.*755G>A:,DNASE1L1:NM_001009934.2:3'UTR:MODIFIER:exon8/8:c.*755G>A:		rs12559	0.6681	0.0000	0/0/0	0.5667							312173 [RPL10 (confirmed) Autism,susceptibility to,X-linked 5,300847];				243	17					RPL10 (inh=n/a pLI=0.90), DNASE1L1 (inh=n/a pLI=0.06)
chrX	153640061	153640061	T	-	hom	hom	hom	low_DP	QUAL=477;DP=1,10,6;MQM=60	TAZ,DNASE1L1	5'UTR,intron,non_coding_transcript_exon	TAZ:NM_001303465.1:5'UTR:MODIFIER:exon1/10:c.-120delT:,TAZ:NM_000116.4:5'UTR:MODIFIER:exon1/11:c.-120delT:,TAZ:NM_181311.3:5'UTR:MODIFIER:exon1/10:c.-120delT:,TAZ:NM_181312.3:5'UTR:MODIFIER:exon1/10:c.-120delT:,TAZ:NM_181313.3:5'UTR:MODIFIER:exon1/9:c.-120delT:,DNASE1L1:NM_001009932.2:intron:MODIFIER:exon1/9:c.-431+167delA:,DNASE1L1:NM_001009933.2:intron:MODIFIER:exon1/8:c.-173+167delA:,DNASE1L1:NM_001009934.2:intron:MODIFIER:exon1/7:c.-88+167delA:,TAZ:NR_024048.2:non_coding_transcript_exon:MODIFIER:exon1/10:n.208delT:		rs11388353	0.7473	0.8577	1111/550/10	0.1659							300394 [TAZ (confirmed) Barth syndrome,302060];				529	35					TAZ (inh=XLR pLI=0.97), DNASE1L1 (inh=n/a pLI=0.06)
chrX	153649813	153649813	G	C	hom	hom	hom		QUAL=8103;DP=73,109,80;MQM=60	TAZ	3'UTR,non_coding_transcript_exon	TAZ:NM_001303465.1:3'UTR:MODIFIER:exon10/10:c.*470G>C:,TAZ:NM_000116.4:3'UTR:MODIFIER:exon11/11:c.*470G>C:,TAZ:NM_181311.3:3'UTR:MODIFIER:exon10/10:c.*470G>C:,TAZ:NM_181312.3:3'UTR:MODIFIER:exon10/10:c.*470G>C:,TAZ:NM_181313.3:3'UTR:MODIFIER:exon9/9:c.*470G>C:,TAZ:NR_024048.2:non_coding_transcript_exon:MODIFIER:exon10/10:n.1692G>C:		rs743547	0.0000	0.8696	1678/879/168	0.1637							300394 [TAZ (confirmed) Barth syndrome,302060];	RCV000298181.1 [benign]; RCV000301850.1 [benign]; RCV000360069.1 [benign]; RCV000395030.1 [benign]; 			662	46					TAZ (inh=XLR pLI=0.97)
chrX	153994596	153994596	G	T	hom	hom	hom		QUAL=17951;DP=198,228,140;MQM=60	DKC1	synonymous,non_coding_transcript_exon	DKC1:NM_001363.4:synonymous:LOW:exon5/15:c.369G>T:p.Thr123Thr,DKC1:NM_001142463.2:synonymous:LOW:exon5/15:c.369G>T:p.Thr123Thr,DKC1:NM_001288747.1:synonymous:LOW:exon5/14:c.369G>T:p.Thr123Thr,DKC1:NR_110021.1:non_coding_transcript_exon:MODIFIER:exon4/14:n.1070G>T:,DKC1:NR_110022.1:non_coding_transcript_exon:MODIFIER:exon5/14:n.593G>T:,DKC1:NR_110023.1:non_coding_transcript_exon:MODIFIER:exon5/15:n.593G>T:		rs2728532	0.9926	0.9974	26889/14628/3152	0.8994	-3.5150		T			10.62	300126 [DKC1 (confirmed) Dyskeratosis congenita,X-linked,305000];	RCV000153151.2 [benign]; 			1752	1					DKC1 (inh=XLR pLI=1.00)
chrX	154064200	154064200	C	T	hom	hom	hom		QUAL=11091;DP=174,105,59;MQM=60	F8	3'UTR	F8:NM_000132.3:3'UTR:MODIFIER:exon26/26:c.*1672G>A:,F8:NM_019863.2:3'UTR:MODIFIER:exon5/5:c.*1672G>A:	LTR37B	rs1050705	0.5560	0.0000	0/0/0	0.0793							300841 [F8 (confirmed) Hemophilia A,306700];	RCV000311167.1 [benign]; 	CR168302 [CLASS=DP MUT=REF PHEN="Haemophilia A modifier of" GENE=F8]; 		182	42					F8 (inh=XLR pLI=1.00)
chrX	154064580	154064580	T	C	hom	hom	hom		QUAL=10757;DP=114,124,91;MQM=60	F8	3'UTR	F8:NM_000132.3:3'UTR:MODIFIER:exon26/26:c.*1292A>G:,F8:NM_019863.2:3'UTR:MODIFIER:exon5/5:c.*1292A>G:		rs1396947	0.9926	0.0000	0/0/0	0.1187							300841 [F8 (confirmed) Hemophilia A,306700];				335	0					F8 (inh=XLR pLI=1.00)
chrX	154488153	154488153	C	T	hom	het	wt		QUAL=7494;DP=182,101,78;MQM=60	RAB39B	3'UTR	RAB39B:NM_171998.3:3'UTR:MODIFIER:exon2/2:c.*1935G>A:		rs782447828	0.0005	0.0000	0/0/0	0.0007							300774 [RAB39B (confirmed) Mental retardation,X-linked 72,300271|Waisman syndrome,311510];	RCV000350071.1 [likely benign]; 			1	1					RAB39B (inh=XLR pLI=0.72)
